<SEC-DOCUMENT>0000885590-22-000010.txt : 20220223
<SEC-HEADER>0000885590-22-000010.hdr.sgml : 20220223
<ACCEPTANCE-DATETIME>20220223172845
ACCESSION NUMBER:		0000885590-22-000010
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		159
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220223
DATE AS OF CHANGE:		20220223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bausch Health Companies Inc.
		CENTRAL INDEX KEY:			0000885590
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14956
		FILM NUMBER:		22665155

	BUSINESS ADDRESS:	
		STREET 1:		2150 ST. ELZEAR BLVD. WEST
		STREET 2:		LAVAL
		CITY:			QUEBEC
		STATE:			A8
		ZIP:			H7L 4A8
		BUSINESS PHONE:		514-744-6792

	MAIL ADDRESS:	
		STREET 1:		2150 ST. ELZEAR BLVD. WEST
		STREET 2:		LAVAL
		CITY:			QUEBEC
		STATE:			A8
		ZIP:			H7L 4A8

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Valeant Pharmaceuticals International, Inc.
		DATE OF NAME CHANGE:	20100928

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOVAIL Corp
		DATE OF NAME CHANGE:	20100416

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOVAIL CORP INTERNATIONAL
		DATE OF NAME CHANGE:	19960522
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>bhc-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:cdc15979-c542-4d25-920c-73804898e32f,g:89bc1415-46fc-4aad-8e83-55f6d8df2ca2,d:eeb1c2023b22439f84a8bdbbd2804ef7--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bhc="http://www.bauschhealth.com/20211231" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:srt="http://fasb.org/srt/2021-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bhc-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN180L2ZyYWc6MGI1N2Q3NTNhMjY2NGMzYjhlYjIxMzJmODNmZGYzODEvdGFibGU6NDZiYWU3YWI4N2QzNDZmZGI5OWI2ODE3OWI3OWUwNTcvdGFibGVyYW5nZTo0NmJhZTdhYjg3ZDM0NmZkYjk5YjY4MTc5Yjc5ZTA1N18zLTEtMS0xLTU5NDcw_767201d0-7f90-41e5-b2e8-bd5c9c90e843">0000885590</ix:nonNumeric><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN180L2ZyYWc6MGI1N2Q3NTNhMjY2NGMzYjhlYjIxMzJmODNmZGYzODEvdGFibGU6NDZiYWU3YWI4N2QzNDZmZGI5OWI2ODE3OWI3OWUwNTcvdGFibGVyYW5nZTo0NmJhZTdhYjg3ZDM0NmZkYjk5YjY4MTc5Yjc5ZTA1N180LTEtMS0xLTU5NDcw_714ab012-2381-4851-9147-244f47a2c6c0">2021</ix:nonNumeric><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN180L2ZyYWc6MGI1N2Q3NTNhMjY2NGMzYjhlYjIxMzJmODNmZGYzODEvdGFibGU6NDZiYWU3YWI4N2QzNDZmZGI5OWI2ODE3OWI3OWUwNTcvdGFibGVyYW5nZTo0NmJhZTdhYjg3ZDM0NmZkYjk5YjY4MTc5Yjc5ZTA1N181LTEtMS0xLTU5NDcw_869613ec-a6b1-450d-b725-1096d1aa1004">FY</ix:nonNumeric><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN180L2ZyYWc6MGI1N2Q3NTNhMjY2NGMzYjhlYjIxMzJmODNmZGYzODEvdGFibGU6NDZiYWU3YWI4N2QzNDZmZGI5OWI2ODE3OWI3OWUwNTcvdGFibGVyYW5nZTo0NmJhZTdhYjg3ZDM0NmZkYjk5YjY4MTc5Yjc5ZTA1N182LTEtMS0xLTU5NDcw_d241bdd7-1fce-4f73-aa99-73b1a1c306f6">false</ix:nonNumeric><ix:nonNumeric contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzExLTAtMS0xLTY2NjQx_23257d93-b538-43fd-a27c-e92b625799be">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member</ix:nonNumeric><ix:nonNumeric contextRef="i9bd7a2707ecb487ab4050dffc0f16a47_D20210101-20211231" name="bhc:RevenuePerformanceObligationPaymentTerms" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM5MzI5_70a72a43-4f7f-4419-aca2-445874d33f43">P30D</ix:nonNumeric><ix:nonNumeric contextRef="ia582e0f09c454720859f9795398a6f4f_I20211231" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM5NDgx_a56638c4-d79f-4701-9cb4-eeba251c7aba">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ia582e0f09c454720859f9795398a6f4f_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM5NTc1_4194aaa1-36a3-4275-bf8a-8595947de005">P1Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i021f572cbdf44c37b86b96f04672a793_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzEvZnJhZzo4MjEzNTcwN2JhNDc0M2FjYmUyNDgzMDVhNGE4ZjM1Yi90YWJsZTplYWU5NWNmZTNhYzA0NzY1OTc0YzMyNjhhOTc4OGMyYy90YWJsZXJhbmdlOmVhZTk1Y2ZlM2FjMDQ3NjU5NzRjMzI2OGE5Nzg4YzJjXzAtMS0xLTEtNTk0NzA_99561522-b91c-4eb4-8204-b6d1d4c321ed">0.5</ix:nonFraction><ix:nonNumeric contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzItMC0xLTEtNTk0NzA_aae53d6e-38d6-4bae-885a-a2f1102e63b7">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzItMC0xLTEtNTk0NzA_efb2683f-68c5-4ec5-ba14-7adb1864ba2c">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzQtMC0xLTEtNTk0NzA_43d158d1-ee05-4bae-a3d5-740a15d049b3">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzQtMC0xLTEtNTk0NzA_fa62fdb0-f620-4627-932e-a0cd84ebc336">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzUtMC0xLTEtNTk0NzA_5aae2037-0b31-4496-a31b-a0628ffc23c9">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzUtMC0xLTEtNTk0NzA_fc2d7485-eeb6-4aa7-8f75-257ecb0d55a3">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bhc-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bce9561cca44aed9496c119874299ef_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i3c51f196215b47d6a61955c462c707de_I20220217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1052f2e72864d03a985b250bef88f8c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53abce993d5a44a596716ca7c9e737ce_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5a8e9aebd5c4e6099f227c88232846a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9288144fc85e414e98cdb30f8362fd03_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35b13f9f8b9048f2abd23eee83da3ef7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb57e7f275e74745bbed5bcd771379f2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceeb259687424b4486f58368d2356d18_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i82b9833a23f042c5a2adb676a8ec5e95_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa34fcb752d94e098590798c475a7b37_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i355151ac32e34c93a32ea5b6e6b9c800_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i451d020caed04e288168a2f8fd5d732f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2de4302e562642bb876564c477eeb8f6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fc6ad19407843c2804930d9e14a236b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88a9900560564bdca7dec25381689c13_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4684b0e1b31043f2a0e0a6337cab6576_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2118e2f41d1f4842a442e5647a35f40b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c17e85c0371428e9ccf57c2288a1310_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if15b2ce8695749b5ac475e5adf790526_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64a4e2f699614549a3fba3f9ac23a215_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id91ab3b642bc46a187257c824bdd77a3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09a05e24b6824378a2ee002ec69b8c4b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e89c666446a456f8cc98146608671d8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb811b454ce14d32b8a17a56eab234cf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0ab88b4629f472db1a3683caad4f40f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8e7ca9b32a444089dfd2ee008ffa4c5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fdde09098974b0f8d7c802d8cb72514_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a01def95a9b4da68b1d7c83300f93c5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ea97ac3ab7a4d41bb8383aabfb051e7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87b994e0a55b42d3b3861f596a5aef18_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff91afb1f5c540bea0a30d424217c405_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if282715453074bb49b8bc1e448ad1f27_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb6b2b32236f4217a22e698f5e6a29c8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaa3fc7070ff4e269eaf1141c23dfc90_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93302786cb504c94b2b462b9a04d7347_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i580ae2bd45844451af6478654bd0361d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaaee956f0c34101b241686ca5a47137_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60f8b472d50d403d9e1baa887a2f2095_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd238c564d9645d68c9bd1f4839b69dc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c869e99e66c44e3807c32b56fd85737_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23e7ea6c4d584b7881937aede46315ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02aa4e2b4a9143c4931349f2b24d03c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e02837ee6ab43329d534e55ff0d3d08_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i332cb35e6b1c4b4499193a2507f556ec_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id69729faeee842779fac160c0f6b01cc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d610c2d7c5741318c7b47c1fa5ff7aa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c4a367db2a74cd19dcf9139adee5405_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8729de31314e44b0be1473a123083daf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd9c5a5d9c13483ca438c56e8327e766_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib970daaae589497d899cb7d978be2dce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i141129182749408e9635a2af36209722_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfd2e58d530c456aa77e190e8c786ffa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie17ca1996294497e9f031629ce871dae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i030df36b6a574871b8a132326549d4ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ee9a6d8577c4318bf54609562d4c3e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="country"><xbrli:measure>bhc:country</xbrli:measure></xbrli:unit><xbrli:unit id="company"><xbrli:measure>bhc:company</xbrli:measure></xbrli:unit><xbrli:context id="i6d07942ff8e3491b92dc863012aacd40_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:ThreeLargestUSWholesalerCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="wholesaler"><xbrli:measure>bhc:wholesaler</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i7cee20a09d6f45c983e7a622d798eb96_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie46cfa6ebbfe4fe3bfce4e96130f07e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d7e258ccc574f96965b59dea148df20_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i366ab3c0cc114fd3b2e77b4af953dd1f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaa57eb8c0df42b19dda8cafee4e2828_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34a41a0fa13145bf8230d44859521d48_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icacb4e180aa541848a91e2776ddcb14a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88a58a70adfc405cb63f4ecc44509a55_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaddfdd394a12495d9cc12de4613f5d31_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c48db1ce8ed4151a1ecb07006cc1eb2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b367dbe73ec48018042069891895784_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:EquipmentOnOperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie10da8de3b1d424385606609168cca9b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e253d2e372545a9be9b1908cb43277f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57f30ccd1de94a63935d2ef0dd575c37_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id146ea0827064b89a7577cc36b0679b2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78e288346972478a97d9a959bb7d3568_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i728cea9c2c2a45178ba159057c1da77b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i931f3f4638c2440d8d4ffbb6ec962733_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i588f12f4c6524d6b8656970aae16788c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37bcb7f77b3249cf8d55cb530b605590_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib131e2e5eaa54a10ae73c558ccbe6438_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11fbfd9dfbeb4355bc882e75f9bee1db_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50ee5aa72d3d409087f4f4c75b43387e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f50340c36654f40b4735a136065dcab_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29d6eccdc67e42d784ec0e124b81624f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7c501561f5644f289468e4d1128d42e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3cb4db468554971984b9ca7a67eb81a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fec29ee013641edab8d6221c9266fd7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i675cd2d759a7429ca02cfef6330b3cc6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9f22e24d99e4b1784cee096b11f5492_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ada5c2b4ba44f6890befae0c5abc3fc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfcf2240c9b14c88b49241f897539daa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2b595cb367c4f14bb366722419c77af_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i833b35b656584bc39c2fb86f6978f755_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b899431086f434796caec1c0bd402a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id26f10d6001d4bfd9222800e3b3bb4e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b52931c7ab643db9a3682345b1db8cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib91d99188bc541b7a824988141b34ae8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i700d81ebc7e14a5ea0134f3fcf286f38_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7af96439d8641e2a7f6c2f01d4642bd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id05dcbb022714c45b985fa95dd3e8361_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6379354597f24e4290ab225072abe15b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87951ceed7ea4e5aa8491f46d9db41d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bac5a748c9c4daca0dcbeb78e404e12_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aa0cd8be82c40ad85b35a58508fa64c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9942400776ce47beaad5aaea33213d31_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74cfba0d37ba44869c896ccd738c2fea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib40c6b7597d6467d804e55df949889b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ff61d6d82a848d6becbe126cfc26963_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09d8280f6d264587b97b2d17bcb992bd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib42d4166d63e4e788726dbd3033cb09c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bd7a2707ecb487ab4050dffc0f16a47_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i973d974eec8c4651854590262490ae2f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia582e0f09c454720859f9795398a6f4f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic93289a0b5264300a6c1b192827b7231_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfeb956295ef4b16a85e6e4149d35c24_D20190306-20190306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-06</xbrli:startDate><xbrli:endDate>2019-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92ebac933dea48b489400e86f7f489fe_I20190306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90f9c8b2069447318643874fdd998562_D20190306-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-06</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1875d6eb59814b65a56bf3c1ee9b5056_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="businesscombination"><xbrli:measure>bhc:businessCombination</xbrli:measure></xbrli:unit><xbrli:context id="i1c4424c16be247649ea9c0793b64485d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">bhc:AllegroOphthalmicsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f2a7103479740d6b997c87b639888ea_D20210623-20210623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-23</xbrli:startDate><xbrli:endDate>2021-06-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d780f8e498d4029a20e1dfba48ddaf8_D20210726-20210726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-26</xbrli:startDate><xbrli:endDate>2021-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1232cd05f1bf44d2a67fedd36c0d6cd8_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2798f6e7b2e943c583b2aca3a95d9902_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fd89ab94eae4b75848759e31a502deb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i814496642aa544b0bd6eb9e21c9c38ce_D20200101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id13cd655709045658273ebf2abdba2e4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:ACertainInternationalBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic96cba168a6f45b0b15835dcb29e9eef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4700fec630cc4d3393d58b8d2b00fd5d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40cc87b109454b6cb74b6178982151c4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02c2d8581fcc4e74af1f8728d7f5cb05_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc7bec622b0e4d06914e435a52d614cc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50d1eaed93cd4379b62a15c354a4c436_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ef833b76dda454f9e12e7a602fedd25_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a1d3254b1a94b428ef1e3c8512a59fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bc0f8f4b2124e1697e59545800c5d9e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e94131e350d4b8b90275b3532694a75_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32d030d4baca4c79874c13a25d51d367_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7f4579ec74b4323bcd997517762bd3e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i226c603a08c64fa89f2932e3d795dd43_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id82b7c18fe4748eca290dd25b0edd254_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07b2e0ad215d4a8e8263f35c5dfd3e26_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39aef971f8c64d94a2d8e897d769f1f3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic994d881fee945cf9668a1135e61ad23_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0345bec09794bf6818fdf23d88bb454_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5ffbb6654b542aa8ccc9d51f2e0cb73_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5fa8ed492a8463a9ef8d402daa38f5e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i923bf4abdb6749c7b03cfcf01cb232fa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i744dc2c483db45c7b8cb3c1300c54643_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if290d3a1005a4badb0ac05c0dbe5aae2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeb1d5a40c474d86b7665045cbbcdd54_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib35ef1ef18f04163ab0711c21275b0be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37dd8e5d148e4ce6a785c5011b46b450_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9aa901695e224cd3bda948346e4c12ed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ac66312bf2147d1906b5192293868da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1889026b5e64c829d9bc334d4f52cfe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8245159f69c94307993efff3243a1178_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23aea785e01a442a92655b06b1baeaf3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d8d666e2aca457593b6a68cc6c05534_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8c7dd3d755f4d23a5c91bada3e42ee9_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc7d3c92717d45fea0d13f8cce709379_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bhc:CrossCurrencyFinalSettlementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44e7b5604e7f428db4023a2105e3040b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfe6b64df5694949b66283a944e675f3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id979f8795ef24a36b2de7dfd5788e85b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9d09cae82ba48e1ab8a7444a671c37c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if40c526d7e7346638f324aeec169b157_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib13c9491b10f4203a909a98994925ea0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51904574a9814c839ec1c948964e42ee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37cde1419dbe4d6b8814f741d3d75967_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i255986411ba145c5be6963ac79d1cdef_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b8d6be7a4a04904afbe947cf98fb1fa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55601d2d01ba43d0ae61dc537370fe98_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i261fb00917f94a52acc0d59b2bdbe652_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifad488da9d8d42f2ae12cbbb6d990611_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic86fe7b9a9b24aec84a84ced04e41054_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8edf93d7795c4edf82cf448e9626bfff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fef8a6744fa477c83018f4c7bea0626_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83278b64958b40958e3243fd2a1b1ae6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaca6d803b964e7891bb81c4ee12ccce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa75d1437f1d4f9b9a633c9849122864_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b8a4232afdb4ff5978b9e0e691223aa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64af0e0d3e4140b1b4407a0c784a6907_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>bhc:rate</xbrli:measure></xbrli:unit><xbrli:context id="i18e557e1adb142668f07f005de10db3a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i570d56f066454c278557839640940613_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bhc:MeasurementInputWeightedAverageDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i669f1ac33f2845c287e6b1bad341253c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24b574ccfce8480da6d68ccf2983c9d6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i779f7dfcb77d4f20b069195568b29fa4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eab42b92e0d40ecb1ef0a51c9b67d8e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71ee14ac1c1d46b7a0ce6c3c7e2a9b99_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fab45399b784a6590e369a44a09cd98_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43aa74e47e0a4098b9e1b70baf38319d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic72dfc3064da478e89d0708906a6270a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ddb15c7970742ed9da4a433d76c5f2a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id50f749937914da499d3aa0713e26497_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d4c04c5a36a498e9735c3b7b90e02ae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8916b7890ddb4f65bd52ab52e5fca2d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b16b99c92d340acae71efc354b677d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53bc5bf59ece4ba7a3fb0dda2961cc78_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49f627a32c304d4e97c853cbdc52fe1d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c417841d2d04bb0aa5f9721b865a03d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6c6af997a5a40d3b472bba2069ff9c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic11c0834d02545e4a4a40fe884590f30_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d9e8838b0b64725a2134d6c808fce63_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:OtherEquipmentAndLeaseholdImprovementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39a4f86638de4f1d85298fc8f9d9e688_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:OtherEquipmentAndLeaseholdImprovementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44211772dd52482e9e4ffe87d1d7ae4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:EquipmentOnOperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbafbc956c894b57be4b8cb6144cea99_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:EquipmentOnOperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6f977b18e2d47869607481b5bbc4690_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i164c1c9b47e74fc793e6991fa1597a81_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf8fe351f9e049048e582a289f5ec940_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae408a1b501d44bfb0d015a59f05ba39_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d7f9da12914489bab1b7bb4cbb4fc83_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbf9196b61c6417e95bd898b4020850c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c9a0557ca2f40e8a6681b9854a4d544_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06187f7ce19446a690591cd1b95c7f26_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea4f798327a64255b8fcebf77a9bfd28_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29ccbe7385f64c2a8f950c5898bc20dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafcb6c30e16d4d609946e1e977a992a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i875f56312a3e4f3aa4e713ccaddb57d8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bd0280d56644e9aa17e3ed84baa5cb9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide8dc03ca5d34e2d82fe875ae8349bfe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib10da3a8baaa43f2882bbc75cea97f73_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9afc2f89d1f4c1dbec3435239ca1668_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fee0ea71e1945109e92e284dc86e65a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ff94dcd862b417485b1c86cab1f0d19_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bhc:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1044279e431a465c8d792ff8c4424f95_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bhc:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i068c904248854bbc871b95c7bda13c2a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i482a42699464403190bb5666f649d099_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6052d5b84a4f4e3dbbd55e3b7b3472af_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65d12a1576654877b8d12fa8e43fad62_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:UnutilizedITInfrastructureImprovementProjectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee78254e5ef24867b4e79676061b9da5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:ACertainInternationalBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic98bb92d4f6c4075b3ea9d057f2dc09e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7814719b55964c3a90f30a661c040f5e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae9620bf07594c2d8b0ae4bda9e46476_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bhc:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4275122509984c548f84f8d98d4710c4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f2bdcc8cabc4a8fbc2220baf550e504_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77368b09b2fe4c1dbf5d0160459ef7d5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f938f0f5c7b48b98d4abfb36c343bf5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bhc:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4962dcdee267427ca7c640643c4b63e0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic87f144240594803b338f3329694b5af_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6485ff11a7784c7d93cdebb81e571cf7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if13a6652f6f14e9380c0faa89ab7253a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieefeebe8556a419b982e4603dccbde45_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if02d06f22a6049fab2752d7559d9139c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25b498657cd04064a8d22a18cb88515c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf8602fc27b744ae97df02360802bb93_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia16b95bd57544fe1b90bd153182259d7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id15e4ba8f40445ec845f103e0aaa553e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i373d7f78aa2349ccaafcb0b37e13b0e1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e7c6b2d77a446c1b4aed9a04f7dbd2e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf22e67019f9453383f473a7440bb889_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e0d98e274204d53b918164aca0779ae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib76ac81df5fa49b68ba3b7819c1fc06a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7300f7b54644f8a9660b750f9e847b8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85a97ee039044646b0f12d8dfddbf0fb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dd56e661cc441b88ce62c077cb8c9c5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9cf2e58ead94c7e812f2a73e8e5a8b0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03a8ce11b6a94d508439a84f941e6341_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ab307cfbe9b4a94b2c883cfc5dd5f07_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a665fac8c5447d6b59c47157917616d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieba4bed7b87c4d64adde44c696279cea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08856af02cf84095b7eda2ff890eaa65_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7042f2109b44a618b5adc51134f2f32_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16b907a0a74e489584cd63b7298ac261_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e15ed3860174023ad86fcfb1fc3d7a7_D20191001-20191001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b80b732bf87464abb356edb40e75c0f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie754db10161f4f43a00a7ccbbb4d5499_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49498b6d16f54144b0e062468813a553_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae72504d531644ac8838bbb4ec27c1c1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:ReportingUnitsExcludingOrthoDermatologicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10b37ca262cc4204a355bbd20f6cd963_D20200630-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-30</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac97f26599824297bb76711a52beec7e_D20200331-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-31</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7fea7ac010346df9ddbd729f74109a4_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c4efa01e28a4063ba07a08f0dec29a3_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4d44a38635a40b4a32e60755373e624_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i774ca80b37c14809aaf69d1ec60caea2_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3ad16bb04674a37884451df0bcbfb99_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2e256a9bac640f8ab017d4f047fb1c9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd4407332fee40f39e8808930a147100_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae738547736443dc961d0df42b4d932b_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iade956227f64477f8bd834744fb0b81c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33a4b28c4d244a908251259f68df10a2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3befa2e27fb94dadb4d2e0b6671d1ea7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief2363e2b42349f1be653bf6588660db_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68ccc3aae7a44c81bc2bc15d199cf675_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39f7dc3af718428fa8639267d86d4723_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc7bc8f12bdf4bd5b49783904d555941_D20210630-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-30</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifae82a26687143d58a5a4cf6c438ebca_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21a45eb6762341e485fcf7416428f6ba_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c01a665a28449b793613ecc5d63522c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9adef68a2e1a41ffb17a60a9075ee559_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19aa307929434141855192ccd5d26e84_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c06253724c04adb9d709a0d06b0a4a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57ba8084e93643d19f4f8c135c1beb71_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9193acd40b7439299521c6fde8c4891_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89af4e1890874416ab318090b1cc294e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes7.00PercentDueMarch2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32e198fb8ac3442ab187a17a7c4f0d2d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes7.00PercentDueMarch2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ec36cf30e35457e8a0b60837b539b1e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8b2f62d73a04aadb052f3835a632303_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66914061a58846f0a2dd9fbf966be49e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b9f7d6a773a492daebe7cb683a831c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic459c1e2b8f44d65a0d2e10bfae297d5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92b27a9dcb1e4c6aac20e9f0f1bb22ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67d99cc27cfc490babc9f17b67fc6c36_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9abe59cd5b4344b3af6d863639ee97e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7069779fddc24154bec1252491718d71_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia90e19da742b46a88993ff20c0ef65e4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bbcb30923264dada2fd327d3b9f97f3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b9d6159d9b345d5a925bedf7aa2f714_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0e3e0b5c7314f4d8c7bad143746ae92_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13a7ac2ee83a40f487e5ff99f59101b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac672bf940144940ab2863657d675904_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie691743843174dfebc02e17db2f8b881_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9fccfd4eb6c4a3da530db148be437ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a7c2483467d42fa92a0d1889a65352c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i637b51dfd22b4d7d8bf9dc99c065d131_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c6b5763866f4cdbb14e92752f777770_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4273b9d256e540e985599fd8f4111808_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d04379800474729927c296a02ee23b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5f8a823e64b4391b5fdc14a2699ca01_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1550fce70ddc4bde9fcc143dba86ed02_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87f54fc33f3647cf854ad3d2446add0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd94b3061443470786f4f2aeefe3ee61_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50ec0b78d915487982eb08953a99cf34_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i300264ba1d81487683635e7eef8d2c8b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i350590e126f747c09b3b536b35e19ffd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08ba959daa4a48e2ac776ce9798a9d5e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aed4915fc8f42e580d71e20a671d348_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5120118135441ab83944681d2efd4b0_I20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i351b85b10d1a4bc4994a95b06fcbbc15_D20180601-20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41ba8fedd17c41849f4e82c6bf1880b3_I20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4661b2464e2e42d289cd362548d23d4e_D20180601-20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedebe3ccdce14516b687ab3595dfe1e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5f0234485054f26ad2c1d49dfdbd799_D20181127-20181127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-27</xbrli:startDate><xbrli:endDate>2018-11-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4e41ed007de4e4ea8f42478579b6eaf_I20181127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27285ba6e43a47799cc65795b7635e66_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i531d4b49e7e14178b135b8a39f88fa6a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31222c8f48ac4a7b9ebdc2458dd1be5d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cd6d35fff84440898e7edf6f94360c3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied9e5eb3fe5b46218dadb86953b97df0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadaBankersAcceptanceRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia22718f8832b4e798f11e810438b3bf7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadaBankersAcceptanceRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb84972c8f344a8896506efbff337098_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredTermCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4515f9481f5f408cbe7a9817cf5107d1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateOrPrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i580615bf5fb84813a4f15d5b64260502_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateOrPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0cd16b6c95c43cf92a6b19bd75a7df2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eab960e05594954ad74b51fbec5de70_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7b27ce3a4694376b7351cac69da0831_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica0eb942508643f38c6a8b5216c7ab26_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateOrPrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d0ab3127bf249bba7383ddaff5d96b9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateOrPrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10e9d909bf8748b1ada82e2b29c7e29c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9bf72ff91f54b6d9dfd299f64fd8858_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bc0bc23890449aa8239cc453f4e1a07_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i844942ee3772417395b5e3b2b42455d8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28ac575b36634a86920565ce2fe16cca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7622a05b204a4dd1a5f310c32b83aa3f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55fc1cd86d124ba798ea0bb114b41e21_I20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes6.50PercentDueMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ff0004e74da4838ab43904393cdd3f0_I20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes7.00PercentDueMarch2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bd6872a182646a082629d18870e0ab0_I20171017"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25ef1a1efaa044929df3a9c4e1c62bb0_I20171121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9806922f86c748b8a9fb0ae15b0d631c_I20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if30a44e3344f420686b02ee5a1668f41_I20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A8.50SeniorNotesDueJanuary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i199861b87bfe4696b2d3547b9feff668_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5875SeniorNotesDueMay2023March2019RefinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e281e9d7a3444ae947ed7b6a12ff125_I20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.875SeniorNotesdueMay2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9399287ac5904b0093d941914ffe1526_D20190308-20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5.625PercentDueDecember2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-08</xbrli:startDate><xbrli:endDate>2019-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e41c5aa1f5f46339004eb9f8abdc897_I20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5.625PercentDueDecember2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib64fedb96e0a40dbbba005b5e30bc256_D20190308-20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-08</xbrli:startDate><xbrli:endDate>2019-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie38650ed8f69484ba8e3e32b255cc9c1_I20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f2634d868b948cd81c47592e26fbaa1_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5.625PercentDueDecember2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8e89da68c2b4a889e5ce5e76dec2863_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotesAndSeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia70cbc9c5ef04337a9cdfcf70d213bff_D20190308-20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-08</xbrli:startDate><xbrli:endDate>2019-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b58a4c00eb84382ad3f4bc0cb5d0c33_D20190308-20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-08</xbrli:startDate><xbrli:endDate>2019-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47b737fa198b4128bcd55e26d3e2cb52_I20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48a5c09856bb4c338e922161515b31c7_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueMarch2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae6d3126236d454cb028cdcb1675739e_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e453510571a42ea972e7213bb0683b3_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36ee75c249b846dea1eab8be020170d9_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i731ff10dfcf54abe98b1740cfb194c1d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i635a4ec4469e4a38ab9bf05cdecd65b3_I20150130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i884c88ec40c64e79b29c807b2a885dc6_D20190523-20190523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-23</xbrli:startDate><xbrli:endDate>2019-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dac4ecf6d0f4130aa4a1059a0869ace_D20200101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5885c91251745a8bd996100382f6c32_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5b7e60d19034d39a78a89ace8a9bdaa_I20150327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.375SeniorNotesdueMarch2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d8eae7cb22c4834939fd13d8bfa0402_I20150327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.875SeniorNotesdueMay2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bec3b624035487c90ff26d75d14b4f5_I20150327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes4.502023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f952abf74d84815948a25d97a9b0e2a_I20150327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A6.125SeniorNotesdueApril2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="icb448caef5334750891c172cec2300d0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5875SeniorNotesDueMay2023May2019RefinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id030b84634ff4592b2dd49390438a1b9_D20191003-20191003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorUnsecuredNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-03</xbrli:startDate><xbrli:endDate>2019-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d5f38a92282494f9530b0fb16484f40_I20200116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorUnsecuredNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc35a805bb9d489a81ba954da2c90dfc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorUnsecuredNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ca7f7ff80664661a5cc30c2112c5f4f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba498b34c6e5496e98017b43ea83814f_I20171218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id56bb838f8ca4688a209a9aa5630486b_I20171218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.375SeniorNotesdueMarch2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63149bfde2e74932af587b7f07bec783_D20171218-20171218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-18</xbrli:startDate><xbrli:endDate>2017-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7612d5c6f03401fb096eeb9f8731268_D20171218-20171218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-18</xbrli:startDate><xbrli:endDate>2017-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e6f4753796c4f9da3ea1142cd2e1c91_I20180326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.25SeniorNotesDueApril2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07bdfabc3951404f8889a947cf3a9686_D20180326-20180326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.25SeniorNotesDueApril2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-26</xbrli:startDate><xbrli:endDate>2018-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20076209e8fa4b958baa1b8f32663a95_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A8.50SeniorNotesDueJanuary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb0e075a0cbd419d8ad9a06043a3352f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A8.50SeniorNotesDueJanuary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28aa526ea8d84f278ee8f1842400571b_I20190523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.00SeniorUnsecuredNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39a070cf27ac4d539b94e8656d4502e5_I20190523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.25SeniorUnsecuredNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05517ba451014901a9d88eb38f3ac23a_D20190523-20190523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-23</xbrli:startDate><xbrli:endDate>2019-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab2a35a3c29f407dad845189bdbe128c_D20190523-20190523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.25SeniorUnsecuredNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-23</xbrli:startDate><xbrli:endDate>2019-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1273409244264cbbb7681d6753625c7b_D20190523-20190523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.00SeniorUnsecuredNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-23</xbrli:startDate><xbrli:endDate>2019-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb700fb0599c4cfdbab4a269de54e805_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.00SeniorNotesDueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie55bd69a58f9418183a1bb030920e901_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.25SeniorNotesDueJanuary2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43c10acd1411494298a8bbca9c5aad00_D20200116-20200116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.875SeniorNotesdueMay2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-16</xbrli:startDate><xbrli:endDate>2020-01-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06c668190ea847209a8da86cf1e73998_D20191216-20191216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-16</xbrli:startDate><xbrli:endDate>2019-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71f877b49bc44738a6ceab709138f307_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.25SeniorNotesDueJanuary2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5389f9afcc9c4deca0f0d09e9a716c2b_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.00SeniorNotesDueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idec8329a9c5d487e88dbc1f38144d98a_I20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia601b6230ea24da1ae27d263526923d9_I20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes6.50PercentDueMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee380ad8627b4f83b469b1ba89c9747b_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025AndNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5925ca8a2c54e8d8795ffb55d368483_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifea6355ea76743f0a61e88e55dcd2ce2_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5839a9c4cc754fa0803795d95447729c_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88e6526a8d134ebab814430fdfa18227_I20201203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a97ad4188494b8781417a8f8d543882_I20201203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes4.502023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5964597f62e744bf9d6aafb14762d4d7_I20201203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5501242b42bc40d7a227556ee3415134_D20201203-20201203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-03</xbrli:startDate><xbrli:endDate>2020-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73e09d09766b4417aacfcfa14a10126c_D20201203-20201203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-03</xbrli:startDate><xbrli:endDate>2020-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie10a5bc9208e4517ad73103ab3f6d59b_D20201203-20201203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-03</xbrli:startDate><xbrli:endDate>2020-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f1fd27861d840c9982cb6007d12ec99_D20220211-20220211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-11</xbrli:startDate><xbrli:endDate>2022-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if80737f8327f4413b9aff0d3dbfe8369_I20220118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9af4b96ef19949f2928ad128d4c72201_I20220210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i021f572cbdf44c37b86b96f04672a793_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredTermCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7563625586364005812392f5b14e44af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ec20e3f4b2f4f599834f9809e4c9d92_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="defined_benefit_plan"><xbrli:measure>bhc:defined_benefit_plan</xbrli:measure></xbrli:unit><xbrli:context id="id71cc4b7c6a54ab0a60acdf0c8a5303c_D20141201-20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-12-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i866959039d2f4c258b6f412bfdedd0a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieafeae30c1bb4e9697860aa43e144e89_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id639a041f43545ba9cbf52ed62530656_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id677830949bf4a7dae2bc84e6d0e68d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddeca17018524ca7b4aa0120b6e125e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7e41e73d53c444f810e26a21d37fd21_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bd0b15dbe944220bf785415eda57379_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebc6bf90ba6048c081b87a24157c36a0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibee8e4ebafb4425eb4bfad3cad142065_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5c96e30d644464397808c237e9a5ddf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i248cf8d382ab417d8f08aa7bb5b3c1ed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c408d4a08264cae9f329fddd9849fcb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2d3dc1e9fc14ff2a726b48981e5c5f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie074f53bc69745fba66921f6f8d38556_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56153b69689b4ecd9dcf4887ed60d362_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a02dcf2c684493ca47da42ad5f0a86a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib55cc79a8c5047d8ab1633dbce4cad44_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia693d6a4e0b14b4c931965ccf754e1f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d7991a8fa0d4d8795903d4ae61c5a6d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d7c434502ca4f2a8223f3e89683dd28_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b1fe039d84a45ce8e43d1c4c89b07d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id453d2c511534fe6837d77baaee83805_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6251e5f5fad7409b9187da5b1b34bf8f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a81a3caa7c94785bd723c5136f85945_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2aa787db2bd488381cd79f25f35617b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaade5d5b17e942f2976fa0e0eaced2a3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cfeb6a24e7c459aa69b339c9936b980_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if07c85a851d7490689bc9a5740104746_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60ef3defb63b42d8b564f10aef937998_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ff1e276f1334094b7e8280d216bb2a6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7af55aa092e044f2afb3019b380424df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1d47b1547ba49eaaf8b343286177935_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c916f8745844151b90043b27bfda10b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccba448cf4a7430c9ab615c9c0db387c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09e4c0369ab74b7aa42c2ca4a081d665_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfe5828d7ce648ba9901225e5f602ffb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac45d6fc735f4300950257942f7987c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e6efe3bfe1b43539fd5441f3e8f1178_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie17c1b0a784541d7991bb6af8b757d2b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic37dcc11c7224eca84dc480d56dc32ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38d00d230e384e1793aa975171d11afd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d2c3cb6c7374e28bf785a1101c1a131_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc9f1c3ceea44453b7dfa2a13ac987b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied1ceb27c69740139dfd77de2155225e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38e21dc226144b94ac36444dcece2004_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e447011ef7645a89efe64052f877da1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fbe7d9aaa8d48bcbb80294df7a9cd60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82a224828a4841bd8e05d44a229d645f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i557a5608d76644fca3792b79c6260a38_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2f6f0decf1a440db6a8df7e4d1cd9c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie614ee2bbc0d41c3937648c0eb4fb366_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a50fd29ab6c4a72809e44c2f372bdd8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib98051f977524d43b7bba256f7160a84_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf30f7d75c6344fc9a13de058b489364_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7365a02480094a778087f003e4453b09_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11eb673cbf1d4f7d84ac5c9df99a3ef2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9a9521608704153b9eb100ac78f0ce3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i809b25b2066b40bf96408dc9e0b225c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1d36468c5de494abc6015ee26da8e73_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dcfebc863894026b3ca1af655064a00_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i560db68718d54136a8a45bfb702d5324_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61e987a4f1b54c88bcbcc12fa7abfb69_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16ed7839b2a04f0fbeb5dce55d268189_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91dfeedfb92b4828a4722c9f88fa1872_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1825b75f97004bc184282968848c0a52_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6242900f15f3401ebaac9f8a3c1b6339_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63b875eacbc446a887982c5d1115d3ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9a62d35ed944986ad939c9b014c654d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92434c9334a54511bdec1d46d8213f3b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcc360791b434eac863d82daef575b6d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ba6ac8d86f64c9385ab1aa7f0d2c220_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0c5d97b9ab244b69b17a46f19cca258_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8b0dc0501c84cac862c7828cee33fd6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42c6f916e85b4a7cb01549ad02518fd8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c12e56dc0f345abb7ab14eb2eb546b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id35cd34eedeb4695bfa8ad28f7c073d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b90dc62606b4697b1fff595e063dce5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c488d1b1a9b41baa5ddb7387a75b0ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida118aeda14146be9fa07183a8d43611_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7404c4a64514d8cba0117dde2032747_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bab925ad83349bfae08cdc351f392a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2ccc52c4ecc49e78eee3d33e2c113fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie92a115bae124a91960ec41c0727d1a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba3925adeb07427b9b35df22f7082c71_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6623925ca56e4d96a7ec9b93e614a8f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib69b353fbcad4f2ea129c8b8af2024fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dc8df13fb424c888d592fddbc492642_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c7b88b7a1da425584d296d8cfb61e31_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85953604b0f4454d8293d1577ad37660_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75e6fc7cd989419aaac17aab91d819e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if060c809f3ab42b79bb79a9e9119eb6c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b463b0ee361495cb1a35797490d8474_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc5b5fd1952143dbb4fc80c09e61d41e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ff8ba240c174921af7e5377f66435da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28879983df974e8dad3a100a9e2eaff5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia617fb33524a429f96a5f4d5de41e8d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafe1692fe13c46099cdb274aae8efa5b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58b06c811115478cb20db99973ade215_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb2a552032894fa0a8dd1d7b70fbf7cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ec30830375949738e95af67de6bf189_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0acdb587dc57405c8f51594ffdc58f35_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79b1763781234b4c91e295caf0806e96_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33703c137cd44896ad4cdeb30fcc6fae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff30b4961b3a486991e363c44db17d42_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i669279a7238d4e8f9dd6fad058ea31b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i481468708dc74adc94731e7319c5a223_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84843ec87bf8430fbff7bd811a71310a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idca3abdd017446218f6e8960ca67c023_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6eb575ca4904425a87bec5e53f208d9d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8fb3dc081ea41aab4e32f39084453f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41e1bb53e0784950afc27fa187a27c3f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc5e2d60ba7148dcba54ff5384e23249_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bef888f50664043863fbf4ec22eb918_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d117480a68f41e29692f8e1120299c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i764e7dd8c6e242209ab1812391a46ead_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03b4ac56aab644b3a3663f4a78369a13_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i612036dfd9af4751b039c09d33e2ca46_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9647f9aaa0af4927aa97fab7f6dce46d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc934bb3b7764915937b42332edc108a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie670eb0132ba453db0ccfc9534e8a176_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i846b3df052964b86bab155c36ffa8b7d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08181df0b76a4b1db12c4d01da570d5e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd4a088a9d1a4225a9b940802b6651dd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dd5dc3a71fc44a288385275d334a636_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i773f8c6eb5314348bd0df5d5f8554717_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06f89c2da51442cf966a159f442d7040_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a942b6a477e44ee80469bf00455c69b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie62be2fe885843928cc89e9a7ae8bb78_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d72936706da4a49a0b60284da13fe0a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2b78164753e4fb69cb995913ce9a5be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i824c5e86c03e4a0389aa5c6cab684353_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i019d538cf2df4702927d2feaebb08210_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42f1505ab33d4d31b29170cf387d3bf1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f2d6658f8c6432eb855fc35c09bc8ae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fb966e248dd4e7db899e8be25bcb6ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e6548e2528e46dca40d1b1d09e39d12_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3190fba7ebb5479dbb06445d6267911d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib72d3400eb8c419bb79a2b659524d6d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8afa60e604994497a1986db946c1937d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ff0e3d8fc3e4f288ffcf7c081bebc05_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbb8aacab7664f5b8279284fc6149b67_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3103a0933124d62871e5fc29bf546fa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e058ef986de49f0bea67e87231e73b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if09958cb78f94a76a7e6f17b2bab67df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d964dd1784d4ad8bd4443d448886eef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb4dc2559a83406c8a242c061666e6c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc69c8ac45694ba2b20fb0ff3a7f39f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe61ce2f0b3946ca8976584ee83df12b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i299b97ed33754f6b8c3da5c29c47a1f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd5a69340ce945b7a60bf0ed0babc543_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie44d119215b549a88ce037813b5be0de_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ca155d300cf42a4b9cfdefca02c609b_I20140531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4442a258b8f44219a1cd0070ea1406e8_D20180430-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-30</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc1c3154bf0046c1b2667e6a53320931_D20180430-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonemployeeDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-30</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id025575230534acb993dae92e7192d0c_D20200428-20200428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-28</xbrli:startDate><xbrli:endDate>2020-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8265f2e72c9e451eb2bd2c997c00db7f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i086597ed1e26464a806168f0ce38c359_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i846d952abe194e548203133638491e9c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2088dbf192f84b6e9cff9dc2cde381cf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie724079581044aa0811350b601ee9cc2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2910d81cb0f045f7a33086454100489d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79264328a7a543f1ac564306154bf1e7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a5a66d1f91043f8bc5742bb410551cc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i936812f8c65d495cb6b6f31769ebb66b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59d93d4490ae467d9a2415b38252c35b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc9346bc756a4ce3b7a716c303df449a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87e1a3e05cd844d9a82820b7441ea2f3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eda91734bd9488387a03d3c1a80263c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fa761390575444b8d5cf87f856db73c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67ab1d6d98e348a2849edb9d66a71b5b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefcbe00a2f7e4f35ae1167fd771c00c1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9615eb6151e4a2da212f24458fc78e6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfe3a038368845f1a17357b6780d71ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12c733996b5f40c9abb282bf8d5d421b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7042672dea544848ba094e3f7c68fe6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i911683c7210b422894ad8e3b68edeb77_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0393ab35e9cc4519bbfe3fe5df85b76b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fe34facb9874ca79ea97f41a97eb1c8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e1cd89faa1647e69cd98100bc41a853_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib899b174c8a5478689ab47ec6929522f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic56b5e163c6d4ad88d725a35418555aa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i903f03ca7b0d4bec8b5dae3db9f4c7a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iede5ac25cc2c49c797a46beb7f132efd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36e8b2657c164c33a91c59ad739b895e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i272f0cc98d024849a92bb2d337033d5d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ROTCPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i789a736034674ddab3556f1ab2711032_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:OtherPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9158150c4cf4379b5bba7c7cb9d7e9a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0b1241118154de6b3af123e431df6a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbb6b356a1fd41fc9c4da52a60b5ad6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8021c14b857946c188b6f072829b7db7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22332303e4634782bd879afa7c52f3f7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bhc:MilestonePaymentRelatedToCertainProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f60772beddd4bd8b351b7519c847285_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i966b3882b2f8446a92d3b73108d3691d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33e256fd4d08472686f2bc331857bc8a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic44ed602f863418a8831ced61d13e546_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie270c7e752794cadbce8d6ea63bace3b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6ce4645221b4e709b3988651ee21064_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic906a904b8264052aa297c4da0661e84_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9019e1c2cf6d46838fe8c8d77147207a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c84dca0789f4214840ddb5f4f8537bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i983ff7f7025446d58e2f36c202de3dca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idee0cbb24fc340c1a64cf7d7df3edec6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc644797e11f42fb9e29854f00a8af84_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bhc:PooledScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5e04a5a10344bad915b3777b2ade249_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bhc:PooledScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12f28aade059421c87f68fa766a6137c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccec7fb29c284c1282bcfd6426b81d26_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida6fd5a3e163430689987e5420387788_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:RevenueCommissionersIrelandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iceef040ee04e4d18be72112cc3158c59_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:RevenueCommissionersIrelandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="subsidiary"><xbrli:measure>bhc:subsidiary</xbrli:measure></xbrli:unit><xbrli:context id="i23bf918ee3914485aeddbbc1554c30ea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f649769ddcb4300a790315728ab809b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c7cd7b9da83461fa9bd41fd621feefc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9ec02f6590e441bbef7d90718b83872_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9654dc8595e40e7b7fb7f68cfe474d9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id511e68e76754c458cbf0c440955486c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie55c0ff42c4544718880dceec02e3876_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id991a25ce8c1481ca65b4088fe2e5c6e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:FR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87eff35348ef4c22b0f0c14d5d1ff9a7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fbc8562b9bc45179604d0b354d37975_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i759223d752d2484cb3624693e092afd2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:IE</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49ed113f8481479a94b3377274581c18_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:IE</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic758f54fa5494dee98621db67459a939_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:NL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3721bdf19944087b6072d188479220b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:NL</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf289905620f424a822098d370171d98_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8197dcace8e546198e3aa3cab5f1e9ab_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1878eebcc48403e8da37dd8ccee3c33_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:LuxembourgInlandRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cecc7e2447a473eacca025ceba50171_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:LuxembourgInlandRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3452627b08104c328663beda89ef7e2b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bhc:TaxYear2005ThroughTaxYear2009Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="i53b67fa0263542b89545f1c28636acdc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70a5dd9dc5d24412b0837e57866d62ab_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie44b34f6fd784806a1de35a90e5cd3c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bhc:TaxYear2015AndTaxYear2016Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd17b9aaa43542b6ad701f3288d43039_D20170808-20170808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-08</xbrli:startDate><xbrli:endDate>2017-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie898e2aab45345c9b42d7a2acb631663_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id033c0ed7fc74052a6c84265f651ad67_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b0d284e351c45f6a89f189993ae032b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a5a4c310e574205b818538430461c33_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i393b10cfe703474a8e599f0e963d3334_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8cc4183f807420fa113cead38c11868_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i246d722a091f4f0080937e3f56bdb622_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91b2ee61b3794c97a503eb91ca7419fb_D20151001-20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="case"><xbrli:measure>bhc:case</xbrli:measure></xbrli:unit><xbrli:context id="id6c40f9f298a435e8a95ba9a81e42595_D20211231-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:RestrictedCashAndOtherSettlementDepositsCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6542cc5b199449eb308666602a70acb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="group"><xbrli:measure>bhc:group</xbrli:measure></xbrli:unit><xbrli:context id="ifd485be691b84f43ab57f11e016f9b16_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if49a279281c940c0bb5c71ec87be9d3c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="action"><xbrli:measure>bhc:action</xbrli:measure></xbrli:unit><xbrli:context id="i3eca502d770d4373a854ca461ac2dffb_D20200804-20200804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-04</xbrli:startDate><xbrli:endDate>2020-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35775310d73b4d409433acee7c99eb8c_I20190215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="entity"><xbrli:measure>bhc:entity</xbrli:measure></xbrli:unit><xbrli:context id="i73250b3b65e14dc084f6d77a1b839bb1_I20210317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="numberofbusiness"><xbrli:measure>bhc:numberOfBusiness</xbrli:measure></xbrli:unit><xbrli:context id="i0f0be9ec6ddf45658d3a7d087aa67006_D20160527-20160916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:RICOClassActionsLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-27</xbrli:startDate><xbrli:endDate>2016-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ebadc5ebb4b4ab7890bec9925824363_D20171207-20171207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-07</xbrli:startDate><xbrli:endDate>2017-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="insurance_policy_period"><xbrli:measure>bhc:insurance_policy_period</xbrli:measure></xbrli:unit><xbrli:context id="i02a698a8f008492cbd69f48f20e081f8_I20210720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="insured"><xbrli:measure>bhc:insured</xbrli:measure></xbrli:unit><xbrli:context id="i32cfd64f67674351a47e22d698db3e9e_D20210720-20210720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-20</xbrli:startDate><xbrli:endDate>2021-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06854e40aeff47b0b797200881bfe88d_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:SandozLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bd7415ed1604a45b4b6bc56767acc83_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PerrigoIsraelPharmaceuticalsLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35ab857c3fb443e7906b7fc3fdb47b2f_D20200501-20200501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PadagisLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i823e4afeb6cf4d59ae626d765f776286_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:MSNLaboratoriesPrivateLtdLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia07d23a8e2fc407d901667681d446493_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2837802deebf438f831c9248b84634f3_D20220202-20220202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LupinPharmaceuticalsIncLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-02</xbrli:startDate><xbrli:endDate>2022-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3142f2cfd5aa4bb08a1afccc27a8a806_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ApotexIncLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cebf3bd98614f709e30c0cad5ae3945_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowertoShowerProductLiabilityLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf59e9f444d44941a03dff00106248fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i668c09254646450da54e4779c1a1cf5c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowertoShowerProductLiabilityLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id333f2cd40c246d686e1bf05143b6d09_I20211215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowertoShowerProductLiabilityLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-BC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id08c64cba12f4488a204547ee19dbb28_D20211216-20211216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowertoShowerProductLiabilityLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-BC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-16</xbrli:startDate><xbrli:endDate>2021-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d1927896b7f467b9ea850d5899edaa8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowertoShowerProductLiabilityLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5a5b7cb1bde4b00b20dc046470c7dbc_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DoctorsAllergyFormulaLLCLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f954393aadc446fa7a66231a8a0176d_D20190128-20190128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LitigationwithFormerSalixCEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-28</xbrli:startDate><xbrli:endDate>2019-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf28153bff85452b8ab343577fbba878_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i705b99b9e9f141cea120e4f7552a841d_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib79efab1243d47f58861ab6f96316996_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b0d134ac84a4b9fb995abee169d3922_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0974c8f474ad4f1ca10ac1d1131053f8_D20210726-20210726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-26</xbrli:startDate><xbrli:endDate>2021-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied24221b489d4f4ba5abd2b2dd8014fb_I20190910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DerivativeLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shareholder"><xbrli:measure>bhc:shareholder</xbrli:measure></xbrli:unit><xbrli:context id="id56dfce34e5c4c43bdd8c62baf232508_I20190913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DerivativeLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81f9ed3c74134a7fabf0feaf1c2120c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf37c45946284359a2d4538803c7b301_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f2f1cfe9dc04f76978526af52bd0a5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:NovaliqGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bdb8b8277cf4e04ada86ca0bed059dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:CedarsSinaiMedicalCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62ab16dfdb214a95ac5f1498f90faa39_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:EyenoviaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="reporting_unit"><xbrli:measure>bhc:reporting_unit</xbrli:measure></xbrli:unit><xbrli:context id="i30bf053c559f4b1c9ed175d768f3d24b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i673b35bd82f24773b53ca856e22be6c2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f6d3e46f96644c89ae14a35eb34a016_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffb4ee2a83284e5aacf40c45394d64ee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc3957b2514e43d4bc57896332a29c98_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i526b3306560a4582bbd5cb84b6634e8e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1aabb4dd84c41e78c5713f72684c58c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12ca69aa53c04d1f9a70ca7832545115_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d617a50cb4e4dc2b9d45dd78b38e32c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fd885b33ea84b91854e977c98d0cdd2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe4fe193ae054da49acc60fb104beaba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fc28f8f6ed74a9089917e8b80f33998_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bb5d7f34e00490896510ef48df89709_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e43bb66906240b1bf5bd13e06e0eb33_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic22f83493b6c49b3bd143623ecdfcef6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i305152159c734293b19863277adb1507_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16716b25f68d437e8b5603c13cad09e4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2acd16c5638f406dbc8a4a64bcfb73c4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4c91dc7a5754f868357dbaaf40b5a60_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40ecfa21f8b642f7807a65183e087f3e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93fdc6cbea484e5d933d9ec17976a64a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>bhc:product</xbrli:measure></xbrli:unit><xbrli:context id="id40c780474fa4a4682a7347b25e2b201_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9af7ef89cda648658a1c3607ee127da7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i045b9dafc68b4cc68fb25904182bba77_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3697d2a9e4ec43ed8d76e098889f36cc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00cbb18e8a4244e0b4ab1c019ad6fbef_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05e5078808d945ada773030e2fff85f6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18975fdb4b2643a18e1536995bd756ae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0efcb1a3e484c1495fe6a62314d10a2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8200ab4980184e4096913b6919701188_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5015918fcb654325817de17b69decef0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1210af6063f04ed085da1d49425cc50d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd3b2b75a9e04acc95e10777983994e6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4db50b822dce470c82556f075e3aa86a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i620b1f27f17d43f7ba80d7206929a42a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i818f730bc4e3452abca0fbc91147a433_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dae557e1e00497a865526614a2c20dc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i741d562c91384842b61fd3597f4f5e01_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29fb9247f04947ea8be74d0fa5e1431d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bbe060476f44a9e9703d61f58e930d7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b52e9e750b14be2b227e83c88613718_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieca5e0bc0aeb4138acf45885703a0f6c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09553df00340400bb7d271aea0f7bbe5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ee94ae398154c9ba283d347ee65f6fe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i111b0987b23747f886225e07ed349f8b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4f1ecad4e074139b813953bc218bf66_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58e2b80073124c139f9beb53118af5e4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6ba58bf0a7a47308743596ca6786020_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c572de04a1547afbb27a25fb70ce6a9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62aa1ea2a03e43139f39c8d0853efab4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49e6f291ff584b48a1622e2e639ba32e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i499995e5502d4c19b0439c7bf1f67b9a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if992199bf6084e97b3622278275b21d3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4853e38d55c49e987573c8d03ec31aa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d94edb1edcc4131b1c8c736826ab425_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica7328b8d6504b7899d1dc8b7505c3c0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4118ed47b4d54cbdb1f54bbd3b175865_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic87b0a379a4e4af4a668a658b4e4dd43_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e7cfdefe46344e69ec8aea55a260650_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee783aab280a472ea992eba9ca598c34_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55591dc8c2f846f5ba4430ce1db261dc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i558d7f511a464c67b2130444ac156e84_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b6212f9cc5f44979bde0e23bc60ea10_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i088daa95a15e437895c8f9f62f3aaf91_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cfe3de8f52f4da6bec0b7e7f3089c8b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i800a26cd6f20436983c15a8c15183252_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie58585239a67458fa764c31745ab5784_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i261608b942e5454e8116aba0eacfa55e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7803df4ff86b424e850a241538857cd4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2f9db866111463eacf119731346b0d6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i867c2a9786c94ae2a5aec06b9a7cf714_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i738e8488fe144fce92ca8ab4ac3908e1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3ccfe8ed3544137991312117c73e03d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i768994e8bab445f2ace72afece0d453a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7a686a8ace843f6b748426e83776b3e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a10926c267e4f7ca73186bb4acb8c87_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5102465bf9f8449faf1eb3625cdf92e0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib145795896ac48f893142cce0eb31900_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9337ed14800f40b0acaa106b8ab1687c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d30a802ae6241198bab6f023ee116ec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d8e87487d774cb5aa73c296d54c373d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01c332dc4b3a40a7a943bd1c4a3ae01c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9673696801474c4ab375773e366c4e88_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7b567c1a1d44f319be957d898bda4cb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87ad55a1ae5b4477a17dbf7c109decc9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02ca962a07074ab0839d092880ab5aaa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d6a9bdc1e8f4460856c8c2141dade5c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13483a8d36774c0090ab1f1dd802483b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd95ebc9b8e2493283e0e5fa94a55b77_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ab4cac0f20f47bea48d93a577e3c68f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9458be242c114b20aae89680bcb5981b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia68492c01598457abbbb8598f9044b5b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2764c82e246f458ab4e6010231d3da10_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38cbd7ab09694b5cb4499dc66ab3535d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ec1bdc6efc9470c9e1dddfa13904883_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia78ff119a7a043648e26b928f005ae89_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib492295e326e40ebbf3dc856ab711aa9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77282ee77e994ae0943e0dd0203f496f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21cd1fcf02454f2aad2528f002a1fe42_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71cdecdee46c4b1893e522d76ed1b394_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedafa6efd5e44f1499ea180b808f257f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91f8e9e0afef4a67b9264f5a03b4ddfa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia337f02e12fd43138589ca394c6f6db4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9bc60fbab2b493da4da40019ac28d5b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief548b6efb9243519ea3dc4dcb13b28d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e4cda890a664abb926b4656d83aa772_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ad550fea28840ca8816e812a29b209b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id96fcda2fdee4cceaec20818540ab7ff_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d9df741d61340bba2aa6c1e15e212ef_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba623fc1e57a4f16a68ade989b914e71_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d8ae893b49345bfb708b151f21b640e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaada16b4b8624fb888a1f0e2f22b1aae_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i389a02cf0b334d2a9bc9e4d299b60faa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97cfe71201a14248b5a32a0be5378bdc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cf07a753f9f497e8b32f6adceb6f310_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia83c0def577047da884ce155c2ca3898_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12d5980aa12348d4bdccb1436660ada0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31434b081601492c8ea95ce2b4f375e6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3b10e36535844bb8d8e1f54883bcc7f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24c3f0d4cce04da181b013c5d63d6613_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81cd80c7bd5e414fbd605f465e39a045_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2742b142133f46b8a6da2018195c82e3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f669422c2a34471ba15be9c22158c50_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11472ddfa02944969a68ae2a1ae9e0aa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id130fccad3254b85b50a4b625a1dcde4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65d94d793a9d4765a3365f16eb32b2a7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic25b58dd47534aecaa1e6fceaca4aea2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbf3d8d385d64c9986eeff60677c124c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc9c0c2f95e04969a40f79d90fbce2c3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ed5256f567f485c9398406ba71740cd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d755014362a46e4b04d95046a5882e2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic48b8c8ee39d43a199bbf9a0ca2aaf23_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c803976e613424da77d662911fc6070_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if21ae7bafd3345088a01d43828a61e14_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11c5ca044d5d4c338ccc82b463e5c0c0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idae5a5e95f9e42db945e914283667476_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9926394966af411883263fa6138b4736_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id455a11708be4744b4a4db362bcbb326_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27fd2a2c4b784f2ca7121666541412f8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib73f7c080cab4bda95891cb8f82106e4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26ab236fac0b4f6aa2edb6c703d1d2d2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia046496cfcb74a4b8dcb288dcf4d65ac_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i686a58e486aa452d93fb9e1315614162_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08449c2242ac44f6bdab497f63ba91ae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68ae7a44ac90426e88c14dd8cda682e3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i109a56ca7b294e69a526b8979a3ddbba_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6d4f781ea0b40538209f115920071e9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2180af989330419e910ab226313818df_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic68cf5e89c634f10804f0199048ac135_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:EG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4331026771c04d61a230465e05e97af9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:EG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i542580a52bd046618b9a580e8e103af3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:EG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic990a51442844403aa60ea9e7d40e464_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6635461f5a48470c8e56e33f2e669734_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0a477db0fde456185567e5b03ecc809_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i585c6fb7766a4a5181f84f4a204170f8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i906af541abda46ea9ee574738de1865e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02eebd70500545f79f2c990d2925d8b5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic22a4e49c9354ba18f292e3feb3e7e01_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2497f962eb7544ca88a07e1e575fc7ed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae37a07b59f444bd8e13c8a1c43209fa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccd485be53574b8e949e379c787d4ef4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc7582499a2b415e93784236f4cb34fd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i168771f1c7d74447915fe4778febc05a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i471e03575d1346b7b9f05bf5ba23116b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4f64c8704264652a24d4ce93c2900c3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if84190a5f2244c92b77538836a840d39_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14de5bc495eb4add9fa84a199741910c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d46d579e1e44fe3ad004f43eaccef30_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2862a5dfd1e645cfb3ebcb20802866e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b8ed490007f4fee9a005a8a805c6894_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c43807d9cda4c16831c9f055db35fb6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3218c6c6aa7d47a6b6e7fe2e3402a5c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b664e37697c4f7891056561bf29f683_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2aea46020d284bf6820326330afd288d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d6aaa98a7a24f74b46d997266d2a452_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34126ade1b28483c9a1ea926b56d408d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3be1fd06e45447f2a98c47d3aa49590f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7ddc11ce20249cba2bdf7921a98775c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic95237c6a18642d8876995496f7f0ec6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66dcb516bc924f7f8ea52045f62987c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90615098fdc24b3394cea58fd0717975_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacfc9f50cdde4a879013a96abcb55983_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie121075f685e4899b526388e85fc73a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief9b76c5e82249468a3e6e7d77de38df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic715be3970fe46419fb02b3a67f6c23d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2da7c3fce6a4a55b940079cd34b7824_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bf0ad3c28494e298de94b94bcbedd3f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dbae836ee6a485199be60177a95f582_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7c19794c8aa4758a7c167c4585fa6ca_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iace25aeeaa0d4c3d986f48d0c8baf029_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19d7ced3035a44ce992df3a4b9291ff4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8131fb2f99f4c7a8028ad6778dc1676_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f416523997c4b338d676cc2d06aaafa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04069591c97a4784ae4185ec478eb90f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29cea92069c14b44a2be0c659664e70f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice846a05c75e458db9e4650442b6067c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i249f7ac9d61242019aa00db1804021d7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i197a960478f74a8e9a871dd7b6a60555_I20220118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityNewRestatedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d92f684e11f4d7195e59fa6354f28b1_I20220118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityNewRestatedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11ef4c89472c48b8a4e820729468ec02_D20220118-20220118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:NewRestatedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-18</xbrli:startDate><xbrli:endDate>2022-01-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0c6700094674a22af02045a72c15ccd_D20220210-20220210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-10</xbrli:startDate><xbrli:endDate>2022-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i590fabe0c9ae4c4db81e12d4cd310bc0_D20220210-20220210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-10</xbrli:startDate><xbrli:endDate>2022-02-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_1"></div><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:36.00pt 40.50pt 31.50pt 40.50pt"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-bottom:9pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjMy_e131ddad-1d02-4eed-b545-a4fa6c17d7ea">10-K</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:530.25pt"><tr><td style="width:1.0pt"></td><td style="width:10.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:256.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:256.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6NjZjMzQ5MWU3YmFiNDA2OGJiMDI1ZTJkZDMyNjNhZTQvdGFibGVyYW5nZTo2NmMzNDkxZTdiYWI0MDY4YmIwMjVlMmRkMzI2M2FlNF8wLTAtMS0xLTU5NDcw_57b2448a-3176-44fd-b36d-00d376b1b39a">&#9746;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr><tr style="height:12pt"><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Fiscal Year Ended</span></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6NjZjMzQ5MWU3YmFiNDA2OGJiMDI1ZTJkZDMyNjNhZTQvdGFibGVyYW5nZTo2NmMzNDkxZTdiYWI0MDY4YmIwMjVlMmRkMzI2M2FlNF8xLTItMS0xLTU5NDcw_ea6685aa-97dd-46aa-a8d7-619f681e180d"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6NjZjMzQ5MWU3YmFiNDA2OGJiMDI1ZTJkZDMyNjNhZTQvdGFibGVyYW5nZTo2NmMzNDkxZTdiYWI0MDY4YmIwMjVlMmRkMzI2M2FlNF8xLTItMS0xLTU5NDcw_c8f31147-2963-4d9d-96d5-8c02aae60bc6">December 31</ix:nonNumeric>, 2021</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OR</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6NjZjMzQ5MWU3YmFiNDA2OGJiMDI1ZTJkZDMyNjNhZTQvdGFibGVyYW5nZTo2NmMzNDkxZTdiYWI0MDY4YmIwMjVlMmRkMzI2M2FlNF8zLTAtMS0xLTU5NDcw_1ff25d37-4999-4412-98e1-6e3819ecc864">&#9744;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr><tr style="height:12pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the transition period from&#160;____________&#160;to ____________</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjQy_8fca6ac0-65a2-4ad1-9987-b9f1c840ca0f">001-14956</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjQz_01fbc6b9-7a44-4dda-b360-967312497111">Bausch Health Companies Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:484.50pt"><tr><td style="width:1.0pt"></td><td style="width:112.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:34.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:49.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:217.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6ZDA2NjJkZWYyYjdkNGU3NGE4ZDZlMTIxNWQxOWI1MmIvdGFibGVyYW5nZTpkMDY2MmRlZjJiN2Q0ZTc0YThkNmUxMjE1ZDE5YjUyYl8wLTAtMS0xLTU5NDcw_4c1238e3-edf1-4d4d-a194-84da2b056ff0">British Columbia</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">,</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6ZDA2NjJkZWYyYjdkNGU3NGE4ZDZlMTIxNWQxOWI1MmIvdGFibGVyYW5nZTpkMDY2MmRlZjJiN2Q0ZTc0YThkNmUxMjE1ZDE5YjUyYl8wLTQtMS0xLTU5NDcw_2e96cf47-3324-4075-8e2b-6230a90f294a">Canada</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6ZDA2NjJkZWYyYjdkNGU3NGE4ZDZlMTIxNWQxOWI1MmIvdGFibGVyYW5nZTpkMDY2MmRlZjJiN2Q0ZTc0YThkNmUxMjE1ZDE5YjUyYl8wLTctMS0xLTU5NDcw_bd96c2cb-d3fc-4cfc-848a-242fb3315f79">98-0448205</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjMz_af0d8e6f-6de2-42b4-94aa-aa5397546328">2150 St. Elz&#233;ar Blvd. West</ix:nonNumeric>, <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjM0_78d23cd0-691d-4eb5-9a8b-7e22992f1daf">Laval</ix:nonNumeric>, <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjI4_749b808d-82cc-468e-84d6-522b799c23d1">Qu&#233;bec</ix:nonNumeric>, <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjM3_7a053eb5-ade9-4fc3-a986-30d8356792e7">Canada</ix:nonNumeric> <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjM1_4614ef47-7e35-4800-8de0-f83000835fa7">H7L 4A8</ix:nonNumeric> </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices) (Zip Code)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjI5_061f3235-39f3-43c5-a9cf-a66de0003097">514</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjM4_a5891910-bec5-4576-8bf5-2cd5956ed5f9">744-6792</ix:nonNumeric> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:465.75pt"><tr><td style="width:1.0pt"></td><td style="width:136.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:79.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:117.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:118.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6NDg5ZjlkNmY0ZmQwNDExMTliZjdkNjc3OGM0NWQ5ZmQvdGFibGVyYW5nZTo0ODlmOWQ2ZjRmZDA0MTExOWJmN2Q2Nzc4YzQ1ZDlmZF8xLTAtMS0xLTU5NDcw_7cffd14a-5deb-4d0b-a630-c326a4e44daf">Common Shares, No Par Value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6NDg5ZjlkNmY0ZmQwNDExMTliZjdkNjc3OGM0NWQ5ZmQvdGFibGVyYW5nZTo0ODlmOWQ2ZjRmZDA0MTExOWJmN2Q2Nzc4YzQ1ZDlmZF8xLTEtMS0xLTU5NDcw_e1524488-b866-4ca0-bc95-07ea3fa15a87">BHC</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6NDg5ZjlkNmY0ZmQwNDExMTliZjdkNjc3OGM0NWQ5ZmQvdGFibGVyYW5nZTo0ODlmOWQ2ZjRmZDA0MTExOWJmN2Q2Nzc4YzQ1ZDlmZF8xLTItMS0xLTU5NDcw_f17e45a8-1d62-4807-a964-00c82ca6f1aa">New York Stock Exchange</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Toronto Stock Exchange</span></td></tr></table></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to section&#160;12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Title of class)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;<ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjMw_1c3d0609-34d0-4614-b08c-be120d1da73e">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjM5_02c003bb-1777-4905-9ce9-2f851c17a104">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or&#160;for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;<ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjQ0_add8d860-47cf-4a2f-a420-42bc1e021729">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or&#160;for such shorter period that the registrant was required to submit such files).&#160;<ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjQw_83e4e411-d7d7-412e-b226-446e179046ac">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.740%"><tr><td style="width:1.0%"></td><td style="width:15.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6MDU3YjQ2ZjkyYzU3NGJjYzk4ZWU0MDc2MDNiM2FkMjEvdGFibGVyYW5nZTowNTdiNDZmOTJjNTc0YmNjOThlZTQwNzYwM2IzYWQyMV8wLTAtMS0xLTU5NDcw_875c3e5c-fdcf-4f5c-9b00-5f4394b0f89d">Large accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer<br/>(Do&#160;not check if a smaller <br/>reporting company)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6MDU3YjQ2ZjkyYzU3NGJjYzk4ZWU0MDc2MDNiM2FkMjEvdGFibGVyYW5nZTowNTdiNDZmOTJjNTc0YmNjOThlZTQwNzYwM2IzYWQyMV8wLTctMS0xLTU5NDcw_1d7538b5-1c7b-43d9-83a4-893a7de38177">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6MDU3YjQ2ZjkyYzU3NGJjYzk4ZWU0MDc2MDNiM2FkMjEvdGFibGVyYW5nZTowNTdiNDZmOTJjNTc0YmNjOThlZTQwNzYwM2IzYWQyMV8wLTktMS0xLTU5NDcw_c25e2ca5-235f-4c9e-bcb6-db37983db0ca">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjMx_a4d13f3a-ce3b-4205-abe2-f81874f299f9">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as&#160;defined in Rule&#160;12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjQx_6c431068-0f74-41d2-b8fe-89a7afc9bd80">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the common shares held by non-affiliates of the registrant as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was $<ix:nonFraction unitRef="usd" contextRef="i6bce9561cca44aed9496c119874299ef_I20210630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18yNzUz_cdaee5f1-6e27-4fc9-b81d-f74d1a07b2d9">8,713,713,918</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">based on the last reported sale price on the New&#160;York Stock Exchange on June&#160;30,&#160;2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of outstanding shares of the registrant&#8217;s common stock as of February&#160;17, 2022 was <ix:nonFraction unitRef="shares" contextRef="i3c51f196215b47d6a61955c462c707de_I20220217" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18yOTM1_a6c9dbd4-5ccd-4d30-b149-5272a8b425bf">359,646,496</ix:nonFraction>.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjQ1_2c6a82a0-a6f8-4044-9039-83e6e08ac7e6" escape="true">Part&#160;III incorporates certain information by reference from the registrant&#8217;s proxy statement for the 2022 Annual Meeting of Shareholders. Such proxy statement will be filed no later than 120&#160;days after the close of the registrant&#8217;s fiscal year ended December&#160;31, 2021.</ix:nonNumeric></span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL INFORMATION</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.173%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk Factors</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_82">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unresolved Staff Comments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_85">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Properties</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_88">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal Proceedings</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_91">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_94">57</a></span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_100">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserved</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_133">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_136">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quantitative and&#160;Qualitative Disclosures About Market Risk</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_223">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Statements and Supplementary Data</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_226">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_229">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controls and Procedures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_232">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_235">114</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_2906">114</a></span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART III</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors, Executive Officers and Corporate Governance</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_241">115</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Compensation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_244">115</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_247">115</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain Relationships and Related Transactions, and Director Independence</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_250">115</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Accounting Fees and Services</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_253">115</a></span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART IV</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibits and&#160;Financial Statement Schedules</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_259">116</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K Summary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_259">116</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SIGNATURES</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_265">121</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where the context otherwise requires, all references in this Annual Report on Form&#160;10-K (&#8220;Form&#160;10-K&#8221;) to&#160;the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221; or similar words or phrases are to Bausch Health Companies&#160;Inc. and its subsidiaries, taken together. In this Form&#160;10-K, references to&#160;&#8220;$&#8221; or &#8220;USD&#8221; are to United&#160;States dollars, references to &#8220;&#8364;&#8221; are to Euros, and references to &#8220;CAD&#8221; are to Canadian dollars. Unless otherwise indicated, the statistical and financial data contained in this Form&#160;10-K are presented as of December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trademarks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following words are some of the trademarks in our Company&#8217;s trademark portfolio and are the subject of either registration, or application for registration, in one or more of Canada, the United&#160;States of America (the&#160;&#8220;U.S.&#8221;) or certain other jurisdictions: AERGEL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, AKREOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ALAWAY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ALREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ALTRENO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, AMMONUL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, APLENZIN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, APRISO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, AQUALOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ARAZLO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ARESTIN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ARTELAC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ATIVAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, B &amp; L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, B + L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BAUSCH &amp; LOMB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BAUSCH + LOMB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BAUSCH + LOMB INFUSE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BAUSCH + LOMB ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BAUSCH HEALTH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BAUSCH HEALTH COMPANIES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BEDOYECTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BENZACLIN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BEPREVE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BESIVANCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BIOTRUE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BISOCARD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BOSTON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BRYHALI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BUPAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CARDIZEM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CLEAR + BRILLIANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CLEARVISC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CLINDAGEL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, COMFORTMOIST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CRYSTALENS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CUPRIMINE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, DEMSER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, DIASTAT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, DUOBRII</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EDECRIN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ENVISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ESPAVEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, FRAXEL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, GLUMETZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, INFUSE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ISTALOL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, IVEXTERM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, JUBLIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, LIBRAX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, LOTEMAX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, LUMIFY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MEPHYTON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MIGRANAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MINIMS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MOISTURESEAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MYSOLINE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NEUTRASAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NORITATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, OCUDOSE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, OCUVITE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ONEXTON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, OPTICALIGN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ORAFIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ORTHO DERMATOLOGICS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PRESERVISION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PROLENSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PUREVISION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RELISTOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RENU</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RENU MULTIPLUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RETIN-A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RETIN-A MICRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SALIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SHOWER TO SHOWER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SILIQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SILSOFT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SIMPLIFEYE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SOFLENS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SOLODYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SOLTA MEDICAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, STELLARIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, STELLARIS ELITE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SYNERGETICS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SYPRINE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TARGRETIN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, THERMAGE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, THERMAGE FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, THROMBO ASS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TIMOPTIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TRULANCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TRULIGN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, UCERIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VALEANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VASERLIPO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VICTUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VIRAZOLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VYZULTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, XENAZINE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, YELLOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ZEGERID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and ZYLET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the trademarks previously noted, we have filed trademark applications and/or obtained trademark registrations for many of our other trademarks in the U.S., Canada and in other jurisdictions and have implemented, on an ongoing basis, a trademark protection program for new&#160;trademarks.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">WELLBUTRIN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, WELLBUTRIN XL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and ZOVIRAX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are trademarks of GlaxoSmithKline LLC and are used by us under license. ELIDEL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and XERESE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are registered trademarks of Meda Pharma SARL and are used by us under license. EMERADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is a registered trademark of Medeca Pharma AB and is used by us under license. ISUPREL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and NITROPRESS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are registered trademarks of Hospira, Inc. and are used by us under license. XIFAXAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is a registered trademark of Alfasigma S.p.A. and is used by us under license. MOVIPREP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is a registered trademark of Velinor AG and is used by us under license. PLENVU</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is a registered trademark of Velinor AG and is used by us under license. LOCOID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is a registered trademark of&#160;Leo Pharma A/S and is used by us under license. TANGIBLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and HYDRA-PEG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are registered trademarks of&#160;Tangible Science, LLC and are used by us under license. XIPERE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is a trademark of Clearside Biomedical, Inc. and is used by us under license.  CONTRAVE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and MYSIMBA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are used by us under license.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_13"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caution regarding forward-looking information and statements and &#8220;Safe-Harbor&#8221; statements under the U.S.&#160;Private Securities Litigation Reform Act of&#160;1995 and applicable Canadian securities laws:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">To the extent any statements made in this Form&#160;10-K contain information that is not historical, these statements are forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively, &#8220;forward-looking statements&#8221;).</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">These forward-looking statements relate to, among other things: our business strategy, business plans and prospects and forecasts and changes thereto; product pipeline, prospective products and product approvals, expected launches of new products, product development and future performance and results of current and anticipated products; anticipated revenues for our products; expected research and development ("R&amp;D") and marketing spend; our expected primary cash and working capital requirements for 2022 and beyond; the Company's plans for continued improvement in operational efficiency and the anticipated impact of such plans; our liquidity and our ability to satisfy our debt maturities as they become due; our ability to reduce debt levels; our ability to comply with the financial and other covenants contained in our Fourth Amended and Restated Credit and Guaranty Agreement</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the "Restated Credit Agreement"), and senior notes indentures; the impact of our distribution, </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">fulfillment and other third-party arrangements; proposed pricing actions; exposure to foreign currency exchange rate changes and interest rate changes; the outcome of contingencies, such as litigation, subpoenas, investigations, reviews, audits and regulatory proceedings; the anticipated impact of the adoption of new accounting standards; general market conditions; our expectations regarding our financial performance, including revenues, expenses, gross margins and income taxes; our impairment assessments, including the assumptions used therein and the results thereof; the anticipated impact of the evolving COVID-19 pandemic and related responses from governments and private sector participants on the Company, its supply chain, third-party suppliers, project development timelines, costs, revenues, margins, liquidity and financial condition, the anticipated timing, speed and magnitude of recovery from these COVID-19 pandemic related impacts and the Company&#8217;s planned actions and responses to this pandemic; the Company&#8217;s plan to separate its eye-health business, including the structure and timing of completing such separation transaction; and the proposed initial public offering (&#8220;IPO&#8221;) of the Company&#8217;s Solta aesthetic medical device business, including the timing of such IPO.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements can generally be identified by the use of words such as &#8220;believe&#8221;, &#8220;anticipate&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;plan&#8221;, &#8220;continue&#8221;, &#8220;will&#8221;, &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;should&#8221;, &#8220;target&#8221;, &#8220;potential&#8221;, &#8220;opportunity&#8221;, &#8220;designed&#8221;, &#8220;create&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;, &#8220;forecast&#8221;, &#8220;seek&#8221;, &#8220;strive&#8221;, &#8220;ongoing&#8221;, "decrease" or &#8220;increase&#8221; and variations or other similar expressions. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements may not be appropriate for other purposes. Although we have previously indicated certain of these statements set out herein, all of the statements in this Form&#160;10-K that contain forward-looking statements are qualified by these cautionary statements. These statements are based upon the current expectations and beliefs of management. Although we believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making such forward-looking statements, including, but not limited to, factors and assumptions regarding the items previously</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">outlined, those factors, risks and uncertainties outlined below and the assumption that none of these factors, risks and uncertainties will cause actual results or events to differ materially from those described in such forward-looking statements. Actual results may differ materially from those expressed or implied in such statements. Important factors, risks and uncertainties that could cause actual results to differ materially from these expectations include, among other things, the&#160;following:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">the risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, the fear of that pandemic, the availability and effectiveness of vaccines for COVID-19 (including with respect to current or future variants), COVID-19 vaccine immunization rates, the emergence of variant strains of COVID-19, the evolving reaction of governments, private sector participants and the public to that pandemic, and the potential effects and economic impact of the pandemic and the reaction to it, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a significant adverse impact on the Company, including but not limited to its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition and costs (which may increase) and revenue and margins (both of which may decrease);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">with respect to the proposed separation of the Company&#8217;s eye-health business, the risks and uncertainties include, but are not limited to, the expected benefits and costs of the separation transaction, the expected timing of completion of the separation transaction and its terms, (including the Company&#8217;s expectation that it will launch the IPO of the Bausch + Lomb entity when financial market conditions are favorable, subject to receipt of regulatory, stock exchange and other approvals, and the Company&#8217;s expectation that the separation transaction will be completed following the expiry of customary lock-ups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to receipt of applicable shareholder and other necessary approvals), the Company&#8217;s ability to complete the separation transaction considering the various conditions to the completion of the separation transaction (some of which are outside the Company&#8217;s control, including conditions related to regulatory matters and a possible shareholder vote, if applicable), that market or other conditions are no longer favorable to completing the transaction, that any stock exchange, regulatory or other approval (if required) is not obtained on the terms or timelines anticipated or at all, business disruption during the pendency of or following the separation transaction, diversion of management time on separation transaction-related issues, retention of existing management team members, the reaction of customers and other parties to the separation transaction, the qualification of the separation transaction as a tax-free transaction for Canadian and/or U.S. federal income tax purposes (including whether or not an advance ruling from the Canada Revenue Agency will be sought or obtained), the ability of the Company and the separated entity to satisfy the conditions required to maintain the tax-free status of the separation transaction (some of which are beyond their control), the potential dissynergy costs resulting from the separation transaction, the impact of the separation transaction on relationships with customers, suppliers, employees and other business counterparties, general economic conditions, conditions in the markets the Company is engaged in, behavior of customers, suppliers and competitors, technological developments, as well as legal and regulatory rules affecting the Company&#8217;s business. In particular, the Company can offer no assurance that any IPO or separation will occur at all, or that any such transaction will occur on the timelines anticipated by the Company;</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">with respect to the proposed IPO of the Company&#8217;s Solta aesthetic medical device business, the risks and uncertainties include, but are not limited to, risks relating to the expected timing of completion of such transaction (including the Company&#8217;s expectation that it will launch such IPO when financial market conditions are favorable, subject to receipt of regulatory, stock exchange and other approvals) and the Company&#8217;s ability to complete such transaction, that market or other conditions are no longer favorable to completing the transaction on a timely basis or at all, the receipt of (or failure to receive) any shareholder, stock exchange, regulatory and other approvals required in connection with the transaction and the timing of receipt of such approvals, business disruption during the pendency of or following such transaction, diversion of management time on transaction-related issues, retention of Solta aesthetic medical device management team members, the reaction of customers and other parties to such transaction, the impact of such transaction on relationships with customers, suppliers, employees and other business counterparties, and other events that could adversely impact the completion of such transaction, including industry or economic conditions outside of Bausch Health&#8217;s control. In particular, the Company can offer no assurance that any IPO will occur at all, or that any such transaction will occur on the timelines anticipated by the Company;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of legal and governmental proceedings, investigations and information requests relating to, among other matters, our past distribution, marketing, pricing, disclosure and accounting practices (including with respect to our former relationship with Philidor Rx Services, LLC ("Philidor")), including a number of pending non-class securities litigations (including certain pending opt-out actions in the U.S. related to the previously settled securities class action (which remains subject to an objector's appeal of the Court's final approval order) and certain opt-out actions in Canada relating to the recently settled class action in Canada), certain pending lawsuits and other claims, investigations or proceedings that may be initiated or that may be asserted;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">potential additional litigation and regulatory investigations (and any costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom), negative publicity and reputational harm on our Company, products and business that may result from the past and ongoing public scrutiny of our past distribution, marketing, pricing, disclosure and accounting practices and from our former relationship with Philidor;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the past and ongoing scrutiny of our legacy business practices, including with respect to pricing, and any pricing controls or price adjustments that may be sought or imposed on our products as a result thereof; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">pricing decisions that we have implemented, or may in the future elect to implement, such as the Patient Access and Pricing Committee&#8217;s historic practice of limiting the average annual price increase for our branded prescription pharmaceutical products to single digits, or any future pricing actions we may take in 2022 or beyond following review by our Patient Access and Pricing Committee (which is responsible for the pricing of our drugs);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">legislative or policy efforts, including those that may be introduced and passed by the U.S. Congress, designed to reduce patient out-of-pocket costs for medicines, which could result in new mandatory rebates and discounts or other pricing restrictions, controls or regulations (including mandatory price reductions);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing oversight and review of our products and facilities by regulatory and governmental agencies, including periodic audits by the U.S.&#160;Food and Drug Administration (the "FDA") and equivalent agencies outside of the U.S. and the results thereof;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">actions by the FDA or other regulatory authorities with respect to our products or facilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with the legal and regulatory requirements of our marketed products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our substantial debt (and potential additional future indebtedness) and current and future debt service obligations, our ability to reduce our outstanding debt levels and the resulting impact on our financial condition, cash flows and results of operations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with the financial and other covenants contained in our Restated Credit Agreement, senior notes indentures, 2023 Revolving Credit Facility (as defined below) and other current or future credit and/or debt agreements and the limitations, restrictions and prohibitions such covenants impose or may impose on the way we conduct our business, including prohibitions on incurring additional debt if certain financial covenants are not met, limitations on the amount of additional obligations we are able to incur pursuant to other covenants, our ability to draw under our 2023 Revolving Credit Facility and restrictions on our ability to make certain investments and other restricted payments;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">any default under the terms of our senior notes indentures or Restated Credit Agreement (and other current or future credit and/or debt agreements) and our ability, if any, to cure or obtain waivers of such default;</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">any downgrade by rating agencies in our credit ratings, which may impact, among other things, our ability to raise debt and the cost of capital for additional debt issuances;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">any reductions in, or changes in the assumptions used in, our forecasts for fiscal year 2022 or beyond, including as a result of the impacts of the COVID-19 pandemic on our business and operations, which could lead to, among other things: (i) a failure to meet the financial and/or other covenants contained in our Restated Credit Agreement and/or senior notes indentures (and other current or future credit and/or debt agreements) and/or (ii) impairment in the goodwill associated with certain of our reporting units or impairment charges related to certain of our products or other intangible assets, which impairments could be material;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the assumptions used in connection with our impairment analyses or assessments, which would lead to a change in such impairment analyses and assessments and which could result in an impairment in the goodwill associated with any of our reporting units or impairment charges related to certain of our products or other intangible assets;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the uncertainties associated with the acquisition and launch of new products, assets and businesses, including, but not limited to, our ability to provide the time, resources, expertise and funds required for the commercial launch of new products, the acceptance and demand for new products, and the impact of competitive products and&#160;pricing, which could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or inability to extend the profitable life of our products, including through line extensions and other life-cycle programs;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain, motivate and recruit executives and other key&#160;employees;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to implement effective succession planning for our executives and key employees;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to stabilize and reposition our Ortho Dermatologics business to generate additional value, including the success of recently launched products  and the approval of pipeline products (and the timing of such approvals);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated revenues for our products, including changes in anticipated marketing spend on such products and launch of competing products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated market acceptance for our products, including acceptance of the pricing, effectiveness of promotional efforts, reputation of our products and launch of competing products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the challenges and difficulties associated with managing a large complex business, which has, in the past, grown rapidly;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to compete against companies that are larger and have greater financial, technical and human resources than we do, as well as other competitive factors, such as technological advances achieved, patents obtained and new products introduced by our competitors;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively operate and grow our businesses in light of the challenges that the Company has faced and market conditions, including with respect to its substantial debt, pending investigations and legal proceedings, scrutiny of our past pricing and other practices, limitations on the way we conduct business imposed by the covenants contained in our Restated Credit Agreement, senior notes indentures and the agreements governing our other indebtedness, and the impacts of the COVID-19 pandemic;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our products are reimbursed by government authorities, pharmacy benefit managers ("PBMs") and other third-party payors; the impact our distribution, pricing and other practices may have on the decisions of such government authorities, PBMs and other third-party payors to reimburse our products; and the impact of obtaining or maintaining such reimbursement on the price and sales of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the inclusion of our products on formularies or our ability to achieve favorable formulary status, as well as the impact on the price and sales of our products in connection therewith;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the consolidation of wholesalers, retail drug chains and other customer groups and the impact of such industry consolidation on our business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain strong relationships with physicians and other healthcare professionals;</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">our eligibility for benefits under tax treaties and the continued availability of low effective tax rates for the business profits of certain of our subsidiaries;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of the Organisation for Economic Co-operation and Development inclusive framework on Base Erosion and Profit Shifting, including the global minimum corporate tax rate, by the countries in which we operate; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of any audits by taxation authorities, which outcomes may differ from the estimates and assumptions that we may use in determining our consolidated tax provisions and accruals;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the actions of our third-party partners or service providers of research, development, manufacturing, marketing, distribution or other services, including their compliance with applicable laws and contracts, which actions may be beyond our control or influence, and the impact of such actions on our Company;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risks associated with the international scope of our operations, including our presence in emerging markets and the challenges we face when entering and operating in new and different geographic markets (including the challenges created by new and different regulatory regimes in such countries and the need to comply with applicable anti-bribery and economic sanctions laws and regulations);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">adverse global economic conditions and credit markets and foreign currency exchange uncertainty and volatility in certain of the countries in which we do&#160;business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the trade conflict between the United States and China;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the potential conflict between Russia and Ukraine and any restrictive actions that may be taken by the U.S. and/or other countries in response thereto, such as sanctions or export controls;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain and license sufficient intellectual property rights over our products and enforce and defend against challenges to such intellectual property (such as in connection with the filing by Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;) of its Abbreviated New Drug Application (&#8220;ANDA&#8221;) for Xifaxan&#174; (rifaximin) 550 mg tablets and the Company&#8217;s related lawsuit filed against Norwich in connection therewith);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of generic, biosimilar or other competitors of our branded products and other products, including the introduction of products that compete against our products that do not have patent or data exclusivity rights;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, finance, acquire, close and integrate acquisition targets successfully and on a timely basis and the difficulties, challenges, time and resources associated with the integration of acquired companies, businesses and products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">any divestitures of our assets or businesses and our ability to successfully complete any such divestitures on commercially reasonable terms and on a timely basis, or at all, and the impact of any such divestitures on our Company, including the reduction in the size or scope of our business or market share, loss of revenue, any loss on sale, including any resultant impairments of goodwill or other assets, or any adverse tax consequences suffered as a result of any such divestitures;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of pending or future legal and governmental proceedings, arbitrations, investigations, subpoenas, tax and other regulatory audits, examinations, reviews and regulatory proceedings against us or relating to us and settlements thereof;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to negotiate the terms of or obtain court approval for the settlement of certain legal and regulatory proceedings;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain components, raw materials or finished products supplied by third&#160;parties (some of which may be single-sourced) and other manufacturing and related supply difficulties, interruptions and delays;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the disruption of delivery of our products and the routine flow of manufactured goods;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">economic factors over which the Company has no control, including changes in inflation, interest rates, foreign currency rates, and the potential effect of such factors on revenues, expenses and resulting margins;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">interest rate risks associated with our floating rate debt borrowings;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively distribute our products and the effectiveness and success of our distribution arrangements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively promote our own products and those of our co-promotion partners;</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vi</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our fulfillment arrangements with Walgreen Co. including market acceptance of, or market reaction to, such arrangements (including by customers, doctors, patients, PBMs, third-party payors and governmental agencies), and the continued compliance of such arrangements with applicable laws;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to secure and maintain third-party research, development, manufacturing, licensing, marketing or distribution arrangements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that our products could cause, or be alleged to cause, personal injury and adverse effects, leading to potential lawsuits, product liability claims and damages and/or recalls or withdrawals of products from the&#160;market;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the mandatory or voluntary recall or withdrawal of our products from the market and the costs associated therewith;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of, and our ability to obtain and maintain, adequate insurance coverage and/or our ability to cover or insure against the total amount of the claims and liabilities we face, whether through third-party insurance or self-insurance;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our indemnity agreements, which may result in an obligation to indemnify or reimburse the relevant counterparty, which amounts may be material;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the difficulty in predicting the expense, timing and outcome within our legal and regulatory environment, including with respect to approvals by the FDA, Health Canada, European Medicines Agency ("EMA") and similar agencies in other countries, legal and regulatory proceedings and settlements thereof, the protection afforded by our patents and other intellectual and proprietary property, successful generic challenges to our products and infringement or alleged infringement of the intellectual property of&#160;others;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the results of continuing safety and efficacy studies by industry and government agencies;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the success of preclinical and clinical trials for our drug development pipeline or delays in clinical trials that adversely impact the timely commercialization of our pipeline products, as well as other factors impacting the commercial success of our products, which could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties around the successful improvement and modification of our existing products and development of new products, which may require significant expenditures and efforts;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">the results of management reviews of our research and development portfolio (including following the receipt of clinical results or feedback from the FDA or other regulatory authorities), which could result in terminations of specific projects which, in turn, could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the seasonality of sales of certain of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">declines in the pricing and sales volume of certain of our products that are distributed or marketed by third parties, over which we have no or limited control;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">compliance by the Company or our third-party partners and service providers (over whom we may have limited influence), or the failure of our Company or these third parties to comply, with health care &#8220;fraud and abuse&#8221; laws and other extensive regulation of our marketing, promotional and business practices (including with respect to pricing), worldwide anti-bribery laws (including the U.S. Foreign Corrupt Practices Act and the Canadian Corruption of Foreign Public Officials Act), worldwide economic sanctions and/or export laws, worldwide environmental laws and regulation and privacy and security regulations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impacts of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 and potential amendment thereof and other legislative and regulatory health care reforms in the countries in which we operate, including with respect to recent government inquiries on pricing;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any changes in or reforms to the legislation, laws, rules, regulation and guidance that apply to the Company and its businesses and products or the enactment of any new or proposed legislation, laws, rules, regulations or guidance that will impact or apply to the Company or its businesses or products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of changes in federal laws and policy that may be undertaken under the Biden administration;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">illegal distribution or sale of counterfeit versions of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">interruptions, breakdowns or breaches in our information technology systems; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risks in Item 1A. &#8220;Risk Factors&#8221; in this Form 10-K.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found elsewhere in this Form 10-K, under Item 1A. "Risk Factors" and in the Company's other filings with the U.S.&#160;Securities and Exchange Commission (the&#160;&#8220;SEC&#8221;) and the Canadian Securities Administrators (the &#8220;CSA&#8221;). When relying on our forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. These forward-looking statements speak only as of the date made. We undertake no obligation to update or revise any of these forward-looking statements to reflect events or circumstances after the date of this Form&#160;10-K or&#160;to reflect actual outcomes, except as required by law. We caution that, as it is not possible to predict or identify all relevant factors that may impact forward-looking statements, the foregoing list of important factors that may affect future results is not exhaustive and should not be considered a complete statement of all potential risks and uncertainties.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">viii</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_19"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Business</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_22"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Introduction</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch Health Companies Inc. is a global company whose mission is to improve people&#8217;s lives with our health care products. We develop, manufacture and market, primarily in the therapeutic areas of eye-health, gastroenterology (&#8220;GI&#8221;) and dermatology, a broad range of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) over-the-counter (&#8220;OTC&#8221;) products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in approximately 100 countries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of products falls into five operating and reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International Rx, (iv) Ortho Dermatologics and (v) Diversified Products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%;padding-left:12.53pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">consists of global sales of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmic Pharmaceuticals products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of GI products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International Rx segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales, with the exception of sales of Bausch +Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Ortho Dermatologics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological) products and (ii) global sales of Solta aesthetic medical devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of our reportable segments, see the discussion in Item 1. "Business &#8212; Segment Information" and Note 22, "SEGMENT INFORMATION" to our audited Consolidated Financial Statements for further details on these reportable segments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, we announced our plan to separate our eye-health business into an independent publicly traded entity, Bausch + Lomb Corporation ("Bausch + Lomb") from the remainder of Bausch Health Companies Inc. (the "B+L Separation"). On August 3, 2021, we announced our plan to conduct an initial public offering ("IPO") of our aesthetic medical device business, Solta Medical ("Solta") (the "Solta IPO"). We believe separating our pharmaceutical, eye-health and aesthetics medical device businesses is an opportunity to unlock value across our portfolio of assets by creating three highly attractive but dissimilar businesses. Since making these announcements, we began executing on those plans and, at the end of 2021, had substantially completed the internal objectives to facilitate the IPOs and related separation of these businesses.  We continue to monitor market conditions and aim to launch the Bausch + Lomb IPO (the "B+L IPO") and the Solta IPO when financial market conditions are favorable (subject to receipt of regulatory, stock exchange and other approvals). However, there can be no assurance as to when we will complete either IPO, if at all. Until such time, we continue to manage these businesses along with our pharmaceutical portfolio of gastrointestinal, dermatology, neurology and other therapeutics, with our continued commitment to bring out additional value for our shareholders. Following the B+L IPO, we expect to complete the separation of Bausch + Lomb after the expiry of customary lockups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to the receipt of applicable shareholder and other necessary approvals and market conditions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to market conditions and receipt of regulatory, stock exchange and other approvals, we expect to launch the B+L IPO and the Solta IPO sometime in the first half of 2022.  Nothing in this Form 10-K shall constitute an offer to sell or the solicitation of an offer to buy any securities of the Bausch + Lomb or Solta Medical entities.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_25"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to closely monitor the impacts of the COVID-19 pandemic and related responses from governments and private sector participants on the Company, our customers, supply chain, third-party suppliers, project development timelines, costs, revenue, margins, liquidity and financial condition and our planned actions and responses to this pandemic. We believe we have responded quickly to the human and commercial challenges brought on by the COVID-19 pandemic and that our early actions have, so far, enabled us to keep our employees safe and our supply lines largely intact and we believe these actions have laid the foundation for us to work our way through the uncertainties to come. To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing. Although our revenues were adversely affected by the impacts of the COVID-19 pandemic, particularly during the second quarter of 2020, our revenues returned to pre-pandemic </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">levels for many of our businesses and geographies in 2021 and, at the current pace of recovery, we expect the COVID-19 pandemic to have a minimal impact on the remaining businesses and geographies in 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212;&#160;Overview &#8212;&#160;Impacts of COVID-19&#8221; of this Form 10-K for additional information on the impacts of the COVID-19 pandemic and Item&#160;1A. &#8220;Risk Factors &#8212;&#160;Risk Relating to COVID-19&#8221; of this Form 10-K for additional risks relating to the COVID-19 pandemic.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_28"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Strategy </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to focus our business on core therapeutic classes and geographies that offer attractive growth opportunities. Within our chosen therapeutic classes, we prioritize durable products which we believe have the potential for strong operating margins and evidence of growth opportunities. We believe this strategy has reduced complexity in our operations and maximizes the value of our: (i) eye-health, (ii) GI and (iii) dermatology businesses, which collectively represent a substantial portion of our revenues. We have found and continue to believe there is significant opportunity in each of these businesses and we believe our existing portfolio, commercial footprint and pipeline of product development projects position us to successfully compete in these markets and provide us with the greatest opportunity to build value for our shareholders.  </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to prepare for the separation of our eye-health and medical device aesthetics businesses, we remain focused on expanding and deepening our geographic reach of all our businesses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to search out new markets where our portfolio of products would expect to flourish, while continually revisiting our existing geographies where our portfolio of pharmaceuticals would help fill unmet needs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we prepare for the separations of the Bausch + Lomb and Solta businesses, we are looking to right size our presence in these geographies, make additional investments in sales force and advertising, to create a greater presence in these geographies where we can capitalize on our existing and future product portfolios to meet unmet needs and generate future revenue streams and value for our company. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have a well-established diversified product portfolio across all our businesses that provides a sustainable revenue stream to fund our operations. Our continued success is dependent upon our ability to continually refresh our pipeline and bring new product solutions to the market that meet changing demands and replace other products that have lost momentum.  We have a robust pipeline that we believe not only provides for the next generation of our existing products, but is also poised to bring new and innovative solutions to market.  Our R&amp;D organization focuses on the development of products through clinical trials and, as of December&#160;31, 2021, included approximately 1,300 dedicated R&amp;D and quality assurance employees in 25 R&amp;D facilities.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have focused our R&amp;D to advance development programs that we believe will drive growth in our core businesses, while creating efficiencies in our R&amp;D efforts and expenses. Although we primarily rely on our R&amp;D organization to build-out and refresh our product portfolio, to supplement those efforts, we continually seek out opportunities, such as co-promotions, licensing agreements and strategic acquisitions, to leverage our commercial footprint, particularly our sales force, by strategically aligning ourselves with other innovative product solutions that, when coupled with our existing product portfolio, address specific needs in the market. See Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212;&#160;Overview &#8212;&#160;Focus on Core Businesses&#8221; of this Form&#160;10-K.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_31"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues for 2021, 2020 and 2019 were $8,434 million, $8,027 million and $8,601 million, respectively. We have approximately 1,200&#160;products in our portfolio of products, which fall into five operating and reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International Rx, (iv) Ortho Dermatologics and (v) Diversified Products.  Segment revenues for the years 2021, 2020 and 2019 were as&#160;follows:</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,778&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Rx</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,601&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comparative segment information for 2021, 2020 and 2019 is further presented in Note 22, "SEGMENT INFORMATION" to our audited Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bausch + Lomb</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Bausch + Lomb segment includes our global Bausch + Lomb eye-health business. Our global Bausch + Lomb eye-health business includes our Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmic Pharmaceuticals products, which in aggregate accounted for approximately 45%, 42% and 44% of our Company's revenues for 2021, 2020 and 2019, respectively.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, on August 6, 2020, we announced our plan to separate our eye-health business into an independent publicly traded entity, Bausch + Lomb Corporation, from the remainder of Bausch Health Companies Inc.  Since making that announcement, we have been executing on this plan and, at the end of 2021, had substantially completed the internal objectives to facilitate the B+L Separation.  As of the date of this filing, we continue to execute on our plan for the B+L Separation and aim to launch the B+L IPO when market conditions are favorable and subject to receipt of regulatory, stock exchange and other approvals. Following the B+L IPO, we expect to complete the B+L Separation after the expiry of customary lockups related to the B+L IPO and the achievement of targeted debt leverage ratios, subject to receipt of applicable shareholder and other necessary approvals and market conditions. Nothing in this Form 10-K shall constitute an offer to sell or the solicitation of an offer to buy any securities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Bausch + Lomb business is a fully integrated eye-health business, which we believe is critical to maintaining and further developing its position in the global eye-health market.  We maintain a fully integrated eye care portfolio of established lines of contact lenses, intraocular lenses and other medical devices, surgical systems and devices, vitamin and mineral supplements, lens care products, prescription eye-medications and other consumer products, to holistically approach solving eye-health problems and keep us in a position to compete in all areas of the eye-health market. Since our beginnings in 1853 as an optical goods shop in Rochester, New York, we have remained focused on advancing eye-health for people all over the world. As part of our longstanding commitment to eye care professionals and the patients they serve, we invest in physician training, patient and customer education, disease prevention and other initiatives through both traditional and digital platforms to continue to advance eye-health. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our global Bausch + Lomb business strategy, we continually look for key trends in the eye-health market to meet changing consumer/patient needs and identify areas for investment and growth.  We believe that the gap between evolving eye-health needs and effective treatments represents a significant growth opportunity, and we believe that we have the ability to increase demand for our products by educating customers and capturing the rising consumerism in our available markets. For example, it is estimated that more than 17 million people suffer from visual impairment in China, of which 8 million are blind, yet only 450 cataract surgeries are performed for every 1 million people each year in China. Myopia represents another significant growth opportunity.  We estimate that myopia affects approximately 25 million children in the United States, and 2.9 billion people globally had some degree of myopia in 2020.  According to the World Health Organization, this population is expected to rise globally by more than 60% between 2020 and 2050. To increase adoption of our products, we intend to continue our focus on patient, consumer and eye care professional education. In addition, we believe that we can grow our market opportunity by expanding into emerging therapeutic areas and researching and securing other indications for our products. We intend to leverage our global regulatory and commercial capabilities to accelerate product approvals and launches across current and future markets.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently our principal products in the eye-health business include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consumer</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Consumer eye care business consists of contact lens care products, OTC eye drops and eye vitamins. Our eye vitamin products include our patented formulas and mineral supplements that address various conditions including eye allergies, conjunctivitis, dry eye, redness and relief. Key Consumer eye care brands include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PreserVision</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS 2 is a patented eye vitamin formula that contains the exact nutrient formula recommended by the National Eye Institute for people with moderate to advanced age-related macular degeneration ("AMD") following the landmark AREDS 2 clinical study.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ocuvite</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is a vitamin and mineral supplement for the eye that contains lutein and zeaxanthin (antioxidant carotenoids), a nutrient that supports macular health by helping filter harmful blue light.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biotrue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> multi-purpose solution helps prevent certain tear proteins from denaturing and fights germs for healthy contact lens wear. Biotrue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> multi-purpose solution uses a lubricant found in eyes and is pH balanced to match healthy tears.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb Renu</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced Formula multi-purpose solution was launched in 2017 and is a novel soft and silicone hydrogel contact lenses solution that makes use of three disinfectants and two moisture agents.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Boston</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> solution is a specialty cleansing solution design for gas permeable contact lenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Artelac</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an eye moisturizer eye drop which enables quick wetting of dry eyes. Artelac</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contains hyaluronic Acid (sodium hyaluronate), a natural lubricant which instantly refreshes and hydrates the eyes. Artelac</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is particularly suitable for alleviating mild symptoms of dry eyes and can also be used to moisten hard contact lenses while being worn.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LUMIFY</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate ophthalmic solution, 0.025%) is an OTC eye drop developed as an ocular redness reliever. LUMIFY</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;text-decoration:line-through;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched in the U.S. in May 2018.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vision Care</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Vision Care portfolio includes contact lenses that span the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses, and contact lenses that are indicated for therapeutic use and that can also provide optical correction during healing, if required. Key Vision Care brands include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb INFUSE</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (known as BAUSCH + LOMB ULTRA</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY in Canada, Australia and Hong Kong), a silicone hydrogel daily disposable contact lens designed with a next generation material infused with ProBalance Technology</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to help maintain ocular surface homeostasis and help reduce symptoms of contact lens dryness. Bausch + Lomb INFUSE</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched in the United States in August 2020 and BAUSCH + LOMB ULTRA</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY was launched in Canada, Australia, and Hong Kong in November 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">AQUALOX</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan, a silicone hydrogel daily disposable contact lens designed to provide clear vision throughout the day. Product validation was completed in June 2018 and SiHy Daily AQUALOX</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched in Japan in September 2018.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb ULTRA</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a silicone hydrogel frequent replacement contact lens for patients with myopia or hyperopia that uses our proprietary MoistureSeal</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology, which allows the contact lens to retain 95% of moisture after 16 hours of wear, limiting lens dryness and resulting symptoms.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb ULTRA</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for Astigmatism, a monthly planned replacement contact lens for astigmatic patients developed using our proprietary MoistureSeal</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology. Bausch + Lomb ULTRA</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for Astigmatism lenses integrate an OpticAlign</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> design engineered for lens stability and to promote a successful wearing experience for the astigmatic patient.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb ULTRA</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for Presbyopia, a monthly planned replacement contact lens for presbyopic patients developed using the Company&#8217;s proprietary MoistureSeal</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology. Bausch + Lomb ULTRA</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for Presbyopia lenses integrate our 3-Zone Progressive&#8482; multifocal design with seamless transitions between near, far and intermediate distances for clear, comfortable vision across all distances.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb ULTRA</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> multifocal for astigmatism, a monthly planned replacement multifocal toric lens combining our 3-Zone Progressive</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> multifocal design with the stability of its OpticAlign</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> toric design to address the lifestyle and vision needs of patients with both astigmatism and presbyopia.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biotrue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday daily disposable contact lenses for patients with myopia or hyperopia, which are made of a unique material inspired by the natural biology of the eye and feature Surface Active Technology</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a patented dehydration barrier. The lens contains 78% water, more moisture than any other soft contact lens and the same water content as the cornea, and maintains nearly 100% of its moisture for up to 16 hours.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biotrue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday for Astigmatism, a daily disposable contact lens for astigmatic patients developed using the Company&#8217;s proprietary Surface Active Technology</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Biotrue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday for Astigmatism includes evolved peri-ballast geometry designed to work with natural blink patterns to deliver stability, clear vision and comfort for the astigmatic patient.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biotrue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday for Presbyopia daily disposable contact lens for presbyopic patients developed using the Company&#8217;s proprietary Surface Active Technology. Biotrue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday for Presbyopia integrates the Company&#8217;s 3-Zone Progressive&#8482; design with seamless transitions between near, far and intermediate distances for clear, comfortable vision across all distances.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PureVision</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a silicone hydrogel frequent replacement contact lens using AerGel</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology lens material to allow natural levels of oxygen to reach the eye as well as resist protein buildup. The lens also incorporates an aspheric optical design that reduces spherical aberration.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SofLens</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Daily Disposable Contact Lenses, which use ComfortMoist</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technology (a combination of thin lens design and moisture-rich packaging solution) and High Definition Optics&#8482; which is an aspheric design that reduces spherical aberration over a range of powers, especially in low light.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ophthalmic Pharmaceuticals</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Ophthalmic Pharmaceuticals business consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Key ophthalmic pharmaceutical brands include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vyzulta</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (latanoprostene bunod ophthalmic solution, 0.024%) is an intraocular pressure lowering single-agent eye drop with dual activity dosed once daily for patients with open angle glaucoma or ocular hypertension and was launched in the U.S. in December 2017.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lotemax</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SM (loteprednol etabonate ophthalmic gel 0.38%), a new gel drop formulation of loteprednol etabonate, which was designed with novel SubMicron (SM) technology for efficient penetration to key ocular tissues at a low preservative (BAK) level (3.5-10) and a pH close to human tears, indicated for the treatment of postoperative inflammation and pain following ocular surgery.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lotemax</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Suspension (loteprednol etabonate ophthalmic suspension, 0.5%) is a topical corticosteroid indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and for the treatment of post-operative inflammation following ocular surgery.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lotemax</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel is a topical corticosteroid indicated for the treatment of inflammation and pain following ocular surgery. This formulation is a technology that allows the drug to adhere to the ocular surface and offers dose uniformity, which eliminates the need to shake the product in order to ensure the drug is in suspension. The product contains a low concentration of preservative and two known moisturizers. We also have an ointment formulation (Lotemax</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Ointment) without any preservatives.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Alrex</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (loteprednol etabonate ophthalmic suspension, 0.2%) is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Besivance</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (besifloxacin ophthalmic suspension, 0.6%) is the first and only chloro-fluoroquinolone indicated for the treatment of bacterial conjunctivitis. It is a new generation potent quinolone antibiotic specifically designed for the ophthalmic use and has no systemic formulation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Zylet</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension) indicated for the steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Minims</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> portfolio including ocular anaesthetics, corticosteroids, mydriatics, cycloplegics, artificial tears, irrigating solutions and diagnostic stain products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Prolensa</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-inflammatory drug (NSAID) indicated to treat inflammation and reduce eye pain in patients after cataract surgery. In international markets, we market Yellox</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (bromfenac ophthalmic solution, 0.9%) which is indicated for the treatment of postoperative ocular inflammation following cataract extraction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Surgical</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Surgical business consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes intraocular lenses ("IOLs") and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Key Surgical brands include: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vitreoretinal Surgery</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Stellaris</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> PC, a combined system with vitreoretinal and cataract surgery capability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cataract Surgery and Laser Systems</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">The Stellaris Elite</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vision enhancement system is our next generation phacoemulsification cataract platform, Stellaris Elite</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the first phacoemulsification platform on the market to offer Adaptive Fluidics</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which combines aspiration control with predictive infusion management to create a responsive and controlled surgical environment for efficient cataract lens removal. Our Stellaris Elite</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vision enhancement system was launched in the United States in 2017 and internationally in 2018.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">VICTUS</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> femtosecond laser for cataract, corneal and refractive surgery, which delivers multi- mode versatility for cataract and corneal procedures on a single platform. This single laser platform enables surgeons to perform capsulotomies, fragmentation, arcuate incisions, corneal incisions, and LASIK flaps.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Teneo VICTUS</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> femtosecond laser for cataract, corneal and refractive surgery and Teneo</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Excimer Laser for refractive surgery.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Excimer Laser for refractive surgery.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intraocular Lenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">A portfolio of ophthalmic surgical IOLs, including implantable IOLs such as Akreos</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, enVista</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Crystalens</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Trulign</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Surgical Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Storz Ophthalmic instruments are our suite of surgical instruments which include precision microsurgical instruments, diamond knives and single-use surgical instruments, as well as instruments customized for individual surgeons under the Storz Ophthalmic Instrument brand, including Synergetics</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and surgical equipment for cataract, refractive and vitreoretinal surgery.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Salix</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment consists of sales in the U.S. of GI products and includes our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product. We have been making investments in our Salix business since 2017, including: (i) hiring 200 trained and experienced sales force representatives to expand the commercial field force for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (ii) increasing the focus on the development of next generation formulations of our Salix products to address new indications, (iii) completing the strategic acquisition of certain assets of Synergy Pharmaceuticals Inc. (&#8220;Synergy&#8221;), which included the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, and (iv) increasing the number of sales force representatives for Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, we have entered into licensing agreements for investigational products, which, once developed and if approved by the FDA, will be new treatments for certain GI and liver diseases and we anticipate will contribute to our future growth. Each of these opportunities potentially provides us with the ability to expand our GI portfolio and allows us to leverage our existing GI sales force, supply channel and distribution channel.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently our principal products in the Salix segment (including products of our third-party co-promotion partners) include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which includes: (i) tablets indicated for the treatment of irritable bowel syndrome with diarrhea ("IBS-D") in adults and for the reduction in risk of overt hepatic encephalopathy recurrence in adults and (ii) tablets indicated for </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the treatment of travelers&#8217; diarrhea caused by noninvasive strains of Escherichia coli in patients 12 years of age and older. Our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product accounted for revenues of $1,644 million, $1,482 million and $1,452 million for 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(metformin hydrochloride) extended release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(methylnaltrexone) is given to adults who use narcotic medicine to treat severe chronic pain that is not caused by cancer to prevent constipation without reducing the pain-relieving effects of the narcotic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) is a once-daily tablet for adults with chronic idiopathic constipation, or CIC, and irritable bowel syndrome with constipation, or IBS-C.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Rx</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our International Rx business, with the exception of our Solta products, includes sales in Canada, Europe, Asia, Australia, Latin America, Africa and the Middle East of branded pharmaceutical products, branded generic pharmaceutical products and OTC products, which in aggregate accounted for approximately 14%, 15% and 13% of our Company's revenues for 2021, 2020 and 2019, respectively.   Our principal products in this segment include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bisocard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (bisoprolol fumarate) is an orally administered tablet dosed once daily for patients with hypertension, angina pectoris or heart failure and is a leading brand in Poland.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Thrombo ASS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (gastroprotective coated form of acetylsalicylic acid 50mg and 100mg) is an antithrombotic agent dosed once daily for secondary prophylaxis of thrombotic complications after such events as a stroke or heart attack. Thrombo ASS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a leading brand in Russia.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contrave</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/Mysimba</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a fixed-dose combination prolonged-release tablet for the treatment of obesity. Used alongside diet and exercise, it is designed to help manage weight in adults who are obese or overweight. The formulation is designed to initiate weight loss and sustain it over a longer period of time by switching off natural compensatory mechanisms involved in the typical weight loss plateau stage. Contrave</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> / Mysimba</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is commercialized in Canada, Greece, and Central Eastern Europe.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(efinaconazole 10% topical solution) is a topical azole approved for the treatment of onychomycosis of the toenails (toenail fungus). Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is commercialized in Canada (the only market outside the U.S.).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ivexterm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Ivermectin 6 mg tablets) is an antiparasitic drug, which is commercialized in Mexico and Central America, and is currently under investigational studies for treating COVID-19 patients.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Espaven</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Dimethicone tablets, drops, suspension) is a complete line of gastrointestinal treatments for diverse digestive indications such as: antiflatulence, dyspepsia, absolute or relative enzyme deficiency, steatorrhea, irritable colon syndrome, pancreatic insufficiency and poor fat digestion. Espaven</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is commercialized primarily in Mexico and South America.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Bedoyecta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.96pt;font-weight:400;line-height:120%">i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s a multivitamin that is used to obtain sufficient energy and have optimal performance during the day, by avoiding deficiencies of the nutrients that the body requires to function properly.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ortho Dermatologics</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ortho Dermatologics segment consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological products) and (ii) global sales of Solta aesthetic medical devices. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ortho Dermatologics business is our medical dermatology business dedicated to the treatment of a range of therapeutic areas, including aesthetics, psoriasis, actinic keratosis, acne, atopic dermatitis, onychomycosis and other dermatoses. As part of our business strategy for the Ortho Dermatologics segment, we continue to look for investments to build out our product portfolios, where we see the greatest opportunities, with a focus on topical gel and lotion products over injectable biologics. We continue to support the use of injectable biologics; however, we believe some patients prefer topical products as an alternative to injectable biologics.  Further, as topical products can, in many cases, defer the use of injectable biologics that often come with associated risk/benefit profiles, a topical product is usually readily adopted by payors, is less expensive and can be more cost-effective than injectable biologics. Therefore, we believe topical products represent alternative treatments for physicians, payors and patients, and as the preferred choice of treatment, have the potential to drive greater volumes, generate better margins and potentially be a key contributing factor of our Ortho Dermatologics business. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently our principal products in the U.S. Ortho Dermatologics business include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(efinaconazole 10% topical solution) is a topical azole approved for the treatment of onychomycosis of the toenails (toenail fungus).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(tazarotene) Lotion, 0.045% is an acne product containing lower concentration of tazarotene in a lotion form to help reduce irritation while maintaining efficacy and was launched in the U.S. in June 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched in the U.S. in June 2019 and is the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene for the treatment of moderate-to-severe plaque psoriasis in adults.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Siliq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched in the U.S. in 2017 and is an IL-17 receptor blocker monoclonal antibody for patients with moderate-to-severe plaque psoriasis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Targretin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (bexarotene) capsules and gel are prescription medicines used to treat the skin problems arising from the disease cutaneous T-cell lymphoma, or CTCL, in patients who have not responded well to other treatments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched in the U.S. in November 2018 and is a novel product that contains a unique, lower concentration of halobetasol propionate for the treatment of moderate-to-severe psoriasis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An acne franchise, which includes Altreno</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tretinoin 0.05%), launched in the U.S. in October 2018 and is a lotion approved for the topical treatment of acne vulgaris in patients 9 years of age and older, and Solodyn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a prescription oral antibiotic approved to treat only the red, pus-filled pimples of moderate to severe acne in patients 12 years of age and older, as well as Retin-A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Clindagel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Onexton</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel, a fixed combination 1.2% clindamycin phosphate and 3.75% benzoyl peroxide medication for the once-daily treatment of comedonal (non-inflammatory) and inflammatory acne in patients 12 years of age and older.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Solta business is dedicated to the development of innovative treatment technologies that provide proven and effective aesthetic medical and therapeutic benefits to consumers. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2021, we announced our plan to conduct an IPO of our aesthetic medical device business, Solta Medical.   Since making that announcement, we have been executing on this plan and, at the end of 2021, had substantially completed the internal objectives to facilitate the IPO of Solta Medical.  As of the date of this filing, we continue to monitor market conditions and aim to launch the Solta IPO when market conditions are favorable and subject to receipt of regulatory, stock exchange and other approvals. Nothing in this Form 10-K shall constitute an offer to sell or the solicitation of an offer to buy any securities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global Solta revenues were $308&#160;million, $253&#160;million and $194&#160;million for 2021, 2020 and 2019, respectively. The increase in revenue is primarily attributable to Next Generation Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a fourth-generation non-invasive treatment option using a radiofrequency platform designed to optimize key functional characteristics and improve patient outcomes. Next Generation Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched in the U.S., Hong Kong, Japan, Korea, Chinese Taipei, Philippines, Singapore, Indonesia, Malaysia, China, Thailand, Vietnam, Australia and various parts of Europe as part of our Solta aesthetic medical devices portfolio. These launches have been successful as Next Generation Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues for 2021, 2020 and 2019 were $154 million, $142 million and $77 million, respectively. We plan to continue to expand into other regions, paced by country-specific regulatory registrations.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently our principal products in the Solta business include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Thermage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a non-invasive radiofrequency treatment that can smooth, tighten and contour skin for an overall younger-looking appearance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fraxel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a treatment that improves tone, texture and radiance for aging, sun damaged or scarred skin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a&#160;laser treatment that can help prevent the visible signs of aging and address the overall effects time and the environment can have on skin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">VASERlipo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for minimally-invasive aesthetic body contouring that yields dramatic results with less pain and downtime of traditional liposuction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversified Products </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products. The Company utilizes the Diversified Products segment to extend the long-term cash flows from a number of assets that are expected to decline over time due to the loss of exclusivity, by launching and selling authorized generic versions of certain branded assets. Our principal products in this segment include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmaceutical</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Wellbutrin XL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is an extended release formulation of bupropion indicated for the treatment of major depressive disorder in adults.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(bupropion hydrobromide extended release tablets) is indicated for the treatment of major depressive disorder, and for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder.&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cuprimine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is a treatment for Wilson's disease (a condition in which high levels of copper in the body cause damage to the liver, brain, and other organs), cystinuria (a condition which leads to&#160;cystine stones in the kidneys) and for patients with severe rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Mysoline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (Primidone) is an anticonvulsant drug used to control seizures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ativan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (lorazepam) is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is indicated for the treatment of chorea associated with Huntington&#8217;s disease. In the U.S., Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is distributed for us by Lundbeck&#160;LLC under an exclusive marketing, distribution and supply agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Syprine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is a treatment for Wilson's disease in patients who cannot take the medication known as penicillamine.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Librax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(chlordiazepoxide and clidinium) is indicated to control emotional and somatic factors in gastrointestinal disorders. Librax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may also be used as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generics</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Diastat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authorized generic (&#8220;AG&#8221;)&#160;(diazepam rectal gel) is a gel formulation of diazepam intended for rectal administration for certain patients with epilepsy who are already taking antiepileptic medications, and who require occasional use of diazepam to control bouts of increased seizure activity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(budesonide) extended release tablets are a prescription corticosteroid medicine used to help get mild to moderate ulcerative colitis under control (induce remission).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Elidel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AG (pimecrolimus) is a second-line therapy for short term and intermittent long-term therapy of mild to moderate atopic dermatitis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dentistry</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(minocycline hydrochloride) is a subgingival sustained-release antibiotic. Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is indicated as an adjunct to scaling and root planing ("SRP") procedures for reduction of pocket depth in patients with adult periodontitis.  Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">NeutraSal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is indicated for dryness of the mouth (hyposalivation, xerostomia) and dryness of the oral mucosa due to drugs that suppress salivary secretion.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">OSSIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a line of cross-linked collagen regenerative products that provide biocompatibility and bio-durability to perform a diverse range of guided bone and tissue regeneration procedures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">OraFit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a custom clear aligner treatment to permanently correct crooked and misaligned teeth using high-performance materials in a three-layer design to provide a balance of strength and comfort, while staying clear and crack-resistant, which we launched in the U.S. in February 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the planned separation of its Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., on February 23, 2022, the Company announced its plan to change its segment structure in a manner which is consistent with the organizational structure of the two separate entities as proposed by the Solta IPO during the first quarter of 2022. The new segment structure will not impact the Company&#8217;s reporting units but will realign the two reporting units of the Ortho Dermatologics segment whereby its medical dermatology reporting unit (Ortho Dermatologics) will now be managed by the CODM as part of the Diversified Products segment and the Solta reporting unit will be managed by the CODM as its own operating and reportable segment. Accordingly, the Company expects to begin reporting under the following reporting segments on a retrospective basis beginning with its first quarter of 2022 as follows: Bausch + Lomb, Salix, International Rx, Solta and Diversified Products.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_34"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our R&amp;D organization focuses on the development of products through clinical trials. Currently, we have approximately 200 R&amp;D projects in our pipeline.  As of December 31, 2021, approximately 1,300 dedicated R&amp;D and quality assurance employees in 25 R&amp;D facilities were involved in our R&amp;D efforts. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our R&amp;D expenses for 2021, 2020 and 2019, were $465 million, $452 million and $471 million, respectively. R&amp;D expenses as a percentage of revenue were approximately 6% in 2021 and 2020, as compared to approximately 5% in 2019. We have rebalanced our portfolio to better align with our long-term plans and focus on core businesses.  Our investment in R&amp;D reflects our commitment to drive organic growth through internal development of new products, a pillar of our strategy. We further supplement these efforts by continually seeking out other opportunities, such as co-promotions, licensing agreements and strategic acquisitions. See Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212;&#160;Overview &#8212;&#160;Focus on Core Businesses&#8221; of this Form&#160;10-K.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_37"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks, Patents, Exclusivity and Proprietary Know-How</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a combination of contractual provisions, confidentiality policies and procedures and patent, trademark, copyright and trade secrecy laws to protect the proprietary aspects of our technology and business.  Our policy is to vigorously protect, enforce and defend our rights to our intellectual property and proprietary rights, as appropriate. See Item 1A. &#8220;Risk Factors&#8221; of this Form 10-K for additional information on the risks associated with our intellectual property and proprietary rights.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trademarks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that trademark protection is an important part of establishing product and brand recognition. We own or license a number of registered trademarks and trademark applications in the U.S., Canada and in various other countries throughout the world. U.S. federal registrations for trademarks remain in force for 10 years and may be renewed every 10 years after issuance, provided the mark is still being used in commerce. Trademark registrations in Canada issued on or before June 17, 2019 remain in force for 15 years and may be renewed for 10-year terms, provided that, as in the case of U.S. federal trademark registrations, the mark is still being used in commerce. Trademark registrations in Canada issued after June 17, 2019 remain in force for 10 years and may be renewed every 10 years after issuance, provided that, as in the case of U.S. federal trademark registrations, the mark is still being used in commerce. Other countries generally have similar but varying terms and renewal policies with respect to trademarks registered in those countries.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data and Patent Exclusivity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain of our products, we rely on a combination of regulatory and patent rights to protect the value of our investment in the development of these&#160;products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A patent is the grant of a property right which allows its holder to exclude others from, among other things, selling the subject invention in, or importing such invention into, the jurisdiction that granted the patent. In the U.S., Canada and the European Union (&#8220;EU&#8221;), generally patents expire 20&#160;years from the date of&#160;application. We have obtained, acquired or in-licensed a number of patents and patent applications covering key aspects of certain of our principal products. In the aggregate, our patents are of material importance to our business taken as a whole. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the Hatch-Waxman Act provides non-patent regulatory exclusivity for five years from the date of the first FDA approval of a new drug compound in a New Drug Application (&#8220;NDA&#8221;). The FDA, with one exception, is prohibited during those five years from accepting for filing a generic, or an Abbreviated New Drug Application (&#8220;ANDA&#8221;), that references the NDA. In reference to the foregoing exception, if a patent is indexed in the FDA Orange Book for the new drug compound, a generic may file an ANDA four years from the NDA approval date if it also files a Paragraph IV Certification with the FDA challenging the patent.  Protection under the Hatch-Waxman Act will not prevent the filing or approval of another full NDA. However, the NDA applicant would be required to conduct its own pre-clinical and adequate and well-controlled clinical trials to independently demonstrate safety and effectiveness.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A similar data exclusivity scheme exists in the EU, whereby only the pioneer drug company can use data obtained at the pioneer&#8217;s expense for up to eight years from the date of the first approval of a drug by the European Medicines Agency (&#8220;EMA&#8221;) and no generic drug can be marketed for ten years from the approval of the innovator product. Under both the U.S. and the EU data exclusivity programs, products without patent protection can be marketed by others so long as they repeat the clinical trials necessary to show safety and efficacy.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the Biologics Price Competition and Innovation Act ("BPCIA") allows companies to seek FDA approval to manufacture and sell biosimilar or interchangeable versions of brand name biological products. Due to the size and complexity of biological products, as compared to small molecule drugs, a biosimilar must be &#8220;highly similar&#8221; to the reference product with &#8220;no clinically meaningful differences&#8221; in safety, purity and potency between the two. The BPCIA provides reference product sponsors with 12 years (with potential for six additional months of pediatric exclusivity) of market exclusivity, but unlike the Hatch-Waxman Act which covers small molecules, it does not require reference product sponsors to list patents in an Orange Book equivalent and does not include an automatic 30-month stay of FDA approval upon the timely filing of a lawsuit. The BPCIA, however, does provide pre-litigation procedures for the parties to follow, including identification of relevant patents and each party&#8217;s basis for infringement and invalidity.&#160; A biosimilar patent application cannot be filed until four years after the reference product is first licensed and a biosimilar cannot be launched, at the earliest (assumes no patent litigation or an adverse decision on all patents), until the expiration of the twelve years of data exclusivity from the approval of the reference product.&#160; </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a disease or condition that affects populations of fewer than 200,000 individuals in the U.S. or a disease whose incidence rates number more than 200,000 where the sponsor establishes that it does not realistically anticipate that its product sales will be sufficient to recover its costs. The sponsor that obtains the first marketing approval for a designated orphan drug for a given rare disease is eligible to receive marketing exclusivity for use of that drug for the orphan indication for a period of seven years.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Canada, the Patented Medicines (Notice of Compliance) Regulations (&#8220;PM(NOC) Regulations&#8221;) create a regime analogous to the U.S. Hatch-Waxman Act, and link the regulatory approval process for generic and biosimilar drugs to the adjudication of innovator patent rights. To be eligible for protection under the PM(NOC) Regulations, patents must first be listed on the Patent Register in connection with an innovator&#8217;s drug submission to Health Canada.  A generic or biosimilar manufacturer must then provide notice to the innovator of its plans to market a drug that it compared to the innovator&#8217;s patented drug in the Health Canada approval process. Within 45 days of receiving such a notice of allegation, an innovator drug company may commence patent infringement proceedings against the generic or biosimilar manufacturer. The commencement of an action by the innovator under the PM(NOC) Regulations may stay Health Canada&#8217;s regulatory approval of the generic or biosimilar drug for a period of 24 months. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada also employs a data exclusivity regime for innovative drugs that provides an eight-year period of data protection from the date of market approval by Health Canada. An additional six months of data exclusivity is provided for drugs studied in clinical trials relating to use in pediatric populations. Drug submissions seeking approval based on a comparison to an innovative drug cannot be filed during the first six years of the data exclusivity period. Generic or biosimilar drug submissions remain on hold until expiry of the innovator&#8217;s data protection term, unless the innovative product is a patented drug subject to further protection under the PM(NOC) Regulations. Canada has no distinct drug submission process for biosimilar or orphan drug products.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proprietary Know-How</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely upon unpatented proprietary know-how, trade secrets and technological innovation in the development and manufacture of many of our principal products. We protect our proprietary rights through a variety of methods, including confidentiality and non-disclosure agreements and proprietary information agreements with vendors, employees, consultants and others who may have access to proprietary information.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_40"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulations </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the U.S., at the federal, state and local level, in Canada, in the EU and in all other countries extensively regulate, among other things, the research, development, testing, approval, manufacturing, labeling, post-approval monitoring and reporting, packaging, advertising and promotion, storage, distribution, marketing and export and import of pharmaceutical products and medical devices. As such, our products and product candidates are subject to extensive regulation both before and after approval. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with these regulations could result in, among other things, warning letters, civil penalties, delays in approving or refusal to approve a product candidate, product recall, product seizure, interruption of production, operating restrictions, suspension or withdrawal of product approval, injunctions or criminal prosecution.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to human use, FDA approval (drugs (in the form of an NDA or ANDA for generic equivalents), biologics (in the form of a Biologics License Application (&#8220;BLA&#8221;)) and some medical devices) or marketing clearance (other devices) must be obtained in the U.S., approval by Health Canada must be obtained in Canada, EMA approval (drugs) or a CE Marking (devices) and/or registration under the European Commission's Medical Device Regulation ("MDR") 2017/745, must be obtained for countries that are part of the EU and approval must be obtained from comparable agencies in other countries prior to manufacturing or marketing new pharmaceutical products or medical devices. Generally, preclinical studies and clinical trials of the products must first be conducted and the results submitted to the applicable regulatory agency (such as the FDA) for approval. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Regulation by other federal agencies, such as the Drug Enforcement Administration, and state and local authorities in the U.S., and by comparable agencies in certain foreign countries, is also required. In the U.S., the Federal Trade Commission (the &#8220;FTC&#8221;), the FDA and state and local authorities regulate the advertising of medical devices, prescription drugs, OTC drugs and cosmetics. The Federal Food, Drug and Cosmetic Act, as amended and the regulations promulgated thereunder, and other federal and state statutes and regulations, govern, among other things, the testing, manufacture, safety, effectiveness, labeling, storage, record keeping, approval, sale, distribution, advertising and promotion of our products. The FDA requires a Boxed Warning (sometimes referred to as a &#8220;Black Box&#8221; Warning) for products that have shown a significant risk of severe or life-threatening adverse events and similar warnings are also required to be displayed on the product in certain other jurisdictions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, with respect to medical devices, in May 2017, the European Commission published the MDR, which replaced the Medical Device Directive (MDD). Pursuant to the terms of the new regulations, in order to continue to market medical device products in the EU, such products must achieve compliance with these new regulations and be re-registered in the EU within a specified transition period, which, for a portion of products, ended as early as May 26, 2021. While EU law is applicable in Northern Ireland, the UK Medical Devices Regulations 2002/68 also need to be complied with in Great Britain. Medical device manufacturers who have CE marked devices will be able to continue to place them on the market in the whole of the United Kingdom (the &#8220;UK&#8221;) until July 1, 2023 without a change in labeling. After that, devices destined for Great Britain will be required to follow the UK regulatory regime and to be labeled with the UKCA mark. Northern Ireland will, however, continue to accept CE marked devices. There are some extra hurdles for manufacturers who are based outside the UK, such as the requirement to appoint a UK Responsible Person (&#8220;UKRP&#8221;) to take on certain regulatory responsibilities with respect to the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) and users or customers in the UK. To enable devices to be placed on the market in the UK after January 1, 2021 (even for CE marked devices), a UK manufacturer must register with the MHRA, as must a UKRP for an overseas manufacturer. Such registering entity will then register each of the devices for which they are responsible for placing on the market in the UK, whether in Great Britain or Northern Ireland. Until May 25, 2021, our products bearing a CE mark could be exported from the EEA to Switzerland. However, as of May 26, 2021, the EU no longer applies the Mutual Recognition Agreement between the EEA and Switzerland. Accordingly, legal manufacturers in Switzerland will be required to appoint a European Union authorized representative, and manufacturers outside of Switzerland will be required to appoint a Swiss authorized representative in compliance with the Medical Device Ordinance. As a consequence, we will be required to appoint an authorized representative in Switzerland in order to export our CE-marked medical devices to Switzerland beginning in January 2022 through August 2022, depending on the class of the device or system in question. Additionally, the name and address of the Swiss authorized representative must be placed on the packaging. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Manufacturers of pharmaceutical products and medical devices are required to comply with manufacturing regulations, including current good manufacturing practices and quality system management requirements, enforced by the FDA and Health </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Canada, in the U.S. and Canada respectively, and similar regulations enforced by regulatory agencies in other countries and we face annual audits of our facilities and plants and those of our contract manufacturers by the FDA and such other regulatory agencies. In addition, we are subject to price control restrictions on our pharmaceutical products in many countries in which we&#160;operate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to extensive U.S.&#160;federal and state health care marketing and fraud and abuse regulations, such as the federal False Claims Act, federal and provincial marketing regulations in Canada and similar regulations in foreign countries in which we may conduct our business. The federal False Claims Act imposes civil and criminal liability on individuals or entities who submit (or&#160;cause the submission of) false or fraudulent claims for payment to the government. The U.S. federal Anti-Kickback Statute prohibits persons or entities from knowingly and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal or state health care program such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical or medical device manufacturers, on the one hand, and prescribers, purchasers, formulary managers and other health care related professionals, on the other hand. Some state anti-kickback laws also prohibit such conduct where commercial insurance, rather than federal or state, programs are involved. Violations of the U.S. federal Anti-Kickback Statute also carry potential federal False Claims Act liability. In addition, in the U.S., Canada and various other countries, companies may not promote drugs or medical devices for &#8220;off-label&#8221; uses - that is, uses that are not described in the product&#8217;s labeling and that differ from those that were approved or cleared by the FDA, Health Canada or applicable regulatory agency in such other countries - and &#8220;off-label promotion&#8221; in the U.S. has also formed the predicate for False Claims Act liability resulting in significant financial settlements. These and other laws and regulations, rules and policies may significantly impact the manner in which we are permitted to market our products. If our operations are found to be in violation of any of these laws, regulations, rules or policies or any other law or governmental regulation, or if interpretations of the foregoing change, we may be subject to civil and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs, the curtailment or restructuring of our&#160;operations or other sanctions, including consent orders or corporate integrity agreements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the U.S. Department of Health and Human Services Office of Inspector General recommends, and increasingly states require pharmaceutical companies to have comprehensive compliance programs. Moreover, the Physician Payment Sunshine Act enacted in 2010 imposes reporting and disclosure requirements on device and drug manufacturers for any &#8220;transfer of value&#8221; made or distributed to prescribers and other health care providers. Failure to submit this required information may result in significant civil monetary penalties. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to the U.S. Foreign Corrupt Practices Act ("FCPA"), the Canadian Corruption of Foreign Public Officials Act and similar worldwide anti-bribery laws, which generally prohibit companies and their intermediaries from making improper payments to officials for the purpose of obtaining or retaining business. Violations of these laws could result in criminal or civil penalties or remedial measures.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to various state, federal and international laws and regulations governing the collection, transmission, dissemination, use, privacy, confidentiality, security, retention, availability, integrity and other processing of health-related and other sensitive and personal information, including, but not limited to, the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (collectively, &#8220;HIPAA&#8221;). HIPAA mandates, among other things, the adoption of uniform standards for the electronic exchange of information in common health care transactions (e.g., health care claims information and plan eligibility, referral certification and authorization, claims status, plan enrollment, coordination of benefits and related information), as well as standards relating to the privacy and security of individually identifiable health information. These standards require the adoption of administrative, physical and technical safeguards to protect such information. Many states in which we operate have laws that protect the privacy and security of sensitive and personal information, including health-related information. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to sensitive and personal information than federal, international or other state laws, and such laws may differ from each other, which may complicate compliance efforts. For example, the California Consumer Privacy Act of 2018 (the &#8220;CCPA&#8221;), which went into effect on January 1, 2020, imposes stringent data privacy and security requirements and obligations with respect to the personal information of California residents, including, among other things, new disclosures to California consumers and providing such consumers new data protection and privacy rights, including the ability to opt out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data breaches that result in the loss of personal data that may increase the likelihood of, and risks associated with, data breach litigation. State laws are changing rapidly and there is discussion in Congress of a new federal data protection and privacy law to which we may be subject. For instance, the California Privacy Rights Act (&#8220;CPRA&#8221;) was passed in November 2020. When it takes effect in January 2023, it will maintain the core framework of the CCPA, while also making a number of substantive changes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some statutory requirements, both in the U.S. and abroad, include obligations for companies to notify individuals of security breaches involving particular personal information, which could result from breaches experienced by us or our service providers. For example, laws in all 50 U.S. states require businesses to provide notice to customers whose </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">personal data has been disclosed as a result of a data breach. The laws are not consistent, and compliance in the event of a widespread data breach is difficult and may be costly. Moreover, states have been frequently amending existing laws, requiring attention to changing regulatory requirements.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internationally, laws and regulations in many jurisdictions apply broadly to the collection, transmission, dissemination, use, privacy, confidentiality, security, retention, availability, integrity and other processing of health-related and other sensitive and personal information. For example, in the European Economic Area (the &#8220;EEA&#8221;) and, for the duration of the transition period (as defined below), the United Kingdom, the collection and use of personal data, including clinical trial data, is governed by the provisions of the General Data Protection Regulation (the &#8220;GDPR&#8221;). The GDPR became effective on May 25, 2018, repealing its predecessor directive and increasing responsibility and liability of companies in relation to the processing of personal data of EU data subjects. The GDPR, together with national legislation, regulations and guidelines of the EU member states and the United Kingdom governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze, store, transfer and otherwise process personal data, including health data from clinical trials and adverse event reporting. In particular, the GDPR includes obligations and restrictions concerning the consent and rights of the individuals to whom the personal data relates, the transfer of personal data out of the EEA or the United Kingdom, security breach notifications and the security and confidentiality of personal data. The GDPR authorizes fines for certain violations of up to 4% of global annual revenue or &#8364;20 million, whichever is greater. European data protection authorities may interpret the GDPR and national laws differently and impose additional requirements, which contributes to the complexity of processing personal data in or from the EEA or United Kingdom. Guidance on implementation and compliance practices is often updated or otherwise revised. We are also subject to Canada's federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Information Protection and Electronic Documents Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and substantially similar equivalents at the provincial level with respect to the collection, use and disclosure of personal information in Canada. Such federal and provincial legislation impose data privacy and security obligations on our processing of personal information of Canadian residents. The federal and Alberta legislation include mandatory data breach notification requirements. Canada&#8217;s Anti-Spam Legislation (&#8220;CASL&#8221;) also applies to the extent that we send commercial electronic messages from Canada or to electronic addresses in Canada. CASL contains prescriptive consent, form, content and unsubscribe mechanism requirements. Penalties for non-compliance with CASL are up to CAD 10 million per violation. These laws and regulations may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is possible they will be interpreted and applied in ways that will materially and adversely affect our business. The regulatory framework for data privacy, data security and data transfers worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Complying with all of these laws and regulations involves costs to our business, and failure to comply with these laws and regulations can result in the imposition of significant civil and criminal penalties, as well as litigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful commercialization of our products may depend, in part, on the availability of governmental and third-party payor reimbursement for the cost of our products. Third-party payors may include government health administration authorities, private health insurers and other organizations. In the U.S., the E.U. and other significant or potentially significant markets for our products and product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, which has resulted in lower average realized prices. In the U.S., these pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and health care reform, pharmaceutical reimbursement policies and pricing in general. In particular, sales of our products may be subject to discounts from list price and rebate obligations, as well as formulary coverage decisions impacting or limiting the types of patients for whom coverage will be provided. Various U.S. health care and other laws regulate our interactions with government agencies, private insurance companies and other third-party payors regarding coverage and reimbursement for our products. Failure to comply with these laws could subject us to civil, criminal and administrative sanctions. In countries outside the U.S., the success of our products may depend, at least in part, on obtaining and maintaining government reimbursement because, in many countries, patients are unlikely to use prescription drugs that are not reimbursed by their governments. In addition, negotiating prices with certain governmental authorities for newly developed products can delay commercialization. In Canada and many international markets, governments control the prices of prescription pharmaceuticals, including through the implementation of reference pricing, price cuts, rebates, revenue-related taxes, tenders and profit control, and they expect prices of prescription pharmaceuticals to decline over the life of the product or as volumes increase.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. and certain foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health care system in ways that could impact our ability to sell our products profitably. The Patient Protection and Affordable Care Act (the &#8220;PPACA&#8221;), as amended by the Health Care Reform Act, may affect the operational results of companies in the pharmaceutical and medical device industries, including the Company and other health care related industries, by imposing on them additional costs. Effective January 1, 2010, the Health Care Reform Act increased the minimum Medicaid drug rebates for pharmaceutical companies, expanded the 340B drug discount program, and made changes to affect the Medicare Part D coverage gap, or &#8220;donut hole.&#8221; The law also revised the definition of &#8220;average manufacturer price&#8221; for reporting purposes, which may affect the amount of our Medicaid drug rebates to states. Beginning in 2011, the law imposed a significant annual fee on companies that manufacture or import branded prescription drug products. More recently, the </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bipartisan Budget Act of 2018 amended the Patient Protection and Affordable Care Act, effective January 1, 2019, to close the donut hole in most Medicare drug plans. In addition, in April 2018, the Centers for Medicare &amp; Medicaid Services published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the Patient Protection and Affordable Care Act for plans sold through such marketplaces.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although efforts at replacing the Health Care Reform Act have stalled in Congress, there could still be changes to this legislation in the near term. Additionally, policy efforts designed specifically to reduce patient out-of-pocket costs for medicines could result in new mandatory rebates and discounts or other pricing restrictions. Legislative efforts relating to drug pricing, the cost of prescription drugs under Medicare, the relationship between pricing and manufacturer patient programs, and government program reimbursement methodologies for drugs have been proposed and considered at the U.S. federal and state level. At the federal level, the Trump Administration&#8217;s budget proposal for fiscal year 2019 contained further drug price control measures that could be enacted in future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid and to eliminate cost sharing for generic drugs for low-income patients. While any proposed measures will require authorization through additional legislation to become effective, Congress and the Biden Administration have each indicated an intent to continue to seek new legislative or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We also anticipate that Congress, state legislatures, and third-party payors may continue to review and assess alternative health care delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations effecting additional fundamental changes in the health care delivery system. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A. &#8220;Risk Factors&#8221; of this Form 10-K for additional information on the risks associated with these regulations and related matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental and Other Regulation </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities and operations are subject to a broad range of federal, state and local environmental and occupational health and safety laws and regulations in both the U.S. and countries outside the U.S. (including Canada), including those governing the discharge of substances into the air, water and land, the handling, treatment, storage and disposal of hazardous substances and wastes, wastewater and solid waste, the cleanup of contaminated properties and other environmental matters.  Certain of our development and manufacturing activities involve the use of hazardous substances. If we fail to comply with these environmental, health and safety laws and regulations, including failing to obtain any necessary permits, we could incur substantial civil or criminal fines or penalties or enforcement actions, including regulatory or judicial orders enjoining or curtailing our operations or requiring us to conduct or fund remedial or corrective measures, install pollution control equipment, reformulate or cease the marketing of our products or perform other actions. Under certain laws, we may be subject to joint and several liability for environmental investigations and cleanups, including at properties that we currently or previously owned or operated, or at sites at which waste we generated was disposed, even if the contamination was not caused by us or was legal at the time it occurred.  We are also subject to extensive and evolving regulations regarding the manufacturing, processing, distribution, importing, exporting and labeling of our products and their raw materials. In the EU, the REACH regulations came into effect in 2007, with implementation rolling out over time. Registered chemicals then can be subject to further evaluation and potential restrictions. Since the promulgation of REACH, other countries have enacted or are in the process of implementing similar comprehensive chemical regulations. These laws and regulations may materially affect our operations by subjecting our products or raw materials to testing or reporting requirements or restrictions, moratoria, phase outs or other limitations on their sale or use. In particular, some of our products might be characterized as nanomaterials and then be subject to evolving, new nanomaterial regulations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we are in compliance in all material respects with applicable environmental and occupational health and safety laws and regulations. We are not aware of any pending environmental or occupational health and safety litigation or significant liabilities that are likely to have a material adverse effect on our financial position. We cannot assure, however, that environmental liabilities relating to us or facilities owned, leased or operated by us will not develop in the future, and we cannot predict whether any such liabilities, if they were to develop, would require significant expenditures on our part. In addition, we are unable to predict what environmental or and occupational health and safety legislation or regulations may be adopted or enacted in the future. See Item 1A. &#8220;Risk Factors&#8221; of this Form 10-K for additional information.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customers and Marketing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the U.S. and Puerto Rico accounted for approximately 58% and China accounted for approximately 6% of our total revenue, respectively. No other country accounted for more than 5%. See Note 22, "SEGMENT INFORMATION" to our audited Consolidated Financial Statements for revenues by geographic area.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of our total revenue for 2021, 2020 and 2019 are as follows: </span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:67.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently promote our pharmaceutical products to physicians, hospitals, pharmacies and wholesalers through our own sales force and sell through wholesalers. In some markets, we additionally sell directly to physicians, hospitals and large drug store chains and we sell through distributors in countries where we do not have our own sales staff.  As part of our marketing program for pharmaceuticals, we use direct to customer advertising, direct mailings, advertise in trade, social media and medical periodicals, exhibit products at medical conventions and sponsor medical education symposia.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_46"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competitive Landscape for Products and Products in Development</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical and medical device industries are highly competitive. Our competitors include specialty and other large pharmaceutical companies, medical device companies, biotechnology companies, OTC companies and generic manufacturers, in the U.S., Canada, Europe, Asia, Latin America, Middle East, Africa and in other countries in which we market our products. The dermatology competitive landscape is highly fragmented, with a large number of mid-size and smaller companies competing in both the prescription sector and the OTC and cosmeceutical sectors. With respect to the GI market, generic entrants continue to capture significant share for treatment of many GI conditions. In the area of irritable bowel syndrome ("IBS") and opioid induced constipation ("OIC"), competitors have recently launched new competing products, which should increase the size of these markets and intensify competition.&#160;The market for Bausch + Lomb products is very competitive, both across product categories and geographies.  In addition to larger diversified pharmaceutical and medical device companies, we face competition in the eye-health market from mid-size and smaller, regional and entrepreneurial companies with fewer products in niche areas or regions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors are pursuing the development and/or acquisition of pharmaceuticals, medical devices and OTC products that target the same diseases and conditions that we are targeting in dermatology, GI, eye-health and other therapeutic areas. Academic and other research and development institutions may also develop products or technologies that compete with our products, which technologies and products may be acquired or licensed by our competitors. These competitors may have greater financial, R&amp;D or marketing resources than we do. If competitors introduce new products, delivery systems or processes with therapeutic or cost advantages, our products can be subject to progressive price reductions or decreased volume of sales, or both. Most new products that we introduce must compete with other products already on the market or products that are later developed by competitors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell a broad range of products, and competitive factors vary by product line and geographic area in which the products are&#160;sold.  The principal methods of competition for our products include quality, efficacy, market acceptance, price and marketing and promotional efforts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Generic Competition and Loss of Exclusivity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face increased competition from manufacturers of generic pharmaceutical products when patents covering certain of our currently marketed products expire or are successfully challenged or when the regulatory exclusivity for our products expires or is otherwise lost. Generic versions are generally significantly less expensive than branded versions, and, where available, may be required to be utilized before or in preference to the branded version under third-party reimbursement programs, or substituted by pharmacies.  Accordingly, when a branded product loses its market exclusivity, it normally faces intense price competition from generic forms of the product. To successfully compete for business with managed care and pharmacy benefits management organizations, we must often demonstrate that our products offer not only medical benefits, but also cost advantages as compared with other forms of&#160;care.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For details regarding products that are facing generic competition, products that could potentially face generic competition, the corresponding potential revenue impact and infringement proceedings we initiated against potential generic </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competition, see Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212;&#160;Business Trends &#8212;&#160;Generic Competition and Loss of Exclusivity&#8221; of this Form&#160;10-K. See Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements for further details regarding certain infringement proceedings. See Item 1A. &#8220;Risk Factors&#8221; of this Form 10-K for additional information on our competition risks.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_49"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently operate approximately 36 manufacturing sites worldwide and continue to make capital investments in these facilities as discussed in Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212;&#160;Overview &#8212;&#160;Focus on Core Businesses&#8221; of this Form&#160;10-K.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the normal course of business, our products, devices and facilities are the subject of ongoing oversight and review by regulatory and governmental agencies, including general, for cause and pre-approval inspections by the relevant competent authorities where we have business operations. Through the date of this filing, all of our global operations and facilities have the relevant operational good manufacturing practices certificates and all Company products and operating sites are in good compliance standing with all relevant notified bodies and global health authorities. Further, all sites under FDA jurisdiction are rated as either No Action Indicated (where there was no Form 483 observation) or Voluntary Action Indicated (&#8220;VAI&#8221;) (where there was a Form 483 with one or more observations). In the case of VAI inspection outcomes, the FDA has accepted our responses to the issues cited, which will be verified when the agency makes its next inspection of those specific facilities. A Form 483 is issued at the end of each inspection when FDA investigators have observed any condition that in their judgment may constitute violations of current good manufacturing practices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also subcontract the manufacturing of certain of our products, including products manufactured under the rights acquired from other pharmaceutical companies. Products representing approximately 20% of our product sales for 2021 are produced in total, or in part, by third-party manufacturers under manufacturing arrangements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, the principal raw materials, including active pharmaceutical ingredients, used by us (or our third-party manufacturers) for our various products are purchased in the open market or are otherwise available from several sources. However, some of the active pharmaceutical ingredients and other raw materials used in our products and some of the finished products themselves are currently only available from a single source; or others may in the future become available from only one source. For example, with respect to some of our largest or most significant products, the supply of the finished product for each of our Siliq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vyzulta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SofLens</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Wellbutrin XL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oral and PureVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products are only available from a single source and the supply of active pharmaceutical ingredient for each of our Siliq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vyzulta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Oral products are also only available from a single source. Any disruption in the supply of any such single-sourced active pharmaceutical ingredient, other raw material or finished product or an increase in the cost of such materials or products could adversely impact our ability to manufacture or sell such products, the ability of our third-party manufacturers to supply us with such products, or our profitability. We attempt to manage the risks associated with reliance on single sources of active pharmaceutical ingredient, other raw materials or finished products by carrying additional inventories or, where possible, developing second sources of supply. See Item 1A. &#8220;Risk Factors&#8221; for additional information on the risks associated with our manufacturing arrangements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global supply team worked diligently to stay ahead of the challenges presented by the COVID-19 pandemic once it appeared in Asia. See Item 7. "Management's Discussion and Analysis &#8212; Impacts of COVID-19 Pandemic" for further information.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_52"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to achieve our vision of being a trusted health care partner, we strive to ensure our employees around the world feel proud to be a part of Bausch Health Companies Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had approximately 19,600 employees (of which 19,100 were full-time employees), which included approximately 9,900&#160;in production, 7,000 in sales and marketing, 1,400&#160;in general and administrative positions and 1,300&#160;in R&amp;D. These employees are located around the world, with 7,380 in the United States and Canada, 6,820 in Europe, 2,420 in Asia-Pacific countries, 2,120 in Latin America, 640 in Russia and Commonwealth of Independent State countries and 220 in the Middle East and Africa.   </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collective bargaining exists for some employees in several countries in which we do business. We consider our relations with our employees to be good and have not experienced any work stoppages, slowdowns or other serious labor problems that have materially impeded our business operations.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the beginning of 2021, our voluntary turnover rate trended higher than in 2020, but in line with what most companies were experiencing in the industries and geographies in which we operate; the voluntary turnover rate has since leveled off and is closer to or at targeted rate. We have not experienced any significant disruption to date as a result of turnover.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_55"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health, Safety and Wellness</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees' health, safety, and wellness are important to us. With the COVID-19 outbreak, a continued focus in 2021 was protecting the health and safety of our employees and their families. We continued to make available our remote work policies, which had been broadened in 2020 to enable our global employees to work from home wherever possible. In circumstances where remote work was not possible (such as at our manufacturing and distribution facilities), we continued to implement safety measures, which had been introduced in 2020 to help prevent the spread of COVID-19 in the workplace, such as mandatory face coverings, social distancing, hand hygiene, plexiglass barriers, limited face-to-face meetings and other procedures as prescribed by global public health organizations, such as the WHO and U.S. Centers for Disease Control and Prevention. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, we measure how well we are fostering the health and safety of our employees through our Days Away Rate ("DAR"), which is a standard used in our industry to capture the number of days that our employees are away from work as a result of a work-related injury or illness.  For the year 2021, our DAR was 6 days per 100 employees. This was favorable when compared to the goal we established for DAR of less than 12 days per 100 employees and was favorable to our industry&#8217;s average DAR of 24 days per 100 employees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recognize that physical, emotional and financial wellbeing are significant contributors to our employees success at work and home.  We aim to support our employees in their everyday life by centering programs and activities around these three pillars of wellbeing. Across each of these pillars, we offer a range of resources to help our employees be healthy and feel successful in both their professional and personal lives, including through employee assistance programs.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_58"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity and Inclusion</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dedicated to fostering an inclusive work environment where everyone feels welcomed, supported and valued for their talents and contributions. Our Bausch Health Diversity, Equity &amp; Inclusion ("DE&amp;I") strategy centers on connecting our employees to our Company, each other, and our communities to cultivate a sense of trust, respect and belonging for all. We have a DE&amp;I Council that is led by our Company's Executive Committee members sponsored by our Chief Human Resources Officer, General Counsel, and Chief Medical Officer/President R&amp;D that provides oversight for our DE&amp;I strategy and initiatives. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to advance candid conversations among our employees about diversity and inclusion and expanding training and education on those issues. Specifically, we have provided all employees with educational tools and resources to understand how to talk about these topics at work and, in 2020, have introduced training aimed at helping employees become more aware of unconscious biases. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on continuing to expand our Employee Resource Groups ("ERGs"), providing opportunities for professional growth, development and informal networking. Our ERGs include the following: Asian Heritage, Black &amp; African Heritage, LGBTQ+, Military, and the Women's Inclusive Network.  In 2021, these ERGs have helped strengthen our focus on DE&amp;I by promoting opportunities for professional growth, development, and informal networking, and providing forums to voice concerns, and multiple perspectives.  Another essential pillar of our ERG program is to establish connections with charities whose missions align with those of our individual ERGs and give back to these communities, which we plan to continue in 2022 and beyond.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_61"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Talent Development</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to the development of our employees and believe that our success coincides with our employees&#8217; achievements of personal and professional goals. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our Employee Development Framework, we endeavor to support our employees&#8217; interests to grow to&#8239;their full potential, achieve career goals, and contribute to&#8239;the success&#8239;of our Company. We empower employees to explore roles that are of interest and gain insights into their strengths and development needs. We provide a variety of development programs to support our employees at every stage of their career and incorporate individual development plans that aim to help our employees reach their career goals. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have a robust, global succession planning process that allows us to define talent needs based on business strategy, identify talent and drive their development and growth, strengthen the pipeline for critical leadership positions, and optimize talent deployment across the business.  As detailed in its charter, the Talent and Compensation Committee of the Board of Directors assists the Board with oversight of our Company&#8217;s talent management and succession planning process. The </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Board of Directors reviews succession planning progress and specifically the plans for Executive Committee roles.  To support this process, the Board interacts with leaders and managers throughout the organization during the year to get to know these employees and their work.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_64"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Rewards</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Company&#8217;s total rewards philosophy is designed to attract, retain, motivate, and engage our employees. We provide comprehensive and market competitive compensation and benefit programs across our geographies, aligning these programs with the interests of our shareholders and balancing appropriate risk taking. Collectively, these programs comprise our Total Rewards package.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation program includes base pay, short-term incentives, and long-term incentives.  We provide the opportunity for our employees to earn more when we deliver against objectives &#8211; both as a total company and individually.  We also provide competitive benefit programs based on local practice in the countries where our employees work. Our programs include medical coverage, retirement benefits, paid time off, and life and other insurances.  Based on local market practice in the geographies in which we operate, we also offer family planning benefits to our employees such as adoption and surrogacy assistance programs.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_67"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Social Responsibility</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we established The Bausch Foundation, which supports initiatives aimed at disease prevention, improving patient outcomes, and community support related to our core businesses. Additionally, it supports global relief efforts and those who need help in the communities in which we live and work. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to supporting patients who have lost employment health benefits due to the COVID-19 pandemic, and because it is essential that our patients continue their prescribed treatments, we are proud to offer certain of our prescription medicines through our Bausch Health Patient Assistance Program.  In the face of the COVID-19 pandemic, some people have financial obstacles that keep them from obtaining and continuing their prescribed treatments. The purpose of the Bausch Health Patient Assistance Program is to provide eligible unemployed patients in the U.S., who meet stated qualifications and have lost their health insurance due to the COVID-19 pandemic, with certain of our prescription products where their financial circumstances or insurance status would otherwise interfere with their ability to access such products. If approved, patients receive their Bausch Health Companies Inc. prescription product(s) at no cost to them for up to one year, and may be able to reapply to the program annually if they continue to meet eligibility requirements and have a valid prescription.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 7. &#8220;Management's Discussion and Analysis &#8212; Overview &#8212; Focus on Core Businesses &#8212; Improve Patient Access&#8221; for additional discussion regarding Company programs to address the affordability and availability of our products.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_70"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Insurance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since March 31, 2014, we have self-insured substantially all of our product liability risk for claims arising after that date. In the future, we will continue to re-evaluate our decision to self-insure and may purchase additional product liability insurance to cover product liability risk. See Item&#160;1A. &#8220;Risk Factors&#8221; of this Form&#160;10-K for additional information.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_73"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality of Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, revenues from our business tend to be weighted toward the second half of the year.  Sales in the first quarter tend to be lower as patient co-pays and deductibles reset at the beginning of each year.&#160;&#160;Sales in the fourth quarter tend to be higher based on consumer and customer purchasing patterns associated with health care reimbursement programs.  However, there are no assurances that these historical trends will continue in the future. </span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_76"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Areas</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenues is generated from operations or otherwise earned outside the U.S. and Canada. All of our foreign operations are subject to risks inherent in conducting business abroad, including price and currency exchange controls, fluctuations in the relative values of currencies, political and economic instability and restrictive governmental actions including possible nationalization or expropriation. Changes in the relative values of currencies may materially affect our results of operations. For a discussion of these risks, see Item&#160;1A. &#8220;Risk Factors&#8221; of this Form&#160;10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 22, "SEGMENT INFORMATION" to our audited Consolidated Financial Statements for revenues and long-lived assets by geographic area.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of our revenue and income was earned in Canada and Ireland, which have low effective tax rates. See Item&#160;1A. &#8220;Risk Factors&#8221; of this Form&#160;10-K relating to tax&#160;rates for more information.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Internet address is </span><span style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.bauschhealth.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We post links on our website to the following filings as soon as reasonably practicable after they are electronically filed or furnished to the SEC: annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K and&#160;any amendment to those reports filed or furnished pursuant to Section&#160;13(a) or&#160;15(d) of the Securities Exchange Act of 1934, as amended. All such filings are available through our website free of charge. The information on our Internet website is not incorporated by reference into this Form&#160;10-K or&#160;our other securities filings and is not a part of such&#160;filings. The SEC also maintains an Internet website at </span><span style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that contains reports, proxy and information statements, and other information regarding issuers, including us, that file electronically with the&#160;SEC.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also required to file reports and other information with the securities commissions in all provinces in Canada. You are invited to read and copy any reports, statements or other information, other than confidential filings, that we file with the provincial securities commissions. These filings are also electronically available from the Canadian System for Electronic Document Analysis and Retrieval (&#8220;SEDAR&#8221;) at </span><span style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.sedar.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Canadian equivalent of the SEC&#8217;s electronic document gathering and retrieval system.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business, financial condition, cash flows and results of operations are subject to various risks and uncertainties. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Form 10-K, including those risks set forth under the heading entitled &#8220;Forward-Looking Statements&#8221; and in other documents that we file with the SEC and the CSA, before making any investment decision with respect to our common shares or debt securities. If any of the risks or uncertainties actually occur or develop, our business, financial condition, cash flows, results of operations and/or future growth prospects could change, and such change could be materially adverse. Under these circumstances, the market value of our common shares and/or debt securities could decline, and you could lose all or part of your investment in our common shares and/or debt securities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the risk factors our business faces. The list below is not exhaustive, and investors should read this &#8220;Risk Factors&#8221; section in full. Some of the risks we face include: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of the COVID-19 pandemic on our business, financial condition, cash flows, and results of operations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact on our business from the separation of our eye-health business into an independent publicly traded entity, including the impact of a failure to maintain the tax-free treatment of such transaction, the continued reliance on Bausch + Lomb employees for certain transitional services, a failure to obtain replacement contracts, any actual or perceived conflict of interest of our directors and officers who also serve roles in Bausch + Lomb and the cross-indemnification obligations on us and Bausch + Lomb;</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact on our business from the proposed Solta IPO, including the continued reliance on any Solta employees for certain transitional services, a failure to obtain replacement contracts, any actual, potential or perceived conflict of interest of our directors and officers who also serve roles in Solta and the cross-indemnification obligations on us and Solta;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ongoing legal proceedings, investigations, and inquiries respecting certain of our historical distribution, marketing, pricing, disclosure and accounting practices;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of changes to our pricing practices, whether imposed, legislated or voluntary;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential adverse impact of legal proceedings, litigation, and government investigations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence on third parties to meet their contractual, legal, regulatory, and other obligations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of product recalls and related product liability claims; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with extensive regulation concerning marketing, promotional and business practices;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with restrictive covenants in our debt agreements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate cash in order to service our debt;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact on our business of restrictions imposed by our significant indebtedness;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of interest rate changes, including the discontinuation of the London Interbank Offered Rate ("LIBOR");</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manage the transition of our key management positions;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recruit and retain executives and key personnel;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential increase of our effective tax rates, including as a result of proposed changes to applicable tax laws;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to compete with generic competitors in products that represent a significant amount of our revenue;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain, enforce or defend the intellectual property rights required to conduct our business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of potential intellectual property litigation; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop or acquire more effective or less costly pharmaceutical or OTC products or medical devices than our competitors;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of our commitment to the cessation of or limitation on pricing increases for certain of our products;</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of divestitures of certain of our assets and business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential adverse effect of acquisitions of assets, products and businesses; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain and provide appropriate training in our products to our health care providers;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize our pipeline products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with ongoing regulatory review of our marketed drugs, including our dietary products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact on our business of interruptions in our manufacturing processes;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence on a limited number of sources for certain of our finished products and raw materials;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of changes in inventory levels or fluctuations in buying patterns by our large distributor and retail customers;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve or maintain expected levels of market acceptance for our new products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence on reimbursements from governmental and other third-party payors; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of a failure to be included in formularies developed by managed care organizations and third-party payors;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of our fulfillment arrangements with Walgreens and our dermatology cash-pay prescription program;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of catastrophic events that may disrupt our business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the illegal distribution and sale of counterfeit versions of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the reduction of profits due to imports from countries where our products are available at lower prices;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the reduction of revenues in future fiscal periods due to our policies regarding returns, allowances, and chargebacks;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the decline in sales volumes or prices of our products as the result of the concentration of sales to wholesalers;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the decline in pricing and/or volume of our products in our distribution agreements with other companies;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with the international scope of our operations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency exposure on the translation into U.S. dollars of the financial results of our international operations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the breakdown, interruption, breach or other compromise of our information technology systems;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with applicable laws and regulations and prevail in any litigation related to noncompliance;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact that reforms of the health care system may have on our ability to sell our products profitably;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with environmental laws and regulations and environmental remediation obligations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential adverse effect of shareholder activism;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact on our profitability from the potential impairment of goodwill and other intangible assets;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively monitor and respond to expectations regarding environmental, social and governance matters;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our potential obligations under our indemnity agreements and arrangements; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the fluctuation of our operating results and financial condition from quarter to quarter. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to COVID-19</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing COVID-19 pandemic, the rapidly evolving reaction of governments, private sector participants and the public to that pandemic and/or the associated economic impact of the pandemic and the reactions to it, could adversely and materially impact our business, financial condition, cash flows and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing COVID-19 pandemic, including the emergence of new variants such as Delta and Omicron, and the rapidly evolving reaction of governments, private sector participants and the public in an effort to contain the spread of COVID-19 (and </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">variants thereof) and/or address its impacts have intensified and have had significant direct and indirect effects on businesses and commerce generally, including disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions, and significantly increased demand for certain goods and services, such as pandemic-related medical services and supplies, alongside decreased demand for others, such as retail, hospitality, travel and elective surgery.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a result of the impact of COVID-19, we have experienced and may continue to experience delays in and postponement of our clinical trial programs, reduced demand for certain of our products due to the deferral of elective medical procedures and of doctor and dentist visits and restrictions on outpatient surgery and other medical procedures, and if such issues recur in the future, our results of operations may be adversely impacted as a result. In addition, certain of our facilities were temporarily closed in connection with the COVID-19 pandemic, and we have also experienced some disruptions to our supply chain as a result of challenges associated with the COVID-19 pandemic. Although we are not currently experiencing these effects, depending on future developments with respect to COVID-19, we may continue to experience those effects as a result of the pandemic, the emergence of new variants (such as Delta and Omicron), the reactions of governments, private sector participants and the public to the pandemic and the associated disruption to business and commerce generally.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we have experienced and/or, in the future, may experience: </span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">further material closures or disruptions to our manufacturing sites (for example, we experienced closures at our Milan, Italy, Bothell, Washington U.S. sites and our two sites in China in 2020); </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">lack of availability of active pharmaceutical ingredients ("API"), and intermediates, or other supply chain disruptions, including for some of our key products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">continued alternative working arrangements, including personnel working remotely and additional physical distancing, cleaning or sterilization protocols at our production facilities, which could negatively impact our business should such arrangements remain for an extended period of time;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">interruption or delays in the operations of the FDA, the EMA and other regulatory authorities, which may impact review and approval timelines for our planned trials and launches;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">delays or difficulties in enrolling patients in our clinical trials;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">diversion of health care resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">interruption or postponement of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by national, federal, state or local governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">limitations on employee resources that would otherwise be focused on our business and operations, such as the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">delays in or postponements of our clinical trial programs as a result of &#8220;stay at home&#8221; orders affecting our research facilities or the closure of such research facilities, which may impact the timing, approval and launch of the affected clinical trial programs; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">recurrence of deferral of elective medical procedures and of doctor and dentist visits, and reduced usage of contact lens, which may reduce demand for certain of the Company&#8217;s products, including our contact lens products and certain branded pharmaceutical products in our eye-care, dermatology, GI and dentistry businesses; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">delays or difficulties in our and our business partners&#8217; ability to access physicians, which may in turn impact our ability to train physicians to use our devices and provide needed services; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">adverse effects on the regional economies in which we operate which could reduce demand for certain of the Company&#8217;s products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent and duration of the pandemic, the reactions of governments, private sector participants and the public to that pandemic and the associated disruption to business and commerce generally, and the extent to which these may impact our business, financial condition, cash flows and results of operations in particular, will depend on future developments which are highly uncertain and many of which are outside our control and cannot be predicted with confidence. Such developments </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include the ultimate geographic spread and duration of the pandemic, the availability and effectiveness of vaccines for COVID-19, vaccine hesitancy, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, including the Delta and Omicron variants, new information which may emerge concerning the severity of COVID-19, the effectiveness and intensity of measures to contain COVID-19 and/or address its impacts, and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline and may exacerbate other risk factors disclosed in this Item 1A. &#8220;Risk Factors.&#8221;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developments such as those described above, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company's business, financial condition, cash flows and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to the B+L Separation and the Solta IPO</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our plan to separate our eye-health business into an independent publicly traded entity from the remainder of the Company is subject to various risks and uncertainties and may not be completed in accordance with the expected plans or anticipated timeline, or at all, and will involve significant time, expense, and distraction, which could disrupt or have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, we announced that we intend to separate our eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc.  The B+L Separation will establish a separate fully integrated eye-health company which will consist of our Bausch + Lomb Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmology Rx businesses. It is anticipated that the B+L Separation will involve (i) an initial public offering of a portion of the shares of Bausch + Lomb and (ii) following the completion of the B+L IPO, the expiry of customary lockups related to the B+L IPO and achievement of targeted debt leverage ratios (and subject to receipt of regulatory, stock exchange and other approvals and market conditions), a distribution of all or a portion of our remaining equity interest in Bausch + Lomb to our shareholders (the &#8220;Distribution&#8221;). It is currently anticipated that the Distribution will take the form of a transfer of all or a portion of the remaining equity interest in Bausch + Lomb to  our shareholders by way of a plan of arrangement under applicable corporate law (the &#8220;Arrangement&#8221;).  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The anticipated B+L Separation is subject to regulatory approvals and certain conditions, including final approval by the Company&#8217;s Board of Directors, any shareholder vote requirements that may be applicable, compliance with (including completion of all necessary filings required by) U.S. and Canadian securities laws and stock exchange rules, receipt of any applicable opinions and/or rulings with respect to the Canadian federal income tax treatment of the Separation, determination of the pro forma capitalizations of the two separate companies, the existence of satisfactory market conditions, the receipt of and compliance with any necessary court orders relating to the B+L Separation and approvals of the NYSE and TSX. There can be no certainty, nor can we provide any assurance, that all of the required conditions to the B+L Separation will be satisfied or, if permissible, waived, or, if satisfied or waived, when they will be satisfied or waived. The failure to satisfy all of the required conditions, many of which are outside of our control, could delay the completion of the B+L Separation (including either or both of the B+L IPO and Distribution) for a significant period of time or prevent it from occurring at all or result it being restructured in a manner that may be more or less advantageous to the Company and its shareholders. In addition, we announced a refinancing of our existing Restated Credit Agreement in January 2022 which is intended to facilitate the B+L Separation by, among other things, permitting us to designate Bausch + Lomb as an &#8220;unrestricted&#8221; subsidiary under the New Restated Credit Agreement (as defined herein) covenants upon achievement of a 7.60:1.00 pro forma &#8220;Remainco Total Leverage Ratio.&#8221; There can be no assurance that the Credit Agreement Refinancing (as defined herein) will occur on the anticipated terms or at all. If we are unable to consummate the Credit Agreement Refinancing, we may be unable to complete the B+L Separation on the anticipated terms or timeline.</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unanticipated developments, including disruptions to business and commerce induced by the COVID-19 pandemic, changes in market conditions, possible delays in obtaining any necessary shareholder, stock exchange, regulatory or other approval or the failure to obtain any such approvals, possible delays in obtaining any required tax opinions or rulings or the failure to obtain any such tax opinions or rulings, negotiating challenges, the uncertainty of the financial markets, changes in the law, and other challenges in executing the B+L Separation, could delay or prevent the completion of the B+L Separation (including either or both of the B+L IPO and Distribution), result in changes to the anticipated structure of the B+L Separation, or cause the B+L Separation to occur on terms or conditions that are different or less favorable than expected. Any changes to the B+L Separation or delay in completing the B+L Separation could cause us not to realize some or all of the expected benefits, or realize them on a different timeline than expected. Further, our Board of Directors could decide, either because of a failure to satisfy conditions or because of market or other factors, to delay, abandon or alter the structure or terms of the B+L Separation. No assurance can be given as to whether and when the B+L Separation will occur, on what terms the B+L </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separation will occur or whether the B+L Separation will achieve the benefits we expect. As a result, there can be no assurance as to the timing of the completion of the B+L Separation or its structure or terms.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the B+L Separation is completed, we may not be able to achieve the full strategic and financial benefits expected to result from the B+L Separation. The B+L Separation is expected to unlock value by creating an independent business and distinct investment identity with enhanced strategic and management focus that allows more efficient allocation of resources and capital. In addition, proceeds from the B+L IPO are expected to facilitate further reductions in the aggregate amount of our outstanding indebtedness. We may not achieve these and other anticipated benefits for a variety of reasons, including, among others: (i) Bausch + Lomb may prove to be less valuable on an independent basis than we anticipate, including because it is more susceptible to economic downturns and other adverse events than if it were still a part of the Company and because its business will be less diversified than the Company&#8217;s business prior to the B+L Separation and (ii) other actions required to separate the respective businesses could disrupt our operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executing the B+L Separation has and will continue to require significant resources, time and attention from our senior management and employees, which could cause distractions and divert attention and resources away from other projects and the day-to-day operation of our business. We may also experience increased difficulties in attracting, retaining, and motivating management and employees during the pendency of the B+L Separation and following its completion. For more information on these and other related risks, see Item 1A. &#8220;Risk Factors&#8212;Employment-related Risks&#8221; of this Form 10-K. The B+L Separation, whether or not completed, may also have an adverse impact on our relationships with our customers, suppliers and other business counterparties. The price of our common shares could also fluctuate significantly in response to developments or market speculation related to the proposed B+L Separation. The B+L Separation, if completed, may also have the effect of exacerbating other risk factors disclosed in this Item 1A. &#8220;Risk Factors.&#8221;</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have already incurred expenses in connection with the B+L Separation, and expect that the process of completing the B+L Separation will be time-consuming and involve significant additional costs and expenses, which may not yield a discernible benefit if the B+L Separation is not completed on the timeline and terms currently anticipated or at all. In addition, if the B+L Separation is not completed or if it is delayed or restructured, we will still be required to pay certain costs and expenses incurred in connection therewith, such as legal, accounting, and other professional and advisory fees. Furthermore, the B+L Separation, if completed, is expected to result in dyssynergy costs, which may be greater than we anticipate and/or may be significant. In addition, we could be subject to legal proceedings or other claims challenging the B+L Separation, which could result in substantial costs and liability and also divert management's attention and resources, any of which could harm our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the above factors could cause the B+L Separation (or the failure to consummate the B+L Separation) to have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the Distribution proceeds pursuant to the Arrangement, to preserve the tax-free treatment of certain transactions related to the Distribution, we may not be able to engage in certain transactions. In such case, we could incur significant tax liabilities, or be liable to Bausch + Lomb, if certain transactions occur which result in these transactions or the Distribution being subject to tax. The application of certain requirements of the public company &#8220;butterfly reorganization&#8221; rules in Section 55 of the Canadian Tax Act depend on events that may not be within our control.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently expect that the Distribution will be effected pursuant to the public company &#8220;butterfly reorganization&#8221; rules in Section 55 of the Income Tax Act (Canada) (the &#8220;Canadian Tax Act&#8221;). If the Distribution is effected pursuant to the public company &#8220;butterfly reorganization&#8221; rules in Section 55 of the Tax Act as currently anticipated, we and Bausch + Lomb will recognize a taxable gain on the Distribution if (a) within three years of the Distribution, Bausch + Lomb engages in a subsequent spin-off or split-up transaction under Section 55 of the Canadian Tax Act or the Company engages in a split-up (but not spin-off) transaction under Section 55 of the Canadian Tax Act; (b) a &#8220;specified shareholder&#8221; as defined for purposes of the &#8220;butterfly reorganization&#8221; rules in Section 55 of the Canadian Tax Act disposes of our shares or shares of Bausch + Lomb, or property that derives 10% or more of its value from such shares and an unrelated person or partnership acquires such property or property substituted therefore as part of the &#8220;series of transactions&#8221; which includes the Distribution; (c) there is an acquisition of control of the Company or Bausch + Lomb that is part of the &#8220;series of transactions&#8221; that includes the Distribution; or (d) certain persons acquire shares in the capital of Bausch + Lomb (other than in specified permitted transactions) in contemplation of and as part of the &#8220;series of transactions&#8221; that includes, the Distribution. If any of the above events, certain of which are outside the control of the Company and Bausch + Lomb, were to occur and to cause the Distribution to be taxable to us and/or to Bausch + Lomb, then we or Bausch + Lomb, as applicable, and, in some cases, both us and Bausch + Lomb, would be liable for a substantial amount of tax.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these potentially significant tax consequences, if the Arrangement is pursued, it is anticipated that we will agree with Bausch + Lomb to certain tax-related covenants, which may restrict us from taking certain actions that we might otherwise </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">choose to take, some of which could be material, and the nature, extent and effect of these restrictions will depend on the manner in which the Distribution is effected. Furthermore, if we breach any of these tax-related covenants, we may be required to indemnify Bausch + Lomb against any taxes or other losses suffered or incurred from or in connection with such breach, which loss may include the taxable gain recognized by Bausch + Lomb if the Separation were to be taxable, as further described above.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our plan to pursue an IPO of our Solta medical device aesthetics business is subject to various risks and uncertainties and may not be completed in accordance with the expected plans or anticipated timeline, or at all, and will involve significant time, expense, and distraction, which could disrupt or have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2021, we announced that we intend to pursue an IPO of Solta Medical. The proposed Solta IPO would establish Solta Medical as a separate publicly traded company that consists of our medical aesthetics business. The proposed Solta IPO is subject to regulatory approvals and certain conditions, including final approval by our Board of Directors and compliance with (including completion of all necessary filings required by) U.S. securities laws and stock exchange rules. The failure to satisfy all of the required conditions could delay the completion of the Solta IPO for a significant period of time or prevent it from occurring at all. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unanticipated developments, including disruptions to business and commerce induced by the COVID-19 pandemic, unfavorable market conditions, possible delays in obtaining any necessary stock exchange, regulatory or other approval or the failure to obtain any such approvals, negotiating challenges, the uncertainty of the financial markets, changes in the laws and regulations (both in the U.S. and in other jurisdictions, including China), reactions of customers and other parties, industry or economic conditions outside of the Company&#8217;s control, and other challenges in executing the Solta IPO, could delay or prevent the completion of the Solta IPO, or cause the Solta IPO to occur on terms or conditions that are different or less favorable than expected. Any changes to the Solta IPO or delay in completing the Solta IPO could cause us not to realize some or all of the expected benefits, or realize them on a different timeline than expected. Further, our Board of Directors could decide, either because of a failure to satisfy conditions or because of market or other factors, to abandon the Solta IPO. No assurance can be given as to whether and when the Solta IPO will occur or whether the Solta IPO will achieve the benefits we expect. As a result, there can be no assurance as to the timing of the completion of the Solta IPO or its terms. Any changes with respect to the timing of the Solta IPO or the terms and conditions on which the Solta IPO occurs could also delay the B+L Separation or cause the B+L Separation to occur on terms or conditions that are different or less favorable than expected.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the Solta IPO is completed, we may not be able to achieve the full strategic and financial benefits expected to result from the Solta IPO. The Solta IPO is expected to unlock value by creating an independent business and distinct investment identity with enhanced strategic and management focus that allows more efficient allocation of resources and capital. In addition, proceeds from the Solta IPO are expected to facilitate further reductions in the aggregate amount of our outstanding indebtedness. We may not achieve these and other anticipated benefits for a variety of reasons, including, among others: (i) following the Solta IPO, Solta may prove to be less valuable on an independent basis than we anticipate, including because it is more susceptible to economic downturns and other adverse events than if it were still a part of the Company and because its business will be less diversified than the Company&#8217;s business prior to the Solta IPO and (ii) other actions required to separate the respective businesses could disrupt our operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executing the Solta IPO will require significant resources, time and attention from our senior management and employees, which senior management and employees are already expending significant resources, time and attention on the B+L Separation. The Solta IPO could cause further distractions and further divert attention and resources away from other projects and the day-to-day operation of our business. Both we and Solta may also experience increased difficulties in attracting, retaining, and motivating management and employees during the pendency of the Solta IPO and following its completion. For more information on these and other related risks, see Item 1A. &#8220;Risk Factors&#8212;Employment-related Risks&#8221; of this Form 10-K. The Solta IPO, whether or not completed, may also have an adverse impact on our relationships with our customers, suppliers and other business counterparties. The price of our common shares could also fluctuate significantly in response to developments or market speculation related to the proposed Solta IPO. The Solta IPO, if completed, may also have the effect of exacerbating other risk factors disclosed in this Item 1A. &#8220;Risk Factors.&#8221;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have already incurred expenses in connection with the Solta IPO, and expect that the process of completing the Solta IPO will be time-consuming and involve significant additional costs and expenses, which may not yield a discernible benefit if the Solta IPO is not completed or is not completed on the timeline or terms anticipated. In addition, if the Solta IPO is not completed, we will still be required to pay certain costs and expenses incurred in connection therewith, such as legal, accounting, and other professional and advisory fees. Furthermore, the Solta IPO, if completed, is expected to result in dyssynergy costs, which may be greater than we anticipate and/or may be significant. In addition, we could be subject to legal </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceedings or other claims challenging the Solta IPO, which could result in substantial costs and liability and also divert management&#8217;s attention and resources, any of which could harm our business. </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the above factors could cause the Solta IPO (or the failure to consummate the Solta IPO) to have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In connection with the B+L Separation and the Solta IPO, we will continue to rely on Bausch + Lomb and, to a lesser degree, Solta for certain services, which services may not be sufficient to meet our needs, which may result in increased costs and otherwise adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the B+L Separation, we anticipate that we and Bausch + Lomb will provide to each other certain services for a transitional period in exchange for certain agreed-upon fees. In addition, in connection with the Solta IPO, we anticipate that we and Solta may provide to each other certain services for a transitional period in exchange for certain agreed-upon fees. If we no longer receive these services from Bausch + Lomb and/or Solta due to the termination or expiration of these transitional services, we may not be able to perform these services ourselves and/or find appropriate third-party arrangements at a reasonable cost (and any such costs may be higher than those charged by Bausch + Lomb or Solta). In addition, in connection with the B+L Separation and the Solta IPO, we expect that a number of the employees that support our business (which number of employees may be significant) will be employed by legal entities that are owned by Bausch + Lomb or Solta and not by us. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain contracts used in our business may need to be replaced in connection with the B+L Separation or Solta IPO and failure to obtain such replacement contracts could increase our expenses or otherwise adversely affect our results of operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the B+L Separation and the Solta IPO, we may be required to replace certain shared contracts. It is possible that, in connection with the replacement process, some parties may seek more favorable contractual terms from us. If we are unable to obtain such replacement contracts, the loss of these contracts could increase our expenses or otherwise materially adversely affect our business, results of operations and financial condition.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In connection with the B+L Separation and Solta IPO, some of our directors and officers may have actual or potential conflicts of interest because of their equity ownership in Bausch + Lomb or Solta, respectively, and/or because they also serve as officers or directors of Bausch + Lomb or Solta.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of their anticipated positions with Bausch + Lomb, in connection with the B+L Separation, and/or with Solta, in connection with the Solta IPO, some of our directors and executive officers may own common shares of Bausch + Lomb and/or Solta or have options to acquire shares of Bausch + Lomb and/or Solta, and the individual holdings may be significant for some of these individuals compared to their total assets. In addition, in connection with the B+L Separation, certain of our current or former officers and directors will also serve as officers or directors of Bausch + Lomb and, in connection with the Solta IPO, certain of our current or former officers and directors will also serve as officers or directors of Solta. A director who has a material interest in a matter before our Board of Directors or any committee on which he or she serves is required to disclose such interest as soon as the director becomes aware of it in accordance with applicable law. In situations where a director has a material interest in a matter to be considered by our Board of Directors or any committee on which he or she serves, such director may be required to excuse himself or herself from the meeting while discussions and voting with respect to the matter are taking place. Although all transactions with related parties will be approved by independent members of our Board of Directors that may meet in the absence of senior executive officers or non-independent directors, the ownership of Bausch + Lomb or Solta equity or service to Bausch + Lomb or Solta may create the appearance of conflicts of interest when the Bausch + Lomb-affiliated or Solta-affiliated directors and officers are faced with decisions that could have different implications for Bausch + Lomb, Solta or us. For example, potential conflicts of interest could arise in connection with the resolution of any dispute that may arise between Bausch + Lomb and us regarding the terms of the B+L Separation or between Solta and us regarding the terms of the Solta IPO. Potential conflicts of interest could also arise if we enter into commercial arrangements with Bausch + Lomb or Solta in the future. As a result of these actual or apparent conflicts, we may be precluded from pursuing certain growth initiatives. While the Board of Directors believes that, given its size and structure, such actual or potential conflicts of interest can be managed adequately, including that the independent members of our Board of Directors may meet in the absence of senior executive officers or non-independent directors in respect of the relevant matter, the actual or perceived conflicts of interest that may arise could cause reputational or other harm.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In connection with both the B+L Separation and the Solta IPO and the various separation-related agreements to be entered into by us and Bausch + Lomb or Solta in connection with those proposed transactions, it is anticipated that we will agree to indemnify Bausch + Lomb and Solta, respectively, for certain liabilities, and Bausch + Lomb and Solta will agree to indemnify us for certain liabilities. However, there can be no assurance that Bausch + Lomb&#8217;s or Solta&#8217;s indemnity will be </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">sufficient to insure us against the full amount of such liabilities, or that Bausch + Lomb&#8217;s or Solta&#8217;s ability to satisfy its indemnification obligation will not be impaired in the future. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is anticipated that, in connection with the various separation-related agreements to be entered into between Bausch + Lomb and us in connection with the Separation and between Solta and us in connection with the Solta IPO, Bausch + Lomb and Solta, respectively, will agree to indemnify us for certain liabilities. However, there can be no assurance that the indemnity from Bausch + Lomb or Solta, as the case may be, will be sufficient to protect us against the full amount of such liabilities, or that Bausch + Lomb or Solta, as the case may be, will be able to fully satisfy its indemnification obligations in the future. Even if we ultimately succeed in recovering from Bausch + Lomb or Solta, as the case may be, any amounts for which we are held liable, we may be temporarily required to bear these losses. Each of these risks could negatively affect our business, financial condition, results of operations and cash flows. Furthermore, any indemnification claim against us either by Bausch + Lomb, including for a breach of the tax-related covenants described above, or by Solta could be substantial, may not be able to be satisfied and may have a material adverse effect on us. Each of these risks could also negatively affect our business, financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal and Reputational Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are the subject of a number of ongoing legal proceedings, investigations and inquiries respecting certain of our historical distribution, marketing, pricing, disclosure and accounting practices, including our former relationship with Philidor, which have had and could continue to have a material adverse effect on our reputation, business, financial condition, cash flows and results of operations, could result in additional claims and material liabilities, and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have successfully settled or otherwise resolved a number of legacy legal proceedings, investigations and inquiries relating to, among other things, our disclosure and accounting practices and our former relationship with Philidor, including the securities class action litigation matters in both the U.S. and Canada, the investigation by the SEC, the investigation order from the Autorit&#233; des marches financiers (the &#8220;AMF&#8221;) (our principal securities regulator in Canada) and certain derivative lawsuits, we are currently still the subject of a number of other ongoing legal proceedings and investigations and inquiries by governmental agencies, including, but not limited to, the following: (i) a number of pending securities litigations,  including certain opt-out actions in the U.S. (related to the U.S. Securities Litigation which has been settled, but remains subject to an objector's appeal of the final court approval), and in Canada (related to the securities class action litigation in Canada which has been settled), have been instituted, the allegations of which relate to, among other things, allegedly false and misleading statements by the Company and/or failures to disclose information about our business and prospects, including relating to drug pricing, our policies and accounting practices, our use of specialty pharmacies, and our former relationship with Philidor, and (ii) a lawsuit brought against the Company in the Superior Court of New Jersey asserting claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. In addition, we could, in the future, face additional legal proceedings and investigations and inquiries by governmental agencies relating to these or similar matters. For more information regarding legal proceedings, see Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict how long such proceedings, investigations and inquiries will continue, but we anticipate that we will continue to incur significant costs in connection with some or all of these matters and that some or all of these proceedings, investigations and inquiries will result in a substantial distraction of management&#8217;s time, regardless of the outcome. Some or all of these proceedings, investigations and inquiries will likely result in damages, settlement payments (such as the $1,210 million payment to be made by the Company in connection with the previously settled U.S. Securities Litigation (subject to an objector's appeal of the final court approval)), fines, penalties, consent orders or other administrative sanctions (including exclusion from federal programs) against the Company and/or certain of our directors and officers, any of which could be material, or in changes to our business practices, which, in turn, may result in or may contribute to an inability by us to meet the financial covenant contained in our Restated Credit Agreement (or that may be contained in our New Restated Credit Agreement, as defined below). Furthermore, publicity surrounding these proceedings, investigations and inquiries or any enforcement action as a result thereof, even if ultimately resolved favorably for us could result in additional investigations and legal proceedings. As a result, these proceedings, investigations and inquiries could have a material adverse effect on our reputation, business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our historical business practices, including with respect to past pricing practices, are under scrutiny. Any changes to our practices relating to pricing or the current prices of products, whether imposed, legislated or voluntary, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are under scrutiny with respect to our historical business practices (including with respect to past pricing practices), including various securities litigations, including certain opt-out actions in the U.S. (related to the previously settled securities class action (subject to an objector's appeal of the final court approval)) and in Canada (related to the settled securities class action), and certain other lawsuits. We are unable to predict how such proceedings, investigations and inquiries will impact our current business practices, including with respect to pricing, or the prices of our products, including whether we will be required to impose pricing freezes or controls, pricing reductions (including on a retroactive basis) or other price regulation for some or all of our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in recent years, in the U.S., state and federal governments have considered implementing legislation that would control or regulate the prices of drugs. Other countries have announced or implemented measures on pricing, including suspensions on price increases, prospective and possibly retroactive price reductions and other recoupments. These measures and proposed measures vary by country. These measures and these proposed measures and legislation, if implemented, could lead to impairment of certain of our intangible assets which could be significant, and/or could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are involved in various other legal and governmental proceedings that are uncertain, costly and time-consuming and could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in a number of other legal and governmental proceedings and may be involved in additional litigation in the future. These proceedings are complex and extended and occupy the resources of our management and employees. These proceedings are also costly to prosecute and defend and may involve substantial awards or damages payable by us if not found in our favor. We may also be required to pay substantial amounts or grant certain rights on unfavorable terms in order to settle such proceedings. Defending against or settling such claims and any unfavorable legal decisions, settlements or orders could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. For more information regarding legal proceedings, see Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the pharmaceutical industry, including our Company, has been the focus of both private payor and governmental concern regarding pricing of pharmaceutical products. Related actions, including Congressional and other governmental investigations and litigation, are costly and time-consuming, and adverse resolution of such actions or changes in our business practices, such as our approach to the pricing of our pharmaceutical products, could adversely affect our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the pharmaceutical and medical device industries historically have generated substantial litigation concerning the manufacture, use and sale of products and we expect this litigation activity to continue. As a result, we expect that patents related to our products will be routinely challenged, and the validity or enforceability of our patents may not be upheld. In order to protect or enforce patent rights, we may initiate litigation against third parties. Our patents may also be challenged in administrative proceedings in the United States Patent and Trademark Office and patent offices outside of the United States. If we are not successful in defending an attack on our patents and maintaining exclusive rights to market one or more of our products still under patent protection, we could lose a significant portion of sales in a very short period. Even in cases where we prevail in an infringement claim, legal remedies available for harm caused to us may not be sufficient to make us whole. We may also become subject to, or threatened with, legal proceedings and infringement claims by third parties and may have to defend against charges that we infringed, misappropriated or otherwise violated patents or the intellectual property or proprietary rights of third parties. Third parties may also request a preliminary or permanent injunction from a court of law to prevent us from marketing a product. Even if we believe third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of infringement, validity, enforceability or priority. If we are found to infringe, misappropriate or otherwise violate the intellectual property rights of others, we could lose our right to develop, manufacture or sell products, including our generic products, or could be required to pay monetary damages or royalties to license proprietary rights from third parties, which could be substantial and include treble damages and attorneys&#8217; fees, if we are found to willfully infringe any intellectual property rights of others. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Any of the foregoing events could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the U.S., it has become increasingly common for patent infringement actions to prompt claims that antitrust laws have been violated during the prosecution of the patent or during litigation involving the defense of that patent. Such claims by direct and indirect purchasers and other payers are typically filed as class actions. The relief sought may include treble damages and restitution claims. Similarly, antitrust claims may be brought by government entities or private parties </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">following settlement of patent litigation, alleging that such settlements are anti-competitive and in violation of antitrust laws. In the U.S. and Europe, regulatory authorities have continued to challenge as anti-competitive so-called &#8220;reverse payment&#8221; settlements between branded and generic drug manufacturers. We may also be subject to other antitrust litigation involving competition claims unrelated to patent infringement and prosecution. For more information regarding legal proceedings, see Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements. A successful antitrust claim by a private party or government entity against us could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on third parties to meet their contractual, legal, regulatory, and other obligations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on distributors, suppliers, contract research organizations, vendors, service providers, business partners and other third parties to research, develop, manufacture, distribute, market and sell many of our products, as well as perform other services relating to our business. We rely on these third parties to meet their contractual, legal, regulatory and other obligations. A failure to maintain these relationships or poor performance by these third parties could negatively impact our business. In addition, we cannot guarantee that the contractual terms and protections and compliance controls, policies and procedures we have put in place will be sufficient to ensure that such third parties will meet their legal, contractual and regulatory obligations or that these terms, controls, policies, procedures and other protections will protect us from acts committed by our agents, contractors, distributors, suppliers, service providers or business partners that violate contractual obligations or the laws or regulations of the jurisdictions in which we operate, including matters respecting anti-corruption, fraud, bribery and kickbacks and false claims, pricing, sales and marketing practices, privacy laws and other legal obligations. Any failure of such third parties to meet these legal, contractual and regulatory obligations or any improper actions by such third parties or even allegations of such non-compliance or actions could damage our reputation, adversely impact our ability to conduct business in certain markets and subject us to civil or criminal legal proceedings and regulatory investigations, monetary and non-monetary damages and penalties and could cause us to incur significant legal and investigatory fees and, as a result, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. For example, the allegations about the activities of Philidor and our former relationship with Philidor have resulted in a number of investigations, inquiries and legal proceedings against us, which have damaged and may further damage our reputation and result in damages, fines, penalties or administrative sanctions against the Company and/or certain of our officers. For more information regarding legal proceedings, see Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our products cause, or are alleged to cause, serious or widespread personal injury, we may have to withdraw those products from the market and/or incur significant costs, including payment of substantial sums in damages, and we may be subject to exposure relating to product liability claims. In addition, our product liability self-insurance program may not be adequate to cover future losses. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent business risk of exposure to significant product liability and other claims in the event that the use of our products caused, or is alleged to have caused, adverse effects. These product liability proceedings may be costly to prosecute and defend and may involve substantial awards or damages payable by us if not found in our favor.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our products may cause, or may appear to have caused, adverse side effects (including death) or potentially dangerous drug interactions that we may not learn about or understand fully until the drug has been administered to patients for some time. The withdrawal of a product following complaints and/or incurring significant costs, including the requirement to pay substantial damages in personal injury cases or product liability cases, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, since March 31, 2014, we have self-insured substantially all of our product liability risk for claims arising after that date. We periodically evaluate and adjust our claims reserves to reflect trends in our own experience, as well as industry trends. However, historical loss trends may not be adequate to cover future losses, as historical trends may not be indicative of future losses. If ultimate results exceed our estimates, this would result in losses in excess of our reserved amounts. If we were required to pay a significant amount on account of these liabilities for which we self-insure, this could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our marketing, promotional and business practices, as well as the manner in which sales forces interact with purchasers, prescribers and patients, are subject to extensive regulation and any material failure to comply could result in significant sanctions against us.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketing, promotional and business practices of pharmaceutical and medical device companies, as well as the manner in which companies&#8217; in-house or third-party sales forces interact with purchasers, prescribers, and patients, are subject </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to extensive regulation, enforcement of which may result in the imposition of civil, regulatory and/or criminal penalties, injunctions, and/or limitations on marketing practice for some of our products and/or pricing restrictions or mandated price reductions for some of our products. Many companies, including us, have been the subject of claims related to these practices asserted by federal authorities. These claims have resulted in fines and other consequences, such as entering into corporate integrity agreements with the U.S. government. Companies may not promote drugs or devices for &#8220;off-label&#8221; uses-that is, uses that are not described in the product&#8217;s labeling and that differ from those approved by the FDA, Health Canada, EMA or other applicable regulatory agencies. A company that is found to have improperly promoted off-label uses may be subject to significant liability, including civil and administrative remedies (such as entering into corporate integrity agreements with the U.S. government), as well as criminal sanctions. In addition, management&#8217;s attention could be diverted from our business operations and our reputation could be damaged. For more information regarding legal proceedings, see Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt-related Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Restated Credit Agreement and the indentures governing our senior notes impose restrictive covenants on us. Our failure to comply with these covenants could trigger events, which could result in the acceleration of the related debt, a cross-default or cross-acceleration to other debt, foreclosure upon any collateral securing the debt and termination of any commitments to lend, each of which would have a material adverse effect on our business, financial condition, cash flows and results of operations and would cause the market value of our common shares and/or debt securities to decline and could lead to bankruptcy or liquidation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Restated Credit Agreement and the various indentures governing our senior notes contain covenants that restrict the way we conduct business and require us to satisfy certain financial tests in order to incur debt or take other actions. For example, our Restated Credit Agreement contains a financial covenant that requires us to maintain a certain financial ratio at fiscal quarter end. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Restated Credit Agreement contains a specified quarterly financial maintenance covenant (consisting of a first lien leverage ratio). As of December 31, 2021, we were in compliance with this financial maintenance covenant. However, we can make no assurance that we will be able to comply with the restrictive covenants contained in the Restated Credit Agreement and indentures in the future. Based on our current forecast for the next twelve months from the date of issuance of this Form 10-K, we expect to remain in compliance with this financial maintenance covenant and meet our debt obligations over that same period. In the event that we perform below our forecasted levels, we may also implement certain additional cost-efficiency initiatives, such as rationalization of selling, general and administrative expenses ("SG&amp;A") and R&amp;D spend, which would allow us to continue to comply with the financial maintenance covenant. The Company may consider taking other actions, including divesting other businesses, refinancing debt, issuing equity or equity-linked securities as deemed appropriate, to provide additional coverage in complying with the financial maintenance covenant and meeting its debt service obligations, or may negotiate with the applicable lenders for an amendment or modification to such covenant, as deemed appropriate. However, we cannot guarantee that any of the above-noted actions would be achieved. If we perform below our forecasted levels and the actions referenced above are not effective, we would fail to comply with our financial maintenance covenant. In that instance, we would be in default, and our lenders would be permitted to accelerate our debt unless we could obtain an amendment. If our debt was accelerated, we would not have sufficient funds to repay our debt absent a refinancing, and we cannot provide assurance that we would be able to obtain a refinancing.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to comply with the covenants in our debt instruments could lead to a default or an event of default under the terms thereof, for which we may need to seek relief from our lenders and noteholders in order to waive the associated default or event of default and avoid a potential acceleration of the related indebtedness or cross-default or cross-acceleration to other debt. There can be no assurance that we would be able to obtain such relief on commercially reasonable terms or otherwise and we may be required to incur significant additional costs. In addition, the lenders under our Restated Credit Agreement and holders of our senior notes may impose additional operating and financial restrictions on us as a condition to granting any such waiver. If an event of default is not cured or is not otherwise waived, a majority of lenders in principal amount under our Restated Credit Agreement or the trustee or holders of at least 25% in principal amount of a series of our senior notes may accelerate the maturity of the related debt under these agreements, foreclose upon any collateral securing the debt and terminate any commitments to lend, any of which would have a material adverse effect on our business, financial condition, cash flows and results of operations and would cause the market value of our common shares and/or debt securities to decline. Furthermore, under these circumstances, we may not have sufficient funds or other resources to satisfy all of our obligations and we may be unable to obtain alternative financing on terms acceptable to us or at all. In such circumstances, we could be forced into bankruptcy or liquidation and, as a result, investors could lose all or a portion of their investment in our securities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, we announced our intention to refinance our existing Restated Credit Agreement with an amended Restated Credit Agreement (the &#8220;New Restated Credit Agreement&#8221; and such refinancing, the &#8220;Credit Agreement Refinancing&#8221;). The New Restated Credit Agreement is expected to consist of approximately $2,500 million of term B loans and a $975 million </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revolving credit facility. The Credit Agreement Refinancing is expected to occur only upon the completion of the B+L IPO and a related debt financing by Bausch + Lomb, and is expected to, among other things, permit us to designate Bausch + Lomb as an &#8220;unrestricted&#8221; subsidiary of the New Restated Credit Agreement covenants upon achievement of a 7.60:1.00 pro forma &#8220;Remainco Total Leverage Ratio.&#8221; The Credit Agreement Refinancing is intended to facilitate the B+L Separation. However, no definitive documentation for the Credit Agreement Refinancing has been executed, and accordingly there can be no assurance that the Credit Agreement Refinancing will occur on the anticipated terms or at all. If we are unable to consummate the Credit Agreement Refinancing, we may be unable to complete the B+L Separation on the anticipated terms or timeline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">To service our debt, we will be required to generate a significant amount of cash. Our ability to generate cash depends on a number of factors, some of which are beyond our control, and any failure to meet our debt obligations would have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a significant amount of indebtedness. For details regarding our debt and the maturity dates thereof, see Note 10, "FINANCING ARRANGEMENTS" to our audited Consolidated Financial Statements. Our ability to satisfy our debt obligations, including any special mandatory redemption of our February 2027 Secured Notes (as defined herein) if the B+L IPO has not occurred on or prior to August 15, 2022, will depend principally upon our future operating performance. As a result, prevailing economic conditions and financial, business and other factors, many of which are beyond our control, may affect our ability to make payments on our debt. If we do not generate sufficient cash flow to satisfy our debt obligations, we may have to undertake alternative financing plans, such as refinancing or restructuring our debt, selling assets, reducing or delaying capital investments or seeking to raise additional capital. Alternatively, as we have done in the past, we may also elect to refinance certain of our debt, for example, to extend maturities. Our ability to restructure or refinance our debt will depend on the capital markets and our financial condition at such time. If we are unable to access the capital markets, whether because of the condition of those capital markets or our own financial condition or reputation within such capital markets, we may be unable to refinance our debt. In addition, any refinancing of our debt could be at higher interest rates and may require us to comply with more onerous covenants, which could further restrict our business operations. Further, given our capital structure, any refinancing of our senior unsecured debt may be with secured debt, thereby increasing our first lien and/or secured leverage ratios. Our inability to generate sufficient cash flow to satisfy our debt obligations or to refinance our obligations on commercially reasonable terms, or at all, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repayment of our indebtedness is dependent on the generation of cash flow by our subsidiaries and their ability to make such cash available to us, by dividend, debt repayment or otherwise. Our subsidiaries may not be able to, or may not be permitted to, make distributions to enable us to make payments in respect of our indebtedness. Each subsidiary is a distinct legal entity and, under certain circumstances, legal and contractual restrictions may limit our ability to obtain cash from our subsidiaries. Certain subsidiaries include non-U.S. subsidiaries that may be prohibited by law or other regulations from distributing funds to us and/or we may be subject to payment of taxes and withholdings on such distributions. In the event that we do not receive distributions from our subsidiaries or receive cash via services rendered, loans and intellectual property licensed, we may be unable to make required principal and interest payments on our indebtedness.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue to reduce our indebtedness will depend upon factors including our future operating performance, our ability to access the capital markets to refinance existing debt and prevailing economic conditions and financial, business and other factors, many of which are beyond our control. Additionally, our ability to reduce our indebtedness using the proceeds of the B+L IPO and the Solta IPO will be subject to the risks and uncertainties relating to those transactions, as previously discussed. We can provide no assurance of the amount by which we will reduce our debt, if at all. In addition, servicing our debt will result in a reduction in the amount of our cash flow available for other purposes, including operating costs and capital expenditures that could improve our competitive position and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant indebtedness, which restricts the manner in which we conduct business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant indebtedness, including in connection with our prior acquisitions. We may incur additional long-term debt and working capital lines of credit to meet future financing needs, subject to certain restrictions and prohibitions under the agreements governing our indebtedness, which would increase our total debt. This additional debt may be substantial and some of this indebtedness may be secured.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreements governing our indebtedness contain restrictive covenants which impose certain limitations on the way we conduct our business, including limitations on the amount of additional debt we are able to incur, prohibitions on incurring additional debt if certain financial covenants are not met and restrictions on our ability to make certain investments and other restricted payments. Any additional debt, to the extent we are able to incur it, may further restrict the manner in which we conduct business. Such restrictions, prohibitions and limitations could impact our ability to implement elements of our strategy, including in the following ways:</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our flexibility to plan for, or react to, competitive challenges in our business and the pharmaceutical and medical device industries may be compromised;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we may be put at a competitive disadvantage relative to competitors that do not have as much debt as we have, and competitors that may be in a more favorable position to access additional capital resources; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to make acquisitions and execute business development activities through acquisitions will be limited and may, in future years, continue to be limited; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to resolve regulatory and litigation matters may be limited.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, our credit ratings have been downgraded. Any further downgrade in our corporate credit ratings or other credit ratings may increase our cost of borrowing and may negatively impact our ability to raise additional debt capital.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are exposed to risks related to interest rates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior secured credit facilities bear interest based on U.S. dollar London Interbank Offering Rates or U.S. Prime Rate, or Federal Funds effective rate (for U.S. dollar loans) and Canadian Prime Rate or Canada Bankers&#8217; Acceptance Rate (for Canadian dollar loans). Thus, a change in the short-term interest rate environment (especially a material change) could have an adverse effect on our business, financial condition, cash flows and results of operations (which adverse effect could be material) and could cause the market value of our common shares and/or debt securities to decline. As of December 31, 2021, we did not have any outstanding interest rate swap contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, the head of the United Kingdom Financial Conduct Authority announced the desire to phase out the use of LIBOR by the end of 2021. In March 2021, ICE Benchmark Administration Limited, the administrator of LIBOR, extended the transition dates of all USD LIBOR settings (other than the one week and two-month USD LIBOR settings) to June 30, 2023, after which USD LIBOR settings will cease to be published. If LIBOR ceases to exist, we will need to endeavor, with the administrative agent thereunder, to amend the credit facilities to substitute LIBOR with an alternative rate of interest that gives due consideration to the then-prevailing market convention for syndicated loans in the U.S., subject to notice to all lenders and the absence of objection by the &#8220;required lenders,&#8221; or pay interest based on the "base rate" until we can otherwise renegotiate our Senior Secured Credit Facilities to include a LIBOR replacement. Any change in accordance with the aforementioned procedures, or the conversion of loans to base rate or U.S. prime rate loans, could have an adverse impact on our cost of capital. Currently, there is no definitive information regarding the future utilization of LIBOR or of any particular replacement rate. As such, the potential effect of any such event on our business, financial condition, cash flows and results of operations cannot yet be determined.  However, any such event could have a material adverse effect on our business, financial condition, cash flows and results from operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment-related Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The transition of our key management positions in connection with the B+L IPO and the Solta IPO will be critical to our success, and the failure to successfully manage this transition could adversely impact our business. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the B+L IPO and the Solta IPO, we have announced the appointment of a new chief executive officer, chief financial officer, general counsel and other executives and key employees. The departure of key leadership personnel often results in the loss of significant knowledge and experience, and the ability of our new management to quickly expand their knowledge of our business will be critical to their ability to make informed decisions about our strategy and operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any significant leadership change or senior management transition involves inherent risks, and any future changes to our management that may occur during the transition could cause significant disruption to the Company and its operations. The failure to adequately manage succession of senior management and other key personnel or the failure of key employees to successfully transition into new roles could cause further disruption to our business. In addition, changes in senior management may create uncertainty among investors, employees, business partners and others concerning the Company&#8217;s future direction and performance. Any disruption in our operations or adverse impacts from such uncertainty could have a material adverse effect on our business, financial condition, cash flows and results of operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The loss of the services of, or our inability to recruit, retain or motivate, our executives and other key employees could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must continue to retain and motivate our executives and other key employees, and to recruit other executives and employees, in order to strengthen our management team and workforce. Our ability to retain or recruit executive and other key employees may be hindered or delayed by, among other things, competition from other employers who may be able to offer more attractive compensation packages, the reputational challenges the Company has faced as a result of historical issues and may in the future continue to face and the perceived or actual uncertainty created by the proposed B+L Separation and Solta IPO, and the changes to our executive team in connection with the proposed B+L IPO and Solta IPO. A failure by us to retain, </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">motivate and recruit executives and other key employees or the unanticipated loss of the services of any of these executives or key employees for any reason, whether temporary or permanent, could create disruptions in our business, could cause concerns and instability for management and employees, current and potential customers, credit rating agencies and other third parties with whom we do business and our shareholders and debt holders and could cause concern regarding our ability to execute our business strategy or to manage operations in the manner previously conducted and, as a result, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. Furthermore, as a result of any failure to retain, or loss of, any executives or key employees, we may experience increased costs in order to identify and recruit a suitable replacement in a timely manner (and, even if we are able to hire a qualified successor, the search process and transition period may be difficult to manage and result in additional periods of uncertainty), which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. In addition, once identified and recruited, the transition of new executives and key employees may be difficult to manage and we cannot guarantee that new executives and employees will efficiently transition into their roles or ultimately be successful in their roles. Finally, as a result of changes in our executives and key employees, there may be changes in the way we conduct our business, as well as changes to our business strategy. We cannot predict what these changes may involve or the timing of any such changes and how they will impact our product sales, revenue, business, financial condition, cash flows or results of operations, but any such changes could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to&#160;decline. Any of these factors could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax-related Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rates may increase.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations in various countries that have differing tax laws and rates. Our tax reporting is supported by current domestic tax laws in the countries in which we operate and the application of tax treaties between the various countries in which we operate. Our income tax reporting is subject to audit by domestic and foreign authorities. Our effective tax rate may change from year to year based on changes in the mix of activities and income earned among the different jurisdictions in which we operate; changes in tax laws in these jurisdictions; changes in the tax treaties between various countries in which we operate; changes in our eligibility for benefits under those tax treaties; and changes in the estimated values of deferred tax assets and liabilities. Tax laws, regulations, and administrative practices in various jurisdictions may be subject to significant change, with or without notice, due to economic, political, and other conditions, and significant judgment is required in evaluating and estimating our provision and accruals for these taxes. Such changes could result in a substantial increase in the effective tax rate on all or a portion of our income. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our business is conducted through U.S. subsidiaries. On December 22, 2017, the Tax Cuts and Jobs Act (the &#8220;TCJA&#8221;) significantly revised U.S. federal corporate income tax law by, among other things, reducing the U.S. federal corporate income tax rate to 21%, limiting the tax deduction for interest expense to 30% of adjusted earnings, allowing immediate expensing for certain new investments, implementing a modified territorial tax system that includes a one-time transition tax on deemed repatriated earnings of non-U.S. subsidiaries of U.S. persons, imposing an additional U.S. tax on such non-U.S. subsidiaries&#8217; earnings which are considered to be Global Intangible Low Taxed Income (referred to as &#8220;GILTI&#8221;) and imposing an alternative &#8220;base erosion and anti-abuse tax&#8221; (&#8220;BEAT&#8221;) on U.S. corporations that make deductible payments to foreign related persons in excess of specified amounts and, effective for net operating losses (&#8220;NOLs&#8221;) arising in taxable years beginning after December 31, 2017, eliminating net operating loss carrybacks, permitting indefinite net operating loss carryforwards and limiting the use of net operating loss carryforwards to 80% of current year taxable income. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of uncertainties and ambiguities as to the interpretation and application of many of the provisions in the TCJA, including the provisions relating to the modified territorial tax system, the one-time transition tax and the BEAT. While the U.S. Treasury Department and the Internal Revenue Service have issued proposed and final regulations and other guidance on many provisions in the TCJA that address some of these uncertainties and ambiguities, there are still no final regulations or other definitive guidance addressing other uncertainties and ambiguities in the TCJA. In the absence of guidance on these issues, we will use what we believe are reasonable interpretations and assumptions in interpreting and applying the TCJA for purposes of determining our U.S. subsidiaries&#8217; cash tax liabilities and results of operations, which may change as we receive additional clarification and implementation guidance and as the interpretation of the TCJA evolves over time. It is possible that the Internal Revenue Service could issue subsequent guidance or take positions on audit that differ from the interpretations and assumptions that we previously made, which could have a material adverse effect on our cash tax liabilities, results of operations and financial condition. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proposed changes to tax law in the U.S. and outside of the U.S. could affect our corporate tax rate</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, U.S. President Joseph Biden proposed changes to the U.S. tax system. Since that date, both houses of Congress have released their own proposals for changes to the U.S. tax system, which proposals differ in a number of respects from the President&#8217;s proposal. The proposals under discussion have included changes to the U.S. corporate tax system that would increase U.S. corporate tax rates, although the most recent proposals do not include any such rate increase, and changes that would raise the tax rate on and make other changes to the taxation of GILTI earned by foreign subsidiaries. Also under consideration are modifications to the BEAT, which would tax certain payments, including some that are related to inventory, made to affiliates that are subject to an effective tax rate of less than specified rates. Certain proposals also include limitations on the participation exemption for foreign dividends received and interest expense. In addition, certain proposals include limitations on the deduction of interest expense and carryforwards of unused interest expense, as well as an excise tax on certain pharmaceutical products that are non-compliant with the proposed drug pricing legislation. We are unable to predict which, if any, U.S. tax reform proposals will be enacted into law, and what effects any enacted legislation might have on our liability for U.S. corporate tax. However, it is possible that the enactment of changes in the U.S. corporate tax system could have a material adverse effect on our liability for U.S. corporate tax and our consolidated effective tax rate. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2021, the Organisation for Economic Co-operation and Development (&#8220;OECD&#8221;)/G20 inclusive framework on Base Erosion and Profit Shifting (the &#8220;Inclusive Framework&#8221;) published a statement updating and finalizing the key components of a two-pillar plan on global tax reform originally agreed on July 1, 2021, and a timetable for implementation by 2023. The Inclusive Framework plan has now been agreed to by 141 OECD members, including several countries which did not agree to the initial plan. Under pillar one, taxing rights over multinational businesses with global turnover above &#8364;20 billion and a profit margin above 10% will generally be re-allocated to market jurisdictions. Under pillar two, the Inclusive Framework has agreed on a global minimum corporate tax rate of 15% for companies with revenue above &#8364;750 million, calculated on a country-by-country basis. On October 30, 2021, the G20 formally endorsed the new global minimum corporate tax rate rules. The Inclusive Framework agreement must now be implemented by the OECD Members who have agreed to the plan, effective in 2023. On December 20, 2021, the OECD published model rules to implement the pillar two rules, which are generally consistent with agreement reached by the Inclusive Framework in October 2021. Additional guidance is expected to be published in 2022. We will continue to monitor the implementation of the Inclusive Framework agreement by the countries in which we operate. While we currently expect our effective tax rate to be in the range of 12-14% over the long-term, we are unable to predict when and how the Inclusive Framework agreement will be enacted into law in these countries, and it is possible that the implementation of the Inclusive Framework agreement, including the global minimum corporate tax rate could have a material effect on our liability for corporate taxes and our consolidated effective tax rate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes is based on certain estimates and assumptions made by management. Our consolidated income tax rate is affected by the amount of pre-tax income earned in our various operating jurisdictions, the availability of benefits under tax treaties, and the rates of taxes payable in respect of that income. We enter into many transactions and arrangements in the ordinary course of business in respect of which the tax treatment is not entirely certain. We therefore make estimates and judgments based on our knowledge and understanding of applicable tax laws and tax treaties, and the application of those tax laws and tax treaties to our business, in determining our consolidated tax provision. For example, certain countries could seek to tax a greater share of income than we will allocate to our business in such countries. The final outcome of any audits by taxation authorities may differ from the estimates and assumptions that we may use in determining our consolidated tax provisions and accruals. This could result in a material adverse effect on our consolidated income tax provision, financial condition and the net income for the period in which such determinations are made. See Note 17, &#8220;INCOME TAXES&#8221; to our audited Consolidated Financial Statements for a discussion of the tax audits, examinations, and other proceedings currently being conducted with respect to the Company and its subsidiaries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred tax liabilities, deferred tax assets and any related valuation allowances are affected by events and transactions arising in the ordinary course of business, acquisitions of assets and businesses, and non-recurring items. The assessment of the appropriate amount of a valuation allowance against the deferred tax assets is dependent upon several factors, including estimates of the realization of deferred income tax assets, which realization will be primarily based on future taxable income, including the reversal of existing taxable temporary differences. Significant judgment is applied to determine the appropriate amount of valuation allowance to record. Changes in the amount of any valuation allowance required could materially increase or decrease our provision for income taxes in a given period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 17, "INCOME TAXES" to our audited Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Intellectual Property and Exclusivity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The expiration or loss of patent protection or regulatory exclusivity rights for our key products could adversely impact our business. In addition, we have faced generic competition in the past and expect to face additional generic competition in the future. Competitors (including generic and biosimilar competitors) of our products could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of new and innovative products, as well as protecting the underlying intellectual property of our product portfolio, is important to our success in all areas of our business. A significant number of the products we sell either: (i) have no meaningful exclusivity protection via patent or marketing or data exclusivity rights or (ii) are protected by patents or regulatory exclusivity periods that will be expiring in the near future. These products represent a significant amount of our revenues (See Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Business Trends &#8212; Generic Competition and Loss of Exclusivity&#8221; in this Form 10-K for a list of some of these products). The expiration or loss of patent protection or regulatory exclusivity rights for our key products could adversely impact our business. In addition, even for our products that have patent protection or exclusivity rights, we face competition from similar products in the markets in which we participate. As a result, we face significant competition with respect to a substantial majority of our product</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">s.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Without exclusivity protection, competitors and other third parties (including generics and biosimilars) face fewer barriers in introducing competing products. Upon the expiration or loss of patent exclusivity or regulatory exclusivity for our products or otherwise upon the introduction of generic, biosimilar or other competitors (which may be sold at significantly lower prices than our products), we could lose a significant portion of sales and market share of the applicable products in a very short period and, as a result, our revenues could be lower. In addition, the introduction of generic and biosimilar competitors may have a significant downward pressure on the pricing of our branded products which compete with such generics and biosimilars. Where we have the rights, we may elect to launch an authorized generic of such product (either ourselves or through a third party) prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with the launch of an authorized generic, the decline in product sales of such product would still be expected to be significant, and the effect on our future revenues could be material. The introduction of competing products (including generic products and biosimilars) could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may fail to obtain, maintain, license, enforce or defend the intellectual property and proprietary rights required to conduct our business, or third parties may allege that we are infringing, misappropriating or otherwise violating their intellectual property rights, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to acquire, maintain, enforce and defend patent, trademark and other intellectual property and proprietary protections over our products and the processes used to manufacture these products. However, we may not be successful in obtaining such protections, or the patent, trademark and other intellectual property and proprietary rights we do obtain may not be sufficient in breadth and scope to fully protect our products or prevent competing products, or such rights may be susceptible to third-party challenges, which could result in the loss of such intellectual property rights or the narrowing of scope of protection afforded by such rights. Our intellectual property and proprietary rights may also be circumvented by third parties. The failure to obtain, maintain, enforce or defend such intellectual property and proprietary rights, for any reason, could allow third parties to manufacture and sell products that compete with our products or may impact our ability to develop, manufacture and market our own products, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the pharmaceutical and medical device industries historically have generated substantial litigation concerning the manufacture, use and sale of products and we expect this litigation activity to continue. As a result, we expect that patents related to our products will be routinely challenged, and the validity or enforceability of our patents may not be upheld. In order to protect or enforce patent rights, we may initiate litigation against third parties. Our patents may also be challenged in administrative proceedings in the United States Patent and Trademark Office and patent offices outside of the United States. If we are not successful in defending an attack on our patents and maintaining exclusive rights to market one or more of our products still under patent protection, we could lose a significant portion of sales in a very short period. Even in cases where we prevail in an infringement claim, legal remedies available for harm caused to us may not be sufficient to make us whole. We may also become subject to, or threatened with, legal proceedings and infringement claims by third parties and may have to defend against charges that we infringed, misappropriated or otherwise violated patents or the intellectual property or proprietary rights of third parties. Third parties may also request a preliminary or permanent injunction from a court of law to prevent us from marketing a product. Even if we believe third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of infringement, validity, enforceability or priority. If we are found to infringe, misappropriate or otherwise violate the intellectual property rights of others, we could lose our right to develop, manufacture or sell products, including our generic products, or could be required to pay monetary damages or royalties to license proprietary rights from third parties, which could be substantial and include treble damages and attorneys&#8217; fees, if we are found to willfully infringe any intellectual property rights of others. However, we may not be able to obtain any required license from any third party on commercially reasonable terms or at all. Any of the foregoing events could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain of our products and manufacturing processes, we rely on trade secrets and other proprietary information, which we seek to protect, in part, through information technology systems discussed in more detail in the following section, and, in part, by confidentiality and nondisclosure agreements with our employees, consultants, advisors and partners. Trade secrets and proprietary information are difficult to protect. We also attempt to enter into agreements whereby such employees, consultants, advisors and partners assign to us the rights in any intellectual property they develop in the course of their engagement with us. These agreements may be breached, and we may not have adequate remedies for any breach. There can be no assurance that these agreements will be self-executing or otherwise provide meaningful protection for our trade secrets or other intellectual property or proprietary information. These agreements may not effectively prevent disclosure or misappropriation of such information and disputes may still arise with respect to the ownership of intellectual property. In addition, third parties may independently develop the same or similar proprietary information or otherwise gain access to our trade secrets or disclose our technology. Further, we have employed and expect to employ individuals who were previously employed at universities or other companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, advisors and partners do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or such persons have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information of their former employers or other third parties, or to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights and face increased competition to our business. The unauthorized access to or disclosure of our proprietary information or the loss of such intellectual property rights may impact our ability to develop, manufacture and market our own products or may assist competitors in the development, manufacture and sale of competing products, which could have a material adverse effect on our revenues, financial condition, cash flows or results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a number of our commercialized products and pipeline products, including Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Siliq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Plenvu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vyzulta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the pipeline products that are the subject of our recently announced licenses with Eyenovia, Inc., Novaliq GmbH, BHVI and Clearside Biomedical, Inc., we rely on licenses to patents and other technologies, know-how and intellectual property and proprietary rights held by third parties. Any loss, expiration, termination or suspension of our rights to such licensed intellectual property would result in our inability to continue to develop, manufacture and market the applicable products or product candidates and, as a result, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. If these licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, third parties, including our competitors, could have the freedom to seek regulatory approval of, and to market, products identical or similar to ours, and we may be required to cease our development and commercialization of certain of our products. Under some license agreements, we may not control the preparation, filing, prosecution or maintenance of the licensed intellectual property, or may not have the first right to enforce the intellectual property. In those cases, we may not be able to adequately influence patent prosecution or enforcement, or prevent inadvertent lapses of coverage due to failure to pay maintenance fees and we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business and that does not compromise the patent rights. In the future, we may also need to obtain such licenses from third parties to develop, manufacture, market or continue to develop, manufacture or market our products. If we are unable to timely obtain these licenses on commercially reasonable terms or at all, our ability to develop, manufacture and market our products may be inhibited or prevented, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation could cause us to spend substantial resources, distract our personnel from their normal responsibilities and cause the value of our common shares to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the value of our common shares. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors or other third parties may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace, including compromising our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development collaborations that would help us commercialize our product candidates, if approved. Any of the foregoing events would harm our business, financial condition, results of operations and prospects and could cause the market value of our common shares and/or debt securities to decline. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Competitive Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We operate in extremely competitive industries. If competitors develop or acquire more effective or less costly pharmaceutical or OTC products or medical devices for our target indications, it could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The pharmaceutical, OTC and medical device industries are extremely competitive. Our success and future growth depend, in part, on our ability to develop, license or acquire products that are more effective than those of our competitors or that incorporate the latest technologies and our ability to effectively manufacture and market those products. New market entrants and existing competitors are also challenging distribution models with innovation in non-traditional, disruptive models such as direct-to-consumer, Internet and other e-commerce sales opportunities. Many of our competitors, particularly larger pharmaceutical, OTC and medical device companies, have substantially greater financial, technical and human resources than we do. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors spend significantly more on research and development related activities than we do. Others may succeed in developing or acquiring products and technologies that are more effective, more advanced or less costly than those currently marketed or proposed for development by us. In addition, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products and may also establish exclusive collaborative or licensing relationships with our competitors. These competitors and the introduction of competing products (that may be more effective or less costly than our products) could make our products less competitive or obsolete, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the timing or impact of the introduction of competitive products, including new market entries, &#8220;generic&#8221; versions of our approved products, or private label products that treat the same conditions as those of our products. In addition, the introduction of alternatives in medical devices and medical prescriptions could also alter the market and impede our sales growth. Our ability to respond to these competitive pressures will depend on our ability to decrease our costs and maintain gross margins and operating results and to introduce new products successfully and on a timely basis, and to achieve manufacturing efficiencies and sufficient manufacturing capacity and capabilities for such products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Business Strategy</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have made commitments and public statements with respect to the cessation of or limitation on pricing increases for certain of our products, and we may implement or recommend similar measures in the future. These pricing decisions could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, we formed a new Patient Access and Pricing Committee responsible for the pricing of our drugs. The new committee&#8217;s first action was a recommendation, which we implemented, for an enhanced rebate program to all hospitals in the U.S. to reduce the price of our Nitropress</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Isuprel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products. In addition, the Patient Access and Pricing Committee made a commitment that the average annual price increase for our branded prescription pharmaceutical products will be set at no greater than single digits. Historically, this commitment has been reaffirmed in subsequent years. All future pricing actions will be subject to review by the Patient Access and Pricing Committee and we expect that the Patient Access and Pricing Committee will implement or recommend additional price changes and/or new programs to enhance patient access to our drugs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, we cannot predict what specific pricing changes the committee will make for 2022 or beyond nor can we predict what other changes in our business practices we may implement with respect to pricing (such as imposing limits or prohibitions on the amount of pricing increases we may take on certain of our products or taking retroactive or future price reductions). We also cannot predict the impact such pricing decisions or changes will or would have on our business. However, any such changes could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, any pricing changes and programs could affect the average realized prices for our products and may have a significant impact on our revenue trends. In addition, limiting or eliminating price increases on certain of our products will result in fewer or lower price appreciation credits from certain of our wholesalers. Price appreciation credits are generated when we increase a product&#8217;s wholesaler acquisition cost (&#8220;WAC&#8221;) under our contracts with certain wholesalers. Under such contracts, we are entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at the wholesalers. In wholesaler contracts, such credits, which can be significant, are offset against the total distribution service fees we pay on all of our products to each wholesaler. As a result, to the extent we decide to cease or limit price increases, we will have fewer or lower price appreciation credits to use to offset against our distribution fees owing to these wholesalers. In addition, under certain of our agreements with our wholesaler customers, we have price protection or price depreciation provisions, pursuant to which we have agreed to adjust the value of any on-hand or in-transit inventory with such customers in the event we reduce the price of any of our products. As a result, to the extent we reduce the WAC price for any of our products, we may owe a payment to such customers (or such customers may earn a credit to be offset against any amounts owing to us) equal to the amount of such inventory multiplied by the difference between the price at which they acquired the product inventory and the new reduced price.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In prior years, we have undertaken a number of divestitures of certain of our assets and business. We may, in the future, seek to divest additional assets and/or businesses, some of which may be material and/or transformative, which could adversely affect our business, prospects and opportunities for growth.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, we have completed a number of divestitures of our assets, products or businesses that were not considered core to our ongoing operations or the needs of our primary-customer base, including the divestitures of our Obagi Medical Products business, our iNova Pharmaceuticals business, our Dendreon Pharmaceuticals subsidiary, our Sprout Pharmaceuticals subsidiary, the CeraVe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, AcneFree</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and AMBI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> skincare brands and our Amoun Pharmaceutical subsidiary.&#160;We may, in the future, seek to complete additional divestitures. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these divestitures has been time-consuming and has diverted management&#8217;s attention. As a result of these divestitures (and others we may complete in the future), we may experience lower revenue and lower cash flows from operations. In addition, as was the case with our sale of our Sprout Pharmaceuticals subsidiary, we may recognize a loss on sale in connection with such divestitures. We may also suffer adverse tax consequences as a result of such divestitures, including capital gains tax or the accelerated use of NOLs or other attributes. Furthermore, divesting certain of our businesses or assets may require us to incur restructuring charges, and we may not be able to achieve the cost savings that we expect from any such restructuring efforts or divestitures. Any such divestiture could reduce the size or scope of our business, our market share in particular markets, our opportunities with respect to certain markets, products or therapeutic categories or our ability to compete in certain markets and therapeutic categories. Furthermore, we will be required to use the net proceeds (or substantial portions thereof) from certain asset sales to repay the term loans under the Restated Credit Agreement, subject to certain reinvestment rights.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, should we seek to divest other of our assets and business, we may be unable to dispose of such businesses and assets on satisfactory or commercially reasonable terms within our anticipated timeline. In addition, our ability to identify, enter into and/or consummate divestitures may be limited by competition we face from other companies in pursuing similar transactions in the pharmaceutical industry. Any divestiture or other disposition we pursue, whether we are able to complete it or not, may be complex, time consuming and expensive, may divert the management&#8217;s attention, have a negative impact on our customer relationships, cause us to incur costs associated with maintaining the business of the targeted divestiture during the disposition process and also to incur costs of closing and disposing the affected business or transferring the operations of the business to other facilities. The divestiture process may also further expose us to operational inefficiencies. In addition, if such transactions are not completed for any reason, the market price of our common shares may reflect a market assumption that such transactions will occur, and a failure to complete such transactions could result in a negative perception by the market of us generally and a decline in the market price of our common shares.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these factors, any divestiture (whether or not completed) could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As part of our business strategy, we seek to identify and acquire certain assets, products and businesses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, part of our business strategy included acquiring and integrating complementary businesses, products, technologies or other assets. As part of our current business strategy, we again are seeking to complete certain acquisitions of assets, products and businesses, including by way of in-license arrangements, although not at the volume and pace that we did historically. Acquisitions or similar arrangements may be complex, time consuming and expensive. We may not consummate some negotiations for acquisitions or other arrangements, which could result in significant diversion of management and other employee time, as well as substantial out-of-pocket costs. In addition, there are a number of risks and uncertainties relating to our closing transactions. If such transactions are not completed for any reason, we will be subject to several risks, including the following: (i)&#160;the market price of our common shares may reflect a market assumption that such transactions will occur, and a failure to complete such transactions could result in a negative perception by the market of us generally and a decline in the market price of our common shares; and (ii)&#160;many costs relating to such transactions may be payable by us whether or not such transactions are&#160;completed.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an acquisition is consummated, the integration of the acquired business, product or other assets into our Company may also be complex and time-consuming and, if such businesses, products and assets are not successfully integrated, we may not achieve the anticipated benefits, cost-savings or growth opportunities. Potential difficulties that may be encountered in the integration process include the&#160;following: integrating personnel, operations and systems, while maintaining focus on selling and promoting existing and newly-acquired products; coordinating geographically dispersed organizations; distracting management and employees from operations; retaining existing customers and attracting new customers; maintaining the business relationships the acquired company has established, including with health care providers; and managing inefficiencies associated with integrating the operations of the&#160;Company and the acquired business, product or other assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we may incur restructuring and integration costs and a number of non-recurring transaction costs associated with these acquisitions, combining the operations of the Company and the acquired company and achieving desired synergies. These fees and costs may be substantial. Non-recurring transaction costs include, but are not limited to, fees paid to legal, financial and accounting advisors, filing fees and printing costs. Additional unanticipated costs may be incurred in the integration of the businesses of the Company and the acquired company. There can be no assurance that the elimination of certain duplicative costs, as well as the realization of other efficiencies related to the integration of the acquired business, will offset the incremental transaction-related costs over time. Therefore, any net benefit may not be achieved in the near term, the long term or at all.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, these acquisitions and other arrangements, even if successfully integrated, may fail to further our business strategy as anticipated or to achieve anticipated benefits and success, expose us to increased competition or challenges with respect to our products or geographic markets, and expose us to additional liabilities associated with an acquired business, product, technology or other asset or arrangement. Any one of these challenges or risks could impair our ability to realize any benefit from our acquisition or arrangement after we have expended resources on&#160;them.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain our relationships with, and provide appropriate training in our products to, health care providers, including physicians, eyecare professionals, hospitals, large drug store chains, wholesale distributors, pharmacies, government entities and group purchasing organizations, customers may not buy certain of our products and our sales and profitability may decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our pharmaceutical products to physicians, hospitals, pharmacies and wholesalers through our own sales force and sell through wholesalers. In some markets, we additionally sell directly to physicians, hospitals and large drug store chains and we sell through distributors in countries where we do not have our own sales staff. We have developed and strive to maintain strong relationships with members of each of these groups who assist in product research and development and advise us on how to satisfy the full range of consumer needs. We rely on these groups to educate their patients and other members of their organizations regarding our products. Consumers in the pharmaceutical industry, particularly the contact lens and lens care customers in the eye-health industry, have a tendency not to switch products regularly and are repeat consumers. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically benefitted from our strong relationships with these physicians, hospitals, pharmacies and wholesalers. Our ability to maintain strong relationships is essential to our future performance; however, we may not be able to maintain these relationships in the future. The success of certain of our products, particularly our vision care products, is impacted by a physician's initial recommendation of such products and a consumer's initial choice to use such products. As a result, the failure of certain of our products, particularly in our vision care business, to retain the support of pharmaceutical professionals, hospitals or group purchasing organizations and to retain the support of the end-users and the distributors and retailers to whom we sell such products, could have a material adverse effect on our sales and profitability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Development and Regulatory Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The successful development of our pipeline products is highly uncertain and requires significant expenditures and time. In addition, obtaining necessary government approvals is time-consuming and not assured. The failure to commercialize certain of our pipeline products could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have a number of pipeline products in development. We and our development partners, as applicable, conduct extensive preclinical studies and clinical trials to demonstrate the safety and efficacy in humans of our pipeline products in order to obtain regulatory approval for the sale of our pipeline products. Preclinical studies and clinical trials are expensive, complex, can take many years and have uncertain outcomes. None of, or only a small number of, our research and development programs may actually result in the commercialization of a product. We will not be able to commercialize our pipeline products if preclinical studies do not produce successful results or if clinical trials do not demonstrate safety and efficacy in humans. Furthermore, success in preclinical studies or early-stage clinical trials does not ensure that later stage clinical trials will be successful nor does it ensure that regulatory approval for the product candidate will be obtained. In addition, the process for the completion of pre-clinical and clinical trials is lengthy and may be subject to a number of delays for </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">various reasons, which would delay the commercialization of any successful product. If our development projects are not successful or are significantly delayed, we may not recover our substantial investments in the pipeline product and our failure to bring these pipeline products to market on a timely basis, or at all, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, FDA and Health Canada approval must be obtained in the U.S. and Canada, respectively, EMA approval (drugs) and CE Marking (devices) and/or registration under the European Commission&#8217;s Medical Device Regulation (&#8220;MDR&#8221;) 2017/745 must be obtained in countries in the EU and similar approvals must be obtained from comparable agencies in other countries, prior to marketing or manufacturing new pharmaceutical and medical device products for use by humans. Obtaining such regulatory approvals for new products and devices and manufacturing processes can take a number of years and involves the expenditure of substantial resources. We may face additional challenges with respect to EMA approval and CE Marking in the EU as a result of additional requirements for approval in the EU that may be more burdensome than those required by the FDA and Health Canada.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if such products appear promising in development stages, regulatory approval may not be achieved and no assurance can be given that we will obtain approval in those countries where we wish to commercialize such products. Nor can any assurance be given that if such approval is secured, the approved labeling will not have significant labeling limitations, including limitations on the indications for which we can market a product, or require onerous risk management programs. Furthermore, from time to time, changes to the applicable legislation, regulations or policies may be introduced that change these review and approval processes for our products, which changes may make it more difficult and costly to obtain or maintain regulatory approvals. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our marketed drugs will be subject to ongoing regulatory review.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following initial regulatory approval of any products, we or our partners may develop or acquire, we will be subject to continuing regulatory review by various government authorities in those countries where our products are marketed or intended to be marketed, including the review of adverse drug events and clinical results that are reported after product candidates become commercially available. In addition, we are subject to ongoing audits and investigations of our facilities and products by the FDA, as well as other regulatory agencies in and outside the U.S.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with the regulatory requirements in those countries where our products are sold, we could lose our marketing approvals or be subject to fines or other sanctions. Also, as a condition to granting marketing approval of a product, the applicable regulatory agencies may require a company to conduct additional clinical trials or remediate Current Good Manufacturing Practice ("CGMP") issues, the results of which could result in the subsequent loss of marketing approval, changes in product labeling or new or increased concerns about side effects or efficacy of a product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2017, the European Union adopted MDR, which repeals and replaces the Medical Device Directive (&#8220;MDD&#8221;) and Active Implantable Medical Devices Directive (&#8220;AIMDD&#8221;) 90/385/EEC. The MDR, for most parts, became applicable on May 26, 2021. Under the MDR, several transitional measures apply to medical devices that are certified under the MDD or AIMDD prior to May 26, 2021 or, for class I devices, for which a declaration of conformity was drawn up prior to May 26, 2021, allowing these devices to be placed on the market after May 26, 2021 under certain conditions for a transitional period. However, if we make any significant changes in the design or intended purpose of our devices, they will no longer benefit from such transitional periods. Generally, the MDR imposes stricter requirements on manufacturers, importers and distributors of medical devices. Moreover, the requirements to provide clinical data for medical devices has become stricter and as a result we may need to conduct new time consuming and costly clinical investigations with our existing medical devices to meet the new requirements, including to obtain CE certificates under the MDR. We may, or may not, be able to provide this data in time to obtain MDR certifications in a timely fashion when our existing certificates expire. These new regulations impact all of our existing and pipeline medical device products being sold in the EEA for which we are legal manufacturer, importer and/or distributor, including contact lens, lens care, eye health, aesthetic and surgical areas, as well as certain of our products outside the EEA, which rely on the EEA registration to support registration in those other countries. These products, in the aggregate, account for a meaningful portion of our net revenue in this region. While we are working to ensure compliance with these new regulations for all impacted products, we may not be able to achieve compliance for all products within the applicable transition period. If we fail to achieve compliance, we will not be able to market and sell the non-compliant products in the EEA, nor will we be able to rely on the non-compliant registration for such products in regions outside of the EEA, which could have a material adverse effect on our business, financial condition, cash flows and results of operations in the EEA and, possibly, on a consolidated basis, and could cause the market value of our common shares to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While EU law is applicable in Northern Ireland, the UK Medical Devices Regulations 2002/68 also need to be complied with in Great Britain. Medical device manufacturers who have CE marked devices will be able to continue to place them on the market in the whole of the United Kingdom  (the &#8220;UK&#8221;) until July 1, 2023 without a change in labeling. After that, devices </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">destined for Great Britain will be required to follow the UK regulatory regime and to be labeled with the UKCA mark. Northern Ireland will, however, continue to accept CE marked devices. There are some extra hurdles for manufacturers who are based outside the UK such as the requirement to appoint a UK Responsible Person (&#8220;UKRP&#8221;) to take on certain regulatory responsibilities with respect to the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) and users or customers in the UK. To enable devices to be placed on the market in the UK after January 1, 2021 (even for CE marked devices), a UK manufacturer must register with the MHRA, as must a UKRP for an overseas manufacturer. Such registering entity will then register each of the devices for which they are responsible for placing on the market in the UK, whether in Great Britain or Northern Ireland. This may create added expense and challenges as explained below. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until May 25, 2021, our products bearing a CE mark could be exported from the EEA to Switzerland. However, as of May 26, 2021, the EU no longer applies the Mutual Recognition Agreement between the EEA and Switzerland. Accordingly, legal manufacturers in Switzerland will be required to appoint a European Union authorized representative, and manufacturers outside of Switzerland will be required to appoint a Swiss authorized representative in compliance with the Medical Device Ordinance. As a consequence, we are or will be required to appoint an authorized representative in Switzerland in order to export our CE-marked medical devices to Switzerland beginning in January 2022 through August 2022, depending on the class of the device or system in question. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, incidents of adverse drug reactions, unintended side effects or misuse relating to our products could result in additional regulatory controls or restrictions, or even lead to the regulatory authority requiring us to recall or withdraw the product from the market. Further, if faced with these incidents of adverse drug reactions, unintended side effects or misuse relating to our products, we may elect to voluntarily implement a recall or market withdrawal of our product. A recall or market withdrawal, whether voluntary or required by a regulatory authority, may involve significant costs to us, potential disruptions in the supply of our products to our customers and reputational harm to our products and business, all of which could harm our ability to market our products and could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Complying with existing government regulation of dietary supplements, including our eye vitamins and mineral supplements, in the U.S., Canada and elsewhere could increase our costs significantly and adversely affect our financial results. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing, formulation, packaging, labeling and advertising of the Company&#8217;s dietary supplement products are also subject to regulation by certain federal, state and foreign agencies, including the FDA, the Federal Trade Commission (the &#8220;FTC&#8221;), and the Consumer Product Safety Commission, in the U.S., and by Health Canada in Canada. The FDA has authority in the U.S. over the adulteration or misbranding of dietary supplements. There are requirements relating to ingredient safety, new dietary ingredient notifications, labeling, claims notifications, and adverse event reporting among other requirements. While we believe our products comply with those requirements, the FDA may challenge positions we have taken with respect to the formulation or labeling of a dietary supplement product. We are also subject to risks relating to evolving regulations of dietary supplement products, including our eye vitamins and mineral supplements, as the FDA and other applicable agencies have in the past and may in the future consider additional or more stringent regulations of dietary supplements and other products. Such developments could require reformulation of certain of our products to meet new standards, additional record-keeping obligations, increased documentation of the properties of certain products, additional or different labeling, additional scientific substantiation, adverse event reporting or similar obligations, or could result in recalls or the discontinuance of certain of our products that are not able to be reformulated. Any such developments could increase our costs significantly. In addition, the FDA also has comprehensive regulations for CGMP for those who manufacture, package or hold dietary supplement products. These regulations focus on practices that ensure the identity, purity, quality, strength and composition of dietary supplements that are manufactured. We or our contract manufacturers may not be able to comply with such regulations without incurring additional expenses, which could be significant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Supply Risks</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our third-party manufacturers are unable to manufacture our products or the manufacturing process is interrupted due to failure to comply with regulations or for other reasons, the interruption of the manufacture of our products could adversely affect our business. Other manufacturing and supply difficulties or delays may also have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing facilities and those of our contract manufacturers must be inspected and found to be in full compliance with CGMP, quality system management requirements or similar standards before approval for marketing. Compliance with CGMP regulations requires the dedication of substantial resources and requires significant expenditures. In addition, while we attempt to build in certain contractual obligations on our third-party manufacturers, we may not be able to ensure that such third-parties comply with these obligations. Our failure or that of our contract manufacturers to comply with </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CGMP regulations, quality system management requirements or similar regulations outside of the U.S. could result in enforcement action by the FDA or its foreign counterparts, including, but not limited to, warning letters, fines, injunctions, civil or criminal penalties, recall or seizure of products, total or partial suspension of production or importation, suspension or withdrawal of regulatory approval for approved or in-market products, refusal of the government to renew marketing applications or approve pending applications or supplements, refusal of certificates for export to foreign jurisdictions, suspension of ongoing clinical trials, imposition of new manufacturing requirements, closure of facilities and criminal prosecution. These enforcement actions could lead to a delay or suspension in production, which could have a material adverse effect on our competitive position, business, financial condition, results of operations and cash flows and could cause the market value of our common shares and/or debt securities to decline. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our manufacturing and other processes use complicated and sophisticated equipment, which sometimes requires a significant amount of time to obtain and install. Manufacturing complexity, testing requirements and safety and security processes combine to increase the overall difficulty of manufacturing these products and resolving manufacturing problems that we may encounter. Although we endeavor to properly maintain our equipment (and require our contract manufacturers to properly maintain their equipment), including through on-site quality control and experienced manufacturing supervision, and have key spare parts on hand, our business could suffer if certain manufacturing or other equipment, or all or a portion of our or their facilities, were to become inoperable for a period of time. We could experience substantial production delays or inventory shortages in the event of any such occurrence until we or they repair such equipment or facility or we or they build or locate replacement equipment or a replacement facility, as applicable, and seek to obtain necessary regulatory approvals for such replacement. For example, in 2021, a third-party supplier of sterilization services for our lens care solution bottles and caps at our Milan, Italy facility notified us of inconsistencies in the sterilization data versus certificates of conformance previously submitted to us by that supplier. Although we determined that this issue did not affect the safety or performance of any of our products and was limited to a specific number of lots for certain of our products, out of an abundance of caution, in conjunction with the appropriate notified body and responsible health authorities, we contained and/or recalled down to the consumer level the limited number of affected lots of products, which resulted in $8 million of manufacturing variances and $6 million of returns. Further, due to the limited availability of qualified materials caused by this issue, production at the Milan facility could not keep up with demand (even with leveraging increased production at another of our manufacturing facilities to support some of the demand), which negatively impacted our sales for the affected products in this region during 2021. Any interruption in our manufacture of products could adversely affect the sales of our current products or introduction of new products and could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supply of our products to our customers (or, in some cases, supply from our contract manufacturers to us) is subject to and dependent upon the use of transportation services. Disruption of transportation services (including as a result of weather conditions) could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. In addition, any prolonged disruption in the operations of our existing distribution facilities, whether due to technical, labor or other difficulties, weather conditions, equipment malfunction, contamination, failure to follow specific protocols and procedures, destruction of or damage to any facility or other reasons, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">For some of our finished products and raw materials, we obtain supply from one or a limited number of sources. If we are unable to obtain components or raw materials, or products supplied by third parties, our ability to manufacture and deliver our products to the market would be impeded, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some components and raw materials used in our manufactured products, and some finished products sold by us, are currently available only from one or a limited number of domestic or foreign suppliers. For example, with respect to some of our largest or most significant products, the supply of the finished product for each of our Siliq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vyzulta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SofLens</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Wellbutrin XL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Oral and PureVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products are only available from a single source and the supply of active pharmaceutical ingredient for each of our Siliq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vyzulta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Oral products are also only available from a single source. In the event an existing supplier fails to supply product on a timely basis and/or in the requested amount, supplies product that fails to meet regulatory requirements, becomes unavailable through business interruption or financial insolvency or loses its regulatory status as an approved source or we are unable to renew current supply agreements when such agreements expire and we do not have a second supplier, we may be unable to obtain the required components, raw materials or products on a timely basis or at commercially reasonable prices. We attempt to mitigate these risks by maintaining safety stock of these products, but such safety stock may not be sufficient. In addition, in some cases, only a single source of active pharmaceutical ingredient is identified in filings with regulatory agencies, including the FDA, and cannot be changed without </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prior regulatory approval, which would involve time and expense to us. A prolonged interruption in the supply of a single-sourced raw material, including the active pharmaceutical ingredient, or single-sourced finished product could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. In addition, these third-party manufacturers may have the ability to increase the supply price payable by us for the manufacture and supply of our products, in some cases without our consent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, our dependence upon others to manufacture and supply our products may adversely affect our profit margins and our ability to obtain approval for and produce our products on a timely and competitive basis, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in inventory levels or fluctuations in buying patterns by our large distributor and retail customers may adversely affect our sales and earnings and add to sales variability from quarter to quarter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We balance the need to maintain inventory levels that are sufficient to ensure competitive lead times against the risk of inventory obsolescence because of changing customer requirements, fluctuating commodity prices, changes to our products, product transfers or the life-cycle of our products. In order to successfully manage our inventories, we must estimate demand from our customers and produce products that substantially correspond to that demand. If we fail to adequately forecast demand for any new or existing product, or fail to determine the appropriate product mix for production purposes, we may face production capacity issues in manufacturing sufficient quantities of a given product. In addition, failures in our information technology systems or human error could also lead to inadequate forecasting of our overall demand or product mix.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a significant number of unique products, and we anticipate that number will continue to grow over time. As a result, the demand forecasting precision required for us to avoid production capacity issues will also increase, which could increase the risk of product unavailability and lost sales. Additionally, an increasing number of unique products could increase global inventory requirements, negatively impacting our working capital performance and leading to write-offs due to obsolescence and expired products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the lead times necessary to obtain and install new equipment and ramp up production of product lines, if we fail to adequately forecast the need for additional manufacturing capacity, whether for new or existing products, we may be unable to scale production in a timely manner to meet demand for our products. In addition, the technically complex manufacturing processes required to manufacture many of our products increase the risk of production failures, and can increase the cost of producing our goods. As a result, because the production process for many of our products is complex and sensitive, the cost of production and the chance of production failures and lengthy supply interruptions is increased, which can have a substantial impact on our inventory levels.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, a significant portion of our products are sold to major health care distributors and major retail chains in Canada, the United States and abroad. Consequently, our sales and quarterly growth comparisons, as well as our estimates for required inventory levels, may be affected by fluctuations in the buying patterns of major distributors, retail chains and other trade buyers. These fluctuations may result from seasonality, pricing, large retailers' and distributors' buying decisions or other factors. If we overestimate demand and produce too much of a particular product, we face a risk of inventory obsolescence, leaving us with inventory that we cannot sell profitably or at all. In addition, we may have to write down such inventory if we are unable to sell it for its recorded value. Conversely, if we underestimate demand and produce insufficient quantities of a product, we could be forced to produce that product at a higher price and forego profitability in order to meet customer demand. For example, if a competitor initiates a recall and there is an unexpected increase in the demand for our products, we may not be able to meet such increased demand. Insufficient inventory levels may lead to shortages that result in loss of sales opportunities altogether as potential end-customers turn to competitors' products that are readily available. If any of these situations occur frequently or in large volumes or if we are unable to effectively manage our inventory and that of our distribution partners, this could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our approved products may not achieve or maintain expected levels of market acceptance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to obtain and maintain regulatory approvals for our pharmaceutical and medical device products, generic or branded, the success of these products is dependent upon achieving and maintaining market acceptance. Launching and commercializing products is time consuming, expensive and unpredictable. The commercial launch of a product takes significant time, resources, personnel and expertise, which we may not have in sufficient levels to achieve success, and is subject to various market conditions, some of which may be beyond our control. There can be no assurance that we will be able to, either by ourselves or in collaboration with our partners or through our licensees or distributors, successfully launch and commercialize new products or gain market acceptance for such products. New product candidates that appear promising in development may fail to reach the market or may have only limited or no commercial success. While we have been successful in launching some of our products, we may not achieve the same level of success with respect to all of our new products. Our inability to successfully launch our new products may negatively impact the commercial success of such product, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. Our inability to successfully launch our new products could also lead to material impairment charges.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Levels of market acceptance for our new products could be impacted by several factors, some of which are not within our control, including but not limited to the following:</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">safety, efficacy, convenience and cost-effectiveness of our products compared to products of our competitors;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">scope of approved uses and marketing approval;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">availability of patent or regulatory exclusivity;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">timing of market approvals and market entry;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">ongoing regulatory obligations following approval, such as the requirement to conduct Risk Evaluation and Mitigation Strategy ("REMS") programs;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">any restrictions or &#8220;black box&#8221; warnings required on the labeling of such products;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">availability of alternative products from our competitors;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">acceptance of the price of our products; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">effectiveness of our sales forces and promotional efforts;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the level of reimbursement of our products;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">acceptance of our products on government and private formularies;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">ability to market our products effectively at the retail level or in the appropriate setting of care; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the reputation of our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the market perception and reputation of our products and their safety and efficacy are important to our business and the continued acceptance of our products. Any negative publicity about our products, such as the discovery of safety issues with our products, adverse events involving our products, or even public rumors about such events, could have a material adverse effect on our business, financial condition, cash flows or results of operation or could cause the market value of our common shares and/or debt securities to decline. In addition, the discovery of significant problems with a product similar to one of our products that implicate (or are perceived to implicate) an entire class of products or the withdrawal or recall of such similar products could have a material adverse effect on sales of our products. Accordingly, new data about our products, or products similar to our products, could cause us reputational harm and could negatively impact demand for our products due to real or perceived side effects or uncertainty regarding safety or efficacy and, in some cases, could result in product withdrawal.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our products fail to gain, or lose, market acceptance, our revenues would be adversely impacted and we may be required to take material impairment charges, all of which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">For certain of our products, we depend on reimbursement from governmental and other third-party payors and a reduction in reimbursement could reduce our product sales and/or revenue. In addition, failure to be included in formularies developed by managed care organizations and coverage by other organizations may negatively impact the utilization of our products, which could harm our market share and could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of certain of our products are dependent, in part, on the availability and extent of reimbursement from government health administration authorities, private health insurers, pharmacy benefit managers and other organizations of the costs of our products and the continued reimbursement and coverage of our products in such programs. Changes in government regulations </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or private third-party payors&#8217; reimbursement policies may reduce reimbursement for our products. In addition, such third-party payors may otherwise make the decision to reduce reimbursement of some or all our products or fail to cover some or all our products in such programs or assert that reimbursements were not in accordance with applicable requirements. For example, these decisions may be based on the price of our products or our current or former pricing practices and decisions. Any reduction or elimination of such reimbursement or coverage could result in a negative impact on the utilization of our products and, as a result, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care organizations and other third-party payors try to negotiate the pricing of medical services and products to control their costs. Managed care organizations and pharmacy benefit managers typically develop formularies to reduce their cost for medications. Formularies can be based on the prices and therapeutic benefits of the available products. Due to their lower costs, generic products are often favored. The breadth of the products covered by formularies varies considerably from one managed care organization to another, and many formularies include alternative and competitive products for treatment of particular medical conditions. Failure to be included in such formularies or to achieve favorable formulary status may negatively impact the utilization and market share of our products. If our products are not included within an adequate number of formularies or adequate reimbursement levels are not provided, or if those policies increasingly favor generic products, this could have a material adverse effect on our business, financial condition, cash flows and results of operations or result in additional pricing pressure on our products and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Our fulfillment arrangements with Walgreens and our dermatology cash-pay prescription program may not be successful.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the beginning of 2016, we launched a brand fulfillment arrangement with Walgreens, pursuant to which we have made certain of our dermatology and ophthalmology products available to eligible patients through a patient access and co-pay program available at Walgreens U.S. retail pharmacy locations, as well as participating independent retail pharmacies. We have, in the past, experienced certain operational and other issues respecting this arrangement, including lower than anticipated average realized prices associated with these products through this arrangement. In July 2019, we entered into an amendment to the existing fulfillment agreement to address some of these issues. We cannot guarantee this arrangement will continue to be successful in the future, nor can we guarantee that additional operational issues will not be encountered, nor can we guarantee that we will be able to successfully negotiate with Walgreens any improvements or amendments to this arrangement we identify as necessary or desired. In addition, we cannot predict how the market, including customers, doctors, patients, pharmacy benefit managers and third-party payors, or governmental agencies, will continue to react to these arrangements and programs. If this arrangement or program fails, if they do not achieve sufficient success and market acceptance, if we face retaliation from third parties as a result of this arrangement and program (for example, in the form of limitations on or exclusions from the reimbursement of our products) or if any part of this arrangement is found to be non-compliant with applicable law or regulations, this could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in February 2019, we launched Dermatology.com, a cash-pay product acquisition program offering certain branded Ortho Dermatologics products directly to patients.  In March 2020, the name Dermatology.com was removed as the cash-pay product program name, with the name Dermatology.com limited to only online usage, including future digital teledermatology and e-commerce offerings. This program is designed to address the affordability and availability of certain branded dermatology products, when insurers and pharmacy benefit managers are no longer offering those branded prescription pharmaceutical products under their designated pharmacy benefit offerings.  We cannot guarantee that this program will be successful or that we will continue to add new products to the program. In addition, we cannot predict how the market, including customers, doctors and patients will react to this program. If this program fails, if it does not achieve sufficient success and market acceptance or if any part of this program is found to be non-compliant with applicable law or regulations, this could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Catastrophic events may disrupt our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations and facilities which sell and distribute our products in many parts of the world. Natural events (such as a hurricane or major earthquake), terrorist attacks, pandemics or other catastrophic events, including adverse weather events, could cause delays in developing, manufacturing or selling our products. Such events that occur in major markets where we sell our products could reduce the demand for our products in those areas and, as a result, impact our sales into those markets. In either case, any such disruption could have a material adverse effect on our business, financial condition and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The illegal distribution and sale of counterfeit versions of our products may reduce demand for our products or have a negative impact on the reputation of our products, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may illegally distribute and sell counterfeit versions of our products, which do not meet or adhere to the rigorous quality, safety, manufacturing, storage and handling standards and regulations that apply to our products. The prevalence of counterfeit products is a growing industry-wide issue due to the widespread use of the Internet, which has greatly facilitated the ease by which counterfeit products can be advertised, purchased and delivered. The discovery of safety or efficacy issues, adverse events or even death or personal injury associated with or caused by counterfeit products may be attributed to our products and may cause reputational harm to our products or the Company. We may not be able to detect or, if detected, prevent or prohibit the sale of such counterfeit products. As a result, the illegal sale or distribution of counterfeit products may negatively impact the demand for and sales of our products, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our revenues and profits could be reduced by imports from countries where our products are available at lower prices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prices for our products are based on local market economics and competition and differ from country to country. Our sales in countries with relatively higher prices may be reduced if products can be imported into those or other countries from lower price markets. If this happens with our products, our revenues and profits may be adversely affected, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our policies regarding returns, allowances and chargebacks, and marketing programs adopted by wholesalers, may reduce our revenues in future fiscal periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide certain rebates, allowances, chargebacks and other credits to our customers with respect to certain of our products. For example, we make payments or give credits to certain wholesalers for the difference between the invoice price paid to us by our wholesaler customer for a particular product and the negotiated price that such wholesaler sells such products to its hospitals, group purchasing organizations, pharmacies or other retail customers. We also give certain of our customers credits on our products that such customers hold in inventory after we have decreased the WAC prices of such products, such credit being for the difference between the old and new price. In addition, we also implement and maintain returns policies, pursuant to which our customers may return product to us in certain circumstances in return for a credit. Although we establish reserves based on our prior experience, wholesaler data, then-current on-hand inventory, our best estimates of the impact that these policies may have in subsequent periods and certain other considerations, we cannot ensure that our reserves are adequate or that actual product returns, rebates, allowances and chargebacks will not exceed our estimates, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience declines in sales volumes or prices of certain of our products as the result of the concentration of sales to wholesalers and the continuing trend towards consolidation of such wholesalers and other customer groups and this could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain of our products, a significant portion of our sales are to a relatively small number of customers. If our relationship with one or more of such customers is disrupted or changes adversely or if one or more of such customers experience financial difficulty or other material adverse changes in their businesses, it could materially and adversely affect our sales and financial results, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, wholesalers and retail drug chains have undergone, and are continuing to undergo, significant consolidation. This consolidation may result in these groups gaining additional purchasing leverage and consequently increasing the product pricing pressures facing our business. The result of these developments could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have entered into distribution agreements with other companies to distribute certain of our products at supply prices based on net sales. Declines in the pricing and/or volume, over which we have no or limited control, of such products, and therefore the amounts paid to us, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products are the subject of third-party distribution or sublicense agreements, pursuant to which we may manufacture and sell products to other companies, which distribute such products in return for a royalty or a supply price, in both cases which are often based on net sales. Our ability to control pricing and volume of these products may be limited and, in some cases, these companies make all distribution and pricing decisions independently of us. If the pricing or volume of such products declines, our revenues would be adversely impacted which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to the International Scope of our Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business, financial condition, cash flows and results of operations are subject to risks arising from the international scope of our operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct a significant portion of our business outside the U.S. and Canada and may, in the future, expand our operations into new countries, including emerging markets. We sell our pharmaceutical and medical device products in many countries around the world. All of our foreign operations are subject to risks inherent in conducting business abroad, including, among other things:</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">difficulties in coordinating and managing foreign operations, including ensuring that foreign operations comply with foreign laws as well as Canadian and U.S. laws applicable to Canadian companies with U.S. and foreign operations, such as export and sanctions laws and the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), the Canadian Corruption of Foreign Public Officials Act, and other applicable worldwide anti-bribery laws; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">price and currency exchange controls;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">restrictions on the repatriation of funds;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">scarcity of hard currency, including the U.S. dollar, which may require a transfer or loan of funds to the operations in such countries, which they may not be able to repay on a timely basis;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">political and economic instability;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">compliance with multiple regulatory regimes;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">compliance with economic sanctions laws and other laws that apply to our activities in the countries where we operate;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">less established legal and regulatory regimes in certain jurisdictions, including as relates to enforcement of anti-bribery and anti-corruption laws and the reliability of the judicial systems;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">differing degrees of protection for intellectual property;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">unexpected changes in foreign regulatory requirements, including quality standards and other certification requirements;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">new export license requirements;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">adverse changes in tariff and trade protection measures;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">differing labor regulations;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">potentially negative consequences from changes in or interpretations of tax laws;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">restrictive governmental actions;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">possible nationalization or expropriation;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">credit market uncertainty;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">restrictions on business activities and other challenges associated with pandemics, including the ongoing COVID-19 pandemic;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">differing local practices, customs and cultures, some of which may not align or comply with our Company practices and policies or U.S. or Canadian laws and regulations;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">difficulties with licensees, contract counterparties, or other commercial partners; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">differing local product preferences and product requirements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of changes to U.S. trade policy, there may be changes to existing trade agreements and greater restrictions on trade generally. On November 30, 2018, the United States, Canada and Mexico signed the United States-Mexico-Canada Agreement (&#8220;USMCA&#8221;) as an overhaul and update to the North American Free Trade Agreement. The USMCA was subsequently revised on December 10, 2019 and fully ratified on March 13, 2020. It is difficult to anticipate the full impact of this agreement on our business, financial condition, cash flows and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the USMCA, support for protectionism and rising anti-globalization sentiment in the United States and other countries may slow global growth. In particular, a protracted and wide-ranging trade conflict between the United States and China could adversely affect global economic growth. Concerns also remain around the social, political and economic impacts of the changing political landscape in Europe. In addition, there are growing concerns over an economic slowdown in emerging markets in light of capital outflows in favor of developed markets and expected interest rate increases. Broader geopolitical tensions remained high amongst the U.S., Russia, Ukraine, China, and across the Middle East. For example, in </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">response to potential conflict between Russia and Ukraine, the U.S. and/or other countries in which we operate may impose sanctions or other restrictive actions against governmental or other entities in Russia.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the international scope of our operations, any of the above factors, including sanctions, export controls, tariffs, trade wars and other governmental actions, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, adverse economic conditions impacting our customers in these countries or uncertainty about global economic conditions could cause purchases of our products to decline, which would adversely affect our revenues and operating results. Moreover, our projected revenues and operating results are based on assumptions concerning certain levels of customer spending. Any failure to attain our projected revenues and operating results as a result of adverse economic or market conditions could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Due to the large portion of our business conducted in currency other than U.S. dollars, we have significant foreign currency risk.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face foreign currency exposure on the translation into U.S. dollars of the financial results of our operations in Europe, Canada, Latin America, Asia, Africa and the Middle East and other regions. Where possible, we manage foreign currency risk by managing same currency revenue in relation to same currency expenses. We may also use derivative financial instruments from time to time to mitigate our foreign currency risk and not for trading or speculative purposes. We face foreign currency exposure in those countries where we have revenue denominated in the local foreign currency and expenses denominated in other currencies. Both favorable and unfavorable foreign currency impacts to our foreign currency-denominated operating expenses are mitigated to a certain extent by the natural, opposite impact on our foreign currency-denominated revenue. In addition, the repurchase of our U.S. dollar denominated debt may result in foreign exchange gains or losses for Canadian income tax purposes. One half of any foreign exchange gains or losses will be included in our Canadian taxable income. Any foreign exchange gain will result in a corresponding reduction in our available Canadian tax attributes. Further strengthening of the U.S. dollar and/or the devaluation of other countries' currencies could have a negative impact on our reported international revenue.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Information Technology</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have become increasingly dependent on information technology systems and infrastructure and any breakdown, interruption, breach or other compromise of our or our third-party service providers&#8217; information technology systems could compromise sensitive information related to our business or prevent us from accessing critical information and subject us to liability or interrupt the operation of our business, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon our information technology systems and infrastructure, as well as those of third parties with whom we interact, and internal and public internet sites, data hosting and processing facilities, cloud-based services and hardware, social media sites and mobile technology, in connection with the conduct of our business.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must constantly update our information technology systems and infrastructure and undertake investments in new information technology systems and infrastructure. However, we cannot provide assurance that the information technology systems and infrastructure on which we depend, including those of third parties, will continue to meet our current and future business needs or adequately safeguard our operations. Furthermore, modification, upgrade or replacement of such systems and infrastructure may be costly or out of our control.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure to so modify, upgrade or replace such systems and infrastructure, any disruptions that occur during the process of such modification, upgrade or replacement and/or any breakdown, interruption or corruption of the information technology systems and infrastructure on which we rely could create system disruptions, shutdowns, delays in generating or the corruption of data and information or other disruptions that could result in negative financial, operational, business or reputational consequences for us.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The size and complexity of the information technology systems and infrastructure on which we rely makes such systems and infrastructure potentially vulnerable to internal or external inadvertent or intentional security breaches, including as a result of private or state-sponsored cybercrimes, terrorism, war, malware, ransomware, human error, system malfunction, telecommunication and electrical failures, natural disaster, fire, misplaced or lost data, socially engineered breaches or other similar events. </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, during the normal course of our business operations, including through the use of information technology systems and infrastructure, we are involved in the collection, transmission, use, retention and other processing of sensitive, confidential, non-public or personal data and information in Canada, the United States and abroad.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber-attacks are increasing in frequency, sophistication and intensity and are made by groups and individuals with a wide range of motives and expertise. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, worms, social engineering, improper modification of information, fraudulent &#8220;phishing&#8221; e-mails and other means to affect service reliability or threaten data confidentiality, integrity or availability. Techniques used in these attacks are often highly sophisticated, change frequently and may be difficult to detect for long periods of time. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established (i) physical, electronic and organizational measures intended to safeguard and secure our systems to prevent a compromise and (ii) policies and procedures designed to provide for the timely investigation of cybersecurity incidents and the timely disclosure of cybersecurity incidents consistent with our legal and contractual obligations. We also rely on commercially available systems, software, tools and monitoring to provide security for the processing, transmission and storage of digital information. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we attempt to take appropriate security and cybersecurity measures to protect our information technology systems and infrastructure (including any trade secrets, confidential or other sensitive information) and to prevent and detect breakdowns, unauthorized breaches and cyber-attacks, we cannot guarantee that such measures will be successful and that breakdowns and breaches of, or attacks on, our systems and data, or those of third parties upon which we rely, will be prevented. Such breakdowns and breaches of, or attacks on, our systems and infrastructure, or the public perception that we or any third party upon which we rely have suffered a cybersecurity incident or breakdown, may cause business interruption and could have a material adverse effect on our business, financial condition, cash flows and results of operations, damage our reputation with customers, employees and third parties with whom we do business and cause the market value of our common shares and/or debt securities to decline, and we may suffer financial damage or other loss, including fines or criminal penalties or may be subject to litigation, including potentially class action lawsuits because of lost or misappropriated information. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we maintain insurance against some of these risks, this insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result from a breakdown, breach, cyber-attack or other compromise of or interruption to our information technology systems and infrastructure or confidential and other sensitive information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we provide confidential and other sensitive information to third parties when necessary to pursue our business objectives. While we obtain assurances that these third parties will protect this information and, where appropriate, monitor the protections employed by these third parties, there is a risk that the confidentiality of information held by third parties, including trade secrets and sensitive personal information, may be compromised, including as a result of cybersecurity breaches, breakdowns or other incidents.  If personal information of our customers or employees is misappropriated, our reputation with our customers and employees may be injured, resulting in loss of business and/or morale. Any such incidents could require us to incur costs to remediate possible injury to our customers and employees, to further improve our protective measures or to pay fines or take other action with respect to litigation, judicial or regulatory actions arising out of such incidents, which may be significant. We also cannot ensure that any limitation of liability or indemnity provisions in our contracts, including with vendors and service providers, for a security lapse or breach or other security incident would be enforceable or adequate or would otherwise protect us from any liabilities or damages with respect to any particular claim. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Specific Legislation and Regulations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to various laws and regulations, including &#8220;fraud and abuse&#8221; laws, anti-bribery laws, environmental laws and privacy and security laws, and a failure to comply with such laws and related regulations or prevail in any litigation related to noncompliance could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and medical device companies have faced lawsuits and investigations pertaining to violations of health care &#8220;fraud and abuse&#8221; laws, such as the federal False Claims Act, the federal Anti-Kickback Statute (&#8220;AKS&#8221;) and other state and federal laws and regulations. The AKS prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any health care item or service reimbursable under federally financed health care programs. This statute has been interpreted to apply to arrangements between pharmaceutical or medical device manufacturers, on the one hand, and prescribers, purchasers, formulary managers and other health care related professionals, on the other hand. More generally, the federal False Claims Act, among other things, prohibits any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government. Pharmaceutical and medical device companies have been prosecuted or faced civil liability under </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these laws for a variety of alleged promotional and marketing activities, including engaging in off-label promotion that caused claims to be submitted for non-covered off-label uses. If we are in violation of any of these requirements or any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, this could have a significant impact on our business, including the imposition of significant criminal and civil fines and penalties, exclusion from federal health care programs or other sanctions, including consent orders or corporate integrity agreements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. Department of Health and Human Services Office of Inspector General recommends, and increasingly states require pharmaceutical companies to have comprehensive compliance programs. Moreover, the Physician Payment Sunshine Act enacted in 2010 imposes reporting and disclosure requirements on device and drug manufacturers for any &#8220;transfer of value&#8221; made or distributed to prescribers and other health care providers. Failure to submit this required information may result in significant civil monetary penalties. While we have developed corporate compliance programs based on what we believe to be current best practices, we cannot provide assurance that we or our employees or agents are or will be in compliance with all applicable federal, state or foreign regulations and laws. If we are in violation of any of these requirements or any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant criminal and civil fines and penalties, exclusion from federal health care programs or other sanctions, including consent orders or corporate integrity agreements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. FCPA, the Canadian Corruption of Foreign Public Officials Act and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to officials for the purpose of obtaining or retaining business. Our policies mandate compliance with these anti-bribery laws. We operate in many parts of the world that have experienced governmental corruption and in certain circumstances, strict compliance with anti-bribery laws may conflict with local customs and practices or may require us to interact with doctors and hospitals, some of which may be state controlled, in a manner that is different than in the U.S. and Canada. We cannot provide assurance that our internal control policies and procedures will protect us from reckless or criminal acts committed by our employees, consultants, distributors, third party contractors or agents. Violations of these laws, or allegations of such violations, could disrupt our business and result in criminal or civil penalties or remedial measures, any of which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to various state, federal and international laws and regulations governing the collection, transmission, dissemination, use, privacy, confidentiality, security, retention, availability, integrity and other processing of health-related and other sensitive and personal information, including HIPAA. Many states in which we operate have laws that protect the privacy and security of sensitive and personal information, including health-related information. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to sensitive and personal information than federal, international or other state laws, and such laws may differ from each other, which may complicate compliance efforts. For example, the California Consumer Privacy Act of 2018 ("CCPA") imposes stringent data privacy and security requirements and obligations with respect to the personal information of California residents and provides for civil penalties for violations, as well as a private right of action for certain data breaches that result in the loss of personal data that may increase the likelihood of, and risks associated with, data breach litigation. The effects on our business of the CCPA and other similar state laws are potentially significant. State laws are changing rapidly and there is discussion in Congress of a new federal data protection and privacy law to which we may be subject.  For instance, the California Privacy Rights Act (&#8220;CPRA&#8221;) was passed in November 2020. When it takes effect in January 2023, it will maintain the core framework of the CCPA, while also making a number of substantive changes. Since these data security regimes are evolving, uncertain and complex, especially for a global business such as ours, we will need to update or enhance our compliance measures from time to time and these updates or enhancements will require further implementation costs. Any failure, or perceived failure, by us to comply with current and future regulatory or customer-driven privacy, data protection, and information security requirements, or to prevent or mitigate security breaches, cyberattacks, or improper access to, use of, or disclosure of data, or any security issues or cyber-attacks affecting our business, could result in significant liability, costs (including the costs of mitigation and recovery), a material loss of revenue resulting from the adverse impact on its reputation and brand, loss of proprietary information and data, disruption to its business and relationships, and diminished ability to retain or attract customers and business partners. Such events may result in governmental enforcement actions and prosecutions, private litigation, fines and penalties or adverse publicity, and could cause customers and business partners to lose trust in us, which could have an adverse effect on our reputation and business.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internationally, laws and regulations in many jurisdictions apply broadly to the collection, transmission, dissemination, use, privacy, confidentiality, security, retention, availability, integrity and other processing of health-related and other sensitive and personal information. For example, the EU&#8217;s General Data Protection Regulation (&#8220;GDPR,&#8221;), and the UK&#8217;s General Data Protection Regulation (&#8220;UK GDPR&#8221;) together with national legislation, regulations and guidelines of the EU member states and the UK governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze, store, transfer and otherwise process personal data, including health data from clinical trials and adverse event reporting. The </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GDPR authorizes fines for certain violations of up to 4% of global annual revenue or &#8364;20 million, (or GBP 17.5 million under the UK GDPR), whichever is greater. European data protection authorities may interpret the GDPR and national laws differently and impose additional requirements, which contributes to the complexity of processing personal data in or from the EEA or the UK. Guidance on implementation and compliance practices is often updated or otherwise revised. These laws require data controllers to implement stringent operational requirements, including, for example, transparent and expanded disclosure to data subjects about how their personal data is collected and processed, grant rights for data subjects to access, delete or object to the processing of their data, mandatory data breach notification requirements (and in certain cases, affected individuals), set limitations on retention of information and outline significant documentary requirements to demonstrate compliance through policies, procedures, training and audits. The GDPR also provides that EU member states may introduce further conditions, including limitations, and make their own laws and regulations, further limiting the processing of &#8216;special categories of personal data,&#8217; including personal data related to health, biometric data used for unique identification purposes and genetic information, which could limit our ability to collect, use and share EU data, and could cause our compliance costs to increase, ultimately having an adverse impact on our business, and harm our business and financial condition. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The withdrawal of the UK from the European Union ("Brexit") also has created uncertainty with regard to the regulation of data protection in the UK. Since January 1, 2021, when the transitional period following Brexit expired, we have been required to comply with the GDPR as well as the UK GDPR (combining the GDPR and the UK&#8217;s Data Protection Act of 2018), which exposes us to two parallel regimes, each of which authorizes similar fines and may subject us to increased compliance risk based on differing, and potentially inconsistent or conflicting, interpretation and enforcement by regulators and authorities (particularly, if the laws are amended in the future in divergent ways). With respect to transfers of personal data from the EEA, on June 28, 2021, the European Commission issued an adequacy decision in respect of the UK&#8217;s data protection framework, enabling data transfers from EU member states to the UK to continue without requiring organizations to put in place contractual or other measures in order to lawfully transfer personal data between the territories. While it is intended to last for at least four years, the European Commission may unilaterally revoke the adequacy decision at any point, and if this occurs, it could lead to additional costs and increase our overall risk exposure. </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to Canada's federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Information Protection and Electronic Documents Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and substantially similar equivalents at the provincial level with respect to the collection, use and disclosure of personal information in Canada. Such federal and provincial legislation impose data privacy and security obligations on our processing of personal information of Canadian residents. The federal and Alberta legislation include mandatory data breach notification requirements. Canada&#8217;s Anti-Spam Legislation (&#8220;CASL&#8221;) also applies to the extent that we send commercial electronic messages from Canada or to electronic addresses in Canada. CASL contains prescriptive consent, form, content and unsubscribe mechanism requirements. Penalties for non-compliance with CASL are up to CAD $10 million per violation. These laws and regulations may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is possible they will be interpreted and applied in ways that will materially and adversely affect our business. The regulatory framework for data privacy, data security and data transfers worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Complying with all of these laws and regulations involves costs to our business, and failure to comply with these laws and regulations can result in the imposition of significant civil and criminal penalties, as well as litigation, all of which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. For more information regarding applicable data privacy and security laws and regulations, see Item 1. &#8220;Business &#8212;&#160;Government Regulations&#8221; of this Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to U.S. federal laws regarding reporting and payment obligations with respect to our participation in federal health care programs, including Medicare and Medicaid. Because our processes for calculating applicable government prices and the judgments involved in making these calculations involve subjective decisions and complex methodologies, these calculations are subject to risk of errors and differing interpretations. In addition, they are subject to review and challenge by the applicable governmental agencies, and it is possible that such reviews could result in changes that could have material adverse legal, regulatory, or economic consequences.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legislative or regulatory reform of the health care system may affect our ability to sell our products profitably and could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. and certain foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health care system in ways that could impact our ability to sell our products profitably. The Patient Protection and Affordable Care Act, as amended by the Health Care Reform Act, may affect the operational results of companies in the pharmaceutical and medical device industries, including the Company and other health care related industries, by imposing on them additional costs. Effective January 1, 2010, the Health Care Reform Act increased the minimum Medicaid drug rebates for pharmaceutical companies, expanded the 340B drug discount program, and made changes to affect the Medicare Part D coverage gap, or &#8220;donut hole.&#8221; The law also revised the definition of &#8220;average manufacturer price&#8221; for reporting purposes, </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which may affect the amount of our Medicaid drug rebates to states. Beginning in 2011, the law imposed a significant annual fee on companies that manufacture or import branded prescription drug products. More recently, the Bipartisan Budget Act of 2018 amended the Patient Protection and Affordable Care Act, effective January 1, 2019, to close the donut hole in most Medicare drug plans. In addition, in April 2018, the Centers for Medicare &amp; Medicaid Services published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the Patient Protection and Affordable Care Act for plans sold through such marketplaces.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although efforts at replacing the Health Care Reform Act have stalled in Congress, there could still be changes to this legislation in the near term. We cannot predict what those changes will be or when they will take effect, and we could face additional risks arising from such changes. Because of this continued uncertainty, including the potential for further legal challenges or repeal of that legislation, we cannot quantify or predict with any certainty the likely impact of this legislation or its repeal on our business model, prospects, financial condition or results of operations, in particular on the pricing, coverage or reimbursement of any of our product candidates that may receive marketing approval. Additionally, policy efforts designed specifically to reduce patient out-of-pocket costs for medicines could result in new mandatory rebates and discounts or other pricing restrictions. Legislative efforts relating to drug pricing, the cost of prescription drugs under Medicare, the relationship between pricing and manufacturer patient programs, and government program reimbursement methodologies for drugs have been proposed and considered at the U.S. federal and state level. At the federal level, the administration&#8217;s budget proposal for fiscal year 2019 contained further drug price control measures that could be enacted in future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid and to eliminate cost sharing for generic drugs for low-income patients. While any proposed measures will require authorization through additional legislation to become effective, Congress and the administration have each indicated an intent to continue to seek new legislative or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We also anticipate that Congress, state legislatures, and third-party payors may continue to review and assess alternative health care delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations effecting additional fundamental changes in the health care delivery system. We cannot provide assurance as to the ultimate content, timing, or effect of changes, nor is it possible at this time to estimate the impact of any such potential legislation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the U.S. Health and Human Services Administration announced a preliminary plan to allow for the importation of certain lower-cost drugs from Canada. The preliminary plan excludes insulin, biological drugs, controlled substances and intravenous drugs. The preliminary plan relies on individual states to develop proposals for safe importation of those drugs from Canada and submit those proposals to the federal government for approval. Although the preliminary plan has some support from the current administration, at this time, studies to evaluate the related costs and benefits, evaluate the reasonableness of the logistics, and measure the public reaction of such a plan have not been performed. We cannot provide assurance as to the ultimate content, timing, effect or impact of such a plan.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Government of Canada (Health Canada) published in the Canada Gazette the new pricing regulation for patented drugs. These regulations were scheduled to become effective on July 1, 2021, but have been delayed until July 1, 2022. The new regulations will, among other things, change the mechanics of establishing the pricing for products submitted for approval after August 21, 2019 and the number and composition of reference countries used to determine if a drug&#8217;s price is excessive. While we do not believe this will have a significant impact on our future cash flows, as additional facts materialize, we cannot provide assurance as to the ultimate content, timing, effect or impact of such regulations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Care Reform Act and further changes to health care laws or regulatory framework that reduce our revenues or increase our costs could also have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to a broad range of environmental laws and regulations and may be subject to environmental remediation obligations under such safety and related laws and regulations. The impact of these obligations and the Company&#8217;s ability to respond effectively to them may have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a broad range of federal, state, provincial and local environmental laws and regulations concerning the environment, safety matters, regulation of chemicals and product safety in the countries where we manufacture and sell our products or otherwise operate our business. These requirements include, among other matters, regulation of the handling, manufacture, transportation, storage, use and disposal of materials, including the discharge of pollutants, hazardous substances and waste into the environment. Compliance with environmental, health and safety laws and regulations could require us to </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incur significant operating or capital expenditures or result in significant restrictions on our operations. If we fail to comply with these environmental, health and safety laws and regulations, including failing to obtain or comply with any necessary permits, we could incur substantial civil or criminal fines or penalties or enforcement actions, including regulatory or judicial orders enjoining or curtailing our operations or requiring us to conduct or fund remedial or corrective measures, install pollution control equipment, reformulate or cease the marketing of our products or perform other actions. In the normal course of our business, regulated substances and waste may be released into the environment, which could cause environmental or property damage or personal injuries, and which could subject us to remediation obligations regarding contaminated soil and groundwater, potential liability for damage claims or to social or reputational harm and other similar adverse impacts. Under certain laws, we may be subject to joint and several liability for environmental investigations and cleanups, including at properties that we currently or previously owned or operated, or at sites at which waste we generated was disposed, even if the contamination was not caused by us or was legal at the time it occurred. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to extensive and evolving regulations regarding the manufacturing, processing, distribution, importing, exporting and labeling of our products and their raw materials. In the EU, the REACH regulations came into effect in 2007, with implementation rolling out over time. Registered chemicals then can be subject to further evaluation and potential restrictions. Since the promulgation of REACH, other countries have enacted or are in the process of implementing similar comprehensive chemical regulations. These laws and regulations may materially affect our operations by subjecting our products or raw materials to testing or reporting requirements or restrictions, moratoria, phase outs or other limitations on their sale or use. In particular, some of our products might be characterized as nanomaterials and then be subject to evolving, new nanomaterial regulations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, legislation and regulation related to environmental protection have become increasingly stringent. Such legislation and regulations are complex and constantly changing. In particular, legislation and regulation relating to climate change, sustainability and product stewardship including greenhouse gas emissions, are at various stages of consideration and implementation. Future events, such as changes in existing laws or regulations or the enforcement thereof or the discovery of contamination at our facilities may, among other things, require us to install additional controls for certain of our emission sources, undertake changes in our manufacturing processes, remediate soil or groundwater contamination at facilities where such cleanup is not currently required, take action to address social expectations or concerns arising from or relating to such changes and our response to such changes or adversely impact our suppliers. These impacts may be significant and could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations could be negatively affected by shareholder activism, which could cause us to incur significant expenses, hinder execution of our business strategy and impact our share price.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, shareholder activism involving corporate governance, fiduciary duties of directors and officers, strategic direction and operations has become increasingly prevalent. One of our investors, which currently owns approximately 9.49% of our outstanding common shares, filed a Schedule 13D with the SEC in February 2021, in which it was indicated that the investor intended to engage in discussions with our management and board regarding ways to enhance shareholder value, including our ongoing strategic review and that it may also seek board representation. We subsequently entered into a Director Appointment and Nomination Agreement with such investor, pursuant to which they have appointed two members to our Board of Directors. Another of our investors, which currently owns approximately 4.75% of our outstanding common shares, filed a Schedule 13D with the SEC in July 2020, in which it indicated that it intended to consider, explore and/or develop plans and/or make proposals respecting, among other things, our businesses, assets, operations, and strategy, and to explore ways to strengthen the Company and enhance shareholder value. In February 2021, this investor also sent the Company a public letter, in which it stated its views on the timing of the completion of the B+L Separation and recommended, among other things, the divestiture of certain of our businesses and assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event such investors continue to pursue such proposals or we become the subject of additional shareholder activism, this may create a significant distraction for our management and employees. This could negatively impact our ability to execute our business plans (including the B+L Separation) and may require our management to expend significant time, resources and costs, including legal fees and other expenses incurred in connection with any proxy contest that may result from any such shareholder activism. Furthermore, when individuals are elected to our Board with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our shareholders and could lead us to adopt other plans that we cannot predict and which could focus on short-term benefits with longer-term costs or that may not be in the best interests of the Company. Such shareholder activism may also create uncertainties with respect to our financial position and operations, may adversely affect our ability to attract and retain key employees and may result in loss of potential business opportunities with our current and potential customers and business partners, any of which could have a material adverse effect on our business, financial condition, cash flows and results of operations. In addition, such shareholder </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activism may cause significant fluctuations in our share price based on temporary or speculative market perceptions, uncertainties or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business, and could cause the market value of our common shares to decline. While we will remain responsive to shareholder demands, there is no assurance that we will achieve their objectives, or that doing so will decrease the likelihood of activist shareholder engagement in the future. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have significant goodwill and other intangible assets and potential impairment of goodwill and other intangibles may have a significant adverse impact on our profitability. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and intangible assets represent a significant portion of our total assets. Finite-lived intangible assets are subject to an impairment analysis whenever events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that the asset may be impaired. If impairment exists, we would be required to take an impairment charge with respect to the impaired asset. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in 2021, 2020 and 2019, we recognized impairments to finite-lived and indefinite-lived intangible assets of $146 million, $18 million and $75 million, respectively. These asset impairments were primarily attributable to revisions in sales forecasts associated with discontinuances, generic competition and other market forces. In addition to impairments to finite-lived and indefinite-lived intangible assets, in 2021, we recognized a $469 million impairment to the goodwill of our Ortho Dermatologics reporting unit. This impairment to goodwill was primarily the result of revisions to our long-term forecasts for the Ortho Dermatologics reporting unit due to changing business dynamics and market conditions. There were no goodwill impairments in 2020 and 2019.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2021. No impairment to the goodwill of any reporting unit was identified. If market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 8, "INTANGIBLE ASSETS AND GOODWILL" to our audited Consolidated Financial Statements for further information on these impairment charges.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Events giving rise to impairment are difficult to predict, including the uncertainties associated with the launch of new products, and are an inherent risk in the pharmaceutical and medical device industries. As a result of the significance of goodwill and intangible assets, our financial condition and results of operations in a future period could be negatively impacted should such an impairment of goodwill or intangible assets occur, which could cause the market value of our common shares and/or debt securities to decline. We may be required to take additional impairment charges in the future and such impairment charges may be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company&#8217;s ability to effectively monitor and respond to the rapid and ongoing developments and expectations relating to environmental, social and governance (&#8220;ESG&#8221;) matters, including related social expectations and concerns, may impose unexpected costs on the Company or result in reputational or other harm to the Company that could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are rapid and ongoing developments and changing expectations relating to ESG matters and factors such as the impact of our operations on climate change, water and waste management, our practices relating to sustainability and product stewardship, product safety, access to health care and affordable drugs, management of business ethics and human capital development, which may result in increased regulatory, social, investor or other scrutiny on us. If we are not able to adequately recognize and respond to such developments and governmental, investor and social expectations, including expectations of lenders, investors and other stakeholders relating to ESG matters, we may miss corporate opportunities for the Company, become subject to additional regulatory, social, investor or other scrutiny, incur unexpected costs or experience damage to the reputation of the Company or its various brands with governments, customers, employees, investors, third parties and the communities in which we operate, in each case that could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have various indemnity agreements and indemnity arrangements in place, which may result in an obligation to indemnify or reimburse the relevant counterparty, which amounts may be material.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All directors and/or officers of the Company, and each of its various subsidiary entities, are indemnified by the Company in respect of their service as directors and/or officers, subject to certain restrictions. We have also purchased directors&#8217; and officers&#8217; liability insurance to mitigate the cost of any potential future lawsuits or actions. The maximum amount of any potential future payment cannot be reasonably estimated but could have a material adverse effect on the Company.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we have entered or may enter into agreements that include indemnities in favor of third parties, such as purchase and sale agreements, license agreements, engagement letters with advisors and consultants and various product and service agreements. These indemnification arrangements may require us to compensate counterparties for losses incurred by the counterparties as a result of breaches in representations, covenants and warranties provided by us or as a result of litigation or other third-party claims or statutory sanctions that may be suffered by the counterparties as a consequence of the relevant transaction. In some instances, the terms of these indemnities are not explicitly defined. We, whenever possible, try to limit this potential liability within the particular agreement or contract, but due to the unpredictability of future events the maximum amount of any potential reimbursement cannot be reasonably estimated, but could have a material adverse effect on the Company.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results and financial condition may fluctuate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results and financial condition may fluctuate from quarter to quarter for a number of reasons. In addition, our stock price can be volatile. The following events or occurrences, among others, could cause fluctuations in our financial performance and/or stock price from period to period:</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of COVID-19;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">development and launch of new competitive products;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and receipt of FDA and other regulatory approvals or lack of approvals;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to business development transactions;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the amount we spend to promote our products;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays between our expenditures to acquire new products, technologies or businesses and the generation of revenues from those acquired products, technologies or businesses;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in treatment practices of physicians that currently prescribe certain of our products;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases in the cost of raw materials used to manufacture our products; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions by the FDA or other regulatory relating to our manufacturers or suppliers;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing and supply interruptions;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our responses to price competition;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new legislation that would control or regulate the prices of drugs;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a protracted and wide-ranging trade conflict between the United States and China;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenditures as a result of legal actions (and settlements thereof), including the defense of our patents and other intellectual property;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market acceptance of our products;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of wholesaler and distributor purchases and success of our wholesaler and distributor arrangements; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic and industry conditions, including potential fluctuations in interest rates; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in seasonality of demand for certain of our products; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency exchange rate fluctuations;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, structure and terms of the B+L Separation and the Solta IPO;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to, or the confidence in, our business strategy;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to, or the confidence in, our management; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expectations for future growth.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, quarter-to-quarter comparisons of results from operations, or any other similar period-to-period comparisons, may not be reliable indicators of our future performance. In any quarterly period, our results may be below the expectations of market analysts and investors, which could cause the market value of our common shares and/or debt securities to decline.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_85"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B.&#160;&#160;&#160;&#160;Unresolved Staff Comments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_88"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Properties </span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own and lease a number of important properties. Our headquarters and one of our manufacturing facilities are located in Laval, Quebec. We own several manufacturing facilities throughout the U.S. We also own or have an interest in manufacturing plants or other properties outside the U.S., including in Canada, Mexico, and certain countries in Europe, Asia and South America.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider our facilities to be in satisfactory condition and suitable for their intended use, although some limited investments to improve our manufacturing and other related facilities are contemplated, based on the needs and requirements of our business. Our administrative, marketing, research/laboratory, distribution and warehousing facilities are located in various </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">parts of the world. We co-locate our R&amp;D activities with our manufacturing at the plant level in a number of facilities. Our scientists, engineers, quality assurance/quality control professionals and manufacturing technicians work side-by-side in designing and manufacturing products that fit the needs and requirements of our customers, regulators and business units.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have sufficient facilities to conduct our operations during 2022. Our facilities in aggregate are approximately 10&#160;million square feet and include, among others, the following list of principal properties by segment:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:24.119%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.219%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purpose</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Owned<br/>or<br/>Leased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Approximate<br/>Square<br/>Footage</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laval, Quebec, Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate headquarters, R&amp;D, manufacturing and warehouse facility</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bridgewater, New&#160;Jersey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Administration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rochester, New York</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offices, R&amp;D and manufacturing facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">953,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">San Juan del Rio, Mexico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offices and manufacturing facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">853,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jelenia Gora, Poland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offices, R&amp;D, manufacturing and warehouse facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Waterford, Ireland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D and manufacturing facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Woodruff, South Carolina</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distribution facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">432,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jinan, China</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offices and manufacturing facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">418,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rzeszow, Poland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offices, R&amp;D, manufacturing and warehouse facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Berlin, Germany</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing, distribution and office facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Greenville, South Carolina</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing and distribution facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Steinbach, Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offices, manufacturing and warehouse facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chattanooga, Tennessee</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distribution facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aubenas, France</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offices, manufacturing and warehouse facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Macherio, Italy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offices, R&amp;D, manufacturing and warehouse facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beijing, China</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) &#8212; A lease for a second building in Bridgewater, New Jersey was signed in 2015 and was not included in the square footage shown in the table above as the Company has never occupied the second building. In 2016, the Company concluded that it would not occupy the second building and recognized the appropriate charge for all future rents due, net of the anticipated sub-let income associated with the second building.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_91"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements for details on legal proceedings.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_94"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_100"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_103"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common shares are traded on the New&#160;York Stock Exchange (&#8220;NYSE&#8221;) and on the Toronto Stock Exchange (&#8220;TSX&#8221;) under the symbol &#8220;BHC&#8221;.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_106"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Price Volatility of Common Shares </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market prices for the securities of pharmaceutical, medical devices and biotechnology companies, including our securities, have historically been highly volatile, and the market has experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. Factors such as fluctuations in our operating results, the aftermath of public announcements by us or by others about us, changes in our executive management, changes in our business strategy, concern as to the safety of drugs and medical devices, the commencement or outcome of legal or governmental proceedings, changes in our ability to access credit markets, changes in the cost of capital, investigations or inquiries, and general market conditions can have an adverse effect on the market price of our common shares and other securities. For example, during 2015 and 2016, we experienced significant fluctuations and decreases in the market price of our common shares as a result of, among other things, legal and governmental proceedings and investigations with respect to certain of our distribution, marketing, pricing, disclosure and accounting practices, rising interest rates and certain public allegations made by short sellers and other third parties relating to certain of these matters. See Item 1A. &#8220;Risk Factors&#8221; of this Form 10-K for additional information.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_109"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approximate number of holders of record of our common shares as of February&#160;17, 2022 was 1,815.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following performance graph compares the cumulative total return on a $100 investment on December 31, 2016, assuming reinvestment of all dividends, in: (i) our common shares, (ii) the S&amp;P 500 Index, (iii) the S&amp;P/TSX Composite Index, (iv) a 2021 composite peer group of 10 major pharmaceutical companies and (v) a 2022 composite peer group of 14 major pharmaceutical companies for the five years ended December&#160;31, 2021. The 2021 composite peer group of 10 major pharmaceutical companies consists of Amgen Inc, Biogen Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, Endo International plc, Jazz Pharmaceuticals plc, Mallinckrodt plc, Perrigo Company plc, United Therapeutics Corporation and Zoetis Inc. As a result of certain mergers involving our peer group, the Company completed an assessment to review its current peers and search for potential new peers. This resulted in the 2022 composite peer group of 14 major pharmaceutical companies, which consists of Alcon Inc., Amgen Inc., Baxter International Inc., Biogen Inc, Cooper Companies Inc., Eli Lilly and Company, Endo International plc, Jazz Pharmaceuticals plc, Perrigo Company plc, Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, Viatris Inc., Zoetis Inc. and Zimmer Biomet Holdings Inc. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Five Year Performance - Cumulative total return on a $100 investment on December 31, 2016</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><img src="bhc-20211231_g1.jpg" alt="bhc-20211231_g1.jpg" style="height:401px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2016</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$143</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$127</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$206</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$143</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$190</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S&amp;P 500</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$100</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$122</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$116</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$153</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$181</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$233</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S&amp;P/TSX Composite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$109</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$122</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$129</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$161</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Peer Group</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$100</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$118</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$133</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$166</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$185</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$247</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022 Peer Group</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$114</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$116</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$144</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$165</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$200</span></td></tr></table></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_115"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No dividends were declared or paid in 2021, 2020 or 2019. While our Board of Directors will review our dividend policy periodically, we currently do not intend to pay any cash dividends in the foreseeable future. In addition, our Restated Credit Agreement and indentures include restrictions on the payment of&#160;dividends.&#160; See Note 10, "FINANCING ARRANGEMENTS" to our audited Consolidated Financial Statements for further details regarding these restrictions.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restrictions on Share Ownership by Non-Canadians</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no limitations under the laws of Canada or in our organizational documents on the right of foreigners to hold or vote securities of our Company, except that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment Canada Act (Canada)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the&#160;&#8220;Investment Canada Act&#8221;) may require review and approval by the Minister of Innovation, Science and Industry(Canada) (the &#8220;Minister&#8221;) of an acquisition of &#8220;control&#8221; of our Company by a &#8220;non-Canadian&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Canada Act</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An acquisition of control of a Canadian business by a non-Canadian is either reviewable (a&#160;&#8220;Reviewable Transaction&#8221;), in which case it is subject to both a reporting obligation and an approval process, or notifiable, in which case it is subject to only a reporting obligation. In the case of a Reviewable Transaction, the non-Canadian acquirer must submit an application for review with the prescribed information. The Minister is then required to determine whether the Reviewable Transaction is likely to be of net benefit to Canada, taking into account the assessment factors specified in the Investment Canada Act and any written undertakings that may have been given by the non-Canadian acquirer.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investment Canada Act provides that any investment by a non-Canadian in a Canadian business, even where control has not been acquired, can be reviewed on grounds of whether it may be injurious to national security. Where an investment is determined to be injurious to national security, Cabinet can prohibit closing or, if closed, can order the investor to divest control. Short of a prohibition or divestment order, Cabinet can impose terms or conditions on the investment or can require the investor to provide binding undertakings to remove the national security concern.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition Act</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part&#160;IX of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Canada) (the&#160;&#8220;Competition Act&#8221;) requires that a pre-merger notification filing be submitted to the Commissioner of Competition (the&#160;&#8220;Commissioner&#8221;) in respect of certain classes of merger transactions that exceed certain prescribed thresholds. If a proposed transaction exceeds such thresholds, subject to certain exceptions, the notification filing must be submitted to the Commissioner and the statutory waiting period must expire or be terminated early or waived by the Commissioner before the transaction can be&#160;completed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All mergers, regardless of whether they are subject to Part&#160;IX of the Competition Act, are subject to the substantive mergers provisions under Section&#160;92 of the Competition Act. In particular, the Commissioner may challenge a transaction before the Competition Tribunal where the transaction prevents or lessens, or is likely to prevent or lessen, competition substantially in a market. The Commissioner may not make an application to the Competition Tribunal under Section&#160;92 of the Competition Act more than one year after the merger has been substantially completed. </span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_121"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Controls</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada has no system of exchange controls. There are no Canadian exchange restrictions on the repatriation of capital or earnings of a Canadian public company to non-resident investors. There are no Canadian exchange restrictions affecting the remittance of dividends, profits, interest, royalties and other payments to non-resident holders of our securities.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_124"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Taxation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Canadian Federal Income Taxation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion is a summary of the principal Canadian federal income tax considerations generally applicable to a holder of our common shares who, at all relevant times, for purposes of the Income Tax&#160;Act (Canada) and the Income Tax Regulations (collectively, the &#8220;Canadian Tax&#160;Act&#8221;) deals at arm&#8217;s-length with, and is not affiliated with, our Company, beneficially owns its common shares as capital property, does not use or hold and is not deemed to use or hold such common shares in carrying on a business in Canada, does not with respect to common shares enter into a &#8220;derivative forward agreement&#8221; as defined in the Canadian Tax Act, and who, at all relevant times, for purposes of the application of the Canadian Tax&#160;Act and the Canada-U.S.&#160;Income Tax Convention (1980, as amended) (the&#160;&#8220;U.S.&#160;Treaty&#8221;), is resident in the U.S., is not, and is not deemed to be, resident in Canada and is eligible for benefits under the U.S.&#160;Treaty (a&#160;&#8220;U.S.&#160;Holder&#8221;). Special rules, which are not discussed in the summary, may apply to a non-resident holder that is an insurer that carries on an insurance business in Canada and elsewhere or that is an &#8220;authorized foreign bank&#8221; as defined in the Canadian Tax&#160;Act.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S.&#160;Treaty includes limitation on benefits rules that restrict the ability of certain persons who are resident in the U.S.&#160;to claim any or all benefits under the U.S.&#160;Treaty. Furthermore, limited liability companies (&#8220;LLCs&#8221;) that are not taxed as corporations pursuant to the provisions of the U.S.&#160;Internal Revenue Code of 1986, as amended do not generally qualify as resident in the U.S.&#160;for purposes of the U.S.&#160;Treaty. Under the U.S.&#160;Treaty, a resident of the U.S.&#160;who is a member of such an&#160;LLC and is otherwise eligible for benefits under the U.S.&#160;Treaty may generally be entitled to claim benefits under the </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S.&#160;Treaty in respect of income, profits or gains derived through the&#160;LLC. Residents of the U.S.&#160;should consult their own tax advisors with respect to their eligibility for benefits under the U.S.&#160;Treaty, having regard to these&#160;rules.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary is based upon the current provisions of the U.S.&#160;Treaty and the Canadian Tax&#160;Act and our understanding of the current administrative policies and assessing practices of the Canada Revenue Agency published in writing prior to the date hereof. This summary takes into account all specific proposals to amend the U.S.&#160;Treaty and the Canadian Tax&#160;Act publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date hereof. This summary does not otherwise take into account or anticipate changes in law or administrative policies and assessing practices, whether by judicial, regulatory, administrative or legislative decision or action, nor does it take into account provincial, territorial or foreign tax legislation or considerations, which may differ from those discussed herein.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">This summary is of a general nature only and is not intended to be, nor should it be construed to be, legal or tax advice generally or to any particular holder. Holders should consult their own tax advisors with respect to their own particular circumstances.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gains on Disposition of Common Shares</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, a U.S.&#160;Holder will not be subject to tax under the Canadian Tax&#160;Act on capital gains arising on the disposition of such holder&#8217;s common shares unless the common shares are &#8220;taxable Canadian property&#8221; to the U.S.&#160;Holder and are not &#8220;treaty-protected property&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As long as the common shares are then listed on a &#8220;designated stock exchange&#8221;, which currently includes the NYSE and TSX, the common shares generally will not constitute taxable Canadian property of a U.S.&#160;Holder, unless: (a)&#160;at any time during the 60-month period preceding the disposition, the U.S.&#160;Holder, persons not dealing at arm&#8217;s length with such U.S.&#160;Holder or the U.S.&#160;Holder together with all such persons, owned 25% or more of the issued shares of any class or series of the capital stock of the Company and (b) more than 50% of the fair market value of the common shares was derived, directly or indirectly, from any combination of: (i)&#160;real or immoveable property situated in Canada, (ii)&#160;&#8220;Canadian resource property&#8221; (as&#160;such term is defined in the Canadian Tax&#160;Act), (iii)&#160;&#8220;timber resource property&#8221; (as&#160;such term is defined in the Canadian Tax&#160;Act) or (iv)&#160;options in respect of, or interests in, or for civil law rights in, any such properties whether or not the property exists or the common shares are otherwise deemed to be taxable Canadian property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares will be treaty-protected property where the U.S.&#160;Holder is exempt from income tax under the Canadian Tax&#160;Act on the disposition of common shares because of the U.S.&#160;Treaty. Common shares owned by a U.S.&#160;Holder will generally be treaty-protected property where the value of the common shares is not derived principally from real property situated in Canada, as defined in the U.S.&#160;Treaty.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends on Common Shares</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends paid or credited on the common shares or deemed to be paid or credited on the common shares to a U.S.&#160;Holder that is the beneficial owner of such dividends will generally be subject to non-resident withholding tax under the Canadian Tax&#160;Act and the U.S.&#160;Treaty at the rate of: (a)&#160;5% of the amounts paid or credited if the U.S.&#160;Holder is a company that owns (or&#160;is deemed to own) at least 10% of our voting stock or (b)&#160;15% of the amounts paid or credited in all other cases. The rate of withholding under the Canadian Tax&#160;Act in respect of dividends paid to non-residents of Canada is 25% where no tax treaty&#160;applies.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_127"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required under this Item will be included in our definitive proxy statement for the 2022 Annual Meeting of Shareholders expected to be filed with the SEC no later than 120&#160;days after the end of the fiscal year covered by this Form&#160;10-K (the&#160;&#8220;2022 Proxy Statement&#8221;), and such required information is incorporated herein by&#160;reference.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_130"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Company and Affiliated Purchases </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no purchases of equity securities by the Company during the fourth quarter of the year ended December&#160;31, 2021.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_133"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Reserved</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_139"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTION</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; has been updated through February&#160;23, 2022 and should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto included elsewhere in this Annual Report on Form 10-K. The matters discussed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively, &#8220;Forward-Looking Statements&#8221;). See &#8220;Forward-Looking Statements&#8221; at the end of this discussion. Additional company information, including this Form&#160;10-K, is available on SEDAR at </span><span style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.sedar.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> and on the U.S.&#160;Securities and Exchange Commission (the&#160;&#8220;SEC&#8221;) website at&#160;</span><span style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  All currency amounts are expressed in U.S.&#160;dollars, unless otherwise noted.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_142"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch Health Companies&#160;Inc. (&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221; or the&#160;&#8220;Company&#8221;) is a global company whose mission is to improve people&#8217;s lives with our health care products. We develop, manufacture and market, primarily in the therapeutic areas of eye-health, gastroenterology (&#8220;GI&#8221;) and dermatology, a broad range of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) over-the-counter (&#8220;OTC&#8221;) products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in approximately 100 countries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generated revenues for 2021, 2020 and 2019, of $8,434 million, $8,027 million and $8,601 million, respectively. Our portfolio of products falls into five operating and reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International Rx, (iv) Ortho Dermatologics and (v) Diversified Products. These segments are discussed in detail in Note 22, "SEGMENT INFORMATION" to our audited Consolidated Financial Statements. The following is a brief description of the Company&#8217;s segments:  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.53pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmic Pharmaceuticals products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of GI products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International Rx segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales, with the exception of sales of Bausch +Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Ortho Dermatologics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological) products and (ii) global sales of Solta aesthetic medical devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of our reportable segments, see the discussion in Item 1. "Business &#8212; Segment Information" and Note 22, "SEGMENT INFORMATION" to our audited Consolidated Financial Statements for further details on these reportable segments.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_145"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Focus on Value</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we retained a new executive team which implemented a multi-year plan designed to transform and bring out value in our Company. The multi-year plan increased our focus on, among other factors, our: product portfolio, infrastructure, geographic footprint, capital structure and risk management.  Since that time, we have been executing and continue to execute on our commitments to transform the Company and generate value. As discussed below, under the multi-year plan, we have taken actions that among other things included: (i) divesting non-core assets, (ii) making strategic investments in our core businesses and (iii) making measurable progress in improving our capital structure.  These measures gave us operating flexibility and put us in a strong position to unlock the additional value to be found in our specific businesses. We believe that these and other positive actions we took to transform our Company, have helped to focus our operations, and improve our capital structure. These positive actions also presented us with an opportunity to unlock potential value across our portfolio of assets by separating our pharmaceutical, eye-health and skincare businesses, and, in 2020 and 2021, we set out to create three highly attractive but dissimilar businesses. Although management believes these transactions will bring out additional value, there can be no assurance that either the B+L Separation or the Solta IPO will be successful in doing so.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separation of the Bausch + Lomb Eye-Health Business and the Solta Medical Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, we announced our plan to separate our eye-health business consisting of our Bausch + Lomb Global Vision Care, Global Consumer, Global Surgical and Global Ophthalmic Pharmaceuticals businesses into an independent publicly traded entity, Bausch + Lomb  from the remainder of Bausch Health Companies Inc (the &#8220;B+L Separation&#8221;). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of our announcement, we have previously emphasized that it is important that the post-separation entities be well capitalized, with appropriate leverage and with access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate capitalization and leverage of these businesses post-separation as a key to maximizing value across our portfolio of assets and, so, it is a primary objective of our plan of separation. We also previously stated that all options for achieving the appropriate capitalization and leverage for these entities post-separation were being considered. Management remains focused on the capitalizations of the post-separation entities and has considered and continues to consider alternative means of achieving the appropriate outcome, including dispositions in our business that we believe represent attractive opportunities for the Company and are in line with our plan of separation. This informed our decision to divest Amoun Pharmaceutical Company S.A.E. ("Amoun") on July 26, 2021 and, as discussed below, use the net proceeds to repay certain debt obligations. It has also informed, in part, our decision to pursue an initial public offering of our Solta aesthetic medical device business (&#8220;Solta Medical&#8221;) (the &#8220;Solta IPO&#8221;), which we announced on August 3, 2021. We believe that the Solta IPO, when and if complete, will allow us to unlock the value of this high-growth business and give us ownership of a valuable financial asset that would compare more favorably to other aesthetic medical device companies. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since announcing the B+L Separation and Solta IPO, we began executing on those plans and, at the end of 2021, had substantially completed the internal objectives necessary to facilitate the IPOs and related separation of those businesses.  We continue to monitor market conditions and aim to launch the B+L IPO and the Solta IPO when financial market conditions are favorable (subject to receipt of regulatory, stock exchange and other approvals). However, there can be no assurance as to when we will complete either IPO, if at all. Until such time, we continue to manage these businesses along with our diverse portfolio of gastrointestinal, dermatology, neurology and other therapeutics, with our commitment to bring out additional value for our shareholders. Following the B+L IPO, we expect to complete the separation of Bausch + Lomb following the expiry of customary lockups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to the receipt of applicable shareholder and other necessary approvals and market conditions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to use the proceeds from the B+L Separation and the Solta IPO to repay, to the extent possible, a portion of our existing debt, thereby improving our capitalization and leverage. We believe the B+L Separation and the Solta IPO provide us with an attractive opportunity for liquidity to support the appropriate capitalization and leverage of the Bausch + Lomb entity, the Solta Medical entity and the remainder of Bausch Health Companies Inc., which we refer to as &#8220;Bausch Pharma&#8221; and will assume a new name upon completion of the B+L Separation. However, management continues to consider the forms of the B+L Separation and the Solta IPO and is exploring a number of alternative capitalization structures in order to properly capitalize the three entities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The B+L Separation and the Solta IPO will establish three separate companies that include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Bausch + Lomb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - a fully integrated, pure play eye-health company built on the iconic Bausch + Lomb brand and long history of innovation; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Solta Medical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - a leading global aesthetic medical device company focused on the development, manufacture and sale of innovative technologies that provide aesthetic and therapeutic benefits; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Bausch Pharma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - a diversified pharmaceutical company with leading positions in gastroenterology, dermatology, neurology and international pharmaceuticals. The remaining pharmaceutical entity will comprise a diversified portfolio of our leading durable brands across the Salix, International Rx, dentistry, neurology, medical dermatology and generics businesses. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe these transactions will result in three highly attractive but dissimilar businesses. As separate entities, management believes that each company will be better positioned to individually focus on its core businesses to drive additional growth, more effectively allocate capital and better manage its respective capital needs.  Further, these transactions allow us and the market to compare the operating results of each entity with other &#8220;pure play&#8221; peer companies. Although management believes these transactions will bring out additional value, there can be no assurance that either the B+L Separation or the Solta IPO will be successful in doing so.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January and February 2022, we took certain actions to, and announced others that we believe will, bring us closer in reaching our targeted capitalization of the post-separation entities. These actions are discussed in more detail in Item &#8220;&#8212; </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221; and Note 23, "SUBSEQUENT EVENTS" to our audited Consolidated Financial Statements.  Although an IPO of the Bausch + Lomb and Solta Medical businesses are among the alternate capital structures being considered, this Form 10-K does not constitute an offer to sell, or the solicitation of an offer to buy, any securities of the Bausch + Lomb or Solta Medical entities. As of the date of this filing, the determination of the capitalization of the three entities continues to evolve, and we do not have a definitive timetable to finalize the respective capital structures. We continue to monitor market conditions and aim to launch the B+L IPO and Solta IPO when financial market conditions are favorable (and subject to receipt of regulatory, stock exchange, and other regulatory approvals). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the capitalization and leverage ratios of each entity, there are considerations, approvals and conditions, including market conditions, that will determine the ultimate timing and structure of these transactions, including regulatory approvals, final approval by our board of directors, any shareholder vote requirements that may be applicable, compliance with U.S. and Canadian securities laws and stock exchange rules, receipt of any applicable opinions and/or rulings with respect to the Canadian and U.S. federal income tax treatment of such transactions and determination of the pro forma capitalization of each of the three entities. The failure to satisfy all of the required conditions could delay the completion of these transactions for a significant period of time or prevent them from occurring at all. In addition to our internal organization and structure work, we will need to complete a number of additional steps that will depend on the ultimate structure of the transactions (in addition to obtaining the regulatory approvals and satisfying the conditions described above) before we can launch the B+L IPO, complete the B+L Separation and/or launch the Solta IPO. As a result, there can be no assurance as to the timing of the completion of any of these transactions or their terms, and the information in this Form 10-K relating to each transaction is preliminary and may change as the transactions progress and any such changes and their impact on the Company, or any of the companies that result from the consummation of any of these transactions, may be material.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item&#160;1A. &#8220;Risk Factors &#8212;&#160;Risk Relating to the B+L Separation&#8221; of this Form 10-K for additional risks relating to the B+L Separation and the Solta IPO.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_2897"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Setting Up Our Company to Unlock Value</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To position ourselves to unlock the value we see in our individual businesses, we have sought to right-size our portfolio of assets and provide financial flexibility. The Company has focused on the following growth drivers, that remain a focus of our growth strategies today:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">divested non-core assets in order to narrow the Company's activities to our core businesses where we believe we have an existing and sustainable competitive edge and the ability to generate operational efficiencies. To date, we received approximately $4,100 million in net proceeds from these divestitures, which includes the sale of Amoun (the "Amoun Sale") which we divested on July 26, 2021, as discussed below;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">made strategic investments in our core businesses in order to support recent revenue growth and prepare for additional growth opportunities we plan to capitalize on for our core businesses;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">made measurable progress in improving our capital structure as we have repaid approximately $10,000&#160;million in debt obligations (net of additional borrowings, amounts refinanced and excluding the $1,210 million financing of the U.S. Securities Litigation settlement discussed below) during the period of January 1, 2016 through December 31, 2021 using the proceeds from the divestiture of non-core assets, cash generated from our operations and improved working capital management. This includes approximately $1,300 million of repayments (net of additional borrowings) during 2021 using cash on hand, cash generated from operations and the net proceeds from the Amoun Sale; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">resolved many of the Company's legacy litigation matters originating back to 2015 and prior, including the most significant legacy legal matter, the U.S. Securities Litigation settlement discussed below, significantly reducing related possible disruptions and other uncertainties to our operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that these and other positive actions we have taken to transform our Company have helped focus our operations, unlocked value across our product portfolios, improved our capital structure and mitigated certain risks associated with legacy litigation matters.  We believe that these measures, along with our continued commitment to improving people's lives through our health products, help position us to unlock potential value across our portfolio of assets by separating our pharmaceutical, eye-health and skincare businesses.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_2821"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divest Assets to Improve Our Capital Structure and Simplify Our Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to better focus on our core businesses, we continue to evaluate opportunities to simplify our operations and improve our capital structure, including dispositions of various assets. For example, on July 26, 2021, we completed the sale of Amoun for total gross consideration of approximately $740&#160;million, subject to certain adjustments. Amoun, which was part of </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the International Rx segment, manufactures, markets and distributes branded generics of human and animal health products. Revenues associated with Amoun were $157&#160;million for the period of January 1, 2021 through July 26, 2021 and were $247&#160;million and $220&#160;million for the years 2020 and 2019, respectively. Following the completion of the Amoun Sale, the Company made aggregate payments of $600&#160;million, to repay $469&#160;million of its June 2025 Term Loan B Facility and $131&#160;million of its November 2025 Term Loan B Facility, using the net proceeds from the Amoun Sale and cash on hand.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to consider further dispositions of various assets in line with this strategy. While we anticipate that any future divestiture activities will be on non-core assets, consistent with our duties to our shareholders and other stakeholders, we will consider dispositions in core areas that we believe represent attractive opportunities for the Company. See Note 3, "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE" to our audited Consolidated Financial Statements for additional information.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_151"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impacts of COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has, and continues to, adversely impact the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facility closures and production suspensions. We believe we responded quickly to these and other human and commercial challenges brought on by the COVID-19 pandemic and that our actions allowed us to: (i) maintain a reliable supply of our products, (ii) protect the health, safety and well-being of our employees, (iii) reduce operating expenses and preserve cash through profit protection measures initiated in response to the COVID-19 pandemic, (iv) limit the disruptions to our product development pipeline and (v) ensure affordability of and access to our products. We will continue to monitor the impacts of the COVID-19 pandemic and related responses from governments and private sector participants on the Company, our customers, supply chain, third-party suppliers, project development timelines, costs, revenue, margins, liquidity and financial condition and our planned actions and responses to this pandemic. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2020 revenues were most negatively impacted during our second quarter by certain social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize prior to our third quarter of 2020. After the launch of effective vaccines in December 2020, infection rates began to decline, signaling the beginning of a recovery from the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues were $8,434 million for 2021, as compared to $8,027 million for 2020, a year-over-year increase of $407 million, or 5%, and primarily reflects the positive impacts of the recovery from the COVID-19 pandemic, partially offset by the impact of our divestiture of Amoun on July 26, 2021. The increase in revenue also represents an improving trend over the decreases in year-over-year revenues for the three-month periods ended June 30, 2020, September 30, 2020 and December 31, 2020 of 23%, 3% and less than 1%, respectively. Presuming there continues to be increased availability of effective vaccines and any resurgence of the COVID-19 virus and variant strains thereof, such as the delta and omicron variants, do not have a material adverse impact on efforts to contain the COVID-19 virus, the Company anticipates an ongoing, gradual global recovery from the significant macroeconomic and health care impacts of the pandemic. Our revenues returned to pre-pandemic levels for many of our businesses and geographies in 2021 and, at the current pace of recovery, we anticipate the COVID-19 pandemic to have a minimal impact on the remaining businesses and geographies in 2022.  However, the rates of recovery for each business will vary by geography and will be dependent upon, among other things, the availability and effectiveness of vaccines for the COVID-19 virus and variant strains thereof, government responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and, once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus or variant strains thereof and other actions taken in response to the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we put in place procedures to mitigate the risks associated with closures and disruptions at our manufacturing facilities, the COVID-19 pandemic temporarily impacted the manner in which we managed our inventories and inventory levels. The negative impact of the COVID-19 pandemic on the demand for many of our products necessitated that we, among other things, shorten production runs during 2020 to reduce inventories and mitigate inventory losses. The shorter production runs, the costs associated with idling certain facilities during government mandated lockdowns and the costs of the precautionary measures taken at our manufacturing facilities in response to the COVID-19 pandemic resulted in manufacturing variances, which temporarily depressed our contribution margins in 2020. However, in 2021, as demand increased and our retailers and distributors replenished their inventories, the pressures on our manufacturing processes experienced during 2020 have been alleviated and we have avoided many of the COVID-19 pandemic-induced manufacturing variances during 2021. </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we monitor the direction and pace of the recovery in each business and geography, we are also continually monitoring the effectiveness of the profit protection measures we initiated to manage and reduce our operating expenses and preserve cash during the COVID-19 pandemic. These profit protection measures were successful in expanding the profit margins in many of our businesses, as referenced in the discussion of our operating results below. In 2021, we began allocating more resources to selling and other promotional activities in support of our existing products, product launches and products in development. As a result, our SG&amp;A and R&amp;D expenses increased 11% and 3% during 2021 as compared to 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our diverse portfolio of durable products and strong brands has served us well through the COVID-19 pandemic and we continue to be well-positioned to grow market share and return to growth as the world recovers. However, this situation remains fluid and we continue to monitor the availability and effectiveness of vaccines and any resurgence of the COVID-19 virus and outbreaks of variant strains thereof, such as the delta and omicron variants, on our operations, businesses and primary goals.  Given these circumstances, we continue to focus on: (i) revising our go-to-market and sales force strategies to address the changing business dynamics created by the COVID-19 pandemic, (ii) building out our e-commerce presence to enable us to reach customers in new ways, (iii) investing in our key promoted brands and product launches to increase market share, (iv) optimizing our cost structure and (v) looking for key trends in the market to meet changing consumer/patient needs and identify areas for investment and growth. We believe focusing on these priorities will best enable us to effectively manage the changing business dynamics created by the COVID-19 pandemic, prepare us for a possible resurgence of the virus and any variant strains thereof and return us to growth during the recovery from the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a further discussion of these and other COVID-19 related risks, see Item 1A. "Risk Factors&#8212; Risks Relating to COVID-19" of this Form 10-K.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_154"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Focus on Core Businesses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to focus on our core businesses we have: (i) directed capital allocation to drive growth within our core businesses, (ii) made measurable progress in effectively managing our capital structure, (iii) increased our efforts to improve patient access and (iv) continued to invest in sustainable growth drivers to position us for long-term growth.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_157"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Direct Capital Allocation to Drive Growth Within Our Core Businesses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital allocation is driven by our long-term growth strategies. We have been aggressively allocating resources to promote our core businesses globally through: (i) strategic acquisitions, (ii) R&amp;D investment, (iii) strategic licensing agreements and (iv) strategic investments in our infrastructure. The outcome of this process allows us to better drive value in our product portfolio and generate operational efficiencies.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_160"></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Strategic Acquisitions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain very selective when considering any acquisition and pursue only those opportunities that we believe align well with our current organization and strategic plan. We sometimes refer to these opportunities as "bolt on" acquisitions.  In being selective, we seek to enter into only those acquisitions that provide us with significant synergies with our existing business, thereby minimizing risks to our core businesses and providing long-term growth opportunities. Recently, we have entered into transactions that although not immediately impactful to our operating results, are expected to be accretive to our bottom line in future years and contribute to our long-term growth strategies. </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, we completed the acquisition of certain assets of Synergy whereby we acquired the worldwide rights to the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) product, a once-daily tablet for adults with chronic idiopathic constipation, or CIC, and irritable bowel syndrome with constipation, or IBS-C. We believe that the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product complements our existing Salix products and allows us to effectively leverage our existing GI sales force. In order to drive growth of the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, we have increased the number of sales force representatives for the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product. We believe this has been successful as Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues were $103 million and $82 million for the years 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we acquired the U.S. rights to EM-100 (an investigational preservative-free formulation eye drop) from Eton Pharmaceuticals, Inc. On September 25, 2020, the Company announced that the FDA had approved Alaway</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Preservative Free (ketotifen fumarate) ophthalmic solution, 0.035%, antihistamine eye drops (EM-100) as the first OTC preservative-free formulation eye drop approved to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander. Alaway</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Preservative Free was launched in February 2021 and is expected to complement our broad range of Bausch + Lomb integrated eye-health products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are considering further acquisition opportunities within our core therapeutic areas, some of which could be material in size.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_163"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">R&amp;D Investment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continuously search for new product opportunities through internal development and strategic licensing agreements, that if successful, will allow us to leverage our commercial footprint, particularly our sales force, and supplement our existing product portfolio and address specific unmet needs in the market. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal R&amp;D organization focuses on the development of products through clinical trials. As of December 31, 2021, approximately 1,300 dedicated R&amp;D and quality assurance employees in 25 R&amp;D facilities were involved in our R&amp;D efforts internally.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have approximately 200 projects in our global pipeline. Certain core internal R&amp;D projects that have received a significant portion of our R&amp;D investment in current and prior periods are listed below. However, due to the challenges of the COVID-19 pandemic, most notably those attributable to "stay at home" orders and travel restrictions, certain of our R&amp;D activities were forced to pause in 2020. Clinical trials that started prior to governmental shutdowns remained enrolled and existing patients progressed, while new patient enrollments were paused as most trial sites were not able to accept new patients. However, during our third quarter of 2020, we saw the pace of new patient enrollments increase, and, although certain of our projects are moving slower than we would like due to the impacts of the COVID-19 pandemic, through the date of this filing we have not had to make changes to our development timelines that would have a material impact on our current or future operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor the timing and completion of our ongoing and anticipated clinical trial programs. As of the date of this filing, the delays in our clinical trials have not had a material impact on our operating results; however, a resurgence of the virus significant enough to necessitate reenacting certain social restrictions could result in unanticipated delays in our ability to conduct new patient enrollments. Other possible COVID-19 pandemic and resurgence related challenges include, but are not limited to, facility closures, delays by third-party service providers, deferrals of doctor visits, postponement of elective medical procedures and surgeries and changes in prioritization by the FDA and other regulatory authorities. Delays, if any, caused by the COVID-19 pandemic and a possible resurgence of the virus or variant strains thereof such as these and others will likely adversely affect the timely approval, launch and commercialization and the commercial success of our products, particularly those in early stage clinical trials. As a result, our estimates regarding the timing and success of our R&amp;D efforts (some of which are set out below), including as it relates to study initiation, enrollment and completion, availability of study results, regulatory submissions, regulatory approvals and commercial launches, may change.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">SiHy Daily - A silicone hydrogel daily disposable contact lens designed to provide clear vision throughout the day. In September 2018, we launched SiHy Daily in Japan under the branded name AQUALOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY.&#160; In August 2020, we launched SiHy Daily in the U.S. under the branded name Bausch + Lomb INFUSE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SiHy Daily Disposable contact lens.  In the fourth quarter of 2020, SiHy Daily was launched in Australia, Hong Kong and Canada under the branded name Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY. SiHy Daily has also received regulatory approval in China, New Zealand, Japan, South Korea, Europe, Singapore and Malaysia, where it will be branded as Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY, and, in the second quarter of 2021, we launched SiHy Daily in South Korea and Singapore as Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate ophthalmic solution, 0.025%) - An OTC eye drop developed as an ocular redness reliever. We launched this product in the U.S. in May 2018. Currently, we have several line extensions under development and expect Phase 3 clinical studies to commence in 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday for Astigmatism - A daily disposable contact lens for astigmatic patients. The Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday contact lens incorporates Surface Active Technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to provide a dehydration barrier.&#160; The Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday for Astigmatism also includes evolved peri-ballast geometry to deliver stability and comfort for the astigmatic patient.&#160;We launched this product in December 2016 and launched an extended power range and further extended power ranges in each of the years 2017 through 2020. Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday for Astigmatism has also received regulatory approval in China.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">New Ophthalmic Viscosurgical Device ("OVD") product - A formulation to protect corneal endothelium during phacoemulsification process during a cataract surgery and to help chamber maintenance and lubrication during intraocular lens delivery.  In January 2020, we commenced an FDA clinical study for the cohesive OVD product which has now achieved its enrollment target, despite COVID-19-related slowdowns, and we expect results in the first quarter of 2022. In addition, in March 2021, we received Premarket Approval from the FDA for Clearvisc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> dispersive OVD, which we launched in the U.S. in June 2021.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">enVista</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Trifocal intraocular lens - An innovative lens design.  We initiated an investigative device exemption study for this product in May 2018 and initiated the last phase of this three phase study in the fourth quarter of 2020. We completed enrollment during the first quarter of 2022 for the Canadian study and expect to complete enrollment during the first half of 2022 for the U.S. study.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10pt">SimplifEYE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> preloaded intraocular lens injector platform for enVista intraocular lens - We have received approvals from the European Union and Canada and received FDA clearance for the injector and launched this platform in October 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Extended depth of focus intraocular lens - Currently under development, however, the timing and completion of which has been delayed due to COVID-19 pandemic related matters.  Once development is completed, and if approved, we anticipate that this product could be launched in 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> monthly silicone hydrogel lens - Specifically designed to address the lifestyle and vision needs of patients with MoistureSeal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology which maintains 95% of contact lens moisture for a full 16 hours. In the second quarter of 2020, Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> received a seven day extended wear indication approval from the European Union and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">received regulatory approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the National</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Products Administration in China.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Multifocal for Astigmatism contact lens - The first and only multifocal toric lens available as a standard offering in the eye care professional's fit set. The new monthly silicone hydrogel lens, which was specifically designed to address the lifestyle and vision needs of patients with both astigmatism and presbyopia, combines the Company's unique 3-Zone Progressive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;multifocal design with the stability of its OpticAlign</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;toric with MoistureSeal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology to provide eye care professionals and their patients an advanced contact lens technology that offers the convenience of same-day fitting during the initial lens exam.&#160;Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Multifocal for Astigmatism was launched in June 2019 and received European Union regulatory approval in the second quarter of 2020.  In July 2021, we launched an extended parameter range of this product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced Multi-Purpose Solution (&#8220;MPS&#8221;) - Contains a triple disinfectant system that kills 99.9% of germs, and has a dual surfactant system that provides up to 20 hours of moisture.  Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced MPS is FDA cleared with indications for use to condition, clean, remove protein, disinfect, rinse and store soft contact lenses including those composed of silicone hydrogels.  Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced MPS has gained regulatory approvals in Korea, India, Mexico, Indonesia, Malaysia, Singapore and, during the second quarter of 2020, the European Union. In 2021, Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced MPS was launched in Greece and gained regulatory approvals in China and Taiwan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Zen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Multifocal Scleral Lens for presbyopia - In January 2019, we launched this product exclusively available with Zenlens</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> RC scleral lenses and will allow eye care professionals to fit presbyopic patients with regular and irregular corneas and those with ocular surface disease, such as dry eye.  The Zen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Multifocal Scleral Lens incorporates decentered optics, enabling the near power to be positioned over the visual axis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Tangible</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hydra-PEG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - A high-water polymer coating that is bonded to the surface of a contact lens and designed to address contact lens discomfort and dry eye. We launched this product in March 2019. Tangible</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hydra-PEG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> coating technology in combination with our Boston</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> materials and Zenlens</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> family of scleral lenses will help eye care professionals provide a better lens wearing experience for their patients with challenging vision needs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gastrointestinal</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10pt">Rifaximin - Top line results from a Phase 2 study for the treatment of overt hepatic encephalopathy with a new formulation (SSD IR) of rifaximin showed a treatment benefit. Patients receiving 40 mg twice daily showed a statistically significant separation from placebo. The top line results from this Phase 2 study will help inform further research on potential new indications for rifaximin; this included the commencement of a Phase 3 study (RED-C) in 2021 to seek an indication for the prevention of the first episode of Hepatic Encephalopathy. </span></div><div style="text-align:justify;text-indent:4.5pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10pt">Rifaximin - Rifaximin recently received orphan drug designation for sickle cell anemia. A novel dosage formulation is planned to be studied for the treatment of sickle cell anemia and clinical sites began enrolling into the trial at the end of 2021.</span></div><div style="text-align:justify;text-indent:4.5pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10pt">Rifaximin - Development of a fit for purpose Patient Reported Outcomes tool for small intestinal bacterial overgrowth, or "SIBO", is continuing in 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10pt">Rifaximin - We have entered into an agreement with Cedars Sinai Medical Center to evaluate a new formulation of rifaximin for the treatment of IBS-D.  Two preclinical studies have been completed. A Proof of Concept study that was paused due to COVID-19 pandemic related factors, has recommenced and is fully enrolled. Based on recent FDA comments dated February 10, 2022, the program is being assessed and related timelines reviewed.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10pt">Envive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> - In October 2020, we launched, on a limited basis, a probiotic supplement that was developed to address gastrointestinal disturbances. In April 2021, we expanded the launch to additional territories in the U.S.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10pt">Amiselimod (S1P modulator) - We commenced a Phase 2 study during the first half of 2021 to evaluate Amiselimod (S1P modulator) for the treatment of mild to moderate ulcerative colitis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dermatology</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(tazarotene) Lotion, 0.045% (formerly Internal Development Project ("IDP") 123) - In June 2020, we launched this acne product containing lower concentration of tazarotene in a lotion form to help reduce irritation while maintaining efficacy. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">IDP-120 - An acne product with a fixed combination of mutually incompatible ingredients: benzoyl peroxide and tretinoin.  Phase 3 clinical studies have been completed and met the primary endpoints. We are currently evaluating next steps for this project.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">IDP-126 - An acne product with a fixed combination of benzoyl peroxide, clindamycin phosphate and adapalene. Phase 3 clinical studies initiated in December 2019 were paused due to COVID-19 pandemic related factors, but resumed in June 2020. Both Phase 3 studies have been completed and have met their primary endpoints. A comparative bridging safety and efficacy study was delayed until 2021 due to COVID-19. The bridging study is ongoing. We anticipate filing a New Drug Application ("NDA") in the second half of 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Touch - Next generation Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> laser that is designed to deliver a customized and more comprehensive treatment protocol by providing patients of all ages and skin types the benefits of two wavelengths. This product was launched in the U.S. in March 2021.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_166"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Strategic Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To supplement our internal R&amp;D initiatives and to build-out and refresh our product portfolio, we also search for opportunities to augment our pipeline through arrangements that allow us to gain access to unique products and investigational treatments, by strategically aligning ourselves with other innovative product solutions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company will enter into select licensing and collaborative agreements for the commercialization and/or development of unique products primarily in the U.S. and Canada. These products are sometimes investigational treatments in early stage development that target unique conditions.  The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by the FDA or other regulators, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. Under certain agreements, the Company may be required to make payments contingent upon the achievement of specific developmental, regulatory, or commercial milestones.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we announced that we had entered into two exclusive license agreements which present us with unique developmental opportunities to address the unmet need of treatment for myopia in children. The first of these two licensing agreements is with Eyenovia, Inc. for the development and commercialization in the United States and Canada of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12. We expect to complete enrollment for a Phase 3 study during the second half of 2022. If approved by the FDA, we believe this investigational product could potentially change the treatment paradigm for the reduction of myopia progression in children. The second is an exclusive global licensing agreement with BHVI for a myopia control contact lens design developed by BHVI. The Company plans to pair BHVI's novel contact lens design with our leading contact lens technologies to develop potential contact lens treatments designed to slow the progression of myopia in children.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we announced that we had acquired an exclusive license from Novaliq GmbH for the commercialization and development in the U.S. and Canada of the investigational treatment NOV03 (perfluorohexyloctane), a first-in-class investigational drug with a novel mechanism of action to treat dry eye disease ("DED") associated with Meibomian gland dysfunction ("MGD"). In an Open Label Safety study, NOV03 has achieved its enrollment target.  In April 2021, we announced statistically significant topline data from the first of two Phase 3 studies and, in September 2021, we announced statistically significant topline data from the second Phase 3 study. We anticipate filing an NDA in the first half of 2022. If approved by the FDA, we believe the addition of this investigational treatment for DED will help build upon our strong portfolio of integrated eye- health products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we acquired an exclusive license from Clearside Biomedical, Inc. ("Clearside") for the commercialization and development of Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (triamcinolone acetonide suprachoroidal injectable suspension) in the U.S. and Canada. Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for suprachoroidal </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administration via Clearside's proprietary SCS Microinjector. In October 2021, the FDA approved Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for suprachoroidal use for the treatment of macular edema associated with uveitis. We launched Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the first quarter of 2022.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, we entered into two licensing agreements which presented us with unique developmental opportunities to address unmet needs of individuals suffering with certain GI and liver diseases. The first of these two licensing agreements was with the University of California for certain intellectual property relating to an investigational compound targeting the pituitary adenylate cyclase receptor 1 in non-alcoholic fatty liver disease (&#8220;NAFLD&#8221;), nonalcoholic steatohepatitis (&#8220;NASH&#8221;) and other GI and liver diseases. However, as some early non-clinical (in-vitro) development work did not meet our internal expectations, in September 2021, we made the decision to terminate this license agreement and notified the University of California accordingly. The second is an exclusive licensing agreement with Mitsubishi Tanabe Pharma Corporation to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as inflammatory bowel disease and ulcerative colitis. We have completed a thorough QTC study, which evaluated the cardiac safety profile of the compound. Topline results were positive, and we commenced a Phase 2 study in the first half of 2021.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_169"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Strategic Investments in our Infrastructure</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In support of our core businesses, we have and continue to make strategic investments in our infrastructure, the most significant of which are at our Waterford facility in Ireland, our Rochester facility in New York and our Lynchburg facility in Virginia. </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To meet the forecasted demand for our Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday range of contact lenses, in July 2017, we placed into service a $175 million multi-year strategic expansion project of the Waterford facility.  The emphasis of the expansion project was to: (i) develop new technology to manufacture, automatically inspect and package contact lenses, (ii) bring that technology to full validation and (iii) increase the size of the Waterford facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To address the expected global demand for our Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> range of contact lenses, in December 2017, we completed a multi-year, $220 million strategic upgrade to our Rochester facility.  The upgrade increased production capacity in support of our Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and SiHy Daily AQUALOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product lines and better supports the production of other well-established contact lenses, such as our PureVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PureVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 (SVS, Toric, and Multifocal), SofLens</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38 and SilSoft</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To address the expected global demand for our SiHy Daily disposable contact lenses, in November 2018, we initiated $300 million of additional projects to add multiple production lines to our Rochester and Waterford facilities. These production lines have recently been completed and we expect to start production of our latest contact lenses, Bausch + Lomb INFUSE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY, at these facilities in early 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further help us meet the anticipated demand of our contact lenses, in 2020, we initiated an expansion of the Company's Lynchburg distribution center. The new facility is expected to create new jobs over the next five years and expand the overall site to 200,000 square feet, which will provide distribution capabilities for medical devices, primarily contact lens products, and be the main point of distribution for these products in the U.S. This expansion program is expected to be completed in the first half of 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 2021, we announced plans to invest an additional $90 million to increase capacity at our Waterford facility to meet the expected demand for our Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday range of daily disposable contact lenses.  The new production lines are expected to be completed in 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If completed as planned, the recently announced expansion of our Waterford facility will be the fifth major expansion of our Bausch + Lomb manufacturing facilities in support of our efforts to increase market share in the contact lens market in the seven years ending 2023. We believe the investments in our Waterford, Rochester and Lynchburg facilities and related expansion of labor forces further demonstrates the growth potential we see in our Bausch + Lomb products and our eye- health business.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_172"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effectively Managing Our Capital Structure  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to effectively manage our capital structure by: (i) executing on our plan for the B+L Separation and Solta IPO, (ii) reducing our debt through repayments, (iii) extending the maturities of debt through refinancing and (iv) improving our credit ratings.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since announcing our plans for the B+L Separation and the Solta IPO, we emphasized that it is important that the post-separation entities be well capitalized, with appropriate leverage and with access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capitalization and leverage of these businesses post-separation as a key to maximizing value across our portfolio of assets and, so, it is a primary objective of our plan of separation.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Repayments and Other Financing Transactions &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, our new executive team committed to improving our Company's capital structure and since that time we have been executing and continue to execute on that commitment.  As a result of a series of debt repayments and transactions since making that commitment, the Company positioned itself to add value through the B+L Separation and Solta IPO while at the same time providing for the appropriate capitalization and leverage of these businesses post-separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the impact of the $1,210 million financing of the U.S. Securities Litigation settlement (discussed in the subsequent section titled "OFF-BALANCE SHEET ARRANGEMENTS AND CONTRACTUAL OBLIGATIONS"), we have repaid (net of additional borrowings) approximately $10,000&#160;million of long-term debt during the period January 1, 2016 through December 31, 2021 using the net cash proceeds from divestitures of non-core assets, cash generated from operations and cash generated from tighter working capital management. This includes approximately $1,300&#160;million of repayments (net of additional borrowings) during 2021 using cash on hand, cash generated from operations and the net proceeds from the Amoun Sale.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Focus on Capitalization of the Post-separation Entities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the B+L Separation and Solta IPO, we have emphasized that it is important that the post-separation entities be well capitalized, with appropriate leverage and with access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate capitalization and leverage of these new entities post-separation as a key to bringing out the maximum value across our portfolio of assets and, so, it is a primary objective of our plan of separation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor market conditions and aim to launch the B+L IPO and Solta IPO when financial market conditions are favorable, subject to receipt of regulatory, stock exchange and other approvals and, in January and February 2022, took certain actions to, and announced others that we believe will, bring us closer in reaching our targeted capitalizations of the post-separation entities.  These actions are discussed in more detail in Item &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221; and Note 23, "SUBSEQUENT EVENTS" to our audited Consolidated Financial Statements.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Continue to Manage our Capital Structure</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor our capital structure and to evaluate other opportunities to simplify our business and improve our capital structure, giving us the ability to better focus on our core businesses. Also, the Company regularly evaluates market conditions, its liquidity profile and various financing alternatives for opportunities to enhance its capital structure. If the Company determines that conditions are favorable, the Company may refinance or repurchase existing debt or issue additional debt, equity or equity-linked securities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, "FINANCING ARRANGEMENTS" and Note 23, "SUBSEQUENT EVENTS" to our audited Consolidated Financial Statements and Item &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221; for further details and additional discussion regarding these matters. Cash requirements for future debt repayments including interest can be found in this Item &#8220;&#8212; Off-Balance Sheet Arrangements and Contractual Obligations.&#8221;</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_175"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improve Patient Access</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Improving patient access to our products, as well as making them more affordable, is a key element of our business strategy.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Access and Pricing Committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2016, we formed the Patient Access and Pricing Committee which is responsible for setting, changing and monitoring the pricing of our products and evaluating contract arrangements that determine the placement of our products on drug formularies. The Patient Access and Pricing Committee considers new to market product pricing, price changes and their impact across channels on patient accessibility and affordability. Since its inception, the Patient Access and Pricing Committee has limited the average annual price increase for our branded prescription pharmaceutical products to single digits. Future pricing changes and programs could affect the average realized pricing for our products and may have a significant impact on our revenues and profits.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch Health Patient Assistance Program - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to supporting patients who have lost employment health benefits due to the COVID-19 pandemic, and because it is essential that our patients continue their prescribed treatments, we are proud to offer certain of our prescription medicines through our Bausch Health Patient Assistance Program.  In the face of the COVID-19 pandemic, some people have financial obstacles that keep them from obtaining and continuing their prescribed treatments. The purpose of the Bausch Health Patient Assistance Program is to provide eligible unemployed patients in the U.S., who meet stated qualifications and have lost their health insurance due to the COVID-19 pandemic, with certain of our prescription products where their financial circumstances or insurance status would otherwise interfere with their ability to access such products. If approved, patients receive their Bausch Health Companies Inc. prescription product(s) at no cost to them for up to one year, and may be able to reapply to the program annually if they continue to meet eligibility requirements and have a valid prescription.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash-pay Prescription Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In February 2019, we launched Dermatology.com, a cash-pay product acquisition program offering certain branded Ortho Dermatologics products directly to patients. In March 2020, the name Dermatology.com was removed as the cash-pay product program name, with the name Dermatology.com limited to only online usage, including future digital teledermatology and e-commerce offerings. The cash-pay program is designed to address the affordability and availability of certain branded dermatology products, when insurers and pharmacy benefit managers are no longer offering those branded prescription pharmaceutical products under their designated pharmacy benefit offerings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Walgreens Fulfillment Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In the beginning of 2016, we launched a brand fulfillment arrangement with Walgreen Co. ("Walgreens"). Under the terms of the brand fulfillment arrangement, as amended in July 2019, we made certain dermatology and ophthalmology products available to eligible patients through patient access and co-pay assistance programs at Walgreens U.S. retail pharmacy locations, as well as participating independent retail pharmacies. </span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_178"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invest in Sustainable Growth Drivers to Position us for Long-Term Growth</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are constantly challenged by the changing dynamics of our industry to innovate and bring new products to market.  We have divested certain businesses where we saw limited growth opportunities, so that we can be more aggressive in redirecting our R&amp;D spend and other corporate investments to innovate within our core businesses where we believe we can be most profitable and where we aim to be an industry leader. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have a well-established product portfolio that is diversified within our core businesses and provides a sustainable revenue stream to fund our operations. However, our future success is also dependent upon our ability to continually refresh our pipeline, to provide a rotation of product launches that meet new and changing demands and replace other products that have lost momentum.  We believe we have a robust pipeline that not only provides for the next generation of our existing products, but is also poised to bring new products to market.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invest in our Eye- Health Business - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our global Bausch + Lomb business strategy, we continually look for key trends in the eye-health market to meet changing consumer/patient needs and identify areas for investment to extend our market share through new launches and effective pricing. For instance, there is an increasing rate of myopia, and importantly, myopia as a potential risk factor for glaucoma, macular degeneration and retinal detachment. We continue to see increased demand for new eye- health products that address conditions brought on by factors such as increased screen time, lack of outdoor activities and academic pressures, as well as conditions brought on by an aging population (for example, as more and more baby-boomers in the U.S. are reaching the age of 65).  To extend our market share in eye- health, we continually seek to identify new products tailored to address these key trends for development internally with our own R&amp;D team to generate organic growth. Recent product launches include Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday daily disposable contact lenses, the next generation of Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contact lenses, SiHy Daily contact lenses (branded as AQUALOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY in Japan, Bausch + Lomb INFUSE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SiHy Daily Disposable in the U.S. and Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY in Australia, Hong Kong and Canada), Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (an eye redness treatment), Vyzulta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (a pressure lowering eye drop for patients with angle glaucoma or ocular hypertension), Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Eye Performance (vitamins to protect the eye from stressors such as sunlight and blue light emitted from digital devices) and SimplifEYE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (preloaded intraocular lens injector platform for enVista intraocular lens). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also license selective molecules or technology in leveraging our own R&amp;D expertise through development, as well as seek out external product development opportunities. As previously discussed, we acquired a global exclusive license for a myopia control contact lens design developed by BHVI, which we plan to pair with our leading contact lens technologies to develop potential contact lens treatments designed to slow the progression of myopia in children, and exclusive licenses for the commercialization and development in the U.S. and Canada of: a microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression in children ages 3-12; Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which was approved by the FDA in October 2021 and launched in the first quarter of 2022, and is the first treatment available in the U.S. that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis; and NOV03, an investigational drug with a novel mechanism of action to treat DED associated with MGD. which has demonstrated statistically significant topline data in two Phase 3 studies. We also acquired the U.S. rights to EM-100, which was launched as Alaway</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Preservative-</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Free and is the first OTC preservative-free formulation eye drop for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair, and dander in adults and children 3 years of age and older. We believe investments in these investigational treatments, if approved by the FDA, will complement, and help build upon, our strong portfolio of integrated eye-health products.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, we have also made strategic investments in our infrastructure, the most significant of which were at our Waterford facility in Ireland to meet the forecasted demand for our Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday lenses, our Rochester facility in New York to address the expected global demand for our Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contact lens and our Lynchburg facility in Virginia to be our main point of distribution for medical devices in the U.S. During late 2018, we began investing in additional expansion projects at the Waterford and Rochester facilities in order to address the expected global demand for our SiHy Daily disposable contact lenses, which we launched in Japan in September 2018, under the branded name AQUALOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY, in the U.S. in August 2020, under the branded name Bausch + Lomb INFUSE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SiHy Daily Disposable contact lens, and in Australia, Hong Kong and Canada in the fourth quarter of 2020, under the branded name Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our recent product launches, licensing arrangements and the investments in our Waterford, Rochester and Lynchburg facilities demonstrate the growth potential we see in our Bausch + Lomb products and our eye-health business and that these investments will position us to further extend our market share in the eye- health market.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leveraging our Salix Infrastructure - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strongly believe in our GI product portfolio and we have implemented initiatives, including increasing our marketing presence and identifying additional opportunities outside our existing GI portfolio, to further capitalize on the value of the infrastructure we built around these products to extend our market share. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2017, we hired approximately 250 trained and experienced sales force representatives and managers to create, bolster and sustain deep relationships with primary care physicians (&#8220;PCP&#8221;). With approximately 70% of IBS-D patients initially presenting symptoms to a PCP, we continue to believe that the dedicated PCP sales force is better positioned to reach more patients in need of IBS-D treatment. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This initiative provided us with positive results, as we experienced consistent growth in demand for our GI products throughout 2017 through 2021 which was evident by our growth in Salix revenues of 32% when comparing 2021 to 2017. These results encouraged us to seek out ways to bring out further value through leveraging our existing sales force and, in the later portion of 2018 and in 2019, we identified and executed on certain opportunities which we describe below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strategic Acquisition - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, in March 2019, we completed the acquisition of certain assets of Synergy, whereby we acquired the worldwide rights to the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, a once-daily tablet for adults with chronic idiopathic constipation, or CIC and irritable bowel syndrome with constipation, or IBS-C. We believe that the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product complements our existing Salix products and allows us to effectively leverage our existing GI sales force.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licensing Arrangements - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, in April 2019, we entered into a licensing agreement to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as inflammatory bowel disease and ulcerative colitis.  This license presents a unique developmental opportunity to address unmet needs of individuals suffering with certain GI and liver diseases and if developed and approved by the FDA, will allow us to further utilize our existing sales force and infrastructure to extend our market share in the future and create value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Next Generation Formulations - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product increased approximately 11%, 2% and 22% in 2021, 2020 and 2019, respectively. In order to extend the growth in Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we continue to directly invest in next generation formulations of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and rifaximin, the principal semi-synthetic antibiotic used in our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product.  In addition to three R&amp;D programs in progress, we have another R&amp;D program planned for a next generation formulation of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) which would address a new indication.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the acquisition and licensing opportunities discussed above will be accretive to our business by providing us access to products and investigational compounds that are a natural pairing to our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> business, allowing us to effectively leverage our existing infrastructure and sales force. We believe these opportunities, coupled with our investment in next generation formulations, will allow our GI franchise to continue to further extend market share.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reposition the Ortho Dermatologics Business to Generate Additional Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - As of January 2022, we have positioned the Solta Medical business to move forward with the Solta IPO.  We continue to monitor market conditions and aim to launch the Solta IPO when financial market conditions are favorable subject to receipt of regulatory, stock exchange and other approvals. However, there can be no assurance as to when we will complete the Solta IPO, if at all. Until such time, we continue to manage our Solta business and our medical dermatology business with our continued commitment to bring out additional value for our shareholders. We continue to make investments in our Solta portfolio and anticipate building out our Solta sales force, </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">particularly in Europe, to address the growing demand for our Solta aesthetic medical devices. Our Ortho Dermatologics business continues to work towards improving the treatment options for medical dermatology patients needing topical acne and psoriasis products. We also continue to explore additional strategic e-commerce and partnership expansion opportunities which can enable increased accessibility for patients and we continue to invest in our on-market products and evaluate various opportunities for our key medical dermatology pipeline products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In support of the complete dermatology portfolio, we continue to take a number of actions that we believe will help our efforts to stabilize our dermatology business. These actions include: (i) building on our legacy brands to improve and meet today&#8217;s physician relevance and customer service, (ii) appointing new leadership, (iii) making key investments in our core medical device and dermatological products portfolios, (iv) optimizing our go to market strategy by building on our relationships with prescribers of our products to balance our sales portfolio with the business' profitability, (v) refocusing our operational and promotional resources and (vi) improving patient access to our Ortho Dermatologics products through our cash-pay prescription program previously discussed. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, we identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist, limiting patient access to topical acne and psoriasis products.  In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;D spend to eliminate projects it has identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Our Core Dermatology Portfolio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - We have made significant investments to build out our aesthetics, psoriasis and acne product portfolios, which are the markets within dermatology where we see the greatest opportunities to extend our market share.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aesthetics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2017, we launched our next generation Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product in the U.S., a fourth-generation non-invasive treatment option using a radiofrequency platform designed to optimize key functional characteristics and improve patient outcomes. Next generation Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched in the U.S., Hong Kong, Japan, Korea, Chinese Taipei, Philippines, Singapore, Indonesia, Malaysia, China, Thailand, Vietnam, Australia and various parts of Europe as part of our Solta aesthetic medical devices portfolio. These launches have been successful as next generation Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues were $154 million, $142 million and $77 million for the years ended December 31, 2021, 2020 and 2019, respectively. We plan to continue to expand into other regions, paced by country-specific regulatory registrations. Consistent with our business strategy to continually update and improve our technology, in 2021, we launched, our next generation Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Touch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> system in the U.S., which is designed to deliver a customized and more comprehensive treatment protocol by providing patients of all ages and skin types the benefits of two wavelengths. The launch of our next generation Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Touch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> system in the U.S. is expected to serve as a foundation for future launches in Asia and Europe.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Psoriasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In response to the increasing number of reported cases of psoriasis in the U.S., we launched Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in June 2019 and launched Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in November 2018, which align well with our topical portfolio of psoriasis treatments. Although, we continue to support a diverse portfolio of topical and injectable biologics, in order to provide a diverse choice of psoriasis treatments to doctors and patients; we believe some patients prefer topical products as an alternative to injectable biologics.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acne</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In support of our established acne product portfolio, we have developed and launched several products, which include Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(tazarotene) Lotion (launched in the U.S. in June 2020), Altreno</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(launched in the U.S. in October 2018), the first lotion (rather than a gel or cream) product containing tretinoin for the treatment of acne, and Retin-A Micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 0.06% (launched in the U.S. in January 2018). We also have a unique acne project in our pipeline that, if approved by the FDA, we believe will further innovate and advance the treatment of acne.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_181"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Trends</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the actions previously outlined, the events described below have affected and may affect our business trends.  The matters discussed in this section contain Forward-Looking Statements.  Please see &#8220;Forward-Looking Statements&#8221; for additional information.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_2828"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Tax Reform</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, U.S. President Joseph Biden proposed changes to the U.S. tax system. Since that date, both houses of Congress have released their own proposals for changes to the U.S. tax system, which differ in a number of respects from the President&#8217;s proposal. The proposals under discussion have included changes to the U.S. corporate tax system that would </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase U.S. corporate tax rates, although the most recent proposals do not include any such rate increase, and changes that would raise the tax rate on and make other changes to the taxation of Global Intangible Low Tax Income earned by foreign subsidiaries. Also under consideration are modifications to the Base Erosion and Anti-Abuse Tax, which would tax certain payments, including some that are related to inventory, made to affiliates that are subject to an effective tax rate of less than specified rates. Certain proposals also include limitations on the participation exemption for foreign dividends received and interest expense. In addition, certain proposals include limitations on the deduction of interest expense and carryforwards of unused interest expense, as well as an excise tax on certain pharmaceutical products that are non-compliant with the proposed drug pricing legislation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict which, if any, U.S. tax reform proposals will be enacted into law, and what effects any enacted legislation might have on our liability for U.S. corporate tax. However, it is possible that the enactment of changes in the U.S. corporate tax system could have a material adverse effect on our liability for U.S. corporate tax and our consolidated effective tax rate.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_2835"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global Minimum Corporate Tax Rate</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2021, the Organisation for Economic Co-operation and Development ("OECD")/G20 inclusive framework on Base Erosion and Profit Shifting (the "Inclusive Framework") published a statement updating and finalizing the key components of a two-pillar plan on global tax reform originally agreed on July 1, 2021, and a timetable for implementation by 2023. The Inclusive Framework plan has now been agreed to by 141 OECD members, including several countries which did not agree to the initial plan. Under pillar one, a portion of the residual profits of multinational businesses with global turnover above &#8364;20 billion and a profit margin above 10% will be allocated to market countries where such allocated profits would be taxed. Under pillar two, the Inclusive Framework has agreed on a global minimum corporate tax rate of 15% for companies with revenue above &#8364;750 million, calculated on a country-by-country basis. On October 30, 2021, the G20 formally endorsed the new global minimum corporate tax rate rules. The Inclusive Framework agreement must now be implemented by the OECD Members who have agreed to the plan, effective in 2023. On December 20, 2021, the OECD published model rules to implement the pillar two rules, which are generally consistent with the agreement reached by the Inclusive Framework in October 2021.  Additional guidance is expected to be published in 2022. We will continue to monitor the implementation of the Inclusive Framework agreement by the countries in which we operate. While we are unable to predict when and how the Inclusive Framework agreement will be enacted into law in these countries, and it is possible that the implementation of the Inclusive Framework agreement, including the global minimum corporate tax rate could have a material effect on our liability for corporate taxes and our consolidated effective tax rate.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_184"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Reform</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal and state governments continue to propose and pass legislation designed to regulate the health care industry. In March&#160;2010, the Patient Protection and Affordable Care Act (the &#8220;ACA&#8221;) was enacted in the U.S.&#160;The ACA contains several provisions that impact our business, including: (i) an increase in the minimum Medicaid rebate to states participating in the Medicaid program, (ii) the extension of the Medicaid rebates to Managed Care Organizations that dispense drugs to Medicaid beneficiaries, (iii) the expansion of the 340(B) Public Health Services drug pricing program, which provides outpatient drugs at reduced rates, to include additional hospitals, clinics and health care centers and (iv) a fee payable to the federal government based on our prior-calendar-year share relative to other companies of branded prescription drug sales to specified government programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in 2013 federal subsidies began to be phased in for brand-name prescription drugs filled in the Medicare Part D coverage gap. The ACA also included provisions designed to increase the number of Americans covered by health insurance. In 2014, the ACA's private health insurance exchanges began to operate. The ACA also allows states to expand Medicaid coverage with most of the expansion&#8217;s cost paid for by the federal government.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2021, 2020 and 2019, we incurred costs of $13 million, $21 million and $20 million, respectively, related to the annual fee assessed on prescription drug manufacturers and importers that sell branded prescription drugs to specified U.S.&#160;government programs (e.g.,&#160;Medicare and Medicaid). For 2021, 2020 and 2019, we also incurred costs of $94 million, $131 million and $137 million, respectively, on Medicare Part&#160;D utilization incurred by beneficiaries whose prescription drug costs cause them to be subject to the Medicare Part&#160;D coverage gap (i.e.,&#160;the &#8220;donut&#160;hole&#8221;). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial impact of the ACA will be affected by certain additional developments over the next few years, including pending implementation guidance and certain health care reform proposals. Additionally, policy efforts designed specifically to reduce patient out-of-pocket costs for medicines could result in new mandatory rebates and discounts or other pricing restrictions. Also, it is possible, as discussed further below, that legislation will be passed by Congress repealing the ACA in whole or in part.  Adoption of legislation at the federal or state level could materially affect demand for, or pricing of, our products.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2011, the law imposed a significant annual fee on companies that manufacture or import branded prescription drug products. More recently, the Bipartisan Budget Act of 2018 amended the Patient Protection and Affordable Care Act, effective January 1, 2019, to close the donut hole in most Medicare drug plans. In addition, in April 2018, the Centers for Medicare &amp; Medicaid Services published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the Patient Protection and Affordable Care Act for plans sold through such marketplaces.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we faced uncertainties due to federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the ACA. However, we believe there is low likelihood of repeal of the ACA, given the recent failure of the Senate&#8217;s multiple attempts to repeal various combinations of ACA provisions and the recent change in administration. There is no assurance that any replacement or administrative modifications of the ACA will not adversely affect our business and financial results, particularly if the replacing legislation reduces incentives for employer-sponsored insurance coverage, and we cannot predict how future federal or state legislative or administrative changes relating to the reform will affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the U.S. Department of Health and Human Services announced a preliminary plan to allow for the importation of certain lower-cost drugs from Canada. The preliminary plan excludes insulin, biological drugs, controlled substances and intravenous drugs. The preliminary plan relies on individual states to develop proposals for safe importation of those drugs from Canada and submit those proposals to the federal government for approval. Although the preliminary plan has some support from the prior administration, at this time, studies to evaluate the related costs and benefits, evaluate the reasonableness of the logistics, and measure the public reaction of such a plan have not been performed. While we do not believe this will have a significant impact on our future cash flows, we cannot provide assurance as to the effect or impact of such a plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Government of Canada (Health Canada) published in the Canada Gazette the new pricing regulation for patented drugs. These regulations were scheduled to become effective on July 1, 2021, but have been delayed until July 1, 2022. The new regulations will, among other things, change the mechanics of establishing the pricing for products submitted for approval after August 21, 2019 and the number and composition of reference countries used to determine if a drug&#8217;s price is excessive. While we do not believe this will have a significant impact on our future cash flows, as additional facts materialize, we cannot provide assurance as to the ultimate content, timing, effect or impact of such regulations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, former U.S. President Donald Trump signed four Executive Orders related to drug pricing, including orders addressing: (i) Part D rebate reform, (ii) the provision of deeply discounted insulin and/or an EpiPen to patients of Federally Qualified Health Centers, (iii) drug importation from Canada and (iv) most favored nation pricing for Medicare. In November 2020, former U.S. President Donald Trump announced the Most Favored Nation Model for Medicare Part B Payment which was to be implemented by the Centers for Medicare &amp; Medicaid Services Innovation Center on January 1, 2021; however, it has not been implemented, as it is currently being challenged in court. It is also uncertain whether the Biden administration intends to reverse these measures or adopt similar policy initiatives. However, U.S. President Joseph Biden and several members of the current U.S. Congress have indicated that lowering drug prices is a legislative and political priority, and some have introduced proposals that seek to address drug pricing. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, as part of a series of drug pricing-related rules issued by the Trump Administration, the Center for Medicare &amp; Medicaid Services issued a Final Rule that makes significant modifications to the Medicaid Drug Rebate Program regulations in several areas, including with respect to the definition of key terms &#8220;line extension&#8221; and &#8220;new formulation&#8221; and best price reporting relating to certain value-based purchasing arrangements (which took effect on January 1, 2022) and the price reporting treatment of manufacturer-sponsored patient benefit programs (which take effect on January 1, 2023). </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the U.S. Congress enacted the American Rescue Plan Act of 2021. One of the provisions included within the American Rescue Plan Act of 2021 eliminated the Maximum Rebate Amount for Single Source drugs and Innovator Multiple Source drugs in the Medicaid Drug Rebate Program.  We are currently reviewing this legislation, the impact of which is uncertain at this time.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative efforts relating to drug pricing have been enacted and others have been proposed at the U.S. federal and state levels. For instance, certain states have enacted legislation related to prescription drug pricing transparency. Several states have passed importation legislation and Florida is working with the U.S. government to implement an importation program from Canada. We also anticipate that Congress, state legislatures and third-party payors may continue to review and assess alternative health care delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations affecting additional fundamental changes in the health care delivery system. We continually review newly enacted and proposed U.S. federal and state legislation, as well as proposed rulemaking and guidance published by the U.S. Department of Health and Human Services and the FDA; however, at this time, it is unclear the effect these matters may have on our businesses.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_187"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Competition and Loss of Exclusivity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products face the expiration of their patent or regulatory exclusivity in 2022 or in later years, following which we anticipate generic competition of these products. In addition, in certain cases, as a result of negotiated settlements of some of our patent infringement proceedings against generic competitors, we have granted licenses to such generic companies, which will permit them to enter the market with their generic products prior to the expiration of our applicable patent or regulatory exclusivity. Finally, for certain of our products that lost patent or regulatory exclusivity in prior years, we anticipate that generic competitors may launch in 2022 or in later years. Following a loss of exclusivity ("LOE") of and/or generic competition for a product, we would anticipate that product sales for such product would decrease significantly shortly following the LOE or entry of a generic competitor. Where we have the rights, we may elect to launch an authorized generic of such product (either ourselves or through a third-party) prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product would still be expected to be significant, and the effect on our future revenues could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of our products already face generic competition.  Prior to and during 2021, in the U.S., these products include, among others, Ammonul</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Benzaclin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bepreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bupap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cuprimine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Demser</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Edecrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Elidel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Istalol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Isuprel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Locoid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lotion, Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gel, Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Suspension, Mephyton</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Migranal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MoviPrep</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Nitropress</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Solodyn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Syprine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Timoptic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Ocudose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tablet, Virazole</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Wellbutrin&#160;XL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zegerid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zovirax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cream.  In Canada, these products include, among others, Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Wellbutrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;XL and Zovirax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ointment.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">2021 LOE Branded Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">- Branded products that began facing generic competition in the U.S. during 2021 included Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Gel, Bepreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, Clindagel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and certain other products. These products accounted for less than 1% of our total revenues in 2020. We believe the entry into the market of generic competition generally would have an adverse impact on the volume and/or pricing of the affected products, however we are unable to predict the magnitude or timing of this impact.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 through 2026 LOE Branded Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Based on current patent expiration dates, settlement agreements and/or competitive information, we have identified branded products that we believe could begin facing potential LOE and/or generic competition in the U.S. during the years 2022 through 2026.  These products and year of expected LOE include, but are not limited to, Noritate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2022), Targretin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel (2022), Xerese</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2022)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and certain other products that are subject to settlement agreements which could impact their exclusivity during the years 2022 through 2026.&#160;In aggregate, these products accounted for 2% of our total revenues in 2021. These dates may change based on, among other things, successful challenge to our patents, settlement of existing or future patent litigation and at-risk generic launches. We believe the entry into the market of generic competition generally would have an adverse impact on the volume and/or pricing of the affected products, however we are unable to predict the magnitude or timing of this impact.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for a number of our products (including Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550mg, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Injection in the U.S and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada.), we have commenced (or anticipate commencing) and have (or may have) ongoing infringement proceedings against potential generic competitors in the U.S. and Canada. If we are not successful in these proceedings, we may face increased generic competition for these products.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Lotion, 0.01% (Glenmark)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In December 2019, the Company announced that it had reached an agreement to resolve&#160;the&#160;outstanding&#160;intellectual&#160;property&#160;litigation&#160;with&#160;Glenmark&#160;Pharmaceuticals,&#160;Ltd. ("Glenmark"). Under the terms of the agreement, the Company will grant Glenmark a non-exclusive license to its intellectual property relating to Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. and, beginning in 2026 (or earlier under certain circumstances), Glenmark will have the option to market a royalty-free generic version of Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lotion, should it receive approval from the FDA. The parties have agreed to dismiss all litigation related to Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lotion, and all intellectual property protecting Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lotion remains intact.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Lotion, 0.01% (Padagis) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-  On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (now Padagis LLC) ("Padagis"), in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis' generic halobetasol propionate lotion, for which an Abbreviated New Drug Application ("ANDA") has been filed by Padagis.&#160; On May 1, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA for halobetasol propionate lotion.&#160;On September 3, 2020, this action was consolidated with the action between the Company and Padagis described below, regarding Padagis' ANDA for generic Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion. The Company remains confident in the strength of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Lotion (Padagis) - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Padagis, in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA's Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacture, use or sale of Padagis' generic lotion, for which an ANDA has been filed by Padagis.  On August 28, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA.  On September 3, 2020, this action was consolidated with the action between the Company and Padagis described above, regarding Padagis' ANDA for generic Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion. We remain confident in the strength of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will vigorously defend our intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> 550mg Patent Litigation (Actavis) - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2016, the Company initiated litigation against Actavis Laboratories FL, Inc.&#8217;s ("Actavis"), which alleged infringement by Actavis of one or more claims of each of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents. On September 12, 2018, we announced that we had reached an agreement with Actavis that resolved the existing litigation and eliminated the pending challenges to our intellectual property protecting Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets. As part of the agreement, the parties agreed to dismiss all litigation related to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin), Actavis acknowledged the validity of the licensed patents for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets and all intellectual property protecting Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets will remain intact and enforceable until expiry in 2029. The agreement also grants Actavis a non-exclusive license to the intellectual property relating to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances). The Company will not make any financial payments or other transfers of value as part of the agreement. In addition, under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Actavis will have the option to: (1) market a royalty-free generic version of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tablets, 550 mg, should it receive approval from the FDA on its ANDA, or (2) market an authorized generic version of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tablets, 550 mg, in which case, we will receive a share of the economics from Actavis on its sales of such an authorized generic. Actavis will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed before January 1, 2028.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">550mg Patent Litigation (Sandoz) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-  In October 2019, the Company announced that it and its licensor, Alfasigma had commenced litigation against Sandoz Inc. ("Sandoz"), a Novartis division, alleging patent infringement of 14 patents by Sandoz's filing of its ANDA for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets. On May 6, 2020, the Company announced that an agreement had been reached with Sandoz that resolved this litigation. Under the terms of the agreement, </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the parties agreed to dismiss all litigation related to Xifaxan</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin), Sandoz acknowledged the validity of the licensed patents for Xifaxan</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin) 550 mg tablets and all intellectual property protecting Xifaxan</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin) 550 mg tablets will remain intact and enforceable until expiry in October 2029. The agreement also grants Sandoz a non-exclusive license to the intellectual property relating to Xifaxan</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin) 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sandoz will have the right to market a royalty-free generic version of </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550 mg tablets, should it receive approval from the FDA on its ANDA. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sandoz will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the U.S. before January 1, 2028.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not make any financial payments or other transfers of value as part of this agreement with Sandoz.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">550mg Patent Litigation (Norwich) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">- On March 26, 2020, the Company and its licensor Alfasigma filed suit against Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;), alleging infringement by Norwich of one or more claims of the 23 Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> patents by Norwich&#8217;s filing of its ANDA for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (rifaximin) 550 mg tablets.  On November 13, 2020, an additional three patents alleged to be infringed by Norwich were added to the suit.  Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 550mg is protected by 26 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. A 3-day bench trial is scheduled to begin March 21, 2022. The Company remains confident in the strength of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">200mg and 550mg Patent Litigation (Sun) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In April 2019, the Company and its licensor, Alfasigma, commenced litigation against Sun Pharmaceutical Industries Ltd. (&#8220;Sun&#8221;), alleging patent infringement by Sun&#8217;s filing of its ANDA for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from Sun, in which Sun asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 200 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Sun&#8217;s generic rifaximin tablets, 200 mg. Subsequently, on August 10, 2020, the Company received an additional Notice of Paragraph IV Certification from Sun, in which Sun asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Sun&#8217;s generic rifaximin tablets, 550 mg, for which an ANDA had been filed by Sun. On September 22, 2020, the Company announced that an agreement had been reached with Sun that resolved the outstanding intellectual property disputes with Sun regarding Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets. Under the terms of the agreement, the parties agreed to dismiss all litigation related to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) and all intellectual property protecting Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets will remain intact and enforceable until expiry in July and October 2029, respectively. </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement also grants Sun a non-exclusive license to the intellectual property relating to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets in the U.S. beginning January 1, 2028 (or earlier under certain circumstances). Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sun will have the right to market royalty-free generic versions of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets, should it receive approval from the FDA on its ANDAs. Sun will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the U.S. before January 1, 2028. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Tablets Patent Litigation (Actavis)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - On December 6, 2016, the Company initiated litigation against Actavis, which alleged infringement by Actavis of one or more claims of U.S.&#160;Patent No. 8,524,276 (the &#8220;&#8216;276 Patent&#8221;), which protects the formulation of RELISTOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets. Actavis had challenged the validity of such patent and alleged non-infringement by its generic version of such product. In July 2019, we announced that the U.S. District Court of New Jersey had upheld the validity of and determined that Actavis infringed the &#8216;276 Patent, expiring in March 2031.  Actavis has appealed this decision to the U.S. Court of Appeals for the Federal Circuit. In March 2021, the Company and Actavis reached a settlement agreement and the appeal was dismissed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Injection Patent Litigation (Gland)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - On February 22, 2022, the Company commenced litigation against Gland Pharma Limited (&#8220;Gland&#8221;) alleging patent infringement by Gland&#8217;s filing of its ANDA No. 216836, referencing Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (methynaltrexone bromide injection, vials) and its ANDA No. 216965, referencing Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (methynaltrexone bromide injection, pre-filled syringes).  This suit had been filed following receipt of two Notices of Paragraph IV Certification from Gland, in which it had asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> methynaltrexone bromide injection, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of its generic methynaltrexone bromide injection.  The filing of this suit triggered a 30-month stay of the approval of the Gland ANDA for its methynaltrexone bromide injection. The Company remains confident in the strength of the Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> 3mg Tablets Patent Litigation (MSN and Mylan)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> -  In March 2021, the Company received Notices of Paragraph IV Certification from MSN Laboratories Private Ltd. (&#8220;MSN&#8221;) and Mylan Pharmaceuticals Inc., (&#8220;Mylan&#8221;) in which MSN and Mylan asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) 3mg tablets, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of their generic plecanatide tablets, for which each of MSN and Mylan had filed an ANDA.  In April 2021, the Company filed suit against MSN and Mylan, alleging infringement of one or more claims of the patents listed for Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. The Company remains confident in the strength of the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Ophthalmic Solution Patent Litigation (Slayback)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In September 2021, the Company commenced litigation against Slayback Pharma LLC and Slayback Pharma India LLP (together, &#8220;Slayback&#8221;) alleging patent infringement by Slayback Pharma LLC&#8217;s filing of its ANDA No. 216361, referencing Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (0.025% brimonidine tartrate ophthalmic solution). This suit had been filed following receipt of a Notice of Paragraph IV Certification from Slayback Pharma LLC, in which it had asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brimonidine tartrate ophthalmic solution, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of its generic brimonidine tartrate solution.  The filing of this suit triggered a 30-month stay of the approval of the Slayback ANDA for its brimonidine tartrate solution. The Company remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Ophthalmic Solution Patent Litigation (Lupin)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; On February 2, 2022 the Company commenced litigation against Lupin Pharmaceuticals, Inc. (&#8220;Lupin&#8221;) alleging patent infringement by Lupin&#8217;s filing of its ANDA No. 216716, referencing Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (0.025% brimonidine tartrate ophthalmic solution). This suit had been filed following receipt of a Notice of Paragraph IV Certification from Lupin, in which it had asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brimonidine tartrate ophthalmic solution, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of its generic brimonidine tartrate solution.  The filing of this suit triggered a 30-month stay of the approval of the Lupin ANDA for its brimonidine tartrate solution. The Company remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Competition to Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, a generic competitor launched a product which will directly compete with our Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tablet product. As disclosed in our prior filings, the Company initiated various infringement proceedings against this generic competitor. The Court construed the claims of the asserted patents on August 2, 2019 and, on October 24, 2019, the Company agreed to a judgment that the asserted patents did not cover the generic tablets under the Court&#8217;s claim construction, while reserving its right to appeal the claim construction. On November 22, 2019, the Company filed a Notice of Appeal with respect to the claim construction in the Court of Appeals for the Federal Circuit.  On December 18, 2020, the Court of Appeals for the Federal Circuit affirmed the District Court&#8217;s claim construction. The ultimate impact of this generic competitor on our </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future revenues cannot be predicted; however, Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tablet revenues for 2021, 2020 and 2019 were approximately $10&#160;million, $15&#160;million and $20&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Competition to Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2018, the U.S. Patent and Trial Appeal Board (&#8220;PTAB&#8221;) completed its inter partes review for an Orange Book-listed patent covering Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (U.S. Patent No 7,214,506 (the &#8220;506 Patent&#8221;)) and issued a written determination invalidating such patent.&#160; On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings.&#160; As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion.   The &#8216;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues for 2021, 2020 and 2019 were approximately $100&#160;million, $111&#160;million and $110&#160;million, respectively. &#160;Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is covered by fourteen additional Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and has timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada against four separate defendants. All cases in the U.S. regarding Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been settled. In Canada, two lawsuits remain pending against Apotex, Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation -  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS 2 are OTC eye vitamin and mineral supplements containing nutrient formulas recommended by the National Eye Institute to reduce the risk of progression of intermediate to advanced AMD. PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products accounted for 3% of our total revenues in 2021.  The PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> U.S. formulation patent expired in March 2021, but a patent covering methods of using the formulation remains in force into 2026. The Company has filed patent infringement proceedings against 16 defendants claiming infringement of these patents and, in certain circumstances, related unfair competition and false advertising causes of action. Eleven of these proceedings were subsequently settled; two resulted in entry of a default. One defendant filed a declaratory judgment action after the Company filed its suit, seeking declaratory judgment related to patent claims as well as false advertising and unfair competition claims. As of the date of this filing, there are four unresolved actions. The Company remains confident in the strength of these patents and will continue to vigorously pursue these matters and defend its intellectual property. While the Company cannot predict the magnitude or timing of the impact from the PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patent expiry, this is an OTC product and thus, the impact is not expected to be as significant as the LOE of a branded pharmaceutical product. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements for further details regarding certain infringement proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks of generic competition are a fact of the health care industry and are not specific to our operations or product portfolio.  These risks are not avoidable, but we believe they are manageable.  To manage these risks, our leadership team continually evaluates the impact that generic competition may have on future profitability and operations.  In addition to aggressively defending the Company's patents and other intellectual property, our leadership team makes operational and investment decisions regarding these products and businesses at risk, not the least of which are decisions regarding our pipeline. Our leadership team actively manages the Company's pipeline in order to identify innovative and realizable projects aligned with our core businesses that are expected to provide incremental and sustainable revenues and growth into the future.  We believe that our current pipeline is strong enough to meet these objectives and provide future sources of revenues, in our core businesses, sufficient enough to sustain our growth and corporate health as other products in our established portfolio face generic competition and lose momentum.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have a well-established product portfolio that is diversified within our core businesses. We also believe that we have a robust pipeline that not only provides for the next generation of our existing products, but also brings new solutions into the market.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A. &#8220;Risk Factors&#8221; of this Form 10-K for additional information on our competition risks. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our products, devices and facilities are the subject of ongoing oversight and review by regulatory and governmental agencies, including general, for cause and pre-approval inspections by the relevant competent authorities where we have business operations. Through the date of this filing, all of our global operations and facilities have the relevant operational good manufacturing practices certificates and all Company products and operating sites are in good compliance standing with all relevant notified bodies and global health authorities. Further, all sites under FDA jurisdiction are rated as either No Action Indicated (where there was no Form 483 observation) or Voluntary Action Indicated (&#8220;VAI&#8221;) (where there was a Form 483 with one or more observations). In the case of VAI inspection outcomes, the FDA has accepted our responses to the issues cited, which will be verified when the agency makes its next inspection of those specific facilities.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_190"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL PERFORMANCE HIGHLIGHTS </span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides financial performance highlights for each of the last three&#160;years: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 to 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019 to 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(574)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(937)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,783)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(378)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(560)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,788)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.08)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.06)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.06)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Performance </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of 2021 Compared with 2020</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for 2021 and 2020 were $8,434 million and $8,027 million, respectively, an increase of $407 million, or 5%. The increase was primarily driven by: (i) a net increase in volumes and (ii) the favorable impact of foreign currencies, primarily in Europe, Asia and Canada. These increases were partially offset by: (i) our divestiture of Amoun on July 26, 2021 and (ii) a decrease in net realized pricing. The net increase in volumes was primarily due to the positive impacts from the recovery from the COVID-19 pandemic and the easing of certain social restrictions, as previously discussed, primarily during the three months ended June 30, 2021, partially offset by the impact of the loss of exclusivity of certain products. The changes in our segment revenues and segment profits are discussed in further detail in the subsequent section titled &#8220;Reportable Segment Revenues and Profits&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income was $450 million and $676 million for 2021 and 2020, respectively, a decrease in our operating results of $226 million which reflects, among other factors:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in contribution (product sales revenue less cost of goods sold, exclusive of amortization and impairments of intangible assets) of $259 million. The increase was primarily driven by: (i) the increase in volumes, as previously discussed, and (ii) the favorable impact of foreign currencies, partially offset by: (i) the impact of our divestiture of Amoun on July 26, 2021 and (ii) the decrease in net realized pricing;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in Selling, general, and administrative (&#8220;SG&amp;A&#8221;) expenses of $257 million, primarily attributable to: (i) the impacts of the non-recurrence of certain profit protection measures taken in 2020 to manage and reduce operating expenses during the COVID-19 pandemic, as previously discussed, (ii) Separation-related and IPO-related costs incurred in 2021 and (iii) the impact of foreign currencies;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in R&amp;D of $13 million primarily attributable to the non-recurrence of the temporary suspension in certain R&amp;D activities and clinical trials in 2020, partially offset by a rebalancing of our portfolio within the Ortho Dermatologics business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Amortization of intangible assets of $270 million primarily attributable to fully amortized intangible assets no longer being amortized in 2021;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Goodwill impairments of $469 million related to the impairment to the goodwill of the Ortho Dermatologics reporting unit during the three months ended March 31, 2021 as a result of revised forecasts due to: (i) certain products that continued to experience longer launch cycles than originally anticipated, in part due to COVID-19 pandemic factors, and (ii) other changes to its product pipeline;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in Asset impairments, including loss on assets held for sale of $120 million, primarily attributable to: (i) higher impairments to certain products and (ii) additional losses during 2021 related to assets classified as held for sale; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Other expense, net of $129 million, primarily attributable: (i) higher insurance recoveries related to certain litigation matters in 2021 as compared to 2020 and (ii) decreases in charges for Acquisition-related contingent consideration and Acquired in-process research and development costs.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income was $450 million and $676 million for 2021 and 2020, respectively, and includes non-cash charges for Depreciation and amortization of intangible assets of $1,552 million and $1,825 million, Asset impairments, including loss on assets held for sale of $234 million and $114 million, Goodwill impairments of $469 million and $0 and Share-based compensation of $128 million and $105&#160;million for 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Loss before benefit from income taxes for 2021 and 2020 was $1,024 million and $934 million, respectively, an increase in our Loss before benefit from income taxes of $90 million. The increase in our Loss before benefit from income taxes is primarily attributable to the decrease in our operating results of $226 million, as previously discussed, partially offset by: (i) a decrease in Interest expense of $108 million and (ii) the favorable net change in Foreign exchange and other of $37 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to Bausch Health Companies Inc. for 2021 and 2020 was $948 million and $560 million, respectively, a decrease in our results of $388 million.  The decrease in our results was primarily due to: (i)  a decrease in the Benefit from income taxes of $288 million, primarily attributable to the release of a portion of our valuation allowance against deferred tax assets in 2020 and (ii) the increase in Loss before benefit from income taxes of $90 million, as previously discussed. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of 2020 Compared with 2019</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for 2020 and 2019 were $8,027 million and $8,601 million, respectively, a decrease of $574 million, or 7%. The decrease was primarily driven by: (i) lower volumes driven by: (a) social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed, and (b) the impact of the LOE of certain products, (ii) the unfavorable effect of foreign currencies, primarily in Latin America, and (iii) the impact of divestitures and discontinuations. These decreases in our revenues were partially offset by the incremental sales of our Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy. Net realized pricing was flat with increases in our Diversified Products, International Rx and Bausch + Lomb segments being offset by decreases in our Salix and Ortho Dermatologics segments. The changes in our segment revenues and segment profits are discussed in further detail in the subsequent section titled &#8220;Reportable Segment Revenues and Profits&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income for 2020 was $676 million compared to Operating loss for 2019 of $203 million, an increase in our operating results of $879 million which reflects, among other factors:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in contribution (product sales revenue less cost of goods sold, exclusive of amortization and impairments of intangible assets) of $470 million. The decrease was primarily driven by: (i) the decrease in revenues, as previously discussed and (ii) higher manufacturing variances primarily due to the impacts of the COVID-19 pandemic. The decrease was partially offset by lower third-party royalty costs;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in SG&amp;A expenses of $187 million, primarily attributable to profit protection measures taken to manage and reduce operating expenses during the COVID-19 pandemic;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in R&amp;D of $19 million primarily attributable to social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Amortization of intangible assets of $252 million primarily attributable to fully amortized intangible assets no longer being amortized in 2020;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in Asset impairments, including loss on assets held for sale of $39 million. Asset impairments, including loss on assets held for sale in 2020 were primarily related to: (i) reclassifying a business within our International Rx segment as held for sale and (ii) certain product lines as a result of changes to forecasted sales. Impairments during 2019 were primarily related to: (i) certain product lines as a result of changes to forecasted sales due to generic competition and other factors and (ii) impairments related to assets being classified as held for sale; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Other expense, net of $924 million, primarily attributable the decrease in net charges to Litigation and other matters.  The decrease in Litigation and other matters was primarily related to the settlement of a legacy U.S. securities class action matter (which is subject to an objector's appeal of the final court approval) in 2019, to which the Company and the other settling defendants admitted no liability as to the claims against it and denied all allegations of wrongdoing.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income for 2020 was $676 million compared to Operating loss for 2019 of $203 million and includes non-cash charges for Depreciation and amortization of intangible assets of $1,825 million and $2,075 million, Asset impairments, including loss on assets held for sale of $114 million and $75 million and Share-based compensation of $105 million and $102&#160;million for 2020 and 2019, respectively.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Loss before benefit from income taxes for 2020 and 2019 was $934 million and $1,837 million, respectively, an increase in our results before benefit from income taxes of $903 million. The decrease in our Loss before benefit from income taxes is primarily attributable to: (i) the increase in our operating results of $879 million, as previously discussed, and (ii) a decrease in Interest expense of $78 million as a result of: (a) a lower weighted average stated rate of interest, (b) lower interest as a result of debt repayments during the year and (c) a benefit related to the Company's cross-currency swaps. These decreases in Interest expense were partially offset by the interest associated with $1,210 million of additional financing in December 2019 relating to the U.S. Securities Litigation. The decrease in our Loss before benefit from income taxes was partially offset by: (i) an unfavorable net change in Foreign exchange and other of $38 million and (ii) an increase in the Loss on extinguishment of debt of $17 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to Bausch Health Companies Inc. for 2020 and 2019 was $560 million and $1,788 million, respectively, an increase in our results of $1,228 million.  The increase in our results was primarily due to: (i) the decrease in Loss before benefit from income taxes of $903 million, as previously discussed, and (ii) the favorable net change in the Benefit from income taxes of $321 million, primarily attributable to the release of a portion of our valuation allowance against deferred tax assets in 2020. </span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_193"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results for the years 2021, 2020 and 2019 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 to 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019 to 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(574)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of goods sold (excluding amortization and impairments of intangible assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(924)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,453)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loss before benefit from income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(937)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,783)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(378)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(560)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,788)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A detailed discussion of the year-over-year changes of the Company&#8217;s 2020 results compared with that of 2019 can be found under "Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations with Retrospective Segment Changes of the 2020 Form 10-K" in Exhibit 99.1 of our Form 8-K filed on May 4, 2021.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_196"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 Compared with 2020</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are primarily generated from product sales, principally in the therapeutic areas of eye-health, GI and dermatology, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material.  See Note 22, "SEGMENT INFORMATION" to our audited Consolidated Financial Statements for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues were $8,434 million and $8,027 million for 2021 and 2020, respectively, an increase of $407 million, or 5%.  The increase was due to: (i) a net increase in volumes of $471 million primarily in our Bausch + Lomb, Salix, Ortho Dermatologics and International Rx segments and (ii) the favorable impact of foreign currencies of $95 million primarily in Europe, Asia and Canada. These increases were partially offset by: (i) the impact of divestitures and discontinuations of $132 million, primarily attributable to our divestiture of Amoun on July 26, 2021 and (ii) a decrease in net realized pricing of $27 million primarily the result of higher sales deductions. The net increase in volumes was primarily due to the positive impacts of the recovery from the COVID-19 pandemic and the easing of certain social restrictions, as previously discussed, partially offset by: (i) the impact of the loss of exclusivity of certain products primarily in our Diversified Products, Bausch + Lomb and Ortho Dermatologics segments and (ii) the impacts of a quality issue at a third-party supplier on the revenues of certain Consumer products included in our Bausch + Lomb segment, as discussed below. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our 2020 revenues were most negatively impacted during our second quarter by the social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize prior to our third quarter of 2020. Our revenues returned to pre-pandemic levels for many of our businesses and geographies in 2021 and, at the current pace of recovery, we anticipate the COVID-19 pandemic to have a minimal impact on the remaining businesses and geographies in 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The changes in our segment revenues and segment profits, including the impacts of COVID-19 pandemic related matters, are discussed in further detail in the respective subsequent section &#8220; &#8212; Reportable Segment Revenues and Profits&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Discounts and Allowances, Chargebacks and Distribution Fees</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at net product sales.&#160;Provisions for these deductions are recognized concurrently with the recognition of gross product sales. These provisions include cash discounts and allowances, chargebacks, and distribution fees, which are paid or credited to direct customers, as well as rebates and returns, which can be paid or credited to direct and indirect customers. As more fully discussed in Note 2, "SIGNIFICANT ACCOUNTING POLICIES" to our audited Consolidated Financial Statements, the Company continually monitors the provisions for these deductions and evaluates the estimates used as additional information becomes available.  Price appreciation credits are generated when we increase a product&#8217;s wholesaler acquisition cost (&#8220;WAC&#8221;) under our contracts with certain wholesalers. Under such contracts, we are entitled to credits from such wholesalers for the impact of that WAC increase on inventory on hand at the wholesalers. In wholesaler contracts, such credits are offset against the total distribution service fees we pay on all of our products to each such wholesaler. In addition, some payor contracts require discounting if a price increase or series of price increases in a contract period exceeds a negotiated threshold. Provision balances relating to amounts payable to direct customers are netted against trade receivables and balances relating to indirect customers are included in accrued liabilities.&#160; </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively manage these offerings, focusing on the incremental costs of our patient assistance programs, the level of discounting to non-retail accounts and identifying opportunities to minimize product returns. We also concentrate on managing our relationships with our payors and wholesalers, reviewing the ranges of our offerings and being disciplined as to the amount and type of incentives we negotiate.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions recorded to reduce gross product sales to net product sales and revenues for 2021 and 2020 were as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions to reduce gross product sales to net product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution service fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,036&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,924&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts and allowances, returns, rebates, chargebacks and distribution service fees as a percentage of gross product sales were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 39.4% and 38.9% in 2021 and 2020, respectively, an increase of 0.5% percentage points and includes:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discounts and allowances as a percentage of gross product sales were lower primarily due to lower discount rates and gross product sales for certain generic products, such as Migranal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, Elidel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and Diastat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, partially offset by the impact of higher discount rates for and lower sales of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">returns as a percentage of gross product sales were higher and represent the impacts of: (i) higher sales of certain products, primarily Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (ii) returns associated with a quality issue at a third-party supplier on the revenues of certain Consumer products included in our Bausch + Lomb segment, as discussed below, offset by improving sales returns experience in 2021 as compared to 2020. Over the last several years, the Company has increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including, but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving the sales return experience, related to branded and generic products. Included in the product returns provision for 2021 and 2020 are reductions in variable consideration for sales returns related to past sales of approximately $28 million and $38 million, respectively. See Note 2, "SIGNIFICANT ACCOUNTING POLICIES" to our audited Consolidated Financial Statements regarding further details related to product sales provisions;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rebates as a percentage of gross product sales were higher primarily due the impact of: (i) an increase in gross product sales of certain branded products with higher rebate rates, such as Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Prolensa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and  (ii) an increase in rebates due to the launch of Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (June 2020) and was partially offset by lower gross product sales for certain branded products, such as Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">chargebacks as a percentage of gross product sales were lower primarily due to the impacts of: (i) lower chargeback rates and gross product sales for certain products, such as Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and Wellbutrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (ii) lower gross product sales for certain products, such as Targretin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, partially offset by higher chargeback rates and gross product sales for certain products, such as Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SLX, Syprine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and Mysoline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distribution service fees as a percentage of gross product sales were unchanged. Price appreciation credits were offset against the distribution service fees we paid wholesalers and were $17 million and $15 million for 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold (excluding amortization and impairments of intangible assets)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold primarily includes: manufacturing and packaging; the cost of products we purchase from third parties; royalty payments we make to third parties; depreciation of manufacturing facilities and equipment; and lower of cost or net </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">realizable value adjustments to inventories. Cost of goods sold typically vary between periods as a result of product mix, volume, royalties, changes in foreign currency and inflation. Cost of goods sold excludes the amortization and impairments of intangible assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold was $2,361 million and $2,202 million for 2021 and 2020, respectively, an increase of $159 million, or 7%. The increase was primarily driven by: (i) the net increase in volumes, as previously discussed, (ii) the unfavorable impact of foreign currencies and (iii) higher manufacturing variances, primarily the result of: (a) charges related to a quality issue at a third-party supplier, as discussed below, and (b) inflationary pressures related to certain manufacturing costs. These increases were partially offset by: (i) the impact of the divestiture of Amoun on July 26, 2021 and (ii) a reduction in third party royalties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the recovery from the COVID-19 pandemic continues and businesses reopen, many companies are reporting increases for certain costs, such as labor, materials, shipping and utilities. The increased costs have resulted in additional manufacturing variances and have had a negative impact on our contribution margins during 2021. Through the date of this filing, we are unable to determine if these inflationary factors are transitory or should be expected to continue over a medium or long term. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold as a percentage of Product sales revenue was 28.3% and 27.8% for 2021 and 2020, respectively, an increase of 0.5 percentage points primarily attributable to the year-over-year changes in product mix.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were notified by a third-party supplier of sterilization services for our lens care solution bottles and caps at our Milan, Italy facility, of inconsistencies in the sterilization data versus certificates of conformance previously submitted to us by that supplier. Based on our internal Health and Safety Analysis, it was determined that this issue did not affect the safety or performance of any of our products and is limited to a specific number of lots for certain Consumer products within our Bausch + Lomb segment. However, out of an abundance of caution and working with the appropriate notified body and responsible health authorities, we have contained and/or recalled down to the consumer level the limited number of affected lots of products resulting in $8&#160;million of manufacturing variances and $6 million of returns. Further, although our Greenville, South Carolina facility increased production to support some of the demand in the near term, due to the limited availability of qualified materials, production at the Milan facility could not keep up with demand, which negatively impacted our sales for the affected products in this region during 2021. At this time, we have removed this supplier from our Approved Supplier List and qualified another sterilization supplier, who, along with an existing secondary supplier, have and will provide bottle sterilization, thereby allowing our Milan facility to return to full production capacity. Although it is possible additional charges may be incurred, at this time we believe no additional charges will be necessary.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses primarily include: employee compensation associated with sales and marketing, finance, legal, information technology, human resources and other administrative functions; certain outside legal fees and consultancy costs; product promotion expenses; overhead and occupancy costs; depreciation of corporate facilities and equipment; separation-related and IPO-related costs; and other general and administrative costs. The Company has incurred, and will incur, Separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and Solta IPO. Separation-related and IPO-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses were $2,624 million and $2,367 million for 2021 and 2020, respectively, an increase of $257 million, or 11%. The increase was primarily attributable to: (i) the impacts of the non-recurrence of certain profit protection measures taken in 2020 to manage and reduce operating expenses during the COVID-19 pandemic, (ii) an increase in Separation-related and IPO-related costs of $111 million and (iii) the impact of foreign currencies. These increases were partially offset by the impact of the Amoun Sale on July 26, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company took certain profit protection measures to manage and reduce operating expenses during the COVID-19 pandemic, which resulted in year-over-year increases primarily in selling expenses and advertising and promotion expenses. These profit protection measures were successful in expanding the profit margins in many of our businesses as previously discussed. As the pace of recovery in each geography accelerated, we continued to allocate more resources to selling and other promotional activities to drive our return to sustainable revenue and profit growth and as a result our operating expenses for 2021 exceeded our operating expenses in 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to our product development and quality assurance programs. Expenses related to product development include: employee compensation costs; overhead and occupancy costs; depreciation of research and development facilities and equipment; clinical trial costs; clinical manufacturing and scale-up costs; and other </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third-party development costs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards and include: employee compensation costs; overhead and occupancy costs; amortization of software; and other third-party costs. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses were $465 million and $452 million for 2021 and 2020, respectively, an increase of $13 million, or 3%. The increase was primarily attributable to the non-recurrence of the temporary suspension in certain R&amp;D activities and clinical trials in 2020 due to social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed, partially offset by the impact of rebalancing our portfolio within the Ortho Dermatologics business. R&amp;D expenses as a percentage of Product sales were approximately 6% and 6% for 2021 and 2020, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, certain of our R&amp;D activities were limited and others, including new patient enrollments in clinical trials, were temporarily paused primarily during our second quarter, as most trial sites were not able to accept new patients due to government-mandated shutdowns. However, during our third quarter of 2020, many of these trial sites began to reopen and we saw the pace of new patient enrollments increase, although at this time certain of our projects are moving slower than we would like due to the impacts of the COVID-19 pandemic. As of the date of this filing, we have not had to make material changes to our development timelines and the pause in our clinical trials has not had a material impact on our operating results; however, a resurgence of the virus could result in unanticipated delays in our ability to conduct new patient enrollments and create other delays, which could have a significant adverse effect on our future operating results. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization of Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives, generally 2 to 20 years. Management continually assesses the useful lives related to the Company's long-lived assets to reflect the most current assumptions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets was $1,375 million and $1,645 million for 2021 and 2020, respectively, a decrease of $270 million, or 16%.  The decrease was primarily attributable to fully amortized intangible assets no longer being amortized in 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, "INTANGIBLE ASSETS AND GOODWILL" to our audited Consolidated Financial Statements for further details related to our intangible assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill Impairments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually at the reporting unit level. An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. A reporting unit is the same as, or one level below, an operating segment. The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of all reporting units using a discounted cash flow model, which utilizes Level 3 unobservable inputs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairments were $469 million and $0 for 2021 and 2020, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products.  In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;D spend to eliminate projects it has identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there is less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company's most recent cash flow projections as revised in the first quarter of 2021 to reflect the business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of 1.0% and a range of discount rates between 9.0% and 10.0%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at March 31, 2021, and the Company recognized a goodwill impairment of $469&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, "INTANGIBLE ASSETS AND GOODWILL" to our audited Consolidated Financial Statements regarding further details related to our goodwill impairment analysis.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset impairments, including loss on assets held for sale </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale were $234 million and $114 million for 2021 and 2020, respectively, an increase of $120 million. Asset impairments, including loss on assets held for sale for 2021 includes: (i) impairments of $105&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, (ii) an $88&#160;million loss on assets held for sale in connection with the Amoun Sale, (iii) impairments of $23&#160;million, in aggregate, related to the discontinuance of certain product lines and (iv) $18&#160;million related to a portion of an IT infrastructure improvement project no longer being utilized.  Asset impairments, including loss on assets held for sale for 2020 includes: (i) a $96&#160;million adjustment to reduce the carrying value of the Amoun business to its estimated fair value less costs to sell due to classifying the business as held for sale, (ii) $16&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, (iii) $1&#160;million, in aggregate, related to the discontinuance of certain product lines not aligned with the focus of the Company's core businesses and (iv) $1&#160;million related to Acquired in-process research and development not in service.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, "INTANGIBLE ASSETS AND GOODWILL" to our audited Consolidated Financial Statements for further details related to our intangible assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Integration, Separation and IPO Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, integration, separation and IPO costs were $50 million and $22 million for 2021 and 2020, respectively, an increase of $28 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring and integration costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and integration costs were $18&#160;million and $11&#160;million for 2021 and 2020, respectively, an increase of $7&#160;million. The Company continues to evaluate opportunities to streamline its operations and identify additional cost savings globally. Although a specific plan does not exist at this time, the Company may identify and take additional exit and cost-rationalization restructuring actions in the future, the costs of which could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation and IPO costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Separation-related and IPO-related costs, which are incremental costs indirectly related to the B+L Separation and Solta IPO and included in Selling, general and administrative expenses, as previously discussed, the Company has incurred, and will incur, costs directly associated with activities to effectuate the B+L Separation and the Solta IPO. These activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company and (ii) registering the Bausch + Lomb and Solta Medical businesses as independent publicly traded entities. Separation and IPO costs are incremental costs directly related to the B+L Separation and Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for the Bausch + Lomb and Solta Medical entities. Separation and IPO costs were  $32&#160;million and $11&#160;million for 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of 2021, we had substantially completed the internal objectives necessary to facilitate the B+L Separation and Solta IPO and related separation of these businesses. We continue to monitor market conditions and aim to launch the B+L IPO and the Solta IPO when financial market conditions become favorable (subject to receipt of regulatory, stock exchange and other approvals). Until such time, we continue to manage these businesses along with our pharmaceutical portfolio of gastrointestinal, dermatology, neurology and other therapeutics, with our continued commitment to bring out additional value for our shareholders.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 4, "RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS" to our audited Consolidated Financial Statements for further details regarding these actions. </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other expense, net </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net for 2021 and 2020 consists of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:77.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.711%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sales of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation and other matters for 2021, includes adjustments related to the Glumetza Antitrust Litigation, partially offset by insurance recoveries of $213 million related to certain litigation matters. See Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements for further details regarding these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation and other matters for 2020, includes adjustments related to an SEC investigation into the Company and its former relationship with Philidor Rx Services, LLC, its accounting practices and policies, its public disclosures and other matters (which investigation has now been settled) (the &#8220;SEC Investigation&#8221;) and the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-outs of each. Litigation and other matters also includes an insurance recovery related to a certain litigation matter. See Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements for further details regarding certain of these matters.</span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development costs primarily consists of costs associated with the upfront payments to enter into certain exclusive licensing agreements. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Operating Income and Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense primarily consists of interest payments due, amortization of debt premiums, discounts and deferred issuance costs on indebtedness under our credit facilities and notes and the amortization of amounts excluded from the assessment of hedge effectiveness over the term of the Company's cross-currency swaps. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $1,426 million and $1,534 million and included non-cash amortization and write-offs of debt discounts and deferred financing costs of $55 million and $61 million for 2021 and 2020, respectively. Interest expense decreased $108 million, or 7%, in 2021 as compared to 2020, primarily due to lower outstanding principal balances. The weighted average stated rate of interest as of December 31, 2021 and 2020 was 5.88% and 6.02%, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, "FINANCING ARRANGEMENTS" to our audited Consolidated Financial Statements for further details. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss on Extinguishment of Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on extinguishment of debt represents the differences between the amounts paid to settle extinguished debts and the carrying value of the related extinguished debt. Loss on extinguishment of debt was $62 million and $59 million for 2021 and 2020, respectively, primarily associated with certain refinancing transactions that occurred each year. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, "FINANCING ARRANGEMENTS" to our audited Consolidated Financial Statements for further details. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange and Other </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange and other was a gain of $7&#160;million for 2021 as compared to a loss of $30 million for 2020, a favorable net change of $37 million primarily due to: (i) translation gains/losses on intercompany loans and third-party liabilities and (ii) the gain/loss due to foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future. Benefit from income taxes was $87 million and $375 million in 2021 and 2020, respectively, an unfavorable net change of $288 million, primarily attributable to the release of a portion of the </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company's valuation allowance against deferred tax assets in 2020 in excess of the release of its valuation allowance in 2021. In 2021, the Company's valuation allowance decreased by $30 million primarily attributable to the impact of book taxable income in Canada, change in deferred tax assets in Canada and use of deferred tax assets in the U.S. in connection with internal restructurings.  In 2020, our valuation allowance decreased by $579 million primarily attributable to the impact of taxable losses in Canada, partially offset by the impact of internal restructurings which resulted in reductions to our deferred tax assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated foreign rate differential reflects the net total tax cost or benefit on income earned or losses incurred in jurisdictions outside of Canada as compared to the net total tax cost or benefit of such income (on a jurisdictional basis) at the Canadian statutory rate of 26.9%.  Tax costs below the Canadian statutory rate generate a beneficial foreign rate differential as do tax benefits generated in jurisdictions where the statutory tax rate exceeds the Canadian statutory tax rate.  The net total foreign rate differentials generated in each jurisdiction in which we operate is not expected to bear a direct relationship to the net total amount of foreign income (or loss) earned outside of Canada. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021 and 2020, our effective tax rate differs from the statutory Canadian income tax rate primarily due to: (i) the recording of valuation allowance on entities for which no tax benefit of losses is expected, (ii) the tax benefit generated from our annualized mix of earnings by jurisdiction and (iii) the discrete treatment of certain tax matters, primarily related to: (a) changes in uncertain tax positions, (b) impairment of United&#160;States generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;) goodwill, (c) internal restructurings, and (d) changes in the manner in which an outside basis difference will be recovered in future periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record a valuation allowance against our deferred tax assets to reduce their net carrying value to an amount that we believe is more likely than not to be realized. In determining our deferred tax asset valuation allowance, we estimate our ability to utilize future sources of income to realize the benefits of our temporary income tax differences including: (i) net operating loss carryforwards in each jurisdiction, primarily in Canada, the U.S. and Ireland, (ii) research and development tax credit carryforwards, (iii) scientific research and experimental development pool carryforwards and (iv) investment tax credit carryforwards. When we establish/increase or reduce/decrease the valuation allowance, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. Our valuation allowance against deferred tax assets as of December 31, 2021 and 2020 was $2,222 million and $2,252 million, respectively, a decrease of $30 million, as discussed above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 17, "INCOME TAXES" to our audited Consolidated Financial Statements for further details.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_199"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segment Revenues and Profits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of products falls into five operating and reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International Rx, (iv) Ortho Dermatologics and (v) Diversified Products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of our segments: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmic Pharmaceuticals products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of GI products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International Rx segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales, with the exception of sales of Bausch +Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Ortho Dermatologics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological) products and (ii) global sales of Solta aesthetic medical devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions.  Certain costs, such as Amortization of intangible assets, Asset impairments, including loss on assets held for sale, Restructuring, integration, separation and IPO costs, and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. See Note 22, "SEGMENT INFORMATION" to our audited Consolidated Financial Statements for a reconciliation of segment profit to Loss before benefit from income taxes.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment revenues, segment revenues as a percentage of total revenues and the year over year changes in segment revenues for 2021 and 2020. The following table also presents segment profits, segment profits as a percentage of segment revenues and the year-over-year changes in segment profits for 2021 and 2020. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.193%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 to 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Segment Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Rx</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Segment Profits / Segment Profit Margins</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Rx</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organic Revenues and Organic Growth Rates (non-GAAP)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organic growth, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of recent acquisitions, divestitures and discontinuations. Organic revenue growth (non-GAAP) is growth in GAAP Revenue (its most directly comparable GAAP financial measure), adjusted for certain items, of businesses that have been owned for one or more years. Organic revenue (non-GAAP) is impacted by changes in product volumes and price. The price component is made up of two key drivers: (i) changes in product gross selling price and (ii) changes in sales deductions. The Company uses organic revenue (non-GAAP) and organic revenue growth (non-GAAP) to assess performance of its reportable segments, and the Company in total, without the impact of foreign currency exchange fluctuations and recent acquisitions, divestitures and product discontinuations. The Company believes that such measures are useful to investors as they provide a supplemental period-to-period comparison.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP measures are not standardized measures under the financial reporting framework used to prepare the Company&#8217;s financial statements and might not be comparable to similar financial measures disclosed by other issuers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organic revenue growth (non-GAAP) reflects adjustments for: (i) the impact of period-over-period changes in foreign currency exchange rates on revenues and (ii) the revenues associated with acquisitions, divestitures and discontinuations of businesses divested and/or discontinued.  These adjustments are determined as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency exchange rates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Although changes in foreign currency exchange rates are part of our business, they are not within management&#8217;s control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the underlying business performance. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions, divestitures and discontinuations:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In order to present period-over-period organic revenues (non-GAAP) on a comparable basis, revenues associated with acquisitions, divestitures and discontinuations are adjusted to include only revenues from those businesses and assets owned during both periods. Accordingly, organic revenue growth (non-GAAP) excludes from the current period, all revenues attributable to each acquisition for twelve months subsequent to the day of acquisition, as there are no revenues from those businesses and assets included in the comparable prior period. Organic revenue growth (non-GAAP) excludes from the prior period (but not the current period), all revenues attributable to each divestiture and discontinuance during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period. There were no acquisitions during 2021.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of GAAP revenues to organic revenues (non-GAAP) and presents organic revenue (Non-GAAP) and the year over year changes in organic revenue (Non-GAAP) for 2021 and 2020 by segment.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.907%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change in<br/>Organic Revenue (Non-GAAP)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue<br/>as<br/>Reported</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Changes in Exchange Rates</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue<br/>as<br/>Reported</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Divestitures and Discontinuations</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,765&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,707&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International Rx</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,339&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,895&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bausch + Lomb Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb segment has a diversified product line with no single product group representing 10% or more of its segment revenues. The Bausch + Lomb segment revenue was $3,765 million and $3,415&#160;million for 2021 and 2020, respectively, an increase of $350 million, or 10%. The increase was primarily attributable to: (i) an increase in volumes across all of our Bausch + Lomb businesses of $337 million primarily due to the positive impacts from the recovery from the COVID-19 pandemic and the easing of certain social restrictions, as previously discussed, partially offset by: (a) the impact of generic competition as certain products, primarily Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel, lost exclusivity and (b) the impacts of a third-party supplier quality issue on the revenues of certain Consumer products, as previously discussed, and (ii) the favorable impact of foreign currencies of $58 million, primarily in Europe and Asia.  These increases were partially offset by: (i) a decrease in net realized pricing of $35 million primarily due to higher sales deductions in our Ophthalmic Pharmaceuticals business and (ii) the impact of divestitures and discontinuations of $10 million, related to several products. The increase in volumes was across all Bausch + Lomb businesses, most notably seen in our Surgical and Vision Care businesses, and across all geographies, most notably in the U.S., Asia and Europe.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the volumes of our Bausch + Lomb segment were most negatively impacted by the social restrictions and other precautionary measures taken in response to the COVID-19 pandemic during the second quarter of 2020. However, as governments began lifting social restrictions, the negative trend in the revenues began to level off and stabilize prior to our third quarter and continued into our fourth quarter of 2020 and first quarter of 2021. Our revenues returned to pre-pandemic levels for many of our Bausch + Lomb businesses and geographies in 2021 and, at the current pace of recovery, we anticipate the COVID-19 pandemic to have a minimal impact on the remaining businesses and geographies in 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb segment profit was $958 million and $909 million for 2021 and 2020, respectively, an increase of $49 million, or 5%. The increase was primarily driven by an increase in contribution primarily attributable to the net increase in revenues, as previously discussed. This increase was partially offset by: (i) the impacts of the non-recurrence of certain profit protection measures taken in 2020 to manage and reduce operating expenses during the COVID-19 pandemic, as previously discussed, which resulted in year-over-year increases primarily in selling expenses and advertising and promotion expenses, (ii) the non-recurrence of the temporary suspension in certain R&amp;D activities and clinical trials in 2020 due to social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed and (iii) inflationary pressures related to certain manufacturing costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 13, 2022, in connection with the B+L Separation, Bausch + Lomb Corporation filed a Registration Statement on Form S-1 with the SEC (the "Registration Statement"), which as of the date of this filing has not been declared effective.  As the Bausch + Lomb business has historically operated as part of the Company, Bausch + Lomb Corporation relied on the Company&#8217;s corporate and other support functions. Therefore, certain corporate and shared costs have been allocated to Bausch + Lomb Corporation in the financial results and other financial information as presented by Bausch + Lomb in its filings with the SEC, including expenses related to the support functions that are provided on a centralized basis by the Company and not included in the measurement of segment profit for any segment in the table above. This includes expenses for executive oversight, treasury, accounting, legal, human resources, shared services, compliance, procurement, information technology and other corporate functions.  Therefore, any measurement of Bausch + Lomb Corporation's net operating results, as presented in Bausch + Lomb Corporation's filings with the SEC, will not agree to Bausch + Lomb's segment profit as presented in the table above.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Salix Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment includes the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product line, which accounted for approximately 79% and 78% of the Salix segment revenues and approximately 19% and 18% of the Company's revenues for 2021 and 2020, respectively. No other single product group represents 10% or more of the Salix segment revenues. The Salix segment revenue was $2,074&#160;million and $1,904 million for 2021 and 2020, respectively, an increase of $170 million, or 9%. The increase was primarily attributable to increases in: (i) volume of $101 million, primarily attributable to increased volumes for our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product lines driven in part by the positive impacts of the recovery from the COVID-19 pandemic and the easing of certain social restrictions, as previously discussed, and (ii) net realized pricing of $69 million, primarily attributable to our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line, partially offset by higher sales adjustments for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SLX.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment profit was $1,493 million and $1,338 million for 2021 and 2020, respectively, an increase of $155&#160;million, or 12%. The increase was primarily driven by the increase in contribution as a result of: (i) the increase in revenue, as previously discussed, and (ii) a reduction in third party royalties. This increase was partially offset by the impacts of the non-recurrence of certain profit protection measures taken in 2020 to manage and reduce operating expenses during the COVID-19 pandemic, as previously discussed, which resulted in year-over-year increases primarily in selling expenses and advertising and promotion expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">International Rx Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Rx Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International Rx segment has a diversified product line with no single product group representing 10% or more of its product sales. The International Rx segment revenue was $1,166 million and $1,181 million for 2021 and 2020, respectively, a decrease of $15 million, or 1%. The decrease was primarily attributable to the impact of divestitures and discontinuations of $113 million, primarily attributable to our divestiture of Amoun on July 26, 2021. Amoun revenues were $157 million for the period of January 1, 2021 through July 26,2021 and were $247 million for the full year 2020. The decreases were partially offset by: (i) an increase in volumes of $51 million, (ii) the favorable impact of foreign currencies of $28 million, primarily in Canada and Latin America, and (iii) an increase in net realized pricing of $19 million. The increase in volumes is primarily due to the positive impacts from the recovery from the COVID-19 pandemic and the easing of certain social restrictions, as previously discussed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we experienced COVID-19 pandemic related declines in year-over-year revenues in certain products and geographies during 2021, at the current pace of recovery, we anticipate the COVID-19 pandemic to have a minimal impact on the remaining businesses and geographies in 2022. .</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Rx Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International Rx segment profit for 2021 and 2020 was $403 million and $386 million, respectively, an increase of $17 million, or 4%. The increase was primarily driven by a decrease in SG&amp;A expenses, partially offset by the decrease in contribution primarily attributable to our divestiture of Amoun on July 26, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ortho Dermatologics Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ortho Dermatologics Segment Revenue</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Ortho Dermatologics segment includes the Thermage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> product lines, which accounted for approximately 42% and 10% of the Ortho Dermatologics segment revenues for 2021, respectively. No other single product group represents 10% or more of the Ortho Dermatologics segment revenues. The Ortho Dermatologics segment revenue was $564 million and $548 million for 2021 and 2020, respectively, an increase of $16 million, or 3%. The increase was primarily attributable to: (i) an increase in volume of $54 million and (ii) the favorable impact of foreign currencies of $9&#160;million. These increases were partially offset by a decrease in net realized pricing of $47&#160;million, as a result of higher sales deductions for our medical dermatology products. The increase in volume was primarily due to: (i) increased demand of Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in our Solta aesthetic medical device business and (ii) the positive impacts from the recovery from the COVID-19 pandemic and the easing of certain social restrictions, as previously discussed, and were partially offset by the impact of generic competition as certain medical dermatology products, such as Elidel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, lost exclusivity.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ortho Dermatologics Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ortho Dermatologics segment profit was $265 million and $228 million for 2021 and 2020, respectively, an increase of $37 million, or 16%. The increase was primarily due to: (i) an increase in contribution primarily attributable to the net increase in revenues, as previously discussed, (ii) a decrease in selling expenses and (iii) a decrease in R&amp;D expenses due to the impact of rebalancing our portfolio within the Ortho Dermatologics business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Diversified Products Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Products Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the Diversified Products segment revenues by product and product revenues as a percentage of segment revenue for 2021 and 2020. </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 to 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wellbutrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ativan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardizem</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mysoline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diastat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elidel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Librium</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other product revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Diversified Products revenues </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment revenue was $865 million and $979 million for 2021 and 2020, respectively, a decrease of $114 million, or 12%. The decrease was primarily driven by: (i) a decrease in volume of $72 million, (ii) a decrease in net realized pricing of $33 million and (iii) the impact of divestitures and discontinuations of $9 million. The decrease in volume was primarily attributable to the impact of generic competition as certain products in our Neurology and Other business, such as Migranal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Mephyton</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Isuprel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Syprine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cuprimine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Demser</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, lost exclusivity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Products Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment profit was $624 million and $717 million for 2021 and 2020, respectively, a decrease of $93 million, or 13% and was primarily driven by the decrease in revenues, as previously discussed.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_202"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized cash flow information for the years 2021, 2020 and 2019 is as follows: </span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.368%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 to 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019 to 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(937)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,783)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(378)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile Net loss to net cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash provided by operating activities before changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,819&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(342)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(366)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(318)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,426&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,501&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(390)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(419)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,513)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,737)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in Cash and cash equivalents and Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,428)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,521&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,949)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents and Restricted cash and other settlement deposits, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents and Restricted cash and other settlement deposits, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,816&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,244&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,428)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A detailed discussion of the year-over-year changes of the Company&#8217;s 2020 results compared with that of 2019 can be found under "Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations with Retrospective Segment Changes of the 2020 Form 10-K" in Exhibit 99.1 of our Form 8-K filed on May 4, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities was $1,426 million and $1,111 million in 2021 and 2020, respectively, an increase of $315 million. The increase was attributable to the year-over-year increases in: (i) Changes in operating assets and liabilities of $238 million and (ii) Cash provided by operating activities before changes in operating assets and liabilities of $77 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities before changes in operating assets and liabilities for the years 2021 and 2020 was $1,554 million and $1,477 million, respectively, an increase of $77 million.  The increase was primarily attributable to: (i) the positive impacts on our operating results of the recovery from the COVID-19 pandemic and the easing of certain social restrictions, as previously discussed, and (ii) higher insurance recoveries during 2021 as compared to 2020 associated with certain litigation matters.  These increases were partially offset by: (i) higher payments of accrued legal settlements during 2021 as compared to 2020, (ii) higher payments for Separation and IPO costs and Separation-related and IPO-related costs during 2021 as compared to 2020 and (iii) the impacts of the non-recurrence of certain profit protection measures taken in 2020 to manage and reduce operating expenses during the COVID-19 pandemic, as previously discussed, which resulted in year-over-year increases in payments primarily for selling expenses and advertising and promotion expenses. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities resulted in a net decrease in cash of $128 million and $366 million in 2021 and 2020, respectively, a favorable change of $238 million. During 2021, Changes in operating assets and liabilities was negatively impacted by: (i) the increase in trade receivables of $229&#160;million, (ii) an increase in inventories of $16&#160;million and (iii) lower interest payable due to the timing of payments of $13 million, partially offset by the positive impact of the timing of other payments in the ordinary course of business of $130&#160;million. During 2020, Changes in operating assets and liabilities was negatively impacted by: (i) the timing of other payments in the ordinary course of business of $495&#160;million and (ii) an increase in inventories of $77&#160;million and was partially offset by: (i) the collection of trade receivables of $170&#160;million and (ii) an increase in accrued interest due to timing of payments of $36&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $409 million in 2021 and was primarily driven by: (i) Proceeds from sale of assets and businesses, net of costs to sell of $669 million, which is primarily attributable to the Amoun Sale and (ii) Settlements from cross-currency swaps of $27 million, partially offset by Purchases of property, plant and equipment of $269 million. </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $261 million in 2020 and was primarily driven by Purchases of property, plant and equipment of $302 million partially offset by: (i) Interest settlements from cross-currency swaps of $23 million and (ii) Proceeds from sale of assets and businesses, net of costs to sell of $21 million, primarily related to the receipt of a milestone payment associated with a prior year divestiture. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities during 2021 was $1,513 million and was primarily driven by the repayments of debt of $3,440 million which consisted of: (i) $1,600 million of 7.000% Senior Secured Notes due 2024 as part of the 2021 Refinancing Transactions (as defined below), (ii) the aggregate prepayments of $1,600&#160;million using cash on hand, cash generated from operations and the net proceeds from the Amoun Sale and (iii) the repayment of $240 million previously drawn under our 2023 Revolving Credit Facility. Issuance of long-term debt  (net of discounts) of $2,100 million primarily includes: (i) the proceeds of $1,575 million from the issuance of $1,600 million in principal amount of 4.875% Senior Secured Notes due June 2028 and (ii) draw downs of $525 million under our 2023 Revolving Credit Facility which we used primarily to make deposits of approximately $300&#160;million, in the aggregate, into escrow funds under the terms of settlement agreements regarding the Glumetza Antitrust Litigation and to pay interest and other business expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities during 2020 was $2,294 million and was primarily driven by repayments of long-term debt, net of issuances and related discounts, of $2,187 million. These repayments primarily include: (i) $1,240 million of 5.875% Senior Unsecured Notes due 2023 (the "May 2023 Unsecured Notes"), which was previously financed as part of the December 2019 Financing and Refinancing Transactions and (ii) debt repayments of $902 million using cash on hand and cash generated from operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, "FINANCING ARRANGEMENTS" to our audited Consolidated Financial Statements for further details regarding the financing activities previously described.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Sources of Liquidity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are our cash and cash equivalents, cash collected from customers, funds as available from our revolving credit facility, issuances of long-term debt and issuances of equity and equity-linked securities. We believe these sources will be sufficient to meet our current liquidity needs for the next twelve months.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, at the end of 2021, we had substantially completed the internal objectives to facilitate the IPOs and related separation of the B+L and Solta Medical businesses. We continue to monitor market conditions and aim to launch the B+L IPO and the Solta IPO when financial market conditions are favorable (subject to receipt of regulatory, stock exchange and other approvals). However, there can be no assurance as to when we will complete either IPO, if at all. Until such time, we continue to manage these businesses along with our diverse portfolio of gastrointestinal, dermatology, neurology and other therapeutics, with our continued commitment to bring out additional value for our shareholders. Following the B+L IPO, we expect to complete the separation of Bausch + Lomb after the expiry of customary lockups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to the receipt of applicable shareholder and other necessary approvals and market conditions. Nothing in the Form 10-K shall constitute an offer to sell or the solicitation of an offer to buy any securities of the Bausch + Lomb or Solta entities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly evaluates market conditions, its liquidity profile, and various financing alternatives for opportunities to enhance its capital structure. If opportunities are favorable, the Company may refinance or repurchase existing debt or issue equity or equity-linked securities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net of unamortized premiums, discounts and issuance costs was $22,654 million and $23,925 million as of December 31, 2021 and 2020, respectively. Aggregate contractual principal amounts due under our debt obligations were $22,870 million and $24,185 million as of December 31, 2021 and 2020, respectively, a decrease of $1,315 million. The decrease during 2021 was attributable to the debt repayments previously discussed under " - Cash Flows - Financing Activities". </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#8220;Senior Secured Credit Facilities&#8221; under the Company&#8217;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#8220;Restated Credit Agreement&#8221;) with a syndicate of financial institutions and investors as lenders. </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restated Credit Agreement provides for a revolving credit facility of $1,225 million, which matures on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. ("BHA") in an aggregate principal amount in excess of $1,000 million (the "2023 Revolving Credit Facility") and term loan facilities of original principal amounts of $4,565 million and $1,500 million, maturing in June 2025 (the &#8220;June 2025 Term Loan B Facility&#8221;) and November 2025 (the "November 2025 Term Loan B Facility"), respectively. Both the Company and BHA are borrowers under the 2023 Revolving Credit Facility, borrowings under which may be made in U.S. dollars or Canadian dollars (or if an amendment to the Restated Credit Agreement is made to replace LIBOR with an alternative benchmark rate with respect to borrowings under the Revolving Credit Facility denominated in euros, euros).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Current Description of Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Senior Secured Credit Facilities in U.S. dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a base rate determined by reference to the highest of: (a) the prime rate (as defined in the Restated Credit Agreement), (b) the federal funds effective rate plus 1/2 of 1.00% or (c) the eurocurrency rate (as defined in the Restated Credit Agreement) for a period of one month plus 1.00% (or if such eurocurrency rate shall not be ascertainable, 1.00%) or (ii) a eurocurrency rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in euros, when available, are expected to bear interest at a term benchmark rate determined by reference to the costs of funds for euro deposits for the interest period relevant to such borrowing (provided however, that the eurocurrency rate is at no time expected to be less than 0.00% per annum), plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in Canadian dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a prime rate determined by reference to the higher of: (a) the rate of interest last quoted by The Wall Street Journal as the &#8220;Canadian Prime Rate&#8221; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus 1.00% (provided however, that the prime rate shall at no time be less than 0.00%) or (ii) the bankers&#8217; acceptance rate for Canadian dollar deposits in the Toronto interbank market (the &#8220;BA rate&#8221;) for the interest period relevant to such borrowing (provided however, that the BA rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i)&#160;100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii)&#160;100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the Restated Credit Agreement), (iii)&#160;50% of Excess Cash Flow (as&#160;defined in the Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv)&#160;100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility are 2.00% and 1.75%, respectively, with respect to base rate and prime rate borrowings and 3.00% and 2.75%, respectively, with respect to eurocurrency rate and BA rate borrowings. As of December 31, 2021, the stated rates of interest on the Company&#8217;s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were 3.09% and 2.84% per annum, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for both the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility is 5.00% per annum. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of December&#160;31, 2021, there were no remaining mandatory quarterly amortization payments for the Senior Secured Credit Facilities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are 1.50% - 2.00% with respect to base rate or prime rate borrowings and 2.50% - 3.00% with respect to eurocurrency rate or BA rate borrowings.&#160; As of December&#160;31, 2021, the stated rate of interest on the 2023 Revolving Credit Facility was 2.84% per annum. As of the date of this filing, the Company had $285 million outstanding borrowings, $54 million of issued and outstanding letters of credit, and remaining availability of $886 million under its 2023 Revolving Credit Facility. In addition, the Company is required to pay commitment fees of 0.25% - 0.50% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency&#160;fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restated Credit Agreement permits the incurrence of incremental credit facility borrowings, up to the greater of $1,000 million and 28.5% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the Restated Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the Restated Credit Agreement under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate principal amount of our Senior Secured Notes as of December 31, 2021 and 2020 was $3,850&#160;million and $4,250&#160;million, respectively, a decrease of $400&#160;million representing the prepayment of $400 million 7.00% Senior Secured Notes due 2024 using cash on hand and cash generated from operations during 2021.  Additionally, in June 2021, we accessed the credit markets and completed a series of transactions, whereby we: (i) extended $1,600 million in aggregate maturities of certain debt obligations due to mature in 2024 out to 2028 and (ii) refinanced $1,600 million in aggregate of existing 7.00% Senior Secured Notes due 2024 with $1,600 million in aggregate of 4.875% Senior Secured Notes due 2028 (the "2021 Refinancing Transactions").</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate principal amount of our Senior Unsecured Notes as of December 31, 2021 and 2020 was $14,900 million and $15,500 million, respectively, a decrease of $600 million, representing the prepayment of $600 million 6.125% Senior Unsecured Notes due 2025 (the "6.125% Notes due 2025") using cash on hand and cash generated from operations during 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to comply with the covenants under the terms of our Restated Credit Agreement, Senior Secured Notes indentures or Senior Unsecured Notes indentures could lead to a default or an event of default for which we may need to seek relief from our lenders and noteholders in order to waive the associated default or event of default and avoid a potential </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acceleration of the related indebtedness or cross-default or cross-acceleration to other debt. There can be no assurance that we would be able to obtain such relief on commercially reasonable terms or otherwise and we may be required to incur significant additional costs. In addition, the lenders under our Restated Credit Agreement, holders of our Senior Secured Notes and holders of our Senior Unsecured Notes may impose additional operating and financial restrictions on us as a condition to granting any such waiver.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2017 through the date of this filing, the Company completed several actions which included repaying debt with proceeds from divestitures and cash flows from operations, as well as refinancing debt with near term maturities. These actions have reduced the Company&#8217;s debt balance and positively affected the Company&#8217;s ability to comply with its financial maintenance covenant. As of December&#160;31, 2021, the Company was in compliance with the financial maintenance covenant related to its outstanding debt. The Company, based on its current forecast for the next twelve months from the date of issuance of this Form 10-K, expects to remain in compliance with the financial maintenance covenant and meet its debt service obligations over that same period. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy. The Company may consider taking other actions, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities including secondary offerings of the common stock of Bausch + Lomb and Solta Medical, as deemed appropriate, to provide additional coverage in complying with the financial maintenance covenant and meeting its debt service obligations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Notes and Secured Notes are guaranteed by a substantial portion of the Company&#8217;s subsidiaries. On a non-consolidated basis, the non-guarantor subsidiaries had total assets of $2,161 million and $2,442 million and total liabilities of $942 million and $1,804 million as of December&#160;31, 2021 and 2020, respectively. On a non-consolidated basis, the non-guarantor subsidiaries had revenues of $1,755 million and $1,320&#160;million for 2021 and 2020, respectively. On a non-consolidated basis, the non-guarantor subsidiaries had operating income of $116 million for 2021 and an operating loss of $38&#160;million for 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Focus on Capitalization of the Post-separation Entities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the B+L Separation and Solta IPO, we have emphasized that it is important that the post-separation entities be well-capitalized, with appropriate leverage and with access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate capitalization and leverage of these businesses post-separation as a key to bringing out the maximum value across our portfolio of assets and, it is a primary objective of our plan of separation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, in connection with the anticipated B+L IPO and Solta IPO, the Company issued conditional notices of redemption to redeem in full all of its outstanding 6.125% Notes due 2025 and to redeem $370 million aggregate principal amount of its outstanding 9.000% Notes due 2025. The redemption and discharge of the indenture governing the 6.125% Notes due 2025 will be conditioned upon the completion of the Credit Agreement Refinancing, as defined below. The redemption of the 9.000% Notes due 2025 will be conditioned upon the receipt of aggregate gross proceeds from the B+L IPO, the B+L Debt Financing as defined below, the Credit Agreement Refinancing and the offering of the February 2027 Secured Notes, as defined below, of at least $7,000 million. The foregoing redemptions are subject to the conditions described above, and there can be no assurance that such conditions will be satisfied and that such redemptions will occur.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company announced its intention to refinance its existing Restated Credit Agreement with an amended Restated Credit Agreement (the "New Restated Credit Agreement" and such refinancing, the "Credit Agreement Refinancing"). The New Restated Credit Agreement is expected to consist of approximately $2,500 million of term B loans and a $975 million revolving credit facility. The Credit Agreement Refinancing is expected to occur only upon completion of the B+L IPO and a related debt financing by Bausch + Lomb (the "B+L Debt Financing"). At the time of the B+L IPO, the Credit Agreement Refinancing will provide that Bausch + Lomb initially be a "restricted" subsidiary subject to the terms of the Credit Agreement covenants, however the Credit Agreement Refinancing is expected to permit the Company to designate Bausch + Lomb as an "unrestricted" subsidiary under the New Restated Credit Agreement covenants upon achievement of a 7.6x pro forma "Remainco Total Leverage Ratio." Such designation could take place at any time after the B+L IPO (including as soon as the closing of the B+L IPO). The Credit Agreement Refinancing is designed to facilitate the separation and distribution of Bausch + Lomb. The Credit Agreement Refinancing will not be consummated until completion of the B+L IPO and related B+L Debt Financing. There can be no assurance that the Credit Agreement Refinancing will occur on the terms described above, or at all.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2022, the Company issued $1,000 million aggregate principal amount of 6.125% Senior Secured Notes due February 2027 (the &#8220;February 2027 Secured Notes&#8221;). The February 2027 Secured Notes accrue interest at a rate of 6.125% per year, payable semi-annually in arrears on each February and August. The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to 100% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to February 2024, the Company may redeem up to 40% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture. If the B+L IPO does not occur on or prior to August 15, 2022, the Company will be required to redeem the February 2027 Secured Notes at such time at a redemption price equal to the issue price of the February 2027 Secured Notes plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Weighted Average Interest Rate</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average stated rate of interest of the Company's debt  as of December 31, 2021 and 2020 was 5.88% and 6.02%, respectively.</span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, "FINANCING ARRANGEMENTS" and Note 23, "SUBSEQUENT EVENTS" to our audited Consolidated Financial Statements for further details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Ratings </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2021, Moody's, Standard &amp; Poor's and Fitch maintained our credit ratings but changed our outlook from Stable to Negative. As of February&#160;23, 2022, the credit ratings and outlook from Moody's, Standard &amp; Poor's and Fitch for certain outstanding obligations of the Company were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rating Agency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate Rating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Rating&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Rating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outlook</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moody&#8217;s&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ba2/Ba3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Negative</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard &amp; Poor&#8217;s</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BB</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Negative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fitch</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BB</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Negative</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a part of the financing transactions launched in January 2022 discussed above, Moody&#8217;s assigned a Ba3 rating to the $2,500 million of term B loans and the $975 million revolving credit facility as anticipated by the Credit Agreement Refinancing and to the newly issued February 2027 Secured Notes. The Ba3 rating is one notch lower than Moody&#8217;s rating of Ba2 for our existing senior secured debt. As the Credit Agreement Refinancing will not be consummated until completion of the B+L IPO and related B+L Debt Financing, there can be no assurance that the Credit Agreement Refinancing will occur on the terms described above, or at all. Should the Credit Agreement Refinancing be completed as described above, Moody's anticipates downgrading its ratings on our existing senior secured notes to Ba3 from Ba2, consistent with the Ba3 rating assigned to the $2,500 million of term B loans and the $975 million revolving credit facility as anticipated by the Credit Agreement Refinancing and to the newly issued February 2027 Secured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any downgrade in our corporate credit ratings or other credit ratings may increase our cost of borrowing and may negatively impact our ability to raise additional debt capital.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_205"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS AND CONTRACTUAL OBLIGATIONS </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material future effect on our results of operations, financial condition, capital expenditures, liquidity, or capital resources. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other future cash requirements relate to working capital, capital expenditures, business development transactions (contingent consideration), restructuring, integration, separation and IPO costs, benefit obligations and litigation settlements. In addition, we may use cash to enter into licensing arrangements and/or to make strategic acquisitions. We are considering further acquisition opportunities within our core therapeutic areas, some of which could be sizable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our working capital requirements, as of December&#160;31, 2021, we expect our primary cash requirements for 2022 to include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Debt repayments and interest payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;On February 11, 2022, we repaid $285 million representing all amounts outstanding under our 2023 Revolving Credit Facility as of December 31, 2021, and, therefore as a result of prepayments and a series of refinancing transactions we have reduced and extended the maturities of a substantial portion of our long-term debt and have no debt maturities until 2025 (other than our obligation to redeem the February 2027 Secured Notes if the B+L IPO does not occur on or prior to August 15, 2022 as discussed above) and have no mandatory amortization payments. Based on our debt portfolio as of December 31, 2021, which does not reflect changes in our capitalization in </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">connection with the B+L Separation and the Solta IPO if and when they occur, we anticipate making interest payments of approximately $1,350 million during 2022. Further, in connection with the conditional notices of redemption discussed above, we anticipate: (i) redeeming in full all of our outstanding 6.125% Notes due 2025 conditioned upon the completion of the Credit Agreement Refinancing, as discussed above, and (ii) redeeming $370 million aggregate principal amount of our 9.000% Notes due 2025 conditioned upon the receipt of aggregate gross proceeds from the B+L IPO, the B+L Debt Financing, the Credit Agreement Refinancing and the February 2027 Secured Notes of at least $7,000 million, as discussed above. The foregoing redemptions are subject to the conditions described above, and there can be no assurance that such conditions will be satisfied and that such redemptions will occur. We may also elect to make additional principal payments under certain circumstances. Further, in the ordinary course of business, we may borrow and repay additional amounts under our credit facilities using cash on hand, cash generated from operations and cash provided from the sale of common stock and additional debt financings in connection with the B+L Separation and the Solta IPO;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">IT Infrastructure Investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make payments of approximately $65&#160;million for licensing, maintenance and capitalizable costs associated with our IT infrastructure improvement projects during 2022;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Capital expenditures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make payments of approximately $275&#160;million for property, plant and equipment during 2022;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Contingent consideration payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make contingent consideration and other development/approval/sales-based milestone payments of approximately $64&#160;million during 2022;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Restructuring and integration payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make payments of $8&#160;million during 2022 for employee separation costs and lease termination obligations associated with restructuring and integration actions we have taken through December&#160;31, 2021;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Benefit obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make aggregate payments under our pension and postretirement obligations of $13&#160;million during 2022. See Note 11, "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS" to our audited Consolidated Financial Statements for further details of our benefit obligations; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In the ordinary course of business, the Company is involved in litigation, claims, government inquiries, investigations, charges and proceedings.  As of December&#160;31, 2021, the Company's Consolidated Balance Sheet includes accrued current loss contingencies of $1,890 million related to matters which are both probable and reasonably estimable, of which $1,567 million, has been paid or is expected to be payable during 2022; however, no assurance can be provided as to when such amount will be payable, if&#160;at all. The amounts which can be expected to be payable during 2022 include among other agreements to resolve: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:42.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation for $1,210&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- The Company reached an agreement to resolve the U.S. Securities Litigation for $1,210 million.  Final court approval of this settlement was granted in January 2021 but is subject to an objector's appeal of the Court's final approval order. The settlement resolves and discharges all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against them and deny all allegations of wrongdoing. This settlement resolves the most significant of the Company's remaining legacy legal matters and eliminates a material uncertainty regarding our Company. As of December&#160;31, 2021, Restricted cash and other settlement deposits includes $1,210&#160;million of payments into an escrow fund under the terms of a settlement agreement regarding the U.S. Securities Litigation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:42.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza Antitrust Litigation for $300 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - On September 14, 2021, the Company executed a final settlement agreement to resolve the class plaintiffs&#8217; claims in the Glumetza Antitrust Litigation for $300 million, subject to court approval. On February 3, 2022, the court granted final approval of the class settlement and ordered dismissal of the class plaintiffs&#8217; claims. Subject to appeal of the final approval of the class settlement, the settlement will resolve and discharge all asserted class claims against the Company. As part of the settlement, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing. As of December&#160;31, 2021, Restricted cash and other settlement deposits includes approximately $300&#160;million of payments into an escrow fund under the terms of a settlement agreement regarding the class plaintiffs' claims in the Glumetza Antitrust Litigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 20, "LEGAL PROCEEDINGS" to our audited interim Consolidated Financial Statements for further details of these and other matters. Our ability to successfully defend the Company against pending and future litigation may impact future cash flows.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Costs of B+L Separation and Solta IPO</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and will incur, costs associated with activities to complete the B+L Separation and the Solta IPO. These activities include the costs of: (i) separating the Bausch + Lomb and the Solta Medical businesses from the remainder of the Company and (ii) registering the Bausch + Lomb and the Solta Medical businesses as independent publicly traded entities. Separation and IPO costs are incremental costs directly related to the B+L Separation and Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing new boards of directors and related board committees for the Bausch + Lomb and Solta Medical entities. The Company has also incurred, and will incur, Separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and Solta IPO. These costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. The extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Cost Savings Programs </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate opportunities to improve our operating results and may initiate additional cost savings programs to streamline our operations and eliminate&#160;redundant processes and expenses. These cost savings programs may include, but are not limited to: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The expenses associated with the implementation of these cost savings programs could be material and may impact our cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Licensing Payments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products primarily in the U.S. and Canada. In connection with these agreements, the Company may pay an upfront fee to secure the agreement. See Note 3, "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our audited Consolidated Financial Statements. Payments associated with the upfront fee for these agreements cannot be reasonably estimated at this time and could be material</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company had unrecognized tax benefits totaling $104 million which are expected to be realized within the next twelve months.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_208"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUTSTANDING SHARE DATA</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common shares are listed on the TSX and the NYSE under the ticker symbol&#160;&#8220;BHC&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At February&#160;17, 2022, we had 359,646,496 issued and outstanding common shares. In addition, as of February&#160;17, 2022, we had 8,734,135 stock options and 5,150,139 time-based restricted share units ("RSUs") that each represent the right of a holder to receive one of the Company&#8217;s common shares, and 2,625,722 performance-based RSUs that represent the right of a holder to receive a number of the Company's common shares up to a specified maximum. A maximum of 3,937,844 common shares could be issued upon vesting of the performance-based RSUs outstanding.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_211"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and financial results are affected by fluctuations in world financial markets, including the impacts of foreign currency exchange rate and interest rate movements. We evaluate our exposure to such risks on an ongoing basis, and seek ways to manage these risks to an acceptable level, based on management&#8217;s judgment of the appropriate trade-off between risk, opportunity and cost. We may use derivative financial instruments from time to time as a risk management tool and not for trading or speculative purposes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation; Seasonality </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to price control restrictions on our pharmaceutical products in a number of countries in which we now operate. As a result, our ability to raise prices in a timely fashion in anticipation of inflation may be limited in some&#160;markets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, revenues from our business tend to be weighted toward the second half of the year.  Sales in the first quarter tend to be lower as patient co-pays and deductibles reset at the beginning of each year.&#160;&#160;Sales in the fourth quarter tend to be higher based on consumer and customer purchasing patterns associated with health care reimbursement programs.  However, there are no assurances that these historical trends will continue in the future.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, a majority of our revenue and expense activities and capital expenditures were denominated in U.S.&#160;dollars.&#160; We have exposure to multiple foreign currencies, including, among others, the Euro, Chinese yuan, Polish zloty, Canadian dollar and Mexican peso. Our operations are subject to risks inherent in conducting business abroad, including price and currency exchange controls and fluctuations in the relative values of currencies. In addition, to the extent that we require, as a source of debt repayment, earnings and cash flows from some of our operations located in foreign countries, we are subject to risk of changes in the value of the U.S.&#160;dollar, relative to all other currencies in which we operate, which may materially affect our results of operations. Where possible, we manage foreign currency risk by managing same currency revenues in relation to same currency expenses. Further strengthening of the U.S. dollar and/or further devaluation of foreign currencies will have a negative impact on our reported revenue and reported results.  As of December 31, 2021, a 1% change in foreign currency exchange rates would have impacted our shareholders&#8217; deficit by approximately $39 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the unrealized foreign exchange gain on the translation of the remaining principal amount of U.S. denominated senior secured and unsecured notes was $285 million, for Canadian income tax purposes. Additionally, as of December&#160;31, 2021, the unrealized foreign exchange loss on certain intercompany balances was equal to $197 million. One-half of any realized foreign exchange gain or loss will be included in our Canadian taxable income. Any resulting gain will result in a corresponding reduction in our available Canadian Losses, Scientific Research and Experimental Development Pool, and/or Investment Tax Credit carryforward balances. However, the repayment of the senior notes and the intercompany loans denominated in U.S. dollars does not result in a foreign exchange gain or loss being recognized in our Consolidated Financial Statements, as these statements are prepared in U.S. dollars.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not hold financial instruments for speculative purposes. Our financial assets are not subject to significant interest rate risk due to their short duration. The primary objective of our policy for the investment of temporary cash surpluses is the protection of principal, and accordingly, we generally invest in high quality, money market investments and time deposits with varying maturities, but typically less than three months. As it is our intent and policy to hold these investments until maturity, we do not have a material exposure to interest rate&#160;risk. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had $18,762 million and $4,108 million principal amount of issued fixed rate debt and variable rate debt, respectively. The estimated fair value of our issued fixed rate debt as of December&#160;31, 2021 was $18,599 million. If interest rates were to increase by 100 basis-points, the fair value of our issued fixed rate debt would decrease by approximately $561 million. If interest rates were to decrease by 100 basis-points, the fair value of our issued fixed rate debt would increase by approximately $478 million. We are subject to interest rate risk on our variable rate debt as changes in interest rates could adversely affect earnings and cash flows. A 100 basis-points increase in interest rates, would have an annualized pre-tax effect of approximately $41 million in our Consolidated Statements of Operations and Consolidated Statements of Cash Flows, based on current outstanding borrowings and effective interest rates on our variable rate debt. While our variable-rate debt may impact earnings and cash flows as interest rates change, it is not subject to changes in fair value. </span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_214"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies and estimates are those policies and estimates that are most important and material to the preparation of our Consolidated Financial Statements, and which require management&#8217;s most subjective and complex judgments due to the need to select policies from among alternatives available, and to make estimates about matters that are inherently uncertain. We base our estimates on historical experience and other factors that we believe to be reasonable under the circumstances. On an ongoing basis, we review our estimates to ensure that these estimates appropriately reflect changes in our business and new information as it becomes available. If historical experience and other factors we use to make these estimates do not reasonably reflect future activity, our results of operations and financial condition could be materially impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye-health, GI and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services.  To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.  The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and application of the critical accounting policies associated with the revenue recognition guidance, including the policies associated with each of our product sales provisions and the table showing the activity and ending balances for our product sales provisions, are discussed in more detail in Note 2, "SIGNIFICANT ACCOUNTING POLICIES" to our audited Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-Related Contingent Consideration </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the business combinations that we have consummated include contingent consideration to be potentially paid based upon the occurrence of future events, such as sales performance and the achievement of certain future development, regulatory and sales milestones. Acquisition-related contingent consideration associated with a business combination is initially recognized at fair value and remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The estimates of fair value involve the use of acceptable valuation methods, such as probability-weighted discounted cash flow analysis and Monte Carlo Simulation (when appropriate), and contain uncertainties as they require assumptions about the likelihood of achieving specified milestone criteria, projections of future financial performance and assumed discount rates. Changes in the fair value of the acquisition-related contingent consideration result from several factors including changes in the timing and amount of revenue estimates, changes in probability assumptions with respect to the likelihood of achieving specified milestone criteria and changes in discount rates.  A change in any of these assumptions could produce a different fair value, which could have a material impact on our results of&#160;operations.  At December&#160;31, 2021, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 6% to 18%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate potential impairments of amortizable intangible assets acquired through asset acquisitions or business combinations if events or changes in circumstances indicate that the carrying amounts of these assets may not be recoverable. Our evaluation is based on an assessment of potential indicators of impairment, such&#160;as:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an adverse change in legal factors or in the business climate that could affect the value of an asset. For example, a successful challenge of our patent rights resulting in earlier than expected generic competition;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an adverse change in the extent or manner in which an asset is used or is expected to be used. For example, a decision not to pursue a product line-extension strategy to enhance an existing product due to changes in market conditions and/or technological advances;&#160;or</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">current or forecasted reductions in revenue, operating income, or cash flows associated with the use of an asset. For example, the introduction of a competing product that results in a significant loss of market&#160;share.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment exists when the carrying value of the asset exceeds the related estimated undiscounted future cash flows expected to be derived from the asset, which include the amount and timing of the projected future cash flows. If impairment exists, the carrying value of the asset is adjusted to its fair value. A discounted cash flow analysis is typically used to determine an asset's fair value, using estimates and assumptions that market participants would apply. Some of the estimates and assumptions inherent in a discounted cash flow model include the amount and timing of the projected future cash flows, and the discount rate used to reflect the risks inherent in the future cash flows. A change in any of these estimates and assumptions </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could produce a different fair value, which could have a material impact on our results of operations. In addition, an intangible asset&#8217;s expected useful life can increase estimation risk, as longer-lived assets necessarily require longer-term cash flow forecasts, which for some of our intangible assets can be up to 20&#160;years. In connection with an impairment evaluation, we also reassess the remaining useful life of the intangible asset and modify it, as&#160;appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management continually assesses the useful lives of the Company's long-lived assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets, including Acquired in-process research and development and the B&amp;L corporate trademark, are tested for impairment annually, or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of their fair value to carrying value, without consideration of any recoverability test. In particular, we will continue to monitor closely the progression of our R&amp;D programs as their likelihood of success is contingent upon the achievement of future milestones.  See Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212;&#160;Overview &#8212;&#160;Focus on Core Business&#8221; for additional information regarding our R&amp;D&#160;programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill </span></div><div style="padding-right:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment.  The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit's terminal value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To forecast a reporting unit's cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management's and a market participant's view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected LOE to the Company's product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#8217;s control could have a positive or negative impact on achieving its targets.  Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2019 by first assessing qualitative factors. Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit. In each quantitative fair value test performed, the fair value was greater than the carrying value of the reporting unit.  As a result, there was no impairment to the goodwill of any reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Interim Goodwill Impairment Assessment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2020, after giving consideration to the nature and timing of the negative impacts of the COVID-19 pandemic on the Company's forecasted cash flows, with the exception of the Ortho Dermatologics reporting unit, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, no impairments were recorded. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020 and June 30, 2020, the operating results for the Ortho Dermatologics reporting unit were less than forecasted primarily due to certain products experiencing longer launch cycles than originally anticipated as a result of the COVID-19 pandemic. The Company revised its long-term forecasts as of March 31, 2020 and as of </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2020 for these matters. Management believed that these events were indicators that there was less headroom as of March 31, 2020 and June 30, 2020 as compared to the headroom calculated on the date Ortho Dermatologics goodwill was previously tested for impairment. Therefore, a quantitative fair value test for impairment to the goodwill of the Ortho Dermatologics reporting unit was performed at March 31, 2020 and at June 30, 2020. Based on the quantitative fair value tests, the fair value of the Ortho Dermatologics reporting unit continued to be greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit at March 31, 2020 or at June 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2020 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2020, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2020, the Company considered, among other matters, a range of potential impacts of COVID-19 pandemic related matters and the limited headroom calculated on the date Ortho Dermatologics goodwill was last tested for impairment (June 30, 2020).  The Company believed that these factors may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2020, utilizing a long-term growth rate of 2.0% and a range of discount rates between 9.50% and 9.75%, in estimation of the fair value of this reporting unit.  Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Interim Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products.  In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;D spend to eliminate projects it has identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there is less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company's most recent cash flow projections as revised in the first quarter of 2021 to reflect the business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of 1.0% and a range of discount rates between 9.0% and 10.0%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at March 31, 2021, and the Company recognized a goodwill impairment of $469&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2021 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2021, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2021, the Company considered, among other matters, the limited headroom as a result of the impairment to the goodwill of the Ortho Dermatologics reporting unit when last tested (March 31, 2021) and macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The Company believed that these facts and circumstances may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2021, utilizing a long-term growth rate of 1.0% and a discount rate of 9.0%, in estimation of the fair value of this reporting unit.  Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, "INTANGIBLE ASSETS AND GOODWILL" to our audited Consolidated Financial Statements for further details on the goodwill impairments recognized in 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we are subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Other than loss contingencies that are assumed in business combinations for which we can reliably estimate the fair value, we are required to accrue for such loss contingencies if it is probable that the outcome will be unfavorable and if the amount of the loss can be reasonably estimated. We evaluate our exposure to loss based on the progress of each contingency, experience in similar contingencies and consultation with our legal counsel. We re-evaluate all contingencies as additional information becomes available. Given the uncertainties inherent in complex litigation and other contingencies, these evaluations can involve significant judgment about future events. The ultimate outcome of any litigation or other contingency may be material to our results of operations, financial condition and cash flows. See Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements for further details regarding our current legal proceedings. If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations in various countries that have differing tax laws and rates. Our tax structure is supported by current domestic tax laws in the countries in which we operate and the application of tax treaties between the various countries in which we operate. Our income tax reporting is subject to audit by domestic and foreign tax authorities. Our effective tax rate may change from year to year based on changes in the mix of activities and income earned under our intercompany arrangements among the different jurisdictions in which we operate, changes in tax laws in these jurisdictions, changes in tax treaties between various countries in which we operate, changes in our eligibility for benefits under those tax treaties and changes in the estimated values of deferred tax assets and liabilities. Such changes could result in an increase in the effective tax rate on all or a portion of our income and/or any of our subsidiaries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes is based on a number of estimates and assumptions made by management. Our consolidated income tax rate is affected by the amount of income earned in our various operating jurisdictions, the availability of benefits under tax treaties and the rates of taxes payable in respect of that income. We enter into many transactions and arrangements in the ordinary course of business in which the tax treatment is not entirely certain. We must therefore make estimates and judgments based on our knowledge and understanding of applicable tax laws and tax treaties, and the application of those tax laws and tax treaties to our business, in determining our consolidated tax provision. For example, certain countries could seek to tax a greater share of income than has been provided for by us. The final outcome of any audits by taxation authorities may differ from the estimates and assumptions we have used in determining our consolidated income tax provisions and accruals. This could result in a material effect on our consolidated income tax provision, results of operations, and financial condition for the period in which such determinations are&#160;made.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax returns are subject to audit in various jurisdictions. Existing and future audits by, or other disputes with, tax authorities may not be resolved favorably for us and could have a material adverse effect on our reported effective tax rate and after-tax cash flows. We record liabilities for uncertain tax positions, which involve significant management judgment. New laws and new interpretations of laws and rulings by tax authorities may affect the liability for uncertain tax positions. Due to the subjectivity and complex nature of the underlying issues, actual payments or assessments may differ from our estimates. To the extent that our estimates differ from amounts eventually assessed and paid our income and cash flows may be materially and adversely affected.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether it is more likely than not that we will realize the tax benefits associated with our deferred tax assets and establish a valuation allowance for assets that are not expected to result in a realized tax benefit. A significant amount of judgment is used in this process, including preparation of forecasts of future taxable income and evaluation of tax planning initiatives. If we revise these forecasts or determine that certain planning events will not occur, an adjustment to the valuation allowance will be made to tax expense in the period such determination is&#160;made.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_217"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEW ACCOUNTING STANDARDS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the recently issued new accounting guidance (adopted and not adopted as of December 31, 2021) is contained in Note 2, "SIGNIFICANT ACCOUNTING POLICIES" to our audited Consolidated Financial Statements.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_220"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caution regarding forward-looking information and statements and &#8220;Safe-Harbor&#8221; statements under the U.S.&#160;Private Securities Litigation Reform Act of&#160;1995 and applicable Canadian securities laws:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent any statements made in this Form&#160;10-K contain information that is not historical, these statements are forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively, &#8220;forward-looking statements&#8221;).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements relate to, among other things: our business strategy, business plans and prospects and forecasts and changes thereto; product pipeline, prospective products and product approvals, expected launches of new products, product development and future performance and results of current and anticipated products; anticipated revenues for our products; expected R&amp;D and marketing spend; our expected primary cash and working capital requirements for 2022 and beyond; the Company's plans for continued improvement in operational efficiency and the anticipated impact of such plans; our liquidity and our ability to satisfy our debt maturities as they become due; our ability to reduce debt levels; our ability to comply with the financial and other covenants contained in the Restated Credit Agreement, and senior notes indentures; the impact of our distribution, fulfillment and other third-party arrangements; proposed pricing actions; exposure to foreign currency exchange rate changes and interest rate changes; the outcome of contingencies, such as litigation, subpoenas, investigations, reviews, audits and regulatory proceedings; the anticipated impact of the adoption of new accounting standards; general market conditions; our expectations regarding our financial performance, including revenues, expenses, gross margins and income taxes; our impairment assessments, including the assumptions used therein and the results thereof; the anticipated impact of the evolving COVID-19 pandemic and related responses from governments and private sector participants on the Company, its supply chain, third-party suppliers, project development timelines, costs, revenues, margins, liquidity and financial condition, the anticipated timing, speed and magnitude of recovery from these COVID-19 pandemic related impacts and the Company&#8217;s planned actions and responses to this pandemic; the Company&#8217;s plan to separate its eye- health business, including the structure and timing of completing such separation transaction; and the proposed initial public offering (&#8220;IPO&#8221;) of the Company&#8217;s Solta aesthetic medical device business, including the timing of such IPO.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements can generally be identified by the use of words such as &#8220;believe&#8221;, &#8220;anticipate&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;plan&#8221;, &#8220;continue&#8221;, &#8220;will&#8221;, &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;should&#8221;, &#8220;target&#8221;, &#8220;potential&#8221;, &#8220;opportunity&#8221;, &#8220;designed&#8221;, &#8220;create&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;, &#8220;forecast&#8221;, &#8220;seek&#8221;, &#8220;strive&#8221;, &#8220;ongoing&#8221;, &#8220;decrease&#8221; or &#8220;increase&#8221; and variations or other similar expressions. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements may not be appropriate for other purposes. Although we have previously indicated certain of these statements set out herein, all of the, statements in this Form&#160;10-K that contain forward-looking statements are qualified by these cautionary statements. These statements are based upon the current expectations and beliefs of management. Although we believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making such forward-looking statements, including, but not limited to, factors and assumptions regarding the items previously outlined, those factors, risks and uncertainties outlined below and the assumption that none of these factors, risks and uncertainties will cause actual results or events to differ materially from those described in such forward-looking statements. Actual results may differ materially from those expressed or implied in such statements. Important factors, risks and uncertainties that could cause actual results to differ materially from these expectations include, among other things, the&#160;following:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">the risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, the fear of that pandemic, the availability and effectiveness of vaccines for COVID-19 (including with respect to current or future variants), COVID-19 vaccine immunization rates, the emergence of variant strains of COVID-19, the evolving reaction of governments, private sector participants and the public to that pandemic, and the potential effects and economic impact of the pandemic and the reaction to it, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a significant adverse impact on the Company, including but not limited to its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition and costs (which may increase) and revenue and margins (both of which may decrease);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">with respect to the proposed separation of the Company&#8217;s eye-health business, the risks and uncertainties include, but are not limited to, the expected benefits and costs of the separation transaction, the expected timing of completion of the separation transaction and its terms, (including the Company&#8217;s expectation that it will launch the IPO of the Bausch </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+ Lomb entity when financial market conditions are favorable, subject to receipt of regulatory, stock exchange and other approvals, and the Company&#8217;s expectation that the separation transaction will be completed following the expiry of customary lockups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to receipt of applicable shareholder and other necessary approvals), the Company&#8217;s ability to complete the separation transaction considering the various conditions to the completion of the separation transaction (some of which are outside the Company&#8217;s control, including conditions related to regulatory matters and a possible shareholder vote, if applicable), that market or other conditions are no longer favorable to completing the transaction, that any shareholder, stock exchange, regulatory or other approval (if required) is not obtained on the terms or timelines anticipated or at all, business disruption during the pendency of or following the separation transaction, diversion of management time on separation transaction-related issues, retention of existing management team members, the reaction of customers and other parties to the separation transaction, the qualification of the separation transaction as a tax-free transaction for Canadian and/or U.S. federal income tax purposes (including whether or not an advance ruling from the Canada Revenue Agency will be sought or obtained), the ability of the Company and the separated entity to satisfy the conditions required to maintain the tax-free status of the separation transaction (some of which are beyond their control), the ability of the Company and the separated entity to satisfy the conditions required to maintain the tax-free status of the separation transaction (some of which are beyond their control), the potential dissynergy costs resulting from the separation transaction, the impact of the separation transaction on relationships with customers, suppliers, employees and other business counterparties, general economic conditions, conditions in the markets the Company is engaged in, behavior of customers, suppliers and competitors, technological developments, as well as legal and regulatory rules affecting the Company&#8217;s business. In particular, the Company can offer no assurance that any IPO or separation will occur at all, or that any such transaction will occur on the timelines anticipated by the Company;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">with respect to the proposed IPO of the Company&#8217;s Solta aesthetic medical device business, the risks and uncertainties include, but are not limited to, risks relating to the expected timing of completion of such transaction (including the Company&#8217;s expectation that it will launch such IPO when financial market conditions are favorable, subject to receipt of regulatory, stock exchange and other approvals) and the Company&#8217;s ability to complete such transaction, that market or other conditions are no longer favorable to completing the transaction on a timely basis or at all, the receipt of (or failure to receive) any stock exchange, regulatory and other approvals required in connection with the transaction and the timing of receipt of such approvals, business disruption during the pendency of or following such transaction, diversion of management time on transaction-related issues, retention of Solta aesthetic medical device management team members, the reaction of customers and other parties to such transaction, the impact of such transaction on relationships with customers, suppliers, employees and other business counterparties, and other events that could adversely impact the completion of such transaction, including industry or economic conditions outside of Bausch Health&#8217;s control. In particular, the Company can offer no assurance that any IPO will occur at all, or that any such transaction will occur on the timelines anticipated by the Company;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of legal and governmental proceedings, investigations and information requests relating to, among other matters, our past distribution, marketing, pricing, disclosure and accounting practices (including with respect to our former relationship with Philidor Rx Services, LLC ("Philidor")), including a number of pending non-class securities litigations (including certain pending opt-out actions in the U.S. related to the previously settled securities class action (which remains subject to an objector's appeal of the Court's final approval order) and certain opt-out actions in Canada relating to the recently settled class action in Canada), certain pending lawsuits and other claims, investigations or proceedings that may be initiated or that may be asserted;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential additional litigation and regulatory investigations (and any costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom), negative publicity and reputational harm on our Company, products and business that may result from the past and ongoing public scrutiny of our past distribution, marketing, pricing, disclosure and accounting practices and from our former relationship with Philidor;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the past and ongoing scrutiny of our legacy business practices, including with respect to pricing, and any pricing controls or price adjustments that may be sought or imposed on our products as a result thereof; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing decisions that we have implemented, or may in the future elect to implement, such as the Patient Access and Pricing Committee&#8217;s historic practice of limiting the average annual price increase for our branded prescription pharmaceutical products to single digits, or any future pricing actions we may take in 2022 or beyond following review by our Patient Access and Pricing Committee (which is responsible for the pricing of our drugs);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">legislative or policy efforts, including those that may be introduced and passed by the U.S. Congress, designed to reduce patient out-of-pocket costs for medicines, which could result in new mandatory rebates and discounts or other pricing restrictions, controls or regulations (including mandatory price reductions);</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing oversight and review of our products and facilities by regulatory and governmental agencies, including periodic audits by the U.S.&#160;Food and Drug Administration (the "FDA") and equivalent agencies outside of the U.S. and the results thereof;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions by the FDA or other regulatory authorities with respect to our products or facilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with the legal and regulatory requirements of our marketed products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our substantial debt (and potential additional future indebtedness) and current and future debt service obligations, our ability to reduce our outstanding debt levels and the resulting impact on our financial condition, cash flows and results of operations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with the financial and other covenants contained in our Restated Credit Agreement, senior notes indentures, 2023 Revolving Credit Facility (as defined below) and other current or future credit and/or debt agreements and the limitations, restrictions and prohibitions such covenants impose or may impose on the way we conduct our business, including prohibitions on incurring additional debt if certain financial covenants are not met, limitations on the amount of additional obligations we are able to incur pursuant to other covenants, our ability to draw under our 2023 Revolving Credit Facility and restrictions on our ability to make certain investments and other restricted payments;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any default under the terms of our senior notes indentures or Restated Credit Agreement (and other current or future credit and/or debt agreements) and our ability, if any, to cure or obtain waivers of such default;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any downgrade by rating agencies in our credit ratings, which may impact, among other things, our ability to raise debt and the cost of capital for additional debt issuances;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any reductions in, or changes in the assumptions used in, our forecasts for fiscal year 2022 or beyond, including as a result of the impacts of the COVID-19 pandemic on our business and operations, which could lead to, among other things: (i) a failure to meet the financial and/or other covenants contained in our Restated Credit Agreement and/or senior notes indentures (and other current or future credit and/or debt agreements) and/or (ii) impairment in the goodwill associated with certain of our reporting units or impairment charges related to certain of our products or other intangible assets, which impairments could be material;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the assumptions used in connection with our impairment analyses or assessments, which would lead to a change in such impairment analyses and assessments and which could result in an impairment in the goodwill associated with any of our reporting units or impairment charges related to certain of our products or other intangible assets;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the uncertainties associated with the acquisition and launch of new products, assets and businesses, including, but not limited to, our ability to provide the time, resources, expertise and funds required for the commercial launch of new products, the acceptance and demand for new products, and the impact of competitive products and&#160;pricing, which could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or inability to extend the profitable life of our products, including through line extensions and other life-cycle programs;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain, motivate and recruit executives and other key&#160;employees;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to implement effective succession planning for our executives and key employees;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to stabilize and reposition our Ortho Dermatologics business to generate additional value, including the success of recently launched products  and the approval of pipeline products (and the timing of such approvals);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated revenues for our products, including changes in anticipated marketing spend on such products and launch of competing products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated market acceptance for our products, including acceptance of the pricing, effectiveness of promotional efforts, reputation of our products and launch of competing products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the challenges and difficulties associated with managing a large complex business, which has, in the past, grown rapidly;</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to compete against companies that are larger and have greater financial, technical and human resources than we do, as well as other competitive factors, such as technological advances achieved, patents obtained and new products introduced by our competitors;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively operate and grow our businesses in light of the challenges that the Company has faced and market conditions, including with respect to its substantial debt, pending investigations and legal proceedings, scrutiny of our past pricing and other practices, limitations on the way we conduct business imposed by the covenants contained in our Restated Credit Agreement, senior notes indentures and the agreements governing our other indebtedness, and the impacts of the COVID-19 pandemic;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our products are reimbursed by government authorities, pharmacy benefit managers ("PBMs") and other third-party payors; the impact our distribution, pricing and other practices may have on the decisions of such government authorities, PBMs and other third-party payors to reimburse our products; and the impact of obtaining or maintaining such reimbursement on the price and sales of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inclusion of our products on formularies or our ability to achieve favorable formulary status, as well as the impact on the price and sales of our products in connection therewith;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the consolidation of wholesalers, retail drug chains and other customer groups and the impact of such industry consolidation on our business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain strong relationships with physicians and other healthcare professionals;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our eligibility for benefits under tax treaties and the continued availability of low effective tax rates for the business profits of certain of our subsidiaries;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of the Organisation for Economic Co-operation and Development inclusive framework on Base Erosion and Profit Shifting, including the global minimum corporate tax rate, by the countries in which we operate; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of any audits by taxation authorities, which outcomes may differ from the estimates and assumptions that we may use in determining our consolidated tax provisions and accruals;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the actions of our third-party partners or service providers of research, development, manufacturing, marketing, distribution or other services, including their compliance with applicable laws and contracts, which actions may be beyond our control or influence, and the impact of such actions on our Company;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risks associated with the international scope of our operations, including our presence in emerging markets and the challenges we face when entering and operating in new and different geographic markets (including the challenges created by new and different regulatory regimes in such countries and the need to comply with applicable anti-bribery and economic sanctions laws and regulations);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse global economic conditions and credit markets and foreign currency exchange uncertainty and volatility in certain of the countries in which we do&#160;business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the trade conflict between the United States and China;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential conflict between Russia and Ukraine and any restrictive actions that may be taken by the U.S. and/or other countries in response thereto, such as sanctions or export controls;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain and license sufficient intellectual property rights over our products and enforce and defend against challenges to such intellectual property (such as in connection with the filing by Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;) of its Abbreviated New Drug Application (&#8220;ANDA&#8221;) for Xifaxan&#174; (rifaximin) 550 mg tablets and the Company&#8217;s related lawsuit filed against Norwich in connection therewith);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of generic, biosimilar or other competitors of our branded products and other products, including the introduction of products that compete against our products that do not have patent or data exclusivity rights;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, finance, acquire, close and integrate acquisition targets successfully and on a timely basis and the difficulties, challenges, time and resources associated with the integration of acquired companies, businesses and products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any divestitures of our assets or businesses and our ability to successfully complete any such divestitures on commercially reasonable terms and on a timely basis, or at all, and the impact of any such divestitures on our Company, including the reduction in the size or scope of our business or market share, loss of revenue, any loss on </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sale, including any resultant impairments of goodwill or other assets, or any adverse tax consequences suffered as a result of any such divestitures;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of pending or future legal and governmental proceedings, arbitrations, investigations, subpoenas, tax and other regulatory audits, examinations, reviews and regulatory proceedings against us or relating to us and settlements thereof;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to negotiate the terms of or obtain court approval for the settlement of certain legal and regulatory proceedings;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain components, raw materials or finished products supplied by third&#160;parties (some of which may be single-sourced) and other manufacturing and related supply difficulties, interruptions and delays;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the disruption of delivery of our products and the routine flow of manufactured goods;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic factors over which the Company has no control, including changes in inflation, interest rates, foreign currency rates, and the potential effect of such factors on revenues, expenses and resulting margins;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interest rate risks associated with our floating rate debt borrowings;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively distribute our products and the effectiveness and success of our distribution arrangements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively promote our own products and those of our co-promotion partners;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our fulfillment arrangements with Walgreen Co. including market acceptance of, or market reaction to, such arrangements (including by customers, doctors, patients, PBMs, third-party payors and governmental agencies), and the continued compliance of such arrangements with applicable laws;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to secure and maintain third-party research, development, manufacturing, licensing, marketing or distribution arrangements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that our products could cause, or be alleged to cause, personal injury and adverse effects, leading to potential lawsuits, product liability claims and damages and/or recalls or withdrawals of products from the&#160;market;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the mandatory or voluntary recall or withdrawal of our products from the market and the costs associated therewith;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of, and our ability to obtain and maintain, adequate insurance coverage and/or our ability to cover or insure against the total amount of the claims and liabilities we face, whether through third-party insurance or self-insurance;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our indemnity agreements, which may result in an obligation to indemnify or reimburse the relevant counterparty, which amounts may be material;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the difficulty in predicting the expense, timing and outcome within our legal and regulatory environment, including with respect to approvals by the FDA, Health Canada, European Medicines Agency ("EMA") and similar agencies in other countries, legal and regulatory proceedings and settlements thereof, the protection afforded by our patents and other intellectual and proprietary property, successful generic challenges to our products and infringement or alleged infringement of the intellectual property of&#160;others;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of continuing safety and efficacy studies by industry and government agencies;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of preclinical and clinical trials for our drug development pipeline or delays in clinical trials that adversely impact the timely commercialization of our pipeline products, as well as other factors impacting the commercial success of our products, which could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties around the successful improvement and modification of our existing products and development of new products, which may require significant expenditures and efforts;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the results of management reviews of our research and development portfolio (including following the receipt of clinical results or feedback from the FDA or other regulatory authorities), which could result in terminations of specific projects which, in turn, could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the seasonality of sales of certain of our products;</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">declines in the pricing and sales volume of certain of our products that are distributed or marketed by third parties, over which we have no or limited control;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance by the Company or our third-party partners and service providers (over whom we may have limited influence), or the failure of our Company or these third parties to comply, with health care &#8220;fraud and abuse&#8221; laws and other extensive regulation of our marketing, promotional and business practices (including with respect to pricing), worldwide anti-bribery laws (including the U.S. Foreign Corrupt Practices Act and the Canadian Corruption of Foreign Public Officials Act), worldwide economic sanctions and/or export laws, worldwide environmental laws and regulation and privacy and security regulations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impacts of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 and potential amendment thereof and other legislative and regulatory health care reforms in the countries in which we operate, including with respect to recent government inquiries on pricing;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any changes in or reforms to the legislation, laws, rules, regulation and guidance that apply to the Company and its businesses and products or the enactment of any new or proposed legislation, laws, rules, regulations or guidance that will impact or apply to the Company or its businesses or products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of changes in federal laws and policy that may be undertaken under the Biden administration;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">illegal distribution or sale of counterfeit versions of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruptions, breakdowns or breaches in our information technology systems; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks in Item 1A. &#8220;Risk Factors&#8221; in this Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found elsewhere in this Form 10-K, under Item 1A. "Risk Factors" and in the Company's other filings with the SEC and the CSA. When relying on our forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. These forward-looking statements speak only as of the date made. We undertake no obligation to update or revise any of these forward-looking statements to reflect events or circumstances after the date of this Form&#160;10-K or&#160;to reflect actual outcomes, except as required by law. We caution that, as it is not possible to predict or identify all relevant factors that may impact forward-looking statements, the foregoing list of important factors that may affect future results is not exhaustive and should not be considered a complete statement of all potential risks and uncertainties.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_223"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A.&#160;&#160;&#160;&#160;Quantitative and&#160;Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to quantitative and qualitative disclosures about market risk is detailed in Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#160;&#8212;&#160;Quantitative and Qualitative Disclosures About Market Risk&#8221; and is incorporated herein by&#160;reference.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_226"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8.&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is contained in the financial statements set forth in Item&#160;15. &#8220;Exhibits and Financial Statement Schedules&#8221; as part of this Form&#160;10-K and&#160;is incorporated herein by&#160;reference.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_229"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_232"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A.&#160;&#160;&#160;&#160;Controls and&#160;Procedures </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management, with the participation of the Company&#8217;s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) as of December&#160;31, 2021.  Based on that evaluation, the Company&#8217;s Chief Executive Officer and the Company&#8217;s Chief Financial Officer have concluded that as of December&#160;31, 2021, the Company&#8217;s disclosure controls and procedures were effective to provide reasonable assurance that the information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules&#160;13a-15(f) and&#160;15d-15(f) under the Exchange Act. The Company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of management, including the Company&#8217;s Chief Executive Officer and the Company&#8217;s Chief Financial Officer, the Company conducted an evaluation of the effectiveness of its internal control over financial reporting as of December&#160;31, 2021 based on the framework described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.  Based on that evaluation, management has concluded that the Company maintained effective internal control over financial reporting as of December&#160;31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of the Company&#8217;s internal control over financial reporting as of December&#160;31, 2021 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears herein.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have not been any changes in the Company&#8217;s internal control over financial reporting (as&#160;such term is defined in Rules&#160;13a-15(f) and&#160;15d-15(f) under the Exchange Act) during the last fiscal quarter of 2021 that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_235"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_2906"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9C.&#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_238"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_241"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;10.&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required under this Item is incorporated herein by reference from information included in the 2022 Proxy Statement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors has adopted a code of ethics (the "Code of Conduct") that applies to our Chief Executive Officer, Chief Financial Officer, the principal accounting officer, controller, and all vice presidents and above in the finance department of the Company worldwide. A copy of the Code of Conduct can be found on our website at: </span><span style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.bauschhealth.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We intend to satisfy the SEC disclosure requirements regarding amendments to, or waivers from, any provisions of our Code of Conduct on our&#160;website.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_244"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;11.&#160;&#160;&#160;&#160;Executive Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required under this Item relating to executive compensation is incorporated herein by reference from information included in the 2022 Proxy Statement.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_247"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;12.&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required under this Item relating to securities authorized for issuance under equity compensation plans and to security ownership of certain beneficial owners and management is incorporated herein by reference from information included in the 2022 Proxy Statement.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_250"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;13.&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required under this Item relating to certain relationships and transactions with related parties and about director independence is incorporated herein by reference from information included in the 2022 Proxy Statement.</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_253"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;14.&#160;&#160;&#160;&#160;Principal Accounting Fees and Services</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required under this Item relating to the fees for professional services rendered by our independent auditors in 2021 and 2020 is incorporated herein by reference from information included in the 2022 Proxy Statement.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_256"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_259"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15.&#160;&#160;&#160;&#160;Exhibits and Financial Statement Schedules</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Documents filed as a part of the report:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The consolidated financial statements required to be filed in the Annual Report on Form&#160;10-K are listed on page F-1 hereof.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All schedules are omitted because they are not applicable or the required information is included in the financial statements or notes.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;16.&#160;&#160;&#160;&#160;Form 10-K Summary</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_262"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="-sec-extract:summary;margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO EXHIBITS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312513331879/d583672dex31.htm">Certificate of Continuation, dated August&#160;9, 2013, originally filed as Exhibit 3.1 to the Company's Current Report on Form 8-K filed on August 13, 2013, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312513331879/d583672dex32.htm">Notice of Articles of Valeant Pharmaceuticals International, Inc., dated August 9, 2013, originally filed as Exhibit 3.2 to the Company's Current Report on Form 8-K filed on August 13, 2013, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312513331879/d583672dex33.htm">Articles of Valeant Pharmaceuticals International, Inc., dated August 8, 2013, originally filed as Exhibit 3.3 to the Company's Current Report on Form 8-K filed on August 13, 2013, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000095010318008539/dp93294_ex0301.htm">Notice of Articles of Bausch Health Companies Inc., as of July 16, 2018, originally filed as Exhibit 3.1 to&#160;the Company's Current Report on Form 8-K filed</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000095010318008539/dp93294_ex0301.htm"> on July 16, 2018, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000095010318008539/dp93294_ex0302.htm">Articles of Bausch Health Companies Inc., as of July 13, 2018, originally filed as Exhibit 3.2 to&#160;the Company's Current Report on Form 8-K filed</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000095010318008539/dp93294_ex0302.htm"> on July 16, 2018, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312515109400/d900048dex41.htm">Indenture, dated as of March 27, 2015 (the &#8220;VRX Escrow Corp Indenture&#8221;), between VRX Escrow Corp., the Bank of New York Mellon Trust Company, N.A., as trustee, registrar and US paying agent, and The Bank of New York Mellon, acting through its London branch, as the Euro paying agent, governing the 5.375% Senior Notes due 2020 (the &#8220;2020 Notes&#8221;), the 5.875% Senior Notes due 2023 (the &#8220;May 2023 Notes&#8221;), the 4.5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312515109400/d900048dex41.htm">0</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312515109400/d900048dex41.htm">0% Senior Notes due 2023 (the &#8220;Euro Notes&#8221;) and the 6.125% Senior Notes due 2025 (the &#8220;2025 Notes&#8221; and together with the 2020 Notes, the May 2023 Notes and the Euro Notes, the &#8220;Notes&#8221;), originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on March 27, 2015, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312515109400/d900048dex42.htm">First Supplemental Indenture to the VRX Escrow Corp Indenture, dated as of March 27, 2015, between Valeant Pharmaceuticals International, Inc., the guarantors named therein and the Bank of New York Mellon Trust Company, N.A., as trustee, governing the Notes, originally filed as Exhibit 4.2 to the Company's Current Report on Form 8-K filed on March 27, 2015, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000095010317002656/dp74230_ex401.htm">Indenture, dated as of March 21, 2017, by and among Valeant Pharmaceuticals International, Inc., the guarantors party thereto, The Bank of New York Mellon, as trustee and the notes collateral agents party thereto, governing the 6.5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000095010317002656/dp74230_ex401.htm">0</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000095010317002656/dp74230_ex401.htm">0% Senior Secured Notes due 2022 and the 7.0</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000095010317002656/dp74230_ex401.htm">0</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000095010317002656/dp74230_ex401.htm">0% Senior Secured Notes due 2024, originally filed as Exhibit&#160;4.1 to&#160;the Company&#8217;s Current Report on Form&#160;8-K filed on March 21, 2017, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312517311840/d213139dex41.htm">Indenture, dated as of October&#160;17, 2017, by and among Valeant Pharmaceuticals International, Inc., the guarantors party thereto, The Bank of New York Mellon, as trustee and the notes collateral agents party thereto, governing the 5.5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312517311840/d213139dex41.htm">0</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312517311840/d213139dex41.htm">0% Senior Secured Notes due 2025, originally filed as Exhibit&#160;4.1 to&#160;the Company&#8217;s Current Report on Form&#160;8-K filed on October 17, 2017, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312517372069/d513316dex41.htm">Indenture, dated as of December 18, 2017, by and among Valeant Pharmaceuticals International, Inc., the guarantors party thereto and The Bank of New York Mellon, as trustee, governing the 9.0</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312517372069/d513316dex41.htm">0</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312517372069/d513316dex41.htm">0% Senior Notes due 2025, originally filed as Exhibit&#160;4.1 to&#160;the Company&#8217;s Current Report on Form&#160;8-K filed on December 18, 2017, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559018000020/a90716981v2-valeantxindent.htm">Indenture, dated as of March 26, 2018, by and among Valeant Pharmaceuticals International, Valeant Pharmaceuticals International, Inc., the other guarantors party thereto and The Bank of New York Mellon, as trustee,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559018000020/a90716981v2-valeantxindent.htm"> governing the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559018000020/a90716981v2-valeantxindent.htm">9.250% Senior Secured Notes due 2026,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559018000020/a90716981v2-valeantxindent.htm"> originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on March 27, 2018, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312518181925/d506785dex41.htm">Indenture, dated as of June 1, 2018, by and among Valeant Pharmaceuticals International, Valeant Pharmaceuticals international, Inc., the other guarantors party thereto and The Bank of New York Mellon, as trustee, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312518181925/d506785dex41.htm">governing the 8.500% Senior Secure</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312518181925/d506785dex41.htm">d Notes due 2027, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312518181925/d506785dex41.htm">originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on June 1, 2018, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312519069218/d717351dex41.htm">Indenture, dated as of March 8, 2019, by and among Bausch Health Companies Inc., the guarantors named therein, The Bank of New York Mellon Trust Company, N.A., as trustee, and the notes collateral agents party thereto, governing the 5.750% Senior Secured Notes due 2027, originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on March 8, 2019, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312519155605/d746123dex41.htm">Indenture, dated as of May 23, 2019, by and among Bausch Health Companies Inc., the guarantors named therein and The Bank of New York Mellon Trust Company, N.A., as trustee, governing the 7.000% Senior Notes due 2028 and the 7.250% Senior Notes due 2029, originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on May 24, 2019, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312519326023/d851034dex41.htm">Indenture, dated as of December 30, 2019, by and among Bausch Health Companies Inc., the guarantors named therein and The Bank of New York Mellon Trust Company, N.A., as trustee, governing the 5.000% Senior Notes due 2028 and the 5.250% Senior Notes due 2030, originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on December 30, 2019, which is incorporated by reference herein.</a></span></div></td></tr></table></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312520151620/d892097dex41.htm">Indenture, dated as of May 26, 2020, by and among Bausch Health Companies Inc., the guarantors named therein and The Bank of New York Mellon Trust Company, N.A., as trustee, governing the 6.250% Senior Notes due 2029, originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on May 26, 2020, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312520309615/d73841dex41.htm">Indenture, dated as of December 3, 2020, by and among Bausch Health Companies Inc., the guarantors named therein and The Bank of New York Mellon, N.A., as trustee, governing the 5.000% Senior Notes due 2029 and the 5.250% Senior Notes due 2031, originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on December 3, 2020, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312521185432/d186085dex41.htm">Indenture, dated as of June 8, 2021, by and among Bausch Health Companies Inc., the guarantors named therein and The Bank of New York Mellon, N.A., as trustee, governing the 4.875% Senior Notes due 2028, originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on June 8, 2021, which is incorporated by reference herein</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312521185432/d186085dex41.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522034549/d293207dex41.htm">Indenture, dated as of February 10, 2022, by and among Bausch Health Companies Inc., the guarantors named therein, The Bank of New York Mellon, N.A., as trustee and the notes collateral agents party thereto, governing the 6.125% Senior Secured Notes due 2027, originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on February 10, 2022, which is incorporated by reference herein</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522034549/d293207dex41.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000095010318008539/dp93294_ex0401.htm">Form of Common Share Certificate of Bausch Health Companies Inc., originally filed as Exhibit 4.1 to&#160;the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on July 16, 2018, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559020000006/exhibit4122019ye.htm">Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, As Amended, originally filed as Exhibit 4.12 to the Company&#8217;s Annual Report on Form 10-K</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559020000006/exhibit4122019ye.htm"> for the fiscal year ended December 31, 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559020000006/exhibit4122019ye.htm">19,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559020000006/exhibit4122019ye.htm"> filed on February 19, 2020, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000011/exhibit1012020ye.htm">Bausch Health Companies Inc. Further Amended and Restated 2014 Omnibus Incentive Plan, effective as of April 28, 2020 (the "Amended and Restated 2014 Omnibus Incentive Plan")</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000011/exhibit1012020ye.htm">, originally filed as Exhibit 10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000011/exhibit1012020ye.htm">.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000011/exhibit1012020ye.htm">1 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed on February 24, 2021, whi</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000011/exhibit1012020ye.htm">ch is incorporated by reference herein</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000011/exhibit1012020ye.htm">.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559018000047/exhibit104msuagreement.htm">Form of Matching Restricted Stock Unit Agreement (Matching Units) under the Amended and Restated 2014 Omnibus Incentive Plan, originally filed as Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559018000047/exhibit104msuagreement.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559018000047/exhibit104msuagreement.htm">for the quarter ended June 30, 2018</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559018000047/exhibit104msuagreement.htm"> filed on August 7, 2018, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559019000017/a10qq12019-exhibit103.htm">Form of 2016 Stock Option Grant Agreement under the Amended and Restated 2014 Omnibus Incentive Plan, originally filed as Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed on May 6, 2019, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559018000017/a10k2017-exhibit103xstocko.htm">Form of Stock Option Grant Agreement (Nonstatutory Stock Options), under the Amended and Restated 2014 Omnibus Incentive Plan, originally filed as Exhibit 10.3 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed on February 28, 2018, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559018000017/a10k2017-exhibit106xdirect.htm">Form of Director Restricted Share Units Award Agreement (Annual Grants), under the Amended and Restated 2014 Omnibus Incentive Plan, originally filed as Exhibit 10.6 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed on February 28, 2018, which is incorporated by reference herein. &#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559017000015/d343902dex1017.htm">Form of Stock Option Grant Agreement (Nonstatutory Stock Options), under the Amended and Restated 2014 Omnibus Incentive Plan, originally filed as Exhibit 10.17 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2016 filed on March 1, 2017, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559018000017/a10k2017-exhibit1011xformo.htm">Form of 2018 Share Unit Grant Agreement (Performance Vesting) (Performance Restricted Share Units), under the Amended and Restated 2014 Omnibus Incentive Plan, originally filed as Exhibit 10.11 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed on February 28, 2018, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559018000017/a10k2017-exhibit1012xformo.htm">Form of 2018 Restricted Stock Unit Agreement, under the Amended and Restated 2014 Omnibus Incentive Plan, originally filed as Exhibit 10.12 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed on February 28, 2018, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559018000017/a10k2017-exhibit1013xformo.htm">Form of 2018 Stock Option Grant Agreement (Nonstatutory Stock Options), under the Amended and Restated 2014 Omnibus Incentive Plan, originally filed as Exhibit 10.13 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed on February 28, 2018, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000030/exhibit102q12021.htm">Form of 2021 Share Unit Grant Agreement (Performance Vesting) (Performance Restricted Share Units), under the Amended and Restated 2014 Omnibus Incentive Plan, originally filed as Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 filed on May 4, 2021, which is incorporated by reference herein.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000030/exhibit102q12021.htm">&#8224; </a></span></div></td></tr></table></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000055/exhibit101-formof2021share.htm">Form of 2021 Share Unit Grant Agreement (TSR Performance Restricted Share Units), under the Amended and Restated 2014 Omnibus Incentive Plan, originally filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 filed on November 2, 2021, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000134100411001049/defa14a.htm">Valeant Pharmaceuticals International,&#160;Inc.&#160;2011 Omnibus Incentive Plan (the &#8220;2011&#160;Omnibus Incentive Plan&#8221;), effective as of April&#160;6, 2011, as amended on and approved by the shareholders on May&#160;16, 2011, originally filed as Annex&#160;A to&#160;the Company's Management Proxy Circular and Proxy Statement on Schedule&#160;14A filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000134100411001049/defa14a.htm">on April&#160;14, 2011, as amended by the Supplement dated May&#160;10, 2011 to the Company's Management Proxy Circular and Proxy Statement filed</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000134100411001049/defa14a.htm"> on May&#160;10, 2011, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000104746912001906/a2207517zex-10_2.htm">Form of Stock Option Grant Agreement under the 2011 Omnibus Incentive Plan, originally filed as Exhibit&#160;10.2 to&#160;the Company's Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2011 filed on February 28, 2012, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000011/exhibit10142020ye.htm">Form of Spinoff Bonus Program Letter Agreement dated November 2, 2020</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000011/exhibit10142020ye.htm">, o</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000011/exhibit10142020ye.htm">riginally filed as Exhibit 10.14 to the Company's Annual Report on Form 10-K for the fisc</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000011/exhibit10142020ye.htm">al year ended December 31, 2020 filed on February 24, 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000011/exhibit10142020ye.htm">021, which</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000011/exhibit10142020ye.htm"> is incorporated by reference herein</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000011/exhibit10142020ye.htm">.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000104746911007046/a2205082zex-10_6.htm">Valeant Pharmaceuticals International,&#160;Inc. Directors Share Unit Plan, effective May&#160;16, 2011, originally filed as Exhibit&#160;10.6 to the Company's Quarterly Report on Form&#160;10-Q for the fiscal quarter ended June&#160;30, 2011 filed on August 8, 2011, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000134100416001356/ex-agmt.htm">Employment Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000134100416001356/ex-agmt.htm">, dated as of April 25, 2016,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000134100416001356/ex-agmt.htm"> between Valeant Pharmaceuticals International, Inc. and Joseph C. Papa, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000134100416001356/ex-agmt.htm">originally filed as Exhibit&#160;10.1 to&#160;the Company's Current Report on Form&#160;8-K filed on April 27, 2016, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312516688829/d244487dex101.htm">Employment Agreement, dated as of August 17, 2016, between Valeant Pharmaceuticals International, Inc. and Paul S. Herendeen, originally filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on August 23, 2016, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000055/exhibit102-amendmenttohere.htm">Amendment to Employment Agreement, dated as of April 28, 2021, between Bausch Health Companies Inc. and Paul Herendeen, originally filed as Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 filed on November 2, 2021, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559017000015/d343902dex1023.htm">Employment Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559017000015/d343902dex1023.htm">, dated July 8, 2016,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559017000015/d343902dex1023.htm"> between Valeant Pharmaceuticals International, Inc. and Christina Ackermann, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559017000015/d343902dex1023.htm">originally filed as Exhibit 10.23 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2016 filed on March 1, 2017, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10202021ye.htm">Amended and Restated Employment Agreement, dated February 18, 2022, between Bausch Health Companies Inc. and Thomas Appio. &#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559019000017/a10qq12019-exhibit102.htm">Employment Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559019000017/a10qq12019-exhibit102.htm">, dated August 2, 2018,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559019000017/a10qq12019-exhibit102.htm"> between Bausch Health Companies Inc. and Joseph F. Gordon,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559019000017/a10qq12019-exhibit102.htm"> originally filed as Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed on May 6, 2019, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000041/exhibit101q22021.htm">Employment Agreement, dated as of June 1, 2021, between Bausch Health Companies Inc. and Sam Eldessouky, originally filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended Jun</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000041/exhibit101q22021.htm">e</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000041/exhibit101q22021.htm"> 30, 2021 filed on August 3, 2021, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559018000017/a10k2017-exhibit1020xhumph.htm">Employment Agreement between Valeant Pharmaceuticals International, Inc. and William Humphries, dated December 1, 2016, originally filed as Exhibit 10.20 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed on February 28, 2018, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312518335247/d595829dex101.htm">First Incremental Amendment, dated as of November 27, 2018, to the Fourth Amended and Restated Credit and Guaranty Agreement, by and among Bausch Health Companies Inc., Valeant Pharmaceuticals International, certain subsidiaries of Bausch Health Companies Inc. as guarantors, each of the financial institutions named therein as lenders and issuing banks and Barclays Bank PLC, as Administrative Agent, originally filed as Exhibit&#160;10.1 to&#160;the Company&#8217;s Current Report on Form&#160;8-K filed on November 27, 2018, which is incorporated by reference herein and which First Incremental Amendment appends, as an exhibit thereto, a copy of such Fourth Amended and Restated Credit and Guaranty Agreement, as amended to date.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559019000006/exhibit10252018ye.htm">Amended and Restated Supply Agreement dated October 25, 2018 among Salix Pharmaceuticals, Inc., Valeant Pharmaceuticals Ireland Limited, Valeant Pharmaceuticals Luxembourg s.&#224; r.l. and Alfasigma S.p.A., originally filed as Exhibit 10.25 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed on February 20, 2019, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1009356/000119312512459233/d402656dex1095.htm">Amended and Restated License Agreement dated August 6, 2012 by and between Alfa Wassermann S.p.A. and Salix Pharmaceuticals, Inc., originally filed as Exhibit 10.95 to Salix</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1009356/000119312512459233/d402656dex1095.htm"> Pharmaceutical Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1009356/000119312512459233/d402656dex1095.htm">&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 filed on November 8, 2012, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1009356/000119312512459233/d402656dex10100.htm">Letter Amendment dated September 5, 2012 by and between Alfa Wassermann S.p.A. and Salix Pharmaceuticals, Inc., originally filed as Exhibit 10.100 to Salix</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1009356/000119312512459233/d402656dex10100.htm"> Pharmaceutical Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1009356/000119312512459233/d402656dex10100.htm">&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 filed on November 8, 2012, which is incorporated by reference herein.</a></span></div></td></tr></table></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559019000006/exhibit10282018ye.htm">Amendment No. 2 to the Amended and Restated License Agreement dated October 25, 2018 among Salix Pharmaceuticals, Inc., Valeant Pharmaceuticals Ireland Limited, Valeant Pharmaceuticals Luxembourg s.&#224; r.l. and Alfasigma S.p.A., originally filed as Exhibit 10.28 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed on February 20, 2019, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1009356/000119312512459233/d402656dex1098.htm">Trademark License Agreement (Alfa to Salix) dated August 6, 2012 by and between Alfa Wassermann Hungary Kft. and Salix Pharmaceuticals, Inc., originally filed as Exhibit 10.98 to Salix</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1009356/000119312512459233/d402656dex1098.htm"> Pharmaceutical Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1009356/000119312512459233/d402656dex1098.htm">&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 filed on November 8, 2012, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312518181925/d506785dex101.htm">Restatement Agreement, dated as of June&#160;1, 2018, among Valeant Pharmaceuticals International, Inc., Valeant Pharmaceuticals International, certain subsidiaries of Valeant Pharmaceuticals International, Inc. as guarantors, each of the financial institutions named therein as lenders and issuing banks and Barclays Bank PLC, as Administrative Agent, originally filed as Exhibit 10.1 to&#160;the Company's Current Report on Form 8-K filed</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312518181925/d506785dex101.htm"> on June 1, 2018, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559019000006/exhibit10322018ye.htm">Amended and Restated Asset Purchase Agreement dated January 4, 2019 among Bausch Health Companies Inc., Bausch Health Ireland Limited, Synergy Pharmaceuticals Inc. and Synergy Advanced Pharmaceuticals, Inc., originally filed as Exhibit 10.32 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed on February 20, 2019, which is incorporated by reference herein. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559020000006/exhibit10302019ye.htm">Stipulation of Settlement dated December 15, 2019 in the U.S. Securities Litigation, originally filed as Exhibit 10.30 to the Company&#8217;s Annual Report on Form 10-K </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559020000006/exhibit10302019ye.htm">for the fiscal year ended December 31, 2019 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559020000006/exhibit10302019ye.htm">filed on February 19, 2020, which is incorporated by reference herein. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000008/ex101-q4x2020.htm">Director Nomination and Appointment Agreement, dated February 23, 2021, by and among Bausch Health Companies Inc., Carl C. Icahn and the persons and entities listed therein, originally filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on February 24, 2021, which is incorporated by reference herein. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit2112021ye.htm">Subsidiaries of Bausch Health Companies Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit2312021ye.htm">Consent of PricewaterhouseCoopers&#160;LLP.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3112021ye.htm">Certification of the Chief Executive Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3122021ye.htm">Certification of the Chief Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3212021ye.htm">Certificate of the Chief Executive Officer of Bausch Health Companies Inc. pursuant to 18&#160;U.S.C. &#167;&#160;1350 as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3222021ye.htm">Certificate of the Chief Financial Officer of Bausch Health Companies Inc. pursuant to 18&#160;U.S.C. &#167;&#160;1350 as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:174%">____________________________________</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*     Filed herewith.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#8224;&#160;&#160;&#160;&#160;One or more exhibits or schedules to this exhibit have been omitted pursuant to Item&#160;601(a)(5) or Item&#160;601(b)(2) of Regulation&#160;S-K. We undertake to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon&#160;request.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_265"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or&#160;15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.750%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAUSCH HEALTH COMPANIES&#160;INC.<br/>(Registrant)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;JOSEPH C. PAPA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph C. Papa</span></div><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</span></div><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer and Chairman of the Board)</span></div></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;JOSEPH C. PAPA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph C. Papa</span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Chairman of the Board</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;SAM ELDESSOUKY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sam Eldessouky</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer (Principal Financial Officer) </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;FREDERICK J. MUNSCH</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frederick J. Munsch</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Controller and Chief Accounting Officer (Principal Accounting Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;RICHARD U. DESCHUTTER</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard U. DeSchutter</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;BRETT ICAHN</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brett Icahn</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;ARGERIS N. KARABELAS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argeris N. Karabelas</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;SARAH B. KAVANAGH</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sarah B. Kavanagh</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;STEVEN D. MILLER</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steven D. Miller</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;JOHN A. PAULSON</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John A. Paulson</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;ROBERT N. POWER</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert N. Power</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;RUSSEL C. ROBERTSON</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russel C. Robertson</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;THOMAS W. ROSS, SR.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas W. Ross, Sr.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;ANDREW C. VON ESCHENBACH</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew C. von Eschenbach</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;AMY B. WECHSLER</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amy B. Wechsler</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr></table></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_268"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:92.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Management on Financial Statements </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_271">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_271">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Report of Independent Registered Public Accounting Firm (PCAOB ID <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yNjgvZnJhZzplOTU4YzVkNGNiNGM0ODU1OGJmZGMwMzEzMjQyMjg2MC90YWJsZTo4OGQ2Yzk1ZDllMjI0N2I2OGQyMzRhMDMwNDc5YjdkNS90YWJsZXJhbmdlOjg4ZDZjOTVkOWUyMjQ3YjY4ZDIzNGEwMzA0NzliN2Q1XzItMC0xLTEtNzk5MDUvdGV4dHJlZ2lvbjo2ZjQ0ZDk4Y2ZmMjk0MTVhOWVlMWRkZjMyY2UwM2I0OV80Mzk4MDQ2NTExMTgz_d9c9c110-43e1-4772-aa14-2aefefabce84">238</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_274">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_274">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets as of December&#160;31, 2021 and 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_280">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_280">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Operations for the years ended December&#160;31, 2021, 2020 and 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_283">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_283">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Comprehensive Loss for the years ended December 31, 2021, 2020 and 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_286">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_286">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Shareholders&#8217; Equity (Deficit) for the years ended December&#160;31, 2021, 2020 and 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_289">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_289">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2021, 2020 and 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_295">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_295">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_298">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ieeb1c2023b22439f84a8bdbbd2804ef7_298">11</a></span></div></td></tr></table></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_271"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF MANAGEMENT ON FINANCIAL STATEMENTS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for preparing the accompanying consolidated financial statements in conformity with United&#160;States generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;). In preparing these consolidated financial statements, management selects appropriate accounting policies and uses its judgment and best estimates to report events and transactions as they occur. Management has determined such amounts on a reasonable basis in order to ensure that the consolidated financial statements are presented fairly, in all material respects. Financial information included throughout this Annual Report is prepared on a basis consistent with that of the accompanying consolidated financial statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PricewaterhouseCoopers&#160;LLP has been engaged by the Company to audit the consolidated financial statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors is responsible for ensuring that management fulfills its responsibility for financial reporting and is ultimately responsible for reviewing and approving the consolidated financial statements. The Board of Directors carries out this responsibility principally through its Audit and Risk Committee. The members of the Audit and Risk Committee are outside Directors. The Audit and Risk Committee considers, for review by the Board of Directors and approval by the shareholders, the engagement or reappointment of the external auditors. PricewaterhouseCoopers&#160;LLP has full and free access to the Audit and Risk&#160;Committee.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:29.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ JOSEPH C. PAPA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ SAM ELDESSOUKY</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph C. Papa<br/>Chief Executive Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sam Eldessouky<br/>Executive Vice President and<br/>Chief Financial Officer</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;23, 2022 </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_274"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Shareholders of Bausch Health Companies Inc.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Bausch Health Companies Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, and the related consolidated statements of operations, of comprehensive loss, of shareholders' equity (deficit) and of cash flows for each of the three years in the period ended December 31, 2021, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). We also have audited the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinions</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management&#8217;s Annual Report on Internal Control Over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicaid Rebates and Sales Returns Allowances</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 2 to the consolidated financial statements, gross product sales are subject to a variety of deductions in arriving at reported net product sales. The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. The provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue as a reduction in revenue. The variable consideration provisions, either recognized within accrued and other current liabilities or as a reduction of trade receivables, included $482 million related to returns allowances and $944 million related to rebates, including Medicaid rebates as of December 31, 2021. For certain rebate programs, such as Medicaid, provisions recognized by management are based on the terms of state government-managed programs, estimates of outstanding and future claims for end-customer sales and the sales mix. As disclosed by management, for sales returns, management estimates provisions utilizing existing return policies with customers, historical return and exchange levels, external data with respect to inventory levels in the wholesale distribution channel, external data with respect to prescription demand for products, remaining shelf lives of products at the date of sale, and estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns.     </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to Medicaid rebates and sales returns allowances is a critical audit matter are the significant judgment by management when developing the estimate of Medicaid rebates and allowances for sales returns as the estimates are based on assumptions developed using terms of state government-managed Medicaid programs, existing return policies with customers, and projected estimated outstanding and future claims for end-customer sales.  This in turn led to a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence relating to these assumptions.   </span><span style="color:#000000;font-family:'Georgia',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to provisions for Medicaid rebates and allowances for sales returns, including controls over the assumptions used to estimate these rebates and allowances. These procedures also included, among others (i) developing an independent estimate of Medicaid rebates by utilizing third-party information on inventory levels in the distribution channel, the terms of the specific Medicaid rebate programs, and the historical trends of actual Medicaid rebate claims paid, adjusted for price and projected market conditions, (ii) comparing the independent estimate for these Medicaid rebates to management&#8217;s estimates, (iii) evaluating management's process for developing the estimate of the allowance for sales returns and the reasonableness of management&#8217;s assumptions related to existing return policies, (iv) evaluating management's assumptions related to existing return policies involved comparing to historical trends and considering whether these assumptions were consistent with evidence obtained in other areas of the audit, (v) evaluating the appropriateness of the method for estimating the allowance for sales returns and testing the completeness and accuracy of underlying data used in the model, and (vi) testing Medicaid rebate and sales returns claims processed by the Company, including evaluating those claims for consistency with the contractual terms of the Company&#8217;s arrangements and policies. </span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finite-Lived Intangible Assets Impairment Assessment</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Notes 2 and 8 to the consolidated financial statements, the Company&#8217;s consolidated finite-lived net intangible assets balance was $5,250 million as of December 31, 2021, which consists of product and corporate brands, product rights/patents, partner relationships and technology and other assets. Finite-lived intangible assets are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset, which include the amount and timing of the projected future cash flows. </span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to the finite-lived intangible assets impairment assessment is a critical audit matter are the significant judgment by management in the identification of events that suggest an asset group might not be recoverable and in developing the assumptions used in the impairment testing assessment. </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This in turn led to a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence related to management&#8217;s undiscounted future cash flow projections.     </span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management&#8217;s finite-lived intangible assets impairment assessment, including controls over the development of assumptions used to estimate recoverability and controls over the identification of events that suggest an asset group might not be recoverable. These procedures also included, among others (i) testing management&#8217;s process for identifying potential impairment events and determining the recoverability of the intangible assets, (ii) evaluating the appropriateness of the undiscounted cash flow model used in the impairment testing assessment, (iii) testing the completeness and accuracy of underlying data used in the model, and (iv) evaluating the reasonableness of the significant assumptions used by management related to the undiscounted future cash flow projections. Evaluating the reasonableness of management's assumptions for undiscounted future cash flow projections involved evaluating whether the assumptions used by management were reasonable considering the current and past performance of the asset group and whether these assumptions were consistent with evidence obtained in other areas of the audit.  </span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill Impairment Assessments &#8211; Ortho Dermatologics Reporting Unit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 2 and 8 to the consolidated financial statements, the Company&#8217;s consolidated goodwill balance was $12,457 million as of December 31, 2021, and the goodwill associated with the Ortho Dermatologics segment was $798 million, inclusive of a goodwill impairment of $469 million. The Ortho Dermatologics segment consists of the Ortho Dermatologics and Global Solta reporting units. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit. Goodwill impairment is measured by the amount the carrying value exceeds the fair value. Fair value of each reporting unit is estimated by management using a discounted cash flow model. During the quarter ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit and thus Management conducted an interim quantitative fair value test for this reporting unit and recognized a goodwill impairment of $469 million. Management also conducted its annual goodwill impairment test on October 1, 2021 and determined that there was no additional impairment of goodwill. Management&#8217;s discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates.      </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:-0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to the goodwill impairment assessments of the Ortho Dermatologics reporting unit is a critical audit matter are the significant judgment by management when developing the fair value estimates of the reporting unit. This in turn led to a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management&#8217;s significant assumptions related to revenue growth rates, gross profit, discount rates, and terminal growth rates. Also, the audit effort involved the use of professionals with specialized skill and knowledge.    </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:-0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management&#8217;s goodwill impairment assessments, including controls over the valuation of the Company&#8217;s Ortho Dermatologics reporting unit. These procedures also included, among others (i) testing management&#8217;s process for developing the fair value estimates of the Ortho Dermatologics reporting unit, (ii) evaluating the appropriateness of the discounted cash flow models, (iii) testing the completeness and accuracy of underlying data used in the models, and (iv) evaluating the reasonableness of the significant assumptions used by management related to the revenue growth rates, gross profit, discount rates, and terminal growth rates. Evaluating management&#8217;s assumptions related to revenue growth rates and gross profit involved evaluating whether the assumptions used by management were reasonable considering (i) the current and past performance of the reporting unit, (ii) the consistency with external market and industry data, and (iii) whether these assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in the evaluation of the Company&#8217;s discounted cash flow models and discount rate and terminal growth rate assumptions. </span><span style="color:#3016f2;font-family:'Georgia',serif;font-size:12pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yNzQvZnJhZzoxMWJiNTE0MWM2NGU0NTYyYjkwYTE1YmYwZWIyNzY5ZS90ZXh0cmVnaW9uOjExYmI1MTQxYzY0ZTQ1NjJiOTBhMTViZjBlYjI3NjllXzEwOTk1MTE2NDQzMzc_d16d1d67-f2e1-4cb0-93fc-62203a11f8d8">PricewaterhouseCoopers LLP</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yNzQvZnJhZzoxMWJiNTE0MWM2NGU0NTYyYjkwYTE1YmYwZWIyNzY5ZS90ZXh0cmVnaW9uOjExYmI1MTQxYzY0ZTQ1NjJiOTBhMTViZjBlYjI3NjllXzEwOTk1MTE2NDQzMzk_c7688c15-26ea-4515-8269-1c4a555a3ec6">Florham Park, New Jersey</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;23, 2022 </span></div><div style="margin-top:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2012. </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_277"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div><span><br/></span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_280"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions, except share amounts)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:75.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.711%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzQtMi0xLTEtNTk0NzA_4cd7f632-7461-4cd6-8485-3ceace812f1d">582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzQtNC0xLTEtNTk0NzA_6b7e0dc0-4836-4870-934a-2bcf4734c442">605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzUtMi0xLTEtNTk0NzA_9b02b544-edc6-4a46-92d9-882df5090cbb">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzUtNC0xLTEtNTk0NzA_44f96318-221b-44d9-850f-7032347a2406">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzYtMi0xLTEtNTk0NzA_45f76a2f-d90d-4e00-8e4f-9d9db6502813">1,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzYtNC0xLTEtNTk0NzA_82648118-7fee-4151-a9e9-6bab251ba892">1,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzctMi0xLTEtNTk0NzA_fb67f469-d682-4556-97d8-0e3a158a8676">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzctNC0xLTEtNTk0NzA_d2a6aa16-d044-406b-b8d7-d7a0ab5a2b40">1,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzgtMi0xLTEtNTk0NzA_b001be39-908b-42bf-9d54-c4dff4741609">720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzgtNC0xLTEtNTk0NzA_15caa44e-ae24-4928-a166-e93333ccaadf">855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzktMi0xLTEtNTk0NzA_73255393-60ee-4847-a2c8-aedb2ffd9dba">5,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzktNC0xLTEtNTk0NzA_2e125241-83ed-4e32-89bf-c7213fe25171">5,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzEwLTItMS0xLTU5NDcw_11da3e3f-7850-4197-ac00-ee8cecd11e6c">1,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzEwLTQtMS0xLTU5NDcw_a8c9d13b-f368-4c73-927f-f52f79add403">1,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzExLTItMS0xLTU5NDcw_dec1c40e-c058-43fe-ab0e-5ea5e84fc105">6,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzExLTQtMS0xLTU5NDcw_294dddba-afdb-4c4c-8df8-c896a0862a77">8,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzEyLTItMS0xLTU5NDcw_abc7c1b2-3018-4f5c-a8e6-da05400df7f1">12,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzEyLTQtMS0xLTU5NDcw_d05c4f72-ce34-4433-8c97-1276d242ab12">13,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzEzLTItMS0xLTU5NDcw_8d4b1e55-593c-4475-af9c-530aaa0fa3d0">2,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzEzLTQtMS0xLTU5NDcw_a6b49735-5080-42d9-8c40-dcbf6a7e20cb">2,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzE0LTItMS0xLTU5NDcw_1cd0bd47-515d-4ac2-8070-499488c838ad">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzE0LTQtMS0xLTU5NDcw_ae128170-6ee9-4c14-9eb8-15dce8ec70dd">664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzE1LTItMS0xLTU5NDcw_c3ec599a-c5fc-4e86-894d-2536f728206c">29,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzE1LTQtMS0xLTU5NDcw_db61cd94-5ec2-49ea-8868-e5bf9e987c53">31,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzE4LTItMS0xLTU5NDcw_89682952-cd55-4b6f-851d-e7da0c9dd8aa">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzE4LTQtMS0xLTU5NDcw_cc142871-e77b-4a43-847e-1e35c0c63941">337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzE5LTItMS0xLTU5NDcw_1c2342b2-0bef-4800-b917-0cd0352afab7">4,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzE5LTQtMS0xLTU5NDcw_1c7d05a5-3fdf-443e-8ea9-0a2f6a12a4ab">4,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzIxLTItMS0xLTU5NDcw_4f0a022f-1e4c-405e-96d1-99f033d8a245">5,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzIxLTQtMS0xLTU5NDcw_96f764b1-e06e-468e-8bb3-f775d7e1697b">4,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationNoncurrentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzIyLTItMS0xLTU5NDcw_3070df21-9458-4234-870d-44186b29a2fc">202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationNoncurrentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzIyLTQtMS0xLTU5NDcw_dd344529-2ff5-4ab5-9f86-cf36e87106db">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzIzLTItMS0xLTU5NDcw_584669dd-aa82-4593-8d82-66f46dfbc530">22,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzIzLTQtMS0xLTU5NDcw_9b147994-964f-499b-98ce-bc96617ea260">23,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI0LTItMS0xLTU5NDcw_44aaaed2-d787-4c30-aebe-10c5a958b4c7">529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI0LTQtMS0xLTU5NDcw_a4efed28-73b4-4557-94a8-757321be2296">528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI1LTItMS0xLTU5NDcw_e72c2c09-acbe-43ac-a81a-158f54d62a0a">653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI1LTQtMS0xLTU5NDcw_62962507-7df2-431a-9f48-35795acdefdf">1,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI2LTItMS0xLTU5NDcw_154f4a4e-966b-47eb-9ff6-84a743266e18">29,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI2LTQtMS0xLTU5NDcw_c56ec283-ae28-4aad-ad7c-8f871a0ee591">30,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Notes&#160;20 and 21)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI3LTItMS0xLTU5NDcw_aba49848-c30f-49c7-81fa-1abc6ee918d1"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI3LTQtMS0xLTU5NDcw_1d0fb845-650b-4ab8-b1af-350982620d05"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares, no par value, unlimited shares authorized, <ix:nonFraction unitRef="shares" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI5LTAtMS0xLTU5NDcwL3RleHRyZWdpb246NGRkYTRkNDM0ZTNmNDhmNjgxN2M4NDQxMGQwNTc2NTlfNjI_116674c0-4114-4094-a543-d6b991703693"><ix:nonFraction unitRef="shares" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI5LTAtMS0xLTU5NDcwL3RleHRyZWdpb246NGRkYTRkNDM0ZTNmNDhmNjgxN2M4NDQxMGQwNTc2NTlfNjI_9c8474f7-7dc0-43e8-b4cf-fe3461a29b62">359,405,748</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI5LTAtMS0xLTU5NDcwL3RleHRyZWdpb246NGRkYTRkNDM0ZTNmNDhmNjgxN2M4NDQxMGQwNTc2NTlfNjk_414b8589-bd21-4295-adcf-634e60260812"><ix:nonFraction unitRef="shares" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI5LTAtMS0xLTU5NDcwL3RleHRyZWdpb246NGRkYTRkNDM0ZTNmNDhmNjgxN2M4NDQxMGQwNTc2NTlfNjk_764bfdd1-3251-45e7-ba96-0ffdcc59bfe4">355,422,347</ix:nonFraction></ix:nonFraction>&#160;issued and outstanding at December&#160;31, 2021 and 2020, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI5LTItMS0xLTU5NDcw_c36e39c9-4719-4e79-b182-2663fb149aeb">10,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI5LTQtMS0xLTU5NDcw_6d20bed2-f7ef-48e1-94dc-0ea8a7dbcbab">10,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzMwLTItMS0xLTU5NDcw_11b2be7a-0567-43df-9a3b-a0f2c3139eee">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzMwLTQtMS0xLTU5NDcw_f711ad0b-7b2d-42aa-b6f7-1742a7039eab">454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzMxLTItMS0xLTU5NDcw_89e04f30-169f-4085-9f84-b0e9c8dfa57b">8,961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzMxLTQtMS0xLTU5NDcw_65bf7f46-ac6d-482d-b4d6-8d274845de35">8,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzMyLTItMS0xLTU5NDcw_874db3c3-9245-4878-970e-78e736de57d6">1,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzMyLTQtMS0xLTU5NDcw_681e1799-564d-4190-9fb0-64e583af4795">2,133</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Bausch Health Companies Inc. shareholders&#8217; (deficit) equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzMzLTItMS0xLTU5NDcw_d0889647-a2d3-412c-aa30-33faeb5a8342">106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzMzLTQtMS0xLTU5NDcw_6d0ea3cd-2470-4798-b6ea-14eb4fffdc5a">535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzM0LTItMS0xLTU5NDcw_039ba2df-3583-4f43-adb8-24d1e6af30cf">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzM0LTQtMS0xLTU5NDcw_98c0bb75-2819-41ab-be77-46eeb9e4281e">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (deficit) equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzM1LTItMS0xLTU5NDcw_e4620b44-9a9f-4b69-b777-2c655ef4f3ed">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzM1LTQtMS0xLTU5NDcw_5e432997-e21d-4dc4-9363-d7bdf24ccb93">605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and (deficit) equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzM2LTItMS0xLTU5NDcw_c855bd50-3f2e-4f4f-80fa-ccd223ff09e7">29,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzM2LTQtMS0xLTU5NDcw_b0598902-b199-4730-ac57-f6c684e9ee3e">31,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On behalf of the Board:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;JOSEPH C. PAPA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;RUSSEL C. ROBERTSON</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph C. Papa</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russel C. Robertson</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairperson, Audit and Risk Committee</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_283"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 36.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions, except per share&#160;amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.866%"><tr><td style="width:1.0%"></td><td style="width:67.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.315%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53abce993d5a44a596716ca7c9e737ce_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzMtMS0xLTEtNTk0NzA_d888cde6-e1df-4d6c-b90d-331a0ad739fd">8,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5a8e9aebd5c4e6099f227c88232846a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzMtMy0xLTEtNTk0NzA_6ba7d2e8-b531-4385-89b6-216d6290d24b">7,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9288144fc85e414e98cdb30f8362fd03_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzMtNS0xLTEtNTk0NzA_c841d351-7e7a-4da1-817d-9c1eb62357ad">8,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35b13f9f8b9048f2abd23eee83da3ef7_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzQtMS0xLTEtNTk0NzA_7ee571da-daf1-48ed-8b09-6b2a37d60280">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb57e7f275e74745bbed5bcd771379f2_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzQtMy0xLTEtNTk0NzA_2adc0743-d082-4033-9cc7-ec7b1a2ba7ed">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceeb259687424b4486f58368d2356d18_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzQtNS0xLTEtNTk0NzA_84f6b529-d3a7-4f97-b1ba-28d849142bb0">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzUtMS0xLTEtNTk0NzA_b3930bb2-f1d9-4629-9629-9e469ae17bd7">8,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzUtMy0xLTEtNTk0NzA_2942a4ef-5266-4383-9a4c-490a14eb11cd">8,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzUtNS0xLTEtNTk0NzA_310da97a-6811-43a6-96d9-7521ee8371d4">8,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold (excluding amortization and impairments of intangible assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53abce993d5a44a596716ca7c9e737ce_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzctMS0xLTEtNTk0NzA_2c4aedfe-116b-4daf-94c4-0fee2633425b">2,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5a8e9aebd5c4e6099f227c88232846a_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzctMy0xLTEtNTk0NzA_13f06dae-f1e5-4dea-a802-feb543010068">2,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9288144fc85e414e98cdb30f8362fd03_D20190101-20191231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzctNS0xLTEtNTk0NzA_1c8d5682-ebc2-46b4-8b9d-249f15664e86">2,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35b13f9f8b9048f2abd23eee83da3ef7_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzgtMS0xLTEtNTk0NzA_789b9a3f-e6b2-4f91-bd56-43d0ecfb08bc">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb57e7f275e74745bbed5bcd771379f2_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzgtMy0xLTEtNTk0NzA_55ffca31-8f4d-4aeb-afb9-9c22112f86e5">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceeb259687424b4486f58368d2356d18_D20190101-20191231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzgtNS0xLTEtNTk0NzA_9627d6f7-179f-415a-b0e6-ad984a591383">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzktMS0xLTEtNTk0NzA_8242de51-6373-4822-9c3c-bbb20b7177d1">2,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzktMy0xLTEtNTk0NzA_ccd9ad1c-62f4-4cf3-83e3-937d535c502d">2,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzktNS0xLTEtNTk0NzA_cf11a4c6-3db8-43d2-9de3-0da213209c6c">2,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzEwLTEtMS0xLTU5NDcw_c0983aa2-698d-423c-9010-bc00a8748dfe">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzEwLTMtMS0xLTU5NDcw_5b9c6c17-88b9-4e8c-869c-7b8458a936fd">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzEwLTUtMS0xLTU5NDcw_f4284b97-5c5e-408d-9102-2ef21c21c409">471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzExLTEtMS0xLTU5NDcw_9f8bf921-bdc7-4bea-a4ae-27c092864f27">1,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzExLTMtMS0xLTU5NDcw_1a72f4c3-7e91-44d2-a69d-9bbec92a2151">1,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzExLTUtMS0xLTU5NDcw_c6e0a9b0-823d-4d2a-bb37-12530f0edecc">1,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzEyLTEtMS0xLTU5NDcw_aa1b7407-d894-49b6-bcab-7d7c3581d88c">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzEyLTMtMS0xLTU5NDcw_4d7d3386-204d-46bf-842d-08d265cdccd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzEyLTUtMS0xLTU5NDcw_39b122df-d22d-49e0-9d09-a6371c63d09a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzEzLTEtMS0xLTU5NDcw_b93dce3f-e470-4b4f-8d9f-7c1b7b088250">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzEzLTMtMS0xLTU5NDcw_5a02892f-bf43-4074-a1f2-dd2c51ca26da">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzEzLTUtMS0xLTU5NDcw_ec1cab68-859d-49f2-92b1-8db993e42e95">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE0LTEtMS0xLTU5NDcw_7cb92526-1c9d-453c-9d0e-93073ac58cda">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE0LTMtMS0xLTU5NDcw_b1d85258-052e-4964-b5c9-1975f4e002e9">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE0LTUtMS0xLTU5NDcw_d6d82719-1488-4faa-8d04-bc882ed43ed8">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE2LTEtMS0xLTU5NDcw_f6d04a9b-c390-4ceb-8f37-700ccd21dfde">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE2LTMtMS0xLTU5NDcw_72db09b6-3dfe-43af-bb7b-96fd62845692">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE2LTUtMS0xLTU5NDcw_a83c8c5c-c0d2-4ad7-a7c8-86d35d664e81">1,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE3LTEtMS0xLTU5NDcw_6f1a15d7-e3d3-4502-bc7b-c8a98e54eecb">7,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE3LTMtMS0xLTU5NDcw_72c4f447-031b-4796-9e59-451e4857d426">7,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE3LTUtMS0xLTU5NDcw_8b99fc9c-2928-4651-8c50-a0c71a9aad88">8,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE4LTEtMS0xLTU5NDcw_52fae1d5-4191-479a-9fd0-0e1d66b54173">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE4LTMtMS0xLTU5NDcw_b66593a0-abd9-4987-a3de-c94bf1652899">676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE4LTUtMS0xLTU5NDcw_258b25fd-4166-4913-b6c9-17948826242c">203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE5LTEtMS0xLTU5NDcw_738e58b5-a08d-4fae-9bda-a01122eee48f">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE5LTMtMS0xLTU5NDcw_ad8adf57-700d-477f-9a50-3f8ba9bce0cd">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE5LTUtMS0xLTU5NDcw_f87e972f-b963-48d5-af0d-2fb246693932">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIwLTEtMS0xLTU5NDcw_af20b858-2a97-4e6d-a940-bb8398a24eb8">1,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIwLTMtMS0xLTU5NDcw_c6f12c7a-3917-4333-837d-da98d2e0cd58">1,534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIwLTUtMS0xLTU5NDcw_ac485a52-2d06-474b-b15c-e80cdb88a0d3">1,612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIxLTEtMS0xLTU5NDcw_f72b0a1d-d224-461f-8f43-f99be553bcdf">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIxLTMtMS0xLTU5NDcw_a5dc5096-7325-4017-bf08-f614b0929abb">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIxLTUtMS0xLTU5NDcw_b9824e5e-148f-4687-90ed-2d8299f417fe">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIyLTEtMS0xLTU5NDcw_88508d63-137f-4651-8894-2c9ec4299bc3">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIyLTMtMS0xLTU5NDcw_2e625b4d-8941-47cb-b4f9-e4e69eae0724">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIyLTUtMS0xLTU5NDcw_71d5394d-1bac-4fd3-997f-90bfc4993744">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before benefit from income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIzLTEtMS0xLTU5NDcw_7951a0a0-1999-4127-ad88-ecf87cbfa243">1,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIzLTMtMS0xLTU5NDcw_320a85a0-8983-47c8-8e70-5a89daad1ab4">934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIzLTUtMS0xLTU5NDcw_49708be3-8ce2-497b-bd78-2cc0850afdaf">1,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI0LTEtMS0xLTU5NDcw_869d8ae8-aedc-42f0-832b-29a8490ca171">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI0LTMtMS0xLTU5NDcw_dba587a0-ed13-4ad0-9124-f0b63a1b5947">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI0LTUtMS0xLTU5NDcw_68bbf7c3-d27b-433a-9d1c-bf6c021de341">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI1LTEtMS0xLTU5NDcw_45f20b4f-6f87-44da-9b7f-19a45946579d">937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI1LTMtMS0xLTU5NDcw_5f5ff2c0-7220-4776-834d-d31aa1ef8f59">559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI1LTUtMS0xLTU5NDcw_4924d9e2-ad10-4d9b-8cb0-53944fc13bf2">1,783</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI2LTEtMS0xLTU5NDcw_bfd0bfa6-7365-4b10-8708-36068f3ab6c4">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI2LTMtMS0xLTU5NDcw_76dc1940-a28a-476d-9688-1faa2fd2a37f">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI2LTUtMS0xLTU5NDcw_9f57dff1-408f-4663-8f02-77a0c5f07db3">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI3LTEtMS0xLTU5NDcw_5aeedabf-c1ba-4d87-9106-b91e5ce5b45f">948</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI3LTMtMS0xLTU5NDcw_6c68ee11-df1a-4769-b14c-6b2a0681e79b">560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI3LTUtMS0xLTU5NDcw_41daeaa9-bfc4-457a-af6a-9ef200b76311">1,788</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI5LTEtMS0xLTU5NDcw_a0748037-5636-47d7-ba74-976e5f270f26"><ix:nonFraction unitRef="usdPerShare" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI5LTEtMS0xLTU5NDcw_c33a3eb4-1b0f-4698-aa2b-8ee9b91cde0f">2.64</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI5LTMtMS0xLTU5NDcw_6713a927-d61c-45a1-ac94-de1dbe965c18"><ix:nonFraction unitRef="usdPerShare" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI5LTMtMS0xLTU5NDcw_7920ead2-a2ff-430c-b93f-162c268fa56f">1.58</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI5LTUtMS0xLTU5NDcw_544d6a97-277f-4266-b898-7d6cab6771a5"><ix:nonFraction unitRef="usdPerShare" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI5LTUtMS0xLTU5NDcw_c3cf0329-22df-48e9-ab79-483ab2cff8e1">5.08</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted weighted-average common shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzMxLTEtMS0xLTU5NDcw_bf7c322b-2330-48c3-a41a-3556374f2264"><ix:nonFraction unitRef="shares" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzMxLTEtMS0xLTU5NDcw_dc217327-9b0c-41d0-aeed-3bbf696361d5">358.9</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzMxLTMtMS0xLTU5NDcw_783f1f4b-0c82-4b21-b81d-c150fe0c8be1"><ix:nonFraction unitRef="shares" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzMxLTMtMS0xLTU5NDcw_b6e8e2ac-a23e-4ead-a816-aafc6e27e366">355.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzMxLTUtMS0xLTU5NDcw_3d22f8e7-5995-4e56-b3ac-10e62f429d06"><ix:nonFraction unitRef="shares" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzMxLTUtMS0xLTU5NDcw_a777cb45-f378-4bdd-83f0-ebe49edbc350">352.1</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_286"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="margin-bottom:16pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzItMS0xLTEtNTk0NzA_4d6b8599-a167-40cc-a3f9-8411657495fa">937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzItMy0xLTEtNTk0NzA_b0f0b00b-996c-419e-813a-6c958dc4b975">559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzItNS0xLTEtNTk0NzA_4570e912-b823-475b-a4ec-4ac16a89f473">1,783</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit plan adjustments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial gain (loss) arising during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzUtMS0xLTEtNTk0NzA_14c75625-1714-4ed0-8401-bb60d75bc144">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzUtMy0xLTEtNTk0NzA_be001235-759b-4bf3-bd76-f3c1c9e69bab">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzUtNS0xLTEtNTk0NzA_3aeb39ec-6ed8-4159-b884-0c5a54054c2f">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzYtMS0xLTEtNTk0NzA_e91cc941-11b7-4966-b873-aa3855d68902">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzYtMy0xLTEtNTk0NzA_763b740a-1e07-4e3d-ba04-082730e00383">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzYtNS0xLTEtNTk0NzA_5c721dc2-7455-447b-8c27-5fbb7e25b1ce">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization or settlement recognition of net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzctMS0xLTEtNTk0NzA_d4332e34-040c-4a53-b92e-afc9a5646402">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzctMy0xLTEtNTk0NzA_fd30511f-d178-4a14-a5dd-bfa13315b5dc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzctNS0xLTEtNTk0NzA_10328809-a5e7-4632-8155-6099e353e155">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzgtMS0xLTEtNTk0NzA_c2487297-f6bb-4ee3-8103-c60ffb8a62d2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzgtMy0xLTEtNTk0NzA_4524516e-8337-4258-86b1-093618c39ee8">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzgtNS0xLTEtNTk0NzA_7e31ede4-f884-451c-b089-c10105d0c7a8">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzktMS0xLTEtNTk0NzA_0d9eb9fa-673e-49a0-b8f2-492a27a38398">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzktMy0xLTEtNTk0NzA_b13be0cb-51f2-46a9-8c96-6d73e7d9f78f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzktNS0xLTEtNTk0NzA_11f4a7b2-27e6-4bad-938c-f32a5f856285">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net pension and postretirement benefit plan adjustments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzEwLTEtMS0xLTU5NDcw_51f3f559-ac78-4888-8898-c904906db80a">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzEwLTMtMS0xLTU5NDcw_370e5e3d-0abb-4dbd-9d30-ad9451ee7658">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzEwLTUtMS0xLTU5NDcw_9feb17e7-dcd5-4f13-b4af-e08c05863329">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzExLTEtMS0xLTU5NDcw_05219e07-730c-429a-9775-89a5e76f82e3">158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzExLTMtMS0xLTU5NDcw_80b72fdd-69f6-4510-b9a7-0a4c164efb81">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzExLTUtMS0xLTU5NDcw_869c9e84-f226-4c5f-8726-befe9b8b4e5a">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzEyLTEtMS0xLTU5NDcw_049dd382-c036-4d62-bfe2-79241d1e49f1">130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzEyLTMtMS0xLTU5NDcw_56c514b3-7819-4045-8f77-bcef4c9fbc81">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzEyLTUtMS0xLTU5NDcw_1a11c785-8e10-4325-94d9-ca0b00b26fab">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzEzLTEtMS0xLTU5NDcw_f9c2948d-69c3-4dc6-92f8-1b1182df3689">1,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzEzLTMtMS0xLTU5NDcw_9132aca2-d6f8-4435-9555-342aa85d1313">604</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzEzLTUtMS0xLTU5NDcw_dd3cecc6-ca2a-49ad-82d9-1329fa288910">1,733</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzE0LTEtMS0xLTU5NDcw_6334558f-ee39-4807-b556-8bc098128af9">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzE0LTMtMS0xLTU5NDcw_ec1aa866-2c3c-4071-8584-c06eedd7a1e9">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzE0LTUtMS0xLTU5NDcw_c35503ab-a2e6-4fae-90f2-7b9d20848022">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzE1LTEtMS0xLTU5NDcw_9222eaf2-df5c-49a4-8c29-ed35b1979fed">1,079</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzE1LTMtMS0xLTU5NDcw_b5bb7470-d2ca-4e9e-89dc-43e45b96299e">607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzE1LTUtMS0xLTU5NDcw_192536a3-eec1-4d47-90c9-6c9653da6e86">1,737</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_289"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY (DEFICIT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:28.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch Health Companies&#160;Inc. Shareholders' Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Bausch Health<br/>Companies&#160;Inc.<br/>Shareholders'<br/>Equity (Deficit)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total<br/>Equity (Deficit)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January&#160;1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82b9833a23f042c5a2adb676a8ec5e95_I20181231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzMtMi0xLTEtNTk0NzA_f521dcad-ad8e-447c-a4b8-09414efec369">349.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82b9833a23f042c5a2adb676a8ec5e95_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzMtNC0xLTEtNTk0NzA_6c53574b-3b79-4aa0-8603-c5bb9363cfed">10,121</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa34fcb752d94e098590798c475a7b37_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzMtNi0xLTEtNTk0NzA_5dd952af-bfee-4ebc-be34-b371d4d73bf4">413</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i355151ac32e34c93a32ea5b6e6b9c800_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzMtOC0xLTEtNTk0NzA_9c54852d-a12a-4311-8d6a-7ed6582bf72a">5,664</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i451d020caed04e288168a2f8fd5d732f_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzMtMTAtMS0xLTU5NDcw_539c901c-0045-4781-983a-7b372e300eb9">2,137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de4302e562642bb876564c477eeb8f6_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzMtMTItMS0xLTU5NDcw_9017d526-8e6d-4ce0-8eb2-42ded015a5c0">2,733</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fc6ad19407843c2804930d9e14a236b_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzMtMTQtMS0xLTU5NDcw_c0677fcc-54d9-4abf-bc29-210477b31aa0">82</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a9900560564bdca7dec25381689c13_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzMtMTYtMS0xLTU5NDcw_304af5c9-f64b-4c52-b26f-80ca5abe7036">2,815</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4684b0e1b31043f2a0e0a6337cab6576_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzUtMi0xLTEtNTk0NzA_3ebc74e3-eae2-4615-aca8-f1021728e117">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4684b0e1b31043f2a0e0a6337cab6576_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzUtNC0xLTEtNTk0NzA_1d2f4088-5a9d-4768-83a7-baf66b4ebb5d">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2118e2f41d1f4842a442e5647a35f40b_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzUtNi0xLTEtNTk0NzA_ad4b02dd-4f1c-4b1c-96f6-5bdb85c2c5ee">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c17e85c0371428e9ccf57c2288a1310_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzUtMTItMS0xLTU5NDcw_c7953594-e218-49d6-aa53-a989a409709b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzUtMTYtMS0xLTU5NDcw_5b33fa20-07ba-4b9e-891a-1ccb53c12949">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2118e2f41d1f4842a442e5647a35f40b_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzYtNi0xLTEtNTk0NzA_957ce2b4-c0c6-49a3-99f6-2403c410aa62">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c17e85c0371428e9ccf57c2288a1310_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzYtMTItMS0xLTU5NDcw_8800e374-88ab-4d7e-aed3-b65ce3062396">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzYtMTYtMS0xLTU5NDcw_ace4c908-1791-4dca-bae8-a0a15822ebee">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based awards tax withholding</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2118e2f41d1f4842a442e5647a35f40b_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzctNi0xLTEtNTk0NzA_81c6dba2-6085-45dc-8fcf-c99ca20bb924">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c17e85c0371428e9ccf57c2288a1310_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzctMTItMS0xLTU5NDcw_35a73bba-6c45-4f23-9996-5a4126831267">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzctMTYtMS0xLTU5NDcw_5b26f10f-7458-4812-81ad-2362185bf12d">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if15b2ce8695749b5ac475e5adf790526_D20190101-20191231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzktMTQtMS0xLTU5NDcw_6016d030-47f2-4eee-aa3b-bf80e0f00cf1">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzktMTYtMS0xLTU5NDcw_ee51812e-3533-4443-998c-04622ff88236">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64a4e2f699614549a3fba3f9ac23a215_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEwLTgtMS0xLTU5NDcw_a2ef641d-bbdc-4a20-9a3e-71aec3e55ee7">1,788</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c17e85c0371428e9ccf57c2288a1310_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEwLTEyLTEtMS01OTQ3MA_d5d54d07-18f0-4f3e-b25b-5d237fb2fde4">1,788</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if15b2ce8695749b5ac475e5adf790526_D20190101-20191231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEwLTE0LTEtMS01OTQ3MA_0817e678-c487-4891-9f58-75785cedef73">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEwLTE2LTEtMS01OTQ3MA_599d76c0-2dcc-48ab-9c42-8f9aaf8e93d3">1,783</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id91ab3b642bc46a187257c824bdd77a3_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzExLTEwLTEtMS01OTQ3MA_d9d78a64-4808-492e-b1e9-157bada09faa">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c17e85c0371428e9ccf57c2288a1310_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzExLTEyLTEtMS01OTQ3MA_25bdfd2e-7daa-4a66-b7bc-d7f9a241c80f">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if15b2ce8695749b5ac475e5adf790526_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzExLTE0LTEtMS01OTQ3MA_5a73a0e8-b0ad-4570-9e98-0875c1db4ba8">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzExLTE2LTEtMS01OTQ3MA_0a646abf-ab45-4920-a9c1-17d59df0553f">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09a05e24b6824378a2ee002ec69b8c4b_I20191231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEyLTItMS0xLTU5NDcw_bb5e368d-5a8d-4800-9ce6-fe2a7ab84543">352.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09a05e24b6824378a2ee002ec69b8c4b_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEyLTQtMS0xLTU5NDcw_b8c060dc-634b-4389-9f46-53f83f5a3907">10,172</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e89c666446a456f8cc98146608671d8_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEyLTYtMS0xLTU5NDcw_aed31375-0413-48da-8791-1a37edfa74cb">429</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb811b454ce14d32b8a17a56eab234cf_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEyLTgtMS0xLTU5NDcw_62ef4c05-a60d-4a05-a150-9e0217b7fa9c">7,452</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0ab88b4629f472db1a3683caad4f40f_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEyLTEwLTEtMS01OTQ3MA_93abca7b-f238-4537-9fac-0c5667087841">2,086</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8e7ca9b32a444089dfd2ee008ffa4c5_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEyLTEyLTEtMS01OTQ3MA_0dbd598d-4397-4f60-ac8f-fbba8db7b01f">1,063</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdde09098974b0f8d7c802d8cb72514_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEyLTE0LTEtMS01OTQ3MA_14fc1960-f69a-4253-984a-6a656d920fac">73</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEyLTE2LTEtMS01OTQ3MA_fb8e3492-f756-43bb-8331-d70c0a1af58b">1,136</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzExLTAtMS0xLTY2NjQx_23257d93-b538-43fd-a27c-e92b625799be">Effect of application of new accounting standard: financial instruments - credit losses</span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ea97ac3ab7a4d41bb8383aabfb051e7_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzExLTgtMS0xLTY2NjQz_cb096318-b3a5-45dd-9b1d-95d67eab5ae0">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87b994e0a55b42d3b3861f596a5aef18_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzExLTEyLTEtMS02NjY0NQ_06321fbf-1032-4870-9b15-56d6c3394327">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff91afb1f5c540bea0a30d424217c405_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzExLTE2LTEtMS02NjY0Nw_cbf5e3b6-048d-4100-974b-c19ee9901d41">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if282715453074bb49b8bc1e448ad1f27_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEzLTItMS0xLTU5NDcw_fd11437f-d97c-4f7b-acd6-87c016788cbe">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if282715453074bb49b8bc1e448ad1f27_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEzLTQtMS0xLTU5NDcw_e858db89-4134-4b1b-8331-80674b59860e">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb6b2b32236f4217a22e698f5e6a29c8_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEzLTYtMS0xLTU5NDcw_9d498fec-a192-460e-9081-76a5b2286a9e">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaa3fc7070ff4e269eaf1141c23dfc90_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEzLTEyLTEtMS01OTQ3MA_af5979bc-2bf7-4d93-82ca-eee1b6cdc77a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEzLTE2LTEtMS01OTQ3MA_6102e182-5d9e-464b-8e60-7a61cb48704d">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb6b2b32236f4217a22e698f5e6a29c8_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE0LTYtMS0xLTU5NDcw_a0731b9d-90d6-4646-831d-f571ef377bcc">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaa3fc7070ff4e269eaf1141c23dfc90_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE0LTEyLTEtMS01OTQ3MA_55e7b6cd-4b1a-41ba-9108-3004ed0597fd">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE0LTE2LTEtMS01OTQ3MA_5efc7670-334f-4897-9f31-a615eef97ac3">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based awards tax withholding</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb6b2b32236f4217a22e698f5e6a29c8_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE1LTYtMS0xLTU5NDcw_623c2108-7b1d-48c8-9320-222c812d9094">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaa3fc7070ff4e269eaf1141c23dfc90_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE1LTEyLTEtMS01OTQ3MA_faa43e90-c0e2-4ef7-a7d6-04155b702b10">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE1LTE2LTEtMS01OTQ3MA_74f7c214-3aed-44d9-8d64-2884f02f80f2">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93302786cb504c94b2b462b9a04d7347_D20200101-20201231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE2LTE0LTEtMS01OTQ3MA_71c7fa49-1c27-4ff3-bebf-a65a405457d7">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE2LTE2LTEtMS01OTQ3MA_4845bef4-fb2b-453a-ba53-dcd713576260">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i580ae2bd45844451af6478654bd0361d_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE3LTgtMS0xLTU5NDcw_4fa76625-b6f0-4030-83a3-24b49b6742a5">560</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaa3fc7070ff4e269eaf1141c23dfc90_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE3LTEyLTEtMS01OTQ3MA_14722cd7-91f1-4d1a-9d98-876fbb35e0d8">560</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93302786cb504c94b2b462b9a04d7347_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE3LTE0LTEtMS01OTQ3MA_3533fb92-36d0-4966-84c3-5775fddfd2b5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE3LTE2LTEtMS01OTQ3MA_2c6fee7d-c489-4dfa-b674-b05d833394a7">559</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icaaee956f0c34101b241686ca5a47137_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE4LTEwLTEtMS01OTQ3MA_6e45bac9-47c0-4618-b4c3-2ea9641c4138">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaa3fc7070ff4e269eaf1141c23dfc90_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE4LTEyLTEtMS01OTQ3MA_eac7d43d-2da7-4e1d-b010-059670019cb6">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93302786cb504c94b2b462b9a04d7347_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE4LTE0LTEtMS01OTQ3MA_c0098710-499e-495b-ae6b-ac833374e1e4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE4LTE2LTEtMS01OTQ3MA_77e342ae-6365-4d03-b2ff-e8c0a295a17e">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60f8b472d50d403d9e1baa887a2f2095_I20201231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE5LTItMS0xLTU5NDcw_e044bca2-6b2d-47e0-be9e-60ad4ee326ad">355.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60f8b472d50d403d9e1baa887a2f2095_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE5LTQtMS0xLTU5NDcw_2e7a8c1f-ee96-4872-9675-419451839eb9">10,227</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd238c564d9645d68c9bd1f4839b69dc_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE5LTYtMS0xLTU5NDcw_b7f1b87e-3343-48a8-a579-2c45aae271b2">454</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c869e99e66c44e3807c32b56fd85737_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE5LTgtMS0xLTU5NDcw_ea795302-b00f-4589-b039-7d28bb054d8b">8,013</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23e7ea6c4d584b7881937aede46315ca_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE5LTEwLTEtMS01OTQ3MA_4d7d06dd-17d8-485c-92fe-85b249935f93">2,133</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02aa4e2b4a9143c4931349f2b24d03c9_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE5LTEyLTEtMS01OTQ3MA_e815ed6d-3045-45e5-9e7d-d999029c0039">535</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e02837ee6ab43329d534e55ff0d3d08_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE5LTE0LTEtMS01OTQ3MA_cfefee51-8e4b-4c34-ab09-9e1abab96ef7">70</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE5LTE2LTEtMS01OTQ3MA_9fd875b3-b608-4b98-8110-bdc214867bc2">605</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i332cb35e6b1c4b4499193a2507f556ec_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIxLTItMS0xLTU5NDcw_32d21b7a-f3c7-4699-a571-716190588e08">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i332cb35e6b1c4b4499193a2507f556ec_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIxLTQtMS0xLTU5NDcw_57d51eeb-66d6-4f62-b6d8-c477ef1f9bb6">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id69729faeee842779fac160c0f6b01cc_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIxLTYtMS0xLTU5NDcw_8faf72a1-6315-4f64-bfbf-fa24878c563f">68</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d610c2d7c5741318c7b47c1fa5ff7aa_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIxLTEyLTEtMS01OTQ3MA_fd914ce5-7cfb-4afe-931a-e03941844474">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIxLTE2LTEtMS01OTQ3MA_0aca5820-2565-4dd0-8a17-7155654b3446">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id69729faeee842779fac160c0f6b01cc_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIyLTYtMS0xLTU5NDcw_a598082e-e106-47a8-8e23-26862390ce03">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d610c2d7c5741318c7b47c1fa5ff7aa_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIyLTEyLTEtMS01OTQ3MA_77fe6ba5-be70-4531-9d06-3bb9eed1866c">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIyLTE2LTEtMS01OTQ3MA_7689e360-5f16-4480-861a-f696726573c9">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based awards tax withholding</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id69729faeee842779fac160c0f6b01cc_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIzLTYtMS0xLTU5NDcw_20146e64-6410-4159-b313-324ea8569675">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d610c2d7c5741318c7b47c1fa5ff7aa_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIzLTEyLTEtMS01OTQ3MA_2fa4086c-eea6-4e50-9198-041ba78df4cb">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIzLTE2LTEtMS01OTQ3MA_a5b9f960-e12d-4a16-bd11-34b6742a5226">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Release of foreign currency translation losses upon disposal of assets           held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c4a367db2a74cd19dcf9139adee5405_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIyLTEwLTEtMS02ODgyMg_5bd621d2-3183-4491-8790-a25d1cc40393">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d610c2d7c5741318c7b47c1fa5ff7aa_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIyLTEyLTEtMS03MTM1Mw_c8cd95c5-fa3c-4c0c-9b94-33c16c4ecd78">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIyLTE2LTEtMS03MTM1NQ_1b9e45d9-2243-4182-8a8a-ee84a5567745">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8729de31314e44b0be1473a123083daf_D20210101-20211231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI0LTE0LTEtMS01OTQ3MA_2effdd9a-e017-47e3-8e80-8c018eb66182">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI0LTE2LTEtMS01OTQ3MA_aeab6305-1537-48d7-af8b-e513ded07c19">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd9c5a5d9c13483ca438c56e8327e766_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI1LTgtMS0xLTU5NDcw_69690f06-1097-415e-99f1-5040a47cc175">948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d610c2d7c5741318c7b47c1fa5ff7aa_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI1LTEyLTEtMS01OTQ3MA_2218e1a6-b2ac-4e66-a34c-d0fc4b24cd84">948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8729de31314e44b0be1473a123083daf_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI1LTE0LTEtMS01OTQ3MA_67494bdf-4aea-4195-aaf8-f10207c89dbf">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI1LTE2LTEtMS01OTQ3MA_1f3bd21b-522c-4e4d-918e-a5c1f0c9e204">937</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c4a367db2a74cd19dcf9139adee5405_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI2LTEwLTEtMS01OTQ3MA_e7304933-5240-4d44-b020-e2581ee2e2c1">131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d610c2d7c5741318c7b47c1fa5ff7aa_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI2LTEyLTEtMS01OTQ3MA_1cb00ed9-deb7-4d4a-8536-4f382763a876">131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8729de31314e44b0be1473a123083daf_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI2LTE0LTEtMS01OTQ3MA_b33531c2-2dd0-4adc-83a8-d7f79daf9ca1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI2LTE2LTEtMS01OTQ3MA_a2b4de3c-d600-462b-a922-8d593ea3b17c">130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib970daaae589497d899cb7d978be2dce_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI3LTItMS0xLTU5NDcw_a47bb932-f4c5-4084-a0d4-4cc265dc61b1">359.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib970daaae589497d899cb7d978be2dce_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI3LTQtMS0xLTU5NDcw_13cf2db2-b57b-4915-bfa0-fa025bbc9849">10,317</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141129182749408e9635a2af36209722_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI3LTYtMS0xLTU5NDcw_b9cbb410-d2f2-421a-8d23-4c5856cb8fa9">462</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd2e58d530c456aa77e190e8c786ffa_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI3LTgtMS0xLTU5NDcw_efa9b60b-6c5e-43fa-bbd2-e09d276951bc">8,961</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie17ca1996294497e9f031629ce871dae_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI3LTEwLTEtMS01OTQ3MA_3420cfc9-b5ef-4a7f-9f69-d6649201aab5">1,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i030df36b6a574871b8a132326549d4ff_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI3LTEyLTEtMS01OTQ3MA_6a1f7091-748b-4c39-b736-5e71a62102aa">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ee9a6d8577c4318bf54609562d4c3e2_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI3LTE0LTEtMS01OTQ3MA_e68769ce-c5cf-44cc-b7ac-879a6d7699a6">72</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI3LTE2LTEtMS01OTQ3MA_2e2f246b-0504-4af7-aed3-b0174214e768">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_295"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:73.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows From Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMtMi0xLTEtNTk0NzA_4d6b8599-a167-40cc-a3f9-8411657495fa">937</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMtNC0xLTEtNTk0NzA_b0f0b00b-996c-419e-813a-6c958dc4b975">559</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMtNi0xLTEtNTk0NzA_4570e912-b823-475b-a4ec-4ac16a89f473">1,783</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUtMi0xLTEtNTk0NzA_1ada3489-f77f-409a-90cb-1418b2706f8e">1,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUtNC0xLTEtNTk0NzA_d5df4677-c0a1-4bf7-8a35-eec821ea54a8">1,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUtNi0xLTEtNTk0NzA_b3d87f02-2619-4110-9e57-53d166018fd2">2,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and write-off of debt discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzYtMi0xLTEtNTk0NzA_0d39f42a-5329-4921-be49-2efba5812b9a">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzYtNC0xLTEtNTk0NzA_2e7287bd-1a61-4c06-af58-45205d24d486">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzYtNi0xLTEtNTk0NzA_f7eec4b6-e2f2-4dd3-b589-83cd71cb8a10">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzctMi0xLTEtNTk0NzA_b93dce3f-e470-4b4f-8d9f-7c1b7b088250">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzctNC0xLTEtNTk0NzA_5a02892f-bf43-4074-a1f2-dd2c51ca26da">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzctNi0xLTEtNTk0NzA_ec1cab68-859d-49f2-92b1-8db993e42e95">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzgtMi0xLTEtNTk0NzA_aa1b7407-d894-49b6-bcab-7d7c3581d88c">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzgtNC0xLTEtNTk0NzA_15730ed5-540c-4712-a1f8-d8787afb3cb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzgtNi0xLTEtNTk0NzA_5fb2ea4a-d187-4b4b-bc82-059470c0c1ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzktMi0xLTEtNTk0NzA_7ce77577-eb90-4734-921f-a48d6d5b0cc9">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzktNC0xLTEtNTk0NzA_c6cd3496-0df8-4825-b9c2-7af751e47e83">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzktNi0xLTEtNTk0NzA_3db63d10-40e1-432a-a49e-e1861c7b2542">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allowances for losses on trade receivables and inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:AllowancesForLossesOnAccountsReceivableAndInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzEwLTItMS0xLTU5NDcw_db2f80ef-c2d5-4d0a-bfb0-1c9fcbb9bf49">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:AllowancesForLossesOnAccountsReceivableAndInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzEwLTQtMS0xLTU5NDcw_2d8eb3b3-b385-41fe-b90e-d1f7fe51e837">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="bhc:AllowancesForLossesOnAccountsReceivableAndInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzEwLTYtMS0xLTU5NDcw_80112040-bfbf-4f69-a65d-bd833a7055e1">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="bhc:DeferredIncomeTaxNoncashExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzExLTItMS0xLTU5NDcw_bec37127-4645-42f8-aaab-00a77c2f2bc7">225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="bhc:DeferredIncomeTaxNoncashExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzExLTQtMS0xLTU5NDcw_078092d7-c479-4228-9f5a-453d99372e87">475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="bhc:DeferredIncomeTaxNoncashExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzExLTYtMS0xLTU5NDcw_ceb94b44-9af3-4a4f-aa2b-a481f0ddcfcc">230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on disposal of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzEyLTItMS0xLTU5NDcw_8319c4fb-e1f4-4eca-9d1a-1a96cf449181">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzEyLTQtMS0xLTU5NDcw_1785037c-4699-459e-9051-a43bb15516b4">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzEyLTYtMS0xLTU5NDcw_4a9f67a2-cadc-49ca-bd8f-a5b373b76509">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to accrued legal settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="bhc:GainLossRelatedToLitigationSettlementGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzEzLTItMS0xLTU5NDcw_75119013-fb96-4f57-b13d-d8ca76ea2abf">569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="bhc:GainLossRelatedToLitigationSettlementGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzEzLTQtMS0xLTU5NDcw_16cae596-b55f-4ed3-8279-8d2fe56836a7">442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="bhc:GainLossRelatedToLitigationSettlementGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzEzLTYtMS0xLTU5NDcw_293887d8-59d8-4987-a3cb-e70060c1514f">1,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of accrued legal settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE0LTItMS0xLTU5NDcw_a6ea0a9c-4fa6-4ce2-8d71-cb56d932729c">351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE0LTQtMS0xLTU5NDcw_477f10ae-1dc0-4c22-85d0-a284a182b9ba">168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE0LTYtMS0xLTU5NDcw_64984f8d-af3b-444f-b5d5-dc054f5314af">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE1LTItMS0xLTU5NDcw_cef6271c-f1f6-4602-9c16-7c393f1062f1">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE1LTQtMS0xLTU5NDcw_be08dcb5-0509-4f70-a6e9-bfe88af95876">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE1LTYtMS0xLTU5NDcw_d5d6e3e8-0459-4f56-9bac-4d0354f3b06e">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE2LTItMS0xLTU5NDcw_54745a3f-4df2-4b34-9ae9-159926e1065d">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE2LTQtMS0xLTU5NDcw_7a95514a-e029-45a5-b777-f9b54626b5e1">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE2LTYtMS0xLTU5NDcw_f8ba9e6d-ddad-463a-b6ba-7453169f3623">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain excluded from hedge effectiveness</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:DerivativeGainExcludedComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE3LTItMS0xLTU5NDcw_030db108-ba1c-4d09-ace0-6c0960a029a8">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:DerivativeGainExcludedComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE3LTQtMS0xLTU5NDcw_dc2c0960-0026-492b-ac2a-00e44e5a7784">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="bhc:DerivativeGainExcludedComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE3LTYtMS0xLTU5NDcw_724a7d91-bcfb-4172-aaf2-4cb8bbf8ad98">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE4LTItMS0xLTU5NDcw_47e71a10-f919-4de4-85ff-fc61e1181d65">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE4LTQtMS0xLTU5NDcw_146d596f-a6fb-466a-94b3-aa43cfa7ec88">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE4LTYtMS0xLTU5NDcw_035b6368-54cc-41d8-8adb-4493ca4cfc93">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of contingent consideration adjustments, including accretion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE5LTItMS0xLTU5NDcw_d55b702b-25ac-41ea-a18e-812ae1d0650f">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE5LTQtMS0xLTU5NDcw_3d5abae1-329b-43e9-800b-81c2bad7efe7">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE5LTYtMS0xLTU5NDcw_6c7d86e8-0326-4f85-9c56-3c84aba2894f">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzIwLTItMS0xLTU5NDcw_80da6c1e-5f9b-4120-99c1-6152f78b932c">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzIwLTQtMS0xLTU5NDcw_be76c20a-fe47-4e84-b349-c8e237aa18ad">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzIwLTYtMS0xLTU5NDcw_7a24874e-4acb-4d43-a0ae-64ac4e2dbd35">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzIyLTItMS0xLTU5NDcw_52d9edc9-f40e-4e35-a972-9f9362934dd7">229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzIyLTQtMS0xLTU5NDcw_63a7c944-13d1-40fa-af20-928f879935ce">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzIyLTYtMS0xLTU5NDcw_e4bd1589-2a06-4925-aeb6-52477491803c">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzIzLTItMS0xLTU5NDcw_ac4fa1cf-3b7c-49b9-bdc2-87ca23361fb5">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzIzLTQtMS0xLTU5NDcw_58dcbb47-0241-40cf-90b9-4761364fe4c9">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzIzLTYtMS0xLTU5NDcw_2d7bc5fd-d650-46dc-81df-8635d1852503">209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI0LTItMS0xLTU5NDcw_0c3766be-5bbf-4981-8f31-681db60cc792">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI0LTQtMS0xLTU5NDcw_644bed6a-1ba4-4544-8fed-b8ceb987369d">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI0LTYtMS0xLTU5NDcw_740bbbc3-1593-44db-8df4-246c04ea0de2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable, accrued and other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI1LTItMS0xLTU5NDcw_f8a44d9d-fa49-4ddc-90e6-e73d858f9580">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI1LTQtMS0xLTU5NDcw_8d868153-00d1-467d-a417-bdcdb9f20477">471</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI1LTYtMS0xLTU5NDcw_bc145763-6317-4fba-8c74-0261a06f4e89">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI2LTItMS0xLTU5NDcw_d2725eae-f390-4610-adb5-5f16f74922dc">1,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI2LTQtMS0xLTU5NDcw_2f2b56eb-4702-4d15-80a4-05e56107060b">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI2LTYtMS0xLTU5NDcw_05fc728f-48b5-4be5-bdd1-bc28a9481ecd">1,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows From Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of businesses, net of cash acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI4LTItMS0xLTU5NDcw_5d42665c-f263-46dc-9e95-e9663126e981">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI4LTQtMS0xLTU5NDcw_567ad31e-9460-47d9-b1f1-18a075a3ca95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI4LTYtMS0xLTU5NDcw_5bcab14e-de30-4993-8b76-7ccf90da2dc1">180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of intangible assets and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI5LTItMS0xLTU5NDcw_ed1baf6a-5828-487c-b608-df527d13e067">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI5LTQtMS0xLTU5NDcw_fdb81ce1-85c1-438e-a6f3-a7006e26da34">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI5LTYtMS0xLTU5NDcw_ae0fbb52-a803-4cbc-877f-026ac6be11b7">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMwLTItMS0xLTU5NDcw_9f7a3f71-2c3e-4aec-b85d-429e86b74525">269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMwLTQtMS0xLTU5NDcw_555dd7a9-cc37-48ca-aea7-91b2497d6e9f">302</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMwLTYtMS0xLTU5NDcw_32413a98-7996-4b94-93df-012e3987bc6a">270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMxLTItMS0xLTU5NDcw_27f5e259-3dbe-42de-bae2-1bb00f524da4">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMxLTQtMS0xLTU5NDcw_ba02451c-0837-4066-9c5a-e089f6d95972">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMxLTYtMS0xLTU5NDcw_5cbe52bd-9af5-4e15-9338-161e5c2ba3a4">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMyLTItMS0xLTU5NDcw_c9643adf-a2e2-4aba-91b7-649d4590f6d8">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMyLTQtMS0xLTU5NDcw_eb4db3ef-efda-4d91-a46c-65ddf62391b8">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMyLTYtMS0xLTU5NDcw_5b17fbd6-85c8-4b43-bf91-a92ef54f48ea">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of assets and businesses, net of costs to sell</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMzLTItMS0xLTU5NDcw_5477f053-8ea9-4e5b-82cd-1b0f00996ff8">669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMzLTQtMS0xLTU5NDcw_08950045-c81a-4ed0-ae87-117850ad41df">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMzLTYtMS0xLTU5NDcw_23b58c6d-01e5-4719-880d-5ea3bce65a35">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements from cross-currency swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:InterestSettlementOnCrossCurrencySwaps" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM0LTItMS0xLTU5NDcw_a4ef0812-ed81-49f3-8588-f60e99b58653">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:InterestSettlementOnCrossCurrencySwaps" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM0LTQtMS0xLTU5NDcw_6e01bf10-5c96-4b1c-a745-9f30d8720b0a">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="bhc:InterestSettlementOnCrossCurrencySwaps" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM0LTYtMS0xLTU5NDcw_75ff7b12-11b2-47f3-8a5c-d3e304496ae4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM1LTItMS0xLTU5NDcw_ddd796d3-a579-49c4-b472-e38f0fe21171">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM1LTQtMS0xLTU5NDcw_fa022c6b-fd27-43ad-a0d6-3465fb644a4e">261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM1LTYtMS0xLTU5NDcw_4f5d8ad6-9d64-464a-8941-565d64bff3b9">419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows From Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of long-term debt, net of discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM3LTItMS0xLTU5NDcw_d897ddc9-245c-4971-aa15-bb47d92d8ca9">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM3LTQtMS0xLTU5NDcw_1c51a1f9-84b2-4ad8-a78b-5d703e770761">3,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM3LTYtMS0xLTU5NDcw_60c77621-df6f-4f8d-83e0-f0af6dc1fbdb">5,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM4LTItMS0xLTU5NDcw_a774be4b-7804-4a90-9063-e5a3cba3a813">3,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM4LTQtMS0xLTU5NDcw_ac2961f8-8ade-47d8-95ca-6cacfbe95b40">5,642</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM4LTYtMS0xLTU5NDcw_36561e3b-0478-41a6-9f5c-1a2bbb8d997c">4,406</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings of short-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM5LTItMS0xLTU5NDcw_8e9e2426-f81c-4f82-ab86-47fa664bf4c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM5LTQtMS0xLTU5NDcw_58f68a0c-e85a-4b83-b9ce-52bc40b63ade">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM5LTYtMS0xLTU5NDcw_f5deb1a2-8278-4c49-8f5f-ebb7fc727f6d">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of short-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQwLTItMS0xLTU5NDcw_33b042ba-f12d-420f-8fec-524f17b286a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQwLTQtMS0xLTU5NDcw_e4566b08-1ac3-4bde-ad49-b7911cd9abea">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQwLTYtMS0xLTU5NDcw_44255a77-bfbe-40d2-b46c-2f53d1a61ca3">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of employee withholding taxes related to share-based awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQxLTItMS0xLTU5NDcw_3e1e0231-faae-4cca-bf5f-8501857840e6">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQxLTQtMS0xLTU5NDcw_1fbe83ab-f36c-4194-9826-c926027d9e5c">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQxLTYtMS0xLTU5NDcw_2ff8b4e7-9c2e-4735-bc47-9211991e6315">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQyLTItMS0xLTU5NDcw_a3f8e4d3-482b-4688-b5f5-560e42621959">83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQyLTQtMS0xLTU5NDcw_01317ea8-20fe-487b-93a1-b83ddd969eba">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQyLTYtMS0xLTU5NDcw_13913fe1-8e28-450c-962a-f24e2cda1544">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of financing costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ0LTItMS0xLTU5NDcw_8db45868-de7e-4ca0-8e4a-7245540fa8a2">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ0LTQtMS0xLTU5NDcw_48bf011d-130a-49d2-9c9f-a4659d51e304">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ0LTYtMS0xLTU5NDcw_0ed2ec64-2c67-4efd-ab50-d0abd4fd9783">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ1LTItMS0xLTU5NDcw_d76c2662-6728-4cb1-bd72-2650cb29cc8d">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ1LTQtMS0xLTU5NDcw_296e6c40-f1ae-4e6c-9ca0-65cb340a2499">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ1LTYtMS0xLTU5NDcw_32bfce0c-4e33-4683-bd10-851fd5952df7">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ2LTItMS0xLTU5NDcw_ee4e0f23-8cee-4543-b415-6d387f6f3523">1,513</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ2LTQtMS0xLTU5NDcw_e3646952-301f-4d7c-9cab-dc3c07774126">2,294</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ2LTYtMS0xLTU5NDcw_1c062c6e-684b-4094-80fb-0871bc76be05">1,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ3LTItMS0xLTU5NDcw_032b5561-78bf-40c3-98a6-ae3a7eb9505f">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ3LTQtMS0xLTU5NDcw_2925f622-4812-4a67-b3db-cb73fb26bcfc">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ3LTYtMS0xLTU5NDcw_930f6a98-1c37-40c8-b999-8f918dcecd4c">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in Cash and cash equivalents and Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ4LTItMS0xLTU5NDcw_04819823-fc62-421d-87a5-012a7ca396d6">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ4LTQtMS0xLTU5NDcw_5b755ac3-52ce-4342-a459-a853074cce11">1,428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ4LTYtMS0xLTU5NDcw_034efbbb-bccb-4548-86da-735f0c759dff">2,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents and Restricted cash and other settlement deposits, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ5LTItMS0xLTU5NDcw_f56bbd4d-c969-4832-a5a1-5682682dabf9">1,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231" decimals="-6" name="bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ5LTQtMS0xLTU5NDcw_e74153a5-94ce-4f8b-b88a-cf06e1175d0a">3,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a9900560564bdca7dec25381689c13_I20181231" decimals="-6" name="bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ5LTYtMS0xLTU5NDcw_dde3a2bd-7d1d-4101-8ebc-8b58b7880eb2">723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents and Restricted cash and other settlement deposits, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUwLTItMS0xLTU5NDcw_856fb697-9917-4dd5-a0a8-fc8d111ea128">2,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUwLTQtMS0xLTU5NDcw_3c06a303-5503-47bc-8aef-b9a2e61a7385">1,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231" decimals="-6" name="bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUwLTYtMS0xLTU5NDcw_c9ef9393-0c9f-4641-9070-40230bb63459">3,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUyLTItMS0xLTU5NDcw_4cd7f632-7461-4cd6-8485-3ceace812f1d">582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUyLTQtMS0xLTU5NDcw_6b7e0dc0-4836-4870-934a-2bcf4734c442">605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUyLTYtMS0xLTU5NDcw_832a9546-9877-484d-b44d-1c8399c5f9c0">3,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUzLTItMS0xLTU5NDcw_9b02b544-edc6-4a46-92d9-882df5090cbb">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUzLTQtMS0xLTU5NDcw_44f96318-221b-44d9-850f-7032347a2406">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUzLTYtMS0xLTU5NDcw_bf6ee8b2-08c2-48a8-baaa-9692a4c54237">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents and Restricted cash and other settlement deposits, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzU0LTItMS0xLTU5NDcw_862e635f-d101-406a-b9ea-1f7c5c114325">2,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzU0LTQtMS0xLTU5NDcw_87f9e4f8-2446-46a3-826c-fb9f91e039f3">1,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231" decimals="-6" name="bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzU0LTYtMS0xLTU5NDcw_dc172e07-3f9d-4856-9e59-091fd310217f">3,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_298"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_301"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDEvZnJhZzoxMGY1ODBjZjIyM2U0OTExYmU3MGUyYmYxMDViNDBlZS90ZXh0cmVnaW9uOjEwZjU4MGNmMjIzZTQ5MTFiZTcwZTJiZjEwNWI0MGVlXzEwOTM_a78610dc-f94b-4fd5-939c-4d63ca997c55" continuedAt="i8a12e036e2ff4fc1ac565194611c426d" escape="true">DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8a12e036e2ff4fc1ac565194611c426d">Bausch Health Companies Inc. (the &#8220;Company&#8221;), formerly known as Valeant Pharmaceuticals International, Inc.,  is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#8220;OTC&#8221;) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in approximately <ix:nonFraction unitRef="country" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-2" name="us-gaap:NumberOfCountriesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDEvZnJhZzoxMGY1ODBjZjIyM2U0OTExYmU3MGUyYmYxMDViNDBlZS90ZXh0cmVnaW9uOjEwZjU4MGNmMjIzZTQ5MTFiZTcwZTJiZjEwNWI0MGVlXzUwNg_b81e6f0e-527b-4346-9d30-74c488f7cef2">100</ix:nonFraction> countries.  Effective August 9, 2013, the Company continued from the federal jurisdiction of Canada to the Province of British Columbia, meaning that the Company became a company registered under the laws of the Province of British Columbia as if it had been incorporated under the laws of the Province of British Columbia. As a result of this continuance, the legal domicile of the Company became the Province of British Columbia, the Canada Business Corporations Act ceased to apply to the Company and the Company became subject to the British Columbia Business Corporations Act.</ix:continuation></span></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_304"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NjM0_b01fe64c-e7c5-4d6a-9d55-a1b149d1b1e0" continuedAt="ia704e025c53c4702a323d2ada5f2f4ef" escape="true">SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="ia704e025c53c4702a323d2ada5f2f4ef" continuedAt="i931ab569d3e5426c999d48e4bde7d66d"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NzA5_6e6d99b8-4316-4090-8a9e-5ce445870389" continuedAt="i4f0d6fc7b4944b10b7e526ea9c1034ce" escape="true">Basis of Presentation and Use of Estimates </ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4f0d6fc7b4944b10b7e526ea9c1034ce">The Consolidated Financial Statements have been prepared by the Company in United&#160;States (&#8220;U.S.&#8221;) dollars and in accordance with U.S.&#160;generally accepted accounting principles (&#8220;U.S. GAAP&#8221;), applied on a consistent basis. The Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.</ix:continuation> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation of the Bausch + Lomb Eye-Health Business and Initial Public Offering of Solta Medical Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, the Company announced its intentions to separate its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc. (the &#8220;B+L Separation&#8221;). On August 3, 2021, the Company announced its intentions to conduct an initial public offering ("IPO") of its aesthetic medical device business, Global Solta (the &#8220;Solta IPO").  In January 2022, the Company completed the internal organizational design and structure of the new eye-health entity, Bausch + Lomb Corporation ("Bausch + Lomb"), and the new Global Solta entity, Solta Medical Corporation ("Solta"), as previously announced and aims to launch the B+L IPO and the Solta IPO when financial market conditions are favorable (and subject to receipt of regulatory, stock exchange and other approvals). Following the B+L IPO the Company expects to complete the separation of Bausch + Lomb after the expiry of customary lockups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to the receipt of applicable shareholder and other necessary approvals. The B+L Separation and the proposed Solta IPO will establish <ix:nonFraction unitRef="company" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="INF" name="bhc:BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzEwOTk1MTE3MDgxODM_c076722a-c085-4e29-ae9e-601892032829">three</ix:nonFraction> separate companies that include: (i) a fully integrated eye-health company which will consist of the Company&#8217;s Bausch + Lomb Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmic Pharmaceuticals businesses, (ii) a global provider of aesthetic medical devices which will consist of the Company&#8217;s Solta business and (iii) a diversified pharmaceutical company which will include the Company&#8217;s Salix, International Rx, dentistry, neurology, medical dermatology and generics pharmaceutical businesses. These audited Consolidated Financial Statements do not include any adjustments to give effect to either the B+L Separation or the proposed Solta IPO.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impacts of COVID-19 Pandemic</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has, and continues to, adversely impact the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facility closures and production suspensions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which these events may continue to impact the Company's business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company's control. Such developments include the availability and effectiveness of vaccines for the COVID-19 virus, COVID-19 vaccine immunization rates, the ultimate geographic spread and duration of the pandemic, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, such as the delta and omicron variants, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company's business, financial condition, cash flows and results of operations. </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i931ab569d3e5426c999d48e4bde7d66d" continuedAt="i52da47ce6934455e873350a3de17201f"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing. Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable. </span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NTky_8c1ea3d3-a37b-45d9-a599-d4e6e96edaa8" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the Company's Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows.  The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of amortizable intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants and making going concern assessments; reporting unit fair values for testing goodwill for impairment and allocating goodwill to new reporting unit structure on a relative fair value basis; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; fair value of cross-currency swaps; fair value of foreign currency exchange contracts; and the recognition of the fair value of assets and liabilities acquired in a business combination, including the fair value of contingent consideration. Under certain product manufacturing and supply agreements, management uses information from the Company&#8217;s commercialization counterparties to arrive at estimates for future returns, rebates and chargebacks. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s Consolidated Financial Statements could be materially impacted.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NzI3_9c2515b1-e952-4650-a158-32bf7327bce0" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1ODA2_9a7f20e2-5ecf-4b9c-9606-441be7e7faa1" continuedAt="i7052a5e3d10f45e3b17e96a6d2074606" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Consolidated Financial Statements after the date of acquisition.  Acquired in-process research and development (&#8220;IPR&amp;D&#8221;) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;D has an alternative future use. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;D with no alternative future use is charged to expense at the acquisition&#160;date and any future contingent consideration is not recorded until it becomes probable.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1Njky_17c6d108-b609-444e-a471-da81be0a8a26" continuedAt="ibd4db6415df5429e9e0f6c7e2da0c808" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibd4db6415df5429e9e0f6c7e2da0c808">The estimated fair values of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities approximate their carrying values due to their short maturity periods. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows or Monte Carlo Simulation (when appropriate) analyses and assessment of the probability of occurrence of potential future events.</ix:continuation> </span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NjY1_e903db98-dfa8-49a4-bf0f-2c65592a4fff" continuedAt="if9837d569d66498391ae2dd4fa346bc5" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Derivative Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cross-currency swaps qualified for and had been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and were remeasured at each reporting date to reflect changes in their </span></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i52da47ce6934455e873350a3de17201f" continuedAt="i4bc30955fae740f2b8639d21a1175104"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if9837d569d66498391ae2dd4fa346bc5" continuedAt="ia909f9a42f1643848ea5898e951ada2f">fair values.  The fair value was determined via a mark-to-market analysis, using observable (Level&#160;2) inputs. These inputs included: (i)&#160;the foreign currency exchange spot rate between the euro and U.S. dollar, (ii)&#160;the interest rate yield curves in the euro and U.S. dollar and (iii)&#160;the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Loss as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulated other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps was ineffective. The Company uses the spot method of assessing hedge effectiveness. The Company had elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as a reduction of Interest expense in the Consolidated Statements of Operations.</ix:continuation></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia909f9a42f1643848ea5898e951ada2f">The Company uses foreign currency exchange contracts to economically hedge the foreign exchange exposure on certain of the Company&#8217;s intercompany and third party balances. The Company's foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other.</ix:continuation> </span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1ODMx_698e1b5d-7d0a-443a-90e0-47f277a2e647" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash in bank accounts and highly liquid investments with maturities of <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzk2Njk_7378fd29-f1ac-49e5-85e0-e9f783c24bd3">three months</ix:nonNumeric> or less when&#160;purchased.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NjU2_dc933ab6-e172-4910-9c98-c100f2c968b6" continuedAt="i52a3ca4a536f44eab1bda925d1048259" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, cross-currency swaps and foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in high-quality, money market instruments and term deposits with varying maturities, but typically less than <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzEwMTI5_2ccf9cf0-7482-4d29-b6c8-75540bae7b3c">three months</ix:nonNumeric>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash deposited at banks may exceed the amount of insurance provided on such deposits. Generally, these cash deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate such risks by spreading its risk across multiple counterparties and monitoring the risk profiles of these counterparties.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i52a3ca4a536f44eab1bda925d1048259">The Company&#8217;s trade receivables primarily represent amounts due from wholesale distributors, retail pharmacies, government entities and group purchasing organizations. Outside of the U.S., concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the number of customers using the Company&#8217;s products, as well as their dispersion across many different geographic regions. The Company performs periodic credit evaluations of customers and does not require collateral. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The credit and economic conditions within Argentina, Brazil, Egypt, Greece, among other members of the European Union, Turkey, Ukraine and Venezuela have been weak in recent years.</ix:continuation> These conditions have increased, and may continue to increase, the average length of time that it takes to collect on the Company&#8217;s trade receivables outstanding in these countries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company&#8217;s <ix:nonFraction unitRef="wholesaler" contextRef="i6d07942ff8e3491b92dc863012aacd40_D20210101-20211231" decimals="INF" name="bhc:NumberOfLargestWholesaleCustomers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzExNjY4_d6f41bba-0783-416e-99d2-65830403a7ea">three</ix:nonFraction> largest U.S. wholesaler customers accounted for approximately <ix:nonFraction unitRef="number" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="2" name="bhc:ConcentrationRiskPercentageofNetTradeReceivables" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzExNzMz_650f04fb-e88e-42ec-8277-97219d114c74">44</ix:nonFraction>% of net trade receivables. In addition, as of December 31, 2021 and 2020, the Company&#8217;s net trade receivable balance from Argentina, Brazil, Egypt, Greece, Serbia, South Africa, Turkey, Ukraine, Venezuela and Vietnam amounted to $<ix:nonFraction unitRef="usd" contextRef="i7cee20a09d6f45c983e7a622d798eb96_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzExOTIw_20173345-80b1-4622-9089-9017002a5335">78</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie46cfa6ebbfe4fe3bfce4e96130f07e5_I20201231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzI3NDg3NzkxNDE5NjI_b2f24b93-ba08-48ae-90e7-88f924f90cfc">166</ix:nonFraction>&#160;million, respectively, the majority of which is current or less than <ix:nonNumeric contextRef="i1d7e258ccc574f96965b59dea148df20_D20210101-20211231" name="bhc:PastDuePeriodForAccountsReceivableToBeNegligible" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzExOTkx_6495b762-5f93-41f0-926c-a030117907e7">90</ix:nonNumeric> days past due. The portion of the net trade receivable from these countries that is past due more than <ix:nonNumeric contextRef="i1d7e258ccc574f96965b59dea148df20_D20210101-20211231" name="bhc:PeriodReceivableOutstanding" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzEyMDk3_38a5fbaf-6186-45c4-b0b5-8c397c7674d6">90</ix:nonNumeric>&#160;days amounted to $<ix:nonFraction unitRef="usd" contextRef="i7cee20a09d6f45c983e7a622d798eb96_I20211231" decimals="-6" name="bhc:TradeReceivableNetPortionPastDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzEyMTE3_28ddabd7-e78d-4529-a523-fb11ec99bf06">2</ix:nonFraction> million, as of December 31, 2021, a portion of which is comprised of public hospitals.  Based on an analysis of credit risk, including an analysis of bad debt experience and assessment of historical payment patterns for such customers, the Company has established a reserve covering more than half of the balance past due more than <ix:nonNumeric contextRef="i1d7e258ccc574f96965b59dea148df20_D20210101-20211231" name="bhc:PeriodReceivableOutstanding" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzEyNDIz_569ac2a0-e7a0-48c9-aea4-130ead830fc3">90</ix:nonNumeric> days for such countries. Over the three-year period ended December&#160;31, 2021, the Company has not experienced any material losses from uncollectible accounts in excess of the established reserves.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not enter into financial instruments for trading or speculative purposes. Further, the Company has a policy of only entering into contracts with parties that have at least an investment grade credit rating. The Company enters into cross-currency swaps and foreign currency exchange contracts with high credit quality financial institutions. The counter-parties to the Company's cross-currency swaps and foreign currency exchange contracts are major financial institutions, and there is no significant concentration of exposure with any one counter-party. To date, no counterparty has failed to meet its obligations to the Company and management believes the risk of loss associated with these contracts is </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i4bc30955fae740f2b8639d21a1175104" continuedAt="i9f793fe6131148489ea512cd588c73a8"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remote.  See Note 5, "FAIR VALUE MEASUREMENTS" for additional details regarding the Company's cross-currency swaps and foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NjU4_85b42cbe-6670-469b-9214-47bc55788fa1" continuedAt="i28dfb6c328034f38a06ab9c5c383a8de" escape="true">Allowance for Credit Losses</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i28dfb6c328034f38a06ab9c5c383a8de">An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160; Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses.</ix:continuation> Allowance for credit losses were $<ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzE0MjQ4_aa18c4c9-7467-4958-a6f3-aad89315bafa">35</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzE0MjUy_5d06e3e0-c9a0-4fc6-a2e9-6f2c749ed1e4">39</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzE0MjU5_700a8a60-4d67-4faa-8a8a-cd8a59f1c356">48</ix:nonFraction>&#160;million as of December 31, 2021, 2020 and 2019, respectively. <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NjU5_34d8af9c-36ce-41d4-aaef-593fde501a09" continuedAt="icef48280453141e59527f7353eff7b44" escape="true">The activity in the allowance for credit losses for trade receivables for the years 2021, 2020 and 2019 is as follows.</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><ix:continuation id="icef48280453141e59527f7353eff7b44"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.965%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzEtMS0xLTEtNTk0NzA_d6349bea-e3aa-4ff4-896a-08d7213698bc">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzEtMy0xLTEtNTk0NzA_f8f99ecc-98e3-4a8f-ba7e-0df3024f0293">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a9900560564bdca7dec25381689c13_I20181231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzEtNS0xLTEtNTk0NzA_d9fe08a9-9acb-4d7f-875e-a320fa764682">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retrospective effect of application of new accounting standard</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzItMS0xLTEtNTk0NzA_15c2d7b0-e1a9-4868-a747-07ef3f5cfa0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzItMy0xLTEtNTk0NzA_cdc95359-7424-4fdb-be7f-433f1dea8d4f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzItNS0xLTEtNTk0NzA_347887a8-6677-4017-9c6d-e5eef3f9597d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzMtMS0xLTEtNTk0NzA_f2b47312-27b9-48d2-b68f-9131da90363f">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzMtMy0xLTEtNTk0NzA_23d5877e-45cd-4afd-935c-0cf9e2f22bb4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzMtNS0xLTEtNTk0NzA_aaff335e-8124-43ea-920b-06b354a1727f">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzQtMS0xLTEtNTk0NzA_e189dcb7-1d63-4eda-b3c2-b5993d366897">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzQtMy0xLTEtNTk0NzA_ef39437c-9ed8-4d08-895e-e411dd29224f">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzQtNS0xLTEtNTk0NzA_1c09511c-c83c-4ec0-9bbf-49bec8f0be3a">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzUtMS0xLTEtNTk0NzA_0c066c28-f7f4-43ae-872a-ff724bdbcc85">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzUtMy0xLTEtNTk0NzA_c59e8c47-be0a-4f79-b61b-bf13aac4cbb1">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzUtNS0xLTEtNTk0NzA_dd0186b7-d4fa-4aa5-80c1-6e67fd7ea403">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:AccountsReceivableAllowanceForForeignExchangeAndOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzYtMS0xLTEtNTk0NzA_e07c1bcb-d64f-48ff-a5c7-048cafe64fb1">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:AccountsReceivableAllowanceForForeignExchangeAndOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzYtMy0xLTEtNTk0NzA_73af98f4-4907-4d7b-8aad-a36f2c69dc09">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="bhc:AccountsReceivableAllowanceForForeignExchangeAndOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzYtNS0xLTEtNTk0NzA_392e24f3-d1f8-41c2-b548-b8f19a8aa893">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzctMS0xLTEtNTk0NzA_aa18c4c9-7467-4958-a6f3-aad89315bafa">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzctMy0xLTEtNTk0NzA_88b91c4e-d8e2-4a41-8d36-3161d1e9f6c7">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzctNS0xLTEtNTk0NzA_740da4e9-dba0-49ca-b851-0ecb95433346">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1Nzc1_364744aa-4f32-4d2a-919d-6ab3ba5f410f" escape="true"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories comprise raw materials, work in process and finished goods, which are valued at the lower of cost or net realizable value, on a first-in, first-out basis. The cost value for work in process and finished goods inventories includes materials, direct labor and an allocation of overheads. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on&#160;hand.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1ODIz_cf1150f1-a370-42a8-9f3c-4814293fa191" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are reported at cost, less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction in progress. <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="bhc:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1Nzky_82de97dd-665f-48fc-abf6-ea47244a616b" continuedAt="i9b2a810de2ab40b2adbfe5421232b092" escape="true">Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful&#160;lives: </ix:nonNumeric></span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><ix:continuation id="i9b2a810de2ab40b2adbfe5421232b092"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:54.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i366ab3c0cc114fd3b2e77b4af953dd1f_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTowMzE4YjM4YmNlZTU0ZWFhOWViZGQzODI4YzY5YjMwMy90YWJsZXJhbmdlOjAzMThiMzhiY2VlNTRlYWE5ZWJkZDM4MjhjNjliMzAzXzAtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjplOGQ3ZDA1Y2E2MmY0YWViODE2ZGI2MDk0ZTA4YTdiZl80_2618f144-f6c6-4684-bb57-a97846f0eece">15</ix:nonNumeric> - <ix:nonNumeric contextRef="iaaa57eb8c0df42b19dda8cafee4e2828_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTowMzE4YjM4YmNlZTU0ZWFhOWViZGQzODI4YzY5YjMwMy90YWJsZXJhbmdlOjAzMThiMzhiY2VlNTRlYWE5ZWJkZDM4MjhjNjliMzAzXzAtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjplOGQ3ZDA1Y2E2MmY0YWViODE2ZGI2MDk0ZTA4YTdiZl85_15caf72d-9099-4ccc-91e7-4b1e2bb1aeb6">30</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to <ix:nonNumeric contextRef="i34a41a0fa13145bf8230d44859521d48_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTowMzE4YjM4YmNlZTU0ZWFhOWViZGQzODI4YzY5YjMwMy90YWJsZXJhbmdlOjAzMThiMzhiY2VlNTRlYWE5ZWJkZDM4MjhjNjliMzAzXzEtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjpiMjAyNmZlMGI2ZTg0N2Y4YWZiZWRmOGNhYzQyNTU3Zl8xMA_0a4142e6-a8fe-4073-a7bf-f78c7f0944b6">40</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icacb4e180aa541848a91e2776ddcb14a_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTowMzE4YjM4YmNlZTU0ZWFhOWViZGQzODI4YzY5YjMwMy90YWJsZXJhbmdlOjAzMThiMzhiY2VlNTRlYWE5ZWJkZDM4MjhjNjliMzAzXzItMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo5MWViNDM0MzExY2I0NmI5YjI5YjBiY2Q5ZTRjZjRlN180_9c471c83-4b3f-4229-baa4-4b21cdfb222d">3</ix:nonNumeric>&#160;-&#160;<ix:nonNumeric contextRef="i88a58a70adfc405cb63f4ecc44509a55_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTowMzE4YjM4YmNlZTU0ZWFhOWViZGQzODI4YzY5YjMwMy90YWJsZXJhbmdlOjAzMThiMzhiY2VlNTRlYWE5ZWJkZDM4MjhjNjliMzAzXzItMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo5MWViNDM0MzExY2I0NmI5YjI5YjBiY2Q5ZTRjZjRlN185_5439701b-dd3e-4dd4-8f69-223c2a04b0a4">20</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaddfdd394a12495d9cc12de4613f5d31_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTowMzE4YjM4YmNlZTU0ZWFhOWViZGQzODI4YzY5YjMwMy90YWJsZXJhbmdlOjAzMThiMzhiY2VlNTRlYWE5ZWJkZDM4MjhjNjliMzAzXzMtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjpkZTQ2MDFlODU4NDM0MGYxYjJlZTQzYTVkNDhmZmRjM180_3d086cb8-ca72-4d3c-9061-a844dfcdf98f">3</ix:nonNumeric>&#160;-&#160;<ix:nonNumeric contextRef="i6c48db1ce8ed4151a1ecb07006cc1eb2_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTowMzE4YjM4YmNlZTU0ZWFhOWViZGQzODI4YzY5YjMwMy90YWJsZXJhbmdlOjAzMThiMzhiY2VlNTRlYWE5ZWJkZDM4MjhjNjliMzAzXzMtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjpkZTQ2MDFlODU4NDM0MGYxYjJlZTQzYTVkNDhmZmRjM185_a7d1e9bb-09e8-4356-975a-258c56707c59">10</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to <ix:nonNumeric contextRef="i8b367dbe73ec48018042069891895784_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTowMzE4YjM4YmNlZTU0ZWFhOWViZGQzODI4YzY5YjMwMy90YWJsZXJhbmdlOjAzMThiMzhiY2VlNTRlYWE5ZWJkZDM4MjhjNjliMzAzXzQtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjplM2IzNjliNDc0ZDk0MWEyYTNkZjExMjFmOGM5MGM4OV8xMA_ca59d1c4-04b6-4f51-af78-bfe81622fe07">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of term of lease or <ix:nonNumeric contextRef="ie10da8de3b1d424385606609168cca9b_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTowMzE4YjM4YmNlZTU0ZWFhOWViZGQzODI4YzY5YjMwMy90YWJsZXJhbmdlOjAzMThiMzhiY2VlNTRlYWE5ZWJkZDM4MjhjNjliMzAzXzUtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjphOTU5MDZkOTVhZjA0MDNlODZjNjEwNWY4M2ZiZmU2ZV8zMQ_aae67618-eed9-44cb-9ba3-c565d2b45c4e">10</ix:nonNumeric> years</span></div></td></tr></table></ix:continuation></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i9f793fe6131148489ea512cd588c73a8" continuedAt="i82d1d094c4234e8b94dfb7249f9d97d1"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1ODIy_d463c23c-69c0-4bbe-9a8a-0209d1ed0a4d" escape="true"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reported at cost, less accumulated amortization and impairments. Intangible assets with finite lives are amortized over their estimated useful lives. <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="bhc:ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NjQ0_2d377c58-a54a-40d7-ba03-87205e9c285a" continuedAt="i3a978dc688074b38897fbbeeff3b02af" escape="true">Amortization is calculated primarily using the straight-line method based on the following estimated useful&#160;lives:</ix:nonNumeric></span></div><div style="margin-top:5pt;padding-left:18pt"><ix:continuation id="i3a978dc688074b38897fbbeeff3b02af"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:54.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8e253d2e372545a9be9b1908cb43277f_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo5MmM2NWM0OGRiZjY0NWJlODFlN2M4MDliYzJmNDQyOC90YWJsZXJhbmdlOjkyYzY1YzQ4ZGJmNjQ1YmU4MWU3YzgwOWJjMmY0NDI4XzAtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjpkZTkzNzA3Nzg5Yjk0NmRkODhmNjJhYzU1MGQ2OTY5OV80_f5fd29ef-146c-4081-9914-e086c8963d15">2</ix:nonNumeric> - <ix:nonNumeric contextRef="i57f30ccd1de94a63935d2ef0dd575c37_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo5MmM2NWM0OGRiZjY0NWJlODFlN2M4MDliYzJmNDQyOC90YWJsZXJhbmdlOjkyYzY1YzQ4ZGJmNjQ1YmU4MWU3YzgwOWJjMmY0NDI4XzAtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjpkZTkzNzA3Nzg5Yjk0NmRkODhmNjJhYzU1MGQ2OTY5OV85_9da0c997-0a57-4dd5-b496-4987aa3e8be9">20</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id146ea0827064b89a7577cc36b0679b2_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo5MmM2NWM0OGRiZjY0NWJlODFlN2M4MDliYzJmNDQyOC90YWJsZXJhbmdlOjkyYzY1YzQ4ZGJmNjQ1YmU4MWU3YzgwOWJjMmY0NDI4XzEtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjozYjBhYWJhMWM1ZTQ0MDM4OGM2M2VlOGM0OTQ5NmQ0NV80_db12a220-7a34-4c10-b478-0a2841e73308">9</ix:nonNumeric> - <ix:nonNumeric contextRef="i78e288346972478a97d9a959bb7d3568_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo5MmM2NWM0OGRiZjY0NWJlODFlN2M4MDliYzJmNDQyOC90YWJsZXJhbmdlOjkyYzY1YzQ4ZGJmNjQ1YmU4MWU3YzgwOWJjMmY0NDI4XzEtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjozYjBhYWJhMWM1ZTQ0MDM4OGM2M2VlOGM0OTQ5NmQ0NV85_59c25ab4-8cf7-4ea0-bed1-60b47dd98387">20</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i728cea9c2c2a45178ba159057c1da77b_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo5MmM2NWM0OGRiZjY0NWJlODFlN2M4MDliYzJmNDQyOC90YWJsZXJhbmdlOjkyYzY1YzQ4ZGJmNjQ1YmU4MWU3YzgwOWJjMmY0NDI4XzItMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo5MTIwNzU2YjMwODU0MGJiYTEyNmQ1ZjFiMmQyNGZiNV80_efc9e48d-fe0b-453c-baa3-8ec4a72b95a7">4</ix:nonNumeric> - <ix:nonNumeric contextRef="i931f3f4638c2440d8d4ffbb6ec962733_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo5MmM2NWM0OGRiZjY0NWJlODFlN2M4MDliYzJmNDQyOC90YWJsZXJhbmdlOjkyYzY1YzQ4ZGJmNjQ1YmU4MWU3YzgwOWJjMmY0NDI4XzItMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo5MTIwNzU2YjMwODU0MGJiYTEyNmQ1ZjFiMmQyNGZiNV85_6bd6155e-2fac-4ffe-9bf4-8b575f078375">15</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i588f12f4c6524d6b8656970aae16788c_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo5MmM2NWM0OGRiZjY0NWJlODFlN2M4MDliYzJmNDQyOC90YWJsZXJhbmdlOjkyYzY1YzQ4ZGJmNjQ1YmU4MWU3YzgwOWJjMmY0NDI4XzMtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjoxM2MwMWQzYWRkMDk0ZDYyYTcxZTA1YzlkOWYyZDVjNF80_b0ae55d1-6214-474a-898b-d659626c4dcf">7</ix:nonNumeric> - <ix:nonNumeric contextRef="i37bcb7f77b3249cf8d55cb530b605590_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo5MmM2NWM0OGRiZjY0NWJlODFlN2M4MDliYzJmNDQyOC90YWJsZXJhbmdlOjkyYzY1YzQ4ZGJmNjQ1YmU4MWU3YzgwOWJjMmY0NDI4XzMtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjoxM2MwMWQzYWRkMDk0ZDYyYTcxZTA1YzlkOWYyZDVjNF85_58d53203-6418-4273-ae77-fff19b56e047">9</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Out-licensed technology and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib131e2e5eaa54a10ae73c558ccbe6438_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo5MmM2NWM0OGRiZjY0NWJlODFlN2M4MDliYzJmNDQyOC90YWJsZXJhbmdlOjkyYzY1YzQ4ZGJmNjQ1YmU4MWU3YzgwOWJjMmY0NDI4XzQtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo1NmVkY2EzZTc1Nzc0ZWI5ODFmNGRlZTU3MjU0OTc5N180_5a8ba40a-92d5-40b8-b88e-063232ddcb43">8</ix:nonNumeric> - <ix:nonNumeric contextRef="i11fbfd9dfbeb4355bc882e75f9bee1db_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo5MmM2NWM0OGRiZjY0NWJlODFlN2M4MDliYzJmNDQyOC90YWJsZXJhbmdlOjkyYzY1YzQ4ZGJmNjQ1YmU4MWU3YzgwOWJjMmY0NDI4XzQtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo1NmVkY2EzZTc1Nzc0ZWI5ODFmNGRlZTU3MjU0OTc5N185_646f7e9e-b34c-442c-8497-be76170e8bff">9</ix:nonNumeric> years</span></div></td></tr></table></ix:continuation></div></ix:nonNumeric><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="bhc:DivestituresOfNoncoreProductsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1Nzg3_8a5f1e47-86fa-4a3a-b220-e459bc62caee" escape="true"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestitures of Products</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds on the divestiture of products and the carrying amount of the related assets is recorded as a gain/loss on sale within Other expense, net. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when realizable.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1ODI4_602da52a-3b70-4766-883b-0ab5d1dfeed0" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IPR&amp;D </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of IPR&amp;D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and&#160;amortized. Acquired IPR&amp;D assets are tested for impairment at least annually or when triggering events are identified.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of an acquired IPR&amp;D intangible asset is typically determined using an income approach. This approach starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#8217;s stage of completion, the probability of technical success, the projected costs to complete, expected market competition and an assessment of the asset&#8217;s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the expected cash flow&#160;streams.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1ODI0_3bc5a329-82b7-483c-b0cc-1617d8a95a44" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.  If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset, which include the amount and timing of the projected future cash flows. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash&#160;flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets, which includes acquired IPR&amp;D and the corporate trademark acquired in the acquisition of Bausch &amp; Lomb Holdings Incorporated (the &#8216;&#8216;B&amp;L Trademark&#8217;&#8217;), are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based on a comparison of the fair value of the asset to its carrying value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1Nzg4_6fd91b32-ce52-41c4-8f75-26447224eb7a" continuedAt="id57ddd65a1304a7791942f3ec2e1c341" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. Goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value. A reporting unit is the same as, or one level below, an operating segment. A</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n entity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is permitted to first assess qualitatively whether it is necessary to perform a quantitative impairment test for any of its reporting units. The quantitative impairment test is required only when the Company concludes that it is more likely than not that a reporting unit&#8217;s fair value is less than its carrying amount. In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company considers the totality of all relevant events or circumstances that affect the fair value or carrying amount of a reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company&#8217;s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, among other factors, the Company monitors </span></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i82d1d094c4234e8b94dfb7249f9d97d1" continuedAt="i5f005bc0121b413c9c5b47cb4e6f25fb"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id57ddd65a1304a7791942f3ec2e1c341">changes in its share price between annual impairment tests. The Company considers a decline in its share price that corresponds to an overall deterioration in stock market conditions to be less of an indicator of goodwill impairment than a unilateral decline in its share price reflecting adverse changes in its underlying operating performance, cash flows, financial condition and/or liquidity. In the event that the Company&#8217;s market capitalization does decline below its book value, the Company would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. The Company believes that short-term fluctuations in share prices may not necessarily reflect underlying values.</ix:continuation></span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:DeferredChargesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NzA1_9b688166-0e5f-47c7-949d-0bf3635a3087" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt discounts, premiums and issuance costs are presented in the Consolidated Balance Sheets as a direct deduction from or addition to the carrying amount of the related debt and are amortized or accreted, using the effective interest method, as interest expense over the contractual lives of the related credit facilities or notes. Deferred financing costs associated with revolving credit facility arrangements are included in the balances of Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets and are amortized as interest expense over the contractual life of the related revolving credit facility.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NzQ3_6cde736a-3424-431f-b75b-8855759874d9" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities of the Company&#8217;s foreign operations having a functional currency other than the U.S.&#160;dollar are translated into U.S.&#160;dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange gains and losses on transactions occurring in a currency other than an operation&#8217;s functional currency are recognized as a component of Foreign exchange and other in the Consolidated Statements of Operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NzE1_4215e8c5-165a-4b71-bc9b-e70350a80569" continuedAt="ia0535407377b46338065cecf315c37cb" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye-health, gastroenterology ("GI") and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 22, "SEGMENT INFORMATION" for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services.  To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract with the Company&#8217;s customers exists for each product sale.  Where a contract with a customer contains more than one performance obligation, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The transaction price is adjusted for variable consideration which is discussed below.  The Company generally recognizes revenue for product sales at a point in time, when the customer obtains control of the products.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160; The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.</span></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i5f005bc0121b413c9c5b47cb4e6f25fb" continuedAt="i94df57375bc044a781702ff706e22083"><ix:continuation id="ia0535407377b46338065cecf315c37cb" continuedAt="i0f73329bd45c423185658890f515b95e"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers.  Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&#160;</span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1Njg3_0f3e1171-1954-413f-abaf-8cd611884741" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity and ending balances of the Company&#8217;s variable consideration provisions the years 2021 and 2020.</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:28.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.881%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, January 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50ee5aa72d3d409087f4f4c75b43387e_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzEtMi0xLTEtNTk0NzA_84793d6b-cd2d-446b-869a-88de4a8efb62">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f50340c36654f40b4735a136065dcab_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzEtNC0xLTEtNTk0NzA_6947c1e5-79be-43c1-abfd-19320f4d98bb">691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d6eccdc67e42d784ec0e124b81624f_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzEtNi0xLTEtNTk0NzA_aee622f2-19a6-4c11-9724-6fa7e0cf16e5">927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7c501561f5644f289468e4d1128d42e_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzEtOC0xLTEtNTk0NzA_cc0eff52-7cc9-4baa-814a-a16af10f6a51">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3cb4db468554971984b9ca7a67eb81a_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzEtMTAtMS0xLTU5NDcw_1610f639-8b9a-4342-a7e4-d52461972498">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzEtMTItMS0xLTU5NDcw_2129bda0-f611-414d-89db-3e745b54b4a4">2,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fec29ee013641edab8d6221c9266fd7_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzMtMi0xLTEtNTk0NzA_e9b8c2df-1a0c-4109-8f06-bc6e50daa6a1">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675cd2d759a7429ca02cfef6330b3cc6_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzMtNC0xLTEtNTk0NzA_89d5b984-c9a8-421b-a1c7-97f2ccb0cdb1">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f22e24d99e4b1784cee096b11f5492_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzMtNi0xLTEtNTk0NzA_580ef4a1-6ec0-4568-b85e-1d79bedc2bcd">2,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ada5c2b4ba44f6890befae0c5abc3fc_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzMtOC0xLTEtNTk0NzA_ef32a0ff-fedc-4c25-8473-641d0740ef30">1,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfcf2240c9b14c88b49241f897539daa_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzMtMTAtMS0xLTU5NDcw_fc1eb6fc-1e24-4084-9f4e-84c30b34d57e">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzMtMTItMS0xLTU5NDcw_69f45d83-1b16-4549-8151-66f70a54a08a">5,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fec29ee013641edab8d6221c9266fd7_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzQtMi0xLTEtNTk0NzA_a7e76937-3a58-462d-a911-2367923047b5">613</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i675cd2d759a7429ca02cfef6330b3cc6_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzQtNC0xLTEtNTk0NzA_c476114b-60e9-45d2-9d7b-f5652179e0a1">236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9f22e24d99e4b1784cee096b11f5492_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzQtNi0xLTEtNTk0NzA_67085882-1d21-4b03-8974-4c72770522d7">2,322</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ada5c2b4ba44f6890befae0c5abc3fc_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzQtOC0xLTEtNTk0NzA_bcbdd162-4fb7-40f7-90d4-e5cfd2fd5618">1,909</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfcf2240c9b14c88b49241f897539daa_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzQtMTAtMS0xLTU5NDcw_4248225c-b15c-40b0-a30b-613a0809a5e8">193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzQtMTItMS0xLTU5NDcw_4acfa920-6ca9-4c87-bea4-5aebbd7e259d">5,273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2b595cb367c4f14bb366722419c77af_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzUtMi0xLTEtNTk0NzA_0420cac8-52a6-47a7-92bd-dfc887cff99b">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i833b35b656584bc39c2fb86f6978f755_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzUtNC0xLTEtNTk0NzA_a98b896c-978a-4a05-997d-100a377ded37">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b899431086f434796caec1c0bd402a8_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzUtNi0xLTEtNTk0NzA_8a397e37-e002-427e-8eaa-09bca0c34789">779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id26f10d6001d4bfd9222800e3b3bb4e3_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzUtOC0xLTEtNTk0NzA_352575fb-2c0c-4691-b5b8-ab3fbbc4062a">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b52931c7ab643db9a3682345b1db8cb_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzUtMTAtMS0xLTU5NDcw_bd6da273-46d7-496b-8861-cf74d0344272">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzUtMTItMS0xLTU5NDcw_032752fe-8a0c-48a1-9498-a07bc84ab022">1,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib91d99188bc541b7a824988141b34ae8_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzYtMi0xLTEtNTk0NzA_9c77bc74-3946-46c2-80fa-ffb07150b3f5">625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i700d81ebc7e14a5ea0134f3fcf286f38_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzYtNC0xLTEtNTk0NzA_713cc418-eac0-468f-94f6-52564932c0b8">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7af96439d8641e2a7f6c2f01d4642bd_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzYtNi0xLTEtNTk0NzA_8610de3e-4e40-49ea-afcb-3e82e5b23c0d">2,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id05dcbb022714c45b985fa95dd3e8361_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzYtOC0xLTEtNTk0NzA_eb2c8f9d-e518-45d7-b65d-af7c8d7da619">1,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6379354597f24e4290ab225072abe15b_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzYtMTAtMS0xLTU5NDcw_29bbf56c-7769-48a8-b50e-57d5f9b4b621">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzYtMTItMS0xLTU5NDcw_f9510c0a-b527-46ce-9ffb-95b27ffc7b50">5,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib91d99188bc541b7a824988141b34ae8_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzctMi0xLTEtNTk0NzA_c05643a9-0077-463c-b1ee-c6fbc9aee8bf">593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i700d81ebc7e14a5ea0134f3fcf286f38_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzctNC0xLTEtNTk0NzA_8f54820e-439f-4233-9169-6187e607a4b4">224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7af96439d8641e2a7f6c2f01d4642bd_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzctNi0xLTEtNTk0NzA_ec9451d8-bbb5-4bd9-980e-4b886c8d2b0c">2,297</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id05dcbb022714c45b985fa95dd3e8361_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzctOC0xLTEtNTk0NzA_77a6e5ae-3b08-45d1-9671-866f39f73a7f">2,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6379354597f24e4290ab225072abe15b_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzctMTAtMS0xLTU5NDcw_d9b80273-d12e-4032-a1a8-53d4e96a1750">251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzctMTItMS0xLTU5NDcw_99aa0af2-939b-4d7f-b87e-2185c604830b">5,378</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87951ceed7ea4e5aa8491f46d9db41d2_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzgtMi0xLTEtNTk0NzA_5aae8d8d-3e43-4185-8d3d-a83973b2ad06">222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bac5a748c9c4daca0dcbeb78e404e12_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzgtNC0xLTEtNTk0NzA_2425e9e0-8169-4ce6-af31-6bd8105571e2">482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aa0cd8be82c40ad85b35a58508fa64c_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzgtNi0xLTEtNTk0NzA_cd9fbb35-a646-4507-a80e-3ba58597d3a7">944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9942400776ce47beaad5aaea33213d31_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzgtOC0xLTEtNTk0NzA_5a2f10a4-420c-4701-86ca-989401fa2535">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cfba0d37ba44869c896ccd738c2fea_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzgtMTAtMS0xLTU5NDcw_9459eb86-218c-4bdb-80c2-58a300938d8b">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzgtMTItMS0xLTU5NDcw_fda4e534-4979-428e-a417-5be3fa7a4e21">1,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $<ix:nonFraction unitRef="usd" contextRef="ib40c6b7597d6467d804e55df949889b0_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzI2MzQ5_fb94851b-a18a-46eb-b9bc-960b00e59480">36</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1ff61d6d82a848d6becbe126cfc26963_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzI2MzU2_301c20f2-a314-489d-9bd3-0ce467fd5ecc">32</ix:nonFraction> million as of December 31, 2021 and 2020, respectively, which are reflected as a reduction of Trade accounts receivable, net in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company's products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis.  This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period.  The Company applies this method consistently for contracts with similar characteristics.  The following describes the major sources of variable consideration in the Company&#8217;s customer arrangements and the methodology, estimates and judgments applied to estimate each type of variable consideration.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Discounts and Allowances</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash discounts are offered for prompt payment and allowances for volume purchases. Provisions for cash discounts and allowances are estimated at the time of sale and recorded as direct reductions to trade receivables and revenue. Management estimates the provisions for cash discounts and allowances based on contractual sales terms with customers, an analysis of unpaid invoices and historical payment experience. Estimated cash discounts and allowances have historically been predictable and less subjective, due to the limited number of assumptions involved, the consistency of historical experience and the fact that these amounts are generally settled within <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="bhc:CashDiscountsAndAllowancesSettlementPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzI4ODU1_1931d3fe-4f6c-48f6-9598-69b85c90fca8">one month</ix:nonNumeric> of incurring the&#160;liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, customers are generally allowed to return a product within a specified period of time before and after its expiration date, excluding European businesses which generally do not provide a right of return. The returns provision is estimated utilizing historical sales and return rates over the period during which customers have a right of return, taking into account available information on competitive products and contract changes. The information utilized to estimate the returns provision includes: (i) historical return and exchange levels, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription demand for products, (iv) remaining shelf lives of products at the date of sale and (v) estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns.</span></div></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i94df57375bc044a781702ff706e22083" continuedAt="i3a247f493e5a497aa8c367bf3f71db34"><ix:continuation id="i0f73329bd45c423185658890f515b95e" continuedAt="ia1970f927cd1499292c991962db54238"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the estimate for returns, management is required to make certain assumptions regarding the timing of the introduction of new products and the potential of these products to capture market share. In addition, certain assumptions with respect to the extent and pattern of decline associated with generic competition are necessary. These assumptions are formulated using market data for similar products, past experience and other available information.  These assumptions are continually reassessed, and changes to the estimates and assumptions are made as new information becomes available. A change of 1% in the estimated return rates would have impacted the Company&#8217;s pre-tax earnings by approximately $<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzMwNTU5_cc96ee34-4572-4c2a-adb3-63d5feaeb76c">81</ix:nonFraction> million for the year 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimate for returns may be impacted by a number of factors, but the principal factor relates to the inventory levels in the distribution channel. When management becomes aware of an increase in such inventory levels, it considers whether the increase may be temporary or other-than-temporary. Temporary increases in wholesaler inventory levels will not warrant revision to the provision for returns. Other-than-temporary increases in wholesaler inventory levels, however, may be an indication that future product returns could be higher than originally anticipated, and, as a result, estimates for returns may need to be adjusted. Factors that suggest increases in wholesaler inventory levels are temporary include: (i) recently implemented or announced price increases for certain products, (ii) new product launches or expanded indications for existing products and (iii) timing of purchases by wholesale customers. Conversely, factors that suggest increases in wholesaler inventory levels are other-than-temporary include: (i) declining sales trends based on prescription demand, (ii) introduction of new products or generic competition, (iii) increasing price competition from generic competitors and (iv) changes to the U.S.&#160;National Drug Codes (&#8220;NDC&#8221;) of products.  Changes in the NDC of products could result in a period of higher returns related to products with the old NDC, as U.S.&#160;customers generally permit only one NDC per product for identification and tracking within their inventory systems.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="i700d81ebc7e14a5ea0134f3fcf286f38_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzMyNTc5_fc9dbb35-4645-47eb-9e1d-35a63f8c15f0">131</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i675cd2d759a7429ca02cfef6330b3cc6_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzMyNTg2_0d510734-cbf7-4094-b75e-122bfe1b5aae">120</ix:nonFraction>&#160;million, respectively, and includes reductions in variable consideration for sales return provisions related to past sales of approximately $<ix:nonFraction unitRef="usd" contextRef="i700d81ebc7e14a5ea0134f3fcf286f38_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzMyNzIx_96715196-9fab-4527-8601-c7387ab5b725">28</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i675cd2d759a7429ca02cfef6330b3cc6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzMyNzI4_f30451e3-9d4a-43df-aeea-e7888de607cd">38</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Chargebacks</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales made under governmental and managed-care pricing programs in the U.S. are subject to rebates.&#160; The Company participates in state government-managed Medicaid programs, as well as certain other qualifying federal and state government programs whereby rebates are provided to participating government entities. Medicaid rebates are generally billed 45 days to 270&#160;days after the quarter in which the product is dispensed to the Medicaid participant.  As a result, the Medicaid rebate reserve includes an estimate of outstanding claims for end-customer sales that occurred, but for which the related claim has not been billed and/or paid, and an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. The calculation of the Medicaid rebate reserve also requires other estimates, such as estimates of sales mix, to determine which sales are subject to rebates and the amount of such rebates. A change of 1% in the estimated rates used in the Medicaid rebate reserve would have impacted the Company&#8217;s pre-tax earnings by approximately $<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzMzODg0_a2fe7464-9f9b-4c77-a814-9d8d617ce72a">76</ix:nonFraction> million for 2021. Quarterly, the Medicaid rebate reserve is adjusted based on actual claims paid. Due to the delay in billing, adjustments to actual claims paid may incorporate revisions of that reserve for several periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market&#160;share.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks relate to contractual agreements to sell products to government agencies, group purchasing organizations and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these group purchasing organizations or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In estimating provisions for rebates and chargebacks, management considers relevant statutes with respect to governmental pricing programs and contractual sales terms with managed-care providers and group purchasing organizations. Management estimates the amount of product sales subject to these programs based on historical utilization levels. Changes in the level of utilization of products through private or public benefit plans and group purchasing organizations will affect the amount of rebates and chargebacks that the Company is obligated to pay. Management continually updates these factors based on new contractual or statutory requirements, and any significant changes in sales trends that may impact the percentage of products subject to rebates or&#160;chargebacks.</span></div></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i3a247f493e5a497aa8c367bf3f71db34" continuedAt="iff8eb90545bd459587ec2ec863e5f3bd"><ix:continuation id="ia1970f927cd1499292c991962db54238" continuedAt="i73c0c9e96b0b47618850859e8603efa8"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of Managed Care, Medicaid and other rebates and chargebacks has become more significant as a result of a combination of deeper discounts implemented in each of the last three years, changes in the Company&#8217;s product portfolio due to recent acquisitions and increased Medicaid utilization due to expansion of government funding for these programs.&#160;Management&#8217;s estimate for rebates and chargebacks may be impacted by a number of factors, but the principal factor relates to the level of inventory in the distribution channel.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebate provisions are based on factors such as timing and terms of plans under contract, time to process rebates, product pricing, sales volumes, amount of inventory in the distribution channel and prescription trends. Adjustments to actual for the years 2021 and 2020 were not material to the Company&#8217;s revenues or earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient Co-Pay Assistance programs, Consumer Rebates and Loyalty Programs are rebates offered on many of the Company&#8217;s products.  Patient Co-Pay Assistance Programs are patient discount programs offered in the form of coupon cards or point of sale discounts, with which patients receive certain discounts off their prescription at participating pharmacies, as defined by the specific product program. An accrual for these programs is established, equal to management&#8217;s estimate of the discount, rebate and loyalty incentives attributable to a sale.  That estimate is based on historical experience and other relevant factors. The accrual is adjusted throughout each quarter based on actual experience and changes in other factors, if any.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Fees</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells products primarily to wholesalers, and in some instances to large pharmacy chains such as CVS and Walmart.  The Company has Distribution Services Agreements ("DSAs") with several large wholesale customers such as McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Specialty.  Under the DSAs, the wholesalers agree to provide services, and the Company pays the contracted DSA distribution service fees for these services based on product volumes.  Additionally, price appreciation credits are generated when the Company increases a product&#8217;s wholesaler acquisition cost (&#8220;WAC&#8221;) under contracts with certain wholesalers. Under such contracts, the Company is entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. Such credits are offset against the total distribution service fees paid to each such wholesaler. The variable consideration associated with price appreciation credits is reflected in the transaction price of products sold when it is determined to be probable that a significant reversal will not occur. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $<ix:nonFraction unitRef="usd" contextRef="i09d8280f6d264587b97b2d17bcb992bd_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM4NTEx_9f2f47ee-a9fc-4a71-b9d5-e7de082a4364">17</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib42d4166d63e4e788726dbd3033cb09c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM4NTE4_4701d43e-56fe-45fb-b1a0-c901af2d1225">15</ix:nonFraction> million for the years 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Commissions </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Component</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i73c0c9e96b0b47618850859e8603efa8">The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less.</ix:continuation> The Company's global payment terms are generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM5MzI5_70a72a43-4f7f-4419-aca2-445874d33f43">thirty</span> to <ix:nonNumeric contextRef="i973d974eec8c4651854590262490ae2f_D20210101-20211231" name="bhc:RevenuePerformanceObligationPaymentTerms" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM5MzM1_5190b05c-a60b-46f8-b878-91e3f0963587">ninety days</ix:nonNumeric>.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain facilities, vehicles and equipment principally under multi-year agreements generally having a lease term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM5NDgx_a56638c4-d79f-4701-9cb4-eeba251c7aba">one</span> to <ix:nonNumeric contextRef="ic93289a0b5264300a6c1b192827b7231_I20211231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM5NDg3_9ea32856-f2b4-4b91-bfa3-c1ddaaf9532d">twenty years</ix:nonNumeric>, some of which include termination options and options to extend the lease term from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM5NTc1_4194aaa1-36a3-4275-bf8a-8595947de005">one</span> to <ix:nonNumeric contextRef="ic93289a0b5264300a6c1b192827b7231_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM5NTgx_713878d5-7c73-4302-a1f6-c4633a82f9e6">five years</ix:nonNumeric> or on a month-to-month basis. The Company includes options that are reasonably certain to be exercised as part of the lease term. The Company may negotiate termination clauses in anticipation of changes in market conditions but generally, these termination options are not exercised. Certain lease agreements also include variable payments that are dependent on usage or may vary month-to-month such as insurance, taxes and maintenance costs. None of the Company's lease agreements contain material residual value guarantees or material restrictive covenants.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to record a right-of-use asset and corresponding lease liability, equal to the present value of the lease payments at the commencement date of each lease. For all asset classes, in determining future lease payments, the Company has elected to aggregate lease components, such as payments for rent, taxes and insurance costs with non-lease components such as maintenance costs, and account for these payments as a single lease component. In limited </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="iff8eb90545bd459587ec2ec863e5f3bd" continuedAt="i0d7804c88d9043c4a5ad8910544e7a23"><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">circumstances, when the information necessary to determine the rate implicit in a lease is available, the present value of the lease payments is determined using the rate implicit in that lease. If the information necessary to determine the rate implicit in a lease is not available, the Company uses its incremental borrowing rate at the commencement of the lease, which represents the rate of interest that the Company would incur to borrow on a collateralized basis over a similar term.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All leases must be classified as either an operating lease or finance lease. The classification is determined based on whether substantive control has been transferred to the lessee.  The classification governs the pattern of lease expense recognition. For leases classified as operating leases, total lease expense over the term of the lease is equal to the undiscounted payments due in accordance with the lease arrangement. Fixed lease expense is recognized periodically on a straight-line basis over the term of each lease and includes: (i) imputed interest during the period on the lease liability determined using the effective interest rate method plus (ii) amortization of the right-of-use asset for that period. Amortization of the right-of-use asset during the period is calculated as the difference between the straight-line expense and the imputed interest on the lease liability for that period. Variable lease expense is recognized when the achievement of the specific target is considered probable.</span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NzAx_e232b6ed-ee44-4316-9990-1f2e19acfd45" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to internal research and development programs, including costs associated with the development of acquired IPR&amp;D, are expensed as goods are delivered or services are performed. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Milestone payments made to third parties before a product receives regulatory approval, but after the milestone is determined to be probable, are expensed and included in Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third parties as reimbursement of development activities conducted under certain research and development arrangements are recognized as a reduction of Research and development expenses.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:LegalCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1Nzk1_fd0a9a8a-fe97-4a36-bd6e-7ba7f2c61769" continuedAt="i6b8beea9654242ceb3dc2634cbcdd24c" escape="true">Legal Costs </ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6b8beea9654242ceb3dc2634cbcdd24c">Legal fees and other costs related to litigation and other legal proceedings or services are expensed as incurred and are included in Selling, general and administrative expenses. Certain legal costs associated with acquisitions are included in Acquisition-related costs and certain legal costs associated with divestitures, legal settlements and other business development activities are included in Litigation and other matters or Net gain on sales of assets within Other expense (income), net, as appropriate. Legal costs expensed are reported net of expected insurance recoveries. A claim for insurance recovery is recognized when realization becomes probable</ix:continuation>.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1ODAy_1210010a-fcae-479b-bfe2-05687b30e636" continuedAt="i1f27433406cc4d21a345abdcb9fe3178" escape="true">Advertising Costs</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1f27433406cc4d21a345abdcb9fe3178">Advertising costs comprise product samples, print media, promotional materials and television advertising and are expensed on the first use of the advertisement.</ix:continuation> Included in Selling, general and administrative expenses are advertising costs of $<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzQ1NDg1_bfc70445-5bdd-4676-a9da-46b365c886a5">515</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzQ1NDg5_2d73d75d-14fc-4bfb-a09b-80f84c363a1c">451</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzQ1NDk2_f4e084e8-4104-4760-88b3-71d55ca8fb52">544</ix:nonFraction> million, for 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1Nzg5_89cd629e-cad2-466a-a955-fe1d5d5e025f" continuedAt="i74931580a19a4445856e8a6459e152df" escape="true">Share-Based Compensation </ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i74931580a19a4445856e8a6459e152df">The Company recognizes all share-based payments to employees, including grants of employee stock options and restricted share units (&#8220;RSUs&#8221;), at estimated fair value. The Company amortizes the fair value of stock option or RSU grants on a straight-line basis over the requisite service period of the individual stock option or RSU grant, which generally equals the vesting period. Stock option and RSU forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based compensation is recorded in Research and development expenses and Selling, general and administrative expenses, as&#160;appropriate.</ix:continuation> </span></div><ix:continuation id="i7052a5e3d10f45e3b17e96a6d2074606"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-Related Contingent Consideration </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related contingent consideration, which primarily consists of potential milestone payments and royalty obligations, is recorded in the Consolidated Balance Sheets at its acquisition date estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in fair value measurement accounting.</span></div></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i0d7804c88d9043c4a5ad8910544e7a23" continuedAt="i7a05fae4adf34cabb03e7426a2d11a94"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:InterestExpensePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1ODE2_a62e1d16-b608-4e87-8951-07e0715671a7" continuedAt="i8b87cf23d17c4a718fb6f576a2f938cc" escape="true">Interest Expense </ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8b87cf23d17c4a718fb6f576a2f938cc">Interest expense includes standby fees, the amortization of debt discounts and deferred financing costs, accretion of debt premiums and the amortization of amounts excluded from the assessment of effectiveness related to the Company's cross-currency swaps. Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized.</ix:continuation> Capitalized interest related to construction in progress as of December 31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzQ3NDIw_9afd653d-2442-4f65-920f-6745964e06bb">60</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzQ3NDI3_08df7943-b0c4-4892-929b-bd557fccff3f">45</ix:nonFraction>&#160;million, respectively, and is included in Property, plant and equipment, net. </span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1Nzg0_cb1a4562-2b30-457a-b542-24173f82121a" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized. Deferred tax assets and liabilities are measured using enacted tax rates and&#160;laws.  Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such position are measured based on the amount for which there is a greater than <ix:nonFraction unitRef="number" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="INF" name="bhc:TaxBenefitRecognitionMeasurementPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzQ5MjY1_4d3eefb4-3f53-4d59-a305-539c9697a6e3">50</ix:nonFraction>% likelihood of being realized upon settlement. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="bhc:MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzQ5NDI4_8e8f4ce3-670e-4a54-9ec0-8c1769083a69">one year</ix:nonNumeric>. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance&#160;sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NjMz_3ea3b7e5-0659-49ba-a001-eab9cbfdbdb0" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share Attributable to Bausch Health Companies Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period. Diluted loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period after giving effect to dilutive potential common shares for stock options and RSUs, determined using the treasury stock&#160;method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NjY0_7d7cad6b-f175-4473-a242-c61730553c5f" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss comprises Net loss and Other comprehensive (loss) income. Other comprehensive (loss) income includes items such as foreign currency translation adjustments, unrealized holding gains and losses on available-for-sale and other investments and certain pension and other postretirement benefit plan adjustments. Accumulated other comprehensive loss is recorded as a component of shareholders&#8217; equity.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1Njg0_808d3477-ef3f-4fee-a87c-6d907c2b3721" continuedAt="i2201a858cd544f989a4f507ce4621fb5" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Accruals for loss contingencies are recorded when the Company determines that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the estimate of the amount of the loss is a range and some amount within the range appears to be a better estimate than any other amount within the range, that amount is accrued as a liability. If no amount within the range is a better estimate than any other amount, the minimum amount of the range is accrued as a&#160;liability. These accruals are adjusted periodically as assessments change or additional information becomes available.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2201a858cd544f989a4f507ce4621fb5">If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred.</ix:continuation> </span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:PensionAndOtherPostretirementPlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NzE2_cc638fb6-21de-4e67-9af7-d03e7d9cff0f" continuedAt="ib731806749454237bd41122b7d8e225c" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Benefit Plans </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors various retirement and pension plans, including defined benefit pension plans, defined contribution plans and a participatory defined benefit postretirement plan. The determination of defined benefit pension and postretirement plan obligations and their associated expenses requires the use of actuarial valuations to estimate the benefits employees earn while working, as well as the present value of those benefits. Net actuarial gains and losses that exceed <ix:nonFraction unitRef="number" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="INF" name="bhc:DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzUyMTQ2_a0289313-cda5-4e24-9917-7e929b62e20b">10</ix:nonFraction> percent of the greater of the plan&#8217;s projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated average future service period of the plan participants (or the </span></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i7a05fae4adf34cabb03e7426a2d11a94"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib731806749454237bd41122b7d8e225c">estimated average future lifetime of the plan participants if the majority of plan participants are inactive) or the period until any anticipated final plan settlements.</ix:continuation> </span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NzM2_1824406d-c129-4088-8fa5-c0ebadb1fcac" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New&#160;Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses.  The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to Accumulated deficit of less than $<ix:nonFraction unitRef="usd" contextRef="i2ea97ac3ab7a4d41bb8383aabfb051e7_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzEwOTk1MTE3MDM1ODE_1a58b810-38d8-41af-a3aa-f2298e300f63">1</ix:nonFraction>&#160;million. The application of this guidance did not have a material effect on the Company's results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement.  The guidance was effective for the Company beginning January 1, 2020. The application of this guidance did not have a material effect on the Company's disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans.  The guidance was effective for annual periods ending after December 15, 2020. The application of this guidance did not have a material effect on the Company's disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160; The guidance is effective for the Company beginning with annual periods beginning January 1, 2021.&#160; The application of this guidance did not have a material effect on the Company's financial position, results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.&#160; Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging.&#160;The optional amendments are effective for all entities as of March 12, 2020, through December 31, 2022. During 2020 and 2021, the Company has not entered into any contract modifications in which the optional expedients were applied.&#160; However, if prior to December 31, 2022, the Company enters into a contract modification in which the optional expedients are applied, the Company will evaluate the impact of adoption of this guidance on its financial position, results of operations and cash flows.</span></div></ix:nonNumeric></ix:continuation><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_307"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzYwMzU_3a8709a9-e357-42f9-bb8a-68d9d9ac1b34" continuedAt="i85299eb6fcca4dce8819b3bc90e68e4d" escape="true">ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE</ix:nonNumeric></span></div><ix:continuation id="i85299eb6fcca4dce8819b3bc90e68e4d" continuedAt="if2c549fa00a14bcd850ccf2b95ab7c36"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition Agreement for Synergy Pharmaceuticals Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 6, 2019, the Company acquired certain assets of Synergy Pharmaceuticals Inc. ("Synergy") for a cash purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="icfeb956295ef4b16a85e6e4149d35c24_D20190306-20190306" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzIwNQ_0dbf81d9-9338-482b-9c10-3bf69abcb511">180</ix:nonFraction> million and the assumption of certain liabilities, pursuant to the terms approved by the U.S. Bankruptcy Court for the Southern District of New York on March 1, 2019. Among the assets acquired are the worldwide rights to the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) product, a once-daily tablet for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. This acquired business is included in the Company's Salix segment and is expected to result in additional revenues and costs savings associated with business synergies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of certain assets of Synergy has been accounted for as a business combination under the acquisition method of accounting since: (i) substantially all of the fair value of the assets acquired is not&#160;concentrated in a single identifiable asset or group of similar identifiable assets and (ii) substantive inputs and processes were acquired to contribute to the creation of outputs. <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzYwMzY_69847499-3b77-408c-8db1-4ea52b0dc2da" continuedAt="i43c51fe6b4464f478325528449aaba2d" escape="true">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date:</ix:nonNumeric></span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="if2c549fa00a14bcd850ccf2b95ab7c36" continuedAt="i28ea2a7114c14826a02ab4cdd3d9d73c"><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><ix:continuation id="i43c51fe6b4464f478325528449aaba2d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:89.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.005%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ebac933dea48b489400e86f7f489fe_I20190306" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZTpmYjQ1Mjk4N2ViYWQ0ZmQ2OTRhNzE3MGM0ZGY5NTQyMS90YWJsZXJhbmdlOmZiNDUyOTg3ZWJhZDRmZDY5NGE3MTcwYzRkZjk1NDIxXzEtMS0xLTEtNTk0NzA_0d71d9df-3acd-4d0e-8d6e-6a14d7333034">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ebac933dea48b489400e86f7f489fe_I20190306" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZTpmYjQ1Mjk4N2ViYWQ0ZmQ2OTRhNzE3MGM0ZGY5NTQyMS90YWJsZXJhbmdlOmZiNDUyOTg3ZWJhZDRmZDY5NGE3MTcwYzRkZjk1NDIxXzItMS0xLTEtNTk0NzA_02bf4c9c-1104-4ea6-9078-341b57d0119d">24</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ebac933dea48b489400e86f7f489fe_I20190306" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZTpmYjQ1Mjk4N2ViYWQ0ZmQ2OTRhNzE3MGM0ZGY5NTQyMS90YWJsZXJhbmdlOmZiNDUyOTg3ZWJhZDRmZDY5NGE3MTcwYzRkZjk1NDIxXzMtMS0xLTEtNTk0NzA_d05194a5-bab6-4578-bfcb-f5cae8b30955">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brand intangible assets (estimated useful life <ix:nonNumeric contextRef="icfeb956295ef4b16a85e6e4149d35c24_D20190306-20190306" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZTpmYjQ1Mjk4N2ViYWQ0ZmQ2OTRhNzE3MGM0ZGY5NTQyMS90YWJsZXJhbmdlOmZiNDUyOTg3ZWJhZDRmZDY5NGE3MTcwYzRkZjk1NDIxXzQtMC0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo4MTFiNDJlM2JjZTA0Y2EzYWZmZWM5Mzg1MzU4ZTZkYV81OQ_cbbc416c-64fc-458b-bed8-6afe0d992452">7</ix:nonNumeric> years)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ebac933dea48b489400e86f7f489fe_I20190306" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZTpmYjQ1Mjk4N2ViYWQ0ZmQ2OTRhNzE3MGM0ZGY5NTQyMS90YWJsZXJhbmdlOmZiNDUyOTg3ZWJhZDRmZDY5NGE3MTcwYzRkZjk1NDIxXzQtMS0xLTEtNTk0NzA_92a0e6a3-34a6-456f-a954-3dbb11be6532">159</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92ebac933dea48b489400e86f7f489fe_I20190306" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZTpmYjQ1Mjk4N2ViYWQ0ZmQ2OTRhNzE3MGM0ZGY5NTQyMS90YWJsZXJhbmdlOmZiNDUyOTg3ZWJhZDRmZDY5NGE3MTcwYzRkZjk1NDIxXzUtMS0xLTEtNTk0NzA_85033299-e695-4ae0-add1-cb4862190bad">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92ebac933dea48b489400e86f7f489fe_I20190306" decimals="-6" name="bhc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZTpmYjQ1Mjk4N2ViYWQ0ZmQ2OTRhNzE3MGM0ZGY5NTQyMS90YWJsZXJhbmdlOmZiNDUyOTg3ZWJhZDRmZDY5NGE3MTcwYzRkZjk1NDIxXzYtMS0xLTEtNTk0NzA_3a0922db-68c5-4de6-9b41-2db9b87d5bef">17</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ebac933dea48b489400e86f7f489fe_I20190306" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZTpmYjQ1Mjk4N2ViYWQ0ZmQ2OTRhNzE3MGM0ZGY5NTQyMS90YWJsZXJhbmdlOmZiNDUyOTg3ZWJhZDRmZDY5NGE3MTcwYzRkZjk1NDIxXzctMS0xLTEtNTk0NzA_52a47c95-c95a-47da-8232-d2e53e0c7d62">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ebac933dea48b489400e86f7f489fe_I20190306" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZTpmYjQ1Mjk4N2ViYWQ0ZmQ2OTRhNzE3MGM0ZGY5NTQyMS90YWJsZXJhbmdlOmZiNDUyOTg3ZWJhZDRmZDY5NGE3MTcwYzRkZjk1NDIxXzgtMS0xLTEtNTk0NzA_02e69166-ad25-4f78-9b00-3dcf188aae4d">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ebac933dea48b489400e86f7f489fe_I20190306" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZTpmYjQ1Mjk4N2ViYWQ0ZmQ2OTRhNzE3MGM0ZGY5NTQyMS90YWJsZXJhbmdlOmZiNDUyOTg3ZWJhZDRmZDY5NGE3MTcwYzRkZjk1NDIxXzktMS0xLTEtNTk0NzA_29fd5e7a-459f-4d39-8757-31953050d033">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill associated with the acquisition of certain assets of Synergy is not deductible for income tax purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue and Operating Results </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 were $<ix:nonFraction unitRef="usd" contextRef="i90f9c8b2069447318643874fdd998562_D20190306-20191231" decimals="-6" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzE2MzI_54648f86-b6b6-41a0-81b0-abbbad3187fd">55</ix:nonFraction> million. Operating results associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 and pro-forma revenues and operating results for the year 2019 were <ix:nonFraction unitRef="usd" contextRef="i1875d6eb59814b65a56bf3c1ee9b5056_D20190101-20191231" decimals="-6" name="bhc:BusinessAcquisitionProFormaOperatingIncomeLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzE4MjU_0ff34a91-86b0-4330-9bf5-ab7b1e5856ec"><ix:nonFraction unitRef="usd" contextRef="i1875d6eb59814b65a56bf3c1ee9b5056_D20190101-20191231" decimals="-6" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzE4MjU_21ef7460-b5ac-4d3e-a65f-68a0d6bf46bc"><ix:nonFraction unitRef="usd" contextRef="i90f9c8b2069447318643874fdd998562_D20190306-20191231" decimals="-6" name="bhc:BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzE4MjU_90048b8d-20dd-483a-a886-3844a23316ff">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t material. Included in Other expense, net for 2019 are acquisition-related costs of $<ix:nonFraction unitRef="usd" contextRef="i1875d6eb59814b65a56bf3c1ee9b5056_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzE4OTQ_deb348a0-0721-48c0-b353-b4df892fc114">8</ix:nonFraction> million directly related to the acquisition of certain assets of Synergy, which include expenditures for advisory, legal, valuation, accounting and other similar services.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="businesscombination" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="INF" name="bhc:NumberOfOtherBusinessesAcquired" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI0Mzc_18387703-fdbb-4e46-868c-ec55023c8b8a"><ix:nonFraction unitRef="businesscombination" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="INF" name="bhc:NumberOfOtherBusinessesAcquired" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI0Mzc_ad0dcd36-9532-485c-8000-f15c973aa01b"><ix:nonFraction unitRef="businesscombination" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="INF" name="bhc:NumberOfOtherBusinessesAcquired" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI0Mzc_ced95c46-bc8d-4a24-966c-b7d74a252f34">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> other material business combinations in 2021, 2020 or 2019. The measurement period for all acquisitions has closed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Option to Purchase All Ophthalmology Assets of Allegro Ophthalmics, LLC ("Allegro")</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 21, 2020, the Company announced that it had entered into an agreement to acquire an option to purchase all of the ophthalmology assets of Allegro (the "Option"), a privately held biopharmaceutical company focused on the development of therapies that regulate integrin functions for the treatment of ocular diseases. Among the assets to be acquired if the Option was exercised, were the worldwide rights to risuteganib (Luminate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), Allegro's lead investigational compound in retina, which is believed to simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry Age-related Macular Degeneration.  During the three months ended September 30, 2020, the Company made and expensed as acquired IPR&amp;D included in Other expense, net, an initial upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i1c4424c16be247649ea9c0793b64485d_D20200701-20200930" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI3NDg3NzkwODI4NDM_b8fd5d79-42ff-4650-beeb-36603dcd421a">10</ix:nonFraction>&#160;million to acquire the Option.  However, on June 23, 2021, Allegro notified the Company that it did not raise the additional funding required under the option agreement.  Pursuant to the terms of the option agreement, the Option thereby terminated, and the Company exercised its right to convert the $<ix:nonFraction unitRef="usd" contextRef="i7f2a7103479740d6b997c87b639888ea_D20210623-20210623" decimals="-6" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI3NDg3NzkwODI4NTY_0db899e9-848b-492f-a06a-cc759c4d90a0">10</ix:nonFraction>&#160;million upfront payment into a minor equity interest in Allegro.  The Company expects that it will make <ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="INF" name="bhc:AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI3NDg3NzkwODI4Njg_0e73c3ad-8b80-4dcb-9c52-39be34d39e3a">no</ix:nonFraction> additional payments pursuant to this option agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions.  The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain.  The commitment periods under these agreements vary and include customary termination provisions.  Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of Amoun Pharmaceutical Company S.A.E. ("Amoun")</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, the Company announced that it and certain of its affiliates had entered into a definitive agreement to sell all of its equity interests in Amoun for total gross consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="i8d780f8e498d4029a20e1dfba48ddaf8_D20210726-20210726" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI3NDg3NzkwODI4Nzc_238d722b-aeab-4b13-9d70-3343529c7f6f">740</ix:nonFraction>&#160;million (including the assignment to the purchasing entity of an intercompany loan granted by the Company to Amoun), subject to certain adjustments (the &#8220;Amoun Sale&#8221;). The Amoun Sale closed on July 26, 2021. As part of the Amoun Sale, cash generated by Amoun during the period from the locked-box date of January 1, 2021 through closing was for the benefit of the purchasing entity, subject to working capital during such period. Amoun manufactures, markets and distributes branded generics of human and animal health products. The Amoun business was part of the International Rx segment (previously </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i28ea2a7114c14826a02ab4cdd3d9d73c"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included within the former Bausch + Lomb/International segment) and was reclassified as held for sale as of December 31, 2020. As a result of meeting the criteria for held for sale classification, the carrying value of the Amoun business, was adjusted to its estimated fair value, less costs to sell, and the Company recognized an impairment loss of $<ix:nonFraction unitRef="usd" contextRef="i1232cd05f1bf44d2a67fedd36c0d6cd8_D20201001-20201231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI3NDg3NzkwODI4OTE_9f784272-e584-4ad4-8dc9-7c0d01c0e64e">96</ix:nonFraction>&#160;million during the three months ended December 31, 2020 and an additional impairment loss of $<ix:nonFraction unitRef="usd" contextRef="i2798f6e7b2e943c583b2aca3a95d9902_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI3NDg3NzkwODI5MDQ_e1d9c911-e4c1-4b29-9cb9-6d6ebb5826e6">88</ix:nonFraction>&#160;million during 2021, included within Asset impairments, including loss on assets held for sale in the Consolidated Statements of Operations. In connection with completing the Amoun Sale, the Company recognized an additional loss of $<ix:nonFraction unitRef="usd" contextRef="i8fd89ab94eae4b75848759e31a502deb_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI3NDg3NzkwODI5MTc_e064cf99-6bce-40de-9f1f-80b9ee22a1c4">26</ix:nonFraction>&#160;million during 2021, included within Other (income) expense, net in the Combined Statements of Operations. The total loss of $<ix:nonFraction unitRef="usd" contextRef="i814496642aa544b0bd6eb9e21c9c38ce_D20200101-20211231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI3NDg3NzkwODI5MzA_e0eea973-7349-4657-bb79-5de59b09f76d">210</ix:nonFraction>&#160;million includes the release of non-cash cumulative foreign currency translation losses of $<ix:nonFraction unitRef="usd" contextRef="i814496642aa544b0bd6eb9e21c9c38ce_D20200101-20211231" decimals="-6" name="bhc:NoncashCumulativeForeignCurrencyTranslationLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI3NDg3NzkwODI5NDQ_a5fea4d9-d9f3-4c21-94ce-ad905721d4b8">340</ix:nonFraction>&#160;million, which were included as part of the carrying value of the Amoun business when measuring for impairment.</span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzYwMjA_6fce20ac-4ebf-42e7-a2fb-59e27624093a" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the Consolidated Balance Sheets as of December 31, 2020 are the following carrying amounts of the Amoun business' assets and liabilities held for sale.</span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:38.353%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.353%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13cd655709045658273ebf2abdba2e4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzItMi0xLTEtNTk0NzA_634f59d1-9ece-40af-85da-e2c32a95d8b0">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13cd655709045658273ebf2abdba2e4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzItNi0xLTEtNjk1NTg_1e76c9e5-a79a-4fd7-905e-053a7d7ca0a5">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13cd655709045658273ebf2abdba2e4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzMtMi0xLTEtNTk0NzA_c87c2100-e489-4b0a-9379-5c616c06ff70">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13cd655709045658273ebf2abdba2e4_I20201231" decimals="-6" name="bhc:DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzMtNi0xLTEtNjk1NTg_eef2ee84-dd49-4955-9fed-f1f473b14413">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13cd655709045658273ebf2abdba2e4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzQtMi0xLTEtNTk0NzA_24d70048-0fcd-43a4-95b3-ff74dbb77d5d">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13cd655709045658273ebf2abdba2e4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzQtNi0xLTEtNjk1NTg_b17e6eea-bc4b-4e87-95bb-034522274b4c">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13cd655709045658273ebf2abdba2e4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzUtMi0xLTEtNTk0NzA_add58399-01e2-4fca-a64c-b873d5cb37c1">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13cd655709045658273ebf2abdba2e4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzctMi0xLTEtNTk0NzA_44085fcb-dd6f-4308-835b-c396e47e2102">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13cd655709045658273ebf2abdba2e4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzctNi0xLTEtNjk1NTg_320a3049-e1bc-46e7-be0d-75d628aaf48e">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13cd655709045658273ebf2abdba2e4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzgtMi0xLTEtNTk0NzA_b3572df5-c4e0-4381-98ce-da5e4b0389fd">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13cd655709045658273ebf2abdba2e4_I20201231" decimals="-6" name="bhc:DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzgtNi0xLTEtNjk1NTg_9e91d667-0300-4e77-a3f9-2dd94e643856">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13cd655709045658273ebf2abdba2e4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzktMi0xLTEtNTk0NzA_fc6278bc-c81b-41f0-8e23-27bd3c932be4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13cd655709045658273ebf2abdba2e4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzktNi0xLTEtNjk2MDM_01a2ba5c-70c9-4dc5-b6aa-8a06cd9895e2">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13cd655709045658273ebf2abdba2e4_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzEwLTItMS0xLTU5NDcw_23b9f93f-205d-4735-92f2-f32d41ba09dc">315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_310"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzI3OTc_cf6cce1a-030a-4a1b-9a5c-3096777a9a05" continuedAt="i891d29161d184278b38e478aa26e5142" escape="true">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</ix:nonNumeric></span></div><ix:continuation id="i891d29161d184278b38e478aa26e5142"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and integration costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of December 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="ic96cba168a6f45b0b15835dcb29e9eef_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzY1OA_f3c21ec5-a387-4c46-ab5e-b73a9e7f0b47">19</ix:nonFraction> million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $<ix:nonFraction unitRef="usd" contextRef="i4700fec630cc4d3393d58b8d2b00fd5d_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzM4NDgyOTA3MDcxMjY_25b0e39e-9c2d-4144-bfc4-ff0fb3712ea8">18</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i40cc87b109454b6cb74b6178982151c4_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzEwOTk1MTE2MzcyNDY_bed656dd-0c37-45c5-b1e5-42632146e1e7">11</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i02c2d8581fcc4e74af1f8728d7f5cb05_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzM4NDgyOTA3MDcxMzg_a94887ef-0d8b-4d8e-919f-abddea7c697b">31</ix:nonFraction>&#160;million of restructuring and integration-related costs and made payments of $<ix:nonFraction unitRef="usd" contextRef="i4700fec630cc4d3393d58b8d2b00fd5d_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzM4NDgyOTA3MDcxMTM_6ef32d67-461a-4d7b-8cc2-6ec65d085b9c">19</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i40cc87b109454b6cb74b6178982151c4_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzEwOTk1MTE2MzcyNTk_0ff48519-96da-47bb-b1ee-5f9184b5e5a8">18</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i02c2d8581fcc4e74af1f8728d7f5cb05_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzExOTU_63981296-8b57-4a64-92fa-40ba058601c7">31</ix:nonFraction> million during 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation costs, Separation-related costs, IPO Costs and IPO-related Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and will incur, costs associated with activities to effectuate the B+L Separation and the Solta IPO. These activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company and (ii) registering the Bausch + Lomb and Solta Medical businesses as independent publicly traded entities. Separation and IPO costs are incremental costs directly related to the B+L Separation and Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for the Bausch + Lomb and Solta Medical entities. Included in Restructuring, integration, separation and IPO costs for the years ended December 31, 2021 and 2020 are Separation and IPO costs of $<ix:nonFraction unitRef="usd" contextRef="idc7bec622b0e4d06914e435a52d614cc_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzM4NDgyOTA3MDYyNTg_7f9f6e58-188c-43bf-a44e-d62ddef29e4c">32</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i50d1eaed93cd4379b62a15c354a4c436_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzM4NDgyOTA3MDYyNzE_45001a23-c830-4c4a-a4d7-347aebefafba">11</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also incurred, and will incur, Separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and Solta IPO. Separation-related and IPO-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative for years ended December 31, 2021 and 2020 are Separation-related and IPO-related costs of $<ix:nonFraction unitRef="usd" contextRef="idc7bec622b0e4d06914e435a52d614cc_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzM4NDgyOTA3MDYyNDU_718f3e79-f3bf-46d4-b5fc-4e8d3ec1b31c">132</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i50d1eaed93cd4379b62a15c354a4c436_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzM4NDgyOTA3MDYyMzM_64116994-3721-44af-944b-0f78ac1b4ad3">21</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_313"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzY5MDE_0a68bd89-bccd-4dba-a6c4-2b220edcca9a" continuedAt="ibc552a58c1704200a0665212c3a70bb1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="ibc552a58c1704200a0665212c3a70bb1" continuedAt="i3e566a6c1a2e46ababb75872c164942c"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#160;&#8212;&#160;Quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzY4Nzk_9fb4270b-8350-4266-af98-055c21eb85e1" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:26.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef833b76dda454f9e12e7a602fedd25_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzMtMi0xLTEtNTk0NzA_b3fb367c-bf07-4cb8-a16a-0f1563ae6463">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1d3254b1a94b428ef1e3c8512a59fd_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzMtNC0xLTEtNTk0NzA_db0bcd80-2b4f-4b7c-b957-057360e37f72">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bc0f8f4b2124e1697e59545800c5d9e_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzMtNi0xLTEtNTk0NzA_c1097163-09e0-44cb-9009-e0fd48e3ef1f">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e94131e350d4b8b90275b3532694a75_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzMtOC0xLTEtNTk0NzA_10f7a767-3c52-49af-a9fb-0d59d84fa1b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32d030d4baca4c79874c13a25d51d367_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzMtMTAtMS0xLTU5NDcw_39934316-92d3-400e-bd0b-f2fad04ea9b5">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7f4579ec74b4323bcd997517762bd3e_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzMtMTItMS0xLTU5NDcw_09395cce-f624-4806-9cb5-3edf91eb23b5">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i226c603a08c64fa89f2932e3d795dd43_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzMtMTQtMS0xLTU5NDcw_d285be8d-da7e-482a-9aae-796b7babe999">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id82b7c18fe4748eca290dd25b0edd254_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzMtMTYtMS0xLTU5NDcw_c51beaab-5f1f-4cc3-b0bf-8899ea3a2f8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef833b76dda454f9e12e7a602fedd25_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzQtMi0xLTEtNTk0NzA_a25634dd-374a-4d84-83b5-e6b8f8e7b1f0">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1d3254b1a94b428ef1e3c8512a59fd_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzQtNC0xLTEtNTk0NzA_b9f24bd1-e356-4018-b1fb-23a2a60586a5">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bc0f8f4b2124e1697e59545800c5d9e_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzQtNi0xLTEtNTk0NzA_dfd8a5d9-6c02-47c8-9983-63b04d4aea12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e94131e350d4b8b90275b3532694a75_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzQtOC0xLTEtNTk0NzA_ac5e3586-19d3-43fe-934a-e6dea6253104">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32d030d4baca4c79874c13a25d51d367_I20201231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzQtMTAtMS0xLTU5NDcw_84cace11-b6a8-4e79-ad69-efe0b6ff3407">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7f4579ec74b4323bcd997517762bd3e_I20201231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzQtMTItMS0xLTU5NDcw_5134916a-86e2-4e51-9eed-8b1ed672898a">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i226c603a08c64fa89f2932e3d795dd43_I20201231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzQtMTQtMS0xLTU5NDcw_69e07de2-c65d-432b-b3a0-fbf6ed04be2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id82b7c18fe4748eca290dd25b0edd254_I20201231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzQtMTYtMS0xLTU5NDcw_3695c75d-f151-46e4-90dc-744e33ec9979">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b2e0ad215d4a8e8263f35c5dfd3e26_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzUtMi0xLTEtNTk0NzA_0c9c6613-0747-425b-982d-45c4b6dac03f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39aef971f8c64d94a2d8e897d769f1f3_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzUtNC0xLTEtNTk0NzA_fd6ad121-9234-4d6d-b45f-d24fc5705dc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic994d881fee945cf9668a1135e61ad23_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzUtNi0xLTEtNTk0NzA_bddc0b10-02ba-41bf-aafb-f3918db66439">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0345bec09794bf6818fdf23d88bb454_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzUtOC0xLTEtNTk0NzA_0117f7a8-3fb8-4c2a-af19-0334321be16d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ffbb6654b542aa8ccc9d51f2e0cb73_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzUtMTAtMS0xLTU5NDcw_e403e8a7-add4-413f-a812-9e3100209748">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5fa8ed492a8463a9ef8d402daa38f5e_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzUtMTItMS0xLTU5NDcw_80c03e22-7dfe-4c8d-bb3c-028f2b94b5de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i923bf4abdb6749c7b03cfcf01cb232fa_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzUtMTQtMS0xLTU5NDcw_7ffa4587-7e0a-4c96-864c-48e84c661f2b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744dc2c483db45c7b8cb3c1300c54643_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzUtMTYtMS0xLTU5NDcw_22398730-dca6-4eeb-a630-c3e602a519a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef833b76dda454f9e12e7a602fedd25_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzctMi0xLTEtNTk0NzA_ad5f4116-eb62-4472-b09a-c0d4a02fda7b">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1d3254b1a94b428ef1e3c8512a59fd_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzctNC0xLTEtNTk0NzA_e20d512c-a9c4-4ee6-96f4-2f4f3f0b8571">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bc0f8f4b2124e1697e59545800c5d9e_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzctNi0xLTEtNTk0NzA_9ee25f6f-bf89-40a8-ae22-baac38d3f09a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e94131e350d4b8b90275b3532694a75_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzctOC0xLTEtNTk0NzA_5f3d825c-d8e4-44ce-bcb4-693ce8461931">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32d030d4baca4c79874c13a25d51d367_I20201231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzctMTAtMS0xLTU5NDcw_628afbcf-6a4c-4536-a6dc-5412afe63f1b">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7f4579ec74b4323bcd997517762bd3e_I20201231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzctMTItMS0xLTU5NDcw_1a466313-3e94-4ac9-b492-195b48fdd808">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i226c603a08c64fa89f2932e3d795dd43_I20201231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzctMTQtMS0xLTU5NDcw_68605804-a1e2-4c78-a738-d0223b3d001a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id82b7c18fe4748eca290dd25b0edd254_I20201231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzctMTYtMS0xLTU5NDcw_e97fc79f-8532-4f97-9291-e4d2ce07ae8c">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swaps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if290d3a1005a4badb0ac05c0dbe5aae2_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzgtMi0xLTEtNTk0NzA_5348a747-fcef-40a0-8fbb-e8da4c5ea2fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb1d5a40c474d86b7665045cbbcdd54_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzgtNC0xLTEtNTk0NzA_1bb40a55-d5ce-407e-be7b-2d732bc41739">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib35ef1ef18f04163ab0711c21275b0be_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzgtNi0xLTEtNTk0NzA_72400037-8498-44b5-81df-b8b20a21ed2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dd8e5d148e4ce6a785c5011b46b450_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzgtOC0xLTEtNTk0NzA_4a70fce6-6e38-403a-a464-98e4f891185b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aa901695e224cd3bda948346e4c12ed_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzgtMTAtMS0xLTU5NDcw_be3b73b6-709d-4287-aa6c-06d3691ad767">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ac66312bf2147d1906b5192293868da_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzgtMTItMS0xLTU5NDcw_a7674e54-9bf0-4739-a330-f62319bd5afa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1889026b5e64c829d9bc334d4f52cfe_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzgtMTQtMS0xLTU5NDcw_38195575-d1ae-4612-adb8-c38f1778ace3">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8245159f69c94307993efff3243a1178_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzgtMTYtMS0xLTU5NDcw_224dd15c-ad0d-4b6b-ae08-dc508f66f55a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b2e0ad215d4a8e8263f35c5dfd3e26_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzktMi0xLTEtNTk0NzA_415b825f-7a00-4466-837d-ecbc6d03e324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39aef971f8c64d94a2d8e897d769f1f3_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzktNC0xLTEtNTk0NzA_fba818f9-d972-438f-8bc8-c0ae8817bdd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic994d881fee945cf9668a1135e61ad23_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzktNi0xLTEtNTk0NzA_b7f2a7df-ca70-4669-8625-dc740fafe6fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0345bec09794bf6818fdf23d88bb454_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzktOC0xLTEtNTk0NzA_c4c735d7-f540-435d-8b5b-be838daa63e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ffbb6654b542aa8ccc9d51f2e0cb73_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzktMTAtMS0xLTU5NDcw_fdb46d82-b530-428a-85d8-f5c327033c38">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5fa8ed492a8463a9ef8d402daa38f5e_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzktMTItMS0xLTU5NDcw_3166e89f-721e-4bd2-9358-844ca264e1aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i923bf4abdb6749c7b03cfcf01cb232fa_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzktMTQtMS0xLTU5NDcw_23f8be8e-9fe1-4132-9331-2fabff664203">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744dc2c483db45c7b8cb3c1300c54643_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzktMTYtMS0xLTU5NDcw_7c7fb190-dc92-4b85-b454-a34d53a5355d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="bhc:HighlyLiquidInvestmentsMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzEzOTA_d67ffe5a-b12b-4636-87f1-1d61eefe3590">three months</ix:nonNumeric> or less when&#160;purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, Restricted cash and other settlement deposits includes $<ix:nonFraction unitRef="usd" contextRef="i23aea785e01a442a92655b06b1baeaf3_D20210101-20211231" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzE1ODY_fd9e6322-2103-480b-912c-e4478be23c34">1,510</ix:nonFraction>&#160;million of payments into escrow funds under the terms of settlement agreements regarding that certain U.S. securities litigation (subject to an objector's appeal of the final court approval) and the Glumetza Antitrust Litigation. These payments are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature.  These payments will remain in escrow until final approval of the settlements as discussed in Note 20, "LEGAL PROCEEDINGS".</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of Level 3 during 2021 and 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cross-currency Swaps</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $<ix:nonFraction unitRef="usd" contextRef="i8d8d666e2aca457593b6a68cc6c05534_I20191231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzIxNzk_837de477-7730-4eac-88cb-638b58c4a5a7">1,250</ix:nonFraction> million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from adverse movements in exchange rates. The euro-denominated net investment being hedged was the Company&#8217;s investment in certain euro-denominated subsidiaries.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2021, the Company entered into a transaction to unwind its cross-currency swaps and received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ic8c7dd3d755f4d23a5c91bada3e42ee9_D20211101-20211130" decimals="-6" name="us-gaap:ProceedsFromHedgeInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzM4NDgyOTA3MTYwMDg_ae4382b6-cfc9-4744-908d-462b90f612e5">4</ix:nonFraction>&#160;million, which included interest income of $<ix:nonFraction unitRef="usd" contextRef="ic8c7dd3d755f4d23a5c91bada3e42ee9_D20211101-20211130" decimals="-6" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzM4NDgyOTA3MTYwMzI_6c6aaed6-ae39-41ec-b1cf-de7b4638556a">6</ix:nonFraction>&#160;million, offset by the amount owed by the Company upon the unwinding of $<ix:nonFraction unitRef="usd" contextRef="idc7d3c92717d45fea0d13f8cce709379_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForProceedsFromHedgeInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzM4NDgyOTA3MTYxNDE_d5bd2108-93b1-4773-a421-2f762935a499">2</ix:nonFraction>&#160;million. The gain arising from the transaction of the swaps has been included as a component of Other comprehensive loss.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i3e566a6c1a2e46ababb75872c164942c" continuedAt="i16609ddf4cdf45f4bdb10444ae47efff"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzEwOTk1MTE2NDQyMDU_ec128c48-0bf2-4b3d-af7b-cda1290e85da" continuedAt="ib5f625a62dc94ebfb783d8e6252fb0bf" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company's cross-currency swaps as included in the Consolidated Balance Sheets as of December 31, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:70.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.647%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44e7b5604e7f428db4023a2105e3040b_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZToxNTgxZTIwOGFlMzA0ZGIzYTI2NzA2ZmU4Nzk0ZDEyNi90YWJsZXJhbmdlOjE1ODFlMjA4YWUzMDRkYjNhMjY3MDZmZTg3OTRkMTI2XzEtMS0xLTEtNjkxOTA_98127287-126e-42a7-be7b-8f24c18d7ec0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe6b64df5694949b66283a944e675f3_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZToxNTgxZTIwOGFlMzA0ZGIzYTI2NzA2ZmU4Nzk0ZDEyNi90YWJsZXJhbmdlOjE1ODFlMjA4YWUzMDRkYjNhMjY3MDZmZTg3OTRkMTI2XzEtMy0xLTEtNjkxOTI_2f25a4e9-8e2e-4019-a92d-1d073a5ac956">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id979f8795ef24a36b2de7dfd5788e85b_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZToxNTgxZTIwOGFlMzA0ZGIzYTI2NzA2ZmU4Nzk0ZDEyNi90YWJsZXJhbmdlOjE1ODFlMjA4YWUzMDRkYjNhMjY3MDZmZTg3OTRkMTI2XzItMS0xLTEtNjkxOTA_13f9f51c-2790-4f12-a365-4cdc5699a37c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d09cae82ba48e1ab8a7444a671c37c_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZToxNTgxZTIwOGFlMzA0ZGIzYTI2NzA2ZmU4Nzk0ZDEyNi90YWJsZXJhbmdlOjE1ODFlMjA4YWUzMDRkYjNhMjY3MDZmZTg3OTRkMTI2XzItMy0xLTEtNjkxOTI_aa26b683-d40d-428a-8641-b513f5f7ca1e">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if40c526d7e7346638f324aeec169b157_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZToxNTgxZTIwOGFlMzA0ZGIzYTI2NzA2ZmU4Nzk0ZDEyNi90YWJsZXJhbmdlOjE1ODFlMjA4YWUzMDRkYjNhMjY3MDZmZTg3OTRkMTI2XzMtMS0xLTEtNjkxOTA_adc5558a-9a2d-49aa-8810-ed0fca6c4f46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib13c9491b10f4203a909a98994925ea0_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZToxNTgxZTIwOGFlMzA0ZGIzYTI2NzA2ZmU4Nzk0ZDEyNi90YWJsZXJhbmdlOjE1ODFlMjA4YWUzMDRkYjNhMjY3MDZmZTg3OTRkMTI2XzMtMy0xLTEtNjkxOTI_be5fb882-0ec7-4115-8edf-7c434849873b">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzY4OTg_f86af5bb-eff1-4a9c-b4bf-4042820b701c" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for 2021 and 2020: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:70.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.647%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Other comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51904574a9814c839ec1c948964e42ee_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphZmRiNGE5ZjI5Mzk0ZmJhYTZiYjk5NDEyZjhjOWRkNC90YWJsZXJhbmdlOmFmZGI0YTlmMjkzOTRmYmFhNmJiOTk0MTJmOGM5ZGQ0XzEtMi0xLTEtNTk0NzA_1d3ab8dd-d2b2-4b30-8b9e-b8e76199e435">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37cde1419dbe4d6b8814f741d3d75967_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphZmRiNGE5ZjI5Mzk0ZmJhYTZiYjk5NDEyZjhjOWRkNC90YWJsZXJhbmdlOmFmZGI0YTlmMjkzOTRmYmFhNmJiOTk0MTJmOGM5ZGQ0XzEtNC0xLTEtNTk0NzA_67f7d699-605f-4eb9-b7c0-ca3191f33ec2">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i255986411ba145c5be6963ac79d1cdef_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphZmRiNGE5ZjI5Mzk0ZmJhYTZiYjk5NDEyZjhjOWRkNC90YWJsZXJhbmdlOmFmZGI0YTlmMjkzOTRmYmFhNmJiOTk0MTJmOGM5ZGQ0XzItMi0xLTEtNTk0NzA_95ca8ad7-3385-49c5-9fba-55d30ed014b4">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8d6be7a4a04904afbe947cf98fb1fa_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphZmRiNGE5ZjI5Mzk0ZmJhYTZiYjk5NDEyZjhjOWRkNC90YWJsZXJhbmdlOmFmZGI0YTlmMjkzOTRmYmFhNmJiOTk0MTJmOGM5ZGQ0XzItNC0xLTEtNTk0NzA_7aea31c5-a228-4153-aa41-f660c84d1694">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021 and 2020, the Company received $<ix:nonFraction unitRef="usd" contextRef="i55601d2d01ba43d0ae61dc537370fe98_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForProceedsFromHedgeInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzEwOTk1MTE2NDQxOTM_9de08b8b-fb6b-4bc8-89eb-8cf5d433d1aa">27</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i261fb00917f94a52acc0d59b2bdbe652_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForProceedsFromHedgeInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzI3NDg3NzkwODA4NTg_1c5e07d0-9b35-41cf-9fe6-d1cc8199495b">23</ix:nonFraction>&#160;million, respectively, in settlements of its cross-currency swaps which are reported as Investing activities in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Contracts</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021 and 2020, the Company entered into foreign currency exchange contracts.  As of December&#160;31, 2021, these contracts had an aggregate outstanding notional amount of $<ix:nonFraction unitRef="usd" contextRef="ifad488da9d8d42f2ae12cbbb6d990611_I20211231" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzM0MDc_937fded0-20fd-4ca4-a15c-1fd852de6b4d">166</ix:nonFraction>&#160;million.</span></div><ix:continuation id="ib5f625a62dc94ebfb783d8e6252fb0bf"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company's foreign exchange contracts as included in the Consolidated Balance Sheets as of December 31, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:70.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.647%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic86fe7b9a9b24aec84a84ced04e41054_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTowYTk1YjViYWFiYzE0NmZkYjBkM2U3ZjFmMTIwOTg0NC90YWJsZXJhbmdlOjBhOTViNWJhYWJjMTQ2ZmRiMGQzZTdmMWYxMjA5ODQ0XzEtMS0xLTEtNjg4Njg_c38f5dd7-fcf7-4a3a-943d-ab17f0b18244">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8edf93d7795c4edf82cf448e9626bfff_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTowYTk1YjViYWFiYzE0NmZkYjBkM2U3ZjFmMTIwOTg0NC90YWJsZXJhbmdlOjBhOTViNWJhYWJjMTQ2ZmRiMGQzZTdmMWYxMjA5ODQ0XzEtMy0xLTEtNjg4NzA_9f6f4436-20c3-4496-9dd2-4b1c1e67da07">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fef8a6744fa477c83018f4c7bea0626_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTowYTk1YjViYWFiYzE0NmZkYjBkM2U3ZjFmMTIwOTg0NC90YWJsZXJhbmdlOjBhOTViNWJhYWJjMTQ2ZmRiMGQzZTdmMWYxMjA5ODQ0XzItMS0xLTEtNjg4Njg_d6c264e9-9b39-45bd-b657-3daa837bc328">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83278b64958b40958e3243fd2a1b1ae6_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTowYTk1YjViYWFiYzE0NmZkYjBkM2U3ZjFmMTIwOTg0NC90YWJsZXJhbmdlOjBhOTViNWJhYWJjMTQ2ZmRiMGQzZTdmMWYxMjA5ODQ0XzItMy0xLTEtNjg4NzA_eba1753f-4a8b-4184-8436-2210679e1712">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifad488da9d8d42f2ae12cbbb6d990611_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTowYTk1YjViYWFiYzE0NmZkYjBkM2U3ZjFmMTIwOTg0NC90YWJsZXJhbmdlOjBhOTViNWJhYWJjMTQ2ZmRiMGQzZTdmMWYxMjA5ODQ0XzMtMS0xLTEtNjg4Njg_f3fe70c7-6b32-4dee-bc25-268553e13a03">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaca6d803b964e7891bb81c4ee12ccce_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTowYTk1YjViYWFiYzE0NmZkYjBkM2U3ZjFmMTIwOTg0NC90YWJsZXJhbmdlOjBhOTViNWJhYWJjMTQ2ZmRiMGQzZTdmMWYxMjA5ODQ0XzMtMy0xLTEtNjg4NzA_ff4efd33-1f14-46b1-a7c1-aa68f267d0fb">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzI3NDg3NzkwODU4NzE_ced2203a-3ae4-498a-b11c-4d592ee3bc64" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company's foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for 2021 and 2020:</span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:70.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.647%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) related to changes in fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa75d1437f1d4f9b9a633c9849122864_D20210101-20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTo4ZjBhNzNlNjcwNGU0N2FhYjczOTdkMjhlNTQ1OWQyYy90YWJsZXJhbmdlOjhmMGE3M2U2NzA0ZTQ3YWFiNzM5N2QyOGU1NDU5ZDJjXzEtMS0xLTEtNjg4Nzg_87ce1382-2d46-4178-8e20-6ac6f1fa4abe">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b8a4232afdb4ff5978b9e0e691223aa_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTo4ZjBhNzNlNjcwNGU0N2FhYjczOTdkMjhlNTQ1OWQyYy90YWJsZXJhbmdlOjhmMGE3M2U2NzA0ZTQ3YWFiNzM5N2QyOGU1NDU5ZDJjXzEtMy0xLTEtNjg4ODA_cc9f1450-80b9-4c86-8a9a-004df8b6d2c4">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss related to settlements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa75d1437f1d4f9b9a633c9849122864_D20210101-20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTo4ZjBhNzNlNjcwNGU0N2FhYjczOTdkMjhlNTQ1OWQyYy90YWJsZXJhbmdlOjhmMGE3M2U2NzA0ZTQ3YWFiNzM5N2QyOGU1NDU5ZDJjXzItMS0xLTEtNjg4Nzg_5fbb87f1-1724-4fa0-98f0-009dbc20c671">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b8a4232afdb4ff5978b9e0e691223aa_D20200101-20201231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTo4ZjBhNzNlNjcwNGU0N2FhYjczOTdkMjhlNTQ1OWQyYy90YWJsZXJhbmdlOjhmMGE3M2U2NzA0ZTQ3YWFiNzM5N2QyOGU1NDU5ZDJjXzItMy0xLTEtNjg4ODA_060f5395-3780-4735-aa23-9a41b57b4259">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related Contingent Consideration Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At December&#160;31, 2021, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from <ix:nonFraction unitRef="rate" contextRef="i64af0e0d3e4140b1b4407a0c784a6907_I20211231" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzUwODU_9d458eda-dfc7-43e2-b2fc-5ac599285440">6</ix:nonFraction>% to <ix:nonFraction unitRef="rate" contextRef="i18e557e1adb142668f07f005de10db3a_I20211231" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzUwOTE_899a54e5-9484-451b-a098-328e10f5c567">18</ix:nonFraction>%, and a weighted average risk-adjusted discount rate of <ix:nonFraction unitRef="rate" contextRef="i570d56f066454c278557839640940613_I20211231" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzUxNDk_a571aafe-6145-4336-a086-c825f618e753">7</ix:nonFraction>%. The weighted average risk-adjusted discount rate was calculated by weighting each contract's relative fair value at December&#160;31, 2021.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i16609ddf4cdf45f4bdb10444ae47efff"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzY4OTk_258ae03a-bee8-4431-aaad-81f078c8f08b" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the years 2021 and 2020:</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:63.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance, January 1, </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzEtNC0xLTEtNTk0NzA_9019532a-42c4-4ee9-afae-512ca12b37ba">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzEtOC0xLTEtNTk0NzA_fd2088f5-f515-4c67-9c00-3d0fe7d65a86">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i669f1ac33f2845c287e6b1bad341253c_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzMtMi0xLTEtNTk0NzA_e0624947-a808-4d86-8d89-7a850b08f7b9">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24b574ccfce8480da6d68ccf2983c9d6_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzMtNi0xLTEtNTk0NzA_3e4827bc-7c4c-4289-8ceb-d165894723e7">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i779f7dfcb77d4f20b069195568b29fa4_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzQtMi0xLTEtNTk0NzA_eff2f75d-7f8d-4320-b9db-37b6a5c290ba">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eab42b92e0d40ecb1ef0a51c9b67d8e_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzQtNi0xLTEtNTk0NzA_7aeb8b16-e469-4cfd-bd54-79a3e5984659">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzUtNC0xLTEtNTk0NzA_85d12db4-5246-4892-acc8-be5156c78ab5">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzUtOC0xLTEtNTk0NzA_46f2897f-85e7-42eb-a5de-41fe93186b03">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments / Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzYtNC0xLTEtNTk0NzA_3b8edbcb-c7f5-449a-bd94-da666f882c8b">99</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzYtOC0xLTEtNTk0NzA_09514c71-c14c-4db2-8a1e-bda0d1add49a">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment included in other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzctNC0xLTEtNTk0NzA_b2e9ecda-bbcf-4537-a465-158fb2a97a7e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzctOC0xLTEtNTk0NzA_1b785b16-e0e1-4f32-8a63-3e6e2be65e2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance, December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzgtNC0xLTEtNTk0NzA_98a793e9-686a-4188-ad52-7ab7c5726410">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzgtOC0xLTEtNTk0NzA_0dd8d04b-cdf0-4c29-a24a-bf40e5110e28">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzktNC0xLTEtNTk0NzA_a22a9c75-30a4-49de-b4db-dfb85eb50987">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzktOC0xLTEtNTk0NzA_60338397-b671-46c7-8bb8-646d69e0907f">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzEwLTQtMS0xLTU5NDcw_dac3f24e-c5b4-48b6-91ac-81b881af7e2b">202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzEwLTgtMS0xLTU5NDcw_64904bce-1b0f-46ea-9287-b3d1ac75f122">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis</span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzY4ODI_1162e262-3998-4829-b832-87662d00395e" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a non-recurring basis:</span></div><div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:24.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.359%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.359%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.359%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.359%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.359%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71ee14ac1c1d46b7a0ce6c3c7e2a9b99_I20211231" decimals="-6" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTpkZWVhYTMyMmZhZGM0OTJkYWM2MTgzMDg5ZDhkZmYwMS90YWJsZXJhbmdlOmRlZWFhMzIyZmFkYzQ5MmRhYzYxODMwODlkOGRmZjAxXzMtMi0xLTEtNTk0NzA_0e7b5893-0c45-4ecb-a73b-65f3bbd31245">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fab45399b784a6590e369a44a09cd98_I20211231" decimals="-6" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTpkZWVhYTMyMmZhZGM0OTJkYWM2MTgzMDg5ZDhkZmYwMS90YWJsZXJhbmdlOmRlZWFhMzIyZmFkYzQ5MmRhYzYxODMwODlkOGRmZjAxXzMtNC0xLTEtNTk0NzA_b3a62146-c90a-4839-99eb-a0a3703f6381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43aa74e47e0a4098b9e1b70baf38319d_I20211231" decimals="-6" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTpkZWVhYTMyMmZhZGM0OTJkYWM2MTgzMDg5ZDhkZmYwMS90YWJsZXJhbmdlOmRlZWFhMzIyZmFkYzQ5MmRhYzYxODMwODlkOGRmZjAxXzMtNi0xLTEtNTk0NzA_e7249ace-643c-44ef-9d2f-4e3d7ec5b8ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic72dfc3064da478e89d0708906a6270a_I20211231" decimals="-6" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTpkZWVhYTMyMmZhZGM0OTJkYWM2MTgzMDg5ZDhkZmYwMS90YWJsZXJhbmdlOmRlZWFhMzIyZmFkYzQ5MmRhYzYxODMwODlkOGRmZjAxXzMtOC0xLTEtNTk0NzA_395e7dd0-4bd6-4d29-bd7a-ec5da2a09b05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ddb15c7970742ed9da4a433d76c5f2a_I20201231" decimals="-6" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTpkZWVhYTMyMmZhZGM0OTJkYWM2MTgzMDg5ZDhkZmYwMS90YWJsZXJhbmdlOmRlZWFhMzIyZmFkYzQ5MmRhYzYxODMwODlkOGRmZjAxXzMtMTAtMS0xLTU5NDcw_288cfa0d-1b72-4c18-9b77-be48a3f3e26f">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50f749937914da499d3aa0713e26497_I20201231" decimals="-6" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTpkZWVhYTMyMmZhZGM0OTJkYWM2MTgzMDg5ZDhkZmYwMS90YWJsZXJhbmdlOmRlZWFhMzIyZmFkYzQ5MmRhYzYxODMwODlkOGRmZjAxXzMtMTItMS0xLTU5NDcw_1c20cafa-b829-4923-ac29-82936825eb04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4c04c5a36a498e9735c3b7b90e02ae_I20201231" decimals="-6" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTpkZWVhYTMyMmZhZGM0OTJkYWM2MTgzMDg5ZDhkZmYwMS90YWJsZXJhbmdlOmRlZWFhMzIyZmFkYzQ5MmRhYzYxODMwODlkOGRmZjAxXzMtMTQtMS0xLTU5NDcw_812b2f8f-30e4-45f8-9497-6ecb8be4f22d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8916b7890ddb4f65bd52ab52e5fca2d1_I20201231" decimals="-6" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTpkZWVhYTMyMmZhZGM0OTJkYWM2MTgzMDg5ZDhkZmYwMS90YWJsZXJhbmdlOmRlZWFhMzIyZmFkYzQ5MmRhYzYxODMwODlkOGRmZjAxXzMtMTYtMS0xLTU5NDcw_d3b6e7e1-52ad-48de-a0d4-970a2fd97246">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current assets held for sale of $<ix:nonFraction unitRef="usd" contextRef="i8916b7890ddb4f65bd52ab52e5fca2d1_I20201231" decimals="-6" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzQzOTgwNDY1MjUzODY_d3b6e7e1-52ad-48de-a0d4-970a2fd97246">245</ix:nonFraction>&#160;million as of December 31, 2020 were remeasured to estimated fair value, less costs to sell, which utilized Level 3 unobservable inputs. See Note 3, "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE" for additional details regarding these assets held for sale.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of long-term debt as of December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i43aa74e47e0a4098b9e1b70baf38319d_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzY3NTY_00db133f-6afc-4e5a-85ee-bdb03d32348a">22,689</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5d4c04c5a36a498e9735c3b7b90e02ae_I20201231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzY3NjM_27c1673c-5343-4351-8924-e10e48f4ac0d">25,378</ix:nonFraction> million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2).</span></div></ix:continuation><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_316"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTYvZnJhZzoyMzA5MDAwNTNjNDA0ODNhOWNkNzFjMmZkOTc1NmFmYy90ZXh0cmVnaW9uOjIzMDkwMDA1M2M0MDQ4M2E5Y2Q3MWMyZmQ5NzU2YWZjXzU5_e44441d6-1f65-4f5c-a36d-537606dc7397" continuedAt="iccf93866d5b244ffbcac0c64c3e4a1bf" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="iccf93866d5b244ffbcac0c64c3e4a1bf"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTYvZnJhZzoyMzA5MDAwNTNjNDA0ODNhOWNkNzFjMmZkOTc1NmFmYy90ZXh0cmVnaW9uOjIzMDkwMDA1M2M0MDQ4M2E5Y2Q3MWMyZmQ5NzU2YWZjXzQ3_c0b38880-fb7f-4d6c-bd7f-4c80459892ab" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net, as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:78.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTYvZnJhZzoyMzA5MDAwNTNjNDA0ODNhOWNkNzFjMmZkOTc1NmFmYy90YWJsZTpkYWI4Mzk1ZjExNTk0Y2U4ODYzM2JlNmIzNGFmYzlkMy90YWJsZXJhbmdlOmRhYjgzOTVmMTE1OTRjZTg4NjMzYmU2YjM0YWZjOWQzXzEtMi0xLTEtNTk0NzA_7d78abcb-17ba-460f-b7d4-13d7a7c7e083">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTYvZnJhZzoyMzA5MDAwNTNjNDA0ODNhOWNkNzFjMmZkOTc1NmFmYy90YWJsZTpkYWI4Mzk1ZjExNTk0Y2U4ODYzM2JlNmIzNGFmYzlkMy90YWJsZXJhbmdlOmRhYjgzOTVmMTE1OTRjZTg4NjMzYmU2YjM0YWZjOWQzXzEtNC0xLTEtNTk0NzA_ef3c61ad-120b-458f-995d-1fbce075faf5">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTYvZnJhZzoyMzA5MDAwNTNjNDA0ODNhOWNkNzFjMmZkOTc1NmFmYy90YWJsZTpkYWI4Mzk1ZjExNTk0Y2U4ODYzM2JlNmIzNGFmYzlkMy90YWJsZXJhbmdlOmRhYjgzOTVmMTE1OTRjZTg4NjMzYmU2YjM0YWZjOWQzXzItMi0xLTEtNTk0NzA_c3736387-f4c0-4e01-8194-d7ed8813271d">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:InventoryWorkInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTYvZnJhZzoyMzA5MDAwNTNjNDA0ODNhOWNkNzFjMmZkOTc1NmFmYy90YWJsZTpkYWI4Mzk1ZjExNTk0Y2U4ODYzM2JlNmIzNGFmYzlkMy90YWJsZXJhbmdlOmRhYjgzOTVmMTE1OTRjZTg4NjMzYmU2YjM0YWZjOWQzXzItNC0xLTEtNTk0NzA_fc669754-b5c9-46bd-88bb-78616f719f6f">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTYvZnJhZzoyMzA5MDAwNTNjNDA0ODNhOWNkNzFjMmZkOTc1NmFmYy90YWJsZTpkYWI4Mzk1ZjExNTk0Y2U4ODYzM2JlNmIzNGFmYzlkMy90YWJsZXJhbmdlOmRhYjgzOTVmMTE1OTRjZTg4NjMzYmU2YjM0YWZjOWQzXzMtMi0xLTEtNTk0NzA_375da9b0-099f-4808-b5e7-31835eb6ae7f">602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTYvZnJhZzoyMzA5MDAwNTNjNDA0ODNhOWNkNzFjMmZkOTc1NmFmYy90YWJsZTpkYWI4Mzk1ZjExNTk0Y2U4ODYzM2JlNmIzNGFmYzlkMy90YWJsZXJhbmdlOmRhYjgzOTVmMTE1OTRjZTg4NjMzYmU2YjM0YWZjOWQzXzMtNC0xLTEtNTk0NzA_2e102151-5617-4e29-ab4c-92ddc70eb38f">665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTYvZnJhZzoyMzA5MDAwNTNjNDA0ODNhOWNkNzFjMmZkOTc1NmFmYy90YWJsZTpkYWI4Mzk1ZjExNTk0Y2U4ODYzM2JlNmIzNGFmYzlkMy90YWJsZXJhbmdlOmRhYjgzOTVmMTE1OTRjZTg4NjMzYmU2YjM0YWZjOWQzXzQtMi0xLTEtNTk0NzA_5f4e8076-6e5b-4445-866b-ab80dd564744">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTYvZnJhZzoyMzA5MDAwNTNjNDA0ODNhOWNkNzFjMmZkOTc1NmFmYy90YWJsZTpkYWI4Mzk1ZjExNTk0Y2U4ODYzM2JlNmIzNGFmYzlkMy90YWJsZXJhbmdlOmRhYjgzOTVmMTE1OTRjZTg4NjMzYmU2YjM0YWZjOWQzXzQtNC0xLTEtNTk0NzA_eb502ccd-db22-4489-905e-24af64f497be">1,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_319"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90ZXh0cmVnaW9uOjQ0MzU5MGViZDFhNzQzZWM5M2U0MGUxMGM4NmMxOGRjXzE2MA_a675f2a6-41e3-4235-a305-a8f4dfc03218" continuedAt="iee4d269c238f4d90818fb43a171cdf27" escape="true">PROPERTY, PLANT AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="iee4d269c238f4d90818fb43a171cdf27"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90ZXh0cmVnaW9uOjQ0MzU5MGViZDFhNzQzZWM5M2U0MGUxMGM4NmMxOGRjXzE2Mw_a2a7fb4d-b2b4-44b6-a022-7ed116bb64e8" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of property, plant and equipment as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:78.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b16b99c92d340acae71efc354b677d3_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzEtMi0xLTEtNTk0NzA_81f65669-f897-40a3-ae3f-59e50f277f06">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53bc5bf59ece4ba7a3fb0dda2961cc78_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzEtNC0xLTEtNTk0NzA_1e85bd5e-91a8-423e-8f71-08e2a3bbf13e">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49f627a32c304d4e97c853cbdc52fe1d_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzItMi0xLTEtNTk0NzA_7c211490-f50c-4d58-9e53-393aaf6d5130">675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c417841d2d04bb0aa5f9721b865a03d_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzItNC0xLTEtNTk0NzA_b8447b50-93fc-4937-8352-e194c111b46c">686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6c6af997a5a40d3b472bba2069ff9c3_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzMtMi0xLTEtNTk0NzA_dd042d5e-8f2e-4048-8d9f-7f7a053b48b5">1,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic11c0834d02545e4a4a40fe884590f30_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzMtNC0xLTEtNTk0NzA_af32bc4c-6162-46b1-b335-438c791c5d19">1,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d9e8838b0b64725a2134d6c808fce63_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzQtMi0xLTEtNTk0NzA_fe0d87d3-384e-4ddc-ac7c-0a423136c24a">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a4f86638de4f1d85298fc8f9d9e688_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzQtNC0xLTEtNTk0NzA_5fc65763-a987-464a-a6c9-a143d1b2eca6">360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44211772dd52482e9e4ffe87d1d7ae4e_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzUtMi0xLTEtNTk0NzA_432edc84-6d2d-4209-bcb7-42f9cc18a7aa">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbafbc956c894b57be4b8cb6144cea99_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzUtNC0xLTEtNTk0NzA_77ee3c42-c853-4791-99c3-30e7afaaf2f9">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f977b18e2d47869607481b5bbc4690_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzYtMi0xLTEtNTk0NzA_2085b8de-d430-43d2-a703-2d7d69c0e2d6">576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i164c1c9b47e74fc793e6991fa1597a81_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzYtNC0xLTEtNTk0NzA_0a5ff03b-50f8-47f0-8dd6-14e7dd0fc426">436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzctMi0xLTEtNTk0NzA_6eca017f-914f-4a73-b7a9-b00bfe1105ec">3,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzctNC0xLTEtNTk0NzA_8ae67e37-27b7-4be9-a6ae-74293676edfd">3,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzgtMi0xLTEtNTk0NzA_b1fd79a2-1ea2-47fc-99c2-ac341cf72322">1,820</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzgtNC0xLTEtNTk0NzA_20ae7477-9214-46ce-803f-0a999d3b2134">1,781</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzktMi0xLTEtNTk0NzA_1418e796-c5e9-4f0c-bddd-4de52821f276">1,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzktNC0xLTEtNTk0NzA_6de7e3d7-eae6-470f-88fc-d2ec3f58603d">1,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90ZXh0cmVnaW9uOjQ0MzU5MGViZDFhNzQzZWM5M2U0MGUxMGM4NmMxOGRjXzEwNg_b3ef953b-3609-4bb1-bb37-dcdce299678e">177</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90ZXh0cmVnaW9uOjQ0MzU5MGViZDFhNzQzZWM5M2U0MGUxMGM4NmMxOGRjXzExMA_23a288c1-b29a-4d61-84b8-327bfd564e4a">180</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90ZXh0cmVnaW9uOjQ0MzU5MGViZDFhNzQzZWM5M2U0MGUxMGM4NmMxOGRjXzExNw_458f6c5d-f626-482e-b2fb-2b07c08a48bf">178</ix:nonFraction> million for 2021, 2020 and 2019, respectively.</span></div></ix:continuation><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_322"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI0NzY3_4b58bd82-0ee5-4f64-8a29-9ba9526b1e01" continuedAt="if498d167eafa44609c8411106e974f10" escape="true">INTANGIBLE ASSETS AND GOODWILL</ix:nonNumeric></span></div><ix:continuation id="if498d167eafa44609c8411106e974f10" continuedAt="id4ca2446ce524ab185e0c1adcab06e36"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI0NzU1_bb26fc12-92a3-4b94-b43a-d3632315dc2d" escape="true"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI0Nzg2_10a2f4a9-4e75-42a2-80e0-1ed3922cd88d" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets as of December&#160;31, 2021 and 2020 consist of:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:27.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.984%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Useful<br/>Lives<br/>(Years)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idf8fe351f9e049048e582a289f5ec940_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzMtMS0xLTEtNTk0NzA_7f0cf7f6-58fa-4711-bb80-d4d10360e249">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae408a1b501d44bfb0d015a59f05ba39_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzMtMy0xLTEtNTk0NzA_a74cd5cf-45b7-4c3c-9e69-18769af557bb">20,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae408a1b501d44bfb0d015a59f05ba39_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzMtNS0xLTEtNTk0NzA_104ee190-a27d-4f77-a1c8-fb1a6e9a992b">16,169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae408a1b501d44bfb0d015a59f05ba39_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzMtNy0xLTEtNTk0NzA_8f30cb3f-fe3c-427a-9026-90f3e4ceffe1">4,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7f9da12914489bab1b7bb4cbb4fc83_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzMtOS0xLTEtNTk0NzA_2aaf69b1-cef5-4e7d-b92f-6bd0eb16c1fd">20,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d7f9da12914489bab1b7bb4cbb4fc83_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzMtMTEtMS0xLTU5NDcw_b9d2b8b0-1d34-4712-96c6-814a76d8eaf2">14,914</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7f9da12914489bab1b7bb4cbb4fc83_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzMtMTMtMS0xLTU5NDcw_32a04b76-a3ae-41da-9450-3452e855883b">5,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idbf9196b61c6417e95bd898b4020850c_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzQtMS0xLTEtNTk0NzA_896e843f-64db-44c6-a95e-45a5cd9d9b5b">6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c9a0557ca2f40e8a6681b9854a4d544_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzQtMy0xLTEtNTk0NzA_1dbe1e19-d214-4515-a785-39a3002d18cf">902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c9a0557ca2f40e8a6681b9854a4d544_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzQtNS0xLTEtNTk0NzA_2c64a14e-f691-43c3-bb29-d8190b910567">473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c9a0557ca2f40e8a6681b9854a4d544_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzQtNy0xLTEtNTk0NzA_90bf589f-7dfa-429b-891e-978348e0603e">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06187f7ce19446a690591cd1b95c7f26_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzQtOS0xLTEtNTk0NzA_8b27a0ee-a48b-4431-9c83-464947565292">907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06187f7ce19446a690591cd1b95c7f26_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzQtMTEtMS0xLTU5NDcw_0ce69435-a9f5-4e2c-8310-64005d7a81f3">404</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06187f7ce19446a690591cd1b95c7f26_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzQtMTMtMS0xLTU5NDcw_7b0ca752-1b6a-4ea7-84ff-08f24241a8c9">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iea4f798327a64255b8fcebf77a9bfd28_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzUtMS0xLTEtNTk0NzA_4d6ca041-2960-475c-8207-ef56fa673ff5">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29ccbe7385f64c2a8f950c5898bc20dc_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzUtMy0xLTEtNTk0NzA_8f2ebe19-258e-41e9-881d-015c86fe3fcf">3,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29ccbe7385f64c2a8f950c5898bc20dc_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzUtNS0xLTEtNTk0NzA_695a2192-b360-4ade-b419-eabf0eac2d1c">3,174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29ccbe7385f64c2a8f950c5898bc20dc_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzUtNy0xLTEtNTk0NzA_883ecb51-4699-4266-9232-74e19a440803">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafcb6c30e16d4d609946e1e977a992a1_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzUtOS0xLTEtNTk0NzA_83f027ad-e7c4-44a6-baa2-73d27514a4ad">3,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafcb6c30e16d4d609946e1e977a992a1_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzUtMTEtMS0xLTU5NDcw_3dd6f200-7b3e-4500-a738-87d0b91a0891">3,055</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafcb6c30e16d4d609946e1e977a992a1_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzUtMTMtMS0xLTU5NDcw_83e24c39-6b4a-464c-92bc-5199e9d85948">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i875f56312a3e4f3aa4e713ccaddb57d8_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzYtMS0xLTEtNTk0NzA_66b6ae1e-5759-475b-8f18-3ad37e593142">0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bd0280d56644e9aa17e3ed84baa5cb9_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzYtMy0xLTEtNTk0NzA_813ee491-5e34-4efb-b0fa-4bf5925dd9b7">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3bd0280d56644e9aa17e3ed84baa5cb9_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzYtNS0xLTEtNTk0NzA_03981c50-7885-4e15-a56a-8303cfcce1ce">158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bd0280d56644e9aa17e3ed84baa5cb9_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzYtNy0xLTEtNTk0NzA_76ba90f2-8962-439a-b6d9-51891489895d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide8dc03ca5d34e2d82fe875ae8349bfe_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzYtOS0xLTEtNTk0NzA_6c9bd322-4013-454e-a478-f7511cd6e38d">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide8dc03ca5d34e2d82fe875ae8349bfe_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzYtMTEtMS0xLTU5NDcw_bd6daf92-da22-410f-9c94-c98f1a357c8d">168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide8dc03ca5d34e2d82fe875ae8349bfe_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzYtMTMtMS0xLTU5NDcw_6e975a79-81fb-41ad-af2c-133302994d97">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib10da3a8baaa43f2882bbc75cea97f73_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzctMS0xLTEtNTk0NzA_c8a43f2b-4e2b-4d75-a7e1-f81510c412c2">1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9afc2f89d1f4c1dbec3435239ca1668_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzctMy0xLTEtNTk0NzA_8d7b7afd-d5a8-470f-9319-b9013669c9b7">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9afc2f89d1f4c1dbec3435239ca1668_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzctNS0xLTEtNTk0NzA_2c8867cb-c34e-4945-b862-8bb5cbfbbcbc">206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9afc2f89d1f4c1dbec3435239ca1668_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzctNy0xLTEtNTk0NzA_02f01bda-1553-4b61-9310-938b38c05780">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fee0ea71e1945109e92e284dc86e65a_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzctOS0xLTEtNTk0NzA_8cdd76d7-4bb8-4daf-8e55-b30663f43580">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fee0ea71e1945109e92e284dc86e65a_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzctMTEtMS0xLTU5NDcw_8400c891-5214-4d90-86b1-685ae1a2c527">200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fee0ea71e1945109e92e284dc86e65a_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzctMTMtMS0xLTU5NDcw_d9849f95-37e3-43bf-9a5d-89595937f94e">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzgtMy0xLTEtNTk0NzA_51bd7643-e03f-4e61-9c44-fd6ff2972af5">25,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzgtNS0xLTEtNTk0NzA_47079c53-aaca-4adf-9081-6e34fab23122">20,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzgtNy0xLTEtNTk0NzA_cda5e621-e692-4179-8e43-93ddc470958f">5,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzgtOS0xLTEtNTk0NzA_9a6c718c-f3de-4964-9b11-d84a0adec80c">25,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzgtMTEtMS0xLTU5NDcw_e2d1b023-a5d5-4632-95ea-0957ce5a1915">18,741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzgtMTMtMS0xLTU5NDcw_ae7dc8a1-f7eb-4e72-a7fc-ba61bdc6ce72">6,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D not in service</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ff94dcd862b417485b1c86cab1f0d19_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzktMy0xLTEtNTk0NzA_064ef316-2711-4dad-8ffc-1925ffc9b123">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ff94dcd862b417485b1c86cab1f0d19_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzktNy0xLTEtNTk0NzA_9ed6996b-41dc-4027-92c4-b80856c401a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1044279e431a465c8d792ff8c4424f95_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzktOS0xLTEtNTk0NzA_ca0c25f1-6b61-4d2f-a01c-0edad8a456ca">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1044279e431a465c8d792ff8c4424f95_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzktMTMtMS0xLTU5NDcw_2a0f0173-8af4-4627-a637-b006477006e6">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B&amp;L Trademark</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i068c904248854bbc871b95c7bda13c2a_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzEwLTMtMS0xLTU5NDcw_c8d92b06-75f8-4163-9f16-178f52c7cc5d">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i068c904248854bbc871b95c7bda13c2a_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzEwLTctMS0xLTU5NDcw_159c0820-85fc-40b9-b54c-5f3e201df70d">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i482a42699464403190bb5666f649d099_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzEwLTktMS0xLTU5NDcw_aa62566c-a359-4139-ba1d-82a1d6cf85f5">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i482a42699464403190bb5666f649d099_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzEwLTEzLTEtMS01OTQ3MA_9dcaeed0-13dd-4667-b190-da7ada05952e">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzExLTMtMS0xLTU5NDcw_9a56cdc2-7dec-4cf3-ac1a-d7f57fefc97f">27,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzExLTUtMS0xLTU5NDcw_ecbbeb4f-e363-44bc-9d68-5a942356e90d">20,180</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzExLTctMS0xLTU5NDcw_b9068089-3420-43fb-ae9f-3aa3c83d7640">6,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzExLTktMS0xLTU5NDcw_f4003d50-d9e4-43e0-bb63-1c10c5cba4ba">27,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzExLTExLTEtMS01OTQ3MA_a72f30b3-c577-4892-ba7a-470042b5a991">18,741</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzExLTEzLTEtMS01OTQ3MA_6f52927d-39db-40ba-a8ce-6623331a2b78">8,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments, including loss on assets held for sale in the Consolidated Statement of Operations.  The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale in 2021 included: (i) impairments of $<ix:nonFraction unitRef="usd" contextRef="idf8fe351f9e049048e582a289f5ec940_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NjA1OTI_847badec-3079-4a8e-be38-6aa7d4866454">105</ix:nonFraction>&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, (ii) an $<ix:nonFraction unitRef="usd" contextRef="i8fd89ab94eae4b75848759e31a502deb_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NjA2MDY_f81bb129-b4af-4af4-b401-52133f4223c6">88</ix:nonFraction>&#160;million loss on assets held for sale in connection with the Amoun Sale, (iii) impairments of $<ix:nonFraction unitRef="usd" contextRef="i6052d5b84a4f4e3dbbd55e3b7b3472af_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NjA2MTk_98da1d33-c84e-4f75-a79f-21b767ef1e04">23</ix:nonFraction>&#160;million, in aggregate, related to the discontinuance of certain product lines and (iv) $<ix:nonFraction unitRef="usd" contextRef="i65d12a1576654877b8d12fa8e43fad62_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzY1MDU_aaa5dcfe-0613-4833-827c-8cd95707f411">18</ix:nonFraction>&#160;million related to a portion of an IT infrastructure improvement project no longer being utilized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale in 2020 included impairments of: (i) $<ix:nonFraction unitRef="usd" contextRef="iee78254e5ef24867b4e79676061b9da5_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzYwNg_6370e89c-e7e6-4598-820c-a2dc67b9d915">96</ix:nonFraction>&#160;million to reduce the carrying value of the Amoun business to its estimated fair value less costs to sell due to classifying the business as held for sale as discussed in Note 3, "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE", (ii) $<ix:nonFraction unitRef="usd" contextRef="ic98bb92d4f6c4075b3ea9d057f2dc09e_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzgyMA_33879e3e-5e37-4091-9144-65a9ed120d9c">16</ix:nonFraction>&#160;million in aggregate, due to decreases in forecasted sales of certain product lines, (iii) $<ix:nonFraction unitRef="usd" contextRef="i7814719b55964c3a90f30a661c040f5e_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzkwNg_1785d896-13c3-4327-8e4a-840025d6be2d">1</ix:nonFraction>&#160;million in aggregate, related to the discontinuance of certain product lines not aligned with the focus of the Company's core businesses and (iv) $<ix:nonFraction unitRef="usd" contextRef="iae9620bf07594c2d8b0ae4bda9e46476_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzEwNDc_a8a887da-dbe5-4cf7-99a3-355306299aa0">1</ix:nonFraction>&#160;million related to Acquired IPR&amp;D not in service.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="id4ca2446ce524ab185e0c1adcab06e36" continuedAt="ibb16fe35883440d098cc3f524d8f3f5d"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale in 2019 included impairments of: (i) $<ix:nonFraction unitRef="usd" contextRef="i4275122509984c548f84f8d98d4710c4_D20190101-20191231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzExMzI_cfbdffdc-5928-49ed-a40d-76b3d7da7a57">58</ix:nonFraction> million reflecting decreases in forecasted sales of certain product lines due to generic competition and other factors, (ii) $<ix:nonFraction unitRef="usd" contextRef="i7f2bdcc8cabc4a8fbc2220baf550e504_D20190101-20191231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzEyNTI_831d23a1-eb5a-40bc-8ee1-b20fd747d3e0">8</ix:nonFraction> million related to assets being classified as held for sale, (iii) $<ix:nonFraction unitRef="usd" contextRef="i77368b09b2fe4c1dbf5d0160459ef7d5_D20190101-20191231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzEzMTQ_33e7ea0c-e4a3-485e-abe2-6aea76535d6d">5</ix:nonFraction> million related to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core businesses and (iv) $<ix:nonFraction unitRef="usd" contextRef="i3f938f0f5c7b48b98d4abfb36c343bf5_D20190101-20191231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzE0ODg_d3094f62-2f64-4ebc-918e-3231ca0b4dc8">4</ix:nonFraction> million related to Acquired IPR&amp;D not in service. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impairments to assets reclassified as held for sale were measured as the difference of the carrying value of these assets as compared to the estimated fair values of these assets less costs to sell determined using a discounted cash flow analysis which utilized Level 3 unobservable inputs. The other impairments and adjustments to finite-lived intangible assets were measured as the difference of the historical carrying value of these finite-lived assets as compared to the estimated fair value as determined using a discounted cash flow analysis using Level 3 unobservable inputs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, the Company&#8217;s products face the expiration of their patent or regulatory exclusivity. The Company anticipates that product sales for such product would decrease shortly following a loss of exclusivity ("LOE"), due to the possible entry of a generic competitor. Where the Company has the rights, it may elect to launch an authorized generic of such product (either as the Company&#8217;s own branded generic or through a third-party).  This may occur prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product could still be significant, and the effect on future revenues could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management continually assesses the useful lives related to the Company's long-lived assets to reflect the most current assumptions.</span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI0Nzk2_d8e919cb-e56b-4089-8fa1-1649f99080e3" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the five years ending December&#160;31 and thereafter are as&#160;follows: </span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:16.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.881%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTpjZDc0YzVhMTQwYmQ0ZjBkODYyYzVmMTliYTFjNjM4MS90YWJsZXJhbmdlOmNkNzRjNWExNDBiZDRmMGQ4NjJjNWYxOWJhMWM2MzgxXzEtMi0xLTEtNTk0NzA_72f392c6-5cab-4cd2-a6cd-4508ab48273c">1,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTpjZDc0YzVhMTQwYmQ0ZjBkODYyYzVmMTliYTFjNjM4MS90YWJsZXJhbmdlOmNkNzRjNWExNDBiZDRmMGQ4NjJjNWYxOWJhMWM2MzgxXzEtNC0xLTEtNTk0NzA_b5e5fe15-4eae-441d-9a54-14bc845f0d81">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTpjZDc0YzVhMTQwYmQ0ZjBkODYyYzVmMTliYTFjNjM4MS90YWJsZXJhbmdlOmNkNzRjNWExNDBiZDRmMGQ4NjJjNWYxOWJhMWM2MzgxXzEtNi0xLTEtNTk0NzA_6a3393db-836f-45d2-acd4-478dff7124f8">902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTpjZDc0YzVhMTQwYmQ0ZjBkODYyYzVmMTliYTFjNjM4MS90YWJsZXJhbmdlOmNkNzRjNWExNDBiZDRmMGQ4NjJjNWYxOWJhMWM2MzgxXzEtOC0xLTEtNTk0NzA_6f65ce0a-7760-4bc4-a949-7894cc8b99cb">795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTpjZDc0YzVhMTQwYmQ0ZjBkODYyYzVmMTliYTFjNjM4MS90YWJsZXJhbmdlOmNkNzRjNWExNDBiZDRmMGQ4NjJjNWYxOWJhMWM2MzgxXzEtMTAtMS0xLTU5NDcw_aaae8bac-1a18-45da-8b36-6e87f4f4b739">664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTpjZDc0YzVhMTQwYmQ0ZjBkODYyYzVmMTliYTFjNjM4MS90YWJsZXJhbmdlOmNkNzRjNWExNDBiZDRmMGQ4NjJjNWYxOWJhMWM2MzgxXzEtMTItMS0xLTU5NDcw_d1237bd3-a319-4357-8204-858e5c7d10f1">682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTpjZDc0YzVhMTQwYmQ0ZjBkODYyYzVmMTliYTFjNjM4MS90YWJsZXJhbmdlOmNkNzRjNWExNDBiZDRmMGQ4NjJjNWYxOWJhMWM2MzgxXzEtMTQtMS0xLTU5NDcw_810d34a5-65d2-4358-af9a-00a9808d8eec">5,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI0NzY0_762629f7-71f9-48aa-878c-151564ab4b6f" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the years ended December 31, 2021, 2020 and 2019 were as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:31.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + <br/>Lomb/<br/>International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + <br/>Lomb</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International Rx</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4962dcdee267427ca7c640643c4b63e0_I20181231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEtMi0xLTEtNTk0NzA_0ba0c9ac-af77-4e02-af17-af802ca5e74d">5,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87f144240594803b338f3329694b5af_I20181231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEtNi0xLTEtNjc5Njg_a54bd4aa-b644-4b25-83ff-48bb9aac608c">3,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6485ff11a7784c7d93cdebb81e571cf7_I20181231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEtMTAtMS0xLTY3OTcw_0265a229-9262-44f3-8a9c-74ee3859bcaa">1,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13a6652f6f14e9380c0faa89ab7253a_I20181231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEtMTItMS0xLTY3OTcy_b815f6e8-c102-492f-8713-f438d6069150">2,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a9900560564bdca7dec25381689c13_I20181231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEtMTQtMS0xLTU5NDcw_f5ce9153-bcdd-48b7-b334-d196d2c009ff">13,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of certain assets of Synergy </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieefeebe8556a419b982e4603dccbde45_D20190101-20191231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzItNi0xLTEtNjc5NDg_3d16a735-bf10-48b3-8c9f-b5890bc3173f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzItMTQtMS0xLTU5NDcw_3b761f09-8cd1-4713-8bec-95c84163fcf5">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if02d06f22a6049fab2752d7559d9139c_D20190101-20191231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzMtMi0xLTEtNTk0NzA_a23a666d-7357-48b8-9f65-f7f636635db5">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzMtMTQtMS0xLTY3OTgx_b5425564-8fbe-4239-a6a7-5b2fe6657e96">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if02d06f22a6049fab2752d7559d9139c_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzctMi0xLTEtNTk0NzA_529f5d8f-e42c-4e10-88ba-798e1e6651e4">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzctMTQtMS0xLTU5NDcw_8814787f-f6cb-4278-90b4-7f0606fb223b">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25b498657cd04064a8d22a18cb88515c_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzgtMi0xLTEtNTk0NzA_b881c708-33aa-4805-ba6d-6b2dcd327265">5,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf8602fc27b744ae97df02360802bb93_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzgtOC0xLTEtNTk0NzA_20c159be-3d7a-449f-a703-f56b4867459f">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia16b95bd57544fe1b90bd153182259d7_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzgtMTAtMS0xLTU5NDcw_ce4f5b95-4e61-4011-b5eb-dda5638cbfd3">1,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id15e4ba8f40445ec845f103e0aaa553e_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzgtMTItMS0xLTU5NDcw_b1b20524-a698-4f90-a5b1-ab8b2f7a9ea9">2,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzgtMTQtMS0xLTU5NDcw_39fdf8c9-563d-441b-b398-bf1346811be2">13,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets held for sale reclassified to goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i373d7f78aa2349ccaafcb0b37e13b0e1_D20200101-20201231" decimals="-6" name="bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzYtMi0xLTEtNjc5NTA_0c4dca79-eae5-4720-b883-d4becada47f4">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzYtMTQtMS0xLTY3OTUy_32757b52-7d3e-41a6-b904-f5f7665fe114">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale (Note 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i373d7f78aa2349ccaafcb0b37e13b0e1_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEwLTItMS0xLTU5NDcw_a2139b88-f038-4da2-a9c0-fe6c305c39cf">217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEwLTE0LTEtMS01OTQ3MA_291eacc3-2189-459d-be75-102062c5645f">217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i373d7f78aa2349ccaafcb0b37e13b0e1_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzExLTItMS0xLTU5NDcw_9933a553-2b46-4dd7-bcaa-1af00ec170a9">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzExLTE0LTEtMS01OTQ3MA_b75b85ca-f8c9-4225-85e2-36197e782baf">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e7c6b2d77a446c1b4aed9a04f7dbd2e_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEyLTItMS0xLTU5NDcw_583b6e4d-47c0-4bbb-bf39-07383499e69a">5,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf22e67019f9453383f473a7440bb889_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEyLTgtMS0xLTU5NDcw_2a366484-f27f-4c5e-ab2d-c94830581c11">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0d98e274204d53b918164aca0779ae_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEyLTEwLTEtMS01OTQ3MA_f543b34f-4a59-4d05-a473-4f5e68126156">1,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib76ac81df5fa49b68ba3b7819c1fc06a_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEyLTEyLTEtMS01OTQ3MA_fe556b01-935e-4271-9f0f-06a53b6fb5d5">2,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEyLTE0LTEtMS01OTQ3MA_6122af82-f0cc-4e01-9d4b-368b6290cdaf">13,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7300f7b54644f8a9660b750f9e847b8_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEzLTItMS0xLTU5NDcw_cf8672a6-2034-4d20-b280-191bacfc479b">5,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85a97ee039044646b0f12d8dfddbf0fb_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEwLTQtMS0xLTY3OTU0_7e62cb82-ea4a-4fff-8771-70fdac8ae8fc">5,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd56e661cc441b88ce62c077cb8c9c5_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEwLTgtMS0xLTY3OTU2_f5f583dc-f48b-4ab4-afa7-6446de0e40d1">887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9cf2e58ead94c7e812f2a73e8e5a8b0_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEwLTEyLTEtMS02Nzk1OA_007b2e57-2260-4502-ab28-1c82008dbaea">578</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEzLTE0LTEtMS01OTQ3MA_3c51a8ab-a869-45d1-bbed-dc2cdcd17cb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7300f7b54644f8a9660b750f9e847b8_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzE0LTItMS0xLTU5NDcw_af7bd707-88fc-445a-9d24-27ddb20e7e95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03a8ce11b6a94d508439a84f941e6341_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzExLTEwLTEtMS02Nzk2MA_ae1566b0-8302-426b-abf8-628d83a8e787">469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzE0LTE0LTEtMS01OTQ3MA_a2b98a85-e598-46e9-85f1-8fe9fb2181fa">469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7300f7b54644f8a9660b750f9e847b8_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzE1LTItMS0xLTU5NDcw_6eb08f9b-0bc1-4926-ba91-4bf021d7e5df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85a97ee039044646b0f12d8dfddbf0fb_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEyLTQtMS0xLTY3OTYy_af02f3dc-4d28-4ef8-9dcd-c64abdbcb53f">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6dd56e661cc441b88ce62c077cb8c9c5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEyLTgtMS0xLTY3OTY0_e92547f1-6034-4f52-8998-fee7b033dcce">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9cf2e58ead94c7e812f2a73e8e5a8b0_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEyLTEyLTEtMS02Nzk2Ng_5acb3572-35ec-48c0-8efe-e83bd9ab1caf">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzE1LTE0LTEtMS01OTQ3MA_8ba6b41b-84da-4b15-9ef3-8d289d72d739">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ab307cfbe9b4a94b2c883cfc5dd5f07_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzE2LTItMS0xLTU5NDcw_a0e135df-4990-452e-b836-c5eda92eadec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a665fac8c5447d6b59c47157917616d_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEzLTQtMS0xLTY3OTYy_82c6d90c-33ba-422d-8ce6-7f0db89bc93e">5,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieba4bed7b87c4d64adde44c696279cea_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzE2LTgtMS0xLTU5NDcw_4eda8731-2265-442a-b1c9-a9b98750182d">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08856af02cf84095b7eda2ff890eaa65_I20211231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEzLTgtMS0xLTY3OTY0_bcb684cf-5b32-4985-82e1-5a68b30e4520">825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7042f2109b44a618b5adc51134f2f32_I20211231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzE2LTEwLTEtMS01OTQ3MA_49c515a8-7e2d-4242-a2cb-b1ddd5f31e40">798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16b907a0a74e489584cd63b7298ac261_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzE2LTEyLTEtMS01OTQ3MA_c34a01b6-5e4e-44ea-8e9d-920dff2de4ce">2,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzE2LTE0LTEtMS01OTQ3MA_ac234e0d-a2c6-4589-a2c8-cdf1a7dc3ee5">12,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment.  The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1). </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ibb16fe35883440d098cc3f524d8f3f5d" continuedAt="ib2d721bc7e014d3d9795708943af16fc"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit's terminal value. </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To forecast a reporting unit's cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management's and a market participant's view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected LOE to the Company's product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#8217;s control could have a positive or negative impact on achieving its targets.  Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2019</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2019 by first assessing qualitative factors. Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit. In each quantitative fair value test performed, the fair value was greater than the carrying value of the reporting unit.  As a result, there was <ix:nonFraction unitRef="usd" contextRef="i9e15ed3860174023ad86fcfb1fc3d7a7_D20191001-20191001" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzM4NDgyOTA3NjEyMTc_a1b3be93-751a-4481-b62b-74ad015c356e">no</ix:nonFraction> impairment to the goodwill of any reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2020</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative impacts of the COVID-19 pandemic on the global economy have led to significant volatility in the global equity markets. The Company has been able to continue its operations with limited disruptions and has assessed the potential impact that the COVID-19 pandemic is likely to have on its forecasted cash flows.  In performing its assessment, the Company considered the possible effects and outcomes of the COVID-19 pandemic on, among other things, its supply chain, customers and distributors, employee base, product sustainability, research and development activities, product pipeline and consumer demand and related rebates and discounts and has made adjustments, although not considered to be material, to its long-term forecasts used in its previous goodwill impairment assessments, for these and other matters. After completing this assessment, although not completely insulated from the negative effects of the COVID-19 pandemic, the Company believes that its long-term forecasted cash flows, as adjusted for the possible outcome of the COVID-19 pandemic and other matters, do not indicate that the fair value of any reporting unit may be below its carrying value. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2020 revenues were most negatively impacted during its second quarter by certain social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize prior to the third quarter of 2020. Revenues for 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzE2MjE3_b133e6d3-a8f6-44ac-a3ce-08da11a8d93c">8,434</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzE2MjI0_5ea33e25-47ac-4585-a299-2b676f7f353a">8,027</ix:nonFraction>&#160;million, respectively. The increase of $<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NjQwMTE_b012affb-7489-46a6-b649-a8ba9b7ba8ca">407</ix:nonFraction>&#160;million in revenue represents an improving trend over the decreases in year-over-year revenues for the three month periods ended June 30, 2020, September 30, 2020 and December 31, 2020 of <ix:nonFraction unitRef="number" contextRef="i6b80b732bf87464abb356edb40e75c0f_D20200401-20200630" decimals="2" sign="-" name="bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzE2NDUx_03dc97f5-9129-4dc3-9987-887bf18305f2">23</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="ie754db10161f4f43a00a7ccbbb4d5499_D20200701-20200930" decimals="2" sign="-" name="bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzE2NDU4_662d7c21-dff9-4a10-8143-f696ecf8db01">3</ix:nonFraction>% and less than <ix:nonFraction unitRef="number" contextRef="i49498b6d16f54144b0e062468813a553_D20201001-20201231" decimals="2" sign="-" name="bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NjQwMDc_c582c767-3fba-49fc-89d8-985d90f6958e">1</ix:nonFraction>%, respectively. The Company's revenues returned to pre-pandemic levels for many of its businesses and geographies in 2021 and, presuming there continues to be increased availability of effective vaccines and any further resurgence of the COVID-19 virus, the delta and omicron variants and other variant strains thereof do not have a material adverse impact on efforts to contain the COVID-19 virus, the Company anticipates the COVID-19 pandemic to have a minimal impact on its remaining businesses and geographies in 2022. However, the rates of recovery for each business will vary by geography and will be dependent upon, among other things, the availability and effectiveness of vaccines for the COVID-19 virus, government responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus and other actions taken in response to the COVID-19 pandemic.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ib2d721bc7e014d3d9795708943af16fc" continuedAt="i5e0dbd5a9163464b8485e9ff723be3dd"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Interim Goodwill Impairment Assessment</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2020, after giving consideration to the nature and timing of the negative impacts of the COVID-19 pandemic on the Company's forecasted cash flows, with the exception of the Ortho Dermatologics reporting unit, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, <ix:nonFraction unitRef="usd" contextRef="iae72504d531644ac8838bbb4ec27c1c1_D20200101-20201231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzEwOTk1MTE2OTIyNDY_97b6bd26-5e9c-4471-90d0-5edcac60578d">no</ix:nonFraction> impairments were recorded. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020 and June 30, 2020, the operating results for the Ortho Dermatologics reporting unit were less than forecasted primarily due to certain products experiencing longer launch cycles than originally anticipated as a result of the COVID-19 pandemic. The Company revised its long-term forecasts as of March 31, 2020 and as of June 30, 2020 for these matters. Management believed that these events were indicators that there was less headroom as of March 31, 2020 and June 30, 2020 as compared to the headroom calculated on the date Ortho Dermatologics goodwill was previously tested for impairment. Therefore, a quantitative fair value test for impairment to the goodwill of the Ortho Dermatologics reporting unit was performed at March 31, 2020 and at June 30, 2020. Based on the quantitative fair value tests, the fair value of the Ortho Dermatologics reporting unit continued to be greater than its carrying value and as a result there was <ix:nonFraction unitRef="usd" contextRef="i10b37ca262cc4204a355bbd20f6cd963_D20200630-20200630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI3NDg3NzkxMzM0MDI_5b482b05-7d51-4709-a169-1d33d9bcc300"><ix:nonFraction unitRef="usd" contextRef="iac97f26599824297bb76711a52beec7e_D20200331-20200331" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI3NDg3NzkxMzM0MDI_b95492ca-8650-4017-8260-cae7fbb95819">no</ix:nonFraction></ix:nonFraction> impairment to the goodwill of the reporting unit at March 31, 2020 and at June 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2020 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2020, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2020, the Company considered, among other matters, a range of potential impacts of COVID-19 pandemic related matters and the limited headroom calculated on the date Ortho Dermatologics goodwill was last tested for impairment (June 30, 2020).  The Company believed that these factors may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2020, utilizing a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="ib7fea7ac010346df9ddbd729f74109a4_I20201001" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzIzNTI0_3ff705e0-bc7d-4cae-b6d2-99b96767ee25">2.0</ix:nonFraction>% and a range of discount rates between <ix:nonFraction unitRef="number" contextRef="i5c4efa01e28a4063ba07a08f0dec29a3_I20201001" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzIzNTY1_91544c46-0de2-4b81-bf0d-a1a64afcc690">9.50</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="id4d44a38635a40b4a32e60755373e624_I20201001" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzIzNTcy_bdf0e49c-292a-4716-bed0-a8c20b75ef0a">9.75</ix:nonFraction>%, in estimation of the fair value of this reporting unit.  Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately <ix:nonFraction unitRef="number" contextRef="ib7fea7ac010346df9ddbd729f74109a4_I20201001" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzIzNzUx_155894fe-ec34-4b80-be36-25218afff224">10</ix:nonFraction>% greater than its carrying value and as a result there was <ix:nonFraction unitRef="usd" contextRef="i774ca80b37c14809aaf69d1ec60caea2_D20201001-20201001" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzIzODEy_4d81974b-1a57-4804-8905-2b1ba8bbf83f">no</ix:nonFraction> impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2021</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Quarter 2021 - Realignment of Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2021, the Company began operating in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International Rx, (iv) Ortho Dermatologics and (v) Diversified Products. The Bausch + Lomb segment consists of the: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. The Salix segment consists of the Salix reporting unit. The International Rx segment consists of the International Rx reporting unit. The Ortho Dermatologics segment consists of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. This realignment in segment structure resulted in a change in the Company's former International reporting unit, which is now divided between the International Bausch + Lomb reporting unit and International Rx reporting unit. In addition, as part of this realignment of segment structure, certain products historically included in the Generics reporting unit are now included in the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. Goodwill previously reported in the former International reporting unit was reassigned to the International Bausch + Lomb and International Rx reporting units, and a portion of goodwill previously reported in the former Generics reporting unit was reassigned to the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in reporting units, the Company performed a qualitative fair value assessment for its former: (i) International and (ii) Generics reporting units. Based on the qualitative fair value assessment performed, management believed that it was more likely than not that the carrying values of its former: (i) International and (ii) </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i5e0dbd5a9163464b8485e9ff723be3dd" continuedAt="iff931d2d31db455e9f8e1ba4ec68954b"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generics reporting units were less than their respective fair values and therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the change in reporting units, as a result of the change in composition of the net assets for its current: (i) International Bausch + Lomb, (ii) International Rx and (iii) Generics reporting units, the Company performed a quantitative fair value test. The quantitative fair value test utilized a range of long-term growth rates of <ix:nonFraction unitRef="number" contextRef="ie3ad16bb04674a37884451df0bcbfb99_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NDU2ODY_f71e53f1-c0e2-4b23-891a-a625a1bb26d8">1.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ib2e256a9bac640f8ab017d4f047fb1c9_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NDU2OTI_73fe84c4-5f7a-487a-9982-688c5db3e7a4">3.0</ix:nonFraction>% and a range of discount rates between <ix:nonFraction unitRef="number" contextRef="ie3ad16bb04674a37884451df0bcbfb99_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NDU2OTg_f5258a2a-bf29-463b-9f32-e142096fc135">11.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ib2e256a9bac640f8ab017d4f047fb1c9_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NDU3MDU_56c2ff0d-b81f-4197-ba4d-e4f3877e4b64">12.25</ix:nonFraction>%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than <ix:nonFraction unitRef="number" contextRef="ibd4407332fee40f39e8808930a147100_I20210331" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NDU3MTM_cc2fae5e-15f2-41c7-9196-32aee8e9e7f4">40</ix:nonFraction>%, and, therefore, there was <ix:nonFraction unitRef="usd" contextRef="iae738547736443dc961d0df42b4d932b_D20210331-20210331" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI3NDg3NzkxMzM0MTA_7261e837-b811-4958-a66d-49ff81e24814">no</ix:nonFraction> impairment to goodwill. In addition, as the U.S. Bausch + Lomb reporting unit had a change in composition of its net assets related to certain products historically included in the Generics reporting unit now being included in the U.S. Bausch + Lomb reporting unit, the Company performed a qualitative assessment of this reporting unit. Based on the qualitative fair value assessment performed, management believed that it was more likely than not that the carrying value of its current U.S. Bausch + Lomb reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">March 31, 2021 Impairment to Goodwill </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products.  In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;D spend to eliminate projects it has identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there is less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company's most recent cash flow projections as revised in the first quarter of 2021 to reflect the business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="iade956227f64477f8bd834744fb0b81c_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzMxMTc_de56a2b9-fb15-4abc-ab98-45499e951915">1.0</ix:nonFraction>% and a range of discount rates between <ix:nonFraction unitRef="number" contextRef="i33a4b28c4d244a908251259f68df10a2_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzMxMjM_98ffce42-8fd8-4edc-aab4-d46a0783cd2f">9.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3befa2e27fb94dadb4d2e0b6671d1ea7_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzMxMjk_07195d55-24e6-487f-ba9c-2252358fab0e">10.0</ix:nonFraction>%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at March 31, 2021, and the Company recognized a goodwill impairment of $<ix:nonFraction unitRef="usd" contextRef="ief2363e2b42349f1be653bf6588660db_D20210331-20210331" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzMxMzY_25432c3d-c866-4dda-907b-64f2ce8cbb77">469</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Quarter 2021 - Realignment of Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the second quarter of 2021, the Company changed the way it reviews the financial information of its Bausch + Lomb segment.  Beginning in the second quarter of 2021, management no longer reviews the financial information of its Bausch + Lomb segment on a geographic basis, but instead reviews this financial information on a business line basis.  This change created a change in the reporting units of the Bausch + Lomb segment. After the change, under its business line view, the Bausch + Lomb segment consists of the global: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. Prior to the second quarter of 2021, under the geographic view, the Bausch + Lomb segment consisted of the former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. The change in Bausch + Lomb reporting units does not impact the reported revenues and segment profits of the Bausch + Lomb segment for any prior periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in its Bausch + Lomb reporting units, the Company performed a qualitative fair value assessment for its former reporting units. Based on the qualitative fair value assessment, management believed that it was more likely than not that the carrying values of its former:  (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units were less than their respective fair values and, therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the change in composition of net assets, the Company performed a quantitative fair value test of its new: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units immediately following the change in the Bausch + Lomb segment. The quantitative fair value test utilized long-term growth rates of <ix:nonFraction unitRef="number" contextRef="i68ccc3aae7a44c81bc2bc15d199cf675_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzMxNTc_1eb949f5-c66e-47b1-8c6c-2ea5b1765b90">2.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i39f7dc3af718428fa8639267d86d4723_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI3NDg3NzkxMzM0MTk_c5970923-e980-41c8-b8cd-1a51f21968c5">3.0</ix:nonFraction>% and a range of discount rates between <ix:nonFraction unitRef="number" contextRef="i68ccc3aae7a44c81bc2bc15d199cf675_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzMxNjM_ee545374-d649-4b4b-8837-58aafdc214cb">7.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i39f7dc3af718428fa8639267d86d4723_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzMxNjk_b4d7b7e2-36f3-49fd-bc0a-49913d4519db">10.0</ix:nonFraction>%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than <ix:nonFraction unitRef="number" contextRef="i6bce9561cca44aed9496c119874299ef_I20210630" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzMxNzY_5a2aa097-e86a-4c44-9ae0-31885d48963c">45</ix:nonFraction>%, and, therefore, there was <ix:nonFraction unitRef="usd" contextRef="idc7bc8f12bdf4bd5b49783904d555941_D20210630-20210630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI3NDg3NzkxMzM0MjQ_e8070eb9-1cde-46ca-8564-2d38e4c16eb0">no</ix:nonFraction> impairment to goodwill.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="iff931d2d31db455e9f8e1ba4ec68954b"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 30, 2021 and September 30, 2021 Interim Assessments of Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor the market conditions impacting the Ortho Dermatologics reporting unit. The  Company's latest forecasts for the Ortho Dermatologics reporting unit include a range of potential outcomes for, among other matters: (i) the impacts of the COVID-19 pandemic on operations, (ii) the impact of the loss of exclusivity of certain products, (iii) the impact of longer launch cycles for certain new products, (iv) progress of its product pipeline and (v) ongoing pricing pressures, which could negatively impact the reporting unit's results over the long term. The changes in the amounts and timing of revenues and expenses in the latest forecast as compared to the forecast used at March 31, 2021 (the last time goodwill of the Ortho Dermatologics reporting unit was tested), were not substantial enough to materially adversely affect the recoverability of the Ortho Dermatologics reporting unit's assets and are not material enough to indicate that the fair value of the Ortho Dermatologics reporting unit might be below its carrying value as last tested at March 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other events occurred or circumstances changed during the period October 1, 2020 (the earliest date goodwill was tested for all other reporting units) through December 31, 2021 that indicated that the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit, might be below its carrying value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2021 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2021, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2021, the Company considered, among other matters, the limited headroom as a result of the impairment to the goodwill of the Ortho Dermatologics reporting unit when last tested (March 31, 2021) and macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The Company believed that these facts and circumstances may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2021, utilizing a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="ifae82a26687143d58a5a4cf6c438ebca_I20211001" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzQ5MDM_605b223c-d383-4140-8a83-5150a1f0d39e">1.0</ix:nonFraction>% and a discount rate of <ix:nonFraction unitRef="number" contextRef="ifae82a26687143d58a5a4cf6c438ebca_I20211001" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzQ5NDE_520f67ec-f3c6-4260-a954-827e7b681f79">9.0</ix:nonFraction>%, in estimation of the fair value of this reporting unit.  Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately <ix:nonFraction unitRef="number" contextRef="ifae82a26687143d58a5a4cf6c438ebca_I20211001" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzQ5NjQ_966ff319-31c7-4440-9ef9-e0ab9ebdb7b2">10</ix:nonFraction>% greater than its carrying value and as a result there was <ix:nonFraction unitRef="usd" contextRef="i21a45eb6762341e485fcf7416428f6ba_D20211001-20211001" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI3NDg3NzkxMzM0MzI_8c510f7e-1424-4a72-a8ec-65ca4a77cce5">no</ix:nonFraction> impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If market conditions deteriorate, if the factors and circumstances regarding the COVID-19 pandemic escalate beyond management&#8217;s current expectations, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and those charges could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated goodwill impairment charges through December 31, 2021 were $<ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI0NzQ3_26f0b4db-6e1e-4fdd-8afb-8bdc70d6bd7c">4,180</ix:nonFraction> million.</span></div></ix:continuation><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_325"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90ZXh0cmVnaW9uOjhmZmNhM2RkOGQ0YjQyOTg5OTA4ODc5N2MwN2UyOWUwXzY0_032279bd-ed29-4bc3-a957-c26cf093bb53" continuedAt="i4aa59d6ba78f480aa77df302888f23fe" escape="true">ACCRUED AND OTHER CURRENT LIABILITIES</ix:nonNumeric></span></div><ix:continuation id="i4aa59d6ba78f480aa77df302888f23fe"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90ZXh0cmVnaW9uOjhmZmNhM2RkOGQ0YjQyOTg5OTA4ODc5N2MwN2UyOWUwXzY3_86e65ca6-f72f-4502-9f6c-9ffd32ae2a57" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:78.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="bhc:Legalsettlementsandrelatedfees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzEtMi0xLTEtNTk0NzA_5c15f5a7-5871-45da-9d93-65eb45878f24">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="bhc:Legalsettlementsandrelatedfees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzEtNC0xLTEtNTk0NzA_722db426-cdc3-46e7-943e-ea7afe3345f3">1,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="bhc:AccruedProductRebateCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzItMi0xLTEtNTk0NzA_62ebedaf-aa28-40a8-bb75-a9622a914ba8">908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="bhc:AccruedProductRebateCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzItNC0xLTEtNTk0NzA_b3acc4d7-331d-4186-ba3d-115e6c89c6e6">747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="bhc:AccruedProductReturnCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzMtMi0xLTEtNTk0NzA_777a8785-4200-46be-b3f4-b9a7353a1bf8">482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="bhc:AccruedProductReturnCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzMtNC0xLTEtNTk0NzA_7390fd84-73cd-4af1-a8ab-3da8b9fa63f8">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzQtMi0xLTEtNzMzMzM_2133f508-2d9d-44b3-b5a0-8fe758b0be55">336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzQtNC0xLTEtNzMzMzM_c2835dbf-4651-4db9-8b4d-eaf60acfdaf7">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzQtMi0xLTEtNTk0NzA_eacd606e-8d3c-4437-8795-6c51cf626558">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzQtNC0xLTEtNTk0NzA_41ea571b-7e39-4c3d-b42d-27a8202b36ca">341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzYtMi0xLTEtNTk0NzA_624c5e33-d523-48c3-aed9-7df9213d643c">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzYtNC0xLTEtNTk0NzA_8ce911c9-663a-4f52-904f-e9313c0ce7e3">158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzctMi0xLTEtNTk0NzA_37c50310-044c-48b7-9ee0-0057d4588351">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzctNC0xLTEtNTk0NzA_f7d5ee36-3fdf-4aaf-a75d-dd363f47d555">767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzgtMi0xLTEtNTk0NzA_b770fd90-7a65-4dc8-a693-fd29f17dc359">4,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzgtNC0xLTEtNTk0NzA_6310eaee-f002-4914-9297-b9686ae3648c">4,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_328"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI3NDg3NzkxMjg0MjY_14274626-e935-4bd2-91d7-e84dc3d76119" continuedAt="i9880b4435faf45cfa6b58a76c75017e8" escape="true">FINANCING ARRANGEMENTS</ix:nonNumeric></span></div><ix:continuation id="i9880b4435faf45cfa6b58a76c75017e8" continuedAt="i734aaa9e943d49b8a91582d848c88e45"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM3NzIw_ea70e2a7-89b2-42d5-a72a-096ad87b7266" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs as of December 31, 2021 and 2020 consists of the following:</span></div><div style="margin-top:11pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:34.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.082%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.082%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c01a665a28449b793613ecc5d63522c_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzMtNC0xLTEtNTk0NzA_1b2481e5-e505-4943-a019-8c532c69f608">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c01a665a28449b793613ecc5d63522c_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzMtNi0xLTEtNTk0NzA_b77c65bb-4e44-4758-9fbc-0d2164ad948f">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9adef68a2e1a41ffb17a60a9075ee559_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzMtOC0xLTEtNTk0NzA_a9a34dec-5bba-4748-aae6-74d7433e3062">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9adef68a2e1a41ffb17a60a9075ee559_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzMtMTAtMS0xLTU5NDcw_d7c7859f-8b43-4df4-9aac-783ba0fdf117">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19aa307929434141855192ccd5d26e84_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzQtNC0xLTEtNTk0NzA_dd0393a8-8814-413b-a8dd-533580fc91a4">2,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19aa307929434141855192ccd5d26e84_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzQtNi0xLTEtNTk0NzA_c195a665-66c9-471a-bc89-fb72148836f3">2,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c06253724c04adb9d709a0d06b0a4a4_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzQtOC0xLTEtNTk0NzA_dda89474-10d5-4771-835c-2061849a7709">3,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c06253724c04adb9d709a0d06b0a4a4_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzQtMTAtMS0xLTU5NDcw_139dc812-f209-40c1-b13d-c56dc821a655">3,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ba8084e93643d19f4f8c135c1beb71_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzUtNC0xLTEtNTk0NzA_d102f8fc-1917-47be-8618-e068003fde84">994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ba8084e93643d19f4f8c135c1beb71_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzUtNi0xLTEtNTk0NzA_937fc63b-778e-4227-9cf3-be910aac5166">984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9193acd40b7439299521c6fde8c4891_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzUtOC0xLTEtNTk0NzA_7a87821b-911b-4d0b-8efd-c556718ae371">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9193acd40b7439299521c6fde8c4891_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzUtMTAtMS0xLTU5NDcw_9e9fdb66-46e1-47a3-b18e-1b4aed5ed626">1,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i89af4e1890874416ab318090b1cc294e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzgtMC0xLTEtNTk0NzAvdGV4dHJlZ2lvbjoyMThmYWI0YjU1ODU0MzlkODM5ZTE1NDk1OTIyYTM4M180_7f43d173-a749-477d-a769-095b6d654e91">7.000</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89af4e1890874416ab318090b1cc294e_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzgtNC0xLTEtNTk0NzA_ee526e2c-2172-42a7-a863-2cf9a844b102">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89af4e1890874416ab318090b1cc294e_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzgtNi0xLTEtNTk0NzA_a544b1c9-f8c7-4d75-ad5e-8490c1230aac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32e198fb8ac3442ab187a17a7c4f0d2d_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzgtOC0xLTEtNTk0NzA_a20c209b-b9dd-4b05-808d-283ec9b2f816">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32e198fb8ac3442ab187a17a7c4f0d2d_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzgtMTAtMS0xLTU5NDcw_6d08ba50-2831-4503-8c09-969e363891bf">1,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ec36cf30e35457e8a0b60837b539b1e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzktMC0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo2MWIxMzVkNzAyMWY0Y2M3YWIxZjMwNTdmOWNmMWM4Zl80_f8c978fe-a538-4c13-8713-5c2987642f36">5.500</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ec36cf30e35457e8a0b60837b539b1e_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzktNC0xLTEtNTk0NzA_c21be697-2074-4059-b4c0-9a7ae4f6cd3e">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ec36cf30e35457e8a0b60837b539b1e_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzktNi0xLTEtNTk0NzA_977f2cbc-669b-4521-915a-f0257ff42212">1,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8b2f62d73a04aadb052f3835a632303_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzktOC0xLTEtNTk0NzA_74eab347-6eea-4044-9b99-06818297d75f">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8b2f62d73a04aadb052f3835a632303_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzktMTAtMS0xLTU5NDcw_296cce30-914b-46d3-81ec-38037a1b3ffb">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i66914061a58846f0a2dd9fbf966be49e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzEwLTAtMS0xLTU5NDcwL3RleHRyZWdpb246MWI0YzcyZTY3ZWFjNDJlNjgwYzM3YjFjYjljN2Y1MWNfNA_a118ca9f-ea64-4d32-abaa-30752f94f5ef">5.750</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66914061a58846f0a2dd9fbf966be49e_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzEwLTQtMS0xLTU5NDcw_dabf5add-2a2a-4e54-a23c-8deea572fac2">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66914061a58846f0a2dd9fbf966be49e_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzEwLTYtMS0xLTU5NDcw_300a143b-a961-438f-9dcb-4e7370dbfa15">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b9f7d6a773a492daebe7cb683a831c7_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzEwLTgtMS0xLTU5NDcw_a05c8e29-2444-46de-8e9b-ee4c5d7034a9">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b9f7d6a773a492daebe7cb683a831c7_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzEwLTEwLTEtMS01OTQ3MA_b77a17d8-e9f6-458b-a251-4dd35a301b96">494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic459c1e2b8f44d65a0d2e10bfae297d5_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzExLTAtMS0xLTY0MjU4L3RleHRyZWdpb246NDljYzYwNmIxODY1NGQ5ZDg0ZTYzNWM5OWMyYzUzMzJfMzg0ODI5MDY5NzI0Ng_d809f6f8-c8c7-4f62-9390-8450cd8ecec0">4.875</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic459c1e2b8f44d65a0d2e10bfae297d5_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzEwLTQtMS0xLTY0NjIz_e359ad08-0ae7-4843-9045-96c4989a980b">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic459c1e2b8f44d65a0d2e10bfae297d5_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzEwLTYtMS0xLTY0NjIz_bebf70bb-d850-4c77-99cd-18fca22a5fa4">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92b27a9dcb1e4c6aac20e9f0f1bb22ff_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzEwLTgtMS0xLTY0NjIz_72d15028-c5a8-4f70-b429-a55c2f61ff78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92b27a9dcb1e4c6aac20e9f0f1bb22ff_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzEwLTEwLTEtMS02NDYyMw_f6e6b978-51e5-4a7a-b000-5ceeb2211769">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i67d99cc27cfc490babc9f17b67fc6c36_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE1LTAtMS0xLTU5NDcwL3RleHRyZWdpb246YjlmZmQ3ZDJhMmQxNDAzMWE4NWIyNmNiMTUyODNkNmFfNA_a15cdbf2-273e-4711-896d-2147cf9835d3">6.125</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d99cc27cfc490babc9f17b67fc6c36_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE1LTQtMS0xLTU5NDcw_3de5d1b4-c69f-435a-8b5a-c6762e2249c7">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d99cc27cfc490babc9f17b67fc6c36_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE1LTYtMS0xLTU5NDcw_fe9297d4-50dc-4414-be77-8248e7606a67">2,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abe59cd5b4344b3af6d863639ee97e3_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE1LTgtMS0xLTU5NDcw_6e962436-5973-43cc-8cf9-af41a670a6a0">3,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abe59cd5b4344b3af6d863639ee97e3_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE1LTEwLTEtMS01OTQ3MA_b191b7c0-6fe9-4017-a01d-28ddc1931c6d">3,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7069779fddc24154bec1252491718d71_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE2LTAtMS0xLTU5NDcwL3RleHRyZWdpb246YjE4NzIyZmFiOWRmNDZmZjhjMjA4YzkxYmRmNzk0OTJfNA_4d0310dd-354b-4b30-a21c-fec4c9566fb9">9.000</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7069779fddc24154bec1252491718d71_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE2LTQtMS0xLTU5NDcw_47e11c2a-4ccf-42a5-bfba-be1dd2e61531">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7069779fddc24154bec1252491718d71_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE2LTYtMS0xLTU5NDcw_7250eb20-742e-414b-86da-f54c668175a3">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90e19da742b46a88993ff20c0ef65e4_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE2LTgtMS0xLTU5NDcw_67b78017-d559-46d7-ae6c-f4999da15aa8">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90e19da742b46a88993ff20c0ef65e4_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE2LTEwLTEtMS01OTQ3MA_1953833f-6fc6-48ce-acce-ff4a2fe1cb40">1,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2bbcb30923264dada2fd327d3b9f97f3_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE3LTAtMS0xLTU5NDcwL3RleHRyZWdpb246ODhjZWRlNjE3MDkwNDBjODhjMjAyNTE5MGYyNDU1YWRfNA_a97b6b4b-abc1-47b0-9050-ada1dfb1fe8c">9.250</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bbcb30923264dada2fd327d3b9f97f3_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE3LTQtMS0xLTU5NDcw_c61ed65a-e55f-492b-b8db-5b6b7c5d4c6f">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bbcb30923264dada2fd327d3b9f97f3_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE3LTYtMS0xLTU5NDcw_17974684-7886-4724-80d7-d3d34f7c1c33">1,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b9d6159d9b345d5a925bedf7aa2f714_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE3LTgtMS0xLTU5NDcw_df0c4adf-aeb2-40b8-991f-659b5d8bc84a">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b9d6159d9b345d5a925bedf7aa2f714_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE3LTEwLTEtMS01OTQ3MA_bfc0cef5-131c-4608-b075-8d202dffa9a9">1,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0e3e0b5c7314f4d8c7bad143746ae92_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE4LTAtMS0xLTU5NDcwL3RleHRyZWdpb246ZWQwZTE3ODM2YzJlNDk5NGE3ZjFjMjIwMDgwOWNiMWRfNA_a89a7799-7a5b-49a6-9130-cb017cfde39b">8.500</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e3e0b5c7314f4d8c7bad143746ae92_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE4LTQtMS0xLTU5NDcw_df440eac-edd8-46de-aa3a-c2ebea212451">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e3e0b5c7314f4d8c7bad143746ae92_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE4LTYtMS0xLTU5NDcw_1c043000-95b1-46b8-a165-a60e31468b1c">1,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a7ac2ee83a40f487e5ff99f59101b6_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE4LTgtMS0xLTU5NDcw_ca95eb22-5f45-4c95-a851-9849fabb3734">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a7ac2ee83a40f487e5ff99f59101b6_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE4LTEwLTEtMS01OTQ3MA_d35f9892-1ed9-4c77-8d62-24761186dab4">1,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iac672bf940144940ab2863657d675904_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE5LTAtMS0xLTU5NDcwL3RleHRyZWdpb246YjhhZDA5ODllMmMyNDUyODg2NzYwOTY1OTMxMzkzYWRfNA_92915137-f1f2-48f6-be57-08455495aeed">7.000</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac672bf940144940ab2863657d675904_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE5LTQtMS0xLTU5NDcw_f34b5db3-247d-48d3-9829-ca590aeb9c82">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac672bf940144940ab2863657d675904_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE5LTYtMS0xLTU5NDcw_f9ff3f3c-b54c-41a0-84b5-2ead264fc93b">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie691743843174dfebc02e17db2f8b881_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE5LTgtMS0xLTU5NDcw_e685c0ab-6338-4e9d-bdeb-ef46a9a2fc4e">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie691743843174dfebc02e17db2f8b881_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE5LTEwLTEtMS01OTQ3MA_e3e0a285-8d13-40b7-a2d1-e3adfe4417c0">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9fccfd4eb6c4a3da530db148be437ed_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIwLTAtMS0xLTU5NDcwL3RleHRyZWdpb246ZTlhY2FlMzdjYjk3NDNjMzgwNTdkYzMyNGQyZTVlZWJfNA_3990c6c3-aed5-41a0-a6c2-ee4bd2ad366d">5.000</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9fccfd4eb6c4a3da530db148be437ed_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIwLTQtMS0xLTU5NDcw_1c612bfb-494a-48d9-a037-63dcc30f2bb5">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9fccfd4eb6c4a3da530db148be437ed_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIwLTYtMS0xLTU5NDcw_66ab185e-3630-4ce3-9a00-89af11ec4ca7">1,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a7c2483467d42fa92a0d1889a65352c_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIwLTgtMS0xLTU5NDcw_0fe21aaa-f88b-46c6-aeee-be7cc7e4b6c4">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a7c2483467d42fa92a0d1889a65352c_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIwLTEwLTEtMS01OTQ3MA_fc687b68-4b9a-4969-afaf-2d668cb1dd24">1,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i637b51dfd22b4d7d8bf9dc99c065d131_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIxLTAtMS0xLTU5NDcwL3RleHRyZWdpb246OWM4MWY1OWZkYTYyNGMyODgxZGI5YWNjZWEzMTFkNzZfNA_1fffe95f-8c8b-4346-8fad-5a777b960f42">6.250</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i637b51dfd22b4d7d8bf9dc99c065d131_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIxLTQtMS0xLTU5NDcw_88057dac-6138-4ee4-a937-80e20f9a7bf9">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i637b51dfd22b4d7d8bf9dc99c065d131_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIxLTYtMS0xLTU5NDcw_93d3354a-48ce-4585-8995-4153ab966709">1,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6b5763866f4cdbb14e92752f777770_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIxLTgtMS0xLTU5NDcw_1d5626ba-65f5-4182-9ae1-41d5e5efee5a">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6b5763866f4cdbb14e92752f777770_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIxLTEwLTEtMS01OTQ3MA_4890dbdc-68a9-433e-b271-63664fad072d">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4273b9d256e540e985599fd8f4111808_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIyLTAtMS0xLTU5NDcwL3RleHRyZWdpb246MjZhNGZjYTE4MWQ1NDQ4MmI4ZDI5Y2M5ODE3NjcxZjhfNA_b45e6b06-728a-4e1b-bb75-d0534ee1c47a">5.000</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4273b9d256e540e985599fd8f4111808_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIyLTQtMS0xLTU5NDcw_e765ed0f-1bb2-4e52-9363-7014767d518c">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4273b9d256e540e985599fd8f4111808_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIyLTYtMS0xLTU5NDcw_b60e7ab3-36a0-458d-bd8e-b4e94d1288f9">990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d04379800474729927c296a02ee23b2_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIyLTgtMS0xLTU5NDcw_12450726-22a8-4177-be37-0c85d9918e61">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d04379800474729927c296a02ee23b2_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIyLTEwLTEtMS01OTQ3MA_aae33f60-cf26-43d8-a6dc-acec6292e6d3">988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id5f8a823e64b4391b5fdc14a2699ca01_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIzLTAtMS0xLTU5NDcwL3RleHRyZWdpb246ZWVjNDgyMThkMTViNDliZTlhZDI3MzVkZWUzOGExZTNfNA_a346bbcd-dbf7-43fd-97d9-43eac3ee38da">7.250</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5f8a823e64b4391b5fdc14a2699ca01_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIzLTQtMS0xLTU5NDcw_cfa9fdf6-5cfc-4aa2-af56-330140ba7e97">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5f8a823e64b4391b5fdc14a2699ca01_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIzLTYtMS0xLTU5NDcw_992640da-afbd-4c5e-bd4e-8c4edc99c15d">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1550fce70ddc4bde9fcc143dba86ed02_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIzLTgtMS0xLTU5NDcw_fb37b71d-0fb4-4173-a57c-bc53c1d520ec">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1550fce70ddc4bde9fcc143dba86ed02_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIzLTEwLTEtMS01OTQ3MA_15ab2a9d-38fc-4fef-91f8-38022ac80fee">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i87f54fc33f3647cf854ad3d2446add0e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI0LTAtMS0xLTU5NDcwL3RleHRyZWdpb246YTY2ZDcyZGY2YzVmNDczZGEwNGVlMDE0ZGEzZDNlYjhfNA_677b8b62-2851-425f-993a-84eedebf3177">5.250</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87f54fc33f3647cf854ad3d2446add0e_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI0LTQtMS0xLTU5NDcw_f85b83f9-c41b-46ff-ba49-d1f5cb92746c">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87f54fc33f3647cf854ad3d2446add0e_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI0LTYtMS0xLTU5NDcw_1097ca95-a822-4376-9c80-ae7f6556cee8">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd94b3061443470786f4f2aeefe3ee61_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI0LTgtMS0xLTU5NDcw_89cd96ac-7e37-4122-929a-054f977d5d2b">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd94b3061443470786f4f2aeefe3ee61_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI0LTEwLTEtMS01OTQ3MA_b09ac559-06a0-4231-9de2-551b5caeaa47">1,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i50ec0b78d915487982eb08953a99cf34_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI1LTAtMS0xLTU5NDcwL3RleHRyZWdpb246YTYzOGNiNWQ0M2U1NDEwYmIzN2JkZTI5NzdjMjNlYjBfNA_0e769752-f3dd-498c-9e63-b607fa279d76">5.250</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50ec0b78d915487982eb08953a99cf34_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI1LTQtMS0xLTU5NDcw_7010e188-9dea-46c0-ae5a-eca35430cbb4">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50ec0b78d915487982eb08953a99cf34_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI1LTYtMS0xLTU5NDcw_1ac9204f-0e06-4305-bcd3-a2df6c8f8461">989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i300264ba1d81487683635e7eef8d2c8b_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI1LTgtMS0xLTU5NDcw_8cc4397c-8258-4c0b-a33b-f9328f448df5">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i300264ba1d81487683635e7eef8d2c8b_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI1LTEwLTEtMS01OTQ3MA_0336786c-c966-4597-ad72-8128c64d0211">988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i350590e126f747c09b3b536b35e19ffd_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI2LTQtMS0xLTU5NDcw_6235dc54-cae7-40db-939d-830ca4566c8a">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i350590e126f747c09b3b536b35e19ffd_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI2LTYtMS0xLTU5NDcw_22e4a55b-0191-4847-834e-f0bb2dbcd3dd">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ba959daa4a48e2ac776ce9798a9d5e_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI2LTgtMS0xLTU5NDcw_0ad3539b-65ac-4119-942f-ec988d8c182f">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ba959daa4a48e2ac776ce9798a9d5e_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI2LTEwLTEtMS01OTQ3MA_90afb8a4-200e-4785-bdeb-7f92ab49be59">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI3LTQtMS0xLTU5NDcw_db3a2877-817e-43e5-924d-19c5ff2ad8f4">22,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI3LTYtMS0xLTU5NDcw_2690f180-bf58-489f-9bb6-c01becca1184">22,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI3LTgtMS0xLTU5NDcw_9b5aa6da-4148-49a2-9470-9c909a7fb147">24,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI3LTEwLTEtMS01OTQ3MA_153c52b3-8b6c-4439-94d3-53a95c9b50b9">23,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI4LTYtMS0xLTU5NDcw_e7edb731-cd3e-4451-a9d4-e81795a0035a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI4LTEwLTEtMS01OTQ3MA_60aaf07c-a276-477a-b813-36fdd1275c3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI5LTYtMS0xLTU5NDcw_347f2d36-2ba2-4a41-a56f-6ff96329eee1">22,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI5LTEwLTEtMS01OTQ3MA_9b147994-964f-499b-98ce-bc96617ea260">23,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes and Senior Unsecured Notes contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#8217;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of December&#160;31, 2021, the amount available for restricted payments under the "builder basket" in the Company&#8217;s most restrictive indentures (as defined by those indentures) was approximately $<ix:nonFraction unitRef="usd" contextRef="i8aed4915fc8f42e580d71e20a671d348_I20211231" decimals="-6" name="bhc:DebtInstrumentAmountAvailableForRestrictedPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzExODQ_e5352bf0-4cab-4573-8ca8-3220ee758fea">13,800</ix:nonFraction>&#160;million (although such availability is subject to the Company's compliance with a <ix:nonFraction unitRef="number" contextRef="i8aed4915fc8f42e580d71e20a671d348_I20211231" decimals="INF" name="bhc:DebtInstrumentCovenantTermsFixedChargeCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyNjE_ef516de4-7c08-4aa2-ba1d-6a575c640ef4">2.00</ix:nonFraction>:1.00 fixed charge coverage ratio). The 2023 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that requires the Company to maintain a first lien net leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i8aed4915fc8f42e580d71e20a671d348_I20211231" decimals="INF" name="bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE0OTA_5dfbff1c-0643-487c-a65d-2d3dfa2bb9bb">4.00</ix:nonFraction>:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period. </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i734aaa9e943d49b8a91582d848c88e45" continuedAt="ifb65e39ed570415db45f5ec61e6eb0fd"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the "Senior Secured Credit Facilities" under the Company's Fourth Amended and Restated Credit and Guaranty Agreement (the &#8220;Restated Credit Agreement&#8221;), with a syndicate of financial institutions and investors as lenders. The Restated Credit Agreement provides for a revolving credit facility of $<ix:nonFraction unitRef="usd" contextRef="ia5120118135441ab83944681d2efd4b0_I20180601" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM2ODE_96c0da86-dc58-429e-a4fb-ee20a719c936">1,225</ix:nonFraction> million (the "2023 Revolving Credit Facility") and a <ix:nonNumeric contextRef="i351b85b10d1a4bc4994a95b06fcbbc15_D20180601-20180601" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI3NDg3NzkxMjgxODM_2513c52c-027f-4b2d-a5c8-3e3a9fd214f8">seven year</ix:nonNumeric> Tranche B Term Loan Facility of $<ix:nonFraction unitRef="usd" contextRef="i41ba8fedd17c41849f4e82c6bf1880b3_I20180601" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM4NjQ_1c5da079-d826-4dbf-9913-2f659aba251f">4,565</ix:nonFraction> million (the &#8220;June 2025 Term Loan B Facility&#8221;) borrowed by the Company&#8217;s subsidiary, Bausch Health Americas, Inc. ("BHA"). </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Revolving Credit Facility matures on the earlier of June 1, 2023 and the date that is <ix:nonNumeric contextRef="i4661b2464e2e42d289cd362548d23d4e_D20180601-20180601" name="bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzQwNzc_16e9d13d-cfe4-4eae-8a3b-9c4b2ffca7ba">91</ix:nonNumeric> calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company or BHA in an aggregate principal amount in excess of $<ix:nonFraction unitRef="usd" contextRef="ia5120118135441ab83944681d2efd4b0_I20180601" decimals="INF" name="bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzQyMjk_aed9d59f-60a3-4087-95a4-3773d1c0575d">1,000</ix:nonFraction> million. Both the Company and BHA are borrowers with respect to the 2023 Revolving Credit Facility. Borrowings under the 2023 Revolving Credit Facility may be made in U.S. dollars or Canadian dollars (or if an amendment to the Restated Credit Agreement is made to replace LIBOR with an alternative benchmark rate with respect to borrowings under the Revolving Credit Facility denominated in euros, euros).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i0c01a665a28449b793613ecc5d63522c_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzg3NTg_af5de66e-cf5f-4f78-8256-8669c86f6f8a">285</ix:nonFraction> million of outstanding borrowings, $<ix:nonFraction unitRef="usd" contextRef="iedebe3ccdce14516b687ab3595dfe1e7_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzg3ODU_297d75a9-243a-4930-8a35-5afac6ccb913">54</ix:nonFraction> million of issued and outstanding letters of credit, and remaining availability of $<ix:nonFraction unitRef="usd" contextRef="i0c01a665a28449b793613ecc5d63522c_I20211231" decimals="-6" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzg4NjM_72844051-d87e-4b67-9859-0c1f35a6540a">886</ix:nonFraction> million under its 2023 Revolving Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2018, the Company entered into the First Incremental Amendment to the Restated Credit Agreement, which provided an additional <ix:nonNumeric contextRef="ic5f0234485054f26ad2c1d49dfdbd799_D20181127-20181127" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI3NDg3NzkxMjg0MjU_e91453ba-79da-4353-bb89-74d78f227d27">seven year</ix:nonNumeric> Tranche B Term Loan Facility of $<ix:nonFraction unitRef="usd" contextRef="ic4e41ed007de4e4ea8f42478579b6eaf_I20181127" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM4NDgyOTA3NTU5Mzc_c8608e83-db5a-422c-afbf-e74a2d94aa89">1,500</ix:nonFraction>&#160;million (the "November 2025 Term Loan B Facility").</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Current Description of Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Senior Secured Credit Facilities in U.S. dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a base rate determined by reference to the highest of: (a) the prime rate (as defined in the Restated Credit Agreement), (b) the federal funds effective rate plus 1/2 of 1.00% or (c) the eurocurrency rate (as defined in the Restated Credit Agreement) for a period of one month plus <ix:nonFraction unitRef="number" contextRef="i27285ba6e43a47799cc65795b7635e66_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzkzOTQ_8242264b-58c5-42b8-b915-22a62e7eaeb1">1.00</ix:nonFraction>% (or if such eurocurrency rate shall not be ascertainable, <ix:nonFraction unitRef="number" contextRef="i531d4b49e7e14178b135b8a39f88fa6a_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzk0NTU_54372c84-eadc-441f-bf4f-d7515ed8bc4d">1.00</ix:nonFraction>%) or (ii) a eurocurrency rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs (provided however, that the eurocurrency rate shall at no time be less than <ix:nonFraction unitRef="number" contextRef="i31222c8f48ac4a7b9ebdc2458dd1be5d_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzk3MjM_c50b61f8-eece-401d-b337-5e6473588a14">0.00</ix:nonFraction>% per annum), in each case plus an applicable margin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in euros, when available, are expected to bear interest at a term benchmark rate determined by reference to the costs of funds for euro deposits for the interest period relevant to such borrowing (provided however, that the eurocurrency rate is at no time expected to be less than <ix:nonFraction unitRef="number" contextRef="i8cd6d35fff84440898e7edf6f94360c3_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEwMDY3_790af769-e2f9-447b-bcf8-e19ba960d6a7">0.00</ix:nonFraction>% per annum), plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in Canadian dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a prime rate determined by reference to the higher of: (a) the rate of interest last quoted by The Wall Street Journal as the &#8220;Canadian Prime Rate&#8221; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus <ix:nonFraction unitRef="number" contextRef="ied9e5eb3fe5b46218dadb86953b97df0_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEwNjI0_461f6f3a-b7e4-4f7e-b9e7-a77ae916d28c">1.00</ix:nonFraction>% (provided however, that the prime rate shall at no time be less than <ix:nonFraction unitRef="number" contextRef="ia22718f8832b4e798f11e810438b3bf7_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEwNjk2_349d8819-b6c1-4a0c-9f4d-df04626d585d">0.00</ix:nonFraction>%) or (ii) the bankers&#8217; acceptance rate for Canadian dollar deposits in the Toronto interbank market (the &#8220;BA rate&#8221;) for the interest period relevant to such borrowing (provided however, that the BA rate shall at no time be less than <ix:nonFraction unitRef="number" contextRef="ia22718f8832b4e798f11e810438b3bf7_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEwOTMx_e9ab1922-adc8-468b-85ad-433b57a991fd">0.00</ix:nonFraction>% per annum), in each case plus an applicable margin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i)&#160;<ix:nonFraction unitRef="number" contextRef="idb84972c8f344a8896506efbff337098_D20210101-20211231" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzExMjQx_94836505-ca4d-4757-88e7-0f589a5bcd09">100</ix:nonFraction>% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii)&#160;<ix:nonFraction unitRef="number" contextRef="idb84972c8f344a8896506efbff337098_D20210101-20211231" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzExNDAz_84e222b2-ddd3-4c29-8ea3-6f4660bb6ba2">100</ix:nonFraction>% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the Restated Credit Agreement), (iii)&#160;<ix:nonFraction unitRef="number" contextRef="idb84972c8f344a8896506efbff337098_D20210101-20211231" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzExNTQw_3656f2d4-7fde-4274-98d3-c32286759b4f">50</ix:nonFraction>% of Excess Cash Flow (as&#160;defined in the Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv)&#160;<ix:nonFraction unitRef="number" contextRef="idb84972c8f344a8896506efbff337098_D20210101-20211231" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzExNjk3_19f0db9a-f1ae-4301-a2d8-3854febc42fc">100</ix:nonFraction>% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility are <ix:nonFraction unitRef="number" contextRef="i4515f9481f5f408cbe7a9817cf5107d1_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzExOTA3_d1939276-88b1-41de-8c42-22bc0bc63186">2.00</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i580615bf5fb84813a4f15d5b64260502_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzExOTE0_6ff2cc76-2b71-46b3-a45c-d3df4dcc8599">1.75</ix:nonFraction>%, respectively, with respect to base rate and prime rate borrowings and <ix:nonFraction unitRef="number" contextRef="if0cd16b6c95c43cf92a6b19bd75a7df2_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzExOTg4_9e4fc05d-dc6b-4f1c-b646-2ec074476963">3.00</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i6eab960e05594954ad74b51fbec5de70_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzExOTk1_6f3c6ae8-e39f-427d-9dc1-d7457d053779">2.75</ix:nonFraction>%, </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ifb65e39ed570415db45f5ec61e6eb0fd" continuedAt="i49d97ecb7aae40f4a6b7e70a30bf9207"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, with respect to eurocurrency rate and BA rate borrowings. As of December 31, 2021, the stated rates of interest on the Company&#8217;s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were <ix:nonFraction unitRef="number" contextRef="i19aa307929434141855192ccd5d26e84_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyMTYx_b5ad6058-cc16-4be5-8fa9-126ac10249aa">3.09</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i57ba8084e93643d19f4f8c135c1beb71_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyMTY4_b8314fd8-3984-4a04-9837-931681622dc8">2.84</ix:nonFraction>% per annum, respectively.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for both the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility is <ix:nonFraction unitRef="number" contextRef="i57ba8084e93643d19f4f8c135c1beb71_I20211231" decimals="INF" name="bhc:DebtInstrumentAnnualAmortizationRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyMjQ4_e2c602e8-fd7b-42e0-bc55-07f663abab62"><ix:nonFraction unitRef="number" contextRef="i19aa307929434141855192ccd5d26e84_I20211231" decimals="INF" name="bhc:DebtInstrumentAnnualAmortizationRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyMjQ4_e9c74332-2b3f-4dee-807d-f1d770accaf7">5.00</ix:nonFraction></ix:nonFraction>% per annum. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of December 31, 2021, there were <ix:nonFraction unitRef="usd" contextRef="if7b27ce3a4694376b7351cac69da0831_D20210101-20211231" decimals="INF" name="bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEwOTk1MTE2Nzc4NDg_7cb62f8a-8e95-44d1-a97a-4d4b88acb47e">no</ix:nonFraction> remaining mandatory quarterly amortization payments for the Senior Secured Credit Facilities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are <ix:nonFraction unitRef="number" contextRef="ica0eb942508643f38c6a8b5216c7ab26_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyNjA3_e5642d44-a7df-4a38-a68f-b10e5bce1819">1.50</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i1d0ab3127bf249bba7383ddaff5d96b9_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyNjEw_6cb36dff-70f5-4790-8b01-fde2fe2a4467">2.00</ix:nonFraction>% with respect to base rate or prime rate borrowings and <ix:nonFraction unitRef="number" contextRef="i10e9d909bf8748b1ada82e2b29c7e29c_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyNjY4_faf62115-c255-43cb-8e12-cea1d2346713">2.50</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="id9bf72ff91f54b6d9dfd299f64fd8858_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyNjcx_aba082b1-d9ce-4247-968f-5fe9ff736072">3.00</ix:nonFraction>% with respect to eurocurrency rate or BA rate borrowings.&#160; As of December 31, 2021, the stated rate of interest on the 2023 Revolving Credit Facility was <ix:nonFraction unitRef="number" contextRef="i0c01a665a28449b793613ecc5d63522c_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyODA2_e40eaa7f-8643-45de-846f-610d18d49c1d">2.84</ix:nonFraction>% per annum. In addition, the Company is required to pay commitment fees of <ix:nonFraction unitRef="number" contextRef="i6bc0bc23890449aa8239cc453f4e1a07_D20210101-20211231" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyODgz_6c8ebb85-fd45-48e7-bdf3-c843d38efbe4">0.25</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i844942ee3772417395b5e3b2b42455d8_D20210101-20211231" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyODg4_9f51edc0-fe3f-4b65-88ac-66fa2ead9b00">0.50</ix:nonFraction>% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency&#160;fees.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restated Credit Agreement permits the incurrence of incremental credit facility borrowings, up to the greater of $<ix:nonFraction unitRef="usd" contextRef="i8aed4915fc8f42e580d71e20a671d348_I20211231" decimals="INF" name="bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEzNTM5_13980b25-0c3f-47fe-831f-9d7786a53089">1,000</ix:nonFraction> million and <ix:nonFraction unitRef="number" contextRef="if7b27ce3a4694376b7351cac69da0831_D20210101-20211231" decimals="INF" name="bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEzNTQ2_88c6aee8-9611-4834-92d3-ec3b353b8296">28.5</ix:nonFraction>% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i28ac575b36634a86920565ce2fe16cca_I20211231" decimals="INF" name="bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEzODA2_a311220f-37ae-4b78-a25f-14c240e9e7e2">3.50</ix:nonFraction>:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i7622a05b204a4dd1a5f310c32b83aa3f_I20211231" decimals="INF" name="bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEzODk0_6878deef-549f-49f3-9f7c-7d3b6c5a1043">6.50</ix:nonFraction>:1.00 or an interest coverage ratio of not less than <ix:nonFraction unitRef="number" contextRef="i8aed4915fc8f42e580d71e20a671d348_I20211231" decimals="INF" name="bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEzOTQ5_808e476c-db6b-47f4-b6ae-b3f6202ccfa3">2.00</ix:nonFraction>:1.00.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the Restated Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the Restated Credit Agreement under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="INF" name="bhc:DebtInstrumentRedemptionPricePercentageChangeinControl" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE1OTI4_84aab520-aa4b-4f9e-bd47-1e7fc52a3d5b">101</ix:nonFraction>% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i55fc1cd86d124ba798ea0bb114b41e21_I20170331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE1OTk3_2884442b-046d-47f7-a8d0-eed1e6880bff">6.500</ix:nonFraction>% Senior Secured Notes due 2022 and <ix:nonFraction unitRef="number" contextRef="i3ff0004e74da4838ab43904393cdd3f0_I20170331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE2MDM0_012d0c45-1db1-42f1-82a0-4bb5cfbe587e">7.00</ix:nonFraction>% Senior Secured Notes due 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i55fc1cd86d124ba798ea0bb114b41e21_I20170331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE2MTAy_40874f19-0395-4290-84c9-19411c832f10">1,250</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i55fc1cd86d124ba798ea0bb114b41e21_I20170331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE2MTM1_2884442b-046d-47f7-a8d0-eed1e6880bff">6.500</ix:nonFraction>% senior secured notes due March 15, 2022 (the &#8220;March 2022 Secured Notes&#8221;) and $<ix:nonFraction unitRef="usd" contextRef="i3ff0004e74da4838ab43904393cdd3f0_I20170331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE2MjE1_9a7a75a8-224a-4107-9888-266976b42279">2,000</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i3ff0004e74da4838ab43904393cdd3f0_I20170331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE2MjQ4_012d0c45-1db1-42f1-82a0-4bb5cfbe587e">7.000</ix:nonFraction>% senior secured notes due March 15, 2024 (the &#8220;March 2024 Secured Notes&#8221;), in a private placement. Interest on these notes is payable semi-annually in arrears on each March 15 and September 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The March 2022 Secured Notes were repaid in full as part of the May 2020 Refinancing Transactions (as defined below).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The March 2024 Secured Notes were repaid in full during 2021 with cash on hand and as part of the June 2021 Refinancing Transactions (as defined below).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i3bd6872a182646a082629d18870e0ab0_I20171017" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE2NzIz_738868ec-95b4-4973-89b8-e9f3fe06b2cf">5.500</ix:nonFraction>% Senior Secured Notes due 2025</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;17, 2017, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i3bd6872a182646a082629d18870e0ab0_I20171017" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE2Nzk2_4703b9d3-20a7-46a1-a724-a6e1d88fa000">1,000</ix:nonFraction>&#160;million, and, on November 21, 2017, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i25ef1a1efaa044929df3a9c4e1c62bb0_I20171121" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE2ODQ2_a3858c1b-b8cb-45e4-8d8d-84cc18671c04">750</ix:nonFraction>&#160;million,  aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i3bd6872a182646a082629d18870e0ab0_I20171017" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE2ODgx_738868ec-95b4-4973-89b8-e9f3fe06b2cf">5.500</ix:nonFraction>% Senior Secured Notes due November 2025 (the &#8220;November 2025 Secured Notes&#8221;), </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i49d97ecb7aae40f4a6b7e70a30bf9207" continuedAt="ice5e878be79f40799d70c12e1a6a0eee"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in a private placement. Interest on the November 2025 Secured Notes is payable semi-annually in arrears on each May 1 and November 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The November 2025 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time, at the redemption prices set forth in the indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i9806922f86c748b8a9fb0ae15b0d631c_I20190308" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE3MjU4_5e5664f3-c471-4b5d-876a-5831214aac38">5.750</ix:nonFraction>% Senior Secured Notes due 2027 - March 2019 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2019, BHA and the Company issued: (i) $<ix:nonFraction unitRef="usd" contextRef="if30a44e3344f420686b02ee5a1668f41_I20190308" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE3Mzc5_470f4f4b-f6bd-4f7d-8c6d-309513dc7877">1,000</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="if30a44e3344f420686b02ee5a1668f41_I20190308" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEwOTk1MTE2Nzc4NTc_b8f5e0b9-0f4a-48c2-b269-3cea23f14c6a">8.500</ix:nonFraction>% Senior Unsecured Notes due 2027 (the "January 2027 Unsecured Notes") and (ii) $<ix:nonFraction unitRef="usd" contextRef="i9806922f86c748b8a9fb0ae15b0d631c_I20190308" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE3NDUw_229af733-7c25-4d84-8de5-275b67a2cd5c">500</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i9806922f86c748b8a9fb0ae15b0d631c_I20190308" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE3NDgz_65cd79fb-fe98-4210-bfa9-cb17d0dabc3d">5.750</ix:nonFraction>% Senior Secured Notes due August 2027 (the "August 2027 Secured Notes"), respectively, in a private placement. A portion of the proceeds and cash on hand were used to: (i) repurchase $<ix:nonFraction unitRef="usd" contextRef="i199861b87bfe4696b2d3547b9feff668_D20190101-20191231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE3NjY4_97d88088-27b8-4968-82e2-adfeaff931c7">584</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="i5e281e9d7a3444ae947ed7b6a12ff125_I20190308" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE3Njc0_155ae3bd-9fe6-44e2-956c-839af9bd180f">5.875</ix:nonFraction>% Senior Unsecured Notes due 2023 (the "May 2023 Unsecured Notes"), (ii) repurchase $<ix:nonFraction unitRef="usd" contextRef="i9399287ac5904b0093d941914ffe1526_D20190308-20190308" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE3NzU5_c7b62112-7efc-434c-bdd1-e3e808ec051b">518</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="i9e41c5aa1f5f46339004eb9f8abdc897_I20190308" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE3NzY1_798cbe54-efc2-44fc-a4b7-95c832e58c1f">5.625</ix:nonFraction>% Senior Unsecured Notes due 2021 (the &#8220;December 2021 Unsecured Notes&#8221;), (iii) repurchase $<ix:nonFraction unitRef="usd" contextRef="ib64fedb96e0a40dbbba005b5e30bc256_D20190308-20190308" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE3ODU2_634d6707-4947-41cc-ad42-3838cd2bdc4b">216</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="ie38650ed8f69484ba8e3e32b255cc9c1_I20190308" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE3ODYy_b8f3de55-630d-445f-9788-fcd63b6bc9c0">5.500</ix:nonFraction>% Senior Unsecured Notes due 2023 (the "March 2023 Unsecured Notes&#8221;) and (iv) pay all fees and expenses associated with these transactions (collectively, the &#8220;March 2019 Refinancing Transactions&#8221;). During April 2019, the Company redeemed $<ix:nonFraction unitRef="usd" contextRef="i7f2634d868b948cd81c47592e26fbaa1_D20190401-20190430" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE4MTAx_acd1e719-5cd2-4db4-a1c2-2b2580c9cbbf">182</ix:nonFraction> million of the December 2021 Unsecured Notes, representing the remaining outstanding principal balance of the December 2021 Unsecured Notes and completing the refinancing of $<ix:nonFraction unitRef="usd" contextRef="ie8e89da68c2b4a889e5ce5e76dec2863_I20190430" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE4Mjcw_5b54cfb0-9516-48e0-a54c-dffc22af5907">1,500</ix:nonFraction> million of debt in connection with the March 2019 Refinancing Transactions. The March 2019 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="ia70cbc9c5ef04337a9cdfcf70d213bff_D20190308-20190308" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE4NDU3_4aeaed6f-393c-4c41-9dbc-45223d5dbf2a">8</ix:nonFraction> million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. Interest on the August 2027 Secured Notes is payable semi-annually in arrears on each February 15 and August 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after August 15, 2022, at the redemption prices set forth in the indenture. The Company may redeem some or all of the August 2027 Secured Notes prior to August 15, 2022 at a price equal to <ix:nonFraction unitRef="number" contextRef="i0b58a4c00eb84382ad3f4bc0cb5d0c33_D20190308-20190308" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE5MDA0_1b17e028-4fd1-4692-bfb6-7f3a5c127e09">100</ix:nonFraction>% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to August 15, 2022, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="i0b58a4c00eb84382ad3f4bc0cb5d0c33_D20190308-20190308" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE5MTIz_be527c52-bc65-430f-88d7-358bebc9b660">40</ix:nonFraction>% of the aggregate principal amount of the August 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i47b737fa198b4128bcd55e26d3e2cb52_I20210608" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzQzOTgwNDY1NTg4MjE_9216e721-e0f0-4f4d-b77f-cbec695520a9">4.875</ix:nonFraction>% Senior Secured Notes due 2028 - June 2021 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i47b737fa198b4128bcd55e26d3e2cb52_I20210608" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEwOTk1MTE2Nzc4MjY_11dd13dd-6bbb-4de9-b7c2-db343c428bd3">1,600</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i47b737fa198b4128bcd55e26d3e2cb52_I20210608" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzQzOTgwNDY1NTg4MzY_9216e721-e0f0-4f4d-b77f-cbec695520a9">4.875</ix:nonFraction>% Senior Secured Notes due June 2028 (the &#8220;June 2028 Secured Notes&#8221;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase a portion and redeem the remainder of $<ix:nonFraction unitRef="usd" contextRef="i48a5c09856bb4c338e922161515b31c7_D20210608-20210608" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzQzOTgwNDY1NTg4NTQ_1c3508e5-f4c7-4130-b929-f3716f8d45ad">1,600</ix:nonFraction>&#160;million of the March 2024 Secured Notes, representing the remaining outstanding principal balance of the March 2024 Secured Notes and (ii) pay all fees and expenses associated with these transactions (collectively, the &#8220;June 2021 Refinancing Transactions&#8221;). The June 2021 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="iae6d3126236d454cb028cdcb1675739e_D20210608-20210608" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzQzOTgwNDY1NTg4NDE_78539abb-deae-43f0-9a12-544fa56ae591">38</ix:nonFraction>&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. Interest on the June 2028 Secured Notes is payable semi-annually in arrears on each June 1 and December 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2028 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after June 1, 2024, at the redemption prices set forth in the June 2028 Secured Notes indenture. The Company may redeem some or all of the June 2028 Secured Notes prior to June 1, 2024 at a price equal to <ix:nonFraction unitRef="number" contextRef="i3e453510571a42ea972e7213bb0683b3_D20210608-20210608" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEwOTk1MTE2Nzc4NDM_f76be3b8-58ff-4c52-9ca8-4c9922509b42">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of the redemption plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to June 1, 2024, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="i36ee75c249b846dea1eab8be020170d9_D20210608-20210608" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzQzOTgwNDY1NTg4NzA_8743bbec-6f84-4d5a-b7b7-613164c2b9ec">40</ix:nonFraction>% of the aggregate principal amount of the June 2028 Secured Notes using the net proceeds of certain equity offerings at the redemption price set forth in the June 2028 Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="i731ff10dfcf54abe98b1740cfb194c1d_D20210101-20211231" decimals="INF" name="bhc:DebtInstrumentRedemptionPricePercentageChangeinControl" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIwMTUy_59d61bd6-b8bd-4771-ae76-53b1d25e58af">101</ix:nonFraction>% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ice5e878be79f40799d70c12e1a6a0eee" continuedAt="i5fc2b14607ad478fbb3651541e4fc6e8"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i635a4ec4469e4a38ab9bf05cdecd65b3_I20150130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIwNjE4_a95721a2-0cba-4c77-815b-79b1bb111937">5.500</ix:nonFraction>% Senior Unsecured Notes due 2023</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2015, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i635a4ec4469e4a38ab9bf05cdecd65b3_I20150130" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIwNjkz_d6161517-e6a9-4641-9f24-d1f3327f168c">1,000</ix:nonFraction> million aggregate principal amount of March 2023 Unsecured Notes in a private placement. The March 2023 Unsecured Notes accrued interest at the rate of <ix:nonFraction unitRef="number" contextRef="i635a4ec4469e4a38ab9bf05cdecd65b3_I20150130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIwODQw_a95721a2-0cba-4c77-815b-79b1bb111937">5.500</ix:nonFraction>% per year, payable semi-annually in arrears. On March 8, 2019 and May 23, 2019, the Company repurchased $<ix:nonFraction unitRef="usd" contextRef="ib64fedb96e0a40dbbba005b5e30bc256_D20190308-20190308" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIwOTQ2_634d6707-4947-41cc-ad42-3838cd2bdc4b">216</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i884c88ec40c64e79b29c807b2a885dc6_D20190523-20190523" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIwOTUz_b88195cd-58b8-4be1-8c3c-107fc3020cd8">382</ix:nonFraction> million of March 2023 Unsecured Notes as part of the March 2019 Refinancing Transactions and the May 2019 Refinancing Transactions (as defined below), respectively. Throughout 2020, the Company repurchased, in aggregate, $<ix:nonFraction unitRef="usd" contextRef="i1dac4ecf6d0f4130aa4a1059a0869ace_D20200101-20201130" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxMDgx_a5b86d03-7742-4394-95be-63f91821b909">169</ix:nonFraction>&#160;million of March 2023 Unsecured Notes using cash on hand. The Company repurchased the remaining outstanding balance of $<ix:nonFraction unitRef="usd" contextRef="ia5885c91251745a8bd996100382f6c32_D20201201-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxMTk1_e34b94e1-f731-4131-b158-628b6b9a19b9">233</ix:nonFraction>&#160;million in December 2020 as part of the December 2020 Refinancing Transactions (as defined below).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="ib5b7e60d19034d39a78a89ace8a9bdaa_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxMjg5_fc240310-0dff-42b1-905c-6feabfc73e52">5.375</ix:nonFraction>% Senior Unsecured Notes due 2020, <ix:nonFraction unitRef="number" contextRef="i8d8eae7cb22c4834939fd13d8bfa0402_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxMzI1_32f26b5a-161f-48b5-8adb-0aac13a93195">5.875</ix:nonFraction>% Senior Unsecured Notes due 2023, <ix:nonFraction unitRef="number" contextRef="i2bec3b624035487c90ff26d75d14b4f5_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxMzYx_a2d335bc-7a84-4651-bea2-805627db1843">4.500</ix:nonFraction>% Senior Unsecured Notes due 2023 and <ix:nonFraction unitRef="number" contextRef="i5f952abf74d84815948a25d97a9b0e2a_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxNDAw_602c8d40-78d5-49e6-91e1-7c94b6fcd488">6.125</ix:nonFraction>% Senior Unsecured Notes due 2025</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2015, VRX Escrow Corp. (the "VRX Issuer"), a newly formed wholly owned subsidiary of the Company, issued $<ix:nonFraction unitRef="usd" contextRef="ib5b7e60d19034d39a78a89ace8a9bdaa_I20150327" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxNTUz_522a5e11-f3d9-46dc-b54a-720f146cd42e">2,000</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="ib5b7e60d19034d39a78a89ace8a9bdaa_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxNTg2_6caf3f6f-7bcc-4d44-ae07-804cdecf0291">5.375</ix:nonFraction>% Senior Unsecured Notes due 2020 (the "March 2020 Unsecured Notes"), $<ix:nonFraction unitRef="usd" contextRef="i8d8eae7cb22c4834939fd13d8bfa0402_I20150327" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxNjU3_9d61cfe5-3b79-4455-b825-3ad9c0ede6c7">3,250</ix:nonFraction> million aggregate principal amount of May 2023 Unsecured Notes, &#8364;<ix:nonFraction unitRef="eur" contextRef="i2bec3b624035487c90ff26d75d14b4f5_I20150327" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxNzU5_b7314cfb-e4c4-4cdf-99d6-18b40b844b67">1,500</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i2bec3b624035487c90ff26d75d14b4f5_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxNzky_c72fce75-dc21-42ce-81b6-638f08ffb915">4.500</ix:nonFraction>% Senior Unsecured Notes due 2023 (the "Euro Notes&#8221;) and $<ix:nonFraction unitRef="usd" contextRef="i5f952abf74d84815948a25d97a9b0e2a_I20150327" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxODUw_92e78a15-e394-4de6-9858-d8f50cade545">3,250</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i5f952abf74d84815948a25d97a9b0e2a_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxODgz_e21f1257-25b1-4b0f-b80f-12539e15e9ce">6.125</ix:nonFraction>% Senior Unsecured Notes due 2025 (the "April 2025 Unsecured Notes" and, together with the March 2020 Unsecured Notes, the May 2023 Unsecured Notes and the Euro Notes, the "VRX Notes") in a private placement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The March 2020 Unsecured Notes accrued interest at the rate of <ix:nonFraction unitRef="number" contextRef="ib5b7e60d19034d39a78a89ace8a9bdaa_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIyMDg2_23e0e79f-2bef-4c6e-a8ae-c10fda0e38dd">5.375</ix:nonFraction>% per year and were repaid in full as part of certain refinancing transactions completed in 2017 and 2018. The May 2023 Unsecured Notes and the Euro Notes accrued interest at the rate of <ix:nonFraction unitRef="number" contextRef="i8d8eae7cb22c4834939fd13d8bfa0402_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIyMzA4_cfbbf295-b101-4a23-b29a-fef9208d158a">5.875</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i2bec3b624035487c90ff26d75d14b4f5_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIyMzE1_ed8b5fa2-819f-4521-a18d-b9c38676efbb">4.500</ix:nonFraction>%  per year, respectively and were each repaid in full as of December 31, 2020, as discussed below. The April 2025 Unsecured Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="i5f952abf74d84815948a25d97a9b0e2a_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIyNDc4_5e9c2c65-3ded-471b-9dc5-9f1c54bd9642">6.125</ix:nonFraction>% per year, payable semi-annually in arrears. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of a refinancing transaction completed in June 2018, the Company repaid the remaining outstanding principal amounts of the March 2020 Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company repurchased $<ix:nonFraction unitRef="usd" contextRef="i199861b87bfe4696b2d3547b9feff668_D20190101-20191231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIyNzM0_97d88088-27b8-4968-82e2-adfeaff931c7">584</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icb448caef5334750891c172cec2300d0_D20190101-20191231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIyNzQx_a67f7e9a-c104-4e30-9ec3-98a7de168f2d">1,118</ix:nonFraction> million of May 2023 Unsecured Notes as part of the March 2019 Refinancing Transactions and the May 2019 Refinancing Transactions (as defined below), respectively, and on October 3, 2019, the Company repaid an additional $<ix:nonFraction unitRef="usd" contextRef="id030b84634ff4592b2dd49390438a1b9_D20191003-20191003" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIyODcw_236142ef-6d8e-4f4d-a232-7bdae807f394">100</ix:nonFraction> million of May 2023 Unsecured Notes using cash on hand. On January 16, 2020, the Company redeemed $<ix:nonFraction unitRef="usd" contextRef="i1d5f38a92282494f9530b0fb16484f40_I20200116" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIyOTQx_0ba752f6-e969-4779-8759-304cd5c97107">1,240</ix:nonFraction> million aggregate principal amount of the May 2023 Unsecured Notes as part of the December 2019 Financing and Refinancing Transactions (as defined below). Throughout 2020, the Company repaid, in aggregate, $<ix:nonFraction unitRef="usd" contextRef="ifc35a805bb9d489a81ba954da2c90dfc_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIzMTIw_304bcbab-ef2e-42d2-8da1-f97cdaa84f2b">208</ix:nonFraction>&#160;million of the May 2023 Unsecured Notes, with the May 2023 Unsecured Notes having been fully repaid during November 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2020, the Company redeemed the remaining outstanding balance of the Euro Notes as part of the December 2020 Refinancing Transactions, as defined below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout 2021, the Company repaid, in aggregate, $<ix:nonFraction unitRef="usd" contextRef="i8ca7f7ff80664661a5cc30c2112c5f4f_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEwOTk1MTE2Nzc4NjQ_398f1099-96b2-4398-925d-7d0919805561">600</ix:nonFraction>&#160;million of the April 2025 Unsecured Notes. The Company may redeem all or a portion of the April 2025 Unsecured Notes at the redemption prices set forth in the applicable indenture, plus accrued and unpaid interest to the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="iba498b34c6e5496e98017b43ea83814f_I20171218" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIzNjAy_7a0daa72-21aa-4f9b-8bb8-d5b41ee3478e">9.000</ix:nonFraction>% Senior Unsecured Notes due 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;18, 2017, the Company issued $<ix:nonFraction unitRef="usd" contextRef="iba498b34c6e5496e98017b43ea83814f_I20171218" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIzNjc5_f8066713-0357-4010-bb9c-1027dd1899a8">1,500</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="iba498b34c6e5496e98017b43ea83814f_I20171218" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIzNzEy_3e42d018-7d35-43a7-b4e6-d76cad8ed221">9.000</ix:nonFraction>% Senior Unsecured Notes due 2025 (the &#8220;December 2025 Unsecured Notes&#8221;) in a private placement, the net proceeds of which were used to repurchase $<ix:nonFraction unitRef="usd" contextRef="id56bb838f8ca4688a209a9aa5630486b_I20171218" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIzODU5_cd504c33-ddf4-4d08-abd0-8a3c54ae73d5">1,500</ix:nonFraction>&#160;million in aggregate principal amount of previously outstanding senior unsecured notes (the "December 2017 Refinancing Transactions"). The related fees and expenses were paid using cash on hand. The December 2025 Unsecured Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="iba498b34c6e5496e98017b43ea83814f_I20171218" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI0MDg3_73fe4bc9-a4f5-43a6-96cd-1fbe7758751d">9.000</ix:nonFraction>% per year, payable semi-annually in arrears on each of June 15 and December 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the December 2025 Unsecured Notes at any time prior to December 15, 2021, at a price equal to <ix:nonFraction unitRef="number" contextRef="i63149bfde2e74932af587b7f07bec783_D20171218-20171218" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI0MzA2_dfa84caf-441b-4909-8c87-2a361a3482f3">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to December 15, 2020, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="ic7612d5c6f03401fb096eeb9f8731268_D20171218-20171218" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI0NTIy_e6fcaaef-7e2e-4863-8f52-7e3fdd847b8f">40</ix:nonFraction>% of the aggregate principal amount of the outstanding December 2025 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the December 2025 Unsecured Notes indenture. On or after December 15, 2021, the Company may redeem all or a portion of the December 2025 Unsecured Notes at the applicable redemption prices set forth in the December 2025 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i6e6f4753796c4f9da3ea1142cd2e1c91_I20180326" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI1MDAy_92030425-f4b7-4a95-b974-831fcc41e9ee">9.250</ix:nonFraction>% Senior Unsecured Notes due 2026</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i5fc2b14607ad478fbb3651541e4fc6e8" continuedAt="i6c97178d36714f8dbca47edd5d5c7629"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 26, 2018, BHA issued $<ix:nonFraction unitRef="usd" contextRef="i6e6f4753796c4f9da3ea1142cd2e1c91_I20180326" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI1MTA1_6ea25dc6-8d9c-4dec-86cd-1cdf73d2eb1c">1,500</ix:nonFraction> million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i6e6f4753796c4f9da3ea1142cd2e1c91_I20180326" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI1MTQx_92030425-f4b7-4a95-b974-831fcc41e9ee">9.250</ix:nonFraction>% Senior Unsecured Notes due 2026 (the &#8220;April 2026 Unsecured Notes&#8221;) in a private placement, the net proceeds of which, and cash on hand, were used to repurchase $<ix:nonFraction unitRef="usd" contextRef="i6e6f4753796c4f9da3ea1142cd2e1c91_I20180326" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI1MzA0_49ff2eeb-fc5e-4f4f-9f5e-71ca8a50a567">1,500</ix:nonFraction> million in aggregate principal amount of unsecured notes. All fees and expenses associated with these transactions were paid with cash on hand (collectively, the &#8220;March 2018 Refinancing Transactions&#8221;). The April 2026 Unsecured Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="i6e6f4753796c4f9da3ea1142cd2e1c91_I20180326" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI1ODEw_92030425-f4b7-4a95-b974-831fcc41e9ee">9.250</ix:nonFraction>% per year, payable semi-annually in arrears on each of April 1 and October 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BHA may redeem all or a portion of the April 2026 Unsecured Notes at any time prior to April 1, 2022, at a price equal to <ix:nonFraction unitRef="number" contextRef="i07bdfabc3951404f8889a947cf3a9686_D20180326-20180326" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI2MDEy_9ebd4dd0-7621-4d9b-b88e-a4e80f2b01c0">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to April 1, 2021, BHA may redeem up to <ix:nonFraction unitRef="number" contextRef="i07bdfabc3951404f8889a947cf3a9686_D20180326-20180326" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI2MjE2_938f5b2e-c675-421a-814b-5b26264db4da">40</ix:nonFraction>% of the aggregate principal amount of the outstanding April 2026 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the April 2026 Unsecured Notes indenture. On or after April 1, 2022, BHA may redeem all or a portion of the April 2026 Unsecured Notes at the applicable redemption prices set forth in the April 2026 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i20076209e8fa4b958baa1b8f32663a95_I20181231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI2Njcy_f11fb6fe-8214-497a-b7c6-d84437d0bc11">8.500</ix:nonFraction>% Senior Unsecured Notes due 2027</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of a 2018 refinancing transaction, BHA issued $<ix:nonFraction unitRef="usd" contextRef="i20076209e8fa4b958baa1b8f32663a95_I20181231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI2ODQ2_3aef37bb-8ab2-4e4d-86c1-2dcd17be3975">750</ix:nonFraction> million in aggregate principal amount of January 2027 Unsecured Notes in a private placement. The January 2027 Unsecured Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="i20076209e8fa4b958baa1b8f32663a95_I20181231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI3Mjgy_f11fb6fe-8214-497a-b7c6-d84437d0bc11">8.500</ix:nonFraction>% per year, payable semi-annually in arrears on each of January 31 and July 31. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the March 2019 Refinancing Transactions described above, BHA issued $<ix:nonFraction unitRef="usd" contextRef="if30a44e3344f420686b02ee5a1668f41_I20190308" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI3NDEw_470f4f4b-f6bd-4f7d-8c6d-309513dc7877">1,000</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i20076209e8fa4b958baa1b8f32663a95_I20181231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI3NDQz_f11fb6fe-8214-497a-b7c6-d84437d0bc11">8.500</ix:nonFraction>% Senior Unsecured Notes due January 2027. These are additional notes and form part of the same series as BHA&#8217;s existing January 2027 Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BHA may redeem all or a portion of the January 2027 Unsecured Notes at any time prior to July 31, 2022, at a price equal to <ix:nonFraction unitRef="number" contextRef="ieb0e075a0cbd419d8ad9a06043a3352f_D20180101-20181231" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI3NzE5_4ff2760c-b1d9-4216-b104-2355c4ab8958">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to July 31, 2021, BHA may redeem up to <ix:nonFraction unitRef="number" contextRef="ieb0e075a0cbd419d8ad9a06043a3352f_D20180101-20181231" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI3OTIz_b234da0f-9e1f-44bc-b02d-ed77d0ddcb6f">40</ix:nonFraction>% of the aggregate principal amount of the outstanding January 2027 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the January 2027 Unsecured Notes indenture. On or after July 31, 2022, BHA may redeem all or a portion of the January 2027 Unsecured Notes at the applicable redemption prices set forth in the January 2027 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i28aa526ea8d84f278ee8f1842400571b_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI4Mzg3_af513f21-a880-4db9-83ae-ef44da0eb2e0">7.000</ix:nonFraction>% Senior Unsecured Notes due 2028 and <ix:nonFraction unitRef="number" contextRef="i39a070cf27ac4d539b94e8656d4502e5_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI4NDI2_2e9c3858-1c34-47ac-bbb6-0d27b36b689e">7.250</ix:nonFraction>% Senior Unsecured Notes due 2029 - May 2019 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 23, 2019, the Company issued: (i) $<ix:nonFraction unitRef="usd" contextRef="i28aa526ea8d84f278ee8f1842400571b_I20190523" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI4NTM4_ce3cd61e-8986-4ca3-a6e2-78e320bf06ce">750</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i28aa526ea8d84f278ee8f1842400571b_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI4NTcx_af513f21-a880-4db9-83ae-ef44da0eb2e0">7.000</ix:nonFraction>% Senior Unsecured Notes due January 2028 (the "<ix:nonFraction unitRef="number" contextRef="i28aa526ea8d84f278ee8f1842400571b_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI4NjIw_b10b5018-02bc-4c2b-b7c5-1015419972d1">7.000</ix:nonFraction>% January 2028 Unsecured Notes") and (ii) $<ix:nonFraction unitRef="usd" contextRef="i39a070cf27ac4d539b94e8656d4502e5_I20190523" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI4NjYz_6e5d21e6-930f-493c-9bfd-c7ec41b44564">750</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i39a070cf27ac4d539b94e8656d4502e5_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI4Njk2_2e9c3858-1c34-47ac-bbb6-0d27b36b689e">7.250</ix:nonFraction>% Senior Unsecured Notes due May 2029 (the "May 2029 Unsecured Notes"), respectively, in a private placement. The proceeds and cash on hand were used to: (i) repurchase $<ix:nonFraction unitRef="usd" contextRef="icb448caef5334750891c172cec2300d0_D20190101-20191231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI4ODY2_a67f7e9a-c104-4e30-9ec3-98a7de168f2d">1,118</ix:nonFraction> million of May 2023 Unsecured Notes, (ii) repurchase $<ix:nonFraction unitRef="usd" contextRef="i884c88ec40c64e79b29c807b2a885dc6_D20190523-20190523" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI4OTE0_b88195cd-58b8-4be1-8c3c-107fc3020cd8">382</ix:nonFraction> million of March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the &#8220;May 2019 Refinancing Transactions&#8221;). The May 2019 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i05517ba451014901a9d88eb38f3ac23a_D20190523-20190523" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI5MTkx_1d0fb422-f4f0-4161-8d71-4daad18de79d">32</ix:nonFraction> million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. Interest on the <ix:nonFraction unitRef="number" contextRef="i28aa526ea8d84f278ee8f1842400571b_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI5MzM4_cd10bc4b-80ab-4e97-b1ed-96b50feb54d9">7.000</ix:nonFraction>% January 2028 Unsecured Notes is payable semi-annually in arrears on each January 15 and July 15. Interest on the May 2029 Unsecured Notes is payable semi-annually in arrears on each May 30 and November 30. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The <ix:nonFraction unitRef="number" contextRef="i28aa526ea8d84f278ee8f1842400571b_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI5NTUy_05710c3e-dda3-4811-af88-ab8fa922d6f5">7.000</ix:nonFraction>% January 2028 Unsecured Notes and the May 2029 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 15, 2023 and May 30, 2024, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the <ix:nonFraction unitRef="number" contextRef="i28aa526ea8d84f278ee8f1842400571b_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI5ODYy_7cd94bdb-9465-40fe-9de0-9ad870a94251">7.000</ix:nonFraction>% January 2028 Unsecured Notes or the May 2029 Unsecured Notes prior to January 15, 2023 and May 30, 2024, respectively, at a price equal to <ix:nonFraction unitRef="number" contextRef="iab2a35a3c29f407dad845189bdbe128c_D20190523-20190523" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwMDA0_504d0c4c-0463-4537-b263-88c55b9fe6f1"><ix:nonFraction unitRef="number" contextRef="i1273409244264cbbb7681d6753625c7b_D20190523-20190523" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwMDA0_d883de2d-2664-4c3d-ad93-930b0920d04e">100</ix:nonFraction></ix:nonFraction>% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to July 15, 2022, and May 30, 2022, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="iab2a35a3c29f407dad845189bdbe128c_D20190523-20190523" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwMTM5_633e938d-8fb6-48b1-a985-48b40429d409"><ix:nonFraction unitRef="number" contextRef="i1273409244264cbbb7681d6753625c7b_D20190523-20190523" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwMTM5_992d0f80-3fe2-49cf-bdd3-6807944c00e6">40</ix:nonFraction></ix:nonFraction>% of the aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="i28aa526ea8d84f278ee8f1842400571b_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwMTgz_a3502148-fd34-4583-922f-d835148d1919">7.000</ix:nonFraction>% January 2028 Unsecured Notes or the May 2029 Unsecured Notes, respectively, using the proceeds of certain equity offerings at the redemption price set forth in the respective indenture. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="ibb700fb0599c4cfdbab4a269de54e805_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwMzcz_46464944-34d5-4bd4-a669-c99f5822db10">5.000</ix:nonFraction>% Senior Unsecured Notes due 2028 and <ix:nonFraction unitRef="number" contextRef="ie55bd69a58f9418183a1bb030920e901_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwNDEy_7280c092-1c37-413d-b99c-c6a406968d76">5.250</ix:nonFraction>% Senior Unsecured Notes due 2030 - December 2019 Financing and Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, the Company issued: (i) $<ix:nonFraction unitRef="usd" contextRef="ibb700fb0599c4cfdbab4a269de54e805_I20191230" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwNTQ4_be51173b-1ed3-478f-89f1-3509abbbc0b9">1,250</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="ibb700fb0599c4cfdbab4a269de54e805_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwNTgx_750193d4-490f-48e3-938b-af05a75f0c87">5.000</ix:nonFraction>% Senior Unsecured Notes due January 2028 (the "<ix:nonFraction unitRef="number" contextRef="ibb700fb0599c4cfdbab4a269de54e805_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwNjMw_ce73afcd-8ca0-4b10-af21-96718c50f7a8">5.000</ix:nonFraction>% January 2028 Unsecured Notes") and (ii) $<ix:nonFraction unitRef="usd" contextRef="ie55bd69a58f9418183a1bb030920e901_I20191230" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwNjcz_a4e9943b-a5e0-4e2e-877b-9e25abd964bb">1,250</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="ie55bd69a58f9418183a1bb030920e901_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwNzA2_98eec442-e009-4841-b905-46fae2c1073e">5.250</ix:nonFraction>% Senior Unsecured Notes due January 2030 (the "January 2030 Unsecured Notes") in a private placement. The </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i6c97178d36714f8dbca47edd5d5c7629" continuedAt="ie3d0b3aaaa084c8aafa1830900344bfe"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeds and cash on hand were used to: (i) redeem $<ix:nonFraction unitRef="usd" contextRef="i43c10acd1411494298a8bbca9c5aad00_D20200116-20200116" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwODY1_bca58849-f8b8-42fa-a427-2bd50e624ffa">1,240</ix:nonFraction> million of May 2023 Unsecured Notes on January 16, 2020, (ii) finance the $<ix:nonFraction unitRef="usd" contextRef="i06c668190ea847209a8da86cf1e73998_D20191216-20191216" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwOTM0_2aa53740-7007-48ba-8c23-e0201a857624">1,210</ix:nonFraction> million settlement of certain U.S. Securities litigation as discussed in Note 20, "LEGAL PROCEEDINGS" and (iii) pay all fees and expenses associated with these transactions (collectively, the "December 2019 Financing and Refinancing Transactions"). The redemption of $<ix:nonFraction unitRef="usd" contextRef="i43c10acd1411494298a8bbca9c5aad00_D20200116-20200116" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMxMTcw_514659b8-5019-48ba-a1a1-66ace11055b8">1,240</ix:nonFraction>&#160;million of May 2023 Unsecured notes was accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i43c10acd1411494298a8bbca9c5aad00_D20200116-20200116" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMxMzA5_62ddc9c4-a3e8-42ec-9416-3443c91b8c58">24</ix:nonFraction>&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on the <ix:nonFraction unitRef="number" contextRef="ibb700fb0599c4cfdbab4a269de54e805_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMxNDU2_ce73afcd-8ca0-4b10-af21-96718c50f7a8">5.000</ix:nonFraction>% January 2028 Unsecured Notes is payable semi-annually in arrears on each January 30 and July 30. Interest on the January 2030 Unsecured Notes is payable semi-annually in arrears on each January 30 and July 30. The <ix:nonFraction unitRef="number" contextRef="ibb700fb0599c4cfdbab4a269de54e805_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMxNjIx_ce73afcd-8ca0-4b10-af21-96718c50f7a8">5.000</ix:nonFraction>% January 2028 Unsecured Notes and the January 2030 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 30, 2023 and January 30, 2025, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the <ix:nonFraction unitRef="number" contextRef="ibb700fb0599c4cfdbab4a269de54e805_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMxODg3_ce73afcd-8ca0-4b10-af21-96718c50f7a8">5.000</ix:nonFraction>% January 2028 Unsecured Notes or the January 2030 Unsecured Notes prior to January 30, 2023 and January 30, 2025, respectively, at a price equal to <ix:nonFraction unitRef="number" contextRef="i71f877b49bc44738a6ceab709138f307_D20191230-20191230" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMxOTg1_bf1ec1c6-e8a3-4ab8-b57b-504be801b048"><ix:nonFraction unitRef="number" contextRef="i5389f9afcc9c4deca0f0d09e9a716c2b_D20191230-20191230" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMxOTg1_e1771dc4-14cf-4fb8-ba53-69f78c6931b9">100</ix:nonFraction></ix:nonFraction>% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to January 30, 2023, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="i71f877b49bc44738a6ceab709138f307_D20191230-20191230" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMyMTA1_1e355811-0265-4adb-8d01-e10ecbfcba3c"><ix:nonFraction unitRef="number" contextRef="i5389f9afcc9c4deca0f0d09e9a716c2b_D20191230-20191230" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMyMTA1_4f6d1d0f-0d29-4cd5-8298-abfafea50aa0">40</ix:nonFraction></ix:nonFraction>% of the aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="ibb700fb0599c4cfdbab4a269de54e805_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMyMTQ5_ce73afcd-8ca0-4b10-af21-96718c50f7a8">5.000</ix:nonFraction>% January 2028 Unsecured Notes or the January 2030 Unsecured Notes using the proceeds of certain equity offerings at the redemption price set forth in the respective indenture. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="idec8329a9c5d487e88dbc1f38144d98a_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMyMjc2_77faba8f-9976-4bbb-ab54-c5fb604def2a">6.250</ix:nonFraction>% Senior Unsecured Notes due 2029 - May 2020 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="idec8329a9c5d487e88dbc1f38144d98a_I20200526" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMyMzgz_7e9226be-87a8-4836-9ec5-6f28f8554de8">1,500</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="idec8329a9c5d487e88dbc1f38144d98a_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMyNDE2_77faba8f-9976-4bbb-ab54-c5fb604def2a">6.250</ix:nonFraction>% Senior Unsecured Notes due February 2029 (the "<ix:nonFraction unitRef="number" contextRef="idec8329a9c5d487e88dbc1f38144d98a_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMyNDY2_77faba8f-9976-4bbb-ab54-c5fb604def2a">6.250</ix:nonFraction>% February 2029 Unsecured Notes") in a private placement. The proceeds and cash on hand were used to: (i) repurchase $<ix:nonFraction unitRef="usd" contextRef="ia601b6230ea24da1ae27d263526923d9_I20200526" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMyNTg0_2de92cc8-20a8-4ad7-b6bf-df5323f7038b">1,250</ix:nonFraction>&#160;million aggregate principal amount of the outstanding March 2022 Secured Notes, (ii) prepay $<ix:nonFraction unitRef="usd" contextRef="iee380ad8627b4f83b469b1ba89c9747b_D20200526-20200526" decimals="-6" name="bhc:PaymentForDebtAmortizationPrepaymentCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMyNjcx_fe8af302-6f5e-4848-9b54-786ee396371d">303</ix:nonFraction>&#160;million of mandatory amortization scheduled for payment in 2022 under the Company's June 2025 and November 2025 Term Loan B Facilities and (iii) pay all fees and expenses associated with these transactions (collectively, the "May 2020 Refinancing Transactions"). The May 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="id5925ca8a2c54e8d8795ffb55d368483_D20200526-20200526" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMzMDc2_38be613f-6f8f-48ab-8304-05e1b1885136">27</ix:nonFraction>&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value. The <ix:nonFraction unitRef="number" contextRef="idec8329a9c5d487e88dbc1f38144d98a_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMzMjEx_77faba8f-9976-4bbb-ab54-c5fb604def2a">6.250</ix:nonFraction>% February 2029 Unsecured Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="idec8329a9c5d487e88dbc1f38144d98a_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMzMjc1_77faba8f-9976-4bbb-ab54-c5fb604def2a">6.250</ix:nonFraction>% per year, payable semi-annually in arrears on each of February 15 and August 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the <ix:nonFraction unitRef="number" contextRef="idec8329a9c5d487e88dbc1f38144d98a_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMzNDA2_77faba8f-9976-4bbb-ab54-c5fb604def2a">6.250</ix:nonFraction>% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to <ix:nonFraction unitRef="number" contextRef="ifea6355ea76743f0a61e88e55dcd2ce2_D20200526-20200526" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMzNDk5_1e5abfe3-e0b5-4d1f-a9ed-64a091a9b141">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to August 15, 2023, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="i5839a9c4cc754fa0803795d95447729c_D20200526-20200526" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMzNzEz_65270d7e-3dec-4d41-909e-23de5f349c25">40</ix:nonFraction>% of the aggregate principal amount of the outstanding <ix:nonFraction unitRef="number" contextRef="idec8329a9c5d487e88dbc1f38144d98a_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMzNzY5_77faba8f-9976-4bbb-ab54-c5fb604def2a">6.250</ix:nonFraction>% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the <ix:nonFraction unitRef="number" contextRef="idec8329a9c5d487e88dbc1f38144d98a_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMzODkz_77faba8f-9976-4bbb-ab54-c5fb604def2a">6.250</ix:nonFraction>% February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the <ix:nonFraction unitRef="number" contextRef="idec8329a9c5d487e88dbc1f38144d98a_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM0MDE1_77faba8f-9976-4bbb-ab54-c5fb604def2a">6.250</ix:nonFraction>% February 2029 Unsecured Notes at the applicable redemption prices set forth in the <ix:nonFraction unitRef="number" contextRef="idec8329a9c5d487e88dbc1f38144d98a_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM0MTAx_77faba8f-9976-4bbb-ab54-c5fb604def2a">6.250</ix:nonFraction>% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM0MjI1_98a14e40-3d99-472d-85f1-1df5e0af1830">5.000</ix:nonFraction>% Senior Unsecured Notes due 2029 and <ix:nonFraction unitRef="number" contextRef="i88e6526a8d134ebab814430fdfa18227_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM0MjY0_5dd23589-354b-4ef4-a418-a3d77f1f097e">5.250</ix:nonFraction>% Senior Unsecured Notes due 2031 &#8211; December 2020 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM0Mzgw_e57e40cb-0b35-4546-b7c1-2260659d850f">1,000</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM0NDEz_98a14e40-3d99-472d-85f1-1df5e0af1830">5.000</ix:nonFraction>% Senior Unsecured Notes due February 2029 (the "<ix:nonFraction unitRef="number" contextRef="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM0NDYz_98a14e40-3d99-472d-85f1-1df5e0af1830">5.000</ix:nonFraction>% February 2029 Unsecured Notes") and $<ix:nonFraction unitRef="usd" contextRef="i88e6526a8d134ebab814430fdfa18227_I20201203" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM0NTAy_af5ae29f-92e3-4464-93e1-9f7c4c0d93bf">1,000</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i88e6526a8d134ebab814430fdfa18227_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM0NTM1_5dd23589-354b-4ef4-a418-a3d77f1f097e">5.250</ix:nonFraction>% Senior Unsecured Notes due February 2031 (the "February 2031 Unsecured Notes") in a private placement. The aggregate proceeds and cash on hand were used to repurchase the remaining outstanding principal amounts of: (i) &#8364;<ix:nonFraction unitRef="eur" contextRef="i9a97ad4188494b8781417a8f8d543882_I20201203" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM0NzU3_d6b0a7bc-907c-4b49-b7c7-57e0eb4593d6">1,500</ix:nonFraction>&#160;million of the Euro Notes, (ii) $<ix:nonFraction unitRef="usd" contextRef="i5964597f62e744bf9d6aafb14762d4d7_I20201203" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM0Nzg0_c8f6caeb-7e35-4576-9a4d-389d637abfab">233</ix:nonFraction>&#160;million of the March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the "December 2020 Refinancing Transactions"). The December 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i5501242b42bc40d7a227556ee3415134_D20201203-20201203" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM1MTA2_0c512d08-0a00-4501-b819-1b17ff6940b0">7</ix:nonFraction>&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value. The <ix:nonFraction unitRef="number" contextRef="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM1MjQx_98a14e40-3d99-472d-85f1-1df5e0af1830">5.000</ix:nonFraction>% February 2029 Unsecured Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM1MzA1_98a14e40-3d99-472d-85f1-1df5e0af1830">5.000</ix:nonFraction>% per year, payable semi-annually in arrears on each of February 15 and August 15. The February 2031 Unsecured Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="i88e6526a8d134ebab814430fdfa18227_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM1NDU0_5dd23589-354b-4ef4-a418-a3d77f1f097e">5.250</ix:nonFraction>% per year, payable semi-annually in arrears on each of February 15 and August 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the <ix:nonFraction unitRef="number" contextRef="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM1NTg1_98a14e40-3d99-472d-85f1-1df5e0af1830">5.000</ix:nonFraction>% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to <ix:nonFraction unitRef="number" contextRef="i73e09d09766b4417aacfcfa14a10126c_D20201203-20201203" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM1Njc4_4f33ba7b-dae2-4523-b841-0bb20eb304f3">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="i73e09d09766b4417aacfcfa14a10126c_D20201203-20201203" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM1ODk0_b0192c18-e4c0-4f2e-932c-d13949e641cc">40</ix:nonFraction>% of the aggregate principal amount of the outstanding <ix:nonFraction unitRef="number" contextRef="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM1OTUw_98a14e40-3d99-472d-85f1-1df5e0af1830">5.000</ix:nonFraction>% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the <ix:nonFraction unitRef="number" contextRef="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM2MDc0_c3391ba4-f8fc-4722-b672-f57eadfe4c8d">5.000</ix:nonFraction>% February 2029 Unsecured Notes </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ie3d0b3aaaa084c8aafa1830900344bfe"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indenture. On or after February 15, 2024, the Company may redeem all or a portion of the <ix:nonFraction unitRef="number" contextRef="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM2MTk2_98a14e40-3d99-472d-85f1-1df5e0af1830">5.000</ix:nonFraction>% February 2029 Unsecured Notes at the applicable redemption prices set forth in the <ix:nonFraction unitRef="number" contextRef="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM2Mjgy_45071907-76b0-4ecc-8e52-beba5e47aaa9">5.000</ix:nonFraction>% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the February 2031 Unsecured Notes at any time prior to February 15, 2026, at a price equal to <ix:nonFraction unitRef="number" contextRef="ie10a5bc9208e4517ad73103ab3f6d59b_D20201203-20201203" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM2NTQz_02d688bd-6930-449b-b19b-67bd5702ca66">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="ie10a5bc9208e4517ad73103ab3f6d59b_D20201203-20201203" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM2NzU5_19aed8f1-dfef-4b0a-908e-2d4a1462b768">40</ix:nonFraction>% of the aggregate principal amount of the outstanding February 2031 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the February 2031 Unsecured Notes indenture. On or after February 15, 2026, the Company may redeem all or a portion of the February 2031 Unsecured Notes at the applicable redemption prices set forth in the February 2031 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Stated Rate of Interest</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average stated rate of interest for the Company's outstanding debt obligations as of December 31, 2021 and 2020 was <ix:nonFraction unitRef="number" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM3Mzk5_ec4dbf28-8686-4180-88f0-e6fc542a3706">5.88</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM3NDA2_8382acb6-1e1e-4762-ba34-356a96483bfe">6.02</ix:nonFraction>%, respectively.</span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM3NzAy_3b0f34a4-c5c2-49e1-b463-baf7c31c5a82" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturities and Mandatory Payments</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities and mandatory payments of debt obligations for the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:88.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo2MTU5NDQ4ZGI3MzU0OGI5OWRiNGYzYWJmMjkwNGRhMC90YWJsZXJhbmdlOjYxNTk0NDhkYjczNTQ4Yjk5ZGI0ZjNhYmYyOTA0ZGEwXzEtMS0xLTEtNTk0NzA_34b86aa7-9d83-4db2-9de3-98a09183ef7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo2MTU5NDQ4ZGI3MzU0OGI5OWRiNGYzYWJmMjkwNGRhMC90YWJsZXJhbmdlOjYxNTk0NDhkYjczNTQ4Yjk5ZGI0ZjNhYmYyOTA0ZGEwXzItMS0xLTEtNTk0NzA_608ab570-2ca9-443d-9361-bcc7d1248c0b">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo2MTU5NDQ4ZGI3MzU0OGI5OWRiNGYzYWJmMjkwNGRhMC90YWJsZXJhbmdlOjYxNTk0NDhkYjczNTQ4Yjk5ZGI0ZjNhYmYyOTA0ZGEwXzMtMS0xLTEtNTk0NzA_30deeb12-8cb6-42e9-b82d-313363d9071a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo2MTU5NDQ4ZGI3MzU0OGI5OWRiNGYzYWJmMjkwNGRhMC90YWJsZXJhbmdlOjYxNTk0NDhkYjczNTQ4Yjk5ZGI0ZjNhYmYyOTA0ZGEwXzQtMS0xLTEtNTk0NzA_b65807bb-a072-47fb-b91e-d66216b5a738">9,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo2MTU5NDQ4ZGI3MzU0OGI5OWRiNGYzYWJmMjkwNGRhMC90YWJsZXJhbmdlOjYxNTk0NDhkYjczNTQ4Yjk5ZGI0ZjNhYmYyOTA0ZGEwXzUtMS0xLTEtNTk0NzA_4764914b-2851-4f03-90dc-49735ea1006b">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo2MTU5NDQ4ZGI3MzU0OGI5OWRiNGYzYWJmMjkwNGRhMC90YWJsZXJhbmdlOjYxNTk0NDhkYjczNTQ4Yjk5ZGI0ZjNhYmYyOTA0ZGEwXzYtMS0xLTEtNTk0NzA_5aa115b6-153f-445d-9f9c-4ae474536f0f">11,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross maturities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo2MTU5NDQ4ZGI3MzU0OGI5OWRiNGYzYWJmMjkwNGRhMC90YWJsZXJhbmdlOjYxNTk0NDhkYjczNTQ4Yjk5ZGI0ZjNhYmYyOTA0ZGEwXzctMS0xLTEtNTk0NzA_307af7e7-98d6-4ecd-b83b-71108e50641d">22,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo2MTU5NDQ4ZGI3MzU0OGI5OWRiNGYzYWJmMjkwNGRhMC90YWJsZXJhbmdlOjYxNTk0NDhkYjczNTQ4Yjk5ZGI0ZjNhYmYyOTA0ZGEwXzgtMS0xLTEtNTk0NzA_654e0ae2-1078-4644-a1f4-fc8feb4ad291">216</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo2MTU5NDQ4ZGI3MzU0OGI5OWRiNGYzYWJmMjkwNGRhMC90YWJsZXJhbmdlOjYxNTk0NDhkYjczNTQ4Yjk5ZGI0ZjNhYmYyOTA0ZGEwXzktMS0xLTEtNTk0NzA_2690f180-bf58-489f-9bb6-c01becca1184">22,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Restated Credit Agreement, there is no Excess Cash Flow payment due for 2021.</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2022, the Company repaid its outstanding balance of $<ix:nonFraction unitRef="usd" contextRef="i8f1fd27861d840c9982cb6007d12ec99_D20220211-20220211" decimals="-6" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM4NDgyOTA3NTc0MTc_70f73ece-ad03-4632-a917-b8f7a50f2764">285</ix:nonFraction>&#160;million under its 2023 Revolving Credit Facility.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As more fully discussed in Note 23, "SUBSEQUENT EVENTS", during January 2022, the Company: (i) issued conditional notices of redemption to redeem in full all of its outstanding April 2025 Unsecured Notes and to redeem $<ix:nonFraction unitRef="usd" contextRef="if80737f8327f4413b9aff0d3dbfe8369_I20220118" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM4NDgyOTA3NTQwMTk_4fb5f3a6-7971-47ab-b85c-c778f7cce324">370</ix:nonFraction>&#160;million aggregate principal amount of its outstanding December 2025 Unsecured Notes and (ii) issued $<ix:nonFraction unitRef="usd" contextRef="i9af4b96ef19949f2928ad128d4c72201_I20220210" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM4NDgyOTA3NTQxNjQ_d3dde3ee-7faa-4fa5-b1f6-8a9c25b805ac">1,000</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i9af4b96ef19949f2928ad128d4c72201_I20220210" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM4NDgyOTA3NTQxOTg_e134234e-18af-4050-a3f4-5597e0724bd5">6.125</ix:nonFraction>% Senior Secured Notes due February 2027.</span></div></ix:continuation><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_334"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzkwMDA_5fba673f-7351-4f21-92af-f94a3216aba2" continuedAt="if66e9854718940348e8be867c5eb52e4" escape="true">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if66e9854718940348e8be867c5eb52e4" continuedAt="i72b9f650fb224315989b8bb82124380d">The Company has defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers a closed grandfathered group of legacy Bausch &amp; Lomb Holdings Incorporated (&#8216;&#8216;B&amp;L&#8217;&#8217;) U.S. employees and employees in certain other countries. The U.S. defined benefit accruals were frozen as of December 31, 2004 and benefits that were earned up to December 31, 2004 were preserved. Participants continue to earn interest credits on their cash balance at an interest crediting rate that is equal to the greater of: (i) the average annual yield on 10-year treasury bonds in effect for the November preceding the plan year or (ii) <ix:nonFraction unitRef="number" contextRef="i7563625586364005812392f5b14e44af_I20211231" decimals="INF" name="bhc:DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzY3Mg_f4dc018f-9657-433d-b50e-542b9df292f4">4.50</ix:nonFraction>%. The most significant non-U.S. plans are <ix:nonFraction unitRef="defined_benefit_plan" contextRef="i5ec20e3f4b2f4f599834f9809e4c9d92_I20211231" decimals="INF" name="bhc:DefinedBenefitPlanNumberofDefinedBenefitPlans" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzcxNg_d60dfb0e-b3f2-4d6c-a195-75e7d397018c">two</ix:nonFraction> defined benefit plans in Ireland. In 2011, both Ireland defined benefit plans were closed to future service benefit accruals; however, additional accruals related to annual salary increases continued. In December 2014, <ix:nonFraction unitRef="defined_benefit_plan" contextRef="id71cc4b7c6a54ab0a60acdf0c8a5303c_D20141201-20141231" decimals="INF" name="bhc:DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzkzOA_0a87db24-8f91-48d1-aa6f-ade8d35a94f3">one</ix:nonFraction> of the Ireland defined benefit plans was amended effective August 2014 to eliminate future benefit accruals related to salary increases. All of the pension benefits accrued through the plan amendment date were preserved. As a result of the plan amendment, there are no active plan participants accruing benefits under the amended Ireland defined benefit plan.  The U.S. postretirement benefit plan was amended effective January 1, 2005 to eliminate employer contributions after age <ix:nonNumeric contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" name="bhc:DefinedBenefitPlanEmployerContributionMaximumAge" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzE0MjM_4a7b08c1-1938-4eff-ba15-4733ed1d3a17">65</ix:nonNumeric> for participants who did not meet the minimum requirements of age and service on that date. The employer contributions for medical and prescription </ix:continuation></span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i72b9f650fb224315989b8bb82124380d" continuedAt="ib9cc1d1324f54a24a4321385a9a19aa0"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug benefits for participants retiring after March 1, 1989 were frozen effective January 1, 2010. Effective January 1, 2014, the Company no longer offers medical and life insurance coverage to new retirees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the B&amp;L benefit plans, outside of the U.S., a limited group of the Company's employees are covered by defined benefit pension plans. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses December 31 as the year-end measurement date for all of its defined benefit pension plans and the postretirement benefit plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Pension Benefit Plans and Postretirement Benefit Plan </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes in its Consolidated Balance Sheets an asset or liability equal to the over- or under-funded benefit obligation of each defined benefit pension plan and postretirement benefit plan. Actuarial gains or losses and prior service costs or credits that arise during the period but are not recognized as components of net periodic benefit cost are recognized, net of tax, as a component of Other comprehensive income (loss). </span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4Xzg5NzU_22e2a78c-36e7-4b32-9ad4-5c73dfb14a88" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts included in Accumulated other comprehensive loss as of December 31, 2021 and 2020 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:38.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.963%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized actuarial losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzMtMi0xLTEtNTk0NzA_872a9217-f54b-44f6-a2a8-93a9de487212">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzMtNC0xLTEtNTk0NzA_134179e3-6270-4acc-be71-15ccd5793929">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id639a041f43545ba9cbf52ed62530656_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzMtNi0xLTEtNTk0NzA_c80a1256-c3ee-4f82-85ed-44972fbe9e75">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzMtOC0xLTEtNTk0NzA_876deee5-471f-4377-b809-6a14c7d74f3a">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzMtMTAtMS0xLTU5NDcw_cffb1307-17db-4461-a859-001237277714">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzMtMTItMS0xLTU5NDcw_5fff52b1-7334-4e1f-ad4e-8ce3b070d4ee">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized prior service credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzQtMi0xLTEtNTk0NzA_13c909a3-47f0-4906-b290-e04d38338082">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzQtNC0xLTEtNTk0NzA_2267bdd3-3c5e-4161-aba7-33062cca1836">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id639a041f43545ba9cbf52ed62530656_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzQtNi0xLTEtNTk0NzA_5e29f9fb-63c1-4b82-b3b6-6f1a030e35c7">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzQtOC0xLTEtNTk0NzA_3cce7299-fcb9-44d7-8a15-62c0b4269624">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzQtMTAtMS0xLTU5NDcw_aac3b681-cf32-4f7d-93fa-8377ff1491b5">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzQtMTItMS0xLTU5NDcw_d22991a6-3fa1-4a84-ac13-4ca78bcc6235">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Periodic (Benefit) Cost</span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4Xzg5ODA_314f63ed-9429-4d2a-9993-b28376daddb2" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of net periodic (benefit) cost for the Company&#8217;s defined benefit pension plans and postretirement benefit plan in 2021, 2020 and 2019:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:25.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.504%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzMtMi0xLTEtNTk0NzA_df570842-1aac-4526-adfb-1bacd3e6247e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzMtNC0xLTEtNTk0NzA_70af092e-d9d2-4679-90e7-39526bb3114f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzMtNi0xLTEtNTk0NzA_58b9df83-01ef-484a-9280-cf86c29a67c9">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzMtOC0xLTEtNTk0NzA_9dd98b71-4c37-4edd-beca-c3c518fefc20">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzMtMTAtMS0xLTU5NDcw_17e7f9f1-df01-4497-860b-c06d7fcdd619">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzMtMTItMS0xLTU5NDcw_e9156983-e179-41d9-a897-00653dd1aea1">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzMtMTQtMS0xLTU5NDcw_465498e6-4417-4db5-b084-83e631d53b64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzMtMTYtMS0xLTU5NDcw_764c803f-ffe8-409d-864e-698621e75878">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzMtMTgtMS0xLTU5NDcw_ac3cc97a-5f80-4890-9c35-6813ad789771">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzQtMi0xLTEtNTk0NzA_a3a7944e-37be-4c5b-9106-11d4761b65b7">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzQtNC0xLTEtNTk0NzA_141c720c-be3c-4c79-becc-ed8a39d2040e">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzQtNi0xLTEtNTk0NzA_3f48da29-acb6-435e-b066-bbc9a74b8f78">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzQtOC0xLTEtNTk0NzA_ceae3094-ae28-4153-96d9-52c6d01e43ac">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzQtMTAtMS0xLTU5NDcw_941ec8b2-49e5-4917-9579-88fedb22a255">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzQtMTItMS0xLTU5NDcw_facaf6d6-f568-4690-97d3-3b850eb99677">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzQtMTQtMS0xLTU5NDcw_29606a61-819f-4169-a354-0f4b22e4c1c4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzQtMTYtMS0xLTU5NDcw_f5bd3af7-ea00-4c3c-b516-6301b1da6a97">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzQtMTgtMS0xLTU5NDcw_e15dadf2-7006-4fda-9de2-641432c11eba">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzUtMi0xLTEtNTk0NzA_ed72817e-cef6-4ce5-8bb3-accce3bd611c">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzUtNC0xLTEtNTk0NzA_d167658a-71e9-48c2-a314-d33da6d79bad">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzUtNi0xLTEtNTk0NzA_7e339fc3-7522-4581-9183-80a7da3c550a">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzUtOC0xLTEtNTk0NzA_49fadc46-9da9-4328-87ef-8d3616943c16">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzUtMTAtMS0xLTU5NDcw_2034022a-88e2-4053-8e78-4831f29ac2e8">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzUtMTItMS0xLTU5NDcw_75686538-e0fd-433d-80b4-acb41728d430">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzUtMTQtMS0xLTU5NDcw_ca4f36f9-7bee-4f14-8469-191eb3363814">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzUtMTYtMS0xLTU5NDcw_fa3cb860-1e8b-4f12-b3a6-4447abde6c2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzUtMTgtMS0xLTU5NDcw_1530602b-426a-4d3d-a91b-398482ad6996">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzYtMi0xLTEtNTk0NzA_679e6835-4401-46c8-902c-535617a23a81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzYtNC0xLTEtNTk0NzA_d881d53f-ddfb-4adb-9b99-d541b3899636">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzYtNi0xLTEtNTk0NzA_886264a7-73e8-4821-a4eb-def415132a87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzYtOC0xLTEtNTk0NzA_1aa78c44-bc09-43b6-b9ed-7624f5ee2de2">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzYtMTAtMS0xLTU5NDcw_8b0ed7d3-87bf-4105-8283-ad3ae3f9f49a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzYtMTItMS0xLTU5NDcw_9554efc2-bc22-49f7-aff5-9789c3762fba">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzYtMTQtMS0xLTU5NDcw_7490f279-6323-46ab-bfaa-fe8127b987d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzYtMTYtMS0xLTU5NDcw_6731a474-35e0-41e9-998c-a1a90a609114">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzYtMTgtMS0xLTU5NDcw_bb8c05ee-b147-45a2-b28a-8a12c2e7cab7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzctMi0xLTEtNTk0NzA_f75b6227-0e0a-46c2-92a4-04dae3ea8bae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzctNC0xLTEtNTk0NzA_2023f2bc-3ab6-419c-9db5-c16f28de0244">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzctNi0xLTEtNTk0NzA_a25e7897-80a0-4670-af9f-0937424c7c09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzctOC0xLTEtNTk0NzA_15c5df9f-b49b-401f-a652-e7de04a843d7">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzctMTAtMS0xLTU5NDcw_8d318c0f-4e36-4a0f-ae19-1e9657d4186e">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzctMTItMS0xLTU5NDcw_d5deb22d-0425-449f-97d2-ef1ff2323b34">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzctMTQtMS0xLTU5NDcw_b31566f4-d425-4eb9-a48a-eac5089f7441">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzctMTYtMS0xLTU5NDcw_d4f08876-7647-4b9e-8c72-9438f429d2d4">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzctMTgtMS0xLTU5NDcw_25b08293-bff8-42ba-9bfa-5ebc4ee4fd62">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement loss recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMi0xLTEtNzc1OTM_8863a4a4-e69e-4b0c-8355-91100cf40fe2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtNC0xLTEtNzc1OTM_d9c30efc-71c6-4b4d-bac2-95a3cdf616cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtNi0xLTEtNzc1OTM_a6d8e23c-8b22-4080-a2fa-b0e33be9cf57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtOC0xLTEtNzc1OTM_f16ebe3f-5401-4e71-9655-c86ae106cc6c">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMTAtMS0xLTc3NTkz_b44618c0-1db5-47f9-a8f3-f8dfbc6c7471">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMTItMS0xLTc3NTkz_17d1d9b1-07a2-4af1-b11c-209119745c32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMTQtMS0xLTc3NTkz_a9e91955-98b5-44ee-a044-0e9a76fff02b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMTYtMS0xLTc3NTkz_6d054d9d-fb38-4e27-b4db-7a9802b2a4e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMTgtMS0xLTc3NTkz_f1c909af-6899-4a11-b29f-b1471ced0a87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMi0xLTEtNTk0NzA_81df4a84-3668-48f2-b605-b12b2992d210">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtNC0xLTEtNTk0NzA_3ebfa1b2-9631-4200-b3e3-4d42cd91e45d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtNi0xLTEtNTk0NzA_1b0edf11-aafa-4359-82fc-c19b772fba45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtOC0xLTEtNTk0NzA_731ba59d-f0dd-4e4e-8666-af1c9d85cdc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMTAtMS0xLTU5NDcw_85aa7af0-44d9-4ee1-831c-411d460701d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMTItMS0xLTU5NDcw_36661b53-e195-4b31-a340-dff29c138167">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMTQtMS0xLTU5NDcw_222f64d5-039f-4ccf-9eec-5442fcb094a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMTYtMS0xLTU5NDcw_be7654cc-94f2-4946-812b-3027b724b39c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMTgtMS0xLTU5NDcw_b2192d95-d2d8-4831-8aea-bce849dba51a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzktMi0xLTEtNTk0NzA_cda6e800-fe05-49df-a6ba-c3a86903f0da">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzktNC0xLTEtNTk0NzA_c5daacbc-3194-4879-984e-880f586cf84a">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzktNi0xLTEtNTk0NzA_651e1c72-47ef-4a92-86f7-435fcf57383f">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzktOC0xLTEtNTk0NzA_cd5f7d8e-4bbc-4312-ad03-3c1ef44a3f6a">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzktMTAtMS0xLTU5NDcw_00ba29d5-4249-4a7e-8357-4d72e7568b8a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzktMTItMS0xLTU5NDcw_b5a222b6-8a5b-425c-a84f-76f43f7a5209">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzktMTQtMS0xLTU5NDcw_e57b10ea-5a3d-4e35-bf9b-6bcf2e0c19b7">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzktMTYtMS0xLTU5NDcw_1f53729d-281c-4fe0-b4a8-fe370c889428">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzktMTgtMS0xLTU5NDcw_6a32e544-ef9a-4e0d-a181-e71ba243d01b">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><span><br/></span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ib9cc1d1324f54a24a4321385a9a19aa0" continuedAt="i711ac8dd0b8e414fac9929972ee81b64"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Benefit Obligation, Change in Plan Assets and Funded Status </span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4Xzg5Njk_97c2111a-f7ef-473a-b214-e3023afe8af8" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents components of the change in projected benefit obligation, change in plan assets and funded status for 2021 and 2020: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:40.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.025%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Projected Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzQtMi0xLTEtNTk0NzA_4df359df-11bd-41de-9cbd-8079687dc3ef">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bd0b15dbe944220bf785415eda57379_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzQtNC0xLTEtNTk0NzA_6faa9679-8be5-40e8-8004-525b0b17aa52">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzQtNi0xLTEtNTk0NzA_173832b0-96f4-45d7-9b3d-09e3cefd8380">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc6bf90ba6048c081b87a24157c36a0_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzQtOC0xLTEtNTk0NzA_b75d4f6e-d821-4bcd-807a-3f8082c9e51d">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzQtMTAtMS0xLTU5NDcw_c5a2a69c-d365-4565-99bc-47d2d960fb84">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibee8e4ebafb4425eb4bfad3cad142065_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzQtMTItMS0xLTU5NDcw_2b07200c-fd92-4b31-b345-f0b29e00d06c">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzUtMi0xLTEtNTk0NzA_41690c87-887e-4cb9-afff-ea4749013fba">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzUtNC0xLTEtNTk0NzA_e47ad52e-b968-4c9d-a137-decd4d2f598e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzUtNi0xLTEtNTk0NzA_53c9397f-a7a8-47cc-b388-a24b02e945c2">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzUtOC0xLTEtNTk0NzA_81f66fc0-989c-4358-ab2a-daab66180ede">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzUtMTAtMS0xLTU5NDcw_0ec36c80-2a76-4182-91ff-eb82cedb27db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzUtMTItMS0xLTU5NDcw_62198903-7ccf-466e-bf0b-716e72f4b3b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzYtMi0xLTEtNTk0NzA_9229509c-c01b-4f89-9782-08c08a7451d4">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzYtNC0xLTEtNTk0NzA_9e0b19be-bbd1-4e1d-bb7b-66996c4353f5">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzYtNi0xLTEtNTk0NzA_47a5043f-0f88-4abc-84a8-901191c671f2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzYtOC0xLTEtNTk0NzA_0f0574c3-bc78-4bc1-a498-801a2b438e83">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzYtMTAtMS0xLTU5NDcw_9ab21aa4-2dcf-47f5-bfd4-01474cd3b34e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzYtMTItMS0xLTU5NDcw_9cd5200f-b7ac-4b19-a75e-74fc9c51f27e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzgtMi0xLTEtNTk0NzA_49b5a922-1865-4f74-bac7-aa7d261de3f3">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzgtNC0xLTEtNTk0NzA_6c01aa5a-e106-49c2-8177-efa2015d97cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzgtNi0xLTEtNTk0NzA_d7524c2e-6c66-4239-814f-063c7faf9d43">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzgtOC0xLTEtNTk0NzA_f5ddef27-8cab-4b8f-ab8a-e0733af033bd">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzgtMTAtMS0xLTU5NDcw_b3d45f42-ee23-40b3-9797-c72bf947ca3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzgtMTItMS0xLTU5NDcw_81966920-fab5-43ec-a888-c7e168e22857">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzktMi0xLTEtNTk0NzA_06fac70d-9abb-4ded-b575-d5b3a2e4b3fa">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzktNC0xLTEtNTk0NzA_322d360c-1976-4c1d-95c6-ed25a459dbb2">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzktNi0xLTEtNTk0NzA_c2a81639-9900-41e7-8dec-847821726240">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzktOC0xLTEtNTk0NzA_9c6fa23d-615f-4471-9b95-63c2820f7c67">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzktMTAtMS0xLTU5NDcw_785858cf-04de-46f8-941b-7c573d6abe55">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzktMTItMS0xLTU5NDcw_8a5f2927-7fa4-4e8f-bb68-da35faef01b0">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial (gain) losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEwLTItMS0xLTU5NDcw_8c2b41a3-1c78-42c3-99d5-2ad81a755976">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEwLTQtMS0xLTU5NDcw_980561d9-501c-4124-8291-cc27c302289b">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEwLTYtMS0xLTU5NDcw_71c682d6-cf88-4ad4-892b-a18206947b36">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEwLTgtMS0xLTU5NDcw_7def058c-8e0a-4034-b93d-e75d0d1551c7">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEwLTEwLTEtMS01OTQ3MA_e40bc1cd-d700-4f35-821f-1b567cdef368">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEwLTEyLTEtMS01OTQ3MA_c2b9c1be-b794-4130-9b4e-4d427f476051">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzExLTItMS0xLTU5NDcw_20a462c5-39f1-45c3-b54e-11d1a298e2f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzExLTQtMS0xLTU5NDcw_99d56205-5280-4905-9011-4ab9c7675b19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzExLTYtMS0xLTU5NDcw_030d6a76-2bfe-42e6-a269-4134a3b6db38">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzExLTgtMS0xLTU5NDcw_5a95135d-ab42-419c-9c63-5e54652dfe5f">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzExLTEwLTEtMS01OTQ3MA_70467004-4722-4591-bb3c-1f5e1356a07f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzExLTEyLTEtMS01OTQ3MA_0365973a-0008-427a-98f9-87182a890c36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEyLTItMS0xLTU5NDcw_6e826c8d-ca8e-4c2a-9b21-035704b3af8d">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEyLTQtMS0xLTU5NDcw_b7efad03-31a8-4e3e-b527-49acb8922a6f">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id639a041f43545ba9cbf52ed62530656_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEyLTYtMS0xLTU5NDcw_553017cc-3173-4839-b6c4-7aaafb16c3e2">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEyLTgtMS0xLTU5NDcw_aca45836-a697-4246-bc00-d674b2e91a72">294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEyLTEwLTEtMS01OTQ3MA_2f5579e6-d1f7-4544-8470-23dce55d708f">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEyLTEyLTEtMS01OTQ3MA_1f1cc5d5-2ed4-465f-a42e-5edaa896cc40">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE1LTItMS0xLTU5NDcw_829f14b6-b4e9-4684-9def-828572b97683">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bd0b15dbe944220bf785415eda57379_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE1LTQtMS0xLTU5NDcw_c3473ae4-7306-4966-8241-5fd6e39f00b1">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE1LTYtMS0xLTU5NDcw_b2ee8838-17fe-4ab0-bfeb-4b355c805fd5">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc6bf90ba6048c081b87a24157c36a0_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE1LTgtMS0xLTU5NDcw_65666ede-6b75-4dd2-bb3d-3bfd5d880e5e">161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE1LTEwLTEtMS01OTQ3MA_f1cd86a4-91fa-460f-8bf8-2cab2a308722">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibee8e4ebafb4425eb4bfad3cad142065_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE1LTEyLTEtMS01OTQ3MA_0d19606b-acfc-469a-aa0c-6fead57620b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE2LTItMS0xLTU5NDcw_4c167260-2669-4a30-8308-0d12f107bab6">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE2LTQtMS0xLTU5NDcw_db417db9-8a57-4aea-af20-adbc60a17ce8">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE2LTYtMS0xLTU5NDcw_22a7dfc9-4a10-46ae-8910-5040e28a2d6e">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE2LTgtMS0xLTU5NDcw_ca84e658-c9b0-4359-946b-483fdf5fcf75">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE2LTEwLTEtMS01OTQ3MA_a0e2a846-d7db-4a27-bc36-84fe77bc504b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE2LTEyLTEtMS01OTQ3MA_d0e7bbbb-be82-47d4-afd6-905aee59033c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE4LTItMS0xLTU5NDcw_1563540b-00ee-40ce-843d-d5bd86503f50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE4LTQtMS0xLTU5NDcw_cf33361c-f5bd-4dff-989c-e95dfc926649">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE4LTYtMS0xLTU5NDcw_8c3ca9b0-fbee-4a77-b554-2f7b4242af6f">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE4LTgtMS0xLTU5NDcw_e39e55b0-67df-4bb7-a203-486e87ce959a">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE4LTEwLTEtMS01OTQ3MA_dbd06404-2e6b-443f-82dd-09e4eff5119d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE4LTEyLTEtMS01OTQ3MA_83a2a0bb-e742-41ee-ad85-9ce486d809c2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE5LTItMS0xLTU5NDcw_5c63cb12-4052-4008-b903-65205b7e2bbc">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE5LTQtMS0xLTU5NDcw_44e88708-4417-4e9e-9ea0-4527cfe0ca4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE5LTYtMS0xLTU5NDcw_1d056dbf-3e36-4c39-afdc-d4ecf1c5898c">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE5LTgtMS0xLTU5NDcw_1d3e2010-12ce-4cc0-8089-b0f92836cd5d">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE5LTEwLTEtMS01OTQ3MA_73c0eb89-4652-498a-a851-aaa80a5d98fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE5LTEyLTEtMS01OTQ3MA_b1075059-70a3-4003-b1ba-be0f9e55bd81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIwLTItMS0xLTU5NDcw_2e4e0a11-2e10-4d47-a926-01a8a806501f">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIwLTQtMS0xLTU5NDcw_6379738b-fb4c-4ac5-8a67-daff61b1dc6d">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIwLTYtMS0xLTU5NDcw_57458aea-2634-41d3-909e-37fbb3c01b2c">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIwLTgtMS0xLTU5NDcw_9d79fcf3-3194-4846-8d32-930f7fc0faf8">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIwLTEwLTEtMS01OTQ3MA_90ed1478-2f07-4bf4-b1d8-d51862e97a6c">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIwLTEyLTEtMS01OTQ3MA_c091239c-6f2b-42f2-ab6c-0f56a9e502ba">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIxLTItMS0xLTU5NDcw_34b59f2d-18e1-4e76-a9be-9e140849e530">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIxLTQtMS0xLTU5NDcw_9d45ac5f-34aa-4d85-8442-fecd63ed7219">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIxLTYtMS0xLTU5NDcw_5b61f5c1-faa8-495c-ba76-7f8d13928827">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIxLTgtMS0xLTU5NDcw_f31eb5a4-9133-4f47-baaf-a375d47fb45c">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIxLTEwLTEtMS01OTQ3MA_0316bc24-66c3-4cd9-b3c7-c6670fb42fe6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIxLTEyLTEtMS01OTQ3MA_35fd2aa1-7c5e-4647-9f9a-93b6f2a18d88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIyLTItMS0xLTU5NDcw_93842cdf-60ad-4747-b5ff-bd1927d1175b">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIyLTQtMS0xLTU5NDcw_3788c1f6-cfcb-4a84-ba96-303c629dd09e">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id639a041f43545ba9cbf52ed62530656_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIyLTYtMS0xLTU5NDcw_fadb5f57-0960-486b-9fb8-fa57da7716ec">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIyLTgtMS0xLTU5NDcw_e16a1122-9fb0-448d-bdf3-e819a7df7a98">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIyLTEwLTEtMS01OTQ3MA_37ddcb8b-c40b-48d3-9f19-83768bce0bda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIyLTEyLTEtMS01OTQ3MA_25ccf006-2d17-4385-92e5-9355f649af8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded status, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIzLTItMS0xLTU5NDcw_7430366f-5c9e-420c-8f5f-0b523fcec07b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIzLTQtMS0xLTU5NDcw_711d19af-3b63-4f9d-af8f-2514a3701c6a">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id639a041f43545ba9cbf52ed62530656_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIzLTYtMS0xLTU5NDcw_1cd01bc0-8b2f-4188-b3c0-cfdfb38a3079">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIzLTgtMS0xLTU5NDcw_33775aa5-32a9-48b1-8894-1f9459b01196">105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIzLTEwLTEtMS01OTQ3MA_2ad9203f-292c-483c-bd79-08a696deaa56">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIzLTEyLTEtMS01OTQ3MA_f79ae0b9-7fa8-4a10-a137-646a963cb934">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231" decimals="-6" name="bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTItMS0xLTc3NjAz_97b83166-93d5-492b-b64a-2d067500e55e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231" decimals="-6" name="bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTQtMS0xLTc3NjAz_fa635a65-63ec-4aba-ab9a-45cb16dfab3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id639a041f43545ba9cbf52ed62530656_I20211231" decimals="-6" name="bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTYtMS0xLTc3NjAz_b7dc5821-b7b5-4ec1-83e8-753c428dfaf6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231" decimals="-6" name="bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTgtMS0xLTc3NjAz_0688e91e-5c60-4b20-9376-bbda8d9ad47b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231" decimals="-6" name="bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTEwLTEtMS03NzYwMw_7793ed68-4429-44bb-b0d7-26c96ca65a26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231" decimals="-6" name="bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTEyLTEtMS03NzYwMw_323a19a9-1f67-4606-a519-1ddf29416593">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231" decimals="-6" name="bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTItMS0xLTU5NDcw_7384b117-f9ac-4d87-80c1-8e3dbef862b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231" decimals="-6" name="bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTQtMS0xLTU5NDcw_3807a509-eb84-414c-9b40-9022057ab730">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id639a041f43545ba9cbf52ed62530656_I20211231" decimals="-6" name="bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTYtMS0xLTU5NDcw_24b7c075-2868-4a5b-8830-1cfe31b8b699">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231" decimals="-6" name="bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTgtMS0xLTU5NDcw_8019283f-2c98-4b34-b972-43d2fdd9bfe5">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231" decimals="-6" name="bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTEwLTEtMS01OTQ3MA_93404a61-ce77-4758-8c04-8e8ad101f9c7">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231" decimals="-6" name="bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTEyLTEtMS01OTQ3MA_8789e274-bf98-4f77-bd4e-2dba7bbb9f60">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI3LTItMS0xLTU5NDcw_fd1b3d2d-17df-4366-a793-dd5b583f0063">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI3LTQtMS0xLTU5NDcw_dc2d57b7-3045-4081-96ae-f87a888291fb">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id639a041f43545ba9cbf52ed62530656_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI3LTYtMS0xLTU5NDcw_5ebf476f-c7b4-4bc4-bed2-ebf8a4102812">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI3LTgtMS0xLTU5NDcw_f7f670dd-0d6d-49c1-87fb-95a0e9abc24f">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI3LTEwLTEtMS01OTQ3MA_1b5c5c48-94a5-430c-ba08-c26724bcf577">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI3LTEyLTEtMS01OTQ3MA_b62c4e71-bdef-4615-af47-58c5b3819e9e">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Settlement loss recognized and Settlements in the tables above are the costs and payments associated with the conversion of a portion of the Company&#8217;s defined benefit plan in Ireland to a defined contribution plan during the fourth quarter of 2021.</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of the Company&#8217;s pension benefit plans were underfunded as of December 31, 2021 and 2020, having accumulated benefit obligations exceeding the fair value of plan assets. There were <ix:nonFraction unitRef="usd" contextRef="ic5c96e30d644464397808c237e9a5ddf_I20211231" decimals="INF" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzEwOTk1MTE2MzkxMTM_17459893-8ed3-4b1d-82fd-d23fcddf29b2">no</ix:nonFraction> U.S. pension benefit plans that were underfunded as of December 31, 2021, having accumulated benefit obligations exceeding the fair value of plan assets. <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4Xzg5ODY_838a15b2-d826-4420-88f2-4f99b4733b14" continuedAt="i25eb4557c9d54987b6bc40f21d79194f" escape="true">Information for the underfunded pension benefit plans is as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><ix:continuation id="i25eb4557c9d54987b6bc40f21d79194f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:56.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.971%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5c96e30d644464397808c237e9a5ddf_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzItMi0xLTEtNTk0NzA_9f3755e5-e213-48b7-aaa1-e82dafeb903a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248cf8d382ab417d8f08aa7bb5b3c1ed_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzItNC0xLTEtNTk0NzA_97e6b630-1f08-4e67-92db-34ca2bb59e9f">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id639a041f43545ba9cbf52ed62530656_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzItNi0xLTEtNTk0NzA_553017cc-3173-4839-b6c4-7aaafb16c3e2">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c408d4a08264cae9f329fddd9849fcb_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzItOC0xLTEtNTk0NzA_3cfcbda8-5196-4861-a85b-2b08f507f738">294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5c96e30d644464397808c237e9a5ddf_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzMtMi0xLTEtNTk0NzA_bf368771-2e4f-41a1-ac91-d6d616668e5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248cf8d382ab417d8f08aa7bb5b3c1ed_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzMtNC0xLTEtNTk0NzA_168fcd7d-3567-47bb-a975-006b199771a9">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d3dc1e9fc14ff2a726b48981e5c5f0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzMtNi0xLTEtNTk0NzA_ae71171b-dcb9-4396-a249-30609d913f40">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c408d4a08264cae9f329fddd9849fcb_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzMtOC0xLTEtNTk0NzA_5e7668b1-8f90-42fe-8646-b0b6b28ac140">286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5c96e30d644464397808c237e9a5ddf_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzQtMi0xLTEtNTk0NzA_27e2ffe6-bf36-4efd-8109-e3fcaec4ca96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248cf8d382ab417d8f08aa7bb5b3c1ed_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzQtNC0xLTEtNTk0NzA_47aa67ba-e781-442d-ae98-e57866f50566">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id639a041f43545ba9cbf52ed62530656_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzQtNi0xLTEtNTk0NzA_fadb5f57-0960-486b-9fb8-fa57da7716ec">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c408d4a08264cae9f329fddd9849fcb_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzQtOC0xLTEtNTk0NzA_4f200fe2-6335-4555-b1fa-f3b27f269ddb">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy for funding its pension benefit plans is to make contributions that meet or exceed the minimum statutory funding requirements. These contributions are determined based upon recommendations made by the actuary under accepted actuarial principles. In 2022, the Company expects to contribute $<ix:nonFraction unitRef="usd" contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzM2MDM_d5e1ae47-5977-488e-b2c1-c484dee71853">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="id639a041f43545ba9cbf52ed62530656_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzM2MDc_b439ecc1-d05a-4900-8337-af957dbc14fb">9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzM2MTQ_32aaa960-2bc2-4482-8511-6815e59652f1">4</ix:nonFraction> million to the U.S. pension benefit plan, the non-U.S. pension benefit plans and the U.S. postretirement benefit plan, respectively. The Company plans to use postretirement benefit plan assets and cash on hand, as necessary, to fund the U.S. postretirement benefit plan benefit payments in 2022.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i711ac8dd0b8e414fac9929972ee81b64" continuedAt="i8dd2265031bb4e13b0cdb24eb3062397"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Benefit Payments</span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4Xzg5NTY_40884d44-4f97-4f50-b83e-47f5926e3741" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future benefit payments over the next <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="bhc:DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzM5NzU_ced26bb2-c59c-43c7-b843-ffa029e6543e">10</ix:nonNumeric> years for the pension benefit plans and the postretirement benefit plan, which reflect expected future service, as appropriate, are expected to be paid as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:54.219%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.430%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>&#160;Benefit<br/>&#160;Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzItMi0xLTEtNTk0NzA_63307245-ffc9-4373-9332-04ed3ef69c66">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id639a041f43545ba9cbf52ed62530656_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzItNC0xLTEtNTk0NzA_b0cfc299-c350-4385-ba95-76109144276e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzItNi0xLTEtNTk0NzA_f5dc74c4-5756-464d-99b5-ab73749d9a52">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzMtMi0xLTEtNTk0NzA_f8f0565d-f68c-4bbb-bff9-94839ada7b30">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id639a041f43545ba9cbf52ed62530656_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzMtNC0xLTEtNTk0NzA_f9f1aeed-736c-4cf8-99e6-72a8c87cf4d0">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzMtNi0xLTEtNTk0NzA_4cd036ae-3a12-4755-a236-cea122d21d42">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzQtMi0xLTEtNTk0NzA_7a9689b1-8475-4732-9962-d28343c1b63b">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id639a041f43545ba9cbf52ed62530656_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzQtNC0xLTEtNTk0NzA_c9f606ef-d9a1-40d2-91d8-01eb85574d73">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzQtNi0xLTEtNTk0NzA_2f1763dc-bace-4d0b-bc1e-55e3adf7a8f0">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzUtMi0xLTEtNTk0NzA_102a0770-5bd1-4409-b88a-e93d4d48906b">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id639a041f43545ba9cbf52ed62530656_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzUtNC0xLTEtNTk0NzA_75b78c37-7031-48e3-98ef-027e37e0d31d">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzUtNi0xLTEtNTk0NzA_6d93109a-7822-4a3e-a75b-63559ff8fb8d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzYtMi0xLTEtNTk0NzA_bee77b0a-cc2b-4cec-b312-9cdb95e12a7f">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id639a041f43545ba9cbf52ed62530656_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzYtNC0xLTEtNTk0NzA_99559ee2-7e5c-4106-9ee5-9c6393ae4c20">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzYtNi0xLTEtNTk0NzA_9830a205-4060-49d2-bc62-ba61e8110111">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzctMi0xLTEtNTk0NzA_d397ea42-2c67-4bb9-8562-fd51fc0a92e8">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id639a041f43545ba9cbf52ed62530656_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzctNC0xLTEtNTk0NzA_4c19ca14-76fa-4389-80d2-769fdac458f4">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzctNi0xLTEtNTk0NzA_e97d087d-2b34-4474-a470-e12e32a7fad3">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assumptions</span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4Xzg5OTE_f3069651-f66f-43cf-9731-9a20b7d1d555" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used to determine net periodic benefit costs and benefit obligations for 2021, 2020 and 2019 were as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:43.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.427%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement Benefit Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For Determining Net Periodic (Benefit) Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzQtMi0xLTEtNTk0NzA_738478c9-0184-4573-9088-d5ad41c728ae">2.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzQtNC0xLTEtNTk0NzA_898203ea-94bd-4980-bdf8-d7afc2e6258b">3.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzQtNi0xLTEtNTk0NzA_2c0d1950-d80e-4d15-a715-50ad707a378a">4.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzQtOC0xLTEtNTk0NzA_fa53cb3c-57e2-409e-8511-4e049119ec18">2.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzQtMTAtMS0xLTU5NDcw_c58d8113-9b3a-4d86-b087-8a9dbb457c8d">3.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzQtMTItMS0xLTU5NDcw_75416455-9e1a-49ed-a7da-26db85bed5e8">4.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzUtMi0xLTEtNTk0NzA_7ef91c1d-4e09-45ff-87b9-53956ac170c9">5.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzUtNC0xLTEtNTk0NzA_f4018ee7-9c50-4b76-9687-411778f4c93e">6.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzUtNi0xLTEtNTk0NzA_ce1a3d73-06f0-4f49-b465-c177f6b31599">7.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzUtOC0xLTEtNTk0NzA_d77b1afc-e2aa-46a3-b4e0-b09575ef5c58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzUtMTAtMS0xLTU5NDcw_a59ac0fe-b2af-4260-8812-a80fa1af1f59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzUtMTItMS0xLTU5NDcw_93caba06-3a96-4a55-b8a4-709eb3469094">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzYtMi0xLTEtNTk0NzA_774197d1-01ad-4779-8139-79c50e1a3bc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzYtNC0xLTEtNTk0NzA_15a016e2-6001-4d80-849d-4c4c018b7298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzYtNi0xLTEtNTk0NzA_16b8936d-81e7-45bb-929b-fce5021914e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzYtOC0xLTEtNTk0NzA_8b2370b9-b3e8-4ca2-a215-c022b1af1862">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzYtMTAtMS0xLTU5NDcw_d4b89a1c-e2d8-447f-ada8-d7f4d1880b22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzYtMTItMS0xLTU5NDcw_9830792e-27f0-4361-9e10-eb16fbe0db7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzctMi0xLTEtNTk0NzA_0a3160e2-9bc0-465e-998b-b76e4730675c">4.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzctNC0xLTEtNTk0NzA_327d25f7-c854-4bcd-96d3-510c075d6eb2">4.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzctNi0xLTEtNTk0NzA_0ea85d2f-b8e1-4fa3-bbdc-8c9221132460">5.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzktMi0xLTEtNTk0NzA_3c699416-d882-4008-99df-2b851d058b30">1.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzktNC0xLTEtNTk0NzA_0479b6af-467b-4db1-a7cd-a016fda4540d">1.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzktNi0xLTEtNTk0NzA_dcc931b1-d90a-42af-b4e8-52c0a5040316">2.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzEwLTItMS0xLTU5NDcw_c45ac8ea-a811-47c7-b7d9-2897e57e9262">2.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzEwLTQtMS0xLTU5NDcw_8cdde867-6751-4ac0-84e8-a4ab09cd6f84">2.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzEwLTYtMS0xLTU5NDcw_8d9cf2df-489a-4ab1-b84e-540c1b2b0916">3.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzExLTItMS0xLTU5NDcw_dc9a8eff-21a9-4ae7-87b9-cbd4eb3deaa2">2.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzExLTQtMS0xLTU5NDcw_270415cd-61fc-4c0f-a434-b74babd1dc67">3.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzExLTYtMS0xLTU5NDcw_8a0f450e-2166-440b-8d7a-f0cd2dbd7b5d">2.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzEyLTItMS0xLTU5NDcw_fdd1ee44-9008-4387-abe0-1e6433abf8a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzEyLTQtMS0xLTU5NDcw_cd732232-477f-42aa-b02a-df3b2febf3a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzEyLTYtMS0xLTU5NDcw_dd268eb2-c5e0-491f-a4dd-5d9d0959cfc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:55.197%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.073%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement Benefit Plan</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For Determining Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzUtMi0xLTEtNTk0NzA_1387c06b-8733-48c5-9f54-1ae8f9a3dad4">2.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzUtNC0xLTEtNTk0NzA_7b545c3d-a4ce-4cac-87a4-cb6b445344fc">2.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzUtNi0xLTEtNTk0NzA_fea2eedc-02ca-47d5-be5b-bc6890ba6827">2.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzUtOC0xLTEtNTk0NzA_b1098777-cf57-4795-9847-34b352d35254">2.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzYtMi0xLTEtNTk0NzA_de9e2a13-3439-4bd2-bc8b-db482088d526">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzYtNC0xLTEtNTk0NzA_f4e32c39-9d26-4f0b-8357-799383dd6dc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzYtNi0xLTEtNTk0NzA_d9c0b1a0-2784-4bb5-9234-3af137682638">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzYtOC0xLTEtNTk0NzA_b5e29e6d-aee3-49de-853e-17608896ae01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzctMi0xLTEtNTk0NzA_9ec02bb8-5faf-4a36-bbda-8ee04de999b3">4.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzctNC0xLTEtNTk0NzA_ce57ace5-e882-4dec-ba13-80bb04bc67bf">4.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id639a041f43545ba9cbf52ed62530656_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzktMi0xLTEtNTk0NzA_b6afbf1b-f28d-428d-b853-4dd8f3fd60db">1.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzktNC0xLTEtNTk0NzA_e181bca9-195e-4865-9162-65462c46132b">1.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id639a041f43545ba9cbf52ed62530656_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzEwLTItMS0xLTU5NDcw_226b4288-446b-4f85-935a-767e8ba33568">2.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzEwLTQtMS0xLTU5NDcw_ad819247-b6e9-4295-979a-2aad6c0aa409">2.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id639a041f43545ba9cbf52ed62530656_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzExLTItMS0xLTU5NDcw_c3d7e09f-5d89-4612-9cdd-b605eacba70a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzExLTQtMS0xLTU5NDcw_474f1b02-5b42-4ee6-9c4f-0267db788afe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected long-term rate of return on plan assets was developed based on a capital markets model that uses expected asset class returns, variance and correlation assumptions. The expected asset class returns were developed starting with current Treasury (for the U.S. pension plan) or Eurozone (for the Ireland pension plans) government yields and then adding corporate bond spreads and equity risk premiums to develop the return expectations for each asset class. The expected asset class returns are forward-looking. The variance and correlation assumptions are also forward-looking. They take into account historical relationships, but are adjusted to reflect expected capital market trends. The expected return on plan assets for the Company&#8217;s U.S. pension plan for 2021 was <ix:nonFraction unitRef="number" contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzUwNjU_7ef91c1d-4e09-45ff-87b9-53956ac170c9">5.00</ix:nonFraction>%. The expected return on plan assets for the Company&#8217;s Ireland pension plans was <ix:nonFraction unitRef="number" contextRef="ie074f53bc69745fba66921f6f8d38556_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzUxNDg_911450fd-f9bc-4d66-a262-84e5d6eccd51">2.75</ix:nonFraction>% for 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i8dd2265031bb4e13b0cdb24eb3062397" continuedAt="ie174e9e95d27435da35802f0896a6a2f"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate used to determine benefit obligations represents the current rate at which the benefit plan liabilities could be effectively settled considering the timing of expected payments for plan participants.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 expected rate of return for the U.S. pension benefit plan will be <ix:nonFraction unitRef="number" contextRef="i56153b69689b4ecd9dcf4887ed60d362_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzU0NTE_1019cae8-8884-488e-ad0d-57080b5b0723">4.50</ix:nonFraction>%. The 2022 expected rate of return for the Ireland pension benefit plans will be <ix:nonFraction unitRef="number" contextRef="i4a02dcf2c684493ca47da42ad5f0a86a_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzU1MzI_45f881ea-8d06-47bc-9405-c1e8c82a48f6">2.75</ix:nonFraction>%. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pension Benefit Plans Assets             </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pension benefit plan assets are invested in several asset categories. <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4Xzg5NjY_20a67e39-7215-4fa0-9193-80f1c0121673" continuedAt="i9ed54a393a0446cd9a306fcbdbe810dd" escape="true">The following presents the actual asset allocation as of December 31, 2021 and 2020:</ix:nonNumeric></span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><ix:continuation id="i9ed54a393a0446cd9a306fcbdbe810dd"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:77.048%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib55cc79a8c5047d8ab1633dbce4cad44_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzItMi0xLTEtNTk0NzA_c328a415-40e2-4a0c-a9ae-149719e82904">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia693d6a4e0b14b4c931965ccf754e1f7_I20201231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzItNC0xLTEtNTk0NzA_d6b26ebd-9641-4e50-9049-c8dda0e80d2a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d7991a8fa0d4d8795903d4ae61c5a6d_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzMtMi0xLTEtNTk0NzA_05c2c606-5ee0-4160-bab2-e5727905bc0c">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d7c434502ca4f2a8223f3e89683dd28_I20201231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzMtNC0xLTEtNTk0NzA_cc352c17-a2a0-43f7-a48e-8376c40221a1">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0b1fe039d84a45ce8e43d1c4c89b07d2_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzQtMi0xLTEtNTk0NzA_11b7ae11-8d16-4453-b3b0-6bbf11f29efb">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id453d2c511534fe6837d77baaee83805_I20201231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzQtNC0xLTEtNTk0NzA_3a7f34a5-3dfb-40a1-89a8-a366aeb17f8d">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6251e5f5fad7409b9187da5b1b34bf8f_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzYtMi0xLTEtNTk0NzA_eeb2c2f0-184d-4f13-b096-d570348b422f">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2a81a3caa7c94785bd723c5136f85945_I20201231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzYtNC0xLTEtNTk0NzA_1e4e4648-3c34-4f30-8c08-4bf6035a7a29">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic2aa787db2bd488381cd79f25f35617b_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzctMi0xLTEtNTk0NzA_1dadb905-3c58-4cbf-bab2-eaf255c8393f">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaade5d5b17e942f2976fa0e0eaced2a3_I20201231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzctNC0xLTEtNTk0NzA_d7b95789-6bf8-4fc2-9cf1-56e979357c31">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2cfeb6a24e7c459aa69b339c9936b980_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzgtMi0xLTEtNTk0NzA_45831da4-b91c-41e5-b0b5-fa866a2544c7">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if07c85a851d7490689bc9a5740104746_I20201231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzgtNC0xLTEtNTk0NzA_05113a39-32a0-48a3-b5c9-e082680f9178">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60ef3defb63b42d8b564f10aef937998_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzktMi0xLTEtNTk0NzA_f0c13bf3-ea31-4b14-9746-76ad3b65ba6c">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3ff1e276f1334094b7e8280d216bb2a6_I20201231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzktNC0xLTEtNTk0NzA_80a44677-d9cf-4c82-b270-12e86080521b">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investment strategy underlying pension plan asset allocation is to manage the assets of the plan to provide for the non-current liabilities while maintaining sufficient liquidity to pay current benefits. Pension plan assets are diversified to protect against large investment losses and to reduce the probability of excessive performance volatility. Diversification of assets is achieved by allocating funds to various asset classes and investment styles within asset classes, and retaining investment management firm(s) with complementary investment philosophies, styles and approaches.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s pension plan assets are managed by outside investment managers using a total return investment approach, whereby a mix of equity and debt securities investments are used to maximize the long-term rate of return on plan assets. A significant portion of the assets of the U.S. and Ireland pension plans have been invested in equity securities, as equity portfolios have historically provided higher returns than debt and other asset classes over extended time horizons. Correspondingly, equity investments also entail greater risks than other investments. Equity risks are balanced by investing a significant portion of plan assets in broadly diversified fixed income securities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Plan Assets </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measured the fair value of plan assets based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. See Note 5, "FAIR VALUE MEASUREMENTS" for details on the Company's fair value measurements based on a three-tier hierarchy.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ie174e9e95d27435da35802f0896a6a2f"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="bhc:ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4Xzg5Njc_7ffa05ce-6a61-4be7-b865-fa911f5fc240" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents total plan assets by investment category as of December 31, 2021 and 2020 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value. There were no transfers between Level 1 and Level 2 during 2021 and 2020.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans - U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7af55aa092e044f2afb3019b380424df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzMtMi0xLTEtNTk0NzA_d520a60e-b4da-4519-b2f6-5c8c43ee8844">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d47b1547ba49eaaf8b343286177935_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzMtNC0xLTEtNTk0NzA_1ddb3cf4-2599-4190-9a10-3d1f33107f84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c916f8745844151b90043b27bfda10b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzMtNi0xLTEtNTk0NzA_a6f1a1f1-154f-4ac3-81ff-12b01eb93df7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccba448cf4a7430c9ab615c9c0db387c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzMtOC0xLTEtNTk0NzA_ec611da8-4164-4faa-9f9c-00f3750f5e50">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09e4c0369ab74b7aa42c2ca4a081d665_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzMtMTAtMS0xLTU5NDcw_a6fa0ea9-67cf-4fb3-9c72-2fbc738c9c04">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe5828d7ce648ba9901225e5f602ffb_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzMtMTItMS0xLTU5NDcw_bb800c0c-38b9-4ed9-8e59-80ff29da8169">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac45d6fc735f4300950257942f7987c7_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzMtMTQtMS0xLTU5NDcw_c9e2f92d-29e0-48fc-9ce1-ba6f9c3d6faf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6efe3bfe1b43539fd5441f3e8f1178_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzMtMTYtMS0xLTU5NDcw_51f70b4e-978d-4d10-8893-18116344a960">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. broad market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie17c1b0a784541d7991bb6af8b757d2b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzYtMi0xLTEtNTk0NzA_6de6f88c-3373-4c33-9cf9-1b951aa2b055">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37dcc11c7224eca84dc480d56dc32ce_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzYtNC0xLTEtNTk0NzA_8474371e-15c3-4228-9fa9-8d1d7c703fea">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d00d230e384e1793aa975171d11afd_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzYtNi0xLTEtNTk0NzA_2a34f240-53cd-4bc8-8d04-42103aa37ac8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d2c3cb6c7374e28bf785a1101c1a131_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzYtOC0xLTEtNTk0NzA_d385d02f-6bf0-4d99-8e2f-ad38f72a044a">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc9f1c3ceea44453b7dfa2a13ac987b7_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzYtMTAtMS0xLTU5NDcw_3abf97e2-70a9-4381-89f1-733ef8db8f67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied1ceb27c69740139dfd77de2155225e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzYtMTItMS0xLTU5NDcw_054f8f1b-4a46-4054-a224-687051cf5a16">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e21dc226144b94ac36444dcece2004_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzYtMTQtMS0xLTU5NDcw_31833739-a465-4cf1-a3eb-236051cacae3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e447011ef7645a89efe64052f877da1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzYtMTYtMS0xLTU5NDcw_c2956e45-f1da-4110-86c5-fc96796debde">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fbe7d9aaa8d48bcbb80294df7a9cd60_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzctMi0xLTEtNTk0NzA_ddaab733-d584-4b98-8807-4cd6a86e92c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a224828a4841bd8e05d44a229d645f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzctNC0xLTEtNTk0NzA_ce71df3c-d30c-4408-a588-0640f6d51765">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a5608d76644fca3792b79c6260a38_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzctNi0xLTEtNTk0NzA_eea63d56-bb6b-4c06-9d00-f469520eec0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f6f0decf1a440db6a8df7e4d1cd9c1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzctOC0xLTEtNTk0NzA_353d9afb-7719-48c7-9cc0-d7aede4f6761">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie614ee2bbc0d41c3937648c0eb4fb366_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzctMTAtMS0xLTU5NDcw_541380db-d4e6-4209-982e-f1cd5fadcf33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a50fd29ab6c4a72809e44c2f372bdd8_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzctMTItMS0xLTU5NDcw_6ebb33a1-5ddc-489b-9562-01bbcc09594e">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib98051f977524d43b7bba256f7160a84_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzctMTQtMS0xLTU5NDcw_fbb0b9de-e714-4b78-87cb-efebd7a41546">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf30f7d75c6344fc9a13de058b489364_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzctMTYtMS0xLTU5NDcw_3fb213b0-db6e-4a78-8c33-45eb4b7e3d87">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide developed markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7365a02480094a778087f003e4453b09_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzgtMi0xLTEtNTk0NzA_f8574885-07ae-4596-87c0-914a415ef638">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11eb673cbf1d4f7d84ac5c9df99a3ef2_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzgtNC0xLTEtNTk0NzA_ffd9355e-ed10-4bcb-9a9e-732e4ff062ef">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a9521608704153b9eb100ac78f0ce3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzgtNi0xLTEtNTk0NzA_bc939608-48b5-4d9b-8ec4-ddb7e3ca2c44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i809b25b2066b40bf96408dc9e0b225c2_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzgtOC0xLTEtNTk0NzA_6dfdbe33-0b85-4344-99cf-9b9d6e397b77">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d36468c5de494abc6015ee26da8e73_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzgtMTAtMS0xLTU5NDcw_5813e766-17cc-44b5-b0bb-c3acb1d524fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dcfebc863894026b3ca1af655064a00_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzgtMTItMS0xLTU5NDcw_ab6393fb-1dab-4898-9fc3-228d7e9eb18c">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i560db68718d54136a8a45bfb702d5324_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzgtMTQtMS0xLTU5NDcw_43c279ae-82a6-487a-91f2-ae00baef188e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e987a4f1b54c88bcbcc12fa7abfb69_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzgtMTYtMS0xLTU5NDcw_c6f2fb62-e81c-402a-9c58-0fe2edb0df84">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ed7839b2a04f0fbeb5dce55d268189_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzktMi0xLTEtNTk0NzA_d17eef4f-a3a3-4570-8ffb-cee6fe3c1534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91dfeedfb92b4828a4722c9f88fa1872_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzktNC0xLTEtNTk0NzA_65500f51-55de-4a63-af26-e3ea0cea3311">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1825b75f97004bc184282968848c0a52_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzktNi0xLTEtNTk0NzA_498711bc-72dd-43ce-ab6f-2d84903d6339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6242900f15f3401ebaac9f8a3c1b6339_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzktOC0xLTEtNTk0NzA_0738ed1a-2643-4b9c-994a-57368cda2862">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63b875eacbc446a887982c5d1115d3ee_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzktMTAtMS0xLTU5NDcw_b8f1f4d8-5154-4c51-9241-0b611908ffa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9a62d35ed944986ad939c9b014c654d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzktMTItMS0xLTU5NDcw_d257c8e6-62b3-4136-90cb-55bd9ffda69e">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92434c9334a54511bdec1d46d8213f3b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzktMTQtMS0xLTU5NDcw_6344a02a-5b3b-4ab4-8c0f-ee3f921a593d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcc360791b434eac863d82daef575b6d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzktMTYtMS0xLTU5NDcw_b7295c26-9fd6-4eb9-a465-dd4ca62b24ec">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba6ac8d86f64c9385ab1aa7f0d2c220_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzExLTItMS0xLTU5NDcw_20e88e54-b86f-4f7d-9867-63b8cce0e855">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0c5d97b9ab244b69b17a46f19cca258_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzExLTQtMS0xLTU5NDcw_8e696adc-1f6e-4a73-8509-88048233f922">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8b0dc0501c84cac862c7828cee33fd6_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzExLTYtMS0xLTU5NDcw_7171fc94-854b-48db-a49f-b9a3c8eb98a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42c6f916e85b4a7cb01549ad02518fd8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzExLTgtMS0xLTU5NDcw_aa93f96b-48e8-4a6e-82de-4e693b4e5937">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c12e56dc0f345abb7ab14eb2eb546b2_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzExLTEwLTEtMS01OTQ3MA_7884c0e4-582c-41fe-aae8-c9c08bc90473">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id35cd34eedeb4695bfa8ad28f7c073d1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzExLTEyLTEtMS01OTQ3MA_1815f372-88c5-409e-9f7f-9540e8cb2b9d">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b90dc62606b4697b1fff595e063dce5_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzExLTE0LTEtMS01OTQ3MA_8b525786-6eaa-4a62-9054-f9a3a2d816cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c488d1b1a9b41baa5ddb7387a75b0ef_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzExLTE2LTEtMS01OTQ3MA_58ddb1fa-19b1-45f7-ae59-e0e5ac12313d">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida118aeda14146be9fa07183a8d43611_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzEyLTItMS0xLTU5NDcw_3bd810f7-5c76-42c8-982e-c98b403c7f81">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7404c4a64514d8cba0117dde2032747_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzEyLTQtMS0xLTU5NDcw_507954f5-f1a6-49a0-82e8-1e3e61d835f8">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bab925ad83349bfae08cdc351f392a2_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzEyLTYtMS0xLTU5NDcw_3bc37ef1-ecf2-422b-aa84-8ec4c178b654">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ccc52c4ecc49e78eee3d33e2c113fa_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzEyLTgtMS0xLTU5NDcw_648d3bec-a465-4953-8883-25bcf1bbbb7d">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie92a115bae124a91960ec41c0727d1a8_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzEyLTEwLTEtMS01OTQ3MA_675edb47-2676-4590-a4b5-0ffe02424f88">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3925adeb07427b9b35df22f7082c71_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzEyLTEyLTEtMS01OTQ3MA_cbe6cfa5-f742-462b-b154-c74c00f9ad5e">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6623925ca56e4d96a7ec9b93e614a8f7_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzEyLTE0LTEtMS01OTQ3MA_8181faef-2765-4c30-a624-1225c0ca0276">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib69b353fbcad4f2ea129c8b8af2024fd_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzEyLTE2LTEtMS01OTQ3MA_42f26377-e7f8-4d02-acac-11ba450d50a6">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:31.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans - Non-U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dc8df13fb424c888d592fddbc492642_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzMtMi0xLTEtNTk0NzA_a5002f9f-c5e7-4f23-a094-8715d8640a74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c7b88b7a1da425584d296d8cfb61e31_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzMtNC0xLTEtNTk0NzA_fca90840-44a8-4499-8ffd-9661c2188f05">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85953604b0f4454d8293d1577ad37660_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzMtNi0xLTEtNTk0NzA_8bebf003-3495-4f99-a720-eab5c95b1326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e6fc7cd989419aaac17aab91d819e2_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzMtOC0xLTEtNTk0NzA_b95bf46d-7ee1-4c04-8c27-96cc178404d6">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if060c809f3ab42b79bb79a9e9119eb6c_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzMtMTAtMS0xLTU5NDcw_262d8928-90ec-4505-b7cd-3e3219036d4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b463b0ee361495cb1a35797490d8474_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzMtMTItMS0xLTU5NDcw_e0323806-9508-4e99-b193-a4b504c93a10">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc5b5fd1952143dbb4fc80c09e61d41e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzMtMTQtMS0xLTU5NDcw_f32e77ed-9f8f-47e2-923f-06492d1085a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ff8ba240c174921af7e5377f66435da_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzMtMTYtMS0xLTU5NDcw_c4e7a14d-0238-497e-9371-79680b457bae">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28879983df974e8dad3a100a9e2eaff5_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzYtMi0xLTEtNTk0NzA_6893e057-da18-4631-a524-c4729dfbd1c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia617fb33524a429f96a5f4d5de41e8d8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzYtNC0xLTEtNTk0NzA_205607d0-fbe2-4e66-98a6-e47771aa4093">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe1692fe13c46099cdb274aae8efa5b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzYtNi0xLTEtNTk0NzA_16671971-ab8a-4250-b86c-eff33c13f274">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b06c811115478cb20db99973ade215_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzYtOC0xLTEtNTk0NzA_edb9f527-c08d-4083-8dbb-5e6d0ac423b5">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2a552032894fa0a8dd1d7b70fbf7cb_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzYtMTAtMS0xLTU5NDcw_7b15142f-a014-4dd1-a171-0ab5afb36354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec30830375949738e95af67de6bf189_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzYtMTItMS0xLTU5NDcw_e4df9070-06c0-4be7-b97c-992eaf457ece">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0acdb587dc57405c8f51594ffdc58f35_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzYtMTQtMS0xLTU5NDcw_d25de54d-6264-41b6-8986-cee05913b3cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79b1763781234b4c91e295caf0806e96_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzYtMTYtMS0xLTU5NDcw_38ae7f7f-dab8-4245-b3f0-135ed8480d5d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide developed markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33703c137cd44896ad4cdeb30fcc6fae_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzctMi0xLTEtNTk0NzA_d8ef77e2-009a-4384-b7aa-19a4119ab259">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff30b4961b3a486991e363c44db17d42_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzctNC0xLTEtNTk0NzA_7714b687-137a-4599-bb25-241419ccf33f">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i669279a7238d4e8f9dd6fad058ea31b6_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzctNi0xLTEtNTk0NzA_4723eff0-eaed-425b-8468-068070b40fe7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i481468708dc74adc94731e7319c5a223_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzctOC0xLTEtNTk0NzA_775c59f0-6379-46b1-8f54-77c4d968c4d5">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84843ec87bf8430fbff7bd811a71310a_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzctMTAtMS0xLTU5NDcw_b89f6060-b4dc-479d-bf6e-649d7f4b03e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idca3abdd017446218f6e8960ca67c023_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzctMTItMS0xLTU5NDcw_36f5a088-9a1d-4b64-9a10-9d2759f88b29">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eb575ca4904425a87bec5e53f208d9d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzctMTQtMS0xLTU5NDcw_3d31cdad-6d54-477f-9b70-e0c7ec72730e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8fb3dc081ea41aab4e32f39084453f9_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzctMTYtMS0xLTU5NDcw_9ca29dce-2ea0-4a34-8019-095e63c6a2c7">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41e1bb53e0784950afc27fa187a27c3f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzktMi0xLTEtNTk0NzA_5b3e174b-dd16-4fb2-b182-7915e64ca7a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc5e2d60ba7148dcba54ff5384e23249_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzktNC0xLTEtNTk0NzA_d2498d36-1dfb-4dce-b00e-a5d0f9b4c18d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bef888f50664043863fbf4ec22eb918_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzktNi0xLTEtNTk0NzA_d8c5d4c3-a8a5-4d95-a215-97e2a4e18970">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d117480a68f41e29692f8e1120299c5_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzktOC0xLTEtNTk0NzA_5c76c789-12a6-473e-99ca-326996d53ba6">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764e7dd8c6e242209ab1812391a46ead_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzktMTAtMS0xLTU5NDcw_fcf42964-eb47-4162-8328-2e78b06f881a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03b4ac56aab644b3a3663f4a78369a13_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzktMTItMS0xLTU5NDcw_b3c754d8-039c-483f-afe2-1136dc345f59">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i612036dfd9af4751b039c09d33e2ca46_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzktMTQtMS0xLTU5NDcw_afc4c5fc-36cd-415e-92c3-120ff175b742">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9647f9aaa0af4927aa97fab7f6dce46d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzktMTYtMS0xLTU5NDcw_f4fcb943-641f-4f85-8be7-34761ae17c43">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global high yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc934bb3b7764915937b42332edc108a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEwLTItMS0xLTU5NDcw_7a9a8758-2c4e-43af-a2a3-4059608d9bdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie670eb0132ba453db0ccfc9534e8a176_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEwLTQtMS0xLTU5NDcw_29e61c00-d7da-4c40-8a04-51fbfe065cf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i846b3df052964b86bab155c36ffa8b7d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEwLTYtMS0xLTU5NDcw_2bd026d0-ef18-4ad1-993e-a7b3e14b09f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08181df0b76a4b1db12c4d01da570d5e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEwLTgtMS0xLTU5NDcw_dccac2cb-25ac-4419-baae-46b518ed4be2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd4a088a9d1a4225a9b940802b6651dd_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEwLTEwLTEtMS01OTQ3MA_de8406ef-eae5-4400-b6a7-cf90b8d7b62b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dd5dc3a71fc44a288385275d334a636_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEwLTEyLTEtMS01OTQ3MA_e01ca2c3-55f0-4501-b78f-346fddc0c333">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i773f8c6eb5314348bd0df5d5f8554717_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEwLTE0LTEtMS01OTQ3MA_5cd8a88c-3c57-4661-aa08-ea2d0f346a2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f89c2da51442cf966a159f442d7040_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEwLTE2LTEtMS01OTQ3MA_3fce531d-f48d-40c0-a457-44d72ece010c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government bond funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a942b6a477e44ee80469bf00455c69b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzExLTItMS0xLTU5NDcw_426214e7-00dc-45d6-a55d-b70cb0c81412">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie62be2fe885843928cc89e9a7ae8bb78_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzExLTQtMS0xLTU5NDcw_24629669-8171-48e1-b2ea-64e7b9b48b80">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d72936706da4a49a0b60284da13fe0a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzExLTYtMS0xLTU5NDcw_372b9dfd-ca8c-4868-aa7c-1e170c76029a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2b78164753e4fb69cb995913ce9a5be_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzExLTgtMS0xLTU5NDcw_87476516-072a-40fa-89ca-6a1bbd8e8249">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824c5e86c03e4a0389aa5c6cab684353_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzExLTEwLTEtMS01OTQ3MA_1d8f573f-2db5-451f-8bda-205398bd713d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i019d538cf2df4702927d2feaebb08210_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzExLTEyLTEtMS01OTQ3MA_bc0ccf53-0830-4059-93be-74fb246b24d7">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42f1505ab33d4d31b29170cf387d3bf1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzExLTE0LTEtMS01OTQ3MA_90667eb1-dbcf-4ed5-a930-0dbb0b1ed172">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f2d6658f8c6432eb855fc35c09bc8ae_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzExLTE2LTEtMS01OTQ3MA_ecc1c905-920b-4373-92e1-374c6c9ac67e">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb966e248dd4e7db899e8be25bcb6ae_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEyLTItMS0xLTU5NDcw_de2c406e-3b03-4676-a272-ffa69e290729">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e6548e2528e46dca40d1b1d09e39d12_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEyLTQtMS0xLTU5NDcw_74ba133d-3bca-44a4-87b8-d8c1dc0cc2aa">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3190fba7ebb5479dbb06445d6267911d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEyLTYtMS0xLTU5NDcw_da0e979f-7cca-4794-95a9-1bca83ad2cbb">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib72d3400eb8c419bb79a2b659524d6d2_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEyLTgtMS0xLTU5NDcw_9397aacf-1cee-483b-94fa-51a66bf70e72">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8afa60e604994497a1986db946c1937d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEyLTEwLTEtMS01OTQ3MA_b59b9ce4-326e-4b24-b6e2-4a5a0537d4ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ff0e3d8fc3e4f288ffcf7c081bebc05_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEyLTEyLTEtMS01OTQ3MA_e23013be-954e-4cf1-8e97-619ec5c8cefb">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbb8aacab7664f5b8279284fc6149b67_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEyLTE0LTEtMS01OTQ3MA_5f15a184-1aff-41e5-8fd2-2e34a779685b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3103a0933124d62871e5fc29bf546fa_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEyLTE2LTEtMS01OTQ3MA_3b170c32-7d08-4c69-b3fe-70af95d12fba">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e058ef986de49f0bea67e87231e73b4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEzLTItMS0xLTU5NDcw_2d70c44b-d79d-4499-b4e8-2cff124c8522">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if09958cb78f94a76a7e6f17b2bab67df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEzLTQtMS0xLTU5NDcw_1d20fea6-1dab-4ea3-b899-9509b3251fe7">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d964dd1784d4ad8bd4443d448886eef_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEzLTYtMS0xLTU5NDcw_b720257f-ac58-4a3f-b301-b0a22b18ff95">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb4dc2559a83406c8a242c061666e6c3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEzLTgtMS0xLTU5NDcw_0b7dac81-d251-41de-bdc5-f8a85962c7e4">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc69c8ac45694ba2b20fb0ff3a7f39f9_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEzLTEwLTEtMS01OTQ3MA_edf04fbc-5d9c-4abc-872b-7552c7ccee05">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe61ce2f0b3946ca8976584ee83df12b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEzLTEyLTEtMS01OTQ3MA_7ddd3922-7c65-4087-a69a-5856cf6bb2f0">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i299b97ed33754f6b8c3da5c29c47a1f6_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEzLTE0LTEtMS01OTQ3MA_ca6c6c0b-8c91-4a86-8e98-a7231a264fdb">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5a69340ce945b7a60bf0ed0babc543_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEzLTE2LTEtMS01OTQ3MA_a17aff74-2d38-4d33-841d-80efed57368e">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consisted primarily of term deposits and money market instruments. The fair value of the term deposits approximates their carrying amounts due to their short term maturities. The money market instruments also have short maturities and are valued using a market approach based on the quoted market prices of identical instruments. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commingled funds are not publicly traded. The underlying assets in these funds are publicly traded on the exchanges and have readily available price quotes. The Ireland pension plans held approximately <ix:nonFraction unitRef="number" contextRef="ie074f53bc69745fba66921f6f8d38556_D20210101-20211231" decimals="2" name="bhc:DefinedBenefitPlanPercentageAllocationofFund" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzgxNjU_b7ec1a3f-8cc0-468d-87bd-f75c2455ba99">95</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ie44d119215b549a88ce037813b5be0de_D20200101-20201231" decimals="2" name="bhc:DefinedBenefitPlanPercentageAllocationofFund" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzgxNzI_1f42e7a1-bc40-4978-b28d-56f5fbb75614">96</ix:nonFraction>% of the non-U.S. commingled funds in 2021 and 2020, respectively. The commingled funds held by the U.S. and Ireland pension plans are primarily invested in index funds.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underlying assets in the fixed income funds are generally valued using the net asset value per fund share, which is derived using a market approach with inputs that include broker quotes, benchmark yields, base spreads and reported trades. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined Contribution Plans </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors defined contribution plans in the U.S., Ireland and certain other countries.&#160;Under these plans, employees are allowed to contribute a portion of their salaries to the plans, and the Company matches a portion of the employee contributions. The Company contributed $<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4Xzg4OTY_6f981577-75a1-4679-975d-8b42142a9d88">44</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4Xzg5MDA_2afdd7ce-10f8-45e4-8941-fde48bb1143f">43</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4Xzg5MDc_62a1f423-1972-4f50-b724-8bfd35f39a25">41</ix:nonFraction> million to these plans during the years ended December 31, 2021, 2020 and 2019, respectively.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-46</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_337"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzExMzI_981ab2be-e69c-4589-8372-9075a9e5490d" continuedAt="ie0b2a379c26748969563468e3b6a6eb6" escape="true">LEASES </ix:nonNumeric></span></div><ix:continuation id="ie0b2a379c26748969563468e3b6a6eb6"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="bhc:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzExMzM_2442ebdd-3f37-4e45-a733-2a62270fc1d2" escape="true"><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities associated with the Company's operating leases are included in the Consolidated Balance Sheet as of December 31, 2021 and 2020 as follows:</span></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:82.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets included in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzItMC0xLTEtNTk0NzA_aae53d6e-38d6-4bae-885a-a2f1102e63b7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzItMC0xLTEtNTk0NzA_efb2683f-68c5-4ec5-ba14-7adb1864ba2c">Other non-current assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzItMS0xLTEtNTk0NzA_17c628f3-83dd-4c0e-9020-5293c4671a40">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzItMy0xLTEtNTk0NzA_4a3348e6-b11e-4114-8ad6-e0ec5ebba064">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities included in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzQtMC0xLTEtNTk0NzA_43d158d1-ee05-4bae-a3d5-740a15d049b3"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzQtMC0xLTEtNTk0NzA_fa62fdb0-f620-4627-932e-a0cd84ebc336">Accrued and other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzQtMS0xLTEtNTk0NzA_6ecf07e8-6e20-4138-a2df-ef53af334921">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzQtMy0xLTEtNTk0NzA_2f4ef1c1-8306-4637-9417-be088e7ec9ab">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzUtMC0xLTEtNTk0NzA_5aae2037-0b31-4496-a31b-a0628ffc23c9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzUtMC0xLTEtNTk0NzA_fc2d7485-eeb6-4aa7-8f75-257ecb0d55a3">Other non-current liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzUtMS0xLTEtNTk0NzA_e8fac724-61c2-4b52-b3a6-e2ed61b8eba1">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzUtMy0xLTEtNTk0NzA_90c9947f-3bab-42c4-86bc-64d7a1a815dc">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzYtMS0xLTEtNTk0NzA_604284dc-e7b1-4c1e-97af-70e7b39629fd">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzYtMy0xLTEtNTk0NzA_95c3e7ef-a627-45ef-87bc-d62b60a669b8">279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, 2020 and 2019 the Company's finance leases were <ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzIxMQ_2aeeeed8-5711-4001-b299-bf7de5b668d9"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:FinanceLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzIxMQ_569d32d4-c3fe-48fd-92e3-28469c374235"><ix:nonFraction unitRef="usd" contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231" decimals="-6" name="us-gaap:FinanceLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzIxMQ_f30b4f30-1893-4a83-9c15-c60ebcdcba03">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t material and for the years 2021, 2020 and 2019 sub-lease income and short-term lease expense were <ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzMwMw_0d22a40e-4c47-43f3-a7b9-55f3102d10a4"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:SubleaseIncome" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzMwMw_2995a5d4-bcb4-4c67-8f1f-d8a42591a7bf"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:SubleaseIncome" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzMwMw_59e38a2e-bff8-4e7c-a610-0f1a71066142"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzMwMw_7a18fdee-d0e1-4b54-9f13-928d6a2b60b2"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzMwMw_7c826464-d0c7-405e-84af-232da531b5c0"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:SubleaseIncome" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzMwMw_f18aa943-8f26-4a21-a9e5-1b196923bd12">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t material. <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzExMzQ_d64d05da-a776-4c24-a576-ca325db5e455" continuedAt="id6e96c652b924e6c84facf0d194994a8" escape="true">Lease expense for the years 2021, 2020 and 2019 include:</ix:nonNumeric></span></div><div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><ix:continuation id="id6e96c652b924e6c84facf0d194994a8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:70.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpiZjMwMTNjYzdiNzI0YWE5OWUwOGM4YTI0Y2NhODgwMS90YWJsZXJhbmdlOmJmMzAxM2NjN2I3MjRhYTk5ZTA4YzhhMjRjY2E4ODAxXzEtMS0xLTEtNTk0NzA_52163a3a-79e6-48a0-bc07-6f1ce2e68d8a">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpiZjMwMTNjYzdiNzI0YWE5OWUwOGM4YTI0Y2NhODgwMS90YWJsZXJhbmdlOmJmMzAxM2NjN2I3MjRhYTk5ZTA4YzhhMjRjY2E4ODAxXzEtMy0xLTEtNTk0NzA_38cdc9e1-d72d-44fc-bdde-d41352e0fde9">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpiZjMwMTNjYzdiNzI0YWE5OWUwOGM4YTI0Y2NhODgwMS90YWJsZXJhbmdlOmJmMzAxM2NjN2I3MjRhYTk5ZTA4YzhhMjRjY2E4ODAxXzEtNS0xLTEtNjg3MzI_b35c0497-55aa-444f-b588-9fd1ac4ccb33">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable operating lease costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpiZjMwMTNjYzdiNzI0YWE5OWUwOGM4YTI0Y2NhODgwMS90YWJsZXJhbmdlOmJmMzAxM2NjN2I3MjRhYTk5ZTA4YzhhMjRjY2E4ODAxXzItMS0xLTEtNTk0NzA_a3357fa9-1aad-487e-b5a3-24fff380a9d8">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpiZjMwMTNjYzdiNzI0YWE5OWUwOGM4YTI0Y2NhODgwMS90YWJsZXJhbmdlOmJmMzAxM2NjN2I3MjRhYTk5ZTA4YzhhMjRjY2E4ODAxXzItMy0xLTEtNTk0NzA_1216ad75-17ba-4479-8ba8-3f82be799020">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpiZjMwMTNjYzdiNzI0YWE5OWUwOGM4YTI0Y2NhODgwMS90YWJsZXJhbmdlOmJmMzAxM2NjN2I3MjRhYTk5ZTA4YzhhMjRjY2E4ODAxXzItNS0xLTEtNjg3MzI_b861fc85-0966-464d-96ec-001cf2f22334">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="bhc:AdditionalOperatingLeaseInformationLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzExMzU_831c9bfd-b2de-4548-ad29-fd0ebc4cccb6" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to operating leases for 2021, 2020 and 2019 is as follows:</span></div><div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:70.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid from operating cash flows for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzEtMS0xLTEtNTk0NzA_8df46e61-19f5-43d8-8706-4ab5a0ff4295">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzEtMy0xLTEtNTk0NzA_7dcac38b-8b2a-4a03-96cf-1021c0c086fd">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzEtNS0xLTEtNjg3NDE_e8b8fdde-bc18-4d36-ad6e-1ca73d899c5c">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzItMS0xLTEtNTk0NzA_aad8116a-f79f-4bec-9852-c036c98e41c7">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzItMy0xLTEtNTk0NzA_afb9363d-83c0-4a19-a23a-f85c179c2641">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzItNS0xLTEtNjg3NDE_0e0803ac-c314-4f9d-8108-811488e14baf">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzMtMS0xLTEtNTk0NzA_bcccefed-9301-4a22-a215-dd5c9333e6a3">7.2</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzMtMy0xLTEtNTk0NzA_663216cd-8022-431b-b40f-4a50edde8d21">7.6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzMtNS0xLTEtNjg3NDE_f6adfc9e-99e9-49a2-b0cb-20ae39969714">8.2</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzQtMS0xLTEtNTk0NzA_539a9319-e87b-49ed-b61b-d266c797fc10">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzQtMy0xLTEtNTk0NzA_20c8f916-1c11-4671-b6ec-0e51d8be18bc">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzQtNS0xLTEtNjg3NDE_176e9b71-4e08-4233-b8c9-317c9dee764d">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzExMzY_d871266b-1e91-4b0b-b825-c9821c01f7d1" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, future payments under noncancelable operating leases for each of the five succeeding years ending December 31 and thereafter are as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:91.594%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTphMDc4MzQwNzllOWE0MWNkYmVmZjZmNzA0MjFjMDYyYi90YWJsZXJhbmdlOmEwNzgzNDA3OWU5YTQxY2RiZWZmNmY3MDQyMWMwNjJiXzEtMi0xLTEtNTk0NzA_9ff66735-96e6-400c-ac0d-d19e7e9512df">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTphMDc4MzQwNzllOWE0MWNkYmVmZjZmNzA0MjFjMDYyYi90YWJsZXJhbmdlOmEwNzgzNDA3OWU5YTQxY2RiZWZmNmY3MDQyMWMwNjJiXzItMi0xLTEtNTk0NzA_293ef331-7a89-427a-be55-661d1237f411">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTphMDc4MzQwNzllOWE0MWNkYmVmZjZmNzA0MjFjMDYyYi90YWJsZXJhbmdlOmEwNzgzNDA3OWU5YTQxY2RiZWZmNmY3MDQyMWMwNjJiXzMtMi0xLTEtNTk0NzA_20a20485-1b37-467d-aa8c-37829c4f300d">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTphMDc4MzQwNzllOWE0MWNkYmVmZjZmNzA0MjFjMDYyYi90YWJsZXJhbmdlOmEwNzgzNDA3OWU5YTQxY2RiZWZmNmY3MDQyMWMwNjJiXzQtMi0xLTEtNTk0NzA_64d1bee5-4dd1-44dd-bdd6-9dc49ccdc584">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTphMDc4MzQwNzllOWE0MWNkYmVmZjZmNzA0MjFjMDYyYi90YWJsZXJhbmdlOmEwNzgzNDA3OWU5YTQxY2RiZWZmNmY3MDQyMWMwNjJiXzUtMi0xLTEtNTk0NzA_9d332061-03fe-4177-8e22-982d886d024c">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTphMDc4MzQwNzllOWE0MWNkYmVmZjZmNzA0MjFjMDYyYi90YWJsZXJhbmdlOmEwNzgzNDA3OWU5YTQxY2RiZWZmNmY3MDQyMWMwNjJiXzYtMi0xLTEtNTk0NzA_7823e16f-8afd-4d98-89fc-5526f99fc65f">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTphMDc4MzQwNzllOWE0MWNkYmVmZjZmNzA0MjFjMDYyYi90YWJsZXJhbmdlOmEwNzgzNDA3OWU5YTQxY2RiZWZmNmY3MDQyMWMwNjJiXzctMi0xLTEtNTk0NzA_3eafd3b0-2636-46e0-b2f3-53041e6e06a5">330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTphMDc4MzQwNzllOWE0MWNkYmVmZjZmNzA0MjFjMDYyYi90YWJsZXJhbmdlOmEwNzgzNDA3OWU5YTQxY2RiZWZmNmY3MDQyMWMwNjJiXzgtMi0xLTEtNTk0NzA_746d0a91-567c-4eb2-ad9a-9a26c238d47e">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of remaining lease payments</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTphMDc4MzQwNzllOWE0MWNkYmVmZjZmNzA0MjFjMDYyYi90YWJsZXJhbmdlOmEwNzgzNDA3OWU5YTQxY2RiZWZmNmY3MDQyMWMwNjJiXzktMi0xLTEtNTk0NzA_0655ef89-5ee7-4d73-a020-7c7776b60100">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTphMDc4MzQwNzllOWE0MWNkYmVmZjZmNzA0MjFjMDYyYi90YWJsZXJhbmdlOmEwNzgzNDA3OWU5YTQxY2RiZWZmNmY3MDQyMWMwNjJiXzEwLTItMS0xLTU5NDcw_70662587-2255-4c4a-b46b-7963a812266e">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTphMDc4MzQwNzllOWE0MWNkYmVmZjZmNzA0MjFjMDYyYi90YWJsZXJhbmdlOmEwNzgzNDA3OWU5YTQxY2RiZWZmNmY3MDQyMWMwNjJiXzExLTItMS0xLTU5NDcw_2f39dca8-35af-4735-b53f-319f0c70b550">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_340"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzExNzE0_e517fc3e-3f8d-4327-b61f-fd068b453bd7" continuedAt="i3a914d4ac9d6440380277eb5c0b8678d" escape="true">SHARE-BASED COMPENSATION</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3a914d4ac9d6440380277eb5c0b8678d" continuedAt="i3ac903ce96974b7d8ea8dc27d79b8d1d">In May 2014, shareholders approved the Company&#8217;s 2014 Omnibus Incentive Plan (the &#8220;2014 Plan&#8221;), which replaced the Company&#8217;s 2011 Omnibus Incentive Plan (the &#8220;2011 Plan&#8221;) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to <ix:nonFraction unitRef="shares" contextRef="i4ca155d300cf42a4b9cfdefca02c609b_I20140531" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzQyMg_4814d78b-caf8-48a4-aeb6-586a6732b821">18,000,000</ix:nonFraction> common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or </ix:continuation></span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i3ac903ce96974b7d8ea8dc27d79b8d1d" continuedAt="if63f83251f4f4e26a8fc36b13c4af962"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">surrendered under the 2011 Plan and the Company&#8217;s 2007 Equity Compensation Plan. The Company registered <ix:nonFraction unitRef="shares" contextRef="i4ca155d300cf42a4b9cfdefca02c609b_I20140531" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzc4Mg_c0e30c9e-2ad4-4722-81ff-dd519a7ded55">20,000,000</ix:nonFraction> common shares of common stock for issuance under the 2014 Plan.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 30, 2018, the Company amended and restated the 2014 Plan (the &#8220;Amended and Restated 2014 Plan&#8221;). The Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Amended and Restated 2014 Plan has been increased by an additional <ix:nonFraction unitRef="shares" contextRef="i4442a258b8f44219a1cd0070ea1406e8_D20180430-20180430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzExNjc_d11aec20-598f-4273-a315-3a39d141765b">11,900,000</ix:nonFraction> common shares, as approved by the requisite number of shareholders at the Company&#8217;s annual general meeting held on April 30, 2018, (ii) introduction of a $<ix:nonFraction unitRef="usd" contextRef="ibc1c3154bf0046c1b2667e6a53320931_D20180430-20180430" decimals="INF" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzEzMjQ_43d81480-1839-47ca-bc4a-e5ded22b0e28">750,000</ix:nonFraction> aggregate fair market value limit on awards (in either equity, cash or other compensation) that can be granted in any calendar year to a participant who is a non-employee director, (iii) housekeeping changes to address recent changes to Section 162(m) of the Internal Revenue Code, (iv) awards are expressly subject to the Company&#8217;s clawback policy and (v) awards not assumed or substituted in connection with a Change of Control (as defined in the Amended and Restated 2014 Plan) will only vest on a pro rata basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 28, 2020, the Company further amended and restated the Amended and Restated 2014 Plan (the &#8220;Further Amended and Restated 2014 Plan&#8221;). The Further Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Further Amended and Restated 2014 Plan has been increased by an additional <ix:nonFraction unitRef="shares" contextRef="id025575230534acb993dae92e7192d0c_D20200428-20200428" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzIyMTM_cfe1572d-59b4-47a0-97f2-a28fd216498e">13,500,000</ix:nonFraction> common shares, as approved by the requisite number of shareholders at the Company&#8217;s annual general meeting held on April 28, 2020, (ii) the exercise price of stock options and share appreciation rights (&#8220;SARs&#8221;) will be based on the closing price of the underlying common shares on the date such stock options or SARs are granted (rather than on the last preceding trading date), (iii)&#160;additional provisions clarifying that: (a)&#160;stock options and SARs will not be eligible for the payment of dividend or dividend equivalents and (b)&#160;the Talent and Compensation Committee of the Board of Directors of the Company cannot, without shareholder approval, seek to effect any repricing of any previously granted &#8220;underwater&#8221; stock option or SAR and (iv) other housekeeping and/or clerical changes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="shares" contextRef="i8265f2e72c9e451eb2bd2c997c00db7f_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzMwMjA_2a02541d-a659-4f43-8f68-7e0688f5a490">11,593,000</ix:nonFraction> common shares were available for future grants as of December&#160;31, 2021. The Company uses reserved and unissued common shares to satisfy its obligation under its share-based compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#8217;s focus on improving its tangible capital usage and allocation, while maintaining focus on improving total shareholder return over the long-term.  The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based RSUs and performance-based RSUs. Performance-based RSUs are comprised of: (i) awards that vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#8220;TSR&#8221;), (ii) awards that vest upon attainment of certain performance targets that are based on the Company&#8217;s return on tangible capital (&#8220;ROTC&#8221;) and (iii) vest fully or partially upon attainment of certain goals that are linked to the B+L Separation.</span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzExNzA1_22bc73bb-08f1-454c-b27c-12eba55afab5" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components and classification of share-based compensation expense related to stock options and&#160;RSUs for the years 2021, 2020 and 2019 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:67.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.934%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.934%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzEtMi0xLTEtNTk0NzA_bc3194d1-8d66-4e0b-9ead-982c4c62aa32">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i086597ed1e26464a806168f0ce38c359_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzEtNC0xLTEtNTk0NzA_934b418a-4646-491c-ae77-6f6b4cea05e0">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i846d952abe194e548203133638491e9c_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzEtNi0xLTEtNTk0NzA_9be291f9-972c-4e5c-8b40-283ce5213fd4">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2088dbf192f84b6e9cff9dc2cde381cf_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzItMi0xLTEtNTk0NzA_0bf7c747-3d78-4695-aa89-815eccf7998e">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie724079581044aa0811350b601ee9cc2_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzItNC0xLTEtNTk0NzA_f8031b73-4c24-4846-8504-d4967321de33">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2910d81cb0f045f7a33086454100489d_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzItNi0xLTEtNTk0NzA_fb6c20cd-c7a4-488a-aa01-d4e4a6f34fed">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzMtMi0xLTEtNTk0NzA_d36b51a6-eaf9-4d11-8ba8-b2b4548ea374">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzMtNC0xLTEtNTk0NzA_c56f68c2-0a62-4e99-baa2-46922fabd581">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzMtNi0xLTEtNTk0NzA_3e2cbb0c-5cc1-4549-9c23-9ee321233f2a">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79264328a7a543f1ac564306154bf1e7_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzUtMi0xLTEtNTk0NzA_c6259f55-f0b8-4b7d-83d3-8ef8baf81b7d">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a5a66d1f91043f8bc5742bb410551cc_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzUtNC0xLTEtNTk0NzA_ff286dfe-6b4d-4f70-8e99-27b4dd957c17">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i936812f8c65d495cb6b6f31769ebb66b_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzUtNi0xLTEtNTk0NzA_69eda6cf-22cc-49c9-9956-ea78d0e23420">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59d93d4490ae467d9a2415b38252c35b_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzYtMi0xLTEtNTk0NzA_e5885ac8-fb1a-4e66-bc7d-a0ae4ccd8e07">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc9346bc756a4ce3b7a716c303df449a_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzYtNC0xLTEtNTk0NzA_d8de1238-c7db-45dc-a19f-9c86b9306836">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87e1a3e05cd844d9a82820b7441ea2f3_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzYtNi0xLTEtNTk0NzA_5e8089ff-8a25-49c5-9ff8-953fe2ad3a85">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzctMi0xLTEtNTk0NzA_772cbe41-0f36-4034-a940-cc74a619b18b">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzctNC0xLTEtNTk0NzA_2881a122-dc9e-4c1f-9025-c0979905960a">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzctNi0xLTEtNTk0NzA_6cf7c800-8a31-4550-843d-c34a480e5da7">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted under the 2011 Plan and the Amended and Restated 2014 Plan generally expire on the fifth or tenth anniversary of the grant date. The exercise price of any stock option granted under the 2011 Plan and the Amended and Restated 2014 Plan will not be less than the closing price per common share on the date of grant. Stock options generally vest <ix:nonFraction unitRef="number" contextRef="i9eda91734bd9488387a03d3c1a80263c_D20210101-20211231" decimals="INF" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzQ0OTY_510812cf-0fb8-49ad-9b6f-b5f1d44ee6ad">33</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i9fa761390575444b8d5cf87f856db73c_D20210101-20211231" decimals="INF" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzQ1MDM_a237e5ce-71ed-4b25-8bf2-a5b3fae3153c">25</ix:nonFraction>% each year over a <ix:nonNumeric contextRef="i67ab1d6d98e348a2849edb9d66a71b5b_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzExNjg1_b69561a1-c90f-407f-921e-dbf31cf06118">three-year</ix:nonNumeric> and <ix:nonNumeric contextRef="iefcbe00a2f7e4f35ae1167fd771c00c1_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzExNjk0_2ac0b9d0-31f4-4947-85a8-b0cee162a8b0">four-year</ix:nonNumeric> period, respectively, on the anniversary of the date of&#160;grant.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="if63f83251f4f4e26a8fc36b13c4af962" continuedAt="id684179aa0674720963aa0ba0c3bc94f"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzExNzI2_d5be8d86-aee3-4c19-b22a-1af01505108c" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of all stock options granted for the years 2021, 2020 and 2019 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock option life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzEtMi0xLTEtNTk0NzA_9e3af595-ee80-484e-bace-71f2ea5e3847">3.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i086597ed1e26464a806168f0ce38c359_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzEtNC0xLTEtNTk0NzA_0c702593-8722-4d98-bc77-4012b9b86876">3.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i846d952abe194e548203133638491e9c_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzEtNi0xLTEtNTk0NzA_11e62480-cfcb-4b42-8cc8-496509e6b6ab">3.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzItMi0xLTEtNTk0NzA_b01ee338-66ec-4072-9a2a-663fc09349a0">50.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i086597ed1e26464a806168f0ce38c359_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzItNC0xLTEtNTk0NzA_c35cf9f4-4bfd-4c10-ad7a-12fba39beeab">38.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i846d952abe194e548203133638491e9c_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzItNi0xLTEtNTk0NzA_172b9133-c3c7-47ca-b4ac-0cc32342a844">46.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzMtMi0xLTEtNTk0NzA_81015d7f-a3a4-4202-8715-019079555be5">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i086597ed1e26464a806168f0ce38c359_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzMtNC0xLTEtNTk0NzA_28b63377-6510-4a99-9f8b-41e354aee9e0">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i846d952abe194e548203133638491e9c_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzMtNi0xLTEtNTk0NzA_c805a174-db6e-46b3-a437-76c200dad99a">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzQtMi0xLTEtNTk0NzA_44a99eae-26e4-4956-bbf3-7986f4541184">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i086597ed1e26464a806168f0ce38c359_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzQtNC0xLTEtNTk0NzA_73e51466-1172-45e3-b046-30896debe3f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i846d952abe194e548203133638491e9c_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzQtNi0xLTEtNTk0NzA_90b4cf95-41be-4220-9e03-14dfeb207f04">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected stock option life was determined based on historical exercise and forfeiture patterns. The expected volatility was determined based on implied volatility in the market traded options of the Company&#8217;s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S. government bonds with maturity dates equal to the expected life of the stock&#160;option. The expected dividend yield was determined based on the stock option&#8217;s exercise price and expected annual dividend rate at the time of&#160;grant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model used by the Company to calculate stock option values was developed to estimate the fair value of freely tradeable, fully transferable stock options without vesting restrictions, which significantly differ from the Company&#8217;s stock option awards. This model also requires highly subjective assumptions, including future stock price volatility and expected time until exercise, which greatly affect the calculated values.</span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzExNjg3_214519e0-b661-4a2b-a77a-2d232d8a8395" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during 2021: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:56.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.706%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January&#160;1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9615eb6151e4a2da212f24458fc78e6_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzEtMi0xLTEtNTk0NzA_e379a275-0901-44e0-8a6f-e722e6d98096">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id9615eb6151e4a2da212f24458fc78e6_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzEtNC0xLTEtNTk0NzA_a5c94b94-108a-4c6a-8908-c6120f498278">25.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzItMi0xLTEtNTk0NzA_e3179f3f-311d-4139-a6fb-888e9a76ce21">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzItNC0xLTEtNTk0NzA_0e496094-eaf1-4be2-a0f3-6ba0a7176608">32.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzMtMi0xLTEtNTk0NzA_801e2423-7c7e-4e8f-810e-ab63a3104e56">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzMtNC0xLTEtNTk0NzA_488c7d53-6363-4e42-b550-47572dfe765e">18.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired or forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzQtMi0xLTEtNTk0NzA_ad6af9ed-628a-4439-b782-8ce296ce4f5d">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzQtNC0xLTEtNTk0NzA_b48eb0a5-46db-4eb4-bda0-340201a33cc9">29.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibfe3a038368845f1a17357b6780d71ec_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzUtMi0xLTEtNTk0NzA_9b386a14-afd6-4272-a9a5-077d45b95c25">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibfe3a038368845f1a17357b6780d71ec_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzUtNC0xLTEtNTk0NzA_59b2b60b-7e5c-4685-aa02-657533f2d207">27.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzUtNi0xLTEtNTk0NzA_8e7bd3f4-7b26-415e-98e3-751f1b92e9ae">6.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfe3a038368845f1a17357b6780d71ec_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzUtOC0xLTEtNTk0NzA_a5e77d4f-beb1-41de-bbc4-de9161cce5ba">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibfe3a038368845f1a17357b6780d71ec_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzYtMi0xLTEtNTk0NzA_8ca6da8b-78ce-426b-bf5f-b1d817b67b63">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibfe3a038368845f1a17357b6780d71ec_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzYtNC0xLTEtNTk0NzA_9a65c328-253c-48c9-8dc9-a4f7dd6ed66a">27.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzYtNi0xLTEtNTk0NzA_1d5b1886-3f3f-4c2d-b75c-d266138d2af2">6.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfe3a038368845f1a17357b6780d71ec_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzYtOC0xLTEtNTk0NzA_2da54063-5a84-4589-a698-8d919ed02c15">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibfe3a038368845f1a17357b6780d71ec_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzctMi0xLTEtNTk0NzA_3132a2e8-9865-40b2-ad59-9b141927f76f">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibfe3a038368845f1a17357b6780d71ec_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzctNC0xLTEtNTk0NzA_1dc69ff8-680d-4bc5-bc19-a9041b8c940c">27.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzctNi0xLTEtNTk0NzA_a888353a-83fb-40ec-b4da-38c367cf84a9">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfe3a038368845f1a17357b6780d71ec_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzctOC0xLTEtNTk0NzA_928559ad-fef2-406b-9fb1-5cbd643d73e7">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair values of all stock options granted in 2021, 2020 and 2019 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzU5NzA_c6861271-8bdf-4658-8b2b-9d83949caea0">10.92</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i086597ed1e26464a806168f0ce38c359_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzU5NzQ_f781b5a7-fc71-4f5c-bd7c-d4e78a977f2b">6.60</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i846d952abe194e548203133638491e9c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzU5ODE_f2ce4276-f2ee-482f-8932-4392393e41df">8.45</ix:nonFraction>, respectively. The total intrinsic values of stock options exercised in 2021, 2020 and 2019 were $<ix:nonFraction unitRef="usd" contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzYwNjQ_1bfd4af0-9a5b-4abc-86ce-ba3cfe94c2b7">15</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i086597ed1e26464a806168f0ce38c359_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzYwNjg_d9c297e4-bc10-440a-af46-c292828c83bc">2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i846d952abe194e548203133638491e9c_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzYwNzU_5775a6fe-4146-428c-8f37-9880e11bc4ce">3</ix:nonFraction> million, respectively. Proceeds received on the exercise of stock options in 2021, 2020 and 2019 were $<ix:nonFraction unitRef="usd" contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzYxNTU_90578d4f-630d-4a33-a1a7-09ec195266f7">22</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i086597ed1e26464a806168f0ce38c359_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzYxNTk_4b1b9630-36df-492d-956d-704ac7ffd2ad">5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i846d952abe194e548203133638491e9c_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzYxNjY_e365ed66-bfe7-414e-8a7d-db3aa0389168">5</ix:nonFraction> million,&#160;respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the total remaining unrecognized compensation expense related to non-vested stock options amounted to $<ix:nonFraction unitRef="usd" contextRef="ibfe3a038368845f1a17357b6780d71ec_I20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzYyOTA_bc068ba1-fb45-481c-bf7a-3e8a7438256e">10</ix:nonFraction> million, which will be amortized over the weighted-average remaining requisite service period of approximately <ix:nonNumeric contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzYzOTY_e4729a43-4f9f-4cd6-8ec4-a99b9214a7a8">1.6</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years. The total fair value of stock options vested in 2021, 2020 and 2019 were $<ix:nonFraction unitRef="usd" contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231" decimals="-6" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzY0NjI_345cac1a-113c-4e9c-bbef-9a0baede1025">15</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i086597ed1e26464a806168f0ce38c359_D20200101-20201231" decimals="-6" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzY0NjY_1232d20b-8824-4eaa-bf19-0341849aa894">15</ix:nonFraction> million and&#160;$<ix:nonFraction unitRef="usd" contextRef="i846d952abe194e548203133638491e9c_D20190101-20191231" decimals="-6" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzY0NzM_fb5f54dd-06e9-405e-8172-0b8752328cc5">18</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs generally vest on the first or third anniversary date from the date of grant or <ix:nonFraction unitRef="number" contextRef="i2088dbf192f84b6e9cff9dc2cde381cf_D20210101-20211231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzY1ODE_cb77c758-0267-4d1d-8e70-fcf353624694">33</ix:nonFraction>% a year over a <ix:nonNumeric contextRef="i2088dbf192f84b6e9cff9dc2cde381cf_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzExNzI4_d7accada-5180-445d-8e67-43da76b4a53d">three-year</ix:nonNumeric> period. Annual RSUs granted to non-management directors vest immediately prior to the next Annual Meeting of Shareholders. Pursuant to the applicable unit agreement, certain RSUs may be subject to the attainment of any applicable performance goals specified by the Board of Directors. If the vesting of the RSUs is conditional upon the attainment of performance goals, any RSUs that do not vest as a result of a determination that the prescribed performance goals failed to be attained will be forfeited immediately upon such determination. RSUs are credited with dividend equivalents, in the form of additional RSUs, when dividends are paid on the Company&#8217;s common shares. Such additional RSUs will have the same vesting dates and will vest under the same terms as the RSUs in respect of which such additional RSUs are&#160;credited.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent provided for in a RSU agreement, the Company may, in lieu of all or a portion of the common shares which would otherwise be provided to a holder, elect to pay a cash amount equivalent to the market price of the Company&#8217;s </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="id684179aa0674720963aa0ba0c3bc94f" continuedAt="i50a000c3f9c1434e9b429fa60be44772"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common shares on the vesting date for each vested RSU. The amount of cash payment will be determined based on the average market price of the Company&#8217;s common shares on the vesting date. The Company&#8217;s current intent is to settle vested RSUs through the issuance of common&#160;shares.   </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Time-Based RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each vested time-based RSU represents the right of a holder to receive one of the Company&#8217;s common shares. The fair value of each RSU granted is estimated based on the trading price of the Company&#8217;s common shares on the date of&#160;grant.</span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzExNzEx_72eea2fb-6c67-4f1b-aba2-88c56d482ccf" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested time-based RSU activity during 2021: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:72.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Time-Based<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January&#160;1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12c733996b5f40c9abb282bf8d5d421b_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTphYjc2OTE1ZmU4Zjg0MjQ3OGQxZjk5MjE2ZjEzYzkxMC90YWJsZXJhbmdlOmFiNzY5MTVmZThmODQyNDc4ZDFmOTkyMTZmMTNjOTEwXzEtMi0xLTEtNTk0NzA_33741cde-4385-4061-8a4f-b666385dbacb">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i12c733996b5f40c9abb282bf8d5d421b_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTphYjc2OTE1ZmU4Zjg0MjQ3OGQxZjk5MjE2ZjEzYzkxMC90YWJsZXJhbmdlOmFiNzY5MTVmZThmODQyNDc4ZDFmOTkyMTZmMTNjOTEwXzEtNC0xLTEtNTk0NzA_eaa4289f-d934-4b41-93ef-38fbb168ad8a">21.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7042672dea544848ba094e3f7c68fe6_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTphYjc2OTE1ZmU4Zjg0MjQ3OGQxZjk5MjE2ZjEzYzkxMC90YWJsZXJhbmdlOmFiNzY5MTVmZThmODQyNDc4ZDFmOTkyMTZmMTNjOTEwXzItMi0xLTEtNTk0NzA_2e525327-c653-46a2-83dc-f72ba6cbb190">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic7042672dea544848ba094e3f7c68fe6_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTphYjc2OTE1ZmU4Zjg0MjQ3OGQxZjk5MjE2ZjEzYzkxMC90YWJsZXJhbmdlOmFiNzY5MTVmZThmODQyNDc4ZDFmOTkyMTZmMTNjOTEwXzItNC0xLTEtNTk0NzA_ed4c4683-5ee4-400f-8798-1f8d788770f1">31.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic7042672dea544848ba094e3f7c68fe6_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTphYjc2OTE1ZmU4Zjg0MjQ3OGQxZjk5MjE2ZjEzYzkxMC90YWJsZXJhbmdlOmFiNzY5MTVmZThmODQyNDc4ZDFmOTkyMTZmMTNjOTEwXzMtMi0xLTEtNTk0NzA_45b5d244-7f69-44fb-88cf-ebc0027c6578">3.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic7042672dea544848ba094e3f7c68fe6_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTphYjc2OTE1ZmU4Zjg0MjQ3OGQxZjk5MjE2ZjEzYzkxMC90YWJsZXJhbmdlOmFiNzY5MTVmZThmODQyNDc4ZDFmOTkyMTZmMTNjOTEwXzMtNC0xLTEtNTk0NzA_46bf3259-dfbf-446b-9606-ae607216ee27">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic7042672dea544848ba094e3f7c68fe6_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTphYjc2OTE1ZmU4Zjg0MjQ3OGQxZjk5MjE2ZjEzYzkxMC90YWJsZXJhbmdlOmFiNzY5MTVmZThmODQyNDc4ZDFmOTkyMTZmMTNjOTEwXzQtMi0xLTEtNTk0NzA_4ddb281a-146c-4750-a7ee-cb5b27a45d89">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic7042672dea544848ba094e3f7c68fe6_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTphYjc2OTE1ZmU4Zjg0MjQ3OGQxZjk5MjE2ZjEzYzkxMC90YWJsZXJhbmdlOmFiNzY5MTVmZThmODQyNDc4ZDFmOTkyMTZmMTNjOTEwXzQtNC0xLTEtNTk0NzA_637a2e38-dbd8-4157-bd8f-8de66f5790ce">26.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i911683c7210b422894ad8e3b68edeb77_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTphYjc2OTE1ZmU4Zjg0MjQ3OGQxZjk5MjE2ZjEzYzkxMC90YWJsZXJhbmdlOmFiNzY5MTVmZThmODQyNDc4ZDFmOTkyMTZmMTNjOTEwXzUtMi0xLTEtNTk0NzA_c774206f-d569-4962-b870-15eef710bd60">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i911683c7210b422894ad8e3b68edeb77_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTphYjc2OTE1ZmU4Zjg0MjQ3OGQxZjk5MjE2ZjEzYzkxMC90YWJsZXJhbmdlOmFiNzY5MTVmZThmODQyNDc4ZDFmOTkyMTZmMTNjOTEwXzUtNC0xLTEtNTk0NzA_a502b88e-4586-4644-a0ca-c516d4797843">28.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the total remaining unrecognized compensation expense related to non-vested time-based RSUs amounted to $<ix:nonFraction unitRef="usd" contextRef="i911683c7210b422894ad8e3b68edeb77_I20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzgzOTM_321ab743-d136-40c0-a127-4452e7cb27b8">68</ix:nonFraction> million, which will be amortized over the weighted-average remaining requisite service period of approximately <ix:nonNumeric contextRef="ic7042672dea544848ba094e3f7c68fe6_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzg0OTk_6a6a739a-32e1-4628-8d8e-aa8aac8f67fa">1.6</ix:nonNumeric> years. The total fair value of time-based RSUs vested in 2021, 2020 and 2019 were $<ix:nonFraction unitRef="usd" contextRef="ic7042672dea544848ba094e3f7c68fe6_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzg1Njc_15143fa5-18ef-4a9e-8089-742a5be08d39">69</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0393ab35e9cc4519bbfe3fe5df85b76b_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzg1NzE_c69d08b0-2028-4c8e-a7a0-257a8c3476b9">66</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1fe34facb9874ca79ea97f41a97eb1c8_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzg1Nzg_c861dea1-e24f-4d5f-8578-298a36725d06">34</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each vested performance-based RSU represents the right of a holder to receive a number of the Company&#8217;s common shares up to a specified maximum. Performance-based RSUs vest upon achievement of certain share price appreciation conditions or attainment of certain performance targets. If the Company&#8217;s performance is below a specified performance level, no common shares will be&#160;paid. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each TSR performance-based RSU granted during 2021, 2020 and 2019 was estimated using a Monte Carlo Simulation model, which utilizes multiple input variables to estimate the probability that the performance condition will be achieved.  The fair value of the ROTC performance-based RSUs is estimated based on the trading price of the Company&#8217;s common shares on the date of grant.  Expense recognized for the ROTC performance-based RSUs in each reporting period reflects the Company&#8217;s latest estimate of the number of ROTC performance-based RSUs that are expected to vest.  If the ROTC performance-based RSUs do not ultimately vest due to the ROTC targets not being met, no compensation expense is recognized and any previously recognized compensation expense is reversed. </span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="bhc:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzExNzE4_63785762-d7d6-4640-98d5-a3f70eba04c9" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of TSR performance-based RSUs granted during 2021, 2020 and 2019 were estimated with the following assumptions:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:58.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.727%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3e1cd89faa1647e69cd98100bc41a853_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTozNmE1NjkwNDFmZjQ0ZTQ3Yjc3M2FlMTRkYWMxOTkyMy90YWJsZXJhbmdlOjM2YTU2OTA0MWZmNDRlNDdiNzczYWUxNGRhYzE5OTIzXzEtMi0xLTEtNTk0NzA_61f12356-bd09-45e8-86c2-9ec8f4d8473d">3.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib899b174c8a5478689ab47ec6929522f_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTozNmE1NjkwNDFmZjQ0ZTQ3Yjc3M2FlMTRkYWMxOTkyMy90YWJsZXJhbmdlOjM2YTU2OTA0MWZmNDRlNDdiNzczYWUxNGRhYzE5OTIzXzEtNC0xLTEtNTk0NzA_683bdeef-1330-4aa2-adcf-8809616a35a9">3.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic56b5e163c6d4ad88d725a35418555aa_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTozNmE1NjkwNDFmZjQ0ZTQ3Yjc3M2FlMTRkYWMxOTkyMy90YWJsZXJhbmdlOjM2YTU2OTA0MWZmNDRlNDdiNzczYWUxNGRhYzE5OTIzXzEtNi0xLTEtNTk0NzA_4ecacba9-601a-44cb-924c-cb8169cde213">3.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected Company share volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e1cd89faa1647e69cd98100bc41a853_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTozNmE1NjkwNDFmZjQ0ZTQ3Yjc3M2FlMTRkYWMxOTkyMy90YWJsZXJhbmdlOjM2YTU2OTA0MWZmNDRlNDdiNzczYWUxNGRhYzE5OTIzXzItMi0xLTEtNTk0NzA_dbddc4a8-5b5f-4fdc-adb1-7622b114762a">52</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib899b174c8a5478689ab47ec6929522f_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTozNmE1NjkwNDFmZjQ0ZTQ3Yjc3M2FlMTRkYWMxOTkyMy90YWJsZXJhbmdlOjM2YTU2OTA0MWZmNDRlNDdiNzczYWUxNGRhYzE5OTIzXzItNC0xLTEtNTk0NzA_bbed43b9-7abf-4cf5-9a3c-39f34cfb85b6">38.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic56b5e163c6d4ad88d725a35418555aa_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTozNmE1NjkwNDFmZjQ0ZTQ3Yjc3M2FlMTRkYWMxOTkyMy90YWJsZXJhbmdlOjM2YTU2OTA0MWZmNDRlNDdiNzczYWUxNGRhYzE5OTIzXzItNi0xLTEtNTk0NzA_9e24525d-c382-48b8-87eb-ff553fcdb488">46.5</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e1cd89faa1647e69cd98100bc41a853_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTozNmE1NjkwNDFmZjQ0ZTQ3Yjc3M2FlMTRkYWMxOTkyMy90YWJsZXJhbmdlOjM2YTU2OTA0MWZmNDRlNDdiNzczYWUxNGRhYzE5OTIzXzMtMi0xLTEtNTk0NzA_b2a9ceea-ff23-49bf-bfca-f8a356eec555">0.4</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib899b174c8a5478689ab47ec6929522f_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTozNmE1NjkwNDFmZjQ0ZTQ3Yjc3M2FlMTRkYWMxOTkyMy90YWJsZXJhbmdlOjM2YTU2OTA0MWZmNDRlNDdiNzczYWUxNGRhYzE5OTIzXzMtNC0xLTEtNTk0NzA_00a12e18-0ebc-4af4-ae9e-c886f1ed74a9">1.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic56b5e163c6d4ad88d725a35418555aa_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTozNmE1NjkwNDFmZjQ0ZTQ3Yjc3M2FlMTRkYWMxOTkyMy90YWJsZXJhbmdlOjM2YTU2OTA0MWZmNDRlNDdiNzczYWUxNGRhYzE5OTIzXzMtNi0xLTEtNTk0NzA_ac760a62-3ebb-4693-9a73-f4bda1fbf6f7">2.5</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected company share volatility was determined based on implied volatility in the market traded options of the Company&#8217;s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S.&#160;government bonds with maturity dates equal to the contractual term of the performance-based&#160;RSUs.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i50a000c3f9c1434e9b429fa60be44772"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzExNjgy_25d59a27-d316-48e0-a9b2-b7ad1388368c" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested performance-based RSU activity during 2021: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:72.799%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.587%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance-based <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January&#160;1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i903f03ca7b0d4bec8b5dae3db9f4c7a1_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTowMzUyYmNiZDg4ZmQ0NWY0OGY5ODRiMDEyODEzODk0My90YWJsZXJhbmdlOjAzNTJiY2JkODhmZDQ1ZjQ4Zjk4NGIwMTI4MTM4OTQzXzEtMi0xLTEtNTk0NzA_2c348f7e-5ba3-4f41-9210-acc4589481c0">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i903f03ca7b0d4bec8b5dae3db9f4c7a1_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTowMzUyYmNiZDg4ZmQ0NWY0OGY5ODRiMDEyODEzODk0My90YWJsZXJhbmdlOjAzNTJiY2JkODhmZDQ1ZjQ4Zjk4NGIwMTI4MTM4OTQzXzEtNC0xLTEtNTk0NzA_34cb3d2f-9741-457e-a328-d17208d46779">28.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e1cd89faa1647e69cd98100bc41a853_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTowMzUyYmNiZDg4ZmQ0NWY0OGY5ODRiMDEyODEzODk0My90YWJsZXJhbmdlOjAzNTJiY2JkODhmZDQ1ZjQ4Zjk4NGIwMTI4MTM4OTQzXzItMi0xLTEtNTk0NzA_3754278e-57db-44a5-9618-1f2eab3029b9">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e1cd89faa1647e69cd98100bc41a853_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTowMzUyYmNiZDg4ZmQ0NWY0OGY5ODRiMDEyODEzODk0My90YWJsZXJhbmdlOjAzNTJiY2JkODhmZDQ1ZjQ4Zjk4NGIwMTI4MTM4OTQzXzItNC0xLTEtNTk0NzA_e5aba872-5a1f-4be9-bae2-9cefed8deb63">40.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3e1cd89faa1647e69cd98100bc41a853_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTowMzUyYmNiZDg4ZmQ0NWY0OGY5ODRiMDEyODEzODk0My90YWJsZXJhbmdlOjAzNTJiY2JkODhmZDQ1ZjQ4Zjk4NGIwMTI4MTM4OTQzXzMtMi0xLTEtNTk0NzA_8c452080-c5ea-4e24-842d-4d5cbf386ab8">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e1cd89faa1647e69cd98100bc41a853_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTowMzUyYmNiZDg4ZmQ0NWY0OGY5ODRiMDEyODEzODk0My90YWJsZXJhbmdlOjAzNTJiY2JkODhmZDQ1ZjQ4Zjk4NGIwMTI4MTM4OTQzXzMtNC0xLTEtNTk0NzA_da114f3c-6ed4-466c-a953-68f637668232">27.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iede5ac25cc2c49c797a46beb7f132efd_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTowMzUyYmNiZDg4ZmQ0NWY0OGY5ODRiMDEyODEzODk0My90YWJsZXJhbmdlOjAzNTJiY2JkODhmZDQ1ZjQ4Zjk4NGIwMTI4MTM4OTQzXzQtMi0xLTEtNTk0NzA_d9932890-9bd6-4528-93c4-8562f266c489">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iede5ac25cc2c49c797a46beb7f132efd_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTowMzUyYmNiZDg4ZmQ0NWY0OGY5ODRiMDEyODEzODk0My90YWJsZXJhbmdlOjAzNTJiY2JkODhmZDQ1ZjQ4Zjk4NGIwMTI4MTM4OTQzXzQtNC0xLTEtNTk0NzA_8b47c778-938a-467a-b46f-6e47a45a4d9b">33.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company granted approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3e1cd89faa1647e69cd98100bc41a853_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzEwMzg1_ea3641af-3e73-497b-b2fe-6b62b695cc6b">1,035,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance-based RSUs, consisting of approximately <ix:nonFraction unitRef="shares" contextRef="i36e8b2657c164c33a91c59ad739b895e_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzEwNDQw_ae799624-0413-4d60-b428-0b7908960703">400,000</ix:nonFraction> units of TSR performance-based RSUs with an average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i36e8b2657c164c33a91c59ad739b895e_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzEwNTIw_311055d9-e368-4fcc-ae47-cea6e668d0a7">56.04</ix:nonFraction> per RSU, approximately <ix:nonFraction unitRef="shares" contextRef="i272f0cc98d024849a92bb2d337033d5d_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzEwNTQ5_acf80ba3-8217-4fcf-9d3f-b5ea6eef5470">413,000</ix:nonFraction> units of ROTC performance-based RSUs with a weighted-average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i272f0cc98d024849a92bb2d337033d5d_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzEwNjM4_09241850-417f-4a25-8855-552cb293efea">31.72</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per RSU and approximately <ix:nonFraction unitRef="shares" contextRef="i789a736034674ddab3556f1ab2711032_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzEwOTk1MTE2NDEzOTg_9161749f-99a2-4435-a2ea-4a074fd21dfd">222,000</ix:nonFraction> of other performance-based RSU's with a weighted-average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i789a736034674ddab3556f1ab2711032_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzU0OTc1NTgxNTI0NTY_2257e060-dd20-4039-af59-7ae361344d7d">28.49</ix:nonFraction>. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the total remaining unrecognized compensation expense related to non-vested performance-based RSUs amounted to $<ix:nonFraction unitRef="usd" contextRef="iede5ac25cc2c49c797a46beb7f132efd_I20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzEwNzY2_82cac885-de5c-45bd-9523-2432cf27e8d3">32</ix:nonFraction> million, which will be amortized over the weighted-average remaining requisite service period of approximately <ix:nonNumeric contextRef="i3e1cd89faa1647e69cd98100bc41a853_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzEwODcy_9808fb1b-19e0-458e-b498-f57579911e51">1.7</ix:nonNumeric> years.  A maximum of approximately <ix:nonFraction unitRef="shares" contextRef="iede5ac25cc2c49c797a46beb7f132efd_I20211231" decimals="INF" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzEwOTEw_996983fc-c100-4e90-a916-3b8daf6952f2">3,476,000</ix:nonFraction> common shares could be issued upon vesting of the performance-based RSUs outstanding as of December 31, 2021.</span></div></ix:continuation><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_343"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDMvZnJhZzo1ZjdmMWNjODZlNDU0M2I0YTg1ZDI5MGNhMTBmZjU3Yi90ZXh0cmVnaW9uOjVmN2YxY2M4NmU0NTQzYjRhODVkMjkwY2ExMGZmNTdiXzQyNQ_7be8b8e1-f305-4353-994d-5a2fc6756aa3" continuedAt="i67f6dcb394c445e2b6d5ac9e34078b03" escape="true">ACCUMULATED OTHER COMPREHENSIVE LOSS</ix:nonNumeric></span></div><ix:continuation id="i67f6dcb394c445e2b6d5ac9e34078b03"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDMvZnJhZzo1ZjdmMWNjODZlNDU0M2I0YTg1ZDI5MGNhMTBmZjU3Yi90ZXh0cmVnaW9uOjVmN2YxY2M4NmU0NTQzYjRhODVkMjkwY2ExMGZmNTdiXzQyMA_598581ec-ff3b-4593-a51f-27c3e516df21" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss as of December&#160;31, 2021 and 2020 consists of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:78.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9158150c4cf4379b5bba7c7cb9d7e9a_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDMvZnJhZzo1ZjdmMWNjODZlNDU0M2I0YTg1ZDI5MGNhMTBmZjU3Yi90YWJsZTo2OWZmZDhlNmNkMDM0OGMzODUwY2JhMmI1OWFiZTJlMi90YWJsZXJhbmdlOjY5ZmZkOGU2Y2QwMzQ4YzM4NTBjYmEyYjU5YWJlMmUyXzEtMi0xLTEtNTk0NzA_782cbce4-449e-454a-9dd7-48e33362e2ba">1,905</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0b1241118154de6b3af123e431df6a1_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDMvZnJhZzo1ZjdmMWNjODZlNDU0M2I0YTg1ZDI5MGNhMTBmZjU3Yi90YWJsZTo2OWZmZDhlNmNkMDM0OGMzODUwY2JhMmI1OWFiZTJlMi90YWJsZXJhbmdlOjY5ZmZkOGU2Y2QwMzQ4YzM4NTBjYmEyYjU5YWJlMmUyXzEtNC0xLTEtNTk0NzA_e4cbc10f-e729-4504-b92f-58cb5f39c7c4">2,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension adjustment, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb6b356a1fd41fc9c4da52a60b5ad6a_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDMvZnJhZzo1ZjdmMWNjODZlNDU0M2I0YTg1ZDI5MGNhMTBmZjU3Yi90YWJsZTo2OWZmZDhlNmNkMDM0OGMzODUwY2JhMmI1OWFiZTJlMi90YWJsZXJhbmdlOjY5ZmZkOGU2Y2QwMzQ4YzM4NTBjYmEyYjU5YWJlMmUyXzItMi0xLTEtNTk0NzA_f7d9fb69-687c-437c-a30b-177c809e6c82">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8021c14b857946c188b6f072829b7db7_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDMvZnJhZzo1ZjdmMWNjODZlNDU0M2I0YTg1ZDI5MGNhMTBmZjU3Yi90YWJsZTo2OWZmZDhlNmNkMDM0OGMzODUwY2JhMmI1OWFiZTJlMi90YWJsZXJhbmdlOjY5ZmZkOGU2Y2QwMzQ4YzM4NTBjYmEyYjU5YWJlMmUyXzItNC0xLTEtNTk0NzA_f110b92d-8a1b-4f8b-a106-6d79175493d9">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie17ca1996294497e9f031629ce871dae_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDMvZnJhZzo1ZjdmMWNjODZlNDU0M2I0YTg1ZDI5MGNhMTBmZjU3Yi90YWJsZTo2OWZmZDhlNmNkMDM0OGMzODUwY2JhMmI1OWFiZTJlMi90YWJsZXJhbmdlOjY5ZmZkOGU2Y2QwMzQ4YzM4NTBjYmEyYjU5YWJlMmUyXzMtMi0xLTEtNTk0NzA_377b597b-ef1c-425d-80d3-d9daa682ff25">1,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23e7ea6c4d584b7881937aede46315ca_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDMvZnJhZzo1ZjdmMWNjODZlNDU0M2I0YTg1ZDI5MGNhMTBmZjU3Yi90YWJsZTo2OWZmZDhlNmNkMDM0OGMzODUwY2JhMmI1OWFiZTJlMi90YWJsZXJhbmdlOjY5ZmZkOGU2Y2QwMzQ4YzM4NTBjYmEyYjU5YWJlMmUyXzMtNC0xLTEtNTk0NzA_1cfe471f-e716-4eed-9b86-62b4d83ff81d">2,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#8217;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#8217;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.</span></div></ix:continuation><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_346"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDYvZnJhZzoyZjlmYzZkNGY3Y2M0ZWQxODJkODk5ZjQ2ZGNlYmI3MS90ZXh0cmVnaW9uOjJmOWZjNmQ0ZjdjYzRlZDE4MmQ4OTlmNDZkY2ViYjcxXzI5MA_003eadb5-17e6-42a7-8177-15e85912ad21" continuedAt="i917d6e80066b4286987fce0618175595" escape="true">RESEARCH AND DEVELOPMENT</ix:nonNumeric></span></div><ix:continuation id="i917d6e80066b4286987fce0618175595"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDYvZnJhZzoyZjlmYzZkNGY3Y2M0ZWQxODJkODk5ZjQ2ZGNlYmI3MS90ZXh0cmVnaW9uOjJmOWZjNmQ0ZjdjYzRlZDE4MmQ4OTlmNDZkY2ViYjcxXzI4Nw_3599e595-8351-4f2b-98e8-2c884c992560" continuedAt="ie6768c4de0864a028eb801cb6e4e1571" escape="true">Research and development costs for the years 2021, 2020 and 2019 consists of:</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><ix:continuation id="ie6768c4de0864a028eb801cb6e4e1571"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDYvZnJhZzoyZjlmYzZkNGY3Y2M0ZWQxODJkODk5ZjQ2ZGNlYmI3MS90YWJsZTphNmY1ZThiOWJmZTU0OTNiOTI1MTAzMmI5N2YyODFkZS90YWJsZXJhbmdlOmE2ZjVlOGI5YmZlNTQ5M2I5MjUxMDMyYjk3ZjI4MWRlXzEtMi0xLTEtNTk0NzA_dff8e2d0-e12b-4a8c-9b28-50660ffce754">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDYvZnJhZzoyZjlmYzZkNGY3Y2M0ZWQxODJkODk5ZjQ2ZGNlYmI3MS90YWJsZTphNmY1ZThiOWJmZTU0OTNiOTI1MTAzMmI5N2YyODFkZS90YWJsZXJhbmdlOmE2ZjVlOGI5YmZlNTQ5M2I5MjUxMDMyYjk3ZjI4MWRlXzEtNC0xLTEtNTk0NzA_ebf046d6-4a8d-47f2-8257-94e3e5563bfa">420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDYvZnJhZzoyZjlmYzZkNGY3Y2M0ZWQxODJkODk5ZjQ2ZGNlYmI3MS90YWJsZTphNmY1ZThiOWJmZTU0OTNiOTI1MTAzMmI5N2YyODFkZS90YWJsZXJhbmdlOmE2ZjVlOGI5YmZlNTQ5M2I5MjUxMDMyYjk3ZjI4MWRlXzEtNi0xLTEtNTk0NzA_c3c6f654-f588-4475-bc61-ca3dc9f48ad2">434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDYvZnJhZzoyZjlmYzZkNGY3Y2M0ZWQxODJkODk5ZjQ2ZGNlYmI3MS90YWJsZTphNmY1ZThiOWJmZTU0OTNiOTI1MTAzMmI5N2YyODFkZS90YWJsZXJhbmdlOmE2ZjVlOGI5YmZlNTQ5M2I5MjUxMDMyYjk3ZjI4MWRlXzItMi0xLTEtNTk0NzA_c9c5a536-2aa4-4e2d-8b3f-b8ddd4f7e846">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDYvZnJhZzoyZjlmYzZkNGY3Y2M0ZWQxODJkODk5ZjQ2ZGNlYmI3MS90YWJsZTphNmY1ZThiOWJmZTU0OTNiOTI1MTAzMmI5N2YyODFkZS90YWJsZXJhbmdlOmE2ZjVlOGI5YmZlNTQ5M2I5MjUxMDMyYjk3ZjI4MWRlXzItNC0xLTEtNTk0NzA_0601dd1e-56a4-498f-b554-0554de01f39d">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDYvZnJhZzoyZjlmYzZkNGY3Y2M0ZWQxODJkODk5ZjQ2ZGNlYmI3MS90YWJsZTphNmY1ZThiOWJmZTU0OTNiOTI1MTAzMmI5N2YyODFkZS90YWJsZXJhbmdlOmE2ZjVlOGI5YmZlNTQ5M2I5MjUxMDMyYjk3ZjI4MWRlXzItNi0xLTEtNTk0NzA_cb603f3c-b64d-4fdf-b4b8-7f6914686fb3">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDYvZnJhZzoyZjlmYzZkNGY3Y2M0ZWQxODJkODk5ZjQ2ZGNlYmI3MS90YWJsZTphNmY1ZThiOWJmZTU0OTNiOTI1MTAzMmI5N2YyODFkZS90YWJsZXJhbmdlOmE2ZjVlOGI5YmZlNTQ5M2I5MjUxMDMyYjk3ZjI4MWRlXzMtMi0xLTEtNTk0NzA_d744fde8-474b-41cf-97ac-13404895538a">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDYvZnJhZzoyZjlmYzZkNGY3Y2M0ZWQxODJkODk5ZjQ2ZGNlYmI3MS90YWJsZTphNmY1ZThiOWJmZTU0OTNiOTI1MTAzMmI5N2YyODFkZS90YWJsZXJhbmdlOmE2ZjVlOGI5YmZlNTQ5M2I5MjUxMDMyYjk3ZjI4MWRlXzMtNC0xLTEtNTk0NzA_abc363a7-78a4-4a99-8405-723ae66cc2c6">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDYvZnJhZzoyZjlmYzZkNGY3Y2M0ZWQxODJkODk5ZjQ2ZGNlYmI3MS90YWJsZTphNmY1ZThiOWJmZTU0OTNiOTI1MTAzMmI5N2YyODFkZS90YWJsZXJhbmdlOmE2ZjVlOGI5YmZlNTQ5M2I5MjUxMDMyYjk3ZjI4MWRlXzMtNi0xLTEtNTk0NzA_de72e617-104b-4378-b78c-44a76699000e">471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_349"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90ZXh0cmVnaW9uOjcyOTNiYmU0MmQ1YjQxYWY4MTM1OWM3MTBhMzAwYzExXzk1NQ_4650e9dc-db5e-4db8-8797-d54014f8f717" continuedAt="icf80d737dacd477ea039d74816e6e7b1" escape="true">OTHER EXPENSE, NET</ix:nonNumeric></span></div><ix:continuation id="icf80d737dacd477ea039d74816e6e7b1" continuedAt="i634daaccfad54ec0bd7cd82ff97045bf"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90ZXh0cmVnaW9uOjcyOTNiYmU0MmQ1YjQxYWY4MTM1OWM3MTBhMzAwYzExXzk2Mg_5542e06d-184b-4ace-b9d0-9385eb8dada5" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net for the years 2021, 2020 and 2019 consists of:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzItMi0xLTEtNTk0NzA_fe588a03-d783-477d-b830-10120eac55d1">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzItNC0xLTEtNTk0NzA_d3bb4188-8db4-48eb-ac80-504f017bc9c8">422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzItNi0xLTEtNTk0NzA_be5df51e-47d9-436b-8130-2b3ea42fb0b5">1,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzMtMi0xLTEtNTk0NzA_d1f17bec-a21f-460e-afeb-c6d8c1e7859f">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzMtNC0xLTEtNTk0NzA_40b38790-f983-4945-b9d6-df144c250904">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzMtNi0xLTEtNTk0NzA_f82fbfa8-5bc7-4db4-8610-4ec2efcceed0">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sales of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzQtMi0xLTEtNTk0NzA_87399a69-21d8-4ea0-99fa-275b494e6469">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzQtNC0xLTEtNTk0NzA_b00d616a-10c7-43b2-8cd5-bea1a02827ab">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzQtNi0xLTEtNTk0NzA_de78cb07-9314-4982-bb9e-1ad061eff965">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzUtMi0xLTEtNTk0NzA_97727077-5a0a-47a8-94ca-5170488f5a22">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzUtNC0xLTEtNTk0NzA_354931ea-e151-42ec-a238-02fb2a855a5a">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzUtNi0xLTEtNTk0NzA_d326c946-b01f-44b9-8a12-ac446d5a1cb3">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:OtherIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzYtMi0xLTEtNTk0NzA_a7d97e76-f097-4e83-b0fe-44926337523a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:OtherIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzYtNC0xLTEtNTk0NzA_38fc8bea-a926-47b1-a2f3-200959cf30f2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="bhc:OtherIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzYtNi0xLTEtNTk0NzA_0d226995-8da8-49d1-b1c4-701e8dd53775">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzctMi0xLTEtNTk0NzA_3fdd49d4-a59d-4f49-9793-228453451735">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzctNC0xLTEtNTk0NzA_3c8d6919-2fef-44c6-9b96-f38795f80e99">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzctNi0xLTEtNTk0NzA_473ff85e-d306-46a0-baf2-9b94cb474528">1,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i634daaccfad54ec0bd7cd82ff97045bf"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, Litigation and other matters of $<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90ZXh0cmVnaW9uOjcyOTNiYmU0MmQ1YjQxYWY4MTM1OWM3MTBhMzAwYzExXzM4NDgyOTA2OTkyODQ_fe588a03-d783-477d-b830-10120eac55d1">356</ix:nonFraction> million includes adjustments related to the Glumetza Antitrust Litigation, partially offset by insurance recoveries related to certain litigation matters. In 2020, Litigation and other matters of $<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90ZXh0cmVnaW9uOjcyOTNiYmU0MmQ1YjQxYWY4MTM1OWM3MTBhMzAwYzExXzM4NDgyOTA2OTkxNzA_d3bb4188-8db4-48eb-ac80-504f017bc9c8">422</ix:nonFraction> million includes net charges related to the U.S. Securities Litigation, the SEC Investigation and the Canadian Securities Litigation and related opt-outs. In 2020, Litigation and other matters also includes an insurance recovery related to a certain litigation matter. In 2019, Litigation and other matters of $<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90ZXh0cmVnaW9uOjcyOTNiYmU0MmQ1YjQxYWY4MTM1OWM3MTBhMzAwYzExXzM4NDgyOTA2OTkxOTA_be5df51e-47d9-436b-8130-2b3ea42fb0b5">1,401</ix:nonFraction> million includes the settlement of a legacy U.S. securities class action matter. Certain of these matters and other significant matters are discussed in further detail in Note 20, "LEGAL PROCEEDINGS".</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 and 2019, Acquired in-process research and development costs of $<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90ZXh0cmVnaW9uOjcyOTNiYmU0MmQ1YjQxYWY4MTM1OWM3MTBhMzAwYzExXzM4NDgyOTA2OTg2MTQ_40b38790-f983-4945-b9d6-df144c250904">32</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90ZXh0cmVnaW9uOjcyOTNiYmU0MmQ1YjQxYWY4MTM1OWM3MTBhMzAwYzExXzM4NDgyOTA2OTg2MTg_f82fbfa8-5bc7-4db4-8610-4ec2efcceed0">41</ix:nonFraction>&#160;million, primarily consist of costs associated with the upfront payments to enter into certain exclusive licensing agreements. </span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Net gain on sales of assets includes $<ix:nonFraction unitRef="usd" contextRef="i22332303e4634782bd879afa7c52f3f7_D20190101-20191231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90ZXh0cmVnaW9uOjcyOTNiYmU0MmQ1YjQxYWY4MTM1OWM3MTBhMzAwYzExXzg4Mg_552b069b-8ae3-48ae-80ae-8476294522d5">20</ix:nonFraction> million related to the achievement of a milestone related to a certain product.</span></div></ix:continuation><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_352"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzEyMzEx_8292eb29-9666-4934-9569-6ffe55d5122c" continuedAt="i375ce5798add47e582985200b06b2535" escape="true">INCOME TAXES </ix:nonNumeric></span></div><ix:continuation id="i375ce5798add47e582985200b06b2535" continuedAt="if6547b15b69144c28a5b53cac5f5bbb1"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzEyMjk0_ae8903e3-885d-4eb7-997e-49b0762440dc" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Loss before benefit from income taxes for 2021, 2020 and 2019 consist of:  </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo2NTE1YWY2ZjEyYWI0ZGJjYThlZmMxNWExYmI1NTc5My90YWJsZXJhbmdlOjY1MTVhZjZmMTJhYjRkYmNhOGVmYzE1YTFiYjU1NzkzXzEtMi0xLTEtNTk0NzA_8d1bfeb6-de8b-4f46-b998-a8f2e0711035">323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo2NTE1YWY2ZjEyYWI0ZGJjYThlZmMxNWExYmI1NTc5My90YWJsZXJhbmdlOjY1MTVhZjZmMTJhYjRkYmNhOGVmYzE1YTFiYjU1NzkzXzEtNC0xLTEtNTk0NzA_ee335d13-cb2b-4689-823e-cc0ddf39aa5e">410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo2NTE1YWY2ZjEyYWI0ZGJjYThlZmMxNWExYmI1NTc5My90YWJsZXJhbmdlOjY1MTVhZjZmMTJhYjRkYmNhOGVmYzE1YTFiYjU1NzkzXzEtNi0xLTEtNTk0NzA_f3bf2d8d-fcb5-4d19-90ed-f8db85faf57c">2,396</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo2NTE1YWY2ZjEyYWI0ZGJjYThlZmMxNWExYmI1NTc5My90YWJsZXJhbmdlOjY1MTVhZjZmMTJhYjRkYmNhOGVmYzE1YTFiYjU1NzkzXzItMi0xLTEtNTk0NzA_349021ea-c7ff-4163-aa83-469165f36279">701</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo2NTE1YWY2ZjEyYWI0ZGJjYThlZmMxNWExYmI1NTc5My90YWJsZXJhbmdlOjY1MTVhZjZmMTJhYjRkYmNhOGVmYzE1YTFiYjU1NzkzXzItNC0xLTEtNTk0NzA_1e2b83d2-61e4-4b79-8d9a-1ea49a025171">524</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo2NTE1YWY2ZjEyYWI0ZGJjYThlZmMxNWExYmI1NTc5My90YWJsZXJhbmdlOjY1MTVhZjZmMTJhYjRkYmNhOGVmYzE1YTFiYjU1NzkzXzItNi0xLTEtNTk0NzA_cd54d733-cbf9-405d-b9c7-14324d49939a">559</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo2NTE1YWY2ZjEyYWI0ZGJjYThlZmMxNWExYmI1NTc5My90YWJsZXJhbmdlOjY1MTVhZjZmMTJhYjRkYmNhOGVmYzE1YTFiYjU1NzkzXzMtMi0xLTEtNTk0NzA_33f4aa68-61e4-4ce6-9a8e-8333953f0c00">1,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo2NTE1YWY2ZjEyYWI0ZGJjYThlZmMxNWExYmI1NTc5My90YWJsZXJhbmdlOjY1MTVhZjZmMTJhYjRkYmNhOGVmYzE1YTFiYjU1NzkzXzMtNC0xLTEtNTk0NzA_663422ba-edd5-48c0-aad2-23df9f542638">934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo2NTE1YWY2ZjEyYWI0ZGJjYThlZmMxNWExYmI1NTc5My90YWJsZXJhbmdlOjY1MTVhZjZmMTJhYjRkYmNhOGVmYzE1YTFiYjU1NzkzXzMtNi0xLTEtNTk0NzA_01c2ed5a-2e34-4d83-b175-57ef91469c3c">1,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzEyMzE3_4efc0c67-360c-45e3-8ee1-90e99d06f5c0" escape="true"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Benefit from income taxes for 2021, 2020 and 2019 consist of: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzItMi0xLTEtNTk0NzA_f7e1f49d-cd31-4cee-8479-3cef2116c87b">23</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzItNC0xLTEtNTk0NzA_b9675682-5efd-47bd-ac4d-a4588db096b6">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzItNi0xLTEtNTk0NzA_919f6c3c-9ba8-4d8e-844a-3335f75256c6">12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzMtMi0xLTEtNTk0NzA_0d4db9fe-d603-4d2e-b51e-3a6195112d28">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzMtNC0xLTEtNTk0NzA_fa655627-9c6f-472b-b535-2ca5889d87a8">216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzMtNi0xLTEtNTk0NzA_8298bf5c-4aff-4521-a84f-8e97c2dcb4c8">116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzQtMi0xLTEtNTk0NzA_9708a48d-0457-41fa-9f90-d40bfd8052b0">51</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzQtNC0xLTEtNTk0NzA_20d00a19-39e0-4575-92e0-80c625ae5ae3">224</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzQtNi0xLTEtNTk0NzA_5b7a7b57-c9be-4764-b485-89bf8951d24a">128</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzYtMi0xLTEtNTk0NzA_7bb7e271-4729-4b8a-96f3-bf303ccf64fa">20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzYtNC0xLTEtNTk0NzA_8bdbe3b0-5797-406c-9f0c-ecf4b62e765a">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzYtNi0xLTEtNTk0NzA_e3abc846-5b97-4d30-8fde-72c00e2f4bf9">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzctMi0xLTEtNTk0NzA_2c97dc51-2ddf-474d-8e94-c54a5865bd92">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzctNC0xLTEtNTk0NzA_44daefa0-d4e6-4276-bec8-adb197d43901">590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzctNi0xLTEtNTk0NzA_7b463fd6-50ca-4258-8f97-3f0fd89bdfe1">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzgtMi0xLTEtNTk0NzA_ab033b33-be88-4e79-aeac-2c23a833ba27">36</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzgtNC0xLTEtNTk0NzA_15e8ab82-37e7-4969-aaa8-931881c2b582">599</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzgtNi0xLTEtNTk0NzA_fb8b3c47-f1bf-4d77-9294-809b31271205">182</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzktMi0xLTEtNTk0NzA_d29af376-c5c1-46dc-841c-1fa2270d6588">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzktNC0xLTEtNTk0NzA_3b24db5f-2d16-4e03-aa33-6ab60796d3ec">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzktNi0xLTEtNTk0NzA_cdfcd15a-f430-4ccb-b990-b60c482c7d49">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="if6547b15b69144c28a5b53cac5f5bbb1" continuedAt="i0dab4ae98016454bbdf592e217a0108b"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzEyMzEw_f3df00b1-d85b-42c5-8af8-949d91466bcd" escape="true"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Benefit from income taxes differs from the expected amount calculated by applying the Company&#8217;s Canadian statutory rate of <ix:nonFraction unitRef="number" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzIyMg_27d3c9e6-9e3d-4257-8542-1530347d710b"><ix:nonFraction unitRef="number" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzIyMg_ca93964e-e504-4a8d-b0b7-46b2775cf635"><ix:nonFraction unitRef="number" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzIyMg_d0006cc3-3efd-47f7-9c05-d5ead59654e8">26.9</ix:nonFraction></ix:nonFraction></ix:nonFraction>% to Loss before benefit from income taxes for 2021, 2020 and 2019 as follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before benefit from income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEtMi0xLTEtNTk0NzA_7c303806-ec3a-4cf3-a210-73af4861c263">1,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEtNC0xLTEtNTk0NzA_514cbe72-345b-4d56-8613-6ccf5d5ae020">934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEtNi0xLTEtNTk0NzA_94b01e0e-2028-4b06-beda-657c61adf349">1,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected benefit from income taxes at Canadian statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzMtMi0xLTEtNTk0NzA_65c4fbcb-e697-4a80-9388-ac50951e26dd">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzMtNC0xLTEtNTk0NzA_4a57e50b-fae2-4ad5-9b12-3e03b2cf5221">251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzMtNi0xLTEtNTk0NzA_58061cf1-8a21-40db-8104-b03fe321bd0e">494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible amount of share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzQtMi0xLTEtNTk0NzA_f72d594f-6da1-4edd-a6da-36b3486c5f86">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzQtNC0xLTEtNTk0NzA_02856983-15b3-44a4-a41e-08c565464e07">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzQtNi0xLTEtNTk0NzA_1cf72019-a756-48ff-8a83-07847082f794">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to tax attributes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzUtMi0xLTEtNTk0NzA_f0d6604b-256a-42b8-80cb-5269c7cef4e0">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzUtNC0xLTEtNTk0NzA_6385e682-12e6-4159-a64a-9208cf3cb49d">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzUtNi0xLTEtNTk0NzA_25c83d49-abde-42ba-9f2a-fb49e8a05900">99</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance related to foreign tax credits and NOLs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzYtMi0xLTEtNTk0NzA_141a8cd9-c03c-4308-9ba3-df06a47d1cef">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzYtNC0xLTEtNTk0NzA_1a14a885-4af7-45aa-aefe-8182657e33de">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzYtNi0xLTEtNTk0NzA_dbf628e8-cbbe-4040-885e-c3371747e34b">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance on Canadian deferred tax assets and tax rate changes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzctMi0xLTEtNTk0NzA_e498b6f0-9cbd-4e62-91bc-1bec773283c0">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzctNC0xLTEtNTk0NzA_33919c6d-82ee-4f90-b610-3a6d5d0ab5d8">687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzctNi0xLTEtNTk0NzA_800dca0d-0367-4602-b692-1d48738c75e4">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="bhc:IncomeTaxReconciliationUncertainTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzgtMi0xLTEtNTk0NzA_c895c9a8-348d-4563-8f01-f849c0ce01ef">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:IncomeTaxReconciliationUncertainTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzgtNC0xLTEtNTk0NzA_7bf7c1c0-76f4-4357-9182-fcba8e588d2f">163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="bhc:IncomeTaxReconciliationUncertainTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzgtNi0xLTEtNTk0NzA_aad3572c-0aed-4796-8ec8-4b168fb70ba1">350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzktMi0xLTEtNTk0NzA_685a9e89-ea6c-4a4c-85bc-300cee0a39d0">198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzktNC0xLTEtNTk0NzA_f1dad0f3-9f2f-4b5b-80a2-ae20acbb9f26">128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzktNi0xLTEtNTk0NzA_09e87b73-22b0-43ad-8f97-4a7af232f16d">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible portion of Goodwill impairments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEwLTItMS0xLTU5NDcw_948ecafa-432e-4f83-bfb8-c9ca583a2067">99</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEwLTQtMS0xLTU5NDcw_a1a7ef7f-6c83-4fa9-9f1c-a13099db3721">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEwLTYtMS0xLTU5NDcw_91c3759c-6f20-44da-9fd7-c9c02cd75667">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit on intra-entity transfers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:IncomeTaxReconciliationDeferredIntercompanyProfit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzExLTItMS0xLTU5NDcw_3971dc9e-b4fd-42cb-be0a-25aa90835b9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:IncomeTaxReconciliationDeferredIntercompanyProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzExLTQtMS0xLTU5NDcw_9137c02b-c7e3-4063-a082-83dc1e85aa28">338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="bhc:IncomeTaxReconciliationDeferredIntercompanyProfit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzExLTYtMS0xLTU5NDcw_1c706f26-fde7-4f45-9315-5e835733aa8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEyLTItMS0xLTU5NDcw_8bb7464b-4f01-474e-bb77-5fc814023558">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEyLTQtMS0xLTU5NDcw_08e9a27f-61c5-4ae5-8999-c2919463a76b">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEyLTYtMS0xLTU5NDcw_7e2f12cc-e6c5-4230-8c16-c9425621ad1a">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEzLTItMS0xLTU5NDcw_517eb76d-6fc9-43fc-90b7-15c50bf40ead">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEzLTQtMS0xLTU5NDcw_a04559e3-86bf-4543-b8c5-331e079998ec">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEzLTYtMS0xLTU5NDcw_1067f5b3-d030-4745-99c3-7addd7ca4241">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzEyMjg5_717777b4-e5ef-44b5-947f-76214d4a31d1" continuedAt="ic79b0dd43a2544e8aee8e4df19f02322" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:78.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="bhc:DeferredTaxAssetsTaxLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzItMi0xLTEtNTk0NzA_ecb29903-592a-4622-9eeb-53bdfb82bdf5">2,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="bhc:DeferredTaxAssetsTaxLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzItNC0xLTEtNTk0NzA_d4fcf50b-67b8-4a0b-8030-dad7fb12c7e1">2,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzMtMi0xLTEtNTk0NzA_48c7beff-7e48-49b6-8c3c-039e09bde09b">991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzMtNC0xLTEtNTk0NzA_a36813bc-8676-4e2b-98e4-91eac4059b9a">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="bhc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzQtMi0xLTEtNTk0NzA_28c8bad1-adf5-41e4-b470-afe69ebfdc44">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="bhc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzQtNC0xLTEtNTk0NzA_8bd80da8-c740-4e04-8573-63bbd8257c36">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific Research and Experimental Development pool</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="bhc:DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzUtMi0xLTEtNTk0NzA_e112abf2-ef96-4d0b-a4eb-f3c07ed8e627">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="bhc:DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzUtNC0xLTEtNTk0NzA_2a052e4c-1920-49fd-b684-2a00b7cb61a8">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzYtMi0xLTEtNTk0NzA_cd6d0cf3-1626-4dd7-8e9b-5965ef974017">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzYtNC0xLTEtNTk0NzA_1a316d42-da0e-4df0-a43c-26289e8a8139">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzctMi0xLTEtNTk0NzA_eb4e6f8a-f5de-4ec1-ba91-cc10c21178e2">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzctNC0xLTEtNTk0NzA_5abe1a47-4aa3-4aad-b700-ad8cdc431552">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="bhc:DeferredTaxAssetsPrepaidExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzktMi0xLTEtNTk0NzA_7349fe55-95b2-4cc2-89de-4c02291b01ac">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="bhc:DeferredTaxAssetsPrepaidExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzktNC0xLTEtNTk0NzA_5a7392ac-8264-42a2-9917-2ffe7d581451">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzEwLTItMS0xLTU5NDcw_99040625-72a5-4271-a61e-7ee04787ac6e">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzEwLTQtMS0xLTU5NDcw_cf1911f9-8f81-4dfe-a491-8b3c88df7ed6">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzExLTItMS0xLTU5NDcw_c1197277-3e41-4d24-bed3-6baf0c1ce092">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzExLTQtMS0xLTU5NDcw_7963511a-743a-42a5-ba1f-25ff82075cb5">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzEyLTItMS0xLTU5NDcw_63534c2f-dfcf-46b4-9703-34fa26f7e570">4,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzEyLTQtMS0xLTU5NDcw_f4e8023a-e3f0-4dd9-853e-6a6305280718">4,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzEzLTItMS0xLTU5NDcw_d815558a-237d-4773-b1fc-f8a296e7b4af">2,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzEzLTQtMS0xLTU5NDcw_4245506a-5647-4698-9544-636678b9d351">2,252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets net of valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzE0LTItMS0xLTU5NDcw_b7624267-58c9-4fbd-bcdc-2adb92d37f16">2,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzE0LTQtMS0xLTU5NDcw_ce6c28d8-edbb-4e9a-8d20-fd3964446ffe">1,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzE2LTItMS0xLTU5NDcw_3796b832-50e7-4259-9a1d-20dcac3fef16">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzE2LTQtMS0xLTU5NDcw_79daedee-b69f-4035-9af7-21928bc19511">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plant, equipment and technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="bhc:DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzE3LTItMS0xLTU5NDcw_24325668-61f5-45cb-9c5c-c1d91bf7f67d">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="bhc:DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzE3LTQtMS0xLTU5NDcw_767531a4-4316-4457-b497-88c74221b56c">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzE4LTItMS0xLTU5NDcw_ee74d0b1-835f-4c76-865f-1512a327306e">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzE4LTQtMS0xLTU5NDcw_dfa8c911-c2d4-40ea-9b8f-670ffb232e49">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized FX on U.S. dollar debt and other financing cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzE5LTItMS0xLTU5NDcw_83eeaa1b-e69d-4b17-96b3-1df94e885eb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzE5LTQtMS0xLTU5NDcw_0f2ac980-d75b-456c-81c4-a506fc721602">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzIwLTItMS0xLTU5NDcw_46809d25-4f0a-4b50-a383-fe77643ff114">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzIwLTQtMS0xLTU5NDcw_2f3fb9c6-6a4b-4682-a288-108416cc8e8f">390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzIxLTItMS0xLTU5NDcw_9b7238dd-d7da-40ac-b8c5-a2ac3686594c">1,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzIxLTQtMS0xLTU5NDcw_7d473130-0d76-482a-9eea-f2014d4879e8">1,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i0dab4ae98016454bbdf592e217a0108b" continuedAt="ib4aefec326e3406ab3abd0f97bcc115d"><ix:continuation id="ic79b0dd43a2544e8aee8e4df19f02322"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the deferred tax asset valuation allowance for 2021, 2020 and 2019: </span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f60772beddd4bd8b351b7519c847285_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzEtMi0xLTEtNTk0NzA_6234f8a3-8969-4446-ac48-c44319a3a100">2,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966b3882b2f8446a92d3b73108d3691d_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzEtNC0xLTEtNTk0NzA_9a446137-1507-48a4-9f40-1c6f33a640b4">2,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33e256fd4d08472686f2bc331857bc8a_I20181231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzEtNi0xLTEtNTk0NzA_1afa112f-e892-4e21-a223-f5818fa236de">2,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to Benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic44ed602f863418a8831ced61d13e546_D20210101-20211231" decimals="-6" sign="-" name="bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzItMi0xLTEtNTk0NzA_93d5b822-8236-4e00-8eb0-d86203c97c18">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie270c7e752794cadbce8d6ea63bace3b_D20200101-20201231" decimals="-6" sign="-" name="bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzItNC0xLTEtNTk0NzA_7694af3a-71fa-4a59-bf09-92321b2b1079">773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6ce4645221b4e709b3988651ee21064_D20190101-20191231" decimals="-6" name="bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzItNi0xLTEtNTk0NzA_fe63acb7-6ea1-4941-9f42-8d9a3ed2ce60">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to other accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic44ed602f863418a8831ced61d13e546_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzMtMi0xLTEtNTk0NzA_02de1cef-7f5c-42bb-ac67-2035af157792">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie270c7e752794cadbce8d6ea63bace3b_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzMtNC0xLTEtNTk0NzA_28d6c26f-65c2-47ca-ba88-50ae4e722135">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6ce4645221b4e709b3988651ee21064_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzMtNi0xLTEtNTk0NzA_4eeae7d1-51c4-4e06-97f2-f83fddac2e02">95</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic906a904b8264052aa297c4da0661e84_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzQtMi0xLTEtNTk0NzA_7e9c4d88-9c42-4d23-a3bb-3e7a53c8cadd">2,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f60772beddd4bd8b351b7519c847285_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzQtNC0xLTEtNTk0NzA_a82b9800-7762-4866-bd48-5935f32f5429">2,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966b3882b2f8446a92d3b73108d3691d_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzQtNi0xLTEtNTk0NzA_5f3ecada-c16f-48dc-ae5a-781dd22ec7a7">2,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. interest expense is subject to limitation rules which limit U.S. interest expense to 30% of adjusted taxable income, defined similar to EBITDA through 2021 and EBIT thereafter.  Disallowed interest can be carried forward indefinitely and any unused interest deduction assessed for recoverability. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was signed into law.  The CARES Act also amended the annual limitation on the deduction of interest in the following respects: (i) increasing the limitation to 50% of adjusted taxable income (&#8220;ATI&#8221;), (ii) providing a rule for a partnership&#8217;s 2019 section 163(j)-disallowed interest expense and (iii) allowing an election to apply 2019 ATI to the 2020 section 163(j) computation.  For corporations, the increase to 50% of ATI applies to all taxable years beginning in 2019 or 2020 and permits taxpayers whose 2020 income will decrease from its 2019 level, an election to apply their 2019 ATI, rather than their 2020 ATI, to their 2020 computation. The Company considered such provisions and expects to fully utilize any interest carry forwards in future periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has provided for income taxes in accordance with guidance issued by accounting regulatory bodies, the U.S. Internal Revenue Service and state and local governments through the date of the issuance of these Consolidated Financial Statements. Additional guidance and interpretations can be expected and such guidance, if any, could impact future results.  While management continues to monitor these matters, the ultimate impact, if any, as a result of the application of any guidance issued in the future cannot be determined at this time.   </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The realization of deferred tax assets is dependent on the Company generating sufficient domestic and foreign taxable income in the years that the temporary differences become deductible. A valuation allowance has been provided for the portion of the deferred tax assets that the Company determined is more likely than not to remain unrealized based on estimated future taxable income and tax planning strategies.  In 2021, the valuation allowance decreased by $<ix:nonFraction unitRef="usd" contextRef="i9019e1c2cf6d46838fe8c8d77147207a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzQ5NDc4MDIzNjQxMDE_cad2017c-587d-486e-8c12-cea41f7ef596">30</ix:nonFraction> million primarily due to book taxable income in Canada, the change in deferred tax assets in Canada and the use of deferred tax assets in the U.S. in connection with internal restructurings. In 2020, the valuation allowance decreased by $<ix:nonFraction unitRef="usd" contextRef="i0c84dca0789f4214840ddb5f4f8537bb_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzQwMDQ_f3200e57-0c33-4662-aead-3212adea3815">579</ix:nonFraction> million as a result of taxable losses in Canada as offset by a reduction of deferred tax assets due to internal restructurings. Given the Company&#8217;s history of pre-tax losses and expected future losses in Canada, the Company maintained that there was insufficient objective evidence to release the valuation allowance against Canadian tax loss carryforwards, International Tax Credits (&#8220;ITC&#8221;) and pooled Scientific Research and Experimental Development Tax Incentive (&#8220;SR&amp;ED&#8221;) expenditures.  The Canadian valuation allowance represents a material portion of the Company's total valuation allowance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the Company had accumulated taxable losses available to offset future years&#8217; federal and provincial taxable income in Canada of approximately $<ix:nonFraction unitRef="usd" contextRef="i983ff7f7025446d58e2f36c202de3dca_I20211231" decimals="-6" name="bhc:AccumulatedLossesAvailableForFederalPurposes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzQ2NDI_56e08d4c-f4a8-43aa-b1cc-7591cf34274e">6,669</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idee0cbb24fc340c1a64cf7d7df3edec6_I20201231" decimals="-6" name="bhc:AccumulatedLossesAvailableForFederalPurposes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzQ2NDk_44537146-ce27-4fe9-b71f-716f51ef63b7">6,530</ix:nonFraction> million, respectively.&#160; As of December 31, 2021 and 2020, unclaimed ITCs available to offset future federal taxes in Canada were approximately $<ix:nonFraction unitRef="usd" contextRef="i983ff7f7025446d58e2f36c202de3dca_I20211231" decimals="-6" name="bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzQ3NjM_881037a0-1f13-4948-ab5b-3fa1da70fb9c">31</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idee0cbb24fc340c1a64cf7d7df3edec6_I20201231" decimals="-6" name="bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzQ3NzA_7e761287-85fb-452e-8c9c-f1a5796fb051">37</ix:nonFraction> million, respectively, which expire in the years 2022 through 2041.&#160; In addition, as of December 31, 2021 and 2020, pooled SR&amp;ED expenditures available to offset against future taxable income in Canada were approximately $<ix:nonFraction unitRef="usd" contextRef="idc644797e11f42fb9e29854f00a8af84_I20211231" decimals="-6" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzQ5NjI_31b314b3-1f63-4491-ba45-31aa81fb88f3">196</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia5e04a5a10344bad915b3777b2ade249_I20201231" decimals="-6" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzQ5Njk_91050bbf-e68e-463b-9cf7-49f5001a1a9b">206</ix:nonFraction> million, respectively, which may be carried forward indefinitely.  As of December 31, 2021 and 2020, a full valuation allowance against the net Canadian deferred tax assets on the parent company has been provided of $<ix:nonFraction unitRef="usd" contextRef="i983ff7f7025446d58e2f36c202de3dca_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzUxMzQ_f462cb8a-5726-4114-95f6-88a8d9e4ebc5">1,965</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idee0cbb24fc340c1a64cf7d7df3edec6_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzUxNDE_5e392202-681b-4535-bd3d-c4641d0b770d">1,966</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the Company had accumulated taxable losses available to offset future years' federal taxable income in the U.S. of approximately $<ix:nonFraction unitRef="usd" contextRef="i12f28aade059421c87f68fa766a6137c_I20211231" decimals="-6" name="bhc:AccumulatedLossesAvailableForFederalPurposes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzUyOTg_a5331785-5221-4c5e-8794-b0cd8375920d">266</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iccec7fb29c284c1282bcfd6426b81d26_I20201231" decimals="-6" name="bhc:AccumulatedLossesAvailableForFederalPurposes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzUzMDU_b4c068c0-5479-4ba8-822e-fe876ce15032">814</ix:nonFraction> million, respectively, including acquired losses which expire in the years 2022 through 2037. While the remaining taxable losses are subject to multiple annual loss limitations as a result of previous ownership changes, the Company believes that the recoverability of the deferred tax assets associated with these taxable losses are more likely than not to be realized. As of December 31, 2021 and 2020 U.S. research and development credits available to offset future years' federal income taxes in the U.S. were approximately $<ix:nonFraction unitRef="usd" contextRef="i12f28aade059421c87f68fa766a6137c_I20211231" decimals="-6" name="bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzU4MDM_dcf5c56b-33b2-4663-96b7-e066e8a0a6d6">119</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iccec7fb29c284c1282bcfd6426b81d26_I20201231" decimals="-6" name="bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzU4MTA_2c0867db-2dcf-4de7-9776-b219cd4727ca">110</ix:nonFraction> million, respectively, which includes acquired research and development credits and which expire in the years 2022 through 2042.  In the U.S. the Company has a capital loss of which is offset by a full valuation allowance since the benefit is not expected to be realized.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the Company had accumulated taxable losses available to offset future years&#8217; taxable income in Ireland of approximately $<ix:nonFraction unitRef="usd" contextRef="ida6fd5a3e163430689987e5420387788_I20211231" decimals="-6" name="bhc:AccumulatedLossesAvailableForFederalPurposes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzYwNjU_9290b20a-f4a9-46b0-9906-401c47325ba1">10,040</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iceef040ee04e4d18be72112cc3158c59_I20201231" decimals="-6" name="bhc:AccumulatedLossesAvailableForFederalPurposes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzYwNzI_9baf480f-617e-4908-b741-c21730df3d35">8,387</ix:nonFraction> million, respectively.&#160; As of  December&#160;31, 2021, the Company continues to have a capital loss which is offset by a valuation allowance on the portion of the loss for which a benefit is not expected to be realized.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ib4aefec326e3406ab3abd0f97bcc115d" continuedAt="idce818350c744c739033bd471cdb141e"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for income taxes on the unremitted earnings of its direct foreign affiliates except for its direct U.S. subsidiaries.  The Company continues to assert that the unremitted earnings of its U.S.&#160;subsidiaries will be permanently reinvested and not repatriated.  As of December 31, 2021, the Company estimates that there will be no tax liability attributable to unremitted earnings of its U.S. subsidiaries. However, distribution of future earnings could be subject to U.S. withholding tax.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, unrecognized tax benefits (including interest and penalties) were $<ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzY3MjY_45cc9159-5687-40b7-a6ed-d7029468626d">927</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzY3MzM_1a929c37-02d3-4c59-aa97-8c76412ff39f">1,025</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzY3NDY_be3ef60d-fe9d-4383-a6bf-248ae7b47f6f">271</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzY3NTM_acff90ca-6609-4748-a560-61d7e0287843">414</ix:nonFraction> million would affect the effective income tax rate, respectively. In 2021 and 2020, the remaining unrecognized tax benefits would not impact the effective tax rate as the tax positions are offset against existing tax attributes or are timing in nature. In 2021 and 2020, the Company recognized net increases to unrecognized tax benefits for current year tax positions of $<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzcxMTE_b0c98737-04fe-451b-ad40-b070ec756019">79</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzcxMTg_6ca59aff-b2f8-4d4c-af2c-3f3abc773b24">66</ix:nonFraction> million, respectively.  The Company recognized a net reduction of $<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzcxNzk_7b1ba0f1-4e23-443f-acd1-abd32c2c1a7c">177</ix:nonFraction> million during 2021 and a net reduction of $<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzcyMTU_2bdc9628-8f5d-4306-911a-61f0ac5ee229">42</ix:nonFraction> million during 2020 in the unrecognized tax benefits related to tax positions taken in the prior years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for interest and penalties related to unrecognized tax benefits in the provision for income taxes. As of December 31, 2021 and 2020, accrued interest and penalties related to unrecognized tax benefits were approximately $<ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5Xzc1Mjk_50ea9ced-58f4-4711-86d6-20aa261726c7">41</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5Xzc1MzY_84a491df-a43a-4330-b114-d1b84ac44444">49</ix:nonFraction> million, respectively. In 2021, the Company recognized a net decrease of approximately $<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5Xzc2MjM_986fd3bd-8b97-4f0a-afa3-e58b2cb4e833">8</ix:nonFraction> million and, in 2020, recognized an increase of  $<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5Xzc2MzA_9a090a53-bf01-4a38-b947-41b54cdc9b1c">4</ix:nonFraction> million of interest and&#160;penalties, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and <ix:nonFraction unitRef="subsidiary" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="INF" name="bhc:IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5Xzc2OTA_2e53e808-2a9d-47aa-af8c-4931edb80e60">one</ix:nonFraction> or more of its subsidiaries file federal income tax returns in Canada, the U.S., and other foreign jurisdictions, as well as various provinces and states in Canada and the U.S.&#160;The Company and its subsidiaries have open tax years, primarily from 2012 to 2020, with significant taxing jurisdictions, respectively, including Canada and the U.S.&#160;These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and regulations and tax treaties, as they relate to the amount, timing, or inclusion of revenues and expenses, or the sustainability of income tax positions of the Company and its subsidiaries. Certain of these tax years are expected to remain open indefinitely.</span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzEyMjc5_648479b6-06ea-4085-9cfa-309a975c9f93" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:82.106%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jurisdiction:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Open Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i23bf918ee3914485aeddbbc1554c30ea_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzEtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjowYzY4YzRmNmEyNmY0OWYzYWU4ODlkMjU0MzZhMWYwYV80_05556cdb-7df1-43f8-8d7b-5455caa365c4">2015</ix:nonNumeric> - <ix:nonNumeric contextRef="i5f649769ddcb4300a790315728ab809b_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzEtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjowYzY4YzRmNmEyNmY0OWYzYWU4ODlkMjU0MzZhMWYwYV85_64d0d404-ef89-4876-b2f8-4e620a776b02">2020</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4c7cd7b9da83461fa9bd41fd621feefc_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzItMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo2NjQwOWUyYjNhMWE0Y2M1YTNiYTYyYTdkMDVlYmM0MV80_2ec84542-80e7-4721-913c-72c0cd918a65">2012</ix:nonNumeric> - <ix:nonNumeric contextRef="ic9ec02f6590e441bbef7d90718b83872_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzItMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo2NjQwOWUyYjNhMWE0Y2M1YTNiYTYyYTdkMDVlYmM0MV85_952b89e9-f439-4a54-a0f2-6f36bfda84a6">2020</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib9654dc8595e40e7b7fb7f68cfe474d9_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzMtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjoxMzJhNmMzZDdhM2I0ZGE1YmZhNWVjM2NhMzJhZGNhYl80_f93f8fcc-9bb9-4e32-a0f4-37f3d31a1c63">2014</ix:nonNumeric> - <ix:nonNumeric contextRef="id511e68e76754c458cbf0c440955486c_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzMtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjoxMzJhNmMzZDdhM2I0ZGE1YmZhNWVjM2NhMzJhZGNhYl85_ffa53776-5c78-4e03-b00e-330647102d5b">2020</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie55c0ff42c4544718880dceec02e3876_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzQtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjpiZTgzMDI5YmE2NTk0ZTZjYjM2MDhkNjhlZjI0M2FmNF80_e017599d-7148-4cde-bb6a-b518bd0a91af">2013</ix:nonNumeric> - <ix:nonNumeric contextRef="id991a25ce8c1481ca65b4088fe2e5c6e_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzQtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjpiZTgzMDI5YmE2NTk0ZTZjYjM2MDhkNjhlZjI0M2FmNF85_08a1ecd6-eab4-4ac3-b108-6983424612ff">2020</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i87eff35348ef4c22b0f0c14d5d1ff9a7_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzUtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjpjYzJhNTQxMmFiZTA0MjcwOTUzMTVmOGZlNjE5YTYwN180_bde02128-c289-43db-81f8-be4aa097cb97">2016</ix:nonNumeric> - <ix:nonNumeric contextRef="i8fbc8562b9bc45179604d0b354d37975_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzUtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjpjYzJhNTQxMmFiZTA0MjcwOTUzMTVmOGZlNjE5YTYwN185_66e7c8d0-845d-436f-8d4e-a024b1a9fac9">2020</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i759223d752d2484cb3624693e092afd2_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzYtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjpmZmI4OTkyOWIwYTk0OTkyYmIwZjQ1ZmQwNzA1OTFlYV80_85c17654-2a19-4ada-bf97-f6d3c8cb457a">2016</ix:nonNumeric> - <ix:nonNumeric contextRef="i49ed113f8481479a94b3377274581c18_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzYtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjpmZmI4OTkyOWIwYTk0OTkyYmIwZjQ1ZmQwNzA1OTFlYV85_97750149-3d26-4f28-b77c-133d3ea20894">2020</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic758f54fa5494dee98621db67459a939_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzctMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjozNWYwZTc1Y2FlNDU0NTI3YWNiZTYzZGM5ZjdhZGVmZF80_ea378a51-0550-4522-9894-6b5c9561029c">2017</ix:nonNumeric> - <ix:nonNumeric contextRef="ib3721bdf19944087b6072d188479220b_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzctMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjozNWYwZTc1Y2FlNDU0NTI3YWNiZTYzZGM5ZjdhZGVmZF85_0f16ec10-0035-4308-9f2a-c87a7e556542">2020</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icf289905620f424a822098d370171d98_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzgtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo2MTUxODFmZDVjYzc0MzE1OTdiNzE3MmFiNzNhMzEyMF80_a8bfc3ad-5cd9-47a4-9887-a62595534492">2011</ix:nonNumeric> - <ix:nonNumeric contextRef="i8197dcace8e546198e3aa3cab5f1e9ab_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzgtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo2MTUxODFmZDVjYzc0MzE1OTdiNzE3MmFiNzNhMzEyMF85_484df506-c68f-4620-b7aa-bf9d65f34777">2020</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib1878eebcc48403e8da37dd8ccee3c33_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzktMi0xLTEtODM0MTMvdGV4dHJlZ2lvbjowMmJhZDcxNDgxZDQ0M2Q2YmQ2NzgyMjMyZDQ4NTkxNV8xMzE5NDEzOTUzMzMxNg_d04e00db-cc22-4e21-b6ed-518cfd504136">2017</ix:nonNumeric> - <ix:nonNumeric contextRef="i5cecc7e2447a473eacca025ceba50171_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzktMi0xLTEtODM0MTMvdGV4dHJlZ2lvbjowMmJhZDcxNDgxZDQ0M2Q2YmQ2NzgyMjMyZDQ4NTkxNV8xMzE5NDEzOTUzMzMyMg_6c1fcd24-9772-466c-b364-fc1f48031ee3">2020</ix:nonNumeric></span></div></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Internal Revenue Service (the "IRS") completed its examinations of the Company&#8217;s U.S. consolidated federal income tax returns for the years 2013 and 2014. There were no material adjustments to the Company's taxable income as a result of these examinations.  However, the 2014 tax year remains open to the extent of a 2017 capital loss carried back to that year. Additionally, the IRS has selected for examination the Company's annual tax filings for 2015 and 2016 and the Company's short period tax return for the period ended September 8, 2017, which was filed as a result of the Company's internal restructuring efforts during 2017. In 2017, the Company undertook an internal restructuring in the form of what is commonly known as a Granite Trust transaction, which resulted in a recorded capital loss (the &#8220;2017 Capital Loss&#8221;). Recently, the Company has received a notice of proposed adjustment from the IRS that would disallow the 2017 Capital Loss and expects to receive a notice of proposed tax deficiency from the IRS, after which the Company intends to contest proposed tax deficiency through the IRS administrative appeals process. If the Company were ultimately unsuccessful in defending its position, and all or a substantial portion of the 2017 Capital Loss deduction were disallowed, the Company could be liable for additional taxes (excluding penalties and interest) of up to $<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzQzOTgwNDY1NDUyMzg_3301367d-b4e4-4b04-80e4-fc164eadc709">2,100</ix:nonFraction>&#160;million, which could have an adverse effect on the Company&#8217;s financial condition and results of operations. The Company intends to vigorously defend its position, including through appropriate litigation, if necessary, and ultimately believes it will sustain its deduction of the 2017 Capital Loss, and, accordingly, no income tax provision has been recorded.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently under examination by the Canada Revenue Agency (&#8220;CRA&#8221;) for three separate cycles: (a) years 2012 through 2013 (b) years 2014 through 2015, and (c) years 2016 through 2017.  The Company believes that the CRA will open an audit cycle for the years 2018 &#8211; 2019 in 2022.  The Company settled the tax years from 2005 through 2009 </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="idce818350c744c739033bd471cdb141e"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the CRA. The Company had previously filed a Notice of Objection related to the assessment of these years and reduced net operating losses with a full valuation allowance by CAD <ix:nonFraction unitRef="cad" contextRef="i3452627b08104c328663beda89ef7e2b_I20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzEwOTk1MTE2Njg1MzE_7fe0c880-a53b-4014-9114-d600f95e457a">44</ix:nonFraction>&#160;million to close these years.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The adjustment did not result in a material change to the provision for income taxes.  The CRA audits of the 2010 and 2011 tax years were closed in 2016 and resulted in no material adjustments. The Company received an assessment for certain transfer pricing matters in 2012 and 2013 for CAD <ix:nonFraction unitRef="cad" contextRef="i53b67fa0263542b89545f1c28636acdc_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzQ5NDc4MDIzNDEyMzQ_8decd5cb-f5b9-42e1-8ba2-41dba49055b9">85</ix:nonFraction>&#160;million and CAD <ix:nonFraction unitRef="cad" contextRef="i70a5dd9dc5d24412b0837e57866d62ab_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzQ5NDc4MDIzNDEyODQ_946388e0-6061-4e77-b894-9b8e6f92f96c">90</ix:nonFraction>&#160;million, respectively.  The Company disagrees with the adjustments and has filed a Notice of Objection for 2012 and 2013.  The Company settled certain transfer pricing matters relating the 2015 and 2016 tax years resulting in a reduction to its NOLs of approximately CAD <ix:nonFraction unitRef="cad" contextRef="ie44b34f6fd784806a1de35a90e5cd3c2_I20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzEwOTk1MTE2NDcwNzQ_10c0f859-2128-4d1a-b029-c7d186d176e5">21</ix:nonFraction>&#160;million for 2015 and will receive a further adjustment for 2016.  The expected adjustment for 2016 will reduce NOLs currently offset by a full valuation allowance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s subsidiaries in Germany are under audit for tax years 2014 through 2016.  At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries in Australia are under audit by the Australian Tax Office for various years beginning in 2010. On August 8, 2017, the Australian Taxation Office issued a notice of assessment for the tax years 2011 through 2017 in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="ifd17b9aaa43542b6ad701f3288d43039_D20170808-20170808" decimals="-6" name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzEwOTMy_8daf7a14-9073-4375-8ff0-56bc1f503d39">117</ix:nonFraction> million, which includes penalties and interest.  The Company disagrees with the assessment and continues to believe that its tax positions are appropriate and supported by the facts, circumstances and applicable laws. The Company intends to defend its tax position in this matter vigorously and has filed a holding objection against the assessment by the Australian Taxation Office and has secured a bank guarantee to cover any potential cash outlays regarding this assessment. The bank guarantee has been reduced over time to now be an immaterial value.  Negotiations with the Australian Tax Office are ongoing and the Company expects to enter into a Settlement Deed in early 2022 with no material adverse results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain affiliates of the Company in regions outside of Canada, the U.S., Germany, Luxembourg and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits.  At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.</span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzEyMjgz_d93e67de-0e74-4a4d-b428-262273532d4d" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the unrecognized tax&#160;benefits for 2021, 2020 and 2019: </span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzEtMi0xLTEtNTk0NzA_3d075610-37b4-4eee-bbea-8c8ff138b8d8">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzEtNC0xLTEtNTk0NzA_803000d1-a24b-47dc-93f2-49ed1ecca8a3">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a9900560564bdca7dec25381689c13_I20181231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzEtNi0xLTEtNTk0NzA_73dccbf3-dc3c-4deb-8312-da8ab4bd9a3f">654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzItMi0xLTEtNTk0NzA_d5b16662-4a19-4e7e-bac3-54e90914bbf1">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzItNC0xLTEtNTk0NzA_c606ccb6-a378-4168-9f18-b1ea7e974c7e">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzItNi0xLTEtNTk0NzA_eaaccc02-5953-4a73-89a5-d1584558989a">361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzMtMi0xLTEtNTk0NzA_1ac6c21e-8b63-483f-ad01-474d1d4ecb18">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzMtNC0xLTEtNTk0NzA_139d2ff1-10a2-433f-81de-5781856ec67b">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzMtNi0xLTEtNTk0NzA_67bd63eb-1672-4f84-b95c-e1b7a60843eb">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzQtMi0xLTEtNTk0NzA_839ebc16-d62c-46df-9051-e171b4eedfd9">129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzQtNC0xLTEtNTk0NzA_62081c18-46d3-4023-9856-e10d9a3aac4a">209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzQtNi0xLTEtNTk0NzA_5b57ea55-560c-4462-9ddc-354222f703ff">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzUtMi0xLTEtNTk0NzA_da88305d-fbc8-4df5-8311-28523ab5ee4b">169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzUtNC0xLTEtNTk0NzA_d1c6d1b1-908c-4bbb-a01f-e728c78f4514">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzUtNi0xLTEtNTk0NzA_8b3b82cb-12d7-475c-b67d-53d24858e0da">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzYtMi0xLTEtNTk0NzA_a937ebc6-7217-4cee-9311-636623a7423a">927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzYtNC0xLTEtNTk0NzA_718335f9-e560-4197-bfb8-1d70a91421e6">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzYtNi0xLTEtNTk0NzA_7ba9d419-2933-40fa-8440-517af0d5cc98">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes it is reasonably possible that the total amount of unrecognized tax benefits at December 31, 2021 could decrease by approximately $<ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzEyMTYw_2a42907c-b4d3-4dbc-a357-d95aa19a0570">104</ix:nonFraction> million in the next twelve months as a result of the resolution of certain tax and transfer pricing audits and other events.</span></div></ix:continuation><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_355"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90ZXh0cmVnaW9uOjgxNTNlNjc0ZWI0NTQ4ZTFiN2ZlMmYxMTI5MGUxNjRhXzg1OQ_4e44e880-ad58-46c3-befe-df2c8109d793" continuedAt="iaa5909ce6b4e432cb95711e6b94fa950" escape="true">LOSS  PER SHARE</ix:nonNumeric></span></div><ix:continuation id="iaa5909ce6b4e432cb95711e6b94fa950" continuedAt="ia70888eb475d4bd6bd80beeafd828b4e"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90ZXh0cmVnaW9uOjgxNTNlNjc0ZWI0NTQ4ZTFiN2ZlMmYxMTI5MGUxNjRhXzg1Mg_1955c916-a15b-4cec-b04b-1f476e7e54e1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per share attributable to Bausch Health Companies Inc. for 2021, 2020 and 2019 were calculated as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzEtMi0xLTEtNTk0NzA_90f95891-ab6f-4f9d-b395-1e052c39e3d7">948</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzEtNC0xLTEtNTk0NzA_e1abced3-bf2d-44ad-8d87-6fa227998996">560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzEtNi0xLTEtNTk0NzA_7072f686-5ae0-4453-aa9b-4d4313d967cd">1,788</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzItMi0xLTEtNTk0NzA_bf7c322b-2330-48c3-a41a-3556374f2264"><ix:nonFraction unitRef="shares" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzItMi0xLTEtNTk0NzA_dc217327-9b0c-41d0-aeed-3bbf696361d5">358.9</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzItNC0xLTEtNTk0NzA_783f1f4b-0c82-4b21-b81d-c150fe0c8be1"><ix:nonFraction unitRef="shares" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzItNC0xLTEtNTk0NzA_b6e8e2ac-a23e-4ead-a816-aafc6e27e366">355.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzItNi0xLTEtNTk0NzA_3d22f8e7-5995-4e56-b3ac-10e62f429d06"><ix:nonFraction unitRef="shares" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzItNi0xLTEtNTk0NzA_a777cb45-f378-4bdd-83f0-ebe49edbc350">352.1</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzMtMi0xLTEtNTk0NzA_6bfe1f29-6bb2-4c98-b985-233951c0848a"><ix:nonFraction unitRef="usdPerShare" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzMtMi0xLTEtNTk0NzA_eaaee5fa-eb36-402e-9c1d-4b7f2d6240d8">2.64</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzMtNC0xLTEtNTk0NzA_32c2d90e-0020-409d-8471-9493205b88cf"><ix:nonFraction unitRef="usdPerShare" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzMtNC0xLTEtNTk0NzA_784778d6-362d-4b89-b0a3-60b718985a9f">1.58</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzMtNi0xLTEtNTk0NzA_2c3528e7-1b3b-43fb-8f04-205c092bb6cd"><ix:nonFraction unitRef="usdPerShare" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzMtNi0xLTEtNTk0NzA_60870a37-eb91-4c1a-a4e1-af86b843ba92">5.08</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ia70888eb475d4bd6bd80beeafd828b4e"><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, 2020 and 2019, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive.  The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately <ix:nonFraction unitRef="shares" contextRef="ie898e2aab45345c9b42d7a2acb631663_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90ZXh0cmVnaW9uOjgxNTNlNjc0ZWI0NTQ4ZTFiN2ZlMmYxMTI5MGUxNjRhXzQ5MA_ef4ecb97-972e-4044-aaa6-ba02054ad1b4">4,932,000</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="id033c0ed7fc74052a6c84265f651ad67_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90ZXh0cmVnaW9uOjgxNTNlNjc0ZWI0NTQ4ZTFiN2ZlMmYxMTI5MGUxNjRhXzQ5NA_3ca271b1-a83c-40b3-b578-426a20c65091">3,154,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6b0d284e351c45f6a89f189993ae032b_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90ZXh0cmVnaW9uOjgxNTNlNjc0ZWI0NTQ4ZTFiN2ZlMmYxMTI5MGUxNjRhXzUwMQ_11863577-112b-467b-9a09-38882601b60e">5,106,000</ix:nonFraction> common shares for 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in 2021, 2020 and 2019, stock options, time-based RSUs and performance-based RSUs to purchase approximately <ix:nonFraction unitRef="shares" contextRef="i4a5a4c310e574205b818538430461c33_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90ZXh0cmVnaW9uOjgxNTNlNjc0ZWI0NTQ4ZTFiN2ZlMmYxMTI5MGUxNjRhXzY0NQ_0c346ada-b1d8-46eb-9463-0c3f39f54bfd">3,428,000</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i393b10cfe703474a8e599f0e963d3334_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90ZXh0cmVnaW9uOjgxNTNlNjc0ZWI0NTQ4ZTFiN2ZlMmYxMTI5MGUxNjRhXzY0OQ_1a1133ea-af6b-48c1-bd78-1435248c5de7">9,551,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic8cc4183f807420fa113cead38c11868_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90ZXh0cmVnaW9uOjgxNTNlNjc0ZWI0NTQ4ZTFiN2ZlMmYxMTI5MGUxNjRhXzY1Ng_f05aa480-5647-4a60-9029-5c2de89cb4b1">2,598,000</ix:nonFraction> common shares of the Company, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During 2021, an additional <ix:nonFraction unitRef="shares" contextRef="i246d722a091f4f0080937e3f56bdb622_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90ZXh0cmVnaW9uOjgxNTNlNjc0ZWI0NTQ4ZTFiN2ZlMmYxMTI5MGUxNjRhXzEwOTk1MTE2Mjg5MDE_8b313ad1-c239-4379-8138-dc284fe84706">156,000</ix:nonFraction> performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.</span></div></ix:continuation><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_358"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTgvZnJhZzplZGY1ZDdhN2IxMTQ0ODNkYmFkNTkwY2JlNGY5YmFlYy90ZXh0cmVnaW9uOmVkZjVkN2E3YjExNDQ4M2RiYWQ1OTBjYmU0ZjliYWVjXzY2_b66a5685-d6cc-48f1-a711-3c8530410002" continuedAt="i075161f405034e7ea67c8367f984ef9f" escape="true">SUPPLEMENTAL CASH FLOW DISCLOSURES </ix:nonNumeric></span></div><ix:continuation id="i075161f405034e7ea67c8367f984ef9f"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTgvZnJhZzplZGY1ZDdhN2IxMTQ0ODNkYmFkNTkwY2JlNGY5YmFlYy90ZXh0cmVnaW9uOmVkZjVkN2E3YjExNDQ4M2RiYWQ1OTBjYmU0ZjliYWVjXzY4_38d3d0df-b71e-4fad-8b68-b8b9a2954a66" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow disclosures for 2021, 2020 and 2019 are as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTgvZnJhZzplZGY1ZDdhN2IxMTQ0ODNkYmFkNTkwY2JlNGY5YmFlYy90YWJsZTpmN2M3ZTA5YjMyODg0ZmExOTJiMjEzY2Y3YmUyYzc5Mi90YWJsZXJhbmdlOmY3YzdlMDliMzI4ODRmYTE5MmIyMTNjZjdiZTJjNzkyXzItMi0xLTEtNTk0NzA_2b6376b5-f4f2-4111-aca4-d69208f1016f">1,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTgvZnJhZzplZGY1ZDdhN2IxMTQ0ODNkYmFkNTkwY2JlNGY5YmFlYy90YWJsZTpmN2M3ZTA5YjMyODg0ZmExOTJiMjEzY2Y3YmUyYzc5Mi90YWJsZXJhbmdlOmY3YzdlMDliMzI4ODRmYTE5MmIyMTNjZjdiZTJjNzkyXzItNC0xLTEtNTk0NzA_632f7e49-0c1e-4e59-bf03-8e435bf40ae5">1,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTgvZnJhZzplZGY1ZDdhN2IxMTQ0ODNkYmFkNTkwY2JlNGY5YmFlYy90YWJsZTpmN2M3ZTA5YjMyODg0ZmExOTJiMjEzY2Y3YmUyYzc5Mi90YWJsZXJhbmdlOmY3YzdlMDliMzI4ODRmYTE5MmIyMTNjZjdiZTJjNzkyXzItNi0xLTEtNTk0NzA_28b2bde8-f90c-452a-9709-bc372490b0cf">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTgvZnJhZzplZGY1ZDdhN2IxMTQ0ODNkYmFkNTkwY2JlNGY5YmFlYy90YWJsZTpmN2M3ZTA5YjMyODg0ZmExOTJiMjEzY2Y3YmUyYzc5Mi90YWJsZXJhbmdlOmY3YzdlMDliMzI4ODRmYTE5MmIyMTNjZjdiZTJjNzkyXzMtMi0xLTEtNTk0NzA_8b9f8028-3e51-4264-a5f2-b2a5d7d30cf4">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTgvZnJhZzplZGY1ZDdhN2IxMTQ0ODNkYmFkNTkwY2JlNGY5YmFlYy90YWJsZTpmN2M3ZTA5YjMyODg0ZmExOTJiMjEzY2Y3YmUyYzc5Mi90YWJsZXJhbmdlOmY3YzdlMDliMzI4ODRmYTE5MmIyMTNjZjdiZTJjNzkyXzMtNC0xLTEtNTk0NzA_f8e68216-e21b-49de-882a-e7912645819f">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTgvZnJhZzplZGY1ZDdhN2IxMTQ0ODNkYmFkNTkwY2JlNGY5YmFlYy90YWJsZTpmN2M3ZTA5YjMyODg0ZmExOTJiMjEzY2Y3YmUyYzc5Mi90YWJsZXJhbmdlOmY3YzdlMDliMzI4ODRmYTE5MmIyMTNjZjdiZTJjNzkyXzMtNi0xLTEtNTk0NzA_2d42b383-44d4-4adf-91a2-a43fc09a5e27">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_361"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzYzNjA5_5e6fbd5c-7b1f-4c16-ad2b-2bed917ecdd2" continuedAt="i4a7ba07e25d04764a84c36e1c195a42b" escape="true">LEGAL PROCEEDINGS</ix:nonNumeric></span></div><ix:continuation id="i4a7ba07e25d04764a84c36e1c195a42b" continuedAt="i5e386ad37ce143409bb0ce7a815fac9b"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described below. Going forward, in the Company's subsequent Quarterly Reports on Form 10-Q, the Company will only include a description of these matters to the extent there has been a material update with respect thereto during the applicable quarter or to the extent otherwise required by law.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of December 31, 2021, the Company's Consolidated Balance Sheets includes accrued current loss contingencies of $<ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="bhc:Legalsettlementsandrelatedfees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEyNjY_5c15f5a7-5871-45da-9d93-65eb45878f24">1,890</ix:nonFraction> million related to matters which the Company believes a potential resolution or settlement is both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental and Regulatory Inquiries</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney's Office for the District of Massachusetts - re OraPharma</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts, requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including related support services, and other matters.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is cooperating with this investigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658). On January 31, 2021, the District Court </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i5e386ad37ce143409bb0ce7a815fac9b" continuedAt="i9008ee78e4214bb7bcd7782b660360cf"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill LLC filed a notice of appeal of the Court&#8217;s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options.  On March 1, 2021, Cathy Lochridge filed a notice of appeal of the Court&#8217;s final approval order, which overruled her objections as to the attorneys&#8217; fees awarded to class counsel. On October 14, 2021, Timber Hill dismissed its appeal of the final approval order. On December 20, 2021, the Third Circuit denied Lochridge&#8217;s appeal. On January 3, 2022, Lochridge filed a petition for rehearing of the appeal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">en banc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which remains pending.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2015, <ix:nonFraction unitRef="case" contextRef="i91b2ee61b3794c97a503eb91ca7419fb_D20151001-20151031" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzM0MDk_2cd9dd78-0008-49be-b2c3-d742fcfd7ccf">four</ix:nonFraction> putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#8217;s business and prospects, including relating to drug pricing, the Company&#8217;s use of specialty pharmacies, and the Company&#8217;s relationship with Philidor. On May 31, 2016, the court entered an order consolidating the <ix:nonFraction unitRef="case" contextRef="i91b2ee61b3794c97a503eb91ca7419fb_D20151001-20151031" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzM5NTA_4a812c39-ca55-4a8d-9139-f6b35c6b366b">four</ix:nonFraction> actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $<ix:nonFraction unitRef="usd" contextRef="i06c668190ea847209a8da86cf1e73998_D20191216-20191216" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzQyNTA_2aa53740-7007-48ba-8c23-e0201a857624">1,210</ix:nonFraction> million, subject to final court approval. This settlement received final approval from the court on January 31, 2021 and will resolve and discharge all claims against the Company in the class action.  As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement remains subject to an appeal of the final court approval (as such appeal is further described above). In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payments have been paid into an escrow account in accordance with the payment schedule outlined in the settlement agreement. These payments, less certain settlement expenses and attorneys' fees, will remain in escrow until resolution of the appeal of the final court approval of the settlement agreement. The opt-out litigations discussed below remain ongoing. As of December 31, 2021, Restricted cash and other settlement deposits includes an aggregate $<ix:nonFraction unitRef="usd" contextRef="id6c40f9f298a435e8a95ba9a81e42595_D20211231-20211231" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzY1OTcwNjk5NTcwNDQ_28ecc69c-47aa-49c7-b763-95b9a2c1beb9">1,210</ix:nonFraction>&#160;million of: (i) payments in the escrow fund and (ii) certain disbursements for settlement expenses and attorney's fees. Disbursements for attorney's fees remain refundable until resolution of the appeal of the final court approval of the settlement agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246) (&#8220;Timber Hill&#8221;), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#8217;s common stock during the period January 4, 2013 through August 11, 2016.  On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658).  On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated putative class action, <ix:nonFraction unitRef="group" contextRef="ia6542cc5b199449eb308666602a70acb_D20210101-20211231" decimals="INF" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzYwNzQ_6425438d-83c7-4e37-9209-40439f0e0e1b">thirty-seven</ix:nonFraction> groups of individual investors in the Company&#8217;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions are captioned: T. Rowe Price Growth Stock Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-5034); Equity Trustees Limited as Responsible Entity for T. Rowe Price Global Equity Fund v. Valeant Pharmaceuticals International Inc. (Case No. 16-cv-6127); Principal Funds, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-6128); BloombergSen Partners Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7212); Discovery Global Citizens Master Fund, Ltd. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7321); MSD Torchlight Partners, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7324); BlueMountain Foinaven Master Fund, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7328) (&#8220;BlueMountain&#8221;); Incline Global Master LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7494); VALIC Company I v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7496); Janus Aspen Series v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7497) (&#8220;Janus Aspen&#8221;); Okumus Opportunistic Value Fund, LTD v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6513) (&#8220;Okumus&#8221;); Lord Abbett Investment Trust- Lord Abbett Short Duration Income Fund, v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6365) (&#8220;Lord Abbett&#8221;); Pentwater Equity Opportunities Master Fund LTD v. Valeant Pharmaceuticals International, Inc., et al. (Case No. 17-cv-7552) (&#8220;Pentwater&#8221;); Public Employees&#8217; Retirement System of Mississippi v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-7625) (&#8220;Mississippi&#8221;); The Boeing Company Employee Retirement Plans Master Trust v. Valeant Pharmaceuticals International Inc., et al., (Case No. 17-cv-7636) (&#8220;Boeing&#8221;); State Board of Administration of Florida v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-12808); The Regents of the University of California v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-13488); GMO Trust v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0089); F&#246;rsta AP Fonden v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-12088); New York City Employees&#8217; Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0032) </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i9008ee78e4214bb7bcd7782b660360cf" continuedAt="i2ed9f904c22d4eed809c462c964a5ebe"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;NYCERS&#8221;); Hound Partners Offshore Fund, LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08705) (&#8220;Hound Partners&#8221;); Blackrock Global Allocation Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0343) (&#8220;Blackrock&#8221;); Colonial First State Investments Limited As Responsible Entity for Commonwealth Global Shares Fund 1 v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0383); Bharat Ahuja v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0846); Brahman Capital Corp. v. Valeant Pharmaceuticals International, Inc (Case No. 18-cv-0893); The Prudential Insurance Company of America v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-01223) (&#8220;Prudential&#8221;); Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) (&#8220;Senzar&#8221;); 2012 Dynasty UC LLC v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08595) ("2012 Dynasty"); Catalyst Dynamic Alpha Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-12673) (&#8220;Catalyst&#8221;); Northwestern Mutual Life Insurance Co., v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-15286) (&#8220;Northwestern Mutual&#8221;); Bahaa Aly, et al. v. Valeant Pharmaceuticals International, Inc., (Case No. 18-cv-17393) (&#8220;Aly&#8221;); Office of the Treasurer as Trustee for the Connecticut Retirement Plans and Trust Funds v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18473) (&#8220;Connecticut&#8221;); Delaware Public Employees&#8217; Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18475) (&#8220;Delaware&#8221;); Maverick Neutral Levered Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-02190) (&#8220;Maverick&#8221;), Templeton v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-05478) (&#8220;Templeton&#8221;), USAA Mutual Funds Trust, et al. v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 20-cv-07462) (&#8220;USAA&#8221;), and GIC Private Ltd. v. Valeant Pharmaceuticals International, Inc., (Case No. 20-cv-07460) (&#8220;GIC&#8221;). <ix:nonFraction unitRef="case" contextRef="ia6542cc5b199449eb308666602a70acb_D20210101-20211231" decimals="INF" name="us-gaap:LossContingencyClaimsDismissedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwNzMx_b719770c-640d-46e4-9e7f-1eeefeecff0b">Sixteen</ix:nonFraction> of the <ix:nonFraction unitRef="group" contextRef="ia6542cc5b199449eb308666602a70acb_D20210101-20211231" decimals="INF" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwNzQx_6425438d-83c7-4e37-9209-40439f0e0e1b">thirty-seven</ix:nonFraction> opt-out actions have been dismissed; and the total number of remaining opt-out actions pending in the District of New Jersey is <ix:nonFraction unitRef="group" contextRef="ia6542cc5b199449eb308666602a70acb_D20210101-20211231" decimals="INF" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwODcy_82e180be-9476-4072-8f27-4b8821bb381f">twenty-one</ix:nonFraction> actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These individual shareholder actions assert claims under Sections 10(b), and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2), and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss have been filed and in most cases decided in many of these individual actions. To date, the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) opt-out action, closing the case.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2019, the Court granted defendants&#8217; motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (&#8220;Aly&#8221;) (Case No. 18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 16, 2021, the Court of Appeals granted plaintiffs&#8217; appeal in the Aly action. This action has been remanded to the District Court. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut, and Delaware actions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, and March 10, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds, Pentwater, Lord Abbett, Equity Trustees, and UC Regents actions. On April 30, 2021, the Court entered a stipulation of voluntary dismissal in the Florida SBA action.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021, the Court entered a stipulation of voluntary dismissal in the Janus action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Securities Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, <ix:nonFraction unitRef="case" contextRef="ifd485be691b84f43ab57f11e016f9b16_D20150101-20151231" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEzMTgz_48d7e1c7-5ad8-4e5b-a417-0053c8209fa4">six</ix:nonFraction> putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. These actions are captioned: (a) Alladina v. Valeant, et al. (Case No. S-1594B6) (Supreme Court of British Columbia) (filed November 17, 2015); (b) Kowalyshyn v. Valeant, et al. (CV-15-540593-00CP) (Ontario Superior Court) (filed November 16, 2015); (c) Kowalyshyn et al. v. Valeant, et al. (CV-15-541082-00CP) (Ontario Superior Court) (filed November 23, 2015); (d) O&#8217;Brien v. Valeant et al. (CV-15-543678-00CP) (Ontario Superior Court) (filed December 30, 2015); (e) Catucci v. Valeant, et al. (Court File No. 540-17-011743159, then Court File No. 500-06-000783-163) (Quebec Superior Court) (filed October 26, 2015); and (f) Rousseau-Godbout v. Valeant, et al. (Court File No. 500-06-000770-152) (Quebec Superior Court) (filed October 27, 2015). </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also aware of <ix:nonFraction unitRef="action" contextRef="if49a279281c940c0bb5c71ec87be9d3c_D20210101-20211231" decimals="INF" name="bhc:LossContingencyNewClaimsFiledButNotYetServedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzE0MTEx_3f82e3aa-8770-4291-8836-ee47eb5e2079">two</ix:nonFraction> additional putative class actions that were filed with the applicable court but which have not been served on the Company. These actions are captioned: (i) Okeley v. Valeant, et al. (Case No. S-159991) (Supreme Court of British Columbia) (filed December 2, 2015); and (ii) Sukenaga v Valeant et al. (CV-15-540567-00CP) (Ontario </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i2ed9f904c22d4eed809c462c964a5ebe" continuedAt="i09a747f569754af184aafc33ff5aec50"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Superior Court) (filed November 16, 2015), and the factual allegations made in these actions are substantially similar to those outlined herein.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, was discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#8217;s auditors and the action was dismissed as against them. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD <ix:nonFraction unitRef="cad" contextRef="i3eca502d770d4373a854ca461ac2dffb_D20200804-20200804" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzE1Nzc4_037f9880-2125-46c4-88bf-587f5fb63ce1">94</ix:nonFraction> million plus payment of an additional amount to cover notice and settlement administration costs and disbursements.  As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action.  On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, <ix:nonFraction unitRef="entity" contextRef="i35775310d73b4d409433acee7c99eb8c_I20190215" decimals="INF" name="bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzE3MjAz_a4a895f8-a420-4774-9b59-419ebfb93e23">one</ix:nonFraction> of the entities which exercised its opt-out rights, the California State Teachers' Retirement System (&#8220;CalSTRS&#8221;), served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#8217; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision. The appeal was heard on September 29, 2021 and, by judgment dated October 29, 2021, the appeals were dismissed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#8220;price appreciation credits&#8221; in respect of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the period covered by the claims. A hearing was held on February 17, 2021 with respect to whether CalSTRS would be permitted to file the proposed amended proceedings. On June 9, 2021, the Quebec Superior Court granted the Company&#8217;s application to strike the new allegations from its Quebec Securities Act claim, but permitted the amendments to its claim under the Quebec Civil Code. On December 8, 2021, CalSTRS delivered its amended pleadings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2021, <ix:nonFraction unitRef="numberofbusiness" contextRef="i73250b3b65e14dc084f6d77a1b839bb1_I20210317" decimals="INF" name="bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwOTk1MTE3OTY0MTI_87bded6f-ba40-4107-b872-b1e8703201aa">four</ix:nonFraction> additional opt-outs from the Catucci class issued a Statement of Claim in the Ontario Superior Court of Justice. That proceeding is captioned The Bank of Korea et al. v. Valeant Pharmaceuticals International Inc. et al. (Court File No. 21-00658966-0000). In addition, these plaintiffs also served and filed a motion for leave to pursue claims under the Ontario Securities Act. The allegations in this proceeding are similar to those made by the plaintiffs in the Catucci class action and the plaintiffs in the opt-out actions described above. </span></div><div style="margin-top:7.5pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i09a747f569754af184aafc33ff5aec50" continuedAt="i39bee5a36b0a4f9ca4593bd332f04909"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RICO Class Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between May 27, 2016 and September 16, 2016, <ix:nonFraction unitRef="action" contextRef="i0f0be9ec6ddf45658d3a7d087aa67006_D20160527-20160916" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzIwMTE1_f23b244a-e747-4bc1-96f3-20f9ac5ce88e">three</ix:nonFraction> actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (&#8220;RICO&#8221;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160; The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#8217;s consent to renew the prescription.&#160; The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.  On August 4, 2021, the Company executed a stipulation of settlement for this action and, on August 17, 2021, the Court preliminarily approved the settlement.  On December 6, 2021 the Special Master overseeing this litigation issued a report and recommendation recommending final approval of the settlement, and on February 22, 2022 the settlement was approved by the district court. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Coverage Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during <ix:nonFraction unitRef="insurance_policy_period" contextRef="i7ebadc5ebb4b4ab7890bec9925824363_D20171207-20171207" decimals="INF" name="bhc:LossContingencyNumberOfInsurancePolicyPeriods" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwOTk1MTE3OTY0MjI_115ecda7-1241-43e9-b862-076f35130d60">two</ix:nonFraction> distinct policy periods, (i) 2013-14 and (ii) 2015-16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; 3:18-CV-00493).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (the &#8220;Allergan Securities Litigation&#8221;) (under the 2013-2014 coverage period), and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and the SEC Investigation and certain of the other investigations described under &#8220;Complete or Inactive Matters&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021 and under &#8220;Governmental and Regulatory Inquiries&#8221; and &#8220;Complete or Inactive Matters&#8221; in Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020 (under the 2015-2016 coverage period).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021, the Company entered into settlement agreements with the insurers in the 2015-2016 coverage period in which the Company agreed to resolve its claims for insurance coverage in connection with the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-out litigation and related investigations matters described above.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On that same day, the Company entered into settlement agreements with <ix:nonFraction unitRef="insured" contextRef="i02a698a8f008492cbd69f48f20e081f8_I20210720" decimals="INF" name="bhc:LossContingencySettlementAgreementsNumberOfInsurers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwOTk1MTE3OTY0MzA_5c8b6cd7-b0ce-4822-9ca5-4aa13fdb3f23">two</ix:nonFraction> of its insurers in the 2013-2014 coverage period in which the Company agreed to resolve its claims against those <ix:nonFraction unitRef="insured" contextRef="i02a698a8f008492cbd69f48f20e081f8_I20210720" decimals="INF" name="bhc:LossContingencySettlementAgreementsNumberOfInsurers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwOTk1MTE3OTY0Mzg_65e81f26-c3ad-41f5-b69a-3e51fad29425">two</ix:nonFraction> insurers only for insurance coverage in connection with the Allergan Securities Litigation. As a result of all of the settlement agreements entered into with the insurers on July 20, 2021, the Company has received an aggregate sum of $<ix:nonFraction unitRef="usd" contextRef="i32cfd64f67674351a47e22d698db3e9e_D20210720-20210720" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwOTk1MTE3OTY0NDc_ae1fc1a5-061f-41f0-936a-fd146e7ebf81">213</ix:nonFraction>&#160;million. The Company&#8217;s insurance claims with respect to the Allergan Securities Litigation against the remaining insurers in the 2013-2014 coverage period remain pending.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hound Partners Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP, and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County.  This action is captioned Hound Partners Offshore Fund, LP et al., v. Valeant Pharmaceuticals International, Inc., et al. (No. MER-L-002185-18).  This suit asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pricing Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's subsidiaries, Oceanside Pharmaceuticals, Inc. (&#8220;Oceanside&#8221;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#8220;Bausch Health US&#8221;), and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#8220;Bausch Health Americas&#8221;) (for the purposes of this paragraph, collectively, the &#8220;Company&#8221;), are defendants in multidistrict antitrust litigation (&#8220;MDL&#8221;) entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Generic Pharmaceuticals Pricing </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i39bee5a36b0a4f9ca4593bd332f04909" continuedAt="i8ebd0d3d49c84a2a99c3752fea637882"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, pending in the United States District Court for the Eastern District of Pennsylvania (MDL No. 2724, 16-MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#8217;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. There are cases pending in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed in the cases. The cases have been put in deferred status. The Company disputes the claims against it and continues to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively &#8220;the Company&#8221;) have been named as defendants in a proposed class proceeding entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kathryn Eaton v. Teva Canada Limited, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that the Company and other defendants violated the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Generic Pharmaceuticals Pricing Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and will defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza State-Law Insurer Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff from the federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822-WHA (N.D. Cal.) (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) (discussed in further detail below) filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;).  The State Court Action alleges that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or grant any other company a license to do so.  The State Court Action alleges that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. On September 20, 2021, the parties stipulated that the insurer plaintiff&#8217;s direct opt-out claims from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, discussed below, were deemed asserted in the State Court Action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defendants&#8217; demurrer in the State Court Action was heard on September 22, 2021.  On November 11, 2021, the court denied the motion in part and granted it in part as to certain state law claims, with leave to amend.  The insurer plaintiff did not amend the complaint. Defendants&#8217; answers were filed on February 3, 2022. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation/Paragraph IV Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550mg, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States, and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Canada or other similar suits.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2020, the Company and Alfasigma S.p.A. ("Alfasigma") received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;), in which Norwich asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#8217;s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (&#8220;ANDA&#8221;) has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and owns or exclusively licenses (from Alfasigma) these patents.  On March 26, 2020, certain of the Company&#8217;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a <ix:nonNumeric contextRef="i06854e40aeff47b0b797200881bfe88d_D20190901-20190930" name="bhc:LossContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzMzMDQ0_beebe9de-747e-49b8-91cb-41fe7601426a">30</ix:nonNumeric>-month stay of the approval of Norwich&#8217;s ANDA for rifaximin tablets, 550 mg. Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is protected by 26 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. A 3-day bench trial is scheduled to begin March 21, 2022. The Company </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i8ebd0d3d49c84a2a99c3752fea637882" continuedAt="i11a94a5e9a984cb280d60850e05e2cb7"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remains confident in the strength of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (now Padagis LLC) (&#8220;Padagis&#8221;), in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA's Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic lotion, for which an ANDA has been filed by Padagis.  On August 28, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a <ix:nonNumeric contextRef="i4bd7415ed1604a45b4b6bc56767acc83_D20200828-20200828" name="bhc:LossContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzQwMjI5_9b6d5ab4-8f32-49a7-9bb7-ef105baf5f10">30</ix:nonNumeric>-month stay of the approval of the Padagis ANDA.  On September 3, 2020, this action was consolidated with the action between the Company and Padagis described below, regarding Padagis&#8217; ANDA for generic Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion. The Company remains confident in the strength of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related patents and will vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Padagis, in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic halobetasol propionate lotion, for which an ANDA has been filed by Padagis.  On May 1, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a <ix:nonNumeric contextRef="i35ab857c3fb443e7906b7fc3fdb47b2f_D20200501-20200501" name="bhc:LossContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzQxMjQ5_9f942def-60da-4d38-944c-1460ad14c8c6">30</ix:nonNumeric>-month stay of the approval of the Padagis ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described above, regarding Padagis&#8217; ANDA for generic Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion. The Company remains confident in the strength of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company commenced litigation against MSN Laboratories Private Ltd. (&#8220;MSN&#8221;) and Mylan Pharmaceuticals Inc., (&#8220;Mylan&#8221;) alleging patent infringement by MSN&#8217;s and Mylan&#8217;s filing of their ANDA for generic Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) 3mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from each of MSN and Mylan, in which they had each asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 3 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of their respective generic plecanatide tablets, 3 mg.  The filing of these suits triggered a <ix:nonNumeric contextRef="i823e4afeb6cf4d59ae626d765f776286_D20210401-20210430" name="bhc:LossContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzI3NDg3NzkyMzgxMjg_360cbb3c-13a3-4c92-8f0c-5397c0e6d696">30</ix:nonNumeric>-month stay of the approval of the MSN and Mylan ANDAs for plecanatide tablets. The Company remains confident in the strength of the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company commenced litigation against Slayback Pharma LLC and Slayback Pharma India LLP (together, &#8220;Slayback&#8221;) alleging patent infringement by Slayback Pharma LLC&#8217;s filing of its ANDA No. 216361, referencing Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (0.025% brimonidine tartrate ophthalmic solution). This suit had been filed following receipt of a Notice of Paragraph IV Certification from Slayback Pharma LLC, in which it had asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brimonidine tartrate ophthalmic solution, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of its generic brimonidine tartrate solution.  The filing of this suit triggered a <ix:nonNumeric contextRef="ia07d23a8e2fc407d901667681d446493_D20210901-20210930" name="bhc:LossContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzI3NDg3NzkyMzgxNDA_2eab434a-96f8-4b9f-b213-1f78afc0b777">30</ix:nonNumeric>-month stay of the approval of the Slayback ANDA for its brimonidine tartrate solution.  The Company remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2022 the Company commenced litigation against Lupin Pharmaceuticals, Inc. (&#8220;Lupin&#8221;) alleging patent infringement by Lupin&#8217;s filing of its ANDA No. 216716, referencing Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (0.025% brimonidine tartrate ophthalmic solution). This suit had been filed following receipt of a Notice of Paragraph IV Certification from Lupin, in which it had asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brimonidine tartrate ophthalmic solution, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of its generic brimonidine tartrate solution.  The filing of this suit triggered a <ix:nonNumeric contextRef="i2837802deebf438f831c9248b84634f3_D20220202-20220202" name="bhc:LossContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwOTk1MTE4MTE0NTA_9a629a30-93ec-43ba-8782-ce852302eb50">30</ix:nonNumeric>-month stay of the approval of the Lupin ANDA for its brimonidine tartrate solution. The Company remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jublia Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patents covering the Company's branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review ("IPR") at the U.S. Patent &amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution. IPR challenges have been brought against patents covering the Company's branded pharmaceutical products. For example, following Acrux DDS&#8217;s IPR petition, the U.S. Patent and Trial Appeal Board ("PTAB"), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(U.S. Patent No. 7,214,506 (the "&#8216;506 Patent")) and, on </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i11a94a5e9a984cb280d60850e05e2cb7" continuedAt="ia7f312402ceb4c57a76ef60ee40e43e5"><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings.  As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion.   The &#8216;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is covered by fourteen Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and has timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada against four separate defendants.  All cases in the U.S. regarding Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been settled. In Canada, <ix:nonFraction unitRef="case" contextRef="i3142f2cfd5aa4bb08a1afccc27a8a806_I20211231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwOTk1MTE4MTE0NTY_33874e55-fd9d-42dd-b911-a53df48146b3">two</ix:nonFraction> lawsuits remain pending against Apotex Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Products Liability Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower&#174; body powder product acquired in September 2012 from Johnson &amp; Johnson; due to dismissals, twenty-nine (<ix:nonFraction unitRef="case" contextRef="i9cebf3bd98614f709e30c0cad5ae3945_I20211231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzQzMzQ2_89f14c44-f97b-4bbe-950f-91d14b695264">29</ix:nonFraction>) of such product liability suits currently remain pending. Potential liability (including its attorneys&#8217; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp; Johnson owed to the Company and its affiliates, and legal fees and costs will be paid by Johnson &amp; Johnson. Twenty-eight (<ix:nonFraction unitRef="case" contextRef="idf59e9f444d44941a03dff00106248fe_I20211231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzQzNDMy_f214bb47-3358-45f0-b1f5-c307308c0a89">28</ix:nonFraction>) of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the plaintiffs to develop ovarian cancer, mesothelioma or breast cancer. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages. The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#8217; fees. Additionally, <ix:nonFraction unitRef="case" contextRef="i668c09254646450da54e4779c1a1cf5c_I20211231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzI3NDg3NzkyMzgxNDY_8a337ed9-f9fd-4a18-82fe-394dab12d06e">two</ix:nonFraction> proposed class actions have been filed in Canada against the Company and various Johnson &amp; Johnson entities (<ix:nonFraction unitRef="case" contextRef="id333f2cd40c246d686e1bf05143b6d09_I20211215" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzI3NDg3NzkyMzgxNTQ_64500c56-9646-4098-a117-c991fb093276"><ix:nonFraction unitRef="case" contextRef="id08c64cba12f4488a204547ee19dbb28_D20211216-20211216" decimals="INF" name="us-gaap:LossContingencyClaimsDismissedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzI3NDg3NzkyMzgxNTQ_e9690e94-c05f-4385-b4ca-2a5765b82c3e">one</ix:nonFraction></ix:nonFraction> in the Supreme Court of British Columbia and <ix:nonFraction unitRef="case" contextRef="i4d1927896b7f467b9ea850d5899edaa8_I20211231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzI3NDg3NzkyMzgxNjI_61a37cc8-7f58-4d33-8688-850426f1911e">one</ix:nonFraction> in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp; Johnson&#8217;s Baby Powder or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. On November 17, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and at this time no appeal of that judgment has been filed. On December 16, 2021, the plaintiff in the British Columbia class action filed a Second Amended Notice of Civil Claim and Application for Certification, removing the Company as a defendant; as a result, the British Columbia class action is concluded as to the Company. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson, through one or more subsidiaries has purported to have completed a Texas divisional merger with respect to any talc liabilities at Johnson &amp; Johnson Consumer, Inc. (&#8220;JJCI&#8221;). LTL Management, LLC (&#8220;LTL&#8221;), the resulting entity of the divisional merger, assumed JJCI&#8217;s talc liabilities and thereafter filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the Western District of North Carolina. Pursuant to a court order, the case was transferred to the United States District Court for the District of New Jersey. Notwithstanding the divisional merger and LTL&#8217;s bankruptcy case, the Company and its affiliates continue to have indemnification claims and rights against Johnson &amp; Johnson and LTL pursuant to the terms of the indemnification agreement entered into between JJCI and its affiliates and the Company and its affiliates, which indemnification agreement remains in effect. As a result, it is the Company's current expectation that it will not incur any material impairments with respect to its indemnification claims as a result of the divisional merger or the bankruptcy. Substantially all cases subject to the indemnification agreement related to Johnson &amp; Johnson&#8217;s talc liability are stayed through February 28, 2022, pursuant to a preliminary injunction issued by the bankruptcy court. Motions to dismiss the LTL bankruptcy, as well as extend the stay beyond February 28, 2022, were argued in the bankruptcy court in February 2022. A decision of the court is pending. To the extent that any cases subject to the indemnification agreement proceed during the pendency of the bankruptcy case, it is the Company's expectation that Johnson &amp; Johnson, in accordance with the indemnification agreement, will continue to vigorously defend the Company in each of the remaining actions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Proposition 65 Related Matter</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp; Johnson (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gutierrez, et al. v. Johnson &amp; Johnson, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ia7f312402ceb4c57a76ef60ee40e43e5" continuedAt="ib17a92e8c4464699a16250a227efbbd3"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. The Company filed a motion to dismiss Plaintiffs&#8217; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted.  In August 2020, Plaintiffs filed the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss with prejudice. On February 19, 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals. On July 1, 2021, Appellants (Plaintiffs) filed their opening brief; Appellees' response briefs were filed on October 8, 2021. This matter was stayed by the Ninth Circuit on December 7, 2021, due to the preliminary injunction entered by the bankruptcy court in the LTL bankruptcy proceeding. This stay included Appellants&#8217; reply brief deadline, which was previously due to be filed on or before December 2, 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Consumer Protection Action</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc., the Company and Bausch Health US related to Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its alleged causal link to mesothelioma and other cancers.  In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its answer on November 16, 2020. On December 30, 2020 Johnson &amp; Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which was denied on March 8, 2021. Trial is scheduled to begin on January 18, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Doctors Allergy Formula Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Doctors Allergy Formula, LLC (&#8220;Doctors Allergy&#8221;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.  Doctors Allergy claims its damages are not less than $<ix:nonFraction unitRef="usd" contextRef="if5a5b7cb1bde4b00b20dc046470c7dbc_D20180401-20180430" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzU0OTkz_eacec469-67a7-4bad-9442-efd779cb73ac">23</ix:nonFraction> million. Bausch Health Americas has asserted counterclaims against Doctors Allergy. Bausch Health Americas filed a motion seeking an order granting Bausch Health Americas summary judgment on its counterclaims against Plaintiff and dismissing Plaintiff&#8217;s claims against it. The motion was fully briefed as of May 2021. The Court held a hearing on the motion on January 25, 2022. The motion remains pending. Bausch Health Americas disputes the claims against it and will continue to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Former Salix CEO</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, Case No. 2019-0059, asserting claims for breach of contract and declaratory relief.  On November 19, 2021, Logan amended her complaint to add a claim for breach of the implied covenant of good faith and fair dealing. The lawsuit arises out of the contractual termination of approximately $<ix:nonFraction unitRef="usd" contextRef="i3f954393aadc446fa7a66231a8a0176d_D20190128-20190128" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzU1OTMw_c1b7b6ef-1537-48c1-86aa-4ac4ab517cf6">30</ix:nonFraction> million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd.  Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification. On June 19, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. Trial is scheduled to commence on September 6, 2022. The Company disputes the claims and intends to vigorously defend the matter.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ib17a92e8c4464699a16250a227efbbd3" continuedAt="i37ab22e8d2d3431c8aea65e0e82d064a"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Completed or Inactive Matters</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following matters have concluded, have settled, are the subject of an agreement to settle or have otherwise been closed since January 1, 2021, have been inactive from the Company&#8217;s perspective for several quarters or the Company anticipates that no further material activity will take place with respect thereto. Due to the closure, settlement, inactivity or change in status of the matters referenced below, these matters will no longer appear in the Company's next public reports and disclosures, unless required. With respect to inactive matters, to the extent material activity takes place in subsequent quarters with respect thereto, the Company will provide updates as required or as deemed appropriate.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza Antitrust Litigation</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between August 2019 and July 2020, eight (<ix:nonFraction unitRef="case" contextRef="iaf28153bff85452b8ab343577fbba878_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzI3NDg3NzkyMzgxNzQ_61146afe-31df-4432-ad7f-b77c653fc543">8</ix:nonFraction>) putative antitrust class actions and four (<ix:nonFraction unitRef="case" contextRef="i705b99b9e9f141cea120e4f7552a841d_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzI3NDg3NzkyMzgxNzg_fb4e35d9-ba4c-467a-bba0-98195adecc40">4</ix:nonFraction>) non-class complaints naming Bausch Health Companies Inc., Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., and Santarus, Inc. (for purposes of this subsection, collectively, the &#8220;Company&#8221;), among other defendants, were filed or transferred to the Northern District of California. Three (<ix:nonFraction unitRef="case" contextRef="ib79efab1243d47f58861ab6f96316996_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzI3NDg3NzkyMzgxODI_5177bc4b-be4a-4159-b855-790d6d3c8d3c">3</ix:nonFraction>) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020.  The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. Three (<ix:nonFraction unitRef="case" contextRef="i2b0d134ac84a4b9fb995abee169d3922_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzM4NDgyOTA4NTU2Njc_7a8765ea-34de-4978-b13f-8233c7ba610d">3</ix:nonFraction>) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020.  In December 2020, the court denied the Company&#8217;s motion to dismiss as to the insurer plaintiff&#8217;s direct claims but dismissed the insurer plaintiff&#8217;s indirect claims. On February 2, 2021, the insurer plaintiff&#8217;s motion for leave to amend its complaint was denied.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These actions were consolidated and coordinated in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822-WHA (N.D. Cal.) (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The lawsuits alleged that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or grant any other company a license to do so. The complaints alleged that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs sought damages under federal antitrust laws for claims based on direct purchases.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2021, the Company reached an agreement in principle and, thereafter, on September 14, 2021, executed a final settlement agreement to resolve the class plaintiffs&#8217; claims for $<ix:nonFraction unitRef="usd" contextRef="i0974c8f474ad4f1ca10ac1d1131053f8_D20210726-20210726" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzM4NDgyOTA4NTU2NzA_b73ab7ee-81bf-4f62-9275-0af0dc90685f">300</ix:nonFraction>&#160;million, subject to court approval. On August 1, 2021, the Company also reached an agreement in principle to resolve the non-class direct purchaser plaintiffs&#8217; claims, described above, for additional consideration.  A final settlement agreement with the non-class direct purchaser plaintiffs was executed on August 6, 2021. As part of the settlements, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing.  On September 20, 2021, the insurer plaintiff voluntarily dismissed its claims in the consolidated federal action. By stipulation, the insurer plaintiff has asserted its direct opt-out claims in the State Court Action, resulting in the consolidation of all of its opt-out claims in the State Court Action.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2021, the court granted preliminary approval of the class settlement agreement and vacated the October 2021 trial date and all other pre-trial deadlines in the consolidated actions. On February 3, 2022, the court granted final  approval of the class settlement and ordered dismissal of the class plaintiffs' claims. Subject to appeal of the final approval of the class settlement, the settlements will resolve and discharge all asserted class and direct purchaser non-class claims against the Company in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Proposition 65 Related Matter</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2020, Plaintiff Jan Graham filed a lawsuit (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Graham v. Bausch Health Companies, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 20STCV03578) in Los Angeles County Superior Court against the Company, Bausch Health US and several other manufacturers, distributors and retailers of talcum powder products, alleging violations of California Proposition 65 by manufacturing and distributing talcum powder products containing chemicals listed under the statue, without a compliant warning on the label. On January 29, 2021, certain defendants including the Company and Bausch Health US filed a Motion for Summary Judgment or in the Alternative Motion for Summary Adjudication, which was granted with prejudice on May 26, 2021; Plaintiff waived the right to appeal.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Lawsuits</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2019 and September 13, 2019, <ix:nonFraction unitRef="shareholder" contextRef="ied24221b489d4f4ba5abd2b2dd8014fb_I20190910" decimals="INF" name="bhc:LossContingencyNumberOfAllegedStockholdersFiledLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwOTk1MTE4MTgxNDA_5931f6d7-1348-4506-bc5a-9cf53cabd5da"><ix:nonFraction unitRef="shareholder" contextRef="id56dfce34e5c4c43bdd8c62baf232508_I20190913" decimals="INF" name="bhc:LossContingencyNumberOfAllegedStockholdersFiledLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwOTk1MTE4MTgxNDA_a6d5ebcc-2482-4094-a9df-a62b4840bfa7">two</ix:nonFraction></ix:nonFraction> alleged stockholders filed derivative lawsuits purportedly on behalf of the Company against former Company board members and executives. On March 7, 2020, a consolidated amended derivative complaint was filed, captioned In re Bausch Health Companies Inc. F/K/A/ Valeant Pharmaceuticals International, Inc. Stockholder Derivative Litigation (Case No. 19-cv-17833). </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><ix:continuation id="i37ab22e8d2d3431c8aea65e0e82d064a"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiffs asserted claims for breach of fiduciary duty, waste of corporate assets, and unjust enrichment related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#8217;s business and prospects, including relating to drug pricing, the Company&#8217;s use of specialty pharmacies, and the Company&#8217;s relationship with Philidor. The consolidated complaint also asserted a claim for contribution and indemnification by the Defendants for any liability the Company ultimately faces as a result of the conduct alleged in the complaint. The claims alleged in these cases were based on the same purported conduct that is at issue in In re Valeant Pharmaceuticals International, Inc. Securities Litigation, all of which occurred prior to 2017. On April 21, 2020, the Defendants filed a motion to dismiss the consolidated amended complaint.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Briefing on this motion concluded on August 3, 2020. On November 24, 2020, the Special Master appointed by the Court issued a report recommending that the motion to dismiss be granted in full.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021, the District Court adopted the report and recommendation of the Special Master and dismissed the action.</span></ix:continuation></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_364"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjQvZnJhZzoxNTYyMzlkNjBkODg0ZDFjYjFlMTZkZGJlYTA2MDVmZi90ZXh0cmVnaW9uOjE1NjIzOWQ2MGQ4ODRkMWNiMWUxNmRkYmVhMDYwNWZmXzUxNjE_6c052370-f710-4585-bf19-6c11adb16161" continuedAt="iaac8a0d52d3047a8b162735d5a5da96c" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="iaac8a0d52d3047a8b162735d5a5da96c" continuedAt="i528c98fef4d04224b6e2005e79f56afb"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has commitments related to capital expenditures of approximately $<ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjQvZnJhZzoxNTYyMzlkNjBkODg0ZDFjYjFlMTZkZGJlYTA2MDVmZi90ZXh0cmVnaW9uOjE1NjIzOWQ2MGQ4ODRkMWNiMWUxNmRkYmVhMDYwNWZmXzg2_8a807c95-9140-49f9-ab80-c56b2052108b">76</ix:nonFraction> million as of December&#160;31, 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain agreements, the Company may be required to make payments contingent upon the achievement of specific developmental, regulatory, or commercial milestones. As of December&#160;31, 2021, the Company believes it is reasonably possible that it may potentially make milestone and license fee payments, including sales-based milestone payments, of approximately $<ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="bhc:CollaborativeAgreementMilestonePaymentsAggregate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjQvZnJhZzoxNTYyMzlkNjBkODg0ZDFjYjFlMTZkZGJlYTA2MDVmZi90ZXh0cmVnaW9uOjE1NjIzOWQ2MGQ4ODRkMWNiMWUxNmRkYmVhMDYwNWZmXzQ0OQ_05cec783-a033-4727-9fb4-7b0642a59d33">340</ix:nonFraction> million over time, in the aggregate, to third parties for products currently under development or being marketed, primarily consisting of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a June 2013 distribution and supply agreement with Mylan Pharmaceuticals Inc. (as assignee of Spear Pharmaceuticals, Inc and Spear Dermatology Products Inc.), the Company may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $<ix:nonFraction unitRef="usd" contextRef="i81f9ed3c74134a7fabf0feaf1c2120c1_I20211231" decimals="INF" name="bhc:CollaborativeAgreementMilestonePaymentsAggregate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjQvZnJhZzoxNTYyMzlkNjBkODg0ZDFjYjFlMTZkZGJlYTA2MDVmZi90ZXh0cmVnaW9uOjE1NjIzOWQ2MGQ4ODRkMWNiMWUxNmRkYmVhMDYwNWZmXzkzNg_376c5bef-ffd7-42a9-b2bd-568e03b4ce61">70</ix:nonFraction> million, in the aggregate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of an April 2019 agreement with Mitsubishi Tanabe Pharma Corporation, the Company has acquired an exclusive license to develop and commercialize&#160;MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as Inflammatory Bowel Disease and ulcerative colitis. The Company may be required to make development and sales-based milestone payments over time of up to $<ix:nonFraction unitRef="usd" contextRef="iaf37c45946284359a2d4538803c7b301_I20211231" decimals="INF" name="bhc:CollaborativeAgreementMilestonePaymentsAggregate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjQvZnJhZzoxNTYyMzlkNjBkODg0ZDFjYjFlMTZkZGJlYTA2MDVmZi90ZXh0cmVnaW9uOjE1NjIzOWQ2MGQ4ODRkMWNiMWUxNmRkYmVhMDYwNWZmXzE0Mjc_12a3b524-a485-4a00-a64d-2033ff959fb8">60</ix:nonFraction> million, in the aggregate, as well as royalties on future sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a December 2019 agreement with Novaliq GmbH, the Company has acquired an exclusive license for the commercialization and development in the U.S. and Canada of NOV03 (perfluorohexyloctane), an investigational drug to treat Dry Eye Disease associated with Meibomian gland dysfunction and may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $<ix:nonFraction unitRef="usd" contextRef="i7f2f1cfe9dc04f76978526af52bd0a5a_I20211231" decimals="INF" name="bhc:CollaborativeAgreementMilestonePaymentsAggregate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjQvZnJhZzoxNTYyMzlkNjBkODg0ZDFjYjFlMTZkZGJlYTA2MDVmZi90ZXh0cmVnaW9uOjE1NjIzOWQ2MGQ4ODRkMWNiMWUxNmRkYmVhMDYwNWZmXzE5NDI_662b660b-7fb3-4bc0-9a93-23a50af4151b">48</ix:nonFraction> million, in the aggregate, as well as royalties on future sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a November 2019 agreement with Cedars-Sinai Medical Center, to evaluate a new formulation of rifaximin for the treatment of irritable bowel syndrome, the Company may be required to make development and sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $<ix:nonFraction unitRef="usd" contextRef="i9bdb8b8277cf4e04ada86ca0bed059dc_I20211231" decimals="INF" name="bhc:CollaborativeAgreementMilestonePaymentsAggregate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjQvZnJhZzoxNTYyMzlkNjBkODg0ZDFjYjFlMTZkZGJlYTA2MDVmZi90ZXh0cmVnaW9uOjE1NjIzOWQ2MGQ4ODRkMWNiMWUxNmRkYmVhMDYwNWZmXzIzNDg_25f9de5e-5a09-4172-b4a3-e4f65e17d6cd">36</ix:nonFraction>&#160;million, in the aggregate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of an October 2020 agreement with Eyenovia, Inc., the Company has acquired an exclusive license in the U.S. and Canada for the development and commercialization of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12. Under the terms of the agreement, the Company may be required to make development and sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $<ix:nonFraction unitRef="usd" contextRef="i62ab16dfdb214a95ac5f1498f90faa39_I20211231" decimals="INF" name="bhc:CollaborativeAgreementMilestonePaymentsAggregate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjQvZnJhZzoxNTYyMzlkNjBkODg0ZDFjYjFlMTZkZGJlYTA2MDVmZi90ZXh0cmVnaW9uOjE1NjIzOWQ2MGQ4ODRkMWNiMWUxNmRkYmVhMDYwNWZmXzI5Nzc_aa99d75c-b7a1-46f1-b9bf-bde9a809239b">35</ix:nonFraction>&#160;million, in the aggregate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a May 2020 agreement with STADA Arzneimittel AG and its development partner, Xbrane Biopharma AB, to commercialize in the U.S. and Canada a biosimilar candidate to Lucentis (ranibizumab), the Company may be required to make development and sales-based milestone payments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of these arrangements, the future potential payments related to the attainment of the specified milestones over a period of several years are inherently uncertain. As of December 31, 2021, no accruals related to the aforementioned agreements exist because the milestone targets are not yet probable of being achieved.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i528c98fef4d04224b6e2005e79f56afb"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into agreements that include indemnification provisions for product liability and other matters. These provisions are generally subject to maximum amounts, specified claim periods and other conditions and limits. In addition, the Company is obligated to indemnify its officers and directors in respect of any legal claims or actions initiated against them in their capacity as officers and directors of the Company in accordance with applicable law. Pursuant to such indemnities, the Company is indemnifying certain former officers and directors in respect of certain litigation and regulatory matters.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, no material amounts were accrued for the Company&#8217;s obligations under these indemnification provisions.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-68</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_367"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 67.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzM5MTY_56ed63f7-6561-4fef-a8b3-1820123212d4" continuedAt="i5c082a4dacb34a049a3470abafe428f0" escape="true">SEGMENT INFORMATION</ix:nonNumeric></span></div><ix:continuation id="i5c082a4dacb34a049a3470abafe428f0" continuedAt="id4458be89ca04df0983f27203b568ba8"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Chief Executive Officer ("CEO"), who is the Company&#8217;s Chief Operating Decision Maker, manages the business through operating and reportable segments consistent with how the Company's CEO: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. The Company operates in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International Rx, (iv) Ortho Dermatologics and (v) Diversified Products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of the Company&#8217;s segments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.53pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmic Pharmaceuticals products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of GI products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International Rx segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales, with the exception of sales of Bausch +Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Ortho Dermatologics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological) products and (ii) global sales of Solta aesthetic medical devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions.  Certain costs, such as Amortization of intangible assets, Asset impairments, including loss on assets held for sale, Restructuring, integration, separation and IPO costs, and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.</span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzM5MTQ_8ea230b5-f046-4d2b-91b8-e5067a5a9ad9" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#8217;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the planned separation of its Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., on February 23, 2022, the Company announced its plan to change its segment structure in a manner which is consistent with the organizational structure of the two separate entities as proposed by the Solta IPO during the first quarter of 2022. The new segment structure will not impact the Company&#8217;s reporting units but will realign the <ix:nonFraction unitRef="reporting_unit" contextRef="i03a8ce11b6a94d508439a84f941e6341_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzM4NDgyOTA3MTAwMjg_90846ce4-db86-4504-acc1-c36bc3001f06">two</ix:nonFraction> reporting units of the Ortho Dermatologics segment whereby its medical dermatology reporting unit (Ortho Dermatologics) will now be managed by the CODM as part of the Diversified Products segment and the Solta reporting unit will be managed by the CODM as its own operating and reportable segment. Accordingly, the Company expects to begin reporting under the following reporting segments on a retrospective basis beginning with its first quarter of 2022 as follows: Bausch + Lomb, Salix, International Rx, Solta and Diversified Products.</span></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 67.50pt"><ix:continuation id="id4458be89ca04df0983f27203b568ba8" continuedAt="i1c69313440df4a28a76e90e19f379d3f"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Revenues and Profit</span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzM4ODI_bf77ee1d-4334-42d4-9186-830da2f4506d" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits for the years 2021, 2020 and 2019 were as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:68.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30bf053c559f4b1c9ed175d768f3d24b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzItMS0xLTEtNTk0NzA_bdeadaa1-7bc1-4212-bbdc-5e61b872f853">3,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i673b35bd82f24773b53ca856e22be6c2_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzItMy0xLTEtNTk0NzA_c59460b9-bc8d-4085-b95e-99164b19f709">3,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6d3e46f96644c89ae14a35eb34a016_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzItNS0xLTEtNTk0NzA_dbdf23a0-273f-485b-94e9-a53a47ec0c77">3,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb4ee2a83284e5aacf40c45394d64ee_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzMtMS0xLTEtNTk0NzA_c3e27cb5-348b-4185-b126-116e7d7f1da7">2,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc3957b2514e43d4bc57896332a29c98_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzMtMy0xLTEtNTk0NzA_3aeae3ab-45c0-483c-9a56-275172e10838">1,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526b3306560a4582bbd5cb84b6634e8e_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzMtNS0xLTEtNTk0NzA_f50cba2d-0d00-4d6c-b34b-c79c68959915">2,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Rx</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1aabb4dd84c41e78c5713f72684c58c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzQtMS0xLTEtNjE1OTM_4a9688e8-4672-4a4a-8db2-d7af35ff6bcb">1,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12ca69aa53c04d1f9a70ca7832545115_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzQtMy0xLTEtNjE1ODM_8ca2df3c-acd7-42ea-a642-83cf61942fef">1,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d617a50cb4e4dc2b9d45dd78b38e32c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzQtNS0xLTEtNjE1NjI_f40932c9-1d1e-4c1b-8274-8be991b59952">1,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fd885b33ea84b91854e977c98d0cdd2_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzQtMS0xLTEtNTk0NzA_7f2f7a01-5b38-43dd-8e72-321e4ff71763">564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe4fe193ae054da49acc60fb104beaba_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzQtMy0xLTEtNTk0NzA_90deb939-aa0d-4c5a-a3b8-4036d6c7d2d3">548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fc28f8f6ed74a9089917e8b80f33998_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzQtNS0xLTEtNTk0NzA_2aaf2093-3358-41d3-9737-2c89153ec32b">560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb5d7f34e00490896510ef48df89709_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzUtMS0xLTEtNTk0NzA_3ec7ccbe-7a6a-4f99-a4ca-180c09290884">865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e43bb66906240b1bf5bd13e06e0eb33_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzUtMy0xLTEtNTk0NzA_f8a037f0-640d-4167-9d12-2da06aaeb841">979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic22f83493b6c49b3bd143623ecdfcef6_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzUtNS0xLTEtNTk0NzA_6528f6ce-beb3-4a35-97af-d1e931f5ad3b">1,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i305152159c734293b19863277adb1507_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzYtMS0xLTEtNTk0NzA_17dcf41c-b279-4e93-b0f8-3b362e58c24f">8,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16716b25f68d437e8b5603c13cad09e4_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzYtMy0xLTEtNTk0NzA_be3a4918-2682-4626-92cd-42182ff2078d">8,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2acd16c5638f406dbc8a4a64bcfb73c4_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzYtNS0xLTEtNTk0NzA_6096691e-eba7-4889-8a06-f0989dfc2e45">8,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profit:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30bf053c559f4b1c9ed175d768f3d24b_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzgtMS0xLTEtNTk0NzA_c2d4611f-fc46-4f70-a1d3-b7d01e5c14ed">958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i673b35bd82f24773b53ca856e22be6c2_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzgtMy0xLTEtNTk0NzA_20f2992a-513b-4a63-a394-09ae1877380f">909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6d3e46f96644c89ae14a35eb34a016_D20190101-20191231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzgtNS0xLTEtNTk0NzA_70945a12-7055-4588-9576-df3031c752c0">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb4ee2a83284e5aacf40c45394d64ee_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzktMS0xLTEtNTk0NzA_71d2dbe6-818e-4e63-a43f-551cb5427020">1,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc3957b2514e43d4bc57896332a29c98_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzktMy0xLTEtNTk0NzA_0ae1a83d-1e70-4bfd-9cf2-0b53765e49a9">1,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526b3306560a4582bbd5cb84b6634e8e_D20190101-20191231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzktNS0xLTEtNTk0NzA_bf741a0b-53fa-4e02-9b01-3cf5cda71e24">1,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Rx</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1aabb4dd84c41e78c5713f72684c58c_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzExLTEtMS0xLTYxNjkw_9ae6d843-678f-41c4-93f9-1aa4b769da6f">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12ca69aa53c04d1f9a70ca7832545115_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzExLTMtMS0xLTYxNjgx_5a4713cb-7fcf-41c5-bfcb-604df189f8de">386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d617a50cb4e4dc2b9d45dd78b38e32c_D20190101-20191231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzExLTUtMS0xLTYxNjgx_4fa2310c-f6c6-4a22-8487-a64ff2b37225">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fd885b33ea84b91854e977c98d0cdd2_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzEwLTEtMS0xLTU5NDcw_b489e960-ba27-479d-8a7d-44895fe55e36">265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe4fe193ae054da49acc60fb104beaba_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzEwLTMtMS0xLTU5NDcw_a0346bbf-0c2a-4006-83de-cf94952a46cb">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fc28f8f6ed74a9089917e8b80f33998_D20190101-20191231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzEwLTUtMS0xLTU5NDcw_040a4dc6-20ab-4ea6-9b69-7b3d93de89f9">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb5d7f34e00490896510ef48df89709_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzExLTEtMS0xLTU5NDcw_09073c28-9c8d-41ed-9895-515347a252df">624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e43bb66906240b1bf5bd13e06e0eb33_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzExLTMtMS0xLTU5NDcw_ead796ca-be15-4fc6-bec1-381214f86a31">717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic22f83493b6c49b3bd143623ecdfcef6_D20190101-20191231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzExLTUtMS0xLTU5NDcw_aed1f20a-41fc-4fd8-a82c-3ad914cd39c9">801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i305152159c734293b19863277adb1507_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzEyLTEtMS0xLTU5NDcw_1d3eb57b-845d-48af-93dc-45c2deb8382f">3,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16716b25f68d437e8b5603c13cad09e4_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzEyLTMtMS0xLTU5NDcw_138065e7-0a4d-4b68-a610-6035df092173">3,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2acd16c5638f406dbc8a4a64bcfb73c4_D20190101-20191231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzEyLTUtMS0xLTU5NDcw_ce2cdbc8-63b8-455d-b849-35d69160b2f2">3,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c91dc7a5754f868357dbaaf40b5a60_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzEzLTEtMS0xLTU5NDcw_fbcc9b3e-bd3a-4775-aae2-e207e929fba4">792</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40ecfa21f8b642f7807a65183e087f3e_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzEzLTMtMS0xLTU5NDcw_73ec405b-d580-4052-b5c9-d37bf54b5e53">619</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93fdc6cbea484e5d933d9ec17976a64a_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzEzLTUtMS0xLTU5NDcw_24f41666-7f60-42b1-b327-c3bc73a2fa0e">609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE0LTEtMS0xLTU5NDcw_6e4309f0-31a3-4896-8e5f-855f6667f133">1,375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE0LTMtMS0xLTU5NDcw_f035d8b5-29e8-4800-8b1c-1f5a860d9335">1,645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE0LTUtMS0xLTU5NDcw_670bbcd4-7635-4428-a3a7-80bbbb1b1d73">1,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE1LTEtMS0xLTU5NDcw_19df4b16-164e-4e40-a126-240a3bcb491f">469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE1LTMtMS0xLTU5NDcw_35afb829-5d7b-43b8-b4ef-9be85d0b210c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE1LTUtMS0xLTU5NDcw_5cf9cb60-13cb-4ee6-be08-cf377d44f47d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE2LTEtMS0xLTU5NDcw_408e218e-4ef4-4562-8196-60f56cdf5dca">234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE2LTMtMS0xLTU5NDcw_0a1932da-2e03-495f-b975-81b6dd32a2c9">114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE2LTUtMS0xLTU5NDcw_4a3eafd2-856f-4742-94e6-576dcc3df232">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE3LTEtMS0xLTU5NDcw_a5735612-63f7-4427-a018-617df0f176d0">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE3LTMtMS0xLTU5NDcw_1b28060a-7adf-4042-904d-abe22594298f">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE3LTUtMS0xLTU5NDcw_e1df5650-84db-4ccf-b5d5-6823b049b075">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE5LTEtMS0xLTU5NDcw_d4da6ded-981f-46f4-ac1b-bb96d45f19f6">373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE5LTMtMS0xLTU5NDcw_edaea381-69cc-4b03-893f-449c4ceec9c4">502</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE5LTUtMS0xLTU5NDcw_014cbc25-9285-4ed2-a3cf-477bd4257ce6">1,426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIwLTEtMS0xLTU5NDcw_1f52d3a3-c17c-4e17-80f6-0a1f2b4141c0">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIwLTMtMS0xLTU5NDcw_aab40356-39c1-4792-848b-06660f6b8c87">676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIwLTUtMS0xLTU5NDcw_5913182b-889a-4fd7-bff5-60e8701df04f">203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIxLTEtMS0xLTU5NDcw_d57dc928-8ce8-49ca-86fa-d3b89156bce2">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIxLTMtMS0xLTU5NDcw_6e73de62-8215-40a7-912a-eae4688b7fef">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIxLTUtMS0xLTU5NDcw_bfa03adb-8999-45fa-ba7b-acd6169db240">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIyLTEtMS0xLTU5NDcw_92bdf1df-0fb0-42a9-bb71-409d5ff698f5">1,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIyLTMtMS0xLTU5NDcw_ef16b3cd-09de-44e0-8a3e-67a6dc16d371">1,534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIyLTUtMS0xLTU5NDcw_b749e6df-860a-4125-9502-876c6d0e8304">1,612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIzLTEtMS0xLTU5NDcw_8c8ed36a-7070-4256-b371-ba1ddcf4c74c">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIzLTMtMS0xLTU5NDcw_3e90a5a6-2640-468d-b738-58639ce3a038">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIzLTUtMS0xLTU5NDcw_18a6a4fa-30a5-4bb9-a6f0-c15be2142ef3">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzI0LTEtMS0xLTU5NDcw_2abe15d7-b041-426b-ad88-ebd0bceb7fba">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzI0LTMtMS0xLTU5NDcw_916c6580-b6cf-4f82-9a00-f146fd61c3b9">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzI0LTUtMS0xLTU5NDcw_865cb0d2-066c-454d-a3a0-11831203da99">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before benefit from income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzI1LTEtMS0xLTU5NDcw_4a7a537d-8f73-498d-a0df-b60d6f3bda49">1,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzI1LTMtMS0xLTU5NDcw_50ebe804-a3be-418b-8b1b-4a25786b68ca">934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzI1LTUtMS0xLTU5NDcw_783291ff-b6c0-4c19-ace3-6c44b48a5b38">1,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to segment revenue and profit in order for the prior years to conform to current year presentation. These reclassifications are not material.</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Expenditures</span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzM5MDA_bab23ce8-4242-45ea-9222-ab4ea509e533" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures by segment for the years 2021, 2020 and 2019 were as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:68.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30bf053c559f4b1c9ed175d768f3d24b_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzItMS0xLTEtNTk0NzA_b3aaee89-8923-4424-9908-4901f0e135b8">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i673b35bd82f24773b53ca856e22be6c2_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzItMy0xLTEtNTk0NzA_d98188e9-c4a4-42a6-9d5d-0386796cc566">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6d3e46f96644c89ae14a35eb34a016_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzItNS0xLTEtNTk0NzA_d73db850-a5f7-4daf-9a98-80861d9faa6f">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb4ee2a83284e5aacf40c45394d64ee_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzMtMS0xLTEtNTk0NzA_5d65b0b0-2c23-42f9-941b-daff31700fcc">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc3957b2514e43d4bc57896332a29c98_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzMtMy0xLTEtNTk0NzA_c3fd4fd4-4d8d-4baf-84a3-59477cbdab7c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526b3306560a4582bbd5cb84b6634e8e_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzMtNS0xLTEtNTk0NzA_bfda9e22-ad43-418f-8491-c7dbb4cab43f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Rx</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1aabb4dd84c41e78c5713f72684c58c_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzQtMS0xLTEtNjg4MDY_50895cf5-4b16-4fa1-a3c9-65377f4ad9df">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12ca69aa53c04d1f9a70ca7832545115_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzQtMy0xLTEtNjg4MDI_59fad681-7a21-4063-b085-a48116a0cff0">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d617a50cb4e4dc2b9d45dd78b38e32c_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzQtNS0xLTEtNjg4MDQ_1ace1edd-2c1d-4cbd-9ac2-0bb493831d6a">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fd885b33ea84b91854e977c98d0cdd2_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzQtMS0xLTEtNTk0NzA_5db70129-24de-4925-aeb2-7050715751bc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe4fe193ae054da49acc60fb104beaba_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzQtMy0xLTEtNTk0NzA_d79f9639-d7c0-423c-ae51-4a8b06182bad">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fc28f8f6ed74a9089917e8b80f33998_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzQtNS0xLTEtNTk0NzA_9d1a5993-f47e-402e-b275-cddd83438db7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb5d7f34e00490896510ef48df89709_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzUtMS0xLTEtNTk0NzA_609ac970-d601-4638-944a-e67d912a58ea">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e43bb66906240b1bf5bd13e06e0eb33_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzUtMy0xLTEtNTk0NzA_1d2b8c5d-9dec-4114-8fe3-65c74ca73eab">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic22f83493b6c49b3bd143623ecdfcef6_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzUtNS0xLTEtNTk0NzA_bdc4eee4-e86d-430b-90b8-96c449561fa9">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i305152159c734293b19863277adb1507_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzYtMS0xLTEtNTk0NzA_1f6710be-7371-4c1a-9356-30ed1833a509">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16716b25f68d437e8b5603c13cad09e4_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzYtMy0xLTEtNTk0NzA_1d583b3d-c791-4ec6-a8f9-faf6f01aedfd">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2acd16c5638f406dbc8a4a64bcfb73c4_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzYtNS0xLTEtNTk0NzA_fed8706a-7ea6-44e2-a712-0aa4fcee4a9a">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c91dc7a5754f868357dbaaf40b5a60_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzctMS0xLTEtNTk0NzA_40396449-f098-4c1b-b6d3-ad38e4868305">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40ecfa21f8b642f7807a65183e087f3e_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzctMy0xLTEtNTk0NzA_f32623fe-7851-4ced-9067-5ddbd5d41283">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93fdc6cbea484e5d933d9ec17976a64a_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzctNS0xLTEtNTk0NzA_bbc1c77b-0cec-42ba-a4a9-bdcde4752cfc">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total capital expenditures</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzgtMS0xLTEtNTk0NzA_4aef459c-b8ec-4a81-9b28-7c3cbf7b1b3e">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzgtMy0xLTEtNTk0NzA_fd93cd3c-d3b4-49e5-abdd-e3eee810085b">302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzgtNS0xLTEtNTk0NzA_0643c6f6-e115-49a8-b66a-6380bbbccd9a">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 67.50pt"><ix:continuation id="i1c69313440df4a28a76e90e19f379d3f" continuedAt="i602df55832564988984eb4fbbbe8c1de"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues by Product and by Product Category </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the Company's top <ix:nonFraction unitRef="product" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="INF" name="bhc:ConcentrationRiskNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzMyNzM_342a96f7-bd80-4243-a728-68a63e7f0e9a"><ix:nonFraction unitRef="product" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="INF" name="bhc:ConcentrationRiskNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzMyNzM_56f73df2-27b1-4b4f-b7b7-e7e8efe18fec"><ix:nonFraction unitRef="product" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="INF" name="bhc:ConcentrationRiskNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzMyNzM_84b75c64-01fb-4d3a-a71d-1ef8bfeb24ba">ten</ix:nonFraction></ix:nonFraction></ix:nonFraction> products for the years 2021, 2020 and 2019 represented <ix:nonFraction unitRef="number" contextRef="id40c780474fa4a4682a7347b25e2b201_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzMzMTQ_e8c990b4-29f1-4bb5-927e-7bb9a4706f86">43</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i9af7ef89cda648658a1c3607ee127da7_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzMzMTg_5350a225-4581-4411-80f9-43c1f9506bc7">41</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i045b9dafc68b4cc68fb25904182bba77_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzMzMjU_77f0145f-b26c-4a5c-86d3-de44e063d197">39</ix:nonFraction>% of total product sales, respectively. <ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzM5MTU_6e5c1642-7caf-45a6-80bd-9e5f39042543" continuedAt="ib800d191554048b5851fd4adc738429f" escape="true">Revenues by segment and product category were as&#160;follows: </ix:nonNumeric></span></div><ix:continuation id="ib800d191554048b5851fd4adc738429f"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"></td><td style="width:23.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International Rx</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3697d2a9e4ec43ed8d76e098889f36cc_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzItMS0xLTEtNzE0MjY_d3cd873b-24d1-4381-8b42-bbef6e663bb0">514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00cbb18e8a4244e0b4ab1c019ad6fbef_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzItMy0xLTEtNzE0Mjg_2ed937b4-6840-4531-a8bf-e54dff2c8936">2,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05e5078808d945ada773030e2fff85f6_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzItNS0xLTEtNzE0MzA_c540e4b3-34f8-443f-a701-d28db05225ba">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18975fdb4b2643a18e1536995bd756ae_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzItNy0xLTEtNzE0MzI_f0552e86-dc59-4489-88ec-232f579ed46f">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0efcb1a3e484c1495fe6a62314d10a2_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzItOS0xLTEtNzE0MzQ_75d601bf-43ae-4ea7-8fcc-a4aae8eb3e18">683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8200ab4980184e4096913b6919701188_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzItMTEtMS0xLTcxNDM2_9155fb65-9782-4986-a8c6-32960ff40d68">3,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5015918fcb654325817de17b69decef0_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzMtMS0xLTEtNzE0MjY_2bc813dd-0bc2-4017-b8c6-31ee4b3733a5">1,596</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1210af6063f04ed085da1d49425cc50d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzMtMy0xLTEtNzE0Mjg_6fd14a56-cc24-4f48-a61f-78b4baef9b35">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd3b2b75a9e04acc95e10777983994e6_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzMtNS0xLTEtNzE0MzA_20f4d453-9e7b-4295-bec1-0a7b3c45fb84">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4db50b822dce470c82556f075e3aa86a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzMtNy0xLTEtNzE0MzI_1a2d225c-7576-4d8e-9dce-fd8c3c5e5cf1">307</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i620b1f27f17d43f7ba80d7206929a42a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzMtOS0xLTEtNzE0MzQ_dbf35a2b-5af5-4204-b281-4561a4b67b94">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i818f730bc4e3452abca0fbc91147a433_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzMtMTEtMS0xLTcxNDM2_a5c0de16-27a2-4349-9104-89b2c7b0fd94">1,903</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dae557e1e00497a865526614a2c20dc_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzQtMS0xLTEtNzE0MjY_9858cd8e-3903-49c2-8431-a06ba507c366">1,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i741d562c91384842b61fd3597f4f5e01_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzQtMy0xLTEtNzE0Mjg_50913166-7159-4ae5-869b-b52f4f36359f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29fb9247f04947ea8be74d0fa5e1431d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzQtNS0xLTEtNzE0MzA_77b548bf-f660-4496-9046-23bb2549bfc1">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bbe060476f44a9e9703d61f58e930d7_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzQtNy0xLTEtNzE0MzI_4e9b7877-7e03-4160-b4ac-76824f8f915b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b52e9e750b14be2b227e83c88613718_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzQtOS0xLTEtNzE0MzQ_4ff69ca5-5932-4a7d-8867-6dca232c5300">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieca5e0bc0aeb4138acf45885703a0f6c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzQtMTEtMS0xLTcxNDM2_1b383a4a-4583-4995-8b69-8cf51f88712f">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09553df00340400bb7d271aea0f7bbe5_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzUtMS0xLTEtNzE0MjY_2bd2ed71-3898-47bb-9021-6373dfa73b8e">240</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ee94ae398154c9ba283d347ee65f6fe_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzUtMy0xLTEtNzE0Mjg_d3073fdb-ccb9-4118-b34a-8e5e98508cf7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111b0987b23747f886225e07ed349f8b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzUtNS0xLTEtNzE0MzA_89b6ff84-d845-43b1-af93-bda003481930">737</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4f1ecad4e074139b813953bc218bf66_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzUtNy0xLTEtNzE0MzI_8c40ee61-e304-42f7-acb8-922e26b4800a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58e2b80073124c139f9beb53118af5e4_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzUtOS0xLTEtNzE0MzQ_13e803f8-1c46-4cb0-a25f-461d5245f67e">167</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6ba58bf0a7a47308743596ca6786020_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzUtMTEtMS0xLTcxNDM2_a52d5049-1669-4af2-a707-e328a8877c1f">1,144</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c572de04a1547afbb27a25fb70ce6a9_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzYtMS0xLTEtNzE0MjY_870b8500-1dae-4b53-b736-1598fe3bc75d">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62aa1ea2a03e43139f39c8d0853efab4_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzYtMy0xLTEtNzE0Mjg_10cbb22c-b89f-4ccc-be77-0450d948a9ef">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49e6f291ff584b48a1622e2e639ba32e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzYtNS0xLTEtNzE0MzA_3686e07a-90f9-4cea-b3be-c003f931f15a">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i499995e5502d4c19b0439c7bf1f67b9a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzYtNy0xLTEtNzE0MzI_567de9d7-594a-47b2-b7f1-c9a069bb1fb8">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if992199bf6084e97b3622278275b21d3_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzYtOS0xLTEtNzE0MzQ_66387285-522f-468a-acf9-2e5cc0d18b52">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4853e38d55c49e987573c8d03ec31aa_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzYtMTEtMS0xLTcxNDM2_0bc56349-250c-4a7c-b631-8733b8bf4fe8">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85a97ee039044646b0f12d8dfddbf0fb_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzctMS0xLTEtNzE0MjY_be39f4b4-ec20-4ed7-8662-69787683383c">3,765</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d94edb1edcc4131b1c8c736826ab425_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzctMy0xLTEtNzE0Mjg_3314283b-3fb3-46bf-a251-b2769a67c65f">2,074</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd56e661cc441b88ce62c077cb8c9c5_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzctNS0xLTEtNzE0MzA_883cfee3-a869-40f3-bfc1-2b03b51fd372">1,166</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a8ce11b6a94d508439a84f941e6341_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzctNy0xLTEtNzE0MzI_57f068a3-55e6-4def-bc62-2828644f5a80">564</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9cf2e58ead94c7e812f2a73e8e5a8b0_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzctOS0xLTEtNzE0MzQ_d84c2284-047f-42a6-a649-df16d8adc0f5">865</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzctMTEtMS0xLTcxNDM2_0df7249e-b519-4651-9490-5396c2568df5">8,434</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"></td><td style="width:23.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International Rx</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica7328b8d6504b7899d1dc8b7505c3c0_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzItMS0xLTEtNzE0NTU_3b33211b-6d70-43c1-8570-0ba7db80f3ed">506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4118ed47b4d54cbdb1f54bbd3b175865_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzItMy0xLTEtNzE0NTc_4d739134-b828-4d8b-973e-f9e9ee8d0a71">1,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87b0a379a4e4af4a668a658b4e4dd43_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzItNS0xLTEtNzE0NTk_1c483551-b3ac-42fc-ae0d-b48cefe23c81">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e7cfdefe46344e69ec8aea55a260650_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzItNy0xLTEtNzE0NjE_e5f3d928-9ab3-4bd5-8c8a-03f2eb6f3cba">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee783aab280a472ea992eba9ca598c34_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzItOS0xLTEtNzE0NjM_6f14e2f4-dc90-4b92-a694-96023746ba55">745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55591dc8c2f846f5ba4430ce1db261dc_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzItMTEtMS0xLTcxNDY1_002281a1-daf9-468d-abae-abe99cc03417">3,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i558d7f511a464c67b2130444ac156e84_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzMtMS0xLTEtNzE0NTU_97c5e37d-fdd0-4613-9f3e-8871f607eeb9">1,313</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6212f9cc5f44979bde0e23bc60ea10_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzMtMy0xLTEtNzE0NTc_c8133cbe-cb42-423c-b6c4-6f76c31218e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088daa95a15e437895c8f9f62f3aaf91_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzMtNS0xLTEtNzE0NTk_1f02ab3d-34cf-4bd9-b54f-db1dfe3d2c0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cfe3de8f52f4da6bec0b7e7f3089c8b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzMtNy0xLTEtNzE0NjE_842a20ba-623f-4426-8bb6-48d412515020">253</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i800a26cd6f20436983c15a8c15183252_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzMtOS0xLTEtNzE0NjM_a51ab24d-46e8-41d2-b008-2056831a8dad">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58585239a67458fa764c31745ab5784_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzMtMTEtMS0xLTcxNDY1_b29c30a7-9a11-4e5d-9c7a-4bf55456c454">1,566</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i261608b942e5454e8116aba0eacfa55e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzQtMS0xLTEtNzE0NTU_1752e08c-ed8e-4b8f-8700-36c171512aea">1,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7803df4ff86b424e850a241538857cd4_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzQtMy0xLTEtNzE0NTc_2487ff0d-6aa4-4606-8265-91c3c8829600">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f9db866111463eacf119731346b0d6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzQtNS0xLTEtNzE0NTk_0dde319c-45a6-4e38-9428-50c64cae7118">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867c2a9786c94ae2a5aec06b9a7cf714_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzQtNy0xLTEtNzE0NjE_58390a6b-c8b2-4657-b9a2-55efe31e59d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i738e8488fe144fce92ca8ab4ac3908e1_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzQtOS0xLTEtNzE0NjM_35b24603-12be-4401-bb56-f156499e292b">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3ccfe8ed3544137991312117c73e03d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzQtMTEtMS0xLTcxNDY1_0f98cef9-6d09-4c03-94c3-dd83b8eae0be">1,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768994e8bab445f2ace72afece0d453a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzUtMS0xLTEtNzE0NTU_2e24eebc-b2a3-4724-adbf-a1dc86e1802b">254</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7a686a8ace843f6b748426e83776b3e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzUtMy0xLTEtNzE0NTc_1449d04b-7c97-47a9-95d0-1f309b7d8ebb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a10926c267e4f7ca73186bb4acb8c87_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzUtNS0xLTEtNzE0NTk_a59c769d-d144-4650-9bdc-717ab1c4fdf1">775</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5102465bf9f8449faf1eb3625cdf92e0_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzUtNy0xLTEtNzE0NjE_0cfef2c9-bfdd-4e79-ad08-a4921d7769c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib145795896ac48f893142cce0eb31900_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzUtOS0xLTEtNzE0NjM_eef4363a-7737-4c0e-85c6-78185763e6e7">219</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9337ed14800f40b0acaa106b8ab1687c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzUtMTEtMS0xLTcxNDY1_49eb95d4-0b65-4941-b30b-5d852d928b70">1,248</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d30a802ae6241198bab6f023ee116ec_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzYtMS0xLTEtNzE0NTU_23380c08-78f7-441c-b410-c863c472e9ec">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d8e87487d774cb5aa73c296d54c373d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzYtMy0xLTEtNzE0NTc_2b8b238c-6a77-4315-be6a-b14dcbff2c6a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01c332dc4b3a40a7a943bd1c4a3ae01c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzYtNS0xLTEtNzE0NTk_2e6991b0-72b3-41ab-b819-8f2112329ed0">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9673696801474c4ab375773e366c4e88_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzYtNy0xLTEtNzE0NjE_6f52ac34-0d0b-491b-a850-6d93e19afcdd">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7b567c1a1d44f319be957d898bda4cb_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzYtOS0xLTEtNzE0NjM_1672697b-9bcd-4d4d-b3ec-25e80459f5b5">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ad55a1ae5b4477a17dbf7c109decc9_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzYtMTEtMS0xLTcxNDY1_6ba3354a-3385-4d8f-b0ea-f564c45436d4">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02ca962a07074ab0839d092880ab5aaa_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzctMS0xLTEtNzE0NTU_1df8f10c-1ae9-454b-bf7b-d4b63a15f10b">3,415</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d6a9bdc1e8f4460856c8c2141dade5c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzctMy0xLTEtNzE0NTc_ef7d5e42-aaa9-46b9-9f96-267b8a7e8e45">1,904</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13483a8d36774c0090ab1f1dd802483b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzctNS0xLTEtNzE0NTk_ef09d87a-4ebf-49a6-b9ee-cb6862c594cb">1,181</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd95ebc9b8e2493283e0e5fa94a55b77_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzctNy0xLTEtNzE0NjE_ba85d17a-362b-45f9-84d1-78f3e5c4d086">548</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ab4cac0f20f47bea48d93a577e3c68f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzctOS0xLTEtNzE0NjM_73ba4f0c-d9b0-4d0e-b429-d05714cc4240">979</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzctMTEtMS0xLTcxNDY1_1896f5f4-19e5-4248-bf9a-450fd7ea531a">8,027</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"></td><td style="width:23.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International Rx</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9458be242c114b20aae89680bcb5981b_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzItMS0xLTEtNzE0Njg_43910959-79c5-4b92-b291-c417c9ac6aa9">623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68492c01598457abbbb8598f9044b5b_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzItMy0xLTEtNzE0NzA_aae627d7-a1af-4c1f-ba87-160a2aaa05e0">2,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2764c82e246f458ab4e6010231d3da10_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzItNS0xLTEtNzE0NzI_e859f62b-e021-4b3f-8ed6-f8d26f3d406c">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38cbd7ab09694b5cb4499dc66ab3535d_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzItNy0xLTEtNzE0NzQ_733e70bd-8ddf-422b-892d-163b88eee72b">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ec1bdc6efc9470c9e1dddfa13904883_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzItOS0xLTEtNzE0NzY_267d495a-f8b7-487e-8cf3-d115ea48a06d">813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia78ff119a7a043648e26b928f005ae89_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzItMTEtMS0xLTcxNDc4_6d3fc7ff-ffde-4496-a43f-27a63ac54f0e">4,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib492295e326e40ebbf3dc856ab711aa9_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzMtMS0xLTEtNzE0Njg_8a5e8374-e167-4008-be9e-7d9986072a55">1,524</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77282ee77e994ae0943e0dd0203f496f_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzMtMy0xLTEtNzE0NzA_d08f5c0f-fa8e-438d-9d88-44a0d4c2800e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21cd1fcf02454f2aad2528f002a1fe42_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzMtNS0xLTEtNzE0NzI_23f869a3-f660-45cc-9687-4d63a8b85d1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71cdecdee46c4b1893e522d76ed1b394_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzMtNy0xLTEtNzE0NzQ_c517a2b4-4691-4a36-8ba3-9ad4b449d879">193</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedafa6efd5e44f1499ea180b808f257f_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzMtOS0xLTEtNzE0NzY_41e79c52-30b6-43b6-9e8a-9eaef5641132">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91f8e9e0afef4a67b9264f5a03b4ddfa_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzMtMTEtMS0xLTcxNDc4_3b81ffa7-01c3-413b-8531-e7befc07ca71">1,717</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia337f02e12fd43138589ca394c6f6db4_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzQtMS0xLTEtNzE0Njg_f1fe8578-5e9a-4ec6-bb56-ed0e40a271df">1,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9bc60fbab2b493da4da40019ac28d5b_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzQtMy0xLTEtNzE0NzA_f65a316e-accf-4354-a611-b539fa4ab2ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief548b6efb9243519ea3dc4dcb13b28d_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzQtNS0xLTEtNzE0NzI_48a2e874-4871-4817-bc08-71c10bdea9e4">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e4cda890a664abb926b4656d83aa772_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzQtNy0xLTEtNzE0NzQ_8a34b82e-c382-4562-b402-67b2717aee02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ad550fea28840ca8816e812a29b209b_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzQtOS0xLTEtNzE0NzY_86b518e4-eac0-4d92-bb2a-af071bd368e2">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id96fcda2fdee4cceaec20818540ab7ff_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzQtMTEtMS0xLTcxNDc4_69516dd8-b130-44f2-ab09-85963a5e6cbc">1,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d9df741d61340bba2aa6c1e15e212ef_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzUtMS0xLTEtNzE0Njg_1f5e8e91-4b0b-4bad-82fc-9aa2739621e8">260</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba623fc1e57a4f16a68ade989b914e71_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzUtMy0xLTEtNzE0NzA_ff4f51e0-eb63-4be9-a5bc-a788b1f3d9c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8ae893b49345bfb708b151f21b640e_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzUtNS0xLTEtNzE0NzI_3b7af92b-9ca9-44e3-8843-0844b351aeab">730</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaada16b4b8624fb888a1f0e2f22b1aae_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzUtNy0xLTEtNzE0NzQ_1197b30c-3820-4528-aecb-f2b7f2523381">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i389a02cf0b334d2a9bc9e4d299b60faa_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzUtOS0xLTEtNzE0NzY_6a2d50a9-7c69-4d05-9ad3-9c6f3136812a">256</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97cfe71201a14248b5a32a0be5378bdc_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzUtMTEtMS0xLTcxNDc4_40c4454b-1c44-41b8-b90e-3f4530f6e1fa">1,246</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cf07a753f9f497e8b32f6adceb6f310_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzYtMS0xLTEtNzE0Njg_da0b2fcb-3e85-4275-8f12-6c210c73f9a9">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83c0def577047da884ce155c2ca3898_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzYtMy0xLTEtNzE0NzA_26c9f14f-efb5-4bca-900d-2cc5c9de08b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12d5980aa12348d4bdccb1436660ada0_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzYtNS0xLTEtNzE0NzI_de061912-1041-446b-9e1e-dc36f932ae85">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31434b081601492c8ea95ce2b4f375e6_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzYtNy0xLTEtNzE0NzQ_571d93bb-b7c6-47d9-9674-6e09b5d88971">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3b10e36535844bb8d8e1f54883bcc7f_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzYtOS0xLTEtNzE0NzY_fa82befa-ca73-4991-9d91-0e40cace8867">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24c3f0d4cce04da181b013c5d63d6613_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzYtMTEtMS0xLTcxNDc4_bd3c6201-519c-41e0-9742-a2aadd23795e">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81cd80c7bd5e414fbd605f465e39a045_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzctMS0xLTEtNzE0Njg_0cd94ed4-4a03-478f-b9b2-1c8898ba8540">3,778</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieefeebe8556a419b982e4603dccbde45_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzctMy0xLTEtNzE0NzA_97cb48e7-a0cc-4de6-b570-70e8eb7c8a2e">2,022</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2742b142133f46b8a6da2018195c82e3_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzctNS0xLTEtNzE0NzI_244ee415-74ef-4e64-a64f-0c8b400f1561">1,154</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f669422c2a34471ba15be9c22158c50_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzctNy0xLTEtNzE0NzQ_1a97427b-0a49-4e6a-9cb0-d9c19808eded">560</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11472ddfa02944969a68ae2a1ae9e0aa_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzctOS0xLTEtNzE0NzY_c1ea260a-aab5-400e-b787-99e0ae518b6b">1,087</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzctMTEtMS0xLTcxNDc4_5ac22510-628a-43bf-b25b-a48931e1cae5">8,601</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 67.50pt"><ix:continuation id="i602df55832564988984eb4fbbbe8c1de"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzM4ODQ_18940afd-53b3-4430-a8a2-22b8756d6ad1" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer for the years 2021, 2020 and 2019 were as&#160;follows:</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:68.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id130fccad3254b85b50a4b625a1dcde4_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEtMS0xLTEtNTk0NzA_bb3e431b-fbe4-4355-947a-4aac1ce34174">4,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65d94d793a9d4765a3365f16eb32b2a7_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEtMy0xLTEtNTk0NzA_53837dc8-3454-4015-9dcf-e98e06ec1efa">4,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25b58dd47534aecaa1e6fceaca4aea2_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEtNS0xLTEtNTk0NzA_7323295c-e9e8-4800-9564-52e5cd5fea1c">5,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbf3d8d385d64c9986eeff60677c124c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzItMS0xLTEtNTk0NzA_36aa8017-9f8f-48f4-99f5-ba6f6a72f97b">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc9c0c2f95e04969a40f79d90fbce2c3_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzItMy0xLTEtNTk0NzA_85516ce0-6b49-4b09-ab51-4b1c94f788cc">341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ed5256f567f485c9398406ba71740cd_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzItNS0xLTEtNTk0NzA_5a27db45-88d1-4175-bd16-db4fd6edbc77">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d755014362a46e4b04d95046a5882e2_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzMtMS0xLTEtNTk0NzA_bfd69a60-52d0-4830-8ea8-f2aaa0086d96">343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic48b8c8ee39d43a199bbf9a0ca2aaf23_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzMtMy0xLTEtNTk0NzA_430ffcaf-bef6-4108-a8de-a9e6cab01179">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c803976e613424da77d662911fc6070_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzMtNS0xLTEtNTk0NzA_b7d28a91-4bb2-48b0-886a-30ee06e010bf">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if21ae7bafd3345088a01d43828a61e14_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzUtMS0xLTEtNTk0NzA_09b7d02d-2f40-44e1-ae20-099a05ebf6f2">280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c5ca044d5d4c338ccc82b463e5c0c0_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzUtMy0xLTEtNTk0NzA_2a8eadd2-a1a4-4234-bbb1-dc4609be1465">238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idae5a5e95f9e42db945e914283667476_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzUtNS0xLTEtNTk0NzA_b8ae6d92-2da6-4751-84f3-134b2143535c">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9926394966af411883263fa6138b4736_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzYtMS0xLTEtNzQyODg_adf021c5-6028-421b-8bdc-8b21b2d50bb5">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id455a11708be4744b4a4db362bcbb326_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzYtMy0xLTEtNzQyODg_d9618920-ff33-4a38-a2b3-740e6b694aa0">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fd2a2c4b784f2ca7121666541412f8_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzYtNS0xLTEtNzQyODg_17e8843f-6044-47fb-a38e-6beff104abb4">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73f7c080cab4bda95891cb8f82106e4_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzYtMS0xLTEtNTk0NzA_1b31884b-b09b-4b8f-b87e-49b2c710ddd4">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26ab236fac0b4f6aa2edb6c703d1d2d2_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzYtMy0xLTEtNTk0NzA_125d89ef-8e96-45a5-9dda-cb9073858792">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia046496cfcb74a4b8dcb288dcf4d65ac_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzYtNS0xLTEtNTk0NzA_815e76dc-2726-4436-9bdf-65fccba98c6b">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i686a58e486aa452d93fb9e1315614162_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzgtMS0xLTEtNTk0NzA_e16bd6d8-ee40-421c-af0c-643d6a713a81">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08449c2242ac44f6bdab497f63ba91ae_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzgtMy0xLTEtNTk0NzA_caad689e-0b3c-4529-af98-ed8ceb506616">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68ae7a44ac90426e88c14dd8cda682e3_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzgtNS0xLTEtNTk0NzA_fbe41ac1-b69a-4f1d-9bf7-ba9a87bee3b4">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i109a56ca7b294e69a526b8979a3ddbba_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzgtMS0xLTEtNzY1MDQ_79fabe91-6e5f-4b18-a9b6-0b472c2c738c">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6d4f781ea0b40538209f115920071e9_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzgtMy0xLTEtNzY1MDY_6b4deb21-351d-4b1c-beb6-8aa30b5bcac7">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2180af989330419e910ab226313818df_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzgtNS0xLTEtNzY1MDg_f8a3025f-3aec-4139-9103-363927012f52">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic68cf5e89c634f10804f0199048ac135_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEwLTEtMS0xLTc0Mjk1_2ea61f57-703c-45fd-8724-a43ad05a885b">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4331026771c04d61a230465e05e97af9_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEwLTMtMS0xLTc0Mjk1_bf9dc39a-946a-4eac-a40a-a5cd737ddc09">243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i542580a52bd046618b9a580e8e103af3_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEwLTUtMS0xLTc0Mjk1_c61bb6f5-e68a-404d-87cc-006998473b74">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic990a51442844403aa60ea9e7d40e464_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzktMS0xLTEtNTk0NzA_d19d851a-98ab-414d-ba80-5c7752d6a692">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6635461f5a48470c8e56e33f2e669734_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzktMy0xLTEtNTk0NzA_520a3559-eb76-4e2e-a906-b913e5176f0e">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0a477db0fde456185567e5b03ecc809_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzktNS0xLTEtNTk0NzA_150882f0-47a9-468b-9c2d-543219f1e34a">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585c6fb7766a4a5181f84f4a204170f8_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzExLTEtMS0xLTU5NDcw_ec0b27b3-56df-40d1-81e7-dfe289b72168">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i906af541abda46ea9ee574738de1865e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzExLTMtMS0xLTU5NDcw_c76047cc-bc34-4b5f-b47b-0cfd17f411fd">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02eebd70500545f79f2c990d2925d8b5_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzExLTUtMS0xLTU5NDcw_8338ad89-cfa7-4d84-9dc6-2d25076d1726">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic22a4e49c9354ba18f292e3feb3e7e01_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEyLTEtMS0xLTU5NDcw_ab5d538d-9657-4237-8946-b9a86c11ccc0">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2497f962eb7544ca88a07e1e575fc7ed_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEyLTMtMS0xLTU5NDcw_389ef9ef-482b-4bcd-8340-0ef4de3b3453">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae37a07b59f444bd8e13c8a1c43209fa_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEyLTUtMS0xLTU5NDcw_84adadca-84b0-4928-bdf9-93f9cd9ee0e1">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd485be53574b8e949e379c787d4ef4_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEzLTEtMS0xLTc2NTEy_13387fed-2880-4849-b4f5-a95ccca4aeb1">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7582499a2b415e93784236f4cb34fd_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEzLTMtMS0xLTc2NTE0_4452cc09-5903-4098-92ee-2f726289e3b7">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i168771f1c7d74447915fe4778febc05a_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEzLTUtMS0xLTc2NTE2_e8a503d8-d969-4751-a601-5b8f54c12d39">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i471e03575d1346b7b9f05bf5ba23116b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEzLTEtMS0xLTU5NDcw_e20b83d3-e271-486a-bb22-917087c37db4">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4f64c8704264652a24d4ce93c2900c3_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEzLTMtMS0xLTU5NDcw_58db5a72-b6dc-498c-a257-46bd9ced9c5c">937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if84190a5f2244c92b77538836a840d39_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEzLTUtMS0xLTU5NDcw_496f94a3-b235-41ab-9b5f-c3afadb20622">995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzE0LTEtMS0xLTU5NDcw_e50c2527-f0bf-4f04-87f4-2d35662ce454">8,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzE0LTMtMS0xLTU5NDcw_535394be-5f70-431d-80bf-bf40f05139ea">8,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzE0LTUtMS0xLTU5NDcw_9dc4156a-a125-47e9-8992-2e50e3b7e1e5">8,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made and are reflected in the table above.</span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzM5MTI_2e22fafb-1c2e-402e-9fa6-056775d5a46d" escape="true"><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December&#160;31, 2021 and 2020 were as&#160;follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:79.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14de5bc495eb4add9fa84a199741910c_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzEtMS0xLTEtNTk0NzA_cee2633f-c024-4f69-a2c5-4dda84a1d0a2">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d46d579e1e44fe3ad004f43eaccef30_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzEtMy0xLTEtNTk0NzA_c2a7dade-a2db-4683-ad87-690128d2c875">725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2862a5dfd1e645cfb3ebcb20802866e8_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzItMS0xLTEtNTk0NzA_d3d17571-4204-4c26-af65-b9a6825775be">336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8ed490007f4fee9a005a8a805c6894_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzItMy0xLTEtNTk0NzA_73ca1431-8c3a-4640-9ebf-422ced7b17e4">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c43807d9cda4c16831c9f055db35fb6_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzMtMS0xLTEtNTk0NzA_4be9d2f8-21f0-4387-a328-6fde2702d771">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3218c6c6aa7d47a6b6e7fe2e3402a5c8_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzMtMy0xLTEtNTk0NzA_98f1d941-3f75-45c0-bd58-c40b4cb6376a">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b664e37697c4f7891056561bf29f683_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzQtMS0xLTEtNTk0NzA_60e958a0-af47-49ba-846d-95d98a9eff92">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aea46020d284bf6820326330afd288d_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzQtMy0xLTEtNTk0NzA_ad89fa7e-2eca-41b6-8dd3-32e152735684">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d6aaa98a7a24f74b46d997266d2a452_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzUtMS0xLTEtNTk0NzA_2f63d152-a8cb-4a72-b928-b3eefb24cac9">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34126ade1b28483c9a1ea926b56d408d_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzUtMy0xLTEtNTk0NzA_ef85673b-815b-4181-9752-ea4ad7c533a8">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3be1fd06e45447f2a98c47d3aa49590f_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzYtMS0xLTEtNTk0NzA_133efe4b-be37-43b6-8901-7607c917a1ac">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ddc11ce20249cba2bdf7921a98775c_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzYtMy0xLTEtNTk0NzA_562b460e-cfb1-4a5e-adc3-6b09617d3129">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic95237c6a18642d8876995496f7f0ec6_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzctMS0xLTEtNTk0NzA_c7661997-7c9f-4e39-b992-43fac60b6d5f">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66dcb516bc924f7f8ea52045f62987c9_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzctMy0xLTEtNTk0NzA_99fd2fc9-186b-4548-a901-4e2c5996ce49">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90615098fdc24b3394cea58fd0717975_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzgtMS0xLTEtNTk0NzA_b06b655d-ec22-48d1-afb8-a7e6add14b32">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacfc9f50cdde4a879013a96abcb55983_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzgtMy0xLTEtNTk0NzA_f37b3c70-e441-4d22-b95b-b66a5fd16d1f">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serbia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie121075f685e4899b526388e85fc73a4_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzktMS0xLTEtNTk0NzA_1df0b44e-3824-4924-aa15-6e56dd4a6afc">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief9b76c5e82249468a3e6e7d77de38df_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzktMy0xLTEtNTk0NzA_128d24e2-a82d-448c-afd7-ee418d5f32a9">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic715be3970fe46419fb02b3a67f6c23d_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzEwLTEtMS0xLTU5NDcw_ba9b19d7-9ca0-4e89-8c4d-277bc091c89c">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2da7c3fce6a4a55b940079cd34b7824_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzEwLTMtMS0xLTU5NDcw_7258840b-dd25-497a-9229-b2ac620fa021">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf0ad3c28494e298de94b94bcbedd3f_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzExLTEtMS0xLTU5NDcw_8ace40ff-8f70-48df-97f0-3e22108b44cf">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dbae836ee6a485199be60177a95f582_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzExLTMtMS0xLTU5NDcw_f379f721-54e4-44f6-9109-773eb12e565d">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzEyLTEtMS0xLTU5NDcw_4cbad290-dc19-4546-a512-12079ce5262b">1,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzEyLTMtMS0xLTU5NDcw_211ec2c5-de5f-47e1-9832-fd7c91166129">1,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers</span></div><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzM5MDk_c52f8c4b-5eec-4c64-81d1-6bdc765a1270" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:68.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id7c19794c8aa4758a7c167c4585fa6ca_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiYjYyMjQyNmY2NTY0ZTkyYjY0NTA1YTllZTBiZTYxOS90YWJsZXJhbmdlOmJiNjIyNDI2ZjY1NjRlOTJiNjQ1MDVhOWVlMGJlNjE5XzEtMS0xLTEtNTk0NzA_9a9de86f-19e0-4a84-83a0-8469e758d6bb">18</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iace25aeeaa0d4c3d986f48d0c8baf029_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiYjYyMjQyNmY2NTY0ZTkyYjY0NTA1YTllZTBiZTYxOS90YWJsZXJhbmdlOmJiNjIyNDI2ZjY1NjRlOTJiNjQ1MDVhOWVlMGJlNjE5XzEtMy0xLTEtNTk0NzA_51f09c8d-2bd5-49cd-a228-1d267a6471f5">17</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i19d7ced3035a44ce992df3a4b9291ff4_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiYjYyMjQyNmY2NTY0ZTkyYjY0NTA1YTllZTBiZTYxOS90YWJsZXJhbmdlOmJiNjIyNDI2ZjY1NjRlOTJiNjQ1MDVhOWVlMGJlNjE5XzEtNS0xLTEtNTk0NzA_e396f69d-3dbb-4115-a61e-ee33e7b7e36a">16</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib8131fb2f99f4c7a8028ad6778dc1676_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiYjYyMjQyNmY2NTY0ZTkyYjY0NTA1YTllZTBiZTYxOS90YWJsZXJhbmdlOmJiNjIyNDI2ZjY1NjRlOTJiNjQ1MDVhOWVlMGJlNjE5XzItMS0xLTEtNTk0NzA_64e4b9ae-eade-4ba7-95c4-41a865efc9ff">16</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f416523997c4b338d676cc2d06aaafa_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiYjYyMjQyNmY2NTY0ZTkyYjY0NTA1YTllZTBiZTYxOS90YWJsZXJhbmdlOmJiNjIyNDI2ZjY1NjRlOTJiNjQ1MDVhOWVlMGJlNjE5XzItMy0xLTEtNTk0NzA_7cc05f47-5d45-42e3-badc-e966f3609860">17</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i04069591c97a4784ae4185ec478eb90f_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiYjYyMjQyNmY2NTY0ZTkyYjY0NTA1YTllZTBiZTYxOS90YWJsZXJhbmdlOmJiNjIyNDI2ZjY1NjRlOTJiNjQ1MDVhOWVlMGJlNjE5XzItNS0xLTEtNTk0NzA_de10931b-8001-408b-84d3-8eb7f7e752d3">17</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29cea92069c14b44a2be0c659664e70f_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiYjYyMjQyNmY2NTY0ZTkyYjY0NTA1YTllZTBiZTYxOS90YWJsZXJhbmdlOmJiNjIyNDI2ZjY1NjRlOTJiNjQ1MDVhOWVlMGJlNjE5XzMtMS0xLTEtNTk0NzA_706c2889-6b8f-40dc-8359-c63370e4759e">12</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice846a05c75e458db9e4650442b6067c_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiYjYyMjQyNmY2NTY0ZTkyYjY0NTA1YTllZTBiZTYxOS90YWJsZXJhbmdlOmJiNjIyNDI2ZjY1NjRlOTJiNjQ1MDVhOWVlMGJlNjE5XzMtMy0xLTEtNTk0NzA_30114290-dc84-4e30-8bc9-9483f24fbf8c">13</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i249f7ac9d61242019aa00db1804021d7_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiYjYyMjQyNmY2NTY0ZTkyYjY0NTA1YTllZTBiZTYxOS90YWJsZXJhbmdlOmJiNjIyNDI2ZjY1NjRlOTJiNjQ1MDVhOWVlMGJlNjE5XzMtNS0xLTEtNTk0NzA_982b9030-92b1-4d93-93ce-5d73e5deff4b">14</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-72</span></div></div></div><div id="ieeb1c2023b22439f84a8bdbbd2804ef7_2844"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">23.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODQ0L2ZyYWc6OGU4OTRkNmUwNTE5NDdlYmJjMjllMWMxMWJmMjRkYjQvdGV4dHJlZ2lvbjo4ZTg5NGQ2ZTA1MTk0N2ViYmMyOWUxYzExYmYyNGRiNF8xMDk5NTExNjMyODk0_433b689e-c2c9-4e42-83d7-05ecdf01f501" continuedAt="i7e1b57c2a7a64b4ba54a908a70d2f75f" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="i7e1b57c2a7a64b4ba54a908a70d2f75f"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company issued conditional notices of redemption to redeem in full all of its outstanding April 2025 Unsecured Notes and to redeem $<ix:nonFraction unitRef="usd" contextRef="if80737f8327f4413b9aff0d3dbfe8369_I20220118" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODQ0L2ZyYWc6OGU4OTRkNmUwNTE5NDdlYmJjMjllMWMxMWJmMjRkYjQvdGV4dHJlZ2lvbjo4ZTg5NGQ2ZTA1MTk0N2ViYmMyOWUxYzExYmYyNGRiNF8zODQ4MjkwNzU3MDE1_4fb5f3a6-7971-47ab-b85c-c778f7cce324">370</ix:nonFraction>&#160;million aggregate principal amount of its outstanding December 2025 Unsecured Notes. On February 10, 2022, the Company extended these conditional notices of redemption through March 15, 2022. The redemption and discharge of the indenture governing the April 2025 Unsecured Notes will be conditioned upon the completion of the Credit Agreement Refinancing, as defined below. The redemption of the December 2025 Unsecured Notes will be conditioned upon the receipt of aggregate gross proceeds from the B+L IPO, the B+L Debt Financing as defined below, the Credit Agreement Refinancing and the offering of the February 2027 Secured Notes, as defined below, of at least $<ix:nonFraction unitRef="usd" contextRef="if80737f8327f4413b9aff0d3dbfe8369_I20220118" decimals="INF" name="bhc:DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODQ0L2ZyYWc6OGU4OTRkNmUwNTE5NDdlYmJjMjllMWMxMWJmMjRkYjQvdGV4dHJlZ2lvbjo4ZTg5NGQ2ZTA1MTk0N2ViYmMyOWUxYzExYmYyNGRiNF8zODQ4MjkwNzU3MDQ3_ec5e90be-4196-410e-a3d3-ca504ca65ec0">7,000</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company announced its intention to refinance its existing Restated Credit Agreement with a Fifth Amended Restated Credit Agreement (the "New Restated Credit Agreement" and such refinancing, the "Credit Agreement Refinancing"). The New Restated Credit Agreement is expected to consist of approximately $<ix:nonFraction unitRef="usd" contextRef="i197a960478f74a8e9a871dd7b6a60555_I20220118" decimals="-6" name="bhc:DebtInstrumentExpectedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODQ0L2ZyYWc6OGU4OTRkNmUwNTE5NDdlYmJjMjllMWMxMWJmMjRkYjQvdGV4dHJlZ2lvbjo4ZTg5NGQ2ZTA1MTk0N2ViYmMyOWUxYzExYmYyNGRiNF8zODQ4MjkwNzU3MDYz_e3dfbfe2-c139-46ab-9710-1b408506491c">2,500</ix:nonFraction>&#160;million of term B loans and a $<ix:nonFraction unitRef="usd" contextRef="i5d92f684e11f4d7195e59fa6354f28b1_I20220118" decimals="-6" name="bhc:LineOfCreditFacilityExpectedMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODQ0L2ZyYWc6OGU4OTRkNmUwNTE5NDdlYmJjMjllMWMxMWJmMjRkYjQvdGV4dHJlZ2lvbjo4ZTg5NGQ2ZTA1MTk0N2ViYmMyOWUxYzExYmYyNGRiNF8zODQ4MjkwNzU3MDc5_8a78cfe8-930e-4a30-8233-3a44db5b0119">975</ix:nonFraction>&#160;million revolving credit facility. The Credit Agreement Refinancing is expected to occur only upon completion of the B+L IPO and a related debt financing by Bausch + Lomb (the "B+L Debt Financing"). At the time of the B+L IPO, the Credit Agreement Refinancing will provide that Bausch + Lomb initially be a "restricted" subsidiary subject to the terms of the Credit Agreement covenants, however the Credit Agreement Refinancing is expected to permit the Company to designate Bausch + Lomb as an "unrestricted" subsidiary under the New Restated Credit Agreement covenants upon achievement of a <ix:nonFraction unitRef="number" contextRef="i11ef4c89472c48b8a4e820729468ec02_D20220118-20220118" decimals="INF" name="bhc:DebtInstrumentCovenantTotalLeverageRatio" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODQ0L2ZyYWc6OGU4OTRkNmUwNTE5NDdlYmJjMjllMWMxMWJmMjRkYjQvdGV4dHJlZ2lvbjo4ZTg5NGQ2ZTA1MTk0N2ViYmMyOWUxYzExYmYyNGRiNF8zODQ4MjkwNzU3MDkz_58209316-bbec-4508-af89-bb580580ea63">7.6</ix:nonFraction>x  pro forma "Remainco Total Leverage Ratio." Such designation could take place at any time after the B+L IPO (including as soon as the closing of the B+L IPO). The Credit Agreement Refinancing is designed to facilitate the separation and distribution of Bausch + Lomb. The Credit Agreement Refinancing will not be consummated until completion of the B+L IPO and related B+L Debt Financing. There can be no assurance that the Credit Agreement Refinancing will occur on the terms described above, or at all. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2022, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i9af4b96ef19949f2928ad128d4c72201_I20220210" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODQ0L2ZyYWc6OGU4OTRkNmUwNTE5NDdlYmJjMjllMWMxMWJmMjRkYjQvdGV4dHJlZ2lvbjo4ZTg5NGQ2ZTA1MTk0N2ViYmMyOWUxYzExYmYyNGRiNF8zODQ4MjkwNzU3MTE3_d3dde3ee-7faa-4fa5-b1f6-8a9c25b805ac">1,000</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i9af4b96ef19949f2928ad128d4c72201_I20220210" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODQ0L2ZyYWc6OGU4OTRkNmUwNTE5NDdlYmJjMjllMWMxMWJmMjRkYjQvdGV4dHJlZ2lvbjo4ZTg5NGQ2ZTA1MTk0N2ViYmMyOWUxYzExYmYyNGRiNF8zODQ4MjkwNzU3MTQw_e134234e-18af-4050-a3f4-5597e0724bd5">6.125</ix:nonFraction>% senior secured notes due February 2027 (the &#8220;February 2027 Secured Notes&#8221;). The February 2027 Secured Notes accrue interest at a rate of <ix:nonFraction unitRef="number" contextRef="i9af4b96ef19949f2928ad128d4c72201_I20220210" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODQ0L2ZyYWc6OGU4OTRkNmUwNTE5NDdlYmJjMjllMWMxMWJmMjRkYjQvdGV4dHJlZ2lvbjo4ZTg5NGQ2ZTA1MTk0N2ViYmMyOWUxYzExYmYyNGRiNF8zODQ4MjkwNzU3MTQ5_e134234e-18af-4050-a3f4-5597e0724bd5">6.125</ix:nonFraction>% per year, payable semi-annually in arrears on each February and August. The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to <ix:nonFraction unitRef="number" contextRef="id0c6700094674a22af02045a72c15ccd_D20220210-20220210" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODQ0L2ZyYWc6OGU4OTRkNmUwNTE5NDdlYmJjMjllMWMxMWJmMjRkYjQvdGV4dHJlZ2lvbjo4ZTg5NGQ2ZTA1MTk0N2ViYmMyOWUxYzExYmYyNGRiNF8zODQ4MjkwNzU3MTUy_397e97ef-dd31-4765-a957-d9961410aa4e">100</ix:nonFraction>% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to February 2024, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="i590fabe0c9ae4c4db81e12d4cd310bc0_D20220210-20220210" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODQ0L2ZyYWc6OGU4OTRkNmUwNTE5NDdlYmJjMjllMWMxMWJmMjRkYjQvdGV4dHJlZ2lvbjo4ZTg5NGQ2ZTA1MTk0N2ViYmMyOWUxYzExYmYyNGRiNF8zODQ4MjkwNzU3MTU4_28eed8cd-be0d-4b44-a212-065055df8a9f">40</ix:nonFraction>% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the B+L IPO does not occur on or prior to August 15, 2022, the Company will be required to redeem the February 2027 Secured Notes at such time at a redemption price equal to the issue price of the February 2027 Secured Notes plus accrued and unpaid interest.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-73</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>2
<FILENAME>exhibit10202021ye.htm
<DESCRIPTION>EX-10.20
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie7dc5065bc8b46a8a75a421dd7576e94_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.20</font></div></div><div style="margin-top:4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BAUSCH HEALTH COMPANIES INC.</font></div><div style="margin-top:4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDED AND RESTATED</font></div><div style="margin-top:8.7pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EMPLOYMENT AGREEMENT</font></div><div style="margin-top:8.7pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THIS EMPLOYMENT AGREEMENT (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">reement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is hereby entered into as of February 18, 2022, by and between Bausch Health Companies Inc., a </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">company incorporated in the Province of British Columbia, Canada (together with any successor thereto</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Bausch Health</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and Thomas J. Appio, an individual (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) (hereinafter collectively referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">the parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Where the context requires, references to the Company shall include the Company&#8217;s subsidiaries and affiliates and any successors in interest thereto, which shall include Bausch Pharma in connection with the separation of the Bausch + Lomb business (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Separation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Company and the Executive entered into that certain employment agreement dated as of March 23, 2017, retroactive to August 17, 2016 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Original Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), pursuant to which the Company continued to employ Executive for the term described therein&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) has determined that it is in the best interests of Bausch Health and its stockholders to separate the global eye health business (such business, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Bausch + Lomb</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) from the remainder of Bausch Health by providing for an initial public offering of the common shares of Bausch + Lomb Corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">B+L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) (such offering, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">IPO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and subsequently separating the Bausch + Lomb business from the Company (the date of such Separation, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Separation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, in connection with the IPO, the Company desires to amend and restate Executive&#8217;s Original Agreement and continue to employ Executive on the terms set forth in this Agreement, for the period provided below, and Executive desires to continue such employment with the Company, subject to the terms and conditions set forth herein&#894; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the respective agreements of the parties contained herein, it is agreed as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Commencement Date&#59; Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The term (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of Executive&#8217;s employment under this Agreement shall be for the period commencing retroactively on September 1, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and ending on the third (3rd) anniversary of the Initial Commencement Date.  Thereafter, the Employment Term shall extend automatically for consecutive periods of one year unless either party provides notice of non-renewal not less than one-hundred and eighty (180) days prior to the end of the Employment Term as then in effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  During the Employment Term&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Executive shall be employed as the Chief Executive Officer of the pharmaceutical business of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Pharma Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) as of the Initial Commencement Date, at which time Executive shall report directly to the Chief Executive Officer of Bausch Health. Contingent and effective upon the closing of the IPO, Executive shall be employed as the Chief Executive Officer of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Bausch Pharma Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), at which time Executive shall report directly to the Board.  Executive shall perform the duties, undertake the responsibilities and exercise the authority customarily performed, undertaken and exercised by persons situated in similar executive capacities.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">During the Employment Term, the Company may nominate Executive for election to the Board and Executive shall not receive separate or additional compensation for such service.  At, or any time after, the time of Executive&#8217;s termination of employment with the Company for any reason, Executive shall resign from the Board if requested to do so by the Company.  The preceding sentence shall survive any termination of the Employment Term.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Excluding periods of vacation and sick leave to which Executive is entitled and other service outside of the Company contemplated in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Executive shall devote his full professional time and attention to the business and affairs of the Company to discharge the responsibilities of Executive hereunder.  Prior to joining or agreeing to serve on corporate, civil or charitable boards or committees, Executive shall obtain approval of the Board.  Executive may manage personal and family investments, participate in industry organizations and deliver lectures at educational institutions, so long as such activities do not interfere with the performance of Executive&#8217;s responsibilities hereunder.  It is understood that, during Executive&#8217;s employment by the Company, Executive shall not engage in any activities that constitute a conflict of interest with the interests of the Company or its direct and indirect subsidiaries, as outlined in the Company&#8217;s conflict of interest policies for employees and executives in effect from time to time.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Executive shall be subject to and shall abide by each of the personnel policies applicable to senior executives, including any policy restricting pledging and hedging investments in Company equity by Company executives, any policy the Company adopts regarding the recovery of incentive compensation (sometimes referred to as &#8220;clawback&#8221;) and any additional clawback provisions as required by law and applicable listing rules.  This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, Executive&#8217;s employment with the Company is &#8220;at will,&#8221; such that each of Executive or the Company has the option to terminate Executive&#8217;s employment at any time, with or without advance notice, and with or without Cause or with or without Good Reason.  This Agreement does not constitute an express or implied agreement of continuing or long-term employment.  The at-will nature of Executive&#8217;s employment can be altered only by a written agreement specifying the altered status of Executive&#8217;s employment.  Such written agreement must be signed by both Executive and the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Annual Compensation.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Base Salar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">y.  Effective on the Initial Commencement Date, during the Employment Term, Executive shall be paid an annual base salary of $1,000,000 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  The Base Salary shall be payable in accordance with the Company&#8217;s regular payroll practices as then in effect.  During the Employment Term, the Base Salary will be reviewed annually by the Talent and Compensation Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and is subject to adjustment at the discretion of the Committee.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Performance Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Effective on the Initial Commencement Date, subject to the terms of the Company&#8217;s annual incentive cash bonus program as in effect from time to time, Executive shall be eligible to receive a target annual cash bonus of 120% of Base Salary (such target bonus, as may hereafter be increased, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) with the opportunity to receive a maximum annual cash bonus of 200% of the Target Bonus&#59; provided that, for the avoidance of doubt, Executive&#8217;s target bonus opportunity for fiscal year 2021 shall be a blended average of Executive&#8217;s target bonus opportunity prior to the Initial Commencement Date and Executive&#8217;s Target Bonus on and after the Initial Commencement Date based on the number of days prior to the Initial Commencement Date and the number of days on and after the Initial Commencement Date, respectively. Annual bonuses, if any, will be payable in the Company&#8217;s discretion and in accordance with the Company&#8217;s customary practices applicable to bonuses paid to senior executives of the Company. During the Employment Term, the Executive&#8217;s Target Bonus will be reviewed annually by the Committee and is subject to adjustment at the discretion of the Committee.  Executive will also be eligible to continue to participate in the Bausch + Lomb Separation Bonus Opportunity, as detailed in the letter dated November 2, 2020.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Additional Compensation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">One-Time Promotion Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Effective as of the Initial Commencement Date, Executive previously received a grant under the Amended and Restated 2014 Omnibus Incentive Plan (as amended and restated from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of (i) a number of performance stock units (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) with a target grant-date fair value equal to $2,500,000 and (ii) a number of restricted stock units (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) with a grant-date fair value equal to $2,500,000 , in each case with respect to common shares of BHC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">BHC Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The PSUs and RSUs are subject to the terms and conditions of the Plan and applicable award agreements, which have been previously provided to</font><font style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive. For the avoidance of doubt, upon the Separation, the PSUs and RSUs described in this Section 4(a) shall be equitably adjusted in accordance with the Plan (including the equitable adjustment of the number BHC Shares underlying such PSUs and RSUs and the performance goals applicable to the PSUs, as applicable) and shall otherwise remain awards entirely with respect to BHC Shares, which such equitable adjustments shall be subject to the terms and conditions of the Plan, the award agreements evidencing such PSUs and RSUs and the applicable Separation-related agreements entered into in connection with the Separation (including the employee matters agreement).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">On</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">oing Grants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive will be eligible for consideration for additional equity grants during the Employment Term in the sole discretion of the Committee commensurate with his position with the Company and as provided to similarly situated executives of the Company.</font></div><div style="margin-bottom:12.5pt;margin-top:3.45pt;padding-left:5.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.8pt;text-decoration:underline">Share Ownership Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive agrees to comply with any share ownership requirements adopted by the Company applicable to Executive, which shall be on the same terms as senior executives of the Company.</font></div><div style="margin-bottom:12.5pt;margin-top:3.45pt;padding-left:5.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.8pt;text-decoration:underline">Other Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  During the Employment Term&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Employee Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive shall be entitled to participate in the employee benefit plans, practices and programs maintained by the Company, and made available to senior executives of the Company generally, including, without limitation, all pension, retirement, profit sharing, savings, medical, hospitalization, disability, dental, life or travel accident insurance benefit plans and matching share program in accordance with the terms of the plans as in effect from time to time.  Executive&#8217;s participation in such plans, practices and programs shall be on the same basis and terms as are applicable to such employees.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Business Ex</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">p</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">enses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Upon submission of proper invoices in accordance with, and subject to, the Company&#8217;s normal policies and procedures, Executive shall be entitled to receive prompt reimbursement of all reasonable out-of-pocket business, entertainment and travel expenses incurred by him in connection with the performance of his duties hereunder.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Repatriation from China</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Effective as of December 31, 2021, Executive&#8217;s expatriate assignment from New Jersey to China, and the associated benefits provided under the Company&#8217;s expatriate program, ended.  The Company will cover reasonable and customary expenses related to the Executive&#8217;s repatriation from China to New Jersey.  In respect of the period ended December 31, 2021, the Company will continue to provide tax equalization for any trailing liabilities as a result of cash or equity compensation granted or earned while on assignment in China, and shall pay the cost of any tax preparation services required in connection with Executive&#8217;s tax equalization.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Vacation and Sick Leave</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive shall be entitled, without loss of pay, to absent himself voluntarily from the performance of Executive&#8217;s employment under this Agreement, pursuant to the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Executive shall be entitled to annual vacation in accordance with and subject to the policies as periodically established for senior executives of the Company&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Executive shall be entitled to sick leave (without loss of pay) in accordance with the Company&#8217;s policies as in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive&#8217;s employment with the Company hereunder may be terminated under the circumstances set forth below&#59; p</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">rovided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that notwithstanding anything contained herein to the contrary, to the extent required by Section 409A (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), Executive shall not be considered to have terminated employment with the Company for purposes of this Agreement until he would be considered to have incurred a &#8220;separation from service&#8221; from the Company within the meaning of Section 409A.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive&#8217;s employment shall be terminated as of the date of Executive&#8217;s death and Executive&#8217;s beneficiaries shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">hereof.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><img alt="image_0a.jpg" src="image_0a.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:2px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Disabilit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">y.  The Company may terminate Executive&#8217;s employment, on written notice to </font><img alt="image_0a.jpg" src="image_0a.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:2px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive after having established Executive&#8217;s Disability and while Executive remains Disabled, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Disabilit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">y&#8221; shall have the meaning assigned to such term in the Plan.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company may terminate Executive&#8217;s employment for Cause effective as of the date of the Notice of Termination (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof) and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  &#8220;Cause&#8221; shall  mean, for purposes of this Agreement&#58; (1) conviction of any felony (other than one related to a vehicular offense) or other criminal act involving fraud&#59; (2) willful misconduct that results in a material economic detriment to the Company&#59; (3) material violation of Company policies and directives, which is not cured after written notice and an opportunity for cure&#59; (4) continued refusal by Executive to perform his duties after written notice identifying the deficiencies and an opportunity for cure&#59; and (5) a material violation by Executive of any of the covenants to the Company set forth in this Agreement, any restrictive covenant or similar agreement or any compensatory plan, agreement or arrangement between Executive and the Company.  No action or inaction shall be deemed willful if (x) not demonstrably willful and (y) taken, or not taken, by Executive in good faith and with the understanding that such action, or inaction, was not adverse to the best interests of the Company.  References in this paragraph to the Company shall also include direct and indirect subsidiaries of the Company, and materiality shall be measured based on the action or inaction and the impact upon the Company taken as a whole.  Without limiting the other rights of the Company under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the Company may suspend Executive, without pay, upon Executive&#8217;s indictment for the commission of a felony as described under clause (1) above.  Such suspension may remain effective until such time as the indictment is either dismissed or a verdict of not guilty has been entered.  If such indictment does not result in a conviction, as soon as practicable following such dismissal or verdict, the Company will pay Executive the base salary and target bonus amount that Executive would have received for the period during which Executive was suspended without pay (with interest from the date such amounts would otherwise have been paid at the short-term applicable federal rate, compounded semi-annually, as determined under Section 1274 of the Code for the month in which payment would have been made but for the delay) and Executive will receive vesting credit for purposes of Executive&#8217;s outstanding equity awards.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Without Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company may terminate Executive&#8217;s employment without Cause.  The Company shall deliver to Executive a Notice of Termination (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof) not less than sixty (60) days prior to the termination of Executive&#8217;s employment without Cause and the Company shall have the option of terminating Executive&#8217;s duties and responsibilities prior to the expiration of such thirty-day notice period, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive may terminate his employment for Good Reason (as defined below) by delivering to the Company a Notice of Termination not less than thirty (30) days </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">prior to the termination of Executive&#8217;s employment for Good Reason and no more than one hundred fifty (150) days following the initial existence of the event or condition constituting Good Reason.  The Company shall have the option of terminating Executive&#8217;s duties and responsibilities prior to the expiration of such thirty (30) day notice period, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean the occurrence of any  of the events  or conditions described in clauses (1) through (4) below during the Employment Term, without Executive&#8217;s prior written consent, which are not cured by the  Company (if susceptible to cure by the Company) within thirty (30) days after the Company has received written notice from Executive within ninety (90) days of the initial existence of the event or condition constituting Good Reason specifying the particular events or conditions which constitute Good Reason and the specific cure requested by Executive. </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Diminution of Res</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">p</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">onsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  (A) Any material reduction in Executive&#8217;s duties or responsibilities as (i) Chief Executive Officer of the Pharma Business between the Initial Commencement Date and the Bausch Pharma Commencement Date or (ii) Chief Executive Officer of the Company following the Bausch Pharma Commencement Date, in each case as in effect immediately prior thereto (other than a reduction where Executive is provided with other duties or responsibilities substantially comparable to Executive&#8217;s overall duties and responsibilities prior to such reduction) or (B) removal of Executive from the position of (i) Chief Executive Officer of the Pharma Business between the Initial Commencement Date and the Bausch Pharma Commencement Date or (ii) Chief Executive Officer of the Company following the Bausch Pharma Commencement Date (or, following a Change in Control or a corporate restructuring, removal from the position of Chief Executive Officer of the ultimate parent company of the resulting entity), except, in each of (A) and (B), in connection with (1) the termination of Executive&#8217;s employment for Disability, Cause, as a result of Executive&#8217;s death or by Executive other than for Good Reason, or (2) for the avoidance of doubt, the changes in the Executive&#8217;s position and reporting relationship contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">p</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ensation Reduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any reduction in Executive&#8217;s Base Salary or Target Bonus opportunity which is not comparable to reductions in the base salary or target bonus opportunity of other senior executives of the Company&#59; </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Relocation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any relocation of Executive&#8217;s primary place of business that results in an increase of Executive&#8217;s one-way commute by fifty (50) miles or more&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that Executive&#8217;s repatriation to New Jersey in connection with Executive&#8217;s commencement of employment shall not constitute Good Reason&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that the Company&#8217;s request that Executive travel from time to time on behalf of the Company shall not constitute Good Reason&#59; or </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">p</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">any Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any other material breach by the Company of any material provision of this Agreement, including, but not limited to, the failure of the Company to consummate the closing of the IPO by the second anniversary of the Initial Commencement Date as contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt;text-decoration:underline">Without Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive may voluntarily terminate his employment without Good Reason by delivering to the Company a Notice of Termination not less than thirty (30) days prior to the termination of Executive&#8217;s employment and the Company shall have the option of terminating Executive&#8217;s duties and responsibilities prior to the expiration of such thirty (30) day notice period, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof through the last day of such notice period.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Notice of Non-Renewal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive&#8217;s employment shall terminate upon expiration of the Employment Term as then in effect following timely provision by either party of notice of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">non-renewal in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Notice of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any purported termination by the Company or by Executive shall be communicated by written Notice of Termination to the other party hereto.  For purposes of this Agreement, a &#8220;Notice of Termination&#8221; shall mean a notice which indicates a termination date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the specific termination provision in this Agreement relied upon and sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive&#8217;s employment under the provision so indicated.  For purposes of this Agreement, no such purported termination of Executive&#8217;s employment hereunder shall be effective without such Notice of Termination (unless waived by the party entitled to receive such notice).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Compensation Upon Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Upon termination of Executive&#8217;s employment during the Employment Term, Executive shall be entitled to the following benefits&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that any such benefits to which Executive is hereunder entitled shall be offset by those benefits that Executive receives, if any, under applicable law or otherwise&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Termination by the Company for Cause or by Executive Without Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment is terminated by the Company for Cause or by Executive without Good Reason, the Company shall pay Executive all amounts earned or accrued hereunder through the Termination Date, including&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">reimbursement for reasonable and necessary expenses incurred by Executive on behalf of the Company for the period ending on the Termination Date&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">any previous compensation which Executive has previously deferred (including any interest earned or credited thereon), in accordance with the terms and conditions of the applicable deferred compensation plans or arrangements then in effect&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">equity and incentive awards, to the extent previously vested, shall be paid or delivered to Executive in accordance with the terms of such awards (including the applicable retirement provisions set forth therein)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">any amount or benefit as provided under any benefit plan or program (the foregoing items in clauses (1) through (4) being collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Accrued Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Termination by the Company for Disability or Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment is terminated by the Company for Disability or by reason of Executive&#8217;s death, then, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, Executive shall be entitled to the benefits provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company shall pay Executive (or his beneficiaries, as applicable) the Accrued Compensation&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company shall pay to Executive (or his beneficiaries, as applicable) within sixty (60) days following the Termination Date, any bonus earned but unpaid in respect of any fiscal year preceding the Termination Date&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Each unvested equity award held by Executive at the time of termination shall be governed by the terms of the applicable award agreement (including the applicable retirement provisions set forth therein).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Termination by the Company Without Cause or by Executive for Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment by the Company shall be terminated by the Company without Cause or by Executive for Good Reason, then, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, Executive shall be entitled to the benefits provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company shall pay to Executive any Accrued Compensation&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company shall pay to Executive any bonus earned but unpaid in respect of any fiscal year preceding the Termination Date within sixty (60) days following the Termination Date&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company shall pay to Executive a bonus or incentive award in respect of the fiscal year in which Executive&#8217;s Termination Date occurs in an amount equal to the product of (A) the lesser of (x) the bonus or incentive award that Executive would have been entitled to receive based on actual achievement against the stated performance objectives and (y) Executive&#8217;s Target Bonus and (B) a fraction (x) the numerator of which is the number of days in such fiscal year through the Termination Date and (y) the denominator of which is 365 (provided that if such termination occurs in contemplation of a Change in Control (as defined in the Plan) or within twelve months following a Change in Control, then in the forgoing calculation, the amount under (A) above shall be equal to Executive&#8217;s Target Bonus).  Any bonus or incentive award payable to Executive under this clause (3) shall be paid in a lump sum payment by March 15 of the year following the fiscal year in which Executive&#8217;s Termination Date occurs&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company shall pay Executive as severance pay, in lieu of any further compensation for the periods subsequent to the Termination Date, an amount in cash, which amount shall be payable in a lump sum payment within sixty (60) days following such termination (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof), equal to two (2) times the sum of Executive&#8217;s Base Salary and Target Bonus, in each case, as in effect immediately prior to termination and without regard to any reduction thereto which constitutes Good Reason&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Each unvested equity award held by Executive at the time of termination shall be governed by the terms of the applicable award agreement (including the applicable retirement provisions set forth therein)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company shall provide Executive with continued coverage through the second anniversary  of Executive&#8217;s Termination Date under any health, medical, dental or vision program or policy in which Executive (and his dependents, as applicable) participated in as of the time of his employment termination on terms no less favorable to Executive and his dependents than those applicable to actively employed senior executives of the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that Executive shall be solely responsible for any taxes incurred in respect of such coverage&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the Company may modify the continuation coverage contemplated by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (including by providing a lump-sum cash payment equal to the value for Executive of the continuation coverage provided herein) to the extent reasonably necessary to avoid the imposition of any excise taxes on the Company for failure to comply with the nondiscrimination requirements of the Patient Protection and Affordable Care Act of 2010, as amended, and&#47;or the Health Care and Education Reconciliation Act of 2010, as amended (to the extent applicable).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Ex</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">p</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">iration of Employment Term Upon Notice of Non-Renewal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment  terminates  upon  expiration of the Employment Term as in effect following timely provision of a notice of non-renewal in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, then&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">If such notice is submitted by Executive, then Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">If such notice is submitted by the Company, then Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Executive shall not be required to mitigate the amount of any payment provided for under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> by seeking other employment or otherwise and no such payment shall be offset or reduced by the amount of any compensation or benefits provided to Executive in any subsequent employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The parties intend for the payments and benefits under this Agreement to be exempt from Section 409A or, if not so exempt, to be paid or provided in a manner which complies with the requirements of such section, and intend that this Agreement shall be construed and administered in accordance with such intention.  If any payments or benefits due to Executive hereunder would cause the application of an accelerated or additional tax under Section 409A, such payments or benefits shall be restructured in a mutually agreed upon manner that to the extent possible preserves the economic benefit and original intent thereof but does not cause such an accelerated or additional tax.  For purposes of the limitations on nonqualified deferred compensation under Section 409A, each payment of compensation under this Agreement shall be treated as a separate payment of compensation.  Without limiting the foregoing and notwithstanding anything contained herein to the contrary, to the extent required in order to avoid accelerated taxation and&#47;or tax penalties under Section 409A amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to this Agreement during the six-month period immediately following Executive&#8217;s separation from service shall instead be paid on the first business day after the date that is six months following Executive&#8217;s Termination Date (or death, if earlier).  Notwithstanding anything to the contrary in this Agreement, all (A) reimbursements and (B) in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A, including, where applicable, the requirement that (x) the amount of expenses eligible for reimbursement, or in kind benefits provided, during a calendar year may not affect the expenses eligible for reimbursement, or in kind benefits to be provided, in any other calendar year&#59; (y) the reimbursement of an eligible expense will be made no later than the last day of the calendar year following the year in which the expense is incurred&#59; and (z) the right to reimbursement or in kind benefits is not subject to liquidation or exchange for another benefit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Employee Protection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Nothing in this Agreement or otherwise limits Executive&#8217;s ability to communicate directly with and provide information, including documents, not otherwise protected from disclosure by any applicable law or privilege to the Securities and Exchange Commission (the &#8220;SEC&#8221;) or any other federal, state or local governmental agency or commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Government Agency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) regarding possible legal violations, without disclosure to the Company.  The Company may not retaliate against Executive for any of these activities, and nothing in this Agreement or otherwise requires Executive to waive any monetary award or other payment that Executive might become entitled to from the SEC or any other Government Agency.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Records and Confidential Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Executive acknowledges that in connection with the performance of his duties during the Employment Term, the Company will make available to Executive, or Executive will have access to, certain Confidential Information (as defined below) of the Company and its affiliates.  Executive acknowledges and agrees that any and all Confidential Information disclosed to, or learned or obtained by, Executive during the course of his employment by the Company or otherwise, whether developed by Executive alone or in conjunction with others or otherwise, shall be and is the sole and exclusive property of the Company or the affiliate of the Company, as applicable, that is Executive&#8217;s employer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  No license or other right to any Confidential Information is granted to Executive under this Agreement.  To the extent that Executive acquires any right, title or interest in or to any Confidential Information, Executive hereby irrevocably assigns, transfers, conveys and delivers to the Employer all such right, title and interest in and to such Confidential Information.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, the Confidential Information will be kept confidential by Executive, will not be used in any manner which is detrimental to the Company or any of its subsidiaries or affiliates (including, for the avoidance of doubt, each of B+L and Solta Medical Corporation and their respective subsidiaries) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), will not be used other than in connection with Executive&#8217;s discharge of his duties hereunder, and will be safeguarded by Executive from unauthorized disclosure.  Executive acknowledges and agrees that the confidentiality restrictions set forth herein shall apply to any and all Confidential Information disclosed to, or learned or obtained by, Executive, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">whether before, on or after the date hereof.  For the avoidance of doubt, nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall prevent Executive from complying with a valid legal requirement (whether by oral questions, interrogatories, requests for information or documents, subpoena, civil investigative demand or similar process) to disclose any Confidential Information&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Executive shall first give notice to the Employer and reasonably cooperate with the Employer to obtain a protective order or other measures preserving the confidential treatment of such Confidential Information and requiring that the information or documents so disclosed be used only for the purposes for which the order was issued or is otherwise required by applicable law.  For the avoidance of doubt, nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall prevent Executive from exercising any legally protected whistleblower rights (including under Rule 21F under the Securities Exchange Act of 1934, as amended) as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Following the termination of Executive&#8217;s employment hereunder or upon the applicable member of the Company Group&#8217;s request, and subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, as soon as possible after such written request, Executive will return to the applicable member of the Company Group all written Confidential Information which has been provided to Executive and Executive will return or destroy all copies of any analyses, compilations, studies or other documents prepared by Executive or for Executive&#8217;s use containing or reflecting any Confidential Information.  Within five (5) business days of the receipt of such request by Executive, he shall, upon written request of the applicable member of the Company Group, deliver to such Company Group member a document certifying that such written Confidential Information has been returned or destroyed in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">For the purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean any and all non-public, proprietary or other confidential information of the Company Group disclosed to Executive, to which Executive has access, or of which Executive otherwise becomes aware, in each case whether in oral, written, graphic or machine readable form, including, without limitation, (A) know-how, trade secrets, inventions, discoveries, concepts, information, works, materials, processes, methods, data, software, programs, apparatus, designs and the like, and any other intellectual property the value of which is contingent upon maintaining the confidentiality thereof, (B) information regarding the business of the Company Group, including its products, services, budgets, contracts, reports, investigations, experiments, research, work in progress, drawings, designs, plans, proposals, codes, marketing and sales programs, client lists, client mailing lists, supplier lists, financial projections, cost summaries, pricing formulae, marketing studies relating to prospective business opportunities, and all other concepts, ideas, materials, or information prepared or performed for or by any member of the Company Group, (C) information regarding the skills and compensation of the employees, contractors, and any other service providers of the Company Group, (D) the existence of any business discussions, negotiations, or agreements between any member of the Company Group and any third party, (E) all documents and other work product generated by you which contain, comment upon, or relate in any way to any information disclosed by any member of the Company Group, (F) all third-party information held in confidence by the Company Group, and (G) the terms and conditions of this Agreement.  For purposes of this Agreement, the Confidential Information shall not include, and Executive&#8217;s obligation shall not extend to (A) information which is generally available to the public and (B) information obtained by Executive other than pursuant to or in connection with Executive&#8217;s employment.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Pursuant to Section 7 of the Defend Trade Secrets Act of 2016 (which added 18 U.S.C. &#167; 1833(b)), the Company Group and Executive acknowledge and agree that Executive shall not have criminal or civil liability under any federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law&#59; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  In addition and without limiting the preceding sentence, if Executive files a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">lawsuit for retaliation by any member of the Company Group for reporting a suspected violation of law, Executive may disclose the trade secret to Executive&#8217;s attorney and may use the trade secret information in the court proceeding, if Executive (X) files any document containing the trade secret under seal and (Y) does not disclose the trade secret, except pursuant to court order.  Nothing in this Agreement or otherwise is intended to conflict with 18 U.S.C. &#167; 1833(b) or create liability for disclosures of trade secrets that are expressly allowed by such Section.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">In connection with Executive&#8217;s employment with the Company, Executive will not use any confidential or proprietary information Executive may have obtained in connection with employment with any prior employer.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Executive&#8217;s obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">Covenant Not to Solicit and Not to Compete&#59; Non-Disparagement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Covenants Not to Solicit or to Interfere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To protect the Confidential Information, Company Intellectual Property (as defined below) and other trade secrets of the Company Group, Executive agrees, during the Employment Term and for a period of twenty-four (24) months after Executive&#8217;s cessation of employment with the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), not to solicit, hire or participate in or assist in any way in the solicitation or hire of any employees of the Company Group (or any person who was an employee of the Company or any of its subsidiaries during the six-month period preceding such action).  For purposes of this covenant, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means directly or indirectly influencing or attempting to influence employees of the Company or any of its subsidiaries to become employed with any other person, partnership, firm, corporation or other entity.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, to protect the Confidential Information, Company Intellectual Property and other trade secrets of the Company Group, Executive agrees, during the Employment Term and the Restricted Period, not to (x) solicit any client or customer to receive services or to purchase any good or services in competition with those provided by the Company Group or any of its subsidiaries or (y) interfere or attempt to interfere in any material respect with the relationship between any member of the Company Group on one hand and any client, customer, supplier, investor, financing source or capital market intermediary on the other hand.  For purposes of this covenant, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means directly or indirectly influencing or attempting to influence clients or customers of the Company or any of its affiliates to accept the services or goods of any other person, partnership, firm, corporation or other entity in competition with those provided by the Company or any of its affiliates.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive agrees that the covenants contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> are reasonable and desirable to protect the Confidential Information and Company Intellectual Property of the Company and its affiliates&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that solicitation through general advertising or the provision of references shall not constitute a breach of such obligations.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Covenant Not to Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To protect the Confidential Information, Company Intellectual Property and other trade secrets of the Company, the Company and its affiliates, Executive agrees (i) during the period beginning on the Initial Commencement Date and ending on the date that is 12 months after the Separation Date (but in no event later than the last day of the Restricted Period) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">First Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), not to engage in Prohibited Activities (as defined below) in any country in which the Company or any of its affiliates and, following the Separation Date, Bausch + Lomb, conducts business, or plans to conduct business, and (ii) following the expiration of the First Period, during the Employment Term and the Restricted Period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Second Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), not to engage in Prohibited Activities in any country in which the Company or any of its affiliates conducts business, or plans to conduct business.  For the purposes of this Agreement, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Prohibited Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means directly or indirectly engaging as an owner, employee, partner, member, consultant or agent of any entity that derives more than 10% of its consolidated revenue from the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">development, manufacturing, marketing and&#47;or distribution (directly or indirectly) of (x) during the First Period, branded or generic prescription or non-prescription pharmaceuticals or medical devices for treatments in the fields of neurology, dermatology, gastroenterology, ophthalmology or dentistry (including, for the avoidance of doubt, the global eye health business and the global aesthetics medical device business) (y) during the Second Period, branded or generic prescription or non-prescription pharmaceuticals or medical devices for treatment in the same fields as clause (x), other than ophthalmology&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that Prohibited Activities shall not mean Executive&#8217;s investment in securities of a publicly-traded company equal to less than five (5%) percent of such company&#8217;s outstanding voting securities&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that, for the avoidance of doubt, Executive complies with the obligations set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 12,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">13(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">13(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  Executive agrees that the covenants contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> are reasonable and desirable to protect the Confidential Information and Company Intellectual Property of the Company and its affiliates.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Non-Disparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive agrees not to make written or oral statements about the Company Group or any of their respective directors, executive officers or non-executive officer employees that are negative or disparaging, except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  The Company shall instruct its directors and executive officers to not make written or oral statements about Executive that are negative or disparaging. Notwithstanding the foregoing, nothing in this Agreement or otherwise shall preclude Executive, the Company, its subsidiaries and affiliates, and the Company&#8217;s directors and executive officers from communicating or testifying truthfully to the extent required by law to any federal, state, provincial or local governmental agency or in response to a subpoena to testify issued by a court of competent jurisdiction.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">It is the intent and desire of Executive and the Company that the restrictive provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> be enforced to the fullest extent permissible under the laws and public policies as applied in each jurisdiction in which enforcement is sought.  If any particular provision of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall be determined to be invalid or unenforceable, such covenant shall be amended, without any action on the part of either party hereto, to delete there from the portion so determined to be invalid or unenforceable, such deletion to apply only with respect to the operation of such covenant in the particular jurisdiction in which such adjudication is made.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Executive&#8217;s obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Remedies for Breach of Obligations under Sections 12 or 13 hereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive acknowledges that the Company Group will suffer irreparable injury, not readily susceptible of valuation in monetary damages, if Executive breaches his obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  Accordingly, Executive agrees that the applicable member of the Company Group will be entitled, in addition to any other available remedies, to obtain injunctive relief against any breach or prospective breach by Executive of his obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  Executive agrees that process in any or all of those actions or proceedings may be served by overnight courier, addressed to the last address provided by Executive to the Company, or in any other manner authorized by law (including personal service).  This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 14 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall survive the termination of the Employment Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Cooperation.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Following Executive&#8217;s termination of employment for any reason, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">hereof, Executive agrees to make himself reasonably available to cooperate with the Company and its affiliates in matters that materially concern&#58; (i) requests for information about the services Executive provided to the Company and its affiliates during his  employment with the Company and its affiliates, (ii) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company and its affiliates which relate to events or occurrences that transpired while Executive was employed the Company and its affiliates and as to which Executive has, or would reasonably be expected to have, personal experience, knowledge </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or information or (iii) any investigation or review by any federal, state or local regulatory, quasi-regulatory or self-governing authority (including, without limitation, the US Department of Justice, the US Federal Trade Commission or the SEC) as any such investigation or review relates to events or occurrences that transpired while Executive was employed by the Company and its affiliates.  Executive&#8217;s cooperation shall include&#58; (A) making himself reasonably available to meet and speak with officers or employees of the Company, the Company&#8217;s counsel or any third-parties at the request of the Company at times and locations to be determined by the Company reasonably and in good faith, taking  into  account  the  Company&#8217;s  business  and  personal  needs  (the  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and (B) giving accurate and truthful information at any interviews and accurate  and  truthful  testimony in any legal proceedings or actions (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Witness Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall be construed to limit in any way any rights Executive may have at applicable law not to provide testimony with regard to specific matters.  Unless required by law or legal process, Executive will not knowingly or intentionally furnish information to or cooperate with any non-governmental entity (other than the Company) in connection with any potential or pending proceeding or legal action involving matters arising during Executive&#8217;s employment with the Company and its affiliates.  In addition, at the request of the Company, Executive shall be required to complete a directors&#8217; and officers&#8217; questionnaire to facilitate the Company&#8217;s preparation and filing of its proxy statement and periodic reports with the SEC.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Executive shall not be entitled to any payments in addition to those otherwise set forth in this Agreement in respect of any Company Cooperation or Witness Cooperation, regardless of when provided.  The Company will reimburse Executive for any reasonable, out-of-pocket travel, hotel and meal expenses incurred in connection with Executive&#8217;s performance of obligations pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> for which Executive has obtained prior approval from the Company.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Nothing in this Agreement or any other agreement by and between the Parties is intended to or shall preclude or in any way limit or restrict Executive from providing accurate and truthful testimony or information to any governmental agency.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Inventions and Intellectual Property.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  As used in this Agreement&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all patents, invention disclosures, invention registrations, trademarks, service marks, trade names, trade dress, logos, domain names, copyrights, mask works, trade secrets, know-how and all other intellectual property and proprietary rights recognized by any applicable law of any jurisdiction, and all registrations and applications for registration of, and all goodwill associated with, the foregoing.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all inventions, discoveries, concepts, information, works, materials, processes, methods, data, software, programs, apparatus, designs and  the like.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive will disclose promptly in writing to the Company any and all Inventions and Intellectual Property, in each case that Executive conceives, develops, creates or reduces to practice, either alone or jointly with others, during the period of Executive&#8217;s employment that (1) are conceived, created or developed using any equipment, supplies, facilities, trade secrets, know-how or other Confidential Information of the Company or any of its affiliates, (2) result from any work performed by Executive for the Company or any of its affiliates and&#47;or (3) otherwise relate to the Company&#8217;s or any of its affiliates&#8217; business or actual or demonstrably anticipated research or development (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Ownership and Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive acknowledges and agrees that the Company will have exclusive title and ownership rights in and to all Company Intellectual Property.  To the extent that exclusive title and&#47;or ownership rights may not originally vest in the Company as contemplated herein, Executive hereby irrevocably assigns, transfers, conveys and delivers to the Company all right, title and interest in and to all Company Intellectual Property.  Executive acknowledges and agrees that, with respect to any Company Intellectual Property that may qualify as a Work Made For Hire as defined in 17 U.S.C. &#167; 101 or other applicable law, such Company Intellectual Property is and will be deemed a Work Made for Hire and the Company will have the sole and exclusive right to the copyright (or, in the event that any such Company Intellectual Property does not qualify as a Work Made for Hire, the copyright and all other rights thereto are automatically assigned to the Company as above).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Prior Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Prior Inventions) attached hereto is a complete list of all Inventions that Executive has, alone or jointly with others, conceived, developed created or reduced to practice prior to the commencement of Executive&#8217;s employment with the Company, that are Executive&#8217;s property, and that the Company acknowledges and agrees are excluded from the scope of this Agreement (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Prior Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  If disclosure of any such Prior Invention would cause Executive to violate any prior confidentiality agreement, Executive understands that he is not to list such Prior Inventions in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> but is only to disclose where indicated a cursory name for each such Prior Invention, a listing of each person or entity to whom it belongs, and the fact that full disclosure as to such Prior Inventions has not been made for that reason (it being understood that, if no Invention or disclosure is provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Executive hereby represents and warrants that there are no Prior Inventions).  If, in the course of Executive&#8217;s employment with the Company, Executive incorporates any Prior Invention into any Company product, process or machine or otherwise uses any Prior Invention, Executive hereby grants to the Company and its affiliates a worldwide, non-exclusive, irrevocable, perpetual, fully paid-up and royalty-free license (with rights to sublicense through multiple tiers of sublicensees) to use, reproduce, modify, make derivative works of, publicly perform, publicly display, make, have made, sell, offer for sale, import and otherwise exploit such Prior Invention for any purpose.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Non-Assi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">nable Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If Executive is an employee whose principal work location is in California, Illinois, Kansas, Minnesota or Washington State, the provisions regarding Executive&#8217;s  assignment of Company Intellectual Property to  the  Company in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 16(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof do not apply to certain Inventions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Assi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">nable Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) as specified in the statutory code of the applicable state.  Executive acknowledges having received and reviewed notification regarding such Non-Assignable Inventions pursuant to such states&#8217; codes.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt;text-decoration:underline">Waiver of Moral Ri</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">hts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To the extent that Executive may do so under applicable law, Executive hereby irrevocably waives and agrees never to assert any Moral Rights that Executive may have in or with respect to any Company Intellectual Property, even after termination of any work on behalf of the Company.  As used in this Agreement, &#8220;Moral Rig</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">hts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any rights to claim authorship of a work, to object to or prevent the modification or destruction of a work, or to withdraw from circulation or control the publication or distribution of a work, and any similar right, existing under any applicable law of any jurisdiction, regardless of whether or not such right is denominated or generally referred to as a &#8220;moral right.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive shall give the Company and its affiliates all reasonable assistance and execute all documents necessary to assist with enabling the Company and its affiliates to prosecute, perfect, register, record, enforce and defend any of their rights in any Company Intellectual Property and Confidential Information.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Miscellaneous.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Successors and Assigns.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">This Agreement shall be binding upon and shall inure to the benefit of the Company, its successors and permitted assigns.  The Company may not assign or delegate any rights or obligations hereunder except to a successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and&#47;or assets of the Company, as applicable.  Except for purposes of determining the occurrence of a Change in Control, the term &#8220;the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as used herein shall mean a corporation or other entity acquiring all or substantially all the assets and business of the Company, as the case may be, (including this Agreement) whether by operation of law or otherwise.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Neither this Agreement nor any right or interest hereunder shall be assignable or transferable by Executive, Executive&#8217;s beneficiaries or legal representatives, except by will or by the, laws of descent and distribution.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">This Agreement shall inure to the benefit of and be enforceable by Executive&#8217;s legal personal representatives.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For the purposes of this Agreement, notices and all other communications provided for in the Agreement (including the Notice of Termination) shall be in writing and shall be deemed to have been duly given when personally delivered or sent by overnight courier, addressed to the respective addresses last given by each party to each other party&#59; p</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">rovided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that all notices to the Company shall be directed to the attention of the General Counsel of the Company.  All notices and communications shall be deemed to have been received on the date of delivery thereof or on the third business day after the mailing thereof, except that notice of change of address shall be effective only upon receipt.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Indemnity Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company agrees to indemnify and hold Executive harmless to the fullest extent permitted by applicable law for actions taken as a director or officer of the Company, as in effect at the time of the subject act or omission.  In connection therewith, Executive shall be entitled to the protection of any insurance policies which the Company elects to maintain generally for the benefit of the Company&#8217;s directors and officers, against all costs, charges and expenses whatsoever incurred or sustained by Executive in connection with any action, suit or proceeding to which he may be made a party by reason of his being or having been a director, officer or employee of the Company.  This provision shall survive any termination of the Employment Term.</font></div><div style="margin-bottom:12.35pt;margin-top:2.7pt;padding-left:108pt;padding-right:5.9pt;text-align:justify;text-indent:-30.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.23pt;text-decoration:underline">Withholdin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g.  The Company shall be entitled to withhold the amount, if any, of all taxes of any applicable jurisdiction required to be withheld by an employer with respect to any amount paid to Executive hereunder.  The Company, in its sole and absolute discretion, shall make all determinations as to whether it is obligated to withhold any taxes hereunder and the amount hereof.</font></div><div style="margin-bottom:12.35pt;margin-top:2.7pt;padding-left:108pt;padding-right:5.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Release of Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The termination benefits described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">9(d)(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof shall be conditioned on Executive delivering to the Company, and failing to revoke, a signed release of claims acceptable to the Company within twenty-one (21) days following Executive&#8217;s Termination Date&#59; provided, however, that Executive shall not be required to release any rights Executive may have to be indemnified by the Company under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  Notwithstanding any provision of this Agreement to the contrary, in no event shall the timing of Executive&#8217;s execution of the release, directly or indirectly, result in Executive designating the calendar year of payment, and, to the extent required by Section 409A, if a payment that is subject to execution of the release could be made in more than one taxable year, payment shall be made in the later </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12.35pt;margin-top:2.7pt;padding-left:108pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">taxable year.  Where applicable, references to Executive in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall refer to Executive&#8217;s representative or estate.</font></div><div style="margin-bottom:12.35pt;margin-top:2.7pt;padding-left:108pt;padding-right:5.9pt;text-align:justify;text-indent:-30.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.07pt;text-decoration:underline">Modification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and signed by Executive and the Company.  No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by the other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time.  No agreement or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by any party which are not expressly set forth in this Agreement.</font></div><div style="margin-bottom:12.35pt;margin-top:2.7pt;padding-left:108pt;padding-right:5.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If any legally actionable dispute arises under this Agreement or otherwise which cannot be resolved by mutual discussion between the parties, then the Company and Executive each agree to resolve that dispute by binding arbitration before an arbitrator experienced in employment law.  Said arbitration will be conducted in accordance with the rules applicable to employment disputes of the Judicial Arbitration and Mediation Services (&#8220;JAMS&#8221;) and the law applicable to the claim.  The parties shall have 30 calendar days after notice of such arbitration has been given to attempt to agree on the selection of an arbitrator from JAMS.  In the event the parties are unable to agree in such time, JAMS will provide a list of five (5) available arbitrators and an arbitrator will be selected from such five member panel provided by JAMS by the parties alternately striking out one name of a potential arbitrator until only one name remains.  The party entitled to strike an arbitrator first shall be selected by a toss of a coin.  The parties agree that this agreement to arbitrate includes any such disputes that the Company may have against Executive, or Executive may have against the Company and&#47;or its related entities and&#47;or employees, arising out of or relating to this Agreement, or Executive&#8217;s employment or Executive&#8217;s termination, including any claims of discrimination or harassment in violation of applicable law and any other aspect of Executive&#8217;s compensation, employment, or Executive&#8217;s termination.  The parties further agree that arbitration as provided for in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> is the exclusive and binding remedy for any such dispute and will be used instead of any court action, which is hereby expressly waived, except for any request by any party for temporary, preliminary or permanent injunctive relief pending arbitration in accordance with applicable law or for breaches by either party of such party&#8217;s obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 12,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">16 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">hereof, as applicable, or an administrative claim with an administrative agency.  The parties agree that the arbitration provided herein shall be conducted in or around Morristown, New Jersey, unless otherwise mutually agreed.  The Company shall pay the cost of any arbitration brought pursuant to this paragraph, excluding, however, the cost of representation of Executive unless such cost is awarded in accordance with law or otherwise awarded by the arbitrators.  Except as otherwise provided above, the arbitrator may award legal fees to the prevailing party in his sole discretion, provided that the percentage of fees so awarded shall not exceed 1% of the net worth of the paying party (i.e., the Company or Executive).  Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, except as may be required by law, neither party nor an arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of both parties.</font></div><div style="margin-bottom:12.35pt;margin-top:2.7pt;padding-left:108pt;padding-right:5.9pt;text-align:justify;text-indent:-30.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.23pt;text-decoration:underline">Effect of Other Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Anything herein to the contrary notwithstanding, the terms of this Agreement shall be modified to the extent required to meet the provisions of the Sarbanes-Oxley Act of 2002, Section 409A, the Dodd-Frank Wall Street Reform and Consumer Protection Act or other federal law applicable to the employment arrangements between Executive and the Company.  Any delay in providing benefits or payments or any failure to provide a benefit or payment shall not in and of itself constitute a breach of this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the Company shall provide economically equivalent payments or benefits to Executive to the extent permitted by law.  Any request or requirement that Executive repay compensation that is required under the first sentence shall not in and of itself constitute a breach of this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12.35pt;margin-top:2.7pt;padding-left:108pt;padding-right:5.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt;text-decoration:underline">Governin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New Jersey applicable to contracts executed in and to be performed entirely within such State, without giving effect to the conflict of law principles thereof.</font></div><div style="margin-bottom:12.35pt;margin-top:2.7pt;padding-left:108pt;padding-right:5.9pt;text-align:justify;text-indent:-30.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.68pt;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  As a condition to the effectiveness of this Agreement, Executive represents and warrants to the Company that he is not a party to or otherwise bound by any agreement or arrangement (including, without limitation, any license, covenant, or commitment of any nature), or subject to any judgment, decree, or order of any court or administrative agency, that would conflict with or will be in conflict with or in any way preclude, limit or inhibit Executive&#8217;s ability to execute this Agreement or to carry out his duties and responsibilities hereunder.  In the event that the Company determines that Executive&#8217;s duties hereunder may conflict with an agreement or arrangement to which Executive is bound, Executive shall be required to cease engaging in any such activities, duties or responsibilities (including providing supervisory services over certain subsets of the Company&#8217;s business operations) and the Company will take steps to restrict Executive&#8217;s access to, and participation in, any such activities.  Any actions taken by the Company under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> to restrict or limit Executive&#8217;s access to information or provision of services shall not constitute Good Reason for purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7(e) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">hereof.</font></div><div style="margin-bottom:12.35pt;margin-top:2.7pt;padding-left:108pt;padding-right:5.9pt;text-align:justify;text-indent:-30.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><img alt="image_0a.jpg" src="image_0a.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:2px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.23pt;text-decoration:underline">Severabilit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">y.  The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement constitutes the entire agreement between the parties hereto and supersedes all prior agreements, if any, understandings and arrangements, oral or written, between the parties hereto with respect to the subject matter hereof, including, without limitation, the Original Agreement and any term sheets or other similar presentations and that certain letter agreement to Executive from Bausch &#38; Lomb Inc. dated as of April 8, 2010, setting forth the global service assignment details applicable to Executive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.  Signatures transmitted via facsimile or PDF will be deemed the equivalent of originals.</font></div><div style="margin-bottom:24.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Remainder of page left intentionally blank</font></div><div style="margin-bottom:24pt;padding-left:5.95pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have executed this Employment Agreement as of the day and year first above written, to be effective as of the Initial Commencement Date.</font></div><div style="margin-bottom:24pt;margin-top:30pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BAUSCH HEALTH COMPANIES INC.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; Joseph C. Papa&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Joseph C. Papa</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Chairman of the Board and CEO</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:24pt;margin-top:30pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTIVE</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; Thomas J. Appio&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;   Thomas J. Appio&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>exhibit2112021ye.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i10ef85bd4f624a51bb948df9f8fa8b81_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div style="margin-bottom:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Exhibit&#160;21.1</font></div><div style="margin-bottom:2pt;text-align:right"><font><br></font></div><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Subsidiary Information </font></div><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">As of February&#160;23, 2022 </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.704%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction&#160;of<br>Incorporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Doing&#160;Business&#160;As</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Argentina S.R.L.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Argentina S.R.L.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Waicon Vision S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Waicon Vision S.A.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Australia) Pty Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Australia) Pty Limited</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Australia Pty Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Australia Pty Limited</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wirra Holdings Pty Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wirra Holdings Pty Limited</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;Bausch &#38; Lomb Australia Holdings Pty </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Limited</font></div><div style="padding-left:6pt"><font><br></font></div><div style="padding-left:6pt"><font><br></font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Australia Holdings Pty  Limited<br></font><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Australia Pty Limited<br></font><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Australia Pty Limited</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Gesellschaft m.b.H.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb GmbH</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAUSCH HEALTH LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belarus</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAUSCH HEALTH LLC</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Pharma S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Pharma S.A.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss BH Dru&#353;tvo za trgovinu na veliko d.o.o. Sarajevo</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bosnia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss BH d.o.o. Sarajevo</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BL Ind&#250;stria &#211;tica Ltda.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BL Ind&#250;stria &#211;tica Ltda.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0909657 B.C. Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British Columbia<br>&#160;(Canada)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0909657 B.C. Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1261229 B.C. Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British Columbia<br>&#160;(Canada)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1261229 B.C. Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss EOOD</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bulgaria</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss EOOD</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12279967 Canada Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12279967 Canada Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12283778 Canada Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12283778 Canada Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Bausch + Lomb Corporation                            </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb Corporation                            </font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Escrow Corporation<br></font><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Escrow Corporation<br></font><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health, Canada Inc.&#47; Sant&#233; Bausch, Canada Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health, Canada Inc. &#47; Sant&#233; Bausch, Canada Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Corporation</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Canada GP Limited&#47; Commandit&#233; Valeant Canada Limit&#233;e</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Canada GP Limited&#47; Commandit&#233; Valeant Canada Limit&#233;e</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Canada Limited &#47; Valeant Canada Limit&#233;e</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Canada Limited &#47; Valeant Canada Limit&#233;e</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Canada S.E.C.&#47;Valeant Canada LP</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Canada S.E.C.&#47;Valeant Canada LP</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">V-BAC Holding Corp.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">V-BAC Holding Corp.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9079-8851 Quebec Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quebec (Canada)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9079-8851 Quebec Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mercury (Cayman) Holdings</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mercury (Cayman) Holdings</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Shanghai) Trading Co., Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Shanghai) Trading Co., Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beijing Bausch &#38; Lomb Eyecare Co., Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beijing Bausch &#38; Lomb Eyecare Co., Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shandong Bausch &#38; Lomb Freda New Packing Materials Co., Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shandong Bausch &#38; Lomb Freda New Packing Materials Co., Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shandong Bausch &#38; Lomb Freda Pharmaceutical Co., Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shandong Bausch &#38; Lomb Freda Pharmaceutical Co., Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta (Shanghai) Health Management Co., Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta (Shanghai) Health Management Co., Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cambridge Pharmaceutical S.A.S.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cambridge Pharmaceutical S.A.S.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Farmatech S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Farmatech S.A.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humax Pharmaceutical S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humax Pharmaceutical S.A.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss dru&#353;tvo s ograni&#269;enom odgovorno&#353;&#263;u za trgovinu i usluge</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Croatia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss dru&#353;tvo s ograni&#269;enom odgovorno&#353;&#263;u za trgovinu i usluge</font></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.704%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss Cesk&#225; republika s.r.o.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Czech Republic</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss Cesk&#225; republika s.r.o.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICN Egypt LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICN Egypt LLC</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss Eesti O&#220;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estonia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss Eesti O&#220;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb France S.A.S.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb France S.A.S.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health France S.A.S.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health France S.A.S.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratoire Chauvin S.A.S.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratoire Chauvin S.A.S.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical France </font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical France </font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb GmbH</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B L E P Holding GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B L E P Holding GmbH</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Croma-Pharma Deutschland Gesellschaft m.b.H.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Croma-Pharma Deutschland Gesellschaft m.b.H.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Gerhard Mann chem.-pharm. Fabrik Gesellschaft mit beschr&#228;nkter Haftung</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Gerhard Mann chem.-pharm. Fabrik GmbH</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Robert Winzer Pharma GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Robert Winzer Pharma GmbH</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grundst&#252;cksverwaltungsgesellschaft Dr.Gerhard Mann chem.- pharm. Fabrik GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grundst&#252;cksverwaltungsgesellschaft Dr.Gerhard Mann chem.- pharm. Fabrik GmbH</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical German GmbH</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical German GmbH</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Synergetics Germany GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Synergetics Germany GmbH</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technolas Perfect Vision GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technolas Perfect Vision GmbH</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Hellas Single-Member Pharmaceuticals Soci&#233;t&#233; Anonyme</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greece</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Hellas </font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Hong Kong) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Hong Kong) Limited</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sino Concept Technology Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sino Concept Technology Limited</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Hong Kong Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Hong Kong Limited</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Magyarorsz&#225;g Korl&#225;tolt Felel&#245;ss&#233;g&#251; T&#225;rsas&#225;g</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hungary</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Magyarorsz&#225;g Kft</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb India Private Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb India Private Limited</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PT Bausch Lomb Indonesia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indonesia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PT Bausch Lomb Indonesia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb Ireland Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb Ireland Limited</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health HoldCo Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health HoldCo Limited</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Ireland Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Ireland Limited</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oceana Therapeutics Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oceana Therapeutics Limited</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical Ireland Limited</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Ireland Limited</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Holdings Ireland Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Holdings Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb-IOM S.p.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb-IOM S.p.A.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical Italy S.R.L.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical Italy S.R.L.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">B.L.J. Company Limited </font></div><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Japanese official name&#58; Bausch &#38; Lomb Japan kabushiki Kaisha)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B.L.J. Company Limited</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health LLP</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kazakhstan</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health LLP</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Bausch Pharma Kazakhstan LLP</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kazakhstan</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Pharma Kazakhstan LLP</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Korea Co., Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Korea</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Korea Co., Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bescon Co., Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Korea</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bescon Co., Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Korea Limited<br></font><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Korea</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Korea Limited<br></font><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UAB PharmaSwiss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lithuania</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UAB PharmaSwiss</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Finance Luxembourg S.&#224; r.l.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Finance Luxembourg S.&#224; r.l.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Malaysia) Sdn. Bhd.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Malaysia) Sdn. Bhd.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Malaysia Sdn. Bhd.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Malaysia Sdn. Bhd.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb M&#233;xico, S.A. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb M&#233;xico, S.A. de C.V.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Bausch &#38; Lomb M&#233;xico Holdings S.A. de C.V.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb M&#233;xico Holdings S.A. de C.V.</font></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.704%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratorios Fedal, S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratorios Fedal, S.A.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratorios Grossman, S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratorios Grossman, S.A.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nysco de M&#233;xico, S.A. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nysco de M&#233;xico, S.A. de C.V.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tecnofarma, S.A. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tecnofarma, S.A. de C.V.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Servicios y Administraci&#243;n, S. de R.L. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Servicios y Administraci&#243;n, S. de R.L. de C.V.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Bausch+Lomb Dutch Holdings B.V.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch+Lomb Dutch Holdings B.V.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Bausch+Lomb Netherlands B.V.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch+Lomb Netherlands B.V.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch+Lomb OPS B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch+Lomb OPS B.V.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Natur Produkt Europe B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Natur Produkt Europe B.V.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical Dutch Holdings B.V.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical Dutch Holdings B.V.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (New Zealand) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (New Zealand) Limited</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Farmac&#233;utica Panam&#225;, S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panama</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Farmac&#233;utica Panam&#225;, S.A.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Per&#250; S.R.L.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peru</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Per&#250; S.R.L.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Philippines Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Philippines Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical Philippines Inc.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Philippines Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Bausch &#38; Lomb Poland sp. z.o.o.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Bausch &#38; Lomb Poland sp. z.o.o.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Poland sp&#243;&#322;ka z ograniczon&#261; </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Poland sp.z o.o.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emo-Farm sp&#243;&#322;ka z ograniczon&#261; odpowiedzialno&#347;ci&#261;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emo-Farm sp. z o.o.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICN Polfa Rzeszow Sp&#243;&#322;ka Akcyjna</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICN Polfa Rzeszow SA</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Przedsiebiorstwo Farmaceutyczne Jelfa Sp&#243;&#322;ka Akcyjna</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Przedsiebiorstwo Farmaceutyczne Jelfa SA</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical Poland sp. z.o.o.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical Poland sp. z.o.o.</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Med sp&#243;&#322;ka z ograniczon&#261; odpowiedzialno&#347;ci&#261;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Med sp. z o.o.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amoun Pharmaceutical Romania SRL</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Romania</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amoun Pharmaceutical Romania SRL</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Romania SRL (f&#47;k&#47;a S.C. Valeant Pharma SRL)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Romania</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Romania SRL (f&#47;k&#47;a Valeant Pharma SRL)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Limited Liability Company </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health LLC </font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Bausch RUMO Holdings Limited Liability Company</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch RUMO LLC</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss doo preduze&#263;e za proizvodnju, unutra&#353;nju, spoljnu trgovinu i zastupanje Beograd</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serbia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss doo, Belgrad</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Singapore) Private Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Singapore) Private Limited</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical Singapore Private Limited</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical Singapore Private Limited</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technolas Singapore Pte. Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technolas Singapore Pte. Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Slovakia s.r.o.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovakia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Slovakia s.r.o.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss, trgovsko in proizvodno podjetje, d.o.o.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovenia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss d.o.o.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (South Africa) (Pty)  Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (South Africa) (Pty) Ltd</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soflens (Pty) Ltd</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soflens (Pty) Ltd</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb S.A.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical Iberia S.L. (fka Wanakie SA)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical Iberia S.L.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Nordic Aktiebolag</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Nordic AB</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Swiss AG</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Swiss AG</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss SA</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss SA</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Taiwan Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Taiwan Limited</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Taiwan Limited</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Taiwan Limited</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Thailand) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thailand</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Thailand) Limited</font></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.704%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical (Thailand) Limited</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thailand</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical (Thailand) Limited</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Sa&#287;lik ve Optik &#220;r&#252;nleri Ticaret Anonim &#350;irketi</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Sa&#287;lik ve Optik &#220;r&#252;nleri Tic.&#350;.&#222;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;Bausch Health&#34; Limited Liability Company</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ukraine</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;Bausch Health&#34; LLC</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Ukraine Limited Liability Company</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ukraine</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Ukraine Limited Liability Company</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Bausch Health Trading DWC-LLC</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UAE</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Bausch Health Trading DWC-LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medpharma Pharmaceutical &#38; Chemical Industries LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UAE</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medpharma Pharma &#38; Chem Ind LLC</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb U.K. Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb U.K. Limited</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical UK Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical UK Limited</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sterimedix Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sterimedix Limited</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix Pharmaceuticals, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix Pharmaceuticals, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visioncare Devices, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visioncare Devices, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audrey Enterprise, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audrey Enterprise, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Americas Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Americas Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb South Asia, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb South Asia, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Foundation, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Foundation, LLC</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Americas, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Americas, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health US, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health US, LLC</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eye Essentials LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eye Essentials LLC</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicis Pharmaceutical Corporation</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicis Pharmaceutical Corporation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Oceanside Pharmaceuticals, Inc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Oceanside Pharmaceuticals, Inc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OraPharma, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OraPharma, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PreCision Dermatology, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PreCision Dermatology, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix Pharmaceuticals, Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix Pharmaceuticals, Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Santarus, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Santarus, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical Distribution, LLC</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical Distribution, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Synergetics IP, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Synergetics IP, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unilens Corp. USA</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unilens Corp. USA</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unilens Vision Sciences Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unilens Vision Sciences Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VRX Holdco LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VRX Holdco LLC</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Synergetics, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Missouri (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Synergetics, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alden Optical Laboratories, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alden Optical Laboratories, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Incorporated</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Incorporated</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">In accordance with the instructions of Item&#160;601 of Regulation&#160;S-K, certain subsidiaries are omitted from the foregoing table.</font></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>exhibit2312021ye.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iaf8ce50a92a44455ad0a7865f7dfd045_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:72.00pt 63.00pt 72.00pt 72.00pt"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;23.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (Nos. 333-238084, 333-226786, 333-196120, 333-176205, 333-168254, 333-168629, and 333-138697 as amended, where applicable) of Bausch Health Companies Inc. of our report dated February&#160;23, 2022 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; PricewaterhouseCoopers LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Florham Park, New Jersey</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;23, 2022</font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>exhibit3112021ye.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1bf1bd334f7345d0b24a72d2c4d8ae5c_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph C. Papa, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form&#160;10-K of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The Company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as&#160;defined in Exchange Act Rules&#160;13a-15(e) and&#160;15d-15(e)) and internal control over financial reporting (as&#160;defined in Exchange Act Rules&#160;13a-15(f) and&#160;15d-15(f)) for the Company and&#160;have&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being&#160;prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The Company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or&#160;persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:49.998%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;23, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JOSEPH C. PAPA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph C. Papa</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board and Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>exhibit3122021ye.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i62a5219cbb1148dab1c839bfeb771040_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Sam Eldessouky, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form&#160;10-K of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The Company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as&#160;defined in Exchange Act Rules&#160;13a-15(e) and&#160;15d-15(e)) and internal control over financial reporting (as&#160;defined in Exchange Act Rules&#160;13a-15(f) and&#160;15d-15(f)) for the Company and&#160;have&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being&#160;prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The Company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or&#160;persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:50.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.196%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;23, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; SAM ELDESSOUKY</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sam Eldessouky</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>exhibit3212021ye.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie7f25048907c404798ea8330c0c7ef56_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18&#160;U.S.C. &#167;&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph C. Papa, Chairman of the Board and Chief Executive Officer of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;), certify, pursuant to 18&#160;U.S.C. &#167;&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my&#160;knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The Annual Report of the Company on Form&#160;10-K for the fiscal year ended December&#160;31, 2021 (the&#160;&#8220;Annual Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the&#160;Company.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:49.998%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;23, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JOSEPH C. PAPA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph C. Papa</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board and Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the&#160;&#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by&#160;reference.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the U.S.&#160;Securities and Exchange Commission or its staff upon&#160;request.</font></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>exhibit3222021ye.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i747e529d7d6c494b963c18e86da9a642_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18&#160;U.S.C. &#167;&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Sam Eldessouky, Executive Vice President and Chief Financial Officer of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;), certify, pursuant to 18&#160;U.S.C. &#167;&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my&#160;knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The Annual Report of the Company on Form&#160;10-K for the fiscal year ended December&#160;31, 2021 (the&#160;&#8220;Annual Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the&#160;Company.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:49.998%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.179%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.838%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;23, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; SAM ELDESSOUKY</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sam Eldessouky</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the&#160;&#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by&#160;reference.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the U.S.&#160;Securities and Exchange Commission or its staff upon&#160;request.</font></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>bhc-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:cdc15979-c542-4d25-920c-73804898e32f,g:89bc1415-46fc-4aad-8e83-55f6d8df2ca2-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bhc="http://www.bauschhealth.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bauschhealth.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.bauschhealth.com/role/DocumentandEntityInformation">
        <link:definition>000010001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AUDITINFORMATION" roleURI="http://www.bauschhealth.com/role/AUDITINFORMATION">
        <link:definition>000020002 - Document - AUDIT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>100010003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>100020004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>100030005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>100040006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT">
        <link:definition>100050007 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>100060008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESS" roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS">
        <link:definition>210011001 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails">
        <link:definition>240024001 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>210031002 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>220042001 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>230053001 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>240064002 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails">
        <link:definition>240074003 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails">
        <link:definition>240084004 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails">
        <link:definition>240094005 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails">
        <link:definition>240104006 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails">
        <link:definition>240114007 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails">
        <link:definition>240124008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails">
        <link:definition>240134009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails">
        <link:definition>240144010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails">
        <link:definition>240154011 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails">
        <link:definition>240164012 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails">
        <link:definition>240174013 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails">
        <link:definition>240184014 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE" roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE">
        <link:definition>210191003 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURETables" roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURETables">
        <link:definition>230203002 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails">
        <link:definition>240214015 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>240224016 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails" roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails">
        <link:definition>240234017 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Assets and Liabilities Held For Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS" roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS">
        <link:definition>210241004 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails">
        <link:definition>240254018 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>210261005 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>230273003 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>240284019 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails">
        <link:definition>240294020 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails">
        <link:definition>240304021 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails">
        <link:definition>240314022 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails">
        <link:definition>240324023 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails">
        <link:definition>240334024 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails">
        <link:definition>240344025 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails">
        <link:definition>240354026 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details">
        <link:definition>240364027 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails">
        <link:definition>240374028 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails">
        <link:definition>240384029 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails">
        <link:definition>240394030 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIES" roleURI="http://www.bauschhealth.com/role/INVENTORIES">
        <link:definition>210401006 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESTables" roleURI="http://www.bauschhealth.com/role/INVENTORIESTables">
        <link:definition>230413004 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESSummaryofInventoriesNetDetails" roleURI="http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails">
        <link:definition>240424031 - Disclosure - INVENTORIES - Summary of Inventories, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYPLANTANDEQUIPMENT" roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT">
        <link:definition>210431007 - Disclosure - PROPERTY, PLANT AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYPLANTANDEQUIPMENTTables" roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTTables">
        <link:definition>230443005 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails">
        <link:definition>240454032 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYPLANTANDEQUIPMENTNarrativeDetails" roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails">
        <link:definition>240464033 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILL" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL">
        <link:definition>210471008 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLTables" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables">
        <link:definition>230483006 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails">
        <link:definition>240494034 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1">
        <link:definition>240494034 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLNarrativeDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails">
        <link:definition>240504035 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails">
        <link:definition>240514036 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails">
        <link:definition>240524037 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIES" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES">
        <link:definition>210531009 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIESTables" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables">
        <link:definition>230543007 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIESDetails" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails">
        <link:definition>240554038 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTS" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS">
        <link:definition>210561010 - Disclosure - FINANCING ARRANGEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSTables" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables">
        <link:definition>230573008 - Disclosure - FINANCING ARRANGEMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails">
        <link:definition>240584039 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSCovenantComplianceDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails">
        <link:definition>240594040 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails">
        <link:definition>240604041 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails">
        <link:definition>240614042 - Disclosure - FINANCING ARRANGEMENTS - Current Description of Senior Secured Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails">
        <link:definition>240624043 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails">
        <link:definition>240634044 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails">
        <link:definition>240644045 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails">
        <link:definition>240654046 - Disclosure - FINANCING ARRANGEMENTS - Maturities, Schedule of Maturities and Mandatory Payments of Debt Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS">
        <link:definition>210661011 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables">
        <link:definition>230673009 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails">
        <link:definition>240684047 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails">
        <link:definition>240694048 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>240704049 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails">
        <link:definition>240714050 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1">
        <link:definition>240714050 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails">
        <link:definition>240724051 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails">
        <link:definition>240734052 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future Benefit Payments for the Pension Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails">
        <link:definition>240744053 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-Average Assumptions Used to Determine Net Periodic Benefit Costs and Benefit Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails">
        <link:definition>240754054 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails">
        <link:definition>240764055 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with the Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.bauschhealth.com/role/LEASES">
        <link:definition>210771012 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.bauschhealth.com/role/LEASESTables">
        <link:definition>230783010 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESRightofuseAssetsandRightofuseLiabilitiesDetails" roleURI="http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails">
        <link:definition>240794056 - Disclosure - LEASES - Right-of-use Assets and Right-of-use Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://www.bauschhealth.com/role/LEASESNarrativeDetails">
        <link:definition>240804057 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseExpensesDetails" roleURI="http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails">
        <link:definition>240814058 - Disclosure - LEASES - Lease Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseAdditionalInformationDetails" roleURI="http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails">
        <link:definition>240824059 - Disclosure - LEASES - Lease Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseFuturePaymentsDetails" roleURI="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails">
        <link:definition>240834060 - Disclosure - LEASES - Lease Future Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseFuturePaymentsDetails_1" roleURI="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1">
        <link:definition>240834060 - Disclosure - LEASES - Lease Future Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATION" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION">
        <link:definition>210841013 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONTables" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables">
        <link:definition>230853011 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>240864061 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails">
        <link:definition>240874062 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONStockOptionsDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails">
        <link:definition>240884063 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONRSUsDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails">
        <link:definition>240894064 - Disclosure - SHARE-BASED COMPENSATION - RSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSS" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS">
        <link:definition>210901014 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables">
        <link:definition>230913012 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails">
        <link:definition>240924065 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENT" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT">
        <link:definition>210931015 - Disclosure - RESEARCH AND DEVELOPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENTTables" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables">
        <link:definition>230943013 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails">
        <link:definition>240954066 - Disclosure - RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSENET" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENET">
        <link:definition>210961016 - Disclosure - OTHER EXPENSE, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSENETTables" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETTables">
        <link:definition>230973014 - Disclosure - OTHER EXPENSE, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails">
        <link:definition>240984067 - Disclosure - OTHER EXPENSE, NET - Schedule of Other Expense (Income), Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSENETNarrativeDetails" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails">
        <link:definition>240994068 - Disclosure - OTHER EXPENSE, NET - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.bauschhealth.com/role/INCOMETAXES">
        <link:definition>211001017 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.bauschhealth.com/role/INCOMETAXESTables">
        <link:definition>231013015 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails">
        <link:definition>241024069 - Disclosure - INCOME TAXES - Components of Benefit from Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails">
        <link:definition>241034070 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>241044071 - Disclosure - INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails">
        <link:definition>241054072 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>241064073 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails">
        <link:definition>241074074 - Disclosure - INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails">
        <link:definition>241084075 - Disclosure - INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHARE" roleURI="http://www.bauschhealth.com/role/LOSSPERSHARE">
        <link:definition>211091018 - Disclosure - LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHARETables" roleURI="http://www.bauschhealth.com/role/LOSSPERSHARETables">
        <link:definition>231103016 - Disclosure - LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails" roleURI="http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails">
        <link:definition>241114076 - Disclosure - LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHARENarrativeDetails" roleURI="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails">
        <link:definition>241124077 - Disclosure - LOSS PER SHARE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALCASHFLOWDISCLOSURES" roleURI="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES">
        <link:definition>211131019 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALCASHFLOWDISCLOSURESTables" roleURI="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESTables">
        <link:definition>231143017 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails" roleURI="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails">
        <link:definition>241154078 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGS" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGS">
        <link:definition>211161020 - Disclosure - LEGAL PROCEEDINGS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails">
        <link:definition>241174079 - Disclosure - LEGAL PROCEEDINGS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>211181021 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESNarrativeDetails" roleURI="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails">
        <link:definition>241194080 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATION" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATION">
        <link:definition>211201022 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONTables" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables">
        <link:definition>231213018 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails">
        <link:definition>241224081 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails">
        <link:definition>241234082 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit, Assets and Capital Expenditures, Depreciation &amp; Amortization of Intangible Assets &amp; Asset Impairments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails">
        <link:definition>241244083 - Disclosure - SEGMENT INFORMATION - Revenues by Product Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONGeographicInformationRevenueDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails">
        <link:definition>241254084 - Disclosure - SEGMENT INFORMATION - Geographic Information, Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails">
        <link:definition>241264085 - Disclosure - SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONMajorCustomersDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails">
        <link:definition>241274086 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.bauschhealth.com/role/SUBSEQUENTEVENTS">
        <link:definition>211281023 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails">
        <link:definition>241294087 - Disclosure - SUBSEQUENT EVENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bhc_DerivativeLawsuitsMember" abstract="true" name="DerivativeLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShowertoShowerProductLiabilityLitigationMember" abstract="true" name="ShowertoShowerProductLiabilityLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" abstract="true" name="ViolationofCanadianProvincialSecuritiesLegislationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" abstract="false" name="DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" abstract="false" name="MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_LossContingencyStayOfApprovalPeriod" abstract="false" name="LossContingencyStayOfApprovalPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_PadagisLitigationMember" abstract="true" name="PadagisLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CardinalHealthIncMember" abstract="true" name="CardinalHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity" abstract="false" name="LineOfCreditFacilityExpectedMaximumBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" abstract="false" name="AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_SeniorSecured4875NotesDueJune2028Member" abstract="true" name="SeniorSecured4875NotesDueJune2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecured5.75NotesDueAugust2027Member" abstract="true" name="SeniorSecured5.75NotesDueAugust2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember" abstract="true" name="A5875SeniorNotesDueMay2023May2019RefinancingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForDiscountsAndAllowancesMember" abstract="true" name="ReserveForDiscountsAndAllowancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ResearchAndDevelopmentExpenseQualityAssurance" abstract="false" name="ResearchAndDevelopmentExpenseQualityAssurance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" abstract="false" name="DebtInstrumentCovenantTermsSecuredLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_DeviceProductsMember" abstract="true" name="DeviceProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" abstract="false" name="SummaryOfResearchAndDevelopmentExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember" abstract="true" name="A5875SeniorNotesDueMay2023March2019RefinancingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CedarsSinaiMedicalCenterMember" abstract="true" name="CedarsSinaiMedicalCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished" abstract="false" name="BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_ScheduleOfOtherIncomeAndExpensesTable" abstract="true" name="ScheduleOfOtherIncomeAndExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_InterestSettlementOnCrossCurrencySwaps" abstract="false" name="InterestSettlementOnCrossCurrencySwaps" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_NumberOfOtherBusinessesAcquired" abstract="false" name="NumberOfOtherBusinessesAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_EmergingMarketsMember" abstract="true" name="EmergingMarketsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_EyenoviaIncMember" abstract="true" name="EyenoviaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_RevenuePerformanceObligationPaymentTerms" abstract="false" name="RevenuePerformanceObligationPaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_ConcentrationRiskPercentageofNetTradeReceivables" abstract="false" name="ConcentrationRiskPercentageofNetTradeReceivables" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_ResearchAndDevelopmentExpenseProductRelated" abstract="false" name="ResearchAndDevelopmentExpenseProductRelated" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AccruedAndOtherCurrentLiabilitiesMember" abstract="true" name="AccruedAndOtherCurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TaxBenefitRecognitionMeasurementPercentage" abstract="false" name="TaxBenefitRecognitionMeasurementPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_ReserveForRebatesMember" abstract="true" name="ReserveForRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes500DueFebruary2029Member" abstract="true" name="SeniorNotes500DueFebruary2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ACertainInternationalBusinessMember" abstract="true" name="ACertainInternationalBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueJune2025Member" abstract="true" name="TermLoanBFacilityDueJune2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="ROTCPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes550DueMarch2023Member" abstract="true" name="SeniorNotes550DueMarch2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" abstract="false" name="AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_OtherPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="OtherPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecuredTermCreditFacilitiesMember" abstract="true" name="SeniorSecuredTermCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes525DueFebruary2031Member" abstract="true" name="SeniorNotes525DueFebruary2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes700DueJanuary2028Member" abstract="true" name="SeniorNotes700DueJanuary2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OutLicensedTechnologyMember" abstract="true" name="OutLicensedTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" abstract="false" name="DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" abstract="false" name="DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" abstract="false" name="OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DeferredTaxAssetsTaxLossCarryforwards" abstract="false" name="DeferredTaxAssetsTaxLossCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_EquipmentOnOperatingLeaseMember" abstract="true" name="EquipmentOnOperatingLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember" abstract="true" name="CertainProductsForDisposalSeptemberTwoThousandNineteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForRebatesAdvertisingCreditsPortionMember" abstract="true" name="ReserveForRebatesAdvertisingCreditsPortionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherCountriesMember" abstract="true" name="OtherCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" abstract="false" name="BusinessCombinationContingentConsiderationNoncurrentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" abstract="false" name="LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_SeniorNotes700DueMarch2024Member" abstract="true" name="SeniorNotes700DueMarch2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DerivativeGainExcludedComponent" abstract="false" name="DerivativeGainExcludedComponent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorNotes5.625PercentDueDecember2021Member" abstract="true" name="SeniorNotes5.625PercentDueDecember2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestructuringAndIntegrationCostsMember" abstract="true" name="RestructuringAndIntegrationCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherEquipmentAndLeaseholdImprovementMember" abstract="true" name="OtherEquipmentAndLeaseholdImprovementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A5.875SeniorNotesdueMay2023Member" abstract="true" name="A5.875SeniorNotesdueMay2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TaxYear2015AndTaxYear2016Member" abstract="true" name="TaxYear2015AndTaxYear2016Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_MitsubishiTanabePharmaCorporationMember" abstract="true" name="MitsubishiTanabePharmaCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" abstract="false" name="UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorNotes925DueApril2026Member" abstract="true" name="SeniorNotes925DueApril2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DeferredIncomeTaxNoncashExpenseBenefit" abstract="false" name="DeferredIncomeTaxNoncashExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorNotes525DueJanuary2030Member" abstract="true" name="SeniorNotes525DueJanuary2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax" abstract="false" name="IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_UnitedStatesandPuertoRicoMember" abstract="true" name="UnitedStatesandPuertoRicoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IncomeTaxReconciliationDeferredIntercompanyProfit" abstract="false" name="IncomeTaxReconciliationDeferredIntercompanyProfit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" abstract="false" name="UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_RICOClassActionsLitigationMember" abstract="true" name="RICOClassActionsLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected" abstract="false" name="AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember" abstract="true" name="SeniorSecuredNotesAndSeniorUnsecuredNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" abstract="true" name="PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" abstract="false" name="IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" abstract="true" name="SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" abstract="false" name="RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" abstract="false" name="PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_MSNLaboratoriesPrivateLtdLitigationMember" abstract="true" name="MSNLaboratoriesPrivateLtdLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bhc_SeniorNotes725DueMay2029Member" abstract="true" name="SeniorNotes725DueMay2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorUnsecuredNotesDue2023Member" abstract="true" name="SeniorUnsecuredNotesDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_InsuranceCoverageLawsuitMember" abstract="true" name="InsuranceCoverageLawsuitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DeferredTaxAssetsPrepaidExpenses" abstract="false" name="DeferredTaxAssetsPrepaidExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" abstract="false" name="DebtInstrumentRedemptionPricePercentageChangeinControl" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" abstract="false" name="DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" abstract="false" name="UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorSecuredCreditFacilitiesMember" abstract="true" name="SeniorSecuredCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IncomeTaxTable" abstract="true" name="IncomeTaxTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" abstract="false" name="GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" abstract="false" name="MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_TaxYear2005ThroughTaxYear2009Member" abstract="true" name="TaxYear2005ThroughTaxYear2009Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_AssetsLesseeAbstract" abstract="true" name="AssetsLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_BauschLombInternationalMember" abstract="true" name="BauschLombInternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestructuringChargesAndInitialPublicOfferingCosts" abstract="false" name="RestructuringChargesAndInitialPublicOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" abstract="true" name="GlumetzaAntitrustLitigationNonClassComplaintsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DefinedBenefitPlanPercentageAllocationofFund" abstract="false" name="DefinedBenefitPlanPercentageAllocationofFund" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_A8.50SeniorNotesDueJanuary2027Member" abstract="true" name="A8.50SeniorNotesDueJanuary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_HighlyLiquidInvestmentsMaturityPeriod" abstract="false" name="HighlyLiquidInvestmentsMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_CustomerTopTenProductsMember" abstract="true" name="CustomerTopTenProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PaymentForDebtAmortizationPrepaymentCost" abstract="false" name="PaymentForDebtAmortizationPrepaymentCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentAmountAvailableForRestrictedPayments" abstract="false" name="DebtInstrumentAmountAvailableForRestrictedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeparationAndInitialPublicOfferingCostsMember" abstract="true" name="SeparationAndInitialPublicOfferingCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" abstract="true" name="ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_DebtInstrumentExpectedFaceAmount" abstract="false" name="DebtInstrumentExpectedFaceAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_NonU.S.DevelopedMarketsMember" abstract="true" name="NonU.S.DevelopedMarketsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DiversifiedProductsSegmentMember" abstract="true" name="DiversifiedProductsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" abstract="false" name="PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_MeasurementInputWeightedAverageDiscountRateMember" abstract="true" name="MeasurementInputWeightedAverageDiscountRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CanadaBankersAcceptanceRateMember" abstract="true" name="CanadaBankersAcceptanceRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ValeantUSSecuritiesLitigationMember" abstract="true" name="ValeantUSSecuritiesLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ConcentrationRiskNumberOfProducts" abstract="false" name="ConcentrationRiskNumberOfProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_RevenuesNetMember" abstract="true" name="RevenuesNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes900DueDecember2025Member" abstract="true" name="SeniorNotes900DueDecember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" abstract="false" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax" abstract="false" name="SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ForeignCountryStateAndLocalMember" abstract="true" name="ForeignCountryStateAndLocalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PharmaceuticalProductsMember" abstract="true" name="PharmaceuticalProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_UnutilizedITInfrastructureImprovementProjectMember" abstract="true" name="UnutilizedITInfrastructureImprovementProjectMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" abstract="false" name="LossContingencyPlaintiffsNumberofGroupsofInvestors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_AllegroOphthalmicsLLCMember" abstract="true" name="AllegroOphthalmicsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_NonU.S.OtherAssetsMember" abstract="true" name="NonU.S.OtherAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes4.502023Member" abstract="true" name="SeniorNotes4.502023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" abstract="false" name="DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ReportingUnitsExcludingOrthoDermatologicsMember" abstract="true" name="ReportingUnitsExcludingOrthoDermatologicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" abstract="false" name="ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_DiscontinuedProductLinesMember" abstract="true" name="DiscontinuedProductLinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" abstract="false" name="DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_LitigationwithFormerSalixCEOMember" abstract="true" name="LitigationwithFormerSalixCEOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IncomeTaxLineItems" abstract="true" name="IncomeTaxLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_OrthoDermatologicsReportingUnitMember" abstract="true" name="OrthoDermatologicsReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_NewRestatedCreditAgreementMember" abstract="true" name="NewRestatedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OrthoDermatologicsSegmentMember" abstract="true" name="OrthoDermatologicsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" abstract="false" name="DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_PerrigoIsraelPharmaceuticalsLitigationMember" abstract="true" name="PerrigoIsraelPharmaceuticalsLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestrictedCashAndOtherSettlementDepositsCurrent" abstract="false" name="RestrictedCashAndOtherSettlementDepositsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember" abstract="true" name="ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes625DueFebruary2029Member" abstract="true" name="SeniorNotes625DueFebruary2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_InternationalRxMember" abstract="true" name="InternationalRxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax" abstract="false" name="SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_Legalsettlementsandrelatedfees" abstract="false" name="Legalsettlementsandrelatedfees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" abstract="false" name="LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_DoctorsAllergyFormulaLLCLitigationMember" abstract="true" name="DoctorsAllergyFormulaLLCLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LupinPharmaceuticalsIncLitigationMember" abstract="true" name="LupinPharmaceuticalsIncLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" abstract="false" name="AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" abstract="false" name="DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_ThreeLargestUSWholesalerCustomersMember" abstract="true" name="ThreeLargestUSWholesalerCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyNumberOfInsurancePolicyPeriods" abstract="false" name="LossContingencyNumberOfInsurancePolicyPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_OtherAssetsFixedIncomeSecuritiesMember" abstract="true" name="OtherAssetsFixedIncomeSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" abstract="false" name="RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_CanadianSecuritiesLitigationMember" abstract="true" name="CanadianSecuritiesLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" abstract="false" name="SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LiabilitiesLesseeAbstract" abstract="true" name="LiabilitiesLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_PartnerRelationshipsMember" abstract="true" name="PartnerRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" abstract="false" name="IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_BrandedandOtherGenericProductsMember" abstract="true" name="BrandedandOtherGenericProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherRevenuesMember" abstract="true" name="OtherRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccruedProductRebateCurrent" abstract="false" name="AccruedProductRebateCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" abstract="true" name="SeniorSecuredNotes7.00PercentDueMarch2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecured5.50NotesDueNovember2025Member" abstract="true" name="SeniorSecured5.50NotesDueNovember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PerformanceBasedRestrictedStockUnitsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CollaborativeAgreementMilestonePaymentsAggregate" abstract="false" name="CollaborativeAgreementMilestonePaymentsAggregate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" abstract="false" name="DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_ApotexIncLitigationMember" abstract="true" name="ApotexIncLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" abstract="false" name="ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_RevolvingCreditFacilityDueJune2023Member" abstract="true" name="RevolvingCreditFacilityDueJune2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ProductBrandsMember" abstract="true" name="ProductBrandsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherIncomeExpenseNet" abstract="false" name="OtherIncomeExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SynergyPharmaceuticalsInc.Member" abstract="true" name="SynergyPharmaceuticalsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DefinedBenefitPlanEmployerContributionMaximumAge" abstract="false" name="DefinedBenefitPlanEmployerContributionMaximumAge" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_A6.125SeniorNotesdueApril2025Member" abstract="true" name="A6.125SeniorNotesdueApril2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember" abstract="true" name="RevolvingCreditFacilityNewRestatedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" abstract="true" name="TermLoanBFacilityDueJune2025AndNovember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" abstract="false" name="DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember" abstract="true" name="SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AcquiredInProcessResearchAndDevelopmentMember" abstract="true" name="AcquiredInProcessResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" abstract="false" name="LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" abstract="false" name="AccountsReceivableAllowanceForForeignExchangeAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_NoncashCumulativeForeignCurrencyTranslationLoss" abstract="false" name="NoncashCumulativeForeignCurrencyTranslationLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" abstract="true" name="ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" abstract="false" name="UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_TSRPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="TSRPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits" abstract="false" name="LossContingencyNumberOfAllegedStockholdersFiledLawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_AccruedProductReturnCurrent" abstract="false" name="AccruedProductReturnCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_U.S.BroadMarketMember" abstract="true" name="U.S.BroadMarketMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" abstract="false" name="SummaryOfValuationAndQualifyingAccountsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit" abstract="false" name="GoodwillTransfersRelatedToSaleOfBusinessUnit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans" abstract="false" name="DefinedBenefitPlanNumberofDefinedBenefitPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_TermLoanBFacilityNewRestatedCreditAgreementMember" abstract="true" name="TermLoanBFacilityNewRestatedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" abstract="false" name="BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueNovember2025Member" abstract="true" name="TermLoanBFacilityDueNovember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" abstract="true" name="SeniorSecuredNotes6.50PercentDueMarch2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DivestituresOfNoncoreProductsPolicyTextBlock" abstract="false" name="DivestituresOfNoncoreProductsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_SeniorNotes6125DueApril2025Member" abstract="true" name="SeniorNotes6125DueApril2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" abstract="false" name="DebtInstrumentPeriodicPaymentQuarterlyAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ScheduleOfCommitmentsTable" abstract="true" name="ScheduleOfCommitmentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_CashDiscountsAndAllowancesSettlementPeriod" abstract="false" name="CashDiscountsAndAllowancesSettlementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" abstract="true" name="RestrictedCashAndOtherSettlementDepositsCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_GainLossRelatedToLitigationSettlementGross" abstract="false" name="GainLossRelatedToLitigationSettlementGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_PriceAppreciationCreditMember" abstract="true" name="PriceAppreciationCreditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReportingUnitImpairmentTestLongTermGrowthRate" abstract="false" name="ReportingUnitImpairmentTestLongTermGrowthRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTotalLeverageRatio" abstract="false" name="DebtInstrumentCovenantTotalLeverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" abstract="false" name="PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AccretionForTimeValueOfMoneyMember" abstract="true" name="AccretionForTimeValueOfMoneyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" abstract="false" name="ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_OvertheCounterProductsMember" abstract="true" name="OvertheCounterProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_GlobalHighYieldMember" abstract="true" name="GlobalHighYieldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AmerisourceBergenCorporationMember" abstract="true" name="AmerisourceBergenCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_NonemployeeDirectorMember" abstract="true" name="NonemployeeDirectorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantInterestCoverageRatioMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" abstract="false" name="UnrecognizedTaxBenefitsIncludingInterestAndPenalties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_IncomeTaxReconciliationUncertainTaxPositions" abstract="false" name="IncomeTaxReconciliationUncertainTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_CrossCurrencyFinalSettlementMember" abstract="true" name="CrossCurrencyFinalSettlementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A5.375SeniorNotesdueMarch2020Member" abstract="true" name="A5.375SeniorNotesdueMarch2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A7.00SeniorUnsecuredNotesDue2028Member" abstract="true" name="A7.00SeniorUnsecuredNotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A9.25SeniorNotesDueApril2026Member" abstract="true" name="A9.25SeniorNotesDueApril2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ScheduleOfOtherIncomeAndExpensesLineItems" abstract="true" name="ScheduleOfOtherIncomeAndExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_SandozLitigationMember" abstract="true" name="SandozLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" abstract="false" name="ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" abstract="false" name="BusinessAcquisitionContingentConsiderationFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_MilestonePaymentRelatedToCertainProductMember" abstract="true" name="MilestonePaymentRelatedToCertainProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_McKessonCorporationMember" abstract="true" name="McKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PeriodReceivableOutstanding" abstract="false" name="PeriodReceivableOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_NovaliqGmbHMember" abstract="true" name="NovaliqGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForDistributionFeesMember" abstract="true" name="ReserveForDistributionFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForCustomerReturnsMember" abstract="true" name="ReserveForCustomerReturnsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentAnnualAmortizationRatePercentage" abstract="false" name="DebtInstrumentAnnualAmortizationRatePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract" abstract="true" name="CapitalExpenditureAndDepreciationAndAmortizationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_SeniorNotes850DueJanuary2027Member" abstract="true" name="SeniorNotes850DueJanuary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TradeReceivableNetPortionPastDue" abstract="false" name="TradeReceivableNetPortionPastDue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantTotalLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_NumberOfLargestWholesaleCustomers" abstract="false" name="NumberOfLargestWholesaleCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" abstract="false" name="DebtInstrumentCovenantTermsFixedChargeCoverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LossContingencySettlementAgreementsNumberOfInsurers" abstract="false" name="LossContingencySettlementAgreementsNumberOfInsurers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_A5.00SeniorNotesDueJanuary2028Member" abstract="true" name="A5.00SeniorNotesDueJanuary2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_InvestmentGradeMember" abstract="true" name="InvestmentGradeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BauschLombMember" abstract="true" name="BauschLombMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock" abstract="false" name="AdditionalOperatingLeaseInformationLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_SalixSegmentMember" abstract="true" name="SalixSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_GlumetzaAntitrustLitigationMember" abstract="true" name="GlumetzaAntitrustLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BaseRateOrPrimeRateMember" abstract="true" name="BaseRateOrPrimeRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A5.25SeniorNotesDueJanuary2030Member" abstract="true" name="A5.25SeniorNotesDueJanuary2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PastDuePeriodForAccountsReceivableToBeNegligible" abstract="false" name="PastDuePeriodForAccountsReceivableToBeNegligible" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_SeniorSecured6125NotesDueFebruary2027Member" abstract="true" name="SeniorSecured6125NotesDueFebruary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ScheduleOfCommitmentsLineItems" abstract="true" name="ScheduleOfCommitmentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_OmnibusIncentivePlan2014Member" abstract="true" name="OmnibusIncentivePlan2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A7.25SeniorUnsecuredNotesDue2029Member" abstract="true" name="A7.25SeniorUnsecuredNotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A9.00SeniorNotesdueDecember2025Member" abstract="true" name="A9.00SeniorNotesdueDecember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AllowancesForLossesOnAccountsReceivableAndInventories" abstract="false" name="AllowancesForLossesOnAccountsReceivableAndInventories" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_OtherLongTermDebtMember" abstract="true" name="OtherLongTermDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccumulatedLossesAvailableForFederalPurposes" abstract="false" name="AccumulatedLossesAvailableForFederalPurposes" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage" abstract="false" name="IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_PlaintiffsDirectPurchasersMember" abstract="true" name="PlaintiffsDirectPurchasersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_FairValueAdjustmentsMember" abstract="true" name="FairValueAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AmounPharmaceuticalCompanySAEMember" abstract="true" name="AmounPharmaceuticalCompanySAEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes500DueJanuary2028Member" abstract="true" name="SeniorNotes500DueJanuary2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SellingGeneralAndAdministrativeExpenseMember" abstract="true" name="SellingGeneralAndAdministrativeExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_ReserveForChargebacksMember" abstract="true" name="ReserveForChargebacksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TimeBasedRSUMember" abstract="true" name="TimeBasedRSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" abstract="false" name="LineOfCreditFacilityThresholdForIncrementalBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_A5.50SeniorNotesdueMarch2023Member" abstract="true" name="A5.50SeniorNotesdueMarch2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" abstract="false" name="LossContingencyNewClaimsFiledButNotYetServedNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_BusinessAcquisitionProFormaOperatingIncomeLoss" abstract="false" name="BusinessAcquisitionProFormaOperatingIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>bhc-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:cdc15979-c542-4d25-920c-73804898e32f,g:89bc1415-46fc-4aad-8e83-55f6d8df2ca2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bhc-20211231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2adf1374-e250-4a5e-89b5-1fd009ec1741" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a5ff585c-ee14-4a77-bc20-47d299f1ebe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2adf1374-e250-4a5e-89b5-1fd009ec1741" xlink:to="loc_us-gaap_LiabilitiesCurrent_a5ff585c-ee14-4a77-bc20-47d299f1ebe3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_985d3317-173c-4cb3-aa5d-98b3729311b0" xlink:href="bhc-20211231.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2adf1374-e250-4a5e-89b5-1fd009ec1741" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_985d3317-173c-4cb3-aa5d-98b3729311b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_68e2f2d7-170a-4130-acb9-b3292a379272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2adf1374-e250-4a5e-89b5-1fd009ec1741" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_68e2f2d7-170a-4130-acb9-b3292a379272" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_614f48eb-f5d7-431e-bc18-beb7f29ef973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2adf1374-e250-4a5e-89b5-1fd009ec1741" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_614f48eb-f5d7-431e-bc18-beb7f29ef973" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f25c1308-3524-453d-9b51-d28358d28636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2adf1374-e250-4a5e-89b5-1fd009ec1741" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f25c1308-3524-453d-9b51-d28358d28636" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_839fc60d-3724-43f7-8c51-44eaca5ce14a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9cca36ce-24d3-4b29-b9dd-50a558c0bfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_839fc60d-3724-43f7-8c51-44eaca5ce14a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9cca36ce-24d3-4b29-b9dd-50a558c0bfc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_29673f8d-00e2-4190-a0d9-b7ef6ba71ae8" xlink:href="bhc-20211231.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_839fc60d-3724-43f7-8c51-44eaca5ce14a" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_29673f8d-00e2-4190-a0d9-b7ef6ba71ae8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_14dceff7-8e18-4a1f-9639-9997351cd525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_839fc60d-3724-43f7-8c51-44eaca5ce14a" xlink:to="loc_us-gaap_ReceivablesNetCurrent_14dceff7-8e18-4a1f-9639-9997351cd525" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d4aa48e6-9d41-43f8-a9aa-3f347d717819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_839fc60d-3724-43f7-8c51-44eaca5ce14a" xlink:to="loc_us-gaap_InventoryNet_d4aa48e6-9d41-43f8-a9aa-3f347d717819" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5984d77e-23e8-43d1-b5c0-74416eec58f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_839fc60d-3724-43f7-8c51-44eaca5ce14a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5984d77e-23e8-43d1-b5c0-74416eec58f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4c0db74e-14e6-4669-b391-21cd66c0912c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8fa4a410-5e67-407a-b2cc-804231d806d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4c0db74e-14e6-4669-b391-21cd66c0912c" xlink:to="loc_us-gaap_StockholdersEquity_8fa4a410-5e67-407a-b2cc-804231d806d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_bb9264d8-72e8-4bcd-8a79-a9a9ccc43688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4c0db74e-14e6-4669-b391-21cd66c0912c" xlink:to="loc_us-gaap_MinorityInterest_bb9264d8-72e8-4bcd-8a79-a9a9ccc43688" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_745c9b42-1c95-447a-884c-83a329d50672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b3bace7d-6808-479e-95c2-fb0ed35e81a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_745c9b42-1c95-447a-884c-83a329d50672" xlink:to="loc_us-gaap_CommonStockValue_b3bace7d-6808-479e-95c2-fb0ed35e81a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0a7fb768-ba9b-4635-88dd-af7de56274cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_745c9b42-1c95-447a-884c-83a329d50672" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0a7fb768-ba9b-4635-88dd-af7de56274cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d706d72f-3b8c-4083-8940-47c5af8218f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_745c9b42-1c95-447a-884c-83a329d50672" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d706d72f-3b8c-4083-8940-47c5af8218f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_852dcde8-9cb1-4523-aefb-b3cccf944eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_745c9b42-1c95-447a-884c-83a329d50672" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_852dcde8-9cb1-4523-aefb-b3cccf944eea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e06c6cba-f39a-4e32-8da4-ea057b2a6c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_676278d2-b425-4802-aaa4-5eeba3ee053f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e06c6cba-f39a-4e32-8da4-ea057b2a6c45" xlink:to="loc_us-gaap_Liabilities_676278d2-b425-4802-aaa4-5eeba3ee053f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_be6e0044-46e5-41cd-b1de-2f970787b5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e06c6cba-f39a-4e32-8da4-ea057b2a6c45" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_be6e0044-46e5-41cd-b1de-2f970787b5cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f0987b74-182d-49c8-9b0a-8426b89d93d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e06c6cba-f39a-4e32-8da4-ea057b2a6c45" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f0987b74-182d-49c8-9b0a-8426b89d93d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_178e4de8-e05b-4345-b1b1-ad16eef57791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_75c9067f-6793-453f-b997-7afd0e41faf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_178e4de8-e05b-4345-b1b1-ad16eef57791" xlink:to="loc_us-gaap_AssetsCurrent_75c9067f-6793-453f-b997-7afd0e41faf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d34b7fd0-036d-4e3d-9df7-332f0ed077cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_178e4de8-e05b-4345-b1b1-ad16eef57791" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d34b7fd0-036d-4e3d-9df7-332f0ed077cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_56cd91d7-13f6-40fc-8605-ea3015a00f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_178e4de8-e05b-4345-b1b1-ad16eef57791" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_56cd91d7-13f6-40fc-8605-ea3015a00f21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_06ceb375-e316-4bb0-8060-135a4ffba035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_178e4de8-e05b-4345-b1b1-ad16eef57791" xlink:to="loc_us-gaap_Goodwill_06ceb375-e316-4bb0-8060-135a4ffba035" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_cd97bf9a-235e-4f2c-8c9c-c7e3fe64d2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_178e4de8-e05b-4345-b1b1-ad16eef57791" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_cd97bf9a-235e-4f2c-8c9c-c7e3fe64d2df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_30b67df6-5547-4bb9-a243-eadfede2834d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_178e4de8-e05b-4345-b1b1-ad16eef57791" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_30b67df6-5547-4bb9-a243-eadfede2834d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3c98435a-398c-4d2b-b1a1-d2f61e4bfa77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_83aae737-9887-402c-a02f-48ea12ad123d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3c98435a-398c-4d2b-b1a1-d2f61e4bfa77" xlink:to="loc_us-gaap_AccountsPayableCurrent_83aae737-9887-402c-a02f-48ea12ad123d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7c07ce24-e568-43cb-89ef-61231008a13d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3c98435a-398c-4d2b-b1a1-d2f61e4bfa77" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7c07ce24-e568-43cb-89ef-61231008a13d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20211231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_163c2102-9e4e-4319-bb1c-3ed055c9c364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8492362f-fd70-463c-a8bf-7fb14cfee03f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_163c2102-9e4e-4319-bb1c-3ed055c9c364" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8492362f-fd70-463c-a8bf-7fb14cfee03f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b4f4f7e0-ea46-4ee7-ab29-2dbbb43a6886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_163c2102-9e4e-4319-bb1c-3ed055c9c364" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b4f4f7e0-ea46-4ee7-ab29-2dbbb43a6886" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5a2e4f6c-84dd-4c15-af6b-3932e4f01d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_163c2102-9e4e-4319-bb1c-3ed055c9c364" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5a2e4f6c-84dd-4c15-af6b-3932e4f01d5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_e5933663-587a-44de-829a-384bf1f6944a" xlink:href="bhc-20211231.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_163c2102-9e4e-4319-bb1c-3ed055c9c364" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_e5933663-587a-44de-829a-384bf1f6944a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_24546b16-4310-47f9-b54d-d8865b0d01f5" xlink:href="bhc-20211231.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_163c2102-9e4e-4319-bb1c-3ed055c9c364" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_24546b16-4310-47f9-b54d-d8865b0d01f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_b385e29c-c030-4bfb-a32b-4e0d1b77b198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_163c2102-9e4e-4319-bb1c-3ed055c9c364" xlink:to="loc_us-gaap_AssetImpairmentCharges_b385e29c-c030-4bfb-a32b-4e0d1b77b198" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_01c79448-8a54-4f44-8df6-27fe3a1719dd" xlink:href="bhc-20211231.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_163c2102-9e4e-4319-bb1c-3ed055c9c364" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_01c79448-8a54-4f44-8df6-27fe3a1719dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_7c8eaf76-e556-4048-9e85-c836be8209d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_163c2102-9e4e-4319-bb1c-3ed055c9c364" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_7c8eaf76-e556-4048-9e85-c836be8209d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_347ee98e-9033-4797-9f6f-1d96bce34cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0542543d-ef18-404f-998f-5ef4b2afe2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_347ee98e-9033-4797-9f6f-1d96bce34cbe" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0542543d-ef18-404f-998f-5ef4b2afe2cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d190df34-3180-43b3-a2f7-69fe84a4fe15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_347ee98e-9033-4797-9f6f-1d96bce34cbe" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d190df34-3180-43b3-a2f7-69fe84a4fe15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2b39dd4c-50da-4793-8a67-a6af0015ccca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0dfea4a5-07c1-45a3-bf59-a01f0127efab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2b39dd4c-50da-4793-8a67-a6af0015ccca" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0dfea4a5-07c1-45a3-bf59-a01f0127efab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_349a1c18-ac0b-4281-a5f2-8b96949e75ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2b39dd4c-50da-4793-8a67-a6af0015ccca" xlink:to="loc_us-gaap_CostsAndExpenses_349a1c18-ac0b-4281-a5f2-8b96949e75ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_37f2852e-1bbb-4f14-928a-57d9a791a7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b34bebe6-bf44-41b2-80f5-112d1cf7ba28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_37f2852e-1bbb-4f14-928a-57d9a791a7e6" xlink:to="loc_us-gaap_ProfitLoss_b34bebe6-bf44-41b2-80f5-112d1cf7ba28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ca152f49-226c-433f-b333-82eb69ab574a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_37f2852e-1bbb-4f14-928a-57d9a791a7e6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ca152f49-226c-433f-b333-82eb69ab574a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2d75b4e0-8599-4086-b321-533fa01eeccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f9ba5ab9-9b7b-4a13-935a-41ae3e9a3e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2d75b4e0-8599-4086-b321-533fa01eeccc" xlink:to="loc_us-gaap_OperatingIncomeLoss_f9ba5ab9-9b7b-4a13-935a-41ae3e9a3e91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_3b70663a-19e8-4250-aa4a-6ec4a61f7e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2d75b4e0-8599-4086-b321-533fa01eeccc" xlink:to="loc_us-gaap_InvestmentIncomeInterest_3b70663a-19e8-4250-aa4a-6ec4a61f7e0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_30ccf1b4-60c4-4f1e-9ea7-fcd0c1b933d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2d75b4e0-8599-4086-b321-533fa01eeccc" xlink:to="loc_us-gaap_InterestExpenseDebt_30ccf1b4-60c4-4f1e-9ea7-fcd0c1b933d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a8871c27-bf60-413a-a688-4bb6bfe38d01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2d75b4e0-8599-4086-b321-533fa01eeccc" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a8871c27-bf60-413a-a688-4bb6bfe38d01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9a998822-1d82-4009-a2e9-9406804e41ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2d75b4e0-8599-4086-b321-533fa01eeccc" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9a998822-1d82-4009-a2e9-9406804e41ed" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhc-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6d66d928-2710-4eea-8267-c321e01ab14d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b8fa073b-7cbe-462d-a0a9-d41e4028ecd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6d66d928-2710-4eea-8267-c321e01ab14d" xlink:to="loc_us-gaap_ProfitLoss_b8fa073b-7cbe-462d-a0a9-d41e4028ecd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_02ade2cb-0b76-4f43-acf0-597a75a5e5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6d66d928-2710-4eea-8267-c321e01ab14d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_02ade2cb-0b76-4f43-acf0-597a75a5e5a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_94ef45b7-da88-44a4-b9fc-4db5144d02e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_14f79d7c-fd8d-4a00-9b1f-31045afd6c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_94ef45b7-da88-44a4-b9fc-4db5144d02e6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_14f79d7c-fd8d-4a00-9b1f-31045afd6c2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_d348749d-7f6d-4210-9bc9-2e2a029f1d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_94ef45b7-da88-44a4-b9fc-4db5144d02e6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_d348749d-7f6d-4210-9bc9-2e2a029f1d4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7f2deb07-3e22-4b84-8ef3-3e509d930451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_b016ae47-c687-4833-af87-98a5532ced61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7f2deb07-3e22-4b84-8ef3-3e509d930451" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_b016ae47-c687-4833-af87-98a5532ced61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d7f76599-adfe-4855-bd08-f8ae5fdb7423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7f2deb07-3e22-4b84-8ef3-3e509d930451" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d7f76599-adfe-4855-bd08-f8ae5fdb7423" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2c3a7e7a-ef6c-46ed-8102-735d60dd0352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_ee7b5324-c710-467d-9aae-d416a65961d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2c3a7e7a-ef6c-46ed-8102-735d60dd0352" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_ee7b5324-c710-467d-9aae-d416a65961d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_57ea826d-bb03-4bee-8c74-3a6f6121f4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2c3a7e7a-ef6c-46ed-8102-735d60dd0352" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_57ea826d-bb03-4bee-8c74-3a6f6121f4c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition_515e0f38-a136-4c27-a7d2-f4a1c4814284" xlink:href="bhc-20211231.xsd#bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2c3a7e7a-ef6c-46ed-8102-735d60dd0352" xlink:to="loc_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition_515e0f38-a136-4c27-a7d2-f4a1c4814284" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_23fe73d4-2c4a-4174-b5bf-11290f992c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2c3a7e7a-ef6c-46ed-8102-735d60dd0352" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_23fe73d4-2c4a-4174-b5bf-11290f992c27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax_b91560d3-d814-44bd-b051-cdc8cddb8483" xlink:href="bhc-20211231.xsd#bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2c3a7e7a-ef6c-46ed-8102-735d60dd0352" xlink:to="loc_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax_b91560d3-d814-44bd-b051-cdc8cddb8483" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bhc-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_76a3350c-c4ce-49c3-b452-b89b3d97187c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1dfef46d-9157-4ef9-969e-07ffbb35a927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_76a3350c-c4ce-49c3-b452-b89b3d97187c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1dfef46d-9157-4ef9-969e-07ffbb35a927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_6182aee5-3897-4180-ba32-786ee45ed6db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_76a3350c-c4ce-49c3-b452-b89b3d97187c" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_6182aee5-3897-4180-ba32-786ee45ed6db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_c35b4b11-9914-4a7e-a6f6-fffd12f7eeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_76a3350c-c4ce-49c3-b452-b89b3d97187c" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_c35b4b11-9914-4a7e-a6f6-fffd12f7eeb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_1837938f-104c-4d28-bd68-86230eafc6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_76a3350c-c4ce-49c3-b452-b89b3d97187c" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_1837938f-104c-4d28-bd68-86230eafc6a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_cb0cb140-2a0d-431b-86fe-e7bb162f0c50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_76a3350c-c4ce-49c3-b452-b89b3d97187c" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_cb0cb140-2a0d-431b-86fe-e7bb162f0c50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_b0ea52a7-40c7-41ab-a0c5-42b8b48a27ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_76a3350c-c4ce-49c3-b452-b89b3d97187c" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_b0ea52a7-40c7-41ab-a0c5-42b8b48a27ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e0012fcb-0c84-4055-8a72-39fd845241c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_76a3350c-c4ce-49c3-b452-b89b3d97187c" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e0012fcb-0c84-4055-8a72-39fd845241c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_df8e69a4-85ee-4828-911f-6f6969cac5da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_76a3350c-c4ce-49c3-b452-b89b3d97187c" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_df8e69a4-85ee-4828-911f-6f6969cac5da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4320de54-f136-475d-a2ce-bb986d42876d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bb6def23-08e2-4f61-9c3b-7bce27238c63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4320de54-f136-475d-a2ce-bb986d42876d" xlink:to="loc_us-gaap_ProfitLoss_bb6def23-08e2-4f61-9c3b-7bce27238c63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_524413d0-fecb-408d-9754-6a4c69a05114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4320de54-f136-475d-a2ce-bb986d42876d" xlink:to="loc_us-gaap_DepreciationAndAmortization_524413d0-fecb-408d-9754-6a4c69a05114" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_428f8a73-f090-454d-9985-24aa5e97e1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4320de54-f136-475d-a2ce-bb986d42876d" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_428f8a73-f090-454d-9985-24aa5e97e1d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_f86bc158-c1d0-4eab-9b12-4230fc2b1bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4320de54-f136-475d-a2ce-bb986d42876d" xlink:to="loc_us-gaap_AssetImpairmentCharges_f86bc158-c1d0-4eab-9b12-4230fc2b1bbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_a8ad7fa6-03a9-4ff2-8781-d4fce71d4790" xlink:href="bhc-20211231.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4320de54-f136-475d-a2ce-bb986d42876d" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_a8ad7fa6-03a9-4ff2-8781-d4fce71d4790" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_2eec29dd-6534-4196-89aa-df2fe394994d" xlink:href="bhc-20211231.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4320de54-f136-475d-a2ce-bb986d42876d" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_2eec29dd-6534-4196-89aa-df2fe394994d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_13506a89-57f3-40fb-8f0b-72899ca31855" xlink:href="bhc-20211231.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4320de54-f136-475d-a2ce-bb986d42876d" xlink:to="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_13506a89-57f3-40fb-8f0b-72899ca31855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_f5ae35fb-d184-49b0-b043-159379a76848" xlink:href="bhc-20211231.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4320de54-f136-475d-a2ce-bb986d42876d" xlink:to="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_f5ae35fb-d184-49b0-b043-159379a76848" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_8521efcc-d61d-40b9-aaef-a83fbea1f6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4320de54-f136-475d-a2ce-bb986d42876d" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_8521efcc-d61d-40b9-aaef-a83fbea1f6f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross_f75b789f-85cb-4738-a8d9-cc82fbca4003" xlink:href="bhc-20211231.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4320de54-f136-475d-a2ce-bb986d42876d" xlink:to="loc_bhc_GainLossRelatedToLitigationSettlementGross_f75b789f-85cb-4738-a8d9-cc82fbca4003" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_b0680e9b-fd45-4118-8b4c-f77234a17ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4320de54-f136-475d-a2ce-bb986d42876d" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_b0680e9b-fd45-4118-8b4c-f77234a17ea3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_da9b1e62-a135-45ef-ad60-35b77d74deda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4320de54-f136-475d-a2ce-bb986d42876d" xlink:to="loc_us-gaap_ShareBasedCompensation_da9b1e62-a135-45ef-ad60-35b77d74deda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_fcbd99b3-b43e-4e8b-8b21-f9a2a4e860d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4320de54-f136-475d-a2ce-bb986d42876d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_fcbd99b3-b43e-4e8b-8b21-f9a2a4e860d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent_970d32a9-aea9-4d2a-97d2-65f247339436" xlink:href="bhc-20211231.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4320de54-f136-475d-a2ce-bb986d42876d" xlink:to="loc_bhc_DerivativeGainExcludedComponent_970d32a9-aea9-4d2a-97d2-65f247339436" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8be38cec-67da-4f88-bc23-a5b6c8ac48bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4320de54-f136-475d-a2ce-bb986d42876d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8be38cec-67da-4f88-bc23-a5b6c8ac48bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_772d1ae4-21a8-4089-a098-f6af08aa88bf" xlink:href="bhc-20211231.xsd#bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4320de54-f136-475d-a2ce-bb986d42876d" xlink:to="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_772d1ae4-21a8-4089-a098-f6af08aa88bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_79c353f1-1598-4a75-8c0e-8f91e3f2f759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4320de54-f136-475d-a2ce-bb986d42876d" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_79c353f1-1598-4a75-8c0e-8f91e3f2f759" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4519e1ba-14e9-4d08-80b4-4367219ae37f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4320de54-f136-475d-a2ce-bb986d42876d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4519e1ba-14e9-4d08-80b4-4367219ae37f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_d597fdb0-1dce-4b78-8f06-61e3b3ec8c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4320de54-f136-475d-a2ce-bb986d42876d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_d597fdb0-1dce-4b78-8f06-61e3b3ec8c8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0c9c95bb-d13a-4bc5-8e16-776476260c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4320de54-f136-475d-a2ce-bb986d42876d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0c9c95bb-d13a-4bc5-8e16-776476260c3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2ab2e39d-71f4-4859-ac8c-a030a4e46229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4320de54-f136-475d-a2ce-bb986d42876d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2ab2e39d-71f4-4859-ac8c-a030a4e46229" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b267dc61-b59f-4cdb-bc4f-dd80a47ec77e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4af58e5b-9ace-4328-aa3a-c9c4d2608916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b267dc61-b59f-4cdb-bc4f-dd80a47ec77e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4af58e5b-9ace-4328-aa3a-c9c4d2608916" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_4c8d9026-0229-4633-b344-4ab3ffa003a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b267dc61-b59f-4cdb-bc4f-dd80a47ec77e" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_4c8d9026-0229-4633-b344-4ab3ffa003a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_21e8caef-16bc-4894-8964-d30cecfa10a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b267dc61-b59f-4cdb-bc4f-dd80a47ec77e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_21e8caef-16bc-4894-8964-d30cecfa10a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_b8ab7bd1-3dfd-45e6-a1cd-7002fd406b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b267dc61-b59f-4cdb-bc4f-dd80a47ec77e" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_b8ab7bd1-3dfd-45e6-a1cd-7002fd406b8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_7d744794-8a3b-4831-9d0b-a615221b208c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b267dc61-b59f-4cdb-bc4f-dd80a47ec77e" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_7d744794-8a3b-4831-9d0b-a615221b208c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_fc02f613-b610-495b-913c-c3d7838b854d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b267dc61-b59f-4cdb-bc4f-dd80a47ec77e" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_fc02f613-b610-495b-913c-c3d7838b854d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps_08c9851c-0a4b-4332-bef1-d236a39c7d37" xlink:href="bhc-20211231.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b267dc61-b59f-4cdb-bc4f-dd80a47ec77e" xlink:to="loc_bhc_InterestSettlementOnCrossCurrencySwaps_08c9851c-0a4b-4332-bef1-d236a39c7d37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6d15c3ce-6f13-42c2-a00d-4fbc05f84571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_292e3d4c-f2d2-4454-b2c1-f6e9a63e144b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6d15c3ce-6f13-42c2-a00d-4fbc05f84571" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_292e3d4c-f2d2-4454-b2c1-f6e9a63e144b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5a187108-cd8e-458a-9c52-a22e04362242" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6d15c3ce-6f13-42c2-a00d-4fbc05f84571" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5a187108-cd8e-458a-9c52-a22e04362242" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca6b9aee-ab0f-4449-a38e-6ea7adb689a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6d15c3ce-6f13-42c2-a00d-4fbc05f84571" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca6b9aee-ab0f-4449-a38e-6ea7adb689a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_735319f2-97fa-4c2e-832b-ce6fa50d2ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6d15c3ce-6f13-42c2-a00d-4fbc05f84571" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_735319f2-97fa-4c2e-832b-ce6fa50d2ee1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_b01f6bfe-95a6-425a-8e4a-c57f4890dce5" xlink:href="bhc-20211231.xsd#bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3b1398a0-038d-4f95-8996-c9e2a8b57f14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_b01f6bfe-95a6-425a-8e4a-c57f4890dce5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3b1398a0-038d-4f95-8996-c9e2a8b57f14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_57b7980e-fd3e-4c79-92a4-edea5725a3c5" xlink:href="bhc-20211231.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_b01f6bfe-95a6-425a-8e4a-c57f4890dce5" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_57b7980e-fd3e-4c79-92a4-edea5725a3c5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e424352-e3ea-49e0-b4b8-8c707bd9f490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_269d6332-8240-4e1c-af89-252a19ad5139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e424352-e3ea-49e0-b4b8-8c707bd9f490" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_269d6332-8240-4e1c-af89-252a19ad5139" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e98bf360-39df-4b95-9ad8-40a46f368844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e424352-e3ea-49e0-b4b8-8c707bd9f490" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e98bf360-39df-4b95-9ad8-40a46f368844" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_3e570959-fb10-4eda-8ea6-5a236b3f3e19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e424352-e3ea-49e0-b4b8-8c707bd9f490" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_3e570959-fb10-4eda-8ea6-5a236b3f3e19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9d7594d1-b8f5-4e21-828a-664c73f7cfdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e424352-e3ea-49e0-b4b8-8c707bd9f490" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9d7594d1-b8f5-4e21-828a-664c73f7cfdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_eea1619b-6bbf-4438-9c05-9eec24a21024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e424352-e3ea-49e0-b4b8-8c707bd9f490" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_eea1619b-6bbf-4438-9c05-9eec24a21024" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_429990e3-cf39-485e-b201-531c142e21f2" xlink:href="bhc-20211231.xsd#bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e424352-e3ea-49e0-b4b8-8c707bd9f490" xlink:to="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_429990e3-cf39-485e-b201-531c142e21f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6053cbd5-cc62-4761-87ef-c1a91f6619ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0e6d5f0e-ae5d-4bfa-ba03-4893b2b24cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6053cbd5-cc62-4761-87ef-c1a91f6619ea" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0e6d5f0e-ae5d-4bfa-ba03-4893b2b24cd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f02d7603-3338-4645-bddf-189d96ba8c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6053cbd5-cc62-4761-87ef-c1a91f6619ea" xlink:to="loc_us-gaap_Goodwill_f02d7603-3338-4645-bddf-189d96ba8c0e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_91fe7d84-dd75-4796-983f-d4926a7db3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_2c8d7abe-ce87-4cbe-8da6-384e188e0538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_91fe7d84-dd75-4796-983f-d4926a7db3a0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_2c8d7abe-ce87-4cbe-8da6-384e188e0538" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_27fc1aa2-0b0d-4289-9d8c-6d7871a9b24e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_91fe7d84-dd75-4796-983f-d4926a7db3a0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_27fc1aa2-0b0d-4289-9d8c-6d7871a9b24e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_62b128fa-fd97-4944-9fc2-8cb4d098c620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_91fe7d84-dd75-4796-983f-d4926a7db3a0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_62b128fa-fd97-4944-9fc2-8cb4d098c620" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_fe1c005f-8a2f-4343-bec1-5836acef0af6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_e2ec5941-1b52-41d9-a9bd-04c1d7c22347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_fe1c005f-8a2f-4343-bec1-5836acef0af6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_e2ec5941-1b52-41d9-a9bd-04c1d7c22347" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent_9c37b3c0-bff0-432c-8e83-7806cbe18f38" xlink:href="bhc-20211231.xsd#bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_fe1c005f-8a2f-4343-bec1-5836acef0af6" xlink:to="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent_9c37b3c0-bff0-432c-8e83-7806cbe18f38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_d61846a0-32cf-49db-b138-e71bebb8c677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_9d3074b6-70aa-4934-adf5-a69ab4eed2af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_d61846a0-32cf-49db-b138-e71bebb8c677" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_9d3074b6-70aa-4934-adf5-a69ab4eed2af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent_a04d3884-00d6-4c58-8659-963214f4c991" xlink:href="bhc-20211231.xsd#bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_d61846a0-32cf-49db-b138-e71bebb8c677" xlink:to="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent_a04d3884-00d6-4c58-8659-963214f4c991" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_c529055d-0a69-4e98-bae9-848b8aa637b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_6fd9200f-5fcb-418c-9306-e14e4008c644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_c529055d-0a69-4e98-bae9-848b8aa637b0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_6fd9200f-5fcb-418c-9306-e14e4008c644" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_66fc5105-84b2-47bd-93e5-9c720c52490f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_c529055d-0a69-4e98-bae9-848b8aa637b0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_66fc5105-84b2-47bd-93e5-9c720c52490f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_9f5137f9-e647-4b20-9d98-4dd44e3a7bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_c529055d-0a69-4e98-bae9-848b8aa637b0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_9f5137f9-e647-4b20-9d98-4dd44e3a7bcf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_fe02da00-86e3-4f43-99e4-57716fd36a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_40459164-3262-4875-ac59-a787999db08f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_fe02da00-86e3-4f43-99e4-57716fd36a4d" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_40459164-3262-4875-ac59-a787999db08f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_c5b1f9a7-4da3-4f8a-87b0-53b38f414f09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_fe02da00-86e3-4f43-99e4-57716fd36a4d" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_c5b1f9a7-4da3-4f8a-87b0-53b38f414f09" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4ec11e75-3032-40de-a9bb-35141a69519b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_82130b37-d825-43a7-9ca5-3c15c2b95bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4ec11e75-3032-40de-a9bb-35141a69519b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_82130b37-d825-43a7-9ca5-3c15c2b95bfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_9debf9c2-0b19-4dce-87c1-2024803b0680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4ec11e75-3032-40de-a9bb-35141a69519b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_9debf9c2-0b19-4dce-87c1-2024803b0680" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INVENTORIESSummaryofInventoriesNetDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ca51f4fe-3a0a-4389-adb8-b4a870af9749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_c110aab0-b9df-4196-b387-ae31d85c7945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_ca51f4fe-3a0a-4389-adb8-b4a870af9749" xlink:to="loc_us-gaap_InventoryRawMaterials_c110aab0-b9df-4196-b387-ae31d85c7945" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_c445eaef-718d-4e5f-9566-9f86e66a7688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_ca51f4fe-3a0a-4389-adb8-b4a870af9749" xlink:to="loc_us-gaap_InventoryWorkInProcess_c445eaef-718d-4e5f-9566-9f86e66a7688" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_8ad484da-ade2-45c0-8cc5-b59ab313ab3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_ca51f4fe-3a0a-4389-adb8-b4a870af9749" xlink:to="loc_us-gaap_InventoryFinishedGoods_8ad484da-ade2-45c0-8cc5-b59ab313ab3d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0ea31596-fd15-4042-a042-99b4887c2923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d6ac81a0-37c7-4145-9e68-ef3e6bcb31b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0ea31596-fd15-4042-a042-99b4887c2923" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d6ac81a0-37c7-4145-9e68-ef3e6bcb31b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c297b28a-f6e0-445d-8326-e2d9fbbc8f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0ea31596-fd15-4042-a042-99b4887c2923" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c297b28a-f6e0-445d-8326-e2d9fbbc8f1c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c66272c4-6954-425e-b4aa-a95aa89b5c89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1619c8b8-4d72-4063-9755-9411e9c134c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c66272c4-6954-425e-b4aa-a95aa89b5c89" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1619c8b8-4d72-4063-9755-9411e9c134c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8c5aff6f-543f-41e4-8cb3-7f0c78a128a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c66272c4-6954-425e-b4aa-a95aa89b5c89" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8c5aff6f-543f-41e4-8cb3-7f0c78a128a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5945064d-1f4a-4a27-91f8-a8031f8a13fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3504cc5b-c95f-4f82-8d8c-1be3b6786d83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5945064d-1f4a-4a27-91f8-a8031f8a13fc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3504cc5b-c95f-4f82-8d8c-1be3b6786d83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_346d734d-cb5d-4819-b357-4320651c47ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5945064d-1f4a-4a27-91f8-a8031f8a13fc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_346d734d-cb5d-4819-b357-4320651c47ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_203fe28c-6a1a-4afe-9116-074dcfb1937c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0e861720-5812-4bdd-af35-d6defc9aa30c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_203fe28c-6a1a-4afe-9116-074dcfb1937c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0e861720-5812-4bdd-af35-d6defc9aa30c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6fbd2d84-cb52-4cd8-90c2-3f2d122c7da4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_203fe28c-6a1a-4afe-9116-074dcfb1937c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6fbd2d84-cb52-4cd8-90c2-3f2d122c7da4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="bhc-20211231.xsd#INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d43c342e-d921-4404-9740-61b1ff83fd45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4498b129-f972-44cc-a5bf-38025f01bf5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d43c342e-d921-4404-9740-61b1ff83fd45" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4498b129-f972-44cc-a5bf-38025f01bf5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_67e94e61-56df-4850-b01c-c520fdd4b3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d43c342e-d921-4404-9740-61b1ff83fd45" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_67e94e61-56df-4850-b01c-c520fdd4b3fd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ae87b3f8-cc39-4f76-a725-42efb2823124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c9bc424d-6e29-4794-8d1d-fc4dee0dc66b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ae87b3f8-cc39-4f76-a725-42efb2823124" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c9bc424d-6e29-4794-8d1d-fc4dee0dc66b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d5195e1a-ef89-4cd1-bf8a-b5aabcbdc306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ae87b3f8-cc39-4f76-a725-42efb2823124" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d5195e1a-ef89-4cd1-bf8a-b5aabcbdc306" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6eecca71-1ad0-4dbc-a182-c08f89962cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ae87b3f8-cc39-4f76-a725-42efb2823124" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6eecca71-1ad0-4dbc-a182-c08f89962cc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e1965c1c-8b5a-4785-aecf-dbbb8fd185ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ae87b3f8-cc39-4f76-a725-42efb2823124" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e1965c1c-8b5a-4785-aecf-dbbb8fd185ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_922cf68c-5623-4fee-bc35-ae8ef5f9ac48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ae87b3f8-cc39-4f76-a725-42efb2823124" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_922cf68c-5623-4fee-bc35-ae8ef5f9ac48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_ab458e99-1757-4d46-8e95-b7feb54a1e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ae87b3f8-cc39-4f76-a725-42efb2823124" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_ab458e99-1757-4d46-8e95-b7feb54a1e5b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_61e3d3f2-34b3-4aac-b3c7-9623c93593fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees_9b3b8dbb-fd6d-4634-af85-5084feda5452" xlink:href="bhc-20211231.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_61e3d3f2-34b3-4aac-b3c7-9623c93593fd" xlink:to="loc_bhc_Legalsettlementsandrelatedfees_9b3b8dbb-fd6d-4634-af85-5084feda5452" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent_3d43d98b-05aa-4f61-a519-ce45d2a2f3e9" xlink:href="bhc-20211231.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_61e3d3f2-34b3-4aac-b3c7-9623c93593fd" xlink:to="loc_bhc_AccruedProductRebateCurrent_3d43d98b-05aa-4f61-a519-ce45d2a2f3e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent_70a83b8b-dbb1-403f-b108-15b30f8f07de" xlink:href="bhc-20211231.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_61e3d3f2-34b3-4aac-b3c7-9623c93593fd" xlink:to="loc_bhc_AccruedProductReturnCurrent_70a83b8b-dbb1-403f-b108-15b30f8f07de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_1298f8ff-c7ab-4497-b0b2-1d3adc8014b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_61e3d3f2-34b3-4aac-b3c7-9623c93593fd" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_1298f8ff-c7ab-4497-b0b2-1d3adc8014b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_b6891c41-5229-4e07-aed8-3bba46827bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_61e3d3f2-34b3-4aac-b3c7-9623c93593fd" xlink:to="loc_us-gaap_InterestPayableCurrent_b6891c41-5229-4e07-aed8-3bba46827bf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_e9f2d669-ad60-475a-8722-0a1955949276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_61e3d3f2-34b3-4aac-b3c7-9623c93593fd" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_e9f2d669-ad60-475a-8722-0a1955949276" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a24901c8-6610-47ac-9d01-fc767b148f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_61e3d3f2-34b3-4aac-b3c7-9623c93593fd" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a24901c8-6610-47ac-9d01-fc767b148f76" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_edc80d81-5b75-42b7-8cf6-be582f49fbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_15c960af-e28b-4bd9-ba6d-4ae90328d936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_edc80d81-5b75-42b7-8cf6-be582f49fbf6" xlink:to="loc_us-gaap_LongTermDebtCurrent_15c960af-e28b-4bd9-ba6d-4ae90328d936" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_acb4c255-9747-43cd-b51c-8e96e77686c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_edc80d81-5b75-42b7-8cf6-be582f49fbf6" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_acb4c255-9747-43cd-b51c-8e96e77686c7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_440a3d2c-e35f-4b50-bd66-801a8c0067e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_84c41df3-d482-4b60-b540-8e343a4b6a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_440a3d2c-e35f-4b50-bd66-801a8c0067e8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_84c41df3-d482-4b60-b540-8e343a4b6a5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c2d78d15-b6d9-4e5b-89ec-cbec11270e09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_440a3d2c-e35f-4b50-bd66-801a8c0067e8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c2d78d15-b6d9-4e5b-89ec-cbec11270e09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2b50b95c-9336-4005-b8c3-5fc7f6e68a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_440a3d2c-e35f-4b50-bd66-801a8c0067e8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2b50b95c-9336-4005-b8c3-5fc7f6e68a9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_06030de8-c9f1-4db6-959d-bb49a09ea094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_440a3d2c-e35f-4b50-bd66-801a8c0067e8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_06030de8-c9f1-4db6-959d-bb49a09ea094" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a321a014-0d04-4208-bff5-c760698b5ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_440a3d2c-e35f-4b50-bd66-801a8c0067e8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a321a014-0d04-4208-bff5-c760698b5ec0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_1aaa570b-cf4f-47cc-bb9c-5a112797db21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_440a3d2c-e35f-4b50-bd66-801a8c0067e8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_1aaa570b-cf4f-47cc-bb9c-5a112797db21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d94108ad-4b24-4502-a927-396820135d80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ab6e3d4c-0b4c-4889-9646-fe8d0fddbcb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_d94108ad-4b24-4502-a927-396820135d80" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ab6e3d4c-0b4c-4889-9646-fe8d0fddbcb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_d54621e5-0b0e-4484-b72b-fe7a20d9010a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_d94108ad-4b24-4502-a927-396820135d80" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_d54621e5-0b0e-4484-b72b-fe7a20d9010a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3884a569-f2fd-43ae-ba15-dea735c1b8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_1bb2b0a3-cc01-445f-94f3-12f6af70a81e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3884a569-f2fd-43ae-ba15-dea735c1b8b1" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_1bb2b0a3-cc01-445f-94f3-12f6af70a81e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_ecdd4a60-e59b-4c61-ba96-9b2e3a0339ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3884a569-f2fd-43ae-ba15-dea735c1b8b1" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_ecdd4a60-e59b-4c61-ba96-9b2e3a0339ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_a5d43f33-768a-4dca-90b5-5d6c78df0073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3884a569-f2fd-43ae-ba15-dea735c1b8b1" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_a5d43f33-768a-4dca-90b5-5d6c78df0073" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_5c59ab7a-0c15-41f4-8bfd-f4c15493c855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3884a569-f2fd-43ae-ba15-dea735c1b8b1" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_5c59ab7a-0c15-41f4-8bfd-f4c15493c855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e61baa12-006b-4399-b700-359262e9abad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3884a569-f2fd-43ae-ba15-dea735c1b8b1" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e61baa12-006b-4399-b700-359262e9abad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_957ba3d3-b76e-4dcb-b8f5-3aef5d60dd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3884a569-f2fd-43ae-ba15-dea735c1b8b1" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_957ba3d3-b76e-4dcb-b8f5-3aef5d60dd2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanOtherCosts_ec4534f7-870e-4e78-98f0-3be0a8eef33a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanOtherCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3884a569-f2fd-43ae-ba15-dea735c1b8b1" xlink:to="loc_us-gaap_DefinedBenefitPlanOtherCosts_ec4534f7-870e-4e78-98f0-3be0a8eef33a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_b2a69a5e-4519-4259-899f-2da37d39af36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_1252c773-3a73-4050-840c-cf8212ca60a5" xlink:href="bhc-20211231.xsd#bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_b2a69a5e-4519-4259-899f-2da37d39af36" xlink:to="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_1252c773-3a73-4050-840c-cf8212ca60a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_a529e5bd-13cc-48e6-9e69-2e8f87867a91" xlink:href="bhc-20211231.xsd#bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_b2a69a5e-4519-4259-899f-2da37d39af36" xlink:to="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_a529e5bd-13cc-48e6-9e69-2e8f87867a91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_0ef40766-8289-4da1-8a69-1be1b8acd056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_b2a69a5e-4519-4259-899f-2da37d39af36" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_0ef40766-8289-4da1-8a69-1be1b8acd056" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_0d4b77eb-5755-4991-a5dc-66035dc7ae58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_7578dc50-5e69-4416-80e0-5e342695de3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_0d4b77eb-5755-4991-a5dc-66035dc7ae58" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_7578dc50-5e69-4416-80e0-5e342695de3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_4d59cb5c-896a-492e-a521-c595587ef8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_0d4b77eb-5755-4991-a5dc-66035dc7ae58" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_4d59cb5c-896a-492e-a521-c595587ef8ea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_faec611e-4416-4c21-af20-805411e8b591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6d92662c-834b-4566-85c1-1853b0020fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_faec611e-4416-4c21-af20-805411e8b591" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6d92662c-834b-4566-85c1-1853b0020fed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ef87e423-b4ff-41a0-bcf9-2fe2ddb7daa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_faec611e-4416-4c21-af20-805411e8b591" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ef87e423-b4ff-41a0-bcf9-2fe2ddb7daa5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#LEASESLeaseFuturePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9b1ff03d-2b00-4ea8-8cae-d4e29dd5c8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b9509151-59e5-467d-ad01-909280bbde66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9b1ff03d-2b00-4ea8-8cae-d4e29dd5c8ec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b9509151-59e5-467d-ad01-909280bbde66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0b8733eb-65a8-45f4-b7b3-10b77e4aa2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9b1ff03d-2b00-4ea8-8cae-d4e29dd5c8ec" xlink:to="loc_us-gaap_OperatingLeaseLiability_0b8733eb-65a8-45f4-b7b3-10b77e4aa2f5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1" xlink:type="simple" xlink:href="bhc-20211231.xsd#LEASESLeaseFuturePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7d4306da-2e16-435b-b05b-4c68194a9be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_88a32ddd-d30b-42fb-b59a-35afc033d56b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7d4306da-2e16-435b-b05b-4c68194a9be3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_88a32ddd-d30b-42fb-b59a-35afc033d56b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fc49beb9-a66e-495b-9a8f-a73fcb32d7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7d4306da-2e16-435b-b05b-4c68194a9be3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fc49beb9-a66e-495b-9a8f-a73fcb32d7e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f4380522-70c7-4442-87b2-df743eb7b811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7d4306da-2e16-435b-b05b-4c68194a9be3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f4380522-70c7-4442-87b2-df743eb7b811" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7655aa3b-6de8-49c2-b8c6-90aad647546a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7d4306da-2e16-435b-b05b-4c68194a9be3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7655aa3b-6de8-49c2-b8c6-90aad647546a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_b676099e-53a9-45d8-b58a-2844fe1eafb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7d4306da-2e16-435b-b05b-4c68194a9be3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_b676099e-53a9-45d8-b58a-2844fe1eafb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7b3e7cad-89b2-4166-9280-5f3097dd2f05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7d4306da-2e16-435b-b05b-4c68194a9be3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7b3e7cad-89b2-4166-9280-5f3097dd2f05" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_82aafe3d-95ab-4dcf-9caa-4b946b3e3968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_42056a2f-5645-4aa2-b57c-38dba4d9f2cc" xlink:href="bhc-20211231.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_82aafe3d-95ab-4dcf-9caa-4b946b3e3968" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_42056a2f-5645-4aa2-b57c-38dba4d9f2cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_6f759536-9f61-4855-a7b0-9b7084bab76d" xlink:href="bhc-20211231.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_82aafe3d-95ab-4dcf-9caa-4b946b3e3968" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_6f759536-9f61-4855-a7b0-9b7084bab76d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c647bef0-3273-4b57-85ee-8b2ceed58a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_e5c584f3-7cc9-49b6-8ff8-b7ec9b7e8313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_c647bef0-3273-4b57-85ee-8b2ceed58a03" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_e5c584f3-7cc9-49b6-8ff8-b7ec9b7e8313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_e9746fd1-6f78-483a-bae3-f404413433c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_c647bef0-3273-4b57-85ee-8b2ceed58a03" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_e9746fd1-6f78-483a-bae3-f404413433c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_335e8227-2890-4447-9837-7694bd30f9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_c647bef0-3273-4b57-85ee-8b2ceed58a03" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_335e8227-2890-4447-9837-7694bd30f9aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_2bd4836d-3a12-40f3-88fc-5955b7257fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_c647bef0-3273-4b57-85ee-8b2ceed58a03" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_2bd4836d-3a12-40f3-88fc-5955b7257fc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherIncomeExpenseNet_2fe2e255-81a3-422a-9e55-c2de168edcfa" xlink:href="bhc-20211231.xsd#bhc_OtherIncomeExpenseNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_c647bef0-3273-4b57-85ee-8b2ceed58a03" xlink:to="loc_bhc_OtherIncomeExpenseNet_2fe2e255-81a3-422a-9e55-c2de168edcfa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_130ab8fc-ebb0-45b0-a5b9-bdcf37a39e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_24ad388e-0fc2-4aed-b143-33afcbef7247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_130ab8fc-ebb0-45b0-a5b9-bdcf37a39e4b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_24ad388e-0fc2-4aed-b143-33afcbef7247" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_c517998b-cebe-4a85-a427-9987fb6a534c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_130ab8fc-ebb0-45b0-a5b9-bdcf37a39e4b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_c517998b-cebe-4a85-a427-9987fb6a534c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_70b85bea-4022-4a3e-8e36-ac662a5da12c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_50820a0c-d40e-41c0-b8af-997320392522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_70b85bea-4022-4a3e-8e36-ac662a5da12c" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_50820a0c-d40e-41c0-b8af-997320392522" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_407802d5-a5e2-4bf0-96db-372843d0e537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_70b85bea-4022-4a3e-8e36-ac662a5da12c" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_407802d5-a5e2-4bf0-96db-372843d0e537" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ed133c11-e626-479e-9fd4-23a9d5d3fda8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_71885efb-825e-4f05-b653-b34e7d8ed49c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ed133c11-e626-479e-9fd4-23a9d5d3fda8" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_71885efb-825e-4f05-b653-b34e7d8ed49c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_f3bbceaf-10d9-45e1-a7b6-7db4af3b096f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ed133c11-e626-479e-9fd4-23a9d5d3fda8" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_f3bbceaf-10d9-45e1-a7b6-7db4af3b096f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_84cc2fb0-3cab-452d-9939-f689b665e3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0738209c-5e37-4261-a1c6-c4d9e5b4508a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_84cc2fb0-3cab-452d-9939-f689b665e3b9" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0738209c-5e37-4261-a1c6-c4d9e5b4508a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6f58128f-d6b7-4e5e-be3d-692e8486173a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_84cc2fb0-3cab-452d-9939-f689b665e3b9" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6f58128f-d6b7-4e5e-be3d-692e8486173a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9acd9cdd-4314-43fc-9840-c521cfd0c114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_d2a7a515-24df-4ce7-bfff-7cbc0e2fe58b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9acd9cdd-4314-43fc-9840-c521cfd0c114" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_d2a7a515-24df-4ce7-bfff-7cbc0e2fe58b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2881345d-59ce-448d-aa6f-ce75a5a45c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9acd9cdd-4314-43fc-9840-c521cfd0c114" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2881345d-59ce-448d-aa6f-ce75a5a45c8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount_25318371-6bb1-4671-b51b-ec8c4920c297" xlink:href="bhc-20211231.xsd#bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9acd9cdd-4314-43fc-9840-c521cfd0c114" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount_25318371-6bb1-4671-b51b-ec8c4920c297" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance_13b2c2b2-2a0f-47f3-80e3-4a076cb5ce3b" xlink:href="bhc-20211231.xsd#bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9acd9cdd-4314-43fc-9840-c521cfd0c114" xlink:to="loc_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance_13b2c2b2-2a0f-47f3-80e3-4a076cb5ce3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9ae0b41b-c9b3-4682-adcf-c8322a5caf20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9acd9cdd-4314-43fc-9840-c521cfd0c114" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9ae0b41b-c9b3-4682-adcf-c8322a5caf20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationUncertainTaxPositions_62ebbc47-7f48-4040-91a6-3af01a2a3743" xlink:href="bhc-20211231.xsd#bhc_IncomeTaxReconciliationUncertainTaxPositions"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9acd9cdd-4314-43fc-9840-c521cfd0c114" xlink:to="loc_bhc_IncomeTaxReconciliationUncertainTaxPositions_62ebbc47-7f48-4040-91a6-3af01a2a3743" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_8b3417f2-679a-429d-a78a-ef3571448557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9acd9cdd-4314-43fc-9840-c521cfd0c114" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_8b3417f2-679a-429d-a78a-ef3571448557" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_edeb98b0-d36c-4e5a-a3e0-2d36ba776438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9acd9cdd-4314-43fc-9840-c521cfd0c114" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_edeb98b0-d36c-4e5a-a3e0-2d36ba776438" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit_07e1d4ab-132b-430a-ad25-e745e2d47780" xlink:href="bhc-20211231.xsd#bhc_IncomeTaxReconciliationDeferredIntercompanyProfit"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9acd9cdd-4314-43fc-9840-c521cfd0c114" xlink:to="loc_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit_07e1d4ab-132b-430a-ad25-e745e2d47780" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_af5fec01-0a5e-4354-9db9-4c6a57f88ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9acd9cdd-4314-43fc-9840-c521cfd0c114" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_af5fec01-0a5e-4354-9db9-4c6a57f88ee0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ab29290c-306f-432e-98b6-5d634604a8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsTaxLossCarryforwards_97f98128-307d-4fd9-ac2d-e0b123d89348" xlink:href="bhc-20211231.xsd#bhc_DeferredTaxAssetsTaxLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ab29290c-306f-432e-98b6-5d634604a8b0" xlink:to="loc_bhc_DeferredTaxAssetsTaxLossCarryforwards_97f98128-307d-4fd9-ac2d-e0b123d89348" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_9185d234-1a13-49b7-bda7-57698ea317c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ab29290c-306f-432e-98b6-5d634604a8b0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_9185d234-1a13-49b7-bda7-57698ea317c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_a2d0bad8-e350-43bc-8db6-ee441f3f1eb8" xlink:href="bhc-20211231.xsd#bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ab29290c-306f-432e-98b6-5d634604a8b0" xlink:to="loc_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_a2d0bad8-e350-43bc-8db6-ee441f3f1eb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool_fa322dfd-a7a0-4c44-985e-f5390ebc9c94" xlink:href="bhc-20211231.xsd#bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ab29290c-306f-432e-98b6-5d634604a8b0" xlink:to="loc_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool_fa322dfd-a7a0-4c44-985e-f5390ebc9c94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_84977c2a-eccf-438f-bcb0-0ec099968c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ab29290c-306f-432e-98b6-5d634604a8b0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_84977c2a-eccf-438f-bcb0-0ec099968c21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_423d6923-7a84-4595-98e2-d069aed620c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ab29290c-306f-432e-98b6-5d634604a8b0" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_423d6923-7a84-4595-98e2-d069aed620c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsPrepaidExpenses_10fc8a2d-b2f8-4265-b27a-5da119cdbbb1" xlink:href="bhc-20211231.xsd#bhc_DeferredTaxAssetsPrepaidExpenses"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ab29290c-306f-432e-98b6-5d634604a8b0" xlink:to="loc_bhc_DeferredTaxAssetsPrepaidExpenses_10fc8a2d-b2f8-4265-b27a-5da119cdbbb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a97e4d8a-23a5-4303-8c5b-7a6b993d2370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ab29290c-306f-432e-98b6-5d634604a8b0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a97e4d8a-23a5-4303-8c5b-7a6b993d2370" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_a7e2ce1e-7e5b-425d-a1cf-3c8652a3443e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ab29290c-306f-432e-98b6-5d634604a8b0" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_a7e2ce1e-7e5b-425d-a1cf-3c8652a3443e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1e6a1611-4531-46e7-a664-9da855ba197d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_94fe96b9-7ad5-4483-989b-6bb0acd16095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1e6a1611-4531-46e7-a664-9da855ba197d" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_94fe96b9-7ad5-4483-989b-6bb0acd16095" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_21753b42-de58-4c86-b23d-3dc04c18f929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1e6a1611-4531-46e7-a664-9da855ba197d" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_21753b42-de58-4c86-b23d-3dc04c18f929" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_3bc4d02f-855f-46ef-a83c-302df0ad1c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_fc729175-018f-4688-92ba-a9d79f75a84c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_3bc4d02f-855f-46ef-a83c-302df0ad1c3a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_fc729175-018f-4688-92ba-a9d79f75a84c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes_204b8c7d-fc72-4b27-b20c-a7e5e7aef852" xlink:href="bhc-20211231.xsd#bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_3bc4d02f-855f-46ef-a83c-302df0ad1c3a" xlink:to="loc_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes_204b8c7d-fc72-4b27-b20c-a7e5e7aef852" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_2081ebce-a90b-4174-a8d6-8090b9e97252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_3bc4d02f-855f-46ef-a83c-302df0ad1c3a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_2081ebce-a90b-4174-a8d6-8090b9e97252" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_12954be8-b31b-48e2-a62f-315abca9a176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_3bc4d02f-855f-46ef-a83c-302df0ad1c3a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_12954be8-b31b-48e2-a62f-315abca9a176" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d50e0e2b-0822-44da-b677-40a23e827ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_6a47a235-1365-4099-8272-1a90403cffef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d50e0e2b-0822-44da-b677-40a23e827ecd" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_6a47a235-1365-4099-8272-1a90403cffef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5c685d38-b4fa-4eb7-a2f7-f9d16ccfd0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d50e0e2b-0822-44da-b677-40a23e827ecd" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_5c685d38-b4fa-4eb7-a2f7-f9d16ccfd0a9" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>bhc-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:cdc15979-c542-4d25-920c-73804898e32f,g:89bc1415-46fc-4aad-8e83-55f6d8df2ca2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20211231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="i45736579c4f242d8aa55b8ce61b6e833_CONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_0d1c1e78-d9db-40a3-b0d8-cc372780b2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_RevenuesAbstract_0d1c1e78-d9db-40a3-b0d8-cc372780b2ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_211b1aff-c708-4895-9f5a-bce0313d09f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_0d1c1e78-d9db-40a3-b0d8-cc372780b2ea" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_211b1aff-c708-4895-9f5a-bce0313d09f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_ed7f7de3-84eb-454f-87da-c48ad44ee179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_ed7f7de3-84eb-454f-87da-c48ad44ee179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d33305ca-43ef-4504-89c5-255de9343faa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ed7f7de3-84eb-454f-87da-c48ad44ee179" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d33305ca-43ef-4504-89c5-255de9343faa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9e286e8f-9773-42de-acea-68c80f9ada33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ed7f7de3-84eb-454f-87da-c48ad44ee179" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9e286e8f-9773-42de-acea-68c80f9ada33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ade018b8-4d7f-406d-91d2-24069d5654e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ed7f7de3-84eb-454f-87da-c48ad44ee179" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ade018b8-4d7f-406d-91d2-24069d5654e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_bbe8cc6a-71cb-466c-9734-d0ce229bfb45" xlink:href="bhc-20211231.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ed7f7de3-84eb-454f-87da-c48ad44ee179" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_bbe8cc6a-71cb-466c-9734-d0ce229bfb45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_a9ee2d44-17cb-4a21-8ca1-838754cc129f" xlink:href="bhc-20211231.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ed7f7de3-84eb-454f-87da-c48ad44ee179" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_a9ee2d44-17cb-4a21-8ca1-838754cc129f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_83e935f6-9f92-444a-83d5-9236250b84d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ed7f7de3-84eb-454f-87da-c48ad44ee179" xlink:to="loc_us-gaap_AssetImpairmentCharges_83e935f6-9f92-444a-83d5-9236250b84d1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_8c31cc29-aacf-4b1a-9335-15c7549f6ef9" xlink:href="bhc-20211231.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ed7f7de3-84eb-454f-87da-c48ad44ee179" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_8c31cc29-aacf-4b1a-9335-15c7549f6ef9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_412d1249-536b-4d9d-95bb-95e358ee6cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ed7f7de3-84eb-454f-87da-c48ad44ee179" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_412d1249-536b-4d9d-95bb-95e358ee6cd3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f06a2491-4cd4-4082-8f38-caffffcefe15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ed7f7de3-84eb-454f-87da-c48ad44ee179" xlink:to="loc_us-gaap_CostsAndExpenses_f06a2491-4cd4-4082-8f38-caffffcefe15" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3ad3bbb3-fb6f-47a9-85c2-0a4255547188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_OperatingIncomeLoss_3ad3bbb3-fb6f-47a9-85c2-0a4255547188" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_389ea205-6281-4f15-a86a-4e96cc136f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_389ea205-6281-4f15-a86a-4e96cc136f4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_3d425156-3ea8-4441-9dee-c589f8cbceb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_InterestExpenseDebt_3d425156-3ea8-4441-9dee-c589f8cbceb2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_20f61d02-5a75-453a-965a-2fbfb896a0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_20f61d02-5a75-453a-965a-2fbfb896a0fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6562e68a-bcfa-4caa-98e1-2709abe956d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6562e68a-bcfa-4caa-98e1-2709abe956d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0e33409-478e-490e-af4c-e957fd70b9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0e33409-478e-490e-af4c-e957fd70b9d6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f3a612e4-770e-4af8-b571-8e44ca7f5fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f3a612e4-770e-4af8-b571-8e44ca7f5fd5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_92867897-8bdc-4560-97d0-2c54a59812bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_ProfitLoss_92867897-8bdc-4560-97d0-2c54a59812bd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f69e8fa7-6bef-43e8-ad62-4a302959cbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f69e8fa7-6bef-43e8-ad62-4a302959cbe4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_12837e14-3a22-403c-b3db-ad20656bae41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_NetIncomeLoss_12837e14-3a22-403c-b3db-ad20656bae41" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7b3b705e-8065-4e80-8c8f-a07c590f33be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_EarningsPerShareBasic_7b3b705e-8065-4e80-8c8f-a07c590f33be" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_be76dbe7-c87f-41e7-aaa3-a901f8b17651" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_be76dbe7-c87f-41e7-aaa3-a901f8b17651" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_296992f4-6602-46a5-8255-3a6ac8826dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_296992f4-6602-46a5-8255-3a6ac8826dab" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9fc495d7-1791-4d5c-b89c-ea14ab48dd32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9fc495d7-1791-4d5c-b89c-ea14ab48dd32" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_80434028-ab90-4729-8af8-6cfe3a2892ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_StatementTable_80434028-ab90-4729-8af8-6cfe3a2892ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_41dba26d-31a8-49ae-9e27-9f8540ca7153" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_80434028-ab90-4729-8af8-6cfe3a2892ac" xlink:to="loc_srt_ProductOrServiceAxis_41dba26d-31a8-49ae-9e27-9f8540ca7153" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_41dba26d-31a8-49ae-9e27-9f8540ca7153_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_41dba26d-31a8-49ae-9e27-9f8540ca7153" xlink:to="loc_srt_ProductsAndServicesDomain_41dba26d-31a8-49ae-9e27-9f8540ca7153_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f1488216-e568-4a8c-9f3e-19fcbc7952a6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_41dba26d-31a8-49ae-9e27-9f8540ca7153" xlink:to="loc_srt_ProductsAndServicesDomain_f1488216-e568-4a8c-9f3e-19fcbc7952a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_fc280fa8-554d-4071-b48d-959c9b8a0ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1488216-e568-4a8c-9f3e-19fcbc7952a6" xlink:to="loc_us-gaap_ProductMember_fc280fa8-554d-4071-b48d-959c9b8a0ffe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_0bd0239c-8fc6-4ac1-a069-e417cf9dec2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1488216-e568-4a8c-9f3e-19fcbc7952a6" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_0bd0239c-8fc6-4ac1-a069-e417cf9dec2e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="bhc-20211231.xsd#CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="extended" id="i68528badd17e46508d7ffa274e8a4324_CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dfe5a18b-14dd-4f23-ae4b-36ba856c32b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dfe5a18b-14dd-4f23-ae4b-36ba856c32b7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_57627746-39b4-4f32-aebd-f79bb827f3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_CommonStockSharesIssued_57627746-39b4-4f32-aebd-f79bb827f3e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6bc95bde-a148-4501-8256-efdd8f494968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6bc95bde-a148-4501-8256-efdd8f494968" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_3e1976cd-133e-44fc-8b06-d8f41dd1a4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_3e1976cd-133e-44fc-8b06-d8f41dd1a4dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5e13c087-c086-4739-9f48-74b564990eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5e13c087-c086-4739-9f48-74b564990eda" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f62c51c5-9421-42e5-8463-2c6f1410b7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f62c51c5-9421-42e5-8463-2c6f1410b7c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b3990cf0-9108-4950-ab77-34e367a3d414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b3990cf0-9108-4950-ab77-34e367a3d414" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8667af72-b3f7-4937-90f9-a641cdaa60b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8667af72-b3f7-4937-90f9-a641cdaa60b5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_3b0073c3-e7dc-4007-91e9-9195c6c3bf4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_3b0073c3-e7dc-4007-91e9-9195c6c3bf4d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0fe9a0e9-61fc-4b40-9a94-a04cf338bee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0fe9a0e9-61fc-4b40-9a94-a04cf338bee7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c812adc7-72ab-47d6-940a-37cb546a18c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_ProfitLoss_c812adc7-72ab-47d6-940a-37cb546a18c4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ce43eb86-9c71-433b-9b8b-a5414f7b9416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ce43eb86-9c71-433b-9b8b-a5414f7b9416" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cbf7f824-4dd6-4325-b9ee-cd602fa8d13a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6bc3f42c-c5d8-483f-b4dc-ea64b7a28311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_39068060-39af-4cf6-ae4d-25861bbbc80a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_dfe5a18b-14dd-4f23-ae4b-36ba856c32b7" xlink:to="loc_us-gaap_StatementTable_39068060-39af-4cf6-ae4d-25861bbbc80a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_62b30b7d-788b-4731-9c33-94c7d7145e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_39068060-39af-4cf6-ae4d-25861bbbc80a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_62b30b7d-788b-4731-9c33-94c7d7145e6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_62b30b7d-788b-4731-9c33-94c7d7145e6e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_62b30b7d-788b-4731-9c33-94c7d7145e6e" xlink:to="loc_us-gaap_EquityComponentDomain_62b30b7d-788b-4731-9c33-94c7d7145e6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7835a223-6458-4b92-96f2-1155d868d5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_62b30b7d-788b-4731-9c33-94c7d7145e6e" xlink:to="loc_us-gaap_EquityComponentDomain_7835a223-6458-4b92-96f2-1155d868d5e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_9ab5c19f-dc64-4379-accc-c24460d6a083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7835a223-6458-4b92-96f2-1155d868d5e0" xlink:to="loc_us-gaap_ParentMember_9ab5c19f-dc64-4379-accc-c24460d6a083" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_44541c63-4ff8-4241-bfc8-093078e95955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_9ab5c19f-dc64-4379-accc-c24460d6a083" xlink:to="loc_us-gaap_CommonStockMember_44541c63-4ff8-4241-bfc8-093078e95955" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_900c03a6-980a-4800-87fb-025c50c4a0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_9ab5c19f-dc64-4379-accc-c24460d6a083" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_900c03a6-980a-4800-87fb-025c50c4a0a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2eb6c755-26c5-428a-a759-e3d3c30a0e29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_9ab5c19f-dc64-4379-accc-c24460d6a083" xlink:to="loc_us-gaap_RetainedEarningsMember_2eb6c755-26c5-428a-a759-e3d3c30a0e29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b810dcd3-56f8-4f1f-8da1-7181c3cfcfe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_9ab5c19f-dc64-4379-accc-c24460d6a083" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b810dcd3-56f8-4f1f-8da1-7181c3cfcfe5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_3de9db06-2a6c-4f1a-8b21-295e567a84fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7835a223-6458-4b92-96f2-1155d868d5e0" xlink:to="loc_us-gaap_NoncontrollingInterestMember_3de9db06-2a6c-4f1a-8b21-295e567a84fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a8ca315a-a707-444d-8b68-30b1114a1251" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_39068060-39af-4cf6-ae4d-25861bbbc80a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a8ca315a-a707-444d-8b68-30b1114a1251" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a8ca315a-a707-444d-8b68-30b1114a1251_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a8ca315a-a707-444d-8b68-30b1114a1251" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a8ca315a-a707-444d-8b68-30b1114a1251_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_379037c4-bb3a-477f-9dd1-da22590e2989" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a8ca315a-a707-444d-8b68-30b1114a1251" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_379037c4-bb3a-477f-9dd1-da22590e2989" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4ef056cf-a946-4d5a-8cdc-b8ec0e43bd99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_379037c4-bb3a-477f-9dd1-da22590e2989" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4ef056cf-a946-4d5a-8cdc-b8ec0e43bd99" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" xlink:type="extended" id="i4615e973dfaf4cf48937af47b3e51466_SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_383a7d4e-16c9-46ba-9235-6c9caea08ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents_4a97ecfb-0746-4d0e-b869-d9497782565d" xlink:href="bhc-20211231.xsd#bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_383a7d4e-16c9-46ba-9235-6c9caea08ac8" xlink:to="loc_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents_4a97ecfb-0746-4d0e-b869-d9497782565d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NumberOfLargestWholesaleCustomers_562432a8-08bf-4561-a0f2-a0fc0ecca22f" xlink:href="bhc-20211231.xsd#bhc_NumberOfLargestWholesaleCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_383a7d4e-16c9-46ba-9235-6c9caea08ac8" xlink:to="loc_bhc_NumberOfLargestWholesaleCustomers_562432a8-08bf-4561-a0f2-a0fc0ecca22f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskPercentageofNetTradeReceivables_e495ece5-f0b7-43f3-bd74-f95c813075db" xlink:href="bhc-20211231.xsd#bhc_ConcentrationRiskPercentageofNetTradeReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_383a7d4e-16c9-46ba-9235-6c9caea08ac8" xlink:to="loc_bhc_ConcentrationRiskPercentageofNetTradeReceivables_e495ece5-f0b7-43f3-bd74-f95c813075db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8ab33496-f429-4702-bc80-fcc8f2d8cf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_383a7d4e-16c9-46ba-9235-6c9caea08ac8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8ab33496-f429-4702-bc80-fcc8f2d8cf6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PastDuePeriodForAccountsReceivableToBeNegligible_2bccbdca-5234-4dfa-91d4-a0a59b0c3b54" xlink:href="bhc-20211231.xsd#bhc_PastDuePeriodForAccountsReceivableToBeNegligible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_383a7d4e-16c9-46ba-9235-6c9caea08ac8" xlink:to="loc_bhc_PastDuePeriodForAccountsReceivableToBeNegligible_2bccbdca-5234-4dfa-91d4-a0a59b0c3b54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PeriodReceivableOutstanding_278d75ab-3949-496c-b930-4fbf3161c8b6" xlink:href="bhc-20211231.xsd#bhc_PeriodReceivableOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_383a7d4e-16c9-46ba-9235-6c9caea08ac8" xlink:to="loc_bhc_PeriodReceivableOutstanding_278d75ab-3949-496c-b930-4fbf3161c8b6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TradeReceivableNetPortionPastDue_835acacb-425e-436f-ad2a-62e0972e7083" xlink:href="bhc-20211231.xsd#bhc_TradeReceivableNetPortionPastDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_383a7d4e-16c9-46ba-9235-6c9caea08ac8" xlink:to="loc_bhc_TradeReceivableNetPortionPastDue_835acacb-425e-436f-ad2a-62e0972e7083" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_13c2769d-33f9-460d-b473-79570e5cf182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_383a7d4e-16c9-46ba-9235-6c9caea08ac8" xlink:to="loc_us-gaap_ConcentrationRiskTable_13c2769d-33f9-460d-b473-79570e5cf182" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41eb44af-7525-45aa-8522-071d95153881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_13c2769d-33f9-460d-b473-79570e5cf182" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41eb44af-7525-45aa-8522-071d95153881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_41eb44af-7525-45aa-8522-071d95153881_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41eb44af-7525-45aa-8522-071d95153881" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_41eb44af-7525-45aa-8522-071d95153881_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9fe80698-c05e-4ea6-aae2-b0618d2d4120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41eb44af-7525-45aa-8522-071d95153881" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9fe80698-c05e-4ea6-aae2-b0618d2d4120" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_dd8d2b51-9bd2-4f0b-b9cb-14194f5102dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9fe80698-c05e-4ea6-aae2-b0618d2d4120" xlink:to="loc_us-gaap_AccountsReceivableMember_dd8d2b51-9bd2-4f0b-b9cb-14194f5102dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b6d93261-f65a-44ec-aa05-9b1d8b226556" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_13c2769d-33f9-460d-b473-79570e5cf182" xlink:to="loc_srt_MajorCustomersAxis_b6d93261-f65a-44ec-aa05-9b1d8b226556" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b6d93261-f65a-44ec-aa05-9b1d8b226556_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_b6d93261-f65a-44ec-aa05-9b1d8b226556" xlink:to="loc_srt_NameOfMajorCustomerDomain_b6d93261-f65a-44ec-aa05-9b1d8b226556_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0f02794c-7d52-481c-8386-fd8d4d04a149" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_b6d93261-f65a-44ec-aa05-9b1d8b226556" xlink:to="loc_srt_NameOfMajorCustomerDomain_0f02794c-7d52-481c-8386-fd8d4d04a149" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ThreeLargestUSWholesalerCustomersMember_e5c90601-f48f-48c9-9b2a-29c424fdbaac" xlink:href="bhc-20211231.xsd#bhc_ThreeLargestUSWholesalerCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0f02794c-7d52-481c-8386-fd8d4d04a149" xlink:to="loc_bhc_ThreeLargestUSWholesalerCustomersMember_e5c90601-f48f-48c9-9b2a-29c424fdbaac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_3117ce54-71b3-4f90-8a67-58e6598851c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_13c2769d-33f9-460d-b473-79570e5cf182" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_3117ce54-71b3-4f90-8a67-58e6598851c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3117ce54-71b3-4f90-8a67-58e6598851c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3117ce54-71b3-4f90-8a67-58e6598851c6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3117ce54-71b3-4f90-8a67-58e6598851c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a0299a51-15c6-4738-b5e3-fdcf7738f134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3117ce54-71b3-4f90-8a67-58e6598851c6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a0299a51-15c6-4738-b5e3-fdcf7738f134" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_707a1700-8135-4fe7-a0b0-0845090321a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a0299a51-15c6-4738-b5e3-fdcf7738f134" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_707a1700-8135-4fe7-a0b0-0845090321a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_29edc6ad-3922-47b9-a870-1e6f67023e99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_13c2769d-33f9-460d-b473-79570e5cf182" xlink:to="loc_srt_StatementGeographicalAxis_29edc6ad-3922-47b9-a870-1e6f67023e99" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_29edc6ad-3922-47b9-a870-1e6f67023e99_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_29edc6ad-3922-47b9-a870-1e6f67023e99" xlink:to="loc_srt_SegmentGeographicalDomain_29edc6ad-3922-47b9-a870-1e6f67023e99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b1b53f95-0e92-41e3-b8e1-f2195f4f671a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_29edc6ad-3922-47b9-a870-1e6f67023e99" xlink:to="loc_srt_SegmentGeographicalDomain_b1b53f95-0e92-41e3-b8e1-f2195f4f671a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember_4d1794c3-e19d-47fb-b9fa-fd0f88b7f683" xlink:href="bhc-20211231.xsd#bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b1b53f95-0e92-41e3-b8e1-f2195f4f671a" xlink:to="loc_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember_4d1794c3-e19d-47fb-b9fa-fd0f88b7f683" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" xlink:type="extended" id="i1c7fe70d765d400fb46a0078645c01b5_SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6dc742b-aae6-439c-b0e0-41ac3ed4aad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_db07faec-8c6f-455d-a8ee-77c8dfcbd987" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6dc742b-aae6-439c-b0e0-41ac3ed4aad9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_db07faec-8c6f-455d-a8ee-77c8dfcbd987" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6476d4ed-77bd-4661-a784-afc0322a90ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6dc742b-aae6-439c-b0e0-41ac3ed4aad9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6476d4ed-77bd-4661-a784-afc0322a90ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5a6d8f88-e67d-472c-ac9b-229f3cdba543" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6476d4ed-77bd-4661-a784-afc0322a90ae" xlink:to="loc_srt_RangeAxis_5a6d8f88-e67d-472c-ac9b-229f3cdba543" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5a6d8f88-e67d-472c-ac9b-229f3cdba543_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5a6d8f88-e67d-472c-ac9b-229f3cdba543" xlink:to="loc_srt_RangeMember_5a6d8f88-e67d-472c-ac9b-229f3cdba543_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e65db82c-586d-4f28-b4df-b6ab2a40c8da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5a6d8f88-e67d-472c-ac9b-229f3cdba543" xlink:to="loc_srt_RangeMember_e65db82c-586d-4f28-b4df-b6ab2a40c8da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cddfe035-a4aa-4dfe-9ca1-6ac7dbed0420" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e65db82c-586d-4f28-b4df-b6ab2a40c8da" xlink:to="loc_srt_MinimumMember_cddfe035-a4aa-4dfe-9ca1-6ac7dbed0420" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_352cbf5a-8f67-4371-94b4-1e3f68dc5e03" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e65db82c-586d-4f28-b4df-b6ab2a40c8da" xlink:to="loc_srt_MaximumMember_352cbf5a-8f67-4371-94b4-1e3f68dc5e03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c9d6148a-c94a-4681-a41c-85b1c136b38f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6476d4ed-77bd-4661-a784-afc0322a90ae" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c9d6148a-c94a-4681-a41c-85b1c136b38f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c9d6148a-c94a-4681-a41c-85b1c136b38f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c9d6148a-c94a-4681-a41c-85b1c136b38f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c9d6148a-c94a-4681-a41c-85b1c136b38f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c860f05d-74cd-4f83-ae62-29d03e160de3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c9d6148a-c94a-4681-a41c-85b1c136b38f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c860f05d-74cd-4f83-ae62-29d03e160de3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandImprovementsMember_1192c9ff-2361-4765-a4f1-1a5fa93590ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c860f05d-74cd-4f83-ae62-29d03e160de3" xlink:to="loc_us-gaap_LandImprovementsMember_1192c9ff-2361-4765-a4f1-1a5fa93590ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_56ca9c46-7569-40a7-9489-994e1b92873a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c860f05d-74cd-4f83-ae62-29d03e160de3" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_56ca9c46-7569-40a7-9489-994e1b92873a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_91a13076-0765-42c3-a477-9942c552b78e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c860f05d-74cd-4f83-ae62-29d03e160de3" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_91a13076-0765-42c3-a477-9942c552b78e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_c9d6f584-1ef3-49fd-b9ca-0d003e9a7220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c860f05d-74cd-4f83-ae62-29d03e160de3" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_c9d6f584-1ef3-49fd-b9ca-0d003e9a7220" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EquipmentOnOperatingLeaseMember_75ff3de2-8689-4452-bfe6-e08b22511b6d" xlink:href="bhc-20211231.xsd#bhc_EquipmentOnOperatingLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c860f05d-74cd-4f83-ae62-29d03e160de3" xlink:to="loc_bhc_EquipmentOnOperatingLeaseMember_75ff3de2-8689-4452-bfe6-e08b22511b6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_df00dcb2-5c82-485b-94fd-df2a898e7d82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c860f05d-74cd-4f83-ae62-29d03e160de3" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_df00dcb2-5c82-485b-94fd-df2a898e7d82" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" xlink:type="extended" id="i389c224d56d54a66aedf1187216840ef_SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f2989966-f807-4d4b-a65e-56ad40c039b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d5bb283d-6a09-4d99-8cc4-c67f943ed42f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f2989966-f807-4d4b-a65e-56ad40c039b1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d5bb283d-6a09-4d99-8cc4-c67f943ed42f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7baa92f3-31ee-48f8-9dac-93b9bb50d4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f2989966-f807-4d4b-a65e-56ad40c039b1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7baa92f3-31ee-48f8-9dac-93b9bb50d4fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d07aad69-0627-4e4b-8f6c-e85e60123798" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7baa92f3-31ee-48f8-9dac-93b9bb50d4fa" xlink:to="loc_srt_RangeAxis_d07aad69-0627-4e4b-8f6c-e85e60123798" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d07aad69-0627-4e4b-8f6c-e85e60123798_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d07aad69-0627-4e4b-8f6c-e85e60123798" xlink:to="loc_srt_RangeMember_d07aad69-0627-4e4b-8f6c-e85e60123798_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3a0e9d11-af1b-4f2a-80f4-ed476d3f4a9c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d07aad69-0627-4e4b-8f6c-e85e60123798" xlink:to="loc_srt_RangeMember_3a0e9d11-af1b-4f2a-80f4-ed476d3f4a9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_036eb790-9483-4296-b89d-9922e40cc080" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3a0e9d11-af1b-4f2a-80f4-ed476d3f4a9c" xlink:to="loc_srt_MinimumMember_036eb790-9483-4296-b89d-9922e40cc080" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c026f5a5-038f-4d82-8f2c-e37f9594359d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3a0e9d11-af1b-4f2a-80f4-ed476d3f4a9c" xlink:to="loc_srt_MaximumMember_c026f5a5-038f-4d82-8f2c-e37f9594359d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_436738d6-cc1a-45c1-bdfd-4307ecb1cf01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7baa92f3-31ee-48f8-9dac-93b9bb50d4fa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_436738d6-cc1a-45c1-bdfd-4307ecb1cf01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_436738d6-cc1a-45c1-bdfd-4307ecb1cf01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_436738d6-cc1a-45c1-bdfd-4307ecb1cf01" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_436738d6-cc1a-45c1-bdfd-4307ecb1cf01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b465af46-ed10-49dd-9cfd-ed71c7a09d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_436738d6-cc1a-45c1-bdfd-4307ecb1cf01" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b465af46-ed10-49dd-9cfd-ed71c7a09d8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_539dceb9-fb66-458d-83ab-3fc37f5c2e31" xlink:href="bhc-20211231.xsd#bhc_ProductBrandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b465af46-ed10-49dd-9cfd-ed71c7a09d8e" xlink:to="loc_bhc_ProductBrandsMember_539dceb9-fb66-458d-83ab-3fc37f5c2e31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_bf16f2e8-3e0b-4535-ac03-1f0a41bf09c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b465af46-ed10-49dd-9cfd-ed71c7a09d8e" xlink:to="loc_us-gaap_TradeNamesMember_bf16f2e8-3e0b-4535-ac03-1f0a41bf09c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_a439a502-bd7f-4913-a489-3f02e36b7b12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b465af46-ed10-49dd-9cfd-ed71c7a09d8e" xlink:to="loc_us-gaap_ContractualRightsMember_a439a502-bd7f-4913-a489-3f02e36b7b12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember_ff7e99a5-a3ea-4ae7-a2c3-2dc3384cd704" xlink:href="bhc-20211231.xsd#bhc_PartnerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b465af46-ed10-49dd-9cfd-ed71c7a09d8e" xlink:to="loc_bhc_PartnerRelationshipsMember_ff7e99a5-a3ea-4ae7-a2c3-2dc3384cd704" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember_644eca12-e7f8-4864-85c9-77a70ad45440" xlink:href="bhc-20211231.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b465af46-ed10-49dd-9cfd-ed71c7a09d8e" xlink:to="loc_bhc_OutLicensedTechnologyMember_644eca12-e7f8-4864-85c9-77a70ad45440" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" xlink:type="extended" id="ic52d9086c84d4899b836d3094298a14e_SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d170b570-9374-44ea-b1df-09cf1ba823f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_10917038-6220-47f8-b9fa-8a167de62fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d170b570-9374-44ea-b1df-09cf1ba823f2" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_10917038-6220-47f8-b9fa-8a167de62fc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_374af331-73b3-4065-b0ce-ef75e478153a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_10917038-6220-47f8-b9fa-8a167de62fc9" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_374af331-73b3-4065-b0ce-ef75e478153a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_0c36ba1b-16d6-491f-9375-dfdac4db99f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_10917038-6220-47f8-b9fa-8a167de62fc9" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_0c36ba1b-16d6-491f-9375-dfdac4db99f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_31c5e280-5de3-4a4a-b0fd-6a2162b0aa86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_10917038-6220-47f8-b9fa-8a167de62fc9" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_31c5e280-5de3-4a4a-b0fd-6a2162b0aa86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_6cc7582d-c195-45dd-8895-f8f1ec6d6f53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_09414784-ce8e-4bbb-a63b-de979a6e8088" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d170b570-9374-44ea-b1df-09cf1ba823f2" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_09414784-ce8e-4bbb-a63b-de979a6e8088" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_55aab197-f4df-4352-983f-86cebfd7ddba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_09414784-ce8e-4bbb-a63b-de979a6e8088" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_55aab197-f4df-4352-983f-86cebfd7ddba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_55aab197-f4df-4352-983f-86cebfd7ddba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_55aab197-f4df-4352-983f-86cebfd7ddba" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_55aab197-f4df-4352-983f-86cebfd7ddba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8b25de3a-08ef-4839-a0af-162359e464b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_55aab197-f4df-4352-983f-86cebfd7ddba" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8b25de3a-08ef-4839-a0af-162359e464b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember_661c259f-614d-4b02-afc7-f12fb62c2e06" xlink:href="bhc-20211231.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8b25de3a-08ef-4839-a0af-162359e464b3" xlink:to="loc_bhc_ReserveForDiscountsAndAllowancesMember_661c259f-614d-4b02-afc7-f12fb62c2e06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_f2ca39fe-823e-4717-b0ca-534b2bf81d20" xlink:href="bhc-20211231.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8b25de3a-08ef-4839-a0af-162359e464b3" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_f2ca39fe-823e-4717-b0ca-534b2bf81d20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember_ce29bf34-7cfe-4216-b151-131211af24a2" xlink:href="bhc-20211231.xsd#bhc_ReserveForRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8b25de3a-08ef-4839-a0af-162359e464b3" xlink:to="loc_bhc_ReserveForRebatesMember_ce29bf34-7cfe-4216-b151-131211af24a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember_e4a3a640-1cd8-4ce2-9597-edce3166163b" xlink:href="bhc-20211231.xsd#bhc_ReserveForChargebacksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8b25de3a-08ef-4839-a0af-162359e464b3" xlink:to="loc_bhc_ReserveForChargebacksMember_e4a3a640-1cd8-4ce2-9597-edce3166163b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember_748e2e08-29b6-48b9-a695-20906a07ca55" xlink:href="bhc-20211231.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8b25de3a-08ef-4839-a0af-162359e464b3" xlink:to="loc_bhc_ReserveForDistributionFeesMember_748e2e08-29b6-48b9-a695-20906a07ca55" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="extended" id="i68678ec48fdf4e98aa349d51ce0a2a62_SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_faa984f4-e547-4985-94df-e7161c4c534c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_6066a457-3ad6-46e9-88cb-b16c75534a38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_faa984f4-e547-4985-94df-e7161c4c534c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_6066a457-3ad6-46e9-88cb-b16c75534a38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CashDiscountsAndAllowancesSettlementPeriod_49e3fdc4-7b7a-4882-bb92-c5ba6e993a5f" xlink:href="bhc-20211231.xsd#bhc_CashDiscountsAndAllowancesSettlementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_faa984f4-e547-4985-94df-e7161c4c534c" xlink:to="loc_bhc_CashDiscountsAndAllowancesSettlementPeriod_49e3fdc4-7b7a-4882-bb92-c5ba6e993a5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax_9ced7e66-0909-4d9a-a86c-f6dfcff9f410" xlink:href="bhc-20211231.xsd#bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_faa984f4-e547-4985-94df-e7161c4c534c" xlink:to="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax_9ced7e66-0909-4d9a-a86c-f6dfcff9f410" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_1d43f463-77c5-4570-86c4-1182ccb634db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_faa984f4-e547-4985-94df-e7161c4c534c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_1d43f463-77c5-4570-86c4-1182ccb634db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_3b49a593-e458-437a-a596-c2664f0d77b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_faa984f4-e547-4985-94df-e7161c4c534c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_3b49a593-e458-437a-a596-c2664f0d77b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax_b9eea4d9-ffe7-4203-a75d-e9e161ca022f" xlink:href="bhc-20211231.xsd#bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_faa984f4-e547-4985-94df-e7161c4c534c" xlink:to="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax_b9eea4d9-ffe7-4203-a75d-e9e161ca022f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_28862b1f-801a-4a7d-b9e1-117feeffc72e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_faa984f4-e547-4985-94df-e7161c4c534c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_28862b1f-801a-4a7d-b9e1-117feeffc72e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuePerformanceObligationPaymentTerms_22f25c32-708c-4b32-85c2-365e39efcfef" xlink:href="bhc-20211231.xsd#bhc_RevenuePerformanceObligationPaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_faa984f4-e547-4985-94df-e7161c4c534c" xlink:to="loc_bhc_RevenuePerformanceObligationPaymentTerms_22f25c32-708c-4b32-85c2-365e39efcfef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a414bdb8-afe0-48d5-b2d0-2ceef31a1129" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_faa984f4-e547-4985-94df-e7161c4c534c" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a414bdb8-afe0-48d5-b2d0-2ceef31a1129" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1543e314-9482-4868-8ce9-4a9f6ce572be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a414bdb8-afe0-48d5-b2d0-2ceef31a1129" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1543e314-9482-4868-8ce9-4a9f6ce572be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_1543e314-9482-4868-8ce9-4a9f6ce572be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1543e314-9482-4868-8ce9-4a9f6ce572be" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_1543e314-9482-4868-8ce9-4a9f6ce572be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_1e49196a-75f7-4eba-84d1-5c7105582bff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1543e314-9482-4868-8ce9-4a9f6ce572be" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_1e49196a-75f7-4eba-84d1-5c7105582bff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_f00825b9-9d33-4dbc-9ba5-f570618daece" xlink:href="bhc-20211231.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1e49196a-75f7-4eba-84d1-5c7105582bff" xlink:to="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_f00825b9-9d33-4dbc-9ba5-f570618daece" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_77796abd-aec0-4c8b-9c7b-28a61076e38b" xlink:href="bhc-20211231.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1e49196a-75f7-4eba-84d1-5c7105582bff" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_77796abd-aec0-4c8b-9c7b-28a61076e38b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_396e7952-4ef4-487e-87af-4d202fc620b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a414bdb8-afe0-48d5-b2d0-2ceef31a1129" xlink:to="loc_srt_RangeAxis_396e7952-4ef4-487e-87af-4d202fc620b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_396e7952-4ef4-487e-87af-4d202fc620b6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_396e7952-4ef4-487e-87af-4d202fc620b6" xlink:to="loc_srt_RangeMember_396e7952-4ef4-487e-87af-4d202fc620b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_06443f2f-260f-4aa5-988a-af035e7281dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_396e7952-4ef4-487e-87af-4d202fc620b6" xlink:to="loc_srt_RangeMember_06443f2f-260f-4aa5-988a-af035e7281dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b54440e2-91fd-4512-b0fc-99fd29bfe228" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_06443f2f-260f-4aa5-988a-af035e7281dd" xlink:to="loc_srt_MinimumMember_b54440e2-91fd-4512-b0fc-99fd29bfe228" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_12b9e1c3-1d72-4aee-add1-d00c10d9800e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_06443f2f-260f-4aa5-988a-af035e7281dd" xlink:to="loc_srt_MaximumMember_12b9e1c3-1d72-4aee-add1-d00c10d9800e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_378faa77-f434-47db-bd76-425795821325" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a414bdb8-afe0-48d5-b2d0-2ceef31a1129" xlink:to="loc_srt_ProductOrServiceAxis_378faa77-f434-47db-bd76-425795821325" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_378faa77-f434-47db-bd76-425795821325_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_378faa77-f434-47db-bd76-425795821325" xlink:to="loc_srt_ProductsAndServicesDomain_378faa77-f434-47db-bd76-425795821325_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_25489d7b-cba5-438e-955d-1196cdf6aec1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_378faa77-f434-47db-bd76-425795821325" xlink:to="loc_srt_ProductsAndServicesDomain_25489d7b-cba5-438e-955d-1196cdf6aec1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember_8b9c522c-0d0c-4850-ba9f-f81b73a82b36" xlink:href="bhc-20211231.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_25489d7b-cba5-438e-955d-1196cdf6aec1" xlink:to="loc_bhc_PriceAppreciationCreditMember_8b9c522c-0d0c-4850-ba9f-f81b73a82b36" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" xlink:type="extended" id="i8efb552d77da485897f04cab4b2ad37c_SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_35152975-c67a-4994-b38f-e9a1a838ba0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_370e2817-ec37-4582-9412-3d763a2adf0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35152975-c67a-4994-b38f-e9a1a838ba0a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_370e2817-ec37-4582-9412-3d763a2adf0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_555e6cca-4c5c-437e-8398-57a0958ddf41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35152975-c67a-4994-b38f-e9a1a838ba0a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_555e6cca-4c5c-437e-8398-57a0958ddf41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_7190e02e-788b-4e63-b5ed-67fea4d401d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35152975-c67a-4994-b38f-e9a1a838ba0a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_7190e02e-788b-4e63-b5ed-67fea4d401d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_000126db-fc05-4c14-9970-ae46be276e80" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7190e02e-788b-4e63-b5ed-67fea4d401d2" xlink:to="loc_srt_RangeAxis_000126db-fc05-4c14-9970-ae46be276e80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_000126db-fc05-4c14-9970-ae46be276e80_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_000126db-fc05-4c14-9970-ae46be276e80" xlink:to="loc_srt_RangeMember_000126db-fc05-4c14-9970-ae46be276e80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_13d62656-ab23-4baf-bf48-e43fb982ab55" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_000126db-fc05-4c14-9970-ae46be276e80" xlink:to="loc_srt_RangeMember_13d62656-ab23-4baf-bf48-e43fb982ab55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_33e5668d-8dd1-47db-b1cb-b1b55b417313" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_13d62656-ab23-4baf-bf48-e43fb982ab55" xlink:to="loc_srt_MinimumMember_33e5668d-8dd1-47db-b1cb-b1b55b417313" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4eaf13c6-ca0c-4586-af0d-82ae8017a40c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_13d62656-ab23-4baf-bf48-e43fb982ab55" xlink:to="loc_srt_MaximumMember_4eaf13c6-ca0c-4586-af0d-82ae8017a40c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails" xlink:type="extended" id="iea4ca4937c93498e8409103ac76d1228_SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f5f7cb77-a5a2-46b0-b1f2-6d2519d1108f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_662d4006-0050-4d74-b2c2-04653f53b572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f5f7cb77-a5a2-46b0-b1f2-6d2519d1108f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_662d4006-0050-4d74-b2c2-04653f53b572" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0fc58e0c-2653-498f-b40c-aebf27228971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f5f7cb77-a5a2-46b0-b1f2-6d2519d1108f" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0fc58e0c-2653-498f-b40c-aebf27228971" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a8a82fce-314f-43f5-b377-beb5db84c1b5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0fc58e0c-2653-498f-b40c-aebf27228971" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a8a82fce-314f-43f5-b377-beb5db84c1b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a8a82fce-314f-43f5-b377-beb5db84c1b5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a8a82fce-314f-43f5-b377-beb5db84c1b5" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a8a82fce-314f-43f5-b377-beb5db84c1b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5dbb36aa-4c20-44d5-a7df-af6c5d0b49d0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a8a82fce-314f-43f5-b377-beb5db84c1b5" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5dbb36aa-4c20-44d5-a7df-af6c5d0b49d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_56514892-7552-4b83-b1d1-923a82187d7c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5dbb36aa-4c20-44d5-a7df-af6c5d0b49d0" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_56514892-7552-4b83-b1d1-923a82187d7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e2c1f5c3-fb82-43de-81cf-e8f8f0704930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0fc58e0c-2653-498f-b40c-aebf27228971" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e2c1f5c3-fb82-43de-81cf-e8f8f0704930" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e2c1f5c3-fb82-43de-81cf-e8f8f0704930_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e2c1f5c3-fb82-43de-81cf-e8f8f0704930" xlink:to="loc_us-gaap_EquityComponentDomain_e2c1f5c3-fb82-43de-81cf-e8f8f0704930_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4a03b68e-7baa-4411-ac6c-9feb4053c1da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e2c1f5c3-fb82-43de-81cf-e8f8f0704930" xlink:to="loc_us-gaap_EquityComponentDomain_4a03b68e-7baa-4411-ac6c-9feb4053c1da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3bdf43d9-1a5f-4267-9ee2-a7342a3ad2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4a03b68e-7baa-4411-ac6c-9feb4053c1da" xlink:to="loc_us-gaap_RetainedEarningsMember_3bdf43d9-1a5f-4267-9ee2-a7342a3ad2c9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="extended" id="ic708b6c7f064481496e44bd8418f20bb_ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_a66b7959-882b-4a29-aae3-f1e055903b67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_a66b7959-882b-4a29-aae3-f1e055903b67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_68342cf6-5ae6-4ce6-874b-6d1dad7a472e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_68342cf6-5ae6-4ce6-874b-6d1dad7a472e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_7248b2a0-b11b-4191-9fad-ae9bc253ab42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_7248b2a0-b11b-4191-9fad-ae9bc253ab42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss_df986f9a-c686-4290-bb97-e97e03d5b703" xlink:href="bhc-20211231.xsd#bhc_BusinessAcquisitionProFormaOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss_df986f9a-c686-4290-bb97-e97e03d5b703" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual_f40b1318-a1cb-4276-9292-9653f80cc8ff" xlink:href="bhc-20211231.xsd#bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual_f40b1318-a1cb-4276-9292-9653f80cc8ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_564e3daa-8ba0-4d93-99b4-bf464f23cfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_564e3daa-8ba0-4d93-99b4-bf464f23cfdb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NumberOfOtherBusinessesAcquired_6e84cc47-7ea6-4333-a64a-b41e6187f424" xlink:href="bhc-20211231.xsd#bhc_NumberOfOtherBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_bhc_NumberOfOtherBusinessesAcquired_6e84cc47-7ea6-4333-a64a-b41e6187f424" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_ee504fbf-aa67-4d89-87e2-c8199e3f6f02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_ee504fbf-aa67-4d89-87e2-c8199e3f6f02" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_d83e791b-97ca-475d-ad5b-1583bb479df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_d83e791b-97ca-475d-ad5b-1583bb479df9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected_f4d8e33e-2748-4442-9661-f7b629b99034" xlink:href="bhc-20211231.xsd#bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected_f4d8e33e-2748-4442-9661-f7b629b99034" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_970e2cb0-acb1-4ba3-b72a-d5b903fb27dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_970e2cb0-acb1-4ba3-b72a-d5b903fb27dd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_24762880-7ef9-4f52-89e0-7a0b50b58703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_24762880-7ef9-4f52-89e0-7a0b50b58703" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NoncashCumulativeForeignCurrencyTranslationLoss_91380459-a4db-4309-923f-7f70c808f3e9" xlink:href="bhc-20211231.xsd#bhc_NoncashCumulativeForeignCurrencyTranslationLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_bhc_NoncashCumulativeForeignCurrencyTranslationLoss_91380459-a4db-4309-923f-7f70c808f3e9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f36fe54d-f562-4a89-a3c7-29aaa69e745e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f36fe54d-f562-4a89-a3c7-29aaa69e745e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d5b62e75-ffd0-454a-8e0e-72c53e646881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f36fe54d-f562-4a89-a3c7-29aaa69e745e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d5b62e75-ffd0-454a-8e0e-72c53e646881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5b62e75-ffd0-454a-8e0e-72c53e646881_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d5b62e75-ffd0-454a-8e0e-72c53e646881" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5b62e75-ffd0-454a-8e0e-72c53e646881_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1992920c-9ed1-48d6-a25d-f7e23ac15ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d5b62e75-ffd0-454a-8e0e-72c53e646881" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1992920c-9ed1-48d6-a25d-f7e23ac15ba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SynergyPharmaceuticalsInc.Member_e6c333f0-a5b3-4d41-b10d-78c6a53bd8b3" xlink:href="bhc-20211231.xsd#bhc_SynergyPharmaceuticalsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1992920c-9ed1-48d6-a25d-f7e23ac15ba6" xlink:to="loc_bhc_SynergyPharmaceuticalsInc.Member_e6c333f0-a5b3-4d41-b10d-78c6a53bd8b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_6383b567-fe47-40dd-9074-5a3e4da16aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f36fe54d-f562-4a89-a3c7-29aaa69e745e" xlink:to="loc_us-gaap_AssetAcquisitionAxis_6383b567-fe47-40dd-9074-5a3e4da16aa7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_6383b567-fe47-40dd-9074-5a3e4da16aa7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_6383b567-fe47-40dd-9074-5a3e4da16aa7" xlink:to="loc_us-gaap_AssetAcquisitionDomain_6383b567-fe47-40dd-9074-5a3e4da16aa7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_bdc73b7c-6a33-4700-98ce-a5ebb4712247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_6383b567-fe47-40dd-9074-5a3e4da16aa7" xlink:to="loc_us-gaap_AssetAcquisitionDomain_bdc73b7c-6a33-4700-98ce-a5ebb4712247" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllegroOphthalmicsLLCMember_df2bab5a-03b1-46d8-aaf5-378d9a9e5505" xlink:href="bhc-20211231.xsd#bhc_AllegroOphthalmicsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_bdc73b7c-6a33-4700-98ce-a5ebb4712247" xlink:to="loc_bhc_AllegroOphthalmicsLLCMember_df2bab5a-03b1-46d8-aaf5-378d9a9e5505" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_37c91b18-a055-4cf4-ad84-2de5c834b1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f36fe54d-f562-4a89-a3c7-29aaa69e745e" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_37c91b18-a055-4cf4-ad84-2de5c834b1e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_37c91b18-a055-4cf4-ad84-2de5c834b1e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_37c91b18-a055-4cf4-ad84-2de5c834b1e2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_37c91b18-a055-4cf4-ad84-2de5c834b1e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4e7901c3-7f1a-4da5-bc70-47238e2aca5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_37c91b18-a055-4cf4-ad84-2de5c834b1e2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4e7901c3-7f1a-4da5-bc70-47238e2aca5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_5ff33eaa-28dd-4555-9a35-dd95df8ebec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4e7901c3-7f1a-4da5-bc70-47238e2aca5e" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_5ff33eaa-28dd-4555-9a35-dd95df8ebec6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_31251b56-f6fe-4249-83fc-5b461f06fd81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4e7901c3-7f1a-4da5-bc70-47238e2aca5e" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_31251b56-f6fe-4249-83fc-5b461f06fd81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_913c94c2-a24a-41dc-80c8-19033f0fa689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4e7901c3-7f1a-4da5-bc70-47238e2aca5e" xlink:to="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_913c94c2-a24a-41dc-80c8-19033f0fa689" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a9a6c43f-9304-40af-b08c-208c2ab1b084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f36fe54d-f562-4a89-a3c7-29aaa69e745e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a9a6c43f-9304-40af-b08c-208c2ab1b084" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a9a6c43f-9304-40af-b08c-208c2ab1b084_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a9a6c43f-9304-40af-b08c-208c2ab1b084" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a9a6c43f-9304-40af-b08c-208c2ab1b084_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1640cafa-872e-415e-a5f6-8d4d3d832641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a9a6c43f-9304-40af-b08c-208c2ab1b084" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1640cafa-872e-415e-a5f6-8d4d3d832641" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_a92739a1-9b7d-485f-9601-8c52120f3b51" xlink:href="bhc-20211231.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1640cafa-872e-415e-a5f6-8d4d3d832641" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_a92739a1-9b7d-485f-9601-8c52120f3b51" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="i25aee8d9ab42473ab215d10e74e89e29_ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_7da16a41-70c0-4763-919e-7ccd2901c5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_7da16a41-70c0-4763-919e-7ccd2901c5ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_87c48f16-5695-489e-be09-0a4c7883cf93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_87c48f16-5695-489e-be09-0a4c7883cf93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1d475429-fbee-43d7-899e-7c4f01e059d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1d475429-fbee-43d7-899e-7c4f01e059d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3794d935-d7f6-403b-a5d4-fd80cfa950c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3794d935-d7f6-403b-a5d4-fd80cfa950c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1183a964-8ca4-4704-a1cb-c850a7516efc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1183a964-8ca4-4704-a1cb-c850a7516efc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_7b598dc3-0dfc-4d48-b7f7-e8e872624204" xlink:href="bhc-20211231.xsd#bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:to="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_7b598dc3-0dfc-4d48-b7f7-e8e872624204" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a73c5bc5-1c0d-4ce3-8b0c-959734928174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a73c5bc5-1c0d-4ce3-8b0c-959734928174" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_70ab78f7-1c6d-4c68-bc45-167059391173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:to="loc_us-gaap_Goodwill_70ab78f7-1c6d-4c68-bc45-167059391173" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a54276af-9450-4722-8751-53cafada9903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a54276af-9450-4722-8751-53cafada9903" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8d0961d0-e055-4cbd-a143-e77644f42155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8d0961d0-e055-4cbd-a143-e77644f42155" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dc8f65ef-8657-4f3c-a56c-c1bc118677cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dc8f65ef-8657-4f3c-a56c-c1bc118677cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7825e10b-b0b4-454a-8c7f-06c5ad0cc571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dc8f65ef-8657-4f3c-a56c-c1bc118677cd" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7825e10b-b0b4-454a-8c7f-06c5ad0cc571" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7825e10b-b0b4-454a-8c7f-06c5ad0cc571_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7825e10b-b0b4-454a-8c7f-06c5ad0cc571" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7825e10b-b0b4-454a-8c7f-06c5ad0cc571_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9c78ed4-137b-4b74-a4bb-d09ee55e389e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7825e10b-b0b4-454a-8c7f-06c5ad0cc571" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9c78ed4-137b-4b74-a4bb-d09ee55e389e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SynergyPharmaceuticalsInc.Member_8ab14590-b86e-4baa-8763-a42bf570ba4f" xlink:href="bhc-20211231.xsd#bhc_SynergyPharmaceuticalsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9c78ed4-137b-4b74-a4bb-d09ee55e389e" xlink:to="loc_bhc_SynergyPharmaceuticalsInc.Member_8ab14590-b86e-4baa-8763-a42bf570ba4f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails" xlink:type="extended" id="ic57ae6b00a184a059bef1b2070654e67_ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9938822f-41c1-4399-a221-483194189562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_d162e377-1bd1-43b8-91b3-b2460b831219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9938822f-41c1-4399-a221-483194189562" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_d162e377-1bd1-43b8-91b3-b2460b831219" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_6fc3275e-e6a3-4046-8477-87549f496ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_d162e377-1bd1-43b8-91b3-b2460b831219" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_6fc3275e-e6a3-4046-8477-87549f496ca3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_eb1c947d-d5f2-442f-b3f5-80b49e10a6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_d162e377-1bd1-43b8-91b3-b2460b831219" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_eb1c947d-d5f2-442f-b3f5-80b49e10a6b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_60243c38-c7e5-451c-9362-2a44f41172b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_d162e377-1bd1-43b8-91b3-b2460b831219" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_60243c38-c7e5-451c-9362-2a44f41172b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_84680f66-a03d-4d8a-b504-21d790709d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_d162e377-1bd1-43b8-91b3-b2460b831219" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_84680f66-a03d-4d8a-b504-21d790709d87" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_21d42264-93f4-46d7-939a-6b7806c3b4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9938822f-41c1-4399-a221-483194189562" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_21d42264-93f4-46d7-939a-6b7806c3b4ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_8811dec7-2ba0-4743-82c2-f9dcb4229f90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_21d42264-93f4-46d7-939a-6b7806c3b4ff" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_8811dec7-2ba0-4743-82c2-f9dcb4229f90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_73cabf41-18d0-462b-ba8e-a1550b81fedb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_21d42264-93f4-46d7-939a-6b7806c3b4ff" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_73cabf41-18d0-462b-ba8e-a1550b81fedb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_d60b56ab-b47a-4b1e-9f43-e2a8d59ea15e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_21d42264-93f4-46d7-939a-6b7806c3b4ff" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_d60b56ab-b47a-4b1e-9f43-e2a8d59ea15e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_73f822d9-0fcc-4c9b-9663-e47325846d41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_21d42264-93f4-46d7-939a-6b7806c3b4ff" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_73f822d9-0fcc-4c9b-9663-e47325846d41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_9b9e07a7-239d-47e2-a2ba-4890eda2c979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9938822f-41c1-4399-a221-483194189562" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_9b9e07a7-239d-47e2-a2ba-4890eda2c979" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_20c00d91-c98c-4bb4-b6e3-d1d758d76b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_9b9e07a7-239d-47e2-a2ba-4890eda2c979" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_20c00d91-c98c-4bb4-b6e3-d1d758d76b5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent_cefc85b8-99fc-4366-99d2-60d23ddf143f" xlink:href="bhc-20211231.xsd#bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_9b9e07a7-239d-47e2-a2ba-4890eda2c979" xlink:to="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent_cefc85b8-99fc-4366-99d2-60d23ddf143f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_b6f1a5f7-5537-47e2-8108-379617b42bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_9b9e07a7-239d-47e2-a2ba-4890eda2c979" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_b6f1a5f7-5537-47e2-8108-379617b42bcc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_617728da-f82a-4073-8e03-9994598551a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9938822f-41c1-4399-a221-483194189562" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_617728da-f82a-4073-8e03-9994598551a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_704bd3e2-642b-45d2-a182-18d673564e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_617728da-f82a-4073-8e03-9994598551a1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_704bd3e2-642b-45d2-a182-18d673564e89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent_ea346236-4226-4825-971d-8591b13c1fa1" xlink:href="bhc-20211231.xsd#bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_617728da-f82a-4073-8e03-9994598551a1" xlink:to="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent_ea346236-4226-4825-971d-8591b13c1fa1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_298dada1-9229-47a2-a048-a98afd395609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_617728da-f82a-4073-8e03-9994598551a1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_298dada1-9229-47a2-a048-a98afd395609" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bd2c1815-9a97-4078-906a-9a70ec28132f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9938822f-41c1-4399-a221-483194189562" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bd2c1815-9a97-4078-906a-9a70ec28132f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ec30a54a-225a-4865-aaa5-c5d3ba335dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bd2c1815-9a97-4078-906a-9a70ec28132f" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ec30a54a-225a-4865-aaa5-c5d3ba335dcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ec30a54a-225a-4865-aaa5-c5d3ba335dcb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ec30a54a-225a-4865-aaa5-c5d3ba335dcb" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ec30a54a-225a-4865-aaa5-c5d3ba335dcb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9d0ecded-af32-4de4-81f0-2af160a56f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ec30a54a-225a-4865-aaa5-c5d3ba335dcb" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9d0ecded-af32-4de4-81f0-2af160a56f9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ACertainInternationalBusinessMember_c2b93961-1b7b-43b9-acea-176fc0506842" xlink:href="bhc-20211231.xsd#bhc_ACertainInternationalBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9d0ecded-af32-4de4-81f0-2af160a56f9a" xlink:to="loc_bhc_ACertainInternationalBusinessMember_c2b93961-1b7b-43b9-acea-176fc0506842" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_d0490235-12d5-4334-b0a9-72823e1669e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bd2c1815-9a97-4078-906a-9a70ec28132f" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_d0490235-12d5-4334-b0a9-72823e1669e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_d0490235-12d5-4334-b0a9-72823e1669e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d0490235-12d5-4334-b0a9-72823e1669e8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_d0490235-12d5-4334-b0a9-72823e1669e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_5d74f0dc-c8e7-4a93-94cb-93d784dc31e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d0490235-12d5-4334-b0a9-72823e1669e8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_5d74f0dc-c8e7-4a93-94cb-93d784dc31e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_3b866bb5-f9a1-4ddc-9c2d-f7c22e9573e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_5d74f0dc-c8e7-4a93-94cb-93d784dc31e6" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_3b866bb5-f9a1-4ddc-9c2d-f7c22e9573e0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="extended" id="i798357a7bccc48438c247566369fb085_RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_42c23f9b-5b41-49c6-b87b-513cf15e77bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_fd87d972-fabd-4bc8-9f09-2f76efa69cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_42c23f9b-5b41-49c6-b87b-513cf15e77bf" xlink:to="loc_us-gaap_RestructuringReserve_fd87d972-fabd-4bc8-9f09-2f76efa69cf6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_7aa44055-28b9-49d2-b6df-e9ff1efe5379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_42c23f9b-5b41-49c6-b87b-513cf15e77bf" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_7aa44055-28b9-49d2-b6df-e9ff1efe5379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_97eb9ec2-2dc8-4470-9c28-deb92e398543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_42c23f9b-5b41-49c6-b87b-513cf15e77bf" xlink:to="loc_us-gaap_PaymentsForRestructuring_97eb9ec2-2dc8-4470-9c28-deb92e398543" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_78441f69-fbe5-4fea-b303-d66725a7325f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_42c23f9b-5b41-49c6-b87b-513cf15e77bf" xlink:to="loc_us-gaap_RestructuringCharges_78441f69-fbe5-4fea-b303-d66725a7325f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_85bf61e7-d240-46d9-9b99-647b478232bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_42c23f9b-5b41-49c6-b87b-513cf15e77bf" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_85bf61e7-d240-46d9-9b99-647b478232bd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f4b50efb-2c28-47e7-b728-63b820dc634e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_42c23f9b-5b41-49c6-b87b-513cf15e77bf" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f4b50efb-2c28-47e7-b728-63b820dc634e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_16a1d9b3-1774-4ae7-9e6b-54483bd761ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f4b50efb-2c28-47e7-b728-63b820dc634e" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_16a1d9b3-1774-4ae7-9e6b-54483bd761ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_16a1d9b3-1774-4ae7-9e6b-54483bd761ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_16a1d9b3-1774-4ae7-9e6b-54483bd761ac" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_16a1d9b3-1774-4ae7-9e6b-54483bd761ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_2fbc87d3-0a57-442f-be77-f5cd67421c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_16a1d9b3-1774-4ae7-9e6b-54483bd761ac" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_2fbc87d3-0a57-442f-be77-f5cd67421c6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember_9ea82e99-56c7-4c57-9623-51c1cb072cf4" xlink:href="bhc-20211231.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2fbc87d3-0a57-442f-be77-f5cd67421c6f" xlink:to="loc_bhc_RestructuringAndIntegrationCostsMember_9ea82e99-56c7-4c57-9623-51c1cb072cf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_c4ccdf92-8b3e-4dba-9c1c-b9e8781384a3" xlink:href="bhc-20211231.xsd#bhc_SeparationAndInitialPublicOfferingCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2fbc87d3-0a57-442f-be77-f5cd67421c6f" xlink:to="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_c4ccdf92-8b3e-4dba-9c1c-b9e8781384a3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="id57744de64634cd0bdf43c3c4e04f013_FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_60fbe99f-4ef1-4b57-b90b-a21abb42aac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e4cee82-e90f-4651-90e4-656927908356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_60fbe99f-4ef1-4b57-b90b-a21abb42aac4" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e4cee82-e90f-4651-90e4-656927908356" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_424879f6-d222-4c9c-b0a1-01e90aa4470f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e4cee82-e90f-4651-90e4-656927908356" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_424879f6-d222-4c9c-b0a1-01e90aa4470f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_a682b0e8-5d81-4020-9b89-467f8993e881" xlink:href="bhc-20211231.xsd#bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e4cee82-e90f-4651-90e4-656927908356" xlink:to="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_a682b0e8-5d81-4020-9b89-467f8993e881" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_d361b6a3-eba3-4057-82c9-cba16a89dc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e4cee82-e90f-4651-90e4-656927908356" xlink:to="loc_us-gaap_DerivativeAssets_d361b6a3-eba3-4057-82c9-cba16a89dc2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0413ba21-ae56-44f2-ac8b-d3a2b979bfd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_60fbe99f-4ef1-4b57-b90b-a21abb42aac4" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0413ba21-ae56-44f2-ac8b-d3a2b979bfd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_1d8a8859-1b32-454e-9f44-6310cba90cf5" xlink:href="bhc-20211231.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0413ba21-ae56-44f2-ac8b-d3a2b979bfd9" xlink:to="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_1d8a8859-1b32-454e-9f44-6310cba90cf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_6527c0a5-f61a-43d5-8530-6948dffc4b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0413ba21-ae56-44f2-ac8b-d3a2b979bfd9" xlink:to="loc_us-gaap_DerivativeLiabilities_6527c0a5-f61a-43d5-8530-6948dffc4b1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85241144-4131-44cc-9fdb-8fea4d72669f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_60fbe99f-4ef1-4b57-b90b-a21abb42aac4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85241144-4131-44cc-9fdb-8fea4d72669f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6b188ce9-ad30-4607-86ac-9c8aa6478159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85241144-4131-44cc-9fdb-8fea4d72669f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6b188ce9-ad30-4607-86ac-9c8aa6478159" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6b188ce9-ad30-4607-86ac-9c8aa6478159_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6b188ce9-ad30-4607-86ac-9c8aa6478159" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6b188ce9-ad30-4607-86ac-9c8aa6478159_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_83aa831f-5bc6-4cea-b21e-c2feb801f6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6b188ce9-ad30-4607-86ac-9c8aa6478159" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_83aa831f-5bc6-4cea-b21e-c2feb801f6e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3e8950ff-a182-446d-af94-aae9af550c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_83aa831f-5bc6-4cea-b21e-c2feb801f6e0" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3e8950ff-a182-446d-af94-aae9af550c59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95704c5d-017d-41d5-8528-9adf7e07391d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85241144-4131-44cc-9fdb-8fea4d72669f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95704c5d-017d-41d5-8528-9adf7e07391d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95704c5d-017d-41d5-8528-9adf7e07391d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95704c5d-017d-41d5-8528-9adf7e07391d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95704c5d-017d-41d5-8528-9adf7e07391d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ac22bff-d82a-4b97-bcbd-f547376f8953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95704c5d-017d-41d5-8528-9adf7e07391d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ac22bff-d82a-4b97-bcbd-f547376f8953" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2b6ce2ab-8b54-4399-b0df-dc01c26d2208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ac22bff-d82a-4b97-bcbd-f547376f8953" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2b6ce2ab-8b54-4399-b0df-dc01c26d2208" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_55db08ce-81d0-4c66-99e6-12d1a3c34f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ac22bff-d82a-4b97-bcbd-f547376f8953" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_55db08ce-81d0-4c66-99e6-12d1a3c34f8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a52b635a-3479-49cf-90e9-2a1e5a9059a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ac22bff-d82a-4b97-bcbd-f547376f8953" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a52b635a-3479-49cf-90e9-2a1e5a9059a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ecd88bf2-5d61-4017-88fb-8d0399d736e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85241144-4131-44cc-9fdb-8fea4d72669f" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ecd88bf2-5d61-4017-88fb-8d0399d736e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ecd88bf2-5d61-4017-88fb-8d0399d736e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ecd88bf2-5d61-4017-88fb-8d0399d736e2" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ecd88bf2-5d61-4017-88fb-8d0399d736e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_14c2a8ca-5b47-4a40-b428-10299c899881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ecd88bf2-5d61-4017-88fb-8d0399d736e2" xlink:to="loc_us-gaap_HedgingRelationshipDomain_14c2a8ca-5b47-4a40-b428-10299c899881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_8a985d45-e69b-400e-9868-81aa3e545208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_14c2a8ca-5b47-4a40-b428-10299c899881" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_8a985d45-e69b-400e-9868-81aa3e545208" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b5284c72-f79f-4c9c-be1f-507d662cd5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85241144-4131-44cc-9fdb-8fea4d72669f" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b5284c72-f79f-4c9c-be1f-507d662cd5a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b5284c72-f79f-4c9c-be1f-507d662cd5a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b5284c72-f79f-4c9c-be1f-507d662cd5a6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b5284c72-f79f-4c9c-be1f-507d662cd5a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d88efe16-0b04-48d2-aa7c-1c61687f58d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b5284c72-f79f-4c9c-be1f-507d662cd5a6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d88efe16-0b04-48d2-aa7c-1c61687f58d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_c02bbc7d-5613-4845-8114-196c438a00db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d88efe16-0b04-48d2-aa7c-1c61687f58d6" xlink:to="loc_us-gaap_CurrencySwapMember_c02bbc7d-5613-4845-8114-196c438a00db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_5cda8505-03a3-4bcb-8c60-feafcc4ff14b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d88efe16-0b04-48d2-aa7c-1c61687f58d6" xlink:to="loc_us-gaap_ForeignExchangeContractMember_5cda8505-03a3-4bcb-8c60-feafcc4ff14b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_3b2f0b0e-a361-421c-98d0-073fd49acc18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85241144-4131-44cc-9fdb-8fea4d72669f" xlink:to="loc_us-gaap_HedgingDesignationAxis_3b2f0b0e-a361-421c-98d0-073fd49acc18" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_3b2f0b0e-a361-421c-98d0-073fd49acc18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_3b2f0b0e-a361-421c-98d0-073fd49acc18" xlink:to="loc_us-gaap_HedgingDesignationDomain_3b2f0b0e-a361-421c-98d0-073fd49acc18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_59789160-3417-4bee-b482-747f7bca9d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_3b2f0b0e-a361-421c-98d0-073fd49acc18" xlink:to="loc_us-gaap_HedgingDesignationDomain_59789160-3417-4bee-b482-747f7bca9d5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_95e54f7b-df10-4e57-a964-8acf070ae034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_59789160-3417-4bee-b482-747f7bca9d5d" xlink:to="loc_us-gaap_NondesignatedMember_95e54f7b-df10-4e57-a964-8acf070ae034" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6b9d5535-bd17-425c-b48d-f625479b6596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_59789160-3417-4bee-b482-747f7bca9d5d" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6b9d5535-bd17-425c-b48d-f625479b6596" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="extended" id="i3c05c8ede5694bbb859ff04057f1fc28_FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_503791d7-6f95-4fc1-846d-7503e59219f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_e32884a1-339a-436d-ace8-af3005d6f2b8" xlink:href="bhc-20211231.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_503791d7-6f95-4fc1-846d-7503e59219f1" xlink:to="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_e32884a1-339a-436d-ace8-af3005d6f2b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_2fd82d88-0f3d-4bd3-a7e9-6b146ad3ff74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_503791d7-6f95-4fc1-846d-7503e59219f1" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_2fd82d88-0f3d-4bd3-a7e9-6b146ad3ff74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6e3c7b83-b57c-49e5-a120-c930c600de8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_503791d7-6f95-4fc1-846d-7503e59219f1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6e3c7b83-b57c-49e5-a120-c930c600de8a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_7fa0c555-1034-4444-a4b1-77711b78f63a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6e3c7b83-b57c-49e5-a120-c930c600de8a" xlink:to="loc_srt_LitigationCaseAxis_7fa0c555-1034-4444-a4b1-77711b78f63a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7fa0c555-1034-4444-a4b1-77711b78f63a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_7fa0c555-1034-4444-a4b1-77711b78f63a" xlink:to="loc_srt_LitigationCaseTypeDomain_7fa0c555-1034-4444-a4b1-77711b78f63a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7ca5f8f6-1af2-47f6-a1b5-a7dddb7dbb67" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_7fa0c555-1034-4444-a4b1-77711b78f63a" xlink:to="loc_srt_LitigationCaseTypeDomain_7ca5f8f6-1af2-47f6-a1b5-a7dddb7dbb67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_5c732a80-f19a-47ca-b6b9-32b0a8147e48" xlink:href="bhc-20211231.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7ca5f8f6-1af2-47f6-a1b5-a7dddb7dbb67" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_5c732a80-f19a-47ca-b6b9-32b0a8147e48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bd19a8c3-b6ce-4cae-b5e4-b0811b090606" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6e3c7b83-b57c-49e5-a120-c930c600de8a" xlink:to="loc_srt_StatementGeographicalAxis_bd19a8c3-b6ce-4cae-b5e4-b0811b090606" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bd19a8c3-b6ce-4cae-b5e4-b0811b090606_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_bd19a8c3-b6ce-4cae-b5e4-b0811b090606" xlink:to="loc_srt_SegmentGeographicalDomain_bd19a8c3-b6ce-4cae-b5e4-b0811b090606_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9acb78be-342f-4e56-ad81-4ff7f18fb341" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_bd19a8c3-b6ce-4cae-b5e4-b0811b090606" xlink:to="loc_srt_SegmentGeographicalDomain_9acb78be-342f-4e56-ad81-4ff7f18fb341" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_a0fea167-156d-45d5-a15d-92918919f305" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9acb78be-342f-4e56-ad81-4ff7f18fb341" xlink:to="loc_stpr_NJ_a0fea167-156d-45d5-a15d-92918919f305" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_d7693423-adcf-4937-b722-f6009c3c4c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6e3c7b83-b57c-49e5-a120-c930c600de8a" xlink:to="loc_us-gaap_LitigationStatusAxis_d7693423-adcf-4937-b722-f6009c3c4c5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_d7693423-adcf-4937-b722-f6009c3c4c5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_d7693423-adcf-4937-b722-f6009c3c4c5b" xlink:to="loc_us-gaap_LitigationStatusDomain_d7693423-adcf-4937-b722-f6009c3c4c5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_dab36475-b166-4ed3-92ad-cedc2097ae79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_d7693423-adcf-4937-b722-f6009c3c4c5b" xlink:to="loc_us-gaap_LitigationStatusDomain_dab36475-b166-4ed3-92ad-cedc2097ae79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_4daf8a3e-e4b4-4803-9e58-7d2d43fbfe5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_dab36475-b166-4ed3-92ad-cedc2097ae79" xlink:to="loc_us-gaap_SettledLitigationMember_4daf8a3e-e4b4-4803-9e58-7d2d43fbfe5c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="extended" id="iea99919fd3324aaa871f3470e88da64c_FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91b64955-796c-40b0-8aa6-2eaa8e2a1042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_8802d33d-de94-449b-bff7-374bbb5d6f13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91b64955-796c-40b0-8aa6-2eaa8e2a1042" xlink:to="loc_us-gaap_DerivativeNotionalAmount_8802d33d-de94-449b-bff7-374bbb5d6f13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_e800f83e-31c1-4d0c-94c8-a8ff798682bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91b64955-796c-40b0-8aa6-2eaa8e2a1042" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_e800f83e-31c1-4d0c-94c8-a8ff798682bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_97372351-3311-4e95-8ed3-04d1bf79a0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91b64955-796c-40b0-8aa6-2eaa8e2a1042" xlink:to="loc_us-gaap_InvestmentIncomeInterest_97372351-3311-4e95-8ed3-04d1bf79a0d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_4085f32a-999d-4776-9fc8-4c3f5db94b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91b64955-796c-40b0-8aa6-2eaa8e2a1042" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_4085f32a-999d-4776-9fc8-4c3f5db94b17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b664136-ac55-4102-8451-6c874bdc8704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91b64955-796c-40b0-8aa6-2eaa8e2a1042" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b664136-ac55-4102-8451-6c874bdc8704" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e49310f3-ac50-43ea-91ae-e3551e10bafe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b664136-ac55-4102-8451-6c874bdc8704" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e49310f3-ac50-43ea-91ae-e3551e10bafe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e49310f3-ac50-43ea-91ae-e3551e10bafe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e49310f3-ac50-43ea-91ae-e3551e10bafe" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e49310f3-ac50-43ea-91ae-e3551e10bafe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_94a8cc09-2942-48ea-9dd5-9e172a679078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e49310f3-ac50-43ea-91ae-e3551e10bafe" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_94a8cc09-2942-48ea-9dd5-9e172a679078" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_44dba963-fd96-4fa2-a6d7-be951bd77dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_94a8cc09-2942-48ea-9dd5-9e172a679078" xlink:to="loc_us-gaap_CurrencySwapMember_44dba963-fd96-4fa2-a6d7-be951bd77dd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CrossCurrencyFinalSettlementMember_5e3fe95c-072f-48e7-bf5d-e1bfccf6a2bd" xlink:href="bhc-20211231.xsd#bhc_CrossCurrencyFinalSettlementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CurrencySwapMember_44dba963-fd96-4fa2-a6d7-be951bd77dd0" xlink:to="loc_bhc_CrossCurrencyFinalSettlementMember_5e3fe95c-072f-48e7-bf5d-e1bfccf6a2bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ebd02123-df59-4699-af7c-79f731b06803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b664136-ac55-4102-8451-6c874bdc8704" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ebd02123-df59-4699-af7c-79f731b06803" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ebd02123-df59-4699-af7c-79f731b06803_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ebd02123-df59-4699-af7c-79f731b06803" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ebd02123-df59-4699-af7c-79f731b06803_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_4a7a8a5d-ee40-4008-87c9-89747ea46eae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ebd02123-df59-4699-af7c-79f731b06803" xlink:to="loc_us-gaap_HedgingRelationshipDomain_4a7a8a5d-ee40-4008-87c9-89747ea46eae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_34508f59-aa81-478f-b0f9-bc638c28bf65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_4a7a8a5d-ee40-4008-87c9-89747ea46eae" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_34508f59-aa81-478f-b0f9-bc638c28bf65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_45c8f37d-7fe2-407f-8b7a-fc5237b7fe27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b664136-ac55-4102-8451-6c874bdc8704" xlink:to="loc_us-gaap_HedgingDesignationAxis_45c8f37d-7fe2-407f-8b7a-fc5237b7fe27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_45c8f37d-7fe2-407f-8b7a-fc5237b7fe27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_45c8f37d-7fe2-407f-8b7a-fc5237b7fe27" xlink:to="loc_us-gaap_HedgingDesignationDomain_45c8f37d-7fe2-407f-8b7a-fc5237b7fe27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_bb62770f-b967-4d41-89f1-2a5ca4c329c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_45c8f37d-7fe2-407f-8b7a-fc5237b7fe27" xlink:to="loc_us-gaap_HedgingDesignationDomain_bb62770f-b967-4d41-89f1-2a5ca4c329c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8acb9873-6e44-4677-8ed0-6aac4094c1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_bb62770f-b967-4d41-89f1-2a5ca4c329c2" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8acb9873-6e44-4677-8ed0-6aac4094c1e9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended" id="i509715eadea54b82a2333a51c531828e_FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d3f8b2c8-d4d8-428b-8b50-d0589c31fc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_94de98f4-65ac-4c34-bf27-8b5b69123562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d3f8b2c8-d4d8-428b-8b50-d0589c31fc1c" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_94de98f4-65ac-4c34-bf27-8b5b69123562" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1ebcde41-0e17-4f71-bac0-b01b4035a0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d3f8b2c8-d4d8-428b-8b50-d0589c31fc1c" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1ebcde41-0e17-4f71-bac0-b01b4035a0ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_76f975d4-1348-4fb4-8864-3166e79fed8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d3f8b2c8-d4d8-428b-8b50-d0589c31fc1c" xlink:to="loc_us-gaap_DerivativeLiabilities_76f975d4-1348-4fb4-8864-3166e79fed8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f52ba58c-aeb0-4863-aa1d-cfb4b14edaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d3f8b2c8-d4d8-428b-8b50-d0589c31fc1c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f52ba58c-aeb0-4863-aa1d-cfb4b14edaf4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_dc60c56a-9afb-4bb0-ae4c-a910e5a81286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f52ba58c-aeb0-4863-aa1d-cfb4b14edaf4" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_dc60c56a-9afb-4bb0-ae4c-a910e5a81286" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_dc60c56a-9afb-4bb0-ae4c-a910e5a81286_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_dc60c56a-9afb-4bb0-ae4c-a910e5a81286" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_dc60c56a-9afb-4bb0-ae4c-a910e5a81286_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cb4eefe8-02ef-4059-978b-4fe871db1de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_dc60c56a-9afb-4bb0-ae4c-a910e5a81286" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cb4eefe8-02ef-4059-978b-4fe871db1de8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a11c06d8-88b4-41a2-a3bc-9f673382b913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb4eefe8-02ef-4059-978b-4fe871db1de8" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a11c06d8-88b4-41a2-a3bc-9f673382b913" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_966b3676-1e2a-4ee3-9fa2-b1fa62016d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb4eefe8-02ef-4059-978b-4fe871db1de8" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_966b3676-1e2a-4ee3-9fa2-b1fa62016d9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_43801754-f1d3-498b-b5ab-cc3220a9ec45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f52ba58c-aeb0-4863-aa1d-cfb4b14edaf4" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_43801754-f1d3-498b-b5ab-cc3220a9ec45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_43801754-f1d3-498b-b5ab-cc3220a9ec45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_43801754-f1d3-498b-b5ab-cc3220a9ec45" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_43801754-f1d3-498b-b5ab-cc3220a9ec45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a109b156-69cb-4d86-b8cc-75238974a29a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_43801754-f1d3-498b-b5ab-cc3220a9ec45" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a109b156-69cb-4d86-b8cc-75238974a29a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_42b253ff-0890-46be-93a9-02bbd976d660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a109b156-69cb-4d86-b8cc-75238974a29a" xlink:to="loc_us-gaap_CurrencySwapMember_42b253ff-0890-46be-93a9-02bbd976d660" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_46dbff37-3a3c-48c2-9fff-b062b9489cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f52ba58c-aeb0-4863-aa1d-cfb4b14edaf4" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_46dbff37-3a3c-48c2-9fff-b062b9489cd9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_46dbff37-3a3c-48c2-9fff-b062b9489cd9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_46dbff37-3a3c-48c2-9fff-b062b9489cd9" xlink:to="loc_us-gaap_HedgingRelationshipDomain_46dbff37-3a3c-48c2-9fff-b062b9489cd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_3909df6f-e8b1-484d-9ddc-e8c92305b261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_46dbff37-3a3c-48c2-9fff-b062b9489cd9" xlink:to="loc_us-gaap_HedgingRelationshipDomain_3909df6f-e8b1-484d-9ddc-e8c92305b261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_24a8fe47-31fd-49c8-a8a2-bdd1dde3dfde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3909df6f-e8b1-484d-9ddc-e8c92305b261" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_24a8fe47-31fd-49c8-a8a2-bdd1dde3dfde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_83601042-b0c8-4533-aeb4-26dbf34e1b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f52ba58c-aeb0-4863-aa1d-cfb4b14edaf4" xlink:to="loc_us-gaap_HedgingDesignationAxis_83601042-b0c8-4533-aeb4-26dbf34e1b1f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_83601042-b0c8-4533-aeb4-26dbf34e1b1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_83601042-b0c8-4533-aeb4-26dbf34e1b1f" xlink:to="loc_us-gaap_HedgingDesignationDomain_83601042-b0c8-4533-aeb4-26dbf34e1b1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f8cf8736-32f0-46cb-82f6-bb50ec48e901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_83601042-b0c8-4533-aeb4-26dbf34e1b1f" xlink:to="loc_us-gaap_HedgingDesignationDomain_f8cf8736-32f0-46cb-82f6-bb50ec48e901" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_13117284-d588-4438-a48b-88273193cbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_f8cf8736-32f0-46cb-82f6-bb50ec48e901" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_13117284-d588-4438-a48b-88273193cbc8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="extended" id="id04e914a3ff647e591e694fc6f8ac0c9_FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a27b83c9-e861-4d85-b830-9dddf180a7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_8a942c3b-e5a9-4321-99b0-3297129ac2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a27b83c9-e861-4d85-b830-9dddf180a7bd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_8a942c3b-e5a9-4321-99b0-3297129ac2c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_ad1c082f-16f1-4492-aa3a-12ab34684335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a27b83c9-e861-4d85-b830-9dddf180a7bd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_ad1c082f-16f1-4492-aa3a-12ab34684335" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_d8f0a741-3f9a-4ab4-a81e-2d8d64b32b57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a27b83c9-e861-4d85-b830-9dddf180a7bd" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_d8f0a741-3f9a-4ab4-a81e-2d8d64b32b57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5f52facd-1aed-4616-8205-aba3b7b9e1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a27b83c9-e861-4d85-b830-9dddf180a7bd" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5f52facd-1aed-4616-8205-aba3b7b9e1a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_08320f9f-2c6a-4734-9203-76d679d625dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5f52facd-1aed-4616-8205-aba3b7b9e1a3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_08320f9f-2c6a-4734-9203-76d679d625dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_08320f9f-2c6a-4734-9203-76d679d625dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_08320f9f-2c6a-4734-9203-76d679d625dd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_08320f9f-2c6a-4734-9203-76d679d625dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a36e9c80-c995-4718-9a51-c6f3d62eabd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_08320f9f-2c6a-4734-9203-76d679d625dd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a36e9c80-c995-4718-9a51-c6f3d62eabd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_4da46ce9-c165-4220-b52f-41a62177a17d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a36e9c80-c995-4718-9a51-c6f3d62eabd5" xlink:to="loc_us-gaap_CurrencySwapMember_4da46ce9-c165-4220-b52f-41a62177a17d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CrossCurrencyFinalSettlementMember_5ba41fad-2460-42bc-9c54-21abed43c389" xlink:href="bhc-20211231.xsd#bhc_CrossCurrencyFinalSettlementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a36e9c80-c995-4718-9a51-c6f3d62eabd5" xlink:to="loc_bhc_CrossCurrencyFinalSettlementMember_5ba41fad-2460-42bc-9c54-21abed43c389" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e62827f5-d4d4-4305-9175-1fca745ce31e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5f52facd-1aed-4616-8205-aba3b7b9e1a3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e62827f5-d4d4-4305-9175-1fca745ce31e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e62827f5-d4d4-4305-9175-1fca745ce31e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e62827f5-d4d4-4305-9175-1fca745ce31e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e62827f5-d4d4-4305-9175-1fca745ce31e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_a9de1fa4-bdd7-47bc-9871-25c9ce29a3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e62827f5-d4d4-4305-9175-1fca745ce31e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_a9de1fa4-bdd7-47bc-9871-25c9ce29a3d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_6fad4df5-184c-4dda-9874-746f835d691f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_a9de1fa4-bdd7-47bc-9871-25c9ce29a3d3" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_6fad4df5-184c-4dda-9874-746f835d691f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7940e7d5-8f50-4ff5-a533-96e8fa7de13d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5f52facd-1aed-4616-8205-aba3b7b9e1a3" xlink:to="loc_us-gaap_HedgingDesignationAxis_7940e7d5-8f50-4ff5-a533-96e8fa7de13d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7940e7d5-8f50-4ff5-a533-96e8fa7de13d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_7940e7d5-8f50-4ff5-a533-96e8fa7de13d" xlink:to="loc_us-gaap_HedgingDesignationDomain_7940e7d5-8f50-4ff5-a533-96e8fa7de13d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e00ae44d-4f87-4cb4-8239-389e8ff4bbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_7940e7d5-8f50-4ff5-a533-96e8fa7de13d" xlink:to="loc_us-gaap_HedgingDesignationDomain_e00ae44d-4f87-4cb4-8239-389e8ff4bbf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_675d9ab7-1ba3-4e3f-b3da-988bf2d0c163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_e00ae44d-4f87-4cb4-8239-389e8ff4bbf4" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_675d9ab7-1ba3-4e3f-b3da-988bf2d0c163" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5c1c86ff-f9f6-4c1b-882a-d39cf1c8900f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5f52facd-1aed-4616-8205-aba3b7b9e1a3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5c1c86ff-f9f6-4c1b-882a-d39cf1c8900f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5c1c86ff-f9f6-4c1b-882a-d39cf1c8900f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5c1c86ff-f9f6-4c1b-882a-d39cf1c8900f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5c1c86ff-f9f6-4c1b-882a-d39cf1c8900f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d4b56ae2-00e4-45ad-ad3b-c994f5479250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5c1c86ff-f9f6-4c1b-882a-d39cf1c8900f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d4b56ae2-00e4-45ad-ad3b-c994f5479250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_677b359a-0457-42f8-95b4-5ec77d44b68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d4b56ae2-00e4-45ad-ad3b-c994f5479250" xlink:to="loc_us-gaap_InterestExpenseMember_677b359a-0457-42f8-95b4-5ec77d44b68a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="extended" id="if1495491024e45b58ea613f2a68dbfe0_FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ac0ba13-64da-4790-bf47-b14dd5fa48a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_f3eaa25d-c714-4656-98e6-61337bdae611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ac0ba13-64da-4790-bf47-b14dd5fa48a7" xlink:to="loc_us-gaap_DerivativeNotionalAmount_f3eaa25d-c714-4656-98e6-61337bdae611" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d013e123-3d5c-4866-9702-3588e1728f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ac0ba13-64da-4790-bf47-b14dd5fa48a7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d013e123-3d5c-4866-9702-3588e1728f2f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_773b98a1-ddd0-4518-8044-d794927c4128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d013e123-3d5c-4866-9702-3588e1728f2f" xlink:to="loc_us-gaap_HedgingDesignationAxis_773b98a1-ddd0-4518-8044-d794927c4128" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_773b98a1-ddd0-4518-8044-d794927c4128_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_773b98a1-ddd0-4518-8044-d794927c4128" xlink:to="loc_us-gaap_HedgingDesignationDomain_773b98a1-ddd0-4518-8044-d794927c4128_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e61768aa-f6f6-4c57-80ea-7b9455ddb85f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_773b98a1-ddd0-4518-8044-d794927c4128" xlink:to="loc_us-gaap_HedgingDesignationDomain_e61768aa-f6f6-4c57-80ea-7b9455ddb85f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_c38a1152-3045-4682-9351-2c98ff197400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_e61768aa-f6f6-4c57-80ea-7b9455ddb85f" xlink:to="loc_us-gaap_NondesignatedMember_c38a1152-3045-4682-9351-2c98ff197400" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_974594c4-4087-4286-8381-78398f48fa91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d013e123-3d5c-4866-9702-3588e1728f2f" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_974594c4-4087-4286-8381-78398f48fa91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_974594c4-4087-4286-8381-78398f48fa91_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_974594c4-4087-4286-8381-78398f48fa91" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_974594c4-4087-4286-8381-78398f48fa91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_bfb679df-0f9d-4017-8ab4-6ff3c5e79f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_974594c4-4087-4286-8381-78398f48fa91" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_bfb679df-0f9d-4017-8ab4-6ff3c5e79f88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_598f8daf-4f16-4f2b-bf4e-4b368a922c33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bfb679df-0f9d-4017-8ab4-6ff3c5e79f88" xlink:to="loc_us-gaap_ForeignExchangeContractMember_598f8daf-4f16-4f2b-bf4e-4b368a922c33" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended" id="iae49690e73ec468a9e953a9df818e6f9_FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fbf80d35-b891-468b-ab5f-41c1452d4b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_28889b0b-9bc7-40fe-886b-2ebfc9900a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fbf80d35-b891-468b-ab5f-41c1452d4b7a" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_28889b0b-9bc7-40fe-886b-2ebfc9900a72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7b527ef4-8a47-47dd-9524-6861325b4be6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fbf80d35-b891-468b-ab5f-41c1452d4b7a" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7b527ef4-8a47-47dd-9524-6861325b4be6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_5dc09872-1b79-4933-bbc0-25a7e500c43a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fbf80d35-b891-468b-ab5f-41c1452d4b7a" xlink:to="loc_us-gaap_DerivativeLiabilities_5dc09872-1b79-4933-bbc0-25a7e500c43a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f7f578f-e3ba-494f-b7dc-8c449df1c376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fbf80d35-b891-468b-ab5f-41c1452d4b7a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f7f578f-e3ba-494f-b7dc-8c449df1c376" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0c414363-c2fd-4871-9e26-8e68dd814840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f7f578f-e3ba-494f-b7dc-8c449df1c376" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0c414363-c2fd-4871-9e26-8e68dd814840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0c414363-c2fd-4871-9e26-8e68dd814840_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0c414363-c2fd-4871-9e26-8e68dd814840" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0c414363-c2fd-4871-9e26-8e68dd814840_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d2831df2-ec8c-4598-8c3e-2e0a59b4773b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0c414363-c2fd-4871-9e26-8e68dd814840" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d2831df2-ec8c-4598-8c3e-2e0a59b4773b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_18da819a-4ff2-4d7f-aaeb-2ddf72ff2210" xlink:href="bhc-20211231.xsd#bhc_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d2831df2-ec8c-4598-8c3e-2e0a59b4773b" xlink:to="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_18da819a-4ff2-4d7f-aaeb-2ddf72ff2210" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_27e04ba8-b3ef-44f6-b72f-43afc68fae49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d2831df2-ec8c-4598-8c3e-2e0a59b4773b" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_27e04ba8-b3ef-44f6-b72f-43afc68fae49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9d465f4f-0478-417d-b12b-7a125f853a83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f7f578f-e3ba-494f-b7dc-8c449df1c376" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9d465f4f-0478-417d-b12b-7a125f853a83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9d465f4f-0478-417d-b12b-7a125f853a83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9d465f4f-0478-417d-b12b-7a125f853a83" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9d465f4f-0478-417d-b12b-7a125f853a83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ada82226-e34d-4119-a16e-696b47fe7442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9d465f4f-0478-417d-b12b-7a125f853a83" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ada82226-e34d-4119-a16e-696b47fe7442" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_5493b742-71bc-4633-9337-e626b2dd5fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ada82226-e34d-4119-a16e-696b47fe7442" xlink:to="loc_us-gaap_ForeignExchangeContractMember_5493b742-71bc-4633-9337-e626b2dd5fe0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_35b2c107-754f-4c41-8286-63b79e6ec779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f7f578f-e3ba-494f-b7dc-8c449df1c376" xlink:to="loc_us-gaap_HedgingDesignationAxis_35b2c107-754f-4c41-8286-63b79e6ec779" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_35b2c107-754f-4c41-8286-63b79e6ec779_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_35b2c107-754f-4c41-8286-63b79e6ec779" xlink:to="loc_us-gaap_HedgingDesignationDomain_35b2c107-754f-4c41-8286-63b79e6ec779_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_5f31d58f-6fa2-4f1d-81b9-6caef8c840b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_35b2c107-754f-4c41-8286-63b79e6ec779" xlink:to="loc_us-gaap_HedgingDesignationDomain_5f31d58f-6fa2-4f1d-81b9-6caef8c840b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_ff2e2a25-92fc-48b0-a8ba-33cc9eccee31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_5f31d58f-6fa2-4f1d-81b9-6caef8c840b7" xlink:to="loc_us-gaap_NondesignatedMember_ff2e2a25-92fc-48b0-a8ba-33cc9eccee31" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="extended" id="ief71d10a8a3a40a0b97c0729c4f7e0dc_FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_30e1be9f-37c7-48b3-b19a-31b0058ec967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_a25ed4f5-d5b1-44c2-a844-72ed4d3b68b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_30e1be9f-37c7-48b3-b19a-31b0058ec967" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_a25ed4f5-d5b1-44c2-a844-72ed4d3b68b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_91adb66b-88b1-46a6-966b-d75f3b2345c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_30e1be9f-37c7-48b3-b19a-31b0058ec967" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_91adb66b-88b1-46a6-966b-d75f3b2345c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f8e9642-5dd8-478f-b858-b1ad2b996bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_30e1be9f-37c7-48b3-b19a-31b0058ec967" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f8e9642-5dd8-478f-b858-b1ad2b996bc4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_8a4dd168-b342-43b5-905f-e32c80362f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f8e9642-5dd8-478f-b858-b1ad2b996bc4" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_8a4dd168-b342-43b5-905f-e32c80362f6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_8a4dd168-b342-43b5-905f-e32c80362f6f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8a4dd168-b342-43b5-905f-e32c80362f6f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_8a4dd168-b342-43b5-905f-e32c80362f6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6daafbbb-589f-46ee-aec6-a6770eb5e00e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8a4dd168-b342-43b5-905f-e32c80362f6f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6daafbbb-589f-46ee-aec6-a6770eb5e00e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d2eedf83-af34-4dec-ad07-4ad0684813fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6daafbbb-589f-46ee-aec6-a6770eb5e00e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d2eedf83-af34-4dec-ad07-4ad0684813fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_a02e3bb3-f586-4df8-b741-c292638accf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f8e9642-5dd8-478f-b858-b1ad2b996bc4" xlink:to="loc_us-gaap_HedgingDesignationAxis_a02e3bb3-f586-4df8-b741-c292638accf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a02e3bb3-f586-4df8-b741-c292638accf2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_a02e3bb3-f586-4df8-b741-c292638accf2" xlink:to="loc_us-gaap_HedgingDesignationDomain_a02e3bb3-f586-4df8-b741-c292638accf2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_78b5df92-6cb8-4c42-b2bf-aa20eb9e1bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_a02e3bb3-f586-4df8-b741-c292638accf2" xlink:to="loc_us-gaap_HedgingDesignationDomain_78b5df92-6cb8-4c42-b2bf-aa20eb9e1bc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_72f04594-9240-4ee4-a0fb-dcd480b7cf67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_78b5df92-6cb8-4c42-b2bf-aa20eb9e1bc5" xlink:to="loc_us-gaap_NondesignatedMember_72f04594-9240-4ee4-a0fb-dcd480b7cf67" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" xlink:type="extended" id="iba13e26badd448008c7d39404e75b1fe_FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8c4e98f4-afad-41c4-9b6b-0bcfeb1c6381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_971c530b-818a-49f2-a80e-ae6326ce159a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8c4e98f4-afad-41c4-9b6b-0bcfeb1c6381" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_971c530b-818a-49f2-a80e-ae6326ce159a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aebefdf7-a28d-4d96-a85b-382b1e268ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8c4e98f4-afad-41c4-9b6b-0bcfeb1c6381" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aebefdf7-a28d-4d96-a85b-382b1e268ce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_75df549b-d2db-47a7-ae86-0e9cd7e8d2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aebefdf7-a28d-4d96-a85b-382b1e268ce6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_75df549b-d2db-47a7-ae86-0e9cd7e8d2ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8dd9e10e-09d4-46fd-9fd6-b03b5600c02f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aebefdf7-a28d-4d96-a85b-382b1e268ce6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8dd9e10e-09d4-46fd-9fd6-b03b5600c02f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_55807de2-c172-4b80-b597-56d0f7bce6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aebefdf7-a28d-4d96-a85b-382b1e268ce6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_55807de2-c172-4b80-b597-56d0f7bce6b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_50968949-ba3f-48d6-aab3-f99056ff2bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aebefdf7-a28d-4d96-a85b-382b1e268ce6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_50968949-ba3f-48d6-aab3-f99056ff2bf4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_39e64f4b-5e5c-45e5-88e1-09a118d8287a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_354b296d-028f-4ddf-94ae-893d0dba78d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8c4e98f4-afad-41c4-9b6b-0bcfeb1c6381" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_354b296d-028f-4ddf-94ae-893d0dba78d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_bc618e8e-15aa-41a0-b00f-07cb7e881c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8c4e98f4-afad-41c4-9b6b-0bcfeb1c6381" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_bc618e8e-15aa-41a0-b00f-07cb7e881c46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cafaad5-2765-45b5-b983-5b97a50204a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8c4e98f4-afad-41c4-9b6b-0bcfeb1c6381" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cafaad5-2765-45b5-b983-5b97a50204a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1dbaac49-47dc-478f-8b54-d526c1401c4c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cafaad5-2765-45b5-b983-5b97a50204a3" xlink:to="loc_srt_RangeAxis_1dbaac49-47dc-478f-8b54-d526c1401c4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1dbaac49-47dc-478f-8b54-d526c1401c4c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1dbaac49-47dc-478f-8b54-d526c1401c4c" xlink:to="loc_srt_RangeMember_1dbaac49-47dc-478f-8b54-d526c1401c4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9e6fed5a-c149-4271-ae67-ee0274ddc8e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1dbaac49-47dc-478f-8b54-d526c1401c4c" xlink:to="loc_srt_RangeMember_9e6fed5a-c149-4271-ae67-ee0274ddc8e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_08ba2d28-839f-4791-bc90-6dc4887cefca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9e6fed5a-c149-4271-ae67-ee0274ddc8e6" xlink:to="loc_srt_MinimumMember_08ba2d28-839f-4791-bc90-6dc4887cefca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8a896908-317f-49ef-9bec-f5c95626d792" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9e6fed5a-c149-4271-ae67-ee0274ddc8e6" xlink:to="loc_srt_MaximumMember_8a896908-317f-49ef-9bec-f5c95626d792" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_cd2ed22d-7055-488f-bf51-b23b28b76301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cafaad5-2765-45b5-b983-5b97a50204a3" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_cd2ed22d-7055-488f-bf51-b23b28b76301" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_cd2ed22d-7055-488f-bf51-b23b28b76301_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_cd2ed22d-7055-488f-bf51-b23b28b76301" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_cd2ed22d-7055-488f-bf51-b23b28b76301_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_746768f5-3d54-401d-afc6-92a28074f081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_cd2ed22d-7055-488f-bf51-b23b28b76301" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_746768f5-3d54-401d-afc6-92a28074f081" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_b1681eb6-a091-48ab-befa-f08c4b225959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_746768f5-3d54-401d-afc6-92a28074f081" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_b1681eb6-a091-48ab-befa-f08c4b225959" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_179e8b33-d7df-460a-bd07-5ce1d80049f7" xlink:href="bhc-20211231.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_746768f5-3d54-401d-afc6-92a28074f081" xlink:to="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_179e8b33-d7df-460a-bd07-5ce1d80049f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9cc57c73-ff68-43b5-a355-f880b6ea48e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cafaad5-2765-45b5-b983-5b97a50204a3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9cc57c73-ff68-43b5-a355-f880b6ea48e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9cc57c73-ff68-43b5-a355-f880b6ea48e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9cc57c73-ff68-43b5-a355-f880b6ea48e4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9cc57c73-ff68-43b5-a355-f880b6ea48e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bd53a9c-2ad2-4480-82ee-b04d62f5f63b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9cc57c73-ff68-43b5-a355-f880b6ea48e4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bd53a9c-2ad2-4480-82ee-b04d62f5f63b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8feee856-18fa-41ff-bca8-368c011e0dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bd53a9c-2ad2-4480-82ee-b04d62f5f63b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8feee856-18fa-41ff-bca8-368c011e0dff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7eb6602c-8a27-4a2b-8800-7033ea5a0f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cafaad5-2765-45b5-b983-5b97a50204a3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7eb6602c-8a27-4a2b-8800-7033ea5a0f8b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7eb6602c-8a27-4a2b-8800-7033ea5a0f8b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7eb6602c-8a27-4a2b-8800-7033ea5a0f8b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7eb6602c-8a27-4a2b-8800-7033ea5a0f8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_15a5349a-8086-4b33-848b-0d930ca4bfff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7eb6602c-8a27-4a2b-8800-7033ea5a0f8b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_15a5349a-8086-4b33-848b-0d930ca4bfff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8aaa8d4b-0ba2-467e-9a16-6e4d9d122374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_15a5349a-8086-4b33-848b-0d930ca4bfff" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8aaa8d4b-0ba2-467e-9a16-6e4d9d122374" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_fbfa6f12-bbbb-42e3-b44a-42293da76a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cafaad5-2765-45b5-b983-5b97a50204a3" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_fbfa6f12-bbbb-42e3-b44a-42293da76a7a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_fbfa6f12-bbbb-42e3-b44a-42293da76a7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_fbfa6f12-bbbb-42e3-b44a-42293da76a7a" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_fbfa6f12-bbbb-42e3-b44a-42293da76a7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_68cf4415-4999-4de7-ad58-3fb82ccd50e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_fbfa6f12-bbbb-42e3-b44a-42293da76a7a" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_68cf4415-4999-4de7-ad58-3fb82ccd50e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember_91c22dba-d681-4a91-967c-f1bb2b8d39d5" xlink:href="bhc-20211231.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_68cf4415-4999-4de7-ad58-3fb82ccd50e8" xlink:to="loc_bhc_AccretionForTimeValueOfMoneyMember_91c22dba-d681-4a91-967c-f1bb2b8d39d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsMember_4caf0034-daca-421c-b229-4eb93df3f652" xlink:href="bhc-20211231.xsd#bhc_FairValueAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_68cf4415-4999-4de7-ad58-3fb82ccd50e8" xlink:to="loc_bhc_FairValueAdjustmentsMember_4caf0034-daca-421c-b229-4eb93df3f652" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails" xlink:type="extended" id="i0fd4d3bad0724103a042c2d328d8c2db_FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2ed7abbb-a3e7-447d-81fc-4bd7bb602b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiabilityAbstract_13823c6c-a9f7-4bf6-8a58-d03deec47252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiabilityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2ed7abbb-a3e7-447d-81fc-4bd7bb602b2e" xlink:to="loc_us-gaap_FairValueNetAssetLiabilityAbstract_13823c6c-a9f7-4bf6-8a58-d03deec47252" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_8d366d08-6a2e-4dcf-94d2-09a9a908b077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetAssetLiabilityAbstract_13823c6c-a9f7-4bf6-8a58-d03deec47252" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_8d366d08-6a2e-4dcf-94d2-09a9a908b077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_97de4cb4-06e8-4f33-acc6-eef3e144154a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2ed7abbb-a3e7-447d-81fc-4bd7bb602b2e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_97de4cb4-06e8-4f33-acc6-eef3e144154a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6c9cf211-5727-48e6-aa4a-b8211d597a31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_97de4cb4-06e8-4f33-acc6-eef3e144154a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6c9cf211-5727-48e6-aa4a-b8211d597a31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6c9cf211-5727-48e6-aa4a-b8211d597a31_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6c9cf211-5727-48e6-aa4a-b8211d597a31" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6c9cf211-5727-48e6-aa4a-b8211d597a31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1b4b1e88-3eb7-4fe3-9127-33ff0fe66b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6c9cf211-5727-48e6-aa4a-b8211d597a31" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1b4b1e88-3eb7-4fe3-9127-33ff0fe66b0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_a8c7c49e-66ee-45f8-8731-3c1a0dd49086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1b4b1e88-3eb7-4fe3-9127-33ff0fe66b0f" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_a8c7c49e-66ee-45f8-8731-3c1a0dd49086" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_618db1cf-ddde-4b65-ad33-4effbefe5cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_97de4cb4-06e8-4f33-acc6-eef3e144154a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_618db1cf-ddde-4b65-ad33-4effbefe5cc3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_618db1cf-ddde-4b65-ad33-4effbefe5cc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_618db1cf-ddde-4b65-ad33-4effbefe5cc3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_618db1cf-ddde-4b65-ad33-4effbefe5cc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9576f3c8-bbb1-44d1-b98a-309bb7507511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_618db1cf-ddde-4b65-ad33-4effbefe5cc3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9576f3c8-bbb1-44d1-b98a-309bb7507511" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_bd057e1e-76b2-46f7-a457-99d01428433b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9576f3c8-bbb1-44d1-b98a-309bb7507511" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_bd057e1e-76b2-46f7-a457-99d01428433b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5de5e30d-76a1-4488-bed6-57d536eff624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9576f3c8-bbb1-44d1-b98a-309bb7507511" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5de5e30d-76a1-4488-bed6-57d536eff624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8da04c8f-63d0-4cda-8755-ffc77ecb2a46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9576f3c8-bbb1-44d1-b98a-309bb7507511" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8da04c8f-63d0-4cda-8755-ffc77ecb2a46" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails" xlink:type="extended" id="if93180bde17e49b4b7d9184b680d3f5b_FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0884b7c2-63d5-4b25-995f-fcde5d62a3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_0866c6e6-1633-46c8-8b37-046ff6118f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0884b7c2-63d5-4b25-995f-fcde5d62a3ef" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_0866c6e6-1633-46c8-8b37-046ff6118f6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_cb073d27-ca55-4ef3-9080-47b119296336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0884b7c2-63d5-4b25-995f-fcde5d62a3ef" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_cb073d27-ca55-4ef3-9080-47b119296336" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_47db55cb-49ea-4a6a-a474-075eaf9aece3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0884b7c2-63d5-4b25-995f-fcde5d62a3ef" xlink:to="loc_us-gaap_Assets_47db55cb-49ea-4a6a-a474-075eaf9aece3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7abb6ec9-a420-412e-906a-3188ced49be2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0884b7c2-63d5-4b25-995f-fcde5d62a3ef" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7abb6ec9-a420-412e-906a-3188ced49be2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9e01037b-6e58-4e2e-8187-a17f097a8289" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7abb6ec9-a420-412e-906a-3188ced49be2" xlink:to="loc_srt_ProductOrServiceAxis_9e01037b-6e58-4e2e-8187-a17f097a8289" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9e01037b-6e58-4e2e-8187-a17f097a8289_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9e01037b-6e58-4e2e-8187-a17f097a8289" xlink:to="loc_srt_ProductsAndServicesDomain_9e01037b-6e58-4e2e-8187-a17f097a8289_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2afb9d92-f334-40c0-9f2c-f8c559a1f8b2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9e01037b-6e58-4e2e-8187-a17f097a8289" xlink:to="loc_srt_ProductsAndServicesDomain_2afb9d92-f334-40c0-9f2c-f8c559a1f8b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_db3164ef-628d-478e-ba4d-f8de78aae3e5" xlink:href="bhc-20211231.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2afb9d92-f334-40c0-9f2c-f8c559a1f8b2" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_db3164ef-628d-478e-ba4d-f8de78aae3e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_c343fa65-1b75-4589-868f-1e0fe2e852fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7abb6ec9-a420-412e-906a-3188ced49be2" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_c343fa65-1b75-4589-868f-1e0fe2e852fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c343fa65-1b75-4589-868f-1e0fe2e852fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_c343fa65-1b75-4589-868f-1e0fe2e852fe" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c343fa65-1b75-4589-868f-1e0fe2e852fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ff7e03da-35b4-4cc2-872d-a33ad32c6aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_c343fa65-1b75-4589-868f-1e0fe2e852fe" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ff7e03da-35b4-4cc2-872d-a33ad32c6aa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_d2d7ad77-1c09-493e-ba42-502ddeebc88f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ff7e03da-35b4-4cc2-872d-a33ad32c6aa8" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_d2d7ad77-1c09-493e-ba42-502ddeebc88f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_48ca87e5-f71c-4c97-b92d-733b18d92a64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7abb6ec9-a420-412e-906a-3188ced49be2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_48ca87e5-f71c-4c97-b92d-733b18d92a64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_48ca87e5-f71c-4c97-b92d-733b18d92a64_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_48ca87e5-f71c-4c97-b92d-733b18d92a64" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_48ca87e5-f71c-4c97-b92d-733b18d92a64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_02630e81-e3b9-404c-9cf5-2a55d85c5d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_48ca87e5-f71c-4c97-b92d-733b18d92a64" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_02630e81-e3b9-404c-9cf5-2a55d85c5d32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_df84d144-da80-4655-ac57-803ebf642188" xlink:href="bhc-20211231.xsd#bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_02630e81-e3b9-404c-9cf5-2a55d85c5d32" xlink:to="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_df84d144-da80-4655-ac57-803ebf642188" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d04e1e4f-2ec5-4075-883a-a7a928de1dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7abb6ec9-a420-412e-906a-3188ced49be2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d04e1e4f-2ec5-4075-883a-a7a928de1dfb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d04e1e4f-2ec5-4075-883a-a7a928de1dfb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d04e1e4f-2ec5-4075-883a-a7a928de1dfb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d04e1e4f-2ec5-4075-883a-a7a928de1dfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_70986020-b0bd-4850-9c38-17937b4d7a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d04e1e4f-2ec5-4075-883a-a7a928de1dfb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_70986020-b0bd-4850-9c38-17937b4d7a1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1343bc16-de7c-40ba-bcff-bd50f228eb88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_70986020-b0bd-4850-9c38-17937b4d7a1e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1343bc16-de7c-40ba-bcff-bd50f228eb88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a619636c-f56f-48c7-8d21-d793c9758421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7abb6ec9-a420-412e-906a-3188ced49be2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a619636c-f56f-48c7-8d21-d793c9758421" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a619636c-f56f-48c7-8d21-d793c9758421_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a619636c-f56f-48c7-8d21-d793c9758421" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a619636c-f56f-48c7-8d21-d793c9758421_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_30931cb9-1ad0-41ae-bf42-0ac9b75efeef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a619636c-f56f-48c7-8d21-d793c9758421" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_30931cb9-1ad0-41ae-bf42-0ac9b75efeef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_ff09f0c4-7b90-4212-b9e5-03c535e01a94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_30931cb9-1ad0-41ae-bf42-0ac9b75efeef" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_ff09f0c4-7b90-4212-b9e5-03c535e01a94" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails" xlink:type="extended" id="ia4d0bb4312bb4523b5de0e8344ea9320_FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_27dc06db-9b98-4e45-93b1-966a3a71ad2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_ad13044f-36ef-42cf-8692-0fd226d3f2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_27dc06db-9b98-4e45-93b1-966a3a71ad2a" xlink:to="loc_us-gaap_DebtInstrumentFairValue_ad13044f-36ef-42cf-8692-0fd226d3f2b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_16b87d9b-fa28-49f3-a0e4-4df123fdc2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_27dc06db-9b98-4e45-93b1-966a3a71ad2a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_16b87d9b-fa28-49f3-a0e4-4df123fdc2b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f95e13cf-24f0-4d4c-ab8b-da980777dc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_16b87d9b-fa28-49f3-a0e4-4df123fdc2b1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f95e13cf-24f0-4d4c-ab8b-da980777dc8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f95e13cf-24f0-4d4c-ab8b-da980777dc8c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f95e13cf-24f0-4d4c-ab8b-da980777dc8c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f95e13cf-24f0-4d4c-ab8b-da980777dc8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_79a10290-aa8f-4752-a056-0f490da5dcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f95e13cf-24f0-4d4c-ab8b-da980777dc8c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_79a10290-aa8f-4752-a056-0f490da5dcb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_329354d9-22d1-4cc1-903a-8b1534037c77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_79a10290-aa8f-4752-a056-0f490da5dcb4" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_329354d9-22d1-4cc1-903a-8b1534037c77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_992fce17-d31a-4151-ba10-08ef91f534ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_16b87d9b-fa28-49f3-a0e4-4df123fdc2b1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_992fce17-d31a-4151-ba10-08ef91f534ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_992fce17-d31a-4151-ba10-08ef91f534ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_992fce17-d31a-4151-ba10-08ef91f534ff" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_992fce17-d31a-4151-ba10-08ef91f534ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bc99b064-61bb-4b80-bf61-f48b13d61f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_992fce17-d31a-4151-ba10-08ef91f534ff" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bc99b064-61bb-4b80-bf61-f48b13d61f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6bcc6940-f5c6-4483-9259-389f6cd73d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bc99b064-61bb-4b80-bf61-f48b13d61f5a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6bcc6940-f5c6-4483-9259-389f6cd73d6d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" xlink:type="extended" id="i2723a70f41dc4d72acce67c64774ef24_PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_afe43052-5c00-4c47-83e2-483639a5d4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c7f9d0a3-22dc-4d59-ad82-761614fb2c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_afe43052-5c00-4c47-83e2-483639a5d4dd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c7f9d0a3-22dc-4d59-ad82-761614fb2c14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9caf5dd0-81a9-432d-aaaa-29882520366f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_afe43052-5c00-4c47-83e2-483639a5d4dd" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9caf5dd0-81a9-432d-aaaa-29882520366f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_655af55e-1669-4558-9d17-76ef06ec307e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_afe43052-5c00-4c47-83e2-483639a5d4dd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_655af55e-1669-4558-9d17-76ef06ec307e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e8966324-05a6-40cf-b007-aa75fcb9fb53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_afe43052-5c00-4c47-83e2-483639a5d4dd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e8966324-05a6-40cf-b007-aa75fcb9fb53" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_61f3aabc-1f8f-4fc0-9a4b-c8b99d511fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e8966324-05a6-40cf-b007-aa75fcb9fb53" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_61f3aabc-1f8f-4fc0-9a4b-c8b99d511fb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61f3aabc-1f8f-4fc0-9a4b-c8b99d511fb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_61f3aabc-1f8f-4fc0-9a4b-c8b99d511fb4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61f3aabc-1f8f-4fc0-9a4b-c8b99d511fb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be03c178-fc88-46c0-bc72-6ad85fbf71f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_61f3aabc-1f8f-4fc0-9a4b-c8b99d511fb4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be03c178-fc88-46c0-bc72-6ad85fbf71f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_0512db3a-a61f-4414-aebe-f59891c23d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be03c178-fc88-46c0-bc72-6ad85fbf71f2" xlink:to="loc_us-gaap_LandMember_0512db3a-a61f-4414-aebe-f59891c23d5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_484d447f-35ec-4b06-8e19-31ffac371066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be03c178-fc88-46c0-bc72-6ad85fbf71f2" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_484d447f-35ec-4b06-8e19-31ffac371066" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_90100220-3dae-4caf-b729-2b155bfc63d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be03c178-fc88-46c0-bc72-6ad85fbf71f2" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_90100220-3dae-4caf-b729-2b155bfc63d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherEquipmentAndLeaseholdImprovementMember_cf5f829b-bdbd-4ad9-b1d5-053256a8d6be" xlink:href="bhc-20211231.xsd#bhc_OtherEquipmentAndLeaseholdImprovementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be03c178-fc88-46c0-bc72-6ad85fbf71f2" xlink:to="loc_bhc_OtherEquipmentAndLeaseholdImprovementMember_cf5f829b-bdbd-4ad9-b1d5-053256a8d6be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EquipmentOnOperatingLeaseMember_ee680c85-6e70-44e1-bdb6-9da73ffb2842" xlink:href="bhc-20211231.xsd#bhc_EquipmentOnOperatingLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be03c178-fc88-46c0-bc72-6ad85fbf71f2" xlink:to="loc_bhc_EquipmentOnOperatingLeaseMember_ee680c85-6e70-44e1-bdb6-9da73ffb2842" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_0195f7da-2dfc-4bba-a3b5-bc67bc20fa89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be03c178-fc88-46c0-bc72-6ad85fbf71f2" xlink:to="loc_us-gaap_ConstructionInProgressMember_0195f7da-2dfc-4bba-a3b5-bc67bc20fa89" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" xlink:type="extended" id="ibe9cc27f6b0f4691a6ac568ef4c5cdd6_INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_114f1522-d4e6-4962-9d85-fc825ea921d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d7e92a23-1533-43fc-9424-57f0df691c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_114f1522-d4e6-4962-9d85-fc825ea921d6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d7e92a23-1533-43fc-9424-57f0df691c8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0d5a2a68-864d-4594-96ba-b1d6444c7527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_114f1522-d4e6-4962-9d85-fc825ea921d6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0d5a2a68-864d-4594-96ba-b1d6444c7527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_eca5c5f0-7e04-465e-88e9-4ecfba086c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_114f1522-d4e6-4962-9d85-fc825ea921d6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_eca5c5f0-7e04-465e-88e9-4ecfba086c20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_36032be9-34ae-4522-804d-328327392b72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_114f1522-d4e6-4962-9d85-fc825ea921d6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_36032be9-34ae-4522-804d-328327392b72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aad9e021-ab3b-4dd5-8278-fee276a9c480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_114f1522-d4e6-4962-9d85-fc825ea921d6" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aad9e021-ab3b-4dd5-8278-fee276a9c480" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c1be9cf8-f575-40a3-96a3-5548d8eb0645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aad9e021-ab3b-4dd5-8278-fee276a9c480" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c1be9cf8-f575-40a3-96a3-5548d8eb0645" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1be9cf8-f575-40a3-96a3-5548d8eb0645_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c1be9cf8-f575-40a3-96a3-5548d8eb0645" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1be9cf8-f575-40a3-96a3-5548d8eb0645_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5bf3ad-77d2-4bd0-a894-31d36bb59c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c1be9cf8-f575-40a3-96a3-5548d8eb0645" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5bf3ad-77d2-4bd0-a894-31d36bb59c5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_d6d9aba8-57e7-498f-b839-e9bc78bb12b3" xlink:href="bhc-20211231.xsd#bhc_ProductBrandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5bf3ad-77d2-4bd0-a894-31d36bb59c5e" xlink:to="loc_bhc_ProductBrandsMember_d6d9aba8-57e7-498f-b839-e9bc78bb12b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_cf315dd9-9f5c-4532-83f3-4c3edff908da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5bf3ad-77d2-4bd0-a894-31d36bb59c5e" xlink:to="loc_us-gaap_TradeNamesMember_cf315dd9-9f5c-4532-83f3-4c3edff908da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_57cc2fa2-48d5-47ab-9cd3-60af983434a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5bf3ad-77d2-4bd0-a894-31d36bb59c5e" xlink:to="loc_us-gaap_ContractualRightsMember_57cc2fa2-48d5-47ab-9cd3-60af983434a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember_1f97f612-fd08-4098-bfeb-06b94f746dd9" xlink:href="bhc-20211231.xsd#bhc_PartnerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5bf3ad-77d2-4bd0-a894-31d36bb59c5e" xlink:to="loc_bhc_PartnerRelationshipsMember_1f97f612-fd08-4098-bfeb-06b94f746dd9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember_aeedb242-d933-4f71-8270-28bfaea8d6d4" xlink:href="bhc-20211231.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5bf3ad-77d2-4bd0-a894-31d36bb59c5e" xlink:to="loc_bhc_OutLicensedTechnologyMember_aeedb242-d933-4f71-8270-28bfaea8d6d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_97983f9d-b1e7-4422-a7f6-31754800dc08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_62e8f882-b06e-4578-b31c-96d713714f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_97983f9d-b1e7-4422-a7f6-31754800dc08" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_62e8f882-b06e-4578-b31c-96d713714f99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_24b7e7a0-cc83-4675-8824-ef4b30df4cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_97983f9d-b1e7-4422-a7f6-31754800dc08" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_24b7e7a0-cc83-4675-8824-ef4b30df4cd1" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4806a443-2e9b-4e58-bea9-70c9af010113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_24b7e7a0-cc83-4675-8824-ef4b30df4cd1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4806a443-2e9b-4e58-bea9-70c9af010113" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4806a443-2e9b-4e58-bea9-70c9af010113_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4806a443-2e9b-4e58-bea9-70c9af010113" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4806a443-2e9b-4e58-bea9-70c9af010113_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b5956abc-9beb-4121-96d5-d61877ede824" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4806a443-2e9b-4e58-bea9-70c9af010113" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b5956abc-9beb-4121-96d5-d61877ede824" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_14892ad6-f722-4a79-9f51-76875a0da20b" xlink:href="bhc-20211231.xsd#bhc_AcquiredInProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b5956abc-9beb-4121-96d5-d61877ede824" xlink:to="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_14892ad6-f722-4a79-9f51-76875a0da20b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_209690a4-231a-4754-acbf-10556ecefa0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b5956abc-9beb-4121-96d5-d61877ede824" xlink:to="loc_us-gaap_TrademarksMember_209690a4-231a-4754-acbf-10556ecefa0a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INTANGIBLEASSETSANDGOODWILLNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="extended" id="ic8c16bd994904d8782c7898298aba520_INTANGIBLEASSETSANDGOODWILLNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a312cf82-1522-436b-8ab0-84a40c386da8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a312cf82-1522-436b-8ab0-84a40c386da8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_01484552-3758-46e4-8caa-2cce214c9199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_01484552-3758-46e4-8caa-2cce214c9199" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_a18d4e70-f9bb-49d0-b647-ac37b05b8479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_a18d4e70-f9bb-49d0-b647-ac37b05b8479" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_42453677-10d1-4b08-a9bb-3ddbc585b306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_42453677-10d1-4b08-a9bb-3ddbc585b306" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_580f69e7-8511-4237-b2fd-1b181373ca49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_580f69e7-8511-4237-b2fd-1b181373ca49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax_73bfbc47-01cc-4a09-8660-d685fe9ced7e" xlink:href="bhc-20211231.xsd#bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax_73bfbc47-01cc-4a09-8660-d685fe9ced7e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage_4bca5015-ed31-4b73-aaa5-ee666625a3e2" xlink:href="bhc-20211231.xsd#bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage_4bca5015-ed31-4b73-aaa5-ee666625a3e2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_a9db8d5e-356f-4f36-8d81-7696a12c7b75" xlink:href="bhc-20211231.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_a9db8d5e-356f-4f36-8d81-7696a12c7b75" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_03a31057-cacb-413b-be2f-af861d9d6082" xlink:href="bhc-20211231.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_03a31057-cacb-413b-be2f-af861d9d6082" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_acea1b33-6f6a-4121-96b2-cbb485ba1950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_acea1b33-6f6a-4121-96b2-cbb485ba1950" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_e9978df8-24b6-47b8-a6a0-7df531668db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_e9978df8-24b6-47b8-a6a0-7df531668db1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_38cb7d34-b201-4adb-9a14-6959f6e0764a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_38cb7d34-b201-4adb-9a14-6959f6e0764a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9055e847-42fa-439f-a625-d29fb7ca381e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_38cb7d34-b201-4adb-9a14-6959f6e0764a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9055e847-42fa-439f-a625-d29fb7ca381e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9055e847-42fa-439f-a625-d29fb7ca381e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9055e847-42fa-439f-a625-d29fb7ca381e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9055e847-42fa-439f-a625-d29fb7ca381e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a716a3a-760d-48d8-8087-9a0a1a713cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9055e847-42fa-439f-a625-d29fb7ca381e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a716a3a-760d-48d8-8087-9a0a1a713cd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_3b62fed8-33a7-43b6-a9d4-4cff98c1d832" xlink:href="bhc-20211231.xsd#bhc_ProductBrandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a716a3a-760d-48d8-8087-9a0a1a713cd9" xlink:to="loc_bhc_ProductBrandsMember_3b62fed8-33a7-43b6-a9d4-4cff98c1d832" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember_d64d9a98-19fb-450f-b112-8cafa442fcea" xlink:href="bhc-20211231.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a716a3a-760d-48d8-8087-9a0a1a713cd9" xlink:to="loc_bhc_DiscontinuedProductLinesMember_d64d9a98-19fb-450f-b112-8cafa442fcea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_f6ceb968-3c80-4e4a-9304-38037b5a231d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a716a3a-760d-48d8-8087-9a0a1a713cd9" xlink:to="loc_us-gaap_ContractualRightsMember_f6ceb968-3c80-4e4a-9304-38037b5a231d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnutilizedITInfrastructureImprovementProjectMember_60ae301a-20b7-4a3f-b017-18e2209323c2" xlink:href="bhc-20211231.xsd#bhc_UnutilizedITInfrastructureImprovementProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a716a3a-760d-48d8-8087-9a0a1a713cd9" xlink:to="loc_bhc_UnutilizedITInfrastructureImprovementProjectMember_60ae301a-20b7-4a3f-b017-18e2209323c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_94479e79-1f05-4fde-8e6d-3ef0ae09a795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_38cb7d34-b201-4adb-9a14-6959f6e0764a" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_94479e79-1f05-4fde-8e6d-3ef0ae09a795" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_94479e79-1f05-4fde-8e6d-3ef0ae09a795_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_94479e79-1f05-4fde-8e6d-3ef0ae09a795" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_94479e79-1f05-4fde-8e6d-3ef0ae09a795_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1ce6e138-926f-4d48-a0d1-ad3b4805cdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_94479e79-1f05-4fde-8e6d-3ef0ae09a795" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_1ce6e138-926f-4d48-a0d1-ad3b4805cdd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f595129d-a9b3-4f29-8393-9a355290aaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1ce6e138-926f-4d48-a0d1-ad3b4805cdd4" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f595129d-a9b3-4f29-8393-9a355290aaa3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_793961c2-71b6-4cfb-a58f-c023f43707d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1ce6e138-926f-4d48-a0d1-ad3b4805cdd4" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_793961c2-71b6-4cfb-a58f-c023f43707d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_96083221-8c2e-4059-9d14-42318918fc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_38cb7d34-b201-4adb-9a14-6959f6e0764a" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_96083221-8c2e-4059-9d14-42318918fc3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_96083221-8c2e-4059-9d14-42318918fc3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_96083221-8c2e-4059-9d14-42318918fc3a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_96083221-8c2e-4059-9d14-42318918fc3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d4365200-12be-424d-9351-5904d5f71dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_96083221-8c2e-4059-9d14-42318918fc3a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d4365200-12be-424d-9351-5904d5f71dfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_cdcb3cc1-afd9-4f11-814b-5eb7b7e8b628" xlink:href="bhc-20211231.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d4365200-12be-424d-9351-5904d5f71dfc" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_cdcb3cc1-afd9-4f11-814b-5eb7b7e8b628" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ACertainInternationalBusinessMember_dc61366f-896c-41dc-8786-b3d1d918baaa" xlink:href="bhc-20211231.xsd#bhc_ACertainInternationalBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d4365200-12be-424d-9351-5904d5f71dfc" xlink:to="loc_bhc_ACertainInternationalBusinessMember_dc61366f-896c-41dc-8786-b3d1d918baaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_6bff19e5-6017-4da4-9a1a-d9df4b75f2d9" xlink:href="bhc-20211231.xsd#bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d4365200-12be-424d-9351-5904d5f71dfc" xlink:to="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_6bff19e5-6017-4da4-9a1a-d9df4b75f2d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2dfea9bf-e14c-4d59-9e06-fc9870752f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_38cb7d34-b201-4adb-9a14-6959f6e0764a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2dfea9bf-e14c-4d59-9e06-fc9870752f0e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2dfea9bf-e14c-4d59-9e06-fc9870752f0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2dfea9bf-e14c-4d59-9e06-fc9870752f0e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2dfea9bf-e14c-4d59-9e06-fc9870752f0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9e2a606b-4fa0-4527-b560-b369d860bbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2dfea9bf-e14c-4d59-9e06-fc9870752f0e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9e2a606b-4fa0-4527-b560-b369d860bbaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_637adf60-fd6b-4299-80d0-ba768be6b883" xlink:href="bhc-20211231.xsd#bhc_AcquiredInProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9e2a606b-4fa0-4527-b560-b369d860bbaa" xlink:to="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_637adf60-fd6b-4299-80d0-ba768be6b883" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fd325754-d2df-4705-99c6-fd4777056de0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_38cb7d34-b201-4adb-9a14-6959f6e0764a" xlink:to="loc_srt_RangeAxis_fd325754-d2df-4705-99c6-fd4777056de0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fd325754-d2df-4705-99c6-fd4777056de0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fd325754-d2df-4705-99c6-fd4777056de0" xlink:to="loc_srt_RangeMember_fd325754-d2df-4705-99c6-fd4777056de0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_07580929-692a-46af-8ce6-e8caf151d698" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fd325754-d2df-4705-99c6-fd4777056de0" xlink:to="loc_srt_RangeMember_07580929-692a-46af-8ce6-e8caf151d698" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_23c83221-5ea8-4999-9faa-382db8f651c9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_07580929-692a-46af-8ce6-e8caf151d698" xlink:to="loc_srt_MinimumMember_23c83221-5ea8-4999-9faa-382db8f651c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1be68648-8e9a-4cbd-814d-c7c890c46d9e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_07580929-692a-46af-8ce6-e8caf151d698" xlink:to="loc_srt_MaximumMember_1be68648-8e9a-4cbd-814d-c7c890c46d9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_063b9b20-8bee-4d40-a8e8-cf8de404b15b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_38cb7d34-b201-4adb-9a14-6959f6e0764a" xlink:to="loc_us-gaap_ReportingUnitAxis_063b9b20-8bee-4d40-a8e8-cf8de404b15b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_063b9b20-8bee-4d40-a8e8-cf8de404b15b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_063b9b20-8bee-4d40-a8e8-cf8de404b15b" xlink:to="loc_us-gaap_ReportingUnitDomain_063b9b20-8bee-4d40-a8e8-cf8de404b15b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_a765decb-32c4-4f94-a1ad-d40e5785ad9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_063b9b20-8bee-4d40-a8e8-cf8de404b15b" xlink:to="loc_us-gaap_ReportingUnitDomain_a765decb-32c4-4f94-a1ad-d40e5785ad9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsReportingUnitMember_ac280024-e090-4999-8ec2-f4d50cb647d8" xlink:href="bhc-20211231.xsd#bhc_OrthoDermatologicsReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_a765decb-32c4-4f94-a1ad-d40e5785ad9c" xlink:to="loc_bhc_OrthoDermatologicsReportingUnitMember_ac280024-e090-4999-8ec2-f4d50cb647d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_a212455d-a302-4906-b2b0-46c416663f67" xlink:href="bhc-20211231.xsd#bhc_ReportingUnitsExcludingOrthoDermatologicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_a765decb-32c4-4f94-a1ad-d40e5785ad9c" xlink:to="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_a212455d-a302-4906-b2b0-46c416663f67" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" xlink:type="extended" id="if38bd48245de40d7b6a14a388e10dc36_INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_b4ab5795-f97e-4896-94bb-0053e6688170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_1113047f-d691-4bb0-a4d1-da8aeb6ec150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_b4ab5795-f97e-4896-94bb-0053e6688170" xlink:to="loc_us-gaap_GoodwillRollForward_1113047f-d691-4bb0-a4d1-da8aeb6ec150" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_105305b9-7303-42b0-bd96-e76983867548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_1113047f-d691-4bb0-a4d1-da8aeb6ec150" xlink:to="loc_us-gaap_Goodwill_105305b9-7303-42b0-bd96-e76983867548" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_8b8c7714-41d3-4a21-a894-c79fb9cd4d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_1113047f-d691-4bb0-a4d1-da8aeb6ec150" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_8b8c7714-41d3-4a21-a894-c79fb9cd4d90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_82818837-598a-4319-9b18-508c405d8159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_1113047f-d691-4bb0-a4d1-da8aeb6ec150" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_82818837-598a-4319-9b18-508c405d8159" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_fe75e274-0626-46b7-8491-13f16cc5a506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_1113047f-d691-4bb0-a4d1-da8aeb6ec150" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_fe75e274-0626-46b7-8491-13f16cc5a506" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit_532983a4-d122-4576-b487-64fdaa722eca" xlink:href="bhc-20211231.xsd#bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_1113047f-d691-4bb0-a4d1-da8aeb6ec150" xlink:to="loc_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit_532983a4-d122-4576-b487-64fdaa722eca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_38ddddc1-a173-410a-80be-12ba6c6c833f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_1113047f-d691-4bb0-a4d1-da8aeb6ec150" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_38ddddc1-a173-410a-80be-12ba6c6c833f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_faaaa542-d1f2-4835-bbfa-d97463058745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_1113047f-d691-4bb0-a4d1-da8aeb6ec150" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_faaaa542-d1f2-4835-bbfa-d97463058745" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_73793cdd-5999-4177-93e2-69ee9d829857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_f4ad738b-9775-4e60-b82d-1fe2aefbf531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_b4ab5795-f97e-4896-94bb-0053e6688170" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_f4ad738b-9775-4e60-b82d-1fe2aefbf531" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_00ff477d-7cf7-4b6c-8693-8632449ed549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_f4ad738b-9775-4e60-b82d-1fe2aefbf531" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_00ff477d-7cf7-4b6c-8693-8632449ed549" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_00ff477d-7cf7-4b6c-8693-8632449ed549_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_00ff477d-7cf7-4b6c-8693-8632449ed549" xlink:to="loc_us-gaap_SegmentDomain_00ff477d-7cf7-4b6c-8693-8632449ed549_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_52b26070-2da8-45c6-b7a0-f6be8e2435ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_00ff477d-7cf7-4b6c-8693-8632449ed549" xlink:to="loc_us-gaap_SegmentDomain_52b26070-2da8-45c6-b7a0-f6be8e2435ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombInternationalMember_925f5869-da63-48b6-94b2-550cb17370e6" xlink:href="bhc-20211231.xsd#bhc_BauschLombInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_52b26070-2da8-45c6-b7a0-f6be8e2435ef" xlink:to="loc_bhc_BauschLombInternationalMember_925f5869-da63-48b6-94b2-550cb17370e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_09e03c12-50a5-4ddb-87b3-ac435053daa1" xlink:href="bhc-20211231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_52b26070-2da8-45c6-b7a0-f6be8e2435ef" xlink:to="loc_bhc_BauschLombMember_09e03c12-50a5-4ddb-87b3-ac435053daa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_600806fe-42e1-45fa-b2bf-8509e5186a4a" xlink:href="bhc-20211231.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_52b26070-2da8-45c6-b7a0-f6be8e2435ef" xlink:to="loc_bhc_SalixSegmentMember_600806fe-42e1-45fa-b2bf-8509e5186a4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_7ce7be55-438e-4e4a-8b4e-242ff13a7803" xlink:href="bhc-20211231.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_52b26070-2da8-45c6-b7a0-f6be8e2435ef" xlink:to="loc_bhc_InternationalRxMember_7ce7be55-438e-4e4a-8b4e-242ff13a7803" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_b48ba529-efe8-4dbe-80c3-3aa44f46a94c" xlink:href="bhc-20211231.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_52b26070-2da8-45c6-b7a0-f6be8e2435ef" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_b48ba529-efe8-4dbe-80c3-3aa44f46a94c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_0eba6f43-dc71-428b-941f-c96fe41b0a10" xlink:href="bhc-20211231.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_52b26070-2da8-45c6-b7a0-f6be8e2435ef" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_0eba6f43-dc71-428b-941f-c96fe41b0a10" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended" id="ie37d7431f6a24517a578d3b3e317103e_FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3d8a0faa-d0fd-4328-9343-e5b4e67e8422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6aa5ef6c-1c04-4cf7-b5c6-f53ca854e628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d8a0faa-d0fd-4328-9343-e5b4e67e8422" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6aa5ef6c-1c04-4cf7-b5c6-f53ca854e628" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_a358565b-a10d-49f8-a527-e6e1d35f5bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d8a0faa-d0fd-4328-9343-e5b4e67e8422" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_a358565b-a10d-49f8-a527-e6e1d35f5bd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_93896447-c68c-40f8-86e9-93182da026ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d8a0faa-d0fd-4328-9343-e5b4e67e8422" xlink:to="loc_us-gaap_LongTermDebt_93896447-c68c-40f8-86e9-93182da026ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_d8b47398-1762-4286-a1da-97b159d5e53d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d8a0faa-d0fd-4328-9343-e5b4e67e8422" xlink:to="loc_us-gaap_LongTermDebtCurrent_d8b47398-1762-4286-a1da-97b159d5e53d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1daa59c3-f37d-4fa7-abdd-b1b5906a2491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d8a0faa-d0fd-4328-9343-e5b4e67e8422" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1daa59c3-f37d-4fa7-abdd-b1b5906a2491" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_55982417-bfb2-4e3c-a2c7-ceb88c165cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d8a0faa-d0fd-4328-9343-e5b4e67e8422" xlink:to="loc_us-gaap_DebtInstrumentTable_55982417-bfb2-4e3c-a2c7-ceb88c165cd6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_9774a7f6-7182-4d7d-9f2f-4fba993c3742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_55982417-bfb2-4e3c-a2c7-ceb88c165cd6" xlink:to="loc_us-gaap_CreditFacilityAxis_9774a7f6-7182-4d7d-9f2f-4fba993c3742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9774a7f6-7182-4d7d-9f2f-4fba993c3742_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_9774a7f6-7182-4d7d-9f2f-4fba993c3742" xlink:to="loc_us-gaap_CreditFacilityDomain_9774a7f6-7182-4d7d-9f2f-4fba993c3742_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_619af6d5-ddaa-42c8-bb38-c499bdc372b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_9774a7f6-7182-4d7d-9f2f-4fba993c3742" xlink:to="loc_us-gaap_CreditFacilityDomain_619af6d5-ddaa-42c8-bb38-c499bdc372b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_e73f2d0c-704a-4885-8185-34d61703d378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_619af6d5-ddaa-42c8-bb38-c499bdc372b0" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_e73f2d0c-704a-4885-8185-34d61703d378" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7dad9541-e1ed-4405-bdf8-e1e1e17ab55e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_55982417-bfb2-4e3c-a2c7-ceb88c165cd6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7dad9541-e1ed-4405-bdf8-e1e1e17ab55e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7dad9541-e1ed-4405-bdf8-e1e1e17ab55e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7dad9541-e1ed-4405-bdf8-e1e1e17ab55e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7dad9541-e1ed-4405-bdf8-e1e1e17ab55e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_405993ef-c63f-426a-bb0c-49d720d734c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7dad9541-e1ed-4405-bdf8-e1e1e17ab55e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_405993ef-c63f-426a-bb0c-49d720d734c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_32d8d806-29b3-41f0-a8f2-92224e22bda4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_405993ef-c63f-426a-bb0c-49d720d734c5" xlink:to="loc_us-gaap_SecuredDebtMember_32d8d806-29b3-41f0-a8f2-92224e22bda4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_beb55e3c-1188-49d7-9e17-e3a4613b5a97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_405993ef-c63f-426a-bb0c-49d720d734c5" xlink:to="loc_us-gaap_UnsecuredDebtMember_beb55e3c-1188-49d7-9e17-e3a4613b5a97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_226f3a43-b2e3-4a8a-9e2c-eeec7edb1fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_55982417-bfb2-4e3c-a2c7-ceb88c165cd6" xlink:to="loc_us-gaap_DebtInstrumentAxis_226f3a43-b2e3-4a8a-9e2c-eeec7edb1fd3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_226f3a43-b2e3-4a8a-9e2c-eeec7edb1fd3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_226f3a43-b2e3-4a8a-9e2c-eeec7edb1fd3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_226f3a43-b2e3-4a8a-9e2c-eeec7edb1fd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_226f3a43-b2e3-4a8a-9e2c-eeec7edb1fd3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_92b3c396-895f-4ec6-bacb-cc46685a8dec" xlink:href="bhc-20211231.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_92b3c396-895f-4ec6-bacb-cc46685a8dec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_6abddc06-be69-4b1a-9adb-e2f5f9f8752c" xlink:href="bhc-20211231.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_6abddc06-be69-4b1a-9adb-e2f5f9f8752c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_980b362a-e9dd-4ea7-a0fc-56756d03967e" xlink:href="bhc-20211231.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_980b362a-e9dd-4ea7-a0fc-56756d03967e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_355e38c7-12c4-4bca-9328-ad878bcdff6e" xlink:href="bhc-20211231.xsd#bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_355e38c7-12c4-4bca-9328-ad878bcdff6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_785a81c9-c007-4836-9edf-e8145f7721c5" xlink:href="bhc-20211231.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_785a81c9-c007-4836-9edf-e8145f7721c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_4d6f55b4-d1df-4bbc-a87a-00a97e4b0c54" xlink:href="bhc-20211231.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_4d6f55b4-d1df-4bbc-a87a-00a97e4b0c54" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_09f6db1b-bfd1-4470-a30b-1e83a87cbad8" xlink:href="bhc-20211231.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_09f6db1b-bfd1-4470-a30b-1e83a87cbad8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_3a9b5013-d86a-4614-a561-7f7d36b7c581" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_3a9b5013-d86a-4614-a561-7f7d36b7c581" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member_842f1031-d780-411d-b0e3-dbd6d8a4af68" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorNotes900DueDecember2025Member_842f1031-d780-411d-b0e3-dbd6d8a4af68" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_47ac3adf-d548-4c69-a52a-9eca26e62f0b" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_47ac3adf-d548-4c69-a52a-9eca26e62f0b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_acb14332-4bbf-4c6b-8416-65913d0105cb" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_acb14332-4bbf-4c6b-8416-65913d0105cb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_3f092d7c-a62c-4efc-a34e-ea43448971f3" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_3f092d7c-a62c-4efc-a34e-ea43448971f3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_e8f0a52b-bef9-42d7-b789-74d7f8ad3954" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_e8f0a52b-bef9-42d7-b789-74d7f8ad3954" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_4839634c-57d1-4a26-9aad-99361d8ebc50" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_4839634c-57d1-4a26-9aad-99361d8ebc50" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_b0aaac12-52bc-472c-9e54-28ef8ff0bb30" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_b0aaac12-52bc-472c-9e54-28ef8ff0bb30" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_54dd702b-db1b-428d-b342-68ec6765b0c0" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_54dd702b-db1b-428d-b342-68ec6765b0c0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member_2355614a-d64d-44fd-8f06-fa3103836096" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorNotes525DueJanuary2030Member_2355614a-d64d-44fd-8f06-fa3103836096" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_4a81bf4f-78d8-4fef-adf5-bf8141e05940" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_4a81bf4f-78d8-4fef-adf5-bf8141e05940" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember_1d112b01-a7c8-46bf-9fd6-19064e7e058e" xlink:href="bhc-20211231.xsd#bhc_OtherLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_OtherLongTermDebtMember_1d112b01-a7c8-46bf-9fd6-19064e7e058e" xlink:type="arc" order="18"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FINANCINGARRANGEMENTSCovenantComplianceDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="extended" id="i007554a979aa4b88a51e2f35594d4f50_FINANCINGARRANGEMENTSCovenantComplianceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f7b15e56-c6fd-4ac9-83f4-f34a04a66f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAmountAvailableForRestrictedPayments_bdba8fa8-26cb-4776-b614-f53dcbb8a7b5" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentAmountAvailableForRestrictedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f7b15e56-c6fd-4ac9-83f4-f34a04a66f1d" xlink:to="loc_bhc_DebtInstrumentAmountAvailableForRestrictedPayments_bdba8fa8-26cb-4776-b614-f53dcbb8a7b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_598fa9b8-e73f-4960-8a70-aaa72ca6b9d1" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f7b15e56-c6fd-4ac9-83f4-f34a04a66f1d" xlink:to="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_598fa9b8-e73f-4960-8a70-aaa72ca6b9d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_831be7c1-d9e7-4b6c-b35c-45a8264fddc8" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f7b15e56-c6fd-4ac9-83f4-f34a04a66f1d" xlink:to="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_831be7c1-d9e7-4b6c-b35c-45a8264fddc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_90ef9b5e-0c02-498d-a482-46dc8c2e7431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f7b15e56-c6fd-4ac9-83f4-f34a04a66f1d" xlink:to="loc_us-gaap_DebtInstrumentTable_90ef9b5e-0c02-498d-a482-46dc8c2e7431" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_b276147e-e00a-4230-a6fc-e7f93fafed14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_90ef9b5e-0c02-498d-a482-46dc8c2e7431" xlink:to="loc_us-gaap_CreditFacilityAxis_b276147e-e00a-4230-a6fc-e7f93fafed14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b276147e-e00a-4230-a6fc-e7f93fafed14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_b276147e-e00a-4230-a6fc-e7f93fafed14" xlink:to="loc_us-gaap_CreditFacilityDomain_b276147e-e00a-4230-a6fc-e7f93fafed14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_54568c54-2686-4ecf-b918-8cefee6a7af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_b276147e-e00a-4230-a6fc-e7f93fafed14" xlink:to="loc_us-gaap_CreditFacilityDomain_54568c54-2686-4ecf-b918-8cefee6a7af9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_d3abb78b-4867-4256-a25f-2515b63b7575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_54568c54-2686-4ecf-b918-8cefee6a7af9" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_d3abb78b-4867-4256-a25f-2515b63b7575" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="extended" id="ibdad1792904c4ff5bf73020cc0ac1d43_FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d69a3401-ea0d-4b23-bfaf-8476dd85d758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1acf76aa-c08a-4251-82e2-d29b209fde96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d69a3401-ea0d-4b23-bfaf-8476dd85d758" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1acf76aa-c08a-4251-82e2-d29b209fde96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_e46211c9-23b3-4df5-b145-0f3481f2ab0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d69a3401-ea0d-4b23-bfaf-8476dd85d758" xlink:to="loc_us-gaap_DebtInstrumentTerm_e46211c9-23b3-4df5-b145-0f3481f2ab0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_786c90eb-45ff-4837-b178-67841f4f0f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d69a3401-ea0d-4b23-bfaf-8476dd85d758" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_786c90eb-45ff-4837-b178-67841f4f0f6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_9a74cc12-dc3d-44d4-8f97-b3028733a566" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d69a3401-ea0d-4b23-bfaf-8476dd85d758" xlink:to="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_9a74cc12-dc3d-44d4-8f97-b3028733a566" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_c57f7a28-bc55-4edd-9a04-b89a1b77de5e" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d69a3401-ea0d-4b23-bfaf-8476dd85d758" xlink:to="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_c57f7a28-bc55-4edd-9a04-b89a1b77de5e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0246ae63-0c60-4a2a-b884-b91afcd000fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d69a3401-ea0d-4b23-bfaf-8476dd85d758" xlink:to="loc_us-gaap_LongTermDebt_0246ae63-0c60-4a2a-b884-b91afcd000fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_2767817d-77f4-4ba0-8ffd-9cd5f2042884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d69a3401-ea0d-4b23-bfaf-8476dd85d758" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_2767817d-77f4-4ba0-8ffd-9cd5f2042884" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a240b3e1-a64f-4b37-b0da-ff0ee38a7ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d69a3401-ea0d-4b23-bfaf-8476dd85d758" xlink:to="loc_us-gaap_DebtInstrumentTable_a240b3e1-a64f-4b37-b0da-ff0ee38a7ed3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_084d7aca-93a9-4d39-a913-a8f362a8fc35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a240b3e1-a64f-4b37-b0da-ff0ee38a7ed3" xlink:to="loc_us-gaap_CreditFacilityAxis_084d7aca-93a9-4d39-a913-a8f362a8fc35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_084d7aca-93a9-4d39-a913-a8f362a8fc35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_084d7aca-93a9-4d39-a913-a8f362a8fc35" xlink:to="loc_us-gaap_CreditFacilityDomain_084d7aca-93a9-4d39-a913-a8f362a8fc35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a0fc9ada-cd76-47b9-8f3f-bf6ec35a336b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_084d7aca-93a9-4d39-a913-a8f362a8fc35" xlink:to="loc_us-gaap_CreditFacilityDomain_a0fc9ada-cd76-47b9-8f3f-bf6ec35a336b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_451baf61-b583-4673-b904-f72caddad0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_a0fc9ada-cd76-47b9-8f3f-bf6ec35a336b" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_451baf61-b583-4673-b904-f72caddad0c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_35c88e8d-013e-488d-adec-4db141197ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_a0fc9ada-cd76-47b9-8f3f-bf6ec35a336b" xlink:to="loc_us-gaap_LetterOfCreditMember_35c88e8d-013e-488d-adec-4db141197ba9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_78cdb7e0-1097-4904-ab42-14d7e98a7f79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a240b3e1-a64f-4b37-b0da-ff0ee38a7ed3" xlink:to="loc_us-gaap_DebtInstrumentAxis_78cdb7e0-1097-4904-ab42-14d7e98a7f79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_78cdb7e0-1097-4904-ab42-14d7e98a7f79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_78cdb7e0-1097-4904-ab42-14d7e98a7f79" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_78cdb7e0-1097-4904-ab42-14d7e98a7f79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_319108be-2df5-44c5-99b0-dcc28ff9ecdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_78cdb7e0-1097-4904-ab42-14d7e98a7f79" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_319108be-2df5-44c5-99b0-dcc28ff9ecdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_1a6b26b8-5e16-4d51-8c16-052c96024c10" xlink:href="bhc-20211231.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_319108be-2df5-44c5-99b0-dcc28ff9ecdc" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_1a6b26b8-5e16-4d51-8c16-052c96024c10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_00c1cecc-8894-429d-a4c9-e91568e3dfd6" xlink:href="bhc-20211231.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_319108be-2df5-44c5-99b0-dcc28ff9ecdc" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_00c1cecc-8894-429d-a4c9-e91568e3dfd6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" xlink:type="extended" id="i6f1851f7f6e249a1b68b2a263279faea_FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6f256ef2-efee-4d4e-a88a-565fdc5eb158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6f256ef2-efee-4d4e-a88a-565fdc5eb158" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_f9331770-3b65-4a13-9215-cdc223f289f6" xlink:href="bhc-20211231.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_f9331770-3b65-4a13-9215-cdc223f289f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_9bcc2ac5-ef7d-4cae-92ff-9f82f82705aa" xlink:href="bhc-20211231.xsd#bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_9bcc2ac5-ef7d-4cae-92ff-9f82f82705aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_f09d7be0-5eae-44be-bcf2-050d285f6214" xlink:href="bhc-20211231.xsd#bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_f09d7be0-5eae-44be-bcf2-050d285f6214" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_57e20acc-1148-4259-98d8-0b8a0ba0b7b4" xlink:href="bhc-20211231.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_57e20acc-1148-4259-98d8-0b8a0ba0b7b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_be8cd2c2-18ee-422f-8876-b1129a74d7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_be8cd2c2-18ee-422f-8876-b1129a74d7cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_cf0d0dfb-18dc-4d13-b0fe-6549e82f7e76" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_cf0d0dfb-18dc-4d13-b0fe-6549e82f7e76" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_bd790ea4-e81c-4497-94e3-1e634c0610aa" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_bd790ea4-e81c-4497-94e3-1e634c0610aa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_601d3046-c063-47ea-964e-fa4d35a4ee95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_601d3046-c063-47ea-964e-fa4d35a4ee95" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_74196d1b-76f5-4589-af17-c6f1c29cd2fb" xlink:href="bhc-20211231.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_74196d1b-76f5-4589-af17-c6f1c29cd2fb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate_8e26b4ea-34e7-4e14-b6aa-bbf32a83771b" xlink:href="bhc-20211231.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate_8e26b4ea-34e7-4e14-b6aa-bbf32a83771b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_0ff20578-dc9d-4577-ad3b-14961f1f442c" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_0ff20578-dc9d-4577-ad3b-14961f1f442c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_3e9d231e-fe74-43c5-94fe-df030a5fb402" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_3e9d231e-fe74-43c5-94fe-df030a5fb402" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_03c56c7c-3c3b-4b12-9868-cb846f14592e" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_03c56c7c-3c3b-4b12-9868-cb846f14592e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6560fb16-6d1f-4a4c-be98-5c5e819ed768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_us-gaap_DebtInstrumentTable_6560fb16-6d1f-4a4c-be98-5c5e819ed768" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_41cab401-f83d-492e-bb7a-3fae5302f2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6560fb16-6d1f-4a4c-be98-5c5e819ed768" xlink:to="loc_us-gaap_VariableRateAxis_41cab401-f83d-492e-bb7a-3fae5302f2e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_41cab401-f83d-492e-bb7a-3fae5302f2e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_41cab401-f83d-492e-bb7a-3fae5302f2e3" xlink:to="loc_us-gaap_VariableRateDomain_41cab401-f83d-492e-bb7a-3fae5302f2e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0bb34aef-2367-463b-94a2-78e45a394b45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_41cab401-f83d-492e-bb7a-3fae5302f2e3" xlink:to="loc_us-gaap_VariableRateDomain_0bb34aef-2367-463b-94a2-78e45a394b45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_d4021592-9b5a-4e5c-8852-12af0a2b4ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0bb34aef-2367-463b-94a2-78e45a394b45" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_d4021592-9b5a-4e5c-8852-12af0a2b4ca4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_917d5abd-7fc0-46e2-a926-05e5dcf9ce9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0bb34aef-2367-463b-94a2-78e45a394b45" xlink:to="loc_us-gaap_EurodollarMember_917d5abd-7fc0-46e2-a926-05e5dcf9ce9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadaBankersAcceptanceRateMember_5c8a2b88-b9ed-4a3d-b212-d0c350c6804e" xlink:href="bhc-20211231.xsd#bhc_CanadaBankersAcceptanceRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0bb34aef-2367-463b-94a2-78e45a394b45" xlink:to="loc_bhc_CanadaBankersAcceptanceRateMember_5c8a2b88-b9ed-4a3d-b212-d0c350c6804e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateOrPrimeRateMember_5bfc3239-e152-4b69-962c-ef47f7ce5a34" xlink:href="bhc-20211231.xsd#bhc_BaseRateOrPrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0bb34aef-2367-463b-94a2-78e45a394b45" xlink:to="loc_bhc_BaseRateOrPrimeRateMember_5bfc3239-e152-4b69-962c-ef47f7ce5a34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_36c4c44f-eb92-44dc-a8e4-755347580ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6560fb16-6d1f-4a4c-be98-5c5e819ed768" xlink:to="loc_us-gaap_DebtInstrumentAxis_36c4c44f-eb92-44dc-a8e4-755347580ff4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_36c4c44f-eb92-44dc-a8e4-755347580ff4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_36c4c44f-eb92-44dc-a8e4-755347580ff4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_36c4c44f-eb92-44dc-a8e4-755347580ff4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a0b3471e-a319-404e-b07b-e2235bb3857d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_36c4c44f-eb92-44dc-a8e4-755347580ff4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a0b3471e-a319-404e-b07b-e2235bb3857d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember_8ba38fd9-b580-43a7-9ff8-164be2164cc9" xlink:href="bhc-20211231.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a0b3471e-a319-404e-b07b-e2235bb3857d" xlink:to="loc_bhc_SeniorSecuredCreditFacilitiesMember_8ba38fd9-b580-43a7-9ff8-164be2164cc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_4086ead9-7ded-41f9-bf22-2f58cf737973" xlink:href="bhc-20211231.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a0b3471e-a319-404e-b07b-e2235bb3857d" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_4086ead9-7ded-41f9-bf22-2f58cf737973" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredTermCreditFacilitiesMember_6632f3fe-cfaa-48bf-a5f6-d0ce83b32486" xlink:href="bhc-20211231.xsd#bhc_SeniorSecuredTermCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a0b3471e-a319-404e-b07b-e2235bb3857d" xlink:to="loc_bhc_SeniorSecuredTermCreditFacilitiesMember_6632f3fe-cfaa-48bf-a5f6-d0ce83b32486" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_922a5d9f-dbb2-4718-ba59-c63a249d8545" xlink:href="bhc-20211231.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a0b3471e-a319-404e-b07b-e2235bb3857d" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_922a5d9f-dbb2-4718-ba59-c63a249d8545" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_3143a891-9812-426d-8dfe-58ad622d64f7" xlink:href="bhc-20211231.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a0b3471e-a319-404e-b07b-e2235bb3857d" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_3143a891-9812-426d-8dfe-58ad622d64f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_51aa96cb-de70-48a1-9f46-4e8f5cbb5e19" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6560fb16-6d1f-4a4c-be98-5c5e819ed768" xlink:to="loc_srt_RangeAxis_51aa96cb-de70-48a1-9f46-4e8f5cbb5e19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_51aa96cb-de70-48a1-9f46-4e8f5cbb5e19_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_51aa96cb-de70-48a1-9f46-4e8f5cbb5e19" xlink:to="loc_srt_RangeMember_51aa96cb-de70-48a1-9f46-4e8f5cbb5e19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4132fa20-ccc2-4a16-a0be-0076b1f364a8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_51aa96cb-de70-48a1-9f46-4e8f5cbb5e19" xlink:to="loc_srt_RangeMember_4132fa20-ccc2-4a16-a0be-0076b1f364a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2f7de1b9-19a2-4cce-ba2c-a2f5dee48843" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4132fa20-ccc2-4a16-a0be-0076b1f364a8" xlink:to="loc_srt_MinimumMember_2f7de1b9-19a2-4cce-ba2c-a2f5dee48843" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_eecb83cc-7b69-4633-9a56-fe3b294f5c5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4132fa20-ccc2-4a16-a0be-0076b1f364a8" xlink:to="loc_srt_MaximumMember_eecb83cc-7b69-4633-9a56-fe3b294f5c5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_16a35264-e27a-4fd8-b94e-4aa2e2617204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6560fb16-6d1f-4a4c-be98-5c5e819ed768" xlink:to="loc_us-gaap_CreditFacilityAxis_16a35264-e27a-4fd8-b94e-4aa2e2617204" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_16a35264-e27a-4fd8-b94e-4aa2e2617204_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_16a35264-e27a-4fd8-b94e-4aa2e2617204" xlink:to="loc_us-gaap_CreditFacilityDomain_16a35264-e27a-4fd8-b94e-4aa2e2617204_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ddcd0b94-9422-4bee-b808-53c6911e1c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_16a35264-e27a-4fd8-b94e-4aa2e2617204" xlink:to="loc_us-gaap_CreditFacilityDomain_ddcd0b94-9422-4bee-b808-53c6911e1c4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_88eacb6d-1d3f-478f-882e-171cab2ae5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_ddcd0b94-9422-4bee-b808-53c6911e1c4e" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_88eacb6d-1d3f-478f-882e-171cab2ae5d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1b812493-75c1-472e-9e06-46839195807e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6560fb16-6d1f-4a4c-be98-5c5e819ed768" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1b812493-75c1-472e-9e06-46839195807e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1b812493-75c1-472e-9e06-46839195807e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1b812493-75c1-472e-9e06-46839195807e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1b812493-75c1-472e-9e06-46839195807e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_21b11aca-4af9-4bc5-a050-8a205bc1c8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1b812493-75c1-472e-9e06-46839195807e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_21b11aca-4af9-4bc5-a050-8a205bc1c8d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_92a3a714-9101-43ad-912e-42378d575b90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_21b11aca-4af9-4bc5-a050-8a205bc1c8d2" xlink:to="loc_us-gaap_SecuredDebtMember_92a3a714-9101-43ad-912e-42378d575b90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_c0c99698-1144-4b50-98fc-87c0b882ab31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_21b11aca-4af9-4bc5-a050-8a205bc1c8d2" xlink:to="loc_us-gaap_UnsecuredDebtMember_c0c99698-1144-4b50-98fc-87c0b882ab31" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="extended" id="i5724e946b7b742cfb8a832d3f39ea0ed_FINANCINGARRANGEMENTSSeniorSecuredNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_951dd377-92ac-4ac1-9bbd-d09168be4c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_d2570e59-821f-4255-a41c-da5111fab652" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951dd377-92ac-4ac1-9bbd-d09168be4c49" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_d2570e59-821f-4255-a41c-da5111fab652" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_aae76848-d377-4bdf-8c3c-916ca234af92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951dd377-92ac-4ac1-9bbd-d09168be4c49" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_aae76848-d377-4bdf-8c3c-916ca234af92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_210ee5ae-7946-4466-ade5-127a72782cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951dd377-92ac-4ac1-9bbd-d09168be4c49" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_210ee5ae-7946-4466-ade5-127a72782cdb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_9fda3845-eaa8-4533-abee-3c8952c3cfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951dd377-92ac-4ac1-9bbd-d09168be4c49" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_9fda3845-eaa8-4533-abee-3c8952c3cfc1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_50e5dd66-ef71-46bb-928a-d2303c7ff5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951dd377-92ac-4ac1-9bbd-d09168be4c49" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_50e5dd66-ef71-46bb-928a-d2303c7ff5f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_2c2ae077-8ee5-490b-b147-ac09a104284f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951dd377-92ac-4ac1-9bbd-d09168be4c49" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_2c2ae077-8ee5-490b-b147-ac09a104284f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_2bc7a526-5470-4f83-b641-6b79811a7ffa" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951dd377-92ac-4ac1-9bbd-d09168be4c49" xlink:to="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_2bc7a526-5470-4f83-b641-6b79811a7ffa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_6372892c-6598-4c3d-911a-3a7154c392ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951dd377-92ac-4ac1-9bbd-d09168be4c49" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_6372892c-6598-4c3d-911a-3a7154c392ac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e21cc6dd-8335-491b-8da4-e43264a176c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951dd377-92ac-4ac1-9bbd-d09168be4c49" xlink:to="loc_us-gaap_DebtInstrumentTable_e21cc6dd-8335-491b-8da4-e43264a176c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_55c689a9-98d7-43eb-8e0a-6eba14effdee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e21cc6dd-8335-491b-8da4-e43264a176c7" xlink:to="loc_us-gaap_DebtInstrumentAxis_55c689a9-98d7-43eb-8e0a-6eba14effdee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_55c689a9-98d7-43eb-8e0a-6eba14effdee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_55c689a9-98d7-43eb-8e0a-6eba14effdee" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_55c689a9-98d7-43eb-8e0a-6eba14effdee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_55c689a9-98d7-43eb-8e0a-6eba14effdee" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_027e13fe-5d8e-4775-ab85-845f1c9d88eb" xlink:href="bhc-20211231.xsd#bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:to="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_027e13fe-5d8e-4775-ab85-845f1c9d88eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_41039361-ea1c-4889-8856-0801537554e5" xlink:href="bhc-20211231.xsd#bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:to="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_41039361-ea1c-4889-8856-0801537554e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_76f1853e-c135-4158-b019-27deb98b2579" xlink:href="bhc-20211231.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:to="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_76f1853e-c135-4158-b019-27deb98b2579" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_f0aa926b-59d0-4ad8-9699-43af58e75a58" xlink:href="bhc-20211231.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_f0aa926b-59d0-4ad8-9699-43af58e75a58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_3e9d2bdc-152d-4683-af90-0b277214a6a5" xlink:href="bhc-20211231.xsd#bhc_A8.50SeniorNotesDueJanuary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:to="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_3e9d2bdc-152d-4683-af90-0b277214a6a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.875SeniorNotesdueMay2023Member_3b8558a5-dc0b-4300-b91c-f07c78dd8a2c" xlink:href="bhc-20211231.xsd#bhc_A5.875SeniorNotesdueMay2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:to="loc_bhc_A5.875SeniorNotesdueMay2023Member_3b8558a5-dc0b-4300-b91c-f07c78dd8a2c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes5.625PercentDueDecember2021Member_d23c0f7e-adba-4f62-93e0-455a540ed519" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes5.625PercentDueDecember2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:to="loc_bhc_SeniorNotes5.625PercentDueDecember2021Member_d23c0f7e-adba-4f62-93e0-455a540ed519" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember_b8d4ae68-f51f-4e1a-abac-e144bce5fd74" xlink:href="bhc-20211231.xsd#bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:to="loc_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember_b8d4ae68-f51f-4e1a-abac-e144bce5fd74" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_0580c76d-c69c-422d-8e64-c5d22eb54487" xlink:href="bhc-20211231.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_0580c76d-c69c-422d-8e64-c5d22eb54487" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueMarch2024Member_b484eb08-2ddc-472c-9542-5070ac3827c9" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes700DueMarch2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:to="loc_bhc_SeniorNotes700DueMarch2024Member_b484eb08-2ddc-472c-9542-5070ac3827c9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_448abcee-c5a2-4234-a0b5-4d3ddfb7e143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e21cc6dd-8335-491b-8da4-e43264a176c7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_448abcee-c5a2-4234-a0b5-4d3ddfb7e143" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_448abcee-c5a2-4234-a0b5-4d3ddfb7e143_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_448abcee-c5a2-4234-a0b5-4d3ddfb7e143" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_448abcee-c5a2-4234-a0b5-4d3ddfb7e143_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b5bccfa9-c919-4908-8cb3-e6b89a117404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_448abcee-c5a2-4234-a0b5-4d3ddfb7e143" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b5bccfa9-c919-4908-8cb3-e6b89a117404" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_8d21d541-8c32-44ad-abae-0c2b7187336b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b5bccfa9-c919-4908-8cb3-e6b89a117404" xlink:to="loc_us-gaap_SecuredDebtMember_8d21d541-8c32-44ad-abae-0c2b7187336b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_49e4be6a-584f-4577-9058-6d4b2f2e03d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b5bccfa9-c919-4908-8cb3-e6b89a117404" xlink:to="loc_us-gaap_UnsecuredDebtMember_49e4be6a-584f-4577-9058-6d4b2f2e03d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_01ea1f7c-86fd-4756-aad5-6655b4ee487c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e21cc6dd-8335-491b-8da4-e43264a176c7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_01ea1f7c-86fd-4756-aad5-6655b4ee487c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_01ea1f7c-86fd-4756-aad5-6655b4ee487c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_01ea1f7c-86fd-4756-aad5-6655b4ee487c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_01ea1f7c-86fd-4756-aad5-6655b4ee487c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_fe962dad-e898-4cfa-a2d9-fee4a1882432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_01ea1f7c-86fd-4756-aad5-6655b4ee487c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_fe962dad-e898-4cfa-a2d9-fee4a1882432" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_6a359974-17db-4d7d-89a8-7fa8c16f0b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_fe962dad-e898-4cfa-a2d9-fee4a1882432" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_6a359974-17db-4d7d-89a8-7fa8c16f0b56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_f061b8bd-0be0-403a-a255-770e84322941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_fe962dad-e898-4cfa-a2d9-fee4a1882432" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_f061b8bd-0be0-403a-a255-770e84322941" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e2d45416-abc1-4743-a7ba-b353b6748766" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e21cc6dd-8335-491b-8da4-e43264a176c7" xlink:to="loc_srt_RangeAxis_e2d45416-abc1-4743-a7ba-b353b6748766" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e2d45416-abc1-4743-a7ba-b353b6748766_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e2d45416-abc1-4743-a7ba-b353b6748766" xlink:to="loc_srt_RangeMember_e2d45416-abc1-4743-a7ba-b353b6748766_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_95b15041-e749-427e-8407-cf45550d85a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e2d45416-abc1-4743-a7ba-b353b6748766" xlink:to="loc_srt_RangeMember_95b15041-e749-427e-8407-cf45550d85a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f5095cc5-2788-45de-b47a-70614367127f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_95b15041-e749-427e-8407-cf45550d85a7" xlink:to="loc_srt_MaximumMember_f5095cc5-2788-45de-b47a-70614367127f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="extended" id="ic045804c0f064ec6a2c75cbdc9bc0e8c_FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_4c1338f1-03af-46a0-afac-c955127b93d4" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_4c1338f1-03af-46a0-afac-c955127b93d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b91813c1-8a9b-4df2-8f8d-0d90617dc6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b91813c1-8a9b-4df2-8f8d-0d90617dc6bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7946a0b3-2752-4428-88cb-38a41184a422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_7946a0b3-2752-4428-88cb-38a41184a422" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_643dc08d-6726-4e56-bea6-06b7d1a6b2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_643dc08d-6726-4e56-bea6-06b7d1a6b2d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_230a4d6d-48b4-4f4c-9f1b-300fe1e96bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_230a4d6d-48b4-4f4c-9f1b-300fe1e96bc1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_64300d13-bd07-43b9-ace7-4b9d351f5b91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_64300d13-bd07-43b9-ace7-4b9d351f5b91" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_74aa4a4d-5370-413c-8475-143d9ba8c0bf" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:to="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_74aa4a4d-5370-413c-8475-143d9ba8c0bf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3c7432ed-4d59-4b5a-9ecf-7d03e626f31d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3c7432ed-4d59-4b5a-9ecf-7d03e626f31d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_5951f624-1770-4bc2-a347-973d3222201d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_5951f624-1770-4bc2-a347-973d3222201d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForDebtAmortizationPrepaymentCost_5c6f62dd-5ba7-40c9-91df-8dd8e50655e7" xlink:href="bhc-20211231.xsd#bhc_PaymentForDebtAmortizationPrepaymentCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:to="loc_bhc_PaymentForDebtAmortizationPrepaymentCost_5c6f62dd-5ba7-40c9-91df-8dd8e50655e7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_23f7a9e9-fb53-4580-8a92-b53401db390c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:to="loc_us-gaap_DebtInstrumentTable_23f7a9e9-fb53-4580-8a92-b53401db390c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_82605553-8764-4db5-9455-c210bb4c80ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_23f7a9e9-fb53-4580-8a92-b53401db390c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_82605553-8764-4db5-9455-c210bb4c80ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_82605553-8764-4db5-9455-c210bb4c80ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_82605553-8764-4db5-9455-c210bb4c80ff" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_82605553-8764-4db5-9455-c210bb4c80ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1acdecdc-1587-4bf1-9a77-2e5b3aa4ac64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_82605553-8764-4db5-9455-c210bb4c80ff" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1acdecdc-1587-4bf1-9a77-2e5b3aa4ac64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_64229880-acbc-4127-8f7d-831792b3f4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1acdecdc-1587-4bf1-9a77-2e5b3aa4ac64" xlink:to="loc_us-gaap_UnsecuredDebtMember_64229880-acbc-4127-8f7d-831792b3f4ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_0b90f54b-8956-41b9-b6be-21081000fbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1acdecdc-1587-4bf1-9a77-2e5b3aa4ac64" xlink:to="loc_us-gaap_SecuredDebtMember_0b90f54b-8956-41b9-b6be-21081000fbfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0d45fa52-fb21-4045-8147-3553f82abe31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_23f7a9e9-fb53-4580-8a92-b53401db390c" xlink:to="loc_us-gaap_DebtInstrumentAxis_0d45fa52-fb21-4045-8147-3553f82abe31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0d45fa52-fb21-4045-8147-3553f82abe31_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0d45fa52-fb21-4045-8147-3553f82abe31" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0d45fa52-fb21-4045-8147-3553f82abe31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0d45fa52-fb21-4045-8147-3553f82abe31" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.50SeniorNotesdueMarch2023Member_cbab4ed4-0223-456c-a11c-d2ad93aa3552" xlink:href="bhc-20211231.xsd#bhc_A5.50SeniorNotesdueMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_A5.50SeniorNotesdueMarch2023Member_cbab4ed4-0223-456c-a11c-d2ad93aa3552" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.375SeniorNotesdueMarch2020Member_79fac39e-f38b-4ab3-9e49-58a5f69a6444" xlink:href="bhc-20211231.xsd#bhc_A5.375SeniorNotesdueMarch2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_A5.375SeniorNotesdueMarch2020Member_79fac39e-f38b-4ab3-9e49-58a5f69a6444" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.875SeniorNotesdueMay2023Member_d3907e52-0a31-45f7-b6b2-61e077f46447" xlink:href="bhc-20211231.xsd#bhc_A5.875SeniorNotesdueMay2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_A5.875SeniorNotesdueMay2023Member_d3907e52-0a31-45f7-b6b2-61e077f46447" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember_ace153fe-ce6d-4fc2-9516-6aa861feafda" xlink:href="bhc-20211231.xsd#bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_A5.875SeniorNotesdueMay2023Member_d3907e52-0a31-45f7-b6b2-61e077f46447" xlink:to="loc_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember_ace153fe-ce6d-4fc2-9516-6aa861feafda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember_d5fc24d8-0108-4a4c-b0fa-2b60520b77f6" xlink:href="bhc-20211231.xsd#bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_A5.875SeniorNotesdueMay2023Member_d3907e52-0a31-45f7-b6b2-61e077f46447" xlink:to="loc_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember_d5fc24d8-0108-4a4c-b0fa-2b60520b77f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes4.502023Member_72bbf45e-9826-4d6b-88e6-4a6b8bdd1008" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes4.502023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_SeniorNotes4.502023Member_72bbf45e-9826-4d6b-88e6-4a6b8bdd1008" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A6.125SeniorNotesdueApril2025Member_d104d0ee-3a8c-4b0d-92d7-c288aea744ed" xlink:href="bhc-20211231.xsd#bhc_A6.125SeniorNotesdueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_A6.125SeniorNotesdueApril2025Member_d104d0ee-3a8c-4b0d-92d7-c288aea744ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorUnsecuredNotesDue2023Member_c610d148-753a-418d-9ae9-9cedcbb95f8d" xlink:href="bhc-20211231.xsd#bhc_SeniorUnsecuredNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_SeniorUnsecuredNotesDue2023Member_c610d148-753a-418d-9ae9-9cedcbb95f8d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_b9eb66fb-b16d-41fd-8efe-fe5dc4f918f8" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_b9eb66fb-b16d-41fd-8efe-fe5dc4f918f8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member_5d640c91-5823-44d0-a1a4-1137218b621a" xlink:href="bhc-20211231.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_A9.00SeniorNotesdueDecember2025Member_5d640c91-5823-44d0-a1a4-1137218b621a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.25SeniorNotesDueApril2026Member_fa222bdd-e961-4caf-81c0-508778659967" xlink:href="bhc-20211231.xsd#bhc_A9.25SeniorNotesDueApril2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_A9.25SeniorNotesDueApril2026Member_fa222bdd-e961-4caf-81c0-508778659967" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_c4ac9a6f-8785-472c-a296-a35b5f3a0ffe" xlink:href="bhc-20211231.xsd#bhc_A8.50SeniorNotesDueJanuary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_c4ac9a6f-8785-472c-a296-a35b5f3a0ffe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A7.00SeniorUnsecuredNotesDue2028Member_3728b413-8ebc-488d-b091-0d15972d8665" xlink:href="bhc-20211231.xsd#bhc_A7.00SeniorUnsecuredNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_A7.00SeniorUnsecuredNotesDue2028Member_3728b413-8ebc-488d-b091-0d15972d8665" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A7.25SeniorUnsecuredNotesDue2029Member_d1ca8cdc-04ea-4b79-a41a-b7f82f37c76d" xlink:href="bhc-20211231.xsd#bhc_A7.25SeniorUnsecuredNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_A7.25SeniorUnsecuredNotesDue2029Member_d1ca8cdc-04ea-4b79-a41a-b7f82f37c76d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.00SeniorNotesDueJanuary2028Member_b3641ec8-d13a-4adc-819f-579d2d437d86" xlink:href="bhc-20211231.xsd#bhc_A5.00SeniorNotesDueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_A5.00SeniorNotesDueJanuary2028Member_b3641ec8-d13a-4adc-819f-579d2d437d86" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.25SeniorNotesDueJanuary2030Member_32645c21-f5d9-4f63-9e7a-d72d3980bca1" xlink:href="bhc-20211231.xsd#bhc_A5.25SeniorNotesDueJanuary2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_A5.25SeniorNotesDueJanuary2030Member_32645c21-f5d9-4f63-9e7a-d72d3980bca1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_dbad1dd4-7439-4a54-85db-dc79e1729f37" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_dbad1dd4-7439-4a54-85db-dc79e1729f37" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_c509b958-f8f8-46e0-a35b-cb9ea049a171" xlink:href="bhc-20211231.xsd#bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_c509b958-f8f8-46e0-a35b-cb9ea049a171" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_c8d6c335-63f4-4ab8-859b-4dc3b3d47a1b" xlink:href="bhc-20211231.xsd#bhc_TermLoanBFacilityDueJune2025AndNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_c8d6c335-63f4-4ab8-859b-4dc3b3d47a1b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_3dc6a31b-4d98-469d-91e4-b89a087dfa81" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_3dc6a31b-4d98-469d-91e4-b89a087dfa81" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_d644a4eb-cfdb-4a32-900d-62c6b99fc15f" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_d644a4eb-cfdb-4a32-900d-62c6b99fc15f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes550DueMarch2023Member_ae3994ae-9fe6-4115-833f-44e8c42dd620" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes550DueMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_SeniorNotes550DueMarch2023Member_ae3994ae-9fe6-4115-833f-44e8c42dd620" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_f7c9e3ef-bb3b-409a-951c-8f1f43b1c77a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_23f7a9e9-fb53-4580-8a92-b53401db390c" xlink:to="loc_us-gaap_LitigationStatusAxis_f7c9e3ef-bb3b-409a-951c-8f1f43b1c77a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_f7c9e3ef-bb3b-409a-951c-8f1f43b1c77a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_f7c9e3ef-bb3b-409a-951c-8f1f43b1c77a" xlink:to="loc_us-gaap_LitigationStatusDomain_f7c9e3ef-bb3b-409a-951c-8f1f43b1c77a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_3b2e6144-eb0e-4c77-a9a3-48029bce6d60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_f7c9e3ef-bb3b-409a-951c-8f1f43b1c77a" xlink:to="loc_us-gaap_LitigationStatusDomain_3b2e6144-eb0e-4c77-a9a3-48029bce6d60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_fd3516e6-956a-4ed7-a1b3-25c104b3be7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_3b2e6144-eb0e-4c77-a9a3-48029bce6d60" xlink:to="loc_us-gaap_SettledLitigationMember_fd3516e6-956a-4ed7-a1b3-25c104b3be7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cc56c809-522e-41d1-85ca-92c53d5ff3cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_23f7a9e9-fb53-4580-8a92-b53401db390c" xlink:to="loc_srt_StatementGeographicalAxis_cc56c809-522e-41d1-85ca-92c53d5ff3cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cc56c809-522e-41d1-85ca-92c53d5ff3cd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_cc56c809-522e-41d1-85ca-92c53d5ff3cd" xlink:to="loc_srt_SegmentGeographicalDomain_cc56c809-522e-41d1-85ca-92c53d5ff3cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e8ee1b24-a980-4a3b-98d3-42abebaebfe4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_cc56c809-522e-41d1-85ca-92c53d5ff3cd" xlink:to="loc_srt_SegmentGeographicalDomain_e8ee1b24-a980-4a3b-98d3-42abebaebfe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_1e9a1a1b-6f8c-4945-9109-46ddc10a56b6" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e8ee1b24-a980-4a3b-98d3-42abebaebfe4" xlink:to="loc_stpr_NJ_1e9a1a1b-6f8c-4945-9109-46ddc10a56b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_f58aa3a5-db45-4ae7-9ed0-1d2ad17be814" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_23f7a9e9-fb53-4580-8a92-b53401db390c" xlink:to="loc_srt_LitigationCaseAxis_f58aa3a5-db45-4ae7-9ed0-1d2ad17be814" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f58aa3a5-db45-4ae7-9ed0-1d2ad17be814_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_f58aa3a5-db45-4ae7-9ed0-1d2ad17be814" xlink:to="loc_srt_LitigationCaseTypeDomain_f58aa3a5-db45-4ae7-9ed0-1d2ad17be814_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_01a1b71c-aa2c-41eb-99b4-ce71c8620b03" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_f58aa3a5-db45-4ae7-9ed0-1d2ad17be814" xlink:to="loc_srt_LitigationCaseTypeDomain_01a1b71c-aa2c-41eb-99b4-ce71c8620b03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_589268a8-0c18-4d6e-971d-033862a95406" xlink:href="bhc-20211231.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_01a1b71c-aa2c-41eb-99b4-ce71c8620b03" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_589268a8-0c18-4d6e-971d-033862a95406" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_5fef6f75-3a00-4133-bf95-9a98fd92c005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_23f7a9e9-fb53-4580-8a92-b53401db390c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_5fef6f75-3a00-4133-bf95-9a98fd92c005" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_5fef6f75-3a00-4133-bf95-9a98fd92c005_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_5fef6f75-3a00-4133-bf95-9a98fd92c005" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_5fef6f75-3a00-4133-bf95-9a98fd92c005_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_3ca0a7a8-1187-4ba1-9cdf-547ac0f3de4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_5fef6f75-3a00-4133-bf95-9a98fd92c005" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_3ca0a7a8-1187-4ba1-9cdf-547ac0f3de4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_a1b87d7b-ae88-4944-9409-2b9286cd492b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_3ca0a7a8-1187-4ba1-9cdf-547ac0f3de4d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_a1b87d7b-ae88-4944-9409-2b9286cd492b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_53a0d1d7-e4ff-4fe4-a1ed-54b9f2c8f14e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_3ca0a7a8-1187-4ba1-9cdf-547ac0f3de4d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_53a0d1d7-e4ff-4fe4-a1ed-54b9f2c8f14e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="extended" id="iad0bc5909e0b499da9fe06c1fb5971dd_FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_aefcd0fc-f173-40ca-93e7-c156c19498c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_68d3e534-2365-4c93-a170-19531d4aae64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aefcd0fc-f173-40ca-93e7-c156c19498c3" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_68d3e534-2365-4c93-a170-19531d4aae64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_424c477d-eec1-4faa-94ff-7b39024089ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aefcd0fc-f173-40ca-93e7-c156c19498c3" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_424c477d-eec1-4faa-94ff-7b39024089ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_df373498-75f3-45d0-92f6-d0dad3dcaf0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aefcd0fc-f173-40ca-93e7-c156c19498c3" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_df373498-75f3-45d0-92f6-d0dad3dcaf0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2305eec9-13aa-4640-8d66-9c2e85a353d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aefcd0fc-f173-40ca-93e7-c156c19498c3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2305eec9-13aa-4640-8d66-9c2e85a353d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_60a97b86-ceec-4587-bcc4-14166af285e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aefcd0fc-f173-40ca-93e7-c156c19498c3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_60a97b86-ceec-4587-bcc4-14166af285e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_bf929558-f060-4f53-b415-346fc39565a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aefcd0fc-f173-40ca-93e7-c156c19498c3" xlink:to="loc_us-gaap_DebtInstrumentTable_bf929558-f060-4f53-b415-346fc39565a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6386e839-dfaf-45fd-b113-383203f8f8de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bf929558-f060-4f53-b415-346fc39565a3" xlink:to="loc_us-gaap_DebtInstrumentAxis_6386e839-dfaf-45fd-b113-383203f8f8de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6386e839-dfaf-45fd-b113-383203f8f8de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6386e839-dfaf-45fd-b113-383203f8f8de" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6386e839-dfaf-45fd-b113-383203f8f8de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e0fcfd7f-f6ee-43a2-a790-abd1ba32c326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6386e839-dfaf-45fd-b113-383203f8f8de" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e0fcfd7f-f6ee-43a2-a790-abd1ba32c326" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_e4e9a8ba-9fce-4804-94e6-6b4c90fc2daf" xlink:href="bhc-20211231.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e0fcfd7f-f6ee-43a2-a790-abd1ba32c326" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_e4e9a8ba-9fce-4804-94e6-6b4c90fc2daf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member_551aae95-9f9d-4b61-9bd4-732efe0f8fb9" xlink:href="bhc-20211231.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e0fcfd7f-f6ee-43a2-a790-abd1ba32c326" xlink:to="loc_bhc_A9.00SeniorNotesdueDecember2025Member_551aae95-9f9d-4b61-9bd4-732efe0f8fb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_e545b211-2366-44a8-b414-9d4e874551f0" xlink:href="bhc-20211231.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e0fcfd7f-f6ee-43a2-a790-abd1ba32c326" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_e545b211-2366-44a8-b414-9d4e874551f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_c9d32bcd-2ceb-4cd7-9efe-08ece0a25e12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bf929558-f060-4f53-b415-346fc39565a3" xlink:to="loc_us-gaap_CreditFacilityAxis_c9d32bcd-2ceb-4cd7-9efe-08ece0a25e12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c9d32bcd-2ceb-4cd7-9efe-08ece0a25e12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_c9d32bcd-2ceb-4cd7-9efe-08ece0a25e12" xlink:to="loc_us-gaap_CreditFacilityDomain_c9d32bcd-2ceb-4cd7-9efe-08ece0a25e12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_fc12d24d-ff1d-42d3-9413-1880b7d0cb49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_c9d32bcd-2ceb-4cd7-9efe-08ece0a25e12" xlink:to="loc_us-gaap_CreditFacilityDomain_fc12d24d-ff1d-42d3-9413-1880b7d0cb49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_43fa2aab-5b0a-4c70-bdfd-2bb2c25336d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_fc12d24d-ff1d-42d3-9413-1880b7d0cb49" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_43fa2aab-5b0a-4c70-bdfd-2bb2c25336d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d4a5ec6c-4988-4875-bb9a-537143bda170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bf929558-f060-4f53-b415-346fc39565a3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d4a5ec6c-4988-4875-bb9a-537143bda170" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d4a5ec6c-4988-4875-bb9a-537143bda170_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d4a5ec6c-4988-4875-bb9a-537143bda170" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d4a5ec6c-4988-4875-bb9a-537143bda170_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a53e30b4-a69c-4e37-90c8-41b327de8af7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d4a5ec6c-4988-4875-bb9a-537143bda170" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a53e30b4-a69c-4e37-90c8-41b327de8af7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_7c81d026-296b-4bc5-b10b-8711d3ff0104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a53e30b4-a69c-4e37-90c8-41b327de8af7" xlink:to="loc_us-gaap_UnsecuredDebtMember_7c81d026-296b-4bc5-b10b-8711d3ff0104" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_7c4cfe16-c17e-485d-9312-6ebf981fe9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a53e30b4-a69c-4e37-90c8-41b327de8af7" xlink:to="loc_us-gaap_SecuredDebtMember_7c4cfe16-c17e-485d-9312-6ebf981fe9bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2ea628e2-5446-4fa7-8694-11cfa6182486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bf929558-f060-4f53-b415-346fc39565a3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2ea628e2-5446-4fa7-8694-11cfa6182486" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2ea628e2-5446-4fa7-8694-11cfa6182486_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2ea628e2-5446-4fa7-8694-11cfa6182486" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2ea628e2-5446-4fa7-8694-11cfa6182486_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6dfbaddc-06de-45ec-a3d2-7cfed82aa8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2ea628e2-5446-4fa7-8694-11cfa6182486" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6dfbaddc-06de-45ec-a3d2-7cfed82aa8d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8319bf97-e76c-4a55-b395-6139ccfc4563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6dfbaddc-06de-45ec-a3d2-7cfed82aa8d0" xlink:to="loc_us-gaap_SubsequentEventMember_8319bf97-e76c-4a55-b395-6139ccfc4563" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="extended" id="ibe507f35b96642b9bec2b9a3f9b4b88d_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance_72d03ce8-ac64-4f63-a8cd-8f4b434333ce" xlink:href="bhc-20211231.xsd#bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:to="loc_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance_72d03ce8-ac64-4f63-a8cd-8f4b434333ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans_0d966dd8-f253-4675-93ed-801115dc748e" xlink:href="bhc-20211231.xsd#bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:to="loc_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans_0d966dd8-f253-4675-93ed-801115dc748e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended_9bc63a0c-616d-48ac-ad86-2d98c4617f60" xlink:href="bhc-20211231.xsd#bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:to="loc_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended_9bc63a0c-616d-48ac-ad86-2d98c4617f60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanEmployerContributionMaximumAge_5a548e7f-1cf8-4d6d-b22b-1e3ec7ce962f" xlink:href="bhc-20211231.xsd#bhc_DefinedBenefitPlanEmployerContributionMaximumAge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:to="loc_bhc_DefinedBenefitPlanEmployerContributionMaximumAge_5a548e7f-1cf8-4d6d-b22b-1e3ec7ce962f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_0c4219c3-d895-4225-9537-c657c282961a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_0c4219c3-d895-4225-9537-c657c282961a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_7630211a-9768-4fea-89e9-0bbfa9f7915a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_7630211a-9768-4fea-89e9-0bbfa9f7915a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod_6905d91c-d245-4aaa-8a5a-b69e796f6ce5" xlink:href="bhc-20211231.xsd#bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:to="loc_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod_6905d91c-d245-4aaa-8a5a-b69e796f6ce5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_9acf8d3d-bb4f-46d9-9d5f-9cff3e508cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_9acf8d3d-bb4f-46d9-9d5f-9cff3e508cd2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanPercentageAllocationofFund_372a0143-2c62-458f-ac4b-34e8521730cf" xlink:href="bhc-20211231.xsd#bhc_DefinedBenefitPlanPercentageAllocationofFund"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:to="loc_bhc_DefinedBenefitPlanPercentageAllocationofFund_372a0143-2c62-458f-ac4b-34e8521730cf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_9200cffc-53b6-42dd-8424-76d433094a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_9200cffc-53b6-42dd-8424-76d433094a7a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2a5c436d-5777-47f6-ba33-21893c0b8573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2a5c436d-5777-47f6-ba33-21893c0b8573" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a7370a88-6273-414c-8979-6f531936a43e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2a5c436d-5777-47f6-ba33-21893c0b8573" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a7370a88-6273-414c-8979-6f531936a43e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a7370a88-6273-414c-8979-6f531936a43e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a7370a88-6273-414c-8979-6f531936a43e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a7370a88-6273-414c-8979-6f531936a43e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_849a422c-1cd8-494d-84f0-ca867891f191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a7370a88-6273-414c-8979-6f531936a43e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_849a422c-1cd8-494d-84f0-ca867891f191" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_6125c35f-18eb-43e7-8e25-9bf04597d4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_849a422c-1cd8-494d-84f0-ca867891f191" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_6125c35f-18eb-43e7-8e25-9bf04597d4cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_63f97cb4-3da0-4997-b60c-63e2734742fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_849a422c-1cd8-494d-84f0-ca867891f191" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_63f97cb4-3da0-4997-b60c-63e2734742fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_18ece77c-c55d-4f14-8bee-1bf49a0fb361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2a5c436d-5777-47f6-ba33-21893c0b8573" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_18ece77c-c55d-4f14-8bee-1bf49a0fb361" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_18ece77c-c55d-4f14-8bee-1bf49a0fb361_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_18ece77c-c55d-4f14-8bee-1bf49a0fb361" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_18ece77c-c55d-4f14-8bee-1bf49a0fb361_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_954289a0-8fe2-4ba4-ac4d-58102a2c0f07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_18ece77c-c55d-4f14-8bee-1bf49a0fb361" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_954289a0-8fe2-4ba4-ac4d-58102a2c0f07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_5224ed56-8591-47e5-a8a0-ee869c6a3cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_954289a0-8fe2-4ba4-ac4d-58102a2c0f07" xlink:to="loc_us-gaap_ForeignPlanMember_5224ed56-8591-47e5-a8a0-ee869c6a3cd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_a7995f39-07f3-4baa-9f32-862203312d10" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignPlanMember_5224ed56-8591-47e5-a8a0-ee869c6a3cd2" xlink:to="loc_country_IE_a7995f39-07f3-4baa-9f32-862203312d10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_feb87026-b975-4d6c-8827-79decc42d878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_954289a0-8fe2-4ba4-ac4d-58102a2c0f07" xlink:to="loc_us-gaap_DomesticPlanMember_feb87026-b975-4d6c-8827-79decc42d878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_9c03eb1c-ddfd-4bcb-922c-532f87aaf6f8" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_feb87026-b975-4d6c-8827-79decc42d878" xlink:to="loc_country_US_9c03eb1c-ddfd-4bcb-922c-532f87aaf6f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_95d503ca-5a4e-41f7-91a1-e057c1430787" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2a5c436d-5777-47f6-ba33-21893c0b8573" xlink:to="loc_srt_StatementScenarioAxis_95d503ca-5a4e-41f7-91a1-e057c1430787" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_95d503ca-5a4e-41f7-91a1-e057c1430787_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_95d503ca-5a4e-41f7-91a1-e057c1430787" xlink:to="loc_srt_ScenarioUnspecifiedDomain_95d503ca-5a4e-41f7-91a1-e057c1430787_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9c27d40a-d7d4-4541-9d77-bc73f36150c5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_95d503ca-5a4e-41f7-91a1-e057c1430787" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9c27d40a-d7d4-4541-9d77-bc73f36150c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_9f31c897-00b4-4397-877b-b05f2b083404" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_9c27d40a-d7d4-4541-9d77-bc73f36150c5" xlink:to="loc_srt_ScenarioForecastMember_9f31c897-00b4-4397-877b-b05f2b083404" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="i474a17e71e004ed7b12dc16cfd66f11e_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_84654169-ce74-4a6c-ad2c-da6c0b0dbb96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_8f27200d-742a-4cad-971a-eed96a81e485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_84654169-ce74-4a6c-ad2c-da6c0b0dbb96" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_8f27200d-742a-4cad-971a-eed96a81e485" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax_08f795e1-184d-4c1f-a8b2-085cc6379f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_84654169-ce74-4a6c-ad2c-da6c0b0dbb96" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax_08f795e1-184d-4c1f-a8b2-085cc6379f88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b915101e-854d-4eb4-806c-576c650581e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_84654169-ce74-4a6c-ad2c-da6c0b0dbb96" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b915101e-854d-4eb4-806c-576c650581e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_16312b7d-4457-410a-ae11-1b2b145f26ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b915101e-854d-4eb4-806c-576c650581e4" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_16312b7d-4457-410a-ae11-1b2b145f26ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_16312b7d-4457-410a-ae11-1b2b145f26ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_16312b7d-4457-410a-ae11-1b2b145f26ee" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_16312b7d-4457-410a-ae11-1b2b145f26ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_875982dc-65a8-4b11-bc7d-e424f6323d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_16312b7d-4457-410a-ae11-1b2b145f26ee" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_875982dc-65a8-4b11-bc7d-e424f6323d8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_ffe4940b-690e-417a-bf17-2c773df291a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_875982dc-65a8-4b11-bc7d-e424f6323d8a" xlink:to="loc_us-gaap_DomesticPlanMember_ffe4940b-690e-417a-bf17-2c773df291a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_10f0045c-153e-400e-bcc1-b8700938c050" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_ffe4940b-690e-417a-bf17-2c773df291a7" xlink:to="loc_country_US_10f0045c-153e-400e-bcc1-b8700938c050" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_7d5a99a8-7363-40df-af7d-b82fbdc615c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_875982dc-65a8-4b11-bc7d-e424f6323d8a" xlink:to="loc_us-gaap_ForeignPlanMember_7d5a99a8-7363-40df-af7d-b82fbdc615c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_9da20370-72be-49a2-a689-f2dcb4280713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b915101e-854d-4eb4-806c-576c650581e4" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_9da20370-72be-49a2-a689-f2dcb4280713" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9da20370-72be-49a2-a689-f2dcb4280713_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9da20370-72be-49a2-a689-f2dcb4280713" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_9da20370-72be-49a2-a689-f2dcb4280713_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_f24cda88-5d99-46b7-80a2-6fb1059d3e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9da20370-72be-49a2-a689-f2dcb4280713" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_f24cda88-5d99-46b7-80a2-6fb1059d3e98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_6100b3d6-2594-4509-852d-8dd0857ca3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_f24cda88-5d99-46b7-80a2-6fb1059d3e98" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_6100b3d6-2594-4509-852d-8dd0857ca3d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_27a600f4-8507-41b7-bd4f-3dcda16a1f30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_f24cda88-5d99-46b7-80a2-6fb1059d3e98" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_27a600f4-8507-41b7-bd4f-3dcda16a1f30" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="i6010945c1e3f440f94fb313e7e83cfc5_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0cf93abd-2342-4cce-b246-d291f921d2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_b75533ee-20cd-402f-9222-d2d230920468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0cf93abd-2342-4cce-b246-d291f921d2fa" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_b75533ee-20cd-402f-9222-d2d230920468" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_1f606a87-ef29-4737-957e-ae63b464ffed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0cf93abd-2342-4cce-b246-d291f921d2fa" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_1f606a87-ef29-4737-957e-ae63b464ffed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_323dc431-6c6a-4f21-b201-3d52a4157c84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0cf93abd-2342-4cce-b246-d291f921d2fa" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_323dc431-6c6a-4f21-b201-3d52a4157c84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_bc9095c9-2300-4cdc-86f4-2a687e5db343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0cf93abd-2342-4cce-b246-d291f921d2fa" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_bc9095c9-2300-4cdc-86f4-2a687e5db343" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_903bad94-3368-4f24-a7fc-895006446a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0cf93abd-2342-4cce-b246-d291f921d2fa" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_903bad94-3368-4f24-a7fc-895006446a3d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_e38362b8-9ee9-48b5-b460-9682c9c90630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0cf93abd-2342-4cce-b246-d291f921d2fa" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_e38362b8-9ee9-48b5-b460-9682c9c90630" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanOtherCosts_e51faa13-6221-4ccb-a33d-f32dad68a966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanOtherCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0cf93abd-2342-4cce-b246-d291f921d2fa" xlink:to="loc_us-gaap_DefinedBenefitPlanOtherCosts_e51faa13-6221-4ccb-a33d-f32dad68a966" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4228abdf-d466-4b9d-b4e6-15001ef5d00b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0cf93abd-2342-4cce-b246-d291f921d2fa" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4228abdf-d466-4b9d-b4e6-15001ef5d00b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_af358374-8274-4907-afb7-bd31040991fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0cf93abd-2342-4cce-b246-d291f921d2fa" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_af358374-8274-4907-afb7-bd31040991fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_f930f5c2-418e-434a-9dde-b3f6cc2cf588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_af358374-8274-4907-afb7-bd31040991fa" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_f930f5c2-418e-434a-9dde-b3f6cc2cf588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_f930f5c2-418e-434a-9dde-b3f6cc2cf588_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_f930f5c2-418e-434a-9dde-b3f6cc2cf588" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_f930f5c2-418e-434a-9dde-b3f6cc2cf588_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_5635708a-ba06-4c57-89a7-5af12d93a9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_f930f5c2-418e-434a-9dde-b3f6cc2cf588" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_5635708a-ba06-4c57-89a7-5af12d93a9a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_e0bf439e-53b4-463a-84c5-310894f8511f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5635708a-ba06-4c57-89a7-5af12d93a9a4" xlink:to="loc_us-gaap_DomesticPlanMember_e0bf439e-53b4-463a-84c5-310894f8511f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_e4fb58b2-923b-452b-8e8b-051f1a29bd03" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_e0bf439e-53b4-463a-84c5-310894f8511f" xlink:to="loc_country_US_e4fb58b2-923b-452b-8e8b-051f1a29bd03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_6d269313-29e0-4e79-8a9e-431984122c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5635708a-ba06-4c57-89a7-5af12d93a9a4" xlink:to="loc_us-gaap_ForeignPlanMember_6d269313-29e0-4e79-8a9e-431984122c8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_ebfa8931-be77-4b70-9a71-8ac26327d1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_af358374-8274-4907-afb7-bd31040991fa" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_ebfa8931-be77-4b70-9a71-8ac26327d1f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ebfa8931-be77-4b70-9a71-8ac26327d1f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ebfa8931-be77-4b70-9a71-8ac26327d1f0" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ebfa8931-be77-4b70-9a71-8ac26327d1f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9b647e2d-e30e-4096-8930-4c9b337359c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ebfa8931-be77-4b70-9a71-8ac26327d1f0" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_9b647e2d-e30e-4096-8930-4c9b337359c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_4edc9370-4fc0-456a-bb8f-d1898c9db6af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9b647e2d-e30e-4096-8930-4c9b337359c8" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_4edc9370-4fc0-456a-bb8f-d1898c9db6af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_85ccd7ab-2f5e-4e98-9503-c82ef554cc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9b647e2d-e30e-4096-8930-4c9b337359c8" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_85ccd7ab-2f5e-4e98-9503-c82ef554cc9f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" xlink:type="extended" id="i14ef63030ec74b30acfc777e99569078_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dbfeecb-993f-4a67-9875-3526cb1ed7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_531b9c23-35b8-46d9-9dc2-574e463fe906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dbfeecb-993f-4a67-9875-3526cb1ed7a2" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_531b9c23-35b8-46d9-9dc2-574e463fe906" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_a0e722da-7a1f-45cf-bda6-52164d21dd66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_531b9c23-35b8-46d9-9dc2-574e463fe906" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_a0e722da-7a1f-45cf-bda6-52164d21dd66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_9fd636c8-f18e-48e6-a039-1980e2048467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_531b9c23-35b8-46d9-9dc2-574e463fe906" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_9fd636c8-f18e-48e6-a039-1980e2048467" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_ac02f09f-5ff2-4383-a382-352de7815fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_531b9c23-35b8-46d9-9dc2-574e463fe906" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_ac02f09f-5ff2-4383-a382-352de7815fb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_e89a1c7f-810e-4abf-bda7-2aa6454c0eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_531b9c23-35b8-46d9-9dc2-574e463fe906" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_e89a1c7f-810e-4abf-bda7-2aa6454c0eb2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_8bd1de96-5ea2-4009-a879-d46ff3ada68c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_531b9c23-35b8-46d9-9dc2-574e463fe906" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_8bd1de96-5ea2-4009-a879-d46ff3ada68c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_148ac9b8-9791-4b3b-823e-7a61f3c4a71b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_531b9c23-35b8-46d9-9dc2-574e463fe906" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_148ac9b8-9791-4b3b-823e-7a61f3c4a71b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_4dafbf9d-c433-46eb-8dca-984184a16eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_531b9c23-35b8-46d9-9dc2-574e463fe906" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_4dafbf9d-c433-46eb-8dca-984184a16eda" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5148d96a-3aeb-40d0-b0ea-92fc66fc9747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_a4d73a6d-9f80-4a0e-91c6-3e62f204a1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dbfeecb-993f-4a67-9875-3526cb1ed7a2" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_a4d73a6d-9f80-4a0e-91c6-3e62f204a1ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_4577665a-fb56-4888-8a37-f8356243f809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_a4d73a6d-9f80-4a0e-91c6-3e62f204a1ed" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_4577665a-fb56-4888-8a37-f8356243f809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_cd46c890-0958-42fc-8e50-e1e91c5694ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_a4d73a6d-9f80-4a0e-91c6-3e62f204a1ed" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_cd46c890-0958-42fc-8e50-e1e91c5694ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_6ba78710-f0ab-4316-8abb-593268d439fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_a4d73a6d-9f80-4a0e-91c6-3e62f204a1ed" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_6ba78710-f0ab-4316-8abb-593268d439fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_1203914f-7162-44c2-b53b-8b36ebce7479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_a4d73a6d-9f80-4a0e-91c6-3e62f204a1ed" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_1203914f-7162-44c2-b53b-8b36ebce7479" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_55ff3afb-b87e-45a8-bec6-f7a919c9075c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_a4d73a6d-9f80-4a0e-91c6-3e62f204a1ed" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_55ff3afb-b87e-45a8-bec6-f7a919c9075c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_9a147a13-f09d-46a2-b437-86b327addd88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_a4d73a6d-9f80-4a0e-91c6-3e62f204a1ed" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_9a147a13-f09d-46a2-b437-86b327addd88" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_ceb32d5b-005e-4f6f-84c6-7a0bf5da0281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_e0ef6af7-d86f-4545-b341-f157d6d94c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dbfeecb-993f-4a67-9875-3526cb1ed7a2" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_e0ef6af7-d86f-4545-b341-f157d6d94c86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_25b71e1c-f8d1-4f8f-b941-cba19ad9f5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dbfeecb-993f-4a67-9875-3526cb1ed7a2" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_25b71e1c-f8d1-4f8f-b941-cba19ad9f5e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_0c6613c7-d343-42c0-97f2-9fb2a62e51f8" xlink:href="bhc-20211231.xsd#bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_25b71e1c-f8d1-4f8f-b941-cba19ad9f5e2" xlink:to="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_0c6613c7-d343-42c0-97f2-9fb2a62e51f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_89e9a839-684b-4cc4-9102-d916262d066f" xlink:href="bhc-20211231.xsd#bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_25b71e1c-f8d1-4f8f-b941-cba19ad9f5e2" xlink:to="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_89e9a839-684b-4cc4-9102-d916262d066f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_4477d8dd-d82a-46a1-9d40-af5f31907286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_25b71e1c-f8d1-4f8f-b941-cba19ad9f5e2" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_4477d8dd-d82a-46a1-9d40-af5f31907286" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3a29774f-eee4-4e26-bad3-9bd11a02c41d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dbfeecb-993f-4a67-9875-3526cb1ed7a2" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3a29774f-eee4-4e26-bad3-9bd11a02c41d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_d2cef5d3-62aa-4881-89aa-8db2d089d5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3a29774f-eee4-4e26-bad3-9bd11a02c41d" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_d2cef5d3-62aa-4881-89aa-8db2d089d5a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_d2cef5d3-62aa-4881-89aa-8db2d089d5a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_d2cef5d3-62aa-4881-89aa-8db2d089d5a3" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_d2cef5d3-62aa-4881-89aa-8db2d089d5a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_8c91ef85-c133-4e2b-aec3-e5e21fb4a974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_d2cef5d3-62aa-4881-89aa-8db2d089d5a3" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_8c91ef85-c133-4e2b-aec3-e5e21fb4a974" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_1a09f786-612d-44b1-8ef6-6fdd94ae761b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_8c91ef85-c133-4e2b-aec3-e5e21fb4a974" xlink:to="loc_us-gaap_DomesticPlanMember_1a09f786-612d-44b1-8ef6-6fdd94ae761b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_9ab0a4b2-d725-41bd-bb6d-6fd85235fa8c" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_1a09f786-612d-44b1-8ef6-6fdd94ae761b" xlink:to="loc_country_US_9ab0a4b2-d725-41bd-bb6d-6fd85235fa8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_92c03e5c-64cf-41fd-ba70-4423d4f8e1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_8c91ef85-c133-4e2b-aec3-e5e21fb4a974" xlink:to="loc_us-gaap_ForeignPlanMember_92c03e5c-64cf-41fd-ba70-4423d4f8e1c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_86b4d45c-1bbb-4228-8dcc-0f676fe7b803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3a29774f-eee4-4e26-bad3-9bd11a02c41d" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_86b4d45c-1bbb-4228-8dcc-0f676fe7b803" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_86b4d45c-1bbb-4228-8dcc-0f676fe7b803_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_86b4d45c-1bbb-4228-8dcc-0f676fe7b803" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_86b4d45c-1bbb-4228-8dcc-0f676fe7b803_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9c93a71f-d900-415f-a106-4118bf9e2a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_86b4d45c-1bbb-4228-8dcc-0f676fe7b803" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_9c93a71f-d900-415f-a106-4118bf9e2a0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_b6325f4f-1252-4e95-a288-b2861ad62509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9c93a71f-d900-415f-a106-4118bf9e2a0a" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_b6325f4f-1252-4e95-a288-b2861ad62509" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_67953420-4dba-47c6-ad2f-1b270809cad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9c93a71f-d900-415f-a106-4118bf9e2a0a" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_67953420-4dba-47c6-ad2f-1b270809cad7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails" xlink:type="extended" id="id72e3040ca3b4aca815dd77b1ce110eb_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_055f2560-f8a1-42e1-aceb-adcfae139d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_7cce9a88-0df4-4e7c-80f7-3dfc20540c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_055f2560-f8a1-42e1-aceb-adcfae139d19" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_7cce9a88-0df4-4e7c-80f7-3dfc20540c10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_78aeb973-461e-45f0-b440-df10eb540749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_7cce9a88-0df4-4e7c-80f7-3dfc20540c10" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_78aeb973-461e-45f0-b440-df10eb540749" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_492a4968-e1a2-4c25-a64a-eed508ea45eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_7cce9a88-0df4-4e7c-80f7-3dfc20540c10" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_492a4968-e1a2-4c25-a64a-eed508ea45eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_9a0745a8-f61a-407c-830b-b896334dd546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_7cce9a88-0df4-4e7c-80f7-3dfc20540c10" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_9a0745a8-f61a-407c-830b-b896334dd546" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2a5d9227-44c1-40bd-ac54-c0eb3ad61a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_055f2560-f8a1-42e1-aceb-adcfae139d19" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2a5d9227-44c1-40bd-ac54-c0eb3ad61a1b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_95a3661f-5748-4b49-8602-f9c5adc62b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2a5d9227-44c1-40bd-ac54-c0eb3ad61a1b" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_95a3661f-5748-4b49-8602-f9c5adc62b87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_95a3661f-5748-4b49-8602-f9c5adc62b87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_95a3661f-5748-4b49-8602-f9c5adc62b87" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_95a3661f-5748-4b49-8602-f9c5adc62b87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_03f4ced9-01e9-453d-a8fa-999a7dce6e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_95a3661f-5748-4b49-8602-f9c5adc62b87" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_03f4ced9-01e9-453d-a8fa-999a7dce6e97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_10daf364-a96a-4ced-ae56-e25f9f9c191a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_03f4ced9-01e9-453d-a8fa-999a7dce6e97" xlink:to="loc_us-gaap_DomesticPlanMember_10daf364-a96a-4ced-ae56-e25f9f9c191a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_56a610f5-1a62-4fb5-a393-51f25c8528b0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_10daf364-a96a-4ced-ae56-e25f9f9c191a" xlink:to="loc_country_US_56a610f5-1a62-4fb5-a393-51f25c8528b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_7ad16381-cd97-4460-9081-4105305d5dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_03f4ced9-01e9-453d-a8fa-999a7dce6e97" xlink:to="loc_us-gaap_ForeignPlanMember_7ad16381-cd97-4460-9081-4105305d5dcc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails" xlink:type="extended" id="id4039b8332ee4fdebf8df550cd011be8_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ef64717d-2aa8-4d0a-96a5-689da641178d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_eeb17238-a77d-434d-b48b-e88ab585af59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ef64717d-2aa8-4d0a-96a5-689da641178d" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_eeb17238-a77d-434d-b48b-e88ab585af59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_61bd579d-66f8-40d8-a00f-a6fda3c9ff67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ef64717d-2aa8-4d0a-96a5-689da641178d" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_61bd579d-66f8-40d8-a00f-a6fda3c9ff67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_34f8eac2-0eb2-4da8-89d6-ac81cadeea05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ef64717d-2aa8-4d0a-96a5-689da641178d" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_34f8eac2-0eb2-4da8-89d6-ac81cadeea05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_4c846caa-9469-481a-a04d-929c2841e948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ef64717d-2aa8-4d0a-96a5-689da641178d" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_4c846caa-9469-481a-a04d-929c2841e948" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_36d35432-3749-4e53-8b5a-6dec41bd7e15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ef64717d-2aa8-4d0a-96a5-689da641178d" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_36d35432-3749-4e53-8b5a-6dec41bd7e15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_9b068906-e30c-441c-acde-85a235274b84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ef64717d-2aa8-4d0a-96a5-689da641178d" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_9b068906-e30c-441c-acde-85a235274b84" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_4e8050ce-5f59-47e7-9e6f-51f63e5b0a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ef64717d-2aa8-4d0a-96a5-689da641178d" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_4e8050ce-5f59-47e7-9e6f-51f63e5b0a9a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_cc29d148-6bb4-4b12-8083-40809bb5b159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_4e8050ce-5f59-47e7-9e6f-51f63e5b0a9a" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_cc29d148-6bb4-4b12-8083-40809bb5b159" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_cc29d148-6bb4-4b12-8083-40809bb5b159_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_cc29d148-6bb4-4b12-8083-40809bb5b159" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_cc29d148-6bb4-4b12-8083-40809bb5b159_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3ef7e9dc-09e9-4bc0-9c89-c5a2b984ec67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_cc29d148-6bb4-4b12-8083-40809bb5b159" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3ef7e9dc-09e9-4bc0-9c89-c5a2b984ec67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_7741104b-42a4-40a6-8515-74a544bc9f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3ef7e9dc-09e9-4bc0-9c89-c5a2b984ec67" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_7741104b-42a4-40a6-8515-74a544bc9f1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_96e4938c-f51f-47b2-aef7-77992bd2fed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3ef7e9dc-09e9-4bc0-9c89-c5a2b984ec67" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_96e4938c-f51f-47b2-aef7-77992bd2fed7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_7953e1c0-9523-48c4-bc38-ebbce715cc75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_4e8050ce-5f59-47e7-9e6f-51f63e5b0a9a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_7953e1c0-9523-48c4-bc38-ebbce715cc75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_7953e1c0-9523-48c4-bc38-ebbce715cc75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_7953e1c0-9523-48c4-bc38-ebbce715cc75" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_7953e1c0-9523-48c4-bc38-ebbce715cc75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_d5da71f4-8edc-4213-9333-562a04b5a90a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_7953e1c0-9523-48c4-bc38-ebbce715cc75" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_d5da71f4-8edc-4213-9333-562a04b5a90a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_df4bc6a3-eee7-4b43-8fbe-1153cde80aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_d5da71f4-8edc-4213-9333-562a04b5a90a" xlink:to="loc_us-gaap_DomesticPlanMember_df4bc6a3-eee7-4b43-8fbe-1153cde80aee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d0c86532-9dcd-4456-9c35-88ddeba84f3b" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_df4bc6a3-eee7-4b43-8fbe-1153cde80aee" xlink:to="loc_country_US_d0c86532-9dcd-4456-9c35-88ddeba84f3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_5462693c-9bb7-468e-b41f-f078996ceee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_d5da71f4-8edc-4213-9333-562a04b5a90a" xlink:to="loc_us-gaap_ForeignPlanMember_5462693c-9bb7-468e-b41f-f078996ceee6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails" xlink:type="extended" id="i5b70fb4bfdc049a6993c21587ca25a16_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c3a3111a-e774-4367-a384-cdb24c871016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_e3bf14f9-9ee9-4f6b-af59-06d3bbb1934d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c3a3111a-e774-4367-a384-cdb24c871016" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_e3bf14f9-9ee9-4f6b-af59-06d3bbb1934d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_66d6979b-c992-4d8a-a502-29718413d6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_e3bf14f9-9ee9-4f6b-af59-06d3bbb1934d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_66d6979b-c992-4d8a-a502-29718413d6c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_0f9beea6-8bd9-407a-b20e-f55c96aedc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_e3bf14f9-9ee9-4f6b-af59-06d3bbb1934d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_0f9beea6-8bd9-407a-b20e-f55c96aedc2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_7cb356f1-18a7-4a4d-9f5f-48f0eb4ad7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_e3bf14f9-9ee9-4f6b-af59-06d3bbb1934d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_7cb356f1-18a7-4a4d-9f5f-48f0eb4ad7fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_3c8f0c1c-e5b7-4e83-87b7-9347ca0fb3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_e3bf14f9-9ee9-4f6b-af59-06d3bbb1934d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_3c8f0c1c-e5b7-4e83-87b7-9347ca0fb3c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a4202e5e-0ef1-4b55-a931-e67956b70fee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c3a3111a-e774-4367-a384-cdb24c871016" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a4202e5e-0ef1-4b55-a931-e67956b70fee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_6a0edc1a-9a0c-4c30-ac25-8f358371e540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a4202e5e-0ef1-4b55-a931-e67956b70fee" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_6a0edc1a-9a0c-4c30-ac25-8f358371e540" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_f4730f4e-0faf-46b2-b03c-30d9de7ae390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a4202e5e-0ef1-4b55-a931-e67956b70fee" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_f4730f4e-0faf-46b2-b03c-30d9de7ae390" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_952f1e36-5836-4d14-a23a-f48d1b8d07b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a4202e5e-0ef1-4b55-a931-e67956b70fee" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_952f1e36-5836-4d14-a23a-f48d1b8d07b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f2d002ab-9539-4302-9a9a-33e9d77fd349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c3a3111a-e774-4367-a384-cdb24c871016" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f2d002ab-9539-4302-9a9a-33e9d77fd349" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_417cc094-3711-4277-9a02-696429f9cf3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f2d002ab-9539-4302-9a9a-33e9d77fd349" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_417cc094-3711-4277-9a02-696429f9cf3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_417cc094-3711-4277-9a02-696429f9cf3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_417cc094-3711-4277-9a02-696429f9cf3f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_417cc094-3711-4277-9a02-696429f9cf3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1998cb78-2b6c-4241-a555-069d00969324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_417cc094-3711-4277-9a02-696429f9cf3f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1998cb78-2b6c-4241-a555-069d00969324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_09e8243d-a72f-4230-a8ac-9419885d017a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1998cb78-2b6c-4241-a555-069d00969324" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_09e8243d-a72f-4230-a8ac-9419885d017a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_03d2ccf9-121d-4d9f-9b56-01ab1f3594bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1998cb78-2b6c-4241-a555-069d00969324" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_03d2ccf9-121d-4d9f-9b56-01ab1f3594bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_7cd9f7ee-39d5-4e01-9a5a-398982b45752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f2d002ab-9539-4302-9a9a-33e9d77fd349" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_7cd9f7ee-39d5-4e01-9a5a-398982b45752" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_7cd9f7ee-39d5-4e01-9a5a-398982b45752_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_7cd9f7ee-39d5-4e01-9a5a-398982b45752" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_7cd9f7ee-39d5-4e01-9a5a-398982b45752_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_e8865e50-20e4-4a05-8327-378b44757164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_7cd9f7ee-39d5-4e01-9a5a-398982b45752" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_e8865e50-20e4-4a05-8327-378b44757164" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_e53cf4ac-841a-46fb-b850-56030421a61b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_e8865e50-20e4-4a05-8327-378b44757164" xlink:to="loc_us-gaap_DomesticPlanMember_e53cf4ac-841a-46fb-b850-56030421a61b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_834c1080-b80f-4c1e-8bc3-ea36037092bc" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_e53cf4ac-841a-46fb-b850-56030421a61b" xlink:to="loc_country_US_834c1080-b80f-4c1e-8bc3-ea36037092bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_7cb88fe2-74d3-4bdb-b9f1-d7a2e7d93852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_e8865e50-20e4-4a05-8327-378b44757164" xlink:to="loc_us-gaap_ForeignPlanMember_7cb88fe2-74d3-4bdb-b9f1-d7a2e7d93852" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails" xlink:type="extended" id="if413eb9ac19f4602afe49a35a101733c_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e1b8f711-8816-4888-988d-3575ebeba272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_944af3c0-bd91-4a79-bd84-fe63695dd662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e1b8f711-8816-4888-988d-3575ebeba272" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_944af3c0-bd91-4a79-bd84-fe63695dd662" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_094ba477-6e4f-473d-abef-50967655780b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e1b8f711-8816-4888-988d-3575ebeba272" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_094ba477-6e4f-473d-abef-50967655780b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a0ff271a-2b2e-4954-a42c-af8ac7ec4978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_094ba477-6e4f-473d-abef-50967655780b" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a0ff271a-2b2e-4954-a42c-af8ac7ec4978" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a0ff271a-2b2e-4954-a42c-af8ac7ec4978_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a0ff271a-2b2e-4954-a42c-af8ac7ec4978" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a0ff271a-2b2e-4954-a42c-af8ac7ec4978_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_987a98d7-79fa-4479-b0c9-37f8200f707c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a0ff271a-2b2e-4954-a42c-af8ac7ec4978" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_987a98d7-79fa-4479-b0c9-37f8200f707c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_2b7dd525-80f3-4ee6-8681-cda468c0db1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_987a98d7-79fa-4479-b0c9-37f8200f707c" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_2b7dd525-80f3-4ee6-8681-cda468c0db1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_92ba6ce5-5f7a-4bd7-94c3-e8ae300f4e90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_094ba477-6e4f-473d-abef-50967655780b" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_92ba6ce5-5f7a-4bd7-94c3-e8ae300f4e90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_92ba6ce5-5f7a-4bd7-94c3-e8ae300f4e90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_92ba6ce5-5f7a-4bd7-94c3-e8ae300f4e90" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_92ba6ce5-5f7a-4bd7-94c3-e8ae300f4e90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_403d8675-10c0-4869-a12b-8af96f83faeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_92ba6ce5-5f7a-4bd7-94c3-e8ae300f4e90" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_403d8675-10c0-4869-a12b-8af96f83faeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_f28a03a4-ee05-4ea0-aa77-24eb343a8031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_403d8675-10c0-4869-a12b-8af96f83faeb" xlink:to="loc_us-gaap_DomesticPlanMember_f28a03a4-ee05-4ea0-aa77-24eb343a8031" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_97da91d8-9ccc-4105-9d7e-02aaf8c77e06" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_f28a03a4-ee05-4ea0-aa77-24eb343a8031" xlink:to="loc_country_US_97da91d8-9ccc-4105-9d7e-02aaf8c77e06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_eb7b339a-22dd-43aa-88cc-45bd8a61b8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_403d8675-10c0-4869-a12b-8af96f83faeb" xlink:to="loc_us-gaap_ForeignPlanMember_eb7b339a-22dd-43aa-88cc-45bd8a61b8c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_67252995-266b-4222-9128-7c9f6c9ba4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_094ba477-6e4f-473d-abef-50967655780b" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_67252995-266b-4222-9128-7c9f6c9ba4b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_67252995-266b-4222-9128-7c9f6c9ba4b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_67252995-266b-4222-9128-7c9f6c9ba4b4" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_67252995-266b-4222-9128-7c9f6c9ba4b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_ced8e453-62ac-4108-9fa3-eb66d5f4ca03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_67252995-266b-4222-9128-7c9f6c9ba4b4" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_ced8e453-62ac-4108-9fa3-eb66d5f4ca03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_af07a288-8c85-47a3-bcbf-5ca719310ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ced8e453-62ac-4108-9fa3-eb66d5f4ca03" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_af07a288-8c85-47a3-bcbf-5ca719310ba0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_902e7c61-6209-4d3e-8290-754a1b879f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ced8e453-62ac-4108-9fa3-eb66d5f4ca03" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_902e7c61-6209-4d3e-8290-754a1b879f45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember_01a36312-4669-4efd-a749-384ecc4ffb81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ced8e453-62ac-4108-9fa3-eb66d5f4ca03" xlink:to="loc_us-gaap_FixedIncomeSecuritiesMember_01a36312-4669-4efd-a749-384ecc4ffb81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_a38e7771-7e5c-4c2f-b68e-481777364af1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ced8e453-62ac-4108-9fa3-eb66d5f4ca03" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_a38e7771-7e5c-4c2f-b68e-481777364af1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails" xlink:type="extended" id="i1278d5c6199a4a19b0f88135e2140e44_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_3db9ec82-e66b-42b9-b59d-891e03752667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_228962d6-9c12-4bd2-89ea-8ca50c623f46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_3db9ec82-e66b-42b9-b59d-891e03752667" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_228962d6-9c12-4bd2-89ea-8ca50c623f46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_1be5cc9c-2802-4c09-a015-141f6c234680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_3db9ec82-e66b-42b9-b59d-891e03752667" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_1be5cc9c-2802-4c09-a015-141f6c234680" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_acb3c028-3d9a-457a-8c0a-8bf4e9d9531c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_1be5cc9c-2802-4c09-a015-141f6c234680" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_acb3c028-3d9a-457a-8c0a-8bf4e9d9531c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_acb3c028-3d9a-457a-8c0a-8bf4e9d9531c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_acb3c028-3d9a-457a-8c0a-8bf4e9d9531c" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_acb3c028-3d9a-457a-8c0a-8bf4e9d9531c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_ff505991-d3e5-4d4c-a3f1-dd630c1af2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_acb3c028-3d9a-457a-8c0a-8bf4e9d9531c" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_ff505991-d3e5-4d4c-a3f1-dd630c1af2d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_0a5ad483-9bca-4cc2-b9bd-437850d7bbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ff505991-d3e5-4d4c-a3f1-dd630c1af2d9" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_0a5ad483-9bca-4cc2-b9bd-437850d7bbd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b4c16e8c-5a9b-4e13-8916-9ecda4ec0e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ff505991-d3e5-4d4c-a3f1-dd630c1af2d9" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b4c16e8c-5a9b-4e13-8916-9ecda4ec0e2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_U.S.BroadMarketMember_bdd19992-b227-4a4e-99b9-45da99fa8f70" xlink:href="bhc-20211231.xsd#bhc_U.S.BroadMarketMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b4c16e8c-5a9b-4e13-8916-9ecda4ec0e2c" xlink:to="loc_bhc_U.S.BroadMarketMember_bdd19992-b227-4a4e-99b9-45da99fa8f70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmergingMarketsMember_061586ba-d626-472c-91c6-edfb2661855e" xlink:href="bhc-20211231.xsd#bhc_EmergingMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b4c16e8c-5a9b-4e13-8916-9ecda4ec0e2c" xlink:to="loc_bhc_EmergingMarketsMember_061586ba-d626-472c-91c6-edfb2661855e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonU.S.DevelopedMarketsMember_d21066eb-0829-4726-a18c-1f4d0f6587eb" xlink:href="bhc-20211231.xsd#bhc_NonU.S.DevelopedMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b4c16e8c-5a9b-4e13-8916-9ecda4ec0e2c" xlink:to="loc_bhc_NonU.S.DevelopedMarketsMember_d21066eb-0829-4726-a18c-1f4d0f6587eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonU.S.OtherAssetsMember_33524852-7de2-4119-836f-19dde2d44681" xlink:href="bhc-20211231.xsd#bhc_NonU.S.OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b4c16e8c-5a9b-4e13-8916-9ecda4ec0e2c" xlink:to="loc_bhc_NonU.S.OtherAssetsMember_33524852-7de2-4119-836f-19dde2d44681" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember_31ab7275-985c-4036-bc4b-14d50e380cda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ff505991-d3e5-4d4c-a3f1-dd630c1af2d9" xlink:to="loc_us-gaap_FixedIncomeSecuritiesMember_31ab7275-985c-4036-bc4b-14d50e380cda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InvestmentGradeMember_1e140968-d37e-4a6a-8d0b-1faab7c6e6f4" xlink:href="bhc-20211231.xsd#bhc_InvestmentGradeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember_31ab7275-985c-4036-bc4b-14d50e380cda" xlink:to="loc_bhc_InvestmentGradeMember_1e140968-d37e-4a6a-8d0b-1faab7c6e6f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlobalHighYieldMember_6b87aedf-7ba0-43c1-a80c-d539c6c3c8ac" xlink:href="bhc-20211231.xsd#bhc_GlobalHighYieldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember_31ab7275-985c-4036-bc4b-14d50e380cda" xlink:to="loc_bhc_GlobalHighYieldMember_6b87aedf-7ba0-43c1-a80c-d539c6c3c8ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_7e95aa55-8551-40aa-82b3-dd94ba07bdf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember_31ab7275-985c-4036-bc4b-14d50e380cda" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_7e95aa55-8551-40aa-82b3-dd94ba07bdf2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherAssetsFixedIncomeSecuritiesMember_44a9cc95-d83e-4134-870f-ea47a336406b" xlink:href="bhc-20211231.xsd#bhc_OtherAssetsFixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ff505991-d3e5-4d4c-a3f1-dd630c1af2d9" xlink:to="loc_bhc_OtherAssetsFixedIncomeSecuritiesMember_44a9cc95-d83e-4134-870f-ea47a336406b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eddbdf5c-5375-4389-be9a-be3cdd130054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_1be5cc9c-2802-4c09-a015-141f6c234680" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eddbdf5c-5375-4389-be9a-be3cdd130054" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eddbdf5c-5375-4389-be9a-be3cdd130054_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eddbdf5c-5375-4389-be9a-be3cdd130054" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eddbdf5c-5375-4389-be9a-be3cdd130054_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4bfc36b0-44b1-4bfc-a30d-05e96f91ac8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eddbdf5c-5375-4389-be9a-be3cdd130054" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4bfc36b0-44b1-4bfc-a30d-05e96f91ac8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c0633708-1920-49ae-9345-c84d43fd133e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4bfc36b0-44b1-4bfc-a30d-05e96f91ac8f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c0633708-1920-49ae-9345-c84d43fd133e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a67e7ad8-8e7b-4c7f-83e4-f34bdc4b6b89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4bfc36b0-44b1-4bfc-a30d-05e96f91ac8f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a67e7ad8-8e7b-4c7f-83e4-f34bdc4b6b89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_541b6eb6-8bda-429e-9754-2a68c251cab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4bfc36b0-44b1-4bfc-a30d-05e96f91ac8f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_541b6eb6-8bda-429e-9754-2a68c251cab2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_6c01210e-fe57-4123-a964-b6fc6c80dfda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_1be5cc9c-2802-4c09-a015-141f6c234680" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_6c01210e-fe57-4123-a964-b6fc6c80dfda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_6c01210e-fe57-4123-a964-b6fc6c80dfda_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_6c01210e-fe57-4123-a964-b6fc6c80dfda" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_6c01210e-fe57-4123-a964-b6fc6c80dfda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_29672b07-04eb-49f7-9490-041d0e6edb94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_6c01210e-fe57-4123-a964-b6fc6c80dfda" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_29672b07-04eb-49f7-9490-041d0e6edb94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_7b5a09d7-5a9e-470c-9fa2-c51f81c9fe5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_29672b07-04eb-49f7-9490-041d0e6edb94" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_7b5a09d7-5a9e-470c-9fa2-c51f81c9fe5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0f70c30e-376f-4ea5-b815-56aa9adf378f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_1be5cc9c-2802-4c09-a015-141f6c234680" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0f70c30e-376f-4ea5-b815-56aa9adf378f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0f70c30e-376f-4ea5-b815-56aa9adf378f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0f70c30e-376f-4ea5-b815-56aa9adf378f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0f70c30e-376f-4ea5-b815-56aa9adf378f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c9a22433-5895-434a-9adf-b78162a01463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0f70c30e-376f-4ea5-b815-56aa9adf378f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c9a22433-5895-434a-9adf-b78162a01463" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_cdfae988-d733-4c33-8c17-976e7bfd2591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c9a22433-5895-434a-9adf-b78162a01463" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_cdfae988-d733-4c33-8c17-976e7bfd2591" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_22be0b03-26d6-4632-8323-72ce19661c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_1be5cc9c-2802-4c09-a015-141f6c234680" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_22be0b03-26d6-4632-8323-72ce19661c96" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_22be0b03-26d6-4632-8323-72ce19661c96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_22be0b03-26d6-4632-8323-72ce19661c96" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_22be0b03-26d6-4632-8323-72ce19661c96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_570d15aa-0d4a-4296-8341-afde2232985c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_22be0b03-26d6-4632-8323-72ce19661c96" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_570d15aa-0d4a-4296-8341-afde2232985c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_138eb159-2847-4505-ae46-2a24dac771c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_570d15aa-0d4a-4296-8341-afde2232985c" xlink:to="loc_us-gaap_DomesticPlanMember_138eb159-2847-4505-ae46-2a24dac771c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1916f641-582a-489b-844b-00ccbc6b15d4" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_138eb159-2847-4505-ae46-2a24dac771c7" xlink:to="loc_country_US_1916f641-582a-489b-844b-00ccbc6b15d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_4605869d-9bcf-4980-b46a-004013b412cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_570d15aa-0d4a-4296-8341-afde2232985c" xlink:to="loc_us-gaap_ForeignPlanMember_4605869d-9bcf-4980-b46a-004013b412cc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="i4a83989c31c3471ea962ba824dc6f33d_SHAREBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2db9acf9-030e-464a-8be8-0e2656b3cfe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2b47d980-ac50-461c-a0f9-2a7255e601a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2db9acf9-030e-464a-8be8-0e2656b3cfe5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2b47d980-ac50-461c-a0f9-2a7255e601a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_89327ef5-b8f3-4588-ad63-7317fdc8f626" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2db9acf9-030e-464a-8be8-0e2656b3cfe5" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_89327ef5-b8f3-4588-ad63-7317fdc8f626" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_12863155-e268-4961-bcbb-00a3094fc082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2db9acf9-030e-464a-8be8-0e2656b3cfe5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_12863155-e268-4961-bcbb-00a3094fc082" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_e098f299-205d-4fcc-a952-7a19b2f5a5e7" xlink:href="bhc-20211231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2db9acf9-030e-464a-8be8-0e2656b3cfe5" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_e098f299-205d-4fcc-a952-7a19b2f5a5e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_da33ee96-9376-44fc-afb7-152bbb9175a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2db9acf9-030e-464a-8be8-0e2656b3cfe5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_da33ee96-9376-44fc-afb7-152bbb9175a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cd070e84-b051-4776-ab35-5fea27f1db0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2db9acf9-030e-464a-8be8-0e2656b3cfe5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cd070e84-b051-4776-ab35-5fea27f1db0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b4333d76-8b3d-4d17-9a61-8eeddb9c8882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cd070e84-b051-4776-ab35-5fea27f1db0a" xlink:to="loc_us-gaap_PlanNameAxis_b4333d76-8b3d-4d17-9a61-8eeddb9c8882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b4333d76-8b3d-4d17-9a61-8eeddb9c8882_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b4333d76-8b3d-4d17-9a61-8eeddb9c8882" xlink:to="loc_us-gaap_PlanNameDomain_b4333d76-8b3d-4d17-9a61-8eeddb9c8882_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_563fdfbb-e7c0-496a-8342-69eaa696bf7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b4333d76-8b3d-4d17-9a61-8eeddb9c8882" xlink:to="loc_us-gaap_PlanNameDomain_563fdfbb-e7c0-496a-8342-69eaa696bf7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member_4fed524e-1563-45e7-8fa4-4ddb9a1765c7" xlink:href="bhc-20211231.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_563fdfbb-e7c0-496a-8342-69eaa696bf7e" xlink:to="loc_bhc_OmnibusIncentivePlan2014Member_4fed524e-1563-45e7-8fa4-4ddb9a1765c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_3330aae1-c32c-4fcb-aa20-9f6ba02ad7e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cd070e84-b051-4776-ab35-5fea27f1db0a" xlink:to="loc_srt_TitleOfIndividualAxis_3330aae1-c32c-4fcb-aa20-9f6ba02ad7e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3330aae1-c32c-4fcb-aa20-9f6ba02ad7e0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_3330aae1-c32c-4fcb-aa20-9f6ba02ad7e0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3330aae1-c32c-4fcb-aa20-9f6ba02ad7e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_acff31ff-1b6f-4a87-ac5b-000c19ea67a8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_3330aae1-c32c-4fcb-aa20-9f6ba02ad7e0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_acff31ff-1b6f-4a87-ac5b-000c19ea67a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonemployeeDirectorMember_53500227-eb75-439b-abaf-4e260ffb81fa" xlink:href="bhc-20211231.xsd#bhc_NonemployeeDirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_acff31ff-1b6f-4a87-ac5b-000c19ea67a8" xlink:to="loc_bhc_NonemployeeDirectorMember_53500227-eb75-439b-abaf-4e260ffb81fa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="extended" id="ia4b4b8365cbc4017975049d0ff41cefe_SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9673964e-f530-43d8-ac7b-7d56fc2ddd15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ce7628c9-d82b-438c-a366-23333c06d543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9673964e-f530-43d8-ac7b-7d56fc2ddd15" xlink:to="loc_us-gaap_ShareBasedCompensation_ce7628c9-d82b-438c-a366-23333c06d543" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c699f75e-a430-4c91-a0c8-a1559580dde9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9673964e-f530-43d8-ac7b-7d56fc2ddd15" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c699f75e-a430-4c91-a0c8-a1559580dde9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6b3773c9-0d6d-490f-ae02-9386b3080e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c699f75e-a430-4c91-a0c8-a1559580dde9" xlink:to="loc_us-gaap_AwardTypeAxis_6b3773c9-0d6d-490f-ae02-9386b3080e56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b3773c9-0d6d-490f-ae02-9386b3080e56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6b3773c9-0d6d-490f-ae02-9386b3080e56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b3773c9-0d6d-490f-ae02-9386b3080e56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0198ef8a-1067-4d98-a438-2c68671b1585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6b3773c9-0d6d-490f-ae02-9386b3080e56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0198ef8a-1067-4d98-a438-2c68671b1585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_14543380-5b40-4ebc-8d59-88c8bb4c561a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0198ef8a-1067-4d98-a438-2c68671b1585" xlink:to="loc_us-gaap_EmployeeStockOptionMember_14543380-5b40-4ebc-8d59-88c8bb4c561a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f743c1f3-6f6a-4b84-9c3b-ff88976e01b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0198ef8a-1067-4d98-a438-2c68671b1585" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f743c1f3-6f6a-4b84-9c3b-ff88976e01b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_be692c5e-b6c1-4475-9c2e-928465ceaa3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c699f75e-a430-4c91-a0c8-a1559580dde9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_be692c5e-b6c1-4475-9c2e-928465ceaa3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_be692c5e-b6c1-4475-9c2e-928465ceaa3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_be692c5e-b6c1-4475-9c2e-928465ceaa3e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_be692c5e-b6c1-4475-9c2e-928465ceaa3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6742ca57-5bf0-437a-b0dc-4a6a1eb3f403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_be692c5e-b6c1-4475-9c2e-928465ceaa3e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6742ca57-5bf0-437a-b0dc-4a6a1eb3f403" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c07d2236-eba2-413e-966c-9a82f02cff3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6742ca57-5bf0-437a-b0dc-4a6a1eb3f403" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c07d2236-eba2-413e-966c-9a82f02cff3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SellingGeneralAndAdministrativeExpenseMember_d6ddbbef-614c-4618-ba0c-ad8b78c20b5f" xlink:href="bhc-20211231.xsd#bhc_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6742ca57-5bf0-437a-b0dc-4a6a1eb3f403" xlink:to="loc_bhc_SellingGeneralAndAdministrativeExpenseMember_d6ddbbef-614c-4618-ba0c-ad8b78c20b5f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SHAREBASEDCOMPENSATIONStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="extended" id="i6e6e9320f8f84f8eb76b65793902d541_SHAREBASEDCOMPENSATIONStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_70941213-0eb2-4b52-a6ec-3d74bd8bbb76" xlink:href="bhc-20211231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_70941213-0eb2-4b52-a6ec-3d74bd8bbb76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_cab7154a-8a3a-4199-b908-7689dd0541cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_cab7154a-8a3a-4199-b908-7689dd0541cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_f4d4369d-50bf-4225-a5fe-e8c4e0924602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_f4d4369d-50bf-4225-a5fe-e8c4e0924602" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cda6068c-1705-4e7b-a448-c205fa5ecf3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_f4d4369d-50bf-4225-a5fe-e8c4e0924602" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cda6068c-1705-4e7b-a448-c205fa5ecf3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_821f1835-034d-422e-9b99-11dac8ee0b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_f4d4369d-50bf-4225-a5fe-e8c4e0924602" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_821f1835-034d-422e-9b99-11dac8ee0b0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d23154e7-ddf6-4720-9dc9-b331aa8a1027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_f4d4369d-50bf-4225-a5fe-e8c4e0924602" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d23154e7-ddf6-4720-9dc9-b331aa8a1027" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_acb4a4e1-ae62-41c3-9d56-b87eda8252ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_f4d4369d-50bf-4225-a5fe-e8c4e0924602" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_acb4a4e1-ae62-41c3-9d56-b87eda8252ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3a9a62e-f76d-40c0-a460-c70533abefaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3a9a62e-f76d-40c0-a460-c70533abefaf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e7bc314e-52c0-4fd6-80b5-06501177bb70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3a9a62e-f76d-40c0-a460-c70533abefaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e7bc314e-52c0-4fd6-80b5-06501177bb70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6fe58ad5-05c2-46ac-9273-03fa8c4c5746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3a9a62e-f76d-40c0-a460-c70533abefaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6fe58ad5-05c2-46ac-9273-03fa8c4c5746" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_dae11194-b2ba-4413-8c7a-b16724d8136f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3a9a62e-f76d-40c0-a460-c70533abefaf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_dae11194-b2ba-4413-8c7a-b16724d8136f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0c92309c-42d3-4361-9e0a-95677f756c39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3a9a62e-f76d-40c0-a460-c70533abefaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0c92309c-42d3-4361-9e0a-95677f756c39" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c5001a1d-89f0-4a78-aafa-f0c3ba332091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_454f2403-7da9-4fa5-be96-d135944d29b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_454f2403-7da9-4fa5-be96-d135944d29b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_384a7ed0-71e3-4b89-8665-687ebcc3eb29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_384a7ed0-71e3-4b89-8665-687ebcc3eb29" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_c83b1ad1-dac7-4113-9d55-6217f80b6e0c" xlink:href="bhc-20211231.xsd#bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_c83b1ad1-dac7-4113-9d55-6217f80b6e0c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c8e6813a-1173-49fe-b0e6-daa8a11d1a65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_c83b1ad1-dac7-4113-9d55-6217f80b6e0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c8e6813a-1173-49fe-b0e6-daa8a11d1a65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c8a0d45a-5693-4950-93a3-3e1c3e4b0be4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_c83b1ad1-dac7-4113-9d55-6217f80b6e0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c8a0d45a-5693-4950-93a3-3e1c3e4b0be4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_51e7d240-3132-4017-9029-669a117000a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_c83b1ad1-dac7-4113-9d55-6217f80b6e0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_51e7d240-3132-4017-9029-669a117000a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_94fb8ef4-b485-421c-adf4-be0aba029b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_c83b1ad1-dac7-4113-9d55-6217f80b6e0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_94fb8ef4-b485-421c-adf4-be0aba029b49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_44f4e105-8277-4b3f-8ef7-93e50b8fb6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_35d8dde8-c0a6-4532-aad6-d0710de88fef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_35d8dde8-c0a6-4532-aad6-d0710de88fef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2f3d3e99-b956-4493-b3cc-c5be189ba123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2f3d3e99-b956-4493-b3cc-c5be189ba123" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0fe0616f-8ff4-4f04-8014-e5aaa792b589" xlink:href="bhc-20211231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0fe0616f-8ff4-4f04-8014-e5aaa792b589" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3f0c0433-3e45-421b-a8f6-8bfab0e064b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0fe0616f-8ff4-4f04-8014-e5aaa792b589" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3f0c0433-3e45-421b-a8f6-8bfab0e064b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_aee20854-7989-4680-a4a3-1e27524ff6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0fe0616f-8ff4-4f04-8014-e5aaa792b589" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_aee20854-7989-4680-a4a3-1e27524ff6ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_4d8e37b8-efb7-42a9-8bb4-233471671d69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0fe0616f-8ff4-4f04-8014-e5aaa792b589" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_4d8e37b8-efb7-42a9-8bb4-233471671d69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_66fcb169-1e17-4bff-b775-b44eca1a2f8c" xlink:href="bhc-20211231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_66fcb169-1e17-4bff-b775-b44eca1a2f8c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_91d3e919-95df-4965-8978-fa722711ffc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_66fcb169-1e17-4bff-b775-b44eca1a2f8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_91d3e919-95df-4965-8978-fa722711ffc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b6ce2f8a-aad0-4849-960e-b0e016029441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_66fcb169-1e17-4bff-b775-b44eca1a2f8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b6ce2f8a-aad0-4849-960e-b0e016029441" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c45ee735-e8a8-4b8a-ab7f-533f3c06bbea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_66fcb169-1e17-4bff-b775-b44eca1a2f8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c45ee735-e8a8-4b8a-ab7f-533f3c06bbea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e8c58caa-8619-44c8-b229-039df97a9e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e8c58caa-8619-44c8-b229-039df97a9e1c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a47da063-2dba-4970-9581-3ef35623fbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e8c58caa-8619-44c8-b229-039df97a9e1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a47da063-2dba-4970-9581-3ef35623fbf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_fadcbe9e-5ad4-4960-9938-69659d6e6abc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e8c58caa-8619-44c8-b229-039df97a9e1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_fadcbe9e-5ad4-4960-9938-69659d6e6abc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e08f3f94-24bc-4113-afc4-2497faa41684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e8c58caa-8619-44c8-b229-039df97a9e1c" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e08f3f94-24bc-4113-afc4-2497faa41684" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_466746f1-d940-40ef-a852-9b8b300f10e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e8c58caa-8619-44c8-b229-039df97a9e1c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_466746f1-d940-40ef-a852-9b8b300f10e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_99986f8f-751e-46d2-bc5a-0542a74e030d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e8c58caa-8619-44c8-b229-039df97a9e1c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_99986f8f-751e-46d2-bc5a-0542a74e030d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue_1777360b-9054-4dbd-bfb9-5c64c062b289" xlink:href="bhc-20211231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e8c58caa-8619-44c8-b229-039df97a9e1c" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue_1777360b-9054-4dbd-bfb9-5c64c062b289" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a03d704-bcdc-4a99-863d-237bde57de3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a03d704-bcdc-4a99-863d-237bde57de3f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_4480a49a-ae4a-4b46-ac12-e0b4af7b82ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a03d704-bcdc-4a99-863d-237bde57de3f" xlink:to="loc_us-gaap_VestingAxis_4480a49a-ae4a-4b46-ac12-e0b4af7b82ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_4480a49a-ae4a-4b46-ac12-e0b4af7b82ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_4480a49a-ae4a-4b46-ac12-e0b4af7b82ba" xlink:to="loc_us-gaap_VestingDomain_4480a49a-ae4a-4b46-ac12-e0b4af7b82ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_aad57ed3-df17-4a83-aef6-f7543e35abb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_4480a49a-ae4a-4b46-ac12-e0b4af7b82ba" xlink:to="loc_us-gaap_VestingDomain_aad57ed3-df17-4a83-aef6-f7543e35abb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_768e3c10-0db3-47ee-bc39-0479f4bd7103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_aad57ed3-df17-4a83-aef6-f7543e35abb0" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_768e3c10-0db3-47ee-bc39-0479f4bd7103" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_89787151-49da-4699-8f3d-54832bd13245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_aad57ed3-df17-4a83-aef6-f7543e35abb0" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_89787151-49da-4699-8f3d-54832bd13245" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_706e4e33-551a-48f2-a4a7-b64758231681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a03d704-bcdc-4a99-863d-237bde57de3f" xlink:to="loc_us-gaap_AwardTypeAxis_706e4e33-551a-48f2-a4a7-b64758231681" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_706e4e33-551a-48f2-a4a7-b64758231681_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_706e4e33-551a-48f2-a4a7-b64758231681" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_706e4e33-551a-48f2-a4a7-b64758231681_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abbeefc9-2c3d-4557-8583-6986dd37ff37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_706e4e33-551a-48f2-a4a7-b64758231681" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abbeefc9-2c3d-4557-8583-6986dd37ff37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a25097d6-6b57-4af7-acf3-64c94c95bc76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abbeefc9-2c3d-4557-8583-6986dd37ff37" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a25097d6-6b57-4af7-acf3-64c94c95bc76" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SHAREBASEDCOMPENSATIONRSUsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" xlink:type="extended" id="ie469ef3d542c47bdabfc890200ef182a_SHAREBASEDCOMPENSATIONRSUsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e8ef887-e985-4a41-b6a5-db76273fb27f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_63db97b3-b9b5-4aeb-ae5e-25137505ca6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e8ef887-e985-4a41-b6a5-db76273fb27f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_63db97b3-b9b5-4aeb-ae5e-25137505ca6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0c68a91b-dcda-413f-bc8d-68b93fc8d051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e8ef887-e985-4a41-b6a5-db76273fb27f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0c68a91b-dcda-413f-bc8d-68b93fc8d051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_80df183f-0778-4a92-bcf1-8fe609cacb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e8ef887-e985-4a41-b6a5-db76273fb27f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_80df183f-0778-4a92-bcf1-8fe609cacb4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_ee077839-f2c2-4d39-ba4e-364ce407fc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e8ef887-e985-4a41-b6a5-db76273fb27f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_ee077839-f2c2-4d39-ba4e-364ce407fc8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0ba615a2-1390-4719-8fe0-f429948f909a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e8ef887-e985-4a41-b6a5-db76273fb27f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0ba615a2-1390-4719-8fe0-f429948f909a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_ebeb2c5a-c603-4faf-b55c-2c10cbc46fe3" xlink:href="bhc-20211231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e8ef887-e985-4a41-b6a5-db76273fb27f" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_ebeb2c5a-c603-4faf-b55c-2c10cbc46fe3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d62e3ce1-9024-4ad9-9761-8794e65647f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e8ef887-e985-4a41-b6a5-db76273fb27f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d62e3ce1-9024-4ad9-9761-8794e65647f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_34ae8d28-cd3d-4e83-b807-2e6e916fda2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d62e3ce1-9024-4ad9-9761-8794e65647f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_34ae8d28-cd3d-4e83-b807-2e6e916fda2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_149b2e4c-c9df-4f02-9848-dc0125f3162d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d62e3ce1-9024-4ad9-9761-8794e65647f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_149b2e4c-c9df-4f02-9848-dc0125f3162d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8e004ed0-582d-457c-970a-81755ba80402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d62e3ce1-9024-4ad9-9761-8794e65647f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8e004ed0-582d-457c-970a-81755ba80402" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_347f903b-ab92-43fd-a3d7-9311d6ec66f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d62e3ce1-9024-4ad9-9761-8794e65647f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_347f903b-ab92-43fd-a3d7-9311d6ec66f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fed1c381-e24d-4053-afa4-eb638df21e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0c7debd-48cc-4b5d-b887-672607fa3769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e8ef887-e985-4a41-b6a5-db76273fb27f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0c7debd-48cc-4b5d-b887-672607fa3769" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_78cba7d1-1f34-434a-b4ac-8fbe61fa51a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0c7debd-48cc-4b5d-b887-672607fa3769" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_78cba7d1-1f34-434a-b4ac-8fbe61fa51a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_74aed50b-ad8f-4379-8d8f-0ede18606078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0c7debd-48cc-4b5d-b887-672607fa3769" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_74aed50b-ad8f-4379-8d8f-0ede18606078" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fc6b9902-e2ea-4753-a99f-78dd6bb6f2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0c7debd-48cc-4b5d-b887-672607fa3769" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fc6b9902-e2ea-4753-a99f-78dd6bb6f2b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_76080314-8ea5-4478-868d-ecc1a7d126ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0c7debd-48cc-4b5d-b887-672607fa3769" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_76080314-8ea5-4478-868d-ecc1a7d126ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9b6159f5-fe13-4fc1-a496-4dc471ebe034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b09f91a1-5635-41b4-b9ae-14f70694c189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e8ef887-e985-4a41-b6a5-db76273fb27f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b09f91a1-5635-41b4-b9ae-14f70694c189" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ebdfebdb-3c48-4a17-a78b-c6795ab3bb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b09f91a1-5635-41b4-b9ae-14f70694c189" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ebdfebdb-3c48-4a17-a78b-c6795ab3bb9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_79b0315e-ccff-4846-93fa-c64683611688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b09f91a1-5635-41b4-b9ae-14f70694c189" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_79b0315e-ccff-4846-93fa-c64683611688" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ad3043eb-ece2-4893-8dda-cd59b3ba36fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b09f91a1-5635-41b4-b9ae-14f70694c189" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ad3043eb-ece2-4893-8dda-cd59b3ba36fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2c61d0c-0190-430f-9876-6cf729a5aca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e8ef887-e985-4a41-b6a5-db76273fb27f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2c61d0c-0190-430f-9876-6cf729a5aca3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6be2ca05-a159-4b1c-8c79-9dea139cea20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2c61d0c-0190-430f-9876-6cf729a5aca3" xlink:to="loc_us-gaap_AwardTypeAxis_6be2ca05-a159-4b1c-8c79-9dea139cea20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6be2ca05-a159-4b1c-8c79-9dea139cea20_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6be2ca05-a159-4b1c-8c79-9dea139cea20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6be2ca05-a159-4b1c-8c79-9dea139cea20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_381f8cb5-21a9-4f28-99e4-6e67b77cf4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6be2ca05-a159-4b1c-8c79-9dea139cea20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_381f8cb5-21a9-4f28-99e4-6e67b77cf4f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_73de3908-c2bb-4f58-89e2-8fc8f4980510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_381f8cb5-21a9-4f28-99e4-6e67b77cf4f8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_73de3908-c2bb-4f58-89e2-8fc8f4980510" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember_fec9d2fd-99a6-4fc8-b505-711441678ee5" xlink:href="bhc-20211231.xsd#bhc_TimeBasedRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_381f8cb5-21a9-4f28-99e4-6e67b77cf4f8" xlink:to="loc_bhc_TimeBasedRSUMember_fec9d2fd-99a6-4fc8-b505-711441678ee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_c2e4b1e8-dcaa-4fbc-8043-ffcd4c91c483" xlink:href="bhc-20211231.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_381f8cb5-21a9-4f28-99e4-6e67b77cf4f8" xlink:to="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_c2e4b1e8-dcaa-4fbc-8043-ffcd4c91c483" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_94a484f8-8931-43ac-912d-e4e06f904723" xlink:href="bhc-20211231.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_c2e4b1e8-dcaa-4fbc-8043-ffcd4c91c483" xlink:to="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_94a484f8-8931-43ac-912d-e4e06f904723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_4effc0d3-f501-4d5c-84dd-849f1cc1ee67" xlink:href="bhc-20211231.xsd#bhc_ROTCPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_c2e4b1e8-dcaa-4fbc-8043-ffcd4c91c483" xlink:to="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_4effc0d3-f501-4d5c-84dd-849f1cc1ee67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherPerformanceBasedRestrictedStockUnitsMember_57d4058a-f17a-4f0c-8192-f0f9e089b352" xlink:href="bhc-20211231.xsd#bhc_OtherPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_c2e4b1e8-dcaa-4fbc-8043-ffcd4c91c483" xlink:to="loc_bhc_OtherPerformanceBasedRestrictedStockUnitsMember_57d4058a-f17a-4f0c-8192-f0f9e089b352" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="i5448eea3ad224a61a666751f8c403a4b_ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b6d6fb30-0166-4abb-85c8-b251a583c44c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4aea01e9-05dd-444f-951f-6c376ad7f494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b6d6fb30-0166-4abb-85c8-b251a583c44c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4aea01e9-05dd-444f-951f-6c376ad7f494" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_d5ae1da6-fccd-45f1-b9ca-e763f97acf3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b6d6fb30-0166-4abb-85c8-b251a583c44c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_d5ae1da6-fccd-45f1-b9ca-e763f97acf3d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c086aeb5-1e30-452c-8379-6b5469df1187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_d5ae1da6-fccd-45f1-b9ca-e763f97acf3d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c086aeb5-1e30-452c-8379-6b5469df1187" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c086aeb5-1e30-452c-8379-6b5469df1187_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c086aeb5-1e30-452c-8379-6b5469df1187" xlink:to="loc_us-gaap_EquityComponentDomain_c086aeb5-1e30-452c-8379-6b5469df1187_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4060ddd7-29d2-4b95-b283-9258f9c60a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c086aeb5-1e30-452c-8379-6b5469df1187" xlink:to="loc_us-gaap_EquityComponentDomain_4060ddd7-29d2-4b95-b283-9258f9c60a52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6334de40-2410-4a2b-90fd-668b1f600cda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4060ddd7-29d2-4b95-b283-9258f9c60a52" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6334de40-2410-4a2b-90fd-668b1f600cda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_ff6dd532-7f46-4bc6-bb76-906db417dc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4060ddd7-29d2-4b95-b283-9258f9c60a52" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_ff6dd532-7f46-4bc6-bb76-906db417dc6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f91ad346-f8d4-4988-8fba-3def51aee571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4060ddd7-29d2-4b95-b283-9258f9c60a52" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f91ad346-f8d4-4988-8fba-3def51aee571" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#OTHEREXPENSENETNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails" xlink:type="extended" id="ia51ff1a57fde49eca436cfaf0256982b_OTHEREXPENSENETNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_c70ec4ea-2842-431b-9f38-fc5c8833879c" xlink:href="bhc-20211231.xsd#bhc_ScheduleOfOtherIncomeAndExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_ce5716c6-b03a-4f4e-b8ce-991a3d8ba2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_c70ec4ea-2842-431b-9f38-fc5c8833879c" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_ce5716c6-b03a-4f4e-b8ce-991a3d8ba2cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_5d59dcbb-3227-4322-8ce4-d3520e67db3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_c70ec4ea-2842-431b-9f38-fc5c8833879c" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_5d59dcbb-3227-4322-8ce4-d3520e67db3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_cf302ca0-0acd-4e4f-a87a-1b27f1065f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_c70ec4ea-2842-431b-9f38-fc5c8833879c" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_cf302ca0-0acd-4e4f-a87a-1b27f1065f5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_d952f664-84eb-4ac9-83a4-f6145528d5a0" xlink:href="bhc-20211231.xsd#bhc_ScheduleOfOtherIncomeAndExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_c70ec4ea-2842-431b-9f38-fc5c8833879c" xlink:to="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_d952f664-84eb-4ac9-83a4-f6145528d5a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5669ade0-ecfc-4c79-bfb0-11fdd4f45fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_d952f664-84eb-4ac9-83a4-f6145528d5a0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5669ade0-ecfc-4c79-bfb0-11fdd4f45fdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5669ade0-ecfc-4c79-bfb0-11fdd4f45fdf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5669ade0-ecfc-4c79-bfb0-11fdd4f45fdf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5669ade0-ecfc-4c79-bfb0-11fdd4f45fdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_37a2b657-f341-4454-ac8a-1056ef3b0ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5669ade0-ecfc-4c79-bfb0-11fdd4f45fdf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_37a2b657-f341-4454-ac8a-1056ef3b0ac8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MilestonePaymentRelatedToCertainProductMember_aeb52821-7111-4f30-950f-4ab086b6ab3c" xlink:href="bhc-20211231.xsd#bhc_MilestonePaymentRelatedToCertainProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_37a2b657-f341-4454-ac8a-1056ef3b0ac8" xlink:to="loc_bhc_MilestonePaymentRelatedToCertainProductMember_aeb52821-7111-4f30-950f-4ab086b6ab3c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails" xlink:type="extended" id="i309cafeecf264afea21e3e6327d0f0f0_INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d321bd64-f4ac-4f12-82a1-741eab8befef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aae030f9-43ef-434b-944d-c43e7289797d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d321bd64-f4ac-4f12-82a1-741eab8befef" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aae030f9-43ef-434b-944d-c43e7289797d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_7308391a-d3ca-4165-b1a2-6fed4e01ccee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aae030f9-43ef-434b-944d-c43e7289797d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_7308391a-d3ca-4165-b1a2-6fed4e01ccee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes_9f04986d-2284-49ad-93fd-a9ea59dc1270" xlink:href="bhc-20211231.xsd#bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aae030f9-43ef-434b-944d-c43e7289797d" xlink:to="loc_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes_9f04986d-2284-49ad-93fd-a9ea59dc1270" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_70eabe17-c657-459f-9836-8050380f70bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aae030f9-43ef-434b-944d-c43e7289797d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_70eabe17-c657-459f-9836-8050380f70bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_f577e0f1-0f90-41a0-91e5-630944459874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9377f622-41b7-499a-8849-6c501a02ebb3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d321bd64-f4ac-4f12-82a1-741eab8befef" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9377f622-41b7-499a-8849-6c501a02ebb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_8c3dffd6-4174-4386-a468-c135be101ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9377f622-41b7-499a-8849-6c501a02ebb3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_8c3dffd6-4174-4386-a468-c135be101ff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8c3dffd6-4174-4386-a468-c135be101ff1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_8c3dffd6-4174-4386-a468-c135be101ff1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8c3dffd6-4174-4386-a468-c135be101ff1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_a03adbbe-d05b-4b22-ba80-f02c743e832e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_8c3dffd6-4174-4386-a468-c135be101ff1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_a03adbbe-d05b-4b22-ba80-f02c743e832e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_56e6fd2c-5a30-4b8c-98e4-51c73098650f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_a03adbbe-d05b-4b22-ba80-f02c743e832e" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_56e6fd2c-5a30-4b8c-98e4-51c73098650f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended" id="i9963f025fabf4c8d9781a48247459348_INCOMETAXESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:href="bhc-20211231.xsd#bhc_IncomeTaxLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_103143f7-362c-418e-8557-6aa34bb4facc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_103143f7-362c-418e-8557-6aa34bb4facc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccumulatedLossesAvailableForFederalPurposes_5de86326-fb79-4516-9b2f-281c97907ec4" xlink:href="bhc-20211231.xsd#bhc_AccumulatedLossesAvailableForFederalPurposes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_bhc_AccumulatedLossesAvailableForFederalPurposes_5de86326-fb79-4516-9b2f-281c97907ec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits_9398ab7c-6090-4db6-ad57-64df1049342b" xlink:href="bhc-20211231.xsd#bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits_9398ab7c-6090-4db6-ad57-64df1049342b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_d826c959-8add-481a-8eae-e86ac912cc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_d826c959-8add-481a-8eae-e86ac912cc0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_323c50fa-613c-4e14-84dc-1f847f7b8d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_323c50fa-613c-4e14-84dc-1f847f7b8d13" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_90371e24-7b04-496d-8869-aff6d4141c19" xlink:href="bhc-20211231.xsd#bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_90371e24-7b04-496d-8869-aff6d4141c19" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1d28fae4-dc31-4b4c-8512-dd93742f5858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1d28fae4-dc31-4b4c-8512-dd93742f5858" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions_955b065f-74b7-43ae-9f42-21984b3210d0" xlink:href="bhc-20211231.xsd#bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions_955b065f-74b7-43ae-9f42-21984b3210d0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions_738d012d-c778-4f58-9bf2-456f21b6170d" xlink:href="bhc-20211231.xsd#bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions_738d012d-c778-4f58-9bf2-456f21b6170d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions_067ff670-253d-46fa-ae48-ab02fda20e6d" xlink:href="bhc-20211231.xsd#bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions_067ff670-253d-46fa-ae48-ab02fda20e6d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_c8c4a030-947e-4bd4-9540-b3acdd971a42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_c8c4a030-947e-4bd4-9540-b3acdd971a42" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_8e8a5748-aa99-405e-a889-d038edb8d204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_8e8a5748-aa99-405e-a889-d038edb8d204" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns_035609b0-8529-4d03-bead-0a8aa6a0e8aa" xlink:href="bhc-20211231.xsd#bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns_035609b0-8529-4d03-bead-0a8aa6a0e8aa" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear_f2944911-ad79-4a97-bab9-435675d600da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear_f2944911-ad79-4a97-bab9-435675d600da" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_1162c5eb-97c1-4e5f-8b65-5b51428a7b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_1162c5eb-97c1-4e5f-8b65-5b51428a7b3b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_e2f6f5da-1b4d-43fa-a114-a111d4e2c5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_e2f6f5da-1b4d-43fa-a114-a111d4e2c5bf" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxTable_82a0957a-1211-442c-b43f-6fa5930e4e31" xlink:href="bhc-20211231.xsd#bhc_IncomeTaxTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_bhc_IncomeTaxTable_82a0957a-1211-442c-b43f-6fa5930e4e31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_83a55bb9-1a75-420e-9713-f1b3fcad018e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_IncomeTaxTable_82a0957a-1211-442c-b43f-6fa5930e4e31" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_83a55bb9-1a75-420e-9713-f1b3fcad018e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_83a55bb9-1a75-420e-9713-f1b3fcad018e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_83a55bb9-1a75-420e-9713-f1b3fcad018e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_83a55bb9-1a75-420e-9713-f1b3fcad018e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b655e1af-98f3-48c0-acc6-1885133f3485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_83a55bb9-1a75-420e-9713-f1b3fcad018e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b655e1af-98f3-48c0-acc6-1885133f3485" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ForeignCountryStateAndLocalMember_0894f45c-4d43-47f8-aa2a-4c4d3a7b3050" xlink:href="bhc-20211231.xsd#bhc_ForeignCountryStateAndLocalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b655e1af-98f3-48c0-acc6-1885133f3485" xlink:to="loc_bhc_ForeignCountryStateAndLocalMember_0894f45c-4d43-47f8-aa2a-4c4d3a7b3050" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_9ccc7edd-8f44-4808-bfba-4b14d5e8bde7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b655e1af-98f3-48c0-acc6-1885133f3485" xlink:to="loc_us-gaap_DomesticCountryMember_9ccc7edd-8f44-4808-bfba-4b14d5e8bde7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_820e35d3-a859-4e3d-8865-1b747538b29b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b655e1af-98f3-48c0-acc6-1885133f3485" xlink:to="loc_us-gaap_ForeignCountryMember_820e35d3-a859-4e3d-8865-1b747538b29b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_a66fc4c8-b708-4f59-a042-12b5190208e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_IncomeTaxTable_82a0957a-1211-442c-b43f-6fa5930e4e31" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_a66fc4c8-b708-4f59-a042-12b5190208e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_a66fc4c8-b708-4f59-a042-12b5190208e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_a66fc4c8-b708-4f59-a042-12b5190208e1" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_a66fc4c8-b708-4f59-a042-12b5190208e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_d5556636-1aa1-4bf5-b601-35bd9382fd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_a66fc4c8-b708-4f59-a042-12b5190208e1" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_d5556636-1aa1-4bf5-b601-35bd9382fd2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember_0c182b51-a239-457c-ba29-8839a3753ab3" xlink:href="bhc-20211231.xsd#bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_d5556636-1aa1-4bf5-b601-35bd9382fd2a" xlink:to="loc_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember_0c182b51-a239-457c-ba29-8839a3753ab3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_e85d33a3-d3ec-4d47-8ec9-8f23845353a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_IncomeTaxTable_82a0957a-1211-442c-b43f-6fa5930e4e31" xlink:to="loc_us-gaap_TaxPeriodAxis_e85d33a3-d3ec-4d47-8ec9-8f23845353a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_e85d33a3-d3ec-4d47-8ec9-8f23845353a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_e85d33a3-d3ec-4d47-8ec9-8f23845353a8" xlink:to="loc_us-gaap_TaxPeriodDomain_e85d33a3-d3ec-4d47-8ec9-8f23845353a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_3d23e356-bdc7-4b46-ba74-5aae331f416a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_e85d33a3-d3ec-4d47-8ec9-8f23845353a8" xlink:to="loc_us-gaap_TaxPeriodDomain_3d23e356-bdc7-4b46-ba74-5aae331f416a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2012Member_4c2097e5-bd11-4e3a-bf10-a09e6c87d31c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2012Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_3d23e356-bdc7-4b46-ba74-5aae331f416a" xlink:to="loc_us-gaap_TaxYear2012Member_4c2097e5-bd11-4e3a-bf10-a09e6c87d31c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2013Member_a6168c37-d921-4552-9b1c-60284e7f4fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_3d23e356-bdc7-4b46-ba74-5aae331f416a" xlink:to="loc_us-gaap_TaxYear2013Member_a6168c37-d921-4552-9b1c-60284e7f4fc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxYear2005ThroughTaxYear2009Member_803933c8-d20e-47f5-87f1-36ac6f1e900a" xlink:href="bhc-20211231.xsd#bhc_TaxYear2005ThroughTaxYear2009Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_3d23e356-bdc7-4b46-ba74-5aae331f416a" xlink:to="loc_bhc_TaxYear2005ThroughTaxYear2009Member_803933c8-d20e-47f5-87f1-36ac6f1e900a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxYear2015AndTaxYear2016Member_3676eb24-59d3-45c4-bcc9-84ab0d7a36a9" xlink:href="bhc-20211231.xsd#bhc_TaxYear2015AndTaxYear2016Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_3d23e356-bdc7-4b46-ba74-5aae331f416a" xlink:to="loc_bhc_TaxYear2015AndTaxYear2016Member_3676eb24-59d3-45c4-bcc9-84ab0d7a36a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_ef94a903-9bc3-44eb-b42a-28267f541ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_IncomeTaxTable_82a0957a-1211-442c-b43f-6fa5930e4e31" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_ef94a903-9bc3-44eb-b42a-28267f541ddb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_ef94a903-9bc3-44eb-b42a-28267f541ddb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_ef94a903-9bc3-44eb-b42a-28267f541ddb" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_ef94a903-9bc3-44eb-b42a-28267f541ddb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_950c18b2-f006-4f74-bd6a-edff0c481718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_ef94a903-9bc3-44eb-b42a-28267f541ddb" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_950c18b2-f006-4f74-bd6a-edff0c481718" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueCommissionersIrelandMember_a56191de-8c9c-44e0-9819-db2e3145eca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueCommissionersIrelandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_950c18b2-f006-4f74-bd6a-edff0c481718" xlink:to="loc_us-gaap_RevenueCommissionersIrelandMember_a56191de-8c9c-44e0-9819-db2e3145eca9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember_48d581c1-1e26-47de-a850-b4d3c878159a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CanadaRevenueAgencyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_950c18b2-f006-4f74-bd6a-edff0c481718" xlink:to="loc_us-gaap_CanadaRevenueAgencyMember_48d581c1-1e26-47de-a850-b4d3c878159a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember_9acbd42c-54d0-4e4f-b62f-78b6d64ab91a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_950c18b2-f006-4f74-bd6a-edff0c481718" xlink:to="loc_us-gaap_AustralianTaxationOfficeMember_9acbd42c-54d0-4e4f-b62f-78b6d64ab91a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails" xlink:type="extended" id="ie391c65f85da4429bd86281166c66691_INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_d0b059b3-2660-4df0-aae4-2132b3f17607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear_42f2d97a-b816-44bc-a4a6-2d452cad8323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d0b059b3-2660-4df0-aae4-2132b3f17607" xlink:to="loc_us-gaap_OpenTaxYear_42f2d97a-b816-44bc-a4a6-2d452cad8323" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_182b8261-287f-4e00-9b2f-2975bc954b26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d0b059b3-2660-4df0-aae4-2132b3f17607" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_182b8261-287f-4e00-9b2f-2975bc954b26" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_9b0ff303-d5af-4615-abfb-ddc3ec73a7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_182b8261-287f-4e00-9b2f-2975bc954b26" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_9b0ff303-d5af-4615-abfb-ddc3ec73a7bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9b0ff303-d5af-4615-abfb-ddc3ec73a7bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_9b0ff303-d5af-4615-abfb-ddc3ec73a7bb" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9b0ff303-d5af-4615-abfb-ddc3ec73a7bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3026dcd4-816e-4928-91c0-f35abfac2c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_9b0ff303-d5af-4615-abfb-ddc3ec73a7bb" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3026dcd4-816e-4928-91c0-f35abfac2c0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_bbda3a17-2ac2-4e44-aaf7-c12f7df40e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3026dcd4-816e-4928-91c0-f35abfac2c0e" xlink:to="loc_us-gaap_DomesticCountryMember_bbda3a17-2ac2-4e44-aaf7-c12f7df40e78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_c1f55dea-c59a-4edb-ac73-4e6cc224ee54" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3026dcd4-816e-4928-91c0-f35abfac2c0e" xlink:to="loc_country_CA_c1f55dea-c59a-4edb-ac73-4e6cc224ee54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_f6c1c136-ac2f-42c0-890e-396357205dc6" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3026dcd4-816e-4928-91c0-f35abfac2c0e" xlink:to="loc_country_DE_f6c1c136-ac2f-42c0-890e-396357205dc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_8bc1503a-bc3b-4c9f-98f2-d29f21cf44da" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3026dcd4-816e-4928-91c0-f35abfac2c0e" xlink:to="loc_country_FR_8bc1503a-bc3b-4c9f-98f2-d29f21cf44da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_b64d0d92-fe7b-4bea-9d19-f5cf45c3c02c" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3026dcd4-816e-4928-91c0-f35abfac2c0e" xlink:to="loc_country_CN_b64d0d92-fe7b-4bea-9d19-f5cf45c3c02c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_8ceb31f5-c596-4e6a-accf-e21a3cef0401" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3026dcd4-816e-4928-91c0-f35abfac2c0e" xlink:to="loc_country_IE_8ceb31f5-c596-4e6a-accf-e21a3cef0401" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_NL_c4455876-c3d2-4459-a855-38cad17b0044" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_NL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3026dcd4-816e-4928-91c0-f35abfac2c0e" xlink:to="loc_country_NL_c4455876-c3d2-4459-a855-38cad17b0044" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember_d63b6364-7795-4e50-a091-65454bb7be84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3026dcd4-816e-4928-91c0-f35abfac2c0e" xlink:to="loc_us-gaap_AustralianTaxationOfficeMember_d63b6364-7795-4e50-a091-65454bb7be84" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LuxembourgInlandRevenueMember_fed9fbdb-e1fe-4848-931a-72f5a942abbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LuxembourgInlandRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3026dcd4-816e-4928-91c0-f35abfac2c0e" xlink:to="loc_us-gaap_LuxembourgInlandRevenueMember_fed9fbdb-e1fe-4848-931a-72f5a942abbf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c328beb5-a0ef-4172-b75b-56f32bb6ca75" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_182b8261-287f-4e00-9b2f-2975bc954b26" xlink:to="loc_srt_RangeAxis_c328beb5-a0ef-4172-b75b-56f32bb6ca75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c328beb5-a0ef-4172-b75b-56f32bb6ca75_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c328beb5-a0ef-4172-b75b-56f32bb6ca75" xlink:to="loc_srt_RangeMember_c328beb5-a0ef-4172-b75b-56f32bb6ca75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4d6861c0-6cc5-4ed4-8da0-7704c7842332" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c328beb5-a0ef-4172-b75b-56f32bb6ca75" xlink:to="loc_srt_RangeMember_4d6861c0-6cc5-4ed4-8da0-7704c7842332" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f223d750-0eb1-4f20-a88a-3376d1c34494" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4d6861c0-6cc5-4ed4-8da0-7704c7842332" xlink:to="loc_srt_MinimumMember_f223d750-0eb1-4f20-a88a-3376d1c34494" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_982764b9-1dbb-4078-8677-664f1e15f547" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4d6861c0-6cc5-4ed4-8da0-7704c7842332" xlink:to="loc_srt_MaximumMember_982764b9-1dbb-4078-8677-664f1e15f547" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#LOSSPERSHARENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" xlink:type="extended" id="ibf749b72c137448aad3e52d8715a5554_LOSSPERSHARENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fdddeddc-6f10-4937-9216-f9ecd606155d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d2b11c96-a07f-4131-b27b-786eefc70ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fdddeddc-6f10-4937-9216-f9ecd606155d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d2b11c96-a07f-4131-b27b-786eefc70ddf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_73b5befc-5e75-4d46-89ca-81d0fbea46f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fdddeddc-6f10-4937-9216-f9ecd606155d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_73b5befc-5e75-4d46-89ca-81d0fbea46f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b3056766-f539-496d-b560-eadf05d3bb96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_73b5befc-5e75-4d46-89ca-81d0fbea46f0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b3056766-f539-496d-b560-eadf05d3bb96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b3056766-f539-496d-b560-eadf05d3bb96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b3056766-f539-496d-b560-eadf05d3bb96" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b3056766-f539-496d-b560-eadf05d3bb96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2008336a-82e0-42ed-88bb-074c6573ff97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b3056766-f539-496d-b560-eadf05d3bb96" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2008336a-82e0-42ed-88bb-074c6573ff97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_691d9bdc-42e9-447b-88d4-db6e95035e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2008336a-82e0-42ed-88bb-074c6573ff97" xlink:to="loc_us-gaap_StockCompensationPlanMember_691d9bdc-42e9-447b-88d4-db6e95035e41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_eff701f3-c614-458d-9d61-abe5848caf36" xlink:href="bhc-20211231.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2008336a-82e0-42ed-88bb-074c6573ff97" xlink:to="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_eff701f3-c614-458d-9d61-abe5848caf36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_39b0b405-ff26-44a9-9764-a725d2b2543b" xlink:href="bhc-20211231.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_eff701f3-c614-458d-9d61-abe5848caf36" xlink:to="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_39b0b405-ff26-44a9-9764-a725d2b2543b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#LEGALPROCEEDINGSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" xlink:type="extended" id="i8bcc8790b7d34dd783860ada024b55fc_LEGALPROCEEDINGSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees_4ab50af3-1df0-4f6c-8607-23d3682b23a7" xlink:href="bhc-20211231.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_bhc_Legalsettlementsandrelatedfees_4ab50af3-1df0-4f6c-8607-23d3682b23a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_c8df5a39-723f-4c0a-af4d-41ded118cc50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_c8df5a39-723f-4c0a-af4d-41ded118cc50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_f67a0da2-d957-49d2-819b-331b67a8aedb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_f67a0da2-d957-49d2-819b-331b67a8aedb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_5c92b26c-7c42-4b21-87bf-e6e3865e8f42" xlink:href="bhc-20211231.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_5c92b26c-7c42-4b21-87bf-e6e3865e8f42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_5c43602b-1116-47ed-b0c7-e7392a1c1cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_5c43602b-1116-47ed-b0c7-e7392a1c1cf1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_e9ac6f02-e7a7-4de3-b5a4-80291574f7ea" xlink:href="bhc-20211231.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_e9ac6f02-e7a7-4de3-b5a4-80291574f7ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_5fd8bc23-c13c-4280-b2fc-ff9cbe3459f5" xlink:href="bhc-20211231.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_5fd8bc23-c13c-4280-b2fc-ff9cbe3459f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_c7c79a9f-a889-4df6-86fc-659b3b51caa5" xlink:href="bhc-20211231.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_c7c79a9f-a889-4df6-86fc-659b3b51caa5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_4f30ed16-205f-4ae3-973a-19918515f6fd" xlink:href="bhc-20211231.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_4f30ed16-205f-4ae3-973a-19918515f6fd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_18f4fa0a-bf55-4710-bbe0-23d2a9c0368c" xlink:href="bhc-20211231.xsd#bhc_LossContingencySettlementAgreementsNumberOfInsurers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_18f4fa0a-bf55-4710-bbe0-23d2a9c0368c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_0e40fe4a-f0c8-4150-8363-5c8693a2033a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_0e40fe4a-f0c8-4150-8363-5c8693a2033a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod_d390992c-0e23-4810-930b-0e4639a301a0" xlink:href="bhc-20211231.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_bhc_LossContingencyStayOfApprovalPeriod_d390992c-0e23-4810-930b-0e4639a301a0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_4dd72ffd-ceb7-4acf-ada9-519712207120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_4dd72ffd-ceb7-4acf-ada9-519712207120" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_250e3686-e443-46f6-a5ab-aab81500f24f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_250e3686-e443-46f6-a5ab-aab81500f24f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits_f5dbdbfb-10ee-428d-8e68-8cf066c28999" xlink:href="bhc-20211231.xsd#bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits_f5dbdbfb-10ee-428d-8e68-8cf066c28999" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_f7835375-a244-4611-8edd-141a154680c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_us-gaap_LossContingenciesTable_f7835375-a244-4611-8edd-141a154680c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_4f817a5f-5f2b-4f99-9383-d160f8badfc8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f7835375-a244-4611-8edd-141a154680c2" xlink:to="loc_srt_LitigationCaseAxis_4f817a5f-5f2b-4f99-9383-d160f8badfc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4f817a5f-5f2b-4f99-9383-d160f8badfc8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_4f817a5f-5f2b-4f99-9383-d160f8badfc8" xlink:to="loc_srt_LitigationCaseTypeDomain_4f817a5f-5f2b-4f99-9383-d160f8badfc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_4f817a5f-5f2b-4f99-9383-d160f8badfc8" xlink:to="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_b2ad9923-b9c9-44d3-a4e5-b19c9c0302e4" xlink:href="bhc-20211231.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_b2ad9923-b9c9-44d3-a4e5-b19c9c0302e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianSecuritiesLitigationMember_9beedea1-6ec2-4ad3-af28-c2c0a2377d52" xlink:href="bhc-20211231.xsd#bhc_CanadianSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_CanadianSecuritiesLitigationMember_9beedea1-6ec2-4ad3-af28-c2c0a2377d52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsLitigationMember_e05a917d-7eb6-4ac0-8728-20ecabd9f34e" xlink:href="bhc-20211231.xsd#bhc_RICOClassActionsLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_RICOClassActionsLitigationMember_e05a917d-7eb6-4ac0-8728-20ecabd9f34e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember_ca2def89-8882-43cf-b066-3b16814aa323" xlink:href="bhc-20211231.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_InsuranceCoverageLawsuitMember_ca2def89-8882-43cf-b066-3b16814aa323" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SandozLitigationMember_f7d9b3f8-fe29-42e7-9770-47e6ea61ffee" xlink:href="bhc-20211231.xsd#bhc_SandozLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_SandozLitigationMember_f7d9b3f8-fe29-42e7-9770-47e6ea61ffee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerrigoIsraelPharmaceuticalsLitigationMember_6060de98-2f65-4197-8e16-8e1fe2ae0799" xlink:href="bhc-20211231.xsd#bhc_PerrigoIsraelPharmaceuticalsLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_PerrigoIsraelPharmaceuticalsLitigationMember_6060de98-2f65-4197-8e16-8e1fe2ae0799" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PadagisLitigationMember_cffad526-f0b4-495b-9cd0-0f2818341d86" xlink:href="bhc-20211231.xsd#bhc_PadagisLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_PadagisLitigationMember_cffad526-f0b4-495b-9cd0-0f2818341d86" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_faa9a7ef-f8e8-4d3f-899a-362bd1e099ce" xlink:href="bhc-20211231.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_faa9a7ef-f8e8-4d3f-899a-362bd1e099ce" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember_6292709f-12ac-41aa-a0b5-84a656030f5a" xlink:href="bhc-20211231.xsd#bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember_6292709f-12ac-41aa-a0b5-84a656030f5a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LupinPharmaceuticalsIncLitigationMember_ee7a630d-65f6-4a01-b791-cb43269f1013" xlink:href="bhc-20211231.xsd#bhc_LupinPharmaceuticalsIncLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_LupinPharmaceuticalsIncLitigationMember_ee7a630d-65f6-4a01-b791-cb43269f1013" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowertoShowerProductLiabilityLitigationMember_6c0a811a-848f-4da2-a5b4-547dfac328d2" xlink:href="bhc-20211231.xsd#bhc_ShowertoShowerProductLiabilityLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_ShowertoShowerProductLiabilityLitigationMember_6c0a811a-848f-4da2-a5b4-547dfac328d2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_26ddbef0-6876-4152-89ed-9dca4835f8ac" xlink:href="bhc-20211231.xsd#bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShowertoShowerProductLiabilityLitigationMember_6c0a811a-848f-4da2-a5b4-547dfac328d2" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_26ddbef0-6876-4152-89ed-9dca4835f8ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_0c6ade87-b960-41de-bd57-e617e8b7a9eb" xlink:href="bhc-20211231.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_0c6ade87-b960-41de-bd57-e617e8b7a9eb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember_ba04b057-6e81-4fd6-9e59-684562d8127b" xlink:href="bhc-20211231.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_LitigationwithFormerSalixCEOMember_ba04b057-6e81-4fd6-9e59-684562d8127b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember_f3a1a5ea-5ea8-42c8-8bb7-1c3bdbab76a7" xlink:href="bhc-20211231.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_GlumetzaAntitrustLitigationMember_f3a1a5ea-5ea8-42c8-8bb7-1c3bdbab76a7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_93f9f15e-636e-4d84-b50e-72ea2b6bf3fb" xlink:href="bhc-20211231.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_GlumetzaAntitrustLitigationMember_f3a1a5ea-5ea8-42c8-8bb7-1c3bdbab76a7" xlink:to="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_93f9f15e-636e-4d84-b50e-72ea2b6bf3fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ApotexIncLitigationMember_a604d3f6-24c5-4bc2-ac89-2eaee4b523ba" xlink:href="bhc-20211231.xsd#bhc_ApotexIncLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_ApotexIncLitigationMember_a604d3f6-24c5-4bc2-ac89-2eaee4b523ba" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeLawsuitsMember_195cf332-4751-470c-91b0-c59a0892f6bc" xlink:href="bhc-20211231.xsd#bhc_DerivativeLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_DerivativeLawsuitsMember_195cf332-4751-470c-91b0-c59a0892f6bc" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ba7bbebb-ce5d-45cf-bf1c-66e7a1d09b8b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f7835375-a244-4611-8edd-141a154680c2" xlink:to="loc_srt_StatementGeographicalAxis_ba7bbebb-ce5d-45cf-bf1c-66e7a1d09b8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ba7bbebb-ce5d-45cf-bf1c-66e7a1d09b8b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ba7bbebb-ce5d-45cf-bf1c-66e7a1d09b8b" xlink:to="loc_srt_SegmentGeographicalDomain_ba7bbebb-ce5d-45cf-bf1c-66e7a1d09b8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_efdced6a-88cd-4abf-a7bd-59a8b14c2839" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ba7bbebb-ce5d-45cf-bf1c-66e7a1d09b8b" xlink:to="loc_srt_SegmentGeographicalDomain_efdced6a-88cd-4abf-a7bd-59a8b14c2839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_67e4259b-b7fc-41a9-94f1-e9d47f26e13f" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_efdced6a-88cd-4abf-a7bd-59a8b14c2839" xlink:to="loc_stpr_NJ_67e4259b-b7fc-41a9-94f1-e9d47f26e13f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_b7c8dc8c-3010-452e-bb68-c8b72ff31ad0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_efdced6a-88cd-4abf-a7bd-59a8b14c2839" xlink:to="loc_country_CA_b7c8dc8c-3010-452e-bb68-c8b72ff31ad0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC_88f22090-d487-420a-b460-13a069b72fa6" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA-BC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_country_CA_b7c8dc8c-3010-452e-bb68-c8b72ff31ad0" xlink:to="loc_stpr_CA-BC_88f22090-d487-420a-b460-13a069b72fa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-QC_379b0a19-c2ef-48a2-85fb-7c7818ed0b4d" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA-QC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_country_CA_b7c8dc8c-3010-452e-bb68-c8b72ff31ad0" xlink:to="loc_stpr_CA-QC_379b0a19-c2ef-48a2-85fb-7c7818ed0b4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ed31af7e-1ea8-4f65-9a8d-72897f56d379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f7835375-a244-4611-8edd-141a154680c2" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ed31af7e-1ea8-4f65-9a8d-72897f56d379" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_ed31af7e-1ea8-4f65-9a8d-72897f56d379_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ed31af7e-1ea8-4f65-9a8d-72897f56d379" xlink:to="loc_us-gaap_LossContingencyNatureDomain_ed31af7e-1ea8-4f65-9a8d-72897f56d379_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_116d1b41-1cba-4fb6-a2b3-834ef4fa3bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ed31af7e-1ea8-4f65-9a8d-72897f56d379" xlink:to="loc_us-gaap_LossContingencyNatureDomain_116d1b41-1cba-4fb6-a2b3-834ef4fa3bd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_6cdf65de-6651-4466-ac5b-f6d467a128d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_116d1b41-1cba-4fb6-a2b3-834ef4fa3bd6" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_6cdf65de-6651-4466-ac5b-f6d467a128d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_626bcd53-11a0-4437-829a-b22dc5232d69" xlink:href="bhc-20211231.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_116d1b41-1cba-4fb6-a2b3-834ef4fa3bd6" xlink:to="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_626bcd53-11a0-4437-829a-b22dc5232d69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_caafe080-2e34-40a5-a17d-cee490cb9227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f7835375-a244-4611-8edd-141a154680c2" xlink:to="loc_us-gaap_LitigationStatusAxis_caafe080-2e34-40a5-a17d-cee490cb9227" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_caafe080-2e34-40a5-a17d-cee490cb9227_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_caafe080-2e34-40a5-a17d-cee490cb9227" xlink:to="loc_us-gaap_LitigationStatusDomain_caafe080-2e34-40a5-a17d-cee490cb9227_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_dd4acfa5-5917-4167-abde-928335fc7b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_caafe080-2e34-40a5-a17d-cee490cb9227" xlink:to="loc_us-gaap_LitigationStatusDomain_dd4acfa5-5917-4167-abde-928335fc7b49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_e8361a6f-5872-4fa0-93f4-8c1759aacbb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_dd4acfa5-5917-4167-abde-928335fc7b49" xlink:to="loc_us-gaap_PendingLitigationMember_e8361a6f-5872-4fa0-93f4-8c1759aacbb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_8ab93618-dda7-4a0a-8c2b-94b19819ae00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_dd4acfa5-5917-4167-abde-928335fc7b49" xlink:to="loc_us-gaap_SettledLitigationMember_8ab93618-dda7-4a0a-8c2b-94b19819ae00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1686111e-adaa-46c0-9285-b1e22a9608e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f7835375-a244-4611-8edd-141a154680c2" xlink:to="loc_srt_CounterpartyNameAxis_1686111e-adaa-46c0-9285-b1e22a9608e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1686111e-adaa-46c0-9285-b1e22a9608e9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1686111e-adaa-46c0-9285-b1e22a9608e9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1686111e-adaa-46c0-9285-b1e22a9608e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dfbbaf2c-6dac-4831-a4bc-168f1b300ec3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1686111e-adaa-46c0-9285-b1e22a9608e9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dfbbaf2c-6dac-4831-a4bc-168f1b300ec3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember_7b14467f-3f86-452f-a12e-68ba9945cfe8" xlink:href="bhc-20211231.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dfbbaf2c-6dac-4831-a4bc-168f1b300ec3" xlink:to="loc_bhc_PlaintiffsDirectPurchasersMember_7b14467f-3f86-452f-a12e-68ba9945cfe8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_83a4f4d4-115b-477c-8f73-da40b290beb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f7835375-a244-4611-8edd-141a154680c2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_83a4f4d4-115b-477c-8f73-da40b290beb9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_83a4f4d4-115b-477c-8f73-da40b290beb9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_83a4f4d4-115b-477c-8f73-da40b290beb9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_83a4f4d4-115b-477c-8f73-da40b290beb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_254bdb6a-c8ac-4efa-abdd-021101d9a162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_83a4f4d4-115b-477c-8f73-da40b290beb9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_254bdb6a-c8ac-4efa-abdd-021101d9a162" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e6d385e9-d35d-4909-b49b-44e10d639b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_254bdb6a-c8ac-4efa-abdd-021101d9a162" xlink:to="loc_us-gaap_SubsequentEventMember_e6d385e9-d35d-4909-b49b-44e10d639b86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a9b59fc7-7c76-4d48-aa1a-468cb73fbc96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f7835375-a244-4611-8edd-141a154680c2" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a9b59fc7-7c76-4d48-aa1a-468cb73fbc96" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a9b59fc7-7c76-4d48-aa1a-468cb73fbc96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a9b59fc7-7c76-4d48-aa1a-468cb73fbc96" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a9b59fc7-7c76-4d48-aa1a-468cb73fbc96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7803e379-c9cc-492f-8ca6-3460cc59bf5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a9b59fc7-7c76-4d48-aa1a-468cb73fbc96" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7803e379-c9cc-492f-8ca6-3460cc59bf5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_bf04f064-e550-4103-bee5-3dd2f907dde8" xlink:href="bhc-20211231.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7803e379-c9cc-492f-8ca6-3460cc59bf5b" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_bf04f064-e550-4103-bee5-3dd2f907dde8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended" id="i16e5d8caf2774a209b647e2f74f5608d_COMMITMENTSANDCONTINGENCIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfCommitmentsLineItems_a433646b-8f59-4afb-85b9-e75e9bb35e39" xlink:href="bhc-20211231.xsd#bhc_ScheduleOfCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_7b65f2bd-f0f5-45f8-b9f2-401496ee7fac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ScheduleOfCommitmentsLineItems_a433646b-8f59-4afb-85b9-e75e9bb35e39" xlink:to="loc_us-gaap_ContractualObligation_7b65f2bd-f0f5-45f8-b9f2-401496ee7fac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CollaborativeAgreementMilestonePaymentsAggregate_1e44c16e-a301-4ad6-bbc7-30cc8c3f2c18" xlink:href="bhc-20211231.xsd#bhc_CollaborativeAgreementMilestonePaymentsAggregate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ScheduleOfCommitmentsLineItems_a433646b-8f59-4afb-85b9-e75e9bb35e39" xlink:to="loc_bhc_CollaborativeAgreementMilestonePaymentsAggregate_1e44c16e-a301-4ad6-bbc7-30cc8c3f2c18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfCommitmentsTable_ebe293cc-7e68-4eeb-bf6d-a04d64f835ae" xlink:href="bhc-20211231.xsd#bhc_ScheduleOfCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bhc_ScheduleOfCommitmentsLineItems_a433646b-8f59-4afb-85b9-e75e9bb35e39" xlink:to="loc_bhc_ScheduleOfCommitmentsTable_ebe293cc-7e68-4eeb-bf6d-a04d64f835ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c8e69659-72d8-454f-88f0-4c2712600b00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfCommitmentsTable_ebe293cc-7e68-4eeb-bf6d-a04d64f835ae" xlink:to="loc_srt_CounterpartyNameAxis_c8e69659-72d8-454f-88f0-4c2712600b00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c8e69659-72d8-454f-88f0-4c2712600b00_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c8e69659-72d8-454f-88f0-4c2712600b00" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c8e69659-72d8-454f-88f0-4c2712600b00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19cc178f-5df9-45e5-bac1-0d691b3f7618" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c8e69659-72d8-454f-88f0-4c2712600b00" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19cc178f-5df9-45e5-bac1-0d691b3f7618" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member_015cd5fe-7bcd-48dd-9836-a614798739e5" xlink:href="bhc-20211231.xsd#bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19cc178f-5df9-45e5-bac1-0d691b3f7618" xlink:to="loc_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member_015cd5fe-7bcd-48dd-9836-a614798739e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MitsubishiTanabePharmaCorporationMember_e6e1a96d-b616-4085-adde-d5a40e6e7c43" xlink:href="bhc-20211231.xsd#bhc_MitsubishiTanabePharmaCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19cc178f-5df9-45e5-bac1-0d691b3f7618" xlink:to="loc_bhc_MitsubishiTanabePharmaCorporationMember_e6e1a96d-b616-4085-adde-d5a40e6e7c43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NovaliqGmbHMember_e66ed164-fe42-4a8f-9368-bff7fbb2603a" xlink:href="bhc-20211231.xsd#bhc_NovaliqGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19cc178f-5df9-45e5-bac1-0d691b3f7618" xlink:to="loc_bhc_NovaliqGmbHMember_e66ed164-fe42-4a8f-9368-bff7fbb2603a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CedarsSinaiMedicalCenterMember_a9097e1d-7235-4b9c-b6c0-85027f0ce28f" xlink:href="bhc-20211231.xsd#bhc_CedarsSinaiMedicalCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19cc178f-5df9-45e5-bac1-0d691b3f7618" xlink:to="loc_bhc_CedarsSinaiMedicalCenterMember_a9097e1d-7235-4b9c-b6c0-85027f0ce28f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EyenoviaIncMember_118ac604-55f4-419a-994f-f00c898c0350" xlink:href="bhc-20211231.xsd#bhc_EyenoviaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19cc178f-5df9-45e5-bac1-0d691b3f7618" xlink:to="loc_bhc_EyenoviaIncMember_118ac604-55f4-419a-994f-f00c898c0350" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended" id="ib76bd354ce9e4a6a9d812d28441fdfc2_SEGMENTINFORMATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_9931bb6c-8e32-4512-957d-05fccb2f9fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_3ae45abb-e958-4454-a840-b2177ab84c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9931bb6c-8e32-4512-957d-05fccb2f9fb4" xlink:to="loc_us-gaap_NumberOfReportingUnits_3ae45abb-e958-4454-a840-b2177ab84c96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7576e8d8-9a1e-4450-a423-d522e86c158e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9931bb6c-8e32-4512-957d-05fccb2f9fb4" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7576e8d8-9a1e-4450-a423-d522e86c158e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3f6dbee9-bc0c-427f-8f67-54d5d887fb16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7576e8d8-9a1e-4450-a423-d522e86c158e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3f6dbee9-bc0c-427f-8f67-54d5d887fb16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3f6dbee9-bc0c-427f-8f67-54d5d887fb16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3f6dbee9-bc0c-427f-8f67-54d5d887fb16" xlink:to="loc_us-gaap_SegmentDomain_3f6dbee9-bc0c-427f-8f67-54d5d887fb16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_246eb1eb-e359-432e-b78a-7d1775fe4415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3f6dbee9-bc0c-427f-8f67-54d5d887fb16" xlink:to="loc_us-gaap_SegmentDomain_246eb1eb-e359-432e-b78a-7d1775fe4415" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_929b10fb-bd7c-4595-97e6-5d3a5d220d72" xlink:href="bhc-20211231.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_246eb1eb-e359-432e-b78a-7d1775fe4415" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_929b10fb-bd7c-4595-97e6-5d3a5d220d72" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" xlink:type="extended" id="i52cd43b047ce4f31871e757f681d8051_SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_46730e14-f62d-4367-97c9-3a6f52e4e147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_46730e14-f62d-4367-97c9-3a6f52e4e147" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_844f6927-cffc-4a00-95c9-2f0a20450c52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_us-gaap_OperatingIncomeLoss_844f6927-cffc-4a00-95c9-2f0a20450c52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_04ea0d93-e692-49c9-87a5-0b3333a03f7f" xlink:href="bhc-20211231.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_04ea0d93-e692-49c9-87a5-0b3333a03f7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_a0acaa7c-a502-44a7-a554-178eee49a9d4" xlink:href="bhc-20211231.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_a0acaa7c-a502-44a7-a554-178eee49a9d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_9dce739c-187f-4574-8f0c-2a7934ce6d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_us-gaap_AssetImpairmentCharges_9dce739c-187f-4574-8f0c-2a7934ce6d48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_606f8810-b860-4cd3-902e-bd3a4dfdb6c6" xlink:href="bhc-20211231.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_606f8810-b860-4cd3-902e-bd3a4dfdb6c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_42255b69-0995-4d0f-a58e-6e6192cf24f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_42255b69-0995-4d0f-a58e-6e6192cf24f6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_cf5c8444-cbbb-4e07-bcaf-9c0eaeeaf2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_us-gaap_InvestmentIncomeInterest_cf5c8444-cbbb-4e07-bcaf-9c0eaeeaf2d4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense_65cd7fb9-395c-4350-ae54-725b13f812e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_us-gaap_InterestAndDebtExpense_65cd7fb9-395c-4350-ae54-725b13f812e6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fb662220-df25-4cb9-81f2-bc6cef4653e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fb662220-df25-4cb9-81f2-bc6cef4653e2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b3d6de1d-e158-4cbc-a19d-2e0a0857810b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b3d6de1d-e158-4cbc-a19d-2e0a0857810b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e1adcc3d-f68a-485f-b29e-6ab990703c33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e1adcc3d-f68a-485f-b29e-6ab990703c33" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_8c5cd505-6060-4ff4-aef7-ddc7e1468c6b" xlink:href="bhc-20211231.xsd#bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_8c5cd505-6060-4ff4-aef7-ddc7e1468c6b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_4e52c549-75fe-4837-a072-9e4ef9f9fd96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_8c5cd505-6060-4ff4-aef7-ddc7e1468c6b" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_4e52c549-75fe-4837-a072-9e4ef9f9fd96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e1a00077-551d-4d76-8f95-1a17ad148fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e1a00077-551d-4d76-8f95-1a17ad148fa1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_1f67f9dc-a9da-4a1f-ad71-7d80a40e9073" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e1a00077-551d-4d76-8f95-1a17ad148fa1" xlink:to="loc_srt_ConsolidationItemsAxis_1f67f9dc-a9da-4a1f-ad71-7d80a40e9073" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_1f67f9dc-a9da-4a1f-ad71-7d80a40e9073_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_1f67f9dc-a9da-4a1f-ad71-7d80a40e9073" xlink:to="loc_srt_ConsolidationItemsDomain_1f67f9dc-a9da-4a1f-ad71-7d80a40e9073_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_1dc7a88d-e840-4323-9ff4-bd0177d1dea1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_1f67f9dc-a9da-4a1f-ad71-7d80a40e9073" xlink:to="loc_srt_ConsolidationItemsDomain_1dc7a88d-e840-4323-9ff4-bd0177d1dea1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_667cbdb1-cec1-4750-a1aa-9b1e201f9e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_1dc7a88d-e840-4323-9ff4-bd0177d1dea1" xlink:to="loc_us-gaap_OperatingSegmentsMember_667cbdb1-cec1-4750-a1aa-9b1e201f9e24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_cea2f4ee-17a1-4557-b358-20121ae1207a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_1dc7a88d-e840-4323-9ff4-bd0177d1dea1" xlink:to="loc_us-gaap_CorporateNonSegmentMember_cea2f4ee-17a1-4557-b358-20121ae1207a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_cdccc784-a14e-46b2-b7d9-1e5e75311561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e1a00077-551d-4d76-8f95-1a17ad148fa1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_cdccc784-a14e-46b2-b7d9-1e5e75311561" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cdccc784-a14e-46b2-b7d9-1e5e75311561_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cdccc784-a14e-46b2-b7d9-1e5e75311561" xlink:to="loc_us-gaap_SegmentDomain_cdccc784-a14e-46b2-b7d9-1e5e75311561_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fbf55f20-5e3b-484e-b386-95eb6f19313f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cdccc784-a14e-46b2-b7d9-1e5e75311561" xlink:to="loc_us-gaap_SegmentDomain_fbf55f20-5e3b-484e-b386-95eb6f19313f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_7d4fe7f4-6d89-446a-bd62-14528ecc10cc" xlink:href="bhc-20211231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_fbf55f20-5e3b-484e-b386-95eb6f19313f" xlink:to="loc_bhc_BauschLombMember_7d4fe7f4-6d89-446a-bd62-14528ecc10cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_00393496-bfd8-4272-bf3c-038a93728ae7" xlink:href="bhc-20211231.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_fbf55f20-5e3b-484e-b386-95eb6f19313f" xlink:to="loc_bhc_SalixSegmentMember_00393496-bfd8-4272-bf3c-038a93728ae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_72d1bf30-22ec-4252-81ff-6456596d24a7" xlink:href="bhc-20211231.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_fbf55f20-5e3b-484e-b386-95eb6f19313f" xlink:to="loc_bhc_InternationalRxMember_72d1bf30-22ec-4252-81ff-6456596d24a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_636068d8-7a71-4401-bbaa-dd7618f42ec5" xlink:href="bhc-20211231.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_fbf55f20-5e3b-484e-b386-95eb6f19313f" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_636068d8-7a71-4401-bbaa-dd7618f42ec5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_7a913ca8-645a-4340-99a3-d0d60a63f877" xlink:href="bhc-20211231.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_fbf55f20-5e3b-484e-b386-95eb6f19313f" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_7a913ca8-645a-4340-99a3-d0d60a63f877" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" xlink:type="extended" id="i989a8b46fe6f4f858b21193a02b289be_SEGMENTINFORMATIONRevenuesbyProductCategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_02a89acb-cc48-4af4-b40b-caf4c7537961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts_57fc88d5-d26f-4314-a504-4fe7100aba26" xlink:href="bhc-20211231.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_02a89acb-cc48-4af4-b40b-caf4c7537961" xlink:to="loc_bhc_ConcentrationRiskNumberOfProducts_57fc88d5-d26f-4314-a504-4fe7100aba26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c15634d3-0aca-4bb0-80ac-6b3f65dddcea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_02a89acb-cc48-4af4-b40b-caf4c7537961" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c15634d3-0aca-4bb0-80ac-6b3f65dddcea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3e4eb4d8-dbf3-44b8-8a67-025a8a84a4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_02a89acb-cc48-4af4-b40b-caf4c7537961" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3e4eb4d8-dbf3-44b8-8a67-025a8a84a4e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8ec5d3c8-0f34-456e-ae9d-4a6c9f5baf08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_02a89acb-cc48-4af4-b40b-caf4c7537961" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8ec5d3c8-0f34-456e-ae9d-4a6c9f5baf08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_835f8303-5747-47ce-9c51-4c5c93659f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8ec5d3c8-0f34-456e-ae9d-4a6c9f5baf08" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_835f8303-5747-47ce-9c51-4c5c93659f7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_835f8303-5747-47ce-9c51-4c5c93659f7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_835f8303-5747-47ce-9c51-4c5c93659f7d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_835f8303-5747-47ce-9c51-4c5c93659f7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_16475f8e-465e-47ba-b285-bbab1f5dfc41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_835f8303-5747-47ce-9c51-4c5c93659f7d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_16475f8e-465e-47ba-b285-bbab1f5dfc41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_a27179b7-c664-45cb-8529-2e996fb25a91" xlink:href="bhc-20211231.xsd#bhc_RevenuesNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_16475f8e-465e-47ba-b285-bbab1f5dfc41" xlink:to="loc_bhc_RevenuesNetMember_a27179b7-c664-45cb-8529-2e996fb25a91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c3eac151-ff0a-484f-89bb-e8498a19b864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8ec5d3c8-0f34-456e-ae9d-4a6c9f5baf08" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c3eac151-ff0a-484f-89bb-e8498a19b864" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c3eac151-ff0a-484f-89bb-e8498a19b864_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c3eac151-ff0a-484f-89bb-e8498a19b864" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c3eac151-ff0a-484f-89bb-e8498a19b864_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_04291016-a062-46cf-8731-b4b14ad65e84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c3eac151-ff0a-484f-89bb-e8498a19b864" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_04291016-a062-46cf-8731-b4b14ad65e84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_55f2d5a6-1aac-46e1-adab-43bbc10bd9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_04291016-a062-46cf-8731-b4b14ad65e84" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_55f2d5a6-1aac-46e1-adab-43bbc10bd9f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2d39c864-3603-46f8-8ae3-34ed4836d886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8ec5d3c8-0f34-456e-ae9d-4a6c9f5baf08" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2d39c864-3603-46f8-8ae3-34ed4836d886" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2d39c864-3603-46f8-8ae3-34ed4836d886_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2d39c864-3603-46f8-8ae3-34ed4836d886" xlink:to="loc_us-gaap_SegmentDomain_2d39c864-3603-46f8-8ae3-34ed4836d886_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e50406bf-d683-4675-a37c-2aab8f92436d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2d39c864-3603-46f8-8ae3-34ed4836d886" xlink:to="loc_us-gaap_SegmentDomain_e50406bf-d683-4675-a37c-2aab8f92436d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_fe6c933f-dcaf-4ae0-9808-1529e8c4145e" xlink:href="bhc-20211231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e50406bf-d683-4675-a37c-2aab8f92436d" xlink:to="loc_bhc_BauschLombMember_fe6c933f-dcaf-4ae0-9808-1529e8c4145e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_7bfcb3f8-6761-41ed-b31e-b38e3b6149d2" xlink:href="bhc-20211231.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e50406bf-d683-4675-a37c-2aab8f92436d" xlink:to="loc_bhc_SalixSegmentMember_7bfcb3f8-6761-41ed-b31e-b38e3b6149d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_bd5c3447-80ca-428c-a554-2a6014ce0b9f" xlink:href="bhc-20211231.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e50406bf-d683-4675-a37c-2aab8f92436d" xlink:to="loc_bhc_InternationalRxMember_bd5c3447-80ca-428c-a554-2a6014ce0b9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_37cfdd27-ff0a-438e-8144-bcdaf758ec7c" xlink:href="bhc-20211231.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e50406bf-d683-4675-a37c-2aab8f92436d" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_37cfdd27-ff0a-438e-8144-bcdaf758ec7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_38a927fc-19eb-486f-a460-71f347feaae1" xlink:href="bhc-20211231.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e50406bf-d683-4675-a37c-2aab8f92436d" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_38a927fc-19eb-486f-a460-71f347feaae1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_00aba816-ac98-4938-b404-da807211a9c5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8ec5d3c8-0f34-456e-ae9d-4a6c9f5baf08" xlink:to="loc_srt_ProductOrServiceAxis_00aba816-ac98-4938-b404-da807211a9c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_00aba816-ac98-4938-b404-da807211a9c5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_00aba816-ac98-4938-b404-da807211a9c5" xlink:to="loc_srt_ProductsAndServicesDomain_00aba816-ac98-4938-b404-da807211a9c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_26380b38-80f0-485e-8119-973a557c5bbb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_00aba816-ac98-4938-b404-da807211a9c5" xlink:to="loc_srt_ProductsAndServicesDomain_26380b38-80f0-485e-8119-973a557c5bbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember_fd942322-eb04-4a64-bd55-181b69542130" xlink:href="bhc-20211231.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_26380b38-80f0-485e-8119-973a557c5bbb" xlink:to="loc_bhc_PharmaceuticalProductsMember_fd942322-eb04-4a64-bd55-181b69542130" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember_787187ed-377d-4d82-bf7b-1a3361052353" xlink:href="bhc-20211231.xsd#bhc_DeviceProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_26380b38-80f0-485e-8119-973a557c5bbb" xlink:to="loc_bhc_DeviceProductsMember_787187ed-377d-4d82-bf7b-1a3361052353" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember_0d73129c-6186-4722-b2c2-97ea9a60169c" xlink:href="bhc-20211231.xsd#bhc_OvertheCounterProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_26380b38-80f0-485e-8119-973a557c5bbb" xlink:to="loc_bhc_OvertheCounterProductsMember_0d73129c-6186-4722-b2c2-97ea9a60169c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember_4d0bf36b-596b-4c62-9b03-3602345fe8be" xlink:href="bhc-20211231.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_26380b38-80f0-485e-8119-973a557c5bbb" xlink:to="loc_bhc_BrandedandOtherGenericProductsMember_4d0bf36b-596b-4c62-9b03-3602345fe8be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember_54b53886-c1ed-4853-85ed-49de1e060a7e" xlink:href="bhc-20211231.xsd#bhc_OtherRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_26380b38-80f0-485e-8119-973a557c5bbb" xlink:to="loc_bhc_OtherRevenuesMember_54b53886-c1ed-4853-85ed-49de1e060a7e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_cd7cb0a4-d396-4d76-9766-f39bde4fc498" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8ec5d3c8-0f34-456e-ae9d-4a6c9f5baf08" xlink:to="loc_srt_MajorCustomersAxis_cd7cb0a4-d396-4d76-9766-f39bde4fc498" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_cd7cb0a4-d396-4d76-9766-f39bde4fc498_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_cd7cb0a4-d396-4d76-9766-f39bde4fc498" xlink:to="loc_srt_NameOfMajorCustomerDomain_cd7cb0a4-d396-4d76-9766-f39bde4fc498_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_73c70877-0324-4170-a798-8c47eab9d0a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_cd7cb0a4-d396-4d76-9766-f39bde4fc498" xlink:to="loc_srt_NameOfMajorCustomerDomain_73c70877-0324-4170-a798-8c47eab9d0a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CustomerTopTenProductsMember_0a9020ce-a4cc-4427-bad5-fccbeeafc41c" xlink:href="bhc-20211231.xsd#bhc_CustomerTopTenProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_73c70877-0324-4170-a798-8c47eab9d0a7" xlink:to="loc_bhc_CustomerTopTenProductsMember_0a9020ce-a4cc-4427-bad5-fccbeeafc41c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SEGMENTINFORMATIONGeographicInformationRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails" xlink:type="extended" id="ifd4e848a934b4037bc00e34bba6412b3_SEGMENTINFORMATIONGeographicInformationRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0a80b2ed-a288-458d-aa57-9423760b9cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a7652fef-678d-4e9f-9339-6337447d2a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0a80b2ed-a288-458d-aa57-9423760b9cc4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a7652fef-678d-4e9f-9339-6337447d2a50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b62eea33-c549-41d9-8e6d-baf9d2d1af71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0a80b2ed-a288-458d-aa57-9423760b9cc4" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b62eea33-c549-41d9-8e6d-baf9d2d1af71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_54724a1c-d7c8-4595-9729-a53949d30917" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b62eea33-c549-41d9-8e6d-baf9d2d1af71" xlink:to="loc_srt_StatementGeographicalAxis_54724a1c-d7c8-4595-9729-a53949d30917" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_54724a1c-d7c8-4595-9729-a53949d30917_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_54724a1c-d7c8-4595-9729-a53949d30917" xlink:to="loc_srt_SegmentGeographicalDomain_54724a1c-d7c8-4595-9729-a53949d30917_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_54724a1c-d7c8-4595-9729-a53949d30917" xlink:to="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember_ae93adde-8f21-404e-823f-92187380ca46" xlink:href="bhc-20211231.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_bhc_UnitedStatesandPuertoRicoMember_ae93adde-8f21-404e-823f-92187380ca46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_1936d9a5-19a4-403a-89ec-ff009c21b317" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_CN_1936d9a5-19a4-403a-89ec-ff009c21b317" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_448b45f1-14f4-41c2-8b22-7562fb7e48cd" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_CA_448b45f1-14f4-41c2-8b22-7562fb7e48cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL_191e1234-8ed3-4eb2-871d-1e6c00040229" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_PL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_PL_191e1234-8ed3-4eb2-871d-1e6c00040229" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_31f77081-40a9-4d82-9422-a639d8573851" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_MX_31f77081-40a9-4d82-9422-a639d8573851" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_425c654c-be8d-4219-84c3-69955c806929" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_JP_425c654c-be8d-4219-84c3-69955c806929" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_6eb4567d-c735-4fe6-94e6-de12fd802be4" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_FR_6eb4567d-c735-4fe6-94e6-de12fd802be4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU_35fe83af-b391-44a0-b26a-e4d5b594ea40" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_RU"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_RU_35fe83af-b391-44a0-b26a-e4d5b594ea40" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_EG_c8a59956-a2a1-4b57-8950-b3707805f24e" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_EG"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_EG_c8a59956-a2a1-4b57-8950-b3707805f24e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_84e45e69-2f2b-4fd9-8397-787efe2a717a" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_DE_84e45e69-2f2b-4fd9-8397-787efe2a717a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_58dcd54a-b5c1-4a3f-a47e-7facf85bc712" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_GB_58dcd54a-b5c1-4a3f-a47e-7facf85bc712" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES_0e64397d-698d-4b78-a62c-018ea1a8ba62" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_ES"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_ES_0e64397d-698d-4b78-a62c-018ea1a8ba62" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT_3f03bef0-fc63-4898-9b57-b8640d0c61a0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_IT_3f03bef0-fc63-4898-9b57-b8640d0c61a0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember_60fb2223-aa85-44af-8fbf-ba410157606a" xlink:href="bhc-20211231.xsd#bhc_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_bhc_OtherCountriesMember_60fb2223-aa85-44af-8fbf-ba410157606a" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" xlink:type="extended" id="ie266c4b699da4efb923ea75edff37c29_SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c897bffb-b5b8-4276-8bf2-f377783ab36a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_159a89b4-6fa3-4973-af18-0128568e958b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c897bffb-b5b8-4276-8bf2-f377783ab36a" xlink:to="loc_us-gaap_NoncurrentAssets_159a89b4-6fa3-4973-af18-0128568e958b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_4a27adef-f73c-4a56-9645-95963da28be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c897bffb-b5b8-4276-8bf2-f377783ab36a" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_4a27adef-f73c-4a56-9645-95963da28be9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_db37e7dd-da4f-44be-8590-c30b659df387" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_4a27adef-f73c-4a56-9645-95963da28be9" xlink:to="loc_srt_StatementGeographicalAxis_db37e7dd-da4f-44be-8590-c30b659df387" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_db37e7dd-da4f-44be-8590-c30b659df387_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_db37e7dd-da4f-44be-8590-c30b659df387" xlink:to="loc_srt_SegmentGeographicalDomain_db37e7dd-da4f-44be-8590-c30b659df387_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_db37e7dd-da4f-44be-8590-c30b659df387" xlink:to="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember_e7555743-e5b9-43fb-b1d5-90aa23f633cd" xlink:href="bhc-20211231.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:to="loc_bhc_UnitedStatesandPuertoRicoMember_e7555743-e5b9-43fb-b1d5-90aa23f633cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_33c2c6fa-1a3f-4b80-a9b7-5d67b01af271" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:to="loc_country_IE_33c2c6fa-1a3f-4b80-a9b7-5d67b01af271" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_488861c7-d3a8-4559-9848-33aeb5a8b33b" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:to="loc_country_CA_488861c7-d3a8-4559-9848-33aeb5a8b33b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL_bd5080df-1dd6-4ba7-b5f7-372d281b482f" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_PL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:to="loc_country_PL_bd5080df-1dd6-4ba7-b5f7-372d281b482f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_5557f3f3-e7ae-453b-92cb-9bdc9f63ebe0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:to="loc_country_DE_5557f3f3-e7ae-453b-92cb-9bdc9f63ebe0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_1ae3eb6c-9dc9-4529-ada9-1e25872bb686" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:to="loc_country_MX_1ae3eb6c-9dc9-4529-ada9-1e25872bb686" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_5664a0c3-99ec-4df9-95ae-ae0db5394292" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:to="loc_country_FR_5664a0c3-99ec-4df9-95ae-ae0db5394292" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_3a5f46d3-63a9-4534-9b30-49f25ece1ee7" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:to="loc_country_CN_3a5f46d3-63a9-4534-9b30-49f25ece1ee7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RS_81694a94-3c10-4866-a655-c4e83cae9358" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_RS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:to="loc_country_RS_81694a94-3c10-4866-a655-c4e83cae9358" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT_7e606d6c-6bcb-45d4-90a7-aac714f9d6a1" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:to="loc_country_IT_7e606d6c-6bcb-45d4-90a7-aac714f9d6a1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember_d05431bf-2f18-4061-a6b6-7b5e9b552e95" xlink:href="bhc-20211231.xsd#bhc_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:to="loc_bhc_OtherCountriesMember_d05431bf-2f18-4061-a6b6-7b5e9b552e95" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SEGMENTINFORMATIONMajorCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="extended" id="ibff5e9ce3198412eab31c04830f2475f_SEGMENTINFORMATIONMajorCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_98ec0f60-f19d-4112-b437-b695b8d59146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b5f798dc-6057-4f3c-afff-01626d13a174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_98ec0f60-f19d-4112-b437-b695b8d59146" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b5f798dc-6057-4f3c-afff-01626d13a174" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7df998e6-5224-4874-b323-4deb224ee03f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_98ec0f60-f19d-4112-b437-b695b8d59146" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7df998e6-5224-4874-b323-4deb224ee03f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b3ff009c-0582-4b2f-842a-d570ec0b9640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7df998e6-5224-4874-b323-4deb224ee03f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b3ff009c-0582-4b2f-842a-d570ec0b9640" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b3ff009c-0582-4b2f-842a-d570ec0b9640_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b3ff009c-0582-4b2f-842a-d570ec0b9640" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b3ff009c-0582-4b2f-842a-d570ec0b9640_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_14f610b4-a91f-429d-949e-0283c6f9c487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b3ff009c-0582-4b2f-842a-d570ec0b9640" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_14f610b4-a91f-429d-949e-0283c6f9c487" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_eeb398e5-b976-4569-ab1f-25c4fa27e095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_14f610b4-a91f-429d-949e-0283c6f9c487" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_eeb398e5-b976-4569-ab1f-25c4fa27e095" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4a6e055b-bbf8-4566-a1a3-c73b0d9480b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7df998e6-5224-4874-b323-4deb224ee03f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4a6e055b-bbf8-4566-a1a3-c73b0d9480b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4a6e055b-bbf8-4566-a1a3-c73b0d9480b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4a6e055b-bbf8-4566-a1a3-c73b0d9480b5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4a6e055b-bbf8-4566-a1a3-c73b0d9480b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_86e8399a-0261-4b6f-8882-3054b6461e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4a6e055b-bbf8-4566-a1a3-c73b0d9480b5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_86e8399a-0261-4b6f-8882-3054b6461e6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_72046388-ee2a-47e0-991f-ea846d5e3bbb" xlink:href="bhc-20211231.xsd#bhc_RevenuesNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_86e8399a-0261-4b6f-8882-3054b6461e6d" xlink:to="loc_bhc_RevenuesNetMember_72046388-ee2a-47e0-991f-ea846d5e3bbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ba1c68b0-8445-4ec7-bdac-260f55d14c82" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7df998e6-5224-4874-b323-4deb224ee03f" xlink:to="loc_srt_MajorCustomersAxis_ba1c68b0-8445-4ec7-bdac-260f55d14c82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ba1c68b0-8445-4ec7-bdac-260f55d14c82_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_ba1c68b0-8445-4ec7-bdac-260f55d14c82" xlink:to="loc_srt_NameOfMajorCustomerDomain_ba1c68b0-8445-4ec7-bdac-260f55d14c82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_77e63bf6-d635-468b-a6e4-f139acaaa414" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_ba1c68b0-8445-4ec7-bdac-260f55d14c82" xlink:to="loc_srt_NameOfMajorCustomerDomain_77e63bf6-d635-468b-a6e4-f139acaaa414" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember_e22a2ad1-e30d-4cf7-a63b-3cfdec32f84d" xlink:href="bhc-20211231.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_77e63bf6-d635-468b-a6e4-f139acaaa414" xlink:to="loc_bhc_AmerisourceBergenCorporationMember_e22a2ad1-e30d-4cf7-a63b-3cfdec32f84d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember_9c11650f-28b7-4c5d-9ae3-6d63064f15ed" xlink:href="bhc-20211231.xsd#bhc_McKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_77e63bf6-d635-468b-a6e4-f139acaaa414" xlink:to="loc_bhc_McKessonCorporationMember_9c11650f-28b7-4c5d-9ae3-6d63064f15ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember_c4221645-9ba3-4625-9544-1166b7dc3692" xlink:href="bhc-20211231.xsd#bhc_CardinalHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_77e63bf6-d635-468b-a6e4-f139acaaa414" xlink:to="loc_bhc_CardinalHealthIncMember_c4221645-9ba3-4625-9544-1166b7dc3692" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SUBSEQUENTEVENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="extended" id="ic52876f2c90148699c4d4a5dbe0d7c11_SUBSEQUENTEVENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_7d9b2cd6-c53e-4fd3-a80a-34a50cf741df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_f990d35b-6d39-4b16-8b44-e187fa57cace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7d9b2cd6-c53e-4fd3-a80a-34a50cf741df" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_f990d35b-6d39-4b16-8b44-e187fa57cace" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_a4d85345-facd-4145-8340-be7425dede1f" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7d9b2cd6-c53e-4fd3-a80a-34a50cf741df" xlink:to="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_a4d85345-facd-4145-8340-be7425dede1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentExpectedFaceAmount_4c9c26e4-7d43-4241-9b76-0ec711ae678d" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentExpectedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7d9b2cd6-c53e-4fd3-a80a-34a50cf741df" xlink:to="loc_bhc_DebtInstrumentExpectedFaceAmount_4c9c26e4-7d43-4241-9b76-0ec711ae678d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity_50a7f3f1-7d38-48a7-8bea-b118350ee84b" xlink:href="bhc-20211231.xsd#bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7d9b2cd6-c53e-4fd3-a80a-34a50cf741df" xlink:to="loc_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity_50a7f3f1-7d38-48a7-8bea-b118350ee84b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_042cc77a-b977-4586-a2f9-45dafa8ae8bb" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7d9b2cd6-c53e-4fd3-a80a-34a50cf741df" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_042cc77a-b977-4586-a2f9-45dafa8ae8bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_62af00d0-6113-4b28-b39c-98465349d128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7d9b2cd6-c53e-4fd3-a80a-34a50cf741df" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_62af00d0-6113-4b28-b39c-98465349d128" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d6844fde-22d3-433a-8f14-423e1a1ce0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7d9b2cd6-c53e-4fd3-a80a-34a50cf741df" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d6844fde-22d3-433a-8f14-423e1a1ce0ba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_edc43eda-ccff-4f3a-b8e9-730d0c262ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7d9b2cd6-c53e-4fd3-a80a-34a50cf741df" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_edc43eda-ccff-4f3a-b8e9-730d0c262ef7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_ed8e8f35-4361-4747-b646-73389db03724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7d9b2cd6-c53e-4fd3-a80a-34a50cf741df" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_ed8e8f35-4361-4747-b646-73389db03724" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_88354868-26cd-4c77-b762-8787f4c88d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_7d9b2cd6-c53e-4fd3-a80a-34a50cf741df" xlink:to="loc_us-gaap_SubsequentEventTable_88354868-26cd-4c77-b762-8787f4c88d6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e3764252-d6da-495f-bf06-ef7b5be306d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_88354868-26cd-4c77-b762-8787f4c88d6a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e3764252-d6da-495f-bf06-ef7b5be306d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e3764252-d6da-495f-bf06-ef7b5be306d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e3764252-d6da-495f-bf06-ef7b5be306d7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e3764252-d6da-495f-bf06-ef7b5be306d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ed9fcf22-17cc-4016-bfc6-eaeb7283677d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e3764252-d6da-495f-bf06-ef7b5be306d7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ed9fcf22-17cc-4016-bfc6-eaeb7283677d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_aabcb07b-4d79-4b1f-8d98-f261ecb45f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ed9fcf22-17cc-4016-bfc6-eaeb7283677d" xlink:to="loc_us-gaap_SubsequentEventMember_aabcb07b-4d79-4b1f-8d98-f261ecb45f12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f5fa0e36-8182-4f68-ad66-72bea00f8fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_88354868-26cd-4c77-b762-8787f4c88d6a" xlink:to="loc_us-gaap_DebtInstrumentAxis_f5fa0e36-8182-4f68-ad66-72bea00f8fbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f5fa0e36-8182-4f68-ad66-72bea00f8fbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f5fa0e36-8182-4f68-ad66-72bea00f8fbb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f5fa0e36-8182-4f68-ad66-72bea00f8fbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f2f9fb39-6e58-4237-b3ee-61a9d0429611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f5fa0e36-8182-4f68-ad66-72bea00f8fbb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f2f9fb39-6e58-4237-b3ee-61a9d0429611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member_46956b35-4355-47fc-8a7c-4161a2442b53" xlink:href="bhc-20211231.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2f9fb39-6e58-4237-b3ee-61a9d0429611" xlink:to="loc_bhc_A9.00SeniorNotesdueDecember2025Member_46956b35-4355-47fc-8a7c-4161a2442b53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NewRestatedCreditAgreementMember_98c3651d-32b5-491e-99d6-0577b2105eb2" xlink:href="bhc-20211231.xsd#bhc_NewRestatedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2f9fb39-6e58-4237-b3ee-61a9d0429611" xlink:to="loc_bhc_NewRestatedCreditAgreementMember_98c3651d-32b5-491e-99d6-0577b2105eb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember_34ed3ace-5f73-492b-b88f-c99f2da66415" xlink:href="bhc-20211231.xsd#bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_NewRestatedCreditAgreementMember_98c3651d-32b5-491e-99d6-0577b2105eb2" xlink:to="loc_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember_34ed3ace-5f73-492b-b88f-c99f2da66415" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember_faed70ce-165b-49f5-9df0-26e4819faaa2" xlink:href="bhc-20211231.xsd#bhc_TermLoanBFacilityNewRestatedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_NewRestatedCreditAgreementMember_98c3651d-32b5-491e-99d6-0577b2105eb2" xlink:to="loc_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember_faed70ce-165b-49f5-9df0-26e4819faaa2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_3be9d9fa-afdf-4bb2-aa5b-0749a8d15ae6" xlink:href="bhc-20211231.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2f9fb39-6e58-4237-b3ee-61a9d0429611" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_3be9d9fa-afdf-4bb2-aa5b-0749a8d15ae6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_df40335d-a2cb-4c16-998b-e3dc2ff0b25e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_88354868-26cd-4c77-b762-8787f4c88d6a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_df40335d-a2cb-4c16-998b-e3dc2ff0b25e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_df40335d-a2cb-4c16-998b-e3dc2ff0b25e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_df40335d-a2cb-4c16-998b-e3dc2ff0b25e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_df40335d-a2cb-4c16-998b-e3dc2ff0b25e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c2eefea4-8009-490a-bd0c-aa8ad26029d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_df40335d-a2cb-4c16-998b-e3dc2ff0b25e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c2eefea4-8009-490a-bd0c-aa8ad26029d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_dcd65869-f11e-4185-abb2-e47ed30f12da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c2eefea4-8009-490a-bd0c-aa8ad26029d8" xlink:to="loc_us-gaap_UnsecuredDebtMember_dcd65869-f11e-4185-abb2-e47ed30f12da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_ff9b81e2-0402-4080-aa01-25743db74b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c2eefea4-8009-490a-bd0c-aa8ad26029d8" xlink:to="loc_us-gaap_SecuredDebtMember_ff9b81e2-0402-4080-aa01-25743db74b9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_5bd7585f-3373-4eb3-802b-0ddf18adee6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_88354868-26cd-4c77-b762-8787f4c88d6a" xlink:to="loc_us-gaap_CreditFacilityAxis_5bd7585f-3373-4eb3-802b-0ddf18adee6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5bd7585f-3373-4eb3-802b-0ddf18adee6b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_5bd7585f-3373-4eb3-802b-0ddf18adee6b" xlink:to="loc_us-gaap_CreditFacilityDomain_5bd7585f-3373-4eb3-802b-0ddf18adee6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a494c137-c1b7-43e0-8f16-f0cbfb431d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_5bd7585f-3373-4eb3-802b-0ddf18adee6b" xlink:to="loc_us-gaap_CreditFacilityDomain_a494c137-c1b7-43e0-8f16-f0cbfb431d92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_855f7b05-5f5b-44ec-9ec7-677252c182b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_a494c137-c1b7-43e0-8f16-f0cbfb431d92" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_855f7b05-5f5b-44ec-9ec7-677252c182b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_19de523a-c00f-4c37-95e4-28c029249789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_88354868-26cd-4c77-b762-8787f4c88d6a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_19de523a-c00f-4c37-95e4-28c029249789" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_19de523a-c00f-4c37-95e4-28c029249789_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_19de523a-c00f-4c37-95e4-28c029249789" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_19de523a-c00f-4c37-95e4-28c029249789_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e6a228f1-a904-4d92-bb30-609c76c492d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_19de523a-c00f-4c37-95e4-28c029249789" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e6a228f1-a904-4d92-bb30-609c76c492d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_2f0c8c32-3421-4646-a80e-38e8c6c9218e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e6a228f1-a904-4d92-bb30-609c76c492d1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_2f0c8c32-3421-4646-a80e-38e8c6c9218e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_8a0f38e2-9385-4efb-9555-2401ac7e68f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e6a228f1-a904-4d92-bb30-609c76c492d1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_8a0f38e2-9385-4efb-9555-2401ac7e68f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_74251b6e-ef78-4208-a9d8-f3d06cf2a051" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_88354868-26cd-4c77-b762-8787f4c88d6a" xlink:to="loc_srt_RangeAxis_74251b6e-ef78-4208-a9d8-f3d06cf2a051" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_74251b6e-ef78-4208-a9d8-f3d06cf2a051_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_74251b6e-ef78-4208-a9d8-f3d06cf2a051" xlink:to="loc_srt_RangeMember_74251b6e-ef78-4208-a9d8-f3d06cf2a051_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dbbd750c-19fa-48ac-a361-e8f6c5321d8a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_74251b6e-ef78-4208-a9d8-f3d06cf2a051" xlink:to="loc_srt_RangeMember_dbbd750c-19fa-48ac-a361-e8f6c5321d8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_627b3e3e-10ad-439c-a05f-878aa2fb3c70" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dbbd750c-19fa-48ac-a361-e8f6c5321d8a" xlink:to="loc_srt_MaximumMember_627b3e3e-10ad-439c-a05f-878aa2fb3c70" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>bhc-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:cdc15979-c542-4d25-920c-73804898e32f,g:89bc1415-46fc-4aad-8e83-55f6d8df2ca2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_008dc0c5-6064-413b-8422-609a775d870b_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other payments</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueCommissionersIrelandMember_e2d2dfd1-2dad-4243-ade9-9b19a59f4e8d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueCommissionersIrelandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Commissioners, Ireland</link:label>
    <link:label id="lab_us-gaap_RevenueCommissionersIrelandMember_label_en-US" xlink:label="lab_us-gaap_RevenueCommissionersIrelandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Commissioners, Ireland [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueCommissionersIrelandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueCommissionersIrelandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueCommissionersIrelandMember" xlink:to="lab_us-gaap_RevenueCommissionersIrelandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_8e161145-d7ca-4061-8751-c27282dcd884_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Major Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_f2d1a95d-9e21-4075-8a0b-c2a8f386df4a_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEGAL PROCEEDINGS</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_a8569896-e03d-44f3-b8a1-ecde3256ad7d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial (gain) losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_665bd69d-d953-4ee0-89d6-974951d6bbce_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f1a7775f-63f4-4b93-b7c8-810ee29e6da6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_9a9cfa6b-c6b5-4414-9a1d-137941d88418_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock_82a2c7c7-b8b2-4586-9f37-00bdf0b5fbae_terseLabel_en-US" xlink:label="lab_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of pension and postretirement benefit plan assets assumed in connection with the Acquisition</link:label>
    <link:label id="lab_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock_label_en-US" xlink:label="lab_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with Acquisition [Table Text Block]</link:label>
    <link:label id="lab_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock_documentation_en-US" xlink:label="lab_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" xlink:href="bhc-20211231.xsd#bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" xlink:to="lab_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_8d8cb459-ca91-4109-8549-eac153fc8cb1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_ec45b10a-9db9-449d-ae59-4303ffcd495d_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_d3aea16e-fcec-49e1-abf6-00dd7caf4d1e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_9ab64364-98fd-4425-85f1-ef3f1ce277ed_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA-BC_6a999f8f-2d57-417a-8254-d340df88d13c_terseLabel_en-US" xlink:label="lab_stpr_CA-BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">British Columbia</link:label>
    <link:label id="lab_stpr_CA-BC_label_en-US" xlink:label="lab_stpr_CA-BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRITISH COLUMBIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA-BC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA-BC" xlink:to="lab_stpr_CA-BC" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_59854c88-82bc-4902-9398-d9341b438034_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f7e409b4-6320-4ac9-a80a-7055a9f58df3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CollaborativeAgreementMilestonePaymentsAggregate_e0afd354-4714-4a0b-8056-672e0099914c_terseLabel_en-US" xlink:label="lab_bhc_CollaborativeAgreementMilestonePaymentsAggregate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments in terms of collaboration and license agreements, aggregate</link:label>
    <link:label id="lab_bhc_CollaborativeAgreementMilestonePaymentsAggregate_label_en-US" xlink:label="lab_bhc_CollaborativeAgreementMilestonePaymentsAggregate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone Payments, Aggregate</link:label>
    <link:label id="lab_bhc_CollaborativeAgreementMilestonePaymentsAggregate_documentation_en-US" xlink:label="lab_bhc_CollaborativeAgreementMilestonePaymentsAggregate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amounts required to be paid by the reporting entity, which are contingent upon the achievement of specific development, regulatory or commercial milestones, in connection with the Collaboration Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CollaborativeAgreementMilestonePaymentsAggregate" xlink:href="bhc-20211231.xsd#bhc_CollaborativeAgreementMilestonePaymentsAggregate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CollaborativeAgreementMilestonePaymentsAggregate" xlink:to="lab_bhc_CollaborativeAgreementMilestonePaymentsAggregate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_88777064-eb10-41d7-b0f4-f5b708f4ae04_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_85ddf765-ef99-413c-ae7e-7263f98261b2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_bef55f5e-978f-4905-aa19-d7c4a6d642ed_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherAssetsFixedIncomeSecuritiesMember_999cd1f1-6ebf-4419-8e0f-f87280238230_terseLabel_en-US" xlink:label="lab_bhc_OtherAssetsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_bhc_OtherAssetsFixedIncomeSecuritiesMember_label_en-US" xlink:label="lab_bhc_OtherAssetsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Fixed Income Securities [Member]</link:label>
    <link:label id="lab_bhc_OtherAssetsFixedIncomeSecuritiesMember_documentation_en-US" xlink:label="lab_bhc_OtherAssetsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Fixed Income Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherAssetsFixedIncomeSecuritiesMember" xlink:href="bhc-20211231.xsd#bhc_OtherAssetsFixedIncomeSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherAssetsFixedIncomeSecuritiesMember" xlink:to="lab_bhc_OtherAssetsFixedIncomeSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromHedgeInvestingActivities_f2d8726b-8042-439c-b853-835726aea6e5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds, cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_ProceedsFromHedgeInvestingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Hedge, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:to="lab_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SynergyPharmaceuticalsInc.Member_924af812-00ed-4dcc-addb-664530cee42b_terseLabel_en-US" xlink:label="lab_bhc_SynergyPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synergy</link:label>
    <link:label id="lab_bhc_SynergyPharmaceuticalsInc.Member_label_en-US" xlink:label="lab_bhc_SynergyPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synergy Pharmaceuticals Inc. [Member]</link:label>
    <link:label id="lab_bhc_SynergyPharmaceuticalsInc.Member_documentation_en-US" xlink:label="lab_bhc_SynergyPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synergy Pharmaceuticals Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SynergyPharmaceuticalsInc.Member" xlink:href="bhc-20211231.xsd#bhc_SynergyPharmaceuticalsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SynergyPharmaceuticalsInc.Member" xlink:to="lab_bhc_SynergyPharmaceuticalsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_57277efe-f63b-4d66-80bc-1c02e3fe03c2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c8912f56-e111-4bdd-9a0b-3a651e6383ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_32b2958c-dc85-4d91-82b7-b0240b32f670_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_da748f06-114c-483f-920c-538abf812896_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for future grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_282e922f-2896-4822-a88d-27dbfd751dce_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in Cash and cash equivalents and Restricted cash and other settlement deposits</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dcf4a4c4-c95c-4934-9948-81e49786a32d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_109c465f-d146-42d9-8e74-71a4e9799e01_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Company share volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember_24936a5b-edc7-4a17-a54b-e4ed7d450e47_terseLabel_en-US" xlink:label="lab_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Argentina, Brazil, Egypt, Greece, Serbia, South Africa, Turkey, Ukraine, Venezuela and Vietnam</link:label>
    <link:label id="lab_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember_label_en-US" xlink:label="lab_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Argentina, Brazil, Egypt, Greece, Serbia, South Africa, Turkey, Ukraine, Venezuela and Vietnam [Member]</link:label>
    <link:label id="lab_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember_documentation_en-US" xlink:label="lab_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Argentina, Brazil, Egypt, Greece, Serbia, South Africa, Turkey, Ukraine, Venezuela and Vietnam</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember" xlink:href="bhc-20211231.xsd#bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember" xlink:to="lab_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0a1466b4-4754-406a-b471-ffcf85ab832c_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a5316eac-b773-489c-88db-f270c9d58472_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_220e0023-b118-48c0-ac09-95aee49e098b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_283829e8-260b-4426-97ab-fa4056e5776a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of stock options exercised in the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_85507223-9f96-4d95-852b-58fa691005f4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration adjustments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncomeTaxLineItems_3286b5c2-bfc5-4c25-b326-20418e706660_terseLabel_en-US" xlink:label="lab_bhc_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:label id="lab_bhc_IncomeTaxLineItems_label_en-US" xlink:label="lab_bhc_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:label id="lab_bhc_IncomeTaxLineItems_documentation_en-US" xlink:label="lab_bhc_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxLineItems" xlink:href="bhc-20211231.xsd#bhc_IncomeTaxLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncomeTaxLineItems" xlink:to="lab_bhc_IncomeTaxLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_b9f1d8e6-6952-4154-928f-b49428a4e24c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on sales of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_26a35415-c04c-41e1-aafa-6ea750b4b804_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone achievement, included in net gain (loss) on other sales of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_c268de4d-4492-4290-9c53-752bc9062b4c_terseLabel_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation</link:label>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_label_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation [Member]</link:label>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_documentation_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:href="bhc-20211231.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:to="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_66f9a829-9df4-40fa-8bbf-28fc58a82701_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_a916b281-4357-45b8-b69a-9ea9d071f028_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_ade7aff0-8906-4e5a-9791-747add2a4996_negatedTerseLabel_en-US" xlink:label="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of contingent consideration adjustments, including accretion</link:label>
    <link:label id="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_label_en-US" xlink:label="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Contingent Consideration Liability, Including Accretion, Operating Activities</link:label>
    <link:label id="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_documentation_en-US" xlink:label="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Contingent Consideration Liability, Including Accretion, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:href="bhc-20211231.xsd#bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:to="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_e124b3fe-6521-41e4-bdda-93fde6e727e5_terseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member" xlink:href="bhc-20211231.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueNovember2025Member" xlink:to="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_10411c9f-4970-4733-a3e0-016dbfef657b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product brand intangible assets (estimated useful life 7 years)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_81462775-4f27-489e-ba14-2b16190877b5_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_cd099952-7cac-4c38-8a24-e599505bd52c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentExpectedFaceAmount_7586c97b-65af-4b88-a3e7-d4441012e24b_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentExpectedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected aggregate principal amount</link:label>
    <link:label id="lab_bhc_DebtInstrumentExpectedFaceAmount_label_en-US" xlink:label="lab_bhc_DebtInstrumentExpectedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Expected Face Amount</link:label>
    <link:label id="lab_bhc_DebtInstrumentExpectedFaceAmount_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentExpectedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Expected Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentExpectedFaceAmount" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentExpectedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentExpectedFaceAmount" xlink:to="lab_bhc_DebtInstrumentExpectedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_e4a1148f-bb0c-4dc0-b7d5-c5c9c9e5b3f4_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Units Excluding Ortho Dermatologics</link:label>
    <link:label id="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_label_en-US" xlink:label="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Units Excluding Ortho Dermatologics [Member]</link:label>
    <link:label id="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_documentation_en-US" xlink:label="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Units Excluding Ortho Dermatologics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:href="bhc-20211231.xsd#bhc_ReportingUnitsExcludingOrthoDermatologicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:to="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SandozLitigationMember_4086f132-7a2e-4e98-9c01-b2ab15e67110_terseLabel_en-US" xlink:label="lab_bhc_SandozLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sandoz Litigation</link:label>
    <link:label id="lab_bhc_SandozLitigationMember_label_en-US" xlink:label="lab_bhc_SandozLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sandoz Litigation [Member]</link:label>
    <link:label id="lab_bhc_SandozLitigationMember_documentation_en-US" xlink:label="lab_bhc_SandozLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sandoz Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SandozLitigationMember" xlink:href="bhc-20211231.xsd#bhc_SandozLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SandozLitigationMember" xlink:to="lab_bhc_SandozLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_d5b41ffb-f781-40f6-9af5-1058a68626ee_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e225f5ea-3685-41e6-b2ba-092d95560398_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excluded from computation of diluted earnings per share, effect anti-dilutive (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_aa733f0e-c777-4022-9a6c-c27b21557d5e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_220a4aa1-3c4c-4627-b5f8-aefba9bc8c5f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the components of inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_30c39db6-32ca-4560-9a07-33e0289796d7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_3bc57e97-9d94-4315-818b-4085d6266f2c_terseLabel_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_3ca6d54c-6389-43a5-92c7-695f83c6b9e8_negatedTerseLabel_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_label_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets Excluding Amortization Allocated to Revenues Cost of Good Sold</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_documentation_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:href="bhc-20211231.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:to="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_1649181e-eb1a-4a8b-aacc-757d4e3969fd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_10b1d334-46e5-4b40-9ff2-cb514c473aa0_periodStartLabel_en-US" xlink:label="lab_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and Restricted cash and other settlement deposits, beginning of year</link:label>
    <link:label id="lab_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_3726ffb1-4721-4936-a324-ebb743b53fd6_periodEndLabel_en-US" xlink:label="lab_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and Restricted cash and other settlement deposits, end of year</link:label>
    <link:label id="lab_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_e855e1ca-f4f0-45cd-ab2c-414bd95aebe8_totalLabel_en-US" xlink:label="lab_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and Restricted cash and other settlement deposits, end of year</link:label>
    <link:label id="lab_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_label_en-US" xlink:label="lab_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, And Other Settlement Deposits</link:label>
    <link:label id="lab_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_documentation_en-US" xlink:label="lab_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, And Other Settlement Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" xlink:href="bhc-20211231.xsd#bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" xlink:to="lab_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_f962d01a-87b6-4e8a-a639-f6cfc54dd9ac_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets net of valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember_fc22c83c-ca61-4f3e-9f2f-f8191894801f_terseLabel_en-US" xlink:label="lab_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Notes due May 2023, May 2019 Refinancing</link:label>
    <link:label id="lab_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember_label_en-US" xlink:label="lab_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Notes due May 2023, May 2019 Refinancing [Member]</link:label>
    <link:label id="lab_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember_documentation_en-US" xlink:label="lab_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Notes due May 2023, May 2019 Refinancing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember" xlink:href="bhc-20211231.xsd#bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember" xlink:to="lab_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_559b33e7-0136-4d40-9a3d-6d32f9c73ef7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_d8e3a601-4bbd-4757-838f-9549115eaa3b_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_352391db-78b2-4af1-8eb4-1ebdafb93a1e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_752ed55f-0bdf-45b0-8307-571e4cb46b22_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59a7c5eb-46af-4d54-a0d7-b09bb037c74c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_340fd081-f300-4718-a8b3-503133d7c812_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_48a3ac22-296d-4d24-8a1e-4844320593dc_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_89d080b3-0877-457c-8fd5-2c26bf6a6481_terseLabel_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality assurance</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_label_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Quality Assurance</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_documentation_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Quality Assurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:href="bhc-20211231.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:to="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_aac41ae9-3625-483b-b901-7747d450b1b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_eae1381d-8fa8-4e4f-92d1-a2e7bb6ecf47_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_266e2e87-8a99-4b1b-bea6-f00aaf389a21_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_471a7196-bf9e-4438-9e2a-e2dfed67f8a9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of net loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_c046d81a-19ce-438b-ab3e-fc6066ee22b4_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Possible decrease in unrecognized tax benefits realized in next twelve months</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0e53ecd3-c6c6-4053-a53c-c0efa83155e1_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanOtherCosts_8f3b04b7-10ba-4ac5-b157-27f2d8c886bb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanOtherCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanOtherCosts_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanOtherCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Other Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanOtherCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanOtherCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanOtherCosts" xlink:to="lab_us-gaap_DefinedBenefitPlanOtherCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_729ad286-87bd-4ba7-801e-55bbc9f417fd_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.250% Senior Notes Due May 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.25%, Due May 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 7.25 Percent Due May 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes725DueMay2029Member" xlink:to="lab_bhc_SeniorNotes725DueMay2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_4563d554-98e2-40bc-95c8-522895edadf1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest distributions</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherIncomeExpenseNet_5e9d7980-856a-470d-8763-27dace023b0a_terseLabel_en-US" xlink:label="lab_bhc_OtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_bhc_OtherIncomeExpenseNet_label_en-US" xlink:label="lab_bhc_OtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_bhc_OtherIncomeExpenseNet_documentation_en-US" xlink:label="lab_bhc_OtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherIncomeExpenseNet" xlink:href="bhc-20211231.xsd#bhc_OtherIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherIncomeExpenseNet" xlink:to="lab_bhc_OtherIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_814d08ac-dcd2-4494-9246-52f814a1dd68_terseLabel_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Other Settlement Deposits</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_label_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Other Settlement Deposits, Current [Member]</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_documentation_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Other Settlement Deposits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:href="bhc-20211231.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:to="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_31910218-8d73-4d8a-aa52-321c10835aa5_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_e28df871-04a8-4672-8f25-15a72881edb1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For Determining Net Periodic (Benefit) Cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_90200fa8-f0bb-412b-90a3-79cab8ac8815_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAmountAvailableForRestrictedPayments_aa68e16f-2807-4676-8f83-991178ec9243_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount available for restricted payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentAmountAvailableForRestrictedPayments_label_en-US" xlink:label="lab_bhc_DebtInstrumentAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Amount Available For Restricted Payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentAmountAvailableForRestrictedPayments_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Amount Available For Restricted Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAmountAvailableForRestrictedPayments" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentAmountAvailableForRestrictedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAmountAvailableForRestrictedPayments" xlink:to="lab_bhc_DebtInstrumentAmountAvailableForRestrictedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_68117c61-3a9d-4f20-928c-5bb913e05388_verboseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_336af9b1-78e0-4cf3-9a57-9a5a63364132_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InvestmentGradeMember_9e20a149-e5ee-4119-96a8-fb99ad4090c6_terseLabel_en-US" xlink:label="lab_bhc_InvestmentGradeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment grade</link:label>
    <link:label id="lab_bhc_InvestmentGradeMember_label_en-US" xlink:label="lab_bhc_InvestmentGradeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Grade [Member]</link:label>
    <link:label id="lab_bhc_InvestmentGradeMember_documentation_en-US" xlink:label="lab_bhc_InvestmentGradeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Grade [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InvestmentGradeMember" xlink:href="bhc-20211231.xsd#bhc_InvestmentGradeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InvestmentGradeMember" xlink:to="lab_bhc_InvestmentGradeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fe1efbbe-290a-4e33-a2e6-a99ca3a7b7b3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_3fe778a6-10f3-47d9-8f42-7cc340094cb9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of loss before benefit of income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_c3751096-53ff-475d-a9c9-1f347bc477c8_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1ebb91c7-727c-4d00-b8cb-bf04a00b7ee7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax_1063f709-3de1-4f68-b75c-014b707656d8_terseLabel_en-US" xlink:label="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, year-over-year increase</link:label>
    <link:label id="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax</link:label>
    <link:label id="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax_documentation_en-US" xlink:label="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="bhc-20211231.xsd#bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_029cf18d-585d-48d2-abed-c370bae15040_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and postretirement benefit plan adjustments:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_b3f92c43-a26a-41d4-8f77-b9ce765cfcd3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_f57439ea-a1ab-4fc4-b91c-7cde79737c7c_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_country_DE_59588173-435f-4582-9b5e-23a783aed231_verboseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_22bf6b6b-67d7-43e7-8b3d-164108591ca5_terseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_label_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e623d9f6-b98a-43fd-9b2c-1801165db567_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_b9ca6d52-7c2b-452c-aaf7-04ce144f65c1_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended_3ab5112b-58de-4915-86a6-14b22fabd183_terseLabel_en-US" xlink:label="lab_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of defined benefit plans amended</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended_label_en-US" xlink:label="lab_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Number of Defined Benefit Plans Amended</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended_documentation_en-US" xlink:label="lab_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Number of Defined Benefit Plans Amended</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" xlink:href="bhc-20211231.xsd#bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" xlink:to="lab_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_fad60f9d-77f6-4808-b3cb-913aa9b87f6e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5bb1ef6e-fa59-498e-9fbb-7a4ab4e684d2_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_0e6004f5-368d-4ce5-a640-99d4ac06bd11_terseLabel_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_label_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Noncash Expense (Benefit)</link:label>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_documentation_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:href="bhc-20211231.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:to="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_74debd66-37df-4bfe-bfb2-3d837444e028_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_605b25cb-edd3-400f-897b-17768eddff6f_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of short-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SellingGeneralAndAdministrativeExpenseMember_398eb99a-f15e-4849-b9e9-fcf728d5156f_terseLabel_en-US" xlink:label="lab_bhc_SellingGeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_bhc_SellingGeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_bhc_SellingGeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling General and Administrative Expense [Member]</link:label>
    <link:label id="lab_bhc_SellingGeneralAndAdministrativeExpenseMember_documentation_en-US" xlink:label="lab_bhc_SellingGeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The allocation (or location) of expense to (in) selling, general and administrative expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SellingGeneralAndAdministrativeExpenseMember" xlink:href="bhc-20211231.xsd#bhc_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SellingGeneralAndAdministrativeExpenseMember" xlink:to="lab_bhc_SellingGeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e1a63a5-5f2e-4eed-bd46-24af12b5864c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components and classification of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_4758b930-3d2f-4247-b903-7a15e2145450_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic loss per share attributable to Bausch Health Companies Inc. (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NonemployeeDirectorMember_30f80151-2855-4ca3-8ff9-ae8a094d7b58_terseLabel_en-US" xlink:label="lab_bhc_NonemployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee Director</link:label>
    <link:label id="lab_bhc_NonemployeeDirectorMember_label_en-US" xlink:label="lab_bhc_NonemployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee Director [Member]</link:label>
    <link:label id="lab_bhc_NonemployeeDirectorMember_documentation_en-US" xlink:label="lab_bhc_NonemployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonemployeeDirectorMember" xlink:href="bhc-20211231.xsd#bhc_NonemployeeDirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NonemployeeDirectorMember" xlink:to="lab_bhc_NonemployeeDirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_8895c1a6-f1b2-40aa-b908-4183bdd3965f_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sub-lease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5e1ad206-b3eb-4504-a57b-ec7947626098_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cd98acb2-6766-4f01-96f2-708a7a3df7eb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3f29b5e6-02be-4c51-9024-255186b28175_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c9c40880-e794-4cdf-92f4-f13e5a2ed5a3_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d48cf522-beb5-4630-aa09-8c5921b02eb8_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherLongTermDebtMember_4860a4f6-b9a3-4fc4-a4e0-4881ae3635d1_terseLabel_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bhc_OtherLongTermDebtMember_label_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Debt [Member]</link:label>
    <link:label id="lab_bhc_OtherLongTermDebtMember_documentation_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents long-term debt obligations not elsewhere enumerated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember" xlink:href="bhc-20211231.xsd#bhc_OtherLongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherLongTermDebtMember" xlink:to="lab_bhc_OtherLongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_3cca26cb-10d0-4c1b-9e0a-8cffaaa554c0_verboseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_a16254c2-66f1-4134-a9e5-cdae1559047c_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_83222b6d-fd89-4ae8-b9da-10b5c0b45f4c_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BauschLombMember_3c9b70e8-7a5e-43c3-8b33-293cfa59898d_terseLabel_en-US" xlink:label="lab_bhc_BauschLombMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb</link:label>
    <link:label id="lab_bhc_BauschLombMember_label_en-US" xlink:label="lab_bhc_BauschLombMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb [Member]</link:label>
    <link:label id="lab_bhc_BauschLombMember_documentation_en-US" xlink:label="lab_bhc_BauschLombMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember" xlink:href="bhc-20211231.xsd#bhc_BauschLombMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BauschLombMember" xlink:to="lab_bhc_BauschLombMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_a9013486-5122-4bde-ba15-feb559d876d6_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_2f244dfc-8788-4698-a5f4-2ac2df5138f5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PerrigoIsraelPharmaceuticalsLitigationMember_d60c9404-cf9f-4194-a2cb-5d2ff163f1fc_terseLabel_en-US" xlink:label="lab_bhc_PerrigoIsraelPharmaceuticalsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perrigo Israel Pharmaceuticals Litigation</link:label>
    <link:label id="lab_bhc_PerrigoIsraelPharmaceuticalsLitigationMember_label_en-US" xlink:label="lab_bhc_PerrigoIsraelPharmaceuticalsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perrigo Israel Pharmaceuticals Litigation [Member]</link:label>
    <link:label id="lab_bhc_PerrigoIsraelPharmaceuticalsLitigationMember_documentation_en-US" xlink:label="lab_bhc_PerrigoIsraelPharmaceuticalsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perrigo Israel Pharmaceuticals Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerrigoIsraelPharmaceuticalsLitigationMember" xlink:href="bhc-20211231.xsd#bhc_PerrigoIsraelPharmaceuticalsLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PerrigoIsraelPharmaceuticalsLitigationMember" xlink:to="lab_bhc_PerrigoIsraelPharmaceuticalsLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_6f9c366a-1fdc-476c-bcf8-86b59bdb282b_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_20551cbc-4695-46e5-8e90-d5a2a76608b4_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_ae0377dd-17e3-4958-842a-dafe2ffaa76f_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_61711e12-1cfc-4c83-a9f1-e720146656ec_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod_3ac397d3-da44-4720-a725-1d489bc3712e_terseLabel_en-US" xlink:label="lab_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future benefit payments period</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod_label_en-US" xlink:label="lab_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Estimated Future Benefit Payments, Period</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod_documentation_en-US" xlink:label="lab_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Estimated Future Benefit Payments, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" xlink:href="bhc-20211231.xsd#bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" xlink:to="lab_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember_938456f7-b280-4845-abe2-63fe49c38ba9_terseLabel_en-US" xlink:label="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued And Other Current Liabilities [Member]</link:label>
    <link:label id="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued And Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:href="bhc-20211231.xsd#bhc_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:to="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax_aa7fcafa-269f-45ee-be28-b3c54eb03bdf_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized prior service credits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans_8ee5cb24-4c0e-4f9b-905e-74ea3ebc9a11_terseLabel_en-US" xlink:label="lab_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of defined benefit plans</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans_label_en-US" xlink:label="lab_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Number of Defined Benefit Plans</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans_documentation_en-US" xlink:label="lab_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Number of Defined Benefit Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans" xlink:href="bhc-20211231.xsd#bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans" xlink:to="lab_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_4fc5d966-87a2-4d9c-a53b-ee209402c32b_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_21f6928d-b4d8-488d-86ca-c6ea6f487eb0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenues by geographic region</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_78d45145-c021-41e1-8134-e9be13b555e1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Significant Acquisitions and Disposals [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_943ebbcd-6b9e-4613-8251-d87ea5036060_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_57852b69-caf5-4859-8eff-738f19a63564_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_f8ede7dd-8bc4-4404-a40a-dad31bd436ae_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_610765ce-6913-4c09-a112-52a78c76b6e7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in variable consideration provision, adjustment</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_8c43b6d2-9e06-445d-a192-53058e8a1c0e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_ead85528-134e-4c4c-9c14-e462c83bf2e2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished_20e631ab-1892-4358-ab11-2f481728a20f_terseLabel_en-US" xlink:label="lab_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business separation and proposed initial public offering, number of companies to be established</link:label>
    <link:label id="lab_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished_label_en-US" xlink:label="lab_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Separation And Proposed Initial Public Offering, Number Of Companies To Be Established</link:label>
    <link:label id="lab_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished_documentation_en-US" xlink:label="lab_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Separation And Proposed Initial Public Offering, Number Of Companies To Be Established</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished" xlink:href="bhc-20211231.xsd#bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished" xlink:to="lab_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_7409c781-54cc-49af-ac35-1b69c0b2754a_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt and other</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_15f0b57f-4eb6-4d68-abdc-df3d1b5a7ffb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GlobalHighYieldMember_abd819b0-458a-4f1d-8ce0-4b3385d38b88_terseLabel_en-US" xlink:label="lab_bhc_GlobalHighYieldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global high yield</link:label>
    <link:label id="lab_bhc_GlobalHighYieldMember_label_en-US" xlink:label="lab_bhc_GlobalHighYieldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global High Yield [Member]</link:label>
    <link:label id="lab_bhc_GlobalHighYieldMember_documentation_en-US" xlink:label="lab_bhc_GlobalHighYieldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global High Yield [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlobalHighYieldMember" xlink:href="bhc-20211231.xsd#bhc_GlobalHighYieldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GlobalHighYieldMember" xlink:to="lab_bhc_GlobalHighYieldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_b465656c-2c73-4d8b-b8b9-5785ee50ce16_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_a88ce717-b9e4-4035-a7ec-fe8f14e34805_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_2c3222fd-e988-4f64-95c8-c56c6df8d81c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected_c48a6082-6461-4b3a-8400-af556703f1f3_terseLabel_en-US" xlink:label="lab_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected additional payments</link:label>
    <link:label id="lab_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected_label_en-US" xlink:label="lab_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Payments To Acquire Equity Securities, FV-NI, Expected</link:label>
    <link:label id="lab_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected_documentation_en-US" xlink:label="lab_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Payments To Acquire Equity Securities, FV-NI, Expected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected" xlink:href="bhc-20211231.xsd#bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected" xlink:to="lab_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_15a3756d-18db-4bc2-9267-0eccd61f8fb1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_64eaf549-810d-4e8b-b638-1bf6770809eb_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Smaller Reporting Company</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_f8bbfe8e-ef03-4409-a18f-9b5a80cf314e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CustomerTopTenProductsMember_d49802f6-b30f-4670-b55e-9dbf056c419e_terseLabel_en-US" xlink:label="lab_bhc_CustomerTopTenProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer, Top Ten Products</link:label>
    <link:label id="lab_bhc_CustomerTopTenProductsMember_label_en-US" xlink:label="lab_bhc_CustomerTopTenProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer, Top Ten Products [Member]</link:label>
    <link:label id="lab_bhc_CustomerTopTenProductsMember_documentation_en-US" xlink:label="lab_bhc_CustomerTopTenProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer, Top Ten Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CustomerTopTenProductsMember" xlink:href="bhc-20211231.xsd#bhc_CustomerTopTenProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CustomerTopTenProductsMember" xlink:to="lab_bhc_CustomerTopTenProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_47f6c010-292d-45d7-92c0-35fe1900c219_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_c67f234c-b6db-42c2-91b7-7524d3e1385a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_a47078b2-b480-49f8-8817-85abc3b1a2f9_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CashDiscountsAndAllowancesSettlementPeriod_f5d8c69a-acbb-4d8a-914d-ff52e0d4d7da_terseLabel_en-US" xlink:label="lab_bhc_CashDiscountsAndAllowancesSettlementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement period for cash discounts and allowances</link:label>
    <link:label id="lab_bhc_CashDiscountsAndAllowancesSettlementPeriod_label_en-US" xlink:label="lab_bhc_CashDiscountsAndAllowancesSettlementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Discounts And Allowances, Settlement Period</link:label>
    <link:label id="lab_bhc_CashDiscountsAndAllowancesSettlementPeriod_documentation_en-US" xlink:label="lab_bhc_CashDiscountsAndAllowancesSettlementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Discounts And Allowances, Settlement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CashDiscountsAndAllowancesSettlementPeriod" xlink:href="bhc-20211231.xsd#bhc_CashDiscountsAndAllowancesSettlementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CashDiscountsAndAllowancesSettlementPeriod" xlink:to="lab_bhc_CashDiscountsAndAllowancesSettlementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_a9a42762-039c-4c43-8583-d93fd3198305_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount_319704ad-a7a9-434e-b611-dc74f5e5c8ce_negatedTerseLabel_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to tax attributes</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount_label_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Adjustments To Tax Attributes, Amount</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount_documentation_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Adjustments To Tax Attributes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" xlink:href="bhc-20211231.xsd#bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" xlink:to="lab_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3c1a52a0-1aa6-4fd0-b463-efcd27df1713_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ca9add83-59fb-40bb-96a6-84eb827c1dab_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of unrecognized tax benefits, if recognized, would affect the Company's effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_16a1e42e-f88d-422c-9854-89f92dd3fec6_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_04dfce39-e62a-4721-985b-9a9713db5c44_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_f86c4997-8bf0-4aad-8f0c-9b49bf49f024_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_9b88af39-417f-49ae-bb5e-4e04d96d0a5a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A5.00SeniorNotesDueJanuary2028Member_f223e48d-7535-4600-aaf4-e19c9baef231_terseLabel_en-US" xlink:label="lab_bhc_A5.00SeniorNotesDueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Unsecured Notes Due January 2028</link:label>
    <link:label id="lab_bhc_A5.00SeniorNotesDueJanuary2028Member_label_en-US" xlink:label="lab_bhc_A5.00SeniorNotesDueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due January 2028 [Member]</link:label>
    <link:label id="lab_bhc_A5.00SeniorNotesDueJanuary2028Member_documentation_en-US" xlink:label="lab_bhc_A5.00SeniorNotesDueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due January 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.00SeniorNotesDueJanuary2028Member" xlink:href="bhc-20211231.xsd#bhc_A5.00SeniorNotesDueJanuary2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A5.00SeniorNotesDueJanuary2028Member" xlink:to="lab_bhc_A5.00SeniorNotesDueJanuary2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_04f9a817-ad13-44fe-ba43-cbe2e03f8d7b_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_f85bd366-a21c-4c75-8ee7-23b1063edaac_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash proceeds from incurrence of debt</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Net Proceeds from Incurrence of Debt Payable as Mandatory Pre-payments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:href="bhc-20211231.xsd#bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpensePolicyTextBlock_16ac0729-cf62-4763-8ac7-a6e5c17897b0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpensePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpensePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpensePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpensePolicyTextBlock" xlink:to="lab_us-gaap_InterestExpensePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_27c9e52f-83b8-4f41-bd19-e7a62e0f974a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement loss recognized</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_37165c79-150f-44bd-93a2-bb6f625b82fb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assets and liabilities measured at fair value on a non-recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_534a6dcb-97ae-4fde-be2e-6b5e929fb57c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f0497311-8361-42a7-be9b-0f9d6478448a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_a6915700-0e9f-4039-9c2d-6435017fac76_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_05631243-2fbf-4dfe-8aa4-6df5e45820de_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_d6bd21c6-dfcc-4343-a32d-61b8367fd9eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_2e6ac9a8-14b6-4e88-a962-75e4702d2063_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_country_FR_d58ee347-c738-4e95-b977-846222cb2b1b_verboseLabel_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">France</link:label>
    <link:label id="lab_country_FR_0e2fd270-198e-42a2-9231-8a76e68a4ef9_terseLabel_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">France</link:label>
    <link:label id="lab_country_FR_label_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FRANCE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_FR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_FR" xlink:to="lab_country_FR" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_dbc2b143-ffee-4271-bc40-633be8c700f7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_daf3019d-886b-4d47-a63d-666b38f8d214_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_23d5db1f-792c-43e2-8b49-c80ddebb4b69_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining restructuring liabilities</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_8f1bea83-1e7d-45bc-bccb-9d2d909dcc43_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages sought</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_40e47f1e-f3ab-45b8-a6fd-4ced139456bc_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stock options that will vest on each of the first, second, third and fourth anniversaries from the date of grant</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Arrangement by Share Based Payment Award, Options Vested Percentage</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents percentage of stock options that will vest in the future period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:href="bhc-20211231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_e4026d13-003b-4202-99ce-b621b45cb6ef_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized FX on U.S. dollar debt and other financing cost</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Unrealized Currency Transaction Gains</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_169945a0-8de1-4cec-8cfd-f2f8b02b53d9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and benefit costs</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_c184245c-fef5-4ca3-ba8b-52ebaf48ca32_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting unit, impairment test, long-term growth rates</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_label_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Long-Term Growth Rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_documentation_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Long-Term Growth Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:href="bhc-20211231.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:to="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_de0c8376-1fdc-4765-9b22-919467c821b2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_b9a53eaf-fc4d-4d4f-a5fa-b5165503434b_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A7.25SeniorUnsecuredNotesDue2029Member_5c70b59f-83cb-4af2-972c-879c792e4fc4_terseLabel_en-US" xlink:label="lab_bhc_A7.25SeniorUnsecuredNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.25% Senior Unsecured Notes due 2029</link:label>
    <link:label id="lab_bhc_A7.25SeniorUnsecuredNotesDue2029Member_label_en-US" xlink:label="lab_bhc_A7.25SeniorUnsecuredNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.25% Senior Unsecured Notes Due 2029 [Member]</link:label>
    <link:label id="lab_bhc_A7.25SeniorUnsecuredNotesDue2029Member_documentation_en-US" xlink:label="lab_bhc_A7.25SeniorUnsecuredNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.25% Senior Unsecured Notes Due 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A7.25SeniorUnsecuredNotesDue2029Member" xlink:href="bhc-20211231.xsd#bhc_A7.25SeniorUnsecuredNotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A7.25SeniorUnsecuredNotesDue2029Member" xlink:to="lab_bhc_A7.25SeniorUnsecuredNotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7d2a6955-1401-42e6-89d4-c2b9fedd4772_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_b34def87-71bd-4414-ba5a-78e92121db60_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_c48e0599-5a66-459d-9b76-df732207e797_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Net Cash Proceeds of Insurance and Condemnation Proceeds from Property or Asset Losses Payable as Mandatory Prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:href="bhc-20211231.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_586254ca-871b-410e-826f-5a731f6095f3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_66492dc3-91b3-4c83-9bf5-0350e9e0ff49_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and penalties related to unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_e54e3e4e-0cbc-4375-8ae5-30b622277265_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_3ffbc33f-b965-4f50-b4e2-a29060cd2d60_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_country_ES_6fa38dc9-36e7-48f7-ba2a-7fec91fa9e34_terseLabel_en-US" xlink:label="lab_country_ES" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spain</link:label>
    <link:label id="lab_country_ES_label_en-US" xlink:label="lab_country_ES" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPAIN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_ES"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_ES" xlink:to="lab_country_ES" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_0eedf93b-75ef-497d-a45e-dd491b15875d_terseLabel_en-US" xlink:label="lab_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures:</link:label>
    <link:label id="lab_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_label_en-US" xlink:label="lab_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditure and Depreciation and Amortization [Abstract]</link:label>
    <link:label id="lab_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_documentation_en-US" xlink:label="lab_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the capital expenditures, depreciation and amortization by segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract" xlink:href="bhc-20211231.xsd#bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract" xlink:to="lab_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_d3839fec-a449-4f06-a3e4-90f2fdbce36a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0aaf9702-e93f-4cdc-bd92-41d10a37c5f4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_c83051af-9dca-4442-88b0-9cabaf7dc697_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_db51832a-4295-4382-abc0-03c870c252a7_terseLabel_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits including interest and penalties</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_label_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Including Interest and Penalties</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_documentation_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:href="bhc-20211231.xsd#bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:to="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_5e5699f0-cc94-48f7-bb77-7f23d6147d71_terseLabel_en-US" xlink:label="lab_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_label_en-US" xlink:label="lab_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Defined Benefit Plans, Accrued and Other Current Liabilities</link:label>
    <link:label id="lab_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Defined Benefit Plans, Accrued and Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" xlink:href="bhc-20211231.xsd#bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" xlink:to="lab_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_5630d19f-4f68-4f7a-848b-a467472ae12b_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Line Items]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_label_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Line Items]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_documentation_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Schedule Of Other Income And Expenses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:href="bhc-20211231.xsd#bhc_ScheduleOfOtherIncomeAndExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:to="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_4f630c69-344a-4f04-855f-9acecb4736c4_terseLabel_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR Performance-Based Restricted Stock Units</link:label>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20211231.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_278e4a90-e188-40d6-bdde-f97276266847_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_d962761d-02e2-4d75-8537-ce841d19f263_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_0627a87e-af68-4da6-ad00-b28c9f990d08_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of remaining lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_107ca01d-c746-4ccb-bd1a-7c7702cdd412_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_ed08ddee-dfd1-43c0-8090-f72c94a622b3_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, no par value, unlimited shares authorized, 359,405,748 and 355,422,347&#160;issued and outstanding at December&#160;31, 2021 and 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AmounPharmaceuticalCompanySAEMember_7db5a210-a0fb-49bc-ad5f-34cba0d13b24_terseLabel_en-US" xlink:label="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amoun Pharmaceutical Company S.A.E</link:label>
    <link:label id="lab_bhc_AmounPharmaceuticalCompanySAEMember_label_en-US" xlink:label="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amoun Pharmaceutical Company S.A.E [Member]</link:label>
    <link:label id="lab_bhc_AmounPharmaceuticalCompanySAEMember_documentation_en-US" xlink:label="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amoun Pharmaceutical Company S.A.E</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember" xlink:href="bhc-20211231.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AmounPharmaceuticalCompanySAEMember" xlink:to="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f1300a04-2476-4b04-949e-49273dd61f08_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_c96ac7e4-9341-46e4-952e-31bf2f9ea2e0_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer concentration</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b1b5dc38-8699-4b1a-bef5-385615aaf996_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_653d1ebf-2538-48b2-82f8-f68da303af1d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_d1b84e97-338f-4193-b250-d81a27545e69_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_e976c996-2054-46e8-93e5-e22bfedb06e1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of assets and businesses, net of costs to sell</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses, Net of Cash Divested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_1c5489c7-a67c-436d-99b7-f0284b4b3f26_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_label_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:to="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_735d6442-06a3-48fb-95d9-2a7d774cfc23_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded status, end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_349614d3-76c7-4bfc-8d89-b8d9f138c077_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2c19deab-eef1-48ee-a5c0-814a28a9dee5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of weighted-average assumption as of the date of grant using the Black Scholes option-pricing model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_77fbd53b-32da-487e-8641-490c0a132dab_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss_e1811c98-4069-452f-a6a6-3179162bded8_terseLabel_en-US" xlink:label="lab_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro-forma operating results</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss_label_en-US" xlink:label="lab_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Operating Income (Loss)</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss_documentation_en-US" xlink:label="lab_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:href="bhc-20211231.xsd#bhc_BusinessAcquisitionProFormaOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:to="lab_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_5d59b779-b9fe-4606-9edf-a58e530827aa_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_512e15c6-a416-47eb-b855-f2aa2a640497_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_dd928e84-910f-4885-b13f-617eb70a5c7f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_817e5927-a722-4275-954a-62f8712cb106_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service credit</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_12e5f346-4ca3-4c2d-9586-73caf28af212_terseLabel_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly liquid investments, maturity period (or less)</link:label>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_label_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly Liquid Investments, Maturity Period</link:label>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_documentation_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly Liquid Investments, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:href="bhc-20211231.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:to="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_country_EG_dc637105-302c-465c-b197-d53b9c162738_terseLabel_en-US" xlink:label="lab_country_EG" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Egypt</link:label>
    <link:label id="lab_country_EG_label_en-US" xlink:label="lab_country_EG" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EGYPT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_EG" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_EG"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_EG" xlink:to="lab_country_EG" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_4a095e90-6331-46e6-aef4-e248bc543e3b_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_b6ab86b7-84f3-4c6b-88b7-ef15ab20e23e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_2e5ad604-cd39-4bbd-8e2b-6f9ec95ff9a9_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of open tax years by jurisdiction</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_69549292-ed8e-432e-ace6-65f38d6f4765_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_b2a0990a-c291-4a6d-bbcd-7a745cc96ad8_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured leverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_45e99743-0b90-4811-a584-101ab61b3ec7_verboseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured leverage ratio (not greater than)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Secured Leverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Secured Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_8469e2c3-3ff4-4378-b66e-06e5804b281c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7c3b0c2c-8a1d-4b48-87e8-e187e6d165ee_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxYear2013Member_5ed3355d-a311-4df3-9118-928192684f3c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxYear2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2013</link:label>
    <link:label id="lab_us-gaap_TaxYear2013Member_label_en-US" xlink:label="lab_us-gaap_TaxYear2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2013 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2013Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2013Member" xlink:to="lab_us-gaap_TaxYear2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_1c78eab4-691e-4a79-80a8-081afe939a3e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a5a89d83-d8e4-438b-a87d-9e5ae65b65cc_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_30e035f6-f1f4-4bed-bd2a-f920cbf7e253_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97733190-8b17-4c3c-9a83-ca4c1f35eb84_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price appreciation credits</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ba92f7de-5f69-475c-b72c-b093da5fea52_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_a76106ab-47f0-4f5d-b5cb-973afaf39b03_terseLabel_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_label_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints [Member]</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_documentation_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:href="bhc-20211231.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:to="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_2e5b7ac9-00a2-445d-ac6a-fa4c49d6b680_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfCommitmentsLineItems_0984dbbb-3431-4960-9ef0-37039d74bd21_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other commitments</link:label>
    <link:label id="lab_bhc_ScheduleOfCommitmentsLineItems_label_en-US" xlink:label="lab_bhc_ScheduleOfCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commitments [Line Items]</link:label>
    <link:label id="lab_bhc_ScheduleOfCommitmentsLineItems_documentation_en-US" xlink:label="lab_bhc_ScheduleOfCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfCommitmentsLineItems" xlink:href="bhc-20211231.xsd#bhc_ScheduleOfCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfCommitmentsLineItems" xlink:to="lab_bhc_ScheduleOfCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_8c477ff4-196b-43f1-a57a-ef1ffa6752a3_terseLabel_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generics</link:label>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_label_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generic Products [Member]</link:label>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_documentation_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generic Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember" xlink:href="bhc-20211231.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BrandedandOtherGenericProductsMember" xlink:to="lab_bhc_BrandedandOtherGenericProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_b7a4950c-dc6b-4d59-bf18-40bba64f0b8b_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_12be2d3a-b121-4dda-84ef-aff013113456_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_c566c371-9e77-438d-8511-5a2c1c029317_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_99372e96-645c-4922-a5bb-0ca92fa41c02_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_4ef156ab-5ba2-40ce-b736-0c97dab04747_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_13e5fefd-e830-4894-9bb6-6f3ac83e58f3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) recognized in Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_53b1b6b6-c7a4-4f7d-87fc-763fc2e0fa09_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_c580900b-4ca7-45f6-9822-f5ade9d0671d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_6d7ac516-4fbf-48ac-bf2c-14ff250a523e_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.250% Senior Notes Due January 2030</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_label_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.25%, Due January 2030 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due January 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes525DueJanuary2030Member" xlink:to="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8be10f45-e352-4a02-baa1-de62dfbaa0dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_2ccc7979-5330-49dd-b248-8249e21dc9aa_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c396dd6a-bf84-4581-9f5b-e06afc2ebd20_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_7a344d4f-938f-45c4-8883-3c7a0ed9aeb0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_e336a842-5824-406c-9ccf-f02a2012d6da_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_ffefc526-cc3b-42fb-8d90-8b882599845e_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_0aabc2db-e3ab-476d-b51e-887e6e69c123_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_45e43ead-b9c7-41a5-b698-543d5581cff2_terseLabel_en-US" xlink:label="lab_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_label_en-US" xlink:label="lab_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension And Other Postretirement Defined Benefit Plans, Other Assets, Noncurrent</link:label>
    <link:label id="lab_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_documentation_en-US" xlink:label="lab_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension And Other Postretirement Defined Benefit Plans, Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" xlink:href="bhc-20211231.xsd#bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" xlink:to="lab_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_b1e2aa7f-f35a-41a3-bc20-7daa6a9fea8e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027-2031</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_6622f53c-7770-4e9b-b06f-6ec779a1f9fe_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount received</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded from Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PerformanceBasedRestrictedStockUnitsMember_308eba4c-e293-4e31-9517-b84b3a6ac482_terseLabel_en-US" xlink:label="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units</link:label>
    <link:label id="lab_bhc_PerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_PerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents stock awards in the form of performance-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20211231.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_16d7fa17-537c-4af5-bb51-f928e26415a8_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_3e77cece-8b4b-481d-b2fe-de3147627cf9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue of acquiree since acquisition date</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_a148ee76-7078-41ff-903c-d441300f07a5_terseLabel_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements from cross-currency swaps</link:label>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_label_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Settlement On Cross-Currency Swaps</link:label>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_documentation_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Settlement On Cross-Currency Swaps</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:href="bhc-20211231.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:to="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_12fe7d16-9a2e-4edc-9e71-fa838e1cfb7c_terseLabel_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceuticals</link:label>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_label_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Products [Member]</link:label>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_documentation_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember" xlink:href="bhc-20211231.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PharmaceuticalProductsMember" xlink:to="lab_bhc_PharmaceuticalProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_1b122e95-ac3f-431c-8471-c8ab7ad92af2_terseLabel_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Revolving Credit Facility Due June 2023</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_label_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due June 2023 [Member]</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_documentation_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due June 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:href="bhc-20211231.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:to="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IT_69419bcc-f145-449b-b809-012a0b384436_terseLabel_en-US" xlink:label="lab_country_IT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Italy</link:label>
    <link:label id="lab_country_IT_label_en-US" xlink:label="lab_country_IT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ITALY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IT" xlink:to="lab_country_IT" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_517a4ec8-44c2-44ac-8eda-f81723fe722e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible amount of share-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_d54dbfdb-672d-4464-8dae-6b680b75ca90_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_5a41e05b-9b25-4009-9856-9446087f06f8_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_d5cfd5ff-fc32-4a8b-89ed-e8c972eabdaa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of principal amount that can be redeemed</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_862b3d85-a815-4d8d-8caa-5f3dcb271d03_verboseLabel_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.750% Senior Notes Due August 2027</link:label>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_label_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.75% Notes Due August 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.75% Notes Due August 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:href="bhc-20211231.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:to="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_f5a6ab2a-ce39-4c00-b10c-2d5bf790e2a6_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfCommitmentsTable_27755e6f-7f3a-44d2-8c40-f5ce10c8277e_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commitments [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfCommitmentsTable_label_en-US" xlink:label="lab_bhc_ScheduleOfCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commitments [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfCommitmentsTable_documentation_en-US" xlink:label="lab_bhc_ScheduleOfCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to commitments of the entity during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfCommitmentsTable" xlink:href="bhc-20211231.xsd#bhc_ScheduleOfCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfCommitmentsTable" xlink:to="lab_bhc_ScheduleOfCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ead869d8-30ac-4f35-90ab-038f16bbdc23_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_8fdfd863-40f8-44a8-b3e1-9612f75dd245_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a8fc3bc8-af75-44d3-b9ad-3d004dbecbd6_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95febcc2-df21-4b50-898c-89930f702f7d_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_bb0b6c53-fb2c-4b9b-90ea-74bc3e4ab03e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherRevenuesMember_eb439c88-1f16-4ab2-95de-9998d0adbbd9_terseLabel_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_bhc_OtherRevenuesMember_label_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Member]</link:label>
    <link:label id="lab_bhc_OtherRevenuesMember_documentation_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember" xlink:href="bhc-20211231.xsd#bhc_OtherRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherRevenuesMember" xlink:to="lab_bhc_OtherRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_343763e1-d670-4361-a92a-6eb083fc9e6e_terseLabel_en-US" xlink:label="lab_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Products For Disposal, September 2019</link:label>
    <link:label id="lab_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_label_en-US" xlink:label="lab_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Products For Disposal, September Two Thousand Nineteen [Member]</link:label>
    <link:label id="lab_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_documentation_en-US" xlink:label="lab_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Products For Disposal, September Two Thousand Nineteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember" xlink:href="bhc-20211231.xsd#bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember" xlink:to="lab_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_6cbd0ae2-94dd-4143-9cb9-d6acef07df20_terseLabel_en-US" xlink:label="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE</link:label>
    <link:label id="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_label_en-US" xlink:label="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]</link:label>
    <link:label id="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_documentation_en-US" xlink:label="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:href="bhc-20211231.xsd#bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:to="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_a95c724b-3031-4ed9-8bdf-4ba8ac84a4db_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e73b5c48-729a-4803-8fef-31d6752608d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_9be4703f-139b-42e6-b261-6e5a8eda0df3_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OrthoDermatologicsReportingUnitMember_fde17abe-e6e7-4898-ac64-c8f423831dda_terseLabel_en-US" xlink:label="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Reporting Unit</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsReportingUnitMember_label_en-US" xlink:label="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Reporting Unit [Member]</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsReportingUnitMember_documentation_en-US" xlink:label="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Reporting Unit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsReportingUnitMember" xlink:href="bhc-20211231.xsd#bhc_OrthoDermatologicsReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OrthoDermatologicsReportingUnitMember" xlink:to="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a94ca46f-6079-4682-91e0-add048aea788_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of operating lease future payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_a0fe2727-62e7-4a57-9231-c4e626a7a75b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of external customers that accounted for 10% or more of total revenues</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit_1b5d7161-34ba-4049-bb39-fa7aa7917943_terseLabel_en-US" xlink:label="lab_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held for sale reclassified to goodwill</link:label>
    <link:label id="lab_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Transfers Related To Sale of Business Unit</link:label>
    <link:label id="lab_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit_documentation_en-US" xlink:label="lab_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Transfers Related To Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit" xlink:href="bhc-20211231.xsd#bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit" xlink:to="lab_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_8ac8890e-e2de-43a2-a593-c8cc7bea8def_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Bausch Health Companies Inc. shareholders&#8217; (deficit) equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_c5a2c0a0-cd70-480a-bd14-d9aa7fe7ca41_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6f1bb42c-f13a-4d7b-ad07-5f7d01d31c2d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_530915ac-9a64-447f-bafd-97c1a6d45f57_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual amortization rate, percentage</link:label>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_label_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Annual Amortization Rate, Percentage</link:label>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Annual Amortization Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:to="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f2386d22-f7e1-4434-b3be-cd5057d31f11_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_9f4facc5-f580-4c0b-89c0-ccfaf1da39e4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_7e64fea6-f878-431b-b9f7-21b390116030_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Cash Flow Disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_037e8f55-c22e-42e3-b86f-678a14738261_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_84049cbb-42e5-4024-8a55-03d082fa560a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IE_fcb1f1bf-b558-4ab8-8817-5f91a489256b_terseLabel_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ireland</link:label>
    <link:label id="lab_country_IE_label_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IRELAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IE" xlink:to="lab_country_IE" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A9.00SeniorNotesdueDecember2025Member_05f3fd39-8940-4a11-ab88-d9405f0b5107_terseLabel_en-US" xlink:label="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Unsecured Notes due December 2025</link:label>
    <link:label id="lab_bhc_A9.00SeniorNotesdueDecember2025Member_label_en-US" xlink:label="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025 [Member]</link:label>
    <link:label id="lab_bhc_A9.00SeniorNotesdueDecember2025Member_documentation_en-US" xlink:label="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:href="bhc-20211231.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:to="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_7b818976-9eef-48ab-983b-2ed67070e3d2_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.000% Senior Notes Due January 2028</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_label_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.00%, Due January 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due January 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes500DueJanuary2028Member" xlink:to="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember_c7969d09-a788-4b7a-91c2-6abb9dd39786_terseLabel_en-US" xlink:label="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D not in service</link:label>
    <link:label id="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember_4c5b8e0d-c1f3-43d6-b92a-fa936c7092a3_verboseLabel_en-US" xlink:label="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in Process Research and Development [Member]</link:label>
    <link:label id="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents intangible assets that the entity has acquired as a result of business acquisition, which is represented through the premium in the purchase price over book value attributed to research and development on new product that is not yet being sold.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:href="bhc-20211231.xsd#bhc_AcquiredInProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:to="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_a0abfa22-a776-472c-99d1-1c2d23898711_terseLabel_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit</link:label>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_label_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit [Member]</link:label>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_documentation_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember" xlink:href="bhc-20211231.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PriceAppreciationCreditMember" xlink:to="lab_bhc_PriceAppreciationCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_38f2e879-7342-4663-8dee-b8c182f73285_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_c810736c-efb1-4971-aafd-4f4e27ff6603_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_f995c64b-ff7c-4d5e-a806-a21a9945224d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_1c735b18-0794-4a04-b0ab-1afc5bdd2c6b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_3935a810-b3f5-4092-b444-55568324853d_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a508d69a-be6e-45ec-b728-373af8aa6bfb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember_061d9e28-a146-4c6f-86a3-66d30113be6d_terseLabel_en-US" xlink:label="lab_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Slayback Pharma LLC And Slayback Pharma India LLP Litigation</link:label>
    <link:label id="lab_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember_label_en-US" xlink:label="lab_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Slayback Pharma LLC And Slayback Pharma India LLP Litigation [Member]</link:label>
    <link:label id="lab_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember_documentation_en-US" xlink:label="lab_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Slayback Pharma LLC And Slayback Pharma India LLP Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember" xlink:href="bhc-20211231.xsd#bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember" xlink:to="lab_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_1d03435b-7d89-4e0e-85b2-f524032bc835_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_f3527c32-7a10-4833-aecc-264d8104c77e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_23808aae-7902-44cb-b315-bdab4689b3ec_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3bbc00d9-6093-4622-ba00-18cc9e4d9f07_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic (benefit) cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_e92de213-fcb4-4d10-ad8f-a63a9a835005_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings of short-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A7.00SeniorUnsecuredNotesDue2028Member_abb6f614-85ed-4a96-8b21-66ef080f319b_terseLabel_en-US" xlink:label="lab_bhc_A7.00SeniorUnsecuredNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.00% Senior Unsecured Notes due 2028</link:label>
    <link:label id="lab_bhc_A7.00SeniorUnsecuredNotesDue2028Member_label_en-US" xlink:label="lab_bhc_A7.00SeniorUnsecuredNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.00% Senior Unsecured Notes Due 2028 [Member]</link:label>
    <link:label id="lab_bhc_A7.00SeniorUnsecuredNotesDue2028Member_documentation_en-US" xlink:label="lab_bhc_A7.00SeniorUnsecuredNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.00% Senior Unsecured Notes Due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A7.00SeniorUnsecuredNotesDue2028Member" xlink:href="bhc-20211231.xsd#bhc_A7.00SeniorUnsecuredNotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A7.00SeniorUnsecuredNotesDue2028Member" xlink:to="lab_bhc_A7.00SeniorUnsecuredNotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable_cc989a82-5107-4f45-9226-5a6c69579cd2_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable_label_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable_documentation_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:href="bhc-20211231.xsd#bhc_ScheduleOfOtherIncomeAndExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:to="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_country_PL_1354886a-1e0b-4dd7-9bc0-31e632bbc166_terseLabel_en-US" xlink:label="lab_country_PL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Poland</link:label>
    <link:label id="lab_country_PL_label_en-US" xlink:label="lab_country_PL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">POLAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_PL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_PL" xlink:to="lab_country_PL" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_0f90279e-b724-4a0a-b3c0-65ee25e289f6_terseLabel_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products represented of total revenue</link:label>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_label_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number Of Products</link:label>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_documentation_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number Of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts" xlink:href="bhc-20211231.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ConcentrationRiskNumberOfProducts" xlink:to="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_09b6db4f-0db7-4b22-b288-1fc15481ffe9_terseLabel_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of research and development</link:label>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_label_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Research And Development Expense [Table Text Block]</link:label>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_documentation_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Research And Development Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:href="bhc-20211231.xsd#bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:to="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_b24f9792-25bd-48ad-ad56-385f5457212e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_d452905f-13e2-4c44-a757-ce9323613ba0_verboseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Compensation Plan</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_da04faf7-d53d-486a-9d51-9f0b9ce6dd67_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_11557fda-8058-49b4-b9fd-555a662e63a4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_e1b6cd00-2d3e-4518-a682-4adb9ef81a62_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_61e7e89b-614a-46b9-bb50-e23cf54adeef_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee, unutilized commitments, percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0215cfbf-8b2b-42e3-afb0-b4c558bd7ff6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair values of assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_65302f74-ebdc-4dee-9f20-5da02d58c57b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LiabilitiesLesseeAbstract_2e980c6a-4c5d-48f4-b721-e6fa54876064_terseLabel_en-US" xlink:label="lab_bhc_LiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities included in:</link:label>
    <link:label id="lab_bhc_LiabilitiesLesseeAbstract_label_en-US" xlink:label="lab_bhc_LiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Lessee [Abstract]</link:label>
    <link:label id="lab_bhc_LiabilitiesLesseeAbstract_documentation_en-US" xlink:label="lab_bhc_LiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LiabilitiesLesseeAbstract" xlink:href="bhc-20211231.xsd#bhc_LiabilitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LiabilitiesLesseeAbstract" xlink:to="lab_bhc_LiabilitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_e5bc145b-2381-40f1-a7f4-140ef233672e_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period provision</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_d2050339-c8ba-4713-9dd2-4074f267854e_netLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales return provisions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_b9ced2ec-9b84-4951-9a8b-fe84c3151b0d_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged to other accounts</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_d730f704-c7e2-4313-9d2f-61ecca8bd3d7_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underfunded pension benefit plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_4c60d313-201c-4f12-aa58-668d4f57dcb7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_7ce25b72-f77a-40f5-9944-ef0f84309464_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_39f4858c-757f-4c4d-8bff-7a67f4156c2e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_29e8e8f8-fa92-4957-8ba7-86f8ac769138_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_fc2ab68f-ec7b-496c-9bee-b234d3bb1946_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a7fb9804-e91b-4e34-9b70-3a3ccef8fb55_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_cb2a5e86-3b95-4ed6-bb9a-90bbd4edc54a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_U.S.BroadMarketMember_5ac80a9b-0dd4-46e9-b438-45cf3e13fdb9_terseLabel_en-US" xlink:label="lab_bhc_U.S.BroadMarketMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. broad market</link:label>
    <link:label id="lab_bhc_U.S.BroadMarketMember_label_en-US" xlink:label="lab_bhc_U.S.BroadMarketMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Broad Market [Member]</link:label>
    <link:label id="lab_bhc_U.S.BroadMarketMember_documentation_en-US" xlink:label="lab_bhc_U.S.BroadMarketMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Broad Market [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_U.S.BroadMarketMember" xlink:href="bhc-20211231.xsd#bhc_U.S.BroadMarketMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_U.S.BroadMarketMember" xlink:to="lab_bhc_U.S.BroadMarketMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b05296fe-545c-49f5-8286-1102d2f8ffd8_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_c3100402-e331-4c22-b07e-777b2bb04794_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of groups of investors</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_label_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_documentation_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:href="bhc-20211231.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:to="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_eaac379d-eddd-44a8-b94c-5362eb90c2a8_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.250% Senior Notes Due April 2026</link:label>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_label_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 9.25%, Due April 2026 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Notes Due April 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes925DueApril2026Member" xlink:to="lab_bhc_SeniorNotes925DueApril2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_ec452b42-9230-46f3-b934-2b5a6478869a_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of countries in which entity operates</link:label>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Countries in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_42215e3d-9c06-4891-bfff-2f7d66ce5e03_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_e3e917cb-8d75-40fc-b7a6-50859b47d7f0_terseLabel_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_label_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration Fair Value Disclosure</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_documentation_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:href="bhc-20211231.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:to="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_d2383515-9aec-4fa7-8b52-c594c43956d7_verboseLabel_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, Time-based RSUs, Performance-based RSUs</link:label>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20211231.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_105ce87d-5058-4e0c-a5ea-6b7aaffd4e62_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and credits</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_4bbaf24f-7ab0-4bab-9a24-55252b95cc0c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d26e4f97-00e6-47dc-ad53-35dc6c135052_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_981bc5a9-29f6-4634-b23b-fcf88ad8271d_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Provision for) benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_26bcb0ce-29b9-49ee-98ff-f514d2bfa11d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realignment of segment goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_57a41f78-a6cb-4e92-b0c3-76902d01c74f_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price Per Share</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Arrangement by Share Based Payment Award Options Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:href="bhc-20211231.xsd#bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:to="lab_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_cae4e40b-02e8-4760-8da7-bafe4cea3d68_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_ef8bebfe-7567-4254-9d57-4484de70ecc7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net trade receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_7f49ad5d-aab4-4bb7-a601-10424fe95c97_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_1d8d362c-94f2-4298-9557-461cd8424d4b_verboseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_574b35a4-4f25-4237-9d4e-eb141c8cbd5e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of cases dismissed</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_45c47ec4-11c3-415f-9c87-9023e0299c31_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d5cce9d8-832c-4bf2-b964-ca1872c0c783_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_1dc94e78-4818-4196-8782-d10a5eb94e76_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Plan Assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_2348eb17-1698-49a6-9270-74fb0223e23a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_6f93f6df-c0c0-4966-9c6c-b1187e3b43c3_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_81560a03-e1ba-4c21-a5ad-73d13d8237b2_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_d68cd446-4201-461f-82dc-c7d632545b1c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_29234063-f9fa-48fa-bdb0-4255674a8c6e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_MX_159447cc-addf-40da-a79a-c8e3a170a361_terseLabel_en-US" xlink:label="lab_country_MX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mexico</link:label>
    <link:label id="lab_country_MX_label_en-US" xlink:label="lab_country_MX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEXICO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_MX" xlink:to="lab_country_MX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e91a2b77-a330-4fe0-9b34-8167bcbe10d3_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SalixSegmentMember_0e9db515-0d3b-4244-8154-a7986721d86e_terseLabel_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix</link:label>
    <link:label id="lab_bhc_SalixSegmentMember_618a3054-fda8-4c03-bc6e-938bb29bf4a8_verboseLabel_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix</link:label>
    <link:label id="lab_bhc_SalixSegmentMember_label_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Segment [Member]</link:label>
    <link:label id="lab_bhc_SalixSegmentMember_documentation_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember" xlink:href="bhc-20211231.xsd#bhc_SalixSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SalixSegmentMember" xlink:to="lab_bhc_SalixSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3e682719-af50-4c31-830f-4b4e55caff10_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance on Canadian deferred tax assets and tax rate changes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c5a0707f-7192-476b-959b-41416f3f2b56_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_6c76e421-7dc0-41ad-acde-e8473495b499_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_4d6cf074-9fc9-4819-806b-6bcced1bb180_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term debt and other</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0fb592a3-b1be-430e-8f0f-24e603ff24dc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9d05e672-92b5-4ace-ad67-d76510bae6a8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_6926367b-cda3-49f0-9be1-dc2c547aa65e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_country_NL_cf6d6e24-c43a-4bff-9eed-4ae5440ae101_terseLabel_en-US" xlink:label="lab_country_NL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Netherlands</link:label>
    <link:label id="lab_country_NL_label_en-US" xlink:label="lab_country_NL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NETHERLANDS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_NL" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_NL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_NL" xlink:to="lab_country_NL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5d57bab6-435b-49c7-867a-9023b4a82799_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value of stock options (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_aefd13ed-5db2-4018-9888-bf04ae81f25c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AuditInformationAbstract_3e9f0dd5-0c12-46cd-ac77-ae1fcc764ff2_terseLabel_en-US" xlink:label="lab_bhc_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_bhc_AuditInformationAbstract_label_en-US" xlink:label="lab_bhc_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_bhc_AuditInformationAbstract_documentation_en-US" xlink:label="lab_bhc_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AuditInformationAbstract" xlink:href="bhc-20211231.xsd#bhc_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AuditInformationAbstract" xlink:to="lab_bhc_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d4a1fe36-2141-4e20-b5a9-f16ea451b147_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_7fd59bf7-3a50-44b5-b056-c64130adb4f3_verboseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_e9bef61e-025b-424a-9c9b-c423435079c8_terseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member" xlink:href="bhc-20211231.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueJune2025Member" xlink:to="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6df9747b-8050-4e30-b709-c3ab7cf2a1fd_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_02aa8833-7735-4a33-952f-89d754f3e653_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_4fb49fc4-ef79-4aa2-a871-3c9c2f0f1963_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_f02dc14c-631a-48ba-8d00-4d3fa793dbc5_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TimeBasedRSUMember_eeff39d4-66fe-4afa-8560-787524d343aa_terseLabel_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-Based RSUs</link:label>
    <link:label id="lab_bhc_TimeBasedRSUMember_label_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based RSU [Member]</link:label>
    <link:label id="lab_bhc_TimeBasedRSUMember_documentation_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents stock awards in the form of time-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember" xlink:href="bhc-20211231.xsd#bhc_TimeBasedRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TimeBasedRSUMember" xlink:to="lab_bhc_TimeBasedRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_b32d31e8-dc44-4473-8c25-dde6b2f6e626_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_243bc107-099f-429b-aa86-3e35f63b9062_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_32448d49-24af-4def-b0df-2d7b7526fa21_negatedTerseLabel_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to accrued legal settlements</link:label>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_label_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related To Litigation Settlement, Gross</link:label>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_documentation_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related To Litigation Settlement, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross" xlink:href="bhc-20211231.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GainLossRelatedToLitigationSettlementGross" xlink:to="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AssetsLesseeAbstract_fa276dc3-cfe2-470f-b284-088f6753f863_terseLabel_en-US" xlink:label="lab_bhc_AssetsLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets included in:</link:label>
    <link:label id="lab_bhc_AssetsLesseeAbstract_label_en-US" xlink:label="lab_bhc_AssetsLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Lessee [Abstract]</link:label>
    <link:label id="lab_bhc_AssetsLesseeAbstract_documentation_en-US" xlink:label="lab_bhc_AssetsLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetsLesseeAbstract" xlink:href="bhc-20211231.xsd#bhc_AssetsLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AssetsLesseeAbstract" xlink:to="lab_bhc_AssetsLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_c8a4077f-79d6-4e5e-9acb-51339eabaf0e_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_49ceccb6-00f5-4f97-a2e6-7ec54789720c_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of fair value in excess of carrying value</link:label>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_label_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:to="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_30360b9f-93cb-4f4f-92ed-de9db4bc2236_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_9f863672-8374-4c8e-8502-9c741558c34f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the components and classification of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_2be285f5-e0db-4f15-b61d-1e569b1d5313_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual asset allocations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_e411f6b0-8137-419e-abf1-42ad8c024214_terseLabel_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and Allowances</link:label>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_label_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Discounts And Allowances [Member]</link:label>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Discounts And Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember" xlink:href="bhc-20211231.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForDiscountsAndAllowancesMember" xlink:to="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_9d5c9ff0-8802-4da2-80d2-17d241b488ce_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ff863c0-0bbd-4714-82e2-47a446f3741d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_bee8b9b0-8ed2-4330-b364-5b18bc07feb4_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_dfb22a7f-39ff-4102-8eab-fdf0b50a44b1_terseLabel_en-US" xlink:label="lab_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_label_en-US" xlink:label="lab_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards Research and Development</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_documentation_en-US" xlink:label="lab_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The tax effect as of the balance sheet date of the amount of future tax deductions arising from unused research and development tax credit carryforwards; a tax credit carryforward is the amount by which tax credits available for utilization exceed statutory limitations for inclusion in historical filings, and which can only be utilized if sufficient tax-basis income is generated in future periods and providing tax laws continue to allow such utilization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:href="bhc-20211231.xsd#bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:to="lab_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_ccfd5e2a-3364-465e-87ed-e66bc80df4eb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_96f7b67d-9216-4d49-98b4-05d7cc769d01_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bf7fe06d-558d-4b1b-993f-31b02181b3e3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_f0e67211-a54d-4a6f-a1ee-5b9b487a4cce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_6eca2566-1ffa-4dee-86ab-c502e238e050_netLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_556ac6b9-b5b9-4033-8af2-4e63b74e2fa6_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct insurance policy periods</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_label_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Insurance Policy Periods</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_documentation_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Insurance Policy Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:href="bhc-20211231.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:to="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_322e622e-b39c-4522-b77a-6cd1f650f552_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ACertainInternationalBusinessMember_cc9c5eaf-e882-4924-9996-b199c18797d3_terseLabel_en-US" xlink:label="lab_bhc_ACertainInternationalBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A Certain International Business</link:label>
    <link:label id="lab_bhc_ACertainInternationalBusinessMember_label_en-US" xlink:label="lab_bhc_ACertainInternationalBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A Certain International Business [Member]</link:label>
    <link:label id="lab_bhc_ACertainInternationalBusinessMember_documentation_en-US" xlink:label="lab_bhc_ACertainInternationalBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A Certain International Business [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ACertainInternationalBusinessMember" xlink:href="bhc-20211231.xsd#bhc_ACertainInternationalBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ACertainInternationalBusinessMember" xlink:to="lab_bhc_ACertainInternationalBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_8b78070b-7feb-425b-82ec-5df20cc2bfb3_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_40319a5b-a921-40bd-800b-2bb5cb0c2f6f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_d9c9986e-aa73-4cb8-a194-f2be861f3d7a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b84e4457-434a-46d3-8b46-f4a317e65471_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3e64a149-c966-4dc3-a111-fc797dfa63ba_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Useful Lives (Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredTermCreditFacilitiesMember_9cfb3f41-c56b-4aad-8c8a-77970315bc29_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities</link:label>
    <link:label id="lab_bhc_SeniorSecuredTermCreditFacilitiesMember_label_en-US" xlink:label="lab_bhc_SeniorSecuredTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Credit Facilities [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredTermCreditFacilitiesMember_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the Senior Secured Credit Facilities which includes the Revolving Credit Facility, New Term Loan A Facility, and the Delayed Draw Facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredTermCreditFacilitiesMember" xlink:href="bhc-20211231.xsd#bhc_SeniorSecuredTermCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredTermCreditFacilitiesMember" xlink:to="lab_bhc_SeniorSecuredTermCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_787aa403-988a-4b53-9e1b-a8709ecbd1cb_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_de363c9a-b341-4d29-a63f-b49e69b5770e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of calculation of loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6b0eb8b3-e184-4fcd-ae37-7b78d89a7766_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_ba70c79d-f63d-45c5-910a-103ee190e15a_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_97c3578c-f2ab-40c1-b6ff-c58787dd3b7d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_22c0e746-4256-4ea6-938c-8cf8643be92b_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_226a2b5f-8364-4dfa-bf9e-a06be449d24e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_bd1db4f6-2028-4ab9-a03e-5e8ee1bc8cfd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of non-vested time-based RSU activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_68e1433a-0863-4d7a-8ba2-1894c43b6470_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED AND OTHER CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_35c11ecc-9761-41c4-81cf-f5df1c7d428b_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage_103082de-883c-4d73-9984-8fbf09b7c2ab_terseLabel_en-US" xlink:label="lab_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage for amortization of net actuarial gains and losses</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage_label_en-US" xlink:label="lab_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Actuarial Gain (Loss), Amortization Threshold Percentage</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage_documentation_en-US" xlink:label="lab_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Actuarial Gain (Loss), Amortization Threshold Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" xlink:href="bhc-20211231.xsd#bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" xlink:to="lab_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NovaliqGmbHMember_8a266d80-25a7-4efa-bc68-57021bc82515_terseLabel_en-US" xlink:label="lab_bhc_NovaliqGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novaliq GmbH</link:label>
    <link:label id="lab_bhc_NovaliqGmbHMember_label_en-US" xlink:label="lab_bhc_NovaliqGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novaliq GmbH [Member]</link:label>
    <link:label id="lab_bhc_NovaliqGmbHMember_documentation_en-US" xlink:label="lab_bhc_NovaliqGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novaliq GmbH [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NovaliqGmbHMember" xlink:href="bhc-20211231.xsd#bhc_NovaliqGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NovaliqGmbHMember" xlink:to="lab_bhc_NovaliqGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9f8492e2-aa92-4d2c-abb6-3ed2274d1f94_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate on debt (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5b7513e2-6801-45f0-8998-6f3605bb35d5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TaxYear2015AndTaxYear2016Member_db86c156-a3f6-4ffa-b8e3-79201ae1d848_terseLabel_en-US" xlink:label="lab_bhc_TaxYear2015AndTaxYear2016Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2015 and Tax Year 2016</link:label>
    <link:label id="lab_bhc_TaxYear2015AndTaxYear2016Member_label_en-US" xlink:label="lab_bhc_TaxYear2015AndTaxYear2016Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2015 And Tax Year 2016 [Member]</link:label>
    <link:label id="lab_bhc_TaxYear2015AndTaxYear2016Member_documentation_en-US" xlink:label="lab_bhc_TaxYear2015AndTaxYear2016Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2015 And Tax Year 2016</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxYear2015AndTaxYear2016Member" xlink:href="bhc-20211231.xsd#bhc_TaxYear2015AndTaxYear2016Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TaxYear2015AndTaxYear2016Member" xlink:to="lab_bhc_TaxYear2015AndTaxYear2016Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_82ea7fc0-4e4d-48a0-a7db-b6e91e12cbc6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9196a321-3e25-41db-8a31-5f5b37afcb57_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3adbe962-129c-48c0-99d9-059123f71466_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_9787f385-b954-4df5-b27e-a328bfc9782c_verboseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_29e2f724-3248-4de5-85a5-1f55132ea631_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_66f20bc7-60ff-40e6-9f87-b4cee60b6ed3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside basis differences</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Undistributed Foreign Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NumberOfOtherBusinessesAcquired_3f2c2bc9-0d27-4d9d-8868-d0b638063a5e_terseLabel_en-US" xlink:label="lab_bhc_NumberOfOtherBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other material business combinations</link:label>
    <link:label id="lab_bhc_NumberOfOtherBusinessesAcquired_label_en-US" xlink:label="lab_bhc_NumberOfOtherBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Other Businesses Acquired</link:label>
    <link:label id="lab_bhc_NumberOfOtherBusinessesAcquired_documentation_en-US" xlink:label="lab_bhc_NumberOfOtherBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Other Businesses Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NumberOfOtherBusinessesAcquired" xlink:href="bhc-20211231.xsd#bhc_NumberOfOtherBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NumberOfOtherBusinessesAcquired" xlink:to="lab_bhc_NumberOfOtherBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_19968bb5-96a9-489b-a644-979f6f64cf2a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherMachineryAndEquipmentMember_44b4a6d8-354d-4470-a564-f5f5f00fda94_terseLabel_en-US" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other equipment</link:label>
    <link:label id="lab_us-gaap_OtherMachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:to="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_df470c1f-b8af-476a-b2cf-22c2b2ce3cf3_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_53c4564f-3254-4a1f-bc22-3d5924db49ed_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of lease expenses</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_d8236518-67ab-4c4c-9c9f-e2a79d27cafc_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_e7162126-39da-4305-9811-c0b6059393d9_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternate term, principal amount maturity threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_label_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:to="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_7313f862-d68a-4eef-aebd-4b3b83577002_terseLabel_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product rebates</link:label>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_label_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Rebate Current</link:label>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_documentation_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the current portion of accrued product rebates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent" xlink:href="bhc-20211231.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedProductRebateCurrent" xlink:to="lab_bhc_AccruedProductRebateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_8cfbf12e-9c46-4e6e-a1e2-bcb573ce8c04_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest crediting rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_96351cad-aaf9-4372-863f-d0b2d1705498_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_5517ac9d-4685-4725-8da4-1c8c8eef266d_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_c529e5e0-7ae7-4901-b3b5-b6916749753f_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f26e0fd9-0d73-404d-97f8-1faf043fe663_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_country_RS_e7f451fc-9d75-46bc-8eba-3af5c8f542f8_terseLabel_en-US" xlink:label="lab_country_RS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Serbia</link:label>
    <link:label id="lab_country_RS_label_en-US" xlink:label="lab_country_RS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SERBIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_RS" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_RS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_RS" xlink:to="lab_country_RS" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_7c65a794-c3bd-4525-a0a8-d8a0898dd11a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ForeignCountryStateAndLocalMember_9ef08024-5b4d-45f8-8152-b8d37e374398_terseLabel_en-US" xlink:label="lab_bhc_ForeignCountryStateAndLocalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Federal and Provincial</link:label>
    <link:label id="lab_bhc_ForeignCountryStateAndLocalMember_label_en-US" xlink:label="lab_bhc_ForeignCountryStateAndLocalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Country State and Local [Member]</link:label>
    <link:label id="lab_bhc_ForeignCountryStateAndLocalMember_documentation_en-US" xlink:label="lab_bhc_ForeignCountryStateAndLocalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The designated tax department of state or local government of a foreign country entitled to levy and collect income taxes from the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ForeignCountryStateAndLocalMember" xlink:href="bhc-20211231.xsd#bhc_ForeignCountryStateAndLocalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ForeignCountryStateAndLocalMember" xlink:to="lab_bhc_ForeignCountryStateAndLocalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_RU_bbc56bf7-8f4a-480c-b46e-369df7880dd9_terseLabel_en-US" xlink:label="lab_country_RU" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Russia</link:label>
    <link:label id="lab_country_RU_label_en-US" xlink:label="lab_country_RU" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RUSSIAN FEDERATION</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_RU"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_RU" xlink:to="lab_country_RU" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_ce3108c4-72c9-463a-b021-b5ea82e8c4e1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_db4ca270-ddf9-4e15-a4d8-7b81c5bb6e1e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign tax rate differences</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorUnsecuredNotesDue2023Member_372fa2c5-3fd2-4a0c-8eb0-1e9c8602e8da_terseLabel_en-US" xlink:label="lab_bhc_SeniorUnsecuredNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes due 2023</link:label>
    <link:label id="lab_bhc_SeniorUnsecuredNotesDue2023Member_label_en-US" xlink:label="lab_bhc_SeniorUnsecuredNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2023 [Member]</link:label>
    <link:label id="lab_bhc_SeniorUnsecuredNotesDue2023Member_documentation_en-US" xlink:label="lab_bhc_SeniorUnsecuredNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorUnsecuredNotesDue2023Member" xlink:href="bhc-20211231.xsd#bhc_SeniorUnsecuredNotesDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorUnsecuredNotesDue2023Member" xlink:to="lab_bhc_SeniorUnsecuredNotesDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a2ed113-a42d-458c-be06-f1dcfa0ee7a4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8760108a-ec99-460c-9d5a-948dff165508_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_fe94bb8e-a0c0-40fd-aafd-d882373ae504_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) recognized in interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3b629330-56c7-4c23-89a7-c807d2a4f201_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_f1e33332-a84e-46e2-a538-f5067a09f124_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration, separation and IPO costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_0b0d820c-6bfc-44c8-94a5-4a8617f01952_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NoncashCumulativeForeignCurrencyTranslationLoss_4d0c3ba6-df6c-4f43-b3b3-3fa1973e48ba_terseLabel_en-US" xlink:label="lab_bhc_NoncashCumulativeForeignCurrencyTranslationLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash cumulative foreign currency translation loss</link:label>
    <link:label id="lab_bhc_NoncashCumulativeForeignCurrencyTranslationLoss_label_en-US" xlink:label="lab_bhc_NoncashCumulativeForeignCurrencyTranslationLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Cumulative Foreign Currency Translation Loss</link:label>
    <link:label id="lab_bhc_NoncashCumulativeForeignCurrencyTranslationLoss_documentation_en-US" xlink:label="lab_bhc_NoncashCumulativeForeignCurrencyTranslationLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Cumulative Foreign Currency Translation Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NoncashCumulativeForeignCurrencyTranslationLoss" xlink:href="bhc-20211231.xsd#bhc_NoncashCumulativeForeignCurrencyTranslationLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NoncashCumulativeForeignCurrencyTranslationLoss" xlink:to="lab_bhc_NoncashCumulativeForeignCurrencyTranslationLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6a414cec-7753-46a0-a70b-e6559b7f1c32_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TaxYear2005ThroughTaxYear2009Member_4a00c45a-7380-4f19-aa1c-22b72ff292f6_terseLabel_en-US" xlink:label="lab_bhc_TaxYear2005ThroughTaxYear2009Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2005 through Tax Year 2009</link:label>
    <link:label id="lab_bhc_TaxYear2005ThroughTaxYear2009Member_label_en-US" xlink:label="lab_bhc_TaxYear2005ThroughTaxYear2009Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2005 Through Tax Year 2009 [Member]</link:label>
    <link:label id="lab_bhc_TaxYear2005ThroughTaxYear2009Member_documentation_en-US" xlink:label="lab_bhc_TaxYear2005ThroughTaxYear2009Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2005 Through Tax Year 2009</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxYear2005ThroughTaxYear2009Member" xlink:href="bhc-20211231.xsd#bhc_TaxYear2005ThroughTaxYear2009Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TaxYear2005ThroughTaxYear2009Member" xlink:to="lab_bhc_TaxYear2005ThroughTaxYear2009Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_d1a48e32-2bd4-454e-81d0-2102937850d4_terseLabel_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion for the time value of money</link:label>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_label_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion For Time Value Of Money [Member]</link:label>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_documentation_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion For Time Value Of Money [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember" xlink:href="bhc-20211231.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccretionForTimeValueOfMoneyMember" xlink:to="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_117db560-c4fe-4585-ae4c-4c8a4d416b2b_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ireland</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_97018a71-edb5-4a12-8c31-4b1acdf42f9b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_9e720f5e-c2b3-438e-9137-715139420380_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes Due April 2025</link:label>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_label_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.125%, Due April 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes due April 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes6125DueApril2025Member" xlink:to="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_f087be5e-5fa9-45d5-aeff-428747a54050_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Acquisition-Related Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5c3db4af-6ce1-48a9-b594-6bf0ed7e676d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_3f42c0cb-abfe-4cbd-a5a7-5145491b75d1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_d79efed9-822b-4210-88d1-bf01b8ac2fbe_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_8bf025e4-3a92-40a3-8a1e-415af5d72322_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_a11ccf00-4e84-4c0a-9210-53dbd0bd1138_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held-for-sale, Long Lived, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:to="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition_39f242c5-f69b-4810-9053-86629ae21e37_negatedTerseLabel_en-US" xlink:label="lab_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization or settlement recognition of net loss</link:label>
    <link:label id="lab_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition_label_en-US" xlink:label="lab_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Amortization or Settlement Recognition</link:label>
    <link:label id="lab_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition_documentation_en-US" xlink:label="lab_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Amortization or Settlement Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" xlink:href="bhc-20211231.xsd#bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" xlink:to="lab_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_900c9e40-947b-44f1-b464-b41067f4abc4_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_2b6e87e6-3d05-4190-976b-fe02386483d0_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_1077db84-10c9-4cf5-a5d3-8b28b1e56dcf_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of intangible assets and other assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_d6f521d2-6db6-4510-89b7-b60bc3047e75_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_3bc7e592-5ad1-4b6b-bdc1-46244663cf6d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_7afcedec-068f-4dd7-89c0-780e55179323_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent_51eaa71a-b7aa-47b7-a51f-70d4d571e8af_terseLabel_en-US" xlink:label="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Current</link:label>
    <link:label id="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent_documentation_en-US" xlink:label="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent" xlink:href="bhc-20211231.xsd#bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent" xlink:to="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FixedIncomeSecuritiesMember_8a421a63-430b-41bb-874e-907c3ee52c2b_terseLabel_en-US" xlink:label="lab_us-gaap_FixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed income securities</link:label>
    <link:label id="lab_us-gaap_FixedIncomeSecuritiesMember_3d51a320-c129-40dd-ad90-b57d32ce124a_verboseLabel_en-US" xlink:label="lab_us-gaap_FixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed income securities:</link:label>
    <link:label id="lab_us-gaap_FixedIncomeSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_FixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FixedIncomeSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember" xlink:to="lab_us-gaap_FixedIncomeSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a27846ac-b775-41dd-95c6-abacd76737f0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndDebtExpense_628736aa-c692-4437-9af1-4d4f6457f47a_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestAndDebtExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestAndDebtExpense_label_en-US" xlink:label="lab_us-gaap_InterestAndDebtExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Debt Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDebtExpense" xlink:to="lab_us-gaap_InterestAndDebtExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_955bdfc2-bc69-47c0-bf37-f081979d330a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_3c966161-0e5a-4372-9d95-de26a75d4a66_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BauschLombInternationalMember_b0b05a51-d3cf-4639-948f-59e6af444750_terseLabel_en-US" xlink:label="lab_bhc_BauschLombInternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb/ International</link:label>
    <link:label id="lab_bhc_BauschLombInternationalMember_label_en-US" xlink:label="lab_bhc_BauschLombInternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch Lomb/International [Member]</link:label>
    <link:label id="lab_bhc_BauschLombInternationalMember_documentation_en-US" xlink:label="lab_bhc_BauschLombInternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch Lomb/International [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombInternationalMember" xlink:href="bhc-20211231.xsd#bhc_BauschLombInternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BauschLombInternationalMember" xlink:to="lab_bhc_BauschLombInternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_b2bab8c0-dde4-478f-9aaf-8cfcced1492e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_f8a28547-9493-446f-82e0-59bfe85a1253_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ProductBrandsMember_d26bebad-0e1b-4c58-ab21-0f02d46d9238_verboseLabel_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product brands</link:label>
    <link:label id="lab_bhc_ProductBrandsMember_688da6cf-5002-4977-a05f-7db33f142736_terseLabel_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product brands</link:label>
    <link:label id="lab_bhc_ProductBrandsMember_label_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Brands [Member]</link:label>
    <link:label id="lab_bhc_ProductBrandsMember_documentation_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the rights to non-patented product brands.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember" xlink:href="bhc-20211231.xsd#bhc_ProductBrandsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ProductBrandsMember" xlink:to="lab_bhc_ProductBrandsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_a12cf55e-5a25-4146-b0d0-8f63585133b6_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_53b6a459-e0ba-401d-ac1a-4e1631206dd6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_5c7e1c68-c02c-404d-baff-b6573a99e158_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held For Sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_638b3f8c-b252-4b2d-9809-72e7276570d3_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of entities, exercised opt-out right, pursuing action</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_label_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_documentation_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:href="bhc-20211231.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:to="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_35a63a86-959a-4812-b611-7629f6819908_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_81446695-865a-40c8-beec-1e25127f8076_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember_9584e564-9429-4f8f-b5be-2fc6c6e8f977_terseLabel_en-US" xlink:label="lab_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pooled Scientific Research and Experimental Development</link:label>
    <link:label id="lab_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember_label_en-US" xlink:label="lab_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pooled Scientific Research and Experimental Development Expenditures [Member]</link:label>
    <link:label id="lab_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember_documentation_en-US" xlink:label="lab_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the details pertaining to pooled scientific research and experimental development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:href="bhc-20211231.xsd#bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:to="lab_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_7e63095d-9228-4bb2-8a0d-aa1b1b9d59d3_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental credit facility borrowings</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Threshold For Incremental Borrowings</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Threshold For Incremental Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:href="bhc-20211231.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:to="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CanadaBankersAcceptanceRateMember_cc192eb3-3032-46f4-ae18-edab64c626fe_terseLabel_en-US" xlink:label="lab_bhc_CanadaBankersAcceptanceRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Bankers Acceptance Rate</link:label>
    <link:label id="lab_bhc_CanadaBankersAcceptanceRateMember_label_en-US" xlink:label="lab_bhc_CanadaBankersAcceptanceRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Bankers Acceptance Rate [Member]</link:label>
    <link:label id="lab_bhc_CanadaBankersAcceptanceRateMember_documentation_en-US" xlink:label="lab_bhc_CanadaBankersAcceptanceRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Bankers Acceptance Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadaBankersAcceptanceRateMember" xlink:href="bhc-20211231.xsd#bhc_CanadaBankersAcceptanceRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CanadaBankersAcceptanceRateMember" xlink:to="lab_bhc_CanadaBankersAcceptanceRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_3747582a-fb43-4c37-983e-ea3b4395c7a4_verboseLabel_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out-licensed technology and other</link:label>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_542fa974-e471-45c2-8541-5bc492fcc844_terseLabel_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology and other</link:label>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_label_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out Licensed Technology [Member]</link:label>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_documentation_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the rights to receive cash flows under an out-license arrangement (for example, license fees, milestone payments and royalties).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember" xlink:href="bhc-20211231.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OutLicensedTechnologyMember" xlink:to="lab_bhc_OutLicensedTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_e2c9d5f2-367e-4ae7-af99-bd543e3ff935_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated aggregate amortization expense for each of the five succeeding years</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_6b72a285-7812-4574-a41f-32b6b69415dd_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_98cb052d-b8b5-4dc9-9cfa-8e787611257b_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_99e83949-ac10-4aec-a9cd-b9f921527e36_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_7f4c9945-3977-4eb7-ba7d-7a00fb6a50e0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_de58c729-b699-4305-b5b1-aa17374c3c9c_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_a1f102b7-eba3-42cb-b917-1e0b125f35f1_periodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_59c19860-18e9-4832-b708-67ed17512f21_periodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_ea5b8696-09f9-4049-8ec0-b0490ed87dc3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of foreign currency translation losses upon disposal of assets held for sale</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_6d92f0b2-fd33-4ef1-b89b-624c9cfb837c_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B&amp;L Trademark</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_f3b0e07e-b13f-4ac0-a14a-0205130fc54c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected benefit from income taxes at Canadian statutory rate</link:label>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_d752b673-7c1b-47ef-a9bb-bef54ea5fc07_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_570f24e6-bdfa-454e-aa11-6cbda3987c78_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_8b55f866-2e29-4abd-94a7-09cd82d8b34d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of foreign exchange contracts on the Consolidated Statements of Operations and Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments Included in Trading Activities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70ff56fc-3c17-40b1-adea-1b5eb2b239cb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6f4e912c-c5c0-4553-8d5a-aec47b53b380_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_4ab01a54-a137-4eec-b06d-6753208a067b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_8ddc6410-2251-417c-9f94-2f07b27c97f3_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total leverage ratio (not greater than)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Total Leverage Ratio, Maximum</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Total Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:to="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BaseRateOrPrimeRateMember_a0caf713-71f8-4ead-9f42-68a8906b3c43_terseLabel_en-US" xlink:label="lab_bhc_BaseRateOrPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate or Prime Rate</link:label>
    <link:label id="lab_bhc_BaseRateOrPrimeRateMember_label_en-US" xlink:label="lab_bhc_BaseRateOrPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate Or Prime Rate [Member]</link:label>
    <link:label id="lab_bhc_BaseRateOrPrimeRateMember_documentation_en-US" xlink:label="lab_bhc_BaseRateOrPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate Or Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateOrPrimeRateMember" xlink:href="bhc-20211231.xsd#bhc_BaseRateOrPrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BaseRateOrPrimeRateMember" xlink:to="lab_bhc_BaseRateOrPrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TradeReceivableNetPortionPastDue_ded44049-597d-4bb9-8318-dd774eec7629_terseLabel_en-US" xlink:label="lab_bhc_TradeReceivableNetPortionPastDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of net trade receivables that is past due</link:label>
    <link:label id="lab_bhc_TradeReceivableNetPortionPastDue_label_en-US" xlink:label="lab_bhc_TradeReceivableNetPortionPastDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Receivable, Net, Portion Past Due</link:label>
    <link:label id="lab_bhc_TradeReceivableNetPortionPastDue_documentation_en-US" xlink:label="lab_bhc_TradeReceivableNetPortionPastDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Receivable, Net, Portion Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TradeReceivableNetPortionPastDue" xlink:href="bhc-20211231.xsd#bhc_TradeReceivableNetPortionPastDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TradeReceivableNetPortionPastDue" xlink:to="lab_bhc_TradeReceivableNetPortionPastDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_9e15e349-7571-4d0d-aadc-7fea9dd8d956_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_eaa6cba0-31bd-41c8-88c7-e634688e85d1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_93cdab42-ed84-42b9-a71a-e8e067cc5b1d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of possible loss, income tax examination (up to)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:to="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5da393fe-54a0-4c3f-a76f-1db07d961ef2_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_15efc212-afe0-4b8a-a7ed-f40812b2a49f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant-Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e7597b01-0638-4009-aed2-a2c8324a058f_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets, beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_d1032cfe-31ec-45ba-a709-55c0cea28fca_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets, end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_85246858-9fee-40fd-96b8-9ac4f4719055_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_95ea6fad-0030-41dc-abfd-c740b04cf633_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_0ab98326-1773-4ee5-9564-1e54129539af_terseLabel_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Costs</link:label>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:to="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevenuePerformanceObligationPaymentTerms_56b4905d-9480-4082-b159-a4402bf23c95_terseLabel_en-US" xlink:label="lab_bhc_RevenuePerformanceObligationPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment terms</link:label>
    <link:label id="lab_bhc_RevenuePerformanceObligationPaymentTerms_label_en-US" xlink:label="lab_bhc_RevenuePerformanceObligationPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Payment Terms</link:label>
    <link:label id="lab_bhc_RevenuePerformanceObligationPaymentTerms_documentation_en-US" xlink:label="lab_bhc_RevenuePerformanceObligationPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuePerformanceObligationPaymentTerms" xlink:href="bhc-20211231.xsd#bhc_RevenuePerformanceObligationPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevenuePerformanceObligationPaymentTerms" xlink:to="lab_bhc_RevenuePerformanceObligationPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_7769d046-c1dd-4f81-a3b2-48f0aef465b4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Debt Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDebtSecuritiesMember" xlink:to="lab_us-gaap_OtherDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_2b2883ff-bc92-4622-8dd0-dc9855b240f4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated company contributions in next fiscal year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_6139654d-0ad1-447c-8a0d-abdaaec4d6cf_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_81494c85-9baf-40a4-a133-c4b2ef4beb50_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredTaxAssetsPrepaidExpenses_041b7a87-ef34-4c90-a41a-0623258d0b0b_terseLabel_en-US" xlink:label="lab_bhc_DeferredTaxAssetsPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsPrepaidExpenses_label_en-US" xlink:label="lab_bhc_DeferredTaxAssetsPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Prepaid Expenses</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsPrepaidExpenses_documentation_en-US" xlink:label="lab_bhc_DeferredTaxAssetsPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsPrepaidExpenses" xlink:href="bhc-20211231.xsd#bhc_DeferredTaxAssetsPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredTaxAssetsPrepaidExpenses" xlink:to="lab_bhc_DeferredTaxAssetsPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_443b5c74-c015-4fca-8d03-526113688690_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable at the end of the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CardinalHealthIncMember_437d281e-198e-47fc-915a-00c6acbb2809_terseLabel_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health,&#160;Inc.</link:label>
    <link:label id="lab_bhc_CardinalHealthIncMember_label_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health Inc [Member]</link:label>
    <link:label id="lab_bhc_CardinalHealthIncMember_documentation_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, Cardinal Health, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember" xlink:href="bhc-20211231.xsd#bhc_CardinalHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CardinalHealthIncMember" xlink:to="lab_bhc_CardinalHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_3192fcd7-8527-4ffc-aae9-9c923934e61b_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_a3f3001f-63d9-42a8-b96c-f2415be6e439_terseLabel_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines</link:label>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_label_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines [Member]</link:label>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_documentation_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember" xlink:href="bhc-20211231.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DiscontinuedProductLinesMember" xlink:to="lab_bhc_DiscontinuedProductLinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_9f795b50-4124-41d1-9492-4e8437acf3e4_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent_664c3988-d5ce-47d1-8780-90892321dc6f_terseLabel_en-US" xlink:label="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent_label_en-US" xlink:label="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Noncurrent</link:label>
    <link:label id="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent_documentation_en-US" xlink:label="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent" xlink:href="bhc-20211231.xsd#bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent" xlink:to="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns_9737cb45-5fba-48dd-a5a1-42dbbac0a0b1_terseLabel_en-US" xlink:label="lab_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of subsidiaries file federal income tax returns in Canada, U.S., and other foreign jurisdictions (or more)</link:label>
    <link:label id="lab_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns_label_en-US" xlink:label="lab_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Number Of Subsidiaries File Federal Income Tax Returns</link:label>
    <link:label id="lab_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns_documentation_en-US" xlink:label="lab_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Number Of Subsidiaries File Federal Income Tax Returns</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" xlink:href="bhc-20211231.xsd#bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" xlink:to="lab_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_e8e32e9e-af26-4723-acf6-06060bbbddbc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0f37a215-5add-490a-861e-294e2fa96789_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_ecf5865a-ad26-467a-8166-83a80188644d_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_c5805e24-ae6b-45aa-a245-8e2847771bec_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_1eb56ec5-a104-439d-b74d-bfdfb48c8519_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_81b47174-0461-40a7-998c-80baca580f03_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OrthoDermatologicsSegmentMember_abe50c89-9501-4958-9d3a-973cb6ff8f6e_terseLabel_en-US" xlink:label="lab_bhc_OrthoDermatologicsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsSegmentMember_ced7fe5f-5042-47cc-b7af-8e0e4bb66221_verboseLabel_en-US" xlink:label="lab_bhc_OrthoDermatologicsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsSegmentMember_label_en-US" xlink:label="lab_bhc_OrthoDermatologicsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Segment [Member]</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsSegmentMember_documentation_en-US" xlink:label="lab_bhc_OrthoDermatologicsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember" xlink:href="bhc-20211231.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OrthoDermatologicsSegmentMember" xlink:to="lab_bhc_OrthoDermatologicsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_49178af4-fc1a-4641-b6d4-2e772ff2228c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of non-vested performance-based RSU activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Performance-based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_a8af43c7-41c5-42a2-a17d-bd5913d9ab9b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bef1ada7-a2d5-45e2-a816-f6fe3319820a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_fff66bf5-fc15-407b-a6ac-16fd44e52891_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5e8156ba-7dfa-42a7-8d8c-10ba6d583027_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted-average common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_9f1819de-2baf-4fbb-a9f6-e2c363268f2d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_a03f54d4-3c79-457a-8dd7-1b8f3f415189_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_895ec84e-573e-4c86-81b1-db97eaaf4436_terseLabel_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_label_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation [Member]</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_documentation_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Class Actions Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember" xlink:href="bhc-20211231.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GlumetzaAntitrustLitigationMember" xlink:to="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_f9bce334-d812-428b-b1fa-05770f8f5f7e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_3b8801c4-de78-4270-a5f6-331f59dfc0e3_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_23ba5908-33ee-4e57-b390-d269c6240413_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_41b5b62a-7a98-40e5-afae-c1122081c923_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_92557cd7-ca92-45ae-a720-7732f0db8e54_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeparationAndInitialPublicOfferingCostsMember_60f4fb02-9bb6-4a0c-bb4f-2734e2fe3cf3_terseLabel_en-US" xlink:label="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation and IPO Costs</link:label>
    <link:label id="lab_bhc_SeparationAndInitialPublicOfferingCostsMember_label_en-US" xlink:label="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation And Initial Public Offering Costs [Member]</link:label>
    <link:label id="lab_bhc_SeparationAndInitialPublicOfferingCostsMember_documentation_en-US" xlink:label="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation And Initial Public Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:href="bhc-20211231.xsd#bhc_SeparationAndInitialPublicOfferingCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:to="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_8bc1b2d3-e002-4b90-9286-3c910bc08f1b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DivestituresOfNoncoreProductsPolicyTextBlock_e5dbd0f2-c3c2-48cc-afb1-3525e099e72c_terseLabel_en-US" xlink:label="lab_bhc_DivestituresOfNoncoreProductsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures of Products</link:label>
    <link:label id="lab_bhc_DivestituresOfNoncoreProductsPolicyTextBlock_label_en-US" xlink:label="lab_bhc_DivestituresOfNoncoreProductsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures Of Non-core Products [Policy Text Block]</link:label>
    <link:label id="lab_bhc_DivestituresOfNoncoreProductsPolicyTextBlock_documentation_en-US" xlink:label="lab_bhc_DivestituresOfNoncoreProductsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures of Non-core Products [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DivestituresOfNoncoreProductsPolicyTextBlock" xlink:href="bhc-20211231.xsd#bhc_DivestituresOfNoncoreProductsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DivestituresOfNoncoreProductsPolicyTextBlock" xlink:to="lab_bhc_DivestituresOfNoncoreProductsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_feec8df7-a9a6-40c8-9049-78cbe7ca27e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_f63c4ede-24e9-4cc0-b61e-d7b78781daf7_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_f3bbb5ed-a2b2-4fad-80da-1973c3ec0334_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_f7fa18d3-98be-4953-9c7c-912f21d5d2e8_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8899be34-9391-4f21-8de3-20bebb9f9da6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ecfa925e-53bb-496f-a16b-b71be40192cd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_42abf494-2830-498a-b6aa-cb5bf1575425_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f8078906-54fb-4dbb-94c7-6a7eab08f0ea_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts_2ca4b511-30a6-4dde-bc11-c0b0ab020f7f_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Losses, Policy for Uncollectible Amounts [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" xlink:to="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CanadaRevenueAgencyMember_0c421268-4fff-4540-bdc0-e116dfbc3733_terseLabel_en-US" xlink:label="lab_us-gaap_CanadaRevenueAgencyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Revenue Agency</link:label>
    <link:label id="lab_us-gaap_CanadaRevenueAgencyMember_label_en-US" xlink:label="lab_us-gaap_CanadaRevenueAgencyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Revenue Agency [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CanadaRevenueAgencyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CanadaRevenueAgencyMember" xlink:to="lab_us-gaap_CanadaRevenueAgencyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_74c8c6e0-c1ca-4176-9122-84ce5a390fd2_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c221cc3c-673c-48ac-81c2-ba66c9cc721a_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock option life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7e298d46-bdbe-428d-b8ee-947f3ccab50f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_c5297251-23a9-40be-95e7-178172512ca0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ec7d7123-2a8d-439d-bf83-dac9f52238ab_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of employee withholding taxes related to share-based awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_c2af2587-32bf-4753-8761-cb6f61fec3cd_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.500% Senior Notes Due November 2025</link:label>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_label_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.50% Notes Due November 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.50% Notes Due November 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:href="bhc-20211231.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:to="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_f0707b62-b174-4bc5-880e-08bb9ec72ce5_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_b3bf25d6-4595-4a73-a09f-fc09671809c9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8d7ff450-5ea3-42c2-bfb4-45d51dddfd66_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at the end of the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_9c111d99-8caa-42b5-a5da-08e7a4beba4a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of underfunded plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_10a56f8c-986a-446a-b28b-5bbcca274c45_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_6ccfcc9f-0c21-4858-b1ca-705b6373a448_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember_33b9a445-245d-44fc-88cc-fff533364973_terseLabel_en-US" xlink:label="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSN Laboratories Private Ltd. Litigation</link:label>
    <link:label id="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember_label_en-US" xlink:label="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSN Laboratories Private Ltd. Litigation [Member]</link:label>
    <link:label id="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember_documentation_en-US" xlink:label="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSN Laboratories Private Ltd. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:href="bhc-20211231.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:to="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_94a1ce25-b2cd-422a-8565-e6852a954c7e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA-QC_af223b67-4d0e-44b5-a958-2309f4d6a0a8_terseLabel_en-US" xlink:label="lab_stpr_CA-QC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quebec</link:label>
    <link:label id="lab_stpr_CA-QC_label_en-US" xlink:label="lab_stpr_CA-QC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QUEBEC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-QC" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA-QC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA-QC" xlink:to="lab_stpr_CA-QC" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_8b0374a8-0a59-41c0-8e41-7194bff459cd_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e5b758f8-045c-45b4-a083-152e1efb056d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption of New Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_70e828ab-35ee-47a9-b121-cb857acaaf67_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_3b2fc57c-cb00-45da-bf52-4564d39f05d8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_6efc1cfd-70e9-4d48-ad4b-3000f28c7177_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Method and assumptions on valuation of stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MitsubishiTanabePharmaCorporationMember_c6213ca6-8f9d-48e0-bbc1-d06526958485_terseLabel_en-US" xlink:label="lab_bhc_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation</link:label>
    <link:label id="lab_bhc_MitsubishiTanabePharmaCorporationMember_label_en-US" xlink:label="lab_bhc_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation [Member]</link:label>
    <link:label id="lab_bhc_MitsubishiTanabePharmaCorporationMember_documentation_en-US" xlink:label="lab_bhc_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MitsubishiTanabePharmaCorporationMember" xlink:href="bhc-20211231.xsd#bhc_MitsubishiTanabePharmaCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MitsubishiTanabePharmaCorporationMember" xlink:to="lab_bhc_MitsubishiTanabePharmaCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_447375c5-4902-44b7-8ac5-fd9f0bad1ab9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining unrecognized compensation expense related to non-vested awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_0ea1da6b-f408-49e5-8f5d-3306ad5747af_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_d2358a2e-6cee-4bcf-ab01-7c18000a13c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of amounts recognized in accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_dd7f522b-756b-48d8-b07c-cc8eed762962_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent suits filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_7a13c397-834e-4ba2-a2ee-acc80af54718_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PastDuePeriodForAccountsReceivableToBeNegligible_63f219c1-7ee8-413e-afd7-81fd3bfd8abc_terseLabel_en-US" xlink:label="lab_bhc_PastDuePeriodForAccountsReceivableToBeNegligible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past due period for receivables to be negligible (less than)</link:label>
    <link:label id="lab_bhc_PastDuePeriodForAccountsReceivableToBeNegligible_label_en-US" xlink:label="lab_bhc_PastDuePeriodForAccountsReceivableToBeNegligible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past Due Period for Accounts Receivable to be Negligible</link:label>
    <link:label id="lab_bhc_PastDuePeriodForAccountsReceivableToBeNegligible_documentation_en-US" xlink:label="lab_bhc_PastDuePeriodForAccountsReceivableToBeNegligible" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the past due period for which accounts receivables are negligible.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PastDuePeriodForAccountsReceivableToBeNegligible" xlink:href="bhc-20211231.xsd#bhc_PastDuePeriodForAccountsReceivableToBeNegligible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PastDuePeriodForAccountsReceivableToBeNegligible" xlink:to="lab_bhc_PastDuePeriodForAccountsReceivableToBeNegligible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_546de826-f3bb-4fdc-b0c8-5b3913d739db_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_314f1fe5-1b74-4a1c-98f1-e186ea44ac2d_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_c120830a-0d7c-4ef1-9d95-9ffbba9ec4c2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss related to settlements</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_edbb09c4-58e2-40c9-8cf6-fc968eab4ef5_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_73950ba0-8052-4be6-9b0d-17a3c9d37d5a_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_75f2cde9-1166-4b20-88d9-cd77a3dd6dba_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_6b5eb785-c92e-412b-ad6d-8a0aa006129a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_3f634894-e322-4fcf-a4d5-fc7633c89973_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_6fcae0a7-1aad-49c1-9e69-756117a32a71_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes_d11b99ed-57e6-48cd-a93f-9c97b3d38773_verboseLabel_en-US" xlink:label="lab_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plant, equipment and technology</link:label>
    <link:label id="lab_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes_label_en-US" xlink:label="lab_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Basis Difference of Convertible Notes</link:label>
    <link:label id="lab_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes_documentation_en-US" xlink:label="lab_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the deferred tax liability recognized for the original basis difference between the principal amount of the Convertible Notes and value allocated to the liability component, which resulted in a corresponding reduction to the valuation allowance recorded against deferred tax assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" xlink:href="bhc-20211231.xsd#bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" xlink:to="lab_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OpenTaxYear_ca79bac5-3ced-4b35-844b-c6241aa4fddf_terseLabel_en-US" xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Years</link:label>
    <link:label id="lab_us-gaap_OpenTaxYear_label_en-US" xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OpenTaxYear" xlink:to="lab_us-gaap_OpenTaxYear" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A5.875SeniorNotesdueMay2023Member_1e1e73f7-e206-44dd-8390-90c5a265a6de_terseLabel_en-US" xlink:label="lab_bhc_A5.875SeniorNotesdueMay2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Unsecured Notes due May 2023</link:label>
    <link:label id="lab_bhc_A5.875SeniorNotesdueMay2023Member_label_en-US" xlink:label="lab_bhc_A5.875SeniorNotesdueMay2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Notes due May 2023 [Member]</link:label>
    <link:label id="lab_bhc_A5.875SeniorNotesdueMay2023Member_documentation_en-US" xlink:label="lab_bhc_A5.875SeniorNotesdueMay2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Notes due May 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.875SeniorNotesdueMay2023Member" xlink:href="bhc-20211231.xsd#bhc_A5.875SeniorNotesdueMay2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A5.875SeniorNotesdueMay2023Member" xlink:to="lab_bhc_A5.875SeniorNotesdueMay2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_3a8e86e3-d59c-48c6-baa7-60c478241647_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_8366ac3c-b36d-4345-b2de-7f525b8859bd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of changes in the carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a6152fea-cf2e-4f08-ac86-5cbbb5e13ac3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_0824a8b6-d894-4a0b-8197-2e3eb8642b21_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Net Cash Proceeds from Asset Sales Outside Ordinary Course of Business Payable as Mandatory Prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:href="bhc-20211231.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_da0fa51a-619b-4e88-95bc-640d9ce64612_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PeriodReceivableOutstanding_e0422e35-bd89-415a-955c-d328245f1ec9_terseLabel_en-US" xlink:label="lab_bhc_PeriodReceivableOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period net trade receivable balance outstanding (more than)</link:label>
    <link:label id="lab_bhc_PeriodReceivableOutstanding_label_en-US" xlink:label="lab_bhc_PeriodReceivableOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Receivable Outstanding</link:label>
    <link:label id="lab_bhc_PeriodReceivableOutstanding_documentation_en-US" xlink:label="lab_bhc_PeriodReceivableOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The period of time the accounts receivable has been outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PeriodReceivableOutstanding" xlink:href="bhc-20211231.xsd#bhc_PeriodReceivableOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PeriodReceivableOutstanding" xlink:to="lab_bhc_PeriodReceivableOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_8bd2874e-f3b0-4b0c-8e35-36c941ec9755_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assets and liabilities associated with derivatives, included in the Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_ae746a81-60ff-43b4-8f00-3b40720c0286_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PadagisLitigationMember_ebdf649a-3994-4f58-a535-7de42e0a2a72_terseLabel_en-US" xlink:label="lab_bhc_PadagisLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Padagis Litigation</link:label>
    <link:label id="lab_bhc_PadagisLitigationMember_label_en-US" xlink:label="lab_bhc_PadagisLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Padagis Litigation [Member]</link:label>
    <link:label id="lab_bhc_PadagisLitigationMember_documentation_en-US" xlink:label="lab_bhc_PadagisLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Padagis Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PadagisLitigationMember" xlink:href="bhc-20211231.xsd#bhc_PadagisLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PadagisLitigationMember" xlink:to="lab_bhc_PadagisLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_fc1fad7e-19e7-42f8-994e-88872044d3b5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_0f8a090e-73ce-49b3-a814-543ad93d6cba_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension adjustment, net of tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevenuesNetMember_9040d1ab-074e-4c4e-9c59-0a6124b03c46_terseLabel_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_bhc_RevenuesNetMember_label_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Net [Member]</link:label>
    <link:label id="lab_bhc_RevenuesNetMember_documentation_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate net revenues during the period in the normal course of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember" xlink:href="bhc-20211231.xsd#bhc_RevenuesNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevenuesNetMember" xlink:to="lab_bhc_RevenuesNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_757ce1f4-c5f4-480b-81c4-69cf79183654_terseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 and November 2025</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 And November 2025 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 And November 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:href="bhc-20211231.xsd#bhc_TermLoanBFacilityDueJune2025AndNovember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:to="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_99823210-b2df-4d86-bc8d-da2179a550c8_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_3724ceb5-4ead-4c89-b863-b98a39edd6c7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AustralianTaxationOfficeMember_c22a5220-7dd5-4406-82fe-6bba8710112b_verboseLabel_en-US" xlink:label="lab_us-gaap_AustralianTaxationOfficeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australian Taxation Office</link:label>
    <link:label id="lab_us-gaap_AustralianTaxationOfficeMember_a3ae6961-d9ca-420c-8600-cc4dd9abbfc0_terseLabel_en-US" xlink:label="lab_us-gaap_AustralianTaxationOfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia</link:label>
    <link:label id="lab_us-gaap_AustralianTaxationOfficeMember_label_en-US" xlink:label="lab_us-gaap_AustralianTaxationOfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australian Taxation Office [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AustralianTaxationOfficeMember" xlink:to="lab_us-gaap_AustralianTaxationOfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_1fca48ef-d81b-44d3-b1ee-fef1d05a13e7_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits_0a570bef-85b5-4743-aba9-12beadf037e7_terseLabel_en-US" xlink:label="lab_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unclaimed investment tax credits and research and development credits</link:label>
    <link:label id="lab_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits_label_en-US" xlink:label="lab_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unclaimed Tax Credits and Research and Development Credits</link:label>
    <link:label id="lab_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits_documentation_en-US" xlink:label="lab_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of unclaimed tax credits and research and development credits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" xlink:href="bhc-20211231.xsd#bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" xlink:to="lab_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes_e0c5c6e6-0893-411c-8d4e-026479bdab8e_terseLabel_en-US" xlink:label="lab_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged to Benefit from income taxes</link:label>
    <link:label id="lab_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes_label_en-US" xlink:label="lab_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Benefit From Income Taxes</link:label>
    <link:label id="lab_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes_documentation_en-US" xlink:label="lab_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Benefit From Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" xlink:href="bhc-20211231.xsd#bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" xlink:to="lab_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_ff0b860c-b91d-4a4d-b2df-c9a3f35ac98b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_32f246fb-7c3e-48eb-a6b4-f692fd31003d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Canadian statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_933c7db9-84ff-4fbd-b5cc-1741e3a8517f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_71d48ad0-53db-463a-aacb-4d0ba9cffd27_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Share Attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_735e9748-57a3-45eb-b240-6efcbee2ae37_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c02dcf9b-0c2f-4c1c-be50-7ee871d3442e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_69fe17e0-0b76-4968-b9ea-f948dc484f94_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_180c84cd-44b7-45d9-9955-306d8b385eae_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_b648b093-6be1-4d43-84c7-0bf594a3ef5a_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_fb9f8c12-a6c9-4be2-8601-f05a018ed3c1_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Plans, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:to="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_5fd06961-ea28-41ff-8b34-b5377e446ec5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ea0c678c-d3ce-47a0-b721-ba395bf8101c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_df51ad01-d000-4019-80d2-8ccb592cb889_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization and Impairments</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_b386ecd9-ed35-4230-8585-43d42a5873ec_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes5.625PercentDueDecember2021Member_b4462a2e-1559-4d7d-b9d6-dc33f1e67f6d_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes5.625PercentDueDecember2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.625 % Senior Unsecured Notes due December 2021</link:label>
    <link:label id="lab_bhc_SeniorNotes5.625PercentDueDecember2021Member_label_en-US" xlink:label="lab_bhc_SeniorNotes5.625PercentDueDecember2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 5.625 Percent Due December 2021 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes5.625PercentDueDecember2021Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes5.625PercentDueDecember2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 5.625 Percent Due December 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes5.625PercentDueDecember2021Member" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes5.625PercentDueDecember2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes5.625PercentDueDecember2021Member" xlink:to="lab_bhc_SeniorNotes5.625PercentDueDecember2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_6108b2aa-350e-4ec8-b32b-5e7fbc44e9d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of aggregate maturities of long-term debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_ca27d97d-e861-4db6-ac29-77e57cf97ce5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NonU.S.OtherAssetsMember_3ce8111d-5fbe-4df3-a611-1ab681ea924e_terseLabel_en-US" xlink:label="lab_bhc_NonU.S.OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_bhc_NonU.S.OtherAssetsMember_label_en-US" xlink:label="lab_bhc_NonU.S.OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Other Assets [Member]</link:label>
    <link:label id="lab_bhc_NonU.S.OtherAssetsMember_documentation_en-US" xlink:label="lab_bhc_NonU.S.OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonU.S.OtherAssetsMember" xlink:href="bhc-20211231.xsd#bhc_NonU.S.OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NonU.S.OtherAssetsMember" xlink:to="lab_bhc_NonU.S.OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CanadianSecuritiesLitigationMember_69ddca16-525b-416b-9275-e3c2b7204d0c_terseLabel_en-US" xlink:label="lab_bhc_CanadianSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Securities Litigation</link:label>
    <link:label id="lab_bhc_CanadianSecuritiesLitigationMember_label_en-US" xlink:label="lab_bhc_CanadianSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Securities Litigation [Member]</link:label>
    <link:label id="lab_bhc_CanadianSecuritiesLitigationMember_documentation_en-US" xlink:label="lab_bhc_CanadianSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Securities Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianSecuritiesLitigationMember" xlink:href="bhc-20211231.xsd#bhc_CanadianSecuritiesLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CanadianSecuritiesLitigationMember" xlink:to="lab_bhc_CanadianSecuritiesLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_06494ddf-dfbb-4baa-bbec-341bba090158_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_04e10f28-11af-411d-8456-6b415b801f48_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Arrangement by Share Based Payment Award, Options Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:href="bhc-20211231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1c2e079d-2390-434b-9352-58da1409a8bf_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_991861f1-473d-4a2e-a983-80bfcc997a0b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_3ddc65d8-1af9-4681-b50f-6c2c4ff0aac1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_1850503a-daf1-4624-9f99-77c400e636e8_terseLabel_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_label_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Noncurrent Liability</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_documentation_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Noncurrent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:href="bhc-20211231.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:to="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage_157bbdd6-46ed-43b8-a932-a83e5f69de3c_negatedTerseLabel_en-US" xlink:label="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, year-over-year decrease, percentage</link:label>
    <link:label id="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage_label_en-US" xlink:label="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax, Percentage</link:label>
    <link:label id="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage_documentation_en-US" xlink:label="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage" xlink:href="bhc-20211231.xsd#bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage" xlink:to="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredTaxAssetsTaxLossCarryforwards_fc997a0d-078d-4238-bb84-a06fafcaea36_terseLabel_en-US" xlink:label="lab_bhc_DeferredTaxAssetsTaxLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax loss carryforwards</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsTaxLossCarryforwards_label_en-US" xlink:label="lab_bhc_DeferredTaxAssetsTaxLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Loss Carryforwards</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsTaxLossCarryforwards_documentation_en-US" xlink:label="lab_bhc_DeferredTaxAssetsTaxLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the deferred tax assets on tax loss carryforwards available to the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsTaxLossCarryforwards" xlink:href="bhc-20211231.xsd#bhc_DeferredTaxAssetsTaxLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredTaxAssetsTaxLossCarryforwards" xlink:to="lab_bhc_DeferredTaxAssetsTaxLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_43745603-53d3-4ac6-bb22-4fcfed3f4613_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_6e987246-b8ff-446c-b49d-dcaf6c56454a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ed809f67-ca63-4051-af68-a3fb2947ed92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_9901fc76-6496-4656-a49a-474c993692a8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds, settlement of cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Hedge, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_f80e04fa-e6a4-425c-8bdb-30ef59adc62c_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions_0d9c9a16-9faf-484c-910f-8e4a6fe07925_terseLabel_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, net increase for tax positions of current year</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net Increase Resulting From Current Period Tax Positions</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions_documentation_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" xlink:href="bhc-20211231.xsd#bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" xlink:to="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_31ae0827-7853-4c22-b358-443abccd9811_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_056c3581-57ee-49cd-9706-afbc7a6f04b7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price percentage (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_0c3dbd95-cdc1-4eee-86be-219a900590d4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other expense, net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ConcentrationRiskPercentageofNetTradeReceivables_72ea56f2-d17c-4e90-962d-1b3ec6ffd171_terseLabel_en-US" xlink:label="lab_bhc_ConcentrationRiskPercentageofNetTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net trade receivables accounted for by largest wholesale customers</link:label>
    <link:label id="lab_bhc_ConcentrationRiskPercentageofNetTradeReceivables_label_en-US" xlink:label="lab_bhc_ConcentrationRiskPercentageofNetTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage of Net Trade Receivables</link:label>
    <link:label id="lab_bhc_ConcentrationRiskPercentageofNetTradeReceivables_documentation_en-US" xlink:label="lab_bhc_ConcentrationRiskPercentageofNetTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage of Net Trade Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskPercentageofNetTradeReceivables" xlink:href="bhc-20211231.xsd#bhc_ConcentrationRiskPercentageofNetTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ConcentrationRiskPercentageofNetTradeReceivables" xlink:to="lab_bhc_ConcentrationRiskPercentageofNetTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_812ca001-150c-4ceb-8e0a-1c88025cdc21_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax_ec965531-1756-47ae-8cf2-dc669a1cacc3_terseLabel_en-US" xlink:label="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1% change in estimated return rates, Impact on pre-tax earnings</link:label>
    <link:label id="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax_label_en-US" xlink:label="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis, Impact Of 1 Percent Change In Estimated Return Rate, Income (Loss) Before Tax</link:label>
    <link:label id="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax_documentation_en-US" xlink:label="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis, Impact Of 1 Percent Change In Estimated Return Rate, Income (Loss) Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax" xlink:href="bhc-20211231.xsd#bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax" xlink:to="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3a1e5282-8888-4797-a610-2067cb0e8584_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EyenoviaIncMember_bca1f88a-6058-400c-baaa-0768f278c38a_terseLabel_en-US" xlink:label="lab_bhc_EyenoviaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eyenovia, Inc.</link:label>
    <link:label id="lab_bhc_EyenoviaIncMember_label_en-US" xlink:label="lab_bhc_EyenoviaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eyenovia, Inc. [Member]</link:label>
    <link:label id="lab_bhc_EyenoviaIncMember_documentation_en-US" xlink:label="lab_bhc_EyenoviaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eyenovia, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EyenoviaIncMember" xlink:href="bhc-20211231.xsd#bhc_EyenoviaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EyenoviaIncMember" xlink:to="lab_bhc_EyenoviaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a376f4fc-9fa3-4b76-a9e0-43eda25ca449_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_9289cd89-3512-4919-875e-bbb5c72db3af_terseLabel_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit concentration</link:label>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditConcentrationRiskMember" xlink:to="lab_us-gaap_CreditConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4ddf578c-ad25-46f4-8dde-3626ba1e0928_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_d04befdf-9ca6-466b-a42e-1e72067370be_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_04c174be-607e-453f-b3bd-ea04ca38da08_terseLabel_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation</link:label>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_label_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amerisource Bergen Corporation [Member]</link:label>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_documentation_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, AmerisourceBergen Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember" xlink:href="bhc-20211231.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AmerisourceBergenCorporationMember" xlink:to="lab_bhc_AmerisourceBergenCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue_ed20b856-45eb-4515-8737-6e40c5aa2cf9_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of stock options vested</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Options Vested in Period, Total Fair Value</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the total fair value of stock options vested during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" xlink:href="bhc-20211231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_d416a66b-33e2-46f9-afed-21f0663d2ed5_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable operating lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers_d47692e4-42ea-431c-b15c-156c09fef3ea_terseLabel_en-US" xlink:label="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement agreements, number of insurers</link:label>
    <link:label id="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers_label_en-US" xlink:label="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Settlement Agreements, Number Of Insurers</link:label>
    <link:label id="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers_documentation_en-US" xlink:label="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Settlement Agreements, Number Of Insurers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:href="bhc-20211231.xsd#bhc_LossContingencySettlementAgreementsNumberOfInsurers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:to="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual_063f5b66-9f30-48e0-9d84-44cd79158c20_terseLabel_en-US" xlink:label="lab_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating results of acquiree since acquisition</link:label>
    <link:label id="lab_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual_label_en-US" xlink:label="lab_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Operating Income (Loss) Since Acquisition, Actual</link:label>
    <link:label id="lab_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual_documentation_en-US" xlink:label="lab_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Operating Income (Loss) Since Acquisition, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" xlink:href="bhc-20211231.xsd#bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" xlink:to="lab_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_62d5c6b1-422d-484e-ac14-266ff952d20a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net actuarial gain (loss) arising during the year</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2481a2c9-077c-44bf-a303-3a7ed9a56bb0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_55b41128-34cd-40ba-be66-e107998ed3c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_b106935a-34ab-4063-8d51-f7fb107c11c3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_a03a3a69-dd9f-4f7b-961e-c5554fbd25aa_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9a2ead0c-2dc9-4ec7-ab5f-4e3bdd415dc2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_4364911f-12e9-4dc9-a0a9-70d30d07c216_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) related to changes in fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_716a28e7-2a50-4b6e-aa5b-56da242965da_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_0adcdfef-8ee7-4811-90cf-d6b3220fcde8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_acd06091-2627-424d-830c-36d6f81cd221_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.000 % Senior Notes Due March 2024</link:label>
    <link:label id="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_label_en-US" xlink:label="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes 7.00 Percent Due March 2024 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes 7.00 Percent Due March 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:href="bhc-20211231.xsd#bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:to="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d2e2e86b-7111-4571-86f5-7fb6a5e5da3d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2b670edd-b610-4c5f-b5f3-4a8517a05f9d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated goodwill impairment charges to date</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_01e6c44b-b539-44c2-9fa3-2b211aced903_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ccd5b310-97f8-4d00-968f-48ebbf8f9cfc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_c873c523-13ec-4b03-987c-26d51021f6e8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underfunded plans having accumulated benefit obligations exceeding the fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ba176c79-cd91-4bba-88f4-c6e014886a8d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_aa0123fc-9e28-45e6-9f7a-9241f8e6f26e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4a2abad8-9c99-417d-a653-b0aac5fe297a_totalLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_6a0a0b6c-c836-4aae-8ce4-c13ee9f5b96a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_f7172a06-b0b2-44f2-90e8-ed4e7ec3bd7e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INTANGIBLE ASSETS AND GOODWILL</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0d427065-5c9f-41f3-9463-379c6215e207_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_07935cc4-e351-4c0b-91c3-c3191514b0fa_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8a456ca7-ac3d-4588-86a7-39b869ddd92e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e11e57f4-f84c-47eb-a9c3-d9e48f80e942_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_24718deb-f207-4e8b-828a-e9802ca696ba_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_a3356217-5d54-46fa-8b26-eb0c02bab827_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate brands</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_7c9ba1ae-f8a2-4bc4-84a1-d599e5dbae24_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ebd33e26-4765-4c66-b1f3-f1174ccfe312_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_cfaecf9f-7520-4297-b871-3b3149557daa_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5520d172-e3e3-4ff0-b643-01ac054b2d73_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_5fa28679-b7aa-4e69-8aba-4effbc590ff7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest crediting rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_ad01268e-67fb-4f46-99f1-a67741c389d2_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated useful lives of property, plant and equipment</link:label>
    <link:label id="lab_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_label_en-US" xlink:label="lab_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Useful Lives of Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label id="lab_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_documentation_en-US" xlink:label="lab_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of estimated useful lives of major classes of property, plant and equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:href="bhc-20211231.xsd#bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="lab_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_6e960d1d-6f93-492e-811d-66f27e45be00_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service credit</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_449ef393-f70c-4e1b-a70b-d6eaa12c36c7_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of carrying amounts of assets and liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Long Lived Assets Held-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:to="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_b6e46acd-d81b-4878-beed-9adcd71126be_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, contingent consideration obligations, discount rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_a05f4d04-0fdb-4337-a2ee-81c6da8133dc_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of long-lived assets by geographic region</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_47b4d884-03b0-41a7-bfb2-248a77d1bf44_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_e893d43a-f2ce-43e4-8717-f702758dc65d_verboseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_dcca9acb-541e-43f3-833c-df2c7d471129_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9744b0da-c8be-480f-a0c6-b334cb4a6075_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of tax effect of major items recorded as deferred tax assets and liabilities and valuation allowance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A5.375SeniorNotesdueMarch2020Member_40ee908e-492a-4327-a1e3-152edf05c3d1_terseLabel_en-US" xlink:label="lab_bhc_A5.375SeniorNotesdueMarch2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.375% Senior Notes due March 2020</link:label>
    <link:label id="lab_bhc_A5.375SeniorNotesdueMarch2020Member_label_en-US" xlink:label="lab_bhc_A5.375SeniorNotesdueMarch2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.375% Senior Notes due March 2020 [Member]</link:label>
    <link:label id="lab_bhc_A5.375SeniorNotesdueMarch2020Member_documentation_en-US" xlink:label="lab_bhc_A5.375SeniorNotesdueMarch2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.375% Senior Notes due March 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.375SeniorNotesdueMarch2020Member" xlink:href="bhc-20211231.xsd#bhc_A5.375SeniorNotesdueMarch2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A5.375SeniorNotesdueMarch2020Member" xlink:to="lab_bhc_A5.375SeniorNotesdueMarch2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_cb1ebf1b-5183-4c1c-8156-92ebf181fc89_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of vesting rights</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_0c00ed6d-f994-41df-90be-0233a174f4d1_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment included in other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_98a3fcca-e78e-46a5-aaab-bef23878a662_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_37a57761-a026-4737-898f-ba55cb2e59b8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan, percentage of actual plan asset allocations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Target Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b27ef063-6499-4a29-bde4-99b2c3a6ffd4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_3f4f6c78-6c3e-4666-aa27-f94f3be8cff8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESEARCH AND DEVELOPMENT</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_7e608a1f-dd7c-4707-a146-70e1c4bce4e9_terseLabel_en-US" xlink:label="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of the change in projected benefit obligations, change in plan assets and funded status</link:label>
    <link:label id="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:to="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CrossCurrencyFinalSettlementMember_492869bf-0760-4586-a638-014ad321ab8c_terseLabel_en-US" xlink:label="lab_bhc_CrossCurrencyFinalSettlementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency swaps, final settlement</link:label>
    <link:label id="lab_bhc_CrossCurrencyFinalSettlementMember_label_en-US" xlink:label="lab_bhc_CrossCurrencyFinalSettlementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency, Final Settlement [Member]</link:label>
    <link:label id="lab_bhc_CrossCurrencyFinalSettlementMember_documentation_en-US" xlink:label="lab_bhc_CrossCurrencyFinalSettlementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency, Final Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CrossCurrencyFinalSettlementMember" xlink:href="bhc-20211231.xsd#bhc_CrossCurrencyFinalSettlementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CrossCurrencyFinalSettlementMember" xlink:to="lab_bhc_CrossCurrencyFinalSettlementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member_6acb02d8-7b55-42e6-ba1c-d03ca36acf75_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 6.125% Notes Due February 2027</link:label>
    <link:label id="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member_label_en-US" xlink:label="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 6.125% Notes Due February 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 6.125% Notes Due February 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:href="bhc-20211231.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:to="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_0d5c22f1-e892-4597-b86b-687d4b3eb031_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining availability</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_cf5f2bc9-06e6-4ef7-9680-7c8afc5b6a03_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForChargebacksMember_2e028c1c-abd1-4a35-826e-e70cd4973d84_terseLabel_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks</link:label>
    <link:label id="lab_bhc_ReserveForChargebacksMember_label_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Chargebacks [Member]</link:label>
    <link:label id="lab_bhc_ReserveForChargebacksMember_documentation_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Chargebacks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember" xlink:href="bhc-20211231.xsd#bhc_ReserveForChargebacksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForChargebacksMember" xlink:to="lab_bhc_ReserveForChargebacksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_3a6d0d78-8889-4ae3-ba3e-dc9919154e0c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of cases</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_76628507-e00a-48d9-9020-bc58bc4958e0_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_96a9cdff-4a59-4a4d-af17-26fa8f5d7b17_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net pension and postretirement benefit plan adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_f24a6229-9e89-49c8-9710-5628d93ebf37_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government bond funds</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a3545f4d-ff41-4f61-ab72-9082037437eb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit_f9515eea-ee88-4dac-9fa2-5e6047c3bdc9_negatedTerseLabel_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit on intra-entity transfers</link:label>
    <link:label id="lab_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit_label_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Deferred Intercompany Profit</link:label>
    <link:label id="lab_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit_documentation_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the portion of the difference between total income tax expense (benefit) as reported in the income statement and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to deferred intercompany profit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit" xlink:href="bhc-20211231.xsd#bhc_IncomeTaxReconciliationDeferredIntercompanyProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit" xlink:to="lab_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_5acd4e66-fd23-44e3-8bfc-924dbdacd3d5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_730fd5b5-dfa4-4aac-b15c-2c4a7633458d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment converted into minor equity interest</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_ee9d6bc0-d002-4346-8d68-2693903c23b7_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_86238830-fae9-4ee7-b183-cf729449312b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_caefe08e-4337-4ca9-9490-cc4bebb026fb_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool_319e3131-00c6-4e3f-b81b-33763c4567a9_terseLabel_en-US" xlink:label="lab_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scientific Research and Experimental Development pool</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool_label_en-US" xlink:label="lab_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Scientific Research and Experimental Development Pool</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool_documentation_en-US" xlink:label="lab_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the deferred tax assets on scientific research and experimental development pool, of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" xlink:href="bhc-20211231.xsd#bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" xlink:to="lab_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_1ee45fb1-b63c-438c-b783-a6c6d6442454_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_451a3f0e-49b0-4eec-862d-595526a863c3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions recognized</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4733b7a9-fc8c-4532-ba7d-c91d5d08e659_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InternationalRxMember_57b3f546-4fdb-42d8-b732-69172e6ee854_terseLabel_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Rx</link:label>
    <link:label id="lab_bhc_InternationalRxMember_label_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Rx [Member]</link:label>
    <link:label id="lab_bhc_InternationalRxMember_documentation_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Rx</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember" xlink:href="bhc-20211231.xsd#bhc_InternationalRxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InternationalRxMember" xlink:to="lab_bhc_InternationalRxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_74bbc5ab-a685-4cdf-b143-8ad88d27a713_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_86780046-fdb5-4f27-8b4e-d922ad38d5be_terseLabel_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product related research and development</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_label_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Product Related</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_documentation_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Product Related</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:href="bhc-20211231.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:to="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_7f12a999-437d-4775-ab4b-7b454967f40b_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facilities</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_label_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember" xlink:href="bhc-20211231.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredCreditFacilitiesMember" xlink:to="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_967fac12-b389-4095-aac3-0cff39d60ee0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based awards tax withholding</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_65b9b4c9-2e61-4c0d-a1ad-85f9c77a86ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of shares approved for grant by the Company under the share-based compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_f6c06e29-6bd5-4b30-abcd-c1318ddf032b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid from operating cash flows for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_75f8d5ae-8333-46b9-9a08-5587e6c08529_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recoveries</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Recovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_aa8adcbf-045e-4c3e-9a48-cf3585282609_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_66a9b888-a260-47ae-aa8a-22662d3bc3e2_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_6c6e3458-a64b-42a9-bc98-e8a24ccc5607_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_bc2e2b68-9f58-4e62-951f-d1ed76613817_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_955dc66c-2108-45be-8850-bd5ce3e65ead_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross maturities</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_903a4504-a4f6-4b8f-ab98-ba1f556652e6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_aa2adac5-5fe9-4499-87a8-d48a81224516_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_d8d3c494-2212-45c6-b6c8-a2405debd1e8_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_53fcf288-fa3a-44f3-8601-5f31f99f63db_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of groups of investors filing action, remain pending</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_label_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_documentation_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:href="bhc-20211231.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:to="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e49c8b9b-dea1-44fb-8ab4-b7e722ddecf7_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EmergingMarketsMember_6b3cb7d3-4b8e-4001-adf2-dac0d4b592a5_verboseLabel_en-US" xlink:label="lab_bhc_EmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging markets</link:label>
    <link:label id="lab_bhc_EmergingMarketsMember_label_en-US" xlink:label="lab_bhc_EmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:label id="lab_bhc_EmergingMarketsMember_documentation_en-US" xlink:label="lab_bhc_EmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the Emerging Markets segment of the entity. The segment consists of branded generic pharmaceutical products, as well as OTC products and agency/in-licensing arrangements with other research-based pharmaceutical companies (where the entity distributes and markets branded, patented products under long-term, renewable contracts). Products are sold primarily in Europe (Poland, Serbia, Hungary, Croatia and Russia), Latin America (Mexico, Brazil and exports out of Mexico to other Latin American markets), South East Asia and South Africa.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmergingMarketsMember" xlink:href="bhc-20211231.xsd#bhc_EmergingMarketsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EmergingMarketsMember" xlink:to="lab_bhc_EmergingMarketsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_bd6ae583-cb0d-4b0c-8f1e-de3efc605429_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and (deficit) equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate_1636df49-e474-4985-8541-c78cd9f108d8_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowings interest rate</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Threshold For Incremental Borrowings Interest Rate</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Threshold For Incremental Borrowings Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" xlink:href="bhc-20211231.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" xlink:to="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_ee50e198-ff25-484a-bf6a-bb8aa9d3a6d0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_72349168-c303-4e53-bd74-3f848ceaa8de_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_d33830e4-edd1-4a77-af29-5bf41f5142d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c7447580-92a6-44fc-a3ea-4bed10dfd51a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_41c132fc-0177-4b7d-b14e-f9fd44b9a376_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_225d25ea-1cb2-4cd1-b880-bb58b5544073_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_853834c8-3013-4985-946c-ec041a59a06f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_72f33842-ab70-477b-bf3b-f43e3793ce44_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</link:label>
    <link:label id="lab_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_label_en-US" xlink:label="lab_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maximum Redemption Percentage With Equity Offering Proceeds</link:label>
    <link:label id="lab_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maximum Redemption Percentage With Equity Offering Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" xlink:to="lab_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_9e949af5-fa28-4e2e-abeb-4f7e9c05414b_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_c65474d0-ec30-494b-a1e8-717415515f84_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_326817d6-597b-497b-9a98-6595ee629319_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_6bf5d8ed-760d-404e-a88f-a98d702b8955_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NumberOfLargestWholesaleCustomers_e63c003d-460a-4909-87fc-75d2f68ca8f2_terseLabel_en-US" xlink:label="lab_bhc_NumberOfLargestWholesaleCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of largest wholesale customers</link:label>
    <link:label id="lab_bhc_NumberOfLargestWholesaleCustomers_label_en-US" xlink:label="lab_bhc_NumberOfLargestWholesaleCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Largest Wholesale Customers</link:label>
    <link:label id="lab_bhc_NumberOfLargestWholesaleCustomers_documentation_en-US" xlink:label="lab_bhc_NumberOfLargestWholesaleCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of largest wholesale customers.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NumberOfLargestWholesaleCustomers" xlink:href="bhc-20211231.xsd#bhc_NumberOfLargestWholesaleCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NumberOfLargestWholesaleCustomers" xlink:to="lab_bhc_NumberOfLargestWholesaleCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_ffb7474f-5562-4b65-91fe-a1883e502064_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1eddb822-ff6f-4233-b10c-64d02e9fd631_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_93ea5735-2077-41c2-9c2d-b38b0636df4a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_fcd11e8b-d52d-4778-9f30-fa26a5ff5b68_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Plans</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_bacad413-8091-4930-b9b0-6fced912510e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_0808f0ed-18ee-421d-80a6-f1d824fc1f00_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bdf5be5b-f9b4-4f53-8d84-a736e957b844_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_180bf0b5-45ab-414e-8290-233c106ba671_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherPerformanceBasedRestrictedStockUnitsMember_0913df9f-7047-4000-a989-4a6b2e746d63_terseLabel_en-US" xlink:label="lab_bhc_OtherPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Based Restricted Stock Units</link:label>
    <link:label id="lab_bhc_OtherPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_OtherPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_OtherPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_OtherPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20211231.xsd#bhc_OtherPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_OtherPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_44c10537-b43c-4eb9-8c91-fb6f0e0c265d_negatedTerseLabel_en-US" xlink:label="lab_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_label_en-US" xlink:label="lab_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses</link:label>
    <link:label id="lab_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_documentation_en-US" xlink:label="lab_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" xlink:href="bhc-20211231.xsd#bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" xlink:to="lab_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_63657f85-5712-4130-bb46-2cb069e28420_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_20b8ddc3-c5d2-4fca-abd7-f43f9867d6ab_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.250% Senior Notes Due February 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.25%, Due February 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.25%, Due February 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes625DueFebruary2029Member" xlink:to="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_48e5aaca-2608-4f2d-9d2d-5094e470d5f1_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_f146d78e-7111-4ff6-b484-aa3d3833007f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired or forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f0cd9341-c5d5-46b5-9914-c7db854f21e5_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c567ab9c-e59f-44d3-99fa-0b48fae95996_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_b3770459-585e-43b1-9154-21f90605658e_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_9b498e92-1256-4f54-a8d2-8b0daa670b06_terseLabel_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration, separation and IPO costs</link:label>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_4f76849b-13d2-4bcc-89b5-4e35d00cab60_negatedLabel_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration, separation and IPO costs</link:label>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_label_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Initial Public Offering Costs</link:label>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_documentation_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Initial Public Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:href="bhc-20211231.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:to="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_8bb531d1-6471-4664-88ab-c0f330d04d41_negatedTerseLabel_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain excluded from hedge effectiveness</link:label>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_label_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain, Excluded Component</link:label>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_documentation_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain, Excluded Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent" xlink:href="bhc-20211231.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DerivativeGainExcludedComponent" xlink:to="lab_bhc_DerivativeGainExcludedComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_a4ef82f3-e900-4150-aea8-dfffbdbbf319_terseLabel_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product returns</link:label>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_label_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Return Current</link:label>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_documentation_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent" xlink:href="bhc-20211231.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedProductReturnCurrent" xlink:to="lab_bhc_AccruedProductReturnCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_0f1a7157-1dda-4213-aac1-850390d260ee_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_836709ed-2dad-4f4b-969a-b7c5ec51ee88_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional suits filed, but not served</link:label>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_label_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency New Claims Filed But Not Yet Served Number</link:label>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_documentation_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency New Claims Filed But Not Yet Served Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:href="bhc-20211231.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:to="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_87189a90-def2-4569-b6f8-48e745f73b53_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_c3820e44-a722-4305-aa7b-8ef1f9344f2a_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL CASH FLOW DISCLOSURES</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5dd60470-8dfe-4d99-8a8d-73d763dbad64_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of businesses, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_e3c0be49-89ba-4bf8-a55d-eaa94da3c363_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_adb31555-90a2-414b-b9ac-24e89afdc90b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCING ARRANGEMENTS</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_53f2fafa-e0d3-405d-8cd5-95bc0dc8a460_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized as:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_62baebea-de1f-422f-a622-20578c7c30dc_terseLabel_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution Fees</link:label>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_label_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Distribution Fees [Member]</link:label>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Distribution Fees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember" xlink:href="bhc-20211231.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForDistributionFeesMember" xlink:to="lab_bhc_ReserveForDistributionFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6598d10b-9123-43fa-86f2-5e66d0554c9a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ebc769ca-c835-4526-bf4d-f17d6ca3561a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_06107e94-25c0-41c0-80d9-be3c2df3319b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_ba4d259d-905f-4038-a6ca-f6f633f1b88f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OvertheCounterProductsMember_fc32ca55-ab4a-42cd-a085-b2155aaf455a_terseLabel_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC</link:label>
    <link:label id="lab_bhc_OvertheCounterProductsMember_label_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over the Counter Products [Member]</link:label>
    <link:label id="lab_bhc_OvertheCounterProductsMember_documentation_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over the Counter Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember" xlink:href="bhc-20211231.xsd#bhc_OvertheCounterProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OvertheCounterProductsMember" xlink:to="lab_bhc_OvertheCounterProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_05e1ceea-dab4-4019-ae53-aca6fd73827a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenues by segment and by product category</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8be089de-e9a6-4cc2-8451-211bce9d397c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_f7856daf-96f7-4d55-be74-baf938d51a27_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of certain assets of Synergy</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_34748df6-96b8-48c2-8091-a0a62f00c76a_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_bd099e0a-9483-4484-a46f-6f8e43e932fb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement Benefit Plan</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0efc9ea0-efbf-486e-b57c-4a94f3ddab8a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Postretirement Benefit Plan</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_42187aca-0c78-47ff-8497-8156d83fe52f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Notes&#160;20 and 21)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualRightsMember_79748f6d-090b-4357-bfe4-71c7e5c3ed19_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product rights/patents</link:label>
    <link:label id="lab_us-gaap_ContractualRightsMember_51469558-2e9d-4cd1-9c2d-9979afb58983_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product rights/patents</link:label>
    <link:label id="lab_us-gaap_ContractualRightsMember_label_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualRightsMember" xlink:to="lab_us-gaap_ContractualRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_a60f5303-bb29-41c2-8650-873b76cc7073_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_Legalsettlementsandrelatedfees_161c3e50-01e8-4a64-acae-25dbc07ef4b5_terseLabel_en-US" xlink:label="lab_bhc_Legalsettlementsandrelatedfees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal matters and related fees</link:label>
    <link:label id="lab_bhc_Legalsettlementsandrelatedfees_label_en-US" xlink:label="lab_bhc_Legalsettlementsandrelatedfees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal settlements and related fees</link:label>
    <link:label id="lab_bhc_Legalsettlementsandrelatedfees_documentation_en-US" xlink:label="lab_bhc_Legalsettlementsandrelatedfees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal settlements and related fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees" xlink:href="bhc-20211231.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_Legalsettlementsandrelatedfees" xlink:to="lab_bhc_Legalsettlementsandrelatedfees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_87e74e7e-ddad-4691-bb5e-e5a4a2233fea_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_74ce51bb-e1c0-46db-b34e-fc2720658b21_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax_3b25e80e-52ac-4bd6-a9a7-5a2b79116f32_terseLabel_en-US" xlink:label="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1% change in volume of product sold through to Medicaid plan participants, Impact on pre-tax earnings</link:label>
    <link:label id="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax_label_en-US" xlink:label="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis, Impact Of 1 Percent Change In Volume Of Product Sold Through To Medicaid Plan Participants, Income (Loss) Before Tax</link:label>
    <link:label id="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax_documentation_en-US" xlink:label="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis, Impact Of 1 Percent Change In Volume Of Product Sold Through To Medicaid Plan Participants, Income (Loss) Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax" xlink:href="bhc-20211231.xsd#bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax" xlink:to="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_b13ba0e4-87d9-4186-86be-1de425ab6317_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_28f82827-61cb-455f-acf3-da1a0eaf4213_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_6e7f8f6e-20f1-4b88-9265-196a47c467b5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_1d7e60aa-b2ef-4c38-ad18-fde85847cbbd_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting unit, impairment test, estimated cash flows, discount rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_label_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_documentation_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:href="bhc-20211231.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:to="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_61e7d0b0-b5d1-4662-9e53-648e4b1e6dd1_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_58131969-760e-4198-9ffe-8f57d005619f_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_d3cbe1ba-612c-4d08-901a-3f00b6421061_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues and long-lived assets by geographic region</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_861a6573-9bd8-4b2f-8aa0-3ccbd77734ac_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CedarsSinaiMedicalCenterMember_985ab0ff-6830-4eb6-a3fa-3d1e5a7da036_terseLabel_en-US" xlink:label="lab_bhc_CedarsSinaiMedicalCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cedars-Sinai Medical Center</link:label>
    <link:label id="lab_bhc_CedarsSinaiMedicalCenterMember_label_en-US" xlink:label="lab_bhc_CedarsSinaiMedicalCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cedars-Sinai Medical Center [Member]</link:label>
    <link:label id="lab_bhc_CedarsSinaiMedicalCenterMember_documentation_en-US" xlink:label="lab_bhc_CedarsSinaiMedicalCenterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cedars-Sinai Medical Center</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CedarsSinaiMedicalCenterMember" xlink:href="bhc-20211231.xsd#bhc_CedarsSinaiMedicalCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CedarsSinaiMedicalCenterMember" xlink:to="lab_bhc_CedarsSinaiMedicalCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_d27336ac-1027-4c4f-bf3f-0af07c87949d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible portion of Goodwill impairments</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b1f2bddc-48e4-45be-af1f-a7c6fb034338_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_25840eb8-75d9-4aa4-94d3-75869aa6fe70_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_ba08e4d1-4bbe-4c58-b531-a58f8116f24a_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of annual excess cash flow</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Consolidated Excess Cash Flow Payable as Mandatory Prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:href="bhc-20211231.xsd#bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_9b85286e-0f17-4b66-a87e-99df3a911bc1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of compensation increase</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions_5539545e-f630-4374-907c-744e4b7e2687_terseLabel_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, net decrease for tax positions of prior years</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net Decrease Resulting From Prior Period Tax Positions</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions_documentation_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net Decrease Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" xlink:href="bhc-20211231.xsd#bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" xlink:to="lab_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_3e8645a9-5c47-41a0-9c99-f1e0a416e2ac_negatedTerseLabel_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_label_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance For Foreign Exchange And Other</link:label>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_documentation_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance For Foreign Exchange And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:href="bhc-20211231.xsd#bhc_AccountsReceivableAllowanceForForeignExchangeAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:to="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_15443770-51dd-4b37-8f6c-4fb262396569_terseLabel_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_label_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Customer Returns [Member]</link:label>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_documentation_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Customer Returns [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember" xlink:href="bhc-20211231.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForCustomerReturnsMember" xlink:to="lab_bhc_ReserveForCustomerReturnsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1c24f7b0-7350-43e0-80c8-47cf2730b69e_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefinedBenefitPlanEmployerContributionMaximumAge_d6439a8b-596c-4d27-843e-d83481890cd1_terseLabel_en-US" xlink:label="lab_bhc_DefinedBenefitPlanEmployerContributionMaximumAge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution maximum age</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanEmployerContributionMaximumAge_label_en-US" xlink:label="lab_bhc_DefinedBenefitPlanEmployerContributionMaximumAge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Employer Contribution, Maximum Age</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanEmployerContributionMaximumAge_documentation_en-US" xlink:label="lab_bhc_DefinedBenefitPlanEmployerContributionMaximumAge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Employer Contribution, Maximum Age</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanEmployerContributionMaximumAge" xlink:href="bhc-20211231.xsd#bhc_DefinedBenefitPlanEmployerContributionMaximumAge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefinedBenefitPlanEmployerContributionMaximumAge" xlink:to="lab_bhc_DefinedBenefitPlanEmployerContributionMaximumAge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_77ee5205-9b38-4bb4-b722-632a9bcb46bf_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_aa316638-5c11-4949-a69c-8824d9f44229_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_660c1536-3930-437e-a1b6-f56faf89931f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_927dbe7b-f1a7-40a3-9a46-e294a9adbb03_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MilestonePaymentRelatedToCertainProductMember_14d525e6-d77a-4d61-9962-010aa8d0c113_terseLabel_en-US" xlink:label="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Related To Certain Product</link:label>
    <link:label id="lab_bhc_MilestonePaymentRelatedToCertainProductMember_label_en-US" xlink:label="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Related To Certain Product [Member]</link:label>
    <link:label id="lab_bhc_MilestonePaymentRelatedToCertainProductMember_documentation_en-US" xlink:label="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Related To Certain Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:href="bhc-20211231.xsd#bhc_MilestonePaymentRelatedToCertainProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:to="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_15a467d6-e601-4a05-9e5a-a7e1a202b651_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_ed806ba6-7f5e-4dc6-aaa1-3557ff805713_terseLabel_en-US" xlink:label="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROTC Performance-Based Restricted Stock Units</link:label>
    <link:label id="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROTC Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROTC Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20211231.xsd#bhc_ROTCPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_b596065c-c290-4ac9-8d8f-b31fb6118d94_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0bc92ec0-d443-4604-8bfe-23a040a441cb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e3068220-8a47-4529-a295-e816b40d92e2_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_97b7f211-f982-40da-9e33-49d2368a596d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes700DueMarch2024Member_0361f942-0c42-44d8-911f-d6c80129db92_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.00%, Due March 2024</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueMarch2024Member_label_en-US" xlink:label="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.00%, Due March 2024 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueMarch2024Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.00%, Due March 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueMarch2024Member" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes700DueMarch2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes700DueMarch2024Member" xlink:to="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_81106cc0-12c1-44a9-b9e3-0fa6a227a018_netLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_79f38856-484e-4e48-83a9-360329c46015_terseLabel_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Integration Costs</link:label>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_label_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Integration Costs [Member]</link:label>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_documentation_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Integration Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember" xlink:href="bhc-20211231.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestructuringAndIntegrationCostsMember" xlink:to="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear_9e9791ef-dd7f-4b98-9619-8915503f339d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in NOLs</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Increase (Decrease) in Liability from Prior Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear" xlink:to="lab_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_73ec3460-3991-452f-926d-90f57039cf2d_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits_a4f2aa8a-64c7-48aa-9573-8c02cbf69548_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of alleged stockholders filed lawsuits</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits_label_en-US" xlink:label="lab_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Alleged Stockholders, Filed Lawsuits</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits_documentation_en-US" xlink:label="lab_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Alleged Stockholders, Filed Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits" xlink:href="bhc-20211231.xsd#bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits" xlink:to="lab_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_68997b1b-bde0-47e6-90f2-e331835e943f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_90e18341-b46b-4914-93aa-a274966b4ad5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_85b455e4-fc8e-4971-826b-464ec7183b36_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ce37439c-563d-4e4f-83c6-11877c97fb7d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2ef45656-1658-4e89-b3b5-e4c92b36df80_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_acbfe174-6cc9-44ad-9336-2d18ddb9f2f2_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_e0e9fdd5-fc4a-4afd-ae5e-2a4a79319b63_terseLabel_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_label_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements Change in Amount of Contingent Consideration Asset Cash</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_documentation_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:href="bhc-20211231.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:to="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured4875NotesDueJune2028Member_8740d346-64d9-49ff-a53e-ec9cc4f20a52_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.875% Senior Notes Due June 2028</link:label>
    <link:label id="lab_bhc_SeniorSecured4875NotesDueJune2028Member_label_en-US" xlink:label="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 4.875% Notes Due June 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured4875NotesDueJune2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 4.875% Notes Due June 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:href="bhc-20211231.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:to="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cdefc188-a855-4305-8a3e-7b98399238c1_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PartnerRelationshipsMember_8624be29-5d4f-4129-bb02-f51f743d4100_terseLabel_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner relationships</link:label>
    <link:label id="lab_bhc_PartnerRelationshipsMember_741da163-a94c-46c8-b6fd-f0366aeceba2_verboseLabel_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner relationships</link:label>
    <link:label id="lab_bhc_PartnerRelationshipsMember_label_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner Relationships [Member]</link:label>
    <link:label id="lab_bhc_PartnerRelationshipsMember_documentation_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to existing arrangements with various other entities, for which the entity provides regulatory, compliance, sales, marketing and distribution functions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember" xlink:href="bhc-20211231.xsd#bhc_PartnerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PartnerRelationshipsMember" xlink:to="lab_bhc_PartnerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_fa9c15ca-7d28-441d-8387-3105addc9482_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_23a2fdbd-2a93-4030-b767-4fec64d6d05b_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments, including loss on assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_fccd54e8-2412-47ff-a1e9-7e2d2f937205_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments, including loss on assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_749d6251-880c-4868-82ef-a0e4e6e65d19_negatedLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments, including loss on assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_a05af3c7-6806-4a54-9ddb-56ace42709e1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LupinPharmaceuticalsIncLitigationMember_778f0220-84b1-4ffd-914b-841094154e37_terseLabel_en-US" xlink:label="lab_bhc_LupinPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lupin Pharmaceuticals, Inc. Litigation</link:label>
    <link:label id="lab_bhc_LupinPharmaceuticalsIncLitigationMember_label_en-US" xlink:label="lab_bhc_LupinPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lupin Pharmaceuticals, Inc. Litigation [Member]</link:label>
    <link:label id="lab_bhc_LupinPharmaceuticalsIncLitigationMember_documentation_en-US" xlink:label="lab_bhc_LupinPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lupin Pharmaceuticals, Inc. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LupinPharmaceuticalsIncLitigationMember" xlink:href="bhc-20211231.xsd#bhc_LupinPharmaceuticalsIncLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LupinPharmaceuticalsIncLitigationMember" xlink:to="lab_bhc_LupinPharmaceuticalsIncLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_b04bc43a-394c-4d67-8b62-62183e042352_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate notional amounts</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_cd30991b-a865-4f49-8cb7-06b945c401c9_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_37053a70-01e9-4dcb-bd4a-390c785f9d53_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D, included in other expense, net</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A8.50SeniorNotesDueJanuary2027Member_e1a5100a-1278-4187-ac54-fdde99f0c76b_terseLabel_en-US" xlink:label="lab_bhc_A8.50SeniorNotesDueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Unsecured Notes Due January 2027</link:label>
    <link:label id="lab_bhc_A8.50SeniorNotesDueJanuary2027Member_label_en-US" xlink:label="lab_bhc_A8.50SeniorNotesDueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Notes Due January 2027 [Member]</link:label>
    <link:label id="lab_bhc_A8.50SeniorNotesDueJanuary2027Member_documentation_en-US" xlink:label="lab_bhc_A8.50SeniorNotesDueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Notes Due January 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A8.50SeniorNotesDueJanuary2027Member" xlink:href="bhc-20211231.xsd#bhc_A8.50SeniorNotesDueJanuary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A8.50SeniorNotesDueJanuary2027Member" xlink:to="lab_bhc_A8.50SeniorNotesDueJanuary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_6d64b1c5-4c46-42ca-9b01-4e11f42f355f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_06b3c996-91e5-4a0b-94b4-4a225b0697ef_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ThreeLargestUSWholesalerCustomersMember_0ba5c56f-3d05-4c69-b8e9-6638073b2432_terseLabel_en-US" xlink:label="lab_bhc_ThreeLargestUSWholesalerCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three largest U.S. wholesaler customers</link:label>
    <link:label id="lab_bhc_ThreeLargestUSWholesalerCustomersMember_label_en-US" xlink:label="lab_bhc_ThreeLargestUSWholesalerCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Largest US Wholesaler Customers [Member]</link:label>
    <link:label id="lab_bhc_ThreeLargestUSWholesalerCustomersMember_documentation_en-US" xlink:label="lab_bhc_ThreeLargestUSWholesalerCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the three largest U.S. wholesaler customers.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ThreeLargestUSWholesalerCustomersMember" xlink:href="bhc-20211231.xsd#bhc_ThreeLargestUSWholesalerCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ThreeLargestUSWholesalerCustomersMember" xlink:to="lab_bhc_ThreeLargestUSWholesalerCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_2531f02f-28ad-424a-bd59-7fb75dc2fe42_terseLabel_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers</link:label>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_label_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers [Member]</link:label>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_documentation_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember" xlink:href="bhc-20211231.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PlaintiffsDirectPurchasersMember" xlink:to="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_1d30a0a3-3c23-470f-b941-cc3d482fd242_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_445332dd-3160-4104-872c-fa3e5fe57fd8_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assumptions used to calculate the fair values of performance-based RSUs</link:label>
    <link:label id="lab_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share Based Payment Award, Equity Instruments Other than Options Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the significant assumptions used during the year to estimate the fair value of equity based payment instruments, excluding stock (or unit) options, including but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:href="bhc-20211231.xsd#bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_fb57fd73-09cc-46b1-962c-fd81da68f38a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_e1f74a3d-97d6-4dda-85e8-ff88476f7ca7_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_dd1c2169-95b5-4747-8e5e-dc8b7372524b_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_3d03ea3f-e5e1-42cb-baea-d0812ec0f8b3_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.500% Senior Notes Due January 2027</link:label>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_label_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 8.50%, Due January 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Notes Due January 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes850DueJanuary2027Member" xlink:to="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_447416d9-c8dc-4c1a-ad95-2892c4dc5393_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3512f32b-ed40-4e3a-aea5-684698af162a_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c73c9454-9bf0-4278-bb20-c70f3ec7fc77_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d3889019-a4b5-4a57-aa22-d6d8ed147031_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_10dc20e7-ce07-4479-8120-fd897a1f206d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_80c01109-11ee-4b73-9165-fa2d78a0a5bc_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_9583bf6c-a677-47ae-9287-4729834c7b6e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember_7c1bc01d-caf0-4b80-bb5d-a3181b036b5b_terseLabel_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility, New Restated Credit Agreement</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember_label_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility, New Restated Credit Agreement [Member]</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember_documentation_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility, New Restated Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember" xlink:href="bhc-20211231.xsd#bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember" xlink:to="lab_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes4.502023Member_81f87eb8-2c06-4407-91c5-605ead54e7bb_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes4.502023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes euro-denominated debt Due May 2023</link:label>
    <link:label id="lab_bhc_SeniorNotes4.502023Member_label_en-US" xlink:label="lab_bhc_SeniorNotes4.502023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.50%, 2023 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes4.502023Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes4.502023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.50%, 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes4.502023Member" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes4.502023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes4.502023Member" xlink:to="lab_bhc_SeniorNotes4.502023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_8bca159c-aea7-4863-84c7-bcbc37d742eb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_655f4eb5-180d-47e9-b153-bceeaa7b3e2c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_6c33f61a-9cc9-40fe-b761-507cd864507e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_465f920b-565c-4334-9773-f9f6a468a9a3_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments / Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_c9c09f1a-f1cd-4839-9f29-410677f3ac77_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_4fce34f8-9253-472f-bde8-4136543ad348_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average assumptions used to determine net periodic benefit costs and benefit obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c6b7abfc-08ac-40d0-94c2-82eae36afa1d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_7af5ec77-0523-4ab6-b1c1-3e9b258f0f56_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_21aa7c4a-9158-45c9-b735-5955fc587c62_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_560927b8-7486-47a8-898b-e7a92aae662e_verboseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_3b9e83c8-e01b-4085-8c36-8554a94fcebd_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized interest</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized" xlink:to="lab_us-gaap_InterestCostsCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EurodollarMember_235b4f90-0fc5-4e20-a9b1-79fe9cc00dd2_terseLabel_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar</link:label>
    <link:label id="lab_us-gaap_EurodollarMember_label_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EurodollarMember" xlink:to="lab_us-gaap_EurodollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_ec3e290c-b931-4af6-a2b2-7f5a1a725fbb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future benefit payments for the pension benefit plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8605459c-7eb4-4065-9420-ae4d4b0bb951_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the components of accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_8db2728e-047f-4d42-b337-560271e06569_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_8726a3e8-cfb9-4dc0-a471-8c2aba6a1295_terseLabel_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and other settlement deposits</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_label_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Other Settlement Deposits, Current</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_documentation_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Other Settlement Deposits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:href="bhc-20211231.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:to="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_52bef567-51b8-4f1c-ac58-a6de33fbe31a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the beginning and ending amounts of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities_a61559a9-f2ec-4545-80da-4929f45a309d_terseLabel_en-US" xlink:label="lab_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum period to classify uncertain tax position liabilities as long term liabilities</link:label>
    <link:label id="lab_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities_label_en-US" xlink:label="lab_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Period to Classify Uncertain Tax Position, Liabilities as Long Term Liabilities</link:label>
    <link:label id="lab_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities_documentation_en-US" xlink:label="lab_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the minimum period to classify uncertain tax position liabilities as long term liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" xlink:href="bhc-20211231.xsd#bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" xlink:to="lab_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_cdba47fe-e2d9-4498-b31b-64cd8c008ea9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_610d9d14-0781-4e8d-8b31-2ec9ef3dcdd3_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_b9a291e7-c4ce-4b5c-967f-04a9ef930204_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED OTHER COMPREHENSIVE LOSS</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_7c7003a3-a81d-4183-bb96-19c7bcb6bfa8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A9.25SeniorNotesDueApril2026Member_a207ce0b-e11d-42f8-8e8b-d1eed143d292_terseLabel_en-US" xlink:label="lab_bhc_A9.25SeniorNotesDueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Unsecured Notes Due April 2026</link:label>
    <link:label id="lab_bhc_A9.25SeniorNotesDueApril2026Member_label_en-US" xlink:label="lab_bhc_A9.25SeniorNotesDueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Notes Due April 2026 [Member]</link:label>
    <link:label id="lab_bhc_A9.25SeniorNotesDueApril2026Member_documentation_en-US" xlink:label="lab_bhc_A9.25SeniorNotesDueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Notes Due April 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.25SeniorNotesDueApril2026Member" xlink:href="bhc-20211231.xsd#bhc_A9.25SeniorNotesDueApril2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A9.25SeniorNotesDueApril2026Member" xlink:to="lab_bhc_A9.25SeniorNotesDueApril2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_51081d33-d64d-4074-b4dd-f2c2a25d07d6_terseLabel_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted-Average Discount Rate</link:label>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_label_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted-Average Discount Rate [Member]</link:label>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_documentation_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted-Average Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:href="bhc-20211231.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:to="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_03e105ec-c3b7-4e81-904a-bafa0040effc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_a71aac5e-68d0-4b02-acf7-7176e93afce6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_eb728aeb-f50f-4524-bf61-44c07882b274_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected rate of return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DerivativeLawsuitsMember_ae9cc535-3131-4523-832b-707921937c84_terseLabel_en-US" xlink:label="lab_bhc_DerivativeLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Lawsuits</link:label>
    <link:label id="lab_bhc_DerivativeLawsuitsMember_label_en-US" xlink:label="lab_bhc_DerivativeLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Lawsuits [Member]</link:label>
    <link:label id="lab_bhc_DerivativeLawsuitsMember_documentation_en-US" xlink:label="lab_bhc_DerivativeLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeLawsuitsMember" xlink:href="bhc-20211231.xsd#bhc_DerivativeLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DerivativeLawsuitsMember" xlink:to="lab_bhc_DerivativeLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_ff7b8684-825e-4141-8b27-1c06994186ba_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_84f02551-9081-4cd8-8862-b0098956a9d3_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_1ed931e1-a5a1-46a3-a7f0-0606f4285f6b_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, redemption and discharge condition, amount, if circumstances met</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:to="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_55a54bfa-597c-4415-974a-2edc4d68e83b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_aa660b04-562f-4f37-a04e-6fab3f7b014a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember_40069feb-1b3c-45d9-adb6-366bb8aa68da_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured and Unsecured Notes</link:label>
    <link:label id="lab_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember_label_en-US" xlink:label="lab_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes And Senior Unsecured Notes [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes And Senior Unsecured Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember" xlink:href="bhc-20211231.xsd#bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember" xlink:to="lab_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_417dedef-d99a-4be8-8fdc-53859ec26a2b_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_5f148efa-1d16-4987-ab1f-49522305cd19_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_9560d46a-8f24-4a4d-9c97-38c4c661af70_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes550DueMarch2023Member_01d07d69-094d-4a52-9b80-4736b34fef04_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes550DueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Senior Notes Due March 2023</link:label>
    <link:label id="lab_bhc_SeniorNotes550DueMarch2023Member_label_en-US" xlink:label="lab_bhc_SeniorNotes550DueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.50%, Due March 2023 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes550DueMarch2023Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes550DueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Senior Notes due March 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes550DueMarch2023Member" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes550DueMarch2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes550DueMarch2023Member" xlink:to="lab_bhc_SeniorNotes550DueMarch2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d1777c8b-960d-4d7f-87b2-f661663ef001_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_a165e069-94b8-435b-a578-e8711a270767_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_5e13fc27-3c29-4e24-9b64-c6bc3a3b5856_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2e5781a7-fe6d-496a-b03c-091c0ebefbd1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_49643905-5bda-4e64-b953-b2880d8e6737_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of lines of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxYear2012Member_6797847c-119f-46e7-9b52-24d24ce15cf1_terseLabel_en-US" xlink:label="lab_us-gaap_TaxYear2012Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2012</link:label>
    <link:label id="lab_us-gaap_TaxYear2012Member_label_en-US" xlink:label="lab_us-gaap_TaxYear2012Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2012 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2012Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2012Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2012Member" xlink:to="lab_us-gaap_TaxYear2012Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_55af4a23-3074-4288-974b-2636b7ae6031_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed charge coverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A5.25SeniorNotesDueJanuary2030Member_3b03aa00-416a-4071-a736-669187ff7ab8_terseLabel_en-US" xlink:label="lab_bhc_A5.25SeniorNotesDueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Unsecured Notes Due January 2030</link:label>
    <link:label id="lab_bhc_A5.25SeniorNotesDueJanuary2030Member_label_en-US" xlink:label="lab_bhc_A5.25SeniorNotesDueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due January 2030 [Member]</link:label>
    <link:label id="lab_bhc_A5.25SeniorNotesDueJanuary2030Member_documentation_en-US" xlink:label="lab_bhc_A5.25SeniorNotesDueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due January 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.25SeniorNotesDueJanuary2030Member" xlink:href="bhc-20211231.xsd#bhc_A5.25SeniorNotesDueJanuary2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A5.25SeniorNotesDueJanuary2030Member" xlink:to="lab_bhc_A5.25SeniorNotesDueJanuary2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_47a0bd19-6840-483b-8f21-ef7f1da725bb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb7931f3-0e6c-4e5e-9ec1-234b335f61e3_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_7f6d9164-cf1e-476e-8c77-5e4d33841546_terseLabel_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit</link:label>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_label_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit [Member]</link:label>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_documentation_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember" xlink:href="bhc-20211231.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InsuranceCoverageLawsuitMember" xlink:to="lab_bhc_InsuranceCoverageLawsuitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6c42016a-f61b-49ce-8532-8cf6c126fb24_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f31effed-e419-43be-a5fe-17832da0e569_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (deficit) equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_303530fb-5530-4948-a2f8-8c7b847ac4cc_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_46a28c77-9abf-49e0-bbfa-440d5421fa16_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_23282b92-49e1-4b8a-b321-07cb2b9f9f6b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase to accumulated deficit (less than)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e5414607-8dcf-4060-ad91-9523034170bf_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_ae38741c-6d61-4889-9688-4a98b9870b78_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price percentage due to change in control (as a percent)</link:label>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_label_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage, Change in Control</link:label>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage, Change in Control</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:to="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_9d8f7b6a-e546-4f1c-96a1-5f7879f564d5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b3b3b704-2d17-4f85-ba5c-e13189dc1d1b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of long-term debt, net of discounts</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_861426ad-5b4a-4ee0-a01e-bc1e76179552_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_c202fa9a-6613-4e2d-83c2-79373d6a4ef8_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_b8cd4cc1-f296-4039-ad3c-d0aabccdad23_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents_bd16fb74-9beb-4358-84e4-44d73779cf45_terseLabel_en-US" xlink:label="lab_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum term of original maturity to classify instruments as cash and cash equivalents (less than)</link:label>
    <link:label id="lab_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents_label_en-US" xlink:label="lab_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Term of Original Maturity to Classify Instruments as Cash and Cash Equivalents</link:label>
    <link:label id="lab_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents_documentation_en-US" xlink:label="lab_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the maximum original term of maturity for an instrument to be classified as cash or cash equivalent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" xlink:href="bhc-20211231.xsd#bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" xlink:to="lab_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a23671d3-85af-4f53-95e6-756d980abf51_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_9b6c5ae5-a4eb-4c21-9a5f-9a48e9166ff1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_78d1ce67-6183-40b4-8947-759bb97db22d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_3607e78a-8b49-474c-b428-64c2b49b7feb_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes525DueFebruary2031Member_12fa6d01-7087-4963-ac62-bf6dd7674cf9_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.250% Senior Notes, Due February 2031</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueFebruary2031Member_label_en-US" xlink:label="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.25%, Due February 2031 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueFebruary2031Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.25%, Due February 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes525DueFebruary2031Member" xlink:to="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_0ee008da-880d-45aa-bd0a-c3a7c50a6d1d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of segment revenues and profit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_050e2ba1-08f5-4bb1-9337-df4cb5e439dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ee2ab91f-cebc-4006-b418-470aa4248700_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ece80dfa-26ca-489c-b77c-d0a59670257c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f899d810-80a4-4025-83fd-19eda702f387_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0de326be-ad22-4eff-b881-c3873e493448_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax_4f4868d9-3677-4240-a553-a3ca435f2e5a_terseLabel_en-US" xlink:label="lab_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency impact</link:label>
    <link:label id="lab_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax_label_en-US" xlink:label="lab_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Foreign Currency Adjustment, Net Of Tax</link:label>
    <link:label id="lab_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax_documentation_en-US" xlink:label="lab_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Foreign Currency Adjustment, Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" xlink:href="bhc-20211231.xsd#bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" xlink:to="lab_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_af989cc5-6764-4c6a-b663-615e6fd1ec3e_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest coverage ratio (not less than)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:to="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1b46e6cc-7b57-461c-a491-aa546c31b7ec_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_d2bbd473-40e1-4e6d-bcc5-bc0387b10650_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_7977aa48-a1ac-404c-8ef8-6ac056201477_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefinedBenefitPlanPercentageAllocationofFund_5b6de6e4-cb6e-4c09-8318-99d2348f4a59_terseLabel_en-US" xlink:label="lab_bhc_DefinedBenefitPlanPercentageAllocationofFund" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage allocation of fund</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanPercentageAllocationofFund_label_en-US" xlink:label="lab_bhc_DefinedBenefitPlanPercentageAllocationofFund" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Percentage Allocation of Fund</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanPercentageAllocationofFund_documentation_en-US" xlink:label="lab_bhc_DefinedBenefitPlanPercentageAllocationofFund" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Percentage Allocation of Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanPercentageAllocationofFund" xlink:href="bhc-20211231.xsd#bhc_DefinedBenefitPlanPercentageAllocationofFund"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefinedBenefitPlanPercentageAllocationofFund" xlink:to="lab_bhc_DefinedBenefitPlanPercentageAllocationofFund" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_13745563-3fdc-4d10-bdc4-e2ffa6bbe6c1_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_91b3a7ed-459d-44b6-9a4e-b595ef37f1d3_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of capital expenditures, depreciation and amortization by segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A5.50SeniorNotesdueMarch2023Member_5a2c93cc-a8d2-4bcf-a22b-cea28da76360_terseLabel_en-US" xlink:label="lab_bhc_A5.50SeniorNotesdueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Senior Unsecured Notes due March 2023</link:label>
    <link:label id="lab_bhc_A5.50SeniorNotesdueMarch2023Member_label_en-US" xlink:label="lab_bhc_A5.50SeniorNotesdueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Senior Notes due March 2023 [Member]</link:label>
    <link:label id="lab_bhc_A5.50SeniorNotesdueMarch2023Member_documentation_en-US" xlink:label="lab_bhc_A5.50SeniorNotesdueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Senior Notes due March 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.50SeniorNotesdueMarch2023Member" xlink:href="bhc-20211231.xsd#bhc_A5.50SeniorNotesdueMarch2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A5.50SeniorNotesdueMarch2023Member" xlink:to="lab_bhc_A5.50SeniorNotesdueMarch2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_984de148-1b2e-434d-93c5-95d1ecdca8f8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER EXPENSE, NET</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_fbdbc656-1160-49da-9ce7-5f9bcb853236_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_998ef189-73c3-4ad7-a415-b3775cc0441a_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalPeriod_ec2a272b-317c-4aac-aebf-6e6d43492150_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stay of the approval period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalPeriod_label_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalPeriod_documentation_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod" xlink:href="bhc-20211231.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyStayOfApprovalPeriod" xlink:to="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShowertoShowerProductLiabilityLitigationMember_ec8d7bde-612a-4198-91c7-c54c975c6f3c_terseLabel_en-US" xlink:label="lab_bhc_ShowertoShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower to Shower Product Liability Litigation</link:label>
    <link:label id="lab_bhc_ShowertoShowerProductLiabilityLitigationMember_label_en-US" xlink:label="lab_bhc_ShowertoShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower to Shower Product Liability Litigation [Member]</link:label>
    <link:label id="lab_bhc_ShowertoShowerProductLiabilityLitigationMember_documentation_en-US" xlink:label="lab_bhc_ShowertoShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower to Shower Product Liability Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowertoShowerProductLiabilityLitigationMember" xlink:href="bhc-20211231.xsd#bhc_ShowertoShowerProductLiabilityLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShowertoShowerProductLiabilityLitigationMember" xlink:to="lab_bhc_ShowertoShowerProductLiabilityLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_0e0e0213-8531-491a-9507-f26ee28665c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease expense</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_63ddb4d0-8bb2-490e-9744-2f5971ca748c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued under share-based compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_ec7cc514-a12a-41db-9630-dd3fb74025ba_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining mandatory quarterly amortization payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_label_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Quarterly Amortization</link:label>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Quarterly Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:to="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9897242b-3f94-4f7c-96d8-0a47d97b7cc8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio_3685245e-6533-4b4e-9637-9e702513355e_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total leverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Total Leverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Total Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_64157c6f-4115-4a7c-aa65-74a551fc6b09_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_46f8f604-2b37-4b42-8fce-55c12cfa28f2_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_16bfe7c6-168a-45c4-89a5-839d0cb18737_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposal of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_ac7ff4c3-ae4e-4960-a9b3-dd4618e69095_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_b6de0a92-3cbb-4c1d-8dc5-652868c3caf5_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement, escrow fund included in restricted cash</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_be095268-0445-4641-87a0-6b90732eb2df_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation, amount agreed to pay</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8fc4ef37-3653-4946-9356-4a3ea3c5a768_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued under share-based compensation plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_0f2c3e52-41b0-470a-8872-e39df39203fa_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States - Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_a2a597e7-23d0-4b12-86c0-b7ed00e6bbf8_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_FairValueAdjustmentsMember_e31d6895-236a-48a0-901b-f9478be272aa_terseLabel_en-US" xlink:label="lab_bhc_FairValueAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustments</link:label>
    <link:label id="lab_bhc_FairValueAdjustmentsMember_label_en-US" xlink:label="lab_bhc_FairValueAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustments [Member]</link:label>
    <link:label id="lab_bhc_FairValueAdjustmentsMember_documentation_en-US" xlink:label="lab_bhc_FairValueAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsMember" xlink:href="bhc-20211231.xsd#bhc_FairValueAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_FairValueAdjustmentsMember" xlink:to="lab_bhc_FairValueAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_0eb97025-95bf-4abe-a50b-0a17ce3be1d9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_5606e0be-cc02-490e-9eaf-c61221877e3a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes500DueFebruary2029Member_63468149-fd83-44a3-af37-e9761c876a4c_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.000% Senior Note Due February 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueFebruary2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.00%, Due February 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueFebruary2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.00%, Due February 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes500DueFebruary2029Member" xlink:to="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_73c882b1-c6ea-4592-90c3-c59e2796dff2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_a096d3c2-114e-4ce9-8cb9-2cc7747b9c8f_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_a7fbb66d-3ce6-4791-b711-53d5487bbf0b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance against deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_14e5c041-8e48-45da-a429-d66b9fc9f73d_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_1506fb81-a2aa-47c2-ab88-e30b7e990b2f_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customers [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_ad679e6a-02ca-4c1e-9c42-8d6dab5f6613_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost-rationalization and integration initiatives</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_61c0ef7f-ec92-4e0d-a7f9-3cdaacdd1ee0_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1d5ac863-2601-45d3-80a7-65925c99c0e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_158f4daf-c172-4a9d-9090-eeb78f93a3ff_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_3a057370-49a5-495c-aa05-4483c717edaf_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_2c4825fc-032b-44e4-b6cf-2b29fdb59062_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_cd70ef21-f8e4-41d9-8ae3-52da0bf33729_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.000 % Senior Notes Due January 2028</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_label_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.00%, Due January 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 7.00 Percent Due January 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes700DueJanuary2028Member" xlink:to="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_63e6f9ab-6956-42c2-9bc9-aebe1d21ff55_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill reclassified to assets held for sale</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_e02c3286-5c12-4980-939f-037a86555a9c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RICOClassActionsLitigationMember_10d49c1f-b7ed-4fa2-819f-e0e9b131cd8d_terseLabel_en-US" xlink:label="lab_bhc_RICOClassActionsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions Litigation</link:label>
    <link:label id="lab_bhc_RICOClassActionsLitigationMember_label_en-US" xlink:label="lab_bhc_RICOClassActionsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions Litigation [Member]</link:label>
    <link:label id="lab_bhc_RICOClassActionsLitigationMember_documentation_en-US" xlink:label="lab_bhc_RICOClassActionsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsLitigationMember" xlink:href="bhc-20211231.xsd#bhc_RICOClassActionsLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RICOClassActionsLitigationMember" xlink:to="lab_bhc_RICOClassActionsLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_ca3b27f4-cf69-44a3-8573-a8158d8dab23_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_bf6ef1b8-b3f5-4165-964f-47c36e822974_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets reclassified, held and used</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_4498550d-b4f6-4fcb-acd1-c4e21bdc631f_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation and other matters</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_af87b4b0-29f1-4c03-b679-ec071240138d_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Senior Notes Due March 2022</link:label>
    <link:label id="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_label_en-US" xlink:label="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes 6.50 Percent Due March 2022 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes 6.50 Percent Due March 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:href="bhc-20211231.xsd#bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:to="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_8709e3fb-490e-4e47-9101-02d7827147b3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_fb70c8de-c594-45e3-b367-1000b3d0b1ea_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_d66fb546-6adb-4a7d-95cf-8fa3ab95fd78_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_6062eb6f-cb66-4b4c-a05e-892558e54b0f_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum common shares issuable upon vesting (in shares)</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Arrangement by Share Based Payment Award, Number of Shares that could be Issued</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the maximum number of common shares that could be issued upon vesting of outstanding awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" xlink:href="bhc-20211231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_da5be99d-13d2-4ac2-8fa1-898d3bdeaacc_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeviceProductsMember_98b8b7db-1ce2-4e65-afe7-d0f976d447c4_terseLabel_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Devices</link:label>
    <link:label id="lab_bhc_DeviceProductsMember_label_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Products [Member]</link:label>
    <link:label id="lab_bhc_DeviceProductsMember_documentation_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember" xlink:href="bhc-20211231.xsd#bhc_DeviceProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeviceProductsMember" xlink:to="lab_bhc_DeviceProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_b619c982-2a0a-48df-85c1-68f6fee1c02c_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_e3ff437c-eb60-4891-b720-ae02958562ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of activity in allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_745b4569-4f15-4853-a799-b507d7b4017f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_78c4cfd5-e7d6-4238-b7d1-94c1442d7ef0_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_abf261ba-4782-49e2-9d3c-602104bb9e8c_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f759bb6c-e408-49f0-994d-f91e1a252242_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_151a4420-fbc3-41e1-8f24-69a416d0fc2c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_2a294a68-08f2-4d06-bbba-875f40e846a9_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_1c3f3f03-4787-49a1-a371-a8ee424e1e8b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of long-term debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_84c5f0e3-6241-4271-9f13-3b653b664c74_terseLabel_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. and Puerto Rico</link:label>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_label_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States and Puerto Rico [Member]</link:label>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_documentation_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States and Puerto Rico [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember" xlink:href="bhc-20211231.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnitedStatesandPuertoRicoMember" xlink:to="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_9815c371-7688-4f2f-8764-24dad63c6fb4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_f3675658-8f36-47b6-a683-176680023e3b_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments, included in acquired in-process research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fb177561-0b12-4249-9e23-8092da77d890_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_00914a18-ba58-451f-941f-8d79e6776ff6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_ef667b13-67e9-4c94-804d-7b131b4e7dfd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_a26f6014-f362-4d1e-bca4-6ec224475ce2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_525a43ac-f4d6-4705-8398-4aff454c2708_terseLabel_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products</link:label>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_134f15f1-9ebf-44a5-99e0-7613ca970bde_verboseLabel_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products</link:label>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_label_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products Segment [Member]</link:label>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_documentation_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember" xlink:href="bhc-20211231.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DiversifiedProductsSegmentMember" xlink:to="lab_bhc_DiversifiedProductsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetAssetLiabilityAbstract_3ab41f16-a2b1-4372-a515-d79b53f6348c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets:</link:label>
    <link:label id="lab_us-gaap_FairValueNetAssetLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Asset (Liability) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetAssetLiabilityAbstract" xlink:to="lab_us-gaap_FairValueNetAssetLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2831f66d-8599-4e92-acae-31b5ba9093a3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted-average common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_4d6ad707-57d2-4e07-be3c-b96f429f8755_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_6bf6a9db-a1e8-4757-bc97-b4dcc2d36a5d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_bd2f1044-6dc3-4a2a-82e9-d57ee42d3b2b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and write-off of debt discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity_bbdcd088-09da-47d9-86b4-37f92541f237_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected maximum borrowing capacity</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Expected Maximum Borrowing Capacity</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Expected Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity" xlink:href="bhc-20211231.xsd#bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity" xlink:to="lab_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_a151bfda-276b-4d30-9077-bbef1f2c9578_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_1db06efd-0707-4f05-8cac-39c8451caf4d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain excluded from assessment of hedge effectiveness</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_93021f6d-0c5a-4feb-ba04-6817d2a2a291_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leaseholds and Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_52e84d65-5fee-48c2-9e3e-3bf4c8c3ae3c_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_feaf7810-d0cd-4e7c-9840-064e5a4a4fa4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NJ_a86f796d-12d1-4981-8a04-3c82907897cd_terseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey</link:label>
    <link:label id="lab_stpr_NJ_label_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NJ" xlink:to="lab_stpr_NJ" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6217e329-72fb-4d62-9965-9e519c8f5dc1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9a945c30-6275-4d2f-8214-0d99bbc4eecf_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_28ada0dc-9058-4ea5-a7b1-036f83612b62_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_7ddf2feb-9d30-48e9-99e8-64de6e094aa0_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccumulatedLossesAvailableForFederalPurposes_f1504261-e316-4ab5-86db-9746eac577e2_terseLabel_en-US" xlink:label="lab_bhc_AccumulatedLossesAvailableForFederalPurposes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated losses available for federal and provincial purposes</link:label>
    <link:label id="lab_bhc_AccumulatedLossesAvailableForFederalPurposes_label_en-US" xlink:label="lab_bhc_AccumulatedLossesAvailableForFederalPurposes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Losses Available for Federal Purposes</link:label>
    <link:label id="lab_bhc_AccumulatedLossesAvailableForFederalPurposes_documentation_en-US" xlink:label="lab_bhc_AccumulatedLossesAvailableForFederalPurposes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the details pertaining to accumulated losses available for federal and provincial purposes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccumulatedLossesAvailableForFederalPurposes" xlink:href="bhc-20211231.xsd#bhc_AccumulatedLossesAvailableForFederalPurposes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccumulatedLossesAvailableForFederalPurposes" xlink:to="lab_bhc_AccumulatedLossesAvailableForFederalPurposes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_80d1be81-0128-4a26-a5f8-3d5c0922e82a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EquipmentOnOperatingLeaseMember_f1e6e8aa-dcee-4d48-a0cf-e50ce5addac9_terseLabel_en-US" xlink:label="lab_bhc_EquipmentOnOperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment on operating lease</link:label>
    <link:label id="lab_bhc_EquipmentOnOperatingLeaseMember_label_en-US" xlink:label="lab_bhc_EquipmentOnOperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment On Operating Lease [Member]</link:label>
    <link:label id="lab_bhc_EquipmentOnOperatingLeaseMember_documentation_en-US" xlink:label="lab_bhc_EquipmentOnOperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment On Operating Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EquipmentOnOperatingLeaseMember" xlink:href="bhc-20211231.xsd#bhc_EquipmentOnOperatingLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EquipmentOnOperatingLeaseMember" xlink:to="lab_bhc_EquipmentOnOperatingLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_McKessonCorporationMember_eb980ea1-dba1-48ff-82ef-163cd0366685_terseLabel_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:label id="lab_bhc_McKessonCorporationMember_label_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mc Kesson Corporation [Member]</link:label>
    <link:label id="lab_bhc_McKessonCorporationMember_documentation_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, McKesson Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember" xlink:href="bhc-20211231.xsd#bhc_McKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_McKessonCorporationMember" xlink:to="lab_bhc_McKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_1ae4f035-cba0-47e5-abca-fe60e6040f53_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_0fccdbd9-f729-48be-ba87-93ee2f836c62_terseLabel_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of variable consideration provisions</link:label>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_label_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Valuation And Qualifying Accounts [Table Text Block]</link:label>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_documentation_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Valuation And Qualifying Accounts [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:href="bhc-20211231.xsd#bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:to="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_2c9980c5-bd33-469b-9e11-4f5d7d9a8604_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9d439a71-01c9-4d8d-b55b-0e121cc10279_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of benefit from income taxes from the expected amount calculated by applying the Canadian statutory rate to loss before benefit of income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_c27a71b8-2140-4386-8b63-28c6b0920bb7_terseLabel_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_c60909c6-3988-4b59-8762-ac5ec7b04342_verboseLabel_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_3beac98d-5c95-486a-a77d-406ecf8865c4_negatedLabel_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_label_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_documentation_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:href="bhc-20211231.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:to="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6f2031e2-202b-480d-b5ff-cff5a664e24f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_d6d79d6c-1dda-46d4-9f0a-924dfbe03aac_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch Health Companies&#160;Inc. Shareholders' Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_5b52a155-4113-4924-8c58-06667f35cffa_verboseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment reporting information</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0089698d-8391-4ff3-a2de-4dfb9714751e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components and classification of financial assets and liabilities measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember_cd3a531b-abca-484b-a86d-978258fc4fb0_terseLabel_en-US" xlink:label="lab_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Notes due May 2023, March 2019 Refinancing</link:label>
    <link:label id="lab_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember_label_en-US" xlink:label="lab_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Notes due May 2023, March 2019 Refinancing [Member]</link:label>
    <link:label id="lab_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember_documentation_en-US" xlink:label="lab_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Notes due May 2023, March 2019 Refinancing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember" xlink:href="bhc-20211231.xsd#bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember" xlink:to="lab_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member_dbfb5f36-f900-4bef-b57c-130eb0152652_terseLabel_en-US" xlink:label="lab_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc.</link:label>
    <link:label id="lab_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member_label_en-US" xlink:label="lab_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc. [Member]</link:label>
    <link:label id="lab_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member_documentation_en-US" xlink:label="lab_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" xlink:href="bhc-20211231.xsd#bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" xlink:to="lab_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PaymentForDebtAmortizationPrepaymentCost_97910992-1d48-4503-84b8-41c008db944e_terseLabel_en-US" xlink:label="lab_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment, outstanding debt</link:label>
    <link:label id="lab_bhc_PaymentForDebtAmortizationPrepaymentCost_label_en-US" xlink:label="lab_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Debt Amortization Prepayment Cost</link:label>
    <link:label id="lab_bhc_PaymentForDebtAmortizationPrepaymentCost_documentation_en-US" xlink:label="lab_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Debt Amortization Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:href="bhc-20211231.xsd#bhc_PaymentForDebtAmortizationPrepaymentCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:to="lab_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_03a6d570-9868-41cc-9b0e-f8c22262a341_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fbcc5fd9-b2c5-42a0-9d16-b2563dd54969_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_72449d2b-e13b-4466-9167-c5e754f61f8d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_080774fc-c272-40fe-b65f-8a0807243fae_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_88af7146-b1ee-4887-95df-5c44609465b9_terseLabel_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action</link:label>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_label_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:to="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_62149575-09be-46a3-880f-39cf2ff98147_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_0b693eb1-9024-45ef-ae61-10ae854d153f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_763a6e5d-6877-4725-ba14-6d1f5f2ddfc3_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_29a04cb0-9259-4554-aafb-b19c86d64c1b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effect of hedging instruments on financial statements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_899644af-b4a9-4ea9-a227-967a421e7aac_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_8c7686a4-c91e-4494-88d4-eff9a14b6f8a_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair market value on awards granted during any calendar year</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:href="bhc-20211231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_94146558-6c2d-4d69-86c3-9ecc5862b87c_terseLabel_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates, Advertising Credits Portion</link:label>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_label_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates, Advertising Credits Portion [Member]</link:label>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_documentation_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates, Advertising Credits Portion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:href="bhc-20211231.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:to="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_cb245d91-5de5-4c4b-af45-02ad4bd223b6_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds from divestiture</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3cc519bb-5438-4f82-a02f-3222b820b4de_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4e40e1c7-aceb-48f2-99a1-131c404e4242_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_f22f1491-74d6-4ebf-a45d-7090e892f378_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_a0f55747-ea01-4320-879c-2f80faa14483_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_70ed6d8f-2dd9-42a2-9aa6-512a6ff70d70_terseLabel_en-US" xlink:label="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and other settlement deposits</link:label>
    <link:label id="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_label_en-US" xlink:label="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure</link:label>
    <link:label id="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_documentation_en-US" xlink:label="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:href="bhc-20211231.xsd#bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:to="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a870eb4a-5309-469e-8545-463a0e8ed332_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held For Sale</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_520f7188-4530-4f97-b092-b27aee3c3eab_terseLabel_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation</link:label>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_label_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation [Member]</link:label>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_documentation_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:href="bhc-20211231.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:to="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_19022eab-3f7b-43d2-89ba-a95c307c2a5e_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherEquipmentAndLeaseholdImprovementMember_90ec4a25-b81a-4de9-a7d0-271aaba22074_terseLabel_en-US" xlink:label="lab_bhc_OtherEquipmentAndLeaseholdImprovementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other equipment and leasehold improvements</link:label>
    <link:label id="lab_bhc_OtherEquipmentAndLeaseholdImprovementMember_label_en-US" xlink:label="lab_bhc_OtherEquipmentAndLeaseholdImprovementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Equipment and Leasehold Improvement [Member]</link:label>
    <link:label id="lab_bhc_OtherEquipmentAndLeaseholdImprovementMember_documentation_en-US" xlink:label="lab_bhc_OtherEquipmentAndLeaseholdImprovementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents other equipment and leasehold improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherEquipmentAndLeaseholdImprovementMember" xlink:href="bhc-20211231.xsd#bhc_OtherEquipmentAndLeaseholdImprovementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherEquipmentAndLeaseholdImprovementMember" xlink:to="lab_bhc_OtherEquipmentAndLeaseholdImprovementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_d4e7deb1-68bc-48a8-bb28-f630c473723a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal proceedings and other matters</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ac68579c-63ee-4946-86c0-d1dbef4f2da9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_a3e87b3c-ff71-4295-b38f-5ac576924abd_terseLabel_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for losses on trade receivables and inventories</link:label>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_label_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for Losses on Accounts Receivable and Inventories</link:label>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_documentation_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:href="bhc-20211231.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:to="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8b904ad8-917d-4714-ac8b-b3554f3112de_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_7108ced9-6a4c-4edc-95de-6f805b121c1b_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligation, beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_357196b1-4307-4111-8f76-7c1ca63f79f4_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligation, end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_224d0d3e-dd8f-4410-b662-d9d573d0965b_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_7292140e-d7e2-4c06-9c00-8f9038f3a328_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_910950f0-db29-4a4c-8a53-fe2f1e26368d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_9eddedee-be57-4090-8e6a-02f98da79dd2_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_8ff75b59-aff1-4da2-aac3-f6724e847465_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_12440541-709c-4b88-bb65-1a5f93e76d37_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_f40e2279-5d15-4c5d-8167-4396ee573380_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_b65d99ba-a260-4507-968f-99a114342065_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro-forma revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption_ab5693af-5595-49a0-800c-be33f6647ce2_terseLabel_en-US" xlink:label="lab_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption_label_en-US" xlink:label="lab_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Excluding Amount Recognized Upon Adoption</link:label>
    <link:label id="lab_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption_documentation_en-US" xlink:label="lab_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Excluding Amount Recognized Upon Adoption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" xlink:href="bhc-20211231.xsd#bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" xlink:to="lab_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncomeTaxReconciliationUncertainTaxPositions_57111847-4e29-4738-87f8-03ab891a039d_negatedTerseLabel_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationUncertainTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in uncertain tax positions</link:label>
    <link:label id="lab_bhc_IncomeTaxReconciliationUncertainTaxPositions_label_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Uncertain Tax Positions</link:label>
    <link:label id="lab_bhc_IncomeTaxReconciliationUncertainTaxPositions_documentation_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to uncertain tax positions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationUncertainTaxPositions" xlink:href="bhc-20211231.xsd#bhc_IncomeTaxReconciliationUncertainTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncomeTaxReconciliationUncertainTaxPositions" xlink:to="lab_bhc_IncomeTaxReconciliationUncertainTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_7d30ff27-a199-4952-9488-0c03c0257c80_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_f7696c20-30c9-484d-b35a-c584edd50c81_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For Determining Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LuxembourgInlandRevenueMember_8309c57b-4c08-419f-829c-0fa29c944288_terseLabel_en-US" xlink:label="lab_us-gaap_LuxembourgInlandRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Luxembourg</link:label>
    <link:label id="lab_us-gaap_LuxembourgInlandRevenueMember_label_en-US" xlink:label="lab_us-gaap_LuxembourgInlandRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Luxembourg Inland Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LuxembourgInlandRevenueMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LuxembourgInlandRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LuxembourgInlandRevenueMember" xlink:to="lab_us-gaap_LuxembourgInlandRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_c32a919d-d9ff-472a-9b24-622d20ec9ac3_terseLabel_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation Alleging Caused Ovarian Cancer Mesothelioma Or Breast Cancer</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_label_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation Alleging Caused Ovarian Cancer Mesothelioma Or Breast Cancer [Member]</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_documentation_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation Alleging Caused Ovarian Cancer Mesothelioma Or Breast Cancer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:href="bhc-20211231.xsd#bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:to="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_07de4d8c-2c2f-46dd-8b5a-0325b93b6902_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.000% Senior Notes Due December 2025</link:label>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_label_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 9.00%, Due December 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes900DueDecember2025Member" xlink:to="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_db17e212-8802-44b1-8106-83d8318e2b6c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_097fda3f-eda9-4656-9c0c-5cb6f6eea681_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_68ada093-1506-4df5-9524-f9b1801eaf8b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_ba9fce5f-d65d-48b1-8594-81bfbcbd0760_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A6.125SeniorNotesdueApril2025Member_7876f1cc-1faf-4c0b-95f4-fbbd0376091a_terseLabel_en-US" xlink:label="lab_bhc_A6.125SeniorNotesdueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Unsecured Notes due April 2025</link:label>
    <link:label id="lab_bhc_A6.125SeniorNotesdueApril2025Member_label_en-US" xlink:label="lab_bhc_A6.125SeniorNotesdueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes due April 2025 [Member]</link:label>
    <link:label id="lab_bhc_A6.125SeniorNotesdueApril2025Member_documentation_en-US" xlink:label="lab_bhc_A6.125SeniorNotesdueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes due April 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A6.125SeniorNotesdueApril2025Member" xlink:href="bhc-20211231.xsd#bhc_A6.125SeniorNotesdueApril2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A6.125SeniorNotesdueApril2025Member" xlink:to="lab_bhc_A6.125SeniorNotesdueApril2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_35aaeb78-bb9b-4b84-b84f-f8baa741355c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NonU.S.DevelopedMarketsMember_37322300-47cb-44d7-826a-15e4329c205f_terseLabel_en-US" xlink:label="lab_bhc_NonU.S.DevelopedMarketsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Worldwide developed markets</link:label>
    <link:label id="lab_bhc_NonU.S.DevelopedMarketsMember_label_en-US" xlink:label="lab_bhc_NonU.S.DevelopedMarketsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Developed Markets [Member]</link:label>
    <link:label id="lab_bhc_NonU.S.DevelopedMarketsMember_documentation_en-US" xlink:label="lab_bhc_NonU.S.DevelopedMarketsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Developed Markets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonU.S.DevelopedMarketsMember" xlink:href="bhc-20211231.xsd#bhc_NonU.S.DevelopedMarketsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NonU.S.DevelopedMarketsMember" xlink:to="lab_bhc_NonU.S.DevelopedMarketsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_2cea41c0-4f94-4fd7-8215-ce6b98ec7723_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_f10566f5-bd60-4afe-8d85-3ca72abf14e5_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_87b32250-c19a-4e7a-9bd5-e44a31f7183e_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate_00e35fb8-8446-4150-9e02-661350dcf32a_terseLabel_en-US" xlink:label="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retrospective effect of application of new accounting standard</link:label>
    <link:label id="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate_label_en-US" xlink:label="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update</link:label>
    <link:label id="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate_documentation_en-US" xlink:label="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:href="bhc-20211231.xsd#bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:to="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TaxBenefitRecognitionMeasurementPercentage_63827428-33e8-46c0-ba6a-b0e392ee1a34_terseLabel_en-US" xlink:label="lab_bhc_TaxBenefitRecognitionMeasurementPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit recognition, measurement percentage (greater than)</link:label>
    <link:label id="lab_bhc_TaxBenefitRecognitionMeasurementPercentage_label_en-US" xlink:label="lab_bhc_TaxBenefitRecognitionMeasurementPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Benefit Recognition, Measurement Percentage</link:label>
    <link:label id="lab_bhc_TaxBenefitRecognitionMeasurementPercentage_documentation_en-US" xlink:label="lab_bhc_TaxBenefitRecognitionMeasurementPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Benefit Recognition, Measurement Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxBenefitRecognitionMeasurementPercentage" xlink:href="bhc-20211231.xsd#bhc_TaxBenefitRecognitionMeasurementPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TaxBenefitRecognitionMeasurementPercentage" xlink:to="lab_bhc_TaxBenefitRecognitionMeasurementPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_6b4d139c-369c-4b67-bffa-ff6a929e8ab9_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_2df8b192-6df0-479b-9f1e-4b9d1f7fc79e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of loss before benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_e58bca27-6873-48cc-a9a3-f1684d6663e9_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NewRestatedCreditAgreementMember_66b1d560-e0ce-4515-ab34-badb54889ebc_terseLabel_en-US" xlink:label="lab_bhc_NewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Restated Credit Agreement</link:label>
    <link:label id="lab_bhc_NewRestatedCreditAgreementMember_label_en-US" xlink:label="lab_bhc_NewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Restated Credit Agreement [Member]</link:label>
    <link:label id="lab_bhc_NewRestatedCreditAgreementMember_documentation_en-US" xlink:label="lab_bhc_NewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Restated Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NewRestatedCreditAgreementMember" xlink:href="bhc-20211231.xsd#bhc_NewRestatedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NewRestatedCreditAgreementMember" xlink:to="lab_bhc_NewRestatedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_f70d5853-b1eb-4328-ba81-542c0846455b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandImprovementsMember_af5c9a8b-28bc-4f06-8f95-5406e32b7184_terseLabel_en-US" xlink:label="lab_us-gaap_LandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land improvements</link:label>
    <link:label id="lab_us-gaap_LandImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandImprovementsMember" xlink:to="lab_us-gaap_LandImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e697457c-4095-41dc-b575-fa63b7729b3d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_f15369c7-3c31-4d90-b4ea-f9ed2e71ba02_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_96ad106a-f89e-419f-8f45-43a4e56d4dbe_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_f0ef063e-f1b2-41a0-ae18-decce7473e8a_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_f36a5b60-8e0f-4a25-8d8a-05af7ad000ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a786218a-9e0b-4fca-9d93-712ddb034768_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_96d79241-82a4-4586-b33b-f0897e2ece1a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b7e12eac-faf2-4640-ad07-81067e3c1c0f_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance_66449e56-b058-41e2-af17-a3ec7c64e7da_terseLabel_en-US" xlink:label="lab_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit accrual, interest percentage earned on cash balance</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance_label_en-US" xlink:label="lab_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Accrual, Interest Percentage Earned On Cash Balance</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance_documentation_en-US" xlink:label="lab_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Accrual, Interest Percentage Earned On Cash Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" xlink:href="bhc-20211231.xsd#bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" xlink:to="lab_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6e856ae7-2ac3-4f10-8aff-f5927d130ded_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_170ba242-fb54-4c63-a103-516dabd02d9b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_631b0aca-b0fc-47a7-b063-8fb6a6442fed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_bde1889d-dcb5-43d9-a4f6-a1816a29732d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_696f2510-2788-4316-a715-aea3665d74c4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-offs</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_37dd057d-f530-4b64-bad5-44822e38b467_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0ca1f84f-aab8-4536-b107-4a89810dbc58_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_e0cfba79-c53b-4758-b7c4-ced1d20b8c66_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_72e4339c-622d-4afb-b4d3-eb0ed21b7fe4_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_94dd76f8-fcfc-40ee-abda-4ed6a322ec0d_terseLabel_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014</link:label>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_label_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</link:label>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_documentation_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member" xlink:href="bhc-20211231.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OmnibusIncentivePlan2014Member" xlink:to="lab_bhc_OmnibusIncentivePlan2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_0ea7a2fc-d296-43ca-a46c-13477480c960_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_1adb5676-55ec-494f-bda3-315c0bcc44e6_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherCountriesMember_a04075f3-bca0-4084-be10-43c72b50e15e_terseLabel_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bhc_OtherCountriesMember_label_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:label id="lab_bhc_OtherCountriesMember_documentation_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember" xlink:href="bhc-20211231.xsd#bhc_OtherCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherCountriesMember" xlink:to="lab_bhc_OtherCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2275dee1-170a-49c0-a042-2513ff903f02_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_307fbc9c-6bbd-4b26-b462-d34d42feefc8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Projected Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_d8964d57-322e-4fa2-b820-4b53ec6da14f_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_4927d7b5-ee54-4c00-893c-84f65267b1b1_verboseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_949467ec-9aed-41c6-86e0-e1ce27a1def9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AllegroOphthalmicsLLCMember_aa948ae2-85fa-49f8-bddc-b45d28145651_terseLabel_en-US" xlink:label="lab_bhc_AllegroOphthalmicsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegro</link:label>
    <link:label id="lab_bhc_AllegroOphthalmicsLLCMember_label_en-US" xlink:label="lab_bhc_AllegroOphthalmicsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegro Ophthalmics, LLC [Member]</link:label>
    <link:label id="lab_bhc_AllegroOphthalmicsLLCMember_documentation_en-US" xlink:label="lab_bhc_AllegroOphthalmicsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegro Ophthalmics, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllegroOphthalmicsLLCMember" xlink:href="bhc-20211231.xsd#bhc_AllegroOphthalmicsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AllegroOphthalmicsLLCMember" xlink:to="lab_bhc_AllegroOphthalmicsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e1d8f62e-944a-4103-8584-2fa43781edb3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock_b7da93a3-5151-4137-96f8-772e3a2c2fc4_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated useful lives of intangible assets</link:label>
    <link:label id="lab_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Useful Lives of Finite Lived Intangible Assets [Table Text Block]</link:label>
    <link:label id="lab_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock_documentation_en-US" xlink:label="lab_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of estimated useful lives of major classes of finite-lived intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="bhc-20211231.xsd#bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_7d407743-2645-4f67-8a03-54cb5bb215db_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments to acquire certain assets and assumed liabilities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_b450987b-6997-4d7e-ac16-a0bd211b573d_terseLabel_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO</link:label>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_label_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO [Member]</link:label>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_documentation_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember" xlink:href="bhc-20211231.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LitigationwithFormerSalixCEOMember" xlink:to="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3a10d4cd-ae88-40a0-9956-d69b3341d68c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_630dbf78-b541-4c0d-9b10-63d7314364d4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnutilizedITInfrastructureImprovementProjectMember_2619f69e-5ff8-4983-989a-0a9139667885_terseLabel_en-US" xlink:label="lab_bhc_UnutilizedITInfrastructureImprovementProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unutilized IT Infrastructure Improvement Project</link:label>
    <link:label id="lab_bhc_UnutilizedITInfrastructureImprovementProjectMember_label_en-US" xlink:label="lab_bhc_UnutilizedITInfrastructureImprovementProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unutilized IT Infrastructure Improvement Project [Member]</link:label>
    <link:label id="lab_bhc_UnutilizedITInfrastructureImprovementProjectMember_documentation_en-US" xlink:label="lab_bhc_UnutilizedITInfrastructureImprovementProjectMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unutilized IT Infrastructure Improvement Project</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnutilizedITInfrastructureImprovementProjectMember" xlink:href="bhc-20211231.xsd#bhc_UnutilizedITInfrastructureImprovementProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnutilizedITInfrastructureImprovementProjectMember" xlink:to="lab_bhc_UnutilizedITInfrastructureImprovementProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_d71481b6-f125-46ab-aca9-7f55567f4aad_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment reporting information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForRebatesMember_53b2c6c5-a857-4a37-b2b1-a3b031d53b58_terseLabel_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_bhc_ReserveForRebatesMember_label_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates [Member]</link:label>
    <link:label id="lab_bhc_ReserveForRebatesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember" xlink:href="bhc-20211231.xsd#bhc_ReserveForRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForRebatesMember" xlink:to="lab_bhc_ReserveForRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_f30ebb5c-2b04-4823-94e6-cab0890a09e4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of accrued legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_86aa7896-e9c1-47a8-b072-ebce5d5d716d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_51c8ca99-0cfc-4855-9157-59336e51388e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ApotexIncLitigationMember_62dc223b-a93f-4ee5-aa70-b7ff84d9ec3e_terseLabel_en-US" xlink:label="lab_bhc_ApotexIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. Litigation</link:label>
    <link:label id="lab_bhc_ApotexIncLitigationMember_label_en-US" xlink:label="lab_bhc_ApotexIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. Litigation [Member]</link:label>
    <link:label id="lab_bhc_ApotexIncLitigationMember_documentation_en-US" xlink:label="lab_bhc_ApotexIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ApotexIncLitigationMember" xlink:href="bhc-20211231.xsd#bhc_ApotexIncLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ApotexIncLitigationMember" xlink:to="lab_bhc_ApotexIncLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_82a7461c-b3de-47a6-b3b4-f8d7a18bf3de_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_525052e4-3620-474a-a8a4-b5c478e8da4c_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Funds Effective Swap Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_b3757908-20f2-4209-aa56-d44265c6f873_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of compensation increase</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions_eef85a28-f7f0-4b61-8ac4-985b809cb807_terseLabel_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, net increase for tax positions of prior years</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net Increase Resulting From Prior Period Tax Positions</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions_documentation_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net Increase Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" xlink:href="bhc-20211231.xsd#bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" xlink:to="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_9dff4932-3827-40fe-bdfb-58b3260d9663_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expenses</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock_e5eea607-495e-4c92-b03a-eb1fcf3f9a09_terseLabel_en-US" xlink:label="lab_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of other operating lease information</link:label>
    <link:label id="lab_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock_label_en-US" xlink:label="lab_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Operating Lease Information, Lessee [Table Text Block]</link:label>
    <link:label id="lab_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock_documentation_en-US" xlink:label="lab_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Operating Lease Information, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock" xlink:href="bhc-20211231.xsd#bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock" xlink:to="lab_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_2f2efb46-9d4e-425f-9d56-e5ecadbd0fda_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AssetsAndLiabilitiesLesseeTableTextBlock_52b68363-60e9-4354-b6b3-408f20eac316_terseLabel_en-US" xlink:label="lab_bhc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of right-of-use assets and right-of-use liabilities</link:label>
    <link:label id="lab_bhc_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_bhc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_bhc_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_bhc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="bhc-20211231.xsd#bhc_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_bhc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncomeTaxTable_9b4ca0cf-f3ce-49a8-b98e-0a7684123b28_terseLabel_en-US" xlink:label="lab_bhc_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Table]</link:label>
    <link:label id="lab_bhc_IncomeTaxTable_label_en-US" xlink:label="lab_bhc_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Table]</link:label>
    <link:label id="lab_bhc_IncomeTaxTable_documentation_en-US" xlink:label="lab_bhc_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of information relating to income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxTable" xlink:href="bhc-20211231.xsd#bhc_IncomeTaxTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncomeTaxTable" xlink:to="lab_bhc_IncomeTaxTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_55733ebf-7b83-4a56-bbfb-51806566d1aa_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Other non-current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_c6943049-38f1-4488-b02e-1738643dbf18_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized actuarial losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_cf0762d4-7eb3-4542-9447-a49bc2fb184e_terseLabel_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valeant US Securities Litigation</link:label>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_71ef5253-2738-4398-a36a-fd853f43e375_verboseLabel_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valeant US Securities Litigation</link:label>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_label_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valeant US Securities Litigation [Member]</link:label>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_documentation_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valeant US Securities Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember" xlink:href="bhc-20211231.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ValeantUSSecuritiesLitigationMember" xlink:to="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance_93ba5ce6-1d06-41c9-afa8-c701ff2127f7_negatedTerseLabel_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance related to foreign tax credits and NOLs</link:label>
    <link:label id="lab_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance_label_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Change in Operating Losses Valuation Allowance</link:label>
    <link:label id="lab_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance_documentation_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to change in valuation allowance related to operating losses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" xlink:href="bhc-20211231.xsd#bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" xlink:to="lab_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_e04db443-2da2-43ab-b982-e9dffa3914bf_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="bhc-20211231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_e26e6430-4a73-45e0-a745-85fa47b0458f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_9522b827-bb8e-40d7-88c1-81209bf3d58e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_bf0371bf-3637-4e88-b4c7-fb817c67a4e2_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cooperative advertising credits included in rebates</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_aed3fbec-2c28-42d2-9042-2f301ca7996b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_d3c1fc7d-7187-4c80-8452-7d1b0abf8707_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_019bd1fb-57ec-4c5c-a19b-15ebad780011_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_48fa6b15-ff58-4026-84ef-b140738497c2_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_9408c3d9-57a2-41f5-9008-db4c458e656a_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_335dcb87-d091-4d4c-b1f9-4d586e36de0b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_6a799c27-66ed-4cfd-9e5c-16a3209b8976_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized discounts</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_593c106a-d01c-441f-8030-7aef97efa762_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetDomain" xlink:to="lab_us-gaap_DeferredTaxAssetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_deab9261-8deb-4c72-b6f0-9e3c62a7bf93_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember_e5430b76-cbcf-4971-b617-150527a55fab_terseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility, New Restated Credit Agreement</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility, New Restated Credit Agreement [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility, New Restated Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember" xlink:href="bhc-20211231.xsd#bhc_TermLoanBFacilityNewRestatedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember" xlink:to="lab_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-13 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>bhc-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:cdc15979-c542-4d25-920c-73804898e32f,g:89bc1415-46fc-4aad-8e83-55f6d8df2ca2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="bhc-20211231.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_81ef3a9a-bd8f-4dc8-a0bd-217ab1f6b1a3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_DocumentType_81ef3a9a-bd8f-4dc8-a0bd-217ab1f6b1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_1d3802fa-60ba-4690-8c39-87e5a0e84bdb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_DocumentAnnualReport_1d3802fa-60ba-4690-8c39-87e5a0e84bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_93b162ae-9a73-44c0-99d7-68a9100a8761" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_DocumentPeriodEndDate_93b162ae-9a73-44c0-99d7-68a9100a8761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_57225e58-f4fe-4c07-9b88-4486f2441254" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_CurrentFiscalYearEndDate_57225e58-f4fe-4c07-9b88-4486f2441254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_97a7a09a-580d-46bf-81a1-86b6ef729111" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_DocumentTransitionReport_97a7a09a-580d-46bf-81a1-86b6ef729111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8ddc5b59-f488-4bbe-b10b-d36c9920e6ae" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_EntityFileNumber_8ddc5b59-f488-4bbe-b10b-d36c9920e6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_8fb842de-7de4-4cf8-a45b-b768082f2ae2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_EntityRegistrantName_8fb842de-7de4-4cf8-a45b-b768082f2ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c87c9cbb-9d50-484f-b89b-261725dd3f9f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c87c9cbb-9d50-484f-b89b-261725dd3f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_ca55f21f-e479-4893-ab7a-239ba2d872db" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_EntityAddressCountry_ca55f21f-e479-4893-ab7a-239ba2d872db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a8dde6b4-90e8-40e1-93df-a60be91f0abe" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_EntityTaxIdentificationNumber_a8dde6b4-90e8-40e1-93df-a60be91f0abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2bf3867b-3ef4-425d-8ffb-a43c1a7512e0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_EntityAddressAddressLine1_2bf3867b-3ef4-425d-8ffb-a43c1a7512e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_5aa9bedb-e1e4-4502-aecf-1a6a3a894ce9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_EntityAddressCityOrTown_5aa9bedb-e1e4-4502-aecf-1a6a3a894ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_82c21cff-080d-464f-9c29-ae8c92383947" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_EntityAddressStateOrProvince_82c21cff-080d-464f-9c29-ae8c92383947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_26913ca0-cb31-464c-922b-1d9b20fb6d4d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_EntityAddressPostalZipCode_26913ca0-cb31-464c-922b-1d9b20fb6d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6dc08813-a284-4b80-9f63-12fa7a1b1344" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_CityAreaCode_6dc08813-a284-4b80-9f63-12fa7a1b1344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f349091a-5504-421d-a38a-1d033b71f622" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_LocalPhoneNumber_f349091a-5504-421d-a38a-1d033b71f622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_461622dd-9dd1-4af2-af86-d9627cc1a4f6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_Security12bTitle_461622dd-9dd1-4af2-af86-d9627cc1a4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_eb63727e-d764-44fb-a2b5-82e4f80c97c6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_TradingSymbol_eb63727e-d764-44fb-a2b5-82e4f80c97c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_17383dfb-f7d3-4f59-ae4d-7a6a51d3fbdb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_SecurityExchangeName_17383dfb-f7d3-4f59-ae4d-7a6a51d3fbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_bb066ea8-20bc-4bda-9867-ab8bef018f10" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_bb066ea8-20bc-4bda-9867-ab8bef018f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_ff71865b-6921-4c9a-942c-4c59358b050c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_EntityVoluntaryFilers_ff71865b-6921-4c9a-942c-4c59358b050c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_32057ace-23c7-4e23-bc2e-065640c1725f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_EntityCurrentReportingStatus_32057ace-23c7-4e23-bc2e-065640c1725f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ea16af55-1bdb-48f6-b08c-b070f1109416" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_EntityInteractiveDataCurrent_ea16af55-1bdb-48f6-b08c-b070f1109416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e219c54c-26a5-43e6-b872-f8e1aed604e0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_EntityFilerCategory_e219c54c-26a5-43e6-b872-f8e1aed604e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_20164de5-4561-41b4-b58b-4da8077dd382" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_EntitySmallBusiness_20164de5-4561-41b4-b58b-4da8077dd382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f7d98018-165b-4d5a-97c5-8c5844b75454" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_EntityEmergingGrowthCompany_f7d98018-165b-4d5a-97c5-8c5844b75454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_8406e3de-8dd7-4a9e-8dde-cf80256cd9aa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_IcfrAuditorAttestationFlag_8406e3de-8dd7-4a9e-8dde-cf80256cd9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_12a92829-64b5-42c3-ba49-86b2cc4409e7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_EntityShellCompany_12a92829-64b5-42c3-ba49-86b2cc4409e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_f89462e8-c1aa-42fc-9d36-d1d13529bbea" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_EntityPublicFloat_f89462e8-c1aa-42fc-9d36-d1d13529bbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9789dc07-2d85-42b1-924d-20600df1e6aa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_9789dc07-2d85-42b1-924d-20600df1e6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f0c8d0f6-9424-4523-8667-8441f06db617" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f0c8d0f6-9424-4523-8667-8441f06db617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3e02959e-a78d-4f1f-a302-30601378aa5c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_EntityCentralIndexKey_3e02959e-a78d-4f1f-a302-30601378aa5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_560b6259-a3fe-4c0c-a474-43f971dda57b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_DocumentFiscalYearFocus_560b6259-a3fe-4c0c-a474-43f971dda57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9a1a3736-fa7b-4ad9-b530-2ecde2bd7c5c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9a1a3736-fa7b-4ad9-b530-2ecde2bd7c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c6fd0c57-aba6-4dd0-aab5-636b43d33908" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fb67774-ffe1-4366-acc7-d672480d7c72" xlink:to="loc_dei_AmendmentFlag_c6fd0c57-aba6-4dd0-aab5-636b43d33908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/AUDITINFORMATION" xlink:type="simple" xlink:href="bhc-20211231.xsd#AUDITINFORMATION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/AUDITINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AuditInformationAbstract_2c622955-59c1-4f12-a798-5ed6143c95ea" xlink:href="bhc-20211231.xsd#bhc_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_ec4779a1-023e-4f26-bf27-a91b4b7b0b6e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AuditInformationAbstract_2c622955-59c1-4f12-a798-5ed6143c95ea" xlink:to="loc_dei_AuditorFirmId_ec4779a1-023e-4f26-bf27-a91b4b7b0b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_130afb32-9290-4ccc-8a1c-4c0954f61cf7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AuditInformationAbstract_2c622955-59c1-4f12-a798-5ed6143c95ea" xlink:to="loc_dei_AuditorName_130afb32-9290-4ccc-8a1c-4c0954f61cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_c656f0d8-6f4c-4052-8e4b-0284eb13126c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AuditInformationAbstract_2c622955-59c1-4f12-a798-5ed6143c95ea" xlink:to="loc_dei_AuditorLocation_c656f0d8-6f4c-4052-8e4b-0284eb13126c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bhc-20211231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c2acdd93-fae6-4147-89d6-1798dabea311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_190fb271-c938-49a4-83fc-d592ebc70b09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c2acdd93-fae6-4147-89d6-1798dabea311" xlink:to="loc_us-gaap_AssetsAbstract_190fb271-c938-49a4-83fc-d592ebc70b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_35198a88-5416-4760-a262-56e67d5ce2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_190fb271-c938-49a4-83fc-d592ebc70b09" xlink:to="loc_us-gaap_AssetsCurrentAbstract_35198a88-5416-4760-a262-56e67d5ce2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1da516fb-72b2-4eba-b000-146315b947f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_35198a88-5416-4760-a262-56e67d5ce2bb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1da516fb-72b2-4eba-b000-146315b947f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_7366eb65-b9f5-4a81-adca-2495a9ff313e" xlink:href="bhc-20211231.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_35198a88-5416-4760-a262-56e67d5ce2bb" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_7366eb65-b9f5-4a81-adca-2495a9ff313e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_660080a8-dddc-4e7f-9613-1872fed117ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_35198a88-5416-4760-a262-56e67d5ce2bb" xlink:to="loc_us-gaap_ReceivablesNetCurrent_660080a8-dddc-4e7f-9613-1872fed117ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d68d10ea-b450-4094-8d2d-d51a67df97da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_35198a88-5416-4760-a262-56e67d5ce2bb" xlink:to="loc_us-gaap_InventoryNet_d68d10ea-b450-4094-8d2d-d51a67df97da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_35f9c37f-ab10-4701-a1bc-b87431b039c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_35198a88-5416-4760-a262-56e67d5ce2bb" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_35f9c37f-ab10-4701-a1bc-b87431b039c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0a25b609-c8ea-423f-8f43-77b51cb33829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_35198a88-5416-4760-a262-56e67d5ce2bb" xlink:to="loc_us-gaap_AssetsCurrent_0a25b609-c8ea-423f-8f43-77b51cb33829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4135ed3f-4134-46e6-b2cb-d04dd817cc23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_190fb271-c938-49a4-83fc-d592ebc70b09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4135ed3f-4134-46e6-b2cb-d04dd817cc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5ddb5ced-9503-4bce-8076-74ee736fe9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_190fb271-c938-49a4-83fc-d592ebc70b09" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5ddb5ced-9503-4bce-8076-74ee736fe9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e3bc2a3e-085b-40cb-a0aa-4bc241a842f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_190fb271-c938-49a4-83fc-d592ebc70b09" xlink:to="loc_us-gaap_Goodwill_e3bc2a3e-085b-40cb-a0aa-4bc241a842f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_cb032c64-ee07-4b6a-bd9e-6f1142a61125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_190fb271-c938-49a4-83fc-d592ebc70b09" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_cb032c64-ee07-4b6a-bd9e-6f1142a61125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f6090dc4-0a85-4305-8958-f2571590ae94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_190fb271-c938-49a4-83fc-d592ebc70b09" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f6090dc4-0a85-4305-8958-f2571590ae94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0a130744-fcfc-4810-a2e8-246d63f117e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_190fb271-c938-49a4-83fc-d592ebc70b09" xlink:to="loc_us-gaap_Assets_0a130744-fcfc-4810-a2e8-246d63f117e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_f0198929-4787-480d-861e-57a29536cdaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c2acdd93-fae6-4147-89d6-1798dabea311" xlink:to="loc_us-gaap_LiabilitiesAbstract_f0198929-4787-480d-861e-57a29536cdaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2aa70d21-f346-4920-b1f1-b9989badf7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_f0198929-4787-480d-861e-57a29536cdaa" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2aa70d21-f346-4920-b1f1-b9989badf7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_65917498-86ff-41d1-be11-21f5e931302d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2aa70d21-f346-4920-b1f1-b9989badf7e5" xlink:to="loc_us-gaap_AccountsPayableCurrent_65917498-86ff-41d1-be11-21f5e931302d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4a55200b-9bc6-473d-8791-c89c6a42d7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2aa70d21-f346-4920-b1f1-b9989badf7e5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4a55200b-9bc6-473d-8791-c89c6a42d7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_be977a03-2ffa-4637-bac6-53b13c8b2e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2aa70d21-f346-4920-b1f1-b9989badf7e5" xlink:to="loc_us-gaap_LiabilitiesCurrent_be977a03-2ffa-4637-bac6-53b13c8b2e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_c2b68ede-8192-4d87-af0c-e57ead8cb24a" xlink:href="bhc-20211231.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_f0198929-4787-480d-861e-57a29536cdaa" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_c2b68ede-8192-4d87-af0c-e57ead8cb24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_df125aba-94fa-4947-bf77-ca991b0a4b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_f0198929-4787-480d-861e-57a29536cdaa" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_df125aba-94fa-4947-bf77-ca991b0a4b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b576b51e-1148-4e7b-b3f5-41ea4b72712e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_f0198929-4787-480d-861e-57a29536cdaa" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b576b51e-1148-4e7b-b3f5-41ea4b72712e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d7841b2d-d7c3-4693-a9ea-d0d0210c9d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_f0198929-4787-480d-861e-57a29536cdaa" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d7841b2d-d7c3-4693-a9ea-d0d0210c9d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_94a73ad2-b161-4e17-a25c-3b6055202596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_f0198929-4787-480d-861e-57a29536cdaa" xlink:to="loc_us-gaap_Liabilities_94a73ad2-b161-4e17-a25c-3b6055202596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1874ce32-2d2c-4aa5-9bb4-f2137aa8eddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c2acdd93-fae6-4147-89d6-1798dabea311" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1874ce32-2d2c-4aa5-9bb4-f2137aa8eddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_9f306709-7469-46c2-b7ae-58213bdbfa83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c2acdd93-fae6-4147-89d6-1798dabea311" xlink:to="loc_us-gaap_StockholdersEquityAbstract_9f306709-7469-46c2-b7ae-58213bdbfa83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7ded7803-a8d1-4b02-af8b-d27e3b4a80ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9f306709-7469-46c2-b7ae-58213bdbfa83" xlink:to="loc_us-gaap_CommonStockValue_7ded7803-a8d1-4b02-af8b-d27e3b4a80ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_342eaa92-025e-426f-9574-e9e5d63c9ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9f306709-7469-46c2-b7ae-58213bdbfa83" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_342eaa92-025e-426f-9574-e9e5d63c9ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_30fba032-1d78-4585-bc58-258d700e579d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9f306709-7469-46c2-b7ae-58213bdbfa83" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_30fba032-1d78-4585-bc58-258d700e579d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3d85fffe-f345-48b6-9992-e372660b6dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9f306709-7469-46c2-b7ae-58213bdbfa83" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3d85fffe-f345-48b6-9992-e372660b6dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9e6c5335-01df-4128-bfe9-1eae0344e211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9f306709-7469-46c2-b7ae-58213bdbfa83" xlink:to="loc_us-gaap_StockholdersEquity_9e6c5335-01df-4128-bfe9-1eae0344e211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_e87ca744-0d72-4c28-8e83-f5cbe2d4a68b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9f306709-7469-46c2-b7ae-58213bdbfa83" xlink:to="loc_us-gaap_MinorityInterest_e87ca744-0d72-4c28-8e83-f5cbe2d4a68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80ebeda8-3b46-45ca-9c85-7bf7c02e4567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9f306709-7469-46c2-b7ae-58213bdbfa83" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80ebeda8-3b46-45ca-9c85-7bf7c02e4567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8a4c1031-2a1d-42a3-8cfa-0eecbf63bd5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c2acdd93-fae6-4147-89d6-1798dabea311" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_8a4c1031-2a1d-42a3-8cfa-0eecbf63bd5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="bhc-20211231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4d541fc5-faa5-4d87-9db7-df899dafa108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_881dc55d-f712-4d09-bd6b-733e6c2db134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4d541fc5-faa5-4d87-9db7-df899dafa108" xlink:to="loc_us-gaap_CommonStockSharesIssued_881dc55d-f712-4d09-bd6b-733e6c2db134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f1f1e18e-d319-49da-9182-24785ea074f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4d541fc5-faa5-4d87-9db7-df899dafa108" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f1f1e18e-d319-49da-9182-24785ea074f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20211231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_93d55aaa-2435-41cb-b2a1-a5009e5b3988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_80434028-ab90-4729-8af8-6cfe3a2892ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_93d55aaa-2435-41cb-b2a1-a5009e5b3988" xlink:to="loc_us-gaap_StatementTable_80434028-ab90-4729-8af8-6cfe3a2892ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_41dba26d-31a8-49ae-9e27-9f8540ca7153" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_80434028-ab90-4729-8af8-6cfe3a2892ac" xlink:to="loc_srt_ProductOrServiceAxis_41dba26d-31a8-49ae-9e27-9f8540ca7153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f1488216-e568-4a8c-9f3e-19fcbc7952a6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_41dba26d-31a8-49ae-9e27-9f8540ca7153" xlink:to="loc_srt_ProductsAndServicesDomain_f1488216-e568-4a8c-9f3e-19fcbc7952a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_fc280fa8-554d-4071-b48d-959c9b8a0ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1488216-e568-4a8c-9f3e-19fcbc7952a6" xlink:to="loc_us-gaap_ProductMember_fc280fa8-554d-4071-b48d-959c9b8a0ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_0bd0239c-8fc6-4ac1-a069-e417cf9dec2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1488216-e568-4a8c-9f3e-19fcbc7952a6" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_0bd0239c-8fc6-4ac1-a069-e417cf9dec2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_80434028-ab90-4729-8af8-6cfe3a2892ac" xlink:to="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_0d1c1e78-d9db-40a3-b0d8-cc372780b2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_RevenuesAbstract_0d1c1e78-d9db-40a3-b0d8-cc372780b2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_211b1aff-c708-4895-9f5a-bce0313d09f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0d1c1e78-d9db-40a3-b0d8-cc372780b2ea" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_211b1aff-c708-4895-9f5a-bce0313d09f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_ed7f7de3-84eb-454f-87da-c48ad44ee179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_ed7f7de3-84eb-454f-87da-c48ad44ee179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d33305ca-43ef-4504-89c5-255de9343faa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ed7f7de3-84eb-454f-87da-c48ad44ee179" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d33305ca-43ef-4504-89c5-255de9343faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9e286e8f-9773-42de-acea-68c80f9ada33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ed7f7de3-84eb-454f-87da-c48ad44ee179" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9e286e8f-9773-42de-acea-68c80f9ada33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ade018b8-4d7f-406d-91d2-24069d5654e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ed7f7de3-84eb-454f-87da-c48ad44ee179" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ade018b8-4d7f-406d-91d2-24069d5654e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_bbe8cc6a-71cb-466c-9734-d0ce229bfb45" xlink:href="bhc-20211231.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ed7f7de3-84eb-454f-87da-c48ad44ee179" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_bbe8cc6a-71cb-466c-9734-d0ce229bfb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_a9ee2d44-17cb-4a21-8ca1-838754cc129f" xlink:href="bhc-20211231.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ed7f7de3-84eb-454f-87da-c48ad44ee179" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_a9ee2d44-17cb-4a21-8ca1-838754cc129f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_83e935f6-9f92-444a-83d5-9236250b84d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ed7f7de3-84eb-454f-87da-c48ad44ee179" xlink:to="loc_us-gaap_AssetImpairmentCharges_83e935f6-9f92-444a-83d5-9236250b84d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_8c31cc29-aacf-4b1a-9335-15c7549f6ef9" xlink:href="bhc-20211231.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ed7f7de3-84eb-454f-87da-c48ad44ee179" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_8c31cc29-aacf-4b1a-9335-15c7549f6ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_412d1249-536b-4d9d-95bb-95e358ee6cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ed7f7de3-84eb-454f-87da-c48ad44ee179" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_412d1249-536b-4d9d-95bb-95e358ee6cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f06a2491-4cd4-4082-8f38-caffffcefe15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ed7f7de3-84eb-454f-87da-c48ad44ee179" xlink:to="loc_us-gaap_CostsAndExpenses_f06a2491-4cd4-4082-8f38-caffffcefe15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3ad3bbb3-fb6f-47a9-85c2-0a4255547188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_OperatingIncomeLoss_3ad3bbb3-fb6f-47a9-85c2-0a4255547188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_389ea205-6281-4f15-a86a-4e96cc136f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_389ea205-6281-4f15-a86a-4e96cc136f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_3d425156-3ea8-4441-9dee-c589f8cbceb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_InterestExpenseDebt_3d425156-3ea8-4441-9dee-c589f8cbceb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_20f61d02-5a75-453a-965a-2fbfb896a0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_20f61d02-5a75-453a-965a-2fbfb896a0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6562e68a-bcfa-4caa-98e1-2709abe956d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6562e68a-bcfa-4caa-98e1-2709abe956d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0e33409-478e-490e-af4c-e957fd70b9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0e33409-478e-490e-af4c-e957fd70b9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f3a612e4-770e-4af8-b571-8e44ca7f5fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f3a612e4-770e-4af8-b571-8e44ca7f5fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_92867897-8bdc-4560-97d0-2c54a59812bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_ProfitLoss_92867897-8bdc-4560-97d0-2c54a59812bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f69e8fa7-6bef-43e8-ad62-4a302959cbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f69e8fa7-6bef-43e8-ad62-4a302959cbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_12837e14-3a22-403c-b3db-ad20656bae41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_NetIncomeLoss_12837e14-3a22-403c-b3db-ad20656bae41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7b3b705e-8065-4e80-8c8f-a07c590f33be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_EarningsPerShareBasic_7b3b705e-8065-4e80-8c8f-a07c590f33be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_be76dbe7-c87f-41e7-aaa3-a901f8b17651" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_be76dbe7-c87f-41e7-aaa3-a901f8b17651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_296992f4-6602-46a5-8255-3a6ac8826dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_296992f4-6602-46a5-8255-3a6ac8826dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9fc495d7-1791-4d5c-b89c-ea14ab48dd32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c0a57f43-64e4-4d0e-aa71-3da09cd71cf0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9fc495d7-1791-4d5c-b89c-ea14ab48dd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhc-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_08b88f05-101c-4eb3-b893-9f6897f90d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1725bf9c-45f8-4f74-9752-fa937b2800eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_08b88f05-101c-4eb3-b893-9f6897f90d88" xlink:to="loc_us-gaap_ProfitLoss_1725bf9c-45f8-4f74-9752-fa937b2800eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_437f5164-6643-4495-b10a-903990543d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_08b88f05-101c-4eb3-b893-9f6897f90d88" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_437f5164-6643-4495-b10a-903990543d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_0c189e50-458c-4186-8f15-60cee10292f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_437f5164-6643-4495-b10a-903990543d50" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_0c189e50-458c-4186-8f15-60cee10292f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_7559636f-aa22-47f0-abd6-a86d8c929199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_0c189e50-458c-4186-8f15-60cee10292f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_7559636f-aa22-47f0-abd6-a86d8c929199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_3fdab022-2690-43bb-8157-cea5ff7ac41f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_0c189e50-458c-4186-8f15-60cee10292f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_3fdab022-2690-43bb-8157-cea5ff7ac41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition_6ea163dd-82e0-49fb-b0ac-6b839e38f91a" xlink:href="bhc-20211231.xsd#bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_0c189e50-458c-4186-8f15-60cee10292f7" xlink:to="loc_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition_6ea163dd-82e0-49fb-b0ac-6b839e38f91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_f31f33da-098d-405f-b477-e6719813b98f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_0c189e50-458c-4186-8f15-60cee10292f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_f31f33da-098d-405f-b477-e6719813b98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax_ded4089a-6fb1-457d-a5d8-7b350fa4b887" xlink:href="bhc-20211231.xsd#bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_0c189e50-458c-4186-8f15-60cee10292f7" xlink:to="loc_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax_ded4089a-6fb1-457d-a5d8-7b350fa4b887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_a9e25074-1b26-440b-be88-6ba284cb0194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_0c189e50-458c-4186-8f15-60cee10292f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_a9e25074-1b26-440b-be88-6ba284cb0194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c2753b6d-016b-4564-9b37-20525e8aa574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_437f5164-6643-4495-b10a-903990543d50" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c2753b6d-016b-4564-9b37-20525e8aa574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f71a411a-bd36-47e8-bd4a-19fb04226238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_437f5164-6643-4495-b10a-903990543d50" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f71a411a-bd36-47e8-bd4a-19fb04226238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3e1977c8-5ddc-4957-a7d5-7d6f7ed897e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_08b88f05-101c-4eb3-b893-9f6897f90d88" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3e1977c8-5ddc-4957-a7d5-7d6f7ed897e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f940deb3-e78e-478c-bac3-bdf8e34a188c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_08b88f05-101c-4eb3-b893-9f6897f90d88" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f940deb3-e78e-478c-bac3-bdf8e34a188c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_47b8cebf-a84f-43f3-8cf0-62c4945e7622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_08b88f05-101c-4eb3-b893-9f6897f90d88" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_47b8cebf-a84f-43f3-8cf0-62c4945e7622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="bhc-20211231.xsd#CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ee9d067f-188b-4486-a56f-807e583ed459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_39068060-39af-4cf6-ae4d-25861bbbc80a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ee9d067f-188b-4486-a56f-807e583ed459" xlink:to="loc_us-gaap_StatementTable_39068060-39af-4cf6-ae4d-25861bbbc80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_62b30b7d-788b-4731-9c33-94c7d7145e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_39068060-39af-4cf6-ae4d-25861bbbc80a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_62b30b7d-788b-4731-9c33-94c7d7145e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7835a223-6458-4b92-96f2-1155d868d5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_62b30b7d-788b-4731-9c33-94c7d7145e6e" xlink:to="loc_us-gaap_EquityComponentDomain_7835a223-6458-4b92-96f2-1155d868d5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_9ab5c19f-dc64-4379-accc-c24460d6a083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7835a223-6458-4b92-96f2-1155d868d5e0" xlink:to="loc_us-gaap_ParentMember_9ab5c19f-dc64-4379-accc-c24460d6a083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_44541c63-4ff8-4241-bfc8-093078e95955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_9ab5c19f-dc64-4379-accc-c24460d6a083" xlink:to="loc_us-gaap_CommonStockMember_44541c63-4ff8-4241-bfc8-093078e95955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_900c03a6-980a-4800-87fb-025c50c4a0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_9ab5c19f-dc64-4379-accc-c24460d6a083" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_900c03a6-980a-4800-87fb-025c50c4a0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2eb6c755-26c5-428a-a759-e3d3c30a0e29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_9ab5c19f-dc64-4379-accc-c24460d6a083" xlink:to="loc_us-gaap_RetainedEarningsMember_2eb6c755-26c5-428a-a759-e3d3c30a0e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b810dcd3-56f8-4f1f-8da1-7181c3cfcfe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_9ab5c19f-dc64-4379-accc-c24460d6a083" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b810dcd3-56f8-4f1f-8da1-7181c3cfcfe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_3de9db06-2a6c-4f1a-8b21-295e567a84fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7835a223-6458-4b92-96f2-1155d868d5e0" xlink:to="loc_us-gaap_NoncontrollingInterestMember_3de9db06-2a6c-4f1a-8b21-295e567a84fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a8ca315a-a707-444d-8b68-30b1114a1251" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_39068060-39af-4cf6-ae4d-25861bbbc80a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a8ca315a-a707-444d-8b68-30b1114a1251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_379037c4-bb3a-477f-9dd1-da22590e2989" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a8ca315a-a707-444d-8b68-30b1114a1251" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_379037c4-bb3a-477f-9dd1-da22590e2989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4ef056cf-a946-4d5a-8cdc-b8ec0e43bd99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_379037c4-bb3a-477f-9dd1-da22590e2989" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4ef056cf-a946-4d5a-8cdc-b8ec0e43bd99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dfe5a18b-14dd-4f23-ae4b-36ba856c32b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_39068060-39af-4cf6-ae4d-25861bbbc80a" xlink:to="loc_us-gaap_StatementLineItems_dfe5a18b-14dd-4f23-ae4b-36ba856c32b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dfe5a18b-14dd-4f23-ae4b-36ba856c32b7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_57627746-39b4-4f32-aebd-f79bb827f3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_CommonStockSharesIssued_57627746-39b4-4f32-aebd-f79bb827f3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6bc95bde-a148-4501-8256-efdd8f494968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6bc95bde-a148-4501-8256-efdd8f494968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_3e1976cd-133e-44fc-8b06-d8f41dd1a4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_3e1976cd-133e-44fc-8b06-d8f41dd1a4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5e13c087-c086-4739-9f48-74b564990eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5e13c087-c086-4739-9f48-74b564990eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f62c51c5-9421-42e5-8463-2c6f1410b7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f62c51c5-9421-42e5-8463-2c6f1410b7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b3990cf0-9108-4950-ab77-34e367a3d414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b3990cf0-9108-4950-ab77-34e367a3d414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8667af72-b3f7-4937-90f9-a641cdaa60b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8667af72-b3f7-4937-90f9-a641cdaa60b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_3b0073c3-e7dc-4007-91e9-9195c6c3bf4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_3b0073c3-e7dc-4007-91e9-9195c6c3bf4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0fe9a0e9-61fc-4b40-9a94-a04cf338bee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0fe9a0e9-61fc-4b40-9a94-a04cf338bee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c812adc7-72ab-47d6-940a-37cb546a18c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_ProfitLoss_c812adc7-72ab-47d6-940a-37cb546a18c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ce43eb86-9c71-433b-9b8b-a5414f7b9416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ce43eb86-9c71-433b-9b8b-a5414f7b9416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cbf7f824-4dd6-4325-b9ee-cd602fa8d13a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_CommonStockSharesIssued_cbf7f824-4dd6-4325-b9ee-cd602fa8d13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6bc3f42c-c5d8-483f-b4dc-ea64b7a28311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8f851a5-62fb-4fa7-b78c-bfdd8024e7ab" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6bc3f42c-c5d8-483f-b4dc-ea64b7a28311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bhc-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_139863eb-2f02-4147-8cab-679e635b6258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a194d938-922c-47c4-8c9c-5b33778b01fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_139863eb-2f02-4147-8cab-679e635b6258" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a194d938-922c-47c4-8c9c-5b33778b01fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_004dcec5-a677-416f-899b-ac9dfbe7e96b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a194d938-922c-47c4-8c9c-5b33778b01fb" xlink:to="loc_us-gaap_ProfitLoss_004dcec5-a677-416f-899b-ac9dfbe7e96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc885c95-762e-425e-8cdb-12b171e65789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a194d938-922c-47c4-8c9c-5b33778b01fb" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc885c95-762e-425e-8cdb-12b171e65789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_d5fabf0c-bba7-4df6-a9d8-6953d8690601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc885c95-762e-425e-8cdb-12b171e65789" xlink:to="loc_us-gaap_DepreciationAndAmortization_d5fabf0c-bba7-4df6-a9d8-6953d8690601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_48226534-e64d-4993-b7e4-32589bcc1d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc885c95-762e-425e-8cdb-12b171e65789" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_48226534-e64d-4993-b7e4-32589bcc1d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_8d907398-fd9c-4a3a-a071-73d44fe3f92e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc885c95-762e-425e-8cdb-12b171e65789" xlink:to="loc_us-gaap_AssetImpairmentCharges_8d907398-fd9c-4a3a-a071-73d44fe3f92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_f5276295-30f8-42cd-ba3f-6b444ad2f963" xlink:href="bhc-20211231.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc885c95-762e-425e-8cdb-12b171e65789" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_f5276295-30f8-42cd-ba3f-6b444ad2f963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_e7a21a34-3ccc-4464-825d-555d43f8eb2d" xlink:href="bhc-20211231.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc885c95-762e-425e-8cdb-12b171e65789" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_e7a21a34-3ccc-4464-825d-555d43f8eb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_288c965d-64b6-4008-babc-a99aa3ab0a5c" xlink:href="bhc-20211231.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc885c95-762e-425e-8cdb-12b171e65789" xlink:to="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_288c965d-64b6-4008-babc-a99aa3ab0a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_26b57914-d680-410c-b672-e5a99c86229b" xlink:href="bhc-20211231.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc885c95-762e-425e-8cdb-12b171e65789" xlink:to="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_26b57914-d680-410c-b672-e5a99c86229b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_b01a0bfd-25ea-481c-8e36-288ce446ffd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc885c95-762e-425e-8cdb-12b171e65789" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_b01a0bfd-25ea-481c-8e36-288ce446ffd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross_acd60501-2282-4722-a68a-2f7bd87c8c1f" xlink:href="bhc-20211231.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc885c95-762e-425e-8cdb-12b171e65789" xlink:to="loc_bhc_GainLossRelatedToLitigationSettlementGross_acd60501-2282-4722-a68a-2f7bd87c8c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_7a9f76a3-9e43-419f-abcd-1e543d95148f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc885c95-762e-425e-8cdb-12b171e65789" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_7a9f76a3-9e43-419f-abcd-1e543d95148f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_31227224-0f7e-47ac-a181-ea06fbe53f66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc885c95-762e-425e-8cdb-12b171e65789" xlink:to="loc_us-gaap_ShareBasedCompensation_31227224-0f7e-47ac-a181-ea06fbe53f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_b95db7bd-e242-4ede-b122-42c5bf04b0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc885c95-762e-425e-8cdb-12b171e65789" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_b95db7bd-e242-4ede-b122-42c5bf04b0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent_ab2b87b0-a992-45d4-84a3-1aacbe6b5bed" xlink:href="bhc-20211231.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc885c95-762e-425e-8cdb-12b171e65789" xlink:to="loc_bhc_DerivativeGainExcludedComponent_ab2b87b0-a992-45d4-84a3-1aacbe6b5bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a4d763b6-d145-46a7-83bd-47bae9baa9db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc885c95-762e-425e-8cdb-12b171e65789" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a4d763b6-d145-46a7-83bd-47bae9baa9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_7f42d051-1292-4088-903c-16c8ac7548d0" xlink:href="bhc-20211231.xsd#bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc885c95-762e-425e-8cdb-12b171e65789" xlink:to="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_7f42d051-1292-4088-903c-16c8ac7548d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_3ec0cf50-fed2-46c3-87fa-84410ab62282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc885c95-762e-425e-8cdb-12b171e65789" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_3ec0cf50-fed2-46c3-87fa-84410ab62282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f1163e07-2c71-4aff-beb1-0fe1b65ff9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bc885c95-762e-425e-8cdb-12b171e65789" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f1163e07-2c71-4aff-beb1-0fe1b65ff9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c8f03365-4c43-4bba-8d45-8b010ccbe870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f1163e07-2c71-4aff-beb1-0fe1b65ff9d7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c8f03365-4c43-4bba-8d45-8b010ccbe870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_23445a37-4324-49ce-bf9e-4ae486934155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f1163e07-2c71-4aff-beb1-0fe1b65ff9d7" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_23445a37-4324-49ce-bf9e-4ae486934155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_527012b5-ae2e-449c-81e5-911e352336da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f1163e07-2c71-4aff-beb1-0fe1b65ff9d7" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_527012b5-ae2e-449c-81e5-911e352336da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8d7c69c8-5b19-4cc3-9bae-3c8b21006418" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f1163e07-2c71-4aff-beb1-0fe1b65ff9d7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8d7c69c8-5b19-4cc3-9bae-3c8b21006418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d41603bb-907a-4464-aed6-b8e59d06c328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a194d938-922c-47c4-8c9c-5b33778b01fb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d41603bb-907a-4464-aed6-b8e59d06c328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_08ffb584-931c-4339-9494-07ed23843412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_139863eb-2f02-4147-8cab-679e635b6258" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_08ffb584-931c-4339-9494-07ed23843412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5d9a275c-b980-4863-95e0-baa379c0ec46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_08ffb584-931c-4339-9494-07ed23843412" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5d9a275c-b980-4863-95e0-baa379c0ec46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_f31cd33f-f0bc-4a91-8ffd-4dfc088fff55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_08ffb584-931c-4339-9494-07ed23843412" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_f31cd33f-f0bc-4a91-8ffd-4dfc088fff55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0bdd0825-e352-4e12-9433-cd76543a36d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_08ffb584-931c-4339-9494-07ed23843412" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0bdd0825-e352-4e12-9433-cd76543a36d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ce65ee2d-6f13-4430-98cd-3bf28d23ba8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_08ffb584-931c-4339-9494-07ed23843412" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ce65ee2d-6f13-4430-98cd-3bf28d23ba8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_06fe7273-b57b-464e-a407-547da789b617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_08ffb584-931c-4339-9494-07ed23843412" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_06fe7273-b57b-464e-a407-547da789b617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_05cb493f-74c8-41df-aed2-d380a753fa84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_08ffb584-931c-4339-9494-07ed23843412" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_05cb493f-74c8-41df-aed2-d380a753fa84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps_d8c8d731-ed70-4726-8aef-e3bab93b7d16" xlink:href="bhc-20211231.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_08ffb584-931c-4339-9494-07ed23843412" xlink:to="loc_bhc_InterestSettlementOnCrossCurrencySwaps_d8c8d731-ed70-4726-8aef-e3bab93b7d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_44978278-6cd1-4072-adba-bcdd81564bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_08ffb584-931c-4339-9494-07ed23843412" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_44978278-6cd1-4072-adba-bcdd81564bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dbb8f22b-19ec-4087-89ab-7bc29512f376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_139863eb-2f02-4147-8cab-679e635b6258" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dbb8f22b-19ec-4087-89ab-7bc29512f376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6662c938-fd3e-4812-870b-48d7a96533ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dbb8f22b-19ec-4087-89ab-7bc29512f376" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6662c938-fd3e-4812-870b-48d7a96533ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_e1dfa43d-0099-4fc0-9b3c-984a92bad570" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dbb8f22b-19ec-4087-89ab-7bc29512f376" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_e1dfa43d-0099-4fc0-9b3c-984a92bad570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_2252f194-2d05-4774-b814-576c058e8751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dbb8f22b-19ec-4087-89ab-7bc29512f376" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_2252f194-2d05-4774-b814-576c058e8751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_8acfde05-9bec-491b-9abf-799962bcce60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dbb8f22b-19ec-4087-89ab-7bc29512f376" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_8acfde05-9bec-491b-9abf-799962bcce60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_26c7bb45-108a-459b-b31f-2d8f63725828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dbb8f22b-19ec-4087-89ab-7bc29512f376" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_26c7bb45-108a-459b-b31f-2d8f63725828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ea168816-ecb3-4066-9b62-285272ba914d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dbb8f22b-19ec-4087-89ab-7bc29512f376" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ea168816-ecb3-4066-9b62-285272ba914d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_3fad144d-33b6-4692-90e2-05d3dc2e906c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dbb8f22b-19ec-4087-89ab-7bc29512f376" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_3fad144d-33b6-4692-90e2-05d3dc2e906c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_dbd9d56b-77e6-4a5a-afaf-5207d51ae52c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dbb8f22b-19ec-4087-89ab-7bc29512f376" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_dbd9d56b-77e6-4a5a-afaf-5207d51ae52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36b5e37f-ffaa-4f6f-beb5-253f84d9ae53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dbb8f22b-19ec-4087-89ab-7bc29512f376" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36b5e37f-ffaa-4f6f-beb5-253f84d9ae53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d9b8ed9c-0c19-4606-966f-b16c8389ed37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_139863eb-2f02-4147-8cab-679e635b6258" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d9b8ed9c-0c19-4606-966f-b16c8389ed37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e2fac442-306d-4718-bb1b-b33db1d3012a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_139863eb-2f02-4147-8cab-679e635b6258" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e2fac442-306d-4718-bb1b-b33db1d3012a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_4eef5771-2be5-4924-80d0-e8d74fa72d71" xlink:href="bhc-20211231.xsd#bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_139863eb-2f02-4147-8cab-679e635b6258" xlink:to="loc_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_4eef5771-2be5-4924-80d0-e8d74fa72d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_f24bdd2e-74d2-42f4-a65a-fab604d2303e" xlink:href="bhc-20211231.xsd#bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_139863eb-2f02-4147-8cab-679e635b6258" xlink:to="loc_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_f24bdd2e-74d2-42f4-a65a-fab604d2303e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5820cbcd-c177-487a-97cc-a30ee5a4ab42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_139863eb-2f02-4147-8cab-679e635b6258" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5820cbcd-c177-487a-97cc-a30ee5a4ab42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_1325f601-7e3f-4159-bc39-16cae65a497d" xlink:href="bhc-20211231.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_139863eb-2f02-4147-8cab-679e635b6258" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_1325f601-7e3f-4159-bc39-16cae65a497d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_10e392df-9977-4197-850a-29053bf4e488" xlink:href="bhc-20211231.xsd#bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_139863eb-2f02-4147-8cab-679e635b6258" xlink:to="loc_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_10e392df-9977-4197-850a-29053bf4e488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="bhc-20211231.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6c4a3dcf-bc2a-4118-bc98-ca0ecb6a443c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_5e230b76-bc76-4aec-b08d-424b9de98aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6c4a3dcf-bc2a-4118-bc98-ca0ecb6a443c" xlink:to="loc_us-gaap_NatureOfOperations_5e230b76-bc76-4aec-b08d-424b9de98aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#DESCRIPTIONOFBUSINESSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b273113-dc71-41e7-9c4a-585e83f14b15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_cffac402-3cc0-41de-bdea-e15622ee5456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b273113-dc71-41e7-9c4a-585e83f14b15" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_cffac402-3cc0-41de-bdea-e15622ee5456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dc00c664-b4e7-4bb2-b3e5-6477eb559a08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_be06cc84-95a4-4c63-a1a2-42ac8178556b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dc00c664-b4e7-4bb2-b3e5-6477eb559a08" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_be06cc84-95a4-4c63-a1a2-42ac8178556b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ce8ca8e0-a848-4a66-99e5-679c499b2d66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ce8ca8e0-a848-4a66-99e5-679c499b2d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_fa1217a7-24de-429a-be4f-1796323d3fba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_UseOfEstimates_fa1217a7-24de-429a-be4f-1796323d3fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_542d8d2e-c5e7-47d6-a352-fa8fed3c3ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_542d8d2e-c5e7-47d6-a352-fa8fed3c3ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_96e743bd-138e-49dd-8385-8c355a40a4db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_96e743bd-138e-49dd-8385-8c355a40a4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_edf69e07-a26f-438c-bde5-1aa02d93852b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_edf69e07-a26f-438c-bde5-1aa02d93852b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_3643b40d-df5a-4b5a-83ba-172afcae9858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_3643b40d-df5a-4b5a-83ba-172afcae9858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_48437e94-d46c-4c06-92dc-0ae1c166a53f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_48437e94-d46c-4c06-92dc-0ae1c166a53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_2d1a3e7c-f0e0-4296-8538-140c0719b51b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_2d1a3e7c-f0e0-4296-8538-140c0719b51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts_535577cd-e662-4d72-a873-a12efe65bd52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts_535577cd-e662-4d72-a873-a12efe65bd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_492e1084-0da0-48e0-a720-e353cb006ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_492e1084-0da0-48e0-a720-e353cb006ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ffb6983e-0816-4cbd-aff6-6e46680b32c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ffb6983e-0816-4cbd-aff6-6e46680b32c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_00f8b2e0-d951-4ce0-945d-ca6d36ce6d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_00f8b2e0-d951-4ce0-945d-ca6d36ce6d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DivestituresOfNoncoreProductsPolicyTextBlock_8a0b9f3a-ac26-4020-bcf2-764630d6fb19" xlink:href="bhc-20211231.xsd#bhc_DivestituresOfNoncoreProductsPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_bhc_DivestituresOfNoncoreProductsPolicyTextBlock_8a0b9f3a-ac26-4020-bcf2-764630d6fb19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_0453ee76-d7fa-4219-b360-f6bbdf015212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_0453ee76-d7fa-4219-b360-f6bbdf015212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3c4e4d4a-7e9d-4ced-9311-e4e58c0ea56b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3c4e4d4a-7e9d-4ced-9311-e4e58c0ea56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_76c02d92-3804-4737-9f1d-1114fb0f6596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_76c02d92-3804-4737-9f1d-1114fb0f6596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_ada5894a-350f-47cd-9c07-d79ecc3af7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_ada5894a-350f-47cd-9c07-d79ecc3af7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_37a76198-9924-42c8-b4d3-9b6857369ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_37a76198-9924-42c8-b4d3-9b6857369ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ae044c95-ca9b-4593-95a1-163e81701f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ae044c95-ca9b-4593-95a1-163e81701f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2db3fd59-9efb-4456-b8ae-c37b4634dd97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2db3fd59-9efb-4456-b8ae-c37b4634dd97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock_91bf6b69-3496-4bf9-9cd5-0df6f7056996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_LegalCostsPolicyTextBlock_91bf6b69-3496-4bf9-9cd5-0df6f7056996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_19b0295b-9ec0-4b84-8649-6990f343a91e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_19b0295b-9ec0-4b84-8649-6990f343a91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_91f4d734-85ac-4fd6-a401-2fa29ea86fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_91f4d734-85ac-4fd6-a401-2fa29ea86fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpensePolicyTextBlock_d87eaeba-18f7-48b2-a41d-12e34bf23bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpensePolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_InterestExpensePolicyTextBlock_d87eaeba-18f7-48b2-a41d-12e34bf23bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_63c814bf-bae3-469f-9704-8780a1e883b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_63c814bf-bae3-469f-9704-8780a1e883b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_8693f254-d22c-4f69-9bb1-83e1a9b78ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_8693f254-d22c-4f69-9bb1-83e1a9b78ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_c73fc0c5-9588-4d9b-86fe-23cdf813d553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_c73fc0c5-9588-4d9b-86fe-23cdf813d553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_dbba2d82-aa36-4685-a031-ae97cc7e8b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_dbba2d82-aa36-4685-a031-ae97cc7e8b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_733590da-24e6-4c54-91bc-7314f84a42fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_733590da-24e6-4c54-91bc-7314f84a42fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a7c759c7-d0cd-4e86-80d6-1a78473f9fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a7c759c7-d0cd-4e86-80d6-1a78473f9fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_67024f5a-c58c-41be-a3d0-1efe77eff703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b44259e8-46bd-4510-b40b-bccd207da9f8" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_67024f5a-c58c-41be-a3d0-1efe77eff703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0a04c1f8-722f-4034-9986-0d9e1dc88fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_e120dcea-e313-4587-9808-f7db8835af5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0a04c1f8-722f-4034-9986-0d9e1dc88fc2" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_e120dcea-e313-4587-9808-f7db8835af5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_5547ced0-9a5a-4b68-b250-de9493f6a5d6" xlink:href="bhc-20211231.xsd#bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0a04c1f8-722f-4034-9986-0d9e1dc88fc2" xlink:to="loc_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_5547ced0-9a5a-4b68-b250-de9493f6a5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock_4e30de07-b688-44da-ab16-ef2147c14d22" xlink:href="bhc-20211231.xsd#bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0a04c1f8-722f-4034-9986-0d9e1dc88fc2" xlink:to="loc_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock_4e30de07-b688-44da-ab16-ef2147c14d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_d8a45021-82d9-4c9b-bb73-7d8ad775e769" xlink:href="bhc-20211231.xsd#bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0a04c1f8-722f-4034-9986-0d9e1dc88fc2" xlink:to="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_d8a45021-82d9-4c9b-bb73-7d8ad775e769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4910db3a-1809-40e0-befd-cf4925998b30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished_6b6e720b-c698-4ac0-aa22-274345f1bf3a" xlink:href="bhc-20211231.xsd#bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4910db3a-1809-40e0-befd-cf4925998b30" xlink:to="loc_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished_6b6e720b-c698-4ac0-aa22-274345f1bf3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_35d581d8-55b2-46db-a3df-2cd079cc5dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_13c2769d-33f9-460d-b473-79570e5cf182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_35d581d8-55b2-46db-a3df-2cd079cc5dbd" xlink:to="loc_us-gaap_ConcentrationRiskTable_13c2769d-33f9-460d-b473-79570e5cf182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41eb44af-7525-45aa-8522-071d95153881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_13c2769d-33f9-460d-b473-79570e5cf182" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41eb44af-7525-45aa-8522-071d95153881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9fe80698-c05e-4ea6-aae2-b0618d2d4120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41eb44af-7525-45aa-8522-071d95153881" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9fe80698-c05e-4ea6-aae2-b0618d2d4120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_dd8d2b51-9bd2-4f0b-b9cb-14194f5102dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9fe80698-c05e-4ea6-aae2-b0618d2d4120" xlink:to="loc_us-gaap_AccountsReceivableMember_dd8d2b51-9bd2-4f0b-b9cb-14194f5102dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b6d93261-f65a-44ec-aa05-9b1d8b226556" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_13c2769d-33f9-460d-b473-79570e5cf182" xlink:to="loc_srt_MajorCustomersAxis_b6d93261-f65a-44ec-aa05-9b1d8b226556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0f02794c-7d52-481c-8386-fd8d4d04a149" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_b6d93261-f65a-44ec-aa05-9b1d8b226556" xlink:to="loc_srt_NameOfMajorCustomerDomain_0f02794c-7d52-481c-8386-fd8d4d04a149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ThreeLargestUSWholesalerCustomersMember_e5c90601-f48f-48c9-9b2a-29c424fdbaac" xlink:href="bhc-20211231.xsd#bhc_ThreeLargestUSWholesalerCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0f02794c-7d52-481c-8386-fd8d4d04a149" xlink:to="loc_bhc_ThreeLargestUSWholesalerCustomersMember_e5c90601-f48f-48c9-9b2a-29c424fdbaac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_3117ce54-71b3-4f90-8a67-58e6598851c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_13c2769d-33f9-460d-b473-79570e5cf182" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_3117ce54-71b3-4f90-8a67-58e6598851c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a0299a51-15c6-4738-b5e3-fdcf7738f134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3117ce54-71b3-4f90-8a67-58e6598851c6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a0299a51-15c6-4738-b5e3-fdcf7738f134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_707a1700-8135-4fe7-a0b0-0845090321a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a0299a51-15c6-4738-b5e3-fdcf7738f134" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_707a1700-8135-4fe7-a0b0-0845090321a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_29edc6ad-3922-47b9-a870-1e6f67023e99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_13c2769d-33f9-460d-b473-79570e5cf182" xlink:to="loc_srt_StatementGeographicalAxis_29edc6ad-3922-47b9-a870-1e6f67023e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b1b53f95-0e92-41e3-b8e1-f2195f4f671a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_29edc6ad-3922-47b9-a870-1e6f67023e99" xlink:to="loc_srt_SegmentGeographicalDomain_b1b53f95-0e92-41e3-b8e1-f2195f4f671a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember_4d1794c3-e19d-47fb-b9fa-fd0f88b7f683" xlink:href="bhc-20211231.xsd#bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b1b53f95-0e92-41e3-b8e1-f2195f4f671a" xlink:to="loc_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember_4d1794c3-e19d-47fb-b9fa-fd0f88b7f683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_383a7d4e-16c9-46ba-9235-6c9caea08ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_13c2769d-33f9-460d-b473-79570e5cf182" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_383a7d4e-16c9-46ba-9235-6c9caea08ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents_4a97ecfb-0746-4d0e-b869-d9497782565d" xlink:href="bhc-20211231.xsd#bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_383a7d4e-16c9-46ba-9235-6c9caea08ac8" xlink:to="loc_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents_4a97ecfb-0746-4d0e-b869-d9497782565d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NumberOfLargestWholesaleCustomers_562432a8-08bf-4561-a0f2-a0fc0ecca22f" xlink:href="bhc-20211231.xsd#bhc_NumberOfLargestWholesaleCustomers"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_383a7d4e-16c9-46ba-9235-6c9caea08ac8" xlink:to="loc_bhc_NumberOfLargestWholesaleCustomers_562432a8-08bf-4561-a0f2-a0fc0ecca22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskPercentageofNetTradeReceivables_e495ece5-f0b7-43f3-bd74-f95c813075db" xlink:href="bhc-20211231.xsd#bhc_ConcentrationRiskPercentageofNetTradeReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_383a7d4e-16c9-46ba-9235-6c9caea08ac8" xlink:to="loc_bhc_ConcentrationRiskPercentageofNetTradeReceivables_e495ece5-f0b7-43f3-bd74-f95c813075db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8ab33496-f429-4702-bc80-fcc8f2d8cf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_383a7d4e-16c9-46ba-9235-6c9caea08ac8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8ab33496-f429-4702-bc80-fcc8f2d8cf6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PastDuePeriodForAccountsReceivableToBeNegligible_2bccbdca-5234-4dfa-91d4-a0a59b0c3b54" xlink:href="bhc-20211231.xsd#bhc_PastDuePeriodForAccountsReceivableToBeNegligible"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_383a7d4e-16c9-46ba-9235-6c9caea08ac8" xlink:to="loc_bhc_PastDuePeriodForAccountsReceivableToBeNegligible_2bccbdca-5234-4dfa-91d4-a0a59b0c3b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PeriodReceivableOutstanding_278d75ab-3949-496c-b930-4fbf3161c8b6" xlink:href="bhc-20211231.xsd#bhc_PeriodReceivableOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_383a7d4e-16c9-46ba-9235-6c9caea08ac8" xlink:to="loc_bhc_PeriodReceivableOutstanding_278d75ab-3949-496c-b930-4fbf3161c8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TradeReceivableNetPortionPastDue_835acacb-425e-436f-ad2a-62e0972e7083" xlink:href="bhc-20211231.xsd#bhc_TradeReceivableNetPortionPastDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_383a7d4e-16c9-46ba-9235-6c9caea08ac8" xlink:to="loc_bhc_TradeReceivableNetPortionPastDue_835acacb-425e-436f-ad2a-62e0972e7083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ee3dfb2f-13e6-427b-abdc-7dc17f89e9de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_975be577-9474-4a4d-98b1-7c64101390ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ee3dfb2f-13e6-427b-abdc-7dc17f89e9de" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_975be577-9474-4a4d-98b1-7c64101390ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e0d696af-9049-4044-8de4-91605f218796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ee3dfb2f-13e6-427b-abdc-7dc17f89e9de" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e0d696af-9049-4044-8de4-91605f218796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_c9ccf08a-5b58-4595-86cb-2727d4c838b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e0d696af-9049-4044-8de4-91605f218796" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_c9ccf08a-5b58-4595-86cb-2727d4c838b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate_7990d476-b2cb-4e22-aeb6-32c70229216c" xlink:href="bhc-20211231.xsd#bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e0d696af-9049-4044-8de4-91605f218796" xlink:to="loc_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate_7990d476-b2cb-4e22-aeb6-32c70229216c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_c8b4efee-a45b-4ae2-9bc6-ebcf3e7d2a84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e0d696af-9049-4044-8de4-91605f218796" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_c8b4efee-a45b-4ae2-9bc6-ebcf3e7d2a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_a97fa753-9c17-4a7d-8a0a-52b9aaaf7417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e0d696af-9049-4044-8de4-91605f218796" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_a97fa753-9c17-4a7d-8a0a-52b9aaaf7417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_faaa9de0-7fa0-466d-9ab9-a8689a18cc62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e0d696af-9049-4044-8de4-91605f218796" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_faaa9de0-7fa0-466d-9ab9-a8689a18cc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_9180ea7e-9d19-49cf-a32c-c9975a8552d9" xlink:href="bhc-20211231.xsd#bhc_AccountsReceivableAllowanceForForeignExchangeAndOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e0d696af-9049-4044-8de4-91605f218796" xlink:to="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_9180ea7e-9d19-49cf-a32c-c9975a8552d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_08a14dfb-92f3-4115-b56c-26b6c8c07d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e0d696af-9049-4044-8de4-91605f218796" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_08a14dfb-92f3-4115-b56c-26b6c8c07d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_393c02aa-5c30-45fe-8d9f-73e033568448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6476d4ed-77bd-4661-a784-afc0322a90ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_393c02aa-5c30-45fe-8d9f-73e033568448" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6476d4ed-77bd-4661-a784-afc0322a90ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5a6d8f88-e67d-472c-ac9b-229f3cdba543" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6476d4ed-77bd-4661-a784-afc0322a90ae" xlink:to="loc_srt_RangeAxis_5a6d8f88-e67d-472c-ac9b-229f3cdba543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e65db82c-586d-4f28-b4df-b6ab2a40c8da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5a6d8f88-e67d-472c-ac9b-229f3cdba543" xlink:to="loc_srt_RangeMember_e65db82c-586d-4f28-b4df-b6ab2a40c8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cddfe035-a4aa-4dfe-9ca1-6ac7dbed0420" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e65db82c-586d-4f28-b4df-b6ab2a40c8da" xlink:to="loc_srt_MinimumMember_cddfe035-a4aa-4dfe-9ca1-6ac7dbed0420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_352cbf5a-8f67-4371-94b4-1e3f68dc5e03" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e65db82c-586d-4f28-b4df-b6ab2a40c8da" xlink:to="loc_srt_MaximumMember_352cbf5a-8f67-4371-94b4-1e3f68dc5e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c9d6148a-c94a-4681-a41c-85b1c136b38f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6476d4ed-77bd-4661-a784-afc0322a90ae" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c9d6148a-c94a-4681-a41c-85b1c136b38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c860f05d-74cd-4f83-ae62-29d03e160de3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c9d6148a-c94a-4681-a41c-85b1c136b38f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c860f05d-74cd-4f83-ae62-29d03e160de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandImprovementsMember_1192c9ff-2361-4765-a4f1-1a5fa93590ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c860f05d-74cd-4f83-ae62-29d03e160de3" xlink:to="loc_us-gaap_LandImprovementsMember_1192c9ff-2361-4765-a4f1-1a5fa93590ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_56ca9c46-7569-40a7-9489-994e1b92873a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c860f05d-74cd-4f83-ae62-29d03e160de3" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_56ca9c46-7569-40a7-9489-994e1b92873a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_91a13076-0765-42c3-a477-9942c552b78e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c860f05d-74cd-4f83-ae62-29d03e160de3" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_91a13076-0765-42c3-a477-9942c552b78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_c9d6f584-1ef3-49fd-b9ca-0d003e9a7220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c860f05d-74cd-4f83-ae62-29d03e160de3" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_c9d6f584-1ef3-49fd-b9ca-0d003e9a7220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EquipmentOnOperatingLeaseMember_75ff3de2-8689-4452-bfe6-e08b22511b6d" xlink:href="bhc-20211231.xsd#bhc_EquipmentOnOperatingLeaseMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c860f05d-74cd-4f83-ae62-29d03e160de3" xlink:to="loc_bhc_EquipmentOnOperatingLeaseMember_75ff3de2-8689-4452-bfe6-e08b22511b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_df00dcb2-5c82-485b-94fd-df2a898e7d82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c860f05d-74cd-4f83-ae62-29d03e160de3" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_df00dcb2-5c82-485b-94fd-df2a898e7d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6dc742b-aae6-439c-b0e0-41ac3ed4aad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6476d4ed-77bd-4661-a784-afc0322a90ae" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6dc742b-aae6-439c-b0e0-41ac3ed4aad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_db07faec-8c6f-455d-a8ee-77c8dfcbd987" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6dc742b-aae6-439c-b0e0-41ac3ed4aad9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_db07faec-8c6f-455d-a8ee-77c8dfcbd987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0c8c3782-5cbd-44a1-a3b1-3d71ae7c0e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7baa92f3-31ee-48f8-9dac-93b9bb50d4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c8c3782-5cbd-44a1-a3b1-3d71ae7c0e8f" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7baa92f3-31ee-48f8-9dac-93b9bb50d4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d07aad69-0627-4e4b-8f6c-e85e60123798" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7baa92f3-31ee-48f8-9dac-93b9bb50d4fa" xlink:to="loc_srt_RangeAxis_d07aad69-0627-4e4b-8f6c-e85e60123798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3a0e9d11-af1b-4f2a-80f4-ed476d3f4a9c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d07aad69-0627-4e4b-8f6c-e85e60123798" xlink:to="loc_srt_RangeMember_3a0e9d11-af1b-4f2a-80f4-ed476d3f4a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_036eb790-9483-4296-b89d-9922e40cc080" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3a0e9d11-af1b-4f2a-80f4-ed476d3f4a9c" xlink:to="loc_srt_MinimumMember_036eb790-9483-4296-b89d-9922e40cc080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c026f5a5-038f-4d82-8f2c-e37f9594359d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3a0e9d11-af1b-4f2a-80f4-ed476d3f4a9c" xlink:to="loc_srt_MaximumMember_c026f5a5-038f-4d82-8f2c-e37f9594359d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_436738d6-cc1a-45c1-bdfd-4307ecb1cf01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7baa92f3-31ee-48f8-9dac-93b9bb50d4fa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_436738d6-cc1a-45c1-bdfd-4307ecb1cf01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b465af46-ed10-49dd-9cfd-ed71c7a09d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_436738d6-cc1a-45c1-bdfd-4307ecb1cf01" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b465af46-ed10-49dd-9cfd-ed71c7a09d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_539dceb9-fb66-458d-83ab-3fc37f5c2e31" xlink:href="bhc-20211231.xsd#bhc_ProductBrandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b465af46-ed10-49dd-9cfd-ed71c7a09d8e" xlink:to="loc_bhc_ProductBrandsMember_539dceb9-fb66-458d-83ab-3fc37f5c2e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_bf16f2e8-3e0b-4535-ac03-1f0a41bf09c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b465af46-ed10-49dd-9cfd-ed71c7a09d8e" xlink:to="loc_us-gaap_TradeNamesMember_bf16f2e8-3e0b-4535-ac03-1f0a41bf09c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_a439a502-bd7f-4913-a489-3f02e36b7b12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b465af46-ed10-49dd-9cfd-ed71c7a09d8e" xlink:to="loc_us-gaap_ContractualRightsMember_a439a502-bd7f-4913-a489-3f02e36b7b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember_ff7e99a5-a3ea-4ae7-a2c3-2dc3384cd704" xlink:href="bhc-20211231.xsd#bhc_PartnerRelationshipsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b465af46-ed10-49dd-9cfd-ed71c7a09d8e" xlink:to="loc_bhc_PartnerRelationshipsMember_ff7e99a5-a3ea-4ae7-a2c3-2dc3384cd704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember_644eca12-e7f8-4864-85c9-77a70ad45440" xlink:href="bhc-20211231.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b465af46-ed10-49dd-9cfd-ed71c7a09d8e" xlink:to="loc_bhc_OutLicensedTechnologyMember_644eca12-e7f8-4864-85c9-77a70ad45440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f2989966-f807-4d4b-a65e-56ad40c039b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7baa92f3-31ee-48f8-9dac-93b9bb50d4fa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f2989966-f807-4d4b-a65e-56ad40c039b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d5bb283d-6a09-4d99-8cc4-c67f943ed42f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f2989966-f807-4d4b-a65e-56ad40c039b1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d5bb283d-6a09-4d99-8cc4-c67f943ed42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b734fe86-0a21-4cd5-b6e3-fbbae7bf84e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_09414784-ce8e-4bbb-a63b-de979a6e8088" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b734fe86-0a21-4cd5-b6e3-fbbae7bf84e4" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_09414784-ce8e-4bbb-a63b-de979a6e8088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_55aab197-f4df-4352-983f-86cebfd7ddba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_09414784-ce8e-4bbb-a63b-de979a6e8088" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_55aab197-f4df-4352-983f-86cebfd7ddba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8b25de3a-08ef-4839-a0af-162359e464b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_55aab197-f4df-4352-983f-86cebfd7ddba" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8b25de3a-08ef-4839-a0af-162359e464b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember_661c259f-614d-4b02-afc7-f12fb62c2e06" xlink:href="bhc-20211231.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8b25de3a-08ef-4839-a0af-162359e464b3" xlink:to="loc_bhc_ReserveForDiscountsAndAllowancesMember_661c259f-614d-4b02-afc7-f12fb62c2e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_f2ca39fe-823e-4717-b0ca-534b2bf81d20" xlink:href="bhc-20211231.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8b25de3a-08ef-4839-a0af-162359e464b3" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_f2ca39fe-823e-4717-b0ca-534b2bf81d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember_ce29bf34-7cfe-4216-b151-131211af24a2" xlink:href="bhc-20211231.xsd#bhc_ReserveForRebatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8b25de3a-08ef-4839-a0af-162359e464b3" xlink:to="loc_bhc_ReserveForRebatesMember_ce29bf34-7cfe-4216-b151-131211af24a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember_e4a3a640-1cd8-4ce2-9597-edce3166163b" xlink:href="bhc-20211231.xsd#bhc_ReserveForChargebacksMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8b25de3a-08ef-4839-a0af-162359e464b3" xlink:to="loc_bhc_ReserveForChargebacksMember_e4a3a640-1cd8-4ce2-9597-edce3166163b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember_748e2e08-29b6-48b9-a695-20906a07ca55" xlink:href="bhc-20211231.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8b25de3a-08ef-4839-a0af-162359e464b3" xlink:to="loc_bhc_ReserveForDistributionFeesMember_748e2e08-29b6-48b9-a695-20906a07ca55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d170b570-9374-44ea-b1df-09cf1ba823f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_09414784-ce8e-4bbb-a63b-de979a6e8088" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d170b570-9374-44ea-b1df-09cf1ba823f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_10917038-6220-47f8-b9fa-8a167de62fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d170b570-9374-44ea-b1df-09cf1ba823f2" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_10917038-6220-47f8-b9fa-8a167de62fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_374af331-73b3-4065-b0ce-ef75e478153a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_10917038-6220-47f8-b9fa-8a167de62fc9" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_374af331-73b3-4065-b0ce-ef75e478153a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_0c36ba1b-16d6-491f-9375-dfdac4db99f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_10917038-6220-47f8-b9fa-8a167de62fc9" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_0c36ba1b-16d6-491f-9375-dfdac4db99f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_31c5e280-5de3-4a4a-b0fd-6a2162b0aa86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_10917038-6220-47f8-b9fa-8a167de62fc9" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_31c5e280-5de3-4a4a-b0fd-6a2162b0aa86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_6cc7582d-c195-45dd-8895-f8f1ec6d6f53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_10917038-6220-47f8-b9fa-8a167de62fc9" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_6cc7582d-c195-45dd-8895-f8f1ec6d6f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a3a3d044-b470-4e1e-8c51-edc2eac81bee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a414bdb8-afe0-48d5-b2d0-2ceef31a1129" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3a3d044-b470-4e1e-8c51-edc2eac81bee" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a414bdb8-afe0-48d5-b2d0-2ceef31a1129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1543e314-9482-4868-8ce9-4a9f6ce572be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a414bdb8-afe0-48d5-b2d0-2ceef31a1129" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1543e314-9482-4868-8ce9-4a9f6ce572be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_1e49196a-75f7-4eba-84d1-5c7105582bff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1543e314-9482-4868-8ce9-4a9f6ce572be" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_1e49196a-75f7-4eba-84d1-5c7105582bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_f00825b9-9d33-4dbc-9ba5-f570618daece" xlink:href="bhc-20211231.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1e49196a-75f7-4eba-84d1-5c7105582bff" xlink:to="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_f00825b9-9d33-4dbc-9ba5-f570618daece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_77796abd-aec0-4c8b-9c7b-28a61076e38b" xlink:href="bhc-20211231.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1e49196a-75f7-4eba-84d1-5c7105582bff" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_77796abd-aec0-4c8b-9c7b-28a61076e38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_396e7952-4ef4-487e-87af-4d202fc620b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a414bdb8-afe0-48d5-b2d0-2ceef31a1129" xlink:to="loc_srt_RangeAxis_396e7952-4ef4-487e-87af-4d202fc620b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_06443f2f-260f-4aa5-988a-af035e7281dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_396e7952-4ef4-487e-87af-4d202fc620b6" xlink:to="loc_srt_RangeMember_06443f2f-260f-4aa5-988a-af035e7281dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b54440e2-91fd-4512-b0fc-99fd29bfe228" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_06443f2f-260f-4aa5-988a-af035e7281dd" xlink:to="loc_srt_MinimumMember_b54440e2-91fd-4512-b0fc-99fd29bfe228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_12b9e1c3-1d72-4aee-add1-d00c10d9800e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_06443f2f-260f-4aa5-988a-af035e7281dd" xlink:to="loc_srt_MaximumMember_12b9e1c3-1d72-4aee-add1-d00c10d9800e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_378faa77-f434-47db-bd76-425795821325" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a414bdb8-afe0-48d5-b2d0-2ceef31a1129" xlink:to="loc_srt_ProductOrServiceAxis_378faa77-f434-47db-bd76-425795821325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_25489d7b-cba5-438e-955d-1196cdf6aec1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_378faa77-f434-47db-bd76-425795821325" xlink:to="loc_srt_ProductsAndServicesDomain_25489d7b-cba5-438e-955d-1196cdf6aec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember_8b9c522c-0d0c-4850-ba9f-f81b73a82b36" xlink:href="bhc-20211231.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_25489d7b-cba5-438e-955d-1196cdf6aec1" xlink:to="loc_bhc_PriceAppreciationCreditMember_8b9c522c-0d0c-4850-ba9f-f81b73a82b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_faa984f4-e547-4985-94df-e7161c4c534c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a414bdb8-afe0-48d5-b2d0-2ceef31a1129" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_faa984f4-e547-4985-94df-e7161c4c534c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_6066a457-3ad6-46e9-88cb-b16c75534a38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_faa984f4-e547-4985-94df-e7161c4c534c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_6066a457-3ad6-46e9-88cb-b16c75534a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CashDiscountsAndAllowancesSettlementPeriod_49e3fdc4-7b7a-4882-bb92-c5ba6e993a5f" xlink:href="bhc-20211231.xsd#bhc_CashDiscountsAndAllowancesSettlementPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_faa984f4-e547-4985-94df-e7161c4c534c" xlink:to="loc_bhc_CashDiscountsAndAllowancesSettlementPeriod_49e3fdc4-7b7a-4882-bb92-c5ba6e993a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax_9ced7e66-0909-4d9a-a86c-f6dfcff9f410" xlink:href="bhc-20211231.xsd#bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_faa984f4-e547-4985-94df-e7161c4c534c" xlink:to="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax_9ced7e66-0909-4d9a-a86c-f6dfcff9f410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_1d43f463-77c5-4570-86c4-1182ccb634db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_faa984f4-e547-4985-94df-e7161c4c534c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_1d43f463-77c5-4570-86c4-1182ccb634db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_3b49a593-e458-437a-a596-c2664f0d77b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_faa984f4-e547-4985-94df-e7161c4c534c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_3b49a593-e458-437a-a596-c2664f0d77b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax_b9eea4d9-ffe7-4203-a75d-e9e161ca022f" xlink:href="bhc-20211231.xsd#bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_faa984f4-e547-4985-94df-e7161c4c534c" xlink:to="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax_b9eea4d9-ffe7-4203-a75d-e9e161ca022f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_28862b1f-801a-4a7d-b9e1-117feeffc72e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_faa984f4-e547-4985-94df-e7161c4c534c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_28862b1f-801a-4a7d-b9e1-117feeffc72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuePerformanceObligationPaymentTerms_22f25c32-708c-4b32-85c2-365e39efcfef" xlink:href="bhc-20211231.xsd#bhc_RevenuePerformanceObligationPaymentTerms"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_faa984f4-e547-4985-94df-e7161c4c534c" xlink:to="loc_bhc_RevenuePerformanceObligationPaymentTerms_22f25c32-708c-4b32-85c2-365e39efcfef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ca625057-39f7-4c9f-9e1d-3b474c704720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_7190e02e-788b-4e63-b5ed-67fea4d401d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca625057-39f7-4c9f-9e1d-3b474c704720" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_7190e02e-788b-4e63-b5ed-67fea4d401d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_000126db-fc05-4c14-9970-ae46be276e80" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7190e02e-788b-4e63-b5ed-67fea4d401d2" xlink:to="loc_srt_RangeAxis_000126db-fc05-4c14-9970-ae46be276e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_13d62656-ab23-4baf-bf48-e43fb982ab55" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_000126db-fc05-4c14-9970-ae46be276e80" xlink:to="loc_srt_RangeMember_13d62656-ab23-4baf-bf48-e43fb982ab55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_33e5668d-8dd1-47db-b1cb-b1b55b417313" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_13d62656-ab23-4baf-bf48-e43fb982ab55" xlink:to="loc_srt_MinimumMember_33e5668d-8dd1-47db-b1cb-b1b55b417313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4eaf13c6-ca0c-4586-af0d-82ae8017a40c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_13d62656-ab23-4baf-bf48-e43fb982ab55" xlink:to="loc_srt_MaximumMember_4eaf13c6-ca0c-4586-af0d-82ae8017a40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_35152975-c67a-4994-b38f-e9a1a838ba0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7190e02e-788b-4e63-b5ed-67fea4d401d2" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_35152975-c67a-4994-b38f-e9a1a838ba0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_370e2817-ec37-4582-9412-3d763a2adf0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35152975-c67a-4994-b38f-e9a1a838ba0a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_370e2817-ec37-4582-9412-3d763a2adf0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_555e6cca-4c5c-437e-8398-57a0958ddf41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_35152975-c67a-4994-b38f-e9a1a838ba0a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_555e6cca-4c5c-437e-8398-57a0958ddf41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a3191f94-b554-4356-b871-49981fbe46a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_1a048f45-ba6d-4e0b-a64e-22d3a60a6633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3191f94-b554-4356-b871-49981fbe46a3" xlink:to="loc_us-gaap_AdvertisingExpense_1a048f45-ba6d-4e0b-a64e-22d3a60a6633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c7e7548c-9446-4f9e-a9a5-7f5c457e84e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_4ed518dd-64dc-43eb-9910-e35ead56bc09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7e7548c-9446-4f9e-a9a5-7f5c457e84e1" xlink:to="loc_us-gaap_InterestCostsCapitalized_4ed518dd-64dc-43eb-9910-e35ead56bc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2a41ca49-f88b-4336-84ce-70e746b537de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxBenefitRecognitionMeasurementPercentage_033674d3-e9e5-4feb-98f2-45fcc9befd4e" xlink:href="bhc-20211231.xsd#bhc_TaxBenefitRecognitionMeasurementPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a41ca49-f88b-4336-84ce-70e746b537de" xlink:to="loc_bhc_TaxBenefitRecognitionMeasurementPercentage_033674d3-e9e5-4feb-98f2-45fcc9befd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities_fff9e213-3778-4118-930b-762918ea2d3e" xlink:href="bhc-20211231.xsd#bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a41ca49-f88b-4336-84ce-70e746b537de" xlink:to="loc_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities_fff9e213-3778-4118-930b-762918ea2d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c76b2a57-07f3-496e-bcec-2422d9ee8409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage_a837f9de-99de-442a-a79d-e48765ac0232" xlink:href="bhc-20211231.xsd#bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c76b2a57-07f3-496e-bcec-2422d9ee8409" xlink:to="loc_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage_a837f9de-99de-442a-a79d-e48765ac0232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_790ee7c3-9465-4e80-81cb-e1159fd712b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0fc58e0c-2653-498f-b40c-aebf27228971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_790ee7c3-9465-4e80-81cb-e1159fd712b4" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0fc58e0c-2653-498f-b40c-aebf27228971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a8a82fce-314f-43f5-b377-beb5db84c1b5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0fc58e0c-2653-498f-b40c-aebf27228971" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a8a82fce-314f-43f5-b377-beb5db84c1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5dbb36aa-4c20-44d5-a7df-af6c5d0b49d0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a8a82fce-314f-43f5-b377-beb5db84c1b5" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5dbb36aa-4c20-44d5-a7df-af6c5d0b49d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_56514892-7552-4b83-b1d1-923a82187d7c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5dbb36aa-4c20-44d5-a7df-af6c5d0b49d0" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_56514892-7552-4b83-b1d1-923a82187d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e2c1f5c3-fb82-43de-81cf-e8f8f0704930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0fc58e0c-2653-498f-b40c-aebf27228971" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e2c1f5c3-fb82-43de-81cf-e8f8f0704930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4a03b68e-7baa-4411-ac6c-9feb4053c1da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e2c1f5c3-fb82-43de-81cf-e8f8f0704930" xlink:to="loc_us-gaap_EquityComponentDomain_4a03b68e-7baa-4411-ac6c-9feb4053c1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3bdf43d9-1a5f-4267-9ee2-a7342a3ad2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4a03b68e-7baa-4411-ac6c-9feb4053c1da" xlink:to="loc_us-gaap_RetainedEarningsMember_3bdf43d9-1a5f-4267-9ee2-a7342a3ad2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f5f7cb77-a5a2-46b0-b1f2-6d2519d1108f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0fc58e0c-2653-498f-b40c-aebf27228971" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f5f7cb77-a5a2-46b0-b1f2-6d2519d1108f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_662d4006-0050-4d74-b2c2-04653f53b572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f5f7cb77-a5a2-46b0-b1f2-6d2519d1108f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_662d4006-0050-4d74-b2c2-04653f53b572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE" xlink:type="simple" xlink:href="bhc-20211231.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ad38570b-f115-45e0-bbfa-553a3f7f488f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_4f138777-82e1-4c39-83a3-6548662d948a" xlink:href="bhc-20211231.xsd#bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ad38570b-f115-45e0-bbfa-553a3f7f488f" xlink:to="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_4f138777-82e1-4c39-83a3-6548662d948a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURETables" xlink:type="simple" xlink:href="bhc-20211231.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURETables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a1c264e1-eb43-4e27-87df-4e849cb44259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0788de25-d35e-42e1-bb71-ed550668c38a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a1c264e1-eb43-4e27-87df-4e849cb44259" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0788de25-d35e-42e1-bb71-ed550668c38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_eca2daac-4260-41cc-b13c-6388e9a32cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a1c264e1-eb43-4e27-87df-4e849cb44259" xlink:to="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_eca2daac-4260-41cc-b13c-6388e9a32cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_48a345a7-a2cf-4b0f-9c87-8edb9ed09a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f36fe54d-f562-4a89-a3c7-29aaa69e745e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_48a345a7-a2cf-4b0f-9c87-8edb9ed09a73" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f36fe54d-f562-4a89-a3c7-29aaa69e745e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d5b62e75-ffd0-454a-8e0e-72c53e646881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f36fe54d-f562-4a89-a3c7-29aaa69e745e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d5b62e75-ffd0-454a-8e0e-72c53e646881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1992920c-9ed1-48d6-a25d-f7e23ac15ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d5b62e75-ffd0-454a-8e0e-72c53e646881" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1992920c-9ed1-48d6-a25d-f7e23ac15ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SynergyPharmaceuticalsInc.Member_e6c333f0-a5b3-4d41-b10d-78c6a53bd8b3" xlink:href="bhc-20211231.xsd#bhc_SynergyPharmaceuticalsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1992920c-9ed1-48d6-a25d-f7e23ac15ba6" xlink:to="loc_bhc_SynergyPharmaceuticalsInc.Member_e6c333f0-a5b3-4d41-b10d-78c6a53bd8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_6383b567-fe47-40dd-9074-5a3e4da16aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f36fe54d-f562-4a89-a3c7-29aaa69e745e" xlink:to="loc_us-gaap_AssetAcquisitionAxis_6383b567-fe47-40dd-9074-5a3e4da16aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_bdc73b7c-6a33-4700-98ce-a5ebb4712247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_6383b567-fe47-40dd-9074-5a3e4da16aa7" xlink:to="loc_us-gaap_AssetAcquisitionDomain_bdc73b7c-6a33-4700-98ce-a5ebb4712247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllegroOphthalmicsLLCMember_df2bab5a-03b1-46d8-aaf5-378d9a9e5505" xlink:href="bhc-20211231.xsd#bhc_AllegroOphthalmicsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_bdc73b7c-6a33-4700-98ce-a5ebb4712247" xlink:to="loc_bhc_AllegroOphthalmicsLLCMember_df2bab5a-03b1-46d8-aaf5-378d9a9e5505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_37c91b18-a055-4cf4-ad84-2de5c834b1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f36fe54d-f562-4a89-a3c7-29aaa69e745e" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_37c91b18-a055-4cf4-ad84-2de5c834b1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4e7901c3-7f1a-4da5-bc70-47238e2aca5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_37c91b18-a055-4cf4-ad84-2de5c834b1e2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4e7901c3-7f1a-4da5-bc70-47238e2aca5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_5ff33eaa-28dd-4555-9a35-dd95df8ebec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4e7901c3-7f1a-4da5-bc70-47238e2aca5e" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_5ff33eaa-28dd-4555-9a35-dd95df8ebec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_31251b56-f6fe-4249-83fc-5b461f06fd81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4e7901c3-7f1a-4da5-bc70-47238e2aca5e" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_31251b56-f6fe-4249-83fc-5b461f06fd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_913c94c2-a24a-41dc-80c8-19033f0fa689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4e7901c3-7f1a-4da5-bc70-47238e2aca5e" xlink:to="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_913c94c2-a24a-41dc-80c8-19033f0fa689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a9a6c43f-9304-40af-b08c-208c2ab1b084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f36fe54d-f562-4a89-a3c7-29aaa69e745e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a9a6c43f-9304-40af-b08c-208c2ab1b084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1640cafa-872e-415e-a5f6-8d4d3d832641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a9a6c43f-9304-40af-b08c-208c2ab1b084" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1640cafa-872e-415e-a5f6-8d4d3d832641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_a92739a1-9b7d-485f-9601-8c52120f3b51" xlink:href="bhc-20211231.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1640cafa-872e-415e-a5f6-8d4d3d832641" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_a92739a1-9b7d-485f-9601-8c52120f3b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f36fe54d-f562-4a89-a3c7-29aaa69e745e" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_a66b7959-882b-4a29-aae3-f1e055903b67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_a66b7959-882b-4a29-aae3-f1e055903b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_68342cf6-5ae6-4ce6-874b-6d1dad7a472e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_68342cf6-5ae6-4ce6-874b-6d1dad7a472e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_7248b2a0-b11b-4191-9fad-ae9bc253ab42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_7248b2a0-b11b-4191-9fad-ae9bc253ab42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss_df986f9a-c686-4290-bb97-e97e03d5b703" xlink:href="bhc-20211231.xsd#bhc_BusinessAcquisitionProFormaOperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss_df986f9a-c686-4290-bb97-e97e03d5b703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual_f40b1318-a1cb-4276-9292-9653f80cc8ff" xlink:href="bhc-20211231.xsd#bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual_f40b1318-a1cb-4276-9292-9653f80cc8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_564e3daa-8ba0-4d93-99b4-bf464f23cfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_564e3daa-8ba0-4d93-99b4-bf464f23cfdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NumberOfOtherBusinessesAcquired_6e84cc47-7ea6-4333-a64a-b41e6187f424" xlink:href="bhc-20211231.xsd#bhc_NumberOfOtherBusinessesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_bhc_NumberOfOtherBusinessesAcquired_6e84cc47-7ea6-4333-a64a-b41e6187f424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_ee504fbf-aa67-4d89-87e2-c8199e3f6f02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_ee504fbf-aa67-4d89-87e2-c8199e3f6f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_d83e791b-97ca-475d-ad5b-1583bb479df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_d83e791b-97ca-475d-ad5b-1583bb479df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected_f4d8e33e-2748-4442-9661-f7b629b99034" xlink:href="bhc-20211231.xsd#bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected_f4d8e33e-2748-4442-9661-f7b629b99034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_970e2cb0-acb1-4ba3-b72a-d5b903fb27dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_970e2cb0-acb1-4ba3-b72a-d5b903fb27dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_24762880-7ef9-4f52-89e0-7a0b50b58703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_24762880-7ef9-4f52-89e0-7a0b50b58703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NoncashCumulativeForeignCurrencyTranslationLoss_91380459-a4db-4309-923f-7f70c808f3e9" xlink:href="bhc-20211231.xsd#bhc_NoncashCumulativeForeignCurrencyTranslationLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_47dbf7cf-f28a-415c-bd44-dd0b99a52799" xlink:to="loc_bhc_NoncashCumulativeForeignCurrencyTranslationLoss_91380459-a4db-4309-923f-7f70c808f3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0b5bcbfc-d78f-4413-815f-d765cc2e7f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dc8f65ef-8657-4f3c-a56c-c1bc118677cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0b5bcbfc-d78f-4413-815f-d765cc2e7f7c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dc8f65ef-8657-4f3c-a56c-c1bc118677cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7825e10b-b0b4-454a-8c7f-06c5ad0cc571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dc8f65ef-8657-4f3c-a56c-c1bc118677cd" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7825e10b-b0b4-454a-8c7f-06c5ad0cc571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9c78ed4-137b-4b74-a4bb-d09ee55e389e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7825e10b-b0b4-454a-8c7f-06c5ad0cc571" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9c78ed4-137b-4b74-a4bb-d09ee55e389e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SynergyPharmaceuticalsInc.Member_8ab14590-b86e-4baa-8763-a42bf570ba4f" xlink:href="bhc-20211231.xsd#bhc_SynergyPharmaceuticalsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9c78ed4-137b-4b74-a4bb-d09ee55e389e" xlink:to="loc_bhc_SynergyPharmaceuticalsInc.Member_8ab14590-b86e-4baa-8763-a42bf570ba4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dc8f65ef-8657-4f3c-a56c-c1bc118677cd" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_7da16a41-70c0-4763-919e-7ccd2901c5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_7da16a41-70c0-4763-919e-7ccd2901c5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_87c48f16-5695-489e-be09-0a4c7883cf93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_87c48f16-5695-489e-be09-0a4c7883cf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1d475429-fbee-43d7-899e-7c4f01e059d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1d475429-fbee-43d7-899e-7c4f01e059d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3794d935-d7f6-403b-a5d4-fd80cfa950c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3794d935-d7f6-403b-a5d4-fd80cfa950c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1183a964-8ca4-4704-a1cb-c850a7516efc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1183a964-8ca4-4704-a1cb-c850a7516efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_7b598dc3-0dfc-4d48-b7f7-e8e872624204" xlink:href="bhc-20211231.xsd#bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:to="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_7b598dc3-0dfc-4d48-b7f7-e8e872624204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a73c5bc5-1c0d-4ce3-8b0c-959734928174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a73c5bc5-1c0d-4ce3-8b0c-959734928174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_70ab78f7-1c6d-4c68-bc45-167059391173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:to="loc_us-gaap_Goodwill_70ab78f7-1c6d-4c68-bc45-167059391173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a54276af-9450-4722-8751-53cafada9903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a54276af-9450-4722-8751-53cafada9903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8d0961d0-e055-4cbd-a143-e77644f42155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_48c89cc2-c5c5-4090-a167-8881c168565f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8d0961d0-e055-4cbd-a143-e77644f42155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d9ade95b-a7fe-405a-99b6-aa025101ae72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bd2c1815-9a97-4078-906a-9a70ec28132f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d9ade95b-a7fe-405a-99b6-aa025101ae72" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bd2c1815-9a97-4078-906a-9a70ec28132f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ec30a54a-225a-4865-aaa5-c5d3ba335dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bd2c1815-9a97-4078-906a-9a70ec28132f" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ec30a54a-225a-4865-aaa5-c5d3ba335dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9d0ecded-af32-4de4-81f0-2af160a56f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ec30a54a-225a-4865-aaa5-c5d3ba335dcb" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9d0ecded-af32-4de4-81f0-2af160a56f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ACertainInternationalBusinessMember_c2b93961-1b7b-43b9-acea-176fc0506842" xlink:href="bhc-20211231.xsd#bhc_ACertainInternationalBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9d0ecded-af32-4de4-81f0-2af160a56f9a" xlink:to="loc_bhc_ACertainInternationalBusinessMember_c2b93961-1b7b-43b9-acea-176fc0506842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_d0490235-12d5-4334-b0a9-72823e1669e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bd2c1815-9a97-4078-906a-9a70ec28132f" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_d0490235-12d5-4334-b0a9-72823e1669e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_5d74f0dc-c8e7-4a93-94cb-93d784dc31e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d0490235-12d5-4334-b0a9-72823e1669e8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_5d74f0dc-c8e7-4a93-94cb-93d784dc31e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_3b866bb5-f9a1-4ddc-9c2d-f7c22e9573e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_5d74f0dc-c8e7-4a93-94cb-93d784dc31e6" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_3b866bb5-f9a1-4ddc-9c2d-f7c22e9573e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9938822f-41c1-4399-a221-483194189562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bd2c1815-9a97-4078-906a-9a70ec28132f" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9938822f-41c1-4399-a221-483194189562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_d162e377-1bd1-43b8-91b3-b2460b831219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9938822f-41c1-4399-a221-483194189562" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_d162e377-1bd1-43b8-91b3-b2460b831219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_6fc3275e-e6a3-4046-8477-87549f496ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_d162e377-1bd1-43b8-91b3-b2460b831219" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_6fc3275e-e6a3-4046-8477-87549f496ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_eb1c947d-d5f2-442f-b3f5-80b49e10a6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_d162e377-1bd1-43b8-91b3-b2460b831219" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_eb1c947d-d5f2-442f-b3f5-80b49e10a6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_60243c38-c7e5-451c-9362-2a44f41172b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_d162e377-1bd1-43b8-91b3-b2460b831219" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_60243c38-c7e5-451c-9362-2a44f41172b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_84680f66-a03d-4d8a-b504-21d790709d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_d162e377-1bd1-43b8-91b3-b2460b831219" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_84680f66-a03d-4d8a-b504-21d790709d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_21d42264-93f4-46d7-939a-6b7806c3b4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9938822f-41c1-4399-a221-483194189562" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_21d42264-93f4-46d7-939a-6b7806c3b4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_8811dec7-2ba0-4743-82c2-f9dcb4229f90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_21d42264-93f4-46d7-939a-6b7806c3b4ff" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_8811dec7-2ba0-4743-82c2-f9dcb4229f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_73cabf41-18d0-462b-ba8e-a1550b81fedb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_21d42264-93f4-46d7-939a-6b7806c3b4ff" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_73cabf41-18d0-462b-ba8e-a1550b81fedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_d60b56ab-b47a-4b1e-9f43-e2a8d59ea15e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_21d42264-93f4-46d7-939a-6b7806c3b4ff" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_d60b56ab-b47a-4b1e-9f43-e2a8d59ea15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_73f822d9-0fcc-4c9b-9663-e47325846d41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_21d42264-93f4-46d7-939a-6b7806c3b4ff" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_73f822d9-0fcc-4c9b-9663-e47325846d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_9b9e07a7-239d-47e2-a2ba-4890eda2c979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9938822f-41c1-4399-a221-483194189562" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_9b9e07a7-239d-47e2-a2ba-4890eda2c979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_20c00d91-c98c-4bb4-b6e3-d1d758d76b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_9b9e07a7-239d-47e2-a2ba-4890eda2c979" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_20c00d91-c98c-4bb4-b6e3-d1d758d76b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent_cefc85b8-99fc-4366-99d2-60d23ddf143f" xlink:href="bhc-20211231.xsd#bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_9b9e07a7-239d-47e2-a2ba-4890eda2c979" xlink:to="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent_cefc85b8-99fc-4366-99d2-60d23ddf143f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_b6f1a5f7-5537-47e2-8108-379617b42bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_9b9e07a7-239d-47e2-a2ba-4890eda2c979" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_b6f1a5f7-5537-47e2-8108-379617b42bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_617728da-f82a-4073-8e03-9994598551a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9938822f-41c1-4399-a221-483194189562" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_617728da-f82a-4073-8e03-9994598551a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_704bd3e2-642b-45d2-a182-18d673564e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_617728da-f82a-4073-8e03-9994598551a1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_704bd3e2-642b-45d2-a182-18d673564e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent_ea346236-4226-4825-971d-8591b13c1fa1" xlink:href="bhc-20211231.xsd#bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_617728da-f82a-4073-8e03-9994598551a1" xlink:to="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent_ea346236-4226-4825-971d-8591b13c1fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_298dada1-9229-47a2-a048-a98afd395609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_617728da-f82a-4073-8e03-9994598551a1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_298dada1-9229-47a2-a048-a98afd395609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS" xlink:type="simple" xlink:href="bhc-20211231.xsd#RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_270e8c5a-9c4f-41fa-a65d-a6a97278c465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_01a52863-f857-4859-9794-840c2846114c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_270e8c5a-9c4f-41fa-a65d-a6a97278c465" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_01a52863-f857-4859-9794-840c2846114c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e5a4b2b2-b5df-4152-8bd4-e6b07d8ad66a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f4b50efb-2c28-47e7-b728-63b820dc634e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e5a4b2b2-b5df-4152-8bd4-e6b07d8ad66a" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f4b50efb-2c28-47e7-b728-63b820dc634e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_16a1d9b3-1774-4ae7-9e6b-54483bd761ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f4b50efb-2c28-47e7-b728-63b820dc634e" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_16a1d9b3-1774-4ae7-9e6b-54483bd761ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_2fbc87d3-0a57-442f-be77-f5cd67421c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_16a1d9b3-1774-4ae7-9e6b-54483bd761ac" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_2fbc87d3-0a57-442f-be77-f5cd67421c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember_9ea82e99-56c7-4c57-9623-51c1cb072cf4" xlink:href="bhc-20211231.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2fbc87d3-0a57-442f-be77-f5cd67421c6f" xlink:to="loc_bhc_RestructuringAndIntegrationCostsMember_9ea82e99-56c7-4c57-9623-51c1cb072cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_c4ccdf92-8b3e-4dba-9c1c-b9e8781384a3" xlink:href="bhc-20211231.xsd#bhc_SeparationAndInitialPublicOfferingCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2fbc87d3-0a57-442f-be77-f5cd67421c6f" xlink:to="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_c4ccdf92-8b3e-4dba-9c1c-b9e8781384a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_42c23f9b-5b41-49c6-b87b-513cf15e77bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f4b50efb-2c28-47e7-b728-63b820dc634e" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_42c23f9b-5b41-49c6-b87b-513cf15e77bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_fd87d972-fabd-4bc8-9f09-2f76efa69cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_42c23f9b-5b41-49c6-b87b-513cf15e77bf" xlink:to="loc_us-gaap_RestructuringReserve_fd87d972-fabd-4bc8-9f09-2f76efa69cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_7aa44055-28b9-49d2-b6df-e9ff1efe5379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_42c23f9b-5b41-49c6-b87b-513cf15e77bf" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_7aa44055-28b9-49d2-b6df-e9ff1efe5379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_97eb9ec2-2dc8-4470-9c28-deb92e398543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_42c23f9b-5b41-49c6-b87b-513cf15e77bf" xlink:to="loc_us-gaap_PaymentsForRestructuring_97eb9ec2-2dc8-4470-9c28-deb92e398543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_78441f69-fbe5-4fea-b303-d66725a7325f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_42c23f9b-5b41-49c6-b87b-513cf15e77bf" xlink:to="loc_us-gaap_RestructuringCharges_78441f69-fbe5-4fea-b303-d66725a7325f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_85bf61e7-d240-46d9-9b99-647b478232bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_42c23f9b-5b41-49c6-b87b-513cf15e77bf" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_85bf61e7-d240-46d9-9b99-647b478232bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_89f72764-b818-4bef-8297-172a1df7cf46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_f637054c-3275-4dc4-90e8-bdf667bbbcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_89f72764-b818-4bef-8297-172a1df7cf46" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_f637054c-3275-4dc4-90e8-bdf667bbbcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6fa5c8ab-ca7f-4527-844a-be7e79fb5498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_799a0df0-8267-4894-bff2-cf28649a9d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6fa5c8ab-ca7f-4527-844a-be7e79fb5498" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_799a0df0-8267-4894-bff2-cf28649a9d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_b377f3aa-0f81-45d2-a1c4-806d9a3d2132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6fa5c8ab-ca7f-4527-844a-be7e79fb5498" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_b377f3aa-0f81-45d2-a1c4-806d9a3d2132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_14383410-5120-4b47-8fec-c3517d68cc93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6fa5c8ab-ca7f-4527-844a-be7e79fb5498" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_14383410-5120-4b47-8fec-c3517d68cc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_c1d6aabb-d34b-460c-be7e-3aa5eb0045b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6fa5c8ab-ca7f-4527-844a-be7e79fb5498" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_c1d6aabb-d34b-460c-be7e-3aa5eb0045b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6bb035ae-e885-4b91-929a-39b4b30a880e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6fa5c8ab-ca7f-4527-844a-be7e79fb5498" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6bb035ae-e885-4b91-929a-39b4b30a880e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_9ee37253-0e0d-4fb4-965a-83ea169823e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6fa5c8ab-ca7f-4527-844a-be7e79fb5498" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_9ee37253-0e0d-4fb4-965a-83ea169823e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d4d29844-6306-4dbf-aaa1-342f24c60fda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85241144-4131-44cc-9fdb-8fea4d72669f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d4d29844-6306-4dbf-aaa1-342f24c60fda" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85241144-4131-44cc-9fdb-8fea4d72669f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6b188ce9-ad30-4607-86ac-9c8aa6478159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85241144-4131-44cc-9fdb-8fea4d72669f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6b188ce9-ad30-4607-86ac-9c8aa6478159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_83aa831f-5bc6-4cea-b21e-c2feb801f6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6b188ce9-ad30-4607-86ac-9c8aa6478159" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_83aa831f-5bc6-4cea-b21e-c2feb801f6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3e8950ff-a182-446d-af94-aae9af550c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_83aa831f-5bc6-4cea-b21e-c2feb801f6e0" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3e8950ff-a182-446d-af94-aae9af550c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95704c5d-017d-41d5-8528-9adf7e07391d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85241144-4131-44cc-9fdb-8fea4d72669f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95704c5d-017d-41d5-8528-9adf7e07391d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ac22bff-d82a-4b97-bcbd-f547376f8953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95704c5d-017d-41d5-8528-9adf7e07391d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ac22bff-d82a-4b97-bcbd-f547376f8953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2b6ce2ab-8b54-4399-b0df-dc01c26d2208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ac22bff-d82a-4b97-bcbd-f547376f8953" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2b6ce2ab-8b54-4399-b0df-dc01c26d2208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_55db08ce-81d0-4c66-99e6-12d1a3c34f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ac22bff-d82a-4b97-bcbd-f547376f8953" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_55db08ce-81d0-4c66-99e6-12d1a3c34f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a52b635a-3479-49cf-90e9-2a1e5a9059a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ac22bff-d82a-4b97-bcbd-f547376f8953" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a52b635a-3479-49cf-90e9-2a1e5a9059a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ecd88bf2-5d61-4017-88fb-8d0399d736e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85241144-4131-44cc-9fdb-8fea4d72669f" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ecd88bf2-5d61-4017-88fb-8d0399d736e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_14c2a8ca-5b47-4a40-b428-10299c899881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ecd88bf2-5d61-4017-88fb-8d0399d736e2" xlink:to="loc_us-gaap_HedgingRelationshipDomain_14c2a8ca-5b47-4a40-b428-10299c899881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_8a985d45-e69b-400e-9868-81aa3e545208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_14c2a8ca-5b47-4a40-b428-10299c899881" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_8a985d45-e69b-400e-9868-81aa3e545208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b5284c72-f79f-4c9c-be1f-507d662cd5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85241144-4131-44cc-9fdb-8fea4d72669f" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b5284c72-f79f-4c9c-be1f-507d662cd5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d88efe16-0b04-48d2-aa7c-1c61687f58d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b5284c72-f79f-4c9c-be1f-507d662cd5a6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d88efe16-0b04-48d2-aa7c-1c61687f58d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_c02bbc7d-5613-4845-8114-196c438a00db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d88efe16-0b04-48d2-aa7c-1c61687f58d6" xlink:to="loc_us-gaap_CurrencySwapMember_c02bbc7d-5613-4845-8114-196c438a00db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_5cda8505-03a3-4bcb-8c60-feafcc4ff14b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d88efe16-0b04-48d2-aa7c-1c61687f58d6" xlink:to="loc_us-gaap_ForeignExchangeContractMember_5cda8505-03a3-4bcb-8c60-feafcc4ff14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_3b2f0b0e-a361-421c-98d0-073fd49acc18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85241144-4131-44cc-9fdb-8fea4d72669f" xlink:to="loc_us-gaap_HedgingDesignationAxis_3b2f0b0e-a361-421c-98d0-073fd49acc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_59789160-3417-4bee-b482-747f7bca9d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_3b2f0b0e-a361-421c-98d0-073fd49acc18" xlink:to="loc_us-gaap_HedgingDesignationDomain_59789160-3417-4bee-b482-747f7bca9d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_95e54f7b-df10-4e57-a964-8acf070ae034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_59789160-3417-4bee-b482-747f7bca9d5d" xlink:to="loc_us-gaap_NondesignatedMember_95e54f7b-df10-4e57-a964-8acf070ae034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6b9d5535-bd17-425c-b48d-f625479b6596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_59789160-3417-4bee-b482-747f7bca9d5d" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6b9d5535-bd17-425c-b48d-f625479b6596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_60fbe99f-4ef1-4b57-b90b-a21abb42aac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85241144-4131-44cc-9fdb-8fea4d72669f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_60fbe99f-4ef1-4b57-b90b-a21abb42aac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e4cee82-e90f-4651-90e4-656927908356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_60fbe99f-4ef1-4b57-b90b-a21abb42aac4" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e4cee82-e90f-4651-90e4-656927908356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_424879f6-d222-4c9c-b0a1-01e90aa4470f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e4cee82-e90f-4651-90e4-656927908356" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_424879f6-d222-4c9c-b0a1-01e90aa4470f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_a682b0e8-5d81-4020-9b89-467f8993e881" xlink:href="bhc-20211231.xsd#bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e4cee82-e90f-4651-90e4-656927908356" xlink:to="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_a682b0e8-5d81-4020-9b89-467f8993e881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_d361b6a3-eba3-4057-82c9-cba16a89dc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e4cee82-e90f-4651-90e4-656927908356" xlink:to="loc_us-gaap_DerivativeAssets_d361b6a3-eba3-4057-82c9-cba16a89dc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0413ba21-ae56-44f2-ac8b-d3a2b979bfd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_60fbe99f-4ef1-4b57-b90b-a21abb42aac4" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0413ba21-ae56-44f2-ac8b-d3a2b979bfd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_1d8a8859-1b32-454e-9f44-6310cba90cf5" xlink:href="bhc-20211231.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0413ba21-ae56-44f2-ac8b-d3a2b979bfd9" xlink:to="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_1d8a8859-1b32-454e-9f44-6310cba90cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_6527c0a5-f61a-43d5-8530-6948dffc4b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_0413ba21-ae56-44f2-ac8b-d3a2b979bfd9" xlink:to="loc_us-gaap_DerivativeLiabilities_6527c0a5-f61a-43d5-8530-6948dffc4b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c8f84f21-596f-43a0-8768-0af78a57b253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6e3c7b83-b57c-49e5-a120-c930c600de8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c8f84f21-596f-43a0-8768-0af78a57b253" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6e3c7b83-b57c-49e5-a120-c930c600de8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_7fa0c555-1034-4444-a4b1-77711b78f63a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6e3c7b83-b57c-49e5-a120-c930c600de8a" xlink:to="loc_srt_LitigationCaseAxis_7fa0c555-1034-4444-a4b1-77711b78f63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7ca5f8f6-1af2-47f6-a1b5-a7dddb7dbb67" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_7fa0c555-1034-4444-a4b1-77711b78f63a" xlink:to="loc_srt_LitigationCaseTypeDomain_7ca5f8f6-1af2-47f6-a1b5-a7dddb7dbb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_5c732a80-f19a-47ca-b6b9-32b0a8147e48" xlink:href="bhc-20211231.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7ca5f8f6-1af2-47f6-a1b5-a7dddb7dbb67" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_5c732a80-f19a-47ca-b6b9-32b0a8147e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bd19a8c3-b6ce-4cae-b5e4-b0811b090606" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6e3c7b83-b57c-49e5-a120-c930c600de8a" xlink:to="loc_srt_StatementGeographicalAxis_bd19a8c3-b6ce-4cae-b5e4-b0811b090606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9acb78be-342f-4e56-ad81-4ff7f18fb341" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_bd19a8c3-b6ce-4cae-b5e4-b0811b090606" xlink:to="loc_srt_SegmentGeographicalDomain_9acb78be-342f-4e56-ad81-4ff7f18fb341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_a0fea167-156d-45d5-a15d-92918919f305" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9acb78be-342f-4e56-ad81-4ff7f18fb341" xlink:to="loc_stpr_NJ_a0fea167-156d-45d5-a15d-92918919f305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_d7693423-adcf-4937-b722-f6009c3c4c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6e3c7b83-b57c-49e5-a120-c930c600de8a" xlink:to="loc_us-gaap_LitigationStatusAxis_d7693423-adcf-4937-b722-f6009c3c4c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_dab36475-b166-4ed3-92ad-cedc2097ae79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_d7693423-adcf-4937-b722-f6009c3c4c5b" xlink:to="loc_us-gaap_LitigationStatusDomain_dab36475-b166-4ed3-92ad-cedc2097ae79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_4daf8a3e-e4b4-4803-9e58-7d2d43fbfe5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_dab36475-b166-4ed3-92ad-cedc2097ae79" xlink:to="loc_us-gaap_SettledLitigationMember_4daf8a3e-e4b4-4803-9e58-7d2d43fbfe5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_503791d7-6f95-4fc1-846d-7503e59219f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6e3c7b83-b57c-49e5-a120-c930c600de8a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_503791d7-6f95-4fc1-846d-7503e59219f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_e32884a1-339a-436d-ace8-af3005d6f2b8" xlink:href="bhc-20211231.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_503791d7-6f95-4fc1-846d-7503e59219f1" xlink:to="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_e32884a1-339a-436d-ace8-af3005d6f2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_2fd82d88-0f3d-4bd3-a7e9-6b146ad3ff74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_503791d7-6f95-4fc1-846d-7503e59219f1" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_2fd82d88-0f3d-4bd3-a7e9-6b146ad3ff74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_40423333-64f9-4488-998d-fa54bd9a9cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b664136-ac55-4102-8451-6c874bdc8704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_40423333-64f9-4488-998d-fa54bd9a9cc3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b664136-ac55-4102-8451-6c874bdc8704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e49310f3-ac50-43ea-91ae-e3551e10bafe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b664136-ac55-4102-8451-6c874bdc8704" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e49310f3-ac50-43ea-91ae-e3551e10bafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_94a8cc09-2942-48ea-9dd5-9e172a679078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e49310f3-ac50-43ea-91ae-e3551e10bafe" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_94a8cc09-2942-48ea-9dd5-9e172a679078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_44dba963-fd96-4fa2-a6d7-be951bd77dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_94a8cc09-2942-48ea-9dd5-9e172a679078" xlink:to="loc_us-gaap_CurrencySwapMember_44dba963-fd96-4fa2-a6d7-be951bd77dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CrossCurrencyFinalSettlementMember_5e3fe95c-072f-48e7-bf5d-e1bfccf6a2bd" xlink:href="bhc-20211231.xsd#bhc_CrossCurrencyFinalSettlementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrencySwapMember_44dba963-fd96-4fa2-a6d7-be951bd77dd0" xlink:to="loc_bhc_CrossCurrencyFinalSettlementMember_5e3fe95c-072f-48e7-bf5d-e1bfccf6a2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ebd02123-df59-4699-af7c-79f731b06803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b664136-ac55-4102-8451-6c874bdc8704" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ebd02123-df59-4699-af7c-79f731b06803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_4a7a8a5d-ee40-4008-87c9-89747ea46eae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ebd02123-df59-4699-af7c-79f731b06803" xlink:to="loc_us-gaap_HedgingRelationshipDomain_4a7a8a5d-ee40-4008-87c9-89747ea46eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_34508f59-aa81-478f-b0f9-bc638c28bf65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_4a7a8a5d-ee40-4008-87c9-89747ea46eae" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_34508f59-aa81-478f-b0f9-bc638c28bf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_45c8f37d-7fe2-407f-8b7a-fc5237b7fe27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b664136-ac55-4102-8451-6c874bdc8704" xlink:to="loc_us-gaap_HedgingDesignationAxis_45c8f37d-7fe2-407f-8b7a-fc5237b7fe27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_bb62770f-b967-4d41-89f1-2a5ca4c329c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_45c8f37d-7fe2-407f-8b7a-fc5237b7fe27" xlink:to="loc_us-gaap_HedgingDesignationDomain_bb62770f-b967-4d41-89f1-2a5ca4c329c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8acb9873-6e44-4677-8ed0-6aac4094c1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_bb62770f-b967-4d41-89f1-2a5ca4c329c2" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8acb9873-6e44-4677-8ed0-6aac4094c1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91b64955-796c-40b0-8aa6-2eaa8e2a1042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b664136-ac55-4102-8451-6c874bdc8704" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91b64955-796c-40b0-8aa6-2eaa8e2a1042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_8802d33d-de94-449b-bff7-374bbb5d6f13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91b64955-796c-40b0-8aa6-2eaa8e2a1042" xlink:to="loc_us-gaap_DerivativeNotionalAmount_8802d33d-de94-449b-bff7-374bbb5d6f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_e800f83e-31c1-4d0c-94c8-a8ff798682bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91b64955-796c-40b0-8aa6-2eaa8e2a1042" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_e800f83e-31c1-4d0c-94c8-a8ff798682bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_97372351-3311-4e95-8ed3-04d1bf79a0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91b64955-796c-40b0-8aa6-2eaa8e2a1042" xlink:to="loc_us-gaap_InvestmentIncomeInterest_97372351-3311-4e95-8ed3-04d1bf79a0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_4085f32a-999d-4776-9fc8-4c3f5db94b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91b64955-796c-40b0-8aa6-2eaa8e2a1042" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_4085f32a-999d-4776-9fc8-4c3f5db94b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0492b902-5072-440d-9f2c-72a5aa1b9969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f52ba58c-aeb0-4863-aa1d-cfb4b14edaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0492b902-5072-440d-9f2c-72a5aa1b9969" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f52ba58c-aeb0-4863-aa1d-cfb4b14edaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_dc60c56a-9afb-4bb0-ae4c-a910e5a81286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f52ba58c-aeb0-4863-aa1d-cfb4b14edaf4" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_dc60c56a-9afb-4bb0-ae4c-a910e5a81286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cb4eefe8-02ef-4059-978b-4fe871db1de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_dc60c56a-9afb-4bb0-ae4c-a910e5a81286" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cb4eefe8-02ef-4059-978b-4fe871db1de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a11c06d8-88b4-41a2-a3bc-9f673382b913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb4eefe8-02ef-4059-978b-4fe871db1de8" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a11c06d8-88b4-41a2-a3bc-9f673382b913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_966b3676-1e2a-4ee3-9fa2-b1fa62016d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb4eefe8-02ef-4059-978b-4fe871db1de8" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_966b3676-1e2a-4ee3-9fa2-b1fa62016d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_43801754-f1d3-498b-b5ab-cc3220a9ec45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f52ba58c-aeb0-4863-aa1d-cfb4b14edaf4" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_43801754-f1d3-498b-b5ab-cc3220a9ec45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a109b156-69cb-4d86-b8cc-75238974a29a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_43801754-f1d3-498b-b5ab-cc3220a9ec45" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a109b156-69cb-4d86-b8cc-75238974a29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_42b253ff-0890-46be-93a9-02bbd976d660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a109b156-69cb-4d86-b8cc-75238974a29a" xlink:to="loc_us-gaap_CurrencySwapMember_42b253ff-0890-46be-93a9-02bbd976d660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_46dbff37-3a3c-48c2-9fff-b062b9489cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f52ba58c-aeb0-4863-aa1d-cfb4b14edaf4" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_46dbff37-3a3c-48c2-9fff-b062b9489cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_3909df6f-e8b1-484d-9ddc-e8c92305b261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_46dbff37-3a3c-48c2-9fff-b062b9489cd9" xlink:to="loc_us-gaap_HedgingRelationshipDomain_3909df6f-e8b1-484d-9ddc-e8c92305b261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_24a8fe47-31fd-49c8-a8a2-bdd1dde3dfde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3909df6f-e8b1-484d-9ddc-e8c92305b261" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_24a8fe47-31fd-49c8-a8a2-bdd1dde3dfde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_83601042-b0c8-4533-aeb4-26dbf34e1b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f52ba58c-aeb0-4863-aa1d-cfb4b14edaf4" xlink:to="loc_us-gaap_HedgingDesignationAxis_83601042-b0c8-4533-aeb4-26dbf34e1b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f8cf8736-32f0-46cb-82f6-bb50ec48e901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_83601042-b0c8-4533-aeb4-26dbf34e1b1f" xlink:to="loc_us-gaap_HedgingDesignationDomain_f8cf8736-32f0-46cb-82f6-bb50ec48e901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_13117284-d588-4438-a48b-88273193cbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_f8cf8736-32f0-46cb-82f6-bb50ec48e901" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_13117284-d588-4438-a48b-88273193cbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d3f8b2c8-d4d8-428b-8b50-d0589c31fc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f52ba58c-aeb0-4863-aa1d-cfb4b14edaf4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d3f8b2c8-d4d8-428b-8b50-d0589c31fc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_94de98f4-65ac-4c34-bf27-8b5b69123562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d3f8b2c8-d4d8-428b-8b50-d0589c31fc1c" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_94de98f4-65ac-4c34-bf27-8b5b69123562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1ebcde41-0e17-4f71-bac0-b01b4035a0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d3f8b2c8-d4d8-428b-8b50-d0589c31fc1c" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1ebcde41-0e17-4f71-bac0-b01b4035a0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_76f975d4-1348-4fb4-8864-3166e79fed8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d3f8b2c8-d4d8-428b-8b50-d0589c31fc1c" xlink:to="loc_us-gaap_DerivativeLiabilities_76f975d4-1348-4fb4-8864-3166e79fed8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_66018e59-8613-445b-8321-a98430950eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5f52facd-1aed-4616-8205-aba3b7b9e1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_66018e59-8613-445b-8321-a98430950eb1" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5f52facd-1aed-4616-8205-aba3b7b9e1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_08320f9f-2c6a-4734-9203-76d679d625dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5f52facd-1aed-4616-8205-aba3b7b9e1a3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_08320f9f-2c6a-4734-9203-76d679d625dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a36e9c80-c995-4718-9a51-c6f3d62eabd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_08320f9f-2c6a-4734-9203-76d679d625dd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a36e9c80-c995-4718-9a51-c6f3d62eabd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_4da46ce9-c165-4220-b52f-41a62177a17d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a36e9c80-c995-4718-9a51-c6f3d62eabd5" xlink:to="loc_us-gaap_CurrencySwapMember_4da46ce9-c165-4220-b52f-41a62177a17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CrossCurrencyFinalSettlementMember_5ba41fad-2460-42bc-9c54-21abed43c389" xlink:href="bhc-20211231.xsd#bhc_CrossCurrencyFinalSettlementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a36e9c80-c995-4718-9a51-c6f3d62eabd5" xlink:to="loc_bhc_CrossCurrencyFinalSettlementMember_5ba41fad-2460-42bc-9c54-21abed43c389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e62827f5-d4d4-4305-9175-1fca745ce31e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5f52facd-1aed-4616-8205-aba3b7b9e1a3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e62827f5-d4d4-4305-9175-1fca745ce31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_a9de1fa4-bdd7-47bc-9871-25c9ce29a3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e62827f5-d4d4-4305-9175-1fca745ce31e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_a9de1fa4-bdd7-47bc-9871-25c9ce29a3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_6fad4df5-184c-4dda-9874-746f835d691f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_a9de1fa4-bdd7-47bc-9871-25c9ce29a3d3" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_6fad4df5-184c-4dda-9874-746f835d691f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7940e7d5-8f50-4ff5-a533-96e8fa7de13d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5f52facd-1aed-4616-8205-aba3b7b9e1a3" xlink:to="loc_us-gaap_HedgingDesignationAxis_7940e7d5-8f50-4ff5-a533-96e8fa7de13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e00ae44d-4f87-4cb4-8239-389e8ff4bbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_7940e7d5-8f50-4ff5-a533-96e8fa7de13d" xlink:to="loc_us-gaap_HedgingDesignationDomain_e00ae44d-4f87-4cb4-8239-389e8ff4bbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_675d9ab7-1ba3-4e3f-b3da-988bf2d0c163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_e00ae44d-4f87-4cb4-8239-389e8ff4bbf4" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_675d9ab7-1ba3-4e3f-b3da-988bf2d0c163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5c1c86ff-f9f6-4c1b-882a-d39cf1c8900f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5f52facd-1aed-4616-8205-aba3b7b9e1a3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5c1c86ff-f9f6-4c1b-882a-d39cf1c8900f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d4b56ae2-00e4-45ad-ad3b-c994f5479250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5c1c86ff-f9f6-4c1b-882a-d39cf1c8900f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d4b56ae2-00e4-45ad-ad3b-c994f5479250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_677b359a-0457-42f8-95b4-5ec77d44b68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d4b56ae2-00e4-45ad-ad3b-c994f5479250" xlink:to="loc_us-gaap_InterestExpenseMember_677b359a-0457-42f8-95b4-5ec77d44b68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a27b83c9-e861-4d85-b830-9dddf180a7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_5f52facd-1aed-4616-8205-aba3b7b9e1a3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a27b83c9-e861-4d85-b830-9dddf180a7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_8a942c3b-e5a9-4321-99b0-3297129ac2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a27b83c9-e861-4d85-b830-9dddf180a7bd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_8a942c3b-e5a9-4321-99b0-3297129ac2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_ad1c082f-16f1-4492-aa3a-12ab34684335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a27b83c9-e861-4d85-b830-9dddf180a7bd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_ad1c082f-16f1-4492-aa3a-12ab34684335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_d8f0a741-3f9a-4ab4-a81e-2d8d64b32b57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a27b83c9-e861-4d85-b830-9dddf180a7bd" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_d8f0a741-3f9a-4ab4-a81e-2d8d64b32b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_12240f59-6c53-4b49-9b30-e39a438ccc40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d013e123-3d5c-4866-9702-3588e1728f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_12240f59-6c53-4b49-9b30-e39a438ccc40" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d013e123-3d5c-4866-9702-3588e1728f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_773b98a1-ddd0-4518-8044-d794927c4128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d013e123-3d5c-4866-9702-3588e1728f2f" xlink:to="loc_us-gaap_HedgingDesignationAxis_773b98a1-ddd0-4518-8044-d794927c4128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e61768aa-f6f6-4c57-80ea-7b9455ddb85f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_773b98a1-ddd0-4518-8044-d794927c4128" xlink:to="loc_us-gaap_HedgingDesignationDomain_e61768aa-f6f6-4c57-80ea-7b9455ddb85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_c38a1152-3045-4682-9351-2c98ff197400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_e61768aa-f6f6-4c57-80ea-7b9455ddb85f" xlink:to="loc_us-gaap_NondesignatedMember_c38a1152-3045-4682-9351-2c98ff197400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_974594c4-4087-4286-8381-78398f48fa91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d013e123-3d5c-4866-9702-3588e1728f2f" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_974594c4-4087-4286-8381-78398f48fa91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_bfb679df-0f9d-4017-8ab4-6ff3c5e79f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_974594c4-4087-4286-8381-78398f48fa91" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_bfb679df-0f9d-4017-8ab4-6ff3c5e79f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_598f8daf-4f16-4f2b-bf4e-4b368a922c33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bfb679df-0f9d-4017-8ab4-6ff3c5e79f88" xlink:to="loc_us-gaap_ForeignExchangeContractMember_598f8daf-4f16-4f2b-bf4e-4b368a922c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ac0ba13-64da-4790-bf47-b14dd5fa48a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d013e123-3d5c-4866-9702-3588e1728f2f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ac0ba13-64da-4790-bf47-b14dd5fa48a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_f3eaa25d-c714-4656-98e6-61337bdae611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ac0ba13-64da-4790-bf47-b14dd5fa48a7" xlink:to="loc_us-gaap_DerivativeNotionalAmount_f3eaa25d-c714-4656-98e6-61337bdae611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_93de7f28-862b-470f-8e39-b9be38f1b109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f7f578f-e3ba-494f-b7dc-8c449df1c376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_93de7f28-862b-470f-8e39-b9be38f1b109" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f7f578f-e3ba-494f-b7dc-8c449df1c376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0c414363-c2fd-4871-9e26-8e68dd814840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f7f578f-e3ba-494f-b7dc-8c449df1c376" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0c414363-c2fd-4871-9e26-8e68dd814840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d2831df2-ec8c-4598-8c3e-2e0a59b4773b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0c414363-c2fd-4871-9e26-8e68dd814840" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d2831df2-ec8c-4598-8c3e-2e0a59b4773b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_18da819a-4ff2-4d7f-aaeb-2ddf72ff2210" xlink:href="bhc-20211231.xsd#bhc_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d2831df2-ec8c-4598-8c3e-2e0a59b4773b" xlink:to="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_18da819a-4ff2-4d7f-aaeb-2ddf72ff2210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_27e04ba8-b3ef-44f6-b72f-43afc68fae49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d2831df2-ec8c-4598-8c3e-2e0a59b4773b" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_27e04ba8-b3ef-44f6-b72f-43afc68fae49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9d465f4f-0478-417d-b12b-7a125f853a83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f7f578f-e3ba-494f-b7dc-8c449df1c376" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9d465f4f-0478-417d-b12b-7a125f853a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ada82226-e34d-4119-a16e-696b47fe7442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9d465f4f-0478-417d-b12b-7a125f853a83" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ada82226-e34d-4119-a16e-696b47fe7442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_5493b742-71bc-4633-9337-e626b2dd5fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ada82226-e34d-4119-a16e-696b47fe7442" xlink:to="loc_us-gaap_ForeignExchangeContractMember_5493b742-71bc-4633-9337-e626b2dd5fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_35b2c107-754f-4c41-8286-63b79e6ec779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f7f578f-e3ba-494f-b7dc-8c449df1c376" xlink:to="loc_us-gaap_HedgingDesignationAxis_35b2c107-754f-4c41-8286-63b79e6ec779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_5f31d58f-6fa2-4f1d-81b9-6caef8c840b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_35b2c107-754f-4c41-8286-63b79e6ec779" xlink:to="loc_us-gaap_HedgingDesignationDomain_5f31d58f-6fa2-4f1d-81b9-6caef8c840b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_ff2e2a25-92fc-48b0-a8ba-33cc9eccee31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_5f31d58f-6fa2-4f1d-81b9-6caef8c840b7" xlink:to="loc_us-gaap_NondesignatedMember_ff2e2a25-92fc-48b0-a8ba-33cc9eccee31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fbf80d35-b891-468b-ab5f-41c1452d4b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f7f578f-e3ba-494f-b7dc-8c449df1c376" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fbf80d35-b891-468b-ab5f-41c1452d4b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_28889b0b-9bc7-40fe-886b-2ebfc9900a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fbf80d35-b891-468b-ab5f-41c1452d4b7a" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_28889b0b-9bc7-40fe-886b-2ebfc9900a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7b527ef4-8a47-47dd-9524-6861325b4be6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fbf80d35-b891-468b-ab5f-41c1452d4b7a" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7b527ef4-8a47-47dd-9524-6861325b4be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_5dc09872-1b79-4933-bbc0-25a7e500c43a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fbf80d35-b891-468b-ab5f-41c1452d4b7a" xlink:to="loc_us-gaap_DerivativeLiabilities_5dc09872-1b79-4933-bbc0-25a7e500c43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0365b5eb-9f7a-491c-af58-d79817591f71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f8e9642-5dd8-478f-b858-b1ad2b996bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0365b5eb-9f7a-491c-af58-d79817591f71" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f8e9642-5dd8-478f-b858-b1ad2b996bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_8a4dd168-b342-43b5-905f-e32c80362f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f8e9642-5dd8-478f-b858-b1ad2b996bc4" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_8a4dd168-b342-43b5-905f-e32c80362f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6daafbbb-589f-46ee-aec6-a6770eb5e00e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8a4dd168-b342-43b5-905f-e32c80362f6f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6daafbbb-589f-46ee-aec6-a6770eb5e00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d2eedf83-af34-4dec-ad07-4ad0684813fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6daafbbb-589f-46ee-aec6-a6770eb5e00e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d2eedf83-af34-4dec-ad07-4ad0684813fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_a02e3bb3-f586-4df8-b741-c292638accf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f8e9642-5dd8-478f-b858-b1ad2b996bc4" xlink:to="loc_us-gaap_HedgingDesignationAxis_a02e3bb3-f586-4df8-b741-c292638accf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_78b5df92-6cb8-4c42-b2bf-aa20eb9e1bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_a02e3bb3-f586-4df8-b741-c292638accf2" xlink:to="loc_us-gaap_HedgingDesignationDomain_78b5df92-6cb8-4c42-b2bf-aa20eb9e1bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_72f04594-9240-4ee4-a0fb-dcd480b7cf67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_78b5df92-6cb8-4c42-b2bf-aa20eb9e1bc5" xlink:to="loc_us-gaap_NondesignatedMember_72f04594-9240-4ee4-a0fb-dcd480b7cf67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_30e1be9f-37c7-48b3-b19a-31b0058ec967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f8e9642-5dd8-478f-b858-b1ad2b996bc4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_30e1be9f-37c7-48b3-b19a-31b0058ec967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_a25ed4f5-d5b1-44c2-a844-72ed4d3b68b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_30e1be9f-37c7-48b3-b19a-31b0058ec967" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_a25ed4f5-d5b1-44c2-a844-72ed4d3b68b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_91adb66b-88b1-46a6-966b-d75f3b2345c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_30e1be9f-37c7-48b3-b19a-31b0058ec967" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_91adb66b-88b1-46a6-966b-d75f3b2345c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9389945d-bf0b-4b6e-813a-6cc5b418320a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cafaad5-2765-45b5-b983-5b97a50204a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9389945d-bf0b-4b6e-813a-6cc5b418320a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cafaad5-2765-45b5-b983-5b97a50204a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1dbaac49-47dc-478f-8b54-d526c1401c4c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cafaad5-2765-45b5-b983-5b97a50204a3" xlink:to="loc_srt_RangeAxis_1dbaac49-47dc-478f-8b54-d526c1401c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9e6fed5a-c149-4271-ae67-ee0274ddc8e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1dbaac49-47dc-478f-8b54-d526c1401c4c" xlink:to="loc_srt_RangeMember_9e6fed5a-c149-4271-ae67-ee0274ddc8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_08ba2d28-839f-4791-bc90-6dc4887cefca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9e6fed5a-c149-4271-ae67-ee0274ddc8e6" xlink:to="loc_srt_MinimumMember_08ba2d28-839f-4791-bc90-6dc4887cefca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8a896908-317f-49ef-9bec-f5c95626d792" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9e6fed5a-c149-4271-ae67-ee0274ddc8e6" xlink:to="loc_srt_MaximumMember_8a896908-317f-49ef-9bec-f5c95626d792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_cd2ed22d-7055-488f-bf51-b23b28b76301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cafaad5-2765-45b5-b983-5b97a50204a3" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_cd2ed22d-7055-488f-bf51-b23b28b76301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_746768f5-3d54-401d-afc6-92a28074f081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_cd2ed22d-7055-488f-bf51-b23b28b76301" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_746768f5-3d54-401d-afc6-92a28074f081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_b1681eb6-a091-48ab-befa-f08c4b225959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_746768f5-3d54-401d-afc6-92a28074f081" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_b1681eb6-a091-48ab-befa-f08c4b225959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_179e8b33-d7df-460a-bd07-5ce1d80049f7" xlink:href="bhc-20211231.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_746768f5-3d54-401d-afc6-92a28074f081" xlink:to="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_179e8b33-d7df-460a-bd07-5ce1d80049f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9cc57c73-ff68-43b5-a355-f880b6ea48e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cafaad5-2765-45b5-b983-5b97a50204a3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9cc57c73-ff68-43b5-a355-f880b6ea48e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bd53a9c-2ad2-4480-82ee-b04d62f5f63b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9cc57c73-ff68-43b5-a355-f880b6ea48e4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bd53a9c-2ad2-4480-82ee-b04d62f5f63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8feee856-18fa-41ff-bca8-368c011e0dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bd53a9c-2ad2-4480-82ee-b04d62f5f63b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8feee856-18fa-41ff-bca8-368c011e0dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7eb6602c-8a27-4a2b-8800-7033ea5a0f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cafaad5-2765-45b5-b983-5b97a50204a3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7eb6602c-8a27-4a2b-8800-7033ea5a0f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_15a5349a-8086-4b33-848b-0d930ca4bfff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7eb6602c-8a27-4a2b-8800-7033ea5a0f8b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_15a5349a-8086-4b33-848b-0d930ca4bfff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8aaa8d4b-0ba2-467e-9a16-6e4d9d122374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_15a5349a-8086-4b33-848b-0d930ca4bfff" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8aaa8d4b-0ba2-467e-9a16-6e4d9d122374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_fbfa6f12-bbbb-42e3-b44a-42293da76a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cafaad5-2765-45b5-b983-5b97a50204a3" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_fbfa6f12-bbbb-42e3-b44a-42293da76a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_68cf4415-4999-4de7-ad58-3fb82ccd50e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_fbfa6f12-bbbb-42e3-b44a-42293da76a7a" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_68cf4415-4999-4de7-ad58-3fb82ccd50e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember_91c22dba-d681-4a91-967c-f1bb2b8d39d5" xlink:href="bhc-20211231.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_68cf4415-4999-4de7-ad58-3fb82ccd50e8" xlink:to="loc_bhc_AccretionForTimeValueOfMoneyMember_91c22dba-d681-4a91-967c-f1bb2b8d39d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsMember_4caf0034-daca-421c-b229-4eb93df3f652" xlink:href="bhc-20211231.xsd#bhc_FairValueAdjustmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_68cf4415-4999-4de7-ad58-3fb82ccd50e8" xlink:to="loc_bhc_FairValueAdjustmentsMember_4caf0034-daca-421c-b229-4eb93df3f652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8c4e98f4-afad-41c4-9b6b-0bcfeb1c6381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cafaad5-2765-45b5-b983-5b97a50204a3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8c4e98f4-afad-41c4-9b6b-0bcfeb1c6381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_971c530b-818a-49f2-a80e-ae6326ce159a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8c4e98f4-afad-41c4-9b6b-0bcfeb1c6381" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_971c530b-818a-49f2-a80e-ae6326ce159a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aebefdf7-a28d-4d96-a85b-382b1e268ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8c4e98f4-afad-41c4-9b6b-0bcfeb1c6381" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aebefdf7-a28d-4d96-a85b-382b1e268ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_75df549b-d2db-47a7-ae86-0e9cd7e8d2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aebefdf7-a28d-4d96-a85b-382b1e268ce6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_75df549b-d2db-47a7-ae86-0e9cd7e8d2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8dd9e10e-09d4-46fd-9fd6-b03b5600c02f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aebefdf7-a28d-4d96-a85b-382b1e268ce6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8dd9e10e-09d4-46fd-9fd6-b03b5600c02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_55807de2-c172-4b80-b597-56d0f7bce6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aebefdf7-a28d-4d96-a85b-382b1e268ce6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_55807de2-c172-4b80-b597-56d0f7bce6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_50968949-ba3f-48d6-aab3-f99056ff2bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aebefdf7-a28d-4d96-a85b-382b1e268ce6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_50968949-ba3f-48d6-aab3-f99056ff2bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_39e64f4b-5e5c-45e5-88e1-09a118d8287a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aebefdf7-a28d-4d96-a85b-382b1e268ce6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_39e64f4b-5e5c-45e5-88e1-09a118d8287a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_354b296d-028f-4ddf-94ae-893d0dba78d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8c4e98f4-afad-41c4-9b6b-0bcfeb1c6381" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_354b296d-028f-4ddf-94ae-893d0dba78d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_bc618e8e-15aa-41a0-b00f-07cb7e881c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8c4e98f4-afad-41c4-9b6b-0bcfeb1c6381" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_bc618e8e-15aa-41a0-b00f-07cb7e881c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ed4fe5db-5ab2-4f77-a612-a0b75117b143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_97de4cb4-06e8-4f33-acc6-eef3e144154a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ed4fe5db-5ab2-4f77-a612-a0b75117b143" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_97de4cb4-06e8-4f33-acc6-eef3e144154a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6c9cf211-5727-48e6-aa4a-b8211d597a31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_97de4cb4-06e8-4f33-acc6-eef3e144154a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6c9cf211-5727-48e6-aa4a-b8211d597a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1b4b1e88-3eb7-4fe3-9127-33ff0fe66b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6c9cf211-5727-48e6-aa4a-b8211d597a31" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1b4b1e88-3eb7-4fe3-9127-33ff0fe66b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_a8c7c49e-66ee-45f8-8731-3c1a0dd49086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1b4b1e88-3eb7-4fe3-9127-33ff0fe66b0f" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_a8c7c49e-66ee-45f8-8731-3c1a0dd49086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_618db1cf-ddde-4b65-ad33-4effbefe5cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_97de4cb4-06e8-4f33-acc6-eef3e144154a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_618db1cf-ddde-4b65-ad33-4effbefe5cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9576f3c8-bbb1-44d1-b98a-309bb7507511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_618db1cf-ddde-4b65-ad33-4effbefe5cc3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9576f3c8-bbb1-44d1-b98a-309bb7507511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_bd057e1e-76b2-46f7-a457-99d01428433b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9576f3c8-bbb1-44d1-b98a-309bb7507511" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_bd057e1e-76b2-46f7-a457-99d01428433b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5de5e30d-76a1-4488-bed6-57d536eff624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9576f3c8-bbb1-44d1-b98a-309bb7507511" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5de5e30d-76a1-4488-bed6-57d536eff624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8da04c8f-63d0-4cda-8755-ffc77ecb2a46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9576f3c8-bbb1-44d1-b98a-309bb7507511" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8da04c8f-63d0-4cda-8755-ffc77ecb2a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2ed7abbb-a3e7-447d-81fc-4bd7bb602b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_97de4cb4-06e8-4f33-acc6-eef3e144154a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2ed7abbb-a3e7-447d-81fc-4bd7bb602b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiabilityAbstract_13823c6c-a9f7-4bf6-8a58-d03deec47252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiabilityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2ed7abbb-a3e7-447d-81fc-4bd7bb602b2e" xlink:to="loc_us-gaap_FairValueNetAssetLiabilityAbstract_13823c6c-a9f7-4bf6-8a58-d03deec47252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_8d366d08-6a2e-4dcf-94d2-09a9a908b077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetAssetLiabilityAbstract_13823c6c-a9f7-4bf6-8a58-d03deec47252" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_8d366d08-6a2e-4dcf-94d2-09a9a908b077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2e987462-f97f-4a75-9a66-38e8e4f0cc97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7abb6ec9-a420-412e-906a-3188ced49be2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2e987462-f97f-4a75-9a66-38e8e4f0cc97" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7abb6ec9-a420-412e-906a-3188ced49be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9e01037b-6e58-4e2e-8187-a17f097a8289" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7abb6ec9-a420-412e-906a-3188ced49be2" xlink:to="loc_srt_ProductOrServiceAxis_9e01037b-6e58-4e2e-8187-a17f097a8289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2afb9d92-f334-40c0-9f2c-f8c559a1f8b2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9e01037b-6e58-4e2e-8187-a17f097a8289" xlink:to="loc_srt_ProductsAndServicesDomain_2afb9d92-f334-40c0-9f2c-f8c559a1f8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_db3164ef-628d-478e-ba4d-f8de78aae3e5" xlink:href="bhc-20211231.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2afb9d92-f334-40c0-9f2c-f8c559a1f8b2" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_db3164ef-628d-478e-ba4d-f8de78aae3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_c343fa65-1b75-4589-868f-1e0fe2e852fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7abb6ec9-a420-412e-906a-3188ced49be2" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_c343fa65-1b75-4589-868f-1e0fe2e852fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ff7e03da-35b4-4cc2-872d-a33ad32c6aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_c343fa65-1b75-4589-868f-1e0fe2e852fe" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ff7e03da-35b4-4cc2-872d-a33ad32c6aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_d2d7ad77-1c09-493e-ba42-502ddeebc88f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ff7e03da-35b4-4cc2-872d-a33ad32c6aa8" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_d2d7ad77-1c09-493e-ba42-502ddeebc88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_48ca87e5-f71c-4c97-b92d-733b18d92a64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7abb6ec9-a420-412e-906a-3188ced49be2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_48ca87e5-f71c-4c97-b92d-733b18d92a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_02630e81-e3b9-404c-9cf5-2a55d85c5d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_48ca87e5-f71c-4c97-b92d-733b18d92a64" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_02630e81-e3b9-404c-9cf5-2a55d85c5d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_df84d144-da80-4655-ac57-803ebf642188" xlink:href="bhc-20211231.xsd#bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_02630e81-e3b9-404c-9cf5-2a55d85c5d32" xlink:to="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_df84d144-da80-4655-ac57-803ebf642188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d04e1e4f-2ec5-4075-883a-a7a928de1dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7abb6ec9-a420-412e-906a-3188ced49be2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d04e1e4f-2ec5-4075-883a-a7a928de1dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_70986020-b0bd-4850-9c38-17937b4d7a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d04e1e4f-2ec5-4075-883a-a7a928de1dfb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_70986020-b0bd-4850-9c38-17937b4d7a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1343bc16-de7c-40ba-bcff-bd50f228eb88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_70986020-b0bd-4850-9c38-17937b4d7a1e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1343bc16-de7c-40ba-bcff-bd50f228eb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a619636c-f56f-48c7-8d21-d793c9758421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7abb6ec9-a420-412e-906a-3188ced49be2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a619636c-f56f-48c7-8d21-d793c9758421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_30931cb9-1ad0-41ae-bf42-0ac9b75efeef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a619636c-f56f-48c7-8d21-d793c9758421" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_30931cb9-1ad0-41ae-bf42-0ac9b75efeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_ff09f0c4-7b90-4212-b9e5-03c535e01a94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_30931cb9-1ad0-41ae-bf42-0ac9b75efeef" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_ff09f0c4-7b90-4212-b9e5-03c535e01a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0884b7c2-63d5-4b25-995f-fcde5d62a3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7abb6ec9-a420-412e-906a-3188ced49be2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0884b7c2-63d5-4b25-995f-fcde5d62a3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_0866c6e6-1633-46c8-8b37-046ff6118f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0884b7c2-63d5-4b25-995f-fcde5d62a3ef" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_0866c6e6-1633-46c8-8b37-046ff6118f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_cb073d27-ca55-4ef3-9080-47b119296336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0884b7c2-63d5-4b25-995f-fcde5d62a3ef" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_cb073d27-ca55-4ef3-9080-47b119296336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_47db55cb-49ea-4a6a-a474-075eaf9aece3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0884b7c2-63d5-4b25-995f-fcde5d62a3ef" xlink:to="loc_us-gaap_Assets_47db55cb-49ea-4a6a-a474-075eaf9aece3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d9a2887f-0df3-4e65-a60c-c1380acfaa07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_16b87d9b-fa28-49f3-a0e4-4df123fdc2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d9a2887f-0df3-4e65-a60c-c1380acfaa07" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_16b87d9b-fa28-49f3-a0e4-4df123fdc2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f95e13cf-24f0-4d4c-ab8b-da980777dc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_16b87d9b-fa28-49f3-a0e4-4df123fdc2b1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f95e13cf-24f0-4d4c-ab8b-da980777dc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_79a10290-aa8f-4752-a056-0f490da5dcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f95e13cf-24f0-4d4c-ab8b-da980777dc8c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_79a10290-aa8f-4752-a056-0f490da5dcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_329354d9-22d1-4cc1-903a-8b1534037c77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_79a10290-aa8f-4752-a056-0f490da5dcb4" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_329354d9-22d1-4cc1-903a-8b1534037c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_992fce17-d31a-4151-ba10-08ef91f534ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_16b87d9b-fa28-49f3-a0e4-4df123fdc2b1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_992fce17-d31a-4151-ba10-08ef91f534ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bc99b064-61bb-4b80-bf61-f48b13d61f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_992fce17-d31a-4151-ba10-08ef91f534ff" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bc99b064-61bb-4b80-bf61-f48b13d61f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6bcc6940-f5c6-4483-9259-389f6cd73d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bc99b064-61bb-4b80-bf61-f48b13d61f5a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6bcc6940-f5c6-4483-9259-389f6cd73d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_27dc06db-9b98-4e45-93b1-966a3a71ad2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_16b87d9b-fa28-49f3-a0e4-4df123fdc2b1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_27dc06db-9b98-4e45-93b1-966a3a71ad2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_ad13044f-36ef-42cf-8692-0fd226d3f2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_27dc06db-9b98-4e45-93b1-966a3a71ad2a" xlink:to="loc_us-gaap_DebtInstrumentFairValue_ad13044f-36ef-42cf-8692-0fd226d3f2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIES" xlink:type="simple" xlink:href="bhc-20211231.xsd#INVENTORIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_17177491-9a7e-45e3-b258-99a46c04e640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_ddbbf237-b7ca-45ee-9674-0eed3bb2552d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_17177491-9a7e-45e3-b258-99a46c04e640" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_ddbbf237-b7ca-45ee-9674-0eed3bb2552d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="bhc-20211231.xsd#INVENTORIESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_781c24b5-2a10-4b14-b68b-ed0e72260f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_016707a2-6941-4dc3-a78c-010a85c59c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_781c24b5-2a10-4b14-b68b-ed0e72260f63" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_016707a2-6941-4dc3-a78c-010a85c59c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INVENTORIESSummaryofInventoriesNetDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5b5187c2-daf2-4560-ad28-1166b6269f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_e5ef8261-3e8f-4d06-9021-19a532a858ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5b5187c2-daf2-4560-ad28-1166b6269f0e" xlink:to="loc_us-gaap_InventoryRawMaterials_e5ef8261-3e8f-4d06-9021-19a532a858ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_b1585625-5d9f-4ce6-a189-9277e4aadd75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5b5187c2-daf2-4560-ad28-1166b6269f0e" xlink:to="loc_us-gaap_InventoryWorkInProcess_b1585625-5d9f-4ce6-a189-9277e4aadd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_68258c44-484a-42f2-9e79-589877d3f1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5b5187c2-daf2-4560-ad28-1166b6269f0e" xlink:to="loc_us-gaap_InventoryFinishedGoods_68258c44-484a-42f2-9e79-589877d3f1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5e9e545e-98f4-422d-893e-fc6132b7a426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5b5187c2-daf2-4560-ad28-1166b6269f0e" xlink:to="loc_us-gaap_InventoryNet_5e9e545e-98f4-422d-893e-fc6132b7a426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT" xlink:type="simple" xlink:href="bhc-20211231.xsd#PROPERTYPLANTANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4ef04314-790d-4c4c-a867-625d439dfb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_edada490-f480-40ac-a161-5ca116933e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4ef04314-790d-4c4c-a867-625d439dfb9a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_edada490-f480-40ac-a161-5ca116933e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTTables" xlink:type="simple" xlink:href="bhc-20211231.xsd#PROPERTYPLANTANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_17a3491f-aff3-4e21-baa5-7772ae3d36dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f6fe4016-c771-4754-b19b-bc5214a7dac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_17a3491f-aff3-4e21-baa5-7772ae3d36dc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f6fe4016-c771-4754-b19b-bc5214a7dac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f628dad6-7108-4bf9-81d1-274fb3a29138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e8966324-05a6-40cf-b007-aa75fcb9fb53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f628dad6-7108-4bf9-81d1-274fb3a29138" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e8966324-05a6-40cf-b007-aa75fcb9fb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_61f3aabc-1f8f-4fc0-9a4b-c8b99d511fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e8966324-05a6-40cf-b007-aa75fcb9fb53" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_61f3aabc-1f8f-4fc0-9a4b-c8b99d511fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be03c178-fc88-46c0-bc72-6ad85fbf71f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_61f3aabc-1f8f-4fc0-9a4b-c8b99d511fb4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be03c178-fc88-46c0-bc72-6ad85fbf71f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_0512db3a-a61f-4414-aebe-f59891c23d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be03c178-fc88-46c0-bc72-6ad85fbf71f2" xlink:to="loc_us-gaap_LandMember_0512db3a-a61f-4414-aebe-f59891c23d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_484d447f-35ec-4b06-8e19-31ffac371066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be03c178-fc88-46c0-bc72-6ad85fbf71f2" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_484d447f-35ec-4b06-8e19-31ffac371066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_90100220-3dae-4caf-b729-2b155bfc63d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be03c178-fc88-46c0-bc72-6ad85fbf71f2" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_90100220-3dae-4caf-b729-2b155bfc63d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherEquipmentAndLeaseholdImprovementMember_cf5f829b-bdbd-4ad9-b1d5-053256a8d6be" xlink:href="bhc-20211231.xsd#bhc_OtherEquipmentAndLeaseholdImprovementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be03c178-fc88-46c0-bc72-6ad85fbf71f2" xlink:to="loc_bhc_OtherEquipmentAndLeaseholdImprovementMember_cf5f829b-bdbd-4ad9-b1d5-053256a8d6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EquipmentOnOperatingLeaseMember_ee680c85-6e70-44e1-bdb6-9da73ffb2842" xlink:href="bhc-20211231.xsd#bhc_EquipmentOnOperatingLeaseMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be03c178-fc88-46c0-bc72-6ad85fbf71f2" xlink:to="loc_bhc_EquipmentOnOperatingLeaseMember_ee680c85-6e70-44e1-bdb6-9da73ffb2842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_0195f7da-2dfc-4bba-a3b5-bc67bc20fa89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be03c178-fc88-46c0-bc72-6ad85fbf71f2" xlink:to="loc_us-gaap_ConstructionInProgressMember_0195f7da-2dfc-4bba-a3b5-bc67bc20fa89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_afe43052-5c00-4c47-83e2-483639a5d4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e8966324-05a6-40cf-b007-aa75fcb9fb53" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_afe43052-5c00-4c47-83e2-483639a5d4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c7f9d0a3-22dc-4d59-ad82-761614fb2c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_afe43052-5c00-4c47-83e2-483639a5d4dd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c7f9d0a3-22dc-4d59-ad82-761614fb2c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9caf5dd0-81a9-432d-aaaa-29882520366f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_afe43052-5c00-4c47-83e2-483639a5d4dd" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9caf5dd0-81a9-432d-aaaa-29882520366f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_655af55e-1669-4558-9d17-76ef06ec307e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_afe43052-5c00-4c47-83e2-483639a5d4dd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_655af55e-1669-4558-9d17-76ef06ec307e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PROPERTYPLANTANDEQUIPMENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3c1377fb-6b3d-4478-a645-de5596810f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_cfe1180c-0cfd-4057-b762-69f5d1ba2df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3c1377fb-6b3d-4478-a645-de5596810f4d" xlink:to="loc_us-gaap_Depreciation_cfe1180c-0cfd-4057-b762-69f5d1ba2df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL" xlink:type="simple" xlink:href="bhc-20211231.xsd#INTANGIBLEASSETSANDGOODWILL"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_16ad8be3-cf33-435a-b807-ff501e933116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_e172af12-2692-4d4b-9647-50aea697fb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_16ad8be3-cf33-435a-b807-ff501e933116" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_e172af12-2692-4d4b-9647-50aea697fb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" xlink:type="simple" xlink:href="bhc-20211231.xsd#INTANGIBLEASSETSANDGOODWILLTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4820183f-2374-4e46-834e-a38b3931a82f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_f8cb413f-0101-49fd-ae1a-7ccead95b281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4820183f-2374-4e46-834e-a38b3931a82f" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_f8cb413f-0101-49fd-ae1a-7ccead95b281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_40035e83-64b7-4d8b-b619-652a0402be94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4820183f-2374-4e46-834e-a38b3931a82f" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_40035e83-64b7-4d8b-b619-652a0402be94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_749aa52d-75df-486a-935f-de4ba09be130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4820183f-2374-4e46-834e-a38b3931a82f" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_749aa52d-75df-486a-935f-de4ba09be130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_039a64ca-067d-4c14-91e8-c7c411565519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4820183f-2374-4e46-834e-a38b3931a82f" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_039a64ca-067d-4c14-91e8-c7c411565519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fd412bcb-5bb8-44f9-9816-6ce932302b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aad9e021-ab3b-4dd5-8278-fee276a9c480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fd412bcb-5bb8-44f9-9816-6ce932302b17" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aad9e021-ab3b-4dd5-8278-fee276a9c480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c1be9cf8-f575-40a3-96a3-5548d8eb0645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aad9e021-ab3b-4dd5-8278-fee276a9c480" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c1be9cf8-f575-40a3-96a3-5548d8eb0645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5bf3ad-77d2-4bd0-a894-31d36bb59c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c1be9cf8-f575-40a3-96a3-5548d8eb0645" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5bf3ad-77d2-4bd0-a894-31d36bb59c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_d6d9aba8-57e7-498f-b839-e9bc78bb12b3" xlink:href="bhc-20211231.xsd#bhc_ProductBrandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5bf3ad-77d2-4bd0-a894-31d36bb59c5e" xlink:to="loc_bhc_ProductBrandsMember_d6d9aba8-57e7-498f-b839-e9bc78bb12b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_cf315dd9-9f5c-4532-83f3-4c3edff908da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5bf3ad-77d2-4bd0-a894-31d36bb59c5e" xlink:to="loc_us-gaap_TradeNamesMember_cf315dd9-9f5c-4532-83f3-4c3edff908da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_57cc2fa2-48d5-47ab-9cd3-60af983434a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5bf3ad-77d2-4bd0-a894-31d36bb59c5e" xlink:to="loc_us-gaap_ContractualRightsMember_57cc2fa2-48d5-47ab-9cd3-60af983434a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember_1f97f612-fd08-4098-bfeb-06b94f746dd9" xlink:href="bhc-20211231.xsd#bhc_PartnerRelationshipsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5bf3ad-77d2-4bd0-a894-31d36bb59c5e" xlink:to="loc_bhc_PartnerRelationshipsMember_1f97f612-fd08-4098-bfeb-06b94f746dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember_aeedb242-d933-4f71-8270-28bfaea8d6d4" xlink:href="bhc-20211231.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5bf3ad-77d2-4bd0-a894-31d36bb59c5e" xlink:to="loc_bhc_OutLicensedTechnologyMember_aeedb242-d933-4f71-8270-28bfaea8d6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_114f1522-d4e6-4962-9d85-fc825ea921d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aad9e021-ab3b-4dd5-8278-fee276a9c480" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_114f1522-d4e6-4962-9d85-fc825ea921d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d7e92a23-1533-43fc-9424-57f0df691c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_114f1522-d4e6-4962-9d85-fc825ea921d6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d7e92a23-1533-43fc-9424-57f0df691c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0d5a2a68-864d-4594-96ba-b1d6444c7527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_114f1522-d4e6-4962-9d85-fc825ea921d6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0d5a2a68-864d-4594-96ba-b1d6444c7527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_eca5c5f0-7e04-465e-88e9-4ecfba086c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_114f1522-d4e6-4962-9d85-fc825ea921d6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_eca5c5f0-7e04-465e-88e9-4ecfba086c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_36032be9-34ae-4522-804d-328327392b72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_114f1522-d4e6-4962-9d85-fc825ea921d6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_36032be9-34ae-4522-804d-328327392b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_24b7e7a0-cc83-4675-8824-ef4b30df4cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fd412bcb-5bb8-44f9-9816-6ce932302b17" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_24b7e7a0-cc83-4675-8824-ef4b30df4cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4806a443-2e9b-4e58-bea9-70c9af010113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_24b7e7a0-cc83-4675-8824-ef4b30df4cd1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4806a443-2e9b-4e58-bea9-70c9af010113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b5956abc-9beb-4121-96d5-d61877ede824" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4806a443-2e9b-4e58-bea9-70c9af010113" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b5956abc-9beb-4121-96d5-d61877ede824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_14892ad6-f722-4a79-9f51-76875a0da20b" xlink:href="bhc-20211231.xsd#bhc_AcquiredInProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b5956abc-9beb-4121-96d5-d61877ede824" xlink:to="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_14892ad6-f722-4a79-9f51-76875a0da20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_209690a4-231a-4754-acbf-10556ecefa0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b5956abc-9beb-4121-96d5-d61877ede824" xlink:to="loc_us-gaap_TrademarksMember_209690a4-231a-4754-acbf-10556ecefa0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_97983f9d-b1e7-4422-a7f6-31754800dc08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_24b7e7a0-cc83-4675-8824-ef4b30df4cd1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_97983f9d-b1e7-4422-a7f6-31754800dc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_62e8f882-b06e-4578-b31c-96d713714f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_97983f9d-b1e7-4422-a7f6-31754800dc08" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_62e8f882-b06e-4578-b31c-96d713714f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1956c66e-ecfc-4e84-ae09-2fe0bd6e0315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fd412bcb-5bb8-44f9-9816-6ce932302b17" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1956c66e-ecfc-4e84-ae09-2fe0bd6e0315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_28bcb9b7-b64f-4f88-8366-2de8b67c5357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fd412bcb-5bb8-44f9-9816-6ce932302b17" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_28bcb9b7-b64f-4f88-8366-2de8b67c5357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="bhc-20211231.xsd#INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INTANGIBLEASSETSANDGOODWILLNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_18ee6a8a-8596-4010-9f52-b8ca367c8a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_38cb7d34-b201-4adb-9a14-6959f6e0764a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_18ee6a8a-8596-4010-9f52-b8ca367c8a73" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_38cb7d34-b201-4adb-9a14-6959f6e0764a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9055e847-42fa-439f-a625-d29fb7ca381e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_38cb7d34-b201-4adb-9a14-6959f6e0764a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9055e847-42fa-439f-a625-d29fb7ca381e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a716a3a-760d-48d8-8087-9a0a1a713cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9055e847-42fa-439f-a625-d29fb7ca381e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a716a3a-760d-48d8-8087-9a0a1a713cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_3b62fed8-33a7-43b6-a9d4-4cff98c1d832" xlink:href="bhc-20211231.xsd#bhc_ProductBrandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a716a3a-760d-48d8-8087-9a0a1a713cd9" xlink:to="loc_bhc_ProductBrandsMember_3b62fed8-33a7-43b6-a9d4-4cff98c1d832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember_d64d9a98-19fb-450f-b112-8cafa442fcea" xlink:href="bhc-20211231.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a716a3a-760d-48d8-8087-9a0a1a713cd9" xlink:to="loc_bhc_DiscontinuedProductLinesMember_d64d9a98-19fb-450f-b112-8cafa442fcea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_f6ceb968-3c80-4e4a-9304-38037b5a231d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a716a3a-760d-48d8-8087-9a0a1a713cd9" xlink:to="loc_us-gaap_ContractualRightsMember_f6ceb968-3c80-4e4a-9304-38037b5a231d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnutilizedITInfrastructureImprovementProjectMember_60ae301a-20b7-4a3f-b017-18e2209323c2" xlink:href="bhc-20211231.xsd#bhc_UnutilizedITInfrastructureImprovementProjectMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a716a3a-760d-48d8-8087-9a0a1a713cd9" xlink:to="loc_bhc_UnutilizedITInfrastructureImprovementProjectMember_60ae301a-20b7-4a3f-b017-18e2209323c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_94479e79-1f05-4fde-8e6d-3ef0ae09a795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_38cb7d34-b201-4adb-9a14-6959f6e0764a" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_94479e79-1f05-4fde-8e6d-3ef0ae09a795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1ce6e138-926f-4d48-a0d1-ad3b4805cdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_94479e79-1f05-4fde-8e6d-3ef0ae09a795" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_1ce6e138-926f-4d48-a0d1-ad3b4805cdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f595129d-a9b3-4f29-8393-9a355290aaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1ce6e138-926f-4d48-a0d1-ad3b4805cdd4" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f595129d-a9b3-4f29-8393-9a355290aaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_793961c2-71b6-4cfb-a58f-c023f43707d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1ce6e138-926f-4d48-a0d1-ad3b4805cdd4" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_793961c2-71b6-4cfb-a58f-c023f43707d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_96083221-8c2e-4059-9d14-42318918fc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_38cb7d34-b201-4adb-9a14-6959f6e0764a" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_96083221-8c2e-4059-9d14-42318918fc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d4365200-12be-424d-9351-5904d5f71dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_96083221-8c2e-4059-9d14-42318918fc3a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d4365200-12be-424d-9351-5904d5f71dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_cdcb3cc1-afd9-4f11-814b-5eb7b7e8b628" xlink:href="bhc-20211231.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d4365200-12be-424d-9351-5904d5f71dfc" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_cdcb3cc1-afd9-4f11-814b-5eb7b7e8b628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ACertainInternationalBusinessMember_dc61366f-896c-41dc-8786-b3d1d918baaa" xlink:href="bhc-20211231.xsd#bhc_ACertainInternationalBusinessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d4365200-12be-424d-9351-5904d5f71dfc" xlink:to="loc_bhc_ACertainInternationalBusinessMember_dc61366f-896c-41dc-8786-b3d1d918baaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_6bff19e5-6017-4da4-9a1a-d9df4b75f2d9" xlink:href="bhc-20211231.xsd#bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d4365200-12be-424d-9351-5904d5f71dfc" xlink:to="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_6bff19e5-6017-4da4-9a1a-d9df4b75f2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2dfea9bf-e14c-4d59-9e06-fc9870752f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_38cb7d34-b201-4adb-9a14-6959f6e0764a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2dfea9bf-e14c-4d59-9e06-fc9870752f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9e2a606b-4fa0-4527-b560-b369d860bbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2dfea9bf-e14c-4d59-9e06-fc9870752f0e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9e2a606b-4fa0-4527-b560-b369d860bbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_637adf60-fd6b-4299-80d0-ba768be6b883" xlink:href="bhc-20211231.xsd#bhc_AcquiredInProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9e2a606b-4fa0-4527-b560-b369d860bbaa" xlink:to="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_637adf60-fd6b-4299-80d0-ba768be6b883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fd325754-d2df-4705-99c6-fd4777056de0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_38cb7d34-b201-4adb-9a14-6959f6e0764a" xlink:to="loc_srt_RangeAxis_fd325754-d2df-4705-99c6-fd4777056de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_07580929-692a-46af-8ce6-e8caf151d698" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fd325754-d2df-4705-99c6-fd4777056de0" xlink:to="loc_srt_RangeMember_07580929-692a-46af-8ce6-e8caf151d698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_23c83221-5ea8-4999-9faa-382db8f651c9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_07580929-692a-46af-8ce6-e8caf151d698" xlink:to="loc_srt_MinimumMember_23c83221-5ea8-4999-9faa-382db8f651c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1be68648-8e9a-4cbd-814d-c7c890c46d9e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_07580929-692a-46af-8ce6-e8caf151d698" xlink:to="loc_srt_MaximumMember_1be68648-8e9a-4cbd-814d-c7c890c46d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_063b9b20-8bee-4d40-a8e8-cf8de404b15b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_38cb7d34-b201-4adb-9a14-6959f6e0764a" xlink:to="loc_us-gaap_ReportingUnitAxis_063b9b20-8bee-4d40-a8e8-cf8de404b15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_a765decb-32c4-4f94-a1ad-d40e5785ad9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_063b9b20-8bee-4d40-a8e8-cf8de404b15b" xlink:to="loc_us-gaap_ReportingUnitDomain_a765decb-32c4-4f94-a1ad-d40e5785ad9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsReportingUnitMember_ac280024-e090-4999-8ec2-f4d50cb647d8" xlink:href="bhc-20211231.xsd#bhc_OrthoDermatologicsReportingUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_a765decb-32c4-4f94-a1ad-d40e5785ad9c" xlink:to="loc_bhc_OrthoDermatologicsReportingUnitMember_ac280024-e090-4999-8ec2-f4d50cb647d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_a212455d-a302-4906-b2b0-46c416663f67" xlink:href="bhc-20211231.xsd#bhc_ReportingUnitsExcludingOrthoDermatologicsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_a765decb-32c4-4f94-a1ad-d40e5785ad9c" xlink:to="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_a212455d-a302-4906-b2b0-46c416663f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_38cb7d34-b201-4adb-9a14-6959f6e0764a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a312cf82-1522-436b-8ab0-84a40c386da8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a312cf82-1522-436b-8ab0-84a40c386da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_01484552-3758-46e4-8caa-2cce214c9199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_01484552-3758-46e4-8caa-2cce214c9199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_a18d4e70-f9bb-49d0-b647-ac37b05b8479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_a18d4e70-f9bb-49d0-b647-ac37b05b8479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_42453677-10d1-4b08-a9bb-3ddbc585b306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_42453677-10d1-4b08-a9bb-3ddbc585b306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_580f69e7-8511-4237-b2fd-1b181373ca49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_580f69e7-8511-4237-b2fd-1b181373ca49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax_73bfbc47-01cc-4a09-8660-d685fe9ced7e" xlink:href="bhc-20211231.xsd#bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax_73bfbc47-01cc-4a09-8660-d685fe9ced7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage_4bca5015-ed31-4b73-aaa5-ee666625a3e2" xlink:href="bhc-20211231.xsd#bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage_4bca5015-ed31-4b73-aaa5-ee666625a3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_a9db8d5e-356f-4f36-8d81-7696a12c7b75" xlink:href="bhc-20211231.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_a9db8d5e-356f-4f36-8d81-7696a12c7b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_03a31057-cacb-413b-be2f-af861d9d6082" xlink:href="bhc-20211231.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_03a31057-cacb-413b-be2f-af861d9d6082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_acea1b33-6f6a-4121-96b2-cbb485ba1950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_acea1b33-6f6a-4121-96b2-cbb485ba1950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_e9978df8-24b6-47b8-a6a0-7df531668db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e70df922-0786-4c81-8939-740de655b737" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_e9978df8-24b6-47b8-a6a0-7df531668db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f964a5a9-8952-4069-abd9-2b7cc6d15deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_90244293-67ef-4941-9b4e-b00578dffd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f964a5a9-8952-4069-abd9-2b7cc6d15deb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_90244293-67ef-4941-9b4e-b00578dffd4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_67d8bc14-d606-48b2-9b85-64f37d0c189c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_90244293-67ef-4941-9b4e-b00578dffd4f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_67d8bc14-d606-48b2-9b85-64f37d0c189c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_534dce1e-d7c5-4ac1-8943-8c7efdb906d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_90244293-67ef-4941-9b4e-b00578dffd4f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_534dce1e-d7c5-4ac1-8943-8c7efdb906d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4a8e51a4-ec56-4946-9f47-f0d3a3259b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_90244293-67ef-4941-9b4e-b00578dffd4f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4a8e51a4-ec56-4946-9f47-f0d3a3259b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_381f005d-fdf8-4c3a-90cf-7a3108921667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_90244293-67ef-4941-9b4e-b00578dffd4f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_381f005d-fdf8-4c3a-90cf-7a3108921667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_02189616-ae1e-43c2-9d99-22205c49533c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_90244293-67ef-4941-9b4e-b00578dffd4f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_02189616-ae1e-43c2-9d99-22205c49533c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_74d29b90-efdf-4110-91e1-cd1b045a523f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_90244293-67ef-4941-9b4e-b00578dffd4f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_74d29b90-efdf-4110-91e1-cd1b045a523f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0f15d776-b0dd-4cf0-b4fb-5efb4d6e5203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_90244293-67ef-4941-9b4e-b00578dffd4f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0f15d776-b0dd-4cf0-b4fb-5efb4d6e5203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d71c0a20-7803-42b9-8990-6454516f317d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_f4ad738b-9775-4e60-b82d-1fe2aefbf531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d71c0a20-7803-42b9-8990-6454516f317d" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_f4ad738b-9775-4e60-b82d-1fe2aefbf531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_00ff477d-7cf7-4b6c-8693-8632449ed549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_f4ad738b-9775-4e60-b82d-1fe2aefbf531" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_00ff477d-7cf7-4b6c-8693-8632449ed549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_52b26070-2da8-45c6-b7a0-f6be8e2435ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_00ff477d-7cf7-4b6c-8693-8632449ed549" xlink:to="loc_us-gaap_SegmentDomain_52b26070-2da8-45c6-b7a0-f6be8e2435ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombInternationalMember_925f5869-da63-48b6-94b2-550cb17370e6" xlink:href="bhc-20211231.xsd#bhc_BauschLombInternationalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_52b26070-2da8-45c6-b7a0-f6be8e2435ef" xlink:to="loc_bhc_BauschLombInternationalMember_925f5869-da63-48b6-94b2-550cb17370e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_09e03c12-50a5-4ddb-87b3-ac435053daa1" xlink:href="bhc-20211231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_52b26070-2da8-45c6-b7a0-f6be8e2435ef" xlink:to="loc_bhc_BauschLombMember_09e03c12-50a5-4ddb-87b3-ac435053daa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_600806fe-42e1-45fa-b2bf-8509e5186a4a" xlink:href="bhc-20211231.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_52b26070-2da8-45c6-b7a0-f6be8e2435ef" xlink:to="loc_bhc_SalixSegmentMember_600806fe-42e1-45fa-b2bf-8509e5186a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_7ce7be55-438e-4e4a-8b4e-242ff13a7803" xlink:href="bhc-20211231.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_52b26070-2da8-45c6-b7a0-f6be8e2435ef" xlink:to="loc_bhc_InternationalRxMember_7ce7be55-438e-4e4a-8b4e-242ff13a7803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_b48ba529-efe8-4dbe-80c3-3aa44f46a94c" xlink:href="bhc-20211231.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_52b26070-2da8-45c6-b7a0-f6be8e2435ef" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_b48ba529-efe8-4dbe-80c3-3aa44f46a94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_0eba6f43-dc71-428b-941f-c96fe41b0a10" xlink:href="bhc-20211231.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_52b26070-2da8-45c6-b7a0-f6be8e2435ef" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_0eba6f43-dc71-428b-941f-c96fe41b0a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_b4ab5795-f97e-4896-94bb-0053e6688170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_f4ad738b-9775-4e60-b82d-1fe2aefbf531" xlink:to="loc_us-gaap_GoodwillLineItems_b4ab5795-f97e-4896-94bb-0053e6688170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_1113047f-d691-4bb0-a4d1-da8aeb6ec150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_b4ab5795-f97e-4896-94bb-0053e6688170" xlink:to="loc_us-gaap_GoodwillRollForward_1113047f-d691-4bb0-a4d1-da8aeb6ec150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_105305b9-7303-42b0-bd96-e76983867548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_1113047f-d691-4bb0-a4d1-da8aeb6ec150" xlink:to="loc_us-gaap_Goodwill_105305b9-7303-42b0-bd96-e76983867548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_8b8c7714-41d3-4a21-a894-c79fb9cd4d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_1113047f-d691-4bb0-a4d1-da8aeb6ec150" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_8b8c7714-41d3-4a21-a894-c79fb9cd4d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_82818837-598a-4319-9b18-508c405d8159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_1113047f-d691-4bb0-a4d1-da8aeb6ec150" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_82818837-598a-4319-9b18-508c405d8159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_fe75e274-0626-46b7-8491-13f16cc5a506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_1113047f-d691-4bb0-a4d1-da8aeb6ec150" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_fe75e274-0626-46b7-8491-13f16cc5a506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit_532983a4-d122-4576-b487-64fdaa722eca" xlink:href="bhc-20211231.xsd#bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_1113047f-d691-4bb0-a4d1-da8aeb6ec150" xlink:to="loc_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit_532983a4-d122-4576-b487-64fdaa722eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_38ddddc1-a173-410a-80be-12ba6c6c833f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_1113047f-d691-4bb0-a4d1-da8aeb6ec150" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_38ddddc1-a173-410a-80be-12ba6c6c833f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_faaaa542-d1f2-4835-bbfa-d97463058745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_1113047f-d691-4bb0-a4d1-da8aeb6ec150" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_faaaa542-d1f2-4835-bbfa-d97463058745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_73793cdd-5999-4177-93e2-69ee9d829857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_1113047f-d691-4bb0-a4d1-da8aeb6ec150" xlink:to="loc_us-gaap_Goodwill_73793cdd-5999-4177-93e2-69ee9d829857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="bhc-20211231.xsd#ACCRUEDANDOTHERCURRENTLIABILITIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8cc8c617-86b5-463d-99fb-cd4272a1c54d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_140c07ac-2463-4da0-a34e-f7dd6f3ccaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8cc8c617-86b5-463d-99fb-cd4272a1c54d" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_140c07ac-2463-4da0-a34e-f7dd6f3ccaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="bhc-20211231.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8215ba49-1487-4abb-a07c-3eb787430a77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_86910dca-b985-49a9-8ba3-e940b8ac28b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8215ba49-1487-4abb-a07c-3eb787430a77" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_86910dca-b985-49a9-8ba3-e940b8ac28b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_7742e094-7359-4c16-aa3d-9a573847a49a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees_69132253-7a0a-4741-8419-87fe4679cc7e" xlink:href="bhc-20211231.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7742e094-7359-4c16-aa3d-9a573847a49a" xlink:to="loc_bhc_Legalsettlementsandrelatedfees_69132253-7a0a-4741-8419-87fe4679cc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent_b12c28b5-bb6c-4fe1-810d-1f3875bde55e" xlink:href="bhc-20211231.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7742e094-7359-4c16-aa3d-9a573847a49a" xlink:to="loc_bhc_AccruedProductRebateCurrent_b12c28b5-bb6c-4fe1-810d-1f3875bde55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent_d23415a2-a778-4782-a220-236bba421705" xlink:href="bhc-20211231.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7742e094-7359-4c16-aa3d-9a573847a49a" xlink:to="loc_bhc_AccruedProductReturnCurrent_d23415a2-a778-4782-a220-236bba421705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_9471a8e4-dfc7-4b66-b882-6a43506c2519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7742e094-7359-4c16-aa3d-9a573847a49a" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_9471a8e4-dfc7-4b66-b882-6a43506c2519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_6769b72a-f253-40e5-9dca-0d22c3dea6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7742e094-7359-4c16-aa3d-9a573847a49a" xlink:to="loc_us-gaap_InterestPayableCurrent_6769b72a-f253-40e5-9dca-0d22c3dea6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_cf35f49b-6649-4bd9-8eb2-55dde81d3ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7742e094-7359-4c16-aa3d-9a573847a49a" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_cf35f49b-6649-4bd9-8eb2-55dde81d3ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_12293f64-19c5-47cb-a447-f2593b77ad32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7742e094-7359-4c16-aa3d-9a573847a49a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_12293f64-19c5-47cb-a447-f2593b77ad32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ca02696d-ab7a-4647-af16-46eb1bff00f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7742e094-7359-4c16-aa3d-9a573847a49a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ca02696d-ab7a-4647-af16-46eb1bff00f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS" xlink:type="simple" xlink:href="bhc-20211231.xsd#FINANCINGARRANGEMENTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e9861ea3-cd91-4828-864c-ab3f91b3890e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_44013eed-c96a-41f3-b2d4-764ad066630b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e9861ea3-cd91-4828-864c-ab3f91b3890e" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_44013eed-c96a-41f3-b2d4-764ad066630b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables" xlink:type="simple" xlink:href="bhc-20211231.xsd#FINANCINGARRANGEMENTSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5e170b81-f849-4f13-9650-6bee9a207dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_8c2a1a8d-2331-40e7-bc5b-a38c88b9eb9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5e170b81-f849-4f13-9650-6bee9a207dc0" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_8c2a1a8d-2331-40e7-bc5b-a38c88b9eb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_58b41a2c-a055-4d5b-a040-849229d92f15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5e170b81-f849-4f13-9650-6bee9a207dc0" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_58b41a2c-a055-4d5b-a040-849229d92f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ecd0c59b-bf3b-4c81-a7ab-4e79ae8d75ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_55982417-bfb2-4e3c-a2c7-ceb88c165cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ecd0c59b-bf3b-4c81-a7ab-4e79ae8d75ed" xlink:to="loc_us-gaap_DebtInstrumentTable_55982417-bfb2-4e3c-a2c7-ceb88c165cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_9774a7f6-7182-4d7d-9f2f-4fba993c3742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_55982417-bfb2-4e3c-a2c7-ceb88c165cd6" xlink:to="loc_us-gaap_CreditFacilityAxis_9774a7f6-7182-4d7d-9f2f-4fba993c3742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_619af6d5-ddaa-42c8-bb38-c499bdc372b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_9774a7f6-7182-4d7d-9f2f-4fba993c3742" xlink:to="loc_us-gaap_CreditFacilityDomain_619af6d5-ddaa-42c8-bb38-c499bdc372b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_e73f2d0c-704a-4885-8185-34d61703d378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_619af6d5-ddaa-42c8-bb38-c499bdc372b0" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_e73f2d0c-704a-4885-8185-34d61703d378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7dad9541-e1ed-4405-bdf8-e1e1e17ab55e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_55982417-bfb2-4e3c-a2c7-ceb88c165cd6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7dad9541-e1ed-4405-bdf8-e1e1e17ab55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_405993ef-c63f-426a-bb0c-49d720d734c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7dad9541-e1ed-4405-bdf8-e1e1e17ab55e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_405993ef-c63f-426a-bb0c-49d720d734c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_32d8d806-29b3-41f0-a8f2-92224e22bda4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_405993ef-c63f-426a-bb0c-49d720d734c5" xlink:to="loc_us-gaap_SecuredDebtMember_32d8d806-29b3-41f0-a8f2-92224e22bda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_beb55e3c-1188-49d7-9e17-e3a4613b5a97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_405993ef-c63f-426a-bb0c-49d720d734c5" xlink:to="loc_us-gaap_UnsecuredDebtMember_beb55e3c-1188-49d7-9e17-e3a4613b5a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_226f3a43-b2e3-4a8a-9e2c-eeec7edb1fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_55982417-bfb2-4e3c-a2c7-ceb88c165cd6" xlink:to="loc_us-gaap_DebtInstrumentAxis_226f3a43-b2e3-4a8a-9e2c-eeec7edb1fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_226f3a43-b2e3-4a8a-9e2c-eeec7edb1fd3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_92b3c396-895f-4ec6-bacb-cc46685a8dec" xlink:href="bhc-20211231.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_92b3c396-895f-4ec6-bacb-cc46685a8dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_6abddc06-be69-4b1a-9adb-e2f5f9f8752c" xlink:href="bhc-20211231.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_6abddc06-be69-4b1a-9adb-e2f5f9f8752c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_980b362a-e9dd-4ea7-a0fc-56756d03967e" xlink:href="bhc-20211231.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_980b362a-e9dd-4ea7-a0fc-56756d03967e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_355e38c7-12c4-4bca-9328-ad878bcdff6e" xlink:href="bhc-20211231.xsd#bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_355e38c7-12c4-4bca-9328-ad878bcdff6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_785a81c9-c007-4836-9edf-e8145f7721c5" xlink:href="bhc-20211231.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_785a81c9-c007-4836-9edf-e8145f7721c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_4d6f55b4-d1df-4bbc-a87a-00a97e4b0c54" xlink:href="bhc-20211231.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_4d6f55b4-d1df-4bbc-a87a-00a97e4b0c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_09f6db1b-bfd1-4470-a30b-1e83a87cbad8" xlink:href="bhc-20211231.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_09f6db1b-bfd1-4470-a30b-1e83a87cbad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_3a9b5013-d86a-4614-a561-7f7d36b7c581" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_3a9b5013-d86a-4614-a561-7f7d36b7c581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member_842f1031-d780-411d-b0e3-dbd6d8a4af68" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorNotes900DueDecember2025Member_842f1031-d780-411d-b0e3-dbd6d8a4af68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_47ac3adf-d548-4c69-a52a-9eca26e62f0b" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_47ac3adf-d548-4c69-a52a-9eca26e62f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_acb14332-4bbf-4c6b-8416-65913d0105cb" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_acb14332-4bbf-4c6b-8416-65913d0105cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_3f092d7c-a62c-4efc-a34e-ea43448971f3" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_3f092d7c-a62c-4efc-a34e-ea43448971f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_e8f0a52b-bef9-42d7-b789-74d7f8ad3954" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_e8f0a52b-bef9-42d7-b789-74d7f8ad3954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_4839634c-57d1-4a26-9aad-99361d8ebc50" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_4839634c-57d1-4a26-9aad-99361d8ebc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_b0aaac12-52bc-472c-9e54-28ef8ff0bb30" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_b0aaac12-52bc-472c-9e54-28ef8ff0bb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_54dd702b-db1b-428d-b342-68ec6765b0c0" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_54dd702b-db1b-428d-b342-68ec6765b0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member_2355614a-d64d-44fd-8f06-fa3103836096" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorNotes525DueJanuary2030Member_2355614a-d64d-44fd-8f06-fa3103836096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_4a81bf4f-78d8-4fef-adf5-bf8141e05940" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_4a81bf4f-78d8-4fef-adf5-bf8141e05940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember_1d112b01-a7c8-46bf-9fd6-19064e7e058e" xlink:href="bhc-20211231.xsd#bhc_OtherLongTermDebtMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a91e5345-8dfc-4834-b3c7-57ed04a2ec53" xlink:to="loc_bhc_OtherLongTermDebtMember_1d112b01-a7c8-46bf-9fd6-19064e7e058e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3d8a0faa-d0fd-4328-9343-e5b4e67e8422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_55982417-bfb2-4e3c-a2c7-ceb88c165cd6" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3d8a0faa-d0fd-4328-9343-e5b4e67e8422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6aa5ef6c-1c04-4cf7-b5c6-f53ca854e628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d8a0faa-d0fd-4328-9343-e5b4e67e8422" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6aa5ef6c-1c04-4cf7-b5c6-f53ca854e628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_a358565b-a10d-49f8-a527-e6e1d35f5bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d8a0faa-d0fd-4328-9343-e5b4e67e8422" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_a358565b-a10d-49f8-a527-e6e1d35f5bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_93896447-c68c-40f8-86e9-93182da026ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d8a0faa-d0fd-4328-9343-e5b4e67e8422" xlink:to="loc_us-gaap_LongTermDebt_93896447-c68c-40f8-86e9-93182da026ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_d8b47398-1762-4286-a1da-97b159d5e53d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d8a0faa-d0fd-4328-9343-e5b4e67e8422" xlink:to="loc_us-gaap_LongTermDebtCurrent_d8b47398-1762-4286-a1da-97b159d5e53d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1daa59c3-f37d-4fa7-abdd-b1b5906a2491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d8a0faa-d0fd-4328-9343-e5b4e67e8422" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1daa59c3-f37d-4fa7-abdd-b1b5906a2491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FINANCINGARRANGEMENTSCovenantComplianceDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fbab59f4-8ac7-466b-bb8a-6e8e0e3fae45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_90ef9b5e-0c02-498d-a482-46dc8c2e7431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fbab59f4-8ac7-466b-bb8a-6e8e0e3fae45" xlink:to="loc_us-gaap_DebtInstrumentTable_90ef9b5e-0c02-498d-a482-46dc8c2e7431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_b276147e-e00a-4230-a6fc-e7f93fafed14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_90ef9b5e-0c02-498d-a482-46dc8c2e7431" xlink:to="loc_us-gaap_CreditFacilityAxis_b276147e-e00a-4230-a6fc-e7f93fafed14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_54568c54-2686-4ecf-b918-8cefee6a7af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_b276147e-e00a-4230-a6fc-e7f93fafed14" xlink:to="loc_us-gaap_CreditFacilityDomain_54568c54-2686-4ecf-b918-8cefee6a7af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_d3abb78b-4867-4256-a25f-2515b63b7575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_54568c54-2686-4ecf-b918-8cefee6a7af9" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_d3abb78b-4867-4256-a25f-2515b63b7575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f7b15e56-c6fd-4ac9-83f4-f34a04a66f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_90ef9b5e-0c02-498d-a482-46dc8c2e7431" xlink:to="loc_us-gaap_DebtInstrumentLineItems_f7b15e56-c6fd-4ac9-83f4-f34a04a66f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAmountAvailableForRestrictedPayments_bdba8fa8-26cb-4776-b614-f53dcbb8a7b5" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentAmountAvailableForRestrictedPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f7b15e56-c6fd-4ac9-83f4-f34a04a66f1d" xlink:to="loc_bhc_DebtInstrumentAmountAvailableForRestrictedPayments_bdba8fa8-26cb-4776-b614-f53dcbb8a7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_598fa9b8-e73f-4960-8a70-aaa72ca6b9d1" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f7b15e56-c6fd-4ac9-83f4-f34a04a66f1d" xlink:to="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_598fa9b8-e73f-4960-8a70-aaa72ca6b9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_831be7c1-d9e7-4b6c-b35c-45a8264fddc8" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f7b15e56-c6fd-4ac9-83f4-f34a04a66f1d" xlink:to="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_831be7c1-d9e7-4b6c-b35c-45a8264fddc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_65523034-9e03-4b6a-a8ee-c0b03cef857a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a240b3e1-a64f-4b37-b0da-ff0ee38a7ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_65523034-9e03-4b6a-a8ee-c0b03cef857a" xlink:to="loc_us-gaap_DebtInstrumentTable_a240b3e1-a64f-4b37-b0da-ff0ee38a7ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_084d7aca-93a9-4d39-a913-a8f362a8fc35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a240b3e1-a64f-4b37-b0da-ff0ee38a7ed3" xlink:to="loc_us-gaap_CreditFacilityAxis_084d7aca-93a9-4d39-a913-a8f362a8fc35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a0fc9ada-cd76-47b9-8f3f-bf6ec35a336b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_084d7aca-93a9-4d39-a913-a8f362a8fc35" xlink:to="loc_us-gaap_CreditFacilityDomain_a0fc9ada-cd76-47b9-8f3f-bf6ec35a336b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_451baf61-b583-4673-b904-f72caddad0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_a0fc9ada-cd76-47b9-8f3f-bf6ec35a336b" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_451baf61-b583-4673-b904-f72caddad0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_35c88e8d-013e-488d-adec-4db141197ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_a0fc9ada-cd76-47b9-8f3f-bf6ec35a336b" xlink:to="loc_us-gaap_LetterOfCreditMember_35c88e8d-013e-488d-adec-4db141197ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_78cdb7e0-1097-4904-ab42-14d7e98a7f79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a240b3e1-a64f-4b37-b0da-ff0ee38a7ed3" xlink:to="loc_us-gaap_DebtInstrumentAxis_78cdb7e0-1097-4904-ab42-14d7e98a7f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_319108be-2df5-44c5-99b0-dcc28ff9ecdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_78cdb7e0-1097-4904-ab42-14d7e98a7f79" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_319108be-2df5-44c5-99b0-dcc28ff9ecdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_1a6b26b8-5e16-4d51-8c16-052c96024c10" xlink:href="bhc-20211231.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_319108be-2df5-44c5-99b0-dcc28ff9ecdc" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_1a6b26b8-5e16-4d51-8c16-052c96024c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_00c1cecc-8894-429d-a4c9-e91568e3dfd6" xlink:href="bhc-20211231.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_319108be-2df5-44c5-99b0-dcc28ff9ecdc" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_00c1cecc-8894-429d-a4c9-e91568e3dfd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d69a3401-ea0d-4b23-bfaf-8476dd85d758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a240b3e1-a64f-4b37-b0da-ff0ee38a7ed3" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d69a3401-ea0d-4b23-bfaf-8476dd85d758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1acf76aa-c08a-4251-82e2-d29b209fde96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d69a3401-ea0d-4b23-bfaf-8476dd85d758" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1acf76aa-c08a-4251-82e2-d29b209fde96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_e46211c9-23b3-4df5-b145-0f3481f2ab0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d69a3401-ea0d-4b23-bfaf-8476dd85d758" xlink:to="loc_us-gaap_DebtInstrumentTerm_e46211c9-23b3-4df5-b145-0f3481f2ab0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_786c90eb-45ff-4837-b178-67841f4f0f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d69a3401-ea0d-4b23-bfaf-8476dd85d758" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_786c90eb-45ff-4837-b178-67841f4f0f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_9a74cc12-dc3d-44d4-8f97-b3028733a566" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d69a3401-ea0d-4b23-bfaf-8476dd85d758" xlink:to="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_9a74cc12-dc3d-44d4-8f97-b3028733a566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_c57f7a28-bc55-4edd-9a04-b89a1b77de5e" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d69a3401-ea0d-4b23-bfaf-8476dd85d758" xlink:to="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_c57f7a28-bc55-4edd-9a04-b89a1b77de5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0246ae63-0c60-4a2a-b884-b91afcd000fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d69a3401-ea0d-4b23-bfaf-8476dd85d758" xlink:to="loc_us-gaap_LongTermDebt_0246ae63-0c60-4a2a-b884-b91afcd000fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_2767817d-77f4-4ba0-8ffd-9cd5f2042884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d69a3401-ea0d-4b23-bfaf-8476dd85d758" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_2767817d-77f4-4ba0-8ffd-9cd5f2042884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_017f29ec-d20c-4d6a-945e-f262d6bf714d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6560fb16-6d1f-4a4c-be98-5c5e819ed768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_017f29ec-d20c-4d6a-945e-f262d6bf714d" xlink:to="loc_us-gaap_DebtInstrumentTable_6560fb16-6d1f-4a4c-be98-5c5e819ed768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_41cab401-f83d-492e-bb7a-3fae5302f2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6560fb16-6d1f-4a4c-be98-5c5e819ed768" xlink:to="loc_us-gaap_VariableRateAxis_41cab401-f83d-492e-bb7a-3fae5302f2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0bb34aef-2367-463b-94a2-78e45a394b45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_41cab401-f83d-492e-bb7a-3fae5302f2e3" xlink:to="loc_us-gaap_VariableRateDomain_0bb34aef-2367-463b-94a2-78e45a394b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_d4021592-9b5a-4e5c-8852-12af0a2b4ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0bb34aef-2367-463b-94a2-78e45a394b45" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_d4021592-9b5a-4e5c-8852-12af0a2b4ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_917d5abd-7fc0-46e2-a926-05e5dcf9ce9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0bb34aef-2367-463b-94a2-78e45a394b45" xlink:to="loc_us-gaap_EurodollarMember_917d5abd-7fc0-46e2-a926-05e5dcf9ce9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadaBankersAcceptanceRateMember_5c8a2b88-b9ed-4a3d-b212-d0c350c6804e" xlink:href="bhc-20211231.xsd#bhc_CanadaBankersAcceptanceRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0bb34aef-2367-463b-94a2-78e45a394b45" xlink:to="loc_bhc_CanadaBankersAcceptanceRateMember_5c8a2b88-b9ed-4a3d-b212-d0c350c6804e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateOrPrimeRateMember_5bfc3239-e152-4b69-962c-ef47f7ce5a34" xlink:href="bhc-20211231.xsd#bhc_BaseRateOrPrimeRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0bb34aef-2367-463b-94a2-78e45a394b45" xlink:to="loc_bhc_BaseRateOrPrimeRateMember_5bfc3239-e152-4b69-962c-ef47f7ce5a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_36c4c44f-eb92-44dc-a8e4-755347580ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6560fb16-6d1f-4a4c-be98-5c5e819ed768" xlink:to="loc_us-gaap_DebtInstrumentAxis_36c4c44f-eb92-44dc-a8e4-755347580ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a0b3471e-a319-404e-b07b-e2235bb3857d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_36c4c44f-eb92-44dc-a8e4-755347580ff4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a0b3471e-a319-404e-b07b-e2235bb3857d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember_8ba38fd9-b580-43a7-9ff8-164be2164cc9" xlink:href="bhc-20211231.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a0b3471e-a319-404e-b07b-e2235bb3857d" xlink:to="loc_bhc_SeniorSecuredCreditFacilitiesMember_8ba38fd9-b580-43a7-9ff8-164be2164cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_4086ead9-7ded-41f9-bf22-2f58cf737973" xlink:href="bhc-20211231.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a0b3471e-a319-404e-b07b-e2235bb3857d" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_4086ead9-7ded-41f9-bf22-2f58cf737973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredTermCreditFacilitiesMember_6632f3fe-cfaa-48bf-a5f6-d0ce83b32486" xlink:href="bhc-20211231.xsd#bhc_SeniorSecuredTermCreditFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a0b3471e-a319-404e-b07b-e2235bb3857d" xlink:to="loc_bhc_SeniorSecuredTermCreditFacilitiesMember_6632f3fe-cfaa-48bf-a5f6-d0ce83b32486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_922a5d9f-dbb2-4718-ba59-c63a249d8545" xlink:href="bhc-20211231.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a0b3471e-a319-404e-b07b-e2235bb3857d" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_922a5d9f-dbb2-4718-ba59-c63a249d8545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_3143a891-9812-426d-8dfe-58ad622d64f7" xlink:href="bhc-20211231.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a0b3471e-a319-404e-b07b-e2235bb3857d" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_3143a891-9812-426d-8dfe-58ad622d64f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_51aa96cb-de70-48a1-9f46-4e8f5cbb5e19" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6560fb16-6d1f-4a4c-be98-5c5e819ed768" xlink:to="loc_srt_RangeAxis_51aa96cb-de70-48a1-9f46-4e8f5cbb5e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4132fa20-ccc2-4a16-a0be-0076b1f364a8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_51aa96cb-de70-48a1-9f46-4e8f5cbb5e19" xlink:to="loc_srt_RangeMember_4132fa20-ccc2-4a16-a0be-0076b1f364a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2f7de1b9-19a2-4cce-ba2c-a2f5dee48843" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4132fa20-ccc2-4a16-a0be-0076b1f364a8" xlink:to="loc_srt_MinimumMember_2f7de1b9-19a2-4cce-ba2c-a2f5dee48843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_eecb83cc-7b69-4633-9a56-fe3b294f5c5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4132fa20-ccc2-4a16-a0be-0076b1f364a8" xlink:to="loc_srt_MaximumMember_eecb83cc-7b69-4633-9a56-fe3b294f5c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_16a35264-e27a-4fd8-b94e-4aa2e2617204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6560fb16-6d1f-4a4c-be98-5c5e819ed768" xlink:to="loc_us-gaap_CreditFacilityAxis_16a35264-e27a-4fd8-b94e-4aa2e2617204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ddcd0b94-9422-4bee-b808-53c6911e1c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_16a35264-e27a-4fd8-b94e-4aa2e2617204" xlink:to="loc_us-gaap_CreditFacilityDomain_ddcd0b94-9422-4bee-b808-53c6911e1c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_88eacb6d-1d3f-478f-882e-171cab2ae5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_ddcd0b94-9422-4bee-b808-53c6911e1c4e" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_88eacb6d-1d3f-478f-882e-171cab2ae5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1b812493-75c1-472e-9e06-46839195807e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6560fb16-6d1f-4a4c-be98-5c5e819ed768" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1b812493-75c1-472e-9e06-46839195807e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_21b11aca-4af9-4bc5-a050-8a205bc1c8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1b812493-75c1-472e-9e06-46839195807e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_21b11aca-4af9-4bc5-a050-8a205bc1c8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_92a3a714-9101-43ad-912e-42378d575b90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_21b11aca-4af9-4bc5-a050-8a205bc1c8d2" xlink:to="loc_us-gaap_SecuredDebtMember_92a3a714-9101-43ad-912e-42378d575b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_c0c99698-1144-4b50-98fc-87c0b882ab31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_21b11aca-4af9-4bc5-a050-8a205bc1c8d2" xlink:to="loc_us-gaap_UnsecuredDebtMember_c0c99698-1144-4b50-98fc-87c0b882ab31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6560fb16-6d1f-4a4c-be98-5c5e819ed768" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6f256ef2-efee-4d4e-a88a-565fdc5eb158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6f256ef2-efee-4d4e-a88a-565fdc5eb158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_f9331770-3b65-4a13-9215-cdc223f289f6" xlink:href="bhc-20211231.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_f9331770-3b65-4a13-9215-cdc223f289f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_9bcc2ac5-ef7d-4cae-92ff-9f82f82705aa" xlink:href="bhc-20211231.xsd#bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_9bcc2ac5-ef7d-4cae-92ff-9f82f82705aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_f09d7be0-5eae-44be-bcf2-050d285f6214" xlink:href="bhc-20211231.xsd#bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_f09d7be0-5eae-44be-bcf2-050d285f6214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_57e20acc-1148-4259-98d8-0b8a0ba0b7b4" xlink:href="bhc-20211231.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_57e20acc-1148-4259-98d8-0b8a0ba0b7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_be8cd2c2-18ee-422f-8876-b1129a74d7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_be8cd2c2-18ee-422f-8876-b1129a74d7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_cf0d0dfb-18dc-4d13-b0fe-6549e82f7e76" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_cf0d0dfb-18dc-4d13-b0fe-6549e82f7e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_bd790ea4-e81c-4497-94e3-1e634c0610aa" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_bd790ea4-e81c-4497-94e3-1e634c0610aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_601d3046-c063-47ea-964e-fa4d35a4ee95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_601d3046-c063-47ea-964e-fa4d35a4ee95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_74196d1b-76f5-4589-af17-c6f1c29cd2fb" xlink:href="bhc-20211231.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_74196d1b-76f5-4589-af17-c6f1c29cd2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate_8e26b4ea-34e7-4e14-b6aa-bbf32a83771b" xlink:href="bhc-20211231.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate_8e26b4ea-34e7-4e14-b6aa-bbf32a83771b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_0ff20578-dc9d-4577-ad3b-14961f1f442c" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_0ff20578-dc9d-4577-ad3b-14961f1f442c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_3e9d231e-fe74-43c5-94fe-df030a5fb402" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_3e9d231e-fe74-43c5-94fe-df030a5fb402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_03c56c7c-3c3b-4b12-9868-cb846f14592e" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d500016a-c51e-4dbc-a162-6ef1d8871f4c" xlink:to="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_03c56c7c-3c3b-4b12-9868-cb846f14592e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c5cb9292-4296-45ea-927c-36278c8cb30c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e21cc6dd-8335-491b-8da4-e43264a176c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c5cb9292-4296-45ea-927c-36278c8cb30c" xlink:to="loc_us-gaap_DebtInstrumentTable_e21cc6dd-8335-491b-8da4-e43264a176c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_55c689a9-98d7-43eb-8e0a-6eba14effdee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e21cc6dd-8335-491b-8da4-e43264a176c7" xlink:to="loc_us-gaap_DebtInstrumentAxis_55c689a9-98d7-43eb-8e0a-6eba14effdee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_55c689a9-98d7-43eb-8e0a-6eba14effdee" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_027e13fe-5d8e-4775-ab85-845f1c9d88eb" xlink:href="bhc-20211231.xsd#bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:to="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_027e13fe-5d8e-4775-ab85-845f1c9d88eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_41039361-ea1c-4889-8856-0801537554e5" xlink:href="bhc-20211231.xsd#bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:to="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_41039361-ea1c-4889-8856-0801537554e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_76f1853e-c135-4158-b019-27deb98b2579" xlink:href="bhc-20211231.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:to="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_76f1853e-c135-4158-b019-27deb98b2579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_f0aa926b-59d0-4ad8-9699-43af58e75a58" xlink:href="bhc-20211231.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_f0aa926b-59d0-4ad8-9699-43af58e75a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_3e9d2bdc-152d-4683-af90-0b277214a6a5" xlink:href="bhc-20211231.xsd#bhc_A8.50SeniorNotesDueJanuary2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:to="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_3e9d2bdc-152d-4683-af90-0b277214a6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.875SeniorNotesdueMay2023Member_3b8558a5-dc0b-4300-b91c-f07c78dd8a2c" xlink:href="bhc-20211231.xsd#bhc_A5.875SeniorNotesdueMay2023Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:to="loc_bhc_A5.875SeniorNotesdueMay2023Member_3b8558a5-dc0b-4300-b91c-f07c78dd8a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes5.625PercentDueDecember2021Member_d23c0f7e-adba-4f62-93e0-455a540ed519" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes5.625PercentDueDecember2021Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:to="loc_bhc_SeniorNotes5.625PercentDueDecember2021Member_d23c0f7e-adba-4f62-93e0-455a540ed519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember_b8d4ae68-f51f-4e1a-abac-e144bce5fd74" xlink:href="bhc-20211231.xsd#bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:to="loc_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember_b8d4ae68-f51f-4e1a-abac-e144bce5fd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_0580c76d-c69c-422d-8e64-c5d22eb54487" xlink:href="bhc-20211231.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_0580c76d-c69c-422d-8e64-c5d22eb54487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueMarch2024Member_b484eb08-2ddc-472c-9542-5070ac3827c9" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes700DueMarch2024Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c898110-304f-4481-88e5-3b96733828ee" xlink:to="loc_bhc_SeniorNotes700DueMarch2024Member_b484eb08-2ddc-472c-9542-5070ac3827c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_448abcee-c5a2-4234-a0b5-4d3ddfb7e143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e21cc6dd-8335-491b-8da4-e43264a176c7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_448abcee-c5a2-4234-a0b5-4d3ddfb7e143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b5bccfa9-c919-4908-8cb3-e6b89a117404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_448abcee-c5a2-4234-a0b5-4d3ddfb7e143" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b5bccfa9-c919-4908-8cb3-e6b89a117404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_8d21d541-8c32-44ad-abae-0c2b7187336b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b5bccfa9-c919-4908-8cb3-e6b89a117404" xlink:to="loc_us-gaap_SecuredDebtMember_8d21d541-8c32-44ad-abae-0c2b7187336b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_49e4be6a-584f-4577-9058-6d4b2f2e03d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b5bccfa9-c919-4908-8cb3-e6b89a117404" xlink:to="loc_us-gaap_UnsecuredDebtMember_49e4be6a-584f-4577-9058-6d4b2f2e03d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_01ea1f7c-86fd-4756-aad5-6655b4ee487c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e21cc6dd-8335-491b-8da4-e43264a176c7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_01ea1f7c-86fd-4756-aad5-6655b4ee487c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_fe962dad-e898-4cfa-a2d9-fee4a1882432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_01ea1f7c-86fd-4756-aad5-6655b4ee487c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_fe962dad-e898-4cfa-a2d9-fee4a1882432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_6a359974-17db-4d7d-89a8-7fa8c16f0b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_fe962dad-e898-4cfa-a2d9-fee4a1882432" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_6a359974-17db-4d7d-89a8-7fa8c16f0b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_f061b8bd-0be0-403a-a255-770e84322941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_fe962dad-e898-4cfa-a2d9-fee4a1882432" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_f061b8bd-0be0-403a-a255-770e84322941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e2d45416-abc1-4743-a7ba-b353b6748766" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e21cc6dd-8335-491b-8da4-e43264a176c7" xlink:to="loc_srt_RangeAxis_e2d45416-abc1-4743-a7ba-b353b6748766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_95b15041-e749-427e-8407-cf45550d85a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e2d45416-abc1-4743-a7ba-b353b6748766" xlink:to="loc_srt_RangeMember_95b15041-e749-427e-8407-cf45550d85a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f5095cc5-2788-45de-b47a-70614367127f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_95b15041-e749-427e-8407-cf45550d85a7" xlink:to="loc_srt_MaximumMember_f5095cc5-2788-45de-b47a-70614367127f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_951dd377-92ac-4ac1-9bbd-d09168be4c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e21cc6dd-8335-491b-8da4-e43264a176c7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_951dd377-92ac-4ac1-9bbd-d09168be4c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_d2570e59-821f-4255-a41c-da5111fab652" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951dd377-92ac-4ac1-9bbd-d09168be4c49" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_d2570e59-821f-4255-a41c-da5111fab652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_aae76848-d377-4bdf-8c3c-916ca234af92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951dd377-92ac-4ac1-9bbd-d09168be4c49" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_aae76848-d377-4bdf-8c3c-916ca234af92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_210ee5ae-7946-4466-ade5-127a72782cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951dd377-92ac-4ac1-9bbd-d09168be4c49" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_210ee5ae-7946-4466-ade5-127a72782cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_9fda3845-eaa8-4533-abee-3c8952c3cfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951dd377-92ac-4ac1-9bbd-d09168be4c49" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_9fda3845-eaa8-4533-abee-3c8952c3cfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_50e5dd66-ef71-46bb-928a-d2303c7ff5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951dd377-92ac-4ac1-9bbd-d09168be4c49" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_50e5dd66-ef71-46bb-928a-d2303c7ff5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_2c2ae077-8ee5-490b-b147-ac09a104284f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951dd377-92ac-4ac1-9bbd-d09168be4c49" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_2c2ae077-8ee5-490b-b147-ac09a104284f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_2bc7a526-5470-4f83-b641-6b79811a7ffa" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951dd377-92ac-4ac1-9bbd-d09168be4c49" xlink:to="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_2bc7a526-5470-4f83-b641-6b79811a7ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_6372892c-6598-4c3d-911a-3a7154c392ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951dd377-92ac-4ac1-9bbd-d09168be4c49" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_6372892c-6598-4c3d-911a-3a7154c392ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_eb64c5db-12d8-4493-9590-a1977079147d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_23f7a9e9-fb53-4580-8a92-b53401db390c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_eb64c5db-12d8-4493-9590-a1977079147d" xlink:to="loc_us-gaap_DebtInstrumentTable_23f7a9e9-fb53-4580-8a92-b53401db390c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_82605553-8764-4db5-9455-c210bb4c80ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_23f7a9e9-fb53-4580-8a92-b53401db390c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_82605553-8764-4db5-9455-c210bb4c80ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1acdecdc-1587-4bf1-9a77-2e5b3aa4ac64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_82605553-8764-4db5-9455-c210bb4c80ff" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1acdecdc-1587-4bf1-9a77-2e5b3aa4ac64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_64229880-acbc-4127-8f7d-831792b3f4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1acdecdc-1587-4bf1-9a77-2e5b3aa4ac64" xlink:to="loc_us-gaap_UnsecuredDebtMember_64229880-acbc-4127-8f7d-831792b3f4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_0b90f54b-8956-41b9-b6be-21081000fbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1acdecdc-1587-4bf1-9a77-2e5b3aa4ac64" xlink:to="loc_us-gaap_SecuredDebtMember_0b90f54b-8956-41b9-b6be-21081000fbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0d45fa52-fb21-4045-8147-3553f82abe31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_23f7a9e9-fb53-4580-8a92-b53401db390c" xlink:to="loc_us-gaap_DebtInstrumentAxis_0d45fa52-fb21-4045-8147-3553f82abe31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0d45fa52-fb21-4045-8147-3553f82abe31" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.50SeniorNotesdueMarch2023Member_cbab4ed4-0223-456c-a11c-d2ad93aa3552" xlink:href="bhc-20211231.xsd#bhc_A5.50SeniorNotesdueMarch2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_A5.50SeniorNotesdueMarch2023Member_cbab4ed4-0223-456c-a11c-d2ad93aa3552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.375SeniorNotesdueMarch2020Member_79fac39e-f38b-4ab3-9e49-58a5f69a6444" xlink:href="bhc-20211231.xsd#bhc_A5.375SeniorNotesdueMarch2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_A5.375SeniorNotesdueMarch2020Member_79fac39e-f38b-4ab3-9e49-58a5f69a6444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.875SeniorNotesdueMay2023Member_d3907e52-0a31-45f7-b6b2-61e077f46447" xlink:href="bhc-20211231.xsd#bhc_A5.875SeniorNotesdueMay2023Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_A5.875SeniorNotesdueMay2023Member_d3907e52-0a31-45f7-b6b2-61e077f46447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember_ace153fe-ce6d-4fc2-9516-6aa861feafda" xlink:href="bhc-20211231.xsd#bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_A5.875SeniorNotesdueMay2023Member_d3907e52-0a31-45f7-b6b2-61e077f46447" xlink:to="loc_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember_ace153fe-ce6d-4fc2-9516-6aa861feafda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember_d5fc24d8-0108-4a4c-b0fa-2b60520b77f6" xlink:href="bhc-20211231.xsd#bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_A5.875SeniorNotesdueMay2023Member_d3907e52-0a31-45f7-b6b2-61e077f46447" xlink:to="loc_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember_d5fc24d8-0108-4a4c-b0fa-2b60520b77f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes4.502023Member_72bbf45e-9826-4d6b-88e6-4a6b8bdd1008" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes4.502023Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_SeniorNotes4.502023Member_72bbf45e-9826-4d6b-88e6-4a6b8bdd1008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A6.125SeniorNotesdueApril2025Member_d104d0ee-3a8c-4b0d-92d7-c288aea744ed" xlink:href="bhc-20211231.xsd#bhc_A6.125SeniorNotesdueApril2025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_A6.125SeniorNotesdueApril2025Member_d104d0ee-3a8c-4b0d-92d7-c288aea744ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorUnsecuredNotesDue2023Member_c610d148-753a-418d-9ae9-9cedcbb95f8d" xlink:href="bhc-20211231.xsd#bhc_SeniorUnsecuredNotesDue2023Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_SeniorUnsecuredNotesDue2023Member_c610d148-753a-418d-9ae9-9cedcbb95f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_b9eb66fb-b16d-41fd-8efe-fe5dc4f918f8" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_b9eb66fb-b16d-41fd-8efe-fe5dc4f918f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member_5d640c91-5823-44d0-a1a4-1137218b621a" xlink:href="bhc-20211231.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_A9.00SeniorNotesdueDecember2025Member_5d640c91-5823-44d0-a1a4-1137218b621a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.25SeniorNotesDueApril2026Member_fa222bdd-e961-4caf-81c0-508778659967" xlink:href="bhc-20211231.xsd#bhc_A9.25SeniorNotesDueApril2026Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_A9.25SeniorNotesDueApril2026Member_fa222bdd-e961-4caf-81c0-508778659967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_c4ac9a6f-8785-472c-a296-a35b5f3a0ffe" xlink:href="bhc-20211231.xsd#bhc_A8.50SeniorNotesDueJanuary2027Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_c4ac9a6f-8785-472c-a296-a35b5f3a0ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A7.00SeniorUnsecuredNotesDue2028Member_3728b413-8ebc-488d-b091-0d15972d8665" xlink:href="bhc-20211231.xsd#bhc_A7.00SeniorUnsecuredNotesDue2028Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_A7.00SeniorUnsecuredNotesDue2028Member_3728b413-8ebc-488d-b091-0d15972d8665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A7.25SeniorUnsecuredNotesDue2029Member_d1ca8cdc-04ea-4b79-a41a-b7f82f37c76d" xlink:href="bhc-20211231.xsd#bhc_A7.25SeniorUnsecuredNotesDue2029Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_A7.25SeniorUnsecuredNotesDue2029Member_d1ca8cdc-04ea-4b79-a41a-b7f82f37c76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.00SeniorNotesDueJanuary2028Member_b3641ec8-d13a-4adc-819f-579d2d437d86" xlink:href="bhc-20211231.xsd#bhc_A5.00SeniorNotesDueJanuary2028Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_A5.00SeniorNotesDueJanuary2028Member_b3641ec8-d13a-4adc-819f-579d2d437d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.25SeniorNotesDueJanuary2030Member_32645c21-f5d9-4f63-9e7a-d72d3980bca1" xlink:href="bhc-20211231.xsd#bhc_A5.25SeniorNotesDueJanuary2030Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_A5.25SeniorNotesDueJanuary2030Member_32645c21-f5d9-4f63-9e7a-d72d3980bca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_dbad1dd4-7439-4a54-85db-dc79e1729f37" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_dbad1dd4-7439-4a54-85db-dc79e1729f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_c509b958-f8f8-46e0-a35b-cb9ea049a171" xlink:href="bhc-20211231.xsd#bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_c509b958-f8f8-46e0-a35b-cb9ea049a171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_c8d6c335-63f4-4ab8-859b-4dc3b3d47a1b" xlink:href="bhc-20211231.xsd#bhc_TermLoanBFacilityDueJune2025AndNovember2025Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_c8d6c335-63f4-4ab8-859b-4dc3b3d47a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_3dc6a31b-4d98-469d-91e4-b89a087dfa81" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_3dc6a31b-4d98-469d-91e4-b89a087dfa81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_d644a4eb-cfdb-4a32-900d-62c6b99fc15f" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_d644a4eb-cfdb-4a32-900d-62c6b99fc15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes550DueMarch2023Member_ae3994ae-9fe6-4115-833f-44e8c42dd620" xlink:href="bhc-20211231.xsd#bhc_SeniorNotes550DueMarch2023Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f8f237a-dd1b-4a60-a51c-442d0a3cf074" xlink:to="loc_bhc_SeniorNotes550DueMarch2023Member_ae3994ae-9fe6-4115-833f-44e8c42dd620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_f7c9e3ef-bb3b-409a-951c-8f1f43b1c77a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_23f7a9e9-fb53-4580-8a92-b53401db390c" xlink:to="loc_us-gaap_LitigationStatusAxis_f7c9e3ef-bb3b-409a-951c-8f1f43b1c77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_3b2e6144-eb0e-4c77-a9a3-48029bce6d60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_f7c9e3ef-bb3b-409a-951c-8f1f43b1c77a" xlink:to="loc_us-gaap_LitigationStatusDomain_3b2e6144-eb0e-4c77-a9a3-48029bce6d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_fd3516e6-956a-4ed7-a1b3-25c104b3be7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_3b2e6144-eb0e-4c77-a9a3-48029bce6d60" xlink:to="loc_us-gaap_SettledLitigationMember_fd3516e6-956a-4ed7-a1b3-25c104b3be7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cc56c809-522e-41d1-85ca-92c53d5ff3cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_23f7a9e9-fb53-4580-8a92-b53401db390c" xlink:to="loc_srt_StatementGeographicalAxis_cc56c809-522e-41d1-85ca-92c53d5ff3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e8ee1b24-a980-4a3b-98d3-42abebaebfe4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_cc56c809-522e-41d1-85ca-92c53d5ff3cd" xlink:to="loc_srt_SegmentGeographicalDomain_e8ee1b24-a980-4a3b-98d3-42abebaebfe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_1e9a1a1b-6f8c-4945-9109-46ddc10a56b6" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e8ee1b24-a980-4a3b-98d3-42abebaebfe4" xlink:to="loc_stpr_NJ_1e9a1a1b-6f8c-4945-9109-46ddc10a56b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_f58aa3a5-db45-4ae7-9ed0-1d2ad17be814" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_23f7a9e9-fb53-4580-8a92-b53401db390c" xlink:to="loc_srt_LitigationCaseAxis_f58aa3a5-db45-4ae7-9ed0-1d2ad17be814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_01a1b71c-aa2c-41eb-99b4-ce71c8620b03" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_f58aa3a5-db45-4ae7-9ed0-1d2ad17be814" xlink:to="loc_srt_LitigationCaseTypeDomain_01a1b71c-aa2c-41eb-99b4-ce71c8620b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_589268a8-0c18-4d6e-971d-033862a95406" xlink:href="bhc-20211231.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_01a1b71c-aa2c-41eb-99b4-ce71c8620b03" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_589268a8-0c18-4d6e-971d-033862a95406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_5fef6f75-3a00-4133-bf95-9a98fd92c005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_23f7a9e9-fb53-4580-8a92-b53401db390c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_5fef6f75-3a00-4133-bf95-9a98fd92c005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_3ca0a7a8-1187-4ba1-9cdf-547ac0f3de4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_5fef6f75-3a00-4133-bf95-9a98fd92c005" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_3ca0a7a8-1187-4ba1-9cdf-547ac0f3de4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_a1b87d7b-ae88-4944-9409-2b9286cd492b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_3ca0a7a8-1187-4ba1-9cdf-547ac0f3de4d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_a1b87d7b-ae88-4944-9409-2b9286cd492b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_53a0d1d7-e4ff-4fe4-a1ed-54b9f2c8f14e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_3ca0a7a8-1187-4ba1-9cdf-547ac0f3de4d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_53a0d1d7-e4ff-4fe4-a1ed-54b9f2c8f14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_23f7a9e9-fb53-4580-8a92-b53401db390c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_4c1338f1-03af-46a0-afac-c955127b93d4" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_4c1338f1-03af-46a0-afac-c955127b93d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b91813c1-8a9b-4df2-8f8d-0d90617dc6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b91813c1-8a9b-4df2-8f8d-0d90617dc6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7946a0b3-2752-4428-88cb-38a41184a422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_7946a0b3-2752-4428-88cb-38a41184a422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_643dc08d-6726-4e56-bea6-06b7d1a6b2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_643dc08d-6726-4e56-bea6-06b7d1a6b2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_230a4d6d-48b4-4f4c-9f1b-300fe1e96bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_230a4d6d-48b4-4f4c-9f1b-300fe1e96bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_64300d13-bd07-43b9-ace7-4b9d351f5b91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_64300d13-bd07-43b9-ace7-4b9d351f5b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_74aa4a4d-5370-413c-8475-143d9ba8c0bf" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:to="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_74aa4a4d-5370-413c-8475-143d9ba8c0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3c7432ed-4d59-4b5a-9ecf-7d03e626f31d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3c7432ed-4d59-4b5a-9ecf-7d03e626f31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_5951f624-1770-4bc2-a347-973d3222201d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_5951f624-1770-4bc2-a347-973d3222201d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForDebtAmortizationPrepaymentCost_5c6f62dd-5ba7-40c9-91df-8dd8e50655e7" xlink:href="bhc-20211231.xsd#bhc_PaymentForDebtAmortizationPrepaymentCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc624a62-32f2-44e4-8511-c1913067bb66" xlink:to="loc_bhc_PaymentForDebtAmortizationPrepaymentCost_5c6f62dd-5ba7-40c9-91df-8dd8e50655e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b8b2ffbe-039d-477e-a93b-71400e015217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_bf929558-f060-4f53-b415-346fc39565a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b8b2ffbe-039d-477e-a93b-71400e015217" xlink:to="loc_us-gaap_DebtInstrumentTable_bf929558-f060-4f53-b415-346fc39565a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6386e839-dfaf-45fd-b113-383203f8f8de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bf929558-f060-4f53-b415-346fc39565a3" xlink:to="loc_us-gaap_DebtInstrumentAxis_6386e839-dfaf-45fd-b113-383203f8f8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e0fcfd7f-f6ee-43a2-a790-abd1ba32c326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6386e839-dfaf-45fd-b113-383203f8f8de" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e0fcfd7f-f6ee-43a2-a790-abd1ba32c326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_e4e9a8ba-9fce-4804-94e6-6b4c90fc2daf" xlink:href="bhc-20211231.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e0fcfd7f-f6ee-43a2-a790-abd1ba32c326" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_e4e9a8ba-9fce-4804-94e6-6b4c90fc2daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member_551aae95-9f9d-4b61-9bd4-732efe0f8fb9" xlink:href="bhc-20211231.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e0fcfd7f-f6ee-43a2-a790-abd1ba32c326" xlink:to="loc_bhc_A9.00SeniorNotesdueDecember2025Member_551aae95-9f9d-4b61-9bd4-732efe0f8fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_e545b211-2366-44a8-b414-9d4e874551f0" xlink:href="bhc-20211231.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e0fcfd7f-f6ee-43a2-a790-abd1ba32c326" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_e545b211-2366-44a8-b414-9d4e874551f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_c9d32bcd-2ceb-4cd7-9efe-08ece0a25e12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bf929558-f060-4f53-b415-346fc39565a3" xlink:to="loc_us-gaap_CreditFacilityAxis_c9d32bcd-2ceb-4cd7-9efe-08ece0a25e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_fc12d24d-ff1d-42d3-9413-1880b7d0cb49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_c9d32bcd-2ceb-4cd7-9efe-08ece0a25e12" xlink:to="loc_us-gaap_CreditFacilityDomain_fc12d24d-ff1d-42d3-9413-1880b7d0cb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_43fa2aab-5b0a-4c70-bdfd-2bb2c25336d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_fc12d24d-ff1d-42d3-9413-1880b7d0cb49" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_43fa2aab-5b0a-4c70-bdfd-2bb2c25336d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d4a5ec6c-4988-4875-bb9a-537143bda170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bf929558-f060-4f53-b415-346fc39565a3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d4a5ec6c-4988-4875-bb9a-537143bda170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a53e30b4-a69c-4e37-90c8-41b327de8af7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d4a5ec6c-4988-4875-bb9a-537143bda170" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a53e30b4-a69c-4e37-90c8-41b327de8af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_7c81d026-296b-4bc5-b10b-8711d3ff0104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a53e30b4-a69c-4e37-90c8-41b327de8af7" xlink:to="loc_us-gaap_UnsecuredDebtMember_7c81d026-296b-4bc5-b10b-8711d3ff0104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_7c4cfe16-c17e-485d-9312-6ebf981fe9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a53e30b4-a69c-4e37-90c8-41b327de8af7" xlink:to="loc_us-gaap_SecuredDebtMember_7c4cfe16-c17e-485d-9312-6ebf981fe9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2ea628e2-5446-4fa7-8694-11cfa6182486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bf929558-f060-4f53-b415-346fc39565a3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2ea628e2-5446-4fa7-8694-11cfa6182486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6dfbaddc-06de-45ec-a3d2-7cfed82aa8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2ea628e2-5446-4fa7-8694-11cfa6182486" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6dfbaddc-06de-45ec-a3d2-7cfed82aa8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8319bf97-e76c-4a55-b395-6139ccfc4563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6dfbaddc-06de-45ec-a3d2-7cfed82aa8d0" xlink:to="loc_us-gaap_SubsequentEventMember_8319bf97-e76c-4a55-b395-6139ccfc4563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_aefcd0fc-f173-40ca-93e7-c156c19498c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bf929558-f060-4f53-b415-346fc39565a3" xlink:to="loc_us-gaap_DebtInstrumentLineItems_aefcd0fc-f173-40ca-93e7-c156c19498c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_68d3e534-2365-4c93-a170-19531d4aae64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aefcd0fc-f173-40ca-93e7-c156c19498c3" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_68d3e534-2365-4c93-a170-19531d4aae64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_424c477d-eec1-4faa-94ff-7b39024089ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aefcd0fc-f173-40ca-93e7-c156c19498c3" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_424c477d-eec1-4faa-94ff-7b39024089ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_df373498-75f3-45d0-92f6-d0dad3dcaf0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aefcd0fc-f173-40ca-93e7-c156c19498c3" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_df373498-75f3-45d0-92f6-d0dad3dcaf0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2305eec9-13aa-4640-8d66-9c2e85a353d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aefcd0fc-f173-40ca-93e7-c156c19498c3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2305eec9-13aa-4640-8d66-9c2e85a353d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_60a97b86-ceec-4587-bcc4-14166af285e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aefcd0fc-f173-40ca-93e7-c156c19498c3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_60a97b86-ceec-4587-bcc4-14166af285e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8c110d28-f07c-4ee1-88a6-d26551bbedc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f0c13db7-c8b8-4c4b-ba58-6cad523e489f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8c110d28-f07c-4ee1-88a6-d26551bbedc7" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f0c13db7-c8b8-4c4b-ba58-6cad523e489f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b5ce8ee2-e4e9-4696-839f-e6e284ffb28f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8c110d28-f07c-4ee1-88a6-d26551bbedc7" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b5ce8ee2-e4e9-4696-839f-e6e284ffb28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ebc921cf-c8f4-4bb2-8a02-2457b327be70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8c110d28-f07c-4ee1-88a6-d26551bbedc7" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ebc921cf-c8f4-4bb2-8a02-2457b327be70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_d8110801-fb5e-4eba-b332-33bbceceb295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8c110d28-f07c-4ee1-88a6-d26551bbedc7" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_d8110801-fb5e-4eba-b332-33bbceceb295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_872a8e4d-2c5a-45d6-8b5b-ff49b93e3336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8c110d28-f07c-4ee1-88a6-d26551bbedc7" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_872a8e4d-2c5a-45d6-8b5b-ff49b93e3336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_4c7fc721-d188-41a0-b805-7e21a6056d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8c110d28-f07c-4ee1-88a6-d26551bbedc7" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_4c7fc721-d188-41a0-b805-7e21a6056d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_75c00ed0-3960-4aec-b9d8-eb1bb3e77d64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8c110d28-f07c-4ee1-88a6-d26551bbedc7" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_75c00ed0-3960-4aec-b9d8-eb1bb3e77d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2e6ad644-493e-47bd-a9d3-a291acfacc45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8c110d28-f07c-4ee1-88a6-d26551bbedc7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2e6ad644-493e-47bd-a9d3-a291acfacc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6e3ece72-6164-4f8f-8d13-6b78b8bf0de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8c110d28-f07c-4ee1-88a6-d26551bbedc7" xlink:to="loc_us-gaap_LongTermDebt_6e3ece72-6164-4f8f-8d13-6b78b8bf0de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_81e93665-4f43-4277-8517-cf125d0cd2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_205fbacb-840d-4052-b0c2-868c7fcbc3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_81e93665-4f43-4277-8517-cf125d0cd2ba" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_205fbacb-840d-4052-b0c2-868c7fcbc3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_421dc812-3b52-4a02-86d6-c1f5b6b8979b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_c8a3ac32-1656-4074-89aa-e09ca25f562c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_421dc812-3b52-4a02-86d6-c1f5b6b8979b" xlink:to="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_c8a3ac32-1656-4074-89aa-e09ca25f562c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_0388aa8c-59a8-4e0d-a3bb-3599d807990e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_421dc812-3b52-4a02-86d6-c1f5b6b8979b" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_0388aa8c-59a8-4e0d-a3bb-3599d807990e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_56eb3967-9121-49d8-a226-888a4a113484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_421dc812-3b52-4a02-86d6-c1f5b6b8979b" xlink:to="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_56eb3967-9121-49d8-a226-888a4a113484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_f9ccebb9-0117-485a-b000-36b91e1c5129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_421dc812-3b52-4a02-86d6-c1f5b6b8979b" xlink:to="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_f9ccebb9-0117-485a-b000-36b91e1c5129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_a6cf340d-84a4-459c-b027-c0f4a9083fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_421dc812-3b52-4a02-86d6-c1f5b6b8979b" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_a6cf340d-84a4-459c-b027-c0f4a9083fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_042a1e44-9e6c-4f00-ab93-94bdff47593b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_421dc812-3b52-4a02-86d6-c1f5b6b8979b" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_042a1e44-9e6c-4f00-ab93-94bdff47593b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_38a0ee86-88ec-4620-a039-ec7ad39903bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_421dc812-3b52-4a02-86d6-c1f5b6b8979b" xlink:to="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_38a0ee86-88ec-4620-a039-ec7ad39903bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock_190ac174-ac5b-47fd-93d8-a5f5a58f9a43" xlink:href="bhc-20211231.xsd#bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_421dc812-3b52-4a02-86d6-c1f5b6b8979b" xlink:to="loc_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock_190ac174-ac5b-47fd-93d8-a5f5a58f9a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1f59df84-a4db-4617-bf7d-433e39dfbb97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2a5c436d-5777-47f6-ba33-21893c0b8573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1f59df84-a4db-4617-bf7d-433e39dfbb97" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2a5c436d-5777-47f6-ba33-21893c0b8573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a7370a88-6273-414c-8979-6f531936a43e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2a5c436d-5777-47f6-ba33-21893c0b8573" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a7370a88-6273-414c-8979-6f531936a43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_849a422c-1cd8-494d-84f0-ca867891f191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a7370a88-6273-414c-8979-6f531936a43e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_849a422c-1cd8-494d-84f0-ca867891f191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_6125c35f-18eb-43e7-8e25-9bf04597d4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_849a422c-1cd8-494d-84f0-ca867891f191" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_6125c35f-18eb-43e7-8e25-9bf04597d4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_63f97cb4-3da0-4997-b60c-63e2734742fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_849a422c-1cd8-494d-84f0-ca867891f191" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_63f97cb4-3da0-4997-b60c-63e2734742fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_18ece77c-c55d-4f14-8bee-1bf49a0fb361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2a5c436d-5777-47f6-ba33-21893c0b8573" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_18ece77c-c55d-4f14-8bee-1bf49a0fb361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_954289a0-8fe2-4ba4-ac4d-58102a2c0f07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_18ece77c-c55d-4f14-8bee-1bf49a0fb361" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_954289a0-8fe2-4ba4-ac4d-58102a2c0f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_5224ed56-8591-47e5-a8a0-ee869c6a3cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_954289a0-8fe2-4ba4-ac4d-58102a2c0f07" xlink:to="loc_us-gaap_ForeignPlanMember_5224ed56-8591-47e5-a8a0-ee869c6a3cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_a7995f39-07f3-4baa-9f32-862203312d10" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignPlanMember_5224ed56-8591-47e5-a8a0-ee869c6a3cd2" xlink:to="loc_country_IE_a7995f39-07f3-4baa-9f32-862203312d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_feb87026-b975-4d6c-8827-79decc42d878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_954289a0-8fe2-4ba4-ac4d-58102a2c0f07" xlink:to="loc_us-gaap_DomesticPlanMember_feb87026-b975-4d6c-8827-79decc42d878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_9c03eb1c-ddfd-4bcb-922c-532f87aaf6f8" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_feb87026-b975-4d6c-8827-79decc42d878" xlink:to="loc_country_US_9c03eb1c-ddfd-4bcb-922c-532f87aaf6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_95d503ca-5a4e-41f7-91a1-e057c1430787" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2a5c436d-5777-47f6-ba33-21893c0b8573" xlink:to="loc_srt_StatementScenarioAxis_95d503ca-5a4e-41f7-91a1-e057c1430787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9c27d40a-d7d4-4541-9d77-bc73f36150c5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_95d503ca-5a4e-41f7-91a1-e057c1430787" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9c27d40a-d7d4-4541-9d77-bc73f36150c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_9f31c897-00b4-4397-877b-b05f2b083404" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_9c27d40a-d7d4-4541-9d77-bc73f36150c5" xlink:to="loc_srt_ScenarioForecastMember_9f31c897-00b4-4397-877b-b05f2b083404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2a5c436d-5777-47f6-ba33-21893c0b8573" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance_72d03ce8-ac64-4f63-a8cd-8f4b434333ce" xlink:href="bhc-20211231.xsd#bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:to="loc_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance_72d03ce8-ac64-4f63-a8cd-8f4b434333ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans_0d966dd8-f253-4675-93ed-801115dc748e" xlink:href="bhc-20211231.xsd#bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:to="loc_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans_0d966dd8-f253-4675-93ed-801115dc748e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended_9bc63a0c-616d-48ac-ad86-2d98c4617f60" xlink:href="bhc-20211231.xsd#bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:to="loc_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended_9bc63a0c-616d-48ac-ad86-2d98c4617f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanEmployerContributionMaximumAge_5a548e7f-1cf8-4d6d-b22b-1e3ec7ce962f" xlink:href="bhc-20211231.xsd#bhc_DefinedBenefitPlanEmployerContributionMaximumAge"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:to="loc_bhc_DefinedBenefitPlanEmployerContributionMaximumAge_5a548e7f-1cf8-4d6d-b22b-1e3ec7ce962f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_0c4219c3-d895-4225-9537-c657c282961a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_0c4219c3-d895-4225-9537-c657c282961a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_7630211a-9768-4fea-89e9-0bbfa9f7915a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_7630211a-9768-4fea-89e9-0bbfa9f7915a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod_6905d91c-d245-4aaa-8a5a-b69e796f6ce5" xlink:href="bhc-20211231.xsd#bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:to="loc_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod_6905d91c-d245-4aaa-8a5a-b69e796f6ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_9acf8d3d-bb4f-46d9-9d5f-9cff3e508cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_9acf8d3d-bb4f-46d9-9d5f-9cff3e508cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanPercentageAllocationofFund_372a0143-2c62-458f-ac4b-34e8521730cf" xlink:href="bhc-20211231.xsd#bhc_DefinedBenefitPlanPercentageAllocationofFund"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:to="loc_bhc_DefinedBenefitPlanPercentageAllocationofFund_372a0143-2c62-458f-ac4b-34e8521730cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_9200cffc-53b6-42dd-8424-76d433094a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b43935d-1c56-473b-8e77-26e11d6bd81d" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_9200cffc-53b6-42dd-8424-76d433094a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d37c6818-db10-4345-ae2c-0e86bb7083ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b915101e-854d-4eb4-806c-576c650581e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d37c6818-db10-4345-ae2c-0e86bb7083ac" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b915101e-854d-4eb4-806c-576c650581e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_16312b7d-4457-410a-ae11-1b2b145f26ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b915101e-854d-4eb4-806c-576c650581e4" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_16312b7d-4457-410a-ae11-1b2b145f26ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_875982dc-65a8-4b11-bc7d-e424f6323d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_16312b7d-4457-410a-ae11-1b2b145f26ee" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_875982dc-65a8-4b11-bc7d-e424f6323d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_ffe4940b-690e-417a-bf17-2c773df291a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_875982dc-65a8-4b11-bc7d-e424f6323d8a" xlink:to="loc_us-gaap_DomesticPlanMember_ffe4940b-690e-417a-bf17-2c773df291a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_10f0045c-153e-400e-bcc1-b8700938c050" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_ffe4940b-690e-417a-bf17-2c773df291a7" xlink:to="loc_country_US_10f0045c-153e-400e-bcc1-b8700938c050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_7d5a99a8-7363-40df-af7d-b82fbdc615c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_875982dc-65a8-4b11-bc7d-e424f6323d8a" xlink:to="loc_us-gaap_ForeignPlanMember_7d5a99a8-7363-40df-af7d-b82fbdc615c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_9da20370-72be-49a2-a689-f2dcb4280713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b915101e-854d-4eb4-806c-576c650581e4" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_9da20370-72be-49a2-a689-f2dcb4280713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_f24cda88-5d99-46b7-80a2-6fb1059d3e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9da20370-72be-49a2-a689-f2dcb4280713" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_f24cda88-5d99-46b7-80a2-6fb1059d3e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_6100b3d6-2594-4509-852d-8dd0857ca3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_f24cda88-5d99-46b7-80a2-6fb1059d3e98" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_6100b3d6-2594-4509-852d-8dd0857ca3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_27a600f4-8507-41b7-bd4f-3dcda16a1f30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_f24cda88-5d99-46b7-80a2-6fb1059d3e98" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_27a600f4-8507-41b7-bd4f-3dcda16a1f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_84654169-ce74-4a6c-ad2c-da6c0b0dbb96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b915101e-854d-4eb4-806c-576c650581e4" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_84654169-ce74-4a6c-ad2c-da6c0b0dbb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_8f27200d-742a-4cad-971a-eed96a81e485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_84654169-ce74-4a6c-ad2c-da6c0b0dbb96" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_8f27200d-742a-4cad-971a-eed96a81e485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax_08f795e1-184d-4c1f-a8b2-085cc6379f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_84654169-ce74-4a6c-ad2c-da6c0b0dbb96" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax_08f795e1-184d-4c1f-a8b2-085cc6379f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d17d22f3-68f1-43e0-a1d8-3959e39fae57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_af358374-8274-4907-afb7-bd31040991fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d17d22f3-68f1-43e0-a1d8-3959e39fae57" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_af358374-8274-4907-afb7-bd31040991fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_f930f5c2-418e-434a-9dde-b3f6cc2cf588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_af358374-8274-4907-afb7-bd31040991fa" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_f930f5c2-418e-434a-9dde-b3f6cc2cf588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_5635708a-ba06-4c57-89a7-5af12d93a9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_f930f5c2-418e-434a-9dde-b3f6cc2cf588" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_5635708a-ba06-4c57-89a7-5af12d93a9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_e0bf439e-53b4-463a-84c5-310894f8511f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5635708a-ba06-4c57-89a7-5af12d93a9a4" xlink:to="loc_us-gaap_DomesticPlanMember_e0bf439e-53b4-463a-84c5-310894f8511f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_e4fb58b2-923b-452b-8e8b-051f1a29bd03" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_e0bf439e-53b4-463a-84c5-310894f8511f" xlink:to="loc_country_US_e4fb58b2-923b-452b-8e8b-051f1a29bd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_6d269313-29e0-4e79-8a9e-431984122c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5635708a-ba06-4c57-89a7-5af12d93a9a4" xlink:to="loc_us-gaap_ForeignPlanMember_6d269313-29e0-4e79-8a9e-431984122c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_ebfa8931-be77-4b70-9a71-8ac26327d1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_af358374-8274-4907-afb7-bd31040991fa" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_ebfa8931-be77-4b70-9a71-8ac26327d1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9b647e2d-e30e-4096-8930-4c9b337359c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ebfa8931-be77-4b70-9a71-8ac26327d1f0" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_9b647e2d-e30e-4096-8930-4c9b337359c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_4edc9370-4fc0-456a-bb8f-d1898c9db6af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9b647e2d-e30e-4096-8930-4c9b337359c8" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_4edc9370-4fc0-456a-bb8f-d1898c9db6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_85ccd7ab-2f5e-4e98-9503-c82ef554cc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9b647e2d-e30e-4096-8930-4c9b337359c8" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_85ccd7ab-2f5e-4e98-9503-c82ef554cc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0cf93abd-2342-4cce-b246-d291f921d2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_af358374-8274-4907-afb7-bd31040991fa" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0cf93abd-2342-4cce-b246-d291f921d2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_b75533ee-20cd-402f-9222-d2d230920468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0cf93abd-2342-4cce-b246-d291f921d2fa" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_b75533ee-20cd-402f-9222-d2d230920468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_1f606a87-ef29-4737-957e-ae63b464ffed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0cf93abd-2342-4cce-b246-d291f921d2fa" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_1f606a87-ef29-4737-957e-ae63b464ffed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_323dc431-6c6a-4f21-b201-3d52a4157c84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0cf93abd-2342-4cce-b246-d291f921d2fa" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_323dc431-6c6a-4f21-b201-3d52a4157c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_bc9095c9-2300-4cdc-86f4-2a687e5db343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0cf93abd-2342-4cce-b246-d291f921d2fa" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_bc9095c9-2300-4cdc-86f4-2a687e5db343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_903bad94-3368-4f24-a7fc-895006446a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0cf93abd-2342-4cce-b246-d291f921d2fa" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_903bad94-3368-4f24-a7fc-895006446a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_e38362b8-9ee9-48b5-b460-9682c9c90630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0cf93abd-2342-4cce-b246-d291f921d2fa" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_e38362b8-9ee9-48b5-b460-9682c9c90630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanOtherCosts_e51faa13-6221-4ccb-a33d-f32dad68a966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanOtherCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0cf93abd-2342-4cce-b246-d291f921d2fa" xlink:to="loc_us-gaap_DefinedBenefitPlanOtherCosts_e51faa13-6221-4ccb-a33d-f32dad68a966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4228abdf-d466-4b9d-b4e6-15001ef5d00b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0cf93abd-2342-4cce-b246-d291f921d2fa" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4228abdf-d466-4b9d-b4e6-15001ef5d00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_446fb9bd-252a-4885-9c21-e6a92c9304b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3a29774f-eee4-4e26-bad3-9bd11a02c41d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_446fb9bd-252a-4885-9c21-e6a92c9304b0" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3a29774f-eee4-4e26-bad3-9bd11a02c41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_d2cef5d3-62aa-4881-89aa-8db2d089d5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3a29774f-eee4-4e26-bad3-9bd11a02c41d" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_d2cef5d3-62aa-4881-89aa-8db2d089d5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_8c91ef85-c133-4e2b-aec3-e5e21fb4a974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_d2cef5d3-62aa-4881-89aa-8db2d089d5a3" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_8c91ef85-c133-4e2b-aec3-e5e21fb4a974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_1a09f786-612d-44b1-8ef6-6fdd94ae761b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_8c91ef85-c133-4e2b-aec3-e5e21fb4a974" xlink:to="loc_us-gaap_DomesticPlanMember_1a09f786-612d-44b1-8ef6-6fdd94ae761b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_9ab0a4b2-d725-41bd-bb6d-6fd85235fa8c" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_1a09f786-612d-44b1-8ef6-6fdd94ae761b" xlink:to="loc_country_US_9ab0a4b2-d725-41bd-bb6d-6fd85235fa8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_92c03e5c-64cf-41fd-ba70-4423d4f8e1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_8c91ef85-c133-4e2b-aec3-e5e21fb4a974" xlink:to="loc_us-gaap_ForeignPlanMember_92c03e5c-64cf-41fd-ba70-4423d4f8e1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_86b4d45c-1bbb-4228-8dcc-0f676fe7b803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3a29774f-eee4-4e26-bad3-9bd11a02c41d" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_86b4d45c-1bbb-4228-8dcc-0f676fe7b803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9c93a71f-d900-415f-a106-4118bf9e2a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_86b4d45c-1bbb-4228-8dcc-0f676fe7b803" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_9c93a71f-d900-415f-a106-4118bf9e2a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_b6325f4f-1252-4e95-a288-b2861ad62509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9c93a71f-d900-415f-a106-4118bf9e2a0a" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_b6325f4f-1252-4e95-a288-b2861ad62509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_67953420-4dba-47c6-ad2f-1b270809cad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9c93a71f-d900-415f-a106-4118bf9e2a0a" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_67953420-4dba-47c6-ad2f-1b270809cad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dbfeecb-993f-4a67-9875-3526cb1ed7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3a29774f-eee4-4e26-bad3-9bd11a02c41d" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dbfeecb-993f-4a67-9875-3526cb1ed7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_531b9c23-35b8-46d9-9dc2-574e463fe906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dbfeecb-993f-4a67-9875-3526cb1ed7a2" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_531b9c23-35b8-46d9-9dc2-574e463fe906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_a0e722da-7a1f-45cf-bda6-52164d21dd66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_531b9c23-35b8-46d9-9dc2-574e463fe906" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_a0e722da-7a1f-45cf-bda6-52164d21dd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_9fd636c8-f18e-48e6-a039-1980e2048467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_531b9c23-35b8-46d9-9dc2-574e463fe906" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_9fd636c8-f18e-48e6-a039-1980e2048467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_ac02f09f-5ff2-4383-a382-352de7815fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_531b9c23-35b8-46d9-9dc2-574e463fe906" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_ac02f09f-5ff2-4383-a382-352de7815fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_e89a1c7f-810e-4abf-bda7-2aa6454c0eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_531b9c23-35b8-46d9-9dc2-574e463fe906" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_e89a1c7f-810e-4abf-bda7-2aa6454c0eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_8bd1de96-5ea2-4009-a879-d46ff3ada68c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_531b9c23-35b8-46d9-9dc2-574e463fe906" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_8bd1de96-5ea2-4009-a879-d46ff3ada68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_148ac9b8-9791-4b3b-823e-7a61f3c4a71b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_531b9c23-35b8-46d9-9dc2-574e463fe906" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_148ac9b8-9791-4b3b-823e-7a61f3c4a71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_4dafbf9d-c433-46eb-8dca-984184a16eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_531b9c23-35b8-46d9-9dc2-574e463fe906" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_4dafbf9d-c433-46eb-8dca-984184a16eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5148d96a-3aeb-40d0-b0ea-92fc66fc9747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_531b9c23-35b8-46d9-9dc2-574e463fe906" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5148d96a-3aeb-40d0-b0ea-92fc66fc9747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_a4d73a6d-9f80-4a0e-91c6-3e62f204a1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dbfeecb-993f-4a67-9875-3526cb1ed7a2" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_a4d73a6d-9f80-4a0e-91c6-3e62f204a1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_4577665a-fb56-4888-8a37-f8356243f809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_a4d73a6d-9f80-4a0e-91c6-3e62f204a1ed" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_4577665a-fb56-4888-8a37-f8356243f809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_cd46c890-0958-42fc-8e50-e1e91c5694ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_a4d73a6d-9f80-4a0e-91c6-3e62f204a1ed" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_cd46c890-0958-42fc-8e50-e1e91c5694ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_6ba78710-f0ab-4316-8abb-593268d439fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_a4d73a6d-9f80-4a0e-91c6-3e62f204a1ed" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_6ba78710-f0ab-4316-8abb-593268d439fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_1203914f-7162-44c2-b53b-8b36ebce7479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_a4d73a6d-9f80-4a0e-91c6-3e62f204a1ed" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_1203914f-7162-44c2-b53b-8b36ebce7479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_55ff3afb-b87e-45a8-bec6-f7a919c9075c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_a4d73a6d-9f80-4a0e-91c6-3e62f204a1ed" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_55ff3afb-b87e-45a8-bec6-f7a919c9075c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_9a147a13-f09d-46a2-b437-86b327addd88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_a4d73a6d-9f80-4a0e-91c6-3e62f204a1ed" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_9a147a13-f09d-46a2-b437-86b327addd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_ceb32d5b-005e-4f6f-84c6-7a0bf5da0281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_a4d73a6d-9f80-4a0e-91c6-3e62f204a1ed" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_ceb32d5b-005e-4f6f-84c6-7a0bf5da0281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_e0ef6af7-d86f-4545-b341-f157d6d94c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dbfeecb-993f-4a67-9875-3526cb1ed7a2" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_e0ef6af7-d86f-4545-b341-f157d6d94c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_25b71e1c-f8d1-4f8f-b941-cba19ad9f5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dbfeecb-993f-4a67-9875-3526cb1ed7a2" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_25b71e1c-f8d1-4f8f-b941-cba19ad9f5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_0c6613c7-d343-42c0-97f2-9fb2a62e51f8" xlink:href="bhc-20211231.xsd#bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_25b71e1c-f8d1-4f8f-b941-cba19ad9f5e2" xlink:to="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_0c6613c7-d343-42c0-97f2-9fb2a62e51f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_89e9a839-684b-4cc4-9102-d916262d066f" xlink:href="bhc-20211231.xsd#bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_25b71e1c-f8d1-4f8f-b941-cba19ad9f5e2" xlink:to="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_89e9a839-684b-4cc4-9102-d916262d066f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_4477d8dd-d82a-46a1-9d40-af5f31907286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_25b71e1c-f8d1-4f8f-b941-cba19ad9f5e2" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_4477d8dd-d82a-46a1-9d40-af5f31907286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_01741f9c-c956-4a4c-9ac2-d34b9997b5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2a5d9227-44c1-40bd-ac54-c0eb3ad61a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_01741f9c-c956-4a4c-9ac2-d34b9997b5f5" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2a5d9227-44c1-40bd-ac54-c0eb3ad61a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_95a3661f-5748-4b49-8602-f9c5adc62b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2a5d9227-44c1-40bd-ac54-c0eb3ad61a1b" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_95a3661f-5748-4b49-8602-f9c5adc62b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_03f4ced9-01e9-453d-a8fa-999a7dce6e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_95a3661f-5748-4b49-8602-f9c5adc62b87" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_03f4ced9-01e9-453d-a8fa-999a7dce6e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_10daf364-a96a-4ced-ae56-e25f9f9c191a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_03f4ced9-01e9-453d-a8fa-999a7dce6e97" xlink:to="loc_us-gaap_DomesticPlanMember_10daf364-a96a-4ced-ae56-e25f9f9c191a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_56a610f5-1a62-4fb5-a393-51f25c8528b0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_10daf364-a96a-4ced-ae56-e25f9f9c191a" xlink:to="loc_country_US_56a610f5-1a62-4fb5-a393-51f25c8528b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_7ad16381-cd97-4460-9081-4105305d5dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_03f4ced9-01e9-453d-a8fa-999a7dce6e97" xlink:to="loc_us-gaap_ForeignPlanMember_7ad16381-cd97-4460-9081-4105305d5dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_055f2560-f8a1-42e1-aceb-adcfae139d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2a5d9227-44c1-40bd-ac54-c0eb3ad61a1b" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_055f2560-f8a1-42e1-aceb-adcfae139d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_7cce9a88-0df4-4e7c-80f7-3dfc20540c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_055f2560-f8a1-42e1-aceb-adcfae139d19" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_7cce9a88-0df4-4e7c-80f7-3dfc20540c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_78aeb973-461e-45f0-b440-df10eb540749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_7cce9a88-0df4-4e7c-80f7-3dfc20540c10" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_78aeb973-461e-45f0-b440-df10eb540749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_492a4968-e1a2-4c25-a64a-eed508ea45eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_7cce9a88-0df4-4e7c-80f7-3dfc20540c10" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_492a4968-e1a2-4c25-a64a-eed508ea45eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_9a0745a8-f61a-407c-830b-b896334dd546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_7cce9a88-0df4-4e7c-80f7-3dfc20540c10" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_9a0745a8-f61a-407c-830b-b896334dd546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d9fc98a3-24da-4186-af74-a278d1b2c3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_4e8050ce-5f59-47e7-9e6f-51f63e5b0a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d9fc98a3-24da-4186-af74-a278d1b2c3e7" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_4e8050ce-5f59-47e7-9e6f-51f63e5b0a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_cc29d148-6bb4-4b12-8083-40809bb5b159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_4e8050ce-5f59-47e7-9e6f-51f63e5b0a9a" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_cc29d148-6bb4-4b12-8083-40809bb5b159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3ef7e9dc-09e9-4bc0-9c89-c5a2b984ec67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_cc29d148-6bb4-4b12-8083-40809bb5b159" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3ef7e9dc-09e9-4bc0-9c89-c5a2b984ec67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_7741104b-42a4-40a6-8515-74a544bc9f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3ef7e9dc-09e9-4bc0-9c89-c5a2b984ec67" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_7741104b-42a4-40a6-8515-74a544bc9f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_96e4938c-f51f-47b2-aef7-77992bd2fed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3ef7e9dc-09e9-4bc0-9c89-c5a2b984ec67" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_96e4938c-f51f-47b2-aef7-77992bd2fed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_7953e1c0-9523-48c4-bc38-ebbce715cc75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_4e8050ce-5f59-47e7-9e6f-51f63e5b0a9a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_7953e1c0-9523-48c4-bc38-ebbce715cc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_d5da71f4-8edc-4213-9333-562a04b5a90a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_7953e1c0-9523-48c4-bc38-ebbce715cc75" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_d5da71f4-8edc-4213-9333-562a04b5a90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_df4bc6a3-eee7-4b43-8fbe-1153cde80aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_d5da71f4-8edc-4213-9333-562a04b5a90a" xlink:to="loc_us-gaap_DomesticPlanMember_df4bc6a3-eee7-4b43-8fbe-1153cde80aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d0c86532-9dcd-4456-9c35-88ddeba84f3b" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_df4bc6a3-eee7-4b43-8fbe-1153cde80aee" xlink:to="loc_country_US_d0c86532-9dcd-4456-9c35-88ddeba84f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_5462693c-9bb7-468e-b41f-f078996ceee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_d5da71f4-8edc-4213-9333-562a04b5a90a" xlink:to="loc_us-gaap_ForeignPlanMember_5462693c-9bb7-468e-b41f-f078996ceee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ef64717d-2aa8-4d0a-96a5-689da641178d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_4e8050ce-5f59-47e7-9e6f-51f63e5b0a9a" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ef64717d-2aa8-4d0a-96a5-689da641178d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_eeb17238-a77d-434d-b48b-e88ab585af59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ef64717d-2aa8-4d0a-96a5-689da641178d" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_eeb17238-a77d-434d-b48b-e88ab585af59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_61bd579d-66f8-40d8-a00f-a6fda3c9ff67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ef64717d-2aa8-4d0a-96a5-689da641178d" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_61bd579d-66f8-40d8-a00f-a6fda3c9ff67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_34f8eac2-0eb2-4da8-89d6-ac81cadeea05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ef64717d-2aa8-4d0a-96a5-689da641178d" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_34f8eac2-0eb2-4da8-89d6-ac81cadeea05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_4c846caa-9469-481a-a04d-929c2841e948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ef64717d-2aa8-4d0a-96a5-689da641178d" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_4c846caa-9469-481a-a04d-929c2841e948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_36d35432-3749-4e53-8b5a-6dec41bd7e15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ef64717d-2aa8-4d0a-96a5-689da641178d" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_36d35432-3749-4e53-8b5a-6dec41bd7e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_9b068906-e30c-441c-acde-85a235274b84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ef64717d-2aa8-4d0a-96a5-689da641178d" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_9b068906-e30c-441c-acde-85a235274b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a91dd16f-bdf0-4b69-9746-357056801778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f2d002ab-9539-4302-9a9a-33e9d77fd349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a91dd16f-bdf0-4b69-9746-357056801778" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f2d002ab-9539-4302-9a9a-33e9d77fd349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_417cc094-3711-4277-9a02-696429f9cf3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f2d002ab-9539-4302-9a9a-33e9d77fd349" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_417cc094-3711-4277-9a02-696429f9cf3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1998cb78-2b6c-4241-a555-069d00969324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_417cc094-3711-4277-9a02-696429f9cf3f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1998cb78-2b6c-4241-a555-069d00969324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_09e8243d-a72f-4230-a8ac-9419885d017a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1998cb78-2b6c-4241-a555-069d00969324" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_09e8243d-a72f-4230-a8ac-9419885d017a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_03d2ccf9-121d-4d9f-9b56-01ab1f3594bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1998cb78-2b6c-4241-a555-069d00969324" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_03d2ccf9-121d-4d9f-9b56-01ab1f3594bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_7cd9f7ee-39d5-4e01-9a5a-398982b45752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f2d002ab-9539-4302-9a9a-33e9d77fd349" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_7cd9f7ee-39d5-4e01-9a5a-398982b45752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_e8865e50-20e4-4a05-8327-378b44757164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_7cd9f7ee-39d5-4e01-9a5a-398982b45752" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_e8865e50-20e4-4a05-8327-378b44757164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_e53cf4ac-841a-46fb-b850-56030421a61b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_e8865e50-20e4-4a05-8327-378b44757164" xlink:to="loc_us-gaap_DomesticPlanMember_e53cf4ac-841a-46fb-b850-56030421a61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_834c1080-b80f-4c1e-8bc3-ea36037092bc" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_e53cf4ac-841a-46fb-b850-56030421a61b" xlink:to="loc_country_US_834c1080-b80f-4c1e-8bc3-ea36037092bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_7cb88fe2-74d3-4bdb-b9f1-d7a2e7d93852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_e8865e50-20e4-4a05-8327-378b44757164" xlink:to="loc_us-gaap_ForeignPlanMember_7cb88fe2-74d3-4bdb-b9f1-d7a2e7d93852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c3a3111a-e774-4367-a384-cdb24c871016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f2d002ab-9539-4302-9a9a-33e9d77fd349" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c3a3111a-e774-4367-a384-cdb24c871016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_e3bf14f9-9ee9-4f6b-af59-06d3bbb1934d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c3a3111a-e774-4367-a384-cdb24c871016" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_e3bf14f9-9ee9-4f6b-af59-06d3bbb1934d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_66d6979b-c992-4d8a-a502-29718413d6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_e3bf14f9-9ee9-4f6b-af59-06d3bbb1934d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_66d6979b-c992-4d8a-a502-29718413d6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_0f9beea6-8bd9-407a-b20e-f55c96aedc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_e3bf14f9-9ee9-4f6b-af59-06d3bbb1934d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_0f9beea6-8bd9-407a-b20e-f55c96aedc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_7cb356f1-18a7-4a4d-9f5f-48f0eb4ad7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_e3bf14f9-9ee9-4f6b-af59-06d3bbb1934d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_7cb356f1-18a7-4a4d-9f5f-48f0eb4ad7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_3c8f0c1c-e5b7-4e83-87b7-9347ca0fb3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_e3bf14f9-9ee9-4f6b-af59-06d3bbb1934d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_3c8f0c1c-e5b7-4e83-87b7-9347ca0fb3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a4202e5e-0ef1-4b55-a931-e67956b70fee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c3a3111a-e774-4367-a384-cdb24c871016" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a4202e5e-0ef1-4b55-a931-e67956b70fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_6a0edc1a-9a0c-4c30-ac25-8f358371e540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a4202e5e-0ef1-4b55-a931-e67956b70fee" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_6a0edc1a-9a0c-4c30-ac25-8f358371e540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_f4730f4e-0faf-46b2-b03c-30d9de7ae390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a4202e5e-0ef1-4b55-a931-e67956b70fee" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_f4730f4e-0faf-46b2-b03c-30d9de7ae390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_952f1e36-5836-4d14-a23a-f48d1b8d07b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a4202e5e-0ef1-4b55-a931-e67956b70fee" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_952f1e36-5836-4d14-a23a-f48d1b8d07b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_24e2ec08-b3a9-4db7-b56c-855e12bf82e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_094ba477-6e4f-473d-abef-50967655780b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_24e2ec08-b3a9-4db7-b56c-855e12bf82e2" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_094ba477-6e4f-473d-abef-50967655780b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a0ff271a-2b2e-4954-a42c-af8ac7ec4978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_094ba477-6e4f-473d-abef-50967655780b" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a0ff271a-2b2e-4954-a42c-af8ac7ec4978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_987a98d7-79fa-4479-b0c9-37f8200f707c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a0ff271a-2b2e-4954-a42c-af8ac7ec4978" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_987a98d7-79fa-4479-b0c9-37f8200f707c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_2b7dd525-80f3-4ee6-8681-cda468c0db1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_987a98d7-79fa-4479-b0c9-37f8200f707c" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_2b7dd525-80f3-4ee6-8681-cda468c0db1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_92ba6ce5-5f7a-4bd7-94c3-e8ae300f4e90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_094ba477-6e4f-473d-abef-50967655780b" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_92ba6ce5-5f7a-4bd7-94c3-e8ae300f4e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_403d8675-10c0-4869-a12b-8af96f83faeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_92ba6ce5-5f7a-4bd7-94c3-e8ae300f4e90" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_403d8675-10c0-4869-a12b-8af96f83faeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_f28a03a4-ee05-4ea0-aa77-24eb343a8031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_403d8675-10c0-4869-a12b-8af96f83faeb" xlink:to="loc_us-gaap_DomesticPlanMember_f28a03a4-ee05-4ea0-aa77-24eb343a8031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_97da91d8-9ccc-4105-9d7e-02aaf8c77e06" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_f28a03a4-ee05-4ea0-aa77-24eb343a8031" xlink:to="loc_country_US_97da91d8-9ccc-4105-9d7e-02aaf8c77e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_eb7b339a-22dd-43aa-88cc-45bd8a61b8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_403d8675-10c0-4869-a12b-8af96f83faeb" xlink:to="loc_us-gaap_ForeignPlanMember_eb7b339a-22dd-43aa-88cc-45bd8a61b8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_67252995-266b-4222-9128-7c9f6c9ba4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_094ba477-6e4f-473d-abef-50967655780b" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_67252995-266b-4222-9128-7c9f6c9ba4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_ced8e453-62ac-4108-9fa3-eb66d5f4ca03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_67252995-266b-4222-9128-7c9f6c9ba4b4" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_ced8e453-62ac-4108-9fa3-eb66d5f4ca03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_af07a288-8c85-47a3-bcbf-5ca719310ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ced8e453-62ac-4108-9fa3-eb66d5f4ca03" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_af07a288-8c85-47a3-bcbf-5ca719310ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_902e7c61-6209-4d3e-8290-754a1b879f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ced8e453-62ac-4108-9fa3-eb66d5f4ca03" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_902e7c61-6209-4d3e-8290-754a1b879f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember_01a36312-4669-4efd-a749-384ecc4ffb81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FixedIncomeSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ced8e453-62ac-4108-9fa3-eb66d5f4ca03" xlink:to="loc_us-gaap_FixedIncomeSecuritiesMember_01a36312-4669-4efd-a749-384ecc4ffb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_a38e7771-7e5c-4c2f-b68e-481777364af1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ced8e453-62ac-4108-9fa3-eb66d5f4ca03" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_a38e7771-7e5c-4c2f-b68e-481777364af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e1b8f711-8816-4888-988d-3575ebeba272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_094ba477-6e4f-473d-abef-50967655780b" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e1b8f711-8816-4888-988d-3575ebeba272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_944af3c0-bd91-4a79-bd84-fe63695dd662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e1b8f711-8816-4888-988d-3575ebeba272" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_944af3c0-bd91-4a79-bd84-fe63695dd662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f43678d6-c300-4c27-966f-15a711984b57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_1be5cc9c-2802-4c09-a015-141f6c234680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f43678d6-c300-4c27-966f-15a711984b57" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_1be5cc9c-2802-4c09-a015-141f6c234680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_acb3c028-3d9a-457a-8c0a-8bf4e9d9531c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_1be5cc9c-2802-4c09-a015-141f6c234680" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_acb3c028-3d9a-457a-8c0a-8bf4e9d9531c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_ff505991-d3e5-4d4c-a3f1-dd630c1af2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_acb3c028-3d9a-457a-8c0a-8bf4e9d9531c" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_ff505991-d3e5-4d4c-a3f1-dd630c1af2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_0a5ad483-9bca-4cc2-b9bd-437850d7bbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ff505991-d3e5-4d4c-a3f1-dd630c1af2d9" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_0a5ad483-9bca-4cc2-b9bd-437850d7bbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b4c16e8c-5a9b-4e13-8916-9ecda4ec0e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ff505991-d3e5-4d4c-a3f1-dd630c1af2d9" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b4c16e8c-5a9b-4e13-8916-9ecda4ec0e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_U.S.BroadMarketMember_bdd19992-b227-4a4e-99b9-45da99fa8f70" xlink:href="bhc-20211231.xsd#bhc_U.S.BroadMarketMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b4c16e8c-5a9b-4e13-8916-9ecda4ec0e2c" xlink:to="loc_bhc_U.S.BroadMarketMember_bdd19992-b227-4a4e-99b9-45da99fa8f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmergingMarketsMember_061586ba-d626-472c-91c6-edfb2661855e" xlink:href="bhc-20211231.xsd#bhc_EmergingMarketsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b4c16e8c-5a9b-4e13-8916-9ecda4ec0e2c" xlink:to="loc_bhc_EmergingMarketsMember_061586ba-d626-472c-91c6-edfb2661855e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonU.S.DevelopedMarketsMember_d21066eb-0829-4726-a18c-1f4d0f6587eb" xlink:href="bhc-20211231.xsd#bhc_NonU.S.DevelopedMarketsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b4c16e8c-5a9b-4e13-8916-9ecda4ec0e2c" xlink:to="loc_bhc_NonU.S.DevelopedMarketsMember_d21066eb-0829-4726-a18c-1f4d0f6587eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonU.S.OtherAssetsMember_33524852-7de2-4119-836f-19dde2d44681" xlink:href="bhc-20211231.xsd#bhc_NonU.S.OtherAssetsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b4c16e8c-5a9b-4e13-8916-9ecda4ec0e2c" xlink:to="loc_bhc_NonU.S.OtherAssetsMember_33524852-7de2-4119-836f-19dde2d44681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember_31ab7275-985c-4036-bc4b-14d50e380cda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FixedIncomeSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ff505991-d3e5-4d4c-a3f1-dd630c1af2d9" xlink:to="loc_us-gaap_FixedIncomeSecuritiesMember_31ab7275-985c-4036-bc4b-14d50e380cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InvestmentGradeMember_1e140968-d37e-4a6a-8d0b-1faab7c6e6f4" xlink:href="bhc-20211231.xsd#bhc_InvestmentGradeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember_31ab7275-985c-4036-bc4b-14d50e380cda" xlink:to="loc_bhc_InvestmentGradeMember_1e140968-d37e-4a6a-8d0b-1faab7c6e6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlobalHighYieldMember_6b87aedf-7ba0-43c1-a80c-d539c6c3c8ac" xlink:href="bhc-20211231.xsd#bhc_GlobalHighYieldMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember_31ab7275-985c-4036-bc4b-14d50e380cda" xlink:to="loc_bhc_GlobalHighYieldMember_6b87aedf-7ba0-43c1-a80c-d539c6c3c8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_7e95aa55-8551-40aa-82b3-dd94ba07bdf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember_31ab7275-985c-4036-bc4b-14d50e380cda" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_7e95aa55-8551-40aa-82b3-dd94ba07bdf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherAssetsFixedIncomeSecuritiesMember_44a9cc95-d83e-4134-870f-ea47a336406b" xlink:href="bhc-20211231.xsd#bhc_OtherAssetsFixedIncomeSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ff505991-d3e5-4d4c-a3f1-dd630c1af2d9" xlink:to="loc_bhc_OtherAssetsFixedIncomeSecuritiesMember_44a9cc95-d83e-4134-870f-ea47a336406b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eddbdf5c-5375-4389-be9a-be3cdd130054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_1be5cc9c-2802-4c09-a015-141f6c234680" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eddbdf5c-5375-4389-be9a-be3cdd130054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4bfc36b0-44b1-4bfc-a30d-05e96f91ac8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eddbdf5c-5375-4389-be9a-be3cdd130054" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4bfc36b0-44b1-4bfc-a30d-05e96f91ac8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c0633708-1920-49ae-9345-c84d43fd133e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4bfc36b0-44b1-4bfc-a30d-05e96f91ac8f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c0633708-1920-49ae-9345-c84d43fd133e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a67e7ad8-8e7b-4c7f-83e4-f34bdc4b6b89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4bfc36b0-44b1-4bfc-a30d-05e96f91ac8f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a67e7ad8-8e7b-4c7f-83e4-f34bdc4b6b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_541b6eb6-8bda-429e-9754-2a68c251cab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4bfc36b0-44b1-4bfc-a30d-05e96f91ac8f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_541b6eb6-8bda-429e-9754-2a68c251cab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_6c01210e-fe57-4123-a964-b6fc6c80dfda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_1be5cc9c-2802-4c09-a015-141f6c234680" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_6c01210e-fe57-4123-a964-b6fc6c80dfda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_29672b07-04eb-49f7-9490-041d0e6edb94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_6c01210e-fe57-4123-a964-b6fc6c80dfda" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_29672b07-04eb-49f7-9490-041d0e6edb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_7b5a09d7-5a9e-470c-9fa2-c51f81c9fe5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_29672b07-04eb-49f7-9490-041d0e6edb94" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_7b5a09d7-5a9e-470c-9fa2-c51f81c9fe5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0f70c30e-376f-4ea5-b815-56aa9adf378f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_1be5cc9c-2802-4c09-a015-141f6c234680" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0f70c30e-376f-4ea5-b815-56aa9adf378f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c9a22433-5895-434a-9adf-b78162a01463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0f70c30e-376f-4ea5-b815-56aa9adf378f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c9a22433-5895-434a-9adf-b78162a01463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_cdfae988-d733-4c33-8c17-976e7bfd2591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c9a22433-5895-434a-9adf-b78162a01463" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_cdfae988-d733-4c33-8c17-976e7bfd2591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_22be0b03-26d6-4632-8323-72ce19661c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_1be5cc9c-2802-4c09-a015-141f6c234680" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_22be0b03-26d6-4632-8323-72ce19661c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_570d15aa-0d4a-4296-8341-afde2232985c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_22be0b03-26d6-4632-8323-72ce19661c96" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_570d15aa-0d4a-4296-8341-afde2232985c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_138eb159-2847-4505-ae46-2a24dac771c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_570d15aa-0d4a-4296-8341-afde2232985c" xlink:to="loc_us-gaap_DomesticPlanMember_138eb159-2847-4505-ae46-2a24dac771c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1916f641-582a-489b-844b-00ccbc6b15d4" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_138eb159-2847-4505-ae46-2a24dac771c7" xlink:to="loc_country_US_1916f641-582a-489b-844b-00ccbc6b15d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_4605869d-9bcf-4980-b46a-004013b412cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_570d15aa-0d4a-4296-8341-afde2232985c" xlink:to="loc_us-gaap_ForeignPlanMember_4605869d-9bcf-4980-b46a-004013b412cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_3db9ec82-e66b-42b9-b59d-891e03752667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_1be5cc9c-2802-4c09-a015-141f6c234680" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_3db9ec82-e66b-42b9-b59d-891e03752667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_228962d6-9c12-4bd2-89ea-8ca50c623f46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_3db9ec82-e66b-42b9-b59d-891e03752667" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_228962d6-9c12-4bd2-89ea-8ca50c623f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASES" xlink:type="simple" xlink:href="bhc-20211231.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_79aef980-7221-4de1-85b6-47509dcf5155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_fcd2e2e3-555a-4008-a6c3-d9dac67d2c98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79aef980-7221-4de1-85b6-47509dcf5155" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_fcd2e2e3-555a-4008-a6c3-d9dac67d2c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESTables" xlink:type="simple" xlink:href="bhc-20211231.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6ddb133d-7941-439c-afdd-4ccd9c37efbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetsAndLiabilitiesLesseeTableTextBlock_85536c3b-c83e-4d27-8543-9392903694ed" xlink:href="bhc-20211231.xsd#bhc_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6ddb133d-7941-439c-afdd-4ccd9c37efbe" xlink:to="loc_bhc_AssetsAndLiabilitiesLesseeTableTextBlock_85536c3b-c83e-4d27-8543-9392903694ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_96d5d25b-faf6-4ab8-926a-c25988671777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6ddb133d-7941-439c-afdd-4ccd9c37efbe" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_96d5d25b-faf6-4ab8-926a-c25988671777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock_e80b7d2e-82a4-4479-88e6-91aafc2e8089" xlink:href="bhc-20211231.xsd#bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6ddb133d-7941-439c-afdd-4ccd9c37efbe" xlink:to="loc_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock_e80b7d2e-82a4-4479-88e6-91aafc2e8089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5368ba44-9450-48b7-95b9-ab6cbb1390de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6ddb133d-7941-439c-afdd-4ccd9c37efbe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5368ba44-9450-48b7-95b9-ab6cbb1390de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ef735197-878c-4bb3-9100-6f8e44aef392" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetsLesseeAbstract_822ca262-7d33-4f99-b782-4473c6eab703" xlink:href="bhc-20211231.xsd#bhc_AssetsLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef735197-878c-4bb3-9100-6f8e44aef392" xlink:to="loc_bhc_AssetsLesseeAbstract_822ca262-7d33-4f99-b782-4473c6eab703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_82d1933a-4617-4e3b-89e3-2017a1851720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetsLesseeAbstract_822ca262-7d33-4f99-b782-4473c6eab703" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_82d1933a-4617-4e3b-89e3-2017a1851720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LiabilitiesLesseeAbstract_dd93a070-ef7f-4d79-a36d-01c8ac191fff" xlink:href="bhc-20211231.xsd#bhc_LiabilitiesLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef735197-878c-4bb3-9100-6f8e44aef392" xlink:to="loc_bhc_LiabilitiesLesseeAbstract_dd93a070-ef7f-4d79-a36d-01c8ac191fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d2bc0df4-9f9a-450a-9e49-9321d0f9bc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_LiabilitiesLesseeAbstract_dd93a070-ef7f-4d79-a36d-01c8ac191fff" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d2bc0df4-9f9a-450a-9e49-9321d0f9bc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_bcd4acb0-2c76-4852-9ac2-2a89ba37699c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_LiabilitiesLesseeAbstract_dd93a070-ef7f-4d79-a36d-01c8ac191fff" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_bcd4acb0-2c76-4852-9ac2-2a89ba37699c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_41cc9bb0-58b5-4453-968b-a3c2c70b5e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_LiabilitiesLesseeAbstract_dd93a070-ef7f-4d79-a36d-01c8ac191fff" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_41cc9bb0-58b5-4453-968b-a3c2c70b5e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_9cdf99a3-1100-49f6-a084-fc34de1ed5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_LiabilitiesLesseeAbstract_dd93a070-ef7f-4d79-a36d-01c8ac191fff" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_9cdf99a3-1100-49f6-a084-fc34de1ed5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4b162673-51e5-461e-b04e-ad584be2f9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_LiabilitiesLesseeAbstract_dd93a070-ef7f-4d79-a36d-01c8ac191fff" xlink:to="loc_us-gaap_OperatingLeaseLiability_4b162673-51e5-461e-b04e-ad584be2f9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_1e3bac34-b5bb-4e44-996a-49020d7abfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_LiabilitiesLesseeAbstract_dd93a070-ef7f-4d79-a36d-01c8ac191fff" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_1e3bac34-b5bb-4e44-996a-49020d7abfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_dce00f09-73bf-4ea5-9219-a698698d8e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_fd3e4842-f5ee-43ed-b591-f16f0eadcc2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dce00f09-73bf-4ea5-9219-a698698d8e7f" xlink:to="loc_us-gaap_FinanceLeaseLiability_fd3e4842-f5ee-43ed-b591-f16f0eadcc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_47448d0f-efee-47fd-b211-97205d06f04a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dce00f09-73bf-4ea5-9219-a698698d8e7f" xlink:to="loc_us-gaap_SubleaseIncome_47448d0f-efee-47fd-b211-97205d06f04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_a25ce625-d979-481f-9efd-694f3dd25417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dce00f09-73bf-4ea5-9219-a698698d8e7f" xlink:to="loc_us-gaap_ShortTermLeaseCost_a25ce625-d979-481f-9efd-694f3dd25417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#LEASESLeaseExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ad937cba-e25b-48f3-9545-9fd6fdffc700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_185e485d-2fac-4790-a9df-ba91a4ea8a82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ad937cba-e25b-48f3-9545-9fd6fdffc700" xlink:to="loc_us-gaap_OperatingLeaseCost_185e485d-2fac-4790-a9df-ba91a4ea8a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_8feff29c-5db9-4cc0-a4c3-3d560fa5e428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ad937cba-e25b-48f3-9545-9fd6fdffc700" xlink:to="loc_us-gaap_VariableLeaseCost_8feff29c-5db9-4cc0-a4c3-3d560fa5e428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#LEASESLeaseAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3d298023-d805-4d71-bedd-c3c1096f0597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_8503eb05-0f75-417f-bea5-a5897082bde5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3d298023-d805-4d71-bedd-c3c1096f0597" xlink:to="loc_us-gaap_OperatingLeasePayments_8503eb05-0f75-417f-bea5-a5897082bde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption_95ceeaa4-a83a-4c38-861d-18c11eb03baf" xlink:href="bhc-20211231.xsd#bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3d298023-d805-4d71-bedd-c3c1096f0597" xlink:to="loc_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption_95ceeaa4-a83a-4c38-861d-18c11eb03baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_68a812bf-5389-4653-aee4-d142a99de96f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3d298023-d805-4d71-bedd-c3c1096f0597" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_68a812bf-5389-4653-aee4-d142a99de96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8b1dba62-5b8d-4522-a998-37c9559dd69e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3d298023-d805-4d71-bedd-c3c1096f0597" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8b1dba62-5b8d-4522-a998-37c9559dd69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#LEASESLeaseFuturePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_33a814a6-4c25-4964-b5d2-fa282ace2aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_549ed9ef-3f6f-49f3-b087-379310152fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_33a814a6-4c25-4964-b5d2-fa282ace2aaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_549ed9ef-3f6f-49f3-b087-379310152fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cccc4122-cc76-46db-9ecd-b130bd24d628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_33a814a6-4c25-4964-b5d2-fa282ace2aaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cccc4122-cc76-46db-9ecd-b130bd24d628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8388f18d-7775-4458-b866-a6bfef90259a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_33a814a6-4c25-4964-b5d2-fa282ace2aaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8388f18d-7775-4458-b866-a6bfef90259a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e7cd4485-3fff-45f5-872c-7cc5108260ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_33a814a6-4c25-4964-b5d2-fa282ace2aaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e7cd4485-3fff-45f5-872c-7cc5108260ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2f5171f5-58cd-4f27-b46d-9e9cfc74b2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_33a814a6-4c25-4964-b5d2-fa282ace2aaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2f5171f5-58cd-4f27-b46d-9e9cfc74b2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_66487202-28ed-4b40-ac81-ef06827fb707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_33a814a6-4c25-4964-b5d2-fa282ace2aaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_66487202-28ed-4b40-ac81-ef06827fb707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0511baed-2e53-4edc-b841-cf413d321743" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_33a814a6-4c25-4964-b5d2-fa282ace2aaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0511baed-2e53-4edc-b841-cf413d321743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_72532f90-274b-45c0-b951-b8fedb9fe4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_33a814a6-4c25-4964-b5d2-fa282ace2aaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_72532f90-274b-45c0-b951-b8fedb9fe4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_63908fc0-d18e-4784-885b-a0c473d1aa0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_33a814a6-4c25-4964-b5d2-fa282ace2aaa" xlink:to="loc_us-gaap_OperatingLeaseLiability_63908fc0-d18e-4784-885b-a0c473d1aa0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ccc860ee-ff3c-4b62-a9fb-e68e1e8729a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_33a814a6-4c25-4964-b5d2-fa282ace2aaa" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ccc860ee-ff3c-4b62-a9fb-e68e1e8729a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_94977343-7a72-4ef4-a51f-29c5a94b84e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_33a814a6-4c25-4964-b5d2-fa282ace2aaa" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_94977343-7a72-4ef4-a51f-29c5a94b84e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1" xlink:type="simple" xlink:href="bhc-20211231.xsd#LEASESLeaseFuturePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="bhc-20211231.xsd#SHAREBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_56ed9f64-0df0-4c4f-b6f2-415f85d3e6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_63d7204d-ca7f-45f4-b6de-f706f9a89dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_56ed9f64-0df0-4c4f-b6f2-415f85d3e6a8" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_63d7204d-ca7f-45f4-b6de-f706f9a89dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="bhc-20211231.xsd#SHAREBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_acf5ece1-301f-4f25-ae2f-1459a1c269c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_fccd65ba-b83b-41d7-af80-f05895ca5d78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_acf5ece1-301f-4f25-ae2f-1459a1c269c7" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_fccd65ba-b83b-41d7-af80-f05895ca5d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_15aa2223-9535-4e07-a358-dbef3a8dfcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_acf5ece1-301f-4f25-ae2f-1459a1c269c7" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_15aa2223-9535-4e07-a358-dbef3a8dfcbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f26f2ee3-ef55-44b6-a762-0ea6bf64518a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_acf5ece1-301f-4f25-ae2f-1459a1c269c7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f26f2ee3-ef55-44b6-a762-0ea6bf64518a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_ce27f2ec-9830-4f01-afe3-a267e9800b31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_acf5ece1-301f-4f25-ae2f-1459a1c269c7" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_ce27f2ec-9830-4f01-afe3-a267e9800b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_a4205415-3595-492a-965b-60308d62f24a" xlink:href="bhc-20211231.xsd#bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_acf5ece1-301f-4f25-ae2f-1459a1c269c7" xlink:to="loc_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_a4205415-3595-492a-965b-60308d62f24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_b2f9e2c0-e668-40e5-b889-d4624067927e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_acf5ece1-301f-4f25-ae2f-1459a1c269c7" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_b2f9e2c0-e668-40e5-b889-d4624067927e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bae17ec8-be0a-4c42-98fe-57c78b5f5c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cd070e84-b051-4776-ab35-5fea27f1db0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bae17ec8-be0a-4c42-98fe-57c78b5f5c45" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cd070e84-b051-4776-ab35-5fea27f1db0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b4333d76-8b3d-4d17-9a61-8eeddb9c8882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cd070e84-b051-4776-ab35-5fea27f1db0a" xlink:to="loc_us-gaap_PlanNameAxis_b4333d76-8b3d-4d17-9a61-8eeddb9c8882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_563fdfbb-e7c0-496a-8342-69eaa696bf7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b4333d76-8b3d-4d17-9a61-8eeddb9c8882" xlink:to="loc_us-gaap_PlanNameDomain_563fdfbb-e7c0-496a-8342-69eaa696bf7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member_4fed524e-1563-45e7-8fa4-4ddb9a1765c7" xlink:href="bhc-20211231.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_563fdfbb-e7c0-496a-8342-69eaa696bf7e" xlink:to="loc_bhc_OmnibusIncentivePlan2014Member_4fed524e-1563-45e7-8fa4-4ddb9a1765c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_3330aae1-c32c-4fcb-aa20-9f6ba02ad7e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cd070e84-b051-4776-ab35-5fea27f1db0a" xlink:to="loc_srt_TitleOfIndividualAxis_3330aae1-c32c-4fcb-aa20-9f6ba02ad7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_acff31ff-1b6f-4a87-ac5b-000c19ea67a8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_3330aae1-c32c-4fcb-aa20-9f6ba02ad7e0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_acff31ff-1b6f-4a87-ac5b-000c19ea67a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonemployeeDirectorMember_53500227-eb75-439b-abaf-4e260ffb81fa" xlink:href="bhc-20211231.xsd#bhc_NonemployeeDirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_acff31ff-1b6f-4a87-ac5b-000c19ea67a8" xlink:to="loc_bhc_NonemployeeDirectorMember_53500227-eb75-439b-abaf-4e260ffb81fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2db9acf9-030e-464a-8be8-0e2656b3cfe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cd070e84-b051-4776-ab35-5fea27f1db0a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2db9acf9-030e-464a-8be8-0e2656b3cfe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2b47d980-ac50-461c-a0f9-2a7255e601a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2db9acf9-030e-464a-8be8-0e2656b3cfe5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2b47d980-ac50-461c-a0f9-2a7255e601a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_89327ef5-b8f3-4588-ad63-7317fdc8f626" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2db9acf9-030e-464a-8be8-0e2656b3cfe5" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_89327ef5-b8f3-4588-ad63-7317fdc8f626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_12863155-e268-4961-bcbb-00a3094fc082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2db9acf9-030e-464a-8be8-0e2656b3cfe5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_12863155-e268-4961-bcbb-00a3094fc082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_e098f299-205d-4fcc-a952-7a19b2f5a5e7" xlink:href="bhc-20211231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2db9acf9-030e-464a-8be8-0e2656b3cfe5" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_e098f299-205d-4fcc-a952-7a19b2f5a5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_da33ee96-9376-44fc-afb7-152bbb9175a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2db9acf9-030e-464a-8be8-0e2656b3cfe5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_da33ee96-9376-44fc-afb7-152bbb9175a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9f90ac04-5b47-4114-aec2-6c736ddfebab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c699f75e-a430-4c91-a0c8-a1559580dde9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9f90ac04-5b47-4114-aec2-6c736ddfebab" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c699f75e-a430-4c91-a0c8-a1559580dde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6b3773c9-0d6d-490f-ae02-9386b3080e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c699f75e-a430-4c91-a0c8-a1559580dde9" xlink:to="loc_us-gaap_AwardTypeAxis_6b3773c9-0d6d-490f-ae02-9386b3080e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0198ef8a-1067-4d98-a438-2c68671b1585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6b3773c9-0d6d-490f-ae02-9386b3080e56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0198ef8a-1067-4d98-a438-2c68671b1585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_14543380-5b40-4ebc-8d59-88c8bb4c561a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0198ef8a-1067-4d98-a438-2c68671b1585" xlink:to="loc_us-gaap_EmployeeStockOptionMember_14543380-5b40-4ebc-8d59-88c8bb4c561a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f743c1f3-6f6a-4b84-9c3b-ff88976e01b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0198ef8a-1067-4d98-a438-2c68671b1585" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f743c1f3-6f6a-4b84-9c3b-ff88976e01b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_be692c5e-b6c1-4475-9c2e-928465ceaa3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c699f75e-a430-4c91-a0c8-a1559580dde9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_be692c5e-b6c1-4475-9c2e-928465ceaa3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6742ca57-5bf0-437a-b0dc-4a6a1eb3f403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_be692c5e-b6c1-4475-9c2e-928465ceaa3e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6742ca57-5bf0-437a-b0dc-4a6a1eb3f403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c07d2236-eba2-413e-966c-9a82f02cff3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6742ca57-5bf0-437a-b0dc-4a6a1eb3f403" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c07d2236-eba2-413e-966c-9a82f02cff3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SellingGeneralAndAdministrativeExpenseMember_d6ddbbef-614c-4618-ba0c-ad8b78c20b5f" xlink:href="bhc-20211231.xsd#bhc_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6742ca57-5bf0-437a-b0dc-4a6a1eb3f403" xlink:to="loc_bhc_SellingGeneralAndAdministrativeExpenseMember_d6ddbbef-614c-4618-ba0c-ad8b78c20b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9673964e-f530-43d8-ac7b-7d56fc2ddd15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c699f75e-a430-4c91-a0c8-a1559580dde9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9673964e-f530-43d8-ac7b-7d56fc2ddd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ce7628c9-d82b-438c-a366-23333c06d543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9673964e-f530-43d8-ac7b-7d56fc2ddd15" xlink:to="loc_us-gaap_ShareBasedCompensation_ce7628c9-d82b-438c-a366-23333c06d543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SHAREBASEDCOMPENSATIONStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9a792388-e859-47b3-a096-e327b0ce14a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a03d704-bcdc-4a99-863d-237bde57de3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9a792388-e859-47b3-a096-e327b0ce14a9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a03d704-bcdc-4a99-863d-237bde57de3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_4480a49a-ae4a-4b46-ac12-e0b4af7b82ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a03d704-bcdc-4a99-863d-237bde57de3f" xlink:to="loc_us-gaap_VestingAxis_4480a49a-ae4a-4b46-ac12-e0b4af7b82ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_aad57ed3-df17-4a83-aef6-f7543e35abb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_4480a49a-ae4a-4b46-ac12-e0b4af7b82ba" xlink:to="loc_us-gaap_VestingDomain_aad57ed3-df17-4a83-aef6-f7543e35abb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_768e3c10-0db3-47ee-bc39-0479f4bd7103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_aad57ed3-df17-4a83-aef6-f7543e35abb0" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_768e3c10-0db3-47ee-bc39-0479f4bd7103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_89787151-49da-4699-8f3d-54832bd13245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_aad57ed3-df17-4a83-aef6-f7543e35abb0" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_89787151-49da-4699-8f3d-54832bd13245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_706e4e33-551a-48f2-a4a7-b64758231681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a03d704-bcdc-4a99-863d-237bde57de3f" xlink:to="loc_us-gaap_AwardTypeAxis_706e4e33-551a-48f2-a4a7-b64758231681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abbeefc9-2c3d-4557-8583-6986dd37ff37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_706e4e33-551a-48f2-a4a7-b64758231681" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abbeefc9-2c3d-4557-8583-6986dd37ff37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a25097d6-6b57-4af7-acf3-64c94c95bc76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abbeefc9-2c3d-4557-8583-6986dd37ff37" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a25097d6-6b57-4af7-acf3-64c94c95bc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a03d704-bcdc-4a99-863d-237bde57de3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_70941213-0eb2-4b52-a6ec-3d74bd8bbb76" xlink:href="bhc-20211231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_70941213-0eb2-4b52-a6ec-3d74bd8bbb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_cab7154a-8a3a-4199-b908-7689dd0541cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_cab7154a-8a3a-4199-b908-7689dd0541cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_f4d4369d-50bf-4225-a5fe-e8c4e0924602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_f4d4369d-50bf-4225-a5fe-e8c4e0924602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cda6068c-1705-4e7b-a448-c205fa5ecf3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_f4d4369d-50bf-4225-a5fe-e8c4e0924602" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cda6068c-1705-4e7b-a448-c205fa5ecf3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_821f1835-034d-422e-9b99-11dac8ee0b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_f4d4369d-50bf-4225-a5fe-e8c4e0924602" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_821f1835-034d-422e-9b99-11dac8ee0b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d23154e7-ddf6-4720-9dc9-b331aa8a1027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_f4d4369d-50bf-4225-a5fe-e8c4e0924602" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d23154e7-ddf6-4720-9dc9-b331aa8a1027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_acb4a4e1-ae62-41c3-9d56-b87eda8252ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_f4d4369d-50bf-4225-a5fe-e8c4e0924602" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_acb4a4e1-ae62-41c3-9d56-b87eda8252ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3a9a62e-f76d-40c0-a460-c70533abefaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3a9a62e-f76d-40c0-a460-c70533abefaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e7bc314e-52c0-4fd6-80b5-06501177bb70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3a9a62e-f76d-40c0-a460-c70533abefaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e7bc314e-52c0-4fd6-80b5-06501177bb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6fe58ad5-05c2-46ac-9273-03fa8c4c5746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3a9a62e-f76d-40c0-a460-c70533abefaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6fe58ad5-05c2-46ac-9273-03fa8c4c5746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_dae11194-b2ba-4413-8c7a-b16724d8136f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3a9a62e-f76d-40c0-a460-c70533abefaf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_dae11194-b2ba-4413-8c7a-b16724d8136f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0c92309c-42d3-4361-9e0a-95677f756c39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3a9a62e-f76d-40c0-a460-c70533abefaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0c92309c-42d3-4361-9e0a-95677f756c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c5001a1d-89f0-4a78-aafa-f0c3ba332091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3a9a62e-f76d-40c0-a460-c70533abefaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c5001a1d-89f0-4a78-aafa-f0c3ba332091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_454f2403-7da9-4fa5-be96-d135944d29b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_454f2403-7da9-4fa5-be96-d135944d29b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_384a7ed0-71e3-4b89-8665-687ebcc3eb29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_384a7ed0-71e3-4b89-8665-687ebcc3eb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_c83b1ad1-dac7-4113-9d55-6217f80b6e0c" xlink:href="bhc-20211231.xsd#bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_c83b1ad1-dac7-4113-9d55-6217f80b6e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c8e6813a-1173-49fe-b0e6-daa8a11d1a65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_c83b1ad1-dac7-4113-9d55-6217f80b6e0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c8e6813a-1173-49fe-b0e6-daa8a11d1a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c8a0d45a-5693-4950-93a3-3e1c3e4b0be4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_c83b1ad1-dac7-4113-9d55-6217f80b6e0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c8a0d45a-5693-4950-93a3-3e1c3e4b0be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_51e7d240-3132-4017-9029-669a117000a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_c83b1ad1-dac7-4113-9d55-6217f80b6e0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_51e7d240-3132-4017-9029-669a117000a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_94fb8ef4-b485-421c-adf4-be0aba029b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_c83b1ad1-dac7-4113-9d55-6217f80b6e0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_94fb8ef4-b485-421c-adf4-be0aba029b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_44f4e105-8277-4b3f-8ef7-93e50b8fb6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_c83b1ad1-dac7-4113-9d55-6217f80b6e0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_44f4e105-8277-4b3f-8ef7-93e50b8fb6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_35d8dde8-c0a6-4532-aad6-d0710de88fef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_35d8dde8-c0a6-4532-aad6-d0710de88fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2f3d3e99-b956-4493-b3cc-c5be189ba123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2f3d3e99-b956-4493-b3cc-c5be189ba123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0fe0616f-8ff4-4f04-8014-e5aaa792b589" xlink:href="bhc-20211231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0fe0616f-8ff4-4f04-8014-e5aaa792b589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3f0c0433-3e45-421b-a8f6-8bfab0e064b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0fe0616f-8ff4-4f04-8014-e5aaa792b589" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3f0c0433-3e45-421b-a8f6-8bfab0e064b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_aee20854-7989-4680-a4a3-1e27524ff6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0fe0616f-8ff4-4f04-8014-e5aaa792b589" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_aee20854-7989-4680-a4a3-1e27524ff6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_4d8e37b8-efb7-42a9-8bb4-233471671d69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_0fe0616f-8ff4-4f04-8014-e5aaa792b589" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_4d8e37b8-efb7-42a9-8bb4-233471671d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_66fcb169-1e17-4bff-b775-b44eca1a2f8c" xlink:href="bhc-20211231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_66fcb169-1e17-4bff-b775-b44eca1a2f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_91d3e919-95df-4965-8978-fa722711ffc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_66fcb169-1e17-4bff-b775-b44eca1a2f8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_91d3e919-95df-4965-8978-fa722711ffc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b6ce2f8a-aad0-4849-960e-b0e016029441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_66fcb169-1e17-4bff-b775-b44eca1a2f8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b6ce2f8a-aad0-4849-960e-b0e016029441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c45ee735-e8a8-4b8a-ab7f-533f3c06bbea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_66fcb169-1e17-4bff-b775-b44eca1a2f8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c45ee735-e8a8-4b8a-ab7f-533f3c06bbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e8c58caa-8619-44c8-b229-039df97a9e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39baae9e-a3a9-48bc-aeaa-34ab562a43dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e8c58caa-8619-44c8-b229-039df97a9e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a47da063-2dba-4970-9581-3ef35623fbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e8c58caa-8619-44c8-b229-039df97a9e1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a47da063-2dba-4970-9581-3ef35623fbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_fadcbe9e-5ad4-4960-9938-69659d6e6abc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e8c58caa-8619-44c8-b229-039df97a9e1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_fadcbe9e-5ad4-4960-9938-69659d6e6abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e08f3f94-24bc-4113-afc4-2497faa41684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e8c58caa-8619-44c8-b229-039df97a9e1c" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e08f3f94-24bc-4113-afc4-2497faa41684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_466746f1-d940-40ef-a852-9b8b300f10e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e8c58caa-8619-44c8-b229-039df97a9e1c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_466746f1-d940-40ef-a852-9b8b300f10e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_99986f8f-751e-46d2-bc5a-0542a74e030d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e8c58caa-8619-44c8-b229-039df97a9e1c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_99986f8f-751e-46d2-bc5a-0542a74e030d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue_1777360b-9054-4dbd-bfb9-5c64c062b289" xlink:href="bhc-20211231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e8c58caa-8619-44c8-b229-039df97a9e1c" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue_1777360b-9054-4dbd-bfb9-5c64c062b289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SHAREBASEDCOMPENSATIONRSUsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c4ce2c6f-9538-4bb2-ade6-cdc76cfaaa12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2c61d0c-0190-430f-9876-6cf729a5aca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c4ce2c6f-9538-4bb2-ade6-cdc76cfaaa12" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2c61d0c-0190-430f-9876-6cf729a5aca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6be2ca05-a159-4b1c-8c79-9dea139cea20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2c61d0c-0190-430f-9876-6cf729a5aca3" xlink:to="loc_us-gaap_AwardTypeAxis_6be2ca05-a159-4b1c-8c79-9dea139cea20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_381f8cb5-21a9-4f28-99e4-6e67b77cf4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6be2ca05-a159-4b1c-8c79-9dea139cea20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_381f8cb5-21a9-4f28-99e4-6e67b77cf4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_73de3908-c2bb-4f58-89e2-8fc8f4980510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_381f8cb5-21a9-4f28-99e4-6e67b77cf4f8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_73de3908-c2bb-4f58-89e2-8fc8f4980510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember_fec9d2fd-99a6-4fc8-b505-711441678ee5" xlink:href="bhc-20211231.xsd#bhc_TimeBasedRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_381f8cb5-21a9-4f28-99e4-6e67b77cf4f8" xlink:to="loc_bhc_TimeBasedRSUMember_fec9d2fd-99a6-4fc8-b505-711441678ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_c2e4b1e8-dcaa-4fbc-8043-ffcd4c91c483" xlink:href="bhc-20211231.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_381f8cb5-21a9-4f28-99e4-6e67b77cf4f8" xlink:to="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_c2e4b1e8-dcaa-4fbc-8043-ffcd4c91c483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_94a484f8-8931-43ac-912d-e4e06f904723" xlink:href="bhc-20211231.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_c2e4b1e8-dcaa-4fbc-8043-ffcd4c91c483" xlink:to="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_94a484f8-8931-43ac-912d-e4e06f904723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_4effc0d3-f501-4d5c-84dd-849f1cc1ee67" xlink:href="bhc-20211231.xsd#bhc_ROTCPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_c2e4b1e8-dcaa-4fbc-8043-ffcd4c91c483" xlink:to="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_4effc0d3-f501-4d5c-84dd-849f1cc1ee67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherPerformanceBasedRestrictedStockUnitsMember_57d4058a-f17a-4f0c-8192-f0f9e089b352" xlink:href="bhc-20211231.xsd#bhc_OtherPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_c2e4b1e8-dcaa-4fbc-8043-ffcd4c91c483" xlink:to="loc_bhc_OtherPerformanceBasedRestrictedStockUnitsMember_57d4058a-f17a-4f0c-8192-f0f9e089b352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e8ef887-e985-4a41-b6a5-db76273fb27f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2c61d0c-0190-430f-9876-6cf729a5aca3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e8ef887-e985-4a41-b6a5-db76273fb27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_63db97b3-b9b5-4aeb-ae5e-25137505ca6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e8ef887-e985-4a41-b6a5-db76273fb27f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_63db97b3-b9b5-4aeb-ae5e-25137505ca6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0c68a91b-dcda-413f-bc8d-68b93fc8d051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e8ef887-e985-4a41-b6a5-db76273fb27f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0c68a91b-dcda-413f-bc8d-68b93fc8d051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_80df183f-0778-4a92-bcf1-8fe609cacb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e8ef887-e985-4a41-b6a5-db76273fb27f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_80df183f-0778-4a92-bcf1-8fe609cacb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_ee077839-f2c2-4d39-ba4e-364ce407fc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e8ef887-e985-4a41-b6a5-db76273fb27f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_ee077839-f2c2-4d39-ba4e-364ce407fc8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0ba615a2-1390-4719-8fe0-f429948f909a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e8ef887-e985-4a41-b6a5-db76273fb27f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0ba615a2-1390-4719-8fe0-f429948f909a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_ebeb2c5a-c603-4faf-b55c-2c10cbc46fe3" xlink:href="bhc-20211231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e8ef887-e985-4a41-b6a5-db76273fb27f" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_ebeb2c5a-c603-4faf-b55c-2c10cbc46fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d62e3ce1-9024-4ad9-9761-8794e65647f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e8ef887-e985-4a41-b6a5-db76273fb27f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d62e3ce1-9024-4ad9-9761-8794e65647f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_34ae8d28-cd3d-4e83-b807-2e6e916fda2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d62e3ce1-9024-4ad9-9761-8794e65647f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_34ae8d28-cd3d-4e83-b807-2e6e916fda2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_149b2e4c-c9df-4f02-9848-dc0125f3162d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d62e3ce1-9024-4ad9-9761-8794e65647f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_149b2e4c-c9df-4f02-9848-dc0125f3162d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8e004ed0-582d-457c-970a-81755ba80402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d62e3ce1-9024-4ad9-9761-8794e65647f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8e004ed0-582d-457c-970a-81755ba80402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_347f903b-ab92-43fd-a3d7-9311d6ec66f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d62e3ce1-9024-4ad9-9761-8794e65647f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_347f903b-ab92-43fd-a3d7-9311d6ec66f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fed1c381-e24d-4053-afa4-eb638df21e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d62e3ce1-9024-4ad9-9761-8794e65647f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fed1c381-e24d-4053-afa4-eb638df21e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0c7debd-48cc-4b5d-b887-672607fa3769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e8ef887-e985-4a41-b6a5-db76273fb27f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0c7debd-48cc-4b5d-b887-672607fa3769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_78cba7d1-1f34-434a-b4ac-8fbe61fa51a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0c7debd-48cc-4b5d-b887-672607fa3769" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_78cba7d1-1f34-434a-b4ac-8fbe61fa51a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_74aed50b-ad8f-4379-8d8f-0ede18606078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0c7debd-48cc-4b5d-b887-672607fa3769" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_74aed50b-ad8f-4379-8d8f-0ede18606078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fc6b9902-e2ea-4753-a99f-78dd6bb6f2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0c7debd-48cc-4b5d-b887-672607fa3769" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fc6b9902-e2ea-4753-a99f-78dd6bb6f2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_76080314-8ea5-4478-868d-ecc1a7d126ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0c7debd-48cc-4b5d-b887-672607fa3769" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_76080314-8ea5-4478-868d-ecc1a7d126ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9b6159f5-fe13-4fc1-a496-4dc471ebe034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0c7debd-48cc-4b5d-b887-672607fa3769" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9b6159f5-fe13-4fc1-a496-4dc471ebe034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b09f91a1-5635-41b4-b9ae-14f70694c189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e8ef887-e985-4a41-b6a5-db76273fb27f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b09f91a1-5635-41b4-b9ae-14f70694c189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ebdfebdb-3c48-4a17-a78b-c6795ab3bb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b09f91a1-5635-41b4-b9ae-14f70694c189" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ebdfebdb-3c48-4a17-a78b-c6795ab3bb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_79b0315e-ccff-4846-93fa-c64683611688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b09f91a1-5635-41b4-b9ae-14f70694c189" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_79b0315e-ccff-4846-93fa-c64683611688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ad3043eb-ece2-4893-8dda-cd59b3ba36fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b09f91a1-5635-41b4-b9ae-14f70694c189" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ad3043eb-ece2-4893-8dda-cd59b3ba36fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhc-20211231.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_429e92af-be08-45ad-8549-36187aa24559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_ac5af2a5-5a92-480c-91a8-e1fc6b2009de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_429e92af-be08-45ad-8549-36187aa24559" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_ac5af2a5-5a92-480c-91a8-e1fc6b2009de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="simple" xlink:href="bhc-20211231.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c98a38a9-c1bb-43b2-97a8-a5ac358b6383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_f298e90b-d075-462c-9ca0-2518d1fdde80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c98a38a9-c1bb-43b2-97a8-a5ac358b6383" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_f298e90b-d075-462c-9ca0-2518d1fdde80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ae4bd388-82a9-405d-bbe5-5694498112db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_d5ae1da6-fccd-45f1-b9ca-e763f97acf3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ae4bd388-82a9-405d-bbe5-5694498112db" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_d5ae1da6-fccd-45f1-b9ca-e763f97acf3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c086aeb5-1e30-452c-8379-6b5469df1187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_d5ae1da6-fccd-45f1-b9ca-e763f97acf3d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c086aeb5-1e30-452c-8379-6b5469df1187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4060ddd7-29d2-4b95-b283-9258f9c60a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c086aeb5-1e30-452c-8379-6b5469df1187" xlink:to="loc_us-gaap_EquityComponentDomain_4060ddd7-29d2-4b95-b283-9258f9c60a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6334de40-2410-4a2b-90fd-668b1f600cda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4060ddd7-29d2-4b95-b283-9258f9c60a52" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6334de40-2410-4a2b-90fd-668b1f600cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_ff6dd532-7f46-4bc6-bb76-906db417dc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4060ddd7-29d2-4b95-b283-9258f9c60a52" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_ff6dd532-7f46-4bc6-bb76-906db417dc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f91ad346-f8d4-4988-8fba-3def51aee571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4060ddd7-29d2-4b95-b283-9258f9c60a52" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f91ad346-f8d4-4988-8fba-3def51aee571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b6d6fb30-0166-4abb-85c8-b251a583c44c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_d5ae1da6-fccd-45f1-b9ca-e763f97acf3d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b6d6fb30-0166-4abb-85c8-b251a583c44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4aea01e9-05dd-444f-951f-6c376ad7f494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b6d6fb30-0166-4abb-85c8-b251a583c44c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4aea01e9-05dd-444f-951f-6c376ad7f494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT" xlink:type="simple" xlink:href="bhc-20211231.xsd#RESEARCHANDDEVELOPMENT"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_c03f2cce-148a-4b9f-a22b-abebb361092e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_e19132ad-4d28-42bb-bd35-fe9800d978aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_c03f2cce-148a-4b9f-a22b-abebb361092e" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_e19132ad-4d28-42bb-bd35-fe9800d978aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables" xlink:type="simple" xlink:href="bhc-20211231.xsd#RESEARCHANDDEVELOPMENTTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_5efea914-c24a-4ac0-8ab3-3f09617166ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_8e98d407-4f00-4f41-92b7-e5c06feec98d" xlink:href="bhc-20211231.xsd#bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_5efea914-c24a-4ac0-8ab3-3f09617166ab" xlink:to="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_8e98d407-4f00-4f41-92b7-e5c06feec98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_cc25c54f-acfc-4c08-89b8-d778ecb7f7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_95bd74ee-7502-453c-a864-f6cc110052a0" xlink:href="bhc-20211231.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_cc25c54f-acfc-4c08-89b8-d778ecb7f7c1" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_95bd74ee-7502-453c-a864-f6cc110052a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_c10b7a43-9ded-4fbf-b0cf-5ebdc09bbf17" xlink:href="bhc-20211231.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_cc25c54f-acfc-4c08-89b8-d778ecb7f7c1" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_c10b7a43-9ded-4fbf-b0cf-5ebdc09bbf17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5abd99d2-8886-4e4d-93e0-c890675ecf37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_cc25c54f-acfc-4c08-89b8-d778ecb7f7c1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5abd99d2-8886-4e4d-93e0-c890675ecf37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENET" xlink:type="simple" xlink:href="bhc-20211231.xsd#OTHEREXPENSENET"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_90838128-c035-4899-b394-7265683be177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_22e1b6e9-0c99-45ee-b999-0e3c64406d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_90838128-c035-4899-b394-7265683be177" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_22e1b6e9-0c99-45ee-b999-0e3c64406d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETTables" xlink:type="simple" xlink:href="bhc-20211231.xsd#OTHEREXPENSENETTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_5ebf8da6-a5a7-4177-ba97-9c54a69927ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_33cefdee-b6cd-434e-b1bf-24d6d1c921c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5ebf8da6-a5a7-4177-ba97-9c54a69927ab" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_33cefdee-b6cd-434e-b1bf-24d6d1c921c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_f4528821-2416-433d-bd94-b49b10478427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_4705776b-c54f-4280-ae36-4b78799c74dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_f4528821-2416-433d-bd94-b49b10478427" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_4705776b-c54f-4280-ae36-4b78799c74dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_c9adb580-20f1-4515-ac2d-bce40fac1b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_f4528821-2416-433d-bd94-b49b10478427" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_c9adb580-20f1-4515-ac2d-bce40fac1b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_183c9068-777d-4bfc-a5a9-77ec617d6379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_f4528821-2416-433d-bd94-b49b10478427" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_183c9068-777d-4bfc-a5a9-77ec617d6379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_57f9d54b-f296-40c1-b36a-77bd36cb2104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_f4528821-2416-433d-bd94-b49b10478427" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_57f9d54b-f296-40c1-b36a-77bd36cb2104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherIncomeExpenseNet_61436615-454d-426a-bde9-6f24d9489c02" xlink:href="bhc-20211231.xsd#bhc_OtherIncomeExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_f4528821-2416-433d-bd94-b49b10478427" xlink:to="loc_bhc_OtherIncomeExpenseNet_61436615-454d-426a-bde9-6f24d9489c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_bc676c05-d773-45a0-85bb-bd18ec6d8539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_f4528821-2416-433d-bd94-b49b10478427" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_bc676c05-d773-45a0-85bb-bd18ec6d8539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#OTHEREXPENSENETNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_aa3c9520-5915-4e85-9f61-c6d6c6298321" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_d952f664-84eb-4ac9-83a4-f6145528d5a0" xlink:href="bhc-20211231.xsd#bhc_ScheduleOfOtherIncomeAndExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_aa3c9520-5915-4e85-9f61-c6d6c6298321" xlink:to="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_d952f664-84eb-4ac9-83a4-f6145528d5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5669ade0-ecfc-4c79-bfb0-11fdd4f45fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_d952f664-84eb-4ac9-83a4-f6145528d5a0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5669ade0-ecfc-4c79-bfb0-11fdd4f45fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_37a2b657-f341-4454-ac8a-1056ef3b0ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5669ade0-ecfc-4c79-bfb0-11fdd4f45fdf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_37a2b657-f341-4454-ac8a-1056ef3b0ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MilestonePaymentRelatedToCertainProductMember_aeb52821-7111-4f30-950f-4ab086b6ab3c" xlink:href="bhc-20211231.xsd#bhc_MilestonePaymentRelatedToCertainProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_37a2b657-f341-4454-ac8a-1056ef3b0ac8" xlink:to="loc_bhc_MilestonePaymentRelatedToCertainProductMember_aeb52821-7111-4f30-950f-4ab086b6ab3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_c70ec4ea-2842-431b-9f38-fc5c8833879c" xlink:href="bhc-20211231.xsd#bhc_ScheduleOfOtherIncomeAndExpensesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_d952f664-84eb-4ac9-83a4-f6145528d5a0" xlink:to="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_c70ec4ea-2842-431b-9f38-fc5c8833879c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_ce5716c6-b03a-4f4e-b8ce-991a3d8ba2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_c70ec4ea-2842-431b-9f38-fc5c8833879c" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_ce5716c6-b03a-4f4e-b8ce-991a3d8ba2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_5d59dcbb-3227-4322-8ce4-d3520e67db3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_c70ec4ea-2842-431b-9f38-fc5c8833879c" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_5d59dcbb-3227-4322-8ce4-d3520e67db3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_cf302ca0-0acd-4e4f-a87a-1b27f1065f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_c70ec4ea-2842-431b-9f38-fc5c8833879c" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_cf302ca0-0acd-4e4f-a87a-1b27f1065f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXES" xlink:type="simple" xlink:href="bhc-20211231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_94009513-3d0a-40a1-86bd-6f992a3569f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_f9efac58-12e2-4db8-ae87-cd7c767f9d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_94009513-3d0a-40a1-86bd-6f992a3569f3" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_f9efac58-12e2-4db8-ae87-cd7c767f9d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="bhc-20211231.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_80efa241-8f14-42ad-9d34-1f138956d7af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_8d581b15-6af9-4971-8235-526e9f34a24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80efa241-8f14-42ad-9d34-1f138956d7af" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_8d581b15-6af9-4971-8235-526e9f34a24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2cf1ec1b-d6dd-4ac0-bee1-272cb2531130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80efa241-8f14-42ad-9d34-1f138956d7af" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2cf1ec1b-d6dd-4ac0-bee1-272cb2531130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_48da8422-42b7-4e4b-92a5-1c2832ad8f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80efa241-8f14-42ad-9d34-1f138956d7af" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_48da8422-42b7-4e4b-92a5-1c2832ad8f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_096f711c-93a1-4e7b-89d8-fac61523828b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80efa241-8f14-42ad-9d34-1f138956d7af" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_096f711c-93a1-4e7b-89d8-fac61523828b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_af385ed3-b718-4268-ba3b-b5f475a27a36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80efa241-8f14-42ad-9d34-1f138956d7af" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_af385ed3-b718-4268-ba3b-b5f475a27a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_aff50bae-acac-4275-ae04-82e319ab0826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80efa241-8f14-42ad-9d34-1f138956d7af" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_aff50bae-acac-4275-ae04-82e319ab0826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5d184f9b-90da-4b23-983d-e7553b9ffe16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_8197f228-506a-418c-8c21-b439984a7f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5d184f9b-90da-4b23-983d-e7553b9ffe16" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_8197f228-506a-418c-8c21-b439984a7f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3be3db5c-02e8-4a84-85b1-3610e4435bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_8197f228-506a-418c-8c21-b439984a7f5c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3be3db5c-02e8-4a84-85b1-3610e4435bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b282c4e0-b345-4204-8f00-07bbe882c998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_8197f228-506a-418c-8c21-b439984a7f5c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b282c4e0-b345-4204-8f00-07bbe882c998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6dfc8f3a-024b-4e7e-83b9-e75fbe85ba04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_8197f228-506a-418c-8c21-b439984a7f5c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6dfc8f3a-024b-4e7e-83b9-e75fbe85ba04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_8fec2b05-d2b5-4531-8cf0-97a203e3c3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5d184f9b-90da-4b23-983d-e7553b9ffe16" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_8fec2b05-d2b5-4531-8cf0-97a203e3c3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_437c2bc0-7e43-42b9-b4d3-1e4cf8663bea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_8fec2b05-d2b5-4531-8cf0-97a203e3c3c9" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_437c2bc0-7e43-42b9-b4d3-1e4cf8663bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_dc770c9a-8217-4895-84e6-f3bdca819053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_8fec2b05-d2b5-4531-8cf0-97a203e3c3c9" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_dc770c9a-8217-4895-84e6-f3bdca819053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f9b39737-0a3a-43b4-8410-f728a2cead8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_8fec2b05-d2b5-4531-8cf0-97a203e3c3c9" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f9b39737-0a3a-43b4-8410-f728a2cead8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_7ed159c3-a175-466e-b511-c0041febe70d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5d184f9b-90da-4b23-983d-e7553b9ffe16" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_7ed159c3-a175-466e-b511-c0041febe70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4e211c93-ae09-477d-b24b-fa309cec9e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_7ed159c3-a175-466e-b511-c0041febe70d" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4e211c93-ae09-477d-b24b-fa309cec9e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_530d85ab-b6d2-49a3-8d20-cf6ae586ec29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_7ed159c3-a175-466e-b511-c0041febe70d" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_530d85ab-b6d2-49a3-8d20-cf6ae586ec29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ac5f4f97-a6d7-457b-805b-d187ffb60ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_7ed159c3-a175-466e-b511-c0041febe70d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ac5f4f97-a6d7-457b-805b-d187ffb60ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5b0eb8c5-a192-41ae-8d3d-66ec7a4d50c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5d184f9b-90da-4b23-983d-e7553b9ffe16" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5b0eb8c5-a192-41ae-8d3d-66ec7a4d50c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_822caa73-fd23-4b5c-80b7-987779b7aa67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cba6a805-d36a-49c6-8673-6e70f9326ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_822caa73-fd23-4b5c-80b7-987779b7aa67" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cba6a805-d36a-49c6-8673-6e70f9326ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9e6c2f33-3e6c-490f-ba81-0a89862eac35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_822caa73-fd23-4b5c-80b7-987779b7aa67" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9e6c2f33-3e6c-490f-ba81-0a89862eac35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1afec415-eb0e-4c8d-8341-fc0bf1079cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_822caa73-fd23-4b5c-80b7-987779b7aa67" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1afec415-eb0e-4c8d-8341-fc0bf1079cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8a3c02d5-d792-40b9-bbef-84684826e816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1afec415-eb0e-4c8d-8341-fc0bf1079cd9" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8a3c02d5-d792-40b9-bbef-84684826e816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_07db5ca5-1d40-4242-9d9f-e2252a6db769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1afec415-eb0e-4c8d-8341-fc0bf1079cd9" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_07db5ca5-1d40-4242-9d9f-e2252a6db769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount_097fe602-2ded-426c-8887-2b0988e63320" xlink:href="bhc-20211231.xsd#bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1afec415-eb0e-4c8d-8341-fc0bf1079cd9" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount_097fe602-2ded-426c-8887-2b0988e63320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance_5b09c84e-7758-485a-aa95-ff1a1336ff56" xlink:href="bhc-20211231.xsd#bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1afec415-eb0e-4c8d-8341-fc0bf1079cd9" xlink:to="loc_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance_5b09c84e-7758-485a-aa95-ff1a1336ff56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_90f6da01-28cc-4894-8e78-215cd455ae15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1afec415-eb0e-4c8d-8341-fc0bf1079cd9" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_90f6da01-28cc-4894-8e78-215cd455ae15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationUncertainTaxPositions_53c62d41-20b3-47c1-b2d8-44c0634225be" xlink:href="bhc-20211231.xsd#bhc_IncomeTaxReconciliationUncertainTaxPositions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1afec415-eb0e-4c8d-8341-fc0bf1079cd9" xlink:to="loc_bhc_IncomeTaxReconciliationUncertainTaxPositions_53c62d41-20b3-47c1-b2d8-44c0634225be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_77629372-2f87-43e0-8170-43ce1f15a087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1afec415-eb0e-4c8d-8341-fc0bf1079cd9" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_77629372-2f87-43e0-8170-43ce1f15a087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_f4c36f87-8382-4b48-ab92-1f837edab920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1afec415-eb0e-4c8d-8341-fc0bf1079cd9" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_f4c36f87-8382-4b48-ab92-1f837edab920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit_f7361752-adec-4e80-a956-799c948fa407" xlink:href="bhc-20211231.xsd#bhc_IncomeTaxReconciliationDeferredIntercompanyProfit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1afec415-eb0e-4c8d-8341-fc0bf1079cd9" xlink:to="loc_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit_f7361752-adec-4e80-a956-799c948fa407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1e35158f-936a-44d2-9796-a9cea8dac80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1afec415-eb0e-4c8d-8341-fc0bf1079cd9" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1e35158f-936a-44d2-9796-a9cea8dac80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8d4b5990-168e-476c-b3e2-51ecb062232b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1afec415-eb0e-4c8d-8341-fc0bf1079cd9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8d4b5990-168e-476c-b3e2-51ecb062232b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_eecbd65c-9400-4f2d-8258-ce7b2e7453ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_9f02e900-12a0-4221-8b3c-bec5512aa737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eecbd65c-9400-4f2d-8258-ce7b2e7453ec" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_9f02e900-12a0-4221-8b3c-bec5512aa737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsTaxLossCarryforwards_527a1d57-5ba6-4741-84f8-208ea4eb40be" xlink:href="bhc-20211231.xsd#bhc_DeferredTaxAssetsTaxLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_9f02e900-12a0-4221-8b3c-bec5512aa737" xlink:to="loc_bhc_DeferredTaxAssetsTaxLossCarryforwards_527a1d57-5ba6-4741-84f8-208ea4eb40be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_d831674b-cc50-437d-a0c9-be42127612ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_9f02e900-12a0-4221-8b3c-bec5512aa737" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_d831674b-cc50-437d-a0c9-be42127612ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_f0a2f958-1083-46b1-95ad-0fb29b79d3a6" xlink:href="bhc-20211231.xsd#bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_9f02e900-12a0-4221-8b3c-bec5512aa737" xlink:to="loc_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_f0a2f958-1083-46b1-95ad-0fb29b79d3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool_fd134f9d-2328-4697-ba21-4d52b8aec891" xlink:href="bhc-20211231.xsd#bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_9f02e900-12a0-4221-8b3c-bec5512aa737" xlink:to="loc_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool_fd134f9d-2328-4697-ba21-4d52b8aec891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_87169ad1-19de-4d10-910f-df5d4930c8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_9f02e900-12a0-4221-8b3c-bec5512aa737" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_87169ad1-19de-4d10-910f-df5d4930c8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_6bcce04a-7cf3-4f0a-a403-830be1167f93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_9f02e900-12a0-4221-8b3c-bec5512aa737" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_6bcce04a-7cf3-4f0a-a403-830be1167f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsPrepaidExpenses_81c8d79d-8d45-48e6-a125-d5c47d4c3660" xlink:href="bhc-20211231.xsd#bhc_DeferredTaxAssetsPrepaidExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_9f02e900-12a0-4221-8b3c-bec5512aa737" xlink:to="loc_bhc_DeferredTaxAssetsPrepaidExpenses_81c8d79d-8d45-48e6-a125-d5c47d4c3660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_86341207-aa27-4ca0-b717-9ee82a954bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_9f02e900-12a0-4221-8b3c-bec5512aa737" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_86341207-aa27-4ca0-b717-9ee82a954bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_f14661bd-d359-4558-890b-7bead1ddc09b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_9f02e900-12a0-4221-8b3c-bec5512aa737" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_f14661bd-d359-4558-890b-7bead1ddc09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c0f6b32b-bcc6-4e12-a369-a5d22f356843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_9f02e900-12a0-4221-8b3c-bec5512aa737" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_c0f6b32b-bcc6-4e12-a369-a5d22f356843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9f03e07a-5ddf-49fc-8b27-90bf336e4e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_9f02e900-12a0-4221-8b3c-bec5512aa737" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9f03e07a-5ddf-49fc-8b27-90bf336e4e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_e290db0b-bed9-48d1-867c-798b3a46af3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_9f02e900-12a0-4221-8b3c-bec5512aa737" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_e290db0b-bed9-48d1-867c-798b3a46af3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_e63f8dd0-a8c9-4550-aa6a-294e1adab5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eecbd65c-9400-4f2d-8258-ce7b2e7453ec" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_e63f8dd0-a8c9-4550-aa6a-294e1adab5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_14cfec91-10c5-4f07-8c51-6a76898136a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_e63f8dd0-a8c9-4550-aa6a-294e1adab5b1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_14cfec91-10c5-4f07-8c51-6a76898136a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes_aa5594cd-cbe2-4c8c-b7e9-5440abca7a21" xlink:href="bhc-20211231.xsd#bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_e63f8dd0-a8c9-4550-aa6a-294e1adab5b1" xlink:to="loc_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes_aa5594cd-cbe2-4c8c-b7e9-5440abca7a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_203f5186-ed05-4fca-9cc8-de15110e40f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_e63f8dd0-a8c9-4550-aa6a-294e1adab5b1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_203f5186-ed05-4fca-9cc8-de15110e40f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_7778fef9-3665-494f-84d3-768706a7a2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_e63f8dd0-a8c9-4550-aa6a-294e1adab5b1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_7778fef9-3665-494f-84d3-768706a7a2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_e3766b76-2af1-4f79-ad3b-cf7d505923f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_e63f8dd0-a8c9-4550-aa6a-294e1adab5b1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_e3766b76-2af1-4f79-ad3b-cf7d505923f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_43c66bc3-c23e-408d-95b1-7d2637d8bad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eecbd65c-9400-4f2d-8258-ce7b2e7453ec" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_43c66bc3-c23e-408d-95b1-7d2637d8bad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e64c5133-9e7d-4f45-98ae-f49daf5f8aed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9377f622-41b7-499a-8849-6c501a02ebb3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e64c5133-9e7d-4f45-98ae-f49daf5f8aed" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9377f622-41b7-499a-8849-6c501a02ebb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_8c3dffd6-4174-4386-a468-c135be101ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9377f622-41b7-499a-8849-6c501a02ebb3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_8c3dffd6-4174-4386-a468-c135be101ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_a03adbbe-d05b-4b22-ba80-f02c743e832e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_8c3dffd6-4174-4386-a468-c135be101ff1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_a03adbbe-d05b-4b22-ba80-f02c743e832e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_56e6fd2c-5a30-4b8c-98e4-51c73098650f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_a03adbbe-d05b-4b22-ba80-f02c743e832e" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_56e6fd2c-5a30-4b8c-98e4-51c73098650f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d321bd64-f4ac-4f12-82a1-741eab8befef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9377f622-41b7-499a-8849-6c501a02ebb3" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d321bd64-f4ac-4f12-82a1-741eab8befef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aae030f9-43ef-434b-944d-c43e7289797d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d321bd64-f4ac-4f12-82a1-741eab8befef" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aae030f9-43ef-434b-944d-c43e7289797d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_7308391a-d3ca-4165-b1a2-6fed4e01ccee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aae030f9-43ef-434b-944d-c43e7289797d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_7308391a-d3ca-4165-b1a2-6fed4e01ccee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes_9f04986d-2284-49ad-93fd-a9ea59dc1270" xlink:href="bhc-20211231.xsd#bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aae030f9-43ef-434b-944d-c43e7289797d" xlink:to="loc_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes_9f04986d-2284-49ad-93fd-a9ea59dc1270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_70eabe17-c657-459f-9836-8050380f70bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aae030f9-43ef-434b-944d-c43e7289797d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_70eabe17-c657-459f-9836-8050380f70bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_f577e0f1-0f90-41a0-91e5-630944459874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aae030f9-43ef-434b-944d-c43e7289797d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_f577e0f1-0f90-41a0-91e5-630944459874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0ae20886-8ff5-462a-a200-950018c1a5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxTable_82a0957a-1211-442c-b43f-6fa5930e4e31" xlink:href="bhc-20211231.xsd#bhc_IncomeTaxTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0ae20886-8ff5-462a-a200-950018c1a5a1" xlink:to="loc_bhc_IncomeTaxTable_82a0957a-1211-442c-b43f-6fa5930e4e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_83a55bb9-1a75-420e-9713-f1b3fcad018e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxTable_82a0957a-1211-442c-b43f-6fa5930e4e31" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_83a55bb9-1a75-420e-9713-f1b3fcad018e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b655e1af-98f3-48c0-acc6-1885133f3485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_83a55bb9-1a75-420e-9713-f1b3fcad018e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b655e1af-98f3-48c0-acc6-1885133f3485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ForeignCountryStateAndLocalMember_0894f45c-4d43-47f8-aa2a-4c4d3a7b3050" xlink:href="bhc-20211231.xsd#bhc_ForeignCountryStateAndLocalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b655e1af-98f3-48c0-acc6-1885133f3485" xlink:to="loc_bhc_ForeignCountryStateAndLocalMember_0894f45c-4d43-47f8-aa2a-4c4d3a7b3050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_9ccc7edd-8f44-4808-bfba-4b14d5e8bde7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b655e1af-98f3-48c0-acc6-1885133f3485" xlink:to="loc_us-gaap_DomesticCountryMember_9ccc7edd-8f44-4808-bfba-4b14d5e8bde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_820e35d3-a859-4e3d-8865-1b747538b29b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b655e1af-98f3-48c0-acc6-1885133f3485" xlink:to="loc_us-gaap_ForeignCountryMember_820e35d3-a859-4e3d-8865-1b747538b29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_a66fc4c8-b708-4f59-a042-12b5190208e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxTable_82a0957a-1211-442c-b43f-6fa5930e4e31" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_a66fc4c8-b708-4f59-a042-12b5190208e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_d5556636-1aa1-4bf5-b601-35bd9382fd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_a66fc4c8-b708-4f59-a042-12b5190208e1" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_d5556636-1aa1-4bf5-b601-35bd9382fd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember_0c182b51-a239-457c-ba29-8839a3753ab3" xlink:href="bhc-20211231.xsd#bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_d5556636-1aa1-4bf5-b601-35bd9382fd2a" xlink:to="loc_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember_0c182b51-a239-457c-ba29-8839a3753ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_e85d33a3-d3ec-4d47-8ec9-8f23845353a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxTable_82a0957a-1211-442c-b43f-6fa5930e4e31" xlink:to="loc_us-gaap_TaxPeriodAxis_e85d33a3-d3ec-4d47-8ec9-8f23845353a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_3d23e356-bdc7-4b46-ba74-5aae331f416a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_e85d33a3-d3ec-4d47-8ec9-8f23845353a8" xlink:to="loc_us-gaap_TaxPeriodDomain_3d23e356-bdc7-4b46-ba74-5aae331f416a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2012Member_4c2097e5-bd11-4e3a-bf10-a09e6c87d31c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2012Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_3d23e356-bdc7-4b46-ba74-5aae331f416a" xlink:to="loc_us-gaap_TaxYear2012Member_4c2097e5-bd11-4e3a-bf10-a09e6c87d31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2013Member_a6168c37-d921-4552-9b1c-60284e7f4fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2013Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_3d23e356-bdc7-4b46-ba74-5aae331f416a" xlink:to="loc_us-gaap_TaxYear2013Member_a6168c37-d921-4552-9b1c-60284e7f4fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxYear2005ThroughTaxYear2009Member_803933c8-d20e-47f5-87f1-36ac6f1e900a" xlink:href="bhc-20211231.xsd#bhc_TaxYear2005ThroughTaxYear2009Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_3d23e356-bdc7-4b46-ba74-5aae331f416a" xlink:to="loc_bhc_TaxYear2005ThroughTaxYear2009Member_803933c8-d20e-47f5-87f1-36ac6f1e900a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxYear2015AndTaxYear2016Member_3676eb24-59d3-45c4-bcc9-84ab0d7a36a9" xlink:href="bhc-20211231.xsd#bhc_TaxYear2015AndTaxYear2016Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_3d23e356-bdc7-4b46-ba74-5aae331f416a" xlink:to="loc_bhc_TaxYear2015AndTaxYear2016Member_3676eb24-59d3-45c4-bcc9-84ab0d7a36a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_ef94a903-9bc3-44eb-b42a-28267f541ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxTable_82a0957a-1211-442c-b43f-6fa5930e4e31" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_ef94a903-9bc3-44eb-b42a-28267f541ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_950c18b2-f006-4f74-bd6a-edff0c481718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_ef94a903-9bc3-44eb-b42a-28267f541ddb" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_950c18b2-f006-4f74-bd6a-edff0c481718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueCommissionersIrelandMember_a56191de-8c9c-44e0-9819-db2e3145eca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueCommissionersIrelandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_950c18b2-f006-4f74-bd6a-edff0c481718" xlink:to="loc_us-gaap_RevenueCommissionersIrelandMember_a56191de-8c9c-44e0-9819-db2e3145eca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember_48d581c1-1e26-47de-a850-b4d3c878159a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CanadaRevenueAgencyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_950c18b2-f006-4f74-bd6a-edff0c481718" xlink:to="loc_us-gaap_CanadaRevenueAgencyMember_48d581c1-1e26-47de-a850-b4d3c878159a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember_9acbd42c-54d0-4e4f-b62f-78b6d64ab91a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_950c18b2-f006-4f74-bd6a-edff0c481718" xlink:to="loc_us-gaap_AustralianTaxationOfficeMember_9acbd42c-54d0-4e4f-b62f-78b6d64ab91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:href="bhc-20211231.xsd#bhc_IncomeTaxLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxTable_82a0957a-1211-442c-b43f-6fa5930e4e31" xlink:to="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_103143f7-362c-418e-8557-6aa34bb4facc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_103143f7-362c-418e-8557-6aa34bb4facc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccumulatedLossesAvailableForFederalPurposes_5de86326-fb79-4516-9b2f-281c97907ec4" xlink:href="bhc-20211231.xsd#bhc_AccumulatedLossesAvailableForFederalPurposes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_bhc_AccumulatedLossesAvailableForFederalPurposes_5de86326-fb79-4516-9b2f-281c97907ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits_9398ab7c-6090-4db6-ad57-64df1049342b" xlink:href="bhc-20211231.xsd#bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits_9398ab7c-6090-4db6-ad57-64df1049342b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_d826c959-8add-481a-8eae-e86ac912cc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_d826c959-8add-481a-8eae-e86ac912cc0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_323c50fa-613c-4e14-84dc-1f847f7b8d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_323c50fa-613c-4e14-84dc-1f847f7b8d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_90371e24-7b04-496d-8869-aff6d4141c19" xlink:href="bhc-20211231.xsd#bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_90371e24-7b04-496d-8869-aff6d4141c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1d28fae4-dc31-4b4c-8512-dd93742f5858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1d28fae4-dc31-4b4c-8512-dd93742f5858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions_955b065f-74b7-43ae-9f42-21984b3210d0" xlink:href="bhc-20211231.xsd#bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions_955b065f-74b7-43ae-9f42-21984b3210d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions_738d012d-c778-4f58-9bf2-456f21b6170d" xlink:href="bhc-20211231.xsd#bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions_738d012d-c778-4f58-9bf2-456f21b6170d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions_067ff670-253d-46fa-ae48-ab02fda20e6d" xlink:href="bhc-20211231.xsd#bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions_067ff670-253d-46fa-ae48-ab02fda20e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_c8c4a030-947e-4bd4-9540-b3acdd971a42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_c8c4a030-947e-4bd4-9540-b3acdd971a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_8e8a5748-aa99-405e-a889-d038edb8d204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_8e8a5748-aa99-405e-a889-d038edb8d204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns_035609b0-8529-4d03-bead-0a8aa6a0e8aa" xlink:href="bhc-20211231.xsd#bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns_035609b0-8529-4d03-bead-0a8aa6a0e8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear_f2944911-ad79-4a97-bab9-435675d600da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear_f2944911-ad79-4a97-bab9-435675d600da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_1162c5eb-97c1-4e5f-8b65-5b51428a7b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_1162c5eb-97c1-4e5f-8b65-5b51428a7b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_e2f6f5da-1b4d-43fa-a114-a111d4e2c5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_7d6ad794-461b-491a-a3c7-9042b6fdfe47" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_e2f6f5da-1b4d-43fa-a114-a111d4e2c5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3b16f8f4-7764-4f77-b42a-6e02b399c2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_182b8261-287f-4e00-9b2f-2975bc954b26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3b16f8f4-7764-4f77-b42a-6e02b399c2d7" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_182b8261-287f-4e00-9b2f-2975bc954b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_9b0ff303-d5af-4615-abfb-ddc3ec73a7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_182b8261-287f-4e00-9b2f-2975bc954b26" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_9b0ff303-d5af-4615-abfb-ddc3ec73a7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3026dcd4-816e-4928-91c0-f35abfac2c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_9b0ff303-d5af-4615-abfb-ddc3ec73a7bb" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3026dcd4-816e-4928-91c0-f35abfac2c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_bbda3a17-2ac2-4e44-aaf7-c12f7df40e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3026dcd4-816e-4928-91c0-f35abfac2c0e" xlink:to="loc_us-gaap_DomesticCountryMember_bbda3a17-2ac2-4e44-aaf7-c12f7df40e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_c1f55dea-c59a-4edb-ac73-4e6cc224ee54" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3026dcd4-816e-4928-91c0-f35abfac2c0e" xlink:to="loc_country_CA_c1f55dea-c59a-4edb-ac73-4e6cc224ee54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_f6c1c136-ac2f-42c0-890e-396357205dc6" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3026dcd4-816e-4928-91c0-f35abfac2c0e" xlink:to="loc_country_DE_f6c1c136-ac2f-42c0-890e-396357205dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_8bc1503a-bc3b-4c9f-98f2-d29f21cf44da" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_FR"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3026dcd4-816e-4928-91c0-f35abfac2c0e" xlink:to="loc_country_FR_8bc1503a-bc3b-4c9f-98f2-d29f21cf44da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_b64d0d92-fe7b-4bea-9d19-f5cf45c3c02c" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3026dcd4-816e-4928-91c0-f35abfac2c0e" xlink:to="loc_country_CN_b64d0d92-fe7b-4bea-9d19-f5cf45c3c02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_8ceb31f5-c596-4e6a-accf-e21a3cef0401" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3026dcd4-816e-4928-91c0-f35abfac2c0e" xlink:to="loc_country_IE_8ceb31f5-c596-4e6a-accf-e21a3cef0401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_NL_c4455876-c3d2-4459-a855-38cad17b0044" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_NL"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3026dcd4-816e-4928-91c0-f35abfac2c0e" xlink:to="loc_country_NL_c4455876-c3d2-4459-a855-38cad17b0044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember_d63b6364-7795-4e50-a091-65454bb7be84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3026dcd4-816e-4928-91c0-f35abfac2c0e" xlink:to="loc_us-gaap_AustralianTaxationOfficeMember_d63b6364-7795-4e50-a091-65454bb7be84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LuxembourgInlandRevenueMember_fed9fbdb-e1fe-4848-931a-72f5a942abbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LuxembourgInlandRevenueMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3026dcd4-816e-4928-91c0-f35abfac2c0e" xlink:to="loc_us-gaap_LuxembourgInlandRevenueMember_fed9fbdb-e1fe-4848-931a-72f5a942abbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c328beb5-a0ef-4172-b75b-56f32bb6ca75" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_182b8261-287f-4e00-9b2f-2975bc954b26" xlink:to="loc_srt_RangeAxis_c328beb5-a0ef-4172-b75b-56f32bb6ca75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4d6861c0-6cc5-4ed4-8da0-7704c7842332" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c328beb5-a0ef-4172-b75b-56f32bb6ca75" xlink:to="loc_srt_RangeMember_4d6861c0-6cc5-4ed4-8da0-7704c7842332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f223d750-0eb1-4f20-a88a-3376d1c34494" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4d6861c0-6cc5-4ed4-8da0-7704c7842332" xlink:to="loc_srt_MinimumMember_f223d750-0eb1-4f20-a88a-3376d1c34494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_982764b9-1dbb-4078-8677-664f1e15f547" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4d6861c0-6cc5-4ed4-8da0-7704c7842332" xlink:to="loc_srt_MaximumMember_982764b9-1dbb-4078-8677-664f1e15f547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_d0b059b3-2660-4df0-aae4-2132b3f17607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_182b8261-287f-4e00-9b2f-2975bc954b26" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_d0b059b3-2660-4df0-aae4-2132b3f17607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear_42f2d97a-b816-44bc-a4a6-2d452cad8323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d0b059b3-2660-4df0-aae4-2132b3f17607" xlink:to="loc_us-gaap_OpenTaxYear_42f2d97a-b816-44bc-a4a6-2d452cad8323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c7c23ba5-05d2-4003-a2b6-0f02b60e62b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_026e7daf-1421-44a6-adeb-ef235808b3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c7c23ba5-05d2-4003-a2b6-0f02b60e62b8" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_026e7daf-1421-44a6-adeb-ef235808b3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_b9a10d72-7c08-4889-b527-e86730a9de52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_026e7daf-1421-44a6-adeb-ef235808b3d0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_b9a10d72-7c08-4889-b527-e86730a9de52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_e77555fe-52f7-4cf1-8f10-1c1c2d705d63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_026e7daf-1421-44a6-adeb-ef235808b3d0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_e77555fe-52f7-4cf1-8f10-1c1c2d705d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_c9f4ae77-37df-4feb-9a4f-e5cded86015c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_026e7daf-1421-44a6-adeb-ef235808b3d0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_c9f4ae77-37df-4feb-9a4f-e5cded86015c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_c4fe388d-f36a-4b21-a8b8-1dfb36ba51e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_026e7daf-1421-44a6-adeb-ef235808b3d0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_c4fe388d-f36a-4b21-a8b8-1dfb36ba51e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_89190466-706c-41d3-8ffd-775f851ecd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_026e7daf-1421-44a6-adeb-ef235808b3d0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_89190466-706c-41d3-8ffd-775f851ecd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_67208517-e385-42a3-96aa-8284acf57eae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_026e7daf-1421-44a6-adeb-ef235808b3d0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_67208517-e385-42a3-96aa-8284acf57eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHARE" xlink:type="simple" xlink:href="bhc-20211231.xsd#LOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3256387d-170b-4026-97ec-769c5d33748e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_0d0ae8e8-6fe5-4429-abca-af610e2d0240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3256387d-170b-4026-97ec-769c5d33748e" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_0d0ae8e8-6fe5-4429-abca-af610e2d0240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHARETables" xlink:type="simple" xlink:href="bhc-20211231.xsd#LOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_317ece36-9540-4693-80e4-d6dd328dec30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_63f43977-c31f-4bfe-bce4-a31d2ad9c09e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_317ece36-9540-4693-80e4-d6dd328dec30" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_63f43977-c31f-4bfe-bce4-a31d2ad9c09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_454c638c-b4c4-4312-9371-902e2dc2dbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9f1c20f9-89cc-4596-83db-f1f9b710eb16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_454c638c-b4c4-4312-9371-902e2dc2dbf4" xlink:to="loc_us-gaap_NetIncomeLoss_9f1c20f9-89cc-4596-83db-f1f9b710eb16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2ee175e4-cafc-4afd-8948-63ada89e8d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_454c638c-b4c4-4312-9371-902e2dc2dbf4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2ee175e4-cafc-4afd-8948-63ada89e8d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9fad3874-5a9b-4f72-8864-c6deb78c206f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_454c638c-b4c4-4312-9371-902e2dc2dbf4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9fad3874-5a9b-4f72-8864-c6deb78c206f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e0ad2497-35f9-4e3c-b18c-839e9f6995c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_454c638c-b4c4-4312-9371-902e2dc2dbf4" xlink:to="loc_us-gaap_EarningsPerShareBasic_e0ad2497-35f9-4e3c-b18c-839e9f6995c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7986bca2-9fbd-4c01-bdbb-f2324395870f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_454c638c-b4c4-4312-9371-902e2dc2dbf4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7986bca2-9fbd-4c01-bdbb-f2324395870f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#LOSSPERSHARENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d08135d2-e710-49ce-9a18-f699d9e7107b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_73b5befc-5e75-4d46-89ca-81d0fbea46f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d08135d2-e710-49ce-9a18-f699d9e7107b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_73b5befc-5e75-4d46-89ca-81d0fbea46f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b3056766-f539-496d-b560-eadf05d3bb96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_73b5befc-5e75-4d46-89ca-81d0fbea46f0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b3056766-f539-496d-b560-eadf05d3bb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2008336a-82e0-42ed-88bb-074c6573ff97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b3056766-f539-496d-b560-eadf05d3bb96" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2008336a-82e0-42ed-88bb-074c6573ff97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_691d9bdc-42e9-447b-88d4-db6e95035e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2008336a-82e0-42ed-88bb-074c6573ff97" xlink:to="loc_us-gaap_StockCompensationPlanMember_691d9bdc-42e9-447b-88d4-db6e95035e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_eff701f3-c614-458d-9d61-abe5848caf36" xlink:href="bhc-20211231.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2008336a-82e0-42ed-88bb-074c6573ff97" xlink:to="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_eff701f3-c614-458d-9d61-abe5848caf36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_39b0b405-ff26-44a9-9764-a725d2b2543b" xlink:href="bhc-20211231.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_eff701f3-c614-458d-9d61-abe5848caf36" xlink:to="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_39b0b405-ff26-44a9-9764-a725d2b2543b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fdddeddc-6f10-4937-9216-f9ecd606155d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_73b5befc-5e75-4d46-89ca-81d0fbea46f0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fdddeddc-6f10-4937-9216-f9ecd606155d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d2b11c96-a07f-4131-b27b-786eefc70ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fdddeddc-6f10-4937-9216-f9ecd606155d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d2b11c96-a07f-4131-b27b-786eefc70ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES" xlink:type="simple" xlink:href="bhc-20211231.xsd#SUPPLEMENTALCASHFLOWDISCLOSURES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_f08fc0d6-cb99-4555-90d8-9806bde08b66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_bec3ad38-720c-4188-8eaf-8f834b0e462e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_f08fc0d6-cb99-4555-90d8-9806bde08b66" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_bec3ad38-720c-4188-8eaf-8f834b0e462e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESTables" xlink:type="simple" xlink:href="bhc-20211231.xsd#SUPPLEMENTALCASHFLOWDISCLOSURESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_dc3c85b7-72fb-460f-bb6f-e647d16b6e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_74056f17-ae8e-48c8-ac9c-9997d563d6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_dc3c85b7-72fb-460f-bb6f-e647d16b6e0c" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_74056f17-ae8e-48c8-ac9c-9997d563d6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_0b028d9e-5e42-4e99-930a-df4fffc04e04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_c5bacf9e-de4e-4dfb-a7cb-6e1d3934ddcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_0b028d9e-5e42-4e99-930a-df4fffc04e04" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_c5bacf9e-de4e-4dfb-a7cb-6e1d3934ddcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_028e08b0-fc9f-4baa-9674-8c762e8265ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c5bacf9e-de4e-4dfb-a7cb-6e1d3934ddcd" xlink:to="loc_us-gaap_InterestPaidNet_028e08b0-fc9f-4baa-9674-8c762e8265ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_2038e0b3-ba97-4a51-b00b-8b4c84956cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c5bacf9e-de4e-4dfb-a7cb-6e1d3934ddcd" xlink:to="loc_us-gaap_IncomeTaxesPaid_2038e0b3-ba97-4a51-b00b-8b4c84956cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGS" xlink:type="simple" xlink:href="bhc-20211231.xsd#LEGALPROCEEDINGS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5a60af21-40c9-4c43-9ce8-c702212d7d79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_7a0ba117-9e59-40fb-9ede-586b29cb26fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5a60af21-40c9-4c43-9ce8-c702212d7d79" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_7a0ba117-9e59-40fb-9ede-586b29cb26fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#LEGALPROCEEDINGSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fc4f67dd-ae12-43f9-a762-045ca848b683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_f7835375-a244-4611-8edd-141a154680c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fc4f67dd-ae12-43f9-a762-045ca848b683" xlink:to="loc_us-gaap_LossContingenciesTable_f7835375-a244-4611-8edd-141a154680c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_4f817a5f-5f2b-4f99-9383-d160f8badfc8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f7835375-a244-4611-8edd-141a154680c2" xlink:to="loc_srt_LitigationCaseAxis_4f817a5f-5f2b-4f99-9383-d160f8badfc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_4f817a5f-5f2b-4f99-9383-d160f8badfc8" xlink:to="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_b2ad9923-b9c9-44d3-a4e5-b19c9c0302e4" xlink:href="bhc-20211231.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_b2ad9923-b9c9-44d3-a4e5-b19c9c0302e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianSecuritiesLitigationMember_9beedea1-6ec2-4ad3-af28-c2c0a2377d52" xlink:href="bhc-20211231.xsd#bhc_CanadianSecuritiesLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_CanadianSecuritiesLitigationMember_9beedea1-6ec2-4ad3-af28-c2c0a2377d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsLitigationMember_e05a917d-7eb6-4ac0-8728-20ecabd9f34e" xlink:href="bhc-20211231.xsd#bhc_RICOClassActionsLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_RICOClassActionsLitigationMember_e05a917d-7eb6-4ac0-8728-20ecabd9f34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember_ca2def89-8882-43cf-b066-3b16814aa323" xlink:href="bhc-20211231.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_InsuranceCoverageLawsuitMember_ca2def89-8882-43cf-b066-3b16814aa323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SandozLitigationMember_f7d9b3f8-fe29-42e7-9770-47e6ea61ffee" xlink:href="bhc-20211231.xsd#bhc_SandozLitigationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_SandozLitigationMember_f7d9b3f8-fe29-42e7-9770-47e6ea61ffee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerrigoIsraelPharmaceuticalsLitigationMember_6060de98-2f65-4197-8e16-8e1fe2ae0799" xlink:href="bhc-20211231.xsd#bhc_PerrigoIsraelPharmaceuticalsLitigationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_PerrigoIsraelPharmaceuticalsLitigationMember_6060de98-2f65-4197-8e16-8e1fe2ae0799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PadagisLitigationMember_cffad526-f0b4-495b-9cd0-0f2818341d86" xlink:href="bhc-20211231.xsd#bhc_PadagisLitigationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_PadagisLitigationMember_cffad526-f0b4-495b-9cd0-0f2818341d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_faa9a7ef-f8e8-4d3f-899a-362bd1e099ce" xlink:href="bhc-20211231.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_faa9a7ef-f8e8-4d3f-899a-362bd1e099ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember_6292709f-12ac-41aa-a0b5-84a656030f5a" xlink:href="bhc-20211231.xsd#bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember_6292709f-12ac-41aa-a0b5-84a656030f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LupinPharmaceuticalsIncLitigationMember_ee7a630d-65f6-4a01-b791-cb43269f1013" xlink:href="bhc-20211231.xsd#bhc_LupinPharmaceuticalsIncLitigationMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_LupinPharmaceuticalsIncLitigationMember_ee7a630d-65f6-4a01-b791-cb43269f1013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowertoShowerProductLiabilityLitigationMember_6c0a811a-848f-4da2-a5b4-547dfac328d2" xlink:href="bhc-20211231.xsd#bhc_ShowertoShowerProductLiabilityLitigationMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_ShowertoShowerProductLiabilityLitigationMember_6c0a811a-848f-4da2-a5b4-547dfac328d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_26ddbef0-6876-4152-89ed-9dca4835f8ac" xlink:href="bhc-20211231.xsd#bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShowertoShowerProductLiabilityLitigationMember_6c0a811a-848f-4da2-a5b4-547dfac328d2" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_26ddbef0-6876-4152-89ed-9dca4835f8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_0c6ade87-b960-41de-bd57-e617e8b7a9eb" xlink:href="bhc-20211231.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_0c6ade87-b960-41de-bd57-e617e8b7a9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember_ba04b057-6e81-4fd6-9e59-684562d8127b" xlink:href="bhc-20211231.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_LitigationwithFormerSalixCEOMember_ba04b057-6e81-4fd6-9e59-684562d8127b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember_f3a1a5ea-5ea8-42c8-8bb7-1c3bdbab76a7" xlink:href="bhc-20211231.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_GlumetzaAntitrustLitigationMember_f3a1a5ea-5ea8-42c8-8bb7-1c3bdbab76a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_93f9f15e-636e-4d84-b50e-72ea2b6bf3fb" xlink:href="bhc-20211231.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_GlumetzaAntitrustLitigationMember_f3a1a5ea-5ea8-42c8-8bb7-1c3bdbab76a7" xlink:to="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_93f9f15e-636e-4d84-b50e-72ea2b6bf3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ApotexIncLitigationMember_a604d3f6-24c5-4bc2-ac89-2eaee4b523ba" xlink:href="bhc-20211231.xsd#bhc_ApotexIncLitigationMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_ApotexIncLitigationMember_a604d3f6-24c5-4bc2-ac89-2eaee4b523ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeLawsuitsMember_195cf332-4751-470c-91b0-c59a0892f6bc" xlink:href="bhc-20211231.xsd#bhc_DerivativeLawsuitsMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_80e404bf-1787-4efd-90c0-35668526f29b" xlink:to="loc_bhc_DerivativeLawsuitsMember_195cf332-4751-470c-91b0-c59a0892f6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ba7bbebb-ce5d-45cf-bf1c-66e7a1d09b8b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f7835375-a244-4611-8edd-141a154680c2" xlink:to="loc_srt_StatementGeographicalAxis_ba7bbebb-ce5d-45cf-bf1c-66e7a1d09b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_efdced6a-88cd-4abf-a7bd-59a8b14c2839" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ba7bbebb-ce5d-45cf-bf1c-66e7a1d09b8b" xlink:to="loc_srt_SegmentGeographicalDomain_efdced6a-88cd-4abf-a7bd-59a8b14c2839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_67e4259b-b7fc-41a9-94f1-e9d47f26e13f" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_efdced6a-88cd-4abf-a7bd-59a8b14c2839" xlink:to="loc_stpr_NJ_67e4259b-b7fc-41a9-94f1-e9d47f26e13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_b7c8dc8c-3010-452e-bb68-c8b72ff31ad0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_efdced6a-88cd-4abf-a7bd-59a8b14c2839" xlink:to="loc_country_CA_b7c8dc8c-3010-452e-bb68-c8b72ff31ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC_88f22090-d487-420a-b460-13a069b72fa6" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA-BC"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_country_CA_b7c8dc8c-3010-452e-bb68-c8b72ff31ad0" xlink:to="loc_stpr_CA-BC_88f22090-d487-420a-b460-13a069b72fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-QC_379b0a19-c2ef-48a2-85fb-7c7818ed0b4d" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA-QC"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_country_CA_b7c8dc8c-3010-452e-bb68-c8b72ff31ad0" xlink:to="loc_stpr_CA-QC_379b0a19-c2ef-48a2-85fb-7c7818ed0b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ed31af7e-1ea8-4f65-9a8d-72897f56d379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f7835375-a244-4611-8edd-141a154680c2" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ed31af7e-1ea8-4f65-9a8d-72897f56d379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_116d1b41-1cba-4fb6-a2b3-834ef4fa3bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ed31af7e-1ea8-4f65-9a8d-72897f56d379" xlink:to="loc_us-gaap_LossContingencyNatureDomain_116d1b41-1cba-4fb6-a2b3-834ef4fa3bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_6cdf65de-6651-4466-ac5b-f6d467a128d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_116d1b41-1cba-4fb6-a2b3-834ef4fa3bd6" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_6cdf65de-6651-4466-ac5b-f6d467a128d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_626bcd53-11a0-4437-829a-b22dc5232d69" xlink:href="bhc-20211231.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_116d1b41-1cba-4fb6-a2b3-834ef4fa3bd6" xlink:to="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_626bcd53-11a0-4437-829a-b22dc5232d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_caafe080-2e34-40a5-a17d-cee490cb9227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f7835375-a244-4611-8edd-141a154680c2" xlink:to="loc_us-gaap_LitigationStatusAxis_caafe080-2e34-40a5-a17d-cee490cb9227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_dd4acfa5-5917-4167-abde-928335fc7b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_caafe080-2e34-40a5-a17d-cee490cb9227" xlink:to="loc_us-gaap_LitigationStatusDomain_dd4acfa5-5917-4167-abde-928335fc7b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_e8361a6f-5872-4fa0-93f4-8c1759aacbb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_dd4acfa5-5917-4167-abde-928335fc7b49" xlink:to="loc_us-gaap_PendingLitigationMember_e8361a6f-5872-4fa0-93f4-8c1759aacbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_8ab93618-dda7-4a0a-8c2b-94b19819ae00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_dd4acfa5-5917-4167-abde-928335fc7b49" xlink:to="loc_us-gaap_SettledLitigationMember_8ab93618-dda7-4a0a-8c2b-94b19819ae00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1686111e-adaa-46c0-9285-b1e22a9608e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f7835375-a244-4611-8edd-141a154680c2" xlink:to="loc_srt_CounterpartyNameAxis_1686111e-adaa-46c0-9285-b1e22a9608e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dfbbaf2c-6dac-4831-a4bc-168f1b300ec3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1686111e-adaa-46c0-9285-b1e22a9608e9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dfbbaf2c-6dac-4831-a4bc-168f1b300ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember_7b14467f-3f86-452f-a12e-68ba9945cfe8" xlink:href="bhc-20211231.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dfbbaf2c-6dac-4831-a4bc-168f1b300ec3" xlink:to="loc_bhc_PlaintiffsDirectPurchasersMember_7b14467f-3f86-452f-a12e-68ba9945cfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_83a4f4d4-115b-477c-8f73-da40b290beb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f7835375-a244-4611-8edd-141a154680c2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_83a4f4d4-115b-477c-8f73-da40b290beb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_254bdb6a-c8ac-4efa-abdd-021101d9a162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_83a4f4d4-115b-477c-8f73-da40b290beb9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_254bdb6a-c8ac-4efa-abdd-021101d9a162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e6d385e9-d35d-4909-b49b-44e10d639b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_254bdb6a-c8ac-4efa-abdd-021101d9a162" xlink:to="loc_us-gaap_SubsequentEventMember_e6d385e9-d35d-4909-b49b-44e10d639b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a9b59fc7-7c76-4d48-aa1a-468cb73fbc96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f7835375-a244-4611-8edd-141a154680c2" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a9b59fc7-7c76-4d48-aa1a-468cb73fbc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7803e379-c9cc-492f-8ca6-3460cc59bf5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a9b59fc7-7c76-4d48-aa1a-468cb73fbc96" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7803e379-c9cc-492f-8ca6-3460cc59bf5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_bf04f064-e550-4103-bee5-3dd2f907dde8" xlink:href="bhc-20211231.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7803e379-c9cc-492f-8ca6-3460cc59bf5b" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_bf04f064-e550-4103-bee5-3dd2f907dde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f7835375-a244-4611-8edd-141a154680c2" xlink:to="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees_4ab50af3-1df0-4f6c-8607-23d3682b23a7" xlink:href="bhc-20211231.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_bhc_Legalsettlementsandrelatedfees_4ab50af3-1df0-4f6c-8607-23d3682b23a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_c8df5a39-723f-4c0a-af4d-41ded118cc50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_c8df5a39-723f-4c0a-af4d-41ded118cc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_f67a0da2-d957-49d2-819b-331b67a8aedb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_f67a0da2-d957-49d2-819b-331b67a8aedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_5c92b26c-7c42-4b21-87bf-e6e3865e8f42" xlink:href="bhc-20211231.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_5c92b26c-7c42-4b21-87bf-e6e3865e8f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_5c43602b-1116-47ed-b0c7-e7392a1c1cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_5c43602b-1116-47ed-b0c7-e7392a1c1cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_e9ac6f02-e7a7-4de3-b5a4-80291574f7ea" xlink:href="bhc-20211231.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_e9ac6f02-e7a7-4de3-b5a4-80291574f7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_5fd8bc23-c13c-4280-b2fc-ff9cbe3459f5" xlink:href="bhc-20211231.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_5fd8bc23-c13c-4280-b2fc-ff9cbe3459f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_c7c79a9f-a889-4df6-86fc-659b3b51caa5" xlink:href="bhc-20211231.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_c7c79a9f-a889-4df6-86fc-659b3b51caa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_4f30ed16-205f-4ae3-973a-19918515f6fd" xlink:href="bhc-20211231.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_4f30ed16-205f-4ae3-973a-19918515f6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_18f4fa0a-bf55-4710-bbe0-23d2a9c0368c" xlink:href="bhc-20211231.xsd#bhc_LossContingencySettlementAgreementsNumberOfInsurers"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_18f4fa0a-bf55-4710-bbe0-23d2a9c0368c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_0e40fe4a-f0c8-4150-8363-5c8693a2033a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_0e40fe4a-f0c8-4150-8363-5c8693a2033a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod_d390992c-0e23-4810-930b-0e4639a301a0" xlink:href="bhc-20211231.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_bhc_LossContingencyStayOfApprovalPeriod_d390992c-0e23-4810-930b-0e4639a301a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_4dd72ffd-ceb7-4acf-ada9-519712207120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_4dd72ffd-ceb7-4acf-ada9-519712207120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_250e3686-e443-46f6-a5ab-aab81500f24f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_250e3686-e443-46f6-a5ab-aab81500f24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits_f5dbdbfb-10ee-428d-8e68-8cf066c28999" xlink:href="bhc-20211231.xsd#bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_38448b50-be4c-4def-8780-8e89b049e0f8" xlink:to="loc_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits_f5dbdbfb-10ee-428d-8e68-8cf066c28999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="bhc-20211231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e2a8e9a1-417d-43d2-8c75-7004d72049ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_daf34c1d-f8ba-482d-a3e3-6e2baddea765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e2a8e9a1-417d-43d2-8c75-7004d72049ff" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_daf34c1d-f8ba-482d-a3e3-6e2baddea765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_987fea59-73b4-4a7c-8d97-3f24aecd93ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfCommitmentsTable_ebe293cc-7e68-4eeb-bf6d-a04d64f835ae" xlink:href="bhc-20211231.xsd#bhc_ScheduleOfCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_987fea59-73b4-4a7c-8d97-3f24aecd93ea" xlink:to="loc_bhc_ScheduleOfCommitmentsTable_ebe293cc-7e68-4eeb-bf6d-a04d64f835ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c8e69659-72d8-454f-88f0-4c2712600b00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfCommitmentsTable_ebe293cc-7e68-4eeb-bf6d-a04d64f835ae" xlink:to="loc_srt_CounterpartyNameAxis_c8e69659-72d8-454f-88f0-4c2712600b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19cc178f-5df9-45e5-bac1-0d691b3f7618" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c8e69659-72d8-454f-88f0-4c2712600b00" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19cc178f-5df9-45e5-bac1-0d691b3f7618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member_015cd5fe-7bcd-48dd-9836-a614798739e5" xlink:href="bhc-20211231.xsd#bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19cc178f-5df9-45e5-bac1-0d691b3f7618" xlink:to="loc_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member_015cd5fe-7bcd-48dd-9836-a614798739e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MitsubishiTanabePharmaCorporationMember_e6e1a96d-b616-4085-adde-d5a40e6e7c43" xlink:href="bhc-20211231.xsd#bhc_MitsubishiTanabePharmaCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19cc178f-5df9-45e5-bac1-0d691b3f7618" xlink:to="loc_bhc_MitsubishiTanabePharmaCorporationMember_e6e1a96d-b616-4085-adde-d5a40e6e7c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NovaliqGmbHMember_e66ed164-fe42-4a8f-9368-bff7fbb2603a" xlink:href="bhc-20211231.xsd#bhc_NovaliqGmbHMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19cc178f-5df9-45e5-bac1-0d691b3f7618" xlink:to="loc_bhc_NovaliqGmbHMember_e66ed164-fe42-4a8f-9368-bff7fbb2603a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CedarsSinaiMedicalCenterMember_a9097e1d-7235-4b9c-b6c0-85027f0ce28f" xlink:href="bhc-20211231.xsd#bhc_CedarsSinaiMedicalCenterMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19cc178f-5df9-45e5-bac1-0d691b3f7618" xlink:to="loc_bhc_CedarsSinaiMedicalCenterMember_a9097e1d-7235-4b9c-b6c0-85027f0ce28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EyenoviaIncMember_118ac604-55f4-419a-994f-f00c898c0350" xlink:href="bhc-20211231.xsd#bhc_EyenoviaIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19cc178f-5df9-45e5-bac1-0d691b3f7618" xlink:to="loc_bhc_EyenoviaIncMember_118ac604-55f4-419a-994f-f00c898c0350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfCommitmentsLineItems_a433646b-8f59-4afb-85b9-e75e9bb35e39" xlink:href="bhc-20211231.xsd#bhc_ScheduleOfCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfCommitmentsTable_ebe293cc-7e68-4eeb-bf6d-a04d64f835ae" xlink:to="loc_bhc_ScheduleOfCommitmentsLineItems_a433646b-8f59-4afb-85b9-e75e9bb35e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_7b65f2bd-f0f5-45f8-b9f2-401496ee7fac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfCommitmentsLineItems_a433646b-8f59-4afb-85b9-e75e9bb35e39" xlink:to="loc_us-gaap_ContractualObligation_7b65f2bd-f0f5-45f8-b9f2-401496ee7fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CollaborativeAgreementMilestonePaymentsAggregate_1e44c16e-a301-4ad6-bbc7-30cc8c3f2c18" xlink:href="bhc-20211231.xsd#bhc_CollaborativeAgreementMilestonePaymentsAggregate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfCommitmentsLineItems_a433646b-8f59-4afb-85b9-e75e9bb35e39" xlink:to="loc_bhc_CollaborativeAgreementMilestonePaymentsAggregate_1e44c16e-a301-4ad6-bbc7-30cc8c3f2c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="bhc-20211231.xsd#SEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1e6a57c6-fc3d-4c31-83dc-179ee366a654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_0f369f95-895f-4471-965f-681c79d98e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1e6a57c6-fc3d-4c31-83dc-179ee366a654" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_0f369f95-895f-4471-965f-681c79d98e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="bhc-20211231.xsd#SEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3a65ff37-57d4-439b-b59f-2b000d164c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_6c6686af-3566-4344-bda0-f6a63d73c5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3a65ff37-57d4-439b-b59f-2b000d164c3d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_6c6686af-3566-4344-bda0-f6a63d73c5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_f051eae8-2166-475b-a085-efaeaff23950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3a65ff37-57d4-439b-b59f-2b000d164c3d" xlink:to="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_f051eae8-2166-475b-a085-efaeaff23950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_f798f25e-f447-4686-8d3c-39676d4c96de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3a65ff37-57d4-439b-b59f-2b000d164c3d" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_f798f25e-f447-4686-8d3c-39676d4c96de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_ad76c9ae-6f21-4814-955e-d85d7c7af407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3a65ff37-57d4-439b-b59f-2b000d164c3d" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_ad76c9ae-6f21-4814-955e-d85d7c7af407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_d2d7045f-1a0a-4be0-aa2c-50aff7dccb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3a65ff37-57d4-439b-b59f-2b000d164c3d" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_d2d7045f-1a0a-4be0-aa2c-50aff7dccb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_28af1ce9-d012-46b8-83d6-89dd3d1f67c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3a65ff37-57d4-439b-b59f-2b000d164c3d" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_28af1ce9-d012-46b8-83d6-89dd3d1f67c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_dcac141a-0abd-4d19-86a7-038e873837a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7576e8d8-9a1e-4450-a423-d522e86c158e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_dcac141a-0abd-4d19-86a7-038e873837a5" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7576e8d8-9a1e-4450-a423-d522e86c158e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3f6dbee9-bc0c-427f-8f67-54d5d887fb16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7576e8d8-9a1e-4450-a423-d522e86c158e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3f6dbee9-bc0c-427f-8f67-54d5d887fb16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_246eb1eb-e359-432e-b78a-7d1775fe4415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3f6dbee9-bc0c-427f-8f67-54d5d887fb16" xlink:to="loc_us-gaap_SegmentDomain_246eb1eb-e359-432e-b78a-7d1775fe4415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_929b10fb-bd7c-4595-97e6-5d3a5d220d72" xlink:href="bhc-20211231.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_246eb1eb-e359-432e-b78a-7d1775fe4415" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_929b10fb-bd7c-4595-97e6-5d3a5d220d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_9931bb6c-8e32-4512-957d-05fccb2f9fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7576e8d8-9a1e-4450-a423-d522e86c158e" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_9931bb6c-8e32-4512-957d-05fccb2f9fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_3ae45abb-e958-4454-a840-b2177ab84c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9931bb6c-8e32-4512-957d-05fccb2f9fb4" xlink:to="loc_us-gaap_NumberOfReportingUnits_3ae45abb-e958-4454-a840-b2177ab84c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_df234cbb-389b-4ef8-babc-748b489cb116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e1a00077-551d-4d76-8f95-1a17ad148fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_df234cbb-389b-4ef8-babc-748b489cb116" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e1a00077-551d-4d76-8f95-1a17ad148fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_1f67f9dc-a9da-4a1f-ad71-7d80a40e9073" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e1a00077-551d-4d76-8f95-1a17ad148fa1" xlink:to="loc_srt_ConsolidationItemsAxis_1f67f9dc-a9da-4a1f-ad71-7d80a40e9073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_1dc7a88d-e840-4323-9ff4-bd0177d1dea1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_1f67f9dc-a9da-4a1f-ad71-7d80a40e9073" xlink:to="loc_srt_ConsolidationItemsDomain_1dc7a88d-e840-4323-9ff4-bd0177d1dea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_667cbdb1-cec1-4750-a1aa-9b1e201f9e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_1dc7a88d-e840-4323-9ff4-bd0177d1dea1" xlink:to="loc_us-gaap_OperatingSegmentsMember_667cbdb1-cec1-4750-a1aa-9b1e201f9e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_cea2f4ee-17a1-4557-b358-20121ae1207a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_1dc7a88d-e840-4323-9ff4-bd0177d1dea1" xlink:to="loc_us-gaap_CorporateNonSegmentMember_cea2f4ee-17a1-4557-b358-20121ae1207a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_cdccc784-a14e-46b2-b7d9-1e5e75311561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e1a00077-551d-4d76-8f95-1a17ad148fa1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_cdccc784-a14e-46b2-b7d9-1e5e75311561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fbf55f20-5e3b-484e-b386-95eb6f19313f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cdccc784-a14e-46b2-b7d9-1e5e75311561" xlink:to="loc_us-gaap_SegmentDomain_fbf55f20-5e3b-484e-b386-95eb6f19313f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_7d4fe7f4-6d89-446a-bd62-14528ecc10cc" xlink:href="bhc-20211231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_fbf55f20-5e3b-484e-b386-95eb6f19313f" xlink:to="loc_bhc_BauschLombMember_7d4fe7f4-6d89-446a-bd62-14528ecc10cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_00393496-bfd8-4272-bf3c-038a93728ae7" xlink:href="bhc-20211231.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_fbf55f20-5e3b-484e-b386-95eb6f19313f" xlink:to="loc_bhc_SalixSegmentMember_00393496-bfd8-4272-bf3c-038a93728ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_72d1bf30-22ec-4252-81ff-6456596d24a7" xlink:href="bhc-20211231.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_fbf55f20-5e3b-484e-b386-95eb6f19313f" xlink:to="loc_bhc_InternationalRxMember_72d1bf30-22ec-4252-81ff-6456596d24a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_636068d8-7a71-4401-bbaa-dd7618f42ec5" xlink:href="bhc-20211231.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_fbf55f20-5e3b-484e-b386-95eb6f19313f" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_636068d8-7a71-4401-bbaa-dd7618f42ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_7a913ca8-645a-4340-99a3-d0d60a63f877" xlink:href="bhc-20211231.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_fbf55f20-5e3b-484e-b386-95eb6f19313f" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_7a913ca8-645a-4340-99a3-d0d60a63f877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e1a00077-551d-4d76-8f95-1a17ad148fa1" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_46730e14-f62d-4367-97c9-3a6f52e4e147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_46730e14-f62d-4367-97c9-3a6f52e4e147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_844f6927-cffc-4a00-95c9-2f0a20450c52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_us-gaap_OperatingIncomeLoss_844f6927-cffc-4a00-95c9-2f0a20450c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_04ea0d93-e692-49c9-87a5-0b3333a03f7f" xlink:href="bhc-20211231.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_04ea0d93-e692-49c9-87a5-0b3333a03f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_a0acaa7c-a502-44a7-a554-178eee49a9d4" xlink:href="bhc-20211231.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_a0acaa7c-a502-44a7-a554-178eee49a9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_9dce739c-187f-4574-8f0c-2a7934ce6d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_us-gaap_AssetImpairmentCharges_9dce739c-187f-4574-8f0c-2a7934ce6d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_606f8810-b860-4cd3-902e-bd3a4dfdb6c6" xlink:href="bhc-20211231.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_606f8810-b860-4cd3-902e-bd3a4dfdb6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_42255b69-0995-4d0f-a58e-6e6192cf24f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_42255b69-0995-4d0f-a58e-6e6192cf24f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_cf5c8444-cbbb-4e07-bcaf-9c0eaeeaf2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_us-gaap_InvestmentIncomeInterest_cf5c8444-cbbb-4e07-bcaf-9c0eaeeaf2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense_65cd7fb9-395c-4350-ae54-725b13f812e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_us-gaap_InterestAndDebtExpense_65cd7fb9-395c-4350-ae54-725b13f812e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fb662220-df25-4cb9-81f2-bc6cef4653e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fb662220-df25-4cb9-81f2-bc6cef4653e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b3d6de1d-e158-4cbc-a19d-2e0a0857810b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b3d6de1d-e158-4cbc-a19d-2e0a0857810b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e1adcc3d-f68a-485f-b29e-6ab990703c33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e1adcc3d-f68a-485f-b29e-6ab990703c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_8c5cd505-6060-4ff4-aef7-ddc7e1468c6b" xlink:href="bhc-20211231.xsd#bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2036fb7d-b2ff-4efc-a95a-b1ee55d52c35" xlink:to="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_8c5cd505-6060-4ff4-aef7-ddc7e1468c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_4e52c549-75fe-4837-a072-9e4ef9f9fd96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_8c5cd505-6060-4ff4-aef7-ddc7e1468c6b" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_4e52c549-75fe-4837-a072-9e4ef9f9fd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_aa7647a3-a5f0-498c-99a9-cb4661dca7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8ec5d3c8-0f34-456e-ae9d-4a6c9f5baf08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_aa7647a3-a5f0-498c-99a9-cb4661dca7ab" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8ec5d3c8-0f34-456e-ae9d-4a6c9f5baf08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_835f8303-5747-47ce-9c51-4c5c93659f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8ec5d3c8-0f34-456e-ae9d-4a6c9f5baf08" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_835f8303-5747-47ce-9c51-4c5c93659f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_16475f8e-465e-47ba-b285-bbab1f5dfc41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_835f8303-5747-47ce-9c51-4c5c93659f7d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_16475f8e-465e-47ba-b285-bbab1f5dfc41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_a27179b7-c664-45cb-8529-2e996fb25a91" xlink:href="bhc-20211231.xsd#bhc_RevenuesNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_16475f8e-465e-47ba-b285-bbab1f5dfc41" xlink:to="loc_bhc_RevenuesNetMember_a27179b7-c664-45cb-8529-2e996fb25a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c3eac151-ff0a-484f-89bb-e8498a19b864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8ec5d3c8-0f34-456e-ae9d-4a6c9f5baf08" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c3eac151-ff0a-484f-89bb-e8498a19b864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_04291016-a062-46cf-8731-b4b14ad65e84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c3eac151-ff0a-484f-89bb-e8498a19b864" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_04291016-a062-46cf-8731-b4b14ad65e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_55f2d5a6-1aac-46e1-adab-43bbc10bd9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_04291016-a062-46cf-8731-b4b14ad65e84" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_55f2d5a6-1aac-46e1-adab-43bbc10bd9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2d39c864-3603-46f8-8ae3-34ed4836d886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8ec5d3c8-0f34-456e-ae9d-4a6c9f5baf08" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2d39c864-3603-46f8-8ae3-34ed4836d886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e50406bf-d683-4675-a37c-2aab8f92436d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2d39c864-3603-46f8-8ae3-34ed4836d886" xlink:to="loc_us-gaap_SegmentDomain_e50406bf-d683-4675-a37c-2aab8f92436d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_fe6c933f-dcaf-4ae0-9808-1529e8c4145e" xlink:href="bhc-20211231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e50406bf-d683-4675-a37c-2aab8f92436d" xlink:to="loc_bhc_BauschLombMember_fe6c933f-dcaf-4ae0-9808-1529e8c4145e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_7bfcb3f8-6761-41ed-b31e-b38e3b6149d2" xlink:href="bhc-20211231.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e50406bf-d683-4675-a37c-2aab8f92436d" xlink:to="loc_bhc_SalixSegmentMember_7bfcb3f8-6761-41ed-b31e-b38e3b6149d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_bd5c3447-80ca-428c-a554-2a6014ce0b9f" xlink:href="bhc-20211231.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e50406bf-d683-4675-a37c-2aab8f92436d" xlink:to="loc_bhc_InternationalRxMember_bd5c3447-80ca-428c-a554-2a6014ce0b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_37cfdd27-ff0a-438e-8144-bcdaf758ec7c" xlink:href="bhc-20211231.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e50406bf-d683-4675-a37c-2aab8f92436d" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_37cfdd27-ff0a-438e-8144-bcdaf758ec7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_38a927fc-19eb-486f-a460-71f347feaae1" xlink:href="bhc-20211231.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e50406bf-d683-4675-a37c-2aab8f92436d" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_38a927fc-19eb-486f-a460-71f347feaae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_00aba816-ac98-4938-b404-da807211a9c5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8ec5d3c8-0f34-456e-ae9d-4a6c9f5baf08" xlink:to="loc_srt_ProductOrServiceAxis_00aba816-ac98-4938-b404-da807211a9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_26380b38-80f0-485e-8119-973a557c5bbb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_00aba816-ac98-4938-b404-da807211a9c5" xlink:to="loc_srt_ProductsAndServicesDomain_26380b38-80f0-485e-8119-973a557c5bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember_fd942322-eb04-4a64-bd55-181b69542130" xlink:href="bhc-20211231.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_26380b38-80f0-485e-8119-973a557c5bbb" xlink:to="loc_bhc_PharmaceuticalProductsMember_fd942322-eb04-4a64-bd55-181b69542130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember_787187ed-377d-4d82-bf7b-1a3361052353" xlink:href="bhc-20211231.xsd#bhc_DeviceProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_26380b38-80f0-485e-8119-973a557c5bbb" xlink:to="loc_bhc_DeviceProductsMember_787187ed-377d-4d82-bf7b-1a3361052353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember_0d73129c-6186-4722-b2c2-97ea9a60169c" xlink:href="bhc-20211231.xsd#bhc_OvertheCounterProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_26380b38-80f0-485e-8119-973a557c5bbb" xlink:to="loc_bhc_OvertheCounterProductsMember_0d73129c-6186-4722-b2c2-97ea9a60169c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember_4d0bf36b-596b-4c62-9b03-3602345fe8be" xlink:href="bhc-20211231.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_26380b38-80f0-485e-8119-973a557c5bbb" xlink:to="loc_bhc_BrandedandOtherGenericProductsMember_4d0bf36b-596b-4c62-9b03-3602345fe8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember_54b53886-c1ed-4853-85ed-49de1e060a7e" xlink:href="bhc-20211231.xsd#bhc_OtherRevenuesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_26380b38-80f0-485e-8119-973a557c5bbb" xlink:to="loc_bhc_OtherRevenuesMember_54b53886-c1ed-4853-85ed-49de1e060a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_cd7cb0a4-d396-4d76-9766-f39bde4fc498" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8ec5d3c8-0f34-456e-ae9d-4a6c9f5baf08" xlink:to="loc_srt_MajorCustomersAxis_cd7cb0a4-d396-4d76-9766-f39bde4fc498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_73c70877-0324-4170-a798-8c47eab9d0a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_cd7cb0a4-d396-4d76-9766-f39bde4fc498" xlink:to="loc_srt_NameOfMajorCustomerDomain_73c70877-0324-4170-a798-8c47eab9d0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CustomerTopTenProductsMember_0a9020ce-a4cc-4427-bad5-fccbeeafc41c" xlink:href="bhc-20211231.xsd#bhc_CustomerTopTenProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_73c70877-0324-4170-a798-8c47eab9d0a7" xlink:to="loc_bhc_CustomerTopTenProductsMember_0a9020ce-a4cc-4427-bad5-fccbeeafc41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_02a89acb-cc48-4af4-b40b-caf4c7537961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8ec5d3c8-0f34-456e-ae9d-4a6c9f5baf08" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_02a89acb-cc48-4af4-b40b-caf4c7537961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts_57fc88d5-d26f-4314-a504-4fe7100aba26" xlink:href="bhc-20211231.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_02a89acb-cc48-4af4-b40b-caf4c7537961" xlink:to="loc_bhc_ConcentrationRiskNumberOfProducts_57fc88d5-d26f-4314-a504-4fe7100aba26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c15634d3-0aca-4bb0-80ac-6b3f65dddcea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_02a89acb-cc48-4af4-b40b-caf4c7537961" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c15634d3-0aca-4bb0-80ac-6b3f65dddcea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3e4eb4d8-dbf3-44b8-8a67-025a8a84a4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_02a89acb-cc48-4af4-b40b-caf4c7537961" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3e4eb4d8-dbf3-44b8-8a67-025a8a84a4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SEGMENTINFORMATIONGeographicInformationRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1ce48a4d-8b69-4d5f-a4e8-a7f041c526ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b62eea33-c549-41d9-8e6d-baf9d2d1af71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1ce48a4d-8b69-4d5f-a4e8-a7f041c526ad" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b62eea33-c549-41d9-8e6d-baf9d2d1af71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_54724a1c-d7c8-4595-9729-a53949d30917" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b62eea33-c549-41d9-8e6d-baf9d2d1af71" xlink:to="loc_srt_StatementGeographicalAxis_54724a1c-d7c8-4595-9729-a53949d30917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_54724a1c-d7c8-4595-9729-a53949d30917" xlink:to="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember_ae93adde-8f21-404e-823f-92187380ca46" xlink:href="bhc-20211231.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_bhc_UnitedStatesandPuertoRicoMember_ae93adde-8f21-404e-823f-92187380ca46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_1936d9a5-19a4-403a-89ec-ff009c21b317" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_CN_1936d9a5-19a4-403a-89ec-ff009c21b317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_448b45f1-14f4-41c2-8b22-7562fb7e48cd" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_CA_448b45f1-14f4-41c2-8b22-7562fb7e48cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL_191e1234-8ed3-4eb2-871d-1e6c00040229" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_PL"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_PL_191e1234-8ed3-4eb2-871d-1e6c00040229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_31f77081-40a9-4d82-9422-a639d8573851" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MX"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_MX_31f77081-40a9-4d82-9422-a639d8573851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_425c654c-be8d-4219-84c3-69955c806929" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_JP_425c654c-be8d-4219-84c3-69955c806929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_6eb4567d-c735-4fe6-94e6-de12fd802be4" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_FR"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_FR_6eb4567d-c735-4fe6-94e6-de12fd802be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU_35fe83af-b391-44a0-b26a-e4d5b594ea40" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_RU"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_RU_35fe83af-b391-44a0-b26a-e4d5b594ea40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_EG_c8a59956-a2a1-4b57-8950-b3707805f24e" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_EG"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_EG_c8a59956-a2a1-4b57-8950-b3707805f24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_84e45e69-2f2b-4fd9-8397-787efe2a717a" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_DE_84e45e69-2f2b-4fd9-8397-787efe2a717a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_58dcd54a-b5c1-4a3f-a47e-7facf85bc712" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_GB_58dcd54a-b5c1-4a3f-a47e-7facf85bc712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES_0e64397d-698d-4b78-a62c-018ea1a8ba62" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_ES"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_ES_0e64397d-698d-4b78-a62c-018ea1a8ba62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT_3f03bef0-fc63-4898-9b57-b8640d0c61a0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IT"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_country_IT_3f03bef0-fc63-4898-9b57-b8640d0c61a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember_60fb2223-aa85-44af-8fbf-ba410157606a" xlink:href="bhc-20211231.xsd#bhc_OtherCountriesMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_466f8b5e-481d-47e9-93b3-ead291bfcd42" xlink:to="loc_bhc_OtherCountriesMember_60fb2223-aa85-44af-8fbf-ba410157606a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0a80b2ed-a288-458d-aa57-9423760b9cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b62eea33-c549-41d9-8e6d-baf9d2d1af71" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0a80b2ed-a288-458d-aa57-9423760b9cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a7652fef-678d-4e9f-9339-6337447d2a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0a80b2ed-a288-458d-aa57-9423760b9cc4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a7652fef-678d-4e9f-9339-6337447d2a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7cebb928-d766-4eda-910d-3a889df9bb20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_4a27adef-f73c-4a56-9645-95963da28be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7cebb928-d766-4eda-910d-3a889df9bb20" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_4a27adef-f73c-4a56-9645-95963da28be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_db37e7dd-da4f-44be-8590-c30b659df387" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_4a27adef-f73c-4a56-9645-95963da28be9" xlink:to="loc_srt_StatementGeographicalAxis_db37e7dd-da4f-44be-8590-c30b659df387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_db37e7dd-da4f-44be-8590-c30b659df387" xlink:to="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember_e7555743-e5b9-43fb-b1d5-90aa23f633cd" xlink:href="bhc-20211231.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:to="loc_bhc_UnitedStatesandPuertoRicoMember_e7555743-e5b9-43fb-b1d5-90aa23f633cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_33c2c6fa-1a3f-4b80-a9b7-5d67b01af271" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:to="loc_country_IE_33c2c6fa-1a3f-4b80-a9b7-5d67b01af271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_488861c7-d3a8-4559-9848-33aeb5a8b33b" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:to="loc_country_CA_488861c7-d3a8-4559-9848-33aeb5a8b33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL_bd5080df-1dd6-4ba7-b5f7-372d281b482f" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_PL"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:to="loc_country_PL_bd5080df-1dd6-4ba7-b5f7-372d281b482f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_5557f3f3-e7ae-453b-92cb-9bdc9f63ebe0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:to="loc_country_DE_5557f3f3-e7ae-453b-92cb-9bdc9f63ebe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_1ae3eb6c-9dc9-4529-ada9-1e25872bb686" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MX"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:to="loc_country_MX_1ae3eb6c-9dc9-4529-ada9-1e25872bb686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_5664a0c3-99ec-4df9-95ae-ae0db5394292" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_FR"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:to="loc_country_FR_5664a0c3-99ec-4df9-95ae-ae0db5394292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_3a5f46d3-63a9-4534-9b30-49f25ece1ee7" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:to="loc_country_CN_3a5f46d3-63a9-4534-9b30-49f25ece1ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RS_81694a94-3c10-4866-a655-c4e83cae9358" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_RS"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:to="loc_country_RS_81694a94-3c10-4866-a655-c4e83cae9358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT_7e606d6c-6bcb-45d4-90a7-aac714f9d6a1" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IT"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:to="loc_country_IT_7e606d6c-6bcb-45d4-90a7-aac714f9d6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember_d05431bf-2f18-4061-a6b6-7b5e9b552e95" xlink:href="bhc-20211231.xsd#bhc_OtherCountriesMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e12a739e-df3d-478b-a106-2b9a94b03374" xlink:to="loc_bhc_OtherCountriesMember_d05431bf-2f18-4061-a6b6-7b5e9b552e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c897bffb-b5b8-4276-8bf2-f377783ab36a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_4a27adef-f73c-4a56-9645-95963da28be9" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c897bffb-b5b8-4276-8bf2-f377783ab36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_159a89b4-6fa3-4973-af18-0128568e958b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c897bffb-b5b8-4276-8bf2-f377783ab36a" xlink:to="loc_us-gaap_NoncurrentAssets_159a89b4-6fa3-4973-af18-0128568e958b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SEGMENTINFORMATIONMajorCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2589f8ba-449c-47d6-ab69-888800a15d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7df998e6-5224-4874-b323-4deb224ee03f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2589f8ba-449c-47d6-ab69-888800a15d4d" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7df998e6-5224-4874-b323-4deb224ee03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b3ff009c-0582-4b2f-842a-d570ec0b9640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7df998e6-5224-4874-b323-4deb224ee03f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b3ff009c-0582-4b2f-842a-d570ec0b9640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_14f610b4-a91f-429d-949e-0283c6f9c487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b3ff009c-0582-4b2f-842a-d570ec0b9640" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_14f610b4-a91f-429d-949e-0283c6f9c487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_eeb398e5-b976-4569-ab1f-25c4fa27e095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_14f610b4-a91f-429d-949e-0283c6f9c487" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_eeb398e5-b976-4569-ab1f-25c4fa27e095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4a6e055b-bbf8-4566-a1a3-c73b0d9480b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7df998e6-5224-4874-b323-4deb224ee03f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4a6e055b-bbf8-4566-a1a3-c73b0d9480b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_86e8399a-0261-4b6f-8882-3054b6461e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4a6e055b-bbf8-4566-a1a3-c73b0d9480b5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_86e8399a-0261-4b6f-8882-3054b6461e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_72046388-ee2a-47e0-991f-ea846d5e3bbb" xlink:href="bhc-20211231.xsd#bhc_RevenuesNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_86e8399a-0261-4b6f-8882-3054b6461e6d" xlink:to="loc_bhc_RevenuesNetMember_72046388-ee2a-47e0-991f-ea846d5e3bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ba1c68b0-8445-4ec7-bdac-260f55d14c82" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7df998e6-5224-4874-b323-4deb224ee03f" xlink:to="loc_srt_MajorCustomersAxis_ba1c68b0-8445-4ec7-bdac-260f55d14c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_77e63bf6-d635-468b-a6e4-f139acaaa414" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_ba1c68b0-8445-4ec7-bdac-260f55d14c82" xlink:to="loc_srt_NameOfMajorCustomerDomain_77e63bf6-d635-468b-a6e4-f139acaaa414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember_e22a2ad1-e30d-4cf7-a63b-3cfdec32f84d" xlink:href="bhc-20211231.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_77e63bf6-d635-468b-a6e4-f139acaaa414" xlink:to="loc_bhc_AmerisourceBergenCorporationMember_e22a2ad1-e30d-4cf7-a63b-3cfdec32f84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember_9c11650f-28b7-4c5d-9ae3-6d63064f15ed" xlink:href="bhc-20211231.xsd#bhc_McKessonCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_77e63bf6-d635-468b-a6e4-f139acaaa414" xlink:to="loc_bhc_McKessonCorporationMember_9c11650f-28b7-4c5d-9ae3-6d63064f15ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember_c4221645-9ba3-4625-9544-1166b7dc3692" xlink:href="bhc-20211231.xsd#bhc_CardinalHealthIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_77e63bf6-d635-468b-a6e4-f139acaaa414" xlink:to="loc_bhc_CardinalHealthIncMember_c4221645-9ba3-4625-9544-1166b7dc3692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_98ec0f60-f19d-4112-b437-b695b8d59146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7df998e6-5224-4874-b323-4deb224ee03f" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_98ec0f60-f19d-4112-b437-b695b8d59146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b5f798dc-6057-4f3c-afff-01626d13a174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_98ec0f60-f19d-4112-b437-b695b8d59146" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b5f798dc-6057-4f3c-afff-01626d13a174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="bhc-20211231.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_da2bea28-4cd9-4dff-a481-692f4c7d66b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_81a2852c-8bf7-4075-beea-95dc7c92e7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_da2bea28-4cd9-4dff-a481-692f4c7d66b4" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_81a2852c-8bf7-4075-beea-95dc7c92e7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20211231.xsd#SUBSEQUENTEVENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_e1680cbf-116e-402b-a1e3-e1977c7effc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_88354868-26cd-4c77-b762-8787f4c88d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_e1680cbf-116e-402b-a1e3-e1977c7effc9" xlink:to="loc_us-gaap_SubsequentEventTable_88354868-26cd-4c77-b762-8787f4c88d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e3764252-d6da-495f-bf06-ef7b5be306d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_88354868-26cd-4c77-b762-8787f4c88d6a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e3764252-d6da-495f-bf06-ef7b5be306d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ed9fcf22-17cc-4016-bfc6-eaeb7283677d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e3764252-d6da-495f-bf06-ef7b5be306d7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ed9fcf22-17cc-4016-bfc6-eaeb7283677d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_aabcb07b-4d79-4b1f-8d98-f261ecb45f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ed9fcf22-17cc-4016-bfc6-eaeb7283677d" xlink:to="loc_us-gaap_SubsequentEventMember_aabcb07b-4d79-4b1f-8d98-f261ecb45f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f5fa0e36-8182-4f68-ad66-72bea00f8fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_88354868-26cd-4c77-b762-8787f4c88d6a" xlink:to="loc_us-gaap_DebtInstrumentAxis_f5fa0e36-8182-4f68-ad66-72bea00f8fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f2f9fb39-6e58-4237-b3ee-61a9d0429611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f5fa0e36-8182-4f68-ad66-72bea00f8fbb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f2f9fb39-6e58-4237-b3ee-61a9d0429611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member_46956b35-4355-47fc-8a7c-4161a2442b53" xlink:href="bhc-20211231.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2f9fb39-6e58-4237-b3ee-61a9d0429611" xlink:to="loc_bhc_A9.00SeniorNotesdueDecember2025Member_46956b35-4355-47fc-8a7c-4161a2442b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NewRestatedCreditAgreementMember_98c3651d-32b5-491e-99d6-0577b2105eb2" xlink:href="bhc-20211231.xsd#bhc_NewRestatedCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2f9fb39-6e58-4237-b3ee-61a9d0429611" xlink:to="loc_bhc_NewRestatedCreditAgreementMember_98c3651d-32b5-491e-99d6-0577b2105eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember_34ed3ace-5f73-492b-b88f-c99f2da66415" xlink:href="bhc-20211231.xsd#bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_NewRestatedCreditAgreementMember_98c3651d-32b5-491e-99d6-0577b2105eb2" xlink:to="loc_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember_34ed3ace-5f73-492b-b88f-c99f2da66415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember_faed70ce-165b-49f5-9df0-26e4819faaa2" xlink:href="bhc-20211231.xsd#bhc_TermLoanBFacilityNewRestatedCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_NewRestatedCreditAgreementMember_98c3651d-32b5-491e-99d6-0577b2105eb2" xlink:to="loc_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember_faed70ce-165b-49f5-9df0-26e4819faaa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_3be9d9fa-afdf-4bb2-aa5b-0749a8d15ae6" xlink:href="bhc-20211231.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2f9fb39-6e58-4237-b3ee-61a9d0429611" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_3be9d9fa-afdf-4bb2-aa5b-0749a8d15ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_df40335d-a2cb-4c16-998b-e3dc2ff0b25e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_88354868-26cd-4c77-b762-8787f4c88d6a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_df40335d-a2cb-4c16-998b-e3dc2ff0b25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c2eefea4-8009-490a-bd0c-aa8ad26029d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_df40335d-a2cb-4c16-998b-e3dc2ff0b25e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c2eefea4-8009-490a-bd0c-aa8ad26029d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_dcd65869-f11e-4185-abb2-e47ed30f12da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c2eefea4-8009-490a-bd0c-aa8ad26029d8" xlink:to="loc_us-gaap_UnsecuredDebtMember_dcd65869-f11e-4185-abb2-e47ed30f12da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_ff9b81e2-0402-4080-aa01-25743db74b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c2eefea4-8009-490a-bd0c-aa8ad26029d8" xlink:to="loc_us-gaap_SecuredDebtMember_ff9b81e2-0402-4080-aa01-25743db74b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_5bd7585f-3373-4eb3-802b-0ddf18adee6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_88354868-26cd-4c77-b762-8787f4c88d6a" xlink:to="loc_us-gaap_CreditFacilityAxis_5bd7585f-3373-4eb3-802b-0ddf18adee6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a494c137-c1b7-43e0-8f16-f0cbfb431d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_5bd7585f-3373-4eb3-802b-0ddf18adee6b" xlink:to="loc_us-gaap_CreditFacilityDomain_a494c137-c1b7-43e0-8f16-f0cbfb431d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_855f7b05-5f5b-44ec-9ec7-677252c182b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_a494c137-c1b7-43e0-8f16-f0cbfb431d92" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_855f7b05-5f5b-44ec-9ec7-677252c182b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_19de523a-c00f-4c37-95e4-28c029249789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_88354868-26cd-4c77-b762-8787f4c88d6a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_19de523a-c00f-4c37-95e4-28c029249789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e6a228f1-a904-4d92-bb30-609c76c492d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_19de523a-c00f-4c37-95e4-28c029249789" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e6a228f1-a904-4d92-bb30-609c76c492d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_2f0c8c32-3421-4646-a80e-38e8c6c9218e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e6a228f1-a904-4d92-bb30-609c76c492d1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_2f0c8c32-3421-4646-a80e-38e8c6c9218e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_8a0f38e2-9385-4efb-9555-2401ac7e68f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e6a228f1-a904-4d92-bb30-609c76c492d1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_8a0f38e2-9385-4efb-9555-2401ac7e68f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_74251b6e-ef78-4208-a9d8-f3d06cf2a051" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_88354868-26cd-4c77-b762-8787f4c88d6a" xlink:to="loc_srt_RangeAxis_74251b6e-ef78-4208-a9d8-f3d06cf2a051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dbbd750c-19fa-48ac-a361-e8f6c5321d8a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_74251b6e-ef78-4208-a9d8-f3d06cf2a051" xlink:to="loc_srt_RangeMember_dbbd750c-19fa-48ac-a361-e8f6c5321d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_627b3e3e-10ad-439c-a05f-878aa2fb3c70" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dbbd750c-19fa-48ac-a361-e8f6c5321d8a" xlink:to="loc_srt_MaximumMember_627b3e3e-10ad-439c-a05f-878aa2fb3c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_7d9b2cd6-c53e-4fd3-a80a-34a50cf741df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_88354868-26cd-4c77-b762-8787f4c88d6a" xlink:to="loc_us-gaap_SubsequentEventLineItems_7d9b2cd6-c53e-4fd3-a80a-34a50cf741df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_f990d35b-6d39-4b16-8b44-e187fa57cace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7d9b2cd6-c53e-4fd3-a80a-34a50cf741df" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_f990d35b-6d39-4b16-8b44-e187fa57cace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_a4d85345-facd-4145-8340-be7425dede1f" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7d9b2cd6-c53e-4fd3-a80a-34a50cf741df" xlink:to="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_a4d85345-facd-4145-8340-be7425dede1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentExpectedFaceAmount_4c9c26e4-7d43-4241-9b76-0ec711ae678d" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentExpectedFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7d9b2cd6-c53e-4fd3-a80a-34a50cf741df" xlink:to="loc_bhc_DebtInstrumentExpectedFaceAmount_4c9c26e4-7d43-4241-9b76-0ec711ae678d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity_50a7f3f1-7d38-48a7-8bea-b118350ee84b" xlink:href="bhc-20211231.xsd#bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7d9b2cd6-c53e-4fd3-a80a-34a50cf741df" xlink:to="loc_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity_50a7f3f1-7d38-48a7-8bea-b118350ee84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_042cc77a-b977-4586-a2f9-45dafa8ae8bb" xlink:href="bhc-20211231.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatio"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7d9b2cd6-c53e-4fd3-a80a-34a50cf741df" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_042cc77a-b977-4586-a2f9-45dafa8ae8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_62af00d0-6113-4b28-b39c-98465349d128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7d9b2cd6-c53e-4fd3-a80a-34a50cf741df" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_62af00d0-6113-4b28-b39c-98465349d128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d6844fde-22d3-433a-8f14-423e1a1ce0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7d9b2cd6-c53e-4fd3-a80a-34a50cf741df" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d6844fde-22d3-433a-8f14-423e1a1ce0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_edc43eda-ccff-4f3a-b8e9-730d0c262ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7d9b2cd6-c53e-4fd3-a80a-34a50cf741df" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_edc43eda-ccff-4f3a-b8e9-730d0c262ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_ed8e8f35-4361-4747-b646-73389db03724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7d9b2cd6-c53e-4fd3-a80a-34a50cf741df" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_ed8e8f35-4361-4747-b646-73389db03724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>bhc-20211231_g1.jpg
<DESCRIPTION>PERFORMANCEGRAPH
<TEXT>
begin 644 bhc-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1"@17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0>NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UO<F5A+"!#
M:&%R;&5S     >H<  <   @,   (;      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG/X5<[RBJNE:C#J^CV>I6@<07D"7$0<88*ZAAD>N#5JHV):L[!1110(****
M/,],^!7AK2O&BZU;W%\;&&1+BVT=IC]F@G5F8.!W +$JIZ$MR0<!LGP-TW^W
M]2UFS\8>+["\U.8RW+V6I)#O))('$>2!G !S@5Z=10!P?B?X0:!XJU5=0O+W
M5[69[=+:]%E>>4NH1+C"SC!W=.V#^0Q8\4_"S0O%"Z<1<:CHL^G0&UM[G2+C
MR)! 5P822""F.V/YG/:44 9^@Z'I_AK0;31]&@%O96<?EQ1YS@=22>Y)))/J
M:T*** ,[P]_R+.E_]><7_H K1K.\/?\ (LZ7_P!><7_H K1H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBJ]_J%GI5A->ZE<Q6MK"NZ2:9PJH/<FFDV[("Q7"?$#XN>'/ $+0W<WV
MW5-N4T^W8%_8N>B#Z\^@->9^+?C3K_C?6#X7^$EI<'S"5:_5,2N.A*YXC3_:
M;!_W:Z'P!^SYINC3+JWC:5=;U5F\PPL2T$;=<G/,A]VX]N]>G'"4Z$5/%.W:
M*W?KV(YF](G%"/XI?'5\NW]B>&I#_M1PNOT^],?_ !W(_AKU;P5\$?"/@Z..
M9[1=6U%<$W=Z@;!_V$^ZOZGWKT155%"H JJ,  8 %+65;'5)QY*?NQ[+]7U&
MHK=A1117 4%%%% !1110 5EZ]X9T7Q18_9/$&F6]_#V$R9*>ZMU4^X(K4HIQ
MDXNZ=F!X!XG_ &>+W1[X:S\+M7GL[N([DM)9BC#V24?R;\34/AWX]Z]X5U-=
M"^*^CSQRI@&\2'9*!TW,GW7'^TN/H:^A:Q_$OA31/%^EFP\0Z?%>0\[2XPT9
M]58<J?I7I1QRJ+DQ4>9=^J^9'+;8LZ+KFF>(M,CU#0[Z&^M)/NRPMD9]#W!]
MCR*OU\W:U\*/&WPKU.37OACJ5Q>V0^:6U S*%'9X_NRCW S[#K7;?#KX]Z-X
MJ:/3?$8CT76"=HWMB"9O]EC]T_[+?@34U<%[OM:#YH_BO5 I=&>MT445YQ84
M444 %%%% !1110 4444 %%1SSPVT+2W,J0QK]YY&"@?B:Y'6/BMX2T@,/[2%
M[*/^6=DOF9_X%]W]:B=2$%>3L=6'P>(Q4N6A!R]%<[*D=UC0O(P55&2S'  K
MQ>_^-.MZJ9(_"NAB-5^]/,#*5'J0,*OXDBN(U?5;_67+^+O%#2C.?LMJ?/Q]
M%4B(?]]9]JXIXZFO@5_P1Z\LE6$7/F5>%%=F[R^44>U>(/BSX7T+=''='4KE
M?^65GAP#[O\ =_(D^U<+<^/_ !WXR1_^$;L1I6GC[]R" %'?=,^%'X8-<=HX
M>ZN/*\'^&'O[@'_CYO$^TE#Z[<"-?^!!OK7;6WPG\6^)7CF\8ZW]GB7[L ?S
M63V"C"+^'Y5R^VKU_AO;RT_%G+_;65873+L.ZTOYIZ1^4?\ /4Y26P\,:?<-
M=>*_$,^OWQ.7M]-)=6/^U._4?[O-;.DZ]XJU> V7PY\-1:-9-P9X(P6;_>G?
M@G]:]*T+X4^%-#VN+#[=.O\ RUO3YG_COW?TKLE540*BA548  P *WIX.:W?
M+Z;_ 'GEXW,,US/3%UK1_ECHCQ_3/@G>ZE<_;?&FN2W$S<M' Y=C]9'_ *#\
M:]%T'P;H'AI1_9&F0PR 8,[#?(?^!')_ <5N45V4\/2IZQ6IQTL+1I:Q6O?J
M%%%%;G2%%%8NM>,O#GAX-_;.M6=HZ]8GE!D_[X&6/Y4TFW9#47)V2-JBO(]:
M_:*\,V6Y-&LKS5)!T8@0QG\6RW_CM<Y_PLGXJ^,OE\)^'_L-N_W9DM\_^19?
MD_05T+#5&KO3U.J.#JM7EHO/0]^=UC0O(P55&2S'  KDM:^*?@S0MRWFO6TD
MJ_\ +*U)G;/I\F<?CBO,$^#/CSQ6XE\:^*/+0G/E-*]PR_1<A!^!KK=%^ '@
M_3=KZ@+O59!R?/EV)GV5,?J33]G1C\4K^A7LL/#XYW]/\S"U;]H^R\SR/#>@
MW-Y(QPCW3A,GV5=Q/YBLW^W/C7XS_P"0?8/H]J_\2PBV&/7=(2__ 'S7MND^
M'=&T&/9HVE6=B,8)@A52?J0,G\:9KWBC0_"]G]I\0:I;6$6/E\Z0!G_W5ZL?
M8 U4:D+VIPN_/4/K%*'\."^>IXW:_L_ZYK-P+KQIXJ:67J1&7G<^V]R,?D:[
M?1?@?X(TC:TNGR:E*O\ '>REO_'1A?S%<5XC_:7M3<?8? NBSZI<N=L<URI5
M6/\ LQK\S?CM-8@\+_&GXG'?K]^^A:;)SY,K&W7'IY2?,?\ @?YUV_5\0XWK
M34%Y_P"2,9XVK/1/[M#Z/@@BM;>."VB2&&) D<<:A510,  #H .U/K/T#3&T
M3PUIFE/.;EK&TBMC,5QYA1 N[&3C.,]36A7CRM?0P"BBBD 4444 %%%% !11
M10 4444 9WA[_D6=+_Z\XO\ T 5HUG>'O^19TO\ Z\XO_0!6C0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRH=W+D#U SC/?%=+=:?#>,K3/<*5&!Y-S)$/Q"L,T 5_#W_(LZ7_ -><7_H
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M'DPZC27:,4OQU9RNE_#3PEI.TP:-!,X_CNLS$^^&R!^ KIXH8X(EC@C2.->
MB* !^ KG-8^(GA;0]RWFL0/*O_+*W/FMGT(7./QQ7#:C\=#<S?9O"V@S7,K<
M(UP<D_\ ;-,D_G5.MAZ.B:7I_P  ^:Q>:^TE?$57)^;;9Z_5/4-7T[28O,U2
M_MK-.QGE5,_3)YKR$6OQ;\7\S3-HUL_8M]FQ^"YD_.KNG_ B*67S_$6NSW,C
M'+K;K@D_[[9)_(5/MZD_X<'\]#A^M5I_PJ;]7H;^J_&;PGIVY;:>?49!VMHC
MC/\ O-@?EFN7E^-&OZO(T7A;PP9#T!8/.?R0#'ZUW>E?#+PCI&&AT>&>0?\
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M9?\ 0UW'_@$O_P 75JV_98T)<?:_$.HR^OE1(G\]U>V3ZG8VW_'Q>01GT:0
M_E6=/XNT:'I<F4^D:$_KTK"KGTZ7\2NE]QM#"5)_!!OY,X'3OV;O =D0;I-1
MU#'47%UM!_[]A:Z_2?AAX)T1@^G>&=/5U^[)+%YK#Z,^2*9<>/;<<6EE+(>W
MF,%_EFH/[?\ $M__ ,>.G>4IZ,(C_-N*\>KQ+2F^6-24WVBF_P#@'9'*Z]KR
M2BO-I'9JJHH5%"JHP !@"H;B^M+09NKF*'_?<"N3_L;Q3J'_ !^7WD*>J^;C
M]$XJ>W\!VX.Z]O)93U(C4+^IS7+]>QM7^#AVO.32_#<KZKAH?Q*J_P"W5?\
M$NW7C/2;?(CDDN#Z1I_4XK+D\:WETYCTK3=S=MV7/Y"MZV\,:1:X*6:.WK+E
M_P"?%:<<:1(%B144= HP*7U?,ZW\2LH+M%7_ !8_;8*G\%-R]7^B.,^S^+M4
M_P!;*;6,_P"T(\?]\_-4UOX$#MOU&_>1CU$8Y_[Z/^%=?151R7#-\U=RJ/\
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MZ:_Q7E^9\CWOQHUZZ)\SQ%J!SW@_=?\ H.*KCQAI&I8_MOQ)JS9^]_HS3_\
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M@G2,&U\/6DCC^*Z!G.?7YR?TKJX+>&VA$5M$D,:]$C4*!^ J/885:N+EZO\
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M2^^)7B-[:/.X6YD\YU]@BD1I^&?I7J'ACX.>"/!Z+/!ID=W<Q\F\U$B5@?4
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M:S@XL/#.B0@="UF9F_.1FKTBV^!-G'@OIR,?66Z8_P C6K!\&;2,#&G:4/\
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MK%A[#%/X8Q?I8\X_X1KXY1_=UK?GK_I49Q^8JG<>#_C+<9%R+2Y'K*+1\_\
M?2UZW%X]LS_KK2=/]TAO\*N1>,]'D^_++%_OQG^F:WCGV!J?;A\U;\S&=+%+
MXJ*?RN>"7'PZ^*DW+:)IY/I'%8)_("LU_A-\3'8LVAC_ (#<VH_0/7TU%XBT
MB;[E_"/]\[?YU;BOK2;_ %-U#)_N2 UT1Q>$J_#&#^29Q3BE\>'C\X'RL?A5
M\2#_ ,P%A_VW@_\ BZ/^%5?$G_H!/_W_ (/_ (JOK"BM?W/_ #ZC]QA_L_\
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M^T:AIMNO]TW#L1^ 7%:MM^S5?O@WWB.!?416[-^I(_E7T%167MJB^%V]$O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#.\/?\BSI?_7G%_P"@"M&L[P]_R+.E_P#7
MG%_Z *T: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH SO#W_(LZ7_UYQ?\ H K1K.\/?\BSI?\ UYQ?^@"M&@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH[*&..Y &??-=Q0!G>'O^19TO_KSB_\ 0!6C6=X>_P"19TO_ *\XO_0!6C0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A_B[X2^-=>\47-@N
MNP7GAG47GD:?4&>:?3TDDA=HHU8\C,*[.PPV<'!/N%% 'F/BOP3X[FUC4_\
MA$/$-F-'UFR6TNK35WFD^Q +L+VZC*@E220< GKGC%2^^%6O>'[K0M2^'&I:
M>FHZ;I!T>?\ M97$<T62PD'E@D.')..G3TP?6:* .;^'_A"/P)X%T[P]%/\
M:3:JQDFVX\QV8LQ [#)./8"MNZTVQOF5KVRM[EE&%,T2N0/;(JS10!G>'O\
MD6=+_P"O.+_T 5HUG>'O^19TO_KSB_\ 0!6C0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% &=X>_P"19TO_ *\XO_0!6C6=
MX>_Y%G2_^O.+_P! %:- !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 9WA[_ )%G2_\ KSB_] %:-9WA[_D6=+_Z\XO_ $ 5
MHT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >5^,OB_J6
MB>,QH?AKPK<:XMG<QPZC(C88L\$DPBA3JS[$+YY'RE<98$:7BOXH7.CZE8Z5
MX;\,7>NZM<Z>=3ELGF%HUM;CN^X$[\\;,9S[X!\K^,M[I]G\3C<_8=3\-^(8
M9 UEJMA([C55^RR",[ N-RRB*+&>5D8$XP1M7WB"Y\#_ !#TKQA\08YK9-4\
M')933);L0+T,LC1$*#M8X^G/H#0![+X4\2V/C#PK8:_I6\6M['O59!AD()5E
M..X8$?A6O7 _!#1;[0/@YH=EJL#V]UMEF:&1<,@>5W4$'H=K#CM7:W4=\[+]
MBN;>%<?,)K=I"3[8=<4 5_#W_(LZ7_UYQ?\ H K1K(L]/U:QL8+2'4+(QP1K
M&I:R<DA1@9_>]>*F\G6O^?\ L/\ P!?_ ..T :-%9WDZU_S_ -A_X O_ /':
M/)UK_G_L/_ %_P#X[0!HT5G>3K7_ #_V'_@"_P#\=H\G6O\ G_L/_ %__CM
M&C16=Y.M?\_]A_X O_\ ':/)UK_G_L/_  !?_P".T :-%9WDZU_S_P!A_P"
M+_\ QVCR=:_Y_P"P_P# %_\ X[0!HT5G>3K7_/\ V'_@"_\ \=H\G6O^?^P_
M\ 7_ /CM &C16=Y.M?\ /_8?^ +_ /QVCR=:_P"?^P_\ 7_^.T :-%9WDZU_
MS_V'_@"__P =H\G6O^?^P_\  %__ ([0!HT5G>3K7_/_ &'_ ( O_P#':/)U
MK_G_ +#_ , 7_P#CM &C16=Y.M?\_P#8?^ +_P#QVCR=:_Y_[#_P!?\ ^.T
M7A-&T[0A@9$579>X!) /_CI_*GUD+I^K)?2W8U&R\R6-(V'V)\ *6(_Y:]?G
M/Z5-Y.M?\_\ 8?\ @"__ ,=H T:*SO)UK_G_ +#_ , 7_P#CM'DZU_S_ -A_
MX O_ /': -&BL[R=:_Y_[#_P!?\ ^.T>3K7_ #_V'_@"_P#\=H T:*SO)UK_
M )_[#_P!?_X[1Y.M?\_]A_X O_\ ': -&BL[R=:_Y_[#_P  7_\ CM'DZU_S
M_P!A_P" +_\ QV@#1HK.\G6O^?\ L/\ P!?_ ..T>3K7_/\ V'_@"_\ \=H
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M&BL[R=:_Y_[#_P  7_\ CM'DZU_S_P!A_P" +_\ QV@#1HK.\G6O^?\ L/\
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M^P_\ 7_^.T>3K7_/_8?^ +__ !V@#1HK.\G6O^?^P_\  %__ ([1Y.M?\_\
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M9M/TW0W598[J5B2-L14G>20-V< 8XSC/,Z)X9U'1?!GPV\$ZR62\NM8;4;B
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M5\'V'A!=5&G37,S:KJ,NHW#W+*S>9)C(!"CY>. <GD\UO444 %%%% !1110
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MK8(X[<Y&:M>#OA[IG@VYO+R"^U/5M1O J2W^K77GS^6H^6,-@ *.3TSSR3@
M=710 4444 %%%% !1110 4444 %%%% !1110 4444 %8/B_PC8>--'BTW5)K
MF*&*ZCNE:V958LAR =RD8]>*WJ* .$\9?"C3?&OB>SUZ\UW7M.O+&'RK;^S;
MM(1%R267*$ACNP2#R !VJ]H?P]M=%U*SOY=;UO5KNRMI[>";5+I9W42LK,V2
MH.1L ';&>*ZVB@#R_1?@5IGA^[,^E>,?&-OYEP+B:./5%5+A\Y)D"QC=GOGD
MUHZU\&O#.N^*)]8NYM2CCNY8YKW3(;K;9WLB?=>6/')Z="!Q[G/?T4 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC(SC:5&W/S!?F(Z=<<TSQWXAM_$WPJ\#:G<:'<:%X1EU>(:G91KA$MU.%(V
M'RC\V.%R=I SMH ]UTSQ#HNM6LMUHVKV&H6\)Q++:7*2I&<9PQ4D#CGFJUOX
MR\,7=Q:P6OB/2)YKS_CVCCOHF:?DK\@#?-R"..X->-L/#S?'6#_A61L!IZZ#
M=?VU_9&S[,5V/Y>=GR;MY3I[5YU/X;TA/V6](UF/3X$U2XUO#WP0><5W2)MW
M]=N%'R],C.,T ?6-CXCT34YKJ+3=8T^\DL_^/E+>Z20P=1\X!^7H>OH:K0^-
M?"MQ/:00>)='EEO<?98TOXBT^6*#8 WS?,I7C/((ZBO(;G1=,\,_M&M8>']/
MM].M9/"<I>&VC"*QR_) ZGY%R3UQ7G6E?\*];]F2]6Y&F'Q9Y[!0P7[89/-&
MS9_'LV;>GR_>[YH ^K=7\1:)X?6(Z]K%AI@FR(C>W20^9C&=NXC.,CIZBB?Q
M#HMK8VE[<ZO80VEZRK:W$ERBQSEAE0C$X8D<C&<U\]>++^+4O'%OI?B4Z!H^
MH6GAB WNL>((6NY-VQ79;>"1O*+[SCE=W+D$]*YPPQW_ .S;X)M+G+PR>*3"
MZ[NBL9<CVZG\Z /J:Q\2:+JTMU#H^KZ?J$]J#Y\5M=I(T1Y&& )V\@CFLKPG
MXS37?!I\0:U'I^CQ([B4QZK#=PQJIQN,Z'9^':O.[C1-+\-_M-:5;>'].M=,
MM[CPY,TL-I$L2.=TG)5<#/RKS["O*K3[9_PHWP3L^Q_V=_PD<OVG^TM_V/?D
M>7Y^WG9]_/M0!]:Z;K&F:S8_;-'U&TO[7<5\^UG65,CJ-RDC(JMI/BKP]KUP
M\&A:[IFI31KO>.SO(YF5<XR0I.!D]:\ \,Z=;W"_$3[=K_ARST>XTE8[\>$K
M:ZFMK23 "2JNS8PV[]P1C_%G')#? -SH_A[QWX/LGM_"OB"2?S+?3M6\.3/#
M>0KL^_>0K@,65@"&&5PY))!R >W_ !$\8_\ " ^![WQ%]A^W_96C'V?SO*W;
MY%3[VUL8W9Z=JO-XLT.WCB&I:OI]C</:+=O;W%VB.D1'WR"0=H/&[&.*XK]H
MC_DAVM?[]O\ ^CTKD[S0],U_]I3PY:ZW8P7]LGA>.7R+B,/&S#S ,J>#U[]\
M4 >W6&L:9JNG?;]+U&TO;+G_ $FWG62/CK\RDCCO4&D>)="\0-*-!UK3]3,.
M#*+*Z2;R\YQNVDXS@]?0U\S:K:W-A\/?BMIVA1/#I]KXD4206PP([?S"& '8
M?*F>V!Z5ZAX7D^%*?%K3?^$+,7]JS:0PB&DC_1/+SD^;LZ2X!^_Z#/S;<@'K
ME%%% !1110 4444 %%%% !1110 4444 %%%% !117#^/O#'BW7[RUD\+Z_\
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MSWK2HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HKD)_$/B1+B18]&^4,0/W$C<?4'!J/_A(_$_\ T!O_ "5E_P :
M\5YUAT[<LO\ P%GHK+JS5[K[T=G17&?\)'XG_P"@-_Y*R_XT?\)'XG_Z W_D
MK+_C2_MK#?RR_P# 6/\ LVMW7WH[.L[7]>T[PQH-UK.MW(MK&T0-+*03C)
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MDU3CS,ZL)A9XNJJ--I-]W9?B=Q17C/\ PL;XG?\ 0F_^4NY_^*H_X6-\3O\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>=3_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#$G\%^%KJX>>Y\-:1--(Q9Y)+")F8^I)7DTS_A!/"/_ $*N
MB?\ @NB_^)K>HJN>7<OVD^Y@_P#"">$?^A5T3_P71?\ Q-'_  @GA'_H5=$_
M\%T7_P 36]11SR[A[2?=F#_P@GA'_H5=$_\ !=%_\369XW\!?\)-X#E\+Z!?
MQ>&[:=U\TVMH"K1]2@163&3C)SR 1CFNQHH<F]V)RD]V><^!?ASXE\'?8K"X
M\;1:CX?M8WC.DKH<$"R J1S(&+9W'<2<ECG/4UF:?\#197MA93^*+NY\*:9?
M&_L]">V4>7+DD;I@=S*"2<$=_J3ZS14DGD>J_!OQ#>?$J[\::=X\6ROY24MQ
M)HL=S]EBQ@(GF2$ @<;@ 3EO[QIWC+X.^(?&]KH::SX[$LFDAG=GT:-H[F8N
M2)&B\P)PNU=I!& ?[Q%>M44 <WX0T3Q+HL=TOBGQ9_PD?F%/LY&FQ6GD 9R,
M(3NSD=>F/>JD_@/SOB];^./[1QY&FFP^Q>1][YF._?N_VNFWMUKKZ* ,_7]#
MLO$OA^]T;5$9[2]A:&4(<, >X/8@\CW%<9X5^&^OZ'JNG2ZQX^U/5M-TJ(Q6
M6G1PBU3& J^<48F8* ,;NX],@^AT4 >7-\']3L[^]@\-^.]3T/P]?WGVRXTR
MT@42JY(+B.XR&C!P. .G7-=%;^ A;?%=_&:ZBS!M*&FBS:(L1A@V\REB2>.A
M'XUU]% $-Y:6^H6,]G>PI/;7$;131.,JZ,,,I'H02*\;7]GS4--O7A\+?$?7
MM%T-I=XTV%W^4'&X!UD4<\X)0XXSNQS[510!YO=?!G2TT+PMI&AWTEA:^'M3
M34<RQ^<]TRG+!CE<%CW P.PQ6MXZ^'J>+[K3=5T[59]#U_27+V.I0QB38"1N
M5XS@.I (QD=>X)![*B@#SO1_A';QV?B%_%.MW6O:MXBMC:WNHF)("L6" L2#
M(3'![C*CC'%<^OP+UJXT_0;'5_B!<7UIH%U#-8V_]F)'&B)U4X?<QX4!BQVC
M<,'/'LE% '@&C>'=;UWXW_$=O#7BFX\.7<,EM&TL=LEQ'+&Z'(*-CY@57:X(
M(RP_BKUWP+X,L? ?A2#1-/EEN-C-+/<3??GE8Y9SZ>@'8 <GJ>BHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
/ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_0a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0a.jpg
MB5!.1PT*&@H    -24A$4@    T    %" (    1VO%&    #$E$051X7F-@
8&!X   #(  %4A>.3     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564881097224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 17, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Bausch Health Companies Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0448205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2150 St. Elz&#233;ar Blvd. West<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Laval<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">QC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">H7L 4A8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">744-6792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, No Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BHC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Smaller Reporting Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,713,713,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,646,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Part&#160;III incorporates certain information by reference from the registrant&#8217;s proxy statement for the 2022 Annual Meeting of Shareholders. Such proxy statement will be filed no later than 120&#160;days after the close of the registrant&#8217;s fiscal year ended December&#160;31, 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000885590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564889100056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AUDIT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Florham Park, New Jersey<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564882480392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 582<span></span>
</td>
<td class="nump">$ 605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">1,537<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">1,775<span></span>
</td>
<td class="nump">1,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">993<span></span>
</td>
<td class="nump">1,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">720<span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,607<span></span>
</td>
<td class="nump">5,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,598<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">6,948<span></span>
</td>
<td class="nump">8,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">12,457<span></span>
</td>
<td class="nump">13,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">2,252<span></span>
</td>
<td class="nump">2,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">664<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">29,202<span></span>
</td>
<td class="nump">31,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">407<span></span>
</td>
<td class="nump">337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">4,791<span></span>
</td>
<td class="nump">4,576<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,198<span></span>
</td>
<td class="nump">4,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of long-term debt</a></td>
<td class="nump">22,654<span></span>
</td>
<td class="nump">23,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="nump">529<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">653<span></span>
</td>
<td class="nump">1,012<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">29,236<span></span>
</td>
<td class="nump">30,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes&#160;20 and 21)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, no par value, unlimited shares authorized, 359,405,748 and 355,422,347&#160;issued and outstanding at December&#160;31, 2021 and 2020, respectively</a></td>
<td class="nump">10,317<span></span>
</td>
<td class="nump">10,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">462<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(8,961)<span></span>
</td>
<td class="num">(8,013)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,924)<span></span>
</td>
<td class="num">(2,133)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Bausch Health Companies Inc. shareholders&#8217; (deficit) equity</a></td>
<td class="num">(106)<span></span>
</td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total (deficit) equity</a></td>
<td class="num">(34)<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and (deficit) equity</a></td>
<td class="nump">$ 29,202<span></span>
</td>
<td class="nump">$ 31,199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Noncurrent Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessCombinationContingentConsiderationNoncurrentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash And Other Settlement Deposits, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestrictedCashAndOtherSettlementDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564889080504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">359,405,748<span></span>
</td>
<td class="nump">355,422,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">359,405,748<span></span>
</td>
<td class="nump">355,422,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564882066776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 8,434<span></span>
</td>
<td class="nump">$ 8,027<span></span>
</td>
<td class="nump">$ 8,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,624<span></span>
</td>
<td class="nump">2,367<span></span>
</td>
<td class="nump">2,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">465<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="nump">471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold', window );">Amortization of intangible assets</a></td>
<td class="nump">1,375<span></span>
</td>
<td class="nump">1,645<span></span>
</td>
<td class="nump">1,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges', window );">Goodwill impairments</a></td>
<td class="nump">469<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts', window );">Restructuring, integration, separation and IPO costs</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expense, net</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">502<span></span>
</td>
<td class="nump">1,426<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total Expenses</a></td>
<td class="nump">7,984<span></span>
</td>
<td class="nump">7,351<span></span>
</td>
<td class="nump">8,804<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">450<span></span>
</td>
<td class="nump">676<span></span>
</td>
<td class="num">(203)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="num">(1,426)<span></span>
</td>
<td class="num">(1,534)<span></span>
</td>
<td class="num">(1,612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(62)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange and other</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before benefit from income taxes</a></td>
<td class="num">(1,024)<span></span>
</td>
<td class="num">(934)<span></span>
</td>
<td class="num">(1,837)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(937)<span></span>
</td>
<td class="num">(559)<span></span>
</td>
<td class="num">(1,783)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interest</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Bausch Health Companies Inc.</a></td>
<td class="num">$ (948)<span></span>
</td>
<td class="num">$ (560)<span></span>
</td>
<td class="num">$ (1,788)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to Bausch Health Companies Inc. (in dollars per share)</a></td>
<td class="num">$ (2.64)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
<td class="num">$ (5.08)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share)</a></td>
<td class="num">$ (2.64)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
<td class="num">$ (5.08)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares (in shares)</a></td>
<td class="nump">358.9<span></span>
</td>
<td class="nump">355.0<span></span>
</td>
<td class="nump">352.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares (in shares)</a></td>
<td class="nump">358.9<span></span>
</td>
<td class="nump">355.0<span></span>
</td>
<td class="nump">352.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 8,342<span></span>
</td>
<td class="nump">$ 7,924<span></span>
</td>
<td class="nump">$ 8,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</a></td>
<td class="nump">2,361<span></span>
</td>
<td class="nump">2,202<span></span>
</td>
<td class="nump">2,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges And Initial Public Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestructuringChargesAndInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564882178184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (937)<span></span>
</td>
<td class="num">$ (559)<span></span>
</td>
<td class="num">$ (1,783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Pension and postretirement benefit plan adjustments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax', window );">Net actuarial gain (loss) arising during the year</a></td>
<td class="nump">24<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax', window );">Amortization of prior service credit</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition', window );">Amortization or settlement recognition of net loss</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax', window );">Income tax benefit (expense)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax', window );">Foreign currency impact</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net pension and postretirement benefit plan adjustments</a></td>
<td class="nump">28<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(158)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">(130)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(1,067)<span></span>
</td>
<td class="num">(604)<span></span>
</td>
<td class="num">(1,733)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to noncontrolling interest</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Bausch Health Companies Inc.</a></td>
<td class="num">$ (1,079)<span></span>
</td>
<td class="num">$ (607)<span></span>
</td>
<td class="num">$ (1,737)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Defined Benefit Plan, Foreign Currency Adjustment, Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Amortization or Settlement Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564884312504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Bausch Health Companies&#160;Inc. Shareholders' Equity (Deficit)</div></th>
<th class="th">
<div>Bausch Health Companies&#160;Inc. Shareholders' Equity (Deficit) </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 2,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,121<span></span>
</td>
<td class="nump">$ 413<span></span>
</td>
<td class="num">$ (5,664)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,137)<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">Accounting Standards Update 2016-13 [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Share-based awards tax withholding</a></td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(1,783)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,788)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,788)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="nump">1,136<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 10,172<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="num">(7,452)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(2,086)<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Share-based awards tax withholding</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(559)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(560)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(560)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">$ (45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">355,422,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,227<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="num">(8,013)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,133)<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Share-based awards tax withholding</a></td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Release of foreign currency translation losses upon disposal of assets held for sale</a></td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(937)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(948)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(948)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">$ (130)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(131)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">359,405,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="num">$ (34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,317<span></span>
</td>
<td class="nump">$ 462<span></span>
</td>
<td class="num">$ (8,961)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,924)<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(1)<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(2)<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(01)<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564881175432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (937)<span></span>
</td>
<td class="num">$ (559)<span></span>
</td>
<td class="num">$ (1,783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization of intangible assets</a></td>
<td class="nump">1,552<span></span>
</td>
<td class="nump">1,825<span></span>
</td>
<td class="nump">2,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization and write-off of debt discounts and debt issuance costs</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges', window );">Goodwill impairment</a></td>
<td class="nump">469<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AllowancesForLossesOnAccountsReceivableAndInventories', window );">Allowances for losses on trade receivables and inventories</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DeferredIncomeTaxNoncashExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(225)<span></span>
</td>
<td class="num">(475)<span></span>
</td>
<td class="num">(230)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Gain on disposal of assets</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GainLossRelatedToLitigationSettlementGross', window );">Additions to accrued legal settlements</a></td>
<td class="nump">569<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="nump">1,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments of accrued legal settlements</a></td>
<td class="num">(351)<span></span>
</td>
<td class="num">(168)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Foreign exchange loss</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DerivativeGainExcludedComponent', window );">Gain excluded from hedge effectiveness</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities', window );">Payments of contingent consideration adjustments, including accretion</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables</a></td>
<td class="num">(229)<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="num">(209)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued and other liabilities</a></td>
<td class="nump">121<span></span>
</td>
<td class="num">(471)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">1,426<span></span>
</td>
<td class="nump">1,111<span></span>
</td>
<td class="nump">1,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows From Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of businesses, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of intangible assets and other assets</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(269)<span></span>
</td>
<td class="num">(302)<span></span>
</td>
<td class="num">(270)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested', window );">Proceeds from sale of assets and businesses, net of costs to sell</a></td>
<td class="nump">669<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_InterestSettlementOnCrossCurrencySwaps', window );">Settlements from cross-currency swaps</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">409<span></span>
</td>
<td class="num">(261)<span></span>
</td>
<td class="num">(419)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Issuance of long-term debt, net of discounts</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">3,455<span></span>
</td>
<td class="nump">5,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="num">(3,440)<span></span>
</td>
<td class="num">(5,642)<span></span>
</td>
<td class="num">(4,406)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Borrowings of short-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments of short-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of employee withholding taxes related to share-based awards</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments of acquisition-related contingent consideration</a></td>
<td class="num">(83)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of financing costs</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(1,513)<span></span>
</td>
<td class="num">(2,294)<span></span>
</td>
<td class="nump">1,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(19)<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in Cash and cash equivalents and Restricted cash and other settlement deposits</a></td>
<td class="nump">303<span></span>
</td>
<td class="num">(1,428)<span></span>
</td>
<td class="nump">2,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits', window );">Cash and cash equivalents and Restricted cash and other settlement deposits, beginning of year</a></td>
<td class="nump">1,816<span></span>
</td>
<td class="nump">3,244<span></span>
</td>
<td class="nump">723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits', window );">Cash and cash equivalents and Restricted cash and other settlement deposits, end of year</a></td>
<td class="nump">2,119<span></span>
</td>
<td class="nump">1,816<span></span>
</td>
<td class="nump">3,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">582<span></span>
</td>
<td class="nump">605<span></span>
</td>
<td class="nump">3,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">1,537<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits', window );">Cash and cash equivalents and Restricted cash and other settlement deposits, end of year</a></td>
<td class="nump">$ 2,119<span></span>
</td>
<td class="nump">$ 1,816<span></span>
</td>
<td class="nump">$ 3,244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AllowancesForLossesOnAccountsReceivableAndInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AllowancesForLossesOnAccountsReceivableAndInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, And Other Settlement Deposits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredIncomeTaxNoncashExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredIncomeTaxNoncashExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DerivativeGainExcludedComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative, Gain, Excluded Component</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DerivativeGainExcludedComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GainLossRelatedToLitigationSettlementGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) Related To Litigation Settlement, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GainLossRelatedToLitigationSettlementGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_InterestSettlementOnCrossCurrencySwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Settlement On Cross-Currency Swaps</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_InterestSettlementOnCrossCurrencySwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment For Contingent Consideration Liability, Including Accretion, Operating Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash And Other Settlement Deposits, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestrictedCashAndOtherSettlementDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash inflow during the period from the sale of a component of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883644872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">DESCRIPTION OF BUSINESSBausch Health Companies Inc. (the &#8220;Company&#8221;), formerly known as Valeant Pharmaceuticals International, Inc.,  is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#8220;OTC&#8221;) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in approximately 100 countries.  Effective August 9, 2013, the Company continued from the federal jurisdiction of Canada to the Province of British Columbia, meaning that the Company became a company registered under the laws of the Province of British Columbia as if it had been incorporated under the laws of the Province of British Columbia. As a result of this continuance, the legal domicile of the Company became the Province of British Columbia, the Canada Business Corporations Act ceased to apply to the Company and the Company became subject to the British Columbia Business Corporations Act.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883909688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements have been prepared by the Company in United&#160;States (&#8220;U.S.&#8221;) dollars and in accordance with U.S.&#160;generally accepted accounting principles (&#8220;U.S. GAAP&#8221;), applied on a consistent basis. The Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation of the Bausch + Lomb Eye-Health Business and Initial Public Offering of Solta Medical Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, the Company announced its intentions to separate its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc. (the &#8220;B+L Separation&#8221;). On August 3, 2021, the Company announced its intentions to conduct an initial public offering ("IPO") of its aesthetic medical device business, Global Solta (the &#8220;Solta IPO").  In January 2022, the Company completed the internal organizational design and structure of the new eye-health entity, Bausch + Lomb Corporation ("Bausch + Lomb"), and the new Global Solta entity, Solta Medical Corporation ("Solta"), as previously announced and aims to launch the B+L IPO and the Solta IPO when financial market conditions are favorable (and subject to receipt of regulatory, stock exchange and other approvals). Following the B+L IPO the Company expects to complete the separation of Bausch + Lomb after the expiry of customary lockups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to the receipt of applicable shareholder and other necessary approvals. The B+L Separation and the proposed Solta IPO will establish three separate companies that include: (i) a fully integrated eye-health company which will consist of the Company&#8217;s Bausch + Lomb Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmic Pharmaceuticals businesses, (ii) a global provider of aesthetic medical devices which will consist of the Company&#8217;s Solta business and (iii) a diversified pharmaceutical company which will include the Company&#8217;s Salix, International Rx, dentistry, neurology, medical dermatology and generics pharmaceutical businesses. These audited Consolidated Financial Statements do not include any adjustments to give effect to either the B+L Separation or the proposed Solta IPO.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impacts of COVID-19 Pandemic</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has, and continues to, adversely impact the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facility closures and production suspensions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which these events may continue to impact the Company's business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company's control. Such developments include the availability and effectiveness of vaccines for the COVID-19 virus, COVID-19 vaccine immunization rates, the ultimate geographic spread and duration of the pandemic, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, such as the delta and omicron variants, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company's business, financial condition, cash flows and results of operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing. Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the Company's Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows.  The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of amortizable intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants and making going concern assessments; reporting unit fair values for testing goodwill for impairment and allocating goodwill to new reporting unit structure on a relative fair value basis; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; fair value of cross-currency swaps; fair value of foreign currency exchange contracts; and the recognition of the fair value of assets and liabilities acquired in a business combination, including the fair value of contingent consideration. Under certain product manufacturing and supply agreements, management uses information from the Company&#8217;s commercialization counterparties to arrive at estimates for future returns, rebates and chargebacks. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s Consolidated Financial Statements could be materially impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Consolidated Financial Statements after the date of acquisition.  Acquired in-process research and development (&#8220;IPR&amp;D&#8221;) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;D has an alternative future use. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;D with no alternative future use is charged to expense at the acquisition&#160;date and any future contingent consideration is not recorded until it becomes probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities approximate their carrying values due to their short maturity periods. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows or Monte Carlo Simulation (when appropriate) analyses and assessment of the probability of occurrence of potential future events. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Derivative Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cross-currency swaps qualified for and had been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and were remeasured at each reporting date to reflect changes in their </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair values.  The fair value was determined via a mark-to-market analysis, using observable (Level&#160;2) inputs. These inputs included: (i)&#160;the foreign currency exchange spot rate between the euro and U.S. dollar, (ii)&#160;the interest rate yield curves in the euro and U.S. dollar and (iii)&#160;the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Loss as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulated other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps was ineffective. The Company uses the spot method of assessing hedge effectiveness. The Company had elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as a reduction of Interest expense in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses foreign currency exchange contracts to economically hedge the foreign exchange exposure on certain of the Company&#8217;s intercompany and third party balances. The Company's foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash in bank accounts and highly liquid investments with maturities of three months or less when&#160;purchased.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, cross-currency swaps and foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in high-quality, money market instruments and term deposits with varying maturities, but typically less than three months.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash deposited at banks may exceed the amount of insurance provided on such deposits. Generally, these cash deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate such risks by spreading its risk across multiple counterparties and monitoring the risk profiles of these counterparties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s trade receivables primarily represent amounts due from wholesale distributors, retail pharmacies, government entities and group purchasing organizations. Outside of the U.S., concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the number of customers using the Company&#8217;s products, as well as their dispersion across many different geographic regions. The Company performs periodic credit evaluations of customers and does not require collateral. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The credit and economic conditions within Argentina, Brazil, Egypt, Greece, among other members of the European Union, Turkey, Ukraine and Venezuela have been weak in recent years. These conditions have increased, and may continue to increase, the average length of time that it takes to collect on the Company&#8217;s trade receivables outstanding in these countries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company&#8217;s three largest U.S. wholesaler customers accounted for approximately 44% of net trade receivables. In addition, as of December 31, 2021 and 2020, the Company&#8217;s net trade receivable balance from Argentina, Brazil, Egypt, Greece, Serbia, South Africa, Turkey, Ukraine, Venezuela and Vietnam amounted to $78 million and $166&#160;million, respectively, the majority of which is current or less than 90 days past due. The portion of the net trade receivable from these countries that is past due more than 90&#160;days amounted to $2 million, as of December 31, 2021, a portion of which is comprised of public hospitals.  Based on an analysis of credit risk, including an analysis of bad debt experience and assessment of historical payment patterns for such customers, the Company has established a reserve covering more than half of the balance past due more than 90 days for such countries. Over the three-year period ended December&#160;31, 2021, the Company has not experienced any material losses from uncollectible accounts in excess of the established reserves.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not enter into financial instruments for trading or speculative purposes. Further, the Company has a policy of only entering into contracts with parties that have at least an investment grade credit rating. The Company enters into cross-currency swaps and foreign currency exchange contracts with high credit quality financial institutions. The counter-parties to the Company's cross-currency swaps and foreign currency exchange contracts are major financial institutions, and there is no significant concentration of exposure with any one counter-party. To date, no counterparty has failed to meet its obligations to the Company and management believes the risk of loss associated with these contracts is </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remote.  See Note 5, "FAIR VALUE MEASUREMENTS" for additional details regarding the Company's cross-currency swaps and foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160; Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. Allowance for credit losses were $35 million, $39 million and $48&#160;million as of December 31, 2021, 2020 and 2019, respectively. The activity in the allowance for credit losses for trade receivables for the years 2021, 2020 and 2019 is as follows.</span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.199%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.965%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retrospective effect of application of new accounting standard</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories comprise raw materials, work in process and finished goods, which are valued at the lower of cost or net realizable value, on a first-in, first-out basis. The cost value for work in process and finished goods inventories includes materials, direct labor and an allocation of overheads. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on&#160;hand.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are reported at cost, less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction in progress. Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful&#160;lives: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:54.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;-&#160;20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;-&#160;10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of term of lease or 10 years</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reported at cost, less accumulated amortization and impairments. Intangible assets with finite lives are amortized over their estimated useful lives. Amortization is calculated primarily using the straight-line method based on the following estimated useful&#160;lives:</span></div><div style="margin-top:5pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:54.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 - 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 15 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 9 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Out-licensed technology and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 - 9 years</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestitures of Products</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds on the divestiture of products and the carrying amount of the related assets is recorded as a gain/loss on sale within Other expense, net. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when realizable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IPR&amp;D </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of IPR&amp;D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and&#160;amortized. Acquired IPR&amp;D assets are tested for impairment at least annually or when triggering events are identified.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of an acquired IPR&amp;D intangible asset is typically determined using an income approach. This approach starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#8217;s stage of completion, the probability of technical success, the projected costs to complete, expected market competition and an assessment of the asset&#8217;s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the expected cash flow&#160;streams.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.  If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset, which include the amount and timing of the projected future cash flows. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash&#160;flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets, which includes acquired IPR&amp;D and the corporate trademark acquired in the acquisition of Bausch &amp; Lomb Holdings Incorporated (the &#8216;&#8216;B&amp;L Trademark&#8217;&#8217;), are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based on a comparison of the fair value of the asset to its carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. Goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value. A reporting unit is the same as, or one level below, an operating segment. A</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n entity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is permitted to first assess qualitatively whether it is necessary to perform a quantitative impairment test for any of its reporting units. The quantitative impairment test is required only when the Company concludes that it is more likely than not that a reporting unit&#8217;s fair value is less than its carrying amount. In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company considers the totality of all relevant events or circumstances that affect the fair value or carrying amount of a reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company&#8217;s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, among other factors, the Company monitors </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">changes in its share price between annual impairment tests. The Company considers a decline in its share price that corresponds to an overall deterioration in stock market conditions to be less of an indicator of goodwill impairment than a unilateral decline in its share price reflecting adverse changes in its underlying operating performance, cash flows, financial condition and/or liquidity. In the event that the Company&#8217;s market capitalization does decline below its book value, the Company would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. The Company believes that short-term fluctuations in share prices may not necessarily reflect underlying values.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt discounts, premiums and issuance costs are presented in the Consolidated Balance Sheets as a direct deduction from or addition to the carrying amount of the related debt and are amortized or accreted, using the effective interest method, as interest expense over the contractual lives of the related credit facilities or notes. Deferred financing costs associated with revolving credit facility arrangements are included in the balances of Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets and are amortized as interest expense over the contractual life of the related revolving credit facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities of the Company&#8217;s foreign operations having a functional currency other than the U.S.&#160;dollar are translated into U.S.&#160;dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange gains and losses on transactions occurring in a currency other than an operation&#8217;s functional currency are recognized as a component of Foreign exchange and other in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye-health, gastroenterology ("GI") and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 22, "SEGMENT INFORMATION" for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services.  To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract with the Company&#8217;s customers exists for each product sale.  Where a contract with a customer contains more than one performance obligation, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The transaction price is adjusted for variable consideration which is discussed below.  The Company generally recognizes revenue for product sales at a point in time, when the customer obtains control of the products.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160; The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers.  Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&#160;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity and ending balances of the Company&#8217;s variable consideration provisions the years 2021 and 2020.</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:28.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.881%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, January 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,050&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(593)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,297)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,013)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,378)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $36 million and $32 million as of December 31, 2021 and 2020, respectively, which are reflected as a reduction of Trade accounts receivable, net in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company's products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis.  This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period.  The Company applies this method consistently for contracts with similar characteristics.  The following describes the major sources of variable consideration in the Company&#8217;s customer arrangements and the methodology, estimates and judgments applied to estimate each type of variable consideration.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Discounts and Allowances</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash discounts are offered for prompt payment and allowances for volume purchases. Provisions for cash discounts and allowances are estimated at the time of sale and recorded as direct reductions to trade receivables and revenue. Management estimates the provisions for cash discounts and allowances based on contractual sales terms with customers, an analysis of unpaid invoices and historical payment experience. Estimated cash discounts and allowances have historically been predictable and less subjective, due to the limited number of assumptions involved, the consistency of historical experience and the fact that these amounts are generally settled within one month of incurring the&#160;liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, customers are generally allowed to return a product within a specified period of time before and after its expiration date, excluding European businesses which generally do not provide a right of return. The returns provision is estimated utilizing historical sales and return rates over the period during which customers have a right of return, taking into account available information on competitive products and contract changes. The information utilized to estimate the returns provision includes: (i) historical return and exchange levels, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription demand for products, (iv) remaining shelf lives of products at the date of sale and (v) estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the estimate for returns, management is required to make certain assumptions regarding the timing of the introduction of new products and the potential of these products to capture market share. In addition, certain assumptions with respect to the extent and pattern of decline associated with generic competition are necessary. These assumptions are formulated using market data for similar products, past experience and other available information.  These assumptions are continually reassessed, and changes to the estimates and assumptions are made as new information becomes available. A change of 1% in the estimated return rates would have impacted the Company&#8217;s pre-tax earnings by approximately $81 million for the year 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimate for returns may be impacted by a number of factors, but the principal factor relates to the inventory levels in the distribution channel. When management becomes aware of an increase in such inventory levels, it considers whether the increase may be temporary or other-than-temporary. Temporary increases in wholesaler inventory levels will not warrant revision to the provision for returns. Other-than-temporary increases in wholesaler inventory levels, however, may be an indication that future product returns could be higher than originally anticipated, and, as a result, estimates for returns may need to be adjusted. Factors that suggest increases in wholesaler inventory levels are temporary include: (i) recently implemented or announced price increases for certain products, (ii) new product launches or expanded indications for existing products and (iii) timing of purchases by wholesale customers. Conversely, factors that suggest increases in wholesaler inventory levels are other-than-temporary include: (i) declining sales trends based on prescription demand, (ii) introduction of new products or generic competition, (iii) increasing price competition from generic competitors and (iv) changes to the U.S.&#160;National Drug Codes (&#8220;NDC&#8221;) of products.  Changes in the NDC of products could result in a period of higher returns related to products with the old NDC, as U.S.&#160;customers generally permit only one NDC per product for identification and tracking within their inventory systems.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for 2021 and 2020 were $131&#160;million and $120&#160;million, respectively, and includes reductions in variable consideration for sales return provisions related to past sales of approximately $28 million and $38 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Chargebacks</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales made under governmental and managed-care pricing programs in the U.S. are subject to rebates.&#160; The Company participates in state government-managed Medicaid programs, as well as certain other qualifying federal and state government programs whereby rebates are provided to participating government entities. Medicaid rebates are generally billed 45 days to 270&#160;days after the quarter in which the product is dispensed to the Medicaid participant.  As a result, the Medicaid rebate reserve includes an estimate of outstanding claims for end-customer sales that occurred, but for which the related claim has not been billed and/or paid, and an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. The calculation of the Medicaid rebate reserve also requires other estimates, such as estimates of sales mix, to determine which sales are subject to rebates and the amount of such rebates. A change of 1% in the estimated rates used in the Medicaid rebate reserve would have impacted the Company&#8217;s pre-tax earnings by approximately $76 million for 2021. Quarterly, the Medicaid rebate reserve is adjusted based on actual claims paid. Due to the delay in billing, adjustments to actual claims paid may incorporate revisions of that reserve for several periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market&#160;share.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks relate to contractual agreements to sell products to government agencies, group purchasing organizations and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these group purchasing organizations or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In estimating provisions for rebates and chargebacks, management considers relevant statutes with respect to governmental pricing programs and contractual sales terms with managed-care providers and group purchasing organizations. Management estimates the amount of product sales subject to these programs based on historical utilization levels. Changes in the level of utilization of products through private or public benefit plans and group purchasing organizations will affect the amount of rebates and chargebacks that the Company is obligated to pay. Management continually updates these factors based on new contractual or statutory requirements, and any significant changes in sales trends that may impact the percentage of products subject to rebates or&#160;chargebacks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of Managed Care, Medicaid and other rebates and chargebacks has become more significant as a result of a combination of deeper discounts implemented in each of the last three years, changes in the Company&#8217;s product portfolio due to recent acquisitions and increased Medicaid utilization due to expansion of government funding for these programs.&#160;Management&#8217;s estimate for rebates and chargebacks may be impacted by a number of factors, but the principal factor relates to the level of inventory in the distribution channel.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebate provisions are based on factors such as timing and terms of plans under contract, time to process rebates, product pricing, sales volumes, amount of inventory in the distribution channel and prescription trends. Adjustments to actual for the years 2021 and 2020 were not material to the Company&#8217;s revenues or earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient Co-Pay Assistance programs, Consumer Rebates and Loyalty Programs are rebates offered on many of the Company&#8217;s products.  Patient Co-Pay Assistance Programs are patient discount programs offered in the form of coupon cards or point of sale discounts, with which patients receive certain discounts off their prescription at participating pharmacies, as defined by the specific product program. An accrual for these programs is established, equal to management&#8217;s estimate of the discount, rebate and loyalty incentives attributable to a sale.  That estimate is based on historical experience and other relevant factors. The accrual is adjusted throughout each quarter based on actual experience and changes in other factors, if any.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Fees</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells products primarily to wholesalers, and in some instances to large pharmacy chains such as CVS and Walmart.  The Company has Distribution Services Agreements ("DSAs") with several large wholesale customers such as McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Specialty.  Under the DSAs, the wholesalers agree to provide services, and the Company pays the contracted DSA distribution service fees for these services based on product volumes.  Additionally, price appreciation credits are generated when the Company increases a product&#8217;s wholesaler acquisition cost (&#8220;WAC&#8221;) under contracts with certain wholesalers. Under such contracts, the Company is entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. Such credits are offset against the total distribution service fees paid to each such wholesaler. The variable consideration associated with price appreciation credits is reflected in the transaction price of products sold when it is determined to be probable that a significant reversal will not occur. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $17 million and $15 million for the years 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Commissions </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Component</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less. The Company's global payment terms are generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM5MzI5_70a72a43-4f7f-4419-aca2-445874d33f43">thirty</span> to ninety days.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain facilities, vehicles and equipment principally under multi-year agreements generally having a lease term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM5NDgx_a56638c4-d79f-4701-9cb4-eeba251c7aba">one</span> to twenty years, some of which include termination options and options to extend the lease term from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM5NTc1_4194aaa1-36a3-4275-bf8a-8595947de005">one</span> to five years or on a month-to-month basis. The Company includes options that are reasonably certain to be exercised as part of the lease term. The Company may negotiate termination clauses in anticipation of changes in market conditions but generally, these termination options are not exercised. Certain lease agreements also include variable payments that are dependent on usage or may vary month-to-month such as insurance, taxes and maintenance costs. None of the Company's lease agreements contain material residual value guarantees or material restrictive covenants.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to record a right-of-use asset and corresponding lease liability, equal to the present value of the lease payments at the commencement date of each lease. For all asset classes, in determining future lease payments, the Company has elected to aggregate lease components, such as payments for rent, taxes and insurance costs with non-lease components such as maintenance costs, and account for these payments as a single lease component. In limited </span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">circumstances, when the information necessary to determine the rate implicit in a lease is available, the present value of the lease payments is determined using the rate implicit in that lease. If the information necessary to determine the rate implicit in a lease is not available, the Company uses its incremental borrowing rate at the commencement of the lease, which represents the rate of interest that the Company would incur to borrow on a collateralized basis over a similar term.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All leases must be classified as either an operating lease or finance lease. The classification is determined based on whether substantive control has been transferred to the lessee.  The classification governs the pattern of lease expense recognition. For leases classified as operating leases, total lease expense over the term of the lease is equal to the undiscounted payments due in accordance with the lease arrangement. Fixed lease expense is recognized periodically on a straight-line basis over the term of each lease and includes: (i) imputed interest during the period on the lease liability determined using the effective interest rate method plus (ii) amortization of the right-of-use asset for that period. Amortization of the right-of-use asset during the period is calculated as the difference between the straight-line expense and the imputed interest on the lease liability for that period. Variable lease expense is recognized when the achievement of the specific target is considered probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to internal research and development programs, including costs associated with the development of acquired IPR&amp;D, are expensed as goods are delivered or services are performed. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Milestone payments made to third parties before a product receives regulatory approval, but after the milestone is determined to be probable, are expensed and included in Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third parties as reimbursement of development activities conducted under certain research and development arrangements are recognized as a reduction of Research and development expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Costs </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal fees and other costs related to litigation and other legal proceedings or services are expensed as incurred and are included in Selling, general and administrative expenses. Certain legal costs associated with acquisitions are included in Acquisition-related costs and certain legal costs associated with divestitures, legal settlements and other business development activities are included in Litigation and other matters or Net gain on sales of assets within Other expense (income), net, as appropriate. Legal costs expensed are reported net of expected insurance recoveries. A claim for insurance recovery is recognized when realization becomes probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs comprise product samples, print media, promotional materials and television advertising and are expensed on the first use of the advertisement. Included in Selling, general and administrative expenses are advertising costs of $515 million, $451 million and $544 million, for 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes all share-based payments to employees, including grants of employee stock options and restricted share units (&#8220;RSUs&#8221;), at estimated fair value. The Company amortizes the fair value of stock option or RSU grants on a straight-line basis over the requisite service period of the individual stock option or RSU grant, which generally equals the vesting period. Stock option and RSU forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based compensation is recorded in Research and development expenses and Selling, general and administrative expenses, as&#160;appropriate. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-Related Contingent Consideration </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related contingent consideration, which primarily consists of potential milestone payments and royalty obligations, is recorded in the Consolidated Balance Sheets at its acquisition date estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in fair value measurement accounting.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense includes standby fees, the amortization of debt discounts and deferred financing costs, accretion of debt premiums and the amortization of amounts excluded from the assessment of effectiveness related to the Company's cross-currency swaps. Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized. Capitalized interest related to construction in progress as of December 31, 2021 and 2020 was $60 million and $45&#160;million, respectively, and is included in Property, plant and equipment, net. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized. Deferred tax assets and liabilities are measured using enacted tax rates and&#160;laws.  Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such position are measured based on the amount for which there is a greater than 50% likelihood of being realized upon settlement. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within one year. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance&#160;sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share Attributable to Bausch Health Companies Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period. Diluted loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period after giving effect to dilutive potential common shares for stock options and RSUs, determined using the treasury stock&#160;method.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss comprises Net loss and Other comprehensive (loss) income. Other comprehensive (loss) income includes items such as foreign currency translation adjustments, unrealized holding gains and losses on available-for-sale and other investments and certain pension and other postretirement benefit plan adjustments. Accumulated other comprehensive loss is recorded as a component of shareholders&#8217; equity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Accruals for loss contingencies are recorded when the Company determines that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the estimate of the amount of the loss is a range and some amount within the range appears to be a better estimate than any other amount within the range, that amount is accrued as a liability. If no amount within the range is a better estimate than any other amount, the minimum amount of the range is accrued as a&#160;liability. These accruals are adjusted periodically as assessments change or additional information becomes available.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Benefit Plans </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors various retirement and pension plans, including defined benefit pension plans, defined contribution plans and a participatory defined benefit postretirement plan. The determination of defined benefit pension and postretirement plan obligations and their associated expenses requires the use of actuarial valuations to estimate the benefits employees earn while working, as well as the present value of those benefits. Net actuarial gains and losses that exceed 10 percent of the greater of the plan&#8217;s projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated average future service period of the plan participants (or the </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimated average future lifetime of the plan participants if the majority of plan participants are inactive) or the period until any anticipated final plan settlements. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New&#160;Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses.  The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to Accumulated deficit of less than $1&#160;million. The application of this guidance did not have a material effect on the Company's results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement.  The guidance was effective for the Company beginning January 1, 2020. The application of this guidance did not have a material effect on the Company's disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans.  The guidance was effective for annual periods ending after December 15, 2020. The application of this guidance did not have a material effect on the Company's disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160; The guidance is effective for the Company beginning with annual periods beginning January 1, 2021.&#160; The application of this guidance did not have a material effect on the Company's financial position, results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.&#160; Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging.&#160;The optional amendments are effective for all entities as of March 12, 2020, through December 31, 2022. During 2020 and 2021, the Company has not entered into any contract modifications in which the optional expedients were applied.&#160; However, if prior to December 31, 2022, the Company enters into a contract modification in which the optional expedients are applied, the Company will evaluate the impact of adoption of this guidance on its financial position, results of operations and cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883569816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock', window );">ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE</a></td>
<td class="text">ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition Agreement for Synergy Pharmaceuticals Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 6, 2019, the Company acquired certain assets of Synergy Pharmaceuticals Inc. ("Synergy") for a cash purchase price of approximately $180 million and the assumption of certain liabilities, pursuant to the terms approved by the U.S. Bankruptcy Court for the Southern District of New York on March 1, 2019. Among the assets acquired are the worldwide rights to the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) product, a once-daily tablet for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. This acquired business is included in the Company's Salix segment and is expected to result in additional revenues and costs savings associated with business synergies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of certain assets of Synergy has been accounted for as a business combination under the acquisition method of accounting since: (i) substantially all of the fair value of the assets acquired is not&#160;concentrated in a single identifiable asset or group of similar identifiable assets and (ii) substantive inputs and processes were acquired to contribute to the creation of outputs. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date:</span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:89.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.005%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brand intangible assets (estimated useful life 7 years)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill associated with the acquisition of certain assets of Synergy is not deductible for income tax purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue and Operating Results </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 were $55 million. Operating results associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 and pro-forma revenues and operating results for the year 2019 were not material. Included in Other expense, net for 2019 are acquisition-related costs of $8 million directly related to the acquisition of certain assets of Synergy, which include expenditures for advisory, legal, valuation, accounting and other similar services.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other material business combinations in 2021, 2020 or 2019. The measurement period for all acquisitions has closed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Option to Purchase All Ophthalmology Assets of Allegro Ophthalmics, LLC ("Allegro")</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 21, 2020, the Company announced that it had entered into an agreement to acquire an option to purchase all of the ophthalmology assets of Allegro (the "Option"), a privately held biopharmaceutical company focused on the development of therapies that regulate integrin functions for the treatment of ocular diseases. Among the assets to be acquired if the Option was exercised, were the worldwide rights to risuteganib (Luminate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), Allegro's lead investigational compound in retina, which is believed to simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry Age-related Macular Degeneration.  During the three months ended September 30, 2020, the Company made and expensed as acquired IPR&amp;D included in Other expense, net, an initial upfront payment of $10&#160;million to acquire the Option.  However, on June 23, 2021, Allegro notified the Company that it did not raise the additional funding required under the option agreement.  Pursuant to the terms of the option agreement, the Option thereby terminated, and the Company exercised its right to convert the $10&#160;million upfront payment into a minor equity interest in Allegro.  The Company expects that it will make no additional payments pursuant to this option agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions.  The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain.  The commitment periods under these agreements vary and include customary termination provisions.  Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of Amoun Pharmaceutical Company S.A.E. ("Amoun")</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, the Company announced that it and certain of its affiliates had entered into a definitive agreement to sell all of its equity interests in Amoun for total gross consideration of approximately $740&#160;million (including the assignment to the purchasing entity of an intercompany loan granted by the Company to Amoun), subject to certain adjustments (the &#8220;Amoun Sale&#8221;). The Amoun Sale closed on July 26, 2021. As part of the Amoun Sale, cash generated by Amoun during the period from the locked-box date of January 1, 2021 through closing was for the benefit of the purchasing entity, subject to working capital during such period. Amoun manufactures, markets and distributes branded generics of human and animal health products. The Amoun business was part of the International Rx segment (previously </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included within the former Bausch + Lomb/International segment) and was reclassified as held for sale as of December 31, 2020. As a result of meeting the criteria for held for sale classification, the carrying value of the Amoun business, was adjusted to its estimated fair value, less costs to sell, and the Company recognized an impairment loss of $96&#160;million during the three months ended December 31, 2020 and an additional impairment loss of $88&#160;million during 2021, included within Asset impairments, including loss on assets held for sale in the Consolidated Statements of Operations. In connection with completing the Amoun Sale, the Company recognized an additional loss of $26&#160;million during 2021, included within Other (income) expense, net in the Combined Statements of Operations. The total loss of $210&#160;million includes the release of non-cash cumulative foreign currency translation losses of $340&#160;million, which were included as part of the carrying value of the Amoun business when measuring for impairment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the Consolidated Balance Sheets as of December 31, 2020 are the following carrying amounts of the Amoun business' assets and liabilities held for sale.</span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:38.353%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.353%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883426680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</a></td>
<td class="text">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and integration costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of December 31, 2021 was $19 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $18&#160;million, $11&#160;million and $31&#160;million of restructuring and integration-related costs and made payments of $19&#160;million, $18&#160;million and $31 million during 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation costs, Separation-related costs, IPO Costs and IPO-related Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and will incur, costs associated with activities to effectuate the B+L Separation and the Solta IPO. These activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company and (ii) registering the Bausch + Lomb and Solta Medical businesses as independent publicly traded entities. Separation and IPO costs are incremental costs directly related to the B+L Separation and Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for the Bausch + Lomb and Solta Medical entities. Included in Restructuring, integration, separation and IPO costs for the years ended December 31, 2021 and 2020 are Separation and IPO costs of $32&#160;million and $11&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also incurred, and will incur, Separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and Solta IPO. Separation-related and IPO-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative for years ended December 31, 2021 and 2020 are Separation-related and IPO-related costs of $132&#160;million and $21&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883479992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#160;&#8212;&#160;Quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:26.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.201%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swaps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of three months or less when&#160;purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, Restricted cash and other settlement deposits includes $1,510&#160;million of payments into escrow funds under the terms of settlement agreements regarding that certain U.S. securities litigation (subject to an objector's appeal of the final court approval) and the Glumetza Antitrust Litigation. These payments are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature.  These payments will remain in escrow until final approval of the settlements as discussed in Note 20, "LEGAL PROCEEDINGS".</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of Level 3 during 2021 and 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cross-currency Swaps</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $1,250 million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from adverse movements in exchange rates. The euro-denominated net investment being hedged was the Company&#8217;s investment in certain euro-denominated subsidiaries.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2021, the Company entered into a transaction to unwind its cross-currency swaps and received net proceeds of $4&#160;million, which included interest income of $6&#160;million, offset by the amount owed by the Company upon the unwinding of $2&#160;million. The gain arising from the transaction of the swaps has been included as a component of Other comprehensive loss.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company's cross-currency swaps as included in the Consolidated Balance Sheets as of December 31, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for 2021 and 2020: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Other comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021 and 2020, the Company received $27&#160;million and $23&#160;million, respectively, in settlements of its cross-currency swaps which are reported as Investing activities in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Contracts</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021 and 2020, the Company entered into foreign currency exchange contracts.  As of December&#160;31, 2021, these contracts had an aggregate outstanding notional amount of $166&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company's foreign exchange contracts as included in the Consolidated Balance Sheets as of December 31, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company's foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for 2021 and 2020:</span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) related to changes in fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss related to settlements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related Contingent Consideration Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At December&#160;31, 2021, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 6% to 18%, and a weighted average risk-adjusted discount rate of 7%. The weighted average risk-adjusted discount rate was calculated by weighting each contract's relative fair value at December&#160;31, 2021.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the years 2021 and 2020:</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:63.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance, January 1, </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments / Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment included in other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance, December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a non-recurring basis:</span></div><div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:24.277%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current assets held for sale of $245&#160;million as of December 31, 2020 were remeasured to estimated fair value, less costs to sell, which utilized Level 3 unobservable inputs. See Note 3, "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE" for additional details regarding these assets held for sale.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of long-term debt as of December&#160;31, 2021 and 2020 was $22,689 million and $25,378 million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883572728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net, as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564973957192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT</a></td>
<td class="text">PROPERTY, PLANT AND EQUIPMENT<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of property, plant and equipment as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,820)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,781)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $177 million, $180 million and $178 million for 2021, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564915626360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS AND GOODWILL</a></td>
<td class="text">INTANGIBLE ASSETS AND GOODWILL<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets as of December&#160;31, 2021 and 2020 consist of:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:27.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.984%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Useful<br/>Lives<br/>(Years)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,914)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,055)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,741)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D not in service</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B&amp;L Trademark</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,128&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,948&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,186&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,741)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,445&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments, including loss on assets held for sale in the Consolidated Statement of Operations.  The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale in 2021 included: (i) impairments of $105&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, (ii) an $88&#160;million loss on assets held for sale in connection with the Amoun Sale, (iii) impairments of $23&#160;million, in aggregate, related to the discontinuance of certain product lines and (iv) $18&#160;million related to a portion of an IT infrastructure improvement project no longer being utilized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale in 2020 included impairments of: (i) $96&#160;million to reduce the carrying value of the Amoun business to its estimated fair value less costs to sell due to classifying the business as held for sale as discussed in Note 3, "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE", (ii) $16&#160;million in aggregate, due to decreases in forecasted sales of certain product lines, (iii) $1&#160;million in aggregate, related to the discontinuance of certain product lines not aligned with the focus of the Company's core businesses and (iv) $1&#160;million related to Acquired IPR&amp;D not in service.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale in 2019 included impairments of: (i) $58 million reflecting decreases in forecasted sales of certain product lines due to generic competition and other factors, (ii) $8 million related to assets being classified as held for sale, (iii) $5 million related to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core businesses and (iv) $4 million related to Acquired IPR&amp;D not in service. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impairments to assets reclassified as held for sale were measured as the difference of the carrying value of these assets as compared to the estimated fair values of these assets less costs to sell determined using a discounted cash flow analysis which utilized Level 3 unobservable inputs. The other impairments and adjustments to finite-lived intangible assets were measured as the difference of the historical carrying value of these finite-lived assets as compared to the estimated fair value as determined using a discounted cash flow analysis using Level 3 unobservable inputs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, the Company&#8217;s products face the expiration of their patent or regulatory exclusivity. The Company anticipates that product sales for such product would decrease shortly following a loss of exclusivity ("LOE"), due to the possible entry of a generic competitor. Where the Company has the rights, it may elect to launch an authorized generic of such product (either as the Company&#8217;s own branded generic or through a third-party).  This may occur prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product could still be significant, and the effect on future revenues could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management continually assesses the useful lives related to the Company's long-lived assets to reflect the most current assumptions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the five years ending December&#160;31 and thereafter are as&#160;follows: </span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:16.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.881%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the years ended December 31, 2021, 2020 and 2019 were as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:31.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.408%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + <br/>Lomb/<br/>International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + <br/>Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International Rx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,805&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of certain assets of Synergy </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,786&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets held for sale reclassified to goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale (Note 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,457&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment.  The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1). </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit's terminal value. </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To forecast a reporting unit's cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management's and a market participant's view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected LOE to the Company's product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#8217;s control could have a positive or negative impact on achieving its targets.  Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2019</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2019 by first assessing qualitative factors. Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit. In each quantitative fair value test performed, the fair value was greater than the carrying value of the reporting unit.  As a result, there was no impairment to the goodwill of any reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2020</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative impacts of the COVID-19 pandemic on the global economy have led to significant volatility in the global equity markets. The Company has been able to continue its operations with limited disruptions and has assessed the potential impact that the COVID-19 pandemic is likely to have on its forecasted cash flows.  In performing its assessment, the Company considered the possible effects and outcomes of the COVID-19 pandemic on, among other things, its supply chain, customers and distributors, employee base, product sustainability, research and development activities, product pipeline and consumer demand and related rebates and discounts and has made adjustments, although not considered to be material, to its long-term forecasts used in its previous goodwill impairment assessments, for these and other matters. After completing this assessment, although not completely insulated from the negative effects of the COVID-19 pandemic, the Company believes that its long-term forecasted cash flows, as adjusted for the possible outcome of the COVID-19 pandemic and other matters, do not indicate that the fair value of any reporting unit may be below its carrying value. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2020 revenues were most negatively impacted during its second quarter by certain social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize prior to the third quarter of 2020. Revenues for 2021 and 2020 were $8,434&#160;million and $8,027&#160;million, respectively. The increase of $407&#160;million in revenue represents an improving trend over the decreases in year-over-year revenues for the three month periods ended June 30, 2020, September 30, 2020 and December 31, 2020 of 23%, 3% and less than 1%, respectively. The Company's revenues returned to pre-pandemic levels for many of its businesses and geographies in 2021 and, presuming there continues to be increased availability of effective vaccines and any further resurgence of the COVID-19 virus, the delta and omicron variants and other variant strains thereof do not have a material adverse impact on efforts to contain the COVID-19 virus, the Company anticipates the COVID-19 pandemic to have a minimal impact on its remaining businesses and geographies in 2022. However, the rates of recovery for each business will vary by geography and will be dependent upon, among other things, the availability and effectiveness of vaccines for the COVID-19 virus, government responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus and other actions taken in response to the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Interim Goodwill Impairment Assessment</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2020, after giving consideration to the nature and timing of the negative impacts of the COVID-19 pandemic on the Company's forecasted cash flows, with the exception of the Ortho Dermatologics reporting unit, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, no impairments were recorded. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020 and June 30, 2020, the operating results for the Ortho Dermatologics reporting unit were less than forecasted primarily due to certain products experiencing longer launch cycles than originally anticipated as a result of the COVID-19 pandemic. The Company revised its long-term forecasts as of March 31, 2020 and as of June 30, 2020 for these matters. Management believed that these events were indicators that there was less headroom as of March 31, 2020 and June 30, 2020 as compared to the headroom calculated on the date Ortho Dermatologics goodwill was previously tested for impairment. Therefore, a quantitative fair value test for impairment to the goodwill of the Ortho Dermatologics reporting unit was performed at March 31, 2020 and at June 30, 2020. Based on the quantitative fair value tests, the fair value of the Ortho Dermatologics reporting unit continued to be greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit at March 31, 2020 and at June 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2020 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2020, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2020, the Company considered, among other matters, a range of potential impacts of COVID-19 pandemic related matters and the limited headroom calculated on the date Ortho Dermatologics goodwill was last tested for impairment (June 30, 2020).  The Company believed that these factors may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2020, utilizing a long-term growth rate of 2.0% and a range of discount rates between 9.50% and 9.75%, in estimation of the fair value of this reporting unit.  Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2021</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Quarter 2021 - Realignment of Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2021, the Company began operating in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International Rx, (iv) Ortho Dermatologics and (v) Diversified Products. The Bausch + Lomb segment consists of the: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. The Salix segment consists of the Salix reporting unit. The International Rx segment consists of the International Rx reporting unit. The Ortho Dermatologics segment consists of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. This realignment in segment structure resulted in a change in the Company's former International reporting unit, which is now divided between the International Bausch + Lomb reporting unit and International Rx reporting unit. In addition, as part of this realignment of segment structure, certain products historically included in the Generics reporting unit are now included in the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. Goodwill previously reported in the former International reporting unit was reassigned to the International Bausch + Lomb and International Rx reporting units, and a portion of goodwill previously reported in the former Generics reporting unit was reassigned to the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in reporting units, the Company performed a qualitative fair value assessment for its former: (i) International and (ii) Generics reporting units. Based on the qualitative fair value assessment performed, management believed that it was more likely than not that the carrying values of its former: (i) International and (ii) </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generics reporting units were less than their respective fair values and therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the change in reporting units, as a result of the change in composition of the net assets for its current: (i) International Bausch + Lomb, (ii) International Rx and (iii) Generics reporting units, the Company performed a quantitative fair value test. The quantitative fair value test utilized a range of long-term growth rates of 1.0% to 3.0% and a range of discount rates between 11.0% and 12.25%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than 40%, and, therefore, there was no impairment to goodwill. In addition, as the U.S. Bausch + Lomb reporting unit had a change in composition of its net assets related to certain products historically included in the Generics reporting unit now being included in the U.S. Bausch + Lomb reporting unit, the Company performed a qualitative assessment of this reporting unit. Based on the qualitative fair value assessment performed, management believed that it was more likely than not that the carrying value of its current U.S. Bausch + Lomb reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">March 31, 2021 Impairment to Goodwill </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products.  In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;D spend to eliminate projects it has identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there is less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company's most recent cash flow projections as revised in the first quarter of 2021 to reflect the business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of 1.0% and a range of discount rates between 9.0% and 10.0%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at March 31, 2021, and the Company recognized a goodwill impairment of $469&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Quarter 2021 - Realignment of Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the second quarter of 2021, the Company changed the way it reviews the financial information of its Bausch + Lomb segment.  Beginning in the second quarter of 2021, management no longer reviews the financial information of its Bausch + Lomb segment on a geographic basis, but instead reviews this financial information on a business line basis.  This change created a change in the reporting units of the Bausch + Lomb segment. After the change, under its business line view, the Bausch + Lomb segment consists of the global: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. Prior to the second quarter of 2021, under the geographic view, the Bausch + Lomb segment consisted of the former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. The change in Bausch + Lomb reporting units does not impact the reported revenues and segment profits of the Bausch + Lomb segment for any prior periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in its Bausch + Lomb reporting units, the Company performed a qualitative fair value assessment for its former reporting units. Based on the qualitative fair value assessment, management believed that it was more likely than not that the carrying values of its former:  (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units were less than their respective fair values and, therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the change in composition of net assets, the Company performed a quantitative fair value test of its new: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units immediately following the change in the Bausch + Lomb segment. The quantitative fair value test utilized long-term growth rates of 2.0% and 3.0% and a range of discount rates between 7.0% and 10.0%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than 45%, and, therefore, there was no impairment to goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 30, 2021 and September 30, 2021 Interim Assessments of Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor the market conditions impacting the Ortho Dermatologics reporting unit. The  Company's latest forecasts for the Ortho Dermatologics reporting unit include a range of potential outcomes for, among other matters: (i) the impacts of the COVID-19 pandemic on operations, (ii) the impact of the loss of exclusivity of certain products, (iii) the impact of longer launch cycles for certain new products, (iv) progress of its product pipeline and (v) ongoing pricing pressures, which could negatively impact the reporting unit's results over the long term. The changes in the amounts and timing of revenues and expenses in the latest forecast as compared to the forecast used at March 31, 2021 (the last time goodwill of the Ortho Dermatologics reporting unit was tested), were not substantial enough to materially adversely affect the recoverability of the Ortho Dermatologics reporting unit's assets and are not material enough to indicate that the fair value of the Ortho Dermatologics reporting unit might be below its carrying value as last tested at March 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other events occurred or circumstances changed during the period October 1, 2020 (the earliest date goodwill was tested for all other reporting units) through December 31, 2021 that indicated that the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit, might be below its carrying value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2021 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2021, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2021, the Company considered, among other matters, the limited headroom as a result of the impairment to the goodwill of the Ortho Dermatologics reporting unit when last tested (March 31, 2021) and macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The Company believed that these facts and circumstances may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2021, utilizing a long-term growth rate of 1.0% and a discount rate of 9.0%, in estimation of the fair value of this reporting unit.  Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If market conditions deteriorate, if the factors and circumstances regarding the COVID-19 pandemic escalate beyond management&#8217;s current expectations, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and those charges could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated goodwill impairment charges through December 31, 2021 were $4,180 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564892495480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED AND OTHER CURRENT LIABILITIES</a></td>
<td class="text">ACCRUED AND OTHER CURRENT LIABILITIES<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,791&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,576&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883429688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">FINANCING ARRANGEMENTS</a></td>
<td class="text">FINANCING ARRANGEMENTS<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs as of December 31, 2021 and 2020 consists of the following:</span></div><div style="margin-top:11pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:34.158%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.000% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.500% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.750% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.875% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.000%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.500%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.000%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.000%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.000%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.250%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,925&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes and Senior Unsecured Notes contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#8217;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of December&#160;31, 2021, the amount available for restricted payments under the "builder basket" in the Company&#8217;s most restrictive indentures (as defined by those indentures) was approximately $13,800&#160;million (although such availability is subject to the Company's compliance with a 2.00:1.00 fixed charge coverage ratio). The 2023 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that requires the Company to maintain a first lien net leverage ratio of not greater than 4.00:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the "Senior Secured Credit Facilities" under the Company's Fourth Amended and Restated Credit and Guaranty Agreement (the &#8220;Restated Credit Agreement&#8221;), with a syndicate of financial institutions and investors as lenders. The Restated Credit Agreement provides for a revolving credit facility of $1,225 million (the "2023 Revolving Credit Facility") and a seven year Tranche B Term Loan Facility of $4,565 million (the &#8220;June 2025 Term Loan B Facility&#8221;) borrowed by the Company&#8217;s subsidiary, Bausch Health Americas, Inc. ("BHA"). </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Revolving Credit Facility matures on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company or BHA in an aggregate principal amount in excess of $1,000 million. Both the Company and BHA are borrowers with respect to the 2023 Revolving Credit Facility. Borrowings under the 2023 Revolving Credit Facility may be made in U.S. dollars or Canadian dollars (or if an amendment to the Restated Credit Agreement is made to replace LIBOR with an alternative benchmark rate with respect to borrowings under the Revolving Credit Facility denominated in euros, euros).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had $285 million of outstanding borrowings, $54 million of issued and outstanding letters of credit, and remaining availability of $886 million under its 2023 Revolving Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2018, the Company entered into the First Incremental Amendment to the Restated Credit Agreement, which provided an additional seven year Tranche B Term Loan Facility of $1,500&#160;million (the "November 2025 Term Loan B Facility").</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Current Description of Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Senior Secured Credit Facilities in U.S. dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a base rate determined by reference to the highest of: (a) the prime rate (as defined in the Restated Credit Agreement), (b) the federal funds effective rate plus 1/2 of 1.00% or (c) the eurocurrency rate (as defined in the Restated Credit Agreement) for a period of one month plus 1.00% (or if such eurocurrency rate shall not be ascertainable, 1.00%) or (ii) a eurocurrency rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in euros, when available, are expected to bear interest at a term benchmark rate determined by reference to the costs of funds for euro deposits for the interest period relevant to such borrowing (provided however, that the eurocurrency rate is at no time expected to be less than 0.00% per annum), plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in Canadian dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a prime rate determined by reference to the higher of: (a) the rate of interest last quoted by The Wall Street Journal as the &#8220;Canadian Prime Rate&#8221; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus 1.00% (provided however, that the prime rate shall at no time be less than 0.00%) or (ii) the bankers&#8217; acceptance rate for Canadian dollar deposits in the Toronto interbank market (the &#8220;BA rate&#8221;) for the interest period relevant to such borrowing (provided however, that the BA rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i)&#160;100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii)&#160;100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the Restated Credit Agreement), (iii)&#160;50% of Excess Cash Flow (as&#160;defined in the Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv)&#160;100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility are 2.00% and 1.75%, respectively, with respect to base rate and prime rate borrowings and 3.00% and 2.75%, </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, with respect to eurocurrency rate and BA rate borrowings. As of December 31, 2021, the stated rates of interest on the Company&#8217;s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were 3.09% and 2.84% per annum, respectively.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for both the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility is 5.00% per annum. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of December 31, 2021, there were no remaining mandatory quarterly amortization payments for the Senior Secured Credit Facilities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are 1.50%-2.00% with respect to base rate or prime rate borrowings and 2.50%-3.00% with respect to eurocurrency rate or BA rate borrowings.&#160; As of December 31, 2021, the stated rate of interest on the 2023 Revolving Credit Facility was 2.84% per annum. In addition, the Company is required to pay commitment fees of 0.25% - 0.50% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency&#160;fees.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restated Credit Agreement permits the incurrence of incremental credit facility borrowings, up to the greater of $1,000 million and 28.5% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the Restated Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the Restated Credit Agreement under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">6.500% Senior Secured Notes due 2022 and 7.00% Senior Secured Notes due 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company issued $1,250&#160;million aggregate principal amount of 6.500% senior secured notes due March 15, 2022 (the &#8220;March 2022 Secured Notes&#8221;) and $2,000&#160;million aggregate principal amount of 7.000% senior secured notes due March 15, 2024 (the &#8220;March 2024 Secured Notes&#8221;), in a private placement. Interest on these notes is payable semi-annually in arrears on each March 15 and September 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The March 2022 Secured Notes were repaid in full as part of the May 2020 Refinancing Transactions (as defined below).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The March 2024 Secured Notes were repaid in full during 2021 with cash on hand and as part of the June 2021 Refinancing Transactions (as defined below).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.500% Senior Secured Notes due 2025</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;17, 2017, the Company issued $1,000&#160;million, and, on November 21, 2017, the Company issued $750&#160;million,  aggregate principal amount of 5.500% Senior Secured Notes due November 2025 (the &#8220;November 2025 Secured Notes&#8221;), </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in a private placement. Interest on the November 2025 Secured Notes is payable semi-annually in arrears on each May 1 and November 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The November 2025 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time, at the redemption prices set forth in the indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.750% Senior Secured Notes due 2027 - March 2019 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2019, BHA and the Company issued: (i) $1,000 million aggregate principal amount of 8.500% Senior Unsecured Notes due 2027 (the "January 2027 Unsecured Notes") and (ii) $500 million aggregate principal amount of 5.750% Senior Secured Notes due August 2027 (the "August 2027 Secured Notes"), respectively, in a private placement. A portion of the proceeds and cash on hand were used to: (i) repurchase $584 million of 5.875% Senior Unsecured Notes due 2023 (the "May 2023 Unsecured Notes"), (ii) repurchase $518 million of 5.625% Senior Unsecured Notes due 2021 (the &#8220;December 2021 Unsecured Notes&#8221;), (iii) repurchase $216 million of 5.500% Senior Unsecured Notes due 2023 (the "March 2023 Unsecured Notes&#8221;) and (iv) pay all fees and expenses associated with these transactions (collectively, the &#8220;March 2019 Refinancing Transactions&#8221;). During April 2019, the Company redeemed $182 million of the December 2021 Unsecured Notes, representing the remaining outstanding principal balance of the December 2021 Unsecured Notes and completing the refinancing of $1,500 million of debt in connection with the March 2019 Refinancing Transactions. The March 2019 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $8 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. Interest on the August 2027 Secured Notes is payable semi-annually in arrears on each February 15 and August 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after August 15, 2022, at the redemption prices set forth in the indenture. The Company may redeem some or all of the August 2027 Secured Notes prior to August 15, 2022 at a price equal to 100% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to August 15, 2022, the Company may redeem up to 40% of the aggregate principal amount of the August 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">4.875% Senior Secured Notes due 2028 - June 2021 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, the Company issued $1,600&#160;million aggregate principal amount of 4.875% Senior Secured Notes due June 2028 (the &#8220;June 2028 Secured Notes&#8221;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase a portion and redeem the remainder of $1,600&#160;million of the March 2024 Secured Notes, representing the remaining outstanding principal balance of the March 2024 Secured Notes and (ii) pay all fees and expenses associated with these transactions (collectively, the &#8220;June 2021 Refinancing Transactions&#8221;). The June 2021 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $38&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. Interest on the June 2028 Secured Notes is payable semi-annually in arrears on each June 1 and December 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2028 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after June 1, 2024, at the redemption prices set forth in the June 2028 Secured Notes indenture. The Company may redeem some or all of the June 2028 Secured Notes prior to June 1, 2024 at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of the redemption plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to June 1, 2024, the Company may redeem up to 40% of the aggregate principal amount of the June 2028 Secured Notes using the net proceeds of certain equity offerings at the redemption price set forth in the June 2028 Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.500% Senior Unsecured Notes due 2023</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2015, the Company issued $1,000 million aggregate principal amount of March 2023 Unsecured Notes in a private placement. The March 2023 Unsecured Notes accrued interest at the rate of 5.500% per year, payable semi-annually in arrears. On March 8, 2019 and May 23, 2019, the Company repurchased $216 million and $382 million of March 2023 Unsecured Notes as part of the March 2019 Refinancing Transactions and the May 2019 Refinancing Transactions (as defined below), respectively. Throughout 2020, the Company repurchased, in aggregate, $169&#160;million of March 2023 Unsecured Notes using cash on hand. The Company repurchased the remaining outstanding balance of $233&#160;million in December 2020 as part of the December 2020 Refinancing Transactions (as defined below).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.375% Senior Unsecured Notes due 2020, 5.875% Senior Unsecured Notes due 2023, 4.500% Senior Unsecured Notes due 2023 and 6.125% Senior Unsecured Notes due 2025</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2015, VRX Escrow Corp. (the "VRX Issuer"), a newly formed wholly owned subsidiary of the Company, issued $2,000 million aggregate principal amount of 5.375% Senior Unsecured Notes due 2020 (the "March 2020 Unsecured Notes"), $3,250 million aggregate principal amount of May 2023 Unsecured Notes, &#8364;1,500 million aggregate principal amount of 4.500% Senior Unsecured Notes due 2023 (the "Euro Notes&#8221;) and $3,250 million aggregate principal amount of 6.125% Senior Unsecured Notes due 2025 (the "April 2025 Unsecured Notes" and, together with the March 2020 Unsecured Notes, the May 2023 Unsecured Notes and the Euro Notes, the "VRX Notes") in a private placement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The March 2020 Unsecured Notes accrued interest at the rate of 5.375% per year and were repaid in full as part of certain refinancing transactions completed in 2017 and 2018. The May 2023 Unsecured Notes and the Euro Notes accrued interest at the rate of 5.875% and 4.500%  per year, respectively and were each repaid in full as of December 31, 2020, as discussed below. The April 2025 Unsecured Notes accrue interest at the rate of 6.125% per year, payable semi-annually in arrears. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of a refinancing transaction completed in June 2018, the Company repaid the remaining outstanding principal amounts of the March 2020 Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company repurchased $584 million and $1,118 million of May 2023 Unsecured Notes as part of the March 2019 Refinancing Transactions and the May 2019 Refinancing Transactions (as defined below), respectively, and on October 3, 2019, the Company repaid an additional $100 million of May 2023 Unsecured Notes using cash on hand. On January 16, 2020, the Company redeemed $1,240 million aggregate principal amount of the May 2023 Unsecured Notes as part of the December 2019 Financing and Refinancing Transactions (as defined below). Throughout 2020, the Company repaid, in aggregate, $208&#160;million of the May 2023 Unsecured Notes, with the May 2023 Unsecured Notes having been fully repaid during November 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2020, the Company redeemed the remaining outstanding balance of the Euro Notes as part of the December 2020 Refinancing Transactions, as defined below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout 2021, the Company repaid, in aggregate, $600&#160;million of the April 2025 Unsecured Notes. The Company may redeem all or a portion of the April 2025 Unsecured Notes at the redemption prices set forth in the applicable indenture, plus accrued and unpaid interest to the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">9.000% Senior Unsecured Notes due 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;18, 2017, the Company issued $1,500 million aggregate principal amount of 9.000% Senior Unsecured Notes due 2025 (the &#8220;December 2025 Unsecured Notes&#8221;) in a private placement, the net proceeds of which were used to repurchase $1,500&#160;million in aggregate principal amount of previously outstanding senior unsecured notes (the "December 2017 Refinancing Transactions"). The related fees and expenses were paid using cash on hand. The December 2025 Unsecured Notes accrue interest at the rate of 9.000% per year, payable semi-annually in arrears on each of June 15 and December 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the December 2025 Unsecured Notes at any time prior to December 15, 2021, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to December 15, 2020, the Company may redeem up to 40% of the aggregate principal amount of the outstanding December 2025 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the December 2025 Unsecured Notes indenture. On or after December 15, 2021, the Company may redeem all or a portion of the December 2025 Unsecured Notes at the applicable redemption prices set forth in the December 2025 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">9.250% Senior Unsecured Notes due 2026</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 26, 2018, BHA issued $1,500 million in aggregate principal amount of 9.250% Senior Unsecured Notes due 2026 (the &#8220;April 2026 Unsecured Notes&#8221;) in a private placement, the net proceeds of which, and cash on hand, were used to repurchase $1,500 million in aggregate principal amount of unsecured notes. All fees and expenses associated with these transactions were paid with cash on hand (collectively, the &#8220;March 2018 Refinancing Transactions&#8221;). The April 2026 Unsecured Notes accrue interest at the rate of 9.250% per year, payable semi-annually in arrears on each of April 1 and October 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BHA may redeem all or a portion of the April 2026 Unsecured Notes at any time prior to April 1, 2022, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to April 1, 2021, BHA may redeem up to 40% of the aggregate principal amount of the outstanding April 2026 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the April 2026 Unsecured Notes indenture. On or after April 1, 2022, BHA may redeem all or a portion of the April 2026 Unsecured Notes at the applicable redemption prices set forth in the April 2026 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">8.500% Senior Unsecured Notes due 2027</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of a 2018 refinancing transaction, BHA issued $750 million in aggregate principal amount of January 2027 Unsecured Notes in a private placement. The January 2027 Unsecured Notes accrue interest at the rate of 8.500% per year, payable semi-annually in arrears on each of January 31 and July 31. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the March 2019 Refinancing Transactions described above, BHA issued $1,000 million aggregate principal amount of 8.500% Senior Unsecured Notes due January 2027. These are additional notes and form part of the same series as BHA&#8217;s existing January 2027 Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BHA may redeem all or a portion of the January 2027 Unsecured Notes at any time prior to July 31, 2022, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to July 31, 2021, BHA may redeem up to 40% of the aggregate principal amount of the outstanding January 2027 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the January 2027 Unsecured Notes indenture. On or after July 31, 2022, BHA may redeem all or a portion of the January 2027 Unsecured Notes at the applicable redemption prices set forth in the January 2027 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">7.000% Senior Unsecured Notes due 2028 and 7.250% Senior Unsecured Notes due 2029 - May 2019 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 23, 2019, the Company issued: (i) $750 million aggregate principal amount of 7.000% Senior Unsecured Notes due January 2028 (the "7.000% January 2028 Unsecured Notes") and (ii) $750 million aggregate principal amount of 7.250% Senior Unsecured Notes due May 2029 (the "May 2029 Unsecured Notes"), respectively, in a private placement. The proceeds and cash on hand were used to: (i) repurchase $1,118 million of May 2023 Unsecured Notes, (ii) repurchase $382 million of March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the &#8220;May 2019 Refinancing Transactions&#8221;). The May 2019 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $32 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. Interest on the 7.000% January 2028 Unsecured Notes is payable semi-annually in arrears on each January 15 and July 15. Interest on the May 2029 Unsecured Notes is payable semi-annually in arrears on each May 30 and November 30. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 7.000% January 2028 Unsecured Notes and the May 2029 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 15, 2023 and May 30, 2024, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the 7.000% January 2028 Unsecured Notes or the May 2029 Unsecured Notes prior to January 15, 2023 and May 30, 2024, respectively, at a price equal to 100% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to July 15, 2022, and May 30, 2022, the Company may redeem up to 40% of the aggregate principal amount of the 7.000% January 2028 Unsecured Notes or the May 2029 Unsecured Notes, respectively, using the proceeds of certain equity offerings at the redemption price set forth in the respective indenture. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.000% Senior Unsecured Notes due 2028 and 5.250% Senior Unsecured Notes due 2030 - December 2019 Financing and Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, the Company issued: (i) $1,250 million aggregate principal amount of 5.000% Senior Unsecured Notes due January 2028 (the "5.000% January 2028 Unsecured Notes") and (ii) $1,250 million aggregate principal amount of 5.250% Senior Unsecured Notes due January 2030 (the "January 2030 Unsecured Notes") in a private placement. The </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeds and cash on hand were used to: (i) redeem $1,240 million of May 2023 Unsecured Notes on January 16, 2020, (ii) finance the $1,210 million settlement of certain U.S. Securities litigation as discussed in Note 20, "LEGAL PROCEEDINGS" and (iii) pay all fees and expenses associated with these transactions (collectively, the "December 2019 Financing and Refinancing Transactions"). The redemption of $1,240&#160;million of May 2023 Unsecured notes was accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $24&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on the 5.000% January 2028 Unsecured Notes is payable semi-annually in arrears on each January 30 and July 30. Interest on the January 2030 Unsecured Notes is payable semi-annually in arrears on each January 30 and July 30. The 5.000% January 2028 Unsecured Notes and the January 2030 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 30, 2023 and January 30, 2025, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the 5.000% January 2028 Unsecured Notes or the January 2030 Unsecured Notes prior to January 30, 2023 and January 30, 2025, respectively, at a price equal to 100% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to January 30, 2023, the Company may redeem up to 40% of the aggregate principal amount of the 5.000% January 2028 Unsecured Notes or the January 2030 Unsecured Notes using the proceeds of certain equity offerings at the redemption price set forth in the respective indenture. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">6.250% Senior Unsecured Notes due 2029 - May 2020 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2020, the Company issued $1,500&#160;million aggregate principal amount of 6.250% Senior Unsecured Notes due February 2029 (the "6.250% February 2029 Unsecured Notes") in a private placement. The proceeds and cash on hand were used to: (i) repurchase $1,250&#160;million aggregate principal amount of the outstanding March 2022 Secured Notes, (ii) prepay $303&#160;million of mandatory amortization scheduled for payment in 2022 under the Company's June 2025 and November 2025 Term Loan B Facilities and (iii) pay all fees and expenses associated with these transactions (collectively, the "May 2020 Refinancing Transactions"). The May 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $27&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value. The 6.250% February 2029 Unsecured Notes accrue interest at the rate of 6.250% per year, payable semi-annually in arrears on each of February 15 and August 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the 6.250% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to August 15, 2023, the Company may redeem up to 40% of the aggregate principal amount of the outstanding 6.250% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the 6.250% February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the 6.250% February 2029 Unsecured Notes at the applicable redemption prices set forth in the 6.250% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.000% Senior Unsecured Notes due 2029 and 5.250% Senior Unsecured Notes due 2031 &#8211; December 2020 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2020, the Company issued $1,000&#160;million aggregate principal amount of 5.000% Senior Unsecured Notes due February 2029 (the "5.000% February 2029 Unsecured Notes") and $1,000&#160;million aggregate principal amount of 5.250% Senior Unsecured Notes due February 2031 (the "February 2031 Unsecured Notes") in a private placement. The aggregate proceeds and cash on hand were used to repurchase the remaining outstanding principal amounts of: (i) &#8364;1,500&#160;million of the Euro Notes, (ii) $233&#160;million of the March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the "December 2020 Refinancing Transactions"). The December 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $7&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value. The 5.000% February 2029 Unsecured Notes accrue interest at the rate of 5.000% per year, payable semi-annually in arrears on each of February 15 and August 15. The February 2031 Unsecured Notes accrue interest at the rate of 5.250% per year, payable semi-annually in arrears on each of February 15 and August 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the 5.000% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to 40% of the aggregate principal amount of the outstanding 5.000% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the 5.000% February 2029 Unsecured Notes </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indenture. On or after February 15, 2024, the Company may redeem all or a portion of the 5.000% February 2029 Unsecured Notes at the applicable redemption prices set forth in the 5.000% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the February 2031 Unsecured Notes at any time prior to February 15, 2026, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to 40% of the aggregate principal amount of the outstanding February 2031 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the February 2031 Unsecured Notes indenture. On or after February 15, 2026, the Company may redeem all or a portion of the February 2031 Unsecured Notes at the applicable redemption prices set forth in the February 2031 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Stated Rate of Interest</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average stated rate of interest for the Company's outstanding debt obligations as of December 31, 2021 and 2020 was 5.88% and 6.02%, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturities and Mandatory Payments</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities and mandatory payments of debt obligations for the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:88.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross maturities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Restated Credit Agreement, there is no Excess Cash Flow payment due for 2021.</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2022, the Company repaid its outstanding balance of $285&#160;million under its 2023 Revolving Credit Facility.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As more fully discussed in Note 23, "SUBSEQUENT EVENTS", during January 2022, the Company: (i) issued conditional notices of redemption to redeem in full all of its outstanding April 2025 Unsecured Notes and to redeem $370&#160;million aggregate principal amount of its outstanding December 2025 Unsecured Notes and (ii) issued $1,000&#160;million aggregate principal amount of 6.125% Senior Secured Notes due February 2027.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564882460568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</a></td>
<td class="text">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANSThe Company has defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers a closed grandfathered group of legacy Bausch &amp; Lomb Holdings Incorporated (&#8216;&#8216;B&amp;L&#8217;&#8217;) U.S. employees and employees in certain other countries. The U.S. defined benefit accruals were frozen as of December 31, 2004 and benefits that were earned up to December 31, 2004 were preserved. Participants continue to earn interest credits on their cash balance at an interest crediting rate that is equal to the greater of: (i) the average annual yield on 10-year treasury bonds in effect for the November preceding the plan year or (ii) 4.50%. The most significant non-U.S. plans are two defined benefit plans in Ireland. In 2011, both Ireland defined benefit plans were closed to future service benefit accruals; however, additional accruals related to annual salary increases continued. In December 2014, one of the Ireland defined benefit plans was amended effective August 2014 to eliminate future benefit accruals related to salary increases. All of the pension benefits accrued through the plan amendment date were preserved. As a result of the plan amendment, there are no active plan participants accruing benefits under the amended Ireland defined benefit plan.  The U.S. postretirement benefit plan was amended effective January 1, 2005 to eliminate employer contributions after age 65 for participants who did not meet the minimum requirements of age and service on that date. The employer contributions for medical and prescription <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug benefits for participants retiring after March 1, 1989 were frozen effective January 1, 2010. Effective January 1, 2014, the Company no longer offers medical and life insurance coverage to new retirees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the B&amp;L benefit plans, outside of the U.S., a limited group of the Company's employees are covered by defined benefit pension plans. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses December 31 as the year-end measurement date for all of its defined benefit pension plans and the postretirement benefit plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Pension Benefit Plans and Postretirement Benefit Plan </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes in its Consolidated Balance Sheets an asset or liability equal to the over- or under-funded benefit obligation of each defined benefit pension plan and postretirement benefit plan. Actuarial gains or losses and prior service costs or credits that arise during the period but are not recognized as components of net periodic benefit cost are recognized, net of tax, as a component of Other comprehensive income (loss). </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts included in Accumulated other comprehensive loss as of December 31, 2021 and 2020 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:38.413%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.963%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized actuarial losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized prior service credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Periodic (Benefit) Cost</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of net periodic (benefit) cost for the Company&#8217;s defined benefit pension plans and postretirement benefit plan in 2021, 2020 and 2019:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:25.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.504%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement loss recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Benefit Obligation, Change in Plan Assets and Funded Status </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents components of the change in projected benefit obligation, change in plan assets and funded status for 2021 and 2020: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:40.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.025%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Projected Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial (gain) losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded status, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Settlement loss recognized and Settlements in the tables above are the costs and payments associated with the conversion of a portion of the Company&#8217;s defined benefit plan in Ireland to a defined contribution plan during the fourth quarter of 2021.</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of the Company&#8217;s pension benefit plans were underfunded as of December 31, 2021 and 2020, having accumulated benefit obligations exceeding the fair value of plan assets. There were no U.S. pension benefit plans that were underfunded as of December 31, 2021, having accumulated benefit obligations exceeding the fair value of plan assets. Information for the underfunded pension benefit plans is as follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:56.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.971%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy for funding its pension benefit plans is to make contributions that meet or exceed the minimum statutory funding requirements. These contributions are determined based upon recommendations made by the actuary under accepted actuarial principles. In 2022, the Company expects to contribute $0, $9 million and $4 million to the U.S. pension benefit plan, the non-U.S. pension benefit plans and the U.S. postretirement benefit plan, respectively. The Company plans to use postretirement benefit plan assets and cash on hand, as necessary, to fund the U.S. postretirement benefit plan benefit payments in 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Benefit Payments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future benefit payments over the next 10 years for the pension benefit plans and the postretirement benefit plan, which reflect expected future service, as appropriate, are expected to be paid as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:54.219%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.430%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>&#160;Benefit<br/>&#160;Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assumptions</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used to determine net periodic benefit costs and benefit obligations for 2021, 2020 and 2019 were as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:43.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.427%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement Benefit Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For Determining Net Periodic (Benefit) Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:55.197%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.073%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement Benefit Plan</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For Determining Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected long-term rate of return on plan assets was developed based on a capital markets model that uses expected asset class returns, variance and correlation assumptions. The expected asset class returns were developed starting with current Treasury (for the U.S. pension plan) or Eurozone (for the Ireland pension plans) government yields and then adding corporate bond spreads and equity risk premiums to develop the return expectations for each asset class. The expected asset class returns are forward-looking. The variance and correlation assumptions are also forward-looking. They take into account historical relationships, but are adjusted to reflect expected capital market trends. The expected return on plan assets for the Company&#8217;s U.S. pension plan for 2021 was 5.00%. The expected return on plan assets for the Company&#8217;s Ireland pension plans was 2.75% for 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate used to determine benefit obligations represents the current rate at which the benefit plan liabilities could be effectively settled considering the timing of expected payments for plan participants.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 expected rate of return for the U.S. pension benefit plan will be 4.50%. The 2022 expected rate of return for the Ireland pension benefit plans will be 2.75%. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pension Benefit Plans Assets             </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pension benefit plan assets are invested in several asset categories. The following presents the actual asset allocation as of December 31, 2021 and 2020:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:77.048%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investment strategy underlying pension plan asset allocation is to manage the assets of the plan to provide for the non-current liabilities while maintaining sufficient liquidity to pay current benefits. Pension plan assets are diversified to protect against large investment losses and to reduce the probability of excessive performance volatility. Diversification of assets is achieved by allocating funds to various asset classes and investment styles within asset classes, and retaining investment management firm(s) with complementary investment philosophies, styles and approaches.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s pension plan assets are managed by outside investment managers using a total return investment approach, whereby a mix of equity and debt securities investments are used to maximize the long-term rate of return on plan assets. A significant portion of the assets of the U.S. and Ireland pension plans have been invested in equity securities, as equity portfolios have historically provided higher returns than debt and other asset classes over extended time horizons. Correspondingly, equity investments also entail greater risks than other investments. Equity risks are balanced by investing a significant portion of plan assets in broadly diversified fixed income securities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Plan Assets </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measured the fair value of plan assets based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. See Note 5, "FAIR VALUE MEASUREMENTS" for details on the Company's fair value measurements based on a three-tier hierarchy.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents total plan assets by investment category as of December 31, 2021 and 2020 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value. There were no transfers between Level 1 and Level 2 during 2021 and 2020.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.062%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans - U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. broad market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide developed markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:31.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.360%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans - Non-U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide developed markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global high yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government bond funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consisted primarily of term deposits and money market instruments. The fair value of the term deposits approximates their carrying amounts due to their short term maturities. The money market instruments also have short maturities and are valued using a market approach based on the quoted market prices of identical instruments. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commingled funds are not publicly traded. The underlying assets in these funds are publicly traded on the exchanges and have readily available price quotes. The Ireland pension plans held approximately 95% and 96% of the non-U.S. commingled funds in 2021 and 2020, respectively. The commingled funds held by the U.S. and Ireland pension plans are primarily invested in index funds.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underlying assets in the fixed income funds are generally valued using the net asset value per fund share, which is derived using a market approach with inputs that include broker quotes, benchmark yields, base spreads and reported trades. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined Contribution Plans </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors defined contribution plans in the U.S., Ireland and certain other countries.&#160;Under these plans, employees are allowed to contribute a portion of their salaries to the plans, and the Company matches a portion of the employee contributions. The Company contributed $44 million, $43 million and $41 million to these plans during the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883549176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES <div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities associated with the Company's operating leases are included in the Consolidated Balance Sheet as of December 31, 2021 and 2020 as follows:</span></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:82.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets included in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzItMC0xLTEtNTk0NzA_aae53d6e-38d6-4bae-885a-a2f1102e63b7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzItMC0xLTEtNTk0NzA_efb2683f-68c5-4ec5-ba14-7adb1864ba2c">Other non-current assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities included in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzQtMC0xLTEtNTk0NzA_43d158d1-ee05-4bae-a3d5-740a15d049b3"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzQtMC0xLTEtNTk0NzA_fa62fdb0-f620-4627-932e-a0cd84ebc336">Accrued and other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzUtMC0xLTEtNTk0NzA_5aae2037-0b31-4496-a31b-a0628ffc23c9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzUtMC0xLTEtNTk0NzA_fc2d7485-eeb6-4aa7-8f75-257ecb0d55a3">Other non-current liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, 2020 and 2019 the Company's finance leases were not material and for the years 2021, 2020 and 2019 sub-lease income and short-term lease expense were not material. Lease expense for the years 2021, 2020 and 2019 include:</span></div><div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:70.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable operating lease costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to operating leases for 2021, 2020 and 2019 is as follows:</span></div><div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:70.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid from operating cash flows for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, future payments under noncancelable operating leases for each of the five succeeding years ending December 31 and thereafter are as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:91.594%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of remaining lease payments</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883510536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text">SHARE-BASED COMPENSATIONIn May 2014, shareholders approved the Company&#8217;s 2014 Omnibus Incentive Plan (the &#8220;2014 Plan&#8221;), which replaced the Company&#8217;s 2011 Omnibus Incentive Plan (the &#8220;2011 Plan&#8221;) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">surrendered under the 2011 Plan and the Company&#8217;s 2007 Equity Compensation Plan. The Company registered 20,000,000 common shares of common stock for issuance under the 2014 Plan.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 30, 2018, the Company amended and restated the 2014 Plan (the &#8220;Amended and Restated 2014 Plan&#8221;). The Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Amended and Restated 2014 Plan has been increased by an additional 11,900,000 common shares, as approved by the requisite number of shareholders at the Company&#8217;s annual general meeting held on April 30, 2018, (ii) introduction of a $750,000 aggregate fair market value limit on awards (in either equity, cash or other compensation) that can be granted in any calendar year to a participant who is a non-employee director, (iii) housekeeping changes to address recent changes to Section 162(m) of the Internal Revenue Code, (iv) awards are expressly subject to the Company&#8217;s clawback policy and (v) awards not assumed or substituted in connection with a Change of Control (as defined in the Amended and Restated 2014 Plan) will only vest on a pro rata basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 28, 2020, the Company further amended and restated the Amended and Restated 2014 Plan (the &#8220;Further Amended and Restated 2014 Plan&#8221;). The Further Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Further Amended and Restated 2014 Plan has been increased by an additional 13,500,000 common shares, as approved by the requisite number of shareholders at the Company&#8217;s annual general meeting held on April 28, 2020, (ii) the exercise price of stock options and share appreciation rights (&#8220;SARs&#8221;) will be based on the closing price of the underlying common shares on the date such stock options or SARs are granted (rather than on the last preceding trading date), (iii)&#160;additional provisions clarifying that: (a)&#160;stock options and SARs will not be eligible for the payment of dividend or dividend equivalents and (b)&#160;the Talent and Compensation Committee of the Board of Directors of the Company cannot, without shareholder approval, seek to effect any repricing of any previously granted &#8220;underwater&#8221; stock option or SAR and (iv) other housekeeping and/or clerical changes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 11,593,000 common shares were available for future grants as of December&#160;31, 2021. The Company uses reserved and unissued common shares to satisfy its obligation under its share-based compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#8217;s focus on improving its tangible capital usage and allocation, while maintaining focus on improving total shareholder return over the long-term.  The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based RSUs and performance-based RSUs. Performance-based RSUs are comprised of: (i) awards that vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#8220;TSR&#8221;), (ii) awards that vest upon attainment of certain performance targets that are based on the Company&#8217;s return on tangible capital (&#8220;ROTC&#8221;) and (iii) vest fully or partially upon attainment of certain goals that are linked to the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components and classification of share-based compensation expense related to stock options and&#160;RSUs for the years 2021, 2020 and 2019 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:67.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted under the 2011 Plan and the Amended and Restated 2014 Plan generally expire on the fifth or tenth anniversary of the grant date. The exercise price of any stock option granted under the 2011 Plan and the Amended and Restated 2014 Plan will not be less than the closing price per common share on the date of grant. Stock options generally vest 33% and 25% each year over a three-year and four-year period, respectively, on the anniversary of the date of&#160;grant.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of all stock options granted for the years 2021, 2020 and 2019 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock option life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected stock option life was determined based on historical exercise and forfeiture patterns. The expected volatility was determined based on implied volatility in the market traded options of the Company&#8217;s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S. government bonds with maturity dates equal to the expected life of the stock&#160;option. The expected dividend yield was determined based on the stock option&#8217;s exercise price and expected annual dividend rate at the time of&#160;grant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model used by the Company to calculate stock option values was developed to estimate the fair value of freely tradeable, fully transferable stock options without vesting restrictions, which significantly differ from the Company&#8217;s stock option awards. This model also requires highly subjective assumptions, including future stock price volatility and expected time until exercise, which greatly affect the calculated values.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during 2021: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:56.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.706%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January&#160;1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired or forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair values of all stock options granted in 2021, 2020 and 2019 were $10.92, $6.60 and $8.45, respectively. The total intrinsic values of stock options exercised in 2021, 2020 and 2019 were $15 million, $2 million and $3 million, respectively. Proceeds received on the exercise of stock options in 2021, 2020 and 2019 were $22 million, $5 million and $5 million,&#160;respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the total remaining unrecognized compensation expense related to non-vested stock options amounted to $10 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years. The total fair value of stock options vested in 2021, 2020 and 2019 were $15 million, $15 million and&#160;$18 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs generally vest on the first or third anniversary date from the date of grant or 33% a year over a three-year period. Annual RSUs granted to non-management directors vest immediately prior to the next Annual Meeting of Shareholders. Pursuant to the applicable unit agreement, certain RSUs may be subject to the attainment of any applicable performance goals specified by the Board of Directors. If the vesting of the RSUs is conditional upon the attainment of performance goals, any RSUs that do not vest as a result of a determination that the prescribed performance goals failed to be attained will be forfeited immediately upon such determination. RSUs are credited with dividend equivalents, in the form of additional RSUs, when dividends are paid on the Company&#8217;s common shares. Such additional RSUs will have the same vesting dates and will vest under the same terms as the RSUs in respect of which such additional RSUs are&#160;credited.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent provided for in a RSU agreement, the Company may, in lieu of all or a portion of the common shares which would otherwise be provided to a holder, elect to pay a cash amount equivalent to the market price of the Company&#8217;s </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common shares on the vesting date for each vested RSU. The amount of cash payment will be determined based on the average market price of the Company&#8217;s common shares on the vesting date. The Company&#8217;s current intent is to settle vested RSUs through the issuance of common&#160;shares.   </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Time-Based RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each vested time-based RSU represents the right of a holder to receive one of the Company&#8217;s common shares. The fair value of each RSU granted is estimated based on the trading price of the Company&#8217;s common shares on the date of&#160;grant.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested time-based RSU activity during 2021: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:72.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Time-Based<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January&#160;1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the total remaining unrecognized compensation expense related to non-vested time-based RSUs amounted to $68 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.6 years. The total fair value of time-based RSUs vested in 2021, 2020 and 2019 were $69 million, $66 million and $34 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each vested performance-based RSU represents the right of a holder to receive a number of the Company&#8217;s common shares up to a specified maximum. Performance-based RSUs vest upon achievement of certain share price appreciation conditions or attainment of certain performance targets. If the Company&#8217;s performance is below a specified performance level, no common shares will be&#160;paid. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each TSR performance-based RSU granted during 2021, 2020 and 2019 was estimated using a Monte Carlo Simulation model, which utilizes multiple input variables to estimate the probability that the performance condition will be achieved.  The fair value of the ROTC performance-based RSUs is estimated based on the trading price of the Company&#8217;s common shares on the date of grant.  Expense recognized for the ROTC performance-based RSUs in each reporting period reflects the Company&#8217;s latest estimate of the number of ROTC performance-based RSUs that are expected to vest.  If the ROTC performance-based RSUs do not ultimately vest due to the ROTC targets not being met, no compensation expense is recognized and any previously recognized compensation expense is reversed. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of TSR performance-based RSUs granted during 2021, 2020 and 2019 were estimated with the following assumptions:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:58.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.727%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected Company share volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected company share volatility was determined based on implied volatility in the market traded options of the Company&#8217;s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S.&#160;government bonds with maturity dates equal to the contractual term of the performance-based&#160;RSUs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested performance-based RSU activity during 2021: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:72.799%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.587%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance-based <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January&#160;1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company granted approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,035,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance-based RSUs, consisting of approximately 400,000 units of TSR performance-based RSUs with an average grant date fair value of $56.04 per RSU, approximately 413,000 units of ROTC performance-based RSUs with a weighted-average grant date fair value of $31.72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per RSU and approximately 222,000 of other performance-based RSU's with a weighted-average grant date fair value of $28.49. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the total remaining unrecognized compensation expense related to non-vested performance-based RSUs amounted to $32 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.7 years.  A maximum of approximately 3,476,000 common shares could be issued upon vesting of the performance-based RSUs outstanding as of December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883669400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">ACCUMULATED OTHER COMPREHENSIVE LOSS</a></td>
<td class="text">ACCUMULATED OTHER COMPREHENSIVE LOSS<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss as of December&#160;31, 2021 and 2020 consists of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,905)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,077)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension adjustment, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,924)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,133)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#8217;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#8217;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883672600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">RESEARCH AND DEVELOPMENT</a></td>
<td class="text">RESEARCH AND DEVELOPMENT<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. Research and development costs for the years 2021, 2020 and 2019 consists of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883602424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">OTHER EXPENSE, NET</a></td>
<td class="text">OTHER EXPENSE, NET<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net for the years 2021, 2020 and 2019 consists of:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sales of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,426&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, Litigation and other matters of $356 million includes adjustments related to the Glumetza Antitrust Litigation, partially offset by insurance recoveries related to certain litigation matters. In 2020, Litigation and other matters of $422 million includes net charges related to the U.S. Securities Litigation, the SEC Investigation and the Canadian Securities Litigation and related opt-outs. In 2020, Litigation and other matters also includes an insurance recovery related to a certain litigation matter. In 2019, Litigation and other matters of $1,401 million includes the settlement of a legacy U.S. securities class action matter. Certain of these matters and other significant matters are discussed in further detail in Note 20, "LEGAL PROCEEDINGS".</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 and 2019, Acquired in-process research and development costs of $32&#160;million and $41&#160;million, primarily consist of costs associated with the upfront payments to enter into certain exclusive licensing agreements. </span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Net gain on sales of assets includes $20 million related to the achievement of a milestone related to a certain product.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI http://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI http://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883618984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Loss before benefit from income taxes for 2021, 2020 and 2019 consist of:  </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,396)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(701)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(524)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Benefit from income taxes for 2021, 2020 and 2019 consist of: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Benefit from income taxes differs from the expected amount calculated by applying the Company&#8217;s Canadian statutory rate of 26.9% to Loss before benefit from income taxes for 2021, 2020 and 2019 as follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before benefit from income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected benefit from income taxes at Canadian statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible amount of share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to tax attributes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance related to foreign tax credits and NOLs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance on Canadian deferred tax assets and tax rate changes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible portion of Goodwill impairments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit on intra-entity transfers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific Research and Experimental Development pool</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,252)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets net of valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plant, equipment and technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized FX on U.S. dollar debt and other financing cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the deferred tax asset valuation allowance for 2021, 2020 and 2019: </span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to Benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to other accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. interest expense is subject to limitation rules which limit U.S. interest expense to 30% of adjusted taxable income, defined similar to EBITDA through 2021 and EBIT thereafter.  Disallowed interest can be carried forward indefinitely and any unused interest deduction assessed for recoverability. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was signed into law.  The CARES Act also amended the annual limitation on the deduction of interest in the following respects: (i) increasing the limitation to 50% of adjusted taxable income (&#8220;ATI&#8221;), (ii) providing a rule for a partnership&#8217;s 2019 section 163(j)-disallowed interest expense and (iii) allowing an election to apply 2019 ATI to the 2020 section 163(j) computation.  For corporations, the increase to 50% of ATI applies to all taxable years beginning in 2019 or 2020 and permits taxpayers whose 2020 income will decrease from its 2019 level, an election to apply their 2019 ATI, rather than their 2020 ATI, to their 2020 computation. The Company considered such provisions and expects to fully utilize any interest carry forwards in future periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has provided for income taxes in accordance with guidance issued by accounting regulatory bodies, the U.S. Internal Revenue Service and state and local governments through the date of the issuance of these Consolidated Financial Statements. Additional guidance and interpretations can be expected and such guidance, if any, could impact future results.  While management continues to monitor these matters, the ultimate impact, if any, as a result of the application of any guidance issued in the future cannot be determined at this time.   </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The realization of deferred tax assets is dependent on the Company generating sufficient domestic and foreign taxable income in the years that the temporary differences become deductible. A valuation allowance has been provided for the portion of the deferred tax assets that the Company determined is more likely than not to remain unrealized based on estimated future taxable income and tax planning strategies.  In 2021, the valuation allowance decreased by $30 million primarily due to book taxable income in Canada, the change in deferred tax assets in Canada and the use of deferred tax assets in the U.S. in connection with internal restructurings. In 2020, the valuation allowance decreased by $579 million as a result of taxable losses in Canada as offset by a reduction of deferred tax assets due to internal restructurings. Given the Company&#8217;s history of pre-tax losses and expected future losses in Canada, the Company maintained that there was insufficient objective evidence to release the valuation allowance against Canadian tax loss carryforwards, International Tax Credits (&#8220;ITC&#8221;) and pooled Scientific Research and Experimental Development Tax Incentive (&#8220;SR&amp;ED&#8221;) expenditures.  The Canadian valuation allowance represents a material portion of the Company's total valuation allowance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the Company had accumulated taxable losses available to offset future years&#8217; federal and provincial taxable income in Canada of approximately $6,669 million and $6,530 million, respectively.&#160; As of December 31, 2021 and 2020, unclaimed ITCs available to offset future federal taxes in Canada were approximately $31 million and $37 million, respectively, which expire in the years 2022 through 2041.&#160; In addition, as of December 31, 2021 and 2020, pooled SR&amp;ED expenditures available to offset against future taxable income in Canada were approximately $196 million and $206 million, respectively, which may be carried forward indefinitely.  As of December 31, 2021 and 2020, a full valuation allowance against the net Canadian deferred tax assets on the parent company has been provided of $1,965 million and $1,966 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the Company had accumulated taxable losses available to offset future years' federal taxable income in the U.S. of approximately $266 million and $814 million, respectively, including acquired losses which expire in the years 2022 through 2037. While the remaining taxable losses are subject to multiple annual loss limitations as a result of previous ownership changes, the Company believes that the recoverability of the deferred tax assets associated with these taxable losses are more likely than not to be realized. As of December 31, 2021 and 2020 U.S. research and development credits available to offset future years' federal income taxes in the U.S. were approximately $119 million and $110 million, respectively, which includes acquired research and development credits and which expire in the years 2022 through 2042.  In the U.S. the Company has a capital loss of which is offset by a full valuation allowance since the benefit is not expected to be realized.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the Company had accumulated taxable losses available to offset future years&#8217; taxable income in Ireland of approximately $10,040 million and $8,387 million, respectively.&#160; As of  December&#160;31, 2021, the Company continues to have a capital loss which is offset by a valuation allowance on the portion of the loss for which a benefit is not expected to be realized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for income taxes on the unremitted earnings of its direct foreign affiliates except for its direct U.S. subsidiaries.  The Company continues to assert that the unremitted earnings of its U.S.&#160;subsidiaries will be permanently reinvested and not repatriated.  As of December 31, 2021, the Company estimates that there will be no tax liability attributable to unremitted earnings of its U.S. subsidiaries. However, distribution of future earnings could be subject to U.S. withholding tax.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, unrecognized tax benefits (including interest and penalties) were $927 million and $1,025 million, of which $271 million and $414 million would affect the effective income tax rate, respectively. In 2021 and 2020, the remaining unrecognized tax benefits would not impact the effective tax rate as the tax positions are offset against existing tax attributes or are timing in nature. In 2021 and 2020, the Company recognized net increases to unrecognized tax benefits for current year tax positions of $79 million and $66 million, respectively.  The Company recognized a net reduction of $177 million during 2021 and a net reduction of $42 million during 2020 in the unrecognized tax benefits related to tax positions taken in the prior years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for interest and penalties related to unrecognized tax benefits in the provision for income taxes. As of December 31, 2021 and 2020, accrued interest and penalties related to unrecognized tax benefits were approximately $41 million and $49 million, respectively. In 2021, the Company recognized a net decrease of approximately $8 million and, in 2020, recognized an increase of  $4 million of interest and&#160;penalties, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and one or more of its subsidiaries file federal income tax returns in Canada, the U.S., and other foreign jurisdictions, as well as various provinces and states in Canada and the U.S.&#160;The Company and its subsidiaries have open tax years, primarily from 2012 to 2020, with significant taxing jurisdictions, respectively, including Canada and the U.S.&#160;These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and regulations and tax treaties, as they relate to the amount, timing, or inclusion of revenues and expenses, or the sustainability of income tax positions of the Company and its subsidiaries. Certain of these tax years are expected to remain open indefinitely.</span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:82.106%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jurisdiction:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Open Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2012 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2011 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 - 2020</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Internal Revenue Service (the "IRS") completed its examinations of the Company&#8217;s U.S. consolidated federal income tax returns for the years 2013 and 2014. There were no material adjustments to the Company's taxable income as a result of these examinations.  However, the 2014 tax year remains open to the extent of a 2017 capital loss carried back to that year. Additionally, the IRS has selected for examination the Company's annual tax filings for 2015 and 2016 and the Company's short period tax return for the period ended September 8, 2017, which was filed as a result of the Company's internal restructuring efforts during 2017. In 2017, the Company undertook an internal restructuring in the form of what is commonly known as a Granite Trust transaction, which resulted in a recorded capital loss (the &#8220;2017 Capital Loss&#8221;). Recently, the Company has received a notice of proposed adjustment from the IRS that would disallow the 2017 Capital Loss and expects to receive a notice of proposed tax deficiency from the IRS, after which the Company intends to contest proposed tax deficiency through the IRS administrative appeals process. If the Company were ultimately unsuccessful in defending its position, and all or a substantial portion of the 2017 Capital Loss deduction were disallowed, the Company could be liable for additional taxes (excluding penalties and interest) of up to $2,100&#160;million, which could have an adverse effect on the Company&#8217;s financial condition and results of operations. The Company intends to vigorously defend its position, including through appropriate litigation, if necessary, and ultimately believes it will sustain its deduction of the 2017 Capital Loss, and, accordingly, no income tax provision has been recorded.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently under examination by the Canada Revenue Agency (&#8220;CRA&#8221;) for three separate cycles: (a) years 2012 through 2013 (b) years 2014 through 2015, and (c) years 2016 through 2017.  The Company believes that the CRA will open an audit cycle for the years 2018 &#8211; 2019 in 2022.  The Company settled the tax years from 2005 through 2009 </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the CRA. The Company had previously filed a Notice of Objection related to the assessment of these years and reduced net operating losses with a full valuation allowance by CAD 44&#160;million to close these years.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The adjustment did not result in a material change to the provision for income taxes.  The CRA audits of the 2010 and 2011 tax years were closed in 2016 and resulted in no material adjustments. The Company received an assessment for certain transfer pricing matters in 2012 and 2013 for CAD 85&#160;million and CAD 90&#160;million, respectively.  The Company disagrees with the adjustments and has filed a Notice of Objection for 2012 and 2013.  The Company settled certain transfer pricing matters relating the 2015 and 2016 tax years resulting in a reduction to its NOLs of approximately CAD 21&#160;million for 2015 and will receive a further adjustment for 2016.  The expected adjustment for 2016 will reduce NOLs currently offset by a full valuation allowance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s subsidiaries in Germany are under audit for tax years 2014 through 2016.  At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries in Australia are under audit by the Australian Tax Office for various years beginning in 2010. On August 8, 2017, the Australian Taxation Office issued a notice of assessment for the tax years 2011 through 2017 in the aggregate amount of $117 million, which includes penalties and interest.  The Company disagrees with the assessment and continues to believe that its tax positions are appropriate and supported by the facts, circumstances and applicable laws. The Company intends to defend its tax position in this matter vigorously and has filed a holding objection against the assessment by the Australian Taxation Office and has secured a bank guarantee to cover any potential cash outlays regarding this assessment. The bank guarantee has been reduced over time to now be an immaterial value.  Negotiations with the Australian Tax Office are ongoing and the Company expects to enter into a Settlement Deed in early 2022 with no material adverse results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain affiliates of the Company in regions outside of Canada, the U.S., Germany, Luxembourg and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits.  At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the unrecognized tax&#160;benefits for 2021, 2020 and 2019: </span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes it is reasonably possible that the total amount of unrecognized tax benefits at December 31, 2021 could decrease by approximately $104 million in the next twelve months as a result of the resolution of certain tax and transfer pricing audits and other events.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883670232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER SHARE</a></td>
<td class="text">LOSS  PER SHARE<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per share attributable to Bausch Health Companies Inc. for 2021, 2020 and 2019 were calculated as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(560)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,788)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">358.9&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355.0&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352.1&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.64)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.58)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.08)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, 2020 and 2019, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive.  The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 4,932,000, 3,154,000 and 5,106,000 common shares for 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in 2021, 2020 and 2019, stock options, time-based RSUs and performance-based RSUs to purchase approximately 3,428,000, 9,551,000 and 2,598,000 common shares of the Company, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During 2021, an additional 156,000 performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883548344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL CASH FLOW DISCLOSURES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">SUPPLEMENTAL CASH FLOW DISCLOSURES</a></td>
<td class="text">SUPPLEMENTAL CASH FLOW DISCLOSURES <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow disclosures for 2021, 2020 and 2019 are as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI http://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883494440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">LEGAL PROCEEDINGS</a></td>
<td class="text">LEGAL PROCEEDINGS<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described below. Going forward, in the Company's subsequent Quarterly Reports on Form 10-Q, the Company will only include a description of these matters to the extent there has been a material update with respect thereto during the applicable quarter or to the extent otherwise required by law.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of December 31, 2021, the Company's Consolidated Balance Sheets includes accrued current loss contingencies of $1,890 million related to matters which the Company believes a potential resolution or settlement is both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental and Regulatory Inquiries</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney's Office for the District of Massachusetts - re OraPharma</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts, requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including related support services, and other matters.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is cooperating with this investigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658). On January 31, 2021, the District Court </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill LLC filed a notice of appeal of the Court&#8217;s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options.  On March 1, 2021, Cathy Lochridge filed a notice of appeal of the Court&#8217;s final approval order, which overruled her objections as to the attorneys&#8217; fees awarded to class counsel. On October 14, 2021, Timber Hill dismissed its appeal of the final approval order. On December 20, 2021, the Third Circuit denied Lochridge&#8217;s appeal. On January 3, 2022, Lochridge filed a petition for rehearing of the appeal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">en banc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which remains pending.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2015, four putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#8217;s business and prospects, including relating to drug pricing, the Company&#8217;s use of specialty pharmacies, and the Company&#8217;s relationship with Philidor. On May 31, 2016, the court entered an order consolidating the four actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $1,210 million, subject to final court approval. This settlement received final approval from the court on January 31, 2021 and will resolve and discharge all claims against the Company in the class action.  As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement remains subject to an appeal of the final court approval (as such appeal is further described above). In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payments have been paid into an escrow account in accordance with the payment schedule outlined in the settlement agreement. These payments, less certain settlement expenses and attorneys' fees, will remain in escrow until resolution of the appeal of the final court approval of the settlement agreement. The opt-out litigations discussed below remain ongoing. As of December 31, 2021, Restricted cash and other settlement deposits includes an aggregate $1,210&#160;million of: (i) payments in the escrow fund and (ii) certain disbursements for settlement expenses and attorney's fees. Disbursements for attorney's fees remain refundable until resolution of the appeal of the final court approval of the settlement agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246) (&#8220;Timber Hill&#8221;), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#8217;s common stock during the period January 4, 2013 through August 11, 2016.  On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658).  On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated putative class action, thirty-seven groups of individual investors in the Company&#8217;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions are captioned: T. Rowe Price Growth Stock Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-5034); Equity Trustees Limited as Responsible Entity for T. Rowe Price Global Equity Fund v. Valeant Pharmaceuticals International Inc. (Case No. 16-cv-6127); Principal Funds, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-6128); BloombergSen Partners Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7212); Discovery Global Citizens Master Fund, Ltd. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7321); MSD Torchlight Partners, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7324); BlueMountain Foinaven Master Fund, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7328) (&#8220;BlueMountain&#8221;); Incline Global Master LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7494); VALIC Company I v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7496); Janus Aspen Series v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7497) (&#8220;Janus Aspen&#8221;); Okumus Opportunistic Value Fund, LTD v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6513) (&#8220;Okumus&#8221;); Lord Abbett Investment Trust- Lord Abbett Short Duration Income Fund, v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6365) (&#8220;Lord Abbett&#8221;); Pentwater Equity Opportunities Master Fund LTD v. Valeant Pharmaceuticals International, Inc., et al. (Case No. 17-cv-7552) (&#8220;Pentwater&#8221;); Public Employees&#8217; Retirement System of Mississippi v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-7625) (&#8220;Mississippi&#8221;); The Boeing Company Employee Retirement Plans Master Trust v. Valeant Pharmaceuticals International Inc., et al., (Case No. 17-cv-7636) (&#8220;Boeing&#8221;); State Board of Administration of Florida v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-12808); The Regents of the University of California v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-13488); GMO Trust v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0089); F&#246;rsta AP Fonden v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-12088); New York City Employees&#8217; Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0032) </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;NYCERS&#8221;); Hound Partners Offshore Fund, LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08705) (&#8220;Hound Partners&#8221;); Blackrock Global Allocation Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0343) (&#8220;Blackrock&#8221;); Colonial First State Investments Limited As Responsible Entity for Commonwealth Global Shares Fund 1 v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0383); Bharat Ahuja v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0846); Brahman Capital Corp. v. Valeant Pharmaceuticals International, Inc (Case No. 18-cv-0893); The Prudential Insurance Company of America v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-01223) (&#8220;Prudential&#8221;); Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) (&#8220;Senzar&#8221;); 2012 Dynasty UC LLC v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08595) ("2012 Dynasty"); Catalyst Dynamic Alpha Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-12673) (&#8220;Catalyst&#8221;); Northwestern Mutual Life Insurance Co., v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-15286) (&#8220;Northwestern Mutual&#8221;); Bahaa Aly, et al. v. Valeant Pharmaceuticals International, Inc., (Case No. 18-cv-17393) (&#8220;Aly&#8221;); Office of the Treasurer as Trustee for the Connecticut Retirement Plans and Trust Funds v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18473) (&#8220;Connecticut&#8221;); Delaware Public Employees&#8217; Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18475) (&#8220;Delaware&#8221;); Maverick Neutral Levered Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-02190) (&#8220;Maverick&#8221;), Templeton v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-05478) (&#8220;Templeton&#8221;), USAA Mutual Funds Trust, et al. v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 20-cv-07462) (&#8220;USAA&#8221;), and GIC Private Ltd. v. Valeant Pharmaceuticals International, Inc., (Case No. 20-cv-07460) (&#8220;GIC&#8221;). Sixteen of the thirty-seven opt-out actions have been dismissed; and the total number of remaining opt-out actions pending in the District of New Jersey is twenty-one actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These individual shareholder actions assert claims under Sections 10(b), and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2), and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss have been filed and in most cases decided in many of these individual actions. To date, the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) opt-out action, closing the case.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2019, the Court granted defendants&#8217; motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (&#8220;Aly&#8221;) (Case No. 18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 16, 2021, the Court of Appeals granted plaintiffs&#8217; appeal in the Aly action. This action has been remanded to the District Court. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut, and Delaware actions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, and March 10, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds, Pentwater, Lord Abbett, Equity Trustees, and UC Regents actions. On April 30, 2021, the Court entered a stipulation of voluntary dismissal in the Florida SBA action.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021, the Court entered a stipulation of voluntary dismissal in the Janus action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Securities Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, six putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. These actions are captioned: (a) Alladina v. Valeant, et al. (Case No. S-1594B6) (Supreme Court of British Columbia) (filed November 17, 2015); (b) Kowalyshyn v. Valeant, et al. (CV-15-540593-00CP) (Ontario Superior Court) (filed November 16, 2015); (c) Kowalyshyn et al. v. Valeant, et al. (CV-15-541082-00CP) (Ontario Superior Court) (filed November 23, 2015); (d) O&#8217;Brien v. Valeant et al. (CV-15-543678-00CP) (Ontario Superior Court) (filed December 30, 2015); (e) Catucci v. Valeant, et al. (Court File No. 540-17-011743159, then Court File No. 500-06-000783-163) (Quebec Superior Court) (filed October 26, 2015); and (f) Rousseau-Godbout v. Valeant, et al. (Court File No. 500-06-000770-152) (Quebec Superior Court) (filed October 27, 2015). </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also aware of two additional putative class actions that were filed with the applicable court but which have not been served on the Company. These actions are captioned: (i) Okeley v. Valeant, et al. (Case No. S-159991) (Supreme Court of British Columbia) (filed December 2, 2015); and (ii) Sukenaga v Valeant et al. (CV-15-540567-00CP) (Ontario </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Superior Court) (filed November 16, 2015), and the factual allegations made in these actions are substantially similar to those outlined herein.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, was discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#8217;s auditors and the action was dismissed as against them. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD 94 million plus payment of an additional amount to cover notice and settlement administration costs and disbursements.  As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action.  On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, one of the entities which exercised its opt-out rights, the California State Teachers' Retirement System (&#8220;CalSTRS&#8221;), served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#8217; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision. The appeal was heard on September 29, 2021 and, by judgment dated October 29, 2021, the appeals were dismissed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#8220;price appreciation credits&#8221; in respect of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the period covered by the claims. A hearing was held on February 17, 2021 with respect to whether CalSTRS would be permitted to file the proposed amended proceedings. On June 9, 2021, the Quebec Superior Court granted the Company&#8217;s application to strike the new allegations from its Quebec Securities Act claim, but permitted the amendments to its claim under the Quebec Civil Code. On December 8, 2021, CalSTRS delivered its amended pleadings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2021, four additional opt-outs from the Catucci class issued a Statement of Claim in the Ontario Superior Court of Justice. That proceeding is captioned The Bank of Korea et al. v. Valeant Pharmaceuticals International Inc. et al. (Court File No. 21-00658966-0000). In addition, these plaintiffs also served and filed a motion for leave to pursue claims under the Ontario Securities Act. The allegations in this proceeding are similar to those made by the plaintiffs in the Catucci class action and the plaintiffs in the opt-out actions described above. </span></div><div style="margin-top:7.5pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RICO Class Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between May 27, 2016 and September 16, 2016, three actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (&#8220;RICO&#8221;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160; The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#8217;s consent to renew the prescription.&#160; The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.  On August 4, 2021, the Company executed a stipulation of settlement for this action and, on August 17, 2021, the Court preliminarily approved the settlement.  On December 6, 2021 the Special Master overseeing this litigation issued a report and recommendation recommending final approval of the settlement, and on February 22, 2022 the settlement was approved by the district court. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Coverage Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during two distinct policy periods, (i) 2013-14 and (ii) 2015-16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; 3:18-CV-00493).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (the &#8220;Allergan Securities Litigation&#8221;) (under the 2013-2014 coverage period), and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and the SEC Investigation and certain of the other investigations described under &#8220;Complete or Inactive Matters&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021 and under &#8220;Governmental and Regulatory Inquiries&#8221; and &#8220;Complete or Inactive Matters&#8221; in Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020 (under the 2015-2016 coverage period).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021, the Company entered into settlement agreements with the insurers in the 2015-2016 coverage period in which the Company agreed to resolve its claims for insurance coverage in connection with the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-out litigation and related investigations matters described above.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On that same day, the Company entered into settlement agreements with two of its insurers in the 2013-2014 coverage period in which the Company agreed to resolve its claims against those two insurers only for insurance coverage in connection with the Allergan Securities Litigation. As a result of all of the settlement agreements entered into with the insurers on July 20, 2021, the Company has received an aggregate sum of $213&#160;million. The Company&#8217;s insurance claims with respect to the Allergan Securities Litigation against the remaining insurers in the 2013-2014 coverage period remain pending.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hound Partners Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP, and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County.  This action is captioned Hound Partners Offshore Fund, LP et al., v. Valeant Pharmaceuticals International, Inc., et al. (No. MER-L-002185-18).  This suit asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pricing Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's subsidiaries, Oceanside Pharmaceuticals, Inc. (&#8220;Oceanside&#8221;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#8220;Bausch Health US&#8221;), and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#8220;Bausch Health Americas&#8221;) (for the purposes of this paragraph, collectively, the &#8220;Company&#8221;), are defendants in multidistrict antitrust litigation (&#8220;MDL&#8221;) entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Generic Pharmaceuticals Pricing </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, pending in the United States District Court for the Eastern District of Pennsylvania (MDL No. 2724, 16-MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#8217;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. There are cases pending in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed in the cases. The cases have been put in deferred status. The Company disputes the claims against it and continues to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively &#8220;the Company&#8221;) have been named as defendants in a proposed class proceeding entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kathryn Eaton v. Teva Canada Limited, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that the Company and other defendants violated the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Generic Pharmaceuticals Pricing Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and will defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza State-Law Insurer Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff from the federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822-WHA (N.D. Cal.) (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) (discussed in further detail below) filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;).  The State Court Action alleges that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or grant any other company a license to do so.  The State Court Action alleges that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. On September 20, 2021, the parties stipulated that the insurer plaintiff&#8217;s direct opt-out claims from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, discussed below, were deemed asserted in the State Court Action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defendants&#8217; demurrer in the State Court Action was heard on September 22, 2021.  On November 11, 2021, the court denied the motion in part and granted it in part as to certain state law claims, with leave to amend.  The insurer plaintiff did not amend the complaint. Defendants&#8217; answers were filed on February 3, 2022. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation/Paragraph IV Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550mg, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States, and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Canada or other similar suits.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2020, the Company and Alfasigma S.p.A. ("Alfasigma") received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;), in which Norwich asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#8217;s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (&#8220;ANDA&#8221;) has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and owns or exclusively licenses (from Alfasigma) these patents.  On March 26, 2020, certain of the Company&#8217;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of Norwich&#8217;s ANDA for rifaximin tablets, 550 mg. Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is protected by 26 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. A 3-day bench trial is scheduled to begin March 21, 2022. The Company </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remains confident in the strength of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (now Padagis LLC) (&#8220;Padagis&#8221;), in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA's Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic lotion, for which an ANDA has been filed by Padagis.  On August 28, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA.  On September 3, 2020, this action was consolidated with the action between the Company and Padagis described below, regarding Padagis&#8217; ANDA for generic Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion. The Company remains confident in the strength of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related patents and will vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Padagis, in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic halobetasol propionate lotion, for which an ANDA has been filed by Padagis.  On May 1, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described above, regarding Padagis&#8217; ANDA for generic Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion. The Company remains confident in the strength of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company commenced litigation against MSN Laboratories Private Ltd. (&#8220;MSN&#8221;) and Mylan Pharmaceuticals Inc., (&#8220;Mylan&#8221;) alleging patent infringement by MSN&#8217;s and Mylan&#8217;s filing of their ANDA for generic Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) 3mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from each of MSN and Mylan, in which they had each asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 3 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of their respective generic plecanatide tablets, 3 mg.  The filing of these suits triggered a 30-month stay of the approval of the MSN and Mylan ANDAs for plecanatide tablets. The Company remains confident in the strength of the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company commenced litigation against Slayback Pharma LLC and Slayback Pharma India LLP (together, &#8220;Slayback&#8221;) alleging patent infringement by Slayback Pharma LLC&#8217;s filing of its ANDA No. 216361, referencing Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (0.025% brimonidine tartrate ophthalmic solution). This suit had been filed following receipt of a Notice of Paragraph IV Certification from Slayback Pharma LLC, in which it had asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brimonidine tartrate ophthalmic solution, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of its generic brimonidine tartrate solution.  The filing of this suit triggered a 30-month stay of the approval of the Slayback ANDA for its brimonidine tartrate solution.  The Company remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2022 the Company commenced litigation against Lupin Pharmaceuticals, Inc. (&#8220;Lupin&#8221;) alleging patent infringement by Lupin&#8217;s filing of its ANDA No. 216716, referencing Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (0.025% brimonidine tartrate ophthalmic solution). This suit had been filed following receipt of a Notice of Paragraph IV Certification from Lupin, in which it had asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brimonidine tartrate ophthalmic solution, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of its generic brimonidine tartrate solution.  The filing of this suit triggered a 30-month stay of the approval of the Lupin ANDA for its brimonidine tartrate solution. The Company remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jublia Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patents covering the Company's branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review ("IPR") at the U.S. Patent &amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution. IPR challenges have been brought against patents covering the Company's branded pharmaceutical products. For example, following Acrux DDS&#8217;s IPR petition, the U.S. Patent and Trial Appeal Board ("PTAB"), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(U.S. Patent No. 7,214,506 (the "&#8216;506 Patent")) and, on </span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings.  As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion.   The &#8216;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is covered by fourteen Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and has timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada against four separate defendants.  All cases in the U.S. regarding Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been settled. In Canada, two lawsuits remain pending against Apotex Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Products Liability Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower&#174; body powder product acquired in September 2012 from Johnson &amp; Johnson; due to dismissals, twenty-nine (29) of such product liability suits currently remain pending. Potential liability (including its attorneys&#8217; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp; Johnson owed to the Company and its affiliates, and legal fees and costs will be paid by Johnson &amp; Johnson. Twenty-eight (28) of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the plaintiffs to develop ovarian cancer, mesothelioma or breast cancer. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages. The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#8217; fees. Additionally, two proposed class actions have been filed in Canada against the Company and various Johnson &amp; Johnson entities (one in the Supreme Court of British Columbia and one in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp; Johnson&#8217;s Baby Powder or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. On November 17, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and at this time no appeal of that judgment has been filed. On December 16, 2021, the plaintiff in the British Columbia class action filed a Second Amended Notice of Civil Claim and Application for Certification, removing the Company as a defendant; as a result, the British Columbia class action is concluded as to the Company. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson, through one or more subsidiaries has purported to have completed a Texas divisional merger with respect to any talc liabilities at Johnson &amp; Johnson Consumer, Inc. (&#8220;JJCI&#8221;). LTL Management, LLC (&#8220;LTL&#8221;), the resulting entity of the divisional merger, assumed JJCI&#8217;s talc liabilities and thereafter filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the Western District of North Carolina. Pursuant to a court order, the case was transferred to the United States District Court for the District of New Jersey. Notwithstanding the divisional merger and LTL&#8217;s bankruptcy case, the Company and its affiliates continue to have indemnification claims and rights against Johnson &amp; Johnson and LTL pursuant to the terms of the indemnification agreement entered into between JJCI and its affiliates and the Company and its affiliates, which indemnification agreement remains in effect. As a result, it is the Company's current expectation that it will not incur any material impairments with respect to its indemnification claims as a result of the divisional merger or the bankruptcy. Substantially all cases subject to the indemnification agreement related to Johnson &amp; Johnson&#8217;s talc liability are stayed through February 28, 2022, pursuant to a preliminary injunction issued by the bankruptcy court. Motions to dismiss the LTL bankruptcy, as well as extend the stay beyond February 28, 2022, were argued in the bankruptcy court in February 2022. A decision of the court is pending. To the extent that any cases subject to the indemnification agreement proceed during the pendency of the bankruptcy case, it is the Company's expectation that Johnson &amp; Johnson, in accordance with the indemnification agreement, will continue to vigorously defend the Company in each of the remaining actions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Proposition 65 Related Matter</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp; Johnson (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gutierrez, et al. v. Johnson &amp; Johnson, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. The Company filed a motion to dismiss Plaintiffs&#8217; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted.  In August 2020, Plaintiffs filed the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss with prejudice. On February 19, 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals. On July 1, 2021, Appellants (Plaintiffs) filed their opening brief; Appellees' response briefs were filed on October 8, 2021. This matter was stayed by the Ninth Circuit on December 7, 2021, due to the preliminary injunction entered by the bankruptcy court in the LTL bankruptcy proceeding. This stay included Appellants&#8217; reply brief deadline, which was previously due to be filed on or before December 2, 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Consumer Protection Action</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc., the Company and Bausch Health US related to Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its alleged causal link to mesothelioma and other cancers.  In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its answer on November 16, 2020. On December 30, 2020 Johnson &amp; Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which was denied on March 8, 2021. Trial is scheduled to begin on January 18, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Doctors Allergy Formula Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Doctors Allergy Formula, LLC (&#8220;Doctors Allergy&#8221;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.  Doctors Allergy claims its damages are not less than $23 million. Bausch Health Americas has asserted counterclaims against Doctors Allergy. Bausch Health Americas filed a motion seeking an order granting Bausch Health Americas summary judgment on its counterclaims against Plaintiff and dismissing Plaintiff&#8217;s claims against it. The motion was fully briefed as of May 2021. The Court held a hearing on the motion on January 25, 2022. The motion remains pending. Bausch Health Americas disputes the claims against it and will continue to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Former Salix CEO</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, Case No. 2019-0059, asserting claims for breach of contract and declaratory relief.  On November 19, 2021, Logan amended her complaint to add a claim for breach of the implied covenant of good faith and fair dealing. The lawsuit arises out of the contractual termination of approximately $30 million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd.  Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification. On June 19, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. Trial is scheduled to commence on September 6, 2022. The Company disputes the claims and intends to vigorously defend the matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Completed or Inactive Matters</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following matters have concluded, have settled, are the subject of an agreement to settle or have otherwise been closed since January 1, 2021, have been inactive from the Company&#8217;s perspective for several quarters or the Company anticipates that no further material activity will take place with respect thereto. Due to the closure, settlement, inactivity or change in status of the matters referenced below, these matters will no longer appear in the Company's next public reports and disclosures, unless required. With respect to inactive matters, to the extent material activity takes place in subsequent quarters with respect thereto, the Company will provide updates as required or as deemed appropriate.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza Antitrust Litigation</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between August 2019 and July 2020, eight (8) putative antitrust class actions and four (4) non-class complaints naming Bausch Health Companies Inc., Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., and Santarus, Inc. (for purposes of this subsection, collectively, the &#8220;Company&#8221;), among other defendants, were filed or transferred to the Northern District of California. Three (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020.  The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. Three (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020.  In December 2020, the court denied the Company&#8217;s motion to dismiss as to the insurer plaintiff&#8217;s direct claims but dismissed the insurer plaintiff&#8217;s indirect claims. On February 2, 2021, the insurer plaintiff&#8217;s motion for leave to amend its complaint was denied.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These actions were consolidated and coordinated in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822-WHA (N.D. Cal.) (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The lawsuits alleged that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or grant any other company a license to do so. The complaints alleged that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs sought damages under federal antitrust laws for claims based on direct purchases.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2021, the Company reached an agreement in principle and, thereafter, on September 14, 2021, executed a final settlement agreement to resolve the class plaintiffs&#8217; claims for $300&#160;million, subject to court approval. On August 1, 2021, the Company also reached an agreement in principle to resolve the non-class direct purchaser plaintiffs&#8217; claims, described above, for additional consideration.  A final settlement agreement with the non-class direct purchaser plaintiffs was executed on August 6, 2021. As part of the settlements, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing.  On September 20, 2021, the insurer plaintiff voluntarily dismissed its claims in the consolidated federal action. By stipulation, the insurer plaintiff has asserted its direct opt-out claims in the State Court Action, resulting in the consolidation of all of its opt-out claims in the State Court Action.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2021, the court granted preliminary approval of the class settlement agreement and vacated the October 2021 trial date and all other pre-trial deadlines in the consolidated actions. On February 3, 2022, the court granted final  approval of the class settlement and ordered dismissal of the class plaintiffs' claims. Subject to appeal of the final approval of the class settlement, the settlements will resolve and discharge all asserted class and direct purchaser non-class claims against the Company in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Proposition 65 Related Matter</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2020, Plaintiff Jan Graham filed a lawsuit (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Graham v. Bausch Health Companies, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 20STCV03578) in Los Angeles County Superior Court against the Company, Bausch Health US and several other manufacturers, distributors and retailers of talcum powder products, alleging violations of California Proposition 65 by manufacturing and distributing talcum powder products containing chemicals listed under the statue, without a compliant warning on the label. On January 29, 2021, certain defendants including the Company and Bausch Health US filed a Motion for Summary Judgment or in the Alternative Motion for Summary Adjudication, which was granted with prejudice on May 26, 2021; Plaintiff waived the right to appeal.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Lawsuits</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2019 and September 13, 2019, two alleged stockholders filed derivative lawsuits purportedly on behalf of the Company against former Company board members and executives. On March 7, 2020, a consolidated amended derivative complaint was filed, captioned In re Bausch Health Companies Inc. F/K/A/ Valeant Pharmaceuticals International, Inc. Stockholder Derivative Litigation (Case No. 19-cv-17833). </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiffs asserted claims for breach of fiduciary duty, waste of corporate assets, and unjust enrichment related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#8217;s business and prospects, including relating to drug pricing, the Company&#8217;s use of specialty pharmacies, and the Company&#8217;s relationship with Philidor. The consolidated complaint also asserted a claim for contribution and indemnification by the Defendants for any liability the Company ultimately faces as a result of the conduct alleged in the complaint. The claims alleged in these cases were based on the same purported conduct that is at issue in In re Valeant Pharmaceuticals International, Inc. Securities Litigation, all of which occurred prior to 2017. On April 21, 2020, the Defendants filed a motion to dismiss the consolidated amended complaint.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Briefing on this motion concluded on August 3, 2020. On November 24, 2020, the Special Master appointed by the Court issued a report recommending that the motion to dismiss be granted in full.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021, the District Court adopted the report and recommendation of the Special Master and dismissed the action.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883662776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has commitments related to capital expenditures of approximately $76 million as of December&#160;31, 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain agreements, the Company may be required to make payments contingent upon the achievement of specific developmental, regulatory, or commercial milestones. As of December&#160;31, 2021, the Company believes it is reasonably possible that it may potentially make milestone and license fee payments, including sales-based milestone payments, of approximately $340 million over time, in the aggregate, to third parties for products currently under development or being marketed, primarily consisting of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a June 2013 distribution and supply agreement with Mylan Pharmaceuticals Inc. (as assignee of Spear Pharmaceuticals, Inc and Spear Dermatology Products Inc.), the Company may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $70 million, in the aggregate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of an April 2019 agreement with Mitsubishi Tanabe Pharma Corporation, the Company has acquired an exclusive license to develop and commercialize&#160;MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as Inflammatory Bowel Disease and ulcerative colitis. The Company may be required to make development and sales-based milestone payments over time of up to $60 million, in the aggregate, as well as royalties on future sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a December 2019 agreement with Novaliq GmbH, the Company has acquired an exclusive license for the commercialization and development in the U.S. and Canada of NOV03 (perfluorohexyloctane), an investigational drug to treat Dry Eye Disease associated with Meibomian gland dysfunction and may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $48 million, in the aggregate, as well as royalties on future sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a November 2019 agreement with Cedars-Sinai Medical Center, to evaluate a new formulation of rifaximin for the treatment of irritable bowel syndrome, the Company may be required to make development and sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $36&#160;million, in the aggregate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of an October 2020 agreement with Eyenovia, Inc., the Company has acquired an exclusive license in the U.S. and Canada for the development and commercialization of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12. Under the terms of the agreement, the Company may be required to make development and sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $35&#160;million, in the aggregate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a May 2020 agreement with STADA Arzneimittel AG and its development partner, Xbrane Biopharma AB, to commercialize in the U.S. and Canada a biosimilar candidate to Lucentis (ranibizumab), the Company may be required to make development and sales-based milestone payments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of these arrangements, the future potential payments related to the attainment of the specified milestones over a period of several years are inherently uncertain. As of December 31, 2021, no accruals related to the aforementioned agreements exist because the milestone targets are not yet probable of being achieved.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into agreements that include indemnification provisions for product liability and other matters. These provisions are generally subject to maximum amounts, specified claim periods and other conditions and limits. In addition, the Company is obligated to indemnify its officers and directors in respect of any legal claims or actions initiated against them in their capacity as officers and directors of the Company in accordance with applicable law. Pursuant to such indemnities, the Company is indemnifying certain former officers and directors in respect of certain litigation and regulatory matters.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, no material amounts were accrued for the Company&#8217;s obligations under these indemnification provisions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883914376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text">SEGMENT INFORMATION<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Chief Executive Officer ("CEO"), who is the Company&#8217;s Chief Operating Decision Maker, manages the business through operating and reportable segments consistent with how the Company's CEO: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. The Company operates in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International Rx, (iv) Ortho Dermatologics and (v) Diversified Products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of the Company&#8217;s segments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.53pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmic Pharmaceuticals products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of GI products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International Rx segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales, with the exception of sales of Bausch +Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Ortho Dermatologics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological) products and (ii) global sales of Solta aesthetic medical devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions.  Certain costs, such as Amortization of intangible assets, Asset impairments, including loss on assets held for sale, Restructuring, integration, separation and IPO costs, and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#8217;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the planned separation of its Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., on February 23, 2022, the Company announced its plan to change its segment structure in a manner which is consistent with the organizational structure of the two separate entities as proposed by the Solta IPO during the first quarter of 2022. The new segment structure will not impact the Company&#8217;s reporting units but will realign the two reporting units of the Ortho Dermatologics segment whereby its medical dermatology reporting unit (Ortho Dermatologics) will now be managed by the CODM as part of the Diversified Products segment and the Solta reporting unit will be managed by the CODM as its own operating and reportable segment. Accordingly, the Company expects to begin reporting under the following reporting segments on a retrospective basis beginning with its first quarter of 2022 as follows: Bausch + Lomb, Salix, International Rx, Solta and Diversified Products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Revenues and Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits for the years 2021, 2020 and 2019 were as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Rx</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profit:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Rx</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(792)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(619)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,897)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(502)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before benefit from income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to segment revenue and profit in order for the prior years to conform to current year presentation. These reclassifications are not material.</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures by segment for the years 2021, 2020 and 2019 were as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Rx</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total capital expenditures</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues by Product and by Product Category </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the Company's top ten products for the years 2021, 2020 and 2019 represented 43%, 41% and 39% of total product sales, respectively. Revenues by segment and product category were as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:23.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International Rx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:23.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International Rx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,680&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:23.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International Rx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,079&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,717&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,778&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,601&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer for the years 2021, 2020 and 2019 were as&#160;follows:</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,601&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made and are reflected in the table above.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December&#160;31, 2021 and 2020 were as&#160;follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:79.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serbia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883549176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company issued conditional notices of redemption to redeem in full all of its outstanding April 2025 Unsecured Notes and to redeem $370&#160;million aggregate principal amount of its outstanding December 2025 Unsecured Notes. On February 10, 2022, the Company extended these conditional notices of redemption through March 15, 2022. The redemption and discharge of the indenture governing the April 2025 Unsecured Notes will be conditioned upon the completion of the Credit Agreement Refinancing, as defined below. The redemption of the December 2025 Unsecured Notes will be conditioned upon the receipt of aggregate gross proceeds from the B+L IPO, the B+L Debt Financing as defined below, the Credit Agreement Refinancing and the offering of the February 2027 Secured Notes, as defined below, of at least $7,000&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company announced its intention to refinance its existing Restated Credit Agreement with a Fifth Amended Restated Credit Agreement (the "New Restated Credit Agreement" and such refinancing, the "Credit Agreement Refinancing"). The New Restated Credit Agreement is expected to consist of approximately $2,500&#160;million of term B loans and a $975&#160;million revolving credit facility. The Credit Agreement Refinancing is expected to occur only upon completion of the B+L IPO and a related debt financing by Bausch + Lomb (the "B+L Debt Financing"). At the time of the B+L IPO, the Credit Agreement Refinancing will provide that Bausch + Lomb initially be a "restricted" subsidiary subject to the terms of the Credit Agreement covenants, however the Credit Agreement Refinancing is expected to permit the Company to designate Bausch + Lomb as an "unrestricted" subsidiary under the New Restated Credit Agreement covenants upon achievement of a 7.6x  pro forma "Remainco Total Leverage Ratio." Such designation could take place at any time after the B+L IPO (including as soon as the closing of the B+L IPO). The Credit Agreement Refinancing is designed to facilitate the separation and distribution of Bausch + Lomb. The Credit Agreement Refinancing will not be consummated until completion of the B+L IPO and related B+L Debt Financing. There can be no assurance that the Credit Agreement Refinancing will occur on the terms described above, or at all. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2022, the Company issued $1,000&#160;million aggregate principal amount of 6.125% senior secured notes due February 2027 (the &#8220;February 2027 Secured Notes&#8221;). The February 2027 Secured Notes accrue interest at a rate of 6.125% per year, payable semi-annually in arrears on each February and August. The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to 100% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to February 2024, the Company may redeem up to 40% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the B+L IPO does not occur on or prior to August 15, 2022, the Company will be required to redeem the February 2027 Secured Notes at such time at a redemption price equal to the issue price of the February 2027 Secured Notes plus accrued and unpaid interest.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564886020376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation and Use of Estimates The Consolidated Financial Statements have been prepared by the Company in United&#160;States (&#8220;U.S.&#8221;) dollars and in accordance with U.S.&#160;generally accepted accounting principles (&#8220;U.S. GAAP&#8221;), applied on a consistent basis. The Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the Company's Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows.  The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of amortizable intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants and making going concern assessments; reporting unit fair values for testing goodwill for impairment and allocating goodwill to new reporting unit structure on a relative fair value basis; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; fair value of cross-currency swaps; fair value of foreign currency exchange contracts; and the recognition of the fair value of assets and liabilities acquired in a business combination, including the fair value of contingent consideration. Under certain product manufacturing and supply agreements, management uses information from the Company&#8217;s commercialization counterparties to arrive at estimates for future returns, rebates and chargebacks. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s Consolidated Financial Statements could be materially impacted.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions and Acquisition-Related Contingent Consideration</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Consolidated Financial Statements after the date of acquisition.  Acquired in-process research and development (&#8220;IPR&amp;D&#8221;) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;D has an alternative future use. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;D with no alternative future use is charged to expense at the acquisition&#160;date and any future contingent consideration is not recorded until it becomes probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-Related Contingent Consideration </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related contingent consideration, which primarily consists of potential milestone payments and royalty obligations, is recorded in the Consolidated Balance Sheets at its acquisition date estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in fair value measurement accounting.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial InstrumentsThe estimated fair values of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities approximate their carrying values due to their short maturity periods. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows or Monte Carlo Simulation (when appropriate) analyses and assessment of the probability of occurrence of potential future events.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Fair Value of Derivative Instruments</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Derivative Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cross-currency swaps qualified for and had been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and were remeasured at each reporting date to reflect changes in their </span></div>fair values.  The fair value was determined via a mark-to-market analysis, using observable (Level&#160;2) inputs. These inputs included: (i)&#160;the foreign currency exchange spot rate between the euro and U.S. dollar, (ii)&#160;the interest rate yield curves in the euro and U.S. dollar and (iii)&#160;the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Loss as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulated other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps was ineffective. The Company uses the spot method of assessing hedge effectiveness. The Company had elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as a reduction of Interest expense in the Consolidated Statements of Operations.The Company uses foreign currency exchange contracts to economically hedge the foreign exchange exposure on certain of the Company&#8217;s intercompany and third party balances. The Company's foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash in bank accounts and highly liquid investments with maturities of three months or less when&#160;purchased.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, cross-currency swaps and foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in high-quality, money market instruments and term deposits with varying maturities, but typically less than three months.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash deposited at banks may exceed the amount of insurance provided on such deposits. Generally, these cash deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate such risks by spreading its risk across multiple counterparties and monitoring the risk profiles of these counterparties.</span></div>The Company&#8217;s trade receivables primarily represent amounts due from wholesale distributors, retail pharmacies, government entities and group purchasing organizations. Outside of the U.S., concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the number of customers using the Company&#8217;s products, as well as their dispersion across many different geographic regions. The Company performs periodic credit evaluations of customers and does not require collateral. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The credit and economic conditions within Argentina, Brazil, Egypt, Greece, among other members of the European Union, Turkey, Ukraine and Venezuela have been weak in recent years.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts', window );">Allowance for Credit Losses</a></td>
<td class="text">Allowance for Credit LossesAn allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160; Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories comprise raw materials, work in process and finished goods, which are valued at the lower of cost or net realizable value, on a first-in, first-out basis. The cost value for work in process and finished goods inventories includes materials, direct labor and an allocation of overheads. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on&#160;hand.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are reported at cost, less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction in progress. Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful&#160;lives: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:54.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;-&#160;20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;-&#160;10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of term of lease or 10 years</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reported at cost, less accumulated amortization and impairments. Intangible assets with finite lives are amortized over their estimated useful lives. Amortization is calculated primarily using the straight-line method based on the following estimated useful&#160;lives:</span></div><div style="margin-top:5pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:54.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 - 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 15 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 9 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Out-licensed technology and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 - 9 years</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DivestituresOfNoncoreProductsPolicyTextBlock', window );">Divestitures of Products</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestitures of Products</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds on the divestiture of products and the carrying amount of the related assets is recorded as a gain/loss on sale within Other expense, net. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when realizable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">IPR&amp;D</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IPR&amp;D </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of IPR&amp;D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and&#160;amortized. Acquired IPR&amp;D assets are tested for impairment at least annually or when triggering events are identified.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of an acquired IPR&amp;D intangible asset is typically determined using an income approach. This approach starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#8217;s stage of completion, the probability of technical success, the projected costs to complete, expected market competition and an assessment of the asset&#8217;s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the expected cash flow&#160;streams.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.  If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset, which include the amount and timing of the projected future cash flows. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash&#160;flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets, which includes acquired IPR&amp;D and the corporate trademark acquired in the acquisition of Bausch &amp; Lomb Holdings Incorporated (the &#8216;&#8216;B&amp;L Trademark&#8217;&#8217;), are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based on a comparison of the fair value of the asset to its carrying value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. Goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value. A reporting unit is the same as, or one level below, an operating segment. A</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n entity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is permitted to first assess qualitatively whether it is necessary to perform a quantitative impairment test for any of its reporting units. The quantitative impairment test is required only when the Company concludes that it is more likely than not that a reporting unit&#8217;s fair value is less than its carrying amount. In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company considers the totality of all relevant events or circumstances that affect the fair value or carrying amount of a reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company&#8217;s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, among other factors, the Company monitors </span></div>changes in its share price between annual impairment tests. The Company considers a decline in its share price that corresponds to an overall deterioration in stock market conditions to be less of an indicator of goodwill impairment than a unilateral decline in its share price reflecting adverse changes in its underlying operating performance, cash flows, financial condition and/or liquidity. In the event that the Company&#8217;s market capitalization does decline below its book value, the Company would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. The Company believes that short-term fluctuations in share prices may not necessarily reflect underlying values.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt discounts, premiums and issuance costs are presented in the Consolidated Balance Sheets as a direct deduction from or addition to the carrying amount of the related debt and are amortized or accreted, using the effective interest method, as interest expense over the contractual lives of the related credit facilities or notes. Deferred financing costs associated with revolving credit facility arrangements are included in the balances of Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets and are amortized as interest expense over the contractual life of the related revolving credit facility.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities of the Company&#8217;s foreign operations having a functional currency other than the U.S.&#160;dollar are translated into U.S.&#160;dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange gains and losses on transactions occurring in a currency other than an operation&#8217;s functional currency are recognized as a component of Foreign exchange and other in the Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye-health, gastroenterology ("GI") and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 22, "SEGMENT INFORMATION" for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services.  To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract with the Company&#8217;s customers exists for each product sale.  Where a contract with a customer contains more than one performance obligation, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The transaction price is adjusted for variable consideration which is discussed below.  The Company generally recognizes revenue for product sales at a point in time, when the customer obtains control of the products.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160; The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers.  Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&#160;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity and ending balances of the Company&#8217;s variable consideration provisions the years 2021 and 2020.</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:28.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.881%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, January 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,050&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(593)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,297)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,013)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,378)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $36 million and $32 million as of December 31, 2021 and 2020, respectively, which are reflected as a reduction of Trade accounts receivable, net in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company's products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis.  This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period.  The Company applies this method consistently for contracts with similar characteristics.  The following describes the major sources of variable consideration in the Company&#8217;s customer arrangements and the methodology, estimates and judgments applied to estimate each type of variable consideration.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Discounts and Allowances</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash discounts are offered for prompt payment and allowances for volume purchases. Provisions for cash discounts and allowances are estimated at the time of sale and recorded as direct reductions to trade receivables and revenue. Management estimates the provisions for cash discounts and allowances based on contractual sales terms with customers, an analysis of unpaid invoices and historical payment experience. Estimated cash discounts and allowances have historically been predictable and less subjective, due to the limited number of assumptions involved, the consistency of historical experience and the fact that these amounts are generally settled within one month of incurring the&#160;liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, customers are generally allowed to return a product within a specified period of time before and after its expiration date, excluding European businesses which generally do not provide a right of return. The returns provision is estimated utilizing historical sales and return rates over the period during which customers have a right of return, taking into account available information on competitive products and contract changes. The information utilized to estimate the returns provision includes: (i) historical return and exchange levels, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription demand for products, (iv) remaining shelf lives of products at the date of sale and (v) estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the estimate for returns, management is required to make certain assumptions regarding the timing of the introduction of new products and the potential of these products to capture market share. In addition, certain assumptions with respect to the extent and pattern of decline associated with generic competition are necessary. These assumptions are formulated using market data for similar products, past experience and other available information.  These assumptions are continually reassessed, and changes to the estimates and assumptions are made as new information becomes available. A change of 1% in the estimated return rates would have impacted the Company&#8217;s pre-tax earnings by approximately $81 million for the year 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimate for returns may be impacted by a number of factors, but the principal factor relates to the inventory levels in the distribution channel. When management becomes aware of an increase in such inventory levels, it considers whether the increase may be temporary or other-than-temporary. Temporary increases in wholesaler inventory levels will not warrant revision to the provision for returns. Other-than-temporary increases in wholesaler inventory levels, however, may be an indication that future product returns could be higher than originally anticipated, and, as a result, estimates for returns may need to be adjusted. Factors that suggest increases in wholesaler inventory levels are temporary include: (i) recently implemented or announced price increases for certain products, (ii) new product launches or expanded indications for existing products and (iii) timing of purchases by wholesale customers. Conversely, factors that suggest increases in wholesaler inventory levels are other-than-temporary include: (i) declining sales trends based on prescription demand, (ii) introduction of new products or generic competition, (iii) increasing price competition from generic competitors and (iv) changes to the U.S.&#160;National Drug Codes (&#8220;NDC&#8221;) of products.  Changes in the NDC of products could result in a period of higher returns related to products with the old NDC, as U.S.&#160;customers generally permit only one NDC per product for identification and tracking within their inventory systems.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for 2021 and 2020 were $131&#160;million and $120&#160;million, respectively, and includes reductions in variable consideration for sales return provisions related to past sales of approximately $28 million and $38 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Chargebacks</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales made under governmental and managed-care pricing programs in the U.S. are subject to rebates.&#160; The Company participates in state government-managed Medicaid programs, as well as certain other qualifying federal and state government programs whereby rebates are provided to participating government entities. Medicaid rebates are generally billed 45 days to 270&#160;days after the quarter in which the product is dispensed to the Medicaid participant.  As a result, the Medicaid rebate reserve includes an estimate of outstanding claims for end-customer sales that occurred, but for which the related claim has not been billed and/or paid, and an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. The calculation of the Medicaid rebate reserve also requires other estimates, such as estimates of sales mix, to determine which sales are subject to rebates and the amount of such rebates. A change of 1% in the estimated rates used in the Medicaid rebate reserve would have impacted the Company&#8217;s pre-tax earnings by approximately $76 million for 2021. Quarterly, the Medicaid rebate reserve is adjusted based on actual claims paid. Due to the delay in billing, adjustments to actual claims paid may incorporate revisions of that reserve for several periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market&#160;share.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks relate to contractual agreements to sell products to government agencies, group purchasing organizations and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these group purchasing organizations or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In estimating provisions for rebates and chargebacks, management considers relevant statutes with respect to governmental pricing programs and contractual sales terms with managed-care providers and group purchasing organizations. Management estimates the amount of product sales subject to these programs based on historical utilization levels. Changes in the level of utilization of products through private or public benefit plans and group purchasing organizations will affect the amount of rebates and chargebacks that the Company is obligated to pay. Management continually updates these factors based on new contractual or statutory requirements, and any significant changes in sales trends that may impact the percentage of products subject to rebates or&#160;chargebacks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of Managed Care, Medicaid and other rebates and chargebacks has become more significant as a result of a combination of deeper discounts implemented in each of the last three years, changes in the Company&#8217;s product portfolio due to recent acquisitions and increased Medicaid utilization due to expansion of government funding for these programs.&#160;Management&#8217;s estimate for rebates and chargebacks may be impacted by a number of factors, but the principal factor relates to the level of inventory in the distribution channel.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebate provisions are based on factors such as timing and terms of plans under contract, time to process rebates, product pricing, sales volumes, amount of inventory in the distribution channel and prescription trends. Adjustments to actual for the years 2021 and 2020 were not material to the Company&#8217;s revenues or earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient Co-Pay Assistance programs, Consumer Rebates and Loyalty Programs are rebates offered on many of the Company&#8217;s products.  Patient Co-Pay Assistance Programs are patient discount programs offered in the form of coupon cards or point of sale discounts, with which patients receive certain discounts off their prescription at participating pharmacies, as defined by the specific product program. An accrual for these programs is established, equal to management&#8217;s estimate of the discount, rebate and loyalty incentives attributable to a sale.  That estimate is based on historical experience and other relevant factors. The accrual is adjusted throughout each quarter based on actual experience and changes in other factors, if any.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Fees</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells products primarily to wholesalers, and in some instances to large pharmacy chains such as CVS and Walmart.  The Company has Distribution Services Agreements ("DSAs") with several large wholesale customers such as McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Specialty.  Under the DSAs, the wholesalers agree to provide services, and the Company pays the contracted DSA distribution service fees for these services based on product volumes.  Additionally, price appreciation credits are generated when the Company increases a product&#8217;s wholesaler acquisition cost (&#8220;WAC&#8221;) under contracts with certain wholesalers. Under such contracts, the Company is entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. Such credits are offset against the total distribution service fees paid to each such wholesaler. The variable consideration associated with price appreciation credits is reflected in the transaction price of products sold when it is determined to be probable that a significant reversal will not occur. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $17 million and $15 million for the years 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Commissions </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Component</span></div>The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to internal research and development programs, including costs associated with the development of acquired IPR&amp;D, are expensed as goods are delivered or services are performed. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Milestone payments made to third parties before a product receives regulatory approval, but after the milestone is determined to be probable, are expensed and included in Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third parties as reimbursement of development activities conducted under certain research and development arrangements are recognized as a reduction of Research and development expenses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Legal Costs</a></td>
<td class="text">Legal Costs Legal fees and other costs related to litigation and other legal proceedings or services are expensed as incurred and are included in Selling, general and administrative expenses. Certain legal costs associated with acquisitions are included in Acquisition-related costs and certain legal costs associated with divestitures, legal settlements and other business development activities are included in Litigation and other matters or Net gain on sales of assets within Other expense (income), net, as appropriate. Legal costs expensed are reported net of expected insurance recoveries. A claim for insurance recovery is recognized when realization becomes probable<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text">Advertising CostsAdvertising costs comprise product samples, print media, promotional materials and television advertising and are expensed on the first use of the advertisement.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation The Company recognizes all share-based payments to employees, including grants of employee stock options and restricted share units (&#8220;RSUs&#8221;), at estimated fair value. The Company amortizes the fair value of stock option or RSU grants on a straight-line basis over the requisite service period of the individual stock option or RSU grant, which generally equals the vesting period. Stock option and RSU forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based compensation is recorded in Research and development expenses and Selling, general and administrative expenses, as&#160;appropriate.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpensePolicyTextBlock', window );">Interest Expense</a></td>
<td class="text">Interest Expense Interest expense includes standby fees, the amortization of debt discounts and deferred financing costs, accretion of debt premiums and the amortization of amounts excluded from the assessment of effectiveness related to the Company's cross-currency swaps. Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized. Deferred tax assets and liabilities are measured using enacted tax rates and&#160;laws.  Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such position are measured based on the amount for which there is a greater than 50% likelihood of being realized upon settlement. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within one year. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance&#160;sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share Attributable to Bausch Health Companies Inc.</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share Attributable to Bausch Health Companies Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period. Diluted loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period after giving effect to dilutive potential common shares for stock options and RSUs, determined using the treasury stock&#160;method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss comprises Net loss and Other comprehensive (loss) income. Other comprehensive (loss) income includes items such as foreign currency translation adjustments, unrealized holding gains and losses on available-for-sale and other investments and certain pension and other postretirement benefit plan adjustments. Accumulated other comprehensive loss is recorded as a component of shareholders&#8217; equity.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Accruals for loss contingencies are recorded when the Company determines that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the estimate of the amount of the loss is a range and some amount within the range appears to be a better estimate than any other amount within the range, that amount is accrued as a liability. If no amount within the range is a better estimate than any other amount, the minimum amount of the range is accrued as a&#160;liability. These accruals are adjusted periodically as assessments change or additional information becomes available.</span></div>If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansPolicy', window );">Employee Benefit Plans</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Benefit Plans </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors various retirement and pension plans, including defined benefit pension plans, defined contribution plans and a participatory defined benefit postretirement plan. The determination of defined benefit pension and postretirement plan obligations and their associated expenses requires the use of actuarial valuations to estimate the benefits employees earn while working, as well as the present value of those benefits. Net actuarial gains and losses that exceed 10 percent of the greater of the plan&#8217;s projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated average future service period of the plan participants (or the </span></div>estimated average future lifetime of the plan participants if the majority of plan participants are inactive) or the period until any anticipated final plan settlements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of New Accounting Standards</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New&#160;Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses.  The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to Accumulated deficit of less than $1&#160;million. The application of this guidance did not have a material effect on the Company's results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement.  The guidance was effective for the Company beginning January 1, 2020. The application of this guidance did not have a material effect on the Company's disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans.  The guidance was effective for annual periods ending after December 15, 2020. The application of this guidance did not have a material effect on the Company's disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160; The guidance is effective for the Company beginning with annual periods beginning January 1, 2021.&#160; The application of this guidance did not have a material effect on the Company's financial position, results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.&#160; Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging.&#160;The optional amendments are effective for all entities as of March 12, 2020, through December 31, 2022. During 2020 and 2021, the Company has not entered into any contract modifications in which the optional expedients were applied.&#160; However, if prior to December 31, 2022, the Company enters into a contract modification in which the optional expedients are applied, the Company will evaluate the impact of adoption of this guidance on its financial position, results of operations and cash flows.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#8217;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the planned separation of its Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., on February 23, 2022, the Company announced its plan to change its segment structure in a manner which is consistent with the organizational structure of the two separate entities as proposed by the Solta IPO during the first quarter of 2022. The new segment structure will not impact the Company&#8217;s reporting units but will realign the two reporting units of the Ortho Dermatologics segment whereby its medical dermatology reporting unit (Ortho Dermatologics) will now be managed by the CODM as part of the Diversified Products segment and the Solta reporting unit will be managed by the CODM as its own operating and reportable segment. Accordingly, the Company expects to begin reporting under the following reporting segments on a retrospective basis beginning with its first quarter of 2022 as follows: Bausch + Lomb, Salix, International Rx, Solta and Diversified Products.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DivestituresOfNoncoreProductsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Divestitures of Non-core Products [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DivestituresOfNoncoreProductsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for charging off uncollectible financing receivables, including, but not limited to, factors and methodologies used in estimating the allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (a,b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 10<br> -Section 05<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28365394&amp;loc=d3e23770-108382<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66047640&amp;loc=d3e39622-114963<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65877416&amp;loc=d3e29149-114947<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6412939&amp;loc=d3e15145-114933<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564881320008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Summary of activity in allowance for credit losses</a></td>
<td class="text">The activity in the allowance for credit losses for trade receivables for the years 2021, 2020 and 2019 is as follows.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.199%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.965%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retrospective effect of application of new accounting standard</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock', window );">Schedule of estimated useful lives of property, plant and equipment</a></td>
<td class="text">Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful&#160;lives: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:54.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;-&#160;20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;-&#160;10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of term of lease or 10 years</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of estimated useful lives of intangible assets</a></td>
<td class="text">Amortization is calculated primarily using the straight-line method based on the following estimated useful&#160;lives:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:54.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 - 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 15 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 9 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Out-licensed technology and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 - 9 years</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock', window );">Summary of variable consideration provisions</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity and ending balances of the Company&#8217;s variable consideration provisions the years 2021 and 2020.</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:28.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.881%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, January 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,050&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(593)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,297)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,013)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,378)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated useful lives of major classes of finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated useful lives of major classes of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Valuation And Qualifying Accounts [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883575656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Estimated fair values of assets acquired and liabilities assumed</a></td>
<td class="text">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:89.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.005%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brand intangible assets (estimated useful life 7 years)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock', window );">Schedule of carrying amounts of assets and liabilities held for sale</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the Consolidated Balance Sheets as of December 31, 2020 are the following carrying amounts of the Amoun business' assets and liabilities held for sale.</span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:38.353%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.353%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564889139864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of components and classification of financial assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:26.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.201%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swaps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of assets and liabilities associated with derivatives, included in the Consolidated Balance Sheets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company's cross-currency swaps as included in the Consolidated Balance Sheets as of December 31, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company's foreign exchange contracts as included in the Consolidated Balance Sheets as of December 31, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of effect of hedging instruments on financial statements</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for 2021 and 2020: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Other comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock', window );">Schedule of foreign exchange contracts on the Consolidated Statements of Operations and Consolidated Statements of Cash Flows</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company's foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for 2021 and 2020:</span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) related to changes in fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss related to settlements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the years 2021 and 2020:</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:63.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance, January 1, </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments / Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment included in other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance, December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of assets and liabilities measured at fair value on a non-recurring basis</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a non-recurring basis:</span></div><div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:24.277%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of gains and losses on derivative instruments included in an entity's trading activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4F<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624186-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 55<br> -Paragraph 184<br> -URI http://asc.fasb.org/extlink&amp;oid=123421605&amp;loc=SL5634876-113961<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883584280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of the components of inventories</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net, as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883569224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property, plant and equipment</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of property, plant and equipment as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,820)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,781)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564886579880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of components of finite-lived intangible assets</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets as of December&#160;31, 2021 and 2020 consist of:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:27.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.984%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Useful<br/>Lives<br/>(Years)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,914)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,055)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,741)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D not in service</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B&amp;L Trademark</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,128&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,948&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,186&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,741)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,445&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of components of indefinite-lived intangible assets</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets as of December&#160;31, 2021 and 2020 consist of:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:27.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.984%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Useful<br/>Lives<br/>(Years)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,914)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,055)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,741)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D not in service</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B&amp;L Trademark</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,128&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,948&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,186&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,741)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,445&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated aggregate amortization expense for each of the five succeeding years</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the five years ending December&#160;31 and thereafter are as&#160;follows: </span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:16.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.881%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of changes in the carrying amount of goodwill</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the years ended December 31, 2021, 2020 and 2019 were as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:31.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.408%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + <br/>Lomb/<br/>International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + <br/>Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International Rx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,805&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of certain assets of Synergy </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,786&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets held for sale reclassified to goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale (Note 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,457&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883647384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued and other current liabilities</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,791&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,576&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883596520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of long-term debt</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs as of December 31, 2021 and 2020 consists of the following:</span></div><div style="margin-top:11pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:34.158%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.000% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.500% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.750% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.875% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.000%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.500%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.000%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.000%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.000%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.250%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,925&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of aggregate maturities of long-term debt</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturities and Mandatory Payments</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities and mandatory payments of debt obligations for the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:88.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross maturities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564887914968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of amounts recognized in accumulated other comprehensive loss</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts included in Accumulated other comprehensive loss as of December 31, 2021 and 2020 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:38.413%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.963%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized actuarial losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized prior service credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of net periodic benefit cost</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of net periodic (benefit) cost for the Company&#8217;s defined benefit pension plans and postretirement benefit plan in 2021, 2020 and 2019:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:25.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.504%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement loss recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock', window );">Components of the change in projected benefit obligations, change in plan assets and funded status</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents components of the change in projected benefit obligation, change in plan assets and funded status for 2021 and 2020: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:40.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.025%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Projected Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial (gain) losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded status, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock', window );">Schedule of underfunded plans</a></td>
<td class="text">Information for the underfunded pension benefit plans is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:56.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.971%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Future benefit payments for the pension benefit plans</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future benefit payments over the next 10 years for the pension benefit plans and the postretirement benefit plan, which reflect expected future service, as appropriate, are expected to be paid as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:54.219%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.430%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>&#160;Benefit<br/>&#160;Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Weighted-average assumptions used to determine net periodic benefit costs and benefit obligations</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used to determine net periodic benefit costs and benefit obligations for 2021, 2020 and 2019 were as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:43.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.427%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement Benefit Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For Determining Net Periodic (Benefit) Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:55.197%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.073%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement Benefit Plan</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For Determining Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">Actual asset allocations</a></td>
<td class="text">The following presents the actual asset allocation as of December 31, 2021 and 2020:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:77.048%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock', window );">Fair value of pension and postretirement benefit plan assets assumed in connection with the Acquisition</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents total plan assets by investment category as of December 31, 2021 and 2020 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value. There were no transfers between Level 1 and Level 2 during 2021 and 2020.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.062%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans - U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. broad market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide developed markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:31.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.360%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans - Non-U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide developed markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global high yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government bond funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with Acquisition [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(b)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans.  This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564882444840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Summary of right-of-use assets and right-of-use liabilities</a></td>
<td class="text"><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities associated with the Company's operating leases are included in the Consolidated Balance Sheet as of December 31, 2021 and 2020 as follows:</span></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:82.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets included in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzItMC0xLTEtNTk0NzA_aae53d6e-38d6-4bae-885a-a2f1102e63b7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzItMC0xLTEtNTk0NzA_efb2683f-68c5-4ec5-ba14-7adb1864ba2c">Other non-current assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities included in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzQtMC0xLTEtNTk0NzA_43d158d1-ee05-4bae-a3d5-740a15d049b3"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzQtMC0xLTEtNTk0NzA_fa62fdb0-f620-4627-932e-a0cd84ebc336">Accrued and other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzUtMC0xLTEtNTk0NzA_5aae2037-0b31-4496-a31b-a0628ffc23c9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzUtMC0xLTEtNTk0NzA_fc2d7485-eeb6-4aa7-8f75-257ecb0d55a3">Other non-current liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of lease expenses</a></td>
<td class="text">Lease expense for the years 2021, 2020 and 2019 include:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:70.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable operating lease costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock', window );">Summary of other operating lease information</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to operating leases for 2021, 2020 and 2019 is as follows:</span></div><div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:70.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid from operating cash flows for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of operating lease future payments</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, future payments under noncancelable operating leases for each of the five succeeding years ending December 31 and thereafter are as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:91.594%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of remaining lease payments</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Operating Lease Information, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564888877656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of the components and classification of share-based compensation expense</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components and classification of share-based compensation expense related to stock options and&#160;RSUs for the years 2021, 2020 and 2019 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:67.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumption as of the date of grant using the Black Scholes option-pricing model</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of all stock options granted for the years 2021, 2020 and 2019 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock option life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during 2021: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:56.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.706%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January&#160;1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired or forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of non-vested time-based RSU activity</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested time-based RSU activity during 2021: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:72.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Time-Based<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January&#160;1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to calculate the fair values of performance-based RSUs</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of TSR performance-based RSUs granted during 2021, 2020 and 2019 were estimated with the following assumptions:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:58.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.727%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected Company share volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Summary of non-vested performance-based RSU activity</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested performance-based RSU activity during 2021: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:72.799%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.587%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance-based <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January&#160;1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of equity based payment instruments, excluding stock (or unit) options, including but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883615368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of the components of accumulated other comprehensive loss</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss as of December&#160;31, 2021 and 2020 consists of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,905)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,077)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension adjustment, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,924)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,133)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883608248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock', window );">Summary of research and development</a></td>
<td class="text">Research and development costs for the years 2021, 2020 and 2019 consists of:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Research And Development Expense [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883659544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of other expense, net</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net for the years 2021, 2020 and 2019 consists of:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sales of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,426&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564888894776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Components of loss before benefit from income taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Loss before benefit from income taxes for 2021, 2020 and 2019 consist of:  </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,396)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(701)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(524)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of benefit from income taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Benefit from income taxes for 2021, 2020 and 2019 consist of: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of benefit from income taxes from the expected amount calculated by applying the Canadian statutory rate to loss before benefit of income taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Benefit from income taxes differs from the expected amount calculated by applying the Company&#8217;s Canadian statutory rate of 26.9% to Loss before benefit from income taxes for 2021, 2020 and 2019 as follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before benefit from income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected benefit from income taxes at Canadian statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible amount of share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to tax attributes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance related to foreign tax credits and NOLs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance on Canadian deferred tax assets and tax rate changes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible portion of Goodwill impairments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit on intra-entity transfers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of tax effect of major items recorded as deferred tax assets and liabilities and valuation allowance</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific Research and Experimental Development pool</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,252)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets net of valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plant, equipment and technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized FX on U.S. dollar debt and other financing cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the deferred tax asset valuation allowance for 2021, 2020 and 2019: </span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to Benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to other accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of open tax years by jurisdiction</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:82.106%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jurisdiction:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Open Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2012 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2011 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 - 2020</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of the beginning and ending amounts of unrecognized tax benefits</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the unrecognized tax&#160;benefits for 2021, 2020 and 2019: </span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883617032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of calculation of loss per share</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per share attributable to Bausch Health Companies Inc. for 2021, 2020 and 2019 were calculated as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(560)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,788)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">358.9&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355.0&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352.1&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.64)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.58)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.08)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883511416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Supplemental Cash Flow Disclosures</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow disclosures for 2021, 2020 and 2019 are as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564888929368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment revenues and profit</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits for the years 2021, 2020 and 2019 were as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Rx</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profit:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Rx</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(792)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(619)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,897)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(502)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before benefit from income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock', window );">Schedule of capital expenditures, depreciation and amortization by segment</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures by segment for the years 2021, 2020 and 2019 were as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Rx</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total capital expenditures</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of revenues by segment and by product category</a></td>
<td class="text">Revenues by segment and product category were as&#160;follows: <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:23.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International Rx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:23.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International Rx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,680&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:23.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International Rx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,079&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,717&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,778&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,601&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of revenues by geographic region</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer for the years 2021, 2020 and 2019 were as&#160;follows:</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,601&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Schedule of long-lived assets by geographic region</a></td>
<td class="text"><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December&#160;31, 2021 and 2020 were as&#160;follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:79.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serbia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of external customers that accounted for 10% or more of total revenues</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of each significant reconciling item, other than profit (loss), revenues, or assets, in the reconciliation of totals of such items in reportable segments to the entity's corresponding consolidated amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883646824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>country</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfCountriesInWhichEntityOperates', window );">Number of countries in which entity operates</a></td>
<td class="nump">100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfCountriesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of countries in which the entity operates as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfCountriesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883940040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>company</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished', window );">Business separation and proposed initial public offering, number of companies to be established</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Separation And Proposed Initial Public Offering, Number Of Companies To Be Established</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564886026840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations of Credit Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents', window );">Maximum term of original maturity to classify instruments as cash and cash equivalents (less than)</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ConcentrationRiskPercentageofNetTradeReceivables', window );">Percentage of net trade receivables accounted for by largest wholesale customers</a></td>
<td class="nump">44.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember', window );">Argentina, Brazil, Egypt, Greece, Serbia, South Africa, Turkey, Ukraine, Venezuela and Vietnam</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations of Credit Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Net trade receivable</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PastDuePeriodForAccountsReceivableToBeNegligible', window );">Past due period for receivables to be negligible (less than)</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PeriodReceivableOutstanding', window );">Period net trade receivable balance outstanding (more than)</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_TradeReceivableNetPortionPastDue', window );">Portion of net trade receivables that is past due</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Trade receivables | Three largest U.S. wholesaler customers | Credit concentration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations of Credit Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_NumberOfLargestWholesaleCustomers', window );">Number of largest wholesale customers | wholesaler</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ConcentrationRiskPercentageofNetTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Percentage of Net Trade Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ConcentrationRiskPercentageofNetTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum original term of maturity for an instrument to be classified as cash or cash equivalent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_NumberOfLargestWholesaleCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of largest wholesale customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_NumberOfLargestWholesaleCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PastDuePeriodForAccountsReceivableToBeNegligible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the past due period for which accounts receivables are negligible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PastDuePeriodForAccountsReceivableToBeNegligible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PeriodReceivableOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time the accounts receivable has been outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PeriodReceivableOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_TradeReceivableNetPortionPastDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trade Receivable, Net, Portion Past Due</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_TradeReceivableNetPortionPastDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_ThreeLargestUSWholesalerCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_ThreeLargestUSWholesalerCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564881197704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance, beginning of period</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate', window );">Retrospective effect of application of new accounting standard</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Recoveries</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther', window );">Foreign exchange and other</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance, end of period</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance For Foreign Exchange And Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccountsReceivableAllowanceForForeignExchangeAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in allowance for credit loss on accounts receivable, from recovery.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564880321640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Land improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Other equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Land improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">30 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Buildings and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">40 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Other equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Equipment on operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_EquipmentOnOperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_EquipmentOnOperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564885509800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember', window );">Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate brands</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Product rights/patents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember', window );">Partner relationships</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember', window );">Out-licensed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Corporate brands</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Product rights/patents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Partner relationships</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Out-licensed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Corporate brands</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Product rights/patents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Partner relationships</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Out-licensed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564884742904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">$ 1,813<span></span>
</td>
<td class="nump">$ 2,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provision</a></td>
<td class="nump">5,428<span></span>
</td>
<td class="nump">5,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(5,378)<span></span>
</td>
<td class="num">(5,273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">1,863<span></span>
</td>
<td class="nump">1,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember', window );">Discounts and Allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provision</a></td>
<td class="nump">625<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(593)<span></span>
</td>
<td class="num">(613)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">575<span></span>
</td>
<td class="nump">691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provision</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(224)<span></span>
</td>
<td class="num">(236)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">779<span></span>
</td>
<td class="nump">927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provision</a></td>
<td class="nump">2,462<span></span>
</td>
<td class="nump">2,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(2,297)<span></span>
</td>
<td class="num">(2,322)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">944<span></span>
</td>
<td class="nump">779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember', window );">Chargebacks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provision</a></td>
<td class="nump">1,999<span></span>
</td>
<td class="nump">1,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(2,013)<span></span>
</td>
<td class="num">(1,909)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember', window );">Distribution Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provision</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(251)<span></span>
</td>
<td class="num">(193)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564884632376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">$ 1,863<span></span>
</td>
<td class="nump">$ 1,813<span></span>
</td>
<td class="nump">$ 2,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CashDiscountsAndAllowancesSettlementPeriod', window );">Settlement period for cash discounts and allowances</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax', window );">1% change in estimated return rates, Impact on pre-tax earnings</a></td>
<td class="nump">$ 81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Sales return provisions</a></td>
<td class="nump">5,428<span></span>
</td>
<td class="nump">5,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax', window );">1% change in volume of product sold through to Medicaid plan participants, Impact on pre-tax earnings</a></td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Price appreciation credits</a></td>
<td class="nump">8,434<span></span>
</td>
<td class="nump">8,027<span></span>
</td>
<td class="nump">8,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember', window );">Price Appreciation Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Price appreciation credits</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RevenuePerformanceObligationPaymentTerms', window );">Payment terms</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RevenuePerformanceObligationPaymentTerms', window );">Payment terms</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember', window );">Rebates, Advertising Credits Portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">575<span></span>
</td>
<td class="nump">$ 691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Sales return provisions</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Reduction in variable consideration provision, adjustment</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_CashDiscountsAndAllowancesSettlementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Discounts And Allowances, Settlement Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_CashDiscountsAndAllowancesSettlementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RevenuePerformanceObligationPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Payment Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RevenuePerformanceObligationPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis, Impact Of 1 Percent Change In Estimated Return Rate, Income (Loss) Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis, Impact Of 1 Percent Change In Volume Of Product Sold Through To Medicaid Plan Participants, Income (Loss) Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564887866616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564884065416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expenses</a></td>
<td class="nump">$ 515<span></span>
</td>
<td class="nump">$ 451<span></span>
</td>
<td class="nump">$ 544<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564886179144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Capitalized interest</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883535160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_TaxBenefitRecognitionMeasurementPercentage', window );">Tax benefit recognition, measurement percentage (greater than)</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities', window );">Minimum period to classify uncertain tax position liabilities as long term liabilities</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum period to classify uncertain tax position liabilities as long term liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_TaxBenefitRecognitionMeasurementPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Benefit Recognition, Measurement Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_TaxBenefitRecognitionMeasurementPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564919735096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage', window );">Threshold percentage for amortization of net actuarial gains and losses</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Actuarial Gain (Loss), Amortization Threshold Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564880442600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Increase to accumulated deficit (less than)</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="num">$ (605)<span></span>
</td>
<td class="num">$ (1,136)<span></span>
</td>
<td class="num">$ (2,815)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Increase to accumulated deficit (less than)</a></td>
<td class="nump">$ 8,961<span></span>
</td>
<td class="nump">$ 8,013<span></span>
</td>
<td class="nump">7,452<span></span>
</td>
<td class="nump">$ 5,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Increase to accumulated deficit (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Increase to accumulated deficit (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564803763720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 26, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 23, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 06, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>businessCombination</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>businessCombination</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>businessCombination</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 373,000,000<span></span>
</td>
<td class="nump">$ 502,000,000<span></span>
</td>
<td class="nump">$ 1,426,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_NumberOfOtherBusinessesAcquired', window );">Number of other material business combinations | businessCombination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Upfront payment converted into minor equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected', window );">Expected additional payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held For Sale | Amoun Pharmaceutical Company S.A.E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Amoun Pharmaceutical Company S.A.E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Cash proceeds from divestiture</a></td>
<td class="nump">$ 740,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Amoun Pharmaceutical Company S.A.E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_NoncashCumulativeForeignCurrencyTranslationLoss', window );">Noncash cumulative foreign currency translation loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=bhc_AllegroOphthalmicsLLCMember', window );">Allegro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired IPR&amp;D, included in other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bhc_SynergyPharmaceuticalsInc.Member', window );">Synergy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash payments to acquire certain assets and assumed liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Revenue of acquiree since acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Pro-forma revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss', window );">Pro-forma operating results</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual', window );">Operating results of acquiree since acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Payments To Acquire Equity Securities, FV-NI, Expected</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Pro Forma Operating Income (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessAcquisitionProFormaOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Pro Forma Information, Operating Income (Loss) Since Acquisition, Actual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_NoncashCumulativeForeignCurrencyTranslationLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Cumulative Foreign Currency Translation Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_NoncashCumulativeForeignCurrencyTranslationLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_NumberOfOtherBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Other Businesses Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_NumberOfOtherBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=bhc_AllegroOphthalmicsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=bhc_AllegroOphthalmicsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bhc_SynergyPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bhc_SynergyPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564885548728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 06, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,457<span></span>
</td>
<td class="nump">$ 13,044<span></span>
</td>
<td class="nump">$ 13,126<span></span>
</td>
<td class="nump">$ 13,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bhc_SynergyPharmaceuticalsInc.Member', window );">Synergy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Product brand intangible assets (estimated useful life 7 years)</a></td>
<td class="nump">159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses', window );">Accrued expenses</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total fair value of consideration transferred</a></td>
<td class="nump">$ 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted- Average Remaining Useful Lives (Years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bhc_SynergyPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bhc_SynergyPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564885960664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Assets and Liabilities Held For Sale (Details) - A Certain International Business - Held For Sale<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Prepaid expenses and other current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Trade receivables, net</a></td>
<td class="nump">$ 91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventories, net</a></td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets', window );">Total Prepaid expenses and other current assets</a></td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent', window );">Property, plant and equipment, net</a></td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Goodwill and Intangible assets, net</a></td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets', window );">Deferred tax assets, net</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets', window );">Total Other non-current assets</a></td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Accrued and other current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities', window );">Total Accrued and other current liabilities</a></td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract', window );"><strong>Other non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities', window );">Total Other non-current liabilities</a></td>
<td class="nump">$ 57<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred tax assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_ACertainInternationalBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_ACertainInternationalBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564884047144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">$ 2,624<span></span>
</td>
<td class="nump">$ 2,367<span></span>
</td>
<td class="nump">$ 2,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember', window );">Restructuring and Integration Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Remaining restructuring liabilities</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Restructuring payments</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationAndInitialPublicOfferingCostsMember', window );">Separation and IPO Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, integration, separation and IPO costs</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationAndInitialPublicOfferingCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationAndInitialPublicOfferingCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564884927432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">1,537<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency exchange contracts</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">1,537<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level 1 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency exchange contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level 1 | Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;2 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency exchange contracts</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;2 | Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;3 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency exchange contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;3 | Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564886405528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 16, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_HighlyLiquidInvestmentsMaturityPeriod', window );">Highly liquid investments, maturity period (or less)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">Valeant US Securities Litigation | New Jersey | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, escrow fund included in restricted cash</a></td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="nump">$ 1,510<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_HighlyLiquidInvestmentsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Highly Liquid Investments, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_HighlyLiquidInvestmentsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564885527096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Cross-currency swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromHedgeInvestingActivities', window );">Net proceeds, cross-currency swaps</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Net proceeds, settlement of cross-currency swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Cross-currency swaps | Net Investment Hedging | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Aggregate notional amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bhc_CrossCurrencyFinalSettlementMember', window );">Cross-currency swaps, final settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Net proceeds, settlement of cross-currency swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3581-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bhc_CrossCurrencyFinalSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bhc_CrossCurrencyFinalSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564803445528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details) - Cross-currency swaps - Net Investment Hedging - Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Net fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Other non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564880324024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Cross-currency swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Net proceeds, settlement of cross-currency swaps</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Cross-currency swaps | Net Investment Hedging | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Gain (loss) recognized in Other comprehensive loss</a></td>
<td class="nump">77<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Cross-currency swaps | Net Investment Hedging | Designated as Hedging Instrument | Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain excluded from assessment of hedge effectiveness</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bhc_CrossCurrencyFinalSettlementMember', window );">Cross-currency swaps, final settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Net proceeds, settlement of cross-currency swaps</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bhc_CrossCurrencyFinalSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bhc_CrossCurrencyFinalSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564892495480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Foreign currency exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Aggregate notional amounts</a></td>
<td class="nump">$ 166,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564887786984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details) - Foreign currency exchange contracts - Not Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Net fair value</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=bhc_AccruedAndOtherCurrentLiabilitiesMember', window );">Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Accrued and other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=bhc_AccruedAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=bhc_AccruedAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564890020808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details) - Foreign currency exchange contracts - Not Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Gain (loss) related to changes in fair value</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss', window );">Loss related to settlements</a></td>
<td class="num">$ (17)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized loss of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564884710840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>rate</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 328<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration adjustments</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments / Settlements</a></td>
<td class="num">(99)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Foreign currency translation adjustment included in other comprehensive loss</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current portion</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember', window );">Accretion for the time value of money</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration adjustments</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsMember', window );">Fair value adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration adjustments</a></td>
<td class="num">$ (6)<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=bhc_MeasurementInputWeightedAverageDiscountRateMember', window );">Measurement Input, Weighted-Average Discount Rate | Level&#160;3 | Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate | rate</a></td>
<td class="nump">0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Measurement Input, Discount Rate | Level&#160;3 | Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate | rate</a></td>
<td class="nump">0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Measurement Input, Discount Rate | Level&#160;3 | Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate | rate</a></td>
<td class="nump">0.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=bhc_MeasurementInputWeightedAverageDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=bhc_MeasurementInputWeightedAverageDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564803599528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details) - Fair Value, Nonrecurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Non-current assets held for sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Non-current assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Non-current assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Non-current assets held for sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets classified as held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564884408808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis, Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets reclassified, held and used</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,202<span></span>
</td>
<td class="nump">$ 31,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Non-recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Non-current assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Non-recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Non-current assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held For Sale | Certain Products For Disposal, September 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets classified as held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883698888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Non-recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of long-term debt</a></td>
<td class="nump">$ 22,689<span></span>
</td>
<td class="nump">$ 25,378<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564803438104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES - Summary of Inventories, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 279<span></span>
</td>
<td class="nump">$ 286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">602<span></span>
</td>
<td class="nump">665<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="nump">$ 1,094<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564885549384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 3,418<span></span>
</td>
<td class="nump">$ 3,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(1,820)<span></span>
</td>
<td class="num">(1,781)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,598<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">1,678<span></span>
</td>
<td class="nump">1,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_OtherEquipmentAndLeaseholdImprovementMember', window );">Other equipment and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_EquipmentOnOperatingLeaseMember', window );">Equipment on operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 576<span></span>
</td>
<td class="nump">$ 436<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_OtherEquipmentAndLeaseholdImprovementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_OtherEquipmentAndLeaseholdImprovementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_EquipmentOnOperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_EquipmentOnOperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883808184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564884829128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 25,430<span></span>
</td>
<td class="nump">$ 25,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(20,180)<span></span>
</td>
<td class="num">(18,741)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">5,250<span></span>
</td>
<td class="nump">6,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">27,128<span></span>
</td>
<td class="nump">27,186<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net (Excluding Goodwill)</a></td>
<td class="nump">6,948<span></span>
</td>
<td class="nump">8,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bhc_AcquiredInProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D not in service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">B&amp;L Trademark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">$ 1,698<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember', window );">Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted- Average Remaining Useful Lives (Years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 20,842<span></span>
</td>
<td class="nump">20,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(16,169)<span></span>
</td>
<td class="num">(14,914)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 4,673<span></span>
</td>
<td class="nump">5,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted- Average Remaining Useful Lives (Years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 902<span></span>
</td>
<td class="nump">907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(473)<span></span>
</td>
<td class="num">(404)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 429<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Product rights/patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted- Average Remaining Useful Lives (Years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 3,321<span></span>
</td>
<td class="nump">3,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(3,174)<span></span>
</td>
<td class="num">(3,055)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember', window );">Partner relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted- Average Remaining Useful Lives (Years)</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(158)<span></span>
</td>
<td class="num">(168)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember', window );">Technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted- Average Remaining Useful Lives (Years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 207<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(206)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bhc_AcquiredInProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bhc_AcquiredInProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564805941752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Oct. 01, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Oct. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,434,000,000<span></span>
</td>
<td class="nump">$ 8,027,000,000<span></span>
</td>
<td class="nump">$ 8,601,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, year-over-year increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage', window );">Revenue, year-over-year decrease, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Percentage of fair value in excess of carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment charges to date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportingUnitMember', window );">Ortho Dermatologics Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rates</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Percentage of fair value in excess of carrying value</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_ReportingUnitsExcludingOrthoDermatologicsMember', window );">Reporting Units Excluding Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Ortho Dermatologics Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">12.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Ortho Dermatologics Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">9.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bhc_AcquiredInProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Amoun Pharmaceutical Company S.A.E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held For Sale | Amoun Pharmaceutical Company S.A.E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held For Sale | A Certain International Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held For Sale | Certain Products For Disposal, September 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember', window );">Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,000,000<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="nump">58,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember', window );">Discontinued Product Lines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Product rights/patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_UnutilizedITInfrastructureImprovementProjectMember', window );">Unutilized IT Infrastructure Improvement Project</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reporting Unit, Impairment Test, Long-Term Growth Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ReportingUnitImpairmentTestLongTermGrowthRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair value of reporting unit in excess of carrying amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_ReportingUnitsExcludingOrthoDermatologicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_ReportingUnitsExcludingOrthoDermatologicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bhc_AcquiredInProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bhc_AcquiredInProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_ACertainInternationalBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_ACertainInternationalBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_UnutilizedITInfrastructureImprovementProjectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_UnutilizedITInfrastructureImprovementProjectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564887018504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Estimated aggregate amortization expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 1,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">1,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="nump">664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 5,250<span></span>
</td>
<td class="nump">$ 6,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564885626920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Oct. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,044,000,000<span></span>
</td>
<td class="nump">$ 13,126,000,000<span></span>
</td>
<td class="nump">$ 13,142,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisition of certain assets of Synergy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill reclassified to assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(217,000,000)<span></span>
</td>
<td class="num">(18,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118,000,000)<span></span>
</td>
<td class="nump">117,000,000<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit', window );">Assets held for sale reclassified to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(469,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,457,000,000<span></span>
</td>
<td class="nump">13,044,000,000<span></span>
</td>
<td class="nump">13,126,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombInternationalMember', window );">Bausch + Lomb/ International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,704,000,000<span></span>
</td>
<td class="nump">5,786,000,000<span></span>
</td>
<td class="nump">5,805,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill reclassified to assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(217,000,000)<span></span>
</td>
<td class="num">(18,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">117,000,000<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit', window );">Assets held for sale reclassified to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,704,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,704,000,000<span></span>
</td>
<td class="nump">5,786,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,395,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,318,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,156,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisition of certain assets of Synergy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International Rx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">887,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,267,000,000<span></span>
</td>
<td class="nump">1,267,000,000<span></span>
</td>
<td class="nump">1,267,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(469,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">798,000,000<span></span>
</td>
<td class="nump">1,267,000,000<span></span>
</td>
<td class="nump">1,267,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,914,000,000<span></span>
</td>
<td class="nump">2,914,000,000<span></span>
</td>
<td class="nump">2,914,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(578,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,357,000,000<span></span>
</td>
<td class="nump">$ 2,914,000,000<span></span>
</td>
<td class="nump">$ 2,914,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Transfers Related To Sale of Business Unit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564884488792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_Legalsettlementsandrelatedfees', window );">Legal matters and related fees</a></td>
<td class="nump">$ 1,890<span></span>
</td>
<td class="nump">$ 1,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccruedProductRebateCurrent', window );">Product rebates</a></td>
<td class="nump">908<span></span>
</td>
<td class="nump">747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccruedProductReturnCurrent', window );">Product returns</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee compensation and benefit costs</a></td>
<td class="nump">336<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">749<span></span>
</td>
<td class="nump">767<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 4,791<span></span>
</td>
<td class="nump">$ 4,576<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccruedProductRebateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the current portion of accrued product rebates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccruedProductRebateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccruedProductReturnCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccruedProductReturnCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_Legalsettlementsandrelatedfees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Legal settlements and related fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_Legalsettlementsandrelatedfees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564805228136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 03, 2020</div></th>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>Mar. 08, 2019</div></th>
<th class="th"><div>Oct. 17, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 22,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">22,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of long-term debt</a></td>
<td class="nump">$ 22,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member', window );">Term Loan B Facility Due June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">3.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 2,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 2,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member', window );">Term Loan B Facility Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">2.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 7.000 % Senior Notes Due March 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 5.500% Senior Notes Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 5.750% Senior Notes Due August 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 4.875% Senior Notes Due June 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">4.875%<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.125% Senior Notes Due April 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 2,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 2,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.000% Senior Notes Due December 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.250% Senior Notes Due April 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 8.500% Senior Notes Due January 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.000 % Senior Notes Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.000% Senior Notes Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.250% Senior Notes Due February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.000% Senior Note Due February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.250% Senior Notes Due May 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.250% Senior Notes Due January 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.250% Senior Notes, Due February 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Senior Secured Credit Facilities | 2023 Revolving Credit Facility Due June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">2.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_OtherLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_OtherLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564881063816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Covenant Compliance (Details) - Revolving credit facility<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAmountAvailableForRestrictedPayments', window );">Amount available for restricted payments</a></td>
<td class="nump">$ 13,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio', window );">Fixed charge coverage ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio', window );">Secured leverage ratio</a></td>
<td class="nump">4.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAmountAvailableForRestrictedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Amount Available For Restricted Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAmountAvailableForRestrictedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Secured Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564803748424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Nov. 27, 2018</div></th>
<th class="th"><div>Jun. 01, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,654,000,000<span></span>
</td>
<td class="nump">$ 23,925,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member', window );">Term Loan B Facility Due June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="nump">$ 4,565,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,772,000,000<span></span>
</td>
<td class="nump">3,220,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | 2023 Revolving Credit Facility Due June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold', window );">Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">91 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold', window );">Alternate term, principal amount maturity threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">886,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | 2023 Revolving Credit Facility Due June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564885686024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Current Description of Senior Secured Credit Facilities (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization', window );">Remaining mandatory quarterly amortization payments</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings', window );">Incremental credit facility borrowings</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate', window );">Incremental borrowings interest rate</a></td>
<td class="nump">28.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio', window );">Secured leverage ratio (not greater than)</a></td>
<td class="nump">4.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum', window );">Interest coverage ratio (not less than)</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio', window );">Secured leverage ratio (not greater than)</a></td>
<td class="nump">3.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum', window );">Total leverage ratio (not greater than)</a></td>
<td class="nump">6.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember', window );">Senior Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member', window );">2023 Revolving Credit Facility Due June 2023 | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.84%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member', window );">2023 Revolving Credit Facility Due June 2023 | Minimum | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee, unutilized commitments, percentage</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member', window );">2023 Revolving Credit Facility Due June 2023 | Maximum | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee, unutilized commitments, percentage</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredTermCreditFacilitiesMember', window );">Senior Secured Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments', window );">Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from incurrence of debt</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments', window );">Percentage of annual excess cash flow</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member', window );">Term Loan B Facility Due June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.09%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage', window );">Annual amortization rate, percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member', window );">Term Loan B Facility Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.84%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage', window );">Annual amortization rate, percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember', window );">Federal Funds Effective Swap Rate | Senior Secured Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar | Senior Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar | Senior Credit Facilities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar | 2023 Revolving Credit Facility Due June 2023 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar | 2023 Revolving Credit Facility Due June 2023 | Minimum | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar | 2023 Revolving Credit Facility Due June 2023 | Maximum | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar | Term Loan B Facility Due June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar | Term Loan B Facility Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">2.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_CanadaBankersAcceptanceRateMember', window );">Canada Bankers Acceptance Rate | 2023 Revolving Credit Facility Due June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_CanadaBankersAcceptanceRateMember', window );">Canada Bankers Acceptance Rate | 2023 Revolving Credit Facility Due June 2023 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_BaseRateOrPrimeRateMember', window );">Base Rate or Prime Rate | 2023 Revolving Credit Facility Due June 2023 | Minimum | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_BaseRateOrPrimeRateMember', window );">Base Rate or Prime Rate | 2023 Revolving Credit Facility Due June 2023 | Maximum | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_BaseRateOrPrimeRateMember', window );">Base Rate or Prime Rate | Term Loan B Facility Due June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_BaseRateOrPrimeRateMember', window );">Base Rate or Prime Rate | Term Loan B Facility Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Annual Amortization Rate, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAnnualAmortizationRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Secured Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Total Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Quarterly Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Threshold For Incremental Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility Threshold For Incremental Borrowings Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredTermCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredTermCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_CanadaBankersAcceptanceRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_CanadaBankersAcceptanceRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_BaseRateOrPrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_BaseRateOrPrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564804343288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Secured Notes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>Jan. 16, 2020</div></th>
<th class="th"><div>May 23, 2019</div></th>
<th class="th"><div>Mar. 08, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Nov. 21, 2017</div></th>
<th class="th"><div>Oct. 17, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 27, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage due to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,440,000,000<span></span>
</td>
<td class="nump">$ 5,642,000,000<span></span>
</td>
<td class="nump">$ 4,406,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="nump">$ 27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,000,000<span></span>
</td>
<td class="nump">$ 59,000,000<span></span>
</td>
<td class="nump">$ 42,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage due to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member', window );">6.50% Senior Notes Due March 2022 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member', window );">7.000 % Senior Notes Due March 2024 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member', window );">5.500% Senior Notes Due November 2025 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member', window );">5.750% Senior Notes Due August 2027 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_A8.50SeniorNotesDueJanuary2027Member', window );">8.50% Senior Unsecured Notes Due January 2027 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_A5.875SeniorNotesdueMay2023Member', window );">5.875% Senior Unsecured Notes due May 2023 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.875%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,240,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes5.625PercentDueDecember2021Member', window );">5.625 % Senior Unsecured Notes due December 2021 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 518,000,000<span></span>
</td>
<td class="nump">$ 182,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember', window );">Senior Secured and Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member', window );">4.875% Senior Notes Due June 2028 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member', window );">4.875% Senior Notes Due June 2028 | Senior Secured Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member', window );">4.875% Senior Notes Due June 2028 | Senior Secured Notes | Debt Instrument, Redemption, Period Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Maximum percentage of principal amount that can be redeemed</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueMarch2024Member', window );">Senior Notes, 7.00%, Due March 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Maximum Redemption Percentage With Equity Offering Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage, Change in Control</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentRedemptionPricePercentageChangeinControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A8.50SeniorNotesDueJanuary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A8.50SeniorNotesDueJanuary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A5.875SeniorNotesdueMay2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A5.875SeniorNotesdueMay2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes5.625PercentDueDecember2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes5.625PercentDueDecember2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueMarch2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueMarch2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564795703736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 08, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 26, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 16, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 16, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 03, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 23, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 08, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 26, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 18, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 03, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 27, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 27, 2015 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage due to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,440,000,000<span></span>
</td>
<td class="nump">$ 5,642,000,000<span></span>
</td>
<td class="nump">$ 4,406,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000,000<span></span>
</td>
<td class="nump">59,000,000<span></span>
</td>
<td class="nump">42,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation | New Jersey | Valeant US Securities Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation, amount agreed to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,210,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,510,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025AndNovember2025Member', window );">Term Loan B Facility Due June 2025 and November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PaymentForDebtAmortizationPrepaymentCost', window );">Repayment, outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 303,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage due to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.50% Senior Unsecured Notes due March 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 382,000,000<span></span>
</td>
<td class="nump">$ 216,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233,000,000<span></span>
</td>
<td class="nump">$ 169,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.375% Senior Notes due March 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.875% Senior Unsecured Notes due May 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.875%<span></span>
</td>
<td class="nump">5.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,240,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.875% Senior Notes due May 2023, March 2019 Refinancing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">584,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.875% Senior Notes due May 2023, May 2019 Refinancing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,118,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 4.50% Senior Unsecured Notes euro-denominated debt Due May 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.125% Senior Unsecured Notes due April 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | Senior Unsecured Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,240,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.125% Senior Notes Due April 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.00% Senior Unsecured Notes due December 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.00% Senior Unsecured Notes due December 2025 | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.00% Senior Unsecured Notes due December 2025 | Debt Instrument, Redemption, Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.25% Senior Unsecured Notes Due April 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 8.50% Senior Unsecured Notes Due January 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.00% Senior Unsecured Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.25% Senior Unsecured Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.00% Senior Unsecured Notes Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.25% Senior Unsecured Notes Due January 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.250% Senior Notes Due February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.250% Senior Notes Due February 2029 | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.250% Senior Notes Due February 2029 | Debt Instrument, Redemption, Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.000% Senior Note Due February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.250% Senior Notes, Due February 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.50% Senior Notes Due March 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 6.50% Senior Notes Due March 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Maximum Redemption Percentage With Equity Offering Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage, Change in Control</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentRedemptionPricePercentageChangeinControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PaymentForDebtAmortizationPrepaymentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment For Debt Amortization Prepayment Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PaymentForDebtAmortizationPrepaymentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025AndNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025AndNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A5.50SeniorNotesdueMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A5.50SeniorNotesdueMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A5.375SeniorNotesdueMarch2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A5.375SeniorNotesdueMarch2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A5.875SeniorNotesdueMay2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A5.875SeniorNotesdueMay2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes4.502023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes4.502023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A6.125SeniorNotesdueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A6.125SeniorNotesdueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorUnsecuredNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorUnsecuredNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A9.25SeniorNotesDueApril2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A9.25SeniorNotesDueApril2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A8.50SeniorNotesDueJanuary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A8.50SeniorNotesDueJanuary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A7.00SeniorUnsecuredNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A7.00SeniorUnsecuredNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A7.25SeniorUnsecuredNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A7.25SeniorUnsecuredNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A5.00SeniorNotesDueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A5.00SeniorNotesDueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A5.25SeniorNotesDueJanuary2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A5.25SeniorNotesDueJanuary2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes550DueMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes550DueMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564803477320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Feb. 11, 2022</div></th>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Jan. 18, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 18, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.88%<span></span>
</td>
<td class="nump">6.02%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member', window );">2023 Revolving Credit Facility Due June 2023 | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member', window );">2023 Revolving Credit Facility Due June 2023 | Revolving credit facility | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of lines of credit</a></td>
<td class="nump">$ 285,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member', window );">9.00% Senior Unsecured Notes due December 2025 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member', window );">9.00% Senior Unsecured Notes due December 2025 | Senior Unsecured Notes | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member', window );">Senior Secured 6.125% Notes Due February 2027 | Senior Secured Notes | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564887622696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Maturities, Schedule of Maturities and Mandatory Payments of Debt Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">9,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2026</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">11,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total gross maturities</a></td>
<td class="nump">22,870<span></span>
</td>
<td class="nump">$ 24,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discounts</a></td>
<td class="num">(216)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 22,654<span></span>
</td>
<td class="nump">$ 23,925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564805136136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>defined_benefit_plan</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>defined_benefit_plan</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod', window );">Future benefit payments period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contributions recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,000,000<span></span>
</td>
<td class="nump">$ 43,000,000<span></span>
</td>
<td class="nump">$ 41,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Underfunded pension benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Underfunded pension benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 231,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance', window );">Benefit accrual, interest percentage earned on cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Estimated company contributions in next fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Percentage of expected return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.74%<span></span>
</td>
<td class="nump">2.98%<span></span>
</td>
<td class="nump">3.46%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans', window );">Number of defined benefit plans | defined_benefit_plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended', window );">Number of defined benefit plans amended | defined_benefit_plan</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Percentage of expected return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DefinedBenefitPlanPercentageAllocationofFund', window );">Percentage allocation of fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | Ireland | Scenario, Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Percentage of expected return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Estimated company contributions in next fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Percentage of expected return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | United States | Scenario, Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Percentage of expected return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DefinedBenefitPlanEmployerContributionMaximumAge', window );">Employer contribution maximum age</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">65 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Estimated company contributions in next fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Percentage of expected return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Benefit Accrual, Interest Percentage Earned On Cash Balance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DefinedBenefitPlanEmployerContributionMaximumAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Employer Contribution, Maximum Age</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DefinedBenefitPlanEmployerContributionMaximumAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Estimated Future Benefit Payments, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Number of Defined Benefit Plans Amended</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Number of Defined Benefit Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DefinedBenefitPlanPercentageAllocationofFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Percentage Allocation of Fund</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DefinedBenefitPlanPercentageAllocationofFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2919-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564804268264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">U.S. Postretirement Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax', window );">Unrecognized actuarial losses</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax', window );">Unrecognized prior service credits</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax', window );">Unrecognized actuarial losses</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax', window );">Unrecognized prior service credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Non-U.S. Plans | Pension Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax', window );">Unrecognized actuarial losses</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax', window );">Unrecognized prior service credits</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564803845688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">U.S. Postretirement Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlement loss recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanOtherCosts', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlement loss recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanOtherCosts', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Non-U.S. Plans | Pension Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net loss</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlement loss recognized</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanOtherCosts', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of defined benefit plan cost (credit), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564803906360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">U.S. Postretirement Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in Projected Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation, beginning of year</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gain) losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation, end of year</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in Plan Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, beginning of year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, end of year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status, end of year</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in Projected Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation, beginning of year</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gain) losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation, end of year</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in Plan Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, beginning of year</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, end of year</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status, end of year</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Non-U.S. Plans | Pension Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in Projected Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation, beginning of year</a></td>
<td class="nump">294<span></span>
</td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gain) losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Currency translation adjustments</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation, end of year</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in Plan Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, beginning of year</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Currency translation adjustments</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, end of year</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">$ 161<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status, end of year</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pension And Other Postretirement Defined Benefit Plans, Other Assets, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pension and Other Postretirement Defined Benefit Plans, Accrued and Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564887640424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Underfunded plans having accumulated benefit obligations exceeding the fair value of plan assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation', window );">Projected benefit obligation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 236,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">236,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">231,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Underfunded plans having accumulated benefit obligations exceeding the fair value of plan assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation', window );">Projected benefit obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="nump">$ 219,000,000<span></span>
</td>
<td class="nump">286,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564884877912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future Benefit Payments for the Pension Benefit Plans (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2023</a></td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2024</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2025</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2026</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2027-2031</a></td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2022</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2023</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2024</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2025</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2026</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2027-2031</a></td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">U.S. Postretirement Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2022</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2023</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2024</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2025</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2026</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2027-2031</a></td>
<td class="nump">$ 11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564884469080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-Average Assumptions Used to Determine Net Periodic Benefit Costs and Benefit Obligations (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>For Determining Net Periodic (Benefit) Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">3.16%<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>For Determining Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.69%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>For Determining Net Periodic (Benefit) Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate</a></td>
<td class="nump">1.37%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">2.39%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="nump">2.74%<span></span>
</td>
<td class="nump">2.98%<span></span>
</td>
<td class="nump">3.46%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">3.05%<span></span>
</td>
<td class="nump">2.89%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>For Determining Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">1.72%<span></span>
</td>
<td class="nump">1.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">2.63%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">U.S. Postretirement Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>For Determining Net Periodic (Benefit) Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">3.04%<span></span>
</td>
<td class="nump">4.16%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>For Determining Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.57%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2919-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average interest crediting rate used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564887005512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details) - Pension Benefit Plans<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">United States | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Defined benefit plan, percentage of actual plan asset allocations</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">United States | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Defined benefit plan, percentage of actual plan asset allocations</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">United States | Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Defined benefit plan, percentage of actual plan asset allocations</a></td>
<td class="nump">69.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Plans | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Defined benefit plan, percentage of actual plan asset allocations</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Plans | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Defined benefit plan, percentage of actual plan asset allocations</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Plans | Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Defined benefit plan, percentage of actual plan asset allocations</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Plans | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Defined benefit plan, percentage of actual plan asset allocations</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564807031688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with the Acquisition (Details) - Pension Benefit Plans - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 224<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">$ 161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Level 1 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Level 1 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Level&#160;2 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Level&#160;2 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Level&#160;3 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Level&#160;3 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_U.S.BroadMarketMember', window );">U.S. broad market | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_U.S.BroadMarketMember', window );">U.S. broad market | Level 1 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_U.S.BroadMarketMember', window );">U.S. broad market | Level&#160;2 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_U.S.BroadMarketMember', window );">U.S. broad market | Level&#160;3 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Level 1 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Level 1 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Level&#160;2 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Level&#160;2 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Level&#160;3 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Level&#160;3 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Level 1 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Level 1 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Level&#160;2 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Level&#160;2 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Level&#160;3 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Level&#160;3 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.OtherAssetsMember', window );">Other assets | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.OtherAssetsMember', window );">Other assets | Level 1 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.OtherAssetsMember', window );">Other assets | Level&#160;2 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.OtherAssetsMember', window );">Other assets | Level&#160;3 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Level 1 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Level 1 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Level&#160;2 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Level&#160;2 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Level&#160;3 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Level&#160;3 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_GlobalHighYieldMember', window );">Global high yield | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_GlobalHighYieldMember', window );">Global high yield | Level 1 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_GlobalHighYieldMember', window );">Global high yield | Level&#160;2 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_GlobalHighYieldMember', window );">Global high yield | Level&#160;3 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Government bond funds | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Government bond funds | Level 1 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Government bond funds | Level&#160;2 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Government bond funds | Level&#160;3 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_OtherAssetsFixedIncomeSecuritiesMember', window );">Other assets | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_OtherAssetsFixedIncomeSecuritiesMember', window );">Other assets | Level 1 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_OtherAssetsFixedIncomeSecuritiesMember', window );">Other assets | Level&#160;2 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_OtherAssetsFixedIncomeSecuritiesMember', window );">Other assets | Level&#160;3 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_U.S.BroadMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_U.S.BroadMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_GlobalHighYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_GlobalHighYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_OtherAssetsFixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_OtherAssetsFixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564889083896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Right-of-use Assets and Right-of-use Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AssetsLesseeAbstract', window );"><strong>Right-of-use assets included in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Other non-current assets</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="nump">$ 259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LiabilitiesLesseeAbstract', window );"><strong>Lease liabilities included in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other non-current liabilities<span></span>
</td>
<td class="text">Other non-current liabilities<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of remaining lease payments</a></td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other non-current assets<span></span>
</td>
<td class="text">Other non-current assets<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AssetsLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets, Lessee [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AssetsLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities, Lessee [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564881232632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance leases</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sub-lease income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564887725832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Lease Expenses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable operating lease costs</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564888192760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Lease Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid from operating cash flows for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Excluding Amount Recognized Upon Adoption</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564886056824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Lease Future Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of remaining lease payments</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564804283320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Narrative (Details) - Omnibus Incentive Plan 2014 - USD ($)<br></strong></div></th>
<th class="th"><div>Apr. 28, 2020</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total number of shares approved for grant by the Company under the share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares available for issuance (in shares)</a></td>
<td class="nump">13,500,000<span></span>
</td>
<td class="nump">11,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,593,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member', window );">Nonemployee Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant', window );">Aggregate fair market value on awards granted during any calendar year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bhc_NonemployeeDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bhc_NonemployeeDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564803412440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 128<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=bhc_SellingGeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bhc_SellingGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bhc_SellingGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564884848696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Stock Options (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Method and assumptions on valuation of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected stock option life (years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">50.20%<span></span>
</td>
<td class="nump">38.70%<span></span>
</td>
<td class="nump">46.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning of the period (in shares)</a></td>
<td class="nump">8.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Expired or forfeited (in shares)</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">End of the period (in shares)</a></td>
<td class="nump">8.9<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end of the period (in shares)</a></td>
<td class="nump">8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable at the end of the period (in shares)</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward', window );"><strong>Weighted- Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 25.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">32.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">18.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired or forfeited (in dollars per share)</a></td>
<td class="nump">29.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">End of the period (in dollars per share)</a></td>
<td class="nump">27.65<span></span>
</td>
<td class="nump">$ 25.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at the end of the period (in dollars per share)</a></td>
<td class="nump">27.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and exercisable at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 27.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted- Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at the end of the period</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at the end of the period</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable at the end of the period</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the end of the period</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest at the end of the period</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and exercisable at the end of the period</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of stock options (in dollars per share)</a></td>
<td class="nump">$ 10.92<span></span>
</td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="nump">$ 8.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock options exercised in the period</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue', window );">Fair value of stock options vested</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Vesting Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Vesting Period One | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage', window );">Percentage of stock options that will vest on each of the first, second, third and fourth anniversaries from the date of grant</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Vesting Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Vesting Period Two | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage', window );">Percentage of stock options that will vest on each of the first, second, third and fourth anniversaries from the date of grant</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total fair value of stock options vested during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of stock options that will vest in the future period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564803698360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - RSUs (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting rights</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember', window );">Time-Based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="nump">$ 68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning of the period (in shares)</a></td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(3,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">End of the period (in shares)</a></td>
<td class="nump">5,400,000<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant-Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 21.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">31.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">21.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">26.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">End of the period (in dollars per share)</a></td>
<td class="nump">$ 28.16<span></span>
</td>
<td class="nump">$ 21.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued', window );">Maximum common shares issuable upon vesting (in shares)</a></td>
<td class="nump">3,476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning of the period (in shares)</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(1,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">End of the period (in shares)</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant-Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 28.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">40.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">27.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">End of the period (in dollars per share)</a></td>
<td class="nump">$ 33.92<span></span>
</td>
<td class="nump">$ 28.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Method and assumptions on valuation of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual term (years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Company share volatility</a></td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="nump">46.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember', window );">TSR Performance-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant-Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 56.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_ROTCPerformanceBasedRestrictedStockUnitsMember', window );">ROTC Performance-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">413,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant-Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 31.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_OtherPerformanceBasedRestrictedStockUnitsMember', window );">Other Performance Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">222,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant-Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 28.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum number of common shares that could be issued upon vesting of outstanding awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_ROTCPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_ROTCPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_OtherPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_OtherPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564803409576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">$ (34)<span></span>
</td>
<td class="nump">$ 605<span></span>
</td>
<td class="nump">$ 1,136<span></span>
</td>
<td class="nump">$ 2,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,905)<span></span>
</td>
<td class="num">(2,077)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Pension adjustment, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">$ (1,924)<span></span>
</td>
<td class="num">$ (2,133)<span></span>
</td>
<td class="num">$ (2,086)<span></span>
</td>
<td class="num">$ (2,137)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564803835736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ResearchAndDevelopmentExpenseProductRelated', window );">Product related research and development</a></td>
<td class="nump">$ 440<span></span>
</td>
<td class="nump">$ 420<span></span>
</td>
<td class="nump">$ 434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ResearchAndDevelopmentExpenseQualityAssurance', window );">Quality assurance</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 465<span></span>
</td>
<td class="nump">$ 452<span></span>
</td>
<td class="nump">$ 471<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ResearchAndDevelopmentExpenseProductRelated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Product Related</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ResearchAndDevelopmentExpenseProductRelated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ResearchAndDevelopmentExpenseQualityAssurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Quality Assurance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ResearchAndDevelopmentExpenseQualityAssurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564889096536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE, NET - Schedule of Other Expense (Income), Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation and other matters</a></td>
<td class="nump">$ 356<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
<td class="nump">$ 1,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development costs</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Net gain on sales of assets</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_OtherIncomeExpenseNet', window );">Other, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">$ 502<span></span>
</td>
<td class="nump">$ 1,426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_OtherIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Income (Expense), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_OtherIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564881146296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE, NET - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfOtherIncomeAndExpensesLineItems', window );"><strong>Schedule Of Other Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation and other matters</a></td>
<td class="nump">$ 356<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
<td class="nump">$ 1,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Upfront payments, included in acquired in-process research and development costs</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Milestone achievement, included in net gain (loss) on other sales of assets</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bhc_MilestonePaymentRelatedToCertainProductMember', window );">Milestone Payment Related To Certain Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfOtherIncomeAndExpensesLineItems', window );"><strong>Schedule Of Other Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Milestone achievement, included in net gain (loss) on other sales of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ScheduleOfOtherIncomeAndExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Schedule Of Other Income And Expenses [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ScheduleOfOtherIncomeAndExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bhc_MilestonePaymentRelatedToCertainProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bhc_MilestonePaymentRelatedToCertainProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564803476216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Components of Benefit from Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Components of loss before benefit of income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (323)<span></span>
</td>
<td class="num">$ (410)<span></span>
</td>
<td class="num">$ (2,396)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(701)<span></span>
</td>
<td class="num">(524)<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before benefit from income taxes</a></td>
<td class="num">(1,024)<span></span>
</td>
<td class="num">(934)<span></span>
</td>
<td class="num">(1,837)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Domestic</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">74<span></span>
</td>
<td class="num">(216)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">51<span></span>
</td>
<td class="num">(224)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Domestic</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">590<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">599<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Provision for) benefit from income taxes</a></td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564888143560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Expected Canadian statutory rate</a></td>
<td class="nump">26.90%<span></span>
</td>
<td class="nump">26.90%<span></span>
</td>
<td class="nump">26.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before benefit from income taxes</a></td>
<td class="num">$ (1,024)<span></span>
</td>
<td class="num">$ (934)<span></span>
</td>
<td class="num">$ (1,837)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Benefit from income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations', window );">Expected benefit from income taxes at Canadian statutory rate</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Non-deductible amount of share-based compensation</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount', window );">Adjustments to tax attributes</a></td>
<td class="num">(59)<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance', window );">Change in valuation allowance related to foreign tax credits and NOLs</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance on Canadian deferred tax assets and tax rate changes</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">687<span></span>
</td>
<td class="num">(142)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxReconciliationUncertainTaxPositions', window );">Change in uncertain tax positions</a></td>
<td class="nump">112<span></span>
</td>
<td class="num">(163)<span></span>
</td>
<td class="num">(350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax rate differences</a></td>
<td class="num">(198)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses', window );">Non-deductible portion of Goodwill impairments</a></td>
<td class="num">(99)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit', window );">Tax benefit on intra-entity transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(338)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Provision for) benefit from income taxes</a></td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Adjustments To Tax Attributes, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to change in valuation allowance related to operating losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of the difference between total income tax expense (benefit) as reported in the income statement and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to deferred intercompany profit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncomeTaxReconciliationDeferredIntercompanyProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncomeTaxReconciliationUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to uncertain tax positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncomeTaxReconciliationUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564803869256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DeferredTaxAssetsTaxLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="nump">$ 2,973<span></span>
</td>
<td class="nump">$ 2,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Provisions</a></td>
<td class="nump">991<span></span>
</td>
<td class="nump">1,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment', window );">Research and development tax credits</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool', window );">Scientific Research and Experimental Development pool</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DeferredTaxAssetsPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">4,287<span></span>
</td>
<td class="nump">4,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(2,222)<span></span>
</td>
<td class="num">(2,252)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets net of valuation allowance</a></td>
<td class="nump">2,065<span></span>
</td>
<td class="nump">1,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes', window );">Plant, equipment and technology</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Outside basis differences</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains', window );">Unrealized FX on U.S. dollar debt and other financing cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 1,723<span></span>
</td>
<td class="nump">$ 1,609<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredTaxAssetsPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Prepaid Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredTaxAssetsPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the deferred tax assets on scientific research and experimental development pool, of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tax effect as of the balance sheet date of the amount of future tax deductions arising from unused research and development tax credit carryforwards; a tax credit carryforward is the amount by which tax credits available for utilization exceed statutory limitations for inclusion in historical filings, and which can only be utilized if sufficient tax-basis income is generated in future periods and providing tax laws continue to allow such utilization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredTaxAssetsTaxLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the deferred tax assets on tax loss carryforwards available to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredTaxAssetsTaxLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the deferred tax liability recognized for the original basis difference between the principal amount of the Convertible Notes and value allocated to the liability component, which resulted in a corresponding reduction to the valuation allowance recorded against deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on foreign currency transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564886796312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">$ 1,813<span></span>
</td>
<td class="nump">$ 2,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged to other accounts</a></td>
<td class="nump">5,428<span></span>
</td>
<td class="nump">5,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">1,863<span></span>
</td>
<td class="nump">1,813<span></span>
</td>
<td class="nump">$ 2,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">2,252<span></span>
</td>
<td class="nump">2,831<span></span>
</td>
<td class="nump">2,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes', window );">Charged to Benefit from income taxes</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(773)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged to other accounts</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">$ 2,222<span></span>
</td>
<td class="nump">$ 2,252<span></span>
</td>
<td class="nump">$ 2,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Benefit From Income Taxes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564885849400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details)<br> $ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 08, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>subsidiary</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($) </div>
<div>subsidiary</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance against deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties', window );">Unrecognized tax benefits including interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Portion of unrecognized tax benefits, if recognized, would affect the Company's effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions', window );">Unrecognized tax benefits, net increase for tax positions of current year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions', window );">Unrecognized tax benefits, net decrease for tax positions of prior years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions', window );">Unrecognized tax benefits, net increase for tax positions of prior years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties related to unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Net increase (decrease) recognized in interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns', window );">Number of subsidiaries file federal income tax returns in Canada, U.S., and other foreign jurisdictions (or more) | subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss', window );">Estimate of possible loss, income tax examination (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Possible decrease in unrecognized tax benefits realized in next twelve months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2013Member', window );">Tax Year 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss', window );">Estimate of possible loss, income tax examination (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=bhc_ForeignCountryStateAndLocalMember', window );">Canadian Federal and Provincial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Decrease in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccumulatedLossesAvailableForFederalPurposes', window );">Accumulated losses available for federal and provincial purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits', window );">Unclaimed investment tax credits and research and development credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance against deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=bhc_ForeignCountryStateAndLocalMember', window );">Canadian Federal and Provincial | Pooled Scientific Research and Experimental Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">United States - Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccumulatedLossesAvailableForFederalPurposes', window );">Accumulated losses available for federal and provincial purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits', window );">Unclaimed investment tax credits and research and development credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">United States - Federal | Revenue Commissioners, Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccumulatedLossesAvailableForFederalPurposes', window );">Accumulated losses available for federal and provincial purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Ireland | Revenue Commissioners, Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccumulatedLossesAvailableForFederalPurposes', window );">Accumulated losses available for federal and provincial purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Ireland | Australian Taxation Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss', window );">Estimate of possible loss, income tax examination (up to)</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Ireland | Tax Year 2012 | Canada Revenue Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss', window );">Estimate of possible loss, income tax examination (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Ireland | Tax Year 2005 through Tax Year 2009 | Canada Revenue Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear', window );">Reduction in NOLs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Ireland | Tax Year 2015 and Tax Year 2016 | Canada Revenue Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear', window );">Reduction in NOLs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccumulatedLossesAvailableForFederalPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the details pertaining to accumulated losses available for federal and provincial purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccumulatedLossesAvailableForFederalPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax, Number Of Subsidiaries File Federal Income Tax Returns</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unclaimed tax credits and research and development credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Net Decrease Resulting From Prior Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Net Increase Resulting from Current Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Net Increase Resulting From Prior Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated amount of loss resulting from an adverse tax position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount the liability recorded for the income tax examination increased or decreased in the current year/accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=bhc_ForeignCountryStateAndLocalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=bhc_ForeignCountryStateAndLocalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_RevenueCommissionersIrelandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_RevenueCommissionersIrelandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=bhc_TaxYear2005ThroughTaxYear2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=bhc_TaxYear2005ThroughTaxYear2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=bhc_TaxYear2015AndTaxYear2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=bhc_TaxYear2015AndTaxYear2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564804154152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">United States - Federal | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2015<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">United States - Federal | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_CA', window );">Canada | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_CA', window );">Canada | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_DE', window );">Germany | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_DE', window );">Germany | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_FR', window );">France | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_FR', window );">France | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_CN', window );">China | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_CN', window );">China | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_IE', window );">Ireland | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_IE', window );">Ireland | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_NL', window );">Netherlands | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_NL', window );">Netherlands | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_AustralianTaxationOfficeMember', window );">Australia | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_AustralianTaxationOfficeMember', window );">Australia | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_LuxembourgInlandRevenueMember', window );">Luxembourg | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_LuxembourgInlandRevenueMember', window );">Luxembourg | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_NL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_NL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_LuxembourgInlandRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_LuxembourgInlandRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564889139736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, beginning of year</a></td>
<td class="nump">$ 1,025<span></span>
</td>
<td class="nump">$ 1,002<span></span>
</td>
<td class="nump">$ 654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="num">(129)<span></span>
</td>
<td class="num">(209)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statute of limitations</a></td>
<td class="num">(169)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, end of year</a></td>
<td class="nump">$ 927<span></span>
</td>
<td class="nump">$ 1,025<span></span>
</td>
<td class="nump">$ 1,002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564886661944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Bausch Health Companies Inc.</a></td>
<td class="num">$ (948)<span></span>
</td>
<td class="num">$ (560)<span></span>
</td>
<td class="num">$ (1,788)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares (in shares)</a></td>
<td class="nump">358.9<span></span>
</td>
<td class="nump">355.0<span></span>
</td>
<td class="nump">352.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares (in shares)</a></td>
<td class="nump">358.9<span></span>
</td>
<td class="nump">355.0<span></span>
</td>
<td class="nump">352.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to Bausch Health Companies Inc. (in dollars per share)</a></td>
<td class="num">$ (2.64)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
<td class="num">$ (5.08)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share)</a></td>
<td class="num">$ (2.64)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
<td class="num">$ (5.08)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564884832440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE - Narrative (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Stock Compensation Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Excluded from computation of diluted earnings per share, effect anti-dilutive (in shares)</a></td>
<td class="nump">4,932<span></span>
</td>
<td class="nump">3,154<span></span>
</td>
<td class="nump">5,106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember', window );">Stock options, Time-based RSUs, Performance-based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Excluded from computation of diluted earnings per share, effect anti-dilutive (in shares)</a></td>
<td class="nump">3,428<span></span>
</td>
<td class="nump">9,551<span></span>
</td>
<td class="nump">2,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Excluded from computation of diluted earnings per share, effect anti-dilutive (in shares)</a></td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R128.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883620792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Other payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 1,419<span></span>
</td>
<td class="nump">$ 1,474<span></span>
</td>
<td class="nump">$ 1,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R129.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564797611368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Narrative (Details)<br> $ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 02, 2022</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>case</div>
</th>
<th class="th">
<div>Dec. 16, 2021 </div>
<div>case</div>
</th>
<th class="th">
<div>Jul. 26, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 20, 2021 </div>
<div>USD ($) </div>
<div>insured</div>
</th>
<th class="th"><div>Aug. 28, 2020</div></th>
<th class="th">
<div>Aug. 04, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th"><div>May 01, 2020</div></th>
<th class="th">
<div>Dec. 16, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 07, 2017 </div>
<div>insurance_policy_period</div>
</th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>case</div>
</th>
<th class="th">
<div>Sep. 16, 2016 </div>
<div>action</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>group </div>
<div>action </div>
<div>case</div>
</th>
<th class="th">
<div>Jul. 30, 2020 </div>
<div>case</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>case</div>
</th>
<th class="th">
<div>Dec. 15, 2021 </div>
<div>case</div>
</th>
<th class="th">
<div>Mar. 17, 2021 </div>
<div>numberOfBusiness</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 13, 2019 </div>
<div>shareholder</div>
</th>
<th class="th">
<div>Sep. 10, 2019 </div>
<div>shareholder</div>
</th>
<th class="th">
<div>Feb. 15, 2019 </div>
<div>entity</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_Legalsettlementsandrelatedfees', window );">Legal matters and related fees | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">Valeant US Securities Litigation | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors', window );">Number of groups of investors | group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Number of cases dismissed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending', window );">Number of groups of investors filing action, remain pending | group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">Valeant US Securities Litigation | New Jersey | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation, amount agreed to pay | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">Valeant US Securities Litigation | New Jersey | Settled Litigation | Restricted Cash and Other Settlement Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation, amount agreed to pay | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">Valeant US Securities Litigation | New Jersey | Unfavorable Regulatory Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Recent suits filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember', window );">Canadian Securities Litigation | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Recent suits filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember', window );">Canadian Securities Litigation | Canada | Violation of Canadian Provincial Securities Legislation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber', window );">Number of additional suits filed, but not served | action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction', window );">Number of entities, exercised opt-out right, pursuing action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember', window );">Canadian Securities Litigation | Canada | Violation of Canadian Provincial Securities Legislation | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation, amount agreed to pay | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_RICOClassActionsLitigationMember', window );">RICO Class Actions Litigation | New Jersey | Unfavorable Regulatory Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Recent suits filed | action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember', window );">Insurance Coverage Lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyNumberOfInsurancePolicyPeriods', window );">Number of distinct insurance policy periods | insurance_policy_period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember', window );">Insurance Coverage Lawsuit | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencySettlementAgreementsNumberOfInsurers', window );">Settlement agreements, number of insurers | insured</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Aggregate amount received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_SandozLitigationMember', window );">Sandoz Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalPeriod', window );">Stay of the approval period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PerrigoIsraelPharmaceuticalsLitigationMember', window );">Perrigo Israel Pharmaceuticals Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalPeriod', window );">Stay of the approval period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PadagisLitigationMember', window );">Padagis Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalPeriod', window );">Stay of the approval period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember', window );">MSN Laboratories Private Ltd. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalPeriod', window );">Stay of the approval period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember', window );">Slayback Pharma LLC And Slayback Pharma India LLP Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalPeriod', window );">Stay of the approval period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_LupinPharmaceuticalsIncLitigationMember', window );">Lupin Pharmaceuticals, Inc. Litigation | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalPeriod', window );">Stay of the approval period</a></td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowertoShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowertoShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | Canada | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowertoShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | British Columbia | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowertoShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | British Columbia | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Number of cases dismissed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowertoShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | Quebec | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember', window );">Shower To Shower Product Liability Litigation Alleging Caused Ovarian Cancer Mesothelioma Or Breast Cancer | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember', window );">Doctors Allergy Formula, LLC Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember', window );">Litigation with Former Salix CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Recent suits filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation | Plaintiffs, Direct Purchasers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Recent suits filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation, amount agreed to pay | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember', window );">Glumetza Antitrust Litigation, Non-Class Complaints</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Recent suits filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember', window );">Glumetza Antitrust Litigation, Non-Class Complaints | Plaintiffs, Direct Purchasers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Recent suits filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ApotexIncLitigationMember', window );">Apotex Inc. Litigation | Canada | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_DerivativeLawsuitsMember', window );">Derivative Lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits', window );">Number of alleged stockholders filed lawsuits | shareholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_Legalsettlementsandrelatedfees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Legal settlements and related fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_Legalsettlementsandrelatedfees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency New Claims Filed But Not Yet Served Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNewClaimsFiledButNotYetServedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Alleged Stockholders, Filed Lawsuits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNumberOfInsurancePolicyPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Insurance Policy Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNumberOfInsurancePolicyPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Plaintiffs, Number of Groups of Investors</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencySettlementAgreementsNumberOfInsurers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Settlement Agreements, Number Of Insurers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencySettlementAgreementsNumberOfInsurers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyStayOfApprovalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Stay Of Approval, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyStayOfApprovalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=bhc_ViolationofCanadianProvincialSecuritiesLegislationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=bhc_ViolationofCanadianProvincialSecuritiesLegislationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_RICOClassActionsLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_RICOClassActionsLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_SandozLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_SandozLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_PerrigoIsraelPharmaceuticalsLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_PerrigoIsraelPharmaceuticalsLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_PadagisLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_PadagisLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_LupinPharmaceuticalsIncLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_LupinPharmaceuticalsIncLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ShowertoShowerProductLiabilityLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ShowertoShowerProductLiabilityLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA-BC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA-BC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA-QC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA-QC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bhc_PlaintiffsDirectPurchasersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bhc_PlaintiffsDirectPurchasersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ApotexIncLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ApotexIncLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_DerivativeLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_DerivativeLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R130.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564886336888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfCommitmentsLineItems', window );"><strong>Other commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Capital expenditures</a></td>
<td class="nump">$ 76,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CollaborativeAgreementMilestonePaymentsAggregate', window );">Milestone payments in terms of collaboration and license agreements, aggregate</a></td>
<td class="nump">340,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member', window );">Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfCommitmentsLineItems', window );"><strong>Other commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CollaborativeAgreementMilestonePaymentsAggregate', window );">Milestone payments in terms of collaboration and license agreements, aggregate</a></td>
<td class="nump">70,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bhc_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfCommitmentsLineItems', window );"><strong>Other commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CollaborativeAgreementMilestonePaymentsAggregate', window );">Milestone payments in terms of collaboration and license agreements, aggregate</a></td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bhc_NovaliqGmbHMember', window );">Novaliq GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfCommitmentsLineItems', window );"><strong>Other commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CollaborativeAgreementMilestonePaymentsAggregate', window );">Milestone payments in terms of collaboration and license agreements, aggregate</a></td>
<td class="nump">48,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bhc_CedarsSinaiMedicalCenterMember', window );">Cedars-Sinai Medical Center</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfCommitmentsLineItems', window );"><strong>Other commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CollaborativeAgreementMilestonePaymentsAggregate', window );">Milestone payments in terms of collaboration and license agreements, aggregate</a></td>
<td class="nump">36,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bhc_EyenoviaIncMember', window );">Eyenovia, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfCommitmentsLineItems', window );"><strong>Other commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CollaborativeAgreementMilestonePaymentsAggregate', window );">Milestone payments in terms of collaboration and license agreements, aggregate</a></td>
<td class="nump">$ 35,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_CollaborativeAgreementMilestonePaymentsAggregate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amounts required to be paid by the reporting entity, which are contingent upon the achievement of specific development, regulatory or commercial milestones, in connection with the Collaboration Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_CollaborativeAgreementMilestonePaymentsAggregate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ScheduleOfCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ScheduleOfCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bhc_MitsubishiTanabePharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bhc_MitsubishiTanabePharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bhc_NovaliqGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bhc_NovaliqGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bhc_CedarsSinaiMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bhc_CedarsSinaiMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bhc_EyenoviaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bhc_EyenoviaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R131.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564883547512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>reporting_unit</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R132.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564807645672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Segment Revenues and Profit, Assets and Capital Expenditures, Depreciation &amp; Amortization of Intangible Assets &amp; Asset Impairments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>Mar. 08, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,434<span></span>
</td>
<td class="nump">$ 8,027<span></span>
</td>
<td class="nump">$ 8,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">676<span></span>
</td>
<td class="num">(203)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,375)<span></span>
</td>
<td class="num">(1,645)<span></span>
</td>
<td class="num">(1,897)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(469)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts', window );">Restructuring, integration, separation and IPO costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(373)<span></span>
</td>
<td class="num">(502)<span></span>
</td>
<td class="num">(1,426)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,426)<span></span>
</td>
<td class="num">(1,534)<span></span>
</td>
<td class="num">(1,612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">$ (38)<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before benefit from income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,024)<span></span>
</td>
<td class="num">(934)<span></span>
</td>
<td class="num">(1,837)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">302<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,765<span></span>
</td>
<td class="nump">3,415<span></span>
</td>
<td class="nump">3,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,074<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International Rx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">1,181<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">564<span></span>
</td>
<td class="nump">548<span></span>
</td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">865<span></span>
</td>
<td class="nump">979<span></span>
</td>
<td class="nump">1,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,434<span></span>
</td>
<td class="nump">8,027<span></span>
</td>
<td class="nump">8,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,743<span></span>
</td>
<td class="nump">3,578<span></span>
</td>
<td class="nump">3,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,765<span></span>
</td>
<td class="nump">3,415<span></span>
</td>
<td class="nump">3,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="nump">909<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,074<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,493<span></span>
</td>
<td class="nump">1,338<span></span>
</td>
<td class="nump">1,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | International Rx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">1,181<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="nump">386<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">564<span></span>
</td>
<td class="nump">548<span></span>
</td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">865<span></span>
</td>
<td class="nump">979<span></span>
</td>
<td class="nump">1,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">624<span></span>
</td>
<td class="nump">717<span></span>
</td>
<td class="nump">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(792)<span></span>
</td>
<td class="num">(619)<span></span>
</td>
<td class="num">(609)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the capital expenditures, depreciation and amortization by segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges And Initial Public Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestructuringChargesAndInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R133.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564885327448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Revenues by Product Category (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>product</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ConcentrationRiskNumberOfProducts', window );">Number of products represented of total revenue | product</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 8,434<span></span>
</td>
<td class="nump">$ 8,027<span></span>
</td>
<td class="nump">$ 8,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember', window );">Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,763<span></span>
</td>
<td class="nump">3,680<span></span>
</td>
<td class="nump">4,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_DeviceProductsMember', window );">Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,903<span></span>
</td>
<td class="nump">1,566<span></span>
</td>
<td class="nump">1,717<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember', window );">OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
<td class="nump">1,447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember', window );">Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,144<span></span>
</td>
<td class="nump">1,248<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_OtherRevenuesMember', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,765<span></span>
</td>
<td class="nump">3,415<span></span>
</td>
<td class="nump">3,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">514<span></span>
</td>
<td class="nump">506<span></span>
</td>
<td class="nump">623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,596<span></span>
</td>
<td class="nump">1,313<span></span>
</td>
<td class="nump">1,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,388<span></span>
</td>
<td class="nump">1,311<span></span>
</td>
<td class="nump">1,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,074<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,066<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International Rx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">1,181<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International Rx | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International Rx | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International Rx | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International Rx | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">737<span></span>
</td>
<td class="nump">775<span></span>
</td>
<td class="nump">730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International Rx | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">564<span></span>
</td>
<td class="nump">548<span></span>
</td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">865<span></span>
</td>
<td class="nump">979<span></span>
</td>
<td class="nump">1,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">683<span></span>
</td>
<td class="nump">745<span></span>
</td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember', window );">Revenues | Product Concentration Risk | Customer, Top Ten Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ConcentrationRiskNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number Of Products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ConcentrationRiskNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_DeviceProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_DeviceProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_OtherRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_OtherRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_CustomerTopTenProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_CustomerTopTenProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R134.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564807644424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Geographic Information, Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 8,434<span></span>
</td>
<td class="nump">$ 8,027<span></span>
</td>
<td class="nump">$ 8,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember', window );">U.S. and Puerto Rico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">4,887<span></span>
</td>
<td class="nump">4,791<span></span>
</td>
<td class="nump">5,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">490<span></span>
</td>
<td class="nump">341<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">343<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_PL', window );">Poland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">280<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MX', window );">Mexico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_RU', window );">Russia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_EG', window );">Egypt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_ES', window );">Spain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IT', window );">Italy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 986<span></span>
</td>
<td class="nump">$ 937<span></span>
</td>
<td class="nump">$ 995<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_PL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_PL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_RU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_RU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_EG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_EG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_ES">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_ES</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R135.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564885326776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 1,598<span></span>
</td>
<td class="nump">$ 1,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember', window );">U.S. and Puerto Rico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">743<span></span>
</td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IE', window );">Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">336<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_PL', window );">Poland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MX', window );">Mexico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_RS', window );">Serbia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IT', window );">Italy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_PL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_PL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_RS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_RS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R136.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564886917800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Major Customers (Details) - Customer concentration - Revenues<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Cardinal Health,&#160;Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_AmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_AmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_McKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_McKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_CardinalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_CardinalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R137.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140564804193080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Jan. 18, 2022</div></th>
<th class="th"><div>Dec. 18, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member', window );">9.00% Senior Unsecured Notes due December 2025 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member', window );">9.00% Senior Unsecured Notes due December 2025 | Senior Unsecured Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 9.00% Senior Unsecured Notes due December 2025 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet', window );">Debt covenant, redemption and discharge condition, amount, if circumstances met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | New Restated Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTotalLeverageRatio', window );">Total leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Revolving Credit Facility, New Restated Credit Agreement | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity', window );">Expected maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 975,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Term Loan B Facility, New Restated Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentExpectedFaceAmount', window );">Expected aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Senior Secured 6.125% Notes Due February 2027 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Senior Secured 6.125% Notes Due February 2027 | Senior Secured Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Senior Secured 6.125% Notes Due February 2027 | Senior Secured Notes | Debt Instrument, Redemption, Period Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Maximum percentage of principal amount that can be redeemed</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTotalLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Total Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTotalLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentExpectedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Expected Face Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentExpectedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Expected Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_NewRestatedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_NewRestatedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityNewRestatedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityNewRestatedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>bhc-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bhc="http://www.bauschhealth.com/20211231"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bhc-20211231.xsd" xlink:type="simple"/>
    <context id="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6bce9561cca44aed9496c119874299ef_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3c51f196215b47d6a61955c462c707de_I20220217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2022-02-17</instant>
        </period>
    </context>
    <context id="i973e30c58524481ca5eaa5ee3b0263f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1052f2e72864d03a985b250bef88f8c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i53abce993d5a44a596716ca7c9e737ce_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia5a8e9aebd5c4e6099f227c88232846a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9288144fc85e414e98cdb30f8362fd03_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i35b13f9f8b9048f2abd23eee83da3ef7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieb57e7f275e74745bbed5bcd771379f2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iceeb259687424b4486f58368d2356d18_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i82b9833a23f042c5a2adb676a8ec5e95_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iaa34fcb752d94e098590798c475a7b37_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i355151ac32e34c93a32ea5b6e6b9c800_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i451d020caed04e288168a2f8fd5d732f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2de4302e562642bb876564c477eeb8f6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0fc6ad19407843c2804930d9e14a236b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i88a9900560564bdca7dec25381689c13_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4684b0e1b31043f2a0e0a6337cab6576_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2118e2f41d1f4842a442e5647a35f40b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0c17e85c0371428e9ccf57c2288a1310_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if15b2ce8695749b5ac475e5adf790526_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i64a4e2f699614549a3fba3f9ac23a215_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id91ab3b642bc46a187257c824bdd77a3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i09a05e24b6824378a2ee002ec69b8c4b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0e89c666446a456f8cc98146608671d8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idb811b454ce14d32b8a17a56eab234cf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic0ab88b4629f472db1a3683caad4f40f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id8e7ca9b32a444089dfd2ee008ffa4c5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3fdde09098974b0f8d7c802d8cb72514_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9a01def95a9b4da68b1d7c83300f93c5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2ea97ac3ab7a4d41bb8383aabfb051e7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i87b994e0a55b42d3b3861f596a5aef18_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iff91afb1f5c540bea0a30d424217c405_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if282715453074bb49b8bc1e448ad1f27_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibb6b2b32236f4217a22e698f5e6a29c8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idaa3fc7070ff4e269eaf1141c23dfc90_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i93302786cb504c94b2b462b9a04d7347_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i580ae2bd45844451af6478654bd0361d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icaaee956f0c34101b241686ca5a47137_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i60f8b472d50d403d9e1baa887a2f2095_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibd238c564d9645d68c9bd1f4839b69dc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1c869e99e66c44e3807c32b56fd85737_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i23e7ea6c4d584b7881937aede46315ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i02aa4e2b4a9143c4931349f2b24d03c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e02837ee6ab43329d534e55ff0d3d08_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i332cb35e6b1c4b4499193a2507f556ec_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id69729faeee842779fac160c0f6b01cc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d610c2d7c5741318c7b47c1fa5ff7aa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8c4a367db2a74cd19dcf9139adee5405_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8729de31314e44b0be1473a123083daf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibd9c5a5d9c13483ca438c56e8327e766_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib970daaae589497d899cb7d978be2dce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i141129182749408e9635a2af36209722_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icfd2e58d530c456aa77e190e8c786ffa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie17ca1996294497e9f031629ce871dae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i030df36b6a574871b8a132326549d4ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ee9a6d8577c4318bf54609562d4c3e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d07942ff8e3491b92dc863012aacd40_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:ThreeLargestUSWholesalerCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7cee20a09d6f45c983e7a622d798eb96_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie46cfa6ebbfe4fe3bfce4e96130f07e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1d7e258ccc574f96965b59dea148df20_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i366ab3c0cc114fd3b2e77b4af953dd1f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaaa57eb8c0df42b19dda8cafee4e2828_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i34a41a0fa13145bf8230d44859521d48_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icacb4e180aa541848a91e2776ddcb14a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i88a58a70adfc405cb63f4ecc44509a55_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaddfdd394a12495d9cc12de4613f5d31_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c48db1ce8ed4151a1ecb07006cc1eb2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8b367dbe73ec48018042069891895784_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:EquipmentOnOperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie10da8de3b1d424385606609168cca9b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8e253d2e372545a9be9b1908cb43277f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i57f30ccd1de94a63935d2ef0dd575c37_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id146ea0827064b89a7577cc36b0679b2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i78e288346972478a97d9a959bb7d3568_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i728cea9c2c2a45178ba159057c1da77b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i931f3f4638c2440d8d4ffbb6ec962733_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i588f12f4c6524d6b8656970aae16788c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i37bcb7f77b3249cf8d55cb530b605590_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib131e2e5eaa54a10ae73c558ccbe6438_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i11fbfd9dfbeb4355bc882e75f9bee1db_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i50ee5aa72d3d409087f4f4c75b43387e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7f50340c36654f40b4735a136065dcab_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i29d6eccdc67e42d784ec0e124b81624f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if7c501561f5644f289468e4d1128d42e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia3cb4db468554971984b9ca7a67eb81a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2fec29ee013641edab8d6221c9266fd7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i675cd2d759a7429ca02cfef6330b3cc6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic9f22e24d99e4b1784cee096b11f5492_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8ada5c2b4ba44f6890befae0c5abc3fc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibfcf2240c9b14c88b49241f897539daa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib2b595cb367c4f14bb366722419c77af_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i833b35b656584bc39c2fb86f6978f755_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9b899431086f434796caec1c0bd402a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id26f10d6001d4bfd9222800e3b3bb4e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b52931c7ab643db9a3682345b1db8cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib91d99188bc541b7a824988141b34ae8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i700d81ebc7e14a5ea0134f3fcf286f38_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if7af96439d8641e2a7f6c2f01d4642bd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id05dcbb022714c45b985fa95dd3e8361_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6379354597f24e4290ab225072abe15b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i87951ceed7ea4e5aa8491f46d9db41d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1bac5a748c9c4daca0dcbeb78e404e12_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6aa0cd8be82c40ad85b35a58508fa64c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9942400776ce47beaad5aaea33213d31_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i74cfba0d37ba44869c896ccd738c2fea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib40c6b7597d6467d804e55df949889b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ff61d6d82a848d6becbe126cfc26963_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i09d8280f6d264587b97b2d17bcb992bd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib42d4166d63e4e788726dbd3033cb09c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9bd7a2707ecb487ab4050dffc0f16a47_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i973d974eec8c4651854590262490ae2f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia582e0f09c454720859f9795398a6f4f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic93289a0b5264300a6c1b192827b7231_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icfeb956295ef4b16a85e6e4149d35c24_D20190306-20190306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-06</startDate>
            <endDate>2019-03-06</endDate>
        </period>
    </context>
    <context id="i92ebac933dea48b489400e86f7f489fe_I20190306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-06</instant>
        </period>
    </context>
    <context id="i90f9c8b2069447318643874fdd998562_D20190306-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-06</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1875d6eb59814b65a56bf3c1ee9b5056_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1c4424c16be247649ea9c0793b64485d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">bhc:AllegroOphthalmicsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7f2a7103479740d6b997c87b639888ea_D20210623-20210623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-06-23</startDate>
            <endDate>2021-06-23</endDate>
        </period>
    </context>
    <context id="i8d780f8e498d4029a20e1dfba48ddaf8_D20210726-20210726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-26</startDate>
            <endDate>2021-07-26</endDate>
        </period>
    </context>
    <context id="i1232cd05f1bf44d2a67fedd36c0d6cd8_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2798f6e7b2e943c583b2aca3a95d9902_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8fd89ab94eae4b75848759e31a502deb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i814496642aa544b0bd6eb9e21c9c38ce_D20200101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id13cd655709045658273ebf2abdba2e4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:ACertainInternationalBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic96cba168a6f45b0b15835dcb29e9eef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4700fec630cc4d3393d58b8d2b00fd5d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i40cc87b109454b6cb74b6178982151c4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i02c2d8581fcc4e74af1f8728d7f5cb05_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idc7bec622b0e4d06914e435a52d614cc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i50d1eaed93cd4379b62a15c354a4c436_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8ef833b76dda454f9e12e7a602fedd25_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a1d3254b1a94b428ef1e3c8512a59fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1bc0f8f4b2124e1697e59545800c5d9e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e94131e350d4b8b90275b3532694a75_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32d030d4baca4c79874c13a25d51d367_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia7f4579ec74b4323bcd997517762bd3e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i226c603a08c64fa89f2932e3d795dd43_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id82b7c18fe4748eca290dd25b0edd254_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i07b2e0ad215d4a8e8263f35c5dfd3e26_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39aef971f8c64d94a2d8e897d769f1f3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic994d881fee945cf9668a1135e61ad23_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0345bec09794bf6818fdf23d88bb454_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5ffbb6654b542aa8ccc9d51f2e0cb73_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib5fa8ed492a8463a9ef8d402daa38f5e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i923bf4abdb6749c7b03cfcf01cb232fa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i744dc2c483db45c7b8cb3c1300c54643_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if290d3a1005a4badb0ac05c0dbe5aae2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifeb1d5a40c474d86b7665045cbbcdd54_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib35ef1ef18f04163ab0711c21275b0be_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i37dd8e5d148e4ce6a785c5011b46b450_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9aa901695e224cd3bda948346e4c12ed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7ac66312bf2147d1906b5192293868da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id1889026b5e64c829d9bc334d4f52cfe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8245159f69c94307993efff3243a1178_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i23aea785e01a442a92655b06b1baeaf3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8d8d666e2aca457593b6a68cc6c05534_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic8c7dd3d755f4d23a5c91bada3e42ee9_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="idc7d3c92717d45fea0d13f8cce709379_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bhc:CrossCurrencyFinalSettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i44e7b5604e7f428db4023a2105e3040b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icfe6b64df5694949b66283a944e675f3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id979f8795ef24a36b2de7dfd5788e85b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id9d09cae82ba48e1ab8a7444a671c37c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if40c526d7e7346638f324aeec169b157_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib13c9491b10f4203a909a98994925ea0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i51904574a9814c839ec1c948964e42ee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i37cde1419dbe4d6b8814f741d3d75967_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i255986411ba145c5be6963ac79d1cdef_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2b8d6be7a4a04904afbe947cf98fb1fa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i55601d2d01ba43d0ae61dc537370fe98_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i261fb00917f94a52acc0d59b2bdbe652_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifad488da9d8d42f2ae12cbbb6d990611_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic86fe7b9a9b24aec84a84ced04e41054_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8edf93d7795c4edf82cf448e9626bfff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8fef8a6744fa477c83018f4c7bea0626_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i83278b64958b40958e3243fd2a1b1ae6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icaca6d803b964e7891bb81c4ee12ccce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa75d1437f1d4f9b9a633c9849122864_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2b8a4232afdb4ff5978b9e0e691223aa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i64af0e0d3e4140b1b4407a0c784a6907_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18e557e1adb142668f07f005de10db3a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i570d56f066454c278557839640940613_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bhc:MeasurementInputWeightedAverageDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i669f1ac33f2845c287e6b1bad341253c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i24b574ccfce8480da6d68ccf2983c9d6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i779f7dfcb77d4f20b069195568b29fa4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3eab42b92e0d40ecb1ef0a51c9b67d8e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i71ee14ac1c1d46b7a0ce6c3c7e2a9b99_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8fab45399b784a6590e369a44a09cd98_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i43aa74e47e0a4098b9e1b70baf38319d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic72dfc3064da478e89d0708906a6270a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ddb15c7970742ed9da4a433d76c5f2a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id50f749937914da499d3aa0713e26497_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5d4c04c5a36a498e9735c3b7b90e02ae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8916b7890ddb4f65bd52ab52e5fca2d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b16b99c92d340acae71efc354b677d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53bc5bf59ece4ba7a3fb0dda2961cc78_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i49f627a32c304d4e97c853cbdc52fe1d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c417841d2d04bb0aa5f9721b865a03d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id6c6af997a5a40d3b472bba2069ff9c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic11c0834d02545e4a4a40fe884590f30_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8d9e8838b0b64725a2134d6c808fce63_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:OtherEquipmentAndLeaseholdImprovementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39a4f86638de4f1d85298fc8f9d9e688_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:OtherEquipmentAndLeaseholdImprovementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44211772dd52482e9e4ffe87d1d7ae4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:EquipmentOnOperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icbafbc956c894b57be4b8cb6144cea99_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:EquipmentOnOperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id6f977b18e2d47869607481b5bbc4690_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i164c1c9b47e74fc793e6991fa1597a81_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idf8fe351f9e049048e582a289f5ec940_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iae408a1b501d44bfb0d015a59f05ba39_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d7f9da12914489bab1b7bb4cbb4fc83_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idbf9196b61c6417e95bd898b4020850c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8c9a0557ca2f40e8a6681b9854a4d544_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06187f7ce19446a690591cd1b95c7f26_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea4f798327a64255b8fcebf77a9bfd28_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i29ccbe7385f64c2a8f950c5898bc20dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iafcb6c30e16d4d609946e1e977a992a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i875f56312a3e4f3aa4e713ccaddb57d8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3bd0280d56644e9aa17e3ed84baa5cb9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ide8dc03ca5d34e2d82fe875ae8349bfe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib10da3a8baaa43f2882bbc75cea97f73_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic9afc2f89d1f4c1dbec3435239ca1668_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5fee0ea71e1945109e92e284dc86e65a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ff94dcd862b417485b1c86cab1f0d19_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bhc:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1044279e431a465c8d792ff8c4424f95_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bhc:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i068c904248854bbc871b95c7bda13c2a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i482a42699464403190bb5666f649d099_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6052d5b84a4f4e3dbbd55e3b7b3472af_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i65d12a1576654877b8d12fa8e43fad62_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:UnutilizedITInfrastructureImprovementProjectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iee78254e5ef24867b4e79676061b9da5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:ACertainInternationalBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic98bb92d4f6c4075b3ea9d057f2dc09e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7814719b55964c3a90f30a661c040f5e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iae9620bf07594c2d8b0ae4bda9e46476_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bhc:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4275122509984c548f84f8d98d4710c4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7f2bdcc8cabc4a8fbc2220baf550e504_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i77368b09b2fe4c1dbf5d0160459ef7d5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3f938f0f5c7b48b98d4abfb36c343bf5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bhc:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4962dcdee267427ca7c640643c4b63e0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic87f144240594803b338f3329694b5af_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6485ff11a7784c7d93cdebb81e571cf7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if13a6652f6f14e9380c0faa89ab7253a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ieefeebe8556a419b982e4603dccbde45_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if02d06f22a6049fab2752d7559d9139c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i25b498657cd04064a8d22a18cb88515c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icf8602fc27b744ae97df02360802bb93_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia16b95bd57544fe1b90bd153182259d7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id15e4ba8f40445ec845f103e0aaa553e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i373d7f78aa2349ccaafcb0b37e13b0e1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8e7c6b2d77a446c1b4aed9a04f7dbd2e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaf22e67019f9453383f473a7440bb889_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4e0d98e274204d53b918164aca0779ae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib76ac81df5fa49b68ba3b7819c1fc06a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib7300f7b54644f8a9660b750f9e847b8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i85a97ee039044646b0f12d8dfddbf0fb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6dd56e661cc441b88ce62c077cb8c9c5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id9cf2e58ead94c7e812f2a73e8e5a8b0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i03a8ce11b6a94d508439a84f941e6341_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5ab307cfbe9b4a94b2c883cfc5dd5f07_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a665fac8c5447d6b59c47157917616d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieba4bed7b87c4d64adde44c696279cea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08856af02cf84095b7eda2ff890eaa65_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id7042f2109b44a618b5adc51134f2f32_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16b907a0a74e489584cd63b7298ac261_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9e15ed3860174023ad86fcfb1fc3d7a7_D20191001-20191001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-01</endDate>
        </period>
    </context>
    <context id="i6b80b732bf87464abb356edb40e75c0f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie754db10161f4f43a00a7ccbbb4d5499_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i49498b6d16f54144b0e062468813a553_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iae72504d531644ac8838bbb4ec27c1c1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:ReportingUnitsExcludingOrthoDermatologicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i10b37ca262cc4204a355bbd20f6cd963_D20200630-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iac97f26599824297bb76711a52beec7e_D20200331-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-31</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib7fea7ac010346df9ddbd729f74109a4_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i5c4efa01e28a4063ba07a08f0dec29a3_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="id4d44a38635a40b4a32e60755373e624_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i774ca80b37c14809aaf69d1ec60caea2_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="ie3ad16bb04674a37884451df0bcbfb99_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib2e256a9bac640f8ab017d4f047fb1c9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibd4407332fee40f39e8808930a147100_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iae738547736443dc961d0df42b4d932b_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iade956227f64477f8bd834744fb0b81c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i33a4b28c4d244a908251259f68df10a2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3befa2e27fb94dadb4d2e0b6671d1ea7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ief2363e2b42349f1be653bf6588660db_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i68ccc3aae7a44c81bc2bc15d199cf675_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i39f7dc3af718428fa8639267d86d4723_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idc7bc8f12bdf4bd5b49783904d555941_D20210630-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-06-30</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifae82a26687143d58a5a4cf6c438ebca_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i21a45eb6762341e485fcf7416428f6ba_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i0c01a665a28449b793613ecc5d63522c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9adef68a2e1a41ffb17a60a9075ee559_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i19aa307929434141855192ccd5d26e84_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c06253724c04adb9d709a0d06b0a4a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i57ba8084e93643d19f4f8c135c1beb71_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib9193acd40b7439299521c6fde8c4891_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89af4e1890874416ab318090b1cc294e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes7.00PercentDueMarch2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32e198fb8ac3442ab187a17a7c4f0d2d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes7.00PercentDueMarch2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ec36cf30e35457e8a0b60837b539b1e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia8b2f62d73a04aadb052f3835a632303_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66914061a58846f0a2dd9fbf966be49e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b9f7d6a773a492daebe7cb683a831c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic459c1e2b8f44d65a0d2e10bfae297d5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92b27a9dcb1e4c6aac20e9f0f1bb22ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i67d99cc27cfc490babc9f17b67fc6c36_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9abe59cd5b4344b3af6d863639ee97e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7069779fddc24154bec1252491718d71_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia90e19da742b46a88993ff20c0ef65e4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2bbcb30923264dada2fd327d3b9f97f3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b9d6159d9b345d5a925bedf7aa2f714_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie0e3e0b5c7314f4d8c7bad143746ae92_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13a7ac2ee83a40f487e5ff99f59101b6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac672bf940144940ab2863657d675904_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie691743843174dfebc02e17db2f8b881_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia9fccfd4eb6c4a3da530db148be437ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a7c2483467d42fa92a0d1889a65352c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i637b51dfd22b4d7d8bf9dc99c065d131_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4c6b5763866f4cdbb14e92752f777770_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4273b9d256e540e985599fd8f4111808_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3d04379800474729927c296a02ee23b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id5f8a823e64b4391b5fdc14a2699ca01_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1550fce70ddc4bde9fcc143dba86ed02_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i87f54fc33f3647cf854ad3d2446add0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd94b3061443470786f4f2aeefe3ee61_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i50ec0b78d915487982eb08953a99cf34_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i300264ba1d81487683635e7eef8d2c8b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i350590e126f747c09b3b536b35e19ffd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08ba959daa4a48e2ac776ce9798a9d5e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8aed4915fc8f42e580d71e20a671d348_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5120118135441ab83944681d2efd4b0_I20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-01</instant>
        </period>
    </context>
    <context id="i351b85b10d1a4bc4994a95b06fcbbc15_D20180601-20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-01</endDate>
        </period>
    </context>
    <context id="i41ba8fedd17c41849f4e82c6bf1880b3_I20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-01</instant>
        </period>
    </context>
    <context id="i4661b2464e2e42d289cd362548d23d4e_D20180601-20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-01</endDate>
        </period>
    </context>
    <context id="iedebe3ccdce14516b687ab3595dfe1e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5f0234485054f26ad2c1d49dfdbd799_D20181127-20181127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-27</startDate>
            <endDate>2018-11-27</endDate>
        </period>
    </context>
    <context id="ic4e41ed007de4e4ea8f42478579b6eaf_I20181127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-27</instant>
        </period>
    </context>
    <context id="i27285ba6e43a47799cc65795b7635e66_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i531d4b49e7e14178b135b8a39f88fa6a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i31222c8f48ac4a7b9ebdc2458dd1be5d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8cd6d35fff84440898e7edf6f94360c3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ied9e5eb3fe5b46218dadb86953b97df0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadaBankersAcceptanceRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia22718f8832b4e798f11e810438b3bf7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadaBankersAcceptanceRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idb84972c8f344a8896506efbff337098_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredTermCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4515f9481f5f408cbe7a9817cf5107d1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateOrPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i580615bf5fb84813a4f15d5b64260502_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateOrPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if0cd16b6c95c43cf92a6b19bd75a7df2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6eab960e05594954ad74b51fbec5de70_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if7b27ce3a4694376b7351cac69da0831_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ica0eb942508643f38c6a8b5216c7ab26_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateOrPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1d0ab3127bf249bba7383ddaff5d96b9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateOrPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i10e9d909bf8748b1ada82e2b29c7e29c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id9bf72ff91f54b6d9dfd299f64fd8858_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6bc0bc23890449aa8239cc453f4e1a07_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i844942ee3772417395b5e3b2b42455d8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i28ac575b36634a86920565ce2fe16cca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7622a05b204a4dd1a5f310c32b83aa3f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i55fc1cd86d124ba798ea0bb114b41e21_I20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes6.50PercentDueMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="i3ff0004e74da4838ab43904393cdd3f0_I20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes7.00PercentDueMarch2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="i3bd6872a182646a082629d18870e0ab0_I20171017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-17</instant>
        </period>
    </context>
    <context id="i25ef1a1efaa044929df3a9c4e1c62bb0_I20171121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-21</instant>
        </period>
    </context>
    <context id="i9806922f86c748b8a9fb0ae15b0d631c_I20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-08</instant>
        </period>
    </context>
    <context id="if30a44e3344f420686b02ee5a1668f41_I20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A8.50SeniorNotesDueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-08</instant>
        </period>
    </context>
    <context id="i199861b87bfe4696b2d3547b9feff668_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5875SeniorNotesDueMay2023March2019RefinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5e281e9d7a3444ae947ed7b6a12ff125_I20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.875SeniorNotesdueMay2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-08</instant>
        </period>
    </context>
    <context id="i9399287ac5904b0093d941914ffe1526_D20190308-20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5.625PercentDueDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-08</startDate>
            <endDate>2019-03-08</endDate>
        </period>
    </context>
    <context id="i9e41c5aa1f5f46339004eb9f8abdc897_I20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5.625PercentDueDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-08</instant>
        </period>
    </context>
    <context id="ib64fedb96e0a40dbbba005b5e30bc256_D20190308-20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-08</startDate>
            <endDate>2019-03-08</endDate>
        </period>
    </context>
    <context id="ie38650ed8f69484ba8e3e32b255cc9c1_I20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-08</instant>
        </period>
    </context>
    <context id="i7f2634d868b948cd81c47592e26fbaa1_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5.625PercentDueDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="ie8e89da68c2b4a889e5ce5e76dec2863_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotesAndSeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="ia70cbc9c5ef04337a9cdfcf70d213bff_D20190308-20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2019-03-08</startDate>
            <endDate>2019-03-08</endDate>
        </period>
    </context>
    <context id="i0b58a4c00eb84382ad3f4bc0cb5d0c33_D20190308-20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-08</startDate>
            <endDate>2019-03-08</endDate>
        </period>
    </context>
    <context id="i47b737fa198b4128bcd55e26d3e2cb52_I20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-08</instant>
        </period>
    </context>
    <context id="i48a5c09856bb4c338e922161515b31c7_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueMarch2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="iae6d3126236d454cb028cdcb1675739e_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="i3e453510571a42ea972e7213bb0683b3_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="i36ee75c249b846dea1eab8be020170d9_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="i731ff10dfcf54abe98b1740cfb194c1d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i635a4ec4469e4a38ab9bf05cdecd65b3_I20150130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-01-30</instant>
        </period>
    </context>
    <context id="i884c88ec40c64e79b29c807b2a885dc6_D20190523-20190523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-23</startDate>
            <endDate>2019-05-23</endDate>
        </period>
    </context>
    <context id="i1dac4ecf6d0f4130aa4a1059a0869ace_D20200101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="ia5885c91251745a8bd996100382f6c32_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib5b7e60d19034d39a78a89ace8a9bdaa_I20150327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.375SeniorNotesdueMarch2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-27</instant>
        </period>
    </context>
    <context id="i8d8eae7cb22c4834939fd13d8bfa0402_I20150327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.875SeniorNotesdueMay2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-27</instant>
        </period>
    </context>
    <context id="i2bec3b624035487c90ff26d75d14b4f5_I20150327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes4.502023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-27</instant>
        </period>
    </context>
    <context id="i5f952abf74d84815948a25d97a9b0e2a_I20150327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A6.125SeniorNotesdueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-27</instant>
        </period>
    </context>
    <context id="icb448caef5334750891c172cec2300d0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5875SeniorNotesDueMay2023May2019RefinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id030b84634ff4592b2dd49390438a1b9_D20191003-20191003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorUnsecuredNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-03</startDate>
            <endDate>2019-10-03</endDate>
        </period>
    </context>
    <context id="i1d5f38a92282494f9530b0fb16484f40_I20200116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorUnsecuredNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-16</instant>
        </period>
    </context>
    <context id="ifc35a805bb9d489a81ba954da2c90dfc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorUnsecuredNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8ca7f7ff80664661a5cc30c2112c5f4f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iba498b34c6e5496e98017b43ea83814f_I20171218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-18</instant>
        </period>
    </context>
    <context id="id56bb838f8ca4688a209a9aa5630486b_I20171218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.375SeniorNotesdueMarch2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-18</instant>
        </period>
    </context>
    <context id="i63149bfde2e74932af587b7f07bec783_D20171218-20171218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-18</startDate>
            <endDate>2017-12-18</endDate>
        </period>
    </context>
    <context id="ic7612d5c6f03401fb096eeb9f8731268_D20171218-20171218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-18</startDate>
            <endDate>2017-12-18</endDate>
        </period>
    </context>
    <context id="i6e6f4753796c4f9da3ea1142cd2e1c91_I20180326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.25SeniorNotesDueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-26</instant>
        </period>
    </context>
    <context id="i07bdfabc3951404f8889a947cf3a9686_D20180326-20180326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.25SeniorNotesDueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-26</startDate>
            <endDate>2018-03-26</endDate>
        </period>
    </context>
    <context id="i20076209e8fa4b958baa1b8f32663a95_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A8.50SeniorNotesDueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ieb0e075a0cbd419d8ad9a06043a3352f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A8.50SeniorNotesDueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i28aa526ea8d84f278ee8f1842400571b_I20190523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.00SeniorUnsecuredNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-23</instant>
        </period>
    </context>
    <context id="i39a070cf27ac4d539b94e8656d4502e5_I20190523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.25SeniorUnsecuredNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-23</instant>
        </period>
    </context>
    <context id="i05517ba451014901a9d88eb38f3ac23a_D20190523-20190523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-23</startDate>
            <endDate>2019-05-23</endDate>
        </period>
    </context>
    <context id="iab2a35a3c29f407dad845189bdbe128c_D20190523-20190523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.25SeniorUnsecuredNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-23</startDate>
            <endDate>2019-05-23</endDate>
        </period>
    </context>
    <context id="i1273409244264cbbb7681d6753625c7b_D20190523-20190523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.00SeniorUnsecuredNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-23</startDate>
            <endDate>2019-05-23</endDate>
        </period>
    </context>
    <context id="ibb700fb0599c4cfdbab4a269de54e805_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.00SeniorNotesDueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="ie55bd69a58f9418183a1bb030920e901_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.25SeniorNotesDueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="i43c10acd1411494298a8bbca9c5aad00_D20200116-20200116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.875SeniorNotesdueMay2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-16</startDate>
            <endDate>2020-01-16</endDate>
        </period>
    </context>
    <context id="i06c668190ea847209a8da86cf1e73998_D20191216-20191216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-16</startDate>
            <endDate>2019-12-16</endDate>
        </period>
    </context>
    <context id="i71f877b49bc44738a6ceab709138f307_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.25SeniorNotesDueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="i5389f9afcc9c4deca0f0d09e9a716c2b_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.00SeniorNotesDueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="idec8329a9c5d487e88dbc1f38144d98a_I20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-26</instant>
        </period>
    </context>
    <context id="ia601b6230ea24da1ae27d263526923d9_I20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes6.50PercentDueMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-26</instant>
        </period>
    </context>
    <context id="iee380ad8627b4f83b469b1ba89c9747b_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025AndNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="id5925ca8a2c54e8d8795ffb55d368483_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="ifea6355ea76743f0a61e88e55dcd2ce2_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="i5839a9c4cc754fa0803795d95447729c_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-03</instant>
        </period>
    </context>
    <context id="i88e6526a8d134ebab814430fdfa18227_I20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-03</instant>
        </period>
    </context>
    <context id="i9a97ad4188494b8781417a8f8d543882_I20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes4.502023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-03</instant>
        </period>
    </context>
    <context id="i5964597f62e744bf9d6aafb14762d4d7_I20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-03</instant>
        </period>
    </context>
    <context id="i5501242b42bc40d7a227556ee3415134_D20201203-20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-03</startDate>
            <endDate>2020-12-03</endDate>
        </period>
    </context>
    <context id="i73e09d09766b4417aacfcfa14a10126c_D20201203-20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-03</startDate>
            <endDate>2020-12-03</endDate>
        </period>
    </context>
    <context id="ie10a5bc9208e4517ad73103ab3f6d59b_D20201203-20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-03</startDate>
            <endDate>2020-12-03</endDate>
        </period>
    </context>
    <context id="i8f1fd27861d840c9982cb6007d12ec99_D20220211-20220211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-11</startDate>
            <endDate>2022-02-11</endDate>
        </period>
    </context>
    <context id="if80737f8327f4413b9aff0d3dbfe8369_I20220118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <context id="i9af4b96ef19949f2928ad128d4c72201_I20220210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-10</instant>
        </period>
    </context>
    <context id="i021f572cbdf44c37b86b96f04672a793_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredTermCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7563625586364005812392f5b14e44af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ec20e3f4b2f4f599834f9809e4c9d92_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id71cc4b7c6a54ab0a60acdf0c8a5303c_D20141201-20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i866959039d2f4c258b6f412bfdedd0a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieafeae30c1bb4e9697860aa43e144e89_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id639a041f43545ba9cbf52ed62530656_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id677830949bf4a7dae2bc84e6d0e68d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iddeca17018524ca7b4aa0120b6e125e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie7e41e73d53c444f810e26a21d37fd21_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9a242b0365824d3494f144468024f7d3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9bd0b15dbe944220bf785415eda57379_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iebc6bf90ba6048c081b87a24157c36a0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibee8e4ebafb4425eb4bfad3cad142065_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic5c96e30d644464397808c237e9a5ddf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i248cf8d382ab417d8f08aa7bb5b3c1ed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c408d4a08264cae9f329fddd9849fcb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie2d3dc1e9fc14ff2a726b48981e5c5f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie074f53bc69745fba66921f6f8d38556_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i56153b69689b4ecd9dcf4887ed60d362_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4a02dcf2c684493ca47da42ad5f0a86a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib55cc79a8c5047d8ab1633dbce4cad44_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia693d6a4e0b14b4c931965ccf754e1f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2d7991a8fa0d4d8795903d4ae61c5a6d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d7c434502ca4f2a8223f3e89683dd28_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b1fe039d84a45ce8e43d1c4c89b07d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id453d2c511534fe6837d77baaee83805_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6251e5f5fad7409b9187da5b1b34bf8f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a81a3caa7c94785bd723c5136f85945_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic2aa787db2bd488381cd79f25f35617b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaade5d5b17e942f2976fa0e0eaced2a3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2cfeb6a24e7c459aa69b339c9936b980_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if07c85a851d7490689bc9a5740104746_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60ef3defb63b42d8b564f10aef937998_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ff1e276f1334094b7e8280d216bb2a6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7af55aa092e044f2afb3019b380424df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1d47b1547ba49eaaf8b343286177935_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4c916f8745844151b90043b27bfda10b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iccba448cf4a7430c9ab615c9c0db387c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i09e4c0369ab74b7aa42c2ca4a081d665_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icfe5828d7ce648ba9901225e5f602ffb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac45d6fc735f4300950257942f7987c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e6efe3bfe1b43539fd5441f3e8f1178_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie17c1b0a784541d7991bb6af8b757d2b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic37dcc11c7224eca84dc480d56dc32ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i38d00d230e384e1793aa975171d11afd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d2c3cb6c7374e28bf785a1101c1a131_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc9f1c3ceea44453b7dfa2a13ac987b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ied1ceb27c69740139dfd77de2155225e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i38e21dc226144b94ac36444dcece2004_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e447011ef7645a89efe64052f877da1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7fbe7d9aaa8d48bcbb80294df7a9cd60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i82a224828a4841bd8e05d44a229d645f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i557a5608d76644fca3792b79c6260a38_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if2f6f0decf1a440db6a8df7e4d1cd9c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie614ee2bbc0d41c3937648c0eb4fb366_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a50fd29ab6c4a72809e44c2f372bdd8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib98051f977524d43b7bba256f7160a84_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icf30f7d75c6344fc9a13de058b489364_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7365a02480094a778087f003e4453b09_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11eb673cbf1d4f7d84ac5c9df99a3ef2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia9a9521608704153b9eb100ac78f0ce3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i809b25b2066b40bf96408dc9e0b225c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1d36468c5de494abc6015ee26da8e73_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1dcfebc863894026b3ca1af655064a00_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i560db68718d54136a8a45bfb702d5324_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i61e987a4f1b54c88bcbcc12fa7abfb69_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i16ed7839b2a04f0fbeb5dce55d268189_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i91dfeedfb92b4828a4722c9f88fa1872_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1825b75f97004bc184282968848c0a52_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6242900f15f3401ebaac9f8a3c1b6339_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i63b875eacbc446a887982c5d1115d3ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie9a62d35ed944986ad939c9b014c654d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i92434c9334a54511bdec1d46d8213f3b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibcc360791b434eac863d82daef575b6d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ba6ac8d86f64c9385ab1aa7f0d2c220_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0c5d97b9ab244b69b17a46f19cca258_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8b0dc0501c84cac862c7828cee33fd6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i42c6f916e85b4a7cb01549ad02518fd8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0c12e56dc0f345abb7ab14eb2eb546b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id35cd34eedeb4695bfa8ad28f7c073d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4b90dc62606b4697b1fff595e063dce5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c488d1b1a9b41baa5ddb7387a75b0ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida118aeda14146be9fa07183a8d43611_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie7404c4a64514d8cba0117dde2032747_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8bab925ad83349bfae08cdc351f392a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if2ccc52c4ecc49e78eee3d33e2c113fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie92a115bae124a91960ec41c0727d1a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iba3925adeb07427b9b35df22f7082c71_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6623925ca56e4d96a7ec9b93e614a8f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib69b353fbcad4f2ea129c8b8af2024fd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3dc8df13fb424c888d592fddbc492642_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c7b88b7a1da425584d296d8cfb61e31_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85953604b0f4454d8293d1577ad37660_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75e6fc7cd989419aaac17aab91d819e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if060c809f3ab42b79bb79a9e9119eb6c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b463b0ee361495cb1a35797490d8474_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idc5b5fd1952143dbb4fc80c09e61d41e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ff8ba240c174921af7e5377f66435da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i28879983df974e8dad3a100a9e2eaff5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia617fb33524a429f96a5f4d5de41e8d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iafe1692fe13c46099cdb274aae8efa5b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58b06c811115478cb20db99973ade215_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieb2a552032894fa0a8dd1d7b70fbf7cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ec30830375949738e95af67de6bf189_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0acdb587dc57405c8f51594ffdc58f35_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79b1763781234b4c91e295caf0806e96_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i33703c137cd44896ad4cdeb30fcc6fae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff30b4961b3a486991e363c44db17d42_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i669279a7238d4e8f9dd6fad058ea31b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i481468708dc74adc94731e7319c5a223_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84843ec87bf8430fbff7bd811a71310a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idca3abdd017446218f6e8960ca67c023_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6eb575ca4904425a87bec5e53f208d9d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib8fb3dc081ea41aab4e32f39084453f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41e1bb53e0784950afc27fa187a27c3f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc5e2d60ba7148dcba54ff5384e23249_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7bef888f50664043863fbf4ec22eb918_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d117480a68f41e29692f8e1120299c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i764e7dd8c6e242209ab1812391a46ead_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i03b4ac56aab644b3a3663f4a78369a13_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i612036dfd9af4751b039c09d33e2ca46_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9647f9aaa0af4927aa97fab7f6dce46d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifc934bb3b7764915937b42332edc108a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie670eb0132ba453db0ccfc9534e8a176_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i846b3df052964b86bab155c36ffa8b7d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08181df0b76a4b1db12c4d01da570d5e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd4a088a9d1a4225a9b940802b6651dd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1dd5dc3a71fc44a288385275d334a636_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i773f8c6eb5314348bd0df5d5f8554717_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i06f89c2da51442cf966a159f442d7040_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5a942b6a477e44ee80469bf00455c69b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie62be2fe885843928cc89e9a7ae8bb78_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5d72936706da4a49a0b60284da13fe0a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib2b78164753e4fb69cb995913ce9a5be_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i824c5e86c03e4a0389aa5c6cab684353_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i019d538cf2df4702927d2feaebb08210_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i42f1505ab33d4d31b29170cf387d3bf1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0f2d6658f8c6432eb855fc35c09bc8ae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6fb966e248dd4e7db899e8be25bcb6ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e6548e2528e46dca40d1b1d09e39d12_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3190fba7ebb5479dbb06445d6267911d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib72d3400eb8c419bb79a2b659524d6d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8afa60e604994497a1986db946c1937d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ff0e3d8fc3e4f288ffcf7c081bebc05_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifbb8aacab7664f5b8279284fc6149b67_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3103a0933124d62871e5fc29bf546fa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9e058ef986de49f0bea67e87231e73b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if09958cb78f94a76a7e6f17b2bab67df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d964dd1784d4ad8bd4443d448886eef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb4dc2559a83406c8a242c061666e6c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc69c8ac45694ba2b20fb0ff3a7f39f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe61ce2f0b3946ca8976584ee83df12b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i299b97ed33754f6b8c3da5c29c47a1f6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd5a69340ce945b7a60bf0ed0babc543_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie44d119215b549a88ce037813b5be0de_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4ca155d300cf42a4b9cfdefca02c609b_I20140531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-05-31</instant>
        </period>
    </context>
    <context id="i4442a258b8f44219a1cd0070ea1406e8_D20180430-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-30</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ibc1c3154bf0046c1b2667e6a53320931_D20180430-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonemployeeDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-30</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="id025575230534acb993dae92e7192d0c_D20200428-20200428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-28</startDate>
            <endDate>2020-04-28</endDate>
        </period>
    </context>
    <context id="i8265f2e72c9e451eb2bd2c997c00db7f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i086597ed1e26464a806168f0ce38c359_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i846d952abe194e548203133638491e9c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2088dbf192f84b6e9cff9dc2cde381cf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie724079581044aa0811350b601ee9cc2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2910d81cb0f045f7a33086454100489d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i79264328a7a543f1ac564306154bf1e7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7a5a66d1f91043f8bc5742bb410551cc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i936812f8c65d495cb6b6f31769ebb66b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i59d93d4490ae467d9a2415b38252c35b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icc9346bc756a4ce3b7a716c303df449a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87e1a3e05cd844d9a82820b7441ea2f3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9eda91734bd9488387a03d3c1a80263c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9fa761390575444b8d5cf87f856db73c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i67ab1d6d98e348a2849edb9d66a71b5b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iefcbe00a2f7e4f35ae1167fd771c00c1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id9615eb6151e4a2da212f24458fc78e6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibfe3a038368845f1a17357b6780d71ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i12c733996b5f40c9abb282bf8d5d421b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic7042672dea544848ba094e3f7c68fe6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i911683c7210b422894ad8e3b68edeb77_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0393ab35e9cc4519bbfe3fe5df85b76b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1fe34facb9874ca79ea97f41a97eb1c8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3e1cd89faa1647e69cd98100bc41a853_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib899b174c8a5478689ab47ec6929522f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic56b5e163c6d4ad88d725a35418555aa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i903f03ca7b0d4bec8b5dae3db9f4c7a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iede5ac25cc2c49c797a46beb7f132efd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36e8b2657c164c33a91c59ad739b895e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i272f0cc98d024849a92bb2d337033d5d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ROTCPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i789a736034674ddab3556f1ab2711032_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:OtherPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia9158150c4cf4379b5bba7c7cb9d7e9a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if0b1241118154de6b3af123e431df6a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibbb6b356a1fd41fc9c4da52a60b5ad6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8021c14b857946c188b6f072829b7db7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i22332303e4634782bd879afa7c52f3f7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bhc:MilestonePaymentRelatedToCertainProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9f60772beddd4bd8b351b7519c847285_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i966b3882b2f8446a92d3b73108d3691d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i33e256fd4d08472686f2bc331857bc8a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic44ed602f863418a8831ced61d13e546_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie270c7e752794cadbce8d6ea63bace3b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic6ce4645221b4e709b3988651ee21064_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic906a904b8264052aa297c4da0661e84_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9019e1c2cf6d46838fe8c8d77147207a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0c84dca0789f4214840ddb5f4f8537bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i983ff7f7025446d58e2f36c202de3dca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idee0cbb24fc340c1a64cf7d7df3edec6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idc644797e11f42fb9e29854f00a8af84_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bhc:PooledScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5e04a5a10344bad915b3777b2ade249_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bhc:PooledScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12f28aade059421c87f68fa766a6137c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iccec7fb29c284c1282bcfd6426b81d26_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida6fd5a3e163430689987e5420387788_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:RevenueCommissionersIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iceef040ee04e4d18be72112cc3158c59_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:RevenueCommissionersIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i23bf918ee3914485aeddbbc1554c30ea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5f649769ddcb4300a790315728ab809b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4c7cd7b9da83461fa9bd41fd621feefc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic9ec02f6590e441bbef7d90718b83872_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib9654dc8595e40e7b7fb7f68cfe474d9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id511e68e76754c458cbf0c440955486c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie55c0ff42c4544718880dceec02e3876_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id991a25ce8c1481ca65b4088fe2e5c6e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i87eff35348ef4c22b0f0c14d5d1ff9a7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8fbc8562b9bc45179604d0b354d37975_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i759223d752d2484cb3624693e092afd2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i49ed113f8481479a94b3377274581c18_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic758f54fa5494dee98621db67459a939_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib3721bdf19944087b6072d188479220b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icf289905620f424a822098d370171d98_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8197dcace8e546198e3aa3cab5f1e9ab_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib1878eebcc48403e8da37dd8ccee3c33_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:LuxembourgInlandRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5cecc7e2447a473eacca025ceba50171_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:LuxembourgInlandRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3452627b08104c328663beda89ef7e2b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bhc:TaxYear2005ThroughTaxYear2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53b67fa0263542b89545f1c28636acdc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i70a5dd9dc5d24412b0837e57866d62ab_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie44b34f6fd784806a1de35a90e5cd3c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bhc:TaxYear2015AndTaxYear2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd17b9aaa43542b6ad701f3288d43039_D20170808-20170808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-08</startDate>
            <endDate>2017-08-08</endDate>
        </period>
    </context>
    <context id="ie898e2aab45345c9b42d7a2acb631663_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id033c0ed7fc74052a6c84265f651ad67_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6b0d284e351c45f6a89f189993ae032b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4a5a4c310e574205b818538430461c33_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i393b10cfe703474a8e599f0e963d3334_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic8cc4183f807420fa113cead38c11868_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i246d722a091f4f0080937e3f56bdb622_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i91b2ee61b3794c97a503eb91ca7419fb_D20151001-20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="id6c40f9f298a435e8a95ba9a81e42595_D20211231-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:RestrictedCashAndOtherSettlementDepositsCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia6542cc5b199449eb308666602a70acb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifd485be691b84f43ab57f11e016f9b16_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="if49a279281c940c0bb5c71ec87be9d3c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3eca502d770d4373a854ca461ac2dffb_D20200804-20200804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-04</startDate>
            <endDate>2020-08-04</endDate>
        </period>
    </context>
    <context id="i35775310d73b4d409433acee7c99eb8c_I20190215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-15</instant>
        </period>
    </context>
    <context id="i73250b3b65e14dc084f6d77a1b839bb1_I20210317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-17</instant>
        </period>
    </context>
    <context id="i0f0be9ec6ddf45658d3a7d087aa67006_D20160527-20160916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:RICOClassActionsLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-27</startDate>
            <endDate>2016-09-16</endDate>
        </period>
    </context>
    <context id="i7ebadc5ebb4b4ab7890bec9925824363_D20171207-20171207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-07</startDate>
            <endDate>2017-12-07</endDate>
        </period>
    </context>
    <context id="i02a698a8f008492cbd69f48f20e081f8_I20210720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-20</instant>
        </period>
    </context>
    <context id="i32cfd64f67674351a47e22d698db3e9e_D20210720-20210720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-20</startDate>
            <endDate>2021-07-20</endDate>
        </period>
    </context>
    <context id="i06854e40aeff47b0b797200881bfe88d_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:SandozLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4bd7415ed1604a45b4b6bc56767acc83_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PerrigoIsraelPharmaceuticalsLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="i35ab857c3fb443e7906b7fc3fdb47b2f_D20200501-20200501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PadagisLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-01</endDate>
        </period>
    </context>
    <context id="i823e4afeb6cf4d59ae626d765f776286_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:MSNLaboratoriesPrivateLtdLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ia07d23a8e2fc407d901667681d446493_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2837802deebf438f831c9248b84634f3_D20220202-20220202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LupinPharmaceuticalsIncLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-02</startDate>
            <endDate>2022-02-02</endDate>
        </period>
    </context>
    <context id="i3142f2cfd5aa4bb08a1afccc27a8a806_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ApotexIncLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9cebf3bd98614f709e30c0cad5ae3945_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowertoShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf59e9f444d44941a03dff00106248fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i668c09254646450da54e4779c1a1cf5c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowertoShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id333f2cd40c246d686e1bf05143b6d09_I20211215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowertoShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-BC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-15</instant>
        </period>
    </context>
    <context id="id08c64cba12f4488a204547ee19dbb28_D20211216-20211216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowertoShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-BC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-16</startDate>
            <endDate>2021-12-16</endDate>
        </period>
    </context>
    <context id="i4d1927896b7f467b9ea850d5899edaa8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowertoShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5a5b7cb1bde4b00b20dc046470c7dbc_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DoctorsAllergyFormulaLLCLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i3f954393aadc446fa7a66231a8a0176d_D20190128-20190128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LitigationwithFormerSalixCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-28</startDate>
            <endDate>2019-01-28</endDate>
        </period>
    </context>
    <context id="iaf28153bff85452b8ab343577fbba878_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i705b99b9e9f141cea120e4f7552a841d_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="ib79efab1243d47f58861ab6f96316996_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i2b0d134ac84a4b9fb995abee169d3922_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i0974c8f474ad4f1ca10ac1d1131053f8_D20210726-20210726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-26</startDate>
            <endDate>2021-07-26</endDate>
        </period>
    </context>
    <context id="ied24221b489d4f4ba5abd2b2dd8014fb_I20190910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DerivativeLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-10</instant>
        </period>
    </context>
    <context id="id56dfce34e5c4c43bdd8c62baf232508_I20190913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DerivativeLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-13</instant>
        </period>
    </context>
    <context id="i81f9ed3c74134a7fabf0feaf1c2120c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf37c45946284359a2d4538803c7b301_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f2f1cfe9dc04f76978526af52bd0a5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:NovaliqGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9bdb8b8277cf4e04ada86ca0bed059dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:CedarsSinaiMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i62ab16dfdb214a95ac5f1498f90faa39_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:EyenoviaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i30bf053c559f4b1c9ed175d768f3d24b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i673b35bd82f24773b53ca856e22be6c2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4f6d3e46f96644c89ae14a35eb34a016_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iffb4ee2a83284e5aacf40c45394d64ee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icc3957b2514e43d4bc57896332a29c98_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i526b3306560a4582bbd5cb84b6634e8e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib1aabb4dd84c41e78c5713f72684c58c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i12ca69aa53c04d1f9a70ca7832545115_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5d617a50cb4e4dc2b9d45dd78b38e32c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3fd885b33ea84b91854e977c98d0cdd2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibe4fe193ae054da49acc60fb104beaba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8fc28f8f6ed74a9089917e8b80f33998_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9bb5d7f34e00490896510ef48df89709_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7e43bb66906240b1bf5bd13e06e0eb33_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic22f83493b6c49b3bd143623ecdfcef6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i305152159c734293b19863277adb1507_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i16716b25f68d437e8b5603c13cad09e4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2acd16c5638f406dbc8a4a64bcfb73c4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if4c91dc7a5754f868357dbaaf40b5a60_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i40ecfa21f8b642f7807a65183e087f3e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i93fdc6cbea484e5d933d9ec17976a64a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id40c780474fa4a4682a7347b25e2b201_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9af7ef89cda648658a1c3607ee127da7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i045b9dafc68b4cc68fb25904182bba77_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3697d2a9e4ec43ed8d76e098889f36cc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i00cbb18e8a4244e0b4ab1c019ad6fbef_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i05e5078808d945ada773030e2fff85f6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i18975fdb4b2643a18e1536995bd756ae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib0efcb1a3e484c1495fe6a62314d10a2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8200ab4980184e4096913b6919701188_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5015918fcb654325817de17b69decef0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1210af6063f04ed085da1d49425cc50d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibd3b2b75a9e04acc95e10777983994e6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4db50b822dce470c82556f075e3aa86a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i620b1f27f17d43f7ba80d7206929a42a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i818f730bc4e3452abca0fbc91147a433_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3dae557e1e00497a865526614a2c20dc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i741d562c91384842b61fd3597f4f5e01_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i29fb9247f04947ea8be74d0fa5e1431d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4bbe060476f44a9e9703d61f58e930d7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6b52e9e750b14be2b227e83c88613718_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieca5e0bc0aeb4138acf45885703a0f6c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i09553df00340400bb7d271aea0f7bbe5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6ee94ae398154c9ba283d347ee65f6fe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i111b0987b23747f886225e07ed349f8b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie4f1ecad4e074139b813953bc218bf66_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i58e2b80073124c139f9beb53118af5e4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib6ba58bf0a7a47308743596ca6786020_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2c572de04a1547afbb27a25fb70ce6a9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i62aa1ea2a03e43139f39c8d0853efab4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i49e6f291ff584b48a1622e2e639ba32e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i499995e5502d4c19b0439c7bf1f67b9a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if992199bf6084e97b3622278275b21d3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia4853e38d55c49e987573c8d03ec31aa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5d94edb1edcc4131b1c8c736826ab425_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ica7328b8d6504b7899d1dc8b7505c3c0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4118ed47b4d54cbdb1f54bbd3b175865_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic87b0a379a4e4af4a668a658b4e4dd43_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1e7cfdefe46344e69ec8aea55a260650_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iee783aab280a472ea992eba9ca598c34_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i55591dc8c2f846f5ba4430ce1db261dc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i558d7f511a464c67b2130444ac156e84_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5b6212f9cc5f44979bde0e23bc60ea10_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i088daa95a15e437895c8f9f62f3aaf91_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8cfe3de8f52f4da6bec0b7e7f3089c8b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i800a26cd6f20436983c15a8c15183252_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie58585239a67458fa764c31745ab5784_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i261608b942e5454e8116aba0eacfa55e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7803df4ff86b424e850a241538857cd4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie2f9db866111463eacf119731346b0d6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i867c2a9786c94ae2a5aec06b9a7cf714_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i738e8488fe144fce92ca8ab4ac3908e1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if3ccfe8ed3544137991312117c73e03d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i768994e8bab445f2ace72afece0d453a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic7a686a8ace843f6b748426e83776b3e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5a10926c267e4f7ca73186bb4acb8c87_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5102465bf9f8449faf1eb3625cdf92e0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib145795896ac48f893142cce0eb31900_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9337ed14800f40b0acaa106b8ab1687c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5d30a802ae6241198bab6f023ee116ec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5d8e87487d774cb5aa73c296d54c373d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i01c332dc4b3a40a7a943bd1c4a3ae01c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9673696801474c4ab375773e366c4e88_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id7b567c1a1d44f319be957d898bda4cb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87ad55a1ae5b4477a17dbf7c109decc9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i02ca962a07074ab0839d092880ab5aaa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d6a9bdc1e8f4460856c8c2141dade5c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i13483a8d36774c0090ab1f1dd802483b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibd95ebc9b8e2493283e0e5fa94a55b77_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3ab4cac0f20f47bea48d93a577e3c68f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9458be242c114b20aae89680bcb5981b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia68492c01598457abbbb8598f9044b5b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2764c82e246f458ab4e6010231d3da10_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i38cbd7ab09694b5cb4499dc66ab3535d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3ec1bdc6efc9470c9e1dddfa13904883_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia78ff119a7a043648e26b928f005ae89_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib492295e326e40ebbf3dc856ab711aa9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i77282ee77e994ae0943e0dd0203f496f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i21cd1fcf02454f2aad2528f002a1fe42_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i71cdecdee46c4b1893e522d76ed1b394_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iedafa6efd5e44f1499ea180b808f257f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i91f8e9e0afef4a67b9264f5a03b4ddfa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia337f02e12fd43138589ca394c6f6db4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic9bc60fbab2b493da4da40019ac28d5b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ief548b6efb9243519ea3dc4dcb13b28d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1e4cda890a664abb926b4656d83aa772_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8ad550fea28840ca8816e812a29b209b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id96fcda2fdee4cceaec20818540ab7ff_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6d9df741d61340bba2aa6c1e15e212ef_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iba623fc1e57a4f16a68ade989b914e71_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6d8ae893b49345bfb708b151f21b640e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaada16b4b8624fb888a1f0e2f22b1aae_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i389a02cf0b334d2a9bc9e4d299b60faa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i97cfe71201a14248b5a32a0be5378bdc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7cf07a753f9f497e8b32f6adceb6f310_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia83c0def577047da884ce155c2ca3898_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i12d5980aa12348d4bdccb1436660ada0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i31434b081601492c8ea95ce2b4f375e6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia3b10e36535844bb8d8e1f54883bcc7f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i24c3f0d4cce04da181b013c5d63d6613_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i81cd80c7bd5e414fbd605f465e39a045_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2742b142133f46b8a6da2018195c82e3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8f669422c2a34471ba15be9c22158c50_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i11472ddfa02944969a68ae2a1ae9e0aa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id130fccad3254b85b50a4b625a1dcde4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i65d94d793a9d4765a3365f16eb32b2a7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic25b58dd47534aecaa1e6fceaca4aea2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idbf3d8d385d64c9986eeff60677c124c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibc9c0c2f95e04969a40f79d90fbce2c3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4ed5256f567f485c9398406ba71740cd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6d755014362a46e4b04d95046a5882e2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic48b8c8ee39d43a199bbf9a0ca2aaf23_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c803976e613424da77d662911fc6070_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if21ae7bafd3345088a01d43828a61e14_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i11c5ca044d5d4c338ccc82b463e5c0c0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idae5a5e95f9e42db945e914283667476_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9926394966af411883263fa6138b4736_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id455a11708be4744b4a4db362bcbb326_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i27fd2a2c4b784f2ca7121666541412f8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib73f7c080cab4bda95891cb8f82106e4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i26ab236fac0b4f6aa2edb6c703d1d2d2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia046496cfcb74a4b8dcb288dcf4d65ac_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i686a58e486aa452d93fb9e1315614162_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i08449c2242ac44f6bdab497f63ba91ae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i68ae7a44ac90426e88c14dd8cda682e3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i109a56ca7b294e69a526b8979a3ddbba_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic6d4f781ea0b40538209f115920071e9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2180af989330419e910ab226313818df_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic68cf5e89c634f10804f0199048ac135_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:EG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4331026771c04d61a230465e05e97af9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:EG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i542580a52bd046618b9a580e8e103af3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:EG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic990a51442844403aa60ea9e7d40e464_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6635461f5a48470c8e56e33f2e669734_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id0a477db0fde456185567e5b03ecc809_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i585c6fb7766a4a5181f84f4a204170f8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i906af541abda46ea9ee574738de1865e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i02eebd70500545f79f2c990d2925d8b5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic22a4e49c9354ba18f292e3feb3e7e01_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2497f962eb7544ca88a07e1e575fc7ed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iae37a07b59f444bd8e13c8a1c43209fa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iccd485be53574b8e949e379c787d4ef4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idc7582499a2b415e93784236f4cb34fd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i168771f1c7d74447915fe4778febc05a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i471e03575d1346b7b9f05bf5ba23116b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie4f64c8704264652a24d4ce93c2900c3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if84190a5f2244c92b77538836a840d39_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i14de5bc495eb4add9fa84a199741910c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d46d579e1e44fe3ad004f43eaccef30_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2862a5dfd1e645cfb3ebcb20802866e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b8ed490007f4fee9a005a8a805c6894_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c43807d9cda4c16831c9f055db35fb6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3218c6c6aa7d47a6b6e7fe2e3402a5c8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1b664e37697c4f7891056561bf29f683_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2aea46020d284bf6820326330afd288d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5d6aaa98a7a24f74b46d997266d2a452_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i34126ade1b28483c9a1ea926b56d408d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3be1fd06e45447f2a98c47d3aa49590f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id7ddc11ce20249cba2bdf7921a98775c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic95237c6a18642d8876995496f7f0ec6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66dcb516bc924f7f8ea52045f62987c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i90615098fdc24b3394cea58fd0717975_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iacfc9f50cdde4a879013a96abcb55983_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie121075f685e4899b526388e85fc73a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief9b76c5e82249468a3e6e7d77de38df_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic715be3970fe46419fb02b3a67f6c23d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic2da7c3fce6a4a55b940079cd34b7824_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0bf0ad3c28494e298de94b94bcbedd3f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9dbae836ee6a485199be60177a95f582_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id7c19794c8aa4758a7c167c4585fa6ca_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iace25aeeaa0d4c3d986f48d0c8baf029_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i19d7ced3035a44ce992df3a4b9291ff4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib8131fb2f99f4c7a8028ad6778dc1676_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7f416523997c4b338d676cc2d06aaafa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i04069591c97a4784ae4185ec478eb90f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i29cea92069c14b44a2be0c659664e70f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ice846a05c75e458db9e4650442b6067c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i249f7ac9d61242019aa00db1804021d7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i197a960478f74a8e9a871dd7b6a60555_I20220118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityNewRestatedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <context id="i5d92f684e11f4d7195e59fa6354f28b1_I20220118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityNewRestatedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <context id="i11ef4c89472c48b8a4e820729468ec02_D20220118-20220118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:NewRestatedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-18</startDate>
            <endDate>2022-01-18</endDate>
        </period>
    </context>
    <context id="id0c6700094674a22af02045a72c15ccd_D20220210-20220210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <context id="i590fabe0c9ae4c4db81e12d4cd310bc0_D20220210-20220210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="country">
        <measure>bhc:country</measure>
    </unit>
    <unit id="company">
        <measure>bhc:company</measure>
    </unit>
    <unit id="wholesaler">
        <measure>bhc:wholesaler</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="businesscombination">
        <measure>bhc:businessCombination</measure>
    </unit>
    <unit id="rate">
        <measure>bhc:rate</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="defined_benefit_plan">
        <measure>bhc:defined_benefit_plan</measure>
    </unit>
    <unit id="subsidiary">
        <measure>bhc:subsidiary</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="case">
        <measure>bhc:case</measure>
    </unit>
    <unit id="group">
        <measure>bhc:group</measure>
    </unit>
    <unit id="action">
        <measure>bhc:action</measure>
    </unit>
    <unit id="entity">
        <measure>bhc:entity</measure>
    </unit>
    <unit id="numberofbusiness">
        <measure>bhc:numberOfBusiness</measure>
    </unit>
    <unit id="insurance_policy_period">
        <measure>bhc:insurance_policy_period</measure>
    </unit>
    <unit id="insured">
        <measure>bhc:insured</measure>
    </unit>
    <unit id="shareholder">
        <measure>bhc:shareholder</measure>
    </unit>
    <unit id="reporting_unit">
        <measure>bhc:reporting_unit</measure>
    </unit>
    <unit id="product">
        <measure>bhc:product</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN180L2ZyYWc6MGI1N2Q3NTNhMjY2NGMzYjhlYjIxMzJmODNmZGYzODEvdGFibGU6NDZiYWU3YWI4N2QzNDZmZGI5OWI2ODE3OWI3OWUwNTcvdGFibGVyYW5nZTo0NmJhZTdhYjg3ZDM0NmZkYjk5YjY4MTc5Yjc5ZTA1N18zLTEtMS0xLTU5NDcw_767201d0-7f90-41e5-b2e8-bd5c9c90e843">0000885590</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN180L2ZyYWc6MGI1N2Q3NTNhMjY2NGMzYjhlYjIxMzJmODNmZGYzODEvdGFibGU6NDZiYWU3YWI4N2QzNDZmZGI5OWI2ODE3OWI3OWUwNTcvdGFibGVyYW5nZTo0NmJhZTdhYjg3ZDM0NmZkYjk5YjY4MTc5Yjc5ZTA1N180LTEtMS0xLTU5NDcw_714ab012-2381-4851-9147-244f47a2c6c0">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN180L2ZyYWc6MGI1N2Q3NTNhMjY2NGMzYjhlYjIxMzJmODNmZGYzODEvdGFibGU6NDZiYWU3YWI4N2QzNDZmZGI5OWI2ODE3OWI3OWUwNTcvdGFibGVyYW5nZTo0NmJhZTdhYjg3ZDM0NmZkYjk5YjY4MTc5Yjc5ZTA1N181LTEtMS0xLTU5NDcw_869613ec-a6b1-450d-b725-1096d1aa1004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN180L2ZyYWc6MGI1N2Q3NTNhMjY2NGMzYjhlYjIxMzJmODNmZGYzODEvdGFibGU6NDZiYWU3YWI4N2QzNDZmZGI5OWI2ODE3OWI3OWUwNTcvdGFibGVyYW5nZTo0NmJhZTdhYjg3ZDM0NmZkYjk5YjY4MTc5Yjc5ZTA1N182LTEtMS0xLTU5NDcw_d241bdd7-1fce-4f73-aa99-73b1a1c306f6">false</dei:AmendmentFlag>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzExLTAtMS0xLTY2NjQx_23257d93-b538-43fd-a27c-e92b625799be">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <bhc:RevenuePerformanceObligationPaymentTerms
      contextRef="i9bd7a2707ecb487ab4050dffc0f16a47_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM5MzI5_70a72a43-4f7f-4419-aca2-445874d33f43">P30D</bhc:RevenuePerformanceObligationPaymentTerms>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ia582e0f09c454720859f9795398a6f4f_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM5NDgx_a56638c4-d79f-4701-9cb4-eeba251c7aba">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ia582e0f09c454720859f9795398a6f4f_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM5NTc1_4194aaa1-36a3-4275-bf8a-8595947de005">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i021f572cbdf44c37b86b96f04672a793_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzEvZnJhZzo4MjEzNTcwN2JhNDc0M2FjYmUyNDgzMDVhNGE4ZjM1Yi90YWJsZTplYWU5NWNmZTNhYzA0NzY1OTc0YzMyNjhhOTc4OGMyYy90YWJsZXJhbmdlOmVhZTk1Y2ZlM2FjMDQ3NjU5NzRjMzI2OGE5Nzg4YzJjXzAtMS0xLTEtNTk0NzA_99561522-b91c-4eb4-8204-b6d1d4c321ed"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzItMC0xLTEtNTk0NzA_aae53d6e-38d6-4bae-885a-a2f1102e63b7">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzItMC0xLTEtNTk0NzA_efb2683f-68c5-4ec5-ba14-7adb1864ba2c">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzQtMC0xLTEtNTk0NzA_43d158d1-ee05-4bae-a3d5-740a15d049b3">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzQtMC0xLTEtNTk0NzA_fa62fdb0-f620-4627-932e-a0cd84ebc336">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzUtMC0xLTEtNTk0NzA_5aae2037-0b31-4496-a31b-a0628ffc23c9">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzUtMC0xLTEtNTk0NzA_fc2d7485-eeb6-4aa7-8f75-257ecb0d55a3">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjMy_e131ddad-1d02-4eed-b545-a4fa6c17d7ea">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6NjZjMzQ5MWU3YmFiNDA2OGJiMDI1ZTJkZDMyNjNhZTQvdGFibGVyYW5nZTo2NmMzNDkxZTdiYWI0MDY4YmIwMjVlMmRkMzI2M2FlNF8wLTAtMS0xLTU5NDcw_57b2448a-3176-44fd-b36d-00d376b1b39a">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6NjZjMzQ5MWU3YmFiNDA2OGJiMDI1ZTJkZDMyNjNhZTQvdGFibGVyYW5nZTo2NmMzNDkxZTdiYWI0MDY4YmIwMjVlMmRkMzI2M2FlNF8xLTItMS0xLTU5NDcw_ea6685aa-97dd-46aa-a8d7-619f681e180d">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6NjZjMzQ5MWU3YmFiNDA2OGJiMDI1ZTJkZDMyNjNhZTQvdGFibGVyYW5nZTo2NmMzNDkxZTdiYWI0MDY4YmIwMjVlMmRkMzI2M2FlNF8xLTItMS0xLTU5NDcw_c8f31147-2963-4d9d-96d5-8c02aae60bc6">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6NjZjMzQ5MWU3YmFiNDA2OGJiMDI1ZTJkZDMyNjNhZTQvdGFibGVyYW5nZTo2NmMzNDkxZTdiYWI0MDY4YmIwMjVlMmRkMzI2M2FlNF8zLTAtMS0xLTU5NDcw_1ff25d37-4999-4412-98e1-6e3819ecc864">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjQy_8fca6ac0-65a2-4ad1-9987-b9f1c840ca0f">001-14956</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjQz_01fbc6b9-7a44-4dda-b360-967312497111">Bausch Health Companies Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6ZDA2NjJkZWYyYjdkNGU3NGE4ZDZlMTIxNWQxOWI1MmIvdGFibGVyYW5nZTpkMDY2MmRlZjJiN2Q0ZTc0YThkNmUxMjE1ZDE5YjUyYl8wLTAtMS0xLTU5NDcw_4c1238e3-edf1-4d4d-a194-84da2b056ff0">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressCountry
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6ZDA2NjJkZWYyYjdkNGU3NGE4ZDZlMTIxNWQxOWI1MmIvdGFibGVyYW5nZTpkMDY2MmRlZjJiN2Q0ZTc0YThkNmUxMjE1ZDE5YjUyYl8wLTQtMS0xLTU5NDcw_2e96cf47-3324-4075-8e2b-6230a90f294a">CA</dei:EntityAddressCountry>
    <dei:EntityTaxIdentificationNumber
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6ZDA2NjJkZWYyYjdkNGU3NGE4ZDZlMTIxNWQxOWI1MmIvdGFibGVyYW5nZTpkMDY2MmRlZjJiN2Q0ZTc0YThkNmUxMjE1ZDE5YjUyYl8wLTctMS0xLTU5NDcw_bd96c2cb-d3fc-4cfc-848a-242fb3315f79">98-0448205</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjMz_af0d8e6f-6de2-42b4-94aa-aa5397546328">2150 St. Elz&#xe9;ar Blvd. West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjM0_78d23cd0-691d-4eb5-9a8b-7e22992f1daf">Laval</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjI4_749b808d-82cc-468e-84d6-522b799c23d1">QC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjM3_7a053eb5-ade9-4fc3-a986-30d8356792e7">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjM1_4614ef47-7e35-4800-8de0-f83000835fa7">H7L 4A8</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjI5_061f3235-39f3-43c5-a9cf-a66de0003097">514</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjM4_a5891910-bec5-4576-8bf5-2cd5956ed5f9">744-6792</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6NDg5ZjlkNmY0ZmQwNDExMTliZjdkNjc3OGM0NWQ5ZmQvdGFibGVyYW5nZTo0ODlmOWQ2ZjRmZDA0MTExOWJmN2Q2Nzc4YzQ1ZDlmZF8xLTAtMS0xLTU5NDcw_7cffd14a-5deb-4d0b-a630-c326a4e44daf">Common Shares, No Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6NDg5ZjlkNmY0ZmQwNDExMTliZjdkNjc3OGM0NWQ5ZmQvdGFibGVyYW5nZTo0ODlmOWQ2ZjRmZDA0MTExOWJmN2Q2Nzc4YzQ1ZDlmZF8xLTEtMS0xLTU5NDcw_e1524488-b866-4ca0-bc95-07ea3fa15a87">BHC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6NDg5ZjlkNmY0ZmQwNDExMTliZjdkNjc3OGM0NWQ5ZmQvdGFibGVyYW5nZTo0ODlmOWQ2ZjRmZDA0MTExOWJmN2Q2Nzc4YzQ1ZDlmZF8xLTItMS0xLTU5NDcw_f17e45a8-1d62-4807-a964-00c82ca6f1aa">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjMw_1c3d0609-34d0-4614-b08c-be120d1da73e">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjM5_02c003bb-1777-4905-9ce9-2f851c17a104">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjQ0_add8d860-47cf-4a2f-a420-42bc1e021729">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjQw_83e4e411-d7d7-412e-b226-446e179046ac">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6MDU3YjQ2ZjkyYzU3NGJjYzk4ZWU0MDc2MDNiM2FkMjEvdGFibGVyYW5nZTowNTdiNDZmOTJjNTc0YmNjOThlZTQwNzYwM2IzYWQyMV8wLTAtMS0xLTU5NDcw_875c3e5c-fdcf-4f5c-9b00-5f4394b0f89d">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6MDU3YjQ2ZjkyYzU3NGJjYzk4ZWU0MDc2MDNiM2FkMjEvdGFibGVyYW5nZTowNTdiNDZmOTJjNTc0YmNjOThlZTQwNzYwM2IzYWQyMV8wLTctMS0xLTU5NDcw_1d7538b5-1c7b-43d9-83a4-893a7de38177">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGFibGU6MDU3YjQ2ZjkyYzU3NGJjYzk4ZWU0MDc2MDNiM2FkMjEvdGFibGVyYW5nZTowNTdiNDZmOTJjNTc0YmNjOThlZTQwNzYwM2IzYWQyMV8wLTktMS0xLTU5NDcw_c25e2ca5-235f-4c9e-bcb6-db37983db0ca">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjMx_a4d13f3a-ce3b-4205-abe2-f81874f299f9">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjQx_6c431068-0f74-41d2-b8fe-89a7afc9bd80">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i6bce9561cca44aed9496c119874299ef_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18yNzUz_cdaee5f1-6e27-4fc9-b81d-f74d1a07b2d9"
      unitRef="usd">8713713918</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i3c51f196215b47d6a61955c462c707de_I20220217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18yOTM1_a6c9dbd4-5ccd-4d30-b149-5272a8b425bf"
      unitRef="shares">359646496</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18xL2ZyYWc6N2RkZjE3MTFjMDMzNDUwMGFmMjVhOGFmNmJkMDUyMjMvdGV4dHJlZ2lvbjo3ZGRmMTcxMWMwMzM0NTAwYWYyNWE4YWY2YmQwNTIyM18zMjQ1_2c6a82a0-a6f8-4044-9039-83e6e08ac7e6">Part&#160;III incorporates certain information by reference from the registrant&#x2019;s proxy statement for the 2022 Annual Meeting of Shareholders. Such proxy statement will be filed no later than 120&#160;days after the close of the registrant&#x2019;s fiscal year ended December&#160;31, 2021.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yNjgvZnJhZzplOTU4YzVkNGNiNGM0ODU1OGJmZGMwMzEzMjQyMjg2MC90YWJsZTo4OGQ2Yzk1ZDllMjI0N2I2OGQyMzRhMDMwNDc5YjdkNS90YWJsZXJhbmdlOjg4ZDZjOTVkOWUyMjQ3YjY4ZDIzNGEwMzA0NzliN2Q1XzItMC0xLTEtNzk5MDUvdGV4dHJlZ2lvbjo2ZjQ0ZDk4Y2ZmMjk0MTVhOWVlMWRkZjMyY2UwM2I0OV80Mzk4MDQ2NTExMTgz_d9c9c110-43e1-4772-aa14-2aefefabce84">238</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yNzQvZnJhZzoxMWJiNTE0MWM2NGU0NTYyYjkwYTE1YmYwZWIyNzY5ZS90ZXh0cmVnaW9uOjExYmI1MTQxYzY0ZTQ1NjJiOTBhMTViZjBlYjI3NjllXzEwOTk1MTE2NDQzMzc_d16d1d67-f2e1-4cb0-93fc-62203a11f8d8">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yNzQvZnJhZzoxMWJiNTE0MWM2NGU0NTYyYjkwYTE1YmYwZWIyNzY5ZS90ZXh0cmVnaW9uOjExYmI1MTQxYzY0ZTQ1NjJiOTBhMTViZjBlYjI3NjllXzEwOTk1MTE2NDQzMzk_c7688c15-26ea-4515-8269-1c4a555a3ec6">Florham Park, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzQtMi0xLTEtNTk0NzA_4cd7f632-7461-4cd6-8485-3ceace812f1d"
      unitRef="usd">582000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzQtNC0xLTEtNTk0NzA_6b7e0dc0-4836-4870-934a-2bcf4734c442"
      unitRef="usd">605000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzUtMi0xLTEtNTk0NzA_9b02b544-edc6-4a46-92d9-882df5090cbb"
      unitRef="usd">1537000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzUtNC0xLTEtNTk0NzA_44f96318-221b-44d9-850f-7032347a2406"
      unitRef="usd">1211000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzYtMi0xLTEtNTk0NzA_45f76a2f-d90d-4e00-8e4f-9d9db6502813"
      unitRef="usd">1775000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzYtNC0xLTEtNTk0NzA_82648118-7fee-4151-a9e9-6bab251ba892"
      unitRef="usd">1577000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzctMi0xLTEtNTk0NzA_fb67f469-d682-4556-97d8-0e3a158a8676"
      unitRef="usd">993000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzctNC0xLTEtNTk0NzA_d2a6aa16-d044-406b-b8d7-d7a0ab5a2b40"
      unitRef="usd">1094000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzgtMi0xLTEtNTk0NzA_b001be39-908b-42bf-9d54-c4dff4741609"
      unitRef="usd">720000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzgtNC0xLTEtNTk0NzA_15caa44e-ae24-4928-a166-e93333ccaadf"
      unitRef="usd">855000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzktMi0xLTEtNTk0NzA_73255393-60ee-4847-a2c8-aedb2ffd9dba"
      unitRef="usd">5607000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzktNC0xLTEtNTk0NzA_2e125241-83ed-4e32-89bf-c7213fe25171"
      unitRef="usd">5342000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzEwLTItMS0xLTU5NDcw_11da3e3f-7850-4197-ac00-ee8cecd11e6c"
      unitRef="usd">1598000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzEwLTQtMS0xLTU5NDcw_a8c9d13b-f368-4c73-927f-f52f79add403"
      unitRef="usd">1567000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzExLTItMS0xLTU5NDcw_dec1c40e-c058-43fe-ab0e-5ea5e84fc105"
      unitRef="usd">6948000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzExLTQtMS0xLTU5NDcw_294dddba-afdb-4c4c-8df8-c896a0862a77"
      unitRef="usd">8445000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzEyLTItMS0xLTU5NDcw_abc7c1b2-3018-4f5c-a8e6-da05400df7f1"
      unitRef="usd">12457000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzEyLTQtMS0xLTU5NDcw_d05c4f72-ce34-4433-8c97-1276d242ab12"
      unitRef="usd">13044000000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzEzLTItMS0xLTU5NDcw_8d4b1e55-593c-4475-af9c-530aaa0fa3d0"
      unitRef="usd">2252000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzEzLTQtMS0xLTU5NDcw_a6b49735-5080-42d9-8c40-dcbf6a7e20cb"
      unitRef="usd">2137000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzE0LTItMS0xLTU5NDcw_1cd0bd47-515d-4ac2-8070-499488c838ad"
      unitRef="usd">340000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzE0LTQtMS0xLTU5NDcw_ae128170-6ee9-4c14-9eb8-15dce8ec70dd"
      unitRef="usd">664000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzE1LTItMS0xLTU5NDcw_c3ec599a-c5fc-4e86-894d-2536f728206c"
      unitRef="usd">29202000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzE1LTQtMS0xLTU5NDcw_db61cd94-5ec2-49ea-8868-e5bf9e987c53"
      unitRef="usd">31199000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzE4LTItMS0xLTU5NDcw_89682952-cd55-4b6f-851d-e7da0c9dd8aa"
      unitRef="usd">407000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzE4LTQtMS0xLTU5NDcw_cc142871-e77b-4a43-847e-1e35c0c63941"
      unitRef="usd">337000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzE5LTItMS0xLTU5NDcw_1c2342b2-0bef-4800-b917-0cd0352afab7"
      unitRef="usd">4791000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzE5LTQtMS0xLTU5NDcw_1c7d05a5-3fdf-443e-8ea9-0a2f6a12a4ab"
      unitRef="usd">4576000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzIxLTItMS0xLTU5NDcw_4f0a022f-1e4c-405e-96d1-99f033d8a245"
      unitRef="usd">5198000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzIxLTQtMS0xLTU5NDcw_96f764b1-e06e-468e-8bb3-f775d7e1697b"
      unitRef="usd">4913000000</us-gaap:LiabilitiesCurrent>
    <bhc:BusinessCombinationContingentConsiderationNoncurrentLiability
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzIyLTItMS0xLTU5NDcw_3070df21-9458-4234-870d-44186b29a2fc"
      unitRef="usd">202000000</bhc:BusinessCombinationContingentConsiderationNoncurrentLiability>
    <bhc:BusinessCombinationContingentConsiderationNoncurrentLiability
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzIyLTQtMS0xLTU5NDcw_dd344529-2ff5-4ab5-9f86-cf36e87106db"
      unitRef="usd">216000000</bhc:BusinessCombinationContingentConsiderationNoncurrentLiability>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzIzLTItMS0xLTU5NDcw_584669dd-aa82-4593-8d82-66f46dfbc530"
      unitRef="usd">22654000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzIzLTQtMS0xLTU5NDcw_9b147994-964f-499b-98ce-bc96617ea260"
      unitRef="usd">23925000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI0LTItMS0xLTU5NDcw_44aaaed2-d787-4c30-aebe-10c5a958b4c7"
      unitRef="usd">529000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI0LTQtMS0xLTU5NDcw_a4efed28-73b4-4557-94a8-757321be2296"
      unitRef="usd">528000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI1LTItMS0xLTU5NDcw_e72c2c09-acbe-43ac-a81a-158f54d62a0a"
      unitRef="usd">653000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI1LTQtMS0xLTU5NDcw_62962507-7df2-431a-9f48-35795acdefdf"
      unitRef="usd">1012000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI2LTItMS0xLTU5NDcw_154f4a4e-966b-47eb-9ff6-84a743266e18"
      unitRef="usd">29236000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI2LTQtMS0xLTU5NDcw_c56ec283-ae28-4aad-ad7c-8f871a0ee591"
      unitRef="usd">30594000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI3LTItMS0xLTU5NDcw_aba49848-c30f-49c7-81fa-1abc6ee918d1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI3LTQtMS0xLTU5NDcw_1d0fb845-650b-4ab8-b1af-350982620d05"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI5LTAtMS0xLTU5NDcwL3RleHRyZWdpb246NGRkYTRkNDM0ZTNmNDhmNjgxN2M4NDQxMGQwNTc2NTlfNjI_116674c0-4114-4094-a543-d6b991703693"
      unitRef="shares">359405748</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI5LTAtMS0xLTU5NDcwL3RleHRyZWdpb246NGRkYTRkNDM0ZTNmNDhmNjgxN2M4NDQxMGQwNTc2NTlfNjI_9c8474f7-7dc0-43e8-b4cf-fe3461a29b62"
      unitRef="shares">359405748</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI5LTAtMS0xLTU5NDcwL3RleHRyZWdpb246NGRkYTRkNDM0ZTNmNDhmNjgxN2M4NDQxMGQwNTc2NTlfNjk_414b8589-bd21-4295-adcf-634e60260812"
      unitRef="shares">355422347</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI5LTAtMS0xLTU5NDcwL3RleHRyZWdpb246NGRkYTRkNDM0ZTNmNDhmNjgxN2M4NDQxMGQwNTc2NTlfNjk_764bfdd1-3251-45e7-ba96-0ffdcc59bfe4"
      unitRef="shares">355422347</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI5LTItMS0xLTU5NDcw_c36e39c9-4719-4e79-b182-2663fb149aeb"
      unitRef="usd">10317000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzI5LTQtMS0xLTU5NDcw_6d20bed2-f7ef-48e1-94dc-0ea8a7dbcbab"
      unitRef="usd">10227000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzMwLTItMS0xLTU5NDcw_11b2be7a-0567-43df-9a3b-a0f2c3139eee"
      unitRef="usd">462000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzMwLTQtMS0xLTU5NDcw_f711ad0b-7b2d-42aa-b6f7-1742a7039eab"
      unitRef="usd">454000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzMxLTItMS0xLTU5NDcw_89e04f30-169f-4085-9f84-b0e9c8dfa57b"
      unitRef="usd">-8961000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzMxLTQtMS0xLTU5NDcw_65bf7f46-ac6d-482d-b4d6-8d274845de35"
      unitRef="usd">-8013000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzMyLTItMS0xLTU5NDcw_874db3c3-9245-4878-970e-78e736de57d6"
      unitRef="usd">-1924000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzMyLTQtMS0xLTU5NDcw_681e1799-564d-4190-9fb0-64e583af4795"
      unitRef="usd">-2133000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzMzLTItMS0xLTU5NDcw_d0889647-a2d3-412c-aa30-33faeb5a8342"
      unitRef="usd">-106000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzMzLTQtMS0xLTU5NDcw_6d0ea3cd-2470-4798-b6ea-14eb4fffdc5a"
      unitRef="usd">535000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzM0LTItMS0xLTU5NDcw_039ba2df-3583-4f43-adb8-24d1e6af30cf"
      unitRef="usd">72000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzM0LTQtMS0xLTU5NDcw_98c0bb75-2819-41ab-be77-46eeb9e4281e"
      unitRef="usd">70000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzM1LTItMS0xLTU5NDcw_e4620b44-9a9f-4b69-b777-2c655ef4f3ed"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzM1LTQtMS0xLTU5NDcw_5e432997-e21d-4dc4-9363-d7bdf24ccb93"
      unitRef="usd">605000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzM2LTItMS0xLTU5NDcw_c855bd50-3f2e-4f4f-80fa-ccd223ff09e7"
      unitRef="usd">29202000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODAvZnJhZzo3ZjZhOTFjYWY0NDU0MzA3ODFlMDZmNzE2NDg0NzQ4Ny90YWJsZTo5YTQxNmE5NzIzMjI0MzNiOGI3OTg2YjQ2ZDY3Y2RjZS90YWJsZXJhbmdlOjlhNDE2YTk3MjMyMjQzM2I4Yjc5ODZiNDZkNjdjZGNlXzM2LTQtMS0xLTU5NDcw_b0598902-b199-4730-ac57-f6c684e9ee3e"
      unitRef="usd">31199000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53abce993d5a44a596716ca7c9e737ce_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzMtMS0xLTEtNTk0NzA_d888cde6-e1df-4d6c-b90d-331a0ad739fd"
      unitRef="usd">8342000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5a8e9aebd5c4e6099f227c88232846a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzMtMy0xLTEtNTk0NzA_6ba7d2e8-b531-4385-89b6-216d6290d24b"
      unitRef="usd">7924000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9288144fc85e414e98cdb30f8362fd03_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzMtNS0xLTEtNTk0NzA_c841d351-7e7a-4da1-817d-9c1eb62357ad"
      unitRef="usd">8489000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35b13f9f8b9048f2abd23eee83da3ef7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzQtMS0xLTEtNTk0NzA_7ee571da-daf1-48ed-8b09-6b2a37d60280"
      unitRef="usd">92000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb57e7f275e74745bbed5bcd771379f2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzQtMy0xLTEtNTk0NzA_2adc0743-d082-4033-9cc7-ec7b1a2ba7ed"
      unitRef="usd">103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iceeb259687424b4486f58368d2356d18_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzQtNS0xLTEtNTk0NzA_84f6b529-d3a7-4f97-b1ba-28d849142bb0"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzUtMS0xLTEtNTk0NzA_b3930bb2-f1d9-4629-9629-9e469ae17bd7"
      unitRef="usd">8434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzUtMy0xLTEtNTk0NzA_2942a4ef-5266-4383-9a4c-490a14eb11cd"
      unitRef="usd">8027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzUtNS0xLTEtNTk0NzA_310da97a-6811-43a6-96d9-7521ee8371d4"
      unitRef="usd">8601000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i53abce993d5a44a596716ca7c9e737ce_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzctMS0xLTEtNTk0NzA_2c4aedfe-116b-4daf-94c4-0fee2633425b"
      unitRef="usd">2361000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia5a8e9aebd5c4e6099f227c88232846a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzctMy0xLTEtNTk0NzA_13f06dae-f1e5-4dea-a802-feb543010068"
      unitRef="usd">2202000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9288144fc85e414e98cdb30f8362fd03_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzctNS0xLTEtNTk0NzA_1c8d5682-ebc2-46b4-8b9d-249f15664e86"
      unitRef="usd">2297000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i35b13f9f8b9048f2abd23eee83da3ef7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzgtMS0xLTEtNTk0NzA_789b9a3f-e6b2-4f91-bd56-43d0ecfb08bc"
      unitRef="usd">33000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ieb57e7f275e74745bbed5bcd771379f2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzgtMy0xLTEtNTk0NzA_55ffca31-8f4d-4aeb-afb9-9c22112f86e5"
      unitRef="usd">47000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iceeb259687424b4486f58368d2356d18_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzgtNS0xLTEtNTk0NzA_9627d6f7-179f-415a-b0e6-ad984a591383"
      unitRef="usd">53000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzktMS0xLTEtNTk0NzA_8242de51-6373-4822-9c3c-bbb20b7177d1"
      unitRef="usd">2624000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzktMy0xLTEtNTk0NzA_ccd9ad1c-62f4-4cf3-83e3-937d535c502d"
      unitRef="usd">2367000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzktNS0xLTEtNTk0NzA_cf11a4c6-3db8-43d2-9de3-0da213209c6c"
      unitRef="usd">2554000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzEwLTEtMS0xLTU5NDcw_c0983aa2-698d-423c-9010-bc00a8748dfe"
      unitRef="usd">465000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzEwLTMtMS0xLTU5NDcw_5b9c6c17-88b9-4e8c-869c-7b8458a936fd"
      unitRef="usd">452000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzEwLTUtMS0xLTU5NDcw_f4284b97-5c5e-408d-9102-2ef21c21c409"
      unitRef="usd">471000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzExLTEtMS0xLTU5NDcw_9f8bf921-bdc7-4bea-a4ae-27c092864f27"
      unitRef="usd">1375000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzExLTMtMS0xLTU5NDcw_1a72f4c3-7e91-44d2-a69d-9bbec92a2151"
      unitRef="usd">1645000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzExLTUtMS0xLTU5NDcw_c6e0a9b0-823d-4d2a-bb37-12530f0edecc"
      unitRef="usd">1897000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzEyLTEtMS0xLTU5NDcw_aa1b7407-d894-49b6-bcab-7d7c3581d88c"
      unitRef="usd">469000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzEyLTMtMS0xLTU5NDcw_4d7d3386-204d-46bf-842d-08d265cdccd2"
      unitRef="usd">0</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzEyLTUtMS0xLTU5NDcw_39b122df-d22d-49e0-9d09-a6371c63d09a"
      unitRef="usd">0</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzEzLTEtMS0xLTU5NDcw_b93dce3f-e470-4b4f-8d9f-7c1b7b088250"
      unitRef="usd">234000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzEzLTMtMS0xLTU5NDcw_5a02892f-bf43-4074-a1f2-dd2c51ca26da"
      unitRef="usd">114000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzEzLTUtMS0xLTU5NDcw_ec1cab68-859d-49f2-92b1-8db993e42e95"
      unitRef="usd">75000000</us-gaap:AssetImpairmentCharges>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE0LTEtMS0xLTU5NDcw_7cb92526-1c9d-453c-9d0e-93073ac58cda"
      unitRef="usd">50000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE0LTMtMS0xLTU5NDcw_b1d85258-052e-4964-b5c9-1975f4e002e9"
      unitRef="usd">22000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE0LTUtMS0xLTU5NDcw_d6d82719-1488-4faa-8d04-bc882ed43ed8"
      unitRef="usd">31000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE2LTEtMS0xLTU5NDcw_f6d04a9b-c390-4ceb-8f37-700ccd21dfde"
      unitRef="usd">-373000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE2LTMtMS0xLTU5NDcw_72db09b6-3dfe-43af-bb7b-96fd62845692"
      unitRef="usd">-502000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE2LTUtMS0xLTU5NDcw_a83c8c5c-c0d2-4ad7-a7c8-86d35d664e81"
      unitRef="usd">-1426000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE3LTEtMS0xLTU5NDcw_6f1a15d7-e3d3-4502-bc7b-c8a98e54eecb"
      unitRef="usd">7984000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE3LTMtMS0xLTU5NDcw_72c4f447-031b-4796-9e59-451e4857d426"
      unitRef="usd">7351000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE3LTUtMS0xLTU5NDcw_8b99fc9c-2928-4651-8c50-a0c71a9aad88"
      unitRef="usd">8804000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE4LTEtMS0xLTU5NDcw_52fae1d5-4191-479a-9fd0-0e1d66b54173"
      unitRef="usd">450000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE4LTMtMS0xLTU5NDcw_b66593a0-abd9-4987-a3de-c94bf1652899"
      unitRef="usd">676000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE4LTUtMS0xLTU5NDcw_258b25fd-4166-4913-b6c9-17948826242c"
      unitRef="usd">-203000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE5LTEtMS0xLTU5NDcw_738e58b5-a08d-4fae-9bda-a01122eee48f"
      unitRef="usd">7000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE5LTMtMS0xLTU5NDcw_ad8adf57-700d-477f-9a50-3f8ba9bce0cd"
      unitRef="usd">13000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzE5LTUtMS0xLTU5NDcw_f87e972f-b963-48d5-af0d-2fb246693932"
      unitRef="usd">12000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseDebt
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIwLTEtMS0xLTU5NDcw_af20b858-2a97-4e6d-a940-bb8398a24eb8"
      unitRef="usd">1426000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIwLTMtMS0xLTU5NDcw_c6f12c7a-3917-4333-837d-da98d2e0cd58"
      unitRef="usd">1534000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIwLTUtMS0xLTU5NDcw_ac485a52-2d06-474b-b15c-e80cdb88a0d3"
      unitRef="usd">1612000000</us-gaap:InterestExpenseDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIxLTEtMS0xLTU5NDcw_f72b0a1d-d224-461f-8f43-f99be553bcdf"
      unitRef="usd">-62000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIxLTMtMS0xLTU5NDcw_a5dc5096-7325-4017-bf08-f614b0929abb"
      unitRef="usd">-59000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIxLTUtMS0xLTU5NDcw_b9824e5e-148f-4687-90ed-2d8299f417fe"
      unitRef="usd">-42000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIyLTEtMS0xLTU5NDcw_88508d63-137f-4651-8894-2c9ec4299bc3"
      unitRef="usd">7000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIyLTMtMS0xLTU5NDcw_2e625b4d-8941-47cb-b4f9-e4e69eae0724"
      unitRef="usd">-30000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIyLTUtMS0xLTU5NDcw_71d5394d-1bac-4fd3-997f-90bfc4993744"
      unitRef="usd">8000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIzLTEtMS0xLTU5NDcw_7951a0a0-1999-4127-ad88-ecf87cbfa243"
      unitRef="usd">-1024000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIzLTMtMS0xLTU5NDcw_320a85a0-8983-47c8-8e70-5a89daad1ab4"
      unitRef="usd">-934000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzIzLTUtMS0xLTU5NDcw_49708be3-8ce2-497b-bd78-2cc0850afdaf"
      unitRef="usd">-1837000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI0LTEtMS0xLTU5NDcw_869d8ae8-aedc-42f0-832b-29a8490ca171"
      unitRef="usd">-87000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI0LTMtMS0xLTU5NDcw_dba587a0-ed13-4ad0-9124-f0b63a1b5947"
      unitRef="usd">-375000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI0LTUtMS0xLTU5NDcw_68bbf7c3-d27b-433a-9d1c-bf6c021de341"
      unitRef="usd">-54000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI1LTEtMS0xLTU5NDcw_45f20b4f-6f87-44da-9b7f-19a45946579d"
      unitRef="usd">-937000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI1LTMtMS0xLTU5NDcw_5f5ff2c0-7220-4776-834d-d31aa1ef8f59"
      unitRef="usd">-559000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI1LTUtMS0xLTU5NDcw_4924d9e2-ad10-4d9b-8cb0-53944fc13bf2"
      unitRef="usd">-1783000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI2LTEtMS0xLTU5NDcw_bfd0bfa6-7365-4b10-8708-36068f3ab6c4"
      unitRef="usd">11000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI2LTMtMS0xLTU5NDcw_76dc1940-a28a-476d-9688-1faa2fd2a37f"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI2LTUtMS0xLTU5NDcw_9f57dff1-408f-4663-8f02-77a0c5f07db3"
      unitRef="usd">5000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI3LTEtMS0xLTU5NDcw_5aeedabf-c1ba-4d87-9106-b91e5ce5b45f"
      unitRef="usd">-948000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI3LTMtMS0xLTU5NDcw_6c68ee11-df1a-4769-b14c-6b2a0681e79b"
      unitRef="usd">-560000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI3LTUtMS0xLTU5NDcw_41daeaa9-bfc4-457a-af6a-9ef200b76311"
      unitRef="usd">-1788000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI5LTEtMS0xLTU5NDcw_a0748037-5636-47d7-ba74-976e5f270f26"
      unitRef="usdPerShare">-2.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI5LTEtMS0xLTU5NDcw_c33a3eb4-1b0f-4698-aa2b-8ee9b91cde0f"
      unitRef="usdPerShare">-2.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI5LTMtMS0xLTU5NDcw_6713a927-d61c-45a1-ac94-de1dbe965c18"
      unitRef="usdPerShare">-1.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI5LTMtMS0xLTU5NDcw_7920ead2-a2ff-430c-b93f-162c268fa56f"
      unitRef="usdPerShare">-1.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI5LTUtMS0xLTU5NDcw_544d6a97-277f-4266-b898-7d6cab6771a5"
      unitRef="usdPerShare">-5.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzI5LTUtMS0xLTU5NDcw_c3cf0329-22df-48e9-ab79-483ab2cff8e1"
      unitRef="usdPerShare">-5.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzMxLTEtMS0xLTU5NDcw_bf7c322b-2330-48c3-a41a-3556374f2264"
      unitRef="shares">358900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzMxLTEtMS0xLTU5NDcw_dc217327-9b0c-41d0-aeed-3bbf696361d5"
      unitRef="shares">358900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzMxLTMtMS0xLTU5NDcw_783f1f4b-0c82-4b21-b81d-c150fe0c8be1"
      unitRef="shares">355000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzMxLTMtMS0xLTU5NDcw_b6e8e2ac-a23e-4ead-a816-aafc6e27e366"
      unitRef="shares">355000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzMxLTUtMS0xLTU5NDcw_3d22f8e7-5995-4e56-b3ac-10e62f429d06"
      unitRef="shares">352100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODMvZnJhZzphODViMDZhNTI3ODU0MTc5YjJjNDJlNGYzODNiMzIxMS90YWJsZTo4Yjk1NjY5ZjNhMjY0NmU1OWYyZWU2ZDI0NjViNmYwZS90YWJsZXJhbmdlOjhiOTU2NjlmM2EyNjQ2ZTU5ZjJlZTZkMjQ2NWI2ZjBlXzMxLTUtMS0xLTU5NDcw_a777cb45-f378-4bdd-83f0-ebe49edbc350"
      unitRef="shares">352100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzItMS0xLTEtNTk0NzA_4d6b8599-a167-40cc-a3f9-8411657495fa"
      unitRef="usd">-937000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzItMy0xLTEtNTk0NzA_b0f0b00b-996c-419e-813a-6c958dc4b975"
      unitRef="usd">-559000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzItNS0xLTEtNTk0NzA_4570e912-b823-475b-a4ec-4ac16a89f473"
      unitRef="usd">-1783000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzUtMS0xLTEtNTk0NzA_14c75625-1714-4ed0-8401-bb60d75bc144"
      unitRef="usd">24000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzUtMy0xLTEtNTk0NzA_be001235-759b-4bf3-bd76-f3c1c9e69bab"
      unitRef="usd">-15000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzUtNS0xLTEtNTk0NzA_3aeb39ec-6ed8-4159-b884-0c5a54054c2f"
      unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzYtMS0xLTEtNTk0NzA_e91cc941-11b7-4966-b873-aa3855d68902"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzYtMy0xLTEtNTk0NzA_763b740a-1e07-4e3d-ba04-082730e00383"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzYtNS0xLTEtNTk0NzA_5c721dc2-7455-447b-8c27-5fbb7e25b1ce"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax>
    <bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzctMS0xLTEtNTk0NzA_d4332e34-040c-4a53-b92e-afc9a5646402"
      unitRef="usd">-10000000</bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition>
    <bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzctMy0xLTEtNTk0NzA_fd30511f-d178-4a14-a5dd-bfa13315b5dc"
      unitRef="usd">-1000000</bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition>
    <bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzctNS0xLTEtNTk0NzA_10328809-a5e7-4632-8155-6099e353e155"
      unitRef="usd">-2000000</bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzgtMS0xLTEtNTk0NzA_c2487297-f6bb-4ee3-8103-c60ffb8a62d2"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzgtMy0xLTEtNTk0NzA_4524516e-8337-4258-86b1-093618c39ee8"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzgtNS0xLTEtNTk0NzA_7e31ede4-f884-451c-b089-c10105d0c7a8"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzktMS0xLTEtNTk0NzA_0d9eb9fa-673e-49a0-b8f2-492a27a38398"
      unitRef="usd">-3000000</bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax>
    <bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzktMy0xLTEtNTk0NzA_b13be0cb-51f2-46a9-8c96-6d73e7d9f78f"
      unitRef="usd">0</bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax>
    <bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzktNS0xLTEtNTk0NzA_11f4a7b2-27e6-4bad-938c-f32a5f856285"
      unitRef="usd">-2000000</bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzEwLTEtMS0xLTU5NDcw_51f3f559-ac78-4888-8898-c904906db80a"
      unitRef="usd">-28000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzEwLTMtMS0xLTU5NDcw_370e5e3d-0abb-4dbd-9d30-ad9451ee7658"
      unitRef="usd">16000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzEwLTUtMS0xLTU5NDcw_9feb17e7-dcd5-4f13-b4af-e08c05863329"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzExLTEtMS0xLTU5NDcw_05219e07-730c-429a-9775-89a5e76f82e3"
      unitRef="usd">-158000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzExLTMtMS0xLTU5NDcw_80b72fdd-69f6-4510-b9a7-0a4c164efb81"
      unitRef="usd">-29000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzExLTUtMS0xLTU5NDcw_869c9e84-f226-4c5f-8726-befe9b8b4e5a"
      unitRef="usd">64000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzEyLTEtMS0xLTU5NDcw_049dd382-c036-4d62-bfe2-79241d1e49f1"
      unitRef="usd">-130000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzEyLTMtMS0xLTU5NDcw_56c514b3-7819-4045-8f77-bcef4c9fbc81"
      unitRef="usd">-45000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzEyLTUtMS0xLTU5NDcw_1a11c785-8e10-4325-94d9-ca0b00b26fab"
      unitRef="usd">50000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzEzLTEtMS0xLTU5NDcw_f9c2948d-69c3-4dc6-92f8-1b1182df3689"
      unitRef="usd">-1067000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzEzLTMtMS0xLTU5NDcw_9132aca2-d6f8-4435-9555-342aa85d1313"
      unitRef="usd">-604000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzEzLTUtMS0xLTU5NDcw_dd3cecc6-ca2a-49ad-82d9-1329fa288910"
      unitRef="usd">-1733000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzE0LTEtMS0xLTU5NDcw_6334558f-ee39-4807-b556-8bc098128af9"
      unitRef="usd">12000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzE0LTMtMS0xLTU5NDcw_ec1aa866-2c3c-4071-8584-c06eedd7a1e9"
      unitRef="usd">3000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzE0LTUtMS0xLTU5NDcw_c35503ab-a2e6-4fae-90f2-7b9d20848022"
      unitRef="usd">4000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzE1LTEtMS0xLTU5NDcw_9222eaf2-df5c-49a4-8c29-ed35b1979fed"
      unitRef="usd">-1079000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzE1LTMtMS0xLTU5NDcw_b5bb7470-d2ca-4e9e-89dc-43e45b96299e"
      unitRef="usd">-607000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODYvZnJhZzpiMmExZGQzMzYxN2Y0NDNlOWI3Y2Y4NTQ2NjRlMjI3YS90YWJsZTo0MTdjOWQ4NTMxYmY0MmNiOWY2OWU4OWE1MmI3NjBhNi90YWJsZXJhbmdlOjQxN2M5ZDg1MzFiZjQyY2I5ZjY5ZTg5YTUyYjc2MGE2XzE1LTUtMS0xLTU5NDcw_192536a3-eec1-4d47-90c9-6c9653da6e86"
      unitRef="usd">-1737000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i82b9833a23f042c5a2adb676a8ec5e95_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzMtMi0xLTEtNTk0NzA_f521dcad-ad8e-447c-a4b8-09414efec369"
      unitRef="shares">349900000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i82b9833a23f042c5a2adb676a8ec5e95_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzMtNC0xLTEtNTk0NzA_6c53574b-3b79-4aa0-8603-c5bb9363cfed"
      unitRef="usd">10121000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa34fcb752d94e098590798c475a7b37_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzMtNi0xLTEtNTk0NzA_5dd952af-bfee-4ebc-be34-b371d4d73bf4"
      unitRef="usd">413000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i355151ac32e34c93a32ea5b6e6b9c800_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzMtOC0xLTEtNTk0NzA_9c54852d-a12a-4311-8d6a-7ed6582bf72a"
      unitRef="usd">-5664000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i451d020caed04e288168a2f8fd5d732f_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzMtMTAtMS0xLTU5NDcw_539c901c-0045-4781-983a-7b372e300eb9"
      unitRef="usd">-2137000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2de4302e562642bb876564c477eeb8f6_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzMtMTItMS0xLTU5NDcw_9017d526-8e6d-4ce0-8eb2-42ded015a5c0"
      unitRef="usd">2733000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0fc6ad19407843c2804930d9e14a236b_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzMtMTQtMS0xLTU5NDcw_c0677fcc-54d9-4abf-bc29-210477b31aa0"
      unitRef="usd">82000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i88a9900560564bdca7dec25381689c13_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzMtMTYtMS0xLTU5NDcw_304af5c9-f64b-4c52-b26f-80ca5abe7036"
      unitRef="usd">2815000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i4684b0e1b31043f2a0e0a6337cab6576_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzUtMi0xLTEtNTk0NzA_3ebc74e3-eae2-4615-aca8-f1021728e117"
      unitRef="shares">2700000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4684b0e1b31043f2a0e0a6337cab6576_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzUtNC0xLTEtNTk0NzA_1d2f4088-5a9d-4768-83a7-baf66b4ebb5d"
      unitRef="usd">51000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2118e2f41d1f4842a442e5647a35f40b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzUtNi0xLTEtNTk0NzA_ad4b02dd-4f1c-4b1c-96f6-5bdb85c2c5ee"
      unitRef="usd">-46000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0c17e85c0371428e9ccf57c2288a1310_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzUtMTItMS0xLTU5NDcw_c7953594-e218-49d6-aa53-a989a409709b"
      unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzUtMTYtMS0xLTU5NDcw_5b33fa20-07ba-4b9e-891a-1ccb53c12949"
      unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2118e2f41d1f4842a442e5647a35f40b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzYtNi0xLTEtNTk0NzA_957ce2b4-c0c6-49a3-99f6-2403c410aa62"
      unitRef="usd">102000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0c17e85c0371428e9ccf57c2288a1310_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzYtMTItMS0xLTU5NDcw_8800e374-88ab-4d7e-aed3-b65ce3062396"
      unitRef="usd">102000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzYtMTYtMS0xLTU5NDcw_ace4c908-1791-4dca-bae8-a0a15822ebee"
      unitRef="usd">102000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i2118e2f41d1f4842a442e5647a35f40b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzctNi0xLTEtNTk0NzA_81c6dba2-6085-45dc-8fcf-c99ca20bb924"
      unitRef="usd">40000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0c17e85c0371428e9ccf57c2288a1310_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzctMTItMS0xLTU5NDcw_35a73bba-6c45-4f23-9996-5a4126831267"
      unitRef="usd">40000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzctMTYtMS0xLTU5NDcw_5b26f10f-7458-4812-81ad-2362185bf12d"
      unitRef="usd">40000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="if15b2ce8695749b5ac475e5adf790526_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzktMTQtMS0xLTU5NDcw_6016d030-47f2-4eee-aa3b-bf80e0f00cf1"
      unitRef="usd">13000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzktMTYtMS0xLTU5NDcw_ee51812e-3533-4443-998c-04622ff88236"
      unitRef="usd">13000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="i64a4e2f699614549a3fba3f9ac23a215_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEwLTgtMS0xLTU5NDcw_a2ef641d-bbdc-4a20-9a3e-71aec3e55ee7"
      unitRef="usd">-1788000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0c17e85c0371428e9ccf57c2288a1310_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEwLTEyLTEtMS01OTQ3MA_d5d54d07-18f0-4f3e-b25b-5d237fb2fde4"
      unitRef="usd">-1788000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if15b2ce8695749b5ac475e5adf790526_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEwLTE0LTEtMS01OTQ3MA_0817e678-c487-4891-9f58-75785cedef73"
      unitRef="usd">5000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEwLTE2LTEtMS01OTQ3MA_599d76c0-2dcc-48ab-9c42-8f9aaf8e93d3"
      unitRef="usd">-1783000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id91ab3b642bc46a187257c824bdd77a3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzExLTEwLTEtMS01OTQ3MA_d9d78a64-4808-492e-b1e9-157bada09faa"
      unitRef="usd">51000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0c17e85c0371428e9ccf57c2288a1310_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzExLTEyLTEtMS01OTQ3MA_25bdfd2e-7daa-4a66-b7bc-d7f9a241c80f"
      unitRef="usd">51000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if15b2ce8695749b5ac475e5adf790526_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzExLTE0LTEtMS01OTQ3MA_5a73a0e8-b0ad-4570-9e98-0875c1db4ba8"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzExLTE2LTEtMS01OTQ3MA_0a646abf-ab45-4920-a9c1-17d59df0553f"
      unitRef="usd">50000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i09a05e24b6824378a2ee002ec69b8c4b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEyLTItMS0xLTU5NDcw_bb5e368d-5a8d-4800-9ce6-fe2a7ab84543"
      unitRef="shares">352600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i09a05e24b6824378a2ee002ec69b8c4b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEyLTQtMS0xLTU5NDcw_b8c060dc-634b-4389-9f46-53f83f5a3907"
      unitRef="usd">10172000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0e89c666446a456f8cc98146608671d8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEyLTYtMS0xLTU5NDcw_aed31375-0413-48da-8791-1a37edfa74cb"
      unitRef="usd">429000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb811b454ce14d32b8a17a56eab234cf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEyLTgtMS0xLTU5NDcw_62ef4c05-a60d-4a05-a150-9e0217b7fa9c"
      unitRef="usd">-7452000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic0ab88b4629f472db1a3683caad4f40f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEyLTEwLTEtMS01OTQ3MA_93abca7b-f238-4537-9fac-0c5667087841"
      unitRef="usd">-2086000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id8e7ca9b32a444089dfd2ee008ffa4c5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEyLTEyLTEtMS01OTQ3MA_0dbd598d-4397-4f60-ac8f-fbba8db7b01f"
      unitRef="usd">1063000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3fdde09098974b0f8d7c802d8cb72514_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEyLTE0LTEtMS01OTQ3MA_14fc1960-f69a-4253-984a-6a656d920fac"
      unitRef="usd">73000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEyLTE2LTEtMS01OTQ3MA_fb8e3492-f756-43bb-8331-d70c0a1af58b"
      unitRef="usd">1136000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2ea97ac3ab7a4d41bb8383aabfb051e7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzExLTgtMS0xLTY2NjQz_cb096318-b3a5-45dd-9b1d-95d67eab5ae0"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i87b994e0a55b42d3b3861f596a5aef18_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzExLTEyLTEtMS02NjY0NQ_06321fbf-1032-4870-9b15-56d6c3394327"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff91afb1f5c540bea0a30d424217c405_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzExLTE2LTEtMS02NjY0Nw_cbf5e3b6-048d-4100-974b-c19ee9901d41"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if282715453074bb49b8bc1e448ad1f27_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEzLTItMS0xLTU5NDcw_fd11437f-d97c-4f7b-acd6-87c016788cbe"
      unitRef="shares">2800000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if282715453074bb49b8bc1e448ad1f27_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEzLTQtMS0xLTU5NDcw_e858db89-4134-4b1b-8331-80674b59860e"
      unitRef="usd">55000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibb6b2b32236f4217a22e698f5e6a29c8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEzLTYtMS0xLTU5NDcw_9d498fec-a192-460e-9081-76a5b2286a9e"
      unitRef="usd">-50000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="idaa3fc7070ff4e269eaf1141c23dfc90_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEzLTEyLTEtMS01OTQ3MA_af5979bc-2bf7-4d93-82ca-eee1b6cdc77a"
      unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzEzLTE2LTEtMS01OTQ3MA_6102e182-5d9e-464b-8e60-7a61cb48704d"
      unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibb6b2b32236f4217a22e698f5e6a29c8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE0LTYtMS0xLTU5NDcw_a0731b9d-90d6-4646-831d-f571ef377bcc"
      unitRef="usd">105000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idaa3fc7070ff4e269eaf1141c23dfc90_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE0LTEyLTEtMS01OTQ3MA_55e7b6cd-4b1a-41ba-9108-3004ed0597fd"
      unitRef="usd">105000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE0LTE2LTEtMS01OTQ3MA_5efc7670-334f-4897-9f31-a615eef97ac3"
      unitRef="usd">105000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ibb6b2b32236f4217a22e698f5e6a29c8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE1LTYtMS0xLTU5NDcw_623c2108-7b1d-48c8-9320-222c812d9094"
      unitRef="usd">30000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="idaa3fc7070ff4e269eaf1141c23dfc90_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE1LTEyLTEtMS01OTQ3MA_faa43e90-c0e2-4ef7-a7d6-04155b702b10"
      unitRef="usd">30000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE1LTE2LTEtMS01OTQ3MA_74f7c214-3aed-44d9-8d64-2884f02f80f2"
      unitRef="usd">30000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i93302786cb504c94b2b462b9a04d7347_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE2LTE0LTEtMS01OTQ3MA_71c7fa49-1c27-4ff3-bebf-a65a405457d7"
      unitRef="usd">6000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE2LTE2LTEtMS01OTQ3MA_4845bef4-fb2b-453a-ba53-dcd713576260"
      unitRef="usd">6000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="i580ae2bd45844451af6478654bd0361d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE3LTgtMS0xLTU5NDcw_4fa76625-b6f0-4030-83a3-24b49b6742a5"
      unitRef="usd">-560000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idaa3fc7070ff4e269eaf1141c23dfc90_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE3LTEyLTEtMS01OTQ3MA_14722cd7-91f1-4d1a-9d98-876fbb35e0d8"
      unitRef="usd">-560000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i93302786cb504c94b2b462b9a04d7347_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE3LTE0LTEtMS01OTQ3MA_3533fb92-36d0-4966-84c3-5775fddfd2b5"
      unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE3LTE2LTEtMS01OTQ3MA_2c6fee7d-c489-4dfa-b674-b05d833394a7"
      unitRef="usd">-559000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icaaee956f0c34101b241686ca5a47137_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE4LTEwLTEtMS01OTQ3MA_6e45bac9-47c0-4618-b4c3-2ea9641c4138"
      unitRef="usd">-47000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="idaa3fc7070ff4e269eaf1141c23dfc90_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE4LTEyLTEtMS01OTQ3MA_eac7d43d-2da7-4e1d-b010-059670019cb6"
      unitRef="usd">-47000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i93302786cb504c94b2b462b9a04d7347_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE4LTE0LTEtMS01OTQ3MA_c0098710-499e-495b-ae6b-ac833374e1e4"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE4LTE2LTEtMS01OTQ3MA_77e342ae-6365-4d03-b2ff-e8c0a295a17e"
      unitRef="usd">-45000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i60f8b472d50d403d9e1baa887a2f2095_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE5LTItMS0xLTU5NDcw_e044bca2-6b2d-47e0-be9e-60ad4ee326ad"
      unitRef="shares">355400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i60f8b472d50d403d9e1baa887a2f2095_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE5LTQtMS0xLTU5NDcw_2e7a8c1f-ee96-4872-9675-419451839eb9"
      unitRef="usd">10227000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibd238c564d9645d68c9bd1f4839b69dc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE5LTYtMS0xLTU5NDcw_b7f1b87e-3343-48a8-a579-2c45aae271b2"
      unitRef="usd">454000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1c869e99e66c44e3807c32b56fd85737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE5LTgtMS0xLTU5NDcw_ea795302-b00f-4589-b039-7d28bb054d8b"
      unitRef="usd">-8013000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i23e7ea6c4d584b7881937aede46315ca_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE5LTEwLTEtMS01OTQ3MA_4d7d06dd-17d8-485c-92fe-85b249935f93"
      unitRef="usd">-2133000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i02aa4e2b4a9143c4931349f2b24d03c9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE5LTEyLTEtMS01OTQ3MA_e815ed6d-3045-45e5-9e7d-d999029c0039"
      unitRef="usd">535000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3e02837ee6ab43329d534e55ff0d3d08_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE5LTE0LTEtMS01OTQ3MA_cfefee51-8e4b-4c34-ab09-9e1abab96ef7"
      unitRef="usd">70000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzE5LTE2LTEtMS01OTQ3MA_9fd875b3-b608-4b98-8110-bdc214867bc2"
      unitRef="usd">605000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i332cb35e6b1c4b4499193a2507f556ec_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIxLTItMS0xLTU5NDcw_32d21b7a-f3c7-4699-a571-716190588e08"
      unitRef="shares">4000000.0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i332cb35e6b1c4b4499193a2507f556ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIxLTQtMS0xLTU5NDcw_57d51eeb-66d6-4f62-b6d8-c477ef1f9bb6"
      unitRef="usd">90000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id69729faeee842779fac160c0f6b01cc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIxLTYtMS0xLTU5NDcw_8faf72a1-6315-4f64-bfbf-fa24878c563f"
      unitRef="usd">-68000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7d610c2d7c5741318c7b47c1fa5ff7aa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIxLTEyLTEtMS01OTQ3MA_fd914ce5-7cfb-4afe-931a-e03941844474"
      unitRef="usd">22000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIxLTE2LTEtMS01OTQ3MA_0aca5820-2565-4dd0-8a17-7155654b3446"
      unitRef="usd">22000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id69729faeee842779fac160c0f6b01cc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIyLTYtMS0xLTU5NDcw_a598082e-e106-47a8-8e23-26862390ce03"
      unitRef="usd">128000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7d610c2d7c5741318c7b47c1fa5ff7aa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIyLTEyLTEtMS01OTQ3MA_77fe6ba5-be70-4531-9d06-3bb9eed1866c"
      unitRef="usd">128000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIyLTE2LTEtMS01OTQ3MA_7689e360-5f16-4480-861a-f696726573c9"
      unitRef="usd">128000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id69729faeee842779fac160c0f6b01cc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIzLTYtMS0xLTU5NDcw_20146e64-6410-4159-b313-324ea8569675"
      unitRef="usd">52000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7d610c2d7c5741318c7b47c1fa5ff7aa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIzLTEyLTEtMS01OTQ3MA_2fa4086c-eea6-4e50-9198-041ba78df4cb"
      unitRef="usd">52000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIzLTE2LTEtMS01OTQ3MA_a5b9f960-e12d-4a16-bd11-34b6742a5226"
      unitRef="usd">52000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i8c4a367db2a74cd19dcf9139adee5405_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIyLTEwLTEtMS02ODgyMg_5bd621d2-3183-4491-8790-a25d1cc40393"
      unitRef="usd">340000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i7d610c2d7c5741318c7b47c1fa5ff7aa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIyLTEyLTEtMS03MTM1Mw_c8cd95c5-fa3c-4c0c-9b94-33c16c4ecd78"
      unitRef="usd">340000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzIyLTE2LTEtMS03MTM1NQ_1b9e45d9-2243-4182-8a8a-ee84a5567745"
      unitRef="usd">340000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i8729de31314e44b0be1473a123083daf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI0LTE0LTEtMS01OTQ3MA_2effdd9a-e017-47e3-8e80-8c018eb66182"
      unitRef="usd">10000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI0LTE2LTEtMS01OTQ3MA_aeab6305-1537-48d7-af8b-e513ded07c19"
      unitRef="usd">10000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="ibd9c5a5d9c13483ca438c56e8327e766_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI1LTgtMS0xLTU5NDcw_69690f06-1097-415e-99f1-5040a47cc175"
      unitRef="usd">-948000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7d610c2d7c5741318c7b47c1fa5ff7aa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI1LTEyLTEtMS01OTQ3MA_2218e1a6-b2ac-4e66-a34c-d0fc4b24cd84"
      unitRef="usd">-948000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8729de31314e44b0be1473a123083daf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI1LTE0LTEtMS01OTQ3MA_67494bdf-4aea-4195-aaf8-f10207c89dbf"
      unitRef="usd">11000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI1LTE2LTEtMS01OTQ3MA_1f3bd21b-522c-4e4d-918e-a5c1f0c9e204"
      unitRef="usd">-937000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8c4a367db2a74cd19dcf9139adee5405_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI2LTEwLTEtMS01OTQ3MA_e7304933-5240-4d44-b020-e2581ee2e2c1"
      unitRef="usd">-131000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7d610c2d7c5741318c7b47c1fa5ff7aa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI2LTEyLTEtMS01OTQ3MA_1cb00ed9-deb7-4d4a-8536-4f382763a876"
      unitRef="usd">-131000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8729de31314e44b0be1473a123083daf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI2LTE0LTEtMS01OTQ3MA_b33531c2-2dd0-4adc-83a8-d7f79daf9ca1"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI2LTE2LTEtMS01OTQ3MA_a2b4de3c-d600-462b-a922-8d593ea3b17c"
      unitRef="usd">-130000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib970daaae589497d899cb7d978be2dce_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI3LTItMS0xLTU5NDcw_a47bb932-f4c5-4084-a0d4-4cc265dc61b1"
      unitRef="shares">359400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib970daaae589497d899cb7d978be2dce_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI3LTQtMS0xLTU5NDcw_13cf2db2-b57b-4915-bfa0-fa025bbc9849"
      unitRef="usd">10317000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i141129182749408e9635a2af36209722_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI3LTYtMS0xLTU5NDcw_b9cbb410-d2f2-421a-8d23-4c5856cb8fa9"
      unitRef="usd">462000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icfd2e58d530c456aa77e190e8c786ffa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI3LTgtMS0xLTU5NDcw_efa9b60b-6c5e-43fa-bbd2-e09d276951bc"
      unitRef="usd">-8961000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie17ca1996294497e9f031629ce871dae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI3LTEwLTEtMS01OTQ3MA_3420cfc9-b5ef-4a7f-9f69-d6649201aab5"
      unitRef="usd">-1924000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i030df36b6a574871b8a132326549d4ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI3LTEyLTEtMS01OTQ3MA_6a1f7091-748b-4c39-b736-5e71a62102aa"
      unitRef="usd">-106000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ee9a6d8577c4318bf54609562d4c3e2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI3LTE0LTEtMS01OTQ3MA_e68769ce-c5cf-44cc-b7ac-879a6d7699a6"
      unitRef="usd">72000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODkvZnJhZzphNGFiZGM3OTAwY2E0ZWZlOWE1ZGNjZTY1ZTEyMTg3ZC90YWJsZTo4NzU3YmU5ZGExYzc0ZmYyYjQzYWUyMTE0MGMxN2ExMy90YWJsZXJhbmdlOjg3NTdiZTlkYTFjNzRmZjJiNDNhZTIxMTQwYzE3YTEzXzI3LTE2LTEtMS01OTQ3MA_2e2f246b-0504-4af7-aed3-b0174214e768"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMtMi0xLTEtNTk0NzA_4d6b8599-a167-40cc-a3f9-8411657495fa"
      unitRef="usd">-937000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMtNC0xLTEtNTk0NzA_b0f0b00b-996c-419e-813a-6c958dc4b975"
      unitRef="usd">-559000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMtNi0xLTEtNTk0NzA_4570e912-b823-475b-a4ec-4ac16a89f473"
      unitRef="usd">-1783000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUtMi0xLTEtNTk0NzA_1ada3489-f77f-409a-90cb-1418b2706f8e"
      unitRef="usd">1552000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUtNC0xLTEtNTk0NzA_d5df4677-c0a1-4bf7-8a35-eec821ea54a8"
      unitRef="usd">1825000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUtNi0xLTEtNTk0NzA_b3d87f02-2619-4110-9e57-53d166018fd2"
      unitRef="usd">2075000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzYtMi0xLTEtNTk0NzA_0d39f42a-5329-4921-be49-2efba5812b9a"
      unitRef="usd">55000000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzYtNC0xLTEtNTk0NzA_2e7287bd-1a61-4c06-af58-45205d24d486"
      unitRef="usd">61000000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzYtNi0xLTEtNTk0NzA_f7eec4b6-e2f2-4dd3-b589-83cd71cb8a10"
      unitRef="usd">63000000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AssetImpairmentCharges
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzctMi0xLTEtNTk0NzA_b93dce3f-e470-4b4f-8d9f-7c1b7b088250"
      unitRef="usd">234000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzctNC0xLTEtNTk0NzA_5a02892f-bf43-4074-a1f2-dd2c51ca26da"
      unitRef="usd">114000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzctNi0xLTEtNTk0NzA_ec1cab68-859d-49f2-92b1-8db993e42e95"
      unitRef="usd">75000000</us-gaap:AssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzgtMi0xLTEtNTk0NzA_aa1b7407-d894-49b6-bcab-7d7c3581d88c"
      unitRef="usd">469000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzgtNC0xLTEtNTk0NzA_15730ed5-540c-4712-a1f8-d8787afb3cb4"
      unitRef="usd">0</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzgtNi0xLTEtNTk0NzA_5fb2ea4a-d187-4b4b-bc82-059470c0c1ec"
      unitRef="usd">0</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzktMi0xLTEtNTk0NzA_7ce77577-eb90-4734-921f-a48d6d5b0cc9"
      unitRef="usd">11000000</bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash>
    <bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzktNC0xLTEtNTk0NzA_c6cd3496-0df8-4825-b9c2-7af751e47e83"
      unitRef="usd">48000000</bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash>
    <bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzktNi0xLTEtNTk0NzA_3db63d10-40e1-432a-a49e-e1861c7b2542"
      unitRef="usd">12000000</bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash>
    <bhc:AllowancesForLossesOnAccountsReceivableAndInventories
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzEwLTItMS0xLTU5NDcw_db2f80ef-c2d5-4d0a-bfb0-1c9fcbb9bf49"
      unitRef="usd">60000000</bhc:AllowancesForLossesOnAccountsReceivableAndInventories>
    <bhc:AllowancesForLossesOnAccountsReceivableAndInventories
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzEwLTQtMS0xLTU5NDcw_2d8eb3b3-b385-41fe-b90e-d1f7fe51e837"
      unitRef="usd">60000000</bhc:AllowancesForLossesOnAccountsReceivableAndInventories>
    <bhc:AllowancesForLossesOnAccountsReceivableAndInventories
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzEwLTYtMS0xLTU5NDcw_80112040-bfbf-4f69-a65d-bd833a7055e1"
      unitRef="usd">75000000</bhc:AllowancesForLossesOnAccountsReceivableAndInventories>
    <bhc:DeferredIncomeTaxNoncashExpenseBenefit
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzExLTItMS0xLTU5NDcw_bec37127-4645-42f8-aaab-00a77c2f2bc7"
      unitRef="usd">-225000000</bhc:DeferredIncomeTaxNoncashExpenseBenefit>
    <bhc:DeferredIncomeTaxNoncashExpenseBenefit
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzExLTQtMS0xLTU5NDcw_078092d7-c479-4228-9f5a-453d99372e87"
      unitRef="usd">-475000000</bhc:DeferredIncomeTaxNoncashExpenseBenefit>
    <bhc:DeferredIncomeTaxNoncashExpenseBenefit
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzExLTYtMS0xLTU5NDcw_ceb94b44-9af3-4a4f-aa2b-a481f0ddcfcc"
      unitRef="usd">-230000000</bhc:DeferredIncomeTaxNoncashExpenseBenefit>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzEyLTItMS0xLTU5NDcw_8319c4fb-e1f4-4eca-9d1a-1a96cf449181"
      unitRef="usd">2000000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzEyLTQtMS0xLTU5NDcw_1785037c-4699-459e-9051-a43bb15516b4"
      unitRef="usd">1000000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzEyLTYtMS0xLTU5NDcw_4a9f67a2-cadc-49ca-bd8f-a5b373b76509"
      unitRef="usd">31000000</us-gaap:GainLossOnDispositionOfAssets>
    <bhc:GainLossRelatedToLitigationSettlementGross
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzEzLTItMS0xLTU5NDcw_75119013-fb96-4f57-b13d-d8ca76ea2abf"
      unitRef="usd">-569000000</bhc:GainLossRelatedToLitigationSettlementGross>
    <bhc:GainLossRelatedToLitigationSettlementGross
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzEzLTQtMS0xLTU5NDcw_16cae596-b55f-4ed3-8279-8d2fe56836a7"
      unitRef="usd">-442000000</bhc:GainLossRelatedToLitigationSettlementGross>
    <bhc:GainLossRelatedToLitigationSettlementGross
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzEzLTYtMS0xLTU5NDcw_293887d8-59d8-4987-a3cb-e70060c1514f"
      unitRef="usd">-1401000000</bhc:GainLossRelatedToLitigationSettlementGross>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE0LTItMS0xLTU5NDcw_a6ea0a9c-4fa6-4ce2-8d71-cb56d932729c"
      unitRef="usd">351000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE0LTQtMS0xLTU5NDcw_477f10ae-1dc0-4c22-85d0-a284a182b9ba"
      unitRef="usd">168000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE0LTYtMS0xLTU5NDcw_64984f8d-af3b-444f-b5d5-dc054f5314af"
      unitRef="usd">15000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:ShareBasedCompensation
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE1LTItMS0xLTU5NDcw_cef6271c-f1f6-4602-9c16-7c393f1062f1"
      unitRef="usd">128000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE1LTQtMS0xLTU5NDcw_be08dcb5-0509-4f70-a6e9-bfe88af95876"
      unitRef="usd">105000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE1LTYtMS0xLTU5NDcw_d5d6e3e8-0459-4f56-9bac-4d0354f3b06e"
      unitRef="usd">102000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE2LTItMS0xLTU5NDcw_54745a3f-4df2-4b34-9ae9-159926e1065d"
      unitRef="usd">-6000000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE2LTQtMS0xLTU5NDcw_7a95514a-e029-45a5-b777-f9b54626b5e1"
      unitRef="usd">-8000000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE2LTYtMS0xLTU5NDcw_f8ba9e6d-ddad-463a-b6ba-7453169f3623"
      unitRef="usd">-7000000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <bhc:DerivativeGainExcludedComponent
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE3LTItMS0xLTU5NDcw_030db108-ba1c-4d09-ace0-6c0960a029a8"
      unitRef="usd">20000000</bhc:DerivativeGainExcludedComponent>
    <bhc:DerivativeGainExcludedComponent
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE3LTQtMS0xLTU5NDcw_dc2c0960-0026-492b-ac2a-00e44e5a7784"
      unitRef="usd">23000000</bhc:DerivativeGainExcludedComponent>
    <bhc:DerivativeGainExcludedComponent
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE3LTYtMS0xLTU5NDcw_724a7d91-bcfb-4172-aaf2-4cb8bbf8ad98"
      unitRef="usd">9000000</bhc:DerivativeGainExcludedComponent>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE4LTItMS0xLTU5NDcw_47e71a10-f919-4de4-85ff-fc61e1181d65"
      unitRef="usd">-62000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE4LTQtMS0xLTU5NDcw_146d596f-a6fb-466a-94b3-aa43cfa7ec88"
      unitRef="usd">-59000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE4LTYtMS0xLTU5NDcw_035b6368-54cc-41d8-8adb-4493ca4cfc93"
      unitRef="usd">-42000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE5LTItMS0xLTU5NDcw_d55b702b-25ac-41ea-a18e-812ae1d0650f"
      unitRef="usd">16000000</bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities>
    <bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE5LTQtMS0xLTU5NDcw_3d5abae1-329b-43e9-800b-81c2bad7efe7"
      unitRef="usd">1000000</bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities>
    <bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzE5LTYtMS0xLTU5NDcw_6c7d86e8-0326-4f85-9c56-3c84aba2894f"
      unitRef="usd">1000000</bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzIwLTItMS0xLTU5NDcw_80da6c1e-5f9b-4120-99c1-6152f78b932c"
      unitRef="usd">41000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzIwLTQtMS0xLTU5NDcw_be76c20a-fe47-4e84-b349-c8e237aa18ad"
      unitRef="usd">18000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzIwLTYtMS0xLTU5NDcw_7a24874e-4acb-4d43-a0ae-64ac4e2dbd35"
      unitRef="usd">-36000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzIyLTItMS0xLTU5NDcw_52d9edc9-f40e-4e35-a972-9f9362934dd7"
      unitRef="usd">229000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzIyLTQtMS0xLTU5NDcw_63a7c944-13d1-40fa-af20-928f879935ce"
      unitRef="usd">-170000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzIyLTYtMS0xLTU5NDcw_e4bd1589-2a06-4925-aeb6-52477491803c"
      unitRef="usd">-39000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzIzLTItMS0xLTU5NDcw_ac4fa1cf-3b7c-49b9-bdc2-87ca23361fb5"
      unitRef="usd">16000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzIzLTQtMS0xLTU5NDcw_58dcbb47-0241-40cf-90b9-4761364fe4c9"
      unitRef="usd">77000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzIzLTYtMS0xLTU5NDcw_2d7bc5fd-d650-46dc-81df-8635d1852503"
      unitRef="usd">209000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI0LTItMS0xLTU5NDcw_0c3766be-5bbf-4981-8f31-681db60cc792"
      unitRef="usd">4000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI0LTQtMS0xLTU5NDcw_644bed6a-1ba4-4544-8fed-b8ceb987369d"
      unitRef="usd">-12000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI0LTYtMS0xLTU5NDcw_740bbbc3-1593-44db-8df4-246c04ea0de2"
      unitRef="usd">-1000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI1LTItMS0xLTU5NDcw_f8a44d9d-fa49-4ddc-90e6-e73d858f9580"
      unitRef="usd">121000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI1LTQtMS0xLTU5NDcw_8d868153-00d1-467d-a417-bdcdb9f20477"
      unitRef="usd">-471000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI1LTYtMS0xLTU5NDcw_bc145763-6317-4fba-8c74-0261a06f4e89"
      unitRef="usd">-149000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI2LTItMS0xLTU5NDcw_d2725eae-f390-4610-adb5-5f16f74922dc"
      unitRef="usd">1426000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI2LTQtMS0xLTU5NDcw_2f2b56eb-4702-4d15-80a4-05e56107060b"
      unitRef="usd">1111000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI2LTYtMS0xLTU5NDcw_05fc728f-48b5-4be5-bdd1-bc28a9481ecd"
      unitRef="usd">1501000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI4LTItMS0xLTU5NDcw_5d42665c-f263-46dc-9e95-e9663126e981"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI4LTQtMS0xLTU5NDcw_567ad31e-9460-47d9-b1f1-18a075a3ca95"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI4LTYtMS0xLTU5NDcw_5bcab14e-de30-4993-8b76-7ccf90da2dc1"
      unitRef="usd">180000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI5LTItMS0xLTU5NDcw_ed1baf6a-5828-487c-b608-df527d13e067"
      unitRef="usd">14000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI5LTQtMS0xLTU5NDcw_fdb81ce1-85c1-438e-a6f3-a7006e26da34"
      unitRef="usd">7000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzI5LTYtMS0xLTU5NDcw_ae0fbb52-a803-4cbc-877f-026ac6be11b7"
      unitRef="usd">8000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMwLTItMS0xLTU5NDcw_9f7a3f71-2c3e-4aec-b85d-429e86b74525"
      unitRef="usd">269000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMwLTQtMS0xLTU5NDcw_555dd7a9-cc37-48ca-aea7-91b2497d6e9f"
      unitRef="usd">302000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMwLTYtMS0xLTU5NDcw_32413a98-7996-4b94-93df-012e3987bc6a"
      unitRef="usd">270000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMxLTItMS0xLTU5NDcw_27f5e259-3dbe-42de-bae2-1bb00f524da4"
      unitRef="usd">19000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMxLTQtMS0xLTU5NDcw_ba02451c-0837-4066-9c5a-e089f6d95972"
      unitRef="usd">4000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMxLTYtMS0xLTU5NDcw_5cbe52bd-9af5-4e15-9338-161e5c2ba3a4"
      unitRef="usd">16000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMyLTItMS0xLTU5NDcw_c9643adf-a2e2-4aba-91b7-649d4590f6d8"
      unitRef="usd">15000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMyLTQtMS0xLTU5NDcw_eb4db3ef-efda-4d91-a46c-65ddf62391b8"
      unitRef="usd">8000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMyLTYtMS0xLTU5NDcw_5b17fbd6-85c8-4b43-bf91-a92ef54f48ea"
      unitRef="usd">10000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMzLTItMS0xLTU5NDcw_5477f053-8ea9-4e5b-82cd-1b0f00996ff8"
      unitRef="usd">669000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMzLTQtMS0xLTU5NDcw_08950045-c81a-4ed0-ae87-117850ad41df"
      unitRef="usd">21000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzMzLTYtMS0xLTU5NDcw_23b58c6d-01e5-4719-880d-5ea3bce65a35"
      unitRef="usd">45000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <bhc:InterestSettlementOnCrossCurrencySwaps
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM0LTItMS0xLTU5NDcw_a4ef0812-ed81-49f3-8588-f60e99b58653"
      unitRef="usd">27000000</bhc:InterestSettlementOnCrossCurrencySwaps>
    <bhc:InterestSettlementOnCrossCurrencySwaps
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM0LTQtMS0xLTU5NDcw_6e01bf10-5c96-4b1c-a745-9f30d8720b0a"
      unitRef="usd">23000000</bhc:InterestSettlementOnCrossCurrencySwaps>
    <bhc:InterestSettlementOnCrossCurrencySwaps
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM0LTYtMS0xLTU5NDcw_75ff7b12-11b2-47f3-8a5c-d3e304496ae4"
      unitRef="usd">0</bhc:InterestSettlementOnCrossCurrencySwaps>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM1LTItMS0xLTU5NDcw_ddd796d3-a579-49c4-b472-e38f0fe21171"
      unitRef="usd">409000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM1LTQtMS0xLTU5NDcw_fa022c6b-fd27-43ad-a0d6-3465fb644a4e"
      unitRef="usd">-261000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM1LTYtMS0xLTU5NDcw_4f5d8ad6-9d64-464a-8941-565d64bff3b9"
      unitRef="usd">-419000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM3LTItMS0xLTU5NDcw_d897ddc9-245c-4971-aa15-bb47d92d8ca9"
      unitRef="usd">2100000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM3LTQtMS0xLTU5NDcw_1c51a1f9-84b2-4ad8-a78b-5d703e770761"
      unitRef="usd">3455000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM3LTYtMS0xLTU5NDcw_60c77621-df6f-4f8d-83e0-f0af6dc1fbdb"
      unitRef="usd">5960000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM4LTItMS0xLTU5NDcw_a774be4b-7804-4a90-9063-e5a3cba3a813"
      unitRef="usd">3440000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM4LTQtMS0xLTU5NDcw_ac2961f8-8ade-47d8-95ca-6cacfbe95b40"
      unitRef="usd">5642000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM4LTYtMS0xLTU5NDcw_36561e3b-0478-41a6-9f5c-1a2bbb8d997c"
      unitRef="usd">4406000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM5LTItMS0xLTU5NDcw_8e9e2426-f81c-4f82-ab86-47fa664bf4c9"
      unitRef="usd">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM5LTQtMS0xLTU5NDcw_58f68a0c-e85a-4b83-b9ce-52bc40b63ade"
      unitRef="usd">1000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzM5LTYtMS0xLTU5NDcw_f5deb1a2-8278-4c49-8f5f-ebb7fc727f6d"
      unitRef="usd">12000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQwLTItMS0xLTU5NDcw_33b042ba-f12d-420f-8fec-524f17b286a3"
      unitRef="usd">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQwLTQtMS0xLTU5NDcw_e4566b08-1ac3-4bde-ad49-b7911cd9abea"
      unitRef="usd">1000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQwLTYtMS0xLTU5NDcw_44255a77-bfbe-40d2-b46c-2f53d1a61ca3"
      unitRef="usd">12000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQxLTItMS0xLTU5NDcw_3e1e0231-faae-4cca-bf5f-8501857840e6"
      unitRef="usd">52000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQxLTQtMS0xLTU5NDcw_1fbe83ab-f36c-4194-9826-c926027d9e5c"
      unitRef="usd">30000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQxLTYtMS0xLTU5NDcw_2ff8b4e7-9c2e-4735-bc47-9211991e6315"
      unitRef="usd">40000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQyLTItMS0xLTU5NDcw_a3f8e4d3-482b-4688-b5f5-560e42621959"
      unitRef="usd">83000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQyLTQtMS0xLTU5NDcw_01317ea8-20fe-487b-93a1-b83ddd969eba"
      unitRef="usd">35000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQyLTYtMS0xLTU5NDcw_13913fe1-8e28-450c-962a-f24e2cda1544"
      unitRef="usd">35000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ0LTItMS0xLTU5NDcw_8db45868-de7e-4ca0-8e4a-7245540fa8a2"
      unitRef="usd">48000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ0LTQtMS0xLTU5NDcw_48bf011d-130a-49d2-9c9f-a4659d51e304"
      unitRef="usd">39000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ0LTYtMS0xLTU5NDcw_0ed2ec64-2c67-4efd-ab50-d0abd4fd9783"
      unitRef="usd">28000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ1LTItMS0xLTU5NDcw_d76c2662-6728-4cb1-bd72-2650cb29cc8d"
      unitRef="usd">10000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ1LTQtMS0xLTU5NDcw_296e6c40-f1ae-4e6c-9ca0-65cb340a2499"
      unitRef="usd">-3000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ1LTYtMS0xLTU5NDcw_32bfce0c-4e33-4683-bd10-851fd5952df7"
      unitRef="usd">-8000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ2LTItMS0xLTU5NDcw_ee4e0f23-8cee-4543-b415-6d387f6f3523"
      unitRef="usd">-1513000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ2LTQtMS0xLTU5NDcw_e3646952-301f-4d7c-9cab-dc3c07774126"
      unitRef="usd">-2294000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ2LTYtMS0xLTU5NDcw_1c062c6e-684b-4094-80fb-0871bc76be05"
      unitRef="usd">1443000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ3LTItMS0xLTU5NDcw_032b5561-78bf-40c3-98a6-ae3a7eb9505f"
      unitRef="usd">-19000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ3LTQtMS0xLTU5NDcw_2925f622-4812-4a67-b3db-cb73fb26bcfc"
      unitRef="usd">16000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ3LTYtMS0xLTU5NDcw_930f6a98-1c37-40c8-b999-8f918dcecd4c"
      unitRef="usd">-4000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ4LTItMS0xLTU5NDcw_04819823-fc62-421d-87a5-012a7ca396d6"
      unitRef="usd">303000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ4LTQtMS0xLTU5NDcw_5b755ac3-52ce-4342-a459-a853074cce11"
      unitRef="usd">-1428000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ4LTYtMS0xLTU5NDcw_034efbbb-bccb-4548-86da-735f0c759dff"
      unitRef="usd">2521000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ5LTItMS0xLTU5NDcw_f56bbd4d-c969-4832-a5a1-5682682dabf9"
      unitRef="usd">1816000000</bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits>
    <bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits
      contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ5LTQtMS0xLTU5NDcw_e74153a5-94ce-4f8b-b88a-cf06e1175d0a"
      unitRef="usd">3244000000</bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits>
    <bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits
      contextRef="i88a9900560564bdca7dec25381689c13_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzQ5LTYtMS0xLTU5NDcw_dde3a2bd-7d1d-4101-8ebc-8b58b7880eb2"
      unitRef="usd">723000000</bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits>
    <bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUwLTItMS0xLTU5NDcw_856fb697-9917-4dd5-a0a8-fc8d111ea128"
      unitRef="usd">2119000000</bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits>
    <bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUwLTQtMS0xLTU5NDcw_3c06a303-5503-47bc-8aef-b9a2e61a7385"
      unitRef="usd">1816000000</bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits>
    <bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits
      contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUwLTYtMS0xLTU5NDcw_c9ef9393-0c9f-4641-9070-40230bb63459"
      unitRef="usd">3244000000</bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUyLTItMS0xLTU5NDcw_4cd7f632-7461-4cd6-8485-3ceace812f1d"
      unitRef="usd">582000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUyLTQtMS0xLTU5NDcw_6b7e0dc0-4836-4870-934a-2bcf4734c442"
      unitRef="usd">605000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUyLTYtMS0xLTU5NDcw_832a9546-9877-484d-b44d-1c8399c5f9c0"
      unitRef="usd">3243000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUzLTItMS0xLTU5NDcw_9b02b544-edc6-4a46-92d9-882df5090cbb"
      unitRef="usd">1537000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUzLTQtMS0xLTU5NDcw_44f96318-221b-44d9-850f-7032347a2406"
      unitRef="usd">1211000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzUzLTYtMS0xLTU5NDcw_bf6ee8b2-08c2-48a8-baaa-9692a4c54237"
      unitRef="usd">1000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzU0LTItMS0xLTU5NDcw_862e635f-d101-406a-b9ea-1f7c5c114325"
      unitRef="usd">2119000000</bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits>
    <bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzU0LTQtMS0xLTU5NDcw_87f9e4f8-2446-46a3-826c-fb9f91e039f3"
      unitRef="usd">1816000000</bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits>
    <bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits
      contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yOTUvZnJhZzo1YmE4OTNhNjIzNTI0ZjZjOWM5NTg0MGE5NGJiMDk3ZC90YWJsZTphNTg1NzNhYWNlNDY0NjkyOTkzNmY4YzJjZThhNmFlNC90YWJsZXJhbmdlOmE1ODU3M2FhY2U0NjQ2OTI5OTM2ZjhjMmNlOGE2YWU0XzU0LTYtMS0xLTU5NDcw_dc172e07-3f9d-4856-9e59-091fd310217f"
      unitRef="usd">3244000000</bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits>
    <us-gaap:NatureOfOperations
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDEvZnJhZzoxMGY1ODBjZjIyM2U0OTExYmU3MGUyYmYxMDViNDBlZS90ZXh0cmVnaW9uOjEwZjU4MGNmMjIzZTQ5MTFiZTcwZTJiZjEwNWI0MGVlXzEwOTM_a78610dc-f94b-4fd5-939c-4d63ca997c55">DESCRIPTION OF BUSINESSBausch Health Companies Inc. (the &#x201c;Company&#x201d;), formerly known as Valeant Pharmaceuticals International, Inc.,  is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#x201c;OTC&#x201d;) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in approximately 100 countries.  Effective August 9, 2013, the Company continued from the federal jurisdiction of Canada to the Province of British Columbia, meaning that the Company became a company registered under the laws of the Province of British Columbia as if it had been incorporated under the laws of the Province of British Columbia. As a result of this continuance, the legal domicile of the Company became the Province of British Columbia, the Canada Business Corporations Act ceased to apply to the Company and the Company became subject to the British Columbia Business Corporations Act.</us-gaap:NatureOfOperations>
    <us-gaap:NumberOfCountriesInWhichEntityOperates
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDEvZnJhZzoxMGY1ODBjZjIyM2U0OTExYmU3MGUyYmYxMDViNDBlZS90ZXh0cmVnaW9uOjEwZjU4MGNmMjIzZTQ5MTFiZTcwZTJiZjEwNWI0MGVlXzUwNg_b81e6f0e-527b-4346-9d30-74c488f7cef2"
      unitRef="country">100</us-gaap:NumberOfCountriesInWhichEntityOperates>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NjM0_b01fe64c-e7c5-4d6a-9d55-a1b149d1b1e0">SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements have been prepared by the Company in United&#160;States (&#x201c;U.S.&#x201d;) dollars and in accordance with U.S.&#160;generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;), applied on a consistent basis. The Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Separation of the Bausch + Lomb Eye-Health Business and Initial Public Offering of Solta Medical Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 6, 2020, the Company announced its intentions to separate its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc. (the &#x201c;B+L Separation&#x201d;). On August 3, 2021, the Company announced its intentions to conduct an initial public offering ("IPO") of its aesthetic medical device business, Global Solta (the &#x201c;Solta IPO").  In January 2022, the Company completed the internal organizational design and structure of the new eye-health entity, Bausch + Lomb Corporation ("Bausch + Lomb"), and the new Global Solta entity, Solta Medical Corporation ("Solta"), as previously announced and aims to launch the B+L IPO and the Solta IPO when financial market conditions are favorable (and subject to receipt of regulatory, stock exchange and other approvals). Following the B+L IPO the Company expects to complete the separation of Bausch + Lomb after the expiry of customary lockups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to the receipt of applicable shareholder and other necessary approvals. The B+L Separation and the proposed Solta IPO will establish three separate companies that include: (i) a fully integrated eye-health company which will consist of the Company&#x2019;s Bausch + Lomb Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmic Pharmaceuticals businesses, (ii) a global provider of aesthetic medical devices which will consist of the Company&#x2019;s Solta business and (iii) a diversified pharmaceutical company which will include the Company&#x2019;s Salix, International Rx, dentistry, neurology, medical dermatology and generics pharmaceutical businesses. These audited Consolidated Financial Statements do not include any adjustments to give effect to either the B+L Separation or the proposed Solta IPO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impacts of COVID-19 Pandemic&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unprecedented nature of the COVID-19 pandemic has, and continues to, adversely impact the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facility closures and production suspensions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which these events may continue to impact the Company's business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company's control. Such developments include the availability and effectiveness of vaccines for the COVID-19 virus, COVID-19 vaccine immunization rates, the ultimate geographic spread and duration of the pandemic, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, such as the delta and omicron variants, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company's business, financial condition, cash flows and results of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing. Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In preparing the Company's Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows.  The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of amortizable intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants and making going concern assessments; reporting unit fair values for testing goodwill for impairment and allocating goodwill to new reporting unit structure on a relative fair value basis; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; fair value of cross-currency swaps; fair value of foreign currency exchange contracts; and the recognition of the fair value of assets and liabilities acquired in a business combination, including the fair value of contingent consideration. Under certain product manufacturing and supply agreements, management uses information from the Company&#x2019;s commercialization counterparties to arrive at estimates for future returns, rebates and chargebacks. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#x2019;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#x2019;s Consolidated Financial Statements could be materially impacted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior year amounts to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisitions &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Consolidated Financial Statements after the date of acquisition.  Acquired in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;amp;D has an alternative future use. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;amp;D with no alternative future use is charged to expense at the acquisition&#160;date and any future contingent consideration is not recorded until it becomes probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair values of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities approximate their carrying values due to their short maturity periods. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows or Monte Carlo Simulation (when appropriate) analyses and assessment of the probability of occurrence of potential future events. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cross-currency swaps qualified for and had been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and were remeasured at each reporting date to reflect changes in their &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fair values.  The fair value was determined via a mark-to-market analysis, using observable (Level&#160;2) inputs. These inputs included: (i)&#160;the foreign currency exchange spot rate between the euro and U.S. dollar, (ii)&#160;the interest rate yield curves in the euro and U.S. dollar and (iii)&#160;the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Loss as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulated other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps was ineffective. The Company uses the spot method of assessing hedge effectiveness. The Company had elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as a reduction of Interest expense in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses foreign currency exchange contracts to economically hedge the foreign exchange exposure on certain of the Company&#x2019;s intercompany and third party balances. The Company's foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash in bank accounts and highly liquid investments with maturities of three months or less when&#160;purchased.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, cross-currency swaps and foreign currency exchange contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests its excess cash in high-quality, money market instruments and term deposits with varying maturities, but typically less than three months.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash deposited at banks may exceed the amount of insurance provided on such deposits. Generally, these cash deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate such risks by spreading its risk across multiple counterparties and monitoring the risk profiles of these counterparties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s trade receivables primarily represent amounts due from wholesale distributors, retail pharmacies, government entities and group purchasing organizations. Outside of the U.S., concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the number of customers using the Company&#x2019;s products, as well as their dispersion across many different geographic regions. The Company performs periodic credit evaluations of customers and does not require collateral. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The credit and economic conditions within Argentina, Brazil, Egypt, Greece, among other members of the European Union, Turkey, Ukraine and Venezuela have been weak in recent years. These conditions have increased, and may continue to increase, the average length of time that it takes to collect on the Company&#x2019;s trade receivables outstanding in these countries. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the Company&#x2019;s three largest U.S. wholesaler customers accounted for approximately 44% of net trade receivables. In addition, as of December 31, 2021 and 2020, the Company&#x2019;s net trade receivable balance from Argentina, Brazil, Egypt, Greece, Serbia, South Africa, Turkey, Ukraine, Venezuela and Vietnam amounted to $78 million and $166&#160;million, respectively, the majority of which is current or less than 90 days past due. The portion of the net trade receivable from these countries that is past due more than 90&#160;days amounted to $2 million, as of December 31, 2021, a portion of which is comprised of public hospitals.  Based on an analysis of credit risk, including an analysis of bad debt experience and assessment of historical payment patterns for such customers, the Company has established a reserve covering more than half of the balance past due more than 90 days for such countries. Over the three-year period ended December&#160;31, 2021, the Company has not experienced any material losses from uncollectible accounts in excess of the established reserves.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not enter into financial instruments for trading or speculative purposes. Further, the Company has a policy of only entering into contracts with parties that have at least an investment grade credit rating. The Company enters into cross-currency swaps and foreign currency exchange contracts with high credit quality financial institutions. The counter-parties to the Company's cross-currency swaps and foreign currency exchange contracts are major financial institutions, and there is no significant concentration of exposure with any one counter-party. To date, no counterparty has failed to meet its obligations to the Company and management believes the risk of loss associated with these contracts is &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;remote.  See Note 5, "FAIR VALUE MEASUREMENTS" for additional details regarding the Company's cross-currency swaps and foreign currency exchange contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160; Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. Allowance for credit losses were $35 million, $39 million and $48&#160;million as of December 31, 2021, 2020 and 2019, respectively. The activity in the allowance for credit losses for trade receivables for the years 2021, 2020 and 2019 is as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.199%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retrospective effect of application of new accounting standard&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories comprise raw materials, work in process and finished goods, which are valued at the lower of cost or net realizable value, on a first-in, first-out basis. The cost value for work in process and finished goods inventories includes materials, direct labor and an allocation of overheads. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on&#160;hand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are reported at cost, less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction in progress. Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful&#160;lives: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15 - 30 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 40 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;-&#160;20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;-&#160;10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment on operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of term of lease or 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reported at cost, less accumulated amortization and impairments. Intangible assets with finite lives are amortized over their estimated useful lives. Amortization is calculated primarily using the straight-line method based on the following estimated useful&#160;lives:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4 - 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 - 9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Out-licensed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8 - 9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Divestitures of Products&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net proceeds on the divestiture of products and the carrying amount of the related assets is recorded as a gain/loss on sale within Other expense, net. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when realizable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IPR&amp;amp;D &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of IPR&amp;amp;D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and&#160;amortized. Acquired IPR&amp;amp;D assets are tested for impairment at least annually or when triggering events are identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of an acquired IPR&amp;amp;D intangible asset is typically determined using an income approach. This approach starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#x2019;s stage of completion, the probability of technical success, the projected costs to complete, expected market competition and an assessment of the asset&#x2019;s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the expected cash flow&#160;streams.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.  If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset, which include the amount and timing of the projected future cash flows. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash&#160;flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets, which includes acquired IPR&amp;amp;D and the corporate trademark acquired in the acquisition of Bausch &amp;amp; Lomb Holdings Incorporated (the &#x2018;&#x2018;B&amp;amp;L Trademark&#x2019;&#x2019;), are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based on a comparison of the fair value of the asset to its carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. Goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value. A reporting unit is the same as, or one level below, an operating segment. A&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n entity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is permitted to first assess qualitatively whether it is necessary to perform a quantitative impairment test for any of its reporting units. The quantitative impairment test is required only when the Company concludes that it is more likely than not that a reporting unit&#x2019;s fair value is less than its carrying amount. In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company considers the totality of all relevant events or circumstances that affect the fair value or carrying amount of a reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company&#x2019;s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, among other factors, the Company monitors &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;changes in its share price between annual impairment tests. The Company considers a decline in its share price that corresponds to an overall deterioration in stock market conditions to be less of an indicator of goodwill impairment than a unilateral decline in its share price reflecting adverse changes in its underlying operating performance, cash flows, financial condition and/or liquidity. In the event that the Company&#x2019;s market capitalization does decline below its book value, the Company would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. The Company believes that short-term fluctuations in share prices may not necessarily reflect underlying values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt discounts, premiums and issuance costs are presented in the Consolidated Balance Sheets as a direct deduction from or addition to the carrying amount of the related debt and are amortized or accreted, using the effective interest method, as interest expense over the contractual lives of the related credit facilities or notes. Deferred financing costs associated with revolving credit facility arrangements are included in the balances of Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets and are amortized as interest expense over the contractual life of the related revolving credit facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities of the Company&#x2019;s foreign operations having a functional currency other than the U.S.&#160;dollar are translated into U.S.&#160;dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency exchange gains and losses on transactions occurring in a currency other than an operation&#x2019;s functional currency are recognized as a component of Foreign exchange and other in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye-health, gastroenterology ("GI") and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 22, "SEGMENT INFORMATION" for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services.  To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A contract with the Company&#x2019;s customers exists for each product sale.  Where a contract with a customer contains more than one performance obligation, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The transaction price is adjusted for variable consideration which is discussed below.  The Company generally recognizes revenue for product sales at a point in time, when the customer obtains control of the products.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160; The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers.  Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the activity and ending balances of the Company&#x2019;s variable consideration provisions the years 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,909)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $36 million and $32 million as of December 31, 2021 and 2020, respectively, which are reflected as a reduction of Trade accounts receivable, net in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company's products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis.  This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#x2019;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period.  The Company applies this method consistently for contracts with similar characteristics.  The following describes the major sources of variable consideration in the Company&#x2019;s customer arrangements and the methodology, estimates and judgments applied to estimate each type of variable consideration.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash discounts are offered for prompt payment and allowances for volume purchases. Provisions for cash discounts and allowances are estimated at the time of sale and recorded as direct reductions to trade receivables and revenue. Management estimates the provisions for cash discounts and allowances based on contractual sales terms with customers, an analysis of unpaid invoices and historical payment experience. Estimated cash discounts and allowances have historically been predictable and less subjective, due to the limited number of assumptions involved, the consistency of historical experience and the fact that these amounts are generally settled within one month of incurring the&#160;liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, customers are generally allowed to return a product within a specified period of time before and after its expiration date, excluding European businesses which generally do not provide a right of return. The returns provision is estimated utilizing historical sales and return rates over the period during which customers have a right of return, taking into account available information on competitive products and contract changes. The information utilized to estimate the returns provision includes: (i) historical return and exchange levels, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription demand for products, (iv) remaining shelf lives of products at the date of sale and (v) estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the estimate for returns, management is required to make certain assumptions regarding the timing of the introduction of new products and the potential of these products to capture market share. In addition, certain assumptions with respect to the extent and pattern of decline associated with generic competition are necessary. These assumptions are formulated using market data for similar products, past experience and other available information.  These assumptions are continually reassessed, and changes to the estimates and assumptions are made as new information becomes available. A change of 1% in the estimated return rates would have impacted the Company&#x2019;s pre-tax earnings by approximately $81 million for the year 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimate for returns may be impacted by a number of factors, but the principal factor relates to the inventory levels in the distribution channel. When management becomes aware of an increase in such inventory levels, it considers whether the increase may be temporary or other-than-temporary. Temporary increases in wholesaler inventory levels will not warrant revision to the provision for returns. Other-than-temporary increases in wholesaler inventory levels, however, may be an indication that future product returns could be higher than originally anticipated, and, as a result, estimates for returns may need to be adjusted. Factors that suggest increases in wholesaler inventory levels are temporary include: (i) recently implemented or announced price increases for certain products, (ii) new product launches or expanded indications for existing products and (iii) timing of purchases by wholesale customers. Conversely, factors that suggest increases in wholesaler inventory levels are other-than-temporary include: (i) declining sales trends based on prescription demand, (ii) introduction of new products or generic competition, (iii) increasing price competition from generic competitors and (iv) changes to the U.S.&#160;National Drug Codes (&#x201c;NDC&#x201d;) of products.  Changes in the NDC of products could result in a period of higher returns related to products with the old NDC, as U.S.&#160;customers generally permit only one NDC per product for identification and tracking within their inventory systems.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for 2021 and 2020 were $131&#160;million and $120&#160;million, respectively, and includes reductions in variable consideration for sales return provisions related to past sales of approximately $28 million and $38 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates and Chargebacks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales made under governmental and managed-care pricing programs in the U.S. are subject to rebates.&#160; The Company participates in state government-managed Medicaid programs, as well as certain other qualifying federal and state government programs whereby rebates are provided to participating government entities. Medicaid rebates are generally billed 45 days to 270&#160;days after the quarter in which the product is dispensed to the Medicaid participant.  As a result, the Medicaid rebate reserve includes an estimate of outstanding claims for end-customer sales that occurred, but for which the related claim has not been billed and/or paid, and an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. The calculation of the Medicaid rebate reserve also requires other estimates, such as estimates of sales mix, to determine which sales are subject to rebates and the amount of such rebates. A change of 1% in the estimated rates used in the Medicaid rebate reserve would have impacted the Company&#x2019;s pre-tax earnings by approximately $76 million for 2021. Quarterly, the Medicaid rebate reserve is adjusted based on actual claims paid. Due to the delay in billing, adjustments to actual claims paid may incorporate revisions of that reserve for several periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market&#160;share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks relate to contractual agreements to sell products to government agencies, group purchasing organizations and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these group purchasing organizations or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In estimating provisions for rebates and chargebacks, management considers relevant statutes with respect to governmental pricing programs and contractual sales terms with managed-care providers and group purchasing organizations. Management estimates the amount of product sales subject to these programs based on historical utilization levels. Changes in the level of utilization of products through private or public benefit plans and group purchasing organizations will affect the amount of rebates and chargebacks that the Company is obligated to pay. Management continually updates these factors based on new contractual or statutory requirements, and any significant changes in sales trends that may impact the percentage of products subject to rebates or&#160;chargebacks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of Managed Care, Medicaid and other rebates and chargebacks has become more significant as a result of a combination of deeper discounts implemented in each of the last three years, changes in the Company&#x2019;s product portfolio due to recent acquisitions and increased Medicaid utilization due to expansion of government funding for these programs.&#160;Management&#x2019;s estimate for rebates and chargebacks may be impacted by a number of factors, but the principal factor relates to the level of inventory in the distribution channel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebate provisions are based on factors such as timing and terms of plans under contract, time to process rebates, product pricing, sales volumes, amount of inventory in the distribution channel and prescription trends. Adjustments to actual for the years 2021 and 2020 were not material to the Company&#x2019;s revenues or earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient Co-Pay Assistance programs, Consumer Rebates and Loyalty Programs are rebates offered on many of the Company&#x2019;s products.  Patient Co-Pay Assistance Programs are patient discount programs offered in the form of coupon cards or point of sale discounts, with which patients receive certain discounts off their prescription at participating pharmacies, as defined by the specific product program. An accrual for these programs is established, equal to management&#x2019;s estimate of the discount, rebate and loyalty incentives attributable to a sale.  That estimate is based on historical experience and other relevant factors. The accrual is adjusted throughout each quarter based on actual experience and changes in other factors, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distribution Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells products primarily to wholesalers, and in some instances to large pharmacy chains such as CVS and Walmart.  The Company has Distribution Services Agreements ("DSAs") with several large wholesale customers such as McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Specialty.  Under the DSAs, the wholesalers agree to provide services, and the Company pays the contracted DSA distribution service fees for these services based on product volumes.  Additionally, price appreciation credits are generated when the Company increases a product&#x2019;s wholesaler acquisition cost (&#x201c;WAC&#x201d;) under contracts with certain wholesalers. Under such contracts, the Company is entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. Such credits are offset against the total distribution service fees paid to each such wholesaler. The variable consideration associated with price appreciation credits is reflected in the transaction price of products sold when it is determined to be probable that a significant reversal will not occur. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $17 million and $15 million for the years 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Assets and Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Commissions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financing Component&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less. The Company's global payment terms are generally between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM5MzI5_70a72a43-4f7f-4419-aca2-445874d33f43"&gt;thirty&lt;/span&gt; to ninety days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain facilities, vehicles and equipment principally under multi-year agreements generally having a lease term of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM5NDgx_a56638c4-d79f-4701-9cb4-eeba251c7aba"&gt;one&lt;/span&gt; to twenty years, some of which include termination options and options to extend the lease term from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM5NTc1_4194aaa1-36a3-4275-bf8a-8595947de005"&gt;one&lt;/span&gt; to five years or on a month-to-month basis. The Company includes options that are reasonably certain to be exercised as part of the lease term. The Company may negotiate termination clauses in anticipation of changes in market conditions but generally, these termination options are not exercised. Certain lease agreements also include variable payments that are dependent on usage or may vary month-to-month such as insurance, taxes and maintenance costs. None of the Company's lease agreements contain material residual value guarantees or material restrictive covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to record a right-of-use asset and corresponding lease liability, equal to the present value of the lease payments at the commencement date of each lease. For all asset classes, in determining future lease payments, the Company has elected to aggregate lease components, such as payments for rent, taxes and insurance costs with non-lease components such as maintenance costs, and account for these payments as a single lease component. In limited &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;circumstances, when the information necessary to determine the rate implicit in a lease is available, the present value of the lease payments is determined using the rate implicit in that lease. If the information necessary to determine the rate implicit in a lease is not available, the Company uses its incremental borrowing rate at the commencement of the lease, which represents the rate of interest that the Company would incur to borrow on a collateralized basis over a similar term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All leases must be classified as either an operating lease or finance lease. The classification is determined based on whether substantive control has been transferred to the lessee.  The classification governs the pattern of lease expense recognition. For leases classified as operating leases, total lease expense over the term of the lease is equal to the undiscounted payments due in accordance with the lease arrangement. Fixed lease expense is recognized periodically on a straight-line basis over the term of each lease and includes: (i) imputed interest during the period on the lease liability determined using the effective interest rate method plus (ii) amortization of the right-of-use asset for that period. Amortization of the right-of-use asset during the period is calculated as the difference between the straight-line expense and the imputed interest on the lease liability for that period. Variable lease expense is recognized when the achievement of the specific target is considered probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs related to internal research and development programs, including costs associated with the development of acquired IPR&amp;amp;D, are expensed as goods are delivered or services are performed. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Milestone payments made to third parties before a product receives regulatory approval, but after the milestone is determined to be probable, are expensed and included in Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from third parties as reimbursement of development activities conducted under certain research and development arrangements are recognized as a reduction of Research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal fees and other costs related to litigation and other legal proceedings or services are expensed as incurred and are included in Selling, general and administrative expenses. Certain legal costs associated with acquisitions are included in Acquisition-related costs and certain legal costs associated with divestitures, legal settlements and other business development activities are included in Litigation and other matters or Net gain on sales of assets within Other expense (income), net, as appropriate. Legal costs expensed are reported net of expected insurance recoveries. A claim for insurance recovery is recognized when realization becomes probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs comprise product samples, print media, promotional materials and television advertising and are expensed on the first use of the advertisement. Included in Selling, general and administrative expenses are advertising costs of $515 million, $451 million and $544 million, for 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes all share-based payments to employees, including grants of employee stock options and restricted share units (&#x201c;RSUs&#x201d;), at estimated fair value. The Company amortizes the fair value of stock option or RSU grants on a straight-line basis over the requisite service period of the individual stock option or RSU grant, which generally equals the vesting period. Stock option and RSU forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based compensation is recorded in Research and development expenses and Selling, general and administrative expenses, as&#160;appropriate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition-Related Contingent Consideration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquisition-related contingent consideration, which primarily consists of potential milestone payments and royalty obligations, is recorded in the Consolidated Balance Sheets at its acquisition date estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in fair value measurement accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Interest Expense &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense includes standby fees, the amortization of debt discounts and deferred financing costs, accretion of debt premiums and the amortization of amounts excluded from the assessment of effectiveness related to the Company's cross-currency swaps. Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized. Capitalized interest related to construction in progress as of December 31, 2021 and 2020 was $60 million and $45&#160;million, respectively, and is included in Property, plant and equipment, net. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized. Deferred tax assets and liabilities are measured using enacted tax rates and&#160;laws.  Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such position are measured based on the amount for which there is a greater than 50% likelihood of being realized upon settlement. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within one year. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance&#160;sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss Per Share Attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period. Diluted loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period after giving effect to dilutive potential common shares for stock options and RSUs, determined using the treasury stock&#160;method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss comprises Net loss and Other comprehensive (loss) income. Other comprehensive (loss) income includes items such as foreign currency translation adjustments, unrealized holding gains and losses on available-for-sale and other investments and certain pension and other postretirement benefit plan adjustments. Accumulated other comprehensive loss is recorded as a component of shareholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company is subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Accruals for loss contingencies are recorded when the Company determines that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the estimate of the amount of the loss is a range and some amount within the range appears to be a better estimate than any other amount within the range, that amount is accrued as a liability. If no amount within the range is a better estimate than any other amount, the minimum amount of the range is accrued as a&#160;liability. These accruals are adjusted periodically as assessments change or additional information becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Benefit Plans &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors various retirement and pension plans, including defined benefit pension plans, defined contribution plans and a participatory defined benefit postretirement plan. The determination of defined benefit pension and postretirement plan obligations and their associated expenses requires the use of actuarial valuations to estimate the benefits employees earn while working, as well as the present value of those benefits. Net actuarial gains and losses that exceed 10 percent of the greater of the plan&#x2019;s projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated average future service period of the plan participants (or the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;estimated average future lifetime of the plan participants if the majority of plan participants are inactive) or the period until any anticipated final plan settlements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New&#160;Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board ("FASB") issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses.  The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to Accumulated deficit of less than $1&#160;million. The application of this guidance did not have a material effect on the Company's results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement.  The guidance was effective for the Company beginning January 1, 2020. The application of this guidance did not have a material effect on the Company's disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans.  The guidance was effective for annual periods ending after December 15, 2020. The application of this guidance did not have a material effect on the Company's disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160; The guidance is effective for the Company beginning with annual periods beginning January 1, 2021.&#160; The application of this guidance did not have a material effect on the Company's financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.&#160; Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging.&#160;The optional amendments are effective for all entities as of March 12, 2020, through December 31, 2022. During 2020 and 2021, the Company has not entered into any contract modifications in which the optional expedients were applied.&#160; However, if prior to December 31, 2022, the Company enters into a contract modification in which the optional expedients are applied, the Company will evaluate the impact of adoption of this guidance on its financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NzA5_6e6d99b8-4316-4090-8a9e-5ce445870389">Basis of Presentation and Use of Estimates The Consolidated Financial Statements have been prepared by the Company in United&#160;States (&#x201c;U.S.&#x201d;) dollars and in accordance with U.S.&#160;generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;), applied on a consistent basis. The Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <bhc:BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzEwOTk1MTE3MDgxODM_c076722a-c085-4e29-ae9e-601892032829"
      unitRef="company">3</bhc:BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished>
    <us-gaap:UseOfEstimates
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NTky_8c1ea3d3-a37b-45d9-a599-d4e6e96edaa8">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In preparing the Company's Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows.  The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of amortizable intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants and making going concern assessments; reporting unit fair values for testing goodwill for impairment and allocating goodwill to new reporting unit structure on a relative fair value basis; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; fair value of cross-currency swaps; fair value of foreign currency exchange contracts; and the recognition of the fair value of assets and liabilities acquired in a business combination, including the fair value of contingent consideration. Under certain product manufacturing and supply agreements, management uses information from the Company&#x2019;s commercialization counterparties to arrive at estimates for future returns, rebates and chargebacks. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#x2019;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#x2019;s Consolidated Financial Statements could be materially impacted.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NzI3_9c2515b1-e952-4650-a158-32bf7327bce0">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior year amounts to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1ODA2_9a7f20e2-5ecf-4b9c-9606-441be7e7faa1">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisitions &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Consolidated Financial Statements after the date of acquisition.  Acquired in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;amp;D has an alternative future use. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;amp;D with no alternative future use is charged to expense at the acquisition&#160;date and any future contingent consideration is not recorded until it becomes probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition-Related Contingent Consideration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquisition-related contingent consideration, which primarily consists of potential milestone payments and royalty obligations, is recorded in the Consolidated Balance Sheets at its acquisition date estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in fair value measurement accounting.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1Njky_17c6d108-b609-444e-a471-da81be0a8a26">Fair Value of Financial InstrumentsThe estimated fair values of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities approximate their carrying values due to their short maturity periods. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows or Monte Carlo Simulation (when appropriate) analyses and assessment of the probability of occurrence of potential future events.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NjY1_e903db98-dfa8-49a4-bf0f-2c65592a4fff">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cross-currency swaps qualified for and had been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and were remeasured at each reporting date to reflect changes in their &lt;/span&gt;&lt;/div&gt;fair values.  The fair value was determined via a mark-to-market analysis, using observable (Level&#160;2) inputs. These inputs included: (i)&#160;the foreign currency exchange spot rate between the euro and U.S. dollar, (ii)&#160;the interest rate yield curves in the euro and U.S. dollar and (iii)&#160;the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Loss as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulated other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps was ineffective. The Company uses the spot method of assessing hedge effectiveness. The Company had elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as a reduction of Interest expense in the Consolidated Statements of Operations.The Company uses foreign currency exchange contracts to economically hedge the foreign exchange exposure on certain of the Company&#x2019;s intercompany and third party balances. The Company's foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1ODMx_698e1b5d-7d0a-443a-90e0-47f277a2e647">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash in bank accounts and highly liquid investments with maturities of three months or less when&#160;purchased.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzk2Njk_7378fd29-f1ac-49e5-85e0-e9f783c24bd3">P3M</bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NjU2_dc933ab6-e172-4910-9c98-c100f2c968b6">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, cross-currency swaps and foreign currency exchange contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests its excess cash in high-quality, money market instruments and term deposits with varying maturities, but typically less than three months.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash deposited at banks may exceed the amount of insurance provided on such deposits. Generally, these cash deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate such risks by spreading its risk across multiple counterparties and monitoring the risk profiles of these counterparties.&lt;/span&gt;&lt;/div&gt;The Company&#x2019;s trade receivables primarily represent amounts due from wholesale distributors, retail pharmacies, government entities and group purchasing organizations. Outside of the U.S., concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the number of customers using the Company&#x2019;s products, as well as their dispersion across many different geographic regions. The Company performs periodic credit evaluations of customers and does not require collateral. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The credit and economic conditions within Argentina, Brazil, Egypt, Greece, among other members of the European Union, Turkey, Ukraine and Venezuela have been weak in recent years.</us-gaap:ConcentrationRiskCreditRisk>
    <bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzEwMTI5_2ccf9cf0-7482-4d29-b6c8-75540bae7b3c">P3M</bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents>
    <bhc:NumberOfLargestWholesaleCustomers
      contextRef="i6d07942ff8e3491b92dc863012aacd40_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzExNjY4_d6f41bba-0783-416e-99d2-65830403a7ea"
      unitRef="wholesaler">3</bhc:NumberOfLargestWholesaleCustomers>
    <bhc:ConcentrationRiskPercentageofNetTradeReceivables
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzExNzMz_650f04fb-e88e-42ec-8277-97219d114c74"
      unitRef="number">0.44</bhc:ConcentrationRiskPercentageofNetTradeReceivables>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7cee20a09d6f45c983e7a622d798eb96_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzExOTIw_20173345-80b1-4622-9089-9017002a5335"
      unitRef="usd">78000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie46cfa6ebbfe4fe3bfce4e96130f07e5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzI3NDg3NzkxNDE5NjI_b2f24b93-ba08-48ae-90e7-88f924f90cfc"
      unitRef="usd">166000000</us-gaap:AccountsReceivableNetCurrent>
    <bhc:PastDuePeriodForAccountsReceivableToBeNegligible
      contextRef="i1d7e258ccc574f96965b59dea148df20_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzExOTkx_6495b762-5f93-41f0-926c-a030117907e7">P90D</bhc:PastDuePeriodForAccountsReceivableToBeNegligible>
    <bhc:PeriodReceivableOutstanding
      contextRef="i1d7e258ccc574f96965b59dea148df20_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzEyMDk3_38a5fbaf-6186-45c4-b0b5-8c397c7674d6">P90D</bhc:PeriodReceivableOutstanding>
    <bhc:TradeReceivableNetPortionPastDue
      contextRef="i7cee20a09d6f45c983e7a622d798eb96_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzEyMTE3_28ddabd7-e78d-4529-a523-fb11ec99bf06"
      unitRef="usd">2000000</bhc:TradeReceivableNetPortionPastDue>
    <bhc:PeriodReceivableOutstanding
      contextRef="i1d7e258ccc574f96965b59dea148df20_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzEyNDIz_569ac2a0-e7a0-48c9-aea4-130ead830fc3">P90D</bhc:PeriodReceivableOutstanding>
    <us-gaap:FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NjU4_85b42cbe-6670-469b-9214-47bc55788fa1">Allowance for Credit LossesAn allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160; Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses.</us-gaap:FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzE0MjQ4_aa18c4c9-7467-4958-a6f3-aad89315bafa"
      unitRef="usd">35000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzE0MjUy_5d06e3e0-c9a0-4fc6-a2e9-6f2c749ed1e4"
      unitRef="usd">39000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzE0MjU5_700a8a60-4d67-4faa-8a8a-cd8a59f1c356"
      unitRef="usd">48000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NjU5_34d8af9c-36ce-41d4-aaef-593fde501a09">The activity in the allowance for credit losses for trade receivables for the years 2021, 2020 and 2019 is as follows.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.199%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retrospective effect of application of new accounting standard&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzEtMS0xLTEtNTk0NzA_d6349bea-e3aa-4ff4-896a-08d7213698bc"
      unitRef="usd">39000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzEtMy0xLTEtNTk0NzA_f8f99ecc-98e3-4a8f-ba7e-0df3024f0293"
      unitRef="usd">48000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i88a9900560564bdca7dec25381689c13_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzEtNS0xLTEtNTk0NzA_d9fe08a9-9acb-4d7f-875e-a320fa764682"
      unitRef="usd">47000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzItMS0xLTEtNTk0NzA_15c2d7b0-e1a9-4868-a747-07ef3f5cfa0d"
      unitRef="usd">0</bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate>
    <bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzItMy0xLTEtNTk0NzA_cdc95359-7424-4fdb-be7f-433f1dea8d4f"
      unitRef="usd">1000000</bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate>
    <bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzItNS0xLTEtNTk0NzA_347887a8-6677-4017-9c6d-e5eef3f9597d"
      unitRef="usd">0</bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzMtMS0xLTEtNTk0NzA_f2b47312-27b9-48d2-b68f-9131da90363f"
      unitRef="usd">-2000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzMtMy0xLTEtNTk0NzA_23d5877e-45cd-4afd-935c-0cf9e2f22bb4"
      unitRef="usd">2000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzMtNS0xLTEtNTk0NzA_aaff335e-8124-43ea-920b-06b354a1727f"
      unitRef="usd">10000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzQtMS0xLTEtNTk0NzA_e189dcb7-1d63-4eda-b3c2-b5993d366897"
      unitRef="usd">3000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzQtMy0xLTEtNTk0NzA_ef39437c-9ed8-4d08-895e-e411dd29224f"
      unitRef="usd">12000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzQtNS0xLTEtNTk0NzA_1c09511c-c83c-4ec0-9bbf-49bec8f0be3a"
      unitRef="usd">10000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzUtMS0xLTEtNTk0NzA_0c066c28-f7f4-43ae-872a-ff724bdbcc85"
      unitRef="usd">2000000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzUtMy0xLTEtNTk0NzA_c59e8c47-be0a-4f79-b61b-bf13aac4cbb1"
      unitRef="usd">3000000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzUtNS0xLTEtNTk0NzA_dd0186b7-d4fa-4aa5-80c1-6e67fd7ea403"
      unitRef="usd">1000000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <bhc:AccountsReceivableAllowanceForForeignExchangeAndOther
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzYtMS0xLTEtNTk0NzA_e07c1bcb-d64f-48ff-a5c7-048cafe64fb1"
      unitRef="usd">1000000</bhc:AccountsReceivableAllowanceForForeignExchangeAndOther>
    <bhc:AccountsReceivableAllowanceForForeignExchangeAndOther
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzYtMy0xLTEtNTk0NzA_73af98f4-4907-4d7b-8aad-a36f2c69dc09"
      unitRef="usd">3000000</bhc:AccountsReceivableAllowanceForForeignExchangeAndOther>
    <bhc:AccountsReceivableAllowanceForForeignExchangeAndOther
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzYtNS0xLTEtNTk0NzA_392e24f3-d1f8-41c2-b548-b8f19a8aa893"
      unitRef="usd">0</bhc:AccountsReceivableAllowanceForForeignExchangeAndOther>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzctMS0xLTEtNTk0NzA_aa18c4c9-7467-4958-a6f3-aad89315bafa"
      unitRef="usd">35000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzctMy0xLTEtNTk0NzA_88b91c4e-d8e2-4a41-8d36-3161d1e9f6c7"
      unitRef="usd">39000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo1Mjg1NWY1YWVmMGE0YzUzODEyM2M3ZTIyOTA1ODFmYi90YWJsZXJhbmdlOjUyODU1ZjVhZWYwYTRjNTM4MTIzYzdlMjI5MDU4MWZiXzctNS0xLTEtNTk0NzA_740da4e9-dba0-49ca-b851-0ecb95433346"
      unitRef="usd">48000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1Nzc1_364744aa-4f32-4d2a-919d-6ab3ba5f410f">&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories comprise raw materials, work in process and finished goods, which are valued at the lower of cost or net realizable value, on a first-in, first-out basis. The cost value for work in process and finished goods inventories includes materials, direct labor and an allocation of overheads. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on&#160;hand.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1ODIz_cf1150f1-a370-42a8-9f3c-4814293fa191">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are reported at cost, less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction in progress. Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful&#160;lives: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15 - 30 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 40 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;-&#160;20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;-&#160;10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment on operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of term of lease or 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <bhc:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1Nzky_82de97dd-665f-48fc-abf6-ea47244a616b">Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful&#160;lives: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15 - 30 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 40 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;-&#160;20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;-&#160;10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment on operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of term of lease or 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bhc:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i366ab3c0cc114fd3b2e77b4af953dd1f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTowMzE4YjM4YmNlZTU0ZWFhOWViZGQzODI4YzY5YjMwMy90YWJsZXJhbmdlOjAzMThiMzhiY2VlNTRlYWE5ZWJkZDM4MjhjNjliMzAzXzAtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjplOGQ3ZDA1Y2E2MmY0YWViODE2ZGI2MDk0ZTA4YTdiZl80_2618f144-f6c6-4684-bb57-a97846f0eece">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iaaa57eb8c0df42b19dda8cafee4e2828_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTowMzE4YjM4YmNlZTU0ZWFhOWViZGQzODI4YzY5YjMwMy90YWJsZXJhbmdlOjAzMThiMzhiY2VlNTRlYWE5ZWJkZDM4MjhjNjliMzAzXzAtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjplOGQ3ZDA1Y2E2MmY0YWViODE2ZGI2MDk0ZTA4YTdiZl85_15caf72d-9099-4ccc-91e7-4b1e2bb1aeb6">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i34a41a0fa13145bf8230d44859521d48_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTowMzE4YjM4YmNlZTU0ZWFhOWViZGQzODI4YzY5YjMwMy90YWJsZXJhbmdlOjAzMThiMzhiY2VlNTRlYWE5ZWJkZDM4MjhjNjliMzAzXzEtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjpiMjAyNmZlMGI2ZTg0N2Y4YWZiZWRmOGNhYzQyNTU3Zl8xMA_0a4142e6-a8fe-4073-a7bf-f78c7f0944b6">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="icacb4e180aa541848a91e2776ddcb14a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTowMzE4YjM4YmNlZTU0ZWFhOWViZGQzODI4YzY5YjMwMy90YWJsZXJhbmdlOjAzMThiMzhiY2VlNTRlYWE5ZWJkZDM4MjhjNjliMzAzXzItMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo5MWViNDM0MzExY2I0NmI5YjI5YjBiY2Q5ZTRjZjRlN180_9c471c83-4b3f-4229-baa4-4b21cdfb222d">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i88a58a70adfc405cb63f4ecc44509a55_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTowMzE4YjM4YmNlZTU0ZWFhOWViZGQzODI4YzY5YjMwMy90YWJsZXJhbmdlOjAzMThiMzhiY2VlNTRlYWE5ZWJkZDM4MjhjNjliMzAzXzItMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo5MWViNDM0MzExY2I0NmI5YjI5YjBiY2Q5ZTRjZjRlN185_5439701b-dd3e-4dd4-8f69-223c2a04b0a4">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iaddfdd394a12495d9cc12de4613f5d31_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTowMzE4YjM4YmNlZTU0ZWFhOWViZGQzODI4YzY5YjMwMy90YWJsZXJhbmdlOjAzMThiMzhiY2VlNTRlYWE5ZWJkZDM4MjhjNjliMzAzXzMtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjpkZTQ2MDFlODU4NDM0MGYxYjJlZTQzYTVkNDhmZmRjM180_3d086cb8-ca72-4d3c-9061-a844dfcdf98f">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6c48db1ce8ed4151a1ecb07006cc1eb2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTowMzE4YjM4YmNlZTU0ZWFhOWViZGQzODI4YzY5YjMwMy90YWJsZXJhbmdlOjAzMThiMzhiY2VlNTRlYWE5ZWJkZDM4MjhjNjliMzAzXzMtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjpkZTQ2MDFlODU4NDM0MGYxYjJlZTQzYTVkNDhmZmRjM185_a7d1e9bb-09e8-4356-975a-258c56707c59">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i8b367dbe73ec48018042069891895784_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTowMzE4YjM4YmNlZTU0ZWFhOWViZGQzODI4YzY5YjMwMy90YWJsZXJhbmdlOjAzMThiMzhiY2VlNTRlYWE5ZWJkZDM4MjhjNjliMzAzXzQtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjplM2IzNjliNDc0ZDk0MWEyYTNkZjExMjFmOGM5MGM4OV8xMA_ca59d1c4-04b6-4f51-af78-bfe81622fe07">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie10da8de3b1d424385606609168cca9b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTowMzE4YjM4YmNlZTU0ZWFhOWViZGQzODI4YzY5YjMwMy90YWJsZXJhbmdlOjAzMThiMzhiY2VlNTRlYWE5ZWJkZDM4MjhjNjliMzAzXzUtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjphOTU5MDZkOTVhZjA0MDNlODZjNjEwNWY4M2ZiZmU2ZV8zMQ_aae67618-eed9-44cb-9ba3-c565d2b45c4e">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1ODIy_d463c23c-69c0-4bbe-9a8a-0209d1ed0a4d">&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reported at cost, less accumulated amortization and impairments. Intangible assets with finite lives are amortized over their estimated useful lives. Amortization is calculated primarily using the straight-line method based on the following estimated useful&#160;lives:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4 - 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 - 9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Out-licensed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8 - 9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <bhc:ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NjQ0_2d377c58-a54a-40d7-ba03-87205e9c285a">Amortization is calculated primarily using the straight-line method based on the following estimated useful&#160;lives:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4 - 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 - 9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Out-licensed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8 - 9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bhc:ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i8e253d2e372545a9be9b1908cb43277f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo5MmM2NWM0OGRiZjY0NWJlODFlN2M4MDliYzJmNDQyOC90YWJsZXJhbmdlOjkyYzY1YzQ4ZGJmNjQ1YmU4MWU3YzgwOWJjMmY0NDI4XzAtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjpkZTkzNzA3Nzg5Yjk0NmRkODhmNjJhYzU1MGQ2OTY5OV80_f5fd29ef-146c-4081-9914-e086c8963d15">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i57f30ccd1de94a63935d2ef0dd575c37_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo5MmM2NWM0OGRiZjY0NWJlODFlN2M4MDliYzJmNDQyOC90YWJsZXJhbmdlOjkyYzY1YzQ4ZGJmNjQ1YmU4MWU3YzgwOWJjMmY0NDI4XzAtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjpkZTkzNzA3Nzg5Yjk0NmRkODhmNjJhYzU1MGQ2OTY5OV85_9da0c997-0a57-4dd5-b496-4987aa3e8be9">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id146ea0827064b89a7577cc36b0679b2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo5MmM2NWM0OGRiZjY0NWJlODFlN2M4MDliYzJmNDQyOC90YWJsZXJhbmdlOjkyYzY1YzQ4ZGJmNjQ1YmU4MWU3YzgwOWJjMmY0NDI4XzEtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjozYjBhYWJhMWM1ZTQ0MDM4OGM2M2VlOGM0OTQ5NmQ0NV80_db12a220-7a34-4c10-b478-0a2841e73308">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i78e288346972478a97d9a959bb7d3568_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo5MmM2NWM0OGRiZjY0NWJlODFlN2M4MDliYzJmNDQyOC90YWJsZXJhbmdlOjkyYzY1YzQ4ZGJmNjQ1YmU4MWU3YzgwOWJjMmY0NDI4XzEtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjozYjBhYWJhMWM1ZTQ0MDM4OGM2M2VlOGM0OTQ5NmQ0NV85_59c25ab4-8cf7-4ea0-bed1-60b47dd98387">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i728cea9c2c2a45178ba159057c1da77b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo5MmM2NWM0OGRiZjY0NWJlODFlN2M4MDliYzJmNDQyOC90YWJsZXJhbmdlOjkyYzY1YzQ4ZGJmNjQ1YmU4MWU3YzgwOWJjMmY0NDI4XzItMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo5MTIwNzU2YjMwODU0MGJiYTEyNmQ1ZjFiMmQyNGZiNV80_efc9e48d-fe0b-453c-baa3-8ec4a72b95a7">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i931f3f4638c2440d8d4ffbb6ec962733_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo5MmM2NWM0OGRiZjY0NWJlODFlN2M4MDliYzJmNDQyOC90YWJsZXJhbmdlOjkyYzY1YzQ4ZGJmNjQ1YmU4MWU3YzgwOWJjMmY0NDI4XzItMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo5MTIwNzU2YjMwODU0MGJiYTEyNmQ1ZjFiMmQyNGZiNV85_6bd6155e-2fac-4ffe-9bf4-8b575f078375">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i588f12f4c6524d6b8656970aae16788c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo5MmM2NWM0OGRiZjY0NWJlODFlN2M4MDliYzJmNDQyOC90YWJsZXJhbmdlOjkyYzY1YzQ4ZGJmNjQ1YmU4MWU3YzgwOWJjMmY0NDI4XzMtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjoxM2MwMWQzYWRkMDk0ZDYyYTcxZTA1YzlkOWYyZDVjNF80_b0ae55d1-6214-474a-898b-d659626c4dcf">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i37bcb7f77b3249cf8d55cb530b605590_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo5MmM2NWM0OGRiZjY0NWJlODFlN2M4MDliYzJmNDQyOC90YWJsZXJhbmdlOjkyYzY1YzQ4ZGJmNjQ1YmU4MWU3YzgwOWJjMmY0NDI4XzMtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjoxM2MwMWQzYWRkMDk0ZDYyYTcxZTA1YzlkOWYyZDVjNF85_58d53203-6418-4273-ae77-fff19b56e047">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ib131e2e5eaa54a10ae73c558ccbe6438_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo5MmM2NWM0OGRiZjY0NWJlODFlN2M4MDliYzJmNDQyOC90YWJsZXJhbmdlOjkyYzY1YzQ4ZGJmNjQ1YmU4MWU3YzgwOWJjMmY0NDI4XzQtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo1NmVkY2EzZTc1Nzc0ZWI5ODFmNGRlZTU3MjU0OTc5N180_5a8ba40a-92d5-40b8-b88e-063232ddcb43">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i11fbfd9dfbeb4355bc882e75f9bee1db_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTo5MmM2NWM0OGRiZjY0NWJlODFlN2M4MDliYzJmNDQyOC90YWJsZXJhbmdlOjkyYzY1YzQ4ZGJmNjQ1YmU4MWU3YzgwOWJjMmY0NDI4XzQtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo1NmVkY2EzZTc1Nzc0ZWI5ODFmNGRlZTU3MjU0OTc5N185_646f7e9e-b34c-442c-8497-be76170e8bff">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <bhc:DivestituresOfNoncoreProductsPolicyTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1Nzg3_8a5f1e47-86fa-4a3a-b220-e459bc62caee">&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Divestitures of Products&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net proceeds on the divestiture of products and the carrying amount of the related assets is recorded as a gain/loss on sale within Other expense, net. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when realizable.&lt;/span&gt;&lt;/div&gt;</bhc:DivestituresOfNoncoreProductsPolicyTextBlock>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1ODI4_602da52a-3b70-4766-883b-0ab5d1dfeed0">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IPR&amp;amp;D &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of IPR&amp;amp;D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and&#160;amortized. Acquired IPR&amp;amp;D assets are tested for impairment at least annually or when triggering events are identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of an acquired IPR&amp;amp;D intangible asset is typically determined using an income approach. This approach starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#x2019;s stage of completion, the probability of technical success, the projected costs to complete, expected market competition and an assessment of the asset&#x2019;s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the expected cash flow&#160;streams.&lt;/span&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1ODI0_3bc5a329-82b7-483c-b0cc-1617d8a95a44">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.  If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset, which include the amount and timing of the projected future cash flows. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash&#160;flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets, which includes acquired IPR&amp;amp;D and the corporate trademark acquired in the acquisition of Bausch &amp;amp; Lomb Holdings Incorporated (the &#x2018;&#x2018;B&amp;amp;L Trademark&#x2019;&#x2019;), are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based on a comparison of the fair value of the asset to its carrying value.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1Nzg4_6fd91b32-ce52-41c4-8f75-26447224eb7a">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. Goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value. A reporting unit is the same as, or one level below, an operating segment. A&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n entity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is permitted to first assess qualitatively whether it is necessary to perform a quantitative impairment test for any of its reporting units. The quantitative impairment test is required only when the Company concludes that it is more likely than not that a reporting unit&#x2019;s fair value is less than its carrying amount. In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company considers the totality of all relevant events or circumstances that affect the fair value or carrying amount of a reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company&#x2019;s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, among other factors, the Company monitors &lt;/span&gt;&lt;/div&gt;changes in its share price between annual impairment tests. The Company considers a decline in its share price that corresponds to an overall deterioration in stock market conditions to be less of an indicator of goodwill impairment than a unilateral decline in its share price reflecting adverse changes in its underlying operating performance, cash flows, financial condition and/or liquidity. In the event that the Company&#x2019;s market capitalization does decline below its book value, the Company would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. The Company believes that short-term fluctuations in share prices may not necessarily reflect underlying values.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NzA1_9b688166-0e5f-47c7-949d-0bf3635a3087">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt discounts, premiums and issuance costs are presented in the Consolidated Balance Sheets as a direct deduction from or addition to the carrying amount of the related debt and are amortized or accreted, using the effective interest method, as interest expense over the contractual lives of the related credit facilities or notes. Deferred financing costs associated with revolving credit facility arrangements are included in the balances of Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets and are amortized as interest expense over the contractual life of the related revolving credit facility.&lt;/span&gt;&lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NzQ3_6cde736a-3424-431f-b75b-8855759874d9">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities of the Company&#x2019;s foreign operations having a functional currency other than the U.S.&#160;dollar are translated into U.S.&#160;dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency exchange gains and losses on transactions occurring in a currency other than an operation&#x2019;s functional currency are recognized as a component of Foreign exchange and other in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NzE1_4215e8c5-165a-4b71-bc9b-e70350a80569">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye-health, gastroenterology ("GI") and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 22, "SEGMENT INFORMATION" for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services.  To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A contract with the Company&#x2019;s customers exists for each product sale.  Where a contract with a customer contains more than one performance obligation, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The transaction price is adjusted for variable consideration which is discussed below.  The Company generally recognizes revenue for product sales at a point in time, when the customer obtains control of the products.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160; The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers.  Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the activity and ending balances of the Company&#x2019;s variable consideration provisions the years 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,909)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $36 million and $32 million as of December 31, 2021 and 2020, respectively, which are reflected as a reduction of Trade accounts receivable, net in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company's products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis.  This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#x2019;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period.  The Company applies this method consistently for contracts with similar characteristics.  The following describes the major sources of variable consideration in the Company&#x2019;s customer arrangements and the methodology, estimates and judgments applied to estimate each type of variable consideration.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash discounts are offered for prompt payment and allowances for volume purchases. Provisions for cash discounts and allowances are estimated at the time of sale and recorded as direct reductions to trade receivables and revenue. Management estimates the provisions for cash discounts and allowances based on contractual sales terms with customers, an analysis of unpaid invoices and historical payment experience. Estimated cash discounts and allowances have historically been predictable and less subjective, due to the limited number of assumptions involved, the consistency of historical experience and the fact that these amounts are generally settled within one month of incurring the&#160;liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, customers are generally allowed to return a product within a specified period of time before and after its expiration date, excluding European businesses which generally do not provide a right of return. The returns provision is estimated utilizing historical sales and return rates over the period during which customers have a right of return, taking into account available information on competitive products and contract changes. The information utilized to estimate the returns provision includes: (i) historical return and exchange levels, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription demand for products, (iv) remaining shelf lives of products at the date of sale and (v) estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the estimate for returns, management is required to make certain assumptions regarding the timing of the introduction of new products and the potential of these products to capture market share. In addition, certain assumptions with respect to the extent and pattern of decline associated with generic competition are necessary. These assumptions are formulated using market data for similar products, past experience and other available information.  These assumptions are continually reassessed, and changes to the estimates and assumptions are made as new information becomes available. A change of 1% in the estimated return rates would have impacted the Company&#x2019;s pre-tax earnings by approximately $81 million for the year 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimate for returns may be impacted by a number of factors, but the principal factor relates to the inventory levels in the distribution channel. When management becomes aware of an increase in such inventory levels, it considers whether the increase may be temporary or other-than-temporary. Temporary increases in wholesaler inventory levels will not warrant revision to the provision for returns. Other-than-temporary increases in wholesaler inventory levels, however, may be an indication that future product returns could be higher than originally anticipated, and, as a result, estimates for returns may need to be adjusted. Factors that suggest increases in wholesaler inventory levels are temporary include: (i) recently implemented or announced price increases for certain products, (ii) new product launches or expanded indications for existing products and (iii) timing of purchases by wholesale customers. Conversely, factors that suggest increases in wholesaler inventory levels are other-than-temporary include: (i) declining sales trends based on prescription demand, (ii) introduction of new products or generic competition, (iii) increasing price competition from generic competitors and (iv) changes to the U.S.&#160;National Drug Codes (&#x201c;NDC&#x201d;) of products.  Changes in the NDC of products could result in a period of higher returns related to products with the old NDC, as U.S.&#160;customers generally permit only one NDC per product for identification and tracking within their inventory systems.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for 2021 and 2020 were $131&#160;million and $120&#160;million, respectively, and includes reductions in variable consideration for sales return provisions related to past sales of approximately $28 million and $38 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates and Chargebacks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales made under governmental and managed-care pricing programs in the U.S. are subject to rebates.&#160; The Company participates in state government-managed Medicaid programs, as well as certain other qualifying federal and state government programs whereby rebates are provided to participating government entities. Medicaid rebates are generally billed 45 days to 270&#160;days after the quarter in which the product is dispensed to the Medicaid participant.  As a result, the Medicaid rebate reserve includes an estimate of outstanding claims for end-customer sales that occurred, but for which the related claim has not been billed and/or paid, and an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. The calculation of the Medicaid rebate reserve also requires other estimates, such as estimates of sales mix, to determine which sales are subject to rebates and the amount of such rebates. A change of 1% in the estimated rates used in the Medicaid rebate reserve would have impacted the Company&#x2019;s pre-tax earnings by approximately $76 million for 2021. Quarterly, the Medicaid rebate reserve is adjusted based on actual claims paid. Due to the delay in billing, adjustments to actual claims paid may incorporate revisions of that reserve for several periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market&#160;share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks relate to contractual agreements to sell products to government agencies, group purchasing organizations and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these group purchasing organizations or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In estimating provisions for rebates and chargebacks, management considers relevant statutes with respect to governmental pricing programs and contractual sales terms with managed-care providers and group purchasing organizations. Management estimates the amount of product sales subject to these programs based on historical utilization levels. Changes in the level of utilization of products through private or public benefit plans and group purchasing organizations will affect the amount of rebates and chargebacks that the Company is obligated to pay. Management continually updates these factors based on new contractual or statutory requirements, and any significant changes in sales trends that may impact the percentage of products subject to rebates or&#160;chargebacks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of Managed Care, Medicaid and other rebates and chargebacks has become more significant as a result of a combination of deeper discounts implemented in each of the last three years, changes in the Company&#x2019;s product portfolio due to recent acquisitions and increased Medicaid utilization due to expansion of government funding for these programs.&#160;Management&#x2019;s estimate for rebates and chargebacks may be impacted by a number of factors, but the principal factor relates to the level of inventory in the distribution channel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebate provisions are based on factors such as timing and terms of plans under contract, time to process rebates, product pricing, sales volumes, amount of inventory in the distribution channel and prescription trends. Adjustments to actual for the years 2021 and 2020 were not material to the Company&#x2019;s revenues or earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient Co-Pay Assistance programs, Consumer Rebates and Loyalty Programs are rebates offered on many of the Company&#x2019;s products.  Patient Co-Pay Assistance Programs are patient discount programs offered in the form of coupon cards or point of sale discounts, with which patients receive certain discounts off their prescription at participating pharmacies, as defined by the specific product program. An accrual for these programs is established, equal to management&#x2019;s estimate of the discount, rebate and loyalty incentives attributable to a sale.  That estimate is based on historical experience and other relevant factors. The accrual is adjusted throughout each quarter based on actual experience and changes in other factors, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distribution Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells products primarily to wholesalers, and in some instances to large pharmacy chains such as CVS and Walmart.  The Company has Distribution Services Agreements ("DSAs") with several large wholesale customers such as McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Specialty.  Under the DSAs, the wholesalers agree to provide services, and the Company pays the contracted DSA distribution service fees for these services based on product volumes.  Additionally, price appreciation credits are generated when the Company increases a product&#x2019;s wholesaler acquisition cost (&#x201c;WAC&#x201d;) under contracts with certain wholesalers. Under such contracts, the Company is entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. Such credits are offset against the total distribution service fees paid to each such wholesaler. The variable consideration associated with price appreciation credits is reflected in the transaction price of products sold when it is determined to be probable that a significant reversal will not occur. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $17 million and $15 million for the years 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Assets and Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Commissions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financing Component&lt;/span&gt;&lt;/div&gt;The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1Njg3_0f3e1171-1954-413f-abaf-8cd611884741">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the activity and ending balances of the Company&#x2019;s variable consideration provisions the years 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,909)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i50ee5aa72d3d409087f4f4c75b43387e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzEtMi0xLTEtNTk0NzA_84793d6b-cd2d-446b-869a-88de4a8efb62"
      unitRef="usd">182000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i7f50340c36654f40b4735a136065dcab_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzEtNC0xLTEtNTk0NzA_6947c1e5-79be-43c1-abfd-19320f4d98bb"
      unitRef="usd">691000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i29d6eccdc67e42d784ec0e124b81624f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzEtNi0xLTEtNTk0NzA_aee622f2-19a6-4c11-9724-6fa7e0cf16e5"
      unitRef="usd">927000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if7c501561f5644f289468e4d1128d42e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzEtOC0xLTEtNTk0NzA_cc0eff52-7cc9-4baa-814a-a16af10f6a51"
      unitRef="usd">168000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia3cb4db468554971984b9ca7a67eb81a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzEtMTAtMS0xLTU5NDcw_1610f639-8b9a-4342-a7e4-d52461972498"
      unitRef="usd">82000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzEtMTItMS0xLTU5NDcw_2129bda0-f611-414d-89db-3e745b54b4a4"
      unitRef="usd">2050000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i2fec29ee013641edab8d6221c9266fd7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzMtMi0xLTEtNTk0NzA_e9b8c2df-1a0c-4109-8f06-bc6e50daa6a1"
      unitRef="usd">621000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i675cd2d759a7429ca02cfef6330b3cc6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzMtNC0xLTEtNTk0NzA_89d5b984-c9a8-421b-a1c7-97f2ccb0cdb1"
      unitRef="usd">120000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ic9f22e24d99e4b1784cee096b11f5492_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzMtNi0xLTEtNTk0NzA_580ef4a1-6ec0-4568-b85e-1d79bedc2bcd"
      unitRef="usd">2174000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i8ada5c2b4ba44f6890befae0c5abc3fc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzMtOC0xLTEtNTk0NzA_ef32a0ff-fedc-4c25-8473-641d0740ef30"
      unitRef="usd">1925000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ibfcf2240c9b14c88b49241f897539daa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzMtMTAtMS0xLTU5NDcw_fc1eb6fc-1e24-4084-9f4e-84c30b34d57e"
      unitRef="usd">196000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzMtMTItMS0xLTU5NDcw_69f45d83-1b16-4549-8151-66f70a54a08a"
      unitRef="usd">5036000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i2fec29ee013641edab8d6221c9266fd7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzQtMi0xLTEtNTk0NzA_a7e76937-3a58-462d-a911-2367923047b5"
      unitRef="usd">613000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i675cd2d759a7429ca02cfef6330b3cc6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzQtNC0xLTEtNTk0NzA_c476114b-60e9-45d2-9d7b-f5652179e0a1"
      unitRef="usd">236000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ic9f22e24d99e4b1784cee096b11f5492_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzQtNi0xLTEtNTk0NzA_67085882-1d21-4b03-8974-4c72770522d7"
      unitRef="usd">2322000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i8ada5c2b4ba44f6890befae0c5abc3fc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzQtOC0xLTEtNTk0NzA_bcbdd162-4fb7-40f7-90d4-e5cfd2fd5618"
      unitRef="usd">1909000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ibfcf2240c9b14c88b49241f897539daa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzQtMTAtMS0xLTU5NDcw_4248225c-b15c-40b0-a30b-613a0809a5e8"
      unitRef="usd">193000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzQtMTItMS0xLTU5NDcw_4acfa920-6ca9-4c87-bea4-5aebbd7e259d"
      unitRef="usd">5273000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ib2b595cb367c4f14bb366722419c77af_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzUtMi0xLTEtNTk0NzA_0420cac8-52a6-47a7-92bd-dfc887cff99b"
      unitRef="usd">190000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i833b35b656584bc39c2fb86f6978f755_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzUtNC0xLTEtNTk0NzA_a98b896c-978a-4a05-997d-100a377ded37"
      unitRef="usd">575000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i9b899431086f434796caec1c0bd402a8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzUtNi0xLTEtNTk0NzA_8a397e37-e002-427e-8eaa-09bca0c34789"
      unitRef="usd">779000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id26f10d6001d4bfd9222800e3b3bb4e3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzUtOC0xLTEtNTk0NzA_352575fb-2c0c-4691-b5b8-ab3fbbc4062a"
      unitRef="usd">184000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0b52931c7ab643db9a3682345b1db8cb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzUtMTAtMS0xLTU5NDcw_bd6da273-46d7-496b-8861-cf74d0344272"
      unitRef="usd">85000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzUtMTItMS0xLTU5NDcw_032752fe-8a0c-48a1-9498-a07bc84ab022"
      unitRef="usd">1813000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ib91d99188bc541b7a824988141b34ae8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzYtMi0xLTEtNTk0NzA_9c77bc74-3946-46c2-80fa-ffb07150b3f5"
      unitRef="usd">625000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i700d81ebc7e14a5ea0134f3fcf286f38_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzYtNC0xLTEtNTk0NzA_713cc418-eac0-468f-94f6-52564932c0b8"
      unitRef="usd">131000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="if7af96439d8641e2a7f6c2f01d4642bd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzYtNi0xLTEtNTk0NzA_8610de3e-4e40-49ea-afcb-3e82e5b23c0d"
      unitRef="usd">2462000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="id05dcbb022714c45b985fa95dd3e8361_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzYtOC0xLTEtNTk0NzA_eb2c8f9d-e518-45d7-b65d-af7c8d7da619"
      unitRef="usd">1999000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i6379354597f24e4290ab225072abe15b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzYtMTAtMS0xLTU5NDcw_29bbf56c-7769-48a8-b50e-57d5f9b4b621"
      unitRef="usd">211000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzYtMTItMS0xLTU5NDcw_f9510c0a-b527-46ce-9ffb-95b27ffc7b50"
      unitRef="usd">5428000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ib91d99188bc541b7a824988141b34ae8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzctMi0xLTEtNTk0NzA_c05643a9-0077-463c-b1ee-c6fbc9aee8bf"
      unitRef="usd">593000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i700d81ebc7e14a5ea0134f3fcf286f38_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzctNC0xLTEtNTk0NzA_8f54820e-439f-4233-9169-6187e607a4b4"
      unitRef="usd">224000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="if7af96439d8641e2a7f6c2f01d4642bd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzctNi0xLTEtNTk0NzA_ec9451d8-bbb5-4bd9-980e-4b886c8d2b0c"
      unitRef="usd">2297000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="id05dcbb022714c45b985fa95dd3e8361_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzctOC0xLTEtNTk0NzA_77a6e5ae-3b08-45d1-9671-866f39f73a7f"
      unitRef="usd">2013000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i6379354597f24e4290ab225072abe15b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzctMTAtMS0xLTU5NDcw_d9b80273-d12e-4032-a1a8-53d4e96a1750"
      unitRef="usd">251000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzctMTItMS0xLTU5NDcw_99aa0af2-939b-4d7f-b87e-2185c604830b"
      unitRef="usd">5378000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i87951ceed7ea4e5aa8491f46d9db41d2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzgtMi0xLTEtNTk0NzA_5aae8d8d-3e43-4185-8d3d-a83973b2ad06"
      unitRef="usd">222000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i1bac5a748c9c4daca0dcbeb78e404e12_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzgtNC0xLTEtNTk0NzA_2425e9e0-8169-4ce6-af31-6bd8105571e2"
      unitRef="usd">482000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6aa0cd8be82c40ad85b35a58508fa64c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzgtNi0xLTEtNTk0NzA_cd9fbb35-a646-4507-a80e-3ba58597d3a7"
      unitRef="usd">944000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i9942400776ce47beaad5aaea33213d31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzgtOC0xLTEtNTk0NzA_5a2f10a4-420c-4701-86ca-989401fa2535"
      unitRef="usd">170000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i74cfba0d37ba44869c896ccd738c2fea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzgtMTAtMS0xLTU5NDcw_9459eb86-218c-4bdb-80c2-58a300938d8b"
      unitRef="usd">45000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90YWJsZTpmZDU5MjhkZmE5ODU0NmU3ODgxNDA2MWQ4NWRiODYyZC90YWJsZXJhbmdlOmZkNTkyOGRmYTk4NTQ2ZTc4ODE0MDYxZDg1ZGI4NjJkXzgtMTItMS0xLTU5NDcw_fda4e534-4979-428e-a417-5be3fa7a4e21"
      unitRef="usd">1863000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ib40c6b7597d6467d804e55df949889b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzI2MzQ5_fb94851b-a18a-46eb-b9bc-960b00e59480"
      unitRef="usd">36000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i1ff61d6d82a848d6becbe126cfc26963_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzI2MzU2_301c20f2-a314-489d-9bd3-0ce467fd5ecc"
      unitRef="usd">32000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <bhc:CashDiscountsAndAllowancesSettlementPeriod
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzI4ODU1_1931d3fe-4f6c-48f6-9598-69b85c90fca8">P1M</bhc:CashDiscountsAndAllowancesSettlementPeriod>
    <bhc:SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzMwNTU5_cc96ee34-4572-4c2a-adb3-63d5feaeb76c"
      unitRef="usd">81000000</bhc:SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i700d81ebc7e14a5ea0134f3fcf286f38_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzMyNTc5_fc9dbb35-4645-47eb-9e1d-35a63f8c15f0"
      unitRef="usd">131000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i675cd2d759a7429ca02cfef6330b3cc6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzMyNTg2_0d510734-cbf7-4094-b75e-122bfe1b5aae"
      unitRef="usd">120000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="i700d81ebc7e14a5ea0134f3fcf286f38_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzMyNzIx_96715196-9fab-4527-8601-c7387ab5b725"
      unitRef="usd">-28000000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="i675cd2d759a7429ca02cfef6330b3cc6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzMyNzI4_f30451e3-9d4a-43df-aeea-e7888de607cd"
      unitRef="usd">-38000000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <bhc:SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzMzODg0_a2fe7464-9f9b-4c77-a814-9d8d617ce72a"
      unitRef="usd">76000000</bhc:SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09d8280f6d264587b97b2d17bcb992bd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM4NTEx_9f2f47ee-a9fc-4a71-b9d5-e7de082a4364"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib42d4166d63e4e788726dbd3033cb09c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM4NTE4_4701d43e-56fe-45fb-b1a0-c901af2d1225"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <bhc:RevenuePerformanceObligationPaymentTerms
      contextRef="i973d974eec8c4651854590262490ae2f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM5MzM1_5190b05c-a60b-46f8-b878-91e3f0963587">P90D</bhc:RevenuePerformanceObligationPaymentTerms>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ic93289a0b5264300a6c1b192827b7231_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM5NDg3_9ea32856-f2b4-4b91-bfa3-c1ddaaf9532d">P20Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ic93289a0b5264300a6c1b192827b7231_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzM5NTgx_713878d5-7c73-4302-a1f6-c4633a82f9e6">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NzAx_e232b6ed-ee44-4316-9990-1f2e19acfd45">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs related to internal research and development programs, including costs associated with the development of acquired IPR&amp;amp;D, are expensed as goods are delivered or services are performed. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Milestone payments made to third parties before a product receives regulatory approval, but after the milestone is determined to be probable, are expensed and included in Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from third parties as reimbursement of development activities conducted under certain research and development arrangements are recognized as a reduction of Research and development expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LegalCostsPolicyTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1Nzk1_fd0a9a8a-fe97-4a36-bd6e-7ba7f2c61769">Legal Costs Legal fees and other costs related to litigation and other legal proceedings or services are expensed as incurred and are included in Selling, general and administrative expenses. Certain legal costs associated with acquisitions are included in Acquisition-related costs and certain legal costs associated with divestitures, legal settlements and other business development activities are included in Litigation and other matters or Net gain on sales of assets within Other expense (income), net, as appropriate. Legal costs expensed are reported net of expected insurance recoveries. A claim for insurance recovery is recognized when realization becomes probable</us-gaap:LegalCostsPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1ODAy_1210010a-fcae-479b-bfe2-05687b30e636">Advertising CostsAdvertising costs comprise product samples, print media, promotional materials and television advertising and are expensed on the first use of the advertisement.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzQ1NDg1_bfc70445-5bdd-4676-a9da-46b365c886a5"
      unitRef="usd">515000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzQ1NDg5_2d73d75d-14fc-4bfb-a09b-80f84c363a1c"
      unitRef="usd">451000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzQ1NDk2_f4e084e8-4104-4760-88b3-71d55ca8fb52"
      unitRef="usd">544000000</us-gaap:AdvertisingExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1Nzg5_89cd629e-cad2-466a-a955-fe1d5d5e025f">Share-Based Compensation The Company recognizes all share-based payments to employees, including grants of employee stock options and restricted share units (&#x201c;RSUs&#x201d;), at estimated fair value. The Company amortizes the fair value of stock option or RSU grants on a straight-line basis over the requisite service period of the individual stock option or RSU grant, which generally equals the vesting period. Stock option and RSU forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based compensation is recorded in Research and development expenses and Selling, general and administrative expenses, as&#160;appropriate.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:InterestExpensePolicyTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1ODE2_a62e1d16-b608-4e87-8951-07e0715671a7">Interest Expense Interest expense includes standby fees, the amortization of debt discounts and deferred financing costs, accretion of debt premiums and the amortization of amounts excluded from the assessment of effectiveness related to the Company's cross-currency swaps. Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized.</us-gaap:InterestExpensePolicyTextBlock>
    <us-gaap:InterestCostsCapitalized
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzQ3NDIw_9afd653d-2442-4f65-920f-6745964e06bb"
      unitRef="usd">60000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzQ3NDI3_08df7943-b0c4-4892-929b-bd557fccff3f"
      unitRef="usd">45000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1Nzg0_cb1a4562-2b30-457a-b542-24173f82121a">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized. Deferred tax assets and liabilities are measured using enacted tax rates and&#160;laws.  Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such position are measured based on the amount for which there is a greater than 50% likelihood of being realized upon settlement. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within one year. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance&#160;sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <bhc:TaxBenefitRecognitionMeasurementPercentage
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzQ5MjY1_4d3eefb4-3f53-4d59-a305-539c9697a6e3"
      unitRef="number">0.50</bhc:TaxBenefitRecognitionMeasurementPercentage>
    <bhc:MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzQ5NDI4_8e8f4ce3-670e-4a54-9ec0-8c1769083a69">P1Y</bhc:MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NjMz_3ea3b7e5-0659-49ba-a001-eab9cbfdbdb0">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss Per Share Attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period. Diluted loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period after giving effect to dilutive potential common shares for stock options and RSUs, determined using the treasury stock&#160;method.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NjY0_7d7cad6b-f175-4473-a242-c61730553c5f">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss comprises Net loss and Other comprehensive (loss) income. Other comprehensive (loss) income includes items such as foreign currency translation adjustments, unrealized holding gains and losses on available-for-sale and other investments and certain pension and other postretirement benefit plan adjustments. Accumulated other comprehensive loss is recorded as a component of shareholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1Njg0_808d3477-ef3f-4fee-a87c-6d907c2b3721">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company is subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Accruals for loss contingencies are recorded when the Company determines that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the estimate of the amount of the loss is a range and some amount within the range appears to be a better estimate than any other amount within the range, that amount is accrued as a liability. If no amount within the range is a better estimate than any other amount, the minimum amount of the range is accrued as a&#160;liability. These accruals are adjusted periodically as assessments change or additional information becomes available.&lt;/span&gt;&lt;/div&gt;If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred.</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:PensionAndOtherPostretirementPlansPolicy
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NzE2_cc638fb6-21de-4e67-9af7-d03e7d9cff0f">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Benefit Plans &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors various retirement and pension plans, including defined benefit pension plans, defined contribution plans and a participatory defined benefit postretirement plan. The determination of defined benefit pension and postretirement plan obligations and their associated expenses requires the use of actuarial valuations to estimate the benefits employees earn while working, as well as the present value of those benefits. Net actuarial gains and losses that exceed 10 percent of the greater of the plan&#x2019;s projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated average future service period of the plan participants (or the &lt;/span&gt;&lt;/div&gt;estimated average future lifetime of the plan participants if the majority of plan participants are inactive) or the period until any anticipated final plan settlements.</us-gaap:PensionAndOtherPostretirementPlansPolicy>
    <bhc:DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzUyMTQ2_a0289313-cda5-4e24-9917-7e929b62e20b"
      unitRef="number">0.10</bhc:DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzU1NzM2_1824406d-c129-4088-8fa5-c0ebadb1fcac">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New&#160;Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board ("FASB") issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses.  The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to Accumulated deficit of less than $1&#160;million. The application of this guidance did not have a material effect on the Company's results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement.  The guidance was effective for the Company beginning January 1, 2020. The application of this guidance did not have a material effect on the Company's disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans.  The guidance was effective for annual periods ending after December 15, 2020. The application of this guidance did not have a material effect on the Company's disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160; The guidance is effective for the Company beginning with annual periods beginning January 1, 2021.&#160; The application of this guidance did not have a material effect on the Company's financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.&#160; Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging.&#160;The optional amendments are effective for all entities as of March 12, 2020, through December 31, 2022. During 2020 and 2021, the Company has not entered into any contract modifications in which the optional expedients were applied.&#160; However, if prior to December 31, 2022, the Company enters into a contract modification in which the optional expedients are applied, the Company will evaluate the impact of adoption of this guidance on its financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2ea97ac3ab7a4d41bb8383aabfb051e7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDQvZnJhZzo0YTBiMjYzOGUzNGI0NWEwYmJhZjVhNDExMzEzNDcyMS90ZXh0cmVnaW9uOjRhMGIyNjM4ZTM0YjQ1YTBiYmFmNWE0MTEzMTM0NzIxXzEwOTk1MTE3MDM1ODE_1a58b810-38d8-41af-a3aa-f2298e300f63"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzYwMzU_3a8709a9-e357-42f9-bb8a-68d9d9ac1b34">ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition Agreement for Synergy Pharmaceuticals Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 6, 2019, the Company acquired certain assets of Synergy Pharmaceuticals Inc. ("Synergy") for a cash purchase price of approximately $180 million and the assumption of certain liabilities, pursuant to the terms approved by the U.S. Bankruptcy Court for the Southern District of New York on March 1, 2019. Among the assets acquired are the worldwide rights to the Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (plecanatide) product, a once-daily tablet for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. This acquired business is included in the Company's Salix segment and is expected to result in additional revenues and costs savings associated with business synergies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of certain assets of Synergy has been accounted for as a business combination under the acquisition method of accounting since: (i) substantially all of the fair value of the assets acquired is not&#160;concentrated in a single identifiable asset or group of similar identifiable assets and (ii) substantive inputs and processes were acquired to contribute to the creation of outputs. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product brand intangible assets (estimated useful life 7 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill associated with the acquisition of certain assets of Synergy is not deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue and Operating Results &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 were $55 million. Operating results associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 and pro-forma revenues and operating results for the year 2019 were not material. Included in Other expense, net for 2019 are acquisition-related costs of $8 million directly related to the acquisition of certain assets of Synergy, which include expenditures for advisory, legal, valuation, accounting and other similar services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no other material business combinations in 2021, 2020 or 2019. The measurement period for all acquisitions has closed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Option to Purchase All Ophthalmology Assets of Allegro Ophthalmics, LLC ("Allegro")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 21, 2020, the Company announced that it had entered into an agreement to acquire an option to purchase all of the ophthalmology assets of Allegro (the "Option"), a privately held biopharmaceutical company focused on the development of therapies that regulate integrin functions for the treatment of ocular diseases. Among the assets to be acquired if the Option was exercised, were the worldwide rights to risuteganib (Luminate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), Allegro's lead investigational compound in retina, which is believed to simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry Age-related Macular Degeneration.  During the three months ended September 30, 2020, the Company made and expensed as acquired IPR&amp;amp;D included in Other expense, net, an initial upfront payment of $10&#160;million to acquire the Option.  However, on June 23, 2021, Allegro notified the Company that it did not raise the additional funding required under the option agreement.  Pursuant to the terms of the option agreement, the Option thereby terminated, and the Company exercised its right to convert the $10&#160;million upfront payment into a minor equity interest in Allegro.  The Company expects that it will make no additional payments pursuant to this option agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions.  The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain.  The commitment periods under these agreements vary and include customary termination provisions.  Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Divestiture of Amoun Pharmaceutical Company S.A.E. ("Amoun")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 31, 2021, the Company announced that it and certain of its affiliates had entered into a definitive agreement to sell all of its equity interests in Amoun for total gross consideration of approximately $740&#160;million (including the assignment to the purchasing entity of an intercompany loan granted by the Company to Amoun), subject to certain adjustments (the &#x201c;Amoun Sale&#x201d;). The Amoun Sale closed on July 26, 2021. As part of the Amoun Sale, cash generated by Amoun during the period from the locked-box date of January 1, 2021 through closing was for the benefit of the purchasing entity, subject to working capital during such period. Amoun manufactures, markets and distributes branded generics of human and animal health products. The Amoun business was part of the International Rx segment (previously &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;included within the former Bausch + Lomb/International segment) and was reclassified as held for sale as of December 31, 2020. As a result of meeting the criteria for held for sale classification, the carrying value of the Amoun business, was adjusted to its estimated fair value, less costs to sell, and the Company recognized an impairment loss of $96&#160;million during the three months ended December 31, 2020 and an additional impairment loss of $88&#160;million during 2021, included within Asset impairments, including loss on assets held for sale in the Consolidated Statements of Operations. In connection with completing the Amoun Sale, the Company recognized an additional loss of $26&#160;million during 2021, included within Other (income) expense, net in the Combined Statements of Operations. The total loss of $210&#160;million includes the release of non-cash cumulative foreign currency translation losses of $340&#160;million, which were included as part of the carrying value of the Amoun business when measuring for impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in the Consolidated Balance Sheets as of December 31, 2020 are the following carrying amounts of the Amoun business' assets and liabilities held for sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.009%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill and Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="icfeb956295ef4b16a85e6e4149d35c24_D20190306-20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzIwNQ_0dbf81d9-9338-482b-9c10-3bf69abcb511"
      unitRef="usd">180000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzYwMzY_69847499-3b77-408c-8db1-4ea52b0dc2da">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product brand intangible assets (estimated useful life 7 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i92ebac933dea48b489400e86f7f489fe_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZTpmYjQ1Mjk4N2ViYWQ0ZmQ2OTRhNzE3MGM0ZGY5NTQyMS90YWJsZXJhbmdlOmZiNDUyOTg3ZWJhZDRmZDY5NGE3MTcwYzRkZjk1NDIxXzEtMS0xLTEtNTk0NzA_0d71d9df-3acd-4d0e-8d6e-6a14d7333034"
      unitRef="usd">7000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i92ebac933dea48b489400e86f7f489fe_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZTpmYjQ1Mjk4N2ViYWQ0ZmQ2OTRhNzE3MGM0ZGY5NTQyMS90YWJsZXJhbmdlOmZiNDUyOTg3ZWJhZDRmZDY5NGE3MTcwYzRkZjk1NDIxXzItMS0xLTEtNTk0NzA_02bf4c9c-1104-4ea6-9078-341b57d0119d"
      unitRef="usd">24000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="i92ebac933dea48b489400e86f7f489fe_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZTpmYjQ1Mjk4N2ViYWQ0ZmQ2OTRhNzE3MGM0ZGY5NTQyMS90YWJsZXJhbmdlOmZiNDUyOTg3ZWJhZDRmZDY5NGE3MTcwYzRkZjk1NDIxXzMtMS0xLTEtNTk0NzA_d05194a5-bab6-4578-bfcb-f5cae8b30955"
      unitRef="usd">5000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="icfeb956295ef4b16a85e6e4149d35c24_D20190306-20190306"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZTpmYjQ1Mjk4N2ViYWQ0ZmQ2OTRhNzE3MGM0ZGY5NTQyMS90YWJsZXJhbmdlOmZiNDUyOTg3ZWJhZDRmZDY5NGE3MTcwYzRkZjk1NDIxXzQtMC0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo4MTFiNDJlM2JjZTA0Y2EzYWZmZWM5Mzg1MzU4ZTZkYV81OQ_cbbc416c-64fc-458b-bed8-6afe0d992452">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i92ebac933dea48b489400e86f7f489fe_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZTpmYjQ1Mjk4N2ViYWQ0ZmQ2OTRhNzE3MGM0ZGY5NTQyMS90YWJsZXJhbmdlOmZiNDUyOTg3ZWJhZDRmZDY5NGE3MTcwYzRkZjk1NDIxXzQtMS0xLTEtNTk0NzA_92a0e6a3-34a6-456f-a954-3dbb11be6532"
      unitRef="usd">159000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i92ebac933dea48b489400e86f7f489fe_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZTpmYjQ1Mjk4N2ViYWQ0ZmQ2OTRhNzE3MGM0ZGY5NTQyMS90YWJsZXJhbmdlOmZiNDUyOTg3ZWJhZDRmZDY5NGE3MTcwYzRkZjk1NDIxXzUtMS0xLTEtNTk0NzA_85033299-e695-4ae0-add1-cb4862190bad"
      unitRef="usd">1000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <bhc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses
      contextRef="i92ebac933dea48b489400e86f7f489fe_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZTpmYjQ1Mjk4N2ViYWQ0ZmQ2OTRhNzE3MGM0ZGY5NTQyMS90YWJsZXJhbmdlOmZiNDUyOTg3ZWJhZDRmZDY5NGE3MTcwYzRkZjk1NDIxXzYtMS0xLTEtNTk0NzA_3a0922db-68c5-4de6-9b41-2db9b87d5bef"
      unitRef="usd">17000000</bhc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i92ebac933dea48b489400e86f7f489fe_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZTpmYjQ1Mjk4N2ViYWQ0ZmQ2OTRhNzE3MGM0ZGY5NTQyMS90YWJsZXJhbmdlOmZiNDUyOTg3ZWJhZDRmZDY5NGE3MTcwYzRkZjk1NDIxXzctMS0xLTEtNTk0NzA_52a47c95-c95a-47da-8232-d2e53e0c7d62"
      unitRef="usd">177000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="i92ebac933dea48b489400e86f7f489fe_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZTpmYjQ1Mjk4N2ViYWQ0ZmQ2OTRhNzE3MGM0ZGY5NTQyMS90YWJsZXJhbmdlOmZiNDUyOTg3ZWJhZDRmZDY5NGE3MTcwYzRkZjk1NDIxXzgtMS0xLTEtNTk0NzA_02e69166-ad25-4f78-9b00-3dcf188aae4d"
      unitRef="usd">3000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i92ebac933dea48b489400e86f7f489fe_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZTpmYjQ1Mjk4N2ViYWQ0ZmQ2OTRhNzE3MGM0ZGY5NTQyMS90YWJsZXJhbmdlOmZiNDUyOTg3ZWJhZDRmZDY5NGE3MTcwYzRkZjk1NDIxXzktMS0xLTEtNTk0NzA_29fd5e7a-459f-4d39-8757-31953050d033"
      unitRef="usd">180000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="i90f9c8b2069447318643874fdd998562_D20190306-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzE2MzI_54648f86-b6b6-41a0-81b0-abbbad3187fd"
      unitRef="usd">55000000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <bhc:BusinessAcquisitionProFormaOperatingIncomeLoss
      contextRef="i1875d6eb59814b65a56bf3c1ee9b5056_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzE4MjU_0ff34a91-86b0-4330-9bf5-ab7b1e5856ec"
      unitRef="usd">0</bhc:BusinessAcquisitionProFormaOperatingIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i1875d6eb59814b65a56bf3c1ee9b5056_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzE4MjU_21ef7460-b5ac-4d3e-a65f-68a0d6bf46bc"
      unitRef="usd">0</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <bhc:BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual
      contextRef="i90f9c8b2069447318643874fdd998562_D20190306-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzE4MjU_90048b8d-20dd-483a-a886-3844a23316ff"
      unitRef="usd">0</bhc:BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1875d6eb59814b65a56bf3c1ee9b5056_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzE4OTQ_deb348a0-0721-48c0-b353-b4df892fc114"
      unitRef="usd">-8000000</us-gaap:OtherNonoperatingIncomeExpense>
    <bhc:NumberOfOtherBusinessesAcquired
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI0Mzc_18387703-fdbb-4e46-868c-ec55023c8b8a"
      unitRef="businesscombination">0</bhc:NumberOfOtherBusinessesAcquired>
    <bhc:NumberOfOtherBusinessesAcquired
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI0Mzc_ad0dcd36-9532-485c-8000-f15c973aa01b"
      unitRef="businesscombination">0</bhc:NumberOfOtherBusinessesAcquired>
    <bhc:NumberOfOtherBusinessesAcquired
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI0Mzc_ced95c46-bc8d-4a24-966c-b7d74a252f34"
      unitRef="businesscombination">0</bhc:NumberOfOtherBusinessesAcquired>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i1c4424c16be247649ea9c0793b64485d_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI3NDg3NzkwODI4NDM_b8fd5d79-42ff-4650-beeb-36603dcd421a"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="i7f2a7103479740d6b997c87b639888ea_D20210623-20210623"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI3NDg3NzkwODI4NTY_0db899e9-848b-492f-a06a-cc759c4d90a0"
      unitRef="usd">10000000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <bhc:AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI3NDg3NzkwODI4Njg_0e73c3ad-8b80-4dcb-9c52-39be34d39e3a"
      unitRef="usd">0</bhc:AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i8d780f8e498d4029a20e1dfba48ddaf8_D20210726-20210726"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI3NDg3NzkwODI4Nzc_238d722b-aeab-4b13-9d70-3343529c7f6f"
      unitRef="usd">740000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i1232cd05f1bf44d2a67fedd36c0d6cd8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI3NDg3NzkwODI4OTE_9f784272-e584-4ad4-8dc9-7c0d01c0e64e"
      unitRef="usd">96000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i2798f6e7b2e943c583b2aca3a95d9902_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI3NDg3NzkwODI5MDQ_e1d9c911-e4c1-4b29-9cb9-6d6ebb5826e6"
      unitRef="usd">88000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i8fd89ab94eae4b75848759e31a502deb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI3NDg3NzkwODI5MTc_e064cf99-6bce-40de-9f1f-80b9ee22a1c4"
      unitRef="usd">26000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i814496642aa544b0bd6eb9e21c9c38ce_D20200101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI3NDg3NzkwODI5MzA_e0eea973-7349-4657-bb79-5de59b09f76d"
      unitRef="usd">210000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <bhc:NoncashCumulativeForeignCurrencyTranslationLoss
      contextRef="i814496642aa544b0bd6eb9e21c9c38ce_D20200101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzI3NDg3NzkwODI5NDQ_a5fea4d9-d9f3-4c21-94ce-ad905721d4b8"
      unitRef="usd">340000000</bhc:NoncashCumulativeForeignCurrencyTranslationLoss>
    <us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90ZXh0cmVnaW9uOmYxODU2NGRjNmI5NzQ3NWE4OWY3NzgyYzgyNjVlODFhXzYwMjA_6fce20ac-4ebf-42e7-a2fb-59e27624093a">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in the Consolidated Balance Sheets as of December 31, 2020 are the following carrying amounts of the Amoun business' assets and liabilities held for sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.009%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill and Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="id13cd655709045658273ebf2abdba2e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzItMi0xLTEtNTk0NzA_634f59d1-9ece-40af-85da-e2c32a95d8b0"
      unitRef="usd">91000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
      contextRef="id13cd655709045658273ebf2abdba2e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzItNi0xLTEtNjk1NTg_1e76c9e5-a79a-4fd7-905e-053a7d7ca0a5"
      unitRef="usd">7000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
      contextRef="id13cd655709045658273ebf2abdba2e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzMtMi0xLTEtNTk0NzA_c87c2100-e489-4b0a-9379-5c616c06ff70"
      unitRef="usd">63000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <bhc:DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent
      contextRef="id13cd655709045658273ebf2abdba2e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzMtNi0xLTEtNjk1NTg_eef2ee84-dd49-4955-9fed-f1f473b14413"
      unitRef="usd">28000000</bhc:DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="id13cd655709045658273ebf2abdba2e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzQtMi0xLTEtNTk0NzA_24d70048-0fcd-43a4-95b3-ff74dbb77d5d"
      unitRef="usd">8000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities
      contextRef="id13cd655709045658273ebf2abdba2e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzQtNi0xLTEtNjk1NTg_b17e6eea-bc4b-4e87-95bb-034522274b4c"
      unitRef="usd">35000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets
      contextRef="id13cd655709045658273ebf2abdba2e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzUtMi0xLTEtNTk0NzA_add58399-01e2-4fca-a64c-b873d5cb37c1"
      unitRef="usd">162000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
      contextRef="id13cd655709045658273ebf2abdba2e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzctMi0xLTEtNTk0NzA_44085fcb-dd6f-4308-835b-c396e47e2102"
      unitRef="usd">68000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities
      contextRef="id13cd655709045658273ebf2abdba2e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzctNi0xLTEtNjk1NTg_320a3049-e1bc-46e7-be0d-75d628aaf48e"
      unitRef="usd">36000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="id13cd655709045658273ebf2abdba2e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzgtMi0xLTEtNTk0NzA_b3572df5-c4e0-4381-98ce-da5e4b0389fd"
      unitRef="usd">245000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <bhc:DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent
      contextRef="id13cd655709045658273ebf2abdba2e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzgtNi0xLTEtNjk1NTg_9e91d667-0300-4e77-a3f9-2dd94e643856"
      unitRef="usd">21000000</bhc:DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets
      contextRef="id13cd655709045658273ebf2abdba2e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzktMi0xLTEtNTk0NzA_fc6278bc-c81b-41f0-8e23-27bd3c932be4"
      unitRef="usd">2000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities
      contextRef="id13cd655709045658273ebf2abdba2e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzktNi0xLTEtNjk2MDM_01a2ba5c-70c9-4dc5-b6aa-8a06cd9895e2"
      unitRef="usd">57000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets
      contextRef="id13cd655709045658273ebf2abdba2e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMDcvZnJhZzpmMTg1NjRkYzZiOTc0NzVhODlmNzc4MmM4MjY1ZTgxYS90YWJsZToyM2I3MGY4OTQ4MmE0NTRhODE5Y2RiYjcxNWMxYzFmMi90YWJsZXJhbmdlOjIzYjcwZjg5NDgyYTQ1NGE4MTljZGJiNzE1YzFjMWYyXzEwLTItMS0xLTU5NDcw_23b9f93f-205d-4735-92f2-f32d41ba09dc"
      unitRef="usd">315000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzI3OTc_cf6cce1a-030a-4a1b-9a5c-3096777a9a05">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restructuring and integration costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of December 31, 2021 was $19 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred $18&#160;million, $11&#160;million and $31&#160;million of restructuring and integration-related costs and made payments of $19&#160;million, $18&#160;million and $31 million during 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Separation costs, Separation-related costs, IPO Costs and IPO-related Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred, and will incur, costs associated with activities to effectuate the B+L Separation and the Solta IPO. These activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company and (ii) registering the Bausch + Lomb and Solta Medical businesses as independent publicly traded entities. Separation and IPO costs are incremental costs directly related to the B+L Separation and Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for the Bausch + Lomb and Solta Medical entities. Included in Restructuring, integration, separation and IPO costs for the years ended December 31, 2021 and 2020 are Separation and IPO costs of $32&#160;million and $11&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has also incurred, and will incur, Separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and Solta IPO. Separation-related and IPO-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative for years ended December 31, 2021 and 2020 are Separation-related and IPO-related costs of $132&#160;million and $21&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="ic96cba168a6f45b0b15835dcb29e9eef_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzY1OA_f3c21ec5-a387-4c46-ab5e-b73a9e7f0b47"
      unitRef="usd">19000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4700fec630cc4d3393d58b8d2b00fd5d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzM4NDgyOTA3MDcxMjY_25b0e39e-9c2d-4144-bfc4-ff0fb3712ea8"
      unitRef="usd">18000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i40cc87b109454b6cb74b6178982151c4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzEwOTk1MTE2MzcyNDY_bed656dd-0c37-45c5-b1e5-42632146e1e7"
      unitRef="usd">11000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i02c2d8581fcc4e74af1f8728d7f5cb05_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzM4NDgyOTA3MDcxMzg_a94887ef-0d8b-4d8e-919f-abddea7c697b"
      unitRef="usd">31000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:PaymentsForRestructuring
      contextRef="i4700fec630cc4d3393d58b8d2b00fd5d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzM4NDgyOTA3MDcxMTM_6ef32d67-461a-4d7b-8cc2-6ec65d085b9c"
      unitRef="usd">19000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i40cc87b109454b6cb74b6178982151c4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzEwOTk1MTE2MzcyNTk_0ff48519-96da-47bb-b1ee-5f9184b5e5a8"
      unitRef="usd">18000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i02c2d8581fcc4e74af1f8728d7f5cb05_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzExOTU_63981296-8b57-4a64-92fa-40ba058601c7"
      unitRef="usd">31000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringCharges
      contextRef="idc7bec622b0e4d06914e435a52d614cc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzM4NDgyOTA3MDYyNTg_7f9f6e58-188c-43bf-a44e-d62ddef29e4c"
      unitRef="usd">32000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i50d1eaed93cd4379b62a15c354a4c436_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzM4NDgyOTA3MDYyNzE_45001a23-c830-4c4a-a4d7-347aebefafba"
      unitRef="usd">11000000</us-gaap:RestructuringCharges>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="idc7bec622b0e4d06914e435a52d614cc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzM4NDgyOTA3MDYyNDU_718f3e79-f3bf-46d4-b5fc-4e8d3ec1b31c"
      unitRef="usd">132000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i50d1eaed93cd4379b62a15c354a4c436_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTAvZnJhZzozNWRkNDVlZDU0NGQ0NTZkYjdiN2Q4YjM2MmU3ZmRhZi90ZXh0cmVnaW9uOjM1ZGQ0NWVkNTQ0ZDQ1NmRiN2I3ZDhiMzYyZTdmZGFmXzM4NDgyOTA3MDYyMzM_64116994-3721-44af-944b-0f78ac1b4ad3"
      unitRef="usd">21000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzY5MDE_0a68bd89-bccd-4dba-a6c4-2b220edcca9a">FAIR VALUE MEASUREMENTS&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1&#160;&#x2014;&#160;Quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2&#160;&#x2014;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3&#160;&#x2014;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents the components and classification of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis as of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash and other settlement deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of three months or less when&#160;purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, Restricted cash and other settlement deposits includes $1,510&#160;million of payments into escrow funds under the terms of settlement agreements regarding that certain U.S. securities litigation (subject to an objector's appeal of the final court approval) and the Glumetza Antitrust Litigation. These payments are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature.  These payments will remain in escrow until final approval of the settlements as discussed in Note 20, "LEGAL PROCEEDINGS".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers into or out of Level 3 during 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cross-currency Swaps&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $1,250 million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from adverse movements in exchange rates. The euro-denominated net investment being hedged was the Company&#x2019;s investment in certain euro-denominated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During November 2021, the Company entered into a transaction to unwind its cross-currency swaps and received net proceeds of $4&#160;million, which included interest income of $6&#160;million, offset by the amount owed by the Company upon the unwinding of $2&#160;million. The gain arising from the transaction of the swaps has been included as a component of Other comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with the Company's cross-currency swaps as included in the Consolidated Balance Sheets as of December 31, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain excluded from assessment of hedge effectiveness&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location of gain of excluded component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2021 and 2020, the Company received $27&#160;million and $23&#160;million, respectively, in settlements of its cross-currency swaps which are reported as Investing activities in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Exchange Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021 and 2020, the Company entered into foreign currency exchange contracts.  As of December&#160;31, 2021, these contracts had an aggregate outstanding notional amount of $166&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with the Company's foreign exchange contracts as included in the Consolidated Balance Sheets as of December 31, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of the Company's foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) related to changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss related to settlements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition-related Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At December&#160;31, 2021, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 6% to 18%, and a weighted average risk-adjusted discount rate of 7%. The weighted average risk-adjusted discount rate was calculated by weighting each contract's relative fair value at December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the years 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning balance, January 1, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to Acquisition-related contingent consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion for the time value of money&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments / Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment included in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance, December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components and classification of the Company&#x2019;s financial assets and liabilities measured at fair value on a non-recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.277%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.364%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current assets held for sale of $245&#160;million as of December 31, 2020 were remeasured to estimated fair value, less costs to sell, which utilized Level 3 unobservable inputs. See Note 3, "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE" for additional details regarding these assets held for sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Long-term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of long-term debt as of December&#160;31, 2021 and 2020 was $22,689 million and $25,378 million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2).&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzY4Nzk_9fb4270b-8350-4266-af98-055c21eb85e1">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents the components and classification of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis as of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash and other settlement deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8ef833b76dda454f9e12e7a602fedd25_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzMtMi0xLTEtNTk0NzA_b3fb367c-bf07-4cb8-a16a-0f1563ae6463"
      unitRef="usd">76000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9a1d3254b1a94b428ef1e3c8512a59fd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzMtNC0xLTEtNTk0NzA_db0bcd80-2b4f-4b7c-b957-057360e37f72"
      unitRef="usd">58000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1bc0f8f4b2124e1697e59545800c5d9e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzMtNi0xLTEtNTk0NzA_c1097163-09e0-44cb-9009-e0fd48e3ef1f"
      unitRef="usd">18000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4e94131e350d4b8b90275b3532694a75_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzMtOC0xLTEtNTk0NzA_10f7a767-3c52-49af-a9fb-0d59d84fa1b1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i32d030d4baca4c79874c13a25d51d367_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzMtMTAtMS0xLTU5NDcw_39934316-92d3-400e-bd0b-f2fad04ea9b5"
      unitRef="usd">41000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia7f4579ec74b4323bcd997517762bd3e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzMtMTItMS0xLTU5NDcw_09395cce-f624-4806-9cb5-3edf91eb23b5"
      unitRef="usd">8000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i226c603a08c64fa89f2932e3d795dd43_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzMtMTQtMS0xLTU5NDcw_d285be8d-da7e-482a-9aae-796b7babe999"
      unitRef="usd">33000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id82b7c18fe4748eca290dd25b0edd254_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzMtMTYtMS0xLTU5NDcw_c51beaab-5f1f-4cc3-b0bf-8899ea3a2f8d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i8ef833b76dda454f9e12e7a602fedd25_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzQtMi0xLTEtNTk0NzA_a25634dd-374a-4d84-83b5-e6b8f8e7b1f0"
      unitRef="usd">1537000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i9a1d3254b1a94b428ef1e3c8512a59fd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzQtNC0xLTEtNTk0NzA_b9f24bd1-e356-4018-b1fb-23a2a60586a5"
      unitRef="usd">1537000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i1bc0f8f4b2124e1697e59545800c5d9e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzQtNi0xLTEtNTk0NzA_dfd8a5d9-6c02-47c8-9983-63b04d4aea12"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i4e94131e350d4b8b90275b3532694a75_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzQtOC0xLTEtNTk0NzA_ac5e3586-19d3-43fe-934a-e6dea6253104"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i32d030d4baca4c79874c13a25d51d367_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzQtMTAtMS0xLTU5NDcw_84cace11-b6a8-4e79-ad69-efe0b6ff3407"
      unitRef="usd">1211000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="ia7f4579ec74b4323bcd997517762bd3e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzQtMTItMS0xLTU5NDcw_5134916a-86e2-4e51-9eed-8b1ed672898a"
      unitRef="usd">1211000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i226c603a08c64fa89f2932e3d795dd43_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzQtMTQtMS0xLTU5NDcw_69e07de2-c65d-432b-b3a0-fbf6ed04be2e"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="id82b7c18fe4748eca290dd25b0edd254_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzQtMTYtMS0xLTU5NDcw_3695c75d-f151-46e4-90dc-744e33ec9979"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <us-gaap:DerivativeAssets
      contextRef="i07b2e0ad215d4a8e8263f35c5dfd3e26_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzUtMi0xLTEtNTk0NzA_0c9c6613-0747-425b-982d-45c4b6dac03f"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i39aef971f8c64d94a2d8e897d769f1f3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzUtNC0xLTEtNTk0NzA_fd6ad121-9234-4d6d-b45f-d24fc5705dc6"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ic994d881fee945cf9668a1135e61ad23_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzUtNi0xLTEtNTk0NzA_bddc0b10-02ba-41bf-aafb-f3918db66439"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ie0345bec09794bf6818fdf23d88bb454_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzUtOC0xLTEtNTk0NzA_0117f7a8-3fb8-4c2a-af19-0334321be16d"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ic5ffbb6654b542aa8ccc9d51f2e0cb73_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzUtMTAtMS0xLTU5NDcw_e403e8a7-add4-413f-a812-9e3100209748"
      unitRef="usd">3000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ib5fa8ed492a8463a9ef8d402daa38f5e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzUtMTItMS0xLTU5NDcw_80c03e22-7dfe-4c8d-bb3c-028f2b94b5de"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i923bf4abdb6749c7b03cfcf01cb232fa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzUtMTQtMS0xLTU5NDcw_7ffa4587-7e0a-4c96-864c-48e84c661f2b"
      unitRef="usd">3000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i744dc2c483db45c7b8cb3c1300c54643_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzUtMTYtMS0xLTU5NDcw_22398730-dca6-4eeb-a630-c3e602a519a3"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i8ef833b76dda454f9e12e7a602fedd25_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzctMi0xLTEtNTk0NzA_ad5f4116-eb62-4472-b09a-c0d4a02fda7b"
      unitRef="usd">241000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i9a1d3254b1a94b428ef1e3c8512a59fd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzctNC0xLTEtNTk0NzA_e20d512c-a9c4-4ee6-96f4-2f4f3f0b8571"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i1bc0f8f4b2124e1697e59545800c5d9e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzctNi0xLTEtNTk0NzA_9ee25f6f-bf89-40a8-ae22-baac38d3f09a"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i4e94131e350d4b8b90275b3532694a75_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzctOC0xLTEtNTk0NzA_5f3d825c-d8e4-44ce-bcb4-693ce8461931"
      unitRef="usd">241000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i32d030d4baca4c79874c13a25d51d367_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzctMTAtMS0xLTU5NDcw_628afbcf-6a4c-4536-a6dc-5412afe63f1b"
      unitRef="usd">328000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="ia7f4579ec74b4323bcd997517762bd3e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzctMTItMS0xLTU5NDcw_1a466313-3e94-4ac9-b492-195b48fdd808"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i226c603a08c64fa89f2932e3d795dd43_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzctMTQtMS0xLTU5NDcw_68605804-a1e2-4c78-a738-d0223b3d001a"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="id82b7c18fe4748eca290dd25b0edd254_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzctMTYtMS0xLTU5NDcw_e97fc79f-8532-4f97-9291-e4d2ce07ae8c"
      unitRef="usd">328000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="if290d3a1005a4badb0ac05c0dbe5aae2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzgtMi0xLTEtNTk0NzA_5348a747-fcef-40a0-8fbb-e8da4c5ea2fe"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ifeb1d5a40c474d86b7665045cbbcdd54_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzgtNC0xLTEtNTk0NzA_1bb40a55-d5ce-407e-be7b-2d732bc41739"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ib35ef1ef18f04163ab0711c21275b0be_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzgtNi0xLTEtNTk0NzA_72400037-8498-44b5-81df-b8b20a21ed2c"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i37dd8e5d148e4ce6a785c5011b46b450_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzgtOC0xLTEtNTk0NzA_4a70fce6-6e38-403a-a464-98e4f891185b"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i9aa901695e224cd3bda948346e4c12ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzgtMTAtMS0xLTU5NDcw_be3b73b6-709d-4287-aa6c-06d3691ad767"
      unitRef="usd">70000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i7ac66312bf2147d1906b5192293868da_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzgtMTItMS0xLTU5NDcw_a7674e54-9bf0-4739-a330-f62319bd5afa"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id1889026b5e64c829d9bc334d4f52cfe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzgtMTQtMS0xLTU5NDcw_38195575-d1ae-4612-adb8-c38f1778ace3"
      unitRef="usd">70000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i8245159f69c94307993efff3243a1178_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzgtMTYtMS0xLTU5NDcw_224dd15c-ad0d-4b6b-ae08-dc508f66f55a"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i07b2e0ad215d4a8e8263f35c5dfd3e26_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzktMi0xLTEtNTk0NzA_415b825f-7a00-4466-837d-ecbc6d03e324"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i39aef971f8c64d94a2d8e897d769f1f3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzktNC0xLTEtNTk0NzA_fba818f9-d972-438f-8bc8-c0ae8817bdd7"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ic994d881fee945cf9668a1135e61ad23_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzktNi0xLTEtNTk0NzA_b7f2a7df-ca70-4669-8625-dc740fafe6fb"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ie0345bec09794bf6818fdf23d88bb454_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzktOC0xLTEtNTk0NzA_c4c735d7-f540-435d-8b5b-be838daa63e9"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ic5ffbb6654b542aa8ccc9d51f2e0cb73_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzktMTAtMS0xLTU5NDcw_fdb46d82-b530-428a-85d8-f5c327033c38"
      unitRef="usd">11000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ib5fa8ed492a8463a9ef8d402daa38f5e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzktMTItMS0xLTU5NDcw_3166e89f-721e-4bd2-9358-844ca264e1aa"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i923bf4abdb6749c7b03cfcf01cb232fa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzktMTQtMS0xLTU5NDcw_23f8be8e-9fe1-4132-9331-2fabff664203"
      unitRef="usd">11000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i744dc2c483db45c7b8cb3c1300c54643_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphNThkNWE0Nzk3NDE0NmVlYjRiNTIyYjJjZGRmZjY2ZS90YWJsZXJhbmdlOmE1OGQ1YTQ3OTc0MTQ2ZWViNGI1MjJiMmNkZGZmNjZlXzktMTYtMS0xLTU5NDcw_7c7fb190-dc92-4b85-b454-a34d53a5355d"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <bhc:HighlyLiquidInvestmentsMaturityPeriod
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzEzOTA_d67ffe5a-b12b-4636-87f1-1d61eefe3590">P3M</bhc:HighlyLiquidInvestmentsMaturityPeriod>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i23aea785e01a442a92655b06b1baeaf3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzE1ODY_fd9e6322-2103-480b-912c-e4478be23c34"
      unitRef="usd">1510000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8d8d666e2aca457593b6a68cc6c05534_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzIxNzk_837de477-7730-4eac-88cb-638b58c4a5a7"
      unitRef="usd">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ProceedsFromHedgeInvestingActivities
      contextRef="ic8c7dd3d755f4d23a5c91bada3e42ee9_D20211101-20211130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzM4NDgyOTA3MTYwMDg_ae4382b6-cfc9-4744-908d-462b90f612e5"
      unitRef="usd">4000000</us-gaap:ProceedsFromHedgeInvestingActivities>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ic8c7dd3d755f4d23a5c91bada3e42ee9_D20211101-20211130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzM4NDgyOTA3MTYwMzI_6c6aaed6-ae39-41ec-b1cf-de7b4638556a"
      unitRef="usd">6000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities
      contextRef="idc7d3c92717d45fea0d13f8cce709379_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzM4NDgyOTA3MTYxNDE_d5bd2108-93b1-4773-a421-2f762935a499"
      unitRef="usd">2000000</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzEwOTk1MTE2NDQyMDU_ec128c48-0bf2-4b3d-af7b-cda1290e85da">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with the Company's cross-currency swaps as included in the Consolidated Balance Sheets as of December 31, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with the Company's foreign exchange contracts as included in the Consolidated Balance Sheets as of December 31, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i44e7b5604e7f428db4023a2105e3040b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZToxNTgxZTIwOGFlMzA0ZGIzYTI2NzA2ZmU4Nzk0ZDEyNi90YWJsZXJhbmdlOjE1ODFlMjA4YWUzMDRkYjNhMjY3MDZmZTg3OTRkMTI2XzEtMS0xLTEtNjkxOTA_98127287-126e-42a7-be7b-8f24c18d7ec0"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="icfe6b64df5694949b66283a944e675f3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZToxNTgxZTIwOGFlMzA0ZGIzYTI2NzA2ZmU4Nzk0ZDEyNi90YWJsZXJhbmdlOjE1ODFlMjA4YWUzMDRkYjNhMjY3MDZmZTg3OTRkMTI2XzEtMy0xLTEtNjkxOTI_2f25a4e9-8e2e-4019-a92d-1d073a5ac956"
      unitRef="usd">79000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="id979f8795ef24a36b2de7dfd5788e85b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZToxNTgxZTIwOGFlMzA0ZGIzYTI2NzA2ZmU4Nzk0ZDEyNi90YWJsZXJhbmdlOjE1ODFlMjA4YWUzMDRkYjNhMjY3MDZmZTg3OTRkMTI2XzItMS0xLTEtNjkxOTA_13f9f51c-2790-4f12-a365-4cdc5699a37c"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="id9d09cae82ba48e1ab8a7444a671c37c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZToxNTgxZTIwOGFlMzA0ZGIzYTI2NzA2ZmU4Nzk0ZDEyNi90YWJsZXJhbmdlOjE1ODFlMjA4YWUzMDRkYjNhMjY3MDZmZTg3OTRkMTI2XzItMy0xLTEtNjkxOTI_aa26b683-d40d-428a-8641-b513f5f7ca1e"
      unitRef="usd">9000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeLiabilities
      contextRef="if40c526d7e7346638f324aeec169b157_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZToxNTgxZTIwOGFlMzA0ZGIzYTI2NzA2ZmU4Nzk0ZDEyNi90YWJsZXJhbmdlOjE1ODFlMjA4YWUzMDRkYjNhMjY3MDZmZTg3OTRkMTI2XzMtMS0xLTEtNjkxOTA_adc5558a-9a2d-49aa-8810-ed0fca6c4f46"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ib13c9491b10f4203a909a98994925ea0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZToxNTgxZTIwOGFlMzA0ZGIzYTI2NzA2ZmU4Nzk0ZDEyNi90YWJsZXJhbmdlOjE1ODFlMjA4YWUzMDRkYjNhMjY3MDZmZTg3OTRkMTI2XzMtMy0xLTEtNjkxOTI_be5fb882-0ec7-4115-8edf-7c434849873b"
      unitRef="usd">70000000</us-gaap:DerivativeLiabilities>
    <us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzY4OTg_f86af5bb-eff1-4a9c-b4bf-4042820b701c">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain excluded from assessment of hedge effectiveness&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location of gain of excluded component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i51904574a9814c839ec1c948964e42ee_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphZmRiNGE5ZjI5Mzk0ZmJhYTZiYjk5NDEyZjhjOWRkNC90YWJsZXJhbmdlOmFmZGI0YTlmMjkzOTRmYmFhNmJiOTk0MTJmOGM5ZGQ0XzEtMi0xLTEtNTk0NzA_1d3ab8dd-d2b2-4b30-8b9e-b8e76199e435"
      unitRef="usd">77000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i37cde1419dbe4d6b8814f741d3d75967_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphZmRiNGE5ZjI5Mzk0ZmJhYTZiYjk5NDEyZjhjOWRkNC90YWJsZXJhbmdlOmFmZGI0YTlmMjkzOTRmYmFhNmJiOTk0MTJmOGM5ZGQ0XzEtNC0xLTEtNTk0NzA_67f7d699-605f-4eb9-b7c0-ca3191f33ec2"
      unitRef="usd">-57000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i255986411ba145c5be6963ac79d1cdef_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphZmRiNGE5ZjI5Mzk0ZmJhYTZiYjk5NDEyZjhjOWRkNC90YWJsZXJhbmdlOmFmZGI0YTlmMjkzOTRmYmFhNmJiOTk0MTJmOGM5ZGQ0XzItMi0xLTEtNTk0NzA_95ca8ad7-3385-49c5-9fba-55d30ed014b4"
      unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i2b8d6be7a4a04904afbe947cf98fb1fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTphZmRiNGE5ZjI5Mzk0ZmJhYTZiYjk5NDEyZjhjOWRkNC90YWJsZXJhbmdlOmFmZGI0YTlmMjkzOTRmYmFhNmJiOTk0MTJmOGM5ZGQ0XzItNC0xLTEtNTk0NzA_7aea31c5-a228-4153-aa41-f660c84d1694"
      unitRef="usd">23000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities
      contextRef="i55601d2d01ba43d0ae61dc537370fe98_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzEwOTk1MTE2NDQxOTM_9de08b8b-fb6b-4bc8-89eb-8cf5d433d1aa"
      unitRef="usd">27000000</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
    <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities
      contextRef="i261fb00917f94a52acc0d59b2bdbe652_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzI3NDg3NzkwODA4NTg_1c5e07d0-9b35-41cf-9fe6-d1cc8199495b"
      unitRef="usd">23000000</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ifad488da9d8d42f2ae12cbbb6d990611_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzM0MDc_937fded0-20fd-4ca4-a15c-1fd852de6b4d"
      unitRef="usd">166000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="ic86fe7b9a9b24aec84a84ced04e41054_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTowYTk1YjViYWFiYzE0NmZkYjBkM2U3ZjFmMTIwOTg0NC90YWJsZXJhbmdlOjBhOTViNWJhYWJjMTQ2ZmRiMGQzZTdmMWYxMjA5ODQ0XzEtMS0xLTEtNjg4Njg_c38f5dd7-fcf7-4a3a-943d-ab17f0b18244"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i8edf93d7795c4edf82cf448e9626bfff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTowYTk1YjViYWFiYzE0NmZkYjBkM2U3ZjFmMTIwOTg0NC90YWJsZXJhbmdlOjBhOTViNWJhYWJjMTQ2ZmRiMGQzZTdmMWYxMjA5ODQ0XzEtMy0xLTEtNjg4NzA_9f6f4436-20c3-4496-9dd2-4b1c1e67da07"
      unitRef="usd">11000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i8fef8a6744fa477c83018f4c7bea0626_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTowYTk1YjViYWFiYzE0NmZkYjBkM2U3ZjFmMTIwOTg0NC90YWJsZXJhbmdlOjBhOTViNWJhYWJjMTQ2ZmRiMGQzZTdmMWYxMjA5ODQ0XzItMS0xLTEtNjg4Njg_d6c264e9-9b39-45bd-b657-3daa837bc328"
      unitRef="usd">1000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i83278b64958b40958e3243fd2a1b1ae6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTowYTk1YjViYWFiYzE0NmZkYjBkM2U3ZjFmMTIwOTg0NC90YWJsZXJhbmdlOjBhOTViNWJhYWJjMTQ2ZmRiMGQzZTdmMWYxMjA5ODQ0XzItMy0xLTEtNjg4NzA_eba1753f-4a8b-4184-8436-2210679e1712"
      unitRef="usd">3000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeLiabilities
      contextRef="ifad488da9d8d42f2ae12cbbb6d990611_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTowYTk1YjViYWFiYzE0NmZkYjBkM2U3ZjFmMTIwOTg0NC90YWJsZXJhbmdlOjBhOTViNWJhYWJjMTQ2ZmRiMGQzZTdmMWYxMjA5ODQ0XzMtMS0xLTEtNjg4Njg_f3fe70c7-6b32-4dee-bc25-268553e13a03"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="icaca6d803b964e7891bb81c4ee12ccce_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTowYTk1YjViYWFiYzE0NmZkYjBkM2U3ZjFmMTIwOTg0NC90YWJsZXJhbmdlOjBhOTViNWJhYWJjMTQ2ZmRiMGQzZTdmMWYxMjA5ODQ0XzMtMy0xLTEtNjg4NzA_ff4efd33-1f14-46b1-a7c1-aa68f267d0fb"
      unitRef="usd">8000000</us-gaap:DerivativeLiabilities>
    <us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzI3NDg3NzkwODU4NzE_ced2203a-3ae4-498a-b11c-4d592ee3bc64">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of the Company's foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) related to changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss related to settlements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ifa75d1437f1d4f9b9a633c9849122864_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTo4ZjBhNzNlNjcwNGU0N2FhYjczOTdkMjhlNTQ1OWQyYy90YWJsZXJhbmdlOjhmMGE3M2U2NzA0ZTQ3YWFiNzM5N2QyOGU1NDU5ZDJjXzEtMS0xLTEtNjg4Nzg_87ce1382-2d46-4178-8e20-6ac6f1fa4abe"
      unitRef="usd">9000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i2b8a4232afdb4ff5978b9e0e691223aa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTo4ZjBhNzNlNjcwNGU0N2FhYjczOTdkMjhlNTQ1OWQyYy90YWJsZXJhbmdlOjhmMGE3M2U2NzA0ZTQ3YWFiNzM5N2QyOGU1NDU5ZDJjXzEtMy0xLTEtNjg4ODA_cc9f1450-80b9-4c86-8a9a-004df8b6d2c4"
      unitRef="usd">-8000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss
      contextRef="ifa75d1437f1d4f9b9a633c9849122864_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTo4ZjBhNzNlNjcwNGU0N2FhYjczOTdkMjhlNTQ1OWQyYy90YWJsZXJhbmdlOjhmMGE3M2U2NzA0ZTQ3YWFiNzM5N2QyOGU1NDU5ZDJjXzItMS0xLTEtNjg4Nzg_5fbb87f1-1724-4fa0-98f0-009dbc20c671"
      unitRef="usd">17000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss
      contextRef="i2b8a4232afdb4ff5978b9e0e691223aa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTo4ZjBhNzNlNjcwNGU0N2FhYjczOTdkMjhlNTQ1OWQyYy90YWJsZXJhbmdlOjhmMGE3M2U2NzA0ZTQ3YWFiNzM5N2QyOGU1NDU5ZDJjXzItMy0xLTEtNjg4ODA_060f5395-3780-4735-aa23-9a41b57b4259"
      unitRef="usd">2000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i64af0e0d3e4140b1b4407a0c784a6907_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzUwODU_9d458eda-dfc7-43e2-b2fc-5ac599285440"
      unitRef="rate">0.06</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i18e557e1adb142668f07f005de10db3a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzUwOTE_899a54e5-9484-451b-a098-328e10f5c567"
      unitRef="rate">0.18</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i570d56f066454c278557839640940613_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzUxNDk_a571aafe-6145-4336-a086-c825f618e753"
      unitRef="rate">0.07</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzY4OTk_258ae03a-bee8-4431-aaad-81f078c8f08b">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the years 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning balance, January 1, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to Acquisition-related contingent consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion for the time value of money&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments / Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment included in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance, December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzEtNC0xLTEtNTk0NzA_9019532a-42c4-4ee9-afae-512ca12b37ba"
      unitRef="usd">328000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzEtOC0xLTEtNTk0NzA_fd2088f5-f515-4c67-9c00-3d0fe7d65a86"
      unitRef="usd">316000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i669f1ac33f2845c287e6b1bad341253c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzMtMi0xLTEtNTk0NzA_e0624947-a808-4d86-8d89-7a850b08f7b9"
      unitRef="usd">17000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i24b574ccfce8480da6d68ccf2983c9d6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzMtNi0xLTEtNTk0NzA_3e4827bc-7c4c-4289-8ceb-d165894723e7"
      unitRef="usd">23000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i779f7dfcb77d4f20b069195568b29fa4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzQtMi0xLTEtNTk0NzA_eff2f75d-7f8d-4320-b9db-37b6a5c290ba"
      unitRef="usd">-6000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i3eab42b92e0d40ecb1ef0a51c9b67d8e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzQtNi0xLTEtNTk0NzA_7aeb8b16-e469-4cfd-bd54-79a3e5984659"
      unitRef="usd">25000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzUtNC0xLTEtNTk0NzA_85d12db4-5246-4892-acc8-be5156c78ab5"
      unitRef="usd">11000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzUtOC0xLTEtNTk0NzA_46f2897f-85e7-42eb-a5de-41fe93186b03"
      unitRef="usd">48000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzYtNC0xLTEtNTk0NzA_3b8edbcb-c7f5-449a-bd94-da666f882c8b"
      unitRef="usd">99000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzYtOC0xLTEtNTk0NzA_09514c71-c14c-4db2-8a1e-bda0d1add49a"
      unitRef="usd">36000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzctNC0xLTEtNTk0NzA_b2e9ecda-bbcf-4537-a465-158fb2a97a7e"
      unitRef="usd">1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzctOC0xLTEtNTk0NzA_1b785b16-e0e1-4f32-8a63-3e6e2be65e2e"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzgtNC0xLTEtNTk0NzA_98a793e9-686a-4188-ad52-7ab7c5726410"
      unitRef="usd">241000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzgtOC0xLTEtNTk0NzA_0dd8d04b-cdf0-4c29-a24a-bf40e5110e28"
      unitRef="usd">328000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzktNC0xLTEtNTk0NzA_a22a9c75-30a4-49de-b4db-dfb85eb50987"
      unitRef="usd">39000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzktOC0xLTEtNTk0NzA_60338397-b671-46c7-8bb8-646d69e0907f"
      unitRef="usd">112000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzEwLTQtMS0xLTU5NDcw_dac3f24e-c5b4-48b6-91ac-81b881af7e2b"
      unitRef="usd">202000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTplOGVjOGQ1NTllYzk0YzZhYWM3NDNhNzcyOGI0YmRlNy90YWJsZXJhbmdlOmU4ZWM4ZDU1OWVjOTRjNmFhYzc0M2E3NzI4YjRiZGU3XzEwLTgtMS0xLTU5NDcw_64904bce-1b0f-46ea-9287-b3d1ac75f122"
      unitRef="usd">216000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzY4ODI_1162e262-3998-4829-b832-87662d00395e">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components and classification of the Company&#x2019;s financial assets and liabilities measured at fair value on a non-recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.277%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.364%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="i71ee14ac1c1d46b7a0ce6c3c7e2a9b99_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTpkZWVhYTMyMmZhZGM0OTJkYWM2MTgzMDg5ZDhkZmYwMS90YWJsZXJhbmdlOmRlZWFhMzIyZmFkYzQ5MmRhYzYxODMwODlkOGRmZjAxXzMtMi0xLTEtNTk0NzA_0e7b5893-0c45-4ecb-a73b-65f3bbd31245"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="i8fab45399b784a6590e369a44a09cd98_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTpkZWVhYTMyMmZhZGM0OTJkYWM2MTgzMDg5ZDhkZmYwMS90YWJsZXJhbmdlOmRlZWFhMzIyZmFkYzQ5MmRhYzYxODMwODlkOGRmZjAxXzMtNC0xLTEtNTk0NzA_b3a62146-c90a-4839-99eb-a0a3703f6381"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="i43aa74e47e0a4098b9e1b70baf38319d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTpkZWVhYTMyMmZhZGM0OTJkYWM2MTgzMDg5ZDhkZmYwMS90YWJsZXJhbmdlOmRlZWFhMzIyZmFkYzQ5MmRhYzYxODMwODlkOGRmZjAxXzMtNi0xLTEtNTk0NzA_e7249ace-643c-44ef-9d2f-4e3d7ec5b8ef"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="ic72dfc3064da478e89d0708906a6270a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTpkZWVhYTMyMmZhZGM0OTJkYWM2MTgzMDg5ZDhkZmYwMS90YWJsZXJhbmdlOmRlZWFhMzIyZmFkYzQ5MmRhYzYxODMwODlkOGRmZjAxXzMtOC0xLTEtNTk0NzA_395e7dd0-4bd6-4d29-bd7a-ec5da2a09b05"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="i2ddb15c7970742ed9da4a433d76c5f2a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTpkZWVhYTMyMmZhZGM0OTJkYWM2MTgzMDg5ZDhkZmYwMS90YWJsZXJhbmdlOmRlZWFhMzIyZmFkYzQ5MmRhYzYxODMwODlkOGRmZjAxXzMtMTAtMS0xLTU5NDcw_288cfa0d-1b72-4c18-9b77-be48a3f3e26f"
      unitRef="usd">245000000</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="id50f749937914da499d3aa0713e26497_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTpkZWVhYTMyMmZhZGM0OTJkYWM2MTgzMDg5ZDhkZmYwMS90YWJsZXJhbmdlOmRlZWFhMzIyZmFkYzQ5MmRhYzYxODMwODlkOGRmZjAxXzMtMTItMS0xLTU5NDcw_1c20cafa-b829-4923-ac29-82936825eb04"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="i5d4c04c5a36a498e9735c3b7b90e02ae_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTpkZWVhYTMyMmZhZGM0OTJkYWM2MTgzMDg5ZDhkZmYwMS90YWJsZXJhbmdlOmRlZWFhMzIyZmFkYzQ5MmRhYzYxODMwODlkOGRmZjAxXzMtMTQtMS0xLTU5NDcw_812b2f8f-30e4-45f8-9497-6ecb8be4f22d"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="i8916b7890ddb4f65bd52ab52e5fca2d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90YWJsZTpkZWVhYTMyMmZhZGM0OTJkYWM2MTgzMDg5ZDhkZmYwMS90YWJsZXJhbmdlOmRlZWFhMzIyZmFkYzQ5MmRhYzYxODMwODlkOGRmZjAxXzMtMTYtMS0xLTU5NDcw_d3b6e7e1-52ad-48de-a0d4-970a2fd97246"
      unitRef="usd">245000000</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="i8916b7890ddb4f65bd52ab52e5fca2d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzQzOTgwNDY1MjUzODY_d3b6e7e1-52ad-48de-a0d4-970a2fd97246"
      unitRef="usd">245000000</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i43aa74e47e0a4098b9e1b70baf38319d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzY3NTY_00db133f-6afc-4e5a-85ee-bdb03d32348a"
      unitRef="usd">22689000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i5d4c04c5a36a498e9735c3b7b90e02ae_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTMvZnJhZzo5YjViNzU3M2ZhMTY0OGQwYjM1YWUwZGYxMDlmMmY5ZC90ZXh0cmVnaW9uOjliNWI3NTczZmExNjQ4ZDBiMzVhZTBkZjEwOWYyZjlkXzY3NjM_27c1673c-5343-4351-8924-e10e48f4ac0d"
      unitRef="usd">25378000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTYvZnJhZzoyMzA5MDAwNTNjNDA0ODNhOWNkNzFjMmZkOTc1NmFmYy90ZXh0cmVnaW9uOjIzMDkwMDA1M2M0MDQ4M2E5Y2Q3MWMyZmQ5NzU2YWZjXzU5_e44441d6-1f65-4f5c-a36d-537606dc7397">INVENTORIES&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net, as of December 31, 2021 and 2020 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTYvZnJhZzoyMzA5MDAwNTNjNDA0ODNhOWNkNzFjMmZkOTc1NmFmYy90ZXh0cmVnaW9uOjIzMDkwMDA1M2M0MDQ4M2E5Y2Q3MWMyZmQ5NzU2YWZjXzQ3_c0b38880-fb7f-4d6c-bd7f-4c80459892ab">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net, as of December 31, 2021 and 2020 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTYvZnJhZzoyMzA5MDAwNTNjNDA0ODNhOWNkNzFjMmZkOTc1NmFmYy90YWJsZTpkYWI4Mzk1ZjExNTk0Y2U4ODYzM2JlNmIzNGFmYzlkMy90YWJsZXJhbmdlOmRhYjgzOTVmMTE1OTRjZTg4NjMzYmU2YjM0YWZjOWQzXzEtMi0xLTEtNTk0NzA_7d78abcb-17ba-460f-b7d4-13d7a7c7e083"
      unitRef="usd">279000000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTYvZnJhZzoyMzA5MDAwNTNjNDA0ODNhOWNkNzFjMmZkOTc1NmFmYy90YWJsZTpkYWI4Mzk1ZjExNTk0Y2U4ODYzM2JlNmIzNGFmYzlkMy90YWJsZXJhbmdlOmRhYjgzOTVmMTE1OTRjZTg4NjMzYmU2YjM0YWZjOWQzXzEtNC0xLTEtNTk0NzA_ef3c61ad-120b-458f-995d-1fbce075faf5"
      unitRef="usd">286000000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTYvZnJhZzoyMzA5MDAwNTNjNDA0ODNhOWNkNzFjMmZkOTc1NmFmYy90YWJsZTpkYWI4Mzk1ZjExNTk0Y2U4ODYzM2JlNmIzNGFmYzlkMy90YWJsZXJhbmdlOmRhYjgzOTVmMTE1OTRjZTg4NjMzYmU2YjM0YWZjOWQzXzItMi0xLTEtNTk0NzA_c3736387-f4c0-4e01-8194-d7ed8813271d"
      unitRef="usd">112000000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTYvZnJhZzoyMzA5MDAwNTNjNDA0ODNhOWNkNzFjMmZkOTc1NmFmYy90YWJsZTpkYWI4Mzk1ZjExNTk0Y2U4ODYzM2JlNmIzNGFmYzlkMy90YWJsZXJhbmdlOmRhYjgzOTVmMTE1OTRjZTg4NjMzYmU2YjM0YWZjOWQzXzItNC0xLTEtNTk0NzA_fc669754-b5c9-46bd-88bb-78616f719f6f"
      unitRef="usd">143000000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTYvZnJhZzoyMzA5MDAwNTNjNDA0ODNhOWNkNzFjMmZkOTc1NmFmYy90YWJsZTpkYWI4Mzk1ZjExNTk0Y2U4ODYzM2JlNmIzNGFmYzlkMy90YWJsZXJhbmdlOmRhYjgzOTVmMTE1OTRjZTg4NjMzYmU2YjM0YWZjOWQzXzMtMi0xLTEtNTk0NzA_375da9b0-099f-4808-b5e7-31835eb6ae7f"
      unitRef="usd">602000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTYvZnJhZzoyMzA5MDAwNTNjNDA0ODNhOWNkNzFjMmZkOTc1NmFmYy90YWJsZTpkYWI4Mzk1ZjExNTk0Y2U4ODYzM2JlNmIzNGFmYzlkMy90YWJsZXJhbmdlOmRhYjgzOTVmMTE1OTRjZTg4NjMzYmU2YjM0YWZjOWQzXzMtNC0xLTEtNTk0NzA_2e102151-5617-4e29-ab4c-92ddc70eb38f"
      unitRef="usd">665000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTYvZnJhZzoyMzA5MDAwNTNjNDA0ODNhOWNkNzFjMmZkOTc1NmFmYy90YWJsZTpkYWI4Mzk1ZjExNTk0Y2U4ODYzM2JlNmIzNGFmYzlkMy90YWJsZXJhbmdlOmRhYjgzOTVmMTE1OTRjZTg4NjMzYmU2YjM0YWZjOWQzXzQtMi0xLTEtNTk0NzA_5f4e8076-6e5b-4445-866b-ab80dd564744"
      unitRef="usd">993000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTYvZnJhZzoyMzA5MDAwNTNjNDA0ODNhOWNkNzFjMmZkOTc1NmFmYy90YWJsZTpkYWI4Mzk1ZjExNTk0Y2U4ODYzM2JlNmIzNGFmYzlkMy90YWJsZXJhbmdlOmRhYjgzOTVmMTE1OTRjZTg4NjMzYmU2YjM0YWZjOWQzXzQtNC0xLTEtNTk0NzA_eb502ccd-db22-4489-905e-24af64f497be"
      unitRef="usd">1094000000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90ZXh0cmVnaW9uOjQ0MzU5MGViZDFhNzQzZWM5M2U0MGUxMGM4NmMxOGRjXzE2MA_a675f2a6-41e3-4235-a305-a8f4dfc03218">PROPERTY, PLANT AND EQUIPMENT&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of property, plant and equipment as of December 31, 2021 and 2020 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other equipment and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment on operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $177 million, $180 million and $178 million for 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90ZXh0cmVnaW9uOjQ0MzU5MGViZDFhNzQzZWM5M2U0MGUxMGM4NmMxOGRjXzE2Mw_a2a7fb4d-b2b4-44b6-a022-7ed116bb64e8">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of property, plant and equipment as of December 31, 2021 and 2020 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other equipment and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment on operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8b16b99c92d340acae71efc354b677d3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzEtMi0xLTEtNTk0NzA_81f65669-f897-40a3-ae3f-59e50f277f06"
      unitRef="usd">74000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i53bc5bf59ece4ba7a3fb0dda2961cc78_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzEtNC0xLTEtNTk0NzA_1e85bd5e-91a8-423e-8f71-08e2a3bbf13e"
      unitRef="usd">79000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i49f627a32c304d4e97c853cbdc52fe1d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzItMi0xLTEtNTk0NzA_7c211490-f50c-4d58-9e53-393aaf6d5130"
      unitRef="usd">675000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5c417841d2d04bb0aa5f9721b865a03d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzItNC0xLTEtNTk0NzA_b8447b50-93fc-4937-8352-e194c111b46c"
      unitRef="usd">686000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id6c6af997a5a40d3b472bba2069ff9c3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzMtMi0xLTEtNTk0NzA_dd042d5e-8f2e-4048-8d9f-7f7a053b48b5"
      unitRef="usd">1678000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic11c0834d02545e4a4a40fe884590f30_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzMtNC0xLTEtNTk0NzA_af32bc4c-6162-46b1-b335-438c791c5d19"
      unitRef="usd">1722000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8d9e8838b0b64725a2134d6c808fce63_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzQtMi0xLTEtNTk0NzA_fe0d87d3-384e-4ddc-ac7c-0a423136c24a"
      unitRef="usd">342000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i39a4f86638de4f1d85298fc8f9d9e688_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzQtNC0xLTEtNTk0NzA_5fc65763-a987-464a-a6c9-a143d1b2eca6"
      unitRef="usd">360000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i44211772dd52482e9e4ffe87d1d7ae4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzUtMi0xLTEtNTk0NzA_432edc84-6d2d-4209-bcb7-42f9cc18a7aa"
      unitRef="usd">73000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icbafbc956c894b57be4b8cb6144cea99_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzUtNC0xLTEtNTk0NzA_77ee3c42-c853-4791-99c3-30e7afaaf2f9"
      unitRef="usd">65000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id6f977b18e2d47869607481b5bbc4690_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzYtMi0xLTEtNTk0NzA_2085b8de-d430-43d2-a703-2d7d69c0e2d6"
      unitRef="usd">576000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i164c1c9b47e74fc793e6991fa1597a81_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzYtNC0xLTEtNTk0NzA_0a5ff03b-50f8-47f0-8dd6-14e7dd0fc426"
      unitRef="usd">436000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzctMi0xLTEtNTk0NzA_6eca017f-914f-4a73-b7a9-b00bfe1105ec"
      unitRef="usd">3418000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzctNC0xLTEtNTk0NzA_8ae67e37-27b7-4be9-a6ae-74293676edfd"
      unitRef="usd">3348000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzgtMi0xLTEtNTk0NzA_b1fd79a2-1ea2-47fc-99c2-ac341cf72322"
      unitRef="usd">1820000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzgtNC0xLTEtNTk0NzA_20ae7477-9214-46ce-803f-0a999d3b2134"
      unitRef="usd">1781000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzktMi0xLTEtNTk0NzA_1418e796-c5e9-4f0c-bddd-4de52821f276"
      unitRef="usd">1598000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90YWJsZTpiOGZkYWQ1ZGU0ZjM0MGJmODk3OGNiZDAzMjIzMTQ2Yy90YWJsZXJhbmdlOmI4ZmRhZDVkZTRmMzQwYmY4OTc4Y2JkMDMyMjMxNDZjXzktNC0xLTEtNTk0NzA_6de7e3d7-eae6-470f-88fc-d2ec3f58603d"
      unitRef="usd">1567000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90ZXh0cmVnaW9uOjQ0MzU5MGViZDFhNzQzZWM5M2U0MGUxMGM4NmMxOGRjXzEwNg_b3ef953b-3609-4bb1-bb37-dcdce299678e"
      unitRef="usd">177000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90ZXh0cmVnaW9uOjQ0MzU5MGViZDFhNzQzZWM5M2U0MGUxMGM4NmMxOGRjXzExMA_23a288c1-b29a-4d61-84b8-327bfd564e4a"
      unitRef="usd">180000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMTkvZnJhZzo0NDM1OTBlYmQxYTc0M2VjOTNlNDBlMTBjODZjMThkYy90ZXh0cmVnaW9uOjQ0MzU5MGViZDFhNzQzZWM5M2U0MGUxMGM4NmMxOGRjXzExNw_458f6c5d-f626-482e-b2fb-2b07c08a48bf"
      unitRef="usd">178000000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI0NzY3_4b58bd82-0ee5-4f64-8a29-9ba9526b1e01">INTANGIBLE ASSETS AND GOODWILL&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets as of December&#160;31, 2021 and 2020 consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Useful&lt;br/&gt;Lives&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:36pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization and Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization and Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D not in service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B&amp;amp;L Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments, including loss on assets held for sale in the Consolidated Statement of Operations.  The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairments, including loss on assets held for sale in 2021 included: (i) impairments of $105&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, (ii) an $88&#160;million loss on assets held for sale in connection with the Amoun Sale, (iii) impairments of $23&#160;million, in aggregate, related to the discontinuance of certain product lines and (iv) $18&#160;million related to a portion of an IT infrastructure improvement project no longer being utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairments, including loss on assets held for sale in 2020 included impairments of: (i) $96&#160;million to reduce the carrying value of the Amoun business to its estimated fair value less costs to sell due to classifying the business as held for sale as discussed in Note 3, "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE", (ii) $16&#160;million in aggregate, due to decreases in forecasted sales of certain product lines, (iii) $1&#160;million in aggregate, related to the discontinuance of certain product lines not aligned with the focus of the Company's core businesses and (iv) $1&#160;million related to Acquired IPR&amp;amp;D not in service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairments, including loss on assets held for sale in 2019 included impairments of: (i) $58 million reflecting decreases in forecasted sales of certain product lines due to generic competition and other factors, (ii) $8 million related to assets being classified as held for sale, (iii) $5 million related to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core businesses and (iv) $4 million related to Acquired IPR&amp;amp;D not in service. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The impairments to assets reclassified as held for sale were measured as the difference of the carrying value of these assets as compared to the estimated fair values of these assets less costs to sell determined using a discounted cash flow analysis which utilized Level 3 unobservable inputs. The other impairments and adjustments to finite-lived intangible assets were measured as the difference of the historical carrying value of these finite-lived assets as compared to the estimated fair value as determined using a discounted cash flow analysis using Level 3 unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Periodically, the Company&#x2019;s products face the expiration of their patent or regulatory exclusivity. The Company anticipates that product sales for such product would decrease shortly following a loss of exclusivity ("LOE"), due to the possible entry of a generic competitor. Where the Company has the rights, it may elect to launch an authorized generic of such product (either as the Company&#x2019;s own branded generic or through a third-party).  This may occur prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product could still be significant, and the effect on future revenues could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management continually assesses the useful lives related to the Company's long-lived assets to reflect the most current assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated amortization expense of finite-lived intangible assets for the five years ending December&#160;31 and thereafter are as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amounts of goodwill during the years ended December 31, 2021, 2020 and 2019 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Bausch + &lt;br/&gt;Lomb/&lt;br/&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Bausch + &lt;br/&gt;Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;International Rx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisition of certain assets of Synergy &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill reclassified to assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets held for sale reclassified to goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill reclassified to assets held for sale (Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realignment of segment goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment.  The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit's terminal value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To forecast a reporting unit's cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management's and a market participant's view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected LOE to the Company's product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#x2019;s control could have a positive or negative impact on achieving its targets.  Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 Annual Goodwill Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company conducted its annual goodwill impairment test as of October 1, 2019 by first assessing qualitative factors. Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit. In each quantitative fair value test performed, the fair value was greater than the carrying value of the reporting unit.  As a result, there was no impairment to the goodwill of any reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The negative impacts of the COVID-19 pandemic on the global economy have led to significant volatility in the global equity markets. The Company has been able to continue its operations with limited disruptions and has assessed the potential impact that the COVID-19 pandemic is likely to have on its forecasted cash flows.  In performing its assessment, the Company considered the possible effects and outcomes of the COVID-19 pandemic on, among other things, its supply chain, customers and distributors, employee base, product sustainability, research and development activities, product pipeline and consumer demand and related rebates and discounts and has made adjustments, although not considered to be material, to its long-term forecasts used in its previous goodwill impairment assessments, for these and other matters. After completing this assessment, although not completely insulated from the negative effects of the COVID-19 pandemic, the Company believes that its long-term forecasted cash flows, as adjusted for the possible outcome of the COVID-19 pandemic and other matters, do not indicate that the fair value of any reporting unit may be below its carrying value. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's 2020 revenues were most negatively impacted during its second quarter by certain social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize prior to the third quarter of 2020. Revenues for 2021 and 2020 were $8,434&#160;million and $8,027&#160;million, respectively. The increase of $407&#160;million in revenue represents an improving trend over the decreases in year-over-year revenues for the three month periods ended June 30, 2020, September 30, 2020 and December 31, 2020 of 23%, 3% and less than 1%, respectively. The Company's revenues returned to pre-pandemic levels for many of its businesses and geographies in 2021 and, presuming there continues to be increased availability of effective vaccines and any further resurgence of the COVID-19 virus, the delta and omicron variants and other variant strains thereof do not have a material adverse impact on efforts to contain the COVID-19 virus, the Company anticipates the COVID-19 pandemic to have a minimal impact on its remaining businesses and geographies in 2022. However, the rates of recovery for each business will vary by geography and will be dependent upon, among other things, the availability and effectiveness of vaccines for the COVID-19 virus, government responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus and other actions taken in response to the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020 Interim Goodwill Impairment Assessment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the interim periods of 2020, after giving consideration to the nature and timing of the negative impacts of the COVID-19 pandemic on the Company's forecasted cash flows, with the exception of the Ortho Dermatologics reporting unit, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, no impairments were recorded. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2020 and June 30, 2020, the operating results for the Ortho Dermatologics reporting unit were less than forecasted primarily due to certain products experiencing longer launch cycles than originally anticipated as a result of the COVID-19 pandemic. The Company revised its long-term forecasts as of March 31, 2020 and as of June 30, 2020 for these matters. Management believed that these events were indicators that there was less headroom as of March 31, 2020 and June 30, 2020 as compared to the headroom calculated on the date Ortho Dermatologics goodwill was previously tested for impairment. Therefore, a quantitative fair value test for impairment to the goodwill of the Ortho Dermatologics reporting unit was performed at March 31, 2020 and at June 30, 2020. Based on the quantitative fair value tests, the fair value of the Ortho Dermatologics reporting unit continued to be greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit at March 31, 2020 and at June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020 Annual Goodwill Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company conducted its annual goodwill impairment test as of October 1, 2020 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2020, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2020, the Company considered, among other matters, a range of potential impacts of COVID-19 pandemic related matters and the limited headroom calculated on the date Ortho Dermatologics goodwill was last tested for impairment (June 30, 2020).  The Company believed that these factors may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2020, utilizing a long-term growth rate of 2.0% and a range of discount rates between 9.50% and 9.75%, in estimation of the fair value of this reporting unit.  Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;First Quarter 2021 - Realignment of Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the first quarter of 2021, the Company began operating in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International Rx, (iv) Ortho Dermatologics and (v) Diversified Products. The Bausch + Lomb segment consists of the: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. The Salix segment consists of the Salix reporting unit. The International Rx segment consists of the International Rx reporting unit. The Ortho Dermatologics segment consists of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. This realignment in segment structure resulted in a change in the Company's former International reporting unit, which is now divided between the International Bausch + Lomb reporting unit and International Rx reporting unit. In addition, as part of this realignment of segment structure, certain products historically included in the Generics reporting unit are now included in the U.S. Bausch + Lomb reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. Goodwill previously reported in the former International reporting unit was reassigned to the International Bausch + Lomb and International Rx reporting units, and a portion of goodwill previously reported in the former Generics reporting unit was reassigned to the U.S. Bausch + Lomb reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the change in reporting units, the Company performed a qualitative fair value assessment for its former: (i) International and (ii) Generics reporting units. Based on the qualitative fair value assessment performed, management believed that it was more likely than not that the carrying values of its former: (i) International and (ii) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generics reporting units were less than their respective fair values and therefore, concluded a quantitative assessment was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately following the change in reporting units, as a result of the change in composition of the net assets for its current: (i) International Bausch + Lomb, (ii) International Rx and (iii) Generics reporting units, the Company performed a quantitative fair value test. The quantitative fair value test utilized a range of long-term growth rates of 1.0% to 3.0% and a range of discount rates between 11.0% and 12.25%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than 40%, and, therefore, there was no impairment to goodwill. In addition, as the U.S. Bausch + Lomb reporting unit had a change in composition of its net assets related to certain products historically included in the Generics reporting unit now being included in the U.S. Bausch + Lomb reporting unit, the Company performed a qualitative assessment of this reporting unit. Based on the qualitative fair value assessment performed, management believed that it was more likely than not that the carrying value of its current U.S. Bausch + Lomb reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;March 31, 2021 Impairment to Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products.  In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;amp;D spend to eliminate projects it has identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there is less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company's most recent cash flow projections as revised in the first quarter of 2021 to reflect the business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of 1.0% and a range of discount rates between 9.0% and 10.0%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at March 31, 2021, and the Company recognized a goodwill impairment of $469&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Second Quarter 2021 - Realignment of Bausch + Lomb Reporting Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the second quarter of 2021, the Company changed the way it reviews the financial information of its Bausch + Lomb segment.  Beginning in the second quarter of 2021, management no longer reviews the financial information of its Bausch + Lomb segment on a geographic basis, but instead reviews this financial information on a business line basis.  This change created a change in the reporting units of the Bausch + Lomb segment. After the change, under its business line view, the Bausch + Lomb segment consists of the global: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. Prior to the second quarter of 2021, under the geographic view, the Bausch + Lomb segment consisted of the former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. The change in Bausch + Lomb reporting units does not impact the reported revenues and segment profits of the Bausch + Lomb segment for any prior periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the change in its Bausch + Lomb reporting units, the Company performed a qualitative fair value assessment for its former reporting units. Based on the qualitative fair value assessment, management believed that it was more likely than not that the carrying values of its former:  (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units were less than their respective fair values and, therefore, concluded a quantitative assessment was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the change in composition of net assets, the Company performed a quantitative fair value test of its new: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units immediately following the change in the Bausch + Lomb segment. The quantitative fair value test utilized long-term growth rates of 2.0% and 3.0% and a range of discount rates between 7.0% and 10.0%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than 45%, and, therefore, there was no impairment to goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;June 30, 2021 and September 30, 2021 Interim Assessments of Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to monitor the market conditions impacting the Ortho Dermatologics reporting unit. The  Company's latest forecasts for the Ortho Dermatologics reporting unit include a range of potential outcomes for, among other matters: (i) the impacts of the COVID-19 pandemic on operations, (ii) the impact of the loss of exclusivity of certain products, (iii) the impact of longer launch cycles for certain new products, (iv) progress of its product pipeline and (v) ongoing pricing pressures, which could negatively impact the reporting unit's results over the long term. The changes in the amounts and timing of revenues and expenses in the latest forecast as compared to the forecast used at March 31, 2021 (the last time goodwill of the Ortho Dermatologics reporting unit was tested), were not substantial enough to materially adversely affect the recoverability of the Ortho Dermatologics reporting unit's assets and are not material enough to indicate that the fair value of the Ortho Dermatologics reporting unit might be below its carrying value as last tested at March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No other events occurred or circumstances changed during the period October 1, 2020 (the earliest date goodwill was tested for all other reporting units) through December 31, 2021 that indicated that the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit, might be below its carrying value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Annual Goodwill Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company conducted its annual goodwill impairment test as of October 1, 2021 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2021, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2021, the Company considered, among other matters, the limited headroom as a result of the impairment to the goodwill of the Ortho Dermatologics reporting unit when last tested (March 31, 2021) and macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The Company believed that these facts and circumstances may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2021, utilizing a long-term growth rate of 1.0% and a discount rate of 9.0%, in estimation of the fair value of this reporting unit.  Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If market conditions deteriorate, if the factors and circumstances regarding the COVID-19 pandemic escalate beyond management&#x2019;s current expectations, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and those charges could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated goodwill impairment charges through December 31, 2021 were $4,180 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI0NzU1_bb26fc12-92a3-4b94-b43a-d3632315dc2d">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets as of December&#160;31, 2021 and 2020 consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Useful&lt;br/&gt;Lives&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:36pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization and Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization and Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D not in service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B&amp;amp;L Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI0Nzg2_10a2f4a9-4e75-42a2-80e0-1ed3922cd88d">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets as of December&#160;31, 2021 and 2020 consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Useful&lt;br/&gt;Lives&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:36pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization and Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization and Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D not in service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B&amp;amp;L Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="idf8fe351f9e049048e582a289f5ec940_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzMtMS0xLTEtNTk0NzA_7f0cf7f6-58fa-4711-bb80-d4d10360e249">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iae408a1b501d44bfb0d015a59f05ba39_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzMtMy0xLTEtNTk0NzA_a74cd5cf-45b7-4c3c-9e69-18769af557bb"
      unitRef="usd">20842000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iae408a1b501d44bfb0d015a59f05ba39_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzMtNS0xLTEtNTk0NzA_104ee190-a27d-4f77-a1c8-fb1a6e9a992b"
      unitRef="usd">16169000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iae408a1b501d44bfb0d015a59f05ba39_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzMtNy0xLTEtNTk0NzA_8f30cb3f-fe3c-427a-9026-90f3e4ceffe1"
      unitRef="usd">4673000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6d7f9da12914489bab1b7bb4cbb4fc83_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzMtOS0xLTEtNTk0NzA_2aaf69b1-cef5-4e7d-b92f-6bd0eb16c1fd"
      unitRef="usd">20890000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6d7f9da12914489bab1b7bb4cbb4fc83_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzMtMTEtMS0xLTU5NDcw_b9d2b8b0-1d34-4712-96c6-814a76d8eaf2"
      unitRef="usd">14914000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6d7f9da12914489bab1b7bb4cbb4fc83_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzMtMTMtMS0xLTU5NDcw_32a04b76-a3ae-41da-9450-3452e855883b"
      unitRef="usd">5976000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="idbf9196b61c6417e95bd898b4020850c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzQtMS0xLTEtNTk0NzA_896e843f-64db-44c6-a95e-45a5cd9d9b5b">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8c9a0557ca2f40e8a6681b9854a4d544_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzQtMy0xLTEtNTk0NzA_1dbe1e19-d214-4515-a785-39a3002d18cf"
      unitRef="usd">902000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8c9a0557ca2f40e8a6681b9854a4d544_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzQtNS0xLTEtNTk0NzA_2c64a14e-f691-43c3-bb29-d8190b910567"
      unitRef="usd">473000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8c9a0557ca2f40e8a6681b9854a4d544_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzQtNy0xLTEtNTk0NzA_90bf589f-7dfa-429b-891e-978348e0603e"
      unitRef="usd">429000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i06187f7ce19446a690591cd1b95c7f26_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzQtOS0xLTEtNTk0NzA_8b27a0ee-a48b-4431-9c83-464947565292"
      unitRef="usd">907000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i06187f7ce19446a690591cd1b95c7f26_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzQtMTEtMS0xLTU5NDcw_0ce69435-a9f5-4e2c-8310-64005d7a81f3"
      unitRef="usd">404000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i06187f7ce19446a690591cd1b95c7f26_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzQtMTMtMS0xLTU5NDcw_7b0ca752-1b6a-4ea7-84ff-08f24241a8c9"
      unitRef="usd">503000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="iea4f798327a64255b8fcebf77a9bfd28_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzUtMS0xLTEtNTk0NzA_4d6ca041-2960-475c-8207-ef56fa673ff5">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i29ccbe7385f64c2a8f950c5898bc20dc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzUtMy0xLTEtNTk0NzA_8f2ebe19-258e-41e9-881d-015c86fe3fcf"
      unitRef="usd">3321000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i29ccbe7385f64c2a8f950c5898bc20dc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzUtNS0xLTEtNTk0NzA_695a2192-b360-4ade-b419-eabf0eac2d1c"
      unitRef="usd">3174000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i29ccbe7385f64c2a8f950c5898bc20dc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzUtNy0xLTEtNTk0NzA_883ecb51-4699-4266-9232-74e19a440803"
      unitRef="usd">147000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iafcb6c30e16d4d609946e1e977a992a1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzUtOS0xLTEtNTk0NzA_83f027ad-e7c4-44a6-baa2-73d27514a4ad"
      unitRef="usd">3305000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iafcb6c30e16d4d609946e1e977a992a1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzUtMTEtMS0xLTU5NDcw_3dd6f200-7b3e-4500-a738-87d0b91a0891"
      unitRef="usd">3055000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iafcb6c30e16d4d609946e1e977a992a1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzUtMTMtMS0xLTU5NDcw_83e24c39-6b4a-464c-92bc-5199e9d85948"
      unitRef="usd">250000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i875f56312a3e4f3aa4e713ccaddb57d8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzYtMS0xLTEtNTk0NzA_66b6ae1e-5759-475b-8f18-3ad37e593142">P0Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3bd0280d56644e9aa17e3ed84baa5cb9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzYtMy0xLTEtNTk0NzA_813ee491-5e34-4efb-b0fa-4bf5925dd9b7"
      unitRef="usd">158000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3bd0280d56644e9aa17e3ed84baa5cb9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzYtNS0xLTEtNTk0NzA_03981c50-7885-4e15-a56a-8303cfcce1ce"
      unitRef="usd">158000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3bd0280d56644e9aa17e3ed84baa5cb9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzYtNy0xLTEtNTk0NzA_76ba90f2-8962-439a-b6d9-51891489895d"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ide8dc03ca5d34e2d82fe875ae8349bfe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzYtOS0xLTEtNTk0NzA_6c9bd322-4013-454e-a478-f7511cd6e38d"
      unitRef="usd">169000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ide8dc03ca5d34e2d82fe875ae8349bfe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzYtMTEtMS0xLTU5NDcw_bd6daf92-da22-410f-9c94-c98f1a357c8d"
      unitRef="usd">168000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ide8dc03ca5d34e2d82fe875ae8349bfe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzYtMTMtMS0xLTU5NDcw_6e975a79-81fb-41ad-af2c-133302994d97"
      unitRef="usd">1000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ib10da3a8baaa43f2882bbc75cea97f73_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzctMS0xLTEtNTk0NzA_c8a43f2b-4e2b-4d75-a7e1-f81510c412c2">P1Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic9afc2f89d1f4c1dbec3435239ca1668_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzctMy0xLTEtNTk0NzA_8d7b7afd-d5a8-470f-9319-b9013669c9b7"
      unitRef="usd">207000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic9afc2f89d1f4c1dbec3435239ca1668_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzctNS0xLTEtNTk0NzA_2c8867cb-c34e-4945-b862-8bb5cbfbbcbc"
      unitRef="usd">206000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic9afc2f89d1f4c1dbec3435239ca1668_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzctNy0xLTEtNTk0NzA_02f01bda-1553-4b61-9310-938b38c05780"
      unitRef="usd">1000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5fee0ea71e1945109e92e284dc86e65a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzctOS0xLTEtNTk0NzA_8cdd76d7-4bb8-4daf-8e55-b30663f43580"
      unitRef="usd">210000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5fee0ea71e1945109e92e284dc86e65a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzctMTEtMS0xLTU5NDcw_8400c891-5214-4d90-86b1-685ae1a2c527"
      unitRef="usd">200000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5fee0ea71e1945109e92e284dc86e65a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzctMTMtMS0xLTU5NDcw_d9849f95-37e3-43bf-9a5d-89595937f94e"
      unitRef="usd">10000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzgtMy0xLTEtNTk0NzA_51bd7643-e03f-4e61-9c44-fd6ff2972af5"
      unitRef="usd">25430000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzgtNS0xLTEtNTk0NzA_47079c53-aaca-4adf-9081-6e34fab23122"
      unitRef="usd">20180000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzgtNy0xLTEtNTk0NzA_cda5e621-e692-4179-8e43-93ddc470958f"
      unitRef="usd">5250000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzgtOS0xLTEtNTk0NzA_9a6c718c-f3de-4964-9b11-d84a0adec80c"
      unitRef="usd">25481000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzgtMTEtMS0xLTU5NDcw_e2d1b023-a5d5-4632-95ea-0957ce5a1915"
      unitRef="usd">18741000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzgtMTMtMS0xLTU5NDcw_ae7dc8a1-f7eb-4e72-a7fc-ba61bdc6ce72"
      unitRef="usd">6740000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i1ff94dcd862b417485b1c86cab1f0d19_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzktMy0xLTEtNTk0NzA_064ef316-2711-4dad-8ffc-1925ffc9b123"
      unitRef="usd">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i1ff94dcd862b417485b1c86cab1f0d19_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzktNy0xLTEtNTk0NzA_9ed6996b-41dc-4027-92c4-b80856c401a5"
      unitRef="usd">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i1044279e431a465c8d792ff8c4424f95_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzktOS0xLTEtNTk0NzA_ca0c25f1-6b61-4d2f-a01c-0edad8a456ca"
      unitRef="usd">7000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i1044279e431a465c8d792ff8c4424f95_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzktMTMtMS0xLTU5NDcw_2a0f0173-8af4-4627-a637-b006477006e6"
      unitRef="usd">7000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i068c904248854bbc871b95c7bda13c2a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzEwLTMtMS0xLTU5NDcw_c8d92b06-75f8-4163-9f16-178f52c7cc5d"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i068c904248854bbc871b95c7bda13c2a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzEwLTctMS0xLTU5NDcw_159c0820-85fc-40b9-b54c-5f3e201df70d"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i482a42699464403190bb5666f649d099_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzEwLTktMS0xLTU5NDcw_aa62566c-a359-4139-ba1d-82a1d6cf85f5"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i482a42699464403190bb5666f649d099_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzEwLTEzLTEtMS01OTQ3MA_9dcaeed0-13dd-4667-b190-da7ada05952e"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzExLTMtMS0xLTU5NDcw_9a56cdc2-7dec-4cf3-ac1a-d7f57fefc97f"
      unitRef="usd">27128000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzExLTUtMS0xLTU5NDcw_ecbbeb4f-e363-44bc-9d68-5a942356e90d"
      unitRef="usd">20180000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzExLTctMS0xLTU5NDcw_b9068089-3420-43fb-ae9f-3aa3c83d7640"
      unitRef="usd">6948000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzExLTktMS0xLTU5NDcw_f4003d50-d9e4-43e0-bb63-1c10c5cba4ba"
      unitRef="usd">27186000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzExLTExLTEtMS01OTQ3MA_a72f30b3-c577-4892-ba7a-470042b5a991"
      unitRef="usd">18741000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTo3NjYzMjc1ZDFhODA0ZDMzYWE0N2EwNTRmMDJiZTI3OC90YWJsZXJhbmdlOjc2NjMyNzVkMWE4MDRkMzNhYTQ3YTA1NGYwMmJlMjc4XzExLTEzLTEtMS01OTQ3MA_6f52927d-39db-40ba-a8ce-6623331a2b78"
      unitRef="usd">8445000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="idf8fe351f9e049048e582a289f5ec940_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NjA1OTI_847badec-3079-4a8e-be38-6aa7d4866454"
      unitRef="usd">105000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i8fd89ab94eae4b75848759e31a502deb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NjA2MDY_f81bb129-b4af-4af4-b401-52133f4223c6"
      unitRef="usd">88000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i6052d5b84a4f4e3dbbd55e3b7b3472af_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NjA2MTk_98da1d33-c84e-4f75-a79f-21b767ef1e04"
      unitRef="usd">23000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i65d12a1576654877b8d12fa8e43fad62_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzY1MDU_aaa5dcfe-0613-4833-827c-8cd95707f411"
      unitRef="usd">18000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="iee78254e5ef24867b4e79676061b9da5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzYwNg_6370e89c-e7e6-4598-820c-a2dc67b9d915"
      unitRef="usd">96000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="ic98bb92d4f6c4075b3ea9d057f2dc09e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzgyMA_33879e3e-5e37-4091-9144-65a9ed120d9c"
      unitRef="usd">16000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i7814719b55964c3a90f30a661c040f5e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzkwNg_1785d896-13c3-4327-8e4a-840025d6be2d"
      unitRef="usd">1000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="iae9620bf07594c2d8b0ae4bda9e46476_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzEwNDc_a8a887da-dbe5-4cf7-99a3-355306299aa0"
      unitRef="usd">1000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i4275122509984c548f84f8d98d4710c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzExMzI_cfbdffdc-5928-49ed-a40d-76b3d7da7a57"
      unitRef="usd">58000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i7f2bdcc8cabc4a8fbc2220baf550e504_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzEyNTI_831d23a1-eb5a-40bc-8ee1-b20fd747d3e0"
      unitRef="usd">8000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i77368b09b2fe4c1dbf5d0160459ef7d5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzEzMTQ_33e7ea0c-e4a3-485e-abe2-6aea76535d6d"
      unitRef="usd">5000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i3f938f0f5c7b48b98d4abfb36c343bf5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzE0ODg_d3094f62-2f64-4ebc-918e-3231ca0b4dc8"
      unitRef="usd">4000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI0Nzk2_d8e919cb-e56b-4089-8fa1-1649f99080e3">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated amortization expense of finite-lived intangible assets for the five years ending December&#160;31 and thereafter are as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTpjZDc0YzVhMTQwYmQ0ZjBkODYyYzVmMTliYTFjNjM4MS90YWJsZXJhbmdlOmNkNzRjNWExNDBiZDRmMGQ4NjJjNWYxOWJhMWM2MzgxXzEtMi0xLTEtNTk0NzA_72f392c6-5cab-4cd2-a6cd-4508ab48273c"
      unitRef="usd">1181000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTpjZDc0YzVhMTQwYmQ0ZjBkODYyYzVmMTliYTFjNjM4MS90YWJsZXJhbmdlOmNkNzRjNWExNDBiZDRmMGQ4NjJjNWYxOWJhMWM2MzgxXzEtNC0xLTEtNTk0NzA_b5e5fe15-4eae-441d-9a54-14bc845f0d81"
      unitRef="usd">1026000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTpjZDc0YzVhMTQwYmQ0ZjBkODYyYzVmMTliYTFjNjM4MS90YWJsZXJhbmdlOmNkNzRjNWExNDBiZDRmMGQ4NjJjNWYxOWJhMWM2MzgxXzEtNi0xLTEtNTk0NzA_6a3393db-836f-45d2-acd4-478dff7124f8"
      unitRef="usd">902000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTpjZDc0YzVhMTQwYmQ0ZjBkODYyYzVmMTliYTFjNjM4MS90YWJsZXJhbmdlOmNkNzRjNWExNDBiZDRmMGQ4NjJjNWYxOWJhMWM2MzgxXzEtOC0xLTEtNTk0NzA_6f65ce0a-7760-4bc4-a949-7894cc8b99cb"
      unitRef="usd">795000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTpjZDc0YzVhMTQwYmQ0ZjBkODYyYzVmMTliYTFjNjM4MS90YWJsZXJhbmdlOmNkNzRjNWExNDBiZDRmMGQ4NjJjNWYxOWJhMWM2MzgxXzEtMTAtMS0xLTU5NDcw_aaae8bac-1a18-45da-8b36-6e87f4f4b739"
      unitRef="usd">664000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTpjZDc0YzVhMTQwYmQ0ZjBkODYyYzVmMTliYTFjNjM4MS90YWJsZXJhbmdlOmNkNzRjNWExNDBiZDRmMGQ4NjJjNWYxOWJhMWM2MzgxXzEtMTItMS0xLTU5NDcw_d1237bd3-a319-4357-8204-858e5c7d10f1"
      unitRef="usd">682000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTpjZDc0YzVhMTQwYmQ0ZjBkODYyYzVmMTliYTFjNjM4MS90YWJsZXJhbmdlOmNkNzRjNWExNDBiZDRmMGQ4NjJjNWYxOWJhMWM2MzgxXzEtMTQtMS0xLTU5NDcw_810d34a5-65d2-4358-af9a-00a9808d8eec"
      unitRef="usd">5250000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI0NzY0_762629f7-71f9-48aa-878c-151564ab4b6f">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amounts of goodwill during the years ended December 31, 2021, 2020 and 2019 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Bausch + &lt;br/&gt;Lomb/&lt;br/&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Bausch + &lt;br/&gt;Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;International Rx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisition of certain assets of Synergy &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill reclassified to assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets held for sale reclassified to goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill reclassified to assets held for sale (Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realignment of segment goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i4962dcdee267427ca7c640643c4b63e0_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEtMi0xLTEtNTk0NzA_0ba0c9ac-af77-4e02-af17-af802ca5e74d"
      unitRef="usd">5805000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic87f144240594803b338f3329694b5af_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEtNi0xLTEtNjc5Njg_a54bd4aa-b644-4b25-83ff-48bb9aac608c"
      unitRef="usd">3156000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6485ff11a7784c7d93cdebb81e571cf7_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEtMTAtMS0xLTY3OTcw_0265a229-9262-44f3-8a9c-74ee3859bcaa"
      unitRef="usd">1267000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if13a6652f6f14e9380c0faa89ab7253a_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEtMTItMS0xLTY3OTcy_b815f6e8-c102-492f-8713-f438d6069150"
      unitRef="usd">2914000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i88a9900560564bdca7dec25381689c13_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEtMTQtMS0xLTU5NDcw_f5ce9153-bcdd-48b7-b334-d196d2c009ff"
      unitRef="usd">13142000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ieefeebe8556a419b982e4603dccbde45_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzItNi0xLTEtNjc5NDg_3d16a735-bf10-48b3-8c9f-b5890bc3173f"
      unitRef="usd">3000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzItMTQtMS0xLTU5NDcw_3b761f09-8cd1-4713-8bec-95c84163fcf5"
      unitRef="usd">3000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="if02d06f22a6049fab2752d7559d9139c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzMtMi0xLTEtNTk0NzA_a23a666d-7357-48b8-9f65-f7f636635db5"
      unitRef="usd">18000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzMtMTQtMS0xLTY3OTgx_b5425564-8fbe-4239-a6a7-5b2fe6657e96"
      unitRef="usd">18000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="if02d06f22a6049fab2752d7559d9139c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzctMi0xLTEtNTk0NzA_529f5d8f-e42c-4e10-88ba-798e1e6651e4"
      unitRef="usd">-1000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzctMTQtMS0xLTU5NDcw_8814787f-f6cb-4278-90b4-7f0606fb223b"
      unitRef="usd">-1000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i25b498657cd04064a8d22a18cb88515c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzgtMi0xLTEtNTk0NzA_b881c708-33aa-4805-ba6d-6b2dcd327265"
      unitRef="usd">5786000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="icf8602fc27b744ae97df02360802bb93_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzgtOC0xLTEtNTk0NzA_20c159be-3d7a-449f-a703-f56b4867459f"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia16b95bd57544fe1b90bd153182259d7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzgtMTAtMS0xLTU5NDcw_ce4f5b95-4e61-4011-b5eb-dda5638cbfd3"
      unitRef="usd">1267000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id15e4ba8f40445ec845f103e0aaa553e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzgtMTItMS0xLTU5NDcw_b1b20524-a698-4f90-a5b1-ab8b2f7a9ea9"
      unitRef="usd">2914000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzgtMTQtMS0xLTU5NDcw_39fdf8c9-563d-441b-b398-bf1346811be2"
      unitRef="usd">13126000000</us-gaap:Goodwill>
    <bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit
      contextRef="i373d7f78aa2349ccaafcb0b37e13b0e1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzYtMi0xLTEtNjc5NTA_0c4dca79-eae5-4720-b883-d4becada47f4"
      unitRef="usd">18000000</bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit>
    <bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzYtMTQtMS0xLTY3OTUy_32757b52-7d3e-41a6-b904-f5f7665fe114"
      unitRef="usd">18000000</bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i373d7f78aa2349ccaafcb0b37e13b0e1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEwLTItMS0xLTU5NDcw_a2139b88-f038-4da2-a9c0-fe6c305c39cf"
      unitRef="usd">217000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEwLTE0LTEtMS01OTQ3MA_291eacc3-2189-459d-be75-102062c5645f"
      unitRef="usd">217000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i373d7f78aa2349ccaafcb0b37e13b0e1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzExLTItMS0xLTU5NDcw_9933a553-2b46-4dd7-bcaa-1af00ec170a9"
      unitRef="usd">117000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzExLTE0LTEtMS01OTQ3MA_b75b85ca-f8c9-4225-85e2-36197e782baf"
      unitRef="usd">117000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i8e7c6b2d77a446c1b4aed9a04f7dbd2e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEyLTItMS0xLTU5NDcw_583b6e4d-47c0-4bbb-bf39-07383499e69a"
      unitRef="usd">5704000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iaf22e67019f9453383f473a7440bb889_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEyLTgtMS0xLTU5NDcw_2a366484-f27f-4c5e-ab2d-c94830581c11"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i4e0d98e274204d53b918164aca0779ae_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEyLTEwLTEtMS01OTQ3MA_f543b34f-4a59-4d05-a473-4f5e68126156"
      unitRef="usd">1267000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib76ac81df5fa49b68ba3b7819c1fc06a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEyLTEyLTEtMS01OTQ3MA_fe556b01-935e-4271-9f0f-06a53b6fb5d5"
      unitRef="usd">2914000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEyLTE0LTEtMS01OTQ3MA_6122af82-f0cc-4e01-9d4b-368b6290cdaf"
      unitRef="usd">13044000000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ib7300f7b54644f8a9660b750f9e847b8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEzLTItMS0xLTU5NDcw_cf8672a6-2034-4d20-b280-191bacfc479b"
      unitRef="usd">-5704000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i85a97ee039044646b0f12d8dfddbf0fb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEwLTQtMS0xLTY3OTU0_7e62cb82-ea4a-4fff-8771-70fdac8ae8fc"
      unitRef="usd">5395000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i6dd56e661cc441b88ce62c077cb8c9c5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEwLTgtMS0xLTY3OTU2_f5f583dc-f48b-4ab4-afa7-6446de0e40d1"
      unitRef="usd">887000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="id9cf2e58ead94c7e812f2a73e8e5a8b0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEwLTEyLTEtMS02Nzk1OA_007b2e57-2260-4502-ab28-1c82008dbaea"
      unitRef="usd">-578000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEzLTE0LTEtMS01OTQ3MA_3c51a8ab-a869-45d1-bbed-dc2cdcd17cb1"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ib7300f7b54644f8a9660b750f9e847b8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzE0LTItMS0xLTU5NDcw_af7bd707-88fc-445a-9d24-27ddb20e7e95"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i03a8ce11b6a94d508439a84f941e6341_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzExLTEwLTEtMS02Nzk2MA_ae1566b0-8302-426b-abf8-628d83a8e787"
      unitRef="usd">469000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzE0LTE0LTEtMS01OTQ3MA_a2b98a85-e598-46e9-85f1-8fe9fb2181fa"
      unitRef="usd">469000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ib7300f7b54644f8a9660b750f9e847b8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzE1LTItMS0xLTU5NDcw_6eb08f9b-0bc1-4926-ba91-4bf021d7e5df"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i85a97ee039044646b0f12d8dfddbf0fb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEyLTQtMS0xLTY3OTYy_af02f3dc-4d28-4ef8-9dcd-c64abdbcb53f"
      unitRef="usd">-77000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i6dd56e661cc441b88ce62c077cb8c9c5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEyLTgtMS0xLTY3OTY0_e92547f1-6034-4f52-8998-fee7b033dcce"
      unitRef="usd">-62000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="id9cf2e58ead94c7e812f2a73e8e5a8b0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEyLTEyLTEtMS02Nzk2Ng_5acb3572-35ec-48c0-8efe-e83bd9ab1caf"
      unitRef="usd">21000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzE1LTE0LTEtMS01OTQ3MA_8ba6b41b-84da-4b15-9ef3-8d289d72d739"
      unitRef="usd">-118000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i5ab307cfbe9b4a94b2c883cfc5dd5f07_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzE2LTItMS0xLTU5NDcw_a0e135df-4990-452e-b836-c5eda92eadec"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i4a665fac8c5447d6b59c47157917616d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEzLTQtMS0xLTY3OTYy_82c6d90c-33ba-422d-8ce6-7f0db89bc93e"
      unitRef="usd">5318000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ieba4bed7b87c4d64adde44c696279cea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzE2LTgtMS0xLTU5NDcw_4eda8731-2265-442a-b1c9-a9b98750182d"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i08856af02cf84095b7eda2ff890eaa65_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzEzLTgtMS0xLTY3OTY0_bcb684cf-5b32-4985-82e1-5a68b30e4520"
      unitRef="usd">825000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id7042f2109b44a618b5adc51134f2f32_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzE2LTEwLTEtMS01OTQ3MA_49c515a8-7e2d-4242-a2cb-b1ddd5f31e40"
      unitRef="usd">798000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i16b907a0a74e489584cd63b7298ac261_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzE2LTEyLTEtMS01OTQ3MA_c34a01b6-5e4e-44ea-8e9d-920dff2de4ce"
      unitRef="usd">2357000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90YWJsZTplYTk4ZDgzYzgyYWI0NmYwOWFhZmQ5NTg2MTkwNjU1ZS90YWJsZXJhbmdlOmVhOThkODNjODJhYjQ2ZjA5YWFmZDk1ODYxOTA2NTVlXzE2LTE0LTEtMS01OTQ3MA_ac234e0d-a2c6-4589-a2c8-cdf1a7dc3ee5"
      unitRef="usd">12457000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i9e15ed3860174023ad86fcfb1fc3d7a7_D20191001-20191001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzM4NDgyOTA3NjEyMTc_a1b3be93-751a-4481-b62b-74ad015c356e"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzE2MjE3_b133e6d3-a8f6-44ac-a3ce-08da11a8d93c"
      unitRef="usd">8434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzE2MjI0_5ea33e25-47ac-4585-a299-2b676f7f353a"
      unitRef="usd">8027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NjQwMTE_b012affb-7489-46a6-b649-a8ba9b7ba8ca"
      unitRef="usd">407000000</bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax>
    <bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage
      contextRef="i6b80b732bf87464abb356edb40e75c0f_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzE2NDUx_03dc97f5-9129-4dc3-9987-887bf18305f2"
      unitRef="number">-0.23</bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage>
    <bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage
      contextRef="ie754db10161f4f43a00a7ccbbb4d5499_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzE2NDU4_662d7c21-dff9-4a10-8143-f696ecf8db01"
      unitRef="number">-0.03</bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage>
    <bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage
      contextRef="i49498b6d16f54144b0e062468813a553_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NjQwMDc_c582c767-3fba-49fc-89d8-985d90f6958e"
      unitRef="number">-0.01</bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="iae72504d531644ac8838bbb4ec27c1c1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzEwOTk1MTE2OTIyNDY_97b6bd26-5e9c-4471-90d0-5edcac60578d"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i10b37ca262cc4204a355bbd20f6cd963_D20200630-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI3NDg3NzkxMzM0MDI_5b482b05-7d51-4709-a169-1d33d9bcc300"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="iac97f26599824297bb76711a52beec7e_D20200331-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI3NDg3NzkxMzM0MDI_b95492ca-8650-4017-8260-cae7fbb95819"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="ib7fea7ac010346df9ddbd729f74109a4_I20201001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzIzNTI0_3ff705e0-bc7d-4cae-b6d2-99b96767ee25"
      unitRef="number">0.020</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i5c4efa01e28a4063ba07a08f0dec29a3_I20201001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzIzNTY1_91544c46-0de2-4b81-bf0d-a1a64afcc690"
      unitRef="number">0.0950</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="id4d44a38635a40b4a32e60755373e624_I20201001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzIzNTcy_bdf0e49c-292a-4716-bed0-a8c20b75ef0a"
      unitRef="number">0.0975</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="ib7fea7ac010346df9ddbd729f74109a4_I20201001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzIzNzUx_155894fe-ec34-4b80-be36-25218afff224"
      unitRef="number">0.10</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i774ca80b37c14809aaf69d1ec60caea2_D20201001-20201001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzIzODEy_4d81974b-1a57-4804-8905-2b1ba8bbf83f"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="ie3ad16bb04674a37884451df0bcbfb99_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NDU2ODY_f71e53f1-c0e2-4b23-891a-a625a1bb26d8"
      unitRef="number">0.010</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="ib2e256a9bac640f8ab017d4f047fb1c9_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NDU2OTI_73fe84c4-5f7a-487a-9982-688c5db3e7a4"
      unitRef="number">0.030</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="ie3ad16bb04674a37884451df0bcbfb99_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NDU2OTg_f5258a2a-bf29-463b-9f32-e142096fc135"
      unitRef="number">0.110</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="ib2e256a9bac640f8ab017d4f047fb1c9_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NDU3MDU_56c2ff0d-b81f-4197-ba4d-e4f3877e4b64"
      unitRef="number">0.1225</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="ibd4407332fee40f39e8808930a147100_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NDU3MTM_cc2fae5e-15f2-41c7-9196-32aee8e9e7f4"
      unitRef="number">0.40</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="iae738547736443dc961d0df42b4d932b_D20210331-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI3NDg3NzkxMzM0MTA_7261e837-b811-4958-a66d-49ff81e24814"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="iade956227f64477f8bd834744fb0b81c_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzMxMTc_de56a2b9-fb15-4abc-ab98-45499e951915"
      unitRef="number">0.010</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i33a4b28c4d244a908251259f68df10a2_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzMxMjM_98ffce42-8fd8-4edc-aab4-d46a0783cd2f"
      unitRef="number">0.090</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i3befa2e27fb94dadb4d2e0b6671d1ea7_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzMxMjk_07195d55-24e6-487f-ba9c-2252358fab0e"
      unitRef="number">0.100</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ief2363e2b42349f1be653bf6588660db_D20210331-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzMxMzY_25432c3d-c866-4dda-907b-64f2ce8cbb77"
      unitRef="usd">469000000</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i68ccc3aae7a44c81bc2bc15d199cf675_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzMxNTc_1eb949f5-c66e-47b1-8c6c-2ea5b1765b90"
      unitRef="number">0.020</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i39f7dc3af718428fa8639267d86d4723_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI3NDg3NzkxMzM0MTk_c5970923-e980-41c8-b8cd-1a51f21968c5"
      unitRef="number">0.030</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i68ccc3aae7a44c81bc2bc15d199cf675_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzMxNjM_ee545374-d649-4b4b-8837-58aafdc214cb"
      unitRef="number">0.070</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i39f7dc3af718428fa8639267d86d4723_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzMxNjk_b4d7b7e2-36f3-49fd-bc0a-49913d4519db"
      unitRef="number">0.100</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i6bce9561cca44aed9496c119874299ef_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzMxNzY_5a2aa097-e86a-4c44-9ae0-31885d48963c"
      unitRef="number">0.45</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="idc7bc8f12bdf4bd5b49783904d555941_D20210630-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI3NDg3NzkxMzM0MjQ_e8070eb9-1cde-46ca-8564-2d38e4c16eb0"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="ifae82a26687143d58a5a4cf6c438ebca_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzQ5MDM_605b223c-d383-4140-8a83-5150a1f0d39e"
      unitRef="number">0.010</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="ifae82a26687143d58a5a4cf6c438ebca_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzQ5NDE_520f67ec-f3c6-4260-a954-827e7b681f79"
      unitRef="number">0.090</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="ifae82a26687143d58a5a4cf6c438ebca_I20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzQzOTgwNDY1NzQ5NjQ_966ff319-31c7-4440-9ef9-e0ab9ebdb7b2"
      unitRef="number">0.10</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i21a45eb6762341e485fcf7416428f6ba_D20211001-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI3NDg3NzkxMzM0MzI_8c510f7e-1424-4a72-a8ec-65ca4a77cce5"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjIvZnJhZzo5NWUzODEyMzRjMjA0MjFlOTk3ODhiZWRmMmRmNjYzNi90ZXh0cmVnaW9uOjk1ZTM4MTIzNGMyMDQyMWU5OTc4OGJlZGYyZGY2NjM2XzI0NzQ3_26f0b4db-6e1e-4fdd-8afb-8bdc70d6bd7c"
      unitRef="usd">4180000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90ZXh0cmVnaW9uOjhmZmNhM2RkOGQ0YjQyOTg5OTA4ODc5N2MwN2UyOWUwXzY0_032279bd-ed29-4bc3-a957-c26cf093bb53">ACCRUED AND OTHER CURRENT LIABILITIES&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities as of December 31, 2021 and 2020 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal matters and related fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90ZXh0cmVnaW9uOjhmZmNhM2RkOGQ0YjQyOTg5OTA4ODc5N2MwN2UyOWUwXzY3_86e65ca6-f72f-4502-9f6c-9ffd32ae2a57">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities as of December 31, 2021 and 2020 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal matters and related fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <bhc:Legalsettlementsandrelatedfees
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzEtMi0xLTEtNTk0NzA_5c15f5a7-5871-45da-9d93-65eb45878f24"
      unitRef="usd">1890000000</bhc:Legalsettlementsandrelatedfees>
    <bhc:Legalsettlementsandrelatedfees
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzEtNC0xLTEtNTk0NzA_722db426-cdc3-46e7-943e-ea7afe3345f3"
      unitRef="usd">1672000000</bhc:Legalsettlementsandrelatedfees>
    <bhc:AccruedProductRebateCurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzItMi0xLTEtNTk0NzA_62ebedaf-aa28-40a8-bb75-a9622a914ba8"
      unitRef="usd">908000000</bhc:AccruedProductRebateCurrent>
    <bhc:AccruedProductRebateCurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzItNC0xLTEtNTk0NzA_b3acc4d7-331d-4186-ba3d-115e6c89c6e6"
      unitRef="usd">747000000</bhc:AccruedProductRebateCurrent>
    <bhc:AccruedProductReturnCurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzMtMi0xLTEtNTk0NzA_777a8785-4200-46be-b3f4-b9a7353a1bf8"
      unitRef="usd">482000000</bhc:AccruedProductReturnCurrent>
    <bhc:AccruedProductReturnCurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzMtNC0xLTEtNTk0NzA_7390fd84-73cd-4af1-a8ab-3da8b9fa63f8"
      unitRef="usd">575000000</bhc:AccruedProductReturnCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzQtMi0xLTEtNzMzMzM_2133f508-2d9d-44b3-b5a0-8fe758b0be55"
      unitRef="usd">336000000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzQtNC0xLTEtNzMzMzM_c2835dbf-4651-4db9-8b4d-eaf60acfdaf7"
      unitRef="usd">316000000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzQtMi0xLTEtNTk0NzA_eacd606e-8d3c-4437-8795-6c51cf626558"
      unitRef="usd">328000000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzQtNC0xLTEtNTk0NzA_41ea571b-7e39-4c3d-b42d-27a8202b36ca"
      unitRef="usd">341000000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzYtMi0xLTEtNTk0NzA_624c5e33-d523-48c3-aed9-7df9213d643c"
      unitRef="usd">98000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzYtNC0xLTEtNTk0NzA_8ce911c9-663a-4f52-904f-e9313c0ce7e3"
      unitRef="usd">158000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzctMi0xLTEtNTk0NzA_37c50310-044c-48b7-9ee0-0057d4588351"
      unitRef="usd">749000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzctNC0xLTEtNTk0NzA_f7d5ee36-3fdf-4aaf-a75d-dd363f47d555"
      unitRef="usd">767000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzgtMi0xLTEtNTk0NzA_b770fd90-7a65-4dc8-a693-fd29f17dc359"
      unitRef="usd">4791000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjUvZnJhZzo4ZmZjYTNkZDhkNGI0Mjk4OTkwODg3OTdjMDdlMjllMC90YWJsZTo5ZjU5MTQ3NjEzNGU0NDgxYjE5MWE4ZGE2MTQzNmU0Zi90YWJsZXJhbmdlOjlmNTkxNDc2MTM0ZTQ0ODFiMTkxYThkYTYxNDM2ZTRmXzgtNC0xLTEtNTk0NzA_6310eaee-f002-4914-9297-b9686ae3648c"
      unitRef="usd">4576000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI3NDg3NzkxMjg0MjY_14274626-e935-4bd2-91d7-e84dc3d76119">FINANCING ARRANGEMENTS&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs as of December 31, 2021 and 2020 consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.033%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.000% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.500% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.750% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.875% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Unsecured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.500%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Covenant Compliance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes and Senior Unsecured Notes contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#x2019;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of December&#160;31, 2021, the amount available for restricted payments under the "builder basket" in the Company&#x2019;s most restrictive indentures (as defined by those indentures) was approximately $13,800&#160;million (although such availability is subject to the Company's compliance with a 2.00:1.00 fixed charge coverage ratio). The 2023 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that requires the Company to maintain a first lien net leverage ratio of not greater than 4.00:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#x2019;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Secured Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the "Senior Secured Credit Facilities" under the Company's Fourth Amended and Restated Credit and Guaranty Agreement (the &#x201c;Restated Credit Agreement&#x201d;), with a syndicate of financial institutions and investors as lenders. The Restated Credit Agreement provides for a revolving credit facility of $1,225 million (the "2023 Revolving Credit Facility") and a seven year Tranche B Term Loan Facility of $4,565 million (the &#x201c;June 2025 Term Loan B Facility&#x201d;) borrowed by the Company&#x2019;s subsidiary, Bausch Health Americas, Inc. ("BHA"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2023 Revolving Credit Facility matures on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company or BHA in an aggregate principal amount in excess of $1,000 million. Both the Company and BHA are borrowers with respect to the 2023 Revolving Credit Facility. Borrowings under the 2023 Revolving Credit Facility may be made in U.S. dollars or Canadian dollars (or if an amendment to the Restated Credit Agreement is made to replace LIBOR with an alternative benchmark rate with respect to borrowings under the Revolving Credit Facility denominated in euros, euros).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had $285 million of outstanding borrowings, $54 million of issued and outstanding letters of credit, and remaining availability of $886 million under its 2023 Revolving Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 27, 2018, the Company entered into the First Incremental Amendment to the Restated Credit Agreement, which provided an additional seven year Tranche B Term Loan Facility of $1,500&#160;million (the "November 2025 Term Loan B Facility").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Current Description of Senior Secured Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the Senior Secured Credit Facilities in U.S. dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a base rate determined by reference to the highest of: (a) the prime rate (as defined in the Restated Credit Agreement), (b) the federal funds effective rate plus 1/2 of 1.00% or (c) the eurocurrency rate (as defined in the Restated Credit Agreement) for a period of one month plus 1.00% (or if such eurocurrency rate shall not be ascertainable, 1.00%) or (ii) a eurocurrency rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2023 Revolving Credit Facility in euros, when available, are expected to bear interest at a term benchmark rate determined by reference to the costs of funds for euro deposits for the interest period relevant to such borrowing (provided however, that the eurocurrency rate is at no time expected to be less than 0.00% per annum), plus an applicable margin. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2023 Revolving Credit Facility in Canadian dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a prime rate determined by reference to the higher of: (a) the rate of interest last quoted by The Wall Street Journal as the &#x201c;Canadian Prime Rate&#x201d; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus 1.00% (provided however, that the prime rate shall at no time be less than 0.00%) or (ii) the bankers&#x2019; acceptance rate for Canadian dollar deposits in the Toronto interbank market (the &#x201c;BA rate&#x201d;) for the interest period relevant to such borrowing (provided however, that the BA rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to certain exceptions and customary baskets set forth in the Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i)&#160;100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii)&#160;100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the Restated Credit Agreement), (iii)&#160;50% of Excess Cash Flow (as&#160;defined in the Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv)&#160;100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The applicable interest rate margins for the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility are 2.00% and 1.75%, respectively, with respect to base rate and prime rate borrowings and 3.00% and 2.75%, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively, with respect to eurocurrency rate and BA rate borrowings. As of December 31, 2021, the stated rates of interest on the Company&#x2019;s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were 3.09% and 2.84% per annum, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortization rate for both the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility is 5.00% per annum. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of December 31, 2021, there were no remaining mandatory quarterly amortization payments for the Senior Secured Credit Facilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are 1.50%-2.00% with respect to base rate or prime rate borrowings and 2.50%-3.00% with respect to eurocurrency rate or BA rate borrowings.&#160; As of December 31, 2021, the stated rate of interest on the 2023 Revolving Credit Facility was 2.84% per annum. In addition, the Company is required to pay commitment fees of 0.25% - 0.50% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency&#160;fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Restated Credit Agreement permits the incurrence of incremental credit facility borrowings, up to the greater of $1,000 million and 28.5% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Notes are guaranteed by each of the Company&#x2019;s subsidiaries that is a guarantor under the Restated Credit Agreement and existing Senior Unsecured Notes (together, the &#x201c;Note Guarantors&#x201d;). The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#x2019;s obligations under the Restated Credit Agreement under the terms of the indentures governing the Senior Secured Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#x2019;s and Note Guarantors&#x2019; respective existing and future unsubordinated indebtedness and senior to the Company&#x2019;s and Note Guarantors&#x2019; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;pari passu&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with the Company&#x2019;s and the Note Guarantors&#x2019; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#x2019;s and the Note Guarantors&#x2019; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#x2019;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#x2019;s debt that is secured by assets that are not collateral.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#x2019;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;6.500% Senior Secured Notes due 2022 and 7.00% Senior Secured Notes due 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, the Company issued $1,250&#160;million aggregate principal amount of 6.500% senior secured notes due March 15, 2022 (the &#x201c;March 2022 Secured Notes&#x201d;) and $2,000&#160;million aggregate principal amount of 7.000% senior secured notes due March 15, 2024 (the &#x201c;March 2024 Secured Notes&#x201d;), in a private placement. Interest on these notes is payable semi-annually in arrears on each March 15 and September 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The March 2022 Secured Notes were repaid in full as part of the May 2020 Refinancing Transactions (as defined below).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The March 2024 Secured Notes were repaid in full during 2021 with cash on hand and as part of the June 2021 Refinancing Transactions (as defined below).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5.500% Senior Secured Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October&#160;17, 2017, the Company issued $1,000&#160;million, and, on November 21, 2017, the Company issued $750&#160;million,  aggregate principal amount of 5.500% Senior Secured Notes due November 2025 (the &#x201c;November 2025 Secured Notes&#x201d;), &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in a private placement. Interest on the November 2025 Secured Notes is payable semi-annually in arrears on each May 1 and November 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The November 2025 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time, at the redemption prices set forth in the indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5.750% Senior Secured Notes due 2027 - March 2019 Refinancing Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 8, 2019, BHA and the Company issued: (i) $1,000 million aggregate principal amount of 8.500% Senior Unsecured Notes due 2027 (the "January 2027 Unsecured Notes") and (ii) $500 million aggregate principal amount of 5.750% Senior Secured Notes due August 2027 (the "August 2027 Secured Notes"), respectively, in a private placement. A portion of the proceeds and cash on hand were used to: (i) repurchase $584 million of 5.875% Senior Unsecured Notes due 2023 (the "May 2023 Unsecured Notes"), (ii) repurchase $518 million of 5.625% Senior Unsecured Notes due 2021 (the &#x201c;December 2021 Unsecured Notes&#x201d;), (iii) repurchase $216 million of 5.500% Senior Unsecured Notes due 2023 (the "March 2023 Unsecured Notes&#x201d;) and (iv) pay all fees and expenses associated with these transactions (collectively, the &#x201c;March 2019 Refinancing Transactions&#x201d;). During April 2019, the Company redeemed $182 million of the December 2021 Unsecured Notes, representing the remaining outstanding principal balance of the December 2021 Unsecured Notes and completing the refinancing of $1,500 million of debt in connection with the March 2019 Refinancing Transactions. The March 2019 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $8 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#x2019;s carrying value. Interest on the August 2027 Secured Notes is payable semi-annually in arrears on each February 15 and August 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The August 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after August 15, 2022, at the redemption prices set forth in the indenture. The Company may redeem some or all of the August 2027 Secured Notes prior to August 15, 2022 at a price equal to 100% of the principal amount thereof plus a &#x201c;make-whole&#x201d; premium. Prior to August 15, 2022, the Company may redeem up to 40% of the aggregate principal amount of the August 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;4.875% Senior Secured Notes due 2028 - June 2021 Refinancing Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 8, 2021, the Company issued $1,600&#160;million aggregate principal amount of 4.875% Senior Secured Notes due June 2028 (the &#x201c;June 2028 Secured Notes&#x201d;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase a portion and redeem the remainder of $1,600&#160;million of the March 2024 Secured Notes, representing the remaining outstanding principal balance of the March 2024 Secured Notes and (ii) pay all fees and expenses associated with these transactions (collectively, the &#x201c;June 2021 Refinancing Transactions&#x201d;). The June 2021 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $38&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#x2019;s carrying value. Interest on the June 2028 Secured Notes is payable semi-annually in arrears on each June 1 and December 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The June 2028 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after June 1, 2024, at the redemption prices set forth in the June 2028 Secured Notes indenture. The Company may redeem some or all of the June 2028 Secured Notes prior to June 1, 2024 at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of the redemption plus a &#x201c;make-whole&#x201d; premium. In addition, at any time prior to June 1, 2024, the Company may redeem up to 40% of the aggregate principal amount of the June 2028 Secured Notes using the net proceeds of certain equity offerings at the redemption price set forth in the June 2028 Secured Notes indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Unsecured Notes issued by the Company are the Company&#x2019;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5.500% Senior Unsecured Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 30, 2015, the Company issued $1,000 million aggregate principal amount of March 2023 Unsecured Notes in a private placement. The March 2023 Unsecured Notes accrued interest at the rate of 5.500% per year, payable semi-annually in arrears. On March 8, 2019 and May 23, 2019, the Company repurchased $216 million and $382 million of March 2023 Unsecured Notes as part of the March 2019 Refinancing Transactions and the May 2019 Refinancing Transactions (as defined below), respectively. Throughout 2020, the Company repurchased, in aggregate, $169&#160;million of March 2023 Unsecured Notes using cash on hand. The Company repurchased the remaining outstanding balance of $233&#160;million in December 2020 as part of the December 2020 Refinancing Transactions (as defined below).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5.375% Senior Unsecured Notes due 2020, 5.875% Senior Unsecured Notes due 2023, 4.500% Senior Unsecured Notes due 2023 and 6.125% Senior Unsecured Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2015, VRX Escrow Corp. (the "VRX Issuer"), a newly formed wholly owned subsidiary of the Company, issued $2,000 million aggregate principal amount of 5.375% Senior Unsecured Notes due 2020 (the "March 2020 Unsecured Notes"), $3,250 million aggregate principal amount of May 2023 Unsecured Notes, &#x20ac;1,500 million aggregate principal amount of 4.500% Senior Unsecured Notes due 2023 (the "Euro Notes&#x201d;) and $3,250 million aggregate principal amount of 6.125% Senior Unsecured Notes due 2025 (the "April 2025 Unsecured Notes" and, together with the March 2020 Unsecured Notes, the May 2023 Unsecured Notes and the Euro Notes, the "VRX Notes") in a private placement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The March 2020 Unsecured Notes accrued interest at the rate of 5.375% per year and were repaid in full as part of certain refinancing transactions completed in 2017 and 2018. The May 2023 Unsecured Notes and the Euro Notes accrued interest at the rate of 5.875% and 4.500%  per year, respectively and were each repaid in full as of December 31, 2020, as discussed below. The April 2025 Unsecured Notes accrue interest at the rate of 6.125% per year, payable semi-annually in arrears. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of a refinancing transaction completed in June 2018, the Company repaid the remaining outstanding principal amounts of the March 2020 Unsecured Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company repurchased $584 million and $1,118 million of May 2023 Unsecured Notes as part of the March 2019 Refinancing Transactions and the May 2019 Refinancing Transactions (as defined below), respectively, and on October 3, 2019, the Company repaid an additional $100 million of May 2023 Unsecured Notes using cash on hand. On January 16, 2020, the Company redeemed $1,240 million aggregate principal amount of the May 2023 Unsecured Notes as part of the December 2019 Financing and Refinancing Transactions (as defined below). Throughout 2020, the Company repaid, in aggregate, $208&#160;million of the May 2023 Unsecured Notes, with the May 2023 Unsecured Notes having been fully repaid during November 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 3, 2020, the Company redeemed the remaining outstanding balance of the Euro Notes as part of the December 2020 Refinancing Transactions, as defined below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Throughout 2021, the Company repaid, in aggregate, $600&#160;million of the April 2025 Unsecured Notes. The Company may redeem all or a portion of the April 2025 Unsecured Notes at the redemption prices set forth in the applicable indenture, plus accrued and unpaid interest to the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;9.000% Senior Unsecured Notes due 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;18, 2017, the Company issued $1,500 million aggregate principal amount of 9.000% Senior Unsecured Notes due 2025 (the &#x201c;December 2025 Unsecured Notes&#x201d;) in a private placement, the net proceeds of which were used to repurchase $1,500&#160;million in aggregate principal amount of previously outstanding senior unsecured notes (the "December 2017 Refinancing Transactions"). The related fees and expenses were paid using cash on hand. The December 2025 Unsecured Notes accrue interest at the rate of 9.000% per year, payable semi-annually in arrears on each of June 15 and December 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may redeem all or a portion of the December 2025 Unsecured Notes at any time prior to December 15, 2021, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#x201c;make-whole&#x201d; premium. In addition, at any time prior to December 15, 2020, the Company may redeem up to 40% of the aggregate principal amount of the outstanding December 2025 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the December 2025 Unsecured Notes indenture. On or after December 15, 2021, the Company may redeem all or a portion of the December 2025 Unsecured Notes at the applicable redemption prices set forth in the December 2025 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;9.250% Senior Unsecured Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 26, 2018, BHA issued $1,500 million in aggregate principal amount of 9.250% Senior Unsecured Notes due 2026 (the &#x201c;April 2026 Unsecured Notes&#x201d;) in a private placement, the net proceeds of which, and cash on hand, were used to repurchase $1,500 million in aggregate principal amount of unsecured notes. All fees and expenses associated with these transactions were paid with cash on hand (collectively, the &#x201c;March 2018 Refinancing Transactions&#x201d;). The April 2026 Unsecured Notes accrue interest at the rate of 9.250% per year, payable semi-annually in arrears on each of April 1 and October 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BHA may redeem all or a portion of the April 2026 Unsecured Notes at any time prior to April 1, 2022, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#x201c;make-whole&#x201d; premium. In addition, at any time prior to April 1, 2021, BHA may redeem up to 40% of the aggregate principal amount of the outstanding April 2026 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the April 2026 Unsecured Notes indenture. On or after April 1, 2022, BHA may redeem all or a portion of the April 2026 Unsecured Notes at the applicable redemption prices set forth in the April 2026 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;8.500% Senior Unsecured Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of a 2018 refinancing transaction, BHA issued $750 million in aggregate principal amount of January 2027 Unsecured Notes in a private placement. The January 2027 Unsecured Notes accrue interest at the rate of 8.500% per year, payable semi-annually in arrears on each of January 31 and July 31. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the March 2019 Refinancing Transactions described above, BHA issued $1,000 million aggregate principal amount of 8.500% Senior Unsecured Notes due January 2027. These are additional notes and form part of the same series as BHA&#x2019;s existing January 2027 Unsecured Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BHA may redeem all or a portion of the January 2027 Unsecured Notes at any time prior to July 31, 2022, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#x201c;make-whole&#x201d; premium. In addition, at any time prior to July 31, 2021, BHA may redeem up to 40% of the aggregate principal amount of the outstanding January 2027 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the January 2027 Unsecured Notes indenture. On or after July 31, 2022, BHA may redeem all or a portion of the January 2027 Unsecured Notes at the applicable redemption prices set forth in the January 2027 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;7.000% Senior Unsecured Notes due 2028 and 7.250% Senior Unsecured Notes due 2029 - May 2019 Refinancing Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 23, 2019, the Company issued: (i) $750 million aggregate principal amount of 7.000% Senior Unsecured Notes due January 2028 (the "7.000% January 2028 Unsecured Notes") and (ii) $750 million aggregate principal amount of 7.250% Senior Unsecured Notes due May 2029 (the "May 2029 Unsecured Notes"), respectively, in a private placement. The proceeds and cash on hand were used to: (i) repurchase $1,118 million of May 2023 Unsecured Notes, (ii) repurchase $382 million of March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the &#x201c;May 2019 Refinancing Transactions&#x201d;). The May 2019 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $32 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#x2019;s carrying value. Interest on the 7.000% January 2028 Unsecured Notes is payable semi-annually in arrears on each January 15 and July 15. Interest on the May 2029 Unsecured Notes is payable semi-annually in arrears on each May 30 and November 30. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 7.000% January 2028 Unsecured Notes and the May 2029 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 15, 2023 and May 30, 2024, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the 7.000% January 2028 Unsecured Notes or the May 2029 Unsecured Notes prior to January 15, 2023 and May 30, 2024, respectively, at a price equal to 100% of the principal amount thereof plus a &#x201c;make-whole&#x201d; premium. Prior to July 15, 2022, and May 30, 2022, the Company may redeem up to 40% of the aggregate principal amount of the 7.000% January 2028 Unsecured Notes or the May 2029 Unsecured Notes, respectively, using the proceeds of certain equity offerings at the redemption price set forth in the respective indenture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5.000% Senior Unsecured Notes due 2028 and 5.250% Senior Unsecured Notes due 2030 - December 2019 Financing and Refinancing Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2019, the Company issued: (i) $1,250 million aggregate principal amount of 5.000% Senior Unsecured Notes due January 2028 (the "5.000% January 2028 Unsecured Notes") and (ii) $1,250 million aggregate principal amount of 5.250% Senior Unsecured Notes due January 2030 (the "January 2030 Unsecured Notes") in a private placement. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;proceeds and cash on hand were used to: (i) redeem $1,240 million of May 2023 Unsecured Notes on January 16, 2020, (ii) finance the $1,210 million settlement of certain U.S. Securities litigation as discussed in Note 20, "LEGAL PROCEEDINGS" and (iii) pay all fees and expenses associated with these transactions (collectively, the "December 2019 Financing and Refinancing Transactions"). The redemption of $1,240&#160;million of May 2023 Unsecured notes was accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $24&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on the 5.000% January 2028 Unsecured Notes is payable semi-annually in arrears on each January 30 and July 30. Interest on the January 2030 Unsecured Notes is payable semi-annually in arrears on each January 30 and July 30. The 5.000% January 2028 Unsecured Notes and the January 2030 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 30, 2023 and January 30, 2025, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the 5.000% January 2028 Unsecured Notes or the January 2030 Unsecured Notes prior to January 30, 2023 and January 30, 2025, respectively, at a price equal to 100% of the principal amount thereof plus a &#x201c;make-whole&#x201d; premium. Prior to January 30, 2023, the Company may redeem up to 40% of the aggregate principal amount of the 5.000% January 2028 Unsecured Notes or the January 2030 Unsecured Notes using the proceeds of certain equity offerings at the redemption price set forth in the respective indenture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;6.250% Senior Unsecured Notes due 2029 - May 2020 Refinancing Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 26, 2020, the Company issued $1,500&#160;million aggregate principal amount of 6.250% Senior Unsecured Notes due February 2029 (the "6.250% February 2029 Unsecured Notes") in a private placement. The proceeds and cash on hand were used to: (i) repurchase $1,250&#160;million aggregate principal amount of the outstanding March 2022 Secured Notes, (ii) prepay $303&#160;million of mandatory amortization scheduled for payment in 2022 under the Company's June 2025 and November 2025 Term Loan B Facilities and (iii) pay all fees and expenses associated with these transactions (collectively, the "May 2020 Refinancing Transactions"). The May 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $27&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value. The 6.250% February 2029 Unsecured Notes accrue interest at the rate of 6.250% per year, payable semi-annually in arrears on each of February 15 and August 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may redeem all or a portion of the 6.250% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#x201c;make-whole&#x201d; premium. In addition, at any time prior to August 15, 2023, the Company may redeem up to 40% of the aggregate principal amount of the outstanding 6.250% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the 6.250% February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the 6.250% February 2029 Unsecured Notes at the applicable redemption prices set forth in the 6.250% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5.000% Senior Unsecured Notes due 2029 and 5.250% Senior Unsecured Notes due 2031 &#x2013; December 2020 Refinancing Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 3, 2020, the Company issued $1,000&#160;million aggregate principal amount of 5.000% Senior Unsecured Notes due February 2029 (the "5.000% February 2029 Unsecured Notes") and $1,000&#160;million aggregate principal amount of 5.250% Senior Unsecured Notes due February 2031 (the "February 2031 Unsecured Notes") in a private placement. The aggregate proceeds and cash on hand were used to repurchase the remaining outstanding principal amounts of: (i) &#x20ac;1,500&#160;million of the Euro Notes, (ii) $233&#160;million of the March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the "December 2020 Refinancing Transactions"). The December 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $7&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value. The 5.000% February 2029 Unsecured Notes accrue interest at the rate of 5.000% per year, payable semi-annually in arrears on each of February 15 and August 15. The February 2031 Unsecured Notes accrue interest at the rate of 5.250% per year, payable semi-annually in arrears on each of February 15 and August 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may redeem all or a portion of the 5.000% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#x201c;make-whole&#x201d; premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to 40% of the aggregate principal amount of the outstanding 5.000% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the 5.000% February 2029 Unsecured Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;indenture. On or after February 15, 2024, the Company may redeem all or a portion of the 5.000% February 2029 Unsecured Notes at the applicable redemption prices set forth in the 5.000% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may redeem all or a portion of the February 2031 Unsecured Notes at any time prior to February 15, 2026, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#x201c;make-whole&#x201d; premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to 40% of the aggregate principal amount of the outstanding February 2031 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the February 2031 Unsecured Notes indenture. On or after February 15, 2026, the Company may redeem all or a portion of the February 2031 Unsecured Notes at the applicable redemption prices set forth in the February 2031 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Stated Rate of Interest&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average stated rate of interest for the Company's outstanding debt obligations as of December 31, 2021 and 2020 was 5.88% and 6.02%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Maturities and Mandatory Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities and mandatory payments of debt obligations for the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross maturities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Restated Credit Agreement, there is no Excess Cash Flow payment due for 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 11, 2022, the Company repaid its outstanding balance of $285&#160;million under its 2023 Revolving Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As more fully discussed in Note 23, "SUBSEQUENT EVENTS", during January 2022, the Company: (i) issued conditional notices of redemption to redeem in full all of its outstanding April 2025 Unsecured Notes and to redeem $370&#160;million aggregate principal amount of its outstanding December 2025 Unsecured Notes and (ii) issued $1,000&#160;million aggregate principal amount of 6.125% Senior Secured Notes due February 2027.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM3NzIw_ea70e2a7-89b2-42d5-a72a-096ad87b7266">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs as of December 31, 2021 and 2020 consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.033%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.000% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.500% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.750% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.875% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Unsecured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.500%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0c01a665a28449b793613ecc5d63522c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzMtNC0xLTEtNTk0NzA_1b2481e5-e505-4943-a019-8c532c69f608"
      unitRef="usd">285000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i0c01a665a28449b793613ecc5d63522c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzMtNi0xLTEtNTk0NzA_b77c65bb-4e44-4758-9fbc-0d2164ad948f"
      unitRef="usd">285000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9adef68a2e1a41ffb17a60a9075ee559_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzMtOC0xLTEtNTk0NzA_a9a34dec-5bba-4748-aae6-74d7433e3062"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i9adef68a2e1a41ffb17a60a9075ee559_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzMtMTAtMS0xLTU5NDcw_d7c7859f-8b43-4df4-9aac-783ba0fdf117"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i19aa307929434141855192ccd5d26e84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzQtNC0xLTEtNTk0NzA_dd0393a8-8814-413b-a8dd-533580fc91a4"
      unitRef="usd">2829000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i19aa307929434141855192ccd5d26e84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzQtNi0xLTEtNTk0NzA_c195a665-66c9-471a-bc89-fb72148836f3"
      unitRef="usd">2772000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1c06253724c04adb9d709a0d06b0a4a4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzQtOC0xLTEtNTk0NzA_dda89474-10d5-4771-835c-2061849a7709"
      unitRef="usd">3298000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i1c06253724c04adb9d709a0d06b0a4a4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzQtMTAtMS0xLTU5NDcw_139dc812-f209-40c1-b13d-c56dc821a655"
      unitRef="usd">3220000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i57ba8084e93643d19f4f8c135c1beb71_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzUtNC0xLTEtNTk0NzA_d102f8fc-1917-47be-8618-e068003fde84"
      unitRef="usd">994000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i57ba8084e93643d19f4f8c135c1beb71_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzUtNi0xLTEtNTk0NzA_937fc63b-778e-4227-9cf3-be910aac5166"
      unitRef="usd">984000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib9193acd40b7439299521c6fde8c4891_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzUtOC0xLTEtNTk0NzA_7a87821b-911b-4d0b-8efd-c556718ae371"
      unitRef="usd">1125000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ib9193acd40b7439299521c6fde8c4891_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzUtMTAtMS0xLTU5NDcw_9e9fdb66-46e1-47a3-b18e-1b4aed5ed626"
      unitRef="usd">1112000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i89af4e1890874416ab318090b1cc294e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzgtMC0xLTEtNTk0NzAvdGV4dHJlZ2lvbjoyMThmYWI0YjU1ODU0MzlkODM5ZTE1NDk1OTIyYTM4M180_7f43d173-a749-477d-a769-095b6d654e91"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i89af4e1890874416ab318090b1cc294e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzgtNC0xLTEtNTk0NzA_ee526e2c-2172-42a7-a863-2cf9a844b102"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i89af4e1890874416ab318090b1cc294e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzgtNi0xLTEtNTk0NzA_a544b1c9-f8c7-4d75-ad5e-8490c1230aac"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i32e198fb8ac3442ab187a17a7c4f0d2d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzgtOC0xLTEtNTk0NzA_a20c209b-b9dd-4b05-808d-283ec9b2f816"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i32e198fb8ac3442ab187a17a7c4f0d2d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzgtMTAtMS0xLTU5NDcw_6d08ba50-2831-4503-8c09-969e363891bf"
      unitRef="usd">1987000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2ec36cf30e35457e8a0b60837b539b1e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzktMC0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo2MWIxMzVkNzAyMWY0Y2M3YWIxZjMwNTdmOWNmMWM4Zl80_f8c978fe-a538-4c13-8713-5c2987642f36"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2ec36cf30e35457e8a0b60837b539b1e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzktNC0xLTEtNTk0NzA_c21be697-2074-4059-b4c0-9a7ae4f6cd3e"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i2ec36cf30e35457e8a0b60837b539b1e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzktNi0xLTEtNTk0NzA_977f2cbc-669b-4521-915a-f0257ff42212"
      unitRef="usd">1739000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia8b2f62d73a04aadb052f3835a632303_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzktOC0xLTEtNTk0NzA_74eab347-6eea-4044-9b99-06818297d75f"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ia8b2f62d73a04aadb052f3835a632303_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzktMTAtMS0xLTU5NDcw_296cce30-914b-46d3-81ec-38037a1b3ffb"
      unitRef="usd">1736000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i66914061a58846f0a2dd9fbf966be49e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzEwLTAtMS0xLTU5NDcwL3RleHRyZWdpb246MWI0YzcyZTY3ZWFjNDJlNjgwYzM3YjFjYjljN2Y1MWNfNA_a118ca9f-ea64-4d32-abaa-30752f94f5ef"
      unitRef="number">0.05750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i66914061a58846f0a2dd9fbf966be49e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzEwLTQtMS0xLTU5NDcw_dabf5add-2a2a-4e54-a23c-8deea572fac2"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i66914061a58846f0a2dd9fbf966be49e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzEwLTYtMS0xLTU5NDcw_300a143b-a961-438f-9dcb-4e7370dbfa15"
      unitRef="usd">495000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8b9f7d6a773a492daebe7cb683a831c7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzEwLTgtMS0xLTU5NDcw_a05c8e29-2444-46de-8e9b-ee4c5d7034a9"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i8b9f7d6a773a492daebe7cb683a831c7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzEwLTEwLTEtMS01OTQ3MA_b77a17d8-e9f6-458b-a251-4dd35a301b96"
      unitRef="usd">494000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic459c1e2b8f44d65a0d2e10bfae297d5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzExLTAtMS0xLTY0MjU4L3RleHRyZWdpb246NDljYzYwNmIxODY1NGQ5ZDg0ZTYzNWM5OWMyYzUzMzJfMzg0ODI5MDY5NzI0Ng_d809f6f8-c8c7-4f62-9390-8450cd8ecec0"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic459c1e2b8f44d65a0d2e10bfae297d5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzEwLTQtMS0xLTY0NjIz_e359ad08-0ae7-4843-9045-96c4989a980b"
      unitRef="usd">1600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ic459c1e2b8f44d65a0d2e10bfae297d5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzEwLTYtMS0xLTY0NjIz_bebf70bb-d850-4c77-99cd-18fca22a5fa4"
      unitRef="usd">1580000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i92b27a9dcb1e4c6aac20e9f0f1bb22ff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzEwLTgtMS0xLTY0NjIz_72d15028-c5a8-4f70-b429-a55c2f61ff78"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i92b27a9dcb1e4c6aac20e9f0f1bb22ff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzEwLTEwLTEtMS02NDYyMw_f6e6b978-51e5-4a7a-b000-5ceeb2211769"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i67d99cc27cfc490babc9f17b67fc6c36_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE1LTAtMS0xLTU5NDcwL3RleHRyZWdpb246YjlmZmQ3ZDJhMmQxNDAzMWE4NWIyNmNiMTUyODNkNmFfNA_a15cdbf2-273e-4711-896d-2147cf9835d3"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i67d99cc27cfc490babc9f17b67fc6c36_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE1LTQtMS0xLTU5NDcw_3de5d1b4-c69f-435a-8b5a-c6762e2249c7"
      unitRef="usd">2650000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i67d99cc27cfc490babc9f17b67fc6c36_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE1LTYtMS0xLTU5NDcw_fe9297d4-50dc-4414-be77-8248e7606a67"
      unitRef="usd">2640000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9abe59cd5b4344b3af6d863639ee97e3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE1LTgtMS0xLTU5NDcw_6e962436-5973-43cc-8cf9-af41a670a6a0"
      unitRef="usd">3250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i9abe59cd5b4344b3af6d863639ee97e3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE1LTEwLTEtMS01OTQ3MA_b191b7c0-6fe9-4017-a01d-28ddc1931c6d"
      unitRef="usd">3234000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7069779fddc24154bec1252491718d71_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE2LTAtMS0xLTU5NDcwL3RleHRyZWdpb246YjE4NzIyZmFiOWRmNDZmZjhjMjA4YzkxYmRmNzk0OTJfNA_4d0310dd-354b-4b30-a21c-fec4c9566fb9"
      unitRef="number">0.09000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7069779fddc24154bec1252491718d71_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE2LTQtMS0xLTU5NDcw_47e11c2a-4ccf-42a5-bfba-be1dd2e61531"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i7069779fddc24154bec1252491718d71_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE2LTYtMS0xLTU5NDcw_7250eb20-742e-414b-86da-f54c668175a3"
      unitRef="usd">1482000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia90e19da742b46a88993ff20c0ef65e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE2LTgtMS0xLTU5NDcw_67b78017-d559-46d7-ae6c-f4999da15aa8"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ia90e19da742b46a88993ff20c0ef65e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE2LTEwLTEtMS01OTQ3MA_1953833f-6fc6-48ce-acce-ff4a2fe1cb40"
      unitRef="usd">1478000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2bbcb30923264dada2fd327d3b9f97f3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE3LTAtMS0xLTU5NDcwL3RleHRyZWdpb246ODhjZWRlNjE3MDkwNDBjODhjMjAyNTE5MGYyNDU1YWRfNA_a97b6b4b-abc1-47b0-9050-ada1dfb1fe8c"
      unitRef="number">0.09250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2bbcb30923264dada2fd327d3b9f97f3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE3LTQtMS0xLTU5NDcw_c61ed65a-e55f-492b-b8db-5b6b7c5d4c6f"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i2bbcb30923264dada2fd327d3b9f97f3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE3LTYtMS0xLTU5NDcw_17974684-7886-4724-80d7-d3d34f7c1c33"
      unitRef="usd">1489000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2b9d6159d9b345d5a925bedf7aa2f714_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE3LTgtMS0xLTU5NDcw_df0c4adf-aeb2-40b8-991f-659b5d8bc84a"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i2b9d6159d9b345d5a925bedf7aa2f714_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE3LTEwLTEtMS01OTQ3MA_bfc0cef5-131c-4608-b075-8d202dffa9a9"
      unitRef="usd">1487000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie0e3e0b5c7314f4d8c7bad143746ae92_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE4LTAtMS0xLTU5NDcwL3RleHRyZWdpb246ZWQwZTE3ODM2YzJlNDk5NGE3ZjFjMjIwMDgwOWNiMWRfNA_a89a7799-7a5b-49a6-9130-cb017cfde39b"
      unitRef="number">0.08500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie0e3e0b5c7314f4d8c7bad143746ae92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE4LTQtMS0xLTU5NDcw_df440eac-edd8-46de-aa3a-c2ebea212451"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ie0e3e0b5c7314f4d8c7bad143746ae92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE4LTYtMS0xLTU5NDcw_1c043000-95b1-46b8-a165-a60e31468b1c"
      unitRef="usd">1754000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i13a7ac2ee83a40f487e5ff99f59101b6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE4LTgtMS0xLTU5NDcw_ca95eb22-5f45-4c95-a851-9849fabb3734"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i13a7ac2ee83a40f487e5ff99f59101b6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE4LTEwLTEtMS01OTQ3MA_d35f9892-1ed9-4c77-8d62-24761186dab4"
      unitRef="usd">1755000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iac672bf940144940ab2863657d675904_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE5LTAtMS0xLTU5NDcwL3RleHRyZWdpb246YjhhZDA5ODllMmMyNDUyODg2NzYwOTY1OTMxMzkzYWRfNA_92915137-f1f2-48f6-be57-08455495aeed"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iac672bf940144940ab2863657d675904_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE5LTQtMS0xLTU5NDcw_f34b5db3-247d-48d3-9829-ca590aeb9c82"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="iac672bf940144940ab2863657d675904_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE5LTYtMS0xLTU5NDcw_f9ff3f3c-b54c-41a0-84b5-2ead264fc93b"
      unitRef="usd">743000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie691743843174dfebc02e17db2f8b881_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE5LTgtMS0xLTU5NDcw_e685c0ab-6338-4e9d-bdeb-ef46a9a2fc4e"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ie691743843174dfebc02e17db2f8b881_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzE5LTEwLTEtMS01OTQ3MA_e3e0a285-8d13-40b7-a2d1-e3adfe4417c0"
      unitRef="usd">742000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia9fccfd4eb6c4a3da530db148be437ed_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIwLTAtMS0xLTU5NDcwL3RleHRyZWdpb246ZTlhY2FlMzdjYjk3NDNjMzgwNTdkYzMyNGQyZTVlZWJfNA_3990c6c3-aed5-41a0-a6c2-ee4bd2ad366d"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia9fccfd4eb6c4a3da530db148be437ed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIwLTQtMS0xLTU5NDcw_1c612bfb-494a-48d9-a037-63dcc30f2bb5"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ia9fccfd4eb6c4a3da530db148be437ed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIwLTYtMS0xLTU5NDcw_66ab185e-3630-4ce3-9a00-89af11ec4ca7"
      unitRef="usd">1238000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3a7c2483467d42fa92a0d1889a65352c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIwLTgtMS0xLTU5NDcw_0fe21aaa-f88b-46c6-aeee-be7cc7e4b6c4"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i3a7c2483467d42fa92a0d1889a65352c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIwLTEwLTEtMS01OTQ3MA_fc687b68-4b9a-4969-afaf-2d668cb1dd24"
      unitRef="usd">1236000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i637b51dfd22b4d7d8bf9dc99c065d131_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIxLTAtMS0xLTU5NDcwL3RleHRyZWdpb246OWM4MWY1OWZkYTYyNGMyODgxZGI5YWNjZWEzMTFkNzZfNA_1fffe95f-8c8b-4346-8fad-5a777b960f42"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i637b51dfd22b4d7d8bf9dc99c065d131_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIxLTQtMS0xLTU5NDcw_88057dac-6138-4ee4-a937-80e20f9a7bf9"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i637b51dfd22b4d7d8bf9dc99c065d131_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIxLTYtMS0xLTU5NDcw_93d3354a-48ce-4585-8995-4153ab966709"
      unitRef="usd">1483000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4c6b5763866f4cdbb14e92752f777770_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIxLTgtMS0xLTU5NDcw_1d5626ba-65f5-4182-9ae1-41d5e5efee5a"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i4c6b5763866f4cdbb14e92752f777770_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIxLTEwLTEtMS01OTQ3MA_4890dbdc-68a9-433e-b271-63664fad072d"
      unitRef="usd">1480000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4273b9d256e540e985599fd8f4111808_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIyLTAtMS0xLTU5NDcwL3RleHRyZWdpb246MjZhNGZjYTE4MWQ1NDQ4MmI4ZDI5Y2M5ODE3NjcxZjhfNA_b45e6b06-728a-4e1b-bb75-d0534ee1c47a"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4273b9d256e540e985599fd8f4111808_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIyLTQtMS0xLTU5NDcw_e765ed0f-1bb2-4e52-9363-7014767d518c"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i4273b9d256e540e985599fd8f4111808_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIyLTYtMS0xLTU5NDcw_b60e7ab3-36a0-458d-bd8e-b4e94d1288f9"
      unitRef="usd">990000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3d04379800474729927c296a02ee23b2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIyLTgtMS0xLTU5NDcw_12450726-22a8-4177-be37-0c85d9918e61"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i3d04379800474729927c296a02ee23b2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIyLTEwLTEtMS01OTQ3MA_aae33f60-cf26-43d8-a6dc-acec6292e6d3"
      unitRef="usd">988000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id5f8a823e64b4391b5fdc14a2699ca01_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIzLTAtMS0xLTU5NDcwL3RleHRyZWdpb246ZWVjNDgyMThkMTViNDliZTlhZDI3MzVkZWUzOGExZTNfNA_a346bbcd-dbf7-43fd-97d9-43eac3ee38da"
      unitRef="number">0.07250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id5f8a823e64b4391b5fdc14a2699ca01_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIzLTQtMS0xLTU5NDcw_cfa9fdf6-5cfc-4aa2-af56-330140ba7e97"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="id5f8a823e64b4391b5fdc14a2699ca01_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIzLTYtMS0xLTU5NDcw_992640da-afbd-4c5e-bd4e-8c4edc99c15d"
      unitRef="usd">742000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1550fce70ddc4bde9fcc143dba86ed02_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIzLTgtMS0xLTU5NDcw_fb37b71d-0fb4-4173-a57c-bc53c1d520ec"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i1550fce70ddc4bde9fcc143dba86ed02_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzIzLTEwLTEtMS01OTQ3MA_15ab2a9d-38fc-4fef-91f8-38022ac80fee"
      unitRef="usd">741000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i87f54fc33f3647cf854ad3d2446add0e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI0LTAtMS0xLTU5NDcwL3RleHRyZWdpb246YTY2ZDcyZGY2YzVmNDczZGEwNGVlMDE0ZGEzZDNlYjhfNA_677b8b62-2851-425f-993a-84eedebf3177"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i87f54fc33f3647cf854ad3d2446add0e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI0LTQtMS0xLTU5NDcw_f85b83f9-c41b-46ff-ba49-d1f5cb92746c"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i87f54fc33f3647cf854ad3d2446add0e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI0LTYtMS0xLTU5NDcw_1097ca95-a822-4376-9c80-ae7f6556cee8"
      unitRef="usd">1237000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ibd94b3061443470786f4f2aeefe3ee61_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI0LTgtMS0xLTU5NDcw_89cd96ac-7e37-4122-929a-054f977d5d2b"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ibd94b3061443470786f4f2aeefe3ee61_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI0LTEwLTEtMS01OTQ3MA_b09ac559-06a0-4231-9de2-551b5caeaa47"
      unitRef="usd">1235000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i50ec0b78d915487982eb08953a99cf34_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI1LTAtMS0xLTU5NDcwL3RleHRyZWdpb246YTYzOGNiNWQ0M2U1NDEwYmIzN2JkZTI5NzdjMjNlYjBfNA_0e769752-f3dd-498c-9e63-b607fa279d76"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i50ec0b78d915487982eb08953a99cf34_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI1LTQtMS0xLTU5NDcw_7010e188-9dea-46c0-ae5a-eca35430cbb4"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i50ec0b78d915487982eb08953a99cf34_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI1LTYtMS0xLTU5NDcw_1ac9204f-0e06-4305-bcd3-a2df6c8f8461"
      unitRef="usd">989000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i300264ba1d81487683635e7eef8d2c8b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI1LTgtMS0xLTU5NDcw_8cc4397c-8258-4c0b-a33b-f9328f448df5"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i300264ba1d81487683635e7eef8d2c8b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI1LTEwLTEtMS01OTQ3MA_0336786c-c966-4597-ad72-8128c64d0211"
      unitRef="usd">988000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i350590e126f747c09b3b536b35e19ffd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI2LTQtMS0xLTU5NDcw_6235dc54-cae7-40db-939d-830ca4566c8a"
      unitRef="usd">12000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i350590e126f747c09b3b536b35e19ffd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI2LTYtMS0xLTU5NDcw_22e4a55b-0191-4847-834e-f0bb2dbcd3dd"
      unitRef="usd">12000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i08ba959daa4a48e2ac776ce9798a9d5e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI2LTgtMS0xLTU5NDcw_0ad3539b-65ac-4119-942f-ec988d8c182f"
      unitRef="usd">12000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i08ba959daa4a48e2ac776ce9798a9d5e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI2LTEwLTEtMS01OTQ3MA_90afb8a4-200e-4785-bdeb-7f92ab49be59"
      unitRef="usd">12000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI3LTQtMS0xLTU5NDcw_db3a2877-817e-43e5-924d-19c5ff2ad8f4"
      unitRef="usd">22870000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI3LTYtMS0xLTU5NDcw_2690f180-bf58-489f-9bb6-c01becca1184"
      unitRef="usd">22654000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI3LTgtMS0xLTU5NDcw_9b5aa6da-4148-49a2-9470-9c909a7fb147"
      unitRef="usd">24185000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI3LTEwLTEtMS01OTQ3MA_153c52b3-8b6c-4439-94d3-53a95c9b50b9"
      unitRef="usd">23925000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI4LTYtMS0xLTU5NDcw_e7edb731-cd3e-4451-a9d4-e81795a0035a"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI4LTEwLTEtMS01OTQ3MA_60aaf07c-a276-477a-b813-36fdd1275c3f"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI5LTYtMS0xLTU5NDcw_347f2d36-2ba2-4a41-a56f-6ff96329eee1"
      unitRef="usd">22654000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo0YzRkN2FiM2Q4YTc0NWNiOWI5Y2NmZWFmODk1NjYwNC90YWJsZXJhbmdlOjRjNGQ3YWIzZDhhNzQ1Y2I5YjljY2ZlYWY4OTU2NjA0XzI5LTEwLTEtMS01OTQ3MA_9b147994-964f-499b-98ce-bc96617ea260"
      unitRef="usd">23925000000</us-gaap:LongTermDebtNoncurrent>
    <bhc:DebtInstrumentAmountAvailableForRestrictedPayments
      contextRef="i8aed4915fc8f42e580d71e20a671d348_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzExODQ_e5352bf0-4cab-4573-8ca8-3220ee758fea"
      unitRef="usd">13800000000</bhc:DebtInstrumentAmountAvailableForRestrictedPayments>
    <bhc:DebtInstrumentCovenantTermsFixedChargeCoverageRatio
      contextRef="i8aed4915fc8f42e580d71e20a671d348_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyNjE_ef516de4-7c08-4aa2-ba1d-6a575c640ef4"
      unitRef="number">2.00</bhc:DebtInstrumentCovenantTermsFixedChargeCoverageRatio>
    <bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio
      contextRef="i8aed4915fc8f42e580d71e20a671d348_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE0OTA_5dfbff1c-0643-487c-a65d-2d3dfa2bb9bb"
      unitRef="number">4.00</bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia5120118135441ab83944681d2efd4b0_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM2ODE_96c0da86-dc58-429e-a4fb-ee20a719c936"
      unitRef="usd">1225000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="i351b85b10d1a4bc4994a95b06fcbbc15_D20180601-20180601"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI3NDg3NzkxMjgxODM_2513c52c-027f-4b2d-a5c8-3e3a9fd214f8">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i41ba8fedd17c41849f4e82c6bf1880b3_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM4NjQ_1c5da079-d826-4dbf-9913-2f659aba251f"
      unitRef="usd">4565000000</us-gaap:DebtInstrumentFaceAmount>
    <bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold
      contextRef="i4661b2464e2e42d289cd362548d23d4e_D20180601-20180601"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzQwNzc_16e9d13d-cfe4-4eae-8a3b-9c4b2ffca7ba">P91D</bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold>
    <bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold
      contextRef="ia5120118135441ab83944681d2efd4b0_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzQyMjk_aed9d59f-60a3-4087-95a4-3773d1c0575d"
      unitRef="usd">1000000000</bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold>
    <us-gaap:LongTermDebt
      contextRef="i0c01a665a28449b793613ecc5d63522c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzg3NTg_af5de66e-cf5f-4f78-8256-8669c86f6f8a"
      unitRef="usd">285000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iedebe3ccdce14516b687ab3595dfe1e7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzg3ODU_297d75a9-243a-4930-8a35-5afac6ccb913"
      unitRef="usd">54000000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i0c01a665a28449b793613ecc5d63522c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzg4NjM_72844051-d87e-4b67-9859-0c1f35a6540a"
      unitRef="usd">886000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="ic5f0234485054f26ad2c1d49dfdbd799_D20181127-20181127"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI3NDg3NzkxMjg0MjU_e91453ba-79da-4353-bb89-74d78f227d27">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic4e41ed007de4e4ea8f42478579b6eaf_I20181127"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM4NDgyOTA3NTU5Mzc_c8608e83-db5a-422c-afbf-e74a2d94aa89"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i27285ba6e43a47799cc65795b7635e66_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzkzOTQ_8242264b-58c5-42b8-b915-22a62e7eaeb1"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i531d4b49e7e14178b135b8a39f88fa6a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzk0NTU_54372c84-eadc-441f-bf4f-d7515ed8bc4d"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i31222c8f48ac4a7b9ebdc2458dd1be5d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzk3MjM_c50b61f8-eece-401d-b337-5e6473588a14"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i8cd6d35fff84440898e7edf6f94360c3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEwMDY3_790af769-e2f9-447b-bcf8-e19ba960d6a7"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ied9e5eb3fe5b46218dadb86953b97df0_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEwNjI0_461f6f3a-b7e4-4f7e-b9e7-a77ae916d28c"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia22718f8832b4e798f11e810438b3bf7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEwNjk2_349d8819-b6c1-4a0c-9f4d-df04626d585d"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia22718f8832b4e798f11e810438b3bf7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEwOTMx_e9ab1922-adc8-468b-85ad-433b57a991fd"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments
      contextRef="idb84972c8f344a8896506efbff337098_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzExMjQx_94836505-ca4d-4757-88e7-0f589a5bcd09"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments
      contextRef="idb84972c8f344a8896506efbff337098_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzExNDAz_84e222b2-ddd3-4c29-8ea3-6f4660bb6ba2"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments
      contextRef="idb84972c8f344a8896506efbff337098_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzExNTQw_3656f2d4-7fde-4274-98d3-c32286759b4f"
      unitRef="number">0.50</bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments
      contextRef="idb84972c8f344a8896506efbff337098_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzExNjk3_19f0db9a-f1ae-4301-a2d8-3854febc42fc"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i4515f9481f5f408cbe7a9817cf5107d1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzExOTA3_d1939276-88b1-41de-8c42-22bc0bc63186"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i580615bf5fb84813a4f15d5b64260502_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzExOTE0_6ff2cc76-2b71-46b3-a45c-d3df4dcc8599"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="if0cd16b6c95c43cf92a6b19bd75a7df2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzExOTg4_9e4fc05d-dc6b-4f1c-b646-2ec074476963"
      unitRef="number">0.0300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i6eab960e05594954ad74b51fbec5de70_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzExOTk1_6f3c6ae8-e39f-427d-9dc1-d7457d053779"
      unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i19aa307929434141855192ccd5d26e84_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyMTYx_b5ad6058-cc16-4be5-8fa9-126ac10249aa"
      unitRef="number">0.0309</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i57ba8084e93643d19f4f8c135c1beb71_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyMTY4_b8314fd8-3984-4a04-9837-931681622dc8"
      unitRef="number">0.0284</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:DebtInstrumentAnnualAmortizationRatePercentage
      contextRef="i57ba8084e93643d19f4f8c135c1beb71_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyMjQ4_e2c602e8-fd7b-42e0-bc55-07f663abab62"
      unitRef="number">0.0500</bhc:DebtInstrumentAnnualAmortizationRatePercentage>
    <bhc:DebtInstrumentAnnualAmortizationRatePercentage
      contextRef="i19aa307929434141855192ccd5d26e84_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyMjQ4_e9c74332-2b3f-4dee-807d-f1d770accaf7"
      unitRef="number">0.0500</bhc:DebtInstrumentAnnualAmortizationRatePercentage>
    <bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization
      contextRef="if7b27ce3a4694376b7351cac69da0831_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEwOTk1MTE2Nzc4NDg_7cb62f8a-8e95-44d1-a97a-4d4b88acb47e"
      unitRef="usd">0</bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ica0eb942508643f38c6a8b5216c7ab26_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyNjA3_e5642d44-a7df-4a38-a68f-b10e5bce1819"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i1d0ab3127bf249bba7383ddaff5d96b9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyNjEw_6cb36dff-70f5-4790-8b01-fde2fe2a4467"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i10e9d909bf8748b1ada82e2b29c7e29c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyNjY4_faf62115-c255-43cb-8e12-cea1d2346713"
      unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id9bf72ff91f54b6d9dfd299f64fd8858_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyNjcx_aba082b1-d9ce-4247-968f-5fe9ff736072"
      unitRef="number">0.0300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0c01a665a28449b793613ecc5d63522c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyODA2_e40eaa7f-8643-45de-846f-610d18d49c1d"
      unitRef="number">0.0284</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i6bc0bc23890449aa8239cc453f4e1a07_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyODgz_6c8ebb85-fd45-48e7-bdf3-c843d38efbe4"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i844942ee3772417395b5e3b2b42455d8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEyODg4_9f51edc0-fe3f-4b65-88ac-66fa2ead9b00"
      unitRef="number">0.0050</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings
      contextRef="i8aed4915fc8f42e580d71e20a671d348_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEzNTM5_13980b25-0c3f-47fe-831f-9d7786a53089"
      unitRef="usd">1000000000</bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings>
    <bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate
      contextRef="if7b27ce3a4694376b7351cac69da0831_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEzNTQ2_88c6aee8-9611-4834-92d3-ec3b353b8296"
      unitRef="number">0.285</bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate>
    <bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio
      contextRef="i28ac575b36634a86920565ce2fe16cca_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEzODA2_a311220f-37ae-4b78-a25f-14c240e9e7e2"
      unitRef="number">3.50</bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio>
    <bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum
      contextRef="i7622a05b204a4dd1a5f310c32b83aa3f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEzODk0_6878deef-549f-49f3-9f7c-7d3b6c5a1043"
      unitRef="number">6.50</bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum>
    <bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum
      contextRef="i8aed4915fc8f42e580d71e20a671d348_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEzOTQ5_808e476c-db6b-47f4-b6ae-b3f6202ccfa3"
      unitRef="number">2.00</bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum>
    <bhc:DebtInstrumentRedemptionPricePercentageChangeinControl
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE1OTI4_84aab520-aa4b-4f9e-bd47-1e7fc52a3d5b"
      unitRef="number">1.01</bhc:DebtInstrumentRedemptionPricePercentageChangeinControl>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i55fc1cd86d124ba798ea0bb114b41e21_I20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE1OTk3_2884442b-046d-47f7-a8d0-eed1e6880bff"
      unitRef="number">0.06500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3ff0004e74da4838ab43904393cdd3f0_I20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE2MDM0_012d0c45-1db1-42f1-82a0-4bb5cfbe587e"
      unitRef="number">0.0700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i55fc1cd86d124ba798ea0bb114b41e21_I20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE2MTAy_40874f19-0395-4290-84c9-19411c832f10"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i55fc1cd86d124ba798ea0bb114b41e21_I20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE2MTM1_2884442b-046d-47f7-a8d0-eed1e6880bff"
      unitRef="number">0.06500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3ff0004e74da4838ab43904393cdd3f0_I20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE2MjE1_9a7a75a8-224a-4107-9888-266976b42279"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3ff0004e74da4838ab43904393cdd3f0_I20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE2MjQ4_012d0c45-1db1-42f1-82a0-4bb5cfbe587e"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3bd6872a182646a082629d18870e0ab0_I20171017"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE2NzIz_738868ec-95b4-4973-89b8-e9f3fe06b2cf"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3bd6872a182646a082629d18870e0ab0_I20171017"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE2Nzk2_4703b9d3-20a7-46a1-a724-a6e1d88fa000"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i25ef1a1efaa044929df3a9c4e1c62bb0_I20171121"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE2ODQ2_a3858c1b-b8cb-45e4-8d8d-84cc18671c04"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3bd6872a182646a082629d18870e0ab0_I20171017"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE2ODgx_738868ec-95b4-4973-89b8-e9f3fe06b2cf"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9806922f86c748b8a9fb0ae15b0d631c_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE3MjU4_5e5664f3-c471-4b5d-876a-5831214aac38"
      unitRef="number">0.05750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if30a44e3344f420686b02ee5a1668f41_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE3Mzc5_470f4f4b-f6bd-4f7d-8c6d-309513dc7877"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if30a44e3344f420686b02ee5a1668f41_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEwOTk1MTE2Nzc4NTc_b8f5e0b9-0f4a-48c2-b269-3cea23f14c6a"
      unitRef="number">0.08500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9806922f86c748b8a9fb0ae15b0d631c_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE3NDUw_229af733-7c25-4d84-8de5-275b67a2cd5c"
      unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9806922f86c748b8a9fb0ae15b0d631c_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE3NDgz_65cd79fb-fe98-4210-bfa9-cb17d0dabc3d"
      unitRef="number">0.05750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i199861b87bfe4696b2d3547b9feff668_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE3NjY4_97d88088-27b8-4968-82e2-adfeaff931c7"
      unitRef="usd">584000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5e281e9d7a3444ae947ed7b6a12ff125_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE3Njc0_155ae3bd-9fe6-44e2-956c-839af9bd180f"
      unitRef="number">0.05875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i9399287ac5904b0093d941914ffe1526_D20190308-20190308"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE3NzU5_c7b62112-7efc-434c-bdd1-e3e808ec051b"
      unitRef="usd">518000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9e41c5aa1f5f46339004eb9f8abdc897_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE3NzY1_798cbe54-efc2-44fc-a4b7-95c832e58c1f"
      unitRef="number">0.05625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ib64fedb96e0a40dbbba005b5e30bc256_D20190308-20190308"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE3ODU2_634d6707-4947-41cc-ad42-3838cd2bdc4b"
      unitRef="usd">216000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie38650ed8f69484ba8e3e32b255cc9c1_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE3ODYy_b8f3de55-630d-445f-9788-fcd63b6bc9c0"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i7f2634d868b948cd81c47592e26fbaa1_D20190401-20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE4MTAx_acd1e719-5cd2-4db4-a1c2-2b2580c9cbbf"
      unitRef="usd">182000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie8e89da68c2b4a889e5ce5e76dec2863_I20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE4Mjcw_5b54cfb0-9516-48e0-a54c-dffc22af5907"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ia70cbc9c5ef04337a9cdfcf70d213bff_D20190308-20190308"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE4NDU3_4aeaed6f-393c-4c41-9dbc-45223d5dbf2a"
      unitRef="usd">-8000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i0b58a4c00eb84382ad3f4bc0cb5d0c33_D20190308-20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE5MDA0_1b17e028-4fd1-4692-bfb6-7f3a5c127e09"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="i0b58a4c00eb84382ad3f4bc0cb5d0c33_D20190308-20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzE5MTIz_be527c52-bc65-430f-88d7-358bebc9b660"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i47b737fa198b4128bcd55e26d3e2cb52_I20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzQzOTgwNDY1NTg4MjE_9216e721-e0f0-4f4d-b77f-cbec695520a9"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i47b737fa198b4128bcd55e26d3e2cb52_I20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEwOTk1MTE2Nzc4MjY_11dd13dd-6bbb-4de9-b7c2-db343c428bd3"
      unitRef="usd">1600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i47b737fa198b4128bcd55e26d3e2cb52_I20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzQzOTgwNDY1NTg4MzY_9216e721-e0f0-4f4d-b77f-cbec695520a9"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i48a5c09856bb4c338e922161515b31c7_D20210608-20210608"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzQzOTgwNDY1NTg4NTQ_1c3508e5-f4c7-4130-b929-f3716f8d45ad"
      unitRef="usd">1600000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="iae6d3126236d454cb028cdcb1675739e_D20210608-20210608"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzQzOTgwNDY1NTg4NDE_78539abb-deae-43f0-9a12-544fa56ae591"
      unitRef="usd">-38000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i3e453510571a42ea972e7213bb0683b3_D20210608-20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEwOTk1MTE2Nzc4NDM_f76be3b8-58ff-4c52-9ca8-4c9922509b42"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="i36ee75c249b846dea1eab8be020170d9_D20210608-20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzQzOTgwNDY1NTg4NzA_8743bbec-6f84-4d5a-b7b7-613164c2b9ec"
      unitRef="number">0.40</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <bhc:DebtInstrumentRedemptionPricePercentageChangeinControl
      contextRef="i731ff10dfcf54abe98b1740cfb194c1d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIwMTUy_59d61bd6-b8bd-4771-ae76-53b1d25e58af"
      unitRef="number">1.01</bhc:DebtInstrumentRedemptionPricePercentageChangeinControl>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i635a4ec4469e4a38ab9bf05cdecd65b3_I20150130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIwNjE4_a95721a2-0cba-4c77-815b-79b1bb111937"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i635a4ec4469e4a38ab9bf05cdecd65b3_I20150130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIwNjkz_d6161517-e6a9-4641-9f24-d1f3327f168c"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i635a4ec4469e4a38ab9bf05cdecd65b3_I20150130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIwODQw_a95721a2-0cba-4c77-815b-79b1bb111937"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ib64fedb96e0a40dbbba005b5e30bc256_D20190308-20190308"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIwOTQ2_634d6707-4947-41cc-ad42-3838cd2bdc4b"
      unitRef="usd">216000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i884c88ec40c64e79b29c807b2a885dc6_D20190523-20190523"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIwOTUz_b88195cd-58b8-4be1-8c3c-107fc3020cd8"
      unitRef="usd">382000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i1dac4ecf6d0f4130aa4a1059a0869ace_D20200101-20201130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxMDgx_a5b86d03-7742-4394-95be-63f91821b909"
      unitRef="usd">169000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ia5885c91251745a8bd996100382f6c32_D20201201-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxMTk1_e34b94e1-f731-4131-b158-628b6b9a19b9"
      unitRef="usd">233000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib5b7e60d19034d39a78a89ace8a9bdaa_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxMjg5_fc240310-0dff-42b1-905c-6feabfc73e52"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8d8eae7cb22c4834939fd13d8bfa0402_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxMzI1_32f26b5a-161f-48b5-8adb-0aac13a93195"
      unitRef="number">0.05875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2bec3b624035487c90ff26d75d14b4f5_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxMzYx_a2d335bc-7a84-4651-bea2-805627db1843"
      unitRef="number">0.04500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5f952abf74d84815948a25d97a9b0e2a_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxNDAw_602c8d40-78d5-49e6-91e1-7c94b6fcd488"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib5b7e60d19034d39a78a89ace8a9bdaa_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxNTUz_522a5e11-f3d9-46dc-b54a-720f146cd42e"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib5b7e60d19034d39a78a89ace8a9bdaa_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxNTg2_6caf3f6f-7bcc-4d44-ae07-804cdecf0291"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8d8eae7cb22c4834939fd13d8bfa0402_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxNjU3_9d61cfe5-3b79-4455-b825-3ad9c0ede6c7"
      unitRef="usd">3250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2bec3b624035487c90ff26d75d14b4f5_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxNzU5_b7314cfb-e4c4-4cdf-99d6-18b40b844b67"
      unitRef="eur">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2bec3b624035487c90ff26d75d14b4f5_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxNzky_c72fce75-dc21-42ce-81b6-638f08ffb915"
      unitRef="number">0.04500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5f952abf74d84815948a25d97a9b0e2a_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxODUw_92e78a15-e394-4de6-9858-d8f50cade545"
      unitRef="usd">3250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5f952abf74d84815948a25d97a9b0e2a_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIxODgz_e21f1257-25b1-4b0f-b80f-12539e15e9ce"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib5b7e60d19034d39a78a89ace8a9bdaa_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIyMDg2_23e0e79f-2bef-4c6e-a8ae-c10fda0e38dd"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8d8eae7cb22c4834939fd13d8bfa0402_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIyMzA4_cfbbf295-b101-4a23-b29a-fef9208d158a"
      unitRef="number">0.05875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2bec3b624035487c90ff26d75d14b4f5_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIyMzE1_ed8b5fa2-819f-4521-a18d-b9c38676efbb"
      unitRef="number">0.04500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5f952abf74d84815948a25d97a9b0e2a_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIyNDc4_5e9c2c65-3ded-471b-9dc5-9f1c54bd9642"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i199861b87bfe4696b2d3547b9feff668_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIyNzM0_97d88088-27b8-4968-82e2-adfeaff931c7"
      unitRef="usd">584000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="icb448caef5334750891c172cec2300d0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIyNzQx_a67f7e9a-c104-4e30-9ec3-98a7de168f2d"
      unitRef="usd">1118000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="id030b84634ff4592b2dd49390438a1b9_D20191003-20191003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIyODcw_236142ef-6d8e-4f4d-a232-7bdae807f394"
      unitRef="usd">100000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i1d5f38a92282494f9530b0fb16484f40_I20200116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIyOTQx_0ba752f6-e969-4779-8759-304cd5c97107"
      unitRef="usd">1240000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ifc35a805bb9d489a81ba954da2c90dfc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIzMTIw_304bcbab-ef2e-42d2-8da1-f97cdaa84f2b"
      unitRef="usd">208000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i8ca7f7ff80664661a5cc30c2112c5f4f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzEwOTk1MTE2Nzc4NjQ_398f1099-96b2-4398-925d-7d0919805561"
      unitRef="usd">600000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iba498b34c6e5496e98017b43ea83814f_I20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIzNjAy_7a0daa72-21aa-4f9b-8bb8-d5b41ee3478e"
      unitRef="number">0.09000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iba498b34c6e5496e98017b43ea83814f_I20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIzNjc5_f8066713-0357-4010-bb9c-1027dd1899a8"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iba498b34c6e5496e98017b43ea83814f_I20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIzNzEy_3e42d018-7d35-43a7-b4e6-d76cad8ed221"
      unitRef="number">0.09000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="id56bb838f8ca4688a209a9aa5630486b_I20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzIzODU5_cd504c33-ddf4-4d08-abd0-8a3c54ae73d5"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iba498b34c6e5496e98017b43ea83814f_I20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI0MDg3_73fe4bc9-a4f5-43a6-96cd-1fbe7758751d"
      unitRef="number">0.09000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i63149bfde2e74932af587b7f07bec783_D20171218-20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI0MzA2_dfa84caf-441b-4909-8c87-2a361a3482f3"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="ic7612d5c6f03401fb096eeb9f8731268_D20171218-20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI0NTIy_e6fcaaef-7e2e-4863-8f52-7e3fdd847b8f"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6e6f4753796c4f9da3ea1142cd2e1c91_I20180326"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI1MDAy_92030425-f4b7-4a95-b974-831fcc41e9ee"
      unitRef="number">0.09250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i6e6f4753796c4f9da3ea1142cd2e1c91_I20180326"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI1MTA1_6ea25dc6-8d9c-4dec-86cd-1cdf73d2eb1c"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6e6f4753796c4f9da3ea1142cd2e1c91_I20180326"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI1MTQx_92030425-f4b7-4a95-b974-831fcc41e9ee"
      unitRef="number">0.09250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i6e6f4753796c4f9da3ea1142cd2e1c91_I20180326"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI1MzA0_49ff2eeb-fc5e-4f4f-9f5e-71ca8a50a567"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6e6f4753796c4f9da3ea1142cd2e1c91_I20180326"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI1ODEw_92030425-f4b7-4a95-b974-831fcc41e9ee"
      unitRef="number">0.09250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i07bdfabc3951404f8889a947cf3a9686_D20180326-20180326"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI2MDEy_9ebd4dd0-7621-4d9b-b88e-a4e80f2b01c0"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="i07bdfabc3951404f8889a947cf3a9686_D20180326-20180326"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI2MjE2_938f5b2e-c675-421a-814b-5b26264db4da"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i20076209e8fa4b958baa1b8f32663a95_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI2Njcy_f11fb6fe-8214-497a-b7c6-d84437d0bc11"
      unitRef="number">0.08500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i20076209e8fa4b958baa1b8f32663a95_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI2ODQ2_3aef37bb-8ab2-4e4d-86c1-2dcd17be3975"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i20076209e8fa4b958baa1b8f32663a95_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI3Mjgy_f11fb6fe-8214-497a-b7c6-d84437d0bc11"
      unitRef="number">0.08500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if30a44e3344f420686b02ee5a1668f41_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI3NDEw_470f4f4b-f6bd-4f7d-8c6d-309513dc7877"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i20076209e8fa4b958baa1b8f32663a95_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI3NDQz_f11fb6fe-8214-497a-b7c6-d84437d0bc11"
      unitRef="number">0.08500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ieb0e075a0cbd419d8ad9a06043a3352f_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI3NzE5_4ff2760c-b1d9-4216-b104-2355c4ab8958"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="ieb0e075a0cbd419d8ad9a06043a3352f_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI3OTIz_b234da0f-9e1f-44bc-b02d-ed77d0ddcb6f"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i28aa526ea8d84f278ee8f1842400571b_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI4Mzg3_af513f21-a880-4db9-83ae-ef44da0eb2e0"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i39a070cf27ac4d539b94e8656d4502e5_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI4NDI2_2e9c3858-1c34-47ac-bbb6-0d27b36b689e"
      unitRef="number">0.07250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i28aa526ea8d84f278ee8f1842400571b_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI4NTM4_ce3cd61e-8986-4ca3-a6e2-78e320bf06ce"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i28aa526ea8d84f278ee8f1842400571b_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI4NTcx_af513f21-a880-4db9-83ae-ef44da0eb2e0"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i28aa526ea8d84f278ee8f1842400571b_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI4NjIw_b10b5018-02bc-4c2b-b7c5-1015419972d1"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i39a070cf27ac4d539b94e8656d4502e5_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI4NjYz_6e5d21e6-930f-493c-9bfd-c7ec41b44564"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i39a070cf27ac4d539b94e8656d4502e5_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI4Njk2_2e9c3858-1c34-47ac-bbb6-0d27b36b689e"
      unitRef="number">0.07250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="icb448caef5334750891c172cec2300d0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI4ODY2_a67f7e9a-c104-4e30-9ec3-98a7de168f2d"
      unitRef="usd">1118000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i884c88ec40c64e79b29c807b2a885dc6_D20190523-20190523"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI4OTE0_b88195cd-58b8-4be1-8c3c-107fc3020cd8"
      unitRef="usd">382000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i05517ba451014901a9d88eb38f3ac23a_D20190523-20190523"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI5MTkx_1d0fb422-f4f0-4161-8d71-4daad18de79d"
      unitRef="usd">-32000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i28aa526ea8d84f278ee8f1842400571b_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI5MzM4_cd10bc4b-80ab-4e97-b1ed-96b50feb54d9"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i28aa526ea8d84f278ee8f1842400571b_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI5NTUy_05710c3e-dda3-4811-af88-ab8fa922d6f5"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i28aa526ea8d84f278ee8f1842400571b_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzI5ODYy_7cd94bdb-9465-40fe-9de0-9ad870a94251"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="iab2a35a3c29f407dad845189bdbe128c_D20190523-20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwMDA0_504d0c4c-0463-4537-b263-88c55b9fe6f1"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i1273409244264cbbb7681d6753625c7b_D20190523-20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwMDA0_d883de2d-2664-4c3d-ad93-930b0920d04e"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="iab2a35a3c29f407dad845189bdbe128c_D20190523-20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwMTM5_633e938d-8fb6-48b1-a985-48b40429d409"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="i1273409244264cbbb7681d6753625c7b_D20190523-20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwMTM5_992d0f80-3fe2-49cf-bdd3-6807944c00e6"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i28aa526ea8d84f278ee8f1842400571b_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwMTgz_a3502148-fd34-4583-922f-d835148d1919"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibb700fb0599c4cfdbab4a269de54e805_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwMzcz_46464944-34d5-4bd4-a669-c99f5822db10"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie55bd69a58f9418183a1bb030920e901_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwNDEy_7280c092-1c37-413d-b99c-c6a406968d76"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ibb700fb0599c4cfdbab4a269de54e805_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwNTQ4_be51173b-1ed3-478f-89f1-3509abbbc0b9"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibb700fb0599c4cfdbab4a269de54e805_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwNTgx_750193d4-490f-48e3-938b-af05a75f0c87"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibb700fb0599c4cfdbab4a269de54e805_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwNjMw_ce73afcd-8ca0-4b10-af21-96718c50f7a8"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie55bd69a58f9418183a1bb030920e901_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwNjcz_a4e9943b-a5e0-4e2e-877b-9e25abd964bb"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie55bd69a58f9418183a1bb030920e901_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwNzA2_98eec442-e009-4841-b905-46fae2c1073e"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i43c10acd1411494298a8bbca9c5aad00_D20200116-20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwODY1_bca58849-f8b8-42fa-a427-2bd50e624ffa"
      unitRef="usd">1240000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i06c668190ea847209a8da86cf1e73998_D20191216-20191216"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMwOTM0_2aa53740-7007-48ba-8c23-e0201a857624"
      unitRef="usd">1210000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i43c10acd1411494298a8bbca9c5aad00_D20200116-20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMxMTcw_514659b8-5019-48ba-a1a1-66ace11055b8"
      unitRef="usd">1240000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i43c10acd1411494298a8bbca9c5aad00_D20200116-20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMxMzA5_62ddc9c4-a3e8-42ec-9416-3443c91b8c58"
      unitRef="usd">-24000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibb700fb0599c4cfdbab4a269de54e805_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMxNDU2_ce73afcd-8ca0-4b10-af21-96718c50f7a8"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibb700fb0599c4cfdbab4a269de54e805_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMxNjIx_ce73afcd-8ca0-4b10-af21-96718c50f7a8"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibb700fb0599c4cfdbab4a269de54e805_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMxODg3_ce73afcd-8ca0-4b10-af21-96718c50f7a8"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i71f877b49bc44738a6ceab709138f307_D20191230-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMxOTg1_bf1ec1c6-e8a3-4ab8-b57b-504be801b048"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i5389f9afcc9c4deca0f0d09e9a716c2b_D20191230-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMxOTg1_e1771dc4-14cf-4fb8-ba53-69f78c6931b9"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="i71f877b49bc44738a6ceab709138f307_D20191230-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMyMTA1_1e355811-0265-4adb-8d01-e10ecbfcba3c"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="i5389f9afcc9c4deca0f0d09e9a716c2b_D20191230-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMyMTA1_4f6d1d0f-0d29-4cd5-8298-abfafea50aa0"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibb700fb0599c4cfdbab4a269de54e805_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMyMTQ5_ce73afcd-8ca0-4b10-af21-96718c50f7a8"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idec8329a9c5d487e88dbc1f38144d98a_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMyMjc2_77faba8f-9976-4bbb-ab54-c5fb604def2a"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="idec8329a9c5d487e88dbc1f38144d98a_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMyMzgz_7e9226be-87a8-4836-9ec5-6f28f8554de8"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idec8329a9c5d487e88dbc1f38144d98a_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMyNDE2_77faba8f-9976-4bbb-ab54-c5fb604def2a"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idec8329a9c5d487e88dbc1f38144d98a_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMyNDY2_77faba8f-9976-4bbb-ab54-c5fb604def2a"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ia601b6230ea24da1ae27d263526923d9_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMyNTg0_2de92cc8-20a8-4ad7-b6bf-df5323f7038b"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <bhc:PaymentForDebtAmortizationPrepaymentCost
      contextRef="iee380ad8627b4f83b469b1ba89c9747b_D20200526-20200526"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMyNjcx_fe8af302-6f5e-4848-9b54-786ee396371d"
      unitRef="usd">303000000</bhc:PaymentForDebtAmortizationPrepaymentCost>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id5925ca8a2c54e8d8795ffb55d368483_D20200526-20200526"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMzMDc2_38be613f-6f8f-48ab-8304-05e1b1885136"
      unitRef="usd">-27000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idec8329a9c5d487e88dbc1f38144d98a_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMzMjEx_77faba8f-9976-4bbb-ab54-c5fb604def2a"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idec8329a9c5d487e88dbc1f38144d98a_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMzMjc1_77faba8f-9976-4bbb-ab54-c5fb604def2a"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idec8329a9c5d487e88dbc1f38144d98a_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMzNDA2_77faba8f-9976-4bbb-ab54-c5fb604def2a"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ifea6355ea76743f0a61e88e55dcd2ce2_D20200526-20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMzNDk5_1e5abfe3-e0b5-4d1f-a9ed-64a091a9b141"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="i5839a9c4cc754fa0803795d95447729c_D20200526-20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMzNzEz_65270d7e-3dec-4d41-909e-23de5f349c25"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idec8329a9c5d487e88dbc1f38144d98a_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMzNzY5_77faba8f-9976-4bbb-ab54-c5fb604def2a"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idec8329a9c5d487e88dbc1f38144d98a_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzMzODkz_77faba8f-9976-4bbb-ab54-c5fb604def2a"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idec8329a9c5d487e88dbc1f38144d98a_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM0MDE1_77faba8f-9976-4bbb-ab54-c5fb604def2a"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idec8329a9c5d487e88dbc1f38144d98a_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM0MTAx_77faba8f-9976-4bbb-ab54-c5fb604def2a"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM0MjI1_98a14e40-3d99-472d-85f1-1df5e0af1830"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i88e6526a8d134ebab814430fdfa18227_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM0MjY0_5dd23589-354b-4ef4-a418-a3d77f1f097e"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM0Mzgw_e57e40cb-0b35-4546-b7c1-2260659d850f"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM0NDEz_98a14e40-3d99-472d-85f1-1df5e0af1830"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM0NDYz_98a14e40-3d99-472d-85f1-1df5e0af1830"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i88e6526a8d134ebab814430fdfa18227_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM0NTAy_af5ae29f-92e3-4464-93e1-9f7c4c0d93bf"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i88e6526a8d134ebab814430fdfa18227_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM0NTM1_5dd23589-354b-4ef4-a418-a3d77f1f097e"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i9a97ad4188494b8781417a8f8d543882_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM0NzU3_d6b0a7bc-907c-4b49-b7c7-57e0eb4593d6"
      unitRef="eur">1500000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i5964597f62e744bf9d6aafb14762d4d7_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM0Nzg0_c8f6caeb-7e35-4576-9a4d-389d637abfab"
      unitRef="usd">233000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5501242b42bc40d7a227556ee3415134_D20201203-20201203"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM1MTA2_0c512d08-0a00-4501-b819-1b17ff6940b0"
      unitRef="usd">-7000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM1MjQx_98a14e40-3d99-472d-85f1-1df5e0af1830"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM1MzA1_98a14e40-3d99-472d-85f1-1df5e0af1830"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i88e6526a8d134ebab814430fdfa18227_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM1NDU0_5dd23589-354b-4ef4-a418-a3d77f1f097e"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM1NTg1_98a14e40-3d99-472d-85f1-1df5e0af1830"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i73e09d09766b4417aacfcfa14a10126c_D20201203-20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM1Njc4_4f33ba7b-dae2-4523-b841-0bb20eb304f3"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="i73e09d09766b4417aacfcfa14a10126c_D20201203-20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM1ODk0_b0192c18-e4c0-4f2e-932c-d13949e641cc"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM1OTUw_98a14e40-3d99-472d-85f1-1df5e0af1830"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM2MDc0_c3391ba4-f8fc-4722-b672-f57eadfe4c8d"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM2MTk2_98a14e40-3d99-472d-85f1-1df5e0af1830"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i212c453e3c9d4f59a02b3776ee2ff10e_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM2Mjgy_45071907-76b0-4ecc-8e52-beba5e47aaa9"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ie10a5bc9208e4517ad73103ab3f6d59b_D20201203-20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM2NTQz_02d688bd-6930-449b-b19b-67bd5702ca66"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="ie10a5bc9208e4517ad73103ab3f6d59b_D20201203-20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM2NzU5_19aed8f1-dfef-4b0a-908e-2d4a1462b768"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM3Mzk5_ec4dbf28-8686-4180-88f0-e6fc542a3706"
      unitRef="number">0.0588</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM3NDA2_8382acb6-1e1e-4762-ba34-356a96483bfe"
      unitRef="number">0.0602</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM3NzAy_3b0f34a4-c5c2-49e1-b463-baf7c31c5a82">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Maturities and Mandatory Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities and mandatory payments of debt obligations for the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross maturities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo2MTU5NDQ4ZGI3MzU0OGI5OWRiNGYzYWJmMjkwNGRhMC90YWJsZXJhbmdlOjYxNTk0NDhkYjczNTQ4Yjk5ZGI0ZjNhYmYyOTA0ZGEwXzEtMS0xLTEtNTk0NzA_34b86aa7-9d83-4db2-9de3-98a09183ef7a"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo2MTU5NDQ4ZGI3MzU0OGI5OWRiNGYzYWJmMjkwNGRhMC90YWJsZXJhbmdlOjYxNTk0NDhkYjczNTQ4Yjk5ZGI0ZjNhYmYyOTA0ZGEwXzItMS0xLTEtNTk0NzA_608ab570-2ca9-443d-9361-bcc7d1248c0b"
      unitRef="usd">285000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo2MTU5NDQ4ZGI3MzU0OGI5OWRiNGYzYWJmMjkwNGRhMC90YWJsZXJhbmdlOjYxNTk0NDhkYjczNTQ4Yjk5ZGI0ZjNhYmYyOTA0ZGEwXzMtMS0xLTEtNTk0NzA_30deeb12-8cb6-42e9-b82d-313363d9071a"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo2MTU5NDQ4ZGI3MzU0OGI5OWRiNGYzYWJmMjkwNGRhMC90YWJsZXJhbmdlOjYxNTk0NDhkYjczNTQ4Yjk5ZGI0ZjNhYmYyOTA0ZGEwXzQtMS0xLTEtNTk0NzA_b65807bb-a072-47fb-b91e-d66216b5a738"
      unitRef="usd">9723000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo2MTU5NDQ4ZGI3MzU0OGI5OWRiNGYzYWJmMjkwNGRhMC90YWJsZXJhbmdlOjYxNTk0NDhkYjczNTQ4Yjk5ZGI0ZjNhYmYyOTA0ZGEwXzUtMS0xLTEtNTk0NzA_4764914b-2851-4f03-90dc-49735ea1006b"
      unitRef="usd">1500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo2MTU5NDQ4ZGI3MzU0OGI5OWRiNGYzYWJmMjkwNGRhMC90YWJsZXJhbmdlOjYxNTk0NDhkYjczNTQ4Yjk5ZGI0ZjNhYmYyOTA0ZGEwXzYtMS0xLTEtNTk0NzA_5aa115b6-153f-445d-9f9c-4ae474536f0f"
      unitRef="usd">11362000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo2MTU5NDQ4ZGI3MzU0OGI5OWRiNGYzYWJmMjkwNGRhMC90YWJsZXJhbmdlOjYxNTk0NDhkYjczNTQ4Yjk5ZGI0ZjNhYmYyOTA0ZGEwXzctMS0xLTEtNTk0NzA_307af7e7-98d6-4ecd-b83b-71108e50641d"
      unitRef="usd">22870000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo2MTU5NDQ4ZGI3MzU0OGI5OWRiNGYzYWJmMjkwNGRhMC90YWJsZXJhbmdlOjYxNTk0NDhkYjczNTQ4Yjk5ZGI0ZjNhYmYyOTA0ZGEwXzgtMS0xLTEtNTk0NzA_654e0ae2-1078-4644-a1f4-fc8feb4ad291"
      unitRef="usd">216000000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90YWJsZTo2MTU5NDQ4ZGI3MzU0OGI5OWRiNGYzYWJmMjkwNGRhMC90YWJsZXJhbmdlOjYxNTk0NDhkYjczNTQ4Yjk5ZGI0ZjNhYmYyOTA0ZGEwXzktMS0xLTEtNTk0NzA_2690f180-bf58-489f-9bb6-c01becca1184"
      unitRef="usd">22654000000</us-gaap:LongTermDebt>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i8f1fd27861d840c9982cb6007d12ec99_D20220211-20220211"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM4NDgyOTA3NTc0MTc_70f73ece-ad03-4632-a917-b8f7a50f2764"
      unitRef="usd">285000000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="if80737f8327f4413b9aff0d3dbfe8369_I20220118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM4NDgyOTA3NTQwMTk_4fb5f3a6-7971-47ab-b85c-c778f7cce324"
      unitRef="usd">370000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9af4b96ef19949f2928ad128d4c72201_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM4NDgyOTA3NTQxNjQ_d3dde3ee-7faa-4fa5-b1f6-8a9c25b805ac"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9af4b96ef19949f2928ad128d4c72201_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMjgvZnJhZzoyYmI5OTQ2N2Q3ZTA0MzBhYmNkY2I5YmU1ODE3NDQ1MC90ZXh0cmVnaW9uOjJiYjk5NDY3ZDdlMDQzMGFiY2RjYjliZTU4MTc0NDUwXzM4NDgyOTA3NTQxOTg_e134234e-18af-4050-a3f4-5597e0724bd5"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzkwMDA_5fba673f-7351-4f21-92af-f94a3216aba2">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANSThe Company has defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers a closed grandfathered group of legacy Bausch &amp;amp; Lomb Holdings Incorporated (&#x2018;&#x2018;B&amp;amp;L&#x2019;&#x2019;) U.S. employees and employees in certain other countries. The U.S. defined benefit accruals were frozen as of December 31, 2004 and benefits that were earned up to December 31, 2004 were preserved. Participants continue to earn interest credits on their cash balance at an interest crediting rate that is equal to the greater of: (i) the average annual yield on 10-year treasury bonds in effect for the November preceding the plan year or (ii) 4.50%. The most significant non-U.S. plans are two defined benefit plans in Ireland. In 2011, both Ireland defined benefit plans were closed to future service benefit accruals; however, additional accruals related to annual salary increases continued. In December 2014, one of the Ireland defined benefit plans was amended effective August 2014 to eliminate future benefit accruals related to salary increases. All of the pension benefits accrued through the plan amendment date were preserved. As a result of the plan amendment, there are no active plan participants accruing benefits under the amended Ireland defined benefit plan.  The U.S. postretirement benefit plan was amended effective January 1, 2005 to eliminate employer contributions after age 65 for participants who did not meet the minimum requirements of age and service on that date. The employer contributions for medical and prescription &lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;drug benefits for participants retiring after March 1, 1989 were frozen effective January 1, 2010. Effective January 1, 2014, the Company no longer offers medical and life insurance coverage to new retirees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the B&amp;amp;L benefit plans, outside of the U.S., a limited group of the Company's employees are covered by defined benefit pension plans. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses December 31 as the year-end measurement date for all of its defined benefit pension plans and the postretirement benefit plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Pension Benefit Plans and Postretirement Benefit Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes in its Consolidated Balance Sheets an asset or liability equal to the over- or under-funded benefit obligation of each defined benefit pension plan and postretirement benefit plan. Actuarial gains or losses and prior service costs or credits that arise during the period but are not recognized as components of net periodic benefit cost are recognized, net of tax, as a component of Other comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts included in Accumulated other comprehensive loss as of December 31, 2021 and 2020 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized actuarial losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized prior service credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Periodic (Benefit) Cost&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the components of net periodic (benefit) cost for the Company&#x2019;s defined benefit pension plans and postretirement benefit plan in 2021, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of prior service credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlement loss recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net periodic (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Benefit Obligation, Change in Plan Assets and Funded Status &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents components of the change in projected benefit obligation, change in plan assets and funded status for 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Change in Projected Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actuarial (gain) losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Change in Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Funded status, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Settlement loss recognized and Settlements in the tables above are the costs and payments associated with the conversion of a portion of the Company&#x2019;s defined benefit plan in Ireland to a defined contribution plan during the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A number of the Company&#x2019;s pension benefit plans were underfunded as of December 31, 2021 and 2020, having accumulated benefit obligations exceeding the fair value of plan assets. There were no U.S. pension benefit plans that were underfunded as of December 31, 2021, having accumulated benefit obligations exceeding the fair value of plan assets. Information for the underfunded pension benefit plans is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s policy for funding its pension benefit plans is to make contributions that meet or exceed the minimum statutory funding requirements. These contributions are determined based upon recommendations made by the actuary under accepted actuarial principles. In 2022, the Company expects to contribute $0, $9 million and $4 million to the U.S. pension benefit plan, the non-U.S. pension benefit plans and the U.S. postretirement benefit plan, respectively. The Company plans to use postretirement benefit plan assets and cash on hand, as necessary, to fund the U.S. postretirement benefit plan benefit payments in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Estimated Future Benefit Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future benefit payments over the next 10 years for the pension benefit plans and the postretirement benefit plan, which reflect expected future service, as appropriate, are expected to be paid as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;&#160;Benefit&lt;br/&gt;&#160;Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used to determine net periodic benefit costs and benefit obligations for 2021, 2020 and 2019 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For Determining Net Periodic (Benefit) Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.197%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For Determining Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected long-term rate of return on plan assets was developed based on a capital markets model that uses expected asset class returns, variance and correlation assumptions. The expected asset class returns were developed starting with current Treasury (for the U.S. pension plan) or Eurozone (for the Ireland pension plans) government yields and then adding corporate bond spreads and equity risk premiums to develop the return expectations for each asset class. The expected asset class returns are forward-looking. The variance and correlation assumptions are also forward-looking. They take into account historical relationships, but are adjusted to reflect expected capital market trends. The expected return on plan assets for the Company&#x2019;s U.S. pension plan for 2021 was 5.00%. The expected return on plan assets for the Company&#x2019;s Ireland pension plans was 2.75% for 2021.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The discount rate used to determine benefit obligations represents the current rate at which the benefit plan liabilities could be effectively settled considering the timing of expected payments for plan participants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 expected rate of return for the U.S. pension benefit plan will be 4.50%. The 2022 expected rate of return for the Ireland pension benefit plans will be 2.75%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pension Benefit Plans Assets             &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pension benefit plan assets are invested in several asset categories. The following presents the actual asset allocation as of December 31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The investment strategy underlying pension plan asset allocation is to manage the assets of the plan to provide for the non-current liabilities while maintaining sufficient liquidity to pay current benefits. Pension plan assets are diversified to protect against large investment losses and to reduce the probability of excessive performance volatility. Diversification of assets is achieved by allocating funds to various asset classes and investment styles within asset classes, and retaining investment management firm(s) with complementary investment philosophies, styles and approaches.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s pension plan assets are managed by outside investment managers using a total return investment approach, whereby a mix of equity and debt securities investments are used to maximize the long-term rate of return on plan assets. A significant portion of the assets of the U.S. and Ireland pension plans have been invested in equity securities, as equity portfolios have historically provided higher returns than debt and other asset classes over extended time horizons. Correspondingly, equity investments also entail greater risks than other investments. Equity risks are balanced by investing a significant portion of plan assets in broadly diversified fixed income securities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Plan Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measured the fair value of plan assets based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. See Note 5, "FAIR VALUE MEASUREMENTS" for details on the Company's fair value measurements based on a three-tier hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents total plan assets by investment category as of December 31, 2021 and 2020 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value. There were no transfers between Level 1 and Level 2 during 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans - U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled funds:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. broad market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans - Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled funds:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global high yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government bond funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consisted primarily of term deposits and money market instruments. The fair value of the term deposits approximates their carrying amounts due to their short term maturities. The money market instruments also have short maturities and are valued using a market approach based on the quoted market prices of identical instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commingled funds are not publicly traded. The underlying assets in these funds are publicly traded on the exchanges and have readily available price quotes. The Ireland pension plans held approximately 95% and 96% of the non-U.S. commingled funds in 2021 and 2020, respectively. The commingled funds held by the U.S. and Ireland pension plans are primarily invested in index funds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The underlying assets in the fixed income funds are generally valued using the net asset value per fund share, which is derived using a market approach with inputs that include broker quotes, benchmark yields, base spreads and reported trades. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Defined Contribution Plans &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors defined contribution plans in the U.S., Ireland and certain other countries.&#160;Under these plans, employees are allowed to contribute a portion of their salaries to the plans, and the Company matches a portion of the employee contributions. The Company contributed $44 million, $43 million and $41 million to these plans during the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <bhc:DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance
      contextRef="i7563625586364005812392f5b14e44af_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzY3Mg_f4dc018f-9657-433d-b50e-542b9df292f4"
      unitRef="number">0.0450</bhc:DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance>
    <bhc:DefinedBenefitPlanNumberofDefinedBenefitPlans
      contextRef="i5ec20e3f4b2f4f599834f9809e4c9d92_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzcxNg_d60dfb0e-b3f2-4d6c-a195-75e7d397018c"
      unitRef="defined_benefit_plan">2</bhc:DefinedBenefitPlanNumberofDefinedBenefitPlans>
    <bhc:DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended
      contextRef="id71cc4b7c6a54ab0a60acdf0c8a5303c_D20141201-20141231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzkzOA_0a87db24-8f91-48d1-aa6f-ade8d35a94f3"
      unitRef="defined_benefit_plan">1</bhc:DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended>
    <bhc:DefinedBenefitPlanEmployerContributionMaximumAge
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzE0MjM_4a7b08c1-1938-4eff-ba15-4733ed1d3a17">P65Y</bhc:DefinedBenefitPlanEmployerContributionMaximumAge>
    <us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4Xzg5NzU_22e2a78c-36e7-4b32-9ad4-5c73dfb14a88">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts included in Accumulated other comprehensive loss as of December 31, 2021 and 2020 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized actuarial losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized prior service credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax
      contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzMtMi0xLTEtNTk0NzA_872a9217-f54b-44f6-a2a8-93a9de487212"
      unitRef="usd">-18000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax
      contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzMtNC0xLTEtNTk0NzA_134179e3-6270-4acc-be71-15ccd5793929"
      unitRef="usd">-21000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax
      contextRef="id639a041f43545ba9cbf52ed62530656_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzMtNi0xLTEtNTk0NzA_c80a1256-c3ee-4f82-85ed-44972fbe9e75"
      unitRef="usd">-42000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax
      contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzMtOC0xLTEtNTk0NzA_876deee5-471f-4377-b809-6a14c7d74f3a"
      unitRef="usd">-76000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax
      contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzMtMTAtMS0xLTU5NDcw_cffb1307-17db-4461-a859-001237277714"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax
      contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzMtMTItMS0xLTU5NDcw_5fff52b1-7334-4e1f-ad4e-8ce3b070d4ee"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax
      contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzQtMi0xLTEtNTk0NzA_13c909a3-47f0-4906-b290-e04d38338082"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax
      contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzQtNC0xLTEtNTk0NzA_2267bdd3-3c5e-4161-aba7-33062cca1836"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax
      contextRef="id639a041f43545ba9cbf52ed62530656_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzQtNi0xLTEtNTk0NzA_5e29f9fb-63c1-4b82-b3b6-6f1a030e35c7"
      unitRef="usd">-25000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax
      contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzQtOC0xLTEtNTk0NzA_3cce7299-fcb9-44d7-8a15-62c0b4269624"
      unitRef="usd">-27000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax
      contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzQtMTAtMS0xLTU5NDcw_aac3b681-cf32-4f7d-93fa-8377ff1491b5"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax
      contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxMTQ1NjhkMzFkOWM0MjdiYTdkYzQ1MGY3MTgxYTBiNy90YWJsZXJhbmdlOjExNDU2OGQzMWQ5YzQyN2JhN2RjNDUwZjcxODFhMGI3XzQtMTItMS0xLTU5NDcw_d22991a6-3fa1-4a84-ac13-4ca78bcc6235"
      unitRef="usd">-11000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4Xzg5ODA_314f63ed-9429-4d2a-9993-b28376daddb2">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the components of net periodic (benefit) cost for the Company&#x2019;s defined benefit pension plans and postretirement benefit plan in 2021, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of prior service credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlement loss recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net periodic (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzMtMi0xLTEtNTk0NzA_df570842-1aac-4526-adfb-1bacd3e6247e"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzMtNC0xLTEtNTk0NzA_70af092e-d9d2-4679-90e7-39526bb3114f"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzMtNi0xLTEtNTk0NzA_58b9df83-01ef-484a-9280-cf86c29a67c9"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzMtOC0xLTEtNTk0NzA_9dd98b71-4c37-4edd-beca-c3c518fefc20"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzMtMTAtMS0xLTU5NDcw_17e7f9f1-df01-4497-860b-c06d7fcdd619"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzMtMTItMS0xLTU5NDcw_e9156983-e179-41d9-a897-00653dd1aea1"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzMtMTQtMS0xLTU5NDcw_465498e6-4417-4db5-b084-83e631d53b64"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzMtMTYtMS0xLTU5NDcw_764c803f-ffe8-409d-864e-698621e75878"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzMtMTgtMS0xLTU5NDcw_ac3cc97a-5f80-4890-9c35-6813ad789771"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzQtMi0xLTEtNTk0NzA_a3a7944e-37be-4c5b-9106-11d4761b65b7"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzQtNC0xLTEtNTk0NzA_141c720c-be3c-4c79-becc-ed8a39d2040e"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzQtNi0xLTEtNTk0NzA_3f48da29-acb6-435e-b066-bbc9a74b8f78"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzQtOC0xLTEtNTk0NzA_ceae3094-ae28-4153-96d9-52c6d01e43ac"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzQtMTAtMS0xLTU5NDcw_941ec8b2-49e5-4917-9579-88fedb22a255"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzQtMTItMS0xLTU5NDcw_facaf6d6-f568-4690-97d3-3b850eb99677"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzQtMTQtMS0xLTU5NDcw_29606a61-819f-4169-a354-0f4b22e4c1c4"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzQtMTYtMS0xLTU5NDcw_f5bd3af7-ea00-4c3c-b516-6301b1da6a97"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzQtMTgtMS0xLTU5NDcw_e15dadf2-7006-4fda-9de2-641432c11eba"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzUtMi0xLTEtNTk0NzA_ed72817e-cef6-4ce5-8bb3-accce3bd611c"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzUtNC0xLTEtNTk0NzA_d167658a-71e9-48c2-a314-d33da6d79bad"
      unitRef="usd">13000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzUtNi0xLTEtNTk0NzA_7e339fc3-7522-4581-9183-80a7da3c550a"
      unitRef="usd">13000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzUtOC0xLTEtNTk0NzA_49fadc46-9da9-4328-87ef-8d3616943c16"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzUtMTAtMS0xLTU5NDcw_2034022a-88e2-4053-8e78-4831f29ac2e8"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzUtMTItMS0xLTU5NDcw_75686538-e0fd-433d-80b4-acb41728d430"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzUtMTQtMS0xLTU5NDcw_ca4f36f9-7bee-4f14-8469-191eb3363814"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzUtMTYtMS0xLTU5NDcw_fa3cb860-1e8b-4f12-b3a6-4447abde6c2e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzUtMTgtMS0xLTU5NDcw_1530602b-426a-4d3d-a91b-398482ad6996"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzYtMi0xLTEtNTk0NzA_679e6835-4401-46c8-902c-535617a23a81"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzYtNC0xLTEtNTk0NzA_d881d53f-ddfb-4adb-9b99-d541b3899636"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzYtNi0xLTEtNTk0NzA_886264a7-73e8-4821-a4eb-def415132a87"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzYtOC0xLTEtNTk0NzA_1aa78c44-bc09-43b6-b9ed-7624f5ee2de2"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzYtMTAtMS0xLTU5NDcw_8b0ed7d3-87bf-4105-8283-ad3ae3f9f49a"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzYtMTItMS0xLTU5NDcw_9554efc2-bc22-49f7-aff5-9789c3762fba"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzYtMTQtMS0xLTU5NDcw_7490f279-6323-46ab-bfaa-fe8127b987d9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzYtMTYtMS0xLTU5NDcw_6731a474-35e0-41e9-998c-a1a90a609114"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzYtMTgtMS0xLTU5NDcw_bb8c05ee-b147-45a2-b28a-8a12c2e7cab7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzctMi0xLTEtNTk0NzA_f75b6227-0e0a-46c2-92a4-04dae3ea8bae"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzctNC0xLTEtNTk0NzA_2023f2bc-3ab6-419c-9db5-c16f28de0244"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzctNi0xLTEtNTk0NzA_a25e7897-80a0-4670-af9f-0937424c7c09"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzctOC0xLTEtNTk0NzA_15c5df9f-b49b-401f-a652-e7de04a843d7"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzctMTAtMS0xLTU5NDcw_8d318c0f-4e36-4a0f-ae19-1e9657d4186e"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzctMTItMS0xLTU5NDcw_d5deb22d-0425-449f-97d2-ef1ff2323b34"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzctMTQtMS0xLTU5NDcw_b31566f4-d425-4eb9-a48a-eac5089f7441"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzctMTYtMS0xLTU5NDcw_d4f08876-7647-4b9e-8c72-9438f429d2d4"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzctMTgtMS0xLTU5NDcw_25b08293-bff8-42ba-9bfa-5ebc4ee4fd62"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMi0xLTEtNzc1OTM_8863a4a4-e69e-4b0c-8355-91100cf40fe2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtNC0xLTEtNzc1OTM_d9c30efc-71c6-4b4d-bac2-95a3cdf616cb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtNi0xLTEtNzc1OTM_a6d8e23c-8b22-4080-a2fa-b0e33be9cf57"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtOC0xLTEtNzc1OTM_f16ebe3f-5401-4e71-9655-c86ae106cc6c"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMTAtMS0xLTc3NTkz_b44618c0-1db5-47f9-a8f3-f8dfbc6c7471"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMTItMS0xLTc3NTkz_17d1d9b1-07a2-4af1-b11c-209119745c32"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMTQtMS0xLTc3NTkz_a9e91955-98b5-44ee-a044-0e9a76fff02b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMTYtMS0xLTc3NTkz_6d054d9d-fb38-4e27-b4db-7a9802b2a4e7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMTgtMS0xLTc3NTkz_f1c909af-6899-4a11-b29f-b1471ced0a87"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanOtherCosts
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMi0xLTEtNTk0NzA_81df4a84-3668-48f2-b605-b12b2992d210"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanOtherCosts>
    <us-gaap:DefinedBenefitPlanOtherCosts
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtNC0xLTEtNTk0NzA_3ebfa1b2-9631-4200-b3e3-4d42cd91e45d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanOtherCosts>
    <us-gaap:DefinedBenefitPlanOtherCosts
      contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtNi0xLTEtNTk0NzA_1b0edf11-aafa-4359-82fc-c19b772fba45"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanOtherCosts>
    <us-gaap:DefinedBenefitPlanOtherCosts
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtOC0xLTEtNTk0NzA_731ba59d-f0dd-4e4e-8666-af1c9d85cdc8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanOtherCosts>
    <us-gaap:DefinedBenefitPlanOtherCosts
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMTAtMS0xLTU5NDcw_85aa7af0-44d9-4ee1-831c-411d460701d4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanOtherCosts>
    <us-gaap:DefinedBenefitPlanOtherCosts
      contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMTItMS0xLTU5NDcw_36661b53-e195-4b31-a340-dff29c138167"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanOtherCosts>
    <us-gaap:DefinedBenefitPlanOtherCosts
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMTQtMS0xLTU5NDcw_222f64d5-039f-4ccf-9eec-5442fcb094a0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanOtherCosts>
    <us-gaap:DefinedBenefitPlanOtherCosts
      contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMTYtMS0xLTU5NDcw_be7654cc-94f2-4946-812b-3027b724b39c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanOtherCosts>
    <us-gaap:DefinedBenefitPlanOtherCosts
      contextRef="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzgtMTgtMS0xLTU5NDcw_b2192d95-d2d8-4831-8aea-bce849dba51a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanOtherCosts>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzktMi0xLTEtNTk0NzA_cda6e800-fe05-49df-a6ba-c3a86903f0da"
      unitRef="usd">-6000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzktNC0xLTEtNTk0NzA_c5daacbc-3194-4879-984e-880f586cf84a"
      unitRef="usd">-6000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzktNi0xLTEtNTk0NzA_651e1c72-47ef-4a92-86f7-435fcf57383f"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzktOC0xLTEtNTk0NzA_cd5f7d8e-4bbc-4312-ad03-3c1ef44a3f6a"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzktMTAtMS0xLTU5NDcw_00ba29d5-4249-4a7e-8357-4d72e7568b8a"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzktMTItMS0xLTU5NDcw_b5a222b6-8a5b-425c-a84f-76f43f7a5209"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzktMTQtMS0xLTU5NDcw_e57b10ea-5a3d-4e35-bf9b-6bcf2e0c19b7"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzktMTYtMS0xLTU5NDcw_1f53729d-281c-4fe0-b4a8-fe370c889428"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTphZThkZmE0ZjM4YzM0YTk0OWVmMzcyMjM2YzExZjYxYS90YWJsZXJhbmdlOmFlOGRmYTRmMzhjMzRhOTQ5ZWYzNzIyMzZjMTFmNjFhXzktMTgtMS0xLTU5NDcw_6a32e544-ef9a-4e0d-a181-e71ba243d01b"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4Xzg5Njk_97c2111a-f7ef-473a-b214-e3023afe8af8">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents components of the change in projected benefit obligation, change in plan assets and funded status for 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Change in Projected Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actuarial (gain) losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Change in Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Funded status, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzQtMi0xLTEtNTk0NzA_4df359df-11bd-41de-9cbd-8079687dc3ef"
      unitRef="usd">236000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i9bd0b15dbe944220bf785415eda57379_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzQtNC0xLTEtNTk0NzA_6faa9679-8be5-40e8-8004-525b0b17aa52"
      unitRef="usd">227000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzQtNi0xLTEtNTk0NzA_173832b0-96f4-45d7-9b3d-09e3cefd8380"
      unitRef="usd">294000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="iebc6bf90ba6048c081b87a24157c36a0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzQtOC0xLTEtNTk0NzA_b75d4f6e-d821-4bcd-807a-3f8082c9e51d"
      unitRef="usd">259000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzQtMTAtMS0xLTU5NDcw_c5a2a69c-d365-4565-99bc-47d2d960fb84"
      unitRef="usd">39000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ibee8e4ebafb4425eb4bfad3cad142065_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzQtMTItMS0xLTU5NDcw_2b07200c-fd92-4b31-b345-f0b29e00d06c"
      unitRef="usd">41000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzUtMi0xLTEtNTk0NzA_41690c87-887e-4cb9-afff-ea4749013fba"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzUtNC0xLTEtNTk0NzA_e47ad52e-b968-4c9d-a137-decd4d2f598e"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzUtNi0xLTEtNTk0NzA_53c9397f-a7a8-47cc-b388-a24b02e945c2"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzUtOC0xLTEtNTk0NzA_81f66fc0-989c-4358-ab2a-daab66180ede"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzUtMTAtMS0xLTU5NDcw_0ec36c80-2a76-4182-91ff-eb82cedb27db"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzUtMTItMS0xLTU5NDcw_62198903-7ccf-466e-bf0b-716e72f4b3b3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzYtMi0xLTEtNTk0NzA_9229509c-c01b-4f89-9782-08c08a7451d4"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzYtNC0xLTEtNTk0NzA_9e0b19be-bbd1-4e1d-bb7b-66996c4353f5"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzYtNi0xLTEtNTk0NzA_47a5043f-0f88-4abc-84a8-901191c671f2"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzYtOC0xLTEtNTk0NzA_0f0574c3-bc78-4bc1-a498-801a2b438e83"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzYtMTAtMS0xLTU5NDcw_9ab21aa4-2dcf-47f5-bfd4-01474cd3b34e"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzYtMTItMS0xLTU5NDcw_9cd5200f-b7ac-4b19-a75e-74fc9c51f27e"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzgtMi0xLTEtNTk0NzA_49b5a922-1865-4f74-bac7-aa7d261de3f3"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzgtNC0xLTEtNTk0NzA_6c01aa5a-e106-49c2-8177-efa2015d97cd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzgtNi0xLTEtNTk0NzA_d7524c2e-6c66-4239-814f-063c7faf9d43"
      unitRef="usd">43000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzgtOC0xLTEtNTk0NzA_f5ddef27-8cab-4b8f-ab8a-e0733af033bd"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzgtMTAtMS0xLTU5NDcw_b3d45f42-ee23-40b3-9797-c72bf947ca3a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzgtMTItMS0xLTU5NDcw_81966920-fab5-43ec-a888-c7e168e22857"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzktMi0xLTEtNTk0NzA_06fac70d-9abb-4ded-b575-d5b3a2e4b3fa"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzktNC0xLTEtNTk0NzA_322d360c-1976-4c1d-95c6-ed25a459dbb2"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzktNi0xLTEtNTk0NzA_c2a81639-9900-41e7-8dec-847821726240"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzktOC0xLTEtNTk0NzA_9c6fa23d-615f-4471-9b95-63c2820f7c67"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzktMTAtMS0xLTU5NDcw_785858cf-04de-46f8-941b-7c573d6abe55"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzktMTItMS0xLTU5NDcw_8a5f2927-7fa4-4e8f-bb68-da35faef01b0"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEwLTItMS0xLTU5NDcw_8c2b41a3-1c78-42c3-99d5-2ad81a755976"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEwLTQtMS0xLTU5NDcw_980561d9-501c-4124-8291-cc27c302289b"
      unitRef="usd">-17000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEwLTYtMS0xLTU5NDcw_71c682d6-cf88-4ad4-892b-a18206947b36"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEwLTgtMS0xLTU5NDcw_7def058c-8e0a-4034-b93d-e75d0d1551c7"
      unitRef="usd">-13000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEwLTEwLTEtMS01OTQ3MA_e40bc1cd-d700-4f35-821f-1b567cdef368"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEwLTEyLTEtMS01OTQ3MA_c2b9c1be-b794-4130-9b4e-4d427f476051"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzExLTItMS0xLTU5NDcw_20a462c5-39f1-45c3-b54e-11d1a298e2f8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzExLTQtMS0xLTU5NDcw_99d56205-5280-4905-9011-4ab9c7675b19"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzExLTYtMS0xLTU5NDcw_030d6a76-2bfe-42e6-a269-4134a3b6db38"
      unitRef="usd">-18000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzExLTgtMS0xLTU5NDcw_5a95135d-ab42-419c-9c63-5e54652dfe5f"
      unitRef="usd">22000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzExLTEwLTEtMS01OTQ3MA_70467004-4722-4591-bb3c-1f5e1356a07f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzExLTEyLTEtMS01OTQ3MA_0365973a-0008-427a-98f9-87182a890c36"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEyLTItMS0xLTU5NDcw_6e826c8d-ca8e-4c2a-9b21-035704b3af8d"
      unitRef="usd">220000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEyLTQtMS0xLTU5NDcw_b7efad03-31a8-4e3e-b527-49acb8922a6f"
      unitRef="usd">236000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="id639a041f43545ba9cbf52ed62530656_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEyLTYtMS0xLTU5NDcw_553017cc-3173-4839-b6c4-7aaafb16c3e2"
      unitRef="usd">228000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEyLTgtMS0xLTU5NDcw_aca45836-a697-4246-bc00-d674b2e91a72"
      unitRef="usd">294000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEyLTEwLTEtMS01OTQ3MA_2f5579e6-d1f7-4544-8470-23dce55d708f"
      unitRef="usd">35000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzEyLTEyLTEtMS01OTQ3MA_1f1cc5d5-2ed4-465f-a42e-5edaa896cc40"
      unitRef="usd">39000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE1LTItMS0xLTU5NDcw_829f14b6-b4e9-4684-9def-828572b97683"
      unitRef="usd">231000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9bd0b15dbe944220bf785415eda57379_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE1LTQtMS0xLTU5NDcw_c3473ae4-7306-4966-8241-5fd6e39f00b1"
      unitRef="usd">216000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE1LTYtMS0xLTU5NDcw_b2ee8838-17fe-4ab0-bfeb-4b355c805fd5"
      unitRef="usd">189000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iebc6bf90ba6048c081b87a24157c36a0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE1LTgtMS0xLTU5NDcw_65666ede-6b75-4dd2-bb3d-3bfd5d880e5e"
      unitRef="usd">161000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE1LTEwLTEtMS01OTQ3MA_f1cd86a4-91fa-460f-8bf8-2cab2a308722"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibee8e4ebafb4425eb4bfad3cad142065_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE1LTEyLTEtMS01OTQ3MA_0d19606b-acfc-469a-aa0c-6fead57620b1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE2LTItMS0xLTU5NDcw_4c167260-2669-4a30-8308-0d12f107bab6"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE2LTQtMS0xLTU5NDcw_db417db9-8a57-4aea-af20-adbc60a17ce8"
      unitRef="usd">29000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE2LTYtMS0xLTU5NDcw_22a7dfc9-4a10-46ae-8910-5040e28a2d6e"
      unitRef="usd">18000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE2LTgtMS0xLTU5NDcw_ca84e658-c9b0-4359-946b-483fdf5fcf75"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE2LTEwLTEtMS01OTQ3MA_a0e2a846-d7db-4a27-bc36-84fe77bc504b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE2LTEyLTEtMS01OTQ3MA_d0e7bbbb-be82-47d4-afd6-905aee59033c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE4LTItMS0xLTU5NDcw_1563540b-00ee-40ce-843d-d5bd86503f50"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE4LTQtMS0xLTU5NDcw_cf33361c-f5bd-4dff-989c-e95dfc926649"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE4LTYtMS0xLTU5NDcw_8c3ca9b0-fbee-4a77-b554-2f7b4242af6f"
      unitRef="usd">28000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE4LTgtMS0xLTU5NDcw_e39e55b0-67df-4bb7-a203-486e87ce959a"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE4LTEwLTEtMS01OTQ3MA_dbd06404-2e6b-443f-82dd-09e4eff5119d"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE4LTEyLTEtMS01OTQ3MA_83a2a0bb-e742-41ee-ad85-9ce486d809c2"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE5LTItMS0xLTU5NDcw_5c63cb12-4052-4008-b903-65205b7e2bbc"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE5LTQtMS0xLTU5NDcw_44e88708-4417-4e9e-9ea0-4527cfe0ca4b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE5LTYtMS0xLTU5NDcw_1d056dbf-3e36-4c39-afdc-d4ecf1c5898c"
      unitRef="usd">43000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE5LTgtMS0xLTU5NDcw_1d3e2010-12ce-4cc0-8089-b0f92836cd5d"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE5LTEwLTEtMS01OTQ3MA_73c0eb89-4652-498a-a851-aaa80a5d98fb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzE5LTEyLTEtMS01OTQ3MA_b1075059-70a3-4003-b1ba-be0f9e55bd81"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIwLTItMS0xLTU5NDcw_2e4e0a11-2e10-4d47-a926-01a8a806501f"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIwLTQtMS0xLTU5NDcw_6379738b-fb4c-4ac5-8a67-daff61b1dc6d"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIwLTYtMS0xLTU5NDcw_57458aea-2634-41d3-909e-37fbb3c01b2c"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIwLTgtMS0xLTU5NDcw_9d79fcf3-3194-4846-8d32-930f7fc0faf8"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIwLTEwLTEtMS01OTQ3MA_90ed1478-2f07-4bf4-b1d8-d51862e97a6c"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIwLTEyLTEtMS01OTQ3MA_c091239c-6f2b-42f2-ab6c-0f56a9e502ba"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIxLTItMS0xLTU5NDcw_34b59f2d-18e1-4e76-a9be-9e140849e530"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIxLTQtMS0xLTU5NDcw_9d45ac5f-34aa-4d85-8442-fecd63ed7219"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIxLTYtMS0xLTU5NDcw_5b61f5c1-faa8-495c-ba76-7f8d13928827"
      unitRef="usd">-13000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIxLTgtMS0xLTU5NDcw_f31eb5a4-9133-4f47-baaf-a375d47fb45c"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIxLTEwLTEtMS01OTQ3MA_0316bc24-66c3-4cd9-b3c7-c6670fb42fe6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIxLTEyLTEtMS01OTQ3MA_35fd2aa1-7c5e-4647-9f9a-93b6f2a18d88"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIyLTItMS0xLTU5NDcw_93842cdf-60ad-4747-b5ff-bd1927d1175b"
      unitRef="usd">224000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIyLTQtMS0xLTU5NDcw_3788c1f6-cfcb-4a84-ba96-303c629dd09e"
      unitRef="usd">231000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id639a041f43545ba9cbf52ed62530656_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIyLTYtMS0xLTU5NDcw_fadb5f57-0960-486b-9fb8-fa57da7716ec"
      unitRef="usd">175000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIyLTgtMS0xLTU5NDcw_e16a1122-9fb0-448d-bdf3-e819a7df7a98"
      unitRef="usd">189000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIyLTEwLTEtMS01OTQ3MA_37ddcb8b-c40b-48d3-9f19-83768bce0bda"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIyLTEyLTEtMS01OTQ3MA_25ccf006-2d17-4385-92e5-9355f649af8b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIzLTItMS0xLTU5NDcw_7430366f-5c9e-420c-8f5f-0b523fcec07b"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIzLTQtMS0xLTU5NDcw_711d19af-3b63-4f9d-af8f-2514a3701c6a"
      unitRef="usd">-5000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="id639a041f43545ba9cbf52ed62530656_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIzLTYtMS0xLTU5NDcw_1cd01bc0-8b2f-4188-b3c0-cfdfb38a3079"
      unitRef="usd">-53000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIzLTgtMS0xLTU5NDcw_33775aa5-32a9-48b1-8894-1f9459b01196"
      unitRef="usd">-105000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIzLTEwLTEtMS01OTQ3MA_2ad9203f-292c-483c-bd79-08a696deaa56"
      unitRef="usd">-35000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzIzLTEyLTEtMS01OTQ3MA_f79ae0b9-7fa8-4a10-a137-646a963cb934"
      unitRef="usd">-39000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent
      contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTItMS0xLTc3NjAz_97b83166-93d5-492b-b64a-2d067500e55e"
      unitRef="usd">4000000</bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent>
    <bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent
      contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTQtMS0xLTc3NjAz_fa635a65-63ec-4aba-ab9a-45cb16dfab3d"
      unitRef="usd">0</bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent>
    <bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent
      contextRef="id639a041f43545ba9cbf52ed62530656_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTYtMS0xLTc3NjAz_b7dc5821-b7b5-4ec1-83e8-753c428dfaf6"
      unitRef="usd">0</bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent>
    <bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent
      contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTgtMS0xLTc3NjAz_0688e91e-5c60-4b20-9376-bbda8d9ad47b"
      unitRef="usd">0</bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent>
    <bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent
      contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTEwLTEtMS03NzYwMw_7793ed68-4429-44bb-b0d7-26c96ca65a26"
      unitRef="usd">0</bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent>
    <bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent
      contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTEyLTEtMS03NzYwMw_323a19a9-1f67-4606-a519-1ddf29416593"
      unitRef="usd">0</bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent>
    <bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities
      contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTItMS0xLTU5NDcw_7384b117-f9ac-4d87-80c1-8e3dbef862b3"
      unitRef="usd">0</bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities>
    <bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities
      contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTQtMS0xLTU5NDcw_3807a509-eb84-414c-9b40-9022057ab730"
      unitRef="usd">0</bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities>
    <bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities
      contextRef="id639a041f43545ba9cbf52ed62530656_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTYtMS0xLTU5NDcw_24b7c075-2868-4a5b-8830-1cfe31b8b699"
      unitRef="usd">2000000</bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities>
    <bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities
      contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTgtMS0xLTU5NDcw_8019283f-2c98-4b34-b972-43d2fdd9bfe5"
      unitRef="usd">2000000</bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities>
    <bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities
      contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTEwLTEtMS01OTQ3MA_93404a61-ce77-4758-8c04-8e8ad101f9c7"
      unitRef="usd">4000000</bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities>
    <bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities
      contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI2LTEyLTEtMS01OTQ3MA_8789e274-bf98-4f77-bd4e-2dba7bbb9f60"
      unitRef="usd">4000000</bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent
      contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI3LTItMS0xLTU5NDcw_fd1b3d2d-17df-4366-a793-dd5b583f0063"
      unitRef="usd">0</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent
      contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI3LTQtMS0xLTU5NDcw_dc2d57b7-3045-4081-96ae-f87a888291fb"
      unitRef="usd">5000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent
      contextRef="id639a041f43545ba9cbf52ed62530656_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI3LTYtMS0xLTU5NDcw_5ebf476f-c7b4-4bc4-bed2-ebf8a4102812"
      unitRef="usd">51000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent
      contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI3LTgtMS0xLTU5NDcw_f7f670dd-0d6d-49c1-87fb-95a0e9abc24f"
      unitRef="usd">103000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent
      contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI3LTEwLTEtMS01OTQ3MA_1b5c5c48-94a5-430c-ba08-c26724bcf577"
      unitRef="usd">31000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent
      contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo2N2EwNTRlNzZmY2E0MzdjODE3ZDA0MGU2Mjk5NWUzZi90YWJsZXJhbmdlOjY3YTA1NGU3NmZjYTQzN2M4MTdkMDQwZTYyOTk1ZTNmXzI3LTEyLTEtMS01OTQ3MA_b62c4e71-bdef-4615-af47-58c5b3819e9e"
      unitRef="usd">35000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="ic5c96e30d644464397808c237e9a5ddf_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzEwOTk1MTE2MzkxMTM_17459893-8ed3-4b1d-82fd-d23fcddf29b2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4Xzg5ODY_838a15b2-d826-4420-88f2-4f99b4733b14">Information for the underfunded pension benefit plans is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="ic5c96e30d644464397808c237e9a5ddf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzItMi0xLTEtNTk0NzA_9f3755e5-e213-48b7-aaa1-e82dafeb903a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i248cf8d382ab417d8f08aa7bb5b3c1ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzItNC0xLTEtNTk0NzA_97e6b630-1f08-4e67-92db-34ca2bb59e9f"
      unitRef="usd">236000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="id639a041f43545ba9cbf52ed62530656_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzItNi0xLTEtNTk0NzA_553017cc-3173-4839-b6c4-7aaafb16c3e2"
      unitRef="usd">228000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i7c408d4a08264cae9f329fddd9849fcb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzItOC0xLTEtNTk0NzA_3cfcbda8-5196-4861-a85b-2b08f507f738"
      unitRef="usd">294000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="ic5c96e30d644464397808c237e9a5ddf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzMtMi0xLTEtNTk0NzA_bf368771-2e4f-41a1-ac91-d6d616668e5c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i248cf8d382ab417d8f08aa7bb5b3c1ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzMtNC0xLTEtNTk0NzA_168fcd7d-3567-47bb-a975-006b199771a9"
      unitRef="usd">236000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="ie2d3dc1e9fc14ff2a726b48981e5c5f0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzMtNi0xLTEtNTk0NzA_ae71171b-dcb9-4396-a249-30609d913f40"
      unitRef="usd">219000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i7c408d4a08264cae9f329fddd9849fcb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzMtOC0xLTEtNTk0NzA_5e7668b1-8f90-42fe-8646-b0b6b28ac140"
      unitRef="usd">286000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="ic5c96e30d644464397808c237e9a5ddf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzQtMi0xLTEtNTk0NzA_27e2ffe6-bf36-4efd-8109-e3fcaec4ca96"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i248cf8d382ab417d8f08aa7bb5b3c1ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzQtNC0xLTEtNTk0NzA_47aa67ba-e781-442d-ae98-e57866f50566"
      unitRef="usd">231000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id639a041f43545ba9cbf52ed62530656_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzQtNi0xLTEtNTk0NzA_fadb5f57-0960-486b-9fb8-fa57da7716ec"
      unitRef="usd">175000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i7c408d4a08264cae9f329fddd9849fcb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo4OTdiY2QxZDgwMGM0MWYyYjRhZDkwNWVlZDVhNThlNS90YWJsZXJhbmdlOjg5N2JjZDFkODAwYzQxZjJiNGFkOTA1ZWVkNWE1OGU1XzQtOC0xLTEtNTk0NzA_4f200fe2-6335-4555-b1fa-f3b27f269ddb"
      unitRef="usd">189000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzM2MDM_d5e1ae47-5977-488e-b2c1-c484dee71853"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="id639a041f43545ba9cbf52ed62530656_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzM2MDc_b439ecc1-d05a-4900-8337-af957dbc14fb"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzM2MTQ_32aaa960-2bc2-4482-8511-6815e59652f1"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4Xzg5NTY_40884d44-4f97-4f50-b83e-47f5926e3741">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future benefit payments over the next 10 years for the pension benefit plans and the postretirement benefit plan, which reflect expected future service, as appropriate, are expected to be paid as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;&#160;Benefit&lt;br/&gt;&#160;Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <bhc:DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzM5NzU_ced26bb2-c59c-43c7-b843-ffa029e6543e">P10Y</bhc:DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzItMi0xLTEtNTk0NzA_63307245-ffc9-4373-9332-04ed3ef69c66"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="id639a041f43545ba9cbf52ed62530656_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzItNC0xLTEtNTk0NzA_b0cfc299-c350-4385-ba95-76109144276e"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzItNi0xLTEtNTk0NzA_f5dc74c4-5756-464d-99b5-ab73749d9a52"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzMtMi0xLTEtNTk0NzA_f8f0565d-f68c-4bbb-bff9-94839ada7b30"
      unitRef="usd">19000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="id639a041f43545ba9cbf52ed62530656_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzMtNC0xLTEtNTk0NzA_f9f1aeed-736c-4cf8-99e6-72a8c87cf4d0"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzMtNi0xLTEtNTk0NzA_4cd036ae-3a12-4755-a236-cea122d21d42"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzQtMi0xLTEtNTk0NzA_7a9689b1-8475-4732-9962-d28343c1b63b"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="id639a041f43545ba9cbf52ed62530656_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzQtNC0xLTEtNTk0NzA_c9f606ef-d9a1-40d2-91d8-01eb85574d73"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzQtNi0xLTEtNTk0NzA_2f1763dc-bace-4d0b-bc1e-55e3adf7a8f0"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzUtMi0xLTEtNTk0NzA_102a0770-5bd1-4409-b88a-e93d4d48906b"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="id639a041f43545ba9cbf52ed62530656_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzUtNC0xLTEtNTk0NzA_75b78c37-7031-48e3-98ef-027e37e0d31d"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzUtNi0xLTEtNTk0NzA_6d93109a-7822-4a3e-a75b-63559ff8fb8d"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzYtMi0xLTEtNTk0NzA_bee77b0a-cc2b-4cec-b312-9cdb95e12a7f"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="id639a041f43545ba9cbf52ed62530656_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzYtNC0xLTEtNTk0NzA_99559ee2-7e5c-4106-9ee5-9c6393ae4c20"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzYtNi0xLTEtNTk0NzA_9830a205-4060-49d2-bc62-ba61e8110111"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzctMi0xLTEtNTk0NzA_d397ea42-2c67-4bb9-8562-fd51fc0a92e8"
      unitRef="usd">73000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="id639a041f43545ba9cbf52ed62530656_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzctNC0xLTEtNTk0NzA_4c19ca14-76fa-4389-80d2-769fdac458f4"
      unitRef="usd">42000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpkM2YwMTJiZTIxOTc0YTMzYmUzMDE0MjMxOTBkNjZlZC90YWJsZXJhbmdlOmQzZjAxMmJlMjE5NzRhMzNiZTMwMTQyMzE5MGQ2NmVkXzctNi0xLTEtNTk0NzA_e97d087d-2b34-4474-a470-e12e32a7fad3"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4Xzg5OTE_f3069651-f66f-43cf-9731-9a20b7d1d555">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used to determine net periodic benefit costs and benefit obligations for 2021, 2020 and 2019 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For Determining Net Periodic (Benefit) Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.197%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For Determining Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzQtMi0xLTEtNTk0NzA_738478c9-0184-4573-9088-d5ad41c728ae"
      unitRef="number">0.0225</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzQtNC0xLTEtNTk0NzA_898203ea-94bd-4980-bdf8-d7afc2e6258b"
      unitRef="number">0.0316</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzQtNi0xLTEtNTk0NzA_2c0d1950-d80e-4d15-a715-50ad707a378a"
      unitRef="number">0.0425</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzQtOC0xLTEtNTk0NzA_fa53cb3c-57e2-409e-8511-4e049119ec18"
      unitRef="number">0.0209</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzQtMTAtMS0xLTU5NDcw_c58d8113-9b3a-4d86-b087-8a9dbb457c8d"
      unitRef="number">0.0304</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzQtMTItMS0xLTU5NDcw_75416455-9e1a-49ed-a7da-26db85bed5e8"
      unitRef="number">0.0416</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzUtMi0xLTEtNTk0NzA_7ef91c1d-4e09-45ff-87b9-53956ac170c9"
      unitRef="number">0.0500</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzUtNC0xLTEtNTk0NzA_f4018ee7-9c50-4b76-9687-411778f4c93e"
      unitRef="number">0.0625</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzUtNi0xLTEtNTk0NzA_ce1a3d73-06f0-4f49-b465-c177f6b31599"
      unitRef="number">0.0725</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzUtOC0xLTEtNTk0NzA_d77b1afc-e2aa-46a3-b4e0-b09575ef5c58"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzUtMTAtMS0xLTU5NDcw_a59ac0fe-b2af-4260-8812-a80fa1af1f59"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzUtMTItMS0xLTU5NDcw_93caba06-3a96-4a55-b8a4-709eb3469094"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzYtMi0xLTEtNTk0NzA_774197d1-01ad-4779-8139-79c50e1a3bc2"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzYtNC0xLTEtNTk0NzA_15a016e2-6001-4d80-849d-4c4c018b7298"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzYtNi0xLTEtNTk0NzA_16b8936d-81e7-45bb-929b-fce5021914e7"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzYtOC0xLTEtNTk0NzA_8b2370b9-b3e8-4ca2-a215-c022b1af1862"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i9a242b0365824d3494f144468024f7d3_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzYtMTAtMS0xLTU5NDcw_d4b89a1c-e2d8-447f-ada8-d7f4d1880b22"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="ic2b60b94f9124a76acbcde35c8c8885c_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzYtMTItMS0xLTU5NDcw_9830792e-27f0-4361-9e10-eb16fbe0db7a"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzctMi0xLTEtNTk0NzA_0a3160e2-9bc0-465e-998b-b76e4730675c"
      unitRef="number">0.0475</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i5ef3b83158934a3cb2f5a58715b20ab8_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzctNC0xLTEtNTk0NzA_327d25f7-c854-4bcd-96d3-510c075d6eb2"
      unitRef="number">0.0475</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i95f63ded4fe34c53b32c45d3e356d1ae_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzctNi0xLTEtNTk0NzA_0ea85d2f-b8e1-4fa3-bbdc-8c9221132460"
      unitRef="number">0.0500</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzktMi0xLTEtNTk0NzA_3c699416-d882-4008-99df-2b851d058b30"
      unitRef="number">0.0137</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzktNC0xLTEtNTk0NzA_0479b6af-467b-4db1-a7cd-a016fda4540d"
      unitRef="number">0.0168</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzktNi0xLTEtNTk0NzA_dcc931b1-d90a-42af-b4e8-52c0a5040316"
      unitRef="number">0.0239</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzEwLTItMS0xLTU5NDcw_c45ac8ea-a811-47c7-b7d9-2897e57e9262"
      unitRef="number">0.0274</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzEwLTQtMS0xLTU5NDcw_8cdde867-6751-4ac0-84e8-a4ab09cd6f84"
      unitRef="number">0.0298</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzEwLTYtMS0xLTU5NDcw_8d9cf2df-489a-4ab1-b84e-540c1b2b0916"
      unitRef="number">0.0346</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzExLTItMS0xLTU5NDcw_dc9a8eff-21a9-4ae7-87b9-cbd4eb3deaa2"
      unitRef="number">0.0260</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzExLTQtMS0xLTU5NDcw_270415cd-61fc-4c0f-a434-b74babd1dc67"
      unitRef="number">0.0305</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzExLTYtMS0xLTU5NDcw_8a0f450e-2166-440b-8d7a-f0cd2dbd7b5d"
      unitRef="number">0.0289</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="ia9c4aedcade94cd19199ecaa74775196_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzEyLTItMS0xLTU5NDcw_fdd1ee44-9008-4387-abe0-1e6433abf8a1"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i841bdcc1815b4315a2b7630d67537a4d_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzEyLTQtMS0xLTU5NDcw_cd732232-477f-42aa-b02a-df3b2febf3a6"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i4d4c1966c8c4428f9c7cf5a94fd8d1b5_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZToxN2JhZWMzMTYxZDA0Y2MzYTVkZWZjNjAxN2FhNTJlZi90YWJsZXJhbmdlOjE3YmFlYzMxNjFkMDRjYzNhNWRlZmM2MDE3YWE1MmVmXzEyLTYtMS0xLTU5NDcw_dd268eb2-c5e0-491f-a4dd-5d9d0959cfc4"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzUtMi0xLTEtNTk0NzA_1387c06b-8733-48c5-9f54-1ae8f9a3dad4"
      unitRef="number">0.0269</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzUtNC0xLTEtNTk0NzA_7b545c3d-a4ce-4cac-87a4-cb6b445344fc"
      unitRef="number">0.0225</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzUtNi0xLTEtNTk0NzA_fea2eedc-02ca-47d5-be5b-bc6890ba6827"
      unitRef="number">0.0257</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzUtOC0xLTEtNTk0NzA_b1098777-cf57-4795-9847-34b352d35254"
      unitRef="number">0.0209</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzYtMi0xLTEtNTk0NzA_de9e2a13-3439-4bd2-bc8b-db482088d526"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzYtNC0xLTEtNTk0NzA_f4e32c39-9d26-4f0b-8357-799383dd6dc8"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="iddeca17018524ca7b4aa0120b6e125e0_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzYtNi0xLTEtNTk0NzA_d9c0b1a0-2784-4bb5-9234-3af137682638"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="ie7e41e73d53c444f810e26a21d37fd21_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzYtOC0xLTEtNTk0NzA_b5e29e6d-aee3-49de-853e-17608896ae01"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="i866959039d2f4c258b6f412bfdedd0a8_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzctMi0xLTEtNTk0NzA_9ec02bb8-5faf-4a36-bbda-8ee04de999b3"
      unitRef="number">0.0475</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="ieafeae30c1bb4e9697860aa43e144e89_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzctNC0xLTEtNTk0NzA_ce57ace5-e882-4dec-ba13-80bb04bc67bf"
      unitRef="number">0.0475</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="id639a041f43545ba9cbf52ed62530656_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzktMi0xLTEtNTk0NzA_b6afbf1b-f28d-428d-b853-4dd8f3fd60db"
      unitRef="number">0.0172</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzktNC0xLTEtNTk0NzA_e181bca9-195e-4865-9162-65462c46132b"
      unitRef="number">0.0137</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="id639a041f43545ba9cbf52ed62530656_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzEwLTItMS0xLTU5NDcw_226b4288-446b-4f85-935a-767e8ba33568"
      unitRef="number">0.0263</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzEwLTQtMS0xLTU5NDcw_ad819247-b6e9-4295-979a-2aad6c0aa409"
      unitRef="number">0.0260</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="id639a041f43545ba9cbf52ed62530656_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzExLTItMS0xLTU5NDcw_c3d7e09f-5d89-4612-9cdd-b605eacba70a"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="id677830949bf4a7dae2bc84e6d0e68d7_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0YjYzMWEyMGNiZDQ0ZTJiYjFmNDAzY2YzNTg3ZGJiZS90YWJsZXJhbmdlOjRiNjMxYTIwY2JkNDRlMmJiMWY0MDNjZjM1ODdkYmJlXzExLTQtMS0xLTU5NDcw_474f1b02-5b42-4ee6-9c4f-0267db788afe"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzUwNjU_7ef91c1d-4e09-45ff-87b9-53956ac170c9"
      unitRef="number">0.0500</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="ie074f53bc69745fba66921f6f8d38556_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzUxNDg_911450fd-f9bc-4d66-a262-84e5d6eccd51"
      unitRef="number">0.0275</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i56153b69689b4ecd9dcf4887ed60d362_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzU0NTE_1019cae8-8884-488e-ad0d-57080b5b0723"
      unitRef="number">0.0450</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i4a02dcf2c684493ca47da42ad5f0a86a_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzU1MzI_45f881ea-8d06-47bc-9405-c1e8c82a48f6"
      unitRef="number">0.0275</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4Xzg5NjY_20a67e39-7215-4fa0-9193-80f1c0121673">The following presents the actual asset allocation as of December 31, 2021 and 2020:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ib55cc79a8c5047d8ab1633dbce4cad44_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzItMi0xLTEtNTk0NzA_c328a415-40e2-4a0c-a9ae-149719e82904"
      unitRef="number">0.01</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ia693d6a4e0b14b4c931965ccf754e1f7_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzItNC0xLTEtNTk0NzA_d6b26ebd-9641-4e50-9049-c8dda0e80d2a"
      unitRef="number">0.01</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i2d7991a8fa0d4d8795903d4ae61c5a6d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzMtMi0xLTEtNTk0NzA_05c2c606-5ee0-4160-bab2-e5727905bc0c"
      unitRef="number">0.30</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i9d7c434502ca4f2a8223f3e89683dd28_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzMtNC0xLTEtNTk0NzA_cc352c17-a2a0-43f7-a48e-8376c40221a1"
      unitRef="number">0.39</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i0b1fe039d84a45ce8e43d1c4c89b07d2_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzQtMi0xLTEtNTk0NzA_11b7ae11-8d16-4453-b3b0-6bbf11f29efb"
      unitRef="number">0.69</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="id453d2c511534fe6837d77baaee83805_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzQtNC0xLTEtNTk0NzA_3a7f34a5-3dfb-40a1-89a8-a366aeb17f8d"
      unitRef="number">0.60</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i6251e5f5fad7409b9187da5b1b34bf8f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzYtMi0xLTEtNTk0NzA_eeb2c2f0-184d-4f13-b096-d570348b422f"
      unitRef="number">0.09</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i2a81a3caa7c94785bd723c5136f85945_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzYtNC0xLTEtNTk0NzA_1e4e4648-3c34-4f30-8c08-4bf6035a7a29"
      unitRef="number">0.03</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ic2aa787db2bd488381cd79f25f35617b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzctMi0xLTEtNTk0NzA_1dadb905-3c58-4cbf-bab2-eaf255c8393f"
      unitRef="number">0.31</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="iaade5d5b17e942f2976fa0e0eaced2a3_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzctNC0xLTEtNTk0NzA_d7b95789-6bf8-4fc2-9cf1-56e979357c31"
      unitRef="number">0.28</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i2cfeb6a24e7c459aa69b339c9936b980_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzgtMi0xLTEtNTk0NzA_45831da4-b91c-41e5-b0b5-fa866a2544c7"
      unitRef="number">0.39</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="if07c85a851d7490689bc9a5740104746_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzgtNC0xLTEtNTk0NzA_05113a39-32a0-48a3-b5c9-e082680f9178"
      unitRef="number">0.58</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i60ef3defb63b42d8b564f10aef937998_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzktMi0xLTEtNTk0NzA_f0c13bf3-ea31-4b14-9746-76ad3b65ba6c"
      unitRef="number">0.21</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i3ff1e276f1334094b7e8280d216bb2a6_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTpjMWFmMTE1M2YzZTM0N2Q5YjAyNmMwNjNmZThhY2Q3Mi90YWJsZXJhbmdlOmMxYWYxMTUzZjNlMzQ3ZDliMDI2YzA2M2ZlOGFjZDcyXzktNC0xLTEtNTk0NzA_80a44677-d9cf-4c82-b270-12e86080521b"
      unitRef="number">0.11</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <bhc:ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4Xzg5Njc_7ffa05ce-6a61-4be7-b865-fa911f5fc240">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents total plan assets by investment category as of December 31, 2021 and 2020 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value. There were no transfers between Level 1 and Level 2 during 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans - U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled funds:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. broad market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans - Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled funds:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global high yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government bond funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bhc:ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7af55aa092e044f2afb3019b380424df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzMtMi0xLTEtNTk0NzA_d520a60e-b4da-4519-b2f6-5c8c43ee8844"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia1d47b1547ba49eaaf8b343286177935_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzMtNC0xLTEtNTk0NzA_1ddb3cf4-2599-4190-9a10-3d1f33107f84"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4c916f8745844151b90043b27bfda10b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzMtNi0xLTEtNTk0NzA_a6f1a1f1-154f-4ac3-81ff-12b01eb93df7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iccba448cf4a7430c9ab615c9c0db387c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzMtOC0xLTEtNTk0NzA_ec611da8-4164-4faa-9f9c-00f3750f5e50"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i09e4c0369ab74b7aa42c2ca4a081d665_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzMtMTAtMS0xLTU5NDcw_a6fa0ea9-67cf-4fb3-9c72-2fbc738c9c04"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icfe5828d7ce648ba9901225e5f602ffb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzMtMTItMS0xLTU5NDcw_bb800c0c-38b9-4ed9-8e59-80ff29da8169"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iac45d6fc735f4300950257942f7987c7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzMtMTQtMS0xLTU5NDcw_c9e2f92d-29e0-48fc-9ce1-ba6f9c3d6faf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5e6efe3bfe1b43539fd5441f3e8f1178_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzMtMTYtMS0xLTU5NDcw_51f70b4e-978d-4d10-8893-18116344a960"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie17c1b0a784541d7991bb6af8b757d2b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzYtMi0xLTEtNTk0NzA_6de6f88c-3373-4c33-9cf9-1b951aa2b055"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic37dcc11c7224eca84dc480d56dc32ce_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzYtNC0xLTEtNTk0NzA_8474371e-15c3-4228-9fa9-8d1d7c703fea"
      unitRef="usd">36000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i38d00d230e384e1793aa975171d11afd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzYtNi0xLTEtNTk0NzA_2a34f240-53cd-4bc8-8d04-42103aa37ac8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0d2c3cb6c7374e28bf785a1101c1a131_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzYtOC0xLTEtNTk0NzA_d385d02f-6bf0-4d99-8e2f-ad38f72a044a"
      unitRef="usd">36000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idc9f1c3ceea44453b7dfa2a13ac987b7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzYtMTAtMS0xLTU5NDcw_3abf97e2-70a9-4381-89f1-733ef8db8f67"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ied1ceb27c69740139dfd77de2155225e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzYtMTItMS0xLTU5NDcw_054f8f1b-4a46-4054-a224-687051cf5a16"
      unitRef="usd">48000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i38e21dc226144b94ac36444dcece2004_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzYtMTQtMS0xLTU5NDcw_31833739-a465-4cf1-a3eb-236051cacae3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1e447011ef7645a89efe64052f877da1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzYtMTYtMS0xLTU5NDcw_c2956e45-f1da-4110-86c5-fc96796debde"
      unitRef="usd">48000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7fbe7d9aaa8d48bcbb80294df7a9cd60_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzctMi0xLTEtNTk0NzA_ddaab733-d584-4b98-8807-4cd6a86e92c9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i82a224828a4841bd8e05d44a229d645f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzctNC0xLTEtNTk0NzA_ce71df3c-d30c-4408-a588-0640f6d51765"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i557a5608d76644fca3792b79c6260a38_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzctNi0xLTEtNTk0NzA_eea63d56-bb6b-4c06-9d00-f469520eec0b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if2f6f0decf1a440db6a8df7e4d1cd9c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzctOC0xLTEtNTk0NzA_353d9afb-7719-48c7-9cc0-d7aede4f6761"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie614ee2bbc0d41c3937648c0eb4fb366_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzctMTAtMS0xLTU5NDcw_541380db-d4e6-4209-982e-f1cd5fadcf33"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8a50fd29ab6c4a72809e44c2f372bdd8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzctMTItMS0xLTU5NDcw_6ebb33a1-5ddc-489b-9562-01bbcc09594e"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib98051f977524d43b7bba256f7160a84_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzctMTQtMS0xLTU5NDcw_fbb0b9de-e714-4b78-87cb-efebd7a41546"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icf30f7d75c6344fc9a13de058b489364_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzctMTYtMS0xLTU5NDcw_3fb213b0-db6e-4a78-8c33-45eb4b7e3d87"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7365a02480094a778087f003e4453b09_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzgtMi0xLTEtNTk0NzA_f8574885-07ae-4596-87c0-914a415ef638"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i11eb673cbf1d4f7d84ac5c9df99a3ef2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzgtNC0xLTEtNTk0NzA_ffd9355e-ed10-4bcb-9a9e-732e4ff062ef"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia9a9521608704153b9eb100ac78f0ce3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzgtNi0xLTEtNTk0NzA_bc939608-48b5-4d9b-8ec4-ddb7e3ca2c44"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i809b25b2066b40bf96408dc9e0b225c2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzgtOC0xLTEtNTk0NzA_6dfdbe33-0b85-4344-99cf-9b9d6e397b77"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie1d36468c5de494abc6015ee26da8e73_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzgtMTAtMS0xLTU5NDcw_5813e766-17cc-44b5-b0bb-c3acb1d524fd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1dcfebc863894026b3ca1af655064a00_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzgtMTItMS0xLTU5NDcw_ab6393fb-1dab-4898-9fc3-228d7e9eb18c"
      unitRef="usd">20000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i560db68718d54136a8a45bfb702d5324_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzgtMTQtMS0xLTU5NDcw_43c279ae-82a6-487a-91f2-ae00baef188e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i61e987a4f1b54c88bcbcc12fa7abfb69_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzgtMTYtMS0xLTU5NDcw_c6f2fb62-e81c-402a-9c58-0fe2edb0df84"
      unitRef="usd">20000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i16ed7839b2a04f0fbeb5dce55d268189_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzktMi0xLTEtNTk0NzA_d17eef4f-a3a3-4570-8ffb-cee6fe3c1534"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i91dfeedfb92b4828a4722c9f88fa1872_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzktNC0xLTEtNTk0NzA_65500f51-55de-4a63-af26-e3ea0cea3311"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1825b75f97004bc184282968848c0a52_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzktNi0xLTEtNTk0NzA_498711bc-72dd-43ce-ab6f-2d84903d6339"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6242900f15f3401ebaac9f8a3c1b6339_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzktOC0xLTEtNTk0NzA_0738ed1a-2643-4b9c-994a-57368cda2862"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i63b875eacbc446a887982c5d1115d3ee_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzktMTAtMS0xLTU5NDcw_b8f1f4d8-5154-4c51-9241-0b611908ffa2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie9a62d35ed944986ad939c9b014c654d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzktMTItMS0xLTU5NDcw_d257c8e6-62b3-4136-90cb-55bd9ffda69e"
      unitRef="usd">14000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i92434c9334a54511bdec1d46d8213f3b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzktMTQtMS0xLTU5NDcw_6344a02a-5b3b-4ab4-8c0f-ee3f921a593d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibcc360791b434eac863d82daef575b6d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzktMTYtMS0xLTU5NDcw_b7295c26-9fd6-4eb9-a465-dd4ca62b24ec"
      unitRef="usd">14000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6ba6ac8d86f64c9385ab1aa7f0d2c220_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzExLTItMS0xLTU5NDcw_20e88e54-b86f-4f7d-9867-63b8cce0e855"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id0c5d97b9ab244b69b17a46f19cca258_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzExLTQtMS0xLTU5NDcw_8e696adc-1f6e-4a73-8509-88048233f922"
      unitRef="usd">155000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if8b0dc0501c84cac862c7828cee33fd6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzExLTYtMS0xLTU5NDcw_7171fc94-854b-48db-a49f-b9a3c8eb98a5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i42c6f916e85b4a7cb01549ad02518fd8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzExLTgtMS0xLTU5NDcw_aa93f96b-48e8-4a6e-82de-4e693b4e5937"
      unitRef="usd">155000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0c12e56dc0f345abb7ab14eb2eb546b2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzExLTEwLTEtMS01OTQ3MA_7884c0e4-582c-41fe-aae8-c9c08bc90473"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id35cd34eedeb4695bfa8ad28f7c073d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzExLTEyLTEtMS01OTQ3MA_1815f372-88c5-409e-9f7f-9540e8cb2b9d"
      unitRef="usd">138000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4b90dc62606b4697b1fff595e063dce5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzExLTE0LTEtMS01OTQ3MA_8b525786-6eaa-4a62-9054-f9a3a2d816cf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9c488d1b1a9b41baa5ddb7387a75b0ef_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzExLTE2LTEtMS01OTQ3MA_58ddb1fa-19b1-45f7-ae59-e0e5ac12313d"
      unitRef="usd">138000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ida118aeda14146be9fa07183a8d43611_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzEyLTItMS0xLTU5NDcw_3bd810f7-5c76-42c8-982e-c98b403c7f81"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie7404c4a64514d8cba0117dde2032747_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzEyLTQtMS0xLTU5NDcw_507954f5-f1a6-49a0-82e8-1e3e61d835f8"
      unitRef="usd">223000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8bab925ad83349bfae08cdc351f392a2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzEyLTYtMS0xLTU5NDcw_3bc37ef1-ecf2-422b-aa84-8ec4c178b654"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if2ccc52c4ecc49e78eee3d33e2c113fa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzEyLTgtMS0xLTU5NDcw_648d3bec-a465-4953-8883-25bcf1bbbb7d"
      unitRef="usd">224000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie92a115bae124a91960ec41c0727d1a8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzEyLTEwLTEtMS01OTQ3MA_675edb47-2676-4590-a4b5-0ffe02424f88"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iba3925adeb07427b9b35df22f7082c71_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzEyLTEyLTEtMS01OTQ3MA_cbe6cfa5-f742-462b-b154-c74c00f9ad5e"
      unitRef="usd">229000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6623925ca56e4d96a7ec9b93e614a8f7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzEyLTE0LTEtMS01OTQ3MA_8181faef-2765-4c30-a624-1225c0ca0276"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib69b353fbcad4f2ea129c8b8af2024fd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo0OGI2ZTUxNDk2MjI0ZDYzYWYyMjQ1NzU5YTY1YTk5YS90YWJsZXJhbmdlOjQ4YjZlNTE0OTYyMjRkNjNhZjIyNDU3NTlhNjVhOTlhXzEyLTE2LTEtMS01OTQ3MA_42f26377-e7f8-4d02-acac-11ba450d50a6"
      unitRef="usd">231000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3dc8df13fb424c888d592fddbc492642_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzMtMi0xLTEtNTk0NzA_a5002f9f-c5e7-4f23-a094-8715d8640a74"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2c7b88b7a1da425584d296d8cfb61e31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzMtNC0xLTEtNTk0NzA_fca90840-44a8-4499-8ffd-9661c2188f05"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i85953604b0f4454d8293d1577ad37660_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzMtNi0xLTEtNTk0NzA_8bebf003-3495-4f99-a720-eab5c95b1326"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i75e6fc7cd989419aaac17aab91d819e2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzMtOC0xLTEtNTk0NzA_b95bf46d-7ee1-4c04-8c27-96cc178404d6"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if060c809f3ab42b79bb79a9e9119eb6c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzMtMTAtMS0xLTU5NDcw_262d8928-90ec-4505-b7cd-3e3219036d4d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2b463b0ee361495cb1a35797490d8474_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzMtMTItMS0xLTU5NDcw_e0323806-9508-4e99-b193-a4b504c93a10"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idc5b5fd1952143dbb4fc80c09e61d41e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzMtMTQtMS0xLTU5NDcw_f32e77ed-9f8f-47e2-923f-06492d1085a4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1ff8ba240c174921af7e5377f66435da_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzMtMTYtMS0xLTU5NDcw_c4e7a14d-0238-497e-9371-79680b457bae"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i28879983df974e8dad3a100a9e2eaff5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzYtMi0xLTEtNTk0NzA_6893e057-da18-4631-a524-c4729dfbd1c4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia617fb33524a429f96a5f4d5de41e8d8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzYtNC0xLTEtNTk0NzA_205607d0-fbe2-4e66-98a6-e47771aa4093"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iafe1692fe13c46099cdb274aae8efa5b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzYtNi0xLTEtNTk0NzA_16671971-ab8a-4250-b86c-eff33c13f274"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i58b06c811115478cb20db99973ade215_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzYtOC0xLTEtNTk0NzA_edb9f527-c08d-4083-8dbb-5e6d0ac423b5"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ieb2a552032894fa0a8dd1d7b70fbf7cb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzYtMTAtMS0xLTU5NDcw_7b15142f-a014-4dd1-a171-0ab5afb36354"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6ec30830375949738e95af67de6bf189_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzYtMTItMS0xLTU5NDcw_e4df9070-06c0-4be7-b97c-992eaf457ece"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0acdb587dc57405c8f51594ffdc58f35_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzYtMTQtMS0xLTU5NDcw_d25de54d-6264-41b6-8986-cee05913b3cd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i79b1763781234b4c91e295caf0806e96_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzYtMTYtMS0xLTU5NDcw_38ae7f7f-dab8-4245-b3f0-135ed8480d5d"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i33703c137cd44896ad4cdeb30fcc6fae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzctMi0xLTEtNTk0NzA_d8ef77e2-009a-4384-b7aa-19a4119ab259"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iff30b4961b3a486991e363c44db17d42_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzctNC0xLTEtNTk0NzA_7714b687-137a-4599-bb25-241419ccf33f"
      unitRef="usd">51000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i669279a7238d4e8f9dd6fad058ea31b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzctNi0xLTEtNTk0NzA_4723eff0-eaed-425b-8468-068070b40fe7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i481468708dc74adc94731e7319c5a223_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzctOC0xLTEtNTk0NzA_775c59f0-6379-46b1-8f54-77c4d968c4d5"
      unitRef="usd">51000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i84843ec87bf8430fbff7bd811a71310a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzctMTAtMS0xLTU5NDcw_b89f6060-b4dc-479d-bf6e-649d7f4b03e1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idca3abdd017446218f6e8960ca67c023_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzctMTItMS0xLTU5NDcw_36f5a088-9a1d-4b64-9a10-9d2759f88b29"
      unitRef="usd">51000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6eb575ca4904425a87bec5e53f208d9d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzctMTQtMS0xLTU5NDcw_3d31cdad-6d54-477f-9b70-e0c7ec72730e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib8fb3dc081ea41aab4e32f39084453f9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzctMTYtMS0xLTU5NDcw_9ca29dce-2ea0-4a34-8019-095e63c6a2c7"
      unitRef="usd">51000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i41e1bb53e0784950afc27fa187a27c3f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzktMi0xLTEtNTk0NzA_5b3e174b-dd16-4fb2-b182-7915e64ca7a9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idc5e2d60ba7148dcba54ff5384e23249_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzktNC0xLTEtNTk0NzA_d2498d36-1dfb-4dce-b00e-a5d0f9b4c18d"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7bef888f50664043863fbf4ec22eb918_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzktNi0xLTEtNTk0NzA_d8c5d4c3-a8a5-4d95-a215-97e2a4e18970"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9d117480a68f41e29692f8e1120299c5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzktOC0xLTEtNTk0NzA_5c76c789-12a6-473e-99ca-326996d53ba6"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i764e7dd8c6e242209ab1812391a46ead_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzktMTAtMS0xLTU5NDcw_fcf42964-eb47-4162-8328-2e78b06f881a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i03b4ac56aab644b3a3663f4a78369a13_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzktMTItMS0xLTU5NDcw_b3c754d8-039c-483f-afe2-1136dc345f59"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i612036dfd9af4751b039c09d33e2ca46_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzktMTQtMS0xLTU5NDcw_afc4c5fc-36cd-415e-92c3-120ff175b742"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9647f9aaa0af4927aa97fab7f6dce46d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzktMTYtMS0xLTU5NDcw_f4fcb943-641f-4f85-8be7-34761ae17c43"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifc934bb3b7764915937b42332edc108a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEwLTItMS0xLTU5NDcw_7a9a8758-2c4e-43af-a2a3-4059608d9bdc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie670eb0132ba453db0ccfc9534e8a176_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEwLTQtMS0xLTU5NDcw_29e61c00-d7da-4c40-8a04-51fbfe065cf4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i846b3df052964b86bab155c36ffa8b7d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEwLTYtMS0xLTU5NDcw_2bd026d0-ef18-4ad1-993e-a7b3e14b09f6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i08181df0b76a4b1db12c4d01da570d5e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEwLTgtMS0xLTU5NDcw_dccac2cb-25ac-4419-baae-46b518ed4be2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibd4a088a9d1a4225a9b940802b6651dd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEwLTEwLTEtMS01OTQ3MA_de8406ef-eae5-4400-b6a7-cf90b8d7b62b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1dd5dc3a71fc44a288385275d334a636_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEwLTEyLTEtMS01OTQ3MA_e01ca2c3-55f0-4501-b78f-346fddc0c333"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i773f8c6eb5314348bd0df5d5f8554717_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEwLTE0LTEtMS01OTQ3MA_5cd8a88c-3c57-4661-aa08-ea2d0f346a2e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i06f89c2da51442cf966a159f442d7040_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEwLTE2LTEtMS01OTQ3MA_3fce531d-f48d-40c0-a457-44d72ece010c"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5a942b6a477e44ee80469bf00455c69b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzExLTItMS0xLTU5NDcw_426214e7-00dc-45d6-a55d-b70cb0c81412"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie62be2fe885843928cc89e9a7ae8bb78_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzExLTQtMS0xLTU5NDcw_24629669-8171-48e1-b2ea-64e7b9b48b80"
      unitRef="usd">65000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5d72936706da4a49a0b60284da13fe0a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzExLTYtMS0xLTU5NDcw_372b9dfd-ca8c-4868-aa7c-1e170c76029a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib2b78164753e4fb69cb995913ce9a5be_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzExLTgtMS0xLTU5NDcw_87476516-072a-40fa-89ca-6a1bbd8e8249"
      unitRef="usd">66000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i824c5e86c03e4a0389aa5c6cab684353_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzExLTEwLTEtMS01OTQ3MA_1d8f573f-2db5-451f-8bda-205398bd713d"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i019d538cf2df4702927d2feaebb08210_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzExLTEyLTEtMS01OTQ3MA_bc0ccf53-0830-4059-93be-74fb246b24d7"
      unitRef="usd">102000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i42f1505ab33d4d31b29170cf387d3bf1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzExLTE0LTEtMS01OTQ3MA_90667eb1-dbcf-4ed5-a930-0dbb0b1ed172"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0f2d6658f8c6432eb855fc35c09bc8ae_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzExLTE2LTEtMS01OTQ3MA_ecc1c905-920b-4373-92e1-374c6c9ac67e"
      unitRef="usd">103000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6fb966e248dd4e7db899e8be25bcb6ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEyLTItMS0xLTU5NDcw_de2c406e-3b03-4676-a272-ffa69e290729"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3e6548e2528e46dca40d1b1d09e39d12_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEyLTQtMS0xLTU5NDcw_74ba133d-3bca-44a4-87b8-d8c1dc0cc2aa"
      unitRef="usd">35000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3190fba7ebb5479dbb06445d6267911d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEyLTYtMS0xLTU5NDcw_da0e979f-7cca-4794-95a9-1bca83ad2cbb"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib72d3400eb8c419bb79a2b659524d6d2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEyLTgtMS0xLTU5NDcw_9397aacf-1cee-483b-94fa-51a66bf70e72"
      unitRef="usd">37000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8afa60e604994497a1986db946c1937d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEyLTEwLTEtMS01OTQ3MA_b59b9ce4-326e-4b24-b6e2-4a5a0537d4ef"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0ff0e3d8fc3e4f288ffcf7c081bebc05_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEyLTEyLTEtMS01OTQ3MA_e23013be-954e-4cf1-8e97-619ec5c8cefb"
      unitRef="usd">20000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifbb8aacab7664f5b8279284fc6149b67_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEyLTE0LTEtMS01OTQ3MA_5f15a184-1aff-41e5-8fd2-2e34a779685b"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if3103a0933124d62871e5fc29bf546fa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEyLTE2LTEtMS01OTQ3MA_3b170c32-7d08-4c69-b3fe-70af95d12fba"
      unitRef="usd">22000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9e058ef986de49f0bea67e87231e73b4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEzLTItMS0xLTU5NDcw_2d70c44b-d79d-4499-b4e8-2cff124c8522"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if09958cb78f94a76a7e6f17b2bab67df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEzLTQtMS0xLTU5NDcw_1d20fea6-1dab-4ea3-b899-9509b3251fe7"
      unitRef="usd">172000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2d964dd1784d4ad8bd4443d448886eef_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEzLTYtMS0xLTU5NDcw_b720257f-ac58-4a3f-b301-b0a22b18ff95"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibb4dc2559a83406c8a242c061666e6c3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEzLTgtMS0xLTU5NDcw_0b7dac81-d251-41de-bdc5-f8a85962c7e4"
      unitRef="usd">175000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibc69c8ac45694ba2b20fb0ff3a7f39f9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEzLTEwLTEtMS01OTQ3MA_edf04fbc-5d9c-4abc-872b-7552c7ccee05"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibe61ce2f0b3946ca8976584ee83df12b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEzLTEyLTEtMS01OTQ3MA_7ddd3922-7c65-4087-a69a-5856cf6bb2f0"
      unitRef="usd">186000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i299b97ed33754f6b8c3da5c29c47a1f6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEzLTE0LTEtMS01OTQ3MA_ca6c6c0b-8c91-4a86-8e98-a7231a264fdb"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icd5a69340ce945b7a60bf0ed0babc543_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90YWJsZTo1YjZmZWM3ZmJkOGE0ZGU3OTI3NDg3MTk5MzU3NDg1Yi90YWJsZXJhbmdlOjViNmZlYzdmYmQ4YTRkZTc5Mjc0ODcxOTkzNTc0ODViXzEzLTE2LTEtMS01OTQ3MA_a17aff74-2d38-4d33-841d-80efed57368e"
      unitRef="usd">189000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <bhc:DefinedBenefitPlanPercentageAllocationofFund
      contextRef="ie074f53bc69745fba66921f6f8d38556_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzgxNjU_b7ec1a3f-8cc0-468d-87bd-f75c2455ba99"
      unitRef="number">0.95</bhc:DefinedBenefitPlanPercentageAllocationofFund>
    <bhc:DefinedBenefitPlanPercentageAllocationofFund
      contextRef="ie44d119215b549a88ce037813b5be0de_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4XzgxNzI_1f42e7a1-bc40-4978-b28d-56f5fbb75614"
      unitRef="number">0.96</bhc:DefinedBenefitPlanPercentageAllocationofFund>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4Xzg4OTY_6f981577-75a1-4679-975d-8b42142a9d88"
      unitRef="usd">44000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4Xzg5MDA_2afdd7ce-10f8-45e4-8941-fde48bb1143f"
      unitRef="usd">43000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzQvZnJhZzpiM2QwZjVhMDhlZjQ0Yjk2YWNkODhiMzI2Mjk1OGVmOC90ZXh0cmVnaW9uOmIzZDBmNWEwOGVmNDRiOTZhY2Q4OGIzMjYyOTU4ZWY4Xzg5MDc_62a1f423-1972-4f50-b724-8bfd35f39a25"
      unitRef="usd">41000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzExMzI_981ab2be-e69c-4589-8372-9075a9e5490d">LEASES &lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets and lease liabilities associated with the Company's operating leases are included in the Consolidated Balance Sheet as of December 31, 2021 and 2020 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets included in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzItMC0xLTEtNTk0NzA_aae53d6e-38d6-4bae-885a-a2f1102e63b7"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzItMC0xLTEtNTk0NzA_efb2683f-68c5-4ec5-ba14-7adb1864ba2c"&gt;Other non-current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities included in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzQtMC0xLTEtNTk0NzA_43d158d1-ee05-4bae-a3d5-740a15d049b3"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzQtMC0xLTEtNTk0NzA_fa62fdb0-f620-4627-932e-a0cd84ebc336"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzUtMC0xLTEtNTk0NzA_5aae2037-0b31-4496-a31b-a0628ffc23c9"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzUtMC0xLTEtNTk0NzA_fc2d7485-eeb6-4aa7-8f75-257ecb0d55a3"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, 2020 and 2019 the Company's finance leases were not material and for the years 2021, 2020 and 2019 sub-lease income and short-term lease expense were not material. Lease expense for the years 2021, 2020 and 2019 include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to operating leases for 2021, 2020 and 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid from operating cash flows for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, future payments under noncancelable operating leases for each of the five succeeding years ending December 31 and thereafter are as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:91.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <bhc:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzExMzM_2442ebdd-3f37-4e45-a733-2a62270fc1d2">&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets and lease liabilities associated with the Company's operating leases are included in the Consolidated Balance Sheet as of December 31, 2021 and 2020 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets included in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzItMC0xLTEtNTk0NzA_aae53d6e-38d6-4bae-885a-a2f1102e63b7"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzItMC0xLTEtNTk0NzA_efb2683f-68c5-4ec5-ba14-7adb1864ba2c"&gt;Other non-current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities included in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzQtMC0xLTEtNTk0NzA_43d158d1-ee05-4bae-a3d5-740a15d049b3"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzQtMC0xLTEtNTk0NzA_fa62fdb0-f620-4627-932e-a0cd84ebc336"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzUtMC0xLTEtNTk0NzA_5aae2037-0b31-4496-a31b-a0628ffc23c9"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzUtMC0xLTEtNTk0NzA_fc2d7485-eeb6-4aa7-8f75-257ecb0d55a3"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bhc:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzItMS0xLTEtNTk0NzA_17c628f3-83dd-4c0e-9020-5293c4671a40"
      unitRef="usd">247000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzItMy0xLTEtNTk0NzA_4a3348e6-b11e-4114-8ad6-e0ec5ebba064"
      unitRef="usd">259000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzQtMS0xLTEtNTk0NzA_6ecf07e8-6e20-4138-a2df-ef53af334921"
      unitRef="usd">50000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzQtMy0xLTEtNTk0NzA_2f4ef1c1-8306-4637-9417-be088e7ec9ab"
      unitRef="usd">52000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzUtMS0xLTEtNTk0NzA_e8fac724-61c2-4b52-b3a6-e2ed61b8eba1"
      unitRef="usd">214000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzUtMy0xLTEtNTk0NzA_90c9947f-3bab-42c4-86bc-64d7a1a815dc"
      unitRef="usd">227000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzYtMS0xLTEtNTk0NzA_604284dc-e7b1-4c1e-97af-70e7b39629fd"
      unitRef="usd">264000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpjZjFlNjA5MTRkN2U0ZTM0OGMxMTkxYzEzN2M5ODdlMi90YWJsZXJhbmdlOmNmMWU2MDkxNGQ3ZTRlMzQ4YzExOTFjMTM3Yzk4N2UyXzYtMy0xLTEtNTk0NzA_95c3e7ef-a627-45ef-87bc-d62b60a669b8"
      unitRef="usd">279000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzIxMQ_2aeeeed8-5711-4001-b299-bf7de5b668d9"
      unitRef="usd">0</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzIxMQ_569d32d4-c3fe-48fd-92e3-28469c374235"
      unitRef="usd">0</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzIxMQ_f30b4f30-1893-4a83-9c15-c60ebcdcba03"
      unitRef="usd">0</us-gaap:FinanceLeaseLiability>
    <us-gaap:ShortTermLeaseCost
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzMwMw_0d22a40e-4c47-43f3-a7b9-55f3102d10a4"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzMwMw_2995a5d4-bcb4-4c67-8f1f-d8a42591a7bf"
      unitRef="usd">0</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzMwMw_59e38a2e-bff8-4e7c-a610-0f1a71066142"
      unitRef="usd">0</us-gaap:SubleaseIncome>
    <us-gaap:ShortTermLeaseCost
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzMwMw_7a18fdee-d0e1-4b54-9f13-928d6a2b60b2"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzMwMw_7c826464-d0c7-405e-84af-232da531b5c0"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzMwMw_f18aa943-8f26-4a21-a9e5-1b196923bd12"
      unitRef="usd">0</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzExMzQ_d64d05da-a776-4c24-a576-ca325db5e455">Lease expense for the years 2021, 2020 and 2019 include:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpiZjMwMTNjYzdiNzI0YWE5OWUwOGM4YTI0Y2NhODgwMS90YWJsZXJhbmdlOmJmMzAxM2NjN2I3MjRhYTk5ZTA4YzhhMjRjY2E4ODAxXzEtMS0xLTEtNTk0NzA_52163a3a-79e6-48a0-bc07-6f1ce2e68d8a"
      unitRef="usd">67000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpiZjMwMTNjYzdiNzI0YWE5OWUwOGM4YTI0Y2NhODgwMS90YWJsZXJhbmdlOmJmMzAxM2NjN2I3MjRhYTk5ZTA4YzhhMjRjY2E4ODAxXzEtMy0xLTEtNTk0NzA_38cdc9e1-d72d-44fc-bdde-d41352e0fde9"
      unitRef="usd">65000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpiZjMwMTNjYzdiNzI0YWE5OWUwOGM4YTI0Y2NhODgwMS90YWJsZXJhbmdlOmJmMzAxM2NjN2I3MjRhYTk5ZTA4YzhhMjRjY2E4ODAxXzEtNS0xLTEtNjg3MzI_b35c0497-55aa-444f-b588-9fd1ac4ccb33"
      unitRef="usd">62000000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpiZjMwMTNjYzdiNzI0YWE5OWUwOGM4YTI0Y2NhODgwMS90YWJsZXJhbmdlOmJmMzAxM2NjN2I3MjRhYTk5ZTA4YzhhMjRjY2E4ODAxXzItMS0xLTEtNTk0NzA_a3357fa9-1aad-487e-b5a3-24fff380a9d8"
      unitRef="usd">12000000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpiZjMwMTNjYzdiNzI0YWE5OWUwOGM4YTI0Y2NhODgwMS90YWJsZXJhbmdlOmJmMzAxM2NjN2I3MjRhYTk5ZTA4YzhhMjRjY2E4ODAxXzItMy0xLTEtNTk0NzA_1216ad75-17ba-4479-8ba8-3f82be799020"
      unitRef="usd">12000000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTpiZjMwMTNjYzdiNzI0YWE5OWUwOGM4YTI0Y2NhODgwMS90YWJsZXJhbmdlOmJmMzAxM2NjN2I3MjRhYTk5ZTA4YzhhMjRjY2E4ODAxXzItNS0xLTEtNjg3MzI_b861fc85-0966-464d-96ec-001cf2f22334"
      unitRef="usd">16000000</us-gaap:VariableLeaseCost>
    <bhc:AdditionalOperatingLeaseInformationLesseeTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzExMzU_831c9bfd-b2de-4548-ad29-fd0ebc4cccb6">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to operating leases for 2021, 2020 and 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid from operating cash flows for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bhc:AdditionalOperatingLeaseInformationLesseeTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzEtMS0xLTEtNTk0NzA_8df46e61-19f5-43d8-8706-4ab5a0ff4295"
      unitRef="usd">76000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzEtMy0xLTEtNTk0NzA_7dcac38b-8b2a-4a03-96cf-1021c0c086fd"
      unitRef="usd">74000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzEtNS0xLTEtNjg3NDE_e8b8fdde-bc18-4d36-ad6e-1ca73d899c5c"
      unitRef="usd">73000000</us-gaap:OperatingLeasePayments>
    <bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzItMS0xLTEtNTk0NzA_aad8116a-f79f-4bec-9852-c036c98e41c7"
      unitRef="usd">46000000</bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption>
    <bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzItMy0xLTEtNTk0NzA_afb9363d-83c0-4a19-a23a-f85c179c2641"
      unitRef="usd">39000000</bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption>
    <bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzItNS0xLTEtNjg3NDE_0e0803ac-c314-4f9d-8108-811488e14baf"
      unitRef="usd">47000000</bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzMtMS0xLTEtNTk0NzA_bcccefed-9301-4a22-a215-dd5c9333e6a3">P7Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzMtMy0xLTEtNTk0NzA_663216cd-8022-431b-b40f-4a50edde8d21">P7Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzMtNS0xLTEtNjg3NDE_f6adfc9e-99e9-49a2-b0cb-20ae39969714">P8Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzQtMS0xLTEtNTk0NzA_539a9319-e87b-49ed-b61b-d266c797fc10"
      unitRef="number">0.061</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzQtMy0xLTEtNTk0NzA_20c8f916-1c11-4671-b6ec-0e51d8be18bc"
      unitRef="number">0.062</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTo1NjQxOTBmZTc4MjU0N2YyYjM0MmFmN2YwZTc2MDYwZi90YWJsZXJhbmdlOjU2NDE5MGZlNzgyNTQ3ZjJiMzQyYWY3ZjBlNzYwNjBmXzQtNS0xLTEtNjg3NDE_176e9b71-4e08-4233-b8c9-317c9dee764d"
      unitRef="number">0.062</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90ZXh0cmVnaW9uOjM0YzhjMjlmNDBhOTQ1MTk5MzUzMmUzYmM0NGE0YWIyXzExMzY_d871266b-1e91-4b0b-b825-c9821c01f7d1">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, future payments under noncancelable operating leases for each of the five succeeding years ending December 31 and thereafter are as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:91.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTphMDc4MzQwNzllOWE0MWNkYmVmZjZmNzA0MjFjMDYyYi90YWJsZXJhbmdlOmEwNzgzNDA3OWU5YTQxY2RiZWZmNmY3MDQyMWMwNjJiXzEtMi0xLTEtNTk0NzA_9ff66735-96e6-400c-ac0d-d19e7e9512df"
      unitRef="usd">64000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTphMDc4MzQwNzllOWE0MWNkYmVmZjZmNzA0MjFjMDYyYi90YWJsZXJhbmdlOmEwNzgzNDA3OWU5YTQxY2RiZWZmNmY3MDQyMWMwNjJiXzItMi0xLTEtNTk0NzA_293ef331-7a89-427a-be55-661d1237f411"
      unitRef="usd">53000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTphMDc4MzQwNzllOWE0MWNkYmVmZjZmNzA0MjFjMDYyYi90YWJsZXJhbmdlOmEwNzgzNDA3OWU5YTQxY2RiZWZmNmY3MDQyMWMwNjJiXzMtMi0xLTEtNTk0NzA_20a20485-1b37-467d-aa8c-37829c4f300d"
      unitRef="usd">41000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTphMDc4MzQwNzllOWE0MWNkYmVmZjZmNzA0MjFjMDYyYi90YWJsZXJhbmdlOmEwNzgzNDA3OWU5YTQxY2RiZWZmNmY3MDQyMWMwNjJiXzQtMi0xLTEtNTk0NzA_64d1bee5-4dd1-44dd-bdd6-9dc49ccdc584"
      unitRef="usd">38000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTphMDc4MzQwNzllOWE0MWNkYmVmZjZmNzA0MjFjMDYyYi90YWJsZXJhbmdlOmEwNzgzNDA3OWU5YTQxY2RiZWZmNmY3MDQyMWMwNjJiXzUtMi0xLTEtNTk0NzA_9d332061-03fe-4177-8e22-982d886d024c"
      unitRef="usd">34000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTphMDc4MzQwNzllOWE0MWNkYmVmZjZmNzA0MjFjMDYyYi90YWJsZXJhbmdlOmEwNzgzNDA3OWU5YTQxY2RiZWZmNmY3MDQyMWMwNjJiXzYtMi0xLTEtNTk0NzA_7823e16f-8afd-4d98-89fc-5526f99fc65f"
      unitRef="usd">100000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTphMDc4MzQwNzllOWE0MWNkYmVmZjZmNzA0MjFjMDYyYi90YWJsZXJhbmdlOmEwNzgzNDA3OWU5YTQxY2RiZWZmNmY3MDQyMWMwNjJiXzctMi0xLTEtNTk0NzA_3eafd3b0-2636-46e0-b2f3-53041e6e06a5"
      unitRef="usd">330000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTphMDc4MzQwNzllOWE0MWNkYmVmZjZmNzA0MjFjMDYyYi90YWJsZXJhbmdlOmEwNzgzNDA3OWU5YTQxY2RiZWZmNmY3MDQyMWMwNjJiXzgtMi0xLTEtNTk0NzA_746d0a91-567c-4eb2-ad9a-9a26c238d47e"
      unitRef="usd">66000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTphMDc4MzQwNzllOWE0MWNkYmVmZjZmNzA0MjFjMDYyYi90YWJsZXJhbmdlOmEwNzgzNDA3OWU5YTQxY2RiZWZmNmY3MDQyMWMwNjJiXzktMi0xLTEtNTk0NzA_0655ef89-5ee7-4d73-a020-7c7776b60100"
      unitRef="usd">264000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTphMDc4MzQwNzllOWE0MWNkYmVmZjZmNzA0MjFjMDYyYi90YWJsZXJhbmdlOmEwNzgzNDA3OWU5YTQxY2RiZWZmNmY3MDQyMWMwNjJiXzEwLTItMS0xLTU5NDcw_70662587-2255-4c4a-b46b-7963a812266e"
      unitRef="usd">50000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zMzcvZnJhZzozNGM4YzI5ZjQwYTk0NTE5OTM1MzJlM2JjNDRhNGFiMi90YWJsZTphMDc4MzQwNzllOWE0MWNkYmVmZjZmNzA0MjFjMDYyYi90YWJsZXJhbmdlOmEwNzgzNDA3OWU5YTQxY2RiZWZmNmY3MDQyMWMwNjJiXzExLTItMS0xLTU5NDcw_2f39dca8-35af-4735-b53f-319f0c70b550"
      unitRef="usd">214000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzExNzE0_e517fc3e-3f8d-4327-b61f-fd068b453bd7">SHARE-BASED COMPENSATIONIn May 2014, shareholders approved the Company&#x2019;s 2014 Omnibus Incentive Plan (the &#x201c;2014 Plan&#x201d;), which replaced the Company&#x2019;s 2011 Omnibus Incentive Plan (the &#x201c;2011 Plan&#x201d;) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or &lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;surrendered under the 2011 Plan and the Company&#x2019;s 2007 Equity Compensation Plan. The Company registered 20,000,000 common shares of common stock for issuance under the 2014 Plan.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective April 30, 2018, the Company amended and restated the 2014 Plan (the &#x201c;Amended and Restated 2014 Plan&#x201d;). The Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Amended and Restated 2014 Plan has been increased by an additional 11,900,000 common shares, as approved by the requisite number of shareholders at the Company&#x2019;s annual general meeting held on April 30, 2018, (ii) introduction of a $750,000 aggregate fair market value limit on awards (in either equity, cash or other compensation) that can be granted in any calendar year to a participant who is a non-employee director, (iii) housekeeping changes to address recent changes to Section 162(m) of the Internal Revenue Code, (iv) awards are expressly subject to the Company&#x2019;s clawback policy and (v) awards not assumed or substituted in connection with a Change of Control (as defined in the Amended and Restated 2014 Plan) will only vest on a pro rata basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective April 28, 2020, the Company further amended and restated the Amended and Restated 2014 Plan (the &#x201c;Further Amended and Restated 2014 Plan&#x201d;). The Further Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Further Amended and Restated 2014 Plan has been increased by an additional 13,500,000 common shares, as approved by the requisite number of shareholders at the Company&#x2019;s annual general meeting held on April 28, 2020, (ii) the exercise price of stock options and share appreciation rights (&#x201c;SARs&#x201d;) will be based on the closing price of the underlying common shares on the date such stock options or SARs are granted (rather than on the last preceding trading date), (iii)&#160;additional provisions clarifying that: (a)&#160;stock options and SARs will not be eligible for the payment of dividend or dividend equivalents and (b)&#160;the Talent and Compensation Committee of the Board of Directors of the Company cannot, without shareholder approval, seek to effect any repricing of any previously granted &#x201c;underwater&#x201d; stock option or SAR and (iv) other housekeeping and/or clerical changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 11,593,000 common shares were available for future grants as of December&#160;31, 2021. The Company uses reserved and unissued common shares to satisfy its obligation under its share-based compensation plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#x2019;s focus on improving its tangible capital usage and allocation, while maintaining focus on improving total shareholder return over the long-term.  The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based RSUs and performance-based RSUs. Performance-based RSUs are comprised of: (i) awards that vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#x201c;TSR&#x201d;), (ii) awards that vest upon attainment of certain performance targets that are based on the Company&#x2019;s return on tangible capital (&#x201c;ROTC&#x201d;) and (iii) vest fully or partially upon attainment of certain goals that are linked to the B+L Separation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components and classification of share-based compensation expense related to stock options and&#160;RSUs for the years 2021, 2020 and 2019 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.033%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options granted under the 2011 Plan and the Amended and Restated 2014 Plan generally expire on the fifth or tenth anniversary of the grant date. The exercise price of any stock option granted under the 2011 Plan and the Amended and Restated 2014 Plan will not be less than the closing price per common share on the date of grant. Stock options generally vest 33% and 25% each year over a three-year and four-year period, respectively, on the anniversary of the date of&#160;grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of all stock options granted for the years 2021, 2020 and 2019 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock option life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected stock option life was determined based on historical exercise and forfeiture patterns. The expected volatility was determined based on implied volatility in the market traded options of the Company&#x2019;s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S. government bonds with maturity dates equal to the expected life of the stock&#160;option. The expected dividend yield was determined based on the stock option&#x2019;s exercise price and expected annual dividend rate at the time of&#160;grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model used by the Company to calculate stock option values was developed to estimate the fair value of freely tradeable, fully transferable stock options without vesting restrictions, which significantly differ from the Company&#x2019;s stock option awards. This model also requires highly subjective assumptions, including future stock price volatility and expected time until exercise, which greatly affect the calculated values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average fair values of all stock options granted in 2021, 2020 and 2019 were $10.92, $6.60 and $8.45, respectively. The total intrinsic values of stock options exercised in 2021, 2020 and 2019 were $15 million, $2 million and $3 million, respectively. Proceeds received on the exercise of stock options in 2021, 2020 and 2019 were $22 million, $5 million and $5 million,&#160;respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the total remaining unrecognized compensation expense related to non-vested stock options amounted to $10 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;years. The total fair value of stock options vested in 2021, 2020 and 2019 were $15 million, $15 million and&#160;$18 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs generally vest on the first or third anniversary date from the date of grant or 33% a year over a three-year period. Annual RSUs granted to non-management directors vest immediately prior to the next Annual Meeting of Shareholders. Pursuant to the applicable unit agreement, certain RSUs may be subject to the attainment of any applicable performance goals specified by the Board of Directors. If the vesting of the RSUs is conditional upon the attainment of performance goals, any RSUs that do not vest as a result of a determination that the prescribed performance goals failed to be attained will be forfeited immediately upon such determination. RSUs are credited with dividend equivalents, in the form of additional RSUs, when dividends are paid on the Company&#x2019;s common shares. Such additional RSUs will have the same vesting dates and will vest under the same terms as the RSUs in respect of which such additional RSUs are&#160;credited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent provided for in a RSU agreement, the Company may, in lieu of all or a portion of the common shares which would otherwise be provided to a holder, elect to pay a cash amount equivalent to the market price of the Company&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;common shares on the vesting date for each vested RSU. The amount of cash payment will be determined based on the average market price of the Company&#x2019;s common shares on the vesting date. The Company&#x2019;s current intent is to settle vested RSUs through the issuance of common&#160;shares.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Time-Based RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each vested time-based RSU represents the right of a holder to receive one of the Company&#x2019;s common shares. The fair value of each RSU granted is estimated based on the trading price of the Company&#x2019;s common shares on the date of&#160;grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes non-vested time-based RSU activity during 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Time-Based&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the total remaining unrecognized compensation expense related to non-vested time-based RSUs amounted to $68 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.6 years. The total fair value of time-based RSUs vested in 2021, 2020 and 2019 were $69 million, $66 million and $34 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance-Based RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each vested performance-based RSU represents the right of a holder to receive a number of the Company&#x2019;s common shares up to a specified maximum. Performance-based RSUs vest upon achievement of certain share price appreciation conditions or attainment of certain performance targets. If the Company&#x2019;s performance is below a specified performance level, no common shares will be&#160;paid. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each TSR performance-based RSU granted during 2021, 2020 and 2019 was estimated using a Monte Carlo Simulation model, which utilizes multiple input variables to estimate the probability that the performance condition will be achieved.  The fair value of the ROTC performance-based RSUs is estimated based on the trading price of the Company&#x2019;s common shares on the date of grant.  Expense recognized for the ROTC performance-based RSUs in each reporting period reflects the Company&#x2019;s latest estimate of the number of ROTC performance-based RSUs that are expected to vest.  If the ROTC performance-based RSUs do not ultimately vest due to the ROTC targets not being met, no compensation expense is recognized and any previously recognized compensation expense is reversed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of TSR performance-based RSUs granted during 2021, 2020 and 2019 were estimated with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contractual term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected Company share volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected company share volatility was determined based on implied volatility in the market traded options of the Company&#x2019;s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S.&#160;government bonds with maturity dates equal to the contractual term of the performance-based&#160;RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes non-vested performance-based RSU activity during 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.799%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Performance-based &lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, the Company granted approximately&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,035,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance-based RSUs, consisting of approximately 400,000 units of TSR performance-based RSUs with an average grant date fair value of $56.04 per RSU, approximately 413,000 units of ROTC performance-based RSUs with a weighted-average grant date fair value of $31.72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;per RSU and approximately 222,000 of other performance-based RSU's with a weighted-average grant date fair value of $28.49. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the total remaining unrecognized compensation expense related to non-vested performance-based RSUs amounted to $32 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.7 years.  A maximum of approximately 3,476,000 common shares could be issued upon vesting of the performance-based RSUs outstanding as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i4ca155d300cf42a4b9cfdefca02c609b_I20140531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzQyMg_4814d78b-caf8-48a4-aeb6-586a6732b821"
      unitRef="shares">18000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i4ca155d300cf42a4b9cfdefca02c609b_I20140531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzc4Mg_c0e30c9e-2ad4-4722-81ff-dd519a7ded55"
      unitRef="shares">20000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i4442a258b8f44219a1cd0070ea1406e8_D20180430-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzExNjc_d11aec20-598f-4273-a315-3a39d141765b"
      unitRef="shares">11900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant
      contextRef="ibc1c3154bf0046c1b2667e6a53320931_D20180430-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzEzMjQ_43d81480-1839-47ca-bc4a-e5ded22b0e28"
      unitRef="usd">750000</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="id025575230534acb993dae92e7192d0c_D20200428-20200428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzIyMTM_cfe1572d-59b4-47a0-97f2-a28fd216498e"
      unitRef="shares">13500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i8265f2e72c9e451eb2bd2c997c00db7f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzMwMjA_2a02541d-a659-4f43-8f68-7e0688f5a490"
      unitRef="shares">11593000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzExNzA1_22bc73bb-08f1-454c-b27c-12eba55afab5">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components and classification of share-based compensation expense related to stock options and&#160;RSUs for the years 2021, 2020 and 2019 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.033%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzEtMi0xLTEtNTk0NzA_bc3194d1-8d66-4e0b-9ead-982c4c62aa32"
      unitRef="usd">15000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i086597ed1e26464a806168f0ce38c359_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzEtNC0xLTEtNTk0NzA_934b418a-4646-491c-ae77-6f6b4cea05e0"
      unitRef="usd">15000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i846d952abe194e548203133638491e9c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzEtNi0xLTEtNTk0NzA_9be291f9-972c-4e5c-8b40-283ce5213fd4"
      unitRef="usd">21000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2088dbf192f84b6e9cff9dc2cde381cf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzItMi0xLTEtNTk0NzA_0bf7c747-3d78-4695-aa89-815eccf7998e"
      unitRef="usd">113000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie724079581044aa0811350b601ee9cc2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzItNC0xLTEtNTk0NzA_f8031b73-4c24-4846-8504-d4967321de33"
      unitRef="usd">90000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2910d81cb0f045f7a33086454100489d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzItNi0xLTEtNTk0NzA_fb6c20cd-c7a4-488a-aa01-d4e4a6f34fed"
      unitRef="usd">81000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzMtMi0xLTEtNTk0NzA_d36b51a6-eaf9-4d11-8ba8-b2b4548ea374"
      unitRef="usd">128000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzMtNC0xLTEtNTk0NzA_c56f68c2-0a62-4e99-baa2-46922fabd581"
      unitRef="usd">105000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzMtNi0xLTEtNTk0NzA_3e2cbb0c-5cc1-4549-9c23-9ee321233f2a"
      unitRef="usd">102000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i79264328a7a543f1ac564306154bf1e7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzUtMi0xLTEtNTk0NzA_c6259f55-f0b8-4b7d-83d3-8ef8baf81b7d"
      unitRef="usd">10000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7a5a66d1f91043f8bc5742bb410551cc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzUtNC0xLTEtNTk0NzA_ff286dfe-6b4d-4f70-8e99-27b4dd957c17"
      unitRef="usd">11000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i936812f8c65d495cb6b6f31769ebb66b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzUtNi0xLTEtNTk0NzA_69eda6cf-22cc-49c9-9956-ea78d0e23420"
      unitRef="usd">9000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i59d93d4490ae467d9a2415b38252c35b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzYtMi0xLTEtNTk0NzA_e5885ac8-fb1a-4e66-bc7d-a0ae4ccd8e07"
      unitRef="usd">118000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="icc9346bc756a4ce3b7a716c303df449a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzYtNC0xLTEtNTk0NzA_d8de1238-c7db-45dc-a19f-9c86b9306836"
      unitRef="usd">94000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i87e1a3e05cd844d9a82820b7441ea2f3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzYtNi0xLTEtNTk0NzA_5e8089ff-8a25-49c5-9ff8-953fe2ad3a85"
      unitRef="usd">93000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzctMi0xLTEtNTk0NzA_772cbe41-0f36-4034-a940-cc74a619b18b"
      unitRef="usd">128000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzctNC0xLTEtNTk0NzA_2881a122-dc9e-4c1f-9025-c0979905960a"
      unitRef="usd">105000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTpiOTgzZWM3YmI4OTY0NTdkYWQzMDVlMzM3M2U3MjVkNS90YWJsZXJhbmdlOmI5ODNlYzdiYjg5NjQ1N2RhZDMwNWUzMzczZTcyNWQ1XzctNi0xLTEtNTk0NzA_6cf7c800-8a31-4550-843d-c34a480e5da7"
      unitRef="usd">102000000</us-gaap:ShareBasedCompensation>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage
      contextRef="i9eda91734bd9488387a03d3c1a80263c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzQ0OTY_510812cf-0fb8-49ad-9b6f-b5f1d44ee6ad"
      unitRef="number">0.33</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage
      contextRef="i9fa761390575444b8d5cf87f856db73c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzQ1MDM_a237e5ce-71ed-4b25-8bf2-a5b3fae3153c"
      unitRef="number">0.25</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i67ab1d6d98e348a2849edb9d66a71b5b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzExNjg1_b69561a1-c90f-407f-921e-dbf31cf06118">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iefcbe00a2f7e4f35ae1167fd771c00c1_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzExNjk0_2ac0b9d0-31f4-4947-85a8-b0cee162a8b0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzExNzI2_d5be8d86-aee3-4c19-b22a-1af01505108c">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of all stock options granted for the years 2021, 2020 and 2019 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock option life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzEtMi0xLTEtNTk0NzA_9e3af595-ee80-484e-bace-71f2ea5e3847">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i086597ed1e26464a806168f0ce38c359_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzEtNC0xLTEtNTk0NzA_0c702593-8722-4d98-bc77-4012b9b86876">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i846d952abe194e548203133638491e9c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzEtNi0xLTEtNTk0NzA_11e62480-cfcb-4b42-8cc8-496509e6b6ab">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzItMi0xLTEtNTk0NzA_b01ee338-66ec-4072-9a2a-663fc09349a0"
      unitRef="number">0.502</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i086597ed1e26464a806168f0ce38c359_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzItNC0xLTEtNTk0NzA_c35cf9f4-4bfd-4c10-ad7a-12fba39beeab"
      unitRef="number">0.387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i846d952abe194e548203133638491e9c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzItNi0xLTEtNTk0NzA_172b9133-c3c7-47ca-b4ac-0cc32342a844"
      unitRef="number">0.465</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzMtMi0xLTEtNTk0NzA_81015d7f-a3a4-4202-8715-019079555be5"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i086597ed1e26464a806168f0ce38c359_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzMtNC0xLTEtNTk0NzA_28b63377-6510-4a99-9f8b-41e354aee9e0"
      unitRef="number">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i846d952abe194e548203133638491e9c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzMtNi0xLTEtNTk0NzA_c805a174-db6e-46b3-a437-76c200dad99a"
      unitRef="number">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzQtMi0xLTEtNTk0NzA_44a99eae-26e4-4956-bbf3-7986f4541184"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i086597ed1e26464a806168f0ce38c359_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzQtNC0xLTEtNTk0NzA_73e51466-1172-45e3-b046-30896debe3f5"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i846d952abe194e548203133638491e9c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3Yjk5Nzg2MWI3ZWY0MDEzODQzMjVhMzQ2OTI0Y2ZjMi90YWJsZXJhbmdlOjdiOTk3ODYxYjdlZjQwMTM4NDMyNWEzNDY5MjRjZmMyXzQtNi0xLTEtNTk0NzA_90b4cf95-41be-4220-9e03-14dfeb207f04"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzExNjg3_214519e0-b661-4a2b-a77a-2d232d8a8395">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id9615eb6151e4a2da212f24458fc78e6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzEtMi0xLTEtNTk0NzA_e379a275-0901-44e0-8a6f-e722e6d98096"
      unitRef="shares">8700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id9615eb6151e4a2da212f24458fc78e6_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzEtNC0xLTEtNTk0NzA_a5c94b94-108a-4c6a-8908-c6120f498278"
      unitRef="usdPerShare">25.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzItMi0xLTEtNTk0NzA_e3179f3f-311d-4139-a6fb-888e9a76ce21"
      unitRef="shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzItNC0xLTEtNTk0NzA_0e496094-eaf1-4be2-a0f3-6ba0a7176608"
      unitRef="usdPerShare">32.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzMtMi0xLTEtNTk0NzA_801e2423-7c7e-4e8f-810e-ab63a3104e56"
      unitRef="shares">1200000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzMtNC0xLTEtNTk0NzA_488c7d53-6363-4e42-b550-47572dfe765e"
      unitRef="usdPerShare">18.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzQtMi0xLTEtNTk0NzA_ad6af9ed-628a-4439-b782-8ce296ce4f5d"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzQtNC0xLTEtNTk0NzA_b48eb0a5-46db-4eb4-bda0-340201a33cc9"
      unitRef="usdPerShare">29.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ibfe3a038368845f1a17357b6780d71ec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzUtMi0xLTEtNTk0NzA_9b386a14-afd6-4272-a9a5-077d45b95c25"
      unitRef="shares">8900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ibfe3a038368845f1a17357b6780d71ec_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzUtNC0xLTEtNTk0NzA_59b2b60b-7e5c-4685-aa02-657533f2d207"
      unitRef="usdPerShare">27.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzUtNi0xLTEtNTk0NzA_8e7bd3f4-7b26-415e-98e3-751f1b92e9ae">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ibfe3a038368845f1a17357b6780d71ec_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzUtOC0xLTEtNTk0NzA_a5e77d4f-beb1-41de-bbc4-de9161cce5ba"
      unitRef="usd">36000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ibfe3a038368845f1a17357b6780d71ec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzYtMi0xLTEtNTk0NzA_8ca6da8b-78ce-426b-bf5f-b1d817b67b63"
      unitRef="shares">8500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ibfe3a038368845f1a17357b6780d71ec_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzYtNC0xLTEtNTk0NzA_9a65c328-253c-48c9-8dc9-a4f7dd6ed66a"
      unitRef="usdPerShare">27.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzYtNi0xLTEtNTk0NzA_1d5b1886-3f3f-4c2d-b75c-d266138d2af2">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ibfe3a038368845f1a17357b6780d71ec_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzYtOC0xLTEtNTk0NzA_2da54063-5a84-4589-a698-8d919ed02c15"
      unitRef="usd">35000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="ibfe3a038368845f1a17357b6780d71ec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzctMi0xLTEtNTk0NzA_3132a2e8-9865-40b2-ad59-9b141927f76f"
      unitRef="shares">5500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="ibfe3a038368845f1a17357b6780d71ec_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzctNC0xLTEtNTk0NzA_1dc69ff8-680d-4bc5-bc19-a9041b8c940c"
      unitRef="usdPerShare">27.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzctNi0xLTEtNTk0NzA_a888353a-83fb-40ec-b4da-38c367cf84a9">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="ibfe3a038368845f1a17357b6780d71ec_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTo3OGM3NDQ5ZjA0MWE0YTRlYjY3ZWUyM2YyYTgxZTY2Mi90YWJsZXJhbmdlOjc4Yzc0NDlmMDQxYTRhNGViNjdlZTIzZjJhODFlNjYyXzctOC0xLTEtNTk0NzA_928559ad-fef2-406b-9fb1-5cbd643d73e7"
      unitRef="usd">30000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzU5NzA_c6861271-8bdf-4658-8b2b-9d83949caea0"
      unitRef="usdPerShare">10.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i086597ed1e26464a806168f0ce38c359_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzU5NzQ_f781b5a7-fc71-4f5c-bd7c-d4e78a977f2b"
      unitRef="usdPerShare">6.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i846d952abe194e548203133638491e9c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzU5ODE_f2ce4276-f2ee-482f-8932-4392393e41df"
      unitRef="usdPerShare">8.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzYwNjQ_1bfd4af0-9a5b-4abc-86ce-ba3cfe94c2b7"
      unitRef="usd">15000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i086597ed1e26464a806168f0ce38c359_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzYwNjg_d9c297e4-bc10-440a-af46-c292828c83bc"
      unitRef="usd">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i846d952abe194e548203133638491e9c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzYwNzU_5775a6fe-4146-428c-8f37-9880e11bc4ce"
      unitRef="usd">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzYxNTU_90578d4f-630d-4a33-a1a7-09ec195266f7"
      unitRef="usd">22000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i086597ed1e26464a806168f0ce38c359_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzYxNTk_4b1b9630-36df-492d-956d-704ac7ffd2ad"
      unitRef="usd">5000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i846d952abe194e548203133638491e9c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzYxNjY_e365ed66-bfe7-414e-8a7d-db3aa0389168"
      unitRef="usd">5000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ibfe3a038368845f1a17357b6780d71ec_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzYyOTA_bc068ba1-fb45-481c-bf7a-3e8a7438256e"
      unitRef="usd">10000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzYzOTY_e4729a43-4f9f-4cd6-8ec4-a99b9214a7a8">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue
      contextRef="i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzY0NjI_345cac1a-113c-4e9c-bbef-9a0baede1025"
      unitRef="usd">15000000</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue
      contextRef="i086597ed1e26464a806168f0ce38c359_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzY0NjY_1232d20b-8824-4eaa-bf19-0341849aa894"
      unitRef="usd">15000000</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue
      contextRef="i846d952abe194e548203133638491e9c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzY0NzM_fb5f54dd-06e9-405e-8172-0b8752328cc5"
      unitRef="usd">18000000</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i2088dbf192f84b6e9cff9dc2cde381cf_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzY1ODE_cb77c758-0267-4d1d-8e70-fcf353624694"
      unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i2088dbf192f84b6e9cff9dc2cde381cf_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzExNzI4_d7accada-5180-445d-8e67-43da76b4a53d">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzExNzEx_72eea2fb-6c67-4f1b-aba2-88c56d482ccf">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes non-vested time-based RSU activity during 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Time-Based&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i12c733996b5f40c9abb282bf8d5d421b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTphYjc2OTE1ZmU4Zjg0MjQ3OGQxZjk5MjE2ZjEzYzkxMC90YWJsZXJhbmdlOmFiNzY5MTVmZThmODQyNDc4ZDFmOTkyMTZmMTNjOTEwXzEtMi0xLTEtNTk0NzA_33741cde-4385-4061-8a4f-b666385dbacb"
      unitRef="shares">5700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i12c733996b5f40c9abb282bf8d5d421b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTphYjc2OTE1ZmU4Zjg0MjQ3OGQxZjk5MjE2ZjEzYzkxMC90YWJsZXJhbmdlOmFiNzY5MTVmZThmODQyNDc4ZDFmOTkyMTZmMTNjOTEwXzEtNC0xLTEtNTk0NzA_eaa4289f-d934-4b41-93ef-38fbb168ad8a"
      unitRef="usdPerShare">21.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic7042672dea544848ba094e3f7c68fe6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTphYjc2OTE1ZmU4Zjg0MjQ3OGQxZjk5MjE2ZjEzYzkxMC90YWJsZXJhbmdlOmFiNzY5MTVmZThmODQyNDc4ZDFmOTkyMTZmMTNjOTEwXzItMi0xLTEtNTk0NzA_2e525327-c653-46a2-83dc-f72ba6cbb190"
      unitRef="shares">3400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic7042672dea544848ba094e3f7c68fe6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTphYjc2OTE1ZmU4Zjg0MjQ3OGQxZjk5MjE2ZjEzYzkxMC90YWJsZXJhbmdlOmFiNzY5MTVmZThmODQyNDc4ZDFmOTkyMTZmMTNjOTEwXzItNC0xLTEtNTk0NzA_ed4c4683-5ee4-400f-8798-1f8d788770f1"
      unitRef="usdPerShare">31.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ic7042672dea544848ba094e3f7c68fe6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTphYjc2OTE1ZmU4Zjg0MjQ3OGQxZjk5MjE2ZjEzYzkxMC90YWJsZXJhbmdlOmFiNzY5MTVmZThmODQyNDc4ZDFmOTkyMTZmMTNjOTEwXzMtMi0xLTEtNTk0NzA_45b5d244-7f69-44fb-88cf-ebc0027c6578"
      unitRef="shares">3300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic7042672dea544848ba094e3f7c68fe6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTphYjc2OTE1ZmU4Zjg0MjQ3OGQxZjk5MjE2ZjEzYzkxMC90YWJsZXJhbmdlOmFiNzY5MTVmZThmODQyNDc4ZDFmOTkyMTZmMTNjOTEwXzMtNC0xLTEtNTk0NzA_46bf3259-dfbf-446b-9606-ae607216ee27"
      unitRef="usdPerShare">21.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ic7042672dea544848ba094e3f7c68fe6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTphYjc2OTE1ZmU4Zjg0MjQ3OGQxZjk5MjE2ZjEzYzkxMC90YWJsZXJhbmdlOmFiNzY5MTVmZThmODQyNDc4ZDFmOTkyMTZmMTNjOTEwXzQtMi0xLTEtNTk0NzA_4ddb281a-146c-4750-a7ee-cb5b27a45d89"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ic7042672dea544848ba094e3f7c68fe6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTphYjc2OTE1ZmU4Zjg0MjQ3OGQxZjk5MjE2ZjEzYzkxMC90YWJsZXJhbmdlOmFiNzY5MTVmZThmODQyNDc4ZDFmOTkyMTZmMTNjOTEwXzQtNC0xLTEtNTk0NzA_637a2e38-dbd8-4157-bd8f-8de66f5790ce"
      unitRef="usdPerShare">26.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i911683c7210b422894ad8e3b68edeb77_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTphYjc2OTE1ZmU4Zjg0MjQ3OGQxZjk5MjE2ZjEzYzkxMC90YWJsZXJhbmdlOmFiNzY5MTVmZThmODQyNDc4ZDFmOTkyMTZmMTNjOTEwXzUtMi0xLTEtNTk0NzA_c774206f-d569-4962-b870-15eef710bd60"
      unitRef="shares">5400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i911683c7210b422894ad8e3b68edeb77_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTphYjc2OTE1ZmU4Zjg0MjQ3OGQxZjk5MjE2ZjEzYzkxMC90YWJsZXJhbmdlOmFiNzY5MTVmZThmODQyNDc4ZDFmOTkyMTZmMTNjOTEwXzUtNC0xLTEtNTk0NzA_a502b88e-4586-4644-a0ca-c516d4797843"
      unitRef="usdPerShare">28.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i911683c7210b422894ad8e3b68edeb77_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzgzOTM_321ab743-d136-40c0-a127-4452e7cb27b8"
      unitRef="usd">68000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic7042672dea544848ba094e3f7c68fe6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzg0OTk_6a6a739a-32e1-4628-8d8e-aa8aac8f67fa">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ic7042672dea544848ba094e3f7c68fe6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzg1Njc_15143fa5-18ef-4a9e-8089-742a5be08d39"
      unitRef="usd">69000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i0393ab35e9cc4519bbfe3fe5df85b76b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzg1NzE_c69d08b0-2028-4c8e-a7a0-257a8c3476b9"
      unitRef="usd">66000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i1fe34facb9874ca79ea97f41a97eb1c8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzg1Nzg_c861dea1-e24f-4d5f-8578-298a36725d06"
      unitRef="usd">34000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <bhc:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzExNzE4_63785762-d7d6-4640-98d5-a3f70eba04c9">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of TSR performance-based RSUs granted during 2021, 2020 and 2019 were estimated with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contractual term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected Company share volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bhc:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3e1cd89faa1647e69cd98100bc41a853_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTozNmE1NjkwNDFmZjQ0ZTQ3Yjc3M2FlMTRkYWMxOTkyMy90YWJsZXJhbmdlOjM2YTU2OTA0MWZmNDRlNDdiNzczYWUxNGRhYzE5OTIzXzEtMi0xLTEtNTk0NzA_61f12356-bd09-45e8-86c2-9ec8f4d8473d">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib899b174c8a5478689ab47ec6929522f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTozNmE1NjkwNDFmZjQ0ZTQ3Yjc3M2FlMTRkYWMxOTkyMy90YWJsZXJhbmdlOjM2YTU2OTA0MWZmNDRlNDdiNzczYWUxNGRhYzE5OTIzXzEtNC0xLTEtNTk0NzA_683bdeef-1330-4aa2-adcf-8809616a35a9">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic56b5e163c6d4ad88d725a35418555aa_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTozNmE1NjkwNDFmZjQ0ZTQ3Yjc3M2FlMTRkYWMxOTkyMy90YWJsZXJhbmdlOjM2YTU2OTA0MWZmNDRlNDdiNzczYWUxNGRhYzE5OTIzXzEtNi0xLTEtNTk0NzA_4ecacba9-601a-44cb-924c-cb8169cde213">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3e1cd89faa1647e69cd98100bc41a853_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTozNmE1NjkwNDFmZjQ0ZTQ3Yjc3M2FlMTRkYWMxOTkyMy90YWJsZXJhbmdlOjM2YTU2OTA0MWZmNDRlNDdiNzczYWUxNGRhYzE5OTIzXzItMi0xLTEtNTk0NzA_dbddc4a8-5b5f-4fdc-adb1-7622b114762a"
      unitRef="number">0.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ib899b174c8a5478689ab47ec6929522f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTozNmE1NjkwNDFmZjQ0ZTQ3Yjc3M2FlMTRkYWMxOTkyMy90YWJsZXJhbmdlOjM2YTU2OTA0MWZmNDRlNDdiNzczYWUxNGRhYzE5OTIzXzItNC0xLTEtNTk0NzA_bbed43b9-7abf-4cf5-9a3c-39f34cfb85b6"
      unitRef="number">0.386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic56b5e163c6d4ad88d725a35418555aa_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTozNmE1NjkwNDFmZjQ0ZTQ3Yjc3M2FlMTRkYWMxOTkyMy90YWJsZXJhbmdlOjM2YTU2OTA0MWZmNDRlNDdiNzczYWUxNGRhYzE5OTIzXzItNi0xLTEtNTk0NzA_9e24525d-c382-48b8-87eb-ff553fcdb488"
      unitRef="number">0.465</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3e1cd89faa1647e69cd98100bc41a853_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTozNmE1NjkwNDFmZjQ0ZTQ3Yjc3M2FlMTRkYWMxOTkyMy90YWJsZXJhbmdlOjM2YTU2OTA0MWZmNDRlNDdiNzczYWUxNGRhYzE5OTIzXzMtMi0xLTEtNTk0NzA_b2a9ceea-ff23-49bf-bfca-f8a356eec555"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ib899b174c8a5478689ab47ec6929522f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTozNmE1NjkwNDFmZjQ0ZTQ3Yjc3M2FlMTRkYWMxOTkyMy90YWJsZXJhbmdlOjM2YTU2OTA0MWZmNDRlNDdiNzczYWUxNGRhYzE5OTIzXzMtNC0xLTEtNTk0NzA_00a12e18-0ebc-4af4-ae9e-c886f1ed74a9"
      unitRef="number">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic56b5e163c6d4ad88d725a35418555aa_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTozNmE1NjkwNDFmZjQ0ZTQ3Yjc3M2FlMTRkYWMxOTkyMy90YWJsZXJhbmdlOjM2YTU2OTA0MWZmNDRlNDdiNzczYWUxNGRhYzE5OTIzXzMtNi0xLTEtNTk0NzA_ac760a62-3ebb-4693-9a73-f4bda1fbf6f7"
      unitRef="number">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzExNjgy_25d59a27-d316-48e0-a9b2-b7ad1388368c">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes non-vested performance-based RSU activity during 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.799%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Performance-based &lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i903f03ca7b0d4bec8b5dae3db9f4c7a1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTowMzUyYmNiZDg4ZmQ0NWY0OGY5ODRiMDEyODEzODk0My90YWJsZXJhbmdlOjAzNTJiY2JkODhmZDQ1ZjQ4Zjk4NGIwMTI4MTM4OTQzXzEtMi0xLTEtNTk0NzA_2c348f7e-5ba3-4f41-9210-acc4589481c0"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i903f03ca7b0d4bec8b5dae3db9f4c7a1_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTowMzUyYmNiZDg4ZmQ0NWY0OGY5ODRiMDEyODEzODk0My90YWJsZXJhbmdlOjAzNTJiY2JkODhmZDQ1ZjQ4Zjk4NGIwMTI4MTM4OTQzXzEtNC0xLTEtNTk0NzA_34cb3d2f-9741-457e-a328-d17208d46779"
      unitRef="usdPerShare">28.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i3e1cd89faa1647e69cd98100bc41a853_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTowMzUyYmNiZDg4ZmQ0NWY0OGY5ODRiMDEyODEzODk0My90YWJsZXJhbmdlOjAzNTJiY2JkODhmZDQ1ZjQ4Zjk4NGIwMTI4MTM4OTQzXzItMi0xLTEtNTk0NzA_3754278e-57db-44a5-9618-1f2eab3029b9"
      unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3e1cd89faa1647e69cd98100bc41a853_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTowMzUyYmNiZDg4ZmQ0NWY0OGY5ODRiMDEyODEzODk0My90YWJsZXJhbmdlOjAzNTJiY2JkODhmZDQ1ZjQ4Zjk4NGIwMTI4MTM4OTQzXzItNC0xLTEtNTk0NzA_e5aba872-5a1f-4be9-bae2-9cefed8deb63"
      unitRef="usdPerShare">40.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i3e1cd89faa1647e69cd98100bc41a853_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTowMzUyYmNiZDg4ZmQ0NWY0OGY5ODRiMDEyODEzODk0My90YWJsZXJhbmdlOjAzNTJiY2JkODhmZDQ1ZjQ4Zjk4NGIwMTI4MTM4OTQzXzMtMi0xLTEtNTk0NzA_8c452080-c5ea-4e24-842d-4d5cbf386ab8"
      unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3e1cd89faa1647e69cd98100bc41a853_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTowMzUyYmNiZDg4ZmQ0NWY0OGY5ODRiMDEyODEzODk0My90YWJsZXJhbmdlOjAzNTJiY2JkODhmZDQ1ZjQ4Zjk4NGIwMTI4MTM4OTQzXzMtNC0xLTEtNTk0NzA_da114f3c-6ed4-466c-a953-68f637668232"
      unitRef="usdPerShare">27.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iede5ac25cc2c49c797a46beb7f132efd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTowMzUyYmNiZDg4ZmQ0NWY0OGY5ODRiMDEyODEzODk0My90YWJsZXJhbmdlOjAzNTJiY2JkODhmZDQ1ZjQ4Zjk4NGIwMTI4MTM4OTQzXzQtMi0xLTEtNTk0NzA_d9932890-9bd6-4528-93c4-8562f266c489"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iede5ac25cc2c49c797a46beb7f132efd_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90YWJsZTowMzUyYmNiZDg4ZmQ0NWY0OGY5ODRiMDEyODEzODk0My90YWJsZXJhbmdlOjAzNTJiY2JkODhmZDQ1ZjQ4Zjk4NGIwMTI4MTM4OTQzXzQtNC0xLTEtNTk0NzA_8b47c778-938a-467a-b46f-6e47a45a4d9b"
      unitRef="usdPerShare">33.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i3e1cd89faa1647e69cd98100bc41a853_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzEwMzg1_ea3641af-3e73-497b-b2fe-6b62b695cc6b"
      unitRef="shares">1035000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i36e8b2657c164c33a91c59ad739b895e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzEwNDQw_ae799624-0413-4d60-b428-0b7908960703"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i36e8b2657c164c33a91c59ad739b895e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzEwNTIw_311055d9-e368-4fcc-ae47-cea6e668d0a7"
      unitRef="usdPerShare">56.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i272f0cc98d024849a92bb2d337033d5d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzEwNTQ5_acf80ba3-8217-4fcf-9d3f-b5ea6eef5470"
      unitRef="shares">413000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i272f0cc98d024849a92bb2d337033d5d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzEwNjM4_09241850-417f-4a25-8855-552cb293efea"
      unitRef="usdPerShare">31.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i789a736034674ddab3556f1ab2711032_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzEwOTk1MTE2NDEzOTg_9161749f-99a2-4435-a2ea-4a074fd21dfd"
      unitRef="shares">222000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i789a736034674ddab3556f1ab2711032_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzU0OTc1NTgxNTI0NTY_2257e060-dd20-4039-af59-7ae361344d7d"
      unitRef="usdPerShare">28.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="iede5ac25cc2c49c797a46beb7f132efd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzEwNzY2_82cac885-de5c-45bd-9523-2432cf27e8d3"
      unitRef="usd">32000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i3e1cd89faa1647e69cd98100bc41a853_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzEwODcy_9808fb1b-19e0-458e-b498-f57579911e51">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued
      contextRef="iede5ac25cc2c49c797a46beb7f132efd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDAvZnJhZzo4YWU1ZWIyZTJjNjc0ZmU4OTllYTQ5ZjM5Yzg3NGFlZC90ZXh0cmVnaW9uOjhhZTVlYjJlMmM2NzRmZTg5OWVhNDlmMzljODc0YWVkXzEwOTEw_996983fc-c100-4e90-a916-3b8daf6952f2"
      unitRef="shares">3476000</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDMvZnJhZzo1ZjdmMWNjODZlNDU0M2I0YTg1ZDI5MGNhMTBmZjU3Yi90ZXh0cmVnaW9uOjVmN2YxY2M4NmU0NTQzYjRhODVkMjkwY2ExMGZmNTdiXzQyNQ_7be8b8e1-f305-4353-994d-5a2fc6756aa3">ACCUMULATED OTHER COMPREHENSIVE LOSS&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss as of December&#160;31, 2021 and 2020 consists of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,905)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension adjustment, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#x2019;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#x2019;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDMvZnJhZzo1ZjdmMWNjODZlNDU0M2I0YTg1ZDI5MGNhMTBmZjU3Yi90ZXh0cmVnaW9uOjVmN2YxY2M4NmU0NTQzYjRhODVkMjkwY2ExMGZmNTdiXzQyMA_598581ec-ff3b-4593-a51f-27c3e516df21">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss as of December&#160;31, 2021 and 2020 consists of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,905)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension adjustment, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia9158150c4cf4379b5bba7c7cb9d7e9a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDMvZnJhZzo1ZjdmMWNjODZlNDU0M2I0YTg1ZDI5MGNhMTBmZjU3Yi90YWJsZTo2OWZmZDhlNmNkMDM0OGMzODUwY2JhMmI1OWFiZTJlMi90YWJsZXJhbmdlOjY5ZmZkOGU2Y2QwMzQ4YzM4NTBjYmEyYjU5YWJlMmUyXzEtMi0xLTEtNTk0NzA_782cbce4-449e-454a-9dd7-48e33362e2ba"
      unitRef="usd">-1905000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if0b1241118154de6b3af123e431df6a1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDMvZnJhZzo1ZjdmMWNjODZlNDU0M2I0YTg1ZDI5MGNhMTBmZjU3Yi90YWJsZTo2OWZmZDhlNmNkMDM0OGMzODUwY2JhMmI1OWFiZTJlMi90YWJsZXJhbmdlOjY5ZmZkOGU2Y2QwMzQ4YzM4NTBjYmEyYjU5YWJlMmUyXzEtNC0xLTEtNTk0NzA_e4cbc10f-e729-4504-b92f-58cb5f39c7c4"
      unitRef="usd">-2077000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibbb6b356a1fd41fc9c4da52a60b5ad6a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDMvZnJhZzo1ZjdmMWNjODZlNDU0M2I0YTg1ZDI5MGNhMTBmZjU3Yi90YWJsZTo2OWZmZDhlNmNkMDM0OGMzODUwY2JhMmI1OWFiZTJlMi90YWJsZXJhbmdlOjY5ZmZkOGU2Y2QwMzQ4YzM4NTBjYmEyYjU5YWJlMmUyXzItMi0xLTEtNTk0NzA_f7d9fb69-687c-437c-a30b-177c809e6c82"
      unitRef="usd">-19000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8021c14b857946c188b6f072829b7db7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDMvZnJhZzo1ZjdmMWNjODZlNDU0M2I0YTg1ZDI5MGNhMTBmZjU3Yi90YWJsZTo2OWZmZDhlNmNkMDM0OGMzODUwY2JhMmI1OWFiZTJlMi90YWJsZXJhbmdlOjY5ZmZkOGU2Y2QwMzQ4YzM4NTBjYmEyYjU5YWJlMmUyXzItNC0xLTEtNTk0NzA_f110b92d-8a1b-4f8b-a106-6d79175493d9"
      unitRef="usd">-56000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie17ca1996294497e9f031629ce871dae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDMvZnJhZzo1ZjdmMWNjODZlNDU0M2I0YTg1ZDI5MGNhMTBmZjU3Yi90YWJsZTo2OWZmZDhlNmNkMDM0OGMzODUwY2JhMmI1OWFiZTJlMi90YWJsZXJhbmdlOjY5ZmZkOGU2Y2QwMzQ4YzM4NTBjYmEyYjU5YWJlMmUyXzMtMi0xLTEtNTk0NzA_377b597b-ef1c-425d-80d3-d9daa682ff25"
      unitRef="usd">-1924000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i23e7ea6c4d584b7881937aede46315ca_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDMvZnJhZzo1ZjdmMWNjODZlNDU0M2I0YTg1ZDI5MGNhMTBmZjU3Yi90YWJsZTo2OWZmZDhlNmNkMDM0OGMzODUwY2JhMmI1OWFiZTJlMi90YWJsZXJhbmdlOjY5ZmZkOGU2Y2QwMzQ4YzM4NTBjYmEyYjU5YWJlMmUyXzMtNC0xLTEtNTk0NzA_1cfe471f-e716-4eed-9b86-62b4d83ff81d"
      unitRef="usd">-2133000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDYvZnJhZzoyZjlmYzZkNGY3Y2M0ZWQxODJkODk5ZjQ2ZGNlYmI3MS90ZXh0cmVnaW9uOjJmOWZjNmQ0ZjdjYzRlZDE4MmQ4OTlmNDZkY2ViYjcxXzI5MA_003eadb5-17e6-42a7-8177-15e85912ad21">RESEARCH AND DEVELOPMENT&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. Research and development costs for the years 2021, 2020 and 2019 consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product related research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quality assurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDYvZnJhZzoyZjlmYzZkNGY3Y2M0ZWQxODJkODk5ZjQ2ZGNlYmI3MS90ZXh0cmVnaW9uOjJmOWZjNmQ0ZjdjYzRlZDE4MmQ4OTlmNDZkY2ViYjcxXzI4Nw_3599e595-8351-4f2b-98e8-2c884c992560">Research and development costs for the years 2021, 2020 and 2019 consists of:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product related research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quality assurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDYvZnJhZzoyZjlmYzZkNGY3Y2M0ZWQxODJkODk5ZjQ2ZGNlYmI3MS90YWJsZTphNmY1ZThiOWJmZTU0OTNiOTI1MTAzMmI5N2YyODFkZS90YWJsZXJhbmdlOmE2ZjVlOGI5YmZlNTQ5M2I5MjUxMDMyYjk3ZjI4MWRlXzEtMi0xLTEtNTk0NzA_dff8e2d0-e12b-4a8c-9b28-50660ffce754"
      unitRef="usd">440000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDYvZnJhZzoyZjlmYzZkNGY3Y2M0ZWQxODJkODk5ZjQ2ZGNlYmI3MS90YWJsZTphNmY1ZThiOWJmZTU0OTNiOTI1MTAzMmI5N2YyODFkZS90YWJsZXJhbmdlOmE2ZjVlOGI5YmZlNTQ5M2I5MjUxMDMyYjk3ZjI4MWRlXzEtNC0xLTEtNTk0NzA_ebf046d6-4a8d-47f2-8257-94e3e5563bfa"
      unitRef="usd">420000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDYvZnJhZzoyZjlmYzZkNGY3Y2M0ZWQxODJkODk5ZjQ2ZGNlYmI3MS90YWJsZTphNmY1ZThiOWJmZTU0OTNiOTI1MTAzMmI5N2YyODFkZS90YWJsZXJhbmdlOmE2ZjVlOGI5YmZlNTQ5M2I5MjUxMDMyYjk3ZjI4MWRlXzEtNi0xLTEtNTk0NzA_c3c6f654-f588-4475-bc61-ca3dc9f48ad2"
      unitRef="usd">434000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDYvZnJhZzoyZjlmYzZkNGY3Y2M0ZWQxODJkODk5ZjQ2ZGNlYmI3MS90YWJsZTphNmY1ZThiOWJmZTU0OTNiOTI1MTAzMmI5N2YyODFkZS90YWJsZXJhbmdlOmE2ZjVlOGI5YmZlNTQ5M2I5MjUxMDMyYjk3ZjI4MWRlXzItMi0xLTEtNTk0NzA_c9c5a536-2aa4-4e2d-8b3f-b8ddd4f7e846"
      unitRef="usd">25000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDYvZnJhZzoyZjlmYzZkNGY3Y2M0ZWQxODJkODk5ZjQ2ZGNlYmI3MS90YWJsZTphNmY1ZThiOWJmZTU0OTNiOTI1MTAzMmI5N2YyODFkZS90YWJsZXJhbmdlOmE2ZjVlOGI5YmZlNTQ5M2I5MjUxMDMyYjk3ZjI4MWRlXzItNC0xLTEtNTk0NzA_0601dd1e-56a4-498f-b554-0554de01f39d"
      unitRef="usd">32000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDYvZnJhZzoyZjlmYzZkNGY3Y2M0ZWQxODJkODk5ZjQ2ZGNlYmI3MS90YWJsZTphNmY1ZThiOWJmZTU0OTNiOTI1MTAzMmI5N2YyODFkZS90YWJsZXJhbmdlOmE2ZjVlOGI5YmZlNTQ5M2I5MjUxMDMyYjk3ZjI4MWRlXzItNi0xLTEtNTk0NzA_cb603f3c-b64d-4fdf-b4b8-7f6914686fb3"
      unitRef="usd">37000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDYvZnJhZzoyZjlmYzZkNGY3Y2M0ZWQxODJkODk5ZjQ2ZGNlYmI3MS90YWJsZTphNmY1ZThiOWJmZTU0OTNiOTI1MTAzMmI5N2YyODFkZS90YWJsZXJhbmdlOmE2ZjVlOGI5YmZlNTQ5M2I5MjUxMDMyYjk3ZjI4MWRlXzMtMi0xLTEtNTk0NzA_d744fde8-474b-41cf-97ac-13404895538a"
      unitRef="usd">465000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDYvZnJhZzoyZjlmYzZkNGY3Y2M0ZWQxODJkODk5ZjQ2ZGNlYmI3MS90YWJsZTphNmY1ZThiOWJmZTU0OTNiOTI1MTAzMmI5N2YyODFkZS90YWJsZXJhbmdlOmE2ZjVlOGI5YmZlNTQ5M2I5MjUxMDMyYjk3ZjI4MWRlXzMtNC0xLTEtNTk0NzA_abc363a7-78a4-4a99-8405-723ae66cc2c6"
      unitRef="usd">452000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDYvZnJhZzoyZjlmYzZkNGY3Y2M0ZWQxODJkODk5ZjQ2ZGNlYmI3MS90YWJsZTphNmY1ZThiOWJmZTU0OTNiOTI1MTAzMmI5N2YyODFkZS90YWJsZXJhbmdlOmE2ZjVlOGI5YmZlNTQ5M2I5MjUxMDMyYjk3ZjI4MWRlXzMtNi0xLTEtNTk0NzA_de72e617-104b-4378-b78c-44a76699000e"
      unitRef="usd">471000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90ZXh0cmVnaW9uOjcyOTNiYmU0MmQ1YjQxYWY4MTM1OWM3MTBhMzAwYzExXzk1NQ_4650e9dc-db5e-4db8-8797-d54014f8f717">OTHER EXPENSE, NET&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense, net for the years 2021, 2020 and 2019 consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation and other matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gain on sales of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, Litigation and other matters of $356 million includes adjustments related to the Glumetza Antitrust Litigation, partially offset by insurance recoveries related to certain litigation matters. In 2020, Litigation and other matters of $422 million includes net charges related to the U.S. Securities Litigation, the SEC Investigation and the Canadian Securities Litigation and related opt-outs. In 2020, Litigation and other matters also includes an insurance recovery related to a certain litigation matter. In 2019, Litigation and other matters of $1,401 million includes the settlement of a legacy U.S. securities class action matter. Certain of these matters and other significant matters are discussed in further detail in Note 20, "LEGAL PROCEEDINGS".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020 and 2019, Acquired in-process research and development costs of $32&#160;million and $41&#160;million, primarily consist of costs associated with the upfront payments to enter into certain exclusive licensing agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, Net gain on sales of assets includes $20 million related to the achievement of a milestone related to a certain product.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90ZXh0cmVnaW9uOjcyOTNiYmU0MmQ1YjQxYWY4MTM1OWM3MTBhMzAwYzExXzk2Mg_5542e06d-184b-4ace-b9d0-9385eb8dada5">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense, net for the years 2021, 2020 and 2019 consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation and other matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gain on sales of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzItMi0xLTEtNTk0NzA_fe588a03-d783-477d-b830-10120eac55d1"
      unitRef="usd">-356000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzItNC0xLTEtNTk0NzA_d3bb4188-8db4-48eb-ac80-504f017bc9c8"
      unitRef="usd">-422000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzItNi0xLTEtNTk0NzA_be5df51e-47d9-436b-8130-2b3ea42fb0b5"
      unitRef="usd">-1401000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzMtMi0xLTEtNTk0NzA_d1f17bec-a21f-460e-afeb-c6d8c1e7859f"
      unitRef="usd">8000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzMtNC0xLTEtNTk0NzA_40b38790-f983-4945-b9d6-df144c250904"
      unitRef="usd">32000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzMtNi0xLTEtNTk0NzA_f82fbfa8-5bc7-4db4-8610-4ec2efcceed0"
      unitRef="usd">41000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzQtMi0xLTEtNTk0NzA_87399a69-21d8-4ea0-99fa-275b494e6469"
      unitRef="usd">2000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzQtNC0xLTEtNTk0NzA_b00d616a-10c7-43b2-8cd5-bea1a02827ab"
      unitRef="usd">1000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzQtNi0xLTEtNTk0NzA_de78cb07-9314-4982-bb9e-1ad061eff965"
      unitRef="usd">31000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzUtMi0xLTEtNTk0NzA_97727077-5a0a-47a8-94ca-5170488f5a22"
      unitRef="usd">11000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzUtNC0xLTEtNTk0NzA_354931ea-e151-42ec-a238-02fb2a855a5a"
      unitRef="usd">48000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzUtNi0xLTEtNTk0NzA_d326c946-b01f-44b9-8a12-ac446d5a1cb3"
      unitRef="usd">20000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <bhc:OtherIncomeExpenseNet
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzYtMi0xLTEtNTk0NzA_a7d97e76-f097-4e83-b0fe-44926337523a"
      unitRef="usd">0</bhc:OtherIncomeExpenseNet>
    <bhc:OtherIncomeExpenseNet
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzYtNC0xLTEtNTk0NzA_38fc8bea-a926-47b1-a2f3-200959cf30f2"
      unitRef="usd">1000000</bhc:OtherIncomeExpenseNet>
    <bhc:OtherIncomeExpenseNet
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzYtNi0xLTEtNTk0NzA_0d226995-8da8-49d1-b1c4-701e8dd53775"
      unitRef="usd">-5000000</bhc:OtherIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzctMi0xLTEtNTk0NzA_3fdd49d4-a59d-4f49-9793-228453451735"
      unitRef="usd">-373000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzctNC0xLTEtNTk0NzA_3c8d6919-2fef-44c6-9b96-f38795f80e99"
      unitRef="usd">-502000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90YWJsZTo4YTYxMmQxZjMxZTc0MjAwYmE1OTlhYzlhZDgxYmM1My90YWJsZXJhbmdlOjhhNjEyZDFmMzFlNzQyMDBiYTU5OWFjOWFkODFiYzUzXzctNi0xLTEtNTk0NzA_473ff85e-d306-46a0-baf2-9b94cb474528"
      unitRef="usd">-1426000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90ZXh0cmVnaW9uOjcyOTNiYmU0MmQ1YjQxYWY4MTM1OWM3MTBhMzAwYzExXzM4NDgyOTA2OTkyODQ_fe588a03-d783-477d-b830-10120eac55d1"
      unitRef="usd">-356000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90ZXh0cmVnaW9uOjcyOTNiYmU0MmQ1YjQxYWY4MTM1OWM3MTBhMzAwYzExXzM4NDgyOTA2OTkxNzA_d3bb4188-8db4-48eb-ac80-504f017bc9c8"
      unitRef="usd">-422000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90ZXh0cmVnaW9uOjcyOTNiYmU0MmQ1YjQxYWY4MTM1OWM3MTBhMzAwYzExXzM4NDgyOTA2OTkxOTA_be5df51e-47d9-436b-8130-2b3ea42fb0b5"
      unitRef="usd">-1401000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90ZXh0cmVnaW9uOjcyOTNiYmU0MmQ1YjQxYWY4MTM1OWM3MTBhMzAwYzExXzM4NDgyOTA2OTg2MTQ_40b38790-f983-4945-b9d6-df144c250904"
      unitRef="usd">32000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90ZXh0cmVnaW9uOjcyOTNiYmU0MmQ1YjQxYWY4MTM1OWM3MTBhMzAwYzExXzM4NDgyOTA2OTg2MTg_f82fbfa8-5bc7-4db4-8610-4ec2efcceed0"
      unitRef="usd">41000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i22332303e4634782bd879afa7c52f3f7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNDkvZnJhZzo3MjkzYmJlNDJkNWI0MWFmODEzNTljNzEwYTMwMGMxMS90ZXh0cmVnaW9uOjcyOTNiYmU0MmQ1YjQxYWY4MTM1OWM3MTBhMzAwYzExXzg4Mg_552b069b-8ae3-48ae-80ae-8476294522d5"
      unitRef="usd">20000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzEyMzEx_8292eb29-9666-4934-9569-6ffe55d5122c">INCOME TAXES &lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of Loss before benefit from income taxes for 2021, 2020 and 2019 consist of:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(701)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(524)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of Benefit from income taxes for 2021, 2020 and 2019 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Benefit from income taxes differs from the expected amount calculated by applying the Company&#x2019;s Canadian statutory rate of 26.9% to Loss before benefit from income taxes for 2021, 2020 and 2019 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss before benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected benefit from income taxes at Canadian statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible amount of share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to tax attributes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance related to foreign tax credits and NOLs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance on Canadian deferred tax assets and tax rate changes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax rate differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible portion of Goodwill impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit on intra-entity transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities as of December 31, 2021 and 2020 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Scientific Research and Experimental Development pool&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plant, equipment and technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside basis differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized FX on U.S. dollar debt and other financing cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of the deferred tax asset valuation allowance for 2021, 2020 and 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to Benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to other accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s U.S. interest expense is subject to limitation rules which limit U.S. interest expense to 30% of adjusted taxable income, defined similar to EBITDA through 2021 and EBIT thereafter.  Disallowed interest can be carried forward indefinitely and any unused interest deduction assessed for recoverability. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#x201c;CARES Act&#x201d;) was signed into law.  The CARES Act also amended the annual limitation on the deduction of interest in the following respects: (i) increasing the limitation to 50% of adjusted taxable income (&#x201c;ATI&#x201d;), (ii) providing a rule for a partnership&#x2019;s 2019 section 163(j)-disallowed interest expense and (iii) allowing an election to apply 2019 ATI to the 2020 section 163(j) computation.  For corporations, the increase to 50% of ATI applies to all taxable years beginning in 2019 or 2020 and permits taxpayers whose 2020 income will decrease from its 2019 level, an election to apply their 2019 ATI, rather than their 2020 ATI, to their 2020 computation. The Company considered such provisions and expects to fully utilize any interest carry forwards in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has provided for income taxes in accordance with guidance issued by accounting regulatory bodies, the U.S. Internal Revenue Service and state and local governments through the date of the issuance of these Consolidated Financial Statements. Additional guidance and interpretations can be expected and such guidance, if any, could impact future results.  While management continues to monitor these matters, the ultimate impact, if any, as a result of the application of any guidance issued in the future cannot be determined at this time.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The realization of deferred tax assets is dependent on the Company generating sufficient domestic and foreign taxable income in the years that the temporary differences become deductible. A valuation allowance has been provided for the portion of the deferred tax assets that the Company determined is more likely than not to remain unrealized based on estimated future taxable income and tax planning strategies.  In 2021, the valuation allowance decreased by $30 million primarily due to book taxable income in Canada, the change in deferred tax assets in Canada and the use of deferred tax assets in the U.S. in connection with internal restructurings. In 2020, the valuation allowance decreased by $579 million as a result of taxable losses in Canada as offset by a reduction of deferred tax assets due to internal restructurings. Given the Company&#x2019;s history of pre-tax losses and expected future losses in Canada, the Company maintained that there was insufficient objective evidence to release the valuation allowance against Canadian tax loss carryforwards, International Tax Credits (&#x201c;ITC&#x201d;) and pooled Scientific Research and Experimental Development Tax Incentive (&#x201c;SR&amp;amp;ED&#x201d;) expenditures.  The Canadian valuation allowance represents a material portion of the Company's total valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021 and 2020, the Company had accumulated taxable losses available to offset future years&#x2019; federal and provincial taxable income in Canada of approximately $6,669 million and $6,530 million, respectively.&#160; As of December 31, 2021 and 2020, unclaimed ITCs available to offset future federal taxes in Canada were approximately $31 million and $37 million, respectively, which expire in the years 2022 through 2041.&#160; In addition, as of December 31, 2021 and 2020, pooled SR&amp;amp;ED expenditures available to offset against future taxable income in Canada were approximately $196 million and $206 million, respectively, which may be carried forward indefinitely.  As of December 31, 2021 and 2020, a full valuation allowance against the net Canadian deferred tax assets on the parent company has been provided of $1,965 million and $1,966 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021 and 2020, the Company had accumulated taxable losses available to offset future years' federal taxable income in the U.S. of approximately $266 million and $814 million, respectively, including acquired losses which expire in the years 2022 through 2037. While the remaining taxable losses are subject to multiple annual loss limitations as a result of previous ownership changes, the Company believes that the recoverability of the deferred tax assets associated with these taxable losses are more likely than not to be realized. As of December 31, 2021 and 2020 U.S. research and development credits available to offset future years' federal income taxes in the U.S. were approximately $119 million and $110 million, respectively, which includes acquired research and development credits and which expire in the years 2022 through 2042.  In the U.S. the Company has a capital loss of which is offset by a full valuation allowance since the benefit is not expected to be realized.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021 and 2020, the Company had accumulated taxable losses available to offset future years&#x2019; taxable income in Ireland of approximately $10,040 million and $8,387 million, respectively.&#160; As of  December&#160;31, 2021, the Company continues to have a capital loss which is offset by a valuation allowance on the portion of the loss for which a benefit is not expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for income taxes on the unremitted earnings of its direct foreign affiliates except for its direct U.S. subsidiaries.  The Company continues to assert that the unremitted earnings of its U.S.&#160;subsidiaries will be permanently reinvested and not repatriated.  As of December 31, 2021, the Company estimates that there will be no tax liability attributable to unremitted earnings of its U.S. subsidiaries. However, distribution of future earnings could be subject to U.S. withholding tax.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021 and 2020, unrecognized tax benefits (including interest and penalties) were $927 million and $1,025 million, of which $271 million and $414 million would affect the effective income tax rate, respectively. In 2021 and 2020, the remaining unrecognized tax benefits would not impact the effective tax rate as the tax positions are offset against existing tax attributes or are timing in nature. In 2021 and 2020, the Company recognized net increases to unrecognized tax benefits for current year tax positions of $79 million and $66 million, respectively.  The Company recognized a net reduction of $177 million during 2021 and a net reduction of $42 million during 2020 in the unrecognized tax benefits related to tax positions taken in the prior years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for interest and penalties related to unrecognized tax benefits in the provision for income taxes. As of December 31, 2021 and 2020, accrued interest and penalties related to unrecognized tax benefits were approximately $41 million and $49 million, respectively. In 2021, the Company recognized a net decrease of approximately $8 million and, in 2020, recognized an increase of  $4 million of interest and&#160;penalties, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and one or more of its subsidiaries file federal income tax returns in Canada, the U.S., and other foreign jurisdictions, as well as various provinces and states in Canada and the U.S.&#160;The Company and its subsidiaries have open tax years, primarily from 2012 to 2020, with significant taxing jurisdictions, respectively, including Canada and the U.S.&#160;These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and regulations and tax treaties, as they relate to the amount, timing, or inclusion of revenues and expenses, or the sustainability of income tax positions of the Company and its subsidiaries. Certain of these tax years are expected to remain open indefinitely.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.931%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jurisdiction:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Open Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States - Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2015 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2012 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2013 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2016 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2016 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Netherlands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2011 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Luxembourg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Internal Revenue Service (the "IRS") completed its examinations of the Company&#x2019;s U.S. consolidated federal income tax returns for the years 2013 and 2014. There were no material adjustments to the Company's taxable income as a result of these examinations.  However, the 2014 tax year remains open to the extent of a 2017 capital loss carried back to that year. Additionally, the IRS has selected for examination the Company's annual tax filings for 2015 and 2016 and the Company's short period tax return for the period ended September 8, 2017, which was filed as a result of the Company's internal restructuring efforts during 2017. In 2017, the Company undertook an internal restructuring in the form of what is commonly known as a Granite Trust transaction, which resulted in a recorded capital loss (the &#x201c;2017 Capital Loss&#x201d;). Recently, the Company has received a notice of proposed adjustment from the IRS that would disallow the 2017 Capital Loss and expects to receive a notice of proposed tax deficiency from the IRS, after which the Company intends to contest proposed tax deficiency through the IRS administrative appeals process. If the Company were ultimately unsuccessful in defending its position, and all or a substantial portion of the 2017 Capital Loss deduction were disallowed, the Company could be liable for additional taxes (excluding penalties and interest) of up to $2,100&#160;million, which could have an adverse effect on the Company&#x2019;s financial condition and results of operations. The Company intends to vigorously defend its position, including through appropriate litigation, if necessary, and ultimately believes it will sustain its deduction of the 2017 Capital Loss, and, accordingly, no income tax provision has been recorded.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is currently under examination by the Canada Revenue Agency (&#x201c;CRA&#x201d;) for three separate cycles: (a) years 2012 through 2013 (b) years 2014 through 2015, and (c) years 2016 through 2017.  The Company believes that the CRA will open an audit cycle for the years 2018 &#x2013; 2019 in 2022.  The Company settled the tax years from 2005 through 2009 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with the CRA. The Company had previously filed a Notice of Objection related to the assessment of these years and reduced net operating losses with a full valuation allowance by CAD 44&#160;million to close these years.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The adjustment did not result in a material change to the provision for income taxes.  The CRA audits of the 2010 and 2011 tax years were closed in 2016 and resulted in no material adjustments. The Company received an assessment for certain transfer pricing matters in 2012 and 2013 for CAD 85&#160;million and CAD 90&#160;million, respectively.  The Company disagrees with the adjustments and has filed a Notice of Objection for 2012 and 2013.  The Company settled certain transfer pricing matters relating the 2015 and 2016 tax years resulting in a reduction to its NOLs of approximately CAD 21&#160;million for 2015 and will receive a further adjustment for 2016.  The expected adjustment for 2016 will reduce NOLs currently offset by a full valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s subsidiaries in Germany are under audit for tax years 2014 through 2016.  At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s subsidiaries in Australia are under audit by the Australian Tax Office for various years beginning in 2010. On August 8, 2017, the Australian Taxation Office issued a notice of assessment for the tax years 2011 through 2017 in the aggregate amount of $117 million, which includes penalties and interest.  The Company disagrees with the assessment and continues to believe that its tax positions are appropriate and supported by the facts, circumstances and applicable laws. The Company intends to defend its tax position in this matter vigorously and has filed a holding objection against the assessment by the Australian Taxation Office and has secured a bank guarantee to cover any potential cash outlays regarding this assessment. The bank guarantee has been reduced over time to now be an immaterial value.  Negotiations with the Australian Tax Office are ongoing and the Company expects to enter into a Settlement Deed in early 2022 with no material adverse results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain affiliates of the Company in regions outside of Canada, the U.S., Germany, Luxembourg and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits.  At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of the unrecognized tax&#160;benefits for 2021, 2020 and 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes it is reasonably possible that the total amount of unrecognized tax benefits at December 31, 2021 could decrease by approximately $104 million in the next twelve months as a result of the resolution of certain tax and transfer pricing audits and other events.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzEyMjk0_ae8903e3-885d-4eb7-997e-49b0762440dc">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of Loss before benefit from income taxes for 2021, 2020 and 2019 consist of:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(701)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(524)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo2NTE1YWY2ZjEyYWI0ZGJjYThlZmMxNWExYmI1NTc5My90YWJsZXJhbmdlOjY1MTVhZjZmMTJhYjRkYmNhOGVmYzE1YTFiYjU1NzkzXzEtMi0xLTEtNTk0NzA_8d1bfeb6-de8b-4f46-b998-a8f2e0711035"
      unitRef="usd">-323000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo2NTE1YWY2ZjEyYWI0ZGJjYThlZmMxNWExYmI1NTc5My90YWJsZXJhbmdlOjY1MTVhZjZmMTJhYjRkYmNhOGVmYzE1YTFiYjU1NzkzXzEtNC0xLTEtNTk0NzA_ee335d13-cb2b-4689-823e-cc0ddf39aa5e"
      unitRef="usd">-410000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo2NTE1YWY2ZjEyYWI0ZGJjYThlZmMxNWExYmI1NTc5My90YWJsZXJhbmdlOjY1MTVhZjZmMTJhYjRkYmNhOGVmYzE1YTFiYjU1NzkzXzEtNi0xLTEtNTk0NzA_f3bf2d8d-fcb5-4d19-90ed-f8db85faf57c"
      unitRef="usd">-2396000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo2NTE1YWY2ZjEyYWI0ZGJjYThlZmMxNWExYmI1NTc5My90YWJsZXJhbmdlOjY1MTVhZjZmMTJhYjRkYmNhOGVmYzE1YTFiYjU1NzkzXzItMi0xLTEtNTk0NzA_349021ea-c7ff-4163-aa83-469165f36279"
      unitRef="usd">-701000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo2NTE1YWY2ZjEyYWI0ZGJjYThlZmMxNWExYmI1NTc5My90YWJsZXJhbmdlOjY1MTVhZjZmMTJhYjRkYmNhOGVmYzE1YTFiYjU1NzkzXzItNC0xLTEtNTk0NzA_1e2b83d2-61e4-4b79-8d9a-1ea49a025171"
      unitRef="usd">-524000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo2NTE1YWY2ZjEyYWI0ZGJjYThlZmMxNWExYmI1NTc5My90YWJsZXJhbmdlOjY1MTVhZjZmMTJhYjRkYmNhOGVmYzE1YTFiYjU1NzkzXzItNi0xLTEtNTk0NzA_cd54d733-cbf9-405d-b9c7-14324d49939a"
      unitRef="usd">559000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo2NTE1YWY2ZjEyYWI0ZGJjYThlZmMxNWExYmI1NTc5My90YWJsZXJhbmdlOjY1MTVhZjZmMTJhYjRkYmNhOGVmYzE1YTFiYjU1NzkzXzMtMi0xLTEtNTk0NzA_33f4aa68-61e4-4ce6-9a8e-8333953f0c00"
      unitRef="usd">-1024000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo2NTE1YWY2ZjEyYWI0ZGJjYThlZmMxNWExYmI1NTc5My90YWJsZXJhbmdlOjY1MTVhZjZmMTJhYjRkYmNhOGVmYzE1YTFiYjU1NzkzXzMtNC0xLTEtNTk0NzA_663422ba-edd5-48c0-aad2-23df9f542638"
      unitRef="usd">-934000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo2NTE1YWY2ZjEyYWI0ZGJjYThlZmMxNWExYmI1NTc5My90YWJsZXJhbmdlOjY1MTVhZjZmMTJhYjRkYmNhOGVmYzE1YTFiYjU1NzkzXzMtNi0xLTEtNTk0NzA_01c2ed5a-2e34-4d83-b175-57ef91469c3c"
      unitRef="usd">-1837000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzEyMzE3_4efc0c67-360c-45e3-8ee1-90e99d06f5c0">&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of Benefit from income taxes for 2021, 2020 and 2019 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzItMi0xLTEtNTk0NzA_f7e1f49d-cd31-4cee-8479-3cef2116c87b"
      unitRef="usd">23000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzItNC0xLTEtNTk0NzA_b9675682-5efd-47bd-ac4d-a4588db096b6"
      unitRef="usd">8000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzItNi0xLTEtNTk0NzA_919f6c3c-9ba8-4d8e-844a-3335f75256c6"
      unitRef="usd">12000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzMtMi0xLTEtNTk0NzA_0d4db9fe-d603-4d2e-b51e-3a6195112d28"
      unitRef="usd">-74000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzMtNC0xLTEtNTk0NzA_fa655627-9c6f-472b-b535-2ca5889d87a8"
      unitRef="usd">216000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzMtNi0xLTEtNTk0NzA_8298bf5c-4aff-4521-a84f-8e97c2dcb4c8"
      unitRef="usd">116000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzQtMi0xLTEtNTk0NzA_9708a48d-0457-41fa-9f90-d40bfd8052b0"
      unitRef="usd">-51000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzQtNC0xLTEtNTk0NzA_20d00a19-39e0-4575-92e0-80c625ae5ae3"
      unitRef="usd">224000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzQtNi0xLTEtNTk0NzA_5b7a7b57-c9be-4764-b485-89bf8951d24a"
      unitRef="usd">128000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzYtMi0xLTEtNTk0NzA_7bb7e271-4729-4b8a-96f3-bf303ccf64fa"
      unitRef="usd">-20000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzYtNC0xLTEtNTk0NzA_8bdbe3b0-5797-406c-9f0c-ecf4b62e765a"
      unitRef="usd">-9000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzYtNi0xLTEtNTk0NzA_e3abc846-5b97-4d30-8fde-72c00e2f4bf9"
      unitRef="usd">5000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzctMi0xLTEtNTk0NzA_2c97dc51-2ddf-474d-8e94-c54a5865bd92"
      unitRef="usd">-16000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzctNC0xLTEtNTk0NzA_44daefa0-d4e6-4276-bec8-adb197d43901"
      unitRef="usd">-590000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzctNi0xLTEtNTk0NzA_7b463fd6-50ca-4258-8f97-3f0fd89bdfe1"
      unitRef="usd">-187000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzgtMi0xLTEtNTk0NzA_ab033b33-be88-4e79-aeac-2c23a833ba27"
      unitRef="usd">-36000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzgtNC0xLTEtNTk0NzA_15e8ab82-37e7-4969-aaa8-931881c2b582"
      unitRef="usd">-599000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzgtNi0xLTEtNTk0NzA_fb8b3c47-f1bf-4d77-9294-809b31271205"
      unitRef="usd">-182000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzktMi0xLTEtNTk0NzA_d29af376-c5c1-46dc-841c-1fa2270d6588"
      unitRef="usd">-87000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzktNC0xLTEtNTk0NzA_3b24db5f-2d16-4e03-aa33-6ab60796d3ec"
      unitRef="usd">-375000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5OWRhYzdiMTk0YWY0NGYyYTVhM2NjMmQ0MzRjMTljYy90YWJsZXJhbmdlOjk5ZGFjN2IxOTRhZjQ0ZjJhNWEzY2MyZDQzNGMxOWNjXzktNi0xLTEtNTk0NzA_cdfcd15a-f430-4ccb-b990-b60c482c7d49"
      unitRef="usd">-54000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzEyMzEw_f3df00b1-d85b-42c5-8af8-949d91466bcd">&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Benefit from income taxes differs from the expected amount calculated by applying the Company&#x2019;s Canadian statutory rate of 26.9% to Loss before benefit from income taxes for 2021, 2020 and 2019 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss before benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected benefit from income taxes at Canadian statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible amount of share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to tax attributes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance related to foreign tax credits and NOLs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance on Canadian deferred tax assets and tax rate changes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax rate differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible portion of Goodwill impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit on intra-entity transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzIyMg_27d3c9e6-9e3d-4257-8542-1530347d710b"
      unitRef="number">0.269</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzIyMg_ca93964e-e504-4a8d-b0b7-46b2775cf635"
      unitRef="number">0.269</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzIyMg_d0006cc3-3efd-47f7-9c05-d5ead59654e8"
      unitRef="number">0.269</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEtMi0xLTEtNTk0NzA_7c303806-ec3a-4cf3-a210-73af4861c263"
      unitRef="usd">-1024000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEtNC0xLTEtNTk0NzA_514cbe72-345b-4d56-8613-6ccf5d5ae020"
      unitRef="usd">-934000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEtNi0xLTEtNTk0NzA_94b01e0e-2028-4b06-beda-657c61adf349"
      unitRef="usd">-1837000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzMtMi0xLTEtNTk0NzA_65c4fbcb-e697-4a80-9388-ac50951e26dd"
      unitRef="usd">-275000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzMtNC0xLTEtNTk0NzA_4a57e50b-fae2-4ad5-9b12-3e03b2cf5221"
      unitRef="usd">-251000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzMtNi0xLTEtNTk0NzA_58061cf1-8a21-40db-8104-b03fe321bd0e"
      unitRef="usd">-494000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzQtMi0xLTEtNTk0NzA_f72d594f-6da1-4edd-a6da-36b3486c5f86"
      unitRef="usd">9000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzQtNC0xLTEtNTk0NzA_02856983-15b3-44a4-a41e-08c565464e07"
      unitRef="usd">9000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzQtNi0xLTEtNTk0NzA_1cf72019-a756-48ff-8a83-07847082f794"
      unitRef="usd">7000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzUtMi0xLTEtNTk0NzA_f0d6604b-256a-42b8-80cb-5269c7cef4e0"
      unitRef="usd">59000000</bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount>
    <bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzUtNC0xLTEtNTk0NzA_6385e682-12e6-4159-a64a-9208cf3cb49d"
      unitRef="usd">-26000000</bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount>
    <bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzUtNi0xLTEtNTk0NzA_25c83d49-abde-42ba-9f2a-fb49e8a05900"
      unitRef="usd">99000000</bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount>
    <bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzYtMi0xLTEtNTk0NzA_141a8cd9-c03c-4308-9ba3-df06a47d1cef"
      unitRef="usd">-28000000</bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance>
    <bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzYtNC0xLTEtNTk0NzA_1a14a885-4af7-45aa-aefe-8182657e33de"
      unitRef="usd">-62000000</bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance>
    <bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzYtNi0xLTEtNTk0NzA_dbf628e8-cbbe-4040-885e-c3371747e34b"
      unitRef="usd">-21000000</bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzctMi0xLTEtNTk0NzA_e498b6f0-9cbd-4e62-91bc-1bec773283c0"
      unitRef="usd">-40000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzctNC0xLTEtNTk0NzA_33919c6d-82ee-4f90-b610-3a6d5d0ab5d8"
      unitRef="usd">-687000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzctNi0xLTEtNTk0NzA_800dca0d-0367-4602-b692-1d48738c75e4"
      unitRef="usd">142000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <bhc:IncomeTaxReconciliationUncertainTaxPositions
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzgtMi0xLTEtNTk0NzA_c895c9a8-348d-4563-8f01-f849c0ce01ef"
      unitRef="usd">-112000000</bhc:IncomeTaxReconciliationUncertainTaxPositions>
    <bhc:IncomeTaxReconciliationUncertainTaxPositions
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzgtNC0xLTEtNTk0NzA_7bf7c1c0-76f4-4357-9182-fcba8e588d2f"
      unitRef="usd">163000000</bhc:IncomeTaxReconciliationUncertainTaxPositions>
    <bhc:IncomeTaxReconciliationUncertainTaxPositions
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzgtNi0xLTEtNTk0NzA_aad3572c-0aed-4796-8ec8-4b168fb70ba1"
      unitRef="usd">350000000</bhc:IncomeTaxReconciliationUncertainTaxPositions>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzktMi0xLTEtNTk0NzA_685a9e89-ea6c-4a4c-85bc-300cee0a39d0"
      unitRef="usd">198000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzktNC0xLTEtNTk0NzA_f1dad0f3-9f2f-4b5b-80a2-ae20acbb9f26"
      unitRef="usd">128000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzktNi0xLTEtNTk0NzA_09e87b73-22b0-43ad-8f97-4a7af232f16d"
      unitRef="usd">-186000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEwLTItMS0xLTU5NDcw_948ecafa-432e-4f83-bfb8-c9ca583a2067"
      unitRef="usd">99000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEwLTQtMS0xLTU5NDcw_a1a7ef7f-6c83-4fa9-9f1c-a13099db3721"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEwLTYtMS0xLTU5NDcw_91c3759c-6f20-44da-9fd7-c9c02cd75667"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <bhc:IncomeTaxReconciliationDeferredIntercompanyProfit
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzExLTItMS0xLTU5NDcw_3971dc9e-b4fd-42cb-be0a-25aa90835b9a"
      unitRef="usd">0</bhc:IncomeTaxReconciliationDeferredIntercompanyProfit>
    <bhc:IncomeTaxReconciliationDeferredIntercompanyProfit
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzExLTQtMS0xLTU5NDcw_9137c02b-c7e3-4063-a082-83dc1e85aa28"
      unitRef="usd">338000000</bhc:IncomeTaxReconciliationDeferredIntercompanyProfit>
    <bhc:IncomeTaxReconciliationDeferredIntercompanyProfit
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzExLTYtMS0xLTU5NDcw_1c706f26-fde7-4f45-9315-5e835733aa8f"
      unitRef="usd">0</bhc:IncomeTaxReconciliationDeferredIntercompanyProfit>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEyLTItMS0xLTU5NDcw_8bb7464b-4f01-474e-bb77-5fc814023558"
      unitRef="usd">3000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEyLTQtMS0xLTU5NDcw_08e9a27f-61c5-4ae5-8999-c2919463a76b"
      unitRef="usd">13000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEyLTYtMS0xLTU5NDcw_7e2f12cc-e6c5-4230-8c16-c9425621ad1a"
      unitRef="usd">49000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEzLTItMS0xLTU5NDcw_517eb76d-6fc9-43fc-90b7-15c50bf40ead"
      unitRef="usd">-87000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEzLTQtMS0xLTU5NDcw_a04559e3-86bf-4543-b8c5-331e079998ec"
      unitRef="usd">-375000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5YjQ0MTAxYWFlMzk0MDFiOTRhYzgzNzNiZjE1ZGU1YS90YWJsZXJhbmdlOjliNDQxMDFhYWUzOTQwMWI5NGFjODM3M2JmMTVkZTVhXzEzLTYtMS0xLTU5NDcw_1067f5b3-d030-4745-99c3-7addd7ca4241"
      unitRef="usd">-54000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzEyMjg5_717777b4-e5ef-44b5-947f-76214d4a31d1">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities as of December 31, 2021 and 2020 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Scientific Research and Experimental Development pool&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plant, equipment and technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside basis differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized FX on U.S. dollar debt and other financing cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of the deferred tax asset valuation allowance for 2021, 2020 and 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to Benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to other accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <bhc:DeferredTaxAssetsTaxLossCarryforwards
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzItMi0xLTEtNTk0NzA_ecb29903-592a-4622-9eeb-53bdfb82bdf5"
      unitRef="usd">2973000000</bhc:DeferredTaxAssetsTaxLossCarryforwards>
    <bhc:DeferredTaxAssetsTaxLossCarryforwards
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzItNC0xLTEtNTk0NzA_d4fcf50b-67b8-4a0b-8030-dad7fb12c7e1"
      unitRef="usd">2924000000</bhc:DeferredTaxAssetsTaxLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzMtMi0xLTEtNTk0NzA_48c7beff-7e48-49b6-8c3c-039e09bde09b"
      unitRef="usd">991000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzMtNC0xLTEtNTk0NzA_a36813bc-8676-4e2b-98e4-91eac4059b9a"
      unitRef="usd">1004000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <bhc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzQtMi0xLTEtNTk0NzA_28c8bad1-adf5-41e4-b470-afe69ebfdc44"
      unitRef="usd">173000000</bhc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment>
    <bhc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzQtNC0xLTEtNTk0NzA_8bd80da8-c740-4e04-8573-63bbd8257c36"
      unitRef="usd">172000000</bhc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment>
    <bhc:DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzUtMi0xLTEtNTk0NzA_e112abf2-ef96-4d0b-a4eb-f3c07ed8e627"
      unitRef="usd">52000000</bhc:DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool>
    <bhc:DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzUtNC0xLTEtNTk0NzA_2a052e4c-1920-49fd-b684-2a00b7cb61a8"
      unitRef="usd">55000000</bhc:DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzYtMi0xLTEtNTk0NzA_cd6d0cf3-1626-4dd7-8e9b-5965ef974017"
      unitRef="usd">14000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzYtNC0xLTEtNTk0NzA_1a316d42-da0e-4df0-a43c-26289e8a8139"
      unitRef="usd">20000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzctMi0xLTEtNTk0NzA_eb4e6f8a-f5de-4ec1-ba91-cc10c21178e2"
      unitRef="usd">3000000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzctNC0xLTEtNTk0NzA_5abe1a47-4aa3-4aad-b700-ad8cdc431552"
      unitRef="usd">9000000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <bhc:DeferredTaxAssetsPrepaidExpenses
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzktMi0xLTEtNTk0NzA_7349fe55-95b2-4cc2-89de-4c02291b01ac"
      unitRef="usd">26000000</bhc:DeferredTaxAssetsPrepaidExpenses>
    <bhc:DeferredTaxAssetsPrepaidExpenses
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzktNC0xLTEtNTk0NzA_5a7392ac-8264-42a2-9917-2ffe7d581451"
      unitRef="usd">27000000</bhc:DeferredTaxAssetsPrepaidExpenses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzEwLTItMS0xLTU5NDcw_99040625-72a5-4271-a61e-7ee04787ac6e"
      unitRef="usd">17000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzEwLTQtMS0xLTU5NDcw_cf1911f9-8f81-4dfe-a491-8b3c88df7ed6"
      unitRef="usd">16000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzExLTItMS0xLTU5NDcw_c1197277-3e41-4d24-bed3-6baf0c1ce092"
      unitRef="usd">38000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzExLTQtMS0xLTU5NDcw_7963511a-743a-42a5-ba1f-25ff82075cb5"
      unitRef="usd">24000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzEyLTItMS0xLTU5NDcw_63534c2f-dfcf-46b4-9703-34fa26f7e570"
      unitRef="usd">4287000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzEyLTQtMS0xLTU5NDcw_f4e8023a-e3f0-4dd9-853e-6a6305280718"
      unitRef="usd">4251000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzEzLTItMS0xLTU5NDcw_d815558a-237d-4773-b1fc-f8a296e7b4af"
      unitRef="usd">2222000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzEzLTQtMS0xLTU5NDcw_4245506a-5647-4698-9544-636678b9d351"
      unitRef="usd">2252000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzE0LTItMS0xLTU5NDcw_b7624267-58c9-4fbd-bcdc-2adb92d37f16"
      unitRef="usd">2065000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzE0LTQtMS0xLTU5NDcw_ce6c28d8-edbb-4e9a-8d20-fd3964446ffe"
      unitRef="usd">1999000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzE2LTItMS0xLTU5NDcw_3796b832-50e7-4259-9a1d-20dcac3fef16"
      unitRef="usd">188000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzE2LTQtMS0xLTU5NDcw_79daedee-b69f-4035-9af7-21928bc19511"
      unitRef="usd">228000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <bhc:DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzE3LTItMS0xLTU5NDcw_24325668-61f5-45cb-9c5c-c1d91bf7f67d"
      unitRef="usd">44000000</bhc:DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes>
    <bhc:DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzE3LTQtMS0xLTU5NDcw_767531a4-4316-4457-b497-88c74221b56c"
      unitRef="usd">89000000</bhc:DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzE4LTItMS0xLTU5NDcw_ee74d0b1-835f-4c76-865f-1512a327306e"
      unitRef="usd">110000000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzE4LTQtMS0xLTU5NDcw_dfa8c911-c2d4-40ea-9b8f-670ffb232e49"
      unitRef="usd">71000000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzE5LTItMS0xLTU5NDcw_83eeaa1b-e69d-4b17-96b3-1df94e885eb2"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains>
    <us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzE5LTQtMS0xLTU5NDcw_0f2ac980-d75b-456c-81c4-a506fc721602"
      unitRef="usd">2000000</us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzIwLTItMS0xLTU5NDcw_46809d25-4f0a-4b50-a383-fe77643ff114"
      unitRef="usd">342000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzIwLTQtMS0xLTU5NDcw_2f3fb9c6-6a4b-4682-a288-108416cc8e8f"
      unitRef="usd">390000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzIxLTItMS0xLTU5NDcw_9b7238dd-d7da-40ac-b8c5-a2ac3686594c"
      unitRef="usd">1723000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo0MWQxYmU0NTg2NmI0NWQyOTE5MjQ2Y2NjYjg2ODM2OS90YWJsZXJhbmdlOjQxZDFiZTQ1ODY2YjQ1ZDI5MTkyNDZjY2NiODY4MzY5XzIxLTQtMS0xLTU5NDcw_7d473130-0d76-482a-9eea-f2014d4879e8"
      unitRef="usd">1609000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i9f60772beddd4bd8b351b7519c847285_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzEtMi0xLTEtNTk0NzA_6234f8a3-8969-4446-ac48-c44319a3a100"
      unitRef="usd">2252000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i966b3882b2f8446a92d3b73108d3691d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzEtNC0xLTEtNTk0NzA_9a446137-1507-48a4-9f40-1c6f33a640b4"
      unitRef="usd">2831000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i33e256fd4d08472686f2bc331857bc8a_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzEtNi0xLTEtNTk0NzA_1afa112f-e892-4e21-a223-f5818fa236de"
      unitRef="usd">2913000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes
      contextRef="ic44ed602f863418a8831ced61d13e546_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzItMi0xLTEtNTk0NzA_93d5b822-8236-4e00-8eb0-d86203c97c18"
      unitRef="usd">-63000000</bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes>
    <bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes
      contextRef="ie270c7e752794cadbce8d6ea63bace3b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzItNC0xLTEtNTk0NzA_7694af3a-71fa-4a59-bf09-92321b2b1079"
      unitRef="usd">-773000000</bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes>
    <bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes
      contextRef="ic6ce4645221b4e709b3988651ee21064_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzItNi0xLTEtNTk0NzA_fe63acb7-6ea1-4941-9f42-8d9a3ed2ce60"
      unitRef="usd">13000000</bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ic44ed602f863418a8831ced61d13e546_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzMtMi0xLTEtNTk0NzA_02de1cef-7f5c-42bb-ac67-2035af157792"
      unitRef="usd">33000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ie270c7e752794cadbce8d6ea63bace3b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzMtNC0xLTEtNTk0NzA_28d6c26f-65c2-47ca-ba88-50ae4e722135"
      unitRef="usd">194000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ic6ce4645221b4e709b3988651ee21064_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzMtNi0xLTEtNTk0NzA_4eeae7d1-51c4-4e06-97f2-f83fddac2e02"
      unitRef="usd">-95000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ic906a904b8264052aa297c4da0661e84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzQtMi0xLTEtNTk0NzA_7e9c4d88-9c42-4d23-a3bb-3e7a53c8cadd"
      unitRef="usd">2222000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i9f60772beddd4bd8b351b7519c847285_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzQtNC0xLTEtNTk0NzA_a82b9800-7762-4866-bd48-5935f32f5429"
      unitRef="usd">2252000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i966b3882b2f8446a92d3b73108d3691d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo4ZWQxZjMxZTQ0ODE0OTM5OWU5NzM5YTk0MjA0ZDRmNi90YWJsZXJhbmdlOjhlZDFmMzFlNDQ4MTQ5Mzk5ZTk3MzlhOTQyMDRkNGY2XzQtNi0xLTEtNTk0NzA_5f3ecada-c16f-48dc-ae5a-781dd22ec7a7"
      unitRef="usd">2831000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i9019e1c2cf6d46838fe8c8d77147207a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzQ5NDc4MDIzNjQxMDE_cad2017c-587d-486e-8c12-cea41f7ef596"
      unitRef="usd">-30000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i0c84dca0789f4214840ddb5f4f8537bb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzQwMDQ_f3200e57-0c33-4662-aead-3212adea3815"
      unitRef="usd">-579000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <bhc:AccumulatedLossesAvailableForFederalPurposes
      contextRef="i983ff7f7025446d58e2f36c202de3dca_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzQ2NDI_56e08d4c-f4a8-43aa-b1cc-7591cf34274e"
      unitRef="usd">6669000000</bhc:AccumulatedLossesAvailableForFederalPurposes>
    <bhc:AccumulatedLossesAvailableForFederalPurposes
      contextRef="idee0cbb24fc340c1a64cf7d7df3edec6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzQ2NDk_44537146-ce27-4fe9-b71f-716f51ef63b7"
      unitRef="usd">6530000000</bhc:AccumulatedLossesAvailableForFederalPurposes>
    <bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits
      contextRef="i983ff7f7025446d58e2f36c202de3dca_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzQ3NjM_881037a0-1f13-4948-ab5b-3fa1da70fb9c"
      unitRef="usd">31000000</bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits>
    <bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits
      contextRef="idee0cbb24fc340c1a64cf7d7df3edec6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzQ3NzA_7e761287-85fb-452e-8c9c-f1a5796fb051"
      unitRef="usd">37000000</bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="idc644797e11f42fb9e29854f00a8af84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzQ5NjI_31b314b3-1f63-4491-ba45-31aa81fb88f3"
      unitRef="usd">196000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ia5e04a5a10344bad915b3777b2ade249_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzQ5Njk_91050bbf-e68e-463b-9cf7-49f5001a1a9b"
      unitRef="usd">206000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i983ff7f7025446d58e2f36c202de3dca_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzUxMzQ_f462cb8a-5726-4114-95f6-88a8d9e4ebc5"
      unitRef="usd">1965000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="idee0cbb24fc340c1a64cf7d7df3edec6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzUxNDE_5e392202-681b-4535-bd3d-c4641d0b770d"
      unitRef="usd">1966000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <bhc:AccumulatedLossesAvailableForFederalPurposes
      contextRef="i12f28aade059421c87f68fa766a6137c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzUyOTg_a5331785-5221-4c5e-8794-b0cd8375920d"
      unitRef="usd">266000000</bhc:AccumulatedLossesAvailableForFederalPurposes>
    <bhc:AccumulatedLossesAvailableForFederalPurposes
      contextRef="iccec7fb29c284c1282bcfd6426b81d26_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzUzMDU_b4c068c0-5479-4ba8-822e-fe876ce15032"
      unitRef="usd">814000000</bhc:AccumulatedLossesAvailableForFederalPurposes>
    <bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits
      contextRef="i12f28aade059421c87f68fa766a6137c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzU4MDM_dcf5c56b-33b2-4663-96b7-e066e8a0a6d6"
      unitRef="usd">119000000</bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits>
    <bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits
      contextRef="iccec7fb29c284c1282bcfd6426b81d26_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzU4MTA_2c0867db-2dcf-4de7-9776-b219cd4727ca"
      unitRef="usd">110000000</bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits>
    <bhc:AccumulatedLossesAvailableForFederalPurposes
      contextRef="ida6fd5a3e163430689987e5420387788_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzYwNjU_9290b20a-f4a9-46b0-9906-401c47325ba1"
      unitRef="usd">10040000000</bhc:AccumulatedLossesAvailableForFederalPurposes>
    <bhc:AccumulatedLossesAvailableForFederalPurposes
      contextRef="iceef040ee04e4d18be72112cc3158c59_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzYwNzI_9baf480f-617e-4908-b741-c21730df3d35"
      unitRef="usd">8387000000</bhc:AccumulatedLossesAvailableForFederalPurposes>
    <bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzY3MjY_45cc9159-5687-40b7-a6ed-d7029468626d"
      unitRef="usd">927000000</bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties>
    <bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzY3MzM_1a929c37-02d3-4c59-aa97-8c76412ff39f"
      unitRef="usd">1025000000</bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzY3NDY_be3ef60d-fe9d-4383-a6bf-248ae7b47f6f"
      unitRef="usd">271000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzY3NTM_acff90ca-6609-4748-a560-61d7e0287843"
      unitRef="usd">414000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzcxMTE_b0c98737-04fe-451b-ad40-b070ec756019"
      unitRef="usd">79000000</bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions>
    <bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzcxMTg_6ca59aff-b2f8-4d4c-af2c-3f3abc773b24"
      unitRef="usd">66000000</bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions>
    <bhc:UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzcxNzk_7b1ba0f1-4e23-443f-acd1-abd32c2c1a7c"
      unitRef="usd">177000000</bhc:UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions>
    <bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzcyMTU_2bdc9628-8f5d-4306-911a-61f0ac5ee229"
      unitRef="usd">42000000</bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5Xzc1Mjk_50ea9ced-58f4-4711-86d6-20aa261726c7"
      unitRef="usd">41000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5Xzc1MzY_84a491df-a43a-4330-b114-d1b84ac44444"
      unitRef="usd">49000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5Xzc2MjM_986fd3bd-8b97-4f0a-afa3-e58b2cb4e833"
      unitRef="usd">-8000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5Xzc2MzA_9a090a53-bf01-4a38-b947-41b54cdc9b1c"
      unitRef="usd">4000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <bhc:IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5Xzc2OTA_2e53e808-2a9d-47aa-af8c-4931edb80e60"
      unitRef="subsidiary">1</bhc:IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzEyMjc5_648479b6-06ea-4085-9cfa-309a975c9f93">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.931%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jurisdiction:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Open Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States - Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2015 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2012 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2013 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2016 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2016 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Netherlands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2011 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Luxembourg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:OpenTaxYear
      contextRef="i23bf918ee3914485aeddbbc1554c30ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzEtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjowYzY4YzRmNmEyNmY0OWYzYWU4ODlkMjU0MzZhMWYwYV80_05556cdb-7df1-43f8-8d7b-5455caa365c4">2015</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i5f649769ddcb4300a790315728ab809b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzEtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjowYzY4YzRmNmEyNmY0OWYzYWU4ODlkMjU0MzZhMWYwYV85_64d0d404-ef89-4876-b2f8-4e620a776b02">2020</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i4c7cd7b9da83461fa9bd41fd621feefc_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzItMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo2NjQwOWUyYjNhMWE0Y2M1YTNiYTYyYTdkMDVlYmM0MV80_2ec84542-80e7-4721-913c-72c0cd918a65">2012</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="ic9ec02f6590e441bbef7d90718b83872_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzItMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo2NjQwOWUyYjNhMWE0Y2M1YTNiYTYyYTdkMDVlYmM0MV85_952b89e9-f439-4a54-a0f2-6f36bfda84a6">2020</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="ib9654dc8595e40e7b7fb7f68cfe474d9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzMtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjoxMzJhNmMzZDdhM2I0ZGE1YmZhNWVjM2NhMzJhZGNhYl80_f93f8fcc-9bb9-4e32-a0f4-37f3d31a1c63">2014</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="id511e68e76754c458cbf0c440955486c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzMtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjoxMzJhNmMzZDdhM2I0ZGE1YmZhNWVjM2NhMzJhZGNhYl85_ffa53776-5c78-4e03-b00e-330647102d5b">2020</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="ie55c0ff42c4544718880dceec02e3876_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzQtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjpiZTgzMDI5YmE2NTk0ZTZjYjM2MDhkNjhlZjI0M2FmNF80_e017599d-7148-4cde-bb6a-b518bd0a91af">2013</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="id991a25ce8c1481ca65b4088fe2e5c6e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzQtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjpiZTgzMDI5YmE2NTk0ZTZjYjM2MDhkNjhlZjI0M2FmNF85_08a1ecd6-eab4-4ac3-b108-6983424612ff">2020</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i87eff35348ef4c22b0f0c14d5d1ff9a7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzUtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjpjYzJhNTQxMmFiZTA0MjcwOTUzMTVmOGZlNjE5YTYwN180_bde02128-c289-43db-81f8-be4aa097cb97">2016</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i8fbc8562b9bc45179604d0b354d37975_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzUtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjpjYzJhNTQxMmFiZTA0MjcwOTUzMTVmOGZlNjE5YTYwN185_66e7c8d0-845d-436f-8d4e-a024b1a9fac9">2020</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i759223d752d2484cb3624693e092afd2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzYtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjpmZmI4OTkyOWIwYTk0OTkyYmIwZjQ1ZmQwNzA1OTFlYV80_85c17654-2a19-4ada-bf97-f6d3c8cb457a">2016</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i49ed113f8481479a94b3377274581c18_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzYtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjpmZmI4OTkyOWIwYTk0OTkyYmIwZjQ1ZmQwNzA1OTFlYV85_97750149-3d26-4f28-b77c-133d3ea20894">2020</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="ic758f54fa5494dee98621db67459a939_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzctMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjozNWYwZTc1Y2FlNDU0NTI3YWNiZTYzZGM5ZjdhZGVmZF80_ea378a51-0550-4522-9894-6b5c9561029c">2017</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="ib3721bdf19944087b6072d188479220b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzctMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjozNWYwZTc1Y2FlNDU0NTI3YWNiZTYzZGM5ZjdhZGVmZF85_0f16ec10-0035-4308-9f2a-c87a7e556542">2020</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="icf289905620f424a822098d370171d98_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzgtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo2MTUxODFmZDVjYzc0MzE1OTdiNzE3MmFiNzNhMzEyMF80_a8bfc3ad-5cd9-47a4-9887-a62595534492">2011</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i8197dcace8e546198e3aa3cab5f1e9ab_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzgtMi0xLTEtNTk0NzAvdGV4dHJlZ2lvbjo2MTUxODFmZDVjYzc0MzE1OTdiNzE3MmFiNzNhMzEyMF85_484df506-c68f-4620-b7aa-bf9d65f34777">2020</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="ib1878eebcc48403e8da37dd8ccee3c33_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzktMi0xLTEtODM0MTMvdGV4dHJlZ2lvbjowMmJhZDcxNDgxZDQ0M2Q2YmQ2NzgyMjMyZDQ4NTkxNV8xMzE5NDEzOTUzMzMxNg_d04e00db-cc22-4e21-b6ed-518cfd504136">2017</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i5cecc7e2447a473eacca025ceba50171_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTo5NTRkYTFkZTI1YzM0MzQ4OTFhY2IyMWUxNDBmMzk4OC90YWJsZXJhbmdlOjk1NGRhMWRlMjVjMzQzNDg5MWFjYjIxZTE0MGYzOTg4XzktMi0xLTEtODM0MTMvdGV4dHJlZ2lvbjowMmJhZDcxNDgxZDQ0M2Q2YmQ2NzgyMjMyZDQ4NTkxNV8xMzE5NDEzOTUzMzMyMg_6c1fcd24-9772-466c-b364-fc1f48031ee3">2020</us-gaap:OpenTaxYear>
    <us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzQzOTgwNDY1NDUyMzg_3301367d-b4e4-4b04-80e4-fc164eadc709"
      unitRef="usd">2100000000</us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss>
    <us-gaap:IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear
      contextRef="i3452627b08104c328663beda89ef7e2b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzEwOTk1MTE2Njg1MzE_7fe0c880-a53b-4014-9114-d600f95e457a"
      unitRef="cad">-44000000</us-gaap:IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear>
    <us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss
      contextRef="i53b67fa0263542b89545f1c28636acdc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzQ5NDc4MDIzNDEyMzQ_8decd5cb-f5b9-42e1-8ba2-41dba49055b9"
      unitRef="cad">85000000</us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss>
    <us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss
      contextRef="i70a5dd9dc5d24412b0837e57866d62ab_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzQ5NDc4MDIzNDEyODQ_946388e0-6061-4e77-b894-9b8e6f92f96c"
      unitRef="cad">90000000</us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss>
    <us-gaap:IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear
      contextRef="ie44b34f6fd784806a1de35a90e5cd3c2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzEwOTk1MTE2NDcwNzQ_10c0f859-2128-4d1a-b029-c7d186d176e5"
      unitRef="cad">-21000000</us-gaap:IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear>
    <us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss
      contextRef="ifd17b9aaa43542b6ad701f3288d43039_D20170808-20170808"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzEwOTMy_8daf7a14-9073-4375-8ff0-56bc1f503d39"
      unitRef="usd">117000000</us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzEyMjgz_d93e67de-0e74-4a4d-b428-262273532d4d">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of the unrecognized tax&#160;benefits for 2021, 2020 and 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzEtMi0xLTEtNTk0NzA_3d075610-37b4-4eee-bbea-8c8ff138b8d8"
      unitRef="usd">1025000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzEtNC0xLTEtNTk0NzA_803000d1-a24b-47dc-93f2-49ed1ecca8a3"
      unitRef="usd">1002000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i88a9900560564bdca7dec25381689c13_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzEtNi0xLTEtNTk0NzA_73dccbf3-dc3c-4deb-8312-da8ab4bd9a3f"
      unitRef="usd">654000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzItMi0xLTEtNTk0NzA_d5b16662-4a19-4e7e-bac3-54e90914bbf1"
      unitRef="usd">79000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzItNC0xLTEtNTk0NzA_c606ccb6-a378-4168-9f18-b1ea7e974c7e"
      unitRef="usd">66000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzItNi0xLTEtNTk0NzA_eaaccc02-5953-4a73-89a5-d1584558989a"
      unitRef="usd">361000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzMtMi0xLTEtNTk0NzA_1ac6c21e-8b63-483f-ad01-474d1d4ecb18"
      unitRef="usd">121000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzMtNC0xLTEtNTk0NzA_139d2ff1-10a2-433f-81de-5781856ec67b"
      unitRef="usd">171000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzMtNi0xLTEtNTk0NzA_67bd63eb-1672-4f84-b95c-e1b7a60843eb"
      unitRef="usd">63000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzQtMi0xLTEtNTk0NzA_839ebc16-d62c-46df-9051-e171b4eedfd9"
      unitRef="usd">129000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzQtNC0xLTEtNTk0NzA_62081c18-46d3-4023-9856-e10d9a3aac4a"
      unitRef="usd">209000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzQtNi0xLTEtNTk0NzA_5b57ea55-560c-4462-9ddc-354222f703ff"
      unitRef="usd">58000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzUtMi0xLTEtNTk0NzA_da88305d-fbc8-4df5-8311-28523ab5ee4b"
      unitRef="usd">169000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzUtNC0xLTEtNTk0NzA_d1c6d1b1-908c-4bbb-a01f-e728c78f4514"
      unitRef="usd">5000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzUtNi0xLTEtNTk0NzA_8b3b82cb-12d7-475c-b67d-53d24858e0da"
      unitRef="usd">18000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzYtMi0xLTEtNTk0NzA_a937ebc6-7217-4cee-9311-636623a7423a"
      unitRef="usd">927000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzYtNC0xLTEtNTk0NzA_718335f9-e560-4197-bfb8-1d70a91421e6"
      unitRef="usd">1025000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i9a01def95a9b4da68b1d7c83300f93c5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90YWJsZTpkOTQ3ODI2MDc3YWE0YjczYTFmNGZjODMyMTY5OTY4MC90YWJsZXJhbmdlOmQ5NDc4MjYwNzdhYTRiNzNhMWY0ZmM4MzIxNjk5NjgwXzYtNi0xLTEtNTk0NzA_7ba9d419-2933-40fa-8440-517af0d5cc98"
      unitRef="usd">1002000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTIvZnJhZzo1OTlkZTU0ZjZmODI0NmY5OTc1NzA3NDFiNWIwYmRmOS90ZXh0cmVnaW9uOjU5OWRlNTRmNmY4MjQ2Zjk5NzU3MDc0MWI1YjBiZGY5XzEyMTYw_2a42907c-b4d3-4dbc-a357-d95aa19a0570"
      unitRef="usd">104000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90ZXh0cmVnaW9uOjgxNTNlNjc0ZWI0NTQ4ZTFiN2ZlMmYxMTI5MGUxNjRhXzg1OQ_4e44e880-ad58-46c3-befe-df2c8109d793">LOSS  PER SHARE&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss per share attributable to Bausch Health Companies Inc. for 2021, 2020 and 2019 were calculated as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,788)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic and diluted weighted-average common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;358.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;355.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic and diluted loss per share attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, 2020 and 2019, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive.  The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 4,932,000, 3,154,000 and 5,106,000 common shares for 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, in 2021, 2020 and 2019, stock options, time-based RSUs and performance-based RSUs to purchase approximately 3,428,000, 9,551,000 and 2,598,000 common shares of the Company, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During 2021, an additional 156,000 performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90ZXh0cmVnaW9uOjgxNTNlNjc0ZWI0NTQ4ZTFiN2ZlMmYxMTI5MGUxNjRhXzg1Mg_1955c916-a15b-4cec-b04b-1f476e7e54e1">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss per share attributable to Bausch Health Companies Inc. for 2021, 2020 and 2019 were calculated as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,788)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic and diluted weighted-average common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;358.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;355.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic and diluted loss per share attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzEtMi0xLTEtNTk0NzA_90f95891-ab6f-4f9d-b395-1e052c39e3d7"
      unitRef="usd">-948000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzEtNC0xLTEtNTk0NzA_e1abced3-bf2d-44ad-8d87-6fa227998996"
      unitRef="usd">-560000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzEtNi0xLTEtNTk0NzA_7072f686-5ae0-4453-aa9b-4d4313d967cd"
      unitRef="usd">-1788000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzItMi0xLTEtNTk0NzA_bf7c322b-2330-48c3-a41a-3556374f2264"
      unitRef="shares">358900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzItMi0xLTEtNTk0NzA_dc217327-9b0c-41d0-aeed-3bbf696361d5"
      unitRef="shares">358900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzItNC0xLTEtNTk0NzA_783f1f4b-0c82-4b21-b81d-c150fe0c8be1"
      unitRef="shares">355000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzItNC0xLTEtNTk0NzA_b6e8e2ac-a23e-4ead-a816-aafc6e27e366"
      unitRef="shares">355000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzItNi0xLTEtNTk0NzA_3d22f8e7-5995-4e56-b3ac-10e62f429d06"
      unitRef="shares">352100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzItNi0xLTEtNTk0NzA_a777cb45-f378-4bdd-83f0-ebe49edbc350"
      unitRef="shares">352100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzMtMi0xLTEtNTk0NzA_6bfe1f29-6bb2-4c98-b985-233951c0848a"
      unitRef="usdPerShare">-2.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzMtMi0xLTEtNTk0NzA_eaaee5fa-eb36-402e-9c1d-4b7f2d6240d8"
      unitRef="usdPerShare">-2.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzMtNC0xLTEtNTk0NzA_32c2d90e-0020-409d-8471-9493205b88cf"
      unitRef="usdPerShare">-1.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzMtNC0xLTEtNTk0NzA_784778d6-362d-4b89-b0a3-60b718985a9f"
      unitRef="usdPerShare">-1.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzMtNi0xLTEtNTk0NzA_2c3528e7-1b3b-43fb-8f04-205c092bb6cd"
      unitRef="usdPerShare">-5.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90YWJsZTo3ODYwZmZjN2Y4YTA0YjRlODE2NzYwZjQ5Nzc2M2EyZi90YWJsZXJhbmdlOjc4NjBmZmM3ZjhhMDRiNGU4MTY3NjBmNDk3NzYzYTJmXzMtNi0xLTEtNTk0NzA_60870a37-eb91-4c1a-a4e1-af86b843ba92"
      unitRef="usdPerShare">-5.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie898e2aab45345c9b42d7a2acb631663_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90ZXh0cmVnaW9uOjgxNTNlNjc0ZWI0NTQ4ZTFiN2ZlMmYxMTI5MGUxNjRhXzQ5MA_ef4ecb97-972e-4044-aaa6-ba02054ad1b4"
      unitRef="shares">4932000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id033c0ed7fc74052a6c84265f651ad67_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90ZXh0cmVnaW9uOjgxNTNlNjc0ZWI0NTQ4ZTFiN2ZlMmYxMTI5MGUxNjRhXzQ5NA_3ca271b1-a83c-40b3-b578-426a20c65091"
      unitRef="shares">3154000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6b0d284e351c45f6a89f189993ae032b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90ZXh0cmVnaW9uOjgxNTNlNjc0ZWI0NTQ4ZTFiN2ZlMmYxMTI5MGUxNjRhXzUwMQ_11863577-112b-467b-9a09-38882601b60e"
      unitRef="shares">5106000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4a5a4c310e574205b818538430461c33_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90ZXh0cmVnaW9uOjgxNTNlNjc0ZWI0NTQ4ZTFiN2ZlMmYxMTI5MGUxNjRhXzY0NQ_0c346ada-b1d8-46eb-9463-0c3f39f54bfd"
      unitRef="shares">3428000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i393b10cfe703474a8e599f0e963d3334_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90ZXh0cmVnaW9uOjgxNTNlNjc0ZWI0NTQ4ZTFiN2ZlMmYxMTI5MGUxNjRhXzY0OQ_1a1133ea-af6b-48c1-bd78-1435248c5de7"
      unitRef="shares">9551000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic8cc4183f807420fa113cead38c11868_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90ZXh0cmVnaW9uOjgxNTNlNjc0ZWI0NTQ4ZTFiN2ZlMmYxMTI5MGUxNjRhXzY1Ng_f05aa480-5647-4a60-9029-5c2de89cb4b1"
      unitRef="shares">2598000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i246d722a091f4f0080937e3f56bdb622_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTUvZnJhZzo4MTUzZTY3NGViNDU0OGUxYjdmZTJmMTEyOTBlMTY0YS90ZXh0cmVnaW9uOjgxNTNlNjc0ZWI0NTQ4ZTFiN2ZlMmYxMTI5MGUxNjRhXzEwOTk1MTE2Mjg5MDE_8b313ad1-c239-4379-8138-dc284fe84706"
      unitRef="shares">156000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTgvZnJhZzplZGY1ZDdhN2IxMTQ0ODNkYmFkNTkwY2JlNGY5YmFlYy90ZXh0cmVnaW9uOmVkZjVkN2E3YjExNDQ4M2RiYWQ1OTBjYmU0ZjliYWVjXzY2_b66a5685-d6cc-48f1-a711-3c8530410002">SUPPLEMENTAL CASH FLOW DISCLOSURES &lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow disclosures for 2021, 2020 and 2019 are as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTgvZnJhZzplZGY1ZDdhN2IxMTQ0ODNkYmFkNTkwY2JlNGY5YmFlYy90ZXh0cmVnaW9uOmVkZjVkN2E3YjExNDQ4M2RiYWQ1OTBjYmU0ZjliYWVjXzY4_38d3d0df-b71e-4fad-8b68-b8b9a2954a66">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow disclosures for 2021, 2020 and 2019 are as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:InterestPaidNet
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTgvZnJhZzplZGY1ZDdhN2IxMTQ0ODNkYmFkNTkwY2JlNGY5YmFlYy90YWJsZTpmN2M3ZTA5YjMyODg0ZmExOTJiMjEzY2Y3YmUyYzc5Mi90YWJsZXJhbmdlOmY3YzdlMDliMzI4ODRmYTE5MmIyMTNjZjdiZTJjNzkyXzItMi0xLTEtNTk0NzA_2b6376b5-f4f2-4111-aca4-d69208f1016f"
      unitRef="usd">1419000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTgvZnJhZzplZGY1ZDdhN2IxMTQ0ODNkYmFkNTkwY2JlNGY5YmFlYy90YWJsZTpmN2M3ZTA5YjMyODg0ZmExOTJiMjEzY2Y3YmUyYzc5Mi90YWJsZXJhbmdlOmY3YzdlMDliMzI4ODRmYTE5MmIyMTNjZjdiZTJjNzkyXzItNC0xLTEtNTk0NzA_632f7e49-0c1e-4e59-bf03-8e435bf40ae5"
      unitRef="usd">1474000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTgvZnJhZzplZGY1ZDdhN2IxMTQ0ODNkYmFkNTkwY2JlNGY5YmFlYy90YWJsZTpmN2M3ZTA5YjMyODg0ZmExOTJiMjEzY2Y3YmUyYzc5Mi90YWJsZXJhbmdlOmY3YzdlMDliMzI4ODRmYTE5MmIyMTNjZjdiZTJjNzkyXzItNi0xLTEtNTk0NzA_28b2bde8-f90c-452a-9709-bc372490b0cf"
      unitRef="usd">1537000000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTgvZnJhZzplZGY1ZDdhN2IxMTQ0ODNkYmFkNTkwY2JlNGY5YmFlYy90YWJsZTpmN2M3ZTA5YjMyODg0ZmExOTJiMjEzY2Y3YmUyYzc5Mi90YWJsZXJhbmdlOmY3YzdlMDliMzI4ODRmYTE5MmIyMTNjZjdiZTJjNzkyXzMtMi0xLTEtNTk0NzA_8b9f8028-3e51-4264-a5f2-b2a5d7d30cf4"
      unitRef="usd">240000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTgvZnJhZzplZGY1ZDdhN2IxMTQ0ODNkYmFkNTkwY2JlNGY5YmFlYy90YWJsZTpmN2M3ZTA5YjMyODg0ZmExOTJiMjEzY2Y3YmUyYzc5Mi90YWJsZXJhbmdlOmY3YzdlMDliMzI4ODRmYTE5MmIyMTNjZjdiZTJjNzkyXzMtNC0xLTEtNTk0NzA_f8e68216-e21b-49de-882a-e7912645819f"
      unitRef="usd">162000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNTgvZnJhZzplZGY1ZDdhN2IxMTQ0ODNkYmFkNTkwY2JlNGY5YmFlYy90YWJsZTpmN2M3ZTA5YjMyODg0ZmExOTJiMjEzY2Y3YmUyYzc5Mi90YWJsZXJhbmdlOmY3YzdlMDliMzI4ODRmYTE5MmIyMTNjZjdiZTJjNzkyXzMtNi0xLTEtNTk0NzA_2d42b383-44d4-4adf-91a2-a43fc09a5e27"
      unitRef="usd">172000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzYzNjA5_5e6fbd5c-7b1f-4c16-ad2b-2bed917ecdd2">LEGAL PROCEEDINGS&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described below. Going forward, in the Company's subsequent Quarterly Reports on Form 10-Q, the Company will only include a description of these matters to the extent there has been a material update with respect thereto during the applicable quarter or to the extent otherwise required by law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of December 31, 2021, the Company's Consolidated Balance Sheets includes accrued current loss contingencies of $1,890 million related to matters which the Company believes a potential resolution or settlement is both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#x2019;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Governmental and Regulatory Inquiries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investigation by the U.S. Attorney's Office for the District of Massachusetts - re OraPharma&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts, requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, including related support services, and other matters.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is cooperating with this investigation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Securities and RICO Class Actions and Related Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Securities Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658). On January 31, 2021, the District Court &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill LLC filed a notice of appeal of the Court&#x2019;s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options.  On March 1, 2021, Cathy Lochridge filed a notice of appeal of the Court&#x2019;s final approval order, which overruled her objections as to the attorneys&#x2019; fees awarded to class counsel. On October 14, 2021, Timber Hill dismissed its appeal of the final approval order. On December 20, 2021, the Third Circuit denied Lochridge&#x2019;s appeal. On January 3, 2022, Lochridge filed a petition for rehearing of the appeal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;en banc&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which remains pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2015, four putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#x2019;s business and prospects, including relating to drug pricing, the Company&#x2019;s use of specialty pharmacies, and the Company&#x2019;s relationship with Philidor. On May 31, 2016, the court entered an order consolidating the four actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $1,210 million, subject to final court approval. This settlement received final approval from the court on January 31, 2021 and will resolve and discharge all claims against the Company in the class action.  As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement remains subject to an appeal of the final court approval (as such appeal is further described above). In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payments have been paid into an escrow account in accordance with the payment schedule outlined in the settlement agreement. These payments, less certain settlement expenses and attorneys' fees, will remain in escrow until resolution of the appeal of the final court approval of the settlement agreement. The opt-out litigations discussed below remain ongoing. As of December 31, 2021, Restricted cash and other settlement deposits includes an aggregate $1,210&#160;million of: (i) payments in the escrow fund and (ii) certain disbursements for settlement expenses and attorney's fees. Disbursements for attorney's fees remain refundable until resolution of the appeal of the final court approval of the settlement agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246) (&#x201c;Timber Hill&#x201d;), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#x2019;s common stock during the period January 4, 2013 through August 11, 2016.  On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658).  On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the consolidated putative class action, thirty-seven groups of individual investors in the Company&#x2019;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions are captioned: T. Rowe Price Growth Stock Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-5034); Equity Trustees Limited as Responsible Entity for T. Rowe Price Global Equity Fund v. Valeant Pharmaceuticals International Inc. (Case No. 16-cv-6127); Principal Funds, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-6128); BloombergSen Partners Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7212); Discovery Global Citizens Master Fund, Ltd. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7321); MSD Torchlight Partners, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7324); BlueMountain Foinaven Master Fund, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7328) (&#x201c;BlueMountain&#x201d;); Incline Global Master LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7494); VALIC Company I v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7496); Janus Aspen Series v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7497) (&#x201c;Janus Aspen&#x201d;); Okumus Opportunistic Value Fund, LTD v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6513) (&#x201c;Okumus&#x201d;); Lord Abbett Investment Trust- Lord Abbett Short Duration Income Fund, v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6365) (&#x201c;Lord Abbett&#x201d;); Pentwater Equity Opportunities Master Fund LTD v. Valeant Pharmaceuticals International, Inc., et al. (Case No. 17-cv-7552) (&#x201c;Pentwater&#x201d;); Public Employees&#x2019; Retirement System of Mississippi v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-7625) (&#x201c;Mississippi&#x201d;); The Boeing Company Employee Retirement Plans Master Trust v. Valeant Pharmaceuticals International Inc., et al., (Case No. 17-cv-7636) (&#x201c;Boeing&#x201d;); State Board of Administration of Florida v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-12808); The Regents of the University of California v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-13488); GMO Trust v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0089); F&#xf6;rsta AP Fonden v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-12088); New York City Employees&#x2019; Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0032) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;NYCERS&#x201d;); Hound Partners Offshore Fund, LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08705) (&#x201c;Hound Partners&#x201d;); Blackrock Global Allocation Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0343) (&#x201c;Blackrock&#x201d;); Colonial First State Investments Limited As Responsible Entity for Commonwealth Global Shares Fund 1 v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0383); Bharat Ahuja v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0846); Brahman Capital Corp. v. Valeant Pharmaceuticals International, Inc (Case No. 18-cv-0893); The Prudential Insurance Company of America v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-01223) (&#x201c;Prudential&#x201d;); Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) (&#x201c;Senzar&#x201d;); 2012 Dynasty UC LLC v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08595) ("2012 Dynasty"); Catalyst Dynamic Alpha Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-12673) (&#x201c;Catalyst&#x201d;); Northwestern Mutual Life Insurance Co., v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-15286) (&#x201c;Northwestern Mutual&#x201d;); Bahaa Aly, et al. v. Valeant Pharmaceuticals International, Inc., (Case No. 18-cv-17393) (&#x201c;Aly&#x201d;); Office of the Treasurer as Trustee for the Connecticut Retirement Plans and Trust Funds v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18473) (&#x201c;Connecticut&#x201d;); Delaware Public Employees&#x2019; Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18475) (&#x201c;Delaware&#x201d;); Maverick Neutral Levered Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-02190) (&#x201c;Maverick&#x201d;), Templeton v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-05478) (&#x201c;Templeton&#x201d;), USAA Mutual Funds Trust, et al. v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 20-cv-07462) (&#x201c;USAA&#x201d;), and GIC Private Ltd. v. Valeant Pharmaceuticals International, Inc., (Case No. 20-cv-07460) (&#x201c;GIC&#x201d;). Sixteen of the thirty-seven opt-out actions have been dismissed; and the total number of remaining opt-out actions pending in the District of New Jersey is twenty-one actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These individual shareholder actions assert claims under Sections 10(b), and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2), and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss have been filed and in most cases decided in many of these individual actions. To date, the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) opt-out action, closing the case.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 10, 2019, the Court granted defendants&#x2019; motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (&#x201c;Aly&#x201d;) (Case No. 18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 16, 2021, the Court of Appeals granted plaintiffs&#x2019; appeal in the Aly action. This action has been remanded to the District Court. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut, and Delaware actions.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, and March 10, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds, Pentwater, Lord Abbett, Equity Trustees, and UC Regents actions. On April 30, 2021, the Court entered a stipulation of voluntary dismissal in the Florida SBA action.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 20, 2021, the Court entered a stipulation of voluntary dismissal in the Janus action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Canadian Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, six putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. These actions are captioned: (a) Alladina v. Valeant, et al. (Case No. S-1594B6) (Supreme Court of British Columbia) (filed November 17, 2015); (b) Kowalyshyn v. Valeant, et al. (CV-15-540593-00CP) (Ontario Superior Court) (filed November 16, 2015); (c) Kowalyshyn et al. v. Valeant, et al. (CV-15-541082-00CP) (Ontario Superior Court) (filed November 23, 2015); (d) O&#x2019;Brien v. Valeant et al. (CV-15-543678-00CP) (Ontario Superior Court) (filed December 30, 2015); (e) Catucci v. Valeant, et al. (Court File No. 540-17-011743159, then Court File No. 500-06-000783-163) (Quebec Superior Court) (filed October 26, 2015); and (f) Rousseau-Godbout v. Valeant, et al. (Court File No. 500-06-000770-152) (Quebec Superior Court) (filed October 27, 2015). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also aware of two additional putative class actions that were filed with the applicable court but which have not been served on the Company. These actions are captioned: (i) Okeley v. Valeant, et al. (Case No. S-159991) (Supreme Court of British Columbia) (filed December 2, 2015); and (ii) Sukenaga v Valeant et al. (CV-15-540567-00CP) (Ontario &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Superior Court) (filed November 16, 2015), and the factual allegations made in these actions are substantially similar to those outlined herein.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, was discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#x2019;s auditors and the action was dismissed as against them. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD 94 million plus payment of an additional amount to cover notice and settlement administration costs and disbursements.  As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action.  On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, one of the entities which exercised its opt-out rights, the California State Teachers' Retirement System (&#x201c;CalSTRS&#x201d;), served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#x2019; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision. The appeal was heard on September 29, 2021 and, by judgment dated October 29, 2021, the appeals were dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#x201c;price appreciation credits&#x201d; in respect of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the period covered by the claims. A hearing was held on February 17, 2021 with respect to whether CalSTRS would be permitted to file the proposed amended proceedings. On June 9, 2021, the Quebec Superior Court granted the Company&#x2019;s application to strike the new allegations from its Quebec Securities Act claim, but permitted the amendments to its claim under the Quebec Civil Code. On December 8, 2021, CalSTRS delivered its amended pleadings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 17, 2021, four additional opt-outs from the Catucci class issued a Statement of Claim in the Ontario Superior Court of Justice. That proceeding is captioned The Bank of Korea et al. v. Valeant Pharmaceuticals International Inc. et al. (Court File No. 21-00658966-0000). In addition, these plaintiffs also served and filed a motion for leave to pursue claims under the Ontario Securities Act. The allegations in this proceeding are similar to those made by the plaintiffs in the Catucci class action and the plaintiffs in the opt-out actions described above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7.5pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RICO Class Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between May 27, 2016 and September 16, 2016, three actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (&#x201c;RICO&#x201d;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160; The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#x2019;s consent to renew the prescription.&#160; The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.  On August 4, 2021, the Company executed a stipulation of settlement for this action and, on August 17, 2021, the Court preliminarily approved the settlement.  On December 6, 2021 the Special Master overseeing this litigation issued a report and recommendation recommending final approval of the settlement, and on February 22, 2022 the settlement was approved by the district court. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Insurance Coverage Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during two distinct policy periods, (i) 2013-14 and (ii) 2015-16.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; 3:18-CV-00493).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (the &#x201c;Allergan Securities Litigation&#x201d;) (under the 2013-2014 coverage period), and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and the SEC Investigation and certain of the other investigations described under &#x201c;Complete or Inactive Matters&#x201d; in Note 20, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021 and under &#x201c;Governmental and Regulatory Inquiries&#x201d; and &#x201c;Complete or Inactive Matters&#x201d; in Note 21, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020 (under the 2015-2016 coverage period).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 20, 2021, the Company entered into settlement agreements with the insurers in the 2015-2016 coverage period in which the Company agreed to resolve its claims for insurance coverage in connection with the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-out litigation and related investigations matters described above.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On that same day, the Company entered into settlement agreements with two of its insurers in the 2013-2014 coverage period in which the Company agreed to resolve its claims against those two insurers only for insurance coverage in connection with the Allergan Securities Litigation. As a result of all of the settlement agreements entered into with the insurers on July 20, 2021, the Company has received an aggregate sum of $213&#160;million. The Company&#x2019;s insurance claims with respect to the Allergan Securities Litigation against the remaining insurers in the 2013-2014 coverage period remain pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hound Partners Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP, and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County.  This action is captioned Hound Partners Offshore Fund, LP et al., v. Valeant Pharmaceuticals International, Inc., et al. (No. MER-L-002185-18).  This suit asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The Company disputes the claims and intends to vigorously defend this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Antitrust&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Generic Pricing Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's subsidiaries, Oceanside Pharmaceuticals, Inc. (&#x201c;Oceanside&#x201d;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#x201c;Bausch Health US&#x201d;), and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#x201c;Bausch Health Americas&#x201d;) (for the purposes of this paragraph, collectively, the &#x201c;Company&#x201d;), are defendants in multidistrict antitrust litigation (&#x201c;MDL&#x201d;) entitled &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re: Generic Pharmaceuticals Pricing &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, pending in the United States District Court for the Eastern District of Pennsylvania (MDL No. 2724, 16-MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#x2019;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. There are cases pending in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed in the cases. The cases have been put in deferred status. The Company disputes the claims against it and continues to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively &#x201c;the Company&#x201d;) have been named as defendants in a proposed class proceeding entitled &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Kathryn Eaton v. Teva Canada Limited, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that the Company and other defendants violated the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Competition Act&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re: Generic Pharmaceuticals Pricing Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and will defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Glumetza State-Law Insurer Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 8, 2021, the insurer plaintiff from the federal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 3:19-cv-05822-WHA (N.D. Cal.) (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) (discussed in further detail below) filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#x201c;State Court Action&#x201d;).  The State Court Action alleges that a 2012 settlement of a patent litigation regarding Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or grant any other company a license to do so.  The State Court Action alleges that the settlement agreement resulted in higher prices for Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and its generic equivalent both prior to and after generic entry. On September 20, 2021, the parties stipulated that the insurer plaintiff&#x2019;s direct opt-out claims from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, discussed below, were deemed asserted in the State Court Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defendants&#x2019; demurrer in the State Court Action was heard on September 22, 2021.  On November 11, 2021, the court denied the motion in part and granted it in part as to certain state law claims, with leave to amend.  The insurer plaintiff did not amend the complaint. Defendants&#x2019; answers were filed on February 3, 2022. The Company disputes the claims and intends to vigorously defend this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intellectual Property&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patent Litigation/Paragraph IV Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 550mg, Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Relistor&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Injection&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the United States, and Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in Canada or other similar suits.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 17, 2020, the Company and Alfasigma S.p.A. ("Alfasigma") received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#x201c;Norwich&#x201d;), in which Norwich asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#x2019;s Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#x2019;s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (&#x201c;ANDA&#x201d;) has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and owns or exclusively licenses (from Alfasigma) these patents.  On March 26, 2020, certain of the Company&#x2019;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents, thereby triggering a 30-month stay of the approval of Norwich&#x2019;s ANDA for rifaximin tablets, 550 mg. Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is protected by 26 patents covering the composition of matter and the use of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; listed in the FDA&#x2019;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. A 3-day bench trial is scheduled to begin March 21, 2022. The Company &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;remains confident in the strength of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and will continue to vigorously pursue this matter and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (now Padagis LLC) (&#x201c;Padagis&#x201d;), in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA's Orange Book for Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate and tazarotine) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#x2019; generic lotion, for which an ANDA has been filed by Padagis.  On August 28, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA.  On September 3, 2020, this action was consolidated with the action between the Company and Padagis described below, regarding Padagis&#x2019; ANDA for generic Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate) lotion. The Company remains confident in the strength of the Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related patents and will vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Padagis, in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#x2019; generic halobetasol propionate lotion, for which an ANDA has been filed by Padagis.  On May 1, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described above, regarding Padagis&#x2019; ANDA for generic Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate and tazarotine) lotion. The Company remains confident in the strength of the Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents and intends to vigorously pursue this matter and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company commenced litigation against MSN Laboratories Private Ltd. (&#x201c;MSN&#x201d;) and Mylan Pharmaceuticals Inc., (&#x201c;Mylan&#x201d;) alleging patent infringement by MSN&#x2019;s and Mylan&#x2019;s filing of their ANDA for generic Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (plecanatide) 3mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from each of MSN and Mylan, in which they had each asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#x2019;s Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, 3 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of their respective generic plecanatide tablets, 3 mg.  The filing of these suits triggered a 30-month stay of the approval of the MSN and Mylan ANDAs for plecanatide tablets. The Company remains confident in the strength of the Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and intends to vigorously pursue this matter and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company commenced litigation against Slayback Pharma LLC and Slayback Pharma India LLP (together, &#x201c;Slayback&#x201d;) alleging patent infringement by Slayback Pharma LLC&#x2019;s filing of its ANDA No. 216361, referencing Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (0.025% brimonidine tartrate ophthalmic solution). This suit had been filed following receipt of a Notice of Paragraph IV Certification from Slayback Pharma LLC, in which it had asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#x2019;s Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; brimonidine tartrate ophthalmic solution, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of its generic brimonidine tartrate solution.  The filing of this suit triggered a 30-month stay of the approval of the Slayback ANDA for its brimonidine tartrate solution.  The Company remains confident in the strength of the Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and intends to vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 2, 2022 the Company commenced litigation against Lupin Pharmaceuticals, Inc. (&#x201c;Lupin&#x201d;) alleging patent infringement by Lupin&#x2019;s filing of its ANDA No. 216716, referencing Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (0.025% brimonidine tartrate ophthalmic solution). This suit had been filed following receipt of a Notice of Paragraph IV Certification from Lupin, in which it had asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#x2019;s Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; brimonidine tartrate ophthalmic solution, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of its generic brimonidine tartrate solution.  The filing of this suit triggered a 30-month stay of the approval of the Lupin ANDA for its brimonidine tartrate solution. The Company remains confident in the strength of the Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and will continue to vigorously pursue this matter and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Jublia Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, patents covering the Company's branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review ("IPR") at the U.S. Patent &amp;amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution. IPR challenges have been brought against patents covering the Company's branded pharmaceutical products. For example, following Acrux DDS&#x2019;s IPR petition, the U.S. Patent and Trial Appeal Board ("PTAB"), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(U.S. Patent No. 7,214,506 (the "&#x2018;506 Patent")) and, on &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings.  As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion.   The &#x2018;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;is covered by fourteen Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and has timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada against four separate defendants.  All cases in the U.S. regarding Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; have been settled. In Canada, two lawsuits remain pending against Apotex Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Liability &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Products Liability Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower&#xae; body powder product acquired in September 2012 from Johnson &amp;amp; Johnson; due to dismissals, twenty-nine (29) of such product liability suits currently remain pending. Potential liability (including its attorneys&#x2019; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp;amp; Johnson owed to the Company and its affiliates, and legal fees and costs will be paid by Johnson &amp;amp; Johnson. Twenty-eight (28) of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; caused the plaintiffs to develop ovarian cancer, mesothelioma or breast cancer. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages. The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#x2019; fees. Additionally, two proposed class actions have been filed in Canada against the Company and various Johnson &amp;amp; Johnson entities (one in the Supreme Court of British Columbia and one in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp;amp; Johnson&#x2019;s Baby Powder or Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. On November 17, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and at this time no appeal of that judgment has been filed. On December 16, 2021, the plaintiff in the British Columbia class action filed a Second Amended Notice of Civil Claim and Application for Certification, removing the Company as a defendant; as a result, the British Columbia class action is concluded as to the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson, through one or more subsidiaries has purported to have completed a Texas divisional merger with respect to any talc liabilities at Johnson &amp;amp; Johnson Consumer, Inc. (&#x201c;JJCI&#x201d;). LTL Management, LLC (&#x201c;LTL&#x201d;), the resulting entity of the divisional merger, assumed JJCI&#x2019;s talc liabilities and thereafter filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the Western District of North Carolina. Pursuant to a court order, the case was transferred to the United States District Court for the District of New Jersey. Notwithstanding the divisional merger and LTL&#x2019;s bankruptcy case, the Company and its affiliates continue to have indemnification claims and rights against Johnson &amp;amp; Johnson and LTL pursuant to the terms of the indemnification agreement entered into between JJCI and its affiliates and the Company and its affiliates, which indemnification agreement remains in effect. As a result, it is the Company's current expectation that it will not incur any material impairments with respect to its indemnification claims as a result of the divisional merger or the bankruptcy. Substantially all cases subject to the indemnification agreement related to Johnson &amp;amp; Johnson&#x2019;s talc liability are stayed through February 28, 2022, pursuant to a preliminary injunction issued by the bankruptcy court. Motions to dismiss the LTL bankruptcy, as well as extend the stay beyond February 28, 2022, were argued in the bankruptcy court in February 2022. A decision of the court is pending. To the extent that any cases subject to the indemnification agreement proceed during the pendency of the bankruptcy case, it is the Company's expectation that Johnson &amp;amp; Johnson, in accordance with the indemnification agreement, will continue to vigorously defend the Company in each of the remaining actions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;General Civil Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;California Proposition 65 Related Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp;amp; Johnson (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gutierrez, et al. v. Johnson &amp;amp; Johnson, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. The Company filed a motion to dismiss Plaintiffs&#x2019; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted.  In August 2020, Plaintiffs filed the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss with prejudice. On February 19, 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals. On July 1, 2021, Appellants (Plaintiffs) filed their opening brief; Appellees' response briefs were filed on October 8, 2021. This matter was stayed by the Ninth Circuit on December 7, 2021, due to the preliminary injunction entered by the bankruptcy court in the LTL bankruptcy proceeding. This stay included Appellants&#x2019; reply brief deadline, which was previously due to be filed on or before December 2, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New Mexico Attorney General Consumer Protection Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp;amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp;amp; Johnson and Johnson &amp;amp; Johnson Consumer Companies, Inc., the Company and Bausch Health US related to Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and its alleged causal link to mesothelioma and other cancers.  In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its answer on November 16, 2020. On December 30, 2020 Johnson &amp;amp; Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which was denied on March 8, 2021. Trial is scheduled to begin on January 18, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Doctors Allergy Formula Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, Doctors Allergy Formula, LLC (&#x201c;Doctors Allergy&#x201d;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.  Doctors Allergy claims its damages are not less than $23 million. Bausch Health Americas has asserted counterclaims against Doctors Allergy. Bausch Health Americas filed a motion seeking an order granting Bausch Health Americas summary judgment on its counterclaims against Plaintiff and dismissing Plaintiff&#x2019;s claims against it. The motion was fully briefed as of May 2021. The Court held a hearing on the motion on January 25, 2022. The motion remains pending. Bausch Health Americas disputes the claims against it and will continue to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation with Former Salix CEO&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, Case No. 2019-0059, asserting claims for breach of contract and declaratory relief.  On November 19, 2021, Logan amended her complaint to add a claim for breach of the implied covenant of good faith and fair dealing. The lawsuit arises out of the contractual termination of approximately $30 million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd.  Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification. On June 19, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. Trial is scheduled to commence on September 6, 2022. The Company disputes the claims and intends to vigorously defend the matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Completed or Inactive Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following matters have concluded, have settled, are the subject of an agreement to settle or have otherwise been closed since January 1, 2021, have been inactive from the Company&#x2019;s perspective for several quarters or the Company anticipates that no further material activity will take place with respect thereto. Due to the closure, settlement, inactivity or change in status of the matters referenced below, these matters will no longer appear in the Company's next public reports and disclosures, unless required. With respect to inactive matters, to the extent material activity takes place in subsequent quarters with respect thereto, the Company will provide updates as required or as deemed appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Glumetza Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between August 2019 and July 2020, eight (8) putative antitrust class actions and four (4) non-class complaints naming Bausch Health Companies Inc., Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., and Santarus, Inc. (for purposes of this subsection, collectively, the &#x201c;Company&#x201d;), among other defendants, were filed or transferred to the Northern District of California. Three (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020.  The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. Three (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020.  In December 2020, the court denied the Company&#x2019;s motion to dismiss as to the insurer plaintiff&#x2019;s direct claims but dismissed the insurer plaintiff&#x2019;s indirect claims. On February 2, 2021, the insurer plaintiff&#x2019;s motion for leave to amend its complaint was denied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These actions were consolidated and coordinated in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 3:19-cv-05822-WHA (N.D. Cal.) (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;). The lawsuits alleged that a 2012 settlement of a patent litigation regarding Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or grant any other company a license to do so. The complaints alleged that the settlement agreement resulted in higher prices for Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs sought damages under federal antitrust laws for claims based on direct purchases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 26, 2021, the Company reached an agreement in principle and, thereafter, on September 14, 2021, executed a final settlement agreement to resolve the class plaintiffs&#x2019; claims for $300&#160;million, subject to court approval. On August 1, 2021, the Company also reached an agreement in principle to resolve the non-class direct purchaser plaintiffs&#x2019; claims, described above, for additional consideration.  A final settlement agreement with the non-class direct purchaser plaintiffs was executed on August 6, 2021. As part of the settlements, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing.  On September 20, 2021, the insurer plaintiff voluntarily dismissed its claims in the consolidated federal action. By stipulation, the insurer plaintiff has asserted its direct opt-out claims in the State Court Action, resulting in the consolidation of all of its opt-out claims in the State Court Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 22, 2021, the court granted preliminary approval of the class settlement agreement and vacated the October 2021 trial date and all other pre-trial deadlines in the consolidated actions. On February 3, 2022, the court granted final  approval of the class settlement and ordered dismissal of the class plaintiffs' claims. Subject to appeal of the final approval of the class settlement, the settlements will resolve and discharge all asserted class and direct purchaser non-class claims against the Company in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;California Proposition 65 Related Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 29, 2020, Plaintiff Jan Graham filed a lawsuit (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Graham v. Bausch Health Companies, Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 20STCV03578) in Los Angeles County Superior Court against the Company, Bausch Health US and several other manufacturers, distributors and retailers of talcum powder products, alleging violations of California Proposition 65 by manufacturing and distributing talcum powder products containing chemicals listed under the statue, without a compliant warning on the label. On January 29, 2021, certain defendants including the Company and Bausch Health US filed a Motion for Summary Judgment or in the Alternative Motion for Summary Adjudication, which was granted with prejudice on May 26, 2021; Plaintiff waived the right to appeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Lawsuits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 10, 2019 and September 13, 2019, two alleged stockholders filed derivative lawsuits purportedly on behalf of the Company against former Company board members and executives. On March 7, 2020, a consolidated amended derivative complaint was filed, captioned In re Bausch Health Companies Inc. F/K/A/ Valeant Pharmaceuticals International, Inc. Stockholder Derivative Litigation (Case No. 19-cv-17833). &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Plaintiffs asserted claims for breach of fiduciary duty, waste of corporate assets, and unjust enrichment related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#x2019;s business and prospects, including relating to drug pricing, the Company&#x2019;s use of specialty pharmacies, and the Company&#x2019;s relationship with Philidor. The consolidated complaint also asserted a claim for contribution and indemnification by the Defendants for any liability the Company ultimately faces as a result of the conduct alleged in the complaint. The claims alleged in these cases were based on the same purported conduct that is at issue in In re Valeant Pharmaceuticals International, Inc. Securities Litigation, all of which occurred prior to 2017. On April 21, 2020, the Defendants filed a motion to dismiss the consolidated amended complaint.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Briefing on this motion concluded on August 3, 2020. On November 24, 2020, the Special Master appointed by the Court issued a report recommending that the motion to dismiss be granted in full.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 20, 2021, the District Court adopted the report and recommendation of the Special Master and dismissed the action.&lt;/span&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <bhc:Legalsettlementsandrelatedfees
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEyNjY_5c15f5a7-5871-45da-9d93-65eb45878f24"
      unitRef="usd">1890000000</bhc:Legalsettlementsandrelatedfees>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i91b2ee61b3794c97a503eb91ca7419fb_D20151001-20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzM0MDk_2cd9dd78-0008-49be-b2c3-d742fcfd7ccf"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i91b2ee61b3794c97a503eb91ca7419fb_D20151001-20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzM5NTA_4a812c39-ca55-4a8d-9139-f6b35c6b366b"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i06c668190ea847209a8da86cf1e73998_D20191216-20191216"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzQyNTA_2aa53740-7007-48ba-8c23-e0201a857624"
      unitRef="usd">1210000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="id6c40f9f298a435e8a95ba9a81e42595_D20211231-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzY1OTcwNjk5NTcwNDQ_28ecc69c-47aa-49c7-b763-95b9a2c1beb9"
      unitRef="usd">1210000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors
      contextRef="ia6542cc5b199449eb308666602a70acb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzYwNzQ_6425438d-83c7-4e37-9209-40439f0e0e1b"
      unitRef="group">37</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="ia6542cc5b199449eb308666602a70acb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwNzMx_b719770c-640d-46e4-9e7f-1eeefeecff0b"
      unitRef="case">16</us-gaap:LossContingencyClaimsDismissedNumber>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors
      contextRef="ia6542cc5b199449eb308666602a70acb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwNzQx_6425438d-83c7-4e37-9209-40439f0e0e1b"
      unitRef="group">37</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending
      contextRef="ia6542cc5b199449eb308666602a70acb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwODcy_82e180be-9476-4072-8f27-4b8821bb381f"
      unitRef="group">21</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="ifd485be691b84f43ab57f11e016f9b16_D20150101-20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEzMTgz_48d7e1c7-5ad8-4e5b-a417-0053c8209fa4"
      unitRef="case">6</us-gaap:LossContingencyNewClaimsFiledNumber>
    <bhc:LossContingencyNewClaimsFiledButNotYetServedNumber
      contextRef="if49a279281c940c0bb5c71ec87be9d3c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzE0MTEx_3f82e3aa-8770-4291-8836-ee47eb5e2079"
      unitRef="action">2</bhc:LossContingencyNewClaimsFiledButNotYetServedNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i3eca502d770d4373a854ca461ac2dffb_D20200804-20200804"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzE1Nzc4_037f9880-2125-46c4-88bf-587f5fb63ce1"
      unitRef="cad">94000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction
      contextRef="i35775310d73b4d409433acee7c99eb8c_I20190215"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzE3MjAz_a4a895f8-a420-4774-9b59-419ebfb93e23"
      unitRef="entity">1</bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction>
    <bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction
      contextRef="i73250b3b65e14dc084f6d77a1b839bb1_I20210317"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwOTk1MTE3OTY0MTI_87bded6f-ba40-4107-b872-b1e8703201aa"
      unitRef="numberofbusiness">4</bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i0f0be9ec6ddf45658d3a7d087aa67006_D20160527-20160916"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzIwMTE1_f23b244a-e747-4bc1-96f3-20f9ac5ce88e"
      unitRef="action">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <bhc:LossContingencyNumberOfInsurancePolicyPeriods
      contextRef="i7ebadc5ebb4b4ab7890bec9925824363_D20171207-20171207"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwOTk1MTE3OTY0MjI_115ecda7-1241-43e9-b862-076f35130d60"
      unitRef="insurance_policy_period">2</bhc:LossContingencyNumberOfInsurancePolicyPeriods>
    <bhc:LossContingencySettlementAgreementsNumberOfInsurers
      contextRef="i02a698a8f008492cbd69f48f20e081f8_I20210720"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwOTk1MTE3OTY0MzA_5c8b6cd7-b0ce-4822-9ca5-4aa13fdb3f23"
      unitRef="insured">2</bhc:LossContingencySettlementAgreementsNumberOfInsurers>
    <bhc:LossContingencySettlementAgreementsNumberOfInsurers
      contextRef="i02a698a8f008492cbd69f48f20e081f8_I20210720"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwOTk1MTE3OTY0Mzg_65e81f26-c3ad-41f5-b69a-3e51fad29425"
      unitRef="insured">2</bhc:LossContingencySettlementAgreementsNumberOfInsurers>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="i32cfd64f67674351a47e22d698db3e9e_D20210720-20210720"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwOTk1MTE3OTY0NDc_ae1fc1a5-061f-41f0-936a-fd146e7ebf81"
      unitRef="usd">213000000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <bhc:LossContingencyStayOfApprovalPeriod
      contextRef="i06854e40aeff47b0b797200881bfe88d_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzMzMDQ0_beebe9de-747e-49b8-91cb-41fe7601426a">P30M</bhc:LossContingencyStayOfApprovalPeriod>
    <bhc:LossContingencyStayOfApprovalPeriod
      contextRef="i4bd7415ed1604a45b4b6bc56767acc83_D20200828-20200828"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzQwMjI5_9b6d5ab4-8f32-49a7-9bb7-ef105baf5f10">P30M</bhc:LossContingencyStayOfApprovalPeriod>
    <bhc:LossContingencyStayOfApprovalPeriod
      contextRef="i35ab857c3fb443e7906b7fc3fdb47b2f_D20200501-20200501"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzQxMjQ5_9f942def-60da-4d38-944c-1460ad14c8c6">P30M</bhc:LossContingencyStayOfApprovalPeriod>
    <bhc:LossContingencyStayOfApprovalPeriod
      contextRef="i823e4afeb6cf4d59ae626d765f776286_D20210401-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzI3NDg3NzkyMzgxMjg_360cbb3c-13a3-4c92-8f0c-5397c0e6d696">P30M</bhc:LossContingencyStayOfApprovalPeriod>
    <bhc:LossContingencyStayOfApprovalPeriod
      contextRef="ia07d23a8e2fc407d901667681d446493_D20210901-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzI3NDg3NzkyMzgxNDA_2eab434a-96f8-4b9f-b213-1f78afc0b777">P30M</bhc:LossContingencyStayOfApprovalPeriod>
    <bhc:LossContingencyStayOfApprovalPeriod
      contextRef="i2837802deebf438f831c9248b84634f3_D20220202-20220202"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwOTk1MTE4MTE0NTA_9a629a30-93ec-43ba-8782-ce852302eb50">P30M</bhc:LossContingencyStayOfApprovalPeriod>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i3142f2cfd5aa4bb08a1afccc27a8a806_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwOTk1MTE4MTE0NTY_33874e55-fd9d-42dd-b911-a53df48146b3"
      unitRef="case">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i9cebf3bd98614f709e30c0cad5ae3945_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzQzMzQ2_89f14c44-f97b-4bbe-950f-91d14b695264"
      unitRef="case">29</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="idf59e9f444d44941a03dff00106248fe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzQzNDMy_f214bb47-3358-45f0-b1f5-c307308c0a89"
      unitRef="case">28</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i668c09254646450da54e4779c1a1cf5c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzI3NDg3NzkyMzgxNDY_8a337ed9-f9fd-4a18-82fe-394dab12d06e"
      unitRef="case">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="id333f2cd40c246d686e1bf05143b6d09_I20211215"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzI3NDg3NzkyMzgxNTQ_64500c56-9646-4098-a117-c991fb093276"
      unitRef="case">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="id08c64cba12f4488a204547ee19dbb28_D20211216-20211216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzI3NDg3NzkyMzgxNTQ_e9690e94-c05f-4385-b4ca-2a5765b82c3e"
      unitRef="case">1</us-gaap:LossContingencyClaimsDismissedNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i4d1927896b7f467b9ea850d5899edaa8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzI3NDg3NzkyMzgxNjI_61a37cc8-7f58-4d33-8688-850426f1911e"
      unitRef="case">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="if5a5b7cb1bde4b00b20dc046470c7dbc_D20180401-20180430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzU0OTkz_eacec469-67a7-4bad-9442-efd779cb73ac"
      unitRef="usd">23000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i3f954393aadc446fa7a66231a8a0176d_D20190128-20190128"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzU1OTMw_c1b7b6ef-1537-48c1-86aa-4ac4ab517cf6"
      unitRef="usd">30000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="iaf28153bff85452b8ab343577fbba878_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzI3NDg3NzkyMzgxNzQ_61146afe-31df-4432-ad7f-b77c653fc543"
      unitRef="case">8</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i705b99b9e9f141cea120e4f7552a841d_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzI3NDg3NzkyMzgxNzg_fb4e35d9-ba4c-467a-bba0-98195adecc40"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="ib79efab1243d47f58861ab6f96316996_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzI3NDg3NzkyMzgxODI_5177bc4b-be4a-4159-b855-790d6d3c8d3c"
      unitRef="case">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i2b0d134ac84a4b9fb995abee169d3922_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzM4NDgyOTA4NTU2Njc_7a8765ea-34de-4978-b13f-8233c7ba610d"
      unitRef="case">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i0974c8f474ad4f1ca10ac1d1131053f8_D20210726-20210726"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzM4NDgyOTA4NTU2NzA_b73ab7ee-81bf-4f62-9275-0af0dc90685f"
      unitRef="usd">300000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LossContingencyNumberOfAllegedStockholdersFiledLawsuits
      contextRef="ied24221b489d4f4ba5abd2b2dd8014fb_I20190910"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwOTk1MTE4MTgxNDA_5931f6d7-1348-4506-bc5a-9cf53cabd5da"
      unitRef="shareholder">2</bhc:LossContingencyNumberOfAllegedStockholdersFiledLawsuits>
    <bhc:LossContingencyNumberOfAllegedStockholdersFiledLawsuits
      contextRef="id56dfce34e5c4c43bdd8c62baf232508_I20190913"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjEvZnJhZzplYTUwYjVjYzAxZmY0MTllOTI1MjVmNjAwNmM0MjFhZS90ZXh0cmVnaW9uOmVhNTBiNWNjMDFmZjQxOWU5MjUyNWY2MDA2YzQyMWFlXzEwOTk1MTE4MTgxNDA_a6d5ebcc-2482-4094-a9df-a62b4840bfa7"
      unitRef="shareholder">2</bhc:LossContingencyNumberOfAllegedStockholdersFiledLawsuits>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjQvZnJhZzoxNTYyMzlkNjBkODg0ZDFjYjFlMTZkZGJlYTA2MDVmZi90ZXh0cmVnaW9uOjE1NjIzOWQ2MGQ4ODRkMWNiMWUxNmRkYmVhMDYwNWZmXzUxNjE_6c052370-f710-4585-bf19-6c11adb16161">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has commitments related to capital expenditures of approximately $76 million as of December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under certain agreements, the Company may be required to make payments contingent upon the achievement of specific developmental, regulatory, or commercial milestones. As of December&#160;31, 2021, the Company believes it is reasonably possible that it may potentially make milestone and license fee payments, including sales-based milestone payments, of approximately $340 million over time, in the aggregate, to third parties for products currently under development or being marketed, primarily consisting of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Under the terms of a June 2013 distribution and supply agreement with Mylan Pharmaceuticals Inc. (as assignee of Spear Pharmaceuticals, Inc and Spear Dermatology Products Inc.), the Company may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $70 million, in the aggregate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Under the terms of an April 2019 agreement with Mitsubishi Tanabe Pharma Corporation, the Company has acquired an exclusive license to develop and commercialize&#160;MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as Inflammatory Bowel Disease and ulcerative colitis. The Company may be required to make development and sales-based milestone payments over time of up to $60 million, in the aggregate, as well as royalties on future sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Under the terms of a December 2019 agreement with Novaliq GmbH, the Company has acquired an exclusive license for the commercialization and development in the U.S. and Canada of NOV03 (perfluorohexyloctane), an investigational drug to treat Dry Eye Disease associated with Meibomian gland dysfunction and may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $48 million, in the aggregate, as well as royalties on future sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Under the terms of a November 2019 agreement with Cedars-Sinai Medical Center, to evaluate a new formulation of rifaximin for the treatment of irritable bowel syndrome, the Company may be required to make development and sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $36&#160;million, in the aggregate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Under the terms of an October 2020 agreement with Eyenovia, Inc., the Company has acquired an exclusive license in the U.S. and Canada for the development and commercialization of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12. Under the terms of the agreement, the Company may be required to make development and sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $35&#160;million, in the aggregate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Under the terms of a May 2020 agreement with STADA Arzneimittel AG and its development partner, Xbrane Biopharma AB, to commercialize in the U.S. and Canada a biosimilar candidate to Lucentis (ranibizumab), the Company may be required to make development and sales-based milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the nature of these arrangements, the future potential payments related to the attainment of the specified milestones over a period of several years are inherently uncertain. As of December 31, 2021, no accruals related to the aforementioned agreements exist because the milestone targets are not yet probable of being achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Indemnification Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into agreements that include indemnification provisions for product liability and other matters. These provisions are generally subject to maximum amounts, specified claim periods and other conditions and limits. In addition, the Company is obligated to indemnify its officers and directors in respect of any legal claims or actions initiated against them in their capacity as officers and directors of the Company in accordance with applicable law. Pursuant to such indemnities, the Company is indemnifying certain former officers and directors in respect of certain litigation and regulatory matters.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021 and 2020, no material amounts were accrued for the Company&#x2019;s obligations under these indemnification provisions.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ContractualObligation
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjQvZnJhZzoxNTYyMzlkNjBkODg0ZDFjYjFlMTZkZGJlYTA2MDVmZi90ZXh0cmVnaW9uOjE1NjIzOWQ2MGQ4ODRkMWNiMWUxNmRkYmVhMDYwNWZmXzg2_8a807c95-9140-49f9-ab80-c56b2052108b"
      unitRef="usd">76000000</us-gaap:ContractualObligation>
    <bhc:CollaborativeAgreementMilestonePaymentsAggregate
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjQvZnJhZzoxNTYyMzlkNjBkODg0ZDFjYjFlMTZkZGJlYTA2MDVmZi90ZXh0cmVnaW9uOjE1NjIzOWQ2MGQ4ODRkMWNiMWUxNmRkYmVhMDYwNWZmXzQ0OQ_05cec783-a033-4727-9fb4-7b0642a59d33"
      unitRef="usd">340000000</bhc:CollaborativeAgreementMilestonePaymentsAggregate>
    <bhc:CollaborativeAgreementMilestonePaymentsAggregate
      contextRef="i81f9ed3c74134a7fabf0feaf1c2120c1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjQvZnJhZzoxNTYyMzlkNjBkODg0ZDFjYjFlMTZkZGJlYTA2MDVmZi90ZXh0cmVnaW9uOjE1NjIzOWQ2MGQ4ODRkMWNiMWUxNmRkYmVhMDYwNWZmXzkzNg_376c5bef-ffd7-42a9-b2bd-568e03b4ce61"
      unitRef="usd">70000000</bhc:CollaborativeAgreementMilestonePaymentsAggregate>
    <bhc:CollaborativeAgreementMilestonePaymentsAggregate
      contextRef="iaf37c45946284359a2d4538803c7b301_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjQvZnJhZzoxNTYyMzlkNjBkODg0ZDFjYjFlMTZkZGJlYTA2MDVmZi90ZXh0cmVnaW9uOjE1NjIzOWQ2MGQ4ODRkMWNiMWUxNmRkYmVhMDYwNWZmXzE0Mjc_12a3b524-a485-4a00-a64d-2033ff959fb8"
      unitRef="usd">60000000</bhc:CollaborativeAgreementMilestonePaymentsAggregate>
    <bhc:CollaborativeAgreementMilestonePaymentsAggregate
      contextRef="i7f2f1cfe9dc04f76978526af52bd0a5a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjQvZnJhZzoxNTYyMzlkNjBkODg0ZDFjYjFlMTZkZGJlYTA2MDVmZi90ZXh0cmVnaW9uOjE1NjIzOWQ2MGQ4ODRkMWNiMWUxNmRkYmVhMDYwNWZmXzE5NDI_662b660b-7fb3-4bc0-9a93-23a50af4151b"
      unitRef="usd">48000000</bhc:CollaborativeAgreementMilestonePaymentsAggregate>
    <bhc:CollaborativeAgreementMilestonePaymentsAggregate
      contextRef="i9bdb8b8277cf4e04ada86ca0bed059dc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjQvZnJhZzoxNTYyMzlkNjBkODg0ZDFjYjFlMTZkZGJlYTA2MDVmZi90ZXh0cmVnaW9uOjE1NjIzOWQ2MGQ4ODRkMWNiMWUxNmRkYmVhMDYwNWZmXzIzNDg_25f9de5e-5a09-4172-b4a3-e4f65e17d6cd"
      unitRef="usd">36000000</bhc:CollaborativeAgreementMilestonePaymentsAggregate>
    <bhc:CollaborativeAgreementMilestonePaymentsAggregate
      contextRef="i62ab16dfdb214a95ac5f1498f90faa39_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjQvZnJhZzoxNTYyMzlkNjBkODg0ZDFjYjFlMTZkZGJlYTA2MDVmZi90ZXh0cmVnaW9uOjE1NjIzOWQ2MGQ4ODRkMWNiMWUxNmRkYmVhMDYwNWZmXzI5Nzc_aa99d75c-b7a1-46f1-b9bf-bde9a809239b"
      unitRef="usd">35000000</bhc:CollaborativeAgreementMilestonePaymentsAggregate>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzM5MTY_56ed63f7-6561-4fef-a8b3-1820123212d4">SEGMENT INFORMATION&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Chief Executive Officer ("CEO"), who is the Company&#x2019;s Chief Operating Decision Maker, manages the business through operating and reportable segments consistent with how the Company's CEO: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. The Company operates in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International Rx, (iv) Ortho Dermatologics and (v) Diversified Products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a brief description of the Company&#x2019;s segments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.53pt"&gt;The Bausch + Lomb segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of global sales of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmic Pharmaceuticals products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Salix segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of sales in the U.S. of GI products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The International Rx segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of sales, with the exception of sales of Bausch +Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Ortho Dermatologics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological) products and (ii) global sales of Solta aesthetic medical devices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Diversified Products segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment profit is based on operating income after the elimination of intercompany transactions.  Certain costs, such as Amortization of intangible assets, Asset impairments, including loss on assets held for sale, Restructuring, integration, separation and IPO costs, and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#x2019;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the planned separation of its Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., on February 23, 2022, the Company announced its plan to change its segment structure in a manner which is consistent with the organizational structure of the two separate entities as proposed by the Solta IPO during the first quarter of 2022. The new segment structure will not impact the Company&#x2019;s reporting units but will realign the two reporting units of the Ortho Dermatologics segment whereby its medical dermatology reporting unit (Ortho Dermatologics) will now be managed by the CODM as part of the Diversified Products segment and the Solta reporting unit will be managed by the CODM as its own operating and reportable segment. Accordingly, the Company expects to begin reporting under the following reporting segments on a retrospective basis beginning with its first quarter of 2022 as follows: Bausch + Lomb, Salix, International Rx, Solta and Diversified Products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Revenues and Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment revenues and profits for the years 2021, 2020 and 2019 were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International Rx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International Rx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairments, including loss on assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, integration, separation and IPO costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(502)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss before benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to segment revenue and profit in order for the prior years to conform to current year presentation. These reclassifications are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Capital Expenditures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capital expenditures by segment for the years 2021, 2020 and 2019 were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital expenditures:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International Rx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenues by Product and by Product Category &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues for the Company's top ten products for the years 2021, 2020 and 2019 represented 43%, 41% and 39% of total product sales, respectively. Revenues by segment and product category were as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;International Rx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;International Rx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;International Rx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are attributed to a geographic region based on the location of the customer for the years 2021, 2020 and 2019 were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Russia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Egypt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made and are reflected in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December&#160;31, 2021 and 2020 were as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Serbia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customers that accounted for 10% or more of total revenues were as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health,&#160;Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzM5MTQ_8ea230b5-f046-4d2b-91b8-e5067a5a9ad9">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#x2019;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the planned separation of its Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., on February 23, 2022, the Company announced its plan to change its segment structure in a manner which is consistent with the organizational structure of the two separate entities as proposed by the Solta IPO during the first quarter of 2022. The new segment structure will not impact the Company&#x2019;s reporting units but will realign the two reporting units of the Ortho Dermatologics segment whereby its medical dermatology reporting unit (Ortho Dermatologics) will now be managed by the CODM as part of the Diversified Products segment and the Solta reporting unit will be managed by the CODM as its own operating and reportable segment. Accordingly, the Company expects to begin reporting under the following reporting segments on a retrospective basis beginning with its first quarter of 2022 as follows: Bausch + Lomb, Salix, International Rx, Solta and Diversified Products.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="i03a8ce11b6a94d508439a84f941e6341_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzM4NDgyOTA3MTAwMjg_90846ce4-db86-4504-acc1-c36bc3001f06"
      unitRef="reporting_unit">2</us-gaap:NumberOfReportingUnits>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzM4ODI_bf77ee1d-4334-42d4-9186-830da2f4506d">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment revenues and profits for the years 2021, 2020 and 2019 were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International Rx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International Rx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairments, including loss on assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, integration, separation and IPO costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(502)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss before benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30bf053c559f4b1c9ed175d768f3d24b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzItMS0xLTEtNTk0NzA_bdeadaa1-7bc1-4212-bbdc-5e61b872f853"
      unitRef="usd">3765000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i673b35bd82f24773b53ca856e22be6c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzItMy0xLTEtNTk0NzA_c59460b9-bc8d-4085-b95e-99164b19f709"
      unitRef="usd">3415000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f6d3e46f96644c89ae14a35eb34a016_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzItNS0xLTEtNTk0NzA_dbdf23a0-273f-485b-94e9-a53a47ec0c77"
      unitRef="usd">3778000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffb4ee2a83284e5aacf40c45394d64ee_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzMtMS0xLTEtNTk0NzA_c3e27cb5-348b-4185-b126-116e7d7f1da7"
      unitRef="usd">2074000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc3957b2514e43d4bc57896332a29c98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzMtMy0xLTEtNTk0NzA_3aeae3ab-45c0-483c-9a56-275172e10838"
      unitRef="usd">1904000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i526b3306560a4582bbd5cb84b6634e8e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzMtNS0xLTEtNTk0NzA_f50cba2d-0d00-4d6c-b34b-c79c68959915"
      unitRef="usd">2022000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1aabb4dd84c41e78c5713f72684c58c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzQtMS0xLTEtNjE1OTM_4a9688e8-4672-4a4a-8db2-d7af35ff6bcb"
      unitRef="usd">1166000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12ca69aa53c04d1f9a70ca7832545115_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzQtMy0xLTEtNjE1ODM_8ca2df3c-acd7-42ea-a642-83cf61942fef"
      unitRef="usd">1181000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d617a50cb4e4dc2b9d45dd78b38e32c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzQtNS0xLTEtNjE1NjI_f40932c9-1d1e-4c1b-8274-8be991b59952"
      unitRef="usd">1154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fd885b33ea84b91854e977c98d0cdd2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzQtMS0xLTEtNTk0NzA_7f2f7a01-5b38-43dd-8e72-321e4ff71763"
      unitRef="usd">564000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe4fe193ae054da49acc60fb104beaba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzQtMy0xLTEtNTk0NzA_90deb939-aa0d-4c5a-a3b8-4036d6c7d2d3"
      unitRef="usd">548000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fc28f8f6ed74a9089917e8b80f33998_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzQtNS0xLTEtNTk0NzA_2aaf2093-3358-41d3-9737-2c89153ec32b"
      unitRef="usd">560000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9bb5d7f34e00490896510ef48df89709_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzUtMS0xLTEtNTk0NzA_3ec7ccbe-7a6a-4f99-a4ca-180c09290884"
      unitRef="usd">865000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e43bb66906240b1bf5bd13e06e0eb33_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzUtMy0xLTEtNTk0NzA_f8a037f0-640d-4167-9d12-2da06aaeb841"
      unitRef="usd">979000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic22f83493b6c49b3bd143623ecdfcef6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzUtNS0xLTEtNTk0NzA_6528f6ce-beb3-4a35-97af-d1e931f5ad3b"
      unitRef="usd">1087000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i305152159c734293b19863277adb1507_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzYtMS0xLTEtNTk0NzA_17dcf41c-b279-4e93-b0f8-3b362e58c24f"
      unitRef="usd">8434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16716b25f68d437e8b5603c13cad09e4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzYtMy0xLTEtNTk0NzA_be3a4918-2682-4626-92cd-42182ff2078d"
      unitRef="usd">8027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2acd16c5638f406dbc8a4a64bcfb73c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzYtNS0xLTEtNTk0NzA_6096691e-eba7-4889-8a06-f0989dfc2e45"
      unitRef="usd">8601000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i30bf053c559f4b1c9ed175d768f3d24b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzgtMS0xLTEtNTk0NzA_c2d4611f-fc46-4f70-a1d3-b7d01e5c14ed"
      unitRef="usd">958000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i673b35bd82f24773b53ca856e22be6c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzgtMy0xLTEtNTk0NzA_20f2992a-513b-4a63-a394-09ae1877380f"
      unitRef="usd">909000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4f6d3e46f96644c89ae14a35eb34a016_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzgtNS0xLTEtNTk0NzA_70945a12-7055-4588-9576-df3031c752c0"
      unitRef="usd">1117000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iffb4ee2a83284e5aacf40c45394d64ee_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzktMS0xLTEtNTk0NzA_71d2dbe6-818e-4e63-a43f-551cb5427020"
      unitRef="usd">1493000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icc3957b2514e43d4bc57896332a29c98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzktMy0xLTEtNTk0NzA_0ae1a83d-1e70-4bfd-9cf2-0b53765e49a9"
      unitRef="usd">1338000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i526b3306560a4582bbd5cb84b6634e8e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzktNS0xLTEtNTk0NzA_bf741a0b-53fa-4e02-9b01-3cf5cda71e24"
      unitRef="usd">1349000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib1aabb4dd84c41e78c5713f72684c58c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzExLTEtMS0xLTYxNjkw_9ae6d843-678f-41c4-93f9-1aa4b769da6f"
      unitRef="usd">403000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i12ca69aa53c04d1f9a70ca7832545115_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzExLTMtMS0xLTYxNjgx_5a4713cb-7fcf-41c5-bfcb-604df189f8de"
      unitRef="usd">386000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5d617a50cb4e4dc2b9d45dd78b38e32c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzExLTUtMS0xLTYxNjgx_4fa2310c-f6c6-4a22-8487-a64ff2b37225"
      unitRef="usd">352000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3fd885b33ea84b91854e977c98d0cdd2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzEwLTEtMS0xLTU5NDcw_b489e960-ba27-479d-8a7d-44895fe55e36"
      unitRef="usd">265000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibe4fe193ae054da49acc60fb104beaba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzEwLTMtMS0xLTU5NDcw_a0346bbf-0c2a-4006-83de-cf94952a46cb"
      unitRef="usd">228000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8fc28f8f6ed74a9089917e8b80f33998_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzEwLTUtMS0xLTU5NDcw_040a4dc6-20ab-4ea6-9b69-7b3d93de89f9"
      unitRef="usd">216000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9bb5d7f34e00490896510ef48df89709_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzExLTEtMS0xLTU5NDcw_09073c28-9c8d-41ed-9895-515347a252df"
      unitRef="usd">624000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7e43bb66906240b1bf5bd13e06e0eb33_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzExLTMtMS0xLTU5NDcw_ead796ca-be15-4fc6-bec1-381214f86a31"
      unitRef="usd">717000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic22f83493b6c49b3bd143623ecdfcef6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzExLTUtMS0xLTU5NDcw_aed1f20a-41fc-4fd8-a82c-3ad914cd39c9"
      unitRef="usd">801000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i305152159c734293b19863277adb1507_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzEyLTEtMS0xLTU5NDcw_1d3eb57b-845d-48af-93dc-45c2deb8382f"
      unitRef="usd">3743000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i16716b25f68d437e8b5603c13cad09e4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzEyLTMtMS0xLTU5NDcw_138065e7-0a4d-4b68-a610-6035df092173"
      unitRef="usd">3578000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2acd16c5638f406dbc8a4a64bcfb73c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzEyLTUtMS0xLTU5NDcw_ce2cdbc8-63b8-455d-b849-35d69160b2f2"
      unitRef="usd">3835000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if4c91dc7a5754f868357dbaaf40b5a60_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzEzLTEtMS0xLTU5NDcw_fbcc9b3e-bd3a-4775-aae2-e207e929fba4"
      unitRef="usd">-792000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i40ecfa21f8b642f7807a65183e087f3e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzEzLTMtMS0xLTU5NDcw_73ec405b-d580-4052-b5c9-d37bf54b5e53"
      unitRef="usd">-619000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i93fdc6cbea484e5d933d9ec17976a64a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzEzLTUtMS0xLTU5NDcw_24f41666-7f60-42b1-b327-c3bc73a2fa0e"
      unitRef="usd">-609000000</us-gaap:OperatingIncomeLoss>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE0LTEtMS0xLTU5NDcw_6e4309f0-31a3-4896-8e5f-855f6667f133"
      unitRef="usd">1375000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE0LTMtMS0xLTU5NDcw_f035d8b5-29e8-4800-8b1c-1f5a860d9335"
      unitRef="usd">1645000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE0LTUtMS0xLTU5NDcw_670bbcd4-7635-4428-a3a7-80bbbb1b1d73"
      unitRef="usd">1897000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE1LTEtMS0xLTU5NDcw_19df4b16-164e-4e40-a126-240a3bcb491f"
      unitRef="usd">469000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE1LTMtMS0xLTU5NDcw_35afb829-5d7b-43b8-b4ef-9be85d0b210c"
      unitRef="usd">0</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE1LTUtMS0xLTU5NDcw_5cf9cb60-13cb-4ee6-be08-cf377d44f47d"
      unitRef="usd">0</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE2LTEtMS0xLTU5NDcw_408e218e-4ef4-4562-8196-60f56cdf5dca"
      unitRef="usd">234000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE2LTMtMS0xLTU5NDcw_0a1932da-2e03-495f-b975-81b6dd32a2c9"
      unitRef="usd">114000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE2LTUtMS0xLTU5NDcw_4a3eafd2-856f-4742-94e6-576dcc3df232"
      unitRef="usd">75000000</us-gaap:AssetImpairmentCharges>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE3LTEtMS0xLTU5NDcw_a5735612-63f7-4427-a018-617df0f176d0"
      unitRef="usd">50000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE3LTMtMS0xLTU5NDcw_1b28060a-7adf-4042-904d-abe22594298f"
      unitRef="usd">22000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE3LTUtMS0xLTU5NDcw_e1df5650-84db-4ccf-b5d5-6823b049b075"
      unitRef="usd">31000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE5LTEtMS0xLTU5NDcw_d4da6ded-981f-46f4-ac1b-bb96d45f19f6"
      unitRef="usd">-373000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE5LTMtMS0xLTU5NDcw_edaea381-69cc-4b03-893f-449c4ceec9c4"
      unitRef="usd">-502000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzE5LTUtMS0xLTU5NDcw_014cbc25-9285-4ed2-a3cf-477bd4257ce6"
      unitRef="usd">-1426000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIwLTEtMS0xLTU5NDcw_1f52d3a3-c17c-4e17-80f6-0a1f2b4141c0"
      unitRef="usd">450000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIwLTMtMS0xLTU5NDcw_aab40356-39c1-4792-848b-06660f6b8c87"
      unitRef="usd">676000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIwLTUtMS0xLTU5NDcw_5913182b-889a-4fd7-bff5-60e8701df04f"
      unitRef="usd">-203000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIxLTEtMS0xLTU5NDcw_d57dc928-8ce8-49ca-86fa-d3b89156bce2"
      unitRef="usd">7000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIxLTMtMS0xLTU5NDcw_6e73de62-8215-40a7-912a-eae4688b7fef"
      unitRef="usd">13000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIxLTUtMS0xLTU5NDcw_bfa03adb-8999-45fa-ba7b-acd6169db240"
      unitRef="usd">12000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestAndDebtExpense
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIyLTEtMS0xLTU5NDcw_92bdf1df-0fb0-42a9-bb71-409d5ff698f5"
      unitRef="usd">1426000000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIyLTMtMS0xLTU5NDcw_ef16b3cd-09de-44e0-8a3e-67a6dc16d371"
      unitRef="usd">1534000000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIyLTUtMS0xLTU5NDcw_b749e6df-860a-4125-9502-876c6d0e8304"
      unitRef="usd">1612000000</us-gaap:InterestAndDebtExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIzLTEtMS0xLTU5NDcw_8c8ed36a-7070-4256-b371-ba1ddcf4c74c"
      unitRef="usd">-62000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIzLTMtMS0xLTU5NDcw_3e90a5a6-2640-468d-b738-58639ce3a038"
      unitRef="usd">-59000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzIzLTUtMS0xLTU5NDcw_18a6a4fa-30a5-4bb9-a6f0-c15be2142ef3"
      unitRef="usd">-42000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzI0LTEtMS0xLTU5NDcw_2abe15d7-b041-426b-ad88-ebd0bceb7fba"
      unitRef="usd">7000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzI0LTMtMS0xLTU5NDcw_916c6580-b6cf-4f82-9a00-f146fd61c3b9"
      unitRef="usd">-30000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzI0LTUtMS0xLTU5NDcw_865cb0d2-066c-454d-a3a0-11831203da99"
      unitRef="usd">8000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzI1LTEtMS0xLTU5NDcw_4a7a537d-8f73-498d-a0df-b60d6f3bda49"
      unitRef="usd">-1024000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzI1LTMtMS0xLTU5NDcw_50ebe804-a3be-418b-8b1b-4a25786b68ca"
      unitRef="usd">-934000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTowNWU5MGE1ZDhiZjA0MWE4OWQ1YWJlOWEwNGIyMjhiNy90YWJsZXJhbmdlOjA1ZTkwYTVkOGJmMDQxYTg5ZDVhYmU5YTA0YjIyOGI3XzI1LTUtMS0xLTU5NDcw_783291ff-b6c0-4c19-ace3-6c44b48a5b38"
      unitRef="usd">-1837000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzM5MDA_bab23ce8-4242-45ea-9222-ab4ea509e533">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capital expenditures by segment for the years 2021, 2020 and 2019 were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital expenditures:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International Rx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i30bf053c559f4b1c9ed175d768f3d24b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzItMS0xLTEtNTk0NzA_b3aaee89-8923-4424-9908-4901f0e135b8"
      unitRef="usd">201000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i673b35bd82f24773b53ca856e22be6c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzItMy0xLTEtNTk0NzA_d98188e9-c4a4-42a6-9d5d-0386796cc566"
      unitRef="usd">253000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i4f6d3e46f96644c89ae14a35eb34a016_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzItNS0xLTEtNTk0NzA_d73db850-a5f7-4daf-9a98-80861d9faa6f"
      unitRef="usd">186000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="iffb4ee2a83284e5aacf40c45394d64ee_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzMtMS0xLTEtNTk0NzA_5d65b0b0-2c23-42f9-941b-daff31700fcc"
      unitRef="usd">2000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="icc3957b2514e43d4bc57896332a29c98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzMtMy0xLTEtNTk0NzA_c3fd4fd4-4d8d-4baf-84a3-59477cbdab7c"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i526b3306560a4582bbd5cb84b6634e8e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzMtNS0xLTEtNTk0NzA_bfda9e22-ad43-418f-8491-c7dbb4cab43f"
      unitRef="usd">2000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ib1aabb4dd84c41e78c5713f72684c58c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzQtMS0xLTEtNjg4MDY_50895cf5-4b16-4fa1-a3c9-65377f4ad9df"
      unitRef="usd">22000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i12ca69aa53c04d1f9a70ca7832545115_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzQtMy0xLTEtNjg4MDI_59fad681-7a21-4063-b085-a48116a0cff0"
      unitRef="usd">29000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i5d617a50cb4e4dc2b9d45dd78b38e32c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzQtNS0xLTEtNjg4MDQ_1ace1edd-2c1d-4cbd-9ac2-0bb493831d6a"
      unitRef="usd">39000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i3fd885b33ea84b91854e977c98d0cdd2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzQtMS0xLTEtNTk0NzA_5db70129-24de-4925-aeb2-7050715751bc"
      unitRef="usd">1000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ibe4fe193ae054da49acc60fb104beaba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzQtMy0xLTEtNTk0NzA_d79f9639-d7c0-423c-ae51-4a8b06182bad"
      unitRef="usd">2000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i8fc28f8f6ed74a9089917e8b80f33998_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzQtNS0xLTEtNTk0NzA_9d1a5993-f47e-402e-b275-cddd83438db7"
      unitRef="usd">1000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i9bb5d7f34e00490896510ef48df89709_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzUtMS0xLTEtNTk0NzA_609ac970-d601-4638-944a-e67d912a58ea"
      unitRef="usd">1000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i7e43bb66906240b1bf5bd13e06e0eb33_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzUtMy0xLTEtNTk0NzA_1d2b8c5d-9dec-4114-8fe3-65c74ca73eab"
      unitRef="usd">2000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ic22f83493b6c49b3bd143623ecdfcef6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzUtNS0xLTEtNTk0NzA_bdc4eee4-e86d-430b-90b8-96c449561fa9"
      unitRef="usd">2000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i305152159c734293b19863277adb1507_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzYtMS0xLTEtNTk0NzA_1f6710be-7371-4c1a-9356-30ed1833a509"
      unitRef="usd">227000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i16716b25f68d437e8b5603c13cad09e4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzYtMy0xLTEtNTk0NzA_1d583b3d-c791-4ec6-a8f9-faf6f01aedfd"
      unitRef="usd">289000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i2acd16c5638f406dbc8a4a64bcfb73c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzYtNS0xLTEtNTk0NzA_fed8706a-7ea6-44e2-a712-0aa4fcee4a9a"
      unitRef="usd">230000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="if4c91dc7a5754f868357dbaaf40b5a60_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzctMS0xLTEtNTk0NzA_40396449-f098-4c1b-b6d3-ad38e4868305"
      unitRef="usd">42000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i40ecfa21f8b642f7807a65183e087f3e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzctMy0xLTEtNTk0NzA_f32623fe-7851-4ced-9067-5ddbd5d41283"
      unitRef="usd">13000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i93fdc6cbea484e5d933d9ec17976a64a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzctNS0xLTEtNTk0NzA_bbc1c77b-0cec-42ba-a4a9-bdcde4752cfc"
      unitRef="usd">40000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzgtMS0xLTEtNTk0NzA_4aef459c-b8ec-4a81-9b28-7c3cbf7b1b3e"
      unitRef="usd">269000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzgtMy0xLTEtNTk0NzA_fd93cd3c-d3b4-49e5-abdd-e3eee810085b"
      unitRef="usd">302000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo3MWQ1MjQ4MzZjZTI0MzEzOTA3ZmMyMjMwZDkxYzRhNC90YWJsZXJhbmdlOjcxZDUyNDgzNmNlMjQzMTM5MDdmYzIyMzBkOTFjNGE0XzgtNS0xLTEtNTk0NzA_0643c6f6-e115-49a8-b66a-6380bbbccd9a"
      unitRef="usd">270000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <bhc:ConcentrationRiskNumberOfProducts
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzMyNzM_342a96f7-bd80-4243-a728-68a63e7f0e9a"
      unitRef="product">10</bhc:ConcentrationRiskNumberOfProducts>
    <bhc:ConcentrationRiskNumberOfProducts
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzMyNzM_56f73df2-27b1-4b4f-b7b7-e7e8efe18fec"
      unitRef="product">10</bhc:ConcentrationRiskNumberOfProducts>
    <bhc:ConcentrationRiskNumberOfProducts
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzMyNzM_84b75c64-01fb-4d3a-a71d-1ef8bfeb24ba"
      unitRef="product">10</bhc:ConcentrationRiskNumberOfProducts>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id40c780474fa4a4682a7347b25e2b201_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzMzMTQ_e8c990b4-29f1-4bb5-927e-7bb9a4706f86"
      unitRef="number">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9af7ef89cda648658a1c3607ee127da7_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzMzMTg_5350a225-4581-4411-80f9-43c1f9506bc7"
      unitRef="number">0.41</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i045b9dafc68b4cc68fb25904182bba77_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzMzMjU_77f0145f-b26c-4a5c-86d3-de44e063d197"
      unitRef="number">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzM5MTU_6e5c1642-7caf-45a6-80bd-9e5f39042543">Revenues by segment and product category were as&#160;follows: &lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;International Rx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;International Rx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;International Rx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3697d2a9e4ec43ed8d76e098889f36cc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzItMS0xLTEtNzE0MjY_d3cd873b-24d1-4381-8b42-bbef6e663bb0"
      unitRef="usd">514000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00cbb18e8a4244e0b4ab1c019ad6fbef_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzItMy0xLTEtNzE0Mjg_2ed937b4-6840-4531-a8bf-e54dff2c8936"
      unitRef="usd">2066000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05e5078808d945ada773030e2fff85f6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzItNS0xLTEtNzE0MzA_c540e4b3-34f8-443f-a701-d28db05225ba"
      unitRef="usd">259000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18975fdb4b2643a18e1536995bd756ae_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzItNy0xLTEtNzE0MzI_f0552e86-dc59-4489-88ec-232f579ed46f"
      unitRef="usd">241000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0efcb1a3e484c1495fe6a62314d10a2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzItOS0xLTEtNzE0MzQ_75d601bf-43ae-4ea7-8fcc-a4aae8eb3e18"
      unitRef="usd">683000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8200ab4980184e4096913b6919701188_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzItMTEtMS0xLTcxNDM2_9155fb65-9782-4986-a8c6-32960ff40d68"
      unitRef="usd">3763000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5015918fcb654325817de17b69decef0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzMtMS0xLTEtNzE0MjY_2bc813dd-0bc2-4017-b8c6-31ee4b3733a5"
      unitRef="usd">1596000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1210af6063f04ed085da1d49425cc50d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzMtMy0xLTEtNzE0Mjg_6fd14a56-cc24-4f48-a61f-78b4baef9b35"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd3b2b75a9e04acc95e10777983994e6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzMtNS0xLTEtNzE0MzA_20f4d453-9e7b-4295-bec1-0a7b3c45fb84"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4db50b822dce470c82556f075e3aa86a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzMtNy0xLTEtNzE0MzI_1a2d225c-7576-4d8e-9dce-fd8c3c5e5cf1"
      unitRef="usd">307000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i620b1f27f17d43f7ba80d7206929a42a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzMtOS0xLTEtNzE0MzQ_dbf35a2b-5af5-4204-b281-4561a4b67b94"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i818f730bc4e3452abca0fbc91147a433_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzMtMTEtMS0xLTcxNDM2_a5c0de16-27a2-4349-9104-89b2c7b0fd94"
      unitRef="usd">1903000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3dae557e1e00497a865526614a2c20dc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzQtMS0xLTEtNzE0MjY_9858cd8e-3903-49c2-8431-a06ba507c366"
      unitRef="usd">1388000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i741d562c91384842b61fd3597f4f5e01_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzQtMy0xLTEtNzE0Mjg_50913166-7159-4ae5-869b-b52f4f36359f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29fb9247f04947ea8be74d0fa5e1431d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzQtNS0xLTEtNzE0MzA_77b548bf-f660-4496-9046-23bb2549bfc1"
      unitRef="usd">136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4bbe060476f44a9e9703d61f58e930d7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzQtNy0xLTEtNzE0MzI_4e9b7877-7e03-4160-b4ac-76824f8f915b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b52e9e750b14be2b227e83c88613718_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzQtOS0xLTEtNzE0MzQ_4ff69ca5-5932-4a7d-8867-6dca232c5300"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieca5e0bc0aeb4138acf45885703a0f6c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzQtMTEtMS0xLTcxNDM2_1b383a4a-4583-4995-8b69-8cf51f88712f"
      unitRef="usd">1532000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09553df00340400bb7d271aea0f7bbe5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzUtMS0xLTEtNzE0MjY_2bd2ed71-3898-47bb-9021-6373dfa73b8e"
      unitRef="usd">240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ee94ae398154c9ba283d347ee65f6fe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzUtMy0xLTEtNzE0Mjg_d3073fdb-ccb9-4118-b34a-8e5e98508cf7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i111b0987b23747f886225e07ed349f8b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzUtNS0xLTEtNzE0MzA_89b6ff84-d845-43b1-af93-bda003481930"
      unitRef="usd">737000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4f1ecad4e074139b813953bc218bf66_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzUtNy0xLTEtNzE0MzI_8c40ee61-e304-42f7-acb8-922e26b4800a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58e2b80073124c139f9beb53118af5e4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzUtOS0xLTEtNzE0MzQ_13e803f8-1c46-4cb0-a25f-461d5245f67e"
      unitRef="usd">167000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6ba58bf0a7a47308743596ca6786020_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzUtMTEtMS0xLTcxNDM2_a52d5049-1669-4af2-a707-e328a8877c1f"
      unitRef="usd">1144000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c572de04a1547afbb27a25fb70ce6a9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzYtMS0xLTEtNzE0MjY_870b8500-1dae-4b53-b736-1598fe3bc75d"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62aa1ea2a03e43139f39c8d0853efab4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzYtMy0xLTEtNzE0Mjg_10cbb22c-b89f-4ccc-be77-0450d948a9ef"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49e6f291ff584b48a1622e2e639ba32e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzYtNS0xLTEtNzE0MzA_3686e07a-90f9-4cea-b3be-c003f931f15a"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i499995e5502d4c19b0439c7bf1f67b9a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzYtNy0xLTEtNzE0MzI_567de9d7-594a-47b2-b7f1-c9a069bb1fb8"
      unitRef="usd">16000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if992199bf6084e97b3622278275b21d3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzYtOS0xLTEtNzE0MzQ_66387285-522f-468a-acf9-2e5cc0d18b52"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4853e38d55c49e987573c8d03ec31aa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzYtMTEtMS0xLTcxNDM2_0bc56349-250c-4a7c-b631-8733b8bf4fe8"
      unitRef="usd">92000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85a97ee039044646b0f12d8dfddbf0fb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzctMS0xLTEtNzE0MjY_be39f4b4-ec20-4ed7-8662-69787683383c"
      unitRef="usd">3765000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d94edb1edcc4131b1c8c736826ab425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzctMy0xLTEtNzE0Mjg_3314283b-3fb3-46bf-a251-b2769a67c65f"
      unitRef="usd">2074000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6dd56e661cc441b88ce62c077cb8c9c5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzctNS0xLTEtNzE0MzA_883cfee3-a869-40f3-bfc1-2b03b51fd372"
      unitRef="usd">1166000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03a8ce11b6a94d508439a84f941e6341_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzctNy0xLTEtNzE0MzI_57f068a3-55e6-4def-bc62-2828644f5a80"
      unitRef="usd">564000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9cf2e58ead94c7e812f2a73e8e5a8b0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzctOS0xLTEtNzE0MzQ_d84c2284-047f-42a6-a649-df16d8adc0f5"
      unitRef="usd">865000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiNGU5N2UxNDg0MjQ0YTM4ODc5NWVjNTFkZmQ1ODU3Mi90YWJsZXJhbmdlOmI0ZTk3ZTE0ODQyNDRhMzg4Nzk1ZWM1MWRmZDU4NTcyXzctMTEtMS0xLTcxNDM2_0df7249e-b519-4651-9490-5396c2568df5"
      unitRef="usd">8434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica7328b8d6504b7899d1dc8b7505c3c0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzItMS0xLTEtNzE0NTU_3b33211b-6d70-43c1-8570-0ba7db80f3ed"
      unitRef="usd">506000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4118ed47b4d54cbdb1f54bbd3b175865_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzItMy0xLTEtNzE0NTc_4d739134-b828-4d8b-973e-f9e9ee8d0a71"
      unitRef="usd">1899000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic87b0a379a4e4af4a668a658b4e4dd43_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzItNS0xLTEtNzE0NTk_1c483551-b3ac-42fc-ae0d-b48cefe23c81"
      unitRef="usd">255000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e7cfdefe46344e69ec8aea55a260650_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzItNy0xLTEtNzE0NjE_e5f3d928-9ab3-4bd5-8c8a-03f2eb6f3cba"
      unitRef="usd">275000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee783aab280a472ea992eba9ca598c34_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzItOS0xLTEtNzE0NjM_6f14e2f4-dc90-4b92-a694-96023746ba55"
      unitRef="usd">745000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55591dc8c2f846f5ba4430ce1db261dc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzItMTEtMS0xLTcxNDY1_002281a1-daf9-468d-abae-abe99cc03417"
      unitRef="usd">3680000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i558d7f511a464c67b2130444ac156e84_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzMtMS0xLTEtNzE0NTU_97c5e37d-fdd0-4613-9f3e-8871f607eeb9"
      unitRef="usd">1313000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b6212f9cc5f44979bde0e23bc60ea10_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzMtMy0xLTEtNzE0NTc_c8133cbe-cb42-423c-b6c4-6f76c31218e8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i088daa95a15e437895c8f9f62f3aaf91_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzMtNS0xLTEtNzE0NTk_1f02ab3d-34cf-4bd9-b54f-db1dfe3d2c0f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8cfe3de8f52f4da6bec0b7e7f3089c8b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzMtNy0xLTEtNzE0NjE_842a20ba-623f-4426-8bb6-48d412515020"
      unitRef="usd">253000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i800a26cd6f20436983c15a8c15183252_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzMtOS0xLTEtNzE0NjM_a51ab24d-46e8-41d2-b008-2056831a8dad"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie58585239a67458fa764c31745ab5784_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzMtMTEtMS0xLTcxNDY1_b29c30a7-9a11-4e5d-9c7a-4bf55456c454"
      unitRef="usd">1566000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i261608b942e5454e8116aba0eacfa55e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzQtMS0xLTEtNzE0NTU_1752e08c-ed8e-4b8f-8700-36c171512aea"
      unitRef="usd">1311000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7803df4ff86b424e850a241538857cd4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzQtMy0xLTEtNzE0NTc_2487ff0d-6aa4-4606-8265-91c3c8829600"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2f9db866111463eacf119731346b0d6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzQtNS0xLTEtNzE0NTk_0dde319c-45a6-4e38-9428-50c64cae7118"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i867c2a9786c94ae2a5aec06b9a7cf714_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzQtNy0xLTEtNzE0NjE_58390a6b-c8b2-4657-b9a2-55efe31e59d7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i738e8488fe144fce92ca8ab4ac3908e1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzQtOS0xLTEtNzE0NjM_35b24603-12be-4401-bb56-f156499e292b"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3ccfe8ed3544137991312117c73e03d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzQtMTEtMS0xLTcxNDY1_0f98cef9-6d09-4c03-94c3-dd83b8eae0be"
      unitRef="usd">1430000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i768994e8bab445f2ace72afece0d453a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzUtMS0xLTEtNzE0NTU_2e24eebc-b2a3-4724-adbf-a1dc86e1802b"
      unitRef="usd">254000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7a686a8ace843f6b748426e83776b3e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzUtMy0xLTEtNzE0NTc_1449d04b-7c97-47a9-95d0-1f309b7d8ebb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a10926c267e4f7ca73186bb4acb8c87_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzUtNS0xLTEtNzE0NTk_a59c769d-d144-4650-9bdc-717ab1c4fdf1"
      unitRef="usd">775000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5102465bf9f8449faf1eb3625cdf92e0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzUtNy0xLTEtNzE0NjE_0cfef2c9-bfdd-4e79-ad08-a4921d7769c2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib145795896ac48f893142cce0eb31900_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzUtOS0xLTEtNzE0NjM_eef4363a-7737-4c0e-85c6-78185763e6e7"
      unitRef="usd">219000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9337ed14800f40b0acaa106b8ab1687c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzUtMTEtMS0xLTcxNDY1_49eb95d4-0b65-4941-b30b-5d852d928b70"
      unitRef="usd">1248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d30a802ae6241198bab6f023ee116ec_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzYtMS0xLTEtNzE0NTU_23380c08-78f7-441c-b410-c863c472e9ec"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d8e87487d774cb5aa73c296d54c373d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzYtMy0xLTEtNzE0NTc_2b8b238c-6a77-4315-be6a-b14dcbff2c6a"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01c332dc4b3a40a7a943bd1c4a3ae01c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzYtNS0xLTEtNzE0NTk_2e6991b0-72b3-41ab-b819-8f2112329ed0"
      unitRef="usd">39000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9673696801474c4ab375773e366c4e88_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzYtNy0xLTEtNzE0NjE_6f52ac34-0d0b-491b-a850-6d93e19afcdd"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7b567c1a1d44f319be957d898bda4cb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzYtOS0xLTEtNzE0NjM_1672697b-9bcd-4d4d-b3ec-25e80459f5b5"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87ad55a1ae5b4477a17dbf7c109decc9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzYtMTEtMS0xLTcxNDY1_6ba3354a-3385-4d8f-b0ea-f564c45436d4"
      unitRef="usd">103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02ca962a07074ab0839d092880ab5aaa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzctMS0xLTEtNzE0NTU_1df8f10c-1ae9-454b-bf7b-d4b63a15f10b"
      unitRef="usd">3415000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d6a9bdc1e8f4460856c8c2141dade5c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzctMy0xLTEtNzE0NTc_ef7d5e42-aaa9-46b9-9f96-267b8a7e8e45"
      unitRef="usd">1904000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13483a8d36774c0090ab1f1dd802483b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzctNS0xLTEtNzE0NTk_ef09d87a-4ebf-49a6-b9ee-cb6862c594cb"
      unitRef="usd">1181000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd95ebc9b8e2493283e0e5fa94a55b77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzctNy0xLTEtNzE0NjE_ba85d17a-362b-45f9-84d1-78f3e5c4d086"
      unitRef="usd">548000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ab4cac0f20f47bea48d93a577e3c68f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzctOS0xLTEtNzE0NjM_73ba4f0c-d9b0-4d0e-b429-d05714cc4240"
      unitRef="usd">979000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4ODhiYzY4N2E0YWY0MTQzYmY4MDljMGUxMzMxZGJhMC90YWJsZXJhbmdlOjg4OGJjNjg3YTRhZjQxNDNiZjgwOWMwZTEzMzFkYmEwXzctMTEtMS0xLTcxNDY1_1896f5f4-19e5-4248-bf9a-450fd7ea531a"
      unitRef="usd">8027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9458be242c114b20aae89680bcb5981b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzItMS0xLTEtNzE0Njg_43910959-79c5-4b92-b291-c417c9ac6aa9"
      unitRef="usd">623000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia68492c01598457abbbb8598f9044b5b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzItMy0xLTEtNzE0NzA_aae627d7-a1af-4c1f-ba87-160a2aaa05e0"
      unitRef="usd">2022000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2764c82e246f458ab4e6010231d3da10_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzItNS0xLTEtNzE0NzI_e859f62b-e021-4b3f-8ed6-f8d26f3d406c"
      unitRef="usd">268000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38cbd7ab09694b5cb4499dc66ab3535d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzItNy0xLTEtNzE0NzQ_733e70bd-8ddf-422b-892d-163b88eee72b"
      unitRef="usd">353000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ec1bdc6efc9470c9e1dddfa13904883_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzItOS0xLTEtNzE0NzY_267d495a-f8b7-487e-8cf3-d115ea48a06d"
      unitRef="usd">813000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia78ff119a7a043648e26b928f005ae89_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzItMTEtMS0xLTcxNDc4_6d3fc7ff-ffde-4496-a43f-27a63ac54f0e"
      unitRef="usd">4079000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib492295e326e40ebbf3dc856ab711aa9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzMtMS0xLTEtNzE0Njg_8a5e8374-e167-4008-be9e-7d9986072a55"
      unitRef="usd">1524000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77282ee77e994ae0943e0dd0203f496f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzMtMy0xLTEtNzE0NzA_d08f5c0f-fa8e-438d-9d88-44a0d4c2800e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21cd1fcf02454f2aad2528f002a1fe42_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzMtNS0xLTEtNzE0NzI_23f869a3-f660-45cc-9687-4d63a8b85d1f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71cdecdee46c4b1893e522d76ed1b394_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzMtNy0xLTEtNzE0NzQ_c517a2b4-4691-4a36-8ba3-9ad4b449d879"
      unitRef="usd">193000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedafa6efd5e44f1499ea180b808f257f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzMtOS0xLTEtNzE0NzY_41e79c52-30b6-43b6-9e8a-9eaef5641132"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91f8e9e0afef4a67b9264f5a03b4ddfa_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzMtMTEtMS0xLTcxNDc4_3b81ffa7-01c3-413b-8531-e7befc07ca71"
      unitRef="usd">1717000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia337f02e12fd43138589ca394c6f6db4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzQtMS0xLTEtNzE0Njg_f1fe8578-5e9a-4ec6-bb56-ed0e40a271df"
      unitRef="usd">1322000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9bc60fbab2b493da4da40019ac28d5b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzQtMy0xLTEtNzE0NzA_f65a316e-accf-4354-a611-b539fa4ab2ee"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief548b6efb9243519ea3dc4dcb13b28d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzQtNS0xLTEtNzE0NzI_48a2e874-4871-4817-bc08-71c10bdea9e4"
      unitRef="usd">119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e4cda890a664abb926b4656d83aa772_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzQtNy0xLTEtNzE0NzQ_8a34b82e-c382-4562-b402-67b2717aee02"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ad550fea28840ca8816e812a29b209b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzQtOS0xLTEtNzE0NzY_86b518e4-eac0-4d92-bb2a-af071bd368e2"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id96fcda2fdee4cceaec20818540ab7ff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzQtMTEtMS0xLTcxNDc4_69516dd8-b130-44f2-ab09-85963a5e6cbc"
      unitRef="usd">1447000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d9df741d61340bba2aa6c1e15e212ef_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzUtMS0xLTEtNzE0Njg_1f5e8e91-4b0b-4bad-82fc-9aa2739621e8"
      unitRef="usd">260000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba623fc1e57a4f16a68ade989b914e71_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzUtMy0xLTEtNzE0NzA_ff4f51e0-eb63-4be9-a5bc-a788b1f3d9c9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d8ae893b49345bfb708b151f21b640e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzUtNS0xLTEtNzE0NzI_3b7af92b-9ca9-44e3-8843-0844b351aeab"
      unitRef="usd">730000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaada16b4b8624fb888a1f0e2f22b1aae_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzUtNy0xLTEtNzE0NzQ_1197b30c-3820-4528-aecb-f2b7f2523381"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i389a02cf0b334d2a9bc9e4d299b60faa_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzUtOS0xLTEtNzE0NzY_6a2d50a9-7c69-4d05-9ad3-9c6f3136812a"
      unitRef="usd">256000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97cfe71201a14248b5a32a0be5378bdc_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzUtMTEtMS0xLTcxNDc4_40c4454b-1c44-41b8-b90e-3f4530f6e1fa"
      unitRef="usd">1246000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7cf07a753f9f497e8b32f6adceb6f310_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzYtMS0xLTEtNzE0Njg_da0b2fcb-3e85-4275-8f12-6c210c73f9a9"
      unitRef="usd">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia83c0def577047da884ce155c2ca3898_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzYtMy0xLTEtNzE0NzA_26c9f14f-efb5-4bca-900d-2cc5c9de08b2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12d5980aa12348d4bdccb1436660ada0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzYtNS0xLTEtNzE0NzI_de061912-1041-446b-9e1e-dc36f932ae85"
      unitRef="usd">37000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31434b081601492c8ea95ce2b4f375e6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzYtNy0xLTEtNzE0NzQ_571d93bb-b7c6-47d9-9674-6e09b5d88971"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3b10e36535844bb8d8e1f54883bcc7f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzYtOS0xLTEtNzE0NzY_fa82befa-ca73-4991-9d91-0e40cace8867"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24c3f0d4cce04da181b013c5d63d6613_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzYtMTEtMS0xLTcxNDc4_bd3c6201-519c-41e0-9742-a2aadd23795e"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81cd80c7bd5e414fbd605f465e39a045_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzctMS0xLTEtNzE0Njg_0cd94ed4-4a03-478f-b9b2-1c8898ba8540"
      unitRef="usd">3778000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieefeebe8556a419b982e4603dccbde45_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzctMy0xLTEtNzE0NzA_97cb48e7-a0cc-4de6-b570-70e8eb7c8a2e"
      unitRef="usd">2022000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2742b142133f46b8a6da2018195c82e3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzctNS0xLTEtNzE0NzI_244ee415-74ef-4e64-a64f-0c8b400f1561"
      unitRef="usd">1154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f669422c2a34471ba15be9c22158c50_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzctNy0xLTEtNzE0NzQ_1a97427b-0a49-4e6a-9cb0-d9c19808eded"
      unitRef="usd">560000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11472ddfa02944969a68ae2a1ae9e0aa_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzctOS0xLTEtNzE0NzY_c1ea260a-aab5-400e-b787-99e0ae518b6b"
      unitRef="usd">1087000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTo4MzNkZWI5NWU0ZTY0MDI1YWE3ZDQ0NzQ0YTgxMTAzZi90YWJsZXJhbmdlOjgzM2RlYjk1ZTRlNjQwMjVhYTdkNDQ3NDRhODExMDNmXzctMTEtMS0xLTcxNDc4_5ac22510-628a-43bf-b25b-a48931e1cae5"
      unitRef="usd">8601000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzM4ODQ_18940afd-53b3-4430-a8a2-22b8756d6ad1">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are attributed to a geographic region based on the location of the customer for the years 2021, 2020 and 2019 were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Russia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Egypt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id130fccad3254b85b50a4b625a1dcde4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEtMS0xLTEtNTk0NzA_bb3e431b-fbe4-4355-947a-4aac1ce34174"
      unitRef="usd">4887000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65d94d793a9d4765a3365f16eb32b2a7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEtMy0xLTEtNTk0NzA_53837dc8-3454-4015-9dcf-e98e06ec1efa"
      unitRef="usd">4791000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic25b58dd47534aecaa1e6fceaca4aea2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEtNS0xLTEtNTk0NzA_7323295c-e9e8-4800-9564-52e5cd5fea1c"
      unitRef="usd">5164000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbf3d8d385d64c9986eeff60677c124c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzItMS0xLTEtNTk0NzA_36aa8017-9f8f-48f4-99f5-ba6f6a72f97b"
      unitRef="usd">490000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc9c0c2f95e04969a40f79d90fbce2c3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzItMy0xLTEtNTk0NzA_85516ce0-6b49-4b09-ab51-4b1c94f788cc"
      unitRef="usd">341000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ed5256f567f485c9398406ba71740cd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzItNS0xLTEtNTk0NzA_5a27db45-88d1-4175-bd16-db4fd6edbc77"
      unitRef="usd">368000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d755014362a46e4b04d95046a5882e2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzMtMS0xLTEtNTk0NzA_bfd69a60-52d0-4830-8ea8-f2aaa0086d96"
      unitRef="usd">343000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic48b8c8ee39d43a199bbf9a0ca2aaf23_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzMtMy0xLTEtNTk0NzA_430ffcaf-bef6-4108-a8de-a9e6cab01179"
      unitRef="usd">331000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c803976e613424da77d662911fc6070_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzMtNS0xLTEtNTk0NzA_b7d28a91-4bb2-48b0-886a-30ee06e010bf"
      unitRef="usd">339000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if21ae7bafd3345088a01d43828a61e14_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzUtMS0xLTEtNTk0NzA_09b7d02d-2f40-44e1-ae20-099a05ebf6f2"
      unitRef="usd">280000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11c5ca044d5d4c338ccc82b463e5c0c0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzUtMy0xLTEtNTk0NzA_2a8eadd2-a1a4-4234-bbb1-dc4609be1465"
      unitRef="usd">238000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idae5a5e95f9e42db945e914283667476_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzUtNS0xLTEtNTk0NzA_b8ae6d92-2da6-4751-84f3-134b2143535c"
      unitRef="usd">231000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9926394966af411883263fa6138b4736_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzYtMS0xLTEtNzQyODg_adf021c5-6028-421b-8bdc-8b21b2d50bb5"
      unitRef="usd">256000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id455a11708be4744b4a4db362bcbb326_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzYtMy0xLTEtNzQyODg_d9618920-ff33-4a38-a2b3-740e6b694aa0"
      unitRef="usd">225000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27fd2a2c4b784f2ca7121666541412f8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzYtNS0xLTEtNzQyODg_17e8843f-6044-47fb-a38e-6beff104abb4"
      unitRef="usd">228000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib73f7c080cab4bda95891cb8f82106e4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzYtMS0xLTEtNTk0NzA_1b31884b-b09b-4b8f-b87e-49b2c710ddd4"
      unitRef="usd">230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26ab236fac0b4f6aa2edb6c703d1d2d2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzYtMy0xLTEtNTk0NzA_125d89ef-8e96-45a5-9dda-cb9073858792"
      unitRef="usd">226000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia046496cfcb74a4b8dcb288dcf4d65ac_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzYtNS0xLTEtNTk0NzA_815e76dc-2726-4436-9bdf-65fccba98c6b"
      unitRef="usd">241000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i686a58e486aa452d93fb9e1315614162_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzgtMS0xLTEtNTk0NzA_e16bd6d8-ee40-421c-af0c-643d6a713a81"
      unitRef="usd">208000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08449c2242ac44f6bdab497f63ba91ae_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzgtMy0xLTEtNTk0NzA_caad689e-0b3c-4529-af98-ed8ceb506616"
      unitRef="usd">179000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68ae7a44ac90426e88c14dd8cda682e3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzgtNS0xLTEtNTk0NzA_fbe41ac1-b69a-4f1d-9bf7-ba9a87bee3b4"
      unitRef="usd">201000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i109a56ca7b294e69a526b8979a3ddbba_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzgtMS0xLTEtNzY1MDQ_79fabe91-6e5f-4b18-a9b6-0b472c2c738c"
      unitRef="usd">160000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6d4f781ea0b40538209f115920071e9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzgtMy0xLTEtNzY1MDY_6b4deb21-351d-4b1c-beb6-8aa30b5bcac7"
      unitRef="usd">137000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2180af989330419e910ab226313818df_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzgtNS0xLTEtNzY1MDg_f8a3025f-3aec-4139-9103-363927012f52"
      unitRef="usd">180000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic68cf5e89c634f10804f0199048ac135_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEwLTEtMS0xLTc0Mjk1_2ea61f57-703c-45fd-8724-a43ad05a885b"
      unitRef="usd">156000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4331026771c04d61a230465e05e97af9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEwLTMtMS0xLTc0Mjk1_bf9dc39a-946a-4eac-a40a-a5cd737ddc09"
      unitRef="usd">243000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i542580a52bd046618b9a580e8e103af3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEwLTUtMS0xLTc0Mjk1_c61bb6f5-e68a-404d-87cc-006998473b74"
      unitRef="usd">218000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic990a51442844403aa60ea9e7d40e464_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzktMS0xLTEtNTk0NzA_d19d851a-98ab-414d-ba80-5c7752d6a692"
      unitRef="usd">154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6635461f5a48470c8e56e33f2e669734_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzktMy0xLTEtNTk0NzA_520a3559-eb76-4e2e-a906-b913e5176f0e"
      unitRef="usd">144000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0a477db0fde456185567e5b03ecc809_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzktNS0xLTEtNTk0NzA_150882f0-47a9-468b-9c2d-543219f1e34a"
      unitRef="usd">150000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i585c6fb7766a4a5181f84f4a204170f8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzExLTEtMS0xLTU5NDcw_ec0b27b3-56df-40d1-81e7-dfe289b72168"
      unitRef="usd">116000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i906af541abda46ea9ee574738de1865e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzExLTMtMS0xLTU5NDcw_c76047cc-bc34-4b5f-b47b-0cfd17f411fd"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02eebd70500545f79f2c990d2925d8b5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzExLTUtMS0xLTU5NDcw_8338ad89-cfa7-4d84-9dc6-2d25076d1726"
      unitRef="usd">115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic22a4e49c9354ba18f292e3feb3e7e01_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEyLTEtMS0xLTU5NDcw_ab5d538d-9657-4237-8946-b9a86c11ccc0"
      unitRef="usd">88000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2497f962eb7544ca88a07e1e575fc7ed_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEyLTMtMS0xLTU5NDcw_389ef9ef-482b-4bcd-8340-0ef4de3b3453"
      unitRef="usd">78000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae37a07b59f444bd8e13c8a1c43209fa_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEyLTUtMS0xLTU5NDcw_84adadca-84b0-4928-bdf9-93f9cd9ee0e1"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iccd485be53574b8e949e379c787d4ef4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEzLTEtMS0xLTc2NTEy_13387fed-2880-4849-b4f5-a95ccca4aeb1"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc7582499a2b415e93784236f4cb34fd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEzLTMtMS0xLTc2NTE0_4452cc09-5903-4098-92ee-2f726289e3b7"
      unitRef="usd">71000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i168771f1c7d74447915fe4778febc05a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEzLTUtMS0xLTc2NTE2_e8a503d8-d969-4751-a601-5b8f54c12d39"
      unitRef="usd">85000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i471e03575d1346b7b9f05bf5ba23116b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEzLTEtMS0xLTU5NDcw_e20b83d3-e271-486a-bb22-917087c37db4"
      unitRef="usd">986000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4f64c8704264652a24d4ce93c2900c3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEzLTMtMS0xLTU5NDcw_58db5a72-b6dc-498c-a257-46bd9ced9c5c"
      unitRef="usd">937000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if84190a5f2244c92b77538836a840d39_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzEzLTUtMS0xLTU5NDcw_496f94a3-b235-41ab-9b5f-c3afadb20622"
      unitRef="usd">995000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzE0LTEtMS0xLTU5NDcw_e50c2527-f0bf-4f04-87f4-2d35662ce454"
      unitRef="usd">8434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i411d954012224686a2c74d7db58a6ea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzE0LTMtMS0xLTU5NDcw_535394be-5f70-431d-80bf-bf40f05139ea"
      unitRef="usd">8027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZToxY2NlZjMyYWUwNjE0YjIzOTM5NDFmMGQxOWRiMzgwNy90YWJsZXJhbmdlOjFjY2VmMzJhZTA2MTRiMjM5Mzk0MWYwZDE5ZGIzODA3XzE0LTUtMS0xLTU5NDcw_9dc4156a-a125-47e9-8992-2e50e3b7e1e5"
      unitRef="usd">8601000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzM5MTI_2e22fafb-1c2e-402e-9fa6-056775d5a46d">&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December&#160;31, 2021 and 2020 were as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Serbia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:NoncurrentAssets
      contextRef="i14de5bc495eb4add9fa84a199741910c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzEtMS0xLTEtNTk0NzA_cee2633f-c024-4f69-a2c5-4dda84a1d0a2"
      unitRef="usd">743000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i0d46d579e1e44fe3ad004f43eaccef30_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzEtMy0xLTEtNTk0NzA_c2a7dade-a2db-4683-ad87-690128d2c875"
      unitRef="usd">725000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i2862a5dfd1e645cfb3ebcb20802866e8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzItMS0xLTEtNTk0NzA_d3d17571-4204-4c26-af65-b9a6825775be"
      unitRef="usd">336000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i7b8ed490007f4fee9a005a8a805c6894_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzItMy0xLTEtNTk0NzA_73ca1431-8c3a-4640-9ebf-422ced7b17e4"
      unitRef="usd">328000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i9c43807d9cda4c16831c9f055db35fb6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzMtMS0xLTEtNTk0NzA_4be9d2f8-21f0-4387-a328-6fde2702d771"
      unitRef="usd">123000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i3218c6c6aa7d47a6b6e7fe2e3402a5c8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzMtMy0xLTEtNTk0NzA_98f1d941-3f75-45c0-bd58-c40b4cb6376a"
      unitRef="usd">110000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i1b664e37697c4f7891056561bf29f683_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzQtMS0xLTEtNTk0NzA_60e958a0-af47-49ba-846d-95d98a9eff92"
      unitRef="usd">75000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i2aea46020d284bf6820326330afd288d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzQtMy0xLTEtNTk0NzA_ad89fa7e-2eca-41b6-8dd3-32e152735684"
      unitRef="usd">83000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i5d6aaa98a7a24f74b46d997266d2a452_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzUtMS0xLTEtNTk0NzA_2f63d152-a8cb-4a72-b928-b3eefb24cac9"
      unitRef="usd">87000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i34126ade1b28483c9a1ea926b56d408d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzUtMy0xLTEtNTk0NzA_ef85673b-815b-4181-9752-ea4ad7c533a8"
      unitRef="usd">80000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i3be1fd06e45447f2a98c47d3aa49590f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzYtMS0xLTEtNTk0NzA_133efe4b-be37-43b6-8901-7607c917a1ac"
      unitRef="usd">45000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="id7ddc11ce20249cba2bdf7921a98775c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzYtMy0xLTEtNTk0NzA_562b460e-cfb1-4a5e-adc3-6b09617d3129"
      unitRef="usd">49000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ic95237c6a18642d8876995496f7f0ec6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzctMS0xLTEtNTk0NzA_c7661997-7c9f-4e39-b992-43fac60b6d5f"
      unitRef="usd">39000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i66dcb516bc924f7f8ea52045f62987c9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzctMy0xLTEtNTk0NzA_99fd2fc9-186b-4548-a901-4e2c5996ce49"
      unitRef="usd">34000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i90615098fdc24b3394cea58fd0717975_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzgtMS0xLTEtNTk0NzA_b06b655d-ec22-48d1-afb8-a7e6add14b32"
      unitRef="usd">30000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="iacfc9f50cdde4a879013a96abcb55983_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzgtMy0xLTEtNTk0NzA_f37b3c70-e441-4d22-b95b-b66a5fd16d1f"
      unitRef="usd">31000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ie121075f685e4899b526388e85fc73a4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzktMS0xLTEtNTk0NzA_1df0b44e-3824-4924-aa15-6e56dd4a6afc"
      unitRef="usd">25000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ief9b76c5e82249468a3e6e7d77de38df_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzktMy0xLTEtNTk0NzA_128d24e2-a82d-448c-afd7-ee418d5f32a9"
      unitRef="usd">30000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ic715be3970fe46419fb02b3a67f6c23d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzEwLTEtMS0xLTU5NDcw_ba9b19d7-9ca0-4e89-8c4d-277bc091c89c"
      unitRef="usd">21000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ic2da7c3fce6a4a55b940079cd34b7824_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzEwLTMtMS0xLTU5NDcw_7258840b-dd25-497a-9229-b2ac620fa021"
      unitRef="usd">23000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i0bf0ad3c28494e298de94b94bcbedd3f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzExLTEtMS0xLTU5NDcw_8ace40ff-8f70-48df-97f0-3e22108b44cf"
      unitRef="usd">74000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i9dbae836ee6a485199be60177a95f582_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzExLTMtMS0xLTU5NDcw_f379f721-54e4-44f6-9109-773eb12e565d"
      unitRef="usd">74000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i973e30c58524481ca5eaa5ee3b0263f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzEyLTEtMS0xLTU5NDcw_4cbad290-dc19-4546-a512-12079ce5262b"
      unitRef="usd">1598000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="id1052f2e72864d03a985b250bef88f8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiODM1MzgyNDk4Njk0OThkYjhlMWNhNjJjZjYyNDNlNy90YWJsZXJhbmdlOmI4MzUzODI0OTg2OTQ5OGRiOGUxY2E2MmNmNjI0M2U3XzEyLTMtMS0xLTU5NDcw_211ec2c5-de5f-47e1-9832-fd7c91166129"
      unitRef="usd">1567000000</us-gaap:NoncurrentAssets>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90ZXh0cmVnaW9uOmYxNDA0MDA1MmRlNDQxOGZhMzAyOTEzYTUxNmI1NDc2XzM5MDk_c52f8c4b-5eec-4c64-81d1-6bdc765a1270">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customers that accounted for 10% or more of total revenues were as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health,&#160;Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id7c19794c8aa4758a7c167c4585fa6ca_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiYjYyMjQyNmY2NTY0ZTkyYjY0NTA1YTllZTBiZTYxOS90YWJsZXJhbmdlOmJiNjIyNDI2ZjY1NjRlOTJiNjQ1MDVhOWVlMGJlNjE5XzEtMS0xLTEtNTk0NzA_9a9de86f-19e0-4a84-83a0-8469e758d6bb"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iace25aeeaa0d4c3d986f48d0c8baf029_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiYjYyMjQyNmY2NTY0ZTkyYjY0NTA1YTllZTBiZTYxOS90YWJsZXJhbmdlOmJiNjIyNDI2ZjY1NjRlOTJiNjQ1MDVhOWVlMGJlNjE5XzEtMy0xLTEtNTk0NzA_51f09c8d-2bd5-49cd-a228-1d267a6471f5"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i19d7ced3035a44ce992df3a4b9291ff4_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiYjYyMjQyNmY2NTY0ZTkyYjY0NTA1YTllZTBiZTYxOS90YWJsZXJhbmdlOmJiNjIyNDI2ZjY1NjRlOTJiNjQ1MDVhOWVlMGJlNjE5XzEtNS0xLTEtNTk0NzA_e396f69d-3dbb-4115-a61e-ee33e7b7e36a"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib8131fb2f99f4c7a8028ad6778dc1676_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiYjYyMjQyNmY2NTY0ZTkyYjY0NTA1YTllZTBiZTYxOS90YWJsZXJhbmdlOmJiNjIyNDI2ZjY1NjRlOTJiNjQ1MDVhOWVlMGJlNjE5XzItMS0xLTEtNTk0NzA_64e4b9ae-eade-4ba7-95c4-41a865efc9ff"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7f416523997c4b338d676cc2d06aaafa_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiYjYyMjQyNmY2NTY0ZTkyYjY0NTA1YTllZTBiZTYxOS90YWJsZXJhbmdlOmJiNjIyNDI2ZjY1NjRlOTJiNjQ1MDVhOWVlMGJlNjE5XzItMy0xLTEtNTk0NzA_7cc05f47-5d45-42e3-badc-e966f3609860"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i04069591c97a4784ae4185ec478eb90f_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiYjYyMjQyNmY2NTY0ZTkyYjY0NTA1YTllZTBiZTYxOS90YWJsZXJhbmdlOmJiNjIyNDI2ZjY1NjRlOTJiNjQ1MDVhOWVlMGJlNjE5XzItNS0xLTEtNTk0NzA_de10931b-8001-408b-84d3-8eb7f7e752d3"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i29cea92069c14b44a2be0c659664e70f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiYjYyMjQyNmY2NTY0ZTkyYjY0NTA1YTllZTBiZTYxOS90YWJsZXJhbmdlOmJiNjIyNDI2ZjY1NjRlOTJiNjQ1MDVhOWVlMGJlNjE5XzMtMS0xLTEtNTk0NzA_706c2889-6b8f-40dc-8359-c63370e4759e"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ice846a05c75e458db9e4650442b6067c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiYjYyMjQyNmY2NTY0ZTkyYjY0NTA1YTllZTBiZTYxOS90YWJsZXJhbmdlOmJiNjIyNDI2ZjY1NjRlOTJiNjQ1MDVhOWVlMGJlNjE5XzMtMy0xLTEtNTk0NzA_30114290-dc84-4e30-8bc9-9483f24fbf8c"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i249f7ac9d61242019aa00db1804021d7_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18zNjcvZnJhZzpmMTQwNDAwNTJkZTQ0MThmYTMwMjkxM2E1MTZiNTQ3Ni90YWJsZTpiYjYyMjQyNmY2NTY0ZTkyYjY0NTA1YTllZTBiZTYxOS90YWJsZXJhbmdlOmJiNjIyNDI2ZjY1NjRlOTJiNjQ1MDVhOWVlMGJlNjE5XzMtNS0xLTEtNTk0NzA_982b9030-92b1-4d93-93ce-5d73e5deff4b"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODQ0L2ZyYWc6OGU4OTRkNmUwNTE5NDdlYmJjMjllMWMxMWJmMjRkYjQvdGV4dHJlZ2lvbjo4ZTg5NGQ2ZTA1MTk0N2ViYmMyOWUxYzExYmYyNGRiNF8xMDk5NTExNjMyODk0_433b689e-c2c9-4e42-83d7-05ecdf01f501">SUBSEQUENT EVENTS&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 18, 2022, the Company issued conditional notices of redemption to redeem in full all of its outstanding April 2025 Unsecured Notes and to redeem $370&#160;million aggregate principal amount of its outstanding December 2025 Unsecured Notes. On February 10, 2022, the Company extended these conditional notices of redemption through March 15, 2022. The redemption and discharge of the indenture governing the April 2025 Unsecured Notes will be conditioned upon the completion of the Credit Agreement Refinancing, as defined below. The redemption of the December 2025 Unsecured Notes will be conditioned upon the receipt of aggregate gross proceeds from the B+L IPO, the B+L Debt Financing as defined below, the Credit Agreement Refinancing and the offering of the February 2027 Secured Notes, as defined below, of at least $7,000&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 18, 2022, the Company announced its intention to refinance its existing Restated Credit Agreement with a Fifth Amended Restated Credit Agreement (the "New Restated Credit Agreement" and such refinancing, the "Credit Agreement Refinancing"). The New Restated Credit Agreement is expected to consist of approximately $2,500&#160;million of term B loans and a $975&#160;million revolving credit facility. The Credit Agreement Refinancing is expected to occur only upon completion of the B+L IPO and a related debt financing by Bausch + Lomb (the "B+L Debt Financing"). At the time of the B+L IPO, the Credit Agreement Refinancing will provide that Bausch + Lomb initially be a "restricted" subsidiary subject to the terms of the Credit Agreement covenants, however the Credit Agreement Refinancing is expected to permit the Company to designate Bausch + Lomb as an "unrestricted" subsidiary under the New Restated Credit Agreement covenants upon achievement of a 7.6x  pro forma "Remainco Total Leverage Ratio." Such designation could take place at any time after the B+L IPO (including as soon as the closing of the B+L IPO). The Credit Agreement Refinancing is designed to facilitate the separation and distribution of Bausch + Lomb. The Credit Agreement Refinancing will not be consummated until completion of the B+L IPO and related B+L Debt Financing. There can be no assurance that the Credit Agreement Refinancing will occur on the terms described above, or at all. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 10, 2022, the Company issued $1,000&#160;million aggregate principal amount of 6.125% senior secured notes due February 2027 (the &#x201c;February 2027 Secured Notes&#x201d;). The February 2027 Secured Notes accrue interest at a rate of 6.125% per year, payable semi-annually in arrears on each February and August. The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to 100% of the principal amount thereof plus a &#x201c;make-whole&#x201d; premium. Prior to February 2024, the Company may redeem up to 40% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the B+L IPO does not occur on or prior to August 15, 2022, the Company will be required to redeem the February 2027 Secured Notes at such time at a redemption price equal to the issue price of the February 2027 Secured Notes plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="if80737f8327f4413b9aff0d3dbfe8369_I20220118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODQ0L2ZyYWc6OGU4OTRkNmUwNTE5NDdlYmJjMjllMWMxMWJmMjRkYjQvdGV4dHJlZ2lvbjo4ZTg5NGQ2ZTA1MTk0N2ViYmMyOWUxYzExYmYyNGRiNF8zODQ4MjkwNzU3MDE1_4fb5f3a6-7971-47ab-b85c-c778f7cce324"
      unitRef="usd">370000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <bhc:DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet
      contextRef="if80737f8327f4413b9aff0d3dbfe8369_I20220118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODQ0L2ZyYWc6OGU4OTRkNmUwNTE5NDdlYmJjMjllMWMxMWJmMjRkYjQvdGV4dHJlZ2lvbjo4ZTg5NGQ2ZTA1MTk0N2ViYmMyOWUxYzExYmYyNGRiNF8zODQ4MjkwNzU3MDQ3_ec5e90be-4196-410e-a3d3-ca504ca65ec0"
      unitRef="usd">7000000000</bhc:DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet>
    <bhc:DebtInstrumentExpectedFaceAmount
      contextRef="i197a960478f74a8e9a871dd7b6a60555_I20220118"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODQ0L2ZyYWc6OGU4OTRkNmUwNTE5NDdlYmJjMjllMWMxMWJmMjRkYjQvdGV4dHJlZ2lvbjo4ZTg5NGQ2ZTA1MTk0N2ViYmMyOWUxYzExYmYyNGRiNF8zODQ4MjkwNzU3MDYz_e3dfbfe2-c139-46ab-9710-1b408506491c"
      unitRef="usd">2500000000</bhc:DebtInstrumentExpectedFaceAmount>
    <bhc:LineOfCreditFacilityExpectedMaximumBorrowingCapacity
      contextRef="i5d92f684e11f4d7195e59fa6354f28b1_I20220118"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODQ0L2ZyYWc6OGU4OTRkNmUwNTE5NDdlYmJjMjllMWMxMWJmMjRkYjQvdGV4dHJlZ2lvbjo4ZTg5NGQ2ZTA1MTk0N2ViYmMyOWUxYzExYmYyNGRiNF8zODQ4MjkwNzU3MDc5_8a78cfe8-930e-4a30-8233-3a44db5b0119"
      unitRef="usd">975000000</bhc:LineOfCreditFacilityExpectedMaximumBorrowingCapacity>
    <bhc:DebtInstrumentCovenantTotalLeverageRatio
      contextRef="i11ef4c89472c48b8a4e820729468ec02_D20220118-20220118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODQ0L2ZyYWc6OGU4OTRkNmUwNTE5NDdlYmJjMjllMWMxMWJmMjRkYjQvdGV4dHJlZ2lvbjo4ZTg5NGQ2ZTA1MTk0N2ViYmMyOWUxYzExYmYyNGRiNF8zODQ4MjkwNzU3MDkz_58209316-bbec-4508-af89-bb580580ea63"
      unitRef="number">0.076</bhc:DebtInstrumentCovenantTotalLeverageRatio>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9af4b96ef19949f2928ad128d4c72201_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODQ0L2ZyYWc6OGU4OTRkNmUwNTE5NDdlYmJjMjllMWMxMWJmMjRkYjQvdGV4dHJlZ2lvbjo4ZTg5NGQ2ZTA1MTk0N2ViYmMyOWUxYzExYmYyNGRiNF8zODQ4MjkwNzU3MTE3_d3dde3ee-7faa-4fa5-b1f6-8a9c25b805ac"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9af4b96ef19949f2928ad128d4c72201_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODQ0L2ZyYWc6OGU4OTRkNmUwNTE5NDdlYmJjMjllMWMxMWJmMjRkYjQvdGV4dHJlZ2lvbjo4ZTg5NGQ2ZTA1MTk0N2ViYmMyOWUxYzExYmYyNGRiNF8zODQ4MjkwNzU3MTQw_e134234e-18af-4050-a3f4-5597e0724bd5"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9af4b96ef19949f2928ad128d4c72201_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODQ0L2ZyYWc6OGU4OTRkNmUwNTE5NDdlYmJjMjllMWMxMWJmMjRkYjQvdGV4dHJlZ2lvbjo4ZTg5NGQ2ZTA1MTk0N2ViYmMyOWUxYzExYmYyNGRiNF8zODQ4MjkwNzU3MTQ5_e134234e-18af-4050-a3f4-5597e0724bd5"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="id0c6700094674a22af02045a72c15ccd_D20220210-20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODQ0L2ZyYWc6OGU4OTRkNmUwNTE5NDdlYmJjMjllMWMxMWJmMjRkYjQvdGV4dHJlZ2lvbjo4ZTg5NGQ2ZTA1MTk0N2ViYmMyOWUxYzExYmYyNGRiNF8zODQ4MjkwNzU3MTUy_397e97ef-dd31-4765-a957-d9961410aa4e"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="i590fabe0c9ae4c4db81e12d4cd310bc0_D20220210-20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlYjFjMjAyM2IyMjQzOWY4NGE4YmRiYmQyODA0ZWY3L3NlYzplZWIxYzIwMjNiMjI0MzlmODRhOGJkYmJkMjgwNGVmN18yODQ0L2ZyYWc6OGU4OTRkNmUwNTE5NDdlYmJjMjllMWMxMWJmMjRkYjQvdGV4dHJlZ2lvbjo4ZTg5NGQ2ZTA1MTk0N2ViYmMyOWUxYzExYmYyNGRiNF8zODQ4MjkwNzU3MTU4_28eed8cd-be0d-4b44-a212-065055df8a9f"
      unitRef="number">0.40</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>154
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M,L*1[@1&J)!W6DO>#XO;=.&8)!;(:5Q.#$>LZ*I"WVDM?9]%FLNTY&"6VNQ
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MGWD [J^$T(<3TT#^4>KR'U!+ P04    " "1BU=4,2Q/-C0"  !Y!0  &
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MRLQ7^?B1MQ,*K+]$9KK^%SVVMMX,)94V,F\'@X)<%,U?]M0&8F\ ]D<&D'8
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MO7%HHX8)^Q?GJ,PI,SC,QB_/\Y>GQ\GP;3HAH^'3\'D\)?.'Z?1M3BYF5('
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M_'UC+ZS<,N%P%1Q<!;6KX)=<-2EM+,/:4E>+EXLD(,'9]*6?. #DX?@8- =
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MB#U%9HDUVP 4"7V3A(U*$F^@:OM=0_;='7FQ87I.J96DUA0O&#K1*^HCR"8
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M""V [VO.U?N+[J \?X_^!U!+ P04    " "1BU=4H+&:46 '  #_)0  &
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M'JXX4RPD :C[2R'DUY/DNY/=-U^G_P%02P,$%     @ D8M75-Y/1.32"0
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M(W9'Y" 7;Y$H9>Z"O7A\TZW18[I! PCU&Z^-?QVK& &H^QKFN0N0:+*2VRY
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M:!H>G)Q/!?IT17N/8HC((5"N(DN$V[3%98)'Z(H(X62@S9Z/4C B)? %>N6
M+0%B5#'.I(?CK/U._'L# %Q1VA!N"A]TR(HX=8+T<M@"X9PAU%"698<>90J)
M-'6)_E0-6^%K +AE6?E0L!N^.*V%CS S0G4  #L=O91%&YT$K \W#0+&+2 _
MZ"*2ED88$W*G0J8XY;"U3;]5BB?=-LK,1:^W9,2(\$(=<G8/M<JQD0N+5*TQ
MV05A$;"XKXE6R:*#&SZ-P#LDLKK?+#C3,$3+@S]U"%,).S@R$&]L54EN"C!^
M@-864PFI9H>/&;$$,P\L64Q15DUK5V.5 =Y&%[$3TPH>$P!H_$W!DD;U&ZLN
M)/)H 1PK5"J!FM+A!;%<R$P)N<%Q3.:Z0=V6\XV<:_*2Q!/!OTQR&V4<ZU2S
M95U6(]=B7\-E6#]L?YB:+"DV79QD0N<K[O@:3FNU)A;B$,^8<S)$2N>\V151
M\,3.:.&H;6,*$HAT,\M>M^:/LIIE;U>WVVZ6O0?NEMLTI6)C$2F\,_EMCS%4
M0[4CZ%3\VL,&@%5]^X[92BR&?P,.]D</,(A" C?6?,\X;*#.?A=I([I$>@$.
M .,=A*D4&1UDP,EM\6A*[C*(IA6<"RZSW%C-F\@Z\UWSE*IJG-=S!X? 7#6P
M))AKU3&S:8G/G#MV5.4$(%_>-!V'8<%1H<\4Y"Q9BB&6':-QZ@$.[D1 @]/3
M_\094=T:K9;=OH4F(YGIM1$X1U4=?I%3(ZN&S SQ?M3Y8MM%:3#AOX?3.%]B
M-&R$);,(10AA2MO59B,,F&V?GYX]!VE25>JF^.GXZ5.],,N"!U_D)&#)[XVF
MM3'[0R^U>&A4_2(A?G8$FODMJI)P%,#^F'8&YM\D+-3JBA%!,"T,!]R%HY%A
MIF1?\["+'<<$-^+EA-V@45R28W>IN;?KQFW+CK+L7ZO/%_5V\:@,9$?,W 9/
M+8Q4 PPBEZF!&44XM^:6KFY-AZR0H[TD]CTZCW.]?%H_ZDL4'6JO+65"D)@/
MH%N;:JEGH2AX!X3#W(% /WGS%XEOG^.+)$\RK#XJ[J%=6B]*DP 0CF-HH)0,
M&#1M$2OZ6A@,1YK4:BAK559E+S$ 9/L#V>>E&.:&MUPUM9PT!"CKHV6]"O</
M%-%+F@8H')B4CG[UOD4^/I%V!S@&&,0^^AKX"\TGF2U-9"*2O/.1?L1VSI[$
MPA$\$8JZ>4_CBHA&<8Z<7>G^:!JI!OMWS ->%^K^.IN8 #O471&1K"WN1YD+
M:8;<O[4D5KY_Q[2'R35$YC.'NW8;:>3.42\';96RJ>MT"[=12FG=)!Y$.F2P
MPRM)WL/Z<$J- _1;&9]GFR2Z<?*HYB1$28BB?<.:*O8)IMI0-_ JD,V_ 1,5
M:Q=M]A%^RY[,LKUWYY>?L]_./WQ[F_WZ]OS+M\]O?WW[\>N7/99V(KZH$@05
M[&&FX%]S2%2/R6EG-*T8W!^8F,_KD)6&VXA,*4IS\^$KP3GF 0,,#]DI493
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MMEP&B_"J3YHJ&N1%0GB:OGJ9E."G<-H]]YC$AZNY=^IAUT4F-L:+KNF,ZH^
MX"%N$O'&A"$R0$)7B7AM[921.5PN6HF<@E1NHD+ X1FBOGAMHG9#PH%CZ@R*
MJ<\L5"D4F#N6<,DQ*]M&,(5A-I2?M/#Z$5?MV!\&=63,9XCR\D$_R<D%L:/\
M6K5H-1NE5#X2+PP,R3]=29%/7WN%1%OY1!9I2.\:AJB(X?5U[$GU"ORUC:Q'
M A#E1U=R@N$,)LBG!M[")B#*!3@YC'_%F54^KA=CED]-B[9+W6S6K'V6D608
MGR:)UM0I'5#5Q( ?CDD;@H6B7[=!YPWW:B55EOJ X3ZU9R>&H*@9YKBS)NMI
ME60\L*W/VK0Z>4>HBA1G$*TE%'G7,L5N(>J00QX BMRU; 8%?BQ<DZ,@0:F;
M;.6$^(!=Z3C+N\00^Z54^ES+>KN'XRVG<^B.2%9PHE_3?%>U-#[_&RK'UT/C
M8 EGME%#AT'O+ATWZJ"%6HW&R/0VEW#Z,A1EFR&8/74N]D<Y0J:T+1&5K^Z3
M=W598>&Z"=VHPIDY;VNI("NC+@;1<6D!V1O,0GJ3-(JY:NVF!/XYRRY!&R&.
M=N$+Z-]H3Q!)EX>A^"8-Y#O.8!\F'D74+QE(*O&#;;>C(E"B:-D7[-0N)3,2
M*BI\Y0R97%$N@V]R<+?CD!*O-'L[\@&W5&7,+JC@R/55/J$Z32,&QH5K6KGC
MRX T!0*9AN^:$R]#XJ_2P5":>,')\:D(E)<>R@*Y@<.@M==-=4WWD^&P!JQ%
M4MT$SY54[RF\?0R>?+66NO_X!D;!Q>O3$4+?%7:DUDV]/[CYD),<P?U/0'%I
MQW[('?L_\#';"\U.^1K5SWV-=/&!"KZCLFE4STGYLX1E8,#6VIK2Y\)HCS0Q
MQI-ZQ=;Z8CZVIIKXOF],Y:/-9+IBMV8#B\09N_@$,_X<!><E$7S%Q)-DW708
M95?#OE3B3Z%N5EG4S,JGUTD$F&,PU*/@@06*(P\]2GQ0Z9DR'U2.>#]B'8SK
M)?V^*:>$S]G;M$E7>*Z:E]QC,WF&)CKY@!,3YSZPA,<;OB.7X,^5_7V6P_H<
MM4SZ.H&YH459:Z-857 $$Q_U'?<,Y<2$YV11N$"SI:[ .!";E:'A\PR@[+JV
MH81##A,]VGM_N?=8?/VAV; H/UH!QL7$%,2RPU;(VJ!9>A/34/JD7IMZ U[Y
M]/4BC2@]*J\?CUHY/Z*&FIA_0&P/L[X ,1IJRNJO-:&5M)/6TW'\&PE.>T4[
M'1G[W].1>N#[)LB5]"9C%:.]9DV+C]([$3GLIJVE\@9[O&P:=6XD&U,6.1IL
M=(3^V(:]G[N&@A$"'@W1[QB6DK#8YQEFH(7[E:3-L9CC:!FHUNJ(7T-30:+<
M1>RZO_?E[7O,5LPN/[[[]/G7\Z^7GS[N!56K=&:UPGQ%A8@',[LC"@L;PH)+
M4  I)")M#[UY&=H?^HYHK.C%''#@764;,@1.1K8-$@2&9]!D6S5QXWC.:9BJ
MM/.LPM-I,/[]NYP<XGOW"@IL*#M=4CE:/2?M($O>=]9_QD&(@?\JZH4\E9L"
M-@:Y522YE1/$K*1;,P_CD\$/?8S60TFSTA(?\0"WP8R(OU0R^"P$?9J$5[F$
M6?9=9[<>-)NFL%4V2IA6VR4'%LW\1,)TMXD2\<@]UIB9@E883/)X9+\D^;M"
M13J:<AH?OV,V&349(HU\QIQ'FP!-/Z2:ZP.G9H8&HWKL29'G$34TXG8(XA!S
M,)+C5BH[9CGP60-?**GI/$SGG:RCAAL^)Y0-F-!I(18G% E& AJ,:%+J(!0/
MU0;H])M>Z0!C!+)N-VAI15A5""C7[1@T^*S9AR=*#F<45K@89ZM*OK&32^1P
M/!N&:35LB,#PW[9)2<Z7F:#%U%-#7C)74^80DG8GV$3<")33T,CQMVU*;D&"
ME5FSAS$3"4*13!FBP55(?#UW7.:CG\(0K!Q\,$"Z$M_.L!S3N>$:6QM_\<(0
M@*SVFQ3+CA">>AR*MNM3@B2/) RXZQS&T$F"[@\X(PTP:8Q$LW8XO8GKA(.Y
M&[JKSD;M%Y.VK-D]S5>5H@YBR-^!2=3K(ZISB5H@3%'L@LPLGP*NKDIO*.^0
M#.RT]5(@B>TA^W-19(0H7#*0_;@[5C\T2L<'*>#GE#^J#9BI_C!\&9%#L[7Q
M57*E#]NC>.]YFD*>MB='&FL=(?, /EUJ RDQ1AJ_SSMG1Z[B#<<XM7O1X&P[
MSAL*^)]D#:'SWS>K]KQXT"EUBMAB94;USQ1Q,VU4J[B;-!">1-4XT5BQ5EPS
M42U:5*8<-R'UI,%C +#)CYT.P\L=CHD&#[T<<O&C.@)XY;JI^HV-]C:QL)$G
MY%P:RXT='I%/@+\JQK>C0H#H$T#WSC-==D!PJ.S4CJ+!Q[#X_V[CZSK..V2G
MOCCB)*ZG)0/D >!ZW-A1-,52=I!V!"A\*Y00^,+88;E <$/J27\6U+F(^.>;
M&"&_8C0('N/2QH7FWNLGO+1<X:?L^/D<?CX].X:?9_-G>.4IEAK0Y?GLZ,F1
M.(JTPUAT)D]AS<=8Q# [?G8*8Y[-GV3'9T^S)[.CDZ?9E>8,DLE 7B@P+)\>
M8T7!_.0I_IR=S*FT8'9V=(;_G^&])[/YLY/'X[4/*SV.8*ZC[,FS)]FS9V>P
MC]/L.4P_>WY\<M>*X9&38UCQZ=,YKOCL+)L?'\.*3^?/=ZSX":UJ/C^E%<_/
MGM'_1[R/)\>TXI-GSQ^P8H3Q?#ZG2@?\>79ZBO!^AN=PBE40L/JG)YA'X?%7
M#UK% #=^7#37EO._&W&^X-\8B@!E-CC]?*/'0!]<*1+5<_]T\C2ML#F9WU=A
M$Q5PIQ70@?^%OJ[CIDY,\;XX-9#^3/K%W>_2&H26L"B?M!<?M\*]WT]^1,M)
MN410 'II;QO5 \8-F"=:+Y]'7W#2_$SM0<QR+)I:6TK0LB/5!.MVEL:[,,8!
M6Q3[:=;*=+_G*+5,'I=&LU$9W6'<&9NZ]0ZZW4Q\>4%T5!SL][[@L*>H/5'C
M'C860I^,>.*)#^'5A=18:7'*+:<UC+XF%XHO@UK^E6 ;%A.GEH7@4OK5E_''
M&W9]Q*.O^0L<WJ?EPQ11HI&:$/*-M]!AAW<1U4$N+#K'$46C%H[37\:*FKD@
M5O95#X &O!)$6#8P*#57Q=G('AA^FLA0[BA]L+!<6L=>^:+M5WYVXROXY>MT
M;2DU365R?(A-DLW-'A1M?Y%16TSY77L1!BP,N9Z<IDM=P8@AA5K.N&*(LEJT
M<8I)O.41)E )?GA^ 2?F\P&[UHJ;AX,CT2<I=C"$:_[HZLZ^\]P_W'.&@9%-
M"W1"X(%]D'E)95.R(*=A2\TB]%]P(=ZA$5VR3<>A6%9Y19GWWS:,&0Y_$X\>
MEIR.V"1,XA>&/L,4-413+\KN3J*1^XF2GJAJ(WP@%QV=33MP/OG:UW'9:Z)M
M%=8!VBV$ W/ANFOZ5C2KG0;2G8Z709A/(M.\</G@7_KYE< _(C351]A1HNUS
MIU<DG;C2D/%Y^+;(Q<"^H.*.):65BDV^V?I"BX'YP78NJ_':MVUL"-]IP:@]
M+%FF6AR,76JPH8^1?M)Q0$J4ZS987U-]GN0UPJ^#[-=0N)_64V__S%J]&1V'
M.=ET8Z.:\"NVJM(V(GU-EA-(D\9[?B>:A@1&=> _7%3<LS3^)* ?B[Z2Q-^W
MQD]8^;[<E'L29.4LKI'1IE>ATU7\[1]<='6MY1Z>QKA%QNYO.W &5QXR0UQH
MV(E''UQFSG;DJQ ',7KPJ)<<%X=JP(\7*M(DF)@7X:/8TH&*G5H  #21XIK_
MX;P$1'7$X&@H?80_R5H,M0^1CW^R[JZME!;<"8Y.@[X P"WXMJ7P X[R<FM2
M7+]O$15]J(&99%B1M,:7-GBHIVJ#*UX@<ZIV9%V7234(]N;Z8] /07QZWK#G
M_IDA?"^;$RDL-K^'FWP7;K":Z=+<4'L9JZ=$.B%];#HN)AH,[S)^F[<T8('=
M-"@D_9*C"Q$$](@I8"[!$-6&*+2 CB?Z2C2<G!FUDQLI@L+O)YKAX3)P@MI6
M&GJX>VPT[$'B\$<VI6EA7%\LD8EQC; DJP1HIM_)\DP4(Q !011HGII$ 9#B
M<(Z;45\@'6.QHX=21=^,#><4J43"(T<'P#VY-!3C<W?T4#FW05Q/]WQSS7]4
M<^='U-+J#0P9-Y'=AZ;-J)8Q*.B^2M _@WJBV9)R*#8#)70-NHQ-+6O4G# X
M.G%B:1;%KG7)79/\H9>'W:N7AZ6#'SG\:YL;^$EY)&\ E5Z]!/I<V0N+6CC1
MWR][QWO15;3C?MD[/_[Y?+YW"&^&QU^]W )P?S7M"F,,E5W"JT<'SY[L,9GK
M'UVSQ2%1IP5F0+]BC;]M\8$G&.D%@,D?. %V&J#EO?H_4$L#!!0    ( )&+
M5U0.;TTO, T   @B   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;+U:
M:7/CQA']*U.TRI8J7%*DSCVKJ)5BRZ7=542M4ZE4/@R!(3%9  // )3H7Y_7
M/8.+E!3;5<F771*8H\_7KYMZ]V#L-Y<H58K'+,W=^T%2EL6;\=A%B<JD&YE"
MY7BS-#:3);[:U=@55LF8-V7I>'IX>#K.I,X''][QLUO[X9VIRE3GZM8*5V69
MM)L+E9J']X/)H'YPIU=)20_&']X5<J7FJOQ:W%I\&S>GQ#I3N=,F%U8MWP]F
MDS<7Q[2>%_RBU8/K?!:DR<*8;_3E.GX_."2!5*JBDDZ0^&^M/JHTI8,@QJ_A
MS$%S)6WL?JY/_ROK#ET6TJF/)OV[CLOD_>!\(&*UE%5:WIF'GU30YX3.BTSJ
M^%_QX->>' ]$5+G29&$S),AT[O^7C\$.G0WGA\]LF(8-4Y;;7\127LI2?GAG
MS8.PM!JGT0=6E7=#.)V34^:EQ5N-?>6'V<>_?;V>7]]??_D\'XJ;ZX]7G^?7
MGW\4LQ_OKJX^77V^GXO9YTMQ>?W+U?S^^O[KW=6[<8E[:?<X"G=<^#NFS]PQ
MF8I/)B\3)Z[R6,7] \80N)%Z6DM],7WQQ$L5C<319"BFA]/)"^<=-58XXO..
MGCGOHG)XXISX:+*%SJ4/F#P6,^>0&+/HUTH[S4__.5NXTB*8_O7"O<?-O<=\
M[_'_U/HOWD%9_<85,E+O!TA;I^Q:#?[$Q3TCS%96*:1F*0 +8K[)E5UMQ&TB
MD2>1JDH=R=2)ZQQ>^I*+3])&B3@E;TU>#T69*+)S(?,-DA*'6A6+2-D2$"(D
M&=P)LWSYU/U!>#TX8!&DB*1+1%'A)N2H**R.%)TBB\*:1XWT5>E&[$W.#Y%%
M:5K[EV3!E556L%[84 N2:KG0*=15;DCGNDI"W=+PEE+9S/FSUQ!^L>&G7T?S
MD;B0^3=;%66T@9*5]1:BMW- 8J)L+BXU DA')=WV&;#U#\"6,+69)MY,(S'+
M3+ZJ!22;-+:25O%SX%T: RZ4L(0]KI;NWE:IS*'_]]]-SH[?BOT"&"@IJF-U
M -.8N(K*(6QFL.A5+#4L4\I%JKRP,@:B.>!0F8@HL2;7D="Q-H4L$WR,3.Y*
M7;0YHJW5O%TLS(-*A=ODL369"B=TEH_$?:([BBSJM,-#G4=I!73 AVZ$_.#$
M7*;Z43BUXH#C&YU0CP5P'<NA,Z(:$M-&&<<<H#+%P[7**^5X0V0<-')RK?.5
M(WN:2$O:S2(V8CB.*7A\Y!/?^:!GF^.4FS8DZ'V5X?D]^:>3&9T(V@UEA*98
M*$6U*#)53@*PP2%2*T34@: *>.FCIWM'ILK$Q!S=_AQH); [4F_$OCY @05$
M(5JU3.%9_$-+Z9"EU%:L95JI^LEV:,&RN2G):1&,;=E&I H=OX*'$4$X=ZG9
MW;Q90(&5-55!1SJ-Y)+VB67>#_NZ*]X:Y^5%%=XA+B/H#]L^**M:D>!@B(.,
M652EJD,\ @&I[8V\HD-&[(NE2<$SR" ^)#W9T+_A6-JG$(L9:]7:PCUG#)*J
M P,>*/#<JE2&T-MVS8ONE^U-G2TQSB*_Y34PN0.$'?O5X:I(Z35KLB?.@'T(
MZM)8DF9Z+&ZM*J2..1ER%V+=$,J .EC+Z>*E.,%:3GNQL)Q!.3RPTAWW[+>F
MJ9Q:5BE47RK<N5'20J3)R>M6K$)N6*;]"<MJ*]418G]R=B#N38DD[,5!KAIQ
M)F=GXD=C %X(SJ.PN!^=A!O8;KV;$8JY6RI+;MD3A.+-]NUL_D,N"?$.W(%M
MV!R4D$@EPJ]2/A+R%\81(MQY0&$;?RE8,$39'6./J]_N@DLC#D?4C@!Q976
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MTR.A.&B.8^)^S"0R%+^M6563CO/1;'1%0RM>Y>F09];U#/._42$6)]!2W$8
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MZH^,LW3+JCG-;.ZHO77!X5L:.]PVB"1R$T=]39/?MQG8U8WV-%QMKA5E_C(
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M!9C0C(^@$A@X"3,W1Z.HVACP3DMJ(JV9^)!:OUCQ:P\\VC@;E,B^-8ZK[3!
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M U76 <_74IJ]81,,OYOI+U!+ P04    " "1BU=4SD]9AV8<  "4;0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6SM75ESW$:2_BL57'E,QD)DH[MY
MV;(BJ,,:3LB21I3MAXU] ('J[K+0J#8.4IQ?/WG4A:,/DK)G-G9>R#Z JJR\
M*O/++/2S6UU^KA92UN++,B^J'_86=;WZ[NBH2A=RF52'>B4+^&:FRV52P]MR
M?E2M2IED=-,R/QJ/1B='RT05>\^?T6<?RN?/=%/GJI ?2E$URV52WKV0N;[]
M82_>LQ]\5/-%C1\</7^V2N;R2M8_KSZ4\.[(C9*II2PJI0M1RMD/>Q?Q=R^F
M>#U=\(N2MU7P6N!*KK7^C&\NLQ_V1DB0S&5:XP@)_+N1+V6>XT! QN]FS#TW
M)=X8OK:C_TAKA[5<)Y5\J?-?558O?M@[VQ.9G"5-7G_4MW^59CW'.%ZJ\XK^
MBEN^]GBR)]*FJO72W P4+%7!_Y,OA@_!#6>C-3>,S0UCHILG(BI?)77R_%FI
M;T6)5\-H^(*62G<#<:I H5S5)7RKX+[Z^>6[3Q?OWER^>/M:7%Q=O?YT)2[>
MO1)OWK]_]>OEV[?/CFJ8 Z\\2LUX+WB\\9KQXK'X21?UHA*OBTQF[0&.@#A'
MX=A2^&*\<<17,CT4DS@2X]$XWC#>Q*UX0N--UHSW1NOL5N6Y2(I,7!9U4LS5
M=2[%157)NA*O5)7FNFI**?[GXKJJ2]";_]TP[=1-.Z5IIU^-T8\9;V!AGQ82
M%.<W78I4+U>ZD 5\J&="^2L3OC*ASX'O<GDM2\=[8AB\&,$ 8)15#5=])WXE
MO9?94[Z&OM]7!>AJGH/950?B3:FK2ERD:;-L\@0N%>_ V0Q_^J,J5"V?YF"I
M69^R[\2'4F=-6HOK$HBIQ+%X C-&9],QO-B/3Z+XY/P 7DZCD].)^>Y\1-]-
MH_-XBM\=1^>G)^*E+E>ZA'GM4"?B?#06^]/3R8&8CL_AW2F\&\$MQZ.)F[?$
MQ59'*[@1V3<5DV@"J]Z?1/$I7!I/3_&3T3%^,CH^/A#CXY'XD)1U 8PL)2P4
M>;)0JTJ,1'Q\!H0=GQV(O_S7V3@>?R^ ?%P&?!*+3S)=%#K7\SMBO*X7, 0R
M&.@:CT[PDG$\PM<C>#T2GW2=Y&*VD8% 3C2=T$U1? ;W'4=(('YZ!JN(SZ+3
M:7P@3N#?"&3S>Z-*&.;RP\>_),O5]Z]$H6L85%2RO%&I%.\N'.7=_Z?!JQ=T
M]UOQJ4PRV%+*SWAC')V<G_F%T[NAST"(IU$\QA>.ZB= X?G4?G=V0@(VM#\1
M9]%T>BS>ZF)NV&#6?JOJA>&/P"] T<'(:UFA\L'V)M1RE:@2=IQ:W"YD(6^
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M*F0&F0<: "BW6A('9C"#N2/'"U)->J_!L4)<8M0FS8%@-:/1<5 W7-)= WR
M@FE@?>0+WFEP1I-([%V\_/O/EU>7GR[?O[N*Q-O+EZ_?75V^>R,NWGQ\_?JG
MU^],T/#J\I?75Y\N/_W\\?6>4;LGL5_QUU9J&G[-Z _4-_2H2:[F1> K@2I@
MB16)<5K?(K-+S\RVK@ZIZM9=\-':%Y]OT;[CT(9FE,_ P ^3@)7?'/:W4J44
M"\I:<8;DPHP9!+W@5ZTR#-LP+XA-T2BKHMVVO4@G\^.A43I$FLC*1Z*]+7!
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M,0E(=K1^J![XR;WNO,G^HNCQN2\Q"#FBA_Q18[2%'\TV^7ZU !^=8WCS89$
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MJ!V [M=*V>/!!3@-^/$O4$L#!!0    ( )&+5U0;=KJ!6!P  "V&   9
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;-T]:6_;R))_A=!Z]CD (^NTY5R
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M@D[ BV[I1,^>P]PE*UQ%5O4>< E@ =@\#58!,"-0*HN?(;AYX@ 9-\#%L(>
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M/)VSRB*S1.P"(BJ0$323QUR\IP@MRG=HW8$66>SBM[91C E:X,X 78=GSG$
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M#T&+/F7I:A8BLCI-,C2A)::U2U0%!C.%]Y"7.G'I0!/K6B6>'CKOBYBQU7/
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M68D!]5M3E](6:EC<2FOFGS/G::$BSYO9\Z/2I MBDG.7V^&D)V4S"WL+Y11
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M]$P"+\&& ZP$1VZUBD)<T1L=;P$= ?(A00BV8I$F(9%8+9=@F 6X%0)P ])
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MI8&F>/E1%VLS+,&BJ/'*$J*KS+KH%X5G)NJR=0RL*E6#7%7@D4Z^L4S+#'"
M)"KCTAX9:TAM1%)2J-Z#0:O.XY;(*/<RCN>YN'\@UO*!:@5.%K%KE""'?@I4
M71U<]JD&I2F9J28EJ2G;=.):EU]?@/#OC^=UPHTU1,Q&X2XBW4CKO)$D_0:?
MO,\'-'7,>-:Y\:SG>RE0QZ'H-3 (G\_Z+9DSNC9@]UWBED8:3"H2"NF#]"53
MW$<D4(!8_E M-T LIZ(9P&%.-<IG9".ITV$7<0MJ)%MY&R8J>JA =V+62)E3
M)9\ZEQ#18470B$8L0X55'RH\DMO?FE(D")7:%(W$$P+S)-";R-2G@&5^L_2E
M*-6@G58(*?$*-.K5F64]J=FK275KJB2]2L$KU,7T3NK:4M%S%=$!5F\W7,6+
MMLUJEM' %,M:>S-))Y2E[@5@ [%'2"6,!)0TSX&* R['OQ"O^L8:9$Y7_:&X
MS L=DV!?<1F\BHKMT*MF>;P"@84G)IYZ@OAR1/XUKQ1[/R7W$I%[9IE:8CO;
M<%V%K>X#EW0VD"6 W, &!B26U6 @ST)QW.):CZ:1^!TR :0B.M6I<;$3?#(6
M8 5F?#W!F/84XB^XGCK7$ ?.[/7IL3\":W *09J/$1Y$EV6\815"&7JD?KL*
MCZO6DS.@-,V92B/[*V2YVXUKV'";)K7J%[^E1M4H@>XO4US!ZI\,^FB"]E6"
M:MJ_$9]T3N59;N#Y0R#P:S$> F%?BPG?^</1&3T<3>@A_5;7+' >V.?NF'LZ
M'(U@](PAG?)77[+]S8#"E!9HQ)[!-HQ>G,SOIF7-)N5D>#JE?="70; IDFVR
M>,/Q*0SRAK,YT6-\]G(*^,/3"4TZFQ,1)TB]_3OUA[,1$YS)/\?E^K;3M_W?
M0<KL55NV.E+O?2(U.Z-=&%F:GM8B]=L8_C(&/\?94Y\X2PQ^EBUCPIVX\U)^
M4+O,B@JVG8Z1D,\(S2,=L  /F&ZJZ  =,[BSC2[ T<<R^X$#XS14$4<HU.NI
M5N*>1Q!)2D)P#<CB'C!*H#8^>L8TH_8L>?S:& Z;&'? 88M6HP?Q3T;[I[S$
M)E'WMH5_:-U9(SK W1YA0'599NE/[$M7XVPZTJ@>'XD5>LN$));."U2>D/MP
ML'YUKH..#0AS[(R/:T! 5FQ%IO,?6#J+=1GG;/%I%[2N805OW3'JU/)QZ/ "
M"J$?A:F/,@N/HS3] =CQK)=P@&;+*$\[04 DB"&J3C!;X]::6.L<XD]J85J
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MTIL#8MX;F4>"Y;K\X@* X?+?_PM<$>NP.IUGD:U,V4(PL+^J]$H[=VX3\*Y
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M0O[A:4P,=_601X'MDCPL?M?>IF4HI%793G7+;J3>V[GI=3U1'Y)X@S7=L=9
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MB)P@%)A8Q\#HL<(Q"N&(2,93S1GL73K#P_6._;./G6*9,X-C);[QU&:#X#2
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MM0/0_5HI>]@X!^WO8OP'4$L#!!0    ( )&+5U2P B=F0@0  " *   9
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MPH1_KX3!'(3:7QG-T5J:3TNI\") Y'A/T[ZBV764AT_B& 89#%.XIMR7]*D
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MZO-(_>#T*IP![K2C$T6X+>@(A\8;T/I"4VLT#SY >R@<_PU02P,$%     @
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MBWVAQ7FM"Q0!":?$M(=GA;9E^2'^B5ZL1[VVQLN=4OQ3(Y5N2/(CJ*W.$LZ
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M_<OG/^O]X>6[M\T>G,2  DC0QSS/Q'!/)RA^R"U+BAP]8' R_PMA-]$UL!#
MYSM=AJ[Z=CJA %KO7>>P9YWZ5B.)IPM4KXAU.K-@<'0FI38&>0,H8LD2O$GD
M.^;6'"4.N/$;0Q# X'0^FL\#G\$ZN#1K@6/DLUF(/;M_"IMUOLXT5)@HZ/Y1
M5CSU3=;AJ+PC4^[1B7JK0^1D,4SAR%53L(.T[$44T!<'U= T8GS1+C48?;=1
M-&JLUYM=Q]P&6?6N- SVC_,<+>==IN/Q_'&N]_K^>T7;4U2H.=-\%!I(JM2
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MA(Z@8R_F0WUPCI$4/O6=B,Z-)9I)"GU9P6;$&@2"[YU'^"&6'"X:.60=*?'
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M8L]O=T8#B^@&?+\I$*[<!]J@^8L=K_\;4$L#!!0    ( )&+5U3'SWF\_0,
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M%3V^4#L!VE\KRM!^X@[8/^=F_P)02P,$%     @ D8M75,^O.?!Z @  :04
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MLI-VGRB"^"A$AAOFL-F\<62VJ<K!2B )'13*F\R8'L+$7C4-!IOG6\)%;CS
M"XS&ZF"HL5S\/>T5(D0'9;W>K>0=:,X9D,^2R!C#TW<JQ6P>QXZ R5O9&4ND
MSD%O!TM))R=S<%@()B!V%Y5Z"G@T*)- QZ:M_H^(O2#=5DHG^UY'-WO1MV(E
MHZL28Q"?0'4!6UT3MCZ"[-%<\SR)Z'/3$7+3X6#_8.=-] %L,J"=&\RM2F)
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M:7WMLR+/,926@(??L1G0;6;]1F[@"Q!V2B"?' 0;YZ9VH)_+#%/P\AEFUP^
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M%1N:O:O"]YXV\#75H'C,;2L@O1.K7*TV@85QY3Y9X7@$BG2\%@5AP=)CW*B
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MK^!-]_B[MTLQDX"F&:(BDU-X=;!W?+C%1R/-+W6QQ"'1D:F+!?T(!CJX\/@
M?#\M@++T+SC!JBAO";QW_P-02P,$%     @ D8M75 Z?4_$G"   9!8  !D
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MK_'MO)>2Y2M5UGE5"JWFKXXNO&_?A#2>!_R2JTT]NA>DR:RJ/M*7F^S5D4N
M5*'2AB1(7#ZI2U44) @P?K4RC_HE:>+XOI-^S;I#EYFLU655_#W/FN6KH_A(
M9&HNVZ)Y7VV^5U:?"<E+JZ+F3[$Q8_WD2*1MW50K.QD(5GEIKO+1VF$T(7:?
MF>#;"3[C-@LQRK>RD:]?ZFHC-(V&-+IA57DVP.4E.>6AT7B;8U[S^N'JW>W5
M3Q_$S4_7=^]O+S[<W/WT\KR!8'I]GEHA;XP0_QDAGB]NJ[)9UN*JS%3V5, Y
M$/6P_ [6&_^S$M^J]$P$GB-\U_<^(R_HU0Q87O"<FFJ!2&K$>[6N=).7"_&/
MBUG=: 3%/S\C/NS%ARP^_.^L^!\+L7CEK%#"JE"+#TLE+JO56I;;/_\I]KWI
M=[6X7.9J+JX>5=I2E(N[^3Q/E18G1Y=7=T>GCM@L*Y'7HGEV[MU::<F6@>US
MSKE;^5%I!]%6(CW-W%E; W5-7W35+I:BZJ?),D.6]G#K#FY:(8/KAJR_R9NE
M6,*T(QA_ 8"KNV_%27XJ9%TK^G\D%3=<><I4"4IB++%H"\FIF-<.IF'>"D!K
MO*FK5F.<+(HJE9STF=6E9G@8C-&9JO-%*1LS94WP9GF1-SDM/!=+F"G+-:J&
M5:<^&YO<8L/8O&0]YA66VQ#6 ]H;O=[(%M54_%7\6*UF%O.#+/)'QT*Z*1NE
M2X8L"_&>GW\Z%7>Z@=O>*JH^55$M\M3J@7=OX69=Y_-<9>)>5UF;=D '0-!$
MBIDF]T+I5.=K-@J4/!0' V9ZY$??L;0GV+LQG5/98(NBF@%U+0MCP*<S?C&Q
M="FU<K!DB>I/0?70:JB#::3/W7K9+&6QRE-QOY30-E4(8[RMQ;I7;0R*C7<0
MC$%A7?/SV<,9/7QW\XR<7;L_+](QP4M2U6.J>D/N:<U*=ZNQ=@]5T4@A58W)
MT$JL5,::9^H3<A22T2OK/%,=9)YTWRK=5.)]GE8D?:8E55:Q?F*>?AVG'[!0
MI=)89&<@6_G#Y3-F.!1G!RQA@OF@A0]).,E&7V5Q^M0JG 2[H?,%4SU%?2@#
MOCHFC"[/F+,;BYB5+*%4K28]M@P=A;4!W1$5QF@:J.6:18BTX!)F4[SWQ8[>
M7(/*!O#T=N21KD?AR3QO*'F);F14]H9ZF)=IM0*R>6.6%JK(00MD%X\Y171J
M2Q7Z6UE+IC^0?VEAIU5-$5.W"%>H=[&BCOC;6((L%SE5,5*&AE[05>00FFLN
M$0[A*-J,$!45V@&59AXLEJK(4((T6]U! X.6T*_5&.LPO(7FM8! K:6Y9\O<
MW-]UV#A<V;KJ$?2SAJ!2-0XY1)158U>';:RC5O!3BW?D["=6=$A#T\#X*7*7
M)G(SJY7(&[5B;YO.0^IT\^<P:IGF%!5#"X(1*XTBC_K?83!]T8P&S$8SE*W3
M1PEZC)*:; VE$,C@P>L.(4RQ@KJ-?.2WA5I@/>ML:EK/5.JN"RL34D#2ZKI?
MT)H,<A?X:H:0D[C?%8">"506DELA@= LQP9ZNB+QAIR@6[O;SCJ2P$[J64'7
M0LY060_8=-S,"16O2P,&E9TQF*P"9EI7(_]!\#LY)M3.Q'6K:7T$,"PO!5,[
M6Y:1V.H;DS^4#3"(";3<$A+4)KR2^-+YDT(/,9D3.$[^5=4:@W"F6*O"@[AF
M'/$VS;[94/$>ZP9YIC)($Y[/T)FYH"0E"PV,@2T'A*7=M?1=9UU(/,S&24/)
MBHPS1;/W 5*L@F!<#50V?#LK\K3@BD!I0]6GV8JYKE8L7"O:O\$FHT[VO9(%
MUC:10-SHIDS/'-+[6LUTBQV<\ ,FZ+XSCAFL7<)R*64GT!%NBI84QE@H?M2Y
ML:L,BC.0'(]Z:2,NWR>.;$F] )C?NHX]2+!QVVRJSD+*:$G()?.(=471,-OR
M0&,T*CD9ER:;Q;INQ*_0K3&F(.4,J2I'X3>LNLF1/5R0H#H(XZ%DU?V6HRU)
M^UG;F'FH% 6(:(][=Z!5Z7/->8,P4]"(A@^]LANYW1$I3@[(.NV4V(B9LLG7
M6^GR[NTM6P\6Z?!\MNU25@_FW5F>%WI^$=9Y4WYQ2W$F+E*D+36?8OLT]"A)
M"0[B;:867'P'!)GMF+N$?52AZFZ/T>BJ)E&TE^*=AI%7TE@.1@)[,%Q($[,"
MB/0.\;><?Y_M6]X#=0_3^F'[^DF5K2W[]X8G=._T^)WI?C4W8M)YBQ94\V::
M,];E0;[K)6*#"'J"^01F6\%35(U/>8J9P:,[ #NJB6,1.--HPM?0,]?I-+9$
MW7?<:2@\)W%#NH>1]HBWYWA11)^Q1Y^3\&#<3Z)03,(85_=P',; D$P3B'#C
MJ?A0-;(8#',L8B<,0KZZ_I2OD>OM$*]]U9))3)]N@D]@\Z96+<\)DP"?01#3
M9YCLJQ6Z@0CB2 03_Z!"/O#Z?BQ\+SJL4.2'8HH58^ TZL"P(80Z$Y@W<.)@
M,N(D)]/$/Q4GD9?0IXO/+[([<0+HT\DI7:/07.-D>BK>557&&3OB?>(DC""4
M:YO_77_]W?Q0G/A!2$MZ]$DH?@]?%"<3%]-]4CWP3@\P1SR?!J<TSF<%0S\Z
M'9UX6%)]0E!/13AQ132-(- -[-8<H+I!4^'!Y_[PO",&G5A<)T8I)_*PW(]6
M?_5(:[5YO>R(5J9F0!81I DY+,3=-;@,-0405=,P25/#LJ;0 GK&1N),P8@H
M3MAC4!7@5FXA@DYRM .!ZP,)[I+ 7.'; +Z][+DI[U@0<ZEEG$M)%4\IU !)
M6]*J+^TVC4;EA=HVZC"@=65FK7/<F6)#/;\JB>WP;:LU2:%W& 9.C$"D);F]
MUNH E(YT(EVPC9(%R+=<YY0"5V3R+*<67/</U?@A6DM/Y/_@$GAHO?V:@:'T
M.0FH9J  V$(H G&@^*$@^HD(DH,E FOCW\'B0*_P'TJ9'R=@8^ZH%(0^!6KH
MVJJ1'K(2 $94U +7I_NI.S08&- NPW8:?;V$]$4%]M>/[2P\G.@UU5J N T[
MWR\[ ;W81 44#(,7C@B]%_PV2%XP]6 UK,#N3(;.[TR7+K9G3\"/"4DW*>V0
M[SG\J?>,K_:\=,@Y!]UB+/XTB*Y'!A"*CVK>JE2M9LB>[IQ[[_#K6$P\:E?H
MF6B.%$[D+3^DT(KBP';= )+X> 1-:))$>]4Y<*?]/?7@@$^"4/7C>'@>#/.H
MF4T"7[RQ1TK#9OR=.="  Q%7W?!I,!(?3:E#AJ&=T+=>A"BZ%3A A#*6^".^
M8+C!L24 Q]SBC[F/=^WZ?^&<KW"'>\@=;L10XX0=,6$%IO0Y#0WIB6)WY(X
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MY=*<)ON-TB%]AM*>F'B8:30]Y18L*L2HAB43 ) 6]HJ=$0_D^99(+1$6FO6
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MKF(X'9Y[+,%I>,234\_Z>R=B8[QHJS9531L0/(2^#+^.F#0#)%01VK758^Z
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M2NN03M4XS_OPZ(/+K'$M^2K$08P>/&JPP47%&GKDA8HT"2;F>;A-@,Y G5H
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MTQC&V^O]P?<FS./\ZO=8FV+])JAL!YPT7C J%?&ZICJD0+W;\85/DMM9@3
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M;85)/0UTQUY1-8M)"Z1^O*^&Y(*X.^DVD'H=W3N-EN;P#NI05V/;9VB.J G
MD@[>1'.A(_P&%X 69HCUA)NNIQAS_[!"=%'*M0X WW?7>L1V>&TC2Y<>1H[;
M2/>O:BFSD<LMQGN9^S)G&I@<GP0XNO&";)4L-%^)EH8+R'>KKF[\.8^WOJ<Z
MGTX;(S\:3\?Z%T42[EZ(3W8F"K?_+*=OZ_G@M@#WPYWV'OQVPG^3DF**4OM<
MJ.![_52D\E,%O2IW5U!@I\\5+!?Q-_VDTG?-(NK5HUC^N9P9+V"<U\6NIT$9
M[MB-U-I8</V X>U%%C-YDC/90XD'0\FWE#R D/VU?1@#]8Y21 G OX#JR5?L
MEB;>'YJW]Z_SP.)==!T^E4KFM+%-\>>" +S+<%[V[ANY \XWRPSU9-)./9>X
M(L5P*7.F_\1=[R)@>]M'E,RIC&V*2L)-0<OI6W[.3 GJ85IYY!CV"X::OT0N
M./O1Q\K=N;#"$*@C);\;MX9">2+JFH1KT9O .8JV:E8)Q9^*"#3N ]PU@5_*
M2X1[DPPFW'ZSG+ZRY@IC?,=OR?!$(0P+.-QJ\/<-=:B_$C;$I1#CL=1Q>AD/
M]A,5/SH7*3M;S/ODMD[R<P(";?TEJ?;!\XQ-'<%L0/REP;FOL3=@/UW]VJ@%
M.TN,6RB+&CW;):M4DR9(4;=@.S\2+0SOETEU)=&53'R[I)>-I.7@G;+>AC3%
M)Q)QN\DSBF8=FF<VJ"XAQQJOE5B7[VT(*KD=!8&%PP =;YRYJ>=@L1;-IV57
M.>5XYYN0F3[CW.%5PWWIO1V!?BSO$?8S<=Q297QEBQAAG08KUA:3;!/%!ZD]
M^,-C9 ZR3;X]T_+.*4H+=Q0M[[EG2#N.B@TP2F&/&R*YZ'<Q]9D\E+>SNI,.
M(1+&"Y>)D=YDN^<*",=[P,ZD3:U],VJV.S:^5H%Q;93K7801+H?QW6Y+CEX<
M*+P>NV%Z'@ 0NOR.Z2)4H>7V_:(,R727(?)H]D/W#LY"5M::$^;#ZT8?GL29
M<%',\IYK7?@2HL_IUP-FZ,-?3^1#2Q^H?][:W[,!'*7SOM!0,,1UJZ8W,&;W
M'&@8V].8U0$3\J-#ID(3I2J$2ZL;;?*I]HVLE_RB5OWIS<W>6)S1W&?(/4X)
M.6$$:=5+;9KAP5L,K: J$TK-H^N9?<Z?;H.ZQ"KV#X&AI>;CC>8KJ>D"&+,J
MY!X!4W^9 9?UN%+RK^"MVL>UBO2V&1^2H-*UZ&D4\6//(6<OJ0;OA('GH,;4
M.C]E3IN#S34DX_-.- E/]V;"6<"?G;G'69J#X8E*4@+QA+0,71_I5[H"W?![
MF9J6DF\>U-0_&D97*+7O3FY3QR;T&D'7F[C,-5(P!&EG'1!!35?.]]ILZ<U9
M&))H?3L>G76PV6@OP;/M5QF==C251&JCC,J:$^) *KO4N^E>G/PG@R2_KEB/
M6#G<@S\:VG>P7^:1@[-O^XP?BE1]%7A;"%7, I\M\'HIN@VT*ZD$N7<7$KG%
M3>$ONA(-\Z;(,F!V0<LP3/C "C0X-HO[<FG_NZ@0*(_87IG9E9O>73QE8'V5
M[_ 8VL%$G::G#?QP <UR^@(:O!X^N83S(YTG.>M%,.6V(8YFB33DNZW7\U&!
M\&^;#7YL\C4WHL9$$U:N^Q'7R1'B>VU6*!* RR)^HJU+(S]J/*'96X<:MLN.
MM=5WR.I SQXB/*ZUB=*931N4?@]P#+D6Y W__V"SXNW;<FM'J;B@!FH  JKA
M]I6R\?B4^SJPOM"\F@WO4^00%?&V.WE+=(L)(CH-EUF<3M\H<1[U2D<D'Z.-
M1P^2Q%_1F:D/H#''6.K]!''/]B?XZU-A0//['PG*>XZU13X0_L .\]0TR#/Z
M:[Z4;+3KNR^D/8:ACWWYN&:S!GW .LE0J8Y]5<".6S0*:BTK#7F&=EGS!S:W
MG^R/3TB'>W)U(P%KZOD]?>O":;AUX73ZFH1SC29@VLLH\CSB?4R+18POL809
MZ0;=U22,Q44XB'V;%$/!,C-<*!V0+'4IGA8;"N4Q^Y%(IWB8!W<6Y53B/6Z[
M4G1I=6Y1"X7R)J\KS;F-5%-1K,5A.>>.A^AX0,8PW,3()< 6!IYC1'=&88>E
M06PZR&A.ES1!QY&:"%X)M[5$!E1AYZ.[X.0(]RCV<H[B%J.*HFE2^]L**)5&
M'@ME@OK ?D^A9ZG318NG-?4@B5RGH+<K'!AF)IOF7W%^[2O96$C0)LKJX&)H
MX0]:P4QB4F6^ZW;]RVS\6 <6\5E*^0012&1J>E34>"YM(OS5.I7ZX5WOIH@^
M7/MP.GUAPX_J17PKK.L2$RQ'J7]RH/&K ,='CY.W]JA>UMPSL.JH\D_9J>C$
MQ',I\=-Z0GU.GO+<^$']F6A<$RU"_G=J$OXPOC<8+6;L^"(;,TJEQH<TO@Y:
M_'"4J(>ZT&I>6[O#.^Y\'15BGKC B5M1\H,WVYM!KQAO;'D7,B6.2F/7VZK^
MPF5 H6:0;09[MS A//HD=; Y2?LP_T"J$IGRK8')XD0SR95RU$93"Q% 8=-)
MY8Y7!:(%DK@?N"#'A[#"977ADLT0>Z7T(ZG \KYFS>:H8FZ7^?MQM!W>J"=Z
M4!Q'+>WQERE"#"D8I]/I$F>9>K8W .A;NABM(^&!%[^4&7IK1LGRCP^+LOJ_
M.C!)ER>+E\S]WGN'U.@+;ROX+WER]/[LZNW14[IG#,"X[<!(I(2=TN>FA0N9
M@X\K)Z_B3E)U$<=SN6_<7)E'MRIX#X"WI077ZK3U_22\Y./?0DHCL&E=$K4I
M<WSM@ V_4+FG<7NU<>)MN 2;?6<Z S("O]M;+&CTUY6IMTSYV\IM\Y*Z(/0;
M "/IW'*$DIK>R;7KN'4VS8%SU)6F:85KU[7,)35-OX_%:C%-&[E1E5<ZD4VM
M<Q\KX2H*I[=R^)Q!>.ML^!9I$?X"R#_Y$G!)!<8-K$U]J $\&%$9>:6DL9;/
MW=+"]D@'^DLC"R-/DKE@B[3PZ KDY*S;PE819U\+S@(R#E"1@'FG]A>Z^N$,
MN>MJ*)OATMH0U!(/%'N'_A5G_6^ 4]C*OP<<(CI\CQ 6TP>EG:\$'!%Y]Q.,
MW+RIX3)I\LUFN>^!O'CQ/P9,/R> \\T$.!DT6&64;_2&F#0PS('O;05:-[:?
M*-E!KW8E!V94E+<65KU8D&<"/'2+UU^1D")W-]\ZDNMM)*;EIC1^E#IN:F1G
MEJ4\@&_K5*>(V!&]GOZ1Z]]:0Y->=CXSK&/S.Z-2<0.[M.'+?=3VB,&XP12+
M:TP\"%Y,C0/8PBU<5'I+2D,(#8#-6!\\H.C^-RUM]FU9\*J?XVX?LG._:@1[
MXZ^6[:%W_C 6P9D[,>(?8B"+?P/.!WFL/N79PYGOSQ1RYE3B@]3!$21NZZ(]
M74"@9KEWK!C$)S8 ^R/F1"TS?CH[NXSN59HEUR[;LB^?73_-=;Z7T)>TCAXY
M3(W1?+AX^_$365CFRZA+<L]C3X%A;CGCT]^T]K W N4"[^;)Q[&-V@8:ME>O
M2'IMN1/0TABO_GZTZ)H&C#[/Z.)P_D0%KUS^@^U6&4J,,Q[T*?#C+&3V]1@P
MF ':OT-ZS_,1+Y8S?\RL=O1[TB^QV0!I<%ZK08R-_3O:[,)1N$-NNM06\@-8
M-''7CS'LH>HYT9SFR5^U0UF^D9[1,/Q@H?&2:"F-K.3 F=R[C#2LHM<[&L-M
MVN#>:\-<J9$:G3RFX8J;M_]NTIRR1$*^Y>ETQN057QJ=?%(W^:C9,3W&N>\<
MD8=[T#7.C2X=<83/[L])#2G?)..HP2]Z\@P4#E0IFO:S$DSOZL8(74UW&5BR
M/:%;4;E686OVXQGM]0N(Y7K]5Q@ASH[4:[FYG29Y@:BODP#>7@;FNPQ%W;'B
M!@)9Y9BZ,"<)1*R.PY;Q/'G?U3@_!HMG=!N7C^,W$TE&6IN#O"\)G4 PR60&
M<IO5GT'K%4W"R=R>:LRE&RX Z?@6-0.[-VO$,8%IYD)T'=I&"MK+;;C1G" '
M*RS=6J+;$L5$?1/UT\:!J>XE)1+5556T:3@#X4#D]\6E$N"I6T!QQYVV,S48
M?=(.IS!D[$*8BE3-$JKJ6=4DPY>G8_PG- _$U9%W 84=^P'IZD Y1D[!Z2AU
ME@0[;+ .%3&A%;QI"V>:&5!2B8X@>-O>5@HA%_%]C/Q7TA<7'V2@75Q^M/$S
MSLG4XDX8DJ6 :GC#=?NJ*=-H8%CEK$$Y3E;$"@%ZC\(YV]*ON_^@;.DCX#CR
M?+U%%"\^U95H2RM\/%RW&NX;C8=,GHR,]50W<<N]EKB[@4#I_..[GPEZ !%=
MSSLL'I$8^Z4O0E/*%-V:P=N;/C1T&IV$]GQ;&FKA=$0<@V($GD30=4,=@K6K
MT.@]FEMBOF$%F@(5;@D(ORKCXL3.V#_!:G%/OV5I-H(N'-3#&9IOE)3^5_*A
MVJUF6#6%S: NN!I(</@3?,/@HGJB$>B.2K]GE*CP+FW3'[[;8;'L.14+DZKU
M_1'&QORWJ,2!=%Q\<[8\>@9OAL=_^&X/)P$*T18%1>$V\.K)_-6+(^X3KA_:
M:H]#8LBFK7;TY[4#1E+C R_PJMBJU0\X 3IB:7D__#=02P,$%     @ D8M7
M5(R,]_.=!0  D T  !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULK5=M
M;]LV$/XK!Z\8$L"))<JVK#0)D#AMYR%-C2;=/@S[0$NT190259*RZ_WZW5&6
MXK2)VP'[HA?R7IZ[>XXGG6^T^6QS(1Q\+51I+WJY<]798&#37!3<GNI*E+BS
MU*;@#E_-:F K(WCFE0HU8$$P'A1<EKW+<[\V-Y?GNG9*EF)NP-9%P<WV6BB]
MN>B%O7;AHUSECA8&E^<57XE[X3Y5<X-O@\Y*)@M16JE+,&)YT;L*SZYCDO<"
M?TBQL7O/0)$LM/Y,+[/LHA<0(*%$ZL@"Q]M:3(529 AA?-G9['4N27'_N;7^
MUL>.L2RX%5.M_I29RR]ZDQYD8LEKY3[JS6]B%\^([*5:67^%32,[1N&TMDX7
M.V5$4,BRN?.ONSSL*4R"%Q383H%YW(TCC_*&.WYY;O0&#$FC-7KPH7IM!"=+
M*LJ],[@K4<]=WL_>W<W>SJ97=P]P-9U^^'3W,+M[!_,/M[/I[,T]'#WPA1+V
M^'S@T!OI#-*=Y>O&,GO!<LC@O2Y=;N%-F8GLJ8$!PNRPLA;K-3MH\4:DIQ"%
M?6 !"P_8B[K8(V\O>L'>59KJNG2R7,%<*YE*8>&OJX5U!KGR]P$'P\[!T#L8
MOI3<ANF@EPW[I-N"1"8J; 5>I@*PJ2 U(I,.E+96V.?2?- '->V9K7@J+GK8
ME5:8M>A=/N3BB4='[R][]2L8=2:PSU(AU[[FS2IJ;@4WUB?=ISX 7F;X$"8@
M+7"2(]/V%([052&5PG:SQUZAD?>RUUR1]SXLQ$J6)64=\U()(W4&KR!*\#*<
MT"6&C\(9;2OA6Q;$<HE//HM5A77BOI_QM<2FYX]%M Z!<9/!K[],6,A>0]@]
MS8U>2W^0'#%$!F$ ?QKIQ(E>+BT<1<=P%#*Z!,?H/-5KA(498!"A$6Q_;.X2
MQ-<TY^5*^/@U9L:@PK'7;OUT00H2V0]OM!?C 6J-.FJ-#E,+3^>L5H*<".LD
MGD\B@]J*9:U 8=:L=V_P]#9NVX<*<3D/7'RI987'JGN.:X>=W@BD6"J;_&/M
M4Z[26NT\4P6(+=0^=!2>D#84PN4ZZT.J"_29DM F%SM&(O><13[@)KZMN51$
M/,\[1)[53?DQJ+X_>3&CC6)#.++U?.AG<$N1R@*MK 7%:B$<P0E$P8[,U[54
M&1JP\)W@IPJ<AF$K^9ZG.0:"7?PD>4B,$^3U3NB#)\/3S;#=?-,M$VNQ'MRS
M50D,:>=MM!.]I;5<JV\@W0K,E*&".F$*NC?*F*?6RP%*C3M*C?\'2LD2NVPE
MJ4Y-_9ZCT6%'5X4V3O[S'(TJ@VZ-5-L?$.J_\F'>T D6!JM(?;U7O*DVE<:B
MB'8WV=]M-0U!L(,*Y:@D0ZIP6[8Y-PXI@H>G\D'97%868A1)6H+4!#_%CQF$
MYD2:EUKIU7;O))D\2A^H9=S5,O[9R;/&?/JV2A&8S#S],&]5>R(^6\"#UE^>
M.8^%<-ZEWZ5TN?V!Y!NII/;#,OKSTC.+9*:ZJ'BY]<=I_-K^&/PW VHWFECP
M[3"ZD=;/"4NSI38EW1=82RQ_SLT*G]//EJ2<D8O:.WG0CBL4\_&U2/OP.R]K
M2FT[#%]!.&%X'2<A7A,6T\J8!IE?9OU@%,"T-H9.@-T\Z/##&#&'-"+[83Q$
MFPD;09B,8=0/HC$2:]N< !16,[)Q6HU#FE<L&M.U'S$_N/I)D- ]H;U1G\71
M\??8\0M*% MD6]2B#Y, 1O$(XCC!.(8P0??]21@=0HPB$4[V_G#,"'&2  M#
M1#QDDQ<0CSPJQH8>,4MB?P^:.$:A1QS%DY] 3#EFC/DY2M=D.*1\QU2'(<U8
M1#^.GIVP@[VOY$)@S>E? $\?HD7SP=RM=K\;5\U7]J-X\Z_R'BDCD4-*+%$U
M.(UQ;IKF^[]Y<;KRW]P+[? +WC_F^,LD# G@_E)KU[Z0@^XG[/)?4$L#!!0
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M7M&/=O1'T<F(MQA?02.\A*@>A2?B-:KM:/AXC4_BC7)#,\; 6*4++EFA')G
MT!CJD&'\,^>&^]F_APMC-:GJGQ.XUQ7NM<>]_@1W8BPGB6$"2\8UO#"1HP&U
M!.9P#8F7@#4M.RZ"LP47Q(),:#U/C[>RV+F3B*[9NR9C,?8#ZF:#^@6#P7R-
ML%2".I7+%5A7Y[)=^;\$9FD9/V/J%K_(EKI9^!!6%6X'VTJ18M26CI-=-)J9
M;27JU99F*J0#EX1B=>&</%(N!,V8"ZI4K'))WAICY"\^DS-HPU2^H+1*.S;1
M-3QJS!A/ %_IE#..(3%6!*"I^;0FTQV+)MFJ)(\M++0SXM(RN>(N;FEQOM^:
MW. R%Y3Z$@ESBTP3I;!YLZ>5L:WG=!YZKCK' Q+G8?L"YLHR 3PA#GS)O;'$
MBD[8;L.=4LF&,H9&:;ROB-]&V@ARUX6(2:K2+%&[LIQ!V*G#"=DV*]DV3\IV
M1G=$DHL"CFF]=;)A:9'B@7J/9+!&0?)1=#<P@1])]R3JQ]*=RECD=*A08;Q
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M3H%C_!,!SH^U=LL."2@>F,__ U!+ P04    " "1BU=4DPX%XGP"   A!0
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M<1Z ;@79;JRJO C6RI*DO%G0&X;:.=#]1BF[V[@$_:LX_PM02P,$%     @
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M%YO[#YOU_>.G"6S>+=\_PO+]+:S__/AV<[>FW<4CVPHTE[/0DB]G$59'WM7
MF[S &R=PIZ1M#*QEC?7_"4(2.2I-3DI7R:N,MUA=01I/((F2^!6^=(P\]7SI
M2Y%K>MG:/E/D@DD+3-:P_M;SCIZ<A<_+K;&:WLR75UQEHZO,N\I></5 I53W
M D'MH!O==J-;/+G]69Y?I78U>VTZ5N$\H*(TJ)\P6#PV2&_D'Z6A4FVG)#&;
M7_H&YC&49FRWJ,=4>Q0M(B*C6C264-=PP24]1R&HLLSE@/.8=P[]&Q29&][
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M;@"Z'27MP:K:MV^N+ T#O]W2]$7M'.A^K90]'!S!<9Z/_P!02P,$%     @
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M&YHO59<0&^SW@D,VH^:R4>)H0?!,OD&PA:Q5IZJNPCU"XXY_59O2H I6[Z'
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MM:/FT$_7U(VC80'ZGVKM=@L^H.[O9_\#4$L#!!0    ( )&+5U06<:$P@@4
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M92JW$+(EYYDU" 8P[,(P>HME#5",:RC&S5"DDIZN!-K0;ER]PO24K<GNA8T
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M64H!2H,Y<LMXXI<DX="+HGV]U#XQ>R 7HF?-0TO:]WHQ]$J-/?A"L+&)0IC
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MRX(>0]0.0.>Y4G;ON 3=\SK^#U!+ P04    " "1BU=44ER=]-H"  #>!0
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ME!J=7W8#T,TT:396U=[!"V5I'OC7@@8P:A= WY=*V=W&%=B/]-%?4$L#!!0
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M7QI%R?L&Q090>LO>RU(:>!@.8XBN/QB?CP4-\=70S]+4*.%H+%V-O3<AVB(
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M:VEH&-TVH]</E76@^XV49G^P NU[.OH/4$L#!!0    ( )&+5U3/! 9*? @
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M'?!T?62_];W;7@JJ,9/\!ZO,?AY\#J#"FG;</,K^*X[]7#F^4G+M?Z$?:\,
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M_BLCU$J)Q&$O$))4@$1(FB*=T"B$]MGL#JP5KTUM;PC5^?%GO&P6VH#3E[[
M^C*?O[E/;ZWTD\D0+;SD0II^([-V]2D(3))ASDQ+K5#2R4+IG%E:ZF5@5AI9
M6@KE(HC#L!ODC,O&H%?NW>M!3Q56<(GW&DR1YTQOKE"H=;\1-5XW'O@RLVXC
M&/16;(E3M+/5O:954*.D/$=IN)*@<=%O#*-/HZCC!,H;WSBNS=XW.%7F2CVY
MQ3CM-T+'" 4FUD$P^GO&$0KAD(C'CPJT4;_I!/>_7]$_E\J3,G-F<*3$=Y[:
MK-^X:$"*"U8(^Z#67[!2Z,SA)4J8\A?6U=VP 4EAK,HK86*0<[G]9R^5(?8$
MVM$1@;@2B'\3B(\)M"N!=JGHEEFIUC6S;-#3:@W:W28T]U':II0F;;AT;IQ:
M3:><Y.Q@.KZ=C#^/1\/)(PQ'HZ^SR>-X<@OW7_\=C\8W4_@'1DHF**UFSNP&
MU )&&E-NX8&;)SBY1LNX,*?P ;B$.RZ$N]8++)%S3P1)1>1J2R0^0B2*X4Y)
MFQFXD2FFOP($I%6M6ORJVE7L1;S&I 7MJ EQ&$>SZ36<?#A=9TJ@80+U 8:C
M/\<+*SP/S7;M@78)VSX"Z[6O![]3XW=*_,X1_#OVPO,B!XLZ=^A*\R673% 4
MV4)SNP&K(!',&+[8D ^-U07EJ37 #"3,9,!DNOW 'P5_)N.YPQ.RHP&;,7EZ
MR-E^3FW(2U][U#NKU3OS0MVC=N:CDN.4DU3XR)0I4HE)D,C.B2;5BD05TF(*
M5/=@O@'!]!*-A3H<JE1#?3!R_0PZG588?O2HTJU5Z7J!AD1*6O)-$ZXT^\E%
M$VZ6FY5MPJU&4J<)4]1S3L=3*L@9#!>:)[1Z+/03;IHP>])4M^G:-Y3XLT#!
M2M=1Z;.2Y1Z"YS7!\[\2JA<U_H77 ),#WCODCRW*68GB^M3SX/RB%SSOI_+;
M*U&W6]_YA=UES>[2'VF,(B8M$%:HN=K&TGZ441K-D2)P*2C!:.>]%/&_=AE"
MRC:^#(G"78T/W\L11_A0<E /%(R\"A11QE*X<+F$DUQI/$[\G=?^@/E>=XK\
MS)4NN_W1U":2%KB!5>6<@WRC-\$0'PZ%*-X1B[W$'M\P^0\>,TK3NK;,6M/6
MKL#H786AFU7:)/OYY+/7KI=$?Z>91+MN$OE+]Z3(YZ0-(7N***GH[;17U2/=
M/9>T?W-)L#?4$.:RG/6H([E*OIUOZMUZGAR64U2PN[X=1N^(*34V$+@@T;!U
M3J&@M_/==F'5JAR1YLJ2 N5G1C,Q:G>!SA=*V=>%>Z">L@?_ U!+ P04
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MIJ,GTDXPSZ="Z.7 )JA^(^C]!5!+ P04    " "1BU=49]<>OQ<$  !R&
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M\@(@?W]E3.POB@?4_^88_0]02P,$%     @ D8M75+:BDW?:!   !A,  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3@N>&ULS5A=;^(X%/TK5VA6FI%H$SM\
M5A2)AIE9I*'#TNGLPVH?W,2 =YR8L1UH__W:29JD$%)66HWZ DFX'^?<ZQQ?
M/-H+^4-M*-7P&/%87;<V6F^O'$<%&QH1=2FV-#:_K(2,B#:W<NVHK:0D3)TB
M[F#7[3D187%K/$J?+>1X)!+-64P7$E02140^W5 N]M<MU'I^L&3KC;8/G/%H
M2];TCNK[[4*:.Z>($K*(QHJ)&"1=7;<FZ&J*>]8AM?C.Z%Y5KL%2>1#BA[V9
MA=<MUR*BG ;:AB#F:T=]RKF-9'#\S(.VBIS6L7K]'/U32MZ0>2"*^H+_R4*]
MN6X-6A#2%4FX7HK][S0GU+7Q L%5^@G[W-9M09 H+:+<V2"(6)Q]D\>\$!4'
MU#OA@','?.C0.>'@Y0[>N0Z=W*&35B:CDM9A2C09CZ38@[36)IJ]2(N9>AOZ
M++9]O]/2_,J,GQ[?S3[?SC[-_,GM-YCX_M?[VV^SV\^P^/IEYL\^WL$%+.F.
MQ@DUWX%8Q\QVJPVW1$IB.P;OIU03QM4'8WI_-X7W[S[ .V QS!GGQE:-'&UP
MVFQ.D&.ZR3#A$Y@0AKF(]4;!QSBDX<L CB%8L,3/+&]P8\0I#2[!0VW +D8U
M@/SSW=T:]^G9[FC8P,8K>N:E\;Q3/?OHPYT1@##AM T(7[C#-GPG/"'9JQ2'
M\$=".%L]L7@-DR 02:P53)D*N%")I/#7%Q,29II&ZN\&0)T"4"<%U#D!R!=&
MA_+U0,(=E9HIFSJ0-&0F,XL#GIA.VF4AZ0/1M'959$FZ:1*K5[LQ&O2\D;.K
M=JK."!T838^-L-MU"Z,7)+L%R6XC22.!FE,C>1H,629",*H+ 5$;"$UELQK;
MVA-NQ)3$03W)YB0((KOR&WK2*^#VFB/]!L&&Q&MJBTZ59D8C30<DU8DT7; ]
M:,,LVAKA!;-HS*9QH<DC4")CT[I:Z+VCJ@Y0?4W[!<A^<TT)I^H9TU:*'5.G
M)",+U*LD[W;PX&!QU!BY7J\>XZ# .#B_D#O!DXB"6%FT86)JIP0/06^D2-8;
MT +F9LD'A(6PY<1P(N9="-B6F,7Q7\L]."+3/T%E6% 9-E)92!:8-W1KL@<L
M$XO\%:W+/SS*/^AXG8.*UQBYN'_P.M88]=P32P>YY<[EGL%F4F7CIVP:WAY4
MV1?1VQ!9A$M(^']L7Q[LA5(>-,;/;:J=0=T3?2EW)^0UPIRSF$5)U$2YW%A0
MYXUTH=P&4+-$+\A3N@EH*J/ZPC?[>RZ$Y$DU82DU'C6+_)P\OE;J4HI1_XV4
MNE1>U"R]KY>ZV7_X>JE+Z43-VKG,YI8V3"H#CI\/. LA;9&:)M52UK#[-OJ
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M,_01I=4&I*:*\B7*A-(*G>:@"67JS-P^SG)T>G*&3A#EZ)8R9IJI8JQ-:C8
M+KLTQFT:X9$T@A#="JYKA:YX!=5+ FPT]<+"G;!Q^"9C#N4Y&@0?4.B'P8&$
MLO?#_0/P_-WPX,L;:@9]FP:.;W"$+RU+L>;:]F J&"TI*/0SG2LMS</Y]4:
MJ \0N0#1L0![789G,U04'&QCRS)T+':D;))A,(SQ9K^R__M$P^"E3WZ )XIZ
MGU8"WONM&Y!+-QX4<I5H?X3^M)] J7MXK\['9C*U@^0?33O6;HE<4JX0@X6A
M],\_F8QD.RI:0XN5>SQSH<U3=-O:3%>0UL'<+X30.\,&Z.=U\A=02P,$%
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M[0+L_DHIVDU<@NYA3'X#4$L#!!0    ( )&+5U3:4GH>= (  &T%   9
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MP2?(5*XEPA-[10MGU^@8%_;C*';$[C'B?,<T:YG2(TS]%.ZU<I6%&U5@\3]
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MUH[:,TPK>@_1^  ZWVCM]@M/T+VPD[]02P,$%     @ D8M75#VW?0E$ @
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M3#42>H62BJJ4) 985J_*Y+0_R6F4J[DKU-Q]H48$J:]A(8T,GFB6+#G%/M<
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MX'4]$L&:[81]4H=O<!+4<G@K)4SZ2PZGN0V/K';&JO@4C QB+H__[.54B+.
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MN%I@KM)_5]GWSS*&>'X# E@!ON?#DH &GX=[)?#PTW#8.J,FR&L66+[@!-^
M2W5MTL\9HN0O2E\@%NNL*[Q,'^@U4<262)YQ6<U=5JW+Z@F7D7XQ"5M6P!(S
M+!"U[E"L&Y)(E79"69U3TIHE-3?02]>O^]6V^U+,?8E14&_L&X4E1K7:CFE/
M5"T753LK:HIU[)NYV@@MS2H:%1)HLGPN=?7<2_V[JM7(738^$&9N?"-*[$FD
M!#T1JCT=>DFKE9+6"SDV[5J6X68>2/,+&9X?9S1UW#QVW#QHDA(3>- BQR8!
M+ ^_E8??^D+X:_2F/WCE"EKG4I<J*#$Y$!FVCIK\E +H[>YW[X,W=XW$KNGL
M)?Y!9\/"QP-^5V]#?^?4_WQ5*D57%2"/U9[LNLS-7L/X!T4KL8&G2K*[OF'P
M/R[3C+78'O XX&,C_S!@MS N)%@L[=@E=:(V3*7?U/PT'^UZ=J Y..^;D<^.
M(3N:=%Z\1V))F 04+S2E=]/0 8ET!$LWBJ_M4/+$E1YQ['*EQU8LC(%^ON!<
MO6^,@WP0[OX#4$L#!!0    ( )&+5U2K_$O.V04  +HC   9    >&PO=V]R
M:W-H965T<R]S:&5E=#8Y+GAM;+V:;4_;.A3'OXK5.UUMTH7&=AP8%RKQ- UI
M3 @NNZ]-:FBT-.EBEV[2/OSL-.2D37)22-4W-&F/#\?GV+_SS\/Q(LV^ZXE2
MAOR<QHD^&4R,F1T-ASJ<J*G4^^E,)?:7QS2;2F-/LZ>AGF5*CO-!TWC(/"\8
M3F64#$;'^7<WV>@XG9LX2M1-1O1\.I79KS,5IXN3 1V\?'$;/4V,^V(X.I[)
M)W6GS/WL)K-GP]++.)JJ1$=I0C+U>#(XI4?G 7<#<HMOD5KHRC%Q4WE(T^_N
MY&I\,O!<1"I6H7$NI/UX5N<JCITG&\>/PNF@_)]N8/7XQ?NG?/)V,@]2J_,T
M_C\:F\G)X'! QNI1SF-SFRX^JV)"POD+TUCG?\FBL/4&))QKDTZ+P3:":90L
M/^7/(A&5 =1O&<"* 6S3 ;P8D&=NN(PLG]:%-')TG*4+DCEKZ\T=Y+G)1]O9
M1(DKXYW)[*^1'6=&GTZO;LFWTR_WE^3Z\O3N_O;R^O+K?W=DCYQJK8PF,AF3
M+Y%\B.+(1$J3:R7U/%-C(@WY)*.,?)/Q7!%7$7*KPGF61<D3.9,ZTN3]A3(R
MBO4'Z^[^[H*\?_>!O"-10JZC.+9%U,=#8^?@(AF&1;QGRWA92[P7*MPGG/Y#
MF,=HP_#SS8=[J\.'-G-E^EB9/I;[\]O2EV9VH23$S5LEX2^B?H83F3PI$J:)
MR>PBU>0W^9H:<J&T-93&94Z3SVK\Y/)TE6B3S>VV,$@PO R&Y\'PEF J93I"
MW/FE.Q^=VX7*HF?I=AF)P7-3R99^1.['<>-Y9$OS7*U*W>*PM%@)3I3!"32X
MKY9P5\FSTL8EK\SG;W*>I5KOE?70"SES)>B1_J ,*=A&^@]*=P=;2O_23U!)
MKK>6_KK%@=><_\,RND,T.MCJ#VZK(_/]6'K\B*9OR1LL<]0#J'EH=.=23XCZ
M,;<)C&UQFSGCU9,2K.6MP<:GS8FC%>+2CM3911>%;BF&+DY'V-1,E&VNRIA8
MY0MZK&:ICEHBI[6HJ. 'Z[$W6#':%CT C[)MK'(*T*(<3<=I:.MDIVK[P5ZF
MXGR+.GC:M>4280]U-%:9= :-V>"U>3)_G3\-1IRU((@"("E.R+5-8#&SDWY
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M8LMRAVV4 ZFYOY42 5XYCM=7E*A.R%J),)/5 (&@'!>@+27Z^R\:>/\R+ ?
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M&BV05> 7YANNV@! &. @W!S50?<%.6JR&B!@-.AZ9M2Q-G?Y/!2 '6SE65$
MF UPS+ZB3KSVQ+E6)\QD&>"P\F*%>ZOE6F8V3YK$ZM&.\?8/[.!L^:+(\L2D
ML_Q=BX?4F'2:'TZ4M,!S!O;WQS0U+R?N]8WR=9W1'U!+ P04    " "1BU=4
M\KU(4\H"  #J!@  &0   'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6S-5=]O
MVC 0_E=.41]:B34D_-A6 1(%JG8"5,'H'J8]F.0@5AV;V@X4:7_\SDF:40E8
M'_<2^^S[SM]]%Y\[.Z6?38)HX345TG2]Q-K-C>^;*,&4F6NU04D[*Z539LG4
M:]]L-+(X!Z7"#^OUMI\R+KU>)U][U+V.RJS@$A\UF"Q-F=[?HE"[KA=X;PLS
MODZL6_![G0U;XQSM8O.HR?*K*#%/41JN)&A<=;U^<#-H.__<X8GCSAS,P66R
M5.K9&0]QUZL[0B@PLBX"HV&+ Q3"!2(:+V5,KSK2 0_G;]'O\MPIER4S.%#B
M!X]MTO6^>!#CBF7"SM3N'LM\6BY>I(3)O[ K?>L>1)FQ*BW!Q"#ELAC9:ZG#
M 2!HG@"$)2#\**!1 AIYH@6S/*TALZS7T6H'VGE3-#?)M<G1E V7KHISJVF7
M$\[V[OH/,WCJCQ<CF(SZ\\5L-!E-O\_A$_2-06N R1C&G"VYX):C@0DRDVF,
M@5FX8US#$Q,9@JL(S##*M.9R#;?,<%.#*=.:N3K!Y1 MX\)<4>3%? B7%U=P
M 5S"A M!]30=WU(ZCI0?E=1O"^KA">I#C*XA:-<@K =?C\ ''X W @</@_=P
MGT2LE PK)<,\7N.4DI48M7]J1VK]U<IY3974[\6#GV,Z !XLIN;7&7J-BEXC
MI]<\0>^>_F>Q!\%?,AZ3\%LTEFZCI2K19<@TMWO8H.8JADNE0: Q5\=$/7]*
M U(E;6+.$&Y6A)MG0Y&4R*2EOP7F3II"PC$-:Y9W@-\PI2[Q#;7!/1G4<*S
M^,#C#(E61:+U/Q:U7=%KG]6HR-F5L09H(H=>9=*5-Q)9C&Y"K=98S2-+5L1,
M<NR>%8>T\D-<V]_V@C"H=_SM8>&/.+4.G K^_D$G<J_ A.DUEX9^IQ7!ZM>?
M":^+SEH85FWRYK14EEI=/DWH,4+M'&A_I91],UR_JYZWWA]02P,$%     @
MD8M75*\P2?J0 P  L P  !D   !X;"]W;W)K<VAE971S+W-H965T-S$N>&UL
MS5?+;MLZ$/V5@=!%"Z31RX^DL WXH:(&8B.PF]S%11>,-):)2J0O2=LMT(\O
M22FRX\AJ@MY%-K9(S9DY\^!PU-MS\5VN$17\R#,F^\Y:J<TGUY7Q&G,B+_D&
MF7ZSXB(G2B]%ZLJ-0))84)ZY@>=UW)Q0Y@QZ=N]6#'I\JS+*\%: W.8Y$3]'
MF/%]W_&=QXT%3=?*;+B#WH:DN$1UM[D5>N566A*:(Y.4,Q"XZCM#_U/DMPW
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MX9CO6!,G[0E!KHMG77]&OYH%O>;_D"+SKOG7]^LPXD_K_+U>8?OTF$CS?57
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M('*"4&!F'0.CSQM.4 A'1#+^MIQ!MZ4#GH]/[ _>.WG9,H,3)7[QW);#X$<
M.>Y8+>Q*'1ZQ]7/K^#(EC'_#H<V- LAJ8U75@DE!Q67S9<>V#F> N'<!$+>
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M2_K7H'8)M+Y3RIX"U__=WRO]#U!+ P04    " "1BU=48Y%8'^L"  ";"
M&0   'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6S-5MMNXC 0_951U(=6:AON
MA0J0N%5%*@C!TGU8[8-)!K#JV*SM0/OW.TY"EEY@^[ K]05L9\[XS#F.)\V=
MTD]FC6CA.1+2M+RUM9M;WS?!&B-FKM4&)3U9*ATQ2U.]\LU&(PL34"3\4J%0
M\R/&I==N)FL3W6ZJV HN<:+!Q%'$]$L7A=JUO**W7YCRU=JZ!;_=W+ 5SM#.
M-Q--,S_/$O((I>%*@L9ER^L4;WL-%Y\$/'+<F8,QN$H62CVYR3!L>05'" 4&
MUF5@]+?%'@KA$A&-7UE.+]_2 0_'^^QW2>U4RX(9["GQG8=VW?+J'H2X9+&P
M4[6[QZR>JLL7*&&27]AEL04/@MA8%65@8A!QF?ZSYTR' T"Q<@10R@"ESP+*
M&:"<%)HR2\KJ,\O:3:UVH%TT97.#1)L$3=5PZ5R<64U/.>%L^ZXSG,)CYV$^
M@-&@,YM/!Z/!^-L,KH!4(@TD#)Z#-9,KA)Z25I/L!H8R$'&((7#I5HT2/&26
MYETFF P09HZ/@?,^6L:%N3A(%\1:HPQ> /=Y@SSO%8R5A3X:"DSR,0/W&*ZX
M7-&>QNJ8SH^EL/FL#^=G%W#F&(RX$'0B3-.W)(@KRP^RXKMI\:4CQ?<QN(9R
M\1)*A5+Q WCO\_#":[A/-N1>E'(O2DF^\C$O&-?PR$2,E] QQBG(9 @/G"VX
MX):C@1$R$VM2AMZ *3HMG38N:JRDSA>ZS' #/QYH QA:C,S/$_3*.;UR0J]R
MA-Z8[I2EH[AU%#]2.\57$[R[/K9M4G5[*.C[B'H>\8I4)2=5.4FJ$P0Z=B>%
M)%!VC3H[8!;$']E.%%_-]ZE^16]J.;W:OY8AM2Q-6SLPI/#&LO<1Q>+'GMWD
M9&].DIUHW# >T@U O<B@^8 U2R0^(4P]WZO^%7UKY/0:_T.*U+O&7U^W]Q'E
M-];Y!ZW#M>T1TW3=&A"X)$SA^H; .FV%Z<2J3=)-%LI2;TJ&:_IZ0.T"Z/E2
M*;N?N :5?X^T?P-02P,$%     @ D8M75-O.N/'O @  R08  !D   !X;"]W
M;W)K<VAE971S+W-H965T-S8N>&ULC57?;]HP$/Y73M$>6JEM($#;58#$KZY(
MT%4PNH=I#R8YB%7'9K8#[7^_LP,9;0'M);8O=Y^_^^YR:6Z4?C$IHH773$C3
M"E)K5W=A:.(4,V:NU HEO5DHG3%+1[T,S4HC2WQ0)L*H4KD.,\9ET&YZVY-N
M-U5N!9?XI,'D6<;T6Q>%VK2":K S3/@RM<X0MILKML0IVMGJ2=,I+%$2GJ$T
M7$G0N&@%G>I=K^'\O<,SQXW9VX/+9*[4BSL,DU90<8108&P= J-EC3T4P@$1
MC3];S*"\T@7N[W?H]SYWRF7.#/:4^,D3F[:"VP 27+!<V(G:/. V'T\P5L+X
M)VRVOI4 XMQ8E6V#B4'&9;&RUZT.>P'5ZR,!T38@^AA0/Q)0VP;4?*(%,Y]6
MGUG6;FJU >V\"<UMO#8^FK+ATE5Q:C6]Y11GV_>=X02>.Z/9 ,:#SG0V&8P'
MCS^F< FD$FD@8? :ITPN$7I*6DVR&QC*6.0))D!U(*M1@B?,TGEJ::$:DX]:
MP/<5:N:*98#)Y)1GCYD4[JFC#)SUT3(NS/D>A3C7&F7\!KCC$I=<+N%16>BC
M(4>/S P\8++D<DD\C=6YNX7<9M,^G'TYAR_ )8RY$(Y8,[0DHI,BC+>"=0O!
MHB."52,8T^6I@8$D"=X#A*1^68)H5X)N=!*QC_$5U*H7$%6BZ@%"O?\/KYR@
M4RL[HN;Q:L<Z@G$-STSD> $=8] 6U1MQ-N>"6XX&QLA,KHOZ3]!5QZGMO!Z5
MU*6ARPPW\&M$%\"0JFU^GZ!7+^G5/;WZ$7K?:#+!F5"&.D2C\"6W"HJ^,*ZV
M"Y? VB5PJ+H%>L.CNQ&W;G]MANM]N3][7-Z6+N\X-TK.C9.<1\1VGRR):D71
M_8<H-CX3J-Y\('G )_I ,MR;"AGJI1^6ACZ=7-JB.TMK.8\[?@Q]L'=I3A=C
M]1],,>3'3-.'9D#@@B K5S=$2!>#LSA8M?*S9ZXL33*_3>E?@]HYT/N%4G9W
M<!>4?Z_V7U!+ P04    " "1BU=4EW%"_-$$  !;$P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970W-RYX;6S56%%OVS80_BL'KQA:((E$.G:<SC%@.RD6("X"
M9VD?BCW0$FUSI4B/I.P&V(\?22F2+4M*'[JNS4-,RL>[[^X[\:,YW$GU6:\I
M-? EX4)?==;&;-X&@8[6-"'Z3&ZHL-\LI4J(L5.U"O1&41+[10D/<!CV@X0P
MT1D-_;-[-1K*U' FZ+T"G28)44\3RN7NJH,ZSP_F;+4V[D$P&F[(BCY0\[BY
M5W86%%YBEE"AF12@Z/*J,T9OI[CG%GB+#XSN]-X87"H+*3^[R6U\U0D=(LII
M9)P+8C^V=$HY=YXLCK]SIYTBIENX/W[V_LXG;Y-9$$VGDG]DL5E?=08=B.F2
MI-S,Y>YWFB?D 4:2:_\?=KEMV($HU48F^6*+(&$B^R1?\D+L+;")UB_ ^0)<
M78 :%G3S!5V?:(;,IW5-#!D-E=R!<M;6FQOXVOC5-ALF'(T/1MEOF5UG1N_&
MMW/X,+Y[O('9S?CA<7XSNWG_QP.<PEAK:C00$<,=(PO&F6%4PXP2G2H: S'P
MCC %'PA/*3A&8$ZC5"DF5C AFFEXU&[\P%:"+5E$A(%'(1>:JBU9< JW8I/:
M"*_OZ);R[AMX?4T-85R_@5? !,P8YY9I/0R,3=3!#:(\J4F6%&Y("F&826'6
M&FY$3.-#!X&M4%$F_%RF"6[U>$VC,^BB$\ A1H\/U_#ZU1M%#*W!-OUZ3V'N
MJ05@M^"QZ]UVFW@LJ#BII\L25*'GI(8-9R-%9%<3]Y:=P)3P*.5^ I_FDG.P
M;\^.J/C/%M#G!>AS#_J\ ?2$KI@0#M""<"*BNG).,A<][\)M2MM1%P^&P7:_
MY#4VJ%_8'&#K%=AZK=C&T=\IT\PE?JJHK8"MH2V-L6BI;60[U"RF*JL,B?^R
MKZK=W4QMMV:1^GOP$*ID<&QR/JA/H%\DT&]-X)X\>4 0@-V,#:>-\/I'L4\O
M+ROX:FRZ#16^* !>M *TC60W60&N*:F(GL H(C2O5M1N!1%/[6OL]@1IUE39
MXB=6L]9.3+84N-2U:5T<5[V2U+%%6)_2H$AIT)J2W6Y>Z.;!44A\7H5U;+/?
M\0? +@M@EZW IK[&!C92N?+6(;L\CEIM@F,3A' ],!26 A2V0GMO7[#H97BY
MEX/*A;@"L,ZH:2- >Q*)7M@*(D5]5]IC$]@.!&-/,K#-A&\)B13TJ64[1+B,
MA'^>71R5VH.ZWVVOS$,=--E%E>9C&]QM8+G4(M0N1K[V&:>-$ ]=EU*">C\1
MK:6 H'8%^::T]H\D^K1?I?78!O<::"U%!K6K3%YCKR2^BB?PT9_M:7PZWEKT
M*PK73$<RM09SFR/\ _Y ^NLOJ!_^UK73DIJ%HZ:MMJ50H,%7M\1+)^V#[G!6
M=LM4E:/VISL; &X-370K^:5@H';%*%^'DV;2Y8*SE1_:AHV?JZBR*C:<CR=Y
MX,M]V3T++\*#/U3/.RYE!;?+RHP)EJ2)Q5'3 =^,<%R*"$8_(N&XU!Z,_R?"
M\\ 5PAMD&9>J@]M59T:^? ^&2P'!YS\DPZ4,X?:?-/\AP[T:AE'US!KL75,D
M5*W\[8T&'R'[*5X\+6Z(QOY>I/)\@MY.LWN>TDUV[30CROZDU,#ITKH,SRXL
M,)7=Y&03(S?^,F0AC9&)'ZXIL=D[ _O]4DKS/'$!BONTT;]02P,$%     @
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M/-3NHNRZRH'B6=&X/'"EVZ#B,=:=*A'&0+_?<*Z>!Z87JGO?V6]02P,$%
M  @ D8M75 =T2XMI @  NP4  !D   !X;"]W;W)K<VAE971S+W-H965T.#,N
M>&ULC51M3]LP$/XK5L0'D!AY::$,I9%:TFE(*\L*;)JF?7"3:V/AV,%V6_CW
M.SMI5E"+^)+X+O<\=X\O=_%&JD== ACR7'&AAUYI3'WE^SHOH:+Z3-8@\,M"
MJHH:--72U[4"6CA0Q?TH""[\BC+A);'S92J)Y<IP)B!31*^JBJJ7,7"Y&7JA
MMW7,V+(TUN$G<4V7< ?FH<X46G['4K *A&92$ 6+H3<*K]*^C7<!/QEL],Z9
M6"5S*1^M<5,,O< 6!!QR8QDHOM9P#9Q;(BSCJ>7TNI06N'O>LG]QVE'+G&JX
MEOP7*TPY]"X]4L""KKB9R<U7:/6<6[Y<<NV>9-/$#BX\DJ^TD54+Q@HJ)IHW
M?6[O80<0'@)$+2!Z"^@? /1:0.^C@'X+<%?M-U+</:34T"16<D.4C48V>W"7
MZ= HGPG;]CNC\"M#G$FRV?=L,KO_?4JR;Z/;>S*Z3<GDQ\---IV@]8G<4J6H
M;0TY3L%0QO4)>A_N4G)\=$*."!-DRCC'%NK8-UB0I?7S-OFX21X=2!Y&9"J%
M*369B **UP0^*NGD1%LYX^A=QA3R,](+3TD41.&>@JX_#@_VP-,/P\//[ZCI
M=<WI.;[>H>8H'&]E7K YG I#J"C(Y&G%:IP[0_Z,YMHH')R_[Z3J=ZGZ+E7_
M8.FX-7)&W3#",VX5#?L:VK"<.Q:[4M9).!C$_GKWCO?$7 :O8])]/)==3"/!
MW_FM*U!+MQXTR>5*F.:7Z+S=!AJYP7OC'^-F:A;)?YIFK4VI6C*A"8<%4@9G
M ZQ(-:NB,8RLW?#,I<%1=,<2MRLH&X#?%U*:K6$3=/LZ^0=02P,$%     @
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M$KI\I*MP?$<85AQE<K8IKLG-U2B46F^36@\N&<<T6'/E7H]E"CT[!7#,^YO
M^F!@=YS%>LSU<TB!A(S/BTL@E(N^%4I-#(--# ,PALMDR2*9]^O2FX&UD%],
MVOFK%N-7+2X&]L1[_@ :8=PQ:MQY"QQY7M6O8;%J<F?"B==U5NU7EW$=1"=.
M8YNBN[EN/7G@5W)=Z2=K]#>Z$LE]&UVFBLN4Y:ADD,Y@(VKX\*J&C:SA0^E:
MU?#V,.O9<^N:T[;OUC67;;_3!6?/"!N&E>W=,H)M?:O5$9<M##5LY!##>O@V
M*<&VI%E39)O4:8C#%!81; 02PPKY;AG!#BF$A]PH'(8E;@\EP;:J'3D6R6Y
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M]<E%N#90[Y>,R<- '[G+C[C^?U!+ P04    " "1BU=4C(<.QS\'   F+0
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M-=O4]*7<Z8J1X^9%V($T1I;-XHBSC*MZ _O[4$KSLE(/,'\U^O@_4$L#!!0
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MAG;=O=_J0"3)NS#)=V*:4[?ALK!^:5D.H=[6A<\C7*D(+GPT\BHRN$; -<A
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M \G\TUI^HL4J^Q0T$UJ+.#M<<C;GTC2 ^PLA]/.)Z:#\P-G_%U!+ P04
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M?=T:M(!/EMXVD(]L]RO) O7B]A8L$,E?L,NTG198;(5D85:L'(0T2O][;]E
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MI;%+<(T$U>>!'0V9CN4FEC)(5Z-X)M0%MF"KB'XOK^ 9 CK66;%+L%%2S'$
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M6I&H[C0.?T>ETZ!&I[%6)*H[C8M5.@UJ=!IK1:*ZT[A8I=.@1J=Q5V2N?7&
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MEEX@?U]2*O8G:8#RY=#H?U!+ P04    " "1BU=4EH)_Q($#  "#$0  &@
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MZ2-X/EP"24"8#7I]P;EZFIAS>/G=9? O4$L#!!0    ( )&+5U3XTVK&>PL
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MQ^@E*6[2MW^)S15YU7P/:9+7_[*W3:QUP!Y>\B)=;@:7&2SCU?K_Z,=F)=
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MY_M U+$E#223!P8J-H$D_$"C8A-TY9AV,U2$]#3#0+)^0+/^>X <79*!)/;
M0*$FD+0?:!1J@JX*T^Z-BI"^X]J2^P.:^VDDI]U9!)+= P-EFP =:M<HVP3#
MQW+(D&:.DO\#FO_? ^3HD@PEQ8<&*C>AY/Y0HW(3#BLW9$@S1]D 0KH!_)EF
MR?PMG@LVKP!,G\5<R^UB*.D]-%"T"27MAQI%FU!Q5J?=(A4Q=A^,DOU#FOWW
MA7%\,4IR#PT4;$+)^J%&P294G,5I'_&@8YI92O(/:?*G<=1Q(QDB[Y.!.@Y8
MV/VDU?[4U6G:!$O'M/)$[B>+[@/O!W6\?\-"/BG+0)$'+.24LG1:I:SA\SMT
M3"M/Y)2RZ-8P E<=-YM@(3N59:#X Q8R5%DZ'566PE+5[J>JH+Z&"A:R55ET
MPYB([AZEB[Q7EH&R$%C(?67IM%]9BA,['0,6'=1RI*+F,>"='0WOM-M2:+AD
M#=2* #ML0:-:M)V,)&8RII4G:B #7MN)V(XO76RK!0/E(\!.7- H(&TGH\$=
M?=8'L"5WP).[7JYU:A-+$S4#,% S NS*!8VJT7:R1E_MPJ<(<OOP0RUBP*';
MPD^+WQQY;\$V4#,"Y-0%6Z-JM)V,K$,RII4G?MP"W0Q4.&K9[B([+M@&:D>
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M!G6%:0I&%0%FK#!24OM*2?"K$:S4[>Y')UOOW2Z):>]YU]6\_Y]#[S2_BX_
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M:.B5=KB!ZPR39@%\7PFAWR>F8=87I-$_4$L#!!0    ( )&+5U0F:%5U00,
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M]TE+N/AGE<G>.YZHVC),?@X;! 9W]VA!5;6\ZAA9N&*UE@9+GVON\/H#RB[
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M;"]W;W)K<VAE971S+W-H965T,3$V+GAM;)5576_:,!3]*U;4AU;:&O)!V"I
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MK32TA49=TR8VM('=M/%ZP-4F#M]OH;%-J ., \,N@9M=.DH+COPMV)X7Y<N
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MER.4BC4O<_NL]C^+XX*2*MY*Y:;^B_;-V+$;O"J-5<41[#(H,ME\\L.1B X
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M45]N!4^%K@:X[]=*V;>;:H+VWQCS?P!02P,$%     @ D8M75-<>CRQI P
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MW%0-UQU56"8UX;!%E\'U&$-251-3#8PLW&?]41IL$MSC'OL^4%: ZULIS<O
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M+GG"7TR2K/@7/%5EK3,0YQDCJ\J8MV"%T_(O_%J%HF%@]Q4&3F7@[!DXGL+
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MFY:8+9V$B-% OR. R$H V(!K/=:3%5%PC'F6O[G'O%;WJJ@W"NJ-2NJS%(A
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M!$!\8&<0 +&V_!G)@?V:0Y^0]/FGRM]XKGN=K,DEKXH4W!-T_YYV(>^HW2,
M4-02B9$@V*]!ZIWP*#7Y2_V22:W^T;3(%Z^21,4OL+3"@)3  ;&; @0;N/L<
M<A;1EA:.C3+!W*L]7\\N<NOL\L&C.;%1!]@O#[[DE=\QX!],EMO>B2,2 !!U
MF!GR%+9(!6RT O:+A4_QJAS/T2_HCWSQZ,N/Z<DX.HKJQZ8E8G]/].E^[#8P
M&@I;74(HAFUU"?H*6PJ/F%Y(_+WP(4Z3%]_QRK0E@H^2:K)U@O.W"U^JB4NP
M) AM&@!0>!#8- #Z(BUL30Q;$S];UWT[J].A:_7>FW5#G(0=)^N&O(C_7.7-
MNGOFP5C8*@-$1=C..H3BK"7KAB&)GR%O"S7/T5!6*<G3?):,2U]:#%>1\#B)
M-]Q%]ATH/(EWU3T7SFX'0"RRTPYY:F%R8EB1^%EQF#S)HDRFB:R'>1-]+O*E
MG1J^HL%QQCB&QZA?7GL'.:X0CAP^!T"#T!:$  @'48O2H(8BJ9\BS2RG290W
MZUNS+7J<K!L>HWX!Z,VZ*\N@^1F  @9H *IU@D8-25(_27:8H5&7YVC([/,Q
MA.*A7;P0*J(M@PQJ.).*'ZI7J6%-ZE=XW?0J=<<TQ+ZB5Q H<LH- -$6EJ.&
MH:F?H=UJ0_^A0T4L-61*!T>I/F98E?E5H*_ZF#O# $0LA')%+.BK3<0R0]G,
M3]E=)M@ .?/(#@8 !?:6 D 8XQ8&9X;!F?\^1=?:8X;$F5]_=JL]YI[R28#M
M1 $@;@_! !".6H9X;.NFQ:%W+;9J;]]IAAE"9_XC^W?7G"%9YA>FWIH#CM?N
M:09  :<9T%?;:889)F=^)N]2<R[Y8C:P.QZ$HO9L;P2BV* E&L/DS#\GZ%QU
MAKR97PEWK#KWE&_/&P&(4W$^+[LWUTR+X/X6 =9;AR,M-VS.CS-(X(9C^?</
M$C@P(G"/M"#*.=*"J+8C+3=$SOU$WJ'TN,N]++ K#P#1R+YE"X%XVZXR+,[]
MXXNN=<>W[@;[%7FWNN.ND+9OJ%U!&%L4 !C:0D[<= J^9X0!E5ZWN08WO,Z/
M,]?@AFOY]\\U^"%S#0CDS#5 3RV*GQLVYWON@'8H/8"$'=D,@8@3"@#"+0)*
M&$(7_DE*U](3AL"%7XYW*ST!Z&C[N0478M^0\'K9C<.T"=%UF*+KKN-D2QA6
M%\>9L0A#MN+[9RP"FHO8NQ4 N9,M -0^V1*&S\4/F[ (EX2%<T<0 (78GA8!
MH*AM6"2V'NGYL>,58<A;_,CQB@"TM)TE8&YBY\@'V8W#M CA;Q$7>:&+(%;2
MEQ5#VN(X\Y/0<&EXJ#C>NSE#=P3R+AS86@-""6R7&H@*6O1&:/@[] OPKOLS
M-(P:^AFUV_X,W4<TF),H%^,\A0/YL95 ?^NYYNK!^)NXF"59B5(YU4;!^U!;
M%^MGS=<?5+ZL'W5^S)7*%_7;N8PGLJ@ ^O_3/%>O'ZJGIS=/_)__#U!+ P04
M    " "1BU=4^MQ?7/T(  "^/@  &@   'AL+W=O<FMS:&5E=',O<VAE970Q
M,S,N>&ULO9M=;^,V%H;_"F%T@1:='?-#I*@B"3"QIVV 9A(DZ>Y%T0O%9F)A
M;"F5Y&0&V!^_DOQQ9/*(]F@ W<S$SDN*/"=\=%Z)/'O+\L_%PIB2?%DMT^)\
MM"C+EU_&XV*V,*NX>)^]F+3ZS5.6K^*R^I@_CXN7W,3SIM%J.>:4JO$J3M+1
MQ5GSW6U^<9:MRV62FMN<%.O5*LZ_7IIE]G8^8J/=%W?)\Z*LOQA?G+W$S^;>
ME'^^W.;5I_&^EWFR,FF19"G)S=/YZ /[9<J8J%LTDO\DYJUH_4SJN3QFV>?Z
MP]7\?$3K(9FEF95U'W'UWZN9F.6R[JH:R#_;7D?[B]8-VS_O>O^UF7TUF\>X
M,)-L^=]D7B[.1WI$YN8I7B_+N^SM=[.=D:S[FV7+HOF7O&VTH1R1V;HHL]6V
M<36"59)N_H^_;"/1:L!U1P.^;<!/;2"V#<2I#8)M@Z")S&8J31RF<1E?G.79
M&\EK==5;_4,3S*9U-?TDK1-_7^;5;Y.J77EQ__&WZX^?'LC5IU]O[JX_/%S=
M?"+_)G?FU:1K4Y#'K^0VS^;K64DF<6F>L_PK^7%JRCA9%C^1'TB2DNMDN:PR
M6)R-RVH\=:_CV?;:EYMK\XYK,TZNL[1<%.1C.C?SPP[&U43VL^&[V5QR;X]3
M,WM/!'M'..7LS_LI^?&'GUXVXT>&-SF],WJTL^G)G;'(U]G!O,4^BZ+I773T
MOLT7><JS%?GXI31Y&B_)I/GS,3GYZX]*3ZY*LRK^]EPMV%\M:*X6=%SMTWKU
M6/6:/9'M#(H* 15V"I.69EY_7V9E=?U\.ZK_D>ZP76XNI9I+U91ZO6#T;/S:
M3M-QR=0K.9BDW$]2>B>Y6P+8F#<M9>MJ.A"!-6I$1'EHC1L1*<KPD:O]R)5W
MY+>+N +BS*S+9!8O"T_"PWV/X0!_7GI_-=T[\MK)LPB5L"*/B)2V_V)<44##
M"(]\M!]YY!WYU+PF,WO@!STQ"ERF \2<M>X#K'?4MTT/EE=$[;!C*JF4%7=,
M%;(0#SSC,'SN'?[-P\07!@ I&X*D#%#*_"SUAAVAFA3<#CNB"H3]YXZJ@JZP
M R29GY*7>5S?NDGU+[DI%U6$?C.IR9.9=Q$ R9@:(AO .1;VST;H1K *H9T-
M1,4#;6<#5:F.;  XF9^<FPSDZ"0.NP2BL6B #'# 'J>],[!MVHY:9*\&1,-L
M4DTQ$>-X]#D0E/L)>AFO*U]&?B9_9*M'7S  :IP/$7R 'Q?]@R^P6Z^TPX^H
M B;M^&-]A;HC <!2[F?I00*JJO/T0H@#\+@<(B5 0.XOYKPI44X8);.!A(FH
M?5-&1(J+CGP 3;F?IG8^CI=''%#']1!Y  YR?VGGS4.$W*<C92<"40GFH GK
MBP=X*@1@5?BQ:J?"7RX)8)Y@ Z1! !&%O\SSI6';]## VKKU3E 58U8:4!7O
MN$6(EDWW ]9.0Z_R20 013!$=@".HK]GWC9M1Y0'MM/'1#*P<X.(5(?;%P!:
MX0>MLT).K:4$\% ,8:,%,%+T-]+"];_VPXD)HA'.0D%\=(>+%@!;X8?M?;Q,
MOO@>5 'W@B%<=  \#/J[Z,!UOIR&]OT:455>VUX#:%]=? H KX$?KTW@OZER
M"H!]P2#/*%L/*?L[Z\!UPYS:CRHFB(KI*+)3@?75F0I@:>!GZ2X5QXNF !@7
M#&&G P!>T-].!ZX%=I[['I5,O9+#40,V S\V=Y'WUT@!T"P8PD)+8)[L;Z&E
MZWSMJ!^73+V2PU$#.:6?G+NH]RJ))!!.#F&I)5!/]K?4TK7!3C*.2J9>R>&H
M@9W2S\[]$CBU")*MURI#&&@)S)/]#;1T;:]M%Q")_30#D70E ,@I_>2\2IO
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M9=23:0BB+L]T3AE+(ZD\_B^"6F6?J6/U_BWZ;5:\*F9+$CKG[+_0E\'4&EG
MISMR9'+-3__0HJ!^&L_C+,E^P:FP=2S@'1/)H\)991"%<7XE+P6(B@-T6QQ0
MX8 N=<"% \X*S3/+RKHADLPF@I^ 2*U5M/0F8Y-YJVK"./T;-U*HMZ'RD[/-
MC[OECX>?8/%P^[A>7O]</#Z K^".\KT@AR#T" .+.!\MBOH7<,_C_==[1=X'
MUTE"90*N;J@D(4L^*[^GS0VX^O09? )A#)8A8\HGF=A2)9IV9WM%4M_SI%!+
M4C?4ZP$,OP#D(-C@/K_<W?G3W59X2D:H9(2R>+@EWIH^T_A($T!B'[ 4 ,L
MD!S ]A7L2UYJ:.]5T89><=DKSGIU6WJ]KW?4Q#$/T<]"I%_L\PSVQZ.)_5RE
MU60T&)9&?V3GEMFYQNR>>IM>QF-UI$)RL X];BBZ7X;M=XAZ4/8Z>#_J/,2@
M0G'HXAKI!AO4;P8]+',;&G-;",H4#$.5HS+2J$.VX[+7\?O9CL^X83RHL6VP
M0:-FMM#1ZN<8LYN3F/C$4":L""GL$"_4X@31^P$7,:KT(*J/WB8CZ+0@UC(&
MS3JVXG\9OU!K#G2[1*Q%"?8_ ''__./OUPF?VXQP"V M7M"L7G=4S<[QJZE2
M+39PV"5A+4UP] &$1^?TAG7"#39M0UA+&#1KV)*^F*<WI 4'.1T"1EJ=$'P_
MX")&%9Y;'\)--N-FP*BRP#)KV*T@L4=-A6JY0;A+P%J;D'E!=!E@]WP2&]<!
M-]BX+8"U@B&S@LV#,#9-<TBK#1ITR5<K$S*O@R[C.SQGY]3Y-MC %KY:OY!9
MOS94;$,C8"TV:-SE;D,K$S8OA2[;;SAG\%!=(1IL<(L$8ZU?V*Q?"TF8:8K#
M6FMPI[NYRG;N(_9S^)POK/-ML&E91& M7]@L7X\RH,)4IY8:W.46#FMAPA^P
MB2MB5/?"0[?.UVB39V=73ES2XZXE$?LP3@"C.^7D](;*6^0G2'E#\D-V"+/E
M4O(HNPTH\:E(#=3['>?RK9&>ZY3G>+/?4$L#!!0    ( )&+5U3AS6Y1VP(
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M9ZB]K<,:<[3V":=;+C(<M>:HR6\/D!14>5I5WFB9%N<W,ZFU3(K+); (E%F
M[^<2(U?=F".A^LQP]#]02P,$%     @ D8M75(/>O14L P  "A(   T   !X
M;"]S='EL97,N>&ULW5C=:MLP%'X5HX[1PJB3N'7C-0EL@<)@&X7V8G=%B>5$
M($N>K'1)+_<\>ZH]R70LQ?FI3NEZL65S2"V=3^<[G\XYKDP&M5D)=C-GS$3+
M4LAZ2.;&5&_CN)[.64GK4U4Q:9%"Z9(:.]6SN*XTHWD-3J6(>YU.&I>42S(:
MR$5Y59HZFJJ%-$-RUIHB=_N0#TDW/2.1HQNKG W)W?'KKPME+E]%[G[TYNBH
M<W=RN6\_;H 3$@=)SY]!>MK!>2V&4:>[U'ZY95I[8HX784T_O_] MKI!MC8;
M^ZR.!H62F^0FQ!EL9%JRZ)Z*(1E3P2>:@U=!2RY6SMP#PU0)I2-CJVJE=,%2
M/SBXZV90<,]3<JET$]M%<'\G?OD>L)Z!0"Y$*[!'G&$TJ*@Q3,LK.VD6-\9'
M4.3'MZO**IQINNKVSLG&H;G9(!.E<Z;;,%VR-HT&@A4@1_/9'.Y&53& QJC2
M#G).9TK21L/:PP\L[90)<0-/PY=BAWM9;-6T Q65[= *\D-'XR; O\WFN+=I
M7\8;5?Q>F?<+NQW9S*%3V+5F!5\V\V71"L#8NS@[K2JQ>B?X3);,;?[9 4<#
MNO:+YDKS!QL-6F5J#4R3Z)YIPZ?;EF^:5K=L:=;MM"QPS;U_4/.?S?.,2::I
MV!9M>_^0L_QBQ?[X^!N:FW\K^XJ#(I.+P]?HC\Q#%YD>OL@D.WR-_F7DX$3&
M_FC<.G]W3M_6&L%;SI!\AO<IL0D:319<&"[];,[SG,E'A["E-W1B7W1W^.WZ
MG!5T(<QM"P[)9OR)Y7Q19NVJ:TB$7[49?X3M==/V%<O&XC)G2Y:/_53/)LTP
ML@,;U5_@L(]<-5<8P7P<%D8 P^)@"C ?YX7%^9_VTT?WXS!,6S^(]%&?/NKC
MO$+(N/E@<<(^F;W".\VR)$E3+*/C<5#!&,M;FL(WS(9I P\L#D3ZO5SCU<8[
MY.D^P&KZ5(=@.\4[$=LIGFM PGD#CRP+5QN+ QY8%;#>@?CA.-!389\D@:IB
MVK G&$>R#$.@%\,]FJ9(=E+XA.N#/25)DF5A!+"P@B3!$'@:<013 !HP)$F:
M<W#O/(K7YU2\^?5G] M02P,$%     @ D8M75)>*NQS     $P(   L   !?
M<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^O
MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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MMA]D064,@$D.:X#6IEP;P&M3L T@MBG9!C#;%&T#J&W*M@'<-H7; '*;TFT
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M^0E02P$"% ,4    " "1BU=4!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( )&+5U3@L+^'[0   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( )&+5U297)PC$ 8  )PG   3              "  <L!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ D8M75.MP<>*2!@  H!H  !@
M         ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( )&+5U0Q+$\V- (  'D%   8              " @=0.  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "1BU=48LFKH4P&  "W&
M&               @($^$0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ D8M75/ X .T\ @  3P4  !@              ("!P!<  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( )&+5U2:%<&PU08
M ",>   8              " @3(:  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    " "1BU=4RC%S16@$  "+#P  &               @($]
M(0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ D8M75*"Q
MFE%@!P  _R4  !@              ("!VR4  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( )&+5U3>3T3DT@D  +0N   8
M  " @7$M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " "1
MBU=4-<42=?H#  #H"   &               @(%Y-P  >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ D8M75'.F5K2/*@  @84  !D
M         ("!J3L  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    " "1BU=4#F]-+S -   ((@  &0              @(%O9@  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( )&+5U3Z_O[O;04  -4.
M   9              " @=9S  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ D8M75 'C)S],#   "24  !D              ("!>GD
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "1BU=44>3Y
MTV$"   &!0  &0              @(']A0  >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( )&+5U0=%;=[ P,  'H&   9
M  " @96(  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
MD8M75,Y/68=F'   E&T  !D              ("!SXL  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    " "1BU=4#@$3#L\"  #L!0  &0
M            @(%LJ   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( )&+5U0;=KJ!6!P  "V&   9              " @7*K  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ D8M75#:]<Y-:$P
M"#\  !D              ("! <@  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    " "1BU=4L8YI.$@$  !Z"@  &0              @(&2
MVP  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( )&+5U1-
M^7V1T!   #<X   9              " @1'@  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ D8M75+HV=R$D P  "0<  !D
M     ("!&/$  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )&+5U3/KSGP>@(  &D%   9              "
M@2H6 0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ D8M7
M5#&*"RH8)P  88<  !D              ("!VQ@! 'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    " "1BU=4#I]3\2<(  !D%@  &0
M        @($J0 $ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( )&+5U2"% U+00T  $4C   9              " @8A( 0!X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ D8M75+4$/OJ-!@  _Q$
M !D              ("! %8! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    " "1BU=4G#U9LO@W  #GP@  &0              @('$7 $
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( )&+5U2,C/?S
MG04  ) -   9              " @?.4 0!X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ D8M75!VQIK@B!   '@H  !D
M ("!QYH! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " "1
MBU=4C'IT%4(&  !L%@  &0              @($@GP$ >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( )&+5U23#@7B? (  "$%   9
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M970T,"YX;6Q02P$"% ,4    " "1BU=4PXGHU]()  !>(P  &0
M    @('MN0$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M )&+5U0^4S/-; 0  .L+   9              " @?;# 0!X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ D8M75!9QH3""!0  Q!   !D
M             ("!F<@! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    " "1BU=4'>1P;98"  "*!0  &0              @(%2S@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( )&+5U0-78A!?@(
M &H%   9              " @1_1 0!X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L! A0#%     @ D8M75%)<G?3: @  W@4  !D              ("!
MU-,! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " "1BU=4
M)(KKH9<'  !F%0  &0              @('EU@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+ 0(4 Q0    ( )&+5U3DTR$SM0(   $&   9
M      " @;/> 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%
M  @ D8M75)A0#FR) @  6P4  !D              ("!G^$! 'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " "1BU=4SP0&2GP(  #S%@
M&0              @(%?Y $ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+
M 0(4 Q0    ( )&+5U1/G$SI&P(  !8$   9              " @1+M 0!X
M;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ D8M75"UB1RHD
M @  '@0  !D              ("!9.\! 'AL+W=O<FMS:&5E=',O<VAE970U
M,BYX;6Q02P$"% ,4    " "1BU=4N.+UP]T#  !Q"P  &0
M@(&_\0$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( )&+
M5U2B8Y,EK@,  ,X+   9              " @=/U 0!X;"]W;W)K<VAE971S
M+W-H965T-30N>&UL4$L! A0#%     @ D8M75&!*[55A P  +Q   !D
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M=#4Y+GAM;%!+ 0(4 Q0    ( )&+5U3@/04D9@(  +L%   9
M  " @78. @!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @
MD8M75+<O[>)5 @  ) 4  !D              ("!$Q$" 'AL+W=O<FMS:&5E
M=',O<VAE970V,2YX;6Q02P$"% ,4    " "1BU=4VE)Z'G0"  !M!0  &0
M            @(&?$P( >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4
M Q0    ( )&+5U0]MWT)1 (  *\$   9              " @4H6 @!X;"]W
M;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ D8M75*=]CW@? P
M,0L  !D              ("!Q1@" 'AL+W=O<FMS:&5E=',O<VAE970V-"YX
M;6Q02P$"% ,4    " "1BU=4$%%B'60%   '%@  &0              @($;
M' ( >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( )&+5U1U
M%-X>UP,  #L,   9              " @;8A @!X;"]W;W)K<VAE971S+W-H
M965T-C8N>&UL4$L! A0#%     @ D8M75);"UR.6 P  8@P  !D
M     ("!Q"4" 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )&+5U0L?E_IY (  (P(   9              "
M@>XY @!X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ D8M7
M5&0$[X1L P  ] H  !D              ("!"3T" 'AL+W=O<FMS:&5E=',O
M<VAE970W,RYX;6Q02P$"% ,4    " "1BU=4.IV*JF,"  #)!   &0
M        @(&L0 ( >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0
M   ( )&+5U1CD5@?ZP(  )L(   9              " @49# @!X;"]W;W)K
M<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ D8M75-O.N/'O @  R08
M !D              ("!:$8" 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q0
M2P$"% ,4    " "1BU=4EW%"_-$$  !;$P  &0              @(&.20(
M>&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( )&+5U0-U$U=
MI@(  +T(   9              " @99. @!X;"]W;W)K<VAE971S+W-H965T
M-S@N>&UL4$L! A0#%     @ D8M75)X;=C-5 P  \PH  !D
M ("!<U$" 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4    " "1
MBU=4G.(8H%P"   O!0  &0              @('_5 ( >&PO=V]R:W-H965T
M<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    ( )&+5U11*WKL;P(  $$&   9
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M970X-2YX;6Q02P$"% ,4    " "1BU=4L% OUHT"   9!P  &0
M    @(%%;@( >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    (
M )&+5U1_Y/[XO@4  %0@   9              " @0EQ @!X;"]W;W)K<VAE
M971S+W-H965T.#<N>&UL4$L! A0#%     @ D8M75#(X_](/ P  X @  !D
M             ("!_G8" 'AL+W=O<FMS:&5E=',O<VAE970X."YX;6Q02P$"
M% ,4    " "1BU=4&C<.(/H(  ![00  &0              @(%$>@( >&PO
M=V]R:W-H965T<R]S:&5E=#@Y+GAM;%!+ 0(4 Q0    ( )&+5U3&=G6F6P(
M  \%   9              " @76# @!X;"]W;W)K<VAE971S+W-H965T.3 N
M>&UL4$L! A0#%     @ D8M75.Y]D[7? P  T T  !D              ("!
M!X8" 'AL+W=O<FMS:&5E=',O<VAE970Y,2YX;6Q02P$"% ,4    " "1BU=4
MC(<.QS\'   F+0  &0              @($=B@( >&PO=V]R:W-H965T<R]S
M:&5E=#DR+GAM;%!+ 0(4 Q0    ( )&+5U2;)FU +0<  &DJ   9
M      " @9.1 @!X;"]W;W)K<VAE971S+W-H965T.3,N>&UL4$L! A0#%
M  @ D8M75+NS'8+O"P  REH  !D              ("!]Y@" 'AL+W=O<FMS
M:&5E=',O<VAE970Y-"YX;6Q02P$"% ,4    " "1BU=4?:B6M]$#   :#P
M&0              @($=I0( >&PO=V]R:W-H965T<R]S:&5E=#DU+GAM;%!+
M 0(4 Q0    ( )&+5U0-M& O\P(  '$(   9              " @26I @!X
M;"]W;W)K<VAE971S+W-H965T.38N>&UL4$L! A0#%     @ D8M75++^]EB0
M!0  [!P  !D              ("!3ZP" 'AL+W=O<FMS:&5E=',O<VAE970Y
M-RYX;6Q02P$"% ,4    " "1BU=4PK5Y##(#  #)"@  &0
M@($6L@( >&PO=V]R:W-H965T<R]S:&5E=#DX+GAM;%!+ 0(4 Q0    ( )&+
M5U1%K<6O] 0  )T9   9              " @7^U @!X;"]W;W)K<VAE971S
M+W-H965T.3DN>&UL4$L! A0#%     @ D8M75*8U.7@/"    S   !H
M         ("!JKH" 'AL+W=O<FMS:&5E=',O<VAE970Q,# N>&UL4$L! A0#
M%     @ D8M75/MW6939 @  .0D  !H              ("!\<(" 'AL+W=O
M<FMS:&5E=',O<VAE970Q,#$N>&UL4$L! A0#%     @ D8M75*"^().  P
M]@T  !H              ("! L8" 'AL+W=O<FMS:&5E=',O<VAE970Q,#(N
M>&UL4$L! A0#%     @ D8M75'^0UO.V!   *!H  !H              ("!
MNLD" 'AL+W=O<FMS:&5E=',O<VAE970Q,#,N>&UL4$L! A0#%     @ D8M7
M5):"?\2! P  @Q$  !H              ("!J,X" 'AL+W=O<FMS:&5E=',O
M<VAE970Q,#0N>&UL4$L! A0#%     @ D8M75/C3:L9["P  #W,  !H
M         ("!8=(" 'AL+W=O<FMS:&5E=',O<VAE970Q,#4N>&UL4$L! A0#
M%     @ D8M75 O00_80 P  LPH  !H              ("!%-X" 'AL+W=O
M<FMS:&5E=',O<VAE970Q,#8N>&UL4$L! A0#%     @ D8M75*SRL=%W @
M^P8  !H              ("!7.$" 'AL+W=O<FMS:&5E=',O<VAE970Q,#<N
M>&UL4$L! A0#%     @ D8M75)\SDTAE @  6@8  !H              ("!
M"^0" 'AL+W=O<FMS:&5E=',O<VAE970Q,#@N>&UL4$L! A0#%     @ D8M7
M5,($ +D? P  + D  !H              ("!J.8" 'AL+W=O<FMS:&5E=',O
M<VAE970Q,#DN>&UL4$L! A0#%     @ D8M75)&Y4G_B @  + D  !H
M         ("!_^D" 'AL+W=O<FMS:&5E=',O<VAE970Q,3 N>&UL4$L! A0#
M%     @ D8M75"9H575! P  7 D  !H              ("!&>T" 'AL+W=O
M<FMS:&5E=',O<VAE970Q,3$N>&UL4$L! A0#%     @ D8M75&M4&&Q& P
MF P  !H              ("!DO " 'AL+W=O<FMS:&5E=',O<VAE970Q,3(N
M>&UL4$L! A0#%     @ D8M75/"&@3I%!P  32,  !H              ("!
M$/0" 'AL+W=O<FMS:&5E=',O<VAE970Q,3,N>&UL4$L! A0#%     @ D8M7
M5'SR"AOG!@  UR(  !H              ("!C?L" 'AL+W=O<FMS:&5E=',O
M<VAE970Q,30N>&UL4$L! A0#%     @ D8M75)J7L:HA P  " L  !H
M         ("!K (# 'AL+W=O<FMS:&5E=',O<VAE970Q,34N>&UL4$L! A0#
M%     @ D8M75!0U-VBT @  :@<  !H              ("!!08# 'AL+W=O
M<FMS:&5E=',O<VAE970Q,38N>&UL4$L! A0#%     @ D8M75 =(LVE/ P
MQ@D  !H              ("!\0@# 'AL+W=O<FMS:&5E=',O<VAE970Q,3<N
M>&UL4$L! A0#%     @ D8M75 XA>-\T P  2 D  !H              ("!
M> P# 'AL+W=O<FMS:&5E=',O<VAE970Q,3@N>&UL4$L! A0#%     @ D8M7
M5+MHFI.7 P  ( T  !H              ("!Y \# 'AL+W=O<FMS:&5E=',O
M<VAE970Q,3DN>&UL4$L! A0#%     @ D8M75'6=&<"P!   QA   !H
M         ("!LQ,# 'AL+W=O<FMS:&5E=',O<VAE970Q,C N>&UL4$L! A0#
M%     @ D8M75 >IL3YS!   *Q   !H              ("!FQ@# 'AL+W=O
M<FMS:&5E=',O<VAE970Q,C$N>&UL4$L! A0#%     @ D8M75 -Z8.)Y P
MK0L  !H              ("!1AT# 'AL+W=O<FMS:&5E=',O<VAE970Q,C(N
M>&UL4$L! A0#%     @ D8M75*('*FGL!@  CA\  !H              ("!
M]R # 'AL+W=O<FMS:&5E=',O<VAE970Q,C,N>&UL4$L! A0#%     @ D8M7
M5/^&XR\Z!   TA@  !H              ("!&R@# 'AL+W=O<FMS:&5E=',O
M<VAE970Q,C0N>&UL4$L! A0#%     @ D8M75-<>CRQI P  50H  !H
M         ("!C2P# 'AL+W=O<FMS:&5E=',O<VAE970Q,C4N>&UL4$L! A0#
M%     @ D8M75'>7Z3,W P  ]PD  !H              ("!+C # 'AL+W=O
M<FMS:&5E=',O<VAE970Q,C8N>&UL4$L! A0#%     @ D8M75, [''LD P
M8@H  !H              ("!G3,# 'AL+W=O<FMS:&5E=',O<VAE970Q,C<N
M>&UL4$L! A0#%     @ D8M75-4/*RV4 @  AP8  !H              ("!
M^38# 'AL+W=O<FMS:&5E=',O<VAE970Q,C@N>&UL4$L! A0#%     @ D8M7
M5-!W]5GF"@  34   !H              ("!Q3D# 'AL+W=O<FMS:&5E=',O
M<VAE970Q,CDN>&UL4$L! A0#%     @ D8M75 NJ+QHK P  S L  !H
M         ("!XT0# 'AL+W=O<FMS:&5E=',O<VAE970Q,S N>&UL4$L! A0#
M%     @ D8M75*+4&Y(E @  M00  !H              ("!1D@# 'AL+W=O
M<FMS:&5E=',O<VAE970Q,S$N>&UL4$L! A0#%     @ D8M75&JQ19%O"
M_2\  !H              ("!HTH# 'AL+W=O<FMS:&5E=',O<VAE970Q,S(N
M>&UL4$L! A0#%     @ D8M75/K<7US]"   OCX  !H              ("!
M2E,# 'AL+W=O<FMS:&5E=',O<VAE970Q,S,N>&UL4$L! A0#%     @ D8M7
M5,'N?K;A!   O!H  !H              ("!?UP# 'AL+W=O<FMS:&5E=',O
M<VAE970Q,S0N>&UL4$L! A0#%     @ D8M75(3>TKS? P  TQ,  !H
M         ("!F&$# 'AL+W=O<FMS:&5E=',O<VAE970Q,S4N>&UL4$L! A0#
M%     @ D8M75.'-;E'; @  [ D  !H              ("!KV4# 'AL+W=O
M<FMS:&5E=',O<VAE970Q,S8N>&UL4$L! A0#%     @ D8M75*S9F<:4!
M/Q0  !H              ("!PF@# 'AL+W=O<FMS:&5E=',O<VAE970Q,S<N
M>&UL4$L! A0#%     @ D8M75(/>O14L P  "A(   T              ( !
MCFT# 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "1BU=4EXJ[',     3 @
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8;6Q02P4&     )$ D0 4*   $X(#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>917</ContextCount>
  <ElementCount>731</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>254</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>23</UnitCount>
  <MyReports>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000020002 - Document - AUDIT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/AUDITINFORMATION</Role>
      <ShortName>AUDIT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100010003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100020004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100030005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100040006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100050007 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100060008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>210011001 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>210031002 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>210191003 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE</Role>
      <ShortName>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>210241004 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS</Role>
      <ShortName>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>210261005 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>210401006 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIES</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>210431007 - Disclosure - PROPERTY, PLANT AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>210471008 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>210531009 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>210561010 - Disclosure - FINANCING ARRANGEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS</Role>
      <ShortName>FINANCING ARRANGEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>210661011 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>210771012 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>210841013 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>210901014 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>210931015 - Disclosure - RESEARCH AND DEVELOPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT</Role>
      <ShortName>RESEARCH AND DEVELOPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>210961016 - Disclosure - OTHER EXPENSE, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSENET</Role>
      <ShortName>OTHER EXPENSE, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>211001017 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>211091018 - Disclosure - LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LOSSPERSHARE</Role>
      <ShortName>LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>211131019 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES</Role>
      <ShortName>SUPPLEMENTAL CASH FLOW DISCLOSURES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>211161020 - Disclosure - LEGAL PROCEEDINGS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGS</Role>
      <ShortName>LEGAL PROCEEDINGS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>211181021 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>211201022 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATION</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>211281023 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>220042001 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>230053001 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>230203002 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURETables</Role>
      <ShortName>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>230273003 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>230413004 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIESTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/INVENTORIES</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>230443005 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>230483006 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>230543007 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>230573008 - Disclosure - FINANCING ARRANGEMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables</Role>
      <ShortName>FINANCING ARRANGEMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>230673009 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>230783010 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/LEASES</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>230853011 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>230913012 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>230943013 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables</Role>
      <ShortName>RESEARCH AND DEVELOPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>230973014 - Disclosure - OTHER EXPENSE, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSENETTables</Role>
      <ShortName>OTHER EXPENSE, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/OTHEREXPENSENET</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>231013015 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/INCOMETAXES</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>231103016 - Disclosure - LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LOSSPERSHARETables</Role>
      <ShortName>LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/LOSSPERSHARE</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>231143017 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESTables</Role>
      <ShortName>SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>231213018 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/SEGMENTINFORMATION</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>240024001 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>240064002 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>240074003 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>240084004 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>240094005 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>240104006 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>240114007 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>240124008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>240134009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>240144010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>240154011 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>240164012 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>240174013 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>240184014 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>240214015 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails</Role>
      <ShortName>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURETables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>240224016 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>240234017 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Assets and Liabilities Held For Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails</Role>
      <ShortName>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Assets and Liabilities Held For Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>240254018 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails</Role>
      <ShortName>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>240284019 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>240294020 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>240304021 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>240314022 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>240324023 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>240334024 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>240344025 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>240354026 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>240364027 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>240374028 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>240384029 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>240394030 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>240424031 - Disclosure - INVENTORIES - Summary of Inventories, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails</Role>
      <ShortName>INVENTORIES - Summary of Inventories, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>240454032 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>240464033 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>240494034 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>240504035 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>240514036 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>240524037 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>240554038 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>240584039 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>240594040 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Covenant Compliance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>240604041 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>240614042 - Disclosure - FINANCING ARRANGEMENTS - Current Description of Senior Secured Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Current Description of Senior Secured Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>240624043 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>240634044 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>240644045 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>240654046 - Disclosure - FINANCING ARRANGEMENTS - Maturities, Schedule of Maturities and Mandatory Payments of Debt Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Maturities, Schedule of Maturities and Mandatory Payments of Debt Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>240684047 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>240694048 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>240704049 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>240714050 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>240724051 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>240734052 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future Benefit Payments for the Pension Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future Benefit Payments for the Pension Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>240744053 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-Average Assumptions Used to Determine Net Periodic Benefit Costs and Benefit Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-Average Assumptions Used to Determine Net Periodic Benefit Costs and Benefit Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>240754054 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>240764055 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with the Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with the Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>240794056 - Disclosure - LEASES - Right-of-use Assets and Right-of-use Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails</Role>
      <ShortName>LEASES - Right-of-use Assets and Right-of-use Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>240804057 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>240814058 - Disclosure - LEASES - Lease Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails</Role>
      <ShortName>LEASES - Lease Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>240824059 - Disclosure - LEASES - Lease Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails</Role>
      <ShortName>LEASES - Lease Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>240834060 - Disclosure - LEASES - Lease Future Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails</Role>
      <ShortName>LEASES - Lease Future Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>240864061 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>240874062 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>240884063 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>240894064 - Disclosure - SHARE-BASED COMPENSATION - RSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - RSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>240924065 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>240954066 - Disclosure - RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails</Role>
      <ShortName>RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>240984067 - Disclosure - OTHER EXPENSE, NET - Schedule of Other Expense (Income), Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails</Role>
      <ShortName>OTHER EXPENSE, NET - Schedule of Other Expense (Income), Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>240994068 - Disclosure - OTHER EXPENSE, NET - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails</Role>
      <ShortName>OTHER EXPENSE, NET - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>241024069 - Disclosure - INCOME TAXES - Components of Benefit from Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES - Components of Benefit from Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>119</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>241034070 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>120</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>241044071 - Disclosure - INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>121</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>241054072 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>122</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>241064073 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>123</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>241074074 - Disclosure - INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails</Role>
      <ShortName>INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>124</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>241084075 - Disclosure - INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>125</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>241114076 - Disclosure - LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails</Role>
      <ShortName>LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>126</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>241124077 - Disclosure - LOSS PER SHARE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails</Role>
      <ShortName>LOSS PER SHARE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>127</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R128.htm</HtmlFileName>
      <LongName>241154078 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails</Role>
      <ShortName>SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>128</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R129.htm</HtmlFileName>
      <LongName>241174079 - Disclosure - LEGAL PROCEEDINGS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>129</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R130.htm</HtmlFileName>
      <LongName>241194080 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>130</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R131.htm</HtmlFileName>
      <LongName>241224081 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>131</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R132.htm</HtmlFileName>
      <LongName>241234082 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit, Assets and Capital Expenditures, Depreciation &amp; Amortization of Intangible Assets &amp; Asset Impairments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails</Role>
      <ShortName>SEGMENT INFORMATION - Segment Revenues and Profit, Assets and Capital Expenditures, Depreciation &amp; Amortization of Intangible Assets &amp; Asset Impairments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>132</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R133.htm</HtmlFileName>
      <LongName>241244083 - Disclosure - SEGMENT INFORMATION - Revenues by Product Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails</Role>
      <ShortName>SEGMENT INFORMATION - Revenues by Product Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>133</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R134.htm</HtmlFileName>
      <LongName>241254084 - Disclosure - SEGMENT INFORMATION - Geographic Information, Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails</Role>
      <ShortName>SEGMENT INFORMATION - Geographic Information, Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>134</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R135.htm</HtmlFileName>
      <LongName>241264085 - Disclosure - SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails</Role>
      <ShortName>SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>135</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R136.htm</HtmlFileName>
      <LongName>241274086 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails</Role>
      <ShortName>SEGMENT INFORMATION - Major Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>136</Position>
    </Report>
    <Report instance="bhc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R137.htm</HtmlFileName>
      <LongName>241294087 - Disclosure - SUBSEQUENT EVENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails</Role>
      <ShortName>SUBSEQUENT EVENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>137</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="bhc-20211231.htm">bhc-20211231.htm</File>
    <File>bhc-20211231.xsd</File>
    <File>bhc-20211231_cal.xml</File>
    <File>bhc-20211231_def.xml</File>
    <File>bhc-20211231_lab.xml</File>
    <File>bhc-20211231_pre.xml</File>
    <File>exhibit10202021ye.htm</File>
    <File>exhibit2112021ye.htm</File>
    <File>exhibit2312021ye.htm</File>
    <File>exhibit3112021ye.htm</File>
    <File>exhibit3122021ye.htm</File>
    <File>exhibit3212021ye.htm</File>
    <File>exhibit3222021ye.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>bhc-20211231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2243">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>160
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bhc-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 53,
   "contextCount": 917,
   "dts": {
    "calculationLink": {
     "local": [
      "bhc-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bhc-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bhc-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bhc-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bhc-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bhc-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 1144,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 10,
    "http://www.bauschhealth.com/20211231": 1,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 15
   },
   "keyCustom": 125,
   "keyStandard": 606,
   "memberCustom": 144,
   "memberStandard": 102,
   "nsprefix": "bhc",
   "nsuri": "http://www.bauschhealth.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000010001 - Document - Document and Entity Information",
     "role": "http://www.bauschhealth.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210031002 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie7e41e73d53c444f810e26a21d37fd21_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240714050 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanSettlementsBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ic5c96e30d644464397808c237e9a5ddf_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240724051 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ic5c96e30d644464397808c237e9a5ddf_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i866959039d2f4c258b6f412bfdedd0a8_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240734052 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future Benefit Payments for the Pension Benefit Plans (Details)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future Benefit Payments for the Pension Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i866959039d2f4c258b6f412bfdedd0a8_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240744053 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-Average Assumptions Used to Determine Net Periodic Benefit Costs and Benefit Obligations (Details)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-Average Assumptions Used to Determine Net Periodic Benefit Costs and Benefit Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ib162d9f7d4394df5824cac733b4b9525_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ib55cc79a8c5047d8ab1633dbce4cad44_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240754054 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ib55cc79a8c5047d8ab1633dbce4cad44_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i866959039d2f4c258b6f412bfdedd0a8_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240764055 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with the Acquisition (Details)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with the Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "if2ccc52c4ecc49e78eee3d33e2c113fa_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240794056 - Disclosure - LEASES - Right-of-use Assets and Right-of-use Liabilities (Details)",
     "role": "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails",
     "shortName": "LEASES - Right-of-use Assets and Right-of-use Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240804057 - Disclosure - LEASES - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/LEASESNarrativeDetails",
     "shortName": "LEASES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240814058 - Disclosure - LEASES - Lease Expenses (Details)",
     "role": "http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails",
     "shortName": "LEASES - Lease Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:AdditionalOperatingLeaseInformationLesseeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240824059 - Disclosure - LEASES - Lease Additional Information (Details)",
     "role": "http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails",
     "shortName": "LEASES - Lease Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:AdditionalOperatingLeaseInformationLesseeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210191003 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE",
     "role": "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE",
     "shortName": "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240834060 - Disclosure - LEASES - Lease Future Payments (Details)",
     "role": "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails",
     "shortName": "LEASES - Lease Future Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i4ca155d300cf42a4b9cfdefca02c609b_I20140531",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240864061 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "SHARE-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i4ca155d300cf42a4b9cfdefca02c609b_I20140531",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240874062 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails",
     "shortName": "SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i79264328a7a543f1ac564306154bf1e7_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240884063 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails",
     "shortName": "SHARE-BASED COMPENSATION - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i8ce2db50c529429bbf653f281af0ed3b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i2088dbf192f84b6e9cff9dc2cde381cf_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240894064 - Disclosure - SHARE-BASED COMPENSATION - RSUs (Details)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
     "shortName": "SHARE-BASED COMPENSATION - RSUs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i2088dbf192f84b6e9cff9dc2cde381cf_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240924065 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details)",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ia9158150c4cf4379b5bba7c7cb9d7e9a_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ResearchAndDevelopmentExpenseProductRelated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240954066 - Disclosure - RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details)",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails",
     "shortName": "RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ResearchAndDevelopmentExpenseProductRelated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R117": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240984067 - Disclosure - OTHER EXPENSE, NET - Schedule of Other Expense (Income), Net (Details)",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails",
     "shortName": "OTHER EXPENSE, NET - Schedule of Other Expense (Income), Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R118": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240994068 - Disclosure - OTHER EXPENSE, NET - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails",
     "shortName": "OTHER EXPENSE, NET - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i22332303e4634782bd879afa7c52f3f7_D20190101-20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GainLossOnDispositionOfAssets1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R119": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241024069 - Disclosure - INCOME TAXES - Components of Benefit from Income Taxes (Details)",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails",
     "shortName": "INCOME TAXES - Components of Benefit from Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210241004 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS",
     "role": "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS",
     "shortName": "RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R120": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "span",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241034070 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details)",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails",
     "shortName": "INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "span",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R121": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DeferredTaxAssetsTaxLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241044071 - Disclosure - INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DeferredTaxAssetsTaxLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R122": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "id1052f2e72864d03a985b250bef88f8c_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241054072 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details)",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
     "shortName": "INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i33e256fd4d08472686f2bc331857bc8a_I20181231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R123": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241064073 - Disclosure - INCOME TAXES - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R124": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i23bf918ee3914485aeddbbc1554c30ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OpenTaxYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241074074 - Disclosure - INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details)",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
     "shortName": "INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i23bf918ee3914485aeddbbc1554c30ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OpenTaxYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R125": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "id1052f2e72864d03a985b250bef88f8c_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241084075 - Disclosure - INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details)",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails",
     "shortName": "INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i88a9900560564bdca7dec25381689c13_I20181231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R126": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241114076 - Disclosure - LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)",
     "role": "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails",
     "shortName": "LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R127": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie898e2aab45345c9b42d7a2acb631663_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241124077 - Disclosure - LOSS PER SHARE - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails",
     "shortName": "LOSS PER SHARE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie898e2aab45345c9b42d7a2acb631663_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R128": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241154078 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details)",
     "role": "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails",
     "shortName": "SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R129": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:Legalsettlementsandrelatedfees",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241174079 - Disclosure - LEGAL PROCEEDINGS - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails",
     "shortName": "LEGAL PROCEEDINGS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ia6542cc5b199449eb308666602a70acb_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "group",
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210261005 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R130": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241194080 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R131": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i03a8ce11b6a94d508439a84f941e6341_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "reporting_unit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241224081 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i03a8ce11b6a94d508439a84f941e6341_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "reporting_unit",
      "xsiNil": "false"
     }
    },
    "R132": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241234082 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit, Assets and Capital Expenditures, Depreciation & Amortization of Intangible Assets & Asset Impairments (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails",
     "shortName": "SEGMENT INFORMATION - Segment Revenues and Profit, Assets and Capital Expenditures, Depreciation & Amortization of Intangible Assets & Asset Impairments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:InterestAndDebtExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R133": {
     "firstAnchor": {
      "ancestors": [
       "bhc:ConcentrationRiskNumberOfProducts",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ConcentrationRiskNumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241244083 - Disclosure - SEGMENT INFORMATION - Revenues by Product Category (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
     "shortName": "SEGMENT INFORMATION - Revenues by Product Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "bhc:ConcentrationRiskNumberOfProducts",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ConcentrationRiskNumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R134": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241254084 - Disclosure - SEGMENT INFORMATION - Geographic Information, Revenue (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
     "shortName": "SEGMENT INFORMATION - Geographic Information, Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "id130fccad3254b85b50a4b625a1dcde4_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R135": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241264085 - Disclosure - SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails",
     "shortName": "SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R136": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "id7c19794c8aa4758a7c167c4585fa6ca_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241274086 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
     "shortName": "SEGMENT INFORMATION - Major Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "id7c19794c8aa4758a7c167c4585fa6ca_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R137": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "iba498b34c6e5496e98017b43ea83814f_I20171218",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241294087 - Disclosure - SUBSEQUENT EVENTS - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails",
     "shortName": "SUBSEQUENT EVENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "if80737f8327f4413b9aff0d3dbfe8369_I20220118",
      "decimals": "INF",
      "lang": "en-US",
      "name": "bhc:DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210401006 - Disclosure - INVENTORIES",
     "role": "http://www.bauschhealth.com/role/INVENTORIES",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210431007 - Disclosure - PROPERTY, PLANT AND EQUIPMENT",
     "role": "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210471008 - Disclosure - INTANGIBLE ASSETS AND GOODWILL",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210531009 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210561010 - Disclosure - FINANCING ARRANGEMENTS",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS",
     "shortName": "FINANCING ARRANGEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210661011 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "000020002 - Document - AUDIT INFORMATION",
     "role": "http://www.bauschhealth.com/role/AUDITINFORMATION",
     "shortName": "AUDIT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210771012 - Disclosure - LEASES",
     "role": "http://www.bauschhealth.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210841013 - Disclosure - SHARE-BASED COMPENSATION",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION",
     "shortName": "SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210901014 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210931015 - Disclosure - RESEARCH AND DEVELOPMENT",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT",
     "shortName": "RESEARCH AND DEVELOPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210961016 - Disclosure - OTHER EXPENSE, NET",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSENET",
     "shortName": "OTHER EXPENSE, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211001017 - Disclosure - INCOME TAXES",
     "role": "http://www.bauschhealth.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211091018 - Disclosure - LOSS PER SHARE",
     "role": "http://www.bauschhealth.com/role/LOSSPERSHARE",
     "shortName": "LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211131019 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES",
     "role": "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES",
     "shortName": "SUPPLEMENTAL CASH FLOW DISCLOSURES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211161020 - Disclosure - LEGAL PROCEEDINGS",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGS",
     "shortName": "LEGAL PROCEEDINGS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211181021 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211201022 - Disclosure - SEGMENT INFORMATION",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211281023 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.bauschhealth.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "220042001 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230053001 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230203002 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE (Tables)",
     "role": "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURETables",
     "shortName": "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230273003 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230413004 - Disclosure - INVENTORIES (Tables)",
     "role": "http://www.bauschhealth.com/role/INVENTORIESTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230443005 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)",
     "role": "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTTables",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230483006 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230543007 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230573008 - Disclosure - FINANCING ARRANGEMENTS (Tables)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables",
     "shortName": "FINANCING ARRANGEMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230673009 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230783010 - Disclosure - LEASES (Tables)",
     "role": "http://www.bauschhealth.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230853011 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230913012 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230943013 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables",
     "shortName": "RESEARCH AND DEVELOPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230973014 - Disclosure - OTHER EXPENSE, NET (Tables)",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSENETTables",
     "shortName": "OTHER EXPENSE, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231013015 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231103016 - Disclosure - LOSS PER SHARE (Tables)",
     "role": "http://www.bauschhealth.com/role/LOSSPERSHARETables",
     "shortName": "LOSS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231143017 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables)",
     "role": "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESTables",
     "shortName": "SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostsAndExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231213018 - Disclosure - SEGMENT INFORMATION (Tables)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240024001 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
     "shortName": "DESCRIPTION OF BUSINESS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished",
      "reportCount": 1,
      "unique": true,
      "unitRef": "company",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240064002 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished",
      "reportCount": 1,
      "unique": true,
      "unitRef": "company",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240074003 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240084004 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i88a9900560564bdca7dec25381689c13_I20181231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i366ab3c0cc114fd3b2e77b4af953dd1f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240094005 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i366ab3c0cc114fd3b2e77b4af953dd1f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "idf8fe351f9e049048e582a289f5ec940_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240104006 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i8e253d2e372545a9be9b1908cb43277f_D20210101-20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "id1052f2e72864d03a985b250bef88f8c_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240114007 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesDeductions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240124008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "bhc:CashDiscountsAndAllowancesSettlementPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ic93289a0b5264300a6c1b192827b7231_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240134009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ic93289a0b5264300a6c1b192827b7231_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240144010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestCostsCapitalized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240154011 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestCostsCapitalized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:TaxBenefitRecognitionMeasurementPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240164012 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:TaxBenefitRecognitionMeasurementPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PensionAndOtherPostretirementPlansPolicy",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240174013 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PensionAndOtherPostretirementPlansPolicy",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240184014 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240214015 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
     "shortName": "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "bhc:NumberOfOtherBusinessesAcquired",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "bhc:NumberOfOtherBusinessesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "businesscombination",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240224016 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i92ebac933dea48b489400e86f7f489fe_I20190306",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "id13cd655709045658273ebf2abdba2e4_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240234017 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Assets and Liabilities Held For Sale (Details)",
     "role": "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails",
     "shortName": "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Assets and Liabilities Held For Sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "id13cd655709045658273ebf2abdba2e4_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240254018 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails",
     "shortName": "RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ic96cba168a6f45b0b15835dcb29e9eef_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ifad488da9d8d42f2ae12cbbb6d990611_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240284019 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i8ef833b76dda454f9e12e7a602fedd25_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i82b9833a23f042c5a2adb676a8ec5e95_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050007 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
     "shortName": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i82b9833a23f042c5a2adb676a8ec5e95_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:HighlyLiquidInvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240294020 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:HighlyLiquidInvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240304021 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ic8c7dd3d755f4d23a5c91bada3e42ee9_D20211101-20211130",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromHedgeInvestingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "if40c526d7e7346638f324aeec169b157_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240314022 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i44e7b5604e7f428db4023a2105e3040b_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetFairValueGrossLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i55601d2d01ba43d0ae61dc537370fe98_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForProceedsFromHedgeInvestingActivities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240324023 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i51904574a9814c839ec1c948964e42ee_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ifad488da9d8d42f2ae12cbbb6d990611_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240334024 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ifad488da9d8d42f2ae12cbbb6d990611_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ifad488da9d8d42f2ae12cbbb6d990611_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240344025 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ic86fe7b9a9b24aec84a84ced04e41054_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetFairValueGrossLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ifa75d1437f1d4f9b9a633c9849122864_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240354026 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ifa75d1437f1d4f9b9a633c9849122864_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "id1052f2e72864d03a985b250bef88f8c_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240364027 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
     "shortName": "FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i9a01def95a9b4da68b1d7c83300f93c5_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i71ee14ac1c1d46b7a0ce6c3c7e2a9b99_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240374028 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i8fab45399b784a6590e369a44a09cd98_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240384029 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i43aa74e47e0a4098b9e1b70baf38319d_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240394030 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i43aa74e47e0a4098b9e1b70baf38319d_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240424031 - Disclosure - INVENTORIES - Summary of Inventories, Net (Details)",
     "role": "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails",
     "shortName": "INVENTORIES - Summary of Inventories, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240454032 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details)",
     "role": "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240464033 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240494034 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "idc7bc8f12bdf4bd5b49783904d555941_D20210630-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240504035 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240514036 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "id1052f2e72864d03a985b250bef88f8c_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240524037 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i56a6cabd1cab41189dad8ed99b7f97b2_D20190101-20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:Legalsettlementsandrelatedfees",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240554038 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Details)",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "bhc:AccruedProductRebateCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240584039 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
     "shortName": "FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210011001 - Disclosure - DESCRIPTION OF BUSINESS",
     "role": "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i8aed4915fc8f42e580d71e20a671d348_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentAmountAvailableForRestrictedPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240594040 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
     "shortName": "FINANCING ARRANGEMENTS - Covenant Compliance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i8aed4915fc8f42e580d71e20a671d348_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentAmountAvailableForRestrictedPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240604041 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ic5f0234485054f26ad2c1d49dfdbd799_D20181127-20181127",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "if7b27ce3a4694376b7351cac69da0831_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240614042 - Disclosure - FINANCING ARRANGEMENTS - Current Description of Senior Secured Credit Facilities (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Current Description of Senior Secured Credit Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "if7b27ce3a4694376b7351cac69da0831_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentRedemptionPricePercentageChangeinControl",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240624043 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Secured Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i3ff0004e74da4838ab43904393cdd3f0_I20170331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentRedemptionPricePercentageChangeinControl",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240634044 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "iee380ad8627b4f83b469b1ba89c9747b_D20200526-20200526",
      "decimals": "-6",
      "lang": "en-US",
      "name": "bhc:PaymentForDebtAmortizationPrepaymentCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240644045 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
     "shortName": "FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240654046 - Disclosure - FINANCING ARRANGEMENTS - Maturities, Schedule of Maturities and Mandatory Payments of Debt Obligations (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails",
     "shortName": "FINANCING ARRANGEMENTS - Maturities, Schedule of Maturities and Mandatory Payments of Debt Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i973e30c58524481ca5eaa5ee3b0263f7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240684047 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "ie4234e7933af4d56b4d1dce4168e8b16_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "iddeca17018524ca7b4aa0120b6e125e0_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240694048 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "iddeca17018524ca7b4aa0120b6e125e0_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240704049 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20211231.htm",
      "contextRef": "i87374f85f6074bb2909d99d26ffbb7e2_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 254,
   "tag": {
    "bhc_A5.00SeniorNotesDueJanuary2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.00% Senior Notes Due January 2028 [Member]",
        "label": "5.00% Senior Notes Due January 2028 [Member]",
        "terseLabel": "5.00% Senior Unsecured Notes Due January 2028"
       }
      }
     },
     "localname": "A5.00SeniorNotesDueJanuary2028Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A5.25SeniorNotesDueJanuary2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.25% Senior Notes Due January 2030 [Member]",
        "label": "5.25% Senior Notes Due January 2030 [Member]",
        "terseLabel": "5.25% Senior Unsecured Notes Due January 2030"
       }
      }
     },
     "localname": "A5.25SeniorNotesDueJanuary2030Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A5.375SeniorNotesdueMarch2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.375% Senior Notes due March 2020 [Member]",
        "label": "5.375% Senior Notes due March 2020 [Member]",
        "terseLabel": "5.375% Senior Notes due March 2020"
       }
      }
     },
     "localname": "A5.375SeniorNotesdueMarch2020Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A5.50SeniorNotesdueMarch2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.50% Senior Notes due March 2023 [Member]",
        "label": "5.50% Senior Notes due March 2023 [Member]",
        "terseLabel": "5.50% Senior Unsecured Notes due March 2023"
       }
      }
     },
     "localname": "A5.50SeniorNotesdueMarch2023Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A5.875SeniorNotesdueMay2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.875% Senior Notes due May 2023 [Member]",
        "label": "5.875% Senior Notes due May 2023 [Member]",
        "terseLabel": "5.875% Senior Unsecured Notes due May 2023"
       }
      }
     },
     "localname": "A5.875SeniorNotesdueMay2023Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.875% Senior Notes due May 2023, March 2019 Refinancing",
        "label": "5.875% Senior Notes due May 2023, March 2019 Refinancing [Member]",
        "terseLabel": "5.875% Senior Notes due May 2023, March 2019 Refinancing"
       }
      }
     },
     "localname": "A5875SeniorNotesDueMay2023March2019RefinancingMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.875% Senior Notes due May 2023, May 2019 Refinancing",
        "label": "5.875% Senior Notes due May 2023, May 2019 Refinancing [Member]",
        "terseLabel": "5.875% Senior Notes due May 2023, May 2019 Refinancing"
       }
      }
     },
     "localname": "A5875SeniorNotesDueMay2023May2019RefinancingMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A6.125SeniorNotesdueApril2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.125% Senior Notes due April 2025 [Member]",
        "label": "6.125% Senior Notes due April 2025 [Member]",
        "terseLabel": "6.125% Senior Unsecured Notes due April 2025"
       }
      }
     },
     "localname": "A6.125SeniorNotesdueApril2025Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A7.00SeniorUnsecuredNotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7.00% Senior Unsecured Notes Due 2028 [Member]",
        "label": "7.00% Senior Unsecured Notes Due 2028 [Member]",
        "terseLabel": "7.00% Senior Unsecured Notes due 2028"
       }
      }
     },
     "localname": "A7.00SeniorUnsecuredNotesDue2028Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A7.25SeniorUnsecuredNotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7.25% Senior Unsecured Notes Due 2029 [Member]",
        "label": "7.25% Senior Unsecured Notes Due 2029 [Member]",
        "terseLabel": "7.25% Senior Unsecured Notes due 2029"
       }
      }
     },
     "localname": "A7.25SeniorUnsecuredNotesDue2029Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A8.50SeniorNotesDueJanuary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "8.50% Senior Notes Due January 2027 [Member]",
        "label": "8.50% Senior Notes Due January 2027 [Member]",
        "terseLabel": "8.50% Senior Unsecured Notes Due January 2027"
       }
      }
     },
     "localname": "A8.50SeniorNotesDueJanuary2027Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A9.00SeniorNotesdueDecember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.00% Senior Notes due December 2025 [Member]",
        "label": "9.00% Senior Notes due December 2025 [Member]",
        "terseLabel": "9.00% Senior Unsecured Notes due December 2025"
       }
      }
     },
     "localname": "A9.00SeniorNotesdueDecember2025Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A9.25SeniorNotesDueApril2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.25% Senior Notes Due April 2026 [Member]",
        "label": "9.25% Senior Notes Due April 2026 [Member]",
        "terseLabel": "9.25% Senior Unsecured Notes Due April 2026"
       }
      }
     },
     "localname": "A9.25SeniorNotesDueApril2026Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ACertainInternationalBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A Certain International Business [Member]",
        "label": "A Certain International Business [Member]",
        "terseLabel": "A Certain International Business"
       }
      }
     },
     "localname": "ACertainInternationalBusinessMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AccountsReceivableAllowanceForForeignExchangeAndOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance For Foreign Exchange And Other",
        "label": "Accounts Receivable, Allowance For Foreign Exchange And Other",
        "negatedTerseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForForeignExchangeAndOther",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update",
        "label": "Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update",
        "terseLabel": "Retrospective effect of application of new accounting standard"
       }
      }
     },
     "localname": "AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccretionForTimeValueOfMoneyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion For Time Value Of Money [Member]",
        "label": "Accretion For Time Value Of Money [Member]",
        "terseLabel": "Accretion for the time value of money"
       }
      }
     },
     "localname": "AccretionForTimeValueOfMoneyMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AccruedAndOtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued And Other Current Liabilities",
        "label": "Accrued And Other Current Liabilities [Member]",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedAndOtherCurrentLiabilitiesMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AccruedProductRebateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the current portion of accrued product rebates.",
        "label": "Accrued Product Rebate Current",
        "terseLabel": "Product rebates"
       }
      }
     },
     "localname": "AccruedProductRebateCurrent",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccruedProductReturnCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Product Return Current",
        "terseLabel": "Product returns"
       }
      }
     },
     "localname": "AccruedProductReturnCurrent",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccumulatedLossesAvailableForFederalPurposes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the details pertaining to accumulated losses available for federal and provincial purposes.",
        "label": "Accumulated Losses Available for Federal Purposes",
        "terseLabel": "Accumulated losses available for federal and provincial purposes"
       }
      }
     },
     "localname": "AccumulatedLossesAvailableForFederalPurposes",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AcquiredInProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents intangible assets that the entity has acquired as a result of business acquisition, which is represented through the premium in the purchase price over book value attributed to research and development on new product that is not yet being sold.",
        "label": "Acquired in Process Research and Development [Member]",
        "terseLabel": "Acquired IPR&amp;D not in service",
        "verboseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "AcquiredInProcessResearchAndDevelopmentMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]",
        "label": "Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]",
        "terseLabel": "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE"
       }
      }
     },
     "localname": "AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Operating Lease Information, Lessee [Table Text Block]",
        "label": "Additional Operating Lease Information, Lessee [Table Text Block]",
        "terseLabel": "Summary of other operating lease information"
       }
      }
     },
     "localname": "AdditionalOperatingLeaseInformationLesseeTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Payments To Acquire Equity Securities, FV-NI, Expected",
        "label": "Additional Payments To Acquire Equity Securities, FV-NI, Expected",
        "terseLabel": "Expected additional payments"
       }
      }
     },
     "localname": "AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AllegroOphthalmicsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allegro Ophthalmics, LLC",
        "label": "Allegro Ophthalmics, LLC [Member]",
        "terseLabel": "Allegro"
       }
      }
     },
     "localname": "AllegroOphthalmicsLLCMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AllowancesForLossesOnAccountsReceivableAndInventories": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.",
        "label": "Allowances for Losses on Accounts Receivable and Inventories",
        "terseLabel": "Allowances for losses on trade receivables and inventories"
       }
      }
     },
     "localname": "AllowancesForLossesOnAccountsReceivableAndInventories",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity, AmerisourceBergen Corporation.",
        "label": "Amerisource Bergen Corporation [Member]",
        "terseLabel": "AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AmerisourceBergenCorporationMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.",
        "label": "Amortization of Intangible Assets Excluding Amortization Allocated to Revenues Cost of Good Sold",
        "negatedTerseLabel": "Amortization of intangible assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AmounPharmaceuticalCompanySAEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amoun Pharmaceutical Company S.A.E",
        "label": "Amoun Pharmaceutical Company S.A.E [Member]",
        "terseLabel": "Amoun Pharmaceutical Company S.A.E"
       }
      }
     },
     "localname": "AmounPharmaceuticalCompanySAEMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ApotexIncLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Apotex Inc. Litigation",
        "label": "Apotex Inc. Litigation [Member]",
        "terseLabel": "Apotex Inc. Litigation"
       }
      }
     },
     "localname": "ApotexIncLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Argentina, Brazil, Egypt, Greece, Serbia, South Africa, Turkey, Ukraine, Venezuela and Vietnam",
        "label": "Argentina, Brazil, Egypt, Greece, Serbia, South Africa, Turkey, Ukraine, Venezuela and Vietnam [Member]",
        "terseLabel": "Argentina, Brazil, Egypt, Greece, Serbia, South Africa, Turkey, Ukraine, Venezuela and Vietnam"
       }
      }
     },
     "localname": "ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Summary of right-of-use assets and right-of-use liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_AssetsLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets, Lessee [Abstract]",
        "label": "Assets, Lessee [Abstract]",
        "terseLabel": "Right-of-use assets included in:"
       }
      }
     },
     "localname": "AssetsLesseeAbstract",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]",
        "terseLabel": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "xbrltype": "stringItemType"
    },
    "bhc_BaseRateOrPrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base Rate Or Prime Rate [Member]",
        "label": "Base Rate Or Prime Rate [Member]",
        "terseLabel": "Base Rate or Prime Rate"
       }
      }
     },
     "localname": "BaseRateOrPrimeRateMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BauschLombInternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bausch Lomb/International [Member]",
        "label": "Bausch Lomb/International [Member]",
        "terseLabel": "Bausch + Lomb/ International"
       }
      }
     },
     "localname": "BauschLombInternationalMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BauschLombMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bausch + Lomb",
        "label": "Bausch + Lomb [Member]",
        "terseLabel": "Bausch + Lomb"
       }
      }
     },
     "localname": "BauschLombMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BrandedandOtherGenericProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Branded and Other Generic Products [Member]",
        "label": "Branded and Other Generic Products [Member]",
        "terseLabel": "Branded and Other Generics"
       }
      }
     },
     "localname": "BrandedandOtherGenericProductsMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.",
        "label": "Business Acquisition, Contingent Consideration Fair Value Disclosure",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationFairValueDisclosure",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessAcquisitionProFormaOperatingIncomeLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Pro Forma Operating Income (Loss)",
        "label": "Business Acquisition, Pro Forma Operating Income (Loss)",
        "terseLabel": "Pro-forma operating results"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaOperatingIncomeLoss",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.",
        "label": "Business Combination, Contingent Consideration Arrangements Change in Amount of Contingent Consideration Asset Cash",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessCombinationContingentConsiderationNoncurrentLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Noncurrent Liability",
        "label": "Business Combination, Contingent Consideration, Noncurrent Liability",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationNoncurrentLiability",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Pro Forma Information, Operating Income (Loss) Since Acquisition, Actual",
        "label": "Business Combination, Pro Forma Information, Operating Income (Loss) Since Acquisition, Actual",
        "terseLabel": "Operating results of acquiree since acquisition"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses",
        "negatedTerseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Separation And Proposed Initial Public Offering, Number Of Companies To Be Established",
        "label": "Business Separation And Proposed Initial Public Offering, Number Of Companies To Be Established",
        "terseLabel": "Business separation and proposed initial public offering, number of companies to be established"
       }
      }
     },
     "localname": "BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_CanadaBankersAcceptanceRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Canada Bankers Acceptance Rate [Member]",
        "label": "Canada Bankers Acceptance Rate [Member]",
        "terseLabel": "Canada Bankers Acceptance Rate"
       }
      }
     },
     "localname": "CanadaBankersAcceptanceRateMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CanadianSecuritiesLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Canadian Securities Litigation",
        "label": "Canadian Securities Litigation [Member]",
        "terseLabel": "Canadian Securities Litigation"
       }
      }
     },
     "localname": "CanadianSecuritiesLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the capital expenditures, depreciation and amortization by segment.",
        "label": "Capital Expenditure and Depreciation and Amortization [Abstract]",
        "terseLabel": "Capital expenditures:"
       }
      }
     },
     "localname": "CapitalExpenditureAndDepreciationAndAmortizationAbstract",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_CardinalHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity, Cardinal Health, Inc.",
        "label": "Cardinal Health Inc [Member]",
        "terseLabel": "Cardinal Health,\u00a0Inc."
       }
      }
     },
     "localname": "CardinalHealthIncMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, And Other Settlement Deposits",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, And Other Settlement Deposits",
        "periodEndLabel": "Cash and cash equivalents and Restricted cash and other settlement deposits, end of year",
        "periodStartLabel": "Cash and cash equivalents and Restricted cash and other settlement deposits, beginning of year",
        "totalLabel": "Cash and cash equivalents and Restricted cash and other settlement deposits, end of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_CashDiscountsAndAllowancesSettlementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Discounts And Allowances, Settlement Period",
        "label": "Cash Discounts And Allowances, Settlement Period",
        "terseLabel": "Settlement period for cash discounts and allowances"
       }
      }
     },
     "localname": "CashDiscountsAndAllowancesSettlementPeriod",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_CedarsSinaiMedicalCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cedars-Sinai Medical Center",
        "label": "Cedars-Sinai Medical Center [Member]",
        "terseLabel": "Cedars-Sinai Medical Center"
       }
      }
     },
     "localname": "CedarsSinaiMedicalCenterMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certain Products For Disposal, September Two Thousand Nineteen [Member]",
        "label": "Certain Products For Disposal, September Two Thousand Nineteen [Member]",
        "terseLabel": "Certain Products For Disposal, September 2019"
       }
      }
     },
     "localname": "CertainProductsForDisposalSeptemberTwoThousandNineteenMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CollaborativeAgreementMilestonePaymentsAggregate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amounts required to be paid by the reporting entity, which are contingent upon the achievement of specific development, regulatory or commercial milestones, in connection with the Collaboration Agreement.",
        "label": "Collaborative Agreement Milestone Payments, Aggregate",
        "terseLabel": "Milestone payments in terms of collaboration and license agreements, aggregate"
       }
      }
     },
     "localname": "CollaborativeAgreementMilestonePaymentsAggregate",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ConcentrationRiskNumberOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk, Number Of Products",
        "label": "Concentration Risk, Number Of Products",
        "terseLabel": "Number of products represented of total revenue"
       }
      }
     },
     "localname": "ConcentrationRiskNumberOfProducts",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_ConcentrationRiskPercentageofNetTradeReceivables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk, Percentage of Net Trade Receivables",
        "label": "Concentration Risk, Percentage of Net Trade Receivables",
        "terseLabel": "Percentage of net trade receivables accounted for by largest wholesale customers"
       }
      }
     },
     "localname": "ConcentrationRiskPercentageofNetTradeReceivables",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_CrossCurrencyFinalSettlementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cross Currency, Final Settlement",
        "label": "Cross Currency, Final Settlement [Member]",
        "terseLabel": "Cross-currency swaps, final settlement"
       }
      }
     },
     "localname": "CrossCurrencyFinalSettlementMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CustomerTopTenProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer, Top Ten Products",
        "label": "Customer, Top Ten Products [Member]",
        "terseLabel": "Customer, Top Ten Products"
       }
      }
     },
     "localname": "CustomerTopTenProductsMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold",
        "label": "Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold",
        "terseLabel": "Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold"
       }
      }
     },
     "localname": "DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Alternate Term, Principal Amount Maturity Threshold",
        "label": "Debt Instrument, Alternate Term, Principal Amount Maturity Threshold",
        "terseLabel": "Alternate term, principal amount maturity threshold"
       }
      }
     },
     "localname": "DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentAmountAvailableForRestrictedPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Amount Available For Restricted Payments",
        "label": "Debt Instrument, Amount Available For Restricted Payments",
        "terseLabel": "Amount available for restricted payments"
       }
      }
     },
     "localname": "DebtInstrumentAmountAvailableForRestrictedPayments",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentAnnualAmortizationRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Annual Amortization Rate, Percentage",
        "label": "Debt Instrument, Annual Amortization Rate, Percentage",
        "terseLabel": "Annual amortization rate, percentage"
       }
      }
     },
     "localname": "DebtInstrumentAnnualAmortizationRatePercentage",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "terseLabel": "Interest coverage ratio (not less than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantInterestCoverageRatioMinimum",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met",
        "label": "Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met",
        "terseLabel": "Debt covenant, redemption and discharge condition, amount, if circumstances met"
       }
      }
     },
     "localname": "DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio",
        "label": "Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio",
        "terseLabel": "Fixed charge coverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsFixedChargeCoverageRatio",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Secured Leverage Ratio",
        "label": "Debt Instrument, Covenant Terms, Secured Leverage Ratio",
        "terseLabel": "Secured leverage ratio",
        "verboseLabel": "Secured leverage ratio (not greater than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsSecuredLeverageRatio",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantTotalLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Total Leverage Ratio",
        "label": "Debt Instrument, Covenant, Total Leverage Ratio",
        "terseLabel": "Total leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTotalLeverageRatio",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Total Leverage Ratio",
        "label": "Debt Instrument, Covenant, Total Leverage Ratio, Maximum",
        "terseLabel": "Total leverage ratio (not greater than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTotalLeverageRatioMaximum",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentExpectedFaceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Expected Face Amount",
        "label": "Debt Instrument, Expected Face Amount",
        "terseLabel": "Expected aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentExpectedFaceAmount",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Maximum Redemption Percentage With Equity Offering Proceeds",
        "label": "Debt Instrument, Maximum Redemption Percentage With Equity Offering Proceeds",
        "terseLabel": "Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings"
       }
      }
     },
     "localname": "DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Periodic Payment, Quarterly Amortization",
        "label": "Debt Instrument, Periodic Payment, Quarterly Amortization",
        "terseLabel": "Remaining mandatory quarterly amortization payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentQuarterlyAmortization",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentRedemptionPricePercentageChangeinControl": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption Price, Percentage, Change in Control",
        "label": "Debt Instrument, Redemption Price, Percentage, Change in Control",
        "terseLabel": "Redemption price percentage due to change in control (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageChangeinControl",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DeferredIncomeTaxNoncashExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.",
        "label": "Deferred Income Tax Noncash Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxNoncashExpenseBenefit",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DeferredTaxAssetsPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Prepaid Expenses",
        "label": "Deferred Tax Assets, Prepaid Expenses",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsPrepaidExpenses",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the deferred tax assets on scientific research and experimental development pool, of the entity.",
        "label": "Deferred Tax Assets, Scientific Research and Experimental Development Pool",
        "terseLabel": "Scientific Research and Experimental Development pool"
       }
      }
     },
     "localname": "DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tax effect as of the balance sheet date of the amount of future tax deductions arising from unused research and development tax credit carryforwards; a tax credit carryforward is the amount by which tax credits available for utilization exceed statutory limitations for inclusion in historical filings, and which can only be utilized if sufficient tax-basis income is generated in future periods and providing tax laws continue to allow such utilization.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards Research and Development",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DeferredTaxAssetsTaxLossCarryforwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the deferred tax assets on tax loss carryforwards available to the entity.",
        "label": "Deferred Tax Assets, Tax Loss Carryforwards",
        "terseLabel": "Tax loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxLossCarryforwards",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the deferred tax liability recognized for the original basis difference between the principal amount of the Convertible Notes and value allocated to the liability component, which resulted in a corresponding reduction to the valuation allowance recorded against deferred tax assets.",
        "label": "Deferred Tax Liabilities, Basis Difference of Convertible Notes",
        "verboseLabel": "Plant, equipment and technology"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Actuarial Gain (Loss), Amortization Threshold Percentage",
        "label": "Defined Benefit Plan, Actuarial Gain (Loss), Amortization Threshold Percentage",
        "terseLabel": "Threshold percentage for amortization of net actuarial gains and losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Benefit Accrual, Interest Percentage Earned On Cash Balance",
        "label": "Defined Benefit Plan, Benefit Accrual, Interest Percentage Earned On Cash Balance",
        "terseLabel": "Benefit accrual, interest percentage earned on cash balance"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DefinedBenefitPlanEmployerContributionMaximumAge": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Employer Contribution, Maximum Age",
        "label": "Defined Benefit Plan, Employer Contribution, Maximum Age",
        "terseLabel": "Employer contribution maximum age"
       }
      }
     },
     "localname": "DefinedBenefitPlanEmployerContributionMaximumAge",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Estimated Future Benefit Payments, Period",
        "label": "Defined Benefit Plan, Estimated Future Benefit Payments, Period",
        "terseLabel": "Future benefit payments period"
       }
      }
     },
     "localname": "DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Number of Defined Benefit Plans Amended",
        "label": "Defined Benefit Plan, Number of Defined Benefit Plans Amended",
        "terseLabel": "Number of defined benefit plans amended"
       }
      }
     },
     "localname": "DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Number of Defined Benefit Plans",
        "label": "Defined Benefit Plan, Number of Defined Benefit Plans",
        "terseLabel": "Number of defined benefit plans"
       }
      }
     },
     "localname": "DefinedBenefitPlanNumberofDefinedBenefitPlans",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_DefinedBenefitPlanPercentageAllocationofFund": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Percentage Allocation of Fund",
        "label": "Defined Benefit Plan, Percentage Allocation of Fund",
        "terseLabel": "Percentage allocation of fund"
       }
      }
     },
     "localname": "DefinedBenefitPlanPercentageAllocationofFund",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DerivativeGainExcludedComponent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative, Gain, Excluded Component",
        "label": "Derivative, Gain, Excluded Component",
        "negatedTerseLabel": "Gain excluded from hedge effectiveness"
       }
      }
     },
     "localname": "DerivativeGainExcludedComponent",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DerivativeLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Lawsuits [Member]",
        "label": "Derivative Lawsuits [Member]",
        "terseLabel": "Derivative Lawsuits"
       }
      }
     },
     "localname": "DerivativeLawsuitsMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DeviceProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Device Products [Member]",
        "label": "Device Products [Member]",
        "terseLabel": "Devices"
       }
      }
     },
     "localname": "DeviceProductsMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DiscontinuedProductLinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discontinued Product Lines",
        "label": "Discontinued Product Lines [Member]",
        "terseLabel": "Discontinued Product Lines"
       }
      }
     },
     "localname": "DiscontinuedProductLinesMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Current",
        "label": "Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Noncurrent",
        "label": "Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DiversifiedProductsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diversified Products Segment [Member]",
        "label": "Diversified Products Segment [Member]",
        "terseLabel": "Diversified Products",
        "verboseLabel": "Diversified Products"
       }
      }
     },
     "localname": "DiversifiedProductsSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DivestituresOfNoncoreProductsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divestitures of Non-core Products [Policy Text Block]",
        "label": "Divestitures Of Non-core Products [Policy Text Block]",
        "terseLabel": "Divestitures of Products"
       }
      }
     },
     "localname": "DivestituresOfNoncoreProductsPolicyTextBlock",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_DoctorsAllergyFormulaLLCLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Doctors Allergy Formula, LLC Litigation [Member]",
        "label": "Doctors Allergy Formula, LLC Litigation [Member]",
        "terseLabel": "Doctors Allergy Formula, LLC Litigation"
       }
      }
     },
     "localname": "DoctorsAllergyFormulaLLCLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Adjustments To Tax Attributes, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Adjustments To Tax Attributes, Amount",
        "negatedTerseLabel": "Adjustments to tax attributes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_EmergingMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Emerging Markets segment of the entity. The segment consists of branded generic pharmaceutical products, as well as OTC products and agency/in-licensing arrangements with other research-based pharmaceutical companies (where the entity distributes and markets branded, patented products under long-term, renewable contracts). Products are sold primarily in Europe (Poland, Serbia, Hungary, Croatia and Russia), Latin America (Mexico, Brazil and exports out of Mexico to other Latin American markets), South East Asia and South Africa.",
        "label": "Emerging Markets [Member]",
        "verboseLabel": "Emerging markets"
       }
      }
     },
     "localname": "EmergingMarketsMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]",
        "label": "Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]",
        "verboseLabel": "Stock options, Time-based RSUs, Performance-based RSUs"
       }
      }
     },
     "localname": "EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_EquipmentOnOperatingLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment On Operating Lease",
        "label": "Equipment On Operating Lease [Member]",
        "terseLabel": "Equipment on operating lease"
       }
      }
     },
     "localname": "EquipmentOnOperatingLeaseMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_EyenoviaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eyenovia, Inc.",
        "label": "Eyenovia, Inc. [Member]",
        "terseLabel": "Eyenovia, Inc."
       }
      }
     },
     "localname": "EyenoviaIncMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_FairValueAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Adjustments",
        "label": "Fair Value Adjustments [Member]",
        "terseLabel": "Fair value adjustments"
       }
      }
     },
     "localname": "FairValueAdjustmentsMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ForeignCountryStateAndLocalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The designated tax department of state or local government of a foreign country entitled to levy and collect income taxes from the entity.",
        "label": "Foreign Country State and Local [Member]",
        "terseLabel": "Canadian Federal and Provincial"
       }
      }
     },
     "localname": "ForeignCountryStateAndLocalMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_GainLossRelatedToLitigationSettlementGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) Related To Litigation Settlement, Gross",
        "label": "Gain (Loss) Related To Litigation Settlement, Gross",
        "negatedTerseLabel": "Additions to accrued legal settlements"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlementGross",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_GlobalHighYieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global High Yield [Member]",
        "label": "Global High Yield [Member]",
        "terseLabel": "Global high yield"
       }
      }
     },
     "localname": "GlobalHighYieldMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_GlumetzaAntitrustLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glumetza Antitrust Class Actions Litigation [Member]",
        "label": "Glumetza Antitrust Litigation [Member]",
        "terseLabel": "Glumetza Antitrust Litigation"
       }
      }
     },
     "localname": "GlumetzaAntitrustLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glumetza Antitrust Litigation, Non-Class Complaints [Member]",
        "label": "Glumetza Antitrust Litigation, Non-Class Complaints [Member]",
        "terseLabel": "Glumetza Antitrust Litigation, Non-Class Complaints"
       }
      }
     },
     "localname": "GlumetzaAntitrustLitigationNonClassComplaintsMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill, Impairment Loss, Not Included In Asset Impairment Charges",
        "label": "Goodwill, Impairment Loss, Not Included In Asset Impairment Charges",
        "negatedLabel": "Goodwill impairments",
        "terseLabel": "Goodwill impairments",
        "verboseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill, Transfers Related To Sale of Business Unit",
        "label": "Goodwill, Transfers Related To Sale of Business Unit",
        "terseLabel": "Assets held for sale reclassified to goodwill"
       }
      }
     },
     "localname": "GoodwillTransfersRelatedToSaleOfBusinessUnit",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_HighlyLiquidInvestmentsMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Highly Liquid Investments, Maturity Period",
        "label": "Highly Liquid Investments, Maturity Period",
        "terseLabel": "Highly liquid investments, maturity period (or less)"
       }
      }
     },
     "localname": "HighlyLiquidInvestmentsMaturityPeriod",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_IncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Income Tax [Line Items]",
        "terseLabel": "Income Tax [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxLineItems",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax, Number Of Subsidiaries File Federal Income Tax Returns",
        "label": "Income Tax, Number Of Subsidiaries File Federal Income Tax Returns",
        "terseLabel": "Number of subsidiaries file federal income tax returns in Canada, U.S., and other foreign jurisdictions (or more)"
       }
      }
     },
     "localname": "IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to change in valuation allowance related to operating losses.",
        "label": "Income Tax Reconciliation Change in Operating Losses Valuation Allowance",
        "negatedTerseLabel": "Change in valuation allowance related to foreign tax credits and NOLs"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_IncomeTaxReconciliationDeferredIntercompanyProfit": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of the difference between total income tax expense (benefit) as reported in the income statement and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to deferred intercompany profit.",
        "label": "Income Tax Reconciliation Deferred Intercompany Profit",
        "negatedTerseLabel": "Tax benefit on intra-entity transfers"
       }
      }
     },
     "localname": "IncomeTaxReconciliationDeferredIntercompanyProfit",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_IncomeTaxReconciliationUncertainTaxPositions": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to uncertain tax positions.",
        "label": "Income Tax Reconciliation, Uncertain Tax Positions",
        "negatedTerseLabel": "Change in uncertain tax positions"
       }
      }
     },
     "localname": "IncomeTaxReconciliationUncertainTaxPositions",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_IncomeTaxTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information relating to income taxes.",
        "label": "Income Tax [Table]",
        "terseLabel": "Income Tax [Table]"
       }
      }
     },
     "localname": "IncomeTaxTable",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax",
        "label": "Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue, year-over-year increase"
       }
      }
     },
     "localname": "IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax, Percentage",
        "label": "Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax, Percentage",
        "negatedTerseLabel": "Revenue, year-over-year decrease, percentage"
       }
      }
     },
     "localname": "IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_InsuranceCoverageLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance Coverage Lawsuit [Member]",
        "label": "Insurance Coverage Lawsuit [Member]",
        "terseLabel": "Insurance Coverage Lawsuit"
       }
      }
     },
     "localname": "InsuranceCoverageLawsuitMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_InterestSettlementOnCrossCurrencySwaps": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Settlement On Cross-Currency Swaps",
        "label": "Interest Settlement On Cross-Currency Swaps",
        "terseLabel": "Settlements from cross-currency swaps"
       }
      }
     },
     "localname": "InterestSettlementOnCrossCurrencySwaps",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_InternationalRxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International Rx",
        "label": "International Rx [Member]",
        "terseLabel": "International Rx"
       }
      }
     },
     "localname": "InternationalRxMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_InvestmentGradeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment Grade [Member]",
        "label": "Investment Grade [Member]",
        "terseLabel": "Investment grade"
       }
      }
     },
     "localname": "InvestmentGradeMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_Legalsettlementsandrelatedfees": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal settlements and related fees",
        "label": "Legal settlements and related fees",
        "terseLabel": "Legal matters and related fees"
       }
      }
     },
     "localname": "Legalsettlementsandrelatedfees",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_LiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities, Lessee [Abstract]",
        "label": "Liabilities, Lessee [Abstract]",
        "terseLabel": "Lease liabilities included in:"
       }
      }
     },
     "localname": "LiabilitiesLesseeAbstract",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Expected Maximum Borrowing Capacity",
        "label": "Line of Credit Facility, Expected Maximum Borrowing Capacity",
        "terseLabel": "Expected maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpectedMaximumBorrowingCapacity",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.",
        "label": "Line of Credit Facility, Percentage of Consolidated Excess Cash Flow Payable as Mandatory Prepayments",
        "terseLabel": "Percentage of annual excess cash flow"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.",
        "label": "Line of Credit Facility, Percentage of Net Cash Proceeds from Asset Sales Outside Ordinary Course of Business Payable as Mandatory Prepayments",
        "terseLabel": "Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.",
        "label": "Line of Credit Facility, Percentage of Net Cash Proceeds of Insurance and Condemnation Proceeds from Property or Asset Losses Payable as Mandatory Prepayments",
        "terseLabel": "Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.",
        "label": "Line of Credit Facility, Percentage of Net Proceeds from Incurrence of Debt Payable as Mandatory Pre-payments",
        "terseLabel": "Percentage of cash proceeds from incurrence of debt"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Threshold For Incremental Borrowings",
        "label": "Line Of Credit Facility, Threshold For Incremental Borrowings",
        "terseLabel": "Incremental credit facility borrowings"
       }
      }
     },
     "localname": "LineOfCreditFacilityThresholdForIncrementalBorrowings",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility Threshold For Incremental Borrowings Interest Rate",
        "label": "Line Of Credit Facility Threshold For Incremental Borrowings Interest Rate",
        "terseLabel": "Incremental borrowings interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LitigationwithFormerSalixCEOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation with Former Salix CEO [Member]",
        "label": "Litigation with Former Salix CEO [Member]",
        "terseLabel": "Litigation with Former Salix CEO"
       }
      }
     },
     "localname": "LitigationwithFormerSalixCEOMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_LossContingencyNewClaimsFiledButNotYetServedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency New Claims Filed But Not Yet Served Number",
        "label": "Loss Contingency New Claims Filed But Not Yet Served Number",
        "terseLabel": "Number of additional suits filed, but not served"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledButNotYetServedNumber",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Alleged Stockholders, Filed Lawsuits",
        "label": "Loss Contingency, Number Of Alleged Stockholders, Filed Lawsuits",
        "terseLabel": "Number of alleged stockholders filed lawsuits"
       }
      }
     },
     "localname": "LossContingencyNumberOfAllegedStockholdersFiledLawsuits",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action",
        "label": "Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action",
        "terseLabel": "Number of entities, exercised opt-out right, pursuing action"
       }
      }
     },
     "localname": "LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyNumberOfInsurancePolicyPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Insurance Policy Periods",
        "label": "Loss Contingency, Number Of Insurance Policy Periods",
        "terseLabel": "Number of distinct insurance policy periods"
       }
      }
     },
     "localname": "LossContingencyNumberOfInsurancePolicyPeriods",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Plaintiffs, Number of Groups of Investors",
        "label": "Loss Contingency, Plaintiffs, Number of Groups of Investors",
        "terseLabel": "Number of groups of investors"
       }
      }
     },
     "localname": "LossContingencyPlaintiffsNumberofGroupsofInvestors",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending",
        "label": "Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending",
        "terseLabel": "Number of groups of investors filing action, remain pending"
       }
      }
     },
     "localname": "LossContingencyPlaintiffsNumberofGroupsofInvestorsPending",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencySettlementAgreementsNumberOfInsurers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Settlement Agreements, Number Of Insurers",
        "label": "Loss Contingency, Settlement Agreements, Number Of Insurers",
        "terseLabel": "Settlement agreements, number of insurers"
       }
      }
     },
     "localname": "LossContingencySettlementAgreementsNumberOfInsurers",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyStayOfApprovalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Stay Of Approval, Period",
        "label": "Loss Contingency, Stay Of Approval, Period",
        "terseLabel": "Stay of the approval period"
       }
      }
     },
     "localname": "LossContingencyStayOfApprovalPeriod",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_LupinPharmaceuticalsIncLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lupin Pharmaceuticals, Inc. Litigation",
        "label": "Lupin Pharmaceuticals, Inc. Litigation [Member]",
        "terseLabel": "Lupin Pharmaceuticals, Inc. Litigation"
       }
      }
     },
     "localname": "LupinPharmaceuticalsIncLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MSNLaboratoriesPrivateLtdLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MSN Laboratories Private Ltd. Litigation",
        "label": "MSN Laboratories Private Ltd. Litigation [Member]",
        "terseLabel": "MSN Laboratories Private Ltd. Litigation"
       }
      }
     },
     "localname": "MSNLaboratoriesPrivateLtdLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum original term of maturity for an instrument to be classified as cash or cash equivalent.",
        "label": "Maximum Term of Original Maturity to Classify Instruments as Cash and Cash Equivalents",
        "terseLabel": "Maximum term of original maturity to classify instruments as cash and cash equivalents (less than)"
       }
      }
     },
     "localname": "MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_McKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity, McKesson Corporation.",
        "label": "Mc Kesson Corporation [Member]",
        "terseLabel": "McKesson Corporation"
       }
      }
     },
     "localname": "McKessonCorporationMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MeasurementInputWeightedAverageDiscountRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Weighted-Average Discount Rate [Member]",
        "label": "Measurement Input, Weighted-Average Discount Rate [Member]",
        "terseLabel": "Measurement Input, Weighted-Average Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputWeightedAverageDiscountRateMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MilestonePaymentRelatedToCertainProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Related To Certain Product [Member]",
        "label": "Milestone Payment Related To Certain Product [Member]",
        "terseLabel": "Milestone Payment Related To Certain Product"
       }
      }
     },
     "localname": "MilestonePaymentRelatedToCertainProductMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the minimum period to classify uncertain tax position liabilities as long term liabilities.",
        "label": "Minimum Period to Classify Uncertain Tax Position, Liabilities as Long Term Liabilities",
        "terseLabel": "Minimum period to classify uncertain tax position liabilities as long term liabilities"
       }
      }
     },
     "localname": "MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_MitsubishiTanabePharmaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mitsubishi Tanabe Pharma Corporation [Member]",
        "label": "Mitsubishi Tanabe Pharma Corporation [Member]",
        "terseLabel": "Mitsubishi Tanabe Pharma Corporation"
       }
      }
     },
     "localname": "MitsubishiTanabePharmaCorporationMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NewRestatedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Restated Credit Agreement",
        "label": "New Restated Credit Agreement [Member]",
        "terseLabel": "New Restated Credit Agreement"
       }
      }
     },
     "localname": "NewRestatedCreditAgreementMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NonU.S.DevelopedMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-U.S. Developed Markets [Member]",
        "label": "Non-U.S. Developed Markets [Member]",
        "terseLabel": "Worldwide developed markets"
       }
      }
     },
     "localname": "NonU.S.DevelopedMarketsMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NonU.S.OtherAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-U.S. Other Assets [Member]",
        "label": "Non-U.S. Other Assets [Member]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "NonU.S.OtherAssetsMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NoncashCumulativeForeignCurrencyTranslationLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Cumulative Foreign Currency Translation Loss",
        "label": "Noncash Cumulative Foreign Currency Translation Loss",
        "terseLabel": "Noncash cumulative foreign currency translation loss"
       }
      }
     },
     "localname": "NoncashCumulativeForeignCurrencyTranslationLoss",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_NonemployeeDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonemployee Director [Member]",
        "label": "Nonemployee Director [Member]",
        "terseLabel": "Nonemployee Director"
       }
      }
     },
     "localname": "NonemployeeDirectorMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NovaliqGmbHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novaliq GmbH [Member]",
        "label": "Novaliq GmbH [Member]",
        "terseLabel": "Novaliq GmbH"
       }
      }
     },
     "localname": "NovaliqGmbHMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NumberOfLargestWholesaleCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of largest wholesale customers.",
        "label": "Number of Largest Wholesale Customers",
        "terseLabel": "Number of largest wholesale customers"
       }
      }
     },
     "localname": "NumberOfLargestWholesaleCustomers",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_NumberOfOtherBusinessesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Other Businesses Acquired",
        "label": "Number Of Other Businesses Acquired",
        "terseLabel": "Number of other material business combinations"
       }
      }
     },
     "localname": "NumberOfOtherBusinessesAcquired",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_OmnibusIncentivePlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omnibus Incentive Plan 2014 [Member]",
        "label": "Omnibus Incentive Plan 2014 [Member]",
        "terseLabel": "Omnibus Incentive Plan 2014"
       }
      }
     },
     "localname": "OmnibusIncentivePlan2014Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OrthoDermatologicsReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ortho Dermatologics Reporting Unit [Member]",
        "label": "Ortho Dermatologics Reporting Unit [Member]",
        "terseLabel": "Ortho Dermatologics Reporting Unit"
       }
      }
     },
     "localname": "OrthoDermatologicsReportingUnitMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OrthoDermatologicsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ortho Dermatologics Segment [Member]",
        "label": "Ortho Dermatologics Segment [Member]",
        "terseLabel": "Ortho Dermatologics",
        "verboseLabel": "Ortho Dermatologics"
       }
      }
     },
     "localname": "OrthoDermatologicsSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherAssetsFixedIncomeSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Assets, Fixed Income Securities [Member]",
        "label": "Other Assets, Fixed Income Securities [Member]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsFixedIncomeSecuritiesMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Foreign Currency Adjustment, Net Of Tax",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Foreign Currency Adjustment, Net Of Tax",
        "terseLabel": "Foreign currency impact"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Amortization or Settlement Recognition",
        "label": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Amortization or Settlement Recognition",
        "negatedTerseLabel": "Amortization or settlement recognition of net loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Countries [Member]",
        "label": "Other Countries [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherEquipmentAndLeaseholdImprovementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents other equipment and leasehold improvements.",
        "label": "Other Equipment and Leasehold Improvement [Member]",
        "terseLabel": "Other equipment and leasehold improvements"
       }
      }
     },
     "localname": "OtherEquipmentAndLeaseholdImprovementMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income (Expense), Net",
        "label": "Other Income (Expense), Net",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherIncomeExpenseNet",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_OtherLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents long-term debt obligations not elsewhere enumerated.",
        "label": "Other Long Term Debt [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLongTermDebtMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Performance Based Restricted Stock Units",
        "label": "Other Performance Based Restricted Stock Units [Member]",
        "terseLabel": "Other Performance Based Restricted Stock Units"
       }
      }
     },
     "localname": "OtherPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Revenues [Member]",
        "label": "Other Revenues [Member]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherRevenuesMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OutLicensedTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the rights to receive cash flows under an out-license arrangement (for example, license fees, milestone payments and royalties).",
        "label": "Out Licensed Technology [Member]",
        "terseLabel": "Technology and other",
        "verboseLabel": "Out-licensed technology and other"
       }
      }
     },
     "localname": "OutLicensedTechnologyMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OvertheCounterProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Over the Counter Products [Member]",
        "label": "Over the Counter Products [Member]",
        "terseLabel": "OTC"
       }
      }
     },
     "localname": "OvertheCounterProductsMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PadagisLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Padagis Litigation",
        "label": "Padagis Litigation [Member]",
        "terseLabel": "Padagis Litigation"
       }
      }
     },
     "localname": "PadagisLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PartnerRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to existing arrangements with various other entities, for which the entity provides regulatory, compliance, sales, marketing and distribution functions.",
        "label": "Partner Relationships [Member]",
        "terseLabel": "Partner relationships",
        "verboseLabel": "Partner relationships"
       }
      }
     },
     "localname": "PartnerRelationshipsMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PastDuePeriodForAccountsReceivableToBeNegligible": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the past due period for which accounts receivables are negligible.",
        "label": "Past Due Period for Accounts Receivable to be Negligible",
        "terseLabel": "Past due period for receivables to be negligible (less than)"
       }
      }
     },
     "localname": "PastDuePeriodForAccountsReceivableToBeNegligible",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment For Contingent Consideration Liability, Including Accretion, Operating Activities",
        "label": "Payment For Contingent Consideration Liability, Including Accretion, Operating Activities",
        "negatedTerseLabel": "Payments of contingent consideration adjustments, including accretion"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_PaymentForDebtAmortizationPrepaymentCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment For Debt Amortization Prepayment Cost",
        "label": "Payment For Debt Amortization Prepayment Cost",
        "terseLabel": "Repayment, outstanding debt"
       }
      }
     },
     "localname": "PaymentForDebtAmortizationPrepaymentCost",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pension And Other Postretirement Defined Benefit Plans, Other Assets, Noncurrent",
        "label": "Pension And Other Postretirement Defined Benefit Plans, Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pension and Other Postretirement Defined Benefit Plans, Accrued and Other Current Liabilities",
        "label": "Pension and Other Postretirement Defined Benefit Plans, Accrued and Other Current Liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_PerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents stock awards in the form of performance-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.",
        "label": "Performance Based Restricted Stock Units [Member]",
        "terseLabel": "Performance-Based Restricted Stock Units"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PeriodReceivableOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time the accounts receivable has been outstanding.",
        "label": "Period Receivable Outstanding",
        "terseLabel": "Period net trade receivable balance outstanding (more than)"
       }
      }
     },
     "localname": "PeriodReceivableOutstanding",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_PerrigoIsraelPharmaceuticalsLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Perrigo Israel Pharmaceuticals Litigation",
        "label": "Perrigo Israel Pharmaceuticals Litigation [Member]",
        "terseLabel": "Perrigo Israel Pharmaceuticals Litigation"
       }
      }
     },
     "localname": "PerrigoIsraelPharmaceuticalsLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PharmaceuticalProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical Products [Member]",
        "label": "Pharmaceutical Products [Member]",
        "terseLabel": "Pharmaceuticals"
       }
      }
     },
     "localname": "PharmaceuticalProductsMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PlaintiffsDirectPurchasersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiffs, Direct Purchasers [Member]",
        "label": "Plaintiffs, Direct Purchasers [Member]",
        "terseLabel": "Plaintiffs, Direct Purchasers"
       }
      }
     },
     "localname": "PlaintiffsDirectPurchasersMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the details pertaining to pooled scientific research and experimental development.",
        "label": "Pooled Scientific Research and Experimental Development Expenditures [Member]",
        "terseLabel": "Pooled Scientific Research and Experimental Development"
       }
      }
     },
     "localname": "PooledScientificResearchAndExperimentalDevelopmentExpendituresMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PriceAppreciationCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price Appreciation Credit [Member]",
        "label": "Price Appreciation Credit [Member]",
        "terseLabel": "Price Appreciation Credit"
       }
      }
     },
     "localname": "PriceAppreciationCreditMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ProductBrandsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the rights to non-patented product brands.",
        "label": "Product Brands [Member]",
        "terseLabel": "Product brands",
        "verboseLabel": "Product brands"
       }
      }
     },
     "localname": "ProductBrandsMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RICOClassActionsLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RICO Class Actions Litigation",
        "label": "RICO Class Actions Litigation [Member]",
        "terseLabel": "RICO Class Actions Litigation"
       }
      }
     },
     "localname": "RICOClassActionsLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ROTCPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ROTC Performance-Based Restricted Stock Units [Member]",
        "label": "ROTC Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "ROTC Performance-Based Restricted Stock Units"
       }
      }
     },
     "localname": "ROTCPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate",
        "label": "Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate",
        "terseLabel": "Reporting unit, impairment test, estimated cash flows, discount rate"
       }
      }
     },
     "localname": "ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ReportingUnitImpairmentTestLongTermGrowthRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Unit, Impairment Test, Long-Term Growth Rate",
        "label": "Reporting Unit, Impairment Test, Long-Term Growth Rate",
        "terseLabel": "Reporting unit, impairment test, long-term growth rates"
       }
      }
     },
     "localname": "ReportingUnitImpairmentTestLongTermGrowthRate",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ReportingUnitsExcludingOrthoDermatologicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Units Excluding Ortho Dermatologics",
        "label": "Reporting Units Excluding Ortho Dermatologics [Member]",
        "terseLabel": "Reporting Units Excluding Ortho Dermatologics"
       }
      }
     },
     "localname": "ReportingUnitsExcludingOrthoDermatologicsMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ResearchAndDevelopmentExpenseProductRelated": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense, Product Related",
        "label": "Research And Development Expense, Product Related",
        "terseLabel": "Product related research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseProductRelated",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ResearchAndDevelopmentExpenseQualityAssurance": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense, Quality Assurance",
        "label": "Research And Development Expense, Quality Assurance",
        "terseLabel": "Quality assurance"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseQualityAssurance",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ReserveForChargebacksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Chargebacks [Member]",
        "label": "Reserve For Chargebacks [Member]",
        "terseLabel": "Chargebacks"
       }
      }
     },
     "localname": "ReserveForChargebacksMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForCustomerReturnsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Customer Returns [Member]",
        "label": "Reserve For Customer Returns [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "ReserveForCustomerReturnsMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Discounts And Allowances [Member]",
        "label": "Reserve For Discounts And Allowances [Member]",
        "terseLabel": "Discounts and Allowances"
       }
      }
     },
     "localname": "ReserveForDiscountsAndAllowancesMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForDistributionFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Distribution Fees [Member]",
        "label": "Reserve For Distribution Fees [Member]",
        "terseLabel": "Distribution Fees"
       }
      }
     },
     "localname": "ReserveForDistributionFeesMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForRebatesAdvertisingCreditsPortionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Rebates, Advertising Credits Portion [Member]",
        "label": "Reserve For Rebates, Advertising Credits Portion [Member]",
        "terseLabel": "Rebates, Advertising Credits Portion"
       }
      }
     },
     "localname": "ReserveForRebatesAdvertisingCreditsPortionMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Rebates [Member]",
        "label": "Reserve For Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "ReserveForRebatesMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure",
        "label": "Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure",
        "terseLabel": "Restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_RestrictedCashAndOtherSettlementDepositsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash And Other Settlement Deposits, Current",
        "label": "Restricted Cash And Other Settlement Deposits, Current",
        "terseLabel": "Restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "RestrictedCashAndOtherSettlementDepositsCurrent",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash And Other Settlement Deposits, Current",
        "label": "Restricted Cash And Other Settlement Deposits, Current [Member]",
        "terseLabel": "Restricted Cash and Other Settlement Deposits"
       }
      }
     },
     "localname": "RestrictedCashAndOtherSettlementDepositsCurrentMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RestructuringAndIntegrationCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Integration Costs",
        "label": "Restructuring And Integration Costs [Member]",
        "terseLabel": "Restructuring and Integration Costs"
       }
      }
     },
     "localname": "RestructuringAndIntegrationCostsMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RestructuringChargesAndInitialPublicOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Charges And Initial Public Offering Costs",
        "label": "Restructuring Charges And Initial Public Offering Costs",
        "negatedLabel": "Restructuring, integration, separation and IPO costs",
        "terseLabel": "Restructuring, integration, separation and IPO costs"
       }
      }
     },
     "localname": "RestructuringChargesAndInitialPublicOfferingCosts",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_RevenuePerformanceObligationPaymentTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Payment Terms",
        "label": "Revenue, Performance Obligation, Payment Terms",
        "terseLabel": "Payment terms"
       }
      }
     },
     "localname": "RevenuePerformanceObligationPaymentTerms",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_RevenuesNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net revenues during the period in the normal course of business.",
        "label": "Revenues Net [Member]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesNetMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RevolvingCreditFacilityDueJune2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility Due June 2023 [Member]",
        "label": "Revolving Credit Facility Due June 2023 [Member]",
        "terseLabel": "2023 Revolving Credit Facility Due June 2023"
       }
      }
     },
     "localname": "RevolvingCreditFacilityDueJune2023Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility, New Restated Credit Agreement",
        "label": "Revolving Credit Facility, New Restated Credit Agreement [Member]",
        "terseLabel": "Revolving Credit Facility, New Restated Credit Agreement"
       }
      }
     },
     "localname": "RevolvingCreditFacilityNewRestatedCreditAgreementMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Excluding Amount Recognized Upon Adoption",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Excluding Amount Recognized Upon Adoption",
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Benefit From Income Taxes",
        "label": "SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Benefit From Income Taxes",
        "terseLabel": "Charged to Benefit from income taxes"
       }
      }
     },
     "localname": "SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_SalixSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Salix Segment [Member]",
        "label": "Salix Segment [Member]",
        "terseLabel": "Salix",
        "verboseLabel": "Salix"
       }
      }
     },
     "localname": "SalixSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SandozLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sandoz Litigation [Member]",
        "label": "Sandoz Litigation [Member]",
        "terseLabel": "Sandoz Litigation"
       }
      }
     },
     "localname": "SandozLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ScheduleOfCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Schedule of Commitments [Line Items]",
        "terseLabel": "Other commitments"
       }
      }
     },
     "localname": "ScheduleOfCommitmentsLineItems",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ScheduleOfCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to commitments of the entity during the reporting period.",
        "label": "Schedule of Commitments [Table]",
        "terseLabel": "Schedule of Commitments [Table]"
       }
      }
     },
     "localname": "ScheduleOfCommitmentsTable",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of estimated useful lives of major classes of finite-lived intangible assets.",
        "label": "Schedule of Estimated Useful Lives of Finite Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of estimated useful lives of intangible assets"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of estimated useful lives of major classes of property, plant and equipment.",
        "label": "Schedule of Estimated Useful Lives of Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of estimated useful lives of property, plant and equipment"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_ScheduleOfOtherIncomeAndExpensesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Schedule Of Other Income And Expenses [Table]",
        "label": "Schedule Of Other Income And Expenses [Line Items]",
        "terseLabel": "Schedule Of Other Income And Expenses [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfOtherIncomeAndExpensesLineItems",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ScheduleOfOtherIncomeAndExpensesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Other Income And Expenses [Table]",
        "label": "Schedule Of Other Income And Expenses [Table]",
        "terseLabel": "Schedule Of Other Income And Expenses [Table]"
       }
      }
     },
     "localname": "ScheduleOfOtherIncomeAndExpensesTable",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of equity based payment instruments, excluding stock (or unit) options, including but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share Based Payment Award, Equity Instruments Other than Options Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used to calculate the fair values of performance-based RSUs"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with Acquisition [Table Text Block]",
        "label": "Schedule of Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with Acquisition [Table Text Block]",
        "terseLabel": "Fair value of pension and postretirement benefit plan assets assumed in connection with the Acquisition"
       }
      }
     },
     "localname": "ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_SellingGeneralAndAdministrativeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The allocation (or location) of expense to (in) selling, general and administrative expense.",
        "label": "Selling General and Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpenseMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes4.502023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 4.50%, 2023 [Member]",
        "label": "Senior Notes, 4.50%, 2023 [Member]",
        "terseLabel": "4.50% Senior Unsecured Notes euro-denominated debt Due May 2023"
       }
      }
     },
     "localname": "SeniorNotes4.502023Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes5.625PercentDueDecember2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes 5.625 Percent Due December 2021 [Member]",
        "label": "Senior Notes 5.625 Percent Due December 2021 [Member]",
        "terseLabel": "5.625 % Senior Unsecured Notes due December 2021"
       }
      }
     },
     "localname": "SeniorNotes5.625PercentDueDecember2021Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes500DueFebruary2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 5.00%, Due February 2029",
        "label": "Senior Notes, 5.00%, Due February 2029 [Member]",
        "terseLabel": "5.000% Senior Note Due February 2029"
       }
      }
     },
     "localname": "SeniorNotes500DueFebruary2029Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes500DueJanuary2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.00% Senior Notes Due January 2028 [Member]",
        "label": "Senior Notes, 5.00%, Due January 2028 [Member]",
        "terseLabel": "5.000% Senior Notes Due January 2028"
       }
      }
     },
     "localname": "SeniorNotes500DueJanuary2028Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes525DueFebruary2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 5.25%, Due February 2031",
        "label": "Senior Notes, 5.25%, Due February 2031 [Member]",
        "terseLabel": "5.250% Senior Notes, Due February 2031"
       }
      }
     },
     "localname": "SeniorNotes525DueFebruary2031Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes525DueJanuary2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.25% Senior Notes Due January 2030 [Member]",
        "label": "Senior Notes, 5.25%, Due January 2030 [Member]",
        "terseLabel": "5.250% Senior Notes Due January 2030"
       }
      }
     },
     "localname": "SeniorNotes525DueJanuary2030Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes550DueMarch2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.50% Senior Notes due March 2023 [Member]",
        "label": "Senior Notes, 5.50%, Due March 2023 [Member]",
        "verboseLabel": "5.50% Senior Notes Due March 2023"
       }
      }
     },
     "localname": "SeniorNotes550DueMarch2023Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes6125DueApril2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.125% Senior Notes due April 2025 [Member]",
        "label": "Senior Notes, 6.125%, Due April 2025 [Member]",
        "terseLabel": "6.125% Senior Notes Due April 2025"
       }
      }
     },
     "localname": "SeniorNotes6125DueApril2025Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes625DueFebruary2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 6.25%, Due February 2029",
        "label": "Senior Notes, 6.25%, Due February 2029 [Member]",
        "terseLabel": "6.250% Senior Notes Due February 2029"
       }
      }
     },
     "localname": "SeniorNotes625DueFebruary2029Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes700DueJanuary2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes 7.00 Percent Due January 2028 [Member]",
        "label": "Senior Notes, 7.00%, Due January 2028 [Member]",
        "terseLabel": "7.000 % Senior Notes Due January 2028"
       }
      }
     },
     "localname": "SeniorNotes700DueJanuary2028Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes700DueMarch2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 7.00%, Due March 2024",
        "label": "Senior Notes, 7.00%, Due March 2024 [Member]",
        "terseLabel": "Senior Notes, 7.00%, Due March 2024"
       }
      }
     },
     "localname": "SeniorNotes700DueMarch2024Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes725DueMay2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes 7.25 Percent Due May 2029 [Member]",
        "label": "Senior Notes, 7.25%, Due May 2029 [Member]",
        "terseLabel": "7.250% Senior Notes Due May 2029"
       }
      }
     },
     "localname": "SeniorNotes725DueMay2029Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes850DueJanuary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "8.50% Senior Notes Due January 2027 [Member]",
        "label": "Senior Notes, 8.50%, Due January 2027 [Member]",
        "terseLabel": "8.500% Senior Notes Due January 2027"
       }
      }
     },
     "localname": "SeniorNotes850DueJanuary2027Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes900DueDecember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.00% Senior Notes due December 2025 [Member]",
        "label": "Senior Notes, 9.00%, Due December 2025 [Member]",
        "terseLabel": "9.000% Senior Notes Due December 2025"
       }
      }
     },
     "localname": "SeniorNotes900DueDecember2025Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes925DueApril2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.25% Senior Notes Due April 2026 [Member]",
        "label": "Senior Notes, 9.25%, Due April 2026 [Member]",
        "verboseLabel": "9.250% Senior Notes Due April 2026"
       }
      }
     },
     "localname": "SeniorNotes925DueApril2026Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured4875NotesDueJune2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 4.875% Notes Due June 2028",
        "label": "Senior Secured 4.875% Notes Due June 2028 [Member]",
        "terseLabel": "4.875% Senior Notes Due June 2028"
       }
      }
     },
     "localname": "SeniorSecured4875NotesDueJune2028Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured5.50NotesDueNovember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 5.50% Notes Due November 2025 [Member]",
        "label": "Senior Secured 5.50% Notes Due November 2025 [Member]",
        "terseLabel": "5.500% Senior Notes Due November 2025"
       }
      }
     },
     "localname": "SeniorSecured5.50NotesDueNovember2025Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured5.75NotesDueAugust2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 5.75% Notes Due August 2027 [Member]",
        "label": "Senior Secured 5.75% Notes Due August 2027 [Member]",
        "verboseLabel": "5.750% Senior Notes Due August 2027"
       }
      }
     },
     "localname": "SeniorSecured5.75NotesDueAugust2027Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured6125NotesDueFebruary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 6.125% Notes Due February 2027",
        "label": "Senior Secured 6.125% Notes Due February 2027 [Member]",
        "terseLabel": "Senior Secured 6.125% Notes Due February 2027"
       }
      }
     },
     "localname": "SeniorSecured6125NotesDueFebruary2027Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Credit Facilities [Member]",
        "label": "Senior Secured Credit Facilities [Member]",
        "terseLabel": "Senior Credit Facilities"
       }
      }
     },
     "localname": "SeniorSecuredCreditFacilitiesMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Notes 6.50 Percent Due March 2022 [Member]",
        "label": "Senior Secured Notes 6.50 Percent Due March 2022 [Member]",
        "terseLabel": "6.50% Senior Notes Due March 2022"
       }
      }
     },
     "localname": "SeniorSecuredNotes6.50PercentDueMarch2022Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Notes 7.00 Percent Due March 2024 [Member]",
        "label": "Senior Secured Notes 7.00 Percent Due March 2024 [Member]",
        "terseLabel": "7.000 % Senior Notes Due March 2024"
       }
      }
     },
     "localname": "SeniorSecuredNotes7.00PercentDueMarch2024Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Notes And Senior Unsecured Notes [Member]",
        "label": "Senior Secured Notes And Senior Unsecured Notes [Member]",
        "terseLabel": "Senior Secured and Unsecured Notes"
       }
      }
     },
     "localname": "SeniorSecuredNotesAndSeniorUnsecuredNotesMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredTermCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Senior Secured Credit Facilities which includes the Revolving Credit Facility, New Term Loan A Facility, and the Delayed Draw Facility.",
        "label": "Senior Secured Term Credit Facilities [Member]",
        "terseLabel": "Senior Secured Credit Facilities"
       }
      }
     },
     "localname": "SeniorSecuredTermCreditFacilitiesMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorUnsecuredNotesDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due 2023 [Member]",
        "label": "Senior Unsecured Notes Due 2023 [Member]",
        "terseLabel": "Senior Unsecured Notes due 2023"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDue2023Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity Analysis, Impact Of 1 Percent Change In Estimated Return Rate, Income (Loss) Before Tax",
        "label": "Sensitivity Analysis, Impact Of 1 Percent Change In Estimated Return Rate, Income (Loss) Before Tax",
        "terseLabel": "1% change in estimated return rates, Impact on pre-tax earnings"
       }
      }
     },
     "localname": "SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity Analysis, Impact Of 1 Percent Change In Volume Of Product Sold Through To Medicaid Plan Participants, Income (Loss) Before Tax",
        "label": "Sensitivity Analysis, Impact Of 1 Percent Change In Volume Of Product Sold Through To Medicaid Plan Participants, Income (Loss) Before Tax",
        "terseLabel": "1% change in volume of product sold through to Medicaid plan participants, Impact on pre-tax earnings"
       }
      }
     },
     "localname": "SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_SeparationAndInitialPublicOfferingCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separation And Initial Public Offering Costs",
        "label": "Separation And Initial Public Offering Costs [Member]",
        "terseLabel": "Separation and IPO Costs"
       }
      }
     },
     "localname": "SeparationAndInitialPublicOfferingCostsMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum number of common shares that could be issued upon vesting of outstanding awards.",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award, Number of Shares that could be Issued",
        "terseLabel": "Maximum common shares issuable upon vesting (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award, Options Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total fair value of stock options vested during the period.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options Vested in Period, Total Fair Value",
        "terseLabel": "Fair value of stock options vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of stock options that will vest in the future period.",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award, Options Vested Percentage",
        "terseLabel": "Percentage of stock options that will vest on each of the first, second, third and fourth anniversaries from the date of grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted- Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant",
        "terseLabel": "Aggregate fair market value on awards granted during any calendar year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award Options Weighted Average Exercise Price [Roll Forward]",
        "terseLabel": "Weighted- Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shower To Shower Product Liability Litigation Alleging Caused Ovarian Cancer Mesothelioma Or Breast Cancer",
        "label": "Shower To Shower Product Liability Litigation Alleging Caused Ovarian Cancer Mesothelioma Or Breast Cancer [Member]",
        "terseLabel": "Shower To Shower Product Liability Litigation Alleging Caused Ovarian Cancer Mesothelioma Or Breast Cancer"
       }
      }
     },
     "localname": "ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ShowertoShowerProductLiabilityLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shower to Shower Product Liability Litigation [Member]",
        "label": "Shower to Shower Product Liability Litigation [Member]",
        "terseLabel": "Shower to Shower Product Liability Litigation"
       }
      }
     },
     "localname": "ShowertoShowerProductLiabilityLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Slayback Pharma LLC And Slayback Pharma India LLP Litigation",
        "label": "Slayback Pharma LLC And Slayback Pharma India LLP Litigation [Member]",
        "terseLabel": "Slayback Pharma LLC And Slayback Pharma India LLP Litigation"
       }
      }
     },
     "localname": "SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc. [Member]",
        "label": "Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc. [Member]",
        "terseLabel": "Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc."
       }
      }
     },
     "localname": "SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Research And Development Expense [Table Text Block]",
        "label": "Summary Of Research And Development Expense [Table Text Block]",
        "terseLabel": "Summary of research and development"
       }
      }
     },
     "localname": "SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Valuation And Qualifying Accounts [Table Text Block]",
        "label": "Summary Of Valuation And Qualifying Accounts [Table Text Block]",
        "terseLabel": "Summary of variable consideration provisions"
       }
      }
     },
     "localname": "SummaryOfValuationAndQualifyingAccountsTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_SynergyPharmaceuticalsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Synergy Pharmaceuticals Inc. [Member]",
        "label": "Synergy Pharmaceuticals Inc. [Member]",
        "terseLabel": "Synergy"
       }
      }
     },
     "localname": "SynergyPharmaceuticalsInc.Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TSRPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TSR Performance-Based Restricted Stock Units [Member]",
        "label": "TSR Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "TSR Performance-Based Restricted Stock Units"
       }
      }
     },
     "localname": "TSRPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TaxBenefitRecognitionMeasurementPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Benefit Recognition, Measurement Percentage",
        "label": "Tax Benefit Recognition, Measurement Percentage",
        "terseLabel": "Tax benefit recognition, measurement percentage (greater than)"
       }
      }
     },
     "localname": "TaxBenefitRecognitionMeasurementPercentage",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_TaxYear2005ThroughTaxYear2009Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Year 2005 Through Tax Year 2009",
        "label": "Tax Year 2005 Through Tax Year 2009 [Member]",
        "terseLabel": "Tax Year 2005 through Tax Year 2009"
       }
      }
     },
     "localname": "TaxYear2005ThroughTaxYear2009Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TaxYear2015AndTaxYear2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Year 2015 And Tax Year 2016",
        "label": "Tax Year 2015 And Tax Year 2016 [Member]",
        "terseLabel": "Tax Year 2015 and Tax Year 2016"
       }
      }
     },
     "localname": "TaxYear2015AndTaxYear2016Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueJune2025AndNovember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility Due June 2025 And November 2025",
        "label": "Term Loan B Facility Due June 2025 And November 2025 [Member]",
        "terseLabel": "Term Loan B Facility Due June 2025 and November 2025"
       }
      }
     },
     "localname": "TermLoanBFacilityDueJune2025AndNovember2025Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueJune2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility Due June 2025 [Member]",
        "label": "Term Loan B Facility Due June 2025 [Member]",
        "terseLabel": "Term Loan B Facility Due June 2025",
        "verboseLabel": "Term Loan B Facility Due June 2025"
       }
      }
     },
     "localname": "TermLoanBFacilityDueJune2025Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueNovember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility Due November 2025 [Member]",
        "label": "Term Loan B Facility Due November 2025 [Member]",
        "terseLabel": "Term Loan B Facility Due November 2025"
       }
      }
     },
     "localname": "TermLoanBFacilityDueNovember2025Member",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityNewRestatedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility, New Restated Credit Agreement",
        "label": "Term Loan B Facility, New Restated Credit Agreement [Member]",
        "terseLabel": "Term Loan B Facility, New Restated Credit Agreement"
       }
      }
     },
     "localname": "TermLoanBFacilityNewRestatedCreditAgreementMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ThreeLargestUSWholesalerCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the three largest U.S. wholesaler customers.",
        "label": "Three Largest US Wholesaler Customers [Member]",
        "terseLabel": "Three largest U.S. wholesaler customers"
       }
      }
     },
     "localname": "ThreeLargestUSWholesalerCustomersMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TimeBasedRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents stock awards in the form of time-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.",
        "label": "Time Based RSU [Member]",
        "terseLabel": "Time-Based RSUs"
       }
      }
     },
     "localname": "TimeBasedRSUMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TradeReceivableNetPortionPastDue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade Receivable, Net, Portion Past Due",
        "label": "Trade Receivable, Net, Portion Past Due",
        "terseLabel": "Portion of net trade receivables that is past due"
       }
      }
     },
     "localname": "TradeReceivableNetPortionPastDue",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_U.S.BroadMarketMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. Broad Market [Member]",
        "label": "U.S. Broad Market [Member]",
        "terseLabel": "U.S. broad market"
       }
      }
     },
     "localname": "U.S.BroadMarketMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unclaimed tax credits and research and development credits.",
        "label": "Unclaimed Tax Credits and Research and Development Credits",
        "terseLabel": "Unclaimed investment tax credits and research and development credits"
       }
      }
     },
     "localname": "UnclaimedTaxCreditsAndResearchAndDevelopmentCredits",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_UnitedStatesandPuertoRicoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United States and Puerto Rico [Member]",
        "label": "United States and Puerto Rico [Member]",
        "terseLabel": "U.S. and Puerto Rico"
       }
      }
     },
     "localname": "UnitedStatesandPuertoRicoMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.",
        "label": "Unrecognized Tax Benefits, Including Interest and Penalties",
        "terseLabel": "Unrecognized tax benefits including interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncludingInterestAndPenalties",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Net Decrease Resulting From Prior Period Tax Positions",
        "label": "Unrecognized Tax Benefits, Net Decrease Resulting From Prior Period Tax Positions",
        "terseLabel": "Unrecognized tax benefits, net decrease for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Net Increase Resulting from Current Period Tax Positions",
        "label": "Unrecognized Tax Benefits, Net Increase Resulting From Current Period Tax Positions",
        "terseLabel": "Unrecognized tax benefits, net increase for tax positions of current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Net Increase Resulting From Prior Period Tax Positions",
        "label": "Unrecognized Tax Benefits, Net Increase Resulting From Prior Period Tax Positions",
        "terseLabel": "Unrecognized tax benefits, net increase for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_UnutilizedITInfrastructureImprovementProjectMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unutilized IT Infrastructure Improvement Project",
        "label": "Unutilized IT Infrastructure Improvement Project [Member]",
        "terseLabel": "Unutilized IT Infrastructure Improvement Project"
       }
      }
     },
     "localname": "UnutilizedITInfrastructureImprovementProjectMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ValeantUSSecuritiesLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valeant US Securities Litigation [Member]",
        "label": "Valeant US Securities Litigation [Member]",
        "terseLabel": "Valeant US Securities Litigation",
        "verboseLabel": "Valeant US Securities Litigation"
       }
      }
     },
     "localname": "ValeantUSSecuritiesLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ViolationofCanadianProvincialSecuritiesLegislationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Violation of Canadian Provincial Securities Legislation [Member]",
        "label": "Violation of Canadian Provincial Securities Legislation [Member]",
        "terseLabel": "Violation of Canadian Provincial Securities Legislation"
       }
      }
     },
     "localname": "ViolationofCanadianProvincialSecuritiesLegislationMember",
     "nsuri": "http://www.bauschhealth.com/20211231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada",
        "verboseLabel": "Canada"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China",
        "verboseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY",
        "terseLabel": "Germany",
        "verboseLabel": "Germany"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_EG": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EGYPT",
        "terseLabel": "Egypt"
       }
      }
     },
     "localname": "EG",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_ES": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SPAIN",
        "terseLabel": "Spain"
       }
      }
     },
     "localname": "ES",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_FR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FRANCE",
        "terseLabel": "France",
        "verboseLabel": "France"
       }
      }
     },
     "localname": "FR",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_GB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "localname": "GB",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IRELAND",
        "terseLabel": "Ireland"
       }
      }
     },
     "localname": "IE",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ITALY",
        "terseLabel": "Italy"
       }
      }
     },
     "localname": "IT",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_MX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MEXICO",
        "terseLabel": "Mexico"
       }
      }
     },
     "localname": "MX",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_NL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NETHERLANDS",
        "terseLabel": "Netherlands"
       }
      }
     },
     "localname": "NL",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_PL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "POLAND",
        "terseLabel": "Poland"
       }
      }
     },
     "localname": "PL",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_RS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SERBIA",
        "terseLabel": "Serbia"
       }
      }
     },
     "localname": "RS",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_RU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RUSSIAN FEDERATION",
        "terseLabel": "Russia"
       }
      }
     },
     "localname": "RU",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r932",
      "r933",
      "r934"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/AUDITINFORMATION"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r932",
      "r933",
      "r934"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/AUDITINFORMATION"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r932",
      "r933",
      "r934"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/AUDITINFORMATION"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r932",
      "r933",
      "r934"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r935"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r930"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r936"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Smaller Reporting Company"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r937"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r932",
      "r933",
      "r934"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r928"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r931"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r173",
      "r235",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r261",
      "r265",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r392",
      "r394",
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r173",
      "r235",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r261",
      "r265",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r392",
      "r394",
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r84",
      "r86",
      "r170",
      "r171",
      "r403",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r185",
      "r193",
      "r199",
      "r290",
      "r602",
      "r603",
      "r604",
      "r652",
      "r653",
      "r737",
      "r740",
      "r742",
      "r743",
      "r940"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r185",
      "r193",
      "r199",
      "r290",
      "r602",
      "r603",
      "r604",
      "r652",
      "r653",
      "r737",
      "r740",
      "r742",
      "r743",
      "r940"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r185",
      "r193",
      "r199",
      "r290",
      "r602",
      "r603",
      "r604",
      "r652",
      "r653",
      "r737",
      "r740",
      "r742",
      "r743",
      "r940"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r273",
      "r454",
      "r457",
      "r892"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Major Customers [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r402",
      "r437",
      "r553",
      "r559",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r832",
      "r889",
      "r893",
      "r925",
      "r926"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r402",
      "r437",
      "r553",
      "r559",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r832",
      "r889",
      "r893",
      "r925",
      "r926"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r273",
      "r454",
      "r457",
      "r892"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Name of Major Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r268",
      "r454",
      "r455",
      "r837",
      "r888",
      "r890"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r268",
      "r454",
      "r455",
      "r837",
      "r888",
      "r890"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r402",
      "r437",
      "r489",
      "r553",
      "r559",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r832",
      "r889",
      "r893",
      "r925",
      "r926"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r402",
      "r437",
      "r489",
      "r553",
      "r559",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r832",
      "r889",
      "r893",
      "r925",
      "r926"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r85",
      "r86",
      "r170",
      "r171",
      "r403",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r194",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario, Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r194",
      "r199",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r269",
      "r270",
      "r454",
      "r456",
      "r891",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r269",
      "r270",
      "r454",
      "r456",
      "r891",
      "r909",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r194",
      "r199",
      "r368",
      "r554",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r275",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA-BC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BRITISH COLUMBIA",
        "terseLabel": "British Columbia"
       }
      }
     },
     "localname": "CA-BC",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA-QC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "QUEBEC",
        "terseLabel": "Quebec"
       }
      }
     },
     "localname": "CA-QC",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW JERSEY",
        "terseLabel": "New Jersey"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r186",
      "r187",
      "r188",
      "r189",
      "r281",
      "r282",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r383",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r652",
      "r653",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r813",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "ACCRUED AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r60",
      "r817"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r910"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Trade receivables"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r23",
      "r41",
      "r276",
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Net trade receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r27",
      "r28",
      "r64"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Employee compensation and benefit costs"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r35",
      "r847",
      "r870"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r93",
      "r99",
      "r109",
      "r110",
      "r111",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Pension adjustment, net of tax"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r57",
      "r340"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r44",
      "r96",
      "r98",
      "r99",
      "r873",
      "r901",
      "r905"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r109",
      "r110",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r95",
      "r99",
      "r109",
      "r110",
      "r111",
      "r182",
      "r183",
      "r184",
      "r697",
      "r896",
      "r897",
      "r942"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "verboseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r90",
      "r99",
      "r109",
      "r110",
      "r111",
      "r697",
      "r780",
      "r781",
      "r782",
      "r783",
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r602",
      "r603",
      "r604",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Share-based awards tax withholding"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r561",
      "r563",
      "r608",
      "r609"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r612"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expenses"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r279",
      "r293",
      "r294",
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Recovery",
        "terseLabel": "Recoveries"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "negatedTerseLabel": "Write-offs"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r153",
      "r422",
      "r432",
      "r433",
      "r793"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization and write-off of debt discounts and debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Excluded from computation of diluted earnings per share, effect anti-dilutive (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "verboseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r153",
      "r335"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "negatedLabel": "Asset impairments, including loss on assets held for sale",
        "terseLabel": "Asset impairments, including loss on assets held for sale",
        "verboseLabel": "Asset impairments, including loss on assets held for sale"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r165",
      "r243",
      "r256",
      "r263",
      "r286",
      "r384",
      "r385",
      "r386",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r395",
      "r397",
      "r398",
      "r691",
      "r698",
      "r765",
      "r815",
      "r817",
      "r845",
      "r869"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets reclassified, held and used",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r24",
      "r25",
      "r79",
      "r165",
      "r286",
      "r384",
      "r385",
      "r386",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r395",
      "r397",
      "r398",
      "r691",
      "r698",
      "r765",
      "r815",
      "r817"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure": {
     "auth_ref": [
      "r745"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of assets classified as held for sale.",
        "label": "Assets Held-for-sale, Long Lived, Fair Value Disclosure",
        "terseLabel": "Non-current assets held for sale"
       }
      }
     },
     "localname": "AssetsHeldForSaleLongLivedFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]",
        "terseLabel": "Prepaid expenses and other current assets:"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]",
        "terseLabel": "Other non-current assets:"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AustralianTaxationOfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Australia.",
        "label": "Australian Taxation Office [Member]",
        "terseLabel": "Australia",
        "verboseLabel": "Australian Taxation Office"
       }
      }
     },
     "localname": "AustralianTaxationOfficeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r565",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r710",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings and improvements",
        "verboseLabel": "Buildings and improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r548",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r548",
      "r555",
      "r671",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r669",
      "r670"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Pro-forma revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r667"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r678",
      "r679"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details": {
       "order": 1.0,
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "verboseLabel": "Current portion"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Fair value, contingent consideration obligations, discount rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r678",
      "r679"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details": {
       "order": 2.0,
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Non-current portion"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r668"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Revenue of acquiree since acquisition date"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r674"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r674"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r674"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedTerseLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r674"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Product brand intangible assets (estimated useful life 7 years)"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r673",
      "r674"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r673",
      "r674"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total identifiable net assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r674"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Total fair value of consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions and Acquisition-Related Contingent Consideration"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CanadaRevenueAgencyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Canada.",
        "label": "Canada Revenue Agency [Member]",
        "terseLabel": "Canada Revenue Agency"
       }
      }
     },
     "localname": "CanadaRevenueAgencyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r21",
      "r54",
      "r155"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r31",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r146",
      "r778"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in Cash and cash equivalents and Restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "SUPPLEMENTAL CASH FLOW DISCLOSURES"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.",
        "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]",
        "terseLabel": "Components of the change in projected benefit obligations, change in plan assets and funded status"
       }
      }
     },
     "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r69",
      "r367",
      "r853",
      "r879"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Notes\u00a020 and 21)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r377",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r380",
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r182",
      "r183",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r40",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r40",
      "r817"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common shares, no par value, unlimited shares authorized, 359,405,748 and 355,422,347\u00a0issued and outstanding at December\u00a031, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r104",
      "r106",
      "r107",
      "r119",
      "r859",
      "r884"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r104",
      "r106",
      "r118",
      "r689",
      "r690",
      "r702",
      "r858",
      "r883"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Comprehensive income attributable to noncontrolling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r104",
      "r106",
      "r117",
      "r688",
      "r702",
      "r857",
      "r882"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r116",
      "r129",
      "r856",
      "r881"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r224",
      "r225",
      "r273",
      "r762",
      "r763",
      "r910"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r224",
      "r225",
      "r273",
      "r762",
      "r763",
      "r907",
      "r910"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r224",
      "r225",
      "r273",
      "r762",
      "r763",
      "r907",
      "r910"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r218",
      "r866"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r224",
      "r225",
      "r273",
      "r762",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r221",
      "r224",
      "r225",
      "r226",
      "r762",
      "r764",
      "r910"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r224",
      "r225",
      "r273",
      "r762",
      "r763",
      "r910"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualRightsMember": {
     "auth_ref": [
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements).",
        "label": "Contractual Rights [Member]",
        "terseLabel": "Product rights/patents",
        "verboseLabel": "Product rights/patents"
       }
      }
     },
     "localname": "ContractualRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r265",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r124",
      "r837"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total Expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Credit concentration"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrencySwapMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.",
        "label": "Currency Swap [Member]",
        "terseLabel": "Cross-currency swaps",
        "verboseLabel": "Cross-currency swaps"
       }
      }
     },
     "localname": "CurrencySwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r166",
      "r646",
      "r656"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "negatedTerseLabel": "Domestic"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r166",
      "r646"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "negatedTerseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r166",
      "r646",
      "r656",
      "r658"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r222",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer concentration"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r163",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r416",
      "r423",
      "r424",
      "r426",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "FINANCING ARRANGEMENTS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r164",
      "r173",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r412",
      "r413",
      "r414",
      "r415",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r430",
      "r431",
      "r432",
      "r433",
      "r794",
      "r846",
      "r850",
      "r868"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable interest rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r36",
      "r427",
      "r850",
      "r868"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal Amount",
        "totalLabel": "Total gross maturities"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r399",
      "r430",
      "r431",
      "r792",
      "r794",
      "r795"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount",
        "verboseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r414",
      "r430",
      "r431",
      "r761"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r66",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate",
        "verboseLabel": "Stated interest rate on debt (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "verboseLabel": "Long-term debt, net of unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r67",
      "r164",
      "r173",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r412",
      "r413",
      "r414",
      "r415",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r430",
      "r431",
      "r432",
      "r433",
      "r794"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r864"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r864"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r864"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r864"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r864"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price percentage (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Maximum percentage of principal amount that can be redeemed"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Repurchased face amount",
        "verboseLabel": "Repurchased aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r67",
      "r164",
      "r173",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r412",
      "r413",
      "r414",
      "r415",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r425",
      "r430",
      "r431",
      "r432",
      "r433",
      "r440",
      "r441",
      "r442",
      "r443",
      "r791",
      "r792",
      "r794",
      "r795",
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r412",
      "r791",
      "r795"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Unamortized discounts"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r626"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Possible decrease in unrecognized tax benefits realized in next twelve months"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r166",
      "r647",
      "r656"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Domestic"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r166",
      "r647",
      "r656"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r619",
      "r620"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r153",
      "r166",
      "r647",
      "r656",
      "r657",
      "r658"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r37",
      "r38",
      "r637",
      "r848",
      "r867"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r619",
      "r620"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetDomain": {
     "auth_ref": [
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.",
        "label": "Deferred Tax Asset [Domain]",
        "terseLabel": "Deferred Tax Asset [Domain]"
       }
      }
     },
     "localname": "DeferredTaxAssetDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r644",
      "r645"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r638"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r640"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r640"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r644",
      "r645"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r643",
      "r644",
      "r645"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r644",
      "r645"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r644",
      "r645"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Provisions"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r639"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance",
        "terseLabel": "Valuation allowance against deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r644",
      "r645"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": {
     "auth_ref": [
      "r644"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.",
        "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings",
        "terseLabel": "Outside basis differences"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains": {
     "auth_ref": [
      "r644",
      "r645"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on foreign currency transactions.",
        "label": "Deferred Tax Liabilities, Unrealized Currency Transaction Gains",
        "terseLabel": "Unrealized FX on U.S. dollar debt and other financing cost"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax": {
     "auth_ref": [
      "r99",
      "r510"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax",
        "terseLabel": "Unrecognized actuarial losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax": {
     "auth_ref": [
      "r99",
      "r510"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax",
        "negatedLabel": "Unrecognized prior service credits"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "auth_ref": [
      "r479",
      "r539"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "terseLabel": "Actual return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "negatedTerseLabel": "Actuarial (gain) losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r464",
      "r505",
      "r533",
      "r539",
      "r540"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedTerseLabel": "Amortization of net loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r464",
      "r506",
      "r534",
      "r539",
      "r540"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of prior service credit"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]",
        "terseLabel": "Recognized as:"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "terseLabel": "Rate of compensation increase"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate",
        "terseLabel": "Interest crediting rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": {
     "auth_ref": [
      "r514",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets",
        "terseLabel": "Percentage of expected return on plan assets",
        "verboseLabel": "Expected rate of return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase",
        "terseLabel": "Rate of compensation increase"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average interest crediting rate used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate",
        "terseLabel": "Interest crediting rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "periodEndLabel": "Projected benefit obligation, end of year",
        "periodStartLabel": "Projected benefit obligation, beginning of year"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "auth_ref": [
      "r473",
      "r545"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "negatedLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "auth_ref": [
      "r489",
      "r490",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r517",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested.",
        "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "terseLabel": "Change in Projected Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "terseLabel": "Change in Plan Assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r481",
      "r490",
      "r492",
      "r537",
      "r539",
      "r540"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Company contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": {
     "auth_ref": [
      "r490",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities [Member]",
        "terseLabel": "Equity securities",
        "verboseLabel": "Equity securities:"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "auth_ref": [
      "r499"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "terseLabel": "2027-2031"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "auth_ref": [
      "r499"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "auth_ref": [
      "r499"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "auth_ref": [
      "r499"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "auth_ref": [
      "r499"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "auth_ref": [
      "r499"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": {
     "auth_ref": [
      "r500",
      "r540"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year",
        "terseLabel": "Estimated company contributions in next fiscal year"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r464",
      "r504",
      "r532",
      "r539",
      "r540"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedTerseLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "auth_ref": [
      "r478",
      "r490",
      "r492",
      "r493",
      "r539"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "periodEndLabel": "Fair value of plan assets, end of year",
        "periodStartLabel": "Fair value of plan assets, beginning of year",
        "terseLabel": "Fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": {
     "auth_ref": [
      "r472"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "auth_ref": [
      "r462",
      "r487",
      "r539"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "totalLabel": "Funded status, end of year"
       }
      }
     },
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r464",
      "r469",
      "r503",
      "r531",
      "r539",
      "r540"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r501",
      "r529",
      "r539",
      "r540"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic (benefit) cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanOtherCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of defined benefit plan cost (credit), classified as other.",
        "label": "Defined Benefit Plan, Other Cost (Credit)",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DefinedBenefitPlanOtherCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]",
        "terseLabel": "Underfunded plans having accumulated benefit obligations exceeding the fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": {
     "auth_ref": [
      "r525",
      "r526",
      "r539"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation",
        "terseLabel": "Accumulated benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": {
     "auth_ref": [
      "r525",
      "r526",
      "r539"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "terseLabel": "Fair value of plan assets",
        "verboseLabel": "Underfunded pension benefit plans"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": {
     "auth_ref": [
      "r525"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation",
        "terseLabel": "Projected benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "auth_ref": [
      "r483",
      "r545"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "negatedTerseLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r480"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": {
     "auth_ref": [
      "r489",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.",
        "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage",
        "terseLabel": "Defined benefit plan, percentage of actual plan asset allocations"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": {
     "auth_ref": [
      "r465",
      "r508",
      "r536"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement",
        "negatedTerseLabel": "Settlement loss recognized"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r467",
      "r502",
      "r530",
      "r539",
      "r540"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.",
        "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": {
     "auth_ref": [
      "r486"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.",
        "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]",
        "terseLabel": "For Determining Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]",
        "terseLabel": "For Determining Net Periodic (Benefit) Cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r523",
      "r524",
      "r527",
      "r528",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r546"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Contributions recognized"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r153",
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r153",
      "r338"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization of intangible assets"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossLiability": {
     "auth_ref": [
      "r81",
      "r88",
      "r712"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Asset, Fair Value, Gross Liability",
        "terseLabel": "Accrued and other current liabilities",
        "verboseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r82",
      "r83",
      "r86",
      "r761"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Foreign currency exchange contracts"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r80",
      "r86",
      "r87",
      "r712",
      "r831"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r86",
      "r711",
      "r713",
      "r719",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r708",
      "r711",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r708",
      "r711",
      "r719",
      "r725",
      "r726",
      "r729",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r718",
      "r720"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Gain (loss) related to changes in fair value"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss": {
     "auth_ref": [
      "r718",
      "r720"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized loss of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Loss",
        "negatedTerseLabel": "Loss related to settlements"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r82",
      "r83",
      "r86",
      "r761"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative liabilities",
        "totalLabel": "Net fair value"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r704",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Aggregate notional amounts"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r172",
      "r703",
      "r705",
      "r708",
      "r709",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Derivative Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).",
        "label": "Disclosure of Long Lived Assets Held-for-sale [Table Text Block]",
        "terseLabel": "Schedule of carrying amounts of assets and liabilities held for sale"
       }
      }
     },
     "localname": "DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r336",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r333",
      "r336",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that either has been sold or is classified as held-for-sale. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r17",
      "r333",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]",
        "terseLabel": "Held For Sale"
       }
      }
     },
     "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r344"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r337",
      "r344"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r344"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as deferred tax assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Assets",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r344"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r332",
      "r344"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent",
        "terseLabel": "Goodwill and Intangible assets, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r337",
      "r344"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory, Current",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r337",
      "r344"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current",
        "totalLabel": "Total Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r337",
      "r344"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current",
        "totalLabel": "Total Accrued and other current liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r332",
      "r344"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent",
        "totalLabel": "Total Other non-current assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r332",
      "r344"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent",
        "totalLabel": "Total Other non-current liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r337",
      "r344"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r332",
      "r344"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r548",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "United States - Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r547",
      "r551",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r120",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r200",
      "r202",
      "r204",
      "r205",
      "r206",
      "r210",
      "r211",
      "r743",
      "r744",
      "r860",
      "r885"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic loss per share attributable to Bausch Health Companies Inc. (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r120",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r202",
      "r204",
      "r205",
      "r206",
      "r210",
      "r211",
      "r743",
      "r744",
      "r860",
      "r885"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r207",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss Per Share Attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r778"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r168",
      "r622",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Expected Canadian statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Components and classification of share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r595"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Remaining unrecognized compensation expense related to non-vested awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "verboseLabel": "Segment reporting information"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r109",
      "r110",
      "r111",
      "r182",
      "r183",
      "r184",
      "r187",
      "r196",
      "r198",
      "r214",
      "r290",
      "r439",
      "r444",
      "r602",
      "r603",
      "r604",
      "r652",
      "r653",
      "r742",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r785",
      "r896",
      "r897",
      "r898",
      "r942"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EurodollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.",
        "label": "Eurodollar [Member]",
        "terseLabel": "Eurodollar"
       }
      }
     },
     "localname": "EurodollarMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "verboseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r745",
      "r746",
      "r747",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r745",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Schedule of assets and liabilities measured at fair value on a non-recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r414",
      "r430",
      "r431",
      "r490",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r539",
      "r746",
      "r822",
      "r823",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r745",
      "r746",
      "r749",
      "r750",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r414",
      "r490",
      "r492",
      "r497",
      "r539",
      "r746",
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r414",
      "r430",
      "r431",
      "r490",
      "r492",
      "r497",
      "r539",
      "r746",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "netLabel": "Level 2",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r414",
      "r430",
      "r431",
      "r490",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r539",
      "r746",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r751",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r752"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Acquisition-related contingent consideration adjustments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "auth_ref": [
      "r753"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "verboseLabel": "Foreign currency translation adjustment included in other comprehensive loss"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r754"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Payments / Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r751"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r414",
      "r430",
      "r431",
      "r490",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r539",
      "r822",
      "r823",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r745",
      "r746",
      "r749",
      "r750",
      "r755",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Non-recurring basis",
        "verboseLabel": "Fair Value, Nonrecurring"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r756",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Net Asset (Liability) [Abstract]",
        "terseLabel": "Other non-current assets:"
       }
      }
     },
     "localname": "FairValueNetAssetLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r759",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "terseLabel": "Federal Funds Effective Swap Rate"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r797",
      "r810"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for charging off uncollectible financing receivables, including, but not limited to, factors and methodologies used in estimating the allowance for credit loss.",
        "label": "Financing Receivable, Allowance for Credit Losses, Policy for Uncollectible Amounts [Policy Text Block]",
        "terseLabel": "Allowance for Credit Losses"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Weighted- Average Remaining Useful Lives (Years)",
        "verboseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization and Impairments"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "netLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r318",
      "r321",
      "r324",
      "r327",
      "r838",
      "r842"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Estimated aggregate amortization expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r324",
      "r842"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r318",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r324",
      "r838"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FixedIncomeSecuritiesMember": {
     "auth_ref": [
      "r490",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment that provides a return in the form of fixed periodic payments and eventual return of principal at maturity.",
        "label": "Fixed Income Securities [Member]",
        "terseLabel": "Fixed income securities",
        "verboseLabel": "Fixed income securities:"
       }
      }
     },
     "localname": "FixedIncomeSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Ireland"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r774",
      "r775",
      "r776",
      "r777"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r154",
      "r776",
      "r777"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Foreign exchange loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r86",
      "r490",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign currency exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations",
        "negatedTerseLabel": "Expected benefit from income taxes at Canadian statutory rate"
       }
      }
     },
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r547",
      "r551",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "Non-U.S. Plans"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r153",
      "r336",
      "r342"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedLabel": "Gain on disposal of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedTerseLabel": "Net gain on sales of assets",
        "terseLabel": "Milestone achievement, included in net gain (loss) on other sales of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedLabel": "Litigation and other matters"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r153",
      "r434",
      "r435"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt",
        "verboseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r303",
      "r305",
      "r817",
      "r844"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "verboseLabel": "Acquisition of certain assets of Synergy"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLE ASSETS AND GOODWILL"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r306",
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment charges to date"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r153",
      "r304",
      "r309",
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedTerseLabel": "Impairment",
        "terseLabel": "Goodwill impairments"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Realignment of segment goodwill"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Change in the carrying amount of goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "negatedTerseLabel": "Goodwill reclassified to assets held for sale"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r708",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r153",
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "verboseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r153",
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Impairment of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r153",
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "verboseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r331",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r58",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r167",
      "r659"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r114",
      "r243",
      "r255",
      "r259",
      "r262",
      "r265",
      "r843",
      "r854",
      "r861",
      "r886"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before benefit from income taxes",
        "totalLabel": "Loss before benefit from income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r167",
      "r659"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Components of loss before benefit of income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r548",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "verboseLabel": "Assets Held For Sale"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r7",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r16",
      "r18",
      "r19",
      "r20",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Schedule of Significant Acquisitions and Disposals [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r343",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r628",
      "r634",
      "r636",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r168",
      "r623",
      "r635",
      "r642",
      "r654",
      "r661",
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss": {
     "auth_ref": [
      "r626"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated amount of loss resulting from an adverse tax position.",
        "label": "Income Tax Examination, Estimate of Possible Loss",
        "terseLabel": "Estimate of possible loss, income tax examination (up to)"
       }
      }
     },
     "localname": "IncomeTaxExaminationEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear": {
     "auth_ref": [
      "r634"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount the liability recorded for the income tax examination increased or decreased in the current year/accounting period.",
        "label": "Income Tax Examination, Increase (Decrease) in Liability from Prior Year",
        "negatedTerseLabel": "Reduction in NOLs"
       }
      }
     },
     "localname": "IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r169",
      "r197",
      "r198",
      "r241",
      "r621",
      "r655",
      "r662",
      "r887"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Benefit from income taxes",
        "negatedTotalLabel": "(Provision for) benefit from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Benefit from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r108",
      "r617",
      "r618",
      "r635",
      "r636",
      "r641",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r622"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "negatedTerseLabel": "Change in valuation allowance on Canadian deferred tax assets and tax rate changes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r622"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "negatedTerseLabel": "Foreign tax rate differences"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r622"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount",
        "negatedTerseLabel": "Non-deductible portion of Goodwill impairments"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r622"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "negatedTerseLabel": "Non-deductible amount of share-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r622"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r148",
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "verboseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r319",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r319",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r160",
      "r323",
      "r834",
      "r835",
      "r836",
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r317",
      "r322"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible Assets, Net (Excluding Goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndDebtExpense": {
     "auth_ref": [
      "r790"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity.",
        "label": "Interest and Debt Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestAndDebtExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestCostsCapitalized": {
     "auth_ref": [
      "r789"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest capitalized during the period.",
        "label": "Interest Costs Capitalized",
        "terseLabel": "Capitalized interest"
       }
      }
     },
     "localname": "InterestCostsCapitalized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r127",
      "r420",
      "r429",
      "r432",
      "r433"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpensePolicyTextBlock": {
     "auth_ref": [
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs.",
        "label": "Interest Expense, Policy [Policy Text Block]",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpensePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r142",
      "r147",
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "verboseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r28",
      "r29",
      "r64"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r22",
      "r77",
      "r817"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net",
        "totalLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r30",
      "r78",
      "r161",
      "r213",
      "r300",
      "r301",
      "r302",
      "r833"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r126",
      "r236"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandImprovementsMember": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to real estate held.",
        "label": "Land Improvements [Member]",
        "terseLabel": "Land improvements"
       }
      }
     },
     "localname": "LandImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of lease expenses"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets held by a lessee under a capital lease and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).",
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalCostsPolicyTextBlock": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.",
        "label": "Legal Costs, Policy [Policy Text Block]",
        "terseLabel": "Legal Costs"
       }
      }
     },
     "localname": "LegalCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "LEGAL PROCEEDINGS"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of operating lease future payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r810"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r810"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r810"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r810"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r810"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r810"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r810"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r810"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r812"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r63",
      "r165",
      "r257",
      "r286",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r393",
      "r395",
      "r397",
      "r398",
      "r692",
      "r698",
      "r699",
      "r765",
      "r815",
      "r816"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r47",
      "r165",
      "r286",
      "r765",
      "r817",
      "r852",
      "r876"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and (deficit) equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r65",
      "r165",
      "r286",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r393",
      "r395",
      "r397",
      "r398",
      "r692",
      "r698",
      "r699",
      "r765",
      "r815",
      "r816",
      "r817"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]",
        "terseLabel": "Accrued and other current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Other non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining availability"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Commitment fee, unutilized commitments, percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded from other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded from Other Party",
        "terseLabel": "Aggregate amount received"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Settlement, escrow fund included in restricted cash",
        "verboseLabel": "Litigation, amount agreed to pay"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
        "label": "Long-lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of long-lived assets by geographic region"
       }
      }
     },
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r36",
      "r413",
      "r428",
      "r430",
      "r431",
      "r850",
      "r872"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total long-term debt and other"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "verboseLabel": "Less: Current portion of long-term debt and other"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r173",
      "r381",
      "r418"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r173",
      "r381",
      "r418"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r173",
      "r381",
      "r418"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r173",
      "r381",
      "r418"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r173",
      "r381",
      "r418"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r173",
      "r381",
      "r418"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Non-current portion of long-term debt",
        "verboseLabel": "Non-current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r67",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r375",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Legal proceedings and other matters"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r375",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims dismissed.",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "terseLabel": "Number of cases dismissed"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r367",
      "r370",
      "r374"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Damages sought"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r375",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Recent suits filed"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of cases"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LuxembourgInlandRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Luxembourg.",
        "label": "Luxembourg Inland Revenue [Member]",
        "terseLabel": "Luxembourg"
       }
      }
     },
     "localname": "LuxembourgInlandRevenueMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r73",
      "r165",
      "r286",
      "r384",
      "r389",
      "r390",
      "r391",
      "r397",
      "r398",
      "r765",
      "r851",
      "r875"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r444"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Noncontrolling interest distributions"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r215",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows From Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows From Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r146",
      "r150",
      "r154"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows From Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r20",
      "r102",
      "r105",
      "r111",
      "r115",
      "r154",
      "r165",
      "r186",
      "r191",
      "r192",
      "r193",
      "r194",
      "r197",
      "r198",
      "r203",
      "r243",
      "r255",
      "r259",
      "r262",
      "r265",
      "r286",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r393",
      "r395",
      "r397",
      "r398",
      "r744",
      "r765",
      "r855",
      "r880"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to Bausch Health Companies Inc.",
        "verboseLabel": "Net loss attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r102",
      "r105",
      "r111",
      "r197",
      "r198",
      "r694",
      "r701"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net income attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r193",
      "r199",
      "r210",
      "r281",
      "r282",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r383",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r650",
      "r651",
      "r652",
      "r653",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r813",
      "r839",
      "r840",
      "r841",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Adoption of New Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r444",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncurrentAssets": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.",
        "label": "Long-Lived Assets",
        "terseLabel": "Long-lived assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfCountriesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of countries in which the entity operates as of balance sheet date.",
        "label": "Number of Countries in which Entity Operates",
        "verboseLabel": "Number of countries in which entity operates"
       }
      }
     },
     "localname": "NumberOfCountriesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Open Years"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r243",
      "r255",
      "r259",
      "r262",
      "r265"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income (loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r802",
      "r811"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r797"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of remaining lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails",
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r797"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Less: Current portion",
        "verboseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails",
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r797"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current portion",
        "verboseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails",
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r799",
      "r806"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid from operating cash flows for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r796"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r808",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r807",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r64"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax [Abstract]",
        "terseLabel": "Pension and postretirement benefit plan adjustments:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r92",
      "r96",
      "r509"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Net actuarial gain (loss) arising during the year"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r688",
      "r689",
      "r696"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Release of foreign currency translation losses upon disposal of assets held for sale"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax": {
     "auth_ref": [
      "r96",
      "r100",
      "r101",
      "r509"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax",
        "terseLabel": "Amortization of prior service credit"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r91",
      "r96",
      "r717",
      "r722",
      "r732"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Gain excluded from assessment of hedge effectiveness"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r721"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Gain (loss) recognized in Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r103",
      "r106",
      "r109",
      "r110",
      "r112",
      "r116",
      "r439",
      "r779",
      "r784",
      "r785",
      "r856",
      "r881"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Other comprehensive (loss) income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive (loss) income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r94",
      "r96"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedTotalLabel": "Net pension and postretirement benefit plan adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": {
     "auth_ref": [
      "r94",
      "r97",
      "r688"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax",
        "terseLabel": "Income tax benefit (expense)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherDebtSecuritiesMember": {
     "auth_ref": [
      "r284",
      "r299",
      "r490",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as other.",
        "label": "Other Debt Obligations [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r459",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "OTHER EXPENSE, NET"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENET"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherMachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services.",
        "label": "Other Machinery and Equipment [Member]",
        "terseLabel": "Other equipment"
       }
      }
     },
     "localname": "OtherMachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r154"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other expense, net",
        "negatedTotalLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 8.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedTerseLabel": "Other expense, net",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r461",
      "r462",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r490",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r512",
      "r514",
      "r515",
      "r517",
      "r520",
      "r524",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Postretirement Benefit Plan",
        "verboseLabel": "U.S. Postretirement Benefit Plan"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Bausch Health Companies\u00a0Inc. Shareholders' Equity (Deficit)"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Payments of acquisition-related contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "negatedLabel": "Payments of accrued legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromHedgeInvestingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.",
        "label": "Payments for (Proceeds from) Hedge, Investing Activities",
        "terseLabel": "Net proceeds, settlement of cross-currency swaps"
       }
      }
     },
     "localname": "PaymentsForProceedsFromHedgeInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r143",
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "terseLabel": "Restructuring payments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payments of financing costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Payment of employee withholding taxes related to share-based awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r132",
      "r680"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash payments to acquire certain assets and assumed liabilities"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition of businesses, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "auth_ref": [
      "r144",
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.",
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "terseLabel": "Upfront payment converted into minor equity interest"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Acquisition of intangible assets and other assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r133",
      "r682",
      "r683",
      "r684"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Total capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r489",
      "r491",
      "r497",
      "r516",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r539",
      "r541",
      "r544",
      "r546",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r463",
      "r487",
      "r849",
      "r871"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans.",
        "label": "Liability, Defined Benefit Plan",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementPlansPolicy": {
     "auth_ref": [
      "r523",
      "r542",
      "r543",
      "r546",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.",
        "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementPlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r460",
      "r462",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r490",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r512",
      "r514",
      "r515",
      "r517",
      "r520",
      "r524",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r546",
      "r547",
      "r555",
      "r556",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Benefit Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "auth_ref": [
      "r489",
      "r490",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r517",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]"
       }
      }
     },
     "localname": "PlanAssetCategoriesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r565",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r24",
      "r52",
      "r53"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "verboseLabel": "Cash proceeds from divestiture"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity.",
        "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested",
        "terseLabel": "Proceeds from sale of assets and businesses, net of costs to sell"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromHedgeInvestingActivities": {
     "auth_ref": [
      "r131",
      "r151"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.",
        "label": "Proceeds from Hedge, Investing Activities",
        "terseLabel": "Net proceeds, cross-currency swaps"
       }
      }
     },
     "localname": "ProceedsFromHedgeInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Issuance of long-term debt, net of discounts"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r136",
      "r141"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Borrowings of short-term debt"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r134",
      "r597"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r20",
      "r102",
      "r105",
      "r111",
      "r145",
      "r165",
      "r186",
      "r197",
      "r198",
      "r243",
      "r255",
      "r259",
      "r262",
      "r265",
      "r286",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r393",
      "r395",
      "r397",
      "r398",
      "r688",
      "r693",
      "r695",
      "r701",
      "r702",
      "r744",
      "r765",
      "r861"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net (loss) income",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r57",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r349",
      "r913",
      "r914",
      "r915"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY, PLANT AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r56",
      "r339"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, plant and equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r32",
      "r33",
      "r341",
      "r817",
      "r863",
      "r878"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r55",
      "r341",
      "r913",
      "r914"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r32",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r32",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "verboseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r121",
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r41",
      "r48",
      "r817",
      "r877",
      "r908"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r257",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of each significant reconciling item, other than profit (loss), revenues, or assets, in the reconciliation of totals of such items in reportable segments to the entity's corresponding consolidated amount.",
        "label": "Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of capital expenditures, depreciation and amortization by segment"
       }
      }
     },
     "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r138",
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "terseLabel": "Repayments of lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayments of long-term debt",
        "terseLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedLabel": "Repayments of short-term debt"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair value of reporting unit in excess of carrying amount.",
        "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount",
        "terseLabel": "Percentage of fair value in excess of carrying value"
       }
      }
     },
     "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Acquired IPR&amp;D, included in other expense, net"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r614"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development",
        "totalLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development costs",
        "verboseLabel": "Upfront payments, included in acquired in-process research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "RESEARCH AND DEVELOPMENT"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r351",
      "r353",
      "r356",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r352",
      "r355",
      "r359",
      "r361"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "verboseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r153",
      "r350",
      "r357",
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring, integration, separation and IPO costs"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r352",
      "r353",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Cost-rationalization and integration initiatives"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r353",
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "terseLabel": "Remaining restructuring liabilities"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r43",
      "r444",
      "r605",
      "r817",
      "r874",
      "r900",
      "r905"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r182",
      "r183",
      "r184",
      "r187",
      "r196",
      "r198",
      "r290",
      "r602",
      "r603",
      "r604",
      "r652",
      "r653",
      "r742",
      "r896",
      "r898"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r490",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r512",
      "r513",
      "r514",
      "r515",
      "r517",
      "r520",
      "r525",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r547",
      "r551",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r490",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r512",
      "r513",
      "r514",
      "r515",
      "r517",
      "r520",
      "r525",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r547",
      "r551",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r460",
      "r461",
      "r462",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r490",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r512",
      "r514",
      "r515",
      "r517",
      "r520",
      "r524",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r555",
      "r556",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r460",
      "r461",
      "r462",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r490",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r512",
      "r514",
      "r515",
      "r517",
      "r520",
      "r524",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r555",
      "r556",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueCommissionersIrelandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Ireland.",
        "label": "Revenue Commissioners, Ireland [Member]",
        "terseLabel": "Revenue Commissioners, Ireland"
       }
      }
     },
     "localname": "RevenueCommissionersIrelandMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r234",
      "r235",
      "r254",
      "r260",
      "r261",
      "r268",
      "r269",
      "r273",
      "r453",
      "r454",
      "r837"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Price appreciation credits",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r162",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues and long-lived assets by geographic region"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving credit facility",
        "verboseLabel": "Senior Secured Credit Facilities"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Summary of activity in allowance for credit losses"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r99",
      "r784",
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of the components of accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans.  This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.",
        "label": "Schedule of Allocation of Plan Assets [Table Text Block]",
        "terseLabel": "Actual asset allocations"
       }
      }
     },
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.",
        "label": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of amounts recognized in accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "terseLabel": "Weighted-average assumptions used to determine net periodic benefit costs and benefit obligations"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r525",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of underfunded plans"
       }
      }
     },
     "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r671",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Disclosures"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of the components and classification of share-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of benefit from income taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of long-term debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of tax effect of major items recorded as deferred tax assets and liabilities and valuation allowance"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r523",
      "r524",
      "r527",
      "r528",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of assets and liabilities associated with derivatives, included in the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock": {
     "auth_ref": [
      "r727",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of gains and losses on derivative instruments included in an entity's trading activities.",
        "label": "Schedule of Derivative Instruments Included in Trading Activities [Table Text Block]",
        "terseLabel": "Schedule of foreign exchange contracts on the Consolidated Statements of Operations and Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of calculation of loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of benefit from income taxes from the expected amount calculated by applying the Canadian statutory rate to loss before benefit of income taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r563",
      "r594",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of revenues by segment and by product category"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "terseLabel": "Future benefit payments for the pension benefit plans"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r745",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of components and classification of financial assets and liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r318",
      "r323",
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r318",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of components of finite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r313",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r313",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of changes in the carrying amount of goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Components of loss before benefit from income taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r326",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r326",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of components of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r30",
      "r49",
      "r50",
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of the components of inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of aggregate maturities of long-term debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Components of net periodic benefit cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of effect of hedging instruments on financial statements"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]",
        "terseLabel": "Summary of non-vested performance-based RSU activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of non-vested time-based RSU activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of other expense, net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r57",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule of Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Estimated fair values of assets acquired and liabilities assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "terseLabel": "Schedule of external customers that accounted for 10% or more of total revenues"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r123",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "terseLabel": "Schedule of revenues by geographic region"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r113",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r243",
      "r246",
      "r258",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r243",
      "r246",
      "r258",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of segment revenues and profit"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r565",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r570",
      "r582",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of weighted-average assumption as of the date of grant using the Black Scholes option-pricing model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r634",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Reconciliation of the beginning and ending amounts of unrecognized tax benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of estimated aggregate amortization expense for each of the five succeeding years"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Senior Secured Notes",
        "verboseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r231",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r273",
      "r355",
      "r361",
      "r888"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r243",
      "r247",
      "r259",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r272",
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment reporting information"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "End of the period (in shares)",
        "periodStartLabel": "Beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "End of the period (in dollars per share)",
        "periodStartLabel": "Beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Grant-Date Fair Value Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r584"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Method and assumptions on valuation of stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected Company share volatility",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Total number of shares approved for grant by the Company under the share-based compensation plans (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for future grants (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r584"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of stock options exercised in the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Expired or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired or forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of stock options (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r596"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding at the end of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r572",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "End of the period (in shares)",
        "periodStartLabel": "Beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "End of the period (in dollars per share)",
        "periodStartLabel": "Beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r587"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Vested and exercisable at the end of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Vested and exercisable at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested and exercisable at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r585"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest at the end of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r562",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Vesting Period One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Vesting Period Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r565",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Percentage of vesting rights"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r589",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Contractual term (years)",
        "verboseLabel": "Expected stock option life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and exercisable at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r803",
      "r811"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease expense"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r159",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r8",
      "r231",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r273",
      "r313",
      "r345",
      "r355",
      "r361",
      "r888"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r71",
      "r109",
      "r110",
      "r111",
      "r182",
      "r183",
      "r184",
      "r187",
      "r196",
      "r198",
      "r214",
      "r290",
      "r439",
      "r444",
      "r602",
      "r603",
      "r604",
      "r652",
      "r653",
      "r742",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r785",
      "r896",
      "r897",
      "r898",
      "r942"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r214",
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "verboseLabel": "Stock Compensation Plan"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r39",
      "r40",
      "r439",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Common shares issued under share-based compensation plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r39",
      "r40",
      "r439",
      "r444",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r39",
      "r40",
      "r444",
      "r564",
      "r583"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Common shares issued under share-based compensation plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r40",
      "r45",
      "r46",
      "r165",
      "r280",
      "r286",
      "r765",
      "r817"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Bausch Health Companies Inc. shareholders\u2019 (deficit) equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r2",
      "r3",
      "r110",
      "r165",
      "r182",
      "r183",
      "r184",
      "r187",
      "r196",
      "r286",
      "r290",
      "r444",
      "r602",
      "r603",
      "r604",
      "r652",
      "r653",
      "r686",
      "r687",
      "r700",
      "r742",
      "r765",
      "r779",
      "r780",
      "r785",
      "r897",
      "r898",
      "r942"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Increase to accumulated deficit (less than)",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Total (deficit) equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r805",
      "r811"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sub-lease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r786",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r786",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r786",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r786",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r818",
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r625",
      "r634",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Summary of open tax years by jurisdiction"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Other payments"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r643"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxYear2012Member": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2012.",
        "label": "Tax Year 2012 [Member]",
        "terseLabel": "Tax Year 2012"
       }
      }
     },
     "localname": "TaxYear2012Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxYear2013Member": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2013.",
        "label": "Tax Year 2013 [Member]",
        "terseLabel": "Tax Year 2013"
       }
      }
     },
     "localname": "TaxYear2013Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Corporate brands"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "B&amp;L Trademark"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r352",
      "r353",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r490",
      "r862",
      "r906"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "Government bond funds"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnfavorableRegulatoryActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A enacted or proposed action, ruling or regulation that is likely to or possibly will have an adverse effect on the entity's financial position or results of operations, excluding tax matters.",
        "label": "Unfavorable Regulatory Action [Member]",
        "terseLabel": "Unfavorable Regulatory Action"
       }
      }
     },
     "localname": "UnfavorableRegulatoryActionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r616",
      "r629"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance, end of year",
        "periodStartLabel": "Balance, beginning of year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r630"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Reductions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r624"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties related to unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r624"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Net increase (decrease) recognized in interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r631"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r630"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r632"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Lapse of statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r633"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Portion of unrecognized tax benefits, if recognized, would affect the Company's effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Senior Unsecured Notes",
        "verboseLabel": "Unsecured Debt"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r216",
      "r217",
      "r219",
      "r220",
      "r227",
      "r228",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": {
     "auth_ref": [
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences.",
        "label": "Valuation Allowance by Deferred Tax Asset [Axis]",
        "terseLabel": "Valuation Allowance by Deferred Tax Asset [Axis]"
       }
      }
     },
     "localname": "ValuationAllowanceByDeferredTaxAssetAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r640"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedLabel": "Decrease in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset"
       }
      }
     },
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesAdjustments": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment",
        "negatedTerseLabel": "Reduction in variable consideration provision, adjustment"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r174",
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance, end of year",
        "periodStartLabel": "Balance, beginning of year",
        "terseLabel": "Cooperative advertising credits included in rebates"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "netLabel": "Sales return provisions",
        "terseLabel": "Charged to other accounts",
        "verboseLabel": "Current period provision"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedLabel": "Payments and credits"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r804",
      "r811"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable operating lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r201",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted weighted-average common shares (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r200",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted-average common shares (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 23
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3581-108585"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "http://asc.fasb.org/topic&trid=2134446"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "b",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a,b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2510-110228"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2599-110228"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2611-110228"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2473-110228"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "http://asc.fasb.org/topic&trid=49130413"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(b)(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "http://asc.fasb.org/topic&trid=2122503"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "184",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5634876-113961"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=28365394&loc=d3e23770-108382"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "http://asc.fasb.org/subtopic&trid=2197926"
  },
  "r928": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r929": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r930": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r931": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r932": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r933": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r934": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r935": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r936": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r937": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r938": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r939": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r940": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r941": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r942": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>161
<FILENAME>0000885590-22-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000885590-22-000010-xbrl.zip
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MWK?(17HT7PH!D%14156LQ9S (<I9^LQ$;];@=IV6J<S/;E;<\>].=/;.Y>Y
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MQ?%L?C@<_9838R^HH! 87/7L<[0M8*1 TNSF^-N7LCI;MOQ-3K.AI<9*D!+
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M' I2Y M#984G!,!D,0-CH42QE\1;VE2DU&3-IR,^[A^\*X,1+->D.!0Q:I_
M2B7.-3IG"[H86QU2$_7U=C76H(UZ"J6JA0M("9S*I'&E28O>&_:EQ(V'^LH=
ME-5C7+ Y)PXJH@!;]6:*RC9&UD!4U;';>(ROS*U9/;:9*H7B&)C4!8H9#4LC
M,240%]_*QF-[I<[0ZO'E5E1X-7!$ME#Z5&AT8%O&%#S6LSZKFXSOU;M0:P"R
MXX"A](+E LT"ZZ.8%':+)25JZ]LE8!ANUI7T LC>LP\<0^SC&8K'XAKGV"*F
MW%)8X]8.:^XP70E:R!D1O#6*$'A(& M)L<5P!>-H #, ULSUN1*4JHO-FAK5
MH%7H:R3.N6R,J*0Q@_A-1>F:,CK+G'3"P:&W)1%'\)61?,S.0V!;.1?>5*2N
M,Z.SS)%<:#7ZL^H_E@"6$V4'F+/5QQY(AK!B/0Q78_7+@\F8FJUP26*!@I"Q
M'IKO<83:OD$4)ZRY@[)ZC)L&!:AZ%VON"5I'J45U/[O5C."X;CS&UY/16<TV
M#A-J83;.)8WXU:!B#HTPU.HE^SBD??-KZ RM'M_H$_H  5-S(.#0$+L^YLH1
MBPU#JOY95Q=J]2#GA,$6D9J$H%?K9$#;(%:L#+8.H!GS>KM95S/1075.H 2Y
M8(%*A8PJ8N&4!0R(W5C0KC.CLSRT(I$I-;-D5\!0S8%]H)"#R8TBE$U%ZSHR
M.LM#"1$<&)-2+ *)A:BJ-A3RWEG?NP!M*$K7E=%9'E()2F-5>3[UI<0<L62,
MI=34-V@U&<"@E'5U1ZX$+@93(B=U(VN$F&HV?:1M;=CS.LAF4^$Z4W\WZBN9
MSD>ST?CY:1?]V<^3:3_90."SK45;8\U.7<-<(XNZ&M;%THJ+&#<VT[U2^):8
M_D9%+IL6JXL0<F),[*KMN\H0AY& Z;LDSGIB/)P^5GA&Y3W$?I[VIT='4RFC
M!<JG,&UBK,;@*M@8:_0"DG).+E:NWGA?V. 02FC6$<N55%(@UT0NF:3J%'(B
MM9+!U-:*:382#+5US@9W 4B^8@*1D@O$8'//C!D7': A<4-MD;6YN\\TPG9B
MFNI%")"<R0$;)@P>,\4&:SS\[3H%ZVI&6:)W&:DOO4?PQE LEBVZ[!(GM\ZQ
M]'6*R!5-$17NH_0P2 -64Y*#1 $+6'TH;M%,U*+Q)NZ</U@W#-XUP%>O6V:S
M&^6_Q^J +SSXMZ["XY.Q3)^?_+Q/TT,JHD%QH8/9_7'Y[FIUF<4=XW=,O(0N
M^_#0+S$^KF=HT/LJ!%D=!@1C),>6FCYN9QO(MF!^DM1]B,^7) ]-PY*YM^T%
M2-[FWEPA0:L5,:LT?B!UZZCYU@ZHSY>ZI;4_R"G4*!PP6^ 8*$1NOE@1Y&!"
M/$/UU.7;HOI9J%[2+_PR5-^.0>2SVU FASP:+T+,CTY9/#_NUKOCSD]]Z0&)
MM@ X*#:R.$@1L+>@,PD]QSX7IYY%Z^DL6C?HS;JR9]$GXZ/4N7%P(,^GDX='
M^_-].C@<E=F#![>N/EY/EX[7#>YXLP1=D)JC9$TOR$Y@:F3$5'+BJ.%$SG(^
MFB8ZOW/^X*K1_(PH3,V/OUP4=N'0+ZDOJ"F;E@4P]_IU)&?$UL;JQM1*[;S(
M+[FX<_Y@7:7@=/3YVY&$-^F@YY(?[XOT?N4W:EW(!AWTTH*#25<2LYLG^N1H
M,J.#>]/)\5'7J0?'?9+3HOQ KVA\+/6L3?UD_%[WF1N'D^/Q185\ZW10\N,;
M=Y;5^.C"M2W:W^@=*O1.PC]ZX.D3O>QV\^0Q'<C>9/[Q7W/U286TXR[C$GQX
MZ)>X!,Z[4DUHEAM =113DUI]+*H32CVELWH$:YR"W=+YPH'_(P>U3::S%3+9
M[%AS[0EHES"W*(F=(/@2LF='A7POX$0T0VK"O67R6R;?G4R[3GXX72,MO8*B
MQE8S$B,("7 *&3220_&6@G%5AE2YNN7VNCD=*Z"S!< 8P?4NGL"&>U("I;>Y
M*3X7N;CNNZ7S^M-Y+57U)ZR#+W,6B"\UAI ,&N@[U%WRPAIL<V5R NM?7G2M
ME+XETSF-QO?U#DY/\U)T<)[;6SVEK]^/OI*:J8*Q,-FX6"<.JF^M>L=]KY-#
M09$U7CD^1^:1S.;3XS(_GO:ZM<EL_J[@[4*MV[N#](!.JN>G2/6/#*6^%)(Q
M34KLDZB@>H^^ALRY.M;7:QA"A=N:P[9Z#P@4VYS8&H0 K-*9]&^;,F9G@RTP
M@,JW(6&\DHHXXXJK.63;5(XE 37;<G*YIA8*FS"@U;8!8'QM:V\7O;V26%6U
M4]TL4$U$"P)],Y2KT4(9PBR43\+XL1S1*:0+@-43I(.?CUE/_; U.?_D1JKL
M8*H5DHKJWX-/R-&1#<4'("C@A]2O<T!0KZ:UH[3>8RS%6DGM<T.Q3A)%X_K:
MB OK[R_?I=&T;Q.1FR>[I^O[_01WI_+?8QF7DXMAS]N#WSMT]DC*\;2C/!"O
M&<E6[]29LH3 X!1#*[[D8!T%;'6+V>=,DGEW26\?_H_^2)J6_9,'\DH._N2J
M[H^/CN>SQ1%V( 2R7$S+#=A9!V(C)@D8(&1C2J@H6P*MB$!N( 0"0>CCJ;QZ
M"L"9T;C4=\9[%Q$H;:W&J@CD!T(@[ZKQG3M4U*5,F!,4Z\F%&M2VQ;3^J>.A
MN!W+2ZU2:A 22DGJ='CGN53$%&Q*T7'ULL5L(]V.Y1'(N5BB\61RB= H8W/H
MG?B:>N,Q&,!V] TET-6Z'4OLW)L=IV)S$TB0I9!#TX-4-HM8=0 +CAM*H*MU
M.Y;84:&7S!FJSH8*E"6[Z)L/&O0T-6 N;OW6SUESUOO_BN:C5\J(GFSKW_)H
M-'OYP;5,IC)Z/K[SNNSW/9JW)J>#R9=U$?\C]7E?A)>9?LE'UKOW)N-Z]I[4
MH3C)2-(PV=;M9=7 RE6E+*::(C;;_):M:^IP;45GU:)3$*'F;)L(0B@-8\QD
MK0\2K:K_K>ALV;I93O;R1$=,'[ @Q6!"X!:S^MNU.:_BQ QG3O96=+:BLRGA
MQ1*M3FB-N0_?YM KOG,I!6NP38..PFF;X-B*SAH%PQR:AL 5L'>'C)Y0VF*?
M;R7RN85M/G<;7FQ%Y\]Z^GANT/<YQ 18$AM?6FG&%G;>-=J*SI:M&Q5>+$]T
M$D MKD#V5:,)%9U<V!?K>^D)Q.TBT%9T-BR\6)[HM+[<Y<D:$PB8*ALJ)A13
MN0]_D0&,#AFLZ-S2+^U7^/AW.KK*;Y[=H]'XP60VNWER)DZ/Y.!T ][^Z.@#
M>9+Y_?$KF<W[!\^.OBY9OOU6D&_,SHY]]R,&$JTW85M5DDR!!#5'3AJY&[5)
MS*76;:)K*TZ;&15^#;+-/O2B^&9S,V"C)S;)VN)LKU,UO*UPWLKV$,1I@R+(
M)99%I%JSA&HA"Q2)E'(HP5C+$#6D',!0HJUL;V5[DT+<96YM(S0V8A#GH%3/
ME1"RAZB2;IW4;79H*]L#D.UUR1@E*C%ZZ[@Y"ZE:-)&#1>?0YYCK=IUB*T[K
M9*6^@A!WB9LA;,Y]B!4'B5"RPXI<O(<*+;C2MLOW6]D>@CAM4(B[/-G.#H(-
MV"(6!&\2HI?6FG?@R=J4M[*]E>VM; ]S%==YDIZR$F,)P!&Z& *K8VY9WVA^
M0'VT'HSFH^<+SO06JL>SBR ]EOG\0.J[@[Z4+7VBW[NSW:+9>RV<E VB@/SR
M^'%7&WJ0S);[Q6^;Q-Z3R?,I'>WWGL1GDP;G1],?]GY:)O-6WP,LUUQCC-('
M"T!(H<\^HIA+B<6$X.%T;-TZLW.K[P<5&GW8JO!+ZO!S2;7ZFD)H4%7AAH*J
M72MY 2>"IRK6OE6Q=GW'=RV=Q%^NC.PG*".[G E>5?'T!5VRJ4)H0J9:WU09
M23+H$P[(9OXUH-V4W9JJECA'].YH3 >GEO1J!'#UE@9 $H=H])\&+E<&HR*K
M< ;Q!@RO_WK>UM*L;63Q?DO_!Y./=<)_.-^7Z=YD7!;PS!^,B$<'"P=R(&MF
MI4GD"+6%B*#_<8PN>T*5JYA"&T!%]59^MO*SPD0Z)FPY]:GK#LA'=E52;36D
MG"6'K?W9RL]5RL_/4SFB4;WS^D@_*[,;X[J0J%.TYHOQO4.Q1!6KP4*279\1
M*Y8X4P( BLD6G\K6$FTE:9,E:8E;?<"4X&)-DCS$Z'-?^R&18B.R#6EKD[:2
MM*Y6@*TO&H98MD;C>:.1B$'"C/J:"T)F:P6VW%U7O1ML'V680/EJH62/JG&5
MS!DC+%+'&Y-HW))X+4B\^NRKNN55+%BL+% C9R5^2V 7RR<8TX!F_6P9/S3&
MKV3DD5/>Y0C6,ED();!$C)Y*PFI5%MJ =/P'\VL_'A8M!LXJM\[BHFTYU=<J
M;2NQ+XZS6A5)!&1 G2MJ+ BI-,R-;:,!V9>MM&VE;<UM6PC1V.JJ4>,&OAJ2
M:&L)/OEDFF >D&U;P\J75:C/:!L;@S8U! J.2C$U(#M6?ST&-R#UN7: KD1"
M&U7(N1+67,$U1V)=8>98$4VT=E,RNP-J-K8NB=.28Y/$2"K>0%(R4(8BU8"
M-4-H2+1QU+CTE_[YZE0OZ;M1RO18G9"+*U+#*S7*4AOZFA*& OHXN]( LF!T
MD5MKFY+:WS)TJ,4\N4G+%!- (TBI9&]L;M!GUY.)0YCPM&7H&J_P+U&5>I<R
M1\"0&8S^+7UW9ZN.+%L-V[:J=$O4M="HA0K%FHWGO@B:,EKF;-7\]\"EE 'T
M&=@XHJX+-1JEWH;-IV8K--3()7I?, -:YW*$C<LV;39'UB#;Q9G >4>M,K06
M4$TDBI'8">5I2(L%6T*M0[8M C4CIGH!"X8M YA$IJ0,%-$,H(YRC1II]&WP
MCSI-S[:]Z]/=T7AT>'RX++Y>1Q^(2U_,>_=P<?HG)T=R\>L_/.+V:%8FQRKG
MRM;U#4..QZ-3Z9CJ9;ZE_>'I;UDD _H;YQ\^?_W\>?_T1T7-9@DAB:7*%ER,
MN9G4C E5K*GL:2MJ7RAJ]'HK:@,3M8MKL\G4$)N)$0(4C?Y57++7H,H@F&BW
M,VF7RYRNR#Y\]S=UMO9[-< K)?IS^002K95<K0NC8Y]#3L7[YC*$XG*211NC
MZL&ZX,N XK_N>2LM]4/Z:*9GG"[<Y9LG%PG5T^32WU#'_8F>98'<P[8[&<O)
M1@9DP"%!*:U(AFPJQ=I[ #6'60/]&@<4D*T_PBN)D%+"EFHKG%*%Y@P;#;8Q
MA)C98:,AY7 NB?!;C7NCOC@^+4N[@ESLZF77"S$X1J?Q+Q@I;*49"K8@QU2S
M;)[LK@#9U<BL%;% Q19;(7)/:$@LOB1QA(SX-7B2>Y/Q])+.Y+JX2[FI0 :/
MR(OTD]Y2\1$)@ R6BGE0L*V^R?=7R2'P1 D$DAC2P+&GQRTGP]1\]A;KH#AT
M];!=*[.',D"I)*<.GS<1*D'*DK&:9#*:2-$E\U5DZM:50T,)_5VM;$-)F$P"
M)Q652@3>UQ1+:.ZKF"QR;>9CB;VN@FD)L/?,M%WZ$:L:%).L%Q<!TZ!@V[H@
M*^%0J% ,E$ ^*H&R8/*A>$ZL_JQQ-(""H,TU'X,9<(%6XU9U.6HO](B!:W#$
MP4EHA5RU6PYMJ@NR1 ZQ<@BQH*L>#!629$7]V@ <4ZH#6$_[>3K1WSL_^?E
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MH5HYI+JQ*G01(*CZ&LOT_0[Y&ZE!/5?C<N]Q$ $$B32P\%(S,%$HO)$A^K5
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MPU";6$GK[WU=&9Y+(?,#F6M\\+"='C,0MZ^$IK<'(&N0#LU%JJY8==)KZX-
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M[L;<]>C./6[^6-*L4K7E!I[P>M@$QQBB1HXY;LS=F'MPYBZ%+*;4XZ"+.P-
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MQ4 ]\Q##TDC&_TQ.<=!*JF[K-:LDUB:%CX#E^UOP2@(U2W#/-0(5E<BY-&I
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MD:VV%?5T.5I@'*0M3)5@"6$D0%&'^JJ,U",2468/.<F*FJX=*S .TYEM]J4
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MHBQPQ^@0Y_T/@Q^EV=.W"TL:6CH;P_@;QBNP)K1MQVA#T&\F([T RLA&1O2
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MRQUHW1+G"J7#^(>A)*/<A3SF6.H(=/6(UBW__/UQ><N  +-Z"1(K#'<Y0IT
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MEN]X/C$\L+ ZFH?*N>F['3-PNSM/!X_;%N%)Z*"C:[;7];J$6+YAD:[;I59
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M]J11,AW12;,?(4IF^HX>=&V#:EI@^);FF-1T H)]4P/==K7MQQ$.=WD@=?0
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MZHW[Q\J;]\JH?](?]<^/^@_<8V=[.<!/&*F=E1/$J/]F#L^F*8T].H87O8F
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M8?:9KV\6B]/(F1++O_)G^)@H9*XMSBPD!@#?\F M2;SX[$/E2!PKLKL4!61
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MF<8/LW3&S2]0+.2",16$!;TP\IPN(/\Z!@5"$. LSKST7K#%, _ ROO:15
M#$'*XA7"JX6/H5_"C(&Q^CQ*)LJ$1=LE2ZXH<YP@Y8$+CQ,J<;3 SOLXK/#S
M>.0A')5EAI,O[2"EM4/F*K!,$!,M4S )$C1LGX75RNA6X0ZKJ<HWE"V<)P9@
MCQ-0P9A[)9U%+%]3V'*R<\I(Z"^]:W9LDG]EZ#3BV"M017 "2?EUX5?P3ADT
M\24KKV3-</JN$!U'2KQD@K*0B RZ C!HX\Z^(=Y6,0*>080WA:FD?+'\4K\&
M_,WF,9@ <R%%N0E<@]%]YUU7Q=<LCJ7*1MQ<O@FG/-6QQ+1658V5>FH5_PIJ
M8Y%6F@I\;!51UL(R* ';J@)9)B4R9I35C@Q8 8VO@3;0J0"$34%_QX22*BE4
M%BCTC<D4N!/W,>34NXE!<[N6(26I?6<LA_*. BIAG)I>B_2E"I\";,2-<E-P
MC28A-\_\W-R<@MO3FD1B,1D6&4..BBZAE&%[P2N9JI%6SX>A>.)YLY*I(>,K
MF"MZ5Y9$.K]><LN53%)$@,3"7C=9-BNR;)HTFZ=*LVFLQUVP'BN&S\:A^A\R
M)?F-2^Z];UF'2TSQ!XU F5;P+);>R[66WBJS9G'K3Z3>LXYT7++,>3^ZJM;-
M==5BOR]0M29A)#+.V"^WS"$UKYHGB\"H60HK %.J9"&SV6(J):#(1E[T"M1S
M12H+Y)D/I6F]J=6P#/QOV0H/-A"^06^/93:L0A^ZF'_^4U3&\A(9W2IC0<)/
MB]%SOK)E6WQY(R4+ (D!Z^/FYPJ-M+#,X3'"W_,'<Y MFN<_K.D]BV[72.'M
MD\)2JL7H\A<LBA=T%&FUI5U2AG$PVZY,B%U,IA7II679%_)+FN4U@5J/A@H?
M4HN7VY L7\C%+ZIH6C*I&%E<YD4\G9B[_HHTVRDFY83>@LF_H'"P5%I8(DUK
MC(1?=W$#$LX'FAA]42YIBJPNX[T 7AS(WPY>OJP2-U'B&2M0 )@AH\;O8N"N
M7D2PS*I2Q!:6D*JL3T:1Y+W)-&]CYHW,T:ST<UWT@%:R>C*:YQ'SOQ?OXPN0
M"@DW_U,Z8?&[BIZ ;(-]2-+_S5 H >LIE;!9FL.WJ(%$I<^,*>5<32ARB)97
M+3PHB\H4BL$XKRRYML[B/H#Q(F2P"G F7?M"K8A(.%E&Q"2MXJG42'A.(LL:
M%5Z[Z@^8^IS"]WO$O?:#5Y4^*9G,!_\LB6G1=;* "B]X[=]<9FV7J?$B%Q58
M V YH_-[E2<1FT_2G"5Z5T/V/IF0:UK!,^XK4U@F/'K+ )EC>DUX022+<<M;
M4SJ=Y;(J#SOJH*!%%E4$@6L%E(7VLOBJPB?'F"@C$-&\6<34,R\%GEKVC7Y$
M9LOBY?C^!['6AKZVC+Y68LTBNJ V  9(62LL3[\J"A=%;8%%D@9E89#09P6C
M1GN"^'A^E=1<P95+1SMHWLQ'(.BC) O>K:HD."P]:7!LNW!,'KQ/O3#C 4T\
M9)F>7.\]GXH\$IXZ);*J(X%3Q:5EI1=>=@'<!EEUS\,8+4.X"_%.X*23$-1,
M6IA3LAE#@<5,WT4W4%'L)"+&)(YG3.G%BV1F2U$?[J:$%;UB'J*7AMQNG[*^
M:!Z=L68U)9ZBL0N/CRCPU.L0A0@Z,( H9!E[O6@.88-@R,EGUG2"U7_#'2)X
M4_H > $;2TR#)3T$#E(9##-9_,,"MT&2"JV27R^+8]/9=;9/>3G[05$1]C/C
ML1#&11-XU+Q44*K^1TR6K:O .4-*46\V)5E6VO#,SC@",9 R;ZHL(:G4YT\%
MBH&ZWTZ"]C3QN$\R$YT*F*>(YY9Q/.,^%,&B 96Q.'*"!9$\U$5=3#KDBA1H
M&ZA?5$HM)#9B'6@JAE:T:@)$Z'Z+=E7Y!DZ];/7LJGU"YGUU4$@])&$:.:H
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M5F+.AUC4>ON(GFZH.6'[]V7NQ',G9'.UA5?5<Z<:=-EZ=%FJ,1 ]K^%P$U8
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M9CS%WN<%)GBF-P2;CKN8&)'S$6DR?N\7;6A2Y&.)^XGWKV8!D8!@P4HN9_+
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MC5<D7(EW<K3T;I#G%%V;V*!,C"3A#(>(BEZ [/5\$-JG2N96!:4JC8LKVZV
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MQ4K&')RTX]=94F'\V,GK>V%,SP.<)Y,LX9%))+VF4;^2HG<,"U?1;3+2&C#
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MGQNWJ%XNP1G55HS>NZV:[2=!T<I&.KK(,SBD_W%_]XF4FOTH@/V']SN_TFD
M3Q]T?WM)NLGW?+IY/AL;&+T_=*MO,8H; 9'Q":*]>8.Y?S_YN7^ ULUAA5Z^
M^O?@AEPMPIF40&QN!],4Q2W0L1V![R!!4"MSVZ(J3K-R@KX1[KX#;PS#!4**
M&^Y8H>=A2*!M*P%!S8PGZ])#UT ,B]NA!/CJ:0!V"U<% C_L^M^33AQ%/Y>T
MM[^4, __BA= Z_Y25NC'/)S!/IKH?9PM3#:*CF=D118+_'($$SF-%XQP/2K(
MMS3<]_DZSN,E_PM?IO^\GY$WRJ;PM\PT13P/B'AEL#))/=+_0'C+H!AF<D&H
M&X*^/X'V]P!MUC+TT/JN=6"HZS:AC]:3E@/IX81]Y1/V*?)AM3)[#SNS9A[T
M)LT\?NS_VK4>OYO0TW,^C$Y.Y!F3XC>0<R$S7A=QHLS_X%2NEMNX7#:AX^/]
M#_YTK7GPOMD?NM[HF9X,76_7I^OM&KF2EQZRV0ND!RS[-2@366LW6+HK6#HM
MM@8><\\Q#M(_7(3%,\Y+LDZCJ,&%-.T#,P;98:P$\_T7W 2&B'9))FM*6@9]
M:NQ\+Q8F1DUO(+G;K.2\K.*/0P'AZG+3DPT- 9'B0HLH#I^EQ(=0,>$!B\:4
M$UAU6T1I#,V5(K%3)S%WNT&"!KG8+&=T3OHI^J_H607W/2Z:042N*"*26\OI
ML:IUEH0;,^P$,SA8IUF=(5F&'(S6:-AB((6;IA6<+BX.J66Q,\R83]@.O3'%
M:5:5A;3QXR9,/E(,@K5YP?KMX.3%NSQ;#(B=*_=.P8!@D,L<Y1;OM?ET$N.]
MU1US-9]E9O*TCM(JGC/U&$F2GX#&K>(\;! BE)9G!<N3#$F6<@C:/&C;:AEI
M_E4K"M>&_.0Y4\5EDXR,\+$-_&YI[03EB[7ONX;_9"WUB9"BG#<?3#_++!NX
M0F':2F@[.%8@&<-I4X1S4!!.R%(PJX+0I-@I9.'8,?H+_0E+B%37TOU12C(Z
M/RRBJX'O3:S%A2_*:3<,PN6/@JE^&_2IH'>819.\/*L%Z4U14LLX51@E>DA+
M084R(6@6$BVFIR81;D(P8+ <I9+<D\O7O![F8Y*W-;BTA/-*,KS6TJ'4Q_]N
MFUE9,6V=70I^D5),HUU&.[1-GFKG[YN#=BUD>?WY/NX<S,'H;]+H_T['>0S>
MMB+Z]ZN;:O@W2CD@[5XK\[K#X1R8[M@JUCT8WKT>\A[_ 694)FQAYR'-:LX#
M#^V3UT1D#A:Y*?X:.K^^@&+ 2P./O1^3#0=2[;RA]TS9<56Y$:BZ_8[&LRJ5
MZ UC_WGEVV9!7T]-%PVO1%MI%D\+2P7B+A$[;)V]\XZ\[2"M&TT7M8#\T$=O
MJKANW+@%<@8I^CW+Z<#_HW:ME5NQ1^9!7*0-:$97H>#UU.3B#Y>+A=@P1PN;
MQ"!EDR2K\\$S9I$CKSDK1@%$KZRF]!;W1E&R!)4X!<]Q][YR4TSY0X97!$\^
M:P#\*WR,]"%+"[-4QL?5UFOMFJAFI@5,.2/7O6IF .L%3:$8J"H1A;:&XI_
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M-2O#XYS_O1/=[ W;:/ SC\DND_X"G3Z']AC D/[!_7-"VH\4E9OB'CIK"[/
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M9OY5!E%F*G00S^*VIGWXV<0YW5LH*# BX:A(=D9@'O+;(,S_^R.^B"6K\",
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M@BD/,M1-YXHNRH7R0?%.3<P9/V$,_,WNB):#>Z-( EM%?_L)>55P@S,.W9
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M5_W!5CDK(]V:$[,-5C*D$OA5%+_ <%2E,M!4I+IO.A$D//;")8$%6H#;S!7
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MPF'WX:%=3J4_FZ/X((7!V"TCOKDB"]HTW3GH$C,H_D%^R%+77HT-8IXSV08
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M,H6L2?V"0<DP7>>J>>/[!]T@_.Y=$(DJ[% 1UZX+TFE/D9AP,;H*HP=($!X
M]5#"D)M'BOCY6*Q)1K;ULFTXF3\6PZ )#9<*;N*/G,X!WLV#*":,$N6G'=E$
MS)+KE$ESR4=G3<3D@T9=9\873!S#CC5;0#S7$7EV/'K,PA%NJ]MTU"M.]\GW
M.I6%D4(E?-TFA "XN//4A.8*/C\ NV6MNZ"0/]PVU+&>&L)'&Z*BM&4%^B-(
MB_+LR8Y.D8-"/OU2@HYCD?E^VN, B*>47?]#W)A1%D&F_/CXX#  ,9T+O^0O
MOV/+*EVHT&D: >%CKH5#.'Z9G[*?_.:#US7*\0I' S<VUI8"L8,(.M0!/!=W
MUX7?'R\UGG!<'?,P>:?SQEZX>D 'J;6W.[I@!9RP2*(45F/>SKU7POT%*OG2
M@WI.MP3::^A?J5[H_H/=9_)EZTK8;@E+[I(ZT DW//H]<#TYQR!,?>Y-Z#1>
MC"+?Z9:61=M$/+#=MC1HB=0R[W$V4.I%J 2Y<$PO8#W'#HT1:R9[O0D[K+8K
M0]'I=0C0"YX[GO-KJM5<OX*0 2Y0[$3/0K86VB8E\F'>-,Y)I3UF0DTG3XS0
M47G$B<"P@C$$E24&Y^&M)ETUEH'3@0HO-_06C>5R&0 <JP".!P. X[L'<#S+
M.):B2T3/VG1JF@ZFUEJ<YK/,6,"ZVM/;3[E!GJ$AHL.<OF-G&9D*IRI%IC&:
M;K7[^(!46JZ%8;8_+$>BS=T%_C.>+W[T2LLUV7DVS9@;77,.E47G8 YE;0NN
M%EP]07U(+3X KJ9AW3DFOW(&C]9.NZT=?UBW<BB1/X\@YH!;W6"FA^IH7G9H
M.%&M"4R>NAM_M&86N69IV5;SZG#^KCLMF$IU>;=#^>,P'0Q#MJQ+S6#A\%EO
MJ_=YD(.<DMY84>@1HX4MH]X%GH90[C:83IB&6%WKH6ILVVB('S@'W%/8+9'P
MC0I,HD//69^0C-,B2_>$,DV5[JKDIS+JE7/-S#ZA@2;"X>URLKTH$_1/2X9X
M8MOMN?[;[RT#PMC7::R5M]4JR:"X9@";GPF+ZSN^.'/J@/V=UA(UUQJ0A4G*
M-2&PG&B?76IFQH$UZEFV\%P2^BP:>P;^CZZ%[X'N)K<<^44WCI<!13Q?0!U%
M>2 ?=D@\H74*AJZES%&K9<$.'T/L*&BX1$C;VQD78Z?#X%?OJW:^Z%&;^_':
MHJ5M*,//-:&-H7_R%$-H65M^ @6C#JYS2^Y9AVQS8!CC@+W1M_)*2:(+7 G:
M$B8A LI?K=36_16OU\T9M:F)7L;48??7[+M<XQG;CYB97AWBV?2NZ5^U>Q%-
M2'()C_-*C9Z[>B94EN$("GD&_(;N15HJP=UL]L9R B/D<6? +0 G]"S0N-/(
MY31K$.F$.H!)"_A.SH".//[?(C^>H?+:.QYR* 7^*&..^51R^D78=4+F6LR
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MNIY_MCKJQF"6$?-2ZV:C 7VAD_L\@ZD7)17E>:F08SM;\U;&13^IQQ;$?[P
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M0)J#GM4RO1/'D;WAR:F%KA(>C+29[MS>%H9J%9^-PHXME8=^<Y9Y0#'A$WS
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MA3,P=N/$<,F;[;?*"/-*RFSTU9_?*^[3M?JO+^\M[IM33]=MM0+GJ5GG)W,
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MPM9SK%AE1 ?RY^QYNYIE/]3MC 3R?RL %YX@!JN_O2*#E*.UX8<G]*#MJI0
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MD"S"?[[Z3L?$K31QQMVS\H-"]B##VRZX_AE^YT5[!!Z1B3OO\U?_8TN7?_X
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M,M68"BE,'DU6EIX3PUM7TU^G4\][R>C:5B1[F[1Y(X,8NR)4[]H )3!!QVU
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M!:@+N9B6O:0Z8WH/[OU"TU!H5.S;!X9;!RZ&=&D:?)A\R$H&5._"P,6:+S6
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M/^$41)ZB6KDGT!1'U=GM?*R\3A^8HFI,5UA!QNCQ0QH;VR/:";]F$TNST]J
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M!@,FL^-R)UB%'#D8FJR4129X_^..ZIKA8DP2[=W<(@.VP\R.^X,-;@K\8L"
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MC,H&#VZON$_T1/N'+>-Z =B\'MHWCB<^>6Q(_Z0^.KN-)FX:'#A) 2*.O&L
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MFSS<>BX-<:?(]OGB*>ZSG4RUA*L)XS:B+S2!&[7X$0>-[W=$PDT;?E8S6+O
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MERZCNB%?')+D.H(L_J:LNI==6Z[<&Q7DKY,E5UJ1YJH_2<&]529I2X?5BFH
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M)"%3=)HBIP6]QC.@/*BK])D<W,_'AE _%30\PY)2 H&//GSPH1#P]-+OJ;U
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MGE#9#O'%O?#AR]K""#N$LT@HCX!<=E[] %:? *\1!N:6.BH)-5!M-(582-U
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M0ZL-6.AP<ZI2DL!V.AC/DF([=URDX#K<F\P$IT(>7CQ:_.6!93IH6F/*)(G
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ML";[1548U-(HO(O^7O'<_4_BT#2R-Q<_$<^VAL[B_+"9\\5)LKCVB"JVI.A
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M-\PR%#]LZ?FWS,FZ-PK^F>0+00*$(WJFYA?TQAW:PG?Y:%WF5=\X+V>9&(N
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M!%0-+1[IE:''%&2/CKM8R4M,^_D"'%U)RXJ/'#>WTR0J?IY=%H#8D&T9BJ:
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M,VB5U(]QCU4#(%"TO _=D=VO;D%>4'XKNY'].6--4CZ\?/K%=H!85:XE)'Q
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MCK4OAS5W].&?=$*2I[#,UNRV;B&X/F64!\#K5J[Q+60[[CZ_;R'>ZT9T((M
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MGM6>O!4WW[75#$ C1]JT%-WCY=[^Y?6[(_YK\ OZE_9+#=TE@!Z9Y4R%G14
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M7F?4((3]$4ORJ>Z5XYZ+L9#EU$X1A^?3F0%N?88N2'%RJN5!&J(L))XM3I<
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MYD$.:_+79V7M!G5N(<SJ3N*"=AG;*6TA*XU#QBY*T,<3LUAPYP30\^FJ/UI
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M<IS;L_E,1KY)Y*<Z"!<$?8Q):S:.42!I@,ET7,(R!_ N7/JDX5*;6)0_X=X
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MI@9.J&-QI>.-TL="ZIJ5Y11"B3,YE2[<FUG+'<L([)&'TP]F9!-I.E&5H"0
MBUBUQ*A>7)FLB3#\V2.4! !:G3C'0P&Z64\6>=4O: X"DZNH. 3#CV7.M1'?
M- \/9'Z/9F]@RD'TU(T&UJGAH'4)4"FXFHE\MYC-DS-QL!$93_Q2KTA)W;,.
M7W<7D+'HY;K76B1NF97<(MP9W3/B.?HR"[3>B#*_28'0Y2^AL JI9OF>56 ;
MYACM@\5DQ%9,MP1ZD;9:-6>J9K+7J".<)J]L;6QUE&+*/EC#Y,:6RDI9;)&F
MXA89%@HOGF$U0_L/L"(Z1]MM12BQ\#F,PU$QP@QL!3ZR+$0YTGNWJ.ZJ]-^=
M^E;]PE4ZP,F;97CZ/:!.@A4@%\F!*3PBO'IGU0SLO;IZ?_'NU?Z?/[:;S(PI
MZ:.?BI&D@DRX9T8:?J5*)^]Z&/:I(&$/%_#JTMS]0=_]:M\;%\8MCX5N;!]S
M,I6N9< "^X@KNO!!F'!*[4%BDU:""2,'8^ 6(N7\,%B(&BED,98D#0?XJ&C"
M31JIS_)O!78<TY B_Q15OW-,!P%EVO(SA+K4F*##1DO-GG@!6-<1@QI"&8GJ
M;9A&#^\Z;'D(4V]$(;BJ*J!"#)RK5E:%!F% &A8]J(Q14R]U>A\6[Z/^HF"0
MD$?5KA#A&<$9-554E6@$NE$1Y5B5POX'[1]1Q3D&AD6*\UM3U?0%#+C.\>%;
M0(BNE>HGU&,])A9U;:OY2]DD)HJ2GE9N3*^$<J>2E!F*1.H+]4I9D^H28\/J
ML\INX? 9Q^M. P^B/&TSW'JDV,*LRHM0:1W]PA8P%?V$&APJ];$*AI.C9ID
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M:<H7(A:!T.G(4X^6/\DQEA&V1#B&21=\HKV&#_')?9XFY'E37$8W; 7FE8)
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M$Z320K[*Y+4KHQ+W ZP_'\''(G*M4I<_0Y_R%C/79G8EV/TJXS\$\AD'OM7
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M,MH%$/BHB(1.&?CV_M/E]?>K;TZ<K.[%*RO&J694]]::+=$BAJW"2<KV)NQ
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MBPBN! :,?!E;NXBQ+$ @XZ,$,6PYP3>BK]SW/EX2_P?B&(D<-CB8^"QS>B
MP@QESQMO+]SWNBE<!R\>#P5<VJ-'B@C>NA?"K[0P? <\2U^IOZN[ VZY^GZA
M-Y#1?7OAS;XWD@%>!0NZ"7NP_SU,8Q"PQP@;#</-89RG(ND5$8A5_5TR'L*:
MHQ&\+"O@H/$!\M]%."91A<\6,@-0P (R_>3]AL<3W@VH 7A1$4@/X!>"D.3F
M.'"&>+F^BN&.D(W@6X!0/*#+>LD![&64Y$H'J&R,,C%P#],/*P]6'9<Y(NL\
MZ!& N+0K!@^^I8$2O/ZQ(6XR!8D86&^@A9N5 )(6??BC2'$'_22%UX<I7"]
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M)Y#:@-&6&1:L!;&F+VZ2E(*1(8C;'BGL?=5JJU>DJ02L5XL[.ZI?V_LB3<:
MS>=9*.CA%Z#7!Z*!@,A*4*A3(#(E/I_T^QG HCMAR.!JRC4 '@+?"Y%.>,5H
MJ,"AAW&A-'Q<4JO3+N%?+FHZR(K0LQZ(MYXCZ:$6_UL!-[2/_?+@"38"B+8\
M(SPS^! !_A%CZB&YX@(LY"E?CSMADPBO&0)2 L&1H(.'(F_%]1-XYB(#HDWY
M0$8@>B[; 3<:5,:*28'\P6:;E%S^XNKWRW<'8'J-4::-E(0C3B$RM7[%:\!8
M)MZ&>7:P.5H?(#LN 21.4F2X!K;,9. O>H0D:J@?;1^[MD5%%MZ$S-;T>XVL
MF4'V=[#'- O[(0#\J[K*KY( [:<._>LQW0*8\/Y=P&'"6L(L0^X*DI:ER 'N
M;0*B>#R.0CBU)%;058S$6CO*AP)9J=F$DL)!+<'J51%<#3#!)@:&WO!VCPFW
MCA035AX"FQ./$M#.8I*7R%?5T: W@H4Z B]#>1;@0:7 R+20JT'4LA$@HFM/
M%,3R@!)&@.?$/G+Q0R+C)F8.=QABFB&1AO>WY!:6FM(I#9"B8D:E+JPV!LVI
M3[-1Z^DE@J-DPNJ3 F@A"^NL((I))TYN0M!R,EQ&*H%WLC RQ AZ((!;\3T9
M*?>%5B_A]AYP$=I8PI^0*$FO4"#U<N#;@=;,ZI"W"\08RPRY,N\,'A7!=1$N
MGK5'X)XA,CRD351TF(VRKJ5/A;P[[2;HH[:T325PV5@&O#YY8!@0O8'U)D"M
MB7:M6(O!-P]D,@#-?QB28FOXLH]DBOMAL93#H?4DZTC,^GQ +K@0-&4P)'(Y
MAPG"FH8"0"2 <<? ="+#L32T1@ @/,9[E]7>0=V)R!8ED_;[*5ZFN)=EW9&%
MP5\"$O;#G"P<Y( (O"F..WL.Y/H"' &^#9B$Y)-*BR_":_M%2E3-OLH2FXU#
M+RNZ&=A*N(),$A5ZZ$AL-]_2OZWV6^^;'"<IZP':_??-WL%77CG=UGK[J.?Y
M=&?'WJ$PA]?U%O Y7*#=@(Y5-#9XV^?(JM!0!+A?@(T[D.AWY]_@2M:>$)X?
MY,[Z*LXS-!/9($)QH?"K:O+#MP%<@<QED*(N4_%;$,X"%OX+L \9B_!N0(F1
MK..4JAX^6J1@U9*1EY/25WE.@T,B7U$P9'2',BU!5%F/P;<ALQO$I(>"?%2L
M$$2H\KB;"[0E6K-JK9B/R]=I_P&9F$$%582%*KT257RME)>XTI=X#5N\).=$
M&*!1!-HM6]0 H2!,$5;:#&4M\U9&$?Z;PJ-S19@L0\SS5/C@CD>2V1]//[\!
M5@FH&[":?A'96BR>"?L#T!UP^?'+Y8?+B_,OW[WSBXNKOW_Y?OGEH_?UZM/E
MQ>7[Z^5= [X=*_&TW8(+&"5P-FB=$Z[==^ H_V]$5!!82'4'*AK1IP(W 4!#
M3[ R\L(8GC)B)T178G$-_'P#O!/Y'QBF7U-TM8@QJDDA7\: 9-0J/72W0U!)
M;BTK5F@,,H&:VV$"J 3H!%#I_;L(.3H!6P7-;D]QX7^<7RC&NJ]"/@A$XWE@
MG-4:2?E .+2_T]59@2>O+V?Q#NL$ (=YQ(>OUT]6#UUO/<<X:&R;!.@/UF69
M\:@9@D3(R4,"FAHA/6L:E35=VFNTE\7+M "IK"(Q@'UE_*0\R=$S:).+=GTA
MV>#6QH+>#UBB]2)C6,!&R9,SM4%:DSY_6 =64\%3$AO&*3H3E61%HJ:2JCX=
M*+Z\! .*^%29^M7?F'^5#K@Q7)<$:-*!XIF11V.0@$%(]#@$^0P+#!J>X69>
M5T3$0%CFDW:0*-]7A@O69OHT\1(P@5GB@PTP4Q$0DY/A#=['1%+[AEEN0 ^T
MK331ZZ4%_!F%I.RB_U#Q8L]%]&8C>H?S(WHN-O?<L;D-4J7^ 8Q9^4C1L ,$
M4+(,.*%$BQZX9#_I%>QV8CV+N L*2^"+*#4RP_6 ?BCVD6$0AZ(9P C!]!HI
ML:KMU I/X\+1@Y1M!:#K4H,)$4( ,'KY&.V!(B92QYO("&0KEU4DI7@T/-Q4
ME"6D9DED?3D)"]J?=E(PM8.H'H9C)<]X"Q,4\?AR2X2@,_DFE+?:/$I-&@+>
M8T#%#$WB5;C!<(SP)E&OO!;,.=F;-QF3"1S2$M'#B9+$\&.0^3NJO%NJ,BJ\
M:<#J0(JZDZQ5U1%!IO5NI6DJ>W#&^\_.*H&_H!*<O;D7F@@[!@K;G#/L)!+C
M3+[1?[R% QY'8O(FC&F+=-/;ZLD@9YQ*2Z)CX)\5TSP[:YP>=9!OJC(J]6+%
M4AO$4J<RK?BWH[/&\7%K[L_-QJJ_'77:*]UYUV*!<YZ>;LE:CQN=XY,M6>NV
MP76QM=Y35GAOF><2E[9;KZ9H75'OO9F(;V>4N^?)U[P_7X7TL/^1 @39>TJ*
M> =*]Z@K4U:0.RV_DL+YC- ^FP;V0CF?&PYIE#QS>UQTEMOQBX-<<Q54W(Q$
M\KG.W#EU!F"UJHAS-E-O\#"ZVR&4H.C^_)8Q"S0!>!B=[210O_;RF9)TAW$.
MXYX1X[:Z4\3]IBUM^N.L\;H26CU.R=;&5V0M"-552[(VM^)JP8VW.O[)27-#
M.]VY/H8//]]FL[&!Q[L.4/SB^*3CDRO34=L_.]Y 0G)\TO'))^636]UM=L$=
M6^&BY:-$#S'JEK';GMPP=(O<S44^DE5,K.N$<S$VF9C?S<E/? KM;QF)N85"
M\;B][.RN.U!G"Y2:+3RBP\9ZCFC]BHG#C\5(>-GI5(Z$GYV$5^QYM/4D_$BV
MQ;9H)M\X=_!)#88M:SZ^L)=ZC3/VW!$M=$1+NT\>YXC6S\4<?BSF0%T/?K@C
M6OB(FHVS%TK"+\Q%\HTK*9TYM33DVO[A<=L95)M]2*V3I1G9KEA4#D$6H^+6
MR8K3'1T5/QL5'SN_R,OPBU@M1IQAM3R=^&=GZ]';W2$M?DC+QVEVQ;9R"+(@
M%2\=;'54_/Q4[#PD+\)#\FY>*QYG;2UO;;5<"'K#CZCELD@<?MR%'V?'CH0W
M_(A>+ D_U%ORI!F]"RC"NU9*<>0?+CW%;5E0;)&=LVO'VSEK+.L[?X;373\;
M<JCU")RCV5E6T7"<8VN.MW.ZJOMDMSG'2VA;\>51RN;<G.%GJ=;>XD'#"T+F
MU.\<KIC'L_Y)P^LK]WXJRMD\!#EN-E9T>:P5/]8OS!PK=ZS\62%SXI^U5TSF
M<JS\1;#R5F/% -0+9^5DE_R9NH[_==<ZQ,_K$N"7HX74O*'*7*/9L4:5.2TX
M< <'H&"S1!QS4#]AB1K':TC;FY]K_SX75#QT[OU"FT1C_1=[P-XB$V^;C:-?
M[/V/D]",6>"Y*MF;U4<.*((Z0.'\YO#H?A0[:)VN#<%HM-'QV[IC?IXE5,&%
M"6@(BWG3NY9!70]NHG&:4P-H^6O]!B\UT[KJ'H3C%/1P)S-/W4QRI5%&L*3/
MX2 5L8B>!(S'")(%X#@SO <1\J#3J)F]T 5"P ?@^;=.#M=X_$#,YQ]][SU(
M).G MQKXU,!#D>4B=R!<$0-KQD%/35U3(["G& <R"(0_<Q5F&G#Q1YR G?\A
MW'FL=!YOG?A=I_A5RN52TE:1!P\C&H/^A>.OJ@-T>;YZ991\S1AUWQ+9_PS[
MXJ>('16M0$5F;GQYFC3QFV9CXI"O31L@[UNL%Y &NQWBE'+"$[T'^1,'-\J8
M)CLJI3_S>CBC-.7I66J4-YP,SUD#L0@OA8\B\B8X"*8ZUG0H,F,;P))Q"B?.
M>.,A:3]QJEI($]=PJ"@/*)4X&!V7H(>;J\FHW'@1Q[33'+EJF\:IP6S6D&G?
M Q/-BY/<B^!M/ Z6"45-6<7W,U7!$_"#G@1IC?SDF>0^GS>.F SS@B;*V</7
M<" F?C<&^]\L'N[ 6PRX]8!,^%N/V-6[H8GC0Q'P#-=^7[)<+.^EV?;6<5FG
MY9M1V0"3;BIH%@\/)*\JU3@.M,0?-5_6!ETY;[9FUAD/%[9'%N,L8YIB!AO+
M<& ]CXS%6ZN89:UO3#BC^1..FDU^TL!:X$BOVZ=Z= F]]G7'?*Y:G0WO6LHG
MG,X++QN(%#%H:L9X=2L51EV.ZG4"=LT"5@V)7E[ 3MFSMHK*;,-V=J#56O,\
MBW]K6C3LFT2#>A<ODS7=TMIU0GEE=/1QH' DX\P9!BM![[>B&X4.=JNJ@]_3
M@D9,.P"N"$!6L*8XK&;FRK_(6F<1 [,$/GN>BC^BQ %\!8#O_5;$DO2Z?9Y"
M++):-PV[7N[SWDX+NE*>O2N2;AJ&[HQ6X<CGH(]D#K]792B?P#X .]/!;P7X
M?921,V/6:L940LX/C\S5>0OYTO)%2\3K9CF]\\H_/-#T#QE%W2)/0V< /L@K
MNYC6,HO#WX$24ID[\#]JJ$\Y/!R?6?\177_ZI^]=3T ZQ,Y0?0"C_CQ!![*#
MX2HP?(L0=+KEFE/ 'IZ^Z*$;1L0#&32\KRD^ :,Y$J.@^-A>*@,,^=&E2AB(
M@<  &BFC\]=P*T&,A(%W.TS@7?"^E&4%/>EUZZ0:(VH=F<\S,:NIJ-'J2#>+
M8L\_\)H0ZHJ#I?' >_]S+.,,GKP=NZ(GO@ES>%UO@7U>)!D%0#\F29!YUTD$
MFIW\J<*ZGA@EP-[^8$2CU%*P;,*48W<8-@7DC0<AAB9%!HB7[3\FD#8HAUF#
M:4!@RA!,I>5G\FT]>$_1!].O, %O, 1_"-CFX"T18T\]IXQ4 0T6*=!W!D29
M)B/.76#U3F9OO329B"B?P!<3ACK<,,+P/)F:E4L#:7$%>$=U,?!7&(6Y#IG+
M?Q?A&)_XULK\PI :+3"EV8O5LYPY406@PS;W&)L5D[=AD ]5NKM]H\*!9GF+
MZ )(BWS^+19R(,>4Z9KPX/2H#BC\_V&J5S,&CG[03:7X<2#ZL-@W(KH5D^S5
MGZL4 <@_!<-YVW]<XOGK?W536,K=IZOJ+6J+PYG'4&A??\4K;S::S5)UT-OR
M#L\:1TW\M_KYP7M<$Q+ P4; %)'KW8@(DXX"7!#3)]"E3FD!6FMX-9PCGXQ1
M903.<2/2B=>5^:V4,6H#(5Y#J@'(TR*R604(WY^^=Y.@5>8KMA"JD@G0#2A/
M!.0RK!-4@B)-9=R;J&J ?D0\H78MS.LQ[0>XT]+L_E$E_6:S>PS<O&[[G>-6
M52UJ^Z  +:H9S51Q@%9U5J;>P,TGOU#&4GD1!8Q*)V,*SXG!V&?'(AX:<FH[
MDL<HDE%R&@B$FS I,KQ3YZFI!"N\M8C[XB9)"9/+'.$I+*HF62D?0U6V4'X2
ME_242^5D.X7%L%RQKSP3E=R>A?/WZI/M:&'=_1+)D: P<3,KTNJ+M*.CNG(4
M=YG.$=-05+ITC8NEA'H)+M:Q;R3EJY$*[IV/DB+&[+O?"KB[?>R7.,&QUS*_
MBQ/$M!R?E(2]JZ1UGBG,Z"5@.T^TTB.]BZO?+]\=M,X $+#.4=BS<A(1<MTB
M@X=E&1UK CJYCV<YX;S)F+"4$N?&R,/@:,O3M/U<=."EDRL2(+_P02"EX:SQ
MEV$X'FOM#8PFUIFJ1!GP8SB9D'&<4_U0[JD,RSD40H\U28@"J'= RI)!*,XW
MI0Q&;;3Q\6)LGIZ%N(3K29-B,&3TPP0G0L40=@M+QHQ,4!0%&8]$WD !@81-
M@M(![R*L)8RWR 97FZ0,QCR%(PXI+1.3#(=)$2'-43)D3U.4.AX/#Q*V,@([
MM!CA]5&"B93PLL:C&DT;A,4U J+&HO]:L>55YC%Q]/9IH\/%?^V3QNDO2\N-
M9N.HIOBO9+XB9_319X]8@HG#!WA6!_B7K3=8*L:NLIU_2&;J<0(+"U& 3.8F
MBO=A<?"62&M"RFG"C 2I$Y/?O![2"9DM> V")=*YU&*<H2##2S^'D0!.=0GV
M^$3;8!.?E2G*YH57L8Q5F<+55P-E"P^.+"LR8F&P]A[Y],E4BV%!(V0KMJ#/
MBNXHS!6-PFU4 P2KT?MK>+\2"U.<)D1K"AG6WT"KQ81ZV,"UZ$N R#E\/8$5
M^EZ8$]8:#A+P(XG?L-P.PH#ROP6G5',6-3T%8 :8:E:*R<@QBE1ZN[&#2=O,
MK/1Q.!W$?]RP%Q>C+A],E.15?CZ;NH^YGW=E[3>\OX&Q>X,:15+DO!Y/=(LX
MT.OKB<)HP+=)^@.9+F64DHZ,F=1 :,AR2V1*@HG*;\_&>*I(=D,%T"(?@BW
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MU:N =@;TD-KJ-RV,2 (.FK/P ZGX7O4E5)R22N2P6/1,M2>:%98@I[H2JK"
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M\<2CE(/)BCM\6O:T-2KR64'&N<PB3<\HTG1OF7(AHE;:Y($8$F3!=S*L3<J
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M9,UXS&E4R0(_6[5<:RT+M<58_://%Y_./EO?KKZ>7UQ\N/SRZ;D":=7T>QK
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M'** &#EP_!PV9F5(5:>32&"E2;B#$F5/5/8^G%5&#IA">A;U &!P7IM=O-+
M?%<)SU@;=?"ZT!3R=VQQ-61;!]G %"%1=W;7%5/RAIAQ*N0YP>3-8QE"@M<Q
MC_#I[.R;CA]1_0]A6O?UO"N.U;KC86[]"!/ Q(#<^JHL<3!78S-T+8H(81;
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M_1(!4<-I/63?G'_]^^6'DT;? LP:BHGG$D3P%U@EG@W,Z(HH<6"]<>AZCH^
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M,)\8QP!YV'WL^##;4" (D&AP/*3RK]-Q,G9\)+IO8R>:.*Y("7%B3?)YL&3
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MHY( 3F@0"FY="30 S(3@P*PR@0-Q28I1U[\-Z $/ J_QIL 4YIP>,C '0.L
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M@S7;LX.-4M\G-BSCKDRP/1H)61ZV3-&7AAUAG>C-YKSHS7.XGX8<WO<9;R4
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M@ O0N$KFQ$>*@QOCL86)Z?Q+>">-@EV&'EL=Y;;G#B+W^UHY*>.' -6;A'A
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M*X6_96Y@)3F@JCW-[("9#QJ$R^^898%9'7!X@,F/R65Y^ZZ'[NM_IYY,CJ<
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M2TL/VUQFV%FYF@Q[9\6Q:]99N7N8F;(DLXCB0DR)3%J3BTZQ4JO9T\&7?-X
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MK,^,N+\%ZL\_M-:MB'7!]7;:F2WJJBTR=J[@,A.$DFDQ*X^,0V9K%T)KI$
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M1!HFN(969DJB.IG3,":E*)3IX5[\G:IH8M!;P GL@/.>I/-8B.\6>@HY<#7
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M;4P^E V7#W-('D!LJ'BH0#LVB'JU65ND?R"!W[6O9Z9-T3E&.(U14_C"N_(
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M;=-WRN$S]&G/5>. T=1JZ9&0I?I6%[;%1QC+WNKB*%Z)$:/AM>'L) MH7K-
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M,&9+DJXC&%1P*Q,:DE>=X4H9$78/JRY]$^4B/X_;0?Z!@1DJ-L*!7Y.@^*B
MZE?ZS!EZ14Y%N8N*AQZG.NKHQ5L:IT77758'^^)V6X$'>UG8"\*0.T@M%F3I
M_-4-L3<Z NV_[=@C&XO0/G&O9H67$R&GNYL:"_O65HT@>!6J*PR'6,82($&.
MKI2-K+6R_M69P]\VC2UAVE&LLEM=#3OUMH5:W(I85TD*I<)38\IU[8=-%LM5
M;G.E2+Z(FY+)E2I:22)0U=%<") S,QB4V',SC+!2?QJFUD1?U@;SYR.0*U0Z
M'43?,ED.K.+KK-<0CT*XO@QD&N]#%KB@,.(G NTH<O1"-Y!I/M\=NA*UZCT%
M13U8!,524*3@X!\*K5A%#ZH?A0,I3(45E;TXE9DQQ'!VMW&8@8BA:G0\T/QY
M3@4Y=(N14HS6<)2<RU,ULJ_.@1<Z5&ME50$R9FHK';C.%__)T%,-HC1+R*9
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MMH?3(CPD0J34;QBKX]\QJ'N6@"]>R;;7(=NXB)#:)!0BF 9^G#%QL8+G+VM
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M6@#$XN/.3+'1%GW43[A8(7&'XBY.OCL;S7JCM>D$:9KE(JTRB(7%C!AFBRF
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M;BYH8'N=@DD\>-M*.WRO$V6ZXR(4>ZOTK.[%V6CU"J%WZRH\NIX/OK!=K=_
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MPWF>,WOCIHQJF)=E==\D+!?U;$<3.%:V=RAFC.+")^:ADL!FEJ.RWMQ.:9^
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MB1R.9N0L2[QE2FE@6;" >LF!5-0!S @/\=S%,,7B8K4>UVQ5TA RM65JJ[=
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MP.0VM@)(%#1 VMA4I!M)A]*^FF*;Y[99%SDL\V9]M,TZG2WK8#"2,L#CRJ0
M3 D,TB$J_E!)S#%TJ<?V-9OU>44:S"^$N?N_B];@LBZ% .LU8[<NP)=G[(E*
M%JZ&D!</DOZ)[A7A.]W&N>XUONKVA5^/QTN[%;G?N^K]AKX8G'1[\?)NO7'M
M651^=BGVFKWFZWG'4;?S<="U7SX6-SJX&/0'4?R,TWX[;0[FP^HVAQ5[>[@U
M<5B])1_:_H\/EY__=N<&4]Y\\^'+T>&'+\V=??CYL'G6W#DY:YX>?V_B?=K<
M>?]]_\W[;\U#BYN'[= \W?L'(<X%M1!0A"B@4%&@&27 <:,4$I!P16X0<1YY
M6^WU^Q?>Y1U5YQVEK*2"AN0V2=N*^"@]41M \(1RI+$R'*]M$J;6*63K@L[&
M;LS\H5!D%]N#=S-+Y3WX'/;@EW\HHD8RJ8!Q& &*%0/:Q3W("?4\DA"4J=MU
M7794/BQ79%NE^@+!.00(9G%;,2^ T8H#&(*SEBD3/$W4QM8IQNN$SM9^O,:>
MVBHXI2Q4.-H,#3UH['CKSXSOE9\C:+V1SL[2LA>WVWHC[I]S'Z_UU;<O'\'0
M]^+#.I;EXQQC@;^28)^='LM%_DP[*>Z)L@I0@>(/+^+9@"0&F,=%,X@J[<W:
M)H+K!-6I8FN&;TW=E1F^#PO?Z5@LA^,2.0R"*.J0^E3EPED O99:.&.-+N&+
M<9W@^[R,P=?4\(E#3=.LVXUSW7*@U6E8?=X:Z/931V(];R9;6FGEJ_5[%Y=O
MK[-=+MX8P67Z6HB^]K_-AEDA@XT7&D#&!:#$!: T,4##@"U!1'GOUS8ISZ5Y
MGC%@EU9$.0-V^8"=DC>"0$@[:( PV &*M0:&!P&0B*\%C( M"B;?OU!%3CQ;
MM*7#Q=E%62C0^="RK5QQ9_%9_.51Q(Q^?,[X:IJ^/OB!CB-RN[K7B?/6'UO2
MG7)%LRZU1&Z;+8XLE8<T$ @05U&7@K*H+T:!@5Y9Z8)FJ5"J7%=\MJ?#O[,1
MY#F ^NZB2 9U34 ];2!A)HA .="61X%%1JG%4,>!=%A029GSA"50PSG5CY\$
MU"_"-#(FK50-J+IGYSU_XCO]UE??:'?[3YZN]LR9;NGBR]B:%IFYV^,K6A8"
M>1N7M>D'!^%0?\^TMT3:FZUY+ 5UAE@"%*8LTIZ00 GH@9!>$.X\$XZG'-WX
M]CUH+UM5:HSPI<LR&>%/BO!IP48BCX12@,75!10I&+45 P&GGDFB Q4J"C9X
M'9'["#;U,\.L6 +^[_JB;T\:?WC='IPT$F1T)V6D1;QLE('*)]VV\[W^____
M28S$;XU?*O/-OQO^[MD$C]'O9D53>)]42"JLT-6"E\DBF0@7(\+9\LD.2JDX
M%4!C1R(18@NT)A 0$K0W3$M"<7*!S^;I+ZS?U29%/^.[3HZGC.HEH'HFL 5Z
M3:P#F H(HC C@>%> T2]H2'%E3*]MLG(LHHIUR\3?P7M.JD$5_Q0K]MNIS#=
M5L1:S_?OYHEZV8K>$\2[[+<ZW5[DKKUJU3*'+<9ALS65(5$F"B4I05I&R210
M K0S,E*:0Y[K$%<MK&V*'-SRC-&Y+!DCH_/>Z)SNV" M-$8P@&6*?$?: ..%
M )1[;Y2G\<\^HA/6")TOTX22+2(ORB*RU['MBS2'[\I>8EN#0:]E+@;:M/UA
M=U+$S&QX-S:<4YJ9<@P-I4#I%/QBN )&1#;$EC/F PW$N[5-<A]O43:BK PE
MU,*(DHG@48A@2BQBGA*LE  >(P>HLY$2""? ">,"IM::5/B"PY=F>%DQH6FL
M\'.1%+T4(>HG6M\MJUV6L_.*Q#EUW8L(YJOEOA^-UFXE_G7'<J#+F*!G<[X\
M0.WLK8Z;9[+/X0I+.U9F"VI;R9AQ# (2985D"PM PJ"!M0YC$@)47I0%M9?6
MAWUY:'IB:UKFU<RKM97;,Z\^+J].B>L&,B45Q, @E8IXI+Z-E@D0N.62>A4/
M2A_U=K0>WWXVO%J(]+\6BN"PJ$_\,1SXF>X=MSK#VS\^$G'1":[3,/Y$MT.C
M&QJ#$]_XO:M[[M5D):+Y@V;%H(NGNUJ+<D;CX-OZO.]?#5_\YEK]\[:^?-7J
M%$,HOO1;=:UJ@9*^,C6;Q6R7;__VK>4&)Z^4VI",) :I-*7JQN6[:*,@EZD-
M4KY'^880XMJWX0:Z]KV;+DLV$&5+OVHQ6'FKR_Y$;;S!+6]],D;4ZESXM?]K
MB?4_#S[NOONCL;W1>+?U;NL62N "Y757=$H^?/KX<?=MFI(/![_O?CC\>-!<
MJ+KN F3W\RF)EWFB^?BSV_?G)\7.T.=Z@9UQ2XGQZ9[L]C6FG\E2?KCH]WV[
MV-%=$P?5[W86V=&KA>/MDY8/C=WOWEZD8G^-@Q!:UO>6OX'K5O7[>2R>;O7.
MHZ[0[:PWMBY<:U 8*S^T^E\:92N'@?>S>_=GHE\E^<@XAC&YBLR;CH=[\.**
MKU(%DI:]A<!X&&5$;6V1('"9HN<ZJ65-0_?BGSM%*-UQKR@EU1M4(F7?)XVN
M8*DBDS*T.KIC6_%#_4'\0]$$8V.J].7TA%5#H'A#)#GQO-LO2JB\ZOFV3G"J
MQ,-*NQS[8C7%</05;>)0+@;7?^41Y_[&F7X-^+Q9&<U-H8EZ;Y"-*C Q&%.2
M"@%H:9PQ#DM(?1#_8)D*@)??.NF-\'?L@>EY_07H$)_QE6Y_TY?]M5\G]VG<
MDE-3?]VLW;BEY>26/KWH#UKALOQ3J^/B++_"M+A^-=>;_S&].)2;-\5(VYC5
M^LI=76RZX9^&LC-,TS_DG^JQ&E1M,)C^K7XGO/C<4^^,F?X=Q<[X?>O3Q^T_
M&G_L;KT]C$+RP?Z[K>;>[L>2?/>:VQO7JF]U>8+M@^;'@[=[.UN'NSN-CX?Q
MG_W=YN''QL'KQL&[W0];AWOQ [5_BE]:G4:\;#O22G^]X;];'W=./";*A*ER
M.?19]R(2W+]KJU'S#<GY731J+C806;[N*S<(NOZ;-UWUYCLR3E_\6&^W6G>7
MNVO7Z>@G\BABM1=(YS_7D=>]?F,W'IUNML3XDI2H55O,AU*0G_29D]-X64]\
MF]93SVKF8)ZYN\T<4D_:N.LI'OJ#_^H[%W=L/W^'&+&:3,;2V]T]=A///)UY
M.E]&UNJ[7M==V+APNCU+4_?.7JO=XRX</?,\XU\8T<9ZI8ACFE+-%!>(6RVL
M\H((Z__922(BC/\%MPLPK ZZU[WN6>H[G(;P=VMPLGW1C_/A>[O?JVCVK7[?
MQ_^Y%2J1M%_%QIR?'.S\U=K?^7S2/-PC!RDVYM"RH],_3YL[?[:;;XY^'.S$
MZ_W8^[[_\2HVAAZ=?D'-TR/V^;1YLG]Z!)MGGU <W^7GOS_ASSM[L'GZ5ZMY
M=O1M-C;FI'5P^ DW3]MG^WCWLIGB: X_Q>O\V?Y\^#F.\3UN_KV'/Y_^GF)C
MJKB8W4'S\ ML_MCZQTDIK?,<>.0"H(Y;8!1T@!"DH7:"J.!2Z4="GV$&;N:M
M9\I;FFGI4U<FQVQJVJ=4P%A8*3'!DG)=\!8<\M8M O@R;STU;UU.\A8W6CB<
MVH,R@@ ED@&I# <8<<=Q9#!,S=JFF%N[,?-6YJUZ\I;"4B)*@Y7,4T2]BF>S
M(3!(PG%PD"3>0JKB+:0R;]6>MYI3\I:5%#G"$!"IHP]U&@&)A /*(F\X)DSH
M0MZB<EF1R#6JJ5!K"BK*M39Z/[/$/<_Z_PMP%&$&D:""C'H"E0%KXS#QWDOB
M-$DQ'X^B$V8:6H"&WL^H?<)[)I#3P.F 4DM$!Z2!"G"#-1&.0RSAVJ:ZM\Z7
M&WG4%\C>L'@(!2R8%U109HQWS%@G!"(B*DR/HR1E("\&Y"D]"&MGH: $."@Q
MH)"0*$I8 ;P5!FD<M:14D@3!V?K6&<G/!LGQ&0UFBDM!H]I+J>2!195!QH.9
M<8?DXZ@-&<D+(7E:,Y T<,.P HYH 6A0 AAD-,#22:H0Q<;$(SG*4S5"\GT]
M7_<IB?B"RPEYBDGJ0D]2"P/'N*$..>LIXM)+@WAVRZP6&7R:D<\-400:@T%
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M,TV93!FECJ=VLSBUJ*>8<V!DE*&%2\O(A4":W>F(>K2-D*65)6T%2VR !"N
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M%ZPS44QR! +M%&7(>\&97-M$? 7*T&6.6#4U*G-$/3EBJ@>?"MX@X05PUC%
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MGU2W2L]00X\AJ3'H-CH36(J?*L'TPDJL/;+N=6L>S-+1\JD-SFA1G!#*F S
M>Z( E5  PQ@'TEBH),)2AZ1%U:0P2RZ]5$-%*"/Z:1$]I>]XBZ)>PSG EEA
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MT?DR#R99YEGVP5,_U*Z,L%._J=LZZU[<4-=_V<I3#2<@CC4Y!'6[(/%WNN7
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M2N;&S(U3=0\8<A!#J[V#U&,I$9<:!QD<B](+#ID;GP$W[A]N3?6?(LHJB"R
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M2D5*VRBE^W1GEB6T<TOHBO-3B*BRDS.']BWBQ%ED"-:(8<QCP,*H%,HBNH7
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M>['J3PW1?#3_[K-;[GPX^%#G@(B[J 9SOYR=^^6>WK?S8XM&OAO>HC)@CVK
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M(L,E1EP%@QQ)!!%ML1*6>6M$@?>6POM>MPBNA^^"XS5QO.2]$0[D1GA$(3+
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MS1\F>._>="C@W1QXEV,20H2@K$'>,P5FO[?(1JN0(8YRHX*,)NWL,;Q:0:2
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M?%5GZ&B[]4<0QGF14O3M[O=/_M3VW\=J:,>Q:G\?58#FQC*S_=#^$O\SJ3\
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M97/HJLTJN++49>TL13AZ;NMFZLT,ZH^G@UX<V1XLCC]G4:5)#X;O0[O<PA#
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M/3]K'F1MW#"9;WY>P)@?O._7BZZ.JU>["<M^RIW9$W09VX!W=],=+[M3.,V
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MZGQ;R0;6-(TAQ&4(7UW9=P-VST#; -3KU69NV_\7>R*M=$(:7(&'>_N?CDM
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MP+GV-JR(@5=_!*^N& 99;@K.F,5*0890Z0P1>:%)HIVPF<LRI>@F7OTVU^?
ML'>086_,,!@8]@<P[*I.+Z5S>5Y8PE.TY',KB<@219)2Y065*<L86O+)'>+8
MGR$>\7I6S2V9.E?_9+&%OUF?_Y8 J3^;0SB: 7RN!3Y_KFGV%J6#5HRDILP)
MM482E6M0[PLA<I.7)1=LZU'^'9K]X$&\P_Q[XZK]P+\_F']7M'WK<D%SIHFP
MAA-J$DZX %W"XLF:3,"QHO+P/:;YP,!WF(%O7-4?&/C',O"J]I_J1!1IJHGF
MN08!K!,BE'($,\XU=XFRN=RH_=\* _\,?GR@<E\HUGZ;XO]3>!AN2>_OCF;
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MW1H0F<VHRXE)'2<T]?%]RHGB+A42>)QCG8?AUL"MEA*S$_/=1<1B%<X<]MN
MZ3ZV[2WTH6;%C6W0@T'\O[L@_H#BUT!QO69@?7/)_.\J:G$#'',_ROD,V#E@
MYU#"\:%@YXIIR[D2J::6@$F3$2II2KC)2Y*G96I2*URIV<V7<!RP<\#. 3N'
M*I'W"SM7O0>,)D92*XA1V*Y':$D4+U*26*U$0?,\IU_JUW+_L-.['?[AVUM<
MWKWWQ_:1>3[Y8"?SZ>PBM*K\J9O$?-;I<5Y21JFOOIR#_#:9)"(5AI12Y4H6
MCJ:)6VWZ\M4=5J[18.4V^J8VM-!/2'U(33%[ZP,^.CN?5;4=S>3'$;9=G%4
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MPA?!"O76:76&LXKSZ83-VMMV<(^6('EI=BLBPU^:A!.97+7X[2!=EK85N]^
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MU9$,(MHZFC02.KB0 /$G-8S42&A\PC]>=TZ8J.,T6-9(!GQ\7 6MJ0K/ ]
M2O87BQI;5RY!+59UKR]Z9:17YP[!Q%2@4*;UO&DT&RH]( IB\W/XV0<[[K^W
M&Q3>=@:#+F;=UD4-"M2\V,=V9;C_7--1[*<0,4#\[39T9[2[.I$JO*&6Z/,
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M(N@GZ\)6]F%V=4P/7P!+ -;G (T^&H6Z*'H^Q^,0O:NFT2RH<!>G^GT7G&K
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ME:^1HD8O NMX7'R0,'6T07)&4=*87$T9^2XGWMM0\2Z;OW[F3;?FN0@;""%
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MH^ZEH7N0#A#7C7O)[%>C7.L'&;<??X8MU"88[HM&R>J/D43"68>?^@3>J-@
M)[4Y(&$QX:[WV#9YNI@.6#F@#[P;C>D:M2?IE?V9+[MS&SCM.?I\.@;:2R'5
MLJ&;<(TMN(VO<-D-&8&790260T;@#\\(O#+#;\51B1F#!<L9_H92R7C*DLPY
MEI0VRQ*>7_:>JQV<R^])',OS3"B#3:JS/.5%67 N$E>DA1+%O72!;B;T%>"?
MA[)/G8A<*OJ$]Q%"6!]O*S3*]JSG/<7TO0WRN.\^:3Q>RU(M.,QZ@JTGQK8W
MR[%&:'K_911I,1&DE6P^$^,CZ,/X9Q21?K16;H8Q (E]&OKR,&&ZJV."WODB
M_!I7&7:O2YG WWP D#NSO<5MF-E:XL6NUK-%O!.UG%_1"X/NC'9A+>'K\^[H
MFIR'KWF/OS0;'1LHDVI?0,QOQ-AN6E%O\/7-^,9E!'WJ[\C9\TUN%V>H2AZZ
MO\*]ENED=V+^Q/M #I.!=F, =6AH^^XD/TY<;M.4I205!26 RHY()1WAVI1I
MRCEE7W6#]!Y@W]%IOQ-NN!@2<\_B-;]PB2-XP^T$U[&4&[5)Z;U$^>PQ*_[*
M%_<<(:WZL>$OR94!<MS1]!K5'O_FUKG%CDC*;VF=F_&=,BM^1.O<,KOQUKEB
MA[.??:XT$?=FKO=I7X>Y<OYU\[D/S6;XE<Z^S97H?P$E"MXS1EGQZ]_6=298
MVW_SSESF]$Q"X>"H/7L;%J2D_W.W-1%^XJV)YL=/O0/>E/N)=^!Q9Q__Q+NP
MUW,*>'QX:G]JJCC".@E+Z[]V.YQE!Z W.L[G(^\"'#7SOQ,"5EQEY$6DP.2,
M-A=[>_1O.5E@7"G=]F;7-W7*B7MT&17=V-XFHWNPP_^QNH4WM_S^LGTKV;NT
M[NBP>CJ+,22L&N+=58O:;*UTR$NL+:1DF<D-6$\)9XXZJEFA:)YS9H^?9TDJ
M@MO*6%V=R7']?[9(N9H"W?FO6C5H=V(BB=<QX1[H%C8(?E7>4Q=6:/=R?O9V
M[U6Q_^[T_=NS)P4VM#PX>Y4?[IU\.MC;S?9?_TD/7K^H#O?>7+Q=;?=R]O;]
MP='[B\-G+\[>'+VG!T=_9F^/-#W<>Y+L[[WY]';O)'W[[#D]>/?O]QO:11]S
MRD1N2D6TR0RA%/[&2R$)Y\92R:U39;;U*.59$TUK2.#1BEOSIOD!O[TF7PRP
M-L#:#X,UYHHDIXG.R[( /,.&Z#E6JRB3LC!:J@'6;A/6#AXOPUHI*-.I+0@3
MRA*:ZY1(Y0Q)19XECAK!E=IZ5(IT@+4!UGYF6,N$*:W61I?,TLPP3JU.;)I1
MQ=,RHVZ M5N%M15M35I;9IG+ ,=D2:A.4R)81DGI)+.)=FEIBZU'(F,#K VP
M]C/#FF.Z2-*B3%U14NHR+FC)+35IFG%#L\$(O558.US1UC2('.>*C#"M!:%*
M@OV94DED6DJ7)JZ410I&:,D'6!M@[6>&-9EK18T"+"L**E@J.%5"2R9!>P.%
M30ZP=JN^M:/=^?Y+A+97!<SAXW%:(GCE@G E)%BA-".@IU%BBHR6*6IN@F\]
M&GQK ZS]W+ F9)(:ZT0A!<";++E*#=,\SY/$B5P7-PQKO8;QOTT69\1,YR0.
M.V#>M3'O^3+F92G>)9 )<258IS2EAG!A%,DMHX4JJ**2;CW*MI,BN2^P=^VP
MLM;6]O#O'H#4XYBW'LMOM1F\WQ0Q7EG^I7D'V?6V<"/:WV?8RYS5F; V2?.2
MIM9(Q4V99:D665DZPWRF?])D^B??BW\AB\8<37U9EN8BP(!XUT*\_;4(JA6*
MZ\PXDLI$ ^ EH.ZYI"1*E[9(C)2E!..US+X[U+ 957ZH(C=P\M=Q<LD*C)^S
M0DA&,[#(DDP["ZI_GJA<ZW+@Y+O(R:M!0]!3"@4F-=%"<D*S5!&98F5OYC*M
M5:*-0C=4]MV*R\#)=Y:3M7!99C-JA+!4I8Q36'0B2I6FKJ B^YLX>3!1;I#-
M5P1VP1/KJ$Q):75":%%RHGAA"=B<0EFC,Z4-6B@IHP.C/UA&Y]+( LZ:*DFI
M*[E(E'72)KJ02N=.#XQ^[QA]-:QD79[)Q#GB@*L)U5E!.&4Y 6/+)(P""N0)
MR/-MD14#HS]81E=.@TBGB18JI9IS!5*<IHX+5N0"S+-!-[^+O+P62W$ZM:IT
MFJ06>R,DH*8+1RUPM$8CBYJ"66!F40ZL_&!9F::I$04%'@6&+GDI,\VH8485
M7)96TD%FWT,^7XD?E,#5A>$Y255:@G9.!>%I <IZZ5@B"RH3+K<>%=M)?I<X
M_5MOGMVC$,$?\B)V49HT79N^YO;AM:/#7X5V&[;O?J#=+W<W/K#75L(:4.Q:
M*/;G6DQ ,LM*D3.2RX(36F:&2)'",>4E$UF>4*:*K4=EFJ]!V%H5A&LBR&WF
M=0R<>TOQ@(%SOYES5V, FK(R3:DB96(%J!\F(\(P15Q1%EG*A$TPFI=M4#X&
MSGT(G/LW^__[G#N8%3?(UBL"N60)+SC/2&JRE%"5Y(0+1@G5+&,L*3( :_3Y
MY]EZ,N; V ^!L?]F?__ V#^&L5=]_$HK8](R(]0I1FCB&!&)H<06VIG,F:),
MN??Q)V)@[ ?)V'^S?W_0M;_=2E[UZ=.,\BPK-%$I_(<F*B$2+"0"AK%,>")D
M89%YQ6 F/TS6_9O]^8-,_E%\O>+#IU([*;*$E%J"$:TY(PJ.DQ32*F68S0IA
MT(>?L3O"V3]!AO]:;;@]J^V9LK-1_CW5X6XP=/E]U[[N'!!>1X7)5"$*K?*2
M:>I2JN!O)0-,3(5F3/HB'-\/?\.USF^!MU=KSOV$9HF6FI,BPR(<3(+)D2E#
MC /MDVGGA%"HM=Q4FO"=N=8Y\/I-Y!WFN<H+56*7':IT+G3F%"]=*1AWK"@&
M7K]-7E\-!TC!%1>E)G ZDE"9%$0(9@@<N\P9,];D##09=E,)A .O/R1>%T [
M@N9I OQ-<\J D*35J4Z4H4DF^<#KM\KKJZ5092Z8S1FQ29(1FC%+N)62)$)I
MF6@X/RZV'C&V[D@<>'W@=9.5+DU,F22IH<H9D6493Q(+TEXI:O.!UV^3UU?#
M!GF1@=!VBF0:+^V6(B6J4)Q(E3NE-$W*3&+9XYNZ 33P^D/B]405F<A3S:0J
M:6Z4D'G)LYP6*C6*:S7P^JW:ZZMA!F5*(S.6 Y\;1JC &N>\3(EVC)HDIR#J
MLZU'?-#A!U[?(-?3I,A<9EG&2Z06L @+E168/<"YX_J&>7V(2]PD$*S$)9(\
M8W"8H-?[4AU<ID10 5(_84IS*E628;.#;;XA,?>.8L%/</'@1FL3_=2QV>N$
M)$1JA$@Y5[J@J6*28[%"GL+?<RHMW]B%>+@U>:N(]V8M5('A(Z49);F@):@_
M.B,\<9(XIQ*6@A#+'=Y#^/[[ST.6Q9WE9)8DAJ<6R,"F5!96)FE.78Y94[QT
M^<#)=Y*35P,1+,VUIBDG5F+1DI([4%U<28JL**G(,YTH3)7*;ZJAR<#)=X^3
M'9-.E#07AN-]P$PR!XCNT.%8TDR9OXF3!Q/E!ME\-091IHFQN2744F!S8261
M3F/U5)Y9L#MSG?C:1+2\J:+1 Z/?/48W26&T0FN4I513+$I7."D*8X .\C(=
M&/W>,?I:;2*5:>Z$(;8 H4X+PX@J"P/<SC0WS,@R%?[>@OCN<./ Z'>6T<N<
MB;R@!5:8!,3/1")5EA4)RZ2R::$&W?PN\O):@"$32KFBU(2Q4J!?D1-5))84
MS!1.**K*#"\-IX-R_G!9&;@WIQ;8.9>.FJ)4U*1&6YJ6W'*5EH/,OH=\OA(_
M<*)($YU(X.Z,H3O-$N&<(@(T<^:<9L#U>*^!9C?5J6JXW/#WUB;ZJ2NQ7>O6
MY=\;'QAN77XCBNFUF(!.BI+F4I D80AB.5Z_M);HTBDMI 5IY0#$ONO2Y5!#
M\>YR[M\<#Q@X]YLY=ZT_@2LHSQ+L9RX< 7TS)R(%@Z-,.;-EPB15V%HI6T]:
M'#CW(7#NW^S_'ZY+_R"V7FT@I 4M4L.)4JH@5!E!!$<N5YR7FIM,)1I]_IE8
M;^L],/9#8.R_V=\_,/:/8>Q5'S]CLK2%M"17B??QIT24+"6\!#U+.)8#@/M6
MB-]5!W1@[+O+V'^S?W_0M;_=2E[UZ1NA>(*7!DR:@2Q.\HS(5')2Y(9:4<J4
MH:\O*]9]^@/K/@36_9O]^8-,_E%\O>+#%T+*1+J,B%PH0@US1('Y3+*4%[I,
M*,\3A3[\G*W[\&^%LW^"#/\K:Q.E/R+7_ZK?Q;L;86-^R^'XS'2AQK:]OS'T
MJ;^I_;G34N,ZQ5V8*%)@?<.LI*#Z2TY%ZFAIA%$T-9F_+/;=LF*X&/HMLN!D
M+1("YV.YX8;DEN:$@@ @W.2&2)X+EJM,FJ1$?^I-I5K>',/<<M+'@)P#<MXP
M<J:P685DE&NAJ9%:)D8KJQBW-*$V'9#S5I%S-1*5T:RPPB:$8_R):EL2Z?*4
ME,KP-"D*EMILZQ'E W(.R#D@YP_.(09[5ANN+,\T3:3AA<H+6? BX4Z65 _(
M>:O(N9I]8X13<$ $C@;;&R8,U,T$0P1X9(*97+*M1X)^=^&A 3D'Y!R0\\OE
M&07-*&;!E=I2IJR4!DU"F>=9FIL\'9#S-I%S-9I:R,REB:0$RR\3RA(,I&I)
M!!<T29W,BKS8>I2R[RZ[/"#G@)P#<GXYAY1JI\!$SQEVT^*ET%@D61N6<YTY
M*P?DO%4_YVHL6]!"6,5+#')IS#!3A"<Z(P67>9*(G(/Y .;Z356!&9!S0,X!
M.2_1.5EN\T2#K9<!<*8:$_#A_S9725;FCMTP<@ZI!#<)JZO7 0T&^7+02 43
MH)9R2R1-&2F4S9UD\"5>^TVW>?G=Y03O#++Z;(1_S"6\%/XTU8='S=(.%F?
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M,N&6K 0]OS[%J(7%J%'G9-J,O/$,FC5L-YXD7^$@'B;@*8:%/GA[.["B3]]
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MPC$IU6\SYO>=LD8RD;O49HI8X7F;<JJ(U))*P8T0";DFTZV5M8>5-;Z]\>$
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MMES8=D#?2^ZL9$8@(QQ%3!.,! ,(E$8D/"/8,)6OO*37Q>BJS+J0^U@#WUQ
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MR1-_V6/_Z+SH_C:=@_:#.[+2A-YTJ_!F]6XUX;B4LN>9%CTG;CGRN<%.!I-
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MBEC)D)\YZ,0T6K^N8ZN/!MW_3&R5.7HZ"0I]; ^'14C>E*-H![EAKS<\:[1
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M?8DS2V_>R;"U>!X,@>8RG BA(L]H@HR6*6+6*B13^*NF-DV(Y%A(^A@MGE^
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MCD)'G0>HBM9+9W@&(E.^5*'7Y'08]5@$*H]UMQ0B S)$M2 9S@SCSLK$8.K
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M3],=G?;D^1_=05C/\*4_9X?@\7CN;CO\8'R[A&J1KH&4>;0NFX64/UP"^5H
M\KD+]_A>EJREG%SZ=K*&+WWOJL=BLI:R]$Z/O?H]SOG###:[T6.O:<AR5X*K
M>SVOXMJ@\?+TG1=PSDK#;_3;#1JM7#'9:![]F.DNP--"2#S,SL/!+28UGX?V
M'.:?S,S_1Y.X_6"=%"8=_0PPN4KU,FZJI=LV="I1W"L"GX<4=%&GFL,CRD.\
MX=K<NJ';S>?_D[(4;SCQ6\0[&%CDBJ<)_,<QDAO%$D(EF.'<TH0EZO;UJ>O>
M0JIM[;?>]*DR%\^?>=[B\-O.WN&W_;VML]VW;WK;%S".MUL77_:VR,[%.MGO
M?V8[%R?)_L;F^4YW+F_QV*="P'>.UQD\_V)[X^/)E^.=H^UCF/W&?G]_[Y#N
M[GT\V89G@1E?YBQNCG>.3[[YS"B18Y+YSMN8I!8Q(K-(B)0[PC3.369U<M_M
MWVY\6AYYH\H6]7XYU-/.IBIEQO%4,/B?2E.24RD #=.,NSLD9U^->BVZW0[=
MSIOHMG5 '.&268%R2SS=&Q9("F(0-DE&)9=:\'3E92:>"K#=4]/+1PU#[PM[
M*F'=[+=3.QC942.IL[)48RSENZI%GADB/Z*"F/L'72,RX?),< M&B:2I(L9F
MQAF>Y;G-^1U,S1IOF_'@@,2MH7DO4+RU8&ABZH3C6".2B00QY_N=TY0CIHT&
M92HDS>Z/[:XMUFO!Z8>!DTF$EC8G2K+<8JD\V35C,LVP!IF^O45X%3BU('0[
M$)JS!Z4D8+[G%!F6F+)32LHP4AS@B;M,2VQ77GZW.7C?Y7G//!2YX\OIZN*!
M[R)3>&;(^8CX(NX?.1U+-">IR6Q&69K2W'-%2&LU3H7"/&L[W/U\"-U>L.,D
MF&N< W *"8XT$Q(@-,<)LB9Q6J::.98^1KZ(7X^\ID6C6_6<PE0+)K#"B?,]
M0Z1(A!2Y@-<(MS)IV[S\4-29,]R4Y4[E.4&)U1EB&'.46^-0IAEEGC\]H^J1
ML67=H+'"C\IY P-KFI(>$HA'=;[;J)GP9HN@-0?:K@_,0A[<NZ$..8![?DZ_
M;B[<%[:[=WC@\E0ZKA0"><&(2:&18LHAEH!;01*5)5C?()_MB62OQ>2P4-@<
MLK=."SL*U5<^^PQ6P%<P^S8:(%O^0]UI:F5GN"1%;2I](>7YU!9!L&*L]XI/
MOIY)BWXW'/FTM6(VG^V/SG49;&V^6INOUN:K/>E\K39?[5?+5WOK2VU>^$J8
MWWREZ/!P %\."="75<RT26QM.L<U3A_'(F$\ ^LMQTSG5%B-P0O,1<I"Z>>M
MB_:"+,Y8*;$"U)LJBU:XEVG_SBL+5HS]:'5/CD9=UXUF-IC@>_+;,W$=3X_V
M80PP%KY_O,6WO9O8_^OHR]Y^]\OQ"=\!EW'_^.AX]Y^/)SNOYSOSO>F#FYE\
MV8-G'I]<@)O8_])_<[33_ZN[NW>2;._]U=]]N\WWWWY(0@[('#T,-E2JW!AD
MB J%*@G*E;!(Y39+L1"640ZN8_94<D#:Y+86#6\Q\1>WX>++M+&886'^'WOO
MVM16DJP+_Q4%[][G],1+,77)NO6<(()N;!\F6J)MX_;@+T1=05@@;PG:AE]_
MLI8$!@EL! ($U/28BY#6JE59^51F5N:3/D%4WB J9@VLJ8VW2C=P2,_@\,I@
MV! ?&'^JN+APN#C9PD_IK*.REB@J,X'D+?$Z4!*<8)9E(5+@2ZMR&A>G'(I'
MA\27D!;7V+_IV[CN;\2%,QRFX?!@7#C>4-F,8S&H7X=I!@NX)J$L('+/0E(I
MI2V)#,P[!C)(GY15P@5M(T-(SW.U8[^?<+P:+\??SP@,\$V#Y(9I/8V^CP!\
M+99@6A/$J]A]"^S>F+)IK0S.N*B)$$82L$$2F[TC4D9!4Z0,/)0XP0(ELM0\
MN@IA/X0P]-&43]J!HX!>N<L^6= A6Y,]R^X&MF>%L 6&L$GS4[N$AB8"E^/<
M$&!2$.> D:P4#08B4[9 F%@@"'L)8=:S,]YB43;L1OC]W.H\)RJZ-OIN[S0;
MCQIKOWH^SJC;6J]&Y2C3<?<7T3OA=7_$?WV2W&#82H=E-5Q/*7*9&?*<UW$6
M.C4I%661HRGC'8A(75(L!BFTT#0G:RJ=V@(0 7W;W&KOV)BH\<:3[)4GX(,A
MQB9/3,@R@A"QZ?K&KXNOGC&PE[4S$R^_8ME3:IG.%ISD+@0:I?7<1_1^))_9
M7J@+9#Z<PZ*SOBLZIY^_XKBAL[6[@YM\HCI28KU 9Z70.-J<%$'7-!A6$NRD
M_\%.?T[FB##\913;Z)TLEX._BQSP8[+A*PF3QESU#>M](2<>\>Z=R[3ESH5Z
M)9_21 I*Z3/QNC E/5FFWVN3":YF3$>%P%\/6[^?S>JK,[IEG*:C(JQG3J!^
M[<YVB?,XCZ?I?/&=LU*'LVE::;5^W,_DJ&F+</[^UIZ+I2O$=R;V_O'1\,B-
M"$HG6-EG)2S-+H(QT=EH(O#,76(\>.]5M)8JQJY.O]_HO*ZL['=D)*7M];!C
MA<YH15'<G7(D$!P0QV0@+$<C>4PEXW-IE:F?<-Q.@-"5;(T_I=U[-BI[:Z*]
M,^6=UME*MU?3%VOZ8DU?K.F+-7WQ#G&DM1 &Q\7QF"(SJ;1[+SY'9Z9>%2HG
M[:VSOA3+!@/.0$ [$A(P*J'2[LU2S_9U>^LS*Y_;_OBZNWU:V@5_^KR]_]OG
M-O\@/NV_/FB76K>M73IU^K'_V][F%M[OX[_W\/7]IETP/D_[S=O33UOQH/T1
M[[>_)C?7QTF)YU6TNX#_=H(P6<:H20Y9$W#"$0N%0MLSG:EGA@-4VKV*>A7U
M1@WD4LQ61*VM#( _&QXR@$E6<>5SSI5V[W'1[>0"NI7TE*Q0/$(13H,@ %81
M&V-)OF:!):6CHZ7C''LJP/82\@LK[5[-R)D W9RR<4H#9 =:!R,H,QF"]LE1
M!-[YTNY5R)T!<C>F#,JH E>%Z=3ZTC!-^DB\DIJ(Z)P1V@?!#4+N F73U(3
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M:MZYKZWB1 VZZ/?>!VW%7.K$%^"T<.X]D69^_F?3\FA>_>S.C6M<Q.VS-;Q
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MME+8.\1;[9XT7;7[1WMI4$N=4-,]H]$)9]#_=B R-X9['[0,R5F=M:AG2 L
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M*#BD7EJ5TQ&<UO==(_=*J!D7U.V,Y3-3>S<=EA-V7#4'7])1@_2-X=)'VV:
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M>08(#2/0F0ZHQV"K?$2WO#%?4KUY15-?-CZN0.BILH/4PR@,IG %[X,G.3N
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M@[P^M_VUJ%:V+.0A*83BUU$W&YQPU8M7%!/S4PQ"V=7&ZY*BF' PT]R%C3T
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M %YI?W0^M5SS4\H%(Y86ZWEO".+>KG89_,S"L-S+S.Y7RTBO[%RO7!)6LBL
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MS&)LE??. 2X*;DPE'&HL'*86CL<5#GXH)0W*4X)"2B <EF"D"6<H22.C3SH
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M]F"CI\H33Z[A@NN0G'OXI%_AF:2Y]Y;N[NU<@,MQ:)23+M"<J,!XQ+DBR."
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M.V<YG4/I ,_E5Y@"W=*D#*]FE3LK'/69O9EB.V(X1LL2S>>%8+IPK)Z]P7)
MSC7OG,GC=M5^XBTW!*<YNF_8E_I,PLW.))#Z3,*#GTFX]HS!PIF$E PC@0;X
MX;C(E^H(OC./7FHCN'M29Q*^7]OE"L2Y^P[_ULP6_\*FVPQ +6W?/_N%9NKQ
M7;/2K C3G5Z=@U8KE)N><BC#4:HPY(+7RX<+0$M7X/,JKW+)))EZ$E?)QW<7
MQ"NIZQMDOZ_J.,SMHUV1^O[6^ZF1V4"D<YA+Q2U36G,N2$C8>9><,65)L>\$
M!=;[J7<[$+W]B>YN[Q\F1:)@B2"/BYTTRI VQ"(KJ;#$.2J#?O&*K-Q:!0OM
MEGL5-%(AK7'62XZ3M@X3%7C"7"5'?#W9#SG9>SN'BJ6HN>=()&41U_ C1^4B
MJ;47P;&H+'_QBOVP??2'5OYZ7_6FLG%TF 05VE*+7,JI5B1SR"1&422<8B.3
M)RR7"ER-!+??4G]H**BG_D93SYK;GPZ%]#3E\ FG24*<&(7 L XH\L2T4I$[
MF;<OZ4MZ]^WUI6C1E0E32X.CG2LQ+3]DAG1:$7R: W!CJ"*)%S91W47I4M\A
MW8L+G&/%&$TQ@IPR$[7&VC!L"5?@PZV6TWI[_2%$=:]YZ$%2;101$9' 7"%>
M(4.,1(S:&'4T426>LYVMDM,BD<J,3W2GK70;%=."*\4DYSD[E20!A\2IX\$P
MZJJT>=5IEN\!6+V5?K_3+'NO#Q65)&JF,G 1Q(W08+?*D//Z)$TBY9KPF^RJ
MC\G<Y8V*&S&RC6,;YK9D%CS"C$@S'N$X\'K5:=([;6SD30T7RYW,6VYMW(Q$
M78QJ7Q$KM1EDZ'BT*V?[!E.W'.0]V^"?F$2Y923"W,DN,GN0"<1\LKOS5 =C
M7<?7R9RXMS-M6VXXER?&YU-2K]K/G@!%N85;,()9W(YZ11-Z526M6)&#P[[-
MA2][9?+LN10:17:EW.:5F9@&Q:=%;<?Q":?E$R231-E%_ME9R"DR)TV3?B\D
M^T[YF%;FM095D; RY_<"^N:L^/V<?Z-1Y*'*925S J@R]U1NU>P+Y\XMG^=]
M_,&P/,F2QZ5*4 6#XPM5[\'_GQ>YPZVOZA.<#V"0[* ]'>*RED.G2-<QL3IG
M:A[D5/?3F;]QV,G0%@5(80[.<TM*/A"  L#"ERG[/_Z7/3O_;;LQR"G!BN'-
M'>GFXPI5(=-<*;NHC3 C038O'D?'9>G-HG9"_BN7TJP8Q<D[YO8QBSJ11>V-
M8IMVIM;=;'F'WFB8CQ]-QSLOFC.YT;Z.JS3EK  %&Y!'86'8IPPF-&7DRR(>
M17.G00Y5"8?R5-JD-M[+^7)%X58*-SL%UR5/N/F1DS4D2FC?($\"N4M6A!N?
MPEHX,//+;;,AW"7?P6WXYOG0EJ)00E6D<5HEN%*)"K:F,_R=:+"RS$!1BK:X
M:)*H;US=<&9//_-<HYQ4<VNF+./*PW;C4BVY[D$^H%< Y]K.'=D0C9"4J@1^
MAU))NZ 95YPGA\'Z]35U^D".YV7S6RZP%:*0ECJ#DB,"<>L\LLYHQ'-R8)@:
M8HBXBB=_".J4,<L=U9X'RKDU6%-!J#!)ZI (MK3FSWZ0;)PT#XU.R4=.D4X!
M)"(&D WK. I<6JPT\X&F?#IE/<PI<S%9&@$)G.'!!@<B$+&34I% HE7US/^H
MF3\]Q(H8$81 E$>9-U02<C8?4Z*",J&3=3BG$\:KIOX6&7VVKG!U;[C^SE&C
ML^[M<,E8&A\"GQI,OG?4K39_5R5FN&W5B4299)&Z7'W").*B%,PE*;26$H?K
MZ+/E:B4W8<_J\A%72/#E_B$5G%'/ O(P 8B'8)'!RB')$_51>^>4>O&*2_/]
M\A$_"\WQ9UF(Z_LG+N8)IPG4-C+6_BS',!8JEJUTB*=I-3,-?Y&=VFQXQZ^#
MRG;O@OM?Y+'HENH\X[.N/!N1CVQ&&++N#1HRP\-T>^/$??=[?5')?.H7^UQ,
ML0W^@!OED'[PP&R8>0.X?U>\(C]EXI,4%12+!Q59,MIC+Z7ABY.#8>DLP.+&
M6+5.7#%@Y2;<-*!IJU&<I)I+3E^V(;=[Z^I'+1WR*.M[EOS&7^U,^#3>9 +H
M'S#_52W(\3&+BJ'8/3\&][B3J:5_'5L8#A_!%?29)YIR!W^.0"G\4N0WC,Z_
M9L.&KYKVLG=%^Z;S=,.NY<4ZS41VK_GHS48%Y._-A;A]M^6-T(LEZ3TIISJ6
MPN+U56F$HH9>-:"9!+Q.-@N&H=B5*.:U2D+\9!>:^T:_+Z/.@\7#WS?4_8$#
MW->I=;>-J9W;0/ZI]H-N=Y;H._&QTYW0NP6L3G=4O_ZPQ060[?JHX>^LLC>G
M/-<55RNU]YY9FT/ZN-?$>>H\$8$8XY-4HF()KDZE6O.%=_:K6GO^D$1GP,$5
MR$L9$5>.(.VE1S1:X8B2PN4,-5>G++HE)V22"C#=21'-J4Y62V:H5$'+P!5E
M]6P_9"#*Z:$71F%#&8I&XQR6I)'3/N1L#R118D ;Q8\,K'UH[:\YPALBP4GS
M,$;!!5,<A5R6DSOND,XQ2T);FX*GA'OWXI5Z(DA0S_Q-9_[TT/&@G(H4,9E8
M#DH+R'F<R\X9P@(7Q 1W%3O\S,-JI?-Y/Y-X#P!E8X"U4GI"C%:<&A/3:C&M
MPVH?0E(O]P^%I=9BHU#4$N33<XZ,C1@QHK4(7!N9RY?SE>'?:PFK#5XYKQ.A
M+B3N@G#<*,U,KF4CA.&DVA>H2@!\#[_JL-K[63,G'PZCQ@J#_8J(#V"[RIPN
M7DB.:& Z<D]D=/A68;7UN?.;G3NG];GS!S]W_JS.D=]R]VHVZW916':YVCJ9
MU+Z;UKDKZ(<QGCY+_FHV/_5<:=VS'JQ95:1;&299U"QHE_%F)=\]MK%N$C28
M7S03TI9C]\I8NEL'((YC_;\?C)8?N#)C?$F=Y5?=I!!?E2L-^ERQ:=,;Q_=U
M>F7]V9BK40_:7ZKRPXLG',:)TN8?L+)N5AZ+\>W=^'7N$5]^R7\>]:NBM]DX
M'<>MGK?/8[%A-4ZP!L\NHJ//^VU?_EM%$8\3895!R./*A/G@Q>(^QGC0BU+/
M97FQ')-<=3S//\S4[*;)8$P(CHLVS%="G-L4R17$<A'>\2T+0K$J G3RW6BP
MHH(4:?R]?$Z._ 0UN6N-JC)J])>M:9CY8.1R3<1"Q&*W-SHZ+I1D6F:W*NB<
M?RL*$U=C6$9P3XM2WZP1?QN,C\P4'$G5ADGQZ&D#KBO&>,,^WZ TXWP\[=+
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MG M48QYA]EDN [L^):OB&U#^Y,%U3*W4,3,9G1__]H5AP2_%.*H"IK&5SU@
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MPL887KQ2:S\=^[/&V<V0=G5EFP>-Z+\3F-65+A\8O!9XN<2X$\&Q;$L$@)_
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MCHLH'99(40U&=B0..:<$"E@P<).)Y\K6H7:;Q-K5&X0W-#7NA&:US_"8T+;
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M;SZ>%W]NS3Q\>&R'C9Q>$C1D6(Q.EBK;O2BH)_4;W.OR6%],AG7\-_2E#0^
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MVRPAKHRI/V(MP(4 X]V]UX<B))<2\0A+SA#7>;M/BH!H8"%9ZIQQ[L4K?J4
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M&:2:C$$!',/L5 ^&\;SXJWT&OEWV"3,7 AH.8PM6%UA&HTZ),^#]C_IQ_ @
ME+O"#2R*Q:M+OWWL*A=(%D8^3J$H6UJ=XIMB',NWK')LI_$?8  !2!X!)I?4
M3.X#S"-XANT)/^-&@W:F%>(@,Q-5B_-UXQ#A#,+Y@VP:9C:E7_V&8'!/8V8!
M .-+CJLP0@&40^D;G_>SG__45]S5W.9U?-\3[_1JY=GM-GX?=6.C,"^(GC<O
M"GNL(H-646X@'!71U@/KK5B$"F:K<H-?7#>B+V8XGJG/_*XWZH,>O*Y,R=R(
MS'P4YDKUB/S9^_+-%XW7X)H49D/C[_E!66DH_FWQELE5Q??DMU^VQA[YX*(;
M,EM9V"13_08;=-@>CJ:\64G+Y9Y"ORN3M;23KGQ7(T-..\!091O)@C:.O3U?
M7CDQ9^'5MZ&;K(#I(T03)C@GUFEF.)>:!!I3X YGEXIH+/%U]7[^ (G8366[
MQZYGTWYKGXW._MGK]WM?H;%O[#E\,[RHV:;5#E>3PG,.C?0X6"U1\/G\,#41
M69X<BMG35<1XPV11:FO%QE=CPC,5>O-]9N!%N<TPH9*J/:;%1(7$:>$(#L1R
MY[DQW!KAL$S>.4_$X?980-!44KYW.#-[VG," (CC?PVC_E>P=<"_^^EF?0>>
M<<1:EZ??X-W?=K>;AU20?+H*7&ZJ$N*.!F2%UXA%9DT*E/"D7[P:Y/V8QD6T
M_<5-PL8> )H' ?AG(X]VXX_L\+Z[(T)PXJQ.\?^S]Z;-;1Q9VNA?0>C>>5\[
M@JG)?6G'501MT1YUF*0D4].C_H+(E8)$$1J -$7^^GLRJ[#O($"14DV/+(I8
MJBKSR;.?YX1 E.=$<Y-XU-1+EXC6V+&U)<0D#.!VXH_0GWL/:<!//KYI$R^"
MQ<J@H*E$/+B$C"$,T22%L<X"5M*S%_Q R%72H-9G14N#8!!CV/AUB(Z!4FNY
M(K0'.8Y92W*HO\&"_-5>]_V'UG_%'-S.^A9 :,%F?'7IG[=^>O;K?QT^^WG:
M"?Y.S)XUXJ\ [9(XZE:Y)CBO%QVP5> 8C@PF^()!:K($.$H(H=-?*IFYE"1/
M>^.11DX#S=-5F:2"ZT#!M8M+)/.<)-$%V%PYH9A!<5*"KZ?I);C5KWM@>9UU
M_P)Q$JXO8CC.3P./]>KRZ*L'W^ TP3O T/EB+ZKC?/8!'O9#]R+,%?+!WOYP
M!_G-S<F=;Q,932 L()\B1SS:B+1E#AD/ CXE;Y6SSUX8,B/,L_R[#+8'R+CM
M@R&8+>':,.X/=J4"V2"C/981+O;B\"Q_[E[&VT'\=&"<PQO@A.:P&!P?>PXF
MYWF&X)?!M@X2K?"&6+;\P6W,%7"= N  H?.!V"B8$2[A&3ZU;0PF").0Q)8A
MCK5"1EB.F%(L$(^%$F'1])>!@GG>^K4[&7$HXBS#RO;B '^].LT/V_)E+,FY
M7'SFKZ[=A_%,_DJ96_()GVTHI0;OGO_UO!6Z%Q<6[@'P_IN]M*"[+H>_^PE^
MV4GE &1OL;A<]>TM]LE /I<+E(#,EPLP:%I_OOKU]&WM#\)WU2C-%00N@D4&
M>NU3SH;%F85P\QYR\?.%>-G]/"P :<7K7C?'NO-?/S_UH,HZ:8QY]2 #Y'VP
M82/QA#TF5DIAJ>;<. 7N%6'1@]TEF:#4-Q1;NQ,YX.><G;=M$B%*&4$5"O!O
MDM)Y])1$6DKCM4PRY?D'= Y?S-"B!2QTKZ]*[BZ?C]'Q.=AH[R-HRLB\#SX2
M+HAT4BOKF# BI$AB0Z^VT[T_??FN38T*2EB#*&<6<<-P-H,$$C99+[UWX-P\
M>S&G4V-\ZW/<N8[HC:/@(EY=92T#[ZC"8E5I897WRV^8*+?9T(K9F9B8$RA[
M.[C#)E2V+IC .3YNJ[P76!!PCC.]II-@N^@\I-Z3Q(25@F,0)%K+Q6BJM&V.
M2*^P0[Y+K7IZV3KI_EU5!E U+W0_$XS_O13Y@&O?*U80^ >':YM,!ZV;#QW_
M81#-#L5(&M75+O-VO4BP/YQK@05/5-I /0G<A!1<4,94WBZ</X4&/S1QR.WC
MD/CXX[MV-* 4F;-(F<SOQ@1#SFF#% ]*)TI5@$5^J#BDYY&3&#!6(<*/T>8:
ML$POKXR3T:;*BZSVO8E#[C8.^?+\]O3L$&RW=^+XSK?!1L,Z:H:"$X +4'[(
M)I=05-S28+BU.E/\'XC5Y; E33$208O"DL^>KE=3E7/D OZ.7RF1JSL#S'5+
MS>3E/XIZRN]Z]F+ VO4R]GVO\V5 Z?!#9IOGQ@16]ME,1P(<R*RLV&(N]6_9
MJYQ8+:&OTL0 $B"7,X!>NNH>Y%<GL\O=L@/@='=RK<0_6C]U?H;/YP*WZDM"
MS'46@S:!7DQPE5SB4>O(#_ T^:K=!!^U/Y???>G!&E6?'B_:K9L4%FK5GP]:
M/[GJ&Q(X-#VXXW2=.TUB2K'J7Z@>Z^*ZWR+_23-J<F7F?^10R$^^^F2.'50%
M>?YVBUNH\])5P5OQSB[KVKWJLIL5^E(P[(2S,H*/P!5H=^\ER'GA5)Y)*V56
M]I1@4D+;2RM^YPO]7VV_T__K2R_:<'J9YU+FQHBW\&1D*.<1_>$$_:<[N$9;
M4Q#HDCLDM!<@W)U&X),)1*F5-*IHHR,@W.?5^_['((Y6>AMF$=7_8"\N2A&X
MBRW;KRM"\MH?; @0P<#V<]S _1!.E':$"0=^I,F]O5;:!B![ 0@&"Z M.%/4
M:XY@<3+U)TG()9X0N/5$Q*"=YV$10'XN(J=31.4L/E:(3-_M5^V'E73+$F=,
MG,.G2\UK?UA&/)3LM53JQ8OXMZW<E(+08=0(G)"LS^"Z^;/#MK619U)=^J>A
MW_*A>Y.;! ZJ1-U\^5FA'5Z^A-O/@AU ?Y'3)UMT/C!"P<H"BU=;SZUR)KK@
M*1<Z!.*B" W>]X)W=OSQN.T%=I(DC6+T$7%, G*,*02*B"LFM+:$/WN!YPO$
MH2GQ\T$)U%N G<\V0M&*V?W]\@4,P]*_6)E?3];0W=Q@6Y'$&24V;CZ ASEL
M]#PH2:6JL+_J/)ACR)4BUZFDR^;R)5__7H)E,Y'1Z8_+B\DGW%IV:!]D8"*E
MI#GG6!N=R4&33(8SB3UK9,=>FJ=NCN%];97'X2EI4*3)@+)4#CF?90DQSAJ)
M@[1J+>&Q6%Y\GX4U6PJ,F<SN'GR\,3=M'2>O-^'C]0;]2X-;NLB=3_][W;VJ
MOB,7%/TK&PY_7?5RN]$_N]>];('8JO&R+N(:/N;K<B_YM-656V!@'603?-'W
M^ C:I[0*E&M6\BK?U,&$6SI:GN&-5LMV[2XZ_0^CNK!?[>6G_#SECFR^S2PI
MQY8H9V &[BFI7<)?#V==S+HU%02&OZY:R@+(^]MMW,<83!31L12%XY(2'6QP
M6AK!G%$AX4;B[4?BG< ]M3G82C(QBYS*=4Y)1? ?HT)6*1L-D8%JO]A_7*(N
MQS"U2]/:4JJ(!K^14<>C,CH1$C7!G&G'7%(-6/8%ED^TS;@)6A.#G/0$<8L]
M,HD'!(<4#JX,0N?BH_GJ<>1+9G0XD$.QUZ_K4UO69Z*8TE-5$)-FJWY&=ET=
MW3KK]KHYRU4D7OZ^K&$_Q<EVD%IT#>MD=VP3#B1C@_"GC_#3L^.O[6BL(X92
M9(/7B$OMD!8V(,Z8$\H:0])"A#?>XZ"C;I8<:L0$5767#5O\*VJ??JL?2T-Y
M;K=<$;R>3'B##U93782*WN)37MO+8*^Z\.V \B&O4%U'F^D$-DI#5&\=/(CO
M]/SUYWZ15?WQ;LS<\EY,SIK-;J,S#_8.-SE,EQCG5FLC!98Q,SDPIK#1ZY_Y
M7'P[KV;E=>SE=G%[#J^<Q*O?;/_#:_!G8PS]T_0JM\#F)SJ\#+]UX7D_7Y9\
MUN =O\.SP<^ [ZO;T]YAYH?ZLYL;35_;VXSFP_[Q8,E?CU;\AQ8G7^$9OK8-
MUPRV4B!O04UR)132X,\CG(0V5C@?<$Z]SI4F-5XS-0L(D5*%43:C<D?J#1MP
M9PRW;/2VK.J^U)M6.#KRM@'\\[ZU?AJC+NK%$?-8J] > K !7+WL>XPX(";Y
M8?HU==S5Z()7@PKNG.'J/)&#, [Q5S5=J(>7LLYLT+T0W2<O#^_:FD=*J:,H
MA, 0]]0@'2U#,G$IL7/26;HQNH?4(9WA;E0<A@XLNP$1(>BTBKVO.)ZEOSV[
MICG3[M9,P7:>!$)_&_+XQ5!U\&3)_3OXW@TX%X/S[,U-&^2N3#1PI%*(B%/%
MD=$ 4\\HU5()XWAZ]D(LP&:UUJV\V*V\VCGV4:%E_1S[F(A=3YJ.?<".I.F0
M.3%'9CI_/P'03MD76;06F^$O@&3_]/JJ#][4:6'$[-W^UKWN]>$SO];D%0VL
M%\/ZXR?6)B;AX(Q%B=@\HAYVS-*@$=."I^@\I\DOD;D+Y&UE&_3S_NS9-!B0
MT,ZWT>M&H.M^9<WWX>OZZ;:5KG-/9CX(O:O.7;%SOD_/*8>!QYS$R6!N]1BC
MO-;RUN!AA^KJ<KV2H-M,H'!!1 +KEB21.-;>17".-5$^"8)5($V08D_\IF>'
MK!V(82;/\-+:$<0)Z#<-!Q^!+>:Q\Y(1+1>05/Y'@<6&U3L:2R(<[#1H$4V8
MY8F(()SD5&*!:;/7^]KK(]R6*5'O51Z7HF"OI6/(<N%1IG/DP7LM3/8@GZO9
M[JO_.!BT+';^CA>W![-=C,/JQPR*L8#]6'OCYG!)V(?<FN6-\)SY9*B5CAB7
M^XA42 U<]@:7<]XVD2>/14#!2X=X)@*%<PKHB1XKSI4TDCU[P78E&F2TSD@<
ML1"&&\%M4-P)DEST(D35I.[VMM>?"(@&YJ6-&D5F4O9P C+!$P1[(%3 @BF5
MAWHO$ T-R>5Z))>B(;G<.\GE2M+**9)+;H)1T3ME;>0X<5 P"J2-9=B!NL'J
M^R&Y7*[ 9TO2"H_#X;06GY[/,$4K7$<P\H?Z$\4NW?GS%N:R'^S.&[F)&[LC
MQ%C8?&6HX8P33K00Q(#=%$2@,FJ^DFI\OOIY52]$UCA_E44:A3E^: 5T>WSV
M_FO;"1O  ]#(>R(1=U$@G:Q!A$KK":8<=J48&V8W?HAR5F/-HV&2,W""$D_:
M$R8\<1&LXV:3=[_)O.TT(SSE")/1/-=\Y#@J4\@P(C61E :OLY6A9SD QC+B
MDZ[(XN#-(Q;%9Q\F(U"C2A4W8-/9G0SL;%I$=^_#,8>UZ3+3(1^./7(^(LWA
MJ _'QS>\':F7F(()GH("=XM&C)P7 F&5I&3662?IDC&(^]%ES4YNLY/&*\X8
M1=0Q<*9"C$AC\*@2"0HL2^]M K-2S'.<E\F]B8$*);P=.KUBO>42LO'0MZLC
MOW7DNXP;&I<VPS=F4N9L@6=+;< CM]S  W-JN4TUV[Z?E*/*1V:Y!!@JL*^9
M(-YZ:8+%H!$V2QA-HO%U*;GK^'J:U9MKVP,-?'$[CL_)[OXR5 ?=Q=X//=_E
M)GO]QV='].3.YR;_MO(@7I*V2$<C$.>!(&N4!?1RI[7UCJOX[,5E=Y9.9<2Q
M,\K#_.]@'Q;@;I!V6%4P]9UV.*R=FIGK':UHA=@\ >,MCLYP*K &?9^8]M)J
M)RB17EE'FY[KO0T).V3M*"2G@7.4 ]I@$S.-K-0).8*C<#X234I0?EYU =K0
M&@C8.D:H<@G\*>>L8IJ%8%,2P4AGFGW>VS"XF[;TCLF0$E(X@8!5!B/M8*53
MB#1%:CF7:F&B;7&VI13F[2;9 H SP6#CDE9<.V*#U3121\&<B?"?!A[[@@>X
MQLDF"6LJD*=@\W/F'6AB0I&/E@3* !R9'(_N0@P$V&%%4S(D">YDR$1:U)@D
MLVNNQ08%/,T^;[;/_FL;_#BLJ2,HF-Q23KE")HM[D:))23&)%5V85%L=L\V,
MSK,AVZK,:^W [;RX[0JC(T^1VPR%VY$J-A&XK>$']TO;D>-HK4I(EY&.(I=[
M<)F0S%,^=.#&D[ Z O>\]6K$D;&TAR+/O_;=SY\[5=E7BE568,/,<"E%H4P;
MS',<6%-FO.>")1Z)Q5MT,<VK.GQWF4O%!NR;OPUO^O?81#>&$#J_ T-&1^>T
M ,N%@Z;*+0@N)(:\YBPP'9.+A11CSHR:_VBA31D,8,,YC9$I13E1S @G(G/4
M@>04(FRAJYJMWW;K>=LD06+P&*68 UM."I1C TC*9"FH>^,PSEL_MQ)ZU%<^
MCPK^^O+Z"O;B+@\\'J[_^E[O098TQ9D>A1XRCP_H1MN;'$5:C4">E5-5CW]%
M)#SB$:Y%5J4$/U=3K6;GSU<T':%G;P:TLKF'<RE!\6#J0O55 R:":KS]=&M?
MOOZLKM\F.-"]K*C:ZIUPV51;OG95_\U8EUWJE?SY>;4RPR;8L:&LL\]:U9L7
M\J?S_ "509*_8&7M;0[G$/KXXSE+!KB5[I+^G$:4SAB5[O0TMW%>\^LO V@,
M1FAOR*"ZD_'9\R3G<-+&[]W>&#'PB,*CH59=(%'O3LZ.19LPH[&C F&?):I*
M8(\QDI )2FEI!<,5G^JR$1S;U%7N-"2_%3#&#?4?6K4"$-[0MLY!UQ@U>(.$
M@%7%.#(T,!0]<TPPIZG)==CZ^3RK*I.PC#5WM0X'G'9'O[XZ>WG8^@G>COXX
M/'S]\Z;LHF/]&Y.CU(>3UBLG (04?/%-O!C2U4Q*NC%"O?6$WMB5#P8W6OK?
MX<OZ=;H@-^L=Y.F;];\G6T=*BTKW:B@RMZ!/H&#<""4<DY)QJZ6A6$CA<\".
M2._M%NG3W^HQOSE3WZ_S'G_6]_TVW_:/G)6Z*SZJ9;"D%"?$5&Y+<DHC2T5"
MA'L*[FMF_BPADCE6YC\RN4P9_3 #FNO+2=A4Q$ZY.:Z;D;AS["A)J<7"4<PM
M#X%8D1@!*4^=9M:R=!_LY#N> $T];O4'Q\XGW)9:Z1!C0H+G.F8#?JE)RB,5
MF)->V$Q]\NR%7(B=TMQ^.8I^Y:G<L[#8FH]O%V;8?$P,U.EOW7%8="X;6)R]
M$6V-=>1*>A1<;F50B2,'ZA8YEB0LN??)L@7)EP*+I]XAN-:T\I/NU7?*&7\V
M6VI0'K;DRNOQX[$BMBM$.Y-C$F<'GV8JE\&<3CN:7SXQOVV1-YC-IOBUTR\N
M='U3[X:ZJ;JMGZZZYS&KIX-QYK_\VF!D>;?BN\H\5%5P8_[CU46"PT?,08^*
M8:^4\N3F<%B!?O79KH.MLB-BG>JE\GT3AN"(+>&B$P<D/(,1[T6ICAAZ#@9D
M@7V07ZU4!LB4.9;9VJL^7A:RNL[<51^_K746>/2>RDZM-[-J9BCC6,^SC"P5
M*W-J4,K*?<=U)VL#);.@E;!4%0XJ'=MY,8=U9O6PPQSHFG]>\K?. 6TF:1M5
M\(X.0WY[W9T-QMIU[@T9SCD<&VM:V VJAZB#(MM=M[[4P@O=_UP-AS# "@[P
M]!A&C3Q[\05D6.N+[?>O]WQ?2^^B M"B':RJF[=!SP1<!I(5Y)"=)X &L5V?
MF0&OR@B-\I%EXJ$2XF.[NQJ/.WJ:@=89>C/CM&&%67JY:CEHE7AM]25C2_/Q
MNKR[2.0IPKGZH4"&Y3-?'_6_[<5U'/QCM'1S$H,+]6ZV8#T\81$P$Z?PJEOS
M[8)HN>A40_LZ5>*P3"U>5SN';N7$#4[I\OVL9A,L_OY"#31GZ0K?17W%_%SY
MDF,K\ETJDG=?ZE/3]1-1GI8'I^B\#-[-CD^O>S$OX+21*O[Y ,!>.USCDU[[
M@,C8\YU,[Y&CZY5^*CPCX !^'M=+E]VZ&2V'BC(\#EHY,EFG*!:"(E=8USFB
MB6M70W^O>_"L_9I%N?JZ(50NJZ,&CWL#KY2JC$ZN?NU='50\U,-/@RB"I1MF
M?S8D.^:4959/QFSB04C' PD^<B)UU(YL4+<YZU>^A57\_*4B[H-;'*5!?RL[
MW+G\K=K?'SIT2T[/7O&VYM8Z03&REN<^>0-^9> *D:B2%]2R(%RFT2&+J<MF
M)JX7,P)>K-@^O>\-AIY>7WZQG3 ,4#Q9\;*SV6@;MC:)Y(D/6@9"N;/*Z&BQ
M<X1PQTFDI;6)*,R:JJ.=G9!/K$UUGC]!'<)<9NK*I)#5 2/PN4F46F.74A65
MFU<X,%<XA^N2ZZ9;)+]82@!?$)P\6*Z9MHXS@^$/\R&PA!L,[!8#]/CE,6YC
M0@/V7" 2,M$0301I:C'BS@F?7!0Z-YBH^86/RR# 'Y=K]7U&#L"L/[9@L^0Q
MP6JZXJ],Y-ZD'&%/4K@9Z+K&63P[O&USK!5/Q"#,<K,7S;T(W!M$#"?$:P:'
M$^>J SHG33(YQ=6>G_?B>1D/,FW";%SFV>CF!\?",;FG;JX#'P-W^'(HF"MI
M0<1!I:7'YR@,! G\>D*@#P<K9)6^B3C9DT)OQ,D:$/IX1-K&*JN$U8A2;A$G
M6"&C-?Q32J/ *Z6TD$?-+6+:GSAIS+P'Q\(;OH&9M[TXX?/%"9\O3DH<IHSN
M^KL:A0S'.F]DCE5.]+CT!Y&B3G]8$=N/GSO(%LJ#B:K84I&;0Z2#&RM"ZZ_X
MY:KJK2'BR7KF*S-(B^1W10R0TT,E0-%*UU4U6(Y[#0(=Q_8V?Q*WWN:0H(4C
M?GG>.NO!'548Z,\9#/8#K"1?8R5#E9/(D;PJ<5*XEP&''TJR-O^97.L!@PSY
M(1;[&P64F M2*VJ)II++W-LGJ0E$:X4CMJ[6,@3^-%IF)UKFY.[575LQK:6.
M'AGA..)&,:2-TRB:Q%+$TE&?"?FW""B)IXK_I<+F]+)UZJ^Z+N<HLKV5??B=
M>/)[@G]C>J]S$#[1-@<#UIG $,56(=@!@JRB'%D92= Z68SQHOZ!"=.[+IJ%
MW1XQBI$=@82*F(@E,5F;&S@!((E9XWDD7E(W! FAC7^V:Y"<OGR3"ZJUT)XX
MY+1WB(O(D0XZY)B/)UHJXC$'FWQ5L.>@M5O_K-&<#XV%\Z_[TIR3-(3C[MGD
M*PL\M(9 >CT":=D02.^=0'HE(?04@;2/(FJE750F<:R,"0I[0B.Q(-1BC-\/
M@?2:<936DB._86SEMD7J:L[Z&\F3]4]7!@.6K9HMX8!<UU16KIX87,VHGZI7
M6U)VE&N7X*Z'T^Y[PQJ?J@YISN348:G6DUWW;Q07,!I+0VG2TF<R+6U-<MA&
M(AP.DI%";T,,9E@WULTNK!MV_/$=;XLHI.29C(3G"3=.@)&KI$5",_ NN+6>
MZ6S=S+-UE\<%5 N-,N!F843MJ9Z25=&#ZM%U<0C-0>O7_SH<5C5/.H95Y>XF
MWF%BV'(>&>,\<8JEE@[3&(4E4NK$R98GI?$.US@S=U[D$$*"E7<H21<03PK.
MC)<!,6P$8<$KK=1J"H(=.H9[ D0C.M?B C[S;:>3B-@9E*U?Q+6GR%%I$//1
M4I8(]](^>Z&7^XC3/6U#.5J<PV?_M&#W]6ZK7TV]]]G/HX+\323)GG1N(TE6
M2Y+\=YM28Y-B#"E/!>)!YSA3%(@JX:2RU ?A\YC<!Y(CC0GVX"#(]'#"!_"$
M09U$HQ&G!".7![EX1U3 P3K/PA8FV.'U.=A XQ)D_#=_38J/Z6&%BQS7P]:7
MS$X^\J&&0V9+3^MX?K5D9.M9LI6-,]8#LHF0(L9H29Q6+D4NC70T,,&5,RFF
M! HN-VT *JNF#6*FFS:0G$;GVR'O_VGZLWMYGIE%,F(;8;40IYEPUZB@-<Y5
M2LH!3HW4*+,=(QM2M"D9$!!Y2,,<(LRAL-J\PC%23:()RH)MPVTT7,6@G+2$
MID2H:"32SG?:XS81PD8&MBT<,8G LJ3(".F19J"NC M$XQ+RUO.&&ZXP9U@M
MC.JZ%C9KRM3\>5M*"\.,H5I9+PSF#F/#@N$@%7A*H,@J:OX*,6@>=!IIL0,,
MW;T3;0^G-'?0(1631YQQCUP(!$46,[>(QX(XP!#1.Y06)G+BA;5E+K9DS.1J
M1M 3VKK@M5&-M-CY3K\G;67R!'+!$6PT!6D!VVVY4R R<F%\S(G4(BWD7'[;
MY=*"3&3&AD3<Y96ICXQR8Q5OYI;RPTF>8G!&1O"I<7#.68P+AVYF5!:-_-@_
MJDY?OJ-MR7B0"BLP-#C\AWA 5> 4,<VT#Q0.- ?Y08G<H?R(3$N!8]!)&JZY
MLQJD%:.."N&]\4T<9?<[_?XV!T\8.+T"288#R ^1D%%@9B8/3J>3#E8>KTRP
MK[0VZKK1&7MCHH?BI\[?/Q<&]MP+7]AZ*_*A+Q$^U,_$!5W?*8P+ R*.3/<P
M41^:B0Q&?M2<JNLEL? 10='+JG3U$%RPBSJ"/!XYKC);&Q85J43SH=)2.T"W
M#YIXKH0!$UXF!TJSEFR\]J,P9[B1;#O%._Q\^+5M?2!1$8/ [P=]&1Q'EO@\
M^XX*C0'MSH&^))HNE6P9#DOU87;IOX#8B17W=)6^' P>&R?:'L6-G+T8,%*O
M_/J:S?3SEXLX]OTC7&_(MQQUU"98J3UUW&IMHLAE DH";*B6K!:]4YAL(I&[
M .5'?],&"X?[Y#!8;7F:L(X86?@-"@F,.FH3>%,EI[$T%@E[7CA?*C*3RUCM
M^I"S: T)6%%(K?'&*KQDO<]["YC,K.HV@S+3[L";KSO]#Y]K^IUR3S/)MXIM
M-[1LZZ+;KTHHYG]R0R1;A7W662(F@"M3UOB0?%(X4,)<2FL8D/W.^27\- WM
M/^#P]O^$FXW]T\NCB9L]38W@789Q^)NUN8TV!IE0[FA#W'."3'#PDZ"4!1%<
MHCE+LQC?,P(U=%**%9F/BU<W,58U('7\O32CY'&B\>KJ(@XXH>I=JVEUA[B<
M>67(C>-MKW>;KU@HI&:+AQ:&=3<J'?H]NE[)+]6=6?6W?L]M68L7;J?50WF)
MLW3*E86C9:W:?+>K+)H9:ULS./6[G\M=C#$Y+7[&PNF6X3EU2S7?TGUHEK 3
MVG*/<72:,TUM8(D[#W)1!.P96R$"5VKUA51+/[0W)8[A?MO$$14QU8BG0!"7
MAB*7G$0J,2L\H?!BGH\PUY=:CUMIX-!\MI\B*LBO_98\4?ES)P^[>KT 6Y->
MS!ARJWD=WPIELV1>-3WX&-"&&/L7F#-'_WO=N;H]S<(?Y-OK.@?V@Z/O[-5=
MVT5!E1> .2_S4$:<D-9!(2:TBV 5.2G!E^=+P+<\G[U<I%WW!XIYF);,$W5J
MIMU8-@U^4^U:?Y'H;6HZ=U;3R9533"5+C':<4.U\$")2&5BD<$QI1=^.91-0
MV\DAA/L_@^N_?$].SL[!KSMJ&TID5)2@B!,&E< #<DHEY%WTT@A!L05MP)=G
M\N:6=^H66J-?^JF>EU75G>7)]?@TT'MT^^WIE#2QC\T*^8X_OF\3$@)A(2#I
MG$,\1 /GQ5,4'./,<]B;P'(81#XH,4LC1K^E&+U[OR\Q.I"?>B++.?KM?+*G
M1;599]N78]EA65=^:VV3CR+&8?/Y>5R#MX&-%G"0.!CC.AJX>TD$$2X7"M5,
MN[(8Y[/8;9(-NP7QR=F;-O%,8!T%2MSGC"K#R!EJ4&**R*0#%S:L)]N&U#3S
MR5CNGWE82/,RK'+>4Y)NM44S.41D#<:8QQNHCJ! ")642=A[[AV('!^\(U()
MQ4Q<XX@V@>J]'MJ71VVE!3,6;)$0\V@W!NK'6$*1X#Q9(6T4ACQ[P6:#UI,G
M]G%&KA=HNHWBUN4[JI[78;[R.^YY7;1D^XM85PM<T<AM$JY>N+G;A+$7?=DP
MB#U^ESN(8+/(!1,$"T4LI]$:1;/]QYS#4C/'5LC&)H*]@[ZJE\?MI*2+S&DD
M=$J(Y\"B\5;#3P;,28&-XW3+8/;!RDD!99"JN[XJ\TF&,V,J<R%/C1U<8?PL
MK!L@GQCZ,G[RY@)ZIV%S)F-4PE-NG.82U J)UFD7<2'W#&9OT#Y-KP=[484E
MWM953#\RYJ<T_MUA6RL.8B9Z!#8Y1SP("[ZF4T@21B3WU)GH[QM"7R1.1P'T
MRWBUXR#Z:GWPQ)7VTI&14]533_Q15P[+FRX6JZ.B]6C#@22S"P88UJ2VHP'$
M\P8M?NR"H :;L)INEV>X9@MQ;#9ECF;,?I6S?3 OQ^96YE%(&\RIG KFU,,4
MZR'NG3@Y!&_Q,A0^@-$DR?F/"G<WX W8Q1-/+'UVF1>MP$_54,HRKQ=NX.=[
M+\GOP\F!HXM,&J7EAN!:8)R6F64'1<VY.)@G5=R1N7/)IM;XJ4N1!=,D)A<K
M!SM@$2^SX3UGA-BLO3"UD-DRR2&((L:GQG,55%13O_(>+9J*M^]178J1E C.
MI7."6Q>-=D1Q[),CAGL2FE%=^S5,X+[.WMVVA0F2N" 1F(AYV($BR$8ED6".
M!"JBT#:M&-6UVAQ9("U'H RKK?7G#2/>>HQXJF'$VSLCWDJ&NRE&/)' KB=<
M8F4#5SHYQZ0@@I/(DY=1/RE&O&]4:R*9L#QZSJ6)W.;I%<8E+#Q\=Y#"51T$
M I,-.PB:).DB_7#R\8BWK1&*$DL1]LXB[I5"F@B'E'$D3R(BAJFMF[>^2U,N
M5X_45#X,%WHP<>\*DCUAOZD@6><4?+IK@XV44]L*16D-XC)W%B3*42"),:H2
MD=K?DQ%L<0?CTH* )1\;&%/#>.<@E%/'-AOQ^ZB!=_KRS<T]Q2\XD:W;:'L'
M*]-MSUO3E(;%!B\D'FS <3C9H3JTW9OV^R<&++C&+MKO-QU*IS7W6H,(P5[F
M(=V.&J^Q<M1J+8(?;+V@# U^:+9^UUO_[J[MM"8&!#<2.O,\N4B0]LPC@E7R
M#%/L@\XE!\O[DY<IGND)5ZN[/0>U!A5KT+)WS@YHFN0VRVJQU[T^_]"]+CT$
M>*'<JEC0!DKY8#/.LF ]:,,D TZYTLI:;@D6QF(M#2CH$KW"@^@5)J3IM=\Q
MEK\>Y^$-5C@->\"04B"\.#,\CW&(2+)DB*;$F=(-)<WJBK<E@*[29N/EEI.U
M#>/*<'$UW%@-W$9E7 +$HS>$@OW)A=4N&",)QG! D_2,5E #WZ.&6D./MWNH
MG7TB[<BX,QR$95*,Y/)*@AP1&DFJG73&$N/R3$_&5D -A,XX\0*>%I>3+S:#
MZO864'+"J2AQR%8F#\Q8I:W.PEM;XX*UM4<#_EWCT>SF&'T\%^WD*<>,8(1#
M+OFA#EQI<".13-&ZY!6+@F:/AFW!/0BZ?C,(Z*"CC<H[2CW7C!MF4NX/T2Y9
MS#%M(+!K"-R](FU&$Y5.6$0D 0AH)Y"VP2&PHCQAUC P3[>FG]P4 M1%SYS,
MH!1<*V]P@KL+2H0\93V)!@([A\![L-MH8$PXCY3-15!2@#*-EB*-A:0J.*(Y
MRPTWVW&"96]B0Q[:9 0%^:,R1[<FPG!MJ0A&@2K D3:Z8-<H.'EY>-.6F'H=
M.$9*!X&XB1(9 A86G$+N9/*!:_!$Y7.R!;/D=SNVM/93U""U\-]O_Z=UU/>]
M[@WX([TOSVM&O/SK5SG3T,N,N[9U&6\N;HN%GQMG/G1S_*][DZW'8=7.[6PA
M^>:IBCU954VJ8HTSE:,[@E(K(@$WA86<J@@>.<$M4A0GPB6<*0J6,GVXX26-
MF?W@,#BG;>EM8DDFI)SWB ?.D8U8@8+E.663,,U]15N:V=.DFW@>R?=&H>']
MV.&-T%@#+1_?L78N O,I"L2<,IFB52"G*?S3!N-Q#%%FZG]V0.>,J%@[OSF?
M#_X@=U,PR7]9")=X_4 V>P.7->"2N=^=8B2S2:+(/5CO/B1D $*(:,>QTQR,
MM]5DDKO4,8T3]^ P^'3;]HHF'Y5 P5."./41:>(DDDPGK%-RAHCMG;A*QQQ=
M][ISB)PW42Y[\NT::;$:)J=Y"):A$4P^(E#,Z1D>LI>GA49!)X&]#5%P<4_E
MTCC[CQP&YW?M2$F>Z*,0%2Y/(L4); SX#_R.F4A$-#YN[>P/)F#5?.KPBVF+
M-(N-@]95]SR6WI<9TN)9(_9@+",]+\M=IZQ'$JKZ0/&\!U/[%I1N?9>QB;.E
MJ[GC<K3&JWS8,WQ[_!*\2LHBSC7O" RNW*\M([+:1N0)3L'BR'0(B[W*03E:
M:\A7U(MUCT<K75]<C&="!_VHXY3S$QPO-35] 52.A*GRK?"#'A1&KGUN=PS-
M)JGTT-"\.^1M<$=<H@8<UUQTPRUER%%C48K)4*P#$=HN3BIMGC%H7(X'W^4C
MTHYPBD3*B2("4H@+\#LLT0$YXYF62D9 P6*78ZP@=KQD;"2/2F_DK% "$3"L
MRF 59P,^R"^$3M]?]_N#$HQ*\BPV0FI!LR,YTYBQ#XS DY>>M[.=2C/Y,0LQ
M-TP2ATSP IE$O. N&)DI2Q:9L9M49'^71N+A2,7;1<I]4K?7O!)$SQ1R%A*K
M-<CG*C^Q/UV/.FNC?I]V>3UK:G<U_,W WF\OBNZ.\2X&]FX:2_..<^UM3((Q
MK@36AGBBJ(^>,HP#;K;^ ;;^S=>VE2JI".8M>%X<\<@P,F"/(J.M"I%(G6CA
M^B0KYJ\N]I*^90W_0?DNN,-3?]4M1M>"%J2L >R(:@MD_29@#ICE;(5D/"4N
M# 4Y%K*WACG3ECA3@3F76J/!#PV8=POFTY?^IDV9))S&A"1XSA7[,KAO%"D7
M;-18)6;X?!:XM: \KWI_K$F7R(.Y?2);3& D022 CJ%44VXXV.< ,)P<D5S#
M8^'"XXTQ(7)#QK6AGFZ2#FM@Z@P$)'96"9HDBD::S&MB$'C^!K%<_R"\4:2:
M=T?G$*VMF718'AU>6-0/@O'WH5C,<FZ3$O^5S4T@$>_3UY0\$U9CX9P)7!NK
MB;-&\&"I-YFK9[JOJ='ONX;OW?'9JYLVP-1Y9QV*B8)(I($B'2Q!R2@?K 5I
M0G-[)E[%"[P"I@?C>9 %2/Y@_R[=2YE". =$AHHW5'[%2??O4;_*]^E!G8ZU
M[+"EVF*M[J_IZ/,V_3]5^&E<.'R?2S\I[\BNY1WX,F!(IZ2QE%Q*8H7W#/O,
M-^9%XFD%"UDC[W;,"?SQ39L9G0@V!N7 0F[IU,A0$9 *V! #NDE(\NS%VD,,
M%D=C%_)3%U[JWMC0C)5?M0%MMOWRY:+C2^AOR(RZ%E?Q!"_QZ$)/]MA_JZX_
MRXUV+.<N!3<R J*(<IQ%JYDF<.)SU%P12II9.[NQ9T[@6=K*8C!;%$646 LN
MGG%(.Z=1$(Z3&!E7&G;2/)]7E;YVI\=C .JS%]]GW'[,!*K$+*EX8M2]N:WV
M=" ;3WF=H^E%N]@^BC"$F5"(@ZV#P/O+="!4A4"T 2_P08MY&PG]T#"X.[IM
MLPA>)B8:["R6)[M:A1R/$@4EO0TZ!DK)UA)Z8O[9N(,S8TFMF()V,)>\_N9#
MQW^8F( V3GB\44@XSS,#F"5P#+C4VE)LK+%62/#(M71;8J^)X&T$R-.7[T3;
M!X'S9#D40LIEPU@CZP)&VC(ON(V*!;%(+LTP;BR73U]Z\>].][J?6R+'7/89
MIO7+ NJJU'0\HJ<6NNG/ZCEBA7,X3P>;&6=64%ML_44L,TO/RVY+2AK1^[!(
MQ\<OSUE;L12Y\P99GHKHE>#[^H!(<E$IH94@8;'H7;^D9#A3"W!1C9\14W.U
MQ)/U)E=6)F_@YZ\X</.F^8PMX6!H\/V'5$E&N'$I1!H5-XS:!%AP*F'EHE>Z
M#*FJ3B/:4BLU0ZKFG<F[0]H.R6KN;4*<$X>XP09IKQ6BEDEB&=<TL;U-IAH-
MR5@8]CG8Y2RJ:?3BG0ZD\DH2&H27"3-P+Y+#H%FB,TFK/)Y2KP_CV4D/Q_9K
MY_/UYS$D#T'\K\[5AZ,RS>BT'F;TNC89?VQXGYR]NFU'F;RU,2$5<WY)2X9T
M$A3^R5((FBNGTWV'4(V;4LM%ZC )M?NI5,LO/#:K\'1L).(<:;[@/&RM0J9"
MP6L$CM=\DB:6_( C"> 8<268 G.-)Q,L&,J$<.H#C<0;4LQEC1G=K-ZC,9<7
MR"YR_/+PMFTH!F><YCG73B%N<\^'41QI1I+WG$032RQY7C_IJDB%;*;,K#=E
M1C=39O8^96;EU)BI*3,RES4I'9A4X*OKX+SE*H8@P/A2DIK)M7S$_MJ(Y:K4
MYN540YZ3M\W@C/U(Z":(MX:L/CLD;1ES2Y*72 >3:8BB1[J$-GQ(BL$F..)7
M)A=6QN\:K?W(D?#FZWZU]D1^85BF(7>77*@JTL=CLP<[R3?L"8M-OF$S@-X=
MXC8W*=$8'4I>E"KTA$R"GQ3Q5EN!K5B#U&BEJ)I*)CQO'8('.9L5L/U^UW=*
MRF#@' .R)AK@1XF#\HYQ;+9^ DU],>JF&#L<PT8.O3!G,3@E4]VL,Z=IMZF'
M1BH_,.CA>V[N*96W2SU4B"(%\(,&'_)D0P]+#=ELM6Y26#CGC,V+U]8K6&)3
M=!>9!JQ<2-9Y9@3A&'P'K8TU7/G$K)&Z&LU3#A_:4A\UF8;9(TB/7Q[=MDUT
M@8> $;AH!$QDXY#3.B++H\:).DP\_FXR#>/()957=\_LPNZ@VV07=@'ICT>T
M;9A.PM&(O%0"<4HLTH0[!+^35/+@>+"[S"XLD9][3"TLN>J"O,*4W-Z)=M@\
MD;#.?3=9A(?+(E",0?1C$W6RW!FAG;7$Z0222H(,JYB$]'3K26/Y;BVC3C[Z
MVW8B)#F9(M*4<,2-LL@I+U'0G#,5L/.$/'NAMR(O54_U!*Q/W5(\R 7\+5M'
M:_=T$IH0R.HS<?KR#6TS&Q-3SB%M<^M5Y"%':PFBP0>B7&1&B6<OU#*>UI4!
MD$';?3XF&TTZ7OK!G88B&H'\L.!C<,W["N0MJR '@]JK:,0_KR_RS]\_]=:Z
ME"XA]GVOX[(%Z+I_QZT%>V+8<AX9XSQQBL$M<YC&*"R14B=>!?=FACTW@GT'
M9^LDA_FXP@E6WJ$D74 \*1#L7@;$,'C-+'BEE;KG_/I&Q#YR&+RYVY_-.ZZ;
MB[;N@U/:B^/$3)=#\MU\4B<D41]VM)6%6D6& #(F1Y:(^J7?BE\[(#)!+"W3
M_D_6X=Q%['BY630O!E=KN=U%CZ/#$2MAL7>!$Q.T#<9BB3FSC F:ZA!<30JW
M^:ENHL?SC_3=D6CSE*B2V"-'\K@O2F0F0.:(,B$\MTZ#;/UNHL?CR-U-]'AW
MT&VBQSN ].G9J[NVHXP'BQ,R,8^'Y0[ C6E ,2C042%X4&&[C!XOE:![C!^O
M\(3G1I"G9/>.=,3F,>3U[KV)(C]@%%E;*ZB,5H?,#J9T!-N::$[ALD(15[M8
M@K+&HMZ%K.+'=^>L;1/X3RFST&N-$0_.(,UL1#'Q+,.BHQ$_>Z&VZIK76TPE
M8*"]%/:P_];S()AQAD<MA0Q<@,<M&A3L& 4G+U_1-HUY_(#0B'@&?A6L/7+.
M280#58Y))[6)&07;U#::%EK-J/M49>7J*G!X\+GDOU40ZA^MGSH_;Y9BV(^8
M;")1:QR5LV/>]I'Y($E$VFB)N+<,61DI@HU@%+N$99X"MC3%L-,X5*,U'QH$
M_NO^M.:86:IKGHX&#X\;#Q]?W;0=P4YD[B%,P=GCGKH<EQ0(W&X!7KE1-)#%
M>)C8])E!U,6(^JFSH9K8DQW5J(EU$/'^KBVC")3D2:$,)\0-\R@S82"OHN?$
M<2XD?T UT9C5#PZ"3WLTJVNN:S.<8U__<\X4^\FQ%,OJ$X;!H>E.H8E&H<IB
MW;);J)F^\LV!>?KR/=W[])6#2F%MB1*MN=<:Y"3VDD=E'#5>8^4H6%NY%[-&
M"0@K-$]J-2C9 4K.CG#;:4V,\ $)G<<SN4B0]BP3:ZKD&:;8!_WL!=-T!4;J
M:67S)YD"4  IL#\E^+M5(]FR9K$5<8?)5K'5@W^*)+3>9RT<2R8X)WSM)=QO
MSO)>=_H?,L[R<P< V'"DT-#KOX3GSPM@6Q?=?E7*,_^3\/<F9P8+092S7(#L
MY"!!K0EPA!S3B5D0KG:-,]/OG%_"3].'YP_;N>S_"3<;^Z>71Q,W>YJ:4[3D
M%(GCLT]?VR3@Y#BE*/$$OB*1<(J"RHTRU@:B P@XD+5LR2$",0I:/%Z6.H*2
M;.CD9$W,TQA<O+K)@RU*!J0R#JNQ@MV<\[BZB.65$<8 >A/ G'EE6+G@;:]W
MFZ_XM[VXCCF[66<\NM75&K_T<6/O+@>K CBFGCNDL76@YXU"CL20)Q,(G*(3
M/)CM_-)6I[]^H>)P4I4852D2,0NI17;L1A?+7\)PN=!PL@O#WVE)Y%ES$!_[
M03PY>W?;SDN+/8LH!,L0UX0@FW0F!-8ICUL+,HDM#^+DU,(YA\?V8IU?+P>H
M3I=WOXPGV&O[I#B(I;@EI^'AYUSE-EG+TAU/Y@_/]4%EX.5[J<Y?^06?F8JX
M]I21T>?&*PD6\*#VNY_+#9?R@=1HI\=_*, +O6TK'PQWP2'#I4 <%!(R(8(K
M:H-6V!I.Q991TPR&I6=B5)&U!83O66UHP9%EPC)/3>)8!7A:,-NU@96(A&J_
MPE1OJ@VW@=SQS3'<;UM@'K#G'F$N00X+!@81S=RAV@N1YS_+1#8M7"%4,8X-
MY9Q*[IUS2FH2I!),4N&5:_9S?_L)3BX+D09$I>2(>Q:0#8;EJ+N#+<$!\SB_
M>G3S<M+U"T%?3]1[UJ*%'DS+%KI3EN+=B96F$G07\#P[%FW)6#1,!Z23DV#V
M.3#[C!;Y)XXY-0'DQK<3-\T^[VJ?C:$!)XT12Y$B;GQ"+@2&I,;*<.XQCG)N
MQ>]]2H ;$_>1 ^/\K@T2&5/"-4HA9P"%!M5$:4)!,P&_#L20;0,P*TS<:;NU
M&LYR-9[GVTD1^'Q'[:D&6[[53$>G,$X."V/ .$W!6<<ME> -B4RB5*?G"66X
M.9R[.9QW_J[-)?P/Q#-B/(!.=H$C*Z5!WI@DP*0+CN!G+\2#U3Y'<$&"-%;H
M9#C11#-+G,,L&[+18-*@8,<H.,GT98IJ[&&)<Y&&0IR "^'@&"(O+<?22!V4
MS"C8HO:9X18:'WM 3.OW85XQX^-'*X<>#2''NZR)WI/X;(K=UCA"9V]XVT5!
MB&(.D0A&;V9Z1]HD@L#X,18\%(^=R>4D\X[0?B9P-OKTH6%P_K6M!"PJ"[DQ
M/]<\ZICC,-HAF["P2B3LM=I*G]Z[*KK!PT/CX>/Q3=M'Q6SRF:K#8K"O" 8H
M4(*,5$1[@9/*@WD7X6$?5=%[LK :1;$.(L#BMCP:PT%16!$!$7ETEU;*(1.I
ML"X8R9U[4$71F-P/#8,\F]#H&#WG%$6,#2@*3L#DQN""R60C]00K%K<RN4<R
M TSO2E%,_&I6C"PKB&Y&*:TW2LDTHY3V/DIIY6BDJ5%*D07LF(7_P[F:VMID
M0;AA@S'CW*6XX5H^8K=RL[:%DE[;Q&3@#.21]8%P0KCAU&BKP:.QQ@MK RXM
M"Q1C0C(]=_5#4XR^6YUQ^O(]:<.2"ZVY0:D4H]-DD>54(>J"P%%2GI(MIL.<
M+,LZ+0L9-<-B$#F8(ELLS"I&4U72;E23+;V4FA@<K>:*@B^L@]72)P*&L3'5
MW%@P+@ITJA^60^=/T WG12C\56I[,XHJN_/PQH+("6?=TYRL?FU[5[<-GA;B
MZ>P8MZFU@BF.$7B&*B=D+;@IE(%) GMAM0"AR@N>R!(\]8?;,)Y,>??\K^=@
MI0"X8+\ 61?#;<O- J'3]]?]+)7@K1EZK0RT9W\>_7'X9^OUV]/?CHY>OCKY
MXZ]G>VR/>+9-4/)9W24QEA/:L$FAD:7?&OM?X>>;MB!<"@-B- =L*NQ;8@F2
M$NQ?0C X17J1+/T__P^1^)?E K6B2KRQ_4?9*K,#%#:M,CO'Y=VA:$L:@C>>
M(\MBUO'1(_#*)0*3E7E#G/:9"Y#R%:!\T'Z9_SO3*?-=)F_NU_W3Q%\?^#C!
MWW2/\=>MNG_JIIR* 1#/=O\LB]3LY(*;-\LTN'UHW'Y\]76?N!V(\:58VW_#
M3%T 7'4;3/U2/)6FF>9P//#A.'UYSO9Y..J*PJ5G8Z9Q9E,HW[-Y1I&4,T;<
M.,^Y8MI*'RT T9#<ZH[5(*;",-H*?4VSQ7SHG9V3MDLD>N(EBCHW,5IP()U0
M#KQ([N# $X>YWK3R43!MD@% 9[L?]LGBA ,VT5A%I*>NV<_][6<D2I$ [A8!
M\8UXROMI!4/2)*6]-(R4LIUOUCPS)6%VVBVS.SG2=%'<'X^WQV>'I$TB$R*W
M1F.:^T%M<$@'3% D.'J7O+/,?SOYTNSSKO:9)QDR*TKF03.(^R"0IB8WPR>;
M8IY4;_$W[I9I;-L'!\8;\:UMVZ9%YA&WR,!W:$9-CM('KE74N0:")*8)Y\%H
MFT\DQ5AL.-B].9$+3^1'3]M*)>NL3L@8)>%$.@=26G#D17(2@T)-U#Y[(>])
M#$_Q#]<)41Y\6&8PVP2Q449K3V>C*6M=XY3<G=^U53242I>+6:U&7#.9Z30%
MDHGJI(6 <U+RJ?/&TDVFKG99V]I(S ?&PLG+HSU*S-^CZPWL&[-5%T0#B <'
MQ/O[ F)RUS>K7WX 0F<K,7$2W*!H*0^6V$A5H)(!A@QEP6P)J;?#NPF-$EH#
M9V?GN$T#:"'O-:(X*R$;%'+2)1228)0EA9E>V%NQB1*:GCXWY/>E5<W;% ?T
MEUZNT=JL2R<RC6W0DBK'DV:.2^,(G"'CC>(5PTD%*C0/7:,RL1RR>5T5B/W>
M[66( 9)Z5YT[6P6$!]5COW7[#;H6H^NC_]I.4=O$, 6;1L3<LJ&1R5),:0G;
M9213)+/88K:Z8 S,YV"ONB#3[-ANP I_B.'ZHBX5JW<FR[<"K>(WCMO)_[??
M^N?U97$DQ"399_E-K@1L_=D%V_[7%HB0SD55BKG'DLJ5KLRS"9;I)6]\O"S3
M01@JO-66^AP'"UH9D9(3(C )D&!KG,RF=&['Y_/N^"4XZB#<HR0LP?G4N??6
M.J09Y@B+2!S16A FG[V@ZG&7SFU1HM,8M0\-MX]'7_=IU-;35D<35@=QUGK"
M:@./1PX/3^X)CR^@Q&^C[1VL7_('N!B"JF89/[P^OP;T$/%]%N0NJ.I:-$&Y
M.36/^M2<O#S<:Z1@_CCZL2,S(#N^?X56BA;\?Q&MDHJSA*TD@)\(-J(/U$>Z
MPD9L*GJV1= GT2916)=B[F)S O% $K(F!B2YQ898\*(YF5_1L[* 9_4H](-6
M)[5*3>S"F>@'ZY<!O0(A#\*W^M1<] X%_![*@X1F6?IQ[Y7@R6*-&;@ZP0C.
ME:+&KP_BIFQD%^"^.[IK2T$5#BHB!@L-X.8$&6PBHO!OD1@WGHJY92,;5(F,
M![8:E?G(,?%>[%5E#H(_K<MXM>.*D 9:CQI:IR\_W>T56F-E0*=C[2%S[+$%
M.JTQ\Y\BL/#QRZ/[.L<KS?RBZ+Y\N>CXXCJOT3;4@.9Q@^;L<+\!MZ$T6FWC
M@R5]T'+75[G%/Z<9+JZSJ72PP-Q_LI&7;U3C2 GU7+#(O D\"6,Q=4PI&2--
MB>!8'2VX9L/1OZ.C]?$5:8/,(CQR#'Z%,8@K&I 6B2 2DHC8ILR;M2T-N-F"
M!ESK"*Z.M#H0QJ.S+DM6AE/(%%Z4J@8%.T?!>]P6(5 FM$%,\#PJ,W%D.='(
ML@"RER1LU':<A+!/I,0["/EEG S\!RQZ'=%_[ZCP=4\"LZDY6N/0W)W?M*-0
M(#B]0]@Q@;C@$CGE":)48BE,T *G7',T3W3NK_"U4:,/C(63ET=W^U.C]R]\
M;0#QX(!X?U] K"I\S7;5)JIB3U95HRK60,/9X6W;)F$C-># TL@0YY(CPR)!
M)BG//0Z&N6^@*AI;^\&Q<$SV9VN/"0TPNBM5,?F[S2KHQZ&V3BW]>!E]E0GX
M;#N7V;P?3RQ-PS8G%:HJ?' 3F.2_+,1PO)X&L+%&V0"+I[GA3BO +U%6)QT$
M9UK3+0'<%.!OANJ[=ZP=I,-6.8\,5AYQQTTVAA4"&QE'QX5A0:[7!58'\X^N
M>]V)6OI-])TP$BZIDJ119<9O$Z2UR1&N) T\;"O9&F!L"(QSW/8Z26^C0RH6
M+TE)9"P/B&G8%*8R[8%[]H*R-6KGJXF/=</%+(?UPS &KU'COMZ['V^ANQ!P
M-#AU\/^>XZ LV )"Y%8'3@28"E7]1SX]:-XQ:@K=]W"8R/'9(6UC+P@-6"-L
M,8;#A D"H\T@XHA*21J.'7@5WU^=>^/#/C3:/K[YND\?=K=U[@T\'AH>=X?W
M31WMNLZ]2)6E[LYN,=<XSP^,.?C[OHFJIK?B6_=6-)+ZH4]-YKK<JR)_L-X*
MQ2(V 4ZXE([G0(_UR8.TY98 8J1?X98TO15;(NBCYVV>&'-6.11LI.!X4 :.
M!R<(.T=Q= S#&[Z;WHKU*U&W(E_=&8R;[HH=P/OTY2?<=I@8ZL&.B-R#7YUH
M1(91C\"V,]Q$R8GWWZZ[HE&:#XV)LW<W>U6:CZ:[HH'6PT*+'K_TN.T9,\19
MCI)./D.+(B<514FH:$,"(:3#MM!JYO:N-;<WR_)F;N^>Y_;^.'-X'TE/4R/.
M'UJ<GWVB^W:O]]W3U(#FH4'S\?RVS056Q&"%E'3@<D3OD8X"#('HK(@<W$)K
MM@5-T].TSXCGBB3#.A$%N8MX6"38"N<-Q3IR090-BA',K&-)!F%<$P_;R^D]
M.7MSU\8T2*U=0-(P.+W<..0(_$<J%X3"U%LIFWC8 \.XB8?M MYW[T2;&!N#
M!A,&G-&$N,,6&=@>1 ,'4T=2IZ3>93QLN4C=8[1D^877M.KEQE;]2A6RN<VW
MYI,T%L&D1:#F6@3_*O^ ]3G\._9 6+0J [;UMG[^@6W[Q!]^L3ET,U@ 6R]
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M2,Q*I(PBB"OKX"@+C[Q2<*+!(&$4SC-;&#5;;]K=-,#&Y^[,QU@9)+7%J%T
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M6(3$3+8EY6RX;[36:&W#:4UEE4@G,\DEI80K/ME4=/"J9)=YU,T$?6!:ZYR
M1<^U\62#(K<>%,\>@B-N8\QHF:O3(/!&:XW6-IS6G)56%:>+85;%6MK59^^S
M,*7$:%'T;8.N=67+1=+=+Y?I3AFMO$-#"APGXS1'#9$Y!4ZBD3QK&8WJK;1E
M([U&>JM,>CX()2*3IB9]9*E(B>-**>.8J#5^9-\F:B.]GDAO_S+I6:.28[)
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M@;>;;I*YL63K!; </2B7!%G\7$&6DFR';'T,F< [?YBS@7<=P+N 7),&WO[
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M#E&,1^^Z"M8*E;NY6H9=083?Y$Q_TZE(6+6=AYD,>^5D_(Q'DZI%GBMH9R6
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M]M5@:^<IW]ZIW__CW=;;K;U7;Y^=;#UYH;9V!GM;="_;]/NRNB))U]+//+,
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M426YP^&H=D@38RO/5M,>:Z1UO:#/#[_MG*7,?:&WGL0/KRTW1FIGF91:,XB
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M#&6&14Y"RE&+?-;3^R8WHC\K.\(WSW/_^%CK=_JV":)LJ/2-";Y)H3?J^?X
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M8?N%TEGCF\T?F#DR6Z%>!54Q]$K96Q)E;Q+/*F5OT8 WK>QQZ1*CPJ"07 +
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M[PR:X8^XW>L-;HMFKT^_R*KPUH]#8Z31+'GD@?L1CR978R,2,:>#31*0+5%
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MM7;L%^<:]N=SUPQ8P<3_NV"D<PYP40 :IL!)\L;S8 7-[9Z$#?+Y-,@*!N\
M@[-E0),*)CEID-3*([ -/+(,.T24\AJ;*+VFH"3.AC3='@.7KP!HQ=>7?*V!
M:SWA3@MEN/1$:R<35E13XU1PZMETGXJO[\37T^I-(@2#/A.0ML0AGK1#EF")
M9%"&*,$-"R:G[2P'7[\&E^!MCJ^>T1]XCW(KK\LD7L0"O1RY$8GREN2D5<.Y
M4=$DS C\X:-6)-A8>1177JC,%A%E2CF1ZP'$1$!9I +$"PX,!1.LE9JF1$7A
M4:2SN:#WM9D7P':KX7*L +@"X#L ,&5112O!#!>:.Z4U,4S9&"*7C AO*Z?E
M"P#@::V>^!2Y(MEIF9LWQQB0<1JT>NIXT"PE37(.TAO"9HOQK2  OYX"565,
M8_9CPC-S*]MVIU\[ZW:^-P*8"\!2^?_;1!3DNQN](MR[7:9AC5TVC  ?%K_Z
M[__(B??_[-4Z9[%;7-"K'=OO10!X+0W:!=G8YM4;2ZNE?VS+)W]=_[(.)-%L
MVNYE+]Y^I_@*EA7&4KSOFE&.Y7K-&U(W]BTL4JA%V\UY-[V)-3@9P!Q#PY=C
M;K2'&3WCA;T:O6()BT _(-+R3:Z(?H?-@B$TS^$EC6%ZS$(CV^5+BVP7KRRR
M_7/L =GYX\WX/38[9T6J2[O(BQF D/O22?T?P**;C9X'FWW07:((Y/V15#L_
M.&FV]B\.3G<^[K-]6H=G?OJYNYFK&YZ*@Y-/]. C/+^US>I?IB.0_VR!=#O9
M:7W"(!E/]B\^-P\VMWB]]2EGP;1V-@].]^G?C?T3__/_+D!"OCO$F$4;G$!$
M11!*U"JDB5*(B*B%(=2&'($\&?)NB HR:HRES(6.I-$J^8@E@3N%,&(Z8OGS
MUI>M=Y_?_V_MW<YF;7/K[ZU_[?Y5W]K9NT>8^XVO7M'PZ%); Z #/!Q1<!'Q
M'*[(N! MOM.;!&"0,V'@^Y,7PHW_'L"\^N<UVP,JS_E"^<JCKFWUUFN?9K[+
MC\X(7#Z^T2[$1O'\5HS]6OS>:1:RQ<,J@:SK%J_HQJ/L$NMTSVM%]E'.4ES_
M9>KD _B[R',;M&!+SW?3:(F L\?X?*M,15ZRQ((G9VN^\^.0"6,B\ /23!#$
M$W7(P!(CZK7FWA@J))YFZRB5U&"21*PEMYCJZ#0FWLG((Q%J)A'A6CHMB2C+
M_$Q21<KD,+6\B-\O _F)F0CD_S46/(*B.!=>;ER"9\@0P(+>)T- JG7-[Q<?
M?T.&@+S?G3=$W4OY&!D"?/%Y!RLV5G7]MU4VP^N+YJ^R&5[U_',LR"O+YOAK
MJ""/=.;N-6I+E<Y1!2P_1@>*Z;/7^YA \VH998/HEW;0D/ _EW2_1.[[^UE$
MI?O^['BGM4\.]HX;N]_^;!WLY5)?.XW=O6U2WWMW46]MBQVZ#^/[<'KP9<I]
MW]JB!R=_-W<_;HO]UD$SES&%^8GZR=>?]<WZ^?[)*3LXV>;U;Y^;\S(R0DHZ
MTH!1)&!-<:L],HYJ)+"4."4?E>!K&YP_N.=VE9118=QJ8QPG)!C!,:&4<JFE
MI5[E"GM.:"NCY07&X1'&S3WGK##N*3!N)J_")<QE;A1F=4!<)8HT%0H9'ED4
M0C*7+& <K3"NPKA7CG%"6NFM"P1^ -YI$VS0,1CC5#+*%75CB1EB'#$5QCT;
MQDWI<9YYF:3@* FM$>=*(.<E0=ZRX$WBV@8*&,=FH^"6%.->0_K8S(E5E3'V
M,HS4X<:^&^UK!6]W@K?9G#!OO+""242MY8C'G$7B<F,.'4+@246=8USH;-6
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M%P.MDQGL,VG%BT@W-B\MW5B^LG3CHL-160  0*GX:PA'RYAB?#I"'E8_.;V
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MJJQ;VYA5-RIV?1'LNG#[H&+7Q;+K;+*>]@XK9!@IRHA1Y)R)B-B )0&"-5*
M3;\D_/IJCA9*,D>C5B1E.M%1>9A0]CHM3NFJ0X65.E3X8]"#\>0TXY9KM(L=
M'-OMX2ELSD&NW!YWP[6O,U:#48HJK!02%EO$E=7(<&^1( ISK9.PE((:LDQN
MCXI_E_V H>+?1^/?:3.""0X:2;0HDMR7E!8GA4PC3).C5@MA12Y]51T0OF#^
M7;@M4?'OX_'OM%W!J/2&2^1P/M_GSB!M"476<RZ#L,3G^J8/[P]3'3O<B?N*
ME.\BU;LZ95@)TR%79AXK'3*LT[ 3I\(R4^-G#.@B=CL5<MT)N?9G+ >K@E%1
M292P48A'S0##4@0,,U0RI@1EH'G\]W]H2N@_%Q236?DREY"'%]H<X1H>KGCU
M3KPZ8R7HY+4#*\$";X*5[PA8"8G!?F CC$\,)SKOL*'BTN7FTB<^<9A*CZCX
M=6'\.B5;<:!4&B.0#E8C;@)!CGB.%"91AR"84F)M8[:<=778\)CVP$0)J,<X
M4KCIOJIF[-,MT'(#_U(4._AUC;Q*"-Q)"/@9 XNE$ #Z.;+"Y-8WW" #VX@H
MU5PP+HAB^<A9L07YAIZ_/FP%HQ6,+BN,/EXAA0I&%PJC,[:OUT$:8A!-,7O8
MO43&&8E2SM$12>-H#.C2>%'I.!6,5C!:P>C3%VFX"4:KZ@P+Q-@I594KEI(6
M$06&)>+28N1LHAEHN7=<<4%U49V!/K@DU]*@[&0S@\O6!1,5TJ]I<3!6 7K(
M1YRNJURO>12X^[:(:&Q\C\,RS4,^&[MQ.'-\=8MU,,E!__I;9FJ'/E,][0](
M7%6)+1=N[.=Q]ZKVZ5%$KAOM*;()AOO6-G_8\][:[Y-UQ!MM-+6*URW C7T@
M9DN.3S2"H+QX_G#9-O['=7_?F#>1B6T:%?">)=ZRRG!!F:./1G63,;XJB3Z:
M5HV;=8'SOY-_KUU3??\6U?1ONS9LN0NT;[>')=A_55LT)P[^YU+X3:IR0@_H
M/5#G.YM'</T[NKMW"F/_](!JD*.BW;5&.W<Z H*T(5-R7O]<IZ8,*N]WBE+_
M'YL Z_T+6WL'C-;OPF5CY/:F=F9!5MAF\QSH+/5BO^;.X;'#-M#P+-\!:=*(
M$X_U(%]R;FOSBFR'Q+I>*VD:+Y:FG[T:8$73-]+TSX>5_9NEZ=ROPA\#F,<9
MFOZZ_F6]]B7Z01=V"[X>)^C\_9>M]T"(WV-O@@3S-^]MVX8&0/W<NXO+1N_J
MG/519]"_-4T#J77&.+(]RT;GX_.PU[/1\(W$+):+JD)S*\!%\.^#BL;-\E$F
M^][E+A1U"&K->&3]><E'O2M.\$W; ]+U$[3X?DBF<",\JA>O"/Z2(#-9-!*8
M'/#\RV^[L18:/3_H]8HZ:K4TZ!87APB/:^9/=CK]6,M\M?:OK8_O_E7[Z_/N
M^ZVMS>V=CU_6UB<5U!>E\5VUVWE3NWNEN6<0GG<LZ5+Q^4U\?D3K>Y\>6G!I
MQ.F92IY8#E0$\0@$<?308CY#@@"EO@M+VP7X&K7SRIA1@@< ?,<W"B7D1Z-_
M7$B'P5GJ H& +7!>FA"@GA2.%@"E,74_YKZJO<;W"!J+C_#<]E'-'G5C(5=
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M<H-S'/PM6LG>&8N702_: R$'Y'$&$JU=VJ19]:BY@G+@GW9,C7X-],I6UHZ
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MREV!W[.#WW1&48R,B4 8\HX"^$EMD*8L(N]Q"(D9:T7,IXNSIQP5^%7@]VK
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M]5 Q\E$B8W5$FC%F!$O88YS3%O$=5*,G8,K5<$%7\%S!\ZI:GK>'YPJ![X3
MTZ:IE(Q3ZBR*(0C$M<?(6K!4*0O)),&I9'IMP[ *?RO\K?#WU1PB5NKQLX#S
M=',$XFD,PB(:&:C'(3<>(DH@H6(RA$OCF<_JL6;J)<#S+>H,/E52V_O+/*51
M@ANPQ;# YA]EIE*5T':QQ0YY3!Y[J1"3V",N<FI;C"0?AAL3L$S"XWLGM"UY
MHO]L0ML?#TIBJW+8JARV*H>MRF&K<MBJ'+8JAZW*88-)OQ]TN[F(RJ/VYKW%
M,^ZB^]^TH/"09UK-^8>YU5I6:[ET:WDWE:8PMU59$GZ9X>P.*;DW.%_OY25]
MOAV^SD5Z-U_F\XW_B<_Y)]TR0R'X(0*KV^:,(^:EN!FS\^5X_R(TZGNG\-D^
MWOFX?[Z_]_=QG>Z<U%N?X-V?3^I[S9/]&3?CJ3CX^.%DAV[_W-W[?'QP\@G>
M^^?QSK>MBWU:/S_8_'2Q\['^<_?;SLF\2.&D(DG< +8&1O(I?%'%SB#F8X+]
MD5XK!_K7[3-<[^<,+*F[@H07" D++RA<0<)B(6'Z6-@9J834%(F80FZC'I#U
M''YPH75PV$@GUS9TA0@5(CS;:6>%"(^*"%-*@B$F2<\\,BXW:@\Y2H]SBQAC
M(BE!A?2 "&2V\OBC0<*"_#^K8CO=/K'Q_A8WO=OJW3[IX_E :2D"E$?@-"J%
M6H'30\!I-HX8!QZ<21$%B1F $XW(Y6XHS$IB!.Q4R%T9U6P0VQU;,OX"01:@
MS51\NVSF1<6OB^'7:?,B62F$I H9+Q.8%]0!OS*!J+=@7YB@E05^I60!M1,J
M7ETN7GTTQ;_BU07QZG0!/&JT2\(C;G,= 4$)LIHGI*-1G@;O>&[01Y:"5V]Y
M:G*'L_';L/&#HKF7+VAYF33F:V(O*Z:^$U-_FE&8C<+:<AT0YD(A3I)%)AF,
M L<N!8US<YNU#7%=VZCK&/MY$CA>,:\N@Y9<\>AB>'1:2:8X8&R)0<Q$#()7
M"60H_*:QEU38"/\Q4)+ODAI;\><2\^=C:<85?RZ(/Z=DJ'#**@?BTQN7&^]*
MCAS7 FGCDC:"!,IM]HC?_I3LN>O\+2ID\ODLT<V8(A!]J (F7UN0WV/4P7G<
M058A?H]=:NR5GSJ-P'!X)E[I 8O0 _9G;&GEG(I4D>S'-H@[#;:T3 RYQ##S
M/DF>[-Q.L(]06^S>$3.OB^<>K]9)Q7./PG/3MG%N7!R9PT@HHQ#'TB.3L$?1
M)^XDC4H*X+DG*>?WFEGN6<W;BM4>A]6FQ%MDUGG-)1(NLUI@&.D4(OI_['WY
M4QM+ENZ_HN#-F^F.(.G<%]\)(KC&ON.)!JYMW+?A%R)7$!823XLQ_/7O9%5)
M:&.1$2"@>L&@I:HR\YSO+'GR.XIZC",%?4MF;5/4=5]UW=>*)=]6RPDOE[%&
MJ66@E)]QPJDW*G@!RQ-"KBCA(6]0<^0%MT)+X8*A:YMS-JF?L@+L4=C(:B5^
M0J^^5N)E*O&T5\]YL#'9O T=)>)42>2BU\@&1T"].0/W$%P-LV H76OQ2]+B
MQ^/!J[7X<;1X)A_&)4L! @;L+6BQT! P0.C $DY!&Q=2!"TF>I:S[OFTN"X<
M>VW^=JW=R]#NXQE'VSK,F&,,++/6**\ALM%Z1#UE5L-;EJJU3;:HHUU7IJRN
MLCZ^7UTKZW*4=:;QE(C:.DT14U$A;B0HJ[4:&4:T)I[""M+L4"^8**^U=86U
M]?']YUI;EZ2MTSPL3COFN4*)N(0 814RU'"DL7&,4$4H%MEQGCUC_;S:6K>P
M6GTBP9JC?Z6CEAI2EP&IWV>BE4"-34Q)Y(4GB,O@D>;$(Y(LI0H'*;1>VUQ:
M*N+Y.?1K^*SA<U7A\[$[3-7P^5#XG(X?F:,<EB<A&HA$/.+<0YPQ)*V36!D9
M6/1KFTS-5G_4^%GC9XV?+R6RK_%S2?@YTW<Z^4"$18DSC+CW#CEC, +T]%R#
M^0L\U\XMBY?H^>'S'BV<\M]9K)OM0=%\;'.VWTVE()R6U7GGG5XS?_)=-[;@
M*S]BU5^F4J"Q+U8CQ]=?L0X&.>C?_)69I@=/CP-%,Z&/2-#)!D#C/T^ZUTG0
MXXA<-]KOR"9XW'>V=6$O>VO_F.P8U&RCJ5F\:0)N;2XTOY-0^5*S'7)K LJ+
MZU?3MOG?K@N/,F<@$\LT[#R4IS85_QG*9O&1=X5D#E\:-GS!^+K3T7!8#6XV
M!,[_3OY= NNXG)4(EJ3@RA'AI"&<>ZJM<()YZT42SCE20BY\)X:MW-4.!\!:
M&XW&1'+!G0M)&!HI41: 5KNUI^M)]B&EZ+/XC]#ZB^W'+Q'NZ)NM9C'(NBG9
MU8>+H\1"PM@1%+1PB%,OD+9)(\--R'WSI//A-3<EN[D-66B"$'5[Y3M]^&@$
M@^_[,33L&1B4?@. W0\ 9>$5=]FPY^>M2QAH\='<$\^V+__S_VB0_M]ZC?>V
M;4.S&*'M#_J=[F6C"U_,?=!N=&K:@S,'$+O4N/#3[L=II;F/JFP-N6*_#A]_
MXL,CWP?1-Z=&,(;C(ZH"\R9W9(\LY#(>A;3@%!'!,.,J*(+=+>[KW)5^8 *U
M7NE'66EO#3.21Q0%YHA;'9##3B$N'55*^"296'2E'QBKU"O]*"L=P/9([QEB
M):U[R@R,6* @H@W"@&\4,^^BW)@M"+C[A?_;Z'<:N<MPPQ7MA.&?1;MAVOQ6
MJ]6YZ+V;="%GC7,VQ:+N?'GO]^K.ER_J6>O.EW7GR[KS9=WY\@UTOIP_Z'LY
M$H]Q*'9IS$ZO>V?FQ6^\/'%+NUMW7K*P?P3A?E_F'F$&]\XAC,F/U?N]T(%1
M'!-['W[VNQ86H=FV$-_TXUEO%T(@^&87W%CXZJ<,8+'77\MN]IG-6<R?_7<0
MI:'0Z:/JJ5[-UL[!Z6>\L[_U\^"OCZV=J^]X!SZ7MVH.KHZO=J]VFX>G'\CA
M']_(P=?IK9U6<W?[\T_X_,G!7]^N]O8_7T#$)';_^'BZM[W#=NC_GNWL_PN>
MYU\G_[[Z,,OZXQEF&DL4/;.(^\20!1% *HN(EL13R=8VR3I>A)]S&6QR+V#;
MN\;.-X2=CUWU\TC86</C0O X73DD"/<N*HH8SULP8#,1@")#TOLD@K 1EGIM
MT[ :'&MP?,/@^-@E/;5CN?K(.=V:@3M,(H[9&FH$?V02C&"1%,I+8D-BN6:(
MK&LV6[6^>MBY<*JBJ@99S53%?(6_<;O]E](34Q/P2X>C)DMJJJJ%Z6*P9=RA
M?LI;GO*-$=5]&):2W+SO9_LW58T\1R;O#?A4+\AM6HETW.W40/.\J-K?6<C?
MF>W=*H7GR7F'HLS\HE9C9)C6R'J!C2"1RA#6-NG2SIB\H(BP!JA5&MM*Y+QJ
M@'IT@)IA);1"18$=2%6D %!!(.,(12QBYJA/@E(" +5PL[P:H&J >GU'R6J
M>GR FFY$IK$D/A&D+26(X^"0)I@CAUF*C!(7<%S;Y&99Q\Q6*"_T4F+CW4X;
MA1@&,.TY;5 =MNBD1N_$=B-RMA?S/)QE72FTXE%31[=QS,Z9YQ?"D?7$!1TW
MG*"=+$B'=;]>]@H*O^8E_SVO^/NQ!7_?J7<=%T3"V;;&2=$@#$](!@M(&$-
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MZ>>?.]L?CB 2!*]!>22T"CF_%I'VA"(?+2=)Q22,7-MDLQS[0VHJT F8U"[
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M8[2*@H,3HI72N@Y'G@9Z#BYV3[\=&6JPH]CFL@'P1J7#R!@L$<?$<\6H<)8
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M#CNLC#4-R0U#;MQ-&MM"&K]]J22 OZ67-[[I-.U<GG1:Q6Y39^1:#CO#3TW
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M]LX(A YL7JUI*HA=0*W!.+L[-V53K-/5[@UF!;XI+$FYF-.Q6*-T![;S% 8
M=T'C)X8U[V]-W"<C?,.*P49I/RER@\P4;70TG# ?B_&\(<_K6B38RU@0#YY'
MW0X,-$QZG15+VWI\S12HNRBBO([I^N__$SEV^ NLP*(&58@#S<%%F::"1D^6
M.,L5P?'2KD>W2;D\TG3#@UM^ -#VG_G<0#U),X!VN$M7 %?]D]1;,C?JIL(>
MI0IV*RKEIVY<A@/:MWU?\D/K2^Y/T;H66M/[)_;FMR\:DMR4FN^,+@5*SN];
M)R#Z\'[5E*.I.LKS(A7,C?CG7?3["T'W> ">'4LO%JA):L,$^32.*G8,\C5A
M3W4*;R+SW%Z<PQ D?Y6NV2JP^06&3 Q=T5G)IZREY;SOI([(X\-% G=1Z9-:
M8^O,RG0A'!I0%:":ILJOK,'0PN5"#\"'&&%)1DVA2HI)@A$0Z7]X['9%3_DN
MR9Y@RPMO,;\#?,(H$Z:[Y46KA:3(,X%W>('IQ-#[Y<>DJ8;E8J2MB#+/]6*&
ML8>!,1.LM=33';/YG5)KSJW&;-RSD/B1;U$]!"YP5TA+B2RQ&(K-+XJZFS1X
M)*OPLR=+>F:#[IC04A"ULC8F[D\C?@OO(R1\Q7%3?^934'JI4#M:SD1<5<'G
M6:%R%NBB)9R2$$@ITW6;#%85-:XJ#')X0,_3?VG)D(3WLK]S9.R,P688VUHF
MYX-40C*1_51GXH[^#%E9;8+>M;F_ISH#-R5*FDR#'8P&G!+<TPOP"S*QHR!F
M0J8D=EYQ$4"*&'"D)R(Q^!A3>G0NF#4O*25+K$U:TD(+&5(2/YE]P.1GP_-$
M"](X-SMTSR&?!^?C-PR1EL;+?8QPC3_ ?<&\HW F4[X@TX]];4&>ITR0E(VH
MS>WPBH^,'4S:')9;ANV;Z:5IA8$?O=HR8-)^8],%YH"[V9G>.&]BD-HT1Q#-
M$<)-<X3OWASAQO.IWGE6;%D1YV'$/<?VDB1,TBP,(R<) LL-"/W]7%0@'=9D
MR%U(LVZ<5XSRHU*-*076> AMTHLTP1N>5*0*/*4)8'2H3O^-QP+OWNU(?<:0
M70XC-K@/W).K.W*A+)H<3O^I."9U)H;A5[4@[8@Y'%*X9+!ELI^-QV7:.%A:
M=DYZ47B0 O[0_ H/&E0NA^@<*; 0),I;!K[6 :O@@8UVVV'SBZ7QKDPOJB*#
M /![O!.Z;]H[L?:U9-1;RQL:F"8V&)[B"!LDS >>/4% 1ZMRE,Y+LFF#JY(5
M]0267<YC=^1#8Z5;-G;2L72=?WI15)FQ4U3I FPC:(8";MM,5#,%XB%=VT&W
M<48#TSJ#@%O80LQ!\@O.Z+1'#E$.^#N[_7?TG$"B$C9-?V8L(B4*0@!63)$"
MDEI[K'?B'Z=2LAV1)E(B#"Z9?PWA= H^2O^,QDX<S@,[<</82^.0^9:+':M2
M%GIVG(NV 3Y81,*]P0_=PYK]PS<KD):RKEL<RQ)><H=.>-^@O!Y2>Y7.L0V\
M=HI'-U>P?6H^?3Q$J3_\U ;NL?OYS$FS.$/Z:)":R/3B!%P9)W7-+/2</,VS
M,$6+FH/2'&!&I</P2[[.7Y8DJ=_J-;-SW#3SGN^?-8<5Z@@1T0FPT-1/!S.0
ME0@7LZ("Q5U6$J< EHA+0(5VVC3"(Q;48Q2J@S6EXQCZ+L_&2R/'8T&Z':AG
M\-XI&U;#Z[<GKGC@D+-B3*1W>-(@./#P7$7('YUT)!C27W="HA (=*A>KR3?
M* 4*-Z\6YP@#22G[.70_/"Q!4PNW*=AXOC1F(MHH5+9NZ"+Q")B:BV(F4DK'
M%P7X?:4P- =,Q148D8FP"1>0O'3=4VFC*96RW6B))ZHE_,/3[3,/O''0"K&9
M,M\WX;?,C&WX-0\2UT_A7T&0K-,22A>TA-TI$_"3[QH-=SVCP0R"%.%;JH\1
MCG3!M]-YNW_HG:Y@1.+;G7P$_'VI92/H?/I2'&!J^E)E%N#I=P$[6$$:!)$=
M6YQ%7NA8,2P)BX(TMWGHQK%DY+>Q:$+]<#V O)W.D\8Y%T3CV\*;/2V)C.N8
M5?/E!@@QO%G>+W&S.(SY;NA99FA9H>E%"3.CU'%-CL5#+/+#0  A''L]$.+&
MK!4:LT[(UY[1]>*$MGT>W:!<31&1.!-63 FI$/PZA2UY3B;3D+BY(5NL>,\U
MRP^1VC:6_E8-G*@=:#^))W:21 3BM^CHC^?@(S,RK=FDF*.5GI8Z**F)P7HC
M@U"'1L\)QCCNV'L8RU4%9CY#N)UP!SH3*+QS;>;9=# &ZRZ%\9+A1>#?R^_"
MNN3P!7RA%ND'EO^2O]I"I2=L)-S^/POPZ/,E[7[6B8H%XYUHI BZ1:6^$>LR
M;\X05).@K#ED('0*2R6.3I]G3>5H #VQ9O"$H@3/!L]^"=X!,R#GG*$K@I",
M7,RS/%\=$V@,E0">K*-;$ AZWY5)5=Q]6A\'K A'I"Q-+\Y/>85P,$*X@"SA
MCU5&H#%YJ,6;^:@E*S4>C&!HTKB5VA-)Y8HDR*G L,@AC R"\2BW4;N$?X&(
MK):G#DU,_P^*YD=J9Z!PX./DB&&T11=UU F!KY.7E2W1&S/F.TST$UM\;TW;
M<4&9 <*,J@&!- MA7@O.^\"%5XU@.R1H;D]JM0%DG/*S.D /5N(<AG6.&*2[
MF*8L2#TKCW,GCICG^CQBL9\P,% V]QP_]D6= N+P;EG!O3%-#U'D8!^=IE>'
MGSZ#/P?_W7U_YD0\38,X-;V0,8C\TM!,PL U8;5BYJ1V B[W.C,EBIP4:*_,
M_V6\+%ZU>UUN2KE3\@7N*OCG90%?4ML/Y+G!: B2\)LVY#]JVI 4/O8N[7U%
M;8Z*X[,)]/>=MNMS/7K[;3'E0J?;T0BM@ KU.^=A5ZQ^5-%]H48V4C$&#*V7
M]!X9EUMWB3E&!D<[#/]]V889$889MN5XP2OC)4;/CO6+]ASZQ/[EU8C* Q"C
MKYG?O&*+3'DM(B@Z49EEVWJ9O)(4^2_9*R5Z>U_ SB/<<UL@+!-^P<9DE%=6
M!AL52X?AZJ+47(24@*VS!I0 &R'#B]O/AI&;G62\YCI(IT'YDI3-MEWX4U4N
MSB\4E,R6V0*1NB>IDA]%(W%HH8E2YPR6;/^#18@OUQR8ZEEOD9%7,:+F@:K<
M]Z2DH8K<#J;I19I=DR_L_0,+BW;\=57PG%+C4XGX*+47A:_QN<!]-,<TMBN>
M3Y&KFC^_&[?BAI*9?$+"WC@BM1\N8+G%TE%H6M3M6&E(3*):IHNQ\J^9PA!+
M*>RLGI[B*:5+^SRUX7[;.JP).71!'52-UZ3%L?YWUO.96.![3IKZB1W'GA?S
MQ+6B /[/<EAHL32Y@?5&RWA1%4,WVW5,JUSD>2TR767^%H=0E[G R(+RW"2_
MAIVFJ\.O[\\"<%L]-\K,R 4?R>-N:,:.%6,O;A=[95K<3E[\"GL*W$^8NTL^
M70WK:=%KT8P>]D6188%@H::_5_#5Z-[V!+2/9*=H*KTH87U0*$&'MUBQV\@G
MW53HM95D5/U(K'FG@J_BK4G_EW&Z!3O[BAO'%9[Q@CA?@;$XH=EZ R95VH*[
M&7K=1@1H([#UTJM?C#V(ID$AGF*Y)B>S K$QVH,:0RNL6RS0P=S#T%R$\KW1
MC<L$%EO>!H=WZX$-CRNPG1#&!7>?IL4,OH7WK!_FG>'>$=S[];@L456<GX!\
M85PUQ16BL;\[_M9GA([MP#.PAQ0>L2_5#.V $'X%MQ]1XE@J*%;RW3S[YK<*
M7<>&)QZ<[!JG)3A$8U3OS7O!,[:.'^(9'LW<@A]@;(K2_@9"<]BHT]X;/<S3
MHM;UU!^J?,]?\$*T9FIZY1@>8/V\&-_TC^UW^SO-)M]_@+L&<%=TQFICNX;X
M#WPYK%=Y@!N'[51I]V]GZNCS8@*?'A&H?8'5WT4JLOUJR4YWOV$8(>TLWW;;
M88@GMB-X![;6V$X2B#$-894IT"2E8W;^>G*!P/M=!5>67(MBF-\Z1#?PVR%J
M#VW'>0RCNL)2#:7/FCDC Z+)^3WF3(5:*P,+?=]I!]:,01O6(AG#DNU1P3LH
M:07'^<#G125B]I,E#&U"12C@)^/_SV;%_36Q&%?@:!.FW;<=&:;S7I<<76^U
M5=0H]=&!C]8J/EKUNPUM,$J58W2U(%4,I1W>"1YAPP 9K#46RFCD!R)'\@:<
M;' DOG&BP*I8D9R-#_R<\C;25_E]6F !(<H2?+*#"?&RFA:W?^(:8;9=+\)'
MOCTXNN.$KMZ0PGW+BF*XWYO__C\0]O]2U7-F;!^#BD?,Y3</UK%HL.A)?2RK
MSV@+E[<1YV]^)Q<VU@8-?#LT<+1! W]W-/"-Z-X>&MCA69S'EI<Z3N9QGD56
MG'J!D\:!QWR>/*-6FTJ%'W[<V?MPTJKP?R.=6.ND'T&<#RY"X[E\B[LG=$04
M6IJ5ZSZN'<;K,4L_5QB!27]SNX7\/DA,)@;C>J[N]\IGML/8@=688G7YFP)4
MM+1OK4?5AF_;:\.W'<IX7G$VAJ!2OLR)J"LGQ\;^]I>(7)PQN)3-C>V+Q:=O
ML79RD3STGE]7[ ($#<SH#.&Q\"K5[(YS/G#KV)6F^[A:9))N87]:@PN*A[3*
MK4'W@4BLOOUE;,?15KE]JN:W\.E75AG_ID5*,3O0<3V_7>@=)]+<)O&X]O'(
M FOL+J?PS*7Q^PZ!Z;]Y!?T8M]D+_=XO4*(9K"18>_IL E[N]GAVP>Z62%CS
M3-L)0FVBU9/:]SP$W_[BBN/,0A"[(%JK=T7..\N_]2V!AQB'WYGM@:=J>H9=
M,/"\QLLF6KAKD+'R]-"-M5F 6VN1H:AEE[[J*5)[+"H0,U:KA%"3$=LIIU,\
MQTD7\U7/'I-;P@NE9,TW3%A,0XZ\SL*UCVZ'O@O.V!7NC-L'1P\P*LU2J &T
M0SI@EZ@@/H-)7$", ;+$+PDX^FW"[%ABR]JQI45C\EGM6=PIIU.7\AN\=?DD
MWPNU[$MSW_91OY]L;ZO](A;\5+"]W5-D5X,[.9(0?)UV)/A8[>P1YO3M_@XF
M"HDM[AZ9M.$G:K,,]U</W+H3QO?A3CS68'P%P'=7U=-L0+[7$3A='7X]^'*6
MA'8<AE9J!IZ5F5[ /3/F86[:G/.<\S3/K>3%KR<P=7SHC$,JR<W!U_,0B/=?
M'N3D2V'9U$E.BP-L:MU^:5"@\W).9]!T?@WR)' \=(K>NXTLH5)'56N.HXKZ
M:8GCL7BKC52ND<JCW71Y%CG<CJR$F[$7!B"+H6-&N0/RF43@V"2)&]DY2.45
M.#9+LYSRM24)SQ.O( Y.M6-FXD1#_ ?ZK4T)*^*2KD,AC:Z'(0TPGFJ/[#U&
MX2>8PI'K94U#8P#/?.BA(VV,]LBP'1C<2T<.U?;5)1H&B"Z2$";P1@7X:F1,
M^3FL%'J^H($J3NROT[G$"M%YM3XHO*>F5#ZP]#,'$UB!BY2/%YQ*/O BB+:K
MQ6QN'%7G;%I\E<!=FBRQ* JJ#DYYPB3MBZPQ:Y!:E!AO4-MXI#U2$*U1A]>.
MS1OVXCG)CRJ?[E3QVBX-3<&)+ 7'ZI?"*1"_ @6)4=8%""B3E*TE$<5F'"'?
MLT:7J2L'809;QD'9U($KB%)K 22P:DKXP4D) TQI!E"C9@)5.)&IA74B!F\"
M=P;W5D=((65M6TE-97JT^HK\MY&];UK5(<'""ZX1KG8$+2("W[A3?1VN0KZ:
M CMXF6*V&#?',Y?E&(]]X2KYO@0KD;O@AZ1(NH89YF1<UDUY 5SQ-V:@.L(C
M[-E<5J!9J\M*A X\T["&*C9?!?9I13AR@9M,R)U7<C73L2XITEW=#H%!K+\/
MCJ+U;]:3,$@ W>]3RL%2=K:6DX'Y0_I2W:14.@P&6RV"-.@2#_>N5K/:ZB@U
MJZH^9]J,6;V7AAUN":_1^YQ*(H=5$AUM/+$H?AG:L=I^K6_8L"K]-M)/J$=Z
M7DGHER:QTW=C_I8[[+?%6$%GAU?@+CI3G*WHTMX6U%@/\X@.0$A[4 L#CI1T
MXV)+MA-K5>+O(6$2F#;JX+M&JTBR!F$QTJ$GHSX43HSP]YWF2+^QR0A@GE7%
M6,W:X,#O,FL*AG#R>EM-VD;JG0>:7(&)ZDWK<XN)&I\:7A]\55ZO*1Z5<])F
M'C2?4UE#W4LFYW7.,<=+]-)HR9&\AX]ASHOS$D+\>KQ\LM-Z1ZZ='39E6<&F
MPW483W42;JH/N#L13IYYD9_P(+:3R,L]ER5^F-LVA]@LCV4S)]M7#>#\NZ>_
M-Q07MT\K?3TX/?]ZYD59R.TT-'V61:;'_<1DGAV:EN6[:>18<<Z\%[_6Q9=K
MB'#6LM^@FJ &,]F#0>114]%V8TT(7I678,E%"N$U[K[Z @$1L/@%&X%1GF.^
M@.[R?L$3GMZ LL?4S_9XC&0W^IG^ $SSQ+3]V'N-9[@GBQD>*K9N>7\@\!TQ
M)X?EI0R-1,3KO_K%P/*W_RFOT ^^6$Z''_H'/,ST/<N/75B<G6.XH7HU>#B6
MI57BZ0-/"MHGI9TGK1S,K3[0MB+GK@]TW/:!V2OC2$8B6!S6.8;L/\L-B)+I
M-L_J>:CB6?P5AA.+-"V&7XD6!U4#+1],IHF2;MNAY\)*DD,Q-?K?LBS3"I H
M*HQ<TP[P %K(T;JA-41A[;13'7#^"A0O%K.SA?FVS(@3Z3;#; <06@@:N/T
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MP6M$8B!;%<BM)WM(>CTZ;\AHM=U?=>[:3IM/E!0P@;-2U/1)H]B"RYEQRK_
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MD,%IN2S'"]00Q7BICL?0V[['#G02*[-=CZ61Q[PDSL%4^0R> =LO<V/'V>S
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M'(3,7-6+&?;'ZJ%R#Y9C>)W5% \R. @D*2P)IU3<"9$L#3% B.-@^O,N1PT
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M%C.\S5UT+,O=,/7\V N<R'/]F#F9Y[M19"')A&MM=.R/U+%[UL&G],QVF)M
M3&$R+_)-CUF6R0(O,QWP:O,\]L&GC5[\&MQ%R8[T#E15N61C\E\1N[C G(H0
MLHTJ?G2J6*<T657&AUBL4?S'>#M)_GU7I:LZ-NO:EC6>K*Z$I##]OG6R17_;
M ;V?,6JY<_0'*N49K_+QHJS*"_YE.2[3.9MR5,_([X+\WC(YAL4R>":-810V
M/C-V06_N+7FK->NZ3 O6P&0/>)&4DP+N<SZF02WK7#6\I7/VI^[@AKD#SFS.
M8VRUDX=!'$:^$[#<!Y_*8C[;*-\?J7S]P]W]LR!PDB"P$C/,$]?TDM0R8Q:[
MIN,RWV*Y9_MV\N)7;Y4H<J-\GY_R;4_I!Y3O#L]859LGQ905LA/G&#Z<4C$\
MJ"(.NGE! "-C"N/.1=,T=58, V=?L%RQ4<2D$U4ZMJ@JV?$R(<>R7DZSJL2T
MU&TB_+NYD(]((<9)ED1)Y(1AFGO<\L#.1$'*K(1GE@]:<J,0?Z!"W/]ZN'M^
MYOAYG'&?FSZS8M.S0\=,/.::W,L#G]MA%J3(0[=Z;M,KR=_$_8]>WTWUXF>K
MK^_ 4YN6EP4;:EA]L[NYQHE4RJ^OL5:]4C' OD,Y*=*JS$KAS^KZE<VK<H;!
M?CF[ 'TUAB\:JDM+TX"YEEGY]JY8@BV'!*^R2-7M9J#?&8*"C,D2[LLP[0_3
M PI18/#JTO@\+:_HD'+*P2[@]/,,T9HD^NE%,<XJCF=XL*ZN:3M;QL 2B!W2
M=)Q\UKH^<%AB!UF>)8[ML=AGJ9_;7ASEL94SYL8;7?\C=;U_^#4]8RR.L]!/
MS21DMND%N6TF<9*;2<9C%EFQX\;@_+K^1M<_>5VO>EVNJ/F3T^W=;6.[^CKE
M!7&[C(WMMPU[EZYM\!1TBL[N_R851/S&ZZ(4 ')C^_6HZ6JE$KGK+  SDJ*L
MX5%C5F';\XQ0QGCYNP46K8!>>@FW+Y+BZV+"DEN><=U1*SY+\(C6+V;**- 4
M%@8S+56%1(8:ED2&H@W>HM7V&AJ+-O4<L2@J3A&I=8*.Z#,K;00SJ/2=&MJI
M:O8E6D=J[5-,D3U,GIA+C$L?2F*T*))I"2Y&6BWP\+0_)E#J]#*B1JS%R8 C
M4M1SD)"48;$#P:*;U5?' ZIQ\I+/T:PG%';!&(1O('$R?0;=3:77NDJO<%/I
M]=T;ISU'G.@P%GR_5PQTC-V:T.M^GE0 ^U-)X@9F=$S<4*)&2Y5^=:T?[73D
MND!JB%;I"0"=[$W?KZ::-1.HPY=T\C:DEI*4(]2,BV(&]/_;*U%E$CLG ?,T
MMKT))K46$RR56Y!M:8V#J/@2!J'6GH)54D7;20<YO#!.@9E07'C=EP:'H!2
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M'EE!*_W=&F5V=Z"ONCK2*HV.#O2;!_J<46%SC3DY*88Z:$#43EK)('(UWA>
M"KZL(]#O1,BD8>&T87%O-#Z8&>:C?4;.B+$[#9Z,7M%^:2 9'3$>>BCEZ@V0
MD_AMMS!604QZP<( &4A/&RE4$&"=%D%%)YRLUN52;<FXM<V+N1Z^CN[N7-N(
M1T?JBI$Z9RM(5-'H@D*3- *BK2)%;QFNR972VEZT$Z!*=:3>4J2NS$;H2%TQ
M4N>4?4!#6 M+4NNJ  ]:1&"-WWI7<C:E:J.WMM<EB> NA ]^IJ/CR;M\_&["
M(V[J_3&]G S1MGNC(WJ+T^]'>%!&3WY\RM-PU,,+UQ5>.+,V,PYZ>%">\./'
MN/_CN[0_SD]KI>%R6YA.4,L1E%E0^M%Z8YW2PIGJ6XC3"Y0J"*=\J;(JYBFY
MM6UECRK<3ORN-*S0\7OU^)T_99UTD$ZB\%A8P9!-P9!0!";2VD;0,=16A+7C
M]W;B=Z71@H[?J\?OG(% JE3KK!0!2A*0,YORMECA@C9)0DS2MRX+B[6<^K&)
MJVJJ</R*)B-Z_Y8.CNC>Z(".NW/_*M7_BTYIM668.ZKU>+HHNW3<B6<YXK$+
MBG^!@JX,%5D5*PZN@L"LDD@IN@*VJE@=$X]?+-#4?8BW KHKT/P[=*\'NO.U
M6@L2FJ"$BSD+2-*($ V#&&(&WKN9_VDV^V64_@[=-8;N"I3^;X1N/VZP2ES/
M=VE0D%/65D0=K  J6J!I;1*]3P6T]9E<.VX >K%/0X\77!J7_GQSX 0,+1.(
MT3#Z2\L#6ICN95P2=[BFV\J3@7HQA\L2T9/%)FRJ6ET,&I&59P6#5#OR5)V0
MJ*IFB0,JRZUM."<J\&WIB6M3N'&%?L<[#/*5YQ%UD*\"Y//MVUAWE,8Z86)6
MK=/BT-\U">F<8["GD(/?VG9^5:V8.\C7'^1K8H1TN*\ [O/'#J(R*N@D0HC8
MND9XD6JUPDD*7JI2);1 H;R,O^^ZD'X7PA!/&&H3.CJ>F1UW+ 9QDR;%DX/?
M>=Y;&N24?TY6HG/0<ARTV ^N6%]RU$&$W$JJQ(PBN(JBF!2BXJ7+U+(AUZ@)
M9?==KKMMT-&Z,K3NS-= \Z90.P6D6TLXB5ZP%H>"D'CE JMYQ!J#6E4'EP[7
M-83KR@\:=+BN#*YS"GZJ* T65O!CC (LR]6$/@G,Q2D72](@&:Z+0<&-;_&\
M&7K\+*.HGR6X3DU^.O</#\HC2L>S0&:/8JZ0AQ9[OT6=2E6E"EE3JP2-4:3D
M%2L0L=A:70S57CZ*V9.2UQC(5Z#D=R!?/9#GTXRJ<LGD(ABX) !(BH"&A//H
M2E:N&*\:D.VE*@)T(*\QD*] _>] OGH@SUL&'B(YELC!#5VC6X:1E6S7>Y==
MD12,A*&2\3G&03]F<$4P_.>LFA /D8?\;GSTJAG%K4]#86#<,7?_>APY^ >.
M#X[:NM#1TX/'9];E:6UTU:EH.2I:;,,6,HL/XU!XZ9MQ8)U(K$:(A*J47('U
MQ+RU[7KF\BT%[]4=.NC@73UXYTN44I1HT0GM@,'K0A')FR!L<"9F,BA-V-JV
MEZE W,&[QN"]NHR?#M[5@W?."%!,L @5A6$,"T@I"G15BJQL(JU 4S5;V[ F
MDO<N1 9^.)SPC\T"R*_PX"4--8<.VP&<.Q8CN,D0P6P1OG\WF=!!_K WX?>8
M#J-Q4J.DOU/EO]G#]YV#EN.@Q:YJ&A,IVS(/)2C6_ET2+$&"H%1DRL1B).$*
M\G^Z2W&-E8BKLP ZE*\2RG.V0%0NN]::.;EV0K$&+2)**:H"5XM3V:2XM6UZ
MW; -@O%-!@8Z>*\2O'.V0' V)UET.^N3!=A6+XRM=\$+:926IF!D\(8UDL.W
M*R)P_DGC(2*0AEW._QQ0'1^/ZN3PS<G!XV-\3PNE2+\T ;.S&-,7>V!X^LOA
MN]8"^N1]+G>$:>V,JO]U@Q.TWNR^'C&6ST>Z?N"M_3T_='SPCF=P=N;K\&#&
M\]._VVM;_O'[XPGR(HP/</+AR3&].=H]/&C#G1SN[P^GQ$Y22'L4>65"8[$!
M':!':WP1H?I6=#ZPT)"EL@(HBZLF%816=/Z>U"LH.[\Z5-ZP^[CS<^?G33*B
MKY2?.P4O2<%S1K>5E"A(8&T]D0 54FM)G@2@MCZXY$+KT!-7T:&G$W GX$[
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MEXMF$U(%&[-(H1$Y!B5BTD'X;'*J/JED:&M;NQ6[;S>@5^07_+N=0#N!KMZ
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M.M84-?C*PAP\84CDH<B*EA23_C7%ISJ:ET+SO+/;^V2A'6RKSDD!$)V($MB
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MM_48XJJ8+B\X]1.96"&!H*RE &(C)#BGA8L^>!>,"29/.Q;8);EN-5BZGN2
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M=TFW+->RW-U@.2&TDS5Y/)>AEK@,=3<Z2A#09)IO<\K_<!2X/%&9!(*T'!A
M70C(.;+HO&.A/E\TPD<;:ZC'_557#]T?$FP9\([2G[%@$\0LZ(<6PH<,F8*"
M$*(KP<7OD#BSI;]K#O<M3^\:H)#=",ZL]%!KWA06I8D,M ]*(#UY-&N;?MUR
M<2O\=W/SO_^< %V.?N?NN\VF[=6VNX,I-(T_[YWF2/JQN(<Y;K3<<(:P=30<
M=^N1#T;8HZ^\PY_>=_/D<(&K$U^<WS7__!6(=(_3R<5?.7&'"0F#H]NG!UG;
M]#-SXM,CG77=B9^'H\^NY(!<Y0CA+8-"S7T O?=P/%[[YZF[ZG<';*D7+^J
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MWD%]_PLX>4_=THDG&D:?3(^:=M0W^T<];*XWO\)C^F9WTGE(?8C5JCN$F>X
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M%L2JBQ?$_C,.\S'].IST>YO_!U!+ P04    " "1BU=4!N94!A8S  !-- (
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M=U_A@%@$SFQ545CXN0;'O$6X9;O$^2I4BXYKEB^E\',-E@(W/>U/6IQ:MO]
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MS&'3I>)4E@W18$FA_W#%;]A%PUU51UMU 'HXUU;]YTU'JH<4I4=DP;PG2V\
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MK@Z%6%:/TX UHJ,=]^[#YQSQ9F&86DA+I610#=>?M-*7&'O:SD]K>B%S1FI
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M\8\:=MB2 1J< 57L*=Q7,!\?O02BNVG<Z71'L:V5X>L1V0K*"'->XX;L45%
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MH4Q3@%N/H"$]JK*-DD?9%*H:$$TUKZ(*"2RO0D+M.@L%4-Y9;F6L.)O:Q#8
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MU>SH_3J>3&?+#5@M*D8OC,H.K*@"(*8,+EA?E0:Y%$E)XUP7R-RG9$B6^@
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M;X3R* #W0^V0QE#M :T#A$";X8WGY]/?:X2G.N)73<:NAJR_Q83CS[68>#F
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M4)P'H47@/F1-.FWPF_W4ZH9@TPSAE-RW9P:'K&8.=LN5714O?!FA=['(VKG
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M@X@D9$N\0G'9)/%],UGE6,<17@'H0#BTG: K1$ ^CD>(8N:F.6ZUL<X0ZV/
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MW'S0P%[O'7[XB(/5[W;";#G'X9O39#KN^ZLB@'?IEG]&VH1GA25(0XWK+0.
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MDAPM#1F<HL'N_;OQ[#)_O!,=T*-"GEB%#>#^7\PG8$P^PO7LGH(Q*\!I26P
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M<UJG:=43H/;#I&I)G:N(LZ4N:MI4]Z#Q!32EHJ?HAQ#+RN#;,!N_E'3I@\-
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M/QO!/-66UHYX?U^MOMLV55O6<85XU!/=I!L ^]'JNUW]-F_UO8%R.FWU+<&
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M:6$1?23>H@IE2N'9*N-P&Z)'29ODFLX^BM')VW,"O-0<1/2N%.ZM8FT>RC:
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MJYM$SJDX"5BD I5R!$R,KGWZLW'*<5G:E*\^IZQN+PWVRNKV$?]X65UD(LM
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M7T(&X8(UDK5Y/-F&Z,?TGP;54X.GCTVX;DN>NR!KVBFR'=MQ>D6&T6$'PSA
M 2,=,:NJ>&6L<477B>9U&C%/4.G9P0L4CEE56*/*U[%-8T?/R-B6T4?N(UC$
M+Y?S.+V>+-[C8G6Y!FX<S\$ LCHNRV& 0)8*A"RJ((3VN@WQ[&YLX[]\#J7)
M'09RH!H&=##KJ)!U=/_*EY\^5V*<O_(,/^4-8+GUV04I(=E4VW@90JC-MCIF
MGAQCRI>UUJ.-\UAZ+_SL#:*]N%N6T[W\=O>W_W%)8&?Q\[=EL\<-F7N,VD8K
MH13C;MK^4=)96IQCP614+C<N3W@2WX_MU3;0X4BU-?/'>%>#(#J ;>KV]H)[
M'$^XA=X[%*4,J[212H2W@S8A:8F>KC!, FJ3'3B1,P2FDA%%%]-H--T)6-@.
MA_KD#*R/KEH:UOU>R-4+5,DY.VV NU+ST85BC(@.I'&1<9Y9*HVKQ1^#.F)U
MP?#JW&8X!^JB91/;R_O]=:]G^;^O\R1^6WXSEL(!PT0$AZ(2V8C*1,D81:A2
M9M3(BFM\ZFP']].;&E)[(U5,W@%<13 =(([N0*V!/+K;-(R".UQI0VAG)$]I
M'2K7J*7R"(Y5RI4:JCKE K#D)8NH0FE]L8UM0-V]HJ/93Q^EC.5AWYW+=SDY
M1)=4K:BJ(SB,S>"1&S!9)9^X$-*.U]*PCNXT7*.#U-K%DSY$)PT\HRWUG2^_
MW3W5EU#0%"X@5"9!);*$H!0Y<4)XF= :;%2VOQ/:C^T5#:NYQZ:E&YG6O3?=
M+@";>D0[(1[''QI8M=T,YT"]-+C3=@.EZ+$HQ>G3\=Y7&E(+]#516%F"$S$F
MS;([)\/9X0<=VV[ZJ&- >ZEIGA<QSG*%\WHZ^T@"6Y[/[\H?TTG^MJIKXE&(
M%!"2<9P\0,_!&QNA\!!$<$GZM$;CN#&-MGNE\3V9@54S;2;7@7.IWV_B]%_7
M\\72P;I%I>AJ94PJ2!BK??,(@8P<5 YDZ446HT4';6]?X9RT/) <MW[3QR=D
MG$[P[7IG[H@$BT\M?RS"Q,XB62- 9&4Y,ZKR?0O%F42F1!1)"I<<_37T)T!\
M"LGQF\+>W#4HB9PLUHL3)7U92MDZPK(.GPS)AF"8"*+-1(*3(C2\ _,V+Y9X
M[IH!7X3YDB3^@DLG9#01T!<25"@&'-(YE)A,.4=EQ?KA.[2@MF)[[OV=?6QP
MZX/$,)IK\!QQ(Z+_R%>)_(T/>)7?3">?WES^E=,=]EJQ<S6M0KL@W\*8Q!P8
M%)FNNUC;HY.HC +T/^8"LVTXF7O!/*+%#:3GZ5A*.NFY;MZFK&)0P$QVH(J4
M@#$:R+G(S*O;I1KS5_R8;<&#G'BC:O_8;<%]\B(F^EC(M05M:U[$Y4HUHQ H
M8. \:6^QT;3R'R+MW<MJ]DA[]]'>D;*572#^3'L/HN ]TI;[:.=8:>^@ L_.
M@<R!H)8LP7,"+64IK&1C ON9]A[;?OHH9:RT]_VS^/85"UVT4?D,I@Y!4[HX
M<%:2IB-'EI(B/[0QQ_C3 $\T^=U'N5V2WP=JIFUEX%,%M8:[%#B%+BDE0AF,
M!DQTF:M<2L@EZQ@;4P*=>;?%0([24#H<B>'WB4+<#F!_=EL,K_?#BN'W4-K1
MNRV\MJ;(Z&I*F%-XG7BM04&0S(=@-;.:-PX GWNWQ7@&UD=7(W5;\%5';6+:
M9I[!FE#KV"KEKM(6O$^,*^&4;-VT\QC4:7A5 ZFS0[?%/KIHZ5/=@R9NH>F4
M=98L$32L6R;G,N1D*#Q)6AKZ8(QH7(+Z&-2/9B;[Z&+LWJV$3$57P,C$0,6$
M%!74!K82K<TQ"&S$'?N,>[>&-I-]=+'5;S[-"I"W.)LMAZ<?N13D$8Y3J@EY
M6DAKQ2'%2^Y82)G;K'Q0P2;/'?E$CB59]$#%(8\@'3]'^#U?Q1SMUT91OQ=-
M[J#0=/'J B72>9N,0)D;OU.>0I5(OR0Q<\9$DPUP4QUG0Z>8"]("(^>E&,Y=
M,9VH:\\VDS^Z91Z6].^CSP8>Z.]?OA*H>EV^*W<X;W;P<?JR OU:L[#ORD4,
MS,HD+$2L1%2Y2/#,T35G ^=>>(+?QM'H#/%'-KHV>FS@R]Y@NE V!:UCJ'R7
M" H-4N!E%9#OE;%XS#&W>2:^6?]'-I4]--#RD??@!_%:\F)R] 1?D!ESD<F@
M:3?D7KF8$_E6N7$)Y8]9;72(#1Y'^\>N-JK<OW_.INDZ+M[-/N397Y?QIMG(
M9\:9M %,UH[.9-J$X\X"<EN8M^B$Z\1UV(D\>1."YY\6ZV4'TP'U,3 Q^BV>
M*HI;1//5JT4'4(//+-@*9_P)!H=KZK':!Q+S:#8@L 2?O( B9>5VC Q\$1&*
MBUI[Y,6%X5C61];]$V,/1E)]'^D.W)7Y"_GKL_EEN<QIA>_#S65S^[:8@N2&
MO'4PR_&,UF4(J!)A2]DZQ"QSEY[,7>N,2Z8_D"JFC>38(-Z^"<3PZK?9]/KK
MJRN<5ZQQV9UX0_<LE2QH-/!@*\^!\^",*\ S*V3A3HO2IG%J![ ?TT%HH;4&
ML=03\%9$\!T -BV2V0GQ.(4Q@RJVN]$<H)4&3S*[@99B,Y.)/A8=Z#2.%/0Y
M*Q*@E)BDB :Q#7O$D<QF1[7+<:VFCS):6TM]Y2[3&?TROYW>T,?7SOMK.I._
MWC;=K]KCDT@6D[7 (_.@O%Q>O (T$RGE'*)S;9(]>P(>_XEP8-4_95B-]-8B
M0;&<\_UA@8OE&\Q+O,))S!\^Y[R@N_Y%2DNEX-7WE,K\Y;<'>[T=(T[>P.9]
M+C]9Y2(ZFS44RR-)UEL(OD[=D#)P1XXHFC;5-N/L[\=VWT[0AAJ0U/<"_!:_
MK*A0NL >SS?L#OPX'N,IVM)3)WUC0VCM8/2 SX21+#L.60:ZJ)B*X&/1(%#K
MY'34=$.>O_WN<%W/V'S[Z'_@U[M7>;8@"*L7I]?3V6H3'_+7Q=*/^OCW]./G
MZ74MW7I[.<F+G"<K!ZLXE;BJO%$U#6^T!HS:@F,RAV*4H!NNP\O>(1B.[.NV
M4O+T"!HZ7N==8BKSK J('"GJ9!1Z.B<1T*(7+F6>2G-:_K/NO#O$!6V@PY'(
M^;>747<!^[/S;GB]']08M8_2CMYY9YEWAM%'%UA(H)QF=.I+!]QZ:8-*%GEC
M.KGGWGDWGH'UT=7(O3)<*ADB-_396O)*64 (L0[829H5(5P.ZY[6SUZ97NKL
MT2O31Q='FG.$AGLC39W$;@IM/9+'ETB_B;9.$8UVY/BU=JC.E_!I(&]J$.TU
MX/3OPAK2!>)/PJ=!%+P'8<\^VCD2X9-D7O)( 3''VGC(,4,H2@##Z(/5N>36
MC53/D/"IM?WT4<H1"9]*8;ZPJ, &SRIMN8#@LP8FHY8Z,XY^Q%%'SX7PJ9=R
M]R1\ZJ.9K2[2..W$=UN:+KN/%GGVY9<<%@,W"^]8I64K<)\-KC7ZHDHL!"6Y
MH#]K(8-.F64GE<KHI6";&WUW+'C\YILWWVEG;8K,I  ^^%J(JS1X&>IL"X,2
M+7TAXG3I?M\,U<9;M?/[9+Z872_/BQ6T"TQ<,D61=R6*H*\X%G#&TTE1DA F
MR2*";B*=+8">>^M;'VM[E%H:0$<M@]&#@RIN@K/)!R@H2#B^2$"6%:A4Z&@M
M*8K0.&3],7OA#C'*XVC_V+UP?3SUXG7FDCY*H0HY0DE%P. ")/2.64NR=VTX
M#WZ(AYA>5K/'0TP?[1TI?NX"\>=#S" *WB.0WD<[1S(DZY$S0=$:HB-'PFI!
MWY(VY$@HSQ+J%,-XP?1S>8AI;3]]E'+$AQ@IO-0J>1 B\5K<3>X#DP@N<"T5
MDS8VFM'SK!]B>BEWSX>8/IHY7OV/]Z+$S"TDR1$4UQP"R0:8R\7S0DA;#[L_
M\_J?@1REH71X=.;M+F!_UO\,K_?#B)'W4-K1ZW]"]#XPH\#P.HPY. :A& Y%
MT1$LDR'<C5\8GWO]SW@&UD=7(]7_K&A\38C1>,6@Z&@JC:\$+[0'Z7PQ,5E"
MET:K_WDFE,J]U-F#4KF/+L9+;OWY_MV?O[[_^'__?//B[<<7;W_Y]7__\_<_
M:S[F#_ROZ>S5],O7Z:2*:UK^G$W)"5E\^_,*)PN<I%__^_KR:Q7E_CFO 1<?
M*!762AQK&3)AA41+'CM/424K,,9L;#3*6I6+4!<#XCCL='GPXU_<^_'?GX*Q
M9"49A2$ZLDH"K2PXF060A1OI*2!1J<TALQO;H6?KUA5^FTWG\XMHBT\,90V3
M(GG%]#5C<@*LX8:K$D3D;1X_GL8U_@D[L)6L'ZL#JJ'%8.(8K[]<7^$BIU_R
M5XJC+F\ZV#,=@$NQ3]*++]/9XO)_EK^_=3,7/F+1*3%P'#TH6?O<Z0\0WCFA
M!9/&M(EGA]K!V1G>453;P$?<"NQM7EP8K0F<SL"-(6Q:._")'&=K<F$F1\EL
MFUZ#IU"=G2D-IH(&KR ?XN><KJ_RN[(5Y<V#4';>&"D4,(VFDI05"(Q9LF6K
M2PR^!-V&Q+@KPK&2Z8V-I8E"3B4!OG5++[]]I!]Q.S>K2,00@9?ZR%TJ&QZJ
M -$%[Y/FO#1**W4 =ZQWW39&T?68VE,Y8UYF%>#=N+W=$)N^U'8 >9SWV<$5
MW-6 #M3.D0PI9"8CMPY*=*Y.JV 0HA5@*,+0)13+2QN.C:,9T([GUU.PGSY*
M:6 W;W"2;A_UF.8BA=I62GL&I;@"S'2<%^V=YU'(I-M0$'S'<$*>\KXJF@XB
MWP:A_<OKRZMTDR)=_>WO7[[.IG_=O"'?@E1.):5L :ES!!68 9>Y)Y65@E%:
MSDR;03&=X)V??0ROE0:'Q!\8/U,L,/MV7P"WT#SCC G!0";,%!H@.6A6>!"!
M:QU*-#*U*7QY M3YF<E0&A@PX*[$/.\6G_/L#D^MSL@XSY^G5^F>$=_"C$47
M)WR D&HO.B8/@2=-CKT4VJ!+)NS*L?1<\GS,H*6L!R0SK##O$+Z;W') 33XM
MD=Y"R]DX%IT&DRVC6S#S"M* 3VAE*4$X)3J8P8YESDOU0\JT ?'0J^FR*R=6
M ?]>'XX_S?)\=74Q[G6Q"4&D4J^N0/Z/#)HV;FR(@A7L-AVG]_WP%*KS,8_!
M=;"536'P=/WO-1O\V^\OW_SZXL.'7S]^>/'VE]_>O?OE7[^_>;-Z'IJ6WVLB
M^--EN+JM -P_07_0<@.EY(?;\EH2/F0?H[#%!%:4\1P-1FU<+BKJF)*Y.&CE
M XMZJKCR<J;A^@+?7Y@Y5X5K(2"I;$!Y(^CTHA.-/@6A,WK!4Z-)V!W0'5S6
MM'6-?\YSN;YZ<UE'!=CL!0H)7-=9HI*^5*^$ FT+2X5T&ETC!L .Z(Y0Z#2T
MU3RJ;QI:*2V*Q[<+X:9<@"6- HT#9Q0Y>MHK\*:R,='&E5+1:M&H[6 'LA_*
M8/901HOBR>WX[N7^[^?X+W)$'75A8#-3E1LU@W/9@\JQ!&3.D',PMOELP?IC
M&=00"FO18K =<4W]2\.D(%<$I*HO$54LCM&G((63PDHO@FTTS/5)7#^6Z?15
M1(-A!M^SNT_@O,GO(B:?JU(QR  J)0U.U! H9V$-^JA<FQ.H.\;12 U:&TTC
MM9Q*+<83FWKY[:;6N([EN1GRQ&O$5&A#N@YYJ@67WM"?M%8NN5QKYMOPNO0
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M-81V>YG/?JIIWJJ^#O/CW].[C+OAP84$+-3\"Y-5%%J#M2P[$H/PJDW/:4>
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M(]*F-+.0Q:+/'DK0$NH3>7W!$4"_4F2+07HV1O'I25 :#N>Y]I?MJ5 :;FS
M<,(PK6D/SAJ*T5+0X)76$ 5G(:CH6&G#\WSJS6J]--RE6:V/I,?K3.J"ZL=N
M5NNEMVXM2OL(?3R3X!A3CDO^%%?C[L+!H[4@L@ZR1E/1_)C-:@TLH8^L&UC
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M8'J+BOQ!H- @W;XK*Q\6Z\46BV_3A+56]V*"]357S!7K-7+@3I&SGGB!X*(
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MSG(&A8582T4-G80807LIC,M*^L$F>-U#XC.&5Q]*&SJZ>.,0<,&DYZJ Y4:
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MC-*1E'7N<VCWD_8X$^-OSE=D7U]9W>'[>GQ8F2]67_ R7/!S=< 0:?/=:#I
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M"%MXCJQ-47\3=H::8CXJO!\<%V,9;%Z?M'?AZT7U=%12RFQK#XVDURK78HU
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MV0B4"7G=$*1(_-F#MX8,1>L5&FV4+2/;*;T3G\_F:!P!C,:T5G1[;J^V!*N
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M=7?_:BK318W16F0_U<\TP==I N5S" ^32/EB5**1JN[)YR'TCE-JA=#X@G+
M4XY#Z0F,[BLU,FIE1,ZNFZ*6P^C;,UF:1ZMN;6CL0,UN9N/X]R(:E/-<-N_O
M_.@A+*(=2RZ@'86H\+DE&N+6)DE2T. 4%0ID-]V<MX!Z*>[5K@RNFIN5Q%_1
M&2JM2\X_?[D;?P>8P[O^,A\G_!'?Q=<>K= /,)U-AG$&:?[KWY& J1\E?)7R
M>/)YWJIVTU][>#+(V5"6!8F:22*53<0ES0B"4%;:Z+-8L0+7MO[I%N6):-H+
MH[-VO^#F*(4+-$BJ2,ZE5EUZ1YS1DGC#5>*!*[DZ_W!]5^ 7J$ OC>-QYP3U
M&(4_?_OJ\OV'Z[/S\S<75V]O:D3BG_O(6M'X5M!7(O(VQ&B-H\$D(5,R5EA-
M??*4RZ!4CH-G/WW/=*#Q=/HC^P'WP1_Q'6&EM*&TF0!9NIM")M982BQ85"'I
M@.9N"E(V8]IG#[N$6W\WA=EL$<<I+V9INH*O2 :8#J3'1\77B[!2R"JSC@29
M,(2+)+3%]T)XTV#?VKY*_X==)7Y_WFLJ"K*#X/*O#_S]"OXXN_/#S_-1UFDQ
MXWH0;<K*HY-AN,A$1NJ)SV66)\,7DS$;X^K$K$XT>RVXHU>1KHCHP"N[1,G>
MSOV!FT=U7ER1O/K#XQKIX_AZ]@DF[_UD]GV0M?$T>4Z24P;]T\2)92X0(5C
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MY1RLCDQ9Z.;]: ^VZRAY;^K3-5&'#J8_/N>RP^KK^RD*;CI]>*)%V;;(.@4
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M0OCJ.?.VS!6V_+3HN2I?AO>=]%6$"LAU]N*&VAOXWW[ 0L,9%#IVD-ZMLXN
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M(3G;9."4T IX5/.2<,F:[=K-'0.+Q(U&$T:P_XV;K[F2A?5MXP%C=2Y&9:!
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MC]S8M;#%668CJP@!8Y#A282CQC0B@.81!<_OC SQ-DBNLONK@<-5$I%3P?T
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M9YE[XD]4OJ@(@*)*\F+R..VV")5*IABG]IV"@'&78+MR31K=O_X25-ASZQ/
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MDUF\A-E[(!*,H)I\47NP8ZIG(/"PL:C7FX(AH?B;_O6_!PGRX+6O3HCS'\E
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MWARG.WX"K>>VV%M,>%>G/?>RL+ O*G75"G#J<BFJ"@(.KV@6-7XN799+QZR
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M'^H%XL1,+GUQBA# ]\.$"HHL&*'3ZYAA>4KOV\!!T6OQ)2K3C*Z=BIU,;+U
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MVOUEML$!E("%NEI/SQH7ES0=377IT#_/W.ZN?L\0]5C+Q"U4R.0/-Q$B&W-
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M>Q['+U%6L]&@2-.[GVJW-H-@V,W+RE\?R#7QO;\$:'9RNHM(B-N)M.D4?MB
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M%LG7)ICTO$BGN.;_M:FC11]$^5&JM>M*G$.6MK%MQXN9=#&' 0XX1)A[4-'
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M)?L@&%?7'5UI7HW5Q^PSO=-[L7ULXH.R<1I5]CK)!5-R:0,1CL2.&[C0PT$
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M1CRK]3D./>YC"9&,4_5/0F"*4@H)BA.4!$3X@5%B8ZM>I[;NUH*#+[*:N55
ME!(>U-*#/[3\H%# PIG&?"BZ%]=! ![ZBF02V%H4XQP"XY%6KB:*168*0_ ?
M=%"^HQRMUOBU5<PT;FN\4IBVZKVI<6G]L#WU/WS[>B_6:O"?]7:^J);Y56T0
MUYEV//^FJZWJ3.]YE:A8L7[HL1C#$"&B78H03*-(0JQ>,$91$L;F*;>M>I[:
M$J"$!PWI85EF>"\_*!0HBL=8F.IV@]&]  P&\<"+@ VZ/;)RV\%LOA8,!O=8
MYXQ.8;=:!GI!U[(4V+4WVG+02\WFDM"O@7XWWU]WVQ&] ?GVLEKFJ_5G/8SZ
MRE[?S09)*A#!'A1^JG8#'H\AY5Q B9,@B8,X3I'5]7=GCU-;!O8"%[MZ4(D,
M:IE[78=WXVYV)^X4S8$9_U(@K>_(C<%Q>E'>W>NHM^7&(!Q>F9L_V-.AO3S=
M^"34(V3Q0'Y4)F]U(#+G.%8$XW/H!2* B.MD#U&80"92[8B*91"'\Z5XU*EC
M'BP\W-N[-9HON)PO1YT/Z%2B=@7Y)F.6;NX=$)MQC O$1G)]KPY7*U&+*^U*
M6/"A$O<GAY[P9L"X]8GOZ'-<[W@S ([\Y T?Z\<K7UY4JSK-Q&>A3*==EO6Y
MI^B$I(F I#C6Y"2&A'L>I$'*L,38XUXZWZPV9&%&)&?ZL3)?=KT->'511J*!
M[V2Q+?*:KG=NPPLM.+!+@=N%LAFE.,!N8"K920@*$6>["YM7=_S1@8)3WCC7
MUZA\T:'P(4]T?=V.'[C(YC?5)OMA39:E$TQ98';N>PDCGC(V6()BB!BC:I?C
M$YBP)/$"QCGRC6H6M74RM8U-+2?8"PI*2<VHH!70=AYP!=/ )- #(6,2,(&@
M)2.#>KR8_/]$^D=8_EC,^-:&1YGN)JK5<]WHNWTC9I^?5\OBP.3O>O&;"[7"
M<RX$Y)+[$(7,@ZF'/2B3@&%$XB"@X?R[6-.5>;CLVRYLWMUF1P.:Q(6$(-<!
M%[IR\TJM]^O2&)B![7*1/1<U7LO/ =ENGE9K[5DV V&$9\B+9@E*"_^%,(IF
M* AF(4K^[7_XL?<?69[O/)/>AK?="%8<3I7?"_V9KOSG%]]4/W@S98/D.NU-
M]ETLSJ^G9H-JN(>Y8*"&WK24(U3(-@-_+T?FML#69=#N:?T=Q^L>=#)RJ.YI
M%8^C=,]\KT<16^VJ>Z^FSK,:VJW:GI.%#GDBR]=O5Q^KJX6$TX@$O@>))RE$
MF#*U[8@D#!&CQ.-^2 /S"K;=_4W-R"A$!F]E!I70X-O/5S]_M*BT:@!W]X69
M8Q '9H=N_/J4K#4 TJ)>K5M 1[H(N^#%M"M0:XY.6W5:@U;&*TUKKM*;NK06
MC_6S^#X^ORQ6KT)\$^OO&1-%E.DOAX&H=ZOE=Y'KH%(=<YH_Z#.8YN?7JWQS
MM]K\E]A\W?G9WQ<!^I]6Z^I/^GO^7/JAYQ$/P0 E:M-(U4\88:%(/DA"SF-?
MZA,E\Z/I<<6?VDI1Q_I"4L6W[P^JUN*?VTSM# 3(2VBJC E@I;Y:%=1Y$RS#
MFH'W3"&BZ^V(.N'F9@6HJ-,MM5A94WC'S,S;Z;XY R^/)[,H["/-9V"G=)U<
M06NI2Y*#5[$!>T6+.F3ZE=(^<@UEW9G@[S-&3@W\D548=?OP/L-SN#EY)RGZ
MWN#FF]6S6%]KA'5"AN+H)LO_49F0#,>$)3H;68A\B&+]4Q0(]591&4@L2""L
M$FQW]#>U!:T6%["FO+8WN.T0F][@.@-N\!O<"K,WH@(MJT-O-$M<'%_@MO<Y
M\@6N$0#'%[AFCUV0\NR(]([SQ_QRF#_FH[(2-Z_[! ]YX5+]\$2656:9'7$>
MY)7Y536]N2$;\8EDZ_)8D?HTXBQ,81ICK&Q[GT J9 3#-(K]2"=(P_&\M$*_
M;<AZ8\9@4U#-9K8?*CC<Q/]%/&;+PMA_DQ,-?,B6@*\6"[(N@MK+@^KS/AS3
M?:'B*.2^H!(&D7JK4$H#F 8RA3)..0F]D$B?5R_4QR7_?_EUJM4;[F7Z>)A:
M[_^=U\ALP9^"J!.R*ASDY"N!:61TRJOHJ8W"9I^Q;P?/B7Q]!41 8P0T2.55
MC^-4?1,9<_>Y^]Y;L?&3^;VWQF=LOTG)UL_ _"SR7(BWWD7YOHPM]VF*!$Y@
M&*82(A^'D :1!WGJDR")4"1BJT*>[=U-;=?Z^>/5-]NJP!V FJU9[F :>#4I
M!=5I6M^X".8#50<VP\4IXW9T.2H7FJE_R%*&3_7CCV9-\YM,<U:1@_Z+_&6;
M9TO=<WXG-E^DKI!>?B[X7!%*S-2F46$>(7T8ED(<B@B*(*!2<.K%PBCKT25"
M3(UK:AV 'G:0DT7AH$QT<?BRUBS=Z3(#2U$D1=.W.;F^PLG%8F%'4[W&S8R\
MAAZ-@2GM[4 T%-"(_](8A+MR$+0:H-;#'=5=@J)3 NPER*BT> E4AV1Y45OV
M7E,W@F[V9N#50C'-4EEW.I'SW5:?'WZ1-^0UOU<;]_7#JDZ0P'\C2JC"@OSX
M@RFAODCUC27+7LBB\"S8/*A7(']:+?C<9Q%*,4L@B1-=)SCF$&.:0.D%*:*(
MAC*(37VN!I=V:J2\4Q&H_SXKWBVTU+.>*SW!BU:TX-]:5?!<Z:HS28I"6_WM
MEUK?.J/EIM;8W%%I^%>EVU]L4B_ P.N UK5QQC$#^Y?AH7@92HUU[ABM,RB4
M!@^K7589#FJ]53.@U%Q_>Z<[*)4'#U-\&<Q]WB;U4HSD,3>EE\/*!6^TP6IQ
MX!M>AM'<_T:#L^D\.%ZGKHJ0?]HNN<[7H230W:J_S),PXK$N(.'%)-29;RG$
M$<<P( E/$L0D"T*;$%233JW,BQ'B44L)05Z(.*NK(+T*<K[,=7_ S39OKF$<
M?)$^54Z\PO7#[TM9_/03*,77Z.IO#%E$_#Q< U<,/]'Q.Y<'/P]%=RWPEF?M
M0UUOF5Q?;7FFQO)JLQ%Y:1U\6I#'>8AP[",>PB16>R1$)8,I3S&D*<?2#U/F
M)48I?=J[F=J^YO;ZTU=0B0H:L@(MK'G$:PNN[6SC#JV!^:4?4%:!K]TX] Y]
M;6EZM.#7;O6:X:\&W^[I2+7++7GZ1JZ(@:LNW_2]6GF3E^?;Y_)O10[0_35.
MP'S,!:%0".DKZT4(2"(=0^LC$J1$?28BJ[*03L6;&MWL\JRJ]??/P] &LM.B
M46Y#%]C0/S\6?@+ZZ.VQ^/LO"\+^H3=12G3UY>(Q^++.F/["\XH+RV-PQZ^%
MH4?*NPWVT+XEC7%N\1\ITRKN_$1V*H*&CE7673#(->(P ^#6T<.MB..Z; P"
M[Y'SQ3"]]+X&Y5NV.>>:GB22\BBD, PX4<M%(F :ZS@ [#&/^/JO1FGDS;J;
M&OU7TI[P8[>^LVP#V?AVTA%TP]]#GD%M .]_,U1<WRNV=3GV#:*!^B?N"DV>
MLK\5K.\:KU@9ZZG:57U]TEEP=VX<97;TSZL\GPL_]7V&=4;:&$,4!1*2F,0*
M\ 3[<4#51MHH]M:^ZPDR#2R2!2O3L'9(4NUO%S99R2W1[[XU&P[3@2FH%APT
M))\!)3LHA&]X?55U$SYH!0Q=R7M ;7XG-1SD(UTPN8;>ZI*H'WHM-SZ6#8YV
M?=-/T>9=3,\6^EF95\M-QK/%5B>+^B:8OLW)1'ZG7J.;E<X/,(]XA&F28$BQ
M%!#%7@RQX&HYB%(1A5X:)(38V)E='4Z-_YOR@KW ,Z!%!G^40ENF)^\$W<SN
M= GEP+1_(8K6QJ<I-$[-S\Y.1S5 32$X-$&-G^M]DRO6:Z%CY47VN"R)[#AW
M=N0'PH]8# GR8X@202%-HPC*@)" Q,A#..F1GMRL=Z.),WZ6\DIHZXM<$[R-
MKW)=P3?:96XA,*@DKDV;@5.7V^'D^A;7I.NQ[W$MX#AQDVOS=#]:^G6UXG]F
MB\7G?0$[CH-4I ABWY,0I6D$J1]*&/N*C!*/1"R1-H;/40]3LW1J >WXY1@X
M,RJY"(Z!6:.6S:Q(HC4[G%7=*1$<]S+JG#^KY.'T/O_%G@4*BMJNJ^>7M7C2
M!6*_B_UFZ:I,2E:>V_/_WN8;O>_6COE77ZYOJWJR5R?KR38+R2HFNA.;PAFN
MRB2D<P)=*X[*-H4KOV*G>:IX(L)! DD2!! %201QA B, YDF?L"H[QEYR4],
MKZFQ5E/URB]^M=XELF.%[):U%Z8!M&FMAVE(.R'VKBJ!-R$!'TI0?@(:EMG)
M>N*SRJ.Z4K',9/>AU/*GF4Y:MR!YGLFL*J>U![0,Z]*0S@"1ZJ77YJ7#.A;3
M&F&W=3,FHMNX=3HFHO29!7EJXME?=OTU>WQ:O'[._KG-^&V1]:#(B%![JY?)
M^N9^("(9%O5(M+LX"[A:H-,8)B$C,DC5_\V*DACW.+6ELQ0:+ JI0;87>[:/
M.:L3_"AB7 BKBQBS0>B^ZG(.[<#+3X5J*3"X;:*ZB\\IA7:-I?E=EG-,1[K"
M<H"MU:V5%4XMEU5F[8QV1V6E5O-JRNY!.^)F.EYH_3K_^.N<LSA,?"^"H1<P
MB.*(0>KC!&I_)\S\.$A"(^^#?9-3H]Z/CZ\OAMN2!B[M9-E/VX'9\..O_W7_
M</ED/-:MQ8.]^G)IA5:_%'.RF(^-ID:9<,>BUS/JQ"?]CCP>U&-?9"-)5%'B
M&!$/1P)[, [#(C]P#(F0"(H I91%*!2AE8?@R5ZF-K&N=19"NM*WY&K;UTQ
MIQ.>-']OY)=[^U"?@M.G1\!L!W\QK@-/X>$AM=X2MT+F=(-ZNJ=1MXNMRAYN
MWMJ_W(]>=C<NUZNE=CX12_:Z/^ZG,:%I3!.8(JFW43&%::I^%=*/" T\$83"
MAF9:>YL:W>RO$X5EA==V4,V8PQE4 S-(X]*U(>E MRM&H#CEB/8>1^4*(^4/
M.</LH9Y!<MOG9[)^_2)/=)(ULQ@&(B(\]A!D/-09P2F'J0@HC"46#$=28F*5
M%M*TXZDQ2B6WOLI8O8@EV*A)H\/W<YU!][_5-BOG&;.O=& \#F;,,P2Z Y-0
M ]B3?)2)@2/$+"%S&_MEVOFX45V6D!S%:]D^?Z']<U76;]V\%M9]C".$ QQ
MP5,!41@(J-Z\&,:1#%,>2Y3$5@&[I[N9&C\UYLY.SEY;IC.H6EH^O;$:S^0Q
MAJF_J7,2A6%LG+==O8]Q<U+=LU;-Z6]?FECQ>O5=+,ERHU,DY86?K."?11F
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MR9"P5'V82J.;KN%$G!I%:9G!AX62^B>P%FSUN,S^)73Q,+!S2VC8 @MK:VJ
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MU#""Y]6Z>&BCTW%;^H8Z'&';L[LQQFW$,[VZV#=]!85"8*>1_M/><*R5&NG
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M ECT.CWC_V.^R9X+'Z)M(2589-]M_5)-X&XGUX$@')QF2VEGH)"W,.1V$L]
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M[2BD#6$S!G&$V\ $\D;* J=9$S2U[5DM,O8*_JC^.T@@G0%43GFEK;]1:<5
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M= MA05/:PCNL1_ZJ,_B:T8,CS(:V"9_(6D!*<L'!/7DMK(ZK]5I]10Q4BM0
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M8AZIGU"*N$@\P9A58;NVSJ;&>$HRL%D3+GH'O[5":\9RK@ ;F,EV<8)[.6>
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M5-_,SOV'W&S;,M((3JU4P'Y\:PV+[U8NQR=*HHQ62J '\F-4&; 1:PH%"'K
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MRTM>/'/)P#K/=Z/8=L74H']BJ6_9)KX@WQ<Q\6#JAPE$?L8A)L*'*, LI5Z
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MDA&4)AA1LQ@:@[%F1_M*MO_X'W[L_9=ED^P^0&-.<1#%,?2%P*J*GMQ-QIA
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ME:%'S$-FS?:@>>2YF/"X>:L)V*D"M"Y *P-:;28Z<CX#V9$.GH=(]$['SV>
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M 2 Z)3>;\2?EN0' [%/>D$<,C8+&)?^X+JN]VI%12)$TGP0, W74BQ7GT2"
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M#E.?>3#PO2 +DS3RF-&IB=EP<R/CK<3*@Z'+6%12;O"L3Q77 CPJT>W:"IW
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M33Z&VZ</S-\HUO*1U8LZ=%7KQ-4?FUR',ZDB3;I&TR*D61S[L9Q4'F$H3;L
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M:L%Q1-(XBZ&7B4P5",I@RE5;1/F3QUF:,&I5OGU2Z>=F*]SR)<>E/CT2M;Z
M-@J#:J<C6,I/G)=@\R1_9FV]'%7H3CO_P8.J3J08H;2N3C3MRV/&U;-])4:F
M?*TW>*4X:(K>_Z)(_B\7H($ M!B #@AZ6]:! >QPT&F^ZH616,A-7(T&Z,*A
M8D-J0-PM)>\RCTY7I&DUF'1A>Y?)V5\?WT>(8<NL');Q1US\<UM&GV6!\$@
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MX%Q(945M6]E&C#?28?+U_FBU7L%&8K#<B6Q)<D[FSI "IYZ1L0FR;8Z@%;H
M6Y5 5Z==":.+9N(ZVG23 !W2J$N@W9*L$\FFI6"78+XA:*</'T;?7_D]7NI
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M!(\$C#P40)10*DU1+.1>TN.(D#@. G_QS NRGAC9[IC_IMCV+P>.\1J9^0\
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M,[X@7/B8X03B@$FVB;ADF]2/H8@%#T,_2P,/F[!-_S!SHYA:4M"(JHXRE+!
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MZ)1C>=M*4KORH0LW2IQIL;7);MF:7W\ D.RF^@JP 3:SIZ8<V2*)M9Y%/E@
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M]-4\7A[FS95#VL$P_%#4GP1Q/*@U2!M'SPG+8Y1A&&;RC#6/4H@CX0XFC*.
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MJ599J^FI-C7GNM%,.="\U4WNU+V(?[;4A&XZV.O&*$Y&X G-$$ICJ%0&?5A
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M2=.L*VJL>6AG+(36%_.VQ+%CNNDWY.E+JE8(MT_/N*C4\83A\9VY>33/\-Q
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MWCZP$4S;;@;/O^""W98W^+E8XKGXGI^DHRV/.GT:<"_)& S"S(,H1 1F813
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M8-&H 5Z4'@;QP2X-?'I2F8K97'OF4@?P3B_>J[UN?[P7:#3>1'9= :5UK[?
M1(QO$"<^D9?@,A/I4IDO/_E- [:JY()-WO.L-+4TCXX!_[$@<9?#CQ<O/@*(
M;T+'QQAOV,;<'[@JY,+PD\R<E$F3,X;\&,O-M3#D@3Q/R2#..8.!GWMQ'+*
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M)Z=-F9RQJN18?WWTIL/)R#NAN=-"U9T&G5Y'G;IM.;$4 &UJ\C08]8,T.IQ
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M[KJ2_:)M;D!8PMCROL2Y4HV\76$)Q-U=#%L//J=B]T=,B_EF$9WX,0Y2GL
M1QY$).80XXC *&8X0$$61\PH3G??(%,CT[;B=">DX5;%43CUN/!<D!S3FS$^
M ^MP[P? 0?GMK8$N4'5[OZK[BVT?N'9@4WJU+;HNHNQA1EG.<YAR\<VCU/=A
MYM$<LIB$0>#EE'&CH(6WCY_:AWX]X(QE"S"]#WHX#(X_Y48P)P6@]^MLMVOY
MVR'&[3&^5[V=CN#[KQK4O[M85-\X%4LX)IP"7B>_>%[;5_3]BO\FGO8H8$)M
M_4),F1=[F0^#.! ?<H 83$./PC!F<9[ZE 6!;]"=VV3LJ7WE4E@/_ ,T:@"E
M !!B R4WD((;M6 VLL-Q?G",KNMXG0;05O066"G\NDWR6Y0'5.HTA=NHG[4K
MV,?K5FT9?M,>U$, /-YAVNB)8_:/'J+J5G?H08\8YM5]6I0/][QZ>L_)\C>\
M7%7%LN#U5_[<Q G5=_F7JBAI\8SGM^5_<US="[/P&0MXP-.8P,07CA^*$A^F
M<1[!)"<QCKA8ZH7,Q/L;)L;4Y@_]">),^/5\2?>@.IXVI )0:@"D"E>@5>+U
M"DAI@1+7GAMZ'EQ6W=6!HHSJUIX'U[;[>^;3AI'?KXL%^U[,Y[=/SUBV5K^F
M8CI>J3WQYI_DT'++;!:0./$X8Y#(MO6(1CDD41Y"A-/(3[ 7Y9D1WVF//#6*
MZPD*'EHE0+$669XC5/(<8;D 3%QDQH;Z]M C0"<H.^:\3N8KT$DMZWAL0-\(
M#J3D]NC/&"RKC*<_^J@D9PS*-J^9/V"@'X=+UO7.\'E,$2*"H<),UKT*FF;"
M 1%>M'CI6.89Q4MO'CTU,I*2&?I;&Y@T?:A!RKOVBV2_-OL]+7=UM>O4;!X_
MKJ.RH]:.\[%[Q<@)A&\2+JY+]N'',Z?BQ_N%_*>[U;)>"AF+\F$K!?+##[$N
M+&HNG"/*9Y2RB(3"0<F2/(6(>>*G.,UE%3Q"\C3/:$Y'222THL[4V*9-!9/?
M'F_UD6Z.+-,.\++M@\*ZEBA-K?;+%B&P\U;I$>7?YUUQO==Y?F[B=O:A?.4^
M]%XY^<_BJ@TT>PH-=/  A<\$4A6MVGD:*8MV5/I[I"Y:-9^U%$:[4ME*9?PB
MBR M5#)1+0/W>TY_>]4=F1</3=CD;?GA!^6UW.%8)Q^M#XUIFH0T"D+HAYQ"
M1+P09FE"81"SR!=O<QZ;G;([E'5JT_7OI3!AOA)_,I4G68-'_")#Z'!O-4W:
MS+_%1D<QN5/.65<5[VV'%HL)E_9>$KT)>B*F=SS['DGI_"Y4?+.5TEVST5*&
MOS9J2F/W$D&=Q#V,8!''::'VY+UP'JEUX$\GGMH?<FI%;]X6[YD1["<Q33)(
M6>:+N8Q@F*8Y@C3FGH_2-,:IT1[Z6()/;6+KU[=3R\DCF>>7M;CCE:-#.TY_
MC3BP)-T$%H(#S3:-)9^I\'^/Q=U DURJ#MR9,]Y77G,91"/6B^_Y"Y\OGN68
M<NE8UF)EV":Y73>-,&3YFVI!5:WU>CG#V/.#,*<PXT$J.]C*1B,)AEF _#SE
M<1[$W&02.T.6J<U+G2IJNXIME#&;G,XQ#L(!)IBE,*-9!I&?,(CC*(3$PYA&
M.0^R!,]4X\UI&6<MT?]FX^@Y R-![GA^?X-V3P_0*@)^6JL".EW4'-UHHQHC
M6BPG9 %4J[/O.?*,.J%: &Y[CK3QR(%9>U+G<MED:W\MZG^W,:7X@?NS&'O8
M(S&%- UCB##F,*5<+,[\D/,LCT@6FV7O'1EL:A/7&UE!)82]DF=UK;B&N7S'
M0-:C0%O0.>:XMZA]5:A].8V:>8:?!AQV,_V.#3ANQI^&ZCN9?SKWG!<N*:CK
M5CRP?"C(G#=[49NJ$??\Q_*=4.+?LSSQDP![L7"_2  1R@.8>3R%G"&><!H2
MEABYRF;#3XUD;C_?7W_^]?;=IP_@^MNW#_??P/7G]^#7N[OW?]Y^^C0L3E+3
M$'JTXPY>QT34":Z<K8WHW<[]1GCPEQ0?*/DM;N,/ \Y)]*2F"!<)H32#YU <
MI>%3AA&=\+G$_+]\E7OMLCJ.W)Y0;MJ7Q;R@KYLORV,H2+PX@A&5E1O]/(09
MBD,8)AF- S_B@9>84)SNP%,CMT[NYJ1MV02L=+*;<9LV]GJLY@)1QWQV%$SQ
MCTIP\%?[7R>49HJ:53+3'GQ4&C.%9)O C.\?1EV?^?=K2A<KU;Y9C%F*'VG3
MM/FNNE%%GF[+_A4JJ6;.[['@TYF79&%$*8(\C'R(J$=@YM,0TM#/_,A'Q,N-
M5H%G23,UDA/*@(VLX*TZPDB@44CNX[RYK-5)>!]2*\/:,.?94X\C1[.28^+L
MH?Y-AGWABM7@]V>9AZ1(]$S[&+.H%5RM4NMY$HW*MU; VR9A.P^]3&Y +YCQ
M\TIEL*0813'%"<0T9!!%:0K36/PUS$@:9XRQ+."S)@Y=? _5TG%8Q2$Y31AB
M6UIW9/&./Q1E*1E@-V!_W*B*@_;EOL^C)$<P3Q&%*.$$XDS,QBSC*,U3CV<H
M:.W[H61_&^MVLKJS[8>]:1@3L:KCH!@;=II^],LZON5-$D2CZ01"7$X981JQ
M+ >E_'L$K9P"V7:2P>&!K+5 JNO54S/8[U),/*<R(%0,N!,1JDHP"R_EJW!N
M9P%*_)2)Z2$/O 0BGA*8!BF&/$N]@.(XBXG1LLV:9%-;PG6R@<JX-H$]:^E-
M !>Q@6/BWQ^<W],+_*[FA(UF>V+TK\#:BE^/6=%&TZ7S$'?=DVF@=)=NV70>
MJ!H=G<X<8!B;WU>8<=G&H>[J*H9A% =^ B,6(8CB',.4!#'DQ*->0#!) Z.S
M@>T!IL:M-XOJ>2%Y%1 QHS+#_*@=^/18\AQ0').=$DTU]J@=U&HXI+A5SMD9
M9%3J.*3B-@,<O&ZH6T:6FTADU<,FH1G!/N9B(8X#B A%,$78ARS*,AXQ@GF
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MN68BC-M/=Q \.SUWASUE8.T=3@69,IE*TJ87HH0@EJ:"X4+B0>3C!)*<!#!
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M</!7^U\W5?R,<1NK:<OV\%/IV'( %H-V+8>>8"T]76X#/I3%?\1BELDSFKS
MF^5LXQRRMTWNQ>]63YQ]YLL9Q3SGJ@5]&"8049S!#&4>I!013H@7Q+G@-_U0
M5,OR&9'@"+&G]\U!0$\/4,KV+4J9LU/:S[*D'G->T#Z.Z75_\OM&.=#7KDT9
MZ):^3!%R3T/0JG@%A)).D^)MH.\Z4_XL&2^=/F\#8(V<>BO#F(<]=*<^]_A'
M,]8W,>>HX6E7>%R,*G<RJT*=K,Y[=<B_+!;S6>AG//1#\2IX5%8M"7-(4I]
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MYU ]21I7CX^Y9N-0X<H=)Z[*SD&!GR:88BA]8NDI)T+ %&4)3'UY-D]#P:/
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M/]RM_N0LISAGZFKR&A?K7+6/DZ[:SFCMDN%#$D0\]3B, DPA(BR&.,,)C'!
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M_@$+,_0&]8IN7?<WJ_0 ;45VKONN/"57!<;-&6 (?]XQV&Y+51S)-F[QBEM
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MG7$A-_.SG<(X\":H9 6?E+"_*1@OWL'XI0M&:Y?:&!JGSO3Q64=UHXU!>.M
MFW^QWZYZN90;$R_7Y^H$>XZ?\C5>Y/_B;!Z2C*<A32'W?"+]YS2"*0UCF$81
MPIF*'1"K.O-#$TUM#VV)!O):9CN;<A!2,U/B JB!+4@C(M R@I:0[LS&,1B<
M6HN#DXUJ)(ZI_-8V'/U\/Y-PL2E6%:=!G;$9A!%!(O.@)]TZB'C@09P1'R:9
MX!FEGL>85:/QMQ-,S03LY+-[\=\!9_;"GP+'T.?EK6@.TUB/Z>WTS7XWR:AO
M]"$5W[[)!S]WZ@U 4S#?M%^K<T_>Q)(Y#7F0>122+/3EP5G$$ <D@(F(L(^3
M(!)F90,]YY_:^_]ULU8-=)M0_E.3L*,:OE;<+\M2%7IO/R"_W3O*;[9"MM%^
MY[@/;&C:+:ZW5"C;*X!F <:)_%MA-] -@)D,'W038 70X1L!NV%.O@NE=/.X
M6:B04'7CNGI\*OB#>I6?^>62KAZY.F:]>>_2V(N0*@E(.$'R%!1',$/*_^&(
M(>(1DD5V7)"GR3,U2]E^;95EE%(_K9;Z796_P3L5FPR5MI)@(?7K?3G::SFM
M+TV'7J01S6I+ESH?Y94VH%*G"0R-=,EZ"KY#7;[VDNFC+F5/ ;#CLO:D8?N9
MZAN^SJM$1G7EOR4*21D)DB#ET$.)@-+J!I"$80*CV L2GTN+'&<V%GC_-%,S
MK#LIJS;8O0E8#J!J9@A/QVI@^]8')FMSU8V"4RMT8*I1C4NWNF]MQI%/]Z%<
M*==%KOS"<UP^G"TK [1+4/["GU9EOB[KC+EYF@0Q#GD*J2"9M ]4.F<H\6%*
M TQPC/T@B\RI5JSFGI[1:,0'5,K?R@PNMRH 5NM@0^AAMR+=MF5@G <W.%N(
ME>A REX[4SOI02/^\4S?D[&V(4T9#//1R%*<8F])E=(+O4Z*%+L11Z1&Z:7J
M:TJ4?D.<>L;_L2PX7=TOU27('?Y5!Q;*F]5B\755*$+1-^?!*"!<1+'T)GV2
M0B1\"C&-4HACQL-0$![ZN-_QWE:4Z>TE[;*AYGQ/MJ7KFB&[;O7PN-K4)_Y-
M2VO=,[,.D?8^YENOJ.T)?\AU&O%PWU9#-^!L% %*$U"K,M*IOB^F QWHK<7Y
MH+-\7]@.'^-[CVCOMO^9+_/'S6/5]N=N=;[ 99F+EQ\2@V*-\Z6<_EK9?&E,
M6HWDS\IOJ^7]'2\>6[^<X]B/H@QG4 2<0A2A"*8>PQ!E0290A$,O,TH]<2S7
MU$QTK5K3BF"] K363MKA6CUMA)]J!<%BIPS )5A('8&J:VG_P=Q7=;GDQ\\,
M'[20 ]OP9@VOMVO8* :VFFE[WNBVJR&O%U'I!Y2"[3]\S"*:'T8^:#%'.Z@\
MR>'T+8ARFAX'>4]_=W.P&6 E.@X]+F<;[4 T $3MP](0PY]ZD+I<,E6&=ZCU
MK?8:YI01C!+!(0]8!A'*4DA"G\ 84992STLYMHK,VTT_M=VX[8WOY#_05KI)
M9; ,YELND.U9R#7L(YY_'"!^PH''!KB!#CE&(GS0P<8&GL.'&:M1^AG FC#N
M]H'S]3>U_JI+C;HNBWV/9<Q'T$M2'R*>,IA*6P?E^23C(F24L=#&U!V::&I&
MK6'0TX*"1M)>%Y$'L36S4BX0&]@>]0/+VNP<0\*I@3DXV:BFY)C*;XW&T<_W
MYHU]FP6AR&EWP4>2X2#S56]&1%5?J(C"+$X$]!"69B(+O<!#E@2RG1-.S5R<
MG9__^//'M[.[BR_@ZNYO%S?@_.K/ZYN+OUU\O[W\SPOP[>KVUIJ!LQMR,^OA
M$LB!K4A74I:26?HQ0T1O31%RS=;9/>G8M)U&$.SA[S3[GCLBSZ\%_^>&+^G+
ME]6C/"+.$YI(A7$(<>HSB/PTA(1D,?0SFA!*8B*P%96/P9Q3LSUM@L:MJ."O
M2EA+7\4$<C/#XQC(H:.1_3!T0E-Y )7!^2;?SOOAQ)$'@#!A@#ST5?OKG+/L
M]R!J\>]_V?"SIR)?2&#CNK@-!UY"N4<@]Y7-"40*4YX2R'S.Y5$I9$%F5!5H
M-MW4S(T2^&#3$=5>1,NO.D#$YL%X ]2/7Y2XQ7)@B_,*QGW@]6@]8H"B^4V%
M6S1'NH!P@*K5)8(Y2!UW P:#C!;R-U>H'<FW^%:/"_8WW0W?=#S6U)*;Y?H&
MKWG]D$>^)[W!,(0L1M) >PF"!#$&14 #'$3,2Y@1'5*OV:=FK]^UZ=SU5(=-
M3_5&"Z#4L+A"M5X9@]ON(?$>T8LT@KJ'C;?'W.)R>DCL1]H!!E@#NVOEOAAV
M71Y;CSG>%7%?=5]=!/<>I"=5.Q>\*-1-B@I9W.%?%Q6E>)TF=EXQ%>?+^RU5
M<7E&RG6!Z7KNA=SW(DXA#4FB+D1\F'D(0X(%]CSD<2&H3<#A!%FFMM,TJOR'
M)0'[":MA%HL8">.!=Y=&BR8TJI*C:D7 IUJ5WV9@I\V.A[T$?S4*.0QF.(#5
M+?7Z"?*,2[Q^.G#O:-<=#-G;F"K:ZH;+0#ZR;PB/S_&"JHI:.?EWOKZN&<2W
M@I7KA@ZAR>NYX>M-L;Q:UBT6<.)C3",.XY2IEN)> #$5"4S\).99B 7E5N2F
M0PL\-;,L%:#*[[K7^2*\X1@IM-"*!U&QN/1KG3'TTG.2!"GF!(K($Q!%@3S(
MB=B'"%$O2=. ! FR8_V<TN*/0QJZ)94IE+,KGX#_#@MOO*]/9C&'W_R/- =0
M^H*6PD!J#!J5M]]32L]V1$-*;Z@3;&_JI^-F^W3HNO*S[J>CC\\PRI*Y=BR&
M%7IL[V.4)=CCHHPSKWV(\8N<ZUE._"R-\<]RDZ_+YJI'T3Q&822?",4/I]C5
MTS @,/&2+/"S,*&I45Y+UR13\Q=V<H)&4//PU$$DCT?^7. SN!5^!TV/$-Y!
MC,PC=2ZP&BD@UPLSJY#;,3 Z(FL'OSI: .V8\.TXV='/]CO!J12KZH!XSY<T
MY^7GE^]8$4%>B=VO7W3*JA )2>,4P320!S+D(Q^FT@F'/O7B+$-^&A.KLG'S
MJ:=F)347?TM&4,G=*T/88@','.-A8!W8N/9$U-H%M0?'J3-I,?VH;J$]+&\=
MO!XC]*Q6V)32DU23/9)\V;1WK<N]+YG<TW*1XVV!Q!G]YR8O./MCM6(_\\7B
M;,E>U9-))Y0SZ7'.4R2\((I41%\5.U"6PC2- T@\+TNS*,:9*G8P;\(ZD)Q6
MIG"T]JQ"]8Q^5GE9ZA@I'[HR9W6H$:P+O"RK *5E[<1 *VUF1B>P?@/;W$9#
MT%)1=^]N&#7:6C;U9(V>,]!H.M.L*.WZ[%K;F8I".*P &79!W!:0#"3KN/4G
MPP+^KGQEX.GZ1 ;(^G)9K@M]5#I?/?,E7JYO..-5X$).J:ZG'W!QS^4FQW2U
M\IGF!;H4YWDACUCE6I7D2%=]/?<YRT*?^Q!'6&XPL<I;3X0'O=B+!0K22,1&
M=//.)9N:=ZV4DWM(I=,,%%NMM*%AC5YJFV$U.T1%QC0#N=Q\VMJ!QPX+-/!Z
MFP0]/F@5!X^4$)5_TRBFKJ6;Q=PIIXGLMNJ!\]UBGM6+>2G *R7!GQ^WF#;1
MF0]:U-%".N,OKF5$:( %Z PCN9QOQ-C3 #"]#E@-,8&K/(7F.J'J>O*F&<-W
M_FM]]Y,OGOF?\NSZ4,ZC"$>(" RC+*$0(3^"68(P##BCB,4I3T.K5C$GRC.U
M'5N^$\&IE\AV"]+WCG@PF#_D"GA[E5OW[GG3.F8&_HOC EPM#Z=U.[C#[07I
MP%>T=C)]\ UL+P"/7[#V&[9W%P.LIK_ A>))+5N=%)1@-%_/,8YCCW@(1G$@
M(!)A K&'.(P%)J%(B.<CJ]N#XU-.S4JV6Y&P2D3KK@;'4#:SBVZQ&]CT-<*"
M1EKPJ8UD+?!O3CL?&*+CN@O"L6G'[HA@",.>[@BFW[0/RE259K=5Y:DN.)..
M9/7+;4&J_G5]KXX\+\X$)] GH:)591G$C,0PC&-"4FF54F9D=WK,/34#5)=&
MUO+K:,J;&E[SX[7M,AR/A@P([L 6Z@VN5>FI.@$?*)2VSQJQ1=L\7#$@ZB,%
M))RC;Q5MZ(E?1SS!=L31(@8]56W'!/H.8;=-E,5Z_BU?Y_?ZR3O')5<=>FH&
M$^0GC$OW"[(LPQ 1GL)4, JC,(TR3H,8!T9'^:Y)IF;X=W*J'B+<DA^F$\YN
MN^X*I*&S3VSQ,381)@!T>9'R^RT/4O[?6^^Q<X)13(.)BHT-,/IL3QI?N<_H
M*M(K<;M>T7\\K!;RR^7%/S?Y^F5;,Q@)'Z5<8.@S/X8H2^4IE/CR/)I%01!Z
M$66^'7NOR:Q3,P=;H56R1EOL_PDJP4TJ!D]8!+-#JG-HA_8"7:!J3\=K@Y);
M%EZCF<<EW[4!XQWGKM67[8P4X_G\8KF6 WW-%[PXES/=KXJ7>1;%'D,QEBY(
M@"#"B,&,9@D,4XIH'/M8))Z).3HP_M0,3R4BT#*"1D@S"W,(P6Y;X@"7@:V&
M'23&YN&(XGL,@?2^?[]?/?^[_*:V ?]$ZD=8_:A?_$-CCO**'U&H>9F/?:QO
MO$D?2J+(^[+A?\JO/TA8POJL[?F:4RB#7J8(AW 4P(RD'D1)&),0"2X\PSI5
MD^EL'MUQ:DRCWR-O#^V6EEO1;H6V88X.K$VC2&[P&R=LI&6= 0WC[ UTO4-%
M'1C:QH;<8#E2,&C/P\@L$>T1_CD.T=%X3\<0(P=XCBOS/J)C\)V>I[H'7/#/
M6!6(KAX5J47%:EX4<M&UL_;Y9?>1^G+S3+5XVQ*%MNI,;_+R'U\+SB^7TMGA
MI>84FC,_21*:$IA)5PPBE@B8)B2 0KI?<1Q*Z^WY5B?"H26>FE.G9(1""@GR
M6DK--F!Y<!Q\G0T/G5-:O:'W'Z4()%AS![2T!2UU 7D![<_5*@.M\PPHK8%6
MNTU', -*<\6EK*C<ZV>BDUW0_M@[UCJY/3(/+O6XQ^VQ%N'=47VTB?NVS%@J
MUIVJ $J-7W6FPGX<<4^>%#*D^BZ'$8$X2E+(T\3W<9!X29S8-<K8-\W4]H=7
M4E:6H5<;L .@FMGUTZ$:V!CW0*E'MXLN$!SWN-@[U<B=+;K4?=_/HO/3_0S!
MY?)9CKDJ7E2F\V*EB"YW5Q'<#P4-$AC2((.(!PAF)$:0QH2&."11&EE1FW7,
M-363L!45[&3M?>?0A;&9<7"$W, 6HB]HUF;"  ZGMJ)KOE$-AH'B;ZV&R5=.
M;(#3JFJLN7+9E:J,W!1%OKR7+DY>_EBN2,F+9V6Q-(FN*IQ<4ODM;<UV?:,"
M+OT-'R=0\%@>=K,80^*%%'J93SU.N"#,ZK [A)!3,U;MAIO%*Y'K6O>*W&#]
MINQ]11;U-;>J0JP@4<QJ6 U2P0*(P@6HNM=[4.;WRUSD%,N1-BVHY*E:8F7)
MT3?(PV-F3#_ZD1C8"N].O*][DO_96N*MDD!K.0-M/2MB<O!:T]K7 X,T.1MR
M189I5.12T(_I;#0 U =;(0TQ5]\RD*>ZON1*?%/%_%?B7$J3K^=RJT%AYD4P
M(@Q+9U?ZN22+0DB"-/58RN,DM#KZ'IQI:KO'3E"U6RR4J'K;T,+:EG\<0M?,
M,CO!;&#S^AJN;PU<Y]UP]2CQ. *%X\J.0[.-7-!Q1.GW=1S'OM#/3-SA7ZHP
M,?#\H+Z3C),L25%"H>]G J*8)_(L' 4P0"Q E/L1%59^Z;L9IF86%'^_+LY4
M(MJ9@??HF;W^)V$R\&O_"@Z'5[1'=7?ZGK^?9=3W^Z"2;]_KPQ]TQ9&C"'K+
MK_DOSL[K^OZJF\N-<C=4-;U . AAJ+IS(>D"J&IZ H,XC$F">>R%1F][S_FG
M9@NTG&!+:E/W*=+'R%/I3KK7H=MNC(#NP%;E(%4)T!K,0(7\>4-24B-_,SSR
MI]+).%N!CR:-.64E'+#"&.%HS?W2/>H',[P8J7R<Q\5LF!XM>*-WW23_-UYN
M</$2>*%7.SPA\4*,/0\B/\:JQZ,/<1+&,(XS/TV$2# Q:OQM.N'4=HSH6!O>
M6@.@5+!H(6N"_?%-PS6B ^\2T?ZVL6T(^[3C-<'2HB&O8TQ'2\=T@*U=4UX+
MH+K:\IH,,UYC7@NE7K7FM?E>O[/\=;&BG+/RJQ18E\U<55DU%[]X0?.2LSE*
ML$>8G\$X_;_LO6USVSB7-OA74+4UN^DJH8<O($@\^\EQG)[,D\2>)#VS4_W!
MA5=',[+HFY3<\?SZ!4!2HFV) BB29FUMW3-IV1:!<RX0%X"#\X(T8V<Q,]$N
M(90J5:&@:90PK]Q9)WN<&ULW @,SJ$#68AJS5FG$!WDEOY\5X#3N;E:!0=$<
MF:F? VFE!;6X8"?O<$8#9V@&-2*<[G52HX(S""^-#.X/]G6M,3F4ULN-_+Q\
M-+4/-_I56>[2 U_]XJNM6*[OFOS MYRE) Y5# .).40RD9!('L(H1BR.$X5#
M&?OYV_@),#=:,B7"+FE1/)F+RBKOHJ_CC><(N#'2F+B.3%![T>'*R [VPC?Y
MT]_MY-\E4!\P=55?[ ;VY_$48F(GGWX0O?;\Z=F._YE8G[ZWA<F$VARRZPI
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M^C,.>2!5JJ#D)()(!@+25!$8<T$I%R*4TJG>[;F"S(W';JZ^?O]T_15<?/T
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M!5AE%J!1Q\Q,]F0GJ?'<K1)S-$J!O5:>L13G#*,;7TXU.&.;IL\<ES&R30Z
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M]%B8_#MV4 !]XP%RVU@/"/K(:^2W-G8M60W6M;3#[:T=81ET>WVJSTEWV(X
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M_53+#$EK,^1:>KI:.8&="J$B<W='C <;RB0Q"8TRB)&06 8$41KX$/[@8$_
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MG73/ZPS"RTVO^X/G1OM<-=F>=I=(W^A&?I-&0[W/ME3X8HDG L6$I@9_KC?
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MK3CUYS2')@U/:0GG6\ZD"U<W[CD?JZD*F%3R&;?*ZM-O8+D&+MCUJ%OB@,G
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M)A!QD\A+H00&$16(B2B*&?;S'G?HU6<J3>1$3LN?IA:RE;PJ_R;VLGNFKW:
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M4QA$BF2"ID0(S^P$1WJ:WQGC<[Z^@WH]N0="B[RP%U:Y EO]C"G/8$(LS!^
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M..7@NKH!O/60C>Y,<"@2M%$2U%J"EIK Z&D.5BU-#PPR^*O1=E!OP#&'8^3
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M?QA+-W(Y'Z&1V<2"TY9PC'3BG2 ,&[-_N*MI8_0[U7T5D]_][9[F_:8\86/
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MH4@SC$1"H#E!@4C1"+(T,JG*22PY%C1$3BS=5J-.S3(VDA;@O Z0=I CP\1
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MHOQU)@,D&$(Z/A0TTO$A9>8,/X+2U#_1. L14[;!^,BR3RVP;\2'H%8 ;#4
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M<G2T<2E73BF]Q[QR\H9^UN%F^4,_9)4_?UHMYORY5287\U!Q(B )4^W.\#2
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M,IM97WFH)TCH5FO5?+:R#P$W@92_S2:7J(#YZLYWOACE;)C5*A#M.(HE.F1
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MBQ'EF)'.HDAR21HD9  8(YQE!4Z@J>7/]>?>XW!ZE)YFT+.7MN\?7/N+O@T
MS2]QU0<R&DFO%*X8B NQ)$$%;C#C\(RW+FHO>3*Q3GG;DR0->ZC5@U$/"F@
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M1T R$[-+$"N]+'B.JF&BI.KPV5\##:#I^I3&J ..\,O%*%*O3.D^J"7(DC4
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M:45-M@O6O_G))3S!8=8\*A85<1(A)3DH8J46A$>=F60TF%CGHGY[6H>MU&\
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M[7BQJM-<C*3E7"LA"6B9B'1.8+0)D@ATIUR(D2519ZI45PJ'-:S-8;2*8EL
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M=3Y#G/C%8G6*KW1R/=#I+2SB?'RQ>JVD)$^VW )'59P$DS3QI0MC]C9#$E%
MJ.-<;4OIL(]W*X&MJKH:@.-5-Z_#V7G 8'J5$5R;XI'38&29Y,F$Q8WE4B)6
M6$5L% J=2>IEI2&M3],T;)5LK0.Q'Q4T *;W?CQ?E1'<RLP<35%$EZO4S(8I
M2%F[,B7$<YV)%#:6K(DJ0XTI+Y,8%*^#JT[D#5M86@EB_2NF ;3=#,]>W'<>
MA<9=(VDB*2N/@37^847PZ!-PGZ,'9U6=B.9IFH:MY*R$JYY4T "8'J^.NL^4
MM%(8<)(DJ2.1L3P]X"D2ZH%%IK57(K]@X=HN$*LWCK0.Q/I73 MHFTTCLK&^
M@?T\7OQQB#2,E^6K$4_,"S"19(K1+\8SFE@E+&&21FJ8"XK5.1Z?(6K8DLA:
MR.I)"0W@Z?J!X,V<TX/)9/9G>9%=&@BL&"L#@:_L-/[P]VF<3280EZN1%.>K
M46LCA7ZE,3$1T)H3F4K32FM*SI@C9UJ%I.I4YO;%P;"EEK7<MR'4VP"LK\:I
M/D@.2L>!42L)3;Z,\BEI0L-I&4\A8J!40ZC3TN0IB@:NGJR$NU[DWP".GAQL
M<I^OG(-V5@"AI76*C"@QG[,F&J36E@;!8Z6I7QTI[(:SUW8E4$4_#>#N_L@G
MM./C)7S <"EM0FY*LPT<MT]RBB%#^)63*I'H=1(Z@DZR3D#Q0]*Z(>VUW1WT
MJY&!'RK<&LNP.,X?T9V=K88XI<OX,$*RG@:7A2<^<MPZ%*UUB)D3HZ46-.D<
MF+N+M$=?'VRS9C<(O98;@:H2;\)8K7KE+,H3"4!*2M3]%K["9';+%(^H5 +
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M]Z(,!;.*>"H8\5 Z#!NP*,Q:R.M(8S?LO;9[@THZ:@!]G\I^6H4PJU:MGS#
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MCUMLO,!38*2#!L-I(%&[TMHX4N(]YX0;*:3*+&3A.QBX_BEK-DK9!E.WK=_
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MN13<6XQ?0B92:8;A3.;ECT@A1L]Y[H"\'R[4V$W+_H#J5[0#X^2!?#[!O/S
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M@44F=! V5W$].Q W[.5C56>BEHI:1MVM?B#1:IJI0I'),B Q6T$\:$ZX2U0
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M]"[4==WZ<P! 1]?,+U.JO#F1/WKHM^8E'ZDH>4<JIBD_WD=$TQ0:)X\I>QT
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M0V%T]J5P(EW+1FT .Q(XK1D[+M1&4E,7 P??X?=:0K7Z?;'\@<<S;S/=^5&
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M.Q>S!TRROF0SN@@-UOW.#M$HZ[AN4X.W W&=X/&XL'D(O"/IL"=8WL?0MC'
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M\RYFGS;+>W&UV2)M"[*HM0;.I*+[C5P:I!L(K+6<!^N*D3L!E#[^%CCII[O
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M+A,C12?(/)08BT$1TA.AQ&[?-"U #M7CHIE0.[ L^T[6#HE@("2DHFMKK/>
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MZN_\ -PHX.6_-].>ZS]<S/-ZM/TRXRK_EC?_O1')L_0_EQMYK;;2P,0C<Z(
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M%7#5J$.R< D+J,+)YA=1]UFK3,&1I*O "Q%EF_*R1\GJ!5:':O]N##F:*GK
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MW12)48Q)OQJG')>E30'LJ3Z2#]+^H$?R(:KH %<//,8A$UF&(('\#4-<%#J
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MYF-_OV)4;76*NJMW+66L<477\<]U?CY/4*?W@!<H'+.J,'<\W/7P=#R.SG<
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M\X!"EUP?D^LT@CJPM;B4%5.!ZW&HSA\LI1,LS(F&"L,8H#4$7<7=%/CJE&,
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MO(M!==T<6JZ8@0SW6$S2D!)2IBJB@T Y+T3E?4@D@@CCY"F[5C,M8@ZU\).
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MBRS0?VT8 NBC"=#2;?C1XYJ)<-!<4OIF3C\YK]8UU_FTKG[B1FEG(;N81!3
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M6]='V0V@91>'FO)9A6P0M*L'=RVY]127@4DJU 'I3(Y$CGDJI'6'(.90A3>
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MO ',/&S58<&SHE4 Y[4A 8*GI#5DH&WD.&.LA#).4+-?7]2QNUP.P<MARFX
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M%<$73AN#L9)Y]B:,-'JWP^):>@X<PS\=;I$&0?;85$[:.XPR7 DA,4JB9?!
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M?0,0>K9^/Q@I=*%=QH46M5): PKG( AG."8C-!N'!?Q4FRGZV+]O,T4?8S0
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M9!!<2. 5]\[I3!Z]3<_?D3;>;Z7_;1OOMU%&!^#:I8N;R2Q2*AZXX)FR4%_
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MJE_Y4&ZWH[R;I06&)=:<26I#21)WP=9EGAE\T91XN\(PJI!M:30\HB%7O;V
M>2V6-1".7L6I=4^G[V9$'"Y7;XB7:?VWUF>Y3,1^X@E0UR?_Z"0X2[\B-=D4
M6(DR'2IY;\%?;T]R7HN=#8ZM+BUN"VT]Z R^Z9M49 &H$1B2\U%1:PA><D!C
MO3;1LM)J^%$3?GJ+";LJ,0R#@BYMX6D/\8#IN\EB8!2PDBY\J,\^4FULJBM/
M7)':2<M1JT/MD=N1A2.N*0R$QSV.C^' <>Q6\4QH6I25K"A21@D4D)HH(#*9
M0++L,]J TG=H(WMF-WW6#3JTF(& <^SVLU'(Z;4H'*4!<A\&5.9UD80,4%1=
M)N$RLW'\=&8GUHZX8M"A30T.IM?R8O4DK<[#V;H0>7)V=MD+<: GI\]_]RAO
M1K<0QPB//H5"@8DYB#)X BCEUE&;!$YKY"(6)[!-(\_1;7-B7L6@K 6#JDZ0
MKP\M(A;0S!MKM+:.'6KGYZO>YK0-(MML<]I&TQV$1$\\8 NL%&$I,1)1("BO
MZ>A1(D$H+B2+2?E&S[E[?#PZ C V>U2ZC9:ZQ-IEDZ-W-GB7+5A? BAE/:41
MR8.T9+",%<MLFPOLHWI4NI6V-WU4NHWH.X#0B^\81;0YZUK"846"0C3@C..0
M<E#&)98C;]-5=Z2/2K?2_[:/2K=11@?@>ODED!<QF(0:=+&A]D];\*JVWKN
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MOIBN2&!7VZR90)L,)X&Q>D<F$9SP#*Q6@8(%ZXLZV * 1RD<-X!K@[0FVND
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MQ_[+=(;O5OAM.1'U:$_% Y,,01E%H41$!XS8UR;*5!J->1V8D7%OP/LY>'O
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M.@!5DW8.,E#$DCR(5(? :6W!:;)BXYW)6=I29)N%4Z^]Y7 K<!VBY7 ;37>
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M3F1$F:-.P 12H$49:7T^PNN6;H9*21UC-P9R170/0.\8D/L;T$[H.$Y#N"R
M3Z)P(BED$*72%,+5Z*T.4&8V1G3T9R3G7NS@DN8>RL"OV@QVP<9Q6L'IGR1@
M0LQT1MGYNO/FB44N)I?DB@SD$%2L]2 $1R=X/<D+R4+'T.CE>4.F>JA-OVH[
M:H*NP<:8[FYH;\X7BW7CXJ-75(^)YD8#!9.(]=6NB/5=N.2D@<+ VR"81)ED
M:O.(>G>:>SANAD\O#J3##HZ%2T[?(BDJG#U@=:*D)782 XM*UDLI3_X@2^"H
M4G'&4"S8IH7C!<+&C?8/A8_'83F(LOH9<7/%U573R7VN<K*6)1_ "6[K8%I=
MG]$8*#+F%.C48KI-[^8+A(WK^D:&X!#*Z@Z"3PAS0J>(]%9:8*&^<9&Q/N3B
M#(H5+HB$(;NF3O )NL8-4<<%X!"J&GKPR>[XN[I^WT68%C/7/DD(W)(PC4&(
MFG-(C"E>,*)E;3I_]B"ZA^1J^*CQ4%KL(&R\8O4R%'G*&A4*SI.7]>+3@ZJ#
M]V)-XDJ0S"=,'AOM)MB,OG&#R(/!Y0F8#JB[?D[R:^8N I2GF-.29:=#A&CJ
MJGD?)+@L&*1B FIGZ'QJDVEO1M^XH>7HP!Q.=_T!\RFN0M*%#AX+P60*G'7M
MJ6,Z IU'MI1H6$AM'FR]0-BX1_784!Q"6_V$F4]:5&087=(D*4\6Q0.215'0
M0R)+-JBL61)-L+</YD;IMMV_9V$_Z1_!K,9;G50W6Q8>Z82_TP4_2-O8]E_7
MHGUL3Z8/\511B!2"E5 RX5?5FWS'HB4D6VM]M"&8-E%YPS:R39Y:G%Q53C^1
MFL_I\W[<^<N3%(,)KI8EZCQFY9,!9TA,ADZ*XJ6@\*+-JZ\!B.^A^V5_M-UW
MF8?6:@>9=<N;5(\FB2(E2/H%B8(5B,$1(H/SS@@,2>J&AC_>/?TXSQ[W 'XO
M*.C&(#8*_9\X9Z\UP@.Y$\4U((5<H)++X.ILOY)8+)Q9GW*;K'\X'OJMG.X/
M]X/KN -T/U_K>$P $Q=D8B+7V>XU7V#UEC=B :>,4TX8=(U> 6Q/:R=1R8%1
M-3^HBOLI<3TA1#J&*)\YIS@NGETM*/CTE33X4UC6I2C?ZD_6?W.]M9K9VEM<
MGSQGQ4 ))<!G7P"%T"*8'*UI[*3W(;^3<&1<Q!\>".,;09U@MU&ZDO_[_++S
M\O.\/K=>K1;3>+["Y<FW^?F,V/:VH&$"! FK/G)-=7^[!1&9=PZ-E/>WTCTZ
M.W<(6CH)-L8!\R@*[0/'3XCSS=<Z+?O=[,/5SIF:G^#R;^'L_$(29V?S?X99
MPEK2],DI!&NU ^5T@!"\AE)XX%*:4K39 ,/[TM%)'7D\_!Y4D>-C]X7SYXKM
M!\,N'F&<LF*3 P4)PJ54^]@4.+0.!-<I*ZT#\I:EDGUH[V1(1)<A2"L(C(_]
M9\S]=^)FO7F _N2WRXFWRXF6R8A,XA0L4KYNZQY"D<G(56)&*@JRXDMW+]M^
M9R<C(KKSQ_LK:'S\O6!X]Y/@&D?]/*7PJFIN&LXFUAKAI:4HJ;@ZWAL9.&XI
M[I<)>>$Z,-?X4FH[@C?"LGVE6#ZDLKN']F-I[;MO?X3IHB8%%Z'5I*A$T1(Q
MZZ03H*)R$*(7P(N3%G/]=9N[Q3V(W@CB[E\3XH,K?7R8/W- W;1#K7!!?^./
M,/OQVV*^;KBWTG"K!82,J:X29$ )@@'K??+*E:"8W3V,>/J+-P*G?Z7@;*^J
M\>'X@@&N=T3<JKU,.$K-M2O@U_?\*@OPUAMB,6%P.23'&@_@?I[ S>Y"V"M%
M;$MM=HC5>RU^+JNHO6? C2.)69,@2A2@.:;(C!!2M!EWNM?#A]=^,3>$MHZK
M(;/RNBYIS\NOX;_GBW6;2)4L:3R'Y8.J2+@S!7:0)LUA2&BS.&)PX1R@F1,)
MD]GH!'6%":@BR "$=I#01H%6:8DM1W4U:>9\(.KWN+I9U5*80$^\<A'JM2 1
MYZ(D$\6D-?TL6-GV3=EC5'72Z+ G/IYZ!;&W'D9>7/J #_I%3='>A,7B1[D8
MWKJ<:&$#S]J"CL&0VZ\#8U5Q! >'06%4;*."Z$9?UL?+P_WU.F\IY [:LQYC
MZNIGEU%#W5NX^(YU8OI)2HOS<+:<9">YL2I"2KI6M6R&P)(G&2K!A34DQC;Q
MWF[T]O'<<# T'E!Y'3JV-_1[BJ5O6]WCJS4GA051?-U-QIP$92('KT,&5J+P
MT?HLPR:W]'L1T<?SPN:.L(U2>D/?IS2M!?XR3;>8JY:VF%;>PMDM1G^;S\\F
M)7.IBL] *94C9KV%&$C.*FL17<#D/-\%@=L2,FZCR&%0V%0YG1[5CYC=Q%EN
M?,@<N,^4W6?.P'-6(!>=E9<L.6PSTW5# L=MWSCH8;RO>GI$W=V7XQ,34T*F
M MA4R)V3=X>@F 0G*=#EO&X ;3.\[ 7"QFW%.!S*]E!';Z?K;PO\(TROUV%/
M'$\N4T  +M<!Q X-!"XT9)V4S?7JT6S2*/S2]XS;Z'"8LW$?T?;HA!XF.K>[
MZ^G<O]I>\TS[O3-2<<$LA" LJ+H3/5INP2,Z$;Q6,;5Y9M2"FW%;&<;,<-LJ
MOD?PK^\2)X4K8WC,D*7VH#1E5,ZS"#8B11<Y)^8/5()9TS-NN\+A +B]\'N$
MT%\6\^5RDE@Q48H(%#084,@%!&D\!)V%*%(;IPX4NZWI&;F!X' 8VE[Z'8Q]
MWZBCO#")S ;0.1=0OB22$OE8,HTBI4&%C=:)#/5JH%U+P.'0M:=>]KWP;P,V
MDM8$A6<YDI>-F,GI.LJAG;$)K"=A!65"D6T'P=ZF9C,XO8([A6TEWY>KNM7
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M PWI'M8P=J&9>IW'.[G>><7KF9=K9SF$V3+%4;!! A64.&D2NB11$J<D)5Y
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M4(B#UL1M:7Y_,<HZL,"$1DIQRY7((;&.)B*<%LIPJF)XR=?=3_'O+VHKENQ
M\7L*L0K%?_@RLCXP14O+KB \D6$U$2MS$KG+G(4LY8NGWOLI_L.781O6]*+X
M/858A>+/KT9>RTBCXR0G4Z98H[URD3F252@-_D6@_*5BQSU-_=4P2??]FOK]
MA%B%XC]>C&Q(7N 65;8G738E*.W9,TF<@0@I4TE?ZCJ^G^(_MC/UG9_&]JKX
M/858@6MW=3D*4BIEC29!1'1&9>EP;94BP@:(S'A*97>NW=7E,-GHO:I]3R%6
M$ V^TKPA:N&UT.70SJER>;7JV<F(5E))[XU/MI_,GPXZ:72>1=YK?-BA(BJ
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M[$7FL+>-O:"L/S55</?Q#',;1^ 1C[C((&(X)(D"YTM3,5[&3"&W.B9O+"Y
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M;Z(>&D(0X6;\F(60,Z"'I$FF'N-_ISQQ(5)"T8=B5D@6;9L2RF<>WPH8YFT
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M2S?C^>1A#J+V(2I!& -T+Z0PQ'*'_A_G,2@N>-1M*A,.?7]-IVC'0^MDFJC
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M\P6NAW2]JF*Y[^ WBMI*%%(BG*.DI!!0DBED*7)(#%A(U/>30]N>QJH.'OH
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M%+MFW I3*6C WXWW<(*) \O")PW^ B[4O\BJAS$#II)8$)(F"@KVI]&M/:.
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MQ6K<<D/VP;"%Z]^\ 3L"0[A19! O,:  .EMBP!@"AE=D<QJCQ?&&'9>86HV
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M7RV(4 Z=DIU=E7/DKZ+0)EX(WW(7Y"!.3SV2?'P>%/>JU(4"0Q_C[/!+),1
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M^Z.[QQ%$0ZE2ED0<Y<  [(60DKRIL,*O\'/<R6A5NFDKA^Z\V\)1W,#>>',
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M?L$WT[.-<VYF;85'>+=3PUQ_V\2K#VOTFWJ&V-K]H>7"R,EDIR)HG-,S@KS
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M_.M0J\RQ72'I[3#;#O;KW+ Q$;._(H8\3QR$'0X&EFV=FWZ )5W4E!G6X=_
M/M=3HD\:/]O-<W!^UFC=G(-6JZE8F%?9[TZ0!VG %$8L2US36/ZN>Y .H.G^
M7MK]NC@8*(Q85GFGC?I% +1'F#%P<@Y.:2#0J93J_(Z >P@X[9([[ ? A^ .
M>;A/@&L1\1^T(86WZ(XH'/N5<U?"?.5JD9FAYG.\TT<Y6^#"=S_L%BOY>ECE
M$<&L6"C4I76@Q5UHY',),"F\QY["@&6:>]I(:/XX?URM'((3JVE)'#8^ CM3
M+H@Y9CW0)%XPL(4XVC3NV/S8A#YTX9["8&:)AMHH9*%8+12+QVMZHZZ"^";>
MJ*-8/D]#;;1QL@Q_=G5UJG T5\X9 Z\+5^W4T%$ G^6:1OI7/#P^KAZ"*&(;
M"5P.O@@UA0'+&-NT43J!Q%'I\/!H;;_34^W6\#L=M>Y%MKW3&.AHO9$-@?#D
M".B_HLZ=YN/J"N"9?PH'^RWRTLVIXT8YNCXCM5'0V=[9,^90,II$S0R6W=X(
MH:..9X3SVM2>4S,^]Y/2U87O6!]VRX=UT(8^_[!;+)7J(#HU=8["PKA%<4+'
M>O;3O 1+$U.; D5Z^D%SJ;76C)XKK.?;0CUM9/47]) (4$E(^GJ=3/^)@E>3
M#$06+DXBV-3IX;E1$E)8,;;(=764V#?BJ#9J.P\0Y,;%D]?V:"/&2@*VA8S4
M5:/;UIG5C&J]TU!=*ZPI6^2R1H07)Z$^*IL[:323=3W"BH7I938"NB&R::.-
MQ_G#X]S14:4 _B= -G),:^]R^,6HF5'$K\X[;83O$E$GH&/)H;&XV=[#VE8*
M1W/5W#""#EPP#_JNRL!ED7K:B.&<1:O;/>AW>Q#OR1WRXL*"M6_&'B_IGCVS
MD\&[T% ;T3Q!^%;",&>8R1@YD*(U_513&5W93W54SU4YJ(V>RJCEDKD(?:'(
MA6$^U^)Q)8J74+@"AAXS"FL4-DO$U$9S7T0MFJ?HH(#'@T., AL%5I^1^NAQ
M.'9KHC(1[_]R"7W81>&>[49[C?8J2D)M=+8)!S;%;A=-AR^YF&/;J.D22(I\
MPN5>U(4LN]331C:_2"0X$N4+LXKO^[F?CMKX#-.T4;_S8 #_S L_"@?QK7(\
M'75O,=)IHWB3"TZYDPMG,T"Z%/KXPVZQ>EQ'/AD XG;)':$^B<Z2*:5ZD%IB
M&X. >4'73'%9PH,I@=PHIU*,#=W_@$/;0Y^3?0^GMTR,C2I5A=5#PK"<&5>C
MR!,O\P[51]CEO60J^L15T4(>M?SC)=!FQ OX["5/;\$X\=FCR9V'HDZ=LRF"
M_1SL"(;7H#>"8Y;.?H#]W*3A2^:9>A#J(CI%HOA@>$I-/!9VDT-11GDK+U]R
MPK52-?P-RI7H[]3OM.D3A+P-&,>=L4@/7]&L21X<,E1+OM1=S(8>'->P'](I
MO*@^@+0KT(A?2&4X2W&9893\B),P+,0JUH8XYSC9"I,2[TNEE8ZMPWSYR>2\
M55@IK6 =5RHK7OFTL8625:P>OH&QU17O^B*RB]U6FY+U9(QL(M87@:]8J0.*
MAH'MX3X$S*(6,>7L)53Z7M;5?D0 .@H#EWTB:E/VOFA^!V?=L3!UU1W;]"PQ
MAY@IC%=66*:E')XA478$5S(0Y>L*QW'EG(YQ8G9^>FW.::-U\X9M0-]!Z_1T
MZJE^$6X* Y9=XKV2("X&QD331GQ]3IY<JX;O9(-0Q:,TYL,4-0:I%_RWR$LW
MK98/S8!J\T\;Z6Q!6RZ\1K"<9M"#P1WVC6H:U52!<TH(9MFJ;$(R"\69-1+C
MD&7$4A^QW 1<SY-.*VV<+=U_'=CG"H=YU5SO*Z+B'F.%$<L<X;1I5CT!+7 &
MKA\65UK9]?14O75<3T?9>Y%NVJA>DXI[Y*(69G"* BY"DEP.!WQ%#'F>^ 4[
M' PLVSHW=42CA<K14!N%/*66 (,*A%PYZ\T'3@\-K-Q00F:!+]"FN#^%%N;
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M%GFG_8"_])Q<4\G<O+-N6BXW/9I^*2IJ(Z-S9@?)._\?@I)I>\!L);6\GS[
MIS!JV6>A-M7,APFVLG_*B;J*Y48_$%Q#'PZB?=/-P*$E40VQR^:\M"R14#<A
MC1=\NT940%+)UZ>72%=/"91S3$0#A>'*+.NTT<O9PL1U#WMX.!1G,G#A.T8F
ME_#&1^@41BW3!-2^:S-=07\2*].Y^3XNJZ..+DA!T[0[/[R1<.-&-K3 O47$
M?].XNZS/DLQNV[BQ=MW5>*AKA32!)AHG*4 K%NM]".X!Z5+H8^>>^"*I6J@#
MA45CB]Q61Y5]@I*6(.&DLVI56ST;D)QL5%O(-8D[)".,W'L,/9^(,\N']7#H
MLTA46#RVR&TWK;8;IJ@%7L-7LRJI%\WO,FIU(/AQC]@]&8'VM-,V^L[XUE=Y
M=<HM<D8=-70.!QMZ*N<UO4<NP\C&A#(^(G'?% KXV+GW$?@;291>U4.-7"H)
M6"9YN:;7;GDC\"NV*!E951(P!5N4EN>@-F*;C/\0X)B::B:\6$?I3;-4[\IJ
M8R">(MXD1Q8^PI@6WE<N*?ZCI; TJ.:%,6H*(Y9AZFDCH>G6[PDXP,?.AUVA
MC_WP4QRRFA9(0EF\D[,X;4]A&=@FC]51.!?FYDNTU$9>TXC%$Q3$7VAC#_,Q
M:)*!>/:QZ4U=PFD#9C9V6IF!K28PXY3FC _Y\?/RZG&^WY..:H8LO9^W:JRP
M(1N%K^HIFA-;M@*7$#"DR WND6P6*M41N(?B",'W=\3U;X-]$/@!I_##;JE2
MJH<'V)!XMWX ..V2.RR^8'$-XX$ [!:!$R2;H51N\U3-A]N(VD9Q5Z7OOF"<
M-\,XW>JSDY-VV^(!X)!0M >N*;Z#'*TU@5Q/87T 46',MH6)IMLUU>7U@-J3
MH)GNU_=PXDV+JR(]L,O041O9O4%.SR<>9)/P<&2!%E]Q(W$CLZIBEE7F:5.A
M3;?!M3UR!_L8 F;1Z7YGM4*_<LX8(Z<P9%DEGC;".%$[WX]:B%B? .P_MBD1
M,"3N+>*W:!^XULS0$+5BOXHNBDR?ZHJM1;-LTTTC4[5S$HBHU>A08> >^'C-
MQWM EB(4#O_*N>,$A K#EDDJ3C-1&PEMDXZ'?/8$#&H%^ZUS2!TU\GG":2R1
M9B?NY7@TA-A7&*_,T4W[T4/IEN@+6]Q%CLQM6>!CIP_!;^B+"C<"[<:>&3GT
M;LZZ:8E4I%]D@HUFA:/),/:=4($0:/0Y1C;Q8%=A25#.*T?(149#UR??B9YU
MQSF%BK#IJ_%5X5"OGA-B?A_M\J(P:IDDGC:R.-GN/+7*A%H!?=N<3T<9?(9L
M&BO?#<0CZ)NQKTM#&0&G,& 99IX9ZQI6HI] R QL?7,/W;0^;KCUYD7B:2R8
M'V]Z$*^_XZ"FHAECIS!D&>=?Z)D''-H>>O#8\'-"YN(<2E5API PS#'Q:Q1Y
MD.,[5!]AE_?B[">OL@GG9%#+/UX";4:\@,]>$F'U^9,M;4D%CXG/'GV4W2[*
MV13!?@YV!%]KT!O!,4MG/\!^;M+P)?-,/0AU$9T*T_'!\)2:>"SL)H>BC/)6
M7KZQA#BE:O@;E"O1WZG?:=,GV'4;,(X[8Y$>OJ)9DSPX9*B6?*F[F T].*YA
M/^1&>%%] &E7H!&_$%%*F>&KS#!*?L1)&!9B%8?M..<XV0J3$E=*I96.K<-\
M^<GDO%58*:U@'5<J*U[YM+&%DE6L'KZ!L=45[_HBLHO=UI2(4]U*SP1!4SI^
M!RG6O'R\% TU+BNWX8?=XM&A.+</[A"X&G+Q16[ FJ^'VS\6Z[XG\@(WPGZ*
M.&CXQ,<#>8=*OHYI'W&L<$E1.8\.!&)CA0';(KI:$4<MF5JLZ]E[(Y?*K:=F
M]X1'P,L+%ZDG-:KY\L\^A>*@PHAEA(OKKE^4<3&.9]W%='IEU]139M=Q38UU
M=B4F:E_M38-W0Z$T"YS^;N8F(YNI\R[HNHVS3"KJIC<N79A^VLCK)7*'T;K"
M4VN'1]6)9@\-HO'/OALP3K'(>;HHHI9F;(NKZJBPTV2<(*$DH+Z+>,Y6\7]:
MWZRU^FTU%4X_+*Q]$^:Z9* P<)GEGS;*F6Y!__G-C*+8A#?J*),+,4\;;6P+
M2HO[N?B/T4.CATIP3A\-% ;\F:HYLGU15G?,,E^+H]@4!G0(E=O_?/S95GG/
MJ6RR3QLI_(49)KX<@@!.T1UVT#J^J*<@OH8OZJB("U%/&UUL!"Y%8W FN3VD
MF*%]TVJZ%("GR(,C228CB*]+.VVT<+;)JC% <J$X9B3QO7U11T%<AG_:Z.*<
MH8K1$HX,0U-M-!JI'@5UT\LO\EF@G!6W>I'5R*21R5>DG6[J& ]22HH+1A>-
M+JI$/MT4,1GOVS:": 11!=9IHX=G8P3.&!.TQM SXTZ-"FZ<<MIH7SBX"+/I
M0>%-0H>$AN5TA0/Z]KFBCD*X) 65V#VANHGY58=R39LK!XFKL8OFCH=(D'HC
MR\([UC 7$#D+V#IO!7VU1&G[(LBFQ7P3,[^VPC&T*7)<41B](3-FR90O-LPW
M;:K8UQ0UPY%;X!0)*+C(MCLV+<[:R;/*W--& 9\8S]SBKE%#HX9J<$\;96Q#
MGT,:F.Y7(X8;IIOV:P>EY[N>8KD.B1W,#A8QJP?IHI"*+)N["!7U$<Q):(QJ
M&M54@'/Z5!W'/J)=)(QAX.+:M*!JIXA*DDX;[?OI8P_Y+.R<ML#/%;< -<IG
ME.]U&*>-[B4P1-//0=O!R'>0F>)I]$\E\FFC@[]^_"\X)Y[K$#-:UXC@)NFF
MC0).%,)-M6_9(::8,1)0;&3O]1BGC=8U/!?YX=Y*LBFX!6TY*IG(%=)-X^>2
M4,K;_)O0OE&_-R.@-GHXN[Z#P"*>,V"6AGU7I]11')>@WYP=KI_;_GD3?9YE
M.2K]P@?0$<_@0E&[!2/,>X#W$, ^XS1P9-\G Z0#+C@:?-@M5//U:KX@#_Q
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MZ=Y@ZKKGEQ.^\:V>(CLVYT.HCTV29YN'?/E%H(WO&VQ\-:CX="\TV5>KCOX
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MVGN[G7^;.WG]WX'COP%02P$"% ,4    " "1BU=4AS"DGR=;" #/,54 $
M            @ $     8FAC+3(P,C$Q,C,Q+FAT;5!+ 0(4 Q0    ( )&+
M5U0&YE0&%C,  $TT @ 0              "  55;" !B:&,M,C R,3$R,S$N
M>'-D4$L! A0#%     @ D8M75+T83_&U/   I74" !0              ( !
MF8X( &)H8RTR,#(Q,3(S,5]C86PN>&UL4$L! A0#%     @ D8M75.VQ-Y<R
M(P$ $$ - !0              ( !@,L( &)H8RTR,#(Q,3(S,5]D968N>&UL
M4$L! A0#%     @ D8M75&=57FYSD@  H,@  !,              ( !Y.X)
M &)H8RTR,#(Q,3(S,5]G,2YJ<&=02P$"% ,4    " "1BU=4=K]76$-1 @#S
MS1< %               @ &(@0H 8FAC+3(P,C$Q,C,Q7VQA8BYX;6Q02P$"
M% ,4    " "1BU=4#]+5[WZ$ 0#C$!( %               @ ']T@P 8FAC
M+3(P,C$Q,C,Q7W!R92YX;6Q02P$"% ,4    " "1BU=4!OJF)(M9  #QG@(
M%0              @ &M5PX 97AH:6)I=#$P,C R,#(Q>64N:'1M4$L! A0#
M%     @ D8M75'AR<E"?&   9D@" !0              ( !:[$. &5X:&EB
M:70R,3$R,#(Q>64N:'1M4$L! A0#%     @ D8M75/&TCAE' P  V@@  !0
M             ( !/,H. &5X:&EB:70R,S$R,#(Q>64N:'1M4$L! A0#%
M  @ D8M75(7P2L^."   M24  !0              ( !M<T. &5X:&EB:70S
M,3$R,#(Q>64N:'1M4$L! A0#%     @ D8M75 \<XBVA"   #B8  !0
M         ( !==8. &5X:&EB:70S,3(R,#(Q>64N:'1M4$L! A0#%     @
MD8M75.H6[%1&!@  0Q@  !0              ( !2-\. &5X:&EB:70S,C$R
M,#(Q>64N:'1M4$L! A0#%     @ D8M75*IJDK)=!@  >!@  !0
M     ( !P.4. &5X:&EB:70S,C(R,#(Q>64N:'1M4$L%!@     .  X E ,
' $_L#@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
